TY  - JOUR
AB  - This is a randomized, double‐blind, placebo‐controlled presurgical trial of 0.228% 4‐hydroxy‐tamoxifen (4‐OHT) gel vs. oral tamoxifen (TAM) 20 mg daily. The study population will consist of 112 pre‐ and postmenopausal women with any grade DCIS, ER positive, non‐palpable DCIS with no evidence of invasion found on diagnostic core needle biopsy (DCNB). In order to accrue a total of 112 participants with DCIS over a period of 22 months, 20 eligible participants total will be screened at the three participating institutions per month with a planned average monthly recruitment of 5 participants total per month. We assume that 22 women (20% of the recruited population, 11 women per arm) will be inevaluable because of the presence of unanticipated invasive disease in the therapeutic surgical excisional (TSE) specimen, or the absence of residual DCIS in the TSE, so that a total of 90 women (45 per arm) will be evaluable for the study endpoints. These estimates are based on numbers from the Lynn Sage Database of NU: over the six‐year period 2000‐2005, the fraction of women diagnosed with DCIS on core needle biopsy who were found to have no residual DCIS in the TSE was 2.5% and that of women with invasive disease (T1a or greater) in the TSE when the DCNB showed pure DCIS was 13.3%, very similar to the data reported by Bonnett et. al. [56] who found that 13% of pure DCIS lesions seen on DCNB (29/122) were in fact invasive in the TSE. With regard to racial/ethnic groups, 25.6% of the DCIS population at NU were of non‐European ancestry (18% African, 4% Hispanic, 3.5% other). WU has higher fractions of African American women with DCIS (24% and 21% respectively). The participants will be consented following diagnostic core needle biopsy at the time of initial surgical consultation. Baseline assessments include medical history, nipple aspirate fluid (NAF) collection, explanation of gel application, BESS questionnaire (symptom assessment) and blood draw for clinical and research labs including plasma estradiol, progesterone and FSH (rushed), CBC, chemistry profile, liver and renal function tests, Factor VIII, von Willebrand Factor, Factor IX, and total protein S, plasma for insulin‐like growth factor (IGF‐1) and sex hormone‐binding globulin (SHBG), and DNA extraction for assessment of polymorphisms in tamoxifen metabolism genes. At Northwestern plasma and RNA from blood will be collected pre‐ and post‐treatment and will be stored for future proteomic and gene expression fingerprinting No run‐in period is planned. The intervention phase will begin within 5 days following randomization and end on the day prior to surgical resection. The 4‐OHT group will apply active gel 2 mg daily to each breast for 4‐10 weeks and take oral placebo. The TAM group will take 20 mg TAM orally daily and apply gel placebo. The last dose of study medication will be used on the morning of the day prior to surgery. Participants will be shipped two 100 ml canisters of 4‐OHT or placebo gel plus 130 capsules of tamoxifen or oral placebo at the time of randomization. Participants will take study agents for 4‐10 week (minimum). However, if surgery needs to be delayed beyond the 8 week study period for clinical reasons (eg scheduling with plastic surgery) the participant will be sent additional medication by mail to allow continuation of therapy until the day before surgery up to a maximum duration of 10 weeks. On the day prior to surgery, baseline assessments will be repeated (with the exception of menopausal determination and tamoxifen metabolism gene polymorphisms, but with the addition of blood draw for tamoxifen metabolites and E and Z 4‐OHT isomer determination). Under unavoidable circumstances, the end of intervention visit will be allowed on the day of surgery prior to TSE. During the TSE breast adipose tissue from the surgical sample will be snap frozen and stored at ‐800C for measurement of TAM metabolites. The paraffin block of the DCNB and TSE samples will be acquired by the recruiting institution and 10 sect ons from each specimen submitted to the NU Pathology Core Facility (NU PCF). The sections will be cut in batches (with pre‐ and post‐samples in the same batch), shipped cold, and processed for immunohistochemistry within a week of sectioning. Compliance assessment will occur through patient diaries, pill counts and the weighing of returned drug (gel) canisters. Patients will be assessed for adverse events at the post‐surgical visit (approximately 7‐14 days after surgery) and by phone at 30 days following the last dose of study agent.
AN  - CN-01525179
AU  - Nct
KW  - Afimoxifene
Breast Neoplasms
Carcinoma
Carcinoma in Situ
Carcinoma, Ductal, Breast
Carcinoma, Intraductal, Noninfiltrating
Citric Acid
Tamoxifen
PY  - 2009
ST  - 4-Hydroxytamoxifen or Tamoxifen Citrate in Treating Women With Newly Diagnosed Ductal Breast Carcinoma in Situ
T2  - https://clinicaltrials.gov/show/NCT00952731
TI  - 4-Hydroxytamoxifen or Tamoxifen Citrate in Treating Women With Newly Diagnosed Ductal Breast Carcinoma in Situ
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01525179/full
ID  - 1444
ER  - 

TY  - JOUR
AB  - The 5,10-methylenetetrahydrofolate reductase (MTHFR) gene plays a critical role in folate metabolism. Studies on the association between MTHFR polymorphisms and length changes in short tandem repeat DNA sequences [microsatellite instability (MSI)] are inconsistent. Using data from colon cancer cases (n = 503) enrolled as part of an existing population-based case-control study, we investigated the association between MTHFR 677 and MTHFR 1298 polymorphisms and MSI. We also examined whether the association was modified by folate intake. Participants were case subjects enrolled as part of the North Carolina Colon Cancer Study. Consenting cases provided information about lifestyle and diet during in-home interviews as well as blood specimens and permission to obtain tumor blocks. DNA from normal and tumor tissue sections was used to determine microsatellite status (MSI). Tumors were classified as MSI if two or more microsatellite markers (BAT25, BAT26, D5S346, D2S123, and D17S250) had changes in the number of DNA sequence repeats compared with matched nontumor tissue. Tumors with one positive marker (MSI-low) or no positive markers (microsatellite stable) were grouped together as non-MSI tumors (microsatellite stable). MTHFR 677 and MTHFR 1298 genotypes were determined by real-time PCR using the 5′ exonuclease (Taqman) assay. Logistic regression was used to calculate odds ratio (OR) and 95% confidence intervals (95% CI). MSI was more common in proximal tumors (OR, 3.8; 95% CI, 1.7-8.4) and in current smokers (OR, 4.0; 95% CI, 1.6-9.7). Compared with MTHFR 677 CC referent, MTHFR 677 CT/TT genotype was inversely associated with MSI among White cases (OR, 0.36; 95% CI, 0.16-0.81) but not significant among African Americans. Although not statistically significant, a similar inverse association was observed between MTHFR 677 CT/TT genotype and MSI among the entire case subjects (OR, 0.54; 95% CI, 0.26-1.10). Among those with adequate folate intake (>400 μg total folate), we found strong inverse associations between combined MTHFR genotypes and MSI (677 CC + 1298 AC/CC, OR, 0.09; 95% CI, 0.01-0.59; 677 CT/TT + 1298 AA, OR, 0.13; 95% CI, 0.02-0.85) compared with the combined wild-type genotypes (677 CC + 1298 AA). This protective effect was not evident among those with low folate (<400 μg total folate) intake. Our results suggest that MTHFR variant genotypes are associated with reduced risk of MSI tumors under conditions of adequate folate intake, although the data are imprecise due to small numbers. These results indicate that the relationship between MTHFR genotypes and MSI is influenced by folate status. Copyright © 2005 American Association for Cancer Research.
AD  - T.O. Keku, Center for Gastrointestinal Biology and Disease, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7555, United States
AU  - Eaton, A. M.
AU  - Sandler, R.
AU  - Carethers, J. M.
AU  - Millikan, R. C.
AU  - Galanko, J.
AU  - Keku, T. O.
DB  - Embase
Medline
DO  - 10.1158/1055-9965.EPI-05-0131
IS  - 8
KW  - 5,10 methylenetetrahydrofolate reductase (FADH2)
folic acid
microsatellite DNA
phosphodiesterase I
adult
African American
aged
article
bioassay
blood analysis
cancer risk
case control study
Caucasian
clinical study
colon cancer
controlled study
diet
DNA sequence
female
folate metabolism
gene
genetic association
genetic polymorphism
genotype
human
human tissue
lifestyle
logistic regression analysis
major clinical study
male
microsatellite instability
microsatellite marker
MTHFR gene
population research
priority journal
real time polymerase chain reaction
short tandem repeat
smoking
vitamin intake
Taqman
LA  - English
M3  - Article
N1  - L41161218
2005-09-20
PY  - 2005
SN  - 1055-9965
SP  - 2023-2029
ST  - 5,10-Methylenetetrahydrofolate reductase 677 and 1298 polymorphisms, folate intake, and microsatellite instability in colon cancer
T2  - Cancer Epidemiology Biomarkers and Prevention
TI  - 5,10-Methylenetetrahydrofolate reductase 677 and 1298 polymorphisms, folate intake, and microsatellite instability in colon cancer
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L41161218&from=export
http://dx.doi.org/10.1158/1055-9965.EPI-05-0131
VL  - 14
ID  - 1262
ER  - 

TY  - JOUR
AB  - OBJECTIVE: To evaluate efficacy, endometrial safety, and overall safety of a single‐capsule 17b‐estradiol‐progesterone (TX‐001HR) for treating menopausal moderate‐to‐severe vasomotor symptoms. METHODS: REPLENISH was a phase 3, 12‐month, randomized, double‐blind, placebo‐controlled, multicenter trial. Women (aged 40‐65 years) with vasomotor symptoms and a uterus were randomized to daily estradiol (mg)‐progesterone (mg) (1/100, 0.5/100, 0.5/50, or 0.25/50), and women in the vasomotor symptoms substudy (women with moderate‐to‐severe hot flushes [seven or greater per day or 50 or greater per week]) to those estradiol‐progesterone doses or placebo. The primary safety endpoint was endometrial hyperplasia incidence at 12 months in all women (the total population), and the primary efficacy endpoints were frequency and severity changes (from daily diaries) in moderate‐to‐severe vasomotor symptoms with estradiol‐progesterone compared with placebo at weeks 4 and 12 in the vasomotor symptoms substudy. A sample size of 250 women in each active treatment arm with two or less endometrial hyperplasia cases would result in 1% or less annual incidence (upper bound 2.5% or less, one‐sided 95% CI). RESULTS: One thousand eight hundred forty‐five women were enrolled and randomized from August 2013 to October 2015; 1,835 received medication (safety population); 1,255 were eligible for the endometrial safety population; 726 comprised the vasomotor symptoms substudy; their mean age and body mass index were 55 years and 27, respectively; one third were African American. No endometrial hyperplasia was found. Frequency and severity of vasomotor symptoms significantly decreased from baseline with 1 mg estradiol and 100 mg progesterone and 0.5 mg estradiol and 100 mg progesterone compared with placebo at week 4 (frequency: by 40.6 and 35.1 points [1 mg and 100 mg and 0.5 mg and 100 mg, respectively] vs 26.4 points [placebo]; severity: by 0.48 and 0.51 vs 0.34 points) and week 12 (by 55.1 and 53.7 vs 40.2; severity: by 1.12 and 0.90 vs 0.56); 0.5 mg estradiol and 50 mg progesterone improved (P,.05) frequency and severity at week 12, and 0.25 mg estradiol and 50 mg progesterone frequency but not severity at weeks 4 and 12. CONCLUSION: No endometrial hyperplasia was observed while single‐capsule estradiol‐progesterone provided clinically meaningfully improvements in moderate‐to‐severe vasomotor symptoms. This estradiol‐progesterone formulation may represent a new option, using naturally occurring hormones, for the estimated millions of women using nonregulatoryapproved, compounded hormone therapy.
AN  - CN-01935305
AU  - Lobo, R. A.
AU  - Archer, D. F.
AU  - Kagan, R.
AU  - Kaunitz, A. M.
AU  - Constantine, G. D.
AU  - Pickar, J. H.
AU  - Graham, S.
AU  - Bernick, B.
AU  - Mirkin, S.
DO  - 10.1097/AOG.0000000000002645
IS  - 1
KW  - *drug efficacy
*drug safety
*postmenopause
*vasomotor system
Acute pancreatitis /side effect
Adult
African American
Age
Aged
Amenorrhea
Body height
Body mass
Body weight
Breast cancer
Breast tenderness /side effect
Bypass surgery
Chronic obstructive lung disease
Clinical Global Impression scale
Conference paper
Controlled study
Deep vein thrombosis /side effect
Disease severity
Drug capsule
Efficacy parameters
Endometrium
Endometrium biopsy
Endometrium hyperplasia
Endometrium polyp
Family history
Female
Follitropin blood level
Headache /side effect
Hot flush
Human
Incidence
Intention to treat analysis
Major clinical study
Multicenter study
Nausea /side effect
Ovariectomy
Patient referral
Pelvic pain /side effect
Phase 3 clinical trial
Priority journal
Randomized controlled trial
Symptom
Uterus
Vagina bleeding /side effect
Vagina discharge /side effect
Vein thrombosis
M3  - Journal: Conference Paper
PY  - 2018
SP  - 161‐170
ST  - A 17β-estradiol-progesterone oral capsule for vasomotor symptoms in postmenopausal women a randomized controlled trial
T2  - Obstetrics and gynecology
TI  - A 17β-estradiol-progesterone oral capsule for vasomotor symptoms in postmenopausal women a randomized controlled trial
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01935305/full
VL  - 132
ID  - 1599
ER  - 

TY  - JOUR
AB  - Objective: Rare disease Background: Papillary renal cell carcinoma (PRCC) is a rare disease and is a carcinoma of the renal tubular epithelium, comprising only 10-15% of all renal cell carcinoma cases. The majority of cases occur in the sixth decade of life. PRCC rarely occurs before the fourth decade in the absence of family history. This paper describes an aggressive, sporadic case of PRCC in a 20-year-old female without family history and no risk factors. Case Report: A 20-year-old African American female was admitted for hemoptysis with elevated blood pressure and was found to have left peri-hilar opacification on chest X-ray. Further radiological studies led to the discovery of a large complex left renal lesion within the collecting system, infiltrating the renal artery and causing severe hydronephrosis with para-aortic lymphadenopathy. An MRI also showed signal heterogeneity in the L2 and L3 vertebrae. Biopsies of the left renal mass and a right endobronchial lesion confirmed metastatic PRCC. Treatment was commenced with a tyrosine kinase inhibitor. Within a few weeks, the vertebral metastatic lesions progressed to cause spinal compression. After targeted radiotherapy, the patient was referred to Memorial Sloan Kettering Cancer Center for enrolment in a clinical trial. Conclusions: PRCC rarely occurs in the second decade of life and even then, most such early cases occur in family clusters. PRCC also has a relatively benign course, constituting less than 10% of all metastatic renal cell carcinomas, further making this case a unique presentation. © Am J Case Rep, 2014.
AD  - Department of Medicine, Lincoln Medical and Mental Health Center, Bronx, NY, United States
AU  - Olaniran, K.
AU  - Cheng, W.
AU  - Pulinthanathu, R.
DB  - Scopus
DO  - 10.12659/AJCR.890424
KW  - Carcinoma, Renal Cell
Hemoptysis
Hydronephrosis
Neoplasm Metastasis
M3  - Article
N1  - Cited By :2
Export Date: 22 March 2021
PY  - 2014
SP  - 254-257
ST  - A 20-year-old female with hemoptysis and high blood pressure: An unusual case of papillary renal cell carcinoma
T2  - American Journal of Case Reports
TI  - A 20-year-old female with hemoptysis and high blood pressure: An unusual case of papillary renal cell carcinoma
UR  - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84902590317&doi=10.12659%2fAJCR.890424&partnerID=40&md5=f57dca6565fc8b5455965da1714e3ef7
VL  - 15
ID  - 2393
ER  - 

TY  - JOUR
AB  - Background: The 21-gene recurrence score (RS) assay is retrospectively validated for assessing prognosis and benefit from chemotherapy in hormone receptor-positive, early-stage breast cancer (EBC) with low RS. We hypothesized that oncologists have already incorporated the RS assay for decision-making in higher-risk, node-positive disease, despite the lack of prospective data and contrary to NCCN Guideline recommendations. This study provides the first analysis of trends and differences in RS use and therapeutic implications in a population-based data set of patients with node-positive EBC. It also assesses the impact of the RxPONDER trial on clinicians' chemotherapy recommendations. Methods: Node-positive EBC cases diagnosed during 2010 through 2012 and included in the National Cancer Data Base were used. Multivariate logistic regression was used to estimate test use and impact on chemotherapy recommendations. Results: The RS assay was ordered for 16.5% of the 80,405 identified patients. Of all variables, the RS assay had the strongest association with chemotherapy recommendation, with adjusted odds ratios (AORs) of 19 for scores >30. Odds of chemotherapy recommendation were significantly lower for the group who received the test (AOR, 0.21; 95% CI, 0.20-0.22). When divided based on the cutoff point of 25 adopted by the RxPONDER trial, those with an RS of 18 to 25 had significantly lower odds of chemotherapy recommendation compared with those with an RS of 26 to 30 (AOR, 0.32; 95% CI, 0.26-0.40). Test use was lower for blacks, community centers, uninsured/governmentally insured patients, higher tumor grade, larger tumor size, and more nodes involved. Chemotherapy recommendation was higher for patients of younger age, with private insurance, and with higher tumor grade, size, and number of nodes involved. Black patients had significantly higher RS (AOR, 1.37; 95% CI, 1.25-1.79). Conclusions: The RS assay influences clinicians' chemotherapy recommendation in node-positive EBC. Clinicians are using the inclusion criteria of the RxPONDER trial before its final release. Black patients have higher RS, likely representing worse biology. Significant differences exist in test use and clinical implications based on race, insurance, and facility.
AD  - Departments of Internal Medicine, University of Colorado, Aurora, Colorado
Departments of Radiation Oncology, University of Colorado, Aurora, Colorado
Departments of Internal Medicine, Division of Medical Oncology, University of Colorado, Aurora, Colorado
AN  - 28404760
AU  - Jasem, J.
AU  - Fisher, C. M.
AU  - Amini, A.
AU  - Shagisultanova, E.
AU  - Rabinovitch, R.
AU  - Borges, V. F.
AU  - Elias, A.
AU  - Kabos, P.
DA  - Apr
DO  - 10.6004/jnccn.2017.0049
DP  - NLM
ET  - 2017/04/14
IS  - 4
KW  - Adult
Aged
Aged, 80 and over
Biomarkers, Tumor
Breast Neoplasms/*diagnosis/*drug therapy/epidemiology/genetics
Chemotherapy, Adjuvant
Clinical Decision-Making
Clinical Trials as Topic
Comorbidity
Female
Gene Expression Profiling/*methods
Humans
Lymphatic Metastasis
Male
Middle Aged
Neoplasm Grading
Neoplasm Recurrence, Local
Neoplasm Staging
Odds Ratio
Prognosis
Retrospective Studies
Risk Factors
LA  - eng
N1  - 1540-1413
Jasem, Jagar
Fisher, Christine M
Amini, Arya
Shagisultanova, Elena
Rabinovitch, Rachel
Borges, Virginia F
Elias, Anthony
Kabos, Peter
Journal Article
United States
J Natl Compr Canc Netw. 2017 Apr;15(4):494-503. doi: 10.6004/jnccn.2017.0049.
PY  - 2017
SN  - 1540-1405
SP  - 494-503
ST  - The 21-Gene Recurrence Score Assay for Node-Positive, Early-Stage Breast Cancer and Impact of RxPONDER Trial on Chemotherapy Decision-Making: Have Clinicians Already Decided?
T2  - J Natl Compr Canc Netw
TI  - The 21-Gene Recurrence Score Assay for Node-Positive, Early-Stage Breast Cancer and Impact of RxPONDER Trial on Chemotherapy Decision-Making: Have Clinicians Already Decided?
VL  - 15
ID  - 173
ER  - 

TY  - JOUR
AB  - Other-cause mortality should have decreased over time in patients with prostate cancer as patient selection for diagnosis and treatment may have improved. We tested this hypothesis in 367,884 patients with prostate cancer treated with radical prostatectomy or radiotherapy within the Surveillance, Epidemiology, and End Results database and observed important other-cause mortality reduction over the last 25 years.
AD  - S. Knipper, Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Martinistraße 52, Hamburg, Germany
AU  - Knipper, S.
AU  - Pecoraro, A.
AU  - Palumbo, C.
AU  - Rosiello, G.
AU  - Luzzago, S.
AU  - Tian, Z.
AU  - Briganti, A.
AU  - Saad, F.
AU  - Tilki, D.
AU  - Graefen, M.
AU  - Karakiewicz, P. I.
DB  - Embase
Medline
DO  - 10.1016/j.clgc.2019.07.008
IS  - 5
KW  - adult
African American
aged
article
cancer radiotherapy
cancer survival
Caucasian
cause of death
external beam radiotherapy
follow up
Hispanic
human
major clinical study
male
mortality
patient selection
prostate cancer
prostatectomy
trend study
LA  - English
M3  - Article
N1  - L2002547992
2019-08-14
2019-10-16
Background: We examined the changes over time in other-cause mortality (OCM) rates in patients with clinically localized prostate cancer (PCa) as an indicator of patient selection. Patients and Methods: Within the Surveillance, Epidemiology, and End Results database (1987-2011), we identified patients with PCa treated with either radical prostatectomy (RP) (n = 230,969; 62.8%) or external beam radiation therapy (EBRT) (n = 136,915; 37.2%). Temporal trends and multivariable Cox regression analyses assessed OCM at 5 years using stratification according to year of diagnosis (1987-1991 vs. 1992-1996 vs. 1997-2001 vs. 2002-2006 vs. 2007-2011), age group, and ethnicity. Results: In patients who had undergone RP, the OCM rates at 5 years of follow-up decreased over time from 7.9% to 2.4% (slope, −0.25%/year) versus from 15.2% to 9.9% after EBRT (slope, −0.29%/year). The greatest decrease in 5-year OCM rates over time was recorded in patients ≥ 75 years (16.0%-12.0%; slope, −0.25%/year), followed by younger age categories (70-74 years, −0.21%/year; 65-69 years, −0.17%/year; 60-64 years, −0.10%/year; < 60 years, −0.07%/year), as well as in African-American men (11.0%-5.1%; slope, −0.32%/year), followed by Caucasian (7.6%-3.4%; slope, −0.21%/year) and Hispanic men (7.0%-3.1%; slope, −0.20%/year; all P <.001), as corroborated in multivariable Cox regression models. Conclusions: OCM rates were highest in oldest individuals and in African-American men. In both groups, an important 5-year OCM reduction over the 25-year study span was recorded. Nonetheless, these 2 patient groups may still represent the ideal target for better patient selection based on OCM considerations, because their most recent OCM rates exceeded those of, respectively, younger and Caucasian patients.
PY  - 2019
SN  - 1938-0682
1558-7673
SP  - 395-401
ST  - A 25-year Period Analysis of Other-cause Mortality in Localized Prostate Cancer
T2  - Clinical Genitourinary Cancer
TI  - A 25-year Period Analysis of Other-cause Mortality in Localized Prostate Cancer
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L2002547992&from=export
http://dx.doi.org/10.1016/j.clgc.2019.07.008
VL  - 17
ID  - 838
ER  - 

TY  - JOUR
AB  - P001 - Sepsis impairs the capillary response within hypoxic capillaries and decreases erythrocyte oxygen-dependent ATP efflux R. M. Bateman, M. D. Sharpe, J. E. Jagger, C. G. Ellis P002 - Lower serum immunoglobulin G2 level does not predispose to severe flu. J. Solé-Violán, M. López-Rodríguez, E. Herrera-Ramos, J. Ruíz-Hernández, L. Borderías, J. Horcajada, N. González-Quevedo, O. Rajas, M. Briones, F. Rodríguez de Castro, C. Rodríguez Gallego P003 - Brain protective effects of intravenous immunoglobulin through inhibition of complement activation and apoptosis in a rat model of sepsis F. Esen, G. Orhun, P. Ergin Ozcan, E. Senturk, C. Ugur Yilmaz, N. Orhan, N. Arican, M. Kaya, M. Kucukerden, M. Giris, U. Akcan, S. Bilgic Gazioglu, E. Tuzun P004 - Adenosine a1 receptor dysfunction is associated with leukopenia: A possible mechanism for sepsis-induced leukopenia R. Riff, O. Naamani, A. Douvdevani P005 - Analysis of neutrophil by hyper spectral imaging - A preliminary report R. Takegawa, H. Yoshida, T. Hirose, N. Yamamoto, H. Hagiya, M. Ojima, Y. Akeda, O. Tasaki, K. Tomono, T. Shimazu P006 - Chemiluminescent intensity assessed by eaa predicts the incidence of postoperative infectious complications following gastrointestinal surgery S. Ono, T. Kubo, S. Suda, T. Ueno, T. Ikeda P007 - Serial change of c1 inhibitor in patients with sepsis – A prospective observational study T. Hirose, H. Ogura, H. Takahashi, M. Ojima, J. Kang, Y. Nakamura, T. Kojima, T. Shimazu P008 - Comparison of bacteremia and sepsis on sepsis related biomarkers T. Ikeda, S. Suda, Y. Izutani, T. Ueno, S. Ono P009 - The changes of procalcitonin levels in critical patients with abdominal septic shock during blood purification T. Taniguchi, M. O P010 - Validation of a new sensitive point of care device for rapid measurement of procalcitonin C. Dinter, J. Lotz, B. Eilers, C. Wissmann, R. Lott P011 - Infection biomarkers in primary care patients with acute respiratory tract infections – Comparison of procalcitonin and C-reactive protein M. M. Meili, P. S. Schuetz P012 - Do we need a lower procalcitonin cut off? H. Hawa, M. Sharshir, M. Aburageila, N. Salahuddin P013 - The predictive role of C-reactive protein and procalcitonin biomarkers in central nervous system infections with extensively drug resistant bacteria V. Chantziara, S. Georgiou, A. Tsimogianni, P. Alexandropoulos, A. Vassi, F. Lagiou, M. Valta, G. Micha, E. Chinou, G. Michaloudis P014 - Changes in endotoxin activity assay and procalcitonin levels after direct hemoperfusion with polymyxin-b immobilized fiber A. Kodaira, T. Ikeda, S. Ono, T. Ueno, S. Suda, Y. Izutani, H. Imaizumi P015 - Diagnostic usefullness of combination biomarkers on ICU admission M. V. De la Torre-Prados, A. Garcia-De la Torre, A. Enguix-Armada, A. Puerto-Morlan, V. Perez-Valero, A. Garcia-Alcantara P016 - Platelet function analysis utilising the PFA-100 does not predict infection, bacteraemia, sepsis or outcome in critically ill patients N. Bolton, J. Dudziak, S. Bonney, A. Tridente, P. Nee P017 - Extracellular histone H3 levels are inversely correlated with antithrombin levels and platelet counts and are associated with mortality in sepsis patients G. Nicolaes, M. Wiewel, M. Schultz, K. Wildhagen, J. Horn, R. Schrijver, T. Van der Poll, C. Reutelingsperger P018 - Il-8: is this a more reliable biomarker for sepsis severity than CRP, Procalcitonin, E-selectin, IL-6 and TNF-[alpha] S. Pillai, G. Davies, G. Mills, R. Aubrey, K. Morris, P. Williams, P. Evans P019 - Relation between adrenomedullin and short-term outcome in ICU patients: Results from the frog ICU study E. G. Gayat, J. Struck, A. Cariou, N. Deye, B. Guidet, S. Jabert, J. Launay, M. Legrand, M. Léone, M. Resche-Rigon, E. Vicaut, A. Vieillard-Baron, A. Mebazaa P020 - Impact of disease severity assessment on performance of heparin-binding protein for the prediction of septic shock R. Arnold, M. Capan, A. Linder, P. Akesson P021 - Kinetics and prognostic value of presepsin (sCD14) in septic patients. A pilot study M. Popescu, D. Tomescu P022 - Comparison of CD64 levels performed by the facs and accellix systems C. L. Sprung, R. Calderon Morales, G. Munteanu, E. Orenbuch-Harroch, P. Levin, H. Kasdan, A. Reiter, T. Volker, Y. Himmel, Y. Cohen, J. Meissonnier P023 - Diagnosing sepsis in 5 minutes: Nanofluidic technology study with pancreatic-stone protein (PSP/ reg) L. Girard, F. Rebeaud P024 - How nanotechnology-based approaches could contribute to sepsis prevention, diagnosis and treatment I. Herrmann P025 - Il7r transcriptional expression analysis during septic shock B. Delwarde, E. Peronnet, E. Cerrato, F. Venet, A. Lepape, T. Rimmelé, G. Monneret, J. Textoris P026 - Disbalance of microbial metabolites of aromatic acids affects the severity in critically ill patients N. Beloborodova, V. Moroz, A. Osipov, A. Bedova, Y. Sarshor, A. Pautova, A. Sergeev, E. Chernevskaya P027 - Copeptin predicts 10-year all-cause mortality in community patients J. Odermatt, R. Bolliger, L. Hersberger, M. Ottiger, M. Christ-Crain, B. Mueller, P. Schuetz P028 - Identification of differential proteomic response in septic patients secondary to community and hospital acquired pneumonia N. K. Sharma, A. K. Tashima, M. K. Brunialti, F. R. Machado, M. Assuncao, O. Rigato, R. Salomao P029 - Monocyte HLA-DR expression in community-acquired bacteremic sepsis - dynamics associated to aetiology and prediction of secondary sepsis S. C. Cajander, G. Rasmussen, E. Tina, B. Söderquist, J. Källman, K. Strålin P030 - Soluble B- and T-lymphocyte attenuator: A possible prognostic marker in sepsis A. L. Lange, J. S. Sundén-Cullberg, A. M. Magnuson, O. H. Hultgren P031 - Fractal dimension: A new biomarker for quantifying clot microstructure in patients across the sepsis spectrum G. Davies, S. Pillai, G. Mills, R. Aubrey, K. Morris, P. Williams, P. Evans P032 - Comparison between the new biomarker for coagulation, clot microstructure (Df) with rotational thromboelastometry (ROTEM) in patients across the sepsis spectrum S. Pillai, G. Davies, G. Mills, R. Aubrey, K. Morris, P. Williams, P. Evans P033 - Changes in fibrinolysis across the sepsis spectrum: The use of rotational thromboelastometry (ROTEM) lysis index (LI60) and D-Dimer concentration S. Pillai, G. Davies, G. Mills, R. Aubrey, K. Morris, P. Williams, P. Evans P034 - The intensive care infection score – a promising marker for the prediction of infection and its severity. P. Van der Geest, M. Mohseni, J. Linssen, R. De Jonge, S. Duran, J. Groeneveld P035 - Challenges in the clinical diagnosis of sepsis R. Miller III, B. K. Lopansri, L. C. McHugh, A. Seldon, J. P. Burke P036 - Does zero heat flux thermometry more accurately identify sepsis on intensive care? J. Johnston, R. Reece-Anthony, A. Bond, A. Molokhia P037 - Advancing quality (AQ) sepsis programme: Improving early identification & treatment of sepsis in North West England. C. Mcgrath, E. Nsutebu P038 - Prehospital transport of acute septic patients P. Bank Pedersen, D. Pilsgaard Henriksen, S. Mikkelsen, A. Touborg Lassen P039 - Vasodilatory plant extracts gel as an alternative treatment for fever in critically ill patients R. Tincu, C. Cobilinschi, D. Tomescu, Z. Ghiorghiu, R. Macovei P040 - Host response and outcome of hypothermic sepsis M. A. Wiewel, M. B. Harmon, L. A. Van Vught, B. P. Scicluna, A. J. Hoogendijk, J. Horn, A. H. Zwinderman, O. L. Cremer, M. J. Bonten, M. J. Schultz, T. Van der Poll, N. P. Juffermans, W. J. Wiersinga P041 - Septic shock alert over SIRS criteria has an impact on outcome but needs to be revised G. Eren, Y Tekdos, M. Dogan, O. Acicbe, E. Kaya, O. Hergunsel P042 - Association between previous prescription of βblockers and mortality rate among septic patients: A retrospective observational study S. Alsolamy, G. Ghamdi, L. Alswaidan, S. Alharbi, F. Alenezi, Y. Arabi P043 - Recognition and treatment of sepsis on labour ward– teaching & information resources can improve knowledge J. Heaton, A. Boyce, L. Nolan, J. Johnston, A. Dukoff-Gordon, A. Dean, A. Molokhia P044 - Culture negative sepsis in the ICU – what is unique to this patient population? T. Mann Ben Yehudah P045 - Organ dysfunction in severe sepsis patients identified in administrative data in Germany, 2007-2013 C. Fleischmann, D. Thomas-Rueddel, C. Haas, U. Dennler, K. Reinhart P046 - A comparison of residents’ knowledge regarding; the Surviving Sepsis Campaign 2012 guideline O. Suntornlohanakul, B. Khwannimit P047 - Effectiveness of a septic shock bundle to improve outcomes in the ICU F. Breckenridge, A. Puxty P048 - Dose of norepinephrine in the first 24 hours as a parameter evaluating the effectiveness of treatment in patients with severe sepsis and septic shock P. Szturz, P. Folwarzcny, J. Svancara, R. Kula, P. Sevcik P049 - Norepinephrine or vasopressin + norepinephrine in septic shock. A retrospective series of 39 patients L. Caneva, A. Casazza, E. Bellazzi, S. Marra, L. Pagani, M. Vetere, R. Vanzino, D. Ciprandi, R. Preda, R. Boschi, L. Carnevale P050 - Methylene blue effectiveness as contributory treatment in patients with septic shock V. Lopez, M. Aguilar Arzapalo, L. Barradas, A. Escalante, J. Gongora, M. Cetina P051 - Coagulation disorders in patients with severe sepsis and DIC evaluated with thromboelastometry. B Adamik, D Jakubczyk, A Kübler P052 - Frequency and outcome of early sepsis-associated coagulopathy A. Radford, T. Lee, J. Singer, J. Boyd, D. Fineberg, M. Williams, J. Russell P053 - Assessment of coagulopathy in cancer patients with severe sepsis or septic shock. A case-control pilot study E. Scarlatescu, D. Tomescu, G. Droc, S. Arama P054 - Thromboelastometry in critically ill patients with disseminated intravascular coagulation M. Müller, M. Straat, S. S. Zeerleder, N. P. Juffermans P055 - Cessation of a preexisting chronic antiplatelet therapy is associated with increased mortality rates in severe sepsis and septic shock C. F. Fuchs, C. S. Scheer, S. W. Wauschkuhn, M. V. Vollmer, K. M. Meissner, S. K. Kuhn, K. H. Hahnenkamp, S. R. Rehberg, M. G. Gründling P056 - Neutrophil Extracellular Traps (NETs) production under hypoxic condition N. Yamamoto, M. Ojima, S. Hamaguchi, T. Hirose, Y. Akeda, R. Takegawa, O. Tasaki, T. Shimazu, K. Tomono P057 - Impact of ultraviolet air sterilizer in intensive care unit room, and clinical outcomes of patients E. Gómez-Sánchez, M. Heredia-Rodríguez, E. Álvarez-Fuente, M. Lorenzo-López, E. Gómez-Pesquera, M. Aragón-Camino, P. Liu-Zhu, A. Sánchez-López, A. Hernández-Lozano, M. T. Peláez-Jareño, E. Tamayo P058 - Focus of infection in severe sepsis - comparison of administrative data and prospective cohorts from Germany D. O. Thomas-Rüddel, C. Fleischmann, C. Haas, U. Dennler, K. Reinhart P059 - “Zero CLABSI” – can we get there? Obstacles on the 4 year journey and our strategies to overcome them – experience from an Indian ICU V. Adora, A. Kar, A. Chakraborty, S. Roy, A. Bandyopadhyay, M. Das P060 - Novel molecular techniques to identify central venous catheter (CVC) associated blood stream infections (BSIs) T. Mann Ben Yehudah, G. Ben Yehudah, M. Salim, N. Kumar, L. Arabi, T. Burger, P. Lephart, E. Toth-martin P061 - Zero clabsi” – can we get there? Obstacles on the 4 year journey and our strategies to overcome them – experience from an Indian ICU R. Rao, A. Kar, A. Chakraborty P062 - Prevention of central line-associated bloodstream infections in intensive care units: An international online survey C. Valencia, N. Hammami, S. Blot, J. L. Vincent, M. L. Lambert P063 - 30 days antimicrobial efficacy of non-leaching central venous catheters J. Brunke, T. Riemann, I. Roschke P064 - Efficacy of noble metal alloy-coated catheter in prevention of bacteriuria R. Tincu, C. Cobilinschi, D. Tomescu, Z. Ghiorghiu, R. Macovei P065 - Predicting bacteremic urinary tract infection in community setting: A prospective observational study S. Nimitvilai, K. Jintanapramote, S. Jarupongprapa P066 - Eight-year analysis of acinetobacter spp. monobacteremia in surgical and medical intensive care units at university hospital in Lithuania D. Adukauskiene, D. Valanciene P067 - Group A and group B streptococcal infections in intensive care unit – our experience in a tertiary centre G. Bose, V. Lostarakos, B. Carr P068 - Improved detection of spontaneous bacterial peritonitis by uritop + tm strip test and inoculation of blood culture bottles with ascitic fluid S. Khedher, A. Maaoui, A. Ezzamouri, M. Salem P069 - Increased risk of cellulitis in patients with congestive heart failure: a population based cohort study J. Chen P070 - Outcomes of severe cellulitis and necrotizing fasciitis in the critically ill D. R. Cranendonk, L. A. Van Vught, M. A. Wiewel, O. L. Cremer, J. Horn, M. J. Bonten, M. J. Schultz, T. Van der Poll, W. J. Wiersinga P071 - Botulism outbreak associated with people who inject drugs (PWIDs) in Scotland. M. Day, G. Penrice, K. Roy, P. Robertson, G. Godbole, B. Jones, M. Booth, L. Donaldson P072 - Surveillance of ESBL-producing enterobacteriaceae fecal carriers in the ICU Y. Kawano, H. Ishikura P073 - Prevalence of ESBL and carbapenemase producing uropathogens in a newly opened hospital in south India S. Sreevidya, N. Brahmananda Reddy, P. Muraray Govind, R. Pratheema, J. Devachandran Apollo Speciality Hospital - OMR, Chennai, India P074 - Prevalence, risk factors and outcomes of methicillin-resistant staphylococcus aureus nasal colonization in critically ill patients H. Al-Dorzi, M. Almutairi, B. Alhamadi, A. Crizaldo Toledo, R. Khan, B. Al Raiy, Y. Arabi P075 - Multidrug-resistant Acinetobacter baumannii infection in intensive care unit patients in a hospital with building construction: Is there an association? H. Talaie P076 - Multidrug-resistant organisms in a Dutch ICU J. A. Van Oers, A. Harts, E. Nieuwkoop, P. Vos P077 - Epidemiology and risk factors of ICU acquired infections caused by multidrug-resistant gram negative bacilli Y. Boussarsar, F. Boutouta, S. Kamoun, I. Mezghani, S. Koubaji, A. Ben Souissi, A. Riahi, M. S. Mebazaa P078 - Improving outcomes of severe infections by multidrug-resistant pathogens with polyclonal IgM-enriched immunoglobulins E. Giamarellos-Bourboulis, N. Tziolos, C. Routsi, C. Katsenos, I. Tsangaris, I. Pneumatikos, G. Vlachogiannis, V. Theodorou, A. Prekates, E. Antypa, V. Koulouras, N. Kapravelos, C. Gogos, E. Antoniadou, K. Mandragos, A. Armaganidis P079 - Must change the medical practice in ICU? A. R. Robles Caballero, B. Civantos, J. C. Figueira, J. López P080 - Mediterranean spotted fever in an infectious diseases intensive care unit A. Silva-Pinto, F. Ceia, A. Sarmento, L. Santos P081 - Clinical features and outcomes of patients with Middle East respiratory syndrome requiring admission to a saudi intensive care unit: A retrospective analysis of 31 cases G. Almekhlafi, Y. Sakr P082 - The ICU response to a hospital outbreak of Middle East respiratory syndrome coronavirus infection H. Al-Dorzi, R. Khan, S. Baharoon, A. Aldawood, A. Matroud, J. Alchin, S. Al Johani, H. Balkhy, Y. Arabi P083 - Middle East respiratory syndrome: Surveillance data analysis S. Alsolamy, S. Y. Yousif, B. O. Alotabi, A. S. Alsaawi P085 - Use of Taqman array card molecular diagnostics in severe pneumonia: A case series J. Ang, MD Curran, D. Enoch, V. Navapurkar, A. Conway Morris P086 - ‘BUNS’: An investigation protocol improves the ICU management of pneumonia R. Sharvill, J. Astin P087 - Pneumonia in patients following secondary peritonitis: epidemiological features and impact on mortality M. Heredia-Rodríguez, E. Gómez-Sánchez, M. T. Peláez-Jareño, E. Gómez-Pesquera, M. Lorenzo-López, P. Liu-Zhu, M. Aragón-Camino, A. Hernández-Lozano, A. Sánchez-López, E. Álvarez-Fuente, E. Tamayo P088 - The use of the “CURB-65 score” by emergency room clinicians in a large teaching hospital J. Patel, C. Kruger P089 - Incidence of community acquired pneumonia with viral infection in mechanically ventilated patients in the medical intensive care unit J. O’Neal, H. Rhodes, J. Jancik P090 - The SAATELLITE Study: Prevention of S aureus Nosocomial Pneumonia (NP) with MEDI4893, a Human Monoclonal Antibody (mAb) Against S aureus B. François, P. F. Laterre, P. Eggimann, A. Torres, M. Sánchez, P. F. Dequin, G. L. Bassi, J. Chastre, H. S. Jafri P091 - Risk factors and microbiological profile for nosocomial infections in trauma patients M. Ben Romdhane, Z. Douira, S. Kamoun, M. Bousselmi, A. Ben Souissi, Y. Boussarsar, A. Riahi, M.S. Mebazaa P092 - Correlation between percentages of ventilated patients developed vap and use of antimicrobial agents in ICU patients. A. Vakalos, V. Avramidis P093 - A comparison of two ventilator associated pneumonia surveillance techniques T. H. Craven, G. Wojcik, K. Kefala, J. McCoubrey, J. Reilly, R. Paterson, D. Inverarity, I. Laurenson, T. S. Walsh P094 - Lung ultrasound before and after fiberbronchoscopy - modifications may improve ventilator-associated pneumonia diagnosis S. Mongodi, B. Bouhemad, A. Orlando, A. Stella, G. Via, G. Iotti, A. Braschi, F. Mojoli P095 - Comparing the accuracy of predictors of mortality in ventilator-associated pneumonia M. Haliloglu, B. Bilgili, U. Kasapoglu, I. Sayan, M. Süzer Aslan, A. Yalcın, I. Cinel P096 - Impact of pRBCs transfusion on percentage of ventilated patients developed VAP in ICU patients A. Vakalos, V. Avramidis P097 - The impact of a series of interventions on the rate of ventilator associated pneumonia in a large teaching hospital H. E. Ellis, K. Bauchmuller, D. Miller, A Temple P098 - The EVADE study: Prevention of Nosocomial Pneumonia (NP) caused by P aeruginosa with MEDI3902, a Novel Bispecific Monoclonal Antibody, against P aeruginosa virulence factors J. Chastre, B. François, A. Torres, C. E. Luyt, M. Sánchez, M. Singer, H. S. Jafri P099 - Short-term inhaled colistin adjunctive therapy for ventilator-associated pneumonia Y. Nassar, M. S. Ayad P100 - Effect of aerosolised colistin on weaning from mechanical ventilation A. Trifi, S. Abdellatif, F. Daly, R. Nasri, S. Ben Lakhal P101 - Septic shock is an independent risk factor for colistin-induced severe acute kidney injury: a retrospective cohort study B. Bilgili, M. Haliloglu, F. Gul, I. Cinel P102 - Nosocomial pneumonia - emphasis on inhaled tobramycin A. Kuzovlev, A. Shabanov, S. Polovnikov, V. Moroz P103 - In vitro evaluation of amikacin inhale and commercial nebulizers in a mechanical ventilator N. Kadrichu, T. Dang, K. Corkery, P. Challoner P104 - The effects of nebulized amikacin/fosfomycin and systemic meropenem on severe amikacin-resistant meropenem-susceptible P.aeruginosa pneumonia G. Li Bassi, E. Aguilera, C. Chiurazzi, C. Travierso, A. Motos, L. Fernandez, R. Amaro, T. Senussi, F. Idone, J. Bobi, M. Rigol, A. Torres P105 - Optimization of gentamicin peak concentrations in critically ill patients C. J. Hodiamont, N. P. Juffermans, J. M. Janssen, C. S. Bouman, R. A. Mathôt, M. D. De Jong, R. M. Van Hest P106 - Systematic review of cefepime induced neurotoxicity L. Payne, G. L. Fraser P107 - Unasyn® causes QT prolongation during treatment of intensive care patients B. Tudor, M. Lahner, G. Roth, C. Krenn P108 - Comparative study between teicoplanin and vancomycin in methicillin-resistant staphylococcus aureus (mrsa) infectious of toxicological intensive care unit (ticu) patients – Tehran, Iran H. Talaie P109 - Phage therapy against antimicrobial resistance, design of the first clinical study phagoburn P. Jault, J. Gabard, T. Leclerc, S. Jennes, Y. Que, A. Rousseau, F. Ravat P110 - Antibiotic dosing errors in critically ill patients with severe sepsis or septic shock H. Al-Dorzi, A. Eissa, S. Al-Harbi, T. Aldabbagh, R. Khan, Y. Arabi P111 - Does empiric antifungal therapy improve survival in septic critically ill patients? (immunocompromised excluded) A. Trifi, S. Abdellatif, F. Daly, R. Nasri, S. Ben Lakhal P112 - Neurocysticercosis-Qatar experience F. Paramba, N. Purayil, V. Naushad, O. Mohammad, V. Negi, P. Chandra P113 - Early indicators in acute haemorrhagic shock A. Kleinsasser P114 - Filtering of red blood cells reduces the inflammatory response of pulmonary cells in an in vitro model of mechanical ventilation M. R. Witrz, J. F. Buchner-Doeven, A. M. Tuip-de Boer, J. C. Goslings, N. P. Juffermans P115 - Microparticles from red blood cell transfusion induce a pro-coagulant and pro-inflammatory endothelial cell response M. Van Hezel, M. Straat, A Boing, R Van Bruggen, N Juffermans P116 - The contribution of cytokines on thrombosis development during hospitalization in ICU D. Markopoulou, K. Venetsanou, V. Kaldis, D. Koutete, D. Chroni, I. Alamanos P117 - Prophylactic enoxaparin dosing and adjustment through anti-xa monitoring in an inpatient burn unit L. Koch, J. Jancik, H. Rhodes, E. Walter P118 - Determination of optimal cut-off values of haemoglobin, platelet count and fibrinogen at 24 hours after injury associated with mortality in trauma patients K. Maekawa, M. Hayakawa, S. Kushimoto, A. Shiraishi, H. Kato, J. Sasaki, H. Ogura, T. Matauoka, T. Uejima, N. Morimura, H. Ishikura, A. Hagiwara, M. Takeda P119 - Trauma-induced coagulopathy - prothrombin complex concentrate vs fresh frozen plasma O. Tarabrin, S. Shcherbakow, D. Gavrychenko, G. Mazurenko, V. Ivanova, O. Chystikov P120 - First study to prove the superiority of prothrombin complex concentrates on mortality rate over fresh frozen plasma in patients with acute bleeding C. Plourde, J. Lessard, J. Chauny, R. Daoust P121 - Prothrombin complex concentrate vs fresh frozen plasma in obstetric massive bleeding S. Shcherbakow, O. Tarabrin, D. Gavrychenko, G. Mazurenko, O. Chystikov P122 - Impact of FFP transfusion on VAP in ICU patients A. Vakalos, V. Avramidis P123 - Preoperative platelet function test and the thrombin generation assay are predictive for blood loss after cardiac surgery L. Kropman, L. In het Panhuis, J. Konings, D. Huskens, E. Schurgers, M. Roest, B. De Laat, M. Lance P124 - Rotational thromboelastometry versus standard coagulation tests before surgical interventions M. Durila, P. Lukas, M. Astraverkhava, J. Jonas P125 - Correction of impaired clot quality and stability by fibrinogen and activated prothrombin complex concentrate in a model of severe thrombocytopenia I. Budnik, B. Shenkman P126 - Assessment of point-of-care prothrombin time analyzer as a monitor after cardiopulmonary bypass H. Hayami, Y. Koide, T. Goto P127 - Disseminated intravascular coagulation (dic) is underdiagnosed in critically ill patients: do we need d-dimer measurements? R. Iqbal, Y. Alhamdi, N. Venugopal, S. Abrams, C. Downey, C. H. Toh, I. D. Welters P128 - Validity of the age-adjusted d-dimer cutoff in patients with COPD B. Bombay, J. M. Chauny, R. D. Daoust, J. L. Lessard, M. M. Marquis, J. P. Paquet P129 - A scoping review of strategies for prevention and management of bleeding following paediatric cardiopulmonary bypass surgery K. Siemens, D. Sangaran, B. J. Hunt, A. Durward, A. Nyman, I. A. Murdoch, S. M. Tibby P130 - Nadir hemoglobulin during cardiopulmonary bypass: impact on postoperative morbidity and mortality F. Ampatzidou, D. Moisidou, E. Dalampini, M. Nastou, E. Vasilarou, V. Kalaizi, H. Chatzikostenoglou, G. Drossos P131 - Red blood cell transfusion do not influence the prognostic value of RDW in critically ill patients S. Spadaro, A. Fogagnolo, T. Fiore, A. Schiavi, V. Fontana, F. Taccone, C. Volta P132 - Reasons for admission in the paediatric intensive care unit and the need for blood and blood products transfusions E. Chochliourou, E. Volakli, A. Violaki, E. Samkinidou, G. Evlavis, V. Panagiotidou, M. Sdougka P133 - The implementation of a massive haemorrhage protocol (mhp) for the management of major trauma: a ten year, single-centre study R. Mothukuri, C. Battle, K. Guy, G. Mills, P. Evans P134 - An integrated major haemorrhage protocol for pre-hospital and retrieval medical teams J. Wijesuriya, S. Keogh P135 - The impact of transfusion thresholds on mortality and cardiovascular events in patients with cardiovascular disease (non-cardiac surgery): a systematic review and meta-analysis A. Docherty, R. O’Donnell, S. Brunskill, M. Trivella, C. Doree, L. Holst, M. Parker, M. Gregersen, J. Almeida, T. Walsh, S. Stanworth P136 - The relationship between poor pre-operative immune status and outcome from cardiac surgery is specific to the peri-operative antigenic threat S. Moravcova, J. Mansell, A. Rogers, R. A. Smith, C. Hamilton-Davies P137 - Impact of simple clinical practice guidelines for reducing post-operative atrial fibrillation after cardiac surgery. A. Omar, M. Allam, O. Bilala, A. Kindawi, H. Ewila P138 - Dexamethasone administration during cardiopulmonary bypass has no beneficial effects on elective postoperative cardiac surgery patients F. Ampatzidou, D. Moisidou, M. Nastou, E. Dalampini, A. Malamas, E. Vasilarou, G. Drossos P139 - Intra-aortic balloon counterpulsation in patients undergoing cardiac surgery (IABCS): preliminary results G. Ferreira, J. Caldas, J. Fukushima, E. A. Osawa, E. Arita, L. Camara, S. Zeferino, J. Jardim, F. Gaioto, L. Dallan, F. B. Jatene, R. Kalil Filho, .F Galas, L. A. Hajjar P140 - Effects of low-dose atrial natriuretic peptide infusion on cardiac surgery-associated acute kidney injury C. Mitaka, T. Ohnuma, T. Murayama, F. Kunimoto, M. Nagashima, T. Takei, M. Tomita P141 - Acute kidney injury influence on high sensitive troponin measurements after cardiac surgery A. Omar, K. Mahmoud, S. Hanoura, S. Sudarsanan, P. Sivadasan, H. Othamn, Y. Shouman, R. Singh, A. Al Khulaifi P142 - Complex evaluation of endothelial dysfunction markers for prognosis of outcomes in patients undergoing cardiac surgery I. Mandel, S. Mikheev, I. Suhodolo, V. Kiselev, Y. Svirko, Y. Podoksenov P143 - New-onset atrial fibrillation in intensive care: incidence, management and outcome S. A. Jenkins, R. Griffin P144 - One single spot measurement of the sublingual microcirculation during acute pulmonary hypertension in a pig model of shock M. S. Tovar Doncel, A. Lima, C. Aldecoa, C. Ince P145 - Assessment of levosimendan as a therapeutic option to recruit the microcirculation in cardiogenic shock – initial experience in cardiac ICU A. Taha, A. Shafie, M. Mostafa, N. Syed, H. Hon P146 - Terlipressin vs. norepinephrine in the Potential Multiorgan Donor(PMD) F. Righetti, E. Colombaroli, G. Castellano P147 - Echocardiography in the potential heart donor exposed to substitution hormonotherapy F. Righetti, E. Colombaroli P148 - Machine learning can reduce rate of monitor alarms M. Hravnak, L. C. Chen, A. D. Dubrawski, G. C. Clermont, M. R. Pinsky P149 - Peripherally inserted central catheters placed in the ICU S. Gonzalez, D. Macias, J. Acosta, P. Jimenez, A. Loza, A. Lesmes, F. Lucena, C. Leon P150 - Recordings of abnormal central venous pressure waveform morphology during an episode of pulmonary hypertension in a porcine shock model M. S. Tovar Doncel, C. Ince, C. Aldecoa, A. Lima P151 - Ultrasound guided central venous access technique among French intensivists M. Bastide, J. Richecoeur, E. Frenoy, C. Lemaire, B. Sauneuf, F. Tamion, S. Nseir, D. Du Cheyron, H. Dupont, J. Maizel P152 - Predictive ability of the Pv-aCO2 gap in patients with shock M. Shaban, R. Kolko, N. Salahuddin, M. Sharshir, M. AbuRageila, A. AlHussain P153 - Comparison of echocardiography and pulmonary artery catheter measurements of hemodynamic parameters in critical ill patients P. Mercado, J. Maizel, L. Kontar, D. Titeca, F. Brazier, A. Riviere, M. Joris, T. Soupison, B. De Cagny, M. Slama P154 - The volume clamp method for noninvasive cardiac output measurement in postoperative cardiothoracic surgery patients: a comparison with intermittent pulmonary artery thermodilution J. Wagner, A. Körner, M. Kubik, S. Kluge, D. Reuter, B. Saugel P155 - Hemodynamic monitoring in patients with septic shock (SS) – CPCCO (continuous pulse contour cardiac output) vs. TEE (transesophageal echocardiography) E. Colombaroli, F. Righetti, G. Castellano P156 - Cardiac output measurement with transthoracic echocardiography in critically ill patients: a pragmatic clinical study T. Tran, D. De Bels, A. Cudia, M. Strachinaru, P. Ghottignies, J. Devriendt, C. Pierrakos P157 - Left ventricular outflow tract velocity time integral correlates with stroke volume index in mechanically ventilated patients Ó. Martínez González, R. Blancas, J. Luján, D. Ballesteros, C. Martínez Díaz, A. Núñez, C. Martín Parra, B. López Matamala, M. Alonso Fernández, M. Chana P158 - Transpulmonary thermodilution (TPTD) derived from femoral vs. jugular central venous catheter: validation of a previously published correction formula and a proprietary correction formula for global end-diastolic volume index (GEDVI) W. Huber, M. Eckmann, F. Elkmann, A. Gruber, I. Klein, R. M. Schmid, T. Lahmer P160 - Dynamic arterial elastance calculated with lidcoplus monitor does not predict changes in arterial pressure after a fluid challenge in postsurgical patients D. Bastoni, H. Aya, L. Toscani, L. Pigozzi, A. Rhodes, M. Cecconi P159 - Venous return driving pressure and resistance in acute blood volume changes P. W. Moller, S. Sondergaard, S. M. Jakob, J. Takala, D. Berger P160 - Dynamic arterial elastance calculated with lidcoplus monitor does not predict changes in arterial pressure after a fluid challenge in postsurgical patients D. Bastoni, H. Aya, L. Toscani, L. Pigozzi, A. Rhodes, M. Cecconi P161 - Analysis of duration of post-operative goal-directed therapy protocol C. Ostrowska, H. Aya, A. Abbas, J. Mellinghoff, C. Ryan, D. Dawson, A. Rhodes, M. Cecconi P162 - Hemodynamic optimization – back to square one? M. Cronhjort, O. Wall, E. Nyberg, R. Zeng, C. Svensen, J. Mårtensson, E. Joelsson-Alm P163 - Effectiveness of fluid thoracic content measurement by bioimpedance guiding intravascular volume optimization in patients with septic shock M. Aguilar Arzapalo, L. Barradas, V. Lopez, M. Cetina P164 - A systematic review on the role of internal jugular vein ultrasound measurements in assessment of volume status in critical shock patients N. Parenti, C. Palazzi, L. A. Amidei, F. B. Borrelli, S. C. Campanale, F. T. Tagliazucchi, G. S. Sedoni, D. L. Lucchesi, E. C. Carella, A. L Luciani P165 - Importance of recognizing dehydration in medical Intensive Care Unit M. Mackovic, N. Maric, M. Bakula P166 - Effect of volume for a fluid challenge in septic patients H. Aya, A. Rhodes, R. M. Grounds, N. Fletcher, M. Cecconi P167 - Fluid bolus practices in a large Australian intensive care unit B. Avard, P. Zhang P168 - Liberal late fluid management is associated with longer ventilation duration and worst outcome in severe trauma patients: a retrospective cohort of 294 patients M. Mezidi, J. Charbit, M. Ould-Chikh, P. Deras, C. Maury, O. Martinez, X. Capdevila P169 - Association of fluids and outcomes in emergency department patients hospitalized with community-acquired pneumonia P. Hou, W. Z. Linde-Zwirble, I. D. Douglas, N. S. Shapiro P170 - Association of positive fluid balance with poor outcome in medicosurgical ICU patients A. Ben Souissi, I. Mezghani, Y. Ben Aicha, S. Kamoun, B. Laribi, B. Jeribi, A. Riahi, M. S. Mebazaa P171 - Impact of fluid balance to organ dysfunction in critically ill patients C. Pereira, R. Marinho, R. Antunes, A. Marinho P172 - Volume bolus in ICU patients: do we need to balance our crystalloids? M. Crivits, M. Raes, J. Decruyenaere, E. Hoste P173 - The use of 6 % HES solution do not reduce total fluid requirement in the therapy of patients with burn shock V. Bagin, V. Rudnov, A. Savitsky, M. Astafyeva, I. Korobko, V. Vein P174 - Electron microscopic assessment of acute kidney injury in septic sheep resuscitated with crystalloids or different colloids T. Kampmeier , P. Arnemann, M. Hessler, A. Wald, K. Bockbreder, A. Morelli, H. Van Aken, S. Rehberg, C. Ertmer P175 - Alterations of conjunctival microcirculation in a sheep model of haemorrhagic shock and resuscitation with 0.9 % saline or balanced tetrastarch P. Arnemann, M. Hessler, T. Kampmeier, S. Rehberg, H. Van Aken, C. Ince, C. Ertmer P176 - A single centre nested pilot study investigating the effect of using 0.9 % saline or Plasma-Lyte 148 ® as crystalloid fluid therapy on gastrointestinal feeding intolerance in mechanically ventilated patients receiving nasogastric enteral nutrition S. Reddy, M. Bailey, R. Beasley, R. Bellomo, D. Mackle, A. Psirides, P. Young P177 - A single centre nested pilot study investigating the effect on post-operative bleeding of using 0.9 % saline or Plasma-Lyte® 148 as crystalloid fluid therapy in adults in ICU after heart surgery S. Reddy, M. Bailey, R. Beasley, R. Bellomo, D. Mackle, P. Young P178 - Extreme hypernatremia and sepsis in a patient with Huntington’s dementia: a conundrum in fluid management H. Venkatesh, S. Ramachandran, A. Basu, H. Nair P179 - Diagnosis and management of severe hypernatraemia in the critical care setting S. Egan, J. Bates P180 - Correlation between arterial blood gas and electrolyte disturbances during hospitalization and outcome in critically ill patients S. Oliveira, N. R. Rangel Neto, F. Q. Reis P181 - Missing the “I” in MUDPILES – a rare cause of high anion gap metabolic acidosis (HAGMA) C. P. Lee, X. L. Lin, C. Choong , K. M. Eu, W. Y. Sim , K. S. Tee, J. Pau , J. Abisheganaden P182 - Plasma NGAL and urinary output: potential parameters for early initiation of renal replacement therapy K. Maas, H. De Geus P183 - Renal replacement therapy for critically ill patients: an intermittent continuity E. Lafuente, R. Marinho, J. Moura, R. Antunes, A. Marinho P184 - A survey of practices related to renal replacement therapy in critically ill patients in the north of England. T. E. Doris, D. Monkhouse, T. Shipley, S. Kardasz, I Gonzalez P185 - High initiation creatinine associated with lower 28-day mortality in critically ill patients necessitating continuous renal replacement therapy S. Stads, A. J. Groeneveld P186 - The impact of Karnofsky performance scale on outcomes in acute kidney injury patients receiving renal replacement therapy on the intensive care unit I. Elsayed, N. Ward, A. Tridente, A. Raithatha P187 - Severe hypophosphatemia during citrate-anticoagulated CRRT A. Steuber, C. Pelletier, S. Schroeder, E. Michael, T. Slowinski, D. Kindgen-Milles P188 - Citrate regional anticoagulation for post dilution continuous renal replacement therapy S. Ghabina P189 - Citrate 18 mmol/l improves anticoagulation during RRT with adsorbing filters F. Turani, A. Belli, S. Busatti, G. Barettin, F. Candidi, F. Gargano, R. Barchetta, M. Falco P190 - Calcium gluconate instead of calcium chloride in citrate-anticoagulated CVVHD O. Demirkiran, M. Kosuk, S. Bozbay P191 - Enhanced clearance of interleukin-6 with continuous veno-venous haemodialysis (CVVHD) using Ultraflux EMiC2 vs. Ultraflux AV1000S V. Weber, J. Hartmann, S. Harm, I. Linsberger, T. Eichhorn, G. Valicek, G. Miestinger, C. Hoermann P192 - Removal of bilirubin with a new adsorbent system: in vitro kinetics S. Faenza, D. Ricci, E. Mancini, C. Gemelli, A. Cuoghi, S. Magnani, M. Atti P193 - Case series of patients with severe sepsis and septic shock treated with a new extracorporeal sorbent T. Laddomada, A. Doronzio, B. Balicco P194 - In vitro adsorption of a broad spectrum of inflammatory mediators with CytoSorb® hemoadsorbent polymer beads M. C. Gruda, P. O’Sullivan, V. P. Dan, T. Guliashvili, A. Scheirer, T. D. Golobish, V. J. Capponi, P. P. Chan P195 - Observations in early vs. late use of cytosorb therapy in critically ill patients K. Kogelmann, M. Drüner, D. Jarczak P196 - Oxiris membrane decreases endotoxin during rrt in septic patients with basal EAA > 0,6 F. Turani, A. B. Belli, S. M. Martni, V. C. Cotticelli, F. Mounajergi, R. Barchetta P197 - An observational prospective study on the onset of augmented renal clearance: the first report S. Morimoto, H. Ishikura P198 - An ultrasound- guided algorithm for the management of oliguria in severe sepsis I. Hussain, N. Salahuddin, A. Nadeem, K. Ghorab, K. Maghrabi P199 - Ultrasound in acute kidney injury (aki). First findings of farius, an education-programme in structural ultrasonography S. K. Kloesel, C. Goldfuss, A. Stieglitz, A. S. Stieglitz, L. Krstevska, G. Albuszies P200 - Effectiveness of renal angina index score predicting acute kidney injury on critically ill patients M. Aguilar Arzapalo, L. Barradas, V. Lopez, A. Escalante, G. Jimmy, M. Cetina P201 - Time length below blood pressure thresholds and progression of acute kidney injury in critically ill patients with or without sepsis: a retrospective, exploratory cohort study J. Izawa, T. Iwami, S. Uchino, M. Takinami, T. Kitamura, T. Kawamura P202 - Anaemia does not affect renal recovery in acute kidney injury J. G. Powell-Tuck, S. Crichton, M. Raimundo, L. Camporota, D. Wyncoll, M. Ostermann P203 - Estimated glomerular filtration rate based on serum creatinine: actual practice in Dutch ICU’s A. Hana, H. R. De Geus P204 - Comparison of estimated glomerular filtration rate calculated by mdrd, ckd-epi-serum-creatinine and ckd-epi-cystatin-c in adult critically ill patients H. R. De Geus, A. Hana P205 - Early diagnosis of septic acute kidney injury in medical critical care patients with a urine cell cycle arrest marker: insulin like growth factor binding protein-7 (IGFBP-7) M. Aydogdu, N. Boyaci, S. Yuksel, G. Gursel, A. B. Cayci Sivri P206 - Urinary neutrophil gelatinase-associated lipocalin as early biomarker of severe acute kidney injury in intensive care J. Meza-Márquez, J. Nava-López, R. Carrillo-Esper P207 - Shrunken pore syndrome is associated with a sharp rise in mortality in patients undergoing elective coronary artery bypass grafting A. Dardashti, A. Grubb P208 - The biomarker nephrocheck™ can discriminate the septic shock patients with an akin 1 or 2 acute renal failure who will not progress toward the akin 3 level J. Maizel, M. Wetzstein, D. Titeca, L. Kontar, F. Brazier, B. De Cagny, A. Riviere, T. Soupison, M. Joris, M. Slama P209 - A worldwide multicentre evaluation of acute kidney injury in septic and non-septic critically ill patients: the intensive care over nations (icon) audit E. Peters, H. Njimi, P. Pickkers, J. L. Vincent P210 - Does enhanced recovery after surgery reduce the incidence of acute kidney injury in those undergoing major gynae-oncological surgery? M. Waraich , J. Doyle, T. Samuels, L. Forni P211 - Identification of risk factors for the development of acute kidney injury after lower limb arthroplasty N. Desai, R. Baumber, P. Gunning, A. Sell P212 - Incidences and associations of acute kidney injury after major trauma S. Lin, H. Torrence, M. O’Dwyer, C. Kirwan, J. Prowle P213 - Acute kidney injury of major trauma patients T Kim P214 - Trajectory of serum creatinine after major surgery and the diagnosis of acute kidney injury M. E. O’Connor, R. W. Hewson, C. J. Kirwan, R. M. Pearse, J. Prowle P215 - Epidemiology of acute kidney injury after cardiac surgery. A single center retrospective study S. Hanoura , A. Omar, H. Othamn, S. Sudarsanan , M. Allam, M. Maksoud, R. Singh, A. Al Khulaifi P216 - Post-operative acute kidney injury after major non-cardiac surgery and its association with death in the following year M. E. O’Connor, R. W. Hewson, C. J. Kirwan, R. M. Pearse, J. Prowle P217 - Factors affecting acute renal failure in intensive care unit and effect of these factors on mortality O. Uzundere, D. Memis , M. Ýnal, A. , N. Turan P218 - Results of the live kidney transplantations according to national data of turkish organ and tissue information system M. A. Aydin, H. Basar, I. Sencan, A. Kapuagasi, M. Ozturk, Z. Uzundurukan, D. Gokmen, A. Ozcan, C. Kaymak P219 - Anaesthesia procedure and intensive therapy in patients with neck phlegmon V. A. Artemenko, A. Budnyuk P220 - Nasal high flow oygen for acute respiratory failure: a systematic review R. Pugh , S. Bhandari P221 - Setting optimal flow rate during high flow nasal cannula support: preliminary results T. Mauri, C. Turrini, T. Langer, P. Taccone, C. A. Volta, C. Marenghi, L. Gattinoni, A. Pesenti P222 - Dose to dose consistency across two different gas flow rates using cystic fibrosis and normal adult breathing profiles during nasal high flow oxygen therapy L. Sweeney, A . O’ Sullivan, P. Kelly, E. Mukeria, R. MacLoughlin P223 - Final results of an evaluation of airway medix closed suction system compared to a standard closed suction system M. Pfeffer, J. T. Thomas, G. B. Bregman, G. K. Karp, E. K. Kishinevsky, D. S. Stavi, N. A. Adi P224 - Different cuff materials and different leak tests - one size does not fit all T. Poropat, R. Knafelj P225 - Observational study on the value of the cuff-leak test and the onset of upper airway obstruction after extubation E. Llopart, M. Batlle, C. De Haro, J. Mesquida, A. Artigas P226 - A device for emergency transtracheal lung ventilation D. Pavlovic, L. Lewerentz, A. Spassov, R. Schneider P227 - Long-term outcome and health-related quality of life in patients discharged from the intensive care unit with a tracheostomy and with or without prolonged mechanical ventilation S. De Smet, S. De Raedt, E. Derom, P Depuydt, S. Oeyen, D. Benoit, J. Decruyenaere P228 - Ultrasound-guided percutaneous dilational tracheostomy versus bronchoscopy-guided percutaneous dilational tracheostomy in critically ill patients (trachus): a randomized clinical trial A. Gobatto, B. Bese, P. Tierno, L. Melro, P. Mendes, F. Cadamuro, M. Park, L. M. Malbouisson P229 - Is it safe to discharge patients with tracheostomy from the ICU to the ward? B. C. Civanto, J. L. Lopez, A. Robles, J. Figueira, S. Yus, A. Garcia P230 - The application of tracheostomy in children in ICU A. Oglinda, G. Ciobanu, C. Oglinda, L. Schirca, T. Sertinean, V. Lupu P231 - The impact of passive humidifiers on aerosol drug delivery during mechanical ventilation P. Kelly, A. O’Sullivan, L. Sweeney, R. MacLoughlin P232 - Evaluation of vibrating mesh and jet nebuliser performance at two different attachment setups in line with a humidifier nebuliser system A. O’Sullivan, P. Kelly, L. Sweeney, E. Mukeria, M. Wolny , R. MacLoughlin P233 - Psv-niv versus cpap in the treatment of acute cardiogenic pulmonary edema A. Pagano, F. Numis, G. Vison, L. Saldamarco, T. Russo, G. Porta, F. Paladino P234 - Noninvasive ventilation in patients with haematologic malignancy: a retrospective review C. Bell, J. Liu, J. Debacker, C. Lee, E. Tamberg, V. Campbell, S. Mehta P235 - Use of non-invasive ventilation in infectious diseases besides classical indications A. Silva-Pinto, A. Sarmento, L. Santos P236 - The impact of fragility on noninvasive mechanical ventilation application and results in the ICU Ý. Kara, F. Yýldýrým, A. Zerman, Z. Güllü, N. Boyacý, B. Basarýk Aydogan, Ü. Gaygýsýz, K. Gönderen, G. Arýk, M. Turkoglu, M. Aydogdu, G. Aygencel, Z. Ülger, G. Gursel P237 - Effects of metabolic alkalosis on noninvasive ventilation success and ICU outcome in patients with hypercapnic respiratory failure N. Boyacý, Z. Isýkdogan, Ö. Özdedeoglu, Z. Güllü, M. Badoglu, U. Gaygýsýz, M. Aydogdu, G. Gursel P238 - Asynchrony index and breathing patterns of acute exacerbation copd patients assisted with noninvasive pressure support ventilation and neurally adjusted ventilatory assist N. Kongpolprom, C. Sittipunt P239 - High frequency jet ventilation for severe acute hypoxemia A. Eden, Y. Kokhanovsky, S. Bursztein – De Myttenaere, R. Pizov P240 - HFOV revisited: a 7 year retrospective analysis of patients receiving HFOV who met oscillate trial entry criteria L. Neilans, N. MacIntyre P241 - Implementation of a goal-directed mechanical ventilation order set driven by respiratory therapists can improve compliance with best practices for mechanical ventilation M. Radosevich, B. Wanta, V. Weber, T. Meyer, N. Smischney, D. Brown, D. Diedrich P242 - A reduction in tidal volumes for ventilated patients on ICU calculated from IBW. can it minimise mortality in comparison to traditional strategies? A . Fuller, P. McLindon, K. Sim P243 - Predictive value of lung aeration scoring using lung ultrasound in weaning failure M. Shoaeir, K. Noeam, A. Mahrous, R. Matsa, A. Ali P244 - Conventional versus automated weaning from mechanical ventilation using SmartCare™ C. Dridi, S. Koubaji, S. Kamoun, F. Haddad, A. Ben Souissi, B. Laribi, A. Riahi, M. S. Mebazaa P245 - Ultrasonographic evaluation protocol for weaning from mechanichal ventilation A. Pérez-Calatayud, R. Carrillo-Esper, A. Zepeda-Mendoza, M. Diaz-Carrillo, E. Arch-Tirado P246 - Diaphragm ultrasonography: a method for weaning patients from mechanical ventilation S. Carbognin, L. Pelacani, F. Zannoni, A. Agnoli, G. Gagliardi P247 - Dorsal diaphragmatic excursion tracks transpulmonary pressure in ventilated ARDS patients: a potential non-invasive indicator of lung recruitment? R. Cho, A. Adams , S. Lunos, S. Ambur, R. Shapiro, M. Prekker P248 - Pulse oximetry in the icu patient: is the perfusion index of any value? M. Thijssen, L. Janssen, N. Foudraine P249 - Ventilation is a better assessment of respiratory status than EtCO2 C. J. Voscopoulos, J. Freeman P250 - Evaluation of the relationship between non-invasive minute ventilation and end-tidal CO2 in patients undergoing general vs spinal anesthesia C. J. Voscopoulos, J. Freeman, E. George P251 - Respiratory volume monitoring provides early warning of respiratory depression and can be used to reduce false alarms in non-intubated patients C. J. Voscopoulos, D. Eversole, J. Freeman, E. George P252 - P/i index: a predictive edi-derived weaning index during nava S. Muttini, R. Bigi, G. Villani, N. Patroniti P253 - Adequacy of ventilation in patients receiving opioids in the post anesthesia care unit: minute ventilation versus respiratory rate G. Williams, C. J. Voscopoulos, J. Freeman, E. George P254 - Comparison of regional and global expiratory time constants measured by electrical impedance tomography (EIT) A. Waldmann, S. Böhm, W. Windisch, S. Strassmann, C. Karagiannidis P255 - Electrical impedance tomography: robustness of a new pixel wise regional expiratory time constant calculation A. Waldmann, S. Böhm, W. Windisch, S. Strassmann, C. Karagiannidis P256 - Validation of regional and global expiratory time constant measurement by electrical impedance tomography in ards and obstructive pulmonary diseases C. K. Karagiannidis, A. W. Waldmann, S. B. Böhm, S. Strassmann, W. W. Windisch P257 - Transpulmonary pressure in a model with elastic recoiling lung and expanding chest wall P. Persson, S. Lundin, O. Stenqvist P258 - Lactate in pleural and abdominal effusion G. Porta, F. Numis, C. S. Serra, A. P. Pagano, M. M. Masarone, L. R. Rinaldi, A. A. Amelia, M. F. Fascione, L. A. Adinolfi, E. R. Ruggiero P259 - Outcome of patients admitted to the intensive care with pulmonary fibrosis F. Asota, K. O’Rourke, S. Ranjan, P. Morgan P260 - Sedation and analgesia practice in extra-corporeal membrane oxygenation (ECMO)-treated patients with acute respiratory distress syndrome (ARDS): a retrospective study J. W. DeBacker, E. Tamberg, L. O’Neill, L. Munshi, L. Burry, E. Fan, S. Mehta P261 - Characteristics and outcomes of patients deemed not eligible when referred for veno-venous extracorporeal membrane oxygenation (vv-ECMO) S. Poo, K. Mahendran, J. Fowles, C. Gerrard, A. Vuylsteke P262 - The SAVE SMR for veno-arterial ECMO R. Loveridge, C. Chaddock, S. Patel, V. Kakar, C. Willars, T. Hurst, C. Park, T. Best, A. Vercueil, G. Auzinger P263 - A simplified score to predict early (48 h) mortality in patients being considered for VA-ECMO A. Borgman, A. G. Proudfoot, E. Grins, K. E. Emiley, J. Schuitema, S. J. Fitch, G. Marco, J. Sturgill, M. G. Dickinson, M. Strueber, A. Khaghani, P. Wilton, S. M. Jovinge P264 - Lung function six months post extra corporeal membrane oxygenation (ECMO) for severe acute respiratory failure in adult survivors C. Sampson, S. Harris-Fox P265 - Bicarbonate dialysis removes carbon dioxide in hypoventilated rodents. M. E. Cove, L. H. Vu, A. Sen, W. J. Federspiel, J. A. Kellum P266 - Procalcitonin as predictor of primary graft dysfunction and mortality in post-lung transplantation C. Mazo Torre, J. Riera, S. Ramirez, B. Borgatta, L. Lagunes, J. Rello P267 - New molecular biomarkers of acute respiratory distress syndrome in abdominal sepsis A. K. Kuzovlev, V. Moroz, A. Goloubev, S. Polovnikov, S. Nenchuk P268 - Tight junction’s proteins claudin -5 and regulation by tnf in experimental murine lung injury model of ali/ards V. Karavana, C. Glynos, A. Asimakos, K. Pappas, C. Vrettou, M. Magkou, E. Ischaki, G. Stathopoulos, S. Zakynthinos P269 - Cell counts in endobronchial aspirate to assess airway inflammation in ARDS patients: a pilot study S. Spadaro, I. Kozhevnikova, F. Dalla Corte, S. Grasso, P. Casolari, G. Caramori, C. Volta P270 - Epidemiological and clinical profile of patients with acute respiratory distress syndrome in the surgical intensive care unit surgical, hospital JRA, Antananarivo T. Andrianjafiarinoa, T. Randriamandrato, T. Rajaonera P271 - Effect of high PEEP after recruitment maneuver on right ventricular function in ARDS. Is it good for the lung and for the heart? S. El-Dash, ELV Costa, MR Tucci, F Leleu, L Kontar, B. De Cagny, F. Brazier, D. Titeca, G. Bacari-Risal, J. Maizel, M. Amato, M. Slama P272 - Effect of recruitment maneuver on left ventricular systolic strain P. Mercado, J. Maizel, L. Kontar, D. Titeca, F. Brazier, A. Riviere, M. Joris, T. Soupison, B. De Cagny, S. El Dash, M. Slama P273 - Inhaled nitric oxide – is switching supplier cost effective? Remmington, A. Fischer, S. Squire, M. Boichat P274 - Epidemiological study of severe acute pancreatitis in Japan, comparison of the etiology and the patient outcomes on 1159 patients. H. Honzawa, H. Yasuda, T. Adati, S. Suzaki, M. Horibe, M. Sasaki, M. Sanui P275 - Extracorporeal liver support therapy. Experience in an intensive care unit R. Marinho, J. Daniel, H. Miranda, A. Marinho P276 - Accuracy of mortality prediction models in acute versus acute-on-chronic liver failure in the intensive care setting K. Milinis, M. Cooper, G. R. Williams, E. McCarron, S. Simants, I. Patanwala, I. Welters P277 - Risk of coronary artery disease in patients with chronic liver disease: a population based cohort study Y. Su P278 - 20 years of liver transplantation in Santiago de Compostela (Spain). Experience review J. Fernández Villanueva, R. Fernández Garda, A. López Lago, E. Rodríguez Ruíz, R. Hernández Vaquero, S. Tomé Martínez de Rituerto, E. Varo Pérez P279 - Diarrhea is a risk factor for liver injury and may lead to intestinal failure associated liver disease in critical illness N. Lefel, F. Schaap, D. Bergmans, S. Olde Damink, M. Van de Poll P280 - Bowel care on the intensive care unit: constipation guideline compliance and complications K. Tizard, C. Lister, L. Poole P281 - Malnutrition assessed by phase angle determines outcomes in low risk cardiac surgery patients D. Ringaitiene, D. Gineityte, V. Vicka, I. Norkiene, J. Sipylaite P282 - Preoperative fasting times in an irish hospital A. O’Loughlin, V. Maraj, J. Dowling P283 - Costs and final outcome of early x delayed feeding in a private Brazil ICU M. B. Velasco, D. M. Dalcomune, E. B. Dias, S. L. Fernandes P284 - Can ventilator derived energy expenditure measurements replace indirect calorimetry? T. Oshima, S. Graf, C. Heidegger, L. Genton, V. Karsegard, Y. Dupertuis, C. Pichard P285 - Revisiting the refeeding syndrome: results of a systematic review N. Friedli, Z. Stanga, B. Mueller, P. Schuetz P286 - Compliance with the new protocol for parenteral nutrition in our ICU L. Vandersteen, B. Stessel, S. Evers, A. Van Assche, L. Jamaer, J. Dubois P287 - Nutrition may be another treatment in the intensive care unit where less is more? R. Marinho, H. Castro, J. Moura, J. Valente, P. Martins, P. Casteloes, C. Magalhaes, S. Cabral, M. Santos, B. Oliveira, A. Salgueiro, A. Marinho P288 - Should we provide more protein to critically ill patients? R. Marinho, M. Santos, E. Lafuente, H. Castro, S. Cabral, J. Moura, P. Martins, B. Oliveira, A. Salgueiro, S. Duarte, S. Castro, M. Melo, P. Casteloes, A. Marinho P289 Protein provision in an adult intensive care unit S. Gray P290 - Prevalence and clinical outcomes of vitamin d deficiency in the medical critically ill patients in Songklanagarind hospital K. Maipang, R. Bhurayanontachai P291 - Vitamin d deficiency strongly predicts adverse medical outcome across different medical inpatient populations: results from a prospective study L. G. Grädel, P. Schütz P292 - Omega-3 fatty acids in patients undergoing cardiac surgery: a systematic review and meta-analysis P. Langlois, W. Manzanares P293 - Can 5-hydroxytriptophan prevent post-traumatic stress disorder in critically ill patients? R. Tincu, C. Cobilinschi, D. Tomescu, Z. Ghiorghiu, R. Macovei P294 - Parenteral selenium in the critically ill: an updated systematic review and meta-analysis W. Manzanares, P. Langlois, M. Lemieux, G. Elke, F. Bloos, K. Reinhart, D. Heyland P295 - Probiotics in the critically ill: an updated systematic review and meta-analysis P. Langlois, M. Lemieux, I. Aramendi, D. Heyland, W. Manzanares P296 - Diabetes with hyperglycemic crisis episodes may be associated with higher risk of pancreatic cancer: a population-based cohort study Y. Su P297 - Incidence of hypoglycemia in an intensive care unit depending on insulin protocol R. Marinho, N. Babo, A. Marinho P298 - Severity of the diseases is two-dimensionally correlated to blood glucose, including blood glucose variability, especially in moderately to severely ill patients with glucose intolerance. M. Hoshino, Y. Haraguchi, S. Kajiwara, T. Mitsuhashi, T. Tsubata, M. Aida P299 - A study of glycemic control by subcutaneous glargine injection transition from continuous regular insulin infusion in critically ill patients T. Rattanapraphat, R. Bhurayanontachai, C. Kongkamol, B. Khwannimit P300 - Glycemic control in Portuguese intensive care unit R. Marinho, M. Santos, H. Castro, E. Lafuente, A. Salgueiro, S. Cabral, P. Martins, J. Moura, B. Oliveira, M. Melo, B. Xavier, J. Valente, C. Magalhaes, P. Casteloes, A. Marinho P301 - Impact of hyperglycemia duration on the day of operation on short-term outcome of cardiac surgery patients D. Moisidou, F. Ampatzidou, C. Koutsogiannidis, M. Moschopoulou, G. Drossos P302 - Lactate levels in diabetic ketoacidosis patients at ICU admissions G. Taskin, M. Çakir, AK Güler, A. Taskin, N. Öcal, S. Özer, L. Yamanel P303 - Intensive care implications of merging heart attack centre units in London J. M. Wong, C. Fitton, S. Anwar, S. Stacey P304 - Special characteristics of in-hospital cardiac arrests M. Aggou, B. Fyntanidou, S. Patsatzakis, E. Oloktsidou, K. Lolakos, E. Papapostolou, V. Grosomanidis P305 - Clinical evaluation of ICU-admitted patients who were resuscitated in the general medicine ward S. Suda , T. Ikeda, S. Ono, T. Ueno, Y. Izutani P306 - Serious game evaluation of a one-hour training basic life support session for secondary school students: new tools for future bystanders S. Gaudry, V. Desailly, P. Pasquier, PB Brun, AT Tesnieres, JD Ricard, D. Dreyfuss, A. Mignon P307 - Public and clinical staff perceptions and knowledge of CPR compared to local and national data J. C White, A. Molokhia, A. Dean, A. Stilwell, G. Friedlaender P308 Dispatcher-assisted telephone cardiopulmonary resuscitation using a French-language compression-ventilation pediatric protocol M. Peters, S. Stipulante, A. Delfosse, AF Donneau, A. Ghuysen P309 Dantrolene versus amiodarone for resuscitation – an experimental study C. Feldmann, D. Freitag, W. Dersch, M. Irqsusi, D. Eschbach, T. Steinfeldt, H. Wulf, T. Wiesmann P310 Long term survival and functional neurological outcome in comatose survivors undergoing therapeutic hypothermia N. Kongpolprom, J. Cholkraisuwat P311 Impact of kidney disease on mortality and neurological outcome in out-of-hospital cardiac arrest: a prospective observational study S. Beitland , E. Nakstad, H. Stær-Jensen , T. Drægni , G. Andersen , D. Jacobsen , C. Brunborg, B. Waldum-Grevbo , K. Sunde P312 ICU dependency of patients admitted after primary percutaneous coronary intervention (PPCI) following out of the hospital cardiac arrest K. Hoyland, D. Pandit P313 Prognostic indicators and outcome prediction model for patients with return of spontaneous circulation from cardiopulmonary arrest: comprehensive registry of in-hospital intensive care on OHCA survival (critical) study in Osaka, Japan K. Hayakawa P314 Cerebral oxygen saturation during resuscitation in a porcine model of cardiac arrest E. Oloktsidou, K. Kotzampassi, B. Fyntanidou, S. Patsatzakis, L. Loukipoudi, E. Doumaki, V. Grosomanidis P315 Presumption of cardiopulmonary resuscitation for sustaining cerebral oxidation using regional cerebral saturation of oxygen: observational cohort study (press study) H. Yasuda P316 EEG reactivity in patients after cardiac arrest: a close look at stimuli MM Admiraal, M. Van Assen, MJ Van Putten, M. Tjepkema-Cloostermans, AF Van Rootselaar, J. Horn P317 Prognostic value of neuron-specific enolase after cardiac arrest F. Ragusa, A. Marudi , S. Baroni, A. Gaspari, E. Bertellini P318 Correlation between electroencephalographic findings and serum neuron specific enolase with outcome of post cardiac arrest patients A. Taha, T. Abdullah, S. Abdel Monem P319 Introduction of a targeted temperature management strategy following cardiac arrest in a district general hospital intensive care unit. S. Alcorn, S. McNeill, S. Russell P320 The evolution of cerebral oxygen saturation in post-cardiac arrest patients treated with therapeutic hypothermia W. Eertmans, C. Genbrugge, I. Meex, J. Dens, F. Jans, C. De Deyne P321 Prognostic factors and neurological outcomes of therapeutic hypothermia in comatose survivors from cardiac arrest: 8-year single center experience J. Cholkraisuwat, N. Kongpolprom P322 Adherence to targeted temperature management after out of hospital cardiac arrest B. Avard, R. Burns P323 Implementation of a therapeutic hypothermia protocol for comatose survivors of out-of-hospital cardiac arrest. A. Patarchi, T. Spina P324 Factors associated with ventilator weaning after targeted temperature management for cardiac arrest patients in japan H. Tanaka, N. Otani, S. Ode, S. Ishimatsu P325 Differential activation of c-fos in paraventricular nuclei of the hypothalamus and thalamus of the rat following myocardial infarction J. Cho, J. B. Moon, C. W. Park, T. G. Ohk, M. C. Shin, M. H. Won P326 Monitoring of cTroponin I in patients with acute ischemic stroke - predictor of inhospital mortality S. Dakova, Z. Ramsheva, K. Ramshev P327 Hyperthermic preconditioning severely accelerates neuronal damage in the gerbil ischemic hippocampal dentate gyrus via decreasing sods expressions J. Cho, J. B. Moon, C. W. Park, T. G. Ohk, M. C. Shin P328 Failure in neuroprotection of remote limb ischemic post conditioning in the hippocampus of a gerbil model of transient cerebral ischemia J. Cho, J. B. Moon, C. W. Park, T. G. Ohk, M. C. Shin P329 Brain death and admission diagnosis in neurologic intensive care unit, a correlation? A Marudi, S Baroni, A Gaspari, E Bertellini P330 Brain magnetic resonance imaging findings in patients with septic shock G. Orhun, E. Senturk, P. E. Ozcan, S. Sencer, C. Ulusoy, E. Tuzun, F . Esen P331 Benefits of L-carnitine in valproic acid induced encephalopathy R. Tincu, C. Cobilinschi, D. Tomescu, Z. Ghiorghiu, R. Macovei P332Automatic analysis of EEG reactivity in comatose patients M. Van Assen, M. M. Admiraal, M. J. Van Putten, M. Tjepkema-Cloostermans, A. F. Van Rootselaar, J. Horn P333 Usefulness of common ICU severity scoring systems in predicting outcome after spontaneous intracerebral hemorrhage M. Fallenius, M. B. Skrifvars, M. Reinikainen, S. Bendel, R. Raj P334 Evalution of patients with suspected subarachnoid haemorrhage and negative ct imaging M. Abu-Habsa, C. Hymers, A. Borowska, H. Sivadhas, S. Sahiba, S. Perkins P335 Timing of endovascular and surgical treatment for aneurysmal subarachnoid haemorrhage: early but not so fast. J. Rubio, J. A. Rubio, R. Sierra P336 Red blood cell transfusion in aneurysmal subarachnoid hemorrhage – the Sahara cohort study S. English, M. Chasse, A. Turgeon, F. Lauzier, D. Griesdale, A. Garland, D. Fergusson, R. Zarychanski, A. Tinmouth, C. Van Walraven, K. Montroy, J. Ziegler, R. Dupont Chouinard, R. Carignan, A. Dhaliwal, C. Lum, J. Sinclair, G. Pagliarello, L. McIntyre P337 - Aneurysmal subarachnoid hemorrhage and anemia: a canadian multi-centre retrospective cohort study S. English, M. Chasse, A. Turgeon, F. Lauzier, D. Griesdale, A. Garland, D. Fergusson, R. Zarychanski, A. Tinmouth, C. Van Walraven, K. Montroy, J. Ziegler, R. Dupont Chouinard, R. Carignan, A. Dhaliwal, C. Lum, J. Sinclair, G. Pagliarello, L. McIntyre P338 - Does the neutrophil-to-lymphocyte (NLR) ratio predict symptomatic vasospasm or delayed cerebral ischemia (DCI) after aneurysmal subarachnoid haemorrhage (SAH)? T. Groza, N. Moreau, D. Castanares-Zapatero, P. Hantson P339 - ICU-acquired infections in aneurysmal subarachnoid hemorrhage patients: impact on ICU and hospital length of stay M. Carbonara , F. Ortolano, T. Zoerle, S. Magnoni, S. Pifferi, V. Conte, N. Stocchetti P340 - Cerebral metabolic effects of normobaric hyperoxia during the acute phase of aneurysmal subarachnoid hemorrhage L. Carteron, T. Suys, C. Patet, H. Quintard, M. Oddo P341 - Postoperative care for elective craniotomy: where is best done? J. A. Rubio, J. Rubio, R. Sierra P342 - 5-year follow-up of patients after transplantation of organs from donors from neurocritical care V. Spatenkova, E. Pokorna, P. Suchomel P343 - Evaluation of levetiracetam pharmacokinetics after severe traumatic brain injury in neurocritical care patients at a level one trauma center N. Ebert, J. Jancik, H. Rhodes P344 - Model based time series cluster analysis to determine unique patient states in traumatic brain injury T. Bylinski, C. Hawthorne, M. Shaw, I. Piper, J. Kinsella P345 - Brain compartment monitoring capabilities from ICP to BI (bioimpedance) during HS (hypertonic saline) administration. State of art simulation outcome depending on brain swelling type A. K. Kink , I. R. Rätsep P346 - Transfusion of red blood cells in patients with traumatic brain injury admitted to Canadian trauma health centers: a multicenter cohort study A. Boutin, L. Moore, M. Chasse, R. Zarychanski, F. Lauzier, S. English, L. McIntyre, J. Lacroix, D. Griesdale, P. Lessard-Bonaventure, A. F. Turgeon P347 - Hemoglobin thresholds and red blood cell transfusions in adult patients with moderate or severe traumatic brain injury: a retrospective cohort study A. Boutin, L. Moore, R. Green, P. Lessard-Bonaventure, M. Erdogan, M. Butler, F. Lauzier, M. Chasse, S. English, L. McIntyre, R. Zarychanski, J. Lacroix, D. Griesdale, P. Desjardins, D. A. Fergusson, A. F. Turgeon P348 - Characteristics of patients with gunshot wounds to the head - an observational Brazilian study B. Goncalves, B. Vidal, C. Valdez, A. C. Rodrigues, L. Miguez, G. Moralez P349 - Base excess as predictor for ICU admission and the injury severity in blunt trauma patients T. Hong P350 - Enhancement of usual emergency department care with proadrenomedullin to improve outcome prediction - Results from the multi-national, prospective, observational TRIAGE study A. Kutz, P. Hausfater, D. Amin, T. Struja, S. Haubitz, A. Huber, B. Mueller, P. Schuetz P351 - Developing an innovative emergency medicine point-of-care simulation programme T. Brown, J. Collinson, C. Pritchett, T. Slade P352 - The InSim program: an in situ simulation program for junior trainees in intensive care M. Le Guen, S. Hellings, R. Ramsaran P353 - Impact of excessive and inappropriate troponin testing in the emergency setting how good are we A. Alsheikhly P354 - The development of time tracking monitor at emergency department T. Abe P355 - Role of focussed echocardiography in emergency assessment of syncope L. Kanapeckaite, M. Abu-Habsa, R. Bahl P356 - Insertion of an open-ended 14-gauge catheter through the chest wall causes a significant pneumothorax in a self-ventilating swine model M. Q Russell, K. J. Real, M. Abu-Habsa , R. M. Lyon, N. P. Oveland P357 - Ez-io® intraosseous access teaching in the workplace using a mobile ‘tea trolley’ training method J. Penketh, M. Mcdonald, F. Kelly P358 - Black widow envenomation in Saudi Arabia: a prospective observational case series M. Alfafi, S. Alsolamy, W. Almutairi, B. Alotaibi P359 - Mechanical ventilation in patients with overdose not yet intubated on icu admission A. E. Van den Berg, Y. Schriel, L. Dawson, I. A. Meynaar P360 - Central nervous system depressants poisoning and ventilator associated pneumonia: an underrated risk factor in toxicological intensive care unit H. Talaie P361 - Acute barium intoxication treated with hemodiafiltration D. Silva, S. Fernandes, J. Gouveia, J. Santos Silva P362 - Major trauma presenting to the emergency department. the spectrum of cycling injuries in Ireland J. Foley, A. Kaskovagheorgescu, D. Evoy, J. Cronin, J. Ryan P363 - Burns from French military operations: a 14-year retrospective observational analysis. M. Huck, C. Hoffmann, J. Renner, P. Laitselart, N. Donat, A. Cirodde, J. V. Schaal, Y. Masson, A. Nau, T. Leclerc P364 - A comparison of mortality scores in burns patients on the intensive care unit. O. Howarth, K. Davenport, P.
AD  - University of Western Ontario, London, Canada. ISNI: 0000 0004 1936 8884. GRID: grid.39381.30
Hospital Dr Negrín, Las Palmas de GC, Spain
Hospital San Jorge, Huesca, Spain. ISNI: 0000 0004 1765 5935. GRID: grid.415076.1
Hospital Universitari del Mar, Barcelona, Spain. ISNI: 0000 0004 1767 8811. GRID: grid.411142.3
Hospital Universitario de la Princesa, Madrid, Spain. ISNI: 0000 0004 1767 647X. GRID: grid.411251.2
Hospital Clínico y Universitario de Valencia, Valencia, Spain. GRID: grid.411308.f
Hospital Universitari Son Espases, Palma de Mallorca, Spain. ISNI: 0000 0004 1796 5984. GRID: grid.411164.7
Medical Faculty of Istanbul, Istanbul University, Anesthesiology and Intensive Care, Istanbul, Turkey. ISNI: 0000 0001 2166 6619. GRID: grid.9601.e
Medical Faculty of Istanbul, Physiology, Istanbul University, Istanbul, Turkey. ISNI: 0000 0001 2166 6619. GRID: grid.9601.e
Institute of Experimental Medicine, Istanbul University, Neuroscience, Istanbul, Turkey. ISNI: 0000 0001 2166 6619. GRID: grid.9601.e
Medical Faculty of Istanbul, Forensic Medicine, Istanbul University, Istanbul, Turkey. ISNI: 0000 0001 2166 6619. GRID: grid.9601.e
Institute of Experimental Medicine, Immunology, Istanbul University, Istanbul, Turkey. ISNI: 0000 0001 2166 6619. GRID: grid.9601.e
Ben-Gurion University of the Negev, Beer-Sheva, Israel. ISNI: 0000 0004 1937 0511. GRID: grid.7489.2
Soroka Medical Center, Beer-Sheva, Israel. ISNI: 0000 0004 0470 8989. GRID: grid.412686.f
Osaka University Graduate School of Medicine, Suita, Japan. ISNI: 0000 0004 0373 3971. GRID: grid.136593.b
Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan. ISNI: 0000 0000 8902 2273. GRID: grid.174567.6
Tokyo Medical University Hachioji Medical Center, Hachioji, Tokyo Japan. GRID: grid.411909.4
National Defense Medical College, Tokorozawa, Saitama Japan. ISNI: 0000 0004 0374 0880. GRID: grid.416614.0
Hachiouji medical center, Tokyo medical university, Tokyo, Japan. ISNI: 0000 0001 0663 3325. GRID: grid.410793.8
Kanazawa University, Kanazawa, Japan. ISNI: 0000 0001 2308 3329. GRID: grid.9707.9
Kanazawa University Hospital, Kanazawa, Japan. ISNI: 0000 0004 0615 9100. GRID: grid.412002.5
ThermoFisher, Hennigsdorf, Germany
Institut für Klinische Chemie und Laboratoriumsmedizin, Mainz, Germany
MVZ Labor Limbach Gruppe, Berlin, Germany
Kantonsspital Aarau, Aarau, Switzerland. ISNI: 0000 0000 8704 3732. GRID: grid.413357.7
King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia. ISNI: 0000 0001 2191 4301. GRID: grid.415310.2
Saint Savvas Hospital, Athens, Greece. GRID: grid.416564.4
Tokyo Medical University, Tokyo, Japan. ISNI: 0000 0001 0663 3325. GRID: grid.410793.8
Tokyo Medical University, Hachioji Medical Center, Tokyo, Japan. GRID: grid.411909.4
Hospital Virgen de la Victoria, Málaga, Spain. ISNI: 0000 0000 9788 2492. GRID: grid.411062.0
St Helens and Knowsley NHS Trust, Merseyside, UK
Maastricht University, Maastricht, Netherlands. ISNI: 0000 0001 0481 6099. GRID: grid.5012.6
Center for Experimental and Molecular medicine, Amsterdam, Netherlands
Academic Medical Center, Amsterdam, Netherlands. ISNI: 0000000404654431. GRID: grid.5650.6
NISCHR Haemostasis Biomarker Research Unit, Swansea, UK
Hôpital Lariboisière, Paris, France. ISNI: 0000 0000 9725 279X. GRID: grid.411296.9
Sphingotec, Berlin, Germany
Hôpital Cochin, Paris, France. ISNI: 0000 0001 0274 3893. GRID: grid.411784.f
Hôpital Saint-Antoine, Paris, France. ISNI: 0000 0004 1937 1100. GRID: grid.412370.3
CHRU de Montpellier, Montpellier, France. ISNI: 0000 0000 9961 060X. GRID: grid.157868.5
Hôpital Saint-Louis, Paris, France. ISNI: 0000 0001 2300 6614. GRID: grid.413328.f
AP-HM, Marseille, France. ISNI: 0000 0001 0407 1584. GRID: grid.414336.7
Hôpital Ambroise Paré, Paris, France. ISNI: 0000 0000 9982 5352. GRID: grid.413756.2
Christiana Care Health System, Newark, USA. ISNI: 0000 0004 0444 1241. GRID: grid.414316.5
Skane University Hospital, Lund University, Lund, Sweden. ISNI: 0000 0001 0930 2361. GRID: grid.4514.4
Carol Davila University of Medicine and Pharmacy, Bucharest, Romania. ISNI: 0000 0000 9828 7548. GRID: grid.8194.4
Hadassah-Hebrew University Medical Center, Jerusalem, Israel. ISNI: 0000 0001 2221 2926. GRID: grid.17788.31
LeukoDx, Jerusalem, Israel
Abionic SA, Lausanne, Switzerland
Swiss Federal Laboratories (Empa), St. Gallen, Switzerland
Pathophysiology of injury induced immunosuppression (PI3) Lab, Lyon 1 University / Hospices Civils de Lyon / bioMérieux, Lyon, France
Negovsky V.A. Research Institute of General Reanimatology, Moscow, Russia
University Hospital Basel, Basel, Switzerland. GRID: grid.410567.1
UNIFESP, Sao Paulo, Brazil. ISNI: 0000 0001 0514 7202. GRID: grid.411249.b
Albert Einstein Hospital, Sao Paulo, Brazil. ISNI: 0000 0001 0385 1941. GRID: grid.413562.7
Sírio Libanês Hospital, Sao Paulo, Brazil
Faculty of Medicine and Health Örebro University, Örebro, Sweden. ISNI: 0000 0001 0738 8966. GRID: grid.15895.30
Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden. ISNI: 0000 0000 9241 5705. GRID: grid.24381.3c
Faculty of Medicine and Health, Örebro, Sweden
Center for Infectious Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden. ISNI: 0000 0000 9241 5705. GRID: grid.24381.3c
Erasmus Medical Center, Rotterdam, Netherlands. ISNI: 000000040459992X. GRID: grid.5645.2
University Witten/Herdecke, Witten, Germany. ISNI: 0000 0000 9024 6397. GRID: grid.412581.b
Maasstad Ziekenhuis, Rotterdam, Netherlands. ISNI: 0000 0004 0460 0556. GRID: grid.416213.3
Intermountain Healthcare, Salt Lake City, USA. ISNI: 0000 0004 0460 774X. GRID: grid.420884.2
Immunexpress, Seattle, USA
Lewisham and Greenwich NHS Trust, London, UK. GRID: grid.429537.e
Wirral trust, Merseyside, UK
RLBUHT, Liverpool, UK
Department of Emergency Medicine, Odense University Hospital, Odense C, Denmark. ISNI: 0000 0004 0512 5013. GRID: grid.7143.1
Department of Respiratory Medicine, Odense University Hospital, Odense C, Denmark. ISNI: 0000 0004 0512 5013. GRID: grid.7143.1
Department of Anaesthesiology and Intensive Care Medicine, Odense University Hospital, Odense C, Denmark. ISNI: 0000 0004 0512 5013. GRID: grid.7143.1
Bucharest Clinical Emergency Hospital, Bucharest, Romania
Fundeni Clinical Institute, Bucharest, Romania. ISNI: 0000 0004 0540 9980. GRID: grid.415180.9
Amsterdam Medical Center, Amsterdam, Netherlands. ISNI: 0000000404654431. GRID: grid.5650.6
University Medical Center Utrecht, Utrecht, Netherlands. ISNI: 0000000090126352. GRID: grid.7692.a
Bakirkoy Dr.Sadi Konuk Training and Research Hospital, Istanbul, Turkey. ISNI: 0000 0004 0419 1043. GRID: grid.414177.0
King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia. ISNI: 0000 0004 0608 0662. GRID: grid.412149.b
Assaf Harofeh MC, Beer Yaakov, Israel
Jena University Hopital, Jena, Germany. ISNI: 0000 0001 1939 2794. GRID: grid.9613.d
Prince of Songkla University, Hat Yai, Thailand. ISNI: 0000 0004 0470 1162. GRID: grid.7130.5
Division of Critical Care Medicine, Hat Yai, Thailand
Glasgow Royal Infirmary, Glasgow, UK. ISNI: 0000 0000 9825 7840. GRID: grid.411714.6
University Hospital and Faculty of Medicine Ostrava University, Ostrava, Czech Republic. ISNI: 0000 0004 0609 0692. GRID: grid.412727.5
Institute of Biostatistics and analyses, Masaryk University, Brno, Czech Republic. ISNI: 0000 0001 2194 0956. GRID: grid.10267.32
Università degli studi di Pavia, scuola di specialità: Anestesia e Rianimazione, Pavia, Italy. ISNI: 0000 0004 1762 5736. GRID: grid.8982.b
UOC Anestesia e Rianimazione Ospedale Civile di Vigevano, AO Pavia, Vigevano, Italy
Università degli studi di Pavia, Pavia, Italy. ISNI: 0000 0004 1762 5736. GRID: grid.8982.b
Hospital O’horan, Mérida, Mexico
Department of Anaesthesiology and Intensive Therapy, Medical University, Wroclaw, Poland. ISNI: 0000 0001 1090 049X. GRID: grid.4495.c
AKPA, Waltham, USA
St. Paul’s Hospital, Vancouver, Canada. ISNI: 0000 0000 8589 2327. GRID: grid.416553.0
University of Medicine and Pharmacy “Carol Davila”, Bucharest, Romania. ISNI: 0000 0000 9828 7548. GRID: grid.8194.4
Acedemisch Medisch Centrum, Amsterdam, Netherlands
University Hospital of Greifswald, Greifswald, Germany. ISNI: 0000 0000 9116 8976. GRID: grid.412469.c
Division of Infection Control and Prevention, Osaka University Graduate School of Medicine, Suita, Japan. ISNI: 0000 0004 0373 3971. GRID: grid.136593.b
Department of Traumatology and Acute Critical Medicine, Osaka University Graduate School of Medicine, Suita, Japan. ISNI: 0000 0004 0373 3971. GRID: grid.136593.b
Department of Emergency Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan. ISNI: 0000 0000 8902 2273. GRID: grid.174567.6
Hospital Clínico Universitario de Valladolid, Valladolid, Spain. ISNI: 0000 0000 9274 367X. GRID: grid.411057.6
Jena University Hospital, Jena, Germany. ISNI: 0000 0000 8517 6224. GRID: grid.275559.9
Medica Superspecialty Hospital, Kolkata, West Bengal India
DMC, Detroit, USA. ISNI: 0000 0001 0088 6903. GRID: grid.413184.b
Wayne State University, Detroit, USA. ISNI: 0000 0001 1456 7807. GRID: grid.254444.7
Scientific Institute of Public Health (WIV-ISP), Brussels, Belgium. ISNI: 0000 0004 0635 3376. GRID: grid.418170.b
Ghent University, Ghent, Belgium. ISNI: 0000 0001 2069 7798. GRID: grid.5342.0
Erasme University, Brussels, Belgium
QualityLabs Bt GmbH, Nuremberg, Germany
B.Braun Melsungen AG, Melsungen, Germany. ISNI: 0000 0001 0699 8877. GRID: grid.462046.2
Dr. Roschke medical marketing GmbH, Cologne, Germany
Nakhonpathom hospital, Nakhonpathom, Thailand
Lithuanian University of Health Sciences, Kaunas,, Lithuania. ISNI: 0000 0004 0432 6841. GRID: grid.45083.3a
University Hospital North Midlands, Stoke-on-Trent, UK
EPS Charles-Nicolle, Bab Saadoun, Tunisia
Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi County, Taiwan
Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands. ISNI: 0000000084992262. GRID: grid.7177.6
Academic Medical Center, University of Amsterdam, Center for Experimental and Molecular Medicine, Amsterdam, Netherlands
Department of Intensive Care Medicine, University Medical Center Utrecht, Utrecht, Netherlands. ISNI: 0000000090126352. GRID: grid.7692.a
Department of Intensive Care Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands. ISNI: 0000000404654431. GRID: grid.5650.6
Department of Medical Microbiology, University Medical Center Utrecht, Utrecht, Netherlands. ISNI: 0000000090126352. GRID: grid.7692.a
NHS Greater Glasgow and Clyde, Glasgow, UK. ISNI: 0000 0001 0523 9342. GRID: grid.413301.4
Health Protection Scotland, Glasgow, UK. ISNI: 0000 0001 2232 4338. GRID: grid.413893.4
Public Health England, London, UK. ISNI: 0000 0001 2196 8713. GRID: grid.9004.d
Fukuoka University Hospital, Fukuoka, Japan. ISNI: 0000 0004 0594 9821. GRID: grid.411556.2
King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia. ISNI: 0000 0004 0608 0662. GRID: grid.412149.b
Toxicological Research Center, Department of Clinical Toxicology, Loghman-Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran. GRID: grid.411600.2
St. Elisabeth Hospital, Tilburg, Netherlands. GRID: grid.416373.4
Mongi Slim University Hospital, La Marsa, Tunisia
University of Athens, Medical School, Athens, Greece. ISNI: 0000 0001 2155 0800. GRID: grid.5216.0
Korgialeneion Benakeion Hospital, Athens, Greece
University of Thrace, Alexandroupolis, Greece. ISNI: 0000 0001 2170 8022. GRID: grid.12284.3d
Aghios Dimitrios Hospital, Thessaloniki, Greece
Tzaneion Hospital, Piraeus, Greece
G.Gennimatas General Hospital, Thessaloniki, Greece. GRID: grid.414012.2
University of Ioannina, Ioannina, Greece. ISNI: 0000 0001 2108 7481. GRID: grid.9594.1
G.Papanikolaou General Hospital, Thessaloniki, Greece. ISNI: 0000 0004 0576 574X. GRID: grid.415248.e
University of Patras, Patras, Greece. ISNI: 0000 0004 0576 5395. GRID: grid.11047.33
Hospital Universitario La Paz, Madrid, Spain. ISNI: 0000 0000 8970 9163. GRID: grid.81821.32
Centro Hospitalar São João, Porto, Portugal. ISNI: 0000 0000 9375 4688. GRID: grid.414556.7
PSMMC, Riyadh, Saudi Arabia
UNIKLINIKUM JENA, JENA, Germany
King Fahad Medical City, Riyadh, Saudi Arabia. ISNI: 0000 0004 0593 1832. GRID: grid.415277.2
Addenbrooke’s Hospital, Cambridge, UK. ISNI: 0000 0004 0622 5016. GRID: grid.120073.7
University of Cambridge, Cambridge, UK. ISNI: 0000000121885934. GRID: grid.5335.0
Royal United Hospital, Bath, UK. ISNI: 0000 0004 0417 0728. GRID: grid.416091.b
Salford Royal Hospital, London, UK. ISNI: 0000 0000 8535 2371. GRID: grid.415721.4
Hennepin County Medical Center, Minneapolis, USA. ISNI: 0000 0000 9206 4546. GRID: grid.414021.2
CHU Dupuytren, Limoges, France. ISNI: 0000 0001 1481 5225. GRID: grid.412212.6
St Luc University Hospital, Brussels, Belgium. ISNI: 0000 0004 0461 6320. GRID: grid.48769.34
CHUV, Lausanne, Switzerland. ISNI: 0000 0001 0423 4662. GRID: grid.8515.9
Hospital Clinic of Barcelona, Barcelona, Spain. ISNI: 0000 0000 9635 9413. GRID: grid.410458.c
Hospital Clínico San Carlos, Madrid, Spain. ISNI: 0000 0001 0671 5785. GRID: grid.411068.a
Université François Rabelais and CHU Bretonneau, Tours, France. ISNI: 0000 0001 2182 6141. GRID: grid.12366.30
Groupe Hospitalier Pitié-Salpêtrière, Paris, France. ISNI: 0000 0001 2150 9058. GRID: grid.411439.a
MedImmune, Gaithersburg, USA. GRID: grid.418152.b
Xanthi General Hospital, Xanthi, Greece
Royal Infirmary of Edinburgh, Edinburgh, UK. ISNI: 0000 0001 0709 1919. GRID: grid.418716.d
Western General Hospital, Edinburgh, UK. ISNI: 0000 0004 0624 9907. GRID: grid.417068.c
Fondazione IRCCS Policlinico S. Matteo, University of Pavia, Pavia, Italy. ISNI: 0000 0004 1762 5736. GRID: grid.8982.b
Centre Hospitalier Universitaire Dijon, Dijon, France. GRID: grid.31151.37
Marmara University Pendik Teaching and Research Hospital, Istanbul, Turkey. ISNI: 0000 0001 0668 8422. GRID: grid.16477.33
Sheffield Teaching Hospital NHS Foundation Trust, Sheffield, UK. GRID: grid.419135.b
University College, London, UK
Cairo University, Giza, Egypt. ISNI: 0000 0004 0639 9286. GRID: grid.7776.1
University hospital Center of La Rabta, Tunis, Tunisia
V.A. Negovsky Research Institute of General Reanimatology, Moscow, Russia
N.V. Sklifosofsky Institute of Emergency Medicine, Moscow, Russia
NN Burdenko Main Military Hospital, Moscow, Russia
Novartis Pharmaceuticals, San Carlos, USA. ISNI: 0000 0004 0439 2056. GRID: grid.418424.f
Nektar Therapeutics, San Francisco, CA USA. ISNI: 0000 0004 0410 3955. GRID: grid.476522.0
Hospital Clinic, Barcelona, Spain. ISNI: 0000 0000 9635 9413. GRID: grid.410458.c
Maine Medical Center, Portland, USA. GRID: grid.240160.1
Medical University of Vienna, Vienna, Austria. ISNI: 0000 0000 9259 8492. GRID: grid.22937.3d
HIA Percy, Clamart, France. ISNI: 0000 0004 1795 3756. GRID: grid.414028.b
Pherecydes Pharma, Romainville, France
Hôpital Reine Astrid, Brussels, Belgium
CHU Liege, Liege, Belgium. ISNI: 0000 0000 8607 6858. GRID: grid.411374.4
CH Saint Jospeh Saint Luc, Lyon, France
Hamad Medical Corporation, Doha, Qatar. ISNI: 0000 0004 0571 546X. GRID: grid.413548.f
MUI, Innsbruck, Austria. ISNI: 0000 0000 8853 2677. GRID: grid.5361.1
Academic Medical Centre, Amsterdam, Netherlands. ISNI: 0000000404654431. GRID: grid.5650.6
Academic Medical Center Amsterdam, Amsterdam, Netherlands. ISNI: 0000000404654431. GRID: grid.5650.6
Sanquin, Amsterdam, Netherlands. ISNI: 0000 0001 2234 6887. GRID: grid.417732.4
KAT Hospital Athens, Kifisia, Greece. ISNI: 0000 0004 0622 8129. GRID: grid.415070.7
ICU-B, KAT Hospital Kifisia, Athens, Greece
Hokkaido University Hospital, Sapporo, Japan. ISNI: 0000 0004 0378 6088. GRID: grid.412167.7
Tohoku University Graduate School of Medicine, Sendai, Japan. ISNI: 0000 0001 2248 6943. GRID: grid.69566.3a
Tokyo Medical and Dental University Hospital of Medicine, Tokyo, Japan. GRID: grid.474906.8
National Hospital Organization Disaster Medical Center, Tokyo, Japan. ISNI: 0000 0004 0569 9594. GRID: grid.416797.a
Keio University School of Medicine, Tokyo, Japan. ISNI: 0000 0004 1936 9959. GRID: grid.26091.3c
Osaka University Graduate School of Medicine, Osaka, Japan. ISNI: 0000 0004 0373 3971. GRID: grid.136593.b
Rinku General Medical Center, Osaka, Japan
Kinki University Faculty of Medicine, Osaka, Japan. ISNI: 0000 0004 1936 9967. GRID: grid.258622.9
Yokohama City University Graduate School of Medicine, Yokohama, Japan. ISNI: 0000 0001 1033 6139. GRID: grid.268441.d
Faculty of Medicine, Fukuoka University, Fukuoka, Japan. ISNI: 0000 0001 0672 2176. GRID: grid.411497.e
National Center For Global Health and Medicine, Tokyo, Japan. ISNI: 0000 0004 0489 0290. GRID: grid.45203.30
Tokyo Women’s Medical University, Tokyo, Japan. ISNI: 0000 0001 0720 6587. GRID: grid.410818.4
Odessa National Medical University, Odessa, Ukraine. GRID: grid.445907.b
Hopital Sacré-Coeur de Montréal, Montreal, Canada. ISNI: 0000 0001 2160 7387. GRID: grid.414056.2
Xanthi General Hospital, Xanth, Greece. GRID: grid.414012.2
Maastricht UMC, Maastricht, Netherlands. GRID: grid.412966.e
Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic. ISNI: 0000 0004 0611 0905. GRID: grid.412826.b
Sechenov First Moscow Stat Medical University, Moscow, Russia
Sheba Medical Center, Tel-Hashomer, Israel. ISNI: 0000 0001 2107 2845. GRID: grid.413795.d
Yokohama Municipal Citizen’s Hospital, Yokohama, Japan. ISNI: 0000 0004 0377 5418. GRID: grid.417366.1
Hayama Heart Center, Hayama, Japan
Yokohama City University Hospital, Yokohama, Japan. ISNI: 0000 0004 1767 0473. GRID: grid.470126.6
Institute of Ageing and Chronic Disease, Liverpool, UK
Institute of Infection and Global Health, Liverpool, UK
Department of Haematology, Royal Liverpool University Hospital (RLUH), Liverpool, UK. ISNI: 0000 0004 0417 2395. GRID: grid.415970.e
Hôpital du Sacré-Coeur de Montréal, Montreal, Canada. ISNI: 0000 0001 2160 7387. GRID: grid.414056.2
Evelina London Children’s Hospital, London, UK
St Thomas Hospital, London, UK. GRID: grid.425213.3
Intensive Care Unit, University of Ferrara, Italy, Ferrara, Italy. ISNI: 0000 0004 1757 2064. GRID: grid.8484.0
Department of Intensive Care, Erasme Hospital, Université Libre de Bruxelles, Bruxelles, Belgium
Hippokration General Hospital Thessaloniki, Thessaloniki, Greece. ISNI: 0000 0004 0621 2899. GRID: grid.414122.0
Morriston Hospital, Swansea, UK. ISNI: 0000 0004 0649 0266. GRID: grid.416122.2
Central London School of Anaesthesia and Intensive Care Medicine, London, UK
University of the Sunshine Coast, Maroochydore, Australia. ISNI: 0000 0001 1555 3415. GRID: grid.1034.6
University of Edinburgh, Edinburgh, UK. ISNI: 0000 0004 1936 7988. GRID: grid.4305.2
John Radcliffe Hospital, Oxford, UK. ISNI: 0000 0001 2306 7492. GRID: grid.8348.7
Copenhagen University Hospital, Copenhagen, Denmark. ISNI: 0000 0004 0646 7373. GRID: grid.4973.9
Peterborough NHS Trust, Peterborough, UK
Aarhus University, Aarhus, Denmark. ISNI: 0000 0001 1956 2722. GRID: grid.7048.b
Hospital de Sao Paulo, Sao Paulo, Brazil. GRID: grid.413463.7
Royal Brompton & Harefield NHS Trust, London, UK. ISNI: 0000 0004 0581 2008. GRID: grid.451052.7
Barts Heart Centre, London, UK
University of Sao Paulo, Brazi, Sao Paulo, Brazil. ISNI: 0000 0004 1937 0722. GRID: grid.11899.38
Juntendo University Hospital, Tokyo, Japan. GRID: grid.411966.d
Saitama Medical Center, Jichi Medical University, Saitama, Japan. ISNI: 0000000123090000. GRID: grid.410804.9
Gunma University Hospital, Maebashi, Japan. ISNI: 0000 0004 0595 7039. GRID: grid.411887.3
Yokohama City Minato Red Cross Hospital, Yokohama, Japan
Research Institution for Cardiology, Tomsk, Russia
Siberian State Medical University, Tomsk, Russia. ISNI: 0000 0001 0027 1685. GRID: grid.412593.8
The Hillingdon Hospitals NHS Foundation Trust, Middlesex, UK. ISNI: 0000 0004 0476 7073. GRID: grid.440199.1
University Hospital Rio Hortega, Valladolid, Spain. ISNI: 0000 0001 1842 3755. GRID: grid.411280.e
Erasmus MC, Rotterdam, Netherlands. ISNI: 000000040459992X. GRID: grid.5645.2
Sheikh Khalifa Medical City, Abu Dhabi, United Arab Emirates. ISNI: 0000 0004 1773 3278. GRID: grid.415670.1
Intensive Care Unit, St. Boniface Hospital, Verona, Italy
University of Pittsburgh, Pittsburgh, USA. ISNI: 0000 0004 1936 9000. GRID: grid.21925.3d
Carnegie Mellon University, Pittsburgh, USA. ISNI: 0000 0001 2097 0344. GRID: grid.147455.6
Valme University Hospital, Seville, Spain. ISNI: 0000 0004 1768 1690. GRID: grid.412800.f
CHU Amiens, Amiens, France. ISNI: 0000 0004 0593 702X. GRID: grid.134996.0
CH Beauvais, Beauvais, France
Réanimation polyvalente, Le Havre, France
CH Roubaix, Roubaix, France. ISNI: 0000 0004 0608 7784. GRID: grid.477297.8
CH Cotentin, Cherbourg, France
CHU Rouen, Rouen, France. GRID: grid.41724.34
CHU Lille, Lille, France. ISNI: 0000 0004 0471 8845. GRID: grid.410463.4
CHU Caen, Caen, France. ISNI: 0000 0004 0472 0160. GRID: grid.411149.8
University Medical Center Hamburg-Eppendorf, Hamburg, Germany. ISNI: 0000 0001 2180 3484. GRID: grid.13648.38
Brugmann Hospital, Brussels, Belgium. ISNI: 0000 0004 0469 8354. GRID: grid.411371.1
Hospital Universitario del Tajo, Aranjuez, Spain
Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Spain. ISNI: 0000 0004 1765 5855. GRID: grid.411338.c
Hospital Universitario de San Carlos, Madrid, Spain. ISNI: 0000 0001 0671 5785. GRID: grid.411068.a
Klinikum rechts der Isar, Technical University of Munich, Munich, Germany. ISNI: 0000000123222966. GRID: grid.6936.a
Department of Intensive Care Medicine, University Hospital Bern, Bern, Switzerland. ISNI: 0000 0004 0479 0855. GRID: grid.411656.1
Institute of Clinical Sciences at the Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital, Gothenburg, Sweden
St George’s Healthcare NHS Trust, London, UK. GRID: grid.451349.e
Karolinska Institutet, Stockholm, Sweden. ISNI: 0000 0004 1937 0626. GRID: grid.4714.6
Wenzhou Medical University, Wenzhou, Zheijang China. ISNI: 0000 0001 0348 3990. GRID: grid.268099.c
Department of Intensive Care, Austin Hospital, Melbourne, VIC Australia. ISNI: 0000 0001 0162 7225. GRID: grid.414094.c
Policlinico Modena, Bologna, Italy. ISNI: 0000 0004 1769 5275. GRID: grid.413363.0
Clinical Hospital Sveti Duh, Zagreb, Croatia
The Canberra Hospital, Hughes, ACT Australia. ISNI: 0000 0000 9984 5644. GRID: grid.413314.0
Australian National University Medical School, Canberra, Australia. ISNI: 0000 0001 2180 7477. GRID: grid.1001.0
Lapeyronie University Hospital, Montpellier, France. ISNI: 0000 0004 0638 8990. GRID: grid.411572.4
Brigham and Women’s Hospital, Boston, USA. ISNI: 0000 0004 0378 8294. GRID: grid.62560.37
Trexin Medical, Chicago, USA
University of Colorado and Denver Health, Denver, USA. ISNI: 0000000107903411. GRID: grid.241116.1
Beth Isreal Deaconess, Boston, USA
Centro Hospitalar do Porto, Porto, Portugal. ISNI: 0000 0004 0392 7039. GRID: grid.418340.a
University Hospital, Ghent, Belgium. ISNI: 0000 0004 0626 3303. GRID: grid.410566.0
City Clinical Hospital 40, Yekaterinburg, Russia
University Hospital Muenster, Muenster, Germany. ISNI: 0000 0004 0551 4246. GRID: grid.16149.3b
Marienhospital Osnabrück, Osnabrück, Germany
Charité, University of Berlin, Berlin, Germany
Sapienza University of Rome, Rome, Italy. GRID: grid.7841.a
University Hospital of Muenster, Muenster, Germany. ISNI: 0000 0004 0551 4246. GRID: grid.16149.3b
Erasmus MC University Hospital Rotterdam, Rotterdam, Netherlands. ISNI: 000000040459992X. GRID: grid.5645.2
Medical Research Institute of New Zealand, Wellington, New Zealand. ISNI: 0000 0004 0445 6830. GRID: grid.415117.7
Monash University, Melbourne, Australia. ISNI: 0000 0004 1936 7857. GRID: grid.1002.3
Austin Hospital, Melbourne, Australia. ISNI: 0000 0001 0162 7225. GRID: grid.414094.c
Wellington Regional Hospital, Wellington, New Zealand. ISNI: 0000 0000 8862 6892. GRID: grid.416979.4
Australian and New Zealand Intensive Care Research Centre, Melbourne, Australia
Princess of Wales Hospital, Bridgend, UK. ISNI: 0000 0004 0648 9337. GRID: grid.415249.f
Imperial College London, London, UK. ISNI: 0000 0001 2113 8111. GRID: grid.7445.2
Glan Clwyd Hospital, Bodelwyddan, UK. ISNI: 0000 0000 9831 5916. GRID: grid.415564.7
University Hospital Galway, Galway, Ireland. ISNI: 0000 0004 0617 9371. GRID: grid.412440.7
Albert Schweitzer State Hospital, Rio de Janeiro, Brazil
Tan Tock Seng Hospital, Singapore, Singapore. GRID: grid.240988.f
National Neuroscience Institute, Singapore, Singapore. ISNI: 0000 0004 0636 696X. GRID: grid.276809.2
Erasmus Medical Centre, Rotterdam, Netherlands. ISNI: 000000040459992X. GRID: grid.5645.2
Centro Hospitalar Tamega e Sousa, Penafiel, Portugal. GRID: grid.466592.a
Unidade Local de Saude do Alto Minho, Viana do Castelo, Portugal
South Tees NHS Trust, Middlesbrough, UK
Ikazia Hospital, Rotterdam, Netherlands. ISNI: 0000 0004 0568 7120. GRID: grid.414565.7
Sheffiled Teaching Hospitals, Sheffield, UK
Whiston Hospital, St Helens & Knowsley, UK. ISNI: 0000 0004 0417 1894. GRID: grid.417083.9
University Hospital Duesseldorf, Düsseldorf, Germany. ISNI: 0000 0000 8922 7789. GRID: grid.14778.3d
Charite University Hospital, Berlin, Germany. ISNI: 0000 0001 2218 4662. GRID: grid.6363.0
Royal London Hospital, London, UK. ISNI: 0000 0001 0738 5466. GRID: grid.416041.6
Aurelia and European Hospital, Rome, Italy. GRID: grid.414645.6
Istanbul University Cerrahpasa Medical School, Istanbul, Turkey. ISNI: 0000 0001 2166 6619. GRID: grid.9601.e
Danube University Krems, Krems, Austria. ISNI: 0000 0001 2108 5830. GRID: grid.15462.34
University Hospital St. Poelten, St. Poelten, Austria
Teaching Hospital Policlinico S.Orsola-Malpighi, Bologna, Italy. GRID: grid.412311.4
Department of Nephrology, Dialysis, Hypertension, Bologna, Italy
Science and Technology Park for Medicine, Mirandola, Italy
Aferetica, Bologna, Italy
San Marco Hospital, Zingonia, Italy
CytoSorbents, Monmouth Junction, USA. GRID: grid.428484.6
Klinikum Emden, Emden, Germany
University Hospital Eppendorf, Hamburg, Germany. ISNI: 0000 0001 2180 3484. GRID: grid.13648.38
Aurelia Hospital /European Hospital, Rome, Italy. GRID: grid.414077.1
King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia. ISNI: 0000 0001 2191 4301. GRID: grid.415310.2
GPR Klinikum Ruesselsheim, Ruesselsheim, Hessen Germany
Jikei University School of Medicine, Tokyo, Japan. ISNI: 0000 0001 0661 2073. GRID: grid.411898.d
Kyoto University, Kyoto, Japan. ISNI: 0000 0004 0372 2033. GRID: grid.258799.8
Osaka University, Osaka, Japan. ISNI: 0000 0004 0373 3971. GRID: grid.136593.b
Guy’s & St Thomas’ NHS Foundation Trust, London, UK. GRID: grid.420545.2
King’s College, London, UK. ISNI: 0000 0001 2322 6764. GRID: grid.13097.3c
Hospital de Santa Maria, Lisbon, Portugal. ISNI: 0000 0001 2295 9747. GRID: grid.411265.5
ErasmusMC, Rotterdam, Netherlands. ISNI: 000000040459992X. GRID: grid.5645.2
Gazi University Medical Faculty, Ankara, Turkey. ISNI: 0000 0001 2169 7132. GRID: grid.25769.3f
Gazi University School of Medicine, Critical Care Fellowship Programme, Ankara, Turkey
Gazi University School of Medicine Biochemistry Department, Ankara, Turkey. ISNI: 0000 0001 2169 7132. GRID: grid.25769.3f
Fundación Clínica Medica Sur, Mexico City, Mexico
Lund University and Skane University Hospital, Lund, Sweden. GRID: grid.411843.b
Radboudumc, Nijmegen, Netherlands. ISNI: 0000 0004 0444 9382. GRID: grid.10417.33
Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium. ISNI: 0000 0001 2348 0746. GRID: grid.4989.c
The Royal Surrey County Hospital, Guildford, UK. ISNI: 0000 0004 0417 0648. GRID: grid.416224.7
Royal National Orthopaedic Hospital, Middlesex, UK. ISNI: 0000 0004 0417 7890. GRID: grid.416177.2
Barts Health NHS Trust, London, UK. ISNI: 0000 0001 0372 5777. GRID: grid.139534.9
Queen Mary University of London, London, UK. ISNI: 0000 0001 2171 1133. GRID: grid.4868.2
Asan medical center, Seoul, South Korea. ISNI: 0000 0001 0842 2126. GRID: grid.413967.e
Trakya Univ, Edirne, Turkey. ISNI: 0000 0001 2342 6459. GRID: grid.411693.8
General Directorate of Health Services, Ministry of Health, Ankara, Turkey. GRID: grid.415700.7
AnkaraNKARA Research and Training Hospital, Ankara, Turkey
Department of Biostatistics, Faculty of Medicine, Ankara University, Ankara, Turkey. ISNI: 0000000109409118. GRID: grid.7256.6
Ankara Research and Training Hospital, Ankara, Turkey. ISNI: 0000 0004 0642 6432. GRID: grid.413783.a
MC Into-Sana, Odessa, Ukraine
Glan Clwyd Hospital, Rhyl, UK. ISNI: 0000 0000 9831 5916. GRID: grid.415564.7
Fondazione IRCCS Ca’ Granda, Maggiore Policlinico Hospital, Milan, Italy
University of Ferrara, Sant’Anna Hospital, Ferrara, Italy
Aerogen, Galway, Ireland
Kaplan Medical Centre, Rehovot, Israel
West Virginia University, Morgantown, West Virginia USA. ISNI: 0000 0001 2156 6140. GRID: grid.268154.c
Rihard Knafelj, Ljubljana, Slovenia
Corporació Sanitària i Universitària Parc Taulí, Universitat Autònoma de Barcelona, CIBER Enfermedades Respiratorias, Sabadell, Barcelona, Spain. GRID: grid.7080.f
Dalhousie University, Halifax, Canada. ISNI: 0000 0004 1936 8200. GRID: grid.55602.34
Ernst-Moritz-Arndt-Universität, Greifswald, Germany. GRID: grid.5603.0
Ghent University Hospital, Gent, Belgium. ISNI: 0000 0004 0626 3303. GRID: grid.410566.0
Universidade de São Paulo, São Paulo, Brazil. ISNI: 0000 0004 1937 0722. GRID: grid.11899.38
Hospital La Paz, Madrid, Spain. ISNI: 0000 0000 8970 9163. GRID: grid.81821.32
Institute of Mother and Child, Chisinau mun., Moldova
Institute of Emergency Medicine, Chisinau mun., Moldova
State University of Medicine and Pharmacy, Chisinau mun., Moldova
Cardarelli Hospital, Naples, Italy. GRID: grid.413172.2
San Paolo Hospital, Naples, Italy
National University of Ireland, Galway, Galway City, Ireland. ISNI: 0000 0004 0488 0789. GRID: grid.6142.1
Mount Sinai Hospital, Toronto, Canada. ISNI: 0000 0004 0473 9881. GRID: grid.416166.2
Gazi University School of Medicine Respiratory Medicine and Critical Care Department, Ankara, Turkey. ISNI: 0000 0001 2169 7132. GRID: grid.25769.3f
Gazi University School of Medicine, Internal Medicine Critical Care Department, Ankara, Turkey
Gazi University School of Medicine, Geriatrics Department, Ankara, Turkey
Chulalongkorn University, Bangkok, Thailand. ISNI: 0000 0001 0244 7875. GRID: grid.7922.e
Carmel, Lady Davis Medical Center, Haifa, Israel. GRID: grid.471000.2
Duke University, Durham, USA. ISNI: 0000 0004 1936 7961. GRID: grid.26009.3d
Mayo Clinic, Rochester, USA. ISNI: 0000 0004 0459 167X. GRID: grid.66875.3a
St Helens and Knoowsley, Prescot, UK
Royal Infirmary, Edinburgh, UK. ISNI: 0000 0001 0709 1919. GRID: grid.418716.d
Alexandria Universitry General Hospital, Alexandria, Egypt. ISNI: 0000 0001 2260 6941. GRID: grid.7155.6
University Hospital North Middlands, Stoke On Trent, UK. ISNI: 0000 0004 0641 4263. GRID: grid.415598.4
Medica Sur, Mexico City, Mexico. GRID: grid.414741.3
Instituto Nacional de Rehabilitacion, Mexico City, Mexico. ISNI: 0000 0004 0633 2911. GRID: grid.419223.f
University of Padua, Padua, Italy. ISNI: 0000 0004 1757 3470. GRID: grid.5608.b
Sant Antony hospital, Padua, Italy
HCMC, Minneapolis, USA. ISNI: 0000 0000 9206 4546. GRID: grid.414021.2
University of Minnesota, Minneapolis, USA. ISNI: 0000000419368657. GRID: grid.17635.36
Viecuri Medical Center, Venlo, Netherlands. ISNI: 0000 0004 0477 5022. GRID: grid.416856.8
University of Hawaii, John A. Burns School of Medicine, Honolulu, USA. ISNI: 0000 0001 2188 0957. GRID: grid.410445.0
Respiratory Motion Inc., Waltham, USA
Massachusetts General Hospital, Boston, USA. ISNI: 0000 0004 0386 9924. GRID: grid.32224.35
AO Desio e Vimercate, Vimercate, Italy
AO Crema, Crema, Italy
University of Milan-Bicocca, Monza, Italy. ISNI: 0000 0001 2174 1754. GRID: grid.7563.7
UT Health Science Center at Houston, Houston, TX USA. ISNI: 0000 0000 9206 2401. GRID: grid.267308.8
University of Hawaii, John A. Burns School of Medicine, Honolulu, HI USA. ISNI: 0000 0001 2188 0957. GRID: grid.410445.0
Respiratory Motion Inc., Waltham, MA USA
Massachusetts General Hospital, Boston, MA USA. ISNI: 0000 0004 0386 9924. GRID: grid.32224.35
Swisstom AG, Landquart, Switzerland
Kliniken der Stadt Köln, Pneumology and Critical Care Medicine, Witten / Herdecke University, Ostmerheimer Str. 200, 51109 Cologne, Germany. ISNI: 0000 0000 9024 6397. GRID: grid.412581.b
Kliniken der Stadt Köln, Pneumology and Critical Care Medicine, Witten/ Herdecke University, Ostmerheimer Str. 200, 51109 Cologne, Germany. ISNI: 0000 0000 9024 6397. GRID: grid.412581.b
ARDS and ECMO Center Köln-Merheim, Cologne, Germany
Swisstom, Chur, Switzerland
Sahlgrenska Univ Hospital, Göteborg, Sweden. ISNI: 000000009445082X. GRID: grid.1649.a
Second University of Naples, Naples, Italy. ISNI: 0000 0001 2200 8888. GRID: grid.9841.4
University of Sassari, Sassari, Italy. ISNI: 0000 0001 2097 9138. GRID: grid.11450.31
University of Saerno, Salerno, Italy
East Surrey Hospital, Surrey and Sussex NHS Trust, Surrey, UK
Mount Sinai Hospital and University of Toronto, Toronto, Canada. ISNI: 0000 0004 0473 9881. GRID: grid.416166.2
University Health Network-Toronto General Hospital and Univeristy of Toronto, Toronto, Canada. ISNI: 0000 0001 0661 1177. GRID: grid.417184.f
Papworth Hospital, Cambridge, UK. ISNI: 0000 0004 0399 2308. GRID: grid.417155.3
King’s College Hospital NHS Foundation Trust, London, UK. ISNI: 0000 0004 0489 4320. GRID: grid.429705.d
Meijer Heart & Vascular Institute, Grand Rapids, USA
Glenfield Hospital, UHL, Leicester, UK. ISNI: 0000 0004 0648 9396. GRID: grid.416025.4
National University Hospital, Singapore, Singapore. ISNI: 0000 0004 0621 9599. GRID: grid.412106.0
National University Singapore, Singapore, Singapore. ISNI: 0000 0001 2180 6431. GRID: grid.4280.e
Mayo Clinic, Phoenix, AZ USA. ISNI: 0000 0000 8875 6339. GRID: grid.417468.8
University of Pittsburgh, Pittsburgh, PA USA. ISNI: 0000 0004 1936 9000. GRID: grid.21925.3d
Vall D’Hebron University Hospital, Barcelona, Spain. ISNI: 0000 0001 0675 8654. GRID: grid.411083.f
Universitat Autonoma de Barcelona, Barcelona, Spain. GRID: grid.7080.f
George P. Livanos and Marianthi Simou Laboratories, Athens, Greece
University of Patras, Rio, Achaia Greece. ISNI: 0000 0004 0576 5395. GRID: grid.11047.33
University of Ferrara, Ferrara, Italy. ISNI: 0000 0004 1757 2064. GRID: grid.8484.0
University of Bari, Bari, Italy. ISNI: 0000 0001 0120 3326. GRID: grid.7644.1
CHU HJRA, Antananarivo, Madagascar
Réanimation médicale, Centre Hospitalier Universitaire, Amiens, France. ISNI: 0000 0004 0593 702X. GRID: grid.134996.0
Cardio-Pulmonary Department, Pulmonary Division, Heart Institute (Incor), University of São Paulo, São Paulo, Brazil. ISNI: 0000 0004 1937 0722. GRID: grid.11899.38
Royal Brompton Hospital, London, UK. GRID: grid.439338.6
Musashino Red Cross Hospital, Tokyo, Japan. ISNI: 0000 0000 9887 307X. GRID: grid.416332.1
JSEPTIC Clinical Trial Group, Tokyo, Japan
University of Liverpool, Liverpool, UK. ISNI: 0000 0004 1936 8470. GRID: grid.10025.36
Royal Liverpool University Hospital, Liverpool, UK. ISNI: 0000 0004 0417 2395. GRID: grid.415970.e
Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain. ISNI: 0000 0000 8816 6945. GRID: grid.411048.8
MUMC, Maastricht, Netherlands. GRID: grid.412966.e
Vilnius University Hospital Santariskiu Clinics, Vilnius, Lithuania. ISNI: 0000 0004 0567 3159. GRID: grid.426597.b
Vilnius University, Faculty of Medicine, Vilnius, Lithuania
Mercy University Hospital, Cork, Ireland. ISNI: 0000 0004 0575 9497. GRID: grid.411785.e
Hospital Meridional S.A., Cariacica, Brazil
Geneva Universtiy Hospital, Geneva, Switzerland. ISNI: 0000 0001 0721 9812. GRID: grid.150338.c
Medical University Department, Kantonsspital Aarau, Aarau, Switzerland. ISNI: 0000 0000 8704 3732. GRID: grid.413357.7
Department of Endocrinology, Diabetes and Clinical Nutrition, University Hospital Bern, Bern, Switzerland. ISNI: 0000 0004 0479 0855. GRID: grid.411656.1
Jessa Ziekenhuis, Hasselt, Belgium. ISNI: 0000 0004 0578 1096. GRID: grid.414977.8
Unidade de Saude Local de Castelo Branco, Castelo Branco, Portugal
Centro Hospitalar e Universitario de Coimbra, Coimbra, Portugal. ISNI: 0000000106861985. GRID: grid.28911.33
Centro Hospitalar de Vila Nova de Gaia, Vila Nova de Gaia, Portugal. ISNI: 0000 0000 8902 4519. GRID: grid.418336.b
Centro Hospitalar do Algarve, Faro, Portugal
Instituto Portugues de Oncologia do Porto, Porto, Portugal. GRID: grid.435544.7
Faculdade de Ciencias da Nutricao e Alimentacao da Universidade do Porto, Porto, Portugal. ISNI: 0000 0001 1503 7226. GRID: grid.5808.5
Faculdade de Ciencias da Nutrição e Alimentação da Universidade do Porto, Porto, Portugal. ISNI: 0000 0001 1503 7226. GRID: grid.5808.5
Instituto Português de Oncologia do Porto, Porto, Portugal. ISNI: 0000 0004 0631 0608. GRID: grid.418711.a
Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal. ISNI: 0000000106861985. GRID: grid.28911.33
Centro Hospitalar do Baixo Vouga, Aveiro, Portugal
Nottingham University Hospital NHS Trust, Nottingham, UK. ISNI: 0000 0001 0440 1889. GRID: grid.240404.6
Prince of Songkla University, Songkla, Thailand. ISNI: 0000 0004 0470 1162. GRID: grid.7130.5
Université de Sherbrooke, Sherbrooke, Canada. ISNI: 0000 0000 9064 6198. GRID: grid.86715.3d
University Hospital, Montevideo, Uruguay
Queen’s University, Kingston, Canada. ISNI: 0000 0004 1936 8331. GRID: grid.410356.5
University Medical Center Schleswig-Holstein, Kiel, Germany. ISNI: 0000 0004 0646 2097. GRID: grid.412468.d
University of Jena, Jena, Germany. ISNI: 0000 0001 1939 2794. GRID: grid.9613.d
Aida Hospital, Fukushima, Japan
Keiyo Hospital, Tokyo, Japan
Shisei Hospital, Saitama, Japan
Prince of Songkla University, Hat Yai City, Songkhla Province Thailand. ISNI: 0000 0004 0470 1162. GRID: grid.7130.5
Centro Hospitalar Baixo Vouga, Aveiro, Portugal
Department of Cardiothoracic Surgery, George Papanikolaou General Hospital, Thessaloniki, Greece. ISNI: 0000 0004 0576 574X. GRID: grid.415248.e
Gülhane Military Medical Academy, Ankara, Turkey. ISNI: 0000 0001 0720 6034. GRID: grid.413460.4
Ankara Mevki Military Hospital, Ankara, Turkey. GRID: grid.461837.f
St Bartholomew’s Hospital, London, UK. ISNI: 0000 0000 9244 0345. GRID: grid.416353.6
Aristotle Medical School, Thessaloniki, Greece
Tokyo Medical University Hachiosi Medical Center, Tokyo, Japan. ISNI: 0000 0001 0663 3325. GRID: grid.410793.8
Hôpital Louis Mourier, Colombes, France. ISNI: 0000 0001 0273 556X. GRID: grid.414205.6
Laboratoire ILUMENS, Paris, France
Institut de Hauts de Seine, Nanterre, France
University Hospital Lewisham, London, UK. GRID: grid.439787.6
Queen Elizabeth Hospital, London, UK. GRID: grid.439484.6
Minet Green Health Practice, London, UK
Department of Public Health, University of Liège, Liège, Belgium. ISNI: 0000 0001 0805 7253. GRID: grid.4861.b
Department of Emergency Medicine, University Hospital of Liège, Liège, Belgium. ISNI: 0000 0000 8607 6858. GRID: grid.411374.4
Department of Medical Biostatistics, University of Liège, Liège, Belgium. ISNI: 0000 0001 0805 7253. GRID: grid.4861.b
University Hospital, Philipps University Marburg, Marburg, Germany. ISNI: 0000 0004 1936 9756. GRID: grid.10253.35
Oslo University Hospital, Oslo, Norway. ISNI: 0000 0004 0389 8485. GRID: grid.55325.34
William Harvey Hospital, Ashford, UK. ISNI: 0000 0004 0398 7998. GRID: grid.417122.3
Kansai Medical University Takii Hospital, Moriguchi, Japan. GRID: grid.410783.9
Japanese Red Cross Musashino Hospital, Tokyo, Japan. ISNI: 0000 0004 1762 2623. GRID: grid.410775.0
Medisch Spectrum Twente, Enschede, Netherlands. ISNI: 0000 0004 0399 8347. GRID: grid.415214.7
University Modena, Modena, Italy. ISNI: 0000000121697570. GRID: grid.7548.e
Nuovo Ospedale Civile Sant’Agostino Estense, Modena, Italy
Faculty of Medicine Alexandria University, Alexandria, Egypt. ISNI: 0000 0001 2260 6941. GRID: grid.7155.6
Victoria Hospital, Kirkcaldy, UK. ISNI: 0000 0004 0624 9667. GRID: grid.416854.a
Ziekenhuis Oost-Limburg, Genk, Belgium. ISNI: 0000 0004 0612 7379. GRID: grid.470040.7
ANU Medical School, Canberra, Australia. ISNI: 0000 0001 2180 7477. GRID: grid.1001.0
“Spirito Santo” Hospital, Pescara, Italy. GRID: grid.416240.5
St Lukes International Hospital, Akashi-Chou Chuo-Ku, Japan. GRID: grid.430395.8
Kangwon National University, Chuncheonsi, South Korea. ISNI: 0000 0001 0707 9039. GRID: grid.412010.6
Military Medical Academy, Sofia, Bulgaria. ISNI: 0000 0004 0621 0228. GRID: grid.413126.3
Istanbul University, Medical Faculty of Istanbul, Anesthesiology and Intensive Care, Istanbul, Turkey
Istanbul University, Medical Faculty of Istanbul, Department of Neuroradiology, Istanbul, Turkey. ISNI: 0000 0001 2166 6619. GRID: grid.9601.e
Istanbul University, Institute of Experimental Medicine, Neuroscience, Istanbul, Turkey. ISNI: 0000 0001 2166 6619. GRID: grid.9601.e
Helsinki University Hospital, Helsinki, Finland. ISNI: 0000 0000 9950 5666. GRID: grid.15485.3d
North Karelia Central Hospital, Joensuu, Finland. ISNI: 0000 0004 0368 0478. GRID: grid.416446.5
Kuopio University Hospital, Kuopio, Finland. ISNI: 0000 0004 0628 207X. GRID: grid.410705.7
King’s College Hospital, London, UK. ISNI: 0000 0004 0391 9020. GRID: grid.46699.34
Hospital Universitario Puerta del Mar, Cadiz, Spain. ISNI: 0000 0004 1771 1175. GRID: grid.411342.1
Hospital Infanta Cristina, Badajoz, Spain. ISNI: 0000 0004 1771 0842. GRID: grid.411319.f
The Ottawa Hospital, Ottawa, Canada. ISNI: 0000 0000 9606 5108. GRID: grid.412687.e
Ulaval, Quebec City, Canada
UBC, Vancouver, Canada. ISNI: 0000 0001 2288 9830. GRID: grid.17091.3e
UManitoba, Winnipeg, Canada
OHRI, Ottawa, Canada
Ottawa Hospital Research Institute, Ottawa, Canada. ISNI: 0000 0000 9606 5108. GRID: grid.412687.e
Cliniques St Luc, Université catholique de Louvain, Brussels, Belgium. ISNI: 0000 0001 2294 713X. GRID: grid.7942.8
Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy. ISNI: 0000 0004 1757 8749. GRID: grid.414818.0
Milan University, Milan, Italy. ISNI: 0000 0004 1757 2822. GRID: grid.4708.b
CHU de Nice, Nice, France. ISNI: 0000 0001 2322 4179. GRID: grid.410528.a
Regional Hospital, Liberec, Czech Republic. ISNI: 0000 0004 0609 0449. GRID: grid.447961.9
Institute of Experimental Medicine, Prague, Czech Republic. ISNI: 0000 0004 0404 6946. GRID: grid.424967.a
University of Glasgow, Glasgow, UK. ISNI: 0000 0001 2193 314X. GRID: grid.8756.c
Institute of Neurological Sciences, NHSGGC, Glasgow, UK. ISNI: 0000 0001 0523 9342. GRID: grid.413301.4
Department of Clinical Physics and Bioengineering, NHSGGC, Glasgow, UK. ISNI: 0000 0001 0523 9342. GRID: grid.413301.4
Academic Unit of Anaesthesia, Pain and Critical Care Medicine, University of Glasgow, Glasgow, UK. ISNI: 0000 0001 2193 314X. GRID: grid.8756.c
Smartimplant Ltd., Tallinn, Estonia
NEMC, Tallinn, Estonia. ISNI: 0000 0004 0631 377X. GRID: grid.454953.a
Universite Laval, Quebec, Canada. ISNI: 0000 0004 1936 8390. GRID: grid.23856.3a
University of Manitoba, Winnipeg, Canada. ISNI: 0000 0004 1936 9609. GRID: grid.21613.37
Universite de Montreal, Montreal, Canada. ISNI: 0000 0001 2292 3357. GRID: grid.14848.31
University of British Columbia, Vancouver, Canada. ISNI: 0000 0001 2288 9830. GRID: grid.17091.3e
Hospital Estadual Getulio Vargas, Rio de Janeiro, Brazil
Yonsei University College of Medicine, Seoul, South Korea. ISNI: 0000 0004 0470 5454. GRID: grid.15444.30
Emergency Department, Groupe Hospitalier Pitié-Salpêtrière, Paris, France. ISNI: 0000 0001 2150 9058. GRID: grid.411439.a
Morton Plant Hospital, Clearwater, USA. ISNI: 0000 0000 8602 0133. GRID: grid.416123.3
Department of Laboratory Medicine, Kantonsspital Aarau, Aarau, Switzerland. ISNI: 0000 0000 8704 3732. GRID: grid.413357.7
Royal Cornwall Hospital Trust, Truro, UK. ISNI: 0000 0004 0474 4488. GRID: grid.412944.e
Manchester Royal Infirmary, Manchester, UK. ISNI: 0000 0004 0641 2823. GRID: grid.419319.7
University of Tsukuba, Tsukuba Medical Center Hospital, Tsukuba, Japan. ISNI: 0000 0004 1764 0856. GRID: grid.417324.7
Kent, Surrey & Sussex Air Ambulance Trust, Kent, UK
Prometheus Delta-Tech, Herefordshire, UK
Stavanger University Hospital, Stavanger, Norway. ISNI: 0000 0004 0627 2891. GRID: grid.412835.9
Aseer Central Hospital, Abha, Saudi Arabia. ISNI: 0000 0004 0607 7156. GRID: grid.413974.c
HagaZiekenhuis, Den Haag, Netherlands. ISNI: 0000 0004 0568 6689. GRID: grid.413591.b
Reinier de Graaf Gasthuis, Delft, Netherlands. ISNI: 0000 0004 0624 5690. GRID: grid.415868.6
Santa Maria University Hospital, Lisboa, Portugal. ISNI: 0000 0001 2295 9747. GRID: grid.411265.5
St. Vincent’s University Hospital, Dublin 4, Ireland. ISNI: 0000 0001 0315 8143. GRID: grid.412751.4
Percy Military Teaching Hospital, Clamart, France
Whiston Hospital, Prescot, UK. ISNI: 0000 0004 0417 1894. GRID: grid.417083.9
King Abdulaziz Medical City, National Guard Hospital, Riyadh, Saudi Arabia. ISNI: 0000 0004 1790 7311. GRID: grid.415254.3
Department of Management, College of Business Administration, King Saud University, Saudi Arabia, Riyadh, Saudi Arabia. ISNI: 0000 0004 1773 5396. GRID: grid.56302.32
Ege University Hospital, Izmir, Turkey. ISNI: 0000 0004 0535 6364. GRID: grid.412190.f
Katip Celebi University, Health Sciences Faculty, Izmir, Turkey
Milton Keynes University Hospital NHS Foundation Trust, Milton Keynes, UK. GRID: grid.415667.7
Faculty of Pharmacy, Mahidol University, Bangkok, Thailand. ISNI: 0000 0004 1937 0490. GRID: grid.10223.32
Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand. ISNI: 0000 0004 1937 0490. GRID: grid.10223.32
Specialist Anesthesia, Doha, Qatar
University of Canterbury, Christchurch, New Zealand. ISNI: 0000 0001 2179 1970. GRID: grid.21006.35
Christchurch Hospital, Christchurch, New Zealand. ISNI: 0000 0004 0614 1349. GRID: grid.414299.3
Clinical Center Ljubljana, Ljubljana, Slovenia. ISNI: 0000 0004 0571 7705. GRID: grid.29524.38
The Royal Marsden Hospital, London, UK. ISNI: 0000 0004 0417 0461. GRID: grid.424926.f
Bogomolets National Medical University, Kiev, Ukraine. GRID: grid.412081.e
Royal Liverpool Intensive Care Unit, Liverpool, UK
Homerton University Hospital, London, UK. GRID: grid.439591.3
University of Sao Paulo, Sao Paulo, Brazil. ISNI: 0000 0004 1937 0722. GRID: grid.11899.38
University of Leicester, Leicester, UK. ISNI: 0000 0004 1936 8411. GRID: grid.9918.9
Research and Education Institute, Sao Paulo, Brazil
Ipswich Hospital NHS Trust, England, UK, Ipswich, UK. ISNI: 0000 0004 0413 7370. GRID: grid.412930.d
Phramongkutklao Hospital, Bangkok, Thailand. ISNI: 0000 0004 0576 1212. GRID: grid.414965.b
Phramongkutklao College of Medicine, Bangkok, Thailand. ISNI: 0000 0004 1937 0490. GRID: grid.10223.32
Pusan National University Hospital, Busan, South Korea. ISNI: 0000 0000 8611 7824. GRID: grid.412588.2
PICU, Hippokration General Hospital, Thessaloniki, Greece. ISNI: 0000 0004 0621 2899. GRID: grid.414122.0
King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia. ISNI: 0000 0001 2191 4301. GRID: grid.415310.2
The Jikei University School of Medicine, Tokyo, Japan. ISNI: 0000 0001 0661 2073. GRID: grid.411898.d
PPG Internal Medicine, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil. ISNI: 0000 0001 2294 473X. GRID: grid.8536.8
Hospital Esperanca Recife, Recife, Brazil
Hospital Total Cor, Rio de Janeiro, Brazil
Hospital viValle, São José dos Campos, Brazil
Hospital Rios DOr, Rio de Janeiro, Brazil
Hospital Norte DOr, Rio de Janeiro, Brazil
Hospital Esperanca Olinda, Olinda, Brazil
DOr Institute for Research and Education - IDOR, Rio de Janeiro, Brazil. GRID: grid.472984.4
Stamford Hospital, Stamford, USA. ISNI: 0000 0004 0377 0318. GRID: grid.416984.6
Darent Valley Hospital, Dartford, UK. ISNI: 0000 0004 0398 7314. GRID: grid.413475.0
St James’s University Hospital, Leeds, UK. GRID: grid.443984.6
Hospital Maciel, Montevideo, Uruguay. GRID: grid.414794.b
Hospital de Cancer de Barretos, Barretos, Brazil. ISNI: 0000 0004 0615 7498. GRID: grid.427783.d
Hospital Sírio Libanês, Sao Paulo, Brazil. ISNI: 0000 0000 9080 8521. GRID: grid.413471.4
Sta. Casa de Porto Alegre, Porto Alegre, Brazil
University of Pittsburgh Medical Center, Pittsburgh, USA. ISNI: 0000 0001 0650 7433. GRID: grid.412689.0
Hospital Sao Lucas, Rio de Janeiro, Brazil
Sheffield Teaching Hospitals, Sheffield, UK. GRID: grid.419135.b
Instituto Português de Oncologia Francisco Gil - Porto, Porto, Portugal. ISNI: 0000 0004 0631 0608. GRID: grid.418711.a
Hôpital Bichat, Paris, France. ISNI: 0000 0000 8588 831X. GRID: grid.411119.d
Abertawe Bro Morgannwg University Health Board, Swansea, UK. ISNI: 0000 0000 8959 0182. GRID: grid.419728.1
Centro Hospitalar Porto, Porto, Portugal. ISNI: 0000 0004 0392 7039. GRID: grid.418340.a
Apollo Speciality Hospital - OMR, Chennai, India. ISNI: 0000 0004 1802 3550. GRID: grid.413839.4
Kingston General Hospital, Kingston, Canada. ISNI: 0000 0004 0633 727X. GRID: grid.415354.2
Milton Keynes Hospital, Milton Keynes, UK. GRID: grid.415667.7
Imperial College, London, UK. ISNI: 0000 0001 2113 8111. GRID: grid.7445.2
Buckinghamshire Healthcare NHS Trust, Aylesbury, UK. ISNI: 0000 0004 0368 863X. GRID: grid.439664.a
IPO -Porto, Porto, Portugal. GRID: grid.435544.7
KU Leuven, Leuven, Belgium. ISNI: 0000 0001 0668 7884. GRID: grid.5596.f
Ernesto Dornelles Hospital, Porto Alegre, Brazil
Gelre Ziekenhuizen, Apeldoorn, Netherlands. ISNI: 0000 0004 0370 4214. GRID: grid.415355.3
Surrey and Sussex NHS Trust, Redhill, UK
Ege University School of Medicine, Izmir, Turkey. ISNI: 0000 0001 1092 2592. GRID: grid.8302.9
katip Celebi University, Izmir, Turkey. ISNI: 0000 0004 0454 9420. GRID: grid.411795.f
Alexandria University Faculty of medicine, Alexandria, Egypt. ISNI: 0000 0001 2260 6941. GRID: grid.7155.6
Fortis Escorts Heart Institute, New Delhi, India. ISNI: 0000 0004 1804 7827. GRID: grid.417966.b
FMRI, Gurgaon, India. ISNI: 0000 0004 4653 2037. GRID: grid.464839.4
Philips Research North America, Cambridge, USA. GRID: grid.417285.d
Hospital Sao Rafael, Salvador, Brazil. GRID: grid.413466.2
Hospital das Clinicas, Sao Paulo, Brazil. ISNI: 0000 0001 2297 2036. GRID: grid.411074.7
St Helens and Knowsley, Liverpool, UK
STH, Sheffield, UK
Freeman Hospital, Newcastle upon Tyne, UK. ISNI: 0000 0004 0641 3308. GRID: grid.415050.5
Hospital Nove de Julho, Sao Paulo, Brazil
University Hospital Coventry and Warwickshire, Coventry, UK. GRID: grid.15628.38
Sunnybrook Health Sciences Centre, Toronto, Canada. ISNI: 0000 0000 9743 1587. GRID: grid.413104.3
NHS Scotland, Glasgow, UK. ISNI: 0000 0000 9506 6213. GRID: grid.422655.2
Royal College of Surgeons of Ireland, Dublin, Ireland. ISNI: 0000 0004 0488 7120. GRID: grid.4912.e
University Leiden, Leiden, Netherlands. ISNI: 0000 0001 2312 1970. GRID: grid.5132.5
Gelre Hospitals, Apeldoorn, Netherlands. ISNI: 0000 0004 0370 4214. GRID: grid.415355.3
VU University Amsterdam, Amsterdam, Netherlands. ISNI: 0000 0004 1754 9227. GRID: grid.12380.38
Hospital de Santo António, Oporto Hospital Center, Porto, Portugal
Faculty of Psychology and Educational Sciences, Heerlen, Netherlands
University of Toronto at Scarborough, Scarborough, ON Canada. ISNI: 0000 0001 2157 2938. GRID: grid.17063.33
University of Szeged, Szeged, Hungary. ISNI: 0000 0001 1016 9625. GRID: grid.9008.1
Jahn Ferenc Hospital, Budapest, Hungary
University of Pécs, Pécs, Hungary. ISNI: 0000 0001 0663 9479. GRID: grid.9679.1
Hospital Clinico Universidad de Chile, Santiago, Chile. GRID: grid.412248.9
Royal Marsden Hospital, London, UK. ISNI: 0000 0004 0417 0461. GRID: grid.424926.f
Centre Hospitalier de Lens, Lens, France. ISNI: 0000 0004 0642 1236. GRID: grid.470048.f
Ntra Sra de Candelaria University Hospital, Santa Cruz de Tenerife, Spain
University of Texas at Austin, San Antonio, USA. ISNI: 0000 0004 1936 9924. GRID: grid.89336.37
Beaumont Hospital, Dublin, Ireland. ISNI: 0000 0004 0617 6058. GRID: grid.414315.6
St Helens and Knowsley teaching hospitals, Liverpool, UK. GRID: grid.430747.3
Maastricht University Medical Center, Maastricht, Netherlands. GRID: grid.412966.e
University Hospital Antwerp, Edegem, Belgium. ISNI: 0000 0004 0626 3418. GRID: grid.411414.5
University of Calgary, Calgary, Canada. ISNI: 0000 0004 1936 7697. GRID: grid.22072.35
Vrije Universiteit Brussel, Brussel, Belgium. ISNI: 0000 0001 2290 8069. GRID: grid.8767.e
EMGO+/VU University medical center, Utrecht, Netherlands. ISNI: 0000000090126352. GRID: grid.7692.a
Universitair Ziekenhuis Brussel, Brussel, Belgium. ISNI: 0000 0004 0626 3362. GRID: grid.411326.3
Lewisham & Greenwich NHS Trust, London, UK. GRID: grid.429537.e
National Burn Unit, Montevideo, Uruguay
St Elisabeth Ziekenhuis, Tilburg, Netherlands. GRID: grid.416373.4
Fondazione IRCCS Ca’ Granda - Ospedale maggiore Policlinico, Milan, Italy. ISNI: 0000 0004 1757 8749. GRID: grid.414818.0
Istituto per lo Studio e la Prevenzione Oncologica, Florence, Italy. ISNI: 0000 0004 1758 0566. GRID: grid.417623.5
AN  - 27885969
AU  - Bateman, R. M.
AU  - Sharpe, M. D.
AU  - Jagger, J. E.
AU  - Ellis, C. G.
AU  - Solé-Violán, J.
AU  - López-Rodríguez, M.
AU  - Herrera-Ramos, E.
AU  - Ruíz-Hernández, J.
AU  - Borderías, L.
AU  - Horcajada, J.
AU  - González-Quevedo, N.
AU  - Rajas, O.
AU  - Briones, M.
AU  - Rodríguez de Castro, F.
AU  - Rodríguez Gallego, C.
AU  - Esen, F.
AU  - Orhun, G.
AU  - Ergin Ozcan, P.
AU  - Senturk, E.
AU  - Ugur Yilmaz, C.
AU  - Orhan, N.
AU  - Arican, N.
AU  - Kaya, M.
AU  - Kucukerden, M.
AU  - Giris, M.
AU  - Akcan, U.
AU  - Bilgic Gazioglu, S.
AU  - Tuzun, E.
AU  - Riff, R.
AU  - Naamani, O.
AU  - Douvdevani, A.
AU  - Takegawa, R.
AU  - Yoshida, H.
AU  - Hirose, T.
AU  - Yamamoto, N.
AU  - Hagiya, H.
AU  - Ojima, M.
AU  - Akeda, Y.
AU  - Tasaki, O.
AU  - Tomono, K.
AU  - Shimazu, T.
AU  - Ono, S.
AU  - Kubo, T.
AU  - Suda, S.
AU  - Ueno, T.
AU  - Ikeda, T.
AU  - Hirose, T.
AU  - Ogura, H.
AU  - Takahashi, H.
AU  - Ojima, M.
AU  - Kang, J.
AU  - Nakamura, Y.
AU  - Kojima, T.
AU  - Shimazu, T.
AU  - Ikeda, T.
AU  - Suda, S.
AU  - Izutani, Y.
AU  - Ueno, T.
AU  - Ono, S.
AU  - Taniguchi, T.
AU  - O, M.
AU  - Dinter, C.
AU  - Lotz, J.
AU  - Eilers, B.
AU  - Wissmann, C.
AU  - Lott, R.
AU  - Meili, M. M.
AU  - Schuetz, P. S.
AU  - Hawa, H.
AU  - Sharshir, M.
AU  - Aburageila, M.
AU  - Salahuddin, N.
AU  - Chantziara, V.
AU  - Georgiou, S.
AU  - Tsimogianni, A.
AU  - Alexandropoulos, P.
AU  - Vassi, A.
AU  - Lagiou, F.
AU  - Valta, M.
AU  - Micha, G.
AU  - Chinou, E.
AU  - Michaloudis, G.
AU  - Kodaira, A.
AU  - Ikeda, T.
AU  - Ono, S.
AU  - Ueno, T.
AU  - Suda, S.
AU  - Izutani, Y.
AU  - Imaizumi, H.
AU  - De la Torre-Prados, M. V.
AU  - Garcia-De la Torre, A.
AU  - Enguix-Armada, A.
AU  - Puerto-Morlan, A.
AU  - Perez-Valero, V.
AU  - Garcia-Alcantara, A.
AU  - Bolton, N.
AU  - Dudziak, J.
AU  - Bonney, S.
AU  - Tridente, A.
AU  - Nee, P.
AU  - Nicolaes, G.
AU  - Wiewel, M.
AU  - Schultz, M.
AU  - Wildhagen, K.
AU  - Horn, J.
AU  - Schrijver, R.
AU  - Van der Poll, T.
AU  - Reutelingsperger, C.
AU  - Pillai, S.
AU  - Davies, G.
AU  - Mills, G.
AU  - Aubrey, R.
AU  - Morris, K.
AU  - Williams, P.
AU  - Evans, P.
AU  - Gayat, E. G.
AU  - Struck, J.
AU  - Cariou, A.
AU  - Deye, N.
AU  - Guidet, B.
AU  - Jabert, S.
AU  - Launay, J.
AU  - Legrand, M.
AU  - Léone, M.
AU  - Resche-Rigon, M.
AU  - Vicaut, E.
AU  - Vieillard-Baron, A.
AU  - Mebazaa, A.
AU  - Arnold, R.
AU  - Capan, M.
AU  - Linder, A.
AU  - Akesson, P.
AU  - Popescu, M.
AU  - Tomescu, D.
AU  - Sprung, C. L.
AU  - Calderon Morales, R.
AU  - Munteanu, G.
AU  - Orenbuch-Harroch, E.
AU  - Levin, P.
AU  - Kasdan, H.
AU  - Reiter, A.
AU  - Volker, T.
AU  - Himmel, Y.
AU  - Cohen, Y.
AU  - Meissonnier, J.
AU  - Girard, L.
AU  - Rebeaud, F.
AU  - Herrmann, I.
AU  - Delwarde, B.
AU  - Peronnet, E.
AU  - Cerrato, E.
AU  - Venet, F.
AU  - Lepape, A.
AU  - Rimmelé, T.
AU  - Monneret, G.
AU  - Textoris, J.
AU  - Beloborodova, N.
AU  - Moroz, V.
AU  - Osipov, A.
AU  - Bedova, A.
AU  - Sarshor, Y.
AU  - Pautova, A.
AU  - Sergeev, A.
AU  - Chernevskaya, E.
AU  - Odermatt, J.
AU  - Bolliger, R.
AU  - Hersberger, L.
AU  - Ottiger, M.
AU  - Christ-Crain, M.
AU  - Mueller, B.
AU  - Schuetz, P.
AU  - Sharma, N. K.
AU  - Tashima, A. K.
AU  - Brunialti, M. K.
AU  - Machado, F. R.
AU  - Assuncao, M.
AU  - Rigato, O.
AU  - Salomao, R.
AU  - Cajander, S. C.
AU  - Rasmussen, G.
AU  - Tina, E.
AU  - Söderquist, B.
AU  - Källman, J.
AU  - Strålin, K.
AU  - Lange, A. L.
AU  - Sundén-Cullberg, J. S.
AU  - Magnuson, A. M.
AU  - Hultgren, O. H.
AU  - Davies, G.
AU  - Pillai, S.
AU  - Mills, G.
AU  - Aubrey, R.
AU  - Morris, K.
AU  - Williams, P.
AU  - Evans, P.
AU  - Pillai, S.
AU  - Davies, G.
AU  - Mills, G.
AU  - Aubrey, R.
AU  - Morris, K.
AU  - Williams, P.
AU  - Evans, P.
AU  - Pillai, S.
AU  - Davies, G.
AU  - Mills, G.
AU  - Aubrey, R.
AU  - Morris, K.
AU  - Williams, P.
AU  - Evans, P.
AU  - Van der Geest, P.
AU  - Mohseni, M.
AU  - Linssen, J.
AU  - De Jonge, R.
AU  - Duran, S.
AU  - Groeneveld, J.
AU  - Miller, R., III
AU  - Lopansri, B. K.
AU  - McHugh, L. C.
AU  - Seldon, A.
AU  - Burke, J. P.
AU  - Johnston, J.
AU  - Reece-Anthony, R.
AU  - Bond, A.
AU  - Molokhia, A.
AU  - McGrath, C.
AU  - Nsutebu, E.
AU  - Bank Pedersen, P.
AU  - Pilsgaard Henriksen, D.
AU  - Mikkelsen, S.
AU  - Touborg Lassen, A.
AU  - Tincu, R.
AU  - Cobilinschi, C.
AU  - Tomescu, D.
AU  - Ghiorghiu, Z.
AU  - Macovei, R.
AU  - Wiewel, M. A.
AU  - Harmon, M. B.
AU  - Van Vught, L. A.
AU  - Scicluna, B. P.
AU  - Hoogendijk, A. J.
AU  - Horn, J.
AU  - Zwinderman, A. H.
AU  - Cremer, O. L.
AU  - Bonten, M. J.
AU  - Schultz, M. J.
AU  - Van der Poll, T.
AU  - Juffermans, N. P.
AU  - Wiersinga, W. J.
AU  - Eren, G.
AU  - Tekdos, Y.
AU  - Dogan, M.
AU  - Acicbe, O.
AU  - Kaya, E.
AU  - Hergunsel, O.
AU  - Alsolamy, S.
AU  - Ghamdi, G.
AU  - Alswaidan, L.
AU  - Alharbi, S.
AU  - Alenezi, F.
AU  - Arabi, Y.
AU  - Heaton, J.
AU  - Boyce, A.
AU  - Nolan, L.
AU  - Johnston, J.
AU  - Dukoff-Gordon, A.
AU  - Dean, A.
AU  - Molokhia, A.
AU  - Mann Ben Yehudah, T.
AU  - Fleischmann, C.
AU  - Thomas-Rueddel, D.
AU  - Haas, C.
AU  - Dennler, U.
AU  - Reinhart, K.
AU  - Suntornlohanakul, O.
AU  - Khwannimit, B.
AU  - Breckenridge, F.
AU  - Puxty, A.
AU  - Szturz, P.
AU  - Folwarzcny, P.
AU  - Svancara, J.
AU  - Kula, R.
AU  - Sevcik, P.
AU  - Caneva, L.
AU  - Casazza, A.
AU  - Bellazzi, E.
AU  - Marra, S.
AU  - Pagani, L.
AU  - Vetere, M.
AU  - Vanzino, R.
AU  - Ciprandi, D.
AU  - Preda, R.
AU  - Boschi, R.
AU  - Carnevale, L.
AU  - Lopez, V.
AU  - Aguilar Arzapalo, M.
AU  - Barradas, L.
AU  - Escalante, A.
AU  - Gongora, J.
AU  - Cetina, M.
AU  - Adamik, B.
AU  - Jakubczyk, D.
AU  - Kübler, A.
AU  - Radford, A.
AU  - Lee, T.
AU  - Singer, J.
AU  - Boyd, J.
AU  - Fineberg, D.
AU  - Williams, M.
AU  - Russell, J.
AU  - Scarlatescu, E.
AU  - Tomescu, D.
AU  - Droc, G.
AU  - Arama, S.
AU  - Müller, M.
AU  - Straat, M.
AU  - Zeerleder, S. S.
AU  - Juffermans, N. P.
AU  - Fuchs, C. F.
AU  - Scheer, C. S.
AU  - Wauschkuhn, S. W.
AU  - Vollmer, M. V.
AU  - Meissner, K. M.
AU  - Kuhn, S. K.
AU  - Hahnenkamp, K. H.
AU  - Rehberg, S. R.
AU  - Gründling, M. G.
AU  - Yamamoto, N.
AU  - Ojima, M.
AU  - Hamaguchi, S.
AU  - Hirose, T.
AU  - Akeda, Y.
AU  - Takegawa, R.
AU  - Tasaki, O.
AU  - Shimazu, T.
AU  - Tomono, K.
AU  - Gómez-Sánchez, E.
AU  - Heredia-Rodríguez, M.
AU  - Álvarez-Fuente, E.
AU  - Lorenzo-López, M.
AU  - Gómez-Pesquera, E.
AU  - Aragón-Camino, M.
AU  - Liu-Zhu, P.
AU  - Sánchez-López, A.
AU  - Hernández-Lozano, A.
AU  - Peláez-Jareño, M. T.
AU  - Tamayo, E.
AU  - Thomas-Rüddel, D. O.
AU  - Fleischmann, C.
AU  - Haas, C.
AU  - Dennler, U.
AU  - Reinhart, K.
AU  - Adora, V.
AU  - Kar, A.
AU  - Chakraborty, A.
AU  - Roy, S.
AU  - Bandyopadhyay, A.
AU  - Das, M.
AU  - Mann Ben Yehudah, T.
AU  - BenYehudah, G.
AU  - Salim, M.
AU  - Kumar, N.
AU  - Arabi, L.
AU  - Burger, T.
AU  - Lephart, P.
AU  - Toth-martin, E.
AU  - Valencia, C.
AU  - Hammami, N.
AU  - Blot, S.
AU  - Vincent, J. L.
AU  - Lambert, M. L.
AU  - Brunke, J.
AU  - Riemann, T.
AU  - Roschke, I.
AU  - Tincu, R.
AU  - Cobilinschi, C.
AU  - Tomescu, D.
AU  - Ghiorghiu, Z.
AU  - Macovei, R.
AU  - Nimitvilai, S.
AU  - Jintanapramote, K.
AU  - Jarupongprapa, S.
AU  - Adukauskiene, D.
AU  - Valanciene, D.
AU  - Bose, G.
AU  - Lostarakos, V.
AU  - Carr, B.
AU  - Khedher, S.
AU  - Maaoui, A.
AU  - Ezzamouri, A.
AU  - Salem, M.
AU  - Chen, J.
AU  - Cranendonk, D. R.
AU  - Van Vught, L. A.
AU  - Wiewel, M. A.
AU  - Cremer, O. L.
AU  - Horn, J.
AU  - Bonten, M. J.
AU  - Schultz, M. J.
AU  - Van der Poll, T.
AU  - Wiersinga, W. J.
AU  - Day, M.
AU  - Penrice, G.
AU  - Roy, K.
AU  - Robertson, P.
AU  - Godbole, G.
AU  - Jones, B.
AU  - Booth, M.
AU  - Donaldson, L.
AU  - Kawano, Y.
AU  - Ishikura, H.
AU  - Al-Dorzi, H.
AU  - Almutairi, M.
AU  - Alhamadi, B.
AU  - Crizaldo Toledo, A.
AU  - Khan, R.
AU  - Al Raiy, B.
AU  - Arabi, Y.
AU  - Talaie, H.
AU  - Van Oers, J. A.
AU  - Harts, A.
AU  - Nieuwkoop, E.
AU  - Vos, P.
AU  - Boussarsar, Y.
AU  - Boutouta, F.
AU  - Kamoun, S.
AU  - Mezghani, I.
AU  - Koubaji, S.
AU  - Ben Souissi, A.
AU  - Riahi, A.
AU  - Mebazaa, M. S.
AU  - Giamarellos-Bourboulis, E.
AU  - Tziolos, N.
AU  - Routsi, C.
AU  - Katsenos, C.
AU  - Tsangaris, I.
AU  - Pneumatikos, I.
AU  - Vlachogiannis, G.
AU  - Theodorou, V.
AU  - Prekates, A.
AU  - Antypa, E.
AU  - Koulouras, V.
AU  - Kapravelos, N.
AU  - Gogos, C.
AU  - Antoniadou, E.
AU  - Mandragos, K.
AU  - Armaganidis, A.
AU  - Robles Caballero, A. R.
AU  - Civantos, B.
AU  - Figueira, J. C.
AU  - López, J.
AU  - Silva-Pinto, A.
AU  - Ceia, F.
AU  - Sarmento, A.
AU  - Santos, L.
AU  - Almekhlafi, G.
AU  - Sakr, Y.
AU  - Al-Dorzi, H.
AU  - Khan, R.
AU  - Baharoon, S.
AU  - Aldawood, A.
AU  - Matroud, A.
AU  - Alchin, J.
AU  - Al Johani, S.
AU  - Balkhy, H.
AU  - Arabi, Y.
AU  - Alsolamy, S.
AU  - Yousif, S. Y.
AU  - Alotabi, B. O.
AU  - Alsaawi, A. S.
AU  - Ang, J.
AU  - Curran, M. D.
AU  - Enoch, D.
AU  - Navapurkar, V.
AU  - Morris, A.
AU  - Sharvill, R.
AU  - Astin, J.
AU  - Heredia-Rodríguez, M.
AU  - Gómez-Sánchez, E.
AU  - Peláez-Jareño, M. T.
AU  - Gómez-Pesquera, E.
AU  - Lorenzo-López, M.
AU  - Liu-Zhu, P.
AU  - Aragón-Camino, M.
AU  - Hernández-Lozano, A.
AU  - Sánchez-López, A.
AU  - Álvarez-Fuente, E.
AU  - Tamayo, E.
AU  - Patel, J.
AU  - Kruger, C.
AU  - O’Neal, J.
AU  - Rhodes, H.
AU  - Jancik, J.
AU  - François, B.
AU  - Laterre, P. F.
AU  - Eggimann, P.
AU  - Torres, A.
AU  - Sánchez, M.
AU  - Dequin, P. F.
AU  - Bassi, G. L.
AU  - Chastre, J.
AU  - Jafri, H. S.
AU  - Ben Romdhane, M.
AU  - Douira, Z.
AU  - Kamoun, S.
AU  - Bousselmi, M.
AU  - Ben Souissi, A.
AU  - Boussarsar, Y.
AU  - Riahi, A.
AU  - Mebazaa, M. S.
AU  - Vakalos, A.
AU  - Avramidis, V.
AU  - Craven, T. H.
AU  - Wojcik, G.
AU  - Kefala, K.
AU  - McCoubrey, J.
AU  - Reilly, J.
AU  - Paterson, R.
AU  - Inverarity, D.
AU  - Laurenson, I.
AU  - Walsh, T. S.
AU  - Mongodi, S.
AU  - Bouhemad, B.
AU  - Orlando, A.
AU  - Stella, A.
AU  - Via, G.
AU  - Iotti, G.
AU  - Braschi, A.
AU  - Mojoli, F.
AU  - Haliloglu, M.
AU  - Bilgili, B.
AU  - Kasapoglu, U.
AU  - Sayan, I.
AU  - Süzer Aslan, M.
AU  - Yalcın, A.
AU  - Cinel, I.
AU  - Vakalos, A.
AU  - Avramidis, V.
AU  - Ellis, H. E.
AU  - Bauchmuller, K.
AU  - Miller, D.
AU  - Temple, A.
AU  - Chastre, J.
AU  - François, B.
AU  - Torres, A.
AU  - Luyt, C. E.
AU  - Sánchez, M.
AU  - Singer, M.
AU  - Jafri, H. S.
AU  - Nassar, Y.
AU  - Ayad, M. S.
AU  - Trifi, A.
AU  - Abdellatif, S.
AU  - Daly, F.
AU  - Nasri, R.
AU  - Ben Lakhal, S.
AU  - Bilgili, B.
AU  - Haliloglu, M.
AU  - Gul, F.
AU  - Cinel, I.
AU  - Kuzovlev, A.
AU  - Shabanov, A.
AU  - Polovnikov, S.
AU  - Moroz, V.
AU  - Kadrichu, N.
AU  - Dang, T.
AU  - Corkery, K.
AU  - Challoner, P.
AU  - Bassi, G. L.
AU  - Aguilera, E.
AU  - Chiurazzi, C.
AU  - Travierso, C.
AU  - Motos, A.
AU  - Fernandez, L.
AU  - Amaro, R.
AU  - Senussi, T.
AU  - Idone, F.
AU  - Bobi, J.
AU  - Rigol, M.
AU  - Torres, A.
AU  - Hodiamont, C. J.
AU  - Juffermans, N. P.
AU  - Janssen, J. M.
AU  - Bouman, C. S.
AU  - Mathôt, R. A.
AU  - De Jong, M. D.
AU  - Van Hest, R. M.
AU  - Payne, L.
AU  - Fraser, G. L.
AU  - Tudor, B.
AU  - Lahner, M.
AU  - Roth, G.
AU  - Krenn, C.
AU  - Talaie, H.
AU  - Jault, P.
AU  - Gabard, J.
AU  - Leclerc, T.
AU  - Jennes, S.
AU  - Que, Y.
AU  - Rousseau, A.
AU  - Ravat, F.
AU  - Al-Dorzi, H.
AU  - Eissa, A.
AU  - Al-Harbi, S.
AU  - Aldabbagh, T.
AU  - Khan, R.
AU  - Arabi, Y.
AU  - Trifi, A.
AU  - Abdellatif, S.
AU  - Daly, F.
AU  - Nasri, R.
AU  - Ben Lakhal, S.
AU  - Paramba, F.
AU  - Purayil, N.
AU  - Naushad, V.
AU  - Mohammad, O.
AU  - Negi, V.
AU  - Chandra, P.
AU  - Kleinsasser, A.
AU  - Witrz, M. R.
AU  - Buchner-Doeven, J. F.
AU  - Tuip-de Boer, A. M.
AU  - Goslings, J. C.
AU  - Juffermans, N. P.
AU  - Van Hezel, M.
AU  - Straat, M.
AU  - Boing, A.
AU  - Van Bruggen, R.
AU  - Juffermans, N.
AU  - Markopoulou, D.
AU  - Venetsanou, K.
AU  - Kaldis, V.
AU  - Koutete, D.
AU  - Chroni, D.
AU  - Alamanos, I.
AU  - Koch, L.
AU  - Jancik, J.
AU  - Rhodes, H.
AU  - Walter, E.
AU  - Maekawa, K.
AU  - Hayakawa, M.
AU  - Kushimoto, S.
AU  - Shiraishi, A.
AU  - Kato, H.
AU  - Sasaki, J.
AU  - Ogura, H.
AU  - Matauoka, T.
AU  - Uejima, T.
AU  - Morimura, N.
AU  - Ishikura, H.
AU  - Hagiwara, A.
AU  - Takeda, M.
AU  - Tarabrin, O.
AU  - Shcherbakow, S.
AU  - Gavrychenko, D.
AU  - Mazurenko, G.
AU  - Ivanova, V.
AU  - Chystikov, O.
AU  - Plourde, C.
AU  - Lessard, J.
AU  - Chauny, J.
AU  - Daoust, R.
AU  - Shcherbakow, S.
AU  - Tarabrin, O.
AU  - Gavrychenko, D.
AU  - Mazurenko, G.
AU  - Chystikov, O.
AU  - Vakalos, A.
AU  - Avramidis, V.
AU  - Kropman, L.
AU  - In het Panhuis, L.
AU  - Konings, J.
AU  - Huskens, D.
AU  - Schurgers, E.
AU  - Roest, M.
AU  - De Laat, B.
AU  - Lance, M.
AU  - Durila, M.
AU  - Lukas, P.
AU  - Astraverkhava, M.
AU  - Jonas, J.
AU  - Budnik, I.
AU  - Shenkman, B.
AU  - Hayami, H.
AU  - Koide, Y.
AU  - Goto, T.
AU  - Iqbal, R.
AU  - Alhamdi, Y.
AU  - Venugopal, N.
AU  - Abrams, S.
AU  - Downey, C.
AU  - Toh, C. H.
AU  - Welters, I. D.
AU  - Bombay, V. B.
AU  - Chauny, J. M.
AU  - Daoust, R. D.
AU  - Lessard, J. L.
AU  - Marquis, M. M.
AU  - Paquet, J. P.
AU  - Siemens, K.
AU  - Sangaran, D.
AU  - Hunt, B. J.
AU  - Durward, A.
AU  - Nyman, A.
AU  - Murdoch, I. A.
AU  - Tibby, S. M.
AU  - Ampatzidou, F.
AU  - Moisidou, D.
AU  - Dalampini, E.
AU  - Nastou, M.
AU  - Vasilarou, E.
AU  - Kalaizi, V.
AU  - Chatzikostenoglou, H.
AU  - Drossos, G.
AU  - Spadaro, S.
AU  - Fogagnolo, A.
AU  - Fiore, T.
AU  - Schiavi, A.
AU  - Fontana, V.
AU  - Taccone, F.
AU  - Volta, C.
AU  - Chochliourou, E.
AU  - Volakli, E.
AU  - Violaki, A.
AU  - Samkinidou, E.
AU  - Evlavis, G.
AU  - Panagiotidou, V.
AU  - Sdougka, M.
AU  - Mothukuri, R.
AU  - Battle, C.
AU  - Guy, K.
AU  - Mills, G.
AU  - Evans, P.
AU  - Wijesuriya, J.
AU  - Keogh, S.
AU  - Docherty, A.
AU  - O’Donnell, R.
AU  - Brunskill, S.
AU  - Trivella, M.
AU  - Doree, C.
AU  - Holst, L.
AU  - Parker, M.
AU  - Gregersen, M.
AU  - Almeida, J.
AU  - Walsh, T.
AU  - Stanworth, S.
AU  - Moravcova, S.
AU  - Mansell, J.
AU  - Rogers, A.
AU  - Smith, R. A.
AU  - Hamilton-Davies, C.
AU  - Omar, A.
AU  - Allam, M.
AU  - Bilala, O.
AU  - Kindawi, A.
AU  - Ewila, H.
AU  - Ampatzidou, F.
AU  - Moisidou, D.
AU  - Nastou, M.
AU  - Dalampini, E.
AU  - Malamas, A.
AU  - Vasilarou, E.
AU  - Drossos, G.
AU  - Ferreira, G.
AU  - Caldas, J.
AU  - Fukushima, J.
AU  - Osawa, E. A.
AU  - Arita, E.
AU  - Camara, L.
AU  - Zeferino, S.
AU  - Jardim, J.
AU  - Gaioto, F.
AU  - Dallan, L.
AU  - Jatene, F. B.
AU  - Kalil Filho, R.
AU  - Galas, F.
AU  - Hajjar, L. A.
AU  - Mitaka, C.
AU  - Ohnuma, T.
AU  - Murayama, T.
AU  - Kunimoto, F.
AU  - Nagashima, M.
AU  - Takei, T.
AU  - Tomita, M.
AU  - Omar, A.
AU  - Mahmoud, K.
AU  - Hanoura, S.
AU  - Sudarsanan, S.
AU  - Sivadasan, P.
AU  - Othamn, H.
AU  - Shouman, Y.
AU  - Singh, R.
AU  - Al Khulaifi, A.
AU  - Mandel, I.
AU  - Mikheev, S.
AU  - Suhodolo, I.
AU  - Kiselev, V.
AU  - Svirko, Y.
AU  - Podoksenov, Y.
AU  - Jenkins, S. A.
AU  - Griffin, R.
AU  - Tovar Doncel, M. S.
AU  - Lima, A.
AU  - Aldecoa, C.
AU  - Ince, C.
AU  - Taha, A.
AU  - Shafie, A.
AU  - Mostafa, M.
AU  - Syed, N.
AU  - Hon, H.
AU  - Righetti, F.
AU  - Colombaroli, E.
AU  - Castellano, G.
AU  - Righetti, F.
AU  - Colombaroli, E.
AU  - Hravnak, M.
AU  - Chen, L. C.
AU  - Dubrawski, A. D.
AU  - Clermont, G. C.
AU  - Pinsky, M. R.
AU  - Gonzalez, S.
AU  - Macias, D.
AU  - Acosta, J.
AU  - Jimenez, P.
AU  - Loza, A.
AU  - Lesmes, A.
AU  - Lucena, F.
AU  - Leon, C.
AU  - Tovar Doncel, M. S.
AU  - Ince, C.
AU  - Aldecoa, C.
AU  - Lima, A.
AU  - Bastide, M.
AU  - Richecoeur, J.
AU  - Frenoy, E.
AU  - Lemaire, C.
AU  - Sauneuf, B.
AU  - Tamion, F.
AU  - Nseir, S.
AU  - Du Cheyron, D.
AU  - Dupont, H.
AU  - Maizel, J.
AU  - Shaban, M.
AU  - Kolko, R.
AU  - Salahuddin, N.
AU  - Sharshir, M.
AU  - AbuRageila, M.
AU  - AlHussain, A.
AU  - Mercado, P.
AU  - Maizel, J.
AU  - Kontar, L.
AU  - Titeca, D.
AU  - Brazier, F.
AU  - Riviere, A.
AU  - Joris, M.
AU  - Soupison, T.
AU  - De Cagny, B.
AU  - Slama, M.
AU  - Wagner, J.
AU  - Körner, A.
AU  - Kubik, M.
AU  - Kluge, S.
AU  - Reuter, D.
AU  - Saugel, B.
AU  - Colombaroli, E.
AU  - Righetti, F.
AU  - Castellano, G.
AU  - Tran, T.
AU  - De Bels, D.
AU  - Cudia, A.
AU  - Strachinaru, M.
AU  - Ghottignies, P.
AU  - Devriendt, J.
AU  - Pierrakos, C.
AU  - Martínez González, Ó
AU  - Blancas, R.
AU  - Luján, J.
AU  - Ballesteros, D.
AU  - Martínez Díaz, C.
AU  - Núñez, A.
AU  - Martín Parra, C.
AU  - López Matamala, B.
AU  - Alonso Fernández, M.
AU  - Chana, M.
AU  - Huber, W.
AU  - Eckmann, M.
AU  - Elkmann, F.
AU  - Gruber, A.
AU  - Klein, I.
AU  - Schmid, R. M.
AU  - Lahmer, T.
AU  - Moller, P. W.
AU  - Sondergaard, S.
AU  - Jakob, S. M.
AU  - Takala, J.
AU  - Berger, D.
AU  - Bastoni, D.
AU  - Aya, H.
AU  - Toscani, L.
AU  - Pigozzi, L.
AU  - Rhodes, A.
AU  - Cecconi, M.
AU  - Ostrowska, C.
AU  - Aya, H.
AU  - Abbas, A.
AU  - Mellinghoff, J.
AU  - Ryan, C.
AU  - Dawson, D.
AU  - Rhodes, A.
AU  - Cecconi, M.
AU  - Cronhjort, M.
AU  - Wall, O.
AU  - Nyberg, E.
AU  - Zeng, R.
AU  - Svensen, C.
AU  - Mårtensson, J.
AU  - Joelsson-Alm, E.
AU  - Aguilar Arzapalo, M.
AU  - Barradas, L.
AU  - Lopez, V.
AU  - Cetina, M.
AU  - Parenti, N.
AU  - Palazzi, C.
AU  - Amidei, L. A.
AU  - Borrelli, F. B.
AU  - Campanale, S. C.
AU  - Tagliazucchi, F. T.
AU  - Sedoni, G. S.
AU  - Lucchesi, D. L.
AU  - Carella, E. C.
AU  - Luciani, A. L.
AU  - Mackovic, M.
AU  - Maric, N.
AU  - Bakula, M.
AU  - Aya, H.
AU  - Rhodes, A.
AU  - Grounds, R. M.
AU  - Fletcher, N.
AU  - Cecconi, M.
AU  - Avard, B.
AU  - Zhang, P.
AU  - Mezidi, M.
AU  - Charbit, J.
AU  - Ould-Chikh, M.
AU  - Deras, P.
AU  - Maury, C.
AU  - Martinez, O.
AU  - Capdevila, X.
AU  - Hou, P.
AU  - Linde-Zwirble, W. Z.
AU  - Douglas, I. D.
AU  - Shapiro, N. S.
AU  - Ben Souissi, A.
AU  - Mezghani, I.
AU  - Ben Aicha, Y.
AU  - Kamoun, S.
AU  - Laribi, B.
AU  - Jeribi, B.
AU  - Riahi, A.
AU  - Mebazaa, M. S.
AU  - Pereira, C.
AU  - Marinho, R.
AU  - Antunes, R.
AU  - Marinho, A.
AU  - Crivits, M.
AU  - Raes, M.
AU  - Decruyenaere, J.
AU  - Hoste, E.
AU  - Bagin, V.
AU  - Rudnov, V.
AU  - Savitsky, A.
AU  - Astafyeva, M.
AU  - Korobko, I.
AU  - Vein, V.
AU  - Kampmeier, T.
AU  - Arnemann, P.
AU  - Hessler, M.
AU  - Wald, A.
AU  - Bockbreder, K.
AU  - Morelli, A.
AU  - Van Aken, H.
AU  - Rehberg, S.
AU  - Ertmer, C.
AU  - Arnemann, P.
AU  - Hessler, M.
AU  - Kampmeier, T.
AU  - Rehberg, S.
AU  - Van Aken, H.
AU  - Ince, C.
AU  - Ertmer, C.
AU  - Reddy, S.
AU  - Bailey, M.
AU  - Beasley, R.
AU  - Bellomo, R.
AU  - Mackle, D.
AU  - Psirides, A.
AU  - Young, P.
AU  - Reddy, S.
AU  - Bailey, M.
AU  - Beasley, R.
AU  - Bellomo, R.
AU  - Mackle, D.
AU  - Young, P.
AU  - Venkatesh, H.
AU  - Ramachandran, S.
AU  - Basu, A.
AU  - Nair, H.
AU  - Egan, S.
AU  - Bates, J.
AU  - Oliveira, S.
AU  - Rangel Neto, N. R.
AU  - Reis, F. Q.
AU  - Lee, C. P.
AU  - Lin, X. L.
AU  - Choong, C.
AU  - Eu, K. M.
AU  - Sim, W. Y.
AU  - Tee, K. S.
AU  - Pau, J.
AU  - Abisheganaden, J.
AU  - Maas, K.
AU  - De Geus, H.
AU  - Lafuente, E.
AU  - Marinho, R.
AU  - Moura, J.
AU  - Antunes, R.
AU  - Marinho, A.
AU  - Doris, T. E.
AU  - Monkhouse, D.
AU  - Shipley, T.
AU  - Kardasz, S.
AU  - Gonzalez, I.
AU  - Stads, S.
AU  - Groeneveld, A. J.
AU  - Elsayed, I.
AU  - Ward, N.
AU  - Tridente, A.
AU  - Raithatha, A.
AU  - Steuber, A.
AU  - Pelletier, C.
AU  - Schroeder, S.
AU  - Michael, E.
AU  - Slowinski, T.
AU  - Kindgen-Milles, D.
AU  - Ghabina, S.
AU  - Turani, F.
AU  - Belli, A.
AU  - Busatti, S.
AU  - Barettin, G.
AU  - Candidi, F.
AU  - Gargano, F.
AU  - Barchetta, R.
AU  - Falco, M.
AU  - Demirkiran, O.
AU  - Kosuk, M.
AU  - Bozbay, S.
AU  - Weber, V.
AU  - Hartmann, J.
AU  - Harm, S.
AU  - Linsberger, I.
AU  - Eichhorn, T.
AU  - Valicek, G.
AU  - Miestinger, G.
AU  - Hoermann, C.
AU  - Faenza, S.
AU  - Ricci, D.
AU  - Mancini, E.
AU  - Gemelli, C.
AU  - Cuoghi, A.
AU  - Magnani, S.
AU  - Atti, M.
AU  - Laddomada, T.
AU  - Doronzio, A.
AU  - Balicco, B.
AU  - Gruda, M. C.
AU  - O’Sullivan, P.
AU  - Dan, V. P.
AU  - Guliashvili, T.
AU  - Scheirer, A.
AU  - Golobish, T. D.
AU  - Capponi, V. J.
AU  - Chan, P. P.
AU  - Kogelmann, K.
AU  - Drüner, M.
AU  - Jarczak, D.
AU  - Turani, F.
AU  - Belli, A. B.
AU  - Martni, S. M.
AU  - Cotticelli, V. C.
AU  - Mounajergi, F.
AU  - Barchetta, R.
AU  - Morimoto, S.
AU  - Ishikura, H.
AU  - Hussain, I.
AU  - Salahuddin, N.
AU  - Nadeem, A.
AU  - Ghorab, K.
AU  - Maghrabi, K.
AU  - Kloesel, S. K.
AU  - Goldfuss, C.
AU  - Stieglitz, A.
AU  - Stieglitz, A. S.
AU  - Krstevska, L.
AU  - Albuszies, G.
AU  - Aguilar Arzapalo, M.
AU  - Barradas, L.
AU  - Lopez, V.
AU  - Escalante, A.
AU  - Jimmy, G.
AU  - Cetina, M.
AU  - Izawa, J.
AU  - Iwami, T.
AU  - Uchino, S.
AU  - Takinami, M.
AU  - Kitamura, T.
AU  - Kawamura, T.
AU  - Powell-Tuck, J. G.
AU  - Crichton, S.
AU  - Raimundo, M.
AU  - Camporota, L.
AU  - Wyncoll, D.
AU  - Ostermann, M.
AU  - Hana, A.
AU  - De Geus, H. R.
AU  - De Geus, H. R.
AU  - Hana, A.
AU  - Aydogdu, M.
AU  - Boyaci, N.
AU  - Yuksel, S.
AU  - Gursel, G.
AU  - Cayci Sivri, A. B.
AU  - Meza-Márquez, J.
AU  - Nava-López, J.
AU  - Carrillo-Esper, R.
AU  - Dardashti, A.
AU  - Grubb, A.
AU  - Maizel, J.
AU  - Wetzstein, M.
AU  - Titeca, D.
AU  - Kontar, L.
AU  - Brazier, F.
AU  - De Cagny, B.
AU  - Riviere, A.
AU  - Soupison, T.
AU  - Joris, M.
AU  - Slama, M.
AU  - Peters, E.
AU  - Njimi, H.
AU  - Pickkers, P.
AU  - Vincent, J. L.
AU  - Waraich, M.
AU  - Doyle, J.
AU  - Samuels, T.
AU  - Forni, L.
AU  - Desai, N.
AU  - Baumber, R.
AU  - Gunning, P.
AU  - Sell, A.
AU  - Lin, S.
AU  - Torrence, H.
AU  - O’Dwyer, M.
AU  - Kirwan, C.
AU  - Prowle, J.
AU  - Kim, T.
AU  - O’Connor, M. E.
AU  - Hewson, R. W.
AU  - Kirwan, C. J.
AU  - Pearse, R. M.
AU  - Prowle, J.
AU  - Hanoura, S.
AU  - Omar, A.
AU  - Othamn, H.
AU  - Sudarsanan, S.
AU  - Allam, M.
AU  - Maksoud, M.
AU  - Singh, R.
AU  - Al Khulaifi, A.
AU  - O’Connor, M. E.
AU  - Hewson, R. W.
AU  - Kirwan, C. J.
AU  - Pearse, R. M.
AU  - Prowle, J.
AU  - Uzundere, O.
AU  - Memis, D.
AU  - Ýnal, M.
AU  - Gultekin, A.
AU  - Turan, N.
AU  - Aydin, M. A.
AU  - Basar, H.
AU  - Sencan, I.
AU  - Kapuagasi, A.
AU  - Ozturk, M.
AU  - Uzundurukan, Z.
AU  - Gokmen, D.
AU  - Ozcan, A.
AU  - Kaymak, C.
AU  - Artemenko, V. A.
AU  - Budnyuk, A.
AU  - Pugh, R.
AU  - Bhandari, S.
AU  - Mauri, T.
AU  - Turrini, C.
AU  - Langer, T.
AU  - Taccone, P.
AU  - Volta, C. A.
AU  - Marenghi, C.
AU  - Gattinoni, L.
AU  - Pesenti, A.
AU  - Sweeney, L.
AU  - O’Sullivan, A.
AU  - Kelly, P.
AU  - Mukeria, E.
AU  - MacLoughlin, R.
AU  - Pfeffer, M.
AU  - Thomas, J. T.
AU  - Bregman, G. B.
AU  - Karp, G. K.
AU  - Kishinevsky, E. K.
AU  - Stavi, D. S.
AU  - Adi, N. A.
AU  - Poropat, T.
AU  - Knafelj, R.
AU  - Llopart, E.
AU  - Batlle, M.
AU  - De Haro, C.
AU  - Mesquida, J.
AU  - Artigas, A.
AU  - Pavlovic, D.
AU  - Lewerentz, L.
AU  - Spassov, A.
AU  - Schneider, R.
AU  - De Smet, S.
AU  - De Raedt, S.
AU  - Derom, E.
AU  - Depuydt, P.
AU  - Oeyen, S.
AU  - Benoit, D.
AU  - Decruyenaere, J.
AU  - Gobatto, A.
AU  - Besen, B.
AU  - Tierno, P.
AU  - Melro, L.
AU  - Mendes, P.
AU  - Cadamuro, F.
AU  - Park, M.
AU  - Malbouisson, L. M.
AU  - Civantos, B. C.
AU  - Lopez, J. L.
AU  - Robles, A.
AU  - Figueira, J.
AU  - Yus, S.
AU  - Garcia, A.
AU  - Oglinda, A.
AU  - Ciobanu, G.
AU  - Oglinda, C.
AU  - Schirca, L.
AU  - Sertinean, T.
AU  - Lupu, V.
AU  - Kelly, P.
AU  - O’Sullivan, A.
AU  - Sweeney, L.
AU  - MacLoughlin, R.
AU  - O’Sullivan, A.
AU  - Kelly, P.
AU  - Sweeney, L.
AU  - Mukeria, E.
AU  - Wolny, M.
AU  - MacLoughlin, R.
AU  - Pagano, A.
AU  - Numis, F.
AU  - Visone, G.
AU  - Saldamarco, L.
AU  - Russo, T.
AU  - Porta, G.
AU  - Paladino, F.
AU  - Bell, C.
AU  - Liu, J.
AU  - Debacker, J.
AU  - Lee, C.
AU  - Tamberg, E.
AU  - Campbell, V.
AU  - Mehta, S.
AU  - Silva-Pinto, A.
AU  - Sarmento, A.
AU  - Santos, L.
AU  - Kara, Ý
AU  - Yýldýrým, F.
AU  - Zerman, A.
AU  - Güllü, Z.
AU  - Boyacý, N.
AU  - Basarýk Aydogan, B.
AU  - Gaygýsýz, Ü
AU  - Gönderen, K.
AU  - Arýk, G.
AU  - Turkoglu, M.
AU  - Aydogdu, M.
AU  - Aygencel, G.
AU  - Ülger, Z.
AU  - Gursel, G.
AU  - Boyacý, N.
AU  - Isýkdogan, Z.
AU  - Özdedeoglu, Ö
AU  - Güllü, Z.
AU  - Badoglu, M.
AU  - Gaygýsýz, U.
AU  - Aydogdu, M.
AU  - Gursel, G.
AU  - Kongpolprom, N.
AU  - Sittipunt, C.
AU  - Eden, A.
AU  - Kokhanovsky, Y.
AU  - Bursztein – De Myttenaere, S.
AU  - Pizov, R.
AU  - Neilans, L.
AU  - MacIntyre, N.
AU  - Radosevich, M.
AU  - Wanta, B.
AU  - Weber, V.
AU  - Meyer, T.
AU  - Smischney, N.
AU  - Brown, D.
AU  - Diedrich, D.
AU  - Fuller, A.
AU  - McLindon, P.
AU  - Sim, K.
AU  - Shoaeir, M.
AU  - Noeam, K.
AU  - Mahrous, A.
AU  - Matsa, R.
AU  - Ali, A.
AU  - Dridi, C.
AU  - Koubaji, S.
AU  - Kamoun, S.
AU  - Haddad, F.
AU  - Ben Souissi, A.
AU  - Laribi, B.
AU  - Riahi, A.
AU  - Mebazaa, M. S.
AU  - Pérez-Calatayud, A.
AU  - Carrillo-Esper, R.
AU  - Zepeda-Mendoza, A.
AU  - Diaz-Carrillo, M.
AU  - Arch-Tirado, E.
AU  - Carbognin, S.
AU  - Pelacani, L.
AU  - Zannoni, F.
AU  - Agnoli, A.
AU  - Gagliardi, G.
AU  - Cho, R.
AU  - Adams, A.
AU  - Lunos, S.
AU  - Ambur, S.
AU  - Shapiro, R.
AU  - Prekker, M.
AU  - Thijssen, M.
AU  - Janssen, L.
AU  - Foudraine, N.
AU  - Voscopoulos, C. J.
AU  - Freeman, J.
AU  - Voscopoulos, C. J.
AU  - Freeman, J.
AU  - George, E.
AU  - Voscopoulos, C. J.
AU  - Eversole, D.
AU  - Freeman, J.
AU  - George, E.
AU  - Muttini, S.
AU  - Bigi, R.
AU  - Villani, G.
AU  - Patroniti, N.
AU  - Williams, G.
AU  - Voscopoulos, C. J.
AU  - Freeman, J.
AU  - George, E.
AU  - Waldmann, A.
AU  - Böhm, S.
AU  - Windisch, W.
AU  - Strassmann, S.
AU  - Karagiannidis, C.
AU  - Waldmann, A.
AU  - Böhm, S.
AU  - Windisch, W.
AU  - Strassmann, S.
AU  - Karagiannidis, C.
AU  - Karagiannidis, C. K.
AU  - Waldmann, A. W.
AU  - Böhm, S. B.
AU  - Strassmann, S.
AU  - Windisch, W. W.
AU  - Persson, P.
AU  - Lundin, S.
AU  - Stenqvist, O.
AU  - Porta, G.
AU  - Numis, F.
AU  - Serra, C. S.
AU  - Pagano, A. P.
AU  - Masarone, M. M.
AU  - Rinaldi, L. R.
AU  - Amelia, A. A.
AU  - Fascione, M. F.
AU  - Adinolfi, L. A.
AU  - Ruggiero, E. R.
AU  - Asota, F.
AU  - O’Rourke, K.
AU  - Ranjan, S.
AU  - Morgan, P.
AU  - DeBacker, J. W.
AU  - Tamberg, E.
AU  - O’Neill, L.
AU  - Munshi, L.
AU  - Burry, L.
AU  - Fan, E.
AU  - Mehta, S.
AU  - Poo, S.
AU  - Mahendran, K.
AU  - Fowles, J.
AU  - Gerrard, C.
AU  - Vuylsteke, A.
AU  - Loveridge, R.
AU  - Chaddock, C.
AU  - Patel, S.
AU  - Kakar, V.
AU  - Willars, C.
AU  - Hurst, T.
AU  - Park, C.
AU  - Best, T.
AU  - Vercueil, A.
AU  - Auzinger, G.
AU  - Borgman, A.
AU  - Proudfoot, A. G.
AU  - Grins, E.
AU  - Emiley, K. E.
AU  - Schuitema, J.
AU  - Fitch, S. J.
AU  - Marco, G.
AU  - Sturgill, J.
AU  - Dickinson, M. G.
AU  - Strueber, M.
AU  - Khaghani, A.
AU  - Wilton, P.
AU  - Jovinge, S. M.
AU  - Sampson, C.
AU  - Harris-Fox, S.
AU  - Cove, M. E.
AU  - Vu, L. H.
AU  - Sen, A.
AU  - Federspiel, W. J.
AU  - Kellum, J. A.
AU  - Mazo Torre, C.
AU  - Riera, J.
AU  - Ramirez, S.
AU  - Borgatta, B.
AU  - Lagunes, L.
AU  - Rello, J.
AU  - Kuzovlev, A. K.
AU  - Moroz, V.
AU  - Goloubev, A.
AU  - Polovnikov, S.
AU  - Nenchuk, S.
AU  - Karavana, V.
AU  - Glynos, C.
AU  - Asimakos, A.
AU  - Pappas, K.
AU  - Vrettou, C.
AU  - Magkou, M.
AU  - Ischaki, E.
AU  - Stathopoulos, G.
AU  - Zakynthinos, S.
AU  - Spadaro, S.
AU  - Kozhevnikova, I.
AU  - Dalla Corte, F.
AU  - Grasso, S.
AU  - Casolari, P.
AU  - Caramori, G.
AU  - Volta, C.
AU  - Andrianjafiarinoa, T.
AU  - Randriamandrato, T.
AU  - Rajaonera, T.
AU  - El-Dash, S.
AU  - Costa, E. L. V.
AU  - Tucci, M. R.
AU  - Leleu, F.
AU  - Kontar, L.
AU  - De Cagny, B.
AU  - Brazier, F.
AU  - Titeca, D.
AU  - Bacari-Risal, G.
AU  - Maizel, J.
AU  - Amato, M.
AU  - Slama, M.
AU  - Mercado, P.
AU  - Maizel, J.
AU  - Kontar, L.
AU  - Titeca, D.
AU  - Brazier, F.
AU  - Riviere, A.
AU  - Joris, M.
AU  - Soupison, T.
AU  - De Cagny, B.
AU  - El Dash, S.
AU  - Slama, M.
AU  - Remmington
AU  - Fischer, A.
AU  - Squire, S.
AU  - Boichat, M.
AU  - Honzawa, H.
AU  - Yasuda, H.
AU  - Adati, T.
AU  - Suzaki, S.
AU  - Horibe, M.
AU  - Sasaki, M.
AU  - Sanui, M.
AU  - Marinho, R.
AU  - Daniel, J.
AU  - Miranda, H.
AU  - Marinho, A.
AU  - Milinis, K.
AU  - Cooper, M.
AU  - Williams, G. R.
AU  - McCarron, E.
AU  - Simants, S.
AU  - Patanwala, I.
AU  - Welters, I.
AU  - Su, Y.
AU  - Fernández Villanueva, J.
AU  - Fernández Garda, R.
AU  - López Lago, A.
AU  - Rodríguez Ruíz, E.
AU  - Hernández Vaquero, R.
AU  - Tomé Martínez de Rituerto, S.
AU  - Varo Pérez, E.
AU  - Lefel, N.
AU  - Schaap, F.
AU  - Bergmans, D.
AU  - Olde Damink, S.
AU  - Van de Poll, M.
AU  - Tizard, K.
AU  - Lister, C.
AU  - Poole, L.
AU  - Ringaitiene, D.
AU  - Gineityte, D.
AU  - Vicka, V.
AU  - Norkiene, I.
AU  - Sipylaite, J.
AU  - O’Loughlin, A.
AU  - Maraj, V.
AU  - Dowling, J.
AU  - Velasco, M. B.
AU  - Dalcomune, D. M.
AU  - Dias, E. B.
AU  - Fernandes, S. L.
AU  - Oshima, T.
AU  - Graf, S.
AU  - Heidegger, C.
AU  - Genton, L.
AU  - Karsegard, V.
AU  - Dupertuis, Y.
AU  - Pichard, C.
AU  - Friedli, N.
AU  - Stanga, Z.
AU  - Mueller, B.
AU  - Schuetz, P.
AU  - Vandersteen, L.
AU  - Stessel, B.
AU  - Evers, S.
AU  - Van Assche, A.
AU  - Jamaer, L.
AU  - Dubois, J.
AU  - Marinho, R.
AU  - Castro, H.
AU  - Moura, J.
AU  - Valente, J.
AU  - Martins, P.
AU  - Casteloes, P.
AU  - Magalhaes, C.
AU  - Cabral, S.
AU  - Santos, M.
AU  - Oliveira, B.
AU  - Salgueiro, A.
AU  - Marinho, A.
AU  - Marinho, R.
AU  - Santos, M.
AU  - Lafuente, E.
AU  - Castro, H.
AU  - Cabral, S.
AU  - Moura, J.
AU  - Martins, P.
AU  - Oliveira, B.
AU  - Salgueiro, A.
AU  - Duarte, S.
AU  - Castro, S.
AU  - Melo, M.
AU  - Casteloes, P.
AU  - Marinho, A.
AU  - Gray, S.
AU  - Maipang, K.
AU  - Bhurayanontachai, R.
AU  - Grädel, L. G.
AU  - Schütz, P.
AU  - Langlois, P.
AU  - Manzanares, W.
AU  - Tincu, R.
AU  - Cobilinschi, C.
AU  - Tomescu, D.
AU  - Ghiorghiu, Z.
AU  - Macovei, R.
AU  - Manzanares, W.
AU  - Langlois, P.
AU  - Lemieux, M.
AU  - Elke, G.
AU  - Bloos, F.
AU  - Reinhart, K.
AU  - Heyland, D.
AU  - Langlois, P.
AU  - Lemieux, M.
AU  - Aramendi, I.
AU  - Heyland, D.
AU  - Manzanares, W.
AU  - Su, Y.
AU  - Marinho, R.
AU  - Babo, N.
AU  - Marinho, A.
AU  - Hoshino, M.
AU  - Haraguchi, Y.
AU  - Kajiwara, S.
AU  - Mitsuhashi, T.
AU  - Tsubata, T.
AU  - Aida, M.
AU  - Rattanapraphat, T.
AU  - Bhurayanontachai, R.
AU  - Kongkamol, C.
AU  - Khwannimit, B.
AU  - Marinho, R.
AU  - Santos, M.
AU  - Castro, H.
AU  - Lafuente, E.
AU  - Salgueiro, A.
AU  - Cabral, S.
AU  - Martins, P.
AU  - Moura, J.
AU  - Oliveira, B.
AU  - Melo, M.
AU  - Xavier, B.
AU  - Valente, J.
AU  - Magalhaes, C.
AU  - Casteloes, P.
AU  - Marinho, A.
AU  - Moisidou, D.
AU  - Ampatzidou, F.
AU  - Koutsogiannidis, C.
AU  - Moschopoulou, M.
AU  - Drossos, G.
AU  - Taskin, G.
AU  - Çakir, M.
AU  - Güler, A. K.
AU  - Taskin, A.
AU  - Öcal, N.
AU  - Özer, S.
AU  - Yamanel, L.
AU  - Wong, J. M.
AU  - Fitton, C.
AU  - Anwar, S.
AU  - Stacey, S.
AU  - Aggou, M.
AU  - Fyntanidou, B.
AU  - Patsatzakis, S.
AU  - Oloktsidou, E.
AU  - Lolakos, K.
AU  - Papapostolou, E.
AU  - Grosomanidis, V.
AU  - Suda, S.
AU  - Ikeda, T.
AU  - Ono, S.
AU  - Ueno, T.
AU  - Izutani, Y.
AU  - Gaudry, S.
AU  - Desailly, V.
AU  - Pasquier, P.
AU  - Brun, P. B.
AU  - Tesnieres, A. T.
AU  - Ricard, J. D.
AU  - Dreyfuss, D.
AU  - Mignon, A.
AU  - White, J. C.
AU  - Molokhia, A.
AU  - Dean, A.
AU  - Stilwell, A.
AU  - Friedlaender, G.
AU  - Peters, M.
AU  - Stipulante, S.
AU  - Delfosse, A.
AU  - Donneau, A. F.
AU  - Ghuysen, A.
AU  - Feldmann, C.
AU  - Freitag, D.
AU  - Dersch, W.
AU  - Irqsusi, M.
AU  - Eschbach, D.
AU  - Steinfeldt, T.
AU  - Wulf, H.
AU  - Wiesmann, T.
AU  - Kongpolprom, N.
AU  - Cholkraisuwat, J.
AU  - Beitland, S.
AU  - Nakstad, E.
AU  - Stær-Jensen, H.
AU  - Drægni, T.
AU  - Andersen, G.
AU  - Jacobsen, D.
AU  - Brunborg, C.
AU  - Waldum-Grevbo, B.
AU  - Sunde, K.
AU  - Hoyland, K.
AU  - Pandit, D.
AU  - Hayakawa, K.
AU  - Oloktsidou, E.
AU  - Kotzampassi, K.
AU  - Fyntanidou, B.
AU  - Patsatzakis, S.
AU  - Loukipoudi, L.
AU  - Doumaki, E.
AU  - Grosomanidis, V.
AU  - Yasuda, H.
AU  - Admiraal, M. M.
AU  - Van Assen, M.
AU  - Van Putten, M. J.
AU  - Tjepkema-Cloostermans, M.
AU  - Van Rootselaar, A. F.
AU  - Horn, J.
AU  - Ragusa, F.
AU  - Marudi, A.
AU  - Baroni, S.
AU  - Gaspari, A.
AU  - Bertellini, E.
AU  - Taha, A.
AU  - Abdullah, T.
AU  - Abdel Monem, S.
AU  - Alcorn, S.
AU  - McNeill, S.
AU  - Russell, S.
AU  - Eertmans, W.
AU  - Genbrugge, C.
AU  - Meex, I.
AU  - Dens, J.
AU  - Jans, F.
AU  - De Deyne, C.
AU  - Cholkraisuwat, J.
AU  - Kongpolprom, N.
AU  - Avard, B.
AU  - Burns, R.
AU  - Patarchi, A.
AU  - Spina, T.
AU  - Tanaka, H.
AU  - Otani, N.
AU  - Ode, S.
AU  - Ishimatsu, S.
AU  - Cho, J.
AU  - Moon, J. B.
AU  - Park, C. W.
AU  - Ohk, T. G.
AU  - Shin, M. C.
AU  - Won, M. H.
AU  - Dakova, S.
AU  - Ramsheva, Z.
AU  - Ramshev, K.
AU  - Cho, J.
AU  - Moon, J. B.
AU  - Park, C. W.
AU  - Ohk, T. G.
AU  - Shin, M. C.
AU  - Cho, J.
AU  - Moon, J. B.
AU  - Park, C. W.
AU  - Ohk, T. G.
AU  - Shin, M. C.
AU  - Marudi, A.
AU  - Baroni, S.
AU  - Gaspari, A.
AU  - Bertellini, E.
AU  - Orhun, G.
AU  - Senturk, E.
AU  - Ozcan, P. E.
AU  - Sencer, S.
AU  - Ulusoy, C.
AU  - Tuzun, E.
AU  - Esen, F.
AU  - Tincu, R.
AU  - Cobilinschi, C.
AU  - Tomescu, D.
AU  - Ghiorghiu, Z.
AU  - Macovei, R.
AU  - Van Assen, M.
AU  - Admiraal, M. M.
AU  - Van Putten, M. J.
AU  - Tjepkema-Cloostermans, M.
AU  - Van Rootselaar, A. F.
AU  - Horn, J.
AU  - Fallenius, M.
AU  - Skrifvars, M. B.
AU  - Reinikainen, M.
AU  - Bendel, S.
AU  - Raj, R.
AU  - Abu-Habsa, M.
AU  - Hymers, C.
AU  - Borowska, A.
AU  - Sivadhas, H.
AU  - Sahiba, S.
AU  - Perkins, S.
AU  - Rubio, J.
AU  - Rubio, J. A.
AU  - Sierra, R.
AU  - English, S.
AU  - Chasse, M.
AU  - Turgeon, A.
AU  - Lauzier, F.
AU  - Griesdale, D.
AU  - Garland, A.
AU  - Fergusson, D.
AU  - Zarychanski, R.
AU  - Tinmouth, A.
AU  - Van Walraven, C.
AU  - Montroy, K.
AU  - Ziegler, J.
AU  - Dupont Chouinard, R.
AU  - Carignan, R.
AU  - Dhaliwal, A.
AU  - Lum, C.
AU  - Sinclair, J.
AU  - Pagliarello, G.
AU  - McIntyre, L.
AU  - English, S.
AU  - Chasse, M.
AU  - Turgeon, A.
AU  - Lauzier, F.
AU  - Griesdale, D.
AU  - Garland, A.
AU  - Fergusson, D.
AU  - Zarychanski, R.
AU  - Tinmouth, A.
AU  - Van Walraven, C.
AU  - Montroy, K.
AU  - Ziegler, J.
AU  - Dupont Chouinard, R.
AU  - Carignan, R.
AU  - Dhaliwal, A.
AU  - Lum, C.
AU  - Sinclair, J.
AU  - Pagliarello, G.
AU  - McIntyre, L.
AU  - Groza, T.
AU  - Moreau, N.
AU  - Castanares-Zapatero, D.
AU  - Hantson, P.
AU  - Carbonara, M.
AU  - Ortolano, F.
AU  - Zoerle, T.
AU  - Magnoni, S.
AU  - Pifferi, S.
AU  - Conte, V.
AU  - Stocchetti, N.
AU  - Carteron, L.
AU  - Suys, T.
AU  - Patet, C.
AU  - Quintard, H.
AU  - Oddo, M.
AU  - Rubio, J. A.
AU  - Rubio, J.
AU  - Sierra, R.
AU  - Spatenkova, V.
AU  - Pokorna, E.
AU  - Suchomel, P.
AU  - Ebert, N.
AU  - Jancik, J.
AU  - Rhodes, H.
AU  - Bylinski, T.
AU  - Hawthorne, C.
AU  - Shaw, M.
AU  - Piper, I.
AU  - Kinsella, J.
AU  - Kink, A. K.
AU  - Rätsep, I. R.
AU  - Boutin, A.
AU  - Moore, L.
AU  - Chasse, M.
AU  - Zarychanski, R.
AU  - Lauzier, F.
AU  - English, S.
AU  - McIntyre, L.
AU  - Lacroix, J.
AU  - Griesdale, D.
AU  - Lessard-Bonaventure, P.
AU  - Turgeon, A. F.
AU  - Boutin, A.
AU  - Moore, L.
AU  - Green, R.
AU  - Lessard-Bonaventure, P.
AU  - Erdogan, M.
AU  - Butler, M.
AU  - Lauzier, F.
AU  - Chasse, M.
AU  - English, S.
AU  - McIntyre, L.
AU  - Zarychanski, R.
AU  - Lacroix, J.
AU  - Griesdale, D.
AU  - Desjardins, P.
AU  - Fergusson, D. A.
AU  - Turgeon, A. F.
AU  - Goncalves, B.
AU  - Vidal, B.
AU  - Valdez, C.
AU  - Rodrigues, A. C.
AU  - Miguez, L.
AU  - Moralez, G.
AU  - Hong, T.
AU  - Kutz, A.
AU  - Hausfater, P.
AU  - Amin, D.
AU  - Struja, T.
AU  - Haubitz, S.
AU  - Huber, A.
AU  - Mueller, B.
AU  - Schuetz, P.
AU  - Brown, T.
AU  - Collinson, J.
AU  - Pritchett, C.
AU  - Slade, T.
AU  - Le Guen, M.
AU  - Hellings, S.
AU  - Ramsaran, R.
AU  - Alsheikhly, A.
AU  - Abe, T.
AU  - Kanapeckaite, L.
AU  - Abu-Habsa, M.
AU  - Bahl, R.
AU  - Russell, M. Q.
AU  - Real, K. J.
AU  - Abu-Habsa, M.
AU  - Lyon, R. M.
AU  - Oveland, N. P.
AU  - Penketh, J.
AU  - McDonald, M.
AU  - Kelly, F.
AU  - Alfafi, M.
AU  - Alsolamy, S.
AU  - Almutairi, W.
AU  - Alotaibi, B.
AU  - Van den Berg, A. E.
AU  - Schriel, Y.
AU  - Dawson, L.
AU  - Meynaar, I. A.
AU  - Talaie, H.
AU  - Silva, D.
AU  - Fernandes, S.
AU  - Gouveia, J.
AU  - Santos Silva, J.
AU  - Foley, J.
AU  - Kaskovagheorgescu, A.
AU  - Evoy, D.
AU  - Cronin, J.
AU  - Ryan, J.
AU  - Huck, M.
AU  - Hoffmann, C.
AU  - Renner, J.
AU  - Laitselart, P.
AU  - Donat, N.
AU  - Cirodde, A.
AU  - Schaal, J. V.
AU  - Masson, Y.
AU  - Nau, A.
AU  - Leclerc, T.
AU  - Howarth, O.
AU  - Davenport, K.
AU  - Jeanrenaud, P.
AU  - Raftery, S.
AU  - MacTavish, P.
AU  - Devine, H.
AU  - McPeake, J.
AU  - Daniel, M.
AU  - Kinsella, J.
AU  - Quasim, T.
AU  - Alrabiee, S.
AU  - Alrashid, A.
AU  - Alsolamy, S.
AU  - Gundogan, O.
AU  - Bor, C.
AU  - Akýn Korhan, E.
AU  - Demirag, K.
AU  - Uyar, M.
AU  - Frame, F.
AU  - Ashton, C.
AU  - Bergstrom Niska, L.
AU  - Dilokpattanamongkol, P.
AU  - Suansanae, T.
AU  - Suthisisang, C.
AU  - Morakul, S.
AU  - Karnjanarachata, C.
AU  - Tangsujaritvijit, V.
AU  - Mahmood, S.
AU  - Al Thani, H.
AU  - Almenyar, A.
AU  - Vakalos, A.
AU  - Avramidis, V.
AU  - Sharvill, R.
AU  - Penketh, J.
AU  - Morton, S. E.
AU  - Chiew, Y. S.
AU  - Pretty, C.
AU  - Chase, J. G.
AU  - Shaw, G. M.
AU  - Knafelj, R.
AU  - Kordis, P.
AU  - Patel, S.
AU  - Grover, V.
AU  - Kuchyn, I.
AU  - Bielka, K.
AU  - Aidoni, Z.
AU  - Grosomanidis, V.
AU  - Kotzampassi, K.
AU  - Stavrou, G.
AU  - Fyntanidou, B.
AU  - Patsatzakis, S.
AU  - Skourtis, C.
AU  - Lee, S. D.
AU  - Williams, K.
AU  - Weltes, I. D.
AU  - Berhane, S.
AU  - Arrowsmith, C.
AU  - Peters, C.
AU  - Robert, S.
AU  - Caldas, J.
AU  - Panerai, R. B.
AU  - Robinson, T. G.
AU  - Camara, L.
AU  - Ferreira, G.
AU  - Borg-Seng-Shu, E.
AU  - De Lima Oliveira, M.
AU  - Mian, N. C.
AU  - Santos, L.
AU  - Nogueira, R.
AU  - Zeferino, S. P.
AU  - Jacobsen Teixeira, M.
AU  - Galas, F.
AU  - Hajjar, L. A.
AU  - Killeen, P.
AU  - McPhail, M.
AU  - Bernal, W.
AU  - Maggs, J.
AU  - Wendon, J.
AU  - Hughes, T.
AU  - Taniguchi, L. U.
AU  - Siqueira, E. M.
AU  - Vieira Jr, J. M.
AU  - Azevedo, L. C.
AU  - Ahmad, A. N.
AU  - Abu-Habsa, M.
AU  - Bahl, R.
AU  - Helme, E.
AU  - Hadfield, S.
AU  - Loveridge, R.
AU  - Shak, J.
AU  - Senver, C.
AU  - Howard-Griffin, R.
AU  - Wacharasint, P.
AU  - Fuengfoo, P.
AU  - Sukcharoen, N.
AU  - Rangsin, R.
AU  - Sbiti-Rohr, D.
AU  - Schuetz, P.
AU  - Na, H.
AU  - Song, S.
AU  - Lee, S.
AU  - Jeong, E.
AU  - Lee, K.
AU  - Cooper, M.
AU  - Milinis, K.
AU  - Williams, G.
AU  - McCarron, E.
AU  - Simants, S.
AU  - Patanwala, I.
AU  - Welters, I. D.
AU  - Zoumpelouli, E.
AU  - Volakli, E. A.
AU  - Chrysohoidou, V.
AU  - Georgiou, S.
AU  - Charisopoulou, K.
AU  - Kotzapanagiotou, E.
AU  - Panagiotidou, V.
AU  - Manavidou, K.
AU  - Stathi, Z.
AU  - Sdougka, M.
AU  - Salahuddin, N.
AU  - AlGhamdi, B.
AU  - Marashly, Q.
AU  - Zaza, K.
AU  - Sharshir, M.
AU  - Khurshid, M.
AU  - Ali, Z.
AU  - Malgapo, M.
AU  - Jamil, M.
AU  - Shafquat, A.
AU  - Shoukri, M.
AU  - Hijazi, M.
AU  - Abe, T.
AU  - Uchino, S.
AU  - Takinami, M.
AU  - Rangel Neto, N. R.
AU  - Oliveira, S.
AU  - Reis, F. Q.
AU  - Rocha, F. A.
AU  - Moralez, G.
AU  - Ebecken, K.
AU  - Rabello, L. S.
AU  - Lima, M. F.
AU  - Hatum, R.
AU  - De Marco, F. V.
AU  - Alves, A.
AU  - Pinto, J. E.
AU  - Godoy, M.
AU  - Brasil, P. E.
AU  - Bozza, F. A.
AU  - Salluh, J. I.
AU  - Soares, M.
AU  - Krinsley, J.
AU  - Kang, G.
AU  - Perry, J.
AU  - Hines, H.
AU  - Wilkinson, K. M.
AU  - Tordoff, C.
AU  - Sloan, B.
AU  - Bellamy, M. C.
AU  - Moreira, E.
AU  - Verga, F.
AU  - Barbato, M.
AU  - Burghi, G.
AU  - Soares, M.
AU  - Silva, U. V.
AU  - Azevedo, L. C.
AU  - Torelly, A. P.
AU  - Kahn, J. M.
AU  - Angus, D. C.
AU  - Knibel, M. F.
AU  - Brasil, P. E.
AU  - Bozza, F. A.
AU  - Salluh, J. I.
AU  - Velasco, M. B.
AU  - Dalcomune, D. M.
AU  - Marshall, R.
AU  - Gilpin, T.
AU  - Tridente, A.
AU  - Raithatha, A.
AU  - Mota, D.
AU  - Loureiro, B.
AU  - Dias, J.
AU  - Afonso, O.
AU  - Coelho, F.
AU  - Martins, A.
AU  - Faria, F.
AU  - Al-Dorzi, H.
AU  - Al Orainni, H.
AU  - AlEid, F.
AU  - Tlaygeh, H.
AU  - Itani, A.
AU  - Hejazi, A.
AU  - Arabi, Y.
AU  - Gaudry, S.
AU  - Messika, J.
AU  - Ricard, J. D.
AU  - Guillo, S.
AU  - Pasquet, B.
AU  - Dubief, E.
AU  - Dreyfuss, D.
AU  - Tubach, F.
AU  - Battle, C.
AU  - James, K.
AU  - Temblett, P.
AU  - Davies, L.
AU  - Battle, C.
AU  - Lynch, C.
AU  - Pereira, S.
AU  - Cavaco, S.
AU  - Fernandes, J.
AU  - Moreira, I.
AU  - Almeida, E.
AU  - Seabra Pereira, F.
AU  - Malheiro, M.
AU  - Cardoso, F.
AU  - Aragão, I.
AU  - Cardoso, T.
AU  - Fister, M.
AU  - Knafelj, R.
AU  - Muraray Govind, P.
AU  - Brahmananda Reddy, N.
AU  - Pratheema, R.
AU  - Arul, E. D.
AU  - Devachandran, J.
AU  - Velasco, M. B.
AU  - Dalcomune, D. M.
AU  - Knafelj, R.
AU  - Fister, M.
AU  - Chin-Yee, N.
AU  - D’Egidio, G.
AU  - Thavorn, K.
AU  - Heyland, D.
AU  - Kyeremanteng, K.
AU  - Murchison, A. G.
AU  - Swalwell, K.
AU  - Mandeville, J.
AU  - Stott, D.
AU  - Guerreiro, I.
AU  - Devine, H.
AU  - MacTavish, P.
AU  - McPeake, J.
AU  - Quasim, T.
AU  - Kinsella, J.
AU  - Daniel, M.
AU  - Goossens, C.
AU  - Marques, M. B.
AU  - Derde, S.
AU  - Vander Perre, S.
AU  - Dufour, T.
AU  - Thiessen, S. E.
AU  - Güiza, F.
AU  - Janssens, T.
AU  - Hermans, G.
AU  - Vanhorebeek, I.
AU  - De Bock, K.
AU  - Van den Berghe, G.
AU  - Langouche, L.
AU  - Devine, H.
AU  - MacTavish, P.
AU  - Quasim, T.
AU  - Kinsella, J.
AU  - Daniel, M.
AU  - McPeake, J.
AU  - Miles, B.
AU  - Madden, S.
AU  - Devine, H.
AU  - Weiler, M.
AU  - Marques, P.
AU  - Rodrigues, C.
AU  - Boeira, M.
AU  - Brenner, K.
AU  - Leães, C.
AU  - Machado, A.
AU  - Townsend, R.
AU  - Andrade, J.
AU  - MacTavish, P.
AU  - McPeake, J.
AU  - Devine, H.
AU  - Kinsella, J.
AU  - Daniel, M.
AU  - Kishore, R.
AU  - Fenlon, C.
AU  - Quasim, T.
AU  - Fiks, T.
AU  - Ruijter, A.
AU  - Te Raa, M.
AU  - Spronk, P.
AU  - Chiew, Y. S.
AU  - Docherty, P.
AU  - Dickson, J.
AU  - Moltchanova, E.
AU  - Scarrot, C.
AU  - Pretty, C.
AU  - Shaw, G. M.
AU  - Chase, J. G.
AU  - Hall, T.
AU  - Ngu, W. C.
AU  - Jack, J. M.
AU  - Morgan, P.
AU  - Avard, B.
AU  - Pavli, A.
AU  - Gee, X.
AU  - Bor, C.
AU  - Akin Korhan, E.
AU  - Demirag, K.
AU  - Uyar, M.
AU  - Shirazy, M.
AU  - Fayed, A.
AU  - Gupta, S.
AU  - Kaushal, A.
AU  - Dewan, S.
AU  - Varma, A.
AU  - Ghosh, E.
AU  - Yang, L.
AU  - Eshelman, L.
AU  - Lord, B.
AU  - Carlson, E.
AU  - Helme, E.
AU  - Broderick, R.
AU  - Hadfield, S.
AU  - Loveridge, R.
AU  - Ramos, J.
AU  - Forte, D.
AU  - Yang, F.
AU  - Hou, P.
AU  - Dudziak, J.
AU  - Feeney, J.
AU  - Wilkinson, K.
AU  - Bauchmuller, K.
AU  - Shuker, K.
AU  - Faulds, M.
AU  - Raithatha, A.
AU  - Bryden, D.
AU  - England, L.
AU  - Bolton, N.
AU  - Tridente, A.
AU  - Bauchmuller, K.
AU  - Shuker, K.
AU  - Tridente, A.
AU  - Faulds, M.
AU  - Matheson, A.
AU  - Gaynor, J.
AU  - Bryden, D.
AU  - Ramos, J.
AU  - Peroni, B.
AU  - Daglius-Dias, R.
AU  - Miranda, L.
AU  - Cohen, C.
AU  - Carvalho, C.
AU  - Velasco, I.
AU  - Forte, D.
AU  - Kelly, J. M.
AU  - Neill, A.
AU  - Rubenfeld, G.
AU  - Masson, N.
AU  - Min, A.
AU  - Boezeman, E.
AU  - Hofhuis, J.
AU  - Hovingh, A.
AU  - De Vries, R.
AU  - Spronk, P.
AU  - Cabral-Campello, G.
AU  - Aragão, I.
AU  - Cardoso, T.
AU  - Van Mol, M.
AU  - Nijkamp, M.
AU  - Kompanje, E.
AU  - Ostrowski, P.
AU  - Omar, A.
AU  - Kiss, K.
AU  - Köves, B.
AU  - Csernus, V.
AU  - Molnár, Z.
AU  - Hoydonckx, Y.
AU  - Vanwing, S.
AU  - Stessel, B.
AU  - Van Assche, A.
AU  - Jamaer, L.
AU  - Dubois, J.
AU  - Medo, V.
AU  - Galvez, R.
AU  - Miranda, J. P.
AU  - Stone, C.
AU  - Wigmore, T.
AU  - Arunan, Y.
AU  - Wheeler, A.
AU  - Bauchmuller, K.
AU  - Bryden, D.
AU  - Wong, Y.
AU  - Poi, C.
AU  - Gu, C.
AU  - Molmy, P.
AU  - Van Grunderbeeck, N.
AU  - Nigeon, O.
AU  - Lemyze, M.
AU  - Thevenin, D.
AU  - Mallat, J.
AU  - Ramos, J.
AU  - Correa, M.
AU  - Carvalho, R. T.
AU  - Forte, D.
AU  - Fernandez, A.
AU  - McBride, C.
AU  - Koonthalloor, E.
AU  - Walsh, C.
AU  - Webber, A.
AU  - Ashe, M.
AU  - Smith, K.
AU  - Jeanrenaud, P.
AU  - Marudi, A.
AU  - Baroni, S.
AU  - Ragusa, F.
AU  - Bertellini, E.
AU  - Volakli, E. A.
AU  - Chochliourou, E.
AU  - Dimitriadou, M.
AU  - Violaki, A.
AU  - Mantzafleri, P.
AU  - Samkinidou, E.
AU  - Vrani, O.
AU  - Arbouti, A.
AU  - Varsami, T.
AU  - Sdougka, M.
AU  - Bollen, J. A.
AU  - Van Smaalen, T. C.
AU  - De Jongh, W. C.
AU  - Ten Hoopen, M. M.
AU  - Ysebaert, D.
AU  - Van Heurn, L. W.
AU  - Van Mook, W. N.
AU  - Sim, K.
AU  - Fuller, A.
AU  - Roze des Ordons, A.
AU  - Couillard, P.
AU  - Doig, C.
AU  - Van Keer, R. V.
AU  - Deschepper, R. D.
AU  - Francke, A. F.
AU  - Huyghens, L. H.
AU  - Bilsen, J. B.
AU  - Nyamaizi, B.
AU  - Dalrymple, C.
AU  - Molokhia, A.
AU  - Dobru, A.
AU  - Marrinan, E.
AU  - Ankuli, A.
AU  - Molokhia, A.
AU  - McPeake, J.
AU  - Struthers, R.
AU  - Crawford, R.
AU  - Devine, H.
AU  - Mactavish, P.
AU  - Quasim, T.
AU  - Morelli, P.
AU  - Degiovanangelo, M.
AU  - Lemos, F.
AU  - V, M. Artinez
AU  - Verga, F.
AU  - Cabrera, J.
AU  - Burghi, G.
AU  - Rutten, A.
AU  - Van Ieperen, S.
AU  - De Geer, S.
AU  - Van Vugt, M.
AU  - Der Kinderen, E.
AU  - Giannini, A.
AU  - Miccinesi, G.
AU  - Marchesi, T.
AU  - Prandi, E.
C2  - PMC5493079
DA  - Apr 20
DO  - 10.1186/s13054-016-1208-6
DP  - NLM
ET  - 2016/11/26
IS  - Suppl 2
LA  - eng
N1  - 1466-609x
Bateman, R M
Sharpe, M D
Jagger, J E
Ellis, C G
Solé-Violán, J
López-Rodríguez, M
Herrera-Ramos, E
Ruíz-Hernández, J
Borderías, L
Horcajada, J
González-Quevedo, N
Rajas, O
Briones, M
Rodríguez de Castro, F
Rodríguez Gallego, C
Esen, F
Orhun, G
Ergin Ozcan, P
Senturk, E
Ugur Yilmaz, C
Orhan, N
Arican, N
Kaya, M
Kucukerden, M
Giris, M
Akcan, U
Bilgic Gazioglu, S
Tuzun, E
Riff, R
Naamani, O
Douvdevani, A
Takegawa, R
Yoshida, H
Hirose, T
Yamamoto, N
Hagiya, H
Ojima, M
Akeda, Y
Tasaki, O
Tomono, K
Shimazu, T
Ono, S
Kubo, T
Suda, S
Ueno, T
Ikeda, T
Ogura, H
Takahashi, H
Kang, J
Nakamura, Y
Kojima, T
Izutani, Y
Taniguchi, T
O, m
Dinter, C
Lotz, J
Eilers, B
Wissmann, C
Lott, R
Meili, M M
Schuetz, P S
Hawa, H
Sharshir, M
Aburageila, M
Salahuddin, N
Chantziara, V
Georgiou, S
Tsimogianni, A
Alexandropoulos, P
Vassi, A
Lagiou, F
Valta, M
Micha, G
Chinou, E
Michaloudis, G
Kodaira, A
Imaizumi, H
De la Torre-Prados, M V
Garcia-De la Torre, A
Enguix-Armada, A
Puerto-Morlan, A
Perez-Valero, V
Garcia-Alcantara, A
Bolton, N
Dudziak, J
Bonney, S
Tridente, A
Nee, P
Nicolaes, G
Wiewel, M
Schultz, M
Wildhagen, K
Horn, J
Schrijver, R
Van der Poll, T
Reutelingsperger, C
Pillai, S
Davies, G
Mills, G
Aubrey, R
Morris, K
Williams, P
Evans, P
Gayat, E G
Struck, J
Cariou, A
Deye, N
Guidet, B
Jabert, S
Launay, J
Legrand, M
Léone, M
Resche-Rigon, M
Vicaut, E
Vieillard-Baron, A
Mebazaa, A
Arnold, R
Capan, M
Linder, A
Akesson, P
Popescu, M
Tomescu, D
Sprung, C L
Calderon Morales, R
Munteanu, G
Orenbuch-Harroch, E
Levin, P
Kasdan, H
Reiter, A
Volker, T
Himmel, Y
Cohen, Y
Meissonnier, J
Girard, L
Rebeaud, F
Herrmann, I
Delwarde, B
Peronnet, E
Cerrato, E
Venet, F
Lepape, A
Rimmelé, T
Monneret, G
Textoris, J
Beloborodova, N
Moroz, V
Osipov, A
Bedova, A
Sarshor, Y
Pautova, A
Sergeev, A
Chernevskaya, E
Odermatt, J
Bolliger, R
Hersberger, L
Ottiger, M
Christ-Crain, M
Mueller, B
Schuetz, P
Sharma, N K
Tashima, A K
Brunialti, M K
Machado, F R
Assuncao, M
Rigato, O
Salomao, R
Cajander, S C
Rasmussen, G
Tina, E
Söderquist, B
Källman, J
Strålin, K
Lange, A L
Sundén-Cullberg, J S
Magnuson, A M
Hultgren, O H
Van der Geest, P
Mohseni, M
Linssen, J
De Jonge, R
Duran, S
Groeneveld, J
Miller, R III
Lopansri, B K
McHugh, L C
Seldon, A
Burke, J P
Johnston, J
Reece-Anthony, R
Bond, A
Molokhia, A
Mcgrath, C
Nsutebu, E
Bank Pedersen, P
Pilsgaard Henriksen, D
Mikkelsen, S
Touborg Lassen, A
Tincu, R
Cobilinschi, C
Ghiorghiu, Z
Macovei, R
Wiewel, M A
Harmon, M B
Van Vught, L A
Scicluna, B P
Hoogendijk, A J
Zwinderman, A H
Cremer, O L
Bonten, M J
Schultz, M J
Juffermans, N P
Wiersinga, W J
Eren, G
Tekdos, Y
Dogan, M
Acicbe, O
Kaya, E
Hergunsel, O
Alsolamy, S
Ghamdi, G
Alswaidan, L
Alharbi, S
Alenezi, F
Arabi, Y
Heaton, J
Boyce, A
Nolan, L
Dukoff-Gordon, A
Dean, A
Mann Ben Yehudah, T
Fleischmann, C
Thomas-Rueddel, D
Haas, C
Dennler, U
Reinhart, K
Suntornlohanakul, O
Khwannimit, B
Breckenridge, F
Puxty, A
Szturz, P
Folwarzcny, P
Svancara, J
Kula, R
Sevcik, P
Caneva, L
Casazza, A
Bellazzi, E
Marra, S
Pagani, L
Vetere, M
Vanzino, R
Ciprandi, D
Preda, R
Boschi, R
Carnevale, L
Lopez, V
Aguilar Arzapalo, M
Barradas, L
Escalante, A
Gongora, J
Cetina, M
Adamik, B
Jakubczyk, D
Kübler, A
Radford, A
Lee, T
Singer, J
Boyd, J
Fineberg, D
Williams, M
Russell, J
Scarlatescu, E
Droc, G
Arama, S
Müller, M
Straat, M
Zeerleder, S S
Fuchs, C F
Scheer, C S
Wauschkuhn, S W
Vollmer, M V
Meissner, K M
Kuhn, S K
Hahnenkamp, K H
Rehberg, S R
Gründling, M G
Hamaguchi, S
Gómez-Sánchez, E
Heredia-Rodríguez, M
Álvarez-Fuente, E
Lorenzo-López, M
Gómez-Pesquera, E
Aragón-Camino, M
Liu-Zhu, P
Sánchez-López, A
Hernández-Lozano, A
Peláez-Jareño, M T
Tamayo, E
Thomas-Rüddel, D O
Adora, V
Kar, A
Chakraborty, A
Roy, S
Bandyopadhyay, A
Das, M
BenYehudah, G
Salim, M
Kumar, N
Arabi, L
Burger, T
Lephart, P
Toth-martin, E
Valencia, C
Hammami, N
Blot, S
Vincent, J L
Lambert, M L
Brunke, J
Riemann, T
Roschke, I
Nimitvilai, S
Jintanapramote, K
Jarupongprapa, S
Adukauskiene, D
Valanciene, D
Bose, G
Lostarakos, V
Carr, B
Khedher, S
Maaoui, A
Ezzamouri, A
Salem, M
Chen, J
Cranendonk, D R
Day, M
Penrice, G
Roy, K
Robertson, P
Godbole, G
Jones, B
Booth, M
Donaldson, L
Kawano, Y
Ishikura, H
Al-Dorzi, H
Almutairi, M
Alhamadi, B
Crizaldo Toledo, A
Khan, R
Al Raiy, B
Talaie, H
Van Oers, J A
Harts, A
Nieuwkoop, E
Vos, P
Boussarsar, Y
Boutouta, F
Kamoun, S
Mezghani, I
Koubaji, S
Ben Souissi, A
Riahi, A
Mebazaa, M S
Giamarellos-Bourboulis, E
Tziolos, N
Routsi, C
Katsenos, C
Tsangaris, I
Pneumatikos, I
Vlachogiannis, G
Theodorou, V
Prekates, A
Antypa, E
Koulouras, V
Kapravelos, N
Gogos, C
Antoniadou, E
Mandragos, K
Armaganidis, A
Robles Caballero, A R
Civantos, B
Figueira, J C
López, J
Silva-Pinto, A
Ceia, F
Sarmento, A
Santos, L
Almekhlafi, G
Sakr, Y
Baharoon, S
Aldawood, A
Matroud, A
Alchin, J
Al Johani, S
Balkhy, H
Yousif, S Y
Alotabi, B O
Alsaawi, A S
Ang, J
Curran, M D
Enoch, D
Navapurkar, V
Morris, A
Sharvill, R
Astin, J
Patel, J
Kruger, C
O’Neal, J
Rhodes, H
Jancik, J
François, B
Laterre, P F
Eggimann, P
Torres, A
Sánchez, M
Dequin, P F
Bassi, G L
Chastre, J
Jafri, H S
Ben Romdhane, M
Douira, Z
Bousselmi, M
Vakalos, A
Avramidis, V
Craven, T H
Wojcik, G
Kefala, K
McCoubrey, J
Reilly, J
Paterson, R
Inverarity, D
Laurenson, I
Walsh, T S
Mongodi, S
Bouhemad, B
Orlando, A
Stella, A
Via, G
Iotti, G
Braschi, A
Mojoli, F
Haliloglu, M
Bilgili, B
Kasapoglu, U
Sayan, I
Süzer Aslan, M
Yalcın, A
Cinel, I
Ellis, H E
Bauchmuller, K
Miller, D
Temple, A
Luyt, C E
Singer, M
Nassar, Y
Ayad, M S
Trifi, A
Abdellatif, S
Daly, F
Nasri, R
Ben Lakhal, S
Gul, F
Kuzovlev, A
Shabanov, A
Polovnikov, S
Kadrichu, N
Dang, T
Corkery, K
Challoner, P
Bassi, G Li
Aguilera, E
Chiurazzi, C
Travierso, C
Motos, A
Fernandez, L
Amaro, R
Senussi, T
Idone, F
Bobi, J
Rigol, M
Hodiamont, C J
Janssen, J M
Bouman, C S
Mathôt, R A
De Jong, M D
Van Hest, R M
Payne, L
Fraser, G L
Tudor, B
Lahner, M
Roth, G
Krenn, C
Jault, P
Gabard, J
Leclerc, T
Jennes, S
Que, Y
Rousseau, A
Ravat, F
Eissa, A
Al-Harbi, S
Aldabbagh, T
Abdellatif., S
Paramba, F
Purayil, N
Naushad, V
Mohammad, O
Negi, V
Chandra, P
Kleinsasser, A
Witrz, M R
Buchner-Doeven, J F
Tuip-de Boer, A M
Goslings, J C
Van Hezel, M
Boing, A
Van Bruggen, R
Juffermans, N
Markopoulou, D
Venetsanou, K
Kaldis, V
Koutete, D
Chroni, D
Alamanos, I
Koch, L
Walter, E
Maekawa, K
Hayakawa, M
Kushimoto, S
Shiraishi, A
Kato, H
Sasaki, J
Matauoka, T
Uejima, T
Morimura, N
Hagiwara, A
Takeda, M
Tarabrin, O
Shcherbakow, S
Gavrychenko, D
Mazurenko, G
Ivanova, V
Chystikov, O
Plourde, C
Lessard, J
Chauny, J
Daoust, R
Kropman, L
In het Panhuis, L
Konings, J
Huskens, D
Schurgers, E
Roest, M
De Laat, B
Lance, M
Durila, M
Lukas, P
Astraverkhava, M
Jonas, J
Budnik, I
Shenkman, B
Hayami, H
Koide, Y
Goto, T
Iqbal, R
Alhamdi, Y
Venugopal, N
Abrams, S
Downey, C
Toh, C H
Welters, I D
Bombay, V B
Chauny, J M
Daoust, R D
Lessard, J L
Marquis, M M
Paquet, J P
Siemens, K
Sangaran, D
Hunt, B J
Durward, A
Nyman, A
Murdoch, I A
Tibby, S M
Ampatzidou, F
Moisidou, D
Dalampini, E
Nastou, M
Vasilarou, E
Kalaizi, V
Chatzikostenoglou, H
Drossos, G
Spadaro, S
Fogagnolo, A
Fiore, T
Schiavi, A
Fontana, V
Taccone, F
Volta, C
Chochliourou, E
Volakli, E
Violaki, A
Samkinidou, E
Evlavis, G
Panagiotidou, V
Sdougka, M
Mothukuri, R
Battle, C
Guy, K
Wijesuriya, J
Keogh, S
Docherty, A
O’Donnell, R
Brunskill, S
Trivella, M
Doree, C
Holst, L
Parker, M
Gregersen, M
Almeida, J
Walsh, T
Stanworth, S
Moravcova, S
Mansell, J
Rogers, A
Smith, R A
Hamilton-Davies, C
Omar, A
Allam, M
Bilala, O
Kindawi, A
Ewila, H
Malamas, A
Ferreira, G
Caldas, J
Fukushima, J
Osawa, E A
Arita, E
Camara, L
Zeferino, S
Jardim, J
Gaioto, F
Dallan, L
Jatene, F B
Kalil Filho, R
Galas, F
Hajjar, L A
Mitaka, C
Ohnuma, T
Murayama, T
Kunimoto, F
Nagashima, M
Takei, T
Tomita, M
Mahmoud, K
Hanoura, S
Sudarsanan, S
Sivadasan, P
Othamn, H
Shouman, Y
Singh, R
Al Khulaifi, A
Mandel, I
Mikheev, S
Suhodolo, I
Kiselev, V
Svirko, Y
Podoksenov, Y
Jenkins, S A
Griffin, R
Tovar Doncel, M S
Lima, A
Aldecoa, C
Ince, C
Taha, A
Shafie, A
Mostafa, M
Syed, N
Hon, H
Righetti, F
Colombaroli, E
Castellano, G
Hravnak, M
Chen, L C
Dubrawski, A D
Clermont, G C
Pinsky, M R
Gonzalez, S
Macias, D
Acosta, J
Jimenez, P
Loza, A
Lesmes, A
Lucena, F
Leon, C
Bastide, M
Richecoeur, J
Frenoy, E
Lemaire, C
Sauneuf, B
Tamion, F
Nseir, S
Du Cheyron, D
Dupont, H
Maizel, J
Shaban, M
Kolko, R
AlHussain, A
Mercado, P
Kontar, L
Titeca, D
Brazier, F
Riviere, A
Joris, M
Soupison, T
De Cagny, B
Slama, M
Wagner, J
Körner, A
Kubik, M
Kluge, S
Reuter, D
Saugel, B
Tran, T
De Bels, D
Cudia, A
Strachinaru, M
Ghottignies, P
Devriendt, J
Pierrakos, C
Martínez González, Ó
Blancas, R
Luján, J
Ballesteros, D
Martínez Díaz, C
Núñez, A
Martín Parra, C
López Matamala, B
Alonso Fernández, M
Chana, M
Huber, W
Eckmann, M
Elkmann, F
Gruber, A
Klein, I
Schmid, R M
Lahmer, T
Moller, P W
Sondergaard, S
Jakob, S M
Takala, J
Berger, D
Bastoni, D
Aya, H
Toscani, L
Pigozzi, L
Rhodes, A
Cecconi, M
Ostrowska, C
Abbas, A
Mellinghoff, J
Ryan, C
Dawson, D
Cronhjort, M
Wall, O
Nyberg, E
Zeng, R
Svensen, C
Mårtensson, J
Joelsson-Alm, E
Parenti, N
Palazzi, C
Amidei, L A
Borrelli, F B
Campanale, S C
Tagliazucchi, F T
Sedoni, G S
Lucchesi, D L
Carella, E C
Luciani, A L
Mackovic, M
Maric, N
Bakula, M
Grounds, R M
Fletcher, N
Avard, B
Zhang, P
Mezidi, M
Charbit, J
Ould-Chikh, M
Deras, P
Maury, C
Martinez, O
Capdevila, X
Hou, P
Linde-Zwirble, W Z
Douglas, I D
Shapiro, N S
Ben Aicha, Y
Laribi, B
Jeribi, B
Pereira, C
Marinho, R
Antunes, R
Marinho, A
Crivits, M
Raes, M
Decruyenaere, J
Hoste, E
Bagin, V
Rudnov, V
Savitsky, A
Astafyeva, M
Korobko, I
Vein, V
Kampmeier, T
Arnemann, P
Hessler, M
Wald, A
Bockbreder, K
Morelli, A
Van Aken, H
Rehberg, S
Ertmer, C
Reddy, S
Bailey, M
Beasley, R
Bellomo, R
Mackle, D
Psirides, A
Young, P
Venkatesh, H
Ramachandran, S
Basu, A
Nair, H
Egan, S
Bates, J
Oliveira, S
Rangel Neto, N R
Reis, F Q
Lee, C P
Lin, X L
Choong, C
Eu, K M
Sim, W Y
Tee, K S
Pau, J
Abisheganaden, J
Maas, K
De Geus, H
Lafuente, E
Moura, J
Doris, T E
Monkhouse, D
Shipley, T
Kardasz, S
Gonzalez, I
Stads, S
Groeneveld, A J
Elsayed, I
Ward, N
Raithatha, A
Steuber, A
Pelletier, C
Schroeder, S
Michael, E
Slowinski, T
Kindgen-Milles, D
Ghabina, S
Turani, F
Belli, A
Busatti, S
Barettin, G
Candidi, F
Gargano, F
Barchetta, R
Falco, M
Demirkiran, O
Kosuk, M
Bozbay, S
Weber, V
Hartmann, J
Harm, S
Linsberger, I
Eichhorn, T
Valicek, G
Miestinger, G
Hoermann, C
Faenza, S
Ricci, D
Mancini, E
Gemelli, C
Cuoghi, A
Magnani, S
Atti, M
Laddomada, T
Doronzio, A
Balicco, B
Gruda, M C
O’Sullivan, P
Dan, V P
Guliashvili, T
Scheirer, A
Golobish, T D
Capponi, V J
Chan, P P
Kogelmann, K
Drüner, M
Jarczak, D
Belli, A B
Martni, S M
Cotticelli, V C
Mounajergi, F
Morimoto, S
Hussain, I
Nadeem, A
Ghorab, K
Maghrabi, K
Kloesel, S K
Goldfuss, C
Stieglitz, A
Stieglitz, A S
Krstevska, L
Albuszies, G
Jimmy, G
Izawa, J
Iwami, T
Uchino, S
Takinami, M
Kitamura, T
Kawamura, T
Powell-Tuck, J G
Crichton, S
Raimundo, M
Camporota, L
Wyncoll, D
Ostermann, M
Hana, A
De Geus, H R
Aydogdu, M
Boyaci, N
Yuksel, S
Gursel, G
Cayci Sivri, A B
Meza-Márquez, J
Nava-López, J
Carrillo-Esper, R
Dardashti, A
Grubb, A
Wetzstein, M
Peters, E
Njimi, H
Pickkers, P
Waraich, M
Doyle, J
Samuels, T
Forni, L
Desai, N
Baumber, R
Gunning, P
Sell, A
Lin, S
Torrence, H
O’Dwyer, M
Kirwan, C
Prowle, J
Kim, T
O’Connor, M E
Hewson, R W
Kirwan, C J
Pearse, R M
Maksoud, M
Uzundere, O
Memis, D
Ýnal, M
Gultekin, A
Turan, N
Aydin, M A
Basar, H
Sencan, I
Kapuagasi, A
Ozturk, M
Uzundurukan, Z
Gokmen, D
Ozcan, A
Kaymak, C
Artemenko, V A
Budnyuk, A
Pugh, R
Bhandari, S
Mauri, T
Turrini, C
Langer, T
Taccone, P
Volta, C A
Marenghi, C
Gattinoni, L
Pesenti, A
Sweeney, L
O’Sullivan, A
Kelly, P
Mukeria, E
MacLoughlin, R
Pfeffer, M
Thomas, J T
Bregman, G B
Karp, G K
Kishinevsky, E K
Stavi, D S
Adi, N A
Poropat, T
Knafelj, R
Llopart, E
Batlle, M
De Haro, C
Mesquida, J
Artigas, A
Pavlovic, D
Lewerentz, L
Spassov, A
Schneider, R
De Smet, S
De Raedt, S
Derom, E
Depuydt, P
Oeyen, S
Benoit, D
Gobatto, A
Besen, B
Tierno, P
Melro, L
Mendes, P
Cadamuro, F
Park, M
Malbouisson, L M
Civantos, B C
Lopez, J L
Robles, A
Figueira, J
Yus, S
Garcia, A
Oglinda, A
Ciobanu, G
Oglinda, C
Schirca, L
Sertinean, T
Lupu, V
Wolny, M
Pagano, A
Numis, F
Visone, G
Saldamarco, L
Russo, T
Porta, G
Paladino, F
Bell, C
Liu, J
Debacker, J
Lee, C
Tamberg, E
Campbell, V
Mehta, S
Kara, Ý
Yýldýrým, F
Zerman, A
Güllü, Z
Boyacý, N
Basarýk Aydogan, B
Gaygýsýz, Ü
Gönderen, K
Arýk, G
Turkoglu, M
Aygencel, G
Ülger, Z
Isýkdogan, Z
Özdedeoglu, Ö
Badoglu, M
Gaygýsýz, U
Kongpolprom, N
Sittipunt, C
Eden, A
Kokhanovsky, Y
Bursztein – De Myttenaere, S
Pizov, R
Neilans, L
MacIntyre, N
Radosevich, M
Wanta, B
Meyer, T
Smischney, N
Brown, D
Diedrich, D
Fuller, A
McLindon, P
Sim, K
Shoaeir, M
Noeam, K
Mahrous, A
Matsa, R
Ali, A
Dridi, C
Haddad, F
Pérez-Calatayud, A
Zepeda-Mendoza, A
Diaz-Carrillo, M
Arch-Tirado, E
Carbognin, S
Pelacani, L
Zannoni, F
Agnoli, A
Gagliardi, G
Cho, R
Adams, A
Lunos, S
Ambur, S
Shapiro, R
Prekker, M
Thijssen, M
Janssen, L
Foudraine, N
Voscopoulos, C J
Freeman, J
George, E
Eversole, D
Muttini, S
Bigi, R
Villani, G
Patroniti, N
Williams, G
Waldmann, A
Böhm, S
Windisch, W
Strassmann, S
Karagiannidis, C
Karagiannidis, C K
Waldmann, A W
Böhm, S B
Windisch, W W
Persson, P
Lundin, S
Stenqvist, O
Serra, C S
Pagano, A P
Masarone, M M
Rinaldi, L R
Amelia, A A
Fascione, M F
Adinolfi, L A
Ruggiero, E R
Asota, F
O’Rourke, K
Ranjan, S
Morgan, P
DeBacker, J W
O’Neill, L
Munshi, L
Burry, L
Fan, E
Poo, S
Mahendran, K
Fowles, J
Gerrard, C
Vuylsteke, A
Loveridge, R
Chaddock, C
Patel, S
Kakar, V
Willars, C
Hurst, T
Park, C
Best, T
Vercueil, A
Auzinger, G
Borgman, A
Proudfoot, A G
Grins, E
Emiley, K E
Schuitema, J
Fitch, S J
Marco, G
Sturgill, J
Dickinson, M G
Strueber, M
Khaghani, A
Wilton, P
Jovinge, S M
Sampson, C
Harris-Fox, S
Cove, M E
Vu, L H
Sen, A
Federspiel, W J
Kellum, J A
Mazo Torre, C
Riera, J
Ramirez, S
Borgatta, B
Lagunes, L
Rello, J
Kuzovlev, A K
Goloubev, A
Nenchuk, S
Karavana, V
Glynos, C
Asimakos, A
Pappas, K
Vrettou, C
Magkou, M
Ischaki, E
Stathopoulos, G
Zakynthinos, S
Kozhevnikova, I
Dalla Corte, F
Grasso, S
Casolari, P
Caramori, G
Andrianjafiarinoa, T
Randriamandrato, T
Rajaonera, T
El-Dash, S
Costa, E L V
Tucci, M R
Leleu, F
Bacari-Risal, G
Amato, M
El Dash, S
Remmington
Fischer, A
Squire, S
Boichat, M
Honzawa, H
Yasuda, H
Adati, T
Suzaki, S
Horibe, M
Sasaki, M
Sanui, M
Daniel, J
Miranda, H
Milinis, K
Cooper, M
Williams, G R
McCarron, E
Simants, S
Patanwala, I
Welters, I
Su, Y
Fernández Villanueva, J
Fernández Garda, R
López Lago, A
Rodríguez Ruíz, E
Hernández Vaquero, R
Tomé Martínez de Rituerto, S
Varo Pérez, E
Lefel, N
Schaap, F
Bergmans, D
Olde Damink, S
Van de Poll, M
Tizard, K
Lister, C
Poole, L
Ringaitiene, D
Gineityte, D
Vicka, V
Norkiene, I
Sipylaite, J
O’Loughlin, A
Maraj, V
Dowling, J
Velasco, M B
Dalcomune, D M
Dias, E B
Fernandes, S L
Oshima, T
Graf, S
Heidegger, C
Genton, L
Karsegard, V
Dupertuis, Y
Pichard, C
Friedli, N
Stanga, Z
Vandersteen, L
Stessel, B
Evers, S
Van Assche, A
Jamaer, L
Dubois, J
Castro, H
Valente, J
Martins, P
Casteloes, P
Magalhaes, C
Cabral, S
Santos, M
Oliveira, B
Salgueiro, A
Duarte, S
Castro, S
Melo, M
Gray, S
Maipang, K
Bhurayanontachai, R
Grädel, L G
Schütz, P
Langlois, P
Manzanares, W
Lemieux, M
Elke, G
Bloos, F
Heyland, D
Aramendi, I
Babo, N
Hoshino, M
Haraguchi, Y
Kajiwara, S
Mitsuhashi, T
Tsubata, T
Aida, M
Rattanapraphat, T
Kongkamol, C
Xavier, B
Koutsogiannidis, C
Moschopoulou, M
Taskin, G
Çakir, M
Güler, AK
Taskin, A
Öcal, N
Özer, S
Yamanel, L
Wong, J M
Fitton, C
Anwar, S
Stacey, S
Aggou, M
Fyntanidou, B
Patsatzakis, S
Oloktsidou, E
Lolakos, K
Papapostolou, E
Grosomanidis, V
Gaudry, S
Desailly, V
Pasquier, P
Brun, PB
Tesnieres, AT
Ricard, JD
Dreyfuss, D
Mignon, A
White, J C
Stilwell, A
Friedlaender, G
Peters, M
Stipulante, S
Delfosse, A
Donneau, AF
Ghuysen, A
Feldmann, C
Freitag, D
Dersch, W
Irqsusi, M
Eschbach, D
Steinfeldt, T
Wulf, H
Wiesmann, T
Cholkraisuwat, J
Beitland, S
Nakstad, E
Stær-Jensen, H
Drægni, T
Andersen, G
Jacobsen, D
Brunborg, C
Waldum-Grevbo, B
Sunde, K
Hoyland, K
Pandit, D
Hayakawa, K
Kotzampassi, K
Loukipoudi, L
Doumaki, E
Admiraal, M M
Van Assen, M
Van Putten, M J
Tjepkema-Cloostermans, M
Van Rootselaar, A F
Ragusa, F
Marudi, A
Baroni, S
Gaspari, A
Bertellini, E
Abdullah, T
Abdel Monem, S
Alcorn, S
McNeill, S
Russell, S
Eertmans, W
Genbrugge, C
Meex, I
Dens, J
Jans, F
De Deyne, C
Burns, R
Patarchi, A
Spina, T
Tanaka, H
Otani, N
Ode, S
Ishimatsu, S
Cho, J
Moon, J B
Park, C W
Ohk, T G
Shin, M C
Won, M H
Dakova, S
Ramsheva, Z
Ramshev, K
Ozcan, P E
Sencer, S
Ulusoy, C
Fallenius, M
Skrifvars, M B
Reinikainen, M
Bendel, S
Raj, R
Abu-Habsa, M
Hymers, C
Borowska, A
Sivadhas, H
Sahiba, S
Perkins, S
Rubio, J
Rubio, J A
Sierra, R
English, S
Chasse, M
Turgeon, A
Lauzier, F
Griesdale, D
Garland, A
Fergusson, D
Zarychanski, R
Tinmouth, A
Van Walraven, C
Montroy, K
Ziegler, J
Dupont Chouinard, R
Carignan, R
Dhaliwal, A
Lum, C
Sinclair, J
Pagliarello, G
McIntyre, L
Groza, T
Moreau, N
Castanares-Zapatero, D
Hantson, P
Carbonara, M
Ortolano, F
Zoerle, T
Magnoni, S
Pifferi, S
Conte, V
Stocchetti, N
Carteron, L
Suys, T
Patet, C
Quintard, H
Oddo, M
Spatenkova, V
Pokorna, E
Suchomel, P
Ebert, N
Bylinski, T
Hawthorne, C
Shaw, M
Piper, I
Kinsella, J
Kink, A K
Rätsep, I R
Boutin, A
Moore, L
Lacroix, J
Lessard-Bonaventure, P
Turgeon, A F
Green, R
Erdogan, M
Butler, M
Desjardins, P
Fergusson, D A
Goncalves, B
Vidal, B
Valdez, C
Rodrigues, A C
Miguez, L
Moralez, G
Hong, T
Kutz, A
Hausfater, P
Amin, D
Struja, T
Haubitz, S
Huber, A
Brown, T
Collinson, J
Pritchett, C
Slade, T
Le Guen, M
Hellings, S
Ramsaran, R
Alsheikhly, A
Abe, T
Kanapeckaite, L
Bahl, R
Russell, M Q
Real, K J
Lyon, R M
Oveland, N P
Penketh, J
Mcdonald, M
Kelly, F
Alfafi, M
Almutairi, W
Alotaibi, B
Van den Berg, A E
Schriel, Y
Dawson, L
Meynaar, I A
Silva, D
Fernandes, S
Gouveia, J
Santos Silva, J
Foley, J
Kaskovagheorgescu, A
Evoy, D
Cronin, J
Ryan, J
Huck, M
Hoffmann, C
Renner, J
Laitselart, P
Donat, N
Cirodde, A
Schaal, J V
Masson, Y
Nau, A
Howarth, O
Davenport, K
Jeanrenaud, P
Raftery, S
MacTavish, P
Devine, H
McPeake, J
Daniel, M
Quasim, T
Alrabiee, S
Alrashid, A
Gundogan, O
Bor, C
Akýn Korhan, E
Demirag, K
Uyar, M
Frame, F
Ashton, C
Bergstrom Niska, L
Dilokpattanamongkol, P
Suansanae, T
Suthisisang, C
Morakul, S
Karnjanarachata, C
Tangsujaritvijit, V
Mahmood, S
Al Thani, H
Almenyar, A
Morton, S E
Chiew, Y S
Pretty, C
Chase, J G
Shaw, G M
Kordis, P
Grover, V
Kuchyn, I
Bielka, K
Aidoni, Z
Stavrou, G
Skourtis, C
Lee, S D
Williams, K
Weltes, I D
Berhane, S
Arrowsmith, C
Peters, C
Robert, S
Panerai, R B
Robinson, T G
Borg-Seng-Shu, E
De Lima Oliveira, M
Mian, N C
Nogueira, R
Zeferino, S P
Jacobsen Teixeira, M
Killeen, P
McPhail, M
Bernal, W
Maggs, J
Wendon, J
Hughes, T
Taniguchi, L U
Siqueira, E M
Vieira Jr, J M
Azevedo, L C
Ahmad, A N
Helme, E
Hadfield, S
Shak, J
Senver, C
Howard-Griffin, R
Wacharasint, P
Fuengfoo, P
Sukcharoen, N
Rangsin, R
Sbiti-Rohr, D
Na, H
Song, S
Lee, S
Jeong, E
Lee, K
Zoumpelouli, E
Volakli, E A
Chrysohoidou, V
Charisopoulou, K
Kotzapanagiotou, E
Manavidou, K
Stathi, Z
AlGhamdi, B
Marashly, Q
Zaza, K
Khurshid, M
Ali, Z
Malgapo, M
Jamil, M
Shafquat, A
Shoukri, M
Hijazi, M
Rocha, F A
Ebecken, K
Rabello, L S
Lima, M F
Hatum, R
De Marco, F V
Alves, A
Pinto, J E
Godoy, M
Brasil, P E
Bozza, F A
Salluh, J I
Soares, M
Krinsley, J
Kang, G
Perry, J
Hines, H
Wilkinson, K M
Tordoff, C
Sloan, B
Bellamy, M C
Moreira, E
Verga, F
Barbato, M
Burghi, G
Silva, U V
Torelly, A P
Kahn, J M
Angus, D C
Knibel, M F
Marshall, R
Gilpin, T
Mota, D
Loureiro, B
Dias, J
Afonso, O
Coelho, F
Martins, A
Faria, F
Al Orainni, H
AlEid, F
Tlaygeh, H
Itani, A
Hejazi, A
Messika, J
Ricard, J D
Guillo, S
Pasquet, B
Dubief, E
Tubach, F
James, K
Temblett, P
Davies, L
Lynch, C
Pereira, S
Cavaco, S
Fernandes, J
Moreira, I
Almeida, E
Seabra Pereira, F
Malheiro, M
Cardoso, F
Aragão, I
Cardoso, T
Fister, M
Muraray Govind, P
Brahmananda Reddy, N
Pratheema, R
Arul, E D
Devachandran, J
Chin-Yee, N
D’Egidio, G
Thavorn, K
Kyeremanteng, K
Murchison, A G
Swalwell, K
Mandeville, J
Stott, D
Guerreiro, I
Goossens, C
Marques, M B
Derde, S
Vander Perre, S
Dufour, T
Thiessen, S E
Güiza, F
Janssens, T
Hermans, G
Vanhorebeek, I
De Bock, K
Van den Berghe, G
Langouche, L
Miles, B
Madden, S
Weiler, M
Marques, P
Rodrigues, C
Boeira, M
Brenner, K
Leães, C
Machado, A
Townsend, R
Andrade, J
Kishore, R
Fenlon, C
Fiks, T
Ruijter, A
Te Raa, M
Spronk, P
Docherty, P
Dickson, J
Moltchanova, E
Scarrot, C
Hall, T
Ngu, W C
Jack, J M
Pavli, A
Gee, X
Akin Korhan, E
Shirazy, M
Fayed, A
Gupta, S
Kaushal, A
Dewan, S
Varma, A
Ghosh, E
Yang, L
Eshelman, L
Lord, B
Carlson, E
Broderick, R
Ramos, J
Forte, D
Yang, F
Feeney, J
Wilkinson, K
Shuker, K
Faulds, M
Bryden, D
England, L
Matheson, A
Gaynor, J
S South Yorkshire Hospitals Research Collaboration
Peroni, B
Daglius-Dias, R
Miranda, L
Cohen, C
Carvalho, C
Velasco, I
Kelly, J M
Neill, A
Rubenfeld, G
Masson, N
Min, A
Boezeman, E
Hofhuis, J
Hovingh, A
De Vries, R
Cabral-Campello, G
Van Mol, M
Nijkamp, M
Kompanje, E
Ostrowski, P
Kiss, K
Köves, B
Csernus, V
Molnár, Z
Hoydonckx, Y
Vanwing, S
Medo, V
Galvez, R
Miranda, J P
Stone, C
Wigmore, T
Arunan, Y
Wheeler, A
Wong, Y
Poi, C
Gu, C
Molmy, P
Van Grunderbeeck, N
Nigeon, O
Lemyze, M
Thevenin, D
Mallat, J
Correa, M
Carvalho, R T
Fernandez, A
McBride, C
Koonthalloor, E
Walsh, C
Webber, A
Ashe, M
Smith, K
Dimitriadou, M
Mantzafleri, P
Vrani, O
Arbouti, A
Varsami, T
Bollen, J A
Van Smaalen, T C
De Jongh, W C
Ten Hoopen, M M
Ysebaert, D
Van Heurn, L W
Van Mook, W N
Roze des Ordons, A
Couillard, P
Doig, C
Van Keer, R V
Deschepper, R D
Francke, A F
Huyghens, L H
Bilsen, J B
Nyamaizi, B
Dalrymple, C
Dobru, A
Marrinan, E
Ankuli, A
Struthers, R
Crawford, R
Morelli, P
Degiovanangelo, M
Lemos, F
MArtinez, V
Cabrera, J
Rutten, A
Van Ieperen, S
De Geer, S
Van Vugt, M
Der Kinderen, E
Giannini, A
Miccinesi, G
Marchesi, T
Prandi, E
Congress
Overall
Crit Care. 2016 Apr 20;20(Suppl 2):94. doi: 10.1186/s13054-016-1208-6.
PY  - 2016
SN  - 1364-8535 (Print)
1364-8535
SP  - 94
ST  - 36th International Symposium on Intensive Care and Emergency Medicine : Brussels, Belgium. 15-18 March 2016
T2  - Crit Care
TI  - 36th International Symposium on Intensive Care and Emergency Medicine : Brussels, Belgium. 15-18 March 2016
VL  - 20
ID  - 193
ER  - 

TY  - JOUR
AB  - Cimicifuga racemosa (CR) extracts are important worldwide as therapy for menopausal symptoms. The first medicinal product from CR has been available since 1956 (Germany, Remifemin® [Schaper & Brümmer, Salzgitter, Germany], isopropanolic extract iCR). This review describes how CR developed, via clinical studies on safety (breast, breast cancer, endometrium, liver) and efficacy, into a successful and safe medicinal product in Germany, Europe and the world. In line with developing legal frameworks for medicinal products in Germany and Europe, clinical studies on CR were observational during the 50s and 70s, and controlled studies since the 80s. The first placebo-controlled study emerged 1986. From 2000 to 2015, a total of 28 clinical studies in Europe, America and Asia were published on the efficacy of CR. In these studies, 11,073 patients received a CR-based medicinal product, 93% thereof iCR. A meta-analysis of all nine placebo-controlled studies published until 2013 confirmed the reliable efficacy of CR-based medicinal products for menopausal symptoms.
Publisher: Abstract available from the publisher.
ger
AD  - Clinical Research, Schaper & Brümmer GmbH & Co. KG, Bahnhofstraße 35, 38259, Salzgitter, Germany. h.v.zepelin@schaper-bruemmer.de.
AN  - 28155126
AU  - Henneicke-von Zepelin, H. H.
C2  - PMC5409920
DA  - May
DO  - 10.1007/s10354-016-0537-z
DP  - NLM
ET  - 2017/02/06
IS  - 7-8
KW  - Adverse Drug Reaction Reporting Systems
Cimicifuga
Climacteric/*drug effects
Controlled Clinical Trials as Topic
Europe
Female
Germany
Humans
Observational Studies as Topic
*Phytotherapy
Plant Extracts/adverse effects/*therapeutic use
Treatment Outcome
United States
Actaea racemosa
Black Cohosh
Cimicifuga racemosa
Climacteric complaints
Cognition
Myoma
Osteoporosis
Survival after breast cancer
However, the author declares that this employment has not biased the scientific
presentation of facts in the current publication.
LA  - eng
N1  - 1563-258x
Henneicke-von Zepelin, Hans-Heinrich
Journal Article
Review
Wien Med Wochenschr. 2017 May;167(7-8):147-159. doi: 10.1007/s10354-016-0537-z. Epub 2017 Feb 2.
OP  - 60 Jahre Arzneimittel aus Cimicifuga racemosa : Meilensteine klinischer Forschung, aktuelle Studienergebnisse und derzeitige Entwicklung.
PY  - 2017
SN  - 0043-5341 (Print)
0043-5341
SP  - 147-159
ST  - 60 years of Cimicifuga racemosa medicinal products : Clinical research milestones, current study findings and current development
T2  - Wien Med Wochenschr
TI  - 60 years of Cimicifuga racemosa medicinal products : Clinical research milestones, current study findings and current development
VL  - 167
ID  - 186
ER  - 

TY  - JOUR
AB  - PURPOSE The purpose of this study was to test an intervention (the Screening Adherence Follow-up Program [SAFe]) that was designed to reduce the number of known barriers to diagnostic follow-up adherence and initiation of treatment among women with low incomes who had abnormal mammogram findings. DESCRIPTION OF PROGRAM: The investigators developed and implemented a highly structured, theory- and evidence-based intervention that combined health education, counseling, and systems navigation, which was delivered by a team consisting of a peer counselor and a social worker who held a masters degree. A scripted baseline telephone interview identified potential barriers to follow-up adherence and provided counseling interventions for each patient. Patients were assigned to different service intensities based on the level of risk for nonadherence. Patients with significant mental health symptoms, psychosocial stressors, or who had received a diagnosis of cancer were referred to the team social worker for further assessment and intervention, Patients also received reinforcing telephone follow-up calls at 6 and 12 months. RESULTS: An observational pilot study of SAFe (N = 605) in two large urban diagnostic centers showed that 71% of women receiving SAFe were Hispanic, 18% were Black, and 11% were from other ethnic backgrounds. Adherence rates through diagnostic resolution and the initiation of treatment for women who had received a diagnosis of cancer were 93% and 90%, respectively, at the two study sites. Rates of adherence among women who could not be located or who refused study consent were significantly lower (72% and 69%, respectively), The rate of timely adherence was also higher among die women served. Patient satisfaction with We was generally high. CLINICAL IMPLICATIONS: Study results support the combining of interventions and the practical utility of a clinical decision-making algorithm to determine individualized nonadherence risk and to assign service intensity based on individual need. Problems in locating women for enrollment were experienced.
AN  - WOS:000175159000004
AU  - Ell, K.
AU  - Padgett, D.
AU  - Vourlekis, B.
AU  - Nissly, J.
AU  - Pineda, D.
AU  - Sarabia, O.
AU  - Walther, V.
AU  - Blumenfield, S.
AU  - Lee, P. J.
DA  - May-Jun
DO  - 10.1046/j.1523-5394.2002.103009.x
IS  - 3
N1  - 53
11972567
PY  - 2002
SN  - 1065-4704
SP  - 130-138
ST  - Abnormal mammogram follow-up - A pilot study in women with low income
T2  - Cancer Practice
TI  - Abnormal mammogram follow-up - A pilot study in women with low income
VL  - 10
ID  - 2702
ER  - 

TY  - JOUR
AB  - Background: Vitamin D has diverse biological effects on proliferation, differentiation, and apoptosis in multiple tissues, including the breast. Observational studies have demonstrated that serum 25‐hydroxyvitamin D (25‐OHD), an objective measure of vitamin D status, is inversely related to breast cancer risk, such that levels >40 ng/ml are associated with a 40% reduction in breast cancer risk compared to women who are vitamin D deficient (25‐OHD <20 ng/ml). Serum 25‐OHD above 32 ng/ml is thought to be sufficient for bone health and vitamin D toxicity occurs with levels above 150 ng/ml. However, uncertainty remains about whether vitamin D supplementation will reduce breast cancer risk, the optimal dose of vitamin D, and the target level of serum 25‐OHD. We examined the safety of high dose vitamin D and the effects on serum 25‐OHD in premenopausal women at high risk for breast cancer. Methods: Twenty high‐risk premenopausal women (5‐year Gail risk score =1.67%, history of LCIS or DCIS, BRCA1 or BRCA2 mutation carrier) were assigned to a 1‐year intervention of cholecalciferol (vitamin D3) 30,000 IU weekly (cohort 1, N=10) or 20,000 IU weekly (cohort 2, N=8/10). Eligibility criteria included baseline serum 25‐OHD =32 ng/ml and no history of kidney stones. Participants were monitored for toxicity, particularly hypercalcemia and hypercalciuria, every 3 months during the 1‐year intervention. They underwent a digital mammogram and random core breast biopsy at baseline and 12 months, as well as serial blood collections at 0, 6, and 12 months. Serum 25‐OHD was measured by Diasorin radioimmunoassay. Results: From November 2007 to March 2010, 18 of 20 participants were enrolled and 12 have completed the 1‐year intervention (10 in cohort 1; 2 in cohort 2). Median age: 47 (37‐52); White/Hispanic/Black: 8/9/1; Median body mass index: 27.7 kg/m2 (21.5‐35.4); Elevated Gail risk/LCIS/DCIS: 11/6/1; Mean baseline serum 25‐OHD: 19 ng/ml (11‐27). Women assigned to a dose of 30,000 IU weekly (cohort 1) rose to a mean serum 25‐OHD of 55 ng/ml (26‐75) at 6 months and 59 ng/ml (49‐71) at 12 months. The dose of 20,000IU weekly (cohort 2) resulted in a mean serum 25‐OHD of 48 ng/ml (35‐59) at 3 months and 50 ng/ml (42‐63) at 6 months. No significant hypercalcemia (serum calcium >10.5 mg/dl) or hypercalciuria (spot urine calcium/creatinine >0.37) occurred at either dose level. One woman dropped out due to worsening gastroesophageal reflux symptoms. Biomarker analyses for samples collected from cohort 1 are ongoing. Discussion: We have demonstrated that a 1‐year intervention of high‐dose vitamin D3 20,000 IU or 30,000 IU weekly is well‐tolerated and able to increase serum 25‐OHD above 40 ng/ml in all participants, without any episodes of hypervitaminosis D. The effects of high‐dose vitamin D on mammographic density, tissue and serum‐based biomarkers of breast cancer risk are currently being evaluated. Large‐scale randomized controlled trials are necessary to determine the safety, efficacy, optimal dose and duration of vitamin D supplementation for breast cancer chemoprevention.
AN  - CN-00989652
AU  - Refice, S. F.
AU  - Hershman, D. L.
AU  - Maurer, M. A.
AU  - Kalinsky, K.
AU  - Feldman, S.
AU  - Brafman, L.
DO  - 10.1158/0008-5472.SABCS10-P1-07-01
PY  - 2010
ST  - Abstract P1-07-01: safety of High-Dose Vitamin D Supplementation in Premenopausal Women at High Risk for Breast Cancer
TI  - Abstract P1-07-01: safety of High-Dose Vitamin D Supplementation in Premenopausal Women at High Risk for Breast Cancer
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00989652/full
VL  - 70
ID  - 1661
ER  - 

TY  - JOUR
AB  - Introduction: Patients with triple negative breast cancer (TNBC) have a worse prognosis compared to other breast cancer subtypes, primarily due to lack of targeted treatment options. EGFR1 (epidermal growth factor receptor) is often over‐expressed in TNBC and could be a promising therapeutic target. Clinical studies have shown platinums and taxanes to be effective in TNBC and in vitro data has demonstrated synergy between carboplatin, docetaxel and an EGFR inhibitor in TNBC cell lines. Aim: To evaluate the efficacy of platinum/taxane based chemotherapy in combination with a small molecule EGFR inhibitor, Erlotinib, in patients with TNBC. Methods: Patients with stage II/III TNBC were eligible for this phase II trial. All patients received 6 cycles of chemotherapy (Carboplatin AUC 6, Docetaxel 75mg/m2 every 21 d). In addition patients were equally randomized between two erlotinib arms. Patients in arm A received Erlotinib (150 mg PO d 3 ‐ 14 every 21 d) during all 6 cycles of chemotherapy & patients in arm B received erlotinib only during the last 4 cycles of chemotherapy. This randomization was intended to reduce bias in the evaluation of the effect of erlotinib on biomarkers in a core biopsy of the tumor performed after the second cycle of chemotherapy. All but one patient underwent comprehensive BRCA analysis (Myriad Genetic Laboratories). Following neo‐adjuvant therapy, all patients underwent breast surgery. The primary end point was pathological complete response (pCR: no evidence of invasive tumor in the breast & axilla). Minimal Residual Disease [MRD= Residual Cancer Burden (RCB) groups 0+1] status was also evaluated. Results: 30 eligible patients with TNBC were enrolled between 8/2007 and 6/2010. This analysis includes 28 patients since 2 patients are still on study treatment. Median age: 51yrs (range 31‐68), 21%: African American, 54%: postmenopausal. Median tumor size was 3.3 cm & 39% had LN+ disease. Fifteen patients were assigned to each arm of erlotinib. Five of 28 patients (17%) carried a BRCA mutation (two BRCA1deleterious, two BRCA2 deleterious, one BRCA1 uncertain). The overall pCR and MRD (RCB 0+1) rates were 39% & 50% respectively. On univariate analysis, tumor size, LN status, menopausal status, age and number of erlotinib cycles did not correlate with pCR. However, BRCA mutation status strongly correlated with pCR, with a pCR rate of 100% in BRCA mutation carriers compared to 27% in those without BRCA mutation (p=0.006). Baseline EGFR and/or p53 expression of =10% was associated with a lower pCR rate in BRCA non‐carriers (pCR: 12% vs. 66%, p = 0.025). Common Erlotinib related AEs were: rash (G3/4:7%) & diarrhea (G3/4:30%) with 32% of subjects requiring erlotinib dose reduction/discontinuation due to AEs. Conclusions: Pathological complete response rates of TNBC to a combination of platinum/taxane chemotherapy & an oral EGFR inhibitor are encouraging and should be explored further. The response to this regimen was significantly influenced by BRCA mutation status, indicating a need to stratify patients by their BRCA status in future TNBC trials. Tissue biomarker analysis of downstream targets of EGFR inhibition should be informative regarding the exact role of erlotinib in this patient population.
AN  - CN-00990075
AU  - Sharma, P.
AU  - Khan, Q. J.
AU  - Kimler, B. F.
AU  - Klemp, J. R.
AU  - Connor, C. J.
AU  - McGinness, M. K.
DO  - 10.1158/0008-5472.SABCS10-P1-11-07
PY  - 2010
ST  - Abstract P1-11-07: results of a Phase II Study of Neoadjuvant Platinum/Taxane Based Chemotherapy and Erlotinib for Triple Negative Breast Cancer
TI  - Abstract P1-11-07: results of a Phase II Study of Neoadjuvant Platinum/Taxane Based Chemotherapy and Erlotinib for Triple Negative Breast Cancer
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00990075/full
VL  - 70
ID  - 1631
ER  - 

TY  - JOUR
AB  - BACKGROUND: Whether accelerated aging develops over the course of chronic HIV infection or can be observed prior to significant immunosuppression on is unknown. We studied DNA methylation in blood to estimate cellular aging in persons living with HIV (PLWH) prior to the initiation of antiretroviral therapy. METHODS: 378 antiretroviral therapy-naïve PLWH with CD4 T cell counts >500 cells/mm 3 enrolled in the Strategic Timing of Antiretroviral Therapy trial (Pulmonary Substudy) were compared to 34 HIV-negative controls. DNA methylation was performed using the Illumina MethylationEPIC BeadChip. Differentially methylated positions (DMPs) and regions (DMRs) in PLWH compared to controls were identified using a robust linear model. Methylation age was calculated using a previously described epigenetic clock. RESULTS: There were a total of 56,639 DMPs and 6,103 DMRs at a false discovery rate<0.1. The top 5 DMPs corresponded to genes NLRC5, VRK2, B2M, and GPR6 and were highly enriched for cancer-related pathways. PLWH had significantly higher methylation age compared to HIV-negative controls (p=0.001), with black race, low CD4, high CD8 T cell counts, and duration of HIV being risk factors for age acceleration. CONCLUSIONS: PLWH prior to the initiation of antiretroviral therapy and with preserved immune status show evidence of advanced methylation aging.
AD  - Centre for Heart Lung Innovation, University of British Columbia, Vancouver, BC.
Department of Medicine, University of British Columbia, Vancouver, BC.
Division of Respiratory Medicine, Department of Medicine, University of British Columbia, Vancouver, BC.
Centre for Molecular Medicine and Therapeutics, University of British Columbia, Vancouver, BC.
Section of Infectious Diseases, University of Illinois at Chicago, Chicago, IL.
MRC Clinical Trials Unit, University College London, London, UK.
University of Würzburg Medical Center, Department of Internal Medicine II, Division of Infectious Diseases, Würzburg, Germany.
Kirby Institute, Sydney, Australia.
Department of Human Genetics, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA.
Respiratory Epidemiology and Clinical Research Unit, McGill University, Montreal, QC.
Minneapolis Veterans Affairs Health Care System, Section of Pulmonary, Critical Care and Sleep Medicine, Minneapolis, MN.
Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, Department of Medicine, University of Minnesota, Minneapolis, MN.
AN  - 32959881
AU  - Yang, C. X.
AU  - Schon, E.
AU  - Obeidat, M.
AU  - Kobor, M. S.
AU  - McEwen, L.
AU  - MacIsaac, J.
AU  - Lin, D.
AU  - Novak, R. M.
AU  - Hudson, F.
AU  - Klinker, H.
AU  - Dharan, N.
AU  - Horvath, S.
AU  - Bourbeau, J.
AU  - Tan, W.
AU  - Sin, D. D.
AU  - Man, S. F. P.
AU  - Kunisaki, K.
AU  - Leung, J. M.
DA  - Sep 22
DO  - 10.1093/infdis/jiaa599
DP  - NLM
ET  - 2020/09/23
KW  - Hiv
aging
epigenetics
methylation
LA  - eng
N1  - 1537-6613
Yang, Chen Xi
Schon, Emma
Obeidat, Ma'en
Kobor, Michael S
McEwen, Lisa
MacIsaac, Julie
Lin, David
Novak, Richard M
Hudson, Fleur
Klinker, Hartwig
Dharan, Nila
Horvath, Steve
Bourbeau, Jean
Tan, Wan
Sin, Don D
Man, S F Paul
Kunisaki, Ken
Leung, Janice M
INSIGHT START study group
Journal Article
United States
J Infect Dis. 2020 Sep 22:jiaa599. doi: 10.1093/infdis/jiaa599.
PY  - 2020
SN  - 0022-1899
ST  - Accelerated Epigenetic Aging and Methylation Disruptions Occur in Human Immunodeficiency Virus Infection Prior to Antiretroviral Therapy
T2  - J Infect Dis
TI  - Accelerated Epigenetic Aging and Methylation Disruptions Occur in Human Immunodeficiency Virus Infection Prior to Antiretroviral Therapy
ID  - 22
ER  - 

TY  - JOUR
AB  - PURPOSE/OBJECTIVES: To identify the personal issues and concerns of African American women who are breast cancer survivors. DESIGN: Exploratory. SETTING: Southeastern United States; urban community. SAMPLE: A total of 24 women were recruited from churches and the community; 16 women participated in focus groups. METHODS: Two focus group sessions were held in a community library. Audiotaped interviews were transcribed and analyzed for themes that described issues the women had to deal with after treatment for breast cancer. MAIN RESEARCH VARIABLE: Women's perceptions of the impact breast cancer had placed on their personal lives, including sexuality. FINDINGS: Five themes emerged-body appearance, social support, health activism, menopause, and learning to live with a chronic illness. CONCLUSIONS: African American women have concerns that are similar to, but different from, those of Caucasian women. Further research is needed to identify culturally appropriate care. IMPLICATIONS FOR NURSING PRACTICE: Assess the effects of treatment on women's personal lives. Know where women can purchase prostheses that match their skin tones. Refer minority women to support groups specifically designed for them.
AD  - Associate Professor, Department of Adult Health Nursing, College of Nursing and Health Professions, University of North Carolina, Charlotte
AN  - 107041752. Language: English. Entry Date: 20050425. Revision Date: 20180507. Publication Type: Journal Article
AU  - Wilmoth, M. C.
AU  - Sanders, L. D.
DB  - CINAHL Complete
DP  - EBSCOhost
IS  - 5
KW  - Breast Neoplasms -- Psychosocial Factors
Black Persons -- Southeastern United States
Exploratory Research
Southeastern United States
Focus Groups
Thematic Analysis
Research Subject Recruitment
Content Analysis
Cancer Patients
Pilot Studies
Adult
Middle Age
Aged
Female
Funding Source
Human
N1  - research; tables/charts. Journal Subset: Core Nursing; Double Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Nursing; Peer Reviewed; USA. Grant Information: Funded by an award to Margaret Chamberlain Wilmoth from the Elinor B. Caddell Scholarship, College of Nursing and Health Professions, University of North Carolina at Charlotte. NLM UID: 7809033.
PMID: NLM11421147.
PY  - 2001
SN  - 0190-535X
SP  - 875-879
ST  - Accept me for myself: African American women's issues after breast cancer
T2  - Oncology Nursing Forum
TI  - Accept me for myself: African American women's issues after breast cancer
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=107041752&site=ehost-live&scope=site
VL  - 28
ID  - 1839
ER  - 

TY  - JOUR
AB  - PURPOSE: Minority women are grossly underserved and suffer poorer quality of life during and after treatment for breast cancer. Despite great need, interventions that are designed to attenuate poorer adaptation to disease among minority women are scarce. Our team translated an evidence‐ based cognitive behavioral stress management intervention and an Enhanced Breast Cancer Education (EE) into a culturally‐appropriate format for underserved black breast cancer survivors (CBSM‐adapted, called Project CARE). METHODS: Participants (n = 56 black women within 6 months of the end of breast cancer treatment, stages 0‐IV, aged 27‐67) were randomized to a manual‐based 10‐week CBSM or EE intervention and followed for 6 months thereafter. The CBSM intervention includes modules on stress awareness, cognitive restructuring, coping, social support, assertiveness, anger awareness/management and goal‐setting. The EE intervention provides information about breast cancer causes, treatment, side effects, late effects, post‐treatment well‐being and healthy lifestyle. Community stakeholders and psycho‐oncology professionals guided the adaptations to inform the culturallysensitive interventions. RESULTS: Average attendance rates at group sessions, an indicator of investment, was 8 sessions. Of those who attended at least one session, more than 95% of participants completely agreed that: the intervention was a good use of my time; the intervention was helpful in general; the intervention was helpful in my daily life; the intervention was applicable to my life experience; I felt comfortable with the group leader; overall this was a good program; I would recommend this program to other women (means > 3.5 of possible 4). Participant retention rate tracking revealed a 95% retention rate between baseline and post‐10‐week intervention, and a 93% retention rate between baseline and six‐month follow‐up. CONCLUSIONS: Given the competing demands and hardships facing the sample, attendance rates and retention rates speak to the extremely high satisfaction rates. Results suggest that an adapted evidence‐based stressmanagement and education intervention can be effectively implemented in natural settings in the community and was highly acceptable to a community‐ dwelling population of black breast cancer survivors. RESEARCH IMPLICATIONS: This evidence‐based behavioral medicine clinical trial is currently enrolling participants in order to examine whether participation in the program confers psychological, social, biological and economic benefits to participants. CLINICAL IMPLICATIONS: The Project CARE clinical interventions can be delivered successfully in community settings and are considered valuable to underserved black women who have recently completed treatment for breast cancer.
AN  - CN-01035056
AU  - Lechner, S. C.
AU  - Whitehead, N. E.
AU  - Annane, D.
AU  - Robertson, B.
AU  - Antoni, M. H.
AU  - Kobetz-Kerman, E.
AU  - Phillips, A.
AU  - Vargas, S.
AU  - Hazan, G.
AU  - Carver, C. S.
DO  - 10.1111/j.1099-1611.2011.03029_1.x
KW  - *breast cancer
*cancer survivor
*evidence based practice
*oncology
*society
*stress management
Adaptation
Assertiveness
Behavioral medicine
Book
Cancer therapy
Clinical trial
Cognitive behavioral stress management
Community
Coping behavior
Education
Female
Follow up
Human
Investment
Lifestyle
Personal experience
Population
Quality of life
Satisfaction
Side effect
Social support
Wellbeing
M3  - Journal: Conference Abstract
PY  - 2012
SP  - 33
ST  - Acceptability and feasibility of an evidence-based stress management intervention adapted for black breast cancer survivors
T2  - Psycho-oncology.
TI  - Acceptability and feasibility of an evidence-based stress management intervention adapted for black breast cancer survivors
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01035056/full
VL  - 21
ID  - 1521
ER  - 

TY  - JOUR
AB  - Clinical availability of genetic testing for cancer predisposition genes is generating a major challenge for U.S. health care systems to provide relevant genetic services to underserved populations. Here we present rates of study enrollment and utilization of genetic testing in a research study on BRCA1 testing acceptance in one large kindred. We also present data on baseline access to genetic information as well as enabling and obstructing factors to study enrollment. The study population included female and male members of an African American kindred based in the rural southern United States with an identified BRCA1 mutation. A combination of quantitative and qualitative data were collected and analyzed. Of the 161 living, eligible, and locatable kindred members. 105 (65%) enrolled in the study. Family, personal, and educational motivations were the most commonly endorsed reasons for study participation. The most commonly cited reasons for refusal to participate in the study were: lack or interest, time constraints, and negative experiences with prior participation in genetic research. Eighty three percent of the participants underwent BRCA1 testing. In multiple logistic regression analysis, age 40-49 (odds ratio (OR) = 6.9; 95% confidence interval (CI) = 1.2-39.5), increased perceived risk of being a BRCA1 mutation carrier (OR = 4.1; 95% CI = 1.1-14.6), and high cancer genetics knowledge levels (OR = 1.5; 95% CI = 1.1-2.3) were associated with BRCA1 testing acceptance. The results of this study indicate that cognitive and demographic factors may influence genetic research participation and genetic testing decisions among African Americans who are at increased risk of carrying a deleterious BRCA1 mutation. © 2006 Wiley-Liss, Inc.
AD  - A.Y. Kinney, Huntsman Cancer Institute, 2000 Circle of Hope Drive, Salt Lake City, UT 84112, United States
AU  - Kinney, A. Y.
AU  - Simonsen, S. E.
AU  - Baty, B. J.
AU  - Mandal, D.
AU  - Neuhausen, S. L.
AU  - Seggar, K.
AU  - Holubkov, R.
AU  - Smith, K.
DB  - Embase
Medline
DO  - 10.1002/ajmg.a.31162
IS  - 8
KW  - BRCA1 protein
adult
African American
aged
article
breast cancer
cancer susceptibility
cognition
demography
hereditary tumor syndrome
female
gene deletion
gene identification
gene mutation
genetic screening
health care system
human
major clinical study
male
motivation
oncogene
ovary cancer
patient decision making
priority journal
qualitative analysis
quantitative analysis
refusal to participate
rural area
United States
LA  - English
M3  - Article
N1  - L43516684
2006-04-27
PY  - 2006
SN  - 1552-4825
1552-4833
SP  - 813-826
ST  - Acceptance of genetic testing for hereditary breast ovarian cancer among study enrollees from an African American kindred
T2  - American Journal of Medical Genetics
TI  - Acceptance of genetic testing for hereditary breast ovarian cancer among study enrollees from an African American kindred
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L43516684&from=export
http://dx.doi.org/10.1002/ajmg.a.31162
VL  - 140 A
ID  - 1248
ER  - 

TY  - JOUR
AB  - Starting in 2002, the Radiation Therapy Oncology Group in North America began the process of developing multicenter prospective trials in lung cancer using Stereotactic Body Radiation Therapy (SBRT). Much of the work was based on the prospective single institution trials from Indiana University that had been presented and published. In late 2004, RTOG 0236 using SBRT for medically inoperable patients with clinical stage I non-small cell lung cancer (NSCLC) was activated for accrual. Prior to activation, representatives from the Lung, Image-Guided Therapy, Physics, and Radiobiology Committees met on regular occasions to design the multicenter study and quality assurance measures. SBRT is not a black box, and the essence of the therapy had to be distilled via guidelines. Issues related to patient selection, method of dosimetry construction, equipment requirements, motion assessments and control, site accreditation, data exchange, and follow-up policies were worked out by compromise and consensus. RTOG 0236 has nearly completed its accrual. The Lung Committee has initiated the development of several other trials, each building on the last, to investigate the therapy in central tumors, in combinations with systemic therapy, in operable patients, and in lung metastases patients. The guidelines developed for RTOG 0236 will be refined to take advantage of more modern innovations including heterogeneity corrections and intensity modulation when appropriate. The development of RTOG 0618 using SBRT in operable patients with early stage NSCLC is a testament to both the enthusiasm from already published works and prospective multicenter clinical testing using SBRT techniques.
AD  - Department of Radiation Oncology, The University of Texas Southwestern Medical Center, Dallas, TX 75390-9183, USA. robert.timmerman@utsouthwestern.edu
AN  - 16982540
AU  - Timmerman, R.
AU  - Galvin, J.
AU  - Michalski, J.
AU  - Straube, W.
AU  - Ibbott, G.
AU  - Martin, E.
AU  - Abdulrahman, R.
AU  - Swann, S.
AU  - Fowler, J.
AU  - Choy, H.
DO  - 10.1080/02841860600902213
DP  - NLM
ET  - 2006/09/20
IS  - 7
KW  - Accreditation/*organization & administration
Carcinoma/pathology/*surgery
*Clinical Trials as Topic/methods
Humans
Lung Neoplasms/pathology/*surgery
Motion
*Multicenter Studies as Topic/methods
Phantoms, Imaging
Quality Assurance, Health Care/*organization & administration
Radiation Dosage
Radiation Oncology/*organization & administration
Radiometry
Radiosurgery/*methods
Radiotherapy/methods
LA  - eng
N1  - Timmerman, Robert
Galvin, James
Michalski, Jeff
Straube, William
Ibbott, Geoffrey
Martin, Elizabeth
Abdulrahman, Ramzi
Swann, Suzanne
Fowler, Jack
Choy, Hak
5R21CA097721-02/CA/NCI NIH HHS/United States
U24 CA 8164/CA/NCI NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
Review
England
Acta Oncol. 2006;45(7):779-86. doi: 10.1080/02841860600902213.
PY  - 2006
SN  - 0284-186X (Print)
0284-186x
SP  - 779-86
ST  - Accreditation and quality assurance for Radiation Therapy Oncology Group: Multicenter clinical trials using Stereotactic Body Radiation Therapy in lung cancer
T2  - Acta Oncol
TI  - Accreditation and quality assurance for Radiation Therapy Oncology Group: Multicenter clinical trials using Stereotactic Body Radiation Therapy in lung cancer
VL  - 45
ID  - 553
ER  - 

TY  - JOUR
AB  - Objective To compare the outcomes of active surveillance (AS) series between African American men (AAM) and non-AAM diagnosed with low-risk prostate cancer at 3 medical centers. Methods Between 2005 and 2012, 214 men accepted AS on the basis of favorable clinical features and parameters after initial and repeat biopsy. Failure was defined as increase in Gleason score >6, total positive cores >33%, maximum cancer volume in any core >50%, or a prostate-specific antigen >10 ng/mL. Disease progression and overall AS failure were compared between the 2 groups. Results Of 214 men, 75 were excluded, leaving 67 AAM and 72 non-AAM on AS. Median age at diagnosis was 64 and 67 years for AAM and non-AAM, respectively, and median follow-up was 34 and 46 months, respectively. During this time, 44 AAM (66%) remained on AS, and 23 (34%) underwent treatment, of whom 6 (26%) were treated by patient choice and 17 (74%) because of disease progression. In the non-AAM group, 59 (82%) men remained on AS, and 13 (18%) underwent treatment, 8 (62%) were treated by patient choice and 5 (38%) because of disease progression. The 3-year freedom from overall treatment was 74% and did not differ by race (P =.06). The 3-year freedom from disease progression was 85%, where AAM were at significantly higher risk of disease progression (hazard ratio = 3.8; 95% confidence interval: 1.4-10.4; P =.01). Conclusion Our study suggests a higher disease progression rate in AAM who choose AS for low-risk prostate cancer compared with non-AAM, signifying a potential need for closer follow-up and more stringent enrollment criteria in AAM. © 2014 Published by Elsevier Inc.
AD  - R. Miocinovic, Detroit Medical Center, Michigan State University College of Osteopathic Medicine, Harper Professional Building, 4160 John R., Detroit, MI 48201, United States
AU  - Odom, B. D.
AU  - Mir, M. C.
AU  - Hughes, S.
AU  - Senechal, C.
AU  - Santy, A.
AU  - Eyraud, R.
AU  - Stephenson, A. J.
AU  - Ylitalo, K.
AU  - Miocinovic, R.
DB  - Embase
Medline
DO  - 10.1016/j.urology.2013.09.038
IS  - 2
KW  - prostate specific antigen
adult
African American
aged
article
cancer epidemiology
cancer growth
cancer radiotherapy
cancer surgery
follow up
Gleason score
human
human tissue
low risk population
major clinical study
male
middle aged
multicenter study (topic)
oncological parameters
onset age
outcome assessment
patient decision making
priority journal
prostate biopsy
prostate cancer
prostatectomy
time to treatment
work experience
LA  - English
M3  - Article
N1  - L52888997
2013-12-02
2014-02-14
PY  - 2014
SN  - 0090-4295
1527-9995
SP  - 364-368
ST  - Active surveillance for low-risk prostate cancer in African American Men: A multi-institutional experience
T2  - Urology
TI  - Active surveillance for low-risk prostate cancer in African American Men: A multi-institutional experience
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L52888997&from=export
http://dx.doi.org/10.1016/j.urology.2013.09.038
VL  - 83
ID  - 1037
ER  - 

TY  - JOUR
AB  - Active surveillance (AS) is a treatment strategy for prostate cancer (PCa) whereby patients diagnosed with PCa undergo ongoing characterization of their disease with the intent of avoiding radical treatment. Previously, AS has been demonstrated to be a reasonable option for men with low-risk PCa, but existing cohorts largely consist of Caucasian Americans. Because African Americans have a greater incidence, more aggressive, and potentially more lethal PCa than Caucasian Americans, it is unclear if AS is appropriate for African Americans. We performed a review of the available literature on AS with a focus on African Americans.
AD  - Department of Urology, Tulane University School of Medicine, New Orleans, LA. Electronic address: jsilbers@tulane.edu.
Department of Urology, Tulane University School of Medicine, New Orleans, LA.
Department of Medical Oncology, Tulane University School of Medicine, New Orleans, LA.
AN  - 25283702
AU  - Silberstein, J. L.
AU  - Feibus, A. H.
AU  - Maddox, M. M.
AU  - Abdel-Mageed, A. B.
AU  - Moparty, K.
AU  - Thomas, R.
AU  - Sartor, O.
DA  - Dec
DO  - 10.1016/j.urology.2014.06.064
DP  - NLM
ET  - 2014/10/07
IS  - 6
KW  - African Americans/*statistics & numerical data
Age Factors
Aged
Aged, 80 and over
Humans
Male
Middle Aged
Neoplasm Invasiveness/pathology
Neoplasm Staging
Prognosis
Prostate-Specific Antigen/*blood
Prostatic Neoplasms/*ethnology/pathology/*therapy
Randomized Controlled Trials as Topic
Risk Assessment
Watchful Waiting/*methods/statistics & numerical data
LA  - eng
N1  - 1527-9995
Silberstein, Jonathan L
Feibus, Allison H
Maddox, Michael M
Abdel-Mageed, Asim B
Moparty, Krishnarao
Thomas, Raju
Sartor, Oliver
U01 CA149204/CA/NCI NIH HHS/United States
Journal Article
Review
United States
Urology. 2014 Dec;84(6):1255-61. doi: 10.1016/j.urology.2014.06.064. Epub 2014 Oct 3.
PY  - 2014
SN  - 0090-4295
SP  - 1255-61
ST  - Active surveillance of prostate cancer in African American men
T2  - Urology
TI  - Active surveillance of prostate cancer in African American men
VL  - 84
ID  - 273
ER  - 

TY  - JOUR
AB  - The purpose of this study was to determine the feasibility of an acupuncture clinical trial to prevent radiation therapy (RT)-induced fatigue. We conducted a cross-sectional survey study and a single-arm acupuncture clinical trial among patients undergoing RT. Patients with a Karnofsky score of less than 60, severe anemia, or substantial psychological diagnoses were excluded. Patients received up to 12 treatments of acupuncture over the entire course of their RT. The Lee Fatigue Scale (LFS) was administered at baseline, in the middle of RT, and at the end of RT, along with the Patient Global Impression of Change (PGIC). Among the 48 of 53 (91% response rate) survey participants, 20 (42%) reported that they would participate if the study were available, 13 (27%) would not participate, and 15 (31%) were unsure. Among the 16 trial participants, average fatigue and energy domains of the LFS remained stable during and after RT, without any expected statistical decline owing to RT. Based on the PGIC at the end of RT, 2 subjects (13%) reported their fatigue as worse, 8 (50%) as stable, and 6 (37%) as better. Acupuncture has the potential to prevent RT-related fatigue, which will need to be confirmed by conducting a randomized controlled trial. © 2009 BC Decker Inc.
AD  - J. J. Mao, Department of Family Medicine and Community Health, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, United States
AU  - Mao, J. J.
AU  - Styles, T.
AU  - Cheville, A.
AU  - Wolf, J.
AU  - Fernandes, S.
AU  - Farrar, J. T.
DB  - Embase
Medline
DO  - 10.2310/7200.2009.0008
IS  - 2
KW  - antineoplastic agent
acupuncture
adult
article
Asian
breast cancer
cancer radiotherapy
Caucasian
clinical article
clinical trial
controlled study
cross-sectional study
digestive system cancer
employment status
fatigue
feasibility study
female
head and neck cancer
human
Karnofsky Performance Status
lung cancer
male
medical research
Black person
patient attitude
patient participation
patient selection
prostate cancer
race difference
rating scale
treatment outcome
LA  - English
M3  - Article
N1  - L358290929
2010-02-23
2010-03-10
PY  - 2009
SN  - 1715-894X
SP  - 52-58
ST  - Acupuncture for nonpalliative radiation therapy-related fatigue: Feasibility study
T2  - Journal of the Society for Integrative Oncology
TI  - Acupuncture for nonpalliative radiation therapy-related fatigue: Feasibility study
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L358290929&from=export
http://dx.doi.org/10.2310/7200.2009.0008
http://journals.bcdecker.com/pubs/JCI/volume%2007,%202009/issue%2002,%20Spring/JCI_2009_0008/JCI_2009_0008.pdf
VL  - 7
ID  - 1195
ER  - 

TY  - JOUR
AB  - Objective To evaluate whether computer-based prostate cancer screening decision aids enhance decision self-efficacy for African-American men, culturally relevant and reliable measures are needed. However, limited psychometric evidence exists on the health-related decision self-efficacy of African-American men. This study describes the development and psychometric evaluation of the 11-item Informed Prostate Cancer Screening Decision Self-Efficacy Scale among 354 African-American men. Methods Exploratory factor analysis was conducted with maximum-likelihood estimation and polychoric correlations followed by Promax and Varimax rotations. Results Exploratory factor analysis yielded a one-factor, 11-item model of the modified scale with excellent internal consistency reliability at 0.95 and factor loadings ranging from 0.70 to 0.90. Both parallel analysis and a scree plot confirmed the retention of one factor, and the standardized root mean square residual (0.06) indicated that the factor structure explained most of the correlations. Conclusions Findings suggest the one-factor, 11-item Informed Prostate Cancer Screening Decision Self-Efficacy Scale has excellent psychometric properties and utility in reliably measuring health-related decision self-efficacy in African-American men. Future research is needed to confirm this factor structure among socio-demographically diverse African Americans.
AN  - WOS:000510066900002
AU  - Owens, O. L.
AU  - Wooten, N. R.
AU  - Tavakoli, A. S.
DA  - Aug
DO  - 10.1007/s40615-020-00702-0
IS  - 4
N1  - 31997285
PY  - 2020
SN  - 2197-3792
SP  - 746-759
ST  - Adaptation and Initial Psychometric Evaluation of an Informed Prostate Cancer Screening Decision Self-Efficacy Scale for African-American Men
T2  - Journal of Racial and Ethnic Health Disparities
TI  - Adaptation and Initial Psychometric Evaluation of an Informed Prostate Cancer Screening Decision Self-Efficacy Scale for African-American Men
VL  - 7
ID  - 2796
ER  - 

TY  - JOUR
AB  - The dearth of evidence-based clinical trial education programs may contribute to the under-representation of African American and Hispanic American women in cancer research studies. This study used focus group-derived data from 80 women distributed among eight Spanish- and English-language focus groups. These data guided the researchers' adaptation and refinement of the National Cancer Institute's various clinical trials education programs into a program that was specifically focused on meeting the information needs of minority women and addressing the barriers to study participation that they perceived. A "sisterhood" theme was adopted and woven throughout the presentation.
AD  - Moores UCSD Cancer Center, La Jolla, CA, USA. gsadler@ucsd.edu
AN  - 20146043
AU  - Sadler, G. R.
AU  - Gonzalez, J.
AU  - Mumman, M.
AU  - Cullen, L.
AU  - Lahousse, S. F.
AU  - Malcarne, V.
AU  - Conde, V.
AU  - Riley, N.
C2  - PMC2878592
DA  - Jun
DO  - 10.1007/s13187-009-0032-y
DP  - NLM
ET  - 2010/02/11
IS  - 2
KW  - African Americans
Breast Neoplasms/*ethnology/therapy
*Clinical Trials as Topic
*Consumer Health Information
Cultural Competency
Female
Focus Groups
Hispanic Americans
Humans
*Minority Health
*Patient Selection
Women's Health
LA  - eng
N1  - 1543-0154
Sadler, Georgia Robins
Gonzalez, Jenny
Mumman, Manpreet
Cullen, Lisa
Lahousse, Sheila F
Malcarne, Vanessa
Conde, Viridiana
Riley, Natasha
U54 CA132384/CA/NCI NIH HHS/United States
P60 MD000220/MD/NIMHD NIH HHS/United States
5P60MD000220/MD/NIMHD NIH HHS/United States
U56 CA092079/CA/NCI NIH HHS/United States
U56 CA092081/CA/NCI NIH HHS/United States
U56CA92079/U56CA92081/CA/NCI NIH HHS/United States
P30 CA023100/CA/NCI NIH HHS/United States
U54 CA132379/CA/NCI NIH HHS/United States
5P30CA023100/CA/NCI NIH HHS/United States
1U54CA132379/1U54CA132384/CA/NCI NIH HHS/United States
5R25CA65745/CA/NCI NIH HHS/United States
R25 CA065745/CA/NCI NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
J Cancer Educ. 2010 Jun;25(2):142-5. doi: 10.1007/s13187-009-0032-y.
PY  - 2010
SN  - 0885-8195 (Print)
0885-8195
SP  - 142-5
ST  - Adapting a program to inform African American and Hispanic American women about cancer clinical trials
T2  - J Cancer Educ
TI  - Adapting a program to inform African American and Hispanic American women about cancer clinical trials
VL  - 25
ID  - 432
ER  - 

TY  - JOUR
AB  - Projects to reduce disparities in cancer treatment and research include collaborative partnerships and multiple strategies to promote community awareness, education, and engagement. This is especially needed in underserved areas such as the Mississippi Delta where more women are diagnosed at regional and distant stages of breast cancer. The purpose for this project was to increase the relatively low screening rate for African American women in the Mississippi Delta through a partnership between the Mississippi Network for Cancer Control and Prevention at The University of Southern Mississippi, The Fannie Lou Hamer Cancer Foundation and the Mississippi State Department of Health to decrease health disparities in breast cancer through increased awareness on self-early detection methods, leveraging resources to provide mammography screenings, and adequate follow-up with services and treatment for abnormal findings. Through this collaborative effort, over 500 women in three rural Mississippi Delta counties were identified, provided community education on early self-detection, and given appointments for mammography screenings within one fiscal year.
AD  - Department of Public Health, The University of Southern Mississippi, 118 College Drive #5122 Hattiesburg 39406 USA
College of Business, Delta State University, Cleveland USA
AN  - 114786191. Language: English. Entry Date: 20160429. Revision Date: 20190422. Publication Type: Article
AU  - Mayfield-Johnson, Susan
AU  - Fastring, Danielle
AU  - Fortune, Melody
AU  - White-Johnson, Freddie
DB  - CINAHL Complete
DO  - 10.1007/s10900-015-0121-2
DP  - EBSCOhost
IS  - 3
KW  - Healthcare Disparities -- Mississippi
Medically Underserved Area -- Mississippi
Breast Neoplasms -- Prevention and Control -- Mississippi
Cancer Screening -- Mississippi
Black Persons -- Mississippi
Community Health Workers -- Mississippi
Health Education -- Mississippi
Human
Mississippi
Foundations
Interinstitutional Relations
Research Subject Recruitment
Female
Adult
Middle Age
Questionnaires
Descriptive Statistics
Mammography -- Utilization
Health Knowledge -- Evaluation
Health Services Accessibility
Socioeconomic Factors
Convenience Sample
Collaboration
Experimental Studies
Funding Source
N1  - research; tables/charts. Journal Subset: Biomedical; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; Public Health; USA. Instrumentation: Avon BHOP Client Intake Form (CIF). Grant Information: Avon Foundation tothe Fannie Lou Hamer Cancer Foundation.. NLM UID: 7600747.
PY  - 2016
SN  - 0094-5145
SP  - 494-501
ST  - Addressing Breast Cancer Health Disparities in the Mississippi Delta Through an Innovative Partnership for Education, Detection, and Screening
T2  - Journal of Community Health
TI  - Addressing Breast Cancer Health Disparities in the Mississippi Delta Through an Innovative Partnership for Education, Detection, and Screening
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=114786191&site=ehost-live&scope=site
VL  - 41
ID  - 1841
ER  - 

TY  - JOUR
AB  - BACKGROUND: Germline mutations in the BRCA1 and BRCA2 genes account for 20-25 % of inherited breast cancers and about 10 % of all breast cancer cases. Detection of BRCA mutation carriers can lead to therapeutic interventions such as mastectomy, oophorectomy, hormonal prevention therapy, improved screening, and targeted therapies such as PARP-inhibition. We estimate that African Americans and Hispanics are 4-5 times less likely to receive BRCA screening, despite having similar mutation frequencies as non-Jewish Caucasians, who have higher breast cancer mortality. To begin addressing this health disparity, we initiated a nationwide trial of BRCA testing of Latin American women with breast cancer. Patients were recruited through community organizations, clinics, public events, and by mail and Internet. Subjects completed the consent process and questionnaire, and provided a saliva sample by mail or in person. DNA from 120 subjects was used to sequence the entirety of BRCA1 and BRCA2 coding regions and splice sites, and validate pathogenic mutations, with a total material cost of $85/subject. Subjects ranged in age from 23 to 81 years (mean age, 51 years), 6 % had bilateral disease, 57 % were ER/PR+, 23 % HER2+, and 17 % had triple-negative disease. RESULTS: A total of seven different predicted deleterious mutations were identified, one newly described and the rest rare. In addition, four variants of unknown effect were found. CONCLUSIONS: Application of this strategy on a larger scale could lead to improved cancer care of minority and underserved populations.
AD  - Laboratory of Experimental Immunology, National Cancer Institute, Frederick, MD 21702 USA.
Cancer Genetics Research Laboratory, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Gaithersburg, MD USA.
Basic Science Program, Leidos Biomedical Research, Inc., Frederick, MD USA.
Nueva Vida Richmond, Richmond, VA USA.
Latino Community Development Agency, Oklahoma City, OK USA.
Texas Tech University Health Sciences Center, El Paso, TX USA.
Texas Tech University Health Sciences Center, Lubbock, TX USA.
AN  - 26543556
AU  - Dean, M.
AU  - Boland, J.
AU  - Yeager, M.
AU  - Im, K. M.
AU  - Garland, L.
AU  - Rodriguez-Herrera, M.
AU  - Perez, M.
AU  - Mitchell, J.
AU  - Roberson, D.
AU  - Jones, K.
AU  - Lee, H. J.
AU  - Eggebeen, R.
AU  - Sawitzke, J.
AU  - Bass, S.
AU  - Zhang, X.
AU  - Robles, V.
AU  - Hollis, C.
AU  - Barajas, C.
AU  - Rath, E.
AU  - Arentz, C.
AU  - Figueroa, J. A.
AU  - Nguyen, D. D.
AU  - Nahleh, Z.
C2  - PMC4634732
DO  - 10.1186/s13742-015-0088-z
DP  - NLM
ET  - 2015/11/07
KW  - Breast Neoplasms/*genetics
Female
*Genes, BRCA1
*Genes, BRCA2
Hispanic Americans/*genetics
Humans
Breast cancer
Genetic testing
Health disparity
Hispanic populations
Underserved populations
LA  - eng
N1  - 2047-217x
Dean, Michael
Boland, Joseph
Yeager, Meredith
Im, Kate M
Garland, Lisa
Rodriguez-Herrera, Maria
Perez, Mylen
Mitchell, Jason
Roberson, David
Jones, Kristine
Lee, Hyo Jung
Eggebeen, Rebecca
Sawitzke, Julie
Bass, Sara
Zhang, Xijun
Robles, Vivian
Hollis, Celia
Barajas, Claudia
Rath, Edna
Arentz, Candy
Figueroa, Jose A
Nguyen, Diane D
Nahleh, Zeina
HHSN261200800001C/RC/CCR NIH HHS/United States
HHSN261200800001E/CA/NCI NIH HHS/United States
HHSN261200800001E/PHS HHS/United States
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Gigascience. 2015 Nov 4;4:50. doi: 10.1186/s13742-015-0088-z. eCollection 2015.
PY  - 2015
SN  - 2047-217X (Print)
2047-217x
SP  - 50
ST  - Addressing health disparities in Hispanic breast cancer: accurate and inexpensive sequencing of BRCA1 and BRCA2
T2  - Gigascience
TI  - Addressing health disparities in Hispanic breast cancer: accurate and inexpensive sequencing of BRCA1 and BRCA2
VL  - 4
ID  - 228
ER  - 

TY  - JOUR
AB  - This pilot study explored the acceptability and feasibility of and estimated the effectiveness of a weight loss/breast health intervention designed to reduce breast cancer risk in African-American women ages 35-65. The study had a one-group repeated-measures design and took place in a community setting. Forty-four African-American women were recruited, 35 completed the program, and 30 returned for the one-year follow-up. The pilot intervention was three weeks in duration and included twice-weekly exercise classes and weekly active learning seminars that addressed weight loss, breast health, healthy eating, and leading an active life. Measures included those of behavior related to diet, physical activity, and breast health. Satisfaction questionnaires and focus groups were also used to assess acceptability and cultural competency. Statistical analyses included Paired t-tests and Wilcoxon signed ranks tests. Significant results postintervention showed improved physical activity, dietary, and breast health behaviors. Results suggest the acceptability, feasibility, and effectiveness of this comprehensive weight/loss breast health program in reducing multiple breast cancer risk factors among African-American women.
AN  - WOS:000226549900006
AU  - Stolley, M. R.
AU  - Fitzgibbon, M. L.
AU  - Wells, A.
AU  - Martinovich, Z.
DA  - Jan
IS  - 1
N1  - 3
14746356
PY  - 2004
SN  - 0027-9684
SP  - 76-86
ST  - Addressing multiple breast cancer risk factors in African-American women
T2  - Journal of the National Medical Association
TI  - Addressing multiple breast cancer risk factors in African-American women
VL  - 96
ID  - 2689
ER  - 

TY  - JOUR
AB  - CONTEXT: Few interventions exist to address patients' existential needs. OBJECTIVES: Determine whether an intervention to address seriously ill patients' existential concerns improves preparation, completion (elements of quality of life [QOL] at end of life), and reduces anxiety and depression. METHODS: A randomized controlled trial comparing outlook intervention, relaxation meditation (RM), and usual care (UC). Measures included primary-a validated measure of QOL at the end of life and secondary-Functional Assessment of Cancer Therapy-General, anxiety (Profile of Mood States), depression (Center for Epidemiological Studies-Depression Scale), and spiritual well-being (Functional Assessment of Chronic Illness Therapy-Spiritual Well-Being). Qualitative interviews assessed outlook intervention acceptability. Enrolled patients were nonhospice eligible veterans with advanced cancer, congestive heart failure, chronic obstructive pulmonary disease, end-stage renal disease, or end-stage liver disease. RESULTS: Patients (n = 221) were randomly assigned 1:1:1 to outlook, RM, and UC. Patients were 96% males, 46% with cancer, 58.4% married, and 43.9% of African American origin. Compared with UC, outlook participants had higher preparation (a validated measure of QOL at the end of life) (mean difference 1.1; 95% CI 0.2, 2.0; P = 0.02) and mean completion (1.6; 95% CI 0.05, 3.1; P = 0.04) at the first but not second postassessment. Compared with RM, outlook participants did not show significant differences over time. Exploratory analyses indicated that in subgroups with cancer and low sense of peace, outlook participants had improved preparation at first and not second postassessment, as compared with UC (mean difference 1.4; 95% CI 0.03, 2.7; P = 0.04) (mean difference = 1.8; 95% CI 0.3, 3.3; P = 0.02), respectively. CONCLUSION: Outlook had an impact on social well-being and preparation compared with UC. The lack of impact on anxiety and depression differs from previous results among hospice patients. Results suggest that outlook is not demonstratively effective in populations not experiencing existential or emotional distress.
AD  - Center for Health Services Research in Primary Care Durham VA Medical Center, Durham, North Carolina, USA; Department of Medicine, Division of General Internal Medicine, Duke University, Durham, North Carolina, USA; Palliative Care Section, Duke University, Durham, North Carolina, USA; Center for the Study of Aging and Human Development, Duke University, Durham, North Carolina, USA. Electronic address: karen.steinhauser@duke.edu.
College of Health and Human Sciences, Purdue University, West Lafayette, Indiana, USA.
Center for Health Services Research in Primary Care Durham VA Medical Center, Durham, North Carolina, USA; Department of Biostatistics and Bioinformatics, Duke University, Durham, North Carolina, USA.
Center for Health Services Research in Primary Care Durham VA Medical Center, Durham, North Carolina, USA.
School of Nursing, Duke University, Durham, North Carolina, USA.
Providence Institute for Human Caring, Torrance, California, USA; Geisel School of Medicine, Dartmouth University, Hanover, New Hampshire, USA.
Dana Farber Cancer Institute, Boston, Massachusetts, USA; Brigham and Women's Hospital, Boston, Massachusetts, USA.
AN  - 28803082
AU  - Steinhauser, K. E.
AU  - Alexander, S.
AU  - Olsen, M. K.
AU  - Stechuchak, K. M.
AU  - Zervakis, J.
AU  - Ammarell, N.
AU  - Byock, I.
AU  - Tulsky, J. A.
DA  - Dec
DO  - 10.1016/j.jpainsymman.2017.06.003
DP  - NLM
ET  - 2017/08/15
IS  - 6
KW  - Aged
Anxiety
Critical Illness/*psychology
*Emotions
Existentialism/*psychology
Female
Follow-Up Studies
Humans
Interviews as Topic
Male
Palliative Care/*methods
Quality of Life
Relaxation Therapy
Spirituality
*Intervention
*quality of life
*spirituality
LA  - eng
N1  - 1873-6513
Steinhauser, Karen E
Alexander, Stewart
Olsen, Maren K
Stechuchak, Karen M
Zervakis, Jennifer
Ammarell, Natalie
Byock, Ira
Tulsky, James A
Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, U.S. Gov't, Non-P.H.S.
United States
J Pain Symptom Manage. 2017 Dec;54(6):898-908. doi: 10.1016/j.jpainsymman.2017.06.003. Epub 2017 Aug 10.
PY  - 2017
SN  - 0885-3924
SP  - 898-908
ST  - Addressing Patient Emotional and Existential Needs During Serious Illness: Results of the Outlook Randomized Controlled Trial
T2  - J Pain Symptom Manage
TI  - Addressing Patient Emotional and Existential Needs During Serious Illness: Results of the Outlook Randomized Controlled Trial
VL  - 54
ID  - 160
ER  - 

TY  - JOUR
AB  - BACKGROUND: The Boston Racial and Ethnic Approaches to Community Health (REACH) 2010 Breast and Cervical Cancer Coalition developed a case management intervention for women of African descent to identify and reduce medical and social obstacles to breast cancer screening and following up abnormal results. METHODS: We targeted black women at high risk for inadequate cancer screening and follow-up as evidenced by a prior pattern of missed clinic appointments and frequent urgent care use. Case managers provided referrals to address patient-identified social concerns (e.g., transportation, housing, language barriers), as well as navigation to prompt screening and follow-up of abnormal tests. We recruited 437 black women aged 40-75, who received care at participating primary care sites. The study was conducted as a prospective cohort study rather than as a controlled trial and evaluated intervention effects on mammography uptake and longitudinal screening rates via logistic regression and timely follow-up of abnormal tests via Cox proportional hazards models. RESULTS: A significant increase in screening uptake was found (OR 1.53, 95% CI 1.13-2.08). Housing concerns (p < 0.05) and lacking a regular provider (p < 0.01) predicted poor mammography uptake. Years of participation in the intervention increased odds of obtaining recommended screening by 20% (OR 1.20, 95% CI 1.02-1.40), but this effect was attenuated by covariates (p = 0.53). Timely follow-up for abnormal results was achieved by most women (85%) but could not be attributed to the intervention (HR 0.95, 95% CI 0.50-1.80). CONCLUSIONS: Case management was successful at promoting mammography screening uptake, although no change in longitudinal patterns was found. Housing concerns and lacking a regular provider should be addressed to promote mammography uptake. Future research should provide social assessment and address social obstacles in a randomized controlled setting to confirm the efficacy of social determinant approaches to improve mammography use.
AD  - Center for Community Health and Health Equity, Brigham and Women's Hospital, Division of General Medicine and Primary Care, Center for Community Health and Health Equity, 1620 Tremont Street, Boston, MA 02120, USA. crclark@partners.org
AN  - 19445616
AU  - Clark, C. R.
AU  - Baril, N.
AU  - Kunicki, M.
AU  - Johnson, N.
AU  - Soukup, J.
AU  - Ferguson, K.
AU  - Lipsitz, S.
AU  - Bigby, J.
DA  - May
DO  - 10.1089/jwh.2008.0972
DP  - NLM
ET  - 2009/05/19
IS  - 5
KW  - Adult
African Continental Ancestry Group/psychology/*statistics & numerical data
Aged
Boston
Breast Neoplasms/*ethnology/prevention & control/psychology
Breast Self-Examination/psychology/*statistics & numerical data
Cohort Studies
Confidence Intervals
Female
Health Behavior/*ethnology
*Health Knowledge, Attitudes, Practice
Health Promotion/*statistics & numerical data
Humans
Mammography/psychology/statistics & numerical data
Middle Aged
Odds Ratio
Prospective Studies
Surveys and Questionnaires
Women's Health
LA  - eng
N1  - 1931-843x
Clark, Cheryl R
Baril, Nashira
Kunicki, Marycarmen
Johnson, Natacha
Soukup, Jane
Ferguson, Kathleen
Lipsitz, Stuart
Bigby, JudyAnn
REACH 2010 Breast and Cervical Cancer Coalition
Journal Article
Research Support, Non-U.S. Gov't
United States
J Womens Health (Larchmt). 2009 May;18(5):677-90. doi: 10.1089/jwh.2008.0972.
PY  - 2009
SN  - 1540-9996
SP  - 677-90
ST  - Addressing social determinants of health to improve access to early breast cancer detection: results of the Boston REACH 2010 Breast and Cervical Cancer Coalition Women's Health Demonstration Project
T2  - J Womens Health (Larchmt)
TI  - Addressing social determinants of health to improve access to early breast cancer detection: results of the Boston REACH 2010 Breast and Cervical Cancer Coalition Women's Health Demonstration Project
VL  - 18
ID  - 468
ER  - 

TY  - JOUR
AB  - Background: Although African ancestry represents a significant risk factor for prostate cancer, few studies have investigated the significance of prostate cancer and relevance of previously defined genetic and epidemiological prostate cancer risk factors within Africa. We recently established the Southern African Prostate Cancer Study (SAPCS), a resource for epidemiological and genetic analysis of prostate cancer risk and outcomes in Black men from South Africa. Biased towards highly aggressive prostate cancer disease, this is the first reported data analysis. Methods. The SAPCS is an ongoing population-based study of Black men with or without prostate cancer. Pilot analysis was performed for the first 837 participants, 522 cases and 315 controls. We investigate 46 pre-defined prostate cancer risk alleles and up to 24 epidemiological measures including demographic, lifestyle and environmental factors, for power to predict disease status and to drive on-going SAPCS recruitment, sampling procedures and research direction. Results: Preliminary results suggest that no previously defined risk alleles significantly predict prostate cancer occurrence within the SAPCS. Furthermore, genetic risk profiles did not enhance the predictive power of prostate specific antigen (PSA) testing. Our study supports several lifestyle/environmental factors contributing to prostate cancer risk including a family history of cancer, diabetes, current sexual activity and erectile dysfunction, balding pattern, frequent aspirin usage and high PSA levels. Conclusions: Despite a clear increased prostate cancer risk associated with an African ancestry, experimental data is lacking within Africa. This pilot study is therefore a significant contribution to the field. While genetic risk factors (largely European-defined) show no evidence for disease prediction in the SAPCS, several epidemiological factors were associated with prostate cancer status. We call for improved study power by building on the SAPCS resource, further validation of associated factors in independent African-based resources, and genome-wide approaches to define African-specific risk alleles. © 2013 Tindall et al.; licensee BioMed Central Ltd.
AD  - J. Craig Venter Institute, Genomic Medicine Group, San Diego, CA, United States
Children's Cancer Institute Australia, Lowy Cancer Research Centre, University of New South Wales, Kensington, Sydney, Australia
Department of Urology, University of Pretoria, Pretoria, South Africa
Department of Urology, University of Limpopo, Medunsa Campus, Medunsa, South Africa
Department of Medical Sciences, University of Limpopo, Turfloop Campus, Sovenga, South Africa
Human Comparative and Prostate Cancer Genomics, Garvan Institute of Medical Research, Kinghorn Cancer Centre, Darlinghurst, Sydney, Australia
AU  - Tindall, E. A.
AU  - Bornman, M. R.
AU  - Van Zyl, S.
AU  - Segone, A. M.
AU  - Monare, L. R.
AU  - Venter, P. A.
AU  - Hayes, V. M.
C7  - 74
DB  - Scopus
DO  - 10.1186/1471-2490-13-74
KW  - African ancestry
Aggressive disease
Epidemiology
Genetics
Pilot analysis
Prostate cancer
Risk factors
Southern Africa
M3  - Article
N1  - Cited By :8
Export Date: 22 March 2021
PY  - 2013
ST  - Addressing the contribution of previously described genetic and epidemiological risk factors associated with increased prostate cancer risk and aggressive disease within men from South Africa
T2  - BMC Urology
TI  - Addressing the contribution of previously described genetic and epidemiological risk factors associated with increased prostate cancer risk and aggressive disease within men from South Africa
UR  - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84891005373&doi=10.1186%2f1471-2490-13-74&partnerID=40&md5=2209c4df2364813b0242c36ce9faa584
VL  - 13
ID  - 2422
ER  - 

TY  - JOUR
AB  - BACKGROUNDThe Community Health Advisor (CHA) model has been widely used to recruit rural and low-income, mostly African American women into clinical and behavioral research studies. However, little is known about its effectiveness in promoting retention and adherence of such women in clinical trials. METHODSThe Community-Based Retention Intervention Study evaluated the effectiveness of a community-based intervention strategy using the CHA model and the empowerment theory to improve the retention and adherence of minority and low-income women in clinical trials. The research strategy included the training and use of the volunteer CHAs as research partners. The target population included women participating in the University of Alabama at Birmingham clinical site of the Atypical Squamous Cells of Undetermined Significance-Low-Grade Squamous Intraepithelial Lesion (ASCUS-LSIL) Triage Study (ALTS), a multicenter, randomized clinical trial. Two communities in Jefferson County, Alabama, that were matched according to population demographics were identified and randomly assigned to either an intervention group or a control group. Thirty community volunteers were recruited to be CHAs and to implement the intervention with the ALTS trial participants. In total, 632 ALTS participants agreed to participate in the project, including 359 in the intervention group, which received CHA care, and 273 in the control group, which received standard care. RESULTSAdherence rates for scheduled clinic visits were significantly higher in the intervention group (80%) compared with the control group (65%; P<.0001). CONCLUSIONSThe results indicate that volunteer CHAs can be trained to serve as research partners and can be effective in improving the retention and adherence of minority and low-income women in clinical trials. Cancer 2014;120(7 suppl):1106-12. (c) 2014 American Cancer Society. In the Community-Based Retention Intervention Study (CRIS), the effectiveness of a community-based intervention strategy is evaluated using Community Health Advisors (CHAs). The results indicate that volunteer CHAs can be trained as research partners to improve the retention and adherence of minority and low-income women in clinical trials.
AN  - WOS:000332916200004
AU  - Fouad, M. N.
AU  - Johnson, R. E.
AU  - Nagy, M. C.
AU  - Person, S. D.
AU  - Partridge, E. E.
DA  - Apr
DO  - 10.1002/cncr.28572
N1  - 7
SI
24643648
PY  - 2014
SN  - 0008-543X
SP  - 1106-1112
ST  - Adherence and Retention in Clinical Trials: A Community-Based Approach
T2  - Cancer
TI  - Adherence and Retention in Clinical Trials: A Community-Based Approach
VL  - 120
ID  - 3015
ER  - 

TY  - JOUR
AB  - African‐American (AA) men suffer the greatest proportion of health disparities of any studied category and adherence to advice among this group has been vastly understudied. Although there are several ongoing trials for behavioral change, either of diet or lifestyle, enrollment rates of AA men (< 25%) often provide insufficient numbers to evaluate adherence issues separately. Tomatoes, more than lycopene alone, may have beneficial effects on prostate health, including BPH and prostate cancer. Efficacy trials would require long‐term adherence to high levels of tomato product (TP) consumption.
AN  - CN-01487928
AU  - Nct
PY  - 2011
ST  - Adherence Dynamics for Whole Food Interventions in African-American Men
T2  - https://clinicaltrials.gov/show/NCT01408459
TI  - Adherence Dynamics for Whole Food Interventions in African-American Men
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01487928/full
ID  - 1479
ER  - 

TY  - JOUR
AB  - PURPOSE: The American Cancer Society (ACS) and the American Institute for Cancer Research (AICR) each created dietary and physical activity guidelines to improve cancer survivorship. Despite African American breast cancer survivors (AABCS) having the lowest survival rates of any racial or ethnic group, limited information exists on their adherence to cancer-specific lifestyle recommendations. The study's purpose was to measure adherence to ACS/AICR dietary recommendations in AABCS. METHODS: Two hundred ten AABCS enrolled in the Moving Forward intervention trial, a randomized, community-based, 6-month weight loss study, were assessed for socio-demographics, dietary intake (via food frequency questionnaire), and related health factors at baseline. We operationalized the dietary recommendations put forth by ACS/AICR and created component and total adherence index scores. Descriptive statistics were used to calculate the proportion of women who met recommendations. Student's t test and χ2 tests were used to compare participant characteristics by median adherence scores. RESULTS: The mean total ACS/AICR score was 12.7 ± 2.5 out of 21 points (median, 13; range, 5 to 21). Over 90% were moderately or completely adherent to limiting alcohol and red & processed meat consumption, but the majority failed to meet the other recommendations to eat whole grains, legumes, fruits, vegetables, and avoid added sugars. Women with total scores below the median were younger, with higher BMI, had fewer years of education, and lower income levels. IMPLICATIONS FOR CANCER SURVIVORS: The present study extends the literature on AABCS adherence to cancer survivor-specific dietary guidelines. Findings will inform future dietary lifestyle interventions in this population.
AD  - Stanford Prevention Research Center, School of Medicine, Stanford University, 3300 Hillview Ave, Palo Alto, CA, 94304, USA. sspring@stanford.edu.
Department of Kinesiology and Nutrition, 646 Applied Health Sciences Building, University of Illinois at Chicago, 1919 West Taylor Street MC 517, Chicago, IL, 60612, USA.
Division of Academic and Internal Medicine, College of Medicine, University of Illinois, Chicago, IL, USA.
University of Illinois Cancer Center, Chicago, IL, USA.
Institute for Health Research and Policy, 416 Westside Research Office Bldg., 1747 West Roosevelt Road, Chicago, IL, 60608, USA.
School of Public Health, University of Illinois at Chicago, 1603 W Taylor St, Chicago, IL, 60612, USA.
Department of Medicine, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI, 53226, USA.
AN  - 30982113
AU  - Springfield, S.
AU  - Odoms-Young, A.
AU  - Tussing-Humphreys, L.
AU  - Freels, S.
AU  - Stolley, M.
C2  - PMC6612676
C6  - NIHMS1037274
DA  - Apr
DO  - 10.1007/s11764-019-00748-y
DP  - NLM
ET  - 2019/04/15
IS  - 2
KW  - African Americans/*statistics & numerical data
Aged
American Cancer Society
Breast Neoplasms/complications/diet therapy/ethnology/*rehabilitation
Cancer Survivors/*statistics & numerical data
Diet
Exercise
Female
Humans
Life Style
Middle Aged
*Nutrition Policy
Overweight/complications/*diet therapy/ethnology
Patient Compliance/*statistics & numerical data
Risk Reduction Behavior
Societies, Medical/standards
United States
Weight Reduction Programs/standards
*African American women
*Breast cancer survivors
*Diet quality
*Dietary adherence
*Racial-ethnic disparities
interest. Angela Odoms-Young, PhD, declares that she has no conflict of interest.
Lisa Tussing-Humphreys, PhD, MS, RD, declares that she has no conflict of interest.
Sally Freels, PhD, declares that she has no conflict of interest. Melinda Stolley,
PhD, declares that she has no conflict of interest.
LA  - eng
N1  - 1932-2267
Springfield, Sparkle
Odoms-Young, Angela
Tussing-Humphreys, Lisa
Freels, Sally
Stolley, Melinda
R25 CA057699/CA/NCI NIH HHS/United States
T32 HL007034/HL/NHLBI NIH HHS/United States
R01 CA116750/CA/NCI NIH HHS/United States
T32 CA057699/CA/NCI NIH HHS/United States
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
J Cancer Surviv. 2019 Apr;13(2):257-268. doi: 10.1007/s11764-019-00748-y. Epub 2019 Apr 13.
PY  - 2019
SN  - 1932-2259 (Print)
1932-2259
SP  - 257-268
ST  - Adherence to American Cancer Society and American Institute of Cancer Research dietary guidelines in overweight African American breast cancer survivors
T2  - J Cancer Surviv
TI  - Adherence to American Cancer Society and American Institute of Cancer Research dietary guidelines in overweight African American breast cancer survivors
VL  - 13
ID  - 77
ER  - 

TY  - JOUR
AB  - BACKGROUND: Despite evidence that several colorectal cancer (CRC) screening strategies can reduce CRC mortality, screening rates remain low. This study aimed to determine whether the approach by which screening is recommended influences adherence. METHODS: We used a cluster randomization design with clinic time block as the unit of randomization. Persons at average risk for development of CRC in a racially/ethnically diverse urban setting were randomized to receive recommendation for screening by fecal occult blood testing (FOBT), colonoscopy, or their choice of FOBT or colonoscopy. The primary outcome was completion of CRC screening within 12 months after enrollment, defined as performance of colonoscopy, or 3 FOBT cards plus colonoscopy for any positive FOBT result. Secondary analyses evaluated sociodemographic factors associated with completion of screening. RESULTS: A total of 997 participants were enrolled; 58% completed the CRC screening strategy they were assigned or chose. However, participants who were recommended colonoscopy completed screening at a significantly lower rate (38%) than participants who were recommended FOBT (67%) (P < .001) or given a choice between FOBT or colonoscopy (69%) (P < .001). Latinos and Asians (primarily Chinese) completed screening more often than African Americans. Moreover, nonwhite participants adhered more often to FOBT, while white participants adhered more often to colonoscopy. CONCLUSIONS: The common practice of universally recommending colonoscopy may reduce adherence to CRC screening, especially among racial/ethnic minorities. Significant variation in overall and strategy-specific adherence exists between racial/ethnic groups; however, this may be a proxy for health beliefs and/or language. These results suggest that patient preferences should be considered when making CRC screening recommendations. Trial Registration  clinicaltrials.gov Identifier: NCT00705731.
AD  - Division of Gastroenterology, Department of Medicine, University of Washington School of Medicine, Seattle, WA 98195, USA. jinadomi@medicine.washington.edu
AN  - 22493463
AU  - Inadomi, J. M.
AU  - Vijan, S.
AU  - Janz, N. K.
AU  - Fagerlin, A.
AU  - Thomas, J. P.
AU  - Lin, Y. V.
AU  - Muñoz, R.
AU  - Lau, C.
AU  - Somsouk, M.
AU  - El-Nachef, N.
AU  - Hayward, R. A.
C2  - PMC3360917
C6  - NIHMS378252
DA  - Apr 9
DO  - 10.1001/archinternmed.2012.332
DP  - NLM
ET  - 2012/04/12
IS  - 7
KW  - Adult
African Americans/statistics & numerical data
Aged
Asian Americans/statistics & numerical data
*Colonoscopy
Colorectal Neoplasms/*diagnosis/*prevention & control
*Early Detection of Cancer/methods
European Continental Ancestry Group/statistics & numerical data
Female
Hispanic Americans/statistics & numerical data
Humans
Male
*Mass Screening/methods
Middle Aged
Multivariate Analysis
*Occult Blood
Patient Compliance/*statistics & numerical data
Risk Factors
Sigmoidoscopy
LA  - eng
N1  - 1538-3679
Inadomi, John M
Vijan, Sandeep
Janz, Nancy K
Fagerlin, Angela
Thomas, Jennifer P
Lin, Yunghui V
Muñoz, Roxana
Lau, Chim
Somsouk, Ma
El-Nachef, Najwa
Hayward, Rodney A
K24 DK080941/DK/NIDDK NIH HHS/United States
K24DK080941/DK/NIDDK NIH HHS/United States
K23 CA157929/CA/NCI NIH HHS/United States
R01 CA106773/CA/NCI NIH HHS/United States
UL1 RR024131/RR/NCRR NIH HHS/United States
R01CA106773/CA/NCI NIH HHS/United States
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Arch Intern Med. 2012 Apr 9;172(7):575-82. doi: 10.1001/archinternmed.2012.332.
PY  - 2012
SN  - 0003-9926 (Print)
0003-9926
SP  - 575-82
ST  - Adherence to colorectal cancer screening: a randomized clinical trial of competing strategies
T2  - Arch Intern Med
TI  - Adherence to colorectal cancer screening: a randomized clinical trial of competing strategies
VL  - 172
ID  - 370
ER  - 

TY  - JOUR
AB  - Postmenopausal women with coronary heart disease (CHD) who volunteered for the Heart and Estrogen/Progestin Replacement Study (HERS) randomized clinical trial had high rates of gynecological abnormalities. We examined compliance with gynecological cancer screening and factors affecting this behavior. Women who met inclusion criteria for HERS and were seen for screening by the study gynecologist were considered eligible for this study. Data were abstracted from study records, and additional information was obtained by telephone questionnaire. Adherence to mammography, breast examination, pelvic examination, and Pap smear recommendations was assessed. Provider behavior and its effect on compliance were assessed. Compliance rates were 59.1% for monthly breast self-examination (BSE), 67.2% for yearly mammography, 73% for yearly Pap smear and pelvic examination, and 75.7% for provider breast examination. Over 50% of patients had most of their screening tests done within the last year. Provider behavior was significantly related to patient screening compliance for mammography, breast examination, Pap smear, and pelvic examination. Provider gender was not significantly related to adherence. There were no significant differences in compliance rates based on the type of most recent coronary event. Compliance rates did not differ significantly between patients with and without gynecological abnormalities, except for mammography (78.3% versus 48.3%, p = 0.02). The majority of patients were compliant with gynecological screening. Among patients with gynecological abnormalities, mammography compliance was significantly lower. Provider behavior was an important factor in influencing women to obtain preventive screening. There were no significant differences in compliance based on provider gender or type of coronary event preceding HERS enrollment.
AD  - Dept of Gynecology and Obstetrics, Emory University School of Medicine, Atlanta, GA
AN  - 107064026. Language: English. Entry Date: 20011102. Revision Date: 20200708. Publication Type: Journal Article
AU  - Castellano, P. Z.
AU  - Wenger, N. K.
AU  - Graves, W. L.
DB  - CINAHL Complete
DO  - 10.1089/152460901300233920
DP  - EBSCOhost
IS  - 5
KW  - Breast Neoplasms -- Prevention and Control
Cervix Neoplasms -- Prevention and Control
Coronary Disease
Health Behavior
Patient Compliance
Postmenopause
Female
Male
Middle Age
Aged
Breast Self-Examination
Georgia
Mammography
Medical Records
Questionnaires
Cervical Smears
Women's Health
Data Analysis Software
Clinical Trials
T-Tests
Chi Square Test
Descriptive Statistics
Black Persons
White Persons
Funding Source
Human
N1  - clinical trial; research; tables/charts. Journal Subset: Biomedical; Core Nursing; Editorial Board Reviewed; Expert Peer Reviewed; Nursing; Peer Reviewed; USA. Grant Information: Emory Medical Care Foundation. NLM UID: 100888719.
PY  - 2001
SN  - 1524-6094
SP  - 451-461
ST  - Adherence to screening guidelines for breast and cervical cancer in postmenopausal women with coronary heart disease: an ancillary study of volunteers for HERS
T2  - Journal of Women's Health & Gender-Based Medicine
TI  - Adherence to screening guidelines for breast and cervical cancer in postmenopausal women with coronary heart disease: an ancillary study of volunteers for HERS
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=107064026&site=ehost-live&scope=site
VL  - 10
ID  - 1845
ER  - 

TY  - JOUR
AB  - The effect of adherence to the World Cancer Research Fund (WCRF) lifestyle recommendations on cancer aggressiveness is unknown. We examined associations between adherence to recommendations and risk of highly aggressive prostate cancer in research subjects enrolled in the North Carolina-Louisiana Prostate Cancer Project (PCaP). We examined associations between adherence to WCRF recommendations and risk of highly aggressive prostate cancer among 2212 newly diagnosed African Americans (AA) or Caucasian Americans (CA) aged 40-70 years in PCaP. Prostate cancer aggressiveness was based on Gleason scores, serum prostate-specific antigens, and TNM stage. Adherence to WCRF recommendations was based on point scores and odds ratios estimated. Results showed that adherence to recommendations was significantly and negatively associated with risk of a highly aggressive prostate cancer. Each additional point in the total adherence score corresponded to a 13% risk reduction. Total adherence score <4 predicted increased risk in both AA (OR = 1.36; 95% CI = 1.01-1.85) and CA (OR = 1.41; 95% CI = 1.01-1.98). Consumption of <500 g red meat per week or ≤125 total kcal/100 g solid food per day is a statistically significant protective factor in the overall cohort. Recommendations aimed at preventing all cancers also may reduce risk of highly aggressive prostate cancer.
AD  - David Geffen School of Medicine, University of California, Los Angeles, California 90095-1736, USA. Larab@ucla.edu
AN  - 23859030
AU  - Arab, L.
AU  - Su, J.
AU  - Steck, S. E.
AU  - Ang, A.
AU  - Fontham, E. T.
AU  - Bensen, J. T.
AU  - Mohler, J. L.
DO  - 10.1080/01635581.2013.789540
DP  - NLM
ET  - 2013/07/19
IS  - 5
KW  - Adult
African Americans
Aged
Body Mass Index
Cross-Sectional Studies
Energy Intake
European Continental Ancestry Group
*Feeding Behavior
Guidelines as Topic
Humans
Life Style
Louisiana
Male
Middle Aged
Motor Activity
Neoplasm Staging
North Carolina
Nutrition Assessment
*Patient Compliance
Prostate-Specific Antigen/blood
Prostatic Neoplasms/*prevention & control
Surveys and Questionnaires
LA  - eng
N1  - 1532-7914
Arab, Lenore
Su, Joseph
Steck, Susan E
Ang, Alfonso
Fontham, Elizabeth T H
Bensen, Jeannette T
Mohler, James L
Journal Article
Research Support, U.S. Gov't, Non-P.H.S.
United States
Nutr Cancer. 2013;65(5):633-43. doi: 10.1080/01635581.2013.789540.
PY  - 2013
SN  - 0163-5581
SP  - 633-43
ST  - Adherence to World Cancer Research Fund/American Institute for Cancer Research lifestyle recommendations reduces prostate cancer aggressiveness among African and Caucasian Americans
T2  - Nutr Cancer
TI  - Adherence to World Cancer Research Fund/American Institute for Cancer Research lifestyle recommendations reduces prostate cancer aggressiveness among African and Caucasian Americans
VL  - 65
ID  - 325
ER  - 

TY  - JOUR
AB  - BACKGROUND: Adjuvant chest wall irradiation after mastectomy remains a core and highly effective element in the loco-regional management of early breast cancer. While the evidence base for postmastectomy radiotherapy (PMRT) in patients with 4 or more involved axillary nodes is robust, its role in 'intermediate' risk patients with 1-3 involved nodes is unclear and practice varies. Traditionally patients have been selected for PMRT on the basis of clinic-pathological factors such tumour size, nodal status, tumour grade and presence of lymphovascular invasion. However these factors alone may not predict the response of individual patients to radiotherapy. There is recent evidence that biological factors such as oestrogen and progesterone receptor and HER-2 status may also influence survival as well as loco-regional control. METHODS: A literature review was undertaken, searching Pubmed using the mesh heading of 'breast cancer' and 'adjuvant chest wall irradiation/radiotherapy'. Priority was given to reports of meta-analyses and randomised trials of postmastectomy radiotherapy. OBSERVATIONS: The 2005 Oxford Overview of randomised trials of postoperative radiotherapy established a clear biological link between loco-regional control and survival. Paradoxically the largest survival benefits do not occur in patients at the highest risk of recurrence. Molecular markers to identify exactly which patients are likely to benefit from PMRT are being actively investigated. Surgeons are encouraged to enter patients with 1-3 involved nodes into a clinical trial of postmastectomy radiotherapy.
AN  - 19932946
AU  - Kunkler, I.
DA  - Apr
DO  - 10.1016/j.ejso.2009.11.004
DP  - NLM
ET  - 2009/11/26
IS  - 4
KW  - Axilla
Breast Neoplasms/drug therapy/pathology/*radiotherapy/surgery
Clinical Trials as Topic
Combined Modality Therapy
Female
Humans
Lymphatic Metastasis/radiotherapy
Mastectomy
*Radiotherapy, Adjuvant
Survival Analysis
Thoracic Wall/*pathology
LA  - eng
N1  - 1532-2157
Kunkler, I
Editorial
Review
England
Eur J Surg Oncol. 2010 Apr;36(4):331-4. doi: 10.1016/j.ejso.2009.11.004. Epub 2009 Nov 24.
PY  - 2010
SN  - 0748-7983
SP  - 331-4
ST  - Adjuvant chest wall radiotherapy for breast cancer: black, white and shades of grey
T2  - Eur J Surg Oncol
TI  - Adjuvant chest wall radiotherapy for breast cancer: black, white and shades of grey
VL  - 36
ID  - 439
ER  - 

TY  - JOUR
AB  - Objective We prospectively evaluated patients with completely resected uterine serous carcinoma (USC) treated with radiation "sandwiched" between carboplatin/paclitaxel (C/T). The primary objective was to determine the safety profile, and the secondary outcome was to evaluate progression-free and overall survival. Methods Surgically staged patients with completely resected USC were enrolled to receive 3 cycles of paclitaxel 175 mg/m2 and carboplatin (area under the curve, 6-7.5) every 21 days, followed by radiotherapy and an additional 3 cycles of T/C at area under the curve of 5-6 (6 cycles + radiotherapy). Toxicity was graded according to National Cancer Institute Common Toxicity Criteria, version 4.03. Kaplan-Meier and log-rank tests were used to compare survival probabilities. Results One hundred forty patients were enrolled, of which 132 were evaluable, completed at least 3 cycles of chemotherapy and radiation. One hundred seven (81%) completed 6 cycles of chemotherapy and radiation. Patients with early-stage (I/II) disease have survival probabilities of 0.96 and 0.81 at 2 and 5 years. Patients with stage I USC and lymphovascular invasion have considerably worse overall survival, with 2.7 times' higher risk of death than those without lymphovascular invasion. Patients with late-stage (III/IV) disease had overall survival probabilities of 0.64 and 0.18 at 2 and 5 years, which is far higher survival than what has been reported in single-modality trials. Interestingly, and different than what is reported in other studies, there is no difference in survival in African Americans versus whites/other races who were evaluable. Of the 779 cycles administered, 22% and 14% of cycles were associated with grades 3 and 4 hematologic toxicities, respectively. Grades 3 and 4 nonhematologic toxicities occurred in 6.9% of cycles. Conclusions The long-term follow-up in this study demonstrates that "sandwich" therapy is an efficacious, well-tolerated treatment approach with acceptable toxicities. Lymphovascular invasion (LVSI) is a significantly poor prognostic factor in stage I USC. Multimodal "sandwich" therapy should be considered in all USC patients who have undergone complete surgical resection and staging.
AD  - M. Frimer, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, and Women's Health, Albert Einstein College of Medicine/Montefiore Medical Center, 1554 Northern Blvd, Manhasset, NY, United States
AU  - Frimer, M.
AU  - Miller, E. M.
AU  - Shankar, V.
AU  - Girda, E.
AU  - Mehta, K.
AU  - Smith, H. O.
AU  - Kuo, D. Y. S.
AU  - Goldberg, G. L.
AU  - Einstein, M. H.
DB  - Embase
Medline
DO  - 10.1097/IGC.0000000000001359
IS  - 9
KW  - NCT00231868)
carboplatin
paclitaxel
African American
aged
anemia
article
brachytherapy
cancer staging
Caucasian
deep vein thrombosis
external beam radiotherapy
female
follow up
gastrointestinal disease
human
infection
lung embolism
lymph vessel metastasis
major clinical study
metabolic disorder
multiple cycle treatment
neurologic disease
neutropenia
overall survival
phase 2 clinical trial
priority journal
progression free survival
prospective study
thrombocytopenia
urosepsis
uterus carcinoma
LA  - English
M3  - Article
N1  - L624776932
2018-11-13
2019-07-25
PY  - 2018
SN  - 1525-1438
1048-891X
SP  - 1781-1788
ST  - Adjuvant Pelvic Radiation "sandwiched" between Paclitaxel/Carboplatin Chemotherapy in Women with Completely Resected Uterine Serous Carcinoma: Long-term Follow-up of a Prospective Phase 2 Trial
T2  - International Journal of Gynecological Cancer
TI  - Adjuvant Pelvic Radiation "sandwiched" between Paclitaxel/Carboplatin Chemotherapy in Women with Completely Resected Uterine Serous Carcinoma: Long-term Follow-up of a Prospective Phase 2 Trial
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L624776932&from=export
http://dx.doi.org/10.1097/IGC.0000000000001359
VL  - 28
ID  - 878
ER  - 

TY  - JOUR
AB  - BACKGROUND: Use of technology is increasing in health promotion and has continued growth potential in intervention research. Guided by the Reach, Effectiveness, Adoption, Implementation, and Maintenance (RE-AIM) framework, this paper reports on the adoption, reach, and implementation of Project HEAL (Health through Early Awareness and Learning)-a community-based implementation trial of a cancer educational intervention in 14 African American churches. We compare adoption, reach, and implementation at the organizational and participant level for churches in which lay peer community health advisors (CHAs) were trained using traditional classroom didactic methods compared with a new online system. METHODS: Fifteen churches were randomized to one of two study groups in which two CHAs per church were trained through either classroom ("Traditional"; n = 16 CHAs in 8 churches) or web-based ("Technology"; n = 14 CHAs in 7 churches) training methods. Once trained and certified, all CHAs conducted a series of three group educational workshops in their churches on cancer early detection (breast, prostate, and colorectal). Adoption, reach, and implementation were assessed using multiple data sources including church-level data, participant engagement in the workshops, and study staff observations of CHA performance. RESULTS: The project had a 41% overall adoption rate at the church level. In terms of reach, a total of 375 participants enrolled in Project HEAL-226 participants in the Traditional group (43% reach) and 149 in the Technology group (21% reach; p < .10). Implementation was evaluated in terms of adherence, dosage, and quality. All churches fully completed the three workshops; however, the Traditional churches took somewhat longer (M = 84 days) to complete the workshop series than churches in the Technology group (M = 64 days). Other implementation outcomes were comparable between both the Traditional and Technology groups (p > .05). CONCLUSIONS: Overall, the Project HEAL intervention had reasonable adoption, though reach could have been better. Implementation was strong across both study groups, suggesting the promise of using web-based methods to disseminate and implement evidence-based interventions in faith-based settings and other areas where community health educators work to eliminate health disparities.
AD  - Department of Behavioral and Community Health, University of Maryland, School of Public Health, 4200 Valley Dr., 1101 E SPH Building 255, College Park, MD, 20742, USA. ssantos1@umd.edu.
Department of Behavioral and Community Health, University of Maryland, School of Public Health, 4200 Valley Dr., 1101 E SPH Building 255, College Park, MD, 20742, USA.
Scheirer Consulting, Princeton, NJ, USA.
Department of Health, Behavior and Society, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Institute for Applied Environmental Health, University of Maryland, School of Public Health, College Park, MD, USA.
Community Ministry of Prince George's County, Upper Marlboro, MD, USA.
AN  - 28292299
AU  - Santos, S. L.
AU  - Tagai, E. K.
AU  - Scheirer, M. A.
AU  - Bowie, J.
AU  - Haider, M.
AU  - Slade, J.
AU  - Wang, M. Q.
AU  - Holt, C. L.
C2  - PMC5351199
DA  - Mar 14
DO  - 10.1186/s13012-017-0566-z
DP  - NLM
ET  - 2017/03/16
IS  - 1
KW  - Adult
*African Americans
Aged
Cluster Analysis
Female
Health Education/*methods
Health Knowledge, Attitudes, Practice
Health Promotion/*methods
Humans
Male
Middle Aged
Neoplasms/diagnosis/*prevention & control/*therapy
*Religion and Medicine
LA  - eng
N1  - 1748-5908
Santos, Sherie Lou Zara
Tagai, Erin K
Scheirer, Mary Ann
Bowie, Janice
Haider, Muhiuddin
Slade, Jimmie
Wang, Min Qi
Holt, Cheryl L
R01 CA147313/CA/NCI NIH HHS/United States
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Implement Sci. 2017 Mar 14;12(1):36. doi: 10.1186/s13012-017-0566-z.
PY  - 2017
SN  - 1748-5908
SP  - 36
ST  - Adoption, reach, and implementation of a cancer education intervention in African American churches
T2  - Implement Sci
TI  - Adoption, reach, and implementation of a cancer education intervention in African American churches
VL  - 12
ID  - 177
ER  - 

TY  - JOUR
AB  - INTRODUCTION: Advanced imaging can inform prognosis and may be a mechanism to de-escalate unnecessary end-of-life care in patients with cancer. Associations between greater use of advanced imaging and less-aggressive end-of-life care in real-world practice has not been examined. METHODS: We conducted a retrospective analysis of SEER-Medicare data on patients who died from breast, lung, colorectal, or prostate cancer between 2002 and 2007. Hospital referral region (HRR)-level use of computerized tomography (CT), magnetic resonance imaging, and positron emission tomography was categorized by tertile of imaging use and correlated with hospice enrollment overall and late hospice enrollment using multivariable logistic regression. RESULTS: A total of 55,058 patients met study criteria. Hospice use ranged from 50.8% (colorectal cancer) to 62.1% (prostate cancer). In multivariable analyses, hospital referral regions (HRRs) with high rates of CT imaging were associated with lower odds of hospice enrollment (odds ratio, 0.80; 95% CI, 0.70-0.90) and late enrollment among those who did enroll (odds ratio, 1.49; 95% CI, 1.26-1.76). HRRs with the highest rates of CT use were predominantly located in the Midwest and Northeast and associated with higher percentage population of black patients (14.5 vs 5.6%), greater comorbidity (28.4 vs 23.7%), metropolitan residence (93.9 vs 78.5%), and less than high school education (26.4 vs 19.3%). CONCLUSION: In this population-based retrospective study, we did not observe evidence that overall and timely hospice are associated with higher rates of imaging near the end of life. An observed association between higher rates of imaging, particularly CT, may be explained in part by HRR-level differences in practice patterns and patient demographic characteristics. Further research is warranted to explore the ability of oncologic imaging to appropriately de-escalate care.
AD  - Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA. michaela.dinan@duke.edu.
Department of Population Health Sciences, Duke University School of Medicine, 2200 W Main St, Suite 720, Durham, NC, 27705, USA. michaela.dinan@duke.edu.
Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA.
Department of Population Health Sciences, Duke University School of Medicine, 2200 W Main St, Suite 720, Durham, NC, 27705, USA.
Department of Epidemiology, Rutgers School of Public Health, Piscataway, NJ, USA.
Department of Oncology, University of Calgary, Calgary, Alberta, Canada.
AN  - 29728843
AU  - Dinan, M. A.
AU  - Curtis, L. H.
AU  - Setoguchi, S.
AU  - Cheung, W. Y.
DA  - Oct
DO  - 10.1007/s00520-018-4223-0
DP  - NLM
ET  - 2018/05/08
IS  - 10
KW  - African Americans/statistics & numerical data
Aged
Aged, 80 and over
Breast Neoplasms/diagnosis/epidemiology/pathology
Colorectal Neoplasms/diagnosis/epidemiology/pathology
Comorbidity
Diagnostic Imaging/economics/*methods/standards
Female
Hospice Care/economics/*methods/standards
*Hospices/methods/standards/statistics & numerical data
Humans
Lung Neoplasms/diagnosis/epidemiology/pathology
Male
Medicare/economics/statistics & numerical data
Middle Aged
Neoplasms/*diagnosis/epidemiology/*therapy
Outcome Assessment, Health Care
Prostatic Neoplasms/diagnosis/epidemiology/pathology
Referral and Consultation/economics/statistics & numerical data
Retrospective Studies
SEER Program
Terminal Care/*methods
United States/epidemiology
Breast neoplasms
Colorectal neoplasms
Diagnostic imaging
Hospice care
Lung neoplasms
Outcome assessment (health care)
Prostatic neoplasms
LA  - eng
N1  - 1433-7339
Dinan, Michaela A
Curtis, Lesley H
Setoguchi, Soko
Cheung, Winson Y
KM1CA156687/National Cancer Institute/
Journal Article
Germany
Support Care Cancer. 2018 Oct;26(10):3619-3625. doi: 10.1007/s00520-018-4223-0. Epub 2018 May 4.
PY  - 2018
SN  - 0941-4355
SP  - 3619-3625
ST  - Advanced imaging and hospice use in end-of-life cancer care
T2  - Support Care Cancer
TI  - Advanced imaging and hospice use in end-of-life cancer care
VL  - 26
ID  - 122
ER  - 

TY  - JOUR
AD  - Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA.
AN  - 18277956
AU  - Gonzalez-Angulo, A. M.
DA  - Dec
DP  - NLM
ET  - 2008/02/19
IS  - 12
KW  - African Americans
*Biomarkers, Tumor
Breast Neoplasms/*drug therapy/*pathology
Clinical Trials as Topic
Disease-Free Survival
Female
Humans
Immunologic Factors/therapeutic use
Neoplasm Recurrence, Local/*drug therapy
Receptor, ErbB-2/metabolism
Receptors, Estrogen/metabolism
Receptors, Progesterone/metabolism
LA  - eng
N1  - Gonzalez-Angulo, Ana M
Journal Article
United States
Clin Adv Hematol Oncol. 2007 Dec;5(12):956-7.
PY  - 2007
SN  - 1543-0790 (Print)
1543-0790
SP  - 956-7
ST  - Advances in triple receptor-negative breast cancer
T2  - Clin Adv Hematol Oncol
TI  - Advances in triple receptor-negative breast cancer
VL  - 5
ID  - 504
ER  - 

TY  - JOUR
AB  - Lay health advisor (LHA) programs have made strong contributions towards the elimination of health disparities and are increasingly being implemented to promote health and prevent disease. Developed in collaboration with African-American survivors, the National Witness Project (NWP) is an evidence-based, community-led LHA program that improves cancer screening among African-American women. NWP has been successfully disseminated, replicated, and implemented nationally in over 40 sites in 22 states in diverse community settings, reaching over 15,000 women annually. We sought to advance understanding of barriers and facilitators to the long-term implementation and sustainability of LHA programs in community settings from the viewpoint of the LHAs, as well as the broader impact of the program on African-American communities and LHAs. In the context of a mixed-methods study, in-depth telephone interviews were conducted among 76 African-American LHAs at eight NWP sites at baseline and 12-18 months later, between 2010 and 2013. Qualitative data provides insight into inner and outer contextual factors (e.g., community partnerships, site leadership, funding), implementation processes (e.g., training), as well as characteristics of the intervention (e.g., perceived need and fit in African-American community) and LHAs (e.g., motivations, burnout) that are perceived to impact the continued implementation and sustainability of NWP. Factors at the contextual levels and related to motivations of LHAs are critical to the sustainability of LHA programs. We discuss how findings are used to inform (1) the development of the LHA Sustainability Framework and (2) strategies to support the continued implementation and sustainability of evidence-based LHA interventions in community settings.
AN  - WOS:000418893900004
AU  - Shelton, R. C.
AU  - Charles, T. A.
AU  - Dunston, S. K.
AU  - Jandorf, L.
AU  - Erwin, D. O.
DA  - Sep
DO  - 10.1007/s13142-017-0491-3
IS  - 3
N1  - 28337722
PY  - 2017
SN  - 1869-6716
SP  - 415-426
ST  - Advancing understanding of the sustainability of lay health advisor (LHA) programs for African-American women in community settings
T2  - Translational Behavioral Medicine
TI  - Advancing understanding of the sustainability of lay health advisor (LHA) programs for African-American women in community settings
VL  - 7
ID  - 2891
ER  - 

TY  - JOUR
AB  - This poster demonstrates that advocacy support enhances diversity recruitment in the WISDOM Study (WomenInformed to Screen Depending on Measures of Risk). Initially funded by a grant from the Patient‐CenteredOutcomes Research Institute, with advocates having a key role in design and planning, WISDOM is a 100,000healthy women preference‐tolerant, pragmatic study comparing annual to personalized risk‐based breast screening.The novelty of WISDOM personalized screening is the integration of previously validated genetics and clinical riskfactors (age, family history, breast biopsy results, ethnicity, mammographic density) into a single risk‐assessmentmodel that directs the starting age, timing, and frequency of screening. Importantly, the genetic component of risk iscalibrated by race/ethnicity (Caucasian, Asian, African American, Hispanic), to provide each woman the mosttailored personalized risk assessment. The goal of WISDOM is to determine if personalized screening, compared toannual screening, is as safe, less morbid, enables prevention, and is preferred by women. The study is registeredon ClinicalTrials.gov, NCT02620852 . The study's “preference‐tolerant design” encourages women to be randomized but also allows self‐assignment (thiscomponent was recommended by advocates) for those with a strong personal preference for either annual or risk‐based screening. WISDOM study researchers aim to help all women make better‐informed decisions by comparingthe outcomes of women who have annual mammograms with those women who received mammograms on aschedule determined by their personal risk. Enrollment and consent take place entirely online at www.wisdomstudy.org , which serves as a patient portal whereparticipants register, complete electronic consent, take health‐related questionnaires and receive screeningrecommendations and genetic test results. Currently the clinical sites and infrastructure associated with this studyare part of the Athena Breast Health Network (Athena), a unique collaboration among the five University of California (UC) medical/cancer centers (UCSF, UC Davis, UCLA, UC Irvine, and UCSD) and the Sanford HealthSystem (based in Sioux Falls, SD). Athena has fostered partnerships with advocates since its inception in 2009 and formed the Consumer and Community Advisory Committee (CCAC). The CCAC comprises patient advocate representatives from each Athenasite and community members with expertise in public heath, breast health, and under‐represented populations. Inaddition to participation at twice‐yearly WISDOM Retreats, advocates participate on regular WebEx WISDOM Studycalls with committee updates on advocacy involvement, marketing and outreach materials, recruitment, bioethics,protocol and adherence. Each advocate's skills and background inform all aspects of the study as we focus onaddressing recruitment strategies for expanding and encouraging enrollment in traditionally under‐representedpopulations including, but not limited to, racial/ethnic, underserved, older women, and women with little or no accessto the internet. Advocates, partnering with study staff, are championing efforts to further WISDOM diversity outreachby identifying key community champions in women's organizations, local nonprofits and faith‐based organizations;identifying people who do community‐based research and have established community relations; working onstrategies on what we can offer to the community such as presentations events and in‐person discussions; and,finally, helping to bridge technology gaps and access. As of July 2018, the WISDOM study is open to all eligible women in California, North Dakota, South Dakota,Minnesota and Iowa. To date, 23,329 eligible women have registered and 14,393 women have consented toparticipate in the trial. The median age is 56 years, 82% Caucasian, 1% African‐American, and 6% Asian, and 9%self‐reporting as Hispanic. WISDOM Study data collected so far do not reflect the diversity of our potentialparticipant population. We are partnering with health insurers and self‐insured companies and expanding to otherstates with enrollment continuing past 2019. With the engagement of patient advocates, expanding diversityrecruitment will help fill gaps in scientific knowledge, resulting in personalized breast cancer screeningrecommendations for all women.
AN  - CN-02204143
AU  - Brain, S.
DO  - 10.1158/1538-7755.DISP18-B078
IS  - 6 SUPPL 1
KW  - *breast cancer
*cancer screening
Adult
Advisory committee
African American
Bioethics
Breast biopsy
Breast density
California
Cancer center
Cancer patient
Caucasian
Conference abstract
Consumer
Controlled study
Ethnicity
Faith‐based organization
Family history
Female
Hispanic
Human
Internet
Iowa
Major clinical study
Mammography
Marketing
Medical record
Middle aged
Minnesota
North Dakota
Outcome assessment
Questionnaire
Randomized controlled trial
Risk assessment
Skill
South Dakota
M3  - Journal: Conference Abstract
PY  - 2020
ST  - Advocating for diversity in the WISDOM Breast Cancer Screening Study
T2  - Cancer epidemiology biomarkers and prevention
TI  - Advocating for diversity in the WISDOM Breast Cancer Screening Study
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02204143/full
VL  - 29
ID  - 1551
ER  - 

TY  - JOUR
AB  - OBJECTIVE Lifestyle intervention remains the cornerstone of management of type 2 diabetes mellitus (T2DM). However, adherence to physical activity (PA) recommendations and the impact of that adherence on cardiorespiratory fitness in this population have been poorly described. We sought to investigate adherence to PA recommendations and its association with cardiorespiratory fitness in a population of patients with T2DM. RESEARCH DESIGN AND METHODS A cross-sectional analysis of baseline data from a randomized clinical trial (NCT00424762) was performed. A total of 150 individuals with medically treated T2DM and atherosclerotic cardiovascular disease (ASCVD) or risk factors for ASCVD were recruited from outpatient clinics at a single academic medical center. All individuals underwent a graded maximal exercise treadmill test to exhaustion with breath-by-breath gas exchange analysis to determine VO2peak. PA was estimated using a structured 7-Day Physical Activity Recall interview. RESULTS Participants had a mean6SD age of 54.969.0 years; 41% were women, 40% were black, and 21% were Hispanic. The mean HbA1c was 7.761.8% and the mean BMI, 34.5 6 7.2 kg/m2. A total of 72% had hypertension, 73% had hyperlipidemia, and 35% had prevalent ASCVD. The mean6SD reported daily PA was 34.364 kcal/kg, only 7% above a sedentary state; 47% of the cohort failed to achieve the minimum recommended PA. Mean 6 SD VO2peak was 27.4 6 6.5 mL/kg fat-free mass/min (18.8 6 5.0 mL/kg/min). CONCLUSIONS On average, patients with T2DM who have or are at risk for ASCVD report low levels of PA and have low measured cardiopulmonary fitness. This underscores the importance of continued efforts to close this therapeutic gap. © 2019 by the American Diabetes Association.
AD  - Division of Cardiology, University of Colorado, School of Medicine, Aurora, CO, United States
Division of Cardiology, University of Texas, Southwestern Medical Center, Dallas, TX, United States
Department of Clinical Sciences, University of Texas, Southwestern Medical Center, Dallas, TX, United States
Manitoba Institute of Child Health, Winnipeg, MB, Canada
Cardio-Metabolic Exercise and Lifestyle Laboratory, Fredericton, NB, Canada
Faculty of Kinesiology, University of New Brunswick, Fredericton, NB, Canada
AU  - Jarvie, J. L.
AU  - Pandey, A.
AU  - Ayers, C. R.
AU  - McGavock, J. M.
AU  - Sénéchal, M.
AU  - Berry, J. D.
AU  - Patel, K. V.
AU  - McGuire, D. K.
DB  - Scopus
DO  - 10.2337/dc18-2634
IS  - 7
M3  - Article
N1  - Cited By :5
Export Date: 22 March 2021
PY  - 2019
SP  - 1333-1339
ST  - Aerobic fitness and adherence to guideline-recommended minimum physical activity among ambulatory patients with type 2 diabetes mellitus
T2  - Diabetes Care
TI  - Aerobic fitness and adherence to guideline-recommended minimum physical activity among ambulatory patients with type 2 diabetes mellitus
UR  - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85068492380&doi=10.2337%2fdc18-2634&partnerID=40&md5=c0a557c2d59f120272f5798f0a5453e4
VL  - 42
ID  - 2248
ER  - 

TY  - JOUR
AB  - Although there has been an increase focus on recruitment of minority populations at safety-net hospitals into cancer clinical trials, there is still a paucity of research exploring minority participation in cancer clinical trials at safety-net settings. The study utilized a multi-level, qualitative approach to assess the clinical and non-clinical facilitators and barriers to African American participation in cancer clinical trials at a safety-net hospital. From June 2018 to July 2019, cancer survivors (n = 25) were recruited from a cancer center at a safety-net hospital in the southeastern USA and participated in a 60-min focus group. Data was coded and analyzed to identify the most prominent themes. Most participants were female (78%), with a mean age of 56 years. The majority were diagnosed with breast cancer (68%) and disabled or unemployed (55%). Major themes identified were (1) lack of understanding of cancer clinical trials, (2) perceptions and fears of cancer clinical trials, and (3) preferred role and characteristics of patient navigator. The barriers and facilitators to enrollment in cancer clinical trials were more pronounced in the safety-net setting, given the overdue burden of social determinants of health. Study findings yield important insights and essential practices for recruiting and engaging underrepresented Black cancer patients into cancer clinical trials, specifically for safety-net settings. Including patient navigators may help traverse potential barriers to cancer clinical trial participation and will allow for the attention to social determinants of health, and ultimately increase the number of African Americans participating in cancer clinical trials.
AD  - Department of Community Health and Preventive Medicine, Morehouse School of Medicine, 720 Westview Drive, Atlanta, GA, 30310, USA. nhernandez@msm.edu.
Division of Preventive Medicine, The University of Alabama at Birmingham, Birmingham, AL, USA.
Department of Community Health and Preventive Medicine, Morehouse School of Medicine, 720 Westview Drive, Atlanta, GA, 30310, USA.
Brandeis University, Waltham, MA, USA.
Tuskegee University, Tuskegee, AL, USA.
AN  - 33728872
AU  - Hernandez, N. D.
AU  - Durant, R.
AU  - Lisovicz, N.
AU  - Nweke, C.
AU  - Belizaire, C.
AU  - Cooper, D.
AU  - Soiro, F.
AU  - Rivers, D.
AU  - Sodeke, S.
AU  - Rivers, B. M.
DA  - Mar 16
DO  - 10.1007/s13187-021-01994-4
DP  - NLM
ET  - 2021/03/18
KW  - African Americans
Cancer clinical trials
Health disparities
Safety-net hospitals
Social determinants of health
LA  - eng
N1  - 1543-0154
Hernandez, N D
Orcid: 0000-0001-8911-6613
Durant, R
Lisovicz, N
Nweke, C
Belizaire, C
Cooper, D
Soiro, F
Rivers, D
Sodeke, S
Rivers, B M
UL1TR002378/TR/NCATS NIH HHS/United States
5U54CA118638-13/CA/NCI NIH HHS/United States
U54CA118948/NH/NIH HHS/United States
UL1TR002378/NH/NIH HHS/United States
R01 MD007783/NH/NIH HHS/United States
Journal Article
England
J Cancer Educ. 2021 Mar 16. doi: 10.1007/s13187-021-01994-4.
PY  - 2021
SN  - 0885-8195
ST  - African American Cancer Survivors' Perspectives on Cancer Clinical Trial Participation in a Safety-Net Hospital: Considering the Role of the Social Determinants of Health
T2  - J Cancer Educ
TI  - African American Cancer Survivors' Perspectives on Cancer Clinical Trial Participation in a Safety-Net Hospital: Considering the Role of the Social Determinants of Health
ID  - 1
ER  - 

TY  - JOUR
AB  - PURPOSE/OBJECTIVES: To explore the process of coping with breast cancer among African American women and their spouses. DESIGN: Exploratory, qualitative study using grounded theory methods. SETTING: Large metropolitan area in the mid-Atlantic United States. SAMPLE: 12 African American couples (N = 24). METHODS: African American women and their spouses were asked to complete a background data sheet and participate in a face-to-face semistructured interview. Qualitative data were audiotaped and transcribed verbatim. Themes were identified using the constant comparative method. Quantitative data were analyzed with descriptive statistics. MAIN RESEARCH VARIABLES: The process of coping with breast cancer among African American couples. FINDINGS: The basic social concern was living through and beyond a breast cancer diagnosis. The core variable was merging strengths to cope with and survive a breast cancer diagnosis. Six main categories emerged to describe how African American couples actively worked together to cope with a breast cancer diagnosis: walking together, praying together, seeking together, trusting together, adjusting together, and being together. CONCLUSIONS: African American couples described the importance of combining their strengths and working together as a couple to cope with a breast cancer diagnosis. IMPLICATIONS FOR NURSING: Nurses must understand the importance of developing culturally sensitive and culturally relevant interventions to assist African American couples with effectively coping with a breast cancer diagnosis. When providing care to African American couples, nurses should incorporate the six categories of walking, praying, seeking, trusting, adjusting, and being together to help couples cope with the various phases of the breast cancer experience.
AD  - Assistant Professor, Department of Nursing, Fayetteville State University, North Carolina; pmorgan@uncfsu.edu
AN  - 106528278. Language: English. Entry Date: 20051021. Revision Date: 20200708. Publication Type: Journal Article
AU  - Morgan, P. D.
AU  - Fogel, J.
AU  - Rose, L.
AU  - Barnett, K.
AU  - Mock, V.
AU  - Davis, B. L.
AU  - Gaskins, M.
AU  - Brown-Davis, C.
DB  - CINAHL Complete
DO  - 10.1188/05.ONF.979-987
DP  - EBSCOhost
IS  - 5
KW  - Black Persons -- Mid Atlantic Region
Breast Neoplasms -- Psychosocial Factors
Cancer Patients -- Psychosocial Factors
Family Coping
Marriage
Spouses -- Psychosocial Factors
Audiorecording
Coding
Constant Comparative Method
Data Analysis Software
Descriptive Statistics
Exploratory Research
Female
Funding Source
Grounded Theory
Interview Guides
Male
Mid Atlantic Region
Middle Age
Purposive Sample
Qualitative Studies
Research Subject Recruitment
Semi-Structured Interview
Spirituality
Support, Psychosocial
Thematic Analysis
Theoretical Sample
Trust
Uncertainty
Human
N1  - research; tables/charts. Journal Subset: Core Nursing; Double Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Nursing; Peer Reviewed; USA. Grant Information: Supported by research grants from the American Academy of Nurse Practitioners Foundation and ONS Foundation/Sigma Theta Tau International. NLM UID: 7809033.
PMID: NLM16136196.
PY  - 2005
SN  - 0190-535X
SP  - 979-987
ST  - African American couples merging strengths to successfully cope with breast cancer
T2  - Oncology Nursing Forum
TI  - African American couples merging strengths to successfully cope with breast cancer
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106528278&site=ehost-live&scope=site
VL  - 32
ID  - 1848
ER  - 

TY  - JOUR
AB  - The risk of prostate cancer diagnosis among African Americans is 66% greater than among European American men. For African Americans with a family history of hereditary prostate cancer the increased risk of diagnosis is even greater. Thus, this population should be a prime target for chemoprevention strategies. In addition to the higher incidence of prostate cancer among African Americans compared with other populations, the mortality of prostate cancer among this high-risk population is significantly greater than 100% compared with other populations, thus further demonstrating the need for chemoprevention in this target population. Autopsy studies and clinical findings support the argument that prostate cancer exhibits more aggressive biological behavior and perhaps more rapid growth among African Americans compared with European Americans. It is hypothesized that genetic and epigenetic factors may be responsible for a more rapid growth rate among African Americans compared with other populations. Accumulating evidence indicates that a diet high in fat content is closely associated with prostate cancer progression. Investigators have reported that fat intake and percentage of energy from fat were highest in African Americans, followed by European Americans, Japanese Americans, and Chinese Americans. In conclusion, African Americans are an important target population to include in chemoprevention trials that include dietary factors as preventive agents.
AD  - Department of Urology, Karmanos Cancer Institute, Wayne State University, Detroit, Michigan 48201, USA. ipowell@med.wayne.edu
AN  - 11295621
AU  - Powell, I. J.
AU  - Meyskens, F. L., Jr.
DA  - Apr
DO  - 10.1016/s0090-4295(00)00968-7
DP  - NLM
ET  - 2001/04/11
IS  - 4 Suppl 1
KW  - Adult
*African Americans/statistics & numerical data
African Continental Ancestry Group
Age Factors
Aged
Chromosomes, Human, Pair 1/genetics
Clinical Trials as Topic
Diet/adverse effects
Dietary Fats/adverse effects
Disease Progression
European Continental Ancestry Group
Genetic Predisposition to Disease
Germ-Line Mutation
Humans
Male
Middle Aged
Neoplasm Staging
Prostate-Specific Antigen/blood
Prostatic Neoplasms/*ethnology/genetics/prevention & control
LA  - eng
N1  - 1527-9995
Powell, I J
Meyskens, F L Jr
Comparative Study
Journal Article
United States
Urology. 2001 Apr;57(4 Suppl 1):178-81. doi: 10.1016/s0090-4295(00)00968-7.
PY  - 2001
SN  - 0090-4295
SP  - 178-81
ST  - African American men and hereditary/familial prostate cancer: Intermediate-risk populations for chemoprevention trials
T2  - Urology
TI  - African American men and hereditary/familial prostate cancer: Intermediate-risk populations for chemoprevention trials
VL  - 57
ID  - 686
ER  - 

TY  - JOUR
AD  - School of Nursing, Loma Linda University, West Hall Room 1149, Loma Linda, CA 92350, USA. lkendrick@llu.edu
AN  - 19437254
AU  - Kendrick, L.
AU  - Montgomery, S.
AU  - Ouattara, D.
AU  - Flaskerud, J. H.
DA  - May
DO  - 10.1080/01612840902754669
DP  - NLM
ET  - 2009/05/14
IS  - 5
KW  - Adult
African Americans/*psychology
Genetic Predisposition to Disease/psychology
*Health Knowledge, Attitudes, Practice
Humans
Male
Mass Screening/*nursing
Patient Participation/psychology
Practice Guidelines as Topic
Prostatic Neoplasms/genetics/*nursing/prevention & control
*Self Efficacy
LA  - eng
N1  - 1096-4673
Kendrick, Lorna
Montgomery, Susanne
Ouattara, Dorena
Flaskerud, Jacquelyn H
Journal Article
England
Issues Ment Health Nurs. 2009 May;30(5):342-3. doi: 10.1080/01612840902754669.
PY  - 2009
SN  - 0161-2840
SP  - 342-3
ST  - African american men and self-efficacy in preventing prostate cancer
T2  - Issues Ment Health Nurs
TI  - African american men and self-efficacy in preventing prostate cancer
VL  - 30
ID  - 470
ER  - 

TY  - JOUR
AB  - While African Americans are at a significantly higher risk for developing certain cancers, they also have low rates of participation in cancer research, particularly clinical trials. This study assessed both African American men's and African American women's (1) knowledge of and participation in cancer-related clinical research and (2) barriers to and motivations for participating in clinical research. Data were collected from a total of 81 participants. Phase I of this research consisted of qualitative focus groups (all 81 participants). Phase II included quantitative pre/post survey data from an education program (56 participants). Findings from the study revealed that African American men and women had poor knowledge about clinical trials and the informed consent process, limited experience in participating in clinical trials, and they feared and mistrusted cancer research. Participants identified incentives, assurance of safety, knowledge and awareness, and benefiting others as motivators to participate in clinical trials research.
AN  - 24185170
AU  - Owens, O. L.
AU  - Jackson, D. D.
AU  - Thomas, T. L.
AU  - Friedman, D. B.
AU  - Hébert, J. R.
C2  - PMC3818250
C6  - NIHMS456765
DA  - Nov
DO  - 10.1353/hpu.2013.0187
DP  - NLM
ET  - 2013/11/05
IS  - 4
KW  - *African Continental Ancestry Group
*Clinical Trials as Topic
Female
Focus Groups
Health Knowledge, Attitudes, Practice/*ethnology
Humans
Male
Middle Aged
Patient Acceptance of Health Care/*ethnology
*Prostatic Neoplasms
South Carolina
Surveys and Questionnaires
LA  - eng
N1  - 1548-6869
Owens, Otis L
Jackson, Dawnyéa D
Thomas, Tracey L
Friedman, Daniela B
Hébert, James R
K05 CA136975/CA/NCI NIH HHS/United States
U54 CA153461/CA/NCI NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
J Health Care Poor Underserved. 2013 Nov;24(4):1784-800. doi: 10.1353/hpu.2013.0187.
PY  - 2013
SN  - 1049-2089 (Print)
1049-2089
SP  - 1784-800
ST  - African American men's and women's perceptions of clinical trials research: focusing on prostate cancer among a high-risk population in the South
T2  - J Health Care Poor Underserved
TI  - African American men's and women's perceptions of clinical trials research: focusing on prostate cancer among a high-risk population in the South
VL  - 24
ID  - 308
ER  - 

TY  - JOUR
AB  - Objective: To elucidate factors that influence African American willingness to participate in health-related research studies. Methods: The African American Alzheimer disease research study group at North Carolina A&T State University designed an in-person questionnaire and surveyed more than 700 African American adults on their willingness to participate in health-related research studies. The questionnaire was distributed and collected in a nonclinical setting during the years 2008 and 2009. This study was approved by the North Carolina A&T State University Institutional Review Board. Results: Of the 733 valid respondents, 16% had previously participated in a health-related research study. Of these, more than 90% were willing to participate again in future research studies. Of the 614 who had never participated in a research study, more than 70% expressed willingness to participate. The majority (75%) of experienced research study participants (RSP) were older than 40 years compared with 45% of non-research study participants. Experienced research participants were also twice as likely to have a college degree compared with non-research study participants. Seventy-three percent of non-research study participants were willing to participate in research studies in the future. The factors that were probable impediments to participation included lack of time and trust. Men with knowledge of the Tuskegee Syphilis Study were 50% less likely to be willing to participate compared with those who had not heard of Tuskegee Syphilis Study. Conclusions: African Americans are willing to participate in health-related research studies. Several factors such as the appropriate incentives, community trust building, outreach, and community partnership creation are necessary for engaging minority participants. Incorporating factors that target African American enrollment in research design and implementation, such as increased training of minority health ambassadors and African American researchers and public health specialists, are needed to better engage minorities across generations, in research.
AN  - WOS:000314342300006
AU  - Lang, R.
AU  - Kelkar, V. A.
AU  - Byrd, J. R.
AU  - Edwards, C. L.
AU  - Pericak-Vance, M.
AU  - Byrd, G. S.
DA  - Mar-Apr
DO  - 10.1097/PHH.0b013e31825717ef
IS  - 2
N1  - 23358288
PY  - 2013
SN  - 1078-4659
SP  - 110-118
ST  - African American Participation in Health-Related Research Studies: Indicators for Effective Recruitment
T2  - Journal of Public Health Management and Practice
TI  - African American Participation in Health-Related Research Studies: Indicators for Effective Recruitment
VL  - 19
ID  - 3048
ER  - 

TY  - JOUR
AB  - In the United States, the incidence and mortality rates of many cancers, especially prostate cancer, are disproportionately high among African American men compared with Caucasian men. Recently, mortality rates for prostate cancer have declined more rapidly in African American versus Caucasian men, but prostate cancer is still the most common cancer and the second leading cause of cancer deaths in African American men in the United States. Compared with Caucasian men, prostate cancer occurs at younger ages, has a higher stage at diagnosis, and is more likely to progress after definitive treatments in African American men. Reasons for racial discrepancies in cancer are multifactorial and potentially include socioeconomic, cultural, nutritional, and biologic elements. In addition to improving access to novel therapies, clinical trial participation is essential to adequately establish the risks and benefits of treatments in African American populations. Considering the disproportionately high mortality rates noted in these groups, our understanding of the natural history and responses to therapies is limited. This review will explore African American underrepresentation in clinical trials with a focus on prostate cancer, and potentially effective strategies to engage African American communities in prostate cancer research. Solutions targeting physicians, investigators, the community, and health care systems are identified. Improvement of African American participation in prostate cancer clinical trials will benefit all stakeholders.
AD  - Department of Urology, College of Medicine, Howard University, Washington, DC. Electronic address: ozondu@me.com.
Dendreon Pharmaceuticals Inc, Seattle, WA.
Departments of Urology and Medicine, Tulane University School of Medicine, New Orleans, LA.
AN  - 26786562
AU  - Ahaghotu, C.
AU  - Tyler, R.
AU  - Sartor, O.
DA  - Apr
DO  - 10.1016/j.clgc.2015.12.003
DP  - NLM
ET  - 2016/01/21
IS  - 2
KW  - *African Americans
Age Factors
*Clinical Trials as Topic
European Continental Ancestry Group
Health Equity/statistics & numerical data
Humans
Male
Mortality/trends
Prognosis
Prostatic Neoplasms/*ethnology/*mortality/pathology
Socioeconomic Factors
Ethnicity
Racial disparities
Recruitment
Sociocultural elements
Underrepresentation
LA  - eng
N1  - 1938-0682
Ahaghotu, Chiledum
Tyler, Robert
Sartor, Oliver
Journal Article
Research Support, Non-U.S. Gov't
Review
United States
Clin Genitourin Cancer. 2016 Apr;14(2):105-16. doi: 10.1016/j.clgc.2015.12.003. Epub 2015 Dec 17.
PY  - 2016
SN  - 1558-7673
SP  - 105-16
ST  - African American Participation in Oncology Clinical Trials--Focus on Prostate Cancer: Implications, Barriers, and Potential Solutions
T2  - Clin Genitourin Cancer
TI  - African American Participation in Oncology Clinical Trials--Focus on Prostate Cancer: Implications, Barriers, and Potential Solutions
VL  - 14
ID  - 222
ER  - 

TY  - JOUR
AB  - INTRODUCTION: Prostate cancer is the most common cancer and the second leading cause of cancer death among men in the United States. African American (AA) men have greater prostate cancer burden than other men. Little is known about AA primary care physicians' (PCPs) practices regarding prostate cancer screening. METHODS: We analyzed data from the 2007-2008 National Survey of Primary Care Physicians' Practices Regarding Prostate Cancer Screening. The current study included 604 AA PCPs. Outcomes assessed were (a) offering screening using the prostate-specific antigen (PSA) test, (b) use of screening discussions to involve patients in the decision to screen, and (c) having a discussion policy to try to talk the patient into getting the screening tests. RESULTS: Most AA PCPs were male (52%), younger than 50 years (61%), and had 21% to 100% AA patients in their practices (74%). The majority (94%) of AA PCPs offered prostate cancer screening using PSA, discussed the tests with their male patients to involve them in the decision to screen (83%), and had a policy to try to talk the patient into getting the screening tests (77%). Multivariate analysis showed that offering screening, use of discussions, and a usual policy to encourage taking the screening tests varied mainly by practice-related factors, including practice type, practice location, and percentage of AA patients in the practice. CONCLUSION: Data from this study indicate that most AA PCPs reported high proscreening behaviors for all 3 outcomes. Additionally, practice- and screening-related factors may be important when examining AA PCP screening behaviors.
AD  - North Carolina A & T State University, Greensboro, NC, USA.
AN  - 24327595
AU  - Ross, L. E.
AU  - Hall, I. J.
C2  - PMC4568547
C6  - NIHMS713855
DA  - Jan 1
DO  - 10.1177/2150131913507454
DP  - NLM
ET  - 2013/12/12
IS  - 1
KW  - Adult
*African Americans
Decision Making
Family Practice/*statistics & numerical data
Female
Humans
Male
*Mass Screening/methods
Middle Aged
Multivariate Analysis
Patient Participation
Physician-Patient Relations
Practice Patterns, Physicians'/*statistics & numerical data
Prostatic Neoplasms/*diagnosis
Referral and Consultation/statistics & numerical data
United States
African American primary care physicians
physician practices
prostate cancer
prostate-specific antigen
screening
of interest with respect to the research, authorship, and/or publication of this
article.
LA  - eng
N1  - 2150-1327
Ross, Louie E
Hall, Ingrid J
CC999999/Intramural CDC HHS/United States
Journal Article
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, U.S. Gov't, P.H.S.
J Prim Care Community Health. 2014 Jan 1;5(1):36-43. doi: 10.1177/2150131913507454. Epub 2013 Oct 17.
PY  - 2014
SN  - 2150-1319 (Print)
2150-1319
SP  - 36-43
ST  - African american primary care physicians' prostate cancer screening practices
T2  - J Prim Care Community Health
TI  - African american primary care physicians' prostate cancer screening practices
VL  - 5
ID  - 302
ER  - 

TY  - JOUR
AB  - OBJECTIVE: To examine African-American prostate cancer (PCa) survivors' involvement in treatment decision-making (TDM), and examine the association between TDM and quality of life (QOL), using secondary data. METHODS: African-American PCa survivors (181) were recruited from the North Carolina Central Cancer Registry. Participants completed a cross-sectional survey that asked about their chosen cancer treatment, TDM factors, and PCa-specific QOL (using the Expanded Prostate Cancer Index Composite--EPIC). Multivariate analysis of covariance was conducted to determine the association between TDM and QOL, controlling for confounders. RESULTS: Most men reported being active (44.2%) or collaborative (38.1%) in TDM, while 14.4% preferred a passive role. Adjusting for marital status, education and treatment, passive patients reported somewhat better QOL compared to active patients in the following QOL domains: urinary summary (p=0.04), urinary function (p=0.01), and urinary incontinence (p=0.03). CONCLUSION: Most African-American PCa survivors preferred to be, and were, actively or collaboratively involved in TDM. However, those who preferred a passive role reported better PCa-specific QOL for the urinary domain compared to others. PRACTICE IMPLICATIONS: It is important to assess patients' TDM preference. Patients' QOL may differ by their TDM role, such that active patients may be more bothered by treatment side effects than other patients.
AD  - Department of Social Sciences and Health Policy, Division of Public Health Sciences, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA. npalmer@wakehealth.edu
AN  - 22940374
AU  - Palmer, N. R.
AU  - Tooze, J. A.
AU  - Turner, A. R.
AU  - Xu, J.
AU  - Avis, N. E.
C2  - PMC3536017
C6  - NIHMS419029
DA  - Jan
DO  - 10.1016/j.pec.2012.08.007
DP  - NLM
ET  - 2012/09/04
IS  - 1
KW  - Adult
African Americans/*psychology/statistics & numerical data
Aged
Cross-Sectional Studies
*Decision Making
Health Care Surveys
Humans
Male
Middle Aged
Multivariate Analysis
North Carolina
*Patient Participation
Patient Preference
Prostatic Neoplasms/ethnology/*psychology/therapy
*Quality of Life
Registries
Retrospective Studies
Socioeconomic Factors
Surveys and Questionnaires
Survivors/psychology/statistics & numerical data
LA  - eng
N1  - 1873-5134
Palmer, Nynikka R A
Tooze, Janet A
Turner, Aubrey R
Xu, Jianfeng
Avis, Nancy E
P30 CA012197/CA/NCI NIH HHS/United States
R25 CA122061/CA/NCI NIH HHS/United States
# 5R25CA122061/CA/NCI NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.
Patient Educ Couns. 2013 Jan;90(1):61-8. doi: 10.1016/j.pec.2012.08.007. Epub 2012 Aug 31.
PY  - 2013
SN  - 0738-3991 (Print)
0738-3991
SP  - 61-8
ST  - African American prostate cancer survivors' treatment decision-making and quality of life
T2  - Patient Educ Couns
TI  - African American prostate cancer survivors' treatment decision-making and quality of life
VL  - 90
ID  - 356
ER  - 

TY  - JOUR
AB  - African American women experience higher breast cancer mortality and lower survival rates compared with white women of comparable age and cancer stage. The literature is lacking in studies that address the influence of past events on current health behaviors among women of diverse cultural groups. This qualitative exploratory study used participant narratives to examine associations between women's memories and feelings concerning their breasts and current breast cancer screening behaviors. Twelve professional African American women, aged 42 to 64 years, shared stories about memories and feelings regarding their breasts. Codes grouped together with related patterns and recurrences revealed categories that encompassed the language and culture of the participants. The categories identified were Seasons of Breast Awareness, Womanhood, Self-Portraits, Breast Cancer and Cancer Beliefs, Breast Cancer Screening Experiences, and Participants' Advice for Change. These categories provide direction for further exploration of barriers to health promotion practices among African American women and women in general.
AD  - College of Nursing, MSC09 5350, 1 University of New Mexico, Albuquerque, NM 87131; Eithomas@salud.unm.edu
AN  - 106661746. Language: English. Entry Date: 20041112. Revision Date: 20150820. Publication Type: Journal Article
AU  - Thomas, E. C.
DB  - CINAHL Complete
DP  - EBSCOhost
IS  - 4
KW  - Black Persons -- United States
Breast Neoplasms -- Diagnosis
Cancer Screening
Health Behavior -- Evaluation
Health Beliefs -- Evaluation
Adult
Audiorecording
Culture
Data Analysis Software
Diaries
Exploratory Research
Female
Feminist Critique
Field Notes
Focus Groups
Funding Source
Interviews
Language
Memory
Middle Age
Midwestern United States
Narratives -- Evaluation
Patient Attitudes -- Evaluation
Purposive Sample
Qualitative Studies
Research Subject Recruitment
Sociological Theory
Thematic Analysis
United States
Human
N1  - research. Journal Subset: Core Nursing; Double Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Nursing; Peer Reviewed; USA. Grant Information: Partially funded by the Sigma Theta Tau Alpha Kappa-at-large Research Award. NLM UID: 7805358.
PMID: NLM15292725.
PY  - 2004
SN  - 0162-220X
SP  - 295-302
ST  - African American women's breast memories, cancer beliefs, and screening behaviors
T2  - Cancer Nursing
TI  - African American women's breast memories, cancer beliefs, and screening behaviors
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106661746&site=ehost-live&scope=site
VL  - 27
ID  - 1849
ER  - 

TY  - JOUR
AB  - Routine prostate cancer screening is not recommended but African American men who are at higher risk for the disease should be offered the opportunity for shared decision-making with their health-care providers. This qualitative study sought to better understand the potential role of women in educating their male spouses/partners about prostate cancer screening. Nine focus groups were conducted (n = 52). Women were recruited from a variety of community venues. Those eligible were African American and married to or in a partnership with an African American male age 45. Women provide numerous types of support to their male partners in an effort to facilitate participation in preventive health care. While women agreed that they would like to educate their partners about prostate cancer screening, they had little information about screening guidelines or the potential harms and limitations. The current findings suggest that women are eager information-seekers and can disseminate information to men and facilitate their efforts to make more informed decisions about prostate cancer screening. Women should be included in educational interventions for to promote informed decision-making for prostate cancer screening.
AN  - WOS:000436019700024
AU  - Allen, J. D.
AU  - Akinyemi, I. C.
AU  - Reich, A.
AU  - Fleary, S.
AU  - Tendulkar, S.
AU  - Lamour, N.
DA  - Jul
DO  - 10.1177/1557988317742257
IS  - 4
N1  - 29298558
PY  - 2018
SN  - 1557-9883
SP  - 884-893
ST  - African American Women's Involvement in Promoting Informed Decision-Making for Prostate Cancer Screening Among Their Partners/Spouses
T2  - American Journal of Mens Health
TI  - African American Women's Involvement in Promoting Informed Decision-Making for Prostate Cancer Screening Among Their Partners/Spouses
VL  - 12
ID  - 2853
ER  - 

TY  - JOUR
AB  - African American women die of breast cancer at a higher rate than any other racial group. The Komen Tissue Bank (KTB) is an ongoing clinical trial that collects healthy breast tissue from women of all racial groups to use as controls in research and represents a critical tool in efforts to treat and prevent breast cancer; however, African Americans display reticence toward donating breast tissue to the KTB. Through the lens of the Integrated Behavioral Model, this study recruited African American women to share their perspectives on donating breast tissue for research purposes. Seventy-one (N = 71) eligible Black women who were previous tissue donors to the KTB responded to an online questionnaire. Findings revealed that (a) participants had positive instrumental attitudes or reasons for donating; (b) participants felt generally supported in their decision to donate, but revealed that the lack of Black women participating in the KTB meant that they themselves were setting the norm for others; and (c) their race was an important element in their donation decision. While acknowledging the negative history of African Americans in medical research, they offered their perceptions regarding the importance of involving themselves in medical research, and suggested that health communication strategies to recruit African Americans into research should embrace race as part of the message. The findings from this study have important implications for other those who work in applied clinical settings and are interested in addressing racial disparities in medical research through more effective and targeted recruitment messaging.
AD  - a Susan G. Komen® Tissue Bank at the IU Simon Cancer Center (Indianapolis).
b Department of Communication Studies , Indiana University-Purdue University Indianapolis.
AN  - 27911088
AU  - Ridley-Merriweather, K. E.
AU  - Head, K. J.
DA  - Dec
DO  - 10.1080/10410236.2016.1250191
DP  - NLM
ET  - 2016/12/03
IS  - 12
KW  - African Americans/*psychology
*Breast
Breast Neoplasms/ethnology/prevention & control
Female
Humans
Internet
*Patient Selection
Qualitative Research
Surveys and Questionnaires
Tissue Donors/*psychology
LA  - eng
N1  - 1532-7027
Ridley-Merriweather, Katherine E
Orcid: 0000-0002-8556-6382
Head, Katharine J
Journal Article
England
Health Commun. 2017 Dec;32(12):1571-1580. doi: 10.1080/10410236.2016.1250191. Epub 2016 Dec 2.
PY  - 2017
SN  - 1041-0236
SP  - 1571-1580
ST  - African American Women's Perspectives on Donating Healthy Breast Tissue for Research: Implications for Recruitment
T2  - Health Commun
TI  - African American Women's Perspectives on Donating Healthy Breast Tissue for Research: Implications for Recruitment
VL  - 32
ID  - 190
ER  - 

TY  - JOUR
AB  - PURPOSE/OBJECTIVES: To explore African American women's recollected experiences of breast cancer treatment.
. RESEARCH APPROACH: Qualitative description and narrative analysis.
. SETTING: South Carolina Oncology Associates, an outpatient oncology clinic serving rural and urban populations.
. PARTICIPANTS: 16 African American women with breast cancer previously enrolled in the control arm (n = 93) of a completed randomized, controlled trial. 
. METHODOLOGIC APPROACH: Feminist narrative analysis of in-depth individual interviews.
. FINDINGS: The authors identified three themes within the African American breast cancer survivors' recollected experiences of treatment adherence. INTERPRETATION: Although little evidence was presented of shared decision making with providers, patients were committed to completing the prescribed therapies. The narratives highlighted the value of in-depth examination of patients' perspectives, particularly among minority and underserved groups. With the exception of voicing personal choice of surgical treatment, the women trusted providers' recommendations with a resolve to "just do it." Although trust may enhance treatment adherence, it may also reflect power differentials based on gender, race, education, and culture.
. IMPLICATIONS FOR NURSING: Nurses should listen to patients describe their experience with cancer treatment and compare the themes from this study with their patients' story. This comparison will help nurses support patients through various aspect of diagnosis and treatment.
AD  - Palmetto Health, South Carolina Cancer Center, Columbia.
University of South Carolina.
South University.
AN  - 28222084
AU  - Heiney, S. P.
AU  - Hilfinger Messias, D. K.
AU  - Felder, T. M.
AU  - Phelps, K. W.
AU  - Quinn, J. C.
DA  - Mar 1
DO  - 10.1188/17.Onf.217-224
DP  - NLM
ET  - 2017/02/22
IS  - 2
KW  - Adult
African Americans/*psychology
Aged
Aged, 80 and over
*Attitude to Health
Breast Neoplasms/*ethnology/*therapy
Cancer Survivors/*psychology
Female
Humans
Middle Aged
Rural Population
South Carolina/ethnology
Treatment Adherence and Compliance/*psychology
Urban Population
*African American
*breast cancer
*survivorship
*treatment adherence

*treatment decision making
LA  - eng
N1  - 1538-0688
Heiney, Sue P
Hilfinger Messias, DeAnne K
Felder, Tisha M
Phelps, Kenneth W
Quinn, Jada C
K01 CA193667/CA/NCI NIH HHS/United States
L60 MD006528/MD/NIMHD NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
United States
Oncol Nurs Forum. 2017 Mar 1;44(2):217-224. doi: 10.1188/17.ONF.217-224.
PY  - 2017
SN  - 0190-535x
SP  - 217-224
ST  - African American Women's Recollected Experiences of Adherence to Breast Cancer Treatment
T2  - Oncol Nurs Forum
TI  - African American Women's Recollected Experiences of Adherence to Breast Cancer Treatment
VL  - 44
ID  - 179
ER  - 

TY  - JOUR
AB  - Ethical and scientifically sound research requires that any sample population represent the population as a whole. African-Americans suffer disproportionately from cancer, hypertension, and heart failure compared with whites, but they are commonly underrepresented in clinical trials of these diseases. Failure to include African-American subjects in clinical trials prevents generalizability of the results to this population. African-Americans are often underrepresented in clinical research for numerous historic, societal, educational, and economic reasons. Efforts to improve enrollment of African-American subjects requires recognition of the problem, planning, educational efforts, and investigator training. The incidence of heart disease and prostate cancer in African-Americans dictates that these patients be targeted for clinical trials of surgical research. The research team must appreciate the importance of community involvement and support in recruiting African-Americans participants. Additionally, the continued effort to recruit and train African-American investigators must be a priority.
AD  - Department of Surgery, University of Cincinnati Medical Center, 231 Albert B. Sabin Way, Cincinnati, OH 45267-0558, USA. richard.branson@uc.edu
AN  - 17188084
AU  - Branson, R. D.
AU  - Davis, K., Jr.
AU  - Butler, K. L.
DA  - Jan
DO  - 10.1016/j.amjsurg.2005.11.007
DP  - NLM
ET  - 2006/12/26
IS  - 1
KW  - Adult
African Americans/*statistics & numerical data
Age Distribution
Biomedical Research/ethics/statistics & numerical data
Clinical Protocols/classification
Clinical Trials as Topic/*ethics/*methods
Epidemiologic Research Design
Female
Humans
Male
Patient Selection/*ethics
Sex Distribution
LA  - eng
N1  - 1879-1883
Branson, Richard D
Davis, Kenneth Jr
Butler, Karyn L
Journal Article
United States
Am J Surg. 2007 Jan;193(1):32-9; discussion 40. doi: 10.1016/j.amjsurg.2005.11.007.
PY  - 2007
SN  - 0002-9610
SP  - 32-9; discussion 40
ST  - African Americans' participation in clinical research: importance, barriers, and solutions
T2  - Am J Surg
TI  - African Americans' participation in clinical research: importance, barriers, and solutions
VL  - 193
ID  - 538
ER  - 

TY  - JOUR
AB  - PURPOSE: To assess whether reactions to genetic explanations for disparities in lung cancer incidence among family members of African American patients with lung cancer are associated with willingness to participate in clinical genetics research. METHODS: Data are reported for 67 self-identified African Americans aged 18 to 55 years who completed a telephone survey assessing reactions to explanations (i.e., genetics, toxin exposure, menthol cigarettes, and race-related stress) for lung cancer disparities. Majority were female (70%), current smokers (57%), and patients' biological relatives (70%). RESULTS: Family members rated the four explanations similarly, each as believable, fair, and not too worrisome. Participants also indicated a high level of willingness to participate in genetics research (M = 4.1 +/- 1.0; scale: 1-5). Endorsements of genetics explanations for disparities as believable and fair, and toxin exposure as believable were associated significantly with willingness to participate in genetics research. CONCLUSION: These results suggest that strategies to encourage African Americans' participation in genetics research would do well to inform potential participants of how their involvement might be used to better understand important environmental factors that affect health disparities.
AD  - Social and Behavioral Research Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland 20892-2073, USA. whitede@mail.nih.gov
AN  - 20613544
AU  - White, D. B.
AU  - Koehly, L. M.
AU  - Omogbehin, A.
AU  - McBride, C. M.
C2  - PMC3518377
C6  - NIHMS420357
DA  - Aug
DO  - 10.1097/GIM.0b013e3181e5e513
DP  - NLM
ET  - 2010/07/09
IS  - 8
KW  - Adult
African Americans/*psychology
Controlled Clinical Trials as Topic/psychology
District of Columbia
Female
Genetic Counseling/*psychology
Humans
Interviews as Topic
Lung Neoplasms/*genetics/psychology
Male
Middle Aged
Patient Participation/*psychology
Risk Factors
Smoking/adverse effects
LA  - eng
N1  - 1530-0366
White, Della Brown
Koehly, Laura M
Omogbehin, Adedamola
McBride, Colleen M
Z01 HG200315-05/Intramural NIH HHS/United States
Journal Article
Research Support, N.I.H., Intramural
Genet Med. 2010 Aug;12(8):496-502. doi: 10.1097/GIM.0b013e3181e5e513.
PY  - 2010
SN  - 1098-3600 (Print)
1098-3600
SP  - 496-502
ST  - African Americans' responses to genetic explanations of lung cancer disparities and their willingness to participate in clinical genetics research
T2  - Genet Med
TI  - African Americans' responses to genetic explanations of lung cancer disparities and their willingness to participate in clinical genetics research
VL  - 12
ID  - 415
ER  - 

TY  - JOUR
AB  - Prostate cancer (PCa) is the second leading cause of cancer-related death among Black men who present with higher incidence, mortality, and survival compared to other racial groups. African immigrant men, however, are underrepresented in PCa research and thus this research sought to address that gap. This study applied a social determinants of health framework to understand the knowledge, perceptions, and behavioral tendencies regarding PCa in African immigrants. African immigrant men and women residing in different parts of the country (California, Texas, Colorado, Oklahoma, and Florida) from various faith-based organizations, African community groups, and social groups were recruited to participate in key informant interviews (n = 10) and two focus groups (n = 23). Four themes were identified in this study: (a) PCa knowledge and attitudes-while knowledge is very limited, perceptions about prostate health are very strong; (b) culture and gender identity strongly influence African health beliefs; (c) preservation of manhood; and (d) psychosocial stressors (e.g., financial, racial, immigration, lack of community, and negative perceptions of invasiveness of screening) are factors that play a major role in the overall health of African immigrant men. The results of this qualitative study unveiled perceptions, attitudes, beliefs, and knowledge of PCa among African immigrants that should inform the planning, development, and implementation of preventive programs to promote men's health and PCa awareness.
AU  - Malika, N.
AU  - Ogundimu, O.
AU  - Roberts, L.
AU  - Alemi, Q.
AU  - Casiano, C.
AU  - Montgomery, S.
DB  - Medline
DO  - 10.1177/1557988320945465
IS  - 4
KW  - adult
article
attitude
awareness
California
cancer research
clinical article
Colorado
controlled study
faith-based organization
female
Florida
gender identity
health belief
human
immigrant
immigration
interview
male
men's health
Oklahoma
perception
prostate cancer
qualitative research
social determinants of health
Texas
LA  - English
M3  - Article
N1  - L632656928
2020-08-27
PY  - 2020
SN  - 1557-9891
SP  - 1557988320945465
ST  - African Immigrant Health: Prostate Cancer Attitudes, Perceptions, and Barriers
T2  - American journal of men's health
TI  - African Immigrant Health: Prostate Cancer Attitudes, Perceptions, and Barriers
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L632656928&from=export
http://dx.doi.org/10.1177/1557988320945465
VL  - 14
ID  - 801
ER  - 

TY  - JOUR
AB  - BACKGROUND: Needs assessments are essential to developing lifestyle interventions for minority populations. To our knowledge, no physical activity (PA) needs assessment studies have been conducted for African-American (AA) breast cancer survivors. The purpose of this study was to determine the PA intervention preferences of AA breast cancer survivors and determine whether these preferences differ according to medical and sociodemographic factors. METHODS: AA breast cancer survivors (n = 475, mean age = 54 years) were recruited using ads sent via email and social media sites. Preferences for the mode of intervention delivery were assessed via web-based questionnaires. Descriptive statistics were used to characterize their interests in PA interventions, and subgroup differences were assessed. RESULTS: About 49 % (142 out of 291) of the participants who completed the survey were obese and 54 % did not meet the recommended guidelines for PA. Most (90 %) participants reported that they could participate in PA, and many (67 %) indicated that they were interested in receiving program materials. Participants expressed the greatest interest in email (50 %)-, web (48 %)-, or mail-based (45 %) over group (39 %), and telephone (10 %). Women also expressed the greatest interest in participating in studies that promoted walking and resistance or strength training. Intervention preferences did not differ significantly (P > 0.05) across sociodemographic or medical factors. CONCLUSION: Most AA breast cancer survivors can participate in PA, and many are interested in interventions that promoted walking and resistance training and were delivered via the email or web. The development of culturally sensitive interventions that provide activities consistent with preferences can assist AA breast cancer survivors to adopt and maintain a healthy lifestyle. IMPLICATIONS FOR CANCER SURVIVORS: Despite evidence that AA breast cancer survivors are at increased risk for poor breast cancer-specific outcomes, they are underrepresented in clinical trials promoting positive health behaviors. In this study, we propose to assess their exercise preferences and receptivity to a culturally appropriate PA intervention developed in collaboration with the Sisters Network Inc. Health promotion programs developed in collaboration with a community-based organization may aid in the development of research tools and resources that AA breast cancer survivors are receptive to using.
AD  - Department of Behavioral and Community Health, University of North Texas Health Science Center, 3500 Camp Bowie Blvd, Fort Worth, TX, 76017, USA, Raheem.Paxton@unthsc.edu.
AN  - 24043292
AU  - Paxton, R. J.
AU  - Nayak, P.
AU  - Taylor, W. C.
AU  - Chang, S.
AU  - Courneya, K. S.
AU  - Schover, L.
AU  - Hodges, K.
AU  - Jones, L. A.
C2  - PMC4096148
C6  - NIHMS525203
DA  - Mar
DO  - 10.1007/s11764-013-0307-5
DP  - NLM
ET  - 2013/09/18
IS  - 1
KW  - Adult
African Americans/*psychology
Aged
Breast Neoplasms/*psychology/therapy
Cd-rom
Comorbidity
Data Collection
Electronic Mail
Female
Habits
*Health Services Needs and Demand
Humans
Internet
Life Style
Middle Aged
*Motor Activity
Obesity/epidemiology/psychology
Pamphlets
Patient Education as Topic/*methods
*Patient Preference
Practice Guidelines as Topic
Quality of Life
Resistance Training
Sedentary Behavior
Surveys and Questionnaires
Survivors/*psychology
Telephone
Texas
LA  - eng
N1  - 1932-2267
Paxton, Raheem J
Nayak, Pratibha
Taylor, Wendell C
Chang, Shine
Courneya, Kerry S
Schover, Leslie
Hodges, Kelly
Jones, Lovell A
K01 CA158000/CA/NCI NIH HHS/United States
P30 CA016672/CA/NCI NIH HHS/United States
5K01CA158000/CA/NCI NIH HHS/United States
CA016672/CA/NCI NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
J Cancer Surviv. 2014 Mar;8(1):31-8. doi: 10.1007/s11764-013-0307-5. Epub 2013 Sep 17.
PY  - 2014
SN  - 1932-2259 (Print)
1932-2259
SP  - 31-8
ST  - African-American breast cancer survivors' preferences for various types of physical activity interventions: a Sisters Network Inc. web-based survey
T2  - J Cancer Surviv
TI  - African-American breast cancer survivors' preferences for various types of physical activity interventions: a Sisters Network Inc. web-based survey
VL  - 8
ID  - 316
ER  - 

TY  - JOUR
AB  - A genome-wide scan of high-risk prostate cancer families in North America has demonstrated linkage of a particular marker to Chromosome 1q (HPC1). An even greater proportion of African-American families have shown linkage to HPC1. Therefore, investigators at the National Human Genome Research Institute (NHGRI) in collaboration with Howard University and a predominantly African-American group of urologists established the African-American Hereditary Prostate Cancer (AAHPC) Study Network to confirm the suggested linkage of HPC in African Americans with a gene on Chromosome 1. Blood samples from recruited families were sent to Howard University for extraction of DNA. The DNA was sent to NHGRI at NIH where the genotyping and genetic sequence analysis was conducted. Genotype data are merged with pedigree information so that statistical analysis can be performed to establish potential linkage. From March 1, 1998, to June 1, 1999, a total of 40 African-American families have been recruited who met the study criteria. Preliminary results suggest that racial/ethnicity grouping may affect the incidence and extent of linkage of prostate cancer to specific loci. The importance of these findings lays in the future treatment of genetic-based diseases.
AD  - Dept of Urology, Karmanos Cancer Institute, Wayne State University, Detroit, MI 48201, USA.
AN  - 12653398
AU  - Powell, I. J.
AU  - Carpten, J.
AU  - Dunston, G.
AU  - Kittles, R.
AU  - Bennett, J.
AU  - Hoke, G.
AU  - Pettaway, C.
AU  - Weinrich, S.
AU  - Vijayakumar, S.
AU  - Ahaghotu, C. A.
AU  - Boykin, W.
AU  - Mason, T.
AU  - Royal, C.
AU  - Baffoe-Bonnie, A.
AU  - Bailey-Wilson, J.
AU  - Berg, K.
AU  - Trent, J.
AU  - Collins, F.
C2  - PMC2593987
DA  - Apr
DP  - NLM
ET  - 2003/03/26
IS  - 4
KW  - Aged
Antigens, Surface/*genetics
Asian Continental Ancestry Group/*genetics
Chromosomes, Human, Pair 1/*genetics
*Genetic Linkage
*Genetic Predisposition to Disease
Genetic Research
Health Surveys
Humans
Incidence
Male
Middle Aged
Models, Genetic
Nerve Tissue Proteins/*genetics
Pedigree
Prostatic Neoplasms/*epidemiology/*genetics
Risk Factors
Sensitivity and Specificity
Surveys and Questionnaires
Syntaxin 1
United States/epidemiology
LA  - eng
N1  - Powell, I J
Carpten, J
Dunston, G
Kittles, R
Bennett, J
Hoke, G
Pettaway, C
Weinrich, S
Vijayakumar, S
Ahaghotu, C A
Boykin, W
Mason, T
Royal, C
Baffoe-Bonnie, A
Bailey-Wilson, J
Berg, K
Trent, J
Collins, F
HG 75418/HG/NHGRI NIH HHS/United States
Comparative Study
Journal Article
Research Support, U.S. Gov't, P.H.S.
J Natl Med Assoc. 2001 Apr;93(4):120-3.
PY  - 2001
SN  - 0027-9684 (Print)
0027-9684
SP  - 120-3
ST  - African-American heredity prostate cancer study: a model for genetic research
T2  - J Natl Med Assoc
TI  - African-American heredity prostate cancer study: a model for genetic research
VL  - 93
ID  - 652
ER  - 

TY  - JOUR
AB  - This qualitative study explores African-American men's perceptions about prostate cancer (CaP) screening and assesses the acceptability of various strategies and settings for interventions to promote informed decision-making. We conducted four focus groups among healthy men (n=37) and two groups among CaP survivors (n=14) aged 35-70 in the greater Boston area, USA. Also, we conducted 14 in-depth interviews with key community informants. The audio-taped focus groups and interviews were transcribed, coded, and analyzed for emergent themes. Except for survivors, men had insufficient information about the prostate, the elevated cancer risk among African-Americans, and the controversy concerning screening. Key informants and focus group participants cited inadequate access to services, mistrust of the health system, poor relationships with medical providers, and perceived threats to male sexuality as major barriers to receiving prostate care. They recommended that interventions be embedded in community settings, address men's overall health, and be administered by culturally competent providers, and repeatedly emphasized trust building and a sustained presence in the community. Efforts to present balanced information about CaP screening may be hindered by lingering mistrust of the medical system, poor relationships between patients and providers, and enthusiastic support for screening on the part of CaP survivors. Implications for interventions are discussed.
AD  - Harvard School of Public Health, Society, Human Development and Health, Boston, MA 02115, USA. jennifer_allen@dfci.harvard.edu
AN  - 17399877
AU  - Allen, J. D.
AU  - Kennedy, M.
AU  - Wilson-Glover, A.
AU  - Gilligan, T. D.
DA  - Jun
DO  - 10.1016/j.socscimed.2007.01.007
DP  - NLM
ET  - 2007/04/03
IS  - 11
KW  - Adult
*African Americans
Aged
*Attitude to Health
Boston
Focus Groups
Humans
Male
Middle Aged
*Patient Education as Topic
Patient Participation
*Prostatic Neoplasms
LA  - eng
N1  - Allen, Jennifer D
Kennedy, Mark
Wilson-Glover, Athene
Gilligan, Timothy D
Journal Article
England
Soc Sci Med. 2007 Jun;64(11):2189-200. doi: 10.1016/j.socscimed.2007.01.007. Epub 2007 Mar 30.
PY  - 2007
SN  - 0277-9536 (Print)
0277-9536
SP  - 2189-200
ST  - African-American men's perceptions about prostate cancer: implications for designing educational interventions
T2  - Soc Sci Med
TI  - African-American men's perceptions about prostate cancer: implications for designing educational interventions
VL  - 64
ID  - 531
ER  - 

TY  - JOUR
AB  - Introduction: Low rates of accrual of African-American (AA) patients with cancer to therapeutic clinical trials (CTs) represent a serious and modifiable racial disparity in healthcare that impedes the development of promising cancer therapies. Suboptimal physician-patient consultation communication is a barrier to the accrual of patients with cancer of any race, but communication difficulties are compounded with AA patients. Providing tailored health messages (THM) to AA patients and their physician about CTs has the potential to improve communication, lower barriers to accrual and ameliorate health disparities. Objective: (1) Demonstrate the efficacy of THM to increase patient activation as measured by direct observation. (2) Demonstrate the efficacy of THM to improve patient outcomes associated with barriers to AA participation. (3) Explore associations among preconsultation levels of: (A) trust in medical researchers, (B) knowledge and attitudes towards CTs, (C) patient-family member congruence in decision-making, and (D) involvement/information preferences, and group assignment. Methods and analysis: First, using established methods, we will develop THM materials. Second, the efficacy of the intervention is determined in a 2 by 2 factorial randomised controlled trial to test the effectiveness of (1) providing 357 AA patients with cancer with THM with 2 different 'depths' of tailoring and (2) either providing feedback to oncologists about the patients' trial THM or not. The primary analysis compares patient engaged communication in 4 groups preconsultation and postconsultation. Ethics and dissemination: This study was approved by the Virginia Commonwealth University Institutional Review Board. To facilitate use of the THM intervention in diverse settings, we will convene 'user groups' at 3 major US cancer centres. To facilitate dissemination, we will post all materials and the implementation guide in publicly available locations.
AN  - WOS:000391303600014
AU  - Brown, R. F.
AU  - Davis, R.
AU  - Genderson, M. W.
AU  - Grant, S.
AU  - Cadet, D.
AU  - Lessard, M.
AU  - Alpert, J.
AU  - Ward, J.
AU  - Ginder, G.
DO  - 10.1136/bmjopen-2016-012864
IS  - 12
N1  - e012864
27986738
PY  - 2016
SN  - 2044-6055
ST  - African-American patients with cancer Talking About Clinical Trials (TACT) with oncologists during consultations: evaluating the efficacy of tailored health messages in a randomised controlled trial-the TACT study protocol
T2  - Bmj Open
TI  - African-American patients with cancer Talking About Clinical Trials (TACT) with oncologists during consultations: evaluating the efficacy of tailored health messages in a randomised controlled trial-the TACT study protocol
VL  - 6
ID  - 2956
ER  - 

TY  - JOUR
AB  - BACKGROUND: African-American (AA) race has been associated with a worse outcome in breast cancer. It is unclear whether this is due to biological factors, socioeconomic factors, or both. METHODS: The records from 2 independent cohorts of breast cancer patients treated on institutional protocols with mastectomy and adjuvant (n = 1456) or neoadjuvant (n = 684) doxorubicin-based chemotherapy were retrospectively reviewed. RESULTS: The adjuvant (Adj) chemotherapy cohort included 1142 Caucasian (CA), 186 Hispanic (HI), and 128 (AA) patients. The neoadjuvant (Neo) chemotherapy protocols included 448 CA, 114 HI, and 122 AA patients. In both groups, AA patients had later-stage tumors (Adj P = .017; Neo P = .051), a higher rate of estrogen receptor (ER)-negative disease (Adj P = .054; Neo P = .039), and a worse 10-year actuarial overall survival rate than CA or HI patients (Adj, 52%, 62%, and 62%, respectively, P = .009; Neo, 40%, 50%, and 56%, respectively, P = .015). In multivariate analyses, AA race remained independently associated with a poorer overall survival rate in both cohorts (Adj, hazard ratio = 1.39, P = .018; Neo, hazard ratio = 1.37, P = .02). CONCLUSIONS: The data suggest that AA race is associated with less favorable biological tumor features, such as an increased likelihood of ER-negative disease, than those found in CA and HI patients. Such differences in tumor biology, as well as previously described socioeconomic factors, likely contribute to the lower rate of survival in the AA breast cancer population.
AD  - Department of Radiation Oncology, University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA. wwoodward@mdanderson.org
AN  - 17061247
AU  - Woodward, W. A.
AU  - Huang, E. H.
AU  - McNeese, M. D.
AU  - Perkins, G. H.
AU  - Tucker, S. L.
AU  - Strom, E. A.
AU  - Middleton, L.
AU  - Hahn, K.
AU  - Hortobagyi, G. N.
AU  - Buchholz, T. A.
DA  - Dec 1
DO  - 10.1002/cncr.22281
DP  - NLM
ET  - 2006/10/25
IS  - 11
KW  - Adolescent
Adult
*African Americans
Aged
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Breast Neoplasms/drug therapy/*ethnology/surgery/*therapy
Chemotherapy, Adjuvant
Clinical Trials as Topic
Cohort Studies
Doxorubicin/administration & dosage
Female
Humans
Mastectomy
Middle Aged
Neoadjuvant Therapy
Retrospective Studies
Tamoxifen/administration & dosage
LA  - eng
N1  - Woodward, Wendy A
Huang, Eugene H
McNeese, Marsha D
Perkins, George H
Tucker, Susan L
Strom, Eric A
Middleton, Lavinia
Hahn, Karin
Hortobagyi, Gabriel N
Buchholz, Thomas A
CA16672/CA/NCI NIH HHS/United States
T32CA77050/CA/NCI NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
United States
Cancer. 2006 Dec 1;107(11):2662-8. doi: 10.1002/cncr.22281.
PY  - 2006
SN  - 0008-543X (Print)
0008-543x
SP  - 2662-8
ST  - African-American race is associated with a poorer overall survival rate for breast cancer patients treated with mastectomy and doxorubicin-based chemotherapy
T2  - Cancer
TI  - African-American race is associated with a poorer overall survival rate for breast cancer patients treated with mastectomy and doxorubicin-based chemotherapy
VL  - 107
ID  - 545
ER  - 

TY  - JOUR
AB  - Objectives: Our purpose was to determine long-term maintenance of physical activity (PA) following the 48-week Women's Lifestyle PA program, targeted/tailored for African-American women. Methods: The parent study consisted of a 3-arm randomized clinical trial with 3 assessment points: baseline (pre-intervention); 24 weeks post-baseline (end active intervention); and 48 weeks post-baseline (end maintenance intervention). Present analyses supplement the original results by adding a long-term maintenance assessment that occurred 2 to 4 years post-baseline. Participants were 288 African-American women aged 40 to 65 without major signs/symptoms of pulmonary/cardiovascular disease. The active intervention included 5 group meetings, with 9 personal motivational calls, 9 automated motivational calls, or no calls between meetings. The maintenance intervention included one group meeting and either 2 calls or no calls. PA was assessed with the Community Healthy Activities Model Program for Seniors. Results: Retention was 90%. Over long-term maintenance, there was a decline in PA, but levels remained significantly higher than baseline for moderate/ vigorous PA (p < .001), leisure moderate/ vigorous PA (p < .001) and walking (p = .006). Variations by condition/site were not statistically significant. Conclusions: Our findings suggest that long-term maintenance of PA increases resulting from group meetings in an active intervention occur when followed by a maintenance intervention.
AN  - WOS:000404468400013
AU  - Wilbur, J.
AU  - Miller, A. M.
AU  - Buchholz, S. W.
AU  - Fogg, L. F.
AU  - Braun, L. T.
AU  - Halloway, S.
AU  - Schoeny, M. E.
DA  - Jul
DO  - 10.5993/AJHB.41.4.13
IS  - 4
N1  - 28601108
PY  - 2017
SN  - 1945-7359
SP  - 484-496
ST  - African-American Women's Long-term Maintenance of Physical Activity Following a Randomized Controlled Trial
T2  - American Journal of Health Behavior
TI  - African-American Women's Long-term Maintenance of Physical Activity Following a Randomized Controlled Trial
VL  - 41
ID  - 2894
ER  - 

TY  - JOUR
AB  - Eight focus groups (N=45) led by an experienced investigator were used to explore African-American women's beliefs and attitudes about breast health, breast cancer, breast cancer prevention, medical research and ways to communicate information about research to the African-American community. Content analysis of session transcripts revealed at least six emerging themes concerning research participation: 1) importance of informed consent; 2) lack of understanding regarding the placebo concept, which was viewed as 'unfair' treatment; 3) distrust of the research process; 4) importance of medical research as a way to help others and increase knowledge 'if used properly;' 5) importance of reimbursing participants for their time and costs; and 6) the perception that research is for people who have the disease, not for healthy people, with participation possibly leading to development of the disease.Major themes related to breast cancer prevention included: 1) awareness of breast cancer risk factors limited to family history; 2) confusion about the difference between screening and prevention; 3) perceived low susceptibility to breast cancer; and 4) fatalistic view of breast cancer outcome.These results identify unique aspects of the African-American view of medical research and breast cancer prevention that have important implications for developing culturally relevant strategies to increase recruitment in cancer prevention trials and participation in breast cancer risk reduction.
AD  - Harbor-UCLA Medical Center, 1124 W Carson St, Bldg J-3, Torrance, CA 90509; llillington@rei.edu
AN  - 107048251. Language: English. Entry Date: 20010831. Revision Date: 20150711. Publication Type: Journal Article
AU  - Lillington, L.
AU  - Johnson, I.
AU  - Chlebowski, R.
DB  - CINAHL Complete
DP  - EBSCOhost
IS  - 1
KW  - Research Subjects
Breast Neoplasms -- Psychosocial Factors
Black Persons
Focus Groups
Female
Adult
Middle Age
Aged
Aged, 80 and Over
Health Beliefs
Audiorecording
Videorecording
Content Analysis
Health Knowledge
Research Subject Recruitment
Denial (Psychology)
Funding Source
Human
N1  - research; tables/charts. Journal Subset: Peer Reviewed; USA. Grant Information: State of California Breast Cancer Research Program Grant No. 93-18850 and the US Dept of the Army Breast Cancer Research Program Grant No. DAMD17-94-J-4163. NLM UID: 100967825.
PY  - 2000
SN  - 1531-3069
SP  - 20-25
ST  - African-American women's perspectives on research participation
T2  - Medicine of the Americas
TI  - African-American women's perspectives on research participation
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=107048251&site=ehost-live&scope=site
VL  - 1
ID  - 1853
ER  - 

TY  - JOUR
AB  - Background: Geriatric patients and minority patients are often under-represented in cancer clinical trials. The presence of multiple comorbidities makes geriatric patients ineligible for most clinical trials. Racial diversity may vary by geographical location and socio-economically backward areas may have a very different racial mix. The increase in cancer incidence in geriatric patients' raises the question of applicability of the results is such clinical trials. This study also explores the representation of different races in phase 3 clinical trials conducted in the past 10 years. Methods: Data about Phase III trials was extracted from the clinical trials.gov for 3 common solid organs and 3 hematological malignancies [breast, colon, lung, diffuse large B-cell lymphoma (DLBCL), acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL)]. The time period studied was for the past 10 years and included only adult patients (≥18 years). The age and race distribution of the patient population in these trials were extracted and analyzed. Results: Geriatric patients and minorities are under-represented in all phase III cancer clinical trials. The range of the proportion of geriatric patients varied from 10% to 40%. African American and Asian patients are under-represented in all phase III cancer clinical trials. Conclusions: The results of phase III clinical trials that are currently conducted on non-geriatric and Caucasian patient population may not meaningfully be applicable to geriatric patients and minorities. This study highlights the disparity of age and race for patients enrolled in clinical trials as against the patients seen in the real world.
AD  - Medical Center of Central Georgia, Mercer University Macon, GA 31201, The United States.
Division of Hematology/Oncology, Georgia Cancer Center, Augusta University Augusta, GA 30909, The United States.
AN  - 33042473
AU  - Gopishetty, S.
AU  - Kota, V.
AU  - Guddati, A. K.
C2  - PMC7540092
DP  - NLM
ET  - 2020/10/13
IS  - 9
KW  - Geriatric population
cancer clinical trial
minorities
racial distribution
LA  - eng
N1  - 1943-8141
Gopishetty, Swathi
Kota, Vamsi
Guddati, Achuta K
Journal Article
Am J Transl Res. 2020 Sep 15;12(9):5977-5983. eCollection 2020.
PY  - 2020
SN  - 1943-8141 (Print)
1943-8141
SP  - 5977-5983
ST  - Age and race distribution in patients in phase III oncology clinical trials
T2  - Am J Transl Res
TI  - Age and race distribution in patients in phase III oncology clinical trials
VL  - 12
ID  - 21
ER  - 

TY  - JOUR
AB  - Study Objective: Menarche is a critical milestone in a woman's life, and historically has been determined using several approaches. The goals of this study were to: (1) determine age at menarche from multiple reports of parents and adolescent participants in a prospective study; (2) examine factors affecting age at menarche; and (3) determine correlates of menarche and pubertal tempo. Design: Longitudinal observational study. Setting: Three sites of the Breast Cancer and the Environment Research Program. Participants: Girls enrolled at 6-8 years of age. Interventions and Main Outcome Measures: Parental and participant reported age of menarche, and tempo of puberty. Results: There were 946 girls who were assigned an age of menarche. The correlation between parent and participant reports was high (Spearman R = 0.799, P <.001), and the difference was insignificant. Median age at menarche overall was 12.25 years. Compared with black participants, Hispanic girls were more likely to have menarche earlier, whereas white and Asian girls were more likely to have menarche later. Age of menarche was highly correlated with age of breast development (Spearman R = 0.547; P <.001), and inversely with body mass index (Spearman R = −0.403; P <.001). Tempo (interval of age of breast development to menarche) was slower in those with earlier breast development. Conclusion: Parental and adolescent reports of menarche are highly correlated. Earlier breast maturation was associated with slower tempo through puberty. Body mass index had a greater effect on age at menarche than did race and ethnicity. © 2018 North American Society for Pediatric and Adolescent Gynecology
AD  - Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
Department of Environmental Medicine and Public Health, Icahn School of Medicine at Mount Sinai, New York, New York, United States
Department of Environmental Health, University of Cincinnati College of Medicine, Cincinnati, Ohio, United States
Division of Environmental and Occupational Disease Control, California Department of Public Health, Richmond, California, United States
Department of Pediatrics, Kaiser Permanente, San Francisco, California, United States
Division of Research, Kaiser Permanente, Oakland, California, United States
AU  - Biro, F. M.
AU  - Pajak, A.
AU  - Wolff, M. S.
AU  - Pinney, S. M.
AU  - Windham, G. C.
AU  - Galvez, M. P.
AU  - Greenspan, L. C.
AU  - Kushi, L. H.
AU  - Teitelbaum, S. L.
DB  - Scopus
DO  - 10.1016/j.jpag.2018.05.002
IS  - 4
KW  - Breast development
Menarche
Pubertal tempo
Puberty
M3  - Article
N1  - Cited By :39
Export Date: 22 March 2021
PY  - 2018
SP  - 339-345
ST  - Age of Menarche in a Longitudinal US Cohort
T2  - Journal of Pediatric and Adolescent Gynecology
TI  - Age of Menarche in a Longitudinal US Cohort
UR  - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85047364897&doi=10.1016%2fj.jpag.2018.05.002&partnerID=40&md5=0fb6e32662e408434348239e24abb199
VL  - 31
ID  - 2264
ER  - 

TY  - JOUR
AB  - Over 17 million U.S. women are in the peri‐ and post‐menopausal age range (45 ‐ 55), and by the year 2015 nearly half of U.S. women will be post‐menopausal. Of these, 25‐33% will experience moderate to severe menopausal symptoms, and all will be faced with decisions related to maintaining their health through mid‐life and beyond. Hormone Replacement Therapy (HRT) is the standard pharmacologic intervention for menopausal symptoms against which other therapies are measured. Concerns about breast cancer and thromboembolism risk, the need for safe alternatives for symptom relief among women in whom HRT is contraindicated, and the resistance to HRT due to its side effects fuel the search for alternatives. The primary aim of this randomized, controlled trial is to compare the effects of three alternative treatments utilizing phytoestrogens, HRT, and placebo on the frequency and intensity of vasomotor symptoms measured by the Wiklund Menopause Symptom Checklist and daily vasomotor symptom diaries. The alternative treatments chosen for the study are a single herbal formula of black cohosh, a multibotanical formula containing black cohosh, alfalfa, boron, chasteberry, dong quai, false unicorn, licorice, oats, pomegranate, and Siberian ginseng, and soy diet counseling in addition to the multibotanical formula. The findings of the Women's Health Initiative study published in July 2002 gave the medical and research communities new information about the long‐term risk of HRT use. In response to these findings, the study design allows women to be randomized either to the 5‐arm trial that includes HRT, or to be randomized only to 4 of the 5 arms: one of the three herbal groups or placebo, without the chance of being assigned to HRT. Secondary aims are to compare the effects of three alternative treatments, HRT, and placebo on: 1. vaginal cytology (vaginal maturation index) 2. serum lipids (total cholesterol, HDL and LDL cholesterol, triglycerides) 3. bone mineral density (hip and spine dual energy x‐ray absorptiometry scan) 4. glucose metabolism (insulin, fasting blood glucose) 5. clotting factors (fibrinogen, PAI‐1). Approximately 400 peri‐ and post‐menopausal women will be recruited and randomized to one of 5 or one of 4 treatment arms for one year. Primary and secondary outcomes will be measured at baseline, 3, 6, and 12 months. Changes in outcomes will be compared between the groups taking alternative treatments and those in the HRT and placebo groups.
AN  - CN-01509325
AU  - Nct
KW  - Hormones
Hot Flashes
Phytoestrogens
PY  - 2003
ST  - Alternative Therapies for Menopause: a Randomized Trial
T2  - https://clinicaltrials.gov/show/NCT00061711
TI  - Alternative Therapies for Menopause: a Randomized Trial
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01509325/full
ID  - 1636
ER  - 

TY  - JOUR
AB  - The strict exclusion criteria of clinical trials in multiple myeloma (MM) limit the enrollment of patients reflective of a general patient population. Using the Connect MM Registry data representative of an unselected newly diagnosed MM population, 563 of 1406 patients (40.0%) were identified as ineligible for clinical trials. This study provides insight into potential modifications of standard eligibility criteria that can lead to improved trial design. Background: The performance of multiple myeloma (MM) therapies in a general patient population and specific eligibility criteria that might limit enrollment into randomized controlled trials (RCTs) have not been evaluated in depth. This study aimed to determine if improvements seen with MM therapies in RCTs are reflected in the general patient population and to identify eligibility criteria that can be modified to increase enrollment. Patients and Methods: The Connect MM Registry is a prospective observational cohort study of patients with newly diagnosed MM (NDMM) in the United States. Using common RCT exclusion criteria collected from 16 published studies, patients in the registry were categorized according to their eligibility for inclusion in RCTs. Results: On the basis of common criteria, 563 of 1406 of registry patients (40.0%) are ineligible for RCTs. Criteria leading to exclusion included M-protein <= 1.0 g/dL (25.2%), creatinine > 2.5 mg/dL (13.9%), low absolute neutrophil count (10.0%), and low hemoglobin (9.6%). Significantly more RCT-ineligible versus RCT-eligible patients had hypercalcemia (11.0% vs. 5.5%), elevated creatinine levels (38.9% vs. 6.2%), low hemoglobin levels (59.5% vs. 39.5%), or International Staging System stage III disease (40.1% vs. 22.1%; P <.001 for all comparisons). RCT-ineligible patients had a lower 3-year survival rate than RCT-eligible patients (63% vs. 70%). The incidence of serious adverse events was similar between groups. Conclusion: Of patients with NDMM enrolled in the Connect MM Registry, 40% are ineligible for RCTs. This study provides insight into potential modifications of standard eligibility criteria that can lead to improved RCT design and accelerated enrollment. (C) 2017 Elsevier Inc. All rights reserved.
AN  - WOS:000410990600006
AU  - Shah, J. J.
AU  - Abonour, R.
AU  - Gasparetto, C.
AU  - Hardin, J. W.
AU  - Toomey, K.
AU  - Narang, M.
AU  - Srinivasan, S.
AU  - Kitali, A.
AU  - Zafar, F.
AU  - Flick, E. D.
AU  - Rifkin, R. M.
DA  - Sep
DO  - 10.1016/j.clml.2017.06.013
IS  - 9
N1  - 28886839
PY  - 2017
SN  - 2152-2650
SP  - 575-+
ST  - Analysis of Common Eligibility Criteria of Randomized Controlled Trials in Newly Diagnosed Multiple Myeloma Patients and Extrapolating Outcomes
T2  - Clinical Lymphoma Myeloma & Leukemia
TI  - Analysis of Common Eligibility Criteria of Randomized Controlled Trials in Newly Diagnosed Multiple Myeloma Patients and Extrapolating Outcomes
VL  - 17
ID  - 2889
ER  - 

TY  - JOUR
AB  - In June of 2008 we initiated a breast clinic designed to serve patients regardless of funding status. We analyzed age, race,tumor size, nodal status, estrogen, progesterone, and her-2-neu status. We compared our results to NSABP B-06 (nodal status), B-15 (estrogen, progesterone, and Her-2-neu receptor status), B-18, and B-27 (age, race, and tumor size) to determine whether our patient population was similar to patients included in these trials. Forty-nine patients with newly diagnosed breast cancer were treated during our first year (53 total cancers). Eight patients had noninvasive cancer; 45 had invasive disease. The mean age was 52.2 +/- 12.2 years compared to a mean age of 48.4 +/- 9.8 years in the B-06 trial (P = 0.005). Thirty six patients were African American (74%) compared to 10% and 12% in the NSABP B-18 and B-27 trials (P < 0.00001). A total of 23 of our patients with invasive cancer had involved axillary lymph nodes which was statistically more common than the 35.3% of node positive patients in the B-06 trial (P = 0.03). Tumor size (3.6 +/- 3.3 cm), estrogen (54.4%), and progesterone (52.8%) receptor status were similar to NSABP trials. Only 6 (13.3%) of our patients were considered Her-2-neu positive compared to 29.4% in the B-15 trial which was significantly less prevalent (P = 0.02). Significantly different demographic and tumor characteristics were identified in our inner city breast cancer patient population compared to NSABP patients. These results question the validity of using recommendations from large cooperative group trials in the development of treatment plans for our inner city patient population.
AD  - Department of Surgery, Atlanta Medical Center, Atlanta, Georgia 30312, USA.
AN  - 20583523
AU  - Colfry, A. J., 3rd
AU  - Humphries, T.
AU  - Fuhrman, G. M.
DA  - Jun
DP  - NLM
ET  - 2010/06/30
IS  - 6
KW  - Adult
African Americans/*statistics & numerical data
Aged
Aged, 80 and over
Breast Neoplasms/*ethnology/metabolism/pathology/*surgery
Female
Georgia/epidemiology
Humans
Lymphatic Metastasis
Middle Aged
Neoplasms, Hormone-Dependent/ethnology
*Randomized Controlled Trials as Topic
Receptor, ErbB-2/metabolism
Receptors, Estradiol/metabolism
Receptors, Progesterone/metabolism
Urban Population/*statistics & numerical data
LA  - eng
N1  - Colfry, Alfred J 3rd
Humphries, Timothy
Fuhrman, George M
Comparative Study
Journal Article
United States
Am Surg. 2010 Jun;76(6):640-3.
PY  - 2010
SN  - 0003-1348 (Print)
0003-1348
SP  - 640-3
ST  - Analysis of demographic and tumor characteristics of an inner city breast cancer patient population compared with patients treated in National Surgical Adjuvant Breast and Bowel Project trials
T2  - Am Surg
TI  - Analysis of demographic and tumor characteristics of an inner city breast cancer patient population compared with patients treated in National Surgical Adjuvant Breast and Bowel Project trials
VL  - 76
ID  - 418
ER  - 

TY  - JOUR
AB  - Anastrozole, a nonsteroidal selective aromatase inhibitor, has recently been approved in the US and several other countries for the adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. In the Arimidex, Tamoxifen alone or in Combination (ATAC) trial, anastrazole 1mg was significantly more effective than tamoxifen 20mg or combined treatment (17 and 19% relative risk reduction) for disease-free survival in postmenopausal women with early breast cancer. black triangle Anastrazole was also significantly more effective than tamoxifen for time to tumour recurrence and the odds of a primary contralateral tumour as a first event. During the first 2 years of treatment with anastrozole, tamoxifen or the combination, patient quality of life was similar in all treatment groups. Compared with tamoxifen, anastrozole was associated with a significantly lower incidence of vaginal bleeding, vaginal discharge, hot flushes, endometrial cancer, ischaemic cerebrovascular events, venous thromboembolic events and deep vein thrombosis including pulmonary embolism; tamoxifen was associated with a lower incidence of musculoskeletal disorders and fracture.
AD  - Adis International Limited, Auckland, New Zealand. demail@adis.co.nz
AN  - 12421108
AU  - Wellington, K.
AU  - Faulds, D. M.
DO  - 10.2165/00003495-200262170-00010
DP  - NLM
ET  - 2002/11/08
IS  - 17
KW  - Administration, Oral
Anastrozole
Antineoplastic Agents, Hormonal/therapeutic use
*Aromatase Inhibitors
Breast Neoplasms/*drug therapy/pathology
Chemotherapy, Adjuvant
Disease-Free Survival
Drug Therapy, Combination
Enzyme Inhibitors/pharmacokinetics/*therapeutic use
Female
Half-Life
Humans
*Neoplasm Recurrence, Local
Neoplasm Staging
Nitriles/adverse effects/pharmacokinetics/*therapeutic use
Randomized Controlled Trials as Topic
Tamoxifen/therapeutic use
Treatment Outcome
Triazoles/adverse effects/pharmacokinetics/*therapeutic use
LA  - eng
N1  - Wellington, Keri
Faulds, Diana M
Journal Article
Review
New Zealand
Drugs. 2002;62(17):2483-90; discussion 2491-2. doi: 10.2165/00003495-200262170-00010.
PY  - 2002
SN  - 0012-6667 (Print)
0012-6667
SP  - 2483-90; discussion 2491-2
ST  - Anastrozole: in early breast cancer
T2  - Drugs
TI  - Anastrozole: in early breast cancer
VL  - 62
ID  - 661
ER  - 

TY  - JOUR
AB  - Objective: To describe the theory of community connection defined as close relationships with women and men who are members of a neighborhood, a church, a work group, or an organization. Antecedent and mediator variables related to community connection are identified. Design/methods: A cross-sectional design was used to assess for relationships among theorized antecedents and mediators of community connection in a sample of 144 African American women aged 21 years and older (mean = 54.9) who had been diagnosed with invasive/infiltrating ductal carcinoma. Measurement and Analyses: Community connection was measured with the relational health indices-community subscale. Mediator analysis was conducted to assess significance of the indirect effects of the mediator variables, which were fear, breast cancer knowledge, and isolation. Results: Community connection was found to be associated with three of the four antecedents, cancer stigma, stress, and spirituality, but not associated with fatalism. Effects were mediated primarily through fear and isolation with isolation as was more dominant of the two mediators. Surprisingly, breast cancer knowledge showed no significant mediator role. Conclusions: The importance of isolation and fear as mediators of community connection is highlighted by this research. The study could serve as a model for other researchers seeking to understand connection in ethnic groups and communities. (PsycINFO Database Record (c) 2018 APA, all rights reserved)
AD  - Heiney, Sue P., College of Nursing, 1601 Green Street, Columbia, SC, US, 29208
AN  - 2011-30357-003
AU  - Heiney, Sue P.
AU  - Hazlett, Linda J.
AU  - Weinrich, Sally P.
AU  - Wells, Linda M.
AU  - Adams, Swann Arp
AU  - Underwood, Sandra Millon
AU  - Parrish, Rudolph S.
DB  - psyh
DO  - 10.1891/1541-6577.25.4.252
DP  - EBSCOhost
IS  - 4
KW  - community connection
African American
women
breast cancer
isolation
fear
Adult
African Americans
Breast Neoplasms
Female
Humans
Middle Aged
Social Support
Blacks
Community Involvement
Human Females
Interpersonal Relationships
Social Isolation
N1  - Palmetto Health Cancer Centers, Columbia, SC, US. Release Date: 20120416. Correction Date: 20180517. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: English. Conference Information: Cancer Nursing Research Conference, Feb, 2009, Orlando, FL, US. Conference Note: An earlier version of this article was presented at the aforementioned conference. Major Descriptor: Blacks; Breast Neoplasms; Community Involvement; Human Females; Interpersonal Relationships. Minor Descriptor: Fear; Social Isolation. Classification: Cancer (3293). Population: Human (10); Female (40). Location: US. Age Group: Adulthood (18 yrs & older) (300); Young Adulthood (18-29 yrs) (320); Thirties (30-39 yrs) (340); Middle Age (40-64 yrs) (360); Aged (65 yrs & older) (380). Tests & Measures: Negative Interaction Scale; Urban Life Stress Scale; Profile of Mood States-Brief Version; Breast Cancer Knowledge Scale; UCLA Loneliness Scale-3; Religiousness Scale DOI: 10.1037/t51443-000; Relational Health Indices DOI: 10.1037/t56815-000; Powe Fatalism Inventory DOI: 10.1037/t52746-000. Methodology: Empirical Study; Quantitative Study. References Available: Y. Page Count: 19. Issue Publication Date: 2011. Copyright Statement: Springer Publishing Company. 2011.
Sponsor: National Cancer Institute. Grant: R01CA107305. Recipients: No recipient indicated
PY  - 2011
SN  - 1541-6577
1945-7286
SP  - 252-270
ST  - Antecedents and mediators of community connection in African American women with breast cancer
T2  - Research and Theory for Nursing Practice: An International Journal
TI  - Antecedents and mediators of community connection in African American women with breast cancer
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2011-30357-003&site=ehost-live&scope=site
heineys@mailbox.sc.edu
VL  - 25
ID  - 1747
ER  - 

TY  - JOUR
AB  - Background: Pancreatic ductal adenocarcinoma (PDAC) remains a leading cause of cancer mortality for which novel gene therapy approaches relying on tumor-tropic adenoviruses are being tested. Methods: We obtained the global transcriptional profiling of primary PDAC using RNA from eight xenografted primary PDAC, three primary PDAC bulk tissues, three chronic pancreatitis and three normal pancreatic tissues. The Affymetrix GeneChip HG-U133A was used. The results of the expression profiles were validated applying immunohistochemical and western blot analysis on a set of 34 primary PDAC and 10 established PDAC cell lines. Permissivity to viral vectors used for gene therapy, Adenovirus 5 and Adeno-Associated Viruses 5 and 6, was assessed on PDAC cell lines. Results: The analysis of the expression profiles allowed the identification of two clearly distinguishable phenotypes according to the expression of interferon-stimulated genes. The two phenotypes could be readily recognized by immunohistochemical detection of the Myxovirus-resistance A protein, whose expression reflects the activation of interferon dependent pathways. The two molecular phenotypes discovered in primary carcinomas were also observed among established pancreatic adenocarcinoma cell lines, suggesting that these phenotypes are an intrinsic characteristic of cancer cells independent of their interaction with the host's microenvironment. The two pancreatic cancer phenotypes are characterized by different permissivity to viral vectors used for gene therapy, as cell lines expressing interferon stimulated genes resisted to Adenovirus 5 mediated lysis in vitro. Similar results were observed when cells were transduced with Adeno-Associated Viruses 5 and 6. Conclusion: Our study identified two molecular phenotypes of pancreatic cancer, characterized by a differential expression of interferon-stimulated genes and easily recognized by the expression of the Myxovirus-resistance A protein. We suggest that the detection of these two phenotypes might help the selection of patients enrolled in virally-mediated gene therapy trials.
AN  - WOS:000275960000001
AU  - Monsurro, V.
AU  - Beghelli, S.
AU  - Wang, R.
AU  - Barbi, S.
AU  - Coin, S.
AU  - Di Pasquale, G.
AU  - Bersani, S.
AU  - Castellucci, M.
AU  - Sorio, C.
AU  - Eleuteri, S.
AU  - Worschech, A.
AU  - Chiorini, J. A.
AU  - Pederzoli, P.
AU  - Alter, H.
AU  - Marincola, F. M.
AU  - Scarpa, A.
DA  - Jan
DO  - 10.1186/1479-5876-8-10
N1  - 10
20113473
PY  - 2010
ST  - Anti-viral state segregates two molecular phenotypes of pancreatic adenocarcinoma: potential relevance for adenoviral gene therapy
T2  - Journal of Translational Medicine
TI  - Anti-viral state segregates two molecular phenotypes of pancreatic adenocarcinoma: potential relevance for adenoviral gene therapy
VL  - 8
ID  - 3128
ER  - 

TY  - JOUR
AB  - Triple negative breast cancer (TNBC) is a heterogeneous disease that comprises 15-20% of all breast cancers and is more frequently seen in younger women, African-Americans, and BRCA1 expression. Advanced TNBC carries aggressive features and is associated with overall poor outcomes. Unfortunately, there are no targeted therapies available for non-BRCA associated TNBC, which remains a high unmet therapeutic need. One emerging treatment modality includes antibody-drug conjugates which are highly selective monoclonal antibodies conjugated to cytotoxic agents, designed to deliver cytotoxic drugs to antigen-expressing tumor cells. This review will highlight three antibody-drug conjugates currently being evaluated in TNBC (CDX-011, SGN-LIV1a, IMMU-132), including one that has been given Breakthrough Therapy designation from the US FDA.
AD  - Perlmutter Cancer Center at New York University Langone Health, New York, NY 10016, USA.
AN  - 30175620
AU  - Tray, N.
AU  - Adams, S.
AU  - Esteva, F. J.
DA  - Oct
DO  - 10.2217/fon-2018-0131
DP  - NLM
ET  - 2018/09/04
IS  - 25
KW  - Antibodies, Monoclonal/therapeutic use
Antibodies, Monoclonal, Humanized/therapeutic use
Camptothecin/analogs & derivatives/therapeutic use
Clinical Trials as Topic
Female
Humans
Immunoconjugates/*therapeutic use
Membrane Glycoproteins/analysis
Poly(ADP-ribose) Polymerase Inhibitors/therapeutic use
Triple Negative Breast Neoplasms/*drug therapy/immunology
biological
breast neoplasm
drug delivery
LA  - eng
N1  - 1744-8301
Tray, Nancy
Adams, Sylvia
Esteva, Francisco J
Journal Article
Review
England
Future Oncol. 2018 Oct;14(25):2651-2661. doi: 10.2217/fon-2018-0131. Epub 2018 Sep 3.
PY  - 2018
SN  - 1479-6694
SP  - 2651-2661
ST  - Antibody-drug conjugates in triple negative breast cancer
T2  - Future Oncol
TI  - Antibody-drug conjugates in triple negative breast cancer
VL  - 14
ID  - 108
ER  - 

TY  - JOUR
AB  - SCOPE: Plant polyphenols are widespread in the American diet, yet estimated intake is uncertain. We examine the application of the Polyphenol Explorer® (PED) database to quantify polyphenol and ellagitannin (ET) intake of men with prostate cancer and tested the implementation of diets restricted in polyphenols or ETs. METHODS AND RESULTS: Twenty-four men enrolled in a 4-week trial were randomized to usual, low-polyphenol or low-ET diet. Estimated polyphenol and ET intakes were calculated from 3-day diet records utilizing the PED. Urine and plasma metabolites were quantified by UPLC-MS. Adherence to the restricted diets was 95% for the low polyphenol and 98% for low-ET diet. In the usual diet, estimated dietary polyphenol intake was 1568 ± 939 mg/day, with coffee/tea beverages (1112 ± 1028 mg/day) being the largest contributors and estimated dietary ET intake was 12 ± 13 mg/day. The low-polyphenol and low-ET groups resulted in a reduction of total polyphenols by 45% and 85%, respectively, and omission of dietary ETs. UPLC analysis of urinary host and microbial metabolites reflect ET intake. CONCLUSION: PED is a useful database for assessing exposure to polyphenols. Diets restricted in total polyphenol or ET intake are feasible and UPLC assessment of ET metabolites is reflective of dietary intake.
AD  - The OSU Interdisciplinary Ph.D. Program in Nutrition, Ohio State University, Columbus, OH, USA.
Comprehensive Cancer Center, Ohio State University, Columbus, OH, USA.
Division of Biostatistics, Ohio State University, Columbus, OH, USA.
Department of Food Science and Technology, Ohio State University, Columbus, OH, USA.
Department of Urology, Ohio State University, Columbus, OH, USA.
Department of Internal Medicine, Division of Medical Oncology, Ohio State University, Columbus, OH, USA.
AN  - 27813248
AU  - Roberts, K. M.
AU  - Grainger, E. M.
AU  - Thomas-Ahner, J. M.
AU  - Hinton, A.
AU  - Gu, J.
AU  - Riedl, K. M.
AU  - Vodovotz, Y.
AU  - Abaza, R.
AU  - Schwartz, S. J.
AU  - Clinton, S. K.
C2  - PMC7249702
C6  - NIHMS1568565
DA  - Mar
DO  - 10.1002/mnfr.201600224
DP  - NLM
ET  - 2016/11/05
IS  - 3
KW  - Aged
Databases, Factual
Diet
Humans
Hydrolyzable Tannins/metabolism/pharmacokinetics/*pharmacology
Male
Middle Aged
Polyphenols/administration & dosage/*pharmacology
Prostatic Neoplasms/*diet therapy/metabolism
*Black raspberries
*Ellagitannins
*Polyphenol explorer database
*Polyphenols
*Urolithins
LA  - eng
N1  - 1613-4133
Roberts, Kristen M
Grainger, Elizabeth M
Thomas-Ahner, Jennifer M
Hinton, Alice
Gu, Junnan
Riedl, Kenneth M
Vodovotz, Yael
Abaza, Ronney
Schwartz, Steven J
Clinton, Steven K
P30 CA016058/CA/NCI NIH HHS/United States
U01 CA188250/CA/NCI NIH HHS/United States
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Mol Nutr Food Res. 2017 Mar;61(3):10.1002/mnfr.201600224. doi: 10.1002/mnfr.201600224. Epub 2017 Jan 17.
PY  - 2017
SN  - 1613-4125 (Print)
1613-4125
ST  - Application of a low polyphenol or low ellagitannin dietary intervention and its impact on ellagitannin metabolism in men
T2  - Mol Nutr Food Res
TI  - Application of a low polyphenol or low ellagitannin dietary intervention and its impact on ellagitannin metabolism in men
VL  - 61
ID  - 196
ER  - 

TY  - JOUR
AB  - This article describes a new approach to formative research in which projective techniques commonly used in psychological assessment were adapted for use in focus groups to help design colorectal-cancer screening materials for African American men and women. Participants (N = 20) were divided into six "design teams." Each team was given a selection of design supplies and asked to create and discuss a visual layout for screening materials. Participants chose design elements that reflected visual preferences that they felt would connect meaningfully with other African Americans. The dynamics within the design teams were different than in traditional focus groups, with participants having more control over the group's direction. Using projective techniques helped draw out unique information from participants by allowing them to "project" their opinions onto objects. This approach may be a valuable tool for health-promotion and health-communication practitioners seeking insight on the implicit values of a priority population.
AD  - Health Communication Research Laboratory, Saint Louis University School of Public Health, St. Louis, Missouri, USA.
AN  - 17003247
AU  - Wiehagen, T.
AU  - Caito, N. M.
AU  - Thompson, V. S.
AU  - Casey, C. M.
AU  - Weaver, N. L.
AU  - Jupka, K.
AU  - Kreuter, M. W.
DA  - Apr
DO  - 10.1177/1524839906289818
DP  - NLM
ET  - 2006/09/28
IS  - 2
KW  - Adult
African Americans/*education/*psychology
Aged
Art
Colorectal Neoplasms/*ethnology/*prevention & control/psychology
Community Participation/*methods/psychology
Culture
Female
*Focus Groups
Health Education/*methods
Health Promotion/*methods
Humans
Male
Medical Illustration
Middle Aged
Photography
*Projective Techniques
*Teaching Materials
United States
LA  - eng
N1  - Wiehagen, Theresa
Caito, Nicole M
Thompson, Vetta Sanders
Casey, Christopher M
Weaver, Nancy L
Jupka, Keri
Kreuter, Matthew W
Journal Article
United States
Health Promot Pract. 2007 Apr;8(2):164-72. doi: 10.1177/1524839906289818. Epub 2006 Sep 26.
PY  - 2007
SN  - 1524-8399 (Print)
1524-8399
SP  - 164-72
ST  - Applying projective techniques to formative research in health communication development
T2  - Health Promot Pract
TI  - Applying projective techniques to formative research in health communication development
VL  - 8
ID  - 550
ER  - 

TY  - JOUR
AB  - BACKGROUND: Prostate cancer screening (PCS) is controversial. Ideally, patients should understand the risks and benefits of screening before undergoing PSA testing. This study assessed whether primary care physicians routinely discuss PCS and explored the barriers to and facilitators of these discussions. METHODS: Qualitative pilot study involving in-depth, semistructured interviews with 18 purposively sampled, academic and community-based primary care physicians. Barriers and facilitators of PCS discussions were ascertained using both interviews and chart-stimulated recall--a technique utilizing patient charts to probe recall and provide context to physician decision-making during clinic encounters. Analysis was performed using consensus conferences based on grounded theory techniques. RESULTS: All 18 participating physicians reported that they generally discussed PCS with patients, though 6 reported sometimes ordering PSA tests without discussion. A PCS discussion occurred in only 16 (36%) of the 44 patient-physician encounters when patients were due for PCS that also met criteria for chart-stimulated recall. Barriers to PCS discussion were patient comorbidity, limited education/health literacy, prior refusal of care, physician forgetfulness, acute-care visits, and lack of time. Facilitators of PCS discussion included patient-requested screening, highly educated patients, family history of prostate cancer, African-American race, visits for routine physicals, review of previous PSA results, extra time during encounters, and reminder systems. CONCLUSIONS: PCS discussions sometimes do not occur. Important barriers to discussion are inadequate time for health maintenance, physician forgetfulness, and patient characteristics. Future research should explore using educational and decision support interventions to involve more patients in PCS decisions.
AD  - Division of General Internal Medicine, University of Pennsylvania School of Medicine, 1221 Blockley Hall, 423 Guardian Drive, Philadelphia, PA 19104, USA. carmen.guerra@uphs.upenn.edu
AN  - 17549576
AU  - Guerra, C. E.
AU  - Jacobs, S. E.
AU  - Holmes, J. H.
AU  - Shea, J. A.
C2  - PMC2219711
DA  - Jul
DO  - 10.1007/s11606-007-0142-3
DP  - NLM
ET  - 2007/06/06
IS  - 7
KW  - Adult
*Attitude of Health Personnel
Cohort Studies
Contraindications
Female
Humans
Interviews as Topic
Male
Mass Screening/*methods
Middle Aged
Patient Education as Topic
Patient Participation/*psychology
Pennsylvania
*Physician-Patient Relations
Physicians, Family
Pilot Projects
Practice Patterns, Physicians'/statistics & numerical data
Primary Health Care/*methods
Prostate-Specific Antigen/blood
Prostatic Neoplasms/*diagnosis
LA  - eng
N1  - 1525-1497
Guerra, Carmen E
Jacobs, Samantha E
Holmes, John H
Shea, Judy A
K01 CA097925/CA/NCI NIH HHS/United States
P50 CA105641/CA/NCI NIH HHS/United States
K01 CA97925/CA/NCI NIH HHS/United States
P50-CA105641/CA/NCI NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
J Gen Intern Med. 2007 Jul;22(7):901-7. doi: 10.1007/s11606-007-0142-3.
PY  - 2007
SN  - 0884-8734 (Print)
0884-8734
SP  - 901-7
ST  - Are physicians discussing prostate cancer screening with their patients and why or why not? A pilot study
T2  - J Gen Intern Med
TI  - Are physicians discussing prostate cancer screening with their patients and why or why not? A pilot study
VL  - 22
ID  - 527
ER  - 

TY  - JOUR
AB  - Background: The alleviation of cancer health disparities makes it necessary to understand and apply the knowledge about cultural behaviors in the design of interventions deemed culturally appropriate. Objective: This review aimed to provide an overview of the ways in which strategies were used to facilitate the cultural appropriateness of psychosocial interventions delivered to African American cancer survivors. Methods: An electronic and hand search of 5 major databases was performed to identify intervention studies that targeted African American cancer patients/survivors 50 years or older. We review researchers’ efforts to achieve culturally appropriate intervention research by evaluating whether peripheral, evidential, linguistic, constituent-involving, or sociocultural strategies were used. Results: Only 6 intervention studies met the criteria for inclusion in this review, with each study using 1 or more strategies to achieve cultural appropriateness. However, few studies incorporated sociocultural factors in the intervention design. Conclusion: Strategies to achieve cultural appropriateness in psychosocial interventions targeting older African Americans have focused more on enhancing recruitment and retention and less on the inclusion of sociocultural concepts into the content of the intervention. Implications for Practice: Intervention studies delivered to older African American cancer patients/survivors should aim to incorporate those concepts of relevance to the population and likely to facilitate healthcare outcomes. (PsycINFO Database Record (c) 2018 APA, all rights reserved)
AD  - Hamilton, Jill B., School of Nursing, University of North Carolina at Chapel Hill, CB# 7460, Chapel Hill, NC, US, 27599-7460
AN  - 2013-15129-011
AU  - Hamilton, Jill B.
AU  - Agarwal, Mansi
AU  - Song, Lixin
AU  - Moore, Angelo D.
AU  - Best, Nakia
DB  - psyh
DO  - 10.1097/NCC.0b013e31821e0b11
DP  - EBSCOhost
IS  - 2
KW  - psychosocial interventions
older cancer survivors
cultural behaviors
strategies
African Americans
Cultural Competency
Health Services Research
Humans
Middle Aged
Neoplasms
Randomized Controlled Trials as Topic
Survivors
Intervention
Psychosocial Development
Sociocultural Factors
Aging
N1  - School of Nursing, University of North Carolina, Chapel Hill, NC, US. Release Date: 20140505. Correction Date: 20180215. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: English. Major Descriptor: Intervention; Neoplasms; Psychosocial Development; Sociocultural Factors. Minor Descriptor: Aging; Strategies; Survivors. Classification: Cancer (3293). Population: Human (10). Location: US. Tests & Measures: Expanded Prostate Cancer Index Composite; Cancer Survivor Knowledge Scale; International Physical Activity Scale; Block 98 Food Frequency Questionnaire; Social Support for Eating and Exercise Questionnaire; Impact of Events Scale; Modified Coping Strategy Questionnaire; Self-efficacy for Symptom Control Inventory; Health Self-Efficacy Scale; Profile of Mood States; Self-Control Scale; Profile of Mood States--Short Form DOI: 10.1037/t20023-000; Functional Assessment of Cancer Therapy DOI: 10.1037/t04236-000; Symptom Distress Scale DOI: 10.1037/t59986-000; SF-36 Health Survey; Mental Health Inventory DOI: 10.1037/t02354-000; Negative Emotions Scales DOI: 10.1037/t06772-000; Social Support Questionnaire. Methodology: Literature Review. References Available: Y. Page Count: 12. Issue Publication Date: Mar-Apr, 2012. Publication History: Accepted Date: Apr 5, 2011. Copyright Statement: Unauthorized reproduction of this article is prohibited. Wolters Kluwer Health. 2012.
PY  - 2012
SN  - 0162-220X
1538-9804
SP  - e12-e23
ST  - Are psychosocial interventions targeting older African American cancer survivors culturally appropriate? A review of the literature
T2  - Cancer Nursing
TI  - Are psychosocial interventions targeting older African American cancer survivors culturally appropriate? A review of the literature
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2013-15129-011&site=ehost-live&scope=site
jhamilto@email.unc.edu
VL  - 35
ID  - 1736
ER  - 

TY  - JOUR
AB  - OBJECTIVES: Although it does not alter the ERCC1 phenotype, the ERCC1 500C>T (rs11615) polymorphism has undergone a myriad of investigations into its role as a marker for nucleotide excision repair (NER) function in different races, diseases and treatment outcomes. The goal of our study was to test the hypothesis that 500C>T is in linkage disequilibrium (LD) with causative alleles, and that these haplotypes are more frequent in Caucasians with melanoma than in healthy Caucasians or African Americans. DESIGN: In this case-control study, we selected race-specific ERCC1 single-nucleotide polymorphism (SNPs), conducted LD analysis with ERCC1 500C>T and compared the frequency of ERCC1 diplotypes in Caucasians with melanoma (n=165), healthy Caucasians (n=150) and healthy African Americans (n=159). The haplotype was further studied using a fusion gene containing multiple ERCC1 SNPs. SETTING: Large cancer institute in the USA. PARTICIPANTS: A total of 165 Caucasian melanoma patients, 159 healthy Caucasian controls and 159 African American healthy controls. Men and women were enrolled in the clinical trial; however, since the screening trial included prostate cancer screening in addition to screening for other cancers, only male controls were available. OUTCOME MEASURES: The outcome measures were melanoma risk in Caucasians, and LD between ERCC1 SNP, N118N and other race-specific allelic variants. RESULTS: When compared to ERCC1 500C>T alone, a race-specific three-SNP variant haplotype in ERCC1 (comprised of rs11615, rs3212950 and rs3212948) was even more frequent in Caucasians with melanoma than in healthy Caucasians (p=0.0034) or African Americans (p<0.0001). A plasmid containing the variant haplotype was not differentially expressed. CONCLUSIONS: We demonstrate that ERCC1 500C>T participates in a previously characterised cancer-risk haplotype found more frequently in Caucasians, while LD is weak in African Americans; this haplotype appears to also be related to melanoma. It is therefore likely that ERCC1 500C>T is only a valid NER, disease or treatment outcome marker in Caucasians.
AD  - Molecular Pharmacology Section, Medical Oncology Branch, Center for Cancer Research, Bethesda, Maryland, USA.
AN  - 23293248
AU  - Gao, R.
AU  - Reece, K. M.
AU  - Sissung, T.
AU  - Fu, S. H.
AU  - Venzon, D. J.
AU  - Reed, E.
AU  - Spencer, S. D.
AU  - Price, D. K.
AU  - Figg, W. D.
C2  - PMC3549215
DA  - Jan 3
DO  - 10.1136/bmjopen-2012-002030
DP  - NLM
ET  - 2013/01/08
IS  - 1
LA  - eng
N1  - 2044-6055
Gao, Rui
Reece, Kelie M
Sissung, Tristan
Fu, Samuel H
Venzon, David J
Reed, Eddie
Spencer, Shawn D
Price, Douglas K
Figg, William D
Journal Article
BMJ Open. 2013 Jan 3;3(1):e002030. doi: 10.1136/bmjopen-2012-002030.
PY  - 2013
SN  - 2044-6055
ST  - Are race-specific ERCC1 haplotypes in melanoma cases versus controls related to the predictive and prognostic value of ERCC1 N118N?
T2  - BMJ Open
TI  - Are race-specific ERCC1 haplotypes in melanoma cases versus controls related to the predictive and prognostic value of ERCC1 N118N?
VL  - 3
ID  - 343
ER  - 

TY  - JOUR
AB  - Background: It is widely claimed that racial and ethnic minorities, especially in the US, are less willing than non-minority individuals to participate in health research. Yet, there is a paucity of empirical data to substantiate this claim. Methods and Findings: We performed a comprehensive literature search to identify all published health research studies that report consent rates by race or ethnicity. We found 20 health research studies that reported consent rates by race or ethnicity. These 20 studies reported the enrollment decisions of over 70,000 individuals for a broad range of research, from interviews to drug treatment to surgical trials. Eighteen of the twenty studies were single-site studies conducted exclusively in the US or multi-site studies where the majority of sites (i.e., at least 2/3) were in the US. Of the remaining two studies, the Concorde study was conducted at 74 sites in the United Kingdom, Ireland, and France, while the Delta study was conducted at 152 sites in Europe and 23 sites in Australia and New Zealand. For the three interview or non-intervention studies, African-Americans had a nonsignificantly lower overall consent rate than non-Hispanic whites (82.2% versus 83.5%; odds ratio [OR] = 0.92; 95% confidence interval [CI] 0.84-1.02). For these same three studies, Hispanics had a nonsignificantly higher overall consent rate than non-Hispanic whites (86.1% versus 83.5%; OR = 1.37; 95% CI 0.94-1.98). For the ten clinical intervention studies, African-Americans' overall consent rate was nonsignificantly higher than that of non-Hispanic whites (45.3% versus 41.8%; OR = 1.06; 95% CI 0.78-1.45). For these same ten studies, Hispanics had a statistically significant higher overall consent rate than non-Hispanic whites (55.9% versus 41.8%; OR = 1.33; 95% CI 1.08-1.65). For the seven surgery trials, which report all minority groups together, minorities as a group had a nonsignificantly higher overall consent rate than non-Hispanic whites (65.8% versus 47.8%; OR = 1.26; 95% CI 0.89-1.77). Given the preponderance of US sites, the vast majority of these individuals from minority groups were African-Americans or Hispanics from the US. Conclusions: We found very small differences in the willingness of minorities, most of whom were African-Americans and Hispanics in the US, to participate in health research compared to non-Hispanic whites. These findings, based on the research enrollment decisions of over 70,000 individuals, the vast majority from the US, suggest that racial and ethnic minorities in the US are as willing as non-Hispanic whites to participate in health research. Hence, efforts to increase minority participation in health research should focus on ensuring access to health research for all groups, rather than changing minority attitudes. Copyright: © 2006 Wendler et al.
AD  - D. Wendler, Department of Clinical Bioethics, National Institutes of Health Clinical Center, National Institutes of Health, Bethesda, MD, United States
AU  - Wendler, D.
AU  - Kington, R.
AU  - Madans, J.
AU  - Van Wye, G.
AU  - Christ-Schmidt, H.
AU  - Pratt, L. A.
AU  - Brawley, O. W.
AU  - Gross, C. P.
AU  - Emanuel, E.
DB  - Embase
DO  - 10.1371/journal.pmed.0030019
IS  - 2
KW  - anti human immunodeficiency virus agent
antiarrhythmic agent
antineoplastic agent
estrogen
neuroleptic agent
adenoidectomy
African American
alcoholism
article
Australia
breast cancer
cancer radiotherapy
cardiovascular disease
Caucasian
clinical trial
coronary artery bypass graft
coronary artery disease
ethnology
France
heart arrhythmia
heart infarction
Hispanic
human
Human immunodeficiency virus infection
informed consent
interview
Ireland
medical research
melanoma
meta analysis
minority group
New Zealand
otitis media
patient participation
percutaneous transluminal angioplasty
pharyngitis
race difference
schizophrenia
statistical significance
substance abuse
systematic review
tonsillectomy
United Kingdom
United States
LA  - English
M3  - Article
N1  - L43362873
2006-03-23
PY  - 2006
SN  - 1549-1277
1549-1676
SP  - 0201-0210
ST  - Are racial and ethnic minorities less willing to participate in health research?
T2  - PLoS Medicine
TI  - Are racial and ethnic minorities less willing to participate in health research?
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L43362873&from=export
http://dx.doi.org/10.1371/journal.pmed.0030019
http://medicine.plosjournals.org/archive/1549-1676/3/2/pdf/10.1371_journal.pmed.0030019-L.pdf
VL  - 3
ID  - 1253
ER  - 

TY  - JOUR
AB  - While the probability of a woman developing invasive breast cancer at age <40 is low (<1%), mammography use reported among younger women (age <40) is substantial, and varies by race/ethnicity. Little detail is known about mammography use among women aged <40, particularly by race/ethnicity. We describe racial/ethnic differences in: (1) mammography indication after considering underlying risk factors (breast symptoms and family history); (2) follow-up recommendations, and (3) mammography outcomes for first mammograms in women aged <40. These 1996-2005 Breast Cancer Surveillance Consortium data are prospectively pooled from seven U.S. mammography registries. Our community-based sample included 99,615 women aged 18-39 who self-reported race/ethnicity and presented for a first mammogram (screening or diagnostic) with no history of breast cancer. Multivariable analyses controlled for registry site, age, family history of breast cancer, symptoms, and exam year. Overall, 73.6% of the women in our sample were seen for a screening mammogram. Following screening mammography, African American (AA) women were more likely than white women to be recommended for additional workup [relative risk (RR): 1.15 (95% CI: 1.07-1.23)]. Following diagnostic mammography, AA [RR: 1.30 (95% CI: 1.17-1.44)] and Asian [RR: 1.44 (95% CI: 1.26-1.64)] women were more likely to be recommended for biopsy, fine-needle aspiration, or surgical consultation. Depending on race/ethnicity, and considering the rate of true positive to total first screening mammograms of younger women, a women has a likelihood of a true positive of 1 in 363-1,122; she has a likelihood of a false positive of 1 in 7-10. This study of community-based practice found racial/ethnic variability in mammography indication, recommendations, and outcomes among women undergoing first mammography before 40. These findings highlight important areas for future research to understand the motivating factors for these practice patterns and the implications of early mammography use.
AD  - Department of Family and Community Medicine, University of Missouri, MA306 Medical Sciences Bldg, 1 Hospital Drive, Columbia, MO 65212, USA. kappj@health.missouri.edu
AN  - 20204501
AU  - Kapp, J. M.
AU  - Walker, R.
AU  - Haneuse, S.
AU  - Buist, D. S.
AU  - Yankaskas, B. C.
C2  - PMC2927744
C6  - NIHMS196438
DA  - Nov
DO  - 10.1007/s10549-010-0812-4
DP  - NLM
ET  - 2010/03/06
IS  - 1
KW  - Adolescent
Adult
African Americans/statistics & numerical data
Age Factors
Asian Americans/statistics & numerical data
Biopsy
Biopsy, Fine-Needle
Breast Neoplasms/*diagnostic imaging/ethnology
Continental Population Groups/*statistics & numerical data
European Continental Ancestry Group/statistics & numerical data
False Positive Reactions
Female
Healthcare Disparities/*ethnology
Hispanic Americans/statistics & numerical data
Humans
Mammography/*statistics & numerical data
Mass Screening/methods/*statistics & numerical data
Patient Selection
Practice Guidelines as Topic
Practice Patterns, Physicians'/*statistics & numerical data
Predictive Value of Tests
Prospective Studies
Referral and Consultation
Registries
Risk Assessment
Risk Factors
United States/epidemiology
Young Adult
LA  - eng
N1  - 1573-7217
Kapp, Julie M
Walker, Rod
Haneuse, Sebastien
Buist, Diana S M
Yankaskas, Bonnie C
R03CA134196/CA/NCI NIH HHS/United States
U01 CA063740/CA/NCI NIH HHS/United States
U01CA70040/CA/NCI NIH HHS/United States
U01CA63740/CA/NCI NIH HHS/United States
U01CA69976/CA/NCI NIH HHS/United States
U01 CA070040/CA/NCI NIH HHS/United States
U01CA70013/CA/NCI NIH HHS/United States
U01 CA086082/CA/NCI NIH HHS/United States
U01 CA063731/CA/NCI NIH HHS/United States
U01 CA086076/CA/NCI NIH HHS/United States
U01CA63736/CA/NCI NIH HHS/United States
U01CA86082/CA/NCI NIH HHS/United States
U01 CA069976/CA/NCI NIH HHS/United States
U01CA86076/CA/NCI NIH HHS/United States
U01 CA063736/CA/NCI NIH HHS/United States
R03 CA134196/CA/NCI NIH HHS/United States
U01 CA070013/CA/NCI NIH HHS/United States
U01CA63731/CA/NCI NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Breast Cancer Res Treat. 2010 Nov;124(1):213-22. doi: 10.1007/s10549-010-0812-4. Epub 2010 Mar 4.
PY  - 2010
SN  - 0167-6806 (Print)
0167-6806
SP  - 213-22
ST  - Are there racial/ethnic disparities among women younger than 40 undergoing mammography?
T2  - Breast Cancer Res Treat
TI  - Are there racial/ethnic disparities among women younger than 40 undergoing mammography?
VL  - 124
ID  - 428
ER  - 

TY  - JOUR
AB  - The purpose of this study was to determine the efficacy of women with breast cancer as teachers of the importance of breast cancer screening to their first-degree female relatives. The sample was restricted to low-income working age women recruited from four hospitals. The study design was a randomized clinical trial. At each hospital, breast cancer patients (probands) were randomized into one of two study groups: (i) intensive, individual educational training on breast cancer screening or (ii) standard clinic education on breast cancer screening. The probands were instructed to teach at least one of their first-degree female relatives (21+ years of age) about breast cancer screening techniques. Three to six months after the enrollment of the probands, their relatives were contacted by telephone to determine breast cancer screening practices. A total of 79 probands and 96 relatives participated in the study. Relatives in the education group when compared with the control group were: 1.25 times more likely to have clinical breast examination (p = 0.005), 2.83 times more likely to have scheduled a clinical breast examination (p = 0.046), and, 1.36 times more likely to have been told about performing breast self-examination (p = 0.05). Additionally, relatives in the education group were more likely to have received a pamphlet on breast cancer screening (RR = 1.58, p = 0.009) and have discussed the importance of breast cancer screening (RR = 1.33, p = 0.020) from the proband. Special education training did not impact mammography utilization of the relatives. From these findings, a tri-ethnic group of low-income women with breast cancer can be effective teachers of breast cancer screening practices, at least for promoting clinical breast examination and transmitting messaging for performance of breast self-examination if given the adequate training. © 2007, Copyright the Authors.
AD  - Department of Preventive Medicine, Rush University Medical Center, Chicago, IL, United States
Advocate Lutheran General Hospital, Park Ridge, IL, United States
Division of Medical Oncology, Rush University Medical Center, Chicago, IL, United States
John R. Stroger, Jr. Hospital, Chicago, IL, United States
Perinatal Center, Northwestern Memorial Hospital, Chicago, IL, United States
Department of Preventive Medicine, Rush University Medical Center, 1700 W. Van Buren, Chicago, IL 60612, United States
AU  - Oleske, D. M.
AU  - Galvez, A.
AU  - Cobleigh, M. A.
AU  - Ganschow, P.
AU  - Ayala, L. D.
DB  - Scopus
DO  - 10.1111/j.1524-4741.2006.00358.x
IS  - 1
KW  - African-Americans
Breast cancer screening
Breast screening education
Latinos
Low income women
Minority women
Randomized clinical trial
M3  - Article
N1  - Cited By :4
Export Date: 22 March 2021
PY  - 2007
SP  - 19-27
ST  - Are tri-ethnic low-income women with breast cancer effective teachers of the importance of breast cancer screening to their first-degree relatives? Results from a randomized clinical trial
T2  - Breast Journal
TI  - Are tri-ethnic low-income women with breast cancer effective teachers of the importance of breast cancer screening to their first-degree relatives? Results from a randomized clinical trial
UR  - https://www.scopus.com/inward/record.uri?eid=2-s2.0-33846019605&doi=10.1111%2fj.1524-4741.2006.00358.x&partnerID=40&md5=3cc888b97bd3e2118b262112a3f712e7
VL  - 13
ID  - 2566
ER  - 

TY  - JOUR
AB  - BACKGROUND: Genetic variation research (GVR) may raise concerns about misuse of information and discrimination. Seemingly contradictory positive views about GVR have also been reported. OBJECTIVE: To dissect this inconsistency, our objectives were to: (1) explore open-ended views of GVR and (2) quantify views of and willingness to participate in GVR by race. DESIGN: Cross-sectional study. PARTICIPANTS: 801 African-American and white prior participants in a case-control genetic epidemiology study of colon cancer risks (NCCCS). MEASURES: Qualitative measures evaluated responses to questions about good and bad things about GVR. Quantitative measures evaluated positive and negative perceptions, perceptions of discrimination, and likelihood of future participation by race. RESULTS: Open-ended queries about GVR resulted in few "negative" responses. In closed-ended questions, however, African Americans were more likely to feel that such research would: result in higher insurance (41% vs. 30%, p = 0.008), not benefit minorities (29% vs. 14%, p=<0.001), reinforce racism (32% vs. 20%, p = 0.002), and use minorities as guinea pigs (27% vs. 6%, p < 0.001). Overall, after adjustment for potential confounding factors, African-American race remained inversely associated with feeling "very positive" about GVR (46% vs. 57%, p = 0.035). In contrast, African Americans were as likely as whites to express willingness to participate in future GVR studies (46%). CONCLUSIONS: Open-ended questions about GVR were unlikely to spontaneously generate "negative" responses. In contrast, when presented specific examples of potentially negative implications, more respondents agreed, and minorities were more likely to express concerns. This suggests that while participants appear generally positive about GVR, their inability to articulate views regarding these complex concepts may require that researchers engage lay audiences, ensure accurate understanding, and provide them with language to express concerns.
AD  - Emory University School of Medicine, 49 Jessie Hill Jr. Drive, Atlanta, GA 30331, USA. jcbusse@emory.edu
AN  - 19101773
AU  - Bussey-Jones, J.
AU  - Henderson, G.
AU  - Garrett, J.
AU  - Moloney, M.
AU  - Blumenthal, C.
AU  - Corbie-Smith, G.
C2  - PMC2642575
DA  - Mar
DO  - 10.1007/s11606-008-0883-7
DP  - NLM
ET  - 2008/12/23
IS  - 3
KW  - Adult
*African Americans
Aged
Aged, 80 and over
Colonic Neoplasms/*ethnology/genetics
Cross-Sectional Studies
*European Continental Ancestry Group
Female
Genetic Predisposition to Disease/*ethnology
*Health Knowledge, Attitudes, Practice
Humans
Interviews as Topic
Male
Middle Aged
Patient Participation
Public Opinion
*Research Subjects
LA  - eng
N1  - 1525-1497
Bussey-Jones, Jada
Henderson, Gail
Garrett, Joanne
Moloney, Mairead
Blumenthal, Connie
Corbie-Smith, Giselle
P50HG004488/HG/NHGRI NIH HHS/United States
1-R01-HG002830/HG/NHGRI NIH HHS/United States
P50 HG004488/HG/NHGRI NIH HHS/United States
R01 HG002830-03/HG/NHGRI NIH HHS/United States
R01 HG002830/HG/NHGRI NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
J Gen Intern Med. 2009 Mar;24(3):299-304. doi: 10.1007/s11606-008-0883-7. Epub 2008 Dec 20.
PY  - 2009
SN  - 0884-8734 (Print)
0884-8734
SP  - 299-304
ST  - Asking the right questions: views on genetic variation research among black and white research participants
T2  - J Gen Intern Med
TI  - Asking the right questions: views on genetic variation research among black and white research participants
VL  - 24
ID  - 481
ER  - 

TY  - JOUR
AB  - Background: NSAIDs appear to moderately reduce prostate cancer risk. However, evidence is limited on whether NSAIDs protect against prostate cancer mortality (death from prostate cancer among men without a cancer history) and case fatality (death from prostate cancer among men with prostate cancer), and whether benefits are consistent in white and black men. This study investigated associations of aspirin and non-aspirin (NA) NSAID use with prostate cancer incidence, mortality, and case fatality in a population-based cohort of white and black men. Methods: We included 6,594 men (5,060 white and 1,534 black) from the Atherosclerosis Risk in Communities study without a cancer history at enrollment from 1987 to 1989. NSAID use was assessed at four study visits (1987–1998). Cancer outcomes were ascertained through 2012. Cox proportional hazards regression was used to estimate adjusted HRs, overall and by race. Results: Aspirin use was not associated with prostate cancer incidence. However, aspirin use was inversely associated with prostate cancer mortality [HR, 0.59; 95% confidence interval (CI), 0.36–0.96]. This association was consistent among white and black men and appeared restricted to men using aspirin daily and/or for cardiovascular disease prevention. Aspirin use was inversely associated with case fatality (HR, 0.45; 95% CI, 0.22–0.94). NA-NSAID use was not associated with these endpoints. Conclusions: Aspirin use was inversely associated with prostate cancer mortality and case fatality among white and black men. Impact: If confirmed by additional studies, benefits of aspirin for preventing prostate cancer mortality may need to be factored into risk–benefit calculations of men considering an aspirin regimen.
AD  - E.A. Platz, Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States
AU  - Hurwitz, L. M.
AU  - Joshu, C. E.
AU  - Barber, J. R.
AU  - Prizment, A. E.
AU  - Vitolins, M. Z.
AU  - Jones, M. R.
AU  - Folsom, A. R.
AU  - Han, M.
AU  - Platz, E. A.
DB  - Embase
Medline
DO  - 10.1158/1055-9965.EPI-18-0965
IS  - 3
KW  - acetylsalicylic acid
hydroxymethylglutaryl coenzyme A reductase inhibitor
nonsteroid antiinflammatory agent
adult
article
atherosclerosis
cancer incidence
cancer mortality
cancer research
cardiovascular disease
case fatality rate
clinical outcome
cohort analysis
disease association
human
major clinical study
male
priority journal
proportional hazards model
prospective study
prostate cancer
race
LA  - English
M3  - Article
N1  - L2001762488
2019-04-05
2019-04-15
PY  - 2019
SN  - 1055-9965
SP  - 563-569
ST  - Aspirin and non-aspirin NSAID use and prostate cancer incidence, mortality, and case fatality in the Atherosclerosis Risk in Communities study
T2  - Cancer Epidemiology Biomarkers and Prevention
TI  - Aspirin and non-aspirin NSAID use and prostate cancer incidence, mortality, and case fatality in the Atherosclerosis Risk in Communities study
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L2001762488&from=export
http://dx.doi.org/10.1158/1055-9965.EPI-18-0965
VL  - 28
ID  - 855
ER  - 

TY  - JOUR
AB  - Background: The association of aspirin use with prostate cancer has been investigated, but few studies included African-American men. Here, we analyzed the relationship of aspirin intake with prostate cancer risk and mortality among African-American men in the Southern Community Cohort Study (SCCS). Methods: SCCS recruited 22,426 African-American men between 2002 and 2009. Aspirin use was assessed at enrollment. Our exposures of interest were any aspirin use (regular strength, low-dose or baby aspirin, or half tablets of aspirin) and regular strength aspirin. Each exposure variable was compared with nonusers. Associations between aspirin use and prostate cancer risk and mortality were examined with Cox proportional hazards models. Results: At enrollment, 5,486 men (25.1%) reported taking any aspirin and 2,634 men (12.1%) reported regular strength aspirin use. During follow-up (median, 13 years), 1,058 men developed prostate cancer, including 103 prostate cancer–specific deaths. Aspirin use was not associated with prostate cancer development [adjusted HR, 1.07; 95% confidence interval (CI), 0.92–1.25 for any aspirin use and HR, 0.97; 95% CI, 0.78–1.19 for regular strength aspirin], but was suggestively associated with reduced prostate cancer mortality (HR, 0.66; 95% CI, 0.39–1.14 for any aspirin use and HR, 0.41; 95% CI, 0.17–1.00 for regular strength aspirin). Conclusions: Aspirin use at enrollment was tentatively associated with reduced prostate cancer mortality, but not risk, among African-American men in SCCS. Impact: Prospective SCCS data suggest that aspirin use may help prevent lethal prostate cancer among this high-risk group of men. ©2020 American Association for Cancer Research.
AD  - Laboratory of Human Carcinogenesis, Center for Cancer Research, NCI, NIH, Bethesda, MD, United States
Department of Preventive Medicine, University of Tennessee Health Science Center, Memphis, TN, United States
Metabolic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, NCI, NIH, Rockville, MD, United States
International Epidemiology Institute, Rockville, MD, United States
Vanderbilt Epidemiology Center, Vanderbilt University School of Medicine, Nashville, TN, United States
AU  - Tang, W.
AU  - Fowke, J. H.
AU  - Hurwitz, L. M.
AU  - Steinwandel, M.
AU  - Blot, W. J.
AU  - Ambs, S.
DB  - Scopus
DO  - 10.1158/1055-9965.EPI-19-0792
IS  - 3
M3  - Article
N1  - Export Date: 22 March 2021
PY  - 2021
SP  - 539-544
ST  - Aspirin use and prostate cancer among African-American men in the southern community cohort study
T2  - Cancer Epidemiology Biomarkers and Prevention
TI  - Aspirin use and prostate cancer among African-American men in the southern community cohort study
UR  - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85102132855&doi=10.1158%2f1055-9965.EPI-19-0792&partnerID=40&md5=64ccd4e99cb791207644d63647bf806c
VL  - 30
ID  - 2153
ER  - 

TY  - JOUR
AB  - Background: African Americans (AA) are not well-represented in cancer clinical trials despite having significantly higher cancer mortality rates than their European-American (EA) counterparts. Objectives: The purpose of this study was to evaluate a program to improve perceptions of cancer clinical trials among AA. Methods: The program was conducted in a convenience sample of 195 participants (75.4% AA) who lived in counties with high racial disparities in cancer mortality rates and who were recruited by community partners. The 30-minute program, part of a larger 3.5-hour cancer education program, was developed by the National Institutes of Health (NIH)/National Cancer Institute (NCI). It was modified to include additional pictures of AA, AA-specific cancer mortality data, and information about the Tuskegee Syphilis Study and the resulting improved participant protection measures. Measures: The seven-item Attitudes to Randomized Trial Questionnaire (ARTQ) was used to evaluate changes in trial perceptions from pre- to posttest. Additional survey items assessed general demographic characteristics. Results: Slightly more than half of the participants had at least a college diploma (54.4%), 45.1% were married/living as married, 53.3% were female, and 45.6% had an annual household income of less than $40,000. For each ARTQ item, most participants who had less favorable perceptions of trials at pretest changed to more positive perceptions at posttest (p < .001). Conclusions: Providing cancer clinical trial information led to more positive perceptions of cancer clinical trials. In future studies, the program could be used to help potential trial participants make informed decisions about participation; trial enrollment rates could then be evaluated.
AN  - WOS:000313396500007
AU  - Ford, M.
AU  - Wahlquist, A.
AU  - Blake, R.
AU  - Green, C.
AU  - Streets, J.
AU  - Fuller, E.
AU  - Johnson, E.
AU  - Jefferson, M.
AU  - Etheredge, J.
AU  - Varner, H.
AU  - Johnson, S.
AU  - Glover, S.
AU  - Turner, D.
AU  - Garrett-Mayer, E.
DA  - Fal
DO  - 10.1353/cpr.2012.0038
IS  - 3
N1  - SI
22982839
PY  - 2012
SN  - 1557-0541
SP  - 249-263
ST  - Assessing an Intervention to Improve Clinical Trial Perceptions Among Predominately African-American Communities in South Carolina
T2  - Progress in Community Health Partnerships-Research Education and Action
TI  - Assessing an Intervention to Improve Clinical Trial Perceptions Among Predominately African-American Communities in South Carolina
VL  - 6
ID  - 3060
ER  - 

TY  - JOUR
AB  - This study assessed the feasibility of recruiting African American men in barbershops, assessing their physical activity, conducting physical measurements, and gauging their interest in barbershop-based health research. The authors recruited African American shop owners (n = 4), barbers (n = 6), and customers (n = 90) from four barbershops in Raleigh and Durham, North Carolina, during 2009. The participation levels were high among owners (100%), barbers (67%), and customers (81%). In addition to completing a self-administered survey, 57% (51/90) of the customers completed physical measurements. According to self-reported data, 34% (30/88) of the customers met national physical activity recommendations within the last week. Customers expressed moderately high interest in learning more about health at barbershops and joining a barbershop-based physical activity contest. The estimated recruiting cost per customer was $105.92. Barbershops offer an effective setting for recruiting African American men and conducting physical measurements as well as an interesting possible location for conducting future interventions.
AN  - WOS:000286679500006
AU  - Linnan, L. A.
AU  - Reiter, P. L.
AU  - Duffy, C.
AU  - Hales, D.
AU  - Ward, D. S.
AU  - Viera, A. J.
DA  - Jan
DO  - 10.1177/1557988309360569
IS  - 1
N1  - 20413387
PY  - 2011
SN  - 1557-9883
SP  - 38-46
ST  - Assessing and Promoting Physical Activity in African American Barbershops: Results of the FITStop Pilot Study
T2  - American Journal of Mens Health
TI  - Assessing and Promoting Physical Activity in African American Barbershops: Results of the FITStop Pilot Study
VL  - 5
ID  - 3101
ER  - 

TY  - JOUR
AB  - Background: Cognitive decline is among the most feared treatment-related outcomes of older adults with cancer. The majority of older patients with breast cancer self-report cognitive problems during and after chemotherapy. Prior neuroimaging research has been performed mostly in younger patients with cancer. The purpose of this study was to evaluate longitudinal changes in brain volumes and cognition in older women with breast cancer receiving adjuvant chemotherapy. Methods: Women aged ≥ 60 years with stage I-III breast cancer receiving adjuvant chemotherapy and age-matched and sex-matched healthy controls were enrolled. All participants underwent neuropsychological testing with the US National Institutes of Health (NIH) Toolbox for Cognition and brain magnetic resonance imaging (MRI) prior to chemotherapy, and again around one month after the last infusion of chemotherapy. Brain volumes were measured using Neuroreader™ software. Longitudinal changes in brain volumes and neuropsychological scores were analyzed utilizing linear mixed models. Results: A total of 16 patients with breast cancer (mean age 67.0, SD 5.39 years) and 14 age-matched and sex-matched healthy controls (mean age 67.8, SD 5.24 years) were included: 7 patients received docetaxel and cyclophosphamide (TC) and 9 received chemotherapy regimens other than TC (non-TC). There were no significant differences in segmented brain volumes between the healthy control group and the chemotherapy group pre-chemotherapy (p > 0.05). Exploratory hypothesis generating analyses focusing on the effect of the chemotherapy regimen demonstrated that the TC group had greater volume reduction in the temporal lobe (change = - 0.26) compared to the non-TC group (change = 0.04, p for interaction = 0.02) and healthy controls (change = 0.08, p for interaction = 0.004). Similarly, the TC group had a decrease in oral reading recognition scores (change = - 6.94) compared to the non-TC group (change = - 1.21, p for interaction = 0.07) and healthy controls (change = 0.09, p for interaction = 0.02). Conclusions: There were no significant differences in segmented brain volumes between the healthy control group and the chemotherapy group; however, exploratory analyses demonstrated a reduction in both temporal lobe volume and oral reading recognition scores among patients on the TC regimen. These results suggest that different chemotherapy regimens may have differential effects on brain volume and cognition. Future, larger studies focusing on older adults with cancer on different treatment regimens are needed to confirm these findings. © 2018 The Author(s).
AD  - City of Hope National Medical Center, Department of Diagnostic Radiology, Duarte, CA 91010, United States
The MRI Institute for Biomedical Research, Magnetic Resonance Innovations, Inc., Detroit, MI, United States
City of Hope National Medical Center, Department of Population Science, Duarte, CA 91010, United States
Center for Cancer and Aging, City of Hope National Medical Center, Duarte, CA 91010, United States
City of Hope National Medical Center, Division of Mathematical Oncology, Duarte, CA 91010, United States
Wayne State University, Department of Biomedical Engineering, Detroit, MI 48202, United States
Memorial Sloan Kettering Cancer Center, Neurocognitive Research Lab, 641 Lexington Avenue, 7th Floor, New York, NY 10022, United States
Center for Neuroimaging, Indiana University School of Medicine, 355 West 16th Street, Indianapolis, IN 46202, United States
Memorial Sloan-Kettering Cancer Center, Department of Radiology, 641 Lexington Avenue, 7th Floor, New York, NY 10022, United States
City of Hope National Medical Center, Division of Neurology, Duarte, CA 91010, United States
City of Hope National Medical Center, Department of Medical Oncology, Duarte, CA 91010, United States
AU  - Chen, B. T.
AU  - Sethi, S. K.
AU  - Jin, T.
AU  - Patel, S. K.
AU  - Ye, N.
AU  - Sun, C. L.
AU  - Rockne, R. C.
AU  - Haacke, E. M.
AU  - Root, J. C.
AU  - Saykin, A. J.
AU  - Ahles, T. A.
AU  - Holodny, A. I.
AU  - Prakash, N.
AU  - Mortimer, J.
AU  - Waisman, J.
AU  - Yuan, Y.
AU  - Somlo, G.
AU  - Li, D.
AU  - Yang, R.
AU  - Tan, H.
AU  - Katheria, V.
AU  - Morrison, R.
AU  - Hurria, A.
C7  - 38
DB  - Scopus
DO  - 10.1186/s13058-018-0965-3
IS  - 1
KW  - Brain MRI
Brain volume
Breast cancer
Cancer-related cognitive impairment
Chemotherapy
M3  - Article
N1  - Cited By :14
Export Date: 22 March 2021
PY  - 2018
ST  - Assessing brain volume changes in older women with breast cancer receiving adjuvant chemotherapy: A brain magnetic resonance imaging pilot study
T2  - Breast Cancer Research
TI  - Assessing brain volume changes in older women with breast cancer receiving adjuvant chemotherapy: A brain magnetic resonance imaging pilot study
UR  - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85046281068&doi=10.1186%2fs13058-018-0965-3&partnerID=40&md5=b6c94e890fa5efdb9fdf1b81cf7d7492
VL  - 20
ID  - 2272
ER  - 

TY  - JOUR
AB  - BACKGROUND: Prostate-specific antigen (PSA) testing is the primary method used to diagnose prostate cancer in the United States. Methods to integrate other risk factors associated with prostate cancer into individualized risk prediction are needed. We used prostate biopsy data from men who participated in the Prostate Cancer Prevention Trial (PCPT) to develop a predictive model of prostate cancer. METHODS: We included 5519 men from the placebo group of the PCPT who underwent prostate biopsy, had at least one PSA measurement and a digital rectal examination (DRE) performed during the year before the biopsy, and had at least two PSA measurements performed during the 3 years before the prostate biopsy. Logistic regression was used to model the risk of prostate cancer and high-grade disease associated with age at biopsy, race, family history of prostate cancer, PSA level, PSA velocity, DRE result, and previous prostate biopsy. Risk equations were created from the estimated logistic regression models. All statistical tests were two-sided. RESULTS: A total of 1211 (21.9%) men were diagnosed with prostate cancer by prostate biopsy. Variables that predicted prostate cancer included higher PSA level, positive family history of prostate cancer, and abnormal DRE result, whereas a previous negative prostate biopsy was associated with reduced risk. Neither age at biopsy nor PSA velocity contributed independent prognostic information. Higher PSA level, abnormal DRE result, older age at biopsy, and African American race were predictive for high-grade disease (Gleason score > or =7) whereas a previous negative prostate biopsy reduced this risk. CONCLUSIONS: This predictive model allows an individualized assessment of prostate cancer risk and risk of high-grade disease for men who undergo a prostate biopsy.
AD  - Department of Urology, University of Texas Health Science Center, San Antonio, TX 78229, USA. thompsoni@uthscsa.edu
AN  - 16622122
AU  - Thompson, I. M.
AU  - Ankerst, D. P.
AU  - Chi, C.
AU  - Goodman, P. J.
AU  - Tangen, C. M.
AU  - Lucia, M. S.
AU  - Feng, Z.
AU  - Parnes, H. L.
AU  - Coltman, C. A., Jr.
DA  - Apr 19
DO  - 10.1093/jnci/djj131
DP  - NLM
ET  - 2006/04/20
IS  - 8
KW  - African Americans/statistics & numerical data
Age Factors
Aged
*Biopsy, Needle
Confounding Factors, Epidemiologic
Digital Rectal Examination
Genetic Predisposition to Disease
Humans
Logistic Models
Male
Predictive Value of Tests
Prognosis
Prostate-Specific Antigen/blood
Prostatic Neoplasms/*epidemiology/ethnology/etiology/*pathology/prevention &
control/surgery
Randomized Controlled Trials as Topic
Research Design
Risk Assessment
Risk Factors
Time Factors
United States/epidemiology
LA  - eng
N1  - 1460-2105
Thompson, Ian M
Ankerst, Donna Pauler
Chi, Chen
Goodman, Phyllis J
Tangen, Catherine M
Lucia, M Scott
Feng, Ziding
Parnes, Howard L
Coltman, Charles A Jr
5UO1CA86402-04/CA/NCI NIH HHS/United States
CA35178/CA/NCI NIH HHS/United States
CA37429/CA/NCI NIH HHS/United States
CA45808/CA/NCI NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
United States
J Natl Cancer Inst. 2006 Apr 19;98(8):529-34. doi: 10.1093/jnci/djj131.
PY  - 2006
SN  - 0027-8874
SP  - 529-34
ST  - Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial
T2  - J Natl Cancer Inst
TI  - Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial
VL  - 98
ID  - 569
ER  - 

TY  - JOUR
AB  - Background: Breast cancer risk assessment and interventions for prevention, such as chemoprevention, are underutilized in the U.S. Reasons for low uptake include inability to routinely screen for high‐risk women in the primary care setting, inadequate time for counseling, and insufficient knowledge about risk‐reducing strategies. We developed an initial prototype of a web‐based decision aid (DA), RealRisks, which incorporates experience‐based dynamic interfaces to communicate risk aimed at reducing inaccurate risk perceptions, particularly in low‐numerate populations. Methods: RealRisks is a patient DA that models patient‐provider dialogue with modules on breast cancer risk, genetic testing, and chemoprevention. Embedded within the narrative are 2 games of experience‐based risk interfaces, demonstrating average 5‐year and lifetime breast cancer risk. Both games ask players to sample from a pictograph of 100 clickable women to better learn the meaning of a pre‐set probability (i.e., 12 out of 100 women or 12%). We conducted four focus groups of 7‐9 English‐speaking women over the age of 18, recruited from the local community in Upper Manhattan in New York City. These recorded sessions lasted about 90 minutes and involved use of RealRisks on a laptop, questionnaire completion before and after interacting with the DA, and a semi‐structured group discussion. Questionnaires included information about demographics, numeracy, internet access, breast cancer risk factors, perceived breast cancer risk, and evaluation of RealRisks on a 7‐point Likert scale. Descriptive statistics were generated to document baseline characteristics and frequencies of positive and negative attitudes about RealRisks. Paired t‐test and McNemar's test were used to compare within‐individual changes in accuracy of perceived breast cancer risk. During the group discussion, verbal responses were condensed into themes using a qualitative approach. Results: From May to June 2013, 34 women were enrolled. Median age was 53.5 (range, 35‐75); 85% were either black or Hispanic; 41% met criteria for low numeracy; and 88% had internet access. After removing 3 women with a history of breast cancer, 3 (9.7%) met high‐risk criteria for breast cancer according to the Gail model (≥1.67% 5‐year risk) and mean 5‐year and lifetime breast cancer risk were 1.11% (±0.77) and 7.46% (±2.87), respectively. After interacting with RealRisks, the difference in perceived vs. actual breast cancer risk according to the Gail model significantly improved for 5‐year risk (p=0.008), but not lifetime risk (p=0.20). Before exposure to RealRisks, 52% had accurate breast cancer risk perceptions (defined as within ±5% of actual lifetime risk according to the Gail model) compared to 70% after RealRisks (p=0.10). In particular, 4 out of 5 women who overestimated their lifetime breast cancer risk by >30% had accurate risk perceptions after exposure to RealRisks. We found a significant association between numeracy and accuracy of risk perception after interacting with RealRisks (p=0.05). Over 85% of the participants thought RealRisks was useful, easy to use, increased their knowledge about breast cancer and understanding of breast cancer risk factors. From the focus group discussions, we found that knowledge about breast cancer risk factors, apart from family history, was limited. Participants were interested in receiving a personalized breast cancer risk assessment and found the interactive games engaging. Discussion: In a multi‐ethnic low‐numerate population, we demonstrated a significant improvement in accuracy of perceived breast cancer risk after exposure to RealRisks. Based upon feedback from our focus groups, we were able to identify information needed to fully represent the important issues of breast cancer risk to further develop our prototype for testing in a randomized controlled trial.
AN  - CN-01023471
AU  - Hurley, R. M.
AU  - Suman, V. J.
AU  - Daly, M.
AU  - Olopade, F.
AU  - Limburg, P. J.
AU  - Pruthi, S.
IS  - 11
KW  - *breast cancer
*cancer prevention
*mutation
*prevention study
Cancer risk
Chemoprophylaxis
Community
Counseling
Exposure
Family history
Feedback system
Female
Genetic screening
Hispanic
Human
Information processing
Internet
Lifespan
Likert scale
McNemar test
Model
Narrative
Patient
Population
Prevention
Primary medical care
Questionnaire
Randomized controlled trial
Risk
Risk assessment
Risk factor
Speech
Statistics
Student t test
United States
M3  - Journal: Conference Abstract
PY  - 2013
ST  - Assessment of interest for breast cancer prevention trial participation among BRCA mutation carriers
T2  - Cancer prevention research (philadelphia, pa.)
TI  - Assessment of interest for breast cancer prevention trial participation among BRCA mutation carriers
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01023471/full
VL  - 6
ID  - 1657
ER  - 

TY  - JOUR
AB  - Purpose: To evaluate the value of sentinel lymph node (SLN) identification using carbon nanoparticles in abdominal lymph node metastasis in elderly (>60 years old) patients with colorectal cancer. Methods: Eighty patients admitted at Weihai Second Municipal Hospital affiliated to Qingdao University from November 2014 to February 2017 were selected and divided into the control group (n=40) and the observation group (n=40) using the random number method. The control group was treated with surgery, while the observation group was administered carbon nanoparticle tracer for intraoperative dye detection and positioning; the first to four black-stained lymph nodes were marked as SLN, then radical surgery for colorectal cancer was performed. Pathological examination of intraoperative specimens was performed to assess the effect of SLN in the abdominal lymph node metastasis. Results: There were no statistically significant differences in the metastasis rate and lymph node metastasis rate between the two groups (p>0.05). The total number of lymph nodes and the number of lymph nodes with micrometastases (<2mm) in the observation group were larger than those in the control group (p<0.05); the ratio of fewer than 12 lymph nodes in the observation group was lower than that in the control group (p<0.05). In the observation group, 8 out of 40 cases had lymph node metastasis, the detection rate of SLN using carbon nanoparticles was 92.50%, the accuracy rate 94.59%, the specificity of diagnosis 87.50%, the false negative rate 12.50% and the negative predictive value 21.88%. There was no statistically significant difference in the metastasis rate of black-stained and non-black-stained lymph nodes in the observation group (p>0.05). The blackstained rate of micro lymph nodes was higher than the total black-stained rate (p<0.05); the rate of micro lymph node metastasis was lower than that of lymph node metastasis >5mm (p<0.05). Conclusion: Preoperative SLN examination can evaluate the abdominal lymph node status in elderly patients with colorectal cancer, which is simple and accurate and can guide the clinical treatment, so it is worthy of popularization and application.
AD  - J. Sun, Department of General Surgery, Affiliated Weihai Second Municipal Hospital of Qingdao University, No.51 Guangming Road Huancui Dist., WeiHai, China
AU  - Sun, J.
AU  - Zhang, J.
C2  - Chongqing Lummy(China)
DB  - Embase
Medline
IS  - 1
KW  - carbon nanoparticle
abdomen
adult
aged
aging
article
cancer patient
cancer size
cancer surgery
colorectal cancer
controlled study
diagnostic accuracy
diagnostic test accuracy study
female
hospital admission
human
human tissue
intraoperative period
lymph node dissection
lymph node metastasis
major clinical study
male
micrometastasis
middle aged
observational study
pathophysiology
patient selection
predictive value
radical resection
sensitivity and specificity
sentinel lymph node
sentinel lymph node biopsy
staining
university hospital
LA  - English
M3  - Article
N1  - L621718145
2018-04-27
2018-05-04
PY  - 2018
SN  - 1107-0625
SP  - 68-72
ST  - Assessment of lymph node metastasis in elderly patients with colorectal cancer by sentinel lymph node identification using carbon nanoparticles
T2  - Journal of B.U.ON.
TI  - Assessment of lymph node metastasis in elderly patients with colorectal cancer by sentinel lymph node identification using carbon nanoparticles
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L621718145&from=export
VL  - 23
ID  - 918
ER  - 

TY  - JOUR
AB  - This study investigates the dimensional structure of the Center for Epidemiologic Studies Depression (CES-D) scale in US Black women with and without history of cancer via single-group and multi-group analyses. The CES-D questionnaire was administered in 1999 to 50,774 black women who are participants in the Black Women's Health Study (BWHS). For our analysis, we utilized a group of 690 women with a history of at least one of the three types of cancer (breast cancer, colon cancer or lung cancer) and an age-matched group of 1,380 healthy women with no history of any cancer or other chronic conditions including myocardial infarctions, stroke, angina, diabetes, lupus, and sarcoidosis. Three a priori hypothesized models were tested via confirmatory factor analysis: single-, three- and four-factor structures. The four-factor model provided the best fit and remained largely invariant across the groups when tested via multi-group comparisons. Two internal consistency measures of the scale (Cronbach's α coefficient and split-half coefficient) were also shown to be satisfactory. We concluded that the CES-D scale is appropriate for use in black women regardless of their cancer status. © 2008 Elsevier Ltd. All rights reserved.
AD  - K.H. Makambi, Howard University Cancer Center, 2041 Georgia Avenue, NW, Washington, DC 20060, United States
AU  - Makambi, K. H.
AU  - Williams, C. D.
AU  - Taylor, T. R.
AU  - Rosenberg, L.
AU  - Adams-Campbell, L. L.
DB  - Embase
Medline
DO  - 10.1016/j.psychres.2008.04.022
IS  - 2
KW  - adult
aged
angina pectoris
article
breast cancer
Center for Epidemiological Studies Depression Scale
cerebrovascular accident
chronic disease
colon cancer
controlled study
Cronbach alpha coefficient
diabetes mellitus
factor analysis
female
groups by age
heart infarction
human
internal consistency
lung cancer
lupus erythematosus
major clinical study
major depression
Black person
patient participation
priority journal
questionnaire
sarcoidosis
split half correlation
women's health
LA  - English
M3  - Article
N1  - L50539001
2009-07-16
PY  - 2009
SN  - 0165-1781
SP  - 163-170
ST  - An assessment of the CES-D scale factor structure in black women: The Black Women's Health Study
T2  - Psychiatry Research
TI  - An assessment of the CES-D scale factor structure in black women: The Black Women's Health Study
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L50539001&from=export
http://dx.doi.org/10.1016/j.psychres.2008.04.022
VL  - 168
ID  - 1185
ER  - 

TY  - JOUR
AB  - Previous studies using different exposure methods to assess air pollution and breast cancer risk among primarily whites have been inconclusive. Air pollutant exposures of particulate matter and oxides of nitrogen were estimated by kriging (NOx, NO2, PM10, PM2.5), land use regression (LUR, NOx, NO2) and California Line Source Dispersion model (CALINE4, NOx, PM2.5) for 57,589 females from the Multiethnic Cohort, residing largely in Los Angeles County from recruitment (1993–1996) through 2010. Cox proportional hazards models were used to examine the associations between time-varying air pollution and breast cancer incidence adjusting for confounding factors. Stratified analyses were conducted by race/ethnicity and distance to major roads. Among all women, breast cancer risk was positively but not significantly associated with NOx (per 50 parts per billion [ppb]) and NO2 (per 20 ppb) determined by kriging and LUR and with PM2.5 and PM10 (per 10 μg/m3) determined by kriging. However, among women who lived within 500 m of major roads, significantly increased risks were observed with NOx (hazard ratio [HR] = 1.35, 95% confidence interval [95% CI]: 1.02–1.79), NO2 (HR = 1.44, 95% CI: 1.04–1.99), PM10 (HR = 1.29, 95% CI: 1.07–1.55) and PM2.5 (HR = 1.85, 95% CI: 1.15–2.99) determined by kriging and NOx (HR = 1.21, 95% CI:1.01–1.45) and NO2 (HR = 1.26, 95% CI: 1.00–1.59) determined by LUR. No overall associations were observed with exposures assessed by CALINE4. Subgroup analyses suggested stronger associations of NOx and NO2 among African Americans and Japanese Americans. Further studies of multiethnic populations to confirm the effects of air pollution, particularly near-roadway exposures, on the risk of breast cancer is warranted. © 2019 UICC
AD  - Department of Epidemiology and Biostatistics, University of California, San Francisco, CA, United States
Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, United States
Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States
Program in Public Health, Susan and Henry Samueli College of Health Sciences, University of Irvine, Irvine, CA, United States
Cancer Prevention Institute of California, Fremont, CA, United States
Epidemiology Program, University of Hawaii Cancer Center, Honolulu, HI, United States
Stanford University School of Medicine, Stanford, CA, United States
Department of Epidemiology, School of Public Health, University of California, Los Angeles, Los Angeles, CA, United States
AU  - Cheng, I.
AU  - Tseng, C.
AU  - Wu, J.
AU  - Yang, J.
AU  - Conroy, S. M.
AU  - Shariff-Marco, S.
AU  - Li, L.
AU  - Hertz, A.
AU  - Gomez, S. L.
AU  - Le Marchand, L.
AU  - Whittemore, A. S.
AU  - Stram, D. O.
AU  - Ritz, B.
AU  - Wu, A. H.
DB  - Scopus
DO  - 10.1002/ijc.32308
IS  - 3
KW  - air pollution
breast cancer
epidemiology
multiethnic cohort
M3  - Article
N1  - Cited By :14
Export Date: 22 March 2021
PY  - 2020
SP  - 699-711
ST  - Association between ambient air pollution and breast cancer risk: The multiethnic cohort study
T2  - International Journal of Cancer
TI  - Association between ambient air pollution and breast cancer risk: The multiethnic cohort study
UR  - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85064957019&doi=10.1002%2fijc.32308&partnerID=40&md5=ad8b8dc1f49bbe4550a275bfe8a6f6e7
VL  - 146
ID  - 2204
ER  - 

TY  - JOUR
AB  - Gene-specific promoter methylation of several genes occurs in aging normal tissues and may predispose to tumorigenesis. In the present study, we investigate the association of blood folate levels and dietary and lifestyle factors with CpG island (CGI) methylation in normal colorectal mucosa. Subjects were enrolled in a multicenter chemoprevention trial of aspirin or folic acid for the prevention of large bowel adenomas. We collected 1,000 biopsy specimens from 389 patients, 501 samples from the right colon and 499 from the rectum at the follow-up colonoscopy. We measured DNA methylation of estrogen receptor alpha (ERα) and secreted frizzled related protein-1 (SFRP1), using bisulfite pyrosequencing. We used generalized estimating equations regression analysis to examine the association between methylation and selected variables. For both ERα and SFRP1, percentage methylation was significantly higher in the rectum than in the right colon (P = 0.001). For each 10 years of age, we observed a 1.7% increase in methylation level for ERα and a 2.9% increase for SFRP1 (P < 0.0001). African Americans had a significantly lower level of ERα and SFRP1 methylation than Caucasians and Hispanics. Higher RBC folate levels were associated with higher levels of both ERα (P = 0.03) and SFRP1 methylation (P = 0.01). Our results suggest that CGI methylation in normal colorectal mucosa is related to advancing age, race, rectal location, and RBC folate levels. These data have important implications regarding the safety of supplementary folate administration in healthy adults, given the hypothesis that methylation in normal mucosa may predispose to colorectal neoplasia.
AD  - Department of Medicine, Dartmouth Medical School, Evergreen Center, Lebanon, NH 03756, USA. john.a.baron@dartmouth.edu
AN  - 21149331
AU  - Wallace, K.
AU  - Grau, M. V.
AU  - Levine, A. J.
AU  - Shen, L.
AU  - Hamdan, R.
AU  - Chen, X.
AU  - Gui, J.
AU  - Haile, R. W.
AU  - Barry, E. L.
AU  - Ahnen, D.
AU  - McKeown-Eyssen, G.
AU  - Baron, J. A.
AU  - Issa, J. P.
C2  - PMC3058541
C6  - NIHMS222691
DA  - Dec
DO  - 10.1158/1940-6207.Capr-10-0047
DP  - NLM
ET  - 2010/12/15
IS  - 12
KW  - Adenoma/blood/*genetics/pathology
Biomarkers, Tumor/blood
Colon/*metabolism/pathology
Colonic Polyps/metabolism/pathology
Colorectal Neoplasms/blood/*genetics/pathology
*CpG Islands
*DNA Methylation
Double-Blind Method
Estrogen Receptor alpha/genetics
Female
Folic Acid/*blood
Follow-Up Studies
Humans
Intercellular Signaling Peptides and Proteins/genetics
Intestinal Mucosa/metabolism
Male
Membrane Proteins/genetics
Middle Aged
Placebos
Prognosis
Rectum/*metabolism/pathology
LA  - eng
N1  - 1940-6215
Wallace, Kristin
Grau, Maria V
Levine, A Joan
Shen, Lanlan
Hamdan, Randala
Chen, Xinli
Gui, Jiang
Haile, Robert W
Barry, Elizabeth L
Ahnen, Dennis
McKeown-Eyssen, Gail
Baron, John A
Issa, Jean Pierre J
R01 CA059005-07/CA/NCI NIH HHS/United States
R01 CA059005-06A1/CA/NCI NIH HHS/United States
R01 CA105346-02/CA/NCI NIH HHS/United States
R01 CA059005-10S1/CA/NCI NIH HHS/United States
R01-CA-059005/CA/NCI NIH HHS/United States
R01 CA105346-01/CA/NCI NIH HHS/United States
R01 CA059005-10/CA/NCI NIH HHS/United States
R01-CA89245/CA/NCI NIH HHS/United States
R01 CA059005-11A2/CA/NCI NIH HHS/United States
R01 CA059005-09/CA/NCI NIH HHS/United States
R01-CA105346/CA/NCI NIH HHS/United States
R01 CA059005-06A1S1/CA/NCI NIH HHS/United States
R01 CA059005-07S1/CA/NCI NIH HHS/United States
P30 CA023108/CA/NCI NIH HHS/United States
N01-CO12400/CO/NCI NIH HHS/United States
R01 CA105346/CA/NCI NIH HHS/United States
R01 CA059005-08/CA/NCI NIH HHS/United States
R01 CA059005-08S2/CA/NCI NIH HHS/United States
R01 CA105346-04/CA/NCI NIH HHS/United States
R01 CA098006/CA/NCI NIH HHS/United States
U54 CA100971/CA/NCI NIH HHS/United States
U54-CA100971/CA/NCI NIH HHS/United States
R01 CA059005-12/CA/NCI NIH HHS/United States
R01 CA098006-05/CA/NCI NIH HHS/United States
N01CO12400/CA/NCI NIH HHS/United States
R01 CA059005-08S1/CA/NCI NIH HHS/United States
R01 CA059005-09S1/CA/NCI NIH HHS/United States
R01 CA105346-03/CA/NCI NIH HHS/United States
R01 CA059005/CA/NCI NIH HHS/United States
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Cancer Prev Res (Phila). 2010 Dec;3(12):1552-64. doi: 10.1158/1940-6207.CAPR-10-0047.
PY  - 2010
SN  - 1940-6207 (Print)
1940-6215
SP  - 1552-64
ST  - Association between folate levels and CpG Island hypermethylation in normal colorectal mucosa
T2  - Cancer Prev Res (Phila)
TI  - Association between folate levels and CpG Island hypermethylation in normal colorectal mucosa
VL  - 3
ID  - 405
ER  - 

TY  - JOUR
AB  - We synthesized the evidence of the association between patient and tumor characteristics with clinical outcomes in women with ductal carcinoma in situ of the breast. We identified five randomized controlled clinical trials and 64 observational studies that were published in English from January 1970 to January 2009. Younger women with clinically presented ductal carcinoma in situ had higher risk of ipsilateral recurrent cancer. African Americans had higher mortality and greater rates of advanced recurrent cancer. Women with larger tumor size, comedo necrosis, worse pathological grading, positive surgical margins, and at a higher risk category, using a composite prognostic index, had worse outcomes. Inconsistent evidence suggested that positive HER2 receptor and negative estrogen receptor status were associated with worse outcomes. Synthesis of evidence was hampered by low statistical power to detect significant differences in predictor categories and inconsistent adjustment practices across the studies. Future research should address composite prediction indices among race groups for all outcomes.
AD  - Division of Health Policy and Management, University of Minnesota School of Public Health, D330-5 Mayo (MMC 729), 420 Delaware St SE, Minneapolis, MN 55455, USA. shaml005@umn.edu
AN  - 20956815
AU  - Shamliyan, T.
AU  - Wang, S. Y.
AU  - Virnig, B. A.
AU  - Tuttle, T. M.
AU  - Kane, R. L.
C2  - PMC5161074
DO  - 10.1093/jncimonographs/lgq034
DP  - NLM
ET  - 2010/10/20
IS  - 41
KW  - Adult
Age Factors
Aged
Body Mass Index
Breast Neoplasms/chemistry/*epidemiology/pathology/therapy
Carcinoma, Intraductal, Noninfiltrating/chemistry/*epidemiology/pathology/therapy
Continental Population Groups/statistics & numerical data
Female
Gonadal Steroid Hormones/adverse effects
Humans
Mammography
Menopause
Neoplasm Recurrence, Local/epidemiology
Neoplasms, Hormone-Dependent/chemistry/epidemiology/pathology/therapy
Prognosis
Randomized Controlled Trials as Topic/statistics & numerical data
Receptor, ErbB-2/analysis
Receptors, Estrogen/analysis
Receptors, Progesterone/analysis
Risk
Socioeconomic Factors
Treatment Outcome
Tumor Burden
LA  - eng
N1  - 1745-6614
Shamliyan, Tatyana
Wang, Shi-Yi
Virnig, Beth A
Tuttle, Todd M
Kane, Robert L
290-02-0009/PHS HHS/United States
Journal Article
Research Support, U.S. Gov't, P.H.S.
Review
J Natl Cancer Inst Monogr. 2010;2010(41):121-9. doi: 10.1093/jncimonographs/lgq034.
PY  - 2010
SN  - 1052-6773 (Print)
1052-6773
SP  - 121-9
ST  - Association between patient and tumor characteristics with clinical outcomes in women with ductal carcinoma in situ
T2  - J Natl Cancer Inst Monogr
TI  - Association between patient and tumor characteristics with clinical outcomes in women with ductal carcinoma in situ
VL  - 2010
ID  - 409
ER  - 

TY  - JOUR
AB  - BACKGROUND: Follow-through of a positive screening test is necessary to reap the potential benefits of cancer screening. Racial variation in follow-through diagnostic care may underlie a proportion of the known disparity in prostate cancer mortality. The authors used data from the screening arm of the Prostate, Lung, Colorectal, and Ovarian (PLCO) cancer screening trial to determine whether race is associated with the use of follow-up diagnostic testing after a positive initial screening evaluation. METHODS: Men who had a prostate-specific antigen (PSA) level >4 ng/mL at any time during the study were included. The proportion of men who underwent follow-up evaluation with a repeat PSA, a prostate biopsy, or either test within 9 months was determined, and the authors tested for differences in follow-through according to race using mixed-effects multivariate models with a random effect for accrual site to account for clustering. Models were stratified according to age (<65 years and ≥65 years). RESULTS: Among 6294 men who had a PSA elevation during the study period, 70% underwent a repeat PSA or prostate biopsy within 9 months. Non-Hispanic black men aged <65 years had 45% lower odds of undergoing a repeat PSA test or prostate biopsy compared with non-Hispanic white men (odds ratio, 0.55; 95% confidence interval, 0.37-0.82), whereas there was no racial difference in follow-through among older men. CONCLUSIONS: The current results suggest that limitations in access to care among non-Hispanic black men under the age of Medicare eligibility may underlie the paradoxically low use of follow-through diagnostic care among non-Hispanic black men in the United States.
AD  - Department of Urologic Surgery, Vanderbilt University, Nashville, Tennessee 37232, USA. dan.barocasVC vanderbilt.edu
AN  - 23559420
AU  - Barocas, D. A.
AU  - Grubb, R., 3rd
AU  - Black, A.
AU  - Penson, D. F.
AU  - Fowke, J. H.
AU  - Andriole, G.
AU  - Crawford, E. D.
DA  - Jun 15
DO  - 10.1002/cncr.28042
DP  - NLM
ET  - 2013/04/06
IS  - 12
KW  - African Americans
Aged
Biopsy
Early Detection of Cancer
European Continental Ancestry Group
Female
Humans
Male
Middle Aged
Multivariate Analysis
Prostate-Specific Antigen/*analysis
Prostatic Neoplasms/*diagnosis
Socioeconomic Factors
United States
LA  - eng
N1  - 1097-0142
Barocas, Daniel A
Grubb, Robert 3rd
Black, Amanda
Penson, David F
Fowke, Jay H
Andriole, Gerald
Crawford, E David
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
United States
Cancer. 2013 Jun 15;119(12):2223-9. doi: 10.1002/cncr.28042. Epub 2013 Apr 4.
PY  - 2013
SN  - 0008-543x
SP  - 2223-9
ST  - Association between race and follow-up diagnostic care after a positive prostate cancer screening test in the prostate, lung, colorectal, and ovarian cancer screening trial
T2  - Cancer
TI  - Association between race and follow-up diagnostic care after a positive prostate cancer screening test in the prostate, lung, colorectal, and ovarian cancer screening trial
VL  - 119
ID  - 332
ER  - 

TY  - JOUR
AB  - BACKGROUND: African-American men have earlier onset of prostate cancer, higher prostate-specific antigen (PSA) levels, more advanced stage at diagnosis, and higher mortality than white men. It is not known whether the poorer survival of African-American men with prostate cancer reflects their later stage at diagnosis or differences in the basic biology of their disease. To evaluate this question, we examined outcomes of African-American and white men with metastatic prostate cancer in the context of a randomized clinical trial. METHODS: Southwest Oncology Group Study 8894 was a randomized phase III trial that compared orchiectomy with or without flutamide in men with metastatic prostate cancer. Using data from 288 African-American and 975 white men in the trial, we conducted a proportional hazards regression analysis to determine if ethnicity was an independent predictor of survival. All statistical tests were two-sided. RESULTS: African-American men were more likely than white men to have extensive disease and bone pain and had poorer performance status, younger age at study entry, higher Gleason score, and higher PSA levels. After adjustment for these prognostic variables, the hazard ratio (HR) for all-cause mortality for African-American men relative to white men was 1.23 (P: =.018). Further adjustment for initial quality-of-life assessments also resulted in higher HRs associated with African-American ethnicity relative to white ethnicity (HR = 1.39; P: =.007). CONCLUSIONS: African-American men with metastatic prostate cancer have a statistically significantly worse prognosis than white men that cannot be explained by the prognostic variables explored in this study. These data should give increased impetus for efforts to detect the disease early in African-American men and for the development of more effective therapies based on potential biologic differences in this ethnic group.
AD  - The University of Texas Health Sciences Center at San Antonio, USA. thompsoni@uthscsa.edu
AN  - 11158191
AU  - Thompson, I.
AU  - Tangen, C.
AU  - Tolcher, A.
AU  - Crawford, E.
AU  - Eisenberger, M.
AU  - Moinpour, C.
DA  - Feb 7
DO  - 10.1093/jnci/93.3.219
DP  - NLM
ET  - 2001/02/07
IS  - 3
KW  - African Americans/*statistics & numerical data
Aged
Aged, 80 and over
Androgen Antagonists/therapeutic use
Antineoplastic Agents, Hormonal/therapeutic use
Bone Neoplasms/ethnology/mortality/secondary
Clinical Trials, Phase III as Topic
European Continental Ancestry Group/*statistics & numerical data
Flutamide/therapeutic use
Humans
Male
Middle Aged
Multicenter Studies as Topic
Multivariate Analysis
Odds Ratio
Orchiectomy
Predictive Value of Tests
Prognosis
Proportional Hazards Models
Prostatic Neoplasms/*ethnology/*mortality/pathology/therapy
Quality of Life
Randomized Controlled Trials as Topic
United States/epidemiology
LA  - eng
N1  - Thompson, I
Tangen, C
Tolcher, A
Crawford, E
Eisenberger, M
Moinpour, C
CA32102/CA/NCI NIH HHS/United States
CA38926/CA/NCI NIH HHS/United States
CA42777/CA/NCI NIH HHS/United States
Journal Article
Research Support, U.S. Gov't, P.H.S.
United States
J Natl Cancer Inst. 2001 Feb 7;93(3):219-25. doi: 10.1093/jnci/93.3.219.
PY  - 2001
SN  - 0027-8874 (Print)
0027-8874
SP  - 219-25
ST  - Association of African-American ethnic background with survival in men with metastatic prostate cancer
T2  - J Natl Cancer Inst
TI  - Association of African-American ethnic background with survival in men with metastatic prostate cancer
VL  - 93
ID  - 695
ER  - 

TY  - JOUR
AB  - Background: Obesity is a cancer risk factor. Although it does not increase the risk of localized prostate cancer, it raises the risk of the aggressive disease in men of European ancestry. Few studies investigated obesity as a prostate cancer risk factor in men of African ancestry. Findings from those studies were heterogeneous, but some reported an association of excess body fatness with aggressive disease. Methods: We examined the relationship of body mass index (BMI), waist circumference, and waist–hip ratio with prostate cancer in African American (AA) and European American (EA) men in the NCI-Maryland Prostate Cancer Case-Control Study consisting of 798 men with incident prostate cancer (402 AA and 496 EA) and 1,008 population-based controls (474 AA and 534 EA). BMI was self-reported. Waist circumference and waist–hip ratio were calculated from measurements at enrollment. Results: A high BMI either at enrollment or years prior to it was associated with a decreased risk of prostate cancer in AA men. In contrast, an elevated BMI tended to increase the disease risk in EA men. Waist circumference was inversely associated with prostate cancer in both AA and EA men, whereas a high waist–hip ratio did not associate with prostate cancer in AA men but tended to be associated with advanced/aggressive disease in EA men. Conclusions: Our findings reveal an obesity paradox among AA men in this study population, where a high BMI and waist circumference associated with a decreased disease risk. Impact: Our observations expand the knowledge of how obesity may affect prostate cancer risks in AAs. © 2018 American Association for Cancer Research.
AD  - Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, Building 37/ Room 3050B, MSC Convent Drive 4258, Bethesda, MD 20892, United States
Cancer Prevention and Control Program, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, District of Columbia, United States
AU  - Pichardo, M. S.
AU  - Smith, C. J.
AU  - Dorsey, T. H.
AU  - Loffredo, C. A.
AU  - Ambs, S.
DB  - Scopus
DO  - 10.1158/1055-9965.EPI-18-0242
IS  - 8
M3  - Article
N1  - Cited By :1
Export Date: 22 March 2021
PY  - 2018
SP  - 936-944
ST  - Association of anthropometric measures with prostate cancer among African American men in the NCI-Maryland prostate cancer case-control study
T2  - Cancer Epidemiology Biomarkers and Prevention
TI  - Association of anthropometric measures with prostate cancer among African American men in the NCI-Maryland prostate cancer case-control study
UR  - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85050945532&doi=10.1158%2f1055-9965.EPI-18-0242&partnerID=40&md5=b28d94596c4c08625ed3e75c980843e1
VL  - 27
ID  - 2260
ER  - 

TY  - JOUR
AB  - IMPORTANCE: Oxidative stress is an established dementia pathway, but it is unknown if the use of antioxidant supplements can prevent dementia. OBJECTIVE: To determine if antioxidant supplements (vitamin E or selenium) used alone or in combination can prevent dementia in asymptomatic older men. DESIGN, SETTING, AND PARTICIPANTS: The Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADViSE) trial began as a double-blind randomized clinical trial in May 2002, which transformed into a cohort study from September 2009 to May 2015. The PREADViSE trial was ancillary to the Selenium and Vitamin E Cancer Prevention Trial (SELECT), a randomized clinical trial of the same antioxidant supplements for preventing prostate cancer, which closed in 2009 owing to findings from a futility analysis. The PREADViSE trial recruited 7540 men, of whom 3786 continued into the cohort study. Participants were at least 60 years old at study entry and were enrolled at 130 SELECT sites, and Cox proportional hazards models were used in a modified intent-to-treat analysis to compare hazard rates among the study arms. INTERVENTIONS: Participants were randomized to vitamin E, selenium, vitamin E and selenium, or placebo. While taking study supplements, enrolled men visited their SELECT site and were evaluated for dementia using a 2-stage screen. During the cohort study, men were contacted by telephone and assessed using an enhanced 2-stage cognitive screen. In both phases, men were encouraged to visit their physician if the screen results indicated possible cognitive impairment. MAIN OUTCOMES AND MEASURES: Dementia case ascertainment relied on a consensus review of the cognitive screens and medical records for men with suspected dementia who visited their physician for an evaluation or by review of all available information, including a functional assessment screen. RESULTS: The mean (SD) baseline age of the 7540 participants was 67.5 (5.3) years, with 3936 (52.2%) reporting a college education or better, 754 (10.0%) reporting black race, and 505 (6.7%) reporting Hispanic ethnicity. Dementia incidence (325 of 7338 men [4.4%]) was not different among the 4 study arms. A Cox model, which adjusted incidence for participant demographic information and baseline self-reported comorbidities, yielded hazard ratios of 0.88 (95% CI, 0.64-1.20) for vitamin E, 0.83 (0.60-1.13) for selenium, and 1.00 (0.75-1.35) for the combination compared with placebo. CONCLUSIONS AND RELEVANCE: Neither supplement prevented dementia. To our knowledge, this is the first study to investigate the long-term association of antioxidant supplement use and dementia incidence among asymptomatic men.
AD  - Sanders-Brown Center on Aging, University of Kentucky, Lexington2Alzheimer's Disease Center, University of Kentucky, Lexington3Department of Biostatistics, University of Kentucky, Lexington4Department of Statistics, University of Kentucky, Lexington.
Sanders-Brown Center on Aging, University of Kentucky, Lexington2Alzheimer's Disease Center, University of Kentucky, Lexington3Department of Biostatistics, University of Kentucky, Lexington5Department of Epidemiology, University of Kentucky, Lexington.
Sanders-Brown Center on Aging, University of Kentucky, Lexington2Alzheimer's Disease Center, University of Kentucky, Lexington.
Sanders-Brown Center on Aging, University of Kentucky, Lexington6Department of Chemistry, University of Kentucky, Lexington.
SWOG Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, Washington.
SWOG Statistical Center, Cancer Research and Biostatistics, Seattle, Washington.
Sanders-Brown Center on Aging, University of Kentucky, Lexington2Alzheimer's Disease Center, University of Kentucky, Lexington9Department of Neurology, College of Medicine, University of Kentucky, Lexington.
AN  - 28319243
AU  - Kryscio, R. J.
AU  - Abner, E. L.
AU  - Caban-Holt, A.
AU  - Lovell, M.
AU  - Goodman, P.
AU  - Darke, A. K.
AU  - Yee, M.
AU  - Crowley, J.
AU  - Schmitt, F. A.
C2  - PMC5506489
C6  - NIHMS870934
DA  - May 1
DO  - 10.1001/jamaneurol.2016.5778
DP  - NLM
ET  - 2017/03/21
IS  - 5
KW  - Aged
Alzheimer Disease/prevention & control
Antioxidants/administration & dosage/*pharmacology
Dementia/*prevention & control
Dietary Supplements
Double-Blind Method
Drug Therapy, Combination
Humans
Longitudinal Studies
Male
Middle Aged
*Outcome Assessment, Health Care
Selenium/administration & dosage/*pharmacology
Vitamin E/administration & dosage/*pharmacology
LA  - eng
N1  - 2168-6157
Kryscio, Richard J
Abner, Erin L
Caban-Holt, Allison
Lovell, Mark
Goodman, Phyllis
Darke, Amy K
Yee, Monica
Crowley, John
Schmitt, Frederick A
U10 CA037429/CA/NCI NIH HHS/United States
UG1 CA189974/CA/NCI NIH HHS/United States
R01 AG038651/AG/NIA NIH HHS/United States
P30 AG028383/AG/NIA NIH HHS/United States
UM1 CA182883/CA/NCI NIH HHS/United States
Journal Article
Randomized Controlled Trial
JAMA Neurol. 2017 May 1;74(5):567-573. doi: 10.1001/jamaneurol.2016.5778.
PY  - 2017
SN  - 2168-6149 (Print)
2168-6149
SP  - 567-573
ST  - Association of Antioxidant Supplement Use and Dementia in the Prevention of Alzheimer's Disease by Vitamin E and Selenium Trial (PREADViSE)
T2  - JAMA Neurol
TI  - Association of Antioxidant Supplement Use and Dementia in the Prevention of Alzheimer's Disease by Vitamin E and Selenium Trial (PREADViSE)
VL  - 74
ID  - 176
ER  - 

TY  - JOUR
AB  - Associations between CHRNA5-A3-B4 variants and smoking behaviors exist; however, the association with smoking abstinence is less understood, particularly that among African Americans. In 1,295 African Americans enrolled in two clinical trials, we investigated the association between CHRNA5-A3-B4 and smoking abstinence. The rs2056527(A) allele was associated with lower abstinence with active pharmacotherapy (during treatment: odds ratio (OR) = 0.42, P < 0.001; end of treatment (EOT): OR = 0.55, P = 0.004), or with nicotine gum alone (during treatment: OR = 0.31, P < 0.001; EOT: OR = 0.51, P = 0.02), but not significantly with bupropion, although similar directions and magnitudes were observed (during treatment: OR = 0.54, P = 0.05; EOT: OR = 0.59, P = 0.08). In addition, the rs588765(T) allele was associated with abstinence with gum during treatment (OR = 2.31, P < 0.01). The SNP rs16969968 occurred at a low frequency and was not consistently associated with abstinence. CHRNA5-A3-B4 variants were not associated with tobacco consumption, and adjustments for smoking behaviors did not alter the associations with smoking abstinence. Together, our data suggest that among African Americans, CHRNA5-A3-B4 variants are not associated with baseline smoking but can influence smoking abstinence during active pharmacotherapy.
AN  - WOS:000339602900037
AU  - Zhu, A. Z. X.
AU  - Zhou, Q.
AU  - Cox, L. S.
AU  - David, S. P.
AU  - Ahluwalia, J. S.
AU  - Benowitz, N. L.
AU  - Tyndale, R. F.
DA  - Aug
DO  - 10.1038/clpt.2014.88
IS  - 2
N1  - 24733007
PY  - 2014
SN  - 0009-9236
SP  - 256-265
ST  - Association of CHRNA5-A3-84 SNP rs2036527 With Smoking Cessation Therapy Response in African-American Smokers
T2  - Clinical Pharmacology & Therapeutics
TI  - Association of CHRNA5-A3-84 SNP rs2036527 With Smoking Cessation Therapy Response in African-American Smokers
VL  - 96
ID  - 3001
ER  - 

TY  - JOUR
AB  - Background: Obesity-related cancers disproportionately affect the Black community. We assessed the relationship between diet quality, physical activity, and their combined effect on obesity-related cancer risk and mortality in Black women enrolled in the Women's Health Initiative (WHI). Methods: Data from postmenopausal (50-79 years of age) Black women enrolled in WHI clinical trials or observational studies were analyzed. Exposure variables included baseline physical activity [metabolic equivalent of tasks (MET)-hours/ week of moderate-to-vigorous physical activity (MVPA)] and diet quality [Healthy Eating Index (HEI)-2015]. Outcomes included adjudicated obesity-related cancer incidence and mortality. Cox proportional hazard models were used to evaluate the association between MVPA and HEI-2015 and obesity-related cancer risk and mortality. Results: The analytical sample included 9,886 Black women, with a baseline mean body mass index (BMI) of 31.1 kg/m2 (SD ¼ 6.8); mean HEI-2015 score of 63.2 (SD ¼ 11.0, possible range 0 to 100); and mean MVPA of 5.0 (SD ¼ 9.4) MET-hours/week. Over an average of 13 years of follow-up, 950 (9.6%) obesity-related cancer cases were observed, with 313 (32.9%) resulting in death. Physical activity [HR, 1.05; 95% confidence interval (CI), 0.86-1.30], diet quality (HR, 0.99; 95% CI, 0.92-1.08), and their combination (HR, 1.05; 95% CI, 0.85-1.29) were not associated with risk for any or site-specific obesity-related cancers. Similarly, these health behaviors had no association with mortality. Conclusions: Diet quality, physical activity and their combined effect, as measured, were not associated with obesity-related cancer risk and mortality in Black women enrolled in WHI. Impact: Other social, behavioral, and biological factors may contribute to racial disparities observed in obesity-related cancer rates.
AD  - C.A. Thomson, University of Arizona, 3950 S. Country Club, Tucson, AZ, United States
AU  - Chebet, J. J.
AU  - Thomson, C. A.
AU  - Kohler, L. N.
AU  - Ehiri, J. E.
AU  - Luo, J.
AU  - Cheng, T. Y. D.
AU  - Pan, K.
AU  - Chlebowski, R. T.
AU  - Nassir, R.
AU  - Sealy-Jefferson, S.
AU  - Manson, J. E.
AU  - Saquib, N.
AU  - Bell, M. L.
DB  - Embase
Medline
DO  - 10.1158/1055-9965.EPI-19-1063
IS  - 3
KW  - adult
aged
alcohol consumption
article
Black person
body mass
breast cancer
cancer mortality
cancer risk
cohort analysis
colorectal cancer
controlled study
female
follow up
health behavior
health care disparity
human
intervention study
major clinical study
metabolic equivalent
middle aged
nutritional parameters
obesity
observational study
physical activity
postmenopause
priority journal
prospective study
questionnaire
randomized controlled trial
sedentary time
smoking
treatment outcome
waist circumference
LA  - English
M3  - Article
N1  - L2005412750
2020-04-07
2020-04-10
PY  - 2020
SN  - 1538-7755
1055-9965
SP  - 591-598
ST  - Association of diet quality and physical activity on obesity-related cancer risk and mortality in black women: Results from the Women's Health Initiative
T2  - Cancer Epidemiology Biomarkers and Prevention
TI  - Association of diet quality and physical activity on obesity-related cancer risk and mortality in black women: Results from the Women's Health Initiative
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L2005412750&from=export
http://dx.doi.org/10.1158/1055-9965.EPI-19-1063
VL  - 29
ID  - 821
ER  - 

TY  - JOUR
AB  - BACKGROUND: This study explores whether externalizing religious and spiritual beliefs is associated with advanced-stage colon cancer at initial oncology presentation and whether this association is stronger for blacks than for whites. METHODS: Patients who had newly diagnosed, invasive colon cancer were recruited at 9 sites in the Chicago metropolitan area. Eligible patients were non-Hispanic white or black, ages 30 to 79 years, and diagnosed with a primary invasive colon cancer. Patients were interviewed on prior screening and diagnosis. Social and attitudinal constructs were measured, including the God Locus of Health Control (GLHC) and Religious Problem Solving. The final response rate was 52% and included 407 patients. RESULTS: The median age was 59 years (range, 30-79 years), and 51% of participants were black. Cancer stage was available for 389 (96%) patients and was divided between late stage (stages III-IV; 60%) and early stage (stages I-II; 40%). Multivariate analysis indicated that patients in the highest tertile of scores on the GLHC were more likely have an advanced stage of disease at presentation (odds ratio, 2.14; 95% confidence interval, 1.00-4.59; P =.05) compared with those in the lowest tertile. No significant interaction was identified between race and GLHC scores for stage at presentation (P =.78). CONCLUSIONS: In a large sample of black and white individuals across diverse health care systems, higher scores on the GLHC predicted late disease stage at presentation. Although blacks had significantly higher GLHC scores, race was not associated with stage at presentation, nor was the association between GLHC and stage limited to blacks. Further work is needed to better understand this association and to develop interventions to better connect the religious and health care spheres. Cancer 2018;124:2578-87. © 2018 American Cancer Society. © 2018 American Cancer Society
AD  - Department of Medicine, University of Chicago, Chicago, IL, United States
Florida State University College of Medicine, Tallahassee, FL, United States
Department of Psychology, University of Notre Dame, Notre Dame, IN, United States
Division of Epidemiology and Biostatistics, School of Public Health, University of Illinois at Chicago, Chicago, IL, United States
Department of Religion, Health, and Human Values, Rush University Medical Center, Chicago, IL, United States
AU  - Polite, B. N.
AU  - Cipriano-Steffens, T. M.
AU  - Hlubocky, F. J.
AU  - Jean-Pierre, P.
AU  - Cheng, Y.
AU  - Brewer, K. C.
AU  - Rauscher, G. H.
AU  - Fitchett, G. A.
DB  - Scopus
DO  - 10.1002/cncr.31351
IS  - 12
KW  - African Americans
colonic neoplasms
health care disparities
minority health
religion
spirituality
M3  - Article
N1  - Cited By :4
Export Date: 22 March 2021
PY  - 2018
SP  - 2578-2587
ST  - Association of externalizing religious and spiritual beliefs on stage of colon cancer diagnosis among black and white multicenter urban patient populations
T2  - Cancer
TI  - Association of externalizing religious and spiritual beliefs on stage of colon cancer diagnosis among black and white multicenter urban patient populations
UR  - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85044428078&doi=10.1002%2fcncr.31351&partnerID=40&md5=73176037a3c01709fe8dcfe2b35e17f3
VL  - 124
ID  - 2268
ER  - 

TY  - JOUR
AB  - Importance Few new treatments tested in phase 3 cancer randomized clinical trials show an overall survival benefit. Although understanding whether the benefits are consistent among all patient groups is critical for informing guideline care, individual trials are designed to assess the benefits of experimental treatments among all patients and are too small to reliably determine whether treatment benefits apply to demographic or insurance subgroups. Objective To systematically examine whether positive treatment effects in cancer randomized clinical trials apply to specific demographic or insurance subgroups. Design, Setting, and Participants Cohort study of pooled patient-level data from 10 804 patients in SWOG Cancer Research Network clinical treatment trials reported from 1985 onward with superior overall survival for those receiving experimental treatment. Patients were enrolled from 1984 to 2012. Maximum follow-up was 5 years. Main Outcomes and Measures Interaction tests were used to assess whether hazard ratios (HRs) for death comparing standard group vs experimental group treatments were associated with age (>= 65 vs <65 years), race/ethnicity (minority vs nonminority populations), sex, or insurance status among patients younger than 65 years (Medicaid or no insurance vs private insurance) in multivariable Cox regression frailty models. Progression- or relapse-free survival was also examined. Data analyses were conducted from August 2019 to February 2020. Results In total, 19 trials including 10 804 patients were identified that reported superior overall survival for patients randomized to experimental treatment. Patients were predominantly younger than 65 years (67.3%) and female (66.3%); 11.4% were black patients, and 5.7% were Hispanic patients. There was evidence of added survival benefits associated with receipt of experimental therapy for all groups except for patients with Medicaid or no insurance (HR, 1.23; 95% CI, 0.97-1.56; P = .09) compared with those with private insurance (HR, 1.66; 95% CI, 1.44-1.92; P < .001; P = .03 for interaction). Receipt of experimental treatment was associated with reduced added overall survival benefits in patients 65 years or older (HR, 1.21; 95% CI, 1.11-1.32; P < .001) compared with patients younger than 65 years (HR, 1.41; 95% CI, 1.30-1.53; P < .001; P = .01 for interaction), although both older and younger patients appeared to strongly benefit from receipt of experimental treatment. The progression- or relapse-free survival HRs did not differ by age, sex, or race/ethnicity but differed between patients with Medicaid or no insurance (HR, 1.32; 95% CI, 1.06-1.64; P = .01) vs private insurance (HR, 1.74; 95% CI, 1.54-1.97; P < .001; P = .03 for interaction). Conclusions and Relevance Patients with Medicaid or no insurance may have smaller added benefits from experimental therapies compared with standard treatments in clinical trials. A better understanding of the quality of survivorship care that patients with suboptimal insurance receive, including supportive care and posttreatment care, could help establish how external factors may affect outcomes for these patients. This cohort study uses pooled patient-level data from the SWOG Cancer Research Network to assess whether positive treatment effects are associated with demographic or insurance subgroups among patients participating in phase 3 cancer randomized clinical trials. Question Do positive treatment effects from cancer clinical trials apply to all sociodemographic groups? Findings In this cohort study using patient-level data recorded for 10 804 patients who participated in cancer randomized clinical trials with positive findings, the receipt of experimental treatment vs standard treatment was associated with improved overall survival among patients 65 years or older compared with patients younger than 65 years. No significant added benefit of experimental treatment was observed among patients having Medicaid or no insurance compared with those with private insurance. Meaning Patients with Medicaid or no insurance may have smaller added benefits from experimental therapies in clinical trials.
AN  - WOS:000531365300003
AU  - Unger, J. M.
AU  - Blanke, C. D.
AU  - LeBlanc, M.
AU  - Barlow, W. E.
AU  - Vaidya, R.
AU  - Ramsey, S. D.
AU  - Hershman, D. L.
DA  - Apr
DO  - 10.1001/jamanetworkopen.2020.3842
IS  - 4
N1  - e203842
32352530
PY  - 2020
SN  - 2574-3805
ST  - Association of Patient Demographic Characteristics and Insurance Status With Survival in Cancer Randomized Clinical Trials With Positive Findings
T2  - Jama Network Open
TI  - Association of Patient Demographic Characteristics and Insurance Status With Survival in Cancer Randomized Clinical Trials With Positive Findings
VL  - 3
ID  - 2781
ER  - 

TY  - JOUR
AB  - Higher risk for prostate cancer (PCa) among African Americans is partly associated with exposure to dietary fatty-acids, the carcinogenic effects of which remain controversial. Odds ratio of PCa risk was determined by unconditional logistic regression comparing highest with lowest quartiles of plasma fatty-acids in a case-control design. Mean age for 173 African Americans and 340 Nigerians was 56.9 +/- 9.8 and 60.1 +/- 14.0, p<.006, median (25th, 75th percentile) plasma fatty-acid was 2598 (2306, 3035) microg/ml and 2420 (2064, 2795) microg/ml, p<.001, with 48 (27.7%) and 66 (19.4%) PCa cases, respectively. African Americans recorded higher total, omega-6, and trans, but lower saturated and omega-3 fatty-acids, with non-significant PCa risk association for total, omega-6 and trans fatty acids. Positive PCa risk trend was observed in both populations with nervonic, erucic, and arachidonic acids, with docosahexaenoic acid (DHA) among African Americans, and with behenic and stearic acids in Nigerians. Non-significant negative PCa risk trend was observed with ecosapentaenoic acid (EPA) in Nigerians only. These preliminary findings need to be further explored in a larger study that will include risk analysis of fatty-acid ratios to clarify their combined impact on PCa risk.
AD  - Dept. of Surgery, Meharry Medical College, Nashville, TN 37208, USA. fukoli@mmc.edu
AN  - 20173289
AU  - Ukoli, F. A.
AU  - Fowke, J. H.
AU  - Akumabor, P.
AU  - Oguike, T.
AU  - Taher, K. A.
AU  - Murff, H. J.
AU  - Amaefuna, E. R.
AU  - Kittles, R.
AU  - Ahaghotu, C.
AU  - Osime, U.
AU  - Beech, D. J.
DA  - Feb
DO  - 10.1353/hpu.0.0242
DP  - NLM
ET  - 2010/02/23
IS  - 1 Suppl
KW  - African Americans/*statistics & numerical data
African Continental Ancestry Group/*statistics & numerical data
Aged
Case-Control Studies
Dietary Fats
Fatty Acids/*blood
*Health Status Disparities
Humans
Logistic Models
Male
Middle Aged
Nigeria
Odds Ratio
Patient Selection
Pilot Projects
Prostatic Neoplasms/blood/*ethnology
Risk Assessment
United States
LA  - eng
N1  - 1548-6869
Ukoli, Flora A
Fowke, Jay H
Akumabor, Phillip
Oguike, Temple
Taher, Khandaker A
Murff, Harvey J
Amaefuna, Emeka R
Kittles, Rick
Ahaghotu, Chiledum
Osime, Usifo
Beech, Derrick J
K07 CA114029/CA/NCI NIH HHS/United States
K07 CA114029-04/CA/NCI NIH HHS/United States
R01 CA143288/CA/NCI NIH HHS/United States
R01 CA143288-01A1/CA/NCI NIH HHS/United States
Journal Article
United States
J Health Care Poor Underserved. 2010 Feb;21(1 Suppl):127-47. doi: 10.1353/hpu.0.0242.
PY  - 2010
SN  - 1049-2089
SP  - 127-47
ST  - The association of plasma fatty acids with prostate cancer risk in African Americans and Africans
T2  - J Health Care Poor Underserved
TI  - The association of plasma fatty acids with prostate cancer risk in African Americans and Africans
VL  - 21
ID  - 430
ER  - 

TY  - JOUR
AB  - IMPORTANCE: Multiple randomized clinical trials have shown that definitive therapy improves overall survival among patients with high-risk prostate cancer. However, many patients do not receive definitive therapy because of sociodemographic and health-related factors. OBJECTIVE: To identify factors associated with receipt of nondefinitive therapy (NDT) among patients aged 70 years and younger with high-risk prostate cancer. DESIGN, SETTING, AND PARTICIPANTS: This cohort study identified 72 036 patients aged 70 years and younger with high-risk prostate cancer and Charlson Comorbidity Index scores of 2 or less who were entered in the National Cancer Database between January 2004 and December 2014. Data analysis was conducted from November 2018 to December 2019. EXPOSURE: Receipt of NDT as an initial treatment approach. MAIN OUTCOMES AND MEASURES: Survival rates were compared based on receipt of definitive therapy or NDT, and sociodemographic and health-related factors were associated with the type of therapy received. Residual life expectancy was estimated from the National Center for Health Statistics to calculate person-years of life lost. RESULTS: A total of 72 036 men with a median (range) age of 63 (30-70) years, Charlson Comorbidity Index scores of 2 or less, and high-risk prostate cancer without regional lymph node or distant metastatic disease were analyzed. Among eligible patients, 5252 (7.3%) received NDT as an initial therapeutic strategy. On univariate and multivariate analyses, NDT was associated with worse overall survival (univariate analysis hazard ratio, 2.54; 95% CI, 2.40-2.69; P < .001; multivariate analysis hazard ratio, 2.40; 95% CI, 2.26-2.56; P < .001). Compared with patients with private insurance or managed care, those with no insurance, Medicaid, or Medicare were more likely to receive systemic therapy only (no insurance: odds ratio [OR], 3.34; 95% CI, 2.81-3.98; P < .001; Medicaid: OR, 2.92; 95% CI, 2.48-3.43; P < .001; Medicare: OR, 1.36; 95% CI, 1.20-1.53; P < .001) or no treatment (no insurance: OR, 2.63; 95% CI, 2.24-3.08; P < .001; Medicaid: OR, 1.71; 95% CI, 1.45-2.01; P < .001; Medicare: OR, 1.14; 95% CI, 1.04-1.24; P = .004). Compared with white patients, black patients were more likely to receive systemic therapy only (OR, 1.93; 95% CI, 1.74-2.14; P < .001) or no treatment (OR, 1.46; 95% CI, 1.32-1.61; P < .001), and Hispanic patients were more likely to receive systemic therapy only (OR, 1.36; 95% CI, 1.13-1.64; P = .001) or no treatment (OR, 1.36; 95% CI, 1.14-1.60; P < .001). Between 2004 and 2014, patients without insurance or enrolled in Medicaid had 1.83-fold greater person-years of life lost compared with patients with private insurance (area under the curve, 77 600 vs 42 300 person-years of life lost). CONCLUSIONS AND RELEVANCE: In this study, receipt of NDT was associated with insurance status and race/ethnicity. While treatment decisions should be individualized for every patient, younger men with high-risk prostate cancer and minimal comorbidities should be encouraged to receive definitive local therapy regardless of other factors. These data suggest that significant barriers to life-extending treatment options for patients with prostate cancer remain.
AD  - Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston.
Department of Urology, The University of Texas MD Anderson Cancer Center, Houston.
Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston.
Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston.
Department of Statistics, The University of Texas MD Anderson Cancer Center, Houston.
AN  - 32191331
AU  - Bagley, A. F.
AU  - Anscher, M. S.
AU  - Choi, S.
AU  - Frank, S. J.
AU  - Hoffman, K. E.
AU  - Kuban, D. A.
AU  - McGuire, S. E.
AU  - Nguyen, Q. N.
AU  - Chapin, B.
AU  - Aparicio, A.
AU  - Pezzi, T. A.
AU  - Smith, G. L.
AU  - Smith, B. D.
AU  - Hess, K.
AU  - Tang, C.
C2  - PMC7082722 Varian Medical Systems and Boston Scientific; receiving grants from Hitachi, Eli Lilly and Co, and ELEKTA; receiving personal fees and grants from C4 Imaging; and holding a patent with C4 Imaging related to magnetic resonance imaging reagents and markers outside the submitted work. Dr Chapin reported receiving personal fees from Blue Earth Diagnostics and Janssen Pharmaceuticals outside the submitted work. Dr G. L. Smith reported receiving grants from the National Cancer Institute outside of the submitted work. Dr B. D. Smith reported receiving grants from Varian Medical Systems and owning equity interest in Oncora Medical Systems outside the submitted work. No other disclosures were reported.
DA  - Mar 2
DO  - 10.1001/jamanetworkopen.2020.1255
DP  - NLM
ET  - 2020/03/20
IS  - 3
KW  - Adult
African Americans/statistics & numerical data
Aged
*Antineoplastic Protocols
Comorbidity
European Continental Ancestry Group/statistics & numerical data
*Health Status Disparities
Healthcare Disparities/ethnology/*statistics & numerical data
Humans
Insurance Coverage/statistics & numerical data
Male
Middle Aged
Odds Ratio
Proportional Hazards Models
Prostatic Neoplasms/ethnology/*mortality/therapy
*Socioeconomic Factors
LA  - eng
N1  - 2574-3805
Bagley, Alexander F
Anscher, Mitchell S
Choi, Seungtaek
Frank, Steven J
Hoffman, Karen E
Kuban, Deborah A
McGuire, Sean E
Nguyen, Quynh-Nhu
Chapin, Brian
Aparicio, Ana
Pezzi, Todd A
Smith, Grace L
Smith, Benjamin D
Hess, Kenneth
Tang, Chad
K07 CA211804/CA/NCI NIH HHS/United States
Journal Article
JAMA Netw Open. 2020 Mar 2;3(3):e201255. doi: 10.1001/jamanetworkopen.2020.1255.
PY  - 2020
SN  - 2574-3805
SP  - e201255
ST  - Association of Sociodemographic and Health-Related Factors With Receipt of Nondefinitive Therapy Among Younger Men With High-Risk Prostate Cancer
T2  - JAMA Netw Open
TI  - Association of Sociodemographic and Health-Related Factors With Receipt of Nondefinitive Therapy Among Younger Men With High-Risk Prostate Cancer
VL  - 3
ID  - 47
ER  - 

TY  - JOUR
AB  - Objective: To determine the relationship between urologic oncology fellowship training (UOFT) and diagnostic yield of prostate biopsy. Methods: Retrospective review was conducted of patients who underwent prostate biopsy across the Cleveland Clinic between 2000 and 2018. Biopsies done by urologists with and without UOFT were detailed via descriptive statistics and appropriate (chi-square, Student t, Wilcoxon rank-sum) tests. Multivariate logistic regression was used to examine the association between UOFT and positive prostate biopsy, adjusting for relevant covariates. Results: A total of 11,241 biopsies by 129 urologists had complete information available for review. Sixteen urologists (12.4%) had UOFT; 113 either completed a different fellowship or no fellowship. Those with UOFT were more likely to use MRI-guided biopsy (7.80% vs 3.05%, P <.0001), more likely to get a positive biopsy (41.25% vs 32.72%, P <.0001), and more likely to obtain an adequate number (by ≥12) of cores (90.25% vs 74.53%, P <.0001). UOFT remained a significant predictor of positivity when adjusting for patient age and race, PSA, 5-alpha-reductase-inhibitor use, year of biopsy, years in practice, and type of biopsy (MRI or transrectal ultrasound guided). UOFT also predicted higher-risk biopsy (Gleason sum ≥7), adjusting for the same variables, though this association lost significance when adjusting for adequacy of biopsy. The learning curve to achieve a higher percentage of positive biopsies was steeper for nonurologic oncology fellowship trained than for UOFT urologists. Conclusion: UOFT is associated with higher diagnostic yield on prostate biopsy, higher uptake of MRI-guided biopsy, and less steep learning curve. This may be due to patient selection, technique, or, as we demonstrate here, adherence to guidelines.
AD  - M.E. DeWitt-Foy, 9500 Euclid Avenue, Q-10 Mail stop, Cleveland, OH, United States
AU  - DeWitt-Foy, M. E.
AU  - Klein, E. A.
AU  - ElShafei, A.
AU  - Coronado, W. M.
AU  - Campbell, S.
AU  - Gong, M.
AU  - Berglund, R.
AU  - Ulchaker, J.
AU  - Fareed, K.
AU  - Abouassaly, R.
DB  - Embase
Medline
DO  - 10.1016/j.urology.2019.11.018
KW  - dutasteride
finasteride
prostate specific antigen
adult
African American
American Indian
article
Asian
Caucasian
cohort analysis
controlled study
diagnostic accuracy
diagnostic value
drug use
Gleason score
human
human tissue
image guided biopsy
infectious complication
learning curve
male
medical education
medical practice
multiracial person
nuclear magnetic resonance imaging
oncology
patient selection
prediction
priority journal
prostate biopsy
prostate volume
protocol compliance
retrospective study
risk factor
transrectal ultrasonography
urologist
urology
LA  - English
M3  - Article
N1  - L2004291245
2019-12-31
2020-03-16
PY  - 2020
SN  - 1527-9995
0090-4295
SP  - 115-120
ST  - The Association of Urologic Oncology Fellowship Training and Diagnostic Yield of Prostate Biopsy
T2  - Urology
TI  - The Association of Urologic Oncology Fellowship Training and Diagnostic Yield of Prostate Biopsy
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L2004291245&from=export
http://dx.doi.org/10.1016/j.urology.2019.11.018
VL  - 137
ID  - 813
ER  - 

TY  - THES
AB  - Published assessments of religion and health scholarship observe the substantial need for the study of African American spirituality, and that what is available has implicated this cultural production as helpful and supportive of good health yet inhibitive in end-of-life decision making. This qualitative study from semi-structured interviews with African American prostate cancer patients finds spirituality as helpful to sustaining patients in their decisions to risk medical research although patients determine their decision to accept risk based on their understanding of the medical science presented to them. They are comforted by the agency available to them through bioethical principles and practices, most notably, informed consent. The findings of this study contest the centrality of the Tuskegee narrative popularly believed to be inhibitive to African American clinical trial participation as well as the over-simplification of the relationship between religion and African Americans' cancer fatalism widely held among members of the health professions. The study acknowledges that structural issues prevent too many African Americans from access to the option of clinical trial participation. Two constructs are offered: a cultural sociological approach (Jeffrey Alexander; Gordon Lynch) to re-imagining Tuskegee as a sacred rhetoric, and a sociological approach to risk acceptance and risk taking referencing institutionalized religion; both constructs are derived from Durkheimian theory. These solutions are offered as responses to the data that emerged through the qualitative research and existing treatments of religion and health in African American religious scholarship. This study suggests that there is a shifting paradigm in which more African Americans will merge their spirituality with scientific knowledge to increase medical research participation with the long term aim of reducing health disparities. In turn, additional theoretical frameworks will emerge beyond the closed loop epistemology inherent in Durkheim's theory. The research agenda begun here points to implications for theory and practice in fields including African American Religions, pastoral theology, health policy, health services, and bioethics. (PsycINFO Database Record (c) 2018 APA, all rights reserved)
AN  - 2018-13258-200
AU  - Laws, Terri
DB  - psyh
DP  - EBSCOhost
KW  - spirituality
clinical trials
patient safety
decision making
N1  - Accession Number: 2018-13258-200. Other Journal Title: Dissertation Abstracts International. Partial author list: First Author & Affiliation: Laws, Terri; Rice University, Religious Studies, US. Release Date: 20180521. Publication Type: Dissertation Abstract (0400). Format Covered: Electronic. Document Type: Dissertation. Dissertation Number: AAI10673569. ISBN: 978-0355384901. Language: English. Major Descriptor: Clinical Trials; Decision Making; Spirituality; Patient Safety. Classification: Health & Mental Health Treatment & Prevention (3300). Population: Human (10); Male (30). Location: US. Methodology: Empirical Study; Interview; Qualitative Study.
PB  - ProQuest Information & Learning
PY  - 2018
SN  - 0419-4209
978-0355384901
ST  - 'At the Cross-Roads': African American spirituality, clinical trials, and patient-subject decision-making
TI  - 'At the Cross-Roads': African American spirituality, clinical trials, and patient-subject decision-making
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2018-13258-200&site=ehost-live&scope=site
VL  - 79
ID  - 1716
ER  - 

TY  - JOUR
AB  - BACKGROUND: Recent literature suggests that living in a rural setting may be associated with adverse cancer outcomes. This study examines the burden of travel from home to cancer center for clinical trial (CT) enrollees. MATERIALS AND METHODS: Patients from the University of California San Francisco Clinical Trial Management System database who enrolled in a cancer CT for a breast, genitourinary, or gastrointestinal malignancy between 1993 and 2014 were included. Cancer type, household zip code, race/ethnicity, phase of study, study sponsor, and year of signed consent were exported. Distance traveled from home to center was calculated using a GoogleMaps application programming interface. The relationships of distance with phase of CT, household income, and race/ethnicity were examined. RESULTS: A total of 1,600 patients were enrolled in breast (55.8%), genitourinary (29.4%), or gastrointestinal (14.9%) cancer CTs. The overall median unidirectional distance traveled from home to study site was 25.8 miles (interquartile range [IQR] 11.5-75.3). Of the trial sponsors examined, principal investigator (56.4%), industry (22.2%), cooperative group (11.6%), and National Institutes of Health (NIH; 9.8%), the longest distance traveled was for NIH-sponsored trials, with a median of 39.4 miles (p < .001). Phase I (8.4%) studies had the longest distance traveled, with a median of 41.2 miles (IQR 14.5-101.0 miles; p = .001). White patients (83%) traveled longer compared with black patients (4.4%), with median distances of 29.9 and 13.9 miles, respectively (p < .001). Patients from lower-income areas (n = 799) traveled longer distances compared with patients from higher-income areas (n = 773; 58.3 vs. 17.8 miles, respectively; p < .001). A multivariable linear model where log10 (distance) was the outcome and adjusting for the exported variables and income revealed that cancer type, year of consent, race/ethnicity, and income were significantly associated with distance traveled. CONCLUSION: This study found that the burden of travel is highest among patients enrolled in NIH-sponsored trials, phase I studies, or living in low-income areas. These data suggest that travel burden for cancer CT participants may be significant. IMPLICATIONS FOR PRACTICE: This study is one of the first to measure travel distance for patients in cancer clinical trials using a real-world GoogleMaps calculator. Out-of-pocket expenses such as travel are not typically covered by health care payers; therefore, patients may face considerable cost to attend each study visit. Using a single-center clinical trials enrollment database, this study found that the burden of travel is highest for patients enrolled in National Institutes of Health-sponsored trials and phase I studies, as well as for patients living in low-income areas. Results suggest that a significant proportion of patients enrolled in clinical trials face a substantial travel burden.
AD  - Department of Medicine, Division of Hematology and Oncology, University of California San Francisco, San Francisco, California, USA hala.borno@ucsf.edu.
Department of Medicine, Division of Hematology and Oncology, University of California San Francisco, San Francisco, California, USA.
Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California, USA.
AN  - 29700209
AU  - Borno, H. T.
AU  - Zhang, L.
AU  - Siegel, A.
AU  - Chang, E.
AU  - Ryan, C. J.
C2  - PMC6263122
DA  - Oct
DO  - 10.1634/theoncologist.2017-0628
DP  - NLM
ET  - 2018/04/28
IS  - 10
KW  - Clinical Trials as Topic/*methods
Early Detection of Cancer/*methods
Female
Humans
Male
Retrospective Studies
Travel/*statistics & numerical data
*Cancer clinical trial disparities
*Health care costs
*Recruitment science
*Representativeness in clinical trials
*Travel distance
article.
LA  - eng
N1  - 1549-490x
Borno, Hala T
Zhang, Li
Siegel, Adam
Chang, Emily
Ryan, Charles J
T32 AG000212/AG/NIA NIH HHS/United States
Journal Article
Oncologist. 2018 Oct;23(10):1242-1249. doi: 10.1634/theoncologist.2017-0628. Epub 2018 Apr 26.
PY  - 2018
SN  - 1083-7159 (Print)
1083-7159
SP  - 1242-1249
ST  - At What Cost to Clinical Trial Enrollment? A Retrospective Study of Patient Travel Burden in Cancer Clinical Trials
T2  - Oncologist
TI  - At What Cost to Clinical Trial Enrollment? A Retrospective Study of Patient Travel Burden in Cancer Clinical Trials
VL  - 23
ID  - 124
ER  - 

TY  - JOUR
AB  - The purpose of this study was to qualitatively assess attitudes associated with the willingness of African-Americans to participate in prostate cancer clinical trials. Fifty-six African-American males, 40 years of age and older, were recruited from South Central Los Angeles. Respondents were divided into lower or middle socio-economic groups based on education and occupation. Focus group discussions were conducted to assess their knowledge about prostate cancer and willingness to participate in prostate cancer clinical trials. In addition, information was obtained to identify their incentives and barriers towards participating in prostate cancer research. Middle socio-economic respondents expressed a greater willingness to participate in prostate cancer clinical trials than did men of lower socio-economic status. Many indicated that they would be more likely to participate if they were encouraged to do so by a physician or researcher who was viewed as being competent and compassionate. Barriers to participation in prostate cancer clinical trials included concerns about drug toxicity, medical experimentation and distrust of the medical establishment. Endeavors aimed at increasing minority representation in prostate cancer clinical studies should address these issues.
AD  - Drew/Meharry/Morehouse Consortium Cancer Center, Drew University School of Medicine and Science, Los Angeles, CA 90061, USA.
AN  - 8728357
AU  - Robinson, S. B.
AU  - Ashley, M.
AU  - Haynes, M. A.
DA  - Apr
DO  - 10.1007/bf01682300
DP  - NLM
ET  - 1996/04/01
IS  - 2
KW  - Adult
African Americans/*psychology
Aged
*Attitude to Health
Clinical Trials as Topic/*psychology
Educational Status
Focus Groups
Health Education
Health Knowledge, Attitudes, Practice
Humans
Los Angeles
Male
Middle Aged
Motivation
*Patient Acceptance of Health Care
Physician-Patient Relations
Prostatic Neoplasms/etiology/prevention & control/*psychology
Socioeconomic Factors
*Urban Population
LA  - eng
N1  - Robinson, S B
Ashley, M
Haynes, M A
CA 54603-02/CA/NCI NIH HHS/United States
Journal Article
Research Support, U.S. Gov't, P.H.S.
Netherlands
J Community Health. 1996 Apr;21(2):77-87. doi: 10.1007/BF01682300.
PY  - 1996
SN  - 0094-5145 (Print)
0094-5145
SP  - 77-87
ST  - Attitude of African-Americans regarding prostate cancer clinical trials
T2  - J Community Health
TI  - Attitude of African-Americans regarding prostate cancer clinical trials
VL  - 21
ID  - 741
ER  - 

TY  - JOUR
AB  - OBJECTIVE: To describe barriers to participation of African Americans in research. DESIGN: Focus group interviews conducted in 1997. PATIENTS: Thirty-three African-American adults presenting to an urban public hospital for outpatient medical care participated in one of five focus groups. MEASUREMENTS AND MAIN RESULTS: African-American patients' attitudes toward medical research were measured. Mistrust of doctors, scientists, and the government was reported consistently by the participants. Many participants described concerns about the ethical conduct of clinicians and investigators when poor or minority patients are involved and cited examples of exploitation as supporting evidence for their mistrust of the medical establishment. While participants were clear about the violation of human rights in the Tuskegee Syphilis Study, all were misinformed of the historical facts of the study. Few participants understood the concept of informed consent. Participants saw signing the document as relinquishing their autonomy and as a legal protection for physicians. Despite these concerns, participants gave recommendations to improve minority participation in research. CONCLUSIONS: African-American participants in this study described distrust of the medical community as a prominent barrier to participation in clinical research. Participants described real and perceived examples of exploitation to support their distrust of researchers. The goal of the consent process, to inform patients of risks and benefits so as to facilitate self-determination, was misinterpreted by these participants. Understanding the importance of interpersonal trust within the clinical relationship may prove to be a significant factor in enhancing participation in clinical trials.
AN  - WOS:000082595600002
AU  - Corbie-Smith, G.
AU  - Thomas, S. B.
AU  - Williams, M. V.
AU  - Moody-Ayers, S.
DA  - Sep
DO  - 10.1046/j.1525-1497.1999.07048.x
IS  - 9
N1  - 669
10491242
PY  - 1999
SN  - 0884-8734
SP  - 537-546
ST  - Attitudes and beliefs of African Americans toward participation in medical research
T2  - Journal of General Internal Medicine
TI  - Attitudes and beliefs of African Americans toward participation in medical research
VL  - 14
ID  - 2725
ER  - 

TY  - JOUR
AB  - The purpose of this study was to qualitatively assess attitudes associated with the willingness of African-Americans to participate in prostate cancer clinical trials. Fifty-six African-American males, 40 years of age and older, were recruited from South Central Los Angeles. Respondents were divided into lower or middle socio-economic groups based on education and occupation. Focus group discussions were conducted to assess their knowledge about prostate cancer and willingness to participate in prostate cancer clinical trials. In addition, information was obtained to identify their incentives and barriers toward participating in prostate cancer research. Middle socio- economic respondents expressed a greater willingness to participate in prostate cancer clinical trials than did men of lower socio-economic status. Many indicated that they would be more likely to participate if they were encouraged to do so by a physician or researcher who was viewed as being competent and compassionate. Barriers to participation in prostate cancer clinical trials included concerns about drug toxicity, medical experimentation and distrust of the medical establishment. Endeavors aimed at increasing minority representation in prostate cancer clinical studies should address these issues.
AD  - S.B. Robinson, Drew/Meharry/Morehouse CCC, 12714 South Avalon Boulevard, Los Angeles, CA 90061, United States
AU  - Robinson, S. B.
AU  - Ashley, M.
AU  - Haynes, M. A.
DB  - Embase
Medline
DO  - 10.1007/BF01682300
IS  - 2
KW  - adult
article
cancer research
clinical trial
controlled clinical trial
controlled study
human
major clinical study
male
Black person
patient attitude
prostate cancer
socioeconomics
LA  - English
M3  - Article
N1  - L26117014
1996-04-30
PY  - 1996
SN  - 0094-5145
SP  - 77-87
ST  - Attitudes of African-Americans regarding prostate cancer clinical trials
T2  - Journal of Community Health
TI  - Attitudes of African-Americans regarding prostate cancer clinical trials
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L26117014&from=export
http://dx.doi.org/10.1007/BF01682300
VL  - 21
ID  - 1338
ER  - 

TY  - THES
AB  - Breast cancer continues to be the most diagnosed cancer for all women, except skin cancer, in the United States. Research findings indicated that the chances of an American women being diagnosed with breast cancer are 1 in 8. Despite all the gains made in the area of cancer research, Black American women continue to have a 67% higher mortality rate than their White counterparts. Advance Directives are legal documents specifically authorized by State laws to ensure that a patient may continue their autonomy. However patient autonomy and self determination are Anglo-centric traditions and therefore may not be equally important to all ethnic and racial groups. The purpose of this qualitative study was to examine the feelings, attitudes, and perspectives of Black American women with a diagnosis of early stage (Stage I and Stage II) breast cancer towards the use and completion of advance directives. Twenty-three Black American women diagnosed with early-stage breast cancer were recruited and interviewed. Interviews were audio-taped, transcribed, and coded using Atlas-ti software. Five psychosocial themes emerged from data analyses: Diagnosis Story, Treatment Story, Stressors Story, Coping Story, and Advance Directive Story. Findings indicated that a majority of respondents were receptive to utilization of advance directives, but they fell into different groups based on stages of readiness to actually create and sign such documents. Participants also differed in their views of how race may impact medical care for women like them. Implications of these findings for practice are discussed. (PsycINFO Database Record (c) 2016 APA, all rights reserved)
AN  - 2009-99190-076
AU  - Gregg, Godfrey A.
DB  - psyh
DP  - EBSCOhost
KW  - attitudes
Black American women
diagnosis
breast cancer
advance directives
Breast Neoplasms
Human Females
N1  - Accession Number: 2009-99190-076. Other Journal Title: Dissertation Abstracts International. Partial author list: First Author & Affiliation: Gregg, Godfrey A.; New York U., US. Release Date: 20100118. Publication Type: Dissertation Abstract (0400). Format Covered: Electronic. Document Type: Dissertation. Dissertation Number: AAI3353019. ISBN: 978-1-109-09098-7. Language: English. Major Descriptor: Advance Directives; Attitudes; Breast Neoplasms; Diagnosis; Human Females. Classification: Social Processes & Social Issues (2900). Population: Human (10); Female (40). Location: US. Methodology: Empirical Study; Quantitative Study. Page Count: 1.
PB  - ProQuest Information & Learning
PY  - 2009
SN  - 0419-4209
978-1-109-09098-7
SP  - 1428-1428
ST  - Attitudes of Black American women with a diagnosis of breast cancer towards advance directives
TI  - Attitudes of Black American women with a diagnosis of breast cancer towards advance directives
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2009-99190-076&site=ehost-live&scope=site
VL  - 70
ID  - 1798
ER  - 

TY  - JOUR
AB  - INTRODUCTION: Black men are diagnosed with prostate cancer at nearly twice the rate of white men and are underrepresented in prostate cancer research, including validation studies of new clinical tools (e.g., genomic testing). Because healthcare system mistrust has contributed to these disparities for centuries, black men may be less inclined to pursue novel testing, and identification of facilitators to their participation in prostate cancer research studies remains warranted. METHODS: A community-engaged approach involving a partnership with a community organization was used to conduct seven focus groups in Minnesota, Alabama, and California to explore black men's attitudes toward prostate cancer research participation and genomic testing for prostate cancer. Data were collected and analyzed from April 2015 to April 2017. RESULTS: Identified genomic testing barriers included a lack of terminology understanding, healthcare system mistrust, reluctance to seek medical care, and unfavorable attitudes toward research. Facilitators included family history, value of prevention, and the desire for health education. Lack of prostate cancer knowledge, prostate-specific antigen testing confusion, healthcare system distrust, and misuse of personal health information were barriers to research study participation. Some black men were motivated to participate in research if it was seen as constructive and transparent. CONCLUSIONS: Disparities for black men can both motivate and disincentivize participation depending upon a positive or negative view of research. Confusion over prostate cancer clinical care has fueled some mistrust among black men affecting both clinical care and research participation. With increased education, health literacy, and assurances of research integrity and transparency, black men may be more willing to participate in prostate cancer testing and research. SUPPLEMENT INFORMATION: This article is part of a supplement entitled African American Men's Health: Research, Practice, and Policy Implications, which is sponsored by the National Institutes of Health.
AD  - Department of Family and Preventive Medicine, University of Utah School of Medicine, Salt Lake City, Utah. Electronic address: charles.rogers@utah.edu.
Department of Health Professions, University of Central Florida, Orlando, Florida.
Department of Family Medicine and Community Health, University of Minnesota Medical School, Minneapolis, Minnesota.
Minnesota State Legislature, Office of the Legislative Auditor, St. Paul, Minnesota.
Health and Wellness Committee, 100 Black Men of America, Inc., Oakland, California.
Department of Urology, University of California, Davis, Sacramento, California.
Department of Urology, University of Alabama at Birmingham, Birmingham, Alabama.
Department of Urology, University of Minnesota Medical School, Minneapolis, Minnesota.
AN  - 30670195
AU  - Rogers, C. R.
AU  - Rovito, M. J.
AU  - Hussein, M.
AU  - Obidike, O. J.
AU  - Pratt, R.
AU  - Alexander, M.
AU  - Berge, J. M.
AU  - Dall'Era, M.
AU  - Nix, J. W.
AU  - Warlick, C.
C2  - PMC6352989
C6  - NIHMS970515 this paper.
DA  - Nov
DO  - 10.1016/j.amepre.2018.05.028
DP  - NLM
ET  - 2019/01/24
IS  - 5 Suppl 1
KW  - Adolescent
Adult
African Americans/*psychology/statistics & numerical data
Aged
Early Detection of Cancer/statistics & numerical data
Genetic Testing/*statistics & numerical data
*Health Knowledge, Attitudes, Practice
Health Literacy/statistics & numerical data
*Health Status Disparities
Healthcare Disparities/statistics & numerical data
Humans
Male
Mass Screening/statistics & numerical data
Middle Aged
Patient Participation/psychology/statistics & numerical data
Prostatic Neoplasms/*diagnosis/genetics/therapy
Trust/psychology
United States
Young Adult
LA  - eng
N1  - 1873-2607
Rogers, Charles R
Rovito, Michael J
Hussein, Musse
Obidike, Ogechi Jessica
Pratt, Rebekah
Alexander, Mark
Berge, Jerica M
Dall'Era, Marc
Nix, Jeffrey W
Warlick, Christopher
K01 CA234319/CA/NCI NIH HHS/United States
R25 CA163184/CA/NCI NIH HHS/United States
U54 MD008620/MD/NIMHD NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
Am J Prev Med. 2018 Nov;55(5 Suppl 1):S103-S111. doi: 10.1016/j.amepre.2018.05.028.
PY  - 2018
SN  - 0749-3797 (Print)
0749-3797
SP  - S103-s111
ST  - Attitudes Toward Genomic Testing and Prostate Cancer Research Among Black Men
T2  - Am J Prev Med
TI  - Attitudes Toward Genomic Testing and Prostate Cancer Research Among Black Men
VL  - 55
ID  - 83
ER  - 

TY  - JOUR
AB  - Participation of African Americans in research trials is low. Understanding the perspectives of African American patients toward participation in clinical trials is essential to understanding the disparities in participation rates compared with whites. A qualitative study was conducted to discover attitudes of the African American community regarding willingness to participate in breast cancer screening and randomized clinical trials. Six focus groups consisting of 8 to I I African American women (N = 58), aged 30 to 65, were recruited from local churches. Focus group sessions involved a 2-hour audio-taped discussion facilitated by 2 moderators. A breast cancer randomized clinical trial involving an experimental breast cancer treatment was discussed to identify the issues related to willingness to participate in such research studies. Six themes surrounding willingness to participate in randomized clinical trials were identified: (1) Significance of the research topic to the individual and/or community; (2) level of trust in the system; (3) understanding of the elements of the trial; (4) preference for "natural treatments" or "religious intervention" over medical care; (5) cost-benefit analysis of incentives and barriers; and (6) openness to risk versus a preference for proven treatments. The majority (80%) expressed willingness or open-mindedness to the idea of participating in the hypothetical trial. Lessons learned from this study support the selection of a culturally diverse research staff and can guide the development of research protocols, recruitment efforts, and clinical procedures that are culturally sensitive and relevant.
AN  - WOS:000248493300002
AU  - Linden, H. M.
AU  - Reisch, L. M.
AU  - Hart, A.
AU  - Harrington, M. A.
AU  - Nakano, C.
AU  - Jackson, J. C.
AU  - Elmore, J. G.
DA  - Jul-Aug
DO  - 10.1097/01.NCC.0000281732.02738.31
IS  - 4
N1  - 17666974
PY  - 2007
SN  - 0162-220X
SP  - 261-269
ST  - Attitudes toward participation in breast cancer randomized clinical trials in the African American community - A focus group study
T2  - Cancer Nursing
TI  - Attitudes toward participation in breast cancer randomized clinical trials in the African American community - A focus group study
VL  - 30
ID  - 3192
ER  - 

TY  - JOUR
AB  - Participation of African Americans in research trials is low. Understanding the perspectives of African American patients toward participation in clinical trials is essential to understanding the disparities in participation rates compared with whites. A qualitative study was conducted to discover attitudes of the African American community regarding willingness to participate in breast cancer screening and randomized clinical trials. Six focus groups consisting of 8 to 11 African American women (N = 58), aged 30 to 65, were recruited from local churches. Focus group sessions involved a 2-hour audio-taped discussion facilitated by 2 moderators. A breast cancer randomized clinical trial involving an experimental breast cancer treatment was discussed to identify the issues related to willingness to participate in such research studies. Six themes surrounding willingness to participate in randomized clinical trials were identified: (1) Significance of the research topic to the individual and/or community; (2) level of trust in the system; (3) understanding of the elements of the trial; (4) preference for "natural treatments" or "religious intervention" over medical care; (5) cost-benefit analysis of incentives and barriers; and (6) openness to risk versus a preference for proven treatments. The majority (80%) expressed willingness or open-mindedness to the idea of participating in the hypothetical trial. Lessons learned from this study support the selection of a culturally diverse research staff and can guide the development of research protocols, recruitment efforts, and clinical procedures that are culturally sensitive and relevant.
AD  - Department of Medicine, Seattle Cancer Care Alliance, University of Washington, Seattle, WA 98109, USA. hmlinden@u.washington.edu
AN  - 17666974
AU  - Linden, H. M.
AU  - Reisch, L. M.
AU  - Hart, A., Jr.
AU  - Harrington, M. A.
AU  - Nakano, C.
AU  - Jackson, J. C.
AU  - Elmore, J. G.
C2  - PMC3908682
C6  - NIHMS499631
DA  - Jul-Aug
DO  - 10.1097/01.Ncc.0000281732.02738.31
DP  - NLM
ET  - 2007/08/02
IS  - 4
KW  - Adult
*African Americans/psychology
Aged
Breast Neoplasms/ethnology/*therapy
Female
Focus Groups
Humans
Mass Screening
Middle Aged
Patient Acceptance of Health Care/*ethnology/psychology
*Patient Selection
*Randomized Controlled Trials as Topic
Washington
LA  - eng
N1  - 1538-9804
Linden, Hannah M
Reisch, Lisa M
Hart, Alton Jr
Harrington, Margaret A
Nakano, Connie
Jackson, J Carey
Elmore, Joann G
K05 CA104699/CA/NCI NIH HHS/United States
K05 CA104699-07/CA/NCI NIH HHS/United States
Journal Article
Research Support, Non-U.S. Gov't
Cancer Nurs. 2007 Jul-Aug;30(4):261-9. doi: 10.1097/01.NCC.0000281732.02738.31.
PY  - 2007
SN  - 0162-220X (Print)
0162-220x
SP  - 261-9
ST  - Attitudes toward participation in breast cancer randomized clinical trials in the African American community: a focus group study
T2  - Cancer Nurs
TI  - Attitudes toward participation in breast cancer randomized clinical trials in the African American community: a focus group study
VL  - 30
ID  - 517
ER  - 

TY  - JOUR
AB  - PURPOSE/OBJECTIVES: to test the effect of a supportive, one-time psychoeducational intervention on treatment adherence among African American women receiving first adjuvant therapy for breast cancer. DESIGN: a pilot, randomized, controlled clinical trial, two-group design, with one-time intervention and four data collection points. SETTING: two University of Pittsburgh Cancer Institute clinics. SAMPLE: 24 African American women. METHODS: the Attitudes, Communication, Treatment, and Support (ACTS) intervention is a 45-minute one-on-one session with an African American woman recommended to have chemotherapy for breast cancer. The interventionist is an African American breast cancer survivor. The intervention consists of a discussion about chemotherapy and the importance of communicating knowledge needs and distress, an explanation of the specific treatment plan according to pathology, and support through the survivor testimonial and video clips from the African American community. MAIN RESEARCH VARIABLES: dose of chemotherapy received and dose of chemotherapy prescribed. FINDINGS: Twenty patients completed chemotherapy, and four chose not to begin or discontinued recommended chemotherapy. The groups were equal in key sociodemographic variables. Compared to usual care, the ACTS intervention participants demonstrated trends toward initiation of chemotherapy (100% versus 82%), overall adherence to chemotherapy (92% versus 73%), and percentage of total dose of chemotherapy received or prescribed (94% versus 74%). Compared to usual care, the ACTS intervention participants demonstrated more rapid initiation of chemotherapy and better overall adherence to chemotherapy. CONCLUSIONS: the pilot ACTS intervention shows promise as a psychoeducational intervention to assist with chemotherapy decision making among African American women. IMPLICATIONS FOR NURSING: African American women are at high risk of not receiving the full dose of prescribed chemotherapy for breast cancer for multiple reasons. Nurses must be sensitive to the unique fears and concerns of this population regarding chemotherapy decisions. An intervention addressing these fears and concerns may help to increase adherence.
AD  - University of Pittsburgh School of Nursing, Pennsylvania, USA. mros@pitt.edu
AN  - 21186164
AU  - Rosenzweig, M.
AU  - Brufsky, A.
AU  - Rastogi, P.
AU  - Puhalla, S.
AU  - Simon, J.
AU  - Underwood, S.
DA  - Jan
DO  - 10.1188/11.Onf.85-89
DP  - NLM
ET  - 2010/12/28
IS  - 1
KW  - Adult
African Americans/*psychology
Antineoplastic Agents/*administration & dosage
*Attitude to Health
*Breast Neoplasms/drug therapy/nursing/psychology
Chemotherapy, Adjuvant
Female
Healthcare Disparities
Humans
Middle Aged
Nurse-Patient Relations
Oncology Nursing/*methods
Patient Education as Topic/*methods
Patient Participation/psychology
Pilot Projects
Social Support
LA  - eng
N1  - 1538-0688
Rosenzweig, Margaret
Brufsky, Adam
Rastogi, Priya
Puhalla, Shannon
Simon, Jacqueline
Underwood, Sandra
Journal Article
Randomized Controlled Trial
United States
Oncol Nurs Forum. 2011 Jan;38(1):85-9. doi: 10.1188/11.ONF.85-89.
PY  - 2011
SN  - 0190-535x
SP  - 85-9
ST  - The attitudes, communication, treatment, and support intervention to reduce breast cancer treatment disparity
T2  - Oncol Nurs Forum
TI  - The attitudes, communication, treatment, and support intervention to reduce breast cancer treatment disparity
VL  - 38
ID  - 403
ER  - 

TY  - JOUR
AB  - CONTEXT: Common perceptions exist within the medical community that retention of Hispanics in clinical trials is difficult, albeit little data is available to support this conviction. METHODS: A total of 541 randomly selected charts from closed clinical trials between 2000 and 2006 were reviewed. Records were from participating institutions in Texas Medical Center, Houston, and targeted diseases of high prevalence, specifically, breast cancer, prostate cancer, and chronic obstructive pulmonary disease (COPD)/asthma. FINDINGS: Overall, 259 participants (48%) completed the trial they were enrolled in (44% whites, 69% Hispanics, 51% blacks; p<.05). Within pediatric trials, whom all were pulmonary patients, retention rates were higher among Hispanics than whites (adjusted odds ratio [OR]=7.49, 95% confidence interval [CI]=1.15-58.03, p=.04). Among adults, patient's ethnicity was unrelated to study completion. All associations were adjusted for possible confounders. Reasons for not completing a trial varied by ethnicity: "patient withdrawing consent" was more common among whites (51.4%) than Hispanics (21.7%) or blacks (26.2%) (p<.05). Hispanics were more inclined to be withdrawn from the trial by the investigator (43.5%) than were whites (24%, p=.04), mostly due to non-compliance with the study protocol. CONCLUSIONS: Hispanic parents of children with COPD may be more likely to complete a trial than parents of non-Hispanic whites. Among adults, Hispanics had similar completion rates as compared to whites. Culturally sensitive, multi-factorial approaches maybe imperative to increasing patient engagement in clinical trials.
AD  - Baylor College of Medicine, Houston, TX 77030, United States. halehs@bcm.tmc.edu
AN  - 19573625
AU  - Sangi-Haghpeykar, H.
AU  - Meddaugh, H. M.
AU  - Liu, H.
AU  - Grino, P.
DA  - Nov
DO  - 10.1016/j.cct.2009.06.004
DP  - NLM
ET  - 2009/07/04
IS  - 6
KW  - Adolescent
Adult
Age Factors
Aged
Breast Neoplasms/therapy
Child
Clinical Trials as Topic/*statistics & numerical data
Continental Population Groups/statistics & numerical data
Female
Hispanic Americans/*statistics & numerical data
Humans
Male
Middle Aged
Patient Dropouts/*statistics & numerical data
Prostatic Neoplasms/therapy
Pulmonary Disease, Chronic Obstructive/therapy
Sex Factors
Young Adult
LA  - eng
N1  - 1559-2030
Sangi-Haghpeykar, Haleh
Meddaugh, Hannah M
Liu, Hao
Grino, Placido
Journal Article
Research Support, Non-U.S. Gov't
United States
Contemp Clin Trials. 2009 Nov;30(6):499-503. doi: 10.1016/j.cct.2009.06.004. Epub 2009 Jun 30.
PY  - 2009
SN  - 1551-7144
SP  - 499-503
ST  - Attrition and retention in clinical trials by ethnic origin
T2  - Contemp Clin Trials
TI  - Attrition and retention in clinical trials by ethnic origin
VL  - 30
ID  - 459
ER  - 

TY  - JOUR
AB  - BACKGROUND: Minority patients with breast cancer are at risk for undertreatment of cancer-related pain. The authors evaluated the feasibility and efficacy of an automated pain intervention for improving pain and symptom management of underserved African American and Latina women with breast cancer. METHODS: Sixty low-income African American and Latina women with breast cancer and cancer-related pain were enrolled in a pilot study of an automated, telephone-based, interactive voice response (IVR) intervention. Women in the intervention group were called twice weekly by the IVR system and asked to rate the intensity of their pain and other symptoms. The patients' oncologists received e-mail alerts if the reported symptoms were moderate to severe. The patients also reported barriers to pain management and received education regarding any reported obstacles. RESULTS: The proportion of women in both groups reporting moderate to severe pain decreased during the study, but the decrease was significantly greater for the intervention group. The IVR intervention also was associated with improvements in other cancer-related symptoms, including sleep disturbance and drowsiness. Although patient adherence to the IVR call schedule was good, the oncologists who were treating the patients rated the intervention as only somewhat useful for improving symptom management. CONCLUSIONS: The IVR intervention reduced pain and symptom severity for underserved minority women with breast cancer. Additional research on technological approaches to symptom management is needed.
AD  - Department of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Office of Cancer Survivorship, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Department of General Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
London Regional Cancer Program, London Health Sciences Center, London, Ontario, Canada.
Department of Psychiatry and Behavioral Sciences, The University of Texas Health Sciences Center, Houston, Texas.
Duke Institute on Care at the End of Life, Duke University Divinity School, Durham, North Carolina.
AN  - 25711974
AU  - Anderson, K. O.
AU  - Palos, G. R.
AU  - Mendoza, T. R.
AU  - Cleeland, C. S.
AU  - Liao, K. P.
AU  - Fisch, M. J.
AU  - Garcia-Gonzalez, A.
AU  - Rieber, A. G.
AU  - Nazario, L. A.
AU  - Valero, V.
AU  - Hahn, K. M.
AU  - Person, C. L.
AU  - Payne, R.
C2  - PMC4527331
C6  - NIHMS652620
DA  - Jun 1
DO  - 10.1002/cncr.29204
DP  - NLM
ET  - 2015/02/26
IS  - 11
KW  - *African Americans
Automation/methods
Breast Neoplasms/complications/*drug therapy/*ethnology
Female
*Hispanic Americans
Humans
Middle Aged
Pain/*ethnology/etiology
Pain Management/*methods
Pain Measurement/*methods
Poverty
Telemedicine/methods
Vulnerable Populations
assessment
breast cancer
minority groups
pain
symptoms
LA  - eng
N1  - 1097-0142
Anderson, Karen O
Palos, Guadalupe R
Mendoza, Tito R
Cleeland, Charles S
Liao, Kai-Ping
Fisch, Michael J
Garcia-Gonzalez, Araceli
Rieber, Alyssa G
Nazario, L Arlene
Valero, Vicente
Hahn, Karin M
Person, Cheryl L
Payne, Richard
P30 CA016672/CA/NCI NIH HHS/United States
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Cancer. 2015 Jun 1;121(11):1882-90. doi: 10.1002/cncr.29204. Epub 2015 Feb 24.
PY  - 2015
SN  - 0008-543X (Print)
0008-543x
SP  - 1882-90
ST  - Automated pain intervention for underserved minority women with breast cancer
T2  - Cancer
TI  - Automated pain intervention for underserved minority women with breast cancer
VL  - 121
ID  - 255
ER  - 

TY  - JOUR
AB  - OBJECTIVE: Little is known about ethnic differences in awareness of cancer-warning signs or help-seeking behaviour in Britain. As part of the National Awareness and Early Diagnosis Initiative (NAEDI), this study aimed to explore these factors as possible contributors to delay in cancer diagnosis. METHODS: We used quota sampling to recruit 1500 men and women from the six largest minority ethnic groups in England (Indian, Pakistani, Bangladeshi, Caribbean, African and Chinese). In face-to-face interviews, participants completed the newly developed cancer awareness measure (CAM), which includes questions about warning signs for cancer, speed of consultation for possible cancer symptoms and barriers to help seeking. RESULTS: Awareness of warning signs was low across all ethnic groups, especially using the open-ended (recall) question format, with lowest awareness in the African group. Women identified more emotional barriers and men more practical barriers to help seeking, with considerable ethnic variation. Anticipated delay in help seeking was higher in individuals who identified fewer warning signs and more barriers. CONCLUSIONS: The study suggests the need for culturally sensitive, community-based interventions to raise awareness and encourage early presentation. British Journal of Cancer (2009) 101, S24-S30. doi: 10.1038/sj.bjc.6605387 www.bjcancer.com (C) 2009 Cancer Research UK
AN  - WOS:000273523000006
AU  - Waller, J.
AU  - Robb, K.
AU  - Stubbings, S.
AU  - Ramirez, A.
AU  - Macleod, U.
AU  - Austoker, J.
AU  - Hiom, S.
AU  - Wardle, J.
DA  - Dec
DO  - 10.1038/sj.bjc.6605387
N1  - 2
19956159
PY  - 2009
SN  - 0007-0920
SP  - S24-S30
ST  - Awareness of cancer symptoms and anticipated help seeking among ethnic minority groups in England
T2  - British Journal of Cancer
TI  - Awareness of cancer symptoms and anticipated help seeking among ethnic minority groups in England
VL  - 101
ID  - 3132
ER  - 

TY  - JOUR
AB  - Objective: The study objective was to identify biobehavioral variables associated with greater intake of nicotine and a tobacco carcinogen among Black light smokers who smoke 1 to 10 cigarettes per day (CPD). Methods:We analyzed baseline data collected from 426 Black light smokers enrolled in Kick It at Swope III (KIS III), a smoking cessation trial for Black smokers. We examined differences in concentrations of tobacco biomarkers, including urinary total nicotine equivalents (TNE) and total 4-(methylnitrosamino)-1-(3)pyridyl-1-butanonol (NNAL; a human carcinogen), across gender, age, plasma nicotine metabolite ratio (NMR), CPD, and measures of tobacco dependence, including time to first cigarette (TFC), using ANOVA. Results: Tobacco biomarker levels were significantly higher among those who smoked more CPD (6-10 vs 1-5 CPD) and those with greater reported physical dependence on tobacco. Concurrently, those who smoked 1-5 CPD smoked each cigarette more intensely than those who smoked 6-10 CPD. While we found no gender differences overall, among those who smoked 1-5 CPD, women had higher NNAL levels compared to men. The rate of nicotine metabolism, measured by the nicotine metabolite ratio, was not significantly related to TNE or NNAL levels. Conclusion: Among Back Light smokers, higher cigarette consumption and greater physical dependence-but not rate of nicotine metabolism, menthol use, or socioeconomic status-were associated with greater toxicant exposure and thus a likely increased risk of tobacco-related diseases. The lack of data on light smokers, and specifically on Blacks, make this observation important given the disproportionate burden of lung cancer in this population.
AN  - WOS:000503160000008
AU  - St Helen, G.
AU  - Benowitz, N. L.
AU  - Ahluwalia, J. S.
AU  - Tyndale, R. F.
AU  - Addo, N.
AU  - Gregorich, S. E.
AU  - Perez-Stable, E. J.
AU  - Cox, L. S.
DA  - Oct
DO  - 10.1016/j.jnma.2019.04.004
IS  - 5
N1  - 31084916
PY  - 2019
SN  - 0027-9684
SP  - 509-520
ST  - Back Light Smokers: How Nicotine Intake and Carcinogen Exposure Differ Across Various Biobehavioral Factors
T2  - Journal of the National Medical Association
TI  - Back Light Smokers: How Nicotine Intake and Carcinogen Exposure Differ Across Various Biobehavioral Factors
VL  - 111
ID  - 2807
ER  - 

TY  - JOUR
AB  - BACKGROUND: Many recently approved medications to manage multiple myeloma (MM) are oral, require supportive medications to prevent adverse effects, and are taken under complex schedules. Medication adherence is a concern; however, little attention has been directed toward understanding adherence in MM or associated barriers and facilitators. Advanced sensored medication devices (SMDs) offer opportunities to intervene; however, acceptability among patients with MM, particularly African American patients, is untested. OBJECTIVE: This study aimed to explore patients' (1) perceptions of their health before MM including experiences with chronic medications, (2) perceptions of adherence barriers and facilitators, and (3) attitudes toward using SMDs. METHODS: An in-person, semistructured, qualitative interview was conducted with a convenience sample of patients being treated for MM. Patients were recruited from within an urban, minority-serving, academic medical center that had an established cancer center. A standardized interview guide included questions targeting medication use, attitudes, adherence, barriers, and facilitators. Demographics included the use of cell phone technology. Patients were shown 2 different pill bottles with sensor technology-Medication Event Monitoring System and the SMRxT bottle. After receiving information on the transmission ability of the bottles, patients were asked to discuss their reactions and concerns with the idea of using such a device. Medical records were reviewed to capture information on medication and diagnoses. The interviews were audio-recorded and transcribed. Interviews were independently coded by 2 members of the team with a third member providing guidance. RESULTS: A total of 20 patients with a mean age of 56 years (median=59 years; range=29-71 years) participated in this study and 80% (16/20) were African American. In addition, 18 (90%, 18/20) owned a smartphone and 85% (17/20) were comfortable using the internet, text messaging, and cell phone apps. The average number of medications reported per patient was 13 medications (median=10; range=3-24). Moreover, 14 (70%, 14/20) patients reported missed doses for a range of reasons such as fatigue, feeling ill, a busy schedule, forgetting, or side effects. Interest in using an SMD ranged from great interest to complete lack of interest. Examples of concerns related to the SMDs included privacy issues, potential added cost, and the size of the bottle (ie, too large). Despite the concerns, 60% (12/20) of the patients expressed interest in trying a bottle in the future. CONCLUSIONS: Results identified numerous patient-reported barriers and facilitators to missed doses of oral anticancer therapy. Many appear to be potentially mutable if uncovered and addressed. SMDs may allow for capture of these data. Although patients expressed concerns with SMDs, most remained willing to use one. A feasibility trial with SMDs is planned.
AD  - Pharmacy Systems, Outcomes & Policy, College of Pharmacy, University of Illinois at Chicago, Chicago, IL, United States.
Pharmacy Practice, College of Pharmacy, University of Illinois at Chicago, Chicago, IL, United States.
College of Medicine, University of Illinois at Chicago, Chicago, IL, United States.
Department of Medicine, Section of Hematology/Oncology, College of Medicine, University of Illinois at Chicago, Chicago, IL, United States.
AN  - 30425032
AU  - Asfaw, A. A.
AU  - Yan, C. H.
AU  - Sweiss, K.
AU  - Wirth, S.
AU  - Ramirez, V. H.
AU  - Patel, P. R.
AU  - Sharp, L. K.
C2  - PMC6256103
DA  - Nov 12
DO  - 10.2196/cancer.9918
DP  - NLM
ET  - 2018/11/15
IS  - 2
KW  - antineoplastic therapy
challenges
medication adherence
multiple myeloma
race/ethnicity
LA  - eng
N1  - 2369-1999
Asfaw, Alemseged Ayele
Orcid: 0000-0002-1014-3510
Yan, Connie H
Orcid: 0000-0003-1467-4666
Sweiss, Karen
Orcid: 0000-0001-9559-0282
Wirth, Scott
Orcid: 0000-0002-3280-042x
Ramirez, Victor H
Orcid: 0000-0002-0155-1731
Patel, Pritesh R
Orcid: 0000-0002-0313-2194
Sharp, Lisa K
Orcid: 0000-0002-7809-9042
Journal Article
JMIR Cancer. 2018 Nov 12;4(2):e12. doi: 10.2196/cancer.9918.
PY  - 2018
SN  - 2369-1999 (Print)
2369-1999
SP  - e12
ST  - Barriers and Facilitators of Using Sensored Medication Adherence Devices in a Diverse Sample of Patients With Multiple Myeloma: Qualitative Study
T2  - JMIR Cancer
TI  - Barriers and Facilitators of Using Sensored Medication Adherence Devices in a Diverse Sample of Patients With Multiple Myeloma: Qualitative Study
VL  - 4
ID  - 96
ER  - 

TY  - JOUR
AB  - Background: Prostate cancer incidence is about 70% higher among African Americans compared to Whites. Factors associated with this differential remain unclear, although several studies suggest that genetic factors may play a role. Before epidemiologic research can adequately identify factors associated with this differential, we need studies to determine the feasibility of recruiting and retaining African-American men in cohort studies, especially those that collect biological and questionnaire data. Methods: We conducted 4 focus group discussions among African-American men aged 40 to 64 years in North Carolina, and an additional group comprised of their partners, using a semi-structured interview protocol (total N=55 subjects). Data were analyzed with QRS NU*DIST to identify themes. Results: Participants' willingness to participate in cohort studies seemed to be motivated by a perceived risk of prostate cancer. Barriers to participation included mistrust of the research community, poor knowledge of cancer-site specific heterogeneity, anticipated time commitment, and the invasive nature of disease detection procedures. To foster trust and increase disease knowledge, recommended strategies included: partnering with known civic organizations that provide education on risk factors; discussing early signs and symptoms at the point of recruitment; recruiting participants from community clusters; and providing periodic feedback on biologic samples (if collected) to reassure participants of their proper usage. Conclusion: Observational cohort studies focused on African-American men are feasible if certain barriers to participation are addressed.
AD  - C. Hoyo, Department of Health Education, North Carolina Central University, P.O. Box 19837, Durham, NC 27707, United States
AU  - Hoyo, C.
AU  - Reid, M. L.
AU  - Godley, P. A.
AU  - Parrish, T.
AU  - Smith, L.
AU  - Gammon, M.
DB  - Embase
Medline
IS  - 4
KW  - adult
aged
article
attitude
cancer diagnosis
cancer incidence
cancer risk
Caucasian
clinical protocol
cohort analysis
community
controlled study
data analysis
ethnic group
ethnology
female
health education
heredity
human
illness behavior
information processing
male
Black person
patient attitude
patient selection
prostate cancer
prostate tumor
questionnaire
risk factor
spouse
symptomatology
trust
United States
LA  - English
M3  - Article
N1  - L37428175
2003-12-03
PY  - 2003
SN  - 1049-510X
SP  - 470-476
ST  - Barriers and strategies for sustained participation of African-American men in cohort studies
T2  - Ethnicity and Disease
TI  - Barriers and strategies for sustained participation of African-American men in cohort studies
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L37428175&from=export
VL  - 13
ID  - 1288
ER  - 

TY  - JOUR
AD  - Department of Preventive Medicine-Epidemiology, University of Mississippi Medical Center, Jackson, Mississippi, USA.
AN  - 14632274
AU  - Hughes, G. D.
AU  - Sellers, D. B.
AU  - Fraser, L. B., Jr.
AU  - Knight, B.
AU  - Areghan, G. A.
DA  - Fall
DP  - NLM
ET  - 2003/11/25
IS  - 4
KW  - Adult
*African Continental Ancestry Group
Aged
*Attitude to Health
Clinical Trials as Topic
Cohort Studies
Humans
Male
Middle Aged
Mississippi
*Patient Selection
Prostatic Neoplasms/diagnosis/*ethnology/therapy
Research Design
*Treatment Refusal
Trust
LA  - eng
N1  - Hughes, Gail D
Sellers, Denethia B
Fraser, Lionel B Jr
Knight, Bern'Nadette
Areghan, Gloria A
Comment
Journal Article
United States
Ethn Dis. 2003 Fall;13(4):534-6.
PY  - 2003
SN  - 1049-510X (Print)
1049-510x
SP  - 534-6
ST  - Barriers and strategies for sustained participation of African-American men in cohort studies
T2  - Ethn Dis
TI  - Barriers and strategies for sustained participation of African-American men in cohort studies
VL  - 13
ID  - 639
ER  - 

TY  - JOUR
AB  - Before the burgeoning field of biospecimen collection can advance prevention and treatment methods, researchers must access diverse molecular data samples. However, minorities, especially African-American men, remain reticent to join these studies. This study, using theory-based approaches, investigated African-American men's barriers to participating in biorepository research. Fourteen focus groups were conducted among 70 African-American men (ages 40 to 80). The groups were stratified by prostate cancer history and educational attainment background. Participants identified perceived factors that promoted or hindered study participation when questioned about their knowledge and attitudes about biospecimen research. Ninety-four percent of participants indicated never participating in a study that collected biological samples. Barriers to their participation included lack of knowledge and understanding regarding biospecimen research practices and uses. In addition, they extensively cited a prevalent mistrust of the medical community and discomfort with study recruitment practices. African-American males were more willing to participate in biorepository studies with physician endorsement or if they understood that participation could benefit future generations. Men also wanted more recruitment and advertising done in familiar places.
AD  - Division of Public Health Sciences, Department of Surgery, Washington University in St. Louis School of Medicine, St. Louis, MO, 63110, USA. drakeb@wustl.edu.
Alvin J. Siteman Cancer Center, St. Louis, MO, 63110, USA. drakeb@wustl.edu.
Division of Public Health Sciences, Department of Surgery, Washington University in St. Louis School of Medicine, St. Louis, MO, 63110, USA.
Department of Social Work, Southern Illinois University-Edwardsville, Edwardsville, IL, 62026, USA.
Alvin J. Siteman Cancer Center, St. Louis, MO, 63110, USA.
Brown School of Social Work, Washington University in St. Louis, St. Louis, MO, 63110, USA.
AN  - 26341221
AU  - Drake, B. F.
AU  - Boyd, D.
AU  - Carter, K.
AU  - Gehlert, S.
AU  - Thompson, V. S.
C2  - PMC4779426
C6  - NIHMS721357
DA  - Mar
DO  - 10.1007/s13187-015-0905-1
DP  - NLM
ET  - 2015/09/06
IS  - 1
KW  - Adult
African Americans/*statistics & numerical data
Aged
Aged, 80 and over
Biomedical Research
Focus Groups
Health Knowledge, Attitudes, Practice
Humans
Male
Middle Aged
*Patient Selection
Prostatic Neoplasms/prevention & control/*therapy
Specimen Handling/methods
United States
*African-American
*Biorepository
*Prostate cancer
*Recruitment
LA  - eng
N1  - 1543-0154
Drake, Bettina F
Boyd, Danielle
Carter, Kimberly
Gehlert, Sarah
Thompson, Vetta Sanders
U01 CA114594/CA/NCI NIH HHS/United States
U54 CA153460/CA/NCI NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
J Cancer Educ. 2017 Mar;32(1):51-58. doi: 10.1007/s13187-015-0905-1.
PY  - 2017
SN  - 0885-8195 (Print)
0885-8195
SP  - 51-58
ST  - Barriers and Strategies to Participation in Tissue Research Among African-American Men
T2  - J Cancer Educ
TI  - Barriers and Strategies to Participation in Tissue Research Among African-American Men
VL  - 32
ID  - 235
ER  - 

TY  - JOUR
AB  - Many factors contribute to the poor survival of malignant brain tumor patients, some of which are not easily remedied. However, one contributor to the lack of progress that may be modifiable is poor clinical trial accrual. Surveys of brain tumor patients and neuro-oncology providers suggest that clinicians do a poor job of discussing clinical trials with patients and referring patients for clinical trials. Yet, data from the Cancer Action Network of the American Cancer Society suggest that most eligible oncology patients asked to enroll on a clinical trial will agree to do so. To this end, the Society for Neuro-Oncology (SNO) in collaboration with the Response Assessment in Neuro-Oncology (RANO) Working Group, patient advocacy groups, clinical trial cooperative groups, including the Adult Brain Tumor Consortium (ABTC), and other partners are working together with the intent to double clinical trial accrual over the next 5 years. Here we describe the factors contributing to poor clinical trial accrual in neuro-oncology and offer possible solutions.
AN  - WOS:000493070900006
AU  - Lee, E. Q.
AU  - Chukwueke, U. N.
AU  - Hervey-Jumper, S. L.
AU  - de Groot, J. F.
AU  - Leone, J. P.
AU  - Armstrong, T. S.
AU  - Chang, S. M.
AU  - Arons, D.
AU  - Oliver, K.
AU  - Verble, K.
AU  - Al, Musella
AU  - Willmarth, N.
AU  - Alexander, B. M.
AU  - Bates, A.
AU  - Doherty, L.
AU  - Galanis, E.
AU  - Gaffey, S.
AU  - Halkin, T.
AU  - Friday, B. E.
AU  - Fouladi, M.
AU  - Lin, N. U.
AU  - Macdonald, D.
AU  - Mehta, M. P.
AU  - Penas-Prado, M.
AU  - Vogelbaum, M. A.
AU  - Sahebjam, S.
AU  - Sandak, D.
AU  - van den Bent, M.
AU  - Weller, M.
AU  - Reardon, D. A.
AU  - Wen, P. Y.
DA  - Sep
DO  - 10.1093/neuonc/noz104
IS  - 9
N1  - 31175826
PY  - 2019
SN  - 1522-8517
SP  - 1100-1117
ST  - Barriers to accrual and enrollment in brain tumor trials
T2  - Neuro-Oncology
TI  - Barriers to accrual and enrollment in brain tumor trials
VL  - 21
ID  - 2810
ER  - 

TY  - JOUR
AB  - Analyzing data from a survey of African American and White residents in South Carolina, this study attempts to understand how to better promote clinical trial participation specifically within the African American population. To explore why participation is lower in the African American population, the authors examined two sets of potential barriers: structural/procedural (limited accessibility, lack of awareness, doctors not discussing clinical trial options, lack of health insurance) and cognitive/psychological (lack of subjective and factual knowledge, misperceptions, distrust, fear, perceived risk). Findings revealed that African Americans were significantly less willing than Whites to participate in a clinical trial. African Americans also had lower subjective and factual knowledge about clinical trials and perceived greater risk involved in participating in a clinical trial. The authors found that lack of subjective knowledge and perceived risk were significant predictors of African Americans' willingness to participate in a clinical trial. Implications of the findings are discussed in detail.
AN  - WOS:000357092700010
AU  - Kim, S. H.
AU  - Tanner, A.
AU  - Friedman, D. B.
AU  - Foster, C.
AU  - Bergeron, C.
DA  - Jul
DO  - 10.1080/10810730.2015.1018599
IS  - 7
N1  - 26042496
PY  - 2015
SN  - 1081-0730
SP  - 816-826
ST  - Barriers to Clinical Trial Participation: Comparing Perceptions and Knowledge of African American and White South Carolinians
T2  - Journal of Health Communication
TI  - Barriers to Clinical Trial Participation: Comparing Perceptions and Knowledge of African American and White South Carolinians
VL  - 20
ID  - 2971
ER  - 

TY  - JOUR
AB  - While CRC screening rates have increased (and mortality decreased), minority subgroups remain disproportionately affected. This report describes barriers to colonoscopy in a low income, minority population. Study subjects were enrolled in the Healthy Colon Project 2, a randomized controlled trial (RCT) to evaluate the effects of multifaceted intervention strategies in increasing uptake of CRC screening. All participants belonged to a healthcare workers union in the New York tri‐state area and CRC screening was available to all at no cost. Data collected at baseline via telephone include: demographics, perceived barriers to CRC screening, perception of normative behavior, relationship with primary care physician (PCP), other health problems, and intention to screen. Five hundred individuals (of N = 564 enrolled in the RCT) completed the baseline survey. Only 40.8% reported annual household income $50k or above, 54.0% reported education beyond high school, 88.8% were working; 69.4% were female, 52.6% were black, 14.2% were Latino, all were between 50 and 75, with 30.8% over 60 years old. Specific barriers cited were fear of the colonoscopy procedure (43.4%), embarrassment (42.4%), having to take a powerful laxative (35.8%), fear of cancer (31.0%), fear of sedation (30.2%), conflict with work schedule (26.4%), needing an escort afterwards (19.7%), competing family responsibilities (13.4%), and other health issues (12.6%). When asked: If at your next visit your doctor told you to get a colonoscopy, would you do it? 78.6% said YES. Predictors of intention to get a colonoscopy if told to do so were identified via crosstabs. Neither income, education, working with patients, being U.S.‐born, Black, Latino, nor having other health problems was associated with intention. Predictive variables were entered into a stepwise logistic regression. The final logistic regression yielded: fear of colonoscopy procedure (OR=.37 p=.000), having to take a powerful laxative (OR=.61 p=.039), having PCP talk about CRC screening (OR=.47 p=.004), years with current PCP (le 1, 2‐4, 5‐9, 10+)(OR=.79 p=.046), having been to the dentist past year (OR=1.82 p=.015), knowing screening recommended for men and women 50+ (OR= 2.62 p=.014) working (OR=2.78 p=.002). Consistent with other reports, fear of the procedure and having to take a powerful laxative were common barriers to colonoscopy. These barriers were predictive of not intending to get a colonoscopy despite being told to by their PCP. Having been talked to about CRC screening by their PCP and having a longer relationship with their PCP were also deterrents. Having been to the dentist (another prospect often viewed with fear) was positively related to intention to comply. These findings highlight the need for physicians to address patients' fear and suggest the importance of offering alternative CRC screening tests.
AN  - CN-01076119
AU  - Basch, C. H.
AU  - Basch, C. E.
AU  - Zybert, P.
AU  - Wolf, R.
IS  - 4
KW  - *colonoscopy
*gastrointestinal disease
*population
*screening
Dentist
Education
Fear
Female
General practitioner
Health
Health care personnel
High school
Hispanic
Household
Human
Income
Logistic regression analysis
Lowest income group
Male
Mortality
Neoplasm
Patient
Physician
Procedures
Randomized controlled trial
Responsibility
Screening test
Sedation
Telephone
United States
Work schedule
M3  - Journal: Conference Abstract
PY  - 2015
SP  - S754‐
ST  - Barriers to colonoscopy screening in an Urban, minority population
T2  - Gastroenterology
TI  - Barriers to colonoscopy screening in an Urban, minority population
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01076119/full
VL  - 148
ID  - 1644
ER  - 

TY  - JOUR
AB  - BACKGROUND: Breast carcinoma prevention trials must recruit large cohorts of women who have an above-average risk of developing breast carcinoma. Recruitment for the Study of Tamoxifen and Raloxifene (STAR) trial required volunteers to complete a risk assessment questionnaire form (RAF). Women whose estimated risk of developing breast carcinoma in the next 5 years was > or = 1.67% based on the Gail model were invited to participate in STAR. Less than 4% of participants in the previously conducted P1 (tamoxifen vs. placebo) trial were minority women. We, therefore, studied barriers to minority participation in STAR among black, white, and Hispanic women who completed an RAF. METHODS: The authors analyzed the association of Gail model risk factors, education, and insurance with race/ethnicity using chi-square tests and two-sided P values. They developed logistic regression models of trial eligibility, controlling for the Gail model risk factors, education, and insurance status. RESULTS: Among 823 women who completed an RAF, white women were 10 times as likely as Hispanic women and 45 times as likely as black women to be eligible for STAR. Age at first birth (P = 0.04), having an affected first-degree relative (P < 0.0001), having had a biopsy (P < 0.0001), education (P < 0.0001), and insurance status (P < 0.0001) varied by race/ethnicity. All variables except insurance status were associated with eligibility when race was excluded from the model. In a model that included race/ethnicity, the same factors remained statistically significant. CONCLUSIONS: These findings suggested that both the race/ethnicity adjustment and socioeconomic factors were barriers to eligibility for and contribute to low minority participation in breast cancer prevention trials.
AD  - Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, New York 10032, USA. vrg2@columbia.edu
AN  - 15937913
AU  - Grann, V. R.
AU  - Jacobson, J. S.
AU  - Troxel, A. B.
AU  - Hershman, D.
AU  - Karp, J.
AU  - Myers, C.
AU  - Neugut, A. I.
DA  - Jul 15
DO  - 10.1002/cncr.21164
DP  - NLM
ET  - 2005/06/07
IS  - 2
KW  - African Americans
Breast Neoplasms/ethnology/*prevention & control
Clinical Trials as Topic/*methods
Educational Status
*Ethnic Groups
European Continental Ancestry Group
Female
Hispanic Americans
Humans
Insurance, Health
*Patient Selection
*Risk Assessment
Surveys and Questionnaires
LA  - eng
N1  - Grann, Victor R
Jacobson, Judith S
Troxel, Andrea B
Hershman, Dawn
Karp, Julie
Myers, Christa
Neugut, Alfred I
K05CA89155/CA/NCI NIH HHS/United States
K07CA95597/CA/NCI NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.
United States
Cancer. 2005 Jul 15;104(2):374-9. doi: 10.1002/cncr.21164.
PY  - 2005
SN  - 0008-543X (Print)
0008-543x
SP  - 374-9
ST  - Barriers to minority participation in breast carcinoma prevention trials
T2  - Cancer
TI  - Barriers to minority participation in breast carcinoma prevention trials
VL  - 104
ID  - 599
ER  - 

TY  - JOUR
AB  - Introduction Cancer clinical trial (CCT) enrollment is low potentially threatening the generalizability of trial results and expedited regulatory approvals. We assessed whether type of initial patient appointment for non-small cell lung cancer (NSCLC) is associated with CCT eligibility. Methods Using a patient-to-accrual framework, we conducted a quasi-retrospective cohort pilot study at Sidney Kimmel Comprehensive Cancer Center (SKCCC), Baltimore, Maryland. 153 NSCLC patients new to SKCCC were categorized based on type of initial appointment: patients diagnosed or treated and patients seen for a consultation. CCT eligibility was determined by comparing eligibility criteria for each open trial to the electronic medical record (EMR) of each patient at every office visit occurring within 6-months of initial visit. Results We found no association between type of initial appointment and CCT eligibility (OR, 1.15; 95% CI, 0.49–2.73). Analyses did suggest current smokers were less likely to be eligible for trials compared to never smokers (OR, 0.15; 95% CI, 0.03–0.64), and stage 4 patients with second line therapy or greater were more likely to be eligible than stage 1 or 2 patients (OR, 5.18; 95% CI, 1.08–24.75). Additional analyses suggested most current smokers and stage 1 or 2 patients had trials available but were still ineligible. Conclusions SKCCC has a diverse portfolio of trials available for NSCLC patients and should consider research strategies to re-examine eligibility criteria for future trials to ensure increased enrollment of current smokers and stage 1 or 2 patients. We could not confirm whether type of initial visit was related to eligibility.
AD  - N.F. Kanarek, Department of Environmental Health Sciences, Johns Hopkins University Bloomberg School of Public Health, 615 North Wolfe Street, Room E7541, Baltimore, MD, United States
AU  - Hardesty, J. J.
AU  - Kanarek, N. F.
DB  - Embase
DO  - 10.1016/j.conctc.2017.11.010
KW  - adult
African American
aged
article
cancer patient
cancer staging
clinical trial (topic)
cohort analysis
female
human
major clinical study
male
middle aged
non small cell lung cancer
open study
outcome assessment
pilot study
priority journal
race
retrospective study
smoking
LA  - English
M3  - Article
N1  - L619591793
2017-12-15
2017-12-20
PY  - 2018
SN  - 2451-8654
SP  - 45-49
ST  - Barriers to non-small cell lung cancer trial eligibility
T2  - Contemporary Clinical Trials Communications
TI  - Barriers to non-small cell lung cancer trial eligibility
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L619591793&from=export
http://dx.doi.org/10.1016/j.conctc.2017.11.010
VL  - 9
ID  - 906
ER  - 

TY  - JOUR
AB  - This qualitative study identified barriers to African American women's participation in a community-based behavioral intervention trial to increase mammography screening. Four themes emerged from focus group discussions with community agency providers and research team members. These themes were (1) going to the gatekeepers; (2) knowing the culture; (3) location is everything; and (4) protocols, policies, and possibilities. A checklist of actions that nurse researchers could consider to increase African American women's participation in community trials is provided.
AD  - School of Nursing, Indiana University, Indianapolis, IN 46202, USA. katrusse@iupui.edu
AN  - 18457748
AU  - Russell, K. M.
AU  - Maraj, M. S.
AU  - Wilson, L. R.
AU  - Shedd-Steele, R.
AU  - Champion, V. L.
DA  - May
DO  - 10.1016/j.apnr.2006.05.001
DP  - NLM
ET  - 2008/05/07
IS  - 2
KW  - Adult
*African Americans/psychology
Aged
Breast Neoplasms/ethnology/*prevention & control
Community Health Services
Female
Focus Groups
Humans
*Mammography/psychology
Middle Aged
Patient Acceptance of Health Care/*ethnology/psychology
*Patient Selection
*Urban Population
LA  - eng
N1  - 1532-8201
Russell, Kathleen M
Maraj, Maltie S
Wilson, Lisa R
Shedd-Steele, Rivienne
Champion, Victoria L
5 R01 CA 77736-04/CA/NCI NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
United States
Appl Nurs Res. 2008 May;21(2):90-7. doi: 10.1016/j.apnr.2006.05.001.
PY  - 2008
SN  - 0897-1897
SP  - 90-7
ST  - Barriers to recruiting urban African American women into research studies in community settings
T2  - Appl Nurs Res
TI  - Barriers to recruiting urban African American women into research studies in community settings
VL  - 21
ID  - 497
ER  - 

TY  - JOUR
AB  - Minority recruitment to cancer trials is low and there are limited data on minority adherence to lifestyle modification interventions. We examined factors related to recruitment and adherence to a pilot weight loss intervention among Hispanic and black breast cancer survivors. Participants completed a detailed screening interview to assess barriers to enrollment. An index was created to assess adherence at 6 months. 112 potentially eligible women were identified; 66 consented and completed a screening interview. After screening, 9 were ineligible; 15 opted to not enroll; and 42 were randomized. Among eligible women, earlier stage at diagnosis, treatment type, and negative beliefs related to exercise and diet after diagnosis were negatively associated with study enrollment (P < 0.05). Self-reported barriers to adherence included fatigue, family responsibilities, illness, work, transportation, and negative perceptions of exercise and diet. Results from this study emphasize the need to adapt recruitment and adherence strategies to address these factors.
AD  - Department of Health and Behavioral Studies, Teachers College, Columbia University, 525 W 120th Street, New York, NY, 10027, USA. aca2129@columbia.edu.
Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY, USA. aca2129@columbia.edu.
Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA.
Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY, USA.
Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, NY, USA.
Department of Biostatistics, Mailman School of Public Health, Columbia University, New York, NY, USA.
AN  - 26801931
AU  - Aycinena, A. C.
AU  - Valdovinos, C.
AU  - Crew, K. D.
AU  - Tsai, W. Y.
AU  - Mata, J. M.
AU  - Sandoval, R.
AU  - Hershman, D.
AU  - Greenlee, H.
DA  - Feb
DO  - 10.1007/s10903-015-0310-1
DP  - NLM
ET  - 2016/01/24
IS  - 1
KW  - Adult
African Americans/*psychology
Aged
Breast Neoplasms/pathology/*psychology/therapy
Cancer Survivors/*psychology
Diet
Exercise
Female
Health Behavior
Health Knowledge, Attitudes, Practice
Hispanic Americans/*psychology
Humans
Life Style
Mental Health/ethnology
Middle Aged
Neoplasm Staging
Patient Compliance
Patient Selection
Perception
Pilot Projects
Quality of Life
Randomized Controlled Trials as Topic/*psychology
Self Efficacy
Social Support
Sociobiology
Weight Reduction Programs/*methods
Young Adult
*Adherence
*Behavioral intervention
*Black
*Cancer survivor
*Hispanic
*Recruitment
LA  - eng
N1  - 1557-1920
Aycinena, A Corina
Valdovinos, Cristina
Crew, Katherine D
Tsai, Wei Yann
Mata, Jennie M
Sandoval, Rossy
Hershman, Dawn
Greenlee, Heather
Journal Article
United States
J Immigr Minor Health. 2017 Feb;19(1):120-129. doi: 10.1007/s10903-015-0310-1.
PY  - 2017
SN  - 1557-1912
SP  - 120-129
ST  - Barriers to Recruitment and Adherence in a Randomized Controlled Diet and Exercise Weight Loss Intervention Among Minority Breast Cancer Survivors
T2  - J Immigr Minor Health
TI  - Barriers to Recruitment and Adherence in a Randomized Controlled Diet and Exercise Weight Loss Intervention Among Minority Breast Cancer Survivors
VL  - 19
ID  - 220
ER  - 

TY  - JOUR
AB  - Background. We conducted this retrospective study to identify reasons that patients referred to a phase I clinical trial failed to enroll or delayed enrollment onto the trial. Materials and Methods. Outcome analyses were conducted independently on data collected from electronic medical records of two sets of consecutive patients referred to a phase I clinical trial facility at MD Anderson Cancer Center. Data from the first set of 300 patients were used to determine relevant variables affecting enrollment; data from the second set of 957 patients were then analyzed for these variables. Results. Results from the two sets of patients were similar. Approximately 55% of patients were enrolled in a phase I trial. Patients referred from within MD Anderson were more likely to be enrolled than patients seen originally outside the institution (p = .006); black patients were more likely than white patients to enroll (69% vs. 43%; p = .04). The median interval from the initial visit to initiation of treatments was 19 days. Major reasons for failure to enroll included failure to return to the clinic (36%), opting for treatment in another clinic (17%), hospice referral (11%), early death (10%), and lack of financial clearance (5%). Treatment was delayed for three weeks or more in 250 patients; in 85 patients (34%), the delay was caused by financial and insurance issues. Conclusion. Failure to return to the clinic, pursuit of other therapy, and rapid deterioration were the major reasons for failure to enroll; lengthy financial clearance was the most common reason for delayed enrollment onto a phase I trial.
AN  - WOS:000328254900012
AU  - Fu, S. Q.
AU  - McQuinn, L.
AU  - Naing, A.
AU  - Wheler, J. J.
AU  - Janku, F.
AU  - Falchook, G. S.
AU  - Piha-Paul, S. A.
AU  - Tu, D.
AU  - Howard, A.
AU  - Tsimberidou, A.
AU  - Zinner, R.
AU  - Hong, D. S.
AU  - Kurzrock, R.
DA  - Dec
DO  - 10.1634/theoncologist.2013-0202
IS  - 12
N1  - 24153239
PY  - 2013
SN  - 1083-7159
SP  - 1315-1320
ST  - Barriers to Study Enrollment in Patients With Advanced Cancer Referred to a Phase I Clinical Trials Unit
T2  - Oncologist
TI  - Barriers to Study Enrollment in Patients With Advanced Cancer Referred to a Phase I Clinical Trials Unit
VL  - 18
ID  - 3030
ER  - 

TY  - JOUR
AB  - Background Clinical trials (CTs) are the mechanism by which research is translated into standards of care. Low recruitment among underserved and minority populations may result in inequity in access to the latest technology and treatments, compromise the generalizability, and lead to failure in identification of important positive or negative treatment effects among under-represented populations. Methods Data were collected over a 39-month period on patient eligibility for available therapeutic cancer CTs. Reasons for ineligibility and refusal were collected. The data were captured using an automated software tool for tracking eligibility pre-enrollment. We examined characteristics associated with being evaluated for a trial, and reasons for ineligibility and refusal, overall and by patient race. Results African-Americans (AAs) were more likely than Whites to be ineligible (odds ratio, (OR) = 1.26, 95% confidence interval (CI) = 1.0-1.58) and if eligible, to refuse participation (OR = 1.79, 95% CI = 1.27-2.52), even after adjusting for insurance, age, gender, study phase, and cancer type. White patients were more likely to be ineligible due to study-specific or cancer characteristics. AAs were more likely to be ineligible due to mental status or perceived noncompliance. Whites were more likely to refuse due to extra burden, due to concerns with randomization and toxicity, or because they express a positive treatment preference. AAs were more likely to refuse because they were not interested in CTs, because of family pressures, or they felt overwhelmed (NS)). Discussion This study is the first to directly compare ineligibility and refusal rates and reasons captured prospectively in AA and White cancer patients. The data are consistent with earlier studies that indicated that AA patients more often are deemed ineligible and, when eligible, more often refuse participation. However, differences in reasons for ineligibility and refusal by race have implications for a cancer center to participate in CTs appropriate for the population of patients served. On a broader scale, consideration should be given to modifying eligibility criteria and other design aspects to permit broader participation of minority and other underserved groups. Clinical Trials 2012; 9: 788-797. http://ctj.sagepub.com
AN  - WOS:000312452600018
AU  - Penberthy, L.
AU  - Brown, R.
AU  - Wilson-Genderson, M.
AU  - Dahman, B.
AU  - Ginder, G.
AU  - Siminoff, L. A.
DA  - Dec
DO  - 10.1177/1740774512458992
IS  - 6
N1  - University-of-Pennsylvania Annual Conference on Statistical Issues in Clinical Trials
APR 13-13, 2011
Philadelphia, PA
23033547
PY  - 2012
SN  - 1740-7745
SP  - 788-797
ST  - Barriers to therapeutic clinical trials enrollment: Differences between African-American and white cancer patients identified at the time of eligibility assessment
T2  - Clinical Trials
TI  - Barriers to therapeutic clinical trials enrollment: Differences between African-American and white cancer patients identified at the time of eligibility assessment
VL  - 9
ID  - 3057
ER  - 

TY  - JOUR
AB  - Background: the Prevention of Alzheimer's Disease (AD) by Vitamin E and Selenium (PREADVISE) trial‐an ancillary study to SELECT (prostate cancer prevention trial)‐was designed as a 2X2 factorial, double blind, RCT. PREADVISE began enrolling volunteers from 130 participating SELECT study sites in 2002. In 2008, SELECT suspended supplementation in light of an interim futility analysis, and both trials converted to exposure studies. In 2010, all study sites closed, and PREADVISE participants who consented to continued observation were enrolled in centralized follow‐up (CFU). Cognitive screenings in CFU are conducted via telephone, and PREADVISE remains blinded to treatment arm. Methods: Subjects:PREADVISE enrolled 7,547 non‐demented men age 62 or older (60 if africanamerican); enrollment ceased in 2009. 4,246 of these men volunteered for CFU. To date, 3,702 have been screened at least once during CFU. Procedures: PREADVISE uses a two‐tiered system of annual cognitive screening. Additional data on medication use and comorbid conditions are collected during the screening interview. The Memory impairment Screen (MIS) has been used throughout the study as the first level screening instrument. Men who obtain poor scores on the MIS (< 6/8) are asked to complete a second, more extensive screening instrument. Pre‐CFU, an expanded Consortium to establish a registry in AD (CERAD) battery was used. Because this battery cannot be completed via telephone, the telephone interview for Cognitive Status‐Modified (TICS‐M) is now used. In either case, men who fail the second level screen are asked to schedule a memory and thinking work‐up with their local physician and submit their medical records. A consensus diagnosis based on the screening and medical record data is given by an expert team. For men who refuse the medical work‐up, a diagnosis based on screening data only is assigned. Levels of certainty designated "confirmed" and "suspected" respectively are assigned to each diagnosis accordingly. Statistical Analysis: a stepwise Cox proportional hazards regression was used to estimate the time (from baseline) until an impairment (either suspected or confirmed) was first observed. Variables included in the full model were both fixed and time‐dependent. Fixed variables include baseline age, education (<high school vs. High school+), race (africanamerican vs. Not african‐american), ethnicity (hispanic vs. Nonhispanic), mother's age at childbirth, dementia family history, comorbidities reported at baseline (macular degeneration, cataract, congestive heart failure, heart attack, CaBG, angioplasty, angina, hypertension, tia, arrhythmia, and statin use), memory complaints (none vs. Changes vs. Problems) reported at baseline, and ever history of diabetes. Time‐dependent variables include reports of depression, anxiety, alcohol problem, elevated cholesterol, anti‐hypertensive use, hypoglycemia, thyroid disorder, and sleep apnea. Time‐dependent variables were considered present only if the first report of the condition preceded the first impairment. Results: PREADVISE participants providing at least one CFU data point in the current study were 67.7+/‐5.0 years old at enrollment and comprise 8.1% africanamericans. The men are highly educated, with over 86% reporting more than a high school education, and contribute an average of 8.0+/‐2.1 assessments. The most common comorbidity reported at baseline was hypertension (36.8%), 21.6% of participants reported using a statin, and memory complaints were made by 22.6%. Family history of dementia was also reported by 22.6%. High cholesterol, which was ascertained over time, was reported by 68.1% of participants. Other commonly reported time‐dependent variables include use of an anti‐hypertensive (63.7%), sleep apnea (18.4%), and depression (11.2 %). Ever history of diabetes was reported by 18.2%. A total of 433 (11.8%) of participants had observed impairments: 330 (8.9%) suspected mild cognitive impairment (MCI), 84 (2.3%) confirmed MCI, 4 (0.1%) suspected dementi , and 15 (0.4%) confirmed dementia. The hazard of an observed impairment was significantly increased by older age at baseline (1‐year increment =1.10), baseline hypertension ( =1.88), baseline memory complaint (changes vs. None =1.36, problems vs. None =2.32), africanamerican race ( =3.13), high school education or less ( =1.61), and ever history of diabetes ( =1.29). A significantly reduced hazard of an observed impairment was associated with antihypertensive use (=0.37) and report of high cholesterol ( =0.75). Conclusion: the presence of memory impairment after 8 years of follow‐up is associated with report of a memory problem at study enrollment. Further, awareness and report of changing memory function is also predictive of reduced performance over time and suggests the utility of self‐report for future prevention trials. Consistent with the epidemiological literature on dementia, hypertension, diabetes, and education emerged as significant risk factors for objectively measured memory dysfunction as did african american ethnicity. Also consistent with prior studies, antihypertensives and hypercholesterolemia (statin use) emerged as 'protective' factors. The effect of education on the evolution of impaired memory may be associated with brain reserve and less sensitivity of memory screening measures in better educated participants. With one additional year of screening, evaluation of these risk factors in light of the 5 years of supplement use should provide additional information of antioxidants as potential modifiers of these risk factors.
AN  - CN-01064110
AU  - Kryscio, R.
AU  - Abner, E.
AU  - Caban-Holt, A.
AU  - Mathews, M.
AU  - Schmitt, F.
IS  - 9
KW  - *Alzheimer disease
*clinical trial (topic)
*follow up
*memory
African American
Alcohol
Alpha tocopherol
Angina pectoris
Angioplasty
Antihypertensive agent
Antioxidant
Anxiety
Arm
Cancer prevention
Cataract
Childbirth
Cholesterol
Cognitive reserve
Colony forming unit
Comorbidity
Congestive heart failure
Consensus
Dementia
Dependent variable
Diabetes mellitus
Diagnosis
Drug therapy
Education
Ethnicity
Exposure
Family history
Hazard
Heart arrhythmia
Heart infarction
High school
Hispanic
Human
Hypercholesterolemia
Hypertension
Hypoglycemia
Interview
Male
Maternal age
Medical record
Memory disorder
Mild cognitive impairment
Model
Physician
Prevention
Prevention study
Procedures
Proportional hazards model
Prostate cancer
Register
Retina macula degeneration
Risk factor
Screening
Selenium
Self report
Sleep disordered breathing
Statin (protein)
Statistical analysis
Supplementation
Telephone
Telephone interview
Thyroid disease
Tic
Volunteer
M3  - Journal: Conference Abstract
PY  - 2013
SP  - 782‐783
ST  - Baseline memory problems associate with clinical impairments eight years later: centralized follow-up in the preadvise trial
T2  - Journal of nutrition, health and aging.
TI  - Baseline memory problems associate with clinical impairments eight years later: centralized follow-up in the preadvise trial
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01064110/full
VL  - 17
ID  - 1581
ER  - 

TY  - JOUR
AB  - Background: Prostate-specific antigen (PSA) measurement in midlife predicts long-term prostate cancer (PCa) mortality among white men. Objective: To determine whether baseline PSA level during midlife predicts risk of aggressive PCa in black men. Design, setting, and participants: Nested case-control study among black men in the Southern Community Cohort Study recruited between 2002 and 2009. A prospective cohort in the southeastern USA with recruitment from community health centers. A total of 197 incident PCa patients aged 40–64 yr at study entry and 569 controls matched on age, date of blood draw, and site of enrollment. Total PSA was measured in blood collected and stored at enrollment. Outcome measurements and statistical analysis: Total and aggressive PCa (91 aggressive: Gleason ≥7, American Joint Committee on Cancer stage III/IV, or PCa-specific death). Exact conditional logistic regression estimated odds ratios (ORs) with 95% confidence intervals (CIs) for PCa by category of baseline PSA. Results and limitations: Median PSA among controls was 0.72, 0.80, 0.94, and 1.03 ng/ml for age groups 40–49, 50–54, 55–59, and 60–64 yr, respectively; 90th percentile levels were 1.68, 1.85, 2.73, and 3.33 ng/ml. Furthermore, 95% of total and 97% of aggressive cases had baseline PSA above the age-specific median. Median follow-up was 9 yr. The OR for total PCa comparing PSA >90th percentile versus ≤median was 83.6 (95% CI, 21.2–539) for 40–54 yr and 71.7 (95% CI, 23.3–288) for 55–64 yr. For aggressive cancer, ORs were 174 (95% CI, 32.3–infinity) for 40–54 yr and 51.8 (95% CI, 11.0–519) for 55–64 yr. A composite endpoint of aggressive PCa based on stage, grade, and mortality was used and is a limitation. Conclusions: PSA levels in midlife strongly predicted total and aggressive PCa among black men. PSA levels among controls were similar to those among white controls in prior studies. Patient summary: Prostate-specific antigen (PSA) level during midlife strongly predicted future development of aggressive prostate cancer among black men. Targeted screening based on a midlife PSA might identify men at high risk while minimizing screening in those men at low risk. © 2018 European Association of Urology Prostate-specific antigen (PSA) level during midlife strongly predicted total and aggressive prostate cancer among black men. Risk-stratified screening based on midlife PSA might retain the benefits of screening while reducing harms. © 2018 European Association of Urology
AD  - Division of Urology, Brigham and Women's Hospital, Boston, MA, United States
Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, United States
Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, FL, United States
Department of Surgery (Urology Service), Memorial Sloan Kettering Cancer Center, New York, NY, United States
Department of Urology, Institute of Clinical Sciences, Sahlgrenska Academy at University of Göteborg, Göteborg, Sweden
Division of Cancer Prevention, National Cancer Institute, Bethesda, MD, United States
Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY, United States
Channing Division of Network Medicine, Brigham and Women's Hospital/Harvard Medical School, Boston, MA, United States
Vanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center, Nashville, TN, United States
Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, United States
Departments of Laboratory Medicine and Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States
Nuffield Department of Surgical Sciences, University of Oxford, Oxford, United Kingdom
Department of Translational Medicine, Lund University, Malmö, Sweden
AU  - Preston, M. A.
AU  - Gerke, T.
AU  - Carlsson, S. V.
AU  - Signorello, L.
AU  - Sjoberg, D. D.
AU  - Markt, S. C.
AU  - Kibel, A. S.
AU  - Trinh, Q. D.
AU  - Steinwandel, M.
AU  - Blot, W.
AU  - Vickers, A. J.
AU  - Lilja, H.
AU  - Mucci, L. A.
AU  - Wilson, K. M.
DB  - Scopus
DO  - 10.1016/j.eururo.2018.08.032
IS  - 3
KW  - African-American
Baseline
Prostate cancer
Prostate-specific antigen
Screening
M3  - Article
N1  - Cited By :16
Export Date: 22 March 2021
PY  - 2019
SP  - 399-407
ST  - Baseline Prostate-specific Antigen Level in Midlife and Aggressive Prostate Cancer in Black Men(Figure presented.)
T2  - European Urology
TI  - Baseline Prostate-specific Antigen Level in Midlife and Aggressive Prostate Cancer in Black Men(Figure presented.)
UR  - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85053320099&doi=10.1016%2fj.eururo.2018.08.032&partnerID=40&md5=543b01604020e7b58e0dba1cc2702be0
VL  - 75
ID  - 2238
ER  - 

TY  - JOUR
AB  - BACKGROUND: The Selenium and Vitamin E Cancer Prevention Trial found no effect of selenium supplementation on prostate cancer (PCa) risk but a 17% increased risk from vitamin E supplementation. This case-cohort study investigates effects of selenium and vitamin E supplementation conditional upon baseline selenium status. METHODS: There were 1739 total and 489 high-grade (Gleason 7-10) PCa cases and 3117 men in the randomly selected cohort. Proportional hazards models estimated hazard ratios (HRs) and 95% confidence intervals (CIs) for effects of supplementation within quintiles of baseline toenail selenium. Cox proportional hazards models were used to estimate hazard ratios, and all statistical tests are two-sided. RESULTS: Toenail selenium, in the absence of supplementation, was not associated with PCa risk. Selenium supplementation (combined selenium only and selenium + vitamin E arms) had no effect among men with low selenium status (<60th percentile of toenail selenium) but increased the risk of high-grade PCa among men with higher selenium status by 91% (P = .007). Vitamin E supplementation (alone) had no effect among men with high selenium status (≥40th percentile of toenail selenium) but increased the risks of total, low-grade, and high-grade PCa among men with lower selenium status (63%, P = .02; 46%, P = .09; 111%, P = .008, respectively). CONCLUSIONS: Selenium supplementation did not benefit men with low selenium status but increased the risk of high-grade PCa among men with high selenium status. Vitamin E increased the risk of PCa among men with low selenium status. Men should avoid selenium or vitamin E supplementation at doses that exceed recommended dietary intakes.
AD  - Affiliations of authors: Cancer Prevention Program (ARK) and SWOG Statistical Center (AKD, CMT, PJG), Fred Hutchinson Cancer Research Center, Seattle, WA; Department of Epidemiology (ARK, GEG) and Department of Environmental Health (GEG), University of Washington, Seattle, WA; University of Missouri, Research Reactor Center, Columbia, MO (JSM); Harry S. Truman Memorial Veterans Hospital, Columbia, MO (JSM); Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, TX (IMT); Chao Family Comprehensive Cancer Center, University of California Irvine, Irvine, CA (FLM); Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD (LMM, HLP); Moores Cancer Center, University of California San Diego, San Diego, CA (SML); Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH (EAK).
AN  - 24563519
AU  - Kristal, A. R.
AU  - Darke, A. K.
AU  - Morris, J. S.
AU  - Tangen, C. M.
AU  - Goodman, P. J.
AU  - Thompson, I. M.
AU  - Meyskens, F. L., Jr.
AU  - Goodman, G. E.
AU  - Minasian, L. M.
AU  - Parnes, H. L.
AU  - Lippman, S. M.
AU  - Klein, E. A.
C2  - PMC3975165
DA  - Mar
DO  - 10.1093/jnci/djt456
DP  - NLM
ET  - 2014/02/25
IS  - 3
KW  - African Americans/*statistics & numerical data
Aged
Antioxidants/administration & dosage/*adverse effects/analysis
Canada/epidemiology
Cohort Studies
Dietary Supplements/*adverse effects
Humans
Male
Middle Aged
Nails/*chemistry
Neoplasm Grading
Odds Ratio
Proportional Hazards Models
Prostatic Neoplasms/*chemically induced/epidemiology/pathology
Puerto Rico/epidemiology
Randomized Controlled Trials as Topic
Risk
Selenium/administration & dosage/*adverse effects/analysis
Trace Elements/adverse effects
United States/epidemiology
Vitamin E/administration & dosage/*adverse effects/analysis
Vitamins/adverse effects
LA  - eng
N1  - 1460-2105
Kristal, Alan R
Darke, Amy K
Morris, J Steven
Tangen, Catherine M
Goodman, Phyllis J
Thompson, Ian M
Meyskens, Frank L Jr
Goodman, Gary E
Minasian, Lori M
Parnes, Howard L
Lippman, Scott M
Klein, Eric A
U10 CA037429/CA/NCI NIH HHS/United States
UG1 CA189974/CA/NCI NIH HHS/United States
UM1 CA182883/CA/NCI NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
J Natl Cancer Inst. 2014 Mar;106(3):djt456. doi: 10.1093/jnci/djt456. Epub 2014 Feb 22.
PY  - 2014
SN  - 0027-8874 (Print)
0027-8874
SP  - djt456
ST  - Baseline selenium status and effects of selenium and vitamin e supplementation on prostate cancer risk
T2  - J Natl Cancer Inst
TI  - Baseline selenium status and effects of selenium and vitamin e supplementation on prostate cancer risk
VL  - 106
ID  - 293
ER  - 

TY  - JOUR
AB  - BACKGROUND: Study compliance is crucial when the study outcome is determined by an invasive procedure, such as prostate biopsy. To investigate predictors of compliance in study-mandated prostate biopsies, we analyzed demographic, clinical and reported lifestyle data from the REDUCE trial. METHODS: We retrospectively identified 8025 men from REDUCE with at least 2 years of follow-up, and used multivariable logistic regression to test the association between baseline demographic and clinical characteristics and undergoing the study-mandated prostate biopsy at 2 years. We then examined whether missing any of these data was associated with undergoing a biopsy. RESULTS: In REDUCE, 22% of men did not undergo a 2-year biopsy. On multivariable analysis, the non-North American region was predictive of 42-44% increased likelihood of undergoing a 2-year biopsy (P⩽0.001). Being enrolled at a center that enrolled >10 subjects (2nd and 3rd tertile) was associated with a 42-48% increased likelihood of undergoing a 2-year biopsy (P<0.001). In addition, black race predicted 44% lower rate of on-study 2-year biopsy (odds ratio (OR)=0.56; P=0.001). Finally, missing one or more baseline variables was associated with a 32% decreased likelihood of undergoing a 2-year biopsy (OR=0.68; P<0.001). CONCLUSIONS: In REDUCE, men outside North America, those at higher volume centers and those with complete baseline data were more likely to undergo study-mandated 2-year biopsies. Given prostate biopsy is becoming increasingly utilized as an endpoint in trials that are often multi-national, regional differences in compliance should be considered when designing future trials. Likewise, efforts are needed to ensure compliance in low-volume centers or among subjects missing baseline data.
AD  - Division of Urology, Department of Surgery, Duke University School of Medicine, Durham, NC, USA.
Surgery Section, Durham VA Medical Center, Durham, NC, USA.
Department of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, NC, USA.
Department of Urology, Mayo Clinic, Rochester, MN, USA.
GlaxoSmithKline Inc., R&D Unit, King of Prussia, PA, USA.
Washington University School of Medicine in St. Louis, St. Louis, MI, USA.
Division of Urology, Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
AN  - 26926927
AU  - Fischer, S.
AU  - Sun, S.
AU  - Howard, L. E.
AU  - Moreira, D. M.
AU  - Castro-Santamaria, R.
AU  - Andriole, G. L.
AU  - Vidal, A. C.
AU  - Freedland, S. J.
C2  - PMC4994539
C6  - NIHMS735495
DA  - Jun
DO  - 10.1038/pcan.2016.5
DP  - NLM
ET  - 2016/03/02
IS  - 2
KW  - Aged
Biopsy
Comorbidity
Humans
Male
Middle Aged
Multicenter Studies as Topic
Odds Ratio
*Patient Compliance
Prostatic Neoplasms/*epidemiology/*pathology
Randomized Controlled Trials as Topic
Retrospective Studies
Risk
LA  - eng
N1  - 1476-5608
Fischer, S
Sun, S
Howard, L E
Moreira, D M
Castro-Santamaria, R
Andriole, G L
Vidal, A C
Freedland, S J
K24 CA160653/CA/NCI NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Prostate Cancer Prostatic Dis. 2016 Jun;19(2):202-8. doi: 10.1038/pcan.2016.5. Epub 2016 Mar 1.
PY  - 2016
SN  - 1365-7852 (Print)
1365-7852
SP  - 202-8
ST  - Baseline subject characteristics predictive of compliance with study-mandated prostate biopsy in men at risk of prostate cancer: results from REDUCE
T2  - Prostate Cancer Prostatic Dis
TI  - Baseline subject characteristics predictive of compliance with study-mandated prostate biopsy in men at risk of prostate cancer: results from REDUCE
VL  - 19
ID  - 218
ER  - 

TY  - JOUR
AB  - Purpose: An earlier randomized controlled trial found that two middle school sexual education programs—a risk avoidance (RA) program and a risk reduction (RR) program—delayed initiation of sexual intercourse (oral, vaginal, or anal sex) and reduced other sexual risk behaviors in ninth grade. We examined whether these effects extended into 10th grade. Methods: Fifteen middle schools were randomly assigned to RA, RR, or control conditions. Follow-up surveys were conducted with participating students in 10th grade (n = 1,187; 29.2% attrition). Results: Participants were 60% female, 50% Hispanic, and 39% black; seventh grade mean age was 12.6 years. In 10th grade, compared with the control condition, both programs significantly delayed anal sex initiation in the total sample (RA: adjusted odds ratio [AOR], .64, 95% confidence interval [CI], .42-.99; RR: AOR, .65, 95% CI, .50-.84) and among Hispanics (RA: AOR, .53, 95% CI, .31-.91; RR: AOR, .82, 95% CI, .74-.93). Risk avoidance students were less likely to report unprotected vaginal sex, either by using a condom or by abstaining from sex (AOR: .61, 95% CI, .45-.85); RR students were less likely to report recent unprotected anal sex (AOR: .34, 95% CI, .20-.56). Both programs sustained positive impact on some psychosocial outcomes. Conclusions: Although both programs delayed anal sex initiation into 10th grade, effects on the delayed initiation of oral and vaginal sex were not sustained. Additional high school sexual education may help to further delay sexual initiation and reduce other sexual risk behaviors in later high school years. (PsycINFO Database Record (c) 2019 APA, all rights reserved)
AD  - Markham, Christine M., Center for Health Promotion and Prevention Research, University of Texas Health Science Center at Houston, 7000 Fannin Street, Room 2616, Houston, TX, US, 77030
AN  - 2014-02619-003
AU  - Markham, Christine M.
AU  - Peskin, Melissa F.
AU  - Shegog, Ross
AU  - Baumler, Elizabeth R.
AU  - Addy, Robert C.
AU  - Thiel, Melanie
AU  - Escobar-Chaves, Soledad Liliana
AU  - Robin, Leah
AU  - Tortolero, Susan R.
DB  - psyh
DO  - 10.1016/j.jadohealth.2013.10.204
DP  - EBSCOhost
IS  - 2
KW  - sexual health education programs
middle school
behavioral effects
psychosocial effects
risk avoidance
sexual risk behaviors
sexual intercourse
Adolescent
Coitus
Condoms
Data Collection
Female
Follow-Up Studies
Humans
Male
Sex Education
Sexual Abstinence
Sexual Behavior
Socioeconomic Factors
United States
Educational Program Evaluation
Health Education
Sexual Health
Avoidance
Middle Schools
Middle School Students
Psychosocial Factors
Sexual Intercourse (Human)
Sexual Risk Taking
N1  - Center for Health Promotion and Prevention Research, University of Texas Health Science Center at Houston, Houston, TX, US. Release Date: 20140505. Correction Date: 20190211. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: English. Major Descriptor: Educational Program Evaluation; Health Education; Sex Education; Sexual Health. Minor Descriptor: Avoidance; Middle Schools; Middle School Students; Psychosocial Factors; Sexual Intercourse (Human); Sexual Risk Taking. Classification: Curriculum & Programs & Teaching Methods (3530); Promotion & Maintenance of Health & Wellness (3365). Population: Human (10); Male (30); Female (40). Location: US. Age Group: Childhood (birth-12 yrs) (100); Adolescence (13-17 yrs) (200). Tests & Measures: Audio-Computer-Assisted Self-Interviews; Behavioral Measures; Psychosocial Measures. Methodology: Empirical Study; Followup Study; Interview; Quantitative Study. References Available: Y. Page Count: 9. Issue Publication Date: Feb, 2014. Publication History: Accepted Date: Oct 28, 2013; First Submitted Date: May 30, 2013. Copyright Statement: All rights reserved. Society for Adolescent Health and Medicine. 2014.
Sponsor: Centers for Disease Control and Prevention. Grant: 5U48DP000057. Recipients: No recipient indicated
Sponsor: US Department of Health and Human Services, US. Grant: 90XF0036. Other Details: Adolescent Family Life. Recipients: No recipient indicated
PY  - 2014
SN  - 1054-139X
1879-1972
SP  - 151-159
ST  - Behavioral and psychosocial effects of two middle school sexual health education programs at tenth-grade follow-up
T2  - Journal of Adolescent Health
TI  - Behavioral and psychosocial effects of two middle school sexual health education programs at tenth-grade follow-up
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2014-02619-003&site=ehost-live&scope=site
Christine.Markham@uth.tmc.edu
VL  - 54
ID  - 1795
ER  - 

TY  - JOUR
AB  - Intention, self-efficacy, perceived susceptibility, perceived benefits, and subjective norms are key constructs of health behavior theories; their predictive validity for cancer screening has not been ascertained in multiethnic populations. Participants were 1,463 African American, Chinese, Filipina, Latina, and White women aged 40 to 74 interviewed by telephone in their preferred languages. The relationship between baseline constructs and mammography 2 years later was assessed using multivariable logistic regression. Intention predicted mammography overall and among Whites (odds ratio [OR] = 5.0, 95% confidence interval [CI] = 2.4, 10), with racial/ethnic differences in association (p = .020). Self-efficacy predicted mammography overall and among Whites (OR = 3.5, 95% CI = 1.1, 11), with no racial/ethnic interaction. Perceived benefits and subjective norms were associated with screening overall and in some racial/ethnic groups. These results generally support cross-cultural applicability of four of the five constructs to screening with mixed predictive value of measures across racial/ethnic groups. Additional in-depth inquiry is required to refine assessment of constructs.
AD  - Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA 94143-0981, USA. SStewart@cc.ucsf.edu
AN  - 19805790
AU  - Stewart, S. L.
AU  - Rakowski, W.
AU  - Pasick, R. J.
C2  - PMC2921882
C6  - NIHMS189457
DA  - Oct
DO  - 10.1177/1090198109338918
DP  - NLM
ET  - 2009/10/15
IS  - 5 Suppl
KW  - Adult
Breast Neoplasms/ethnology
Cross-Cultural Comparison
*Ethnic Groups
Female
*Health Behavior
Humans
Intention
*Mammography/statistics & numerical data
Middle Aged
Patient Acceptance of Health Care/*ethnology
Randomized Controlled Trials as Topic
Self Efficacy
Surveys and Questionnaires
United States
LA  - eng
N1  - 1552-6127
Stewart, Susan L
Rakowski, William
Pasick, Rena J
R01 CA081816/CA/NCI NIH HHS/United States
R01CA81816/CA/NCI NIH HHS/United States
P01CA55112/CA/NCI NIH HHS/United States
R01 CA081816-01A2/CA/NCI NIH HHS/United States
HHSN261200900383P/PHS HHS/United States
Journal Article
Research Support, N.I.H., Extramural
Health Educ Behav. 2009 Oct;36(5 Suppl):36S-54S. doi: 10.1177/1090198109338918.
PY  - 2009
SN  - 1090-1981 (Print)
1090-1981
SP  - 36s-54s
ST  - Behavioral constructs and mammography in five ethnic groups
T2  - Health Educ Behav
TI  - Behavioral constructs and mammography in five ethnic groups
VL  - 36
ID  - 443
ER  - 

TY  - JOUR
AB  - Context: Although behavioral therapy has been shown to improve postoperative recovery of continence, there have been no controlled trials of behavioral therapy for postprostatectomy incontinence persisting more than 1 year. Objective: To evaluate the effectiveness of behavioral therapy for reducing persistent postprostatectomy incontinence and to determine whether the technologies of biofeedback and pelvic floor electrical stimulation enhance the effectiveness of behavioral therapy. Design, Setting, and Participants: A prospective randomized controlled trial involving 208 community-dwelling men aged 51 through 84 years with incontinence persisting 1 to 17 years after radical prostatectomy was conducted at a university and 2 Veterans Affairs continence clinics (2003-2008) and included a 1-year follow-up after active treatment. Twenty-four percent of the men were African American; 75%, white. Interventions:; After stratification by type and frequency of incontinence, participants were randomized to 1 of 3 groups: 8 weeks of behavioral therapy (pelvic floor muscle training and bladder control strategies); behavioral therapy plus in-office, dual-channel electromyograph biofeedback and daily home pelvic floor electrical stimulation at 20 Hz, current up to 100 mA (behavior plus); or delayed treatment, which served as the control group. Main Outcome Measure: Percentage reduction in mean number of incontinence episodes after 8 weeks of treatment as documented in 7-day bladder diaries. Results: Mean incontinence episodes decreased from 28 to 13 per week (55% reduction; 95% confidence interval [CI], 44%-66%) after behavioral therapy and from 26 to 12 (51% reduction; 95% CI, 37%-65%) after behavior plus therapy. Both reductions were significantly greater than the reduction from 25 to 21 (24% reduction; 95% CI, 10%-39%) observed among controls (P = .001 for both treatment groups). However, there was no significant difference in incontinence reduction between the treatment groups (P = .69). Improvements were durable to 12 months in the active treatment groups: 50% reduction (95% CI, 39.8%-61.1%; 13.5 episodes per week) in the behavioral group and 59% reduction (95% CI, 45.0%-73.1%; 9.1 episodes per week) in the behavior plus group (P = .32). Conclusions: Among patients with postprostatectomy incontinence for at least 1 year, 8 weeks of behavioral therapy, compared with a delayed-treatment control, resulted in fewer incontinence episodes. The addition of biofeedback and pelvic floor electrical stimulation did not result in greater effectiveness. (PsycINFO Database Record (c) 2016 APA, all rights reserved)
AD  - Goode, Patricia S., University of Alabama Birmingham Center for Aging, 933 19th St S, Birmingham, AL, US, 35294-2041
AN  - 2011-04179-001
AU  - Goode, Patricia S.
AU  - Burgio, Kathryn L.
AU  - Johnson, Theodore M.
AU  - Clay, Olivio J.
AU  - Roth, David L.
AU  - Markland, Alayne D.
AU  - Burkhardt, Jeffrey H.
AU  - Issa, Muta M.
AU  - Lloyd, L. Keith
DB  - psyh
DO  - 10.1001/jama.2010.1972
DP  - EBSCOhost
IS  - 2
KW  - behavioral therapy
biofeedback
pelvic floor electrical stimulation
persistent postprostatectomy incontinence
randomized trials
Aged
Aged, 80 and over
Behavior Therapy
Biofeedback, Psychology
Electric Stimulation Therapy
Humans
Male
Middle Aged
Pelvic Floor
Prospective Studies
Prostatectomy
Prostatic Neoplasms
Treatment Outcome
Urinary Incontinence
Cognitive Therapy
Electrical Stimulation
Surgery
Clinical Trials
N1  - Department of Veterans Affairs, Birmingham–Atlanta Geriatric Research, Education, and Clinical Center, University of Alabama at Birmingham, Birmingham, AL, US. Release Date: 20110321. Correction Date: 20120618. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: English. Major Descriptor: Behavior Therapy; Biofeedback; Cognitive Therapy; Electrical Stimulation; Surgery. Minor Descriptor: Clinical Trials. Classification: Health & Mental Health Treatment & Prevention (3300). Population: Human (10); Male (30). Location: US. Age Group: Adulthood (18 yrs & older) (300); Middle Age (40-64 yrs) (360); Aged (65 yrs & older) (380). Tests & Measures: American Urological Association– Symptom Index; International Prostate Symptom Score Quality-of-Life; Prostate Cancer Index Composite; Global Perception of Improvement; Patient Satisfaction Question; Mini Mental State Examination; SF-36 Health Survey. Methodology: Empirical Study; Longitudinal Study; Quantitative Study; Treatment Outcome. Supplemental Data: Tables and Figures Internet. References Available: Y. Page Count: 9. Issue Publication Date: Jan 12, 2011. Copyright Statement: All rights reserved. American Medical Association. 2011.
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases, US. Grant: R01 DK60044. Recipients: No recipient indicated
Sponsor: US Department of Veterans Affairs, Birmingham–Atlanta Geriatric Research, Education, and Clinical Center, US. Recipients: No recipient indicated
PY  - 2011
SN  - 0098-7484
1538-3598
SP  - 151-159
ST  - Behavioral therapy with or without biofeedback and pelvic floor electrical stimulation for persistent postprostatectomy incontinence: A randomized controlled trial
T2  - JAMA: Journal of the American Medical Association
TI  - Behavioral therapy with or without biofeedback and pelvic floor electrical stimulation for persistent postprostatectomy incontinence: A randomized controlled trial
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2011-04179-001&site=ehost-live&scope=site
pgoode@uab.edu
VL  - 305
ID  - 1804
ER  - 

TY  - JOUR
AB  - Importance Few weight loss treatments produce clinically meaningful weight loss outcomes among black women, particularly in the primary care setting. New weight management strategies are necessary for this population. Weight gain prevention might be an effective treatment option, with particular benefits for overweight and class 1 obese black women. OBJECTIVE To compare changes in weight and cardiometabolic risk during a 12-month period among black women randomized to a primary care-based behavioral weight gain prevention intervention, relative to usual care. DESIGN. SETTING. AND PARTICIPANTS Two-arm randomized clinical trial (the Shape Program). We recruited patients from a 6-site community health center system. We randomized 194 overweight and class 1 obese (body mass index [calculated as weight in kilograms divided by height in meters squared], 25-34.9) premenopausal black women aged 25 to 44 years. Enrollment began on December 7,2009; 12- and 18-month assessments were completed in February and October 2,2012. interventions The medium-intensity intervention included tailored behavior change goals, weekly self-monitoring via interactive voice response, monthly counseling calls, tailored skills training materials, and a gym membership. MAIN OUTCOMES AND MEASURES Twelve-month change in weight and body mass index and maintenance of change at 18 months. RESULTS Participants had a mean age of 35.4 years, a mean weight of 81.1 kg. and a mean body mass index of 30.2 at baseline. Most were socioeconomically disadvantaged (79.7% with educational level less than a college degree; 74.3% reporting annual income <$30 000). The 12-month weight change was larger among intervention participants (mean [SD], -1.0 [0.5] kg), relative to usual care (0.5 [0.5] kg; mean difference, -1.4 kg [95% CI. -2.8 to -0.1 kg]; P = .04). At month 12,62% of intervention participants were at or below their baseline weights compared with 45% of usual-care participants (P = .03). By 18 months, intervention participants maintained significantly larger changes in weight (mean difference, -1.7 kg; 95% CI.-3.3 to-0.2 kg). CONCLUSIONS and relevance A medium-intensity primary care-based behavioral intervention demonstrated efficacy for weight gain prevention among socioeconomically disadvantaged black women. A "maintain, don't gain" approach might be a useful alternative treatment for reducing obesity-associated disease risk among some premenopausal black women.
AD  - G.G. Bennett, Department of Psychology and Neuroscience, Duke University, PO Box 90086, Durham, NC 27708, United States
AU  - Bennett, G. G.
AU  - Foley, P.
AU  - Levine, E.
AU  - Whiteley, J.
AU  - Askew, S.
AU  - Steinberg, D. M.
AU  - Batch, B.
AU  - Greaney, M. L.
AU  - Miranda, H.
AU  - Wroth, T. H.
AU  - Holder, M. G.
AU  - Emmons, K. M.
AU  - Puleo, E.
DB  - Embase
Medline
DO  - 10.1001/jamainternmed.2013.9263
IS  - 19
KW  - NCT00938535
high density lipoprotein cholesterol
low density lipoprotein cholesterol
triacylglycerol
adult
article
behavior change
behavior modification
body mass
breast abscess
cancer diagnosis
cardiometabolic risk
comparative study
controlled study
female
health care practice
human
income
knee arthroplasty
major clinical study
musculoskeletal injury
Black person
obesity
physical activity
primary medical care
priority journal
randomized controlled trial
risk assessment
socioeconomics
body weight change
body weight gain
L1  - internal-pdf://3797244140/ioi130080.pdf
LA  - English
M3  - Article
N1  - L370188407
2013-11-15
PY  - 2013
SN  - 2168-6106
SP  - 1770-1777
ST  - Behavioral treatment for weight gain prevention among black women in primary care practice: A randomized clinical trial
T2  - JAMA Internal Medicine
TI  - Behavioral treatment for weight gain prevention among black women in primary care practice: A randomized clinical trial
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L370188407&from=export
http://dx.doi.org/10.1001/jamainternmed.2013.9263
VL  - 173
ID  - 1069
ER  - 

TY  - JOUR
AB  - The National Lung Screening Trial (NLST) recently reported that annual computed tomography (CT) screening is associated with decreased lung cancer mortality in high-risk smokers. Beliefs about lung cancer and screening, particularly across race and ethnicity, and their influence on CT screening utilization are largely unexamined. Our study recruited asymptomatic, high-risk smokers, 55-74 years of age from primary care clinics in an academic urban hospital. Guided by the self-regulation theory, we evaluated cognitive and affective beliefs about lung cancer. Intention to screen for lung cancer with a CT scan was assessed by self-report. We used univariate and logistic regression analyses to compare beliefs about screening and intention to screen among minority (Blacks and Hispanics) and non-minority participants. Overall, we enrolled 108 participants, of which 40% were Black and 34% were Hispanic; the mean age was 62.3 years, and median pack-years of smoking was 26. We found that intention to screen was similar among minorities and non-minorities (p=0.19); however, Hispanics were less likely to report intention to screen if they had to pay for the test (p=0.02). Fatalistic beliefs, fear of radiation exposure, and anxiety related to CT scans were significantly associated with decreased intention to screen (p<0.05). Several differences were observed in minority versus non-minority participants' beliefs toward lung cancer and screening. In conclusion, we found that concerns about cost, which were particularly prominent among Hispanics, as well as fatalism and radiation exposure fears may constitute barriers to lung cancer screening. Lung cancer screening programs should address these factors to ensure broad participation, particularly among minorities.
AD  - Doris Duke Clinical Research Fellows, UMDNJ-Robert Wood Johnson Medical School, New York, NY 10029, USA.
AN  - 22681870
AU  - Jonnalagadda, S.
AU  - Bergamo, C.
AU  - Lin, J. J.
AU  - Lurslurchachai, L.
AU  - Diefenbach, M.
AU  - Smith, C.
AU  - Nelson, J. E.
AU  - Wisnivesky, J. P.
C2  - PMC5055380
C6  - NIHMS390509
DA  - Sep
DO  - 10.1016/j.lungcan.2012.05.095
DP  - NLM
ET  - 2012/06/12
IS  - 3
KW  - African Americans
Aged
Anxiety
Cross-Sectional Studies
Early Detection of Cancer/economics/*psychology
Fear
Female
Health Care Costs
Hispanic Americans
Humans
Logistic Models
Lung Neoplasms/*diagnostic imaging
Male
Middle Aged
Patient Acceptance of Health Care/ethnology/*psychology
Religion
Self Report
Spirituality
Tomography, X-Ray Computed/economics/psychology
Urban Population
LA  - eng
N1  - 1872-8332
Jonnalagadda, Sirisha
Bergamo, Cara
Lin, Jenny J
Lurslurchachai, Linda
Diefenbach, Michael
Smith, Cardinale
Nelson, Judith E
Wisnivesky, Juan P
K07 AG034234/AG/NIA NIH HHS/United States
Journal Article
Research Support, Non-U.S. Gov't
Lung Cancer. 2012 Sep;77(3):526-31. doi: 10.1016/j.lungcan.2012.05.095. Epub 2012 Jun 6.
PY  - 2012
SN  - 0169-5002 (Print)
0169-5002
SP  - 526-31
ST  - Beliefs and attitudes about lung cancer screening among smokers
T2  - Lung Cancer
TI  - Beliefs and attitudes about lung cancer screening among smokers
VL  - 77
ID  - 366
ER  - 

TY  - JOUR
AB  - OBJECTIVE: Because shared decision making has been recommended for screening mammography by women under age 50, we studied women's decision-making process regarding the procedure. DESIGN: Qualitative research design using in-depth semi-structured interviews. PATIENTS: Sixteen white and African-American women aged 38 to 45 receiving care at a large New England medical practice. MEASUREMENTS AND MAIN RESULTS: We identified the following content areas in women's decision-making process: intentions for screening, motivating factors to undergo screening, attitudes toward screening mammography, attitudes toward breast cancer, and preferences for information and shared decision making. In our sample, all women had or intended to have a screening mammogram before age 50. They were motivated by the awareness of the recommendation to begin screening at age 40, knowing others with breast cancer, and a sense of personal responsibility for their health. Participants feared breast cancer and thought the benefits of screening mammography far outweighed its risks. Women's preferences for involvement in decision making varied from wanting full responsibility for screening decisions to deferring to their medical providers. All preferred the primary care provider to be the main source of information, yet the participants stated that their own providers played a limited role in educating them about the risks and benefits of screening and the mammography procedure itself. Most of their information was derived from the media. CONCLUSIONS: The women in this study demonstrated little ambivalence in their desire for mammography screening prior to age 50. They reported minimal communication with their medical providers about the risks and benefits of screening. Better information flow regarding mammography screening is necessary. Given the lack of uncertainty among women's perceptions regarding screening mammography, shared decision making in this area may be difficult to achieve.
AD  - Department of Ambulatory Care and Prevention, Harvard Medical School/Harvard Pilgrim Health Care, Boston, Mass 02115, USA. larissa_nekhlyudov@harvardpilgrim.org
AN  - 12648249
AU  - Nekhlyudov, L.
AU  - Ross-Degnan, D.
AU  - Fletcher, S. W.
C2  - PMC1494837
DA  - Mar
DO  - 10.1046/j.1525-1497.2003.20112.x
DP  - NLM
ET  - 2003/03/22
IS  - 3
KW  - Adult
Attitude to Health
Breast Neoplasms/*diagnostic imaging
*Decision Making
Female
Humans
Mammography/*psychology
Mass Media
*Mass Screening
Middle Aged
*Patient Acceptance of Health Care
Patient Participation
Socioeconomic Factors
LA  - eng
N1  - 1525-1497
Nekhlyudov, Larissa
Ross-Degnan, Dennis
Fletcher, Suzanne W
Journal Article
Research Support, Non-U.S. Gov't
J Gen Intern Med. 2003 Mar;18(3):182-9. doi: 10.1046/j.1525-1497.2003.20112.x.
PY  - 2003
SN  - 0884-8734 (Print)
0884-8734
SP  - 182-9
ST  - Beliefs and expectations of women under 50 years old regarding screening mammography: a qualitative study
T2  - J Gen Intern Med
TI  - Beliefs and expectations of women under 50 years old regarding screening mammography: a qualitative study
VL  - 18
ID  - 653
ER  - 

TY  - JOUR
AB  - Tea, next to water, is the most widely consumed beverage in the world. Depending upon the level of fermentation, tea can be categorized into three types: green (unfermented), oolong (partially fermented), and black (highly to fully fermented). In general, green tea has been found to be superior to black and oolong tea in terms of antioxidant and health promoting benefits owing to the higher content of (-)-epigallocatechin-3-gallate. Tea polyphenols comprise about one-third of the weight of the dried leaf, and they exhibit biochemical and pharmacological activities including antioxidant activities, inhibition of cell proliferation, induction of apoptosis, cell cycle arrest and modulation of carcinogen metabolism. Several studies demonstrate that most tea polyphenols exert their effects by scavenging reactive oxygen species (ROS) since excessive production of ROS has been implicated in the development of a variety of ailments including cancer of the prostate gland (CaP). Using cell culture and animal model systems, molecular targets for these remarkable beneficial effects of green tea drinking on CaP prevention and therapy have been defined. Geographical and case-control studies are showing that green tea drinking could afford CaP chemopreventive effects in human population. In this review we attempt to summarize the experimental as well as the epidemiological basis for the possible role of tea and its polyphenols for chemoprevention and chemotherapy of CaP.
AD  - Department of Dermatology, University of Wisconsin, Medical Sciences Center, Madison, WI 53706, USA.
AN  - 16425281
AU  - Siddiqui, I. A.
AU  - Adhami, V. M.
AU  - Saleem, M.
AU  - Mukhtar, H.
DA  - Feb
DO  - 10.1002/mnfr.200500113
DP  - NLM
ET  - 2006/01/21
IS  - 2
KW  - Androgens/metabolism
Animals
Apoptosis/drug effects
Catechin/analogs & derivatives/analysis
Cell Cycle/drug effects
Clinical Trials as Topic
Fermentation
Flavonoids/*administration & dosage/analysis
Gene Expression/drug effects
Humans
Male
Neoplasm Transplantation
Neovascularization, Pathologic/prevention & control
Phenols/*administration & dosage/analysis
Polyamines/metabolism
Polyphenols
Prostate-Specific Antigen/blood
Prostatic Neoplasms/blood supply/*prevention & control
Signal Transduction/drug effects
Tea/*chemistry
LA  - eng
N1  - Siddiqui, Imtiaz A
Adhami, Vaqar M
Saleem, Mohammad
Mukhtar, Hasan
P50 DK065303-01/DK/NIDDK NIH HHS/United States
R01 CA 101039/CA/NCI NIH HHS/United States
R01 CA 78809/CA/NCI NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
Review
Germany
Mol Nutr Food Res. 2006 Feb;50(2):130-43. doi: 10.1002/mnfr.200500113.
PY  - 2006
SN  - 1613-4125 (Print)
1613-4125
SP  - 130-43
ST  - Beneficial effects of tea and its polyphenols against prostate cancer
T2  - Mol Nutr Food Res
TI  - Beneficial effects of tea and its polyphenols against prostate cancer
VL  - 50
ID  - 575
ER  - 

TY  - JOUR
AB  - Endocrine therapy in breast cancer survivors can cause severe 'climacteric' symptoms, which may compromise therapy adherence. To determine whether such symptoms can be treated with herbal medication containing black cohosh in the form of isopropanolic Cimicifuga racemosa extract (iCR) alone or in fixed combination with St John's wort (Hypericum perforatum [HP]) (iCR + HP), a systematic literature search was conducted. Results were viewed in relation to experimental data and metabolism of endocrine therapies. Most breast cancer survivors receiving endocrine therapy experienced reductions in climacteric symptoms under iCR/iCR + HP. Tamoxifen's interference potential may be countered by using higher iCR doses or iCR + HP. No estrogen-like effects at the breast or on hormones were seen. After breast cancer, even if receiving tamoxifen, patients using iCR/iCR + HP had significantly increased recurrence-free survival rates compared to non-users. These results are substantiated by experimental data demonstrating antiproliferative and anti-invasive effects of iCR in breast cancer cells and enhancement of the antineoplastic effects of tamoxifen. There are no known clinical interactions for iCR and HP with endocrine therapies. The HP extract used in iCR + HP did not exhibit any clinically relevant interaction potential. In conclusion, with its positive benefit-risk profile, iCR/iCR + HP may offer a safe non-hormonal therapeutic option for breast cancer survivors receiving endocrine therapy.
AD  - a Department of Gynecological Endocrinology, Beijing Obstetrics and Gynecology Hospital , Capital Medical University , Beijing , China.
b Department of Women's Health, University Women's Hospital and Research Center for Women's Health , University Hospitals of Tuebingen , Tuebingen , Germany.
c Hospital for True Naturopathy, Katholisches Klinikum Bochum , Blankenstein Hospital , Hattingen , Germany.
d Pharmacovigilance , Schaper & Brümmer GmbH & Co. KG , Salzgitter , Germany.
e Medical Service , Schaper & Brümmer GmbH & Co. KG , Salzgitter , Germany.
AN  - 30626212
AU  - Ruan, X.
AU  - Mueck, A. O.
AU  - Beer, A. M.
AU  - Naser, B.
AU  - Pickartz, S.
DA  - Aug
DO  - 10.1080/13697137.2018.1551346
DP  - NLM
ET  - 2019/01/11
IS  - 4
KW  - Breast Neoplasms/*drug therapy/pathology
*Cimicifuga
Drug Therapy, Combination
Female
Humans
*Hypericum
Menopause
Phytotherapy
Plant Extracts/administration & dosage/*therapeutic use
Randomized Controlled Trials as Topic
Risk Assessment
*Black cohosh
*St John’s wort
*benefit–risk profile
*breast cancer
*isopropanolic
*safety
*tamoxifen
LA  - eng
N1  - 1473-0804
Ruan, X
Mueck, A O
Beer, A-M
Naser, B
Pickartz, S
Journal Article
Systematic Review
England
Climacteric. 2019 Aug;22(4):339-347. doi: 10.1080/13697137.2018.1551346. Epub 2019 Jan 10.
PY  - 2019
SN  - 1369-7137
SP  - 339-347
ST  - Benefit-risk profile of black cohosh (isopropanolic Cimicifuga racemosa extract) with and without St John's wort in breast cancer patients
T2  - Climacteric
TI  - Benefit-risk profile of black cohosh (isopropanolic Cimicifuga racemosa extract) with and without St John's wort in breast cancer patients
VL  - 22
ID  - 86
ER  - 

TY  - JOUR
AB  - black triangle Bevacizumab is a recombinant, humanized vascular endothelial growth factor (VEGF) monoclonal antibody that inhibits tumor growth and tumor metastases. VEGF stimulates angiogenesis in tumors, is involved in early metastatic processes, and is overexpressed in non-small cell lung cancer (NSCLC). black triangle The addition of bevacizumab to standard chemotherapy significantly delayed disease progression in two large, randomized, phase III trials in chemotherapy-naive patients with advanced, nonsquamous NSCLC. In the open-label E4599 trial, median overall survival duration was significantly extended by 2 months and median progression-free survival was significantly increased by 1.7 months when intravenous bevacizumab 15 mg/kg once every 3 weeks was added to first-line carboplatin/paclitaxel therapy compared with carboplatin/paclitaxel alone. black triangle In the double-blind AVAiL trial, median progression-free survival was significantly increased (by 0.6 and 0.4 months) by the addition of intravenous bevacizumab 7.5 or 15 mg/kg once every 3 weeks to first-line cisplatin/gemcitabine therapy compared with placebo plus cisplatin/gemcitabine. However, median overall survival duration was not significantly improved (13.6 and 13.4 months vs 13.1 months). black triangle Response rates in the E4599 and AVAiL trials were 30-35% in patients receiving bevacizumab plus platinum-based chemotherapy compared with 15% and 20% without bevacizumab. black triangle The safety and tolerability profile of bevacizumab-containing treatment regimens in patients with advanced NSCLC was generally manageable in the E4599 and AVAiL trials, and in two large, ongoing, trials (the open-label SAiL and the observational ARIES studies).
AD  - Wolters Kluwer Health mid R: Adis, Auckland, New Zealand, an editorial office of Wolters Kluwer Health, Philadelphia, Pennsylvania, USA.
AN  - 19627170
AU  - Wagstaff, A. J.
AU  - Keam, S. J.
AU  - McCormack, P. L.
DO  - 10.2165/00063030-200923030-00005
DP  - NLM
ET  - 2009/07/25
IS  - 3
KW  - Angiogenesis Inhibitors/adverse effects/pharmacokinetics/therapeutic use
Antibodies, Monoclonal/adverse effects/pharmacokinetics/*therapeutic use
Antibodies, Monoclonal, Humanized
Bevacizumab
Carboplatin/*therapeutic use
Carcinoma, Non-Small-Cell Lung/*drug therapy
Cisplatin/*therapeutic use
Clinical Trials as Topic
Drug Therapy, Combination
Humans
Lung Neoplasms/*drug therapy
LA  - eng
N1  - 1179-190x
Wagstaff, Antona J
Keam, Susan J
McCormack, Paul L
Journal Article
Review
New Zealand
BioDrugs. 2009;23(3):187-96. doi: 10.2165/00063030-200923030-00005.
PY  - 2009
SN  - 1173-8804
SP  - 187-96
ST  - Bevacizumab plus platinum-based chemotherapy: in advanced non-small cell lung cancer
T2  - BioDrugs
TI  - Bevacizumab plus platinum-based chemotherapy: in advanced non-small cell lung cancer
VL  - 23
ID  - 454
ER  - 

TY  - JOUR
AB  - RATIONALE: The CHRNA5-CHRNA3-CHRNB4 locus is associated with self-reported smoking behavior and also harbors the strongest genetic associations with chronic obstructive pulmonary disease (COPD) and lung cancer. Because the associations with lung disease remain after adjustment for self-reported smoking behaviors, it has been asserted that CHRNA5-CHRNA3-CHRNB4 variants increase COPD and lung cancer susceptibility independently of their effects on smoking. OBJECTIVES: To compare the genetic associations of exhaled carbon monoxide (CO), a biomarker of current cigarette exposure, with self-reported smoking behaviors. METHODS: A total of 1,521 European American and 247 African American current smokers recruited into smoking cessation studies were assessed for CO at intake before smoking cessation. DNA samples were genotyped using the Illumina Omni2.5 microarray. Genetic associations with CO and smoking behaviors (cigarettes smoked per day, Fagerstrom test for nicotine dependence) were studied. MEASUREMENTS AND MAIN RESULTS: Variants in the CHRNA5-CHRNA3-CHRNB4 locus, including rs16969968, a nonsynonymous variant in CHRNA5, are genomewide association study-significantly associated with CO (β = 2.66; 95% confidence interval [CI], 1.74-3.58; P = 1.65 × 10(-8)), and this association remains strong after adjusting for smoking behavior (β = 2.18; 95% CI, 1.32-3.04; P = 7.47 × 10(-7)). The correlation between CO and cigarettes per day is statistically significantly lower (z = 3.43; P = 6.07 × 10(-4)) in African Americans (r = 0.14; 95% CI, 0.02-0.26; P = 0.003) than in European-Americans (r = 0.36; 95% CI, 0.31-0.40; P = 0.0001). CONCLUSIONS: Exhaled CO, a biomarker that is simple to measure, captures aspects of cigarette smoke exposure in current smokers beyond the number of cigarettes smoked per day. Behavioral measures of smoking are therefore insufficient indices of cigarette smoke exposure, suggesting that genetic associations with COPD or lung cancer that persist after adjusting for self-reported smoking behavior may still reflect genetic effects on smoking exposure.
AD  - 1 Department of Psychiatry, and.
AN  - 25072098
AU  - Bloom, A. J.
AU  - Hartz, S. M.
AU  - Baker, T. B.
AU  - Chen, L. S.
AU  - Piper, M. E.
AU  - Fox, L.
AU  - Martinez, M.
AU  - Hatsukami, D.
AU  - Johnson, E. O.
AU  - Laurie, C. C.
AU  - Saccone, N. L.
AU  - Goate, A.
AU  - Bierut, L. J.
C2  - PMC4214060
DA  - Sep
DO  - 10.1513/AnnalsATS.201401-010OC
DP  - NLM
ET  - 2014/07/30
IS  - 7
KW  - Adult
African Americans/genetics
Biomarkers/analysis
Carbon Monoxide/*analysis
Confidence Intervals
Cytochrome P-450 CYP2A6/*genetics
European Continental Ancestry Group/genetics
Female
Genetic Predisposition to Disease/*epidemiology
Genetic Variation
Genome-Wide Association Study
Humans
Lung Neoplasms/ethnology/genetics
Male
Middle Aged
Nerve Tissue Proteins/*genetics
Pulmonary Disease, Chronic Obstructive/epidemiology/ethnology/genetics
Receptors, Nicotinic/*genetics
Smoking/ethnology/*genetics/psychology
Smoking Cessation/ethnology/*methods/psychology
Tobacco Use Disorder/ethnology/genetics
chronic obstructive pulmonary disease
lung cancer
nicotine
nicotinic receptor
smoking
LA  - eng
N1  - 2325-6621
Bloom, A Joseph
Hartz, Sarah M
Baker, Timothy B
Chen, Li-Shiun
Piper, Megan E
Fox, Louis
Martinez, Maribel
Hatsukami, Dorothy
Johnson, Eric O
Laurie, Cathy C
Saccone, Nancy L
Goate, Alison
Bierut, Laura J
U01HG004446/HG/NHGRI NIH HHS/United States
P50DA019706/DA/NIDA NIH HHS/United States
K08 DA030398/DA/NIDA NIH HHS/United States
P01 CA089392/CA/NCI NIH HHS/United States
P01 CA180945/CA/NCI NIH HHS/United States
T32MH014677/MH/NIMH NIH HHS/United States
R01DA026911/DA/NIDA NIH HHS/United States
K05CA139871/CA/NCI NIH HHS/United States
K08DA030398/DA/NIDA NIH HHS/United States
UL1 TR000448/TR/NCATS NIH HHS/United States
1 X01 HG005274-01/HG/NHGRI NIH HHS/United States
P50CA084724/CA/NCI NIH HHS/United States
P01CA089392/CA/NCI NIH HHS/United States
K05 CA139871/CA/NCI NIH HHS/United States
U01 HG004446/HG/NHGRI NIH HHS/United States
R01 HL109031/HL/NHLBI NIH HHS/United States
R01 DA026911/DA/NIDA NIH HHS/United States
P50 DA019706/DA/NIDA NIH HHS/United States
U01HG004422/HG/NHGRI NIH HHS/United States
K08 DA032680/DA/NIDA NIH HHS/United States
HHSN268200782096C/HG/NHGRI NIH HHS/United States
P50 CA084724/CA/NCI NIH HHS/United States
K02DA021237/DA/NIDA NIH HHS/United States
K02 DA021237/DA/NIDA NIH HHS/United States
T32 MH014677/MH/NIMH NIH HHS/United States
Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Ann Am Thorac Soc. 2014 Sep;11(7):1003-10. doi: 10.1513/AnnalsATS.201401-010OC.
PY  - 2014
SN  - 2329-6933 (Print)
2325-6621
SP  - 1003-10
ST  - Beyond cigarettes per day. A genome-wide association study of the biomarker carbon monoxide
T2  - Ann Am Thorac Soc
TI  - Beyond cigarettes per day. A genome-wide association study of the biomarker carbon monoxide
VL  - 11
ID  - 282
ER  - 

TY  - JOUR
AB  - Cancer screening disparities between black and white groupings are well-documented. Less is known regarding African-descent subpopulations despite elevated risk, distinct cultural backgrounds, and increasing numbers of Caribbean migrants. A systematic search of Medline, Web of Science, PubMed and SCOPUS databases (1980-2012) identified 53 studies reporting rates of breast, prostate, cervical, and colorectal screening behavior among immigrant and non-immigrant Caribbean groups. Few studies were conducted within the Caribbean itself; most work is US-based, and the majority stem from Brooklyn, New York. In general, African-descent Caribbean populations screen for breast, prostate, colorectal, and cervical cancers less frequently than US-born African-Americans and at lower rates than recommendations and guidelines. Haitian immigrants, in particular, screen at very low frequencies. Both immigrant and non-immigrant African-descent Caribbean groups participate in screening less frequently than recommended. Studying screening among specific Caribbean groups of African-descent may yield data that both clarifies health disparities between US-born African-Americans and whites and illuminates the specific subpopulations at risk in these growing immigrant communities.
AD  - Department of Psychological Medicine, The University of Auckland, Private Bag 92019, Auckland, New Zealand, n.consedine@auckland.ac.nz.
AN  - 24522436
AU  - Consedine, N. S.
AU  - Tuck, N. L.
AU  - Ragin, C. R.
AU  - Spencer, B. A.
DA  - Jun
DO  - 10.1007/s10903-014-9991-0
DP  - NLM
ET  - 2014/02/14
IS  - 3
KW  - *African Continental Ancestry Group
Caribbean Region
*Early Detection of Cancer
*Emigrants and Immigrants
Humans
*Patient Participation
LA  - eng
N1  - 1557-1920
Consedine, Nathan S
Tuck, Natalie L
Ragin, Camille R
Spencer, Benjamin A
Journal Article
Review
Systematic Review
United States
J Immigr Minor Health. 2015 Jun;17(3):905-24. doi: 10.1007/s10903-014-9991-0.
PY  - 2015
SN  - 1557-1912
SP  - 905-24
ST  - Beyond the black box: a systematic review of breast, prostate, colorectal, and cervical screening among native and immigrant African-descent Caribbean populations
T2  - J Immigr Minor Health
TI  - Beyond the black box: a systematic review of breast, prostate, colorectal, and cervical screening among native and immigrant African-descent Caribbean populations
VL  - 17
ID  - 294
ER  - 

TY  - JOUR
AB  - BACKGROUND: Sentinel lymph node dissection (SLND) has been shown to be a reasonable treatment option for early-stage breast cancer. Until recently, SLND was limited to clinical trials. Because this technique is now offered outside of trials, its prevalence is unknown. METHODS: All patients with stage I or II breast cancer in the Surveillance, Epidemiology, and End Results national cancer registry (1998-2000) were evaluated. Data were collected for demographics, tumor characteristics, surgical resection, lymph node evaluation (SLND or complete axillary dissection), registry site, and year of diagnosis. Multivariate regression analysis was performed to identify predictors for receiving SLND. RESULTS: A total of 54,772 patients diagnosed with breast cancer had undergone surgical lymph node evaluation; 27.2% patients with stage I disease underwent SLND, as compared with 22.7% for stage II. Older patients and minority groups were less likely to receive SLND. Receipt of SLND varied by registry site (7.9%-32.7%). Multivariate regression showed that older patients had lower odds of receiving SLND (60-69 years: odds ratio, .73; P < .0001) as compared with younger patients. Additionally, blacks, Hispanics, and Asians had lower odds of receiving SLND (odds ratio of .64, .58, and .80, respectively; P < .0001). SLND use increased over the 3 years in the study (P < .0001). CONCLUSIONS: This population-based analysis showed relatively infrequent use of SLND for early-stage breast cancer. These results suggest a slow transition of this procedure from clinical trials into the community. Future work should be targeted at improving the rate at which patients receive this procedure, particularly for elderly and minority groups and low-use regions.
AD  - UCLA School of Medicine, Robert Wood Johnson VA Clinical Scholars Program, 911 Broxton Avenue, 3rd Floor, Los Angeles, California 90024, USA. mmaggard@mednet.ucla.edu
AN  - 15827777
AU  - Maggard, M. A.
AU  - Lane, K. E.
AU  - O'Connell, J. B.
AU  - Nanyakkara, D. D.
AU  - Ko, C. Y.
DA  - Jan
DO  - 10.1007/s10434-004-1168-y
DP  - NLM
ET  - 2005/04/14
IS  - 1
KW  - Adult
Aged
Aged, 80 and over
Breast Neoplasms/*pathology
Clinical Trials as Topic
Female
Humans
Lymphatic Metastasis/*diagnosis
Middle Aged
Multivariate Analysis
Neoplasm Staging/*methods
SEER Program/*statistics & numerical data
Sentinel Lymph Node Biopsy/*statistics & numerical data
LA  - eng
N1  - Maggard, Melinda A
Lane, Karen E
O'Connell, Jessica B
Nanyakkara, Deepa Dharshani
Ko, Clifford Y
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
United States
Ann Surg Oncol. 2005 Jan;12(1):41-7. doi: 10.1007/s10434-004-1168-y. Epub 2004 Dec 27.
PY  - 2005
SN  - 1068-9265 (Print)
1068-9265
SP  - 41-7
ST  - Beyond the clinical trials: how often is sentinel lymph node dissection performed for breast cancer?
T2  - Ann Surg Oncol
TI  - Beyond the clinical trials: how often is sentinel lymph node dissection performed for breast cancer?
VL  - 12
ID  - 605
ER  - 

TY  - JOUR
AB  - Background In recent years, extensive attention has been paid to the possibility that bias among health care professionals contributes to health disparities. In its 2003 report, the Institute of Medicine concluded that bias against racial minorities may affect communication or care offered. However, to the authors' knowledge, the role of bias within the context of recruitment of racial and ethnic minorities to cancer clinical trials has not been explored to date. Therefore, the authors assessed the experiences of clinical and research personnel related to factors influencing the recruitment of racial and ethnic minorities for cancer clinical trials. Methods A total of 91 qualitative interviews were conducted at 5 US cancer centers among 4 stakeholder groups: 1) cancer center leaders; 2) principal investigators; 3) referring clinicians; and 4) research staff. Data analysis was conducted using a content analysis approach to generate themes from the transcribed interviews. Results Five prominent themes emerged: 1) recruitment interactions with potential minority participants were perceived to be challenging; 2) potential minority participants were not perceived to be ideal study candidates; 3) a combination of clinic-level barriers and negative perceptions of minority study participants led to providers withholding clinical trial opportunities from potential minority participants; 4) when clinical trial recruitment practices were tailored to minority patients, addressing research misconceptions to build trust was a common strategy; 5) for some respondents, race was perceived as irrelevant when screening and recruiting potential minority participants for clinical trials. Conclusions Not only did some respondents view racial and ethnic minorities as less promising participants, some respondents reported withholding trial opportunities from minorities based on these perceptions. Some providers endorsed using tailored recruitment strategies whereas others eschewed race as a factor in trial recruitment. The presence of bias and stereotyping among clinical and research professionals recruiting for cancer clinical trials should be considered when designing interventions to increase minority enrollment.
AN  - WOS:000525421100016
AU  - Niranjan, S. J.
AU  - Martin, M. Y.
AU  - Fouad, M. N.
AU  - Vickers, S. M.
AU  - Wenzel, J. A.
AU  - Cook, E. D.
AU  - Konety, B. R.
AU  - Durant, R. W.
DA  - Jan
DO  - 10.1002/cncr.32755
IS  - 9
N1  - 32147815
PY  - 2020
SN  - 0008-543X
SP  - 1958-1968
ST  - Bias and stereotyping among research and clinical professionals: Perspectives on minority recruitment for oncology clinical trials
T2  - Cancer
TI  - Bias and stereotyping among research and clinical professionals: Perspectives on minority recruitment for oncology clinical trials
VL  - 126
ID  - 2799
ER  - 

TY  - JOUR
AB  - Purpose To identify factors related to who undergoes a prostate biopsy in a screened population and to estimate the impact of biopsy verification on risk factor-prostate cancer associations. Patients and Methods Men who were screened regularly from the placebo arms of two large prostate cancer prevention trials (Prostate Cancer Prevention Trial [PCPT] and Selenium and Vitamin E Cancer Prevention Trial [SELECT]) were examined to define incident prostate cancer cohorts. Because PCPT had an end-of-study biopsy, prostate cancer cases were categorized by a preceding prostate-specific antigen/digital rectal examination prompt (yes/no) and noncases by biopsy-proven negative status (yes v no). We estimated the association of risk factors (age, ethnicity, family history, body mass index, medication use) with prostate cancer and quantified differences in risk associations across cohorts. Results Men 60 to 69 years of age, those with benign prostatic hyperplasia, and those with a family history of prostate cancer were more likely, and those with a higher body mass index (≥ 25), diabetes, or a smoking history were less likely, to undergo biopsy, adjusting for age and longitudinal prostate-specific antigen and digital rectal examination. Medication use, education, and marital status also influenced who underwent biopsy. Some risk factor estimates for prostate cancer varied substantially across cohorts. Black ( v other ethnicities) had odds ratios (ORs) that varied from 1.20 for SELECT (community screening standards, epidemiologic-like cohort) to 1.83 for PCPT (end-of-study biopsy supplemented with imputed end points). Statin use in SELECT provided an OR of 0.65 and statin use in in PCPT provided an OR of 0.99, a relative difference of 34%. Conclusion Among screened men enrolled in prostate cancer prevention trials, differences in risk factor estimates for prostate cancer likely underestimate the magnitude of bias found in other cohorts with varying screening and biopsy recommendations and acceptance. Risk factors for prostate cancer derived from epidemiologic studies not only may be erroneous but may lead to misdirected research efforts.
AD  - Catherine M. Tangen, Phyllis J. Goodman, Cathee Till, and Jeannette M. Schenk, Fred Hutchinson Cancer Research Center, Seattle, WA; M. Scott Lucia, University of Colorado Denver School of Medicine, Denver, CO; and Ian M. Thompson Jr, The Cancer Therapy and Research Center, University of Texas Health Science Center at San Antonio, San Antonio, TX.
AN  - 27998216
AU  - Tangen, C. M.
AU  - Goodman, P. J.
AU  - Till, C.
AU  - Schenk, J. M.
AU  - Lucia, M. S.
AU  - Thompson, I. M., Jr.
C2  - PMC5455311 online at www.jco.org. Author contributions are found at the end of this article.
DA  - Dec 20
DO  - 10.1200/jco.2016.68.1965
DP  - NLM
ET  - 2016/12/22
IS  - 36
KW  - Aged
Bias
Biopsy, Needle
Clinical Trials, Phase III as Topic
Early Detection of Cancer
Humans
Immunohistochemistry
Male
Middle Aged
Patient Acceptance of Health Care/*statistics & numerical data
*Practice Guidelines as Topic
Prognosis
Prostate-Specific Antigen/*blood
Prostatic Neoplasms/diagnosis/*pathology
Randomized Controlled Trials as Topic
Risk Assessment
LA  - eng
N1  - 1527-7755
Tangen, Catherine M
Goodman, Phyllis J
Till, Cathee
Schenk, Jeannette M
Lucia, M Scott
Thompson, Ian M Jr
U01 CA086402/CA/NCI NIH HHS/United States
U10 CA037429/CA/NCI NIH HHS/United States
UG1 CA189974/CA/NCI NIH HHS/United States
UM1 CA182883/CA/NCI NIH HHS/United States
Comparative Study
Journal Article
Research Support, N.I.H., Extramural
Review
J Clin Oncol. 2016 Dec 20;34(36):4338-4344. doi: 10.1200/JCO.2016.68.1965. Epub 2016 Oct 28.
PY  - 2016
SN  - 0732-183X (Print)
0732-183x
SP  - 4338-4344
ST  - Biases in Recommendations for and Acceptance of Prostate Biopsy Significantly Affect Assessment of Prostate Cancer Risk Factors: Results From Two Large Randomized Clinical Trials
T2  - J Clin Oncol
TI  - Biases in Recommendations for and Acceptance of Prostate Biopsy Significantly Affect Assessment of Prostate Cancer Risk Factors: Results From Two Large Randomized Clinical Trials
VL  - 34
ID  - 188
ER  - 

TY  - JOUR
AB  - Polycyclic aromatic hydrocarbons (PAHs) such as benzo[a]pyrene (BaP) are widespread air contaminants released by transportation vehicles, power generation, and other combustion sources. Experimental evidence indicates that the developing fetus is more susceptible than the adult to carcinogenic effects of PAHs, although laboratory studies in rodents suggest that the dose to fetal tissues is an order of magnitude lower than that to maternal tissues. To assess fetal versus adult susceptibility to PAHs and environmental tobacco smoke (ETS), we compared carcinogen-DNA adducts (a biomarker associated with increased cancer risk) and cotinine (a biomarker of tobacco smoke exposure) in paired blood samples collected from mothers and newborns in New York City. We enrolled 265 nonsmoker African-American and Latina mother-newborn pairs in New York City between 1997 and 2001 (estimated average ambient air BaP concentrations < 0.5 ng/m(3)). Despite the estimated 10-fold lower fetal dose, mean levels of BaP-DNA adducts as determined by high-performance liquid chromatography-fluorescence were comparable in paired New York City newborn and maternal samples (0.24 adducts per 10(8) nucleotides, 45% of newborns with detectable adducts vs. 0.22 per 10(8) nucleotides, 41% of mothers with detectable adducts). However, by the Wilcoxon signed-rank test, the levels in newborns were higher (p = 0.02). Mean cotinine was higher in newborns than in mothers (1.7 ng/mL, 47% detectable vs. 1.28 ng/mL, 44% detectable). Consistent with our prior study in a Caucasian Polish population, these results indicate increased susceptibility of the fetus to DNA damage and reduced ability to clear ETS constituents. The findings have implications for risk assessment, given the need to protect children as a sensitive subset of the population.
AN  - WOS:000222482300036
AU  - Perera, F. P.
AU  - Tang, D. L.
AU  - Tu, Y. H.
AU  - Cruz, L. A.
AU  - Borjas, M.
AU  - Bernert, T.
AU  - Whyatt, R. M.
DA  - Jul
DO  - 10.1289/ehp.6833
IS  - 10
N1  - 120
15238289
PY  - 2004
SN  - 0091-6765
SP  - 1133-1136
ST  - Biomarkers in maternal and newborn blood indicate heightened fetal susceptibility to procarcinogenic DNA damage
T2  - Environmental Health Perspectives
TI  - Biomarkers in maternal and newborn blood indicate heightened fetal susceptibility to procarcinogenic DNA damage
VL  - 112
ID  - 2680
ER  - 

TY  - JOUR
AB  - PURPOSE: Advances in precision medicine (PM) have potential to reduce and/or eliminate breast cancer disparities in both treatment and survivorship. However, compared to white Americans, black Americans are often underrepresented in genetic research. This report assessed factors that influence receipt of buccal cells via saliva kits. METHODS: This prospective study recruited women with confirmed hormonal-positive (HR+) breast cancer (BC). A standardized telephone survey collected sociodemographic, socio-cultural (e.g., religiosity), and healthcare process factors. Clinical information was abstracted from medical records. After the baseline survey, return postage-paid envelopes and mouthwash collection kits were mailed. Univariate and adjusted logistic regression models estimated the probability of biospecimen donation. RESULTS: Seventy percent of the sample provided buccal cells which were of good quality. No differences were noted by race or other demographic factors. In the multivariable logistic model, time spent with providers (OR 1.61 per 1-point increase; 95% CI 1.242, 2.088) and religiosity (OR 0.957 per 1-point increase; 95% CI 0.931, 0.984) remained associated with biospecimen provision. Women with lower-stage cancer (vs. higher stage III+) were more likely to donate biospecimens (p < 0.05). CONCLUSIONS: Cancer care experiences predicted specimen donation. Understanding the contextual reasons for lower receipt among women with higher religiosity scores and higher stage warrants further examination. IMPLICATIONS FOR CANCER SURVIVORS: PM is relevant to cancer survivors because of its potential to inform targeted therapies, understand disease resistance, and aide in prediction of toxicity and/or recurrence. Future efforts to launch precision medicine trials with BC survivors may benefit from engaging medical oncologists and/or leveraging patient-provider encounters for trial participation.
AD  - School of Medicine, Virginia Commonwealth University, Richmond, VA, USA. vanessa.sheppard@vcuhealth.org.
Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA.
School of Medicine, Virginia Commonwealth University, Richmond, VA, USA.
Kaiser Permanente Georgia, Atlanta, GA, USA.
Southeast Permanente Medical Group, Atlanta, GA, USA.
Henry Ford Health System, Detroit, MI, USA.
AN  - 29147853
AU  - Sheppard, V. B.
AU  - Hurtado-de-Mendoza, A.
AU  - Zheng, Y. L.
AU  - Wang, Y.
AU  - Graves, K. D.
AU  - Lobo, T.
AU  - Xu, H.
AU  - Jennings, Y.
AU  - Tolsma, D.
AU  - Trout, M.
AU  - Robinson, B. E.
AU  - McKinnon, B.
AU  - Tadesse, M.
DA  - Feb
DO  - 10.1007/s11764-017-0646-8
DP  - NLM
ET  - 2017/11/18
IS  - 1
KW  - Adult
African Americans/*statistics & numerical data
Aged
Aged, 80 and over
Biological Specimen Banks/*standards
Breast Neoplasms/*ethnology/mortality/*pathology/therapy
Cancer Survivors
European Continental Ancestry Group/*statistics & numerical data
Female
Humans
Middle Aged
Precision Medicine/*methods
Specimen Handling/methods
*Biospecimen
*Disparities
*Precision medicine
*Survivors
LA  - eng
N1  - 1932-2267
Sheppard, Vanessa B
Hurtado-de-Mendoza, Alejandra
Zheng, Yun-Ling
Wang, Ying
Graves, Kristi D
Lobo, Tania
Xu, Hanfei
Jennings, Yvonne
Tolsma, Dennis
Trout, Martha
Robinson, Brandi E
McKinnon, Brittany
Tadesse, Mahlet
R01CA154848/CA/NCI NIH HHS/United States
P30 CA51008/CA/NCI NIH HHS/United States
KL2 TR001432/TR/NCATS NIH HHS/United States
R01 CA132996/CA/NCI NIH HHS/United States
P30 CA016059/CA/NCI NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
United States
J Cancer Surviv. 2018 Feb;12(1):74-81. doi: 10.1007/s11764-017-0646-8. Epub 2017 Nov 16.
PY  - 2018
SN  - 1932-2259
SP  - 74-81
ST  - Biospecimen donation among black and white breast cancer survivors: opportunities to promote precision medicine
T2  - J Cancer Surviv
TI  - Biospecimen donation among black and white breast cancer survivors: opportunities to promote precision medicine
VL  - 12
ID  - 148
ER  - 

TY  - JOUR
AB  - The Food and Drug Administration (FDA), which oversees and regulates prescription and over-the-counter medications, issues several types of advisories about medication safety. Pharmacists and other practitioners are responsible for carefully evaluating these communications and assessing the potential risk for their individual patients. Focusing on black box warnings - the most serious type of warning from FDA - this article discusses a strategy for evaluating and implementing FDA's safety warnings to provide optimal patient care. © 2012 American Society of Consultant Pharmacists, Inc. All rights reserved.
AD  - C.M. Martin, Greensboro, NC, United States
AU  - Martin, C. M.
AU  - Borgelt, L.
DB  - Embase
Medline
DO  - 10.4140/TCP.n.2012.482
IS  - 7
KW  - aminoglycoside
amiodarone
antianemic agent
antidepressant agent
atypical antipsychotic agent
beta adrenergic receptor blocking agent
beta adrenergic receptor stimulating agent
carbamazepine
cilostazol
clopidogrel
clozapine
disopyramide
dronedarone
estrogen derivative
etanercept
ketoconazole
lamotrigine
long acting beta agonist
loop diuretic agent
low molecular weight heparin
metformin
methadone
methotrexate
methylphenidate
metronidazole
midodrine
modafinil
paracetamol
quinolone derivative
unclassified drug
unindexed drug
absence of side effects
agranulocytosis
article
black box warning
blood dyscrasia
bone marrow suppression
bone necrosis
cardiovascular disease
cerebrovascular disease
clinical evaluation
clinical protocol
dementia
drug approval
drug dependence
drug efficacy
drug fatality
drug labeling
drug manufacture
drug packaging
drug safety
drug withdrawal
electrolyte disturbance
endometrium carcinoma
Food and Drug Administration
general practitioner
atrial fibrillation
heart failure
hematoma
human
hypotension
infection
lactic acidosis
liver dysfunction
liver toxicity
lung toxicity
lymphoma
medicine
medicolegal aspect
mental disease
muscle weakness
myasthenia gravis
neoplasm
nephrotoxicity
nerve paralysis
neurotoxicity
nonhuman
orthostatic hypotension
patient care
patient selection
pharmacist
pneumonia
QT prolongation
respiration depression
risk assessment
seizure
skin manifestation
Stevens Johnson syndrome
suicide attempt
tachycardia
tendon inflammation
tendon rupture
tuberculosis
tumor lysis syndrome
LA  - English
M3  - Article
N1  - L365257348
2012-07-25
2012-07-31
PY  - 2012
SN  - 0888-5109
SP  - 482-492
ST  - Black box warnings: What do they mean to pharmacists and patients
T2  - Consultant Pharmacist
TI  - Black box warnings: What do they mean to pharmacists and patients
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L365257348&from=export
http://dx.doi.org/10.4140/TCP.n.2012.482
http://ascp.metapress.com/content/p74r0r7483220896/fulltext.pdf
VL  - 27
ID  - 1113
ER  - 

TY  - JOUR
AB  - Since the publication of the results of the Women's Health Initiative that described the risks of hormone replacement therapy, many women are actively seeking alternative treatments for menopausal symptoms. Black cohosh (Actaea racemosa, syn. Cimicifuga racemosa) is one such alternative that has been used in the US for over 100 years. To date only two cimicifuga extracts have been tested clinically, and the current recommended dosage is 40-80 mg/day. Review of the published clinical data suggests that cimicifuga may be useful for the treatment of menopausal symptoms, such as hot flashes, profuse sweating, insomnia, and anxiety. However, the methodology used in most of the trials is poor and further clinical assessment of cimicifuga is needed. In terms of safety, transient adverse events such as nausea, vomiting, headaches, dizziness, mastalgia, and weight gain have been observed in clinical trials. A few cases of hepatotoxicity have been reported, but a direct association with the ingestion of cimicifuga has not been demonstrated. The most recent data suggest that cimicifuga is not estrogenic.
AD  - Department of Pharmacy Practice, UIC/NIH Center for Botanical Dietary Supplements Research, Program for Collaborative Research in the Pharmaceutical Sciences, College of Pharmacy, University of Illinois, Chicago, Illinois 60612, USA. mahady@uic.edu
AN  - 15898823
AU  - Mahady, G. B.
DO  - 10.2165/00024677-200504030-00006
DP  - NLM
ET  - 2005/05/19
IS  - 3
KW  - Adult
Animals
Breast Neoplasms
Chemical and Drug Induced Liver Injury
Cimicifuga/*adverse effects/chemistry
Complementary Therapies
Female
Humans
*Menopause
Middle Aged
*Phytotherapy/adverse effects
Plant Extracts/*administration & dosage/*adverse effects
Randomized Controlled Trials as Topic
Treatment Outcome
LA  - eng
N1  - Mahady, Gail B
P50 AT000155-059001/AT/NCCIH NIH HHS/United States
P50-AT00155/AT/NCCIH NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, P.H.S.
Review
New Zealand
Treat Endocrinol. 2005;4(3):177-84. doi: 10.2165/00024677-200504030-00006.
PY  - 2005
SN  - 1175-6349 (Print)
1175-6349
SP  - 177-84
ST  - Black cohosh (Actaea/Cimicifuga racemosa): review of the clinical data for safety and efficacy in menopausal symptoms
T2  - Treat Endocrinol
TI  - Black cohosh (Actaea/Cimicifuga racemosa): review of the clinical data for safety and efficacy in menopausal symptoms
VL  - 4
ID  - 602
ER  - 

TY  - JOUR
AB  - OBJECTIVE: The antihormonal therapy of breast cancer patients with the antiestrogen tamoxifen often induces or aggravates menopausal complaints. As estrogen substitution is contraindicated, herbal alternatives, e.g. extracts of black cohosh are often used. DESIGN: A prospective observational study was carried out in 50 breast cancer patients with tamoxifen treatment. All patients had had surgery, most of them had undergone radiation therapy (87%) and approximately 50% had received chemotherapy. Every patient was treated with an isopropanolic extract of black cohosh (1-4 tablets, 2.5 mg) for 6 months. Patients recorded their complaints before therapy and after 1, 3, and 6 months of therapy using the menopause rating scale (MRS II). RESULTS: The reduction of the total MRS II score under black cohosh treatment from 17.6 to 13.6 was statistically significant. Hot flashes, sweating, sleep problems, and anxiety improved, whereas urogenital and musculoskeletal complaints did not change. In all, 22 patients reported adverse events, none of which were linked with the study medication; 90% reported the tolerability of the black cohosh extract as very good or good. CONCLUSIONS: Black cohosh extract seems to be a reasonable treatment approach in tamoxifen treated breast cancer patients with predominantly psychovegetative symptoms.
AD  - Institute of Complementary Medicine, University Hospital, Zurich, Switzerland. matthias.rostock@usz.ch
AN  - 21231853
AU  - Rostock, M.
AU  - Fischer, J.
AU  - Mumm, A.
AU  - Stammwitz, U.
AU  - Saller, R.
AU  - Bartsch, H. H.
DA  - Oct
DO  - 10.3109/09513590.2010.538097
DP  - NLM
ET  - 2011/01/15
IS  - 10
KW  - Adult
Aged
Antineoplastic Agents, Hormonal/*adverse effects/therapeutic use
Anxiety/chemically induced/prevention & control
Breast Neoplasms/*drug therapy/physiopathology/psychology/therapy
Cimicifuga/*chemistry
Estrogen Antagonists/adverse effects/therapeutic use
Female
Hot Flashes/chemically induced/prevention & control
Humans
Menopause/drug effects/psychology
Middle Aged
Patient Dropouts
*Phytotherapy/adverse effects
Plant Extracts/adverse effects/*therapeutic use
Rhizome/chemistry
Selective Estrogen Receptor Modulators/adverse effects/*therapeutic use
Sleep Wake Disorders/chemically induced/prevention & control
Sweating/drug effects
Tamoxifen/*adverse effects/therapeutic use
LA  - eng
N1  - 1473-0766
Rostock, Matthias
Fischer, Julia
Mumm, Andreas
Stammwitz, Ute
Saller, Reinhard
Bartsch, Hans Helge
Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't
England
Gynecol Endocrinol. 2011 Oct;27(10):844-8. doi: 10.3109/09513590.2010.538097. Epub 2011 Jan 13.
PY  - 2011
SN  - 0951-3590
SP  - 844-8
ST  - Black cohosh (Cimicifuga racemosa) in tamoxifen-treated breast cancer patients with climacteric complaints - a prospective observational study
T2  - Gynecol Endocrinol
TI  - Black cohosh (Cimicifuga racemosa) in tamoxifen-treated breast cancer patients with climacteric complaints - a prospective observational study
VL  - 27
ID  - 401
ER  - 

TY  - JOUR
AB  - The objective of this study was to evaluate the efficacy of fluoxetine and black cohosh in the treatment of women with postmenopausal symptoms. A total of 120 healthy women with menopausal symptoms were recruited to this prospective study with a follow-up period of 6 mo. They were randomly assigned to 1 of 2 groups and were treated with fluoxetine or black cohosh. After entry into the study, patients were examined at the first, second, third, and sixth months of the treatment period. The women kept diaries in which they reported the daily number and intensity of hot flushes and night sweats. In addition, at the beginning and end of the third month, they completed questionnaires consisting of a modified Kupperman Index, Beck's Depression Scale, and a RAND-36 Quality-of-Life Questionnaire. Statistically significant differences were noted in the Kupperman Index and Beck's Depression Scale at the end of the third month in both groups compared with baseline values. In the black: cohosh group, the Kupperman Index decreased significantly compared with that in the fluoxetine group by the end of the third month. On the other hand, in the fluoxetine group, Beck's Depression Scale decreased significantly compared with that in the black cohosh group. Monthly scores for hot flushes and night sweats decreased significantly in both groups; however, black cohosh reduced monthly scores for hot flushes and night sweats to a greater extent than did fluoxetine. At the end of the sixth month of treatment, black cohosh reduced the hot flush score by 85%, compared with a 62% result for fluoxetine. By the sixth month of the study, 40 women had discontinued the study-20 (33%) in the fluoxetine group and 20 (33%) in the black cohosh group. Compared with fluoxetine, black cohosh is more effective for treating hot flushes and night sweats. On the other hand, fluoxetine is more effective in improvements shown on Beck's Depression Scale.
AN  - WOS:000247571900026
AU  - Oktem, M.
AU  - Eroglu, D.
AU  - Karahan, H. B.
AU  - Taskintuna, N.
AU  - Kuscu, E.
AU  - Zeyneloglu, H. B.
DA  - Mar-Apr
DO  - 10.1007/BF02849914
IS  - 2
N1  - 17565936
PY  - 2007
SN  - 0741-238X
SP  - 448-461
ST  - Black cohosh and fluoxetine in the treatment of postmenopausal symptoms: A prospective, randomized trial
T2  - Advances in Therapy
TI  - Black cohosh and fluoxetine in the treatment of postmenopausal symptoms: A prospective, randomized trial
VL  - 24
ID  - 3199
ER  - 

TY  - JOUR
AB  - Background. African Americans suffer a disproportionate burden of illness and premature mortality. Methods. A health education program delivered via cosmetologists was pilot tested as a supplement to other programs seeking to reach this community with information designed to remedy this inequality. Eight cosmetologists were randomized to either an active or a passive educational intervention arm, with the active arm (experimental arm) focused on breast cancer early detection. Results. Both cosmetologists and clients found this an acceptable intervention. Nearly all women in the study demonstrated that they hail heard the mainstream messages about the value of breast cancer early detection, but a considerable proportion appeared not to realize breast cancer's high level of morbidity and mortality within their own community. Conclusion. The results suggest this approach is worthy of further evaluation.
AN  - WOS:000086668500009
AU  - Sadler, G. R.
AU  - Thomas, A. G.
AU  - Gebrekristos, B.
AU  - Dhanjal, S. K.
AU  - Mugo, J.
DA  - Spr
IS  - 1
N1  - 25
10730801
PY  - 2000
SN  - 0885-8195
SP  - 33-37
ST  - Black cosmetologists promoting health program: Pilot study outcomes
T2  - Journal of Cancer Education
TI  - Black cosmetologists promoting health program: Pilot study outcomes
VL  - 15
ID  - 2721
ER  - 

TY  - JOUR
AB  - OBJECTIVE: Colonoscopy is considered as a standard method for detecting various kinds of colorectal polyps. However, conventional colonoscopy (CC) still has chances to miss some lesions. Some scholars have already repor ted that transparent hood assisted colonoscopy (THAC) can improve the detection rate of colorectal polyps. However, the efficacy of detection of colorectal polyps with black hood assisted colonoscopy (BHAC) is still unclear. In this study, BHAC was compared with CC for evaluating the efficacy of detection of colorectal polyps. PATIENTS AND METHODS: Between Sep 2014 and Apr 2015, 542 patients underwent CC and meanwhile 534 patients underwent BHAC were enrolled into this prospective randomized controlled study. Comparison of baseline characteristics, cecal intubation time, withdrawal time, total number of detected polyps, detection rate of polyps, location, size, morphology and pathological diagnosis of polyps between these two groups was performed. RESULTS: Cecal intubation time was significantly shorter in BHAC group than in CC group (6.31 ± 3.51 min vs. 7.05 ± 4.15 min, p = 0.002). The total number of detected polyps and detection rate of polyps were significantly higher in BHAC group than in CC group (349/65.36% vs. 264/48.71%, p = 0.004). CONCLUSIONS: Compared with CC, BHAC could significantly improve the detection rate of colorectal polyps, and cecal intubation time was significantly reduced by BHAC.
AD  - Z.-J. Bao, Digestive Endoscopy Center, Huadong Hospital Affiliated, Fudan University, Shanghai, China
AU  - Huang, R. X.
AU  - Xiao, Z. L.
AU  - Li, F.
AU  - Ji, D. N.
AU  - Zhou, J.
AU  - Xiang, P.
AU  - Bao, Z. J.
DB  - Embase
Medline
IS  - 15
KW  - DCD-15006755
black hood
endoscopic accessory
adult
article
black hood assisted colonoscopy
cancer diagnosis
cancer morphology
cecum intubation time
cecum intubation withdrawal time
colonoscope
colonoscopy
colorectal polyp
comparative effectiveness
controlled study
conventional colonoscopy
demography
female
follow up
human
intermethod comparison
major clinical study
male
middle aged
polyp detection rate
prospective study
randomized controlled trial
time
total number of detected polyp
tumor localization
tumor volume
CF-H260
MAJ-1991
LA  - English
M3  - Article
N1  - L615209923
2017-04-12
2017-04-25
PY  - 2016
SN  - 1128-3602
SP  - 3266-3272
ST  - Black hood assisted colonoscopy for detection of colorectal polyps: A prospective randomized controlled study
T2  - European Review for Medical and Pharmacological Sciences
TI  - Black hood assisted colonoscopy for detection of colorectal polyps: A prospective randomized controlled study
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L615209923&from=export
VL  - 20
ID  - 968
ER  - 

TY  - JOUR
AB  - OBJECTIVE: The study objective was to identify biobehavioral variables associated with greater intake of nicotine and a tobacco carcinogen among Black light smokers who smoke 1 to 10 cigarettes per day (CPD). METHODS: We analyzed baseline data collected from 426 Black light smokers enrolled in Kick It at Swope III (KIS III), a smoking cessation trial for Black smokers. We examined differences in concentrations of tobacco biomarkers, including urinary total nicotine equivalents (TNE) and total 4-(methylnitrosamino)-1-(3)pyridyl-1-butanonol (NNAL; a human carcinogen), across gender, age, plasma nicotine metabolite ratio (NMR), CPD, and measures of tobacco dependence, including time to first cigarette (TFC), using ANOVA. RESULTS: Tobacco biomarker levels were significantly higher among those who smoked more CPD (6-10 vs 1-5 CPD) and those with greater reported physical dependence on tobacco. Concurrently, those who smoked 1-5 CPD smoked each cigarette more intensely than those who smoked 6-10 CPD. While we found no gender differences overall, among those who smoked 1-5 CPD, women had higher NNAL levels compared to men. The rate of nicotine metabolism, measured by the nicotine metabolite ratio, was not significantly related to TNE or NNAL levels. CONCLUSION: Among Black Light smokers, higher cigarette consumption and greater physical dependence-but not rate of nicotine metabolism, menthol use, or socioeconomic status-were associated with greater toxicant exposure and thus a likely increased risk of tobacco-related diseases. The lack of data on light smokers, and specifically on Blacks, make this observation important given the disproportionate burden of lung cancer in this population.
AD  - Clinical Pharmacology Research Program, Division of Cardiology, Department of Medicine, Zuckerberg San Francisco General Hospital, University of California, San Francisco, CA, USA; Center for Tobacco Control Research and Education (CTCRE), University of California, San Francisco, CA, USA. Electronic address: Gideon.Sthelen@ucsf.edu.
Clinical Pharmacology Research Program, Division of Cardiology, Department of Medicine, Zuckerberg San Francisco General Hospital, University of California, San Francisco, CA, USA; Center for Tobacco Control Research and Education (CTCRE), University of California, San Francisco, CA, USA; Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, CA, USA.
Departments of Behavioral and Social Sciences and Medicine, Brown University School of Public Health and Alpert School of Medicine, Providence, RI, USA.
Campbell Family Mental Health Research Institute and Addictions Division, Centre for Addiction and Mental Health (CAMH), Department of Pharmacology and Toxicology, Department of Psychiatry, University of Toronto, ON, Canada.
Clinical Pharmacology Research Program, Division of Cardiology, Department of Medicine, Zuckerberg San Francisco General Hospital, University of California, San Francisco, CA, USA.
Division of General Internal Medicine, Department of Medicine, University of California, San Francisco, CA, USA.
Division of Intramural Research, National Heart, Lung and Blood Institute and Office of the Director, National Institute on Minority Health and Health Disparities, National Institutes of Health, MD, USA.
Department of Preventive Medicine and Public Health, University of Kansas School of Medicine, Kansas City, KS, USA.
AN  - 31084916
AU  - St Helen, G.
AU  - Benowitz, N. L.
AU  - Ahluwalia, J. S.
AU  - Tyndale, R. F.
AU  - Addo, N.
AU  - Gregorich, S. E.
AU  - Pérez-Stable, E. J.
AU  - Cox, L. S.
C2  - PMC6842416
C6  - NIHMS1529169
DA  - Oct
DO  - 10.1016/j.jnma.2019.04.004
DP  - NLM
ET  - 2019/05/16
IS  - 5
KW  - Adult
*African Americans
Age Factors
Aged
Biomarkers/blood/urine
Carcinogens/metabolism
Cotinine/*analogs & derivatives/*blood
Female
Humans
Male
Middle Aged
Nicotine/*metabolism
Nitrosamines/*urine
Sex Factors
*Smoking/blood/urine
Tobacco Products/statistics & numerical data
Tobacco Use Disorder/blood/urine
Young Adult
Black smokers
Carcinogen exposure
Correlates of exposure
Light smokers
Nicotine
LA  - eng
N1  - 1943-4693
St Helen, Gideon
Benowitz, Neal L
Ahluwalia, Jasjit S
Tyndale, Rachel F
Addo, Newton
Gregorich, Steven E
Pérez-Stable, Eliseo J
Cox, Lisa Sanderson
R01 DA002277/DA/NIDA NIH HHS/United States
S10 RR026437/RR/NCRR NIH HHS/United States
R25 DA035163/DA/NIDA NIH HHS/United States
P30 DA012393/DA/NIDA NIH HHS/United States
R01 CA091912/CA/NCI NIH HHS/United States
P30 AG015272/AG/NIA NIH HHS/United States
R37 DA002277/DA/NIDA NIH HHS/United States
Journal Article
J Natl Med Assoc. 2019 Oct;111(5):509-520. doi: 10.1016/j.jnma.2019.04.004. Epub 2019 May 11.
PY  - 2019
SN  - 0027-9684 (Print)
0027-9684
SP  - 509-520
ST  - Black Light Smokers: How Nicotine Intake and Carcinogen Exposure Differ Across Various Biobehavioral Factors
T2  - J Natl Med Assoc
TI  - Black Light Smokers: How Nicotine Intake and Carcinogen Exposure Differ Across Various Biobehavioral Factors
VL  - 111
ID  - 75
ER  - 

TY  - JOUR
AB  - The primary goal of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial is to learn whether widespread use of screening tests to detect these cancers will reduce associated mortality. Blacks have the highest age-adjusted cancer incidence and mortality rates of any population group in the United States, but several barriers to their participation in clinical research such as the PLCO trial exist. These barriers involve sociocultural, economic, and individual factors, as well as factors inherent in trial designs. Population diversity in the PLCO trial is necessary to preserve scientific validity and generalizability of trial results. Therefore, the National Cancer Institute and the Centers for Disease Control and Prevention are collaborating to ensure adequate representation of blacks in the PLCO trial. For example, the agencies have funded several new activities designed to better understand and overcome barriers to participation in the trial. These activities include the African American Men Project, a randomized trial designed to evaluate the efficacy of three increasingly intensive recruitment interventions in recruiting black men; the establishment of a minority-focused PLCO trial screening center, a study to identify factors that influenced the decisions of black women recruited to participate in the PLCO trial; and a study to examine the psychosocial factors that influence blacks' decision making to engage in cancer screening and participation in research similar to the PLCO trial. The results of these activities will allow for a more thorough examination of cancer-related issues of importance to blacks and will help shed light on factors that influence their decisions to participate in cancer screening and prevention clinical trials.
AD  - Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
AN  - 11189689
AU  - Stallings, F. L.
AU  - Ford, M. E.
AU  - Simpson, N. K.
AU  - Fouad, M.
AU  - Jernigan, J. C.
AU  - Trauth, J. M.
AU  - Miller, D. S.
DA  - Dec
DO  - 10.1016/s0197-2456(00)00093-3
DP  - NLM
ET  - 2001/02/24
IS  - 6 Suppl
KW  - Adult
*African Americans
Colorectal Neoplasms/*diagnosis/prevention & control
Female
Humans
Lung Neoplasms/*diagnosis/prevention & control
Male
*Mass Screening
Middle Aged
*Minority Groups
Multicenter Studies as Topic
Ovarian Neoplasms/*diagnosis/prevention & control
*Patient Selection
Prostatic Neoplasms/*diagnosis/prevention & control
*Randomized Controlled Trials as Topic
LA  - eng
N1  - Stallings, F L
Ford, M E
Simpson, N K
Fouad, M
Jernigan, J C
Trauth, J M
Miller, D S
Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial Project Team
Journal Article
United States
Control Clin Trials. 2000 Dec;21(6 Suppl):379S-389S. doi: 10.1016/s0197-2456(00)00093-3.
PY  - 2000
SN  - 0197-2456 (Print)
0197-2456
SP  - 379s-389s
ST  - Black participation in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial
T2  - Control Clin Trials
TI  - Black participation in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial
VL  - 21
ID  - 691
ER  - 

TY  - JOUR
AB  - BACKGROUND: Racial disparities are well-documented in preventive cancer care, but they have not been fully explored in the context of lung cancer screening. We sought to explore racial differences in lung cancer screening outcomes within a lung cancer screening program (LCSP) at our urban academic medical center including differences in baseline low-dose computed tomography (LDCT) results, time to follow-up, adherence, as well as return to annual screening after additional imaging, loss to follow-up, and cancer diagnoses in patients with positive baseline scans. METHODS: A historical cohort study of patients referred to our LCSP was conducted to extract demographic and clinical characteristics, smoking history, and lung cancer screening outcomes. RESULTS: After referral to the LCSP, blacks had significantly lower odds of receiving LDCT compared to whites, even while controlling for individual lung cancer risk factors and neighborhood-level factors. Blacks also demonstrated a trend toward delayed follow-up, decreased adherence, and loss to follow-up across all Lung-RADS categories. CONCLUSIONS: Overall, lung cancer screening annual adherence rates were low, regardless of race, highlighting the need for increased patient education and outreach. Furthermore, the disparities in race we identified encourage further research with the purpose of creating culturally competent and inclusive LCSPs.
AD  - The Jane and Leonard Korman Respiratory Institute, Division of Pulmonary and Critical Care Medicine, 834 Walnut Street, Suite 650, Philadelphia, PA, 19107, USA.
The Jane and Leonard Korman Respiratory Institute, Department of Medicine, Division of Pulmonary and Critical Care Medicine, Sidney Kimmel Medical College at Thomas Jefferson University, 1025 Walnut Street; Suite 826, Philadelphia, PA, 19107, USA.
Department of Medical Oncology, Division of Population Science, Thomas Jefferson University, 834 Chestnut Street; Suite 311, Philadelphia, PA, 19107, USA.
Jefferson College of Population Health, Thomas Jefferson University, 901 Walnut Street; 10th Floor, Philadelphia, PA, 19107, USA.
The Jane and Leonard Korman Respiratory Institute, Department of Surgery, Division of Thoracic Surgery, 1025 Walnut Street; Suite 607, Philadelphia, PA, 19107, USA.
The Jane and Leonard Korman Respiratory Institute, Division of Pulmonary and Critical Care Medicine, 834 Walnut Street, Suite 650, Philadelphia, PA, 19107, USA. Julie.Barta@jefferson.edu.
AN  - 32546140
AU  - Lake, M.
AU  - Shusted, C. S.
AU  - Juon, H. S.
AU  - McIntire, R. K.
AU  - Zeigler-Johnson, C.
AU  - Evans, N. R.
AU  - Kane, G. C.
AU  - Barta, J. A.
C2  - PMC7298866
DA  - Jun 16
DO  - 10.1186/s12885-020-06923-0
DP  - NLM
ET  - 2020/06/18
IS  - 1
KW  - Academic Medical Centers/statistics & numerical data
African Americans/*statistics & numerical data
Aftercare/statistics & numerical data
Aged
Early Detection of Cancer/*statistics & numerical data
European Continental Ancestry Group/statistics & numerical data
Female
Healthcare Disparities/*statistics & numerical data
Humans
Lost to Follow-Up
Lung Neoplasms/*diagnosis
Male
Mass Screening/*statistics & numerical data
Middle Aged
Patient Compliance/statistics & numerical data
Patient Education as Topic/organization & administration
Referral and Consultation/statistics & numerical data
Retrospective Studies
Time Factors
Tomography, X-Ray Computed
Cancer Screening
Lung Cancer
Lung Cancer Screening
Lung Cancer diagnosis
Racial disparities
Screening adherence
LA  - eng
N1  - 1471-2407
Lake, Michael
Shusted, Christine S
Juon, Hee-Soon
McIntire, Russell K
Zeigler-Johnson, Charnita
Evans, Nathaniel R
Kane, Gregory C
Barta, Julie A
Orcid: 0000-0001-6480-0769
Engaging a Learning Community to Increase Lung Cancer Screening in Vulnerable Populations/Bristol-Myers Squibb Foundation/
n/a/The Dreidink Scholarship/
Journal Article
BMC Cancer. 2020 Jun 16;20(1):561. doi: 10.1186/s12885-020-06923-0.
PY  - 2020
SN  - 1471-2407
SP  - 561
ST  - Black patients referred to a lung cancer screening program experience lower rates of screening and longer time to follow-up
T2  - BMC Cancer
TI  - Black patients referred to a lung cancer screening program experience lower rates of screening and longer time to follow-up
VL  - 20
ID  - 34
ER  - 

TY  - JOUR
AB  - OBJECTIVE: To examine differences between African Americans (Blacks) and non-Hispanic Whites in risk of death after diagnosis of later-stage prostate cancer in a large sample of patients from US population-based cancer registries. The theory that Black patients with advanced cancer have a lower survival rate compared to their White counterparts, based on a single clinical trial, was tested with large samples of patients. METHODS: The Cox proportional hazards regression model was used to compare survival rates among 24,136 non-Hispanic White, and 3,817 Black prostate cancer patients diagnosed between 1988 and 1997, whose cancer had spread beyond the prostate capsule, and who resided in 9 geographic areas covered by the National Cancer Institute's Surveillance, Epidemiology and End Results (SEER) Program of population-based cancer registries. Other analyses involved 5- and 10-year relative survival rates (RSRs) among non-Hispanic White and Black patients diagnosed with distant-stage prostate cancer from 1973 to 1994 (with almost all patients having had a chance to survive for at least 5 years). RESULTS: The risk of death from prostate cancer was only slightly higher for Blacks than for Whites (adjusted hazard rate ratio = 1.05), when age, extent of disease, tumor grade, marital status, and surgery were included in the Cox proportional hazards regression model. Five- and 10-year RSRs were about 2%-22% higher for Blacks and Whites in strata defined by extent of disease, or among patients with distant stage cancer, but differences were small among married patients. CONCLUSIONS: The findings do not indicate substantial Black-White differences in survival rates of later-stage prostate cancer patients, after adjusting for clinical characteristics and marital status.
AD  - Connecticut Tumor Registry, Connecticut Department of Public Health, Hartford, Connecticut 06134, USA. anthony.polednak@po.state.ct.us
AN  - 12785419
AU  - Polednak, A. P.
DA  - Spring
DP  - NLM
ET  - 2003/06/06
IS  - 2
KW  - African Americans/*statistics & numerical data
Aged
Aged, 80 and over
Clinical Trials as Topic
European Continental Ancestry Group/*statistics & numerical data
Humans
Male
Middle Aged
Proportional Hazards Models
Prostatic Neoplasms/*ethnology/mortality
SEER Program
*Survival Rate
United States/epidemiology
LA  - eng
N1  - Polednak, Anthony P
N01-CN-67005/CN/NCI NIH HHS/United States
Comparative Study
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.
United States
Ethn Dis. 2003 Spring;13(2):220-5.
PY  - 2003
SN  - 1049-510X (Print)
1049-510x
SP  - 220-5
ST  - Black-white differences in survival from late-stage prostate cancer
T2  - Ethn Dis
TI  - Black-white differences in survival from late-stage prostate cancer
VL  - 13
ID  - 646
ER  - 

TY  - JOUR
AB  - BACKGROUND: In the United States, there are lower rates of breastfeeding among African American mothers, particularly those who are younger women. Recent epidemiological studies have shown a strong association of more aggressive types of breast cancer (estrogen receptor negative) among African American women, with a higher risk in African American women who did not breastfeed their children. OBJECTIVE: This study aims to describe the process evaluation of recruitment and educational strategies to engage pregnant African American participants for a pilot study designed to determine whether social media messaging about breast cancer risk reduction through breastfeeding may positively influence breastfeeding rates. METHODS: This pilot study is conducted in collaboration with a local Women, Infants, and Children (WIC) organization and hospital and prenatal clinics of a local health care network. To engage African American women to enroll in the study, several methods and monitoring processes were explored, including WIC electronic text-based messages sent out to all phones of current WIC recipients (referred to as e-blasts); keyword responses to texts from flyers and posters in local community-based organizations, hospitals, and prenatal clinics; keyword responses using electronic links posted in established Facebook groups; and snowball recruitment of other pregnant women by current participants through Facebook. Once enrolled, participants were randomized to 2 study conditions: (1) an intervention group receiving messages about breast cancer risk reduction and breastfeeding or (2) a control group receiving breastfeeding-only messages. Data were obtained through electronic monitoring, SurveyMonkey, qualitative responses on Facebook, focus groups, and interviews. RESULTS: More than 3000 text messages were sent and received through WIC e-blasts and keyword responses from flyers. A total of 472 women were recruited through WIC e-blast, and 161 responded to flyers and contacts through the local health care network, community-based organizations, Facebook, and friend referrals. A total of 633 women were assessed for eligibility to participate in the study. A total of 288 pregnant African American women were enrolled, consented, and completed presurvey assessments (102.8% of the goal), and 22 participants attended focus groups or interviews reporting on their experiences with Facebook and the educational messages. CONCLUSIONS: This process evaluation suggests that using electronic, smartphone apps with social media holds promise for both recruitment and conduct of health education intervention studies for pregnant African American women. Providing messaging and resources through social media to reinforce and educate women about breastfeeding and potentially provide lactation support is intriguing. Convenience (for researchers and participants) is an attribute of social media for this demographic of women and worthy of further research as an educational tool. TRIAL REGISTRATION: ClinicalTrials.gov NCT03680235; https://clinicaltrials.gov/ct2/show/NCT03680235.
AD  - Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States.
Department of Health Services Administration, D'Youville College, Buffalo, NY, United States.
Department of Health, Behavior and Society, University of Kentucky, Lexington, KY, United States.
Department of Community Health and Health Behavior, State University of New York at Buffalo, Buffalo, NY, United States.
AN  - 32773377
AU  - Dauphin, C.
AU  - Clark, N.
AU  - Cadzow, R.
AU  - Saad-Harfouche, F.
AU  - Rodriguez, E.
AU  - Glaser, K.
AU  - Kiviniemi, M.
AU  - Keller, M.
AU  - Erwin, D.
C2  - PMC7445612
DA  - Aug 10
DO  - 10.2196/16239
DP  - NLM
ET  - 2020/08/11
IS  - 8
KW  - Adolescent
Adult
African Americans/*statistics & numerical data
Breast Feeding/*ethnology/statistics & numerical data
Female
Humans
Internet-Based Intervention/*statistics & numerical data
Pilot Projects
Pregnancy
Pregnant Women
Social Media/*instrumentation
Young Adult
*African American mothers
*Facebook
*breast cancer education
*breastfeeding
*mobile phone, social media
LA  - eng
N1  - 1438-8871
Dauphin, Cassy
Orcid: 0000-0002-2620-1084
Clark, Nikia
Orcid: 0000-0001-8272-8246
Cadzow, Renee
Orcid: 0000-0003-3581-7902
Saad-Harfouche, Frances
Orcid: 0000-0001-6024-6473
Rodriguez, Elisa
Orcid: 0000-0003-1433-5816
Glaser, Kathryn
Orcid: 0000-0002-7654-8684
Kiviniemi, Marc
Orcid: 0000-0002-1299-8416
Keller, Maria
Orcid: 0000-0003-1417-0812
Erwin, Deborah
Orcid: 0000-0003-3388-6453
P30 CA016056/CA/NCI NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
J Med Internet Res. 2020 Aug 10;22(8):e16239. doi: 10.2196/16239.
PY  - 2020
SN  - 1439-4456 (Print)
1438-8871
SP  - e16239
ST  - #BlackBreastsMatter: Process Evaluation of Recruitment and Engagement of Pregnant African American Women for a Social Media Intervention Study to Increase Breastfeeding
T2  - J Med Internet Res
TI  - #BlackBreastsMatter: Process Evaluation of Recruitment and Engagement of Pregnant African American Women for a Social Media Intervention Study to Increase Breastfeeding
VL  - 22
ID  - 30
ER  - 

TY  - JOUR
AB  - Recent studies suggest a diet low in dietary magnesium intake or lower blood magnesium levels is linked with increased prostate cancer risk. This study investigates the race-specific link between blood magnesium and calcium levels, or dietary magnesium intake, and the diagnosis of low-grade and high-grade prostate cancer. The study included 637 prostate cancer cases and 715 biopsy-negative controls (50% black) recruited from Nashville, TN or Durham, NC. Blood was collected at the time of recruitment, and dietary intake was assessed by food frequency questionnaire. Percent genetic African ancestry was determined as a compliment to self-reported race. Blood magnesium levels and dietary magnesium intake were significantly lower in black compared to white men. However, magnesium levels or intake were not associated with risk of total prostate cancer or aggressive prostate cancer. Indeed, a higher calcium-to-magnesium diet intake was significantly protective for high-grade prostate cancer in black (OR = 0.66 (0.45, 0.96), p = 0.03) but not white (OR = 1.00 (0.79, 1.26), p = 0.99) men. In summary, there was a statistically significant difference in magnesium intake between black and white men, but the biological impact was unclear, and we did not confirm a lower prostate cancer risk associated with magnesium levels. © 2019 Elsevier B.V.
AD  - Department of Preventive Medicine, University of Tennessee Health Science CenterTN, United States
Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, United States
Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, United States
Program for Personalized Cancer Care, NorthShore University HealthSystem, Evanston, IL, United States
Department of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, NC, United States
Surgery Section, Durham VA Medical Center, Durham, NC, United States
Department of Surgery, Division of Urology, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, United States
AU  - Fowke, J. H.
AU  - Koyama, T.
AU  - Dai, Q.
AU  - Zheng, S. L.
AU  - Xu, J.
AU  - Howard, L. E.
AU  - Freedland, S. J.
DB  - Scopus
DO  - 10.1016/j.canlet.2019.02.023
KW  - Biomarker
Calcium
Diet
Genetic African ancestry
Race
M3  - Article
N1  - Cited By :1
Export Date: 22 March 2021
PY  - 2019
SP  - 99-105
ST  - Blood and dietary magnesium levels are not linked with lower prostate cancer risk in black or white men
T2  - Cancer Letters
TI  - Blood and dietary magnesium levels are not linked with lower prostate cancer risk in black or white men
UR  - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85061770053&doi=10.1016%2fj.canlet.2019.02.023&partnerID=40&md5=38cd7d2a83c26c2789acaadcae1c9431
VL  - 449
ID  - 2230
ER  - 

TY  - JOUR
AB  - OBJECTIVE: In a large prospective cohort, we examined the relationship of body mass index (BMI) with mortality among blacks and compared the results to those among whites in this population. DESIGN AND METHODS: The study population consisted of 7,446 non-Hispanic black and 130,598 white participants, ages 49-78 at enrollment, in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. BMI at baseline, BMI at age 20, and BMI change were calculated using self-reported and recalled height and weight. Relative risks were stratified by race and sex and adjusted for age, education, marital status, and smoking. RESULTS: During follow-up, 1,495 black and 18,236 white participants died (mean = 13 years). Clear J-shaped associations between BMI and mortality were observed among white men and women. Among black men and women, the bottoms of these curves were flatter, and increasing risks of death with greater BMI were observed only at higher BMI levels (≥35.0). Associations for BMI at age 20 and BMI change also appeared to be stronger in magnitude in whites versus blacks, and these racial differences appeared to be more pronounced among women. CONCLUSION: Our results suggest that BMI may be more weakly associated with mortality in blacks, particularly black women, than in whites.
AD  - Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland, USA.
AN  - 23512729
AU  - Xiao, Q.
AU  - Hsing, A. W.
AU  - Park, Y.
AU  - Moore, S. C.
AU  - Matthews, C. E.
AU  - de González, A. B.
AU  - Kitahara, C. M.
C2  - PMC3690173
C6  - NIHMS439105
DA  - Jan
DO  - 10.1002/oby.20412
DP  - NLM
ET  - 2013/03/21
IS  - 1
KW  - African Continental Ancestry Group
Aged
*Body Mass Index
Colorectal Neoplasms/diagnosis
European Continental Ancestry Group
Female
Follow-Up Studies
Humans
Lung Neoplasms/diagnosis
Male
Middle Aged
Mortality/*ethnology
Ovarian Neoplasms/diagnosis
Prospective Studies
Prostatic Neoplasms/diagnosis
Randomized Controlled Trials as Topic
Risk Factors
Socioeconomic Factors
Surveys and Questionnaires
LA  - eng
N1  - 1930-739x
Xiao, Qian
Hsing, Ann W
Park, Yikyung
Moore, Steven C
Matthews, Charles E
de González, Amy Berrington
Kitahara, Cari M
Z99 CA999999/Intramural NIH HHS/United States
Journal Article
Research Support, N.I.H., Intramural
Obesity (Silver Spring). 2014 Jan;22(1):260-8. doi: 10.1002/oby.20412. Epub 2013 Jul 2.
PY  - 2014
SN  - 1930-7381 (Print)
1930-7381
SP  - 260-8
ST  - Body mass index and mortality among blacks and whites adults in the Prostate, Lung, Colorectal, and Ovarian (PLCO) cancer screening trial
T2  - Obesity (Silver Spring)
TI  - Body mass index and mortality among blacks and whites adults in the Prostate, Lung, Colorectal, and Ovarian (PLCO) cancer screening trial
VL  - 22
ID  - 333
ER  - 

TY  - JOUR
AB  - Breast cancer patients ages 18‐60 who are planned for adjuvant radiotherapy and who meet all inclusion/exclusion criteria will be offered voluntary participation in this trial. Recruitment will be open for approximately 18 months; it is anticipated that 1‐2 patients will be recruited per week until the planned sample size is met. Participants will be stratified into three groups depending on their self‐reported baseline Body‐image satisfaction (BIS) score and will then be randomly allocated to receive conventional dark ink or UV fluorescent tattoos using permutated block randomization (4 patients per block) to ensure balance of BIS baseline average between study arms. The investigators focus is to improve the current tattooing technique for breast cancer patients by introducing an alternate method that takes the patient's psychological perceptions of tattooing into account while first and foremost, continuing to guarantee that the current standard of accuracy in treatment delivery is maintained or improved. The investigators goal of decreasing the psychological effect of permanent radiotherapy tattoos aligns with CancerCare Manitoba's mission to improve the outcomes and quality of life for Manitobans with cancer.
AN  - CN-01493658
AU  - Nct
KW  - Breast Neoplasms
PY  - 2017
ST  - Body-image Satisfaction Following Permanent Black or Invisible UV Ink Tattoos
T2  - https://clinicaltrials.gov/show/NCT03131011
TI  - Body-image Satisfaction Following Permanent Black or Invisible UV Ink Tattoos
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01493658/full
ID  - 1500
ER  - 

TY  - JOUR
AB  - Author summary Why was this study done? The cells around a tumor, also known as the tumor microenvironment (TME), can help a tumor grow by suppressing the immune system or fight a tumor by mounting an immune response. Most studies of multiple myeloma (MM) have focused on the tumor itself, rather than the bone marrow (BM) TME in which the tumor is growing. We hypothesized that the MM TME held clues that could help us better treat patients. What did the researchers do and find? We used a gene-expression-based computational technique to determine which cell types were present in patient BM. Patients with BM lacking a family of innate immune cells called granulocytes presented with worse outcomes compared to other patients. As MM progresses from a predisease to a cancerous state, the percentage of granulocytes decreases; the patients with the fewest granulocytes had more serious diseases. What do these findings mean? If granulocytes help myeloma patients respond to therapy, then addressing the decline in granulocytes may improve MM treatment. Patients with MM and few granulocytes in their BM should be watched for worse outcomes. Background The tumor microenvironment (TME) is increasingly appreciated as an important determinant of cancer outcome, including in multiple myeloma (MM). However, most myeloma microenvironment studies have been based on bone marrow (BM) aspirates, which often do not fully reflect the cellular content of BM tissue itself. To address this limitation in myeloma research, we systematically characterized the whole bone marrow (WBM) microenvironment during premalignant, baseline, on treatment, and post-treatment phases. Methods and findings Between 2004 and 2019, 998 BM samples were taken from 436 patients with newly diagnosed MM (NDMM) at the University of Arkansas for Medical Sciences in Little Rock, Arkansas, United States of America. These patients were 61% male and 39% female, 89% White, 8% Black, and 3% other/refused, with a mean age of 58 years. Using WBM and matched cluster of differentiation (CD)138-selected tumor gene expression to control for tumor burden, we identified a subgroup of patients with an adverse TME associated with 17 fewer months of progression-free survival (PFS) (95% confidence interval [CI] 5-29, 49-69 versus 70-82 months, chi(2) p = 0.001) and 15 fewer months of overall survival (OS; 95% CI -1 to 31, 92-120 versus 113-129 months, chi(2) p = 0.036). Using immunohistochemistry-validated computational tools that identify distinct cell types from bulk gene expression, we showed that the adverse outcome was correlated with elevated CD8(+) T cell and reduced granulocytic cell proportions. This microenvironment develops during the progression of premalignant to malignant disease and becomes less prevalent after therapy, in which it is associated with improved outcomes. In patients with quantified International Staging System (ISS) stage and 70-gene Prognostic Risk Score (GEP-70) scores, taking the microenvironment into consideration would have identified an additional 40 out of 290 patients (14%, premutation p = 0.001) with significantly worse outcomes (PFS, 95% CI 6-36, 49-73 versus 74-90 months) who were not identified by existing clinical (ISS stage III) and tumor (GEP-70) criteria as high risk. The main limitations of this study are that it relies on computationally identified cell types and that patients were treated with thalidomide rather than current therapies. Conclusions In this study, we observe that granulocyte signatures in the MM TME contribute to a more accurate prognosis. This implies that future researchers and clinicians treating patients should quantify TME components, in particular monocytes and granulocytes, which are often ignored in microenvironment studies.
AN  - WOS:000589605800001
AU  - Danziger, S. A.
AU  - McConnell, M.
AU  - Gockley, J.
AU  - Young, M. H.
AU  - Rosenthal, A.
AU  - Schmitz, F.
AU  - Reiss, D. J.
AU  - Farmer, P.
AU  - Alapat, D. V.
AU  - Singh, A.
AU  - Ashby, C.
AU  - Bauer, M.
AU  - Ren, Y.
AU  - Smith, K.
AU  - Couto, S. S.
AU  - van Rhee, F.
AU  - Davies, F.
AU  - Zangari, M.
AU  - Petty, N.
AU  - Orlowski, R. Z.
AU  - Dhodapkar, M. V.
AU  - Copeland, W. B.
AU  - Fox, B.
AU  - Hoering, A.
AU  - Fitch, A.
AU  - Newhall, K.
AU  - Barlogie, B.
AU  - Trotter, M. W. B.
AU  - Hershberg, R. M.
AU  - Walker, B. A.
AU  - Dervan, A. P.
AU  - Ratushny, A. V.
AU  - Morgan, G. J.
DA  - Nov
DO  - 10.1371/journal.pmed.1003323
IS  - 11
N1  - e1003323
33147277
PY  - 2020
SN  - 1549-1277
ST  - Bone marrow microenvironments that contribute to patient outcomes in newly diagnosed multiple myeloma: A cohort study of patients in the Total Therapy clinical trials
T2  - Plos Medicine
TI  - Bone marrow microenvironments that contribute to patient outcomes in newly diagnosed multiple myeloma: A cohort study of patients in the Total Therapy clinical trials
VL  - 17
ID  - 2757
ER  - 

TY  - JOUR
AB  - BACKGROUND: Breast biopsy is essential for definitive breast cancer diagnosis, but may also play a role in determining eligibility for breast cancer preventive measures or clinical trials. In addition, the prevalence of a history of negative breast biopsy can be viewed as an indicator of the adequacy or intensity of health care in a given population. We therefore analyzed the association of a history of breast biopsy with race/ethnicity and other factors in a cohort of women without a cancer diagnosis who completed a risk assessment form for participation in the Study of Tamoxifen and Raloxifene (STAR) and a sociodemographic questionnaire. METHODS: Subjects were recruited at our large, urban teaching hospital. We developed a logistic regression model with biopsy (ever/never) as the outcome and age, race/ethnicity, educational attainment, and insurance coverage as the independent variables. RESULTS: Among 805 unaffected predominantly minority subjects, white women were more than three times as likely as black and Hispanic women (OR=3.3, 95% CI 1.9-5.9), and insured women were twice as likely as uninsured women (OR=2.0, 95% CI 1.4-2.9) to have had a biopsy. Biopsy results were also associated with race/ethnicity. DISCUSSION: We view these observations as hypothesis-generating rather than definitive. If confirmed, the associations we observed between negative biopsies and insurance status may reflect disparities in the timeliness and effectiveness of follow-up of suspicious lesions found via mammography. Our findings may also be relevant to the well-known association of breast cancer stage at diagnosis with low income and minority race/ethnicity.
AD  - Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY 10032, USA.
AN  - 16621329
AU  - Jacobson, J. S.
AU  - Grann, V. R.
AU  - Hershman, D.
AU  - Troxel, A. B.
AU  - Li, H.
AU  - Neugut, A. I.
DO  - 10.1016/j.cdp.2006.02.002
DP  - NLM
ET  - 2006/04/20
IS  - 2
KW  - Adult
African Americans/statistics & numerical data
Aged
Biopsy/*statistics & numerical data
Breast/*pathology
Breast Neoplasms/*diagnosis/*ethnology/prevention & control
European Continental Ancestry Group/statistics & numerical data
Female
Hispanic Americans/statistics & numerical data
Humans
Insurance, Health
Logistic Models
Middle Aged
Minority Groups/*statistics & numerical data
Risk Assessment
Socioeconomic Factors
Surveys and Questionnaires
LA  - eng
N1  - Jacobson, Judith S
Grann, Victor R
Hershman, Dawn
Troxel, Andrea B
Li, Huiling
Neugut, Alfred I
K05 CA89155/CA/NCI NIH HHS/United States
K07 CA-95597/CA/NCI NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
England
Cancer Detect Prev. 2006;30(2):129-33. doi: 10.1016/j.cdp.2006.02.002. Epub 2006 Apr 18.
PY  - 2006
SN  - 0361-090X (Print)
0361-090x
SP  - 129-33
ST  - Breast biopsy and race/ethnicity among women without breast cancer
T2  - Cancer Detect Prev
TI  - Breast biopsy and race/ethnicity among women without breast cancer
VL  - 30
ID  - 570
ER  - 

TY  - JOUR
AB  - Background: The purpose of this study is to present the methodology of developing the Kin Keeper Cancer Prevention Curriculum Guide and Workbook through participatory engagement of women from underserved communities.Methods: It was developed to cross train community health workers (CHWs) from public health programs to deliver cancer education. Data collection included review of existing educational materials, a 10-minute telephone survey of 146 women enrolled in a Breast and Cervical Cancer Control Program and a pair of pre-post training assessments of 31 African American, Latina, and Arab CHWs.Results: The enrollees adequately informed the curriculum and the CHWs increased their scores by 7% (14%) in breast (cervical) cancer literacy; P-values <0.01.Conclusion: The methodology was validated; the curriculum was well-informed and CHWs were effectively cross trained using the curriculum.
AD  - Department of Obstetrics, Gynecology, and Reproductive Biology, College of Human Medicine, Michigan State University, East Lansing, MI 48824, USA
Department of Obstetrics, Gynecology, and Reproductive Biology, College of Human Medicine, Michigan State University, East Lansing, MI, USA
AN  - 105234660. Language: English. Entry Date: 20100108. Revision Date: 20200708. Publication Type: journal article
AU  - Williams, K. P.
AU  - Mabiso, A.
AU  - Jackson, T. L.
AU  - Lawshe, D. C.
AU  - Maurer, J.
AU  - Williams, Karen Patricia
AU  - Mabiso, Athur
AU  - Jackson, Tedra L.
AU  - Lawshe, Dorothy C.
AU  - Maurer, Joel
DB  - CINAHL Complete
DO  - 10.1080/08858190902972939
DP  - EBSCOhost
IS  - 4
KW  - Breast Neoplasms -- Prevention and Control
Cervix Neoplasms -- Prevention and Control
Community Health Services
Curriculum Development
Health Education
Health Knowledge
Adult
Arabs
Black Persons
Cancer Screening
Cervical Smears
Confidence Intervals
Descriptive Statistics
Educational Measurement
Educational Status
Female
Funding Source
Hispanic Americans
Income
Interviews
Medicaid
Medically Underserved Area
Michigan
Middle Age
P-Value
Paired T-Tests
Pretest-Posttest Design
Seminars and Workshops
Surveys
Teaching Materials
N1  - algorithm; research; tables/charts. Journal Subset: Biomedical; Blind Peer Reviewed; Double Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Health Promotion/Education; Peer Reviewed; USA. Grant Information: Michigan Department of Community Health. NLM UID: 8610343.
PMID: NLM19838881.
PY  - 2009
SN  - 0885-8195
SP  - 257-260
ST  - Breast cancer and cervical cancer control program enrollees inform the kin keeper curriculum
T2  - Journal of Cancer Education
TI  - Breast cancer and cervical cancer control program enrollees inform the kin keeper curriculum
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105234660&site=ehost-live&scope=site
VL  - 24
ID  - 1864
ER  - 

TY  - JOUR
AB  - In analyses combining estrogen with or without progestin, some observational studies describe minimal breast cancer risk in obese and black women. Therefore, we examined these suggested interactions in the two Women's Health Initiative (WHI) randomized hormone therapy trials. The estrogen plus progestin trial entered 16 608 postmenopausal women with a uterus, while the estrogen trial entered 10 736 postmenopausal women with prior hysterectomy. Hazard ratios (HRs), 95% confidence intervals (CIs), and P values from log-rank x(2) statistics were estimated from Cox proportional hazards models with subgroup analyses based on tests of interaction. All statistical tests were two-sided. Estrogen plus progestin statistically significantly increased breast cancer incidence (HR = 1.28, 95% CI = 1.11 to 1.48, P < .001), with hazard ratios greater than 1 in all body mass index (BMI) subgroups (P interaction = .58) and hazard ratios greater than 1 in black and white women (P interaction = .96). In contrast, estrogen alone statistically significantly decreased breast cancer incidence (HR = 0.79, 95% CI = 0.65 to 0.90, P = .02), with hazard ratios lower than 1 in all BMI subgroups (P interaction = .86) and hazard ratios lower than 1 in black and white women, where analyses with limited numbers suggest somewhat greater reduction in black women (P interaction = .09). In summary, estrogen plus progestin and estrogen alone have opposite effects on breast cancer incidence, with no statistically significant interactions by race/ethnicity or BMI. Therefore, observational studies should not combine these two regimens when examining breast cancer risk.
AD  - Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA (RTC); Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA (GLA, AKA, RP). rowanchlebowski@gmail.com.
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA (RTC); Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA (GLA, AKA, RP).
AN  - 26546117
AU  - Chlebowski, R. T.
AU  - Anderson, G. L.
AU  - Aragaki, A. K.
AU  - Prentice, R.
C2  - PMC5943827
DA  - Feb
DO  - 10.1093/jnci/djv327
DP  - NLM
ET  - 2015/11/08
IS  - 2
KW  - African Americans/*statistics & numerical data
Aged
*Body Mass Index
Breast Neoplasms/chemically induced/*ethnology/*etiology
Estrogen Replacement Therapy/*adverse effects/methods
Estrogens/administration & dosage
European Continental Ancestry Group/statistics & numerical data
Female
Humans
Incidence
Middle Aged
National Institutes of Health (U.S.)
Obesity/*complications
Odds Ratio
Postmenopause
Progestins/administration & dosage
Proportional Hazards Models
Randomized Controlled Trials as Topic/economics
Research Support as Topic
Risk
United States/epidemiology
Women's Health
LA  - eng
N1  - 1460-2105
Chlebowski, Rowan T
Anderson, Garnet L
Aragaki, Aaron K
Prentice, Ross
Journal Article
Meta-Analysis
Review
J Natl Cancer Inst. 2015 Nov 5;108(2):djv327. doi: 10.1093/jnci/djv327. Print 2016 Feb.
PY  - 2016
SN  - 0027-8874 (Print)
0027-8874
ST  - Breast Cancer and Menopausal Hormone Therapy by Race/Ethnicity and Body Mass Index
T2  - J Natl Cancer Inst
TI  - Breast Cancer and Menopausal Hormone Therapy by Race/Ethnicity and Body Mass Index
VL  - 108
ID  - 227
ER  - 

TY  - JOUR
AB  - Chemoprevention with the anti-estrogens, tamoxifen, raloxifene, and aromatase inhibitors, reduce breast cancer incidence in high-risk women; however, uptake has been poor (<5%) in the prevention setting. We assessed use of anti-estrogens for breast cancer prevention, among high-risk women seen at an academic breast center, to observe how uptake rates compare in this setting. We collected data on demographics, breast cancer risk factors, and health behaviors via self-administered questionnaires and medical chart abstraction. Women eligible for chemoprevention with anti-estrogens had a 5-year predicted breast cancer risk according to the Gail model of ≥1.67%, history of lobular or ductal carcinoma in situ (LCIS/DCIS), and/or BRCA mutation. We dichotomized anti-estrogen use as ever or never. Predictors of use were evaluated using multivariable log-binomial regression. Of 412 high-risk women enrolled, 316 (77%) were eligible for chemoprevention. Among eligible women, 55% were non-Hispanic white, 29% Hispanic, 8% non-Hispanic black, and 7% Asian. Women were grouped based upon their highest category of breast cancer risk (in descending order): BRCA mutation carriers (3%), DCIS (40%), LCIS (22%), and 5-year Gail risk ≥1.67% (36%). Among those eligible for chemoprevention, 162 (51%) had ever initiated anti-estrogen therapy (71% tamoxifen, 23% raloxifene, 5% aromatase inhibitor). Anti-estrogen use was highest among women with DCIS (73%). In multivariable analysis, women with a 5-year Gail risk ≥1.67% had approximately a 20% lower likelihood of anti-estrogen use compared to women with DCIS (p = 0.01). In the primary prevention setting, excluding women diagnosed with DCIS, anti-estrogen use was 37%. Multivariable analysis showed differences in uptake by education and potentially by race/ethnicity. Among high-risk women seen at a breast center, anti-estrogen use for chemoprevention was relatively high as compared to the published literature. Clinicians can support high-risk women by effectively communicating breast cancer risk and enhancing knowledge about the risks and benefits of chemoprevention.
AD  - Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, New York.
Department of Medicine, College of Physicians & Surgeons, Columbia University, New York, New York.
Herbert Irving Comprehensive Cancer Center, Columbia University, New York, New York.
AN  - 25879521
AU  - Reimers, L. L.
AU  - Sivasubramanian, P. S.
AU  - Hershman, D.
AU  - Terry, M. B.
AU  - Greenlee, H.
AU  - Campbell, J.
AU  - Kalinsky, K.
AU  - Maurer, M.
AU  - Jayasena, R.
AU  - Sandoval, R.
AU  - Alvarez, M.
AU  - Crew, K. D.
C2  - PMC4490034
C6  - NIHMS674702
DA  - Jul-Aug
DO  - 10.1111/tbj.12418
DP  - NLM
ET  - 2015/04/17
IS  - 4
KW  - Adult
Anticarcinogenic Agents/*therapeutic use
Aromatase Inhibitors/*therapeutic use
Breast Neoplasms/pathology/*prevention & control
Chemoprevention/*methods
Female
Humans
Middle Aged
Patient Participation
Raloxifene Hydrochloride/therapeutic use
Risk Assessment
*Risk Reduction Behavior
Selective Estrogen Receptor Modulators/therapeutic use
Tamoxifen/therapeutic use
aromatase inhibitor
breast cancer
chemoprevention
high-risk
raloxifene
selective estrogen receptor modulator
tamoxifen
LA  - eng
N1  - 1524-4741
Reimers, Laura L
Sivasubramanian, Parijatham S
Hershman, Dawn
Terry, Mary Beth
Greenlee, Heather
Campbell, Julie
Kalinsky, Kevin
Maurer, Matthew
Jayasena, Ramona
Sandoval, Rossy
Alvarez, Maria
Crew, Katherine D
R01 CA177995/CA/NCI NIH HHS/United States
T32 CA009529/CA/NCI NIH HHS/United States
UL1 RR024156/RR/NCRR NIH HHS/United States
UL1RR024156/RR/NCRR NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
Breast J. 2015 Jul-Aug;21(4):377-86. doi: 10.1111/tbj.12418. Epub 2015 Apr 16.
PY  - 2015
SN  - 1075-122X (Print)
1075-122x
SP  - 377-86
ST  - Breast Cancer Chemoprevention among High-risk Women and those with Ductal Carcinoma In Situ
T2  - Breast J
TI  - Breast Cancer Chemoprevention among High-risk Women and those with Ductal Carcinoma In Situ
VL  - 21
ID  - 250
ER  - 

TY  - JOUR
AB  - Web-based clinical trials matching systems including breast cancer patients are expanding rapidly. However, limited data exist regarding the demographics and attitudes of breast cancer patients using the Internet to search for clinical trials information. Biases in patient populations could be introduced by recruiting patients to trials through the Internet. This study was designed to compare breast cancer patients in the radiation oncology clinic to those using the Internet to search for clinical trials information. A piloted questionnaire assessing demographics and attitudes regarding clinical trials was offered through the radiation oncology clinic at the University of Pennsylvania and on the OncoLink website (http://www.oncolink.org). The questionnaire consisted of 18 questions and was answered by a total of 157 patients with breast cancer. Breast cancer patients using the Web were more likely to be interested in clinical trials testing new drugs or therapies (71 [53%] versus 4 [17%], p = 0.002). More clinic patients indicated they would need a greater than 50% chance of benefiting from a trial (12 [52%] versus 33 [25%], p = 0.01) and a less than 10% potential for serious toxicity from a trial (15 [65%] versus 51 [38%], p = 0.02) for consideration of enrollment. African Americans were more likely than other races to have never used the Internet to search for cancer-related information (4 [40%] versus 18 [12%], p = 0.01), more likely to indicate that they need a greater than 50% chance of benefit to enroll in clinical trials (8 [80%] versus 37 [25%], p = 0.001), and less likely to be interested in clinical trials testing new drugs or therapies (1 [10%] versus 73 [50%], p = 0.01). Breast cancer patients have different attitudes regarding clinical trials based on race, Internet usage, and previous trial enrollment. Biases may be introduced with recruitment for clinical trials through the Internet. Radiation oncologists must consider these issues when offering clinical trials information through the Internet.
AD  - Department of Radiation Oncology, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA. dolinsky@xrt.upenn.edu
AN  - 16848841
AU  - Dolinsky, C. M.
AU  - Wei, S. J.
AU  - Hampshire, M. K.
AU  - Metz, J. M.
DA  - Jul-Aug
DO  - 10.1111/j.1075-122X.2006.00270.x
DP  - NLM
ET  - 2006/07/20
IS  - 4
KW  - *Breast Neoplasms
*Clinical Trials as Topic
Female
Humans
*Internet
Male
Middle Aged
*Patient Satisfaction/ethnology
*Patient Selection
Philadelphia
Pilot Projects
Prospective Studies
LA  - eng
N1  - Dolinsky, Christopher M
Wei, S Jack
Hampshire, Margaret K
Metz, James M
Comparative Study
Journal Article
United States
Breast J. 2006 Jul-Aug;12(4):324-30. doi: 10.1111/j.1075-122X.2006.00270.x.
PY  - 2006
SN  - 1075-122X (Print)
1075-122x
SP  - 324-30
ST  - Breast cancer patients' attitudes toward clinical trials in the radiation oncology clinic versus those searching for trial information on the Internet
T2  - Breast J
TI  - Breast cancer patients' attitudes toward clinical trials in the radiation oncology clinic versus those searching for trial information on the Internet
VL  - 12
ID  - 560
ER  - 

TY  - JOUR
AB  - BACKGROUND: Some women may benefit from taking tamoxifen citrate for breast cancer prevention if the probability of benefit outweighs that of adverse events. We determined the proportion of women aged 40 to 69 years attending general internal medicine practices who were potentially eligible for tamoxifen chemoprevention and calculated the maximum proportion of breast cancers that could be prevented. METHODS: Six hundred five women aged 40 to 69 completed self-administered questionnaires in the waiting rooms of 10 general internal medicine practices in North Carolina in 2001. RESULTS: Among white women, 9.0% (95% confidence interval [CI], 5.1%-15.2%) in their 40s, 24.0% (95% CI, 18.2%-31.0%) in their 50s, and 53.4% (95% CI, 46.1%-61.3%) in their 60s had a 5-year Gail model estimated breast cancer risk of 1.66% or greater. Among black women, 2.9% (95% CI, 0%-15.0%) in their 40s, 7.1% (95% CI, 1.1%-24.4%) in their 50s, and 13.0% (95% CI, 3.1%-34.3%) in their 60s had a similar risk. When adverse events were considered in white women, 10% or fewer in all age groups were potentially eligible for chemoprevention. The maximum proportion of breast cancers prevented in eligible women was 6.0% to 8.3%. CONCLUSIONS: Small numbers of women in primary care practices are eligible for discussions about chemoprevention; the maximum proportion of breast cancers prevented if eligible women take tamoxifen is also small. Challenges lie in targeting discussions to the most appropriate women and in finding new chemoprevention strategies that have less risk of harms.
AD  - Division of General Medicine and Clinical Epidemiology, Department of Medicine, The University of North Carolina at Chapel Hill, NC 27599-7110, USA. Carmen_Lewis@med.unc.edu
AN  - 15451765
AU  - Lewis, C. L.
AU  - Kinsinger, L. S.
AU  - Harris, R. P.
AU  - Schwartz, R. J.
DA  - Sep 27
DO  - 10.1001/archinte.164.17.1897
DP  - NLM
ET  - 2004/09/29
IS  - 17
KW  - Adult
Aged
Anticarcinogenic Agents/adverse effects/*therapeutic use
Breast Neoplasms/*etiology/*prevention & control/psychology
Fear
Female
Health Surveys
Humans
Hysterectomy
Middle Aged
North Carolina
Patient Selection
*Primary Health Care
Risk Assessment
Tamoxifen/adverse effects/*therapeutic use
Thromboembolism/etiology
LA  - eng
N1  - Lewis, Carmen L
Kinsinger, Linda S
Harris, Russell P
Schwartz, Robert J
5 R01 CA068378/CA/NCI NIH HHS/United States
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.
United States
Arch Intern Med. 2004 Sep 27;164(17):1897-903. doi: 10.1001/archinte.164.17.1897.
PY  - 2004
SN  - 0003-9926 (Print)
0003-9926
SP  - 1897-903
ST  - Breast cancer risk in primary care: implications for chemoprevention
T2  - Arch Intern Med
TI  - Breast cancer risk in primary care: implications for chemoprevention
VL  - 164
ID  - 619
ER  - 

TY  - JOUR
AB  - Early detection decreases breast cancer mortality. The ACR recommends annual mammographic screening beginning at age 40 for women of average risk. Higher-risk women should start mammographic screening earlier and may benefit from supplemental screening modalities. For women with genetics-based increased risk (and their untested first-degree relatives), with a calculated lifetime risk of 20% or more or a history of chest or mantle radiation therapy at a young age, supplemental screening with contrast-enhanced breast MRI is recommended. Breast MRI is also recommended for women with personal histories of breast cancer and dense tissue, or those diagnosed by age 50. Others with histories of breast cancer and those with atypia at biopsy should consider additional surveillance with MRI, especially if other risk factors are present. Ultrasound can be considered for those who qualify for but cannot undergo MRI. All women, especially black women and those of Ashkenazi Jewish descent, should be evaluated for breast cancer risk no later than age 30, so that those at higher risk can be identified and can benefit from supplemental screening.
AD  - Scott & White Medical Center, Texas A&M University Health Sciences, Temple, Texas. Electronic address: debra.monticciolo@bswhealth.org.
Department of Radiology and Imaging Sciences, Emory University, Atlanta, Georgia.
Laura and Isaac Perlmutter Cancer Center, NYU School of Medicine, New York, New York.
H. Lee Moffitt Cancer Center, Department of Oncologic Sciences, University of South Florida, Tampa, Florida.
Division of Diagnostic Radiology, Washington University School of Medicine, St. Louis, Missouri.
University of California, San Francisco Medical Center, San Francisco, California.
AN  - 29371086
AU  - Monticciolo, D. L.
AU  - Newell, M. S.
AU  - Moy, L.
AU  - Niell, B.
AU  - Monsees, B.
AU  - Sickles, E. A.
DA  - Mar
DO  - 10.1016/j.jacr.2017.11.034
DP  - NLM
ET  - 2018/01/27
IS  - 3 Pt A
KW  - Adult
Age Factors
Breast Density
Breast Neoplasms/*diagnostic imaging/ethnology/genetics/pathology
*Early Detection of Cancer
Female
Genetic Predisposition to Disease
Humans
Magnetic Resonance Imaging
Mammography
Models, Statistical
Neoplasm Recurrence, Local/diagnostic imaging
Neoplasms, Radiation-Induced/diagnostic imaging
*Patient Selection
Risk Assessment
Risk Factors
Ultrasonography, Mammary
*Breast cancer screening
*breast MRI
*breast cancer
*breast cancer risk assessment
*digital breast tomosynthesis
*higher risk populations
LA  - eng
N1  - 1558-349x
Monticciolo, Debra L
Newell, Mary S
Moy, Linda
Niell, Bethany
Monsees, Barbara
Sickles, Edward A
Journal Article
Practice Guideline
United States
J Am Coll Radiol. 2018 Mar;15(3 Pt A):408-414. doi: 10.1016/j.jacr.2017.11.034. Epub 2018 Jan 19.
PY  - 2018
SN  - 1546-1440
SP  - 408-414
ST  - Breast Cancer Screening in Women at Higher-Than-Average Risk: Recommendations From the ACR
T2  - J Am Coll Radiol
TI  - Breast Cancer Screening in Women at Higher-Than-Average Risk: Recommendations From the ACR
VL  - 15
ID  - 136
ER  - 

TY  - JOUR
AB  - PURPOSE: Acupuncture is a complementary and alternative medicine (CAM) modality that shows promise as a component of supportive breast cancer care. Lack of robust recruitment for clinical trial entry has limited the evidence base for acupuncture as a treatment modality among breast cancer survivors. The objective of this study is to identify key decision-making factors among breast cancer survivors considering entry into an acupuncture clinical trial for treatment of symptoms. METHODS: Semistructured interviews were conducted among African-American (n=12) and Caucasian (n=13) breast cancer survivors. Verbatim transcripts were made and analyzed by two or more independent coders using NVivo software. Major recurring themes were identified and a theoretical framework developed. RESULTS: Six themes emerged reflecting key attributes of the decision to enter a clinical trial: (1) symptom appraisal, (2) practical barriers (e.g., distance and travel), (3) beliefs about the interventions (e.g., fear of needles and dislike of medications), (4) comfort with elements of clinical trial design (e.g., randomization, the nature of the control intervention, and blinding), (5) trust, and (6) altruism. African-American and Caucasian women weighed similar attributes but differed in the information sources sought regarding clinical trial entry and in concerns regarding the use of a placebo in a clinical trial. CONCLUSIONS: Our findings contribute to the development of a theoretical model of decision making for breast cancer survivors considering participation in a CAM clinical trial. Insights regarding the decision making process can inform interventions to support informed decision making and robust recruitment to CAM trials among cancer survivors.
AD  - The Philadelphia VA Center for Health Equity Research and Promotion, University of Pennsylvania, Philadelphia, PA, USA, mschap@upenn.edu.
AN  - 24362843
AU  - Schapira, M. M.
AU  - Mackenzie, E. R.
AU  - Lam, R.
AU  - Casarett, D.
AU  - Seluzicki, C. M.
AU  - Barg, F. K.
AU  - Mao, J. J.
C2  - PMC4162629
C6  - NIHMS622959
DA  - May
DO  - 10.1007/s00520-013-2073-3
DP  - NLM
ET  - 2013/12/24
IS  - 5
KW  - Acupuncture Therapy/methods/*psychology
Adult
African Americans/psychology
Aged
Breast Neoplasms/ethnology/pathology/*psychology/*therapy
Decision Making
European Continental Ancestry Group/psychology
Female
Humans
Middle Aged
Neoplasm Recurrence, Local/ethnology/psychology/therapy
Neoplasm Staging
Patient Acceptance of Health Care/ethnology/*psychology
Survivors/psychology
LA  - eng
N1  - 1433-7339
Schapira, Marilyn M
Mackenzie, Elizabeth R
Lam, Regina
Casarett, David
Seluzicki, Christina M
Barg, Frances K
Mao, Jun J
P30 CA016520/CA/NCI NIH HHS/United States
R21 AT004695/AT/NCCIH NIH HHS/United States
Clinical Trial
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Support Care Cancer. 2014 May;22(5):1207-15. doi: 10.1007/s00520-013-2073-3. Epub 2013 Dec 21.
PY  - 2014
SN  - 0941-4355 (Print)
0941-4355
SP  - 1207-15
ST  - Breast cancer survivors willingness to participate in an acupuncture clinical trial: a qualitative study
T2  - Support Care Cancer
TI  - Breast cancer survivors willingness to participate in an acupuncture clinical trial: a qualitative study
VL  - 22
ID  - 300
ER  - 

TY  - JOUR
AB  - BACKGROUND. The inclusion of ethnic minorities in cancer-related studies continues to be an important concern for researchers. In this article, the authors present 1) a brief discussion of recruitment and measurement challenges in conducting multiethnic survivorship research, and 2) recruitment outcomes and sample characteristics for a health-related quality-of-life study with a multiethnic sample of breast cancer survivors (BCS). METHODS. A case-control, cross-sectional design with mixed sampling methods was used. The Contextual Model for Recruitment and Enrollment of Diverse Samples was used to guide the protocol. BCS were recruited from the California Cancer Surveillance Program, from hospital registries, and from community agencies. Participation rates, demographic factors, and medical factors were compared. The reliability of standard measures by ethnicity was assessed. RESULTS. Seven hundred three women participated, including 135 African-American women (19%), 206 Asian-American women (29%), 183 Latina-American women (26%), and 179 European-American women (26%). Participation was influenced by ethnicity, age, and site of recruitment. Overall, African Americans were least likely to participate, and European Americans most likely to participate. African Americans and Asian Americans were more likely to refuse, European Americans and Latina Americans were more likely to agree to participate, and European Americans and Asian Americans were most likely to complete the survey after consenting. Measures possessed moderate to excellent reliability (0.64-0.91). CONCLUSIONS. Despite important recruitment and measurement challenges, this study obtained acceptable participation rates and good internal consistency of the measures. The results demonstrate the utility of a culturally responsive approach to health disparities research. © 2004 American Cancer Society.
AD  - K.T. Ashing-Giwa, Dept. Psychiat. and Biobehav. Sci., University of California-Los Angeles, Box 62, 760 Westwood Plaza, Los Angeles, CA 90095, United States
AU  - Ashing-Giwa, K. T.
AU  - Padilla, G. V.
AU  - Tejero, J. S.
AU  - Kim, J.
DB  - Embase
Medline
DO  - 10.1002/cncr.20370
IS  - 3
KW  - adult
African American
age
arthritis
article
Asian American
body image
breast cancer
breast reconstruction
cancer chemotherapy
cancer hormone therapy
cancer radiotherapy
cancer research
cancer survival
cardiovascular disease
case control study
controlled study
cultural factor
diabetes mellitus
ethnic difference
European American
female
functional assessment
health care quality
Hispanic
human
hypertension
major clinical study
mastectomy
minority group
osteoporosis
partial mastectomy
patient satisfaction
priority journal
quality of life
reliability
religion
sampling
sexuality
physiological stress
United States
LA  - English
M3  - Article
N1  - L38970596
2004-08-12
PY  - 2004
SN  - 0008-543X
SP  - 450-465
ST  - Breast cancer survivorship in a multiethnic sample: Challenges in recruitment and measurement
T2  - Cancer
TI  - Breast cancer survivorship in a multiethnic sample: Challenges in recruitment and measurement
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L38970596&from=export
http://dx.doi.org/10.1002/cncr.20370
VL  - 101
ID  - 1282
ER  - 

TY  - JOUR
AB  - PURPOSE: A substantial literature describes age-dependent variations in breast cancer treatment, showing that older women are less likely to receive standard treatment than younger women. We sought to identify patient and tumor characteristics associated with the nonreceipt of standard primary tumor and systemic adjuvant therapies. PATIENTS AND METHODS: We studied 1,859 women age 65 years or older with stage I and II breast cancer diagnosed between 1990 and 1994 who were cared for in six geographically dispersed community-based health care systems. We collected demographic, tumor, treatment, and comorbidity data from electronic data sources, including cancer registry, administrative, and clinical databases, and from subjects' medical records. RESULTS: Women 75 years of age or older and women with higher comorbidity indices were more likely to receive nonstandard primary tumor therapy, to not receive axillary lymph node dissection, and to not receive radiation therapy after breast-conserving surgery (BCS). Asian women were less likely to receive BCS, and African American women were less likely to be prescribed tamoxifen. Although nonreceipt of most therapies was associated with a lower baseline risk of recurrence, an important minority of high-risk women (16% to 30%) did not receive guideline therapies. CONCLUSION: Age is an independent risk factor for nonreceipt of effective cancer therapies, even when comorbidity and risk of recurrence are taken into account. Information regarding treatment effectiveness in this age group and tools that allow physicians and patients to estimate the benefits versus the risks of therapies, taking into account age and comorbidity burden, are critically needed.
AD  - Department of Research and Evaluation, Kaiser Permanente Medical Care Program, Pasadena, CA, USA.
AN  - 16983106
AU  - Enger, S. M.
AU  - Thwin, S. S.
AU  - Buist, D. S.
AU  - Field, T.
AU  - Frost, F.
AU  - Geiger, A. M.
AU  - Lash, T. L.
AU  - Prout, M.
AU  - Yood, M. U.
AU  - Wei, F.
AU  - Silliman, R. A.
C2  - PMC1913483
C6  - NIHMS20287
DA  - Sep 20
DO  - 10.1200/jco.2006.06.3065
DP  - NLM
ET  - 2006/09/20
IS  - 27
KW  - African Americans/statistics & numerical data
Age Factors
Aged
Aged, 80 and over
Antineoplastic Agents, Hormonal/administration & dosage
Antineoplastic Combined Chemotherapy Protocols/administration & dosage
Asian Americans/statistics & numerical data
Breast Neoplasms/drug therapy/*epidemiology/pathology/radiotherapy/surgery/*therapy
Chemotherapy, Adjuvant/statistics & numerical data
Comorbidity
Delivery of Health Care, Integrated/*statistics & numerical data
Female
Humans
Managed Care Programs/statistics & numerical data
Mastectomy/methods/statistics & numerical data
Medical Records
Odds Ratio
*Patient Selection
Radiotherapy, Adjuvant/statistics & numerical data
Retrospective Studies
Risk Assessment
Risk Factors
SEER Program
Tamoxifen/administration & dosage
Treatment Outcome
United States/epidemiology
LA  - eng
N1  - 1527-7755
Enger, Shelley M
Thwin, Soe Soe
Buist, Diana S M
Field, Terry
Frost, Floyd
Geiger, Ann M
Lash, Timothy L
Prout, Marianne
Yood, Marianne Ulcickas
Wei, Feifei
Silliman, Rebecca A
R01 CA093772/CA/NCI NIH HHS/United States
Journal Article
Multicenter Study
Research Support, N.I.H., Extramural
J Clin Oncol. 2006 Sep 20;24(27):4377-83. doi: 10.1200/JCO.2006.06.3065.
PY  - 2006
SN  - 0732-183X (Print)
0732-183x
SP  - 4377-83
ST  - Breast cancer treatment of older women in integrated health care settings
T2  - J Clin Oncol
TI  - Breast cancer treatment of older women in integrated health care settings
VL  - 24
ID  - 552
ER  - 

TY  - JOUR
AB  - BACKGROUND: The goal of breast cancer screening is to reduce breast cancer mortality. Mammography is the standard screening method for detecting breast cancer early. Breast MRI is recommended to be used in conjunction with mammography for screening subsets of women at high risk for breast cancer. We offer the first study to provide national estimates of breast MRI use among women in the United States. METHODS: We analyzed data from women who responded to questions about having a breast MRI on the 2010 National Health Interview Survey. We assessed report of having a breast MRI and reasons for it by sociodemographic characteristics and access to health care and computed five-year and lifetime breast cancer risk using the Gail model. RESULTS: Among 11,222 women who responded, almost 5% reported ever having a breast MRI and 2% reported having an MRI within the 2 years preceding the survey. Less than half of the women who reported having a breast MRI were at increased risk. Approximately 60% of women reported having the breast MRI for diagnostic reasons. Women who ever had a breast MRI were more likely to be older, Black, and insured and to report a usual source of health care as compared with women who reported no MRI. CONCLUSIONS: Breast MRI use may be underused or overused in certain subgroups of women. IMPACT: As access to health care improves, the use of breast MRI and the appropriateness of its use for breast cancer detection will be important to monitor.
AD  - Centers for Disease Control and Prevention, 4770 Buford Hwy., NE, Mailstop K-57, Atlanta, GA 30341, USA. JMiller5@cdc.gov
AN  - 23155135
AU  - Miller, J. W.
AU  - Sabatino, S. A.
AU  - Thompson, T. D.
AU  - Breen, N.
AU  - White, M. C.
AU  - Ryerson, A. B.
AU  - Taplin, S.
AU  - Ballard-Barbash, R.
C2  - PMC3538940
C6  - NIHMS421779 Interview Survey and preparation of this manuscript were entirely funded by the U. S. government. The authors have no financial disclosures or conflict of interest.
DA  - Jan
DO  - 10.1158/1055-9965.Epi-12-0967
DP  - NLM
ET  - 2012/11/17
IS  - 1
KW  - Adult
Age Factors
Aged
Breast Neoplasms/*prevention & control
Confidence Intervals
Cross-Sectional Studies
Early Detection of Cancer/*methods/statistics & numerical data
Female
Humans
Incidence
Magnetic Resonance Imaging/methods/*statistics & numerical data
Mammography/methods/*statistics & numerical data
Mass Screening/methods
Middle Aged
Needs Assessment
Patient Selection
Risk Assessment
Surveys and Questionnaires
United States
LA  - eng
N1  - 1538-7755
Miller, Jacqueline W
Sabatino, Susan A
Thompson, Trevor D
Breen, Nancy
White, Mary C
Ryerson, A Blythe
Taplin, Stephen
Ballard-Barbash, Rachel
Z99 CA999999/Intramural NIH HHS/United States
Comparative Study
Journal Article
Cancer Epidemiol Biomarkers Prev. 2013 Jan;22(1):159-66. doi: 10.1158/1055-9965.EPI-12-0967. Epub 2012 Nov 15.
PY  - 2013
SN  - 1055-9965 (Print)
1055-9965
SP  - 159-66
ST  - Breast MRI use uncommon among U.S. women
T2  - Cancer Epidemiol Biomarkers Prev
TI  - Breast MRI use uncommon among U.S. women
VL  - 22
ID  - 349
ER  - 

TY  - JOUR
AB  - BACKGROUND. Various factors affect patients' decisions regarding whether to undergo surgery for the treatment of early-stage breast carcinoma. The 'Arimidex, Tamoxifen Alone or in Combination' (ATAC) trial, the largest multinational randomized trial of adjuvant therapy for patients with operable breast carcinoma to date, offers the opportunity to investigate whether nationality is one such factor. METHODS. After receiving primary therapy for early-stage breast carcinoma, 9366 women (from a total of 21 countries) were randomized to receive anastrozole, tamoxifen, or anastrozole plus tamoxifen for 5 years. In the current study, mastectomy and breast conservation rates were compared among participating countries. The possibility that variations from country to country could be explained by inequalities in terms of pathologic, clinical, and hospital-related correlates of surgical choice was explored first on univariate analysis and then on multivariate logistic analysis. RESULTS. National mastectomy rates ranged from 20% to 97%; 51% of the 2222 enrollees from the United States had undergone mastectomy, compared with 42% of the 3228 enrollees from the United Kingdom (odds ratio [OR], 1.43; 95% confidence interval [CI], 1.28-1.60; P < 0.001). On univariate analysis, larger tumor size, positive lymph node status, higher tumor grade, older age, and adjuvant chemotherapy use were found to be correlated with mastectomy use. In contrast, positive hormone receptor status, increased body weight, and enrollment at a center that had more than 40 enrollees were found to be associated with breast conservation. The same correlates were identified on multivariate logistic analysis (P < 0.05), except that the number of enrollees at a patient's treatment center no longer possessed predictive value. After correction for these correlated factors, residence in the United States (compared with residence in the United Kingdom) remained an independent predictor of mastectomy use (OR, 1.44; 95% Cl, 1.26-1.64; P < 0.001). CONCLUSIONS. American women enrolled in the ATAC trial were more likely to undergo aggressive surgery compared with their counterparts from the United Kingdom. More generally, nationality was found to be an independent determinant of surgical choice in the current study. Cancer 2004;101:735-40. (C) 2004 American Cancer Society.
AN  - WOS:000223111200009
AU  - Locker, G. Y.
AU  - Sainsbury, J. R.
AU  - Cuzick, J.
DA  - Aug 15
DO  - 10.1002/cncr.20435
IS  - 4
N1  - 27
15305403
PY  - 2004
SN  - 0008-543X
SP  - 735-740
ST  - Breast surgery in the 'Arimidex, tamoxifen alone or in combination' (ATAC) trial - American women are more likely than women from the United Kingdom to undergo mastectomy
T2  - Cancer
TI  - Breast surgery in the 'Arimidex, tamoxifen alone or in combination' (ATAC) trial - American women are more likely than women from the United Kingdom to undergo mastectomy
VL  - 101
ID  - 2677
ER  - 

TY  - JOUR
AB  - Purpose: The purpose of this study is to (1) assess the diagnostic yield of ultrasounds performed in the emergency department for suspected breast abscess and determine the rates of reimaging, discordance, and emergent intervention in a large, busy safety net hospital and (2) determine clinical factors significantly associated with abscess as a way to improve patient selection for emergent breast ultrasounds. Methods: A total of 581 consecutive breast ultrasounds performed in the emergency department for suspected abscess over 15 months were retrospectively reviewed for imaging, demographics, laboratory data, and physical exam findings. Breast abscess was confirmed by combining imaging, clinical, and laboratory data. Linear logistic regression analysis estimated the likelihood of abscess, and the cross-validated area under the receiver operating characteristic curve (AUC) evaluated diagnostic performance. Results: Final diagnoses included abscess (153/581, 26%), cancer (29/581, 5%), granulomatous mastitis (41/581, 7%), normal (120/581, 21%), and other/indeterminate (238/581, 41%). Factors associated with abscess included induration, fluctuance, erythema, drainage, smoking, diabetes, and Black race. Based on these factors, the AUC of the characteristics predictive of abscess was 0.77 (CI, 0.72–0.81). Six breast cancers were not diagnosed on ultrasound. 40% of ultrasounds (231/581) were considered incomplete/inadequate. Conclusion: 74% (428/581) of emergent breast ultrasounds in our population were negative for abscess, while 21% (6/29) of cancers were not diagnosed, and 40% (231/581) of exams were incomplete/inadequate. Patient selection for emergent ultrasounds can be improved, allowing patients with a low likelihood of abscess to be imaged in a more optimal setting.
AD  - J.H. Porembka, Department of Radiology, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard MC 8896, Dallas, TX, United States
AU  - Porembka, J. H.
AU  - Compton, L.
AU  - Omar, L.
AU  - Sharma, P.
AU  - Clark, H.
AU  - Ahn, R.
AU  - Ganti, R.
AU  - Xi, Y.
AU  - Metzger, J.
AU  - Leyendecker, J. R.
DB  - Embase
Medline
DO  - 10.1007/s10140-018-1651-6
IS  - 2
KW  - EPIQ7
iU22
real time ultrasound scanner
ultrasound transducer
antibiotic agent
abscess drainage
adult
American Indian
antibiotic therapy
article
Asian
Black person
breast abscess
breast biopsy
breast carcinoma
breast cyst
Caucasian
diabetes mellitus
diagnostic value
echomammography
emergency ward
erythema
female
follow up
granulomatous mastitis
hematoma
Hispanic
human
laboratory test
major clinical study
medical record review
Pacific Islander
patient safety
patient selection
physical examination
predictive value
priority journal
race difference
receiver operating characteristic
retrospective study
safety net hospital
smoking
LA  - English
M3  - Article
N1  - L624731375
2018-11-07
2019-04-04
PY  - 2019
SN  - 1438-1435
1070-3004
SP  - 123-131
ST  - Breast ultrasound utilization in a safety net emergency department
T2  - Emergency Radiology
TI  - Breast ultrasound utilization in a safety net emergency department
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L624731375&from=export
http://dx.doi.org/10.1007/s10140-018-1651-6
VL  - 26
ID  - 850
ER  - 

TY  - JOUR
AB  - BACKGROUND: Despite the availability of breast cancer risk assessment tools and interventions for risk reduction, these tools are not well integrated into clinical practice. As a result, many women do not engage in a discussion of their breast cancer risk with their physician, which may lead to underuse of effective risk reduction interventions. METHODS: We conducted a randomized controlled trial comparing usual care to a tablet‐PC based breast cancer risk assessment and education intervention (BreastCARE) delivered in a primary care setting. We enrolled women aged 40‐74 years with no personal breast cancer history prior to their scheduled primary care visits at two clinics (one academic medical center, one safety‐net) between June 2011 and August 2012, and randomized them to Intervention or Usual Care (UC) arms, stratified by race/ethnicity. The Intervention group completed the BreastCARE intervention at the clinic just prior to their visit and women and physicians received tailored risk reports. The UC group completed a telephone‐based risk assessment after their visit. We categorized women as high or average risk based on family history using the Referral Screening Tool (RST) or breast cancer risk factors using the Gail/Breast Cancer Surveillance Consortium (BCSC) models. We contacted all women for a follow‐up telephone survey 1 week after risk assessment.We used generalized estimating equations to account for clustering by physician, and to estimate differences at follow‐up between Intervention and UC groups in above average knowledge of breast cancer risk factors (cutpoint based on mean knowledge score in sample), and discussion of breast cancer risk and lifestyle behaviors with physician. RESULTS: A total of 1,278 women completed risk assessments and signed consent forms (596 Intervention and 665 UC) and 1,235 (97 %) completed follow‐up interviews (580 Intervention and 655 UC). The mean sample age was 56 years (SD=9) with 35 % non‐Latina White, 23 % Latina, 22 % African American, 18 % Asian/Pacific Islander and 2 % Native American/other. Demographic characteristics and breast cancer risk distributions were well‐balanced between Intervention and UC groups. Nine percent of women qualified for high‐risk referral based on RST score and 16 % qualified based on Gail/BCSC models. Compared to women receiving UC, those in the Intervention group reported greater knowledge of breast cancer risk factors (69 % vs. 55 %), and more discussion of breast cancer risk (41 % vs. 14 %), exercise (75 % vs. 61 %) and weight (67 % vs. 57 %). Discussion of risk was greatest among women at highest risk for breast cancer who received the intervention (51 % Intervention vs. 18 % UC). Multivariable analysis results are presented in Table 1. CONCLUSIONS: Our primary care based intervention increased discussion of breast cancer risk and lifestyle behaviors with physicians and improved women's knowledge of breast cancer risk factors. Our findings support integration of health‐related information technology in a clinic setting to enhance individualized risk assessment and promote patient‐physician discussion, particularly for women at highest risk for breast cancer. (Table Presented).
AN  - CN-01011992
AU  - Kaplan, C. P.
AU  - Livaudais-Toman, J.
AU  - Gregorich, S.
AU  - Tice, J. A.
AU  - Kerlikowske, K.
AU  - Pasick, R.
AU  - Chen, A. H.
AU  - Perez-Stable, E. J.
AU  - Karliner, L.
KW  - *breast cancer
*hospital
*internal medicine
*lifestyle
*primary medical care
*risk
*society
African American
Arm
Cancer epidemiology
Cancer risk
Clinical practice
Demography
Education
Exercise
Family history
Female
Follow up
Health
Human
Information technology
Informed consent
Interview
Model
Patient
Physician
Randomized controlled trial
Risk assessment
Risk factor
Risk reduction
Safety
Screening
Tablet
Telephone
Telephone interview
University hospital
Weight
M3  - Journal: Conference Abstract
PY  - 2013
SP  - S36‐
ST  - Breastcare: a primary care clinic-based RCT to increase breast cancer knowledge and discussion of risk and lifestyle behaviors
T2  - Journal of general internal medicine
TI  - Breastcare: a primary care clinic-based RCT to increase breast cancer knowledge and discussion of risk and lifestyle behaviors
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01011992/full
VL  - 28
ID  - 1559
ER  - 

TY  - JOUR
AB  - Lack of African American females in breast cancer research has been receiving substantial attention. This study seeks to identify research perceptions and motivating factors needed to increase racial/ethnic minority participation in breast cancer research. A total of 57 African American women (Σ = 47.8 years), from Rhode Island and Texas, completed a questionnaire and focus group. While many participants were not breast cancer survivors, they reported knowledge of their racial group's risk for breast cancer. One major finding that could be seen as both a facilitator and barrier is racial concordance between participant and researcher. Cultural sensitivity and trust building is recommended to increase minority participation.
AD  - 1 Rowan University, USA.
2 University of South Carolina, USA.
3 Southern Methodist University, USA.
AN  - 29172809
AU  - Frierson, G. M.
AU  - Pinto, B. M.
AU  - Denman, D. C.
AU  - Leon, P. A.
AU  - Jaffe, A. D.
DA  - Sep
DO  - 10.1177/1359105317740736
DP  - NLM
ET  - 2017/11/28
IS  - 11
KW  - Adult
African Americans/*ethnology
*Biomedical Research
*Breast Neoplasms
Female
Health Knowledge, Attitudes, Practice/*ethnology
Humans
Middle Aged
*Patient Participation
*Patient Selection
*breast cancer
*minority
*psycho-oncology
*racial concordance
*recruitment strategies
LA  - eng
N1  - 1461-7277
Frierson, Georita M
Orcid: 0000-0002-8207-2790
Pinto, Bernardine M
Denman, Deanna C
Leon, Pierre A
Jaffe, Alex D
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
England
J Health Psychol. 2019 Sep;24(11):1548-1561. doi: 10.1177/1359105317740736. Epub 2017 Nov 27.
PY  - 2019
SN  - 1359-1053
SP  - 1548-1561
ST  - Bridging the Gap: Racial concordance as a strategy to increase African American participation in breast cancer research
T2  - J Health Psychol
TI  - Bridging the Gap: Racial concordance as a strategy to increase African American participation in breast cancer research
VL  - 24
ID  - 145
ER  - 

TY  - JOUR
AB  - Objective: To develop a feasibility study of a theory-driven telephone counseling program to enhance psychosocial and physical well-being for cancer survivors after treatment. Methods: Participants (n = 66) were recruited from two Colorado hospitals with self-administered questionnaires at baseline and two weeks post-intervention. The one group, intervention only design included up to six thematic telephone counseling sessions over three months. Topics included nutrition, physical activity, stress management, and medical follow-up. Primary outcomes were cancer-specific distress, self-reported fruit and vegetable consumption and physical activity. Results: Of 66 subjects, 46 completed at least one counseling module and the follow-up assessment (70% retention rate). Mean satisfaction was 9 out of 10, and all participants would recommend C-STEPS to other survivors. Cancer-specific distress (Impact of Event Scale Intrusion subscale) decreased for entire study population (p < 0.001) and stress management session participants (p < 0.001). Fruit and vegetable consumption increased for nutrition and exercise session participants (p = 0.02) and the entire sample (p = NS). Physical activity increased in the entire group (p = 0.006) and for nutrition and exercise session participants (p = 0.01). Conclusion and practice implications: C-STEPS is a feasible telephone counseling program that transcends geographic barriers, demonstrating the potential to decrease distress and promote coping and healthy lifestyles among cancer survivors. (C) 2013 Elsevier Ireland Ltd. All rights reserved.
AN  - WOS:000323806100020
AU  - Garrett, K.
AU  - Okuyama, S.
AU  - Jones, W.
AU  - Barnes, D.
AU  - Tran, Z.
AU  - Spencer, L.
AU  - Lewis, K.
AU  - Maroni, P.
AU  - Chesney, M.
AU  - Marcus, A.
DA  - Aug
DO  - 10.1016/j.pec.2013.04.002
IS  - 2
N1  - 23647980
PY  - 2013
SN  - 0738-3991
SP  - 266-272
ST  - Bridging the transition from cancer patient to survivor: Pilot study results of the Cancer Survivor Telephone Education and Personal Support (C-STEPS) program
T2  - Patient Education and Counseling
TI  - Bridging the transition from cancer patient to survivor: Pilot study results of the Cancer Survivor Telephone Education and Personal Support (C-STEPS) program
VL  - 92
ID  - 3038
ER  - 

TY  - JOUR
AB  - Objectives center dot To test a brief, non-sectarian program of meditation training for effects on perceived stress and negative emotion, and to determine effects of practice frequency and test the moderating effects of neuroticism (emotional lability) on treatment outcome. Design and Setting center dot The study used a single-group, open-label, pre-test post-test design conducted in the setting of a university medical center. Participants center dot Healthy adults (N = 200) interested in learning meditation for stress-reduction were enrolled. One hundred thirty-three (76% females) completed at least 1 follow-up visit and were included in data analyses. Intervention center dot Participants learned a simple mantra-based meditation technique in 4, 1-hour small-group meetings, with instructions to practice for 15-20 minutes twice daily. Instruction was based on a psychophysiological model of meditation practice and its expected effects on stress. Outcome Measures center dot Baseline and monthly follow-up measures of Profile of Mood States; Perceived Stress Scale; State-Trait Anxiety Inventory (STAI); and Brief Symptom Inventory (BSI). Practice frequency was indexed by monthly retrospective ratings. Neuroticism was evaluated as a potential moderator of treatment effects. Results center dot All 4 outcome measures improved significantly after instruction, with reductions from baseline that ranged from 14% (STAI) to 36% (BSI). More frequent practice was associated with better outcome. Higher baseline neuroticism scores were associated with greater improvement. Conclusions center dot Preliminary evidence suggests that even brief instruction in a simple meditation technique can improve negative mood and perceived stress in healthy adults, which could yield long-term health benefits. Frequency of practice does affect outcome. Those most likely to experience negative emotions may benefit the most from the intervention.
AN  - WOS:000243513600008
AU  - Lane, J. D.
AU  - Seskevich, J. E.
AU  - Pieper, C. F.
DA  - Jan-Feb
IS  - 1
N1  - 17283740
PY  - 2007
SN  - 1078-6791
SP  - 38-44
ST  - Brief meditation training can improve perceived stress and negative mood
T2  - Alternative Therapies in Health and Medicine
TI  - Brief meditation training can improve perceived stress and negative mood
VL  - 13
ID  - 3201
ER  - 

TY  - JOUR
AB  - Relative to non-Hispanic whites (NHW), black men are disproportionately affected by prostate cancer (PC) incidence, have poorer PC outcomes, and report greater compromises in health-related quality of life. Despite these challenges, black men are underrepresented in psychosocial cancer research, possibly due to limited access to supportive oncology programs. The purpose of this article is to examine the acceptability and efficacy for reducing disease-specific distress of a tablet-delivered psychosocial intervention for older men with advanced PC (APC) and explore differences by race. Men with APC (N = 192, 37.5% black, age M = 68.84 years) were randomized to 10-week Cognitive Behavioral Stress Management (CBSM) or attention-control Health Promotion (HP), both delivered via tablets. Assessments occurred at baseline in person, weekly during the 10-week program via tablets, and at 6 and 12 months in person. Weekly session evaluations and postprogram exit surveys assessed acceptability. Efficacy was assessed with a measure of PC-anxiety validated with racially diverse PC patients using linear mixed effects modeling. Study retention and group attendance did not differ by race. CBSM and HP were both acceptable among older APC patients. Black men rated both conditions more favorably than NHW men. Men in CBSM (vs. HP) reported greater reductions in PC-anxiety at 6 months (not sustained at 12 months). Black men in CBSM reported greater decreases in PC-anxiety over time compared with all other groups. Tablet-delivered CBSM and HP were acceptable for black and NHW APC patients, although black men rated both conditions more favorably. Black men reported a unique intervention benefit related to reduced disease-specific distress.
AD  - Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Mental Health and Behavioral Sciences Service, Miami Veterans Affairs Healthcare System, Miami, FL, USA.
Department of Urology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Departments of Psychology and Medicine, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA.
AN  - 30285186
AU  - Bouchard, L. C.
AU  - Yanez, B.
AU  - Dahn, J. R.
AU  - Flury, S. C.
AU  - Perry, K. T.
AU  - Mohr, D. C.
AU  - Penedo, F. J.
C2  - PMC7184868
DA  - Jul 16
DO  - 10.1093/tbm/iby089
DP  - NLM
ET  - 2018/10/05
IS  - 4
KW  - African Americans/*psychology/statistics & numerical data
Aged
Anxiety/ethnology/psychology/*therapy
Case-Control Studies
Cognitive Behavioral Therapy/instrumentation
Computers, Handheld/*statistics & numerical data
Counseling/trends
Efficiency, Organizational/statistics & numerical data
Health Services Accessibility/statistics & numerical data
Humans
Incidence
Male
Middle Aged
Patient Acceptance of Health Care/psychology/statistics & numerical data
Prostatic Neoplasms/epidemiology/ethnology/*psychology
Psychosocial Support Systems
Quality of Life/psychology
Surveys and Questionnaires
Telemedicine/instrumentation
*Black men
*Disparities
*E-health
*Prostate cancer
*Psychosocial intervention
LA  - eng
N1  - 1613-9860
Bouchard, Laura C
Yanez, Betina
Dahn, Jason R
Flury, Sarah C
Perry, Kent T
Mohr, David C
Penedo, Frank J
R01 CA157809/CA/NCI NIH HHS/United States
T32 CA193193/CA/NCI NIH HHS/United States
Journal Article
Transl Behav Med. 2019 Jul 16;9(4):629-637. doi: 10.1093/tbm/iby089.
PY  - 2019
SN  - 1869-6716 (Print)
1613-9860
SP  - 629-637
ST  - Brief report of a tablet-delivered psychosocial intervention for men with advanced prostate cancer: Acceptability and efficacy by race
T2  - Transl Behav Med
TI  - Brief report of a tablet-delivered psychosocial intervention for men with advanced prostate cancer: Acceptability and efficacy by race
VL  - 9
ID  - 98
ER  - 

TY  - JOUR
AB  - The utility of breast self-examination (BSE) as an adjunctive and economical means of early detection for breast cancer has been well documented. This preliminary study examined the efficacy of an intervention promoting BSE through standard face-to-face training, written prompts, self-management, personalized feedback, and supplementary training among a sample of women recruited from a federally subsidized housing development. The sample (n = 28) was largely African-American (87%), ranged in age from 20 to 57 (M = 35 years), and had a mean educational attainment of 10th grade. Women reported low levels of BSE frequency, quality, and knowledge at baseline. Analyses of variance revealed a significant effect of the intervention on reported BSE frequency (p < 0.01) and number of BSE records returned (p < 0.05); however, BSE quality was not significantly improved. Continual contacts with participants appeared to be the most important factor in BSE adoption. While this intervention has potential to increase BSE frequency among low SES women, suggestions for improving examination proficiency are also provided.
AD  - Virginia Polytechnic Institute and State University, Department of Psychology, Blacksburg, Virginia 24061
AN  - 107273280. Language: English. Entry Date: 19980801. Revision Date: 20150711. Publication Type: Journal Article
AU  - Russ, C. R.
AU  - Winett, R. A.
DB  - CINAHL Complete
DP  - EBSCOhost
IS  - 4
KW  - Breast Self-Examination -- Education -- Virginia
Women
Poverty
P-Value
Pretest-Posttest Design
Analysis of Variance
Female
Adult
Black Persons
Multidimensional Health Locus of Control Scales
Comparative Studies
Virginia
Prospective Studies
Questionnaires
One-Way Analysis of Variance
Chi Square Test
Multiple Regression
Dependent Variable
Residence Characteristics
Human
N1  - research; tables/charts. Journal Subset: Peer Reviewed; USA. Instrumentation: Multidimensional Health Locus of Control Scale (LOC) (Wallston et al); Health Beliefs Questionnaire (Strauss et al); BSE Self-Efficacy Measure (Baker). NLM UID: 9889882.
PY  - 1996
SN  - 1087-3201
SP  - 309-317
ST  - Brief report. Adoption of breast self-examination among socioeconomically disadvantaged women: the importance of frequent caregiver contact
T2  - Journal of Gender, Culture, & Health
TI  - Brief report. Adoption of breast self-examination among socioeconomically disadvantaged women: the importance of frequent caregiver contact
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=107273280&site=ehost-live&scope=site
VL  - 1
ID  - 1870
ER  - 

TY  - JOUR
AB  - Background: Chronic inflammation is linked to poor lifestyle behaviors and a variety of chronic diseases that are prevalent among African Americans, especially in the southeastern U.S. Purpose: The goal of the study was to test the effect of a community-based diet, physical activity, and stress reduction intervention conducted in 2009-2012 on reducing serum C-reactive protein (CRP) in overweight and obese African-American adults. Methods: An RCT intervention was designed jointly by members of African-American churches and academic researchers. In late 2012, regression (i.e., mixed) models were fit that included both intention-to-treat and post hoc analyses conducted to identify important predictors of intervention success. Outcomes were assessed at 3 months and 1 year. Results: At baseline, the 159 individuals who were recruited in 13 churches and had evaluable outcome data were, on average, obese (BMI=33.1 [+/- 7.1]) and had a mean CRP level of 3.7 (+/- 3.9) mg/L. Reductions were observed in waist-to-hip ratio at 3 months (2%, p=0.03) and 1 year (5%, p<0.01). In female participants attending >= 60% of intervention classes, there was a significant decrease in CRP at 3 months of 0.8 mg/L (p=0.05), but no change after 1 year. No differences were noted in BMI or interleukin-6. Conclusions: In overweight/obese, but otherwise "healthy," African-American church members with very high baseline CRP levels, this intervention produced significant reductions in CRP at 3 and 12 months, and in waist-to-hip ratio, which is an important anthropometric predictor of overall risk of inflammation and downstream health effects. Trial registration: This study is registered at www.clinicaltrials.gov NCT01760902. (C) 2013 American Journal of Preventive Medicine
AN  - WOS:000325193900008
AU  - Hebert, J. R.
AU  - Wirth, M.
AU  - Davis, L.
AU  - Davis, B.
AU  - Harmon, B. E.
AU  - Hurley, T. G.
AU  - Drayton, R.
AU  - Murphy, E. A.
AU  - Shivappa, N.
AU  - Wilcox, S.
AU  - Adams, S. A.
AU  - Brandt, H. M.
AU  - Blake, C. E.
AU  - Armstead, C. A.
AU  - Steck, S. E.
AU  - Blair, S. N.
DA  - Oct
DO  - 10.1016/j.amepre.2013.05.011
IS  - 4
N1  - 24050419
PY  - 2013
SN  - 0749-3797
SP  - 430-440
ST  - C-Reactive Protein Levels in African Americans A Diet and Lifestyle Randomized Community Trial
T2  - American Journal of Preventive Medicine
TI  - C-Reactive Protein Levels in African Americans A Diet and Lifestyle Randomized Community Trial
VL  - 45
ID  - 3033
ER  - 

TY  - JOUR
AB  - Background: Prospective data relating caffeine consumption to breast cancer risk are limited. Methods: We evaluated the association between caffeine consumption and breast cancer risk in women enrolled in a completed cancer prevention trial. Detailed dietary information was obtained at baseline (19921995) from 38 432 women 45 years or older and free of cancer. During a mean follow-up of 10 years, we identified 1188 invasive breast cancer cases. Results: Consumption of caffeine and caffeinated beverages and foods was not statistically significantly associated with overall risk of breast cancer. The multivariate relative risks (RRs) of breast cancer were 1.02 (95% confidence interval [CI], 0.84-1.22) for caffeine (top vs bottom quintile), 1.08 (0.89-1.30) for coffee (>= 4 cups daily vs almost never), and 1.03 (0.85-1.25) for tea (>= 2 cups daily vs almost never). However, in women with benign breast disease, a borderline significant positive association with breast cancer risk was observed for the highest quintile of caffeine consumption (RR, 1.32; 95% CI, 0.99-1.76) and for the highest category of coffee consumption (>= 4 cups daily) (1.35; 1.01-1.80); tests for interaction were marginally significant. Caffeine consumption was also significantly positively associated with risk of estrogen receptor-negative and progesterone receptor negative breast cancer (RR, 1.68; 95% CI, 1.01-2.81) and breast tumors larger than 2 cm (1.79; 1.18-2.72). Conclusions: These data show no overall association between caffeine consumption and breast cancer risk. The possibility of increased risk in women with benign breast disease or for tumors that are estrogen and progesterone receptor negative or larger than 2 cm warrants further study.
AN  - WOS:000259984400013
AU  - Ishitani, K.
AU  - Lin, J.
AU  - Manson, J. E.
AU  - Buring, J. E.
AU  - Zhang, S. M.
DA  - Oct
DO  - 10.1001/archinte.168.18.2022
IS  - 18
N1  - 18852405
PY  - 2008
SN  - 0003-9926
SP  - 2022-2031
ST  - Caffeine consumption and the risk of breast cancer in a large prospective cohort of women
T2  - Archives of Internal Medicine
TI  - Caffeine consumption and the risk of breast cancer in a large prospective cohort of women
VL  - 168
ID  - 3163
ER  - 

TY  - JOUR
AB  - Background: Rising cancer costs demand innovative approaches to improve patient satisfaction and outcomes while reducing expenditures. We developed a novel model that integrates lay health workers (LHWs) into care to assist with documentation of patients' goals and symptoms. We partnered with the VA to implement the approach and to study its efficacy on satisfaction, utilization, and costs. Methods: Newly diagnosed patients with stage 3 and 4 and recurrent cancer were randomly assigned to receive either the LHW intervention or usual care alone. Analyses were performed using intent‐to‐treat. X2, t‐tests, or Wlcoxon Rank Sum were used to compare baseline characteristics and outcomes (satisfaction, utilization, and costs) between the intervention and usual care groups. Mean differences in total costs of care were compared using Wilcoxon Rank Sum. We used regression analysis to estimate differences in satisfaction between baseline and six months between the study arms. Results: Between August 15, 2013 and February 2, 2015, 213 patients were randomized, with 108 in the intervention and 105 in usual care. Median age was 69; 99% were male. The majority (78%) were non‐Hispanic white with 6% non‐ Hispanic black 2% Hispanic, and 2% Asian Pacific Islander. The majority (54%) were unmarried. The average travel distance was 92 miles. Lung cancer was the most common diagnosis (36%). The majority had stage 4 disease (54%). Six months after enrollment, 45% of patients had died in both study arms. More patients in the intervention had a documented goals of care (93% versus 29%; p<0.001) and advance directive (78% versus 38%; p<0.001) and received hospice services (40% versus 23%; p=0.008). Satisfaction was also higher among patients in the intervention group (p<0.001) compared to patients in usual care alone. Patients in the intervention had lower mean total healthcare costs as compared to patients in usual care alone, although not statistically significant ($134,901 versus $116,123; p=0.2). Conclusions: Incorporating timely documentation of patients' goals of care and provision of ongoing patient support via LHWs improved patient satisfaction and reduced total healthcare expenditures.
AN  - CN-01780560
AU  - Patel, M. I.
AU  - Periyakoil, V. J.
AU  - Bundorf, K.
AU  - Thom, D.
AU  - Milstein, A.
AU  - Asch, S. M.
AU  - Kahn, J.
KW  - *advanced cancer
*health care personnel
Aged
Cancer recurrence
Clinical trial
Controlled clinical trial
Controlled study
Diagnosis
Documentation
Female
Health care cost
Hispanic
Hospice
Human
Living will
Lung cancer
Major clinical study
Male
Model
Pacific Islander
Patient satisfaction
Randomized controlled trial
Regression analysis
Student t test
Symptom
Travel
M3  - Journal: Conference Abstract
PY  - 2016
ST  - Can lay health workers achieve the triple aim? Results from the Engagement of Patients with Advanced Cancer (EPAC) trial
T2  - Journal of clinical oncology
TI  - Can lay health workers achieve the triple aim? Results from the Engagement of Patients with Advanced Cancer (EPAC) trial
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01780560/full
VL  - 34
ID  - 1647
ER  - 

TY  - JOUR
AB  - AIM: To study the accuracy of using high definition (HD) scope with narrow band imaging (NBI) vs standard white light colonoscope without NBI (ST), to predict the histology of the colon polyps, particularly those < 1 cm. METHODS: A total of 147 African Americans patients who were referred to Howard University Hospital for screening or, diagnostic or follow up colonoscopy, during a 12-mo period in 2012 were prospectively recruited. Some patients had multiple polyps and total number of polyps was 179. Their colonoscopies were performed by 3 experienced endoscopists who determined the size and stated whether the polyps being removed were hyperplastic or adenomatous polyps using standard colonoscopes or high definition colonoscopes with NBI. The histopathologic diagnosis was reported by pathologists as part of routine care. RESULTS: Of participants in the study, 55 (37%) were male and median (interquartile range) of age was 56 (19-80). Demographic, clinical characteristics, past medical history of patients, and the data obtained by two instruments were not significantly different and two methods detected similar number of polyps. In ST scope 89% of polyps were < 1 cm vs 87% in HD scope (P = 0.7). The ST scope had a positive predictive value (PPV) and positive likelihood ratio (PLR) of 86% and 4.0 for adenoma compared to 74% and 2.6 for HD scope. There was a trend of higher sensitivity for HD scope (68%) compare to ST scope (53%) with almost the same specificity. The ST scope had a PPV and PLR of 38% and 1.8 for hyperplastic polyp (HPP) compared to 42% and 2.2 for HD scope. The sensitivity and specificity of two instruments for HPP diagnosis were similar. CONCLUSION: Our results indicated that HD scope was more sensitive in diagnosis of adenoma than ST scope. Clinical diagnosis of HPP with either scope is less accurate compared to adenoma. Colonoscopy diagnosis is not yet fully matched with pathologic diagnosis of colon polyp. However with the advancement of both imaging and training, it may be possible to increase the sensitivity and specificity of the scopes and hence save money for eliminating time and the cost of Immunohistochemistry/pathology.
AN  - WOS:000380769800019
AU  - Ashktorab, H.
AU  - Etaati, F.
AU  - Rezaeean, F.
AU  - Nouraie, M.
AU  - Paydar, M.
AU  - Namin, H. H.
AU  - Sanderson, A.
AU  - Begum, R.
AU  - Alkhalloufi, K.
AU  - Brim, H.
AU  - Laiyemo, A. O.
DA  - Jul
DO  - 10.3748/wjg.v22.i28.6539
IS  - 28
N1  - 27605888
PY  - 2016
SN  - 1007-9327
SP  - 6539-6546
ST  - Can optical diagnosis of small colon polyps be accurate? Comparing standard scope without narrow banding to high definition scope with narrow banding
T2  - World Journal of Gastroenterology
TI  - Can optical diagnosis of small colon polyps be accurate? Comparing standard scope without narrow banding to high definition scope with narrow banding
VL  - 22
ID  - 2938
ER  - 

TY  - JOUR
AB  - Purpose. Minority patients with cancer experience worse control of their pain than do their white counterparts. This disparity may, in part, reflect more miscommunication between minority patients and their physicians. Therefore, we examined whether patient coaching could reduce disparities in pain control in a secondary analysis of a randomized controlled trial. Methods. Sixty-seven English-speaking adult cancer outpatients, including 15 minorities, with moderate pain over the prior 2 weeks were randomly assigned to the experimental (N = 34) or control group (N = 33). Experimental patients received a 20-minute individualized education and coaching session to increase knowledge of pain self-management, to redress personal misconceptions about pain treatment, and to rehearse an individually scripted patient-physician dialog about pain control. The control group received standardized information on controlling pain. Data on average pain (0-10 scale) were collected at enrollment and 2-week follow-up. Results. At enrollment, minority patients had significantly more pain than their white counterparts (6.0 vs 5.0, P = 0.05). At follow-up, minorities in the control group continued to have more pain (6.4 vs 4.7, P = 0.01), whereas in the experimental group, disparities were eliminated (4.0 vs 4.3, P = 0.71). The effect of the intervention on reducing disparities was significant (P = 0.04). Conclusions. Patient coaching offers promise as a means of reducing racial/ethnic disparities in pain control. Larger studies are needed to validate these findings and to explore possible mechanisms.
AN  - WOS:000244390000006
AU  - Kalauokalani, D.
AU  - Franks, P.
AU  - Oliver, J. W.
AU  - Meyers, F. J.
AU  - Kravitz, R. L.
DA  - Jan-Feb
DO  - 10.1111/j.1526-4637.2007.00170.x
IS  - 1
N1  - 17244100
PY  - 2007
SN  - 1526-2375
SP  - 17-24
ST  - Can patient coaching reduce racial/ethnic disparities in cancer pain control? Secondary analysis of a Randomized controlled trial
T2  - Pain Medicine
TI  - Can patient coaching reduce racial/ethnic disparities in cancer pain control? Secondary analysis of a Randomized controlled trial
VL  - 8
ID  - 3205
ER  - 

TY  - JOUR
AB  - BACKGROUND: Stage II and III rectal cancers have been effectively treated with neoadjuvant chemoradiotherapy (NCRT) followed by definitive resection. Advancements in surgical technique and systemic therapy have prompted investigation of neoadjuvant multiagent chemotherapy (NMAC) regimens with the elimination of radiation (RT). The objective of the current study was to investigate factors that predict for the use of NCRT versus NMAC and compare outcomes using the National Cancer Data Base (NCDB) for select stage II and III rectal cancers. METHODS: In the NCDB, 21,707 patients from 2004 through 2012 with clinical T2N1 (cT2N1), cT3N0, or cT3N1 rectal cancers were identified who had received NCRT or NMAC followed by low anterior resection. Kaplan-Meier analyses, log-rank tests, and Cox-proportional hazards regression analyses were conducted along with propensity score matching analysis to reduce treatment selection bias. RESULTS: The 5-year actuarial overall survival (OS) rate was 75% for patients who received NCRT versus 67.2% for those who received NMAC (P < .01). On MVA, those who received NCRT had improved OS (hazard ratio, 0.77. P < .01), and this effect was confirmed on propensity score matching analysis (hazard ratio, 0.72; P = .01). In the same model, the following variables improved OS: age < 65 years, having private insurance, treatment at an academic center, living in an affluent zip code, a low comorbidity score, receipt of adjuvant chemotherapy, and a shorter interval before surgery (all P < .05). African Americans, men, patients with high-grade tumors, those with cT3N1 tumors, and those who underwent incomplete (R1) resection had worse OS (all P < .05). CONCLUSIONS: In this series, the elimination of neoadjuvant RT for select patients with stage II and III rectal adenocarcinoma was associated with worse OS and should not be recommended outside of a clinical trial. Cancer 2017;123:783-93. © 2016 American Cancer Society.
AD  - Department of Radiation Oncology, Rollins School of Public Health, Emory University, Atlanta, Georgia.
Winship Cancer Institute, Emory University, Atlanta, Georgia.
Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, Georgia.
Department of Medical Oncology, Emory University, Atlanta, Georgia.
Department of Surgery, Emory University, Atlanta, Georgia.
AN  - 27780316
AU  - Cassidy, R. J.
AU  - Liu, Y.
AU  - Patel, K.
AU  - Zhong, J.
AU  - Steuer, C. E.
AU  - Kooby, D. A.
AU  - Russell, M. C.
AU  - Gillespie, T. W.
AU  - Landry, J. C.
C2  - PMC5319877
C6  - NIHMS821781
DA  - Mar 1
DO  - 10.1002/cncr.30410
DP  - NLM
ET  - 2016/10/26
IS  - 5
KW  - Adenocarcinoma/*drug therapy/epidemiology/pathology/*radiotherapy
Adolescent
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
Chemoradiotherapy, Adjuvant/*methods
Chemotherapy, Adjuvant/methods
Clinical Trials as Topic
Databases, Factual
Ethnic Groups
Female
Humans
Kaplan-Meier Estimate
Male
Middle Aged
*Neoadjuvant Therapy
Neoplasm Staging
Proportional Hazards Models
Rectal Neoplasms/*drug therapy/epidemiology/pathology/*radiotherapy
Treatment Outcome
*National Cancer Data base (NCDB)
*health disparities
*neoadjuvant chemoradiation
*neoadjuvant chemotherapy
*rectal cancer
LA  - eng
N1  - 1097-0142
Cassidy, Richard J
Orcid: 0000-0003-0019-0679
Liu, Yuan
Patel, Kirtesh
Zhong, Jim
Steuer, Conor E
Kooby, David A
Russell, Maria C
Gillespie, Theresa W
Landry, Jerome C
P30 CA138292/CA/NCI NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Cancer. 2017 Mar 1;123(5):783-793. doi: 10.1002/cncr.30410. Epub 2016 Oct 25.
PY  - 2017
SN  - 0008-543X (Print)
0008-543x
SP  - 783-793
ST  - Can we eliminate neoadjuvant chemoradiotherapy in favor of neoadjuvant multiagent chemotherapy for select stage II/III rectal adenocarcinomas: Analysis of the National Cancer Data base
T2  - Cancer
TI  - Can we eliminate neoadjuvant chemoradiotherapy in favor of neoadjuvant multiagent chemotherapy for select stage II/III rectal adenocarcinomas: Analysis of the National Cancer Data base
VL  - 123
ID  - 197
ER  - 

TY  - JOUR
AB  - The M-PACT study compared an all-male with a mixed-sex intervention to increase informed decision-making for prostate cancer screening among African-American men in church settings. We recruited 262 men in 18 churches randomized to the two intervention approaches. Trained and certified lay peer community health advisors in each church led a series of four men's health workshops on informed decision-making for prostate cancer screening. African-American male workshop participants completed baseline, post-workshop, and 12-month follow-up surveys. Contrary to our expectations, including women in the workshops did not result in increased intervention efficacy for the informed decision-making outcomes as both groups showed significant improvement over time in several study outcomes including stage of decision-making for prostate cancer screening, preference for role in decision-making, prostate cancer knowledge, and self-reports of prostate specific antigen testing. Finally, men who attended multiple workshops had better informed decision-making outcomes on several indicators. The current findings suggest mixed results from including women in this men's health educational intervention. Future work should consider optimal ways of providing family support for African-American men's health promotion.
AD  - a Department of Behavioral and Community Health, School of Public Health , University of Maryland , College Park , Maryland , USA.
b Community Ministry of Prince George's County , Upper Marlboro , Maryland , USA.
c Access to Wholistic & Productive Living, Inc ., Lanham , Maryland , USA.
d Westat , Rockville , Maryland , USA.
e Department of Urology, University of Maryland Medical Center , Baltimore , Maryland , USA.
AN  - 29173037
AU  - Holt, C. L.
AU  - Le, D.
AU  - Slade, J. L.
AU  - Muwwakkil, B.
AU  - Saunders, D. R.
AU  - Williams, R.
AU  - Atkinson, N. L.
AU  - Naslund, M.
DA  - Dec
DO  - 10.1080/10810730.2017.1382616
DP  - NLM
ET  - 2017/11/28
IS  - 12
KW  - African Americans/*psychology/statistics & numerical data
Aged
*Decision Making
Early Detection of Cancer/*psychology/statistics & numerical data
Faith-Based Organizations
Female
Follow-Up Studies
Health Promotion/*methods
Humans
*Interpersonal Relations
Male
Middle Aged
Program Evaluation
Prostatic Neoplasms/diagnosis/*ethnology
LA  - eng
N1  - 1087-0415
Holt, Cheryl L
Le, Daisy
Slade, Jimmie L
Muwwakkil, Bettye
Saunders, Darlene R
Williams, Ralph
Atkinson, Nancy L
Naslund, Michael
Journal Article
Randomized Controlled Trial
United States
J Health Commun. 2017 Dec;22(12):964-973. doi: 10.1080/10810730.2017.1382616. Epub 2017 Nov 27.
PY  - 2017
SN  - 1081-0730
SP  - 964-973
ST  - Can Women Facilitate Men's Prostate Cancer Screening Informed Decision-Making? The M-PACT Trial
T2  - J Health Commun
TI  - Can Women Facilitate Men's Prostate Cancer Screening Informed Decision-Making? The M-PACT Trial
VL  - 22
ID  - 144
ER  - 

TY  - JOUR
AB  - PURPOSE: Improving health information delivery is especially important for vulnerable (low‐literate, low SES, racial/ethnic minority) populations who experience greater disease burden, are less informed about health care and less satisfied with health care communication. Enhancing knowledge and communication through new technologies may improve treatment adherence, satisfaction with care, and health outcomes. This study evaluated whether a low literacy‐friendly, multimedia information technology system can be used feasibly in oncology practice. METHODS: The C3 system includes cancer‐ specific education and assessment modules on a Talking Touchscreen (TT) that allows patients to: read and/or listen to text read aloud, personalize what information is accessed, create visit‐specific lists for discussion with providers, and self‐administer patient‐reported outcomes questionnaires. We conducted a randomized trial at three cancer centers serving underinsured, racial/ethnic minority populations. All patients completed patientreported measures on the TT kiosk in clinic waiting rooms. Patients randomized to the Intervention arm used the multimedia educational software modules (Diagnosis, Treatment, Nutrition, Pain, Communicating with Providers, and Local Resources) on the kiosks; those in the Standard Care arm received paper booklets. RESULTS: We enrolled 126 patients with newly diagnosed breast or colorectal cancer: 83% women, mean age 53 years, 56% African American, 56% high school education or less. Baseline data for the Intervention participants (n = 65) indicated that they largely found the information in the educational software (60.7% as much as they wanted or 39.3% almost as much), considered the software to be useful (63.2% a lot or 36.8% somewhat) and helpful in understanding their disease and treatment (50.9% a lot or 47.4% somewhat), and would use it again (56.1% definitely or 42.1% maybe). The majority of Intervention participants needed minimal assistance (53.5% none or 42.4 a little) with the educational software at first exposure, and even less so at subsequent exposures. CONCLUSIONS: We developed a low literacy‐friendly multimedia TT system for patient‐reported outcome assessment and patient education that can be used in clinical practice and research. Analysis of the longitudinal trial data will evaluate the system's impact on patient outcomes. If successful, the C3 system could be implemented across cancer centers to promote patient‐centered care and address healthcare disparities. CLINICAL/RESEARCH IMPLICATIONS: The C3 system is a low literacy‐friendly, multimedia talking touch screen system for patientreported outcome assessment and patient education that can be used feasibly and acceptably in clinical practice and research. The C3 system could be implemented across cancer centers to promote patient‐centered care and address healthcare disparities by allowing patients with all levels of literacy to access health information independent of medical providers and to provide patient‐reported outcomes without the use of interviewers.
AN  - CN-01025259
AU  - Garcia, S.
AU  - Peipert, J.
AU  - Miller, E.
AU  - Muench, C.
AU  - Hahn, E.
DO  - 10.10002/pon.3245
KW  - *human
*information technology
*interpersonal communication
*multimedia
*neoplasm
*oncology
*patient care
*reading
*society
African American
Arm
Breast
Cancer center
Clinical practice
Colorectal cancer
Computer program
Diagnosis
Education
Exposure
Female
Health
Health care
Health care disparity
High school
Hospital
Medical information
Medically uninsured
Nutrition
Outcome assessment
Pain
Patient
Patient compliance
Patient education
Population
Questionnaire
Satisfaction
Technology
Waiting room
M3  - Journal: Conference Abstract
PY  - 2013
SP  - 6‐7
ST  - Cancer care communication (C3): a low literacy friendly, multimedia information technology system to enhance patient-centered care
T2  - Psycho-oncology.
TI  - Cancer care communication (C3): a low literacy friendly, multimedia information technology system to enhance patient-centered care
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01025259/full
VL  - 22
ID  - 1548
ER  - 

TY  - JOUR
AB  - Background: Lack of African American participation in cancer clinical trials has been identified as a critical problem. Historical interactions related to race, identity, and power may contribute to continued inequity in healthcare and research participation. Objective: The aim of this study was to explore the perceptions of African Americans regarding cancer and research and how these perceptions shape their beliefs about participating as cancer research subjects. Methods: Three African American focus groups were conducted including people who had never participated in cancer research, those who had, and those who were asked but refused (n = 16). Discussion focused on their perceptions of cancer research and actual or potential participation as research subjects. Data were coded using both structured and inductive coding methods. Results: Fear and fatalism emerged in relation to research, race, power, and identity and were related to larger historical and social issues rather than only individual thoughts or feelings. Participants described fears of the unknown, death, mistrust, conspiracy, and discrimination together with positive/negative tensions between self, family, and community responsibilities. Conclusion: Complex identities linked perceptions of cancer and cancer research with broader historical and cultural issues. Fear, fatalism, and current and historical relationships influence how people perceive themselves as research subjects and may influence their decisions to participate in cancer research. Implication for Practice: Acknowledging how complex factors including race and racism contribute to health disparities may give nurses and other healthcare providers a better appreciation of how historical, social, and cultural dynamics at individual, community, and organizational levels influence access to and participation in cancer research.
AD  - D. Somayaji, Dana-Farber Cancer Institute, University of Massachusetts Boston, Phyllis F. Cantor Center, 450 Brookline Avenue, L522, Boston, MA, United States
AU  - Somayaji, D.
AU  - Cloyes, K. G.
DB  - Embase
Medline
DO  - 10.1097/NCC.0000000000000144
IS  - 2
KW  - adult
African American
aged
article
breast cancer
cancer research
clinical research
clinical trial (topic)
community
educational status
family
fatality
fear
female
health belief
human
information processing
male
medical information
middle aged
nurse patient relationship
patient referral
perception
priority journal
prostate cancer
research subject
social discrimination
social interaction
Spiritualism
unemployment
young adult
LA  - English
M3  - Article
N1  - L602833093
2015-03-13
2015-03-18
PY  - 2015
SN  - 1538-9804
0162-220X
SP  - 133-144
ST  - Cancer fear and fatalism: How African American participants construct the role of research subject in relation to clinical cancer research
T2  - Cancer Nursing
TI  - Cancer fear and fatalism: How African American participants construct the role of research subject in relation to clinical cancer research
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L602833093&from=export
http://dx.doi.org/10.1097/NCC.0000000000000144
VL  - 38
ID  - 1006
ER  - 

TY  - JOUR
AB  - Although it has been well documented that poor health literacy is associated with limited participation in cancer clinical trials, studies assessing the relationships between cancer health literacy (CHL) and participation in research among diverse populations are lacking. In this study, we examined the relationship between CHL and willingness to participate in cancer research and/or donate bio-specimens (WPRDB) among African Americans, Latinos, and Whites. Participants completed the Cancer Health Literacy Test and the Multidimensional Cancer Literacy Questionnaire. Total-scale and subscale scores, frequencies, means, and distributions were computed. Analyses of variance, the Bonferroni procedure, and the Holm method were used to examine significant differences among groups. Cronbach's alphas estimated scales' internal consistency reliability. Significant interactions were found between race/ethnicity, gender, and CHL on WPRDB scales and subscale scores, even after education and age were taken into account. Our study confirms that CHL plays an important role that should be considered and researched further. The majority of participants were more willing to participate in non-invasive research studies (surveys, interviews, and training) or collection of bio-specimens (saliva, check cells, urine, and blood) and in studies led by their own healthcare providers, and local hospitals and universities. However, participants were less willing to participate in more-invasive studies requiring them to take medications, undergo medical procedures or donate skin/tissues. We conclude that addressing low levels of CHL and using community-based participatory approaches to address the lack of knowledge and trust about cancer research among diverse populations may increase not only their willingness to participate in research and donate bio-specimens, but may also have a positive effect on actual participation rates.
AN  - WOS:000448818100033
AU  - Echeverri, M.
AU  - Anderson, D.
AU  - Napoles, A. M.
AU  - Haas, J. M.
AU  - Johnson, M. E.
AU  - Serrano, F. S. A.
DA  - Oct
DO  - 10.3390/ijerph15102091
IS  - 10
N1  - 2091
30249985
PY  - 2018
SN  - 1660-4601
ST  - Cancer Health Literacy and Willingness to Participate in Cancer Research and Donate Bio-Specimens
T2  - International Journal of Environmental Research and Public Health
TI  - Cancer Health Literacy and Willingness to Participate in Cancer Research and Donate Bio-Specimens
VL  - 15
ID  - 2844
ER  - 

TY  - JOUR
AB  - Objective. We assessed how Medicaid enrollment and race influence cancer incidence among patients age 65 years and older. Data Sources and Method. Population-based Michigan Tumor Registry was merged with Medicaid eligibility files for 1996 through 2000. All analyses were age-adjusted and gender-specific. We compared cancer incidence in the elderly Medicaid population to the cancer incidence in the Medicare population. We then examined cancer incidence in patients continuously enrolled in Medicaid 12 or more months relative to the incidence in the Medicare population. Principal Findings. When comparing cancer incidence in Medicaid patients without regard to enrollment before diagnosis, the incidence rates of prostate cancer in black men and colorectal cancer in black women were statistically higher relative to the incidence rates in white patients. The overall cancer incidence rate for all cancers combined was statistically significantly higher for black women and men compared with white women and men (incidence rate ratio=1.18 and 1.48, 95 percent confidence interval 1.05-1.32 and 1.28-1.71, respectively). In dually eligible patients enrolled 12 or more months before diagnosis, an excess cancer incident was observed for black patients relative to white patients in every cancer site examined with the exception of lung cancer. Conclusions. Medicaid data in addition to Medicare data revealed patterns of cancer incidence that varied according to Medicaid enrollment and race. These findings suggest that the cancer burden among African Americans and dually eligible patients is substantial. © Health Research and Educational Trust.
AD  - C. J. Bradley, Department of Health Administration, Massey Cancer Center, Virginia Commonwealth University, 1008 Clay Street, Richmond, VA 23298-0203, United States
AU  - Bradley, C. J.
AU  - Luo, Z.
AU  - Given, C. W.
DB  - Embase
Medline
DO  - 10.1111/j.1475-6773.2008.00855.x
IS  - 5 P1
KW  - aged
article
cancer incidence
cancer registry
colorectal cancer
elderly care
female
geriatric care
groups by age
human
male
medicaid
medicare
population research
prostate cancer
race difference
sex difference
LA  - English
M3  - Article
N1  - L352389759
2008-10-16
PY  - 2008
SN  - 0017-9124
1475-6773
SP  - 1768-1779
ST  - Cancer incidence in elderly medicare and dually eligible beneficiaries
T2  - Health Services Research
TI  - Cancer incidence in elderly medicare and dually eligible beneficiaries
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L352389759&from=export
http://dx.doi.org/10.1111/j.1475-6773.2008.00855.x
VL  - 43
ID  - 1203
ER  - 

TY  - JOUR
AB  - BACKGROUND: Few studies have investigated cancer risks in carbon black workers and the findings were inconclusive. METHODS: The current study explores the mortality of a cohort of 1535 male German blue-collar workers employed at a carbon black manufacturing plant for at least one year between 1960 and 1998. Vital status and causes of death were assessed for the period 1976-98. Occupational histories and information on smoking were abstracted from company records. Standardised mortality ratios (SMR) and Poisson regression models were calculated. RESULTS: The SMRs for all cause mortality (observed deaths (obs) 332, SMR 120, 95% CI 108 to 134), and mortality from lung cancer (obs 50, SMR 218, 95% CI 161 to 287) were increased using national rates as reference. Comparisons to regional rates from the federal state gave SMRs of 120 (95% CI 107 to 133) and 183 (95% CI 136 to 241), respectively. However, there was no apparent dose response relationship between lung cancer mortality and several indicators of occupational exposure, including years of employment and carbon black exposure. CONCLUSIONS: The mortality from lung cancer among German carbon black workers was increased. The high lung cancer SMR can not fully be explained by selection, smoking, or other occupational risk factors, but the results also provide little evidence for an effect of carbon black exposure.
AD  - Institute of Epidemiology and Social Medicine, University of Münster, Münster, Germany. wellmann@uni-muenster.de
AN  - 106273991. Language: English. Entry Date: 20070427. Revision Date: 20200624. Publication Type: Journal Article
AU  - Wellmann, J.
AU  - Weiland, S. K.
AU  - Neiteler, G.
AU  - Klein, G.
AU  - Straif, K.
DB  - CINAHL Complete
DO  - 10.1136/oem.2006.026526
DP  - EBSCOhost
IS  - 8
KW  - Carbon
Neoplasms -- Mortality
Occupational Diseases -- Mortality
Adult
Aged
Aged, 80 and Over
Cause of Death
Confidence Intervals
Data Analysis Software
Descriptive Statistics
Epidemiological Research
Female
Germany
Industry
Male
Middle Age
Occupational Exposure
Occupational Exposure -- Adverse Effects
Regression
Relative Risk
Research Subject Recruitment
Risk Factors
Smoking -- Mortality
Human
N1  - research; tables/charts. Journal Subset: Biomedical; Blind Peer Reviewed; Europe; Expert Peer Reviewed; Peer Reviewed; UK & Ireland. NLM UID: 9422759.
PMID: NLM16497850.
PY  - 2006
SN  - 1351-0711
SP  - 513-521
ST  - Cancer mortality in German carbon black workers 1976-98
T2  - Occupational & Environmental Medicine
TI  - Cancer mortality in German carbon black workers 1976-98
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106273991&site=ehost-live&scope=site
VL  - 63
ID  - 1872
ER  - 

TY  - JOUR
AB  - Among African American seniors, compared to a less intensive intervention (general information and educational materials), does the addition of facilitation services delivered by a health coordinator result in a greater improvement in adherence to recommended treatment among those diagnosed with breast, cervix, colon/rectum, prostate, or lung cancer? Background The Centers for Medicare and Medicaid Services (CMS) received congressional authorization to launch a nationwide demonstration project to address persistent disparities in cancer treatment among racial and ethnic minority populations. Hopkins was selected as one of six national sites to conduct a demonstration project designed to test an intervention strategy to promote adherence to cancer treatment. Aim This demonstration project will evaluate the efficacy of a health coordinator model. We will conduct A RANDOMIZED CONTROLLED TRIAL testing the efficacy of the intervention for African American seniors diagnosed with cancer. The duration of follow‐up post‐randomization will be from date of randomization and September 30th, 2010, the end date for the demonstration. This randomized controlled trial will compare the efficacy of a less intensive intervention (general information and educational materials in the context of "usual care") to that of a more intensive intervention, the addition of a health coordinator (HC), in promoting adherence to treatment among African American seniors who have been diagnosed with breast, cervix, colon/rectum, prostate or lung cancer. The primary outcome variable for the trial will be the difference between the two intervention groups in the time to initiation of therapy, beginning on the date of randomization. Population: The study population will consist of a convenience sample of 200 individuals diagnosed with breast, cervix, colon, lung or prostate cancer, and who intend to receive their cancer treatment from either Johns Hopkins Hospital (JHH) or from Johns Hopkins Bayview Medical Center (JHBMC). The sampling frame will be restricted to African American Medicare beneficiaries, age 65 and older, enrolled in Medicare Parts A and B, but not enrolled in managed care (Medicare Part C), hospice, or some other extended care facility. With a population of 651,154, African Americans constitute 64% of Baltimore City's total population44. Additionally, 13.2% of Baltimoreans are age 65 or older, and this accounts for 68% of the City's cancer deaths.
AN  - CN-01498391
AU  - Nct
KW  - Rectal Neoplasms
Uterine Cervical Neoplasms
PY  - 2007
ST  - Cancer Prevention and Treatment Among African American Older Adults: treatment Trial
T2  - https://clinicaltrials.gov/show/NCT00509444
TI  - Cancer Prevention and Treatment Among African American Older Adults: treatment Trial
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01498391/full
ID  - 1406
ER  - 

TY  - JOUR
AB  - BACKGROUND: To explore the willingness of primary care providers (PCPs) to encourage enrollment of patients into cancer prevention trials. METHODS: A self-administered survey was mailed to a random sample of PCPs in three geographic regions. Physicians were asked questions about their knowledge and attitudes towards cancer prevention trials. We presented a clinical vignette of a woman at high risk for breast cancer and asked if they would encourage her enrollment into a breast cancer chemoprevention trial (yes/no). Each survey included one of 16 possible clinical vignettes where patient characteristics (age, race socioeconomic status, physical mobility and co-morbidity) varied dichotomously. Bivariate analyses and logistic models were used to examine the independent effects of patient and physician characteristics on physician decisions. RESULTS: Two hundred and sixty-six surveys (50% response) were analyzed. The mean age of respondents was 48; 54% were White, 35% Asian and 5% Black. By design physicians were evenly distributed by gender, specialty and geographic location. Overall, 53% would encourage enrollment into a breast cancer chemoprevention trial. Significant predictors of a recommendation to enroll were: geographic location in California or Georgia, younger vignette patient and anticipating an increase in patient trust after recommending enrollment. CONCLUSION: PCPs are less likely to encourage elderly patients to enroll into cancer chemoprevention trials. Decisions differ based on geographic location and perceived trust in the patient-provider relationship. To achieve successful enrollment, trial investigators must continue to educate PCPs and ensure a strong PCP-patient relationship is maintained.
AD  - Women's Health Unit, Section of General Internal Medicine, Evans Department of Medicine, Boston University School of Medicine, 720 Harrison Avenue, DOB Suite 1108, Boston, MA 02118-2334, USA. Tracy.Battaglia@bmc.org
AN  - 16476525
AU  - Battaglia, T. A.
AU  - Ash, A.
AU  - Prout, M. N.
AU  - Freund, K. M.
DO  - 10.1016/j.cdp.2005.09.005
DP  - NLM
ET  - 2006/02/16
IS  - 1
KW  - Aged
Attitude of Health Personnel
Chemoprevention
*Clinical Trials as Topic
Counseling/*statistics & numerical data
*Decision Making
Family Practice/*statistics & numerical data
Female
Health Knowledge, Attitudes, Practice
Humans
Male
Neoplasms/ethnology/etiology/*prevention & control
Patient Acceptance of Health Care/psychology
*Patient Selection
Physicians, Family
Practice Patterns, Physicians'/*statistics & numerical data
LA  - eng
N1  - Battaglia, Tracy A
Ash, Arlene
Prout, Marianne N
Freund, Karen M
CA 73297-01/CA/NCI NIH HHS/United States
K12-HD43444/HD/NICHD NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
England
Cancer Detect Prev. 2006;30(1):34-7. doi: 10.1016/j.cdp.2005.09.005. Epub 2006 Feb 14.
PY  - 2006
SN  - 0361-090X (Print)
0361-090x
SP  - 34-7
ST  - Cancer prevention trials and primary care physicians: factors associated with recommending trial enrollment
T2  - Cancer Detect Prev
TI  - Cancer prevention trials and primary care physicians: factors associated with recommending trial enrollment
VL  - 30
ID  - 574
ER  - 

TY  - JOUR
AB  - Background: African American women have increased mortality rates for cervical, breast, and colorectal cancers, yet not all receive the recommended screening tests for these cancers. We characterized the cancer screening behaviors of African American women enrolled in a community-based cancer prevention trial. Methods: We examined cross-sectional data from 1123 African American customers aged ≥18 years from 37 beauty salons in North Carolina who completed the North Carolina BEAUTY and Health Project baseline survey. Mixed logistic regression models were used to identify correlates of receiving cervical, breast, and colorectal cancer screening tests within recommended screening guidelines. Results: Overall, 94% (1026 of 1089) of women aged ≥18 years reported receiving a Pap smear test within the last 3 years, 70% (298 of 425) of women aged ≥40 years reported receiving a mammography within the last year, and 64% (116 of 180) of women aged ≥50 years were considered to be within recommended screening guidelines for colorectal cancer. Age was correlated with recent Pap smear testing and mammography. Women who reported receiving a recent Pap smear test were more likely to report a mammogram in the last year, and women with a recent mammogram were more likely to be within recommended screening guidelines for colorectal cancer. Many women reported multiple barriers to getting recommended cancer screening tests. Conclusions: Almost all women reported receiving a Pap smear test within the last 3 years. Future interventions should focus on increasing breast and colorectal cancer screening among African American women.
AD  - Gillings School of Global Public Health and Lineberger Comprehensive Cancer Center, University of North Carolina , Chapel Hill, North Carolina.
AN  - 21332413
AU  - Reiter, P. L.
AU  - Linnan, L. A.
C2  - PMC4408974
DA  - Mar
DO  - 10.1089/jwh.2010.2245
DP  - NLM
ET  - 2011/02/22
IS  - 3
LA  - eng
N1  - 1931-843x
Reiter, Paul L
Linnan, Laura A
R25 CA057726/CA/NCI NIH HHS/United States
Journal Article
J Womens Health (Larchmt). 2011 Mar;20(3):429-438. doi: 10.1089/jwh.2010.2245. Epub 2011 Feb 19.
PY  - 2011
SN  - 1540-9996 (Print)
1540-9996
SP  - 429-438
ST  - Cancer Screening Behaviors of African American Women Enrolled in a Community-Based Cancer Prevention Trial
T2  - J Womens Health (Larchmt)
TI  - Cancer Screening Behaviors of African American Women Enrolled in a Community-Based Cancer Prevention Trial
VL  - 20
ID  - 398
ER  - 

TY  - JOUR
AB  - This experimental study attempts to determine if an in-home educational intervention conducted by lay health workers (LHWs) can increase adherence among low-income, inner-city black women to schedules for screening for breast cancer and cervical cancer, as well as increase the women's knowledge and change their attitudes regarding these cancers. This paper is a description of the purposes, hypotheses, design, subject recruitment, intervention, and evaluation of the study conducted by Morehouse School of Medicine. Subjects were recruited from a variety of sources, including patients seen in a community health center, women referred by the National Black Women's Health Project (NBWHP), residents of public and senior citizen housing projects, and persons identified in various community settings. Fewer than half of those asked to participate agreed to do so. The 321 women who were recruited were demographically diverse. Overall, about half of these volunteer subjects self-reported at least one Papanicolaou (Pap) smear and one breast examination within a year before enrollment in the study. There was little variation by source of recruitment in compliance with screening recommendations, except that referrals from NBWHP were more likely (P<0.01) to have had a Pap test and breast self-examination, while residents of public housing projects were somewhat less likely to have done so. About 35 percent of participants ages 35 and older had a mammogram within an appropriate interval. Participants were randomly assigned to intervention and control groups. Women in the intervention group were visited in their homes by LHWs on three occasions; the LHWs provided education on cancer and reproductive health. The groups were comparable in their baseline sociodemographic status and previous screening history.
AD  - D.S. Blumenthal, Morehouse School of Medicine, 720 Westview Dr., SW, Atlanta, GA 30310-1495, United States
AU  - Sung, J. F. C.
AU  - Coates, R. J.
AU  - Williams, J. E.
AU  - Liff, J. M.
AU  - Greenberg, R. S.
AU  - McGrady, G. A.
AU  - Avery, B. Y.
AU  - Blumenthal, D. S.
DB  - Embase
Medline
IS  - 4
KW  - adult
aged
article
attitude
breast cancer
breast examination
cancer screening
cancer survival
clinical trial
controlled study
demography
female
health care personnel
health education
health insurance
human
major clinical study
mammography
marriage
Black person
Papanicolaou test
priority journal
randomized controlled trial
social status
United States
uterine cervix cancer
LA  - English
M3  - Article
N1  - L22255362
1992-08-31
PY  - 1992
SN  - 0033-3539
SP  - 381-388
ST  - Cancer screening intervention among black women in inner-city Atlanta - Design of a study
T2  - Public Health Reports
TI  - Cancer screening intervention among black women in inner-city Atlanta - Design of a study
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L22255362&from=export
VL  - 107
ID  - 1342
ER  - 

TY  - JOUR
AB  - BACKGROUND: Federal policies have been implemented to mitigate underenrollment in cancer trials in the United States. We sought to identify patterns and predictors of enrollment patterns to cancer trials in a contemporary era using a real world setting. STUDY DESIGN: The 2001-2008 California Cancer Registry was used to determine patterns and predictors of enrollment in clinical trials for stage 0 to IV solid organ malignant tumors. Multivariate techniques were used to identify predictors of enrollment in cancer protocols, controlling for covariates. RESULTS: Less than a percent (0.64%) of patients enrolled in clinical trials (1566 of 244,528). Black patients were less likely than whites to enroll in trials (0.48% vs 0.67%, P < 0.05). On multivariate analysis, older persons (>65 years), early stage cancer, and those with lung or gastrointestinal cancers were less likely to be enrolled in cancer trials. Results were consistent when evaluated among only nonbreast cancer protocols. Though approaching significance, black, underinsured, and uninsured patients showed trends toward underenrollment. CONCLUSION: In addition to profoundly low overall cancer trial accrual, vast underrepresentation by age, cancer stage, and site continue to exist. The generalizability of these trials to a real world perspective remains an open question. Physicians, payers, the National Cancer Institute, and other stakeholders need to develop broader cancer trials to benefit the millions of patients with cancer in the United States.
AD  - Department of Surgery, University of Minnesota, Minneapolis, Minnesota 55455, USA. alref003@umn.edu
AN  - 21775882
AU  - Al-Refaie, W. B.
AU  - Vickers, S. M.
AU  - Zhong, W.
AU  - Parsons, H.
AU  - Rothenberger, D.
AU  - Habermann, E. B.
DA  - Sep
DO  - 10.1097/SLA.0b013e31822a7047
DP  - NLM
ET  - 2011/07/22
IS  - 3
KW  - African Americans/*statistics & numerical data
Age Distribution
Aged
California/epidemiology
Clinical Trials as Topic/*statistics & numerical data
Cohort Studies
European Continental Ancestry Group/*statistics & numerical data
Female
Health Services Accessibility
Humans
Male
Middle Aged
Multivariate Analysis
Neoplasm Staging
Neoplasms/*ethnology/pathology/therapy
Patient Selection
Poverty
Retrospective Studies
Risk Factors
LA  - eng
N1  - 1528-1140
Al-Refaie, Waddah B
Vickers, Selwyn M
Zhong, Wei
Parsons, Helen
Rothenberger, David
Habermann, Elizabeth B
RC2 MD004797/MD/NIMHD NIH HHS/United States
Journal Article
Research Support, Non-U.S. Gov't
United States
Ann Surg. 2011 Sep;254(3):438-42; discussion 442-3. doi: 10.1097/SLA.0b013e31822a7047.
PY  - 2011
SN  - 0003-4932
SP  - 438-42; discussion 442-3
ST  - Cancer trials versus the real world in the United States
T2  - Ann Surg
TI  - Cancer trials versus the real world in the United States
VL  - 254
ID  - 389
ER  - 

TY  - JOUR
AB  - Cancer is on the rise in Sub-Saharan Africa. In South Africa, where cancer detection, intervention, and care are available for many citizens, cancer is poorly detected and understood among politically and economically marginalized communities in rural and urban centers. These trends are reflected in a history of systematic marginalization of such contexts from public resources, including education and health care, stemming from racism and wealth inequity. This article investigates how Black South Africans residing in Soweto, a township of Johannesburg, perceive and experience breast and prostate cancers amidst multiple, concurrent medical conditions. We used convenience sampling to recruit 80 study participants already enrolled in longitudinal studies of breast and prostate cancers at a tertiary hospital in Soweto between June and August 2017. This included 50 women diagnosed with breast cancer and 30 men diagnosed with prostate cancer; three-quarters of the sample had two or more comorbidities, including HIV, hypertension, diabetes, anxiety, and others. Many described sickness in terms of any physical ill-health that affected daily routines, but rarely was it associated exclusively with a specific disease. Men and women described more fear associated with cancer than HIV or hypertension—two of the most common diseases. We found that this may be in part a reflection of how people feared and demonized their cancer diagnoses, calling it 'a demon!', and framing cancer through the trauma of aggressive treatments like chemotherapy ('the red devil!') and physical disfiguration from mastectomy. In contrast, men's prostate cancer treatments were often hormonal therapy and men associated cancer to a normal side effect of aging. Intervening in how people think about cancer may improve how people live well with the condition amidst other cascading social and health problems they face. (PsycINFO Database Record (c) 2019 APA, all rights reserved)
AD  - Mendenhall, Emily, Georgetown University, 513 Intercultural Center, 37th and O Street, NW, Washington, DE, US, 20057
AN  - 2019-53437-001
AU  - Mendenhall, Emily
AU  - Bosire, Edna N.
AU  - Kim, Andrew Wooyoung
AU  - Norris, Shane A.
DB  - psyh
DO  - 10.1016/j.socscimed.2019.112461
DP  - EBSCOhost
KW  - Breast cancer
Prostate cancer
Comorbidity
Chronicity
HIV
Chemotherapy
South Africa
Adult Attitudes
Breast Neoplasms
Client Attitudes
Prostate
Towns
Marginalization
N1  - School of Foreign Service, Georgetown University, Washington, DE, US. Release Date: 20191007. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: English. Grant Information: Mendenhall, Emily. Major Descriptor: Adult Attitudes; Breast Neoplasms; Chemotherapy; Comorbidity; HIV. Minor Descriptor: Client Attitudes; Prostate; Towns; Marginalization. Classification: Cancer (3293); Medical Treatment of Physical Illness (3363). Population: Human (10); Male (30); Female (40). Location: South Africa. Age Group: Adulthood (18 yrs & older) (300). Methodology: Empirical Study; Interview; Qualitative Study. ArtID: 112461. Issue Publication Date: Sep, 2019. Publication History: First Posted Date: Jul 30, 2019; Accepted Date: Jul 29, 2019; Revised Date: Jul 27, 2019; First Submitted Date: Apr 15, 2019. Copyright Statement: All rights reserved. Elsevier Ltd. 2019.
Sponsor: School of Foreign Service, US. Other Details: Summer Academic Grant. Recipients: Mendenhall, Emily
Sponsor: Georgetown University. Other Details: Provost's Pilot Research Project Grant. Recipients: Mendenhall, Emily
Sponsor: South African Medical Research Council, South Africa. Recipients: No recipient indicated
Sponsor: National Science Foundation. Other Details: Graduate Research Fellowship. Recipients: Kim, Andrew Wooyoung
Sponsor: National Institutes of Health, National Cancer Institute, US. Grant: 1R01CA192627. Other Details: 4 RAs. Recipients: No recipient indicated
Sponsor: University of the Witwatersrand, DST-NRF Centre of Excellence in Human Development, South Africa. Recipients: Norris, Shane A.
PY  - 2019
SN  - 0277-9536
1873-5347
ST  - Cancer, chemotherapy, and HIV: Living with cancer amidst comorbidity in a South African township
T2  - Social Science & Medicine
TI  - Cancer, chemotherapy, and HIV: Living with cancer amidst comorbidity in a South African township
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2019-53437-001&site=ehost-live&scope=site
ORCID: 0000-0002-5826-1321
em1061@georgetown.edu
VL  - 237
ID  - 1671
ER  - 

TY  - JOUR
AB  - Rationale: Lung cancer is the leading cause of cancer death in the United States. The two most effective interventions to decrease lung cancer mortality are smoking cessation and low dose computed tomography lung cancer screening (LCS). However, among the high‐risk, vulnerable patient population at our large safety‐net hospital, LCS remains underutilized. We sought to understand whether initiating shared decision‐making (SDM) for LCS during hospitalization could increase screening rates among high‐risk smokers. METHODS: We assessed hospitalized patients for LCS eligibility based on pack‐years of smoking, co‐morbidities, and prior imaging. We randomized screen‐eligible smokers (n=100) from November 2017 to October 2018 to receive either Inpatient SDM (SDM by nurse practitioner using a decision aid) or Enhanced Usual Care (furnishing of decision aid for patient to review on their own) during inpatient smoking cessation counseling visits. For Inpatient SDM, primary care providers were notified of the patient's decision regarding LCS and encouraged to place a referral for LCS. We assessed completion of LCS within 3 months post randomization (primary outcome). To explore barriers to the low rates of LCS completion, we conducted semi‐structured interviews with primary care providers (n=10) to learn about their perceptions of Inpatient SDM. RESULTS: Of 655 patients screened for eligibility, 88.7% (581/655) were eligible for LCS by smoking status (>30‐pack year) and age (55‐80 years). However, 38.6% (253/655) were ineligible due to recent diagnostic chest CT, the most common reason for exclusion (Figure 1). 100 patients were enrolled in the pilot RCT, characteristics of which were 62% male, 61% African‐American, and 70% Medicaid‐insured. Interim analysis of 78 patients for which primary outcome data is available shows that 97.4% (76/78) of enrolled inpatients desired LCS. Yet, less than 3% completed LCS by 3 months post‐discharge in either group [Inpatient SDM, 2.5% (1/40); Enhanced Usual Care, 2.6% (1/38)] (Figure 1). Qualitative interviews showed that while most primary care providers favorably viewed Inpatient SDM, competing priorities were barriers to following‐through with LCS referral. CONCLUSION: Our preliminary findings suggest that while hospitalization may be an opportunity to initiate tobacco dependence treatment and engage patients in SDM about LCS, innovative approaches that reduce provider barriers are needed to connect high‐risk smokers to post‐discharge preventative services. A second pilot study is underway in which patients randomized to Inpatient SDM will additionally receive community health worker navigation to facilitate access to LCS and tobacco dependence treatment.
AN  - CN-02073553
AU  - Spring, M.
AU  - Cobb, V.
AU  - Fitzgerald, C.
AU  - Wakeman, C.
AU  - Truong, V.
AU  - Steiling, K. A.
AU  - Lasser, K.
AU  - Wiener, R. S.
AU  - Kathuria, H.
IS  - 9
KW  - *cancer screening
*hospitalization
*lung cancer
*people by smoking status
*social status
Adult
African American
Aged
Cancer patient
Comorbidity
Conference abstract
Controlled study
Counseling
Female
Health auxiliary
Hospital patient
Human
Major clinical study
Male
Medicaid
Nurse practitioner
Outcome assessment
Patient referral
Perception
Pilot study
Primary medical care
Randomization
Randomized controlled trial
Semi structured interview
Shared decision making
Smoking cessation
Thorax
Tobacco dependence
M3  - Journal: Conference Abstract
PY  - 2019
ST  - Capitalizing on hospitalization to engage low socioeconomic status smokers in lung cancer screening
T2  - American journal of respiratory and critical care medicine
TI  - Capitalizing on hospitalization to engage low socioeconomic status smokers in lung cancer screening
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02073553/full
VL  - 199
ID  - 1558
ER  - 

TY  - JOUR
AB  - Background: Expressive writing has been shown to improve quality of life, fatigue, and posttraumatic stress among breast cancer patients across cultures. Understanding how and why the method may be beneficial to patients can increase awareness of the psychosocial impact of breast cancer and enhance interventional work within this population. Qualitative research on experiential aspects of interventions may inform the theoretical understanding and generate hypotheses for future studies. Aim: The aim of the study was to explore and describe the experience and feasibility of expressive writing among women with breast cancer following mastectomy and immediate or delayed reconstructive surgery. Methods: Seven participants enrolled to undertake 4 episodes of expressive writing at home, with semistructured interviews conducted afterward and analyzed using experiential thematic analysis. Results: Three themes emerged through analysis: writing as process, writing as therapeutic, and writing as a means to help others. Conclusions: Findings illuminate experiential variations in expressive writing and how storytelling encourages a release of cognitive and emotional strains, surrendering these to reside in the text. The method was said to process feelings and capture experiences tied to a new and overwhelming illness situation, as impressions became expressions through writing. Expressive writing, therefore, is a valuable tool for healthcare providers to introduce into the plan of care for patients with breast cancer and potentially other cancer patient groups. Implications for Practice: This study augments existing evidence to support the appropriateness of expressive writing as an intervention after a breast cancer diagnosis. Further studies should evaluate its feasibility at different time points in survivorship.
AD  - Department of Research, Stavanger University Hospital, Stavanger
Division of Nursing, University of Texas M. D. Anderson Cancer Center, Houston, Texas
Department of Breast and Endocrine Surgery, Stavanger University Hospital, Stavanger
Department of Clinical Science, University of Bergen, Bergen, Norway
Department of Plastic Surgery, University of Texas M. D. Anderson Cancer Center, Houston, Texas
AN  - 116222771. Language: English. Entry Date: 20160707. Revision Date: 20190212. Publication Type: Article
AU  - Haga Gripsrud, Birgitta
AU  - Brassil, Kelly J.
AU  - Summers, Barbara
AU  - Søiland, Havard
AU  - Kronowitz, Steven
AU  - Lode, Kirsten
DB  - CINAHL Complete
DO  - 10.1097/NCC.0000000000000300
DP  - EBSCOhost
IS  - 4
KW  - Breast Neoplasms -- Therapy
Cancer Patients -- Psychosocial Factors
Women -- Psychosocial Factors
Writing -- Utilization
Life Experiences
Human
Semi-Structured Interview
Thematic Analysis
Prospective Studies
Comparative Studies
Descriptive Research
United States
Audiorecording
Phenomenology
Storytelling
Adult
Aged
Middle Age
Female
White Persons
Black Persons
Asians
Funding Source
Experimental Studies
Emotions
Narratives
Stress Disorders, Post-Traumatic
Norway
N1  - research; tables/charts. Journal Subset: Core Nursing; Double Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Nursing; Peer Reviewed; USA. Grant Information: Funding for this research was partly provided by Folke Hermansen Cancer Research Foundation and Inge Steensland Foundation, Stavanger, Norway. This research was also partly supported by the National Institutes of Health through M. D. Anderson’s cancer center support grant CA016672.. NLM UID: 7805358.
PY  - 2016
SN  - 0162-220X
SP  - E51-E60
ST  - Capturing the Experience
T2  - Cancer Nursing
TI  - Capturing the Experience
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=116222771&site=ehost-live&scope=site
VL  - 39
ID  - 1875
ER  - 

TY  - JOUR
AB  - BACKGROUND: Clinical trial participation among racial and ethnic minorities remains low despite national efforts. We sought to determine how participation in clinical trials by breast surgical oncology patients has changed over time and what characteristics are associated with participation. METHODS: Women with breast cancer enrolled in National Cancer Institute-sponsored, cooperative-group trials from 2000 to 2012 and who underwent oncologic surgery (n = 17 125) were compared with trial-eligible women in the National Cancer Database diagnosed in 2000-2012 (n = 792 719). Race-specific trial participation was plotted over time by income and reported as a proportion of the combined cohorts. Factors associated with trial participation were estimated using logistic regression; we report odds ratios (ORs) with 95% confidence intervals (CIs). A P value less than  .05 was considered statistically significant for all analyses. All tests were two-sided. RESULTS: Participation declined across all groups over time because of a decrease in the scale and number of trials. In 2000-2003, Asian-Pacific Islander (7.17%), Hispanic (3.48%), and white (7.13%) patients from the highest income group had higher participation than their lower-income counterparts (Asian-Pacific Islander: 3.95%; Hispanic: 2.67%; white: 5.96%), but by 2008-2012, only high-income white patients participated more than lower-income whites (0.32% vs 0.25%, all P < .01). Black (OR = 0.80, 95% CI = 0.75 to 0.85) and Hispanic (OR = 0.84, 95% CI = 0.77 to 0.92) patients were less likely to participate than whites, but there were statistically significant interactions between income and race and ethnicity, with high-income black patients being approximately 50% less likely to participate than lower-income blacks (all P < .001). CONCLUSIONS: Multifaceted interventions addressing the intersectionality of race, ethnicity, and other patient characteristics are needed to address persistent disparities in trial participation among breast surgical oncology patients.
AD  - Department of Surgery, Duke University School of Medicine, Durham, NC, USA.
Women's Cancer Program, Duke Cancer Institute, Durham, NC, USA.
Department of Population Health Sciences, Duke University School of Medicine, Durham, NC, USA.
Duke Forge, Duke University, Durham, NC, USA.
Department of Surgery, Durham VA Medical Center, Durham, NC, USA.
Biostatistics Shared Resource, Duke Cancer Institute, Durham, NC, USA.
Department of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, NC, USA.
Department of Surgery, University of Illinois at Chicago, Chicago, IL, USA.
Department of Surgery, University of Illinois Cancer Center, Chicago, IL, USA.
AN  - 32211583
AU  - Fayanju, O. M.
AU  - Ren, Y.
AU  - Thomas, S. M.
AU  - Greenup, R. A.
AU  - Hyslop, T.
AU  - Hwang, E. S.
AU  - Stewart, J. H. th
C2  - PMC7083236
DA  - Apr
DO  - 10.1093/jncics/pkz103
DP  - NLM
ET  - 2020/03/27
IS  - 2
LA  - eng
N1  - 2515-5091
Fayanju, Oluwadamilola M
Orcid: 0000-0002-0876-975x
Ren, Yi
Thomas, Samantha M
Greenup, Rachel A
Hyslop, Terry
Hwang, E Shelley
Stewart, John H 4th
K08 CA241390/CA/NCI NIH HHS/United States
KL2 TR001115/TR/NCATS NIH HHS/United States
UL1 TR002553/TR/NCATS NIH HHS/United States
P30 CA014236/CA/NCI NIH HHS/United States
K12 HD043446/HD/NICHD NIH HHS/United States
Journal Article
JNCI Cancer Spectr. 2019 Dec 16;4(2):pkz103. doi: 10.1093/jncics/pkz103. eCollection 2020 Apr.
PY  - 2020
SN  - 2515-5091
SP  - pkz103
ST  - A Case-Control Study Examining Disparities in Clinical Trial Participation Among Breast Surgical Oncology Patients
T2  - JNCI Cancer Spectr
TI  - A Case-Control Study Examining Disparities in Clinical Trial Participation Among Breast Surgical Oncology Patients
VL  - 4
ID  - 45
ER  - 

TY  - JOUR
AB  - Menstrual characteristics may serve as surrogate measures of endogenous estrogen and may be related to breast cancer risk. No previous studies have systematically investigated menstrual factors in relation to the disease in African-American women. This case-control study is aimed to assess the relationship between menstrual factors and breast cancer in African-American women. Cases were 304 African-American women, aged 20-64 living in three Tennessee counties, diagnosed with breast cancer between 1995 and 1998, Controls were selected through random-digit dialing and frequency matched to cases (n=305). Phone interviews were conducted on menstrual factors-age at menarche, time to regularity, cycle length, flow length, age at menopause-and other risk factors. Logistic regression showed that compared to women with short cycle length (<28 days), women with average cycle length greater than or equal to28 had decreased risk of breast cancer (odds ratio (OR)=0.60, 95% confidence interval (CI), 0.38-0.94). Dose-response analyses showed decreasing risk with longer cycle length. Results by menopausal status revealed an inverse relationship was shown only in postmenopausal women. No significant associations were observed for other menstrual factors. Findings suggest that cycle length has an inverse association with breast cancer in African-American women that may primarily exist for post-menopausal tumors.
AN  - WOS:000222548800001
AU  - Beiler, J. S. B.
AU  - Zhu, K. M.
AU  - Hunter, S.
AU  - Payne-Wilks, K.
AU  - Roland, C. L.
AU  - Chinchilli, V. M.
DA  - Oct
IS  - 10
N1  - 11
14620704
PY  - 2003
SN  - 0027-9684
SP  - 930-938
ST  - A case-control study of menstrual factors in relation to breast cancer risk in African-American women
T2  - Journal of the National Medical Association
TI  - A case-control study of menstrual factors in relation to breast cancer risk in African-American women
VL  - 95
ID  - 2692
ER  - 

TY  - JOUR
AB  - BACKGROUND: Accurate identification of lymph nodes localized around inferior mesenteric artery (IMA), with or without metastasis, is of crucial importance for surgeons when dissecting D2 or D3 lymph nodes in patients with rectal cancer (RC). The following study evaluates whether carbon nanoparticles can be used for detection of decision-making lymph nodes (DLNs) in station 253 lymph nodes found around IMA during RC surgery. METHODS: A total of 66 patients with rectal adenocarcinomas were recruited between January 2014 and August 2017. Patients were divided into carbon nanoparticle (CN) group and control (CL) group; for the CN group, 1 ml nanoparticles were endoscopically injected into submucosal layer of primary tumor 1 day before surgery. DLNs were defined as black-dyed nodes in CN group or macroscopic lymph nodes in CL group localized along the IMA, proximal to the origin of the left colic artery. D3 lymph nodes were dissected using laparoscopic radical resection, and then examined using pathological approach. Intra-operative and post-operative data were compared between the two groups. RESULTS: In CN group, black-dyed DLNs were easily found under laparoscopy; the median number of DLNs was 3 (range 1-9). In CL group, the median number of DLNs was 0 (range 0-3). Consistency between intra-operative DLNs and post-operative station 253 nodes were confirmed by pathological examination. Significant higher number of DLNs in station 253 nodes (2.91 ± 2.47 vs 0.58 ± 0.75, p < 0.001), number of station 251 nodes (12.85 ± 8.99 vs 8.09 ± 5.85, p = 0.014), number of station 253 nodes (5.21 ± 5.26 vs 3.15 ± 2.32, p = 0.045), and the number of total lymph nodes (24.06 ± 13.20 vs 16.21 ± 9.09, p = 0.007) were found in the CN group compared to CL group. CONCLUSIONS: Carbon nanoparticles are useful for identifying DLNs in station 253 LNs around IMA in RC. It is not necessary to perform D3 lymph node dissection if there are no intra-operative DLNs metastases in RC.
AD  - Department of General Surgery, Nanfang Hospital, Southern Medical University, 1838 North Guangzhou Avenue, Guangzhou, 510-515, People's Republic of China.
Department of General Surgery, Nanfang Hospital, Southern Medical University, 1838 North Guangzhou Avenue, Guangzhou, 510-515, People's Republic of China. yanjunfudan@163.com.
AN  - 30116952
AU  - Li, K.
AU  - Chen, D.
AU  - Chen, W.
AU  - Liu, Z.
AU  - Jiang, W.
AU  - Liu, X.
AU  - Cui, Z.
AU  - Wei, Z.
AU  - Li, Z.
AU  - Yan, J.
DA  - Mar
DO  - 10.1007/s00464-018-6384-9
DP  - NLM
ET  - 2018/08/18
IS  - 3
KW  - *Adenocarcinoma/pathology/surgery
Adult
Carbon/*pharmacology
Case-Control Studies
Coloring Agents/*pharmacology
Female
Humans
Laparoscopy/*methods
Lymph Node Excision/methods
*Lymph Nodes/diagnostic imaging/surgery
Male
Mesenteric Artery, Inferior
Middle Aged
Nanoparticles/*therapeutic use
Neoplasm Staging
Outcome Assessment, Health Care
*Rectal Neoplasms/pathology/surgery
*Carbon nanoparticles
*Inferior mesenteric artery
*Lymph node dissection
*Rectal cancer
*Station 253 nodes
LA  - eng
N1  - 1432-2218
Li, Kai
Chen, Dexin
Chen, Weisheng
Liu, Zhangyuanzhu
Jiang, Wei
Liu, Xiumin
Cui, Ziming
Wei, Zhiyao
Li, Zhiming
Yan, Jun
Orcid: 0000-0002-9190-6777
Journal Article
Research Support, Non-U.S. Gov't
Germany
Surg Endosc. 2019 Mar;33(3):904-910. doi: 10.1007/s00464-018-6384-9. Epub 2018 Aug 16.
PY  - 2019
SN  - 0930-2794
SP  - 904-910
ST  - A case-control study of using carbon nanoparticles to trace decision-making lymph nodes around inferior mesenteric artery in rectal cancer
T2  - Surg Endosc
TI  - A case-control study of using carbon nanoparticles to trace decision-making lymph nodes around inferior mesenteric artery in rectal cancer
VL  - 33
ID  - 109
ER  - 

TY  - JOUR
AB  - Engaging family members in an intervention to prevent breast and cervical cancer can be a way to reach underserved women; however, little is known about whether family member recruitment reaches at-risk women. This study reports the kin relationship and risk characteristics of family members who chose to participate in the Kin Keeper(SM) cancer prevention intervention, delivered by community health workers (CHWs) via existing community programs. African American, Latina, and Arab family members reported risk factors for inadequate screening, including comorbid health conditions and inadequate breast or cervical cancer literacy. CHW programs can be leveraged to reach underserved families with cancer preventive interventions.
AD  - Michigan State University, East Lansing, Michigan.
University of Maryland, College Park, Maryland.
Nursing Distinguished Professor of Women's Health, College of Nursing, The Ohio State University, 362 Newton Hall, 1585 Neil Ave, Columbus, OH 43210. Email: Williams.5963@osu.edu.
AN  - 27634780
AU  - Roman, L. A.
AU  - Zambrana, R. E.
AU  - Ford, S.
AU  - Meghea, C.
AU  - Williams, K. P.
C2  - PMC5027846
DA  - Sep 15
DO  - 10.5888/pcd13.160114
DP  - NLM
ET  - 2016/09/17
KW  - Adult
Breast Neoplasms/diagnosis/prevention & control
Community Health Workers/*education
Early Detection of Cancer
Ethnic Groups/*statistics & numerical data
*Family
Female
*Health Knowledge, Attitudes, Practice
Humans
Mass Screening
Michigan
Middle Aged
Neoplasms/diagnosis/*prevention & control
Patient Acceptance of Health Care
Uterine Cervical Neoplasms/diagnosis/prevention & control
LA  - eng
N1  - 1545-1151
Roman, Lee Anne
Zambrana, Ruth Enid
Ford, Sabrina
Meghea, Cristian
Williams, Karen Patricia
R01 NR011323/NR/NINR NIH HHS/United States
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Prev Chronic Dis. 2016 Sep 15;13:E130. doi: 10.5888/pcd13.160114.
PY  - 2016
SN  - 1545-1151
SP  - E130
ST  - Casting a Wider Net: Engaging Community Health Worker Clients and Their Families in Cancer Prevention
T2  - Prev Chronic Dis
TI  - Casting a Wider Net: Engaging Community Health Worker Clients and Their Families in Cancer Prevention
VL  - 13
ID  - 204
ER  - 

TY  - JOUR
AD  - Department of Epidemiology, School of Public Health West Virginia University; Cardiorespiratory Center, West Virginia University
Department of Medicine, Division of Endocrinology, Vanderbilt University
Department of Health Promotion and Development, School of Nursing University of Pittsburgh
International Epidemiology Institute
International Epidemiology Institute; Department of Medicine, Division of Epidemiology, Vanderbilt University
AN  - 103925960. Language: English. Entry Date: 20141216. Revision Date: 20200708. Publication Type: Journal Article
AU  - Conway, B. N.
AU  - May, M. E.
AU  - Fischl, A.
AU  - Frisbee, J.
AU  - Han, X.
AU  - Blot, W. J.
DB  - CINAHL Complete
DO  - 10.1111/dme.12563
DP  - EBSCOhost
IS  - 1
KW  - Income -- Evaluation
Diabetes Mellitus, Type 2 -- Mortality
Race Factors
Ethnic Groups
Black Persons
White Persons
Socioeconomic Factors
After Care
United States
Middle Age
Poverty
Research Subject Recruitment
Prospective Studies
Ambulatory Care Facilities
Geographic Locations
Data Analysis
Human
Cox Proportional Hazards Model
Confidence Intervals
Mortality
Diabetes Mellitus, Type 2 -- Physiopathology
Male
Female
Disease Duration
Body Mass Index -- Evaluation
Insulin -- Administration and Dosage
Hypoglycemic Agents -- Administration and Dosage
Administration, Oral
Lipids -- Analysis
Comorbidity
Heart Diseases -- Mortality
Lung Diseases -- Mortality
Kidney Failure, Chronic
Neoplasms
Sepsis
N1  - research; tables/charts. Journal Subset: Biomedical; Europe; Peer Reviewed; UK & Ireland. NLM UID: 8500858.
PMID: NLM25112863.
PY  - 2015
SN  - 0742-3071
SP  - 33-41
ST  - Cause-specific mortality by race in low-income Black and White people with Type 2 diabetes
T2  - Diabetic Medicine
TI  - Cause-specific mortality by race in low-income Black and White people with Type 2 diabetes
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=103925960&site=ehost-live&scope=site
VL  - 32
ID  - 1877
ER  - 

TY  - JOUR
AB  - BACKGROUND: Although strong scientific evidence has shown that screening for colorectal cancer saves lives, most U.S. adults who are at the recommended age are not being screened. Prior studies suggest that barriers to routine screening vary by race, ethnicity, socioeconomic status, urban/rural residence, health insurance status, and factors related to health care providers and the health care environment. Relatively few studies, however, have identified and tested intervention approaches to promote routine colorectal cancer screening among diverse populations. METHODS: The Division of Cancer Prevention and Control at CDC has funded ongoing projects to develop and test interventions to promote routine colorectal cancer screening among medically underserved populations in Appalachia, the Lower Rio Grande Valley in Texas, the High Plains region of Colorado, and other U.S. communities. RESULTS: This article provides an overview of colorectal cancer screening intervention studies currently funded by CDC that focus on a wide range of populations, including medically underserved persons who live in predominately rural areas, Hispanic and non-Hispanic persons, urban African Americans, persons with low health literacy, and persons enrolled in managed care organizations. CONCLUSIONS: These CDC-funded intervention research projects are likely to contribute importantly to evidence about what works to promote colorectal cancer screening in diverse U.S. communities. .
AD  - Division of Cancer Prevention and Control, Centers for Disease Control and Prevention, Atlanta, Georgia 30341, USA. sic9@cdc.gov
AN  - 16802326
AU  - Coughlin, S. S.
AU  - Costanza, M. E.
AU  - Fernandez, M. E.
AU  - Glanz, K.
AU  - Lee, J. W.
AU  - Smith, S. A.
AU  - Stroud, L.
AU  - Tessaro, I.
AU  - Westfall, J. M.
AU  - Weissfeld, J. L.
AU  - Blumenthal, D. S.
DA  - Sep 1
DO  - 10.1002/cncr.22017
DP  - NLM
ET  - 2006/06/28
IS  - 5 Suppl
KW  - African Americans
Aged
Appalachian Region
*Centers for Disease Control and Prevention, U.S.
Clinical Trials as Topic
Colorado
Colorectal Neoplasms/*prevention & control
*Community Health Services
Female
Florida
Georgia
*Government Programs
Humans
Male
Mass Screening/statistics & numerical data
Massachusetts
Michigan
Middle Aged
New Mexico
Texas
United States
LA  - eng
N1  - Coughlin, Steven S
Costanza, Mary E
Fernandez, Maria E
Glanz, Karen
Lee, Judith W
Smith, Selina A
Stroud, Leonardo
Tessaro, Irene
Westfall, John M
Weissfeld, Joel L
Blumenthal, Daniel S
U54 CA118638/CA/NCI NIH HHS/United States
Journal Article
United States
Cancer. 2006 Sep 1;107(5 Suppl):1196-204. doi: 10.1002/cncr.22017.
PY  - 2006
SN  - 0008-543X (Print)
0008-543x
SP  - 1196-204
ST  - CDC-funded intervention research aimed at promoting colorectal cancer screening in communities
T2  - Cancer
TI  - CDC-funded intervention research aimed at promoting colorectal cancer screening in communities
VL  - 107
ID  - 561
ER  - 

TY  - JOUR
AB  - We describe the use of an online patient portal to recruit and enroll primary care patients in a randomized trial testing the effectiveness of a colorectal cancer (CRC) screening decision support program. We use multiple logistic regression to identify patient characteristics associated with trial recruitment, enrollment, and engagement. We found that compared to Whites, Blacks had lower odds of viewing the portal message (OR = 0.46, 95% CI = 0.37-0.57), opening the attached link containing the study material (OR = 0.75, 95% CI = 0.62-0.92), and consenting to participate in the trial (OR = 0.85, 95% CI = 0.67-0.93). We also found that compared to Whites, Asians had lower odds of viewing the portal message (OR = 0.53, 95% CI = 0.33-0.64), opening the attached link containing the study material (OR = 0.76, 95% CI = 0.54-0.97), consenting to participate in the trial (OR = 0.68, 95% CI = 0.53-0.95), and completing the trial's baseline questionnaire (OR = 0.59, 95% CI = 0.36-0.90). While portals offer an opportunity to mitigate human bias in trial invitations, because of racial disparities-not only in who has a portal account, but in how they interact with trial recruitment and enrollment material within the portal-using portals alone for trial recruitment may generate study samples that are not racially diverse.
AD  - Division of Pharmaceutical Outcomes and Policy, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Department of Biostatistics, Virginia Commonwealth University, Richmond, Virginia, USA.
Department of Health Behavior & Health Education, School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.
Department of Epidemiology and Biostatistics, College of Public Health and Fox Chase Cancer Center, Temple University, Philadelphia, Pennsylvania, USA.
Department of Family Medicine, Oregon Health Sciences University, Portland, Oregon, USA.
School of Social Work, Michigan State University, East Lansing, Michigan, USA.
Department of Medicine, Center for Health Communications Research, University of Michigan and Ann Arbor VA Center for Clinical Management Research, Ann Arbor, Michigan, USA.
Henry Ford Health System, Detroit, Michigan, USA.
UNC Lineberger Comprehensive Cancer Center, Division of Pharmaceutical Outcomes and Policy, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
AN  - 31532482
AU  - Tabriz, A. A.
AU  - Fleming, P. J.
AU  - Shin, Y.
AU  - Resnicow, K.
AU  - Jones, R. M.
AU  - Flocke, S. A.
AU  - Shires, D. A.
AU  - Hawley, S. T.
AU  - Willens, D.
AU  - Lafata, J. E.
C2  - PMC6857600
DA  - Dec 1
DO  - 10.1093/jamia/ocz157
DP  - NLM
ET  - 2019/09/19
IS  - 12
KW  - Aged
Colorectal Neoplasms/*diagnosis/ethnology
Continental Population Groups/statistics & numerical data
*Early Detection of Cancer
Electronic Health Records/statistics & numerical data
Female
Health Status Disparities
Humans
Logistic Models
Male
Middle Aged
Patient Acceptance of Health Care/ethnology
*Patient Portals/statistics & numerical data
*Patient Selection
Pragmatic Clinical Trials as Topic
Primary Health Care
Selection Bias
Surveys and Questionnaires
*colorectal cancer screening
*electronic health record
*health disparities
*patient portal
*pragmatic clinical trial
LA  - eng
N1  - 1527-974x
Tabriz, Amir Alishahi
Fleming, Patrice Jordan
Shin, Yongyun
Resnicow, Ken
Jones, Resa M
Flocke, Susan A
Shires, Deirdre A
Hawley, Sarah T
Willens, David
Lafata, Jennifer Elston
R01 CA197205/CA/NCI NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.
J Am Med Inform Assoc. 2019 Dec 1;26(12):1637-1644. doi: 10.1093/jamia/ocz157.
PY  - 2019
SN  - 1067-5027 (Print)
1067-5027
SP  - 1637-1644
ST  - Challenges and opportunities using online portals to recruit diverse patients to behavioral trials
T2  - J Am Med Inform Assoc
TI  - Challenges and opportunities using online portals to recruit diverse patients to behavioral trials
VL  - 26
ID  - 62
ER  - 

TY  - JOUR
AB  - Background: Enrollment of early‐stage lung cancer patients to randomized trials has historically been challenging. The STARS Trial enrolled 36 of 1,030 intended patients from 28 sites, while the ROSEL Trial recruited 22 of 960 intended patients from 10 sites. Unfortunately, evidence shows African Americans with early‐stage NSCLC are significantly less likely than their European American counterparts to undergo resection and may also be less likely to participate in lung cancer trials as well. Purpose: The purpose of this research is to describe interim recruitment results from an NIMHD‐funded, NCI NCORP‐based patient navigation trial conducted with African Americans with early‐stage, probable/proven nonsmall cell lung cancer (NSCLC). Design: The protocol‐driven, barriers‐focused patient navigation intervention is being conducted in the context of a two‐arm cluster‐randomized trial testing the effectiveness of the intervention in increasing rates of lung‐directed curative‐intent therapy (surgery and SBRT) in African Americans with Stage I‐II NSCLC. The 2 study arms consist of the protocol‐driven, intensive navigation intervention vs. usual care. The trial includes 20 study sites in 11 US states.Specific activities to enhance recruitment in the present trial include reaching out to referring physicians (e.g.,primary care, pulmonologists, radiologists) to increase referrals of African American patients to the participatingNCORP sites, and partnering with the leaders of community engagement activities at the sites to raise community‐level awareness of the trial.Results/Conclusions: To date, 200 African American patients have been recruited and the trial is now on target tomeet its expected accrual goal of 222 patients. The majority of potential participants were ineligible due to receipt ofsurgical resection or radiation therapy prior to enrollment (24%), not having been told that they had probable/provenNSCLC prior to study contact (22%), or a previous history of lung cancer (10%). The median age of the 200participants is 65 years (range 40‐86 years). Most are unmarried (70%) and have a high school diploma or less(71%). The number of enrolled‐to‐date African American participants in this ongoing trial exceeds the total numberof participants recruited to the STARS Trial or to the ROSEL Trial .
AN  - CN-02204151
AU  - Ford, M. E.
AU  - Bryant, D. C.
AU  - Cartmell, K. B.
AU  - Sterba, K.
AU  - Burshell, D. R.
AU  - Hill, E. G.
AU  - Kim, J.
AU  - De Toma, A.
AU  - Knight, K. D.
AU  - Reed, T.
AU  - et al.
DO  - 10.1158/1538-7755.DISP18-A085
IS  - 6 SUPPL 1
KW  - *African American
*cancer staging
*non small cell lung cancer
Adult
Aged
Awareness
Cancer patient
Cancer radiotherapy
Cancer surgery
Conference abstract
Controlled study
Female
High school
Human
Leadership
Major clinical study
Male
Primary medical care
Pulmonologist
Radiologist
Radiotherapy
Randomized controlled trial
Single (marital status)
Stereotactic body radiation therapy
M3  - Journal: Conference Abstract
PY  - 2020
ST  - Challenges and successes in recruiting African Americans with early-stage, non-small cell lung cancer to an NIMHD-funded, NCORP-based patient navigation trial
T2  - Cancer epidemiology biomarkers and prevention
TI  - Challenges and successes in recruiting African Americans with early-stage, non-small cell lung cancer to an NIMHD-funded, NCORP-based patient navigation trial
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02204151/full
VL  - 29
ID  - 1396
ER  - 

TY  - JOUR
AB  - BACKGROUND: African-American women, especially in the southern United States, are underrepresented in cancer genetics research. A study was designed to address this issue by investigating the germline mutation rate in African-American women in Arkansas with a personal and/or family history of breast cancer. Women were tested for these mutations using a large panel of breast cancer susceptibility genes. In this analysis, we discuss the challenges encountered in recruiting African-American women from an existing biorepository to participate in this study. METHODS: We attempted to contact 965 African-American women with a personal and/or family history of breast cancer who participated in Spit for the Cure (SFTC) between 2007 and 2013 and provided consent to be recontacted. The SFTC participants were invited by telephone and email to participate in the genetic study. Enrollment required completion of a phone interview to obtain a family and medical history and return of a signed consent form. RESULTS: Among eligible SFTC participants, 39.6% (382/965) were able to be contacted with the phone numbers and email addresses they provided. Of these, 174 (45.5%) completed a phone interview and returned a signed consent form. Others were not able to be contacted (n = 583), declined to participate (n = 57), did not keep phone interview appointments (n = 82), completed the phone interview but never returned a signed consent (n = 54), were deceased (n = 13), or were too confused to consent to participate (n = 2). CONCLUSIONS: Recruiting African-American women into our breast cancer genetics study proved challenging primarily due to difficulty establishing contact with potential participants. Given their prior participation in breast cancer research, we anticipated that this would be a highly motivated population. Indeed, when we were able to contact SFTC participants, only 14.9% declined to participate in our study. Innovative communication, retention, and recruitment strategies are needed in future studies to address the recruitment challenges we faced.
AD  - 1Division of Gynecologic Oncology, College of Medicine, University of Arkansas for Medical Sciences, 4301 W Markham St. Slot 793, Little Rock, AR 72205 USA. ISNI: 0000 0004 4687 1637. GRID: grid.241054.6
2Division of Medical Genetics, College of Medicine, University of Arkansas for Medical Sciences, 4301 W Markham St., Little Rock, AR 72205 USA. ISNI: 0000 0004 4687 1637. GRID: grid.241054.6
AN  - 29760829
AU  - Compadre, A. J.
AU  - Simonson, M. E.
AU  - Gray, K.
AU  - Runnells, G.
AU  - Kadlubar, S.
AU  - Zorn, K. K.
C2  - PMC5937804
DO  - 10.1186/s13053-018-0091-3
DP  - NLM
ET  - 2018/05/16
KW  - African American
Biorepository
Hereditary breast cancer
Subject recruitment
of Arkansas for Medical Sciences.The authors declare that they have no competing
interests.Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
LA  - eng
N1  - 1897-4287
Compadre, Amanda J
Simonson, Melinda E
Gray, Katy
Runnells, Gail
Kadlubar, Susan
Zorn, Kristin K
Journal Article
Hered Cancer Clin Pract. 2018 Apr 24;16:8. doi: 10.1186/s13053-018-0091-3. eCollection 2018.
PY  - 2018
SN  - 1731-2302 (Print)
1731-2302
SP  - 8
ST  - Challenges in recruiting African-American women for a breast cancer genetics study
T2  - Hered Cancer Clin Pract
TI  - Challenges in recruiting African-American women for a breast cancer genetics study
VL  - 16
ID  - 120
ER  - 

TY  - JOUR
AB  - Older adults are underrepresented in medical research for many reasons, including recruitment difficulties. Recruitment of older adults for research studies is often a time-consuming process and can be more challenging when the study involves older adults with unique exposures to traumatic events and from minority groups. The current article provides a brief overview of (a) challenges encountered while recruiting aging women Holocaust survivors for a case control study and (b) strategies used for meeting those challenges. The case group comprised women Holocaust survivors who were recently diagnosed with breast cancer and the control group comprised healthy women from a Holocaust-survivor community in Israel.
AN  - WOS:000368667200002
AU  - Vin-Raviv, N.
AU  - Dekel, R.
AU  - Barchana, M.
AU  - Linn, S.
AU  - Keinan-Boker, L.
DA  - Nov-Dec
DO  - 10.3928/19404921-20150522-07
IS  - 6
N1  - 26020580
PY  - 2015
SN  - 1940-4921
SP  - 265-272
ST  - Challenges in Recruiting Aging Women Holocaust Survivors to a Case Control Study of Breast Cancer
T2  - Research in Gerontological Nursing
TI  - Challenges in Recruiting Aging Women Holocaust Survivors to a Case Control Study of Breast Cancer
VL  - 8
ID  - 2964
ER  - 

TY  - JOUR
AB  - In this paper, challenges to recruiting African Americans specifically for a dietary feeding trial are examined, learning experiences gained and suggestions to overcome these challenges in future trials are discussed. A total of 333 individuals were randomized in the trial and 234 (167 sibling pairs and 67 parents/siblings) completed the dietary intervention and required DNA blood sampling for genetic analysis. The trial used multiple strategies for recruitment. Hand distributed letters and flyers through mass distribution at various churches resulted in the largest number (n = 153, 46%) of African Americans in the trial. Word of mouth accounted for the second largest number (n = 120, 36%) and included prior study participants. These two recruitment sources represented 82% (n = 273) of the total number of individuals randomized in GET READI. The remaining 18% (n = 60) consisted of a combination of sources including printed message on check stubs, newspaper articles, radio and TV appearances, screening events and presentations. Though challenging, the recruitment efforts for GET READI produced a significant number of African American participants despite the inability to complete the trial as planned because of low recruitment yields. Nevertheless, the recruitment process produced substantial numbers that successfully completed all study requirements.
AN  - WOS:000294809700014
AU  - Kennedy, B. M.
AU  - Harsha, D. W.
AU  - Bookman, E. B.
AU  - Hill, Y. R.
AU  - Rankinen, T.
AU  - Rodarte, R. Q.
AU  - Murla, C. D.
DA  - Oct
DO  - 10.1093/her/cyr061
IS  - 5
N1  - 21865154
PY  - 2011
SN  - 0268-1153
SP  - 923-936
ST  - Challenges to recruitment and retention of African Americans in the gene-environment trial of response to dietary interventions (GET READI) for heart health
T2  - Health Education Research
TI  - Challenges to recruitment and retention of African Americans in the gene-environment trial of response to dietary interventions (GET READI) for heart health
VL  - 26
ID  - 3083
ER  - 

TY  - JOUR
AB  - We assessed the efficacy of a pilot questionnaire designed to elicit information about external risk factors for breast cancer in sub-Saharan African women. Preliminary analysis identified areas of the questionnaire and interviewing process that required modification, as well as socioeconomic factors that contribute to reduced participation among these understudied populations.
AD  - Vanderbilt Epidemiology Center Institute for Medicine and Public Health
AN  - 105120556. Language: English. Entry Date: 20100416. Revision Date: 20200708. Publication Type: Journal Article
AU  - Deming, S. L.
AU  - Egbuji, A.
AU  - Smith, J.
AU  - Gociu, A.
AU  - Young, J.
AU  - Carter, C., Jr.
AU  - Barnes, F.
AU  - Oduma, J.
AU  - Kimende, K.
AU  - Onayade, A.
AU  - Durosinmi, M.
AU  - Lawal, O. O.
AU  - Adegoke, O. J.
AU  - Marshall, D. R.
DB  - CINAHL Complete
DO  - 10.1353/hpu.0.0274
DP  - EBSCOhost
IS  - 1
KW  - Breast Neoplasms -- Risk Factors
Questionnaires
Adult
Black Persons
Case Control Studies
Female
Human
Instrument Construction
Interviews
Kenya
Life Style
Middle Age
Nigeria
Pilot Studies
Research Methodology
Research Subject Retention
Socioeconomic Factors
N1  - research; tables/charts. Supplement Title: 2010 Supplement. Journal Subset: Health Services Administration; Peer Reviewed; Public Health; USA. NLM UID: 9103800.
PMID: NLM20173281.
PY  - 2010
SN  - 1049-2089
SP  - 11-16
ST  - Challenges unique to the design of a comprehensive questionnaire assessing breast cancer risk factors among women in sub-Saharan Africa
T2  - Journal of Health Care for the Poor & Underserved
TI  - Challenges unique to the design of a comprehensive questionnaire assessing breast cancer risk factors among women in sub-Saharan Africa
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105120556&site=ehost-live&scope=site
VL  - 21
ID  - 1879
ER  - 

TY  - JOUR
AB  - Background: Blacks, Latinas, Native Americans, Asians have poorer breast cancer (BC) outcomes and higher mortality rates compared to Northern‐European Whites (NE/W) or non‐Hispanic Whites (NHW). Participation in clinical trials (CTs) could improve these health disparities; however, the majority of CTs disproportionately enroll NE/W or NHW (e.g. over 96% of women enrolled in the BC Prevention Trial (P1) and STAR trial were of NE/W descent). Here we describe a successful recruitment strategy for inclusion of women of diverse races/ethnicities to a BC trial. METHODS: Focus groups emphasized the community's role in the process of mentoring future medical providers. Thus, we recruited 4 bicultural, bilingual clinical research assistants (CRAs) representing the diversity of our Los Angeles catchment area. At City of Hope (CoH), Our CRAs along with 5 breast surgeons, screened and consented all eligible patients. RESULTS: The CRAs were 1) first generation American representing diverse races/ethnicities, 2) raised and attended college in Southern California, and 3) pre‐med/nursing. The CoH clinic population is 48% NHW, 23% Latina, 12% Asians/Pacific Islanders (A/P), 7% Black, and 0.1% Native American (NA). A total of 1,129 patients were screened: 139 women were eligible, 119 consented and 20 declined. Of the consenting population, 31% were NHW, 43% Latina, 16% A/P, 8% Black, and 2% NA. Primary languages included 86% English, 9% Spanish, 4% Chinese, and 1% Armenian. Of the consenting NHW, 92% descended from Northern Europe, while 8% were from the Middle East/North Africa. Recruitment exceeded CoH interventional CT accrual of 55% NHW, 21% Latina, 10% A/P, 4% Black, and 0.1% NA. CONCLUSION: We have demonstrated that Black, Latina, NA and A/P women are equally as likely to participate in CTs when approached by a culturally competent CRA. Our ability to recruit diverse populations to CTs lies in the 1) simplistic act of approaching all those eligible, 2) racial diversity and cultural competency of our CRAs and 3) willingness of women representing diverse races/ethnicities to participate in CTs.
AN  - CN-01469655
AU  - Kruper, L.
AU  - Chavez, T.
AU  - Jones, V.
AU  - Vito, C.
AU  - Clancy, S.
AU  - Polverini, A.
AU  - Thai, C.
AU  - Sanchez, A.
AU  - Robles, M.
AU  - Chavez, N.
AU  - et al.
DO  - 10.1245/s10434-018-6349-1
IS  - 1 Supplement 1
KW  - *ethnicity
*race
Adult
American Indian
Asian
Breast cancer
California
Cancer surgery
Catchment
Clinical research
College
Conference abstract
Controlled clinical trial
Controlled study
Cultural competence
Europe
Female
Human
Information processing
Language
Major clinical study
Mentoring
Middle East
North Africa
Nursing
Pacific Islander
Surgeon
M3  - Conference Abstract
PY  - 2018
SP  - S43
ST  - Challenging the homogeneity of clinical trials to include women of diverse races/ethnicities
T2  - Annals of surgical oncology. Conference: 71st annual cancer symposium of the society of surgical oncology, SSO 2018. United states
TI  - Challenging the homogeneity of clinical trials to include women of diverse races/ethnicities
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01469655/full
VL  - 25
ID  - 1458
ER  - 

TY  - JOUR
AB  - The U.S. Preventive Services Task Force (USPSTF) recommended screening mammography every 1-2 years for women 40 years and older in 2002, and changed its recommendations in 2009 to no routine screening for women between 40 and 49 years of age; and biennial screening for women between 50 and 74 years of age. This study evaluates the change in mammographic use after the issuance of the revised recommendations. Women who participated in a cross-sectional study of breast cancer risk factors from 2007 to 2013 were asked if they had received a mammogram in the preceding 2 years. All 3442 study participants who enrolled in the study after January 1, 2011 were matched by race, age, and educational level with women enrolled between 2007 and 2010. The proportions of women who stated they had received a mammogram in the past 2 years were compared between the two groups. One fourth of the participants were African American and 39% were 40-49 years of age. Among white women, significant decreases in recent mammogram use from 2007-2010 to 2011-2013 were detected for women 40-49 years of age ( -10.3%, p < 0.001) and 50-74 years of age (-8.8%, p < 0.001). Among African-American women, the change in recent mammogram use was not statistically significant for women 40-49 years of age (-2.7%, p = 0.440) or 50-74 years of age (-2.2%, p = 0.398). Following the change in the USPSTF guidelines, mammography use among white women declined; however, no change was observed among African-American women.
AN  - WOS:000397960300007
AU  - Lee, J. Y.
AU  - Malak, S. F.
AU  - Klimberg, V. S.
AU  - Henry-Tillman, R.
AU  - Kadlubar, S.
DA  - Mar-Apr
DO  - 10.1111/tbj.12703
IS  - 2
N1  - 27797121
PY  - 2017
SN  - 1075-122X
SP  - 164-168
ST  - Change in Mammography Use Following the Revised Guidelines from the US Preventive Services Task Force
T2  - Breast Journal
TI  - Change in Mammography Use Following the Revised Guidelines from the US Preventive Services Task Force
VL  - 23
ID  - 2906
ER  - 

TY  - JOUR
AB  - OBJECTIVE: This secondary data analysis was conducted to evaluate the applicability of the Risk Reappraisal Hypothesis, which has been proposed to explain the influence of performing a health behavior on perceived risk. Data were collected in the context of a randomized trial, which found that an individually tailored, multicomponent intervention was successful in increasing colorectal cancer (CRC) screening among first-degree relatives of CRC cases. METHOD: The ethnically diverse study sample (N = 841; 29% Latino, 21% African American, 20% Asian) consisted of adult siblings and children (40-80 years) of CRC cases, identified through the California Cancer Registry. Data were collected at baseline and at 6- and 12-month follow-up. Changes in self-reported risk perception (perceived likelihood of developing CRC) were examined over the study period in relation to study condition and screening status. RESULTS: Greater increases in perceived risk were observed among intervention versus control-group participants over the study period, but increases were limited to intervention participants who had not been screened. We also examined trajectories of perceived risk in relation to timing of screening receipt (e.g., before 6 months, 6-12 months, never). Continued upward shifts in risk were observed during the study period among intervention participants not screened during the study. In contrast, participants screened by 6 months displayed a reduction or leveling off in perceived risk between 6- and 12-month follow-up. CONCLUSION: Results provide support for the applicability of the Risk Reappraisal Hypothesis within a high-risk sample enrolled in a CRC screening promotion trial. Future research is needed to explore the impact of short-term risk reductions on future CRC screening behavior.
AD  - Division of Cancer Prevention & Control Research, School of Public Health & Jonsson Comprehensive Cancer Center, University of California, Los Angeles, CA 90095-6900, USA. bglenn@ucla.edu
AN  - 21744967
AU  - Glenn, B. A.
AU  - Herrmann, A. K.
AU  - Crespi, C. M.
AU  - Mojica, C. M.
AU  - Chang, L. C.
AU  - Maxwell, A. E.
AU  - Bastani, R.
C2  - PMC3201806
C6  - NIHMS325163
DA  - Jul
DO  - 10.1037/a0024288
DP  - NLM
ET  - 2011/07/13
IS  - 4
KW  - Adult
Adult Children/psychology
Aged
Aged, 80 and over
California
Colorectal Neoplasms/*diagnosis/*psychology
Early Detection of Cancer/*psychology
Female
*Health Behavior
Health Knowledge, Attitudes, Practice
Humans
Male
Middle Aged
Registries
Risk Assessment
Self-Assessment
Siblings/psychology
LA  - eng
N1  - 1930-7810
Glenn, Beth A
Herrmann, Alison K
Crespi, Catherine M
Mojica, Cynthia M
Chang, L Cindy
Maxwell, Annette E
Bastani, Roshan
R01 CA075367-03/CA/NCI NIH HHS/United States
Journal Article
Randomized Controlled Trial
Health Psychol. 2011 Jul;30(4):481-91. doi: 10.1037/a0024288.
PY  - 2011
SN  - 0278-6133 (Print)
0278-6133
SP  - 481-91
ST  - Changes in risk perceptions in relation to self-reported colorectal cancer screening among first-degree relatives of colorectal cancer cases enrolled in a randomized trial
T2  - Health Psychol
TI  - Changes in risk perceptions in relation to self-reported colorectal cancer screening among first-degree relatives of colorectal cancer cases enrolled in a randomized trial
VL  - 30
ID  - 391
ER  - 

TY  - JOUR
AB  - We describe here the results of the final 8 years of geographical and temporal data of a 33-year study of the cancer experience of 12.8 million man-years of black miners working on the gold fields of South Africa over the period 1964-96. These workers were recruited from 15 territories, the major areas during the most recent period being Lesotho (26.8%), Transkei (21.5%) and Mozambique (15%). The earliest analyses, 1964-71 and 1972-79, showed hepatocellular and oesophageal cancers to be the most frequent cancers. The final analysis, for 1989-96, however, shows marked temporal changes in the relative position of four cancers or grouped malignancies: respiratory cancer up by 236%, hepatocellular carcinoma down to 32%, oesophageal holding steady, and lymphatic system cancers up by 420%, almost certainly because of association with HIV/AIDS infection. Significant geographical variations occurring between the home areas of the miners are important, as mining operations have little to do with the cancers that develop. The causes are essentially socio-environmental rather than occupational, and this means that the rates of the major cancers in the miners are surrogate measures of the same cancers in the home areas. © 2003 Cancer Research UK.
AD  - N.D. McGlashan, Sch. of Geogr./Environ. Studies, University of Tasmania, GPO Box 252C, Hobart, Tasmania 7001, Australia
AU  - McGlashan, N. D.
AU  - Harington, J. S.
AU  - Chelkowska, E.
DB  - Embase
Medline
DO  - 10.1038/sj.bjc.6600841
IS  - 9
KW  - gold
acquired immune deficiency syndrome
adolescent
adult
aged
article
bladder cancer
cancer incidence
colorectal cancer
environmental factor
esophagus cancer
geography
health survey
human
Human immunodeficiency virus infection
larynx cancer
leukemia
liver cell carcinoma
lung cancer
lymphatic leukemia
major clinical study
miner
mouth cancer
Mozambique
Black person
occupational disease
priority journal
social aspect
socioenvironmental factor
South Africa
statistical analysis
stomach cancer
LA  - English
M3  - Article
N1  - L36606416
2003-06-06
PY  - 2003
SN  - 0007-0920
SP  - 1361-1369
ST  - Changes in the geographical and temporal patterns of cancer incidence among black gold miners working in South Africa, 1964-1996
T2  - British Journal of Cancer
TI  - Changes in the geographical and temporal patterns of cancer incidence among black gold miners working in South Africa, 1964-1996
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L36606416&from=export
http://dx.doi.org/10.1038/sj.bjc.6600841
VL  - 88
ID  - 1291
ER  - 

TY  - JOUR
AB  - BACKGROUND: The recent publication of clinical trial results has led to a dramatic shift in the evidence about postmenopausal hormone therapy. OBJECTIVE: To examine whether the publication of clinical trial results, specifically the Heart and Estrogen/progestin Replacement Study (HERS) in 1998 and the Women's Health Initiative (WHI) in 2002, has influenced the use of hormone therapy among postmenopausal women. DESIGN: Observational cohort (1997 to 2003). SETTING: San Francisco Mammography Registry, San Francisco, California. PARTICIPANTS: Postmenopausal women between the ages of 50 and 74 years without a personal history of breast cancer who underwent mammography (151862 mammograms). MEASUREMENTS: Self-reported current use of hormone therapy. RESULTS: Among menopausal women who had mammography, it was estimated that 41% were currently using hormone therapy in 1997. Before the publication of HERS, the use of hormone therapy was increasing at a rate of 1% (95% CI, 0% to 2%) per quarter. After the publication of HERS, use decreased by 1% (CI, -3% to 0%) per quarter. In contrast, the publication of the WHI in 2002 was associated with a more substantial decline in the use of hormone therapy of 18% (CI, -21% to -16%) per quarter. Similar associations were observed for most subgroups of women, including women older than 65 years of age; women with a previous hysterectomy; and women who described their race or ethnicity as white, African American, Latina, Chinese, or Filipina. CONCLUSIONS: The release of the HERS data was temporally associated with a modest decline in the use of hormone therapy. In contrast, the release of the principal findings from the WHI was associated with a more substantial decline in use by postmenopausal women. The reason for the differences in decline may relate to the fact that the WHI results were widely publicized or were more applicable to most postmenopausal women because the WHI study was performed in healthy women.
AD  - Division of General Medicine and Primary Care, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02120-1613, USA. jhaas@partners.org
AN  - 14757616
AU  - Haas, J. S.
AU  - Kaplan, C. P.
AU  - Gerstenberger, E. P.
AU  - Kerlikowske, K.
DA  - Feb 3
DO  - 10.7326/0003-4819-140-3-200402030-00009
DP  - NLM
ET  - 2004/02/06
IS  - 3
KW  - Age Factors
Aged
Cohort Studies
Continental Population Groups
Estrogen Replacement Therapy/*statistics & numerical data
Ethnic Groups
Female
*Health Knowledge, Attitudes, Practice
Humans
Hysterectomy
*Information Dissemination
Mammography
Mass Media
Middle Aged
*Randomized Controlled Trials as Topic
Registries
San Francisco
LA  - eng
N1  - 1539-3704
Haas, Jennifer S
Kaplan, Celia P
Gerstenberger, Eric P
Kerlikowske, Karla
U01CA63740/CA/NCI NIH HHS/United States
Journal Article
Research Support, U.S. Gov't, P.H.S.
United States
Ann Intern Med. 2004 Feb 3;140(3):184-8. doi: 10.7326/0003-4819-140-3-200402030-00009.
PY  - 2004
SN  - 0003-4819
SP  - 184-8
ST  - Changes in the use of postmenopausal hormone therapy after the publication of clinical trial results
T2  - Ann Intern Med
TI  - Changes in the use of postmenopausal hormone therapy after the publication of clinical trial results
VL  - 140
ID  - 637
ER  - 

TY  - JOUR
AB  - The Women's Health Trial Feasibility Study in Minority Populations (WHT:FSMP) was a multi-center randomized dietary intervention trial. The trial was designed to test whether ethnic minority and low-SES (as measured by education) post-menopausal women, ages 50-69 could be recruited and achieve a dietary pattern that included a reduction in total fat (20% of calories), saturated fat and cholesterol intake, and an increase the intake of fruits, vegetables and grain products. Sixty percent were randomized into a low-fat intervention group and 40% were randomized into a control group (usual diet). The trial was conducted in joint collaboration with the National Cancer Institute; the National Heart, Lung, and Blood Institute; three Clinical Centers - Emory University, University of Alabama at Birmingham, University of Miami; and Fred Hutchinson Cancer Research Center which served as the Statistical and Nutrition Coordinating Center. The recruitment goal for each Clinical Center was 750 women. One center was to randomize 50% or more African-American women, another center was to randomize 50% or more Hispanic women, and the third center was to randomize women in proportions representative of the local population including ethnic minorities and low-SES. A total of 2,208 women (624 African-American, 355 Hispanic and 1,229 Caucasian/Other) were randomized and minority recruitment target goals were successfully met at each Clinical Center. Dietary intake data collected at screening, baseline and follow-up visits included a food frequency questionnaire (FFQ), a four-day food record, and an eating patterns questionnaire. Twenty-four hour recall sub-samples were collected at eight- and fourteen-months post-randomization. Approximately one-half of screened women did not meet the eligibility criteria of consuming 36% or more total calories from fat as determined by the FFQ. The mean baseline fat intake for the intervention group was 39.8% (sd=7.1%, n=1235), and the mean for the control group was 39.0% (sd=6.9%, n=769) as estimated by the FFQ. The dietary intervention counseling program consisted of 18 group sessions during the first year. The group sessions (8 to 15 women per group) were facilitated by trained and certified nutritionists. Both nutritional and behavioral topics were integrated into the sessions, and self-monitoring was an important component of the intervention program. Attendance at group sessions was high and the majority of women met their fat intake goal. The results of this trial demonstrate that it is feasible to recruit women of different minority groups and socioeconomic status, and that these women can achieve and maintain a low-fat eating pattern. (Supported by NCI CN-15343). © 1995 American Dietetic Association.
AD  - H.J. Henry, MS, RD; D. Bowen, PhD; A. Shattuck, MS, RD; E. Burrows, MS, RD: Fred Hutchinson Cancer Research Center, Seattle, WA, USA, United States
AU  - Henry, H. J.
AU  - Bowen, D.
AU  - Shattuck, A.
AU  - Burrows, E.
DB  - Scopus
DO  - 10.1016/S0002-8223(95)00519-6
IS  - 9 SUPPL.
M3  - Article
N1  - Export Date: 22 March 2021
PY  - 1995
ST  - Changing Dietary Fat Intake in a Diverse Population. Women's Health Trial Feasibility Study in Minority Populations
T2  - Journal of the American Dietetic Association
TI  - Changing Dietary Fat Intake in a Diverse Population. Women's Health Trial Feasibility Study in Minority Populations
UR  - https://www.scopus.com/inward/record.uri?eid=2-s2.0-58149323857&doi=10.1016%2fS0002-8223%2895%2900519-6&partnerID=40&md5=152783214fbd8bb3e13ceabe39dd58a5
VL  - 95
ID  - 2656
ER  - 

TY  - JOUR
AB  - Background Black men (BM) are statistically more likely to experience aggressive cases of prostate cancer (CaP)compared to other racial groups, but are less likely to enroll in clinical trials. Several barriers have been documentedas impacting the participation of BM in clinical trials. To address these barriers, there is need for unique approachesto identify successful strategies that will facilitate the implementation of effective interventions. The overall goal ofthis study is to develop a tailored communication strategy for a CaP intervention trial, the MiCaP Research DigestTrial. Specifically, the primary objective was to identify the best intervention trial recruitment channels and locationsfor US‐born BM (USBM), African‐born BM (ABBM), and Caribbean‐born BM (CBBM). Methods The MiCaPResearch Digest Trial uses a randomized waitlist research design to evaluate the effectiveness of disseminatingCaP scientific discoveries for public health and community applications. It is an ongoing trial, which started in 2017.The current study compared two channels (newspaper and radio) and four locations (churches, barber shops,community outreach events) relative to their effectiveness in recruiting BM for the trial. Study location was OrangeCounty (FL). Recruitment efforts included newspaper stories about the study, study ad in newspaper, study ad onradio, information about study at community events and distribution of study flyers at targeted locations. Assessmentfocused on the following for the recruitment channels and locations: (1) reach, which was operationalized as thenumber of BM reached; and (2) impact, operationalized as the number of BM effectively pre‐screened for the Trial. Results The study period is from May to July, 2019. Results presented are for data collected up to June 30, 2019.The reach for BM were: 30 community locations for newspaper; 27,000 people every week from the radio; 130attendees for church events; an average of 12 customers per day for barber shops; and close to 1,200 attendeescombined for the community events. The highest impact (uptake of the intervention trial) was from communityevents, with 8 BM recruited (6 USBM and 2 CBBM). One USBM was recruited through the newspaper and oneUSBBM through radio. There was no recruitment from church or the barbershop. Also, no ABBM has been recruitedso far. Conclusion The reach for intervention trials does not necessarily translate to impact. Although the reach washighest for the radio, uptake of the intervention trial was highest for the community events. It was not surprising thatthe intervention trials uptake was highest for USBM. While 2 CBBM were recruited, recruiting ABBM continues to bechallenging. Engaging ethnically‐diverse BM through appropriate channels and locations is crucial to effectiveuptake of intervention trials.
AN  - CN-02213301
AU  - Ingraham, M.
AU  - Odedina, F.
AU  - Fathi, P.
AU  - Walsh-Childers, K.
AU  - Ezeani, A.
AU  - Elhag, Y.
DO  - 10.1158/1538-7755.DISP19-A044
IS  - 6 SUPPL 2
KW  - *intervention study
*prostate cancer
Adult
Caribbean
Clinical article
Comparative effectiveness
Conference abstract
Controlled study
Hairdresser
Human
Male
Public health
Randomized controlled trial
Religion
M3  - Journal: Conference Abstract
PY  - 2020
ST  - Channels and locations influencing theuptake of prostate cancer intervention trials by ethnicallydiverse Black men
T2  - Cancer epidemiology biomarkers and prevention
TI  - Channels and locations influencing theuptake of prostate cancer intervention trials by ethnicallydiverse Black men
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02213301/full
VL  - 29
ID  - 1511
ER  - 

TY  - JOUR
AB  - PURPOSE: We evaluated demographic and clinical characteristics associated with participation in a clinical trial testing the efficacy of an online tool to support breast cancer risk communication and decision support for risk mitigation to determine the generalizability of trial results. METHODS: Eligible women were members of Kaiser Permanente Washington aged 40-69 years with a recent normal screening mammogram, heterogeneously or extremely dense breasts and a calculated risk of > 1.67% based on the Breast Cancer Surveillance Consortium 5-year breast cancer risk model. Trial outcomes were chemoprevention and breast magnetic resonance imaging by 12-months post-baseline. Women were recruited via mail with phone follow-up using plain language materials notifying them of their density status and higher than average breast cancer risk. Multivariable logistic regression calculated independent odds ratios (ORs) for associations between demographic and clinical characteristics with trial participation. RESULTS: Of 2,569 eligible women contacted, 995 (38.7%) participated. Women with some college (OR = 1.99, 95% confidence interval [CI] 1.34-2.96) or college degree (OR = 3.35, 95% CI 2.29-4.90) were more likely to participate than high school-educated women. Race/ethnicity also was associated with participation (African-American OR = 0.50, 95% CI 0.29-0.87; Asian OR = 0.22, 95% CI 0.12-0.41). Multivariate adjusted ORs for family history of breast/ovarian cancer were not associated with trial participation. DISCUSSION: Use of plain language and potential access to a website providing personal breast cancer risk information and education were insufficient in achieving representative participation in a breast cancer prevention trial. Additional methods of targeting and tailoring, potentially facilitated by clinical and community outreach, are needed to facilitate equitable engagement for all women.
AD  - Kaiser Permanente Washington Health Research Institute, Seattle, WA.
University of Washington, Seattle, WA.
Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC.
AN  - 33482952
AU  - Wernli, K. J.
AU  - Bowles, E. A.
AU  - Knerr, S.
AU  - Leppig, K. A.
AU  - Ehrlich, K.
AU  - Gao, H.
AU  - Schwartz, M. D.
AU  - O'Neill, S. C.
C2  - PMC7849258
DA  - Dec
DO  - 10.7812/tpp/19.205
DP  - NLM
ET  - 2021/01/24
LA  - eng
N1  - 1552-5775
Wernli, Karen J
Bowles, Erin A
Knerr, Sarah
Leppig, Kathleen A
Ehrlich, Kelly
Gao, Hongyuan
Schwartz, Marc D
O'Neill, Suzanne C
K12 HS022982/HS/AHRQ HHS/United States
P01 CA154292/CA/NCI NIH HHS/United States
U54 CA163303/CA/NCI NIH HHS/United States
R50 CA211115/CA/NCI NIH HHS/United States
R01 CA190221/CA/NCI NIH HHS/United States
HHSN261201100031C/CA/NCI NIH HHS/United States
Journal Article
Perm J. 2020 Dec;24:1-4. doi: 10.7812/TPP/19.205.
PY  - 2020
SN  - 1552-5767 (Print)
1552-5767
SP  - 1-4
ST  - Characteristics Associated with Participation in ENGAGED 2 - A Web-based Breast Cancer Risk Communication and Decision Support Trial
T2  - Perm J
TI  - Characteristics Associated with Participation in ENGAGED 2 - A Web-based Breast Cancer Risk Communication and Decision Support Trial
VL  - 24
ID  - 13
ER  - 

TY  - JOUR
AB  - Our team is designing and fully characterizing black raspberry (BRB) food products suitable for long-term cancer prevention studies. The processing, scale-up, and storage effects on the consistency, quality, bioactive stability, and sensory acceptability of two BRB delivery systems of various matrices are presented. BRB dosage, pH, water activity, and texture were consistent in the scale-up production. Confections retained >90% of anthocyanins and ellagitannin after processing. Nectars had >69% of anthocyanins and >66% of ellagitannin retention, which varied with BRB dosage due to the processing difference. Texture remained unchanged during storage. BRB products consumed in a prostate cancer clinical trial were well accepted in sensory tests. Thus, this study demonstrates that two different BRB foods can be formulated to meet quality standards with a consistent bioactive pattern and successfully scaled up for a large human clinical trial focusing on cancer risk and other health outcomes.
AD  - Interdisciplinary Ph.D. Program in Nutrition, ‡Department of Food Science and Technology, §Division of Medical Oncology, Department of Internal Medicine, and #Comprehensive Cancer Center, The Ohio State University , Columbus, Ohio 43210, United States.
AN  - 24345009
AU  - Gu, J.
AU  - Ahn-Jarvis, J. H.
AU  - Riedl, K. M.
AU  - Schwartz, S. J.
AU  - Clinton, S. K.
AU  - Vodovotz, Y.
C2  - PMC4133319
C6  - NIHMS608614
DA  - May 7
DO  - 10.1021/jf404566p
DP  - NLM
ET  - 2013/12/19
IS  - 18
KW  - Anthocyanins/analysis/metabolism
Antioxidants/analysis/metabolism
Food Handling
Fruit/chemistry/*metabolism
Functional Food/*analysis
Humans
Male
Middle Aged
Neoplasms/*prevention & control
Prostatic Neoplasms/diet therapy/metabolism/*prevention & control
Rubus/chemistry/*metabolism
black raspberry
consistency in characteristics
retention of phenolics
scale-up production
sensory acceptance
storage stability
LA  - eng
N1  - 1520-5118
Gu, Junnan
Ahn-Jarvis, Jennifer H
Riedl, Kenneth M
Schwartz, Steven J
Clinton, Steven K
Vodovotz, Yael
P30 CA016058/CA/NCI NIH HHS/United States
Clinical Trial
Journal Article
J Agric Food Chem. 2014 May 7;62(18):3997-4006. doi: 10.1021/jf404566p. Epub 2013 Dec 27.
PY  - 2014
SN  - 0021-8561 (Print)
0021-8561
SP  - 3997-4006
ST  - Characterization of black raspberry functional food products for cancer prevention human clinical trials
T2  - J Agric Food Chem
TI  - Characterization of black raspberry functional food products for cancer prevention human clinical trials
VL  - 62
ID  - 301
ER  - 

TY  - JOUR
AB  - Purpose: To assess the incidence and radiographic and clinical presentation of pneumonitis associated with the mammalian target of rapamycin inhibitor everolimus in patients with advanced non-small cell lung cancer. PATIENTS AND Methods: A retrospective, centralized review of serial computed tomography scans and corresponding clinical data from patients with advanced non-small cell lung cancer treated with 10-mg oral once daily everolimus monotherapy in a phase II clinical study was conducted. Serial chest CT scans underwent a consensus read by two radiologists for presence of pneumonitis. These cases were then reviewed with corresponding clinical data by a pulmonologist to assess the suspected causality to everolimus and outcome. Results: Twenty-four of 64 patients reviewed were found to have radiographic evidence of pneumonitis. In 16 of these 24 patients, pneumonitis was suspected as either possibly (12) or probably (4) related to everolimus. The most common radiographic manifestations were focal areas of consolidation at the lung bases or ground-glass opacities. Pneumonitis evaluated with Common Terminology Criteria for Adverse Events (version 3) was grade 1 or 2 in 12 of 16 suspected cases, with 4 patients experiencing higher grades. In most of the patients, pneumonitis remained at the same or lower grade without discontinuation of therapy. Patients with evidence of interstitial lung disease at baseline had an increased risk of Common Terminology Criteria for Adverse Events grade more than or equal to 3 pneumonitis. Conclusion: Within the limitation of this retrospective study, Results suggest that a mostly low-grade pneumonitis with a possible or probable relationship to everolimus was relatively frequent, occurring in 25% of evaluated patients. These Results suggest a need for monitoring of pulmonary adverse events and the development of guidelines for managing pneumonitis in future studies with everolimus. © 2009 by the International Association for the Study of Lung Cancer. TypeofStudy:An open, retrospective study evaluating the radiographic patterns and clinical features of pneumonitis during Certican therapy in patients with advanced non-small cell lung cancer (NSCLC). DosageDuration:10 mg once daily orally, reduced to 5 mg daily or treatment interrupted for a maximum of 2 weeks in cases of unacceptable toxicity. Duration: 4-20 weeks. Results:Pneumonitis was noted in 24 of 64 patients. Pneumonitis developed within 3 months after starting Certican in 21 of 24 patients. CT scans showed predominantly ground-glass opacities or multifocal areas of air space consolidation with a basilar and peripheral predominance. One patient had extensive airspace consolidation following a more focal pattern of consolidation and there were 2 cases of pure interstitial lung changes. Radiographic patterns changed over observation points, most commonly between focal consolidation and ground-glass opacities. In some cases with, radiographic findings persisted while continuing treatment with Certican. Among 24 patients who developed pneumonitis, 16 cases were suspected to be related to Certican (4 classified as probable and 12 as possible). The worst CTCAE grade for the 16 patients with Certican-induced pneumonitis was grade 1 or 2 in 75% (4 had higher grades, including 1 death). Toxicity for 2 of 16 patients resolved by end of study. Interruptions of treatment (≤2 weeks) occurred in 4 of 16 patients, but only one was for a pulmonary AE: grade 3 infectious pneumopathy, which improved with antibiotics. One interruption was for grade 3 fatigue, but pneumonitis improved during temporal interruption which was maintained with resumption of Certican at a reduced dose. Another was for grade 3 stomatitis but respiratory failure occurred 4 days later with progression of disease, and Certican was discontinued. The last interruption was for grade 1 stomatitis. In the Certican-induced pneumonitis group, discontinuation occurred in 1 patient due to CTCAE grade 4 respiratory failure and left lower lobe pneumonia. One patient received a short course of corticosteroids for AEs other than pneumonitis. A possible relapse of pneumonitis was noted in 1 case. Indications:64 patients with advanced refractory non-small cell lung cancer (adenocarcinoma 36, bronchoalveolar carcinoma 6, large cell carcinoma 6, mixed epithelial cell carcinoma 1, squamous cell carcinoma 13; stage IIIb 8, stage IV 56). Coexisting diseases: pneumonitis (3), interstitial lung disease (10), chronic obstructive pulmonary disease (9). Patients:64 patients, 34 males and 30 females, age range 21-74 years (mean age 58.0 years); 11 Asian, 3 black, 48 white, 1 Pacific Islander, and 1 other; of whom 16 developed Certican-induced pneumonitis [9 males and 7 females, age range 42-74 years (mean age 62.1 years); 1 Asian, 1 black, and 14 white]. Dropouts: n=1 (due to Certican side effects). AuthorsConclusions:This study suggests that a pneumonitis, as assessed by presence of radiographic findings on review of serial chest CTs, was relatively common in patients with lung cancer during treatment with everolimus, occurring in 25% of evaluated patients. In the majority of patients, these events were low grade and persisted during ongoing treatment. These results suggest a need for development of detailed guidelines for managing pneumonitis in future clinical trials with everolimus (Supplement: recommendations for management of everolimus-related pneumonitis). AdverseEffects:16 patients developed pneumonitis [1 fatal; characterized by pleural effusion (n=6), dyspnea (n=6), cough (n=4), fatigue (n=3, 1 grade 3), fever (n=2), and infiltrative abnormalities (n=1)]; 1 grade 3 infectious pneumopathy; 1 grade 3 stomatitis, respiratory failure, and left lower lobe pneumonia leading to withdrawal; and 1 grade 1 stomatitis. FreeText:Tests: serial chest computed tomography (CT) scan, severity of adverse events by Common Terminology Criteria for Adverse Events (CTCAE), body temperature. Concomitant drugs: antibiotics, diuretics, and corticosteroids. Previous therapy: radiotherapy, gemcitabine, docetaxel, paclitaxel, gefitinib, and erlotinib.
AD  - Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, United States
Novartis Pharma AG, Basel, Switzerland
Division of Imaging, Novartis Institutes for BioMedical Research, Cambridge, MA, United States
AU  - White, D. A.
AU  - Schwartz, L. H.
AU  - Dimitrijevic, S.
AU  - Scala, L. D.
AU  - Hayes, W.
AU  - Gross, S. H.
DB  - Scopus
DO  - 10.1097/JTO.0b013e3181ba20b1
IS  - 11
KW  - Everolimus
MTOR inhibitor
Non-small cell lung cancer
Pneumonitis
RAD001
M3  - Article
N1  - Cited By :47
Export Date: 22 March 2021
PY  - 2009
SP  - 1357-1363
ST  - Characterization of pneumonitis in patients with advanced non-small cell lung cancer treated with everolimus (RAD001)
T2  - Journal of Thoracic Oncology
TI  - Characterization of pneumonitis in patients with advanced non-small cell lung cancer treated with everolimus (RAD001)
UR  - https://www.scopus.com/inward/record.uri?eid=2-s2.0-70449588997&doi=10.1097%2fJTO.0b013e3181ba20b1&partnerID=40&md5=105fe9b1cca2fde4169044d341878536
VL  - 4
ID  - 2529
ER  - 

TY  - JOUR
AB  - Although research has been conducted to address specific medical and psychosocial needs of breast cancer survivors, little has been done to address needs along the entire trajectory of care. One such need is chemobrain, a phenomenon recognized as an identifiable psychosocial cognitive change in breast cancer survivors. The purpose of this article is to present the findings of a qualitative study conducted with two focus groups of underserved African American breast cancer survivors. Four themes emerged from the transcribed interviews: the concept of chemobrain, variability among individuals, the stigma of chemobrain, and methods of coping. In addition, findings revealed that health professionals were not used by the participants as a resource to address the issues of chemobrain, which holds significant implications for practice. That fact highlights the implications for oncology nursing with respect to providing education and support for patients experiencing chemobrain. Nursing professionals are in a position to be a frontline resource for breast cancer survivors, providing information, education, and coping methods to help improve their quality of life.
AD  - South College of Pharmacy, Knoxville, TN
College of Social Work, University of Tennessee in Nashville
AN  - 104259232. Language: English. Entry Date: 20130401. Revision Date: 20150820. Publication Type: Journal Article
AU  - Rust, Connie
AU  - Davis, Cindy
DB  - CINAHL Complete
DO  - 10.1188/13.CJON.E29-E34
DP  - EBSCOhost
IS  - 2
KW  - Cognition Disorders -- Chemically Induced
Antineoplastic Agents -- Adverse Effects
Breast Neoplasms
Cancer Survivors
Black Persons -- Tennessee
Medically Underserved
Human
Female
Convenience Sample
Qualitative Studies
Thematic Analysis
Focus Groups
Stigma
Coping
Exploratory Research
Tennessee
Audiorecording
Adult
Middle Age
Aged
Support Groups
Research Subject Recruitment
N1  - research. Journal Subset: Core Nursing; Double Blind Peer Reviewed; Nursing; Peer Reviewed; USA. Special Interest: Oncologic Care. NLM UID: 9705336.
PMID: NLM23538262.
PY  - 2013
SN  - 1092-1095
SP  - E29-34
ST  - Chemobrain in Underserved African American Breast Cancer Survivors
T2  - Clinical Journal of Oncology Nursing
TI  - Chemobrain in Underserved African American Breast Cancer Survivors
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104259232&site=ehost-live&scope=site
VL  - 17
ID  - 1881
ER  - 

TY  - JOUR
AB  - Background: Recommendations for cancer screening are uncertain for the early detection or prevention of prostate cancer in African American men. Thus, chemoprevention strategies are needed to specifically target African American men. Methods: The evidence was examined on the biological etiology of disparities in African Americans related to prostate cancer. Possible chemopreventive agents and biomarkers critical to prostate cancer in African American men were also studied. Results: High-grade prostatic intraepithelial neoplasia may be more prevalent in African American men, even after controlling for age, prostate-specific antigen (PSA) level, abnormal results on digital rectal examination, and prostate volume. Prostate cancer in African American men can lead to the overexpression of signaling receptors that may mediate increased proliferation, angiogenesis, and decreased apoptosis. Use of chemopreventive agents may be useful for select populations of men. Conclusions: Green tea catechins are able to target multiple pathways to address the underlying biology of prostate carcinogenesis in African American men, so they may be ideal as a chemoprevention agent in these men diagnosed with high-grade prostatic intraepithelial neoplasia.
AD  - N.B. Kumar, Department of Epidemiology, Moffitt Cancer Center, 12902 Magnolia Drive, MRC-CAN CONT, Tampa, FL, United States
AU  - Kumar, N. B.
AU  - Pow-Sang, J. M.
AU  - Spiess, P. E.
AU  - Park, J. Y.
AU  - Chornokur, G.
AU  - Leone, A. R.
AU  - Phelan, C. M.
DB  - Embase
Medline
DO  - 10.1177/107327481602300413
IS  - 4
KW  - dutasteride
epigallocatechin gallate
finasteride
sinecatechins
placebo
prostate specific antigen
African American
age
apoptosis
article
cancer grading
cell proliferation
chemoprophylaxis
digital rectal examination
drug efficacy
drug safety
gene overexpression
health care disparity
human
male
nonhuman
patient selection
phase 1 clinical trial (topic)
phase 2 clinical trial (topic)
phase 3 clinical trial (topic)
prevalence
prostate cancer
prostate volume
tumor vascularization
LA  - English
M3  - Article
N1  - L613209795
2016-11-17
2016-11-30
PY  - 2016
SN  - 1526-2359
1073-2748
SP  - 415-423
ST  - Chemoprevention in African american men with prostate cancer
T2  - Cancer Control
TI  - Chemoprevention in African american men with prostate cancer
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L613209795&from=export
http://dx.doi.org/10.1177/107327481602300413
VL  - 23
ID  - 962
ER  - 

TY  - JOUR
AB  - Selective estrogen receptor modulators (SERMs) are anti-estrogens that selectively antagonize the proliferative effects of estrogens on breast cells, thereby inhibiting or reversing neoplastic progression to clinical breast cancer. The goal is to administer these agents to healthy women with an elevated risk for breast cancer. The study reported here assessed the knowledge and attitude of 26 broadly selected women with an elevated risk for breast cancer who participated in three focus groups (eight to ten per group) that discussed the use of SERMs, such as tamoxifen and raloxifen. Data were analyzed by cross-case procedure using variable-oriented strategies. Acceptance of breast cancer chemoprevention treatment with SERMs was found to be influenced by various factors, including a knowledge of breast cancer risk factors, the perception of personal risk for breast cancer, and the perception of barriers and benefits to receiving chemoprevention treatment. The issues involved in making the decision to accept treatment with SERMs are discussed. Most of the participants in the groups indicated they were unlikely to accept breast cancer chemoprevention treatment with SERMs.
AD  - Department of Epidemiology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA
Department of Epidemiology, Box 189, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030. E-mail: mscyrus@mdanderson.org
AN  - 106899431. Language: English. Entry Date: 20020208. Revision Date: 20200708. Publication Type: journal article
AU  - Cyrus-David, M. S.
AU  - Strom, S. S.
AU  - Cyrus-David, M. S.
AU  - Strom, S. S.
DB  - CINAHL Complete
DO  - 10.1002/pon.547
DP  - EBSCOhost
IS  - 6
KW  - Breast Neoplasms
Estrogen Antagonists -- Administration and Dosage
Patient Attitudes
Chemoprevention
Focus Groups
Research Subject Recruitment
Qualitative Studies
Descriptive Statistics
Patient Attitudes -- Evaluation
White Persons
Black Persons
Health Knowledge -- Evaluation
Adult
Middle Age
Aged
Female
Funding Source
Human
N1  - research; tables/charts. Journal Subset: Biomedical; Editorial Board Reviewed; Europe; Expert Peer Reviewed; Peer Reviewed; UK & Ireland. Grant Information: CA57707/CA/NCI NIH HHS/United States. NLM UID: 9214524.
PMID: NLM11747064.
PY  - 2001
SN  - 1057-9249
SP  - 521-533
ST  - Chemoprevention of breast cancer with selective estrogen receptor modulators: views from broadly diverse focus groups of women with elevated risk for breast cancer
T2  - Psycho-Oncology
TI  - Chemoprevention of breast cancer with selective estrogen receptor modulators: views from broadly diverse focus groups of women with elevated risk for breast cancer
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106899431&site=ehost-live&scope=site
VL  - 10
ID  - 1883
ER  - 

TY  - JOUR
AB  - OBJECTIVE: To assess the patterns of chemotherapy use for patients with multiple myeloma and to determine if chemotherapy is effective in prolonging survival outside the clinical trial settings. METHODS: We studied a nationwide and population-based retrospective cohort of 4902 patients > or =65 years of age with stage II or III multiple myeloma from 1992 to 1999, identified from the Surveillance, Epidemiology, and End-Results-Medicare data. Multivariate logistic regression was used to estimate the odds ratio of receiving chemotherapy and Cox proportional hazard model was used to estimate the hazard ratio of mortality associated with chemotherapy. RESULTS: Of 4902 patients with stage II or III multiple myeloma, 52.0% received chemotherapy during the course of the disease. The receipt of chemotherapy decreased significantly with age from 65.7% in the 65- to 69-year age group to 34.3% in those > or =80 years. Blacks (47.6%) were less likely to receive chemotherapy than whites (52.8%). Use of chemotherapy decreased significantly with comorbidity scores and increased over time. Risk of all-cause mortality was significantly reduced in patients who received chemotherapy compared with those who did not (adjusted hazard ratio = 0.65; 95% confidence interval = 0.61-0.69). A similar pattern as observed for myeloma-specific mortality (0.61; 0.56-0.67). Survival benefit increased with increasing cycles of chemotherapy (P < 0.001 for trend) and was significant across different age groups, gender, ethnic groups, and comorbidity scores. CONCLUSION: Chemotherapy was significantly associated with increased survival in patients with multiple myeloma outside the clinical trial settings. This survival benefit was significant across different groups by age, gender, race, and comorbidity. A substantial number of patients with multiple myeloma did not receive chemotherapy.
AD  - Division of Epidemiology, School of Public Health, University of Texas Health Science Center, Houston, TX 77030, USA.
AN  - 17921717
AU  - Rohatgi, N.
AU  - Du, X. L.
AU  - Coker, A. L.
AU  - Moye, L. A.
AU  - Wang, M.
AU  - Fang, S.
DA  - Oct
DO  - 10.1097/COC.0b013e3180592a30
DP  - NLM
ET  - 2007/10/09
IS  - 5
KW  - African Continental Ancestry Group
Aged
Aged, 80 and over
Antineoplastic Agents/*therapeutic use
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Cohort Studies
European Continental Ancestry Group
Humans
Medicare
Melphalan/*therapeutic use
Multiple Myeloma/*drug therapy/mortality/pathology
Neoplasm Staging
Patient Selection
Retrospective Studies
Survival Analysis
Survivors
United States
LA  - eng
N1  - 1537-453x
Rohatgi, Nidhi
Du, Xianglin L
Coker, Ann L
Moye, Lemuel A
Wang, Michael
Fang, Shenying
Journal Article
Multicenter Study
United States
Am J Clin Oncol. 2007 Oct;30(5):540-8. doi: 10.1097/COC.0b013e3180592a30.
PY  - 2007
SN  - 0277-3732
SP  - 540-8
ST  - Chemotherapy and survival for patients with multiple myeloma: findings from a large nationwide and population-based cohort
T2  - Am J Clin Oncol
TI  - Chemotherapy and survival for patients with multiple myeloma: findings from a large nationwide and population-based cohort
VL  - 30
ID  - 512
ER  - 

TY  - JOUR
AB  - Objectives: This feasibility study developed and pilot tested an intervention to: (1) increase knowledge about prostate cancer screening; and (2) promote self-efficacy to participate in the informed decision-making process. Setting: African American men are a priority audience for prostate cancer screening interventions to promote informed decision making, and faith-based settings have been shown to be an effective venue to reach this population. Therefore we used predominantly African American churches to develop and test our Intervention. Participants: Participants (N = 73) were recruited, and the Intervention was administered by an African American health educator. Intervention: We developed and pretested a prostate cancer screening informed decision-making Intervention based on the Ottawa Decision Support Framework and the health belief model. The intervention included a tool called the 'road map,' which depicts the potential consequences of a decision to undergo or forgo screening. A quasi-experimental design was used to test the Intervention. Main Outcome Measures: The main outcome measures were change in knowledge and self-efficacy post intervention. Results: Prostate cancer knowledge (p < .0001) and self-efficacy (p = .025) significantly increased. Conclusions: A church-based intervention delivered by an African American health educator is a promising strategy for promoting informed decision making among African American men. (PsycINFO Database Record (c) 2018 APA, all rights reserved)
AD  - Drake, Bettina F., Washington University School of Medicine, Department of Surgery, 660 S Euclid, Campus, Box 8100, St Louis, MO, US, 63110
AN  - 2010-06426-001
AU  - Drake, Bettina F.
AU  - Shelton, Rachel C.
AU  - Gilligan, Timothy
AU  - Allen, Jennifer D.
DB  - psyh
DO  - 10.1016/S0027-9684(15)30521-6
DP  - EBSCOhost
IS  - 3
KW  - church based intervention
decision making
prostate cancer screening
African American men
self efficacy
health promotion
African Americans
Christianity
Feasibility Studies
Humans
Male
Mass Screening
Middle Aged
Pilot Projects
Prostatic Neoplasms
Surveys and Questionnaires
Blacks
Cancer Screening
Human Males
Self-Efficacy
N1  - Department of Surgery, Washington University School of Medicine, St. Louis, MO, US. Other Publishers: Elsevier Science. Release Date: 20101115. Correction Date: 20180315. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Print. Document Type: Journal Article. Language: English. Major Descriptor: Blacks; Cancer Screening; Decision Making; Human Males; Self-Efficacy. Minor Descriptor: Health Promotion. Classification: Promotion & Maintenance of Health & Wellness (3365). Population: Human (10); Male (30). Location: US. Age Group: Adulthood (18 yrs & older) (300); Middle Age (40-64 yrs) (360); Aged (65 yrs & older) (380). Tests & Measures: Control Preference Scale; Decision Self-Efficacy Scale DOI: 10.1037/t23888-000; Decisional Conflict Scale DOI: 10.1037/t21335-000. Methodology: Empirical Study; Quantitative Study. References Available: Y. Page Count: 8. Issue Publication Date: Mar, 2010.
Sponsor: National Cancer Institute, US. Grant: 5-U01CA86274-05. Recipients: No recipient indicated
PY  - 2010
SN  - 0027-9684
1943-4693
SP  - 164-171
ST  - A church-based intervention to promote informed decision making for prostate cancer screening among African American men
T2  - Journal of the National Medical Association
TI  - A church-based intervention to promote informed decision making for prostate cancer screening among African American men
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2010-06426-001&site=ehost-live&scope=site
drakeb@wudosis.wustl.edu
VL  - 102
ID  - 1772
ER  - 

TY  - JOUR
AB  - INTRODUCTION: African American men have a significantly higher incidence of prostate cancer, are diagnosed at younger ages and more advanced stages, and have higher mortality rates from prostate cancer than do White men. METHODS: This community-based intervention study employed a quasiexperimental delayed-control (crossover) design with randomization at the church level. Forty-five African American churches were randomly assigned to two study groups: early intervention and delayed intervention. A convenience sample of 430 African American male volunteers (ages 40-70) was enrolled through the churches, and 350 men remained in the study through wave 3. The intervention was a culturally tailored group educational program, which included a video and a question-and-answer session with an African American physician. RESULTS: Within each group, knowledge, perceived threat, and screening prevalence all increased significantly. However, the magnitude of increases was similar, so the groups did not differ significantly at wave 2. Knowledge at wave 2 was associated with greater odds of having a digital rectal exam by wave 3 only for the early-intervention group. The early-intervention group was two times more likely to have talked to a physician about prostate cancer screening by wave 3. CONCLUSIONS: The findings suggest that the delayed-intervention group did not function as a pure control and may have unintentionally received a partial intervention. This finding demonstrated that a low-cost prostate cancer awareness campaign within a church may be enough to affect prostate cancer knowledge, attitudes, and behaviors among African American men. Further research should examine the church-specific intervention elements, cultural appropriateness of the messages, and whether group sessions provide additional effect.
AD  - Center for Health Research, Tennessee State University, 3500 John Merritt Blvd, PO Box 9580, Nashville, TN 37209-1561, USA. bhusaini@tnstate.edu
AN  - 18646345
AU  - Husaini, B. A.
AU  - Reece, M. C.
AU  - Emerson, J. S.
AU  - Scales, S.
AU  - Hull, P. C.
AU  - Levine, R. S.
DA  - Spring
DP  - NLM
ET  - 2008/07/23
IS  - 2 Suppl 2
KW  - Adult
*African Americans
Aged
Chi-Square Distribution
Cross-Over Studies
Cultural Characteristics
*Health Education
Humans
Incidence
Male
*Mass Screening
Middle Aged
Prostatic Neoplasms/epidemiology/*prevention & control
Regression Analysis
Religion
Surveys and Questionnaires
LA  - eng
N1  - Husaini, Baqar A
Reece, Michelle C
Emerson, Janice S
Scales, Samuel
Hull, Pamela C
Levine, Robert S
20-P91879/4-01/PHS HHS/United States
Journal Article
Randomized Controlled Trial
Research Support, U.S. Gov't, P.H.S.
United States
Ethn Dis. 2008 Spring;18(2 Suppl 2):S2-179-84.
PY  - 2008
SN  - 1049-510X (Print)
1049-510x
SP  - S2-179-84
ST  - A church-based program on prostate cancer screening for African American men: reducing health disparities
T2  - Ethn Dis
TI  - A church-based program on prostate cancer screening for African American men: reducing health disparities
VL  - 18
ID  - 491
ER  - 

TY  - JOUR
AB  - Comments on an article by E. Dedert et al. (see record [rid]2012-18326-005[/rid]). The present study by Dedert and colleagues, guided by a model of circadian effects of cancer progression, examined associations between psychological responses and disruptions in circadian rest/activity and cortisol rhythms in women newly diagnosed with cancer. Circadian disruptions have been linked to poorer quality of life as well as early mortality in patients with metastatic cancer but have not been widely studied in nonmetastatic populations. Findings from this study indicated that women who reported more intrusive thoughts and avoidant coping displayed circadian disruptions including daytime inactivity and inconsistent activity patterns. In addition, those with more disruptions in their activity/rest cycles had flattened diurnal cortisol rhythms. Given the small sample size and cross-sectional design of this study, these findings should be considered preliminary. However, they do suggest the possibility that psychological responses at the time of cancer diagnosis are associated with disruptions in circadian rhythms, which could influence disease progression. The methodology used to collect saliva samples and verify their timing is a particular strength of this study and should serve as a model for future research. Collection of salivary cortisol took place four times per day to capture both cortisol response to wakening and the diurnal slope. Another notable strength of this study is the diversity of the participants. Two thirds of the participants were recruited from a cancer center that primarily serves low-income patients, and over one third of the participants were African-American. In contrast, the majority of previous studies examining cortisol in cancer patients have been conducted with samples consisting of predominantly Caucasian subjects. As noted above, the findings of this study are preliminary. However, they are intriguing and suggest several avenues for future research. (PsycINFO Database Record (c) 2018 APA, all rights reserved)
AD  - Porter, Laura S., Duke University Medical Center, Box 90399, Durham, NC, US, 27708
AN  - 2012-18326-001
AU  - Porter, Laura S.
DB  - psyh
DO  - 10.1007/s12160-012-9376-3
DP  - EBSCOhost
IS  - 1
KW  - distress
breast cancer surgery
circadian disruption
women
coping behavior
Adaptation, Psychological
Breast Neoplasms
Circadian Rhythm
Female
Humans
Stress, Psychological
Human Biological Rhythms
Human Females
Surgery
N1  - Duke University Medical Center, Durham, NC, US. Other Publishers: Lawrence Erlbaum; Oxford University Press. Release Date: 20120903. Correction Date: 20180503. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Comment/Reply. Language: English. Major Descriptor: Breast Neoplasms; Coping Behavior; Distress. Minor Descriptor: Human Biological Rhythms; Human Females; Surgery. Classification: Cancer (3293). Population: Human (10). References Available: Y. Page Count: 2. Issue Publication Date: Aug, 2012. Publication History: First Posted Date: May 15, 2012. Copyright Statement: Society of Behavioral Medicine. 2012.
PY  - 2012
SN  - 0883-6612
1532-4796
SP  - 1-2
ST  - Circadian disruption—A new direction for psycho-oncology research? A comment on Dedert et al
T2  - Annals of Behavioral Medicine
TI  - Circadian disruption—A new direction for psycho-oncology research? A comment on Dedert et al
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2012-18326-001&site=ehost-live&scope=site
laura.porter@duke.edu
VL  - 44
ID  - 1750
ER  - 

TY  - JOUR
AB  - Background. Community-based peer support may help meet the practical, emotional, and spiritual needs of African Americans with advanced cancer. Support teams are a unique model of peer support for persons facing serious illness, but research is rare. This study sought to (a) implement new volunteer support teams for African Americans with advanced cancer in two distinct regions and (b) evaluate support teams' ability to improve support, awareness of services, and quality of life for these patients. Methods. The study used a pre-post design. Community and academic partners collaborated to implement volunteer support teams and evaluate the intervention using pre-post surveys of volunteers and patients. Patients who declined support teams were also interviewed as a comparison group. Results. Investigators enrolled and trained 130 volunteers who formed 25 support teams in two geographic regions. Volunteers supported 25 African American patients with advanced cancer (72%) or other diseases. After 2 months, patients with support teams reported fewer needs for practical, emotional, and spiritual support on a structured checklist. They more often communicated with someone about their cancer care needs (48% vs. 75%, p = .04), and were more aware of Hospice (4% vs. 25%, p = .04), but quality of life scores were unchanged. Comparison patients who refused a support team had fewer support needs at baseline and follow-up, suggesting that refusals were based on a lack of need. Conclusion. Coordinated volunteer support teams are a promising new model to provide peer support for African Americans facing cancer and other serious illnesses. Further testing in a pragmatic clinical trial is warranted.
AN  - WOS:000336221900007
AU  - Hanson, L. C.
AU  - Green, M. A.
AU  - Hayes, M.
AU  - Diehl, S. J.
AU  - Warnock, S.
AU  - Corbie-Smith, G.
AU  - Lin, F. C.
AU  - Earp, J. A.
DA  - Jun
DO  - 10.1177/1090198113512127
IS  - 3
N1  - 24347144
PY  - 2014
SN  - 1090-1981
SP  - 291-298
ST  - Circles of Care: Implementation and Evaluation of Support Teams for African Americans With Cancer
T2  - Health Education & Behavior
TI  - Circles of Care: Implementation and Evaluation of Support Teams for African Americans With Cancer
VL  - 41
ID  - 3007
ER  - 

TY  - JOUR
AB  - Community health workers (CHWs) can engage elderly persons in advance care planning (ACP) conversations. We report how trained CHWs used Go Wish cards (GW (R) cards) to identify patients' highest priority preferences and evaluated whether engaging in ACP conversations was associated with subsequent health care utilization. A one-year long, pre-post longitudinal design was used to evaluate our educational intervention using mixed-methods. 392 patients (mean of 73.3 years, 82% women, 48% African American, 43% Caucasian) enrolled in the Aging Brain Care (ABC) program and participated in ACP discussions with CHWs. We expanded the role of the ABC's CHW, who work directly with individuals and caregivers during home visits to monitor bio-psycho-social needs, to include ACP conversations. The CHWs received ACP training, practice with tools such as GW (R) cards, and support from an electronic health record (EHR) clinical decision support tool. Quantitative measures of patients' ACP preferences and health care utilization were abstracted from the EHR. Qualitative data about patients' perceptions of CHWs in facilitating ACP discussions was obtained through semi-structured interviews. Eighty-six patients' data indicated that they had engaged in a preferences-for-care process using GW (R) cards. The top-three card choices by patients was attending to spirituality and religious concerns, preparing for end of life, and maintaining personal wholeness. CHWs were able to effectively engage in ACP conversations with patients and GW (R) cards were a positive way to stimulate discussion of issues previously undiscussed.
AN  - WOS:000410472900013
AU  - Litzelman, D. K.
AU  - Inui, T. S.
AU  - Schmitt-Wendholt, K. M.
AU  - Perkins, A.
AU  - Griffin, W. J.
AU  - Cottingham, A. H.
AU  - Ivy, S. S.
DA  - Oct
DO  - 10.1007/s10900-017-0336-5
IS  - 5
N1  - 28353007
PY  - 2017
SN  - 0094-5145
SP  - 926-934
ST  - Clarifying Values and Preferences for Care Near the End of Life: The Role of a New Lay Workforce
T2  - Journal of Community Health
TI  - Clarifying Values and Preferences for Care Near the End of Life: The Role of a New Lay Workforce
VL  - 42
ID  - 2885
ER  - 

TY  - JOUR
AB  - Racial differences in serum prostate specific antigen (PSA) values in men with and without prostate cancer have been observed but have yet to be explained. We aimed to determine if ethnic variations in the rate of metabolism of PSA could explain the different levels of PSA found in African-American and Caucasian men. In a prospective fashion, patients diagnosed with biopsy-proven clinically localized adenocarcinoma of the prostate and scheduled for radical prostatectomy were selected for the study. Eleven patients (six Caucasian, five African-American) were enrolled in the study. All patients demonstrated normal liver and renal function. Sera for total PSA were obtained at the following time intervals: preoperative (within 3 months of operation), time 0 (at time of prostate removal), 1, 4, 8, 24, 48, 72, 168 and 336 h after removal of the prostate. A log - linear regression model was then used to determine the metabolic clearance rate and half-life of serum total PSA. There were no statistically significant differences between Caucasian and African-American patients with regard to age, PSA prior to surgery, prostate weight, Gleason sum and PSA half-life. The metabolic clearance of total PSA followed first order kinetics. When comparing serum PSA levels expressed as a fraction of the baseline PSA, Caucasian and African-American patients demonstrated similar rates of metabolism. This study found similar rates of elimination of serum total PSA between African-Americans and Caucasians. These findings suggest that the rate of metabolism of PSA is similar for these groups. Further studies are needed to explain racial differences of serum PSA in patients with and without prostate cancer.
AD  - C.G. Roehrborn, Department of Urology, The University of Texas, Southwestern Medical Center Dallas, 5323 Harry Hines Blvd., Dallas, TX 75390-9110, United States
AU  - Lotan, Y.
AU  - Roehrborn, C. G.
DB  - Embase
Medline
DO  - 10.1038/sj.pcan.4500567
IS  - 2
KW  - prostate specific antigen
adult
age
aged
article
blood analysis
cancer localization
Caucasian
clinical article
controlled study
ethnic difference
half life time
human
kidney function
kinetics
linear regression analysis
liver function
male
metabolic clearance rate
Black person
organ weight
patient selection
perioperative period
postoperative period
preoperative period
priority journal
prospective study
prostate adenocarcinoma
prostate biopsy
prostatectomy
race difference
statistical model
statistical significance
LA  - English
M3  - Article
N1  - L34777892
2002-07-29
PY  - 2002
SN  - 1365-7852
SP  - 111-114
ST  - Clearance rates of total prostate specific antigen (PSA) after radical prostatectomy in African-Americans and Caucasians
T2  - Prostate Cancer and Prostatic Diseases
TI  - Clearance rates of total prostate specific antigen (PSA) after radical prostatectomy in African-Americans and Caucasians
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L34777892&from=export
http://dx.doi.org/10.1038/sj.pcan.4500567
VL  - 5
ID  - 1302
ER  - 

TY  - JOUR
AB  - Age at diagnosis, pathological characteristics, and tumor behavior differ between African American (AAW) and Caucasian women (CW) with breast cancer, with AAW having more aggressive tumors and higher mortality rates. Although both societal and molecular contributions to these disparities have been suggested, the African American population has traditionally been under-represented in research and clinical protocols, limiting the power of epidemiologic and molecular studies to provide better understanding of disease pathogenesis in this minority population. The Clinical Breast Care Project (CBCP) has developed a large tissue and blood repository from patients undergoing treatment for breast cancer, with previous history of breast cancer, counseled in the Risk Reduction Clinic, screened by routine mammography, or undergoing elective reductive mammoplasty. Recruitment of AAW into the CBCP was successful; 25% of the 2,454 female patients were African American, including 35% disease-free, 3% high-risk, 40% benign, 8% preinvasive and 14% with invasive breast disease. More than 500 data fields regarding lifestyle choices, socioeconomic status, health history and geography were collected from all participants, and all consenting individuals provided blood specimens for genomic and proteomic studies. Tissues were collected from all patients undergoing surgical procedures using protocols that preserve the macromolecules for downstream research applications. In addition, patients were followed after diagnosis, with >85% of patients providing ongoing and updated demographic and clinical information. Thus, recruitment efforts in the CBCP have resulted in collection of well-annotated information and research-quality specimens from a large number of AAW. This unique resource will allow for the identification of biological and environmental factors associated with the identification of genetic and non-genetic factors associated with the occurrence, detection, prognosis, or survival of breast cancer in AAW.
AD  - Clinical Breast Care Project, Windber Research Institute, Windber, PA 15963, USA. r.ellsworth@wriwindber.org
AN  - 17929197
AU  - Ellsworth, R. E.
AU  - Zhu, K.
AU  - Bronfman, L.
AU  - Gutchell, V.
AU  - Hooke, J. A.
AU  - Shriver, C. D.
DA  - Jun
DO  - 10.1007/s10561-007-9054-z
DP  - NLM
ET  - 2007/10/12
IS  - 2
KW  - Adult
*African Americans
Blood Banks
Breast
Breast Neoplasms/epidemiology/*ethnology/genetics/pathology
Databases, Factual
Female
Humans
Military Personnel
Patient Selection
Tissue Banks
United States
LA  - eng
N1  - Ellsworth, Rachel E
Zhu, Kangmin
Bronfman, Lee
Gutchell, Veronica
Hooke, Jeffrey A
Shriver, Craig D
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Netherlands
Cell Tissue Bank. 2008 Jun;9(2):109-20. doi: 10.1007/s10561-007-9054-z. Epub 2007 Oct 11.
PY  - 2008
SN  - 1389-9333 (Print)
1389-9333
SP  - 109-20
ST  - The Clinical Breast Care Project: an important resource in investigating environmental and genetic contributions to breast cancer in African American women
T2  - Cell Tissue Bank
TI  - The Clinical Breast Care Project: an important resource in investigating environmental and genetic contributions to breast cancer in African American women
VL  - 9
ID  - 511
ER  - 

TY  - JOUR
AB  - IMPORTANCE: Black patients have been underrepresented in prospective clinical trials of advanced prostate cancer. This study evaluated the efficacy of enzalutamide compared with bicalutamide, with planned subset analysis of Black patients with metastatic hormone-sensitive prostate cancer (mHSPC), which is a disease state responsive to androgen deprivation therapy (ADT). OBJECTIVE: To compare the efficacy of enzalutamide vs bicalutamide in combination with ADT in men with mHSPC, with a subset analysis of Black patients. DESIGN, SETTING, AND PARTICIPANTS: In this randomized clinical trial, a phase 2 screening design enabled a nondefinitive comparison of the primary outcome by treatment. Patients were stratified by race (Black or other) and bone pain (present or absent). Accrual of at least 30% Black patients was required. This multicenter trial was conducted at 4 centers in the US. Men with mHSPC with no history of seizures and adequate marrow, renal, and liver function were eligible. Data analysis was performed from February 2019 to March 2020. INTERVENTIONS: Participants were randomized 1:1 to receive oral enzalutamide (160 mg daily) or bicalutamide (50 mg daily) in addition to ADT. MAIN OUTCOMES AND MEASURES: The primary end point was the 7-month prostate-specific antigen (PSA) response (SMPR) rate, a previously accepted surrogate for overall survival (OS) outcome. Secondary end points included adverse reactions, time to PSA progression, and OS. RESULTS: A total of 71 men (median [range] age, 65 [51-86] years) were enrolled; 29 (41%) were Black, 41 (58%) were White, and 1 (1%) was Asian. Thirty-six patients were randomized to receive enzalutamide, and 35 were randomized to receive bicalutamide. Twenty-six patients (37%) had bone pain and 37 patients (52%) had extensive disease. SMPR was achieved in 30 of 32 patients (94%; 95% CI, 80%-98%) taking enzalutamide and 17 of 26 patients (65%; 95% CI, 46%-81%) taking bicalutamide (P = .008) (difference, 29%; 95% CI, 5%-50%). Among Black patients, the SMPR was 93% (95% CI, 69%-99%) among those taking enzalutamide and 42% (95% CI, 19%-68%) among those taking bicalutamide (P = .009); among non-Black patients, the SMPR was 94% (95% CI, 74%-99%) among those taking enzalutamide and 86% (95% CI, 60%-96%) among those taking bicalutamide. The 12-month PSA response rates were 84% with enzalutamide and 34% with bicalutamide. CONCLUSIONS AND RELEVANCE: The findings of this randomized clinical trial comparing enzalutamide with bicalutamide suggest that enzalutamide is associated with improved outcomes compared with bicalutamide, in terms of the rate and duration of PSA response, in Black patients with mHSPC. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02058706.
AD  - Department of Oncology, Karmanos Cancer Center, Wayne State University, Detroit, Michigan.
Department of Internal Medicine, University of Michigan, Ann Arbor.
Department of Internal Medicine, The Ohio State University, Columbus.
Department of Internal Medicine, Henry Ford Hospital, Detroit, Michigan.
Department of Internal Medicine, Dana Farber Cancer Institute, Boston, Massachusetts.
John D. Dingell Veterans Affairs Medical Center, Detroit, Michigan.
Department of Urology, Wayne State University, Detroit, Michigan.
AN  - 33496795
AU  - Vaishampayan, U. N.
AU  - Heilbrun, L. K.
AU  - Monk, P., 3rd
AU  - Tejwani, S.
AU  - Sonpavde, G.
AU  - Hwang, C.
AU  - Smith, D.
AU  - Jasti, P.
AU  - Dobson, K.
AU  - Dickow, B.
AU  - Heath, E. I.
AU  - Semaan, L.
AU  - Cher, M. L.
AU  - Fontana, J. A.
AU  - Chinni, S.
C2  - PMC7838941 support from Astellas and BMS and consulting fees and honoraria from AAA, Alkermes, BMS, Eisai, Exelixis, Sanofi, Bayer, Merck, and Pfizer. Dr Monk reported receiving consulting fees from Sanofi, Dendreon, and Bayer and an honorarium from Janssen. Dr Sonpavde reported receiving advisory fees from BMS, Genentech, EMD Serono, Merck, Sanofi, Seattle Genetics/Astellas, AstraZeneca, Exelixis, Janssen, Bicycle Therapeutics, and Pfizer; research support from Sanofi and AstraZeneca; travel reimbursement from BMS and AstraZeneca; speaking fees from Physicians Education Resource, Onclive, Research to Practice, and Medscape; and writing fees from UptoDate and has served on the steering committees for BMS, Bavarian Nordic, Seattle Genetics, and QED (uncompensated), and AstraZeneca, EMD Serono, and Debiopharm (compensated). No other disclosures were reported.
DA  - Jan 4
DO  - 10.1001/jamanetworkopen.2020.34633
DP  - NLM
ET  - 2021/01/27
IS  - 1
KW  - *African Americans
Aged
Aged, 80 and over
Androgen Antagonists/*therapeutic use
Anilides/*therapeutic use
Antineoplastic Agents/*therapeutic use
Biomarkers, Tumor/blood
Drug Therapy, Combination
Humans
Male
Middle Aged
Nitriles/*therapeutic use
Phenylthiohydantoin/*analogs & derivatives/therapeutic use
Prostate-Specific Antigen/blood
Prostatic Neoplasms/*drug therapy/ethnology
Tosyl Compounds/*therapeutic use
Treatment Outcome
LA  - eng
N1  - 2574-3805
Vaishampayan, Ulka N
Heilbrun, Lance K
Monk, Paul 3rd
Tejwani, Sheela
Sonpavde, Guru
Hwang, Clara
Smith, Daryn
Jasti, Pallavi
Dobson, Kimberlee
Dickow, Brenda
Heath, Elisabeth I
Semaan, Louie
Cher, Michael L
Fontana, Joseph A
Chinni, Sreenivasa
Clinical Trial, Phase II
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
JAMA Netw Open. 2021 Jan 4;4(1):e2034633. doi: 10.1001/jamanetworkopen.2020.34633.
PY  - 2021
SN  - 2574-3805
SP  - e2034633
ST  - Clinical Efficacy of Enzalutamide vs Bicalutamide Combined With Androgen Deprivation Therapy in Men With Metastatic Hormone-Sensitive Prostate Cancer: A Randomized Clinical Trial
T2  - JAMA Netw Open
TI  - Clinical Efficacy of Enzalutamide vs Bicalutamide Combined With Androgen Deprivation Therapy in Men With Metastatic Hormone-Sensitive Prostate Cancer: A Randomized Clinical Trial
VL  - 4
ID  - 10
ER  - 

TY  - JOUR
AB  - PURPOSE: We determined if age is a prognostic factor of clinical outcomes, specifically overall survival, disease-free survival and progression-free survival in men with hormone refractory prostate cancer. MATERIALS AND METHODS: Data from 8 multi-institutional trials performed by Cancer and Leukemia Group B were combined. Eligible patients had progressive adenocarcinoma of the prostate after androgen ablation, Eastern Cooperative Oncology Group performance status 0 to 2, and adequate hematological, renal and hepatic function. The proportional hazards model stratified by study was used to assess the prognostic importance of age for predicting clinical outcomes. RESULTS: Of 1,194 men 132 (11%) were 50 to 60 years old and 120 (10%) were 80 to 89 years old. Median survival was 12.2 months (95% CI 10.6 to 13.8) in men 50 to 59 years old, 15.9 months (95% CI 14.2 to 17.6) in men 60 to 69 years old, 15.6 months (95% CI 13.8 to 16.9) in men 70 to 79 years old and 8.9 months (95% CI 6.6 to 12.1) in men 80 to 89 years old. Compared to 70 to 79-year-old men the HR for death in octogenarians was 1.3 (95% CI 1.0 to 1.6, p = 0.015). Furthermore, the HR for prostate cancer death in octogenarians was 1.3 (95% CI 1.1 to 1.7, p = 0.010) and in 50 to 59-year-old men it was 1.3 (95% CI 1.0 to 1.6, p = 0.042) compared to men 70 to 79 years old. Black men were at lower risk for death than white men (HR 0.77, 95 CI% 0.65 to 0.92, p = 0.004). CONCLUSIONS: Octogenarians and white men are at increased risk for death compared to other men with hormone refractory prostate cancer.
AD  - Department of Biostatistics and Bioinformatics, Duke University Medical Center, 2424 Erwin Road, Durham, NC 27705, USA. susan.halabi@duke.edu
AN  - 16753374
AU  - Halabi, S.
AU  - Vogelzang, N. J.
AU  - Ou, S. S.
AU  - Kelly, W. K.
AU  - Small, E. J.
DA  - Jul
DO  - 10.1016/s0022-5347(06)00566-0
DP  - NLM
ET  - 2006/06/07
IS  - 1
KW  - Adenocarcinoma/*mortality
Age Factors
Aged
Aged, 80 and over
Androgen Antagonists/therapeutic use
Antineoplastic Agents, Hormonal/therapeutic use
Clinical Trials as Topic
Disease Progression
Disease-Free Survival
European Continental Ancestry Group
Humans
Male
Middle Aged
Prognosis
Proportional Hazards Models
Prostatic Neoplasms/*mortality
Risk Factors
Survival Rate
LA  - eng
N1  - Halabi, Susan
Vogelzang, Nicholas J
Ou, San-San
Kelly, Wm Kevin
Small, Eric J
CA 02599/CA/NCI NIH HHS/United States
CA 03927/CA/NCI NIH HHS/United States
CA 04326/CA/NCI NIH HHS/United States
CA 04457/CA/NCI NIH HHS/United States
CA 08025/CA/NCI NIH HHS/United States
CA 11028/CA/NCI NIH HHS/United States
CA 11789/CA/NCI NIH HHS/United States
CA 12046/CA/NCI NIH HHS/United States
CA 12449/CA/NCI NIH HHS/United States
CA 16450/CA/NCI NIH HHS/United States
CA 21060/CA/NCI NIH HHS/United States
CA 31983/CA/NCI NIH HHS/United States
CA 32291/CA/NCI NIH HHS/United States
CA 33601/CA/NCI NIH HHS/United States
CA 35091/CA/NCI NIH HHS/United States
CA 35279/CA/NCI NIH HHS/United States
CA 35421/CA/NCI NIH HHS/United States
CA 36601/CA/NCI NIH HHS/United States
CA 37135/CA/NCI NIH HHS/United States
CA 41287/CA/NCI NIH HHS/United States
CA 45374/CA/NCI NIH HHS/United States
CA 45389/CA/NCI NIH HHS/United States
CA 45418/CA/NCI NIH HHS/United States
CA 45808/CA/NCI NIH HHS/United States
CA 47545/CA/NCI NIH HHS/United States
CA 47555/CA/NCI NIH HHS/United States
CA 47559/CA/NCI NIH HHS/United States
CA 47577/CA/NCI NIH HHS/United States
CA 52784/CA/NCI NIH HHS/United States
CA 60138/CA/NCI NIH HHS/United States
CA 71232/CA/NCI NIH HHS/United States
CA 74811/CA/NCI NIH HHS/United States
CA 77298/CA/NCI NIH HHS/United States
CA 77406/CA/NCI NIH HHS/United States
CA 77597/CA/NCI NIH HHS/United States
CA 77658/CA/NCI NIH HHS/United States
Journal Article
Multicenter Study
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.
United States
J Urol. 2006 Jul;176(1):81-6. doi: 10.1016/S0022-5347(06)00566-0.
PY  - 2006
SN  - 0022-5347 (Print)
0022-5347
SP  - 81-6
ST  - Clinical outcomes by age in men with hormone refractory prostate cancer: a pooled analysis of 8 Cancer and Leukemia Group B (CALGB) studies
T2  - J Urol
TI  - Clinical outcomes by age in men with hormone refractory prostate cancer: a pooled analysis of 8 Cancer and Leukemia Group B (CALGB) studies
VL  - 176
ID  - 565
ER  - 

TY  - JOUR
AB  - Background: We have previously shown in multivariable analysis that African American (AA) men had 19% lower risk of death than Caucasian (C) men with metastatic castration resistant prostate cancer (mCRPC) treated with a docetaxel (D) prednisone (P) based regimen. The primary goal of this analysis was to compare progression‐free survival (PFS) and PSA PFS in C men, AA men, and Asian men with mCRPC treated with a DP based regimen. Methods: Individual patient data from 8,820 mCRPC men randomized on nine phase III trials to a DP containing regimen were combined. Race used in the analysis was based on self‐report. The endpoints were PFS and PSA PFS. Per protocol definition of PFS was used in the analysis while PSA PFS was defined per PCWG3 criteria. The proportional hazards model was used to assess the prognostic importance of race in predicting PFS and PSA PFS, adjusting for treatment arm and prognostic factors that were common across the trials (performance status, and sites of metastases). Results: Of 8,820 patients, 7,528 (85%) were C, 500 (6%) were AA, 424 (5%) were Asian and 368 (4%) had race unspecified. Men with race unspecified were excluded from the analysis, leaving 8,452 men. Median PFS was 8.3 months (m) (95% CI = 8.18.5), 8.2 m (95% CI = 7.48.8), and 8.3 m (95% CI = 7.68.8) in C, AA and Asian men, respectively. In multivariable analysis adjusting for risk factors, the pooled hazard ratios for AA vs. C was 1.04 (95% CI = 0.94‐1.15, p‐value = 0.461) and 1.08 (95% CI = 0.961.21, p‐value = 0.192) for Asian vs. C. PSA data were available for 6,685 (89%) C, 456 (91%) AA and 412 (97%) Asian men. Median PSA PFS were 9.7 m (95% CI = 9.4‐10), 8.5 m (95% CI = 7.6‐10) and 10.0 m (95% CI = 9.5‐11.8) in C, AA and Asian, respectively. In multivariable analysis, the pooled hazard ratios were 1.05 (95% CI = 0.94‐1.16, p‐value = 0.408) for AA vs. C and 1.00 (95% CI = 0.82‐1.22, p‐value = 0.996) for Asian vs. C. Conclusions: There were no differences in PFS and PSA PFS outcomes in C, AA, or Asian men with mCRPC enrolled on these phase III clinical trials with DP.
AN  - CN-01938748
AU  - Halabi, S.
AU  - Dutta, S.
AU  - Chi, K. N.
AU  - Tangen, C. M.
AU  - Petrylak, D. P.
AU  - Araujo, J. C.
AU  - Fizazi, K.
AU  - Quinn, D. I.
AU  - Higano, C. S.
AU  - Tannock, I.
AU  - et al.
KW  - *African American
*Asian
*Caucasian
*castration resistant prostate cancer
*clinical outcome
Adult
Cancer patient
Cancer prognosis
Cancer survival
Conference abstract
Controlled study
Drug therapy
Female
Human
Major clinical study
Male
Metastasis
Patient coding
Phase 3 clinical trial
Progression free survival
Randomized controlled trial
Risk factor
Self report
Statistical significance
M3  - Journal: Conference Abstract
PY  - 2019
ST  - Clinical outcomes in Caucasian (C), African American (AA) and Asian men with metastatic castration-resistant prostate cancer (mCRPC)
T2  - Journal of clinical oncology
TI  - Clinical outcomes in Caucasian (C), African American (AA) and Asian men with metastatic castration-resistant prostate cancer (mCRPC)
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01938748/full
VL  - 37
ID  - 1501
ER  - 

TY  - JOUR
AB  - BACKGROUND: We have shown previously in multivariable analysis that black men had 19% lower risk of death than white men with metastatic castration resistant prostate cancer (mCRPC) treated with a docetaxel (D) and prednisone (P)‐based regimen. The primary goal of this analysis was to compare progression‐free survival (PFS), biochemical PFS, ≥50% decline in PSA from baseline and objective response rate (ORR) in white, black and Asian men with mCRPC treated with a DP‐based regimen. PATIENTS AND METHODS: Individual patient data from 8,820 mCRPC men randomized on nine phase III trials to DP‐containing regimen were combined. Race used in the analysis was based on self‐report. Endpoints were PFS, biochemical PSA, ≥50% decline in PSA from baseline and ORR. The proportional hazards and the logistic regression models were employed to assess the prognostic importance of race in predicting outcomes adjusting for established prognostic factors. RESULTS: Of 8,820 patients, 7,528 (85%) were white, 500 (6%) were black, 424 were Asian (5%) and 368 (4%) had race unspecified. Median PFS were in months 8.3 (95% CI 8.1‐8.5), 8.2 (95% CI 7.4‐8.8), and 8.3 (95% CI 7.6‐8.8) in white, black and Asian men, respectively. Median PSA PFS were 9.7 months (95% CI 9.4‐10), 8.5 months (95% CI 7.6‐10) and 10.0 (95% CI 9.5‐11.8) in white, black and Asian men, respectively. CONCLUSIONS: We observed no differences in clinical outcomes by race and ethnic groups in men with mCRPC enrolled on these phase III clinical trials with DP.
AN  - CN-02098245
AU  - Halabi, S.
AU  - Dutta, S.
AU  - Tangen, C. M.
AU  - Rosenthal, M.
AU  - Petrylak, D. P.
AU  - Thompson, I. M.
AU  - Chi, K. N.
AU  - De Bono, J. S.
AU  - Araujo, J. C.
AU  - Logothetis, C.
AU  - et al.
DO  - 10.1016/j.annonc.2020.03.309
KW  - *biochemical progression free survival
*castration resistant prostate cancer
*clinical outcome
Adult
Article
Asian
Cancer patient
Cancer prognosis
Cancer survival
Controlled study
Ethnic group
Human
Major clinical study
Male
Patient coding
Phase 3 clinical trial
Race
Randomized controlled trial
Self report
M3  - Journal: Article in Press
PY  - 2020
ST  - Clinical Outcomes in Men of Diverse Ethnic Backgrounds with Metastatic Castration Resistant Prostate Cancer
T2  - Annals of oncology : official journal of the european society for medical oncology
TI  - Clinical Outcomes in Men of Diverse Ethnic Backgrounds with Metastatic Castration Resistant Prostate Cancer
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02098245/full
ID  - 1597
ER  - 

TY  - JOUR
AB  - BACKGROUND: We have shown previously in multivariable analysis that black men had 19% lower risk of death than white men with metastatic castration-resistant prostate cancer (mCRPC) treated with a docetaxel and prednisone (DP)-based regimen. The primary goal of this analysis was to compare progression-free survival (PFS), biochemical PFS, ≥50% decline in prostate-specific antigen (PSA) from baseline and objective response rate (ORR) in white, black and Asian men with mCRPC treated with a DP-based regimen. PATIENTS AND METHODS: Individual patient data from 8820 mCRPC men randomized on nine phase III trials to a DP-containing regimen were combined. Race used in the analysis was based on self-report. End points were PFS, biochemical PSA, ≥50% decline in PSA from baseline and ORR. The proportional hazards and the logistic regression models were employed to assess the prognostic importance of race in predicting outcomes adjusting for established prognostic factors. RESULTS: Of 8820 patients, 7528 (85%) were white, 500 (6%) were black, 424 were Asian (5%) and 368 (4%) had race unspecified. Median PFS were 8.3 [95% confidence interval (CI) 8.2-8.5], 8.2 (95% CI 7.4-8.8) and 8.3 (95% CI 7.6-8.8) months in white, black and Asian men, respectively. Median PSA PFS were 9.9 (95% CI 9.7-10.4), 8.5 (95% CI 8.0-10.3) and 11.1 (95% CI 9.9-12.5) months in white, black and Asian men, respectively. CONCLUSIONS: We observed no differences in clinical outcomes by race and ethnic groups in men with mCRPC enrolled on these phase III clinical trials with DP.
AD  - Duke University Medical Center and Duke University, Durham, USA. Electronic address: susan.halabi@duke.edu.
Old Dominion University, Norfolk, USA.
Fred Hutchinson Cancer Research Center, Seattle, USA.
The Royal Melbourne Hospital, Parkville, Australia.
Yale School of Medicine, New Haven, USA.
Christus San Rosa Hospital Medical Center, San Antonio, USA.
British Columbia Cancer Agency - Vancouver Centre, Vancouver, Canada.
The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, UK.
The University of Texas MD Anderson Cancer Center, Houston, USA.
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, USA.
University of Southern California Norris Comprehensive Cancer Center, Los Angeles, USA.
Gustave Roussy, Villejuif, France.
Memorial Sloan Kettering Cancer Center, New York, USA.
University of Washington and Fred Hutchinson Cancer Research Center, Seattle, USA.
Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada.
University of California, San Francisco, San Francisco, USA.
Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, USA.
AN  - 32289380
AU  - Halabi, S.
AU  - Dutta, S.
AU  - Tangen, C. M.
AU  - Rosenthal, M.
AU  - Petrylak, D. P.
AU  - Thompson, I. M., Jr.
AU  - Chi, K. N.
AU  - De Bono, J. S.
AU  - Araujo, J. C.
AU  - Logothetis, C.
AU  - Eisenberger, M. A.
AU  - Quinn, D. I.
AU  - Fizazi, K.
AU  - Morris, M. J.
AU  - Higano, C. S.
AU  - Tannock, I. F.
AU  - Small, E. J.
AU  - Kelly, W. K.
C2  - PMC7580036
C6  - NIHMS1629458
DA  - Jul
DO  - 10.1016/j.annonc.2020.03.309
DP  - NLM
ET  - 2020/04/15
IS  - 7
KW  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
Disease-Free Survival
Docetaxel/therapeutic use
Ethnic Groups
Humans
Male
Prednisone/therapeutic use
Prostate-Specific Antigen
*Prostatic Neoplasms, Castration-Resistant/drug therapy
Retrospective Studies
Treatment Outcome
*PSA decline
*biochemical progression
*disparity
*docetaxel
*objective response rate
*progression-free survival
work. DPP consultant fees: Ada Cap (Advanced Accelerator Applications), Amgen,
Astellas, AstraZeneca, Bayer, Bicycle Therapeutics (added January 2020), Boehringer
Ingelheim, Bristol Myer Squibb, Clovis, Eli Lilly, Exelixis, Incyte, Janssen,
Pfizer, Pharmacyclics, Roche Laboratories, Seattle Genetics, Urogen. Grant support:
Ada Cap (Advanced Accelerator Applications), Astellas, AstraZeneca, Bayer, Bristol
Myers Squibb, Clovis, Eli Lilly, Endocyte, Genentech, Innocrin, MedImmune, Merck,
Novartis, Pfizer, Progenics, Roche Laboratories, Sanofi Aventis, Seattle Genetics
Ownership interest/investment: Bellicum, Tyme (sold October 2019). KC reports grants
and personal fees from Janssen, Astellas, Sanofi, Bayer, Roche and AstraZeneca,
outside the submitted work. JDB has served on advisory boards and received fees from
many companies including AstraZeneca, Astellas, Bayer, Boehringer Ingelheim,
Cellcentric, Daiichi, Genentech/Roche, Genmab, GlaxoSmithKline, Janssen, Merck
Serono, Merck Sharp & Dohme, Menarini/Silicon Biosystems, Orion, Pfizer, Qiagen,
Sanofi Aventis, Sierra Oncology, Taiho, Vertex Pharmaceuticals. He is an employee of
the Institute of Cancer Research, which have received funding or other support for
his research work from AstraZeneca, Astellas, Bayer, Cellcentric, Daiichi,
Genentech, Genmab, GlaxoSmithKline, Janssen, Merck Serono, MSD, Menarini/Silicon
Biosystems, Orion, Sanofi Aventis, Sierra Oncology, Taiho, Pfizer, Vertex, and which
has a commercial interest in abiraterone, poly (ADP-ribose) polymerase inhibition in
DNA repair defective cancers and PI3K/AKT pathway inhibitors (no personal income).
He was named as an inventor, with no financial interest, for patent 8,822,438. He
has been the CI/PI of many industry sponsored clinical trials. JDB is a National
Institute for Health Research (NIHR) Senior Investigator. The views expressed in
this article are those of the author(s) and not necessarily those of the NHS, the
NIHR or the Department of Health. CL reports honoraria and consultant fees from
Sanofi, Bayer, Janssen, Astellas Pharma. In addition, he reports research grants
from Sanofi, Bayer, Janssen, Astellas Pharma and Pfizer. DIQ reports compensated
consultant: Astellas, Bayer, BMS, Advanced Accelerator Applications,
Roche/Genentech, Janssen, Merck, Novartis, Pfizer. Travel: Astellas, Bayer, Bristol
Myers Squibb, Genentech, Merck, Pfizer. Research to institution: Bayer, Bristol
Myers Squibb, Roche/Genentech, Merck, Pfizer. KF: participation to advisory
boards/honorarium for: Astellas, Bayer, Curevac, Janssen, MSD, Orion, Sanofi. MJM
reports consultant fees from Bayer, Endocyte, Advanced Accelerator Applications,
Blue Earth Diagnostics, Tokai Pharmaceuticals, Tolmar Pharmaceuticals, ORIC
Pharmaceutical. Travel: Bayer, Endocyte. In addition he reports research funding to
the institution from Bayer, Sanofi, Endocyte, Progenics, Corcept Therapeutics,
Roche/Genentech. CSH reports other from Aptevo, Aragon Pharma, Astellas,
AstraZeneca, Bayer, Clovis, Dendreon, eFFECTOR Therapeutics, Emergent, Ferring,
Genentech, Hoffman-La Roche, Medivation and Pfizer. She reports personal fees from
Aptevo, Asana, Astellas, Bayer, Blue Earth Diagnostics, Pharma, fees from Clovis,
Dendreon, Endocyte, Ferring, Hinova, Janssen, Merck, Myriad, Orion, Pfizer, Tolmar,
Carrick Therapeutics, Novartis, outside the submitted work. IFT reports other from
Sanofi, during the conduct of the study
other from Janssen, Bayer, Roche-Genentech,
outside the submitted work. EJS reports consultant fees and honoraria from Fortis,
Janssen Oncology, Beigene, Tolero Pharmaceuticals. Travel from Janssen. In addition,
he reports research grants to institution from Janssen, Merck. The remaining authors
have declared no conflicts of interest.
LA  - eng
N1  - 1569-8041
Halabi, S
Dutta, S
Tangen, C M
Rosenthal, M
Petrylak, D P
Thompson, I M Jr
Chi, K N
De Bono, J S
Araujo, J C
Logothetis, C
Eisenberger, M A
Quinn, D I
Fizazi, K
Morris, M J
Higano, C S
Tannock, I F
Small, E J
Kelly, W K
P30 CA014236/CA/NCI NIH HHS/United States
U10 CA180819/CA/NCI NIH HHS/United States
U10 CA180888/CA/NCI NIH HHS/United States
Journal Article
Meta-Analysis
Research Support, U.S. Gov't, Non-P.H.S.
Ann Oncol. 2020 Jul;31(7):930-941. doi: 10.1016/j.annonc.2020.03.309. Epub 2020 Apr 11.
PY  - 2020
SN  - 0923-7534 (Print)
0923-7534
SP  - 930-941
ST  - Clinical outcomes in men of diverse ethnic backgrounds with metastatic castration-resistant prostate cancer
T2  - Ann Oncol
TI  - Clinical outcomes in men of diverse ethnic backgrounds with metastatic castration-resistant prostate cancer
VL  - 31
ID  - 42
ER  - 

TY  - JOUR
AB  - Purpose: Minimal clinical trial participation among adolescents and young adults (AYAs) with cancer limits scientific progress and ultimately their clinical care and outcomes. These analyses examine the current state of AYA clinical research participation at a Midwestern comprehensive cancer center and affiliated pediatric hospital to advise program development and increase availability of trials and AYA participation. Enrollment is examined across all diagnoses, the entire AYA age spectrum (15–39), and both cancer therapeutic and supportive care protocols. Methods: his study was a retrospective review of electronic medical records via existing databases and registries for all AYAs. Data were collected for AYAs seen by an oncologist at the adult outpatient cancer center or at the pediatric hospital between the years 2010 and 2014. Descriptive statistics and logistic regression analyses were conducted to characterize this sample. Results: In the pediatric setting, 42.3% of AYAs were enrolled in a study compared to 11.2% in the adult setting. Regression analyses in the pediatric setting revealed that AYAs with private insurance or Caucasian race were more likely to participate. Within the adult setting, ethnicity, race, insurance, and diagnosis were associated with study participation; 54.8% of study enrollments were for cancer therapeutic and 43.4% for supportive care studies. Conclusions: These results are comparable to previously published data and support the need for new local and national AYA initiatives to increase the availability of and enrollment in therapeutic clinical trials. The same is true for supportive care studies which play a crucial role in improving quality of life.
AD  - S.D. Sanford, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, 675 N. St. Clair Street Suite 21-100, Chicago, IL, United States
AU  - Sanford, S. D.
AU  - Beaumont, J. L.
AU  - Snyder, M. A.
AU  - Reichek, J.
AU  - Salsman, J. M.
DB  - Embase
Medline
DO  - 10.1007/s00520-016-3558-7
IS  - 5
KW  - adolescent
adult
article
Black person
brain cancer
breast cancer
cancer center
cancer patient
Caucasian
central nervous system tumor
clinical research
digestive system cancer
female
female genital tract cancer
head and neck cancer
Hispanic
human
leukemia
lymphoma
major clinical study
male
medicaid
myeloma
patient participation
pediatric hospital
priority journal
private health insurance
retrospective study
sarcoma
skin cancer
urogenital tract cancer
young adult
LA  - English
M3  - Article
N1  - L614057719
2017-01-18
2017-04-11
PY  - 2017
SN  - 1433-7339
0941-4355
SP  - 1579-1586
ST  - Clinical research participation among adolescent and young adults at an NCI-designated Comprehensive Cancer Center and affiliated pediatric hospital
T2  - Supportive Care in Cancer
TI  - Clinical research participation among adolescent and young adults at an NCI-designated Comprehensive Cancer Center and affiliated pediatric hospital
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L614057719&from=export
http://dx.doi.org/10.1007/s00520-016-3558-7
VL  - 25
ID  - 936
ER  - 

TY  - JOUR
AB  - BACKGROUND. To the authors' knowledge, only limited data are available regarding clinical trial accrual patterns and the barriers encountered among newly diagnosed patients seen at community-based cancer centers. METHODS. In the current study, the authors prospectively collected clinical and sociodemographic data from all adult patients seen at a community-based cancer center who had new cancers diagnosed between 2003-2004. Clinical trial enrollment decisions were noted and factors that prevented accrual were identified. RESULTS. There was a total of 1012 new cancer patients. In 587 patients (58%), clinical trials appropriate for the diagnosis and stage of disease were not available. Among those patients for whom trials were available, 19.8% did not meet eligibility criteria, and only 9.9% of patients were enrolled. Although more trials were found to be available for women compared with men (51% vs. 32%; P < 0.01), the accrual rates were equal (11.2% vs. 7.6%; P = 0.24). Elderly patients comprised approximately 59.4% of those patients with available trials, but they were less likely to be enrolled (5.1% vs. 16.8%; P < 0.01). The major barriers to nonparticipation can be grouped into protocol limitations (68.1%), physician triage (16%), and patient decisions (15.9%). The overall accrual rate when all patients were included was 4% (42 of 1012 patients). CONCLUSIONS. At the study institution, participation in clinical trials is reported to be low. The unavailability of appropriate clinical trials represents the most significant barrier. Continuing efforts to encourage physicians and to educate patients remain necessary. If the current study findings are found to be applicable to other community-based cancer centers, making a larger variety of clinical trials available to the community may help to improve the accrual of patients to national cancer clinical trials.
AN  - WOS:000234588700025
AU  - Go, R. S.
AU  - Frisby, K. A.
AU  - Lee, J. A.
AU  - Mathiason, M. A.
AU  - Meyer, C. M.
AU  - Ostern, J. L.
AU  - Walther, S. M.
AU  - Schroeder, J. E.
AU  - Meyer, L. A.
AU  - Umberger, K. E.
DA  - Jan
DO  - 10.1002/cncr.21597
IS  - 2
N1  - 16353206
PY  - 2006
SN  - 0008-543X
SP  - 426-433
ST  - Clinical trial accrual among new cancer patients at a community-based cancer center - A prospective study
T2  - Cancer
TI  - Clinical trial accrual among new cancer patients at a community-based cancer center - A prospective study
VL  - 106
ID  - 3223
ER  - 

TY  - JOUR
AB  - The lack of accrual to research studies and clinical trials is a persistent problem with serious consequences: Advances in medical science depend on the participation of large numbers of people, including members of minority and underserved populations. The current study examines a critical determinant of accrual: the approach of patients by professional recruiters who request participation in research studies and clinical trials. Findings indicate that recruiters use a number of verbal strategies in the communication process, including translating study information (such as simplifying, using examples, and substituting specific difficult or problematic words), using linguistic reframing or metaphors, balancing discussions of research participation risks with benefits, and encouraging potential participants to ask questions. The identification of these verbal strategies can form the basis of new communication protocols that will help medical and nonmedical professionals communicate more clearly and effectively with patients and other potential participants about research studies and clinical trials, which should lead to increased accrual in the future.
AN  - WOS:000380157700005
AU  - Morgan, S. E.
AU  - Mouton, A.
AU  - Occa, A.
AU  - Potter, J.
DO  - 10.1080/10810730.2016.1157654
IS  - 7
N1  - 27259754
PY  - 2016
SN  - 1081-0730
SP  - 765-772
ST  - Clinical Trial and Research Study Recruiters' Verbal Communication Behaviors
T2  - Journal of Health Communication
TI  - Clinical Trial and Research Study Recruiters' Verbal Communication Behaviors
VL  - 21
ID  - 2957
ER  - 

TY  - JOUR
AB  - Background: It is estimated only 8-11% of patients with glioblastoma (GBM) enrol in clinical trials, limiting treatment development. We analysed the clinical and demographic features of patients with GBM enroled in clinical trials at the University of Texas MD Anderson Cancer Center (MDACC). Methods: We reviewed the records of adult patients treated for primary GBM between 2007 and 2012 at the MDACC. A total of 755 patients were identified: 133 were deemed noneligible, 111 were deemed trial eligible but received standard care and 511 participated in a clinical trial (311 for newly diagnosed glioblastoma [nGBM] and 200 for recurrent glioblastoma [rGBM]). Population characteristics were analysed using descriptive statistics, and survival end- points were evaluated with the KaplaneMeier method. Results: The median age of clinical trial participants and trial eligible patients was 53.2 years (standard deviation 12.1). Most patients (49.4%) were enroled in a clinical trial protocol for nGBM. The majority of nGBM trial participants were male patients (65.1%), white (86.3%), married (84.4%) and in state (59.9%). Employment status, education, symptoms, tumour location, performance status, extent of resection and treatment facility differed between nGBM trial participants and non-participants. Patients who were eligible but did not enrol tended to be older, have worse performance status and live farther away from the MDACC. Conclusion: Numerous disease and demographic barriers exist in trial enrolment in patients with GBM. This study highlights some of these obstacles, which require attention to improve patient enrolment to clinical trials. Patient and physician engagement in novel therapeutic strategies is essential to improving outcomes in this disease. (C) 2019 Elsevier Ltd. All rights reserved.
AN  - WOS:000466069400014
AU  - Harrison, R. A.
AU  - Anderson, M. D.
AU  - Cachia, D.
AU  - Kamiya-Matsuoka, C.
AU  - Weathers, S. P. S.
AU  - O'Brien, B. J.
AU  - Penas-Prado, M.
AU  - Yung, W. K. A.
AU  - Wu, J. M.
AU  - Yuan, Y.
AU  - de Groot, J. F.
DA  - May
DO  - 10.1016/j.ejca.2019.02.007
N1  - 30951926
PY  - 2019
SN  - 0959-8049
SP  - 83-93
ST  - Clinical trial participation of patients with glioblastoma at The University of Texas MD Anderson Cancer Center
T2  - European Journal of Cancer
TI  - Clinical trial participation of patients with glioblastoma at The University of Texas MD Anderson Cancer Center
VL  - 112
ID  - 2823
ER  - 

TY  - JOUR
AB  - Introduction: Participation in clinical trial (CT) research can help decrease health disparities in rural communities. The purpose of this study was to examine the perceptions of principal investigators (PIs) regarding CT participation barriers and recruitment efforts in rural South Carolina, USA and to assess the actual pool of potential CT participants in rural and urban South Carolina. The ultimate goal was to evaluate the fit between PIs' perceptions and the pool of eligible participants in rural South Carolina. Methods: An online survey was conducted with 119 CT PIs from South Carolina's five main academic medical centers located in urban areas of the state, for a response rate of 31%. Secondary data analyses were also conducted using data from government health insurance plans, including the 2009 South Carolina Medicaid, the 2009 State Health Plan (SHP) data, and census data from the 2005-2009 American Community Survey (ACS). Both parametric and non-parametric statistics were used to analyze survey and secondary data. Results: Principal investigators perceived greater recruitment barriers in rural areas than in the general population. They indicated having difficulty finding CT participants in rural areas compared to the general population (t=-2.985, p=0.004). Rural residents were significantly more likely to be perceived as lacking knowledge and understanding about CT than the general public (t=-2.105, p=0.038), having significantly lower literacy than the general public (t=-2.058, p=0.043), lacking information about available CTs (t=-2.913, p=0.005), and having limited accessibility to trial sites compared to the general population (t=-4.380, p=0.000). Patients' insurance coverage, however, was not found to be a significant barrier for CT participation (t=0.418, p=0.677). Secondary data variables were aligned with these barriers. Data revealed that rural residents have slightly lower educational attainment than urban citizens (t=5.384, p=0.000), and more people live below poverty level in rural areas (23%) than in urban areas (15%) (t=4.86, p=0.000). The secondary data analyses also showed that the majority of rural citizens covered by the SHP and Medicaid are eligible for CTs. ACS data revealed that 75% of people in rural areas meet one or more basic eligibility requirements to participate in CTs compared to 83% in urban areas. Conclusions: Some important barriers hinder CT enrollment of rural participants, such as accessibility to trial sites, poverty, lack of knowledge about CTs, among others. Data suggested that insurance coverage, however, is not a barrier to CT participation. Although CT PIs are correct in considering these barriers in rural areas, there still exists a large pool of potentially eligible CT participants in rural South Carolina. PIs, who were recruited from urban academic medical centers, may therefore be perpetuating unhelpful rural myths about CT eligibility in rural communities. Despite their remote locations, rural citizens should take part in medical research. Greater communication between PIs and rural participants and better education of PIs on communication strategies are needed to enhance CT participation in rural South Carolina.
AN  - WOS:000343520700017
AU  - Bergeron, C. D.
AU  - Foster, C.
AU  - Friedman, D. B.
AU  - Tanner, A.
AU  - Kim, S. H.
DA  - Oct-Dec
IS  - 4
N1  - 2567
24325179
PY  - 2013
SN  - 1445-6354
ST  - Clinical trial recruitment in rural South Carolina: a comparison of investigators' perceptions and potential participant eligibility
T2  - Rural and Remote Health
TI  - Clinical trial recruitment in rural South Carolina: a comparison of investigators' perceptions and potential participant eligibility
VL  - 13
ID  - 3034
ER  - 

TY  - JOUR
AB  - PURPOSE: Internet-based clinical trial information services are being developed to increase recruitment to studies. However, there are limited data that evaluate their ability to reach elderly and underrepresented minority populations. This study was designed to evaluate the ability of an established clinical trials registry to reach these populations based on expected Internet use. PATIENTS AND METHODS: This study compares general Internet users to participants who enrolled in an Internet based colorectal cancer clinical trials registry established by OncoLink (www.oncolink.org) and the National Colorectal Cancer Research Alliance. Observed rates of demographic groupings were compared to those established for general Internet users. RESULTS: Two thousand, four hundred and thirty-seven participants from the continental United States used the Internet to register for the database. New England, the Mid-Atlantic region, and the Southeast had the highest relative frequency of participation in the database, whereas the Upper Midwest, California, and the South had the lowest rates. Compared to general Internet users, there was an overrepresentation of women (73% vs. 50%) and participants over 55 years old (27% vs. 14%). However, there was an underrepresentation of minorities (10.3% vs. 22%), particularly African Americans (3.1% vs. 8%) and Hispanics (2.8% vs. 9%). DISCUSSION: The Internet is a growing medium for registry into clinical trials databases. However, even taking into account the selection bias of Internet accessibility, there are still widely disparate demographics between general Internet users and those registering for clinical trials, particularly the underrepresentation of minorities. Internet-based educational and recruitment services for clinical trials must be designed to reach these underrepresented minorities to avoid selection biases in future clinical trials.
AD  - Fox Chase Virtua Health Cancer Treatment Center, Voorhies, New Jersey 08043, USA. johnjameswilson@gmail.com
AN  - 17207317
AU  - Wilson, J. J.
AU  - Mick, R.
AU  - Wei, S. J.
AU  - Rustgi, A. K.
AU  - Markowitz, S. D.
AU  - Hampshire, M.
AU  - Metz, J. M.
DA  - Nov-Dec
DO  - 10.1097/00130404-200611000-00007
DP  - NLM
ET  - 2007/01/09
IS  - 6
KW  - African Americans
*Clinical Trials as Topic
Female
Hispanic Americans
Humans
*Internet
Male
Middle Aged
*Minority Groups
*Patient Selection
LA  - eng
N1  - Wilson, John J
Mick, Rosemarie
Wei, S Jack
Rustgi, Anil K
Markowitz, Sanford D
Hampshire, Maggie
Metz, James M
Journal Article
Research Support, Non-U.S. Gov't
United States
Cancer J. 2006 Nov-Dec;12(6):475-81. doi: 10.1097/00130404-200611000-00007.
PY  - 2006
SN  - 1528-9117 (Print)
1528-9117
SP  - 475-81
ST  - Clinical trial resources on the internet must be designed to reach underrepresented minorities
T2  - Cancer J
TI  - Clinical trial resources on the internet must be designed to reach underrepresented minorities
VL  - 12
ID  - 537
ER  - 

TY  - JOUR
AB  - Purpose: Current prostate specific antigen markers to detect prostate cancer are limited by low specificity for high grade disease. IsoPSA™ is a blood based, structure focused assay which predicts risk by partitioning the isoforms of prostate specific antigen that are linked to cancer in an aqueous 2-phase reagent system. We validated the clinical performance of this assay for identifying high grade disease in a new contemporary biopsy cohort. Materials and Methods: We performed a multicenter prospective validation in 271 men scheduled for prostate biopsy at a total of 7 academic and community centers who were enrolled between May 2017 and March 2018. Blood samples were obtained for assay prior to biopsy. The discrimination power of the assay to detect high grade prostate cancer (Gleason 7 or greater) was evaluated by ROC analysis and compared to prior results. Clinical performance was further improved by comparison with multiparametric magnetic resonance imaging-ultrasound vs transrectal ultrasound guided biopsies. Results: The assay AUC was 0.784 for high grade vs low grade cancer/benign histology, which was superior to the AUCs of total prostate specific antigen and percent free prostate specific antigen. If 1,000 patients were biopsied, the assay would have reduced the number of unnecessary biopsies from 705 to 402 (43%) with only 22 missed high grade cancers, of which 7 would have been Gleason sum 4 + 3 or higher. Subset analysis of multiparametric magnetic resonance imaging guided biopsy produced a substantial improvement of the AUC to 0.831. Conclusions: Validation of the structure based IsoPSA assay demonstrated statistical concordance with previously reported results and verified its superior performance vs concentration based prostate specific antigen and the free-to-total prostate specific antigen ratio. The assay improvement in detecting high grade prostate cancer using multiparametric magnetic resonance imaging-ultrasound guided biopsy may help define a new diagnostic paradigm. © 2019 by American Urological Association Education and Research, Inc.
AD  - Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Mail Code Q 10-1, 9500 Euclid Ave., Cleveland, OH 44106, United States
Cleveland Diagnostics, Inc., Cleveland, OH, United States
Chesapeake Urology Assoc., Baltimore, MD, United States
Brady Urological Institute, Johns Hopkins University, Baltimore, MD, United States
Kaiser Permanente Northwest, Clackamas, OR, United States
Advanced Urology Institute, Daytona Beach, FL, United States
University of Texas Southwestern Medical Center, Dallas, TX, United States
Rabin Medical Center, Petah-Tikva, Israel
AU  - Stovsky, M.
AU  - Klein, E. A.
AU  - Chait, A.
AU  - Manickam, K.
AU  - Stephenson, A. J.
AU  - Wagner, M.
AU  - Dineen, M.
AU  - Lotan, Y.
AU  - Partin, A.
AU  - Baniel, J.
AU  - Kestranek, A.
AU  - Gawande, P.
AU  - Zaslavsky, B.
DB  - Scopus
DO  - 10.1097/JU.0000000000000185
IS  - 6
KW  - biomarkers
neoplasm grading
prostate specific antigen
prostatic neoplasms
protein isoforms
tumor
M3  - Article
N1  - Cited By :3
Export Date: 22 March 2021
PY  - 2019
SP  - 1115-1120
ST  - Clinical Validation of IsoPSA™, a Single Parameter, Structure Based Assay for Improved Detection of High Grade Prostate Cancer
T2  - Journal of Urology
TI  - Clinical Validation of IsoPSA™, a Single Parameter, Structure Based Assay for Improved Detection of High Grade Prostate Cancer
UR  - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85065805670&doi=10.1097%2fJU.0000000000000185&partnerID=40&md5=4abaea678c29e6f0dee7b0500378fd6c
VL  - 201
ID  - 2228
ER  - 

TY  - JOUR
AB  - Objective: Prostate cancer is reported to be more aggressive in Blacks. We studied the clinicopathologic features of prostate cancer in Ghana, in order to determine the factors responsible for them and to find out if there is any relationship between them. Method: Patients referred with a biopsy proven diagnosis of carcinoma of the prostate to the Cancer Center of Korle Bu Teaching Hospital, Accra, Ghana, from 2003 to 2007 were studied. Information with respect to age at diagnosis, presenting symptoms, initial PSA (iPSA), Gleason score, and disease extent were studied. Age was partitioned into 50-65 and >65 years, Gleason score into 2-6, 7, and 8-10, iPSA into 4-20 ng/ml and >20, and disease extent into T1, T2, vs. T3, T4, M1, and the relationship between them was determined. Various presenting symptoms were described. Known risk factors and screening in a context of high grade disease is discussed. Results: A total of 170 patients were studied. Mean age was 65.4 years. Majority of patients (73.7%) presented with an iPSA > 20 ng/ml, whilst 22 (14.1%) had PSA < 10 ng/ml. Gleason score ≥ 7 was found in 95 (56%) of patients. Asymptomatic patients constituted 24.0%, the rest had bone pain (22.6%), urinary (50.4%), and neurologic symptoms (3.0%).There was a statistically significant relationship between age and Gleason score (. P = 0.049), PSA and Gleason score (. P = 0.0001), and between extent of disease and Gleason score (. P = 0.0002). High fat diet and low intake of fruits and vegetables are probable risk factors in Ghana. Conclusion: Majority of patients present with symptomatic disease at a relatively older age. These patients tend to have high Gleason score partly attributable to advanced disease, age, PSA at the time of diagnosis, and race. Screening with PSA should be recommended and individualized in this group of patients in order to allow diagnosis of less aggressive disease until better screening tools are identified. © 2013 Elsevier Inc.
AD  - J. Yarney, National Center for Radiotherapy and Nuclear Medicine, Korle Bu Teaching Hospital, Accra, Ghana
AU  - Yarney, J.
AU  - Vanderpuye, V.
AU  - Mensah, J.
DB  - Embase
Medline
DO  - 10.1016/j.urolonc.2011.01.018
IS  - 3
KW  - prostate specific antigen
adult
age distribution
aged
article
bone pain
cancer center
cancer patient
chronic inflammation
controlled study
fruit
Ghana
Gleason score
human
human tissue
lipid diet
major clinical study
male
neurologic disease
priority journal
prostate cancer
randomized controlled trial
risk factor
sexually transmitted disease
urine retention
vegetable
LA  - English
M3  - Article
N1  - L51336776
2011-03-30
2013-04-09
PY  - 2013
SN  - 1078-1439
1873-2496
SP  - 325-330
ST  - Clinicopathologic features and determinants of Gleason score of prostate cancer in Ghanaian men
T2  - Urologic Oncology: Seminars and Original Investigations
TI  - Clinicopathologic features and determinants of Gleason score of prostate cancer in Ghanaian men
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L51336776&from=export
http://dx.doi.org/10.1016/j.urolonc.2011.01.018
VL  - 31
ID  - 1085
ER  - 

TY  - JOUR
AB  - Background: African American women have disproportionately higher rates of breast cancer mortality than all other ethnic groups, thus highlighting the importance of promoting early detection. Methods; African American women (N = 984) from San Diego, California, participated in a randomized controlled trial testing the efficacy of breast cancer education sessions offered in beauty salons. Cosmetologists received ongoing support, training, and additional culturally aligned educational materials to help them engage their clients in dialogues about the importance of breast cancer early detection. Posters and literature about breast cancer early detection were displayed throughout the salons and cosmetologists used synthetic breast models to show their clients how breast cancer lumps might feel. Participants in the control group received a comparable diabetes education program. Baseline and 6-month follow-up surveys were administered to evaluate changes in women's breast cancer knowledge, attitudes, and screening behaviors. Results: This intervention was well received by the participants and their cosmetologists and did not interfere with or prolong the client's salon visit. Women in the intervention group reported significantly higher rates of mammography compared to women in the control group. Training a single educator proved sufficient to permeate the entire salon with the health message, and salon clients agreed that cosmetologists could become effective health educators. Conclusions: Cosmetologists are in an ideal position to increase African American women's breast cancer knowledge and adherence to breast cancer screening guidelines. (PsycINFO Database Record (c) 2016 APA, all rights reserved)
AD  - Sadler, Georgia Robins, Moores UCSD Cancer Center, 3855 Health Sciences Dr, La Jolla, CA, US, 92093-0850
AN  - 2011-23916-008
AU  - Sadler, Georgia Robins
AU  - Ko, Celine M.
AU  - Wu, Phillis
AU  - Alisangco, Jennifer
AU  - Castañeda, Sheila F.
AU  - Kelly, Colleen
DB  - psyh
DO  - 10.1016/S0027-9684(15)30413-2
DP  - EBSCOhost
IS  - 8
KW  - randomized controlled trials
breast cancer screening
African American women
Black Cosmetologists Promoting Health Program
Adult
African Americans
Aged
Aged, 80 and over
Beauty Culture
Breast Neoplasms
Cluster Analysis
Female
Health Promotion
Humans
Male
Mammography
Middle Aged
Young Adult
Cancer Screening
Clinical Trials
Blacks
Human Females
N1  - Moores University of California, Son Diego Cancer Center, La Jolla, CA, US. Other Publishers: Elsevier Science. Release Date: 20120319. Correction Date: 20160502. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Print. Document Type: Journal Article. Language: English. Major Descriptor: Breast Neoplasms; Cancer Screening; Clinical Trials; Health Promotion. Minor Descriptor: Blacks; Human Females. Classification: Cancer (3293); Promotion & Maintenance of Health & Wellness (3365). Population: Human (10); Female (40). Location: US. Age Group: Adulthood (18 yrs & older) (300); Young Adulthood (18-29 yrs) (320); Thirties (30-39 yrs) (340); Middle Age (40-64 yrs) (360); Aged (65 yrs & older) (380); Very Old (85 yrs & older) (390). Methodology: Clinical Trial; Empirical Study; Quantitative Study. References Available: Y. Page Count: 11. Issue Publication Date: Aug, 2011.
Sponsor: Bristol Myers Squibb Foundation. Recipients: No recipient indicated
Sponsor: National Cancer Institute, US. Grant: R25 CA65745; P30 CA023100; U56CA92079/U56CA92081I; U54CA132379/U54CA132384. Recipients: No recipient indicated
Sponsor: National Institutes of Health, Division of National, Center on Minority and Health Disparities, US. Grant: P60 MD000220. Other Details: University of California, San Diego, Comprehensive Research Center in Health Disparities. Recipients: No recipient indicated
Sponsor: National Center for Research Resources. Grant: UL1 RR031980. Recipients: No recipient indicated
PY  - 2011
SN  - 0027-9684
1943-4693
SP  - 735-745
ST  - A cluster randomized controlled trial to increase breast cancer screening among African American women: The Black Cosmetologists Promoting Health Program
T2  - Journal of the National Medical Association
TI  - A cluster randomized controlled trial to increase breast cancer screening among African American women: The Black Cosmetologists Promoting Health Program
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2011-23916-008&site=ehost-live&scope=site
gsadler@ucsd.edu
VL  - 103
ID  - 1724
ER  - 

TY  - JOUR
AB  - Action Through Churches in Time to Save Lives (ACTS) of Wellness was a cluster randomized controlled trial developed to promote colorectal cancer screening and physical activity (PA) within urban African American churches. Churches were recruited from North Carolina (n = 12) and Michigan (n = 7) and were randomized to intervention (n = 10) or comparison (n = 9). Intervention participants received three mailed tailored newsletters addressing colorectal cancer screening and PA behaviors over approximately 6 months. Individuals who were not up-to-date for screening at baseline could also receive motivational calls from a peer counselor. The main outcomes were up-to-date colorectal cancer screening and Metabolic Equivalency Task (MET)-hours/week of moderate-vigorous PA. Multivariate analyses examined changes in the main outcomes controlling for church cluster, gender, marital status, weight, and baseline values. Baseline screening was high in both intervention (75.9%, n = 374) and comparison groups (73.7%, n = 338). Screening increased at follow-up: +6.4 and +4.7 percentage points for intervention and comparison, respectively (p = .25). Baseline MET-hours/week of PA was 7.8 (95% confidence interval [6.8, 8.7]) for intervention and 8.7 (95% confidence interval [7.6, 9.8]) for the comparison group. There were no significant changes (p = .15) in PA for intervention (-0.30 MET-hours/week) compared with the comparison (-0.05 MET-hours/week). Among intervention participants, PA increased more for those who participated in church exercise programs, and screening improved more for those who spoke with a peer counselor or recalled the newsletters. Overall, the intervention did not improve PA or screening in an urban church population. These findings support previous research indicating that structured PA opportunities are necessary to promote change in PA and churches need more support to initiate effective peer counselor programs.
AD  - University of North Carolina at Chapel Hill, NC, USA University at Buffalo, Buffalo, NY, USA lucialeo@buffalo.edu.
University of North Carolina at Chapel Hill, NC, USA University of Texas, Dallas, TX, USA.
University of North Carolina at Chapel Hill, NC, USA.
RTI International, Research Triangle Park, NC, USA.
New York University, New York, NY, USA.
University of Michigan, Ann Arbor, MI, USA.
AN  - 26515276
AU  - Leone, L. A.
AU  - Allicock, M.
AU  - Pignone, M. P.
AU  - Walsh, J. F.
AU  - Johnson, L. S.
AU  - Armstrong-Brown, J.
AU  - Carr, C. C.
AU  - Langford, A.
AU  - Ni, A.
AU  - Resnicow, K.
AU  - Campbell, M. K.
C2  - PMC5963515
C6  - NIHMS908619
DA  - Oct
DO  - 10.1177/1090198115611877
DP  - NLM
ET  - 2015/10/31
IS  - 5
KW  - African Americans/*psychology
Aged
Colonoscopy
Colorectal Neoplasms/diagnosis/prevention & control/*psychology
Counseling/methods
Early Detection of Cancer/*methods
Exercise/psychology
Female
*Health Knowledge, Attitudes, Practice/ethnology
Health Promotion/*methods
Humans
Male
Michigan
Middle Aged
Multivariate Analysis
North Carolina
Periodicals as Topic
Program Evaluation
*Religion and Medicine
Social Support
Surveys and Questionnaires
*African American
*church-based
*colorectal cancer screening
*peer counseling
*physical activity
*tailored health messages
LA  - eng
N1  - 1552-6127
Leone, Lucia A
Allicock, Marlyn
Pignone, Michael P
Walsh, Joan F
Johnson, La-Shell
Armstrong-Brown, Janelle
Carr, Carol C
Langford, Aisha
Ni, Andy
Resnicow, Ken
Campbell, Marci K
P30 DK056350/DK/NIDDK NIH HHS/United States
T32 CA128582/CA/NCI NIH HHS/United States
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, P.H.S.
Health Educ Behav. 2016 Oct;43(5):568-76. doi: 10.1177/1090198115611877. Epub 2015 Oct 29.
PY  - 2016
SN  - 1090-1981 (Print)
1090-1981
SP  - 568-76
ST  - Cluster Randomized Trial of a Church-Based Peer Counselor and Tailored Newsletter Intervention to Promote Colorectal Cancer Screening and Physical Activity Among Older African Americans
T2  - Health Educ Behav
TI  - Cluster Randomized Trial of a Church-Based Peer Counselor and Tailored Newsletter Intervention to Promote Colorectal Cancer Screening and Physical Activity Among Older African Americans
VL  - 43
ID  - 229
ER  - 

TY  - JOUR
AB  - PURPOSE: Lack of trust and rapport with health care providers has been identified in the under-representation of racial/ethnic minorities within clinical trials. Our study used a coach to promote trust among minority patients with advanced cancer. PATIENTS AND METHODS: Minority patients with advanced breast, colorectal, lung, or prostate carcinoma were randomly assigned to receive a coach Intervention (CI) or usual care (UC). All patients completed baseline and 6-month telephone interviews to assess demographics, trust in health care providers, attitudes toward clinical trials, and quality of life. Patients randomly assigned to CI were assigned a coach, who made biweekly contacts for 6 months to address general issues, progress or development in cancer care, and available resources. Patients randomly assigned to UC received the standard of care, without this intervention. Clinical trial enrollment was assessed. RESULTS: Over 21 months, we screened 268 patients and enrolled 73 African Americans and two Asian Americans. Patients were randomly assigned to CI (n = 38) or to UC (n = 37). Longitudinal analyses were conducted on 69 patients who completed the 6-month follow-up assessment. Trial enrollment was 16 and 13 patients for the CI and UC groups, respectively. This difference was not significant (P = .351). Higher quality of life (1-point odds ratio on Functional Assessment of Cancer Treatment-General = 1.033, P = .036) and positive attitudes toward trials predicted enrollment. There was no significant difference between these groups in quality of life, attitudes toward clinical trials, perceptions of racism, trust in doctors, or depression. CONCLUSIONS: Quality of life and positive attitude toward trials predicted trial enrollment, regardless of assignment to CI or UC.
AD  - Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, St Louis, MO.
AN  - 24130255
AU  - Fracasso, P. M.
AU  - Goodner, S. A.
AU  - Creekmore, A. N.
AU  - Morgan, H. P.
AU  - Foster, D. M.
AU  - Hardmon, A. A.
AU  - Engel, S. J.
AU  - Springer, B. C.
AU  - Mathews, K. J.
AU  - Fisher, E. B.
AU  - Walker, M. S.
C2  - PMC3825290
DA  - Nov
DO  - 10.1200/jop.2013.000982
DP  - NLM
ET  - 2013/10/17
IS  - 6
KW  - Adult
African Americans/*psychology
Aged
Aged, 80 and over
Asian Americans/*psychology
Attitude to Health/*ethnology
Clinical Trials as Topic/methods/*psychology
Female
Humans
Longitudinal Studies
Male
Middle Aged
Minority Groups/*psychology
Neoplasms/*therapy
Patient Education as Topic/*methods
*Patient Selection
United States
LA  - eng
N1  - 1935-469x
Fracasso, Paula M
Goodner, Sherry A
Creekmore, Allison N
Morgan, Helen P
Foster, Denise M
Hardmon, Angela A
Engel, Seth J
Springer, Brian C
Mathews, Katherine J
Fisher, Edwin B
Walker, Mark S
R21 CA101725/CA/NCI NIH HHS/United States
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
J Oncol Pract. 2013 Nov;9(6):294-9. doi: 10.1200/JOP.2013.000982. Epub 2013 Oct 15.
PY  - 2013
SN  - 1554-7477 (Print)
1554-7477
SP  - 294-9
ST  - Coaching intervention as a strategy for minority recruitment to cancer clinical trials
T2  - J Oncol Pract
TI  - Coaching intervention as a strategy for minority recruitment to cancer clinical trials
VL  - 9
ID  - 311
ER  - 

TY  - JOUR
AB  - This study evaluated the relationship between caffeinated and decaffeinated coffee and prostate cancer (CaP) aggressiveness using data from a population-based incident CaP study within the North Carolina-Louisiana Prostate Cancer Project (PCaP). Classification of CaP aggressiveness at diagnosis was based on clinical criteria for 1,049 African-American (AA) and 1,083 Caucasian-American (CA) research subjects. Coffee consumption was measured using a modified NCI Dietary History Questionnaire. No significant associations were found between CaP aggressiveness and consumption of either caffeinated or decaffeinated coffee. The OR for high aggressive CaP among consumers of more than 4 cups per day was 0.92 (95%CI = 0.61, 1.39), compared to non-coffee-drinkers. Results stratified by race found no significant associations and no noticeable trends in either AAs (P for trend = 0. 62) or CAs (P for trend = 0.42). In contrast to a recent report on a select population that has less complete information on CaP aggressiveness suggesting that coffee prevents aggressive CaP, this rapid case ascertainment population-based study, in a biracial population with differing risks of CaP did not demonstrate a protective relationship between high coffee consumption and risk of high aggressive CaP. Copyright © 2012, Taylor & Francis Group, LLC.
AD  - L. Arab, David Geffen School of Medicine, 12-262 Factor Bldg., University of California at Los Angeles, Los Angeles, CA 90095-1736, United States
AU  - Arab, L.
AU  - Su, L. J.
AU  - Steck, S. E.
AU  - Ang, A.
AU  - Fontham, E. T. H.
AU  - Bensen, J. T.
AU  - Mohler, J. L.
DB  - Embase
Medline
DO  - 10.1080/01635581.2012.676144
IS  - 5
KW  - adult
African American
aged
article
coffee
consumer
disease association
disease course
European American
food intake
human
major clinical study
male
prostate cancer
questionnaire
research subject
risk factor
LA  - English
M3  - Article
N1  - L365209858
2012-07-18
2012-07-24
PY  - 2012
SN  - 0163-5581
1532-7914
SP  - 637-642
ST  - Coffee consumption and prostate cancer aggressiveness among African and caucasian americans in a population-based study
T2  - Nutrition and Cancer
TI  - Coffee consumption and prostate cancer aggressiveness among African and caucasian americans in a population-based study
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L365209858&from=export
http://dx.doi.org/10.1080/01635581.2012.676144
VL  - 64
ID  - 1112
ER  - 

TY  - JOUR
AB  - Many individuals receive information about genomics from the mass media. When media reports are about conditions that are considered behavioral, such as smoking, they may negatively affect some health-promoting cognitions. We examined how informing adult smokers about the genetic basis for nicotine addiction influenced smoking-related health cognitions and affect and whether responses varied by socio-demographics or genetics beliefs. We recruited 392 smokers (Mage = 44.5, 52.8% African American, 51.3% no college experience, 66.2% women) from public locations in a mid-sized Midwestern city. They were randomly assigned to read a news article describing either a pharmacy's decision to stop selling tobacco (n = 78) or the discovery of a gene associated with increased risk of nicotine addiction and lung cancer (n = 314). Participants also completed a survey assessing socio-demographics, health cognitions (quit intentions, self-efficacy, response efficacy, perceived risk), affect (worry, anticipated regret), genetic determinism, and other genetics beliefs. ANOVAs revealed no statistically significant main effects of genetic information on any health cognitions or affects. Linear regressions revealed that socio-demographics and genetics beliefs moderated very few effects. This suggests that concerns that mass media-based dissemination of genetic discoveries may have detrimental effects on smoking-related cognitions and affects are likely unwarranted.
AD  - Department of Surgery, Washington University School of Medicine, Saint Louis, Missouri, USA.
AN  - 31525122
AU  - Waters, E. A.
AU  - Ackerman, N.
AU  - Wheeler, C. S.
C2  - PMC6900866
C6  - NIHMS1541943
DO  - 10.1080/10810730.2019.1664676
DP  - NLM
ET  - 2019/09/17
IS  - 9
KW  - Adolescent
Adult
Affect
Aged
Cognition
Female
*Genetic Predisposition to Disease
*Health Communication
Humans
Male
*Mass Media
Middle Aged
Risk Assessment
Smokers/*psychology/statistics & numerical data
Socioeconomic Factors
Surveys and Questionnaires
Tobacco Use Disorder/*genetics
Young Adult
LA  - eng
N1  - 1087-0415
Waters, Erika A
Orcid: 0000-0001-7402-0133
Ackerman, Nicole
Wheeler, Courtney S
L60 MD006280/MD/NIMHD NIH HHS/United States
UL1 TR000448/TR/NCATS NIH HHS/United States
UL1 TR002345/TR/NCATS NIH HHS/United States
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
J Health Commun. 2019;24(9):700-710. doi: 10.1080/10810730.2019.1664676. Epub 2019 Sep 16.
PY  - 2019
SN  - 1081-0730 (Print)
1081-0730
SP  - 700-710
ST  - Cognitive and Affective Responses to Mass-media Based Genetic Risk Information in a Socio-demographically Diverse Sample of Smokers
T2  - J Health Commun
TI  - Cognitive and Affective Responses to Mass-media Based Genetic Risk Information in a Socio-demographically Diverse Sample of Smokers
VL  - 24
ID  - 63
ER  - 

TY  - JOUR
AB  - PURPOSE/OBJECTIVES: To describe all phases of a collaborative breast health intervention delivered by paraprofessionals or specially trained community health advisors (CHAs) for African American women designed to increase mammography screening. DESIGN: Collaborative pretest, post-test breast health intervention. SETTING: Large city in Ohio. SAMPLE: 68 African American women with a median age of 57.8 (SD = 5.28) obtained mammography screening and participated in the breast health intervention. METHODS: Specially trained CHAs used aggressive recruitment strategies to increase mammography screening and knowledge of breast health and mammography screening in African American women aged 50 and older. MAIN RESEARCH VARIABLES: Knowledge scores of breast health and mammography screening. FINDINGS: Ninety women (81%) met the inclusion criteria and were recruited into the intervention, but only 68 (76%) obtained mammography screening. The women demonstrated increased knowledge by change in pre- to post-test scores. Several questions were statistically significant. CONCLUSIONS: Collaborative breast health interventions delivered by trained CHAs are effective in increasing screenings as well as knowledge of breast health and mammography screening in African American women. The unique role of the CHA is especially important in recruitment of hard-to-reach women and was vital to the success of the educational intervention. Most importantly, the women valued the individualized attention to their breast health and agreed to share the information with significant others. Further collaborative interventions designed to increase screenings and increase knowledge of breast health and mammography screening are needed to reduce the health disparities of later-stage detection and poorer survival of breast cancer in African American women. IMPLICATIONS FOR NURSING: Oncology nurses should build on the findings and deliver further outreach programs to increase mammography screening and knowledge of breast health in a larger number of women of lower socioeconomic status. Future research is needed to determine the influence of reminder phone calls for mammography screening. Oncology nurses should incorporate evaluation strategies at baseline and periodically throughout an intervention to provide more comprehensive data and enhance the credibility of findings. To maximize success, oncology nurses should work collaboratively with other healthcare professionals such as certified x-ray technicians and influential people in the community to increase knowledge of breast health and mammography screening.
AD  - Professor of Nursing, College of Nursing and Health, Wright State University, Dayton, OH; barbara.fowler@wright.edu
AN  - 106549766. Language: English. Entry Date: 20051209. Revision Date: 20200708. Publication Type: Journal Article
AU  - Fowler, B. A.
AU  - Rodney, M.
AU  - Roberts, S.
AU  - Broadus, L.
DB  - CINAHL Complete
DO  - 10.1188/05.ONF.1207-1216
DP  - EBSCOhost
IS  - 6
KW  - Black Persons
Breast Neoplasms -- Prevention and Control
Community Health Services
Health Promotion
Mammography -- Utilization
Poverty
Community Health Workers -- Education
Convenience Sample
Cost Benefit Analysis
Descriptive Statistics
Experimental Studies
Female
Health Education
Health Knowledge -- Evaluation
Middle Age
Ohio
Oncologic Nursing
Paired T-Tests
Pretest-Posttest Design
Purposive Sample
Questionnaires
Research Subject Recruitment
Socioeconomic Factors
Human
N1  - research; tables/charts. Journal Subset: Core Nursing; Double Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Nursing; Peer Reviewed; USA. NLM UID: 7809033.
PMID: NLM16270116.
PY  - 2005
SN  - 0190-535X
SP  - 1207-1216
ST  - Collaborative breast health intervention for African American women of lower socioeconomic status
T2  - Oncology Nursing Forum
TI  - Collaborative breast health intervention for African American women of lower socioeconomic status
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106549766&site=ehost-live&scope=site
VL  - 32
ID  - 1888
ER  - 

TY  - JOUR
AB  - Bronx County, New York is the poorest urban county in the U.S.A., and residents are almost entirely Latino or African American. Cancer is the leading cause of premature death in the Bronx, with morality rates significantly higher than for New York City as a whole. Low‐income/minority populations are more likely to be diagnosed with preventable and late‐stage cancers than the general population, in part, due to lower screening rates. While research has addressed screening barriers in low‐income/minority groups, depression, a common,potentially critical barrier, has received scant attention. Research suggests that depressed women are less likely to engage in cancer screening, especially mammography and Pap testing. The link between mental health and cancer screening is particularly important to address in the Bronx, which has the highest rates of self‐reported serious psychological distress (a measure closely related to depression) in New York City. Depression affects almost 1 in 4 minority women, and while minorities often seek help for depression in primary care, primary care depression management often does not meet evidence‐based standards. Drawing on the expertise and close collaboration of Bronx medical and social service providers and patient stakeholders, this study will determine whether a collaborative care intervention that addresses both depression and cancer screening needs simultaneously among women ages 50‐64 is more effective at improving cancer screening and patient‐reported outcomes for women with depression than an existing evidence‐based cancer screening intervention alone. To achieve this, the investigators will compare the effectiveness of these two interventions using a randomized controlled trial (RCT). In partnership with three Bronx Federally Qualified Health Centers (FQHCs), the investigators will recruit approximately 756 women ages 50‐64 who screen positive for depression and are non‐adherent with recommended cervical, breast, and/or colorectal cancer screenings. The investigators specific aims are to: 1) compare the impact of the two interventions on patient‐reported outcomes, including cancer screening knowledge and attitudes, self‐efficacy, depression‐related stigma, provider referrals, participation in mental health care, medication adherence, quality of life, satisfaction with care and treatment decisions, and depression; 2) compare the effectiveness of the two interventions in increasing breast, cervical, and colorectal cancer screening; 3) determine whether reducing depression increases the likelihood that low‐income women 50‐64 will receive cancer screening; 4) determine whether effectiveness of the two interventions in increasing cancer screening varies according to patient characteristics, such as duration of depression, presence of other chronic conditions, and obesity. This study is designed to increase the investigators understanding of how to enhance primary care systems' ability to improve a range of outcomes related to cancer screening and depression among low‐income minority women, and how to best support this population in making cancer‐screening decisions.
AN  - CN-01549690
AU  - Nct
KW  - Colorectal Neoplasms
Depression
Depressive Disorder
Uterine Cervical Neoplasms
PY  - 2014
ST  - Collaborative Care to Reduce Depression and Increase Cancer Screening Among Low-Income Urban Women Project (Prevention Care Manager 3 Project)
T2  - https://clinicaltrials.gov/show/NCT02273206
TI  - Collaborative Care to Reduce Depression and Increase Cancer Screening Among Low-Income Urban Women Project (Prevention Care Manager 3 Project)
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01549690/full
ID  - 1623
ER  - 

TY  - JOUR
AB  - Community activists in Chicago believed their neighborhoods were being targeted by alcohol and tobacco outdoor advertisers, despite the Outdoor Advertising Association of America's voluntary code of principles, which claims to restrict the placement of ads for age-restricted products and prevent billboard saturation of urban neighborhoods. A research and action plan resulted from a 10-year collaborative partnership among Loyola University Chicago, the American Lung Association of Metropolitan Chicago (ALAMC), and community activists from a predominately African American church, St. Sabina Parish. In 1997 Loyola University and ALAMC researchers conducted a cross-sectional prevalence survey of alcohol and tobacco outdoor advertising. Computer mapping was used to locate all 4,247 licensed billboards in Chicago that were within 500- and 1,000-foot radiuses of schools, parks, and playlots. A 50% sample of billboards was visually surveyed and coded for advertising content. The percentage of alcohol and tobacco billboards within the 500- and 1,000-foot zones ranged from 0% to 54%. African American and Hispanic neighborhoods were disproportionately targeted for outdoor advertising of alcohol and tobacco. Data were used to convince the Chicago City Council to pass one of the nation's toughest anti-alcohol and tobacco billboard ordinances, based on zoning rather than advertising content. The ordinance was challenged in court by advertisers. Recent Supreme Court rulings made enactment of local billboard ordinances problematic. Nevertheless, the research, which resulted in specific legislative action, demonstrated the importance of linkages among academic, practice, and grassroots community groups in working together to diminish one of the social causes of health disparities.
AD  - Marcella Niehoff School of Nursing, Loyola University Chicago, 6525 N. Sheridan Road, Chicago, IL 60626, USA. dhackba@luc.edu
AN  - 12196615
AU  - Hackbarth, D. P.
AU  - Schnopp-Wyatt, D.
AU  - Katz, D.
AU  - Williams, J.
AU  - Silvestri, B.
AU  - Pfleger, M.
C2  - PMC1497388
DA  - Nov-Dec
DO  - 10.1093/phr/116.6.558
DP  - NLM
ET  - 2002/08/28
IS  - 6
KW  - Adolescent
Advertising/*legislation & jurisprudence/standards/statistics & numerical data
African Americans
Catholicism
Chicago
Child
Community Health Planning/*organization & administration
*Community Participation
*Cooperative Behavior
Cross-Sectional Studies
Electronic Data Processing
Geography
Health Services Research/*organization & administration
Hispanic Americans
Humans
Lung Neoplasms/ethnology/etiology
Minority Groups
Residence Characteristics
Small-Area Analysis
Smoking/adverse effects/ethnology
Smoking Prevention
Social Conditions
Socioeconomic Factors
Tobacco Industry/*legislation & jurisprudence/statistics & numerical data
Universities
*Urban Health
Voluntary Health Agencies
LA  - eng
N1  - 1468-2877
Hackbarth, D P
Schnopp-Wyatt, D
Katz, D
Williams, J
Silvestri, B
Pfleger, M
Journal Article
Legal Case
Public Health Rep. 2001 Nov-Dec;116(6):558-67. doi: 10.1093/phr/116.6.558.
PY  - 2001
SN  - 0033-3549 (Print)
0033-3549
SP  - 558-67
ST  - Collaborative research and action to control the geographic placement of outdoor advertising of alcohol and tobacco products in Chicago
T2  - Public Health Rep
TI  - Collaborative research and action to control the geographic placement of outdoor advertising of alcohol and tobacco products in Chicago
VL  - 116
ID  - 664
ER  - 

TY  - JOUR
AB  - Disparities in healthcare among racial and ethnic minorities are associated with poor outcomes. African Americans have the highest incidence of colorectal cancer (CRC) among all racial groups. Using a nonrandom sample of 100 African American men and women, 50 years of age and older, the authors explored CRC knowledge, perceptions, and screening behaviors of African American men and women who resided or worked in an urban low-income housing residence. The extent to which screening may be attributed to demographic, sociopsychological, and structural variables was also investigated. Respondents demonstrated inadequate knowledge of CRC, with a significant difference in mean scores between males and females. Self-report of participation in CRC screening was above the national average, with almost half of the sample reporting fecal occult blood home kit use and more than half of the sample reporting completion of sigmoid and colonoscopy exams and double contrast barium enema exam. A majority perceived CRC as a threat. A very high percentage perceived numerous benefits to CRC screening in preventing CRC susceptibility. Perceived barriers of nearly half of the sample included screening may be painful and afraid to find out something is wrong if I have CRC screening, while more than half did not know how to schedule screening. Barriers and threat were correlated with grade school education. Barriers were negatively correlated with secondary education and post-secondary education and moderately correlated with threat. Predictor variables found in the Health Belief Model accounted for a significant amount of the variance in screening behavior, barriers, and threat. Older African American men and women need more information about CRC in order to increase their awareness of CRC and the importance of screening. There is a need to educate healthcare professionals about the causes, prevention, and detection of CRC and the importance of screening.
AD  - Howard University Division of Nursing, 501 Bryant St. NW, Washington, DC 20059; pgreen@howard.edu
AN  - 106653531. Language: English. Entry Date: 20041022. Revision Date: 20150820. Publication Type: Journal Article
AU  - Green, P. M.
AU  - Kelly, B. A.
DB  - CINAHL Complete
DP  - EBSCOhost
IS  - 3
KW  - Attitude to Illness -- Evaluation
Black Persons -- United States
Cancer Screening -- Utilization
Colorectal Neoplasms
Health Knowledge -- Evaluation
Aged
Bias (Research)
Coefficient Alpha
Conceptual Framework
Convenience Sample
Correlational Studies
Data Analysis Software
Descriptive Research
Descriptive Statistics
Education, Continuing (Credit)
Educational Status
Female
Funding Source
Health Belief Model
Health Services Accessibility
Independent Variable
Male
Middle Age
Poverty
Questionnaires
Race Factors
Regression
Research Subject Recruitment
Sex Factors
Spearman's Rank Correlation Coefficient
Summated Rating Scaling
T-Tests
United States
Urban Areas
Human
N1  - CEU; exam questions; research; tables/charts. Journal Subset: Core Nursing; Double Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Nursing; Peer Reviewed; USA. Instrumentation: CRC Knowledge, Perceptions, and Screening Survey. Grant Information: Grant NIH-NR-020004 Nursing Partnership Centers on Health Disparities. NLM UID: 7805358.
PMID: NLM15238806.
PY  - 2004
SN  - 0162-220X
SP  - 206-217
ST  - Colorectal cancer knowledge, perceptions, and behaviors in African Americans
T2  - Cancer Nursing
TI  - Colorectal cancer knowledge, perceptions, and behaviors in African Americans
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106653531&site=ehost-live&scope=site
VL  - 27
ID  - 1889
ER  - 

TY  - JOUR
AB  - Background: A healthcare provider's recommendation to undergo screening has been shown to be one of the strongest predictors of completing a colorectal cancer (CRC) screening test. We sought to determine the relationship between the general quality of self-rated patient-provider communication and the completion of CRC screening. Methods: A formative study using qualitative data from focus groups and quantitative data from a cross-sectional survey of church members about the quality of their communication with their healthcare provider, their CRC risk knowledge, and whether they had completed CRC screening tests. Focus group participants were a convenience sample of African American church members. Participants for the survey were recruited by telephone from membership lists of 12 African American churches located in rural counties of North Carolina to participate in the WATCH ( Wellness for African Americans Through Churches) Project. Results: Focus Groups. Six focus groups (n = 45) were conducted prior to the baseline survey. Discussions focused on CRC knowledge, and perceived barriers/motivators to CRC screening. A theme that emerged during each groups' discussion about CRC screening was the quality of the participants' communication with their health care provider. Survey. Among the 397 participants over age 50, 31% reported CRC screening within the recommended guidelines. Participants who self-rated their communication as good were more likely to have been screened (36%) within the recommended guidelines than were participants with poor communication (17%) ( OR = 2.8, 95% CI 1.2, 6.4; p = 0.013). Participants who had adequate CRC knowledge completed CRC screening at a higher rate than those with inadequate knowledge ( p = 0.011). The percentage of participants with CRC screening in the recommended guidelines, stratified by communication and knowledge group were: 42% for good communication/adequate knowledge; 27% for good communication/ inadequate knowledge; 29% for poor communication/ adequate knowledge; and 5% for poor communication/ inadequate knowledge. Conclusions: Participants who rated their patient-provider communication as good were more likely to have completed CRC screening tests than those reporting poor communication. Among participants reporting good communication, knowledge about colorectal cancer was also associated with test completion. Interventions to improve patient-provider communication may be important to increase low rates of CRC screening test completion among African Americans.
AN  - WOS:000226530600001
AU  - Katz, M. L.
AU  - James, A. S.
AU  - Pignone, M. P.
AU  - Hudson, M. A.
AU  - Jackson, E.
AU  - Oates, V.
AU  - Campbell, M. K.
DA  - Dec 15
DO  - 10.1186/1471-2458-4-62
N1  - 62
85
15601463
PY  - 2004
SN  - 1471-2458
ST  - Colorectal cancer screening among African American church members: A qualitative and quantitative study of patient-provider communication
T2  - Bmc Public Health
TI  - Colorectal cancer screening among African American church members: A qualitative and quantitative study of patient-provider communication
VL  - 4
ID  - 2670
ER  - 

TY  - JOUR
AB  - BACKGROUND: Patient navigators may increase colorectal cancer (CRC) screening rates among adults in underserved communities, but prior randomized trials have been small or conducted at single sites and have not included substantial numbers of Haitian Creole-speaking or Portuguese-speaking patients. METHODS: We identified 465 primary care patients from 4 community health centers and 2 public hospital-based clinics who were not up-to-date with CRC screening and spoke English, Haitian Creole, Portuguese, or Spanish as their primary language. We enrolled participants from September 1, 2008, through March 31, 2009, and followed them up for 1 year after enrollment. We randomly allocated patients to receive a patient navigation-based intervention or usual care. Intervention patients received an introductory letter from their primary care provider with educational material, followed by telephone calls from a language-concordant navigator. The navigators offered patients the option of being screened by fecal occult blood testing or colonoscopy. The primary outcome was completion of any CRC screening within 1 year. Secondary outcomes included the proportions of patients screened by colonoscopy who had adenomas or cancer detected. RESULTS: During a 1-year period, intervention patients were more likely to undergo CRC screening than control patients (33.6% vs 20.0%; P < .001), to be screened by colonoscopy (26.4% vs 13.0%; P < .001), and to have adenomas detected (8.1% vs 3.9%; P = .06). In prespecified subgroup analyses, the navigator intervention was particularly beneficial for patients whose primary language was other than English (39.8% vs 18.6%; P < .001) and black patients (39.7% vs 16.7%; P = .004). CONCLUSIONS: Patient navigation increased completion of CRC screening among ethnically diverse patients. Targeting patient navigation to black and non-English-speaking patients may be a useful approach to reducing disparities in CRC screening. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01141114.
AD  - Section of General Internal Medicine, Boston Medical Center, USA. Karen.lasser@bmc.org
AN  - 21606094
AU  - Lasser, K. E.
AU  - Murillo, J.
AU  - Lisboa, S.
AU  - Casimir, A. N.
AU  - Valley-Shah, L.
AU  - Emmons, K. M.
AU  - Fletcher, R. H.
AU  - Ayanian, J. Z.
DA  - May 23
DO  - 10.1001/archinternmed.2011.201
DP  - NLM
ET  - 2011/05/25
IS  - 10
KW  - Aged
Colonoscopy/methods/statistics & numerical data
Colorectal Neoplasms/*diagnosis/*ethnology
Communication Barriers
Community Health Centers
Early Detection of Cancer/methods
Ethnic Groups/*statistics & numerical data
Female
*Health Status Disparities
Humans
Male
Mass Screening/*organization & administration
Middle Aged
Needs Assessment
Patient Education as Topic/methods
Poverty
Program Evaluation
Reference Values
Risk Factors
Socioeconomic Factors
Teaching Materials
LA  - eng
N1  - 1538-3679
Lasser, Karen E
Murillo, Jennifer
Lisboa, Sandra
Casimir, A Naomie
Valley-Shah, Lisa
Emmons, Karen M
Fletcher, Robert H
Ayanian, John Z
Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
United States
Arch Intern Med. 2011 May 23;171(10):906-12. doi: 10.1001/archinternmed.2011.201.
PY  - 2011
SN  - 0003-9926
SP  - 906-12
ST  - Colorectal cancer screening among ethnically diverse, low-income patients: a randomized controlled trial
T2  - Arch Intern Med
TI  - Colorectal cancer screening among ethnically diverse, low-income patients: a randomized controlled trial
VL  - 171
ID  - 392
ER  - 

TY  - JOUR
AB  - INTRODUCTION: Low-income, low-literacy, limited English-proficient populations have low colorectal cancer (CRC) screening rates and experience poor patient-provider communication and decision-making processes around screening. The purpose of this study was to test the effect of a CRC screening decision aid on screening-related communication and decision making in primary care visits. STUDY DESIGN: RCT with data collected from patients at baseline and immediately after the provider encounter. SETTING/PARTICIPANTS: Patients aged 50-75 years, due for CRC screening, were recruited from two safety net clinics in North Carolina and New Mexico (data collection, January 2014-September 2015; analysis, 2015). INTERVENTION: Participants viewed a CRC screening decision aid or a food safety (control) video immediately before their provider encounter. MAIN OUTCOME MEASURES: CRC screening-related knowledge, discussion, intent, test preferences, and test ordering. RESULTS: The study population (N=262) had a mean age of 58.3 years and was 66% female, 61% Latino, 17% non-Latino black, and 16% non-Latino white. Among Latino participants, 71% preferred Spanish. Compared with controls, intervention participants had greater screening-related knowledge (on average 4.6 vs 2.8 of six knowledge items correct, adjusted difference [AD]=1.8, 95% CI=1.5, 2.1) and were more likely to report screening discussion (71.0% vs 45.0%, AD=26.1%, 95% CI=14.3%, 38.0%) and high screening intent (93.1% vs 84.7%, AD=9.0%, 95% CI=2.0%, 16.0%). Intervention participants were more likely to indicate a specific screening test preference (93.1% vs 68.0%, AD=26.5%, 95% CI=17.2%, 35.8%) and to report having a test ordered (56.5% vs 32.1%, AD=25.8%, 95% CI=14.4%, 37.2%). CONCLUSIONS: Viewing a CRC screening decision aid before a primary care encounter improves knowledge and shared decision making around screening in a racially, ethnically, and linguistically diverse safety net clinic population. TRIAL REGISTRATION: This study is registered at www.clinicaltrials.gov NCT02054598.
AD  - Cecil G. Sheps Center for Health Services Research, University of North Carolina, Chapel Hill, North Carolina; Division of General Internal Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina.
Division of General Internal Medicine, University of Iowa Carver College of Medicine, Iowa City, Iowa; Holden Comprehensive Cancer Center, University of Iowa, Iowa City, Iowa.
Department of Family Medicine, Carolinas HealthCare System, Charlotte, North Carolina.
Department of Family and Community Medicine, University of New Mexico School of Medicine, Albuquerque, New Mexico; University of New Mexico Cancer Center, Albuquerque, New Mexico;
Division of General Internal Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina; Department of Biostatistics, University of North Carolina, Chapel Hill, North Carolina.
University of New Mexico Cancer Center, Albuquerque, New Mexico;
Cecil G. Sheps Center for Health Services Research, University of North Carolina, Chapel Hill, North Carolina.
Cecil G. Sheps Center for Health Services Research, University of North Carolina, Chapel Hill, North Carolina; Division of General Internal Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina. Electronic address: dreuland@med.unc.edu.
AN  - 27242081
AU  - Brenner, A. T.
AU  - Hoffman, R.
AU  - McWilliams, A.
AU  - Pignone, M. P.
AU  - Rhyne, R. L.
AU  - Tapp, H.
AU  - Weaver, M. A.
AU  - Callan, D.
AU  - de Hernandez, B. U.
AU  - Harbi, K.
AU  - Reuland, D. S.
C2  - PMC5501711
C6  - NIHMS858818
DA  - Oct
DO  - 10.1016/j.amepre.2016.03.025
DP  - NLM
ET  - 2016/06/01
IS  - 4
KW  - Aged
Colorectal Neoplasms/*diagnosis
*Decision Making
*Decision Support Techniques
Female
Humans
Male
Mass Screening/*psychology
Middle Aged
Vulnerable Populations/ethnology/*psychology
LA  - eng
N1  - 1873-2607
Brenner, Alison T
Hoffman, Richard
McWilliams, Andrew
Pignone, Michael P
Rhyne, Robert L
Tapp, Hazel
Weaver, Mark A
Callan, Danelle
de Hernandez, Brisa Urquieta
Harbi, Khalil
Reuland, Daniel S
UL1 TR001111/TR/NCATS NIH HHS/United States
P30 CA086862/CA/NCI NIH HHS/United States
UL1 TR000041/TR/NCATS NIH HHS/United States
UL1 TR001449/TR/NCATS NIH HHS/United States
UL1 TR002489/TR/NCATS NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Am J Prev Med. 2016 Oct;51(4):454-62. doi: 10.1016/j.amepre.2016.03.025. Epub 2016 May 27.
PY  - 2016
SN  - 0749-3797 (Print)
0749-3797
SP  - 454-62
ST  - Colorectal Cancer Screening in Vulnerable Patients: Promoting Informed and Shared Decisions
T2  - Am J Prev Med
TI  - Colorectal Cancer Screening in Vulnerable Patients: Promoting Informed and Shared Decisions
VL  - 51
ID  - 211
ER  - 

TY  - JOUR
AB  - The homeless represent an extremely disadvantaged population that fare worse than minority groups in access to preventive services and health, and minority groups fare worse than Whites. Early detection screening for colorectal cancer (CRC) saves lives, but empirical data about CRC screening practices among homeless Blacks and Whites are limited. Psychosocial risk factors may serve as a barrier to CRC screening completion among homeless Black individuals. A secondary data analysis of a randomized clinical trial for smoking cessation among homeless smokers was conducted to determine whether psychosocial factors and sociodemographic factors were more highly associated with CRC screening uptake among homeless Blacks than among their White counterparts. Study participants ( N = 124) were surveyed on their CRC screening status, sociodemographic variables, and psychosocial correlate measures including anxiety, depression, hopelessness, depression severity, and perceived stress. Associations between these factors were examined with logistic regression. White participants who were currently disabled/unable to work were 6.2 times more likely to ever receive CRC screening than those who were employed. Black participants with public health insurance coverage were 90% less likely to ever obtain CRC screening than participants without health insurance. Black and White participants had similar levels of anxiety symptoms, depression, and hopelessness, yet depression was the only psychosocial variable negatively associated with CRC screening status. Black and White participants with symptoms of depression were 58% less likely to complete screening than those without depression. Mental health risk and sociodemographic factors may serve as barriers to CRC screening among homeless Blacks and Whites.
AD  - 1 University of Minnesota Medical School, Minneapolis, MN, USA.
2 National Cancer Institute, Bethesda, MD, USA.
3 Barnes-Jewish Hospital, St. Louis, MO, USA.
4 University of Minnesota-Twin Cities, Minneapolis, MN, USA.
5 Uganda National Expanded Programme on Immunisation, Kampala, Uganda, Africa.
6 University of Utah, Salt Lake City, UT, USA.
AN  - 28978252
AU  - Rogers, C. R.
AU  - Robinson, C. D.
AU  - Arroyo, C.
AU  - Obidike, O. J.
AU  - Sewali, B.
AU  - Okuyemi, K. S.
C2  - PMC5681385
C6  - NIHMS904889
DA  - Dec
DO  - 10.1177/1090198117734284
DP  - NLM
ET  - 2017/10/06
IS  - 6
KW  - African Continental Ancestry Group
Colorectal Neoplasms/diagnosis/*ethnology
Depression/psychology
Early Detection of Cancer/*psychology
European Continental Ancestry Group
Female
Homeless Persons/psychology/*statistics & numerical data
Humans
Male
*Mass Screening
Middle Aged
Randomized Controlled Trials as Topic
Stress, Psychological/psychology
*cancer early detection
*colon cancer
*homelessness
*mental hygiene
*psychosocial deprivations
interest.
LA  - eng
N1  - 1552-6127
Rogers, Charles R
Robinson, Cendrine D
Arroyo, Cassandra
Obidike, Ogechi Jessica
Sewali, Barrett
Okuyemi, Kolawole S
R01 HL081522/HL/NHLBI NIH HHS/United States
R25 CA163184/CA/NCI NIH HHS/United States
U54 CA153603/CA/NCI NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
Health Educ Behav. 2017 Dec;44(6):928-936. doi: 10.1177/1090198117734284. Epub 2017 Oct 4.
PY  - 2017
SN  - 1090-1981 (Print)
1090-1981
SP  - 928-936
ST  - Colorectal Cancer Screening Uptake's Association With Psychosocial and Sociodemographic Factors Among Homeless Blacks and Whites
T2  - Health Educ Behav
TI  - Colorectal Cancer Screening Uptake's Association With Psychosocial and Sociodemographic Factors Among Homeless Blacks and Whites
VL  - 44
ID  - 154
ER  - 

TY  - JOUR
AB  - Background: Completion of colorectal cancer (CRC) screening testing is lower among low-income and minority groups than the population as a whole. Given the multiple cancer screening health disparities known to exist within the U.S., this study investigated the relationship between perceived discrimination, trust in most doctors, and completion of Fecal Occult Blood Testing (FOBT) among a low-income, minority primary care population in an urban setting. Methods: We recruited a convenience sample of adults over age 40 (n = 282) from a federally qualified community health center (70% African American). Participants completed a survey which included measures of trust in most doctors, perceived discrimination, demographics and report of cancer screening. Results: Participants reported high levels of trust in most doctors, regardless of sex, race, education or income. High trust was associated with low perceived discrimination (p < 0.01). The trend was for older participants to express more trust (p = 0.09) and less perceived discrimination (p < 0.01). Neither trust nor discrimination was associated with race or education. Trust was higher among participants over 50 who were up-to-date on FOBT screening vs. those who were not (31 vs. 29 (median), p < 0.05 by T-test). Among those over 50, up-to-date FOBT screening was nearly associated with high trust (p < 0.06; 95% CI 0.99, 1.28) and low perceived discrimination (p < 0.01; 95% CI 0.76, 0.96). Nevertheless, in multivariate-modeling, age and income explained FOBT completion better than race, trust and discrimination. Conclusion: Perceived discrimination was related to income, but not race, suggesting that discrimination is not unique to minorities, but common to those in poverty. Since trust in most doctors trended toward being related to age, FOBT screening could be negatively influenced by low trust and perceived discrimination in health care settings. A failure to address these issues in middle-aged, low income individuals could exacerbate future disparities in CRC screening.
AN  - WOS:000271328800001
AU  - Born, W.
AU  - Engelman, K.
AU  - Greiner, K. A.
AU  - Bhattacharya, S. B.
AU  - Hall, S.
AU  - Hou, Q. J.
AU  - Ahluwalia, J. S.
DA  - Sep
DO  - 10.1186/1471-2458-9-363
N1  - 363
19781085
PY  - 2009
SN  - 1471-2458
ST  - Colorectal cancer screening, perceived discrimination, and low-income and trust in doctors: a survey of minority patients
T2  - Bmc Public Health
TI  - Colorectal cancer screening, perceived discrimination, and low-income and trust in doctors: a survey of minority patients
VL  - 9
ID  - 3139
ER  - 

TY  - JOUR
AB  - Despite the significant advances in screening methods for early diagnosis, breast cancer remains a global threat and continues to be the leading cancer diagnosed in women, requiring effective therapy. Currently, combination therapy has become the hallmark of breast cancer treatment due to the high incidence of tumor recurrence and disease progression after monotherapeutic treatments, including surgery, radiotherapy, endocrine therapy, and chemotherapy. Over the past decades, there has been considerable interest in studying the anticancer effect of bioactive phytochemicals from medicinal plants combined with these conventional therapies. The rationale for this type of therapy is to use combinations of drugs that work by different mechanisms, thereby decreasing the likelihood that cancer cells will develop resistance, and also reduce the therapeutic dose and toxicity of single treatments. Three agents have received great attention with regard to their anticancer properties: 1) piperine, a dietary phytochemical isolated from black pepper (Piper nigrum L.) and long pepper (Piper longum L.); 2) sulforaphane, an isothiocyanate mainly derived from cruciferous vegetables; and 3) thymoquinone, the active compound from black seed (Nigella sativa L.). This review focused on the combined effect of these 3 compounds on conventional cancer therapy with the objective of observing enhanced efficacy compared with single treatments. This review also highlights the importance of the nanoformulation of such bioactive phytochemicals that could enhance their bioavailability by providing an efficient targeted delivery system with a reduced systemic dose while resulting in a more efficient dosing at the target site.
AD  - Department of Health Sciences, Faculty of Science, University of Mauritius, Reduit, Mauritius.
AN  - 30811596
AU  - Aumeeruddy, M. Z.
AU  - Mahomoodally, M. F.
DA  - May 15
DO  - 10.1002/cncr.32022
DP  - NLM
ET  - 2019/02/28
IS  - 10
KW  - Alkaloids/*administration & dosage
Antineoplastic Agents/administration & dosage
Benzodioxoles/*administration & dosage
Benzoquinones/*administration & dosage
Breast Neoplasms/*drug therapy/mortality/pathology
Cell Line, Tumor/drug effects
Chemotherapy, Adjuvant
Combined Modality Therapy
Female
Humans
In Vitro Techniques
Isothiocyanates/*administration & dosage
Patient Selection
Phytochemicals/*administration & dosage
Phytotherapy/*methods
Piperidines/*administration & dosage
Polyunsaturated Alkamides/*administration & dosage
Radiotherapy, Adjuvant
Sensitivity and Specificity
*breast cancer
*combination therapy
*phytochemicals
*piperine
*sulforaphane
*thymoquinone
LA  - eng
N1  - 1097-0142
Aumeeruddy, M Zakariyyah
Mahomoodally, M Fawzi
Orcid: 0000-0003-3962-8666
Journal Article
Review
United States
Cancer. 2019 May 15;125(10):1600-1611. doi: 10.1002/cncr.32022. Epub 2019 Feb 27.
PY  - 2019
SN  - 0008-543x
SP  - 1600-1611
ST  - Combating breast cancer using combination therapy with 3 phytochemicals: Piperine, sulforaphane, and thymoquinone
T2  - Cancer
TI  - Combating breast cancer using combination therapy with 3 phytochemicals: Piperine, sulforaphane, and thymoquinone
VL  - 125
ID  - 81
ER  - 

TY  - JOUR
AB  - Two regimens of chemotherapy for metastatic breast cancer were compared in a randomized controlled fashion. Regimen 1 consisted of cyclophosphamide, vinblastine, methotrexate and 5-fluorouracil (CVMF). Regimen 2 consisted of cyclophosphamide, adriamycin, methotrexate and 5-fluorouracil (CAMF). The patient population consisted of both black and white postmenopausal females who had not received any prior chemotherapy. Objective responses were observed in 25/57 patients treated with CVMF and in 28/51 patients treated with CAMF. Neither race nor choice of chemotherapeutic regimen affected prognosis, although there were differences in the pattern of metastatic involvement between the two racial groups. The median duration of survival of patients who responded to therapy has not yet been reached but will be in excess of 12 months.
AN  - 383254
AU  - Bezwoda, W. R.
AU  - de Moor, N. G.
AU  - Derman, D.
AU  - Lange, M.
AU  - Saner, R.
AU  - Dando, R.
DA  - Aug
DO  - 10.1002/1097-0142(197908)44:2<392::aid-cncr2820440204>3.0.co;2-d
DP  - NLM
ET  - 1979/08/01
IS  - 2
KW  - Adult
Aged
Antineoplastic Agents/*administration & dosage/adverse effects
Bone Marrow/drug effects
Breast Neoplasms/*drug therapy/secondary
Clinical Trials as Topic
Doxorubicin/*administration & dosage
Drug Therapy, Combination
Female
Humans
Middle Aged
Remission, Spontaneous
Vinblastine/*administration & dosage
LA  - eng
N1  - Bezwoda, W R
de Moor, N G
Derman, D
Lange, M
Saner, R
Dando, R
Clinical Trial
Comparative Study
Journal Article
Randomized Controlled Trial
United States
Cancer. 1979 Aug;44(2):392-7. doi: 10.1002/1097-0142(197908)44:2<392::aid-cncr2820440204>3.0.co;2-d.
PY  - 1979
SN  - 0008-543X (Print)
0008-543x
SP  - 392-7
ST  - Combination chemotherapy of metastatic breast cancer: a randomized trial comparing the use of adriamycin to that of Vinblastine
T2  - Cancer
TI  - Combination chemotherapy of metastatic breast cancer: a randomized trial comparing the use of adriamycin to that of Vinblastine
VL  - 44
ID  - 751
ER  - 

TY  - JOUR
AB  - The study is a randomized interventional comparative Phase II trial. The duration of the trial for each subject is expected to be 3 months.160 adult male and female patients with positive COVID‐19 diagnosis and fulfilling the below outlined inclusion criteria will be enrolled into the study. Trial population will consist of both genders. Study Type:Interventional [Change...] Primary Purpose:Treatment Study Phase:Phase 2 Interventional Study Model:Sequential Assignment Number of Arms:3 Masking: None (Open Label) Allocation:Randomized Enrollment:160 [Anticipated] Isotretinoin(13cis RA) may be able to inhibit COVID 2019 entry via down regulation of ACE2 , AT1 protein and Ang II‐mediated intracellular calcium release rather than inhibition of interleukin‐6 (IL‐6) and this is discussed as follow : The COVID‐19 pandemic caused by SARS‐COV‐2 has infected over 2,000,000 people causing over 150,000 deaths. A key host cellular protein required for the virus entry is angiotensin‐converting enzyme 2 (ACE2) whose expression has been demonstrated in many tissues including alveolar epithelial type II cells in lungs, oral mucosa and intestine, heart, kidney, endothelium and skin. ACE2‐expressing cells can act as home cells and are prone to SARS‐CoV‐2 infection as ACE2 receptor facilitates cellular viral entry and replication. A study demonestrated that patients with hypertension and diabetes mellitus may be at higher risk of SARS‐CoV‐2 infection, as these patients are often treated with ACE inhibitors (ACEIs) or angiotensin II type‐I receptor blockers (ARBs), which have been previously suggested to increase ACE2 expression. In another study by Sinha et al who analyzed a publicly available Connectivity Map (CMAP) dataset of pre/post transcriptomic profiles for drug treatment in cell lines for over 20,000 small molecules, isotretinoin was the strongest down‐regulator of ACE 2 receptors. On the other hand, they found 6 drugs in CMAP that are currently being investigated in clinical trials for treating COVID‐19 (chloroquine, thalidomide, methylprednisolone, losartan, lopinavir and ritonavir, from clinicaltrials.gov), none of which was found to significantly alter ACE2 expression (P>0.1) Moreover, another study demonstrated that isotretinoin is a Potential papain like protease (PLpro) inhibitors which is a protein encoded by SARS‐CoV‐2 genes and considered one of the proteins that should be targeted in COVID‐19 treatment by performing target‐based virtual ligand screening.As Principal Investigator discussed before that (13cRA) is the strongest down‐regulator of ACE2. and the principal investigator expects that 13cRA can inhibit or dowenrgulat ACE2 by direc interaction and binding with the transmembrane ACE2, Suggesting its therapeutic potential in preventing the entry of COVID 2019 to the host cell. Previous studies on the related severe acute respiratory syndrome coronavirus (SARS‐CoV) and SARS‐CoV FP FP have shown that calcium (Ca2+) plays an important role for fusogenic activity via a Ca2+ binding pocket with conserved glutamic acid (E) and aspartic acid (D) residuesdemonstrated that intracellular Ca2+ enhances MERS‐CoV WT PPs infection by approximately two‐fold and that E891 is a crucial residue for Ca2+interaction. Electron spin resonance revealed that this enhancement could be attributed to Ca2+ increasing MERS‐CoV FP fusion‐relevant membrane ordering. Intriguingly, isothermal calorimetry titration showed that MERS‐CoV FP binds one Ca2+, as opposed to SARS‐CoV FP which binds to two Ca2+ ion. Angiotensin II increases the intracellular calcium activity in podocytes of the intact glomerulus. The L‐type Ca2+ channel blocker nicardipine did not influence the Ang II‐mediated [Ca2+] increase and it has been postulated that SARS‐CoV‐2 binding to ACE2 may attenuate residual ACE2 activity, skewing the ACE/ACE2 balance to a state of heightened angiotensin II activity leading to pulmonary vasoconstriction and inflammatory and oxidative organ damage, which increases the risk f r acute lung injury (ALI). AngII via AT1 receptors upregulates many proinflammatory genes, such as vascular cell adhesion molecule‐1 (VCAM‐1), intercellular adhesion molecule‐1 (ICAM‐1), interleukin‐6 (IL‐6).30 but 13cis RA specifically down‐regulated the AT1 protein in a dose‐ and time‐dependent manner. Down‐regulation of the AT1 expression leads to reduced AngII‐mediated intracellular calcium release Similarly with receptor down‐regulation, Treatment with 13cRA resulted in a significant reduction in AT1 mRNA .13cRA has a glucose‐ and RAR/RXR independent mechanism for transcriptional inhibition of AT1, Isotretinoin(13cis RA) may be able to inhibit COVID 2019 infection via reversIing the androgenic induction and activation effect of (DHT) on TMPRSS2 expression and helps to prevent cleaving and activating both the spike protein (S) of COVID 2019 and the viral receptor, and this is discussed as follow : TMPRSS2 is both the most frequently altered gene in primary prostate cancer and a critical factor enabling cellular infection by coronaviruses, including SARS‐CoV‐2. The modulation of its expression by steroids could contribute to the male predominance of severe infections and given that TMPRSS2 has no known indispensable functions, and inhibitors are available, it is an appealing target for prevention or treatment of respiratory viral infections TMPRSS2, a key regulator in prostate cancerTMPRSS2 was first identified in prostate cancer shortly after the gene had been originally cloned. Prostate cancer cell lines strongly upregulated TMPRSS2 expression in response to androgens . TMPRSS2 is expressed on the luminal side of the prostate epithelium, and its expression is increased in prostate cancer tissue compared to non‐cancerous prostate tissue. Notably, the TMPRSS2 gene is a partner in one of the most common gene fusion eventsin solid tumors: somatic gene rearrangements involving TMPRSS2 witha member of the ETS family of oncogenic transcription factors, most commonly ERG. This fusion occurs in approximately 50% of primary prostate cancers among men of European ancestry.While ERG is not normally regulated by androgen, the gene fusion juxtaposes the androgen receptor regulatory elements of TMPRSS2 with the ERG gene. The ERG gene is consequently controlled by androgen receptor signaling and expressed highly in prostate cancers harboring the TMPRSS2: ERG fusion. Intriguingly, the prevalence of the TMPRSS2: ERG fusion is lower in prostate tumors of both black and Asian men. The relevance of this to the current COVID‐19 pandemic is unclear.TMPRSS2: ERG fusion‐ cancers also have a distinct set of risk factors related to hormonal signaling. For example, men with higher genetically determined transcriptional activity of the androgen receptor have a higher risk of TMPRSS2: ERG fusion‐positive prostate cancer but not of fusion‐negative prostate cancer TMPRSS2 is an androgen receptor signaling target gene and an androgen‐regulated cell‐surface serine protease expressed predominantly in prostate and lung epithelial cell TMPRSS2 is normally expressed several fold higher in the prostate relative to any other human tissue, though the normal physiological function(s) remains unknown. Importantly, unlike other TTSPs, TMPRSS2 transcription is regulated by androgenic ligands and the androgen receptor (AR). There is a positive correlation between AR and TMPRSS2 in microdissected primary tumor epithelium (r2 = 0.39 ; p <0.001). Dihydrotestosterone (DHT) significantly and dramatically induced the expression of TMPRSS2 protein with two molecular masses of 60 (full‐length) and 38 kDa (N‐terminus) in a dose responsive manner Data from Chinese outbreak show death rates for men almost 50 per cent higher than for women show that Early research from China suggests women and children are less likely to die than men if they catch the coronavirus. Death rates for Covid‐19, the disease those infected with the coronavirus develop, are low for everyone: only 2.4 per cent of the 44,672 people in the Chinese stu y died. But although roughly even numbers of men and women catch the disease, men are more likely to develop such a serious case of Covid‐19 they die. More than 70 percent of Italy's coronavirus deaths have been among men but scientists there admit they are mystified by the gender gap. At least 3,400 people in Italy have died of the devastating disease ‐ it yesterday announced it had a higher death Toll than China ‐ but less than 1,000 of them have been women. Men are also more likely to pick up the infection in the first place and account for 60 percent of confirmed cases, according to Italy's public health research agency. An earlier analysis found that 80 per cent of the deaths were in men and just 20 per cent were in women ‐ but the gap has narrowed over time According to this data the principal investigator thinks that there is a strong relation between high mortality in males and androgenic effect specifically the effect of DHT on TMPRSS2 protein which is used by covid 2019 in cell invasion and entry and depending on this data related to six hormones specifically (DHT) , The investigator was able to discover whey women and children less likely to die from illness than men. So, the investigator divided infected patients according to their six hormone because TMPRSS2 is an androgen‐regulated cell‐surface serine protease expressed predominantly in prostate and lung epithelial cell TMPRSS2. Androgen(DHT) potential effect on TMPRSS2 expression in children is less than its effect in females and males followed by viral severity and vigrousity in men compared with children and women. . Androgen (DHT) potential effect on TMPRSS2 expression in females is less than in males followed by viral severity and vigrousity in men compared with females . So, the principal investigator thinks that when some researchers investigated the role of sex steroids in SARS‐CoV pathogenesis by comparing gonadectomized and control counterparts after infection. Gonadectomy or treatment with flutamide, a non‐steroidal anti‐androgen did not affect morbidity and mortality in male mice following lethal MA15 infection, They may be were wrong in their conclusions in suggesting that androgens do not play a role in SARS‐CoV pathogenesis because Gonadectomy or treatment with flutamide will not completely affect or inhibit DHT and its derivatives(5α‐Androstan‐3α,17β‐Diol) concentration in tissues and blood because after inhibiting testosterone with flutamide . the pathway of DHT formation will be activated to compensate the inhibited testosterone levels so the TMPRSS2 expression will be significantly induced by DHT and the treated animals will not be affected in case of flutamide treatment but in case of Gonadectomy the expression of TMPRSS2 will be decreased by DHT inhibition only if along time has passed on Gonadectomy in order to make sure that DHT and its derivatives completely declined in levels that will not allow it to affect on expression of TMPRSS2 and in female mice after blocking estrogen receptors it died because increasing formation of androgenic hormones. A study demonstrated that 13‐ cis ‐Retinoic acid competitively and reversibly inhibits Dihydrotestosterone So, the principal investigator expects a significant modulation of TMPRSS2 expression after treating with 13‐ cis ‐Retinoic acid via temporary preventing the effect of dihydrotestosterone(DHT) on TMPRSS2 promoting and expression. And the type II transmembrane serine proteases TMPRSS2 which can cleave and activate the spike protein (S) of the severe acute respiratory syndrome coronavirus (SARS‐CoV) for membrane fusion. In addition, these proteases cleave the viral receptor, the carboxypeptidase angiotensin‐converting enzyme 2 (ACE2), and it was proposed that ACE2 cleavage augments viral infectivity. A study demonstrated that COVID‐19 reduces testosterone levels in men by altering the functioning of the gonads. So could the increased severity of the disease in men be due to lowered testosterone. But according to the principal investigator explanat on COVID‐19 reduces testosterone levels because there is a dramatic reductions in the cholesterol levels of patients infected with COVID 19, compared with healthy controls . Cholesterol levels decline quite rapidly during the early stages of infection and increase as the patient starts to recover.Therefore, indicating that cholesterol may have an important role to play in defending the body against such infections and depending on the principal investigator explanation, Testosterone is synthesized starting from cholesterol through a well‐characterized steroid biosynthetic pathway involving the sequential action of multiple enzymes So, when cholesterol levels are decreased, this decrease will followed by decreasing in testosterone level and according to this explanation testosterone therapy in COVID 2019 is not recommended but temporary inhibitor of DHT is recommended such as Isotretinoin because this treatment by testosterone will inhibit cholesterol synthesis by feedback inhibition and decrease cholesterol uptake by Leydig cells in testis and this also will lead to over increase in DHT lvels and its derivatives in different tissues, which will induce TMPRSS2. because DHT is a potent activator of TMPRSS2 and this will be followed by processing and activation of COVID2019 spike protein to bined its ACE2 receptors in lung and kidney leading to their damage specifically in testis because it contains high levels of proteases and ACE2. Serine proteases are emerging as important contributors to the production, maturation, and functional competence of spermatozoa. Tamoxifen may be able to inhibit COVID 2019 by inhibition acidification of the endosomes and lysosomes rather than inhibition of lysosomal enzymes. A study demonstrated that tamoxifen causes redistribution of weak base chemotherapeutics from acidic organelles to the nucleus in drug‐resistant cells. Agents that disrupt organelle acidification (e.g., monensin, bafilomycin A1) cause a similar redistribution. Measurement of cellular pH in several cell lines reveals that tamoxifen inhibits acidification of endosomes and lysosomes without affecting cytoplasmic pH. Similar to monensin, tamoxifen decreased the rate of vesicular transport though the recycling and secretory pathways. Organellar acidification is required for many cellular functions, and its disruption could account for many of the side effects of tamoxifen. A sudy demonstrated that the phagocytosis is inhabited by tamoxifen and chloroquine in retinal epithelial cells A study demonstrated that Tamoxifen have weak base property and increase endolysosomal pH and alter endosomal dynamics. Importantly, TAM treatment enhanced survival of mice injected with a lethal dose of STx1 or STx2,The protective effect was independent of estrogen receptors but dependent on the weak base property of TAM, which allowed TAM to increase endolysosomal pH and alter endosomal dynamics. A study demonstrated that Tamoxifen have antimalarial effect via treating mice infected with P. berghei, which show lower levels of parasitaemia and do not develop signs of cerebral malaria, Tamoxifen is found to prevent lung fibrosis and reduce serum TGFβ‐1 levels. Astudy demonstrated that Tamoxifen have endosomal and lysosomal cysteine proteases inhibitory effect better than chloroquine , Cathepsins are endosomal and lysosomal cysteine proteases that play important roles in protein degradation in various cellular processes including both the endocytic pathway and autophagy. The role of cathepsins in viral infection was first identified by Huang et al and they found that one cysteine proteases inhibitor E64d and a specific cathepsin L inhibitor Z‐FY(t‐Bu)‐DMK are able to block the SARS‐CoV infection. Cathepsin D was more sensitive to tamoxifen than to chloroquine. Tamoxifen exposures decreased the cathepsin D activity at less than 10 pM concentrations. The effect of chloroquine started at 15 pM .
AN  - CN-02180583
AU  - Nct
KW  - Coronavirus Infections
Isotretinoin
Severe Acute Respiratory Syndrome
Tamoxifen
PY  - 2020
ST  - Combination Therapy With Isotretinoin and Tamoxifen Expected to Provide Complete Protection Against Severe Acute Respiratory Syndrome Coronavirus
T2  - https://clinicaltrials.gov/show/NCT04389580
TI  - Combination Therapy With Isotretinoin and Tamoxifen Expected to Provide Complete Protection Against Severe Acute Respiratory Syndrome Coronavirus
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02180583/full
ID  - 1609
ER  - 

TY  - JOUR
AB  - BACKGROUND: Overall incidence of breast cancer is slightly lower, but mortality rates are higher, for Black women compared to White women. Higher body mass index (BMI), sedentary lifestyles, and lower compliance with recommended breast health behaviors may contribute to higher risk and mortality. METHODS: A randomized pilot intervention trial was conducted to assess feasibility and efficacy of a combined breast health/weight loss intervention for 64 overweight or obese Black women, ages 35-65. The primary objectives were to determine whether a 20-week (twice weekly) intervention could decrease weight and dietary fat intake and increase physical activity and breast self-exam (BSE) proficiency. RESULTS: The project was implemented in two cohorts and retention was high for both (96% and 89%, respectively). Both cohorts showed increased proficiency in BSE in the intervention versus the control group (2.4 vs. -0.4, P<0.05; 3.3 vs. -0.2, P<0.001, respectively), but only cohort 2 showed decreased percent body weight (4.0% decrease vs. 0.9% increase, P<0.01), increased physical activity frequency (2.4 vs. 0.1 times/week, P<0.05), and a trend for decreased dietary fat (-2.6% kcal vs. 0.0% kcal, P=0.07) in the intervention compared to the control group. CONCLUSION: Few studies have documented weight loss among Black women, and no combined breast health/weight loss intervention has been conducted. This study documents the feasibility of recruiting, randomizing, and retaining women in a combined intervention and demonstrated weight loss and associated lifestyle changes.
AD  - Department of Psychiatry and Behavioral Sciences, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611-3008, USA. mlf056@northwestern.edu
AN  - 15530590
AU  - Fitzgibbon, M. L.
AU  - Stolley, M. R.
AU  - Schiffer, L.
AU  - Sanchez-Johnsen, L. A.
AU  - Wells, A. M.
AU  - Dyer, A.
DA  - Apr
DO  - 10.1016/j.ypmed.2004.06.018
DP  - NLM
ET  - 2004/11/09
IS  - 4
KW  - Adult
African Continental Ancestry Group/*statistics & numerical data
Aged
Body Mass Index
Body Weight
Breast/metabolism
Breast Neoplasms/ethnology/*prevention & control
Cohort Studies
Delivery of Health Care/methods/statistics & numerical data
Diet
Educational Status
Exercise/*physiology
Female
Humans
Life Style
Middle Aged
Obesity/physiopathology/prevention & control
Pilot Projects
Socioeconomic Factors
Weight Loss
LA  - eng
N1  - Fitzgibbon, Marian L
Stolley, Melinda R
Schiffer, Linda
Sanchez-Johnsen, Lisa A P
Wells, Anita M
Dyer, Alan
1K01CA098753/CA/NCI NIH HHS/United States
CA-093946-01A2/CA/NCI NIH HHS/United States
CA88935/CA/NCI NIH HHS/United States
CA88935-S/CA/NCI NIH HHS/United States
Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.
United States
Prev Med. 2005 Apr;40(4):373-83. doi: 10.1016/j.ypmed.2004.06.018.
PY  - 2005
SN  - 0091-7435 (Print)
0091-7435
SP  - 373-83
ST  - A combined breast health/weight loss intervention for Black women
T2  - Prev Med
TI  - A combined breast health/weight loss intervention for Black women
VL  - 40
ID  - 615
ER  - 

TY  - JOUR
AB  - BACKGROUND: This article describes the process and results of a smoking cessation intervention randomized clinical trial (RCT) that was conducted as a community-based participatory research project. This RCT tested whether outcomes are improved by adding social justice and tobacco industry targeting messages to a smoking cessation program conducted among African American adults within a low-income community in San Francisco, California. This study provides lessons for future similar research projects that focus on urban low-income populations. METHODS: Participants were randomly allocated to receive a smoking-cessation program (control group [CG]) or CG care plus tobacco industry and media (IAM) messages. Primary interventions were behavioral. At intake, participants reporting severe withdrawal or smoking >= 25 cigarettes daily were offered free nicotine replacement therapy. Baseline data were from an in-person interview. Outcome measures included self-reported smoking status; validation of quitting was by salivary cotinine assays. RESULTS: Of 87 participants providing baseline data, 31% (27) did not join the RCT. Proportions quitting in the CG and IAM group were 11.5% and 13.6% at 6 months and 5.3% and 15.8% at 12 months, respectively. CONCLUSION: African Americans in underserved inner-city neighborhoods can be recruited into RCTs with community participatory approaches. Differences between the CG and IAM in proportions who quit were 2.1% and 10.5% at 6 and 12 months, respectively. More than 3 years with adequate funding, high staffing ratios, and intense outreach and follow-up schedules are needed to achieve recruitment and study goals. (Heart Lung(R) 2010;39:50-63.)
AN  - WOS:000279415200007
AU  - Froelicher, E. S.
AU  - Doolan, D.
AU  - Yerger, V. B.
AU  - McGruder, C. O.
AU  - Malone, R. E.
DA  - Jan-Feb
DO  - 10.1016/j.hrtlng.2009.06.004
IS  - 1
N1  - 20109986
PY  - 2010
SN  - 0147-9563
SP  - 50-63
ST  - Combining community participatory research with a randomized clinical trial: The protecting the hood against tobacco (PHAT) smoking cessation study
T2  - Heart & Lung
TI  - Combining community participatory research with a randomized clinical trial: The protecting the hood against tobacco (PHAT) smoking cessation study
VL  - 39
ID  - 3129
ER  - 

TY  - JOUR
AB  - Background: Castration resistance occurs in most patients with metastatic hormone-sensitive prostate cancer who are receiving androgen-deprivation therapy. Replacing androgens before progression of the disease is hypothesized to prolong androgen dependence. Methods: Men with newly diagnosed, metastatic, hormone-sensitive prostate cancer, a performance status of 0 to 2, and a prostate-specific antigen (PSA) level of 5. ng per milliliter or higher received a luteinizing hormone-releasing hormone analogue and an antiandrogen agent for 7 months. We then randomly assigned patients in whom the PSA level fell to 4. ng per milliliter or lower to continuous or intermittent androgen deprivation, with patients stratified according to prior or no prior hormonal therapy, performance status, and extent of disease (minimal or extensive). The coprimary objectives were to assess whether intermittent therapy was noninferior to continuous therapy with respect to survival, with a one-sided test with an upper boundary of the hazard ratio of 1.20, and whether quality of life differed between the groups 3 months after randomization. Results: A total of 3040 patients were enrolled, of whom 1535 were included in the analysis: 765 randomly assigned to continuous androgen deprivation and 770 assigned to intermittent androgen deprivation. The median follow-up period was 9.8 years. Median survival was 5.8 years in the continuous-therapy group and 5.1 years in the intermittent-therapy group (hazard ratio for death with intermittent therapy, 1.10; 90% confidence interval, 0.99 to 1.23). Intermittent therapy was associated with better erectile function and mental health (P<0.001 and P=0.003, respectively) at month 3 but not thereafter. There were no significant differences between the groups in the number of treatment-related high-grade adverse events. Conclusions: Our findings were statistically inconclusive. In patients with metastatic hormone-sensitive prostate cancer, the confidence interval for survival exceeded the upper boundary for noninferiority, suggesting that we cannot rule out a 20% greater risk of death with intermittent therapy than with continuous therapy, but too few events occurred to rule out significant inferiority of intermittent therapy. Intermittent therapy resulted in small improvements in quality of life. (Funded by the National Cancer Institute and others; ClinicalTrials.gov number, NCT00002651.). © 2014 Elsevier Inc.
AD  - S. Eggener
AU  - Eggener, S.
DB  - Embase
Medline
DO  - 10.1016/j.urolonc.2014.01.009
IS  - 6
KW  - African American
cancer epidemiology
cancer mortality
cancer risk
follow up
health disparity
human
low risk patient
nuclear magnetic resonance imaging
practice guideline
priority journal
prostate biopsy
prostate cancer
prostatectomy
race difference
randomized controlled trial
short survey
LA  - English
M3  - Short Survey
N1  - L373667354
2014-08-11
2014-08-19
PY  - 2014
SN  - 1873-2496
1078-1439
SP  - 936-937
ST  - Commentary on "Intermittent versus continuous androgen deprivation in prostate cancer."
T2  - Urologic Oncology: Seminars and Original Investigations
TI  - Commentary on "Intermittent versus continuous androgen deprivation in prostate cancer."
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L373667354&from=export
http://dx.doi.org/10.1016/j.urolonc.2014.01.009
VL  - 32
ID  - 1045
ER  - 

TY  - JOUR
AB  - OBJECTIVE: Test the impact of tailoring CRC screening messages for African Americans (AAs) using novel theoretical variables and to examine moderating effect of communication preferences. METHODS: Participants were randomized to receive two minimally tailored or two enhanced tailored print newsletters addressing CRC. The enhanced intervention was tailored on Self-Determination Theory and other novel psychological constructs. Minimal tailoring only used information available in the patient's EHR. The primary outcome was CRC screening based on EHR. Participants were AA members aged 50-74 of an integrated health care delivery system not up to date on CRC screening. RESULTS: We enrolled 881 participants. CRC screening participation rates at 1-year follow up were 20.5% and 21.5% in the minimally and enhanced tailored groups, respectively. Communication preferences moderated the impact of the intervention. Specifically, among those with an autonomous communication preference, screening rates in the minimally and enhanced tailored groups were 17.1% and 25.9%, respectively, while no intervention effect was evident among those with a directive preference. CONCLUSION: Future research is needed to explore the impact of communication preference tailoring for other health behaviors and among other populations. PRACTICE IMPLICATIONS: Tailored communications should consider communication style preference to help guide the content and tone of messages.
AD  - University of Michigan School of Public Health, Department of Health Behavior & Health Education, Ann Arbor, USA. Electronic address: kresnic@umich.edu.
University of Michigan, Ann Arbor, USA.
University of South Carolina, Columbia, USA.
Henry Ford Health System, Detroit, USA.
Virginia Commonwealth University, Richmond, USA.
AN  - 25224317
AU  - Resnicow, K.
AU  - Zhou, Y.
AU  - Hawley, S.
AU  - Jimbo, M.
AU  - Ruffin, M. T.
AU  - Davis, R. E.
AU  - Shires, D.
AU  - Lafata, J. E.
C2  - PMC6208142
C6  - NIHMS625555
DA  - Dec
DO  - 10.1016/j.pec.2014.08.013
DP  - NLM
ET  - 2014/09/17
IS  - 3
KW  - African Americans/*education/psychology
Aged
Colorectal Neoplasms/*diagnosis/ethnology/prevention & control
Early Detection of Cancer
Female
Health Communication/*methods
Health Knowledge, Attitudes, Practice
Humans
Male
Mass Screening/methods/*psychology/statistics & numerical data
Michigan
Middle Aged
Patient Acceptance of Health Care/*statistics & numerical data
Patient Compliance/*ethnology/psychology
Patient Education as Topic
Patient Preference/*ethnology/psychology
Teaching Materials
African Americans
Colorectal cancer screening
Tailored intervention
Institute grant P50-CA101451 but no other financial support for this work.
LA  - eng
N1  - 1873-5134
Resnicow, Ken
Zhou, Yan
Hawley, Sarah
Jimbo, Masahito
Ruffin, Mack T
Davis, Rachel E
Shires, Deirdre
Lafata, Jennifer Elston
P50 CA101451/CA/NCI NIH HHS/United States
P50-CA101451/CA/NCI NIH HHS/United States
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Patient Educ Couns. 2014 Dec;97(3):370-5. doi: 10.1016/j.pec.2014.08.013. Epub 2014 Sep 3.
PY  - 2014
SN  - 0738-3991 (Print)
0738-3991
SP  - 370-5
ST  - Communication preference moderates the effect of a tailored intervention to increase colorectal cancer screening among African Americans
T2  - Patient Educ Couns
TI  - Communication preference moderates the effect of a tailored intervention to increase colorectal cancer screening among African Americans
VL  - 97
ID  - 274
ER  - 

TY  - JOUR
AB  - In 2000, the REACH Boston 2010 Breast and Cervical Cancer Coalition conducted a community needs assessment and found several factors that may have contributed to disproportionately high breast and cervical cancer mortality among black women: (a) Focus group participants reported that many women in their communities had limited awareness about risk factors for cancer as well as about screening. (b) Black women experienced barriers to care related to the cultural competence of providers and of institutions. (c) Black women were not receiving adequate follow-up for abnormal mammograms and Pap smears. The Coalition's Community Action Plan to address disparities includes a model primary care service for black women; scholarships to increase the number of black mammogram technologists; primary care provider and radiology technologist training about disparities and cultural competence; and education to increase awareness among black women and to increase leadership and advocacy skills.
AD  - Division of General Medicine, Department of Medicine, Brigham and Women's Hospital, and Center of Excellence in Women's Health, Harvard Medical School, Boston, MA 02115, USA. jbigby@partners.org
AN  - 12815081
AU  - Bigby, J.
AU  - Ko, L. K.
AU  - Johnson, N.
AU  - David, M. M.
AU  - Ferrer, B.
C2  - PMC1497561
DA  - Jul-Aug
DO  - 10.1093/phr/118.4.338
DP  - NLM
ET  - 2003/06/20
IS  - 4
KW  - Adult
*African Americans/education/psychology/statistics & numerical data
Aged
Aged, 80 and over
Boston/epidemiology
Breast Neoplasms/diagnostic imaging/*ethnology/*mortality
Community Health Planning/*organization & administration
*Community Participation
Community-Institutional Relations
Female
Focus Groups
Health Care Coalitions/*organization & administration
Health Services Accessibility
Health Services Research/methods
Humans
Mass Screening/statistics & numerical data
Middle Aged
*Public Health
Quality of Health Care
Radiography
Risk Factors
Technology, Radiologic/education
Uterine Cervical Neoplasms/diagnosis/*ethnology/*mortality
Women's Health Services/*organization & administration
Workforce
LA  - eng
N1  - 1468-2877
Bigby, JudyAnn
Ko, Linda K
Johnson, Natacha
David, Michele M A
Ferrer, Barbara
REACH Boston 2010 Breast and Cervical Cancer Coalition
U50/CCU117261-02/CC/ODCDC CDC HHS/United States
Journal Article
Research Support, U.S. Gov't, P.H.S.
Public Health Rep. 2003 Jul-Aug;118(4):338-47. doi: 10.1093/phr/118.4.338.
PY  - 2003
SN  - 0033-3549 (Print)
0033-3549
SP  - 338-47
ST  - A community approach to addressing excess breast and cervical cancer mortality among women of African descent in Boston
T2  - Public Health Rep
TI  - A community approach to addressing excess breast and cervical cancer mortality among women of African descent in Boston
VL  - 118
ID  - 645
ER  - 

TY  - JOUR
AB  - BACKGROUND: The Metropolitan Chicago Breast Cancer Taskforce was formed to address a growing black/white breast cancer mortality disparity in Chicago. The Taskforce explored three hypotheses: black women in Chicago receive fewer mammograms, black women receive mammograms of inferior quality, and black women have inadequate access to quality of treatment for breast cancer. METHODS: A total of 102 individuals from 74 Chicago area organizations participated in the Task Force participating in three work groups from January to September 2007. The work groups held focus groups of providers, organized town hall meetings in four Chicago communities, gathered black/white breast cancer mortality data for Chicago, the United States, and New York City, and conducted a mammography capacity and quality survey of mammography facilities. RESULTS: Chicago's black and white breast cancer mortality rates were the same in 1980. By the late 1990 s, a substantial disparity was present, and by 2005, the black breast cancer mortality rate was 116% higher than the white rate. In 2007, 206,000 screening mammograms were performed for women living in Chicago, far short of the 588,000 women in the 40-69 age range in Chicago. Facilities that served predominately minority women were less likely to be academic or private institutions (p < .03), less likely to have digital mammography (p < .003), and less likely to have dedicated breast imaging specialists reading the films (p < .003). Black women and providers serving them reported significant difficulties in accessing needed care for breast cancer screening and treatment. CONCLUSION: There are significant access barriers to high quality mammography and treatment services that could be contributing to the mortality differences in Chicago. A metropolitan wide taskforce has been established to address the disparity.
AD  - 544 Academic Facility, Rush University Medical Center, 600 South Paulina Avenue, Chicago, IL 60612, USA. David_ansell@rush.edu
AN  - 19688184
AU  - Ansell, D.
AU  - Grabler, P.
AU  - Whitman, S.
AU  - Ferrans, C.
AU  - Burgess-Bishop, J.
AU  - Murray, L. R.
AU  - Rao, R.
AU  - Marcus, E.
DA  - Nov
DO  - 10.1007/s10552-009-9419-7
DP  - NLM
ET  - 2009/08/19
IS  - 9
KW  - Adult
Advisory Committees/organization & administration
African Americans/*statistics & numerical data
Aged
Breast Neoplasms/*mortality
Chicago
Community Health Planning/*methods
Community Participation/*methods
Continental Population Groups
European Continental Ancestry Group/*statistics & numerical data
Female
Health Services Accessibility
*Healthcare Disparities
Humans
Male
Mammography
Middle Aged
LA  - eng
N1  - 1573-7225
Ansell, David
Grabler, Paula
Whitman, Steven
Ferrans, Carol
Burgess-Bishop, Jacqueline
Murray, Linda Rae
Rao, Ruta
Marcus, Elizabeth
Journal Article
Research Support, Non-U.S. Gov't
Netherlands
Cancer Causes Control. 2009 Nov;20(9):1681-8. doi: 10.1007/s10552-009-9419-7. Epub 2009 Aug 18.
PY  - 2009
SN  - 0957-5243
SP  - 1681-8
ST  - A community effort to reduce the black/white breast cancer mortality disparity in Chicago
T2  - Cancer Causes Control
TI  - A community effort to reduce the black/white breast cancer mortality disparity in Chicago
VL  - 20
ID  - 450
ER  - 

TY  - JOUR
AB  - Purpose of Review Breast cancer disproportionately affects racial/ethnic minority women compared with their non-Hispanic white counterparts. Community-based researchers have long sought to reduce breast cancer-related health disparities using the core principles of community outreach and engagement. The primary goal of this paper is to discuss community outreach and engagement (COE) strategies in the context of breast cancer disparities and discuss evidence-based applications of COE. Recent Findings Evidence-based COE to address breast cancer disparities include patient navigation, co-development of community-based interventions, advisory boards, and patient boards. Recent strategies have included partnering with the Komen Tissue Bank, the development of culturally tailored expressive writing interventions, and the formation of community scientist and community mentorship programs. Partnering with the community across all stages of research can help eliminate breast cancer disparities. We find that community outreach and engagement can improve intervention efficacy, clinical trial retention, and community commitment. We hope that this paper will promote greater adoption of evidence-based COE strategies to help eliminate breast cancer disparities.
AN  - WOS:000569496100001
AU  - McNeill, L. H.
AU  - Wu, I. H. C.
AU  - Cho, D.
AU  - Lu, Q.
AU  - Escoto, K.
AU  - Harris, C.
DA  - Dec
DO  - 10.1007/s12609-020-00374-z
IS  - 4
PY  - 2020
SN  - 1943-4588
SP  - 209-215
ST  - Community Outreach and Engagement Strategies to Address Breast Cancer Disparities
T2  - Current Breast Cancer Reports
TI  - Community Outreach and Engagement Strategies to Address Breast Cancer Disparities
VL  - 12
ID  - 2763
ER  - 

TY  - JOUR
AB  - African American women are at high risk for morbidity and mortality from breast cancer. African American women ages 50 and older have been a difficult group to reach through conventional breast cancer intervention programs. Cultural and health beliefs that differ from mainstream society are reported to be factors contributing to the low rates of breast screening among this group. In addition to these attitudinal factors, older African American women are disproportionately represented among uninsured and under-insured Americans. As a result, cost becomes a barrier to mammography screening for many of these women. This project proposes to increase breast cancer screening awareness and provide a referral or free breast screening, or both, for African American women ages 50 and older. This information will be offered in the culturally familiar setting of local beauty salons. The culturally sensitive educational pamphlets developed by the National Cancer Institute (NCI) and video developed by the NCI-funded project, Cancer Prevention Research Unit, will be used to promote mammography, clinical breast examinations, and breast self-examination. Providers staffing a mobile mammography van provided by Dr. Anitha Mitchell of the Association of Black Women Physicians through a grant from the Breast and Cervical Cancer Control Program, funded by the Centers for Disease Control and Prevention, will perform mammograms for women on site during scheduled intervals. A followup telephone survey will be conducted.
AD  - University of California at Los Angeles School of Public Health, USA.
AN  - 7630996
AU  - Forte, D. A.
C2  - PMC1382099
DA  - Mar-Apr
DP  - NLM
ET  - 1995/03/01
IS  - 2
KW  - *African Americans
Aged
*Beauty Culture
Breast Neoplasms/economics/ethnology/*prevention & control
*Community Participation/economics
Costs and Cost Analysis
Cultural Characteristics
Female
Health Education/economics/methods
Humans
Los Angeles/epidemiology
Middle Aged
Pilot Projects
Poverty
Program Evaluation/methods
Urban Population
Video Recording/economics
LA  - eng
N1  - 1468-2877
Forte, D A
Journal Article
Public Health Rep. 1995 Mar-Apr;110(2):179-83.
PY  - 1995
SN  - 0033-3549 (Print)
0033-3549
SP  - 179-83
ST  - Community-based breast cancer intervention program for older African American women in beauty salons
T2  - Public Health Rep
TI  - Community-based breast cancer intervention program for older African American women in beauty salons
VL  - 110
ID  - 744
ER  - 

TY  - JOUR
AB  - Background: Despite evidence of a decline in both incidence and prevalence of colorectal cancer nationwide, it remains the second most commonly diagnosed cancer and the third highest cause of mortality among Asian Americans, including Korean Americans. This community-based and theoretically guided study evaluated a culturally appropriate intervention program that included a bilingual cancer educational program among Korean Americans including information on CRC risks, counseling to address psychosocial and access barriers, and patient navigation assistance. Methods: A two-group quasi-experimental design with baseline and post-intervention assessment and a 12-month follow-up on screening was used in the Study. Korean Americans (N = 167) were enrolled from six Korean churches. The intervention group received culturally appropriate intervention program addressing accessibility and psychosocial barriers, and navigation assistance for screening. The control group received general health education that included cancer-related health issues and screening. Results: There was a significant difference (p < 0.05) between the post-intervention and control groups in awareness of CRC risk factors. There was also a significant improvement in the pre-post across HBM measures in the intervention group for perceived susceptibility (p < 0.05) and benefits and barriers to screening (p < 0.001). At baseline, 13% of participants in the intervention group and 10% in control group reported having had a CRC cancer screening test in the previous year. At the 12-month post-intervention follow-up, 77.4% of participants in the intervention group had obtained screening compared to 10.8% in the control group. Conclusion: While health disparities result from numerous factors, a culturally appropriate and church-based intervention can be highly effective in increasing knowledge of and access to, and in reducing barriers to CRC screening among underserved Koreans. (C) 2009 Elsevier Ltd. All rights reserved.
AN  - WOS:000273168300011
AU  - Ma, G. X.
AU  - Shive, S.
AU  - Tan, Y.
AU  - Gao, W. Z.
AU  - Rhee, J.
AU  - Park, M.
AU  - Kim, J.
AU  - Toubbeh, J. I.
DA  - Nov
DO  - 10.1016/j.canep.2009.10.001
IS  - 5
N1  - 19914880
PY  - 2009
SN  - 1877-7821
SP  - 381-386
ST  - Community-based colorectal cancer intervention in underserved Korean Americans
T2  - Cancer Epidemiology
TI  - Community-based colorectal cancer intervention in underserved Korean Americans
VL  - 33
ID  - 3134
ER  - 

TY  - JOUR
AB  - BACKGROUND: South Dallas experiences significant disparities in breast cancer mortality, with a high proportion of stage III and IV diagnoses. To address these rates, the Dallas Cancer Disparities Community Research Coalition created an educational intervention to promote breast health and early detection efforts. OBJECTIVES: The goals of the intervention were to increase (a) knowledge regarding the chief contributing factors for breast cancer, (b) awareness of the importance of screening for early detection, and (c) the proportion of women who have engaged in appropriate breast cancer screening practices. METHODS: Eligibility criteria for this nonrandomized, controlled trial included women age 40 and older, English-speaking, and having no personal history of cancer. Control participants received written breast health educational materials. Intervention participants attended 8 weekly sessions that included interactive educational materials, cooking demonstrations, and discussions emphasizing primary and secondary breast cancer prevention. All study participants completed a 1-hour survey at baseline and 4 months later. RESULTS: There were 59 women were enrolled in the intervention and 60 in the control group. At follow-up, after controlling for baseline mammography status, women in the intervention group were 10.4 times more likely (95% confidence interval [CI], 2.9-36.4) to have received a screening mammogram in the last year compared with the control group. Intervention participants demonstrated statistically significantly higher rates of breast self-examination (odds ratio [OR], 3.0; 95% CI, 1.0-8.6) and breast cancer knowledge (p=.003). CONCLUSION: Lessons learned from this community-based participatory research (CBPR) study can be used to create sustainable cancer disparity reduction models that can be replicated in similar communities.
AD  - School of Public Health, University of North Texas Health Science Center, and Parkland Health and Hospital System, Dallas, TX, USA.
AN  - 22616205
AU  - Cardarelli, K.
AU  - Jackson, R.
AU  - Martin, M.
AU  - Linnear, K.
AU  - Lopez, R.
AU  - Senteio, C.
AU  - Weaver, P.
AU  - Hill, A.
AU  - Banda, J.
AU  - Epperson-Brown, M.
AU  - Morrison, J.
AU  - Parrish, D.
AU  - Newton, J. R.
AU  - Royster, M.
AU  - Haley, S.
AU  - Lafayette, C.
AU  - Harris, P.
AU  - Vishwanatha, J. K.
AU  - Johnson, E. S.
C2  - PMC4238068
C6  - NIHMS439985
DA  - Winter
DP  - NLM
ET  - 2011/01/01
IS  - 4
KW  - Adult
*African Americans
Breast Neoplasms/*ethnology/*prevention & control/psychology
Community-Based Participatory Research
Diet
Early Detection of Cancer/methods
Exercise
Female
Health Behavior
Health Education/*organization & administration
*Health Knowledge, Attitudes, Practice
*Health Status Disparities
Humans
Middle Aged
Social Support
Socioeconomic Factors
Texas/epidemiology
Women's Health
LA  - eng
N1  - 1557-055x
Cardarelli, Kathryn
Jackson, Rachael
Martin, Marcus
Linnear, Kim
Lopez, Roy
Senteio, Charles
Weaver, Preston
Hill, Anna
Banda, Jesse
Epperson-Brown, Marva
Morrison, Janet
Parrish, Deborah
Newton, J R
Royster, Marcene
Haley, Sheila
Lafayette, Camille
Harris, Phyllis
Vishwanatha, Jamboor K
Johnson, Eric S
P20 MD006882/MD/NIMHD NIH HHS/United States
R21 CA126732/CA/NCI NIH HHS/United States
1R21CA126732-01/CA/NCI NIH HHS/United States
3R21CA126732-02S2/CA/NCI NIH HHS/United States
P20 MD001633/MD/NIMHD NIH HHS/United States
Clinical Trial
Journal Article
Research Support, N.I.H., Extramural
Prog Community Health Partnersh. 2011 Winter;5(4):375-85.
PY  - 2011
SN  - 1557-0541 (Print)
1557-0541
SP  - 375-85
ST  - Community-based participatory approach to reduce breast cancer disparities in south Dallas
T2  - Prog Community Health Partnersh
TI  - Community-based participatory approach to reduce breast cancer disparities in south Dallas
VL  - 5
ID  - 402
ER  - 

TY  - JOUR
AB  - Introduction: Rates of screening colonoscopies, an effective method of preventing colorectal cancer, have increased in New York City over the past decade, and racial disparities in screening have declined. However, vulnerable subsets of the population may not be reached by traditional surveillance and intervention efforts to improve colorectal cancer screening rates. Methods: We compared rates of screening colonoscopies among black men aged 50 or older from a citywide random-digit-dial sample and a location-based sample focused on hard-to-reach populations to evaluate the representativeness of the random-digit-dial sample. The location-based sample (N = 5,568) was recruited from 2010 through 2013 from community-based organizations in New York City. Descriptive statistics were used to compare these data with data for all black men aged 50 or older from the 2011 cohort of the Community Health Survey (weighted, N = 334) and to compare rates by community-based setting. Results: Significant differences in screening colonoscopy history were observed between the location-based and random-digit-dial samples (49.1% vs 62.8%, P < .001). We observed significant differences between participants with and without a working telephone among the location-based sample and between community-based settings. Conclusions: Vulnerable subsets of the population such as those with inconsistent telephone access are excluded from random-digit-dial samples. Practitioners and researchers should consider the target population of proposed interventions to address disparities, and whether the type of setting reaches those most in need of services. (PsycINFO Database Record (c) 2016 APA, all rights reserved)
AD  - Cole, Helen, CUNY School of Public Health, Graduate Center, City University of New York, 365 Fifth Ave, Room 3317, New York, NY, US, 10016
AN  - 2014-32319-001
AU  - Cole, Helen
AU  - Ravenell, Joseph
AU  - Schoenthaler, Antoinette
AU  - Braithwaite, R. Scott
AU  - Ladapo, Joseph
AU  - Mentor, Sherry
AU  - Uyei, Jennifer
AU  - Trinh-Shevrin, Chau
DB  - psyh
DP  - EBSCOhost
KW  - community-based settings
racial health disparities
black men
screening colonoscopies
colorectal cancer
African Americans
Aged
Behavioral Risk Factor Surveillance System
Cohort Studies
Colonoscopy
Colorectal Neoplasms
Community Health Services
Cross-Sectional Studies
Healthcare Disparities
Humans
Male
Mass Screening
Middle Aged
New York City
Sampling Studies
Socioeconomic Factors
Surveys and Questionnaires
Blacks
Cancer Screening
Community Services
Racial and Ethnic Differences
Health Disparities
Human Males
N1  - CUNY School of Public Health, Graduate Center, City University of New York, New York, NY, US. Release Date: 20141201. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: English. Major Descriptor: Blacks; Cancer Screening; Community Services; Racial and Ethnic Differences; Health Disparities. Minor Descriptor: Human Males. Classification: Promotion & Maintenance of Health & Wellness (3365). Population: Human (10); Male (30). Location: US. Age Group: Adulthood (18 yrs & older) (300); Middle Age (40-64 yrs) (360). Methodology: Empirical Study; Quantitative Study. References Available: Y. ArtID: 140083. Issue Publication Date: Jun 19, 2014.
Sponsor: Centers for Disease Control and Prevention, Prevention Research Centers program. Grant: U48DP002671. Recipients: No recipient indicated
Sponsor: Comprehensive Center of Excellence in Disparities Research and Community Engagement. Grant: 5P60MD003421. Recipients: No recipient indicated
Sponsor: Sponsor name not included. Grant: 1R01HL096946. Other Details: Faith-Based Approaches to Treating Hypertension and Colon Cancer Prevention. Recipients: No recipient indicated
Sponsor: New York University Health Promotion and Prevention Research Center, US. Grant: U58DP001022. Recipients: No recipient indicated
PY  - 2014
SN  - 1545-1151
ST  - Community-based settings and sampling strategies: Implications for reducing racial health disparities among Black men, New York City, 2010-2013
T2  - Preventing Chronic Disease: Public Health Research, Practice, and Policy
TI  - Community-based settings and sampling strategies: Implications for reducing racial health disparities among Black men, New York City, 2010-2013
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2014-32319-001&site=ehost-live&scope=site
hcole@gc.cuny.edu
VL  - 11
ID  - 1714
ER  - 

TY  - JOUR
AB  - Project CARE, an NCI‐funded randomized clinical trial, examined whether participation in an adapted cognitive‐behavioral stress management (CBSM) and enhanced breast cancer wellness and education (CW) program improved psychological outcomes among a sample of underserved Black breast cancer survivors. Both group‐based, 10‐week interventions used in the trial were culturally adapted for Black women in the community from evidence‐based interventions used in previously successful clinical trials. Participants were randomly assigned to CBSM or CW. Participants were 114 Black women (mean age = 51.1, 27‐77 years) who had completed breast cancer treatment 0‐12 months prior to enrollment (all stages of disease, mean time since cancer diagnosis = 14.1mo). Women were assessed at baseline, immediately post‐intervention and at a six‐month follow‐up. We previously reported that there was a remarkable 94% retention rate from baseline to six month follow‐up (mean attendance rate = 7.5 sessions, only 9 participants did not attend any intervention sessions). Participants in both conditions showed statistically significant improvement on indices of psychological well‐being, including mood (Profile of Mood States‐Short Version), quality of life (Functional Assessment of Cancer Therapy‐Breast Cancer), intrusive thoughts (Impact of Event Scale‐Revised), depressive symptoms (Center for Epidemiologic Studies‐Depression), and stress levels (Perceived Stress Scale) over the six‐month post‐intervention follow‐up (all repeated measures ANOVA within subjects time effects: p<.05) but condition x time effects were not statistically significant. Given that women in both conditions showed improvement over the course of the study, we compared our findings to longitudinal, natural history studies of women in the post‐treatment re‐entry phase after breast cancer treatment. The projected course of distress differed from the Project CARE results. Next, we examined potential mediators of the change over time to account for the findings. Using quality of life as the main outcome, we explored candidate mechanisms in mediation models (including session attendance, pain, fatigue, sleep, mood, intrusive thoughts about breast cancer, depressive symptoms, burdens of poverty, perceived stress, ability to relax, and stress management skills). None of the potential mediator models met criteria. Findings suggest that improvements in multiple measures over time may have been due to other, unmeasured factors, such as participation in intervention groups with of individuals from a similar racial background who are undergoing similar stressors or consistent attention from a supportive research team. The wide‐reaching implications of this research program include decisions about appropriate control groups and the timing of intervention delivery during the cancer treatment trajectory.
AN  - CN-01174422
AU  - Lechner, S. C.
DO  - 10.1158/1538-7755.DISP14-IA28
IS  - 10 SUPPL. 1) (no pagination
KW  - *breast cancer
*cancer survivor
*community
*follow up
*health disparity
*human
*medically underserved
*stress management
Analysis of variance
Cancer diagnosis
Cancer therapy
Clinical trial
Clinical trial (topic)
Cognitive behavioral stress management
Control group
Depression
Education program
Epidemiology
Evidence based practice
Fatigue
Female
Functional assessment
History
Impact of Events Scale
Model
Mood
Pain
Perceived Stress Scale
Poverty
Profile of Mood States
Psychological well being
Quality of life
Skill
Sleep
Wellbeing
M3  - Journal: Conference Abstract
PY  - 2015
ST  - Community-based stress management intervention for black breast cancer survivors: a follow up
T2  - Cancer epidemiology biomarkers and prevention. Conference: 7th AACR conference on the science of health disparities in racial/ethnic minorities and the medically underserved san antonio, TX united states. Conference start: 20141109 conference end: 20141112. Conference publication: (var.pagings)
TI  - Community-based stress management intervention for black breast cancer survivors: a follow up
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01174422/full
VL  - 24
ID  - 1520
ER  - 

TY  - JOUR
AB  - BACKGROUND: Intervention studies among individuals in diverse community settings are needed to reduce health disparities in colorectal cancer (CRC) screening and mortality rates. The current study compared the efficacy of 2 intervention conditions promoting CRC screening among black individuals. METHODS: Black individuals ages 50 to 75 years (N = 330) were recruited in community settings in 4 Tampa Bay counties. After obtaining consent and conducting a baseline interview to assess sociodemographic and health-related variables, participants received either a culturally targeted CRC photonovella booklet plus a fecal immunochemical test (FIT) kit or a standard CRC screening brochure plus an FIT kit. The primary outcome was FIT kit screening uptake. RESULTS: FIT screening uptake at 6 months was 86.7% overall (90.3% in the brochure group and 81.9% in the photonovella group). Controlling for baseline between-group differences, there was no influence of intervention on FIT kit uptake (P = .756). Significant predictors of not returning an FIT kit included being unable to work (P = .010), having higher religious belief scores (P = .015), and living farther from the cancer center (P = .015). CONCLUSIONS: Providing FIT kits and educational print materials to black individuals in community settings resulted in high rates of CRC screening. The study also identified subgroups of participants who were less likely to return an FIT kit and provides insight for future interventions. Cancer 2016;122:3288-3296. © 2016 American Cancer Society.
AD  - Division of Population Science, Moffitt Cancer Center and Research Institute, Tampa, Florida.
Morsani College of Medicine, University of South Florida, Tampa, Florida.
School of Public Health, Louisiana State University Health Sciences Center, New Orleans, Louisiana.
Department of Surgery, University of Tennessee Health Science Center, Memphis, Tennessee.
Division of Population Science, Moffitt Cancer Center and Research Institute, Tampa, Florida. clement.gwede@moffitt.org.
Morsani College of Medicine, University of South Florida, Tampa, Florida. clement.gwede@moffitt.org.
AN  - 27420119
AU  - Christy, S. M.
AU  - Davis, S. N.
AU  - Williams, K. R.
AU  - Zhao, X.
AU  - Govindaraju, S. K.
AU  - Quinn, G. P.
AU  - Vadaparampil, S. T.
AU  - Lin, H. Y.
AU  - Sutton, S. K.
AU  - Roethzeim, R. R.
AU  - Shibata, D.
AU  - Meade, C. D.
AU  - Gwede, C. K.
C2  - PMC5073009
C6  - NIHMS799666
DA  - Nov 15
DO  - 10.1002/cncr.30207
DP  - NLM
ET  - 2016/10/21
IS  - 21
KW  - African Americans/*psychology
Aged
Colorectal Neoplasms/diagnosis/ethnology/psychology
Community Health Services/*statistics & numerical data
Delivery of Health Care
Early Detection of Cancer/*statistics & numerical data
Early Intervention, Educational
Female
Follow-Up Studies
Health Knowledge, Attitudes, Practice
Humans
Immunochemistry
Male
Middle Aged
Neoplasm Staging
*Occult Blood
Patient Acceptance of Health Care
*Patient Education as Topic
Prognosis
Reagent Kits, Diagnostic/*statistics & numerical data
*cancer screening
*colorectal cancer
*culturally targeted
*intervention trial
*minority health
LA  - eng
N1  - 1097-0142
Christy, Shannon M
Davis, Stacy N
Williams, Kimberly R
Zhao, Xiuhua
Govindaraju, Swapomthi K
Quinn, Gwendolyn P
Vadaparampil, Susan T
Lin, Hui-Yi
Sutton, Steven K
Roethzeim, Richard R
Shibata, David
Meade, Cathy D
Gwede, Clement K
P30 CA076292/CA/NCI NIH HHS/United States
R25 CA090314/CA/NCI NIH HHS/United States
Journal Article
Cancer. 2016 Nov 15;122(21):3288-3296. doi: 10.1002/cncr.30207. Epub 2016 Jul 15.
PY  - 2016
SN  - 0008-543X (Print)
0008-543x
SP  - 3288-3296
ST  - A community-based trial of educational interventions with fecal immunochemical tests for colorectal cancer screening uptake among blacks in community settings
T2  - Cancer
TI  - A community-based trial of educational interventions with fecal immunochemical tests for colorectal cancer screening uptake among blacks in community settings
VL  - 122
ID  - 198
ER  - 

TY  - JOUR
AB  - OBJECTIVE: We examined the efficacy of a community-based, culturally relevant intervention to promote healthy eating and physical activity among African American (AA) women between the ages of 45-65 years, residing in rural Alabama. METHODS: We conducted a group randomized controlled trial with counties as the unit of randomization that evaluated two interventions based on health priorities identified by the community: (1) promotion of healthy eating and physical activity; and (2) promotion of breast and cervical cancer screening. A total of 6 counties with 565 participants were enrolled in the study between November 2009 and October 2011. RESULTS: The overall retention rate at 24-month follow-up was 54.7%. Higher retention rate was observed in the "healthy lifestyle" arm (63.1%) as compared to the "screening" arm (45.3%). Participants in the "healthy lifestyle" arm showed significant positive changes compared to the "screening" arm at 12-month follow-up with regard to decrease in fried food consumption and an increase in both fruit/vegetable intake and physical activity. At 24-month follow-up, these positive changes were maintained with healthy eating behaviors, but not engagement in physical activity. CONCLUSIONS: A culturally relevant intervention, developed in collaboration with the target audience, can improve (and maintain) healthy eating among AA women living in rural areas.
AD  - Division of Preventive Medicine, University of Alabama at Birmingham, 1717 11th Avenue South, MT 609, Birmingham, AL 35205, USA. Electronic address: scarinci@uab.edu.
Division of Preventive Medicine, University of Alabama at Birmingham, 1717 11th Avenue South, MT 609, Birmingham, AL 35205, USA.
AN  - 25152504
AU  - Scarinci, I. C.
AU  - Moore, A.
AU  - Wynn-Wallace, T.
AU  - Cherrington, A.
AU  - Fouad, M.
AU  - Li, Y.
C2  - PMC4469991
C6  - NIHMS624308
DA  - Dec
DO  - 10.1016/j.ypmed.2014.08.016
DP  - NLM
ET  - 2014/08/26
KW  - Adult
*African Americans
Alabama
Community-Based Participatory Research
*Culture
*Exercise
Feeding Behavior/*ethnology
Female
Health Behavior
*Health Promotion
Humans
Middle Aged
Rural Population
African American
Behavior change
Healthy lifestyle
Rural
Women
interest.
LA  - eng
N1  - 1096-0260
Scarinci, Isabel C
Moore, Artisha
Wynn-Wallace, Theresa
Cherrington, Andrea
Fouad, Mona
Li, Yufeng
P20 MD006899/MD/NIMHD NIH HHS/United States
P30 DK079626/DK/NIDDK NIH HHS/United States
R24 MD002747/MD/NIMHD NIH HHS/United States
MD002747/MD/NIMHD NIH HHS/United States
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Prev Med. 2014 Dec;69:13-20. doi: 10.1016/j.ypmed.2014.08.016. Epub 2014 Aug 23.
PY  - 2014
SN  - 0091-7435 (Print)
0091-7435
SP  - 13-20
ST  - A community-based, culturally relevant intervention to promote healthy eating and physical activity among middle-aged African American women in rural Alabama: findings from a group randomized controlled trial
T2  - Prev Med
TI  - A community-based, culturally relevant intervention to promote healthy eating and physical activity among middle-aged African American women in rural Alabama: findings from a group randomized controlled trial
VL  - 69
ID  - 278
ER  - 

TY  - JOUR
AB  - OBJECTIVES: To test the effectiveness of a preclinical, telephone-based patient navigation intervention to encourage colorectal cancer (CRC) screening among older Black men. METHODS: We conducted a 3-parallel-arm, randomized trial among 731 self-identified Black men recruited at barbershops between 2010 and 2013 in New York City. Participants had to be aged 50 years or older, not be up-to-date on CRC screening, have uncontrolled high blood pressure, and have a working telephone. We randomized participants to 1 of 3 groups: (1) patient navigation by a community health worker for CRC screening (PN), (2) motivational interviewing for blood pressure control by a trained counselor (MINT), or (3) both interventions (PLUS). We assessed CRC screening completion at 6-month follow-up. RESULTS: Intent-to-treat analysis revealed that participants in the navigation interventions were significantly more likely than those in the MINT-only group to be screened for CRC during the 6-month study period (17.5% of participants in PN, 17.8% in PLUS, 8.4% in MINT; P < .01). CONCLUSIONS: Telephone-based preclinical patient navigation has the potential to be effective for older Black men. Our results indicate the importance of community-based health interventions for improving health among minority men.
AD  - At the time of the study, Helen Cole was with the Division of Health Behavior, Department of Population Health, New York University School of Medicine, New York, NY. Hayley S. Thompson is with the Population Studies and Disparities Research Program, Communication and Behavioral Oncology, Karmanos Cancer Institute, Detroit, MI. Marilyn White and Ruth Browne are with the Arthur Ashe Institute for Urban Health, Brooklyn, NY. Chau Trinh-Shevrin, Scott Braithwaite, and Joseph Ravenell are with the Department of Population Health, New York University School of Medicine. Kevin Fiscella is with the Departments of Family Medicine and Public Health Sciences, University of Rochester School of Medicine and Dentistry, Rochester, NY. Carla Boutin-Foster is with the Division of Clinical Epidemiology and Evaluative Sciences, Weill Cornell Medical Center, New York.
AN  - 28727540
AU  - Cole, H.
AU  - Thompson, H. S.
AU  - White, M.
AU  - Browne, R.
AU  - Trinh-Shevrin, C.
AU  - Braithwaite, S.
AU  - Fiscella, K.
AU  - Boutin-Foster, C.
AU  - Ravenell, J.
C2  - PMC5551599
DA  - Sep
DO  - 10.2105/ajph.2017.303885
DP  - NLM
ET  - 2017/07/21
IS  - 9
KW  - African Americans/*psychology
Aged
*Barbering
Colorectal Neoplasms/*diagnosis/ethnology/prevention & control
Community Health Services
Early Detection of Cancer/*methods
Health Knowledge, Attitudes, Practice/ethnology
Healthcare Disparities/ethnology
Humans
Male
Middle Aged
New York City
Patient Navigation/*methods
LA  - eng
N1  - 1541-0048
Cole, Helen
Thompson, Hayley S
White, Marilyn
Browne, Ruth
Trinh-Shevrin, Chau
Braithwaite, Scott
Fiscella, Kevin
Boutin-Foster, Carla
Ravenell, Joseph
U54 MD000538/MD/NIMHD NIH HHS/United States
U48 DP002671/DP/NCCDPHP CDC HHS/United States
U48 DP005008/DP/NCCDPHP CDC HHS/United States
P60 MD000538/MD/NIMHD NIH HHS/United States
P60 MD003421/MD/NIMHD NIH HHS/United States
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, P.H.S.
Am J Public Health. 2017 Sep;107(9):1433-1440. doi: 10.2105/AJPH.2017.303885. Epub 2017 Jul 20.
PY  - 2017
SN  - 0090-0036 (Print)
0090-0036
SP  - 1433-1440
ST  - Community-Based, Preclinical Patient Navigation for Colorectal Cancer Screening Among Older Black Men Recruited From Barbershops: The MISTER B Trial
T2  - Am J Public Health
TI  - Community-Based, Preclinical Patient Navigation for Colorectal Cancer Screening Among Older Black Men Recruited From Barbershops: The MISTER B Trial
VL  - 107
ID  - 162
ER  - 

TY  - JOUR
AB  - BACKGROUND: The objective of Alabama Racial and Ethnic Approaches to Community Health 2010 is to implement and evaluate a community action plan (CAP) developed by a diverse coalition to reduce breast and cervical cancer screening disparities between African American and White women. METHODS: The CAP entailed (1) establishing a core working group (CWG) in each county, (2) training CWG members to promote screenings, and (3) providing coalition members with technical assistance to write mini-grants. RESULTS: Overall, 241 CWG members were trained. They have conducted 2800 cancer screening surveys. A total of 8 coalition members received mini-grants. CONCLUSION: Community capacity building can lead to a sense of ownership and empowerment.
AD  - Division of Preventive Medicine, University of Alabama, Birmingham, AL 35294-4410, USA. mfouad@uab.edu
AN  - 17020510
AU  - Fouad, M. N.
AU  - Partridge, E.
AU  - Dignan, M.
AU  - Holt, C.
AU  - Johnson, R.
AU  - Nagy, C.
AU  - Parham, G.
AU  - Person, S.
AU  - Scarinci, I.
AU  - Wynn, T.
DA  - Spring
DO  - 10.1207/s15430154jce2101s_16
DP  - NLM
ET  - 2006/10/06
IS  - 1 Suppl
KW  - Adult
*African Americans
Aged
Alabama/epidemiology
Breast Neoplasms/diagnosis/*ethnology/*prevention & control
Community Health Planning/*organization & administration/trends
Community Health Workers/education
*Community Participation/trends
Community-Institutional Relations
Confounding Factors, Epidemiologic
*European Continental Ancestry Group
Female
Health Care Coalitions/*organization & administration/trends
Health Education/organization & administration/trends
Health Priorities/organization & administration/trends
Health Promotion/organization & administration/trends
Humans
Mammography
Middle Aged
Rural Population
Urban Population
Uterine Cervical Neoplasms/diagnosis/*ethnology/*prevention & control
Vaginal Smears
Women's Health/*ethnology
LA  - eng
N1  - Fouad, Mona N
Partridge, Edward
Dignan, Mark
Holt, Cheryl
Johnson, Rhoda
Nagy, Christine
Parham, Groesbeck
Person, Sharina
Scarinci, Isabel
Wynn, Theresa
U50/CCU422206/PHS HHS/United States
Journal Article
Research Support, U.S. Gov't, P.H.S.
England
J Cancer Educ. 2006 Spring;21(1 Suppl):S91-100. doi: 10.1207/s15430154jce2101s_16.
PY  - 2006
SN  - 0885-8195 (Print)
0885-8195
SP  - S91-100
ST  - A community-driven action plan to eliminate breast and cervical cancer disparity: successes and limitations
T2  - J Cancer Educ
TI  - A community-driven action plan to eliminate breast and cervical cancer disparity: successes and limitations
VL  - 21
ID  - 548
ER  - 

TY  - JOUR
AB  - Objective: Companions play an important role in cancer care. This investigation compared the communication of unaccompanied patients, accompanied patients, and companions during lung cancer consultations. Factors affecting the active participation of companions were analyzed. Methods: Participants included unaccompanied patients (N = 48), accompanied patients (N = 84), and companions (N = 84) of newly diagnosed lung cancer patients seen at a large southern VA medical center. The consultations were audiotaped, then transcribed. Coded utterances included patients' and companions' active participation (asking questions, expressing concerns, and making assertions) and physicians' use of facilitative communication. Mixed linear regression was used for comparisons of accompanied patients' participation to that of their companions and to determine the independent predictors of companion participation and patient satisfaction. Results: The combined companion plus patient participation did not differ from the participation of unaccompanied patients. Patterns of companion participation varied greatly as almost half the interactions had a relatively passive companion (contributed to less than 40% of the patient plus companion active participation) but 33% of the consultations had an active companion and passive patient. Companions with less active participation accompanied black patients and received proportionally less facilitative communication from physicians. Patient satisfaction was lower when companion and patient had similar levels of participation. Conclusion: Companions vary greatly in their participation in lung cancer visits. Physicians facilitate companion participation through the use of partnership-building and supportive communication. The companions of black patients were less active than their white counterparts which parallels other research indicating that black patients are often less active than white patients. Such communicative discrepancies could contribute to racial disparities in cancer care. Copyright © 2007 John Wiley & Sons, Ltd.
AD  - R.L. Street, Department of Communication, Texas AandM University, College Station, TX 77843-4234, United States
AU  - Street, R. L.
AU  - Gordon, H. S.
DB  - Embase
Medline
DO  - 10.1002/pon.1225
IS  - 3
KW  - aged
article
cancer patient
Caucasian
companion
consultation
controlled study
female
human
interpersonal communication
linear regression analysis
lung cancer
major clinical study
male
miscellaneous named groups
Black person
patient care
patient participation
patient satisfaction
United States
LA  - English
M3  - Article
N1  - L351410762
2008-04-01
PY  - 2008
SN  - 1057-9249
1099-1611
SP  - 244-251
ST  - Companion participation in cancer consultations
T2  - Psycho-Oncology
TI  - Companion participation in cancer consultations
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L351410762&from=export
http://dx.doi.org/10.1002/pon.1225
VL  - 17
ID  - 1214
ER  - 

TY  - JOUR
AB  - BACKGROUND: Predictive models that take race into account like the Prostate Cancer Prevention Trial Risk Calculator 2.0 (PCPT RC) and the new Prostate Biopsy Collaborative Group (PBCG) RC have been developed to equitably mitigate the overdiagnosis of prostate specific antigen (PSA) screening. Few studies have compared the performance of both calculators across racial groups. METHODS: From 1485 prospectively recruited participants, 954 men were identified undergoing initial prostate biopsy for abnormal PSA or digital rectal examination in five Chicago hospitals between 2009 and 2014. Discrimination, calibration, and frequency of avoided biopsies were calculated to assess the performance of both risk calculators. RESULTS: Of 954 participants, 463 (48.5%) were Black, 355 (37.2%) were White, and 136 (14.2%) identified as Other. Biopsy results were as follows: 310 (32.5%) exhibited no cancer, 323 (33.9%) indolent prostate cancer, and 321 (33.6%) clinically significant prostate cancer (csPCa). Differences in area under the curve (AUC)s for the detection of csPCa between PCPT and PBCG were not statistically different across all racial groups. PBCG did not improve calibration plots in Blacks and Others, as it showed higher levels of overprediction at most risk thresholds. PCPT led to an increased number of avoidable biopsies in minorities compared to PBCG at the 30% threshold (68% vs. 28% of all patients) with roughly similar rates of missed csPCa (23% vs. 20%). CONCLUSION: Significant improvements were noticed in PBCG's calibrations and net benefits in Whites compared to PCPT. Since PBCG's improvements in Blacks are disputable and potentially biases a greater number of low risk Black and Other men towards unnecessary biopsies, PCPT may lead to better biopsy decisions in racial minority groups. Further comparisons of commonly used risk calculators across racial groups is warranted to minimize excessive biopsies and overdiagnosis in ethnic minorities.
AD  - Department of Urology, Northwestern University Feinberg School of Medicine, 303 E Chicago Avenue, Tarry 16, Chicago, IL, 60611, USA.
Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Department of Medicine, University of Illinois at Chicago, Chicago, IL, USA.
Division of Urology, Cook County Health and Hospitals System, 303 E Chicago Avenue, Tarry 16, Chicago, IL, 60611, USA.
Section of Urology, Jesse Brown VA Medical Center, 303 E Chicago Avenue, Tarry 16, Chicago, IL, 60611, USA.
Department of Urology, University of Illinois at Chicago School of Medicine, Chicago, IL, USA.
Division of Health Equities, Department of Population Sciences, City of Hope Cancer Center, Duarte, CA, USA.
Department of Pathology, University of Illinois at Chicago School of Medicine, Chicago, IL, USA.
Department of Urology, Northwestern University Feinberg School of Medicine, 303 E Chicago Avenue, Tarry 16, Chicago, IL, 60611, USA. a-murphy2@northwestern.edu.
Division of Urology, Cook County Health and Hospitals System, 303 E Chicago Avenue, Tarry 16, Chicago, IL, 60611, USA. a-murphy2@northwestern.edu.
Section of Urology, Jesse Brown VA Medical Center, 303 E Chicago Avenue, Tarry 16, Chicago, IL, 60611, USA. a-murphy2@northwestern.edu.
AN  - 31771578
AU  - Carbunaru, S.
AU  - Nettey, O. S.
AU  - Gogana, P.
AU  - Helenowski, I. B.
AU  - Jovanovic, B.
AU  - Ruden, M.
AU  - Hollowell, C. M. P.
AU  - Sharifi, R.
AU  - Kittles, R. A.
AU  - Schaeffer, E.
AU  - Gann, P.
AU  - Murphy, A. B.
C2  - PMC6880480
DA  - Nov 27
DO  - 10.1186/s12894-019-0553-6
DP  - NLM
ET  - 2019/11/28
IS  - 1
KW  - Aged
Biopsy
Cohort Studies
*Ethnic Groups
Humans
Male
Middle Aged
Prospective Studies
Prostatic Neoplasms/*pathology/*prevention & control
Risk Assessment/*methods
African American validation
Prostate Cancer prevention trial risk calculator 2.0
Prostate biopsy collaborative group risk calculator
Prostate cancer risk prediction
Risk calculator
LA  - eng
N1  - 1471-2490
Carbunaru, Samuel
Nettey, Oluwarotimi S
Gogana, Pooja
Helenowski, Irene B
Jovanovic, Borko
Ruden, Maria
Hollowell, Courtney M P
Sharifi, Roohollah
Kittles, Rick A
Schaeffer, Edward
Gann, Peter
Murphy, Adam B
W81XWH-16-PCRP-IDA/Defense Health Agency/
R21CA2022552/CA/NCI NIH HHS/United States
1R01MD007105-01/National Institutes of Minority Health & Health Disparities/
Comparative Study
Evaluation Study
Journal Article
BMC Urol. 2019 Nov 27;19(1):121. doi: 10.1186/s12894-019-0553-6.
PY  - 2019
SN  - 1471-2490
SP  - 121
ST  - A comparative effectiveness analysis of the PBCG vs. PCPT risks calculators in a multi-ethnic cohort
T2  - BMC Urol
TI  - A comparative effectiveness analysis of the PBCG vs. PCPT risks calculators in a multi-ethnic cohort
VL  - 19
ID  - 57
ER  - 

TY  - JOUR
AB  - BACKGROUND: Biologic agents have improved the outcomes of patients with metastatic colorectal cancer (mCRC). However, the clinical trials included a predominately white population (85%), with Hispanic and black patients underrepresented. Thus, the real world benefit for the latter remains unknown. Comparative effectiveness research is a tool allowing for this exploration. PATIENTS AND METHODS: The demographic and clinical characteristics of patients treated for mCRC from 2000 to 2011 were extracted from the medical records of Montefiore Medical Center. A semiparametric accelerated failure time model was used to assess the survival differences between patients receiving chemotherapy (CT) alone versus CT plus biologic agents (CBT). RESULTS: Of the 290 patients (black, 45.9%; Hispanic, 26.2%; and white, 27.9%), 53.8% received biologic agents. The median overall survival was 15.2 months in the CT-alone group and 25.6 months in CBT group (P = .004). On univariate analysis, a lower number of metastatic sites, carcinoembryonic antigen < 41 ng/mL, and more lines of CT were associated with improved overall survival. In a propensity score-based analysis of the entire cohort, CBT offered a survival benefit compared with CT alone (increased median survival, 1.44-fold; 95% confidence interval [CI], 1.11-1.86; P = .038). The results of the subgroup analysis suggested a survival benefit for white patients (2.01; 95% CI, 1.26-3.23; P = .031) but not for Hispanic (1.42; 95% CI, 0.91-2.20; P = .370) or black (1.12; 95% CI, 0.76-1.66; P = .596) patients. CONCLUSION: In the present cohort, CBT was associated with longer survival, with the effect mainly driven by the outcomes for white patients, with black patients not appearing to benefit. These data are provocative and warrant further confirmation. Efforts to increase ethnic minority patients' enrollment in clinical trials is required to prospectively define the benefit from novel therapies.
AD  - Department of Medical Oncology, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, NY. Electronic address: sgoel@montefiore.org.
Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY.
Department of Medical Oncology, Montefiore Medical Center, Bronx, NY.
Department of Medicine, Montefiore Medical Center, Bronx, NY.
Department of Medical Oncology, Albert Einstein College of Medicine, Bronx, NY.
Department of Medical Oncology, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, NY.
AN  - 28412139
AU  - Goel, S.
AU  - Negassa, A.
AU  - Khot, A.
AU  - Goyal, D.
AU  - Guo, S.
AU  - Nandikolla, A.
AU  - Bakirhan, K.
AU  - Polineni, R.
AU  - Shah, U.
AU  - Chaudhary, I.
AU  - Ghalib, M. H.
AU  - Rajdev, L.
AU  - Kaubisch, A.
AU  - Chuy, J.
AU  - Aparo, S.
DA  - Dec
DO  - 10.1016/j.clcc.2017.03.004
DP  - NLM
ET  - 2017/04/17
IS  - 4
KW  - Adult
African Americans/statistics & numerical data
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols/administration & dosage/*therapeutic
use
Biological Factors/*administration & dosage
Carcinoembryonic Antigen/blood
Cohort Studies
Colorectal Neoplasms/*drug therapy
Comparative Effectiveness Research
European Continental Ancestry Group/statistics & numerical data
Female
Hispanic Americans/statistics & numerical data
Humans
Male
Middle Aged
*Models, Theoretical
Survival Rate
Treatment Outcome
*Biologic therapy
*Chemotherapy
*Colorectal cancer
*Comparative effectiveness research
*Race
LA  - eng
N1  - 1938-0674
Goel, Sanjay
Negassa, Abdissa
Khot, Ashish
Goyal, Dharmendra
Guo, Shuang
Nandikolla, Amara
Bakirhan, Kamila
Polineni, Rahul
Shah, Umang
Chaudhary, Imran
Ghalib, Mohammad H
Rajdev, Lakshmi
Kaubisch, Andreas
Chuy, Jennifer
Aparo, Santiago
Comparative Study
Journal Article
Research Support, Non-U.S. Gov't
United States
Clin Colorectal Cancer. 2017 Dec;16(4):286-292. doi: 10.1016/j.clcc.2017.03.004. Epub 2017 Mar 14.
PY  - 2017
SN  - 1533-0028
SP  - 286-292
ST  - Comparative Effectiveness Research: The Impact of Biologic Agents in Ethnic Minorities With Metastatic Colorectal Cancer
T2  - Clin Colorectal Cancer
TI  - Comparative Effectiveness Research: The Impact of Biologic Agents in Ethnic Minorities With Metastatic Colorectal Cancer
VL  - 16
ID  - 172
ER  - 

TY  - JOUR
AB  - Purpose: To determine whether racial differences in gene and miRNA expression translates to differences in lung tumor biology with clinical relevance in African Americans (AAs) and European Americans (EAs).Experimental Design: The NCI-Maryland Case Control Study includes seven Baltimore City hospitals and is overrepresented with AA patients (∼40%). Patients that underwent curative NSCLC surgery between 1998 and 2014 were enrolled. Comparative molecular profiling used mRNA (n = 22 AAs and 19 EAs) and miRNA (n = 42 AAs and 55 EAs) expression arrays to track differences in paired fresh frozen normal tissues and lung tumor specimens from AAs and EAs. Pathway enrichment, predicted drug response, tumor microenvironment infiltration, cancer immunotherapy antigen profiling, and miRNA target enrichment were assessed.Results: AA-enriched differential gene expression was characterized by stem cell and invasion pathways. Differential gene expression in lung tumors from EAs was primarily characterized by cell proliferation pathways. Population-specific gene expression was partly driven by population-specific miRNA expression profiles. Drug susceptibility predictions revealed a strong inverse correlation between AA resistance and EA sensitivity to the same panel of drugs. Statistically significant differences in M1 and M2 macrophage infiltration were observed in AAs (P < 0.05); however, PD-L1, PD-L2 expression was similar between both.Conclusions: Comparative transcriptomic profiling revealed clear differences in lung tumor biology between AAs and EAs. Increased participation by AAs in lung cancer clinical trials are needed to integrate, and leverage, transcriptomic differences with other clinical information to maximize therapeutic benefit in both AAs and EAs. Clin Cancer Res; 23(23); 7412-25. ©2017 AACR.
AD  - Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.
Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland Brid.Ryan@nih.gov.
AN  - 29196495
AU  - Mitchell, K. A.
AU  - Zingone, A.
AU  - Toulabi, L.
AU  - Boeckelman, J.
AU  - Ryan, B. M.
DA  - Dec 1
DO  - 10.1158/1078-0432.Ccr-17-0527
DP  - NLM
ET  - 2017/12/03
IS  - 23
KW  - African Americans/genetics
Aged
Carcinoma, Non-Small-Cell Lung/ethnology/*genetics
Case-Control Studies
European Continental Ancestry Group/genetics
Female
*Gene Expression Profiling
Humans
Kaplan-Meier Estimate
Lung Neoplasms/ethnology/*genetics
Male
MicroRNAs/*genetics
Middle Aged
RNA, Messenger/*genetics
United States
LA  - eng
N1  - 1557-3265
Mitchell, Khadijah A
Zingone, Adriana
Toulabi, Leila
Boeckelman, Jacob
Ryan, Bríd M
Comparative Study
Journal Article
United States
Clin Cancer Res. 2017 Dec 1;23(23):7412-7425. doi: 10.1158/1078-0432.CCR-17-0527.
PY  - 2017
SN  - 1078-0432
SP  - 7412-7425
ST  - Comparative Transcriptome Profiling Reveals Coding and Noncoding RNA Differences in NSCLC from African Americans and European Americans
T2  - Clin Cancer Res
TI  - Comparative Transcriptome Profiling Reveals Coding and Noncoding RNA Differences in NSCLC from African Americans and European Americans
VL  - 23
ID  - 143
ER  - 

TY  - JOUR
AB  - OBJECTIVE: The aim of the study was to compare knowledge and awareness of heart attacks/heart disease and perceived risk for future heart attack in Asian/Pacific Islander women, compared to other racial and ethnic groups. MATERIALS AND METHODS: In this cross-sectional study, 318 women enrolled in a mobile phone-based physical activity education trial were analyzed. Heart attack knowledge, self-efficacy for recognizing and responding to heart attack symptoms, and perceived risk for a future heart attack were measured. Analyses were conducted using logistic, proportional odds, and linear regression models, depending on the outcome and adjusting for age. Pairwise differences between Asian/Pacific Islanders and the other four groups were assessed using a Bonferroni correction (p < 0.0125). RESULTS: Asian/Pacific Islander women had significantly lower total scores for knowledge of heart attack and self-efficacy for heart attack recognition and care seeking behavior compared to the Caucasian women (p = 0.001 and p = 0.002, respectively). However, perceived risk did not differ among the groups. Forty-six percent of the Asian American women, compared to 25% of Caucasian women, falsely believed "breast cancer is the number one cause of death for women (p = 0.002)." In addition, Asian/Pacific Islander women were less likely to report "arm pain, numbness, tingling, or radiating" as one of the heart attack symptoms compared to the Caucasian and the multiracial group (34%, 63% [p < 0.001], and 66% [p = 0.004], respectively). CONCLUSIONS: These findings highlight the urgent need to develop effective, tailored campaigns to close the knowledge gap between Asian/Pacific Islander women and Caucasian women.
AD  - 1 Department of Physiological Nursing, Institute for Health & Aging, School of Nursing, University of California , San Francisco, San Francisco, California.
2 Institute for Health & Aging, University of California , San Francisco, San Francisco, California.
3 Department of Epidemiology & Biostatistics, University of California , San Francisco, San Francisco, California.
AN  - 28418750
AU  - Fukuoka, Y.
AU  - Lisha, N. E.
AU  - Vittinghoff, E.
C2  - PMC5646802
DA  - Sep
DO  - 10.1089/jwh.2016.6156
DP  - NLM
ET  - 2017/04/19
IS  - 9
KW  - Adult
African Americans/psychology/statistics & numerical data
Asian Americans/*psychology/statistics & numerical data
Attitude to Health
California/epidemiology
Cross-Cultural Comparison
Cross-Sectional Studies
Ethnic Groups/*psychology/statistics & numerical data
European Continental Ancestry Group/psychology/statistics & numerical data
Female
Health Knowledge, Attitudes, Practice/*ethnology
Heart Diseases/diagnosis/*ethnology/*prevention & control
Hispanic Americans/psychology/statistics & numerical data
Humans
Middle Aged
Myocardial Infarction/diagnosis/*ethnology/*prevention & control
Patient Acceptance of Health Care
Population Surveillance
Risk Factors
*Self Efficacy
*Asian/Pacific Islanders
*cardiovascular risks
*heart attack symptoms
*perceived risk
*women
LA  - eng
N1  - 1931-843x
Fukuoka, Yoshimi
Lisha, Nadra E
Vittinghoff, Eric
R01 HL104147/HL/NHLBI NIH HHS/United States
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
J Womens Health (Larchmt). 2017 Sep;26(9):1012-1019. doi: 10.1089/jwh.2016.6156. Epub 2017 Apr 18.
PY  - 2017
SN  - 1540-9996 (Print)
1540-9996
SP  - 1012-1019
ST  - Comparing Asian American Women's Knowledge, Self-Efficacy, and Perceived Risk of Heart Attack to Other Racial and Ethnic Groups: The mPED Trial
T2  - J Womens Health (Larchmt)
TI  - Comparing Asian American Women's Knowledge, Self-Efficacy, and Perceived Risk of Heart Attack to Other Racial and Ethnic Groups: The mPED Trial
VL  - 26
ID  - 171
ER  - 

TY  - JOUR
AB  - African American and Hispanic men are less likely to participate in prostate and colorectal cancer screening and have poorer outcomes from these diseases. Guided by the Patient/Provider/System Theoretical Model for Cancer Screening, this study compares the relationships among knowledge of prostate and colorectal cancer, perceptions of cancer fatalism, common sources of cancer information, and awareness of cancer resources screening between African American (n = 72) and Hispanic (n = 47) men who attend federally qualified health centers and a hospital-based primary care clinic in a southern state. African American men were older, had higher levels of education, and were more knowledgeable about cancer than Hispanic men were. However, Hispanic men were more fatalistic about cancer. Most men in both groups were more likely to get cancer information from the television and/or radio, with few accessing the Internet for this information. The men were not aware of many of the leading cancer-related organizations and programs. Nurses continue to play a critical role in patient education and enhancing screening rates. These findings suggest that culturally and educationally appropriate intervention strategies are needed to enhance knowledge and that the television/radio may be an effective medium for delivering these strategies.
AD  - Behavioral Research Center, American Cancer Society, Atlanta, Georgia, USA. Barbara.Powe@cancer.org
AN  - 105434062. Language: English. Entry Date: 20091030. Revision Date: 20150820. Publication Type: Journal Article
AU  - Powe, B. D.
AU  - Cooper, D. L.
AU  - Harmond, L.
AU  - Ross, L.
AU  - Mercado, F. E.
AU  - Faulkenberry, R.
DB  - CINAHL Complete
DO  - 10.1097/NCC.0b013e3181aaf10e
DP  - EBSCOhost
IS  - 5
KW  - Black Persons -- United States
Colorectal Neoplasms
Health Knowledge
Hispanic Americans -- United States
Prostatic Neoplasms
Adult
Aged
Aged, 80 and Over
Attitude to Illness -- Evaluation
Cancer Screening
Chi Square Test
Comparative Studies
Conceptual Framework
Convenience Sample
Descriptive Research
Descriptive Statistics
Effect Size
Health Knowledge -- Evaluation
Male
Middle Age
Models, Theoretical
Pearson's Correlation Coefficient
Quantitative Studies
Questionnaires
Race Factors
Research Subject Recruitment
T-Tests
United States
Human
N1  - research; tables/charts. Journal Subset: Core Nursing; Double Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Nursing; Peer Reviewed; USA. Instrumentation: Powe Fatalism Inventory (PFI). NLM UID: 7805358.
PMID: NLM19661793.
PY  - 2009
SN  - 0162-220X
SP  - 412-417
ST  - Comparing knowledge of colorectal and prostate cancer among African American and Hispanic men
T2  - Cancer Nursing
TI  - Comparing knowledge of colorectal and prostate cancer among African American and Hispanic men
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105434062&site=ehost-live&scope=site
VL  - 32
ID  - 1893
ER  - 

TY  - JOUR
AB  - Objective: Compare effects of narrative and informational videos on use of mammography, cancer-related beliefs, recall of core content and a range of reactions to the videos.Method: African American women (n=489) ages 40 and older were recruited from low-income neighborhoods in St. Louis, MO and randomly assigned to watch a narrative video comprised of stories from African American breast cancer survivors (Living Proof) or a content-equivalent informational video using a more expository and didactic approach (Facts for Life). Effects were measured immediately post-exposure and at 3- and 6-month follow-up.Results: The narrative video was better liked, enhanced recall, reduced counterarguing, increased breast cancer discussions with family members and was perceived as more novel. Women who watched the narrative video also reported fewer barriers to mammography, more confidence that mammograms work, and were more likely to perceive cancer as an important problem affecting African Americans. Use of mammography at 6-month follow-up did not differ for the narrative vs. informational groups overall (49% vs. 40%, p=.20), but did among women with less than a high school education (65% vs. 32%, p<.01), and trended in the same direction for those who had no close friends or family with breast cancer (49% vs. 31%, p=.06) and those who were less trusting of traditional cancer information sources (48% vs. 30%, p=.06).Conclusions: Narrative forms of communication may increase the effectiveness of interventions to reduce cancer health disparities.Practice implications: Narratives appear to have particular value in certain population sub-groups; identifying these groups and matching them to specific communication approaches may increase effectiveness. © 2010 Elsevier Ireland Ltd.
AD  - M.W. Kreuter, Health Communication Research Laboratory, George Warren Brown School of Social Work, Washington University in St. Louis, 700 Rosedale Avenue, Campus Box 1009, St. Louis, MO 63112, United States
AU  - Kreuter, M. W.
AU  - Holmes, K.
AU  - Alcaraz, K.
AU  - Kalesan, B.
AU  - Rath, S.
AU  - Richert, M.
AU  - McQueen, A.
AU  - Caito, N.
AU  - Robinson, L.
AU  - Clark, E. M.
DB  - Embase
Medline
DO  - 10.1016/j.pec.2010.09.008
IS  - SUPPL. 1
KW  - adult
African American
article
cancer research
cancer survivor
clinical effectiveness
clinical trial
comparative effectiveness
controlled clinical trial
controlled study
educational status
female
follow up
health belief
health disparity
health education
human
human experiment
lowest income group
mammography
medical informatics
narrative
priority journal
randomized controlled trial
United States
videorecording
women's health
LA  - English
M3  - Article
N1  - L51143554
2010-11-12
2010-12-17
PY  - 2010
SN  - 0738-3991
SP  - S6-S14
ST  - Comparing narrative and informational videos to increase mammography in low-income African American women
T2  - Patient Education and Counseling
TI  - Comparing narrative and informational videos to increase mammography in low-income African American women
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L51143554&from=export
http://dx.doi.org/10.1016/j.pec.2010.09.008
VL  - 81
ID  - 1155
ER  - 

TY  - JOUR
AB  - Between March 1992 and November 1994, 91 patients with stage III and IV ovarian carcinoma were enrolled in a randomized comparative study of cyclophosphamide 600 mg/m2 plus carboplatin 300 mg/m2 vs. cyclophosphamide 600 mg/m2 plus carboplatin 600 mg/m2, each regimen given monthly for six cycles. Patients on the intensive regimen also received 10 micrograms/kg of granulocyte macrophage colony stimulating factor (GM-CSF) (molgramostim) daily for 14 days following each chemotherapy treatment. The study was closed prematurely because of very poor case accrual following the preliminary announcement (in May 1993) that paclitaxel appeared superior to cyclophosphamide in the platinum-based treatment of ovarian cancer. More than 4 years after our last case entry, we analyzed the survival results for the 44 eligible patients who received the conventional dose of carboplatin and the 43 eligible patients receiving our intensified dose of carboplatin. More than 90% of the treated patients receiving the conventional dose regimen received at least 75% of the planned doses at each of the six treatment intervals, whereas the percentage of treated patients able to receive at least 75% of the assigned intensive dose regimen had declined from 95% in cycle 2 to 53% by cycle 6. Furthermore, although 32 patients received all six planned cycles of treatment in the conventional regimen group, only 15 received all six cycles of the intensified regimen. Patients receiving the intensive regimen had more fever, dermatitis, lethargy, musculoskeletal pain, and pulmonary complications than did the conventional dose patients. Median survival times for the two treatment groups were very similar (38.5 and 38.1 months, respectively, for the conventional and intensive regimens), and we saw no evidence that the distribution of survival times differed between the treatment regimens (p = 0.95).
AD  - Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA.
AN  - 11486702
AU  - Edmonson, J. H.
AU  - Suman, V. J.
AU  - Dalton, R. J.
AU  - Bro, W. C.
AU  - Gallenberg, M. M.
AU  - Long, H. J.
AU  - Levitt, R.
AU  - Hatfield, A. K.
AU  - Krook, J. E.
AU  - Mailliard, J. A.
AU  - Gerstner, J. B.
DO  - 10.1081/cnv-100104287
DP  - NLM
ET  - 2001/08/07
IS  - 6
KW  - Adult
African Continental Ancestry Group
Aged
Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use
Carboplatin/*administration & dosage/adverse effects
Combined Modality Therapy
Cyclophosphamide/administration & dosage/adverse effects
Dose-Response Relationship, Drug
Drug Administration Schedule
European Continental Ancestry Group
Female
Granulocyte-Macrophage Colony-Stimulating Factor/administration &
dosage/*therapeutic use
Humans
Middle Aged
Midwestern United States
Ovarian Neoplasms/*drug therapy/mortality/pathology/surgery
Recombinant Proteins/administration & dosage/*therapeutic use
Survival Rate
LA  - eng
N1  - Edmonson, J H
Suman, V J
Dalton, R J
Bro, W C
Gallenberg, M M
Long, H J
Levitt, R
Hatfield, A K
Krook, J E
Mailliard, J A
Gerstner, J B
North Central Cancer Treatment Group
CA-15083/CA/NCI NIH HHS/United States
CA-25224/CA/NCI NIH HHS/United States
CA-35101/CA/NCI NIH HHS/United States
CA-35103/CA/NCI NIH HHS/United States
CA-35113/CA/NCI NIH HHS/United States
CA-35195/CA/NCI NIH HHS/United States
CA-35269/CA/NCI NIH HHS/United States
CA-35272/CA/NCI NIH HHS/United States
CA-35415/CA/NCI NIH HHS/United States
CA-35448/CA/NCI NIH HHS/United States
CA-37404/CA/NCI NIH HHS/United States
CA-37417/CA/NCI NIH HHS/United States
CA-52352/CA/NCI NIH HHS/United States
CA-60276/CA/NCI NIH HHS/United States
CA-63849/CA/NCI NIH HHS/United States
Clinical Trial
Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.
England
Cancer Invest. 2001;19(6):597-602. doi: 10.1081/cnv-100104287.
PY  - 2001
SN  - 0735-7907 (Print)
0735-7907
SP  - 597-602
ST  - Comparison of conventional dose and double dose carboplatin in patients receiving cyclophosphamide plus carboplatin for advanced ovarian carcinoma: a North Central Cancer Treatment Group Study
T2  - Cancer Invest
TI  - Comparison of conventional dose and double dose carboplatin in patients receiving cyclophosphamide plus carboplatin for advanced ovarian carcinoma: a North Central Cancer Treatment Group Study
VL  - 19
ID  - 683
ER  - 

TY  - JOUR
AB  - Induction and maintenance immunosuppression protocols with or without long-term steroid therapy in kidney transplant recipients are variable and are transplant center-specific. The aim of this prospective randomized pilot study was to compare 5-year outcomes in kidney recipients maintained on 4 different calcineurin inhibitor (CNI)-based immunosuppression protocols without long-term steroid therapy. Two hundred consenting patients who received kidney transplants between June 2000 and October 2004 were enrolled in 4 immunosuppression protocol groups, with 50 patients in each group: cyclosporine (CSA)/mycophenolate mofetil (MMF), CSA/sirolimus (SRL), tacrolimus (TAC)/MMF, and TAC/SRL. Induction therapy was done with basiliximab and methylprednisolone. Steroids were withdrawn on post-transplant day 2, and long-term steroid therapy was not used. Demographic characteristics among the four groups were comparable; approximately 50% of the recipients were African American and ≥ 80% of the kidneys transplanted were from deceased donors. Clinical acute rejection (CAR) was confirmed by biopsy and treated with intravenous pulse steroid therapy. Steroid-unresponsive CAR was treated with Thymoglobulin. Surveillance biopsies were performed at 1, 6, 12, 24, 36, 48, and 60 months to evaluate subclinical acute rejection (SCAR), chronic allograft injury (CAI), and other pathological changes per the Banff 2005 schema. The primary end point was CAR, and secondary end points were 5-year patient and graft survival rates, renal function, SCAR, CAI, and adverse events. In the first year post-transplant, the incidence of CAR was 18% in the CSA/MMF group, 8% in the CSA/SRL group, 14% in the TAC/MMF group, and 4% in the TAC/SRL group (CSA/MMF vs. TAC/SRL; p = 0.05). The incidence of SCAR was 22% in the CSA/MMF group, 8% in the CSA/SRL group, 16% in the TAC/MMF group, and 6% in the TAC/SRL group (CSA/MMF vs. CSA/SRL and TAC/SRL; p = 0.05). After the first year, the incidences of CAR and SCAR decreased and were comparable in all 4 groups. At 5 years post-transplant, cumulative CAI due to interstitial fibrosis/tubular atrophy (IF/TA), hypertension (HTN), and chronic calcineurin inhibitor (CNI) toxicity was observed in 54%, 48%, and 8% of the CSA/MMF group vs. 16%, 36%, and 12% of the CSA/SRL group vs. 38%, 24% and 6% of the TAC/MMF group vs. 14%, 25% and 12% of the TAC/SLR group (IF/TA: CSA/MMF vs. CSA/SRL and TAC/SRL; p = 0.04, HTN: CSA/MMF vs. TAC/MMF and TAC/SRL; p = 0.05, CNI toxicity: TAC/SRL and CSA/SRL vs. TAC/MMF; p = 0.05). Five-year patient and graft survival rates were 82% and 60% in the CSA/MMF group, 82% and 60% in the CSA/SRL group, 84% and 62% in the TAC/MMF group, and 82% and 64% in the TAC/SRL group (p = 0.9). Serum creatinine levels and creatinine clearances at 5 years were comparable among the groups. Our data show that the rates of CAR and SCAR in the first year post-transplant were significantly lower in the CSA/SRL and TAC/SRL groups and that cumulative CAI rates due to IF/TA and HTN at 5 years were significantly lower in the TAC/MMF, TAC/SRL, and CSA/SRL groups than in the CSA/MMF group. Despite significant differences in the incidences of CAR and SCAR and prevalence of different types of CAI at 5 years, renal function and patient and graft survival rates at 5 years were comparable among kidney recipients maintained on 4 different immunosuppression protocols without long-term steroid therapy. © 2008 Elsevier B.V. All rights reserved.
AD  - M.S. Anil Kumar, Department of Surgery, Division of Transplantation, Drexel University College of Medicine, PA 19102, United States
AU  - Anil Kumar, M. S.
AU  - Irfan Saeed, M.
AU  - Ranganna, K.
AU  - Malat, G.
AU  - Sustento-Reodica, N.
AU  - Kumar, A. M. S.
AU  - Meyers, W. C.
C2  - Genzyme(United States)
DB  - Embase
Medline
DO  - 10.1016/j.trim.2008.08.005
IS  - 1-2
KW  - basiliximab
calcineurin inhibitor
cotrimoxazole
creatinine
cyclosporine
erythropoietin
insulin
methylprednisolone
mycophenolate mofetil
oral antidiabetic agent
rapamycin
tacrolimus
thymocyte antibody
valganciclovir
acute graft rejection
acute kidney failure
adult
African American
anemia
article
bacterial infection
biopsy
biopsy technique
bladder cancer
breast cancer
clinical trial
colon cancer
comparative study
controlled clinical trial
controlled study
creatinine blood level
creatinine clearance
cytomegalovirus infection
delayed graft function
demography
diabetes mellitus
drug dose increase
drug withdrawal
female
fibrosing alveolitis
gastrointestinal symptom
graft recipient
graft survival
human
human tissue
hyperlipidemia
hypertension
immunosuppressive treatment
infection
kidney
kidney carcinoma
kidney donor
kidney function
kidney graft
leukemia
lung cancer
lymphoproliferative disease
major clinical study
male
monitoring
morbidity
mouth ulcer
outcome assessment
parotid gland cancer
pilot study
pneumocystosis
prevalence
priority journal
prospective study
prostate cancer
pyelonephritis
randomized controlled trial
steroid therapy
survival rate
thyroid cancer
wound healing
wound healing impairment
LA  - English
M3  - Article
N1  - L50259851
2008-12-16
PY  - 2008
SN  - 0966-3274
SP  - 32-42
ST  - Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: Five-year outcomes
T2  - Transplant Immunology
TI  - Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: Five-year outcomes
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L50259851&from=export
http://dx.doi.org/10.1016/j.trim.2008.08.005
VL  - 20
ID  - 1201
ER  - 

TY  - JOUR
AB  - PURPOSE. This study was undertaken to determine if a community screening program designed to overcome key barriers (lack of awareness, cost of program, ease of access to care) could successfully impact on African-American males' knowledge, attitudes, and behaviors regarding prostate cancer screening. The focus of this report is knowledge. To date, there are no reported studies that examine differences in knowledge from a prescreening baseline to a postintervention level for minority participants. PATIENTS AND METHODS. A total of 944 men were enrolled in the study in a 20-month period. Prostate screening and education were offered as a new service at an existing senior health clinic. In addition, mass screenings were offered approximately monthly at various locations in the community (including senior community centers, senior apartment complexes, and some public housing projects). Screening included both the digital rectal examination and the prostate specific antigen test. A brief questionnaire was administered during client intake (the pretest) and repeated after the education and screening participation (the posttest). Test items targeted three constructs: (1) etiology, (2) risk status, and (3) clinical factors. RESULTS. The largest difference on pretest scores between the racial group's resulted from clinical factor knowledge. African-American men were significantly less likely than Caucasian men to correctly identify early symptoms of prostate cancer and the basic components of a prostate checkup. Although scores were initially significantly lower for African-American participants, these differences were not evident after program involvement. There was a significant increase in knowledge level for all men when comparing pretest and posttest scores. Significant improvement was noted for each test item, with the exception of one key item. Even after participation in the program, African-American men were stiff more likely to believe that 'pain' was die first symptom of prostate cancer. DISCUSSION. An itern-by-item analysis revealed that there was only one test item in which program participation did not 'correct' knowledge. African-American men were stiff more likely to believe that pain was the first symptom that would alert them to the presence of cancer. The screening program included information (both printed and oral content) that emphasized the importance of routine screening to detect cancer at an early stage, because most men would experience no symptoms. The only other reported study that examined knowledge documented similar findings with respect to an understanding of symptomology. These findings can be used to direct or guide the educational component of future screening programs that hope to target African-American men.
AD  - Cancer Center, Hurley Medical Center, Flint, Michigan
AN  - 107279928. Language: English. Entry Date: 20070101. Revision Date: 20150711. Publication Type: Journal Article
AU  - Abbott, R. R.
AU  - Taylor, D. K.
AU  - Barber, K.
DB  - CINAHL Complete
DP  - EBSCOhost
IS  - 3
KW  - Health Knowledge
Black Persons
Prostatic Neoplasms -- Prevention and Control
Health Screening
White Persons
Health Behavior
Prostatic Neoplasms -- Diagnosis
Health Screening -- Economics
Pretest-Posttest Design
Item Analysis
Questionnaires
Adult
Middle Age
Male
Funding Source
Human
N1  - research; tables/charts. Journal Subset: Biomedical; Peer Reviewed; USA. Grant Information: Michigan Department of Community Health, Lansing, Michigan. NLM UID: 9513568.
PMID: NLM9612599.
PY  - 1998
SN  - 1081-4442
SP  - 175-177
ST  - A comparison of prostate knowledge of African-American and Caucasian men: changes from prescreening baseline to postintervention
T2  - Cancer Journal from Scientific American
TI  - A comparison of prostate knowledge of African-American and Caucasian men: changes from prescreening baseline to postintervention
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=107279928&site=ehost-live&scope=site
VL  - 4
ID  - 1816
ER  - 

TY  - JOUR
AB  - Introduction: The GREAT Registry is a multicentric observational study in 300 sites and 5000 patients worldwide, aiming to evaluate aortic Gore devices. Our objective is to compare EVAR patients results between LatinAmerica (LA) and other world regions: United States (US), Europe (EU) and Australia/New Zealand (AU/NZ). Methods: The GREAT Registry currently enrolled 3200 EVAR patients in all 300 centers. Data related to demographic, comorbidities, pathologies, AAA morphology, intra‐procedural complications and outcomes were compared between LA and the others regions. Results: All regions have a mean follow up >80%. Demographics differences between regions were: EU had the lowest proportion of female gender (8.6% versus 18.3% in LA, 18.4% in US, 19.7% in AU/NZ, p<0.0001); LA had a younger population (70.4 years in LA versus 73.1 years in US, 73.9 years in EU, 76.2 years in AU/NZ, p<0.0001) with the greatest proportion of African descendants; AU/NZ had almost exclusively Caucasians (11% African American in AL, 6% in US,<0.1% in EU and 0% in AU/NZ, p<0.0001). Regarding comorbidities: EU had a smaller proportion of smoking, peripheral artery disease, diabetes and stroke; LA, a lower proportion of coronary artery disease, COPD and cancer; US, a higher prevalence of carotid disease; and AU/NZ, a lower proportion of erectile dysfunction. Groups were similar regarding pathologies treated, aneurysm diameter, proximal neck morphology and access site. LA had the smallest rate of percutaneous access (13%) while AU/NZ, the highest (93%). Intraoperatively, LA had a higher stroke, mortality and endoleak rates. Also LA had a higher early post‐ procedure type Ib endoleak and more reinterventions. In 2 years, LA had more AAA diameter decreasing and there were no differences in overall endoleak rate and mortality (8%). Conclusion: LA treated younger patients and had higher intraoperative and early complications rates and early reintervention rates. However, there were no differences in AAA morphology and overall endoleak and mortality rates at 2 years between all regions.
AN  - CN-01361850
AU  - Navarro, T. P.
AU  - Inglez, J. C. D.
AU  - Bernardes, T. C.
AU  - Procopio, R. J.
AU  - Silveira, P. G.
AU  - Dardik, A.
DO  - 10.1177/1708538116673764
IS  - 1 Supplement 1
KW  - *Australia
*Europe
*New Zealand
*South and Central America
*register
African American
Aneurysm
Aorta
Cancer epidemiology
Carotid artery disease
Caucasian
Cerebrovascular accident
Chronic obstructive lung disease
Clinical trial
Comorbidity
Controlled clinical trial
Controlled study
Coronary artery disease
Diabetes mellitus
Endoleak
Erectile dysfunction
Female
Follow up
Gender
Human
Major clinical study
Male
Morphology
Mortality rate
Multicenter study
Neck
Observational study
Pathology
Peripheral occlusive artery disease
Prevalence
Smoking
United States
M3  - Conference Abstract
PY  - 2016
SP  - 93‐94
ST  - Comparison of real life EVAR results in latin america (LA) versus USA (US), Europe (EU) and Australia/New Zealand (AU/NZ) with the Excluder AAA device: the GREAT Registry
T2  - Vascular. Conference: 2016 VEITH symposium and ISVS associate faculty global podium presentations. United states
TI  - Comparison of real life EVAR results in latin america (LA) versus USA (US), Europe (EU) and Australia/New Zealand (AU/NZ) with the Excluder AAA device: the GREAT Registry
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01361850/full
VL  - 24
ID  - 1577
ER  - 

TY  - JOUR
AB  - Purpose: Increased clearance of drugs, such as oral cyclosporine, that are CYP3A and/or ABCB1 (P-gp/MDR1) substrates was reported in African-American compared with Caucasian patients. We hypothesized that the pharmacokinetics and pharmacodynamics of docetaxel, an i.v. administered cytotoxic and substrate for CYP3A4, CYP3A5, and ABCB1, would differ between African-American and Caucasian patients. Experimental Design: We investigated population pharmacokinetics and pharmacodynamics and the pharmacogenetics of CYP3A4, CYP3A5, and ABCB1 in African-American and Caucasian cancer patients who received docetaxel 75 or 100 mg/m(2) as a 1-hi.v. infusion. Plasma docetaxel concentrations were measured by high-performance liquid chromatography. Clinical toxicity and absolute neutrophil count (ANC) were monitored on days 8, 15, and 22 postadministration of docetaxel. Using a limited sampling strategy and nonlinear mixed-effects modeling, each patient's docetaxel clearance was estimated. Genotyping for known polymorphisms in CYP3A4, CYP3A5, and ABCB1 was done. Results: We enrolled 109 patients: 40 African-Americans (26 males; 14 females), with a median age of 61 years (range, 29-73), and 69 Caucasians (43 males; 26 females), with a median age of 63 years (range, 38-81). There was no difference in the geometric mean docetaxel clearance between African-American patients [40.3 L/h; 95% confidence interval (95% CI), 19.3-84.1] and Caucasian patients (41.8 L/h; 95% Cl, 22.0-79.7; P = 0.6). We observed no difference between African-American and Caucasian patients in the percentage decrease in ANC nor were docetaxel pharmacokinetic parameters related to the genotypes studied. Conclusions: Docetaxel clearance and its associated myelosuppression were similar in African-American and Caucasian cancer patients.
AN  - WOS:000246788700028
AU  - Lewis, L. D.
AU  - Miller, A. A.
AU  - Rosner, G. L.
AU  - Dowell, J. E.
AU  - Valdivieso, M.
AU  - Relling, M. V.
AU  - Egorin, M. J.
AU  - Bies, R. R.
AU  - Hollis, D. R.
AU  - Levine, E. G.
AU  - Otterson, G. A.
AU  - Millard, F.
AU  - Ratain, M. J.
DA  - Jun
DO  - 10.1158/1078-0432.CCR-06-2345
IS  - 11
N1  - 40th Annual Meeting of the American-Society-of-Clinical-Oncology
JUN 05-08, 2004
New Orleans, LA
Amer Soc Clin Oncol
17545536
PY  - 2007
SN  - 1078-0432
SP  - 3302-3311
ST  - A comparison of the pharmacokinetics and pharmacodynamics of docetaxel between African-American and Caucasian cancer patients: CALGB 9871
T2  - Clinical Cancer Research
TI  - A comparison of the pharmacokinetics and pharmacodynamics of docetaxel between African-American and Caucasian cancer patients: CALGB 9871
VL  - 13
ID  - 3194
ER  - 

TY  - JOUR
AB  - PURPOSE: To investigate the effect of race on the efficacy and safety of standard chemotherapy doublet regimens in African American patients, we conducted a subgroup analysis of a phase III randomized trial. PATIENTS AND METHODS: Chemonaïve patients with a performance status of 0 or 1 and stage IIIB or IV non-small cell lung cancer were randomized to arm A: gemcitabine 1000 mg/m2 on days 1 and 8 plus carboplatin area under the curve 5.5 on day 1; arm B: the same schedule of gemcitabine plus paclitaxel 200 mg/m2 on day 1; or arm C: paclitaxel 225 mg/m2 on day 1 plus carboplatin area under the curve 6.0 on day 1. Cycles were repeated every 21 days up to 6. A site selection tool identified institutions with potential to recruit a minority population. Outcome and toxicity data of white and African American patients were compared. RESULTS: Of 1135 total patients, 972 were white (85.6%) and 138 were African American (12.2%). Median survival was 8.3 months for white patients (95% confidence interval [CI]: 7.7-9.3) and 9.1 months for African American patients (95% CI: 8.2-11.1). Response rates were 29.1 and 29.0%, respectively. Rates of grade 3 or 4 toxicities were comparable. Among African Americans, median survival was 7.2 months (95% CI: 5.1-10.1) for gemcitabine-carboplatin (n = 47), 10.5 months (95% CI: 7.1-15.4) for gemcitabine-paclitaxel (n = 42), and 10.2 months (95% CI: 8.5-13.2) for paclitaxel-carboplatin (n = 49). CONCLUSION: Whites and African Americans had similar outcomes, although there was some variability in survival among African Americans across the three treatment groups.
AD  - Lilly USA, LLC, Indianapolis, IN 46285, USA. cobasaju@lilly.com
AN  - 20593535
AU  - Obasaju, C. K.
AU  - Ansari, R. H.
AU  - Socinski, M. A.
AU  - Chen, R.
AU  - Monberg, M. J.
AU  - Catalano, R. B.
AU  - Marinucci, D. M.
AU  - Liles, D. K.
AU  - Ribeiro, M. J.
AU  - Comis, R. L.
AU  - Treat, J.
DA  - Jul
DO  - 10.1097/jto.0b013e3181e29cf3
DP  - NLM
ET  - 2010/07/02
IS  - 7
KW  - Adult
African Americans/*ethnology
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Carboplatin/administration & dosage
Carcinoma, Non-Small-Cell Lung/*drug therapy/*ethnology
Deoxycytidine/administration & dosage/analogs & derivatives
European Continental Ancestry Group/*ethnology
Female
Humans
Lung Neoplasms/*drug therapy/*ethnology
Male
Middle Aged
Paclitaxel/administration & dosage
Survival Rate
Treatment Outcome
LA  - eng
N1  - 1556-1380
Obasaju, Coleman K
Ansari, Rafat H
Socinski, Mark A
Chen, Ruqin
Monberg, Matthew J
Catalano, Robert B
Marinucci, Donna M
Liles, Darla K
Ribeiro, Maria-Jose
Comis, Robert L
Treat, Joseph
Alpha Oncology Research Network
Clinical Trial, Phase III
Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
United States
J Thorac Oncol. 2010 Jul;5(7):993-1000. doi: 10.1097/jto.0b013e3181e29cf3.
PY  - 2010
SN  - 1556-0864
SP  - 993-1000
ST  - A Comparison of white and African American outcomes from a three-arm, randomized, phase III multicenter trial of advanced or metastatic non-small cell lung cancer
T2  - J Thorac Oncol
TI  - A Comparison of white and African American outcomes from a three-arm, randomized, phase III multicenter trial of advanced or metastatic non-small cell lung cancer
VL  - 5
ID  - 417
ER  - 

TY  - JOUR
AB  - The recent decrease in breast cancer mortality has been linked in part to increased breast cancer screening. Although the percentage of women screened once is rising, rate of continued adherence is poor. The purpose of this article is to assess the effects of tailored mammography interventions implemented prospectively in a factorial design contrasting groups receiving either (a) usual care (no intervention), (b) tailored telephone counseling for mammography, (c) tailored mailed materials promoting mammography, or (d) a combination of tailored mail and telephone counseling. This prospective, randomized study with a 2 x 2 factorial design included women 51 years and older (N = 1,367) who were not adherent with mammography at baseline. The intervention is based on integration of the Transtheoretical and Health Belief Models. Participants were enrolled in one of two health maintenance organizations or seen in a university-related primary care clinic. Baseline data were collected on mammography history and beliefs and knowledge related to mammography. Data were collected via telephone interviews using previously developed scales. The follow-up interviewers were conducted with 976 women. The sample was 41% White, 56% African American, and 3% other. Mean age at baseline was 66.5. Logistic regression indicates that postintervention mammography status in all three intervention groups was significantly better than usual care, with odds ratios ranging from 1.66 (telephone only) to 2.16 (telephone plus mail).
AD  - Indiana University School of Nursing, Indianapolis 46202-5107, USA. vchampio@iupui.edu
AN  - 12173678
AU  - Champion, V. L.
AU  - Skinner, C. S.
AU  - Menon, U.
AU  - Seshadri, R.
AU  - Anzalone, D. C.
AU  - Rawl, S. M.
DA  - Summer
DO  - 10.1207/s15324796abm2403_06
DP  - NLM
ET  - 2002/08/14
IS  - 3
KW  - Aged
Attitude to Health
Breast Neoplasms/*diagnosis/surgery
Female
Humans
Mammography/*methods
Middle Aged
Postoperative Period
Prospective Studies
Random Allocation
LA  - eng
N1  - Champion, Victoria L
Skinner, Celette Sugg
Menon, Usha
Seshadri, Roopa
Anzalone, Deborah C
Rawl, Susan M
R01-04081-01A1/PHS HHS/United States
Clinical Trial
Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, U.S. Gov't, P.H.S.
England
Ann Behav Med. 2002 Summer;24(3):211-8. doi: 10.1207/S15324796ABM2403_06.
PY  - 2002
SN  - 0883-6612 (Print)
0883-6612
SP  - 211-8
ST  - Comparisons of tailored mammography interventions at two months postintervention
T2  - Ann Behav Med
TI  - Comparisons of tailored mammography interventions at two months postintervention
VL  - 24
ID  - 665
ER  - 

TY  - JOUR
AB  - There is an increasing need for accurate prediction methods of assessing individual risk for breast cancer for both clinical and research purposes. The purpose of this study is to compare the Gail and Claus model risk estimates of breast cancer among women with a family history of breast cancer. This study presents risk estimates from two models of breast cancer risk in 491 women 18 to 74 years of age with a family history of breast cancer who were recruited to risk counseling clinical trials in Seattle, Washington between 1996 and 1997. These trials included women from the general population and additional samples of Ashkenazi Jewish, African-American, and lesbian women. We estimated and compared lifetime (to age 79) and 5-year risk for developing breast cancer using the National Surgical Adjuvant Breast and Bowel Project adaptation of the Gail model and the Claus model. About one-quarter of participants fell into the Gail "high" risk category (> or =1.7% risk of developing breast cancer in the next 5 years). The average lifetime risk was estimated at 13.2% by the Gail model and 11.2% by the Claus model. Estimates from the two models were moderately and positively correlated (r = 0.55) with the Gail model yielding a higher estimate than the Claus model for most participants. If women with a family history of breast cancer are being counseled regarding decisions on genetic testing, tamoxifen use, or other preventive measures, presenting both Claus and Gail estimates may be the best option.
AD  - Cancer Prevention Research Program, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA.
AN  - 11319173
AU  - McTiernan, A.
AU  - Kuniyuki, A.
AU  - Yasui, Y.
AU  - Bowen, D.
AU  - Burke, W.
AU  - Culver, J. B.
AU  - Anderson, R.
AU  - Durfy, S.
DA  - Apr
DP  - NLM
ET  - 2001/04/25
IS  - 4
KW  - Adolescent
Adult
Aged
Antineoplastic Agents, Hormonal/therapeutic use
Breast Neoplasms/epidemiology/*etiology/*genetics
Counseling
Female
Genetic Testing
Humans
Middle Aged
*Models, Statistical
Pedigree
*Preventive Medicine
Risk Assessment
Tamoxifen/therapeutic use
LA  - eng
N1  - McTiernan, A
Kuniyuki, A
Yasui, Y
Bowen, D
Burke, W
Culver, J B
Anderson, R
Durfy, S
HG/CA01190-01/HG/NHGRI NIH HHS/United States
Comparative Study
Evaluation Study
Journal Article
Research Support, U.S. Gov't, P.H.S.
United States
Cancer Epidemiol Biomarkers Prev. 2001 Apr;10(4):333-8.
PY  - 2001
SN  - 1055-9965 (Print)
1055-9965
SP  - 333-8
ST  - Comparisons of two breast cancer risk estimates in women with a family history of breast cancer
T2  - Cancer Epidemiol Biomarkers Prev
TI  - Comparisons of two breast cancer risk estimates in women with a family history of breast cancer
VL  - 10
ID  - 685
ER  - 

TY  - JOUR
AD  - Department of Obstetrics and Gynecology, Division of Maternal-Fetal Medicine, New York Medical College/Westchester Medical Center, Valhalla, NY, USA.
AN  - 12815082
AU  - Demasio, K. A.
C2  - PMC1497566
DA  - Jul-Aug
DO  - 10.1093/phr/118.4.348
DP  - NLM
ET  - 2003/06/20
IS  - 4
KW  - *African Americans
*Community Health Planning
*Community Participation
Female
*Health Care Coalitions
Humans
*Public Health
Socioeconomic Factors
Women's Health Services
LA  - eng
N1  - 1468-2877
Demasio, Kafui A
Comment
Journal Article
Public Health Rep. 2003 Jul-Aug;118(4):348. doi: 10.1093/phr/118.4.348.
PY  - 2003
SN  - 0033-3549 (Print)
0033-3549
SP  - 348
ST  - The complexity of finding solutions to reducing racial/ethnic disparities in health care outcomes. Commentary on "A community approach to addressing excess breast and cervical cancer mortality among women of African descent in Boston"
T2  - Public Health Rep
TI  - The complexity of finding solutions to reducing racial/ethnic disparities in health care outcomes. Commentary on "A community approach to addressing excess breast and cervical cancer mortality among women of African descent in Boston"
VL  - 118
ID  - 644
ER  - 

TY  - JOUR
AB  - INTRODUCTION: Compared with White breast cancer survivors, African American survivors are more likely to be overweight and obese. Differences in weight status may be attributed to differences in dietary intake; however, there is limited research pertaining to the dietary habits of African American breast cancer survivors. METHODS: We compared baseline dietary intakes of 31 overweight and obese African American breast cancer survivors enrolled in a healthy lifestyle intervention to national dietary guidelines and also examined beverage intake habits. Dietary intake was assessed using the National Cancer Institute's Diet History Questionnaire and beverage intake was assessed using 3-day food intake records. RESULTS: Overall, the majority of survivors consumed the recommended daily servings of fruits and vegetables (71.0%) and red meat (83.9%); however, survivors exceeded national recommendations for energy intake from fat (64.5%), saturated fat (87.1%), and added sugars (77.4%). Few women met the guidelines for whole grain and fiber intake (6.5% and 35.5%, respectively). Additionally, survivors consumed ~10% of total energy intake from beverages alone and drank only ~3.5 cups of water daily. CONCLUSIONS: Current dietary guidelines for cancer survivors recommend consuming >5 servings per day of fruits and vegetables and broad guidelines regarding limiting discretionary fat and added sugars but do not specify beverage intake recommendations. Future dietary interventions in African American breast cancer survivors should focus on reducing intake from dietary fat and added sugar, as well as increasing whole grain consumption as a means for increasing daily fiber intake. Furthermore, substituting caloric beverages with water or noncaloric beverages may be a strategy to decrease caloric intake in African American breast cancer survivors. Nutrition information targeting these nutrients could be administered during treatments or doctor's visits as a means to prevent weight gain that often occurs following diagnosis.
AD  - Georgetown/Lombardi Comprehensive Cancer Center, Washington, DC, USA.
AN  - 24105362
AU  - Dennis Parker, E. A.
AU  - Sheppard, V. B.
AU  - Adams-Campbell, L.
C2  - PMC4227310
C6  - NIHMS632374
DA  - Mar
DO  - 10.1177/1534735413503550
DP  - NLM
ET  - 2013/10/10
IS  - 2
KW  - African Americans
Aged
Beverages
Breast Neoplasms/*physiopathology
Carbohydrates
Dietary Fats/adverse effects
Dietary Fiber
Energy Intake/physiology
Feeding Behavior/*physiology
Female
Fruit
Humans
Life Style
Middle Aged
*Nutrition Policy
Obesity/complications/physiopathology
Overweight/complications/physiopathology
Vegetables
added sugars
breast cancer
energy intake
fiber intake
survivors
water
LA  - eng
N1  - 1552-695x
Dennis Parker, Elizabeth A
Sheppard, Vanessa B
Adams-Campbell, Lucile
P30 CA051008/CA/NCI NIH HHS/United States
R21 CA149996/CA/NCI NIH HHS/United States
UL1 TR000101/TR/NCATS NIH HHS/United States
R21 CA14996/CA/NCI NIH HHS/United States
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Integr Cancer Ther. 2014 Mar;13(2):114-20. doi: 10.1177/1534735413503550. Epub 2013 Oct 7.
PY  - 2014
SN  - 1534-7354 (Print)
1534-7354
SP  - 114-20
ST  - Compliance with national nutrition recommendations among breast cancer survivors in "stepping stone"
T2  - Integr Cancer Ther
TI  - Compliance with national nutrition recommendations among breast cancer survivors in "stepping stone"
VL  - 13
ID  - 313
ER  - 

TY  - JOUR
AB  - STUDY DESIGN: Retrospective cohort study. OBJECTIVE: Data on patient outcomes after surgery for spinal cord tumors have been derived from single-institution series. The objective of this study is to report inpatient complications, mortality and outcomes on a national level. SETTING: United States, national inpatient care database. METHODS: The National Inpatient Sample (NIS) was used to identify 19,017 admissions for resection of a spinal cord tumor in the United States from 1993 to 2002. The effects of patient and hospital characteristics on inpatient outcomes were analyzed using logistic regression. RESULTS: The in-hospital mortality rate and the complication rate were 0.55 and 17.5%, respectively. Urinary and renal complications (3.7%), postoperative hemorrhages or hematomas (2.5%) and pulmonary complications (2.4%) were the most common complications reported. A single postoperative complication increased the length of stay by 4 days, increased the mortality rate by sixfold and added over $10,000 to hospital charges. Multivariate analysis showed that complications were more likely in African Americans and patients with multiple comorbidities. The odds of an adverse outcome increased significantly with age greater than 64, multiple comorbidities and postoperative complications. CONCLUSION: A national perspective on inpatient outcomes after resection of spinal cord tumors has been provided. The significant negative impact of postoperative complications on mortality and resource utilization has been demonstrated. We have identified advanced age and multiple comorbidities as risk factors that predict adverse outcome. Furthermore, this study highlights the importance of avoidance, recognition and prompt management of nonneurologic complications.
AD  - Department of Neurosurgery, Stanford University School of Medicine, Stanford Hospital, Stanford, CA, USA
AN  - 105751641. Language: English. Entry Date: 20080627. Revision Date: 20200708. Publication Type: Journal Article
AU  - Patil, C. G.
AU  - Patil, T. S.
AU  - Lad, S. P.
AU  - Boakye, M.
DB  - CINAHL Complete
DO  - 10.1038/sj.sc.3102155
DP  - EBSCOhost
IS  - 5
KW  - Neurosurgery -- Adverse Effects
Postoperative Complications
Spinal Cord Neoplasms -- Complications
Spinal Cord Neoplasms -- Surgery
Adolescence
Adult
Age Factors
Aged
Aged, 80 and Over
Chi Square Test
Child
Child, Preschool
Comorbidity
Confidence Intervals
Data Analysis Software
Female
Infant
Infant, Newborn
Kidney Diseases
Logistic Regression
Lung Diseases
Male
Middle Age
Multivariate Analysis
Odds Ratio
Outcomes (Health Care)
Patient Selection
Prospective Studies
Registries, Disease
Retrospective Design
Spinal Cord Neoplasms -- Mortality
Statistical Significance
Human
N1  - research; tables/charts. Journal Subset: Allied Health; Biomedical; Europe; Expert Peer Reviewed; Peer Reviewed; UK & Ireland. NLM UID: 9609749.
PMID: NLM18071353.
PY  - 2008
SN  - 1362-4393
SP  - 375-379
ST  - Complications and outcomes after spinal cord tumor resection in the United States from 1993 to 2002
T2  - Spinal Cord
TI  - Complications and outcomes after spinal cord tumor resection in the United States from 1993 to 2002
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105751641&site=ehost-live&scope=site
VL  - 46
ID  - 1894
ER  - 

TY  - JOUR
AB  - PURPOSE: Tamoxifen therapy is integral in the treatment of patients with hormone receptor-positive breast cancer. However, there is an association between tamoxifen and thromboembolic events. Flap and systemic thromboembolic events have devastating consequences in microvascular breast reconstruction. Currently, there are conflicting data on the association between tamoxifen therapy and thromboembolic complications for patients undergoing microvascular breast reconstruction. The objective of this study is to determine if perioperative tamoxifen therapy modifies the risk of complications and thromboembolic events for patients with breast cancer undergoing microvascular breast reconstruction. METHODS: A comprehensive literature search was performed across six databases from January 2003 to February 2016. Pooled estimates and relative risk (RR) were calculated using a random-effects model, confounding was examined with meta-regression, and risk of bias was evaluated. Primary outcomes were thrombotic flap complications and total flap loss. Study quality was assessed using Downs and Black criteria. RESULTS: Of 95 studies reviewed, 4 studies comprising 1700 patients and 2245 procedures were included for analysis. Compared to non-recipients, patients on tamoxifen were at increased risk of developing thrombotic flap complications (pooled RR 1.5; 95% CI 1.14-1.98) and total flap loss (pooled RR 3.35; 95% CI 0.95-11.91). There was no significant heterogeneity present in either outcome and no evidence of publication bias. CONCLUSIONS: Perioperative tamoxifen therapy may increase the risk of thrombotic flap complications and flap loss for patients with breast cancer undergoing microvascular reconstruction. These findings further the ability of providers to make evidence-based recommendations in the perioperative management of patients with breast cancer.
AD  - Division of Plastic and Reconstructive Surgery, Department of Surgery, Washington University School of Medicine, St. Louis, MO, USA. parikhr@wudosis.wustl.edu.
Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine, St. Louis, MO, USA. parikhr@wudosis.wustl.edu.
Division of Plastic and Reconstructive Surgery, Department of Surgery, Washington University School of Medicine, 660 S. Euclid Ave, Suite 1150 NW Tower, Box 8238, St. Louis, MO, 63110, USA. parikhr@wudosis.wustl.edu.
Division of Plastic and Reconstructive Surgery, Department of Surgery, Washington University School of Medicine, St. Louis, MO, USA.
Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine, St. Louis, MO, USA.
AN  - 28185144
AU  - Parikh, R. P.
AU  - Odom, E. B.
AU  - Yu, L.
AU  - Colditz, G. A.
AU  - Myckatyn, T. M.
C2  - PMC5554619
C6  - NIHMS882407
DA  - May
DO  - 10.1007/s10549-017-4146-3
DP  - NLM
ET  - 2017/02/12
IS  - 1
KW  - Antineoplastic Agents, Hormonal/*adverse effects/therapeutic use
Breast Neoplasms/drug therapy/*surgery
Female
Humans
Mammaplasty
Observational Studies as Topic
Postoperative Complications/*chemically induced
Randomized Controlled Trials as Topic
Surgical Flaps/blood supply
Tamoxifen/*adverse effects/therapeutic use
Thromboembolism/*chemically induced
Treatment Outcome
Breast cancer
Breast reconstruction
Selective estrogen receptor modulator
Tamoxifen
Thromboembolism
declare that they have no conflict of interest.
LA  - eng
N1  - 1573-7217
Parikh, Rajiv P
Odom, Elizabeth B
Yu, Liyang
Colditz, Graham A
Myckatyn, Terence M
T32 CA190194/CA/NCI NIH HHS/United States
Journal Article
Meta-Analysis
Review
Systematic Review
Breast Cancer Res Treat. 2017 May;163(1):1-10. doi: 10.1007/s10549-017-4146-3. Epub 2017 Feb 9.
PY  - 2017
SN  - 0167-6806 (Print)
0167-6806
SP  - 1-10
ST  - Complications and thromboembolic events associated with tamoxifen therapy in patients with breast cancer undergoing microvascular breast reconstruction: a systematic review and meta-analysis
T2  - Breast Cancer Res Treat
TI  - Complications and thromboembolic events associated with tamoxifen therapy in patients with breast cancer undergoing microvascular breast reconstruction: a systematic review and meta-analysis
VL  - 163
ID  - 184
ER  - 

TY  - JOUR
AB  - Purpose: Minority populations continue to experience significant cancer disparities such as increased morbidity and mortality. In our setting, a cancer prevention and control model is being developed and applied across primary, secondary, and tertiary prevention programs. Research is underway on all three levels based on community‐based participatory principles and asset‐based models of engagement. Research studies and outcomes will be provided across all three levels of prevention. Methods: All studies presented are prospective randomized trials or “quasi‐experimental time‐series” designs. Examples include under primary prevention, an educational intervention related to the HPV vaccine where 700 African American (AA) mothers and grandmothers were recruited for the intervention where the intent was to educate about the vaccine, enable them to discuss this issue with their pediatrician, and potentially have the child vaccinated. Under secondary prevention, the COACH intervention sought to recruit AA residents of East Baltimore and a “personal coach” to be educated about screening guidelines so that they could function as a supportive team to complete recommended screenings. This randomized trial recruited 553 AA residents and their 553 AA COACHES. Finally under tertiary prevention, an R21 has been submitted that will attempt to decrease distress and enhance QOL among newly diagnosed AA breast and prostate cancer patients. Results: Under primary prevention and secondary prevention, these trials have just been completed and appropriate analyses are underway. Conclusions: Given the severity of these disparities among minority populations, we found that this area of research requires greater emphasis by organizations such as APOS. Also, innovative methods to engage these high‐risk populations are strongly needed.
AN  - CN-01363577
AU  - Zabora, J.
DO  - 10.1002/pon.4354
KW  - *breast cancer
African American
Cancer patient
Child
Clinical study
Controlled clinical trial
Controlled study
Diagnosis
Distress syndrome
Female
Grandmother
High risk population
Human
Male
Maryland
Organization
Pediatrician
Practice guideline
Primary prevention
Prostate cancer
Quality of life
Randomized controlled trial
Screening
Secondary prevention
Tertiary prevention
M3  - Journal: Conference Abstract
PY  - 2017
SP  - 58‐59
ST  - A comprehensive approach to the reduction of cancer disparities
T2  - Psycho-oncology
TI  - A comprehensive approach to the reduction of cancer disparities
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01363577/full
VL  - 26
ID  - 1535
ER  - 

TY  - JOUR
AB  - African American men experience a disproportionate burden of prostate cancer (CaP) morbidity and mortality. National screening guidelines advise men to make individualized screening decisions through a process termed informed decision making (IDM). In this pilot study, a computer-tailored decision-aid designed to promote IDM was evaluated using a pre-/posttest design. African American men aged 40 years and older were recruited from a variety of community settings (n = 108). At pretest, 43% of men reported having made a screening decision; at posttest 47% reported this to be the case (p = .39). Significant improvements were observed between pre- and posttest on scores of knowledge, decision self-efficacy, and decisional conflict. Men were also more likely to want an active role in decision making after using the tool. These results suggest that use of a computer-tailored decision aid is a promising strategy to promote IDM for CaP screening among African American men.
AN  - WOS:000271992800008
AU  - Allen, J. D.
AU  - Mohllajee, A. P.
AU  - Shelton, R. C.
AU  - Drake, B. F.
AU  - Mars, D. R.
DA  - Dec
DO  - 10.1177/1557988308325460
IS  - 4
N1  - 19477736
PY  - 2009
SN  - 1557-9883
SP  - 340-351
ST  - A Computer-Tailored Intervention to Promote Informed Decision Making for Prostate Cancer Screening Among African American Men
T2  - American Journal of Mens Health
TI  - A Computer-Tailored Intervention to Promote Informed Decision Making for Prostate Cancer Screening Among African American Men
VL  - 3
ID  - 3130
ER  - 

TY  - JOUR
AB  - Background: Fusions of androgen‐regulated genes with ETS transcription family members have been reported in 50% of localized pPCa patients (pts), with TMPRSS2‐ERG fusions being the most common. ETS fusion products functionally depend upon Poly (ADP‐ribose) polymerase 1 (PARP1), and its inhibition is preferentially cytotoxic to ETS translocation positive disease in preclinical models. We hypothesized that targeting ETS gene fusions will improve response rate in pts with these molecular subtypes and in pts with ETS fusion positive tumors, targeting the promoter and transcription factor of ETS fusion is more effective than targeting a single aspect of the fusion. Methods: Eligible mCRPC pts undergo a metastatic site biopsy to determine ETS fusion status by immunohistochemistry (ERG), fluorescent in‐situ hybridization and/or RNA in‐situ hybridization (ETV1) and sequencing (ETV4). Pts are stratified by ETS status and randomized to abiraterone (ABI) +/‐ the PARP inhibitor veliparib. Soft tissue biopsies are done using 18‐gauge needle: 1‐cm core (> 6 specimens), 2‐cm core (>4 specimens). For bone biopsy: 2‐8 cores. We report interim results on rates of positive biopsy, ETS status/type and concordance between primary PCa and metastasis. Results: To date, 86 pts (Caucasians: 80%, African Americans 14%) with a median age 70 years and a median PSA 36.3 ng/ml have been enrolled. Of the 86 pts, 1 had an unreachable bone lesion, 36 had soft tissue and 49 had bone biopsies; all soft tissue and 36/49 (73%) bone biopsies were evaluable for analysis (13 had no tumor), ETS fusion status is positive in 36% pts: ERG positive (31%), ETV1 positive (4%), ETV4 positive (1%). Concordance of ETS status between primary PCa and metastatic site was found in 30/31 pts (97 % [95% CI: 83‐99.9%]. Conclusions: This trial represents one of the first prospective predictive biomarker‐driven trials in mCRPC. Results indicate feasibility of real time biopsy (adequate tissue yield including from bone) and biomarker determination, and demonstrates significant concordance of ETS status between primary PCa and metastasis in the subset analyzed to date.
AN  - CN-01055895
AU  - Kunju, L. P.
AU  - Palanisamy, N.
AU  - Daignault, S.
AU  - Mehra, R.
AU  - Siddiqui, J.
AU  - Carskadon, S. L.
AU  - Twardowski, P.
AU  - Stein, M. N.
AU  - Hahn, N. M.
AU  - Stadler, W. M.
AU  - et al.
IS  - 15 SUPPL. 1
KW  - *castration resistant prostate cancer
*human
*oncology
*phase 2 clinical trial
*prostate cancer
*society
Abiraterone
African American
Androgen
Biological marker
Biopsy
Bone
Bone biopsy
Bone lesion
Electroretinogram
Fluorescence in situ hybridization
Fusion gene
Gauge
Gene
Gene fusion
Immunohistochemistry
In situ hybridization
Male
Metastasis
Model
Needle
Neoplasm
Nicotinamide adenine dinucleotide adenosine diphosphate ribosyltransferase 1
Nicotinamide adenine dinucleotide adenosine diphosphate ribosyltransferase inhibitor
Patient
Promoter region
RNA
Soft tissue
Tissues
Transcription factor
Veliparib
M3  - Journal: Conference Abstract
PY  - 2014
ST  - Concordance of ETS fusion status of matched metastatic castration-resistant prostate cancer and primary prostate cancer: data from NCI 9012, a randomized ETS fusion-stratified phase II trial
T2  - Journal of clinical oncology
TI  - Concordance of ETS fusion status of matched metastatic castration-resistant prostate cancer and primary prostate cancer: data from NCI 9012, a randomized ETS fusion-stratified phase II trial
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01055895/full
VL  - 32
ID  - 1456
ER  - 

TY  - JOUR
AB  - BACKGROUND: Colorectal cancer (CRC) is the second most common cancer in the US. Despite evidence that screening reduces CRC incidence and mortality, screening rates are sub-optimal with disparities by race/ethnicity, income, and geography. Rural-urban differences in CRC screening are understudied even though approximately one-fifth of the US population lives in rural areas. This focus on urban populations limits the generalizability and dissemination potential of screening interventions. METHODS: Using community-based participatory research (CBPR) principles, we designed a cluster-randomized trial, adaptable to a range of settings, including rural and urban health centers. We enrolled 483 participants across 11 health centers representing 2 separate networks. Both networks serve medically-underserved communities; however one is primarily rural and one primarily urban. RESULTS: Our goal in this analysis is to describe baseline characteristics of participants and examine setting-level differences. CBPR was a critical for recruiting networks to the trial. Patient respondents were predominately female (61.3%), African-American (66.5%), and earned <$1200 per month (87.1%). The rural network sample was older; more likely to be female, white, disabled or retired, and have a higher income, but fewer years of education. CONCLUSIONS: Variation in the samples partly reflects the CBPR process and partly reflects inherent differences in the communities. This confirmed the importance of using CBPR when planning for eventual dissemination, as it enhanced our ability to work within diverse settings. These baseline findings indicate that using a uniform approach to implementing a trial or intervention across diverse settings might not be effective or efficient.
AD  - Department of Epidemiology and Biostatistics, Saint Louis University College of Public Health and Social Justice, St. Louis, MO, USA.
Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine, St. Louis, MO, USA.
Division of Gastroenterology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA.
AN  - 29696155
AU  - Muthukrishnan, M.
AU  - Sutcliffe, S.
AU  - Hunleth, J. M.
AU  - Wang, J. S.
AU  - Colditz, G. A.
AU  - James, A. S.
C2  - PMC5898527
DA  - Jun
DO  - 10.1016/j.conctc.2018.02.005
DP  - NLM
ET  - 2018/04/27
KW  - Colorectal cancer screening
Community-based participatory research
Dissemination and implementation
Health disparities
Medically underserved populations
Randomized trial
LA  - eng
N1  - 2451-8654
Muthukrishnan, Meera
Sutcliffe, Siobhan
Hunleth, Jean M
Wang, Jean S
Colditz, Graham A
James, Aimee S
Journal Article
Contemp Clin Trials Commun. 2018 Mar 6;10:29-35. doi: 10.1016/j.conctc.2018.02.005. eCollection 2018 Jun.
PY  - 2018
SN  - 2451-8654
SP  - 29-35
ST  - Conducting a randomized trial in rural and urban safety-net health centers: Added value of community-based participatory research
T2  - Contemp Clin Trials Commun
TI  - Conducting a randomized trial in rural and urban safety-net health centers: Added value of community-based participatory research
VL  - 10
ID  - 127
ER  - 

TY  - JOUR
AB  - Importance Precision medicine is an approach to detecting, treating, and managing disease that is based on individual variation in genetic, environmental, and lifestyle factors. Precision medicine is expected to reduce health disparities, but this will be possible only if studies have adequate representation of racial minorities. Objective It is critical to anticipate the rates at which individuals from diverse populations are likely to participate in precision medicine studies as research initiatives are being developed. We evaluated the likelihood of participating in a clinical study for precision medicine. Design, Setting, Participants Observational study conducted between October 2010 and February 2011 in a national sample of African Americans. Main Outcome Measure Intentions to participate in a government sponsored study that involves providing a biospecimen and generates data that could be shared with other researchers to conduct future studies. Results One third of respondents would participate in a clinical study for precision medicine. Only gender had a significant independent association with participation intentions. Men had a 1.86 (95% CI = 1.11, 3.12, p = 0.02) increased likelihood of participating in a precision medicine study compared to women in the model that included overall barriers and facilitators. In the model with specific participation barriers, distrust was associated with a reduced likelihood of participating in the research described in the vignette (OR = 0.57, 95% CI = 0.34, 0.96, p = 0.04). Conclusion and Relevance African Americans may have low enrollment in PMI research. As PMI research is implemented, extensive efforts will be needed to ensure adequate representation. Additional research is needed to identify optimal ways of ethically describing precision medicine studies to ensure sufficient recruitment of racial minorities.
AN  - WOS:000380797500003
AU  - Halbert, C. H.
AU  - McDonald, J.
AU  - Vadaparampil, S.
AU  - Rice, L.
AU  - Jefferson, M.
DA  - Jul
DO  - 10.1371/journal.pone.0154850
IS  - 7
N1  - e0154850
27441706
PY  - 2016
SN  - 1932-6203
ST  - Conducting Precision Medicine Research with African Americans
T2  - Plos One
TI  - Conducting Precision Medicine Research with African Americans
VL  - 11
ID  - 2940
ER  - 

TY  - JOUR
AB  - Over the last decade, there has been significant controversy about the schedule on which women, particularly women in their 40s, should have mammograms. The purpose of the analysis reported here was to assess whether women in their 40s and 50s were confused as a result of the controversy following the January 1997 National Institutes of Health Consensus Development Conference on Breast Cancer Screening For Women Ages 40-49. We also examined if confusion was related to being off schedule for mammography. The study sample included 1287 women recruited from a random sample of 2165 Blue Cross/Blue Shield of North Carolina members. The data described in this analysis were derived from a baseline telephone interview conducted as part of a larger intervention trial. Study measures included a variety of sociodemographic, medical, belief, and behavioral variables. Overall, 28% of women were confused, and 35% were off schedule. Although a higher proportion of women in their 40s than 50s were confused, more women in their 50s were off schedule. Confusion was a significant predictor for the outcome being off schedule. Predictors of confusion included several belief variables, risk perceptions, age (40s), whether the woman had a regular physician, and whether she had enough information about mammography. Healthcare providers should ask some simple questions to determine if women are confused and then seek to meet their information needs.
AD  - Division of Cancer Control and Population Sciences, National Cancer Institute, 6130 Executive Plaza N, Room 242, Bethesda, MD 20892
AN  - 107220159. Language: English. Entry Date: 19991101. Revision Date: 20200708. Publication Type: Journal Article
AU  - Rimer, B. K.
AU  - Halabi, S.
AU  - Strigo, T. S.
AU  - Crawford, Y.
AU  - Lipkus, I. M.
DB  - CINAHL Complete
DO  - 10.1089/jwh.1.1999.8.509
DP  - EBSCOhost
IS  - 4
KW  - Mammography -- Psychosocial Factors
Appointments and Schedules
Confusion -- Epidemiology
Health Knowledge
Evaluation Research
Epidemiological Research
Mammography -- Utilization
Attitude to Health
Attitude Measures
Stratified Random Sample
Female
Adult
Middle Age
Insurance, Health
Telephone
Interviews
Surveys
Questionnaires
Breast Neoplasms -- Prevention and Control
Cancer Screening
Psychological Tests
Pearson's Correlation Coefficient
Chi Square Test
T-Tests
Coefficient Alpha
Logistic Regression
P-Value
Odds Ratio
Confidence Intervals
Independent Variable
Goodness of Fit Chi Square Test
Descriptive Statistics
White Persons
Black Persons
Demography
Health Beliefs
Women's Health
Human
N1  - research; tables/charts. Journal Subset: Biomedical; Core Nursing; Editorial Board Reviewed; Expert Peer Reviewed; Nursing; Peer Reviewed; USA. Instrumentation: Gail Score; Decisional Balance (DB) Scale; Abbreviated 10-item Version of the Center for Epidemiology Depression Scale. NLM UID: 100888719.
PY  - 1999
SN  - 1524-6094
SP  - 509-520
ST  - Confusion about mammography: prevalence and consequences
T2  - Journal of Women's Health & Gender-Based Medicine
TI  - Confusion about mammography: prevalence and consequences
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=107220159&site=ehost-live&scope=site
VL  - 8
ID  - 1895
ER  - 

TY  - JOUR
AB  - Introduction: Prevention and treatment standards are based on evidence obtained in behavioral and clinical research. However, racial and ethnic minorities remain relatively absent from the science that develops these standards. While investigators have successfully recruited participants for individual studies using tailored recruitment methods, these strategies require considerable time and resources. Research registries, typically developed around a disease or condition, serve as a promising model for a targeted recruitment method to increase minority participation in health research. This study assessed the tailored recruitment methods used to populate a health research registry targeting African-American community members. Methods: We describe six recruitment methods applied between September 2004 and October 2008 to recruit members into a health research registry. Recruitment included direct (existing studies, public databases, community outreach) and indirect methods (radio, interne, and email) targeting the general population, local universities, and African American communities. We conducted retrospective analysis of the recruitment by method using descriptive statistics, frequencies, and chi-square statistics. Results: During the recruitment period, 608 individuals enrolled in the research registry. The majority of enrollees were African American, female, and in good health. Direct and indirect methods were identified as successful strategies for subgroups. Findings suggest significant associations between recruitment methods and age, presence of existing health condition, prior research participation, and motivation to join the registry. Conclusions: A health research registry can be a successful tool to increase minority awareness of research opportunities. Multi-pronged recruitment approaches are needed to reach diverse subpopulations. (C) 2013 Published by Elsevier Inc.
AN  - WOS:000319637800001
AU  - Green, M. A.
AU  - Kim, M. M.
AU  - Barber, S.
AU  - Odulana, A. A.
AU  - Godley, P. A.
AU  - Howard, D. L.
AU  - Corbie-Smith, G. M.
DA  - May
DO  - 10.1016/j.cct.2013.01.001
IS  - 1
N1  - 23340183
PY  - 2013
SN  - 1551-7144
SP  - 1-7
ST  - Connecting communities to health research: Development of the Project CONNECT minority research registry
T2  - Contemporary Clinical Trials
TI  - Connecting communities to health research: Development of the Project CONNECT minority research registry
VL  - 35
ID  - 3044
ER  - 

TY  - JOUR
AB  - Purpose: Quality measures represent the standards of appropriate treatment agreed upon by experts in the field and often supported by data. The extent to which providers in the community adhere to quality measures in radiation therapy (RT) is unknown. Methods and materials: The Comparative Effectiveness Analysis of Surgery and Radiation study enrolled men with clinically localized prostate cancer in 2011 and 2012. Patients completed surveys and medical records were reviewed. Patients were risk-stratified according to D'Amico classification criteria. Patterns of care and compliance with 8 quality measures as endorsed by national consortia as of 2011 were assessed. Results: Overall, 926 men underwent definitive RT (69% external beam radiation therapy [EBRT]), 17% brachytherapy (BT), and 14% combined EBRT and BT with considerable variation in radiation techniques across risk groups. Most men who received EBRT had dose-escalated EBRT (>75 Gy; 93%) delivered with conventional fractionation (<2 Gy; 95%), intensity modulated RT (76%), and image guided RT (85%). Most men treated with BT received I125 (77%). Overall, 73% of the men received EBRT that was compliant with the quality measures (dose-escalation, image-guidance, appropriate use of androgen deprivation therapy, and appropriate treatment target) but only 60% of men received BT that was compliant with quality measures (postimplant dosimetry and appropriate dose). African-American men (64%) and other minorities (62%) were less likely than white men (77%) to receive EBRT that was compliant with quality measures. Conclusions: Most men who received RT for localized prostate cancer were treated with an appropriately high dose and received image guidance and intensity modulated RT. However, compliance with some nationally recognized quality measures was relatively low and varied by race. There are significant opportunities to improve the delivery of RT and especially for men of a minority race. (C) 2018 American Society for Radiation Oncology. Published by Elsevier Inc. All rights reserved.
AN  - WOS:000443345000022
AU  - Lee, D. J.
AU  - Barocas, D. A.
AU  - Zhao, Z. G.
AU  - Huang, L. C.
AU  - Koyama, T.
AU  - Resnick, M. J.
AU  - Conwill, R.
AU  - McCollum, D.
AU  - Cooperberg, M. R.
AU  - Goodman, M.
AU  - Greenfield, S.
AU  - Hamilton, A. S.
AU  - Hashibe, M.
AU  - Kaplan, S. H.
AU  - Paddock, L. E.
AU  - Stroup, A. M.
AU  - Wu, X. C.
AU  - Penson, D. F.
AU  - Hoffman, K. E.
DA  - Sep-Oct
DO  - 10.1016/j.prro.2018.04.009
IS  - 5
N1  - 30177030
PY  - 2018
SN  - 1879-8500
SP  - 307-316
ST  - Contemporary prostate cancer radiation therapy in the United States: Patterns of care and compliance with quality measures
T2  - Practical Radiation Oncology
TI  - Contemporary prostate cancer radiation therapy in the United States: Patterns of care and compliance with quality measures
VL  - 8
ID  - 2847
ER  - 

TY  - JOUR
AB  - BACKGROUND: The purpose of this study was to assess treatment choices among men with prostate cancer who presented at The University of Texas MD Anderson Cancer Center multidisciplinary (MultiD) clinic compared with nationwide trends. METHODS: In total, 4451 men with prostate cancer who presented at the MultiD clinic from 2004 to 2016 were analyzed. To assess nationwide trends, the authors analyzed 392,710 men with prostate cancer who were diagnosed between 2004 and 2015 from the Surveillance, Epidemiology, and End Results (SEER) database. The primary endpoint was treatment choice as a function of pretreatment demographics. RESULTS: Univariate analyses revealed similar treatment trends in the MultiD and SEER cohorts. The use of procedural forms of definitive therapy decreased with age, including brachytherapy and prostatectomy (all P < .05). Later year of diagnosis/clinic visit was associated with decreased use of definitive treatments, whereas higher risk grouping was associated with increased use (all P < .001). Patients with low-risk disease treated at the MultiD clinic were more likely to receive nondefinitive therapy than patients in SEER, whereas the opposite trend was observed for patients with high-risk disease, with a substantial portion of high-risk patients in SEER not receiving definitive therapy. In the MultiD clinic, African American men with intermediate-risk and high-risk disease were more likely to receive definitive therapy than white men, but for SEER the opposite was true. CONCLUSIONS: Presentation at a MultiD clinic facilitates the appropriate disposition of patients with low-risk disease to nondefinitive strategies of patients with high-risk disease to definitive treatment, and it may obviate the influence of race.
AD  - Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Department of Radiation Oncology, Summit Medical Group, Summit, New Jersey.
Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Department of genitourinary medical oncology, The University of Texas MD Anderson cancer center, Houston, Texas.
Banner MD Anderson Cancer Center, Mesa, Arizona.
Scripps MD Anderson Cancer Center, San Diego, California.
Department of Urology, MD Anderson Center at Cooper, Camden, New Jersey.
MD Anderson Cancer Center at Cooper, Camden, New Jersey.
Baptist MD Anderson Cancer Center, Jacksonville, Florida.
AN  - 31742674
AU  - Tang, C.
AU  - Hoffman, K. E.
AU  - Allen, P. K.
AU  - Gabel, M.
AU  - Schreiber, D.
AU  - Choi, S.
AU  - Chapin, B. F.
AU  - Nguyen, Q. N.
AU  - Davis, J. W.
AU  - Corn, P.
AU  - Logothetis, C.
AU  - Ward, J.
AU  - Frank, S. J.
AU  - Navai, N.
AU  - McGuire, S. E.
AU  - Anscher, M.
AU  - Pisters, L.
AU  - Pettaway, C. A.
AU  - Kumar, R.
AU  - Linson, P.
AU  - Tripuraneni, P.
AU  - Tomaszewski, J. J.
AU  - Patel, A. B.
AU  - Augspurger, M.
AU  - Kuban, D. A.
C2  - PMC6980273
C6  - NIHMS1052758
DA  - Feb 1
DO  - 10.1002/cncr.32570
DP  - NLM
ET  - 2019/11/20
IS  - 3
KW  - African Americans
Aged
Brachytherapy/trends
European Continental Ancestry Group
Humans
Male
Middle Aged
Patient Selection
Prostate-Specific Antigen/blood
Prostatectomy/trends
Prostatic Neoplasms/blood/*epidemiology/*therapy
SEER Program
United States/epidemiology
*Epidemiology
*Surveillance
*and End Results (SEER)
*multidisciplinary clinic
*prostate cancer
*treatment access
RefleXion for work outside the current scope of study.
LA  - eng
N1  - 1097-0142
Tang, Chad
Orcid: 0000-0002-5915-1327
Hoffman, Karen E
Allen, Pamela K
Gabel, Molly
Schreiber, David
Choi, Seungtaek
Chapin, Brian F
Nguyen, Quynh-Nhu
Davis, John W
Corn, Paul
Logothetis, Christopher
Ward, John
Frank, Steven J
Navai, Neema
McGuire, Sean E
Anscher, Mitchell
Pisters, Louis
Pettaway, Curtis A
Kumar, Rachit
Linson, Patrick
Tripuraneni, Prabhakar
Tomaszewski, Jeffrey J
Patel, Ashish B
Augspurger, Mark
Kuban, Deborah A
P30 CA016672/CA/NCI NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Cancer. 2020 Feb 1;126(3):506-514. doi: 10.1002/cncr.32570. Epub 2019 Nov 19.
PY  - 2020
SN  - 0008-543X (Print)
0008-543x
SP  - 506-514
ST  - Contemporary prostate cancer treatment choices in multidisciplinary clinics referenced to national trends
T2  - Cancer
TI  - Contemporary prostate cancer treatment choices in multidisciplinary clinics referenced to national trends
VL  - 126
ID  - 59
ER  - 

TY  - JOUR
AB  - National-level data that characterize contemporary prostate cancer patients are limited. We used 2004-2005 data from the Surveillance, Epidemiology, and End Results Program to generate a contemporary profile of prostate cancer patients (N = 82 541) and compared patient characteristics of this 2004-2005 population with those of patients diagnosed in 1998-1989 and 1996-1997. Among newly diagnosed patients in 2004-2005, the majority (94%) had localized (ie, stage T1 or T2) prostate cancer and a median serum prostate-specific antigen (PSA) level of 6.7 ng/mL. Between 1988-1989 and 2004-2005, the average age at prostate cancer diagnosis decreased from 72.2 to 67.2 years, and the incidence rate of T3 or T4 cancer decreased from 52.7 per 100 000 to 7.9 per 100 000 among whites and from 90.9 per 100 000 to 13.3 per 100 000 among blacks. In 2004-2005, compared with whites, blacks were more likely to be diagnosed at a younger age (mean age: 64.7 vs 67.5 years, difference = 2.7 years, 95% confidence interval [CI] = 2.5 to 2.9 years, P < .001) and to have a higher PSA level at diagnosis (median PSA level: 7.4 vs 6.6 ng/mL, difference = 0.8 ng/mL, 95% CI = 0.6 to 1.0 ng/mL, P < .001). In conclusion, more men were diagnosed with prostate cancer at a younger age and earlier stage in 2004-2005 than in earlier years. The racial disparity in cancer stage at diagnosis has decreased statistically significantly over time.
AD  - Department of Population Science, Cancer Institute of New Jersey, New Brunswick, NJ, USA.
AN  - 19713548
AU  - Shao, Y. H.
AU  - Demissie, K.
AU  - Shih, W.
AU  - Mehta, A. R.
AU  - Stein, M. N.
AU  - Roberts, C. B.
AU  - Dipaola, R. S.
AU  - Lu-Yao, G. L.
C2  - PMC2744729
DA  - Sep 16
DO  - 10.1093/jnci/djp262
DP  - NLM
ET  - 2009/08/29
IS  - 18
KW  - Adult
African Americans/statistics & numerical data
Age Factors
Aged
European Continental Ancestry Group/statistics & numerical data
Health Status Disparities
Humans
Incidence
Male
Middle Aged
Neoplasm Staging
Prostate-Specific Antigen/blood
*Prostatectomy
Prostatic
Neoplasms/*diagnosis/*epidemiology/ethnology/immunology/mortality/pathology/surgery
Randomized Controlled Trials as Topic
Risk Assessment
Risk Factors
SEER Program
Severity of Illness Index
Survival Analysis
United States/epidemiology
LA  - eng
N1  - 1460-2105
Shao, Yu-Hsuan
Demissie, Kitaw
Shih, Weichung
Mehta, Amit R
Stein, Mark N
Roberts, Calpurnyia B
Dipaola, Robert S
Lu-Yao, Grace L
R01 CA116399/CA/NCI NIH HHS/United States
R01 CA116399-03/CA/NCI NIH HHS/United States
R01 CA116399-04/CA/NCI NIH HHS/United States
R01 CA 116399/CA/NCI NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
J Natl Cancer Inst. 2009 Sep 16;101(18):1280-3. doi: 10.1093/jnci/djp262. Epub 2009 Aug 27.
PY  - 2009
SN  - 0027-8874 (Print)
0027-8874
SP  - 1280-3
ST  - Contemporary risk profile of prostate cancer in the United States
T2  - J Natl Cancer Inst
TI  - Contemporary risk profile of prostate cancer in the United States
VL  - 101
ID  - 448
ER  - 

TY  - JOUR
AD  - Department of Psychology, University of Miami, Coral Gables, FL 33124-2070
AN  - 106822078. Language: English. Entry Date: 20030411. Revision Date: 20200701. Publication Type: Journal Article
AU  - Culver, J. L.
AU  - Arena, P. L.
AU  - Antoni, M. H.
AU  - Carver, C. S.
DB  - CINAHL Complete
DO  - 10.1002/pon.615
DP  - EBSCOhost
IS  - 6
KW  - Breast Neoplasms -- Psychosocial Factors
Coping -- Ethnology
Race Factors
Stress, Psychological -- Ethnology
Adult
Aged
Analysis of Variance
Black Persons
Center for Epidemiological Studies Depression Scale
Comparative Studies
Psychological Tests
Scales
Descriptive Statistics
Female
Hispanic Americans
Interviews
Middle Age
Prospective Studies
Research Subject Recruitment
White Persons
Funding Source
Human
N1  - research; tables/charts. Journal Subset: Biomedical; Editorial Board Reviewed; Europe; Expert Peer Reviewed; Peer Reviewed; UK & Ireland. Instrumentation: Center for Epidemiologic Studies Depression Scale (CES-D). Grant Information: Supported by grants PBR-56 and PBR-82 from the American Cancer Society, training grant J4236-DAMD1794 from the Department of Defense, and grants CA-64710 and CA-78995 from the National Cancer Institute. NLM UID: 9214524.
PMID: NLM12476431.
PY  - 2002
SN  - 1057-9249
SP  - 495-504
ST  - Coping and distress among women under treatment for early stage breast cancer: comparing African Americans, Hispanics, and non-Hispanic whites
T2  - Psycho-Oncology
TI  - Coping and distress among women under treatment for early stage breast cancer: comparing African Americans, Hispanics, and non-Hispanic whites
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106822078&site=ehost-live&scope=site
VL  - 11
ID  - 1897
ER  - 

TY  - JOUR
AB  - Although coping strategies have proven vital in assisting women to adapt to a diagnosis of breast cancer, few researchers have focused on coping strategies used by African American women with breast cancer. The objectives of this study were to determine the coping strategies used by African American women with breast cancer and to explore sociodemographic variables such as age, income, education, marital status, and length of time since diagnosis on coping strategies among African American women with breast cancer. A cross-sectional design was used to study relationships among these variables. The sample consisted of 86 African American women with a diagnosis of breast cancer living in the southeastern United States. Participants were surveyed with a demographic data sheet and the Ways of Coping Questionnaire (WCQ). Data were analyzed with descriptive statistics and multiple linear regression analyses. Results indicated that positive reappraisal and seeking social support are the most commonly used coping strategies among African American women with breast cancer. No significant relationships were found among sociodemographic variables and coping strategies among African American women. Also, a comparison of our mean coping strategy scores among African American women with breast cancer are higher than the mean coping strategy scores from a previous study of mostly Caucasian women with breast cancer. Further research is needed to explore coping strategies of positive reappraisal and seeking social support as these may be important factors in how African American women survive breast cancer.
AD  - Johns Hopkins University, School of Nursing
AN  - 106693107. Language: English. Entry Date: 20040123. Revision Date: 20171109. Publication Type: Journal Article
AU  - Henderson, P. D.
AU  - Fogel, J.
AU  - Edwards, Q. T.
DB  - CINAHL Complete
DP  - EBSCOhost
IS  - 3
KW  - Black Persons -- United States
Breast Neoplasms
Cancer Patients -- Psychosocial Factors
Coping
Adult
Aged
Coefficient Alpha
Conceptual Framework
Confidence Intervals
Convenience Sample
Cross Sectional Studies
Data Analysis Software
Descriptive Research
Descriptive Statistics
Female
Middle Age
Multiple Linear Regression
Power Analysis
Questionnaires
Research Subject Recruitment
Roy Adaptation Model
Socioeconomic Factors
Southeastern United States
Support, Psychosocial
T-Tests
United States
Ways of Coping Questionnaire
Human
N1  - research; tables/charts. Journal Subset: Blind Peer Reviewed; Expert Peer Reviewed; Nursing; Peer Reviewed; USA. Instrumentation: Ways of Coping Questionnaire (WCQ) (Folkman et al). NLM UID: 101135885.
PY  - 2003
SN  - 1538-0696
SP  - 20p-20p
ST  - Coping strategies among African American women with breast cancer
T2  - Southern Online Journal of Nursing Research
TI  - Coping strategies among African American women with breast cancer
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106693107&site=ehost-live&scope=site
VL  - 4
ID  - 1898
ER  - 

TY  - JOUR
AB  - BACKGROUND: We tested the hypothesis that states with higher rates of cancers associated with human papillomavirus (HPV) would have lower HPV vaccine coverage. METHODS: We gathered state-level data on HPV-related cancer rates and HPV vaccine initiation coverage for girls and boys, separately, and HPV vaccine follow-through (i.e., receipt of 3 doses among those initiating the series) for girls only. In addition, we gathered state-level data on demographic composition and contact with the health care system. We calculated Pearson correlations for these ecological relationships. RESULTS: Human papillomavirus vaccine initiation among girls was lower in states with higher levels of cervical cancer incidence and mortality (r = -0.29 and -0.46, respectively). In addition, vaccine follow-through among girls was lower in states with higher levels of cervical cancer mortality (r = -0.30). Other cancer rates were associated with HPV vaccine initiation and follow-through among girls, but not among boys. Human papillomavirus vaccine initiation among girls was lower in states with higher proportions of non-Hispanic black residents and lower proportions of higher-income residents. Human papillomavirus vaccine follow-through was higher in states with greater levels of adolescents' contact with the health care system. CONCLUSIONS: Human papillomavirus vaccine coverage for girls was lower in states with higher HPV-related cancer rates. Public health efforts should concentrate on geographic areas with higher cancer rates. Strengthening adolescent preventive health care use may be particularly important to increase vaccine follow-through. Cost-effectiveness analyses may overestimate the benefits of current vaccination coverage and underestimate the benefits of increasing coverage.
AD  - From the *Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC; and †College of Medicine, The Ohio State University, Columbus, OH.
AN  - 25585064
AU  - Moss, J. L.
AU  - Reiter, P. L.
AU  - Brewer, N. T.
C2  - PMC4295643
C6  - NIHMS642921
DA  - Feb
DO  - 10.1097/olq.0000000000000225
DP  - NLM
ET  - 2015/01/15
IS  - 2
KW  - Adolescent
Anus Neoplasms/economics/epidemiology/*prevention & control
Cost-Benefit Analysis
Female
Health Knowledge, Attitudes, Practice
Humans
Immunization Programs/*statistics & numerical data
Incidence
Male
*Mass Screening/economics
Papillomavirus Infections/economics/epidemiology/*prevention & control
Papillomavirus Vaccines/*administration & dosage/economics
Patient Acceptance of Health Care
Patient Selection
Public Health
Sex Factors
United States/epidemiology
Uterine Cervical Neoplasms/economics/epidemiology/*prevention & control
Vaccination/economics/*statistics & numerical data
LA  - eng
N1  - 1537-4521
Moss, Jennifer L
Reiter, Paul L
Brewer, Noel T
F31 CA189411/CA/NCI NIH HHS/United States
Journal Article
Multicenter Study
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Sex Transm Dis. 2015 Feb;42(2):71-5. doi: 10.1097/OLQ.0000000000000225.
PY  - 2015
SN  - 0148-5717 (Print)
0148-5717
SP  - 71-5
ST  - Correlates of human papillomavirus vaccine coverage: a state-level analysis
T2  - Sex Transm Dis
TI  - Correlates of human papillomavirus vaccine coverage: a state-level analysis
VL  - 42
ID  - 263
ER  - 

TY  - JOUR
AB  - INTRODUCTION: Information is limited on patient characteristics that influence their preference among screening options and intent to be screened for colorectal cancer (CRC). A mechanistic pathway to intent and preference was examined through a formal mediation analysis. METHODS: From 2012 to 2014, a total of 570 adults aged 50-75 years were recruited from 15 primary care practices in Metro Detroit for a trial on decision aids for CRC screening. Confirmatory factor, regression, and mediation analyses were performed in 2015-2016 on baseline cross-sectional data. Main outcomes were patient intent and preference. Perceived risk and self-efficacy were secondary outcomes. Covariates included demographic information, health status, previous CRC screening experience, patient attitudes, and knowledge. RESULTS: Mean age was 57.7 years, 56.1% were women, and 55.1% white and 36.6% black. Women had 32% and 41% lower odds than men of perceiving CRC to be high/moderate risk (OR=0.68, 95% CI=0.47, 0.97, p=0.03) and having high self-efficacy (OR=0.59, 95% CI=0.42, 0.85, p=0.006), respectively. Whites had 63% and 47% lower odds than blacks of having high self-efficacy (OR=0.37, 95% CI=0.25, 0.57, p<0.001) and intent to undergo CRC screening (OR=0.53, 95% CI=0.34, 0.84, p=0.007), respectively. Younger age, higher knowledge, lower level of test worries, and medium/high versus low self-efficacy increased the odds of intent of being screened. Self-efficacy, but not perceived risk, significantly mediated the association between race, attitude, and test worries and patient screening intent. CONCLUSIONS: Self-efficacy mediated the association between race, attitude, and test worries and patient intent.
AD  - Department of Family Medicine, University of Michigan, Ann Arbor, Michigan.
Department of Family Medicine, University of Michigan, Ann Arbor, Michigan; Department of Biostatistics, University of Michigan, Ann Arbor, Michigan. Electronic address: anandas@med.umich.edu.
Department of Medicine, University of Michigan and Ann Arbor VA Center for Clinical Management Research, Ann Arbor, Michigan.
Center for Ethics and Humanities in the Life Sciences and Department of Medicine, Michigan State University, East Lansing, Michigan.
Department of Family and Community Medicine, Penn State Hershey Medical Center, Hershey, Pennsylvania.
AN  - 28169019
AU  - Jimbo, M.
AU  - Sen, A.
AU  - Plegue, M. A.
AU  - Hawley, S. T.
AU  - Kelly-Blake, K.
AU  - Rapai, M.
AU  - Zhang, M.
AU  - Zhang, Y.
AU  - Ruffin, M. T. th
DA  - Apr
DO  - 10.1016/j.amepre.2016.11.026
DP  - NLM
ET  - 2017/02/09
IS  - 4
KW  - Colorectal Neoplasms/*diagnosis/psychology
Cross-Sectional Studies
*Decision Support Techniques
Female
Humans
*Intention
Male
Mass Screening/*psychology
Middle Aged
*Patient Preference
LA  - eng
N1  - 1873-2607
Jimbo, Masahito
Sen, Ananda
Plegue, Melissa A
Hawley, Sarah T
Kelly-Blake, Karen
Rapai, Mary
Zhang, Minling
Zhang, Yuhong
Ruffin, Mack T 4th
R01 CA152413/CA/NCI NIH HHS/United States
Journal Article
Multicenter Study
Randomized Controlled Trial
Netherlands
Am J Prev Med. 2017 Apr;52(4):443-450. doi: 10.1016/j.amepre.2016.11.026. Epub 2017 Feb 3.
PY  - 2017
SN  - 0749-3797
SP  - 443-450
ST  - Correlates of Patient Intent and Preference on Colorectal Cancer Screening
T2  - Am J Prev Med
TI  - Correlates of Patient Intent and Preference on Colorectal Cancer Screening
VL  - 52
ID  - 185
ER  - 

TY  - JOUR
AB  - BACKGROUND: African Americans continue to suffer disproportionately from cancer morbidity and mortality, with emerging evidence suggesting potential quality of life (QOL) disparities in the survivorship period. OBJECTIVE: The objective of the study was to assess sociodemographic, clinical, and psychosocial factors associated with physical and mental health QOL (PHQOL and MHQOL) among African American and white cancer survivors. METHODS: Patients were recruited from tumor registries. Telephone interviews were conducted with 248 African American and 244 white respondents with a history of breast, prostate, or colorectal cancers. Multivariate regression models were used to assess what factors were associated with PHQOL and MHQOL. RESULTS: Key racial differences in adjusted analyses included poorer MHQOL scores among African Americans compared with white survivors. Furthermore, race moderated the relationship between perceived social support and MHQOL, where higher social support levels were associated with increased MHQOL among African Americans. Other correlates of QOL impacted racial groups similarly. For example, factors associated with PHQOL scores included being unemployed, being uninsured, the presence of medical comorbidities, a longer time since diagnosis, and higher levels of cancer-related stress appraisals. Factors associated with MHQOL scores included being unemployed, higher levels of daily stress, higher levels of stress associated with the diagnosis, higher levels of education, higher levels of perceived social support, and higher levels of spirituality. CONCLUSION: Interventions aimed at increasing social support may have important implications for improving QOL outcomes among African Americans. IMPLICATIONS FOR PRACTICE: Measuring and understanding factors associated with QOL have important implications for patient adjustment and clinical decision making.
AD  - College of Nursing, University of Illinois at Chicago, 60612, USA. aliciak@uic.edu
AN  - 22495496
AU  - Matthews, A. K.
AU  - Tejeda, S.
AU  - Johnson, T. P.
AU  - Berbaum, M. L.
AU  - Manfredi, C.
C2  - PMC3619385
C6  - NIHMS343413 Copyright Transfer and Disclosure Form and no Conflicts of Interest were reported.
DA  - Sep-Oct
DO  - 10.1097/NCC.0b013e31824131d9
DP  - NLM
ET  - 2012/04/13
IS  - 5
KW  - Adult
African Americans/*psychology/statistics & numerical data
Aged
Cross-Sectional Studies
European Continental Ancestry Group/*psychology/statistics & numerical data
Female
Humans
Male
Middle Aged
Neoplasms/*ethnology/therapy
Nursing Methodology Research
Qualitative Research
Quality of Life/*psychology
Registries
Social Support
Socioeconomic Factors
Survivors/*psychology/statistics & numerical data
LA  - eng
N1  - 1538-9804
Matthews, Alicia K
Tejeda, Silvia
Johnson, Timothy P
Berbaum, Michael L
Manfredi, Clara
R01 CA077525/CA/NCI NIH HHS/United States
R25 CA057699/CA/NCI NIH HHS/United States
R01CA775-01A1/CA/NCI NIH HHS/United States
R25CA057699/CA/NCI NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
Cancer Nurs. 2012 Sep-Oct;35(5):355-64. doi: 10.1097/NCC.0b013e31824131d9.
PY  - 2012
SN  - 0162-220X (Print)
0162-220x
SP  - 355-64
ST  - Correlates of quality of life among African American and white cancer survivors
T2  - Cancer Nurs
TI  - Correlates of quality of life among African American and white cancer survivors
VL  - 35
ID  - 369
ER  - 

TY  - JOUR
AB  - OBJECTIVE: The purpose of this analysis was to examine the correlates of the physical and psychosocial domains of quality of life (QOL) in a cohort of breast cancer survivors participating in a weight loss intervention trial. METHODS: Correlates of QOL and psychosocial functioning were examined in 692 overweight or obese breast cancer survivors at entry into a weight loss trial. QOL was explored with three measures: Short-form 36 (SF-36), Impact of Cancer scale (IOC), and the Breast Cancer Prevention Trial (BCPT) symptom scales. Available data included information on weight and physical activity, as well as demographic and medical characteristics. Multivariate analyses were used to identify associations adjusted for other characteristics. RESULTS: In multivariate analysis, younger age was associated with higher negative impact scores (p < 0.0001). Hispanic, African-American, and Asian women had higher positive IOC impact scores compared with White non-Hispanic women (p < 0.01). Increased number of comorbidities was associated with lower physical and mental QOL scores (p < 0.01). Body mass index was not independently associated with QOL measures. Physical activity was directly associated with physical and mental QOL and IOC positive impact, and inversely related to IOC negative impact and Breast Cancer Prevention Trial symptom scales. CONCLUSIONS: Quality-of-life measures in breast cancer survivors are differentially associated with demographic and other characteristics. When adjusted for these characteristics, degree of adiposity among overweight or obese women does not appear to be independently associated with QOL. Among overweight or obese breast cancer survivors, higher level of physical activity is associated with higher QOL across various scales and dimensions.
AD  - Department of Family Medicine and Public Health, School of Medicine, University of California, San Diego, La Jolla, CA, USA.
Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, CA, USA.
UCLA Fielding School of Public Health, University of California, Los Angeles, Los Angeles, CA, USA.
Department of Community and Behavioral Health, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Department of Nutrition Sciences, University of Alabama at Birmingham, Birmingham, AL, USA.
Division of Biostatistics, Washington University School of Medicine, St. Louis, MO, USA.
Coeus Health LLC, Chicago, IL, USA.
Scale Down LLC, Atlanta, GA, USA.
Department of Preventive Medicine, Northwestern University, Chicago, IL, USA.
AN  - 25920528
AU  - Pakiz, B.
AU  - Ganz, P. A.
AU  - Sedjo, R. L.
AU  - Flatt, S. W.
AU  - Demark-Wahnefried, W.
AU  - Liu, J.
AU  - Wolin, K. Y.
AU  - Rock, C. L.
C2  - PMC4626439
C6  - NIHMS717309
DA  - Feb
DO  - 10.1002/pon.3820
DP  - NLM
ET  - 2015/04/30
IS  - 2
KW  - Adult
Aged
Body Mass Index
Body Weight
Breast Neoplasms/*psychology
Ethnic Groups
Female
Humans
Middle Aged
Obesity/complications/*psychology/*therapy
Quality of Life/*psychology
Survivors/psychology
*Weight Loss
LA  - eng
N1  - 1099-1611
Pakiz, Bilgé
Ganz, Patricia A
Sedjo, Rebecca L
Flatt, Shirley W
Demark-Wahnefried, Wendy
Liu, Jingxia
Wolin, Kathleen Y
Rock, Cheryl L
P30 CA023100/CA/NCI NIH HHS/United States
P30 CA091842/CA/NCI NIH HHS/United States
R01 CA148791/CA/NCI NIH HHS/United States
CA148791/CA/NCI NIH HHS/United States
Clinical Trial
Journal Article
Research Support, N.I.H., Extramural
Psychooncology. 2016 Feb;25(2):142-9. doi: 10.1002/pon.3820. Epub 2015 Apr 29.
PY  - 2016
SN  - 1057-9249 (Print)
1057-9249
SP  - 142-9
ST  - Correlates of quality of life in overweight or obese breast cancer survivors at enrollment into a weight loss trial
T2  - Psychooncology
TI  - Correlates of quality of life in overweight or obese breast cancer survivors at enrollment into a weight loss trial
VL  - 25
ID  - 247
ER  - 

TY  - JOUR
AB  - BACKGROUND: Patient navigation (PN) is being used increasingly to help patients complete screening colonoscopy (SC) to prevent colorectal cancer. At their large, urban academic medical center with an open-access endoscopy system, the authors previously demonstrated that PN programs produced a colonoscopy completion rate of 78.5% in a cohort of 503 patients (predominantly African Americans and Latinos with public health insurance). Very little is known about the direct costs of implementing PN programs. The objective of the current study was to perform a detailed cost analysis of PN programs at the authors' institution from an institutional perspective. METHODS: In 2 randomized controlled trials, average-risk patients who were referred for SC by primary care providers were recruited for PN between May 2008 and May 2010. Patients were randomized to 1 of 4 PN groups. The cost of PN and net income to the institution were determined in a cost analysis. RESULTS: Among 395 patients who completed colonoscopy, 53.4% underwent SC alone, 30.1% underwent colonoscopy with biopsy, and 16.5% underwent snare polypectomy. Accounting for the average contribution margins of each procedure type, the total revenue was $95,266.00. The total cost of PN was $14,027.30. Net income was $81,238.70. In a model sample of 1000 patients, net incomes for the institutional completion rate (approximately 80%), the historic PN program (approximately 65%), and the national average (approximately 50%) were compared. The current PN program generated additional net incomes of $35,035.50 and $44,956.00, respectively. CONCLUSIONS: PN among minority patients with mostly public health insurance generated additional income to the institution, mainly because of increased colonoscopy completion rates.
AD  - Department of Oncological Sciences, Mount Sinai School of Medicine, New York, NY 10029, USA. lina.jandorf@mssm.edu
AN  - 22833205
AU  - Jandorf, L.
AU  - Stossel, L. M.
AU  - Cooperman, J. L.
AU  - Graff Zivin, J.
AU  - Ladabaum, U.
AU  - Hall, D.
AU  - Thélémaque, L. D.
AU  - Redd, W.
AU  - Itzkowitz, S. H.
C2  - PMC3492525
C6  - NIHMS392537
DA  - Feb 1
DO  - 10.1002/cncr.27759
DP  - NLM
ET  - 2012/07/27
IS  - 3
KW  - African Americans/statistics & numerical data
Aged
Aged, 80 and over
Carcinoma/diagnosis/economics/epidemiology/prevention & control
Colonoscopy/economics/psychology/*statistics & numerical data
Colorectal Neoplasms/diagnosis/economics/epidemiology/prevention & control
Costs and Cost Analysis
Female
Hispanic Americans/statistics & numerical data
Humans
Male
Mass Screening/economics/psychology/*statistics & numerical data
Middle Aged
Minority Groups/psychology/*statistics & numerical data
Occult Blood
Patient Compliance/psychology/*statistics & numerical data
Patient Navigation/*economics/methods/*statistics & numerical data
Urban Population/*statistics & numerical data
LA  - eng
N1  - 1097-0142
Jandorf, Lina
Stossel, Lauren M
Cooperman, Julia L
Graff Zivin, Joshua
Ladabaum, Uri
Hall, Diana
Thélémaque, Linda D
Redd, William
Itzkowitz, Steven H
K05 CA108955/CA/NCI NIH HHS/United States
R01 CA120658/CA/NCI NIH HHS/United States
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Cancer. 2013 Feb 1;119(3):612-20. doi: 10.1002/cncr.27759. Epub 2012 Jul 25.
PY  - 2013
SN  - 0008-543X (Print)
0008-543x
SP  - 612-20
ST  - Cost analysis of a patient navigation system to increase screening colonoscopy adherence among urban minorities
T2  - Cancer
TI  - Cost analysis of a patient navigation system to increase screening colonoscopy adherence among urban minorities
VL  - 119
ID  - 358
ER  - 

TY  - JOUR
AB  - PURPOSE: African American men report more persistent physical symptoms after treatment for prostate cancer, and data suggests that African American men also experience more emotional distress in response to having cancer. Yet, gaps persist in our knowledge of how to provide psychosocial support to African American prostate cancer survivors. One barrier to creating this knowledge is limited recruitment and retention of African American men in psychosocial oncology research. In this study we set out to develop a culturally sensitive research experience and group intervention to create a "safe space" for African American men to receive support following prostate cancer treatment. METHODS: Participants were 59 African American men participating in a pilot RCT comparing 2 supportive care approaches (prostate cancer education vs. cognitive behavioral coping skills) for improving quality of life. Participants had received prostate cancer treatment (primarily surgery and/or radiation) within the last 2 years. During recruitment, men participated in an enhanced informed consent process that involved viewing a 12‐minute video that discussed the importance of greater inclusion of African Americans in clinical research and described research participants' rights, prior to reading and signing the consent form. Next, participants were randomly assigned to 1 of the 2 supportive care group intervention conditions. While the conditions differed in content (education vs. coping skills), both conditions shared key features related to creating a safe space. Groups consisted of 4‐6 participants and were led by African American female psychologists and co‐led by African American male lay prostate cancer advocates. Female group leaders modeled acceptance to reinforce that prostate cancer had not diminished participants' manhood. Male co‐leaders delivered a portion of educational content in each session and were trained to model help‐seeking as normative behavior for men. Participant attendance at the 8 weekly sessions was used as the primary indicator of treatment adherence and acceptability. Four attendance variables were calculated: 1) mean number of regular group sessions attended, 2) mean number of make‐up sessions attended (either faceto‐ face or by telephone), 3) total session attendance (which included both regularly scheduled sessions attended and make‐up sessions attended), and 4) percentage of participants receiving all 8 intervention sessions either in weekly sessions or by attending make‐up sessions. RESULTS: Across the total sample, session attendance was high (mean of 6.6 out of 8 sessions). Due to high session attendance, participants needed few make‐up sessions (0.95 make‐up sessions on average). When attendance at regularly scheduled weekly sessions and make‐up sessions were combined, average total attendance was 7.6 sessions out of 8. The vast majority of participants (82.8%) received all 8 intervention sessions, either in weekly sessions or by make‐up session. Also relevant to treatment adherence and acceptability were the distances that participants were willing to travel to attend group sessions. It is notable that several participants drove over 100 miles (round trip) to attend each group session. Willingness to expend considerable effort and resources to attend group sessions suggests that sessions were highly valued by participants. CONCLUSIONS: It is hoped that this line of research will lead to increased participation of African American prostate cancer survivors in research on supportive care interventions and, ultimately, reduce disparities in the cancer survivorship experience. CLINICAL/RESEARCH IMPLICATIONS: This work has important implications for increasing the participation of African American prostate cancer survivors in psychosocial intervention research. Without interventions that demonstrate high adherence and acceptability, gaps in the cancer survivorship literature with regard to culturally appropriate supportive care interventions will persist. Also, African American advo ates have long been utilized in outreach and recruitment for survivorship research but have rarely been integrated into intervention delivery. This work suggests that shifting advocates from "margin to center" could be make psychosocial research more accessible to African American prostate cancer survivors.
AN  - CN-01025250
AU  - Campbell, L.
AU  - McKee, D.
AU  - Keefe, F.
DO  - 10.10002/pon.3245
KW  - *African American
*cancer survivor
*human
*model
*oncology
*prostate cancer
*society
Cancer therapy
Clinical research
Coping behavior
Education
Emotional stress
Female
Informed consent
Male
Neoplasm
Patient compliance
Psychologist
Psychosocial care
Quality of life
Radiation
Reading
Skill
Surgery
Telephone
Travel
Videorecording
M3  - Journal: Conference Abstract
PY  - 2013
SP  - 112
ST  - Creating a safe space: a novel group supportive care intervention model for African American prostate cancer survivors
T2  - Psycho-oncology.
TI  - Creating a safe space: a novel group supportive care intervention model for African American prostate cancer survivors
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01025250/full
VL  - 22
ID  - 1410
ER  - 

TY  - JOUR
AB  - PURPOSE/OBJECTIVES: To learn from female survivors of Hodgkin disease about their perceptions of their current health status and future health risks, self-care practices to prevent or diminish health risks, and what kind of breast health program could benefit them, including the most effective methods and optimal times for learning about breast health. DESIGN: Participatory research using focus groups. SETTING: Urban pediatric cancer center. SAMPLE: 1 African American and 19 Caucasian female survivors of Hodgkin disease aged 16-26 years, diagnosed at least two years before the start of the study, and treated with mantle radiation therapy. Participants were recruited during visits to an outpatient clinic. METHODS: Six open-ended questions were asked during three separate focus group sessions. Transcribed data were evaluated by content analysis techniques and analyzed to identify common themes. MAIN RESEARCH VARIABLES: Current health status and perceived health risks, current health practices, and effective methods and timing for breast health teaching. FINDINGS: Survivors reported feeling damaged by their cancer and its treatment and perceived that they were at risk for breast cancer. Self-care and risky behaviors also were reported. Internal influences (e.g., fear) and external influences (e.g., family) motivated survivors to participate in health promotion activities. Effective methods identified for learning about breast health included having access to other survivors, being respected as an adult, and having one-on-one staff teaching and peer support. The preferred timing of teaching varied, but survivors generally supported a gradual provision of information. CONCLUSIONS: A positive listening environment is important for developing a breast health program for survivors. An essential first step is to create an opportunity for survivors to tell about their experiences with cancer, including its impact on their lives. Information regarding breast health must be provided in multiple formats during and after treatment if good practices are to be undertaken. IMPLICATIONS FOR NURSING: The provision of adequate information during and after therapy as well as peer counseling in a positive listening environment are important in helping survivors participate in health promotion activities.
AD  - Department of Hematology/Oncology, St. Jude Children's Research Hospital, Memphis, TN, USA. debbie.crom@stjude.org
AN  - 16270109
AU  - Crom, D. B.
AU  - Hinds, P. S.
AU  - Gattuso, J. S.
AU  - Tyc, V.
AU  - Hudson, M. M.
DA  - Nov 3
DO  - 10.1188/05.Onf.1131-1141
DP  - NLM
ET  - 2005/11/05
IS  - 6
KW  - Adolescent
Adult
Breast Neoplasms/etiology/*prevention & control
Female
Focus Groups
Health Knowledge, Attitudes, Practice
Hodgkin Disease/*radiotherapy
Humans
Models, Theoretical
Neoplasms, Radiation-Induced/etiology/*prevention & control
Neoplasms, Second Primary/etiology/*prevention & control
Patient Education as Topic/*methods
Patient Participation/methods
Program Development/methods
Radiotherapy/adverse effects
Research Design
Risk Factors
*Survivors
LA  - eng
N1  - 1538-0688
Crom, Deborah B
Hinds, Pamela S
Gattuso, Jami S
Tyc, Vida
Hudson, Melissa M
CA21765/CA/NCI NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.
United States
Oncol Nurs Forum. 2005 Nov 3;32(6):1131-41. doi: 10.1188/05.ONF.1131-1141.
PY  - 2005
SN  - 0190-535x
SP  - 1131-41
ST  - Creating the basis for a breast health program for female survivors of Hodgkin disease using a participatory research approach
T2  - Oncol Nurs Forum
TI  - Creating the basis for a breast health program for female survivors of Hodgkin disease using a participatory research approach
VL  - 32
ID  - 585
ER  - 

TY  - JOUR
AB  - PURPOSE/OBJECTIVES: To develop and test the Cues to Participation in Prostate Cancer Screening Theory, which proposes that exposure to information from certain sources cues or triggers screening. DESIGN: Descriptive correlational. SETTING: 11 counties of a southeastern state. SAMPLE: Convenience sample of 1,867 men at risk for prostate cancer (72% African American; 28% Caucasian). METHODS: Recent exposure to prostate cancer information was measured. Men were offered free screening by prostate specific antigen (PSA) and digital rectal exam (DRE). MAIN RESEARCH VARIABLES: Demographic variables (race, age, education, income, and marital status), exposure (electronic media, print media, healthcare provider recommendation, and interpersonal interactions), and screening as measured by PSA and DRE. FINDINGS: Several major propositions of the Cues to Participation Theory were supported. General exposure to prostate cancer information significantly predicted screening participation. Hearing about prostate cancer from a healthcare provider was the best predictor of screening. CONCLUSIONS: Men's demographic characteristics should be considered when providing information about prostate cancer. Hearing about prostate cancer from family and friends was not significantly related to screening behavior. IMPLICATIONS FOR NURSING PRACTICE: The importance of recommendations for prostate cancer screening is underscored.
AD  - Department of Nursing at Armstrong Atlantic State University in Savannah, GA, USA. nivensan@mail.armstrong.edu
AN  - 11683314
AU  - Nivens, A. S.
AU  - Herman, J.
AU  - Pweinrich, S.
AU  - Weinrich, M. C.
DA  - Oct
DP  - NLM
ET  - 2001/10/31
IS  - 9
KW  - Adult
African Americans
Aged
Health Behavior
Health Knowledge, Attitudes, Practice
Humans
Male
Mass Screening/*psychology
Middle Aged
Oncology Nursing
Patient Participation/*psychology
Prostatic Neoplasms/ethnology/nursing/*prevention & control
South Carolina
LA  - eng
N1  - Nivens, A S
Herman, J
Pweinrich, S
Weinrich, M C
R01 CA60561-01/CA/NCI NIH HHS/United States
Journal Article
Research Support, U.S. Gov't, P.H.S.
United States
Oncol Nurs Forum. 2001 Oct;28(9):1449-56.
PY  - 2001
SN  - 0190-535X (Print)
0190-535x
SP  - 1449-56
ST  - Cues to participation in prostate cancer screening: a theory for practice
T2  - Oncol Nurs Forum
TI  - Cues to participation in prostate cancer screening: a theory for practice
VL  - 28
ID  - 678
ER  - 

TY  - JOUR
AB  - Diverse racial and ethnic populations must be included in research studies in order to address health disparities. Retaining hard-to-reach populations including poor, underserved, and racial/ethnic groups in longitudinal studies can be quite difficult. Using innovative retention strategies that address culture and community are imperative. The objective of this report is to identify and describe strategies for successful retention rates among a unique group of hard-to-reach racial/ethnic participants. We analyzed the follow-up rates in two different cohorts using the Kin Keeper(SM) study design. The aim of Study A was to examine the capability of the Kin Keeper(SM) education to increase health literacy in breast and cervical cancer. The primary aim of Study B was to measure changes in breast and cervical cancer screening after receiving the Kin Keeper(SM) education. Retention rates were analyzed and compared over 12 months for both cohorts. We found good retention rates for both cohorts with each having a unique set of differences. The overall follow-up rate was 82 % for Study A and 88 % for Study B with demographic differences between the studies reported herein. Despite changing cultural, community, and geopolitical factors, we were able to maintain consistent participation for each study. We attribute high retention rates to trusted cultural connections and the flexibility to adjust retention strategies.
AN  - WOS:000381993900016
AU  - Williams, K. P.
AU  - Ford, S.
AU  - Meghea, C.
DA  - Sep
DO  - 10.1007/s13187-015-0857-5
IS  - 3
N1  - 26123762
PY  - 2016
SN  - 0885-8195
SP  - 522-528
ST  - Cultural Connections: the Key to Retention of Black, Latina, and Arab Women in the Kin Keeper(SM) Cancer Prevention Intervention Studies
T2  - Journal of Cancer Education
TI  - Cultural Connections: the Key to Retention of Black, Latina, and Arab Women in the Kin Keeper(SM) Cancer Prevention Intervention Studies
VL  - 31
ID  - 2934
ER  - 

TY  - JOUR
AB  - Objectives The primary objective of this 2-year pilot study was to evaluate the effectiveness of a culturally adapted family intervention in improving family communication among African American parents coping with cancer and their school-age children. A secondary objective was to determine its impact on other symptoms of psychosocial distress (depression and anxiety). The third objective was to assess for acceptability and feasibility. Methods Using a two-arm pre-intervention and post-intervention prospective design, 12 African American families received five bi-monthly sessions of either a culturally adapted family intervention (n = 7 families) or psycho-education treatment (n = 5 families). Parents and their children completed pre-intervention and post-intervention questionnaires assessing perceptions of family communication, quality of their relationship, and symptoms of depression. School-age children additionally completed a questionnaire assessing their levels of anxiety. Consumer satisfaction was also evaluated at post-intervention. Results Parents and school-age children who completed the culturally adapted family intervention reported significantly better communication with each other and were more satisfied compared with the psycho-education control group. No changes were noted in symptoms of anxiety or depression. The culturally adapted family intervention was acceptable based on our findings, families' feedback, and rates of retention. Feasibility is uncertain because our oncology clinic approach to recruitment was slower than expected. Conclusions Providing culturally adapted family intervention programs to African American families who are coping with parental cancer may result in improved family communication. This pilot study serves as the first step in the development of culturally adapted family intervention programs to help African American families cope with parental cancer. Copyright © 2012 John Wiley & Sons, Ltd. Copyright © 2012 John Wiley & Sons, Ltd.
AD  - M.P. Davey, Department of Couple and Family Therapy, Drexel University, Mail Stop 905, 1505 Race Street, Philadelphia, PA 19102, United States
AU  - Davey, M. P.
AU  - Kissil, K.
AU  - Lynch, L.
AU  - Harmon, L. R.
AU  - Hodgson, N.
DB  - Embase
Medline
DO  - 10.1002/pon.3172
IS  - 7
KW  - antineoplastic agent
adult
African American
anxiety
article
breast cancer
cancer surgery
chemoradiotherapy
child
child parent relation
clinical article
clinical effectiveness
clinical trial
cultural factor
depression
family coping
family interaction
family therapy
female
human
kidney cancer
lung cancer
male
melanoma
mental stress
pancreas cancer
patient satisfaction
pilot study
psychoeducation
questionnaire
school child
LA  - English
M3  - Article
N1  - L52201188
2012-09-12
2013-07-22
PY  - 2013
SN  - 1057-9249
1099-1611
SP  - 1572-1580
ST  - A culturally adapted family intervention for African American families coping with parental cancer: Outcomes of a pilot study
T2  - Psycho-Oncology
TI  - A culturally adapted family intervention for African American families coping with parental cancer: Outcomes of a pilot study
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L52201188&from=export
http://dx.doi.org/10.1002/pon.3172
VL  - 22
ID  - 1077
ER  - 

TY  - JOUR
AB  - Background: End‐of‐life decision‐making is an important aspect of providing quality healthcare, especially for the elderly population. Increasingly, the appropriateness of many of these decisions is being questioned. Some invasive procedures done in seriously ill patients do not significantly alter their course, many patients die without having pain or other symptoms addressed, and families may feel dissatisfied with the care provided. Additionally, there are striking racial/ethnic disparities in end���of‐life care. Objectives: The explicit identification of values that guide medical decision‐making could improve the decision‐making process for end‐of‐life care for patients of all races/ethnicities. 1) We will directly compare, critically assess, and revise two Values Histories on the basis of qualitative data derived from individual interviews with racially/ethnically diverse patients and surrogates, and explore patients', surrogates', and physicians' values, preferences and concerns that guide decision‐making about medical interventions at the end‐of‐life. 2) We will then adapt the existing Values Histories into a clinically practical tool, the Values Inventory discussion aid. 3) We will conduct preliminary testing of this tool to be used in physician‐patient or physician‐surrogate encounters to improve and facilitate decisions about end‐of‐life care. Methods: To complete Objective 3 we will conduct a pilot randomized trial of the developed Values Inventory discussion aid to test the feasibility of using it in clinical practice. This clinicaltrials.gov number applies to Objective 3 of IIR‐02‐224 only (as the complete study is a mixed‐methods study with several different arms and enrollment goals). Eligible patients are at risk for 6‐12‐month mortality with one of the following diagnoses: congestive heart failure, with ejection fraction of less than 25%; severe chronic obstructive pulmonary disease/emphysema with dependence on oxygen; chronic liver disease with cirrhosis and ascites; colon carcinoma with liver metastases; or non‐small cell cancer of the lung, stage III or IV, and patients with chronic kidney disease on renal replacement therapy, with previous hospitalization. All (patient) participants are age 55 years or older and are recruited through the clinics/wards at the Houston VAMC. Surrogates are surrogates of patients with such conditions; physicians are generalists and medical subspecialists. All participants are African American, Hispanic, or White, reflecting the 3 major races/ethnicities at the Houston VAMC.
AN  - CN-01510546
AU  - Nct
KW  - Heart Failure
Kidney Diseases
Lung Diseases
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
Renal Insufficiency, Chronic
PY  - 2005
ST  - A Culturally Sensitive Values-Guided Aid for End of Life Decision-Making
T2  - https://clinicaltrials.gov/show/NCT00122135
TI  - A Culturally Sensitive Values-Guided Aid for End of Life Decision-Making
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01510546/full
ID  - 1601
ER  - 

TY  - JOUR
AN  - 30577092
AU  - Printz, C.
DA  - Jan 1
DO  - 10.1002/cncr.31898
DP  - NLM
ET  - 2018/12/24
IS  - 1
KW  - African Americans/statistics & numerical data
Chicago/ethnology
Clinical Decision-Making
Clinical Trials as Topic
Early Detection of Cancer/*methods/statistics & numerical data
European Continental Ancestry Group/statistics & numerical data
Female
Hispanic Americans/statistics & numerical data
Humans
Lung Neoplasms/*diagnosis/*ethnology
Male
Mass Screening
Middle Aged
LA  - eng
N1  - 1097-0142
Printz, Carrie
Comparative Study
News
United States
Cancer. 2019 Jan 1;125(1):10-11. doi: 10.1002/cncr.31898.
PY  - 2019
SN  - 0008-543x
SP  - 10-11
ST  - Currently recommended lung cancer screening guidelines may be insufficient for high-risk minorities
T2  - Cancer
TI  - Currently recommended lung cancer screening guidelines may be insufficient for high-risk minorities
VL  - 125
ID  - 90
ER  - 

TY  - JOUR
AB  - Genotyping of the polymorphic cytochrome P450 (CYP) 2D6 gene is used increasingly in clinical practice. Several psychiatric hospitals already use CYP2D6 testing before treating a patient with antidepressant or antipsychotic drug therapy. In other fields of drug therapy, such as for breast cancer, CYP2D6 status has been reported to be an independent predictor for the outcome with tamoxifen. Thus, a more favorable tamoxifen treatment seems to be feasible through a priori genetic assessment of CYP2D6.
AD  - Institute of Pharmacology of Natural Products and Clinical Pharmacology, University of Ulm, Ulm, Germany. julia.kirchheiner@uni-ulm.de
AN  - 18202689
AU  - Kirchheiner, J.
DA  - Feb
DO  - 10.1038/sj.clpt.6100455
DP  - NLM
ET  - 2008/01/19
IS  - 2
KW  - African Continental Ancestry Group/genetics
Antidepressive Agents/metabolism/therapeutic use
Antineoplastic Agents, Hormonal/metabolism/therapeutic use
Antipsychotic Agents/metabolism/therapeutic use
Cluster Analysis
Cytochrome P-450 CYP2D6/*genetics/*metabolism
Dextromethorphan/metabolism/urine
European Continental Ancestry Group/genetics
Gene Frequency
Genetic Testing
Genotype
Humans
Linear Models
*Models, Genetic
Patient Selection
*Pharmacogenetics
Phenotype
*Polymorphism, Genetic
Reproducibility of Results
Substrate Specificity
Tamoxifen/metabolism/therapeutic use
Treatment Outcome
LA  - eng
N1  - 1532-6535
Kirchheiner, J
Comment
Journal Article
United States
Clin Pharmacol Ther. 2008 Feb;83(2):225-7. doi: 10.1038/sj.clpt.6100455.
PY  - 2008
SN  - 0009-9236
SP  - 225-7
ST  - CYP2D6 phenotype prediction from genotype: which system is the best?
T2  - Clin Pharmacol Ther
TI  - CYP2D6 phenotype prediction from genotype: which system is the best?
VL  - 83
ID  - 508
ER  - 

TY  - JOUR
AB  - Cytochrome P450IIE1 is responsible for the activation of carcinogenic/V-nitrosamines, benzene, urethane, and other low-molecular-weight compounds. Restriction fragment length polymorphisms (Pstl and Rsal restriction enzymes) have been identified in the cytochrome P450IIE1 transcription regulatory region that may affect expression. This study describes the Pstl and Rsal polymorphisms in different racial populations and in a case-control study of lung cancer. The allelic frequencies were markedly different in Japanese, African-Americans, and Caucasians: the Pstl rare allele was present at a frequency of 2% in Caucasians, 5% in African-Americans, and 24% in Japanese (P < 0.05). For the Rsal rare allele, frequencies were 2% in Caucasians, 2% in African-Americans, and 27% in Japanese (P < 0.05). The assay was also applied to 128 individuals enrolled in a case-control study of lung cancer. Although limited in statistical power, the data indicate no evidence for an association in the aggregate of cytochrome P450IIE1 Pstl [for which the odds ratio was 0.7 (95% confidence interval (C.I.) = 0.2-2.8)] or Rsal [for which the odds ratio was 0.9 (95% C.I. = 0.2-5.4)] restriction fragment length polymorphisms with lung cancer in this U.S. population. When analyzed by race, the lung cancer odds ratio for the Pstl mutant allele in African-Americans was 0.19 (95% C.I. = 0.03-1.38), and in Caucasians it was 4.13 (95% CI. = 0.34-48.8). For the Rsal mutant allele, the odds ratios were 0.20 (95% CI. = 0.02-2.43) and 4.28 (95% C.I. = 0.35-50.6), respectively. The ethnic differences of these restriction fragment length polymorphisms might be related to genetic susceptibilities for lung cancer among Caucasians and for gastric or esophageal cancer among Japanese. © 1992, American Association for Cancer Research. All rights reserved.
AD  - Laboratory of Human Carcinogenesis, United States
Environmental Epidemiology Branch, Division of Cancer Etiology, National Cancer Institute, NIH, Bethesda, Maryland 20892, United States
Department of Pathology, University of Maryland, Baltimore, Maryland 21201, United States
First Department of Pathology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka 431-31, Japan
Laboratory of Human Carcinogenesis, Division of Etiology, National Cancer Institute, NIH, Building 37, Room 2C16, Bethesda, MD 20892, United States
AU  - Kato, S.
AU  - Shields, P. G.
AU  - Weston, A.
AU  - Harris, C. C.
DB  - Scopus
IS  - 23
M3  - Article
N1  - Cited By :213
Export Date: 22 March 2021
PY  - 1992
SP  - 6712-6715
ST  - Cytochrome P450IIE1 Genetic Polymorphisms, Racial Variation, and Lung Cancer Risk
T2  - Cancer Research
TI  - Cytochrome P450IIE1 Genetic Polymorphisms, Racial Variation, and Lung Cancer Risk
UR  - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0026486899&partnerID=40&md5=b1c8155babbc963e6dbee52938b53db2
VL  - 52
ID  - 2660
ER  - 

TY  - JOUR
AD  - Department of Radiation Medicine, Oregon Health and Science University, Portland.
AN  - 29450467
AU  - McClelland, S., 3rd
AU  - Mitin, T.
DA  - Mar 1
DO  - 10.1001/jamaoncol.2017.5452
DP  - NLM
ET  - 2018/02/17
IS  - 3
KW  - African Americans/statistics & numerical data
*Clinical Trials as Topic/methods/organization & administration
Disease Progression
Disease-Free Survival
Humans
Male
*Minority Groups/statistics & numerical data
Mortality
*Patient Selection
Population Surveillance
Prostatic Neoplasms/*ethnology/*mortality
Research Design
United States/epidemiology
LA  - eng
N1  - 2374-2445
McClelland, Shearwood 3rd
Mitin, Timur
Journal Article
United States
JAMA Oncol. 2018 Mar 1;4(3):291. doi: 10.1001/jamaoncol.2017.5452.
PY  - 2018
SN  - 2374-2437
SP  - 291
ST  - The Danger of Applying the ProtecT Trial to Minority Populations
T2  - JAMA Oncol
TI  - The Danger of Applying the ProtecT Trial to Minority Populations
VL  - 4
ID  - 132
ER  - 

TY  - JOUR
AB  - Darbepoetin alfa, novel erythropoiesis stimulating protein closely related to human erythropoietin, has been developed for the treatment of chemotherapy-related anaemia in patients with non-myeloid malignancies. In three 12-week, phase II studies in patients with cancer and chemotherapy-related anaemia, subcutaneous darbepoetin alfa, administered in once-weekly or 2-, 3- or 4-weekly regimens, dose-dependently increased the mean haemoglobin levels. In a randomised, double-blind, phase III study in 320 patients with lung cancer and chemotherapy-related anaemia, recipients of subcutaneous darbepoetin alfa 2.25 micro g/kg once weekly, received red blood cell (RBC) transfusion approximate, equals 2-fold less frequently than placebo recipients (p < 0.001). In the same study, patients receiving darbepoetin alfa also received fewer standard units of RBC for transfusion and had greater haematopoietic response rate than placebo recipients (both p < 0.001). Subcutaneous darbepoetin alfa 2.25 micro g/kg once weekly also reduced patient-reported fatigue (assessed by a quality-of-life questionnaire) [p = 0.019 vs placebo]. black triangle Darbepoetin alfa was generally well tolerated in clinical trials. The most frequent darbepoetin alfa-related adverse events were: body oedema, arthralgia and skin rash.
AD  - Adis International Limited, Mairangi Bay, Auckland, New Zealand. demail@adis.co.nz
AN  - 12749734
AU  - Cvetkovic, R. S.
AU  - Goa, K. L.
DO  - 10.2165/00003495-200363110-00003
DP  - NLM
ET  - 2003/05/17
IS  - 11
KW  - Anemia/chemically induced/*drug therapy
Animals
Antineoplastic Combined Chemotherapy Protocols/*adverse effects
Biological Availability
Clinical Trials, Phase II as Topic
Clinical Trials, Phase III as Topic
Darbepoetin alfa
Double-Blind Method
Drug Administration Schedule
Erythropoiesis/drug effects
Erythropoietin/adverse effects/*analogs & derivatives/pharmacokinetics/*therapeutic
use
Humans
Randomized Controlled Trials as Topic
Receptors, Erythropoietin/*agonists
Treatment Outcome
LA  - eng
N1  - Cvetkovic, Risto S
Goa, Karen L
Journal Article
Review
New Zealand
Drugs. 2003;63(11):1067-74; discussion 1075-7. doi: 10.2165/00003495-200363110-00003.
PY  - 2003
SN  - 0012-6667 (Print)
0012-6667
SP  - 1067-74; discussion 1075-7
ST  - Darbepoetin alfa: in patients with chemotherapy-related anaemia
T2  - Drugs
TI  - Darbepoetin alfa: in patients with chemotherapy-related anaemia
VL  - 63
ID  - 647
ER  - 

TY  - JOUR
AB  - There is little documentation about the recruitment process for church-based health education programs. In this study, the authors recruit African American, Latino, and white churches and women members (age 50 to 80) for a randomized church-based trial of mammography promotion in Los Angeles County. Efforts to enhance recruitment began 10 months before churches were invited to participate and included a variety of community-based strategies. Subsequently, 45 churches were recruited over a 5-month period through group pastor breakfast meetings and church-specific follow-up. In close collaboration with the 45 churches, the authors administered church-based surveys over 6 months and identified 1,967 age-eligible women who agreed to be contacted by the program team. It was found that an extended resource intensive period of relationship-building and community-based activities were necessary to conduct church-based programs effectively, particularly among older and ethnically diverse urban populations.
AD  - RAND, Santa Monica, California 90407-2138, USA. Kathryn_Derose@rand.org
AN  - 11009131
AU  - Derose, K. P.
AU  - Hawes-Dawson, J.
AU  - Fox, S. A.
AU  - Maldonado, N.
AU  - Tatum, A.
AU  - Kington, R.
DA  - Oct
DO  - 10.1177/109019810002700508
DP  - NLM
ET  - 2000/09/29
IS  - 5
KW  - Aged
Breast Neoplasms/*prevention & control
Community Health Planning
*Community-Institutional Relations
Ethnic Groups
Female
Health Education/*organization & administration
Health Promotion/*organization & administration
Health Services Research
Humans
Los Angeles
Mammography/*statistics & numerical data
Middle Aged
Motivation
*Patient Selection
*Religion
LA  - eng
N1  - Derose, K P
Hawes-Dawson, J
Fox, S A
Maldonado, N
Tatum, A
Kington, R
1 R01 CA65880/CA/NCI NIH HHS/United States
Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, U.S. Gov't, P.H.S.
United States
Health Educ Behav. 2000 Oct;27(5):632-48. doi: 10.1177/109019810002700508.
PY  - 2000
SN  - 1090-1981 (Print)
1090-1981
SP  - 632-48
ST  - Dealing with diversity: recruiting churches and women for a randomized trial of mammography promotion
T2  - Health Educ Behav
TI  - Dealing with diversity: recruiting churches and women for a randomized trial of mammography promotion
VL  - 27
ID  - 700
ER  - 

TY  - JOUR
AB  - Purpose: Financial burden among cancer survivors is often overlooked in survivorship care planning. Cancer survivors with limited incomes may be particularly affected. Yet, little data are available to address financial issues among them. Eliciting the survivors’ perspectives on how to deal with this financial burden is a first crucial step to identifying the means to provide this supportive care. Methods: In this pilot study, three nominal group technique (NGT) sessions were conducted with a convenience sample of 23 older breast cancer survivors (age 52 to 83) recruited from a county safety net hospital and a Comprehensive Cancer Center. One single NGT question was posed in these sessions, namely “What could help women deal with the financial burden that cancer brings to them and their families?” Survivors responded in an iterative fashion and then ranked the most relevant responses. Results: The most relevant responses addressed the (1) need for affordable insurance; (2) need to have prompt information on treatment costs patients will face, insurance coverage, and agencies or programs that provide needed products and services; and (3) need to access social workers, navigators, support groups, or others knowledgeable about available resources. Survivors also suggested that physicians become aware of cancer costs and financial issues faced by patients and consider costs in their treatment plans. Conclusions: Older survivors face financial challenges for which there are few available resources. They suggested several avenues to address cancer-related financial issues that may be considered in developing supportive interventions. © 2014, Springer-Verlag Berlin Heidelberg.
AD  - Division of Preventive Medicine and Comprehensive Cancer Center, University of Alabama at Birmingham, 1720 2nd Avenue South, Birmingham, AL 35294, United States
Department of Health Services Administration, University of Alabama at Birmingham, 1720 2nd Avenue South, Birmingham, AL 35294, United States
School of Nursing and Comprehensive Cancer Center, University of Alabama at Birmingham, 1720 2nd Avenue South, Birmingham, AL 35294, United States
AU  - Pisu, M.
AU  - Martin, M. Y.
AU  - Shewchuk, R.
AU  - Meneses, K.
DB  - Scopus
DO  - 10.1007/s00520-014-2298-9
IS  - 11
KW  - Breast cancer
Financial burden
Financial toxicity
Older women
Survivorship
M3  - Article
N1  - Cited By :19
Export Date: 22 March 2021
PY  - 2014
SP  - 3045-3052
ST  - Dealing with the financial burden of cancer: perspectives of older breast cancer survivors
T2  - Supportive Care in Cancer
TI  - Dealing with the financial burden of cancer: perspectives of older breast cancer survivors
UR  - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84919396001&doi=10.1007%2fs00520-014-2298-9&partnerID=40&md5=278e6a4c4b9515b0b2f431ac01dba68c
VL  - 22
ID  - 2412
ER  - 

TY  - JOUR
AB  - The sudden decision by the National Heart, Lung, and Blood Institute of the National Institutes of Health to terminate the estrogen-progestogen therapy arm of the Women's Health Initiative (WHI) Study a decade ago now begs two questions:--has women's health after menopause been helped or harmed as a result of the findings and the way in which they were presented, and, if harmed, what needs to be done to put things right? Time and multiple reviews of specific publications from the WHI lead to the serious question whether a project designed to be of benefit to women's health has boomeranged, and instead may have resulted in significant impairment to both the quality of life and physical health of postmenopausal women. It is therefore urgent to confirm whether this is so and whether corrective action needs be taken to prevent even more harm. There are two obvious and immediate actions to be called for: (1) The Food and Drug Administration (FDA) needs to revisit the black-box warnings on postmenopausal hormones. Specifically, there needs to be a separation of the advisories for estrogen alone from estrogen and progestogen combined usage. (2) Justification is given to call for an independent commission to scrutinize every major WHI paper to determine whether the data justified the conclusions drawn. Women progressing through and beyond menopause in the next decade need to be spared the unnecessary harm that may have been inflicted on their sisters of the previous decade.
AD  - The North American Menopause Society, and Reproductive Biology, Case Medical School, Cleveland, Ohio, USA.
AN  - 22762439
AU  - Utian, W. H.
DA  - Aug
DO  - 10.3109/13697137.2012.678916
DP  - NLM
ET  - 2012/07/06
IS  - 4
KW  - Adult
Advisory Committees
Age Factors
Aged
Bias
Breast Neoplasms/chemically induced
Cardiovascular Diseases/chemically induced/*prevention & control
Data Interpretation, Statistical
Female
Hip Fractures/prevention & control
Hormone Replacement Therapy/adverse effects/*statistics & numerical data
Humans
Menopause/drug effects
Middle Aged
National Heart, Lung, and Blood Institute (U.S.)
Osteoporosis/prevention & control
Postmenopause/*drug effects
Randomized Controlled Trials as Topic
United States
United States Food and Drug Administration
LA  - eng
N1  - 1473-0804
Utian, W H
Journal Article
Review
England
Climacteric. 2012 Aug;15(4):320-5. doi: 10.3109/13697137.2012.678916.
PY  - 2012
SN  - 1369-7137
SP  - 320-5
ST  - A decade post WHI, menopausal hormone therapy comes full circle--need for independent commission
T2  - Climacteric
TI  - A decade post WHI, menopausal hormone therapy comes full circle--need for independent commission
VL  - 15
ID  - 362
ER  - 

TY  - JOUR
AB  - INTRODUCTION AND OBJECTIVE: Men diagnosed with localized prostate cancer must navigate a highly preference‐sensitive decision between treatment options with varying adverse outcome profiles. Decisional regret has been documented in men after treatment. We evaluated whether use of a decision support tool previously shown to decrease decisional conflict also impacted posttreatment decisional regret. METHODS: Participants at 10 urology or radiation oncology clinics across the United States were randomized to receive personalized decision support via the Personal Patient Profile‐Prostate or usual care. Symptoms were measured at baseline and 6 months after enrollment; decision regret was measured at 6 months along with medical records review to ascertain treatment choices. Regression modeling explored associations between regret, 6‐month symptoms and baseline variables including race, study group, choice, D'Amico risk, and symptoms. RESULTS: At 6 months, 287 of 392 (73%) men returned questionnaires of which 257 (89%) had made a treatment choice. Of that group, 201/257 (78%) completely answered the regret scale. While there was no significant difference between study groups (p=0.360), univariate analyses revealed Black men (p=0.019), men with any hormonal symptoms (p=0.009), and men with any bowel symptoms (p=0.032) reported higher regret. Significant interactions between treatment choice, regret and symptoms were detected. Men receiving definitive treatment and reporting no hormonal symptoms reported lower regret compared to all others (p=0.002). Men choosing active surveillance and reporting bowel symptoms had higher regret compared to all others (p=0.002). Significant interactions were detected between race and study group (intervention vs usual care) in the multivariable model; use of Personal Patient Profile‐Prostate was associated with significantly decreased decisional regret among Black men (p=0.037). CONCLUSIONS: Decisional regret was associated with active surveillance and adverse symptom outcomes for men of various races. The Personal Patient Profile‐Prostate decision support tool may be most beneficial in minimizing decisional regret for Black men considering treatment options for newly‐diagnosed prostate cancer.
AN  - CN-02139164
AU  - Berry, D. L.
AU  - Hong, F.
AU  - Blonquist, T.
AU  - Halpenny, B.
AU  - Xiong, N.
AU  - Filson, C. P.
AU  - Master, V. A.
AU  - Sanda, M. G.
AU  - Chang, P.
AU  - Chien, G.
AU  - et al.
DO  - 10.1097/JU.0000000000000856.019
KW  - *adverse outcome
*prostate cancer
Adult
Cancer patient
Cancer radiotherapy
Conference abstract
Controlled study
Decision support system
Enteropathy
Female
Human
Male
Medical record review
Multicenter study
Questionnaire
Race
Radiation oncology
Randomized controlled trial
United States
Univariate analysis
Urology
M3  - Journal: Conference Abstract
PY  - 2020
SP  - e345‐e346
ST  - Decision regret, adverse outcomes and treatment choice in men with localized prostate cancer: results from a multi-site randomized trial
T2  - Journal of urology
TI  - Decision regret, adverse outcomes and treatment choice in men with localized prostate cancer: results from a multi-site randomized trial
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02139164/full
VL  - 203
ID  - 1611
ER  - 

TY  - JOUR
AB  - BACKGROUND: Decisional conflict is a source of anxiety and stress for men diagnosed with prostate cancer given uncertainty surrounding myriad treatment options. Few data exist to help clinicians identify which patients are at risk for decisional conflict. The purpose of this study was to examine factors associated with decisional conflict in economically disadvantaged men diagnosed with prostate cancer before any treatment choices were made. METHODS: A total of 70 men were surveyed at a Veterans Administration clinic with newly diagnosed localized prostate cancer enrolled in a randomized trial testing a novel shared decision-making tool. Baseline demographic, clinical, and functional data were collected. Independent variables included age, race, education, comorbidity, relationship status, urinary/sexual dysfunction, and prostate cancer knowledge. Tested outcomes were Decisional Conflict Scale, Uncertainty Subscale, and Perceived Effectiveness Subscale. Multiple linear regression modeling was used to identify factors associated with decisional conflict. RESULTS: Mean age was 63 years, 49% were African American, and 70% reported an income less than $30,000. Poor prostate cancer knowledge was associated with increased decisional conflict and higher uncertainty (P < .001 and P = 0.001, respectively). Poor knowledge was also associated with lower perceived effectiveness (P = 0.003) whereas being in a relationship was associated with higher decisional conflict (P = 0.03). CONCLUSIONS: Decreased patient knowledge about prostate cancer is associated with increased decisional conflict and lower perceived effective decision-making. Interventions to increase comprehension of prostate cancer and its treatments may reduce decisional conflict. Further work is needed to better characterize this relationship and identify effective targeted interventions.
AD  - Department of Urology, David Geffen School of Medicine at University of California Los Angeles (UCLA), Los Angeles, California.
AN  - 24816472
AU  - Kaplan, A. L.
AU  - Crespi, C. M.
AU  - Saucedo, J. D.
AU  - Connor, S. E.
AU  - Litwin, M. S.
AU  - Saigal, C. S.
C2  - PMC4552329
C6  - NIHMS716864
DA  - Sep 1
DO  - 10.1002/cncr.28755
DP  - NLM
ET  - 2014/05/13
IS  - 17
KW  - Aged
Choice Behavior
Cross-Sectional Studies
Decision Making
*Dissent and Disputes
Health Knowledge, Attitudes, Practice
Humans
Income
Male
Middle Aged
Prostatic Neoplasms/diagnosis/economics/*therapy
Vulnerable Populations
decisional conflict
knowledge
low socioeconomic status
patient education
prostate cancer
LA  - eng
N1  - 1097-0142
Kaplan, Alan L
Crespi, Catherine M
Saucedo, Josemanuel D
Connor, Sarah E
Litwin, Mark S
Saigal, Christopher S
5R25CA087949-14/CA/NCI NIH HHS/United States
R01 CA134997/CA/NCI NIH HHS/United States
CA16042/CA/NCI NIH HHS/United States
5R01CA134997-02/CA/NCI NIH HHS/United States
R25 CA087949/CA/NCI NIH HHS/United States
P30 CA016042/CA/NCI NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
Cancer. 2014 Sep 1;120(17):2721-7. doi: 10.1002/cncr.28755. Epub 2014 May 9.
PY  - 2014
SN  - 0008-543X (Print)
0008-543x
SP  - 2721-7
ST  - Decisional conflict in economically disadvantaged men with newly diagnosed prostate cancer: baseline results from a shared decision-making trial
T2  - Cancer
TI  - Decisional conflict in economically disadvantaged men with newly diagnosed prostate cancer: baseline results from a shared decision-making trial
VL  - 120
ID  - 288
ER  - 

TY  - JOUR
AB  - African Americans have a substantially increased mortality rate compared to whites in many cancers, including breast and cervix. The Deep South Network for Cancer Control (the Network) was established to develop sustainable community infrastructure to promote cancer awareness, enhance participation of African Americans and other special populations in clinical trials, recruit and train minority investigators, and develop and test innovative community-based cancer control measures to eliminate cancer mortality disparities in special populations. This article describes the steps necessary to form the network and the process and activities required to establish it as an effective infrastructure for eliminating disparities between Whites and African Americans in the United States.
AN  - WOS:000225943300003
AU  - Partridge, E. E.
AU  - Fouad, M. N.
AU  - Hinton, A. W.
AU  - Hardy, C. M.
AU  - Liscovicz, N.
AU  - White-Johnson, F.
AU  - Higginbotham, J. C.
DA  - Jan-Mar
DO  - 10.1097/00003727-200501000-00004
IS  - 1
N1  - 40
15625502
PY  - 2005
SN  - 0160-6379
SP  - 6-19
ST  - The deep south network for cancer control - Eliminating cancer disparities through community-academic collaboration
T2  - Family & Community Health
TI  - The deep south network for cancer control - Eliminating cancer disparities through community-academic collaboration
VL  - 28
ID  - 2668
ER  - 

TY  - JOUR
AB  - African Americans have a substantially increased mortality rate compared to Whites in many cancers, including breast and cervix. The Deep South Network for Cancer Control (the Network) was established to develop sustainable community infrastructure to promote cancer awareness, enhance participation of African Americans and other special populations in clinical trials, recruit and train minority investigators, and develop and test innovative community-based cancer control measures to eliminate cancer mortality disparities in special populations. This article describes the steps necessary to form the network and the process and activities required to establish it as an effective infrastructure for eliminating disparities between Whites and African Americans in the United States.
AD  - Departments of Obstetrics and Gynecology, The University of Alabama at Birmingham, 35233-7333, USA. pakers@uabmc.edu
AN  - 15625502
AU  - Partridge, E. E.
AU  - Fouad, M. N.
AU  - Hinton, A. W.
AU  - Hardy, C. M.
AU  - Liscovicz, N.
AU  - White-Johnson, F.
AU  - Higginbotham, J. C.
DA  - Jan-Mar
DO  - 10.1097/00003727-200501000-00004
DP  - NLM
ET  - 2004/12/31
IS  - 1
KW  - *African Americans
Alabama/epidemiology
Breast Neoplasms/diagnosis/*ethnology/prevention & control
Clinical Trials as Topic
Community Networks/*organization & administration
Community Participation/methods
Female
Health Promotion/methods/organization & administration
Humans
Medically Underserved Area
Mississippi/epidemiology
Schools, Medical
Socioeconomic Factors
United States
Uterine Cervical Neoplasms/diagnosis/*ethnology/prevention & control
LA  - eng
N1  - Partridge, Edward E
Fouad, Mona N
Hinton, Agnes W
Hardy, Claudia M
Liscovicz, Nedra
White-Johnson, Freddie
Higginbotham, John C
U01 CA86128/CA/NCI NIH HHS/United States
Journal Article
Research Support, U.S. Gov't, P.H.S.
United States
Fam Community Health. 2005 Jan-Mar;28(1):6-19. doi: 10.1097/00003727-200501000-00004.
PY  - 2005
SN  - 0160-6379 (Print)
0160-6379
SP  - 6-19
ST  - The deep South network for cancer control: eliminating cancer disparities through community-academic collaboration
T2  - Fam Community Health
TI  - The deep South network for cancer control: eliminating cancer disparities through community-academic collaboration
VL  - 28
ID  - 611
ER  - 

TY  - JOUR
AB  - This is the largest individually randomized, multicenter cancer prevention trial conducted that has maintained high rates of adherence and retention for 4 to 7 years. This trial recruited 35,533 men who were randomly assigned to four groups (selenium, vitamin E, selenium + vitamin E, and placebo) in a double-blind fashion between 2001 and 2004. Eligibility included age 50 years or older (African American men) or 55 years or older (all other men), a serum prostate-specific antigen level of ≤4 ng/ml, and a digital rectal examination not suspicious for prostate cancer. Antioxidant formulations used were oral selenium (200 µg/d from L-selenomethionine) and matched vitamin E placebo, vitamin E (400 IU/d of all rac-α-tocopheryl acetate), and matched selenium placebo, selenium + vitamin E, or placebo + placebo for a follow-up of minimum of 7 years and a maximum of 12 years. The primary outcome was prostate cancer and prespecified secondary outcomes were lung, colorectal, and overall primary cancer. At median overall follow-up of 5.46 years (range: 4.17.7.33 years), hazard ratios for prostate cancer were 1.13 (99% CI, 0.95-1.35; n = 473) for vitamin E, 1.04 (99% CI, 0.87-1.24; n = 432) for selenium, and 1.05 (99% CI, 0.88-1.25; n = 437) for selenium + vitamin E vs. 1.00 (n = 416) for placebo. No significant differences (all were p > 0.15) were seen in any other prespecified cancer endpoints. There were statistically non significant increased risks of prostate cancer in the vitamin E group (p = 0.06) and Type 2 diabetes mellitus in the selenium group (relative risk, 1.07; 99% CI, 0.94-1.22; p = 0.16), but not in the selenium + vitamin E group. This study concluded that selenium or vitamin E alone or in combination at the doses and formulations used did not prevent prostate cancer in this population of relatively healthy men.
AD  - Department of Urology, BYL Nair Hospital and TN Medical College, Mumbai, India; hemantrpathak@gmail.com
AN  - 105337761. Language: English. Entry Date: 20091204. Revision Date: 20180305. Publication Type: Journal Article
AU  - Pathak, H. R.
AU  - Singh, B. P.
DB  - CINAHL Complete
DP  - EBSCOhost
IS  - 3
KW  - Antioxidants
Prostatic Neoplasms -- Prevention and Control
Role
Beta Carotene
Neoplasms -- Mortality
Prostatic Neoplasms -- Risk Factors
Selenium
Vitamin E
N1  - abstract; commentary. Original Study: Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). (JAMA) 1/7/2009; 301 (1): 39-51. Journal Subset: Asia; Biomedical; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed. NLM UID: 8510441.
PY  - 2009
SN  - 0970-1591
SP  - 417-418
ST  - Defining the role of antioxidants in the prevention of prostate cancer
T2  - Indian Journal of Urology
TI  - Defining the role of antioxidants in the prevention of prostate cancer
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105337761&site=ehost-live&scope=site
VL  - 25
ID  - 1905
ER  - 

TY  - JOUR
AB  - Objectives: The risks and benefits of initiating antiretroviral treatment (ART) at high CD4 cell counts have not been reliably quantified. The Strategic Timing of AntiRetroviral Treatment (START) study is a randomized international clinical trial that compares immediate with deferred initiation of ART for HIV-positive individuals with CD4 cell counts above 500cells/μL. We describe the demographics, HIV-specific characteristics and medical history of this cohort. Methods: Data collected at baseline include demographics, HIV-specific laboratory values, prior medical diagnoses and concomitant medications. Baseline characteristics were compared by geographical region, gender and age. Results: START enrolled 4685 HIV-positive participants from 215 sites in 35 countries. The median age is 36 years [interquartile range (IQR) 29-44 years], 27% are female, and 45% self-identify as white, 30% as black, 14% as Latino/Hispanic, 8% as Asian and 3% as other. The route of HIV acquisition is reported as men who have sex with men in 55% of participants, heterosexual sex in 38%, injecting drug use in 1% and other/unknown in 5%. Median time since HIV diagnosis is 1.0 year (IQR 0.4-3.0 years) and the median CD4 cell count and HIV RNA values at study entry are 651cells/μL (IQR 584-765cells/μL) and 12754 HIV RNA copies/mL (IQR 3014-43607 copies/mL), respectively. Conclusions: START has enrolled a diverse group of ART-naïve individuals with high CD4 cell counts who are comparable to the HIV-positive population from the regions in which they were enrolled. The information collected with this robust study design will provide a database with which to evaluate the risks and benefits of early ART use for many important outcomes.
AD  - S. Sharma, Division of Biostatistics, School of Public Health, University of Minnesota, 2221 University Ave SE, Suite 200, Minneapolis, MN, United States
AU  - Sharma, S.
AU  - Babiker, A.
AU  - Emery, S.
AU  - Gordin, F.
AU  - Lundgren, J.
AU  - Neaton, J.
AU  - Bakowska, E.
AU  - Schechter, M.
AU  - Wiselka, M.
AU  - Wolff, M.
DB  - Embase
Medline
DO  - 10.1111/hiv.12231
IS  - S1
KW  - NCT00867048
antidepressant agent
antilipemic agent
antiretrovirus agent
benzodiazepine derivative
nonsteroid antiinflammatory agent
proton pump inhibitor
RNA
acute heart infarction
adult
alcoholism
antiviral therapy
article
CD4 lymphocyte count
cerebrovascular accident
chronic kidney failure
cohort analysis
congestive heart failure
coronary artery disease
deep vein thrombosis
demography
drug use
end stage renal disease
fatty liver
female
heart muscle revascularization
heterosexuality
hormonal therapy
human
Human immunodeficiency virus
Human immunodeficiency virus infection
liver cirrhosis
lung embolism
major clinical study
male
medical history
men who have sex with men
mental disease
myocarditis
pancreatitis
pericarditis
peripheral occlusive artery disease
priority journal
self injection
skin cancer
substance abuse
LA  - English
M3  - Article
N1  - L602522858
2015-03-03
2019-12-20
PY  - 2015
SN  - 1468-1293
1464-2662
SP  - 30-36
ST  - Demographic and HIV-specific characteristics of participants enrolled in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial
T2  - HIV Medicine
TI  - Demographic and HIV-specific characteristics of participants enrolled in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L602522858&from=export
http://dx.doi.org/10.1111/hiv.12231
VL  - 16
ID  - 1003
ER  - 

TY  - JOUR
AB  - Objectives: Individuals with limited health literacy often experience suboptimal health outcomes. This study examined the frequency of limited health literacy and demographic and psychosocial factors associated with limited health literacy in a sample of older Black Americans. Methods: Participants (n = 330) enrolled in a community-based intervention to promote colorectal cancer (CRC) screening completed baseline surveys assessing health literacy with the Rapid Estimate of Adult Literacy in Medicine, Revised (REALM-R) test, CRC awareness, cancer fatalism, Preventive Health Model (PHM) constructs, and demographics. Results: Approximately 52% of participants had limited health literacy, the REALM-R score was 5.4 (SD = 2.7). Univariable correlates of limited health literacy were gender, employment, income, prior screening, cancer fatalism, CRC awareness, and PHM constructs (religious beliefs, salience/coherence, perceived susceptibility). Multivariable correlates of limited health literacy were male gender (OR = 2.3, CI = 1.4-3.8), unable to work (OR = 2.8, CI = 1.3-6.1), lower household income (OR = 3.0, CI = 1.6, 5.5), and higher PHM religious beliefs (OR = 1.1, CI = 1.0-1.2). Conclusion: Limited health literacy was associated with multiple complex factors. Interventions should incorporate patient health literacy and low-literacy materials that can be delivered through multiple channels. Practice implications: Future studies are needed to understand the role of health literacy in an individual's health behavior and the provision of effective healthcare. (C) 2019 Elsevier B.V. All rights reserved.
AN  - WOS:000512927000019
AU  - Davis, S. N.
AU  - Wischhusen, J. W.
AU  - Sutton, S. K.
AU  - Christy, S. M.
AU  - Chavarria, E. A.
AU  - Sutter, M. E.
AU  - Roy, S.
AU  - Meade, C. D.
AU  - Gwede, C. K.
DA  - Feb
DO  - 10.1016/j.pec.2019.08.026
IS  - 2
N1  - 31466881
PY  - 2020
SN  - 0738-3991
SP  - 385-391
ST  - Demographic and psychosocial factors associated with limited health literacy in a community-based sample of older Black Americans
T2  - Patient Education and Counseling
TI  - Demographic and psychosocial factors associated with limited health literacy in a community-based sample of older Black Americans
VL  - 103
ID  - 2794
ER  - 

TY  - JOUR
AB  - Background. Online tools such as Adjuvant! provide tailored estimates of the possible outcomes of adjuvant therapy options available to breast cancer patients. The graphical format typically displays 4 outcomes simultaneously: survival, mortality due to cancer, other-cause mortality, and incremental survival due to adjuvant treatment. Objective. To test whether simpler formats that present only baseline and incremental survival would improve comprehension of the relevant risk statistics and/or affect treatment intentions. Design. Randomized experimental manipulation of risk graphics shown included in Internet-administered survey vignettes about adjuvant therapy decisions for breast cancer patients with ER + tumors. Participants. Demographically diverse, stratified random samples of women ages 40 to 74 y recruited from an Internet research panel. Intervention. Participants were randomized to view either pictographs (icon arrays) that displayed all 4 possible outcomes or pictographs that showed only survival outcomes. Measurements. Comprehension of key statistics, task completion times, graph evaluation ratings, and perceived interest in adjuvant chemotherapy. Results. In the primary study (N = 832), participants who viewed survival-only pictographs had better accuracy when reporting the total chance of survival with both chemotherapy and hormonal therapy (63% v. 50%, P < 0.001), higher graph evaluation ratings (x = 7.98 v. 7.67, P = 0.04), and less interest in adding chemotherapy to hormonal therapy (43% v. 50%, P = 0.04; adjusted odds ratio [OR] = 0.68, P = 0.008). A replication study (N = 714) confirmed that participants who viewed survival-only graphs had higher graph evaluation ratings (x = 8.06 v. 7.72, P = 0.04) and reduced interest in chemotherapy (OR=0.67,P=0.03). Limitations. Studies used general public samples; actual patients may process risk information differently. Conclusions. Taking a ‘‘less is more’’ approach by omitting redundant mortality outcome statistics can be an effective method of risk communication and may be preferable when using visual formats such as pictographs.
AD  - VA Health Services Research & Development Center for Clinical Management Research, VA Ann Arbor Healthcare System, Ann Arbor, MI
Center for Behavioral and Decision Sciences in Medicine, Ann Arbor, MI
Division of General Internal Medicine, University of Michigan, Ann Arbor, MI
Department of Psychology, University of Michigan, Ann Arbor, MI
AN  - 57204732. Language: English. Entry Date: 20110111. Revision Date: 20180530. Publication Type: Article
AU  - Zikmund-Fisher, Brian J.
AU  - Fagerlin, Angela
AU  - Ubel, Peter A.
DB  - CINAHL Complete
DO  - 10.1177/0272989X10364244
DP  - EBSCOhost
IS  - 6
KW  - Breast Neoplasms -- Drug Therapy
Survival
Human
Adult
Middle Age
Aged
Female
Surveys
Descriptive Statistics
P-Value
Chemotherapy, Cancer -- Evaluation
Odds Ratio
Hormone Therapy -- Evaluation
Vignettes
Random Assignment
Black Persons
Hispanic Americans
White Persons
Chi Square Test
T-Tests
Wilcoxon Rank Sum Test
Data Analysis, Statistical
Data Analysis Software
Logistic Regression
N1  - research; tables/charts. Journal Subset: Biomedical; Peer Reviewed; USA. NLM UID: 8109073.
PY  - 2010
SN  - 0272-989X
SP  - 661-671
ST  - A Demonstration of ‘‘Less Can Be More’’ in Risk Graphics
T2  - Medical Decision Making
TI  - A Demonstration of ‘‘Less Can Be More’’ in Risk Graphics
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=57204732&site=ehost-live&scope=site
VL  - 30
ID  - 1817
ER  - 

TY  - JOUR
AB  - Background African American women have the greatest breast cancer mortality and shortest survival rates of any racial or ethnic group. Increased adherence to general population dietary guidelines has been linked to improved breast cancer outcomes. Limited information exists on the dietary habits and level of adherence to general population dietary recommendations in African American breast cancer survivors (AABCS). Objective We explored differences in diet quality assessed via HEI and AHEI by demographic and anthropometric characteristics. Design A cross‐sectional analysis of the baseline interview including a food frequency questionnaire. Participants/setting Study participants were recruited and enrolled in the Moving Forward intervention study. Moving Forward was a randomized, community‐based, 6‐month weight management intervention for AABCS. Main outcome measures Adherence to population‐based dietary recommendations was assessed by the Healthy Eating Index‐2010 (HEI) and the Alternate Healthy Eating Index‐2010 (AHEI). Statistical analyses performed We calculated standard descriptive statistics for nutrient intakes, including total and components scores from HEI and AHEI. Linear regression analysis was conducted to determine the relationship between sociodemographic factors and dietary adherence. Results Participants had a mean age of 57 and were approximately seven years post‐initial breast cancer diagnosis. The mean HEI total score was 65.1 (range: 38.9‐93.9; max score 100) and mean AHEI total score was 56.8 (range: 25.00 ‐ 85.8; max score 110) indicating sub‐optimal diet quality. In the adjusted analysis, HEI and AHEI total scores were positively associated with education, income, moderate physical activity (HEI only) and negatively associated with waist‐hip ratio, and smoking status. Conclusion Generally, non‐smokers, who reported more moderate physical activity, more years of education, and smaller waist circumferences had better quality diets compared to other participants. Understanding deficiencies in the diet of AABCS will help to inform the development of effective lifestyle interventions for this at‐risk group.
AN  - CN-01712185
AU  - Springfield, S.
AU  - Odoms-Young, A.
AU  - Tussing-Humphreys, L.
AU  - Freels, S.
AU  - Fantuzzi, G.
AU  - Stolley, M.
DO  - 10.1158/1538-7755.DISP16-B52
IS  - 2
KW  - *African American
*breast cancer
*cancer survivor
*consensus development
*dietary compliance
*female
*intervention study
*obesity
Adult
Cancer diagnosis
Controlled clinical trial
Controlled study
Cross‐sectional study
Disease course
Education
Feeding behavior
Food frequency questionnaire
High risk population
Human
Interview
Lifestyle
Linear regression analysis
Middle aged
Physical activity
Randomized controlled trial
Smoking
Statistics
Waist circumference
Waist hip ratio
M3  - Journal: Conference Abstract
PY  - 2017
ST  - Describing adherence to dietary guidelines in overweight African American breast cancer survivors
T2  - Cancer epidemiology biomarkers and prevention
TI  - Describing adherence to dietary guidelines in overweight African American breast cancer survivors
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01712185/full
VL  - 26
ID  - 1481
ER  - 

TY  - JOUR
AB  - Background: Prostate cancer (PCa) incidence and survival rates continue to rise among African American men. An estimated 161,360 new cases were expected to occur in 2017. With increased survival rates, individuals are living longer, thus increasing the risk of experiencing adverse physical and psychosocial longterm effects of the cancer and its treatment. This study explores how minorities affected by PCa can become more informed and active in the decision-making process in the context of a support community. Methods: An online registry was created by researchers from the Center for Cancer Research & Therapeutic Development. The registry captures participants' demographics and clinical disease information throughout the PCa continuum. The registry was made available online at www.pcregistry.cau.edu, required registration and informed consent, and included mechanisms to maintain confidentiality. A voluntary response sample was utilized. Conceptual framework from Andersen's version of the Behavioral Model of Health Services Utilization and Wilson and Cleary's Model of Health-Related Quality of Life were used as the basis for the survey. Key consultants were engaged as community relations advisory board members. Comprehensive recruitment strategies were employed yielding a response rate of over 1000 registered survivors, surpassing the goal of 500. Conclusion: The PCa registry targets a specific group of survivors, exploring subsets that may be underserved or high-risk for distress. The registry is not linked to treatment location, thus respondents are more compelled to share their experience. A comprehensive database system provides ongoing information on health and issues facing ethnic PCa survivors and identifies gaps to determine areas of future research while developing a consensus on implications survivors may face.
AD  - Clark Atlanta University, Center for Cancer Research & Therapeutic Development, Atlanta, GA
Centers for Disease Control and Prevention, Atlanta, GA
AN  - 133111377. Language: English. Entry Date: 20181123. Revision Date: 20181124. Publication Type: Article
AU  - Davis, Kimberly E.
AU  - Richards, Antoine
AU  - Gooden, Reginald O.
DB  - CINAHL Complete
DP  - EBSCOhost
IS  - 12
KW  - Database Design
Prostatic Neoplasms -- Therapy
Cancer Survivors -- Psychosocial Factors
Self Report
Registries, Disease
Human
Education, Continuing (Credit)
Conceptual Framework
Cancer Screening
Medically Underserved
Minority Groups
Race Factors
Ethnic Groups
Survivorship -- Psychosocial Factors
Stress, Psychological
Oncologic Care
Questionnaires
Support, Psychosocial
Funding Source
N1  - CEU; research. Note: For CE see www.aonnonline.org.. Journal Subset: Nursing; Peer Reviewed; USA. Instrumentation: Health-Related Quality of Life (HRQOL). Grant Information: The Minority Men’s Health Initiative is supported by the National Institute on Minority Health and Health Disparities of the National Institutes of Health, award number U54MD008621-01..
PY  - 2018
SN  - 2166-0999
SP  - 526-530
ST  - Design and Development of a Prostate Cancer Survivor Self-Reported Registry
T2  - Journal of Oncology Navigation & Survivorship
TI  - Design and Development of a Prostate Cancer Survivor Self-Reported Registry
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=133111377&site=ehost-live&scope=site
VL  - 9
ID  - 1906
ER  - 

TY  - JOUR
AB  - Purpose: The purpose of this study was to enhance retention among African American men enrolled in a cancer screening trial. Design and Methods: A telephone-based, randomized trial design was used. The intervention group included 352 African American men aged 55+. Case managers contacted participants at least monthly and provided information and referral services to participants and their relatives. Results: The mean age of participants was 65.7 years. A total of 14,978 calls were made resulting in 780 referrals. The 10 most frequent referrals were for scheduling medical appointments, health information, insurance information, legal aid, transportation, cancer screening information, information technology/computer information, employment, housekeeping/chore services, and food programs. Conclusions: The case managers served as links between participants and community-based resources. The types of referrals made could be associated with the age-related needs of the participants. (C) 2004 Sage Publications.
AN  - WOS:000224424800004
AU  - Ford, M. E.
AU  - Randolph, V.
AU  - Hopkins-Johnson, L.
AU  - Eason, S. L.
AU  - Havstad, S.
AU  - Jankowski, M.
AU  - Swanson, G. M.
AU  - Johnson, C. C.
AU  - Vernon, S. W.
DA  - Nov
DO  - 10.1177/0898264304268148
IS  - 5
N1  - S
7
15448286
PY  - 2004
SN  - 0898-2643
SP  - 39S-57S
ST  - Design of a case management approach to enhance cancer screening trial retention among older African American men
T2  - Journal of Aging and Health
TI  - Design of a case management approach to enhance cancer screening trial retention among older African American men
VL  - 16
ID  - 2673
ER  - 

TY  - JOUR
AB  - Background: The current trend toward personalized medicine in cancer care relies heavily on cancer genetics research (CGR). However, members of diverse populations are significantly less likely than others to participate in CGR. Therefore, CGR results lack generalizability to these groups. This study tests strategies to recruit European American (EA) and African American (AA) women of varied income levels who are at risk of developing breast cancer (BC) to CGR. Design: Recruitment began in January 2015 and ended in May 2015. Study flyers are strategically placed in the BC screening clinics at a National Cancer Institute‐designated cancer center. Interested patients call the study coordinator for eligibility screening. To supplement low accrual rates using this method, in June 2015, the investigators began using the EPIC electronic health record to identify BC‐screened patients who potentially met study eligibility criteria. EPIC‐identified patients are randomly selected in groups of 50 and are sent a letter describing the study; if interested, they then call the study coordinator for eligibility screening. Results: The original recruitment strategy resulted in 11 participants (7 AA, 4 EA) while 21 participants (10 AA, 11 EA) were recruited using the EPIC approach. Discussion: The EPIC recruitment strategy resulted in a higher number of recruited participants than the study flyer strategy. Identifying effective approaches to recruit diverse populations to CGR is critically important. Study results show that using a targeted recruitment approach such as the pre‐screening approach in the EPIC strategy can bolster participation of diverse populations in CGR.
AN  - CN-01759316
AU  - Bauza, C.
AU  - Fordxs, M. E.
DO  - 10.1158/1538-7755.DISP16-B01
IS  - 2
KW  - *breast cancer
*cancer genetics
African American
Cancer screening
Clinical article
Controlled clinical trial
Controlled study
Electronic health record
European American
Female
Human
National health organization
Randomized controlled trial
M3  - Journal: Conference Abstract
PY  - 2017
ST  - Designing a feasible breast cancer genetics research study: lessons learned
T2  - Cancer epidemiology biomarkers and prevention
TI  - Designing a feasible breast cancer genetics research study: lessons learned
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01759316/full
VL  - 26
ID  - 1463
ER  - 

TY  - JOUR
AB  - OBJECTIVE: To describe the methodology of a 2-arm randomized controlled trial that compared the effects of a narrative and didactic version of the Witness CARES (Community Awareness, Reach, & Empowerment for Screening) intervention on colorectal cancer screening behavior among African Americans, as well as the cognitive and affective determinants of screening. METHODS: Witness CARES targeted cognitive and affective predictors of screening using a culturally competent, community-based, narrative or didactic communication approach. New and existing community partners were recruited in two New York sites. Group randomization allocated programs to the narrative or didactic arm. Five phases of data collection were conducted: baseline, post-intervention, three-month, six-month, and qualitative interviews. The primary outcome was screening behavior; secondary outcomes included cognitive and affective determinants of screening. RESULTS: A total of 183 programs were conducted for 2655 attendees. Of these attendees, 19.4% (N=516) across 158 programs (50% narrative; 50% didactic) were study-eligible and consented to participate. Half (45.6%) of the programs were delivered to new community partners and 34.8% were delivered at faith-based organizations. Mean age of the total sample was 64.7years and 75.4% were female. CONCLUSION: The planned number of programs was delivered, but the proportion of study-eligible attendees was lower than predicted. This community-based participatory research approach was largely successful in involving the community served in the development and implementation of the intervention and study.
AD  - Department of Community Health and Health Behavior, School of Public Health and Health Professions, University at Buffalo, SUNY, Buffalo, NY 14214, United States. Electronic address: erin.ellis@nih.gov.
Office of Cancer Health Disparities Research, Division of Cancer Prevention and Control, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, United States.
Department of Population Health Science and Policy, Center for Behavioral Oncology, Division of Cancer Prevention and Control, Icahn School of Medicine at Mount Sinai, One Gustave Levy Place, New York, NY 10029, United States.
Department of Community Health and Health Behavior, School of Public Health and Health Professions, University at Buffalo, SUNY, Buffalo, NY 14214, United States.
AN  - 29198730
AU  - Ellis, E. M.
AU  - Erwin, D. O.
AU  - Jandorf, L.
AU  - Saad-Harfouche, F.
AU  - Sriphanlop, P.
AU  - Clark, N.
AU  - Dauphin, C.
AU  - Johnson, D.
AU  - Klasko-Foster, L. B.
AU  - Martinez, C.
AU  - Sly, J.
AU  - White, D.
AU  - Winkel, G.
AU  - Kiviniemi, M. T.
C2  - PMC5803387
C6  - NIHMS926102
DA  - Feb
DO  - 10.1016/j.cct.2017.11.019
DP  - NLM
ET  - 2017/12/05
KW  - African Americans/*statistics & numerical data
Aged
Colorectal Neoplasms/*diagnosis/ethnology
Community-Based Participatory Research
Cultural Competency
Early Detection of Cancer/*statistics & numerical data
Female
Health Knowledge, Attitudes, Practice
Health Promotion/*organization & administration/*statistics & numerical data
Humans
Interviews as Topic
Male
Middle Aged
New York
*African American
*Colonoscopy
*Colorectal cancer screening
*Community-based intervention
*Randomized controlled trial
*Recruitment
LA  - eng
N1  - 1559-2030
Ellis, Erin M
Erwin, Deborah O
Jandorf, Lina
Saad-Harfouche, Frances
Sriphanlop, Pathu
Clark, Nikia
Dauphin, Cassandre
Johnson, Detric
Klasko-Foster, Lynne B
Martinez, Clarissa
Sly, Jamilia
White, Drusilla
Winkel, Gary
Kiviniemi, Marc T
P30 CA196521/CA/NCI NIH HHS/United States
R01 CA171935/CA/NCI NIH HHS/United States
Z99 CA999999/Intramural NIH HHS/United States
Clinical Trial Protocol
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Contemp Clin Trials. 2018 Feb;65:8-18. doi: 10.1016/j.cct.2017.11.019. Epub 2017 Dec 1.
PY  - 2018
SN  - 1551-7144 (Print)
1551-7144
SP  - 8-18
ST  - Designing a randomized controlled trial to evaluate a community-based narrative intervention for improving colorectal cancer screening for African Americans
T2  - Contemp Clin Trials
TI  - Designing a randomized controlled trial to evaluate a community-based narrative intervention for improving colorectal cancer screening for African Americans
VL  - 65
ID  - 141
ER  - 

TY  - JOUR
AB  - Prostate cancer continues to be a major health threat, especially among African American men. The Selenium and Vitamin E Cancer Prevention Trial (SELECT), which opened on July 25, 2001, was planned to study possible agents for the prevention of prostate cancer in a population of 32,400 men in the United States, including Puerto Rico, and Canada. SELECT is a phase III randomized, placebo-controlled trial of selenium (200 microg/day from L-selenomethionine) and/or vitamin E (400 IU/day of all rac alpha-tocopheryl acetate) supplementation for a minimum of 7 years (maximum of 12 years) in non-African American men at least 55 years of age and African American men at least 50 years of age. SELECT is a large, simple trial that conforms as closely as possible with community standards of care. This commentary discusses the design problems the SELECT investigators had to resolve in developing the trial, including the role of prostate cancer screening, the best forms and doses of the study agents, and estimation of the event (prostate cancer) rate of men on the placebo arm.
AD  - The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030-4009, USA. slippman@mdanderson.org
AN  - 15657339
AU  - Lippman, S. M.
AU  - Goodman, P. J.
AU  - Klein, E. A.
AU  - Parnes, H. L.
AU  - Thompson, I. M., Jr.
AU  - Kristal, A. R.
AU  - Santella, R. M.
AU  - Probstfield, J. L.
AU  - Moinpour, C. M.
AU  - Albanes, D.
AU  - Taylor, P. R.
AU  - Minasian, L. M.
AU  - Hoque, A.
AU  - Thomas, S. M.
AU  - Crowley, J. J.
AU  - Gaziano, J. M.
AU  - Stanford, J. L.
AU  - Cook, E. D.
AU  - Fleshner, N. E.
AU  - Lieber, M. M.
AU  - Walther, P. J.
AU  - Khuri, F. R.
AU  - Karp, D. D.
AU  - Schwartz, G. G.
AU  - Ford, L. G.
AU  - Coltman, C. A., Jr.
DA  - Jan 19
DO  - 10.1093/jnci/dji009
DP  - NLM
ET  - 2005/01/20
IS  - 2
KW  - African Americans
Aged
Anticarcinogenic Agents/*therapeutic use
Antineoplastic Combined Chemotherapy Protocols/therapeutic use
Canada
*Clinical Trials, Phase III as Topic
Humans
Male
Middle Aged
*Multicenter Studies as Topic
Patient Selection
Prostatic Neoplasms/*prevention & control
Puerto Rico
*Randomized Controlled Trials as Topic
Research Design
Selenium/*therapeutic use
United States
Vitamin E/*therapeutic use
LA  - eng
N1  - 1460-2105
Lippman, Scott M
Goodman, Phyllis J
Klein, Eric A
Parnes, Howard L
Thompson, Ian M Jr
Kristal, Alan R
Santella, Regina M
Probstfield, Jeffrey L
Moinpour, Carol M
Albanes, Demetrius
Taylor, Philip R
Minasian, Lori M
Hoque, Ashraful
Thomas, Sarah Moody
Crowley, John J
Gaziano, J Michael
Stanford, Janet L
Cook, Elise D
Fleshner, Neil E
Lieber, Michael M
Walther, Philip J
Khuri, Fadlo R
Karp, Daniel D
Schwartz, Gary G
Ford, Leslie G
Coltman, Charles A Jr
CA37429/CA/NCI NIH HHS/United States
Journal Article
Research Support, U.S. Gov't, P.H.S.
United States
J Natl Cancer Inst. 2005 Jan 19;97(2):94-102. doi: 10.1093/jnci/dji009.
PY  - 2005
SN  - 0027-8874
SP  - 94-102
ST  - Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT)
T2  - J Natl Cancer Inst
TI  - Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT)
VL  - 97
ID  - 609
ER  - 

TY  - JOUR
AB  - Background: The WISDOM Study (Women Informed to Screen Depending on Measures of risk) aims to examine the effectiveness of personalized breast cancer screening and to bring objective recommendations to the current mammography screening debate. The WISDOM Study is a 100,000 woman randomized trial with a preference‐tolerant design that will determine if risk‐based screening (RBS) vs. annual screening, is as safe, less morbid, enables prevention and is preferred by women. A pilot was conducted to test the logistics of online participation and examine the acceptance of the study design and approach. Methods: Women were recruited from the UCSF site of the Athena Breast Health Network, a clinical care‐research cohort of 110,000 women from the 5 University of California Medical Centers and Sanford Health. The pilot recruited women via email who were 40 ‐74 years of age with no history of breast cancer and a normal mammogram in the past year. Those interested visited the WISDOM Study website (wisdomstudy.org), signed up, elected randomization or self‐selection, provided electronic consent using DocuSign (eConsent), and completed genetic testing (RBS arm). The Breast Cancer Surveillance Consortium (BCSC) model (standard risk factors, ethnicity, and breast density) in addition to genetic testing (9 genes and 75 SNPs) was used to calculate breast cancer risks that informed the start and frequency of screening for women in the RBS arm. BCSC was also used in the annual screening arm but did not inform mammography screening recommendations. The pilot used a mixed method approach (using enrollment data, Exit Survey data, individual interviews and focus groups) to assess enrollment preferences, randomization acceptance and overall study workflow. Results: The online electronic enrollment process and patient engagement portal was successfully implemented. In total, 639 women were invited, 235 registered (34%), and 171 (27%) consented to the pilot. Of these, 74% (127) elected to be randomized, and 26% chose to self‐assign (66% chose annual screening (29)). Mean age was 56 years and the ethnic breakdown of the cohort was: 79% White, 10% Asian, 7% Latino, 3% Black, 1 % other. 92% of those in the risk‐based arm of the study completed genetic testing and were given results; only one genetic mutation was identified and occurred in CHEK2. Within the RBS arm (78), mammography recommendations were: 61% no further mammography until the age of 50, 22% biennial, 11% annual, and 6% every 6 month alternating MRI and mammogram. Exit Survey data illuminated confusion in study arm names (risk‐based vs. annual), randomization acceptance (74%), annual arm preference in the self‐selection group (66%), eConsent satisfaction (90%), enrollment process ease of use (88%), and website content, navigation and appearance satisfaction (66%). The pilot concluded in May 2016 to allow for refinements prior to the full trial. Conclusion: Our pilot demonstrates that the majority of women are willing to be randomized and participate in an online screening study to answer the important question on optimal breast cancer screening. The pilot study results will inform implementation of the 100,000 women WISDOM Study which launches in fall of 2016.
AN  - CN-01377831
AU  - Shimomura, A.
AU  - Shiino, S.
AU  - Kawauchi, J.
AU  - Takizawa, S.
AU  - Sakamoto, H.
AU  - Shimizu, C.
AU  - Takeshita, F.
AU  - Niida, S.
AU  - Kinoshita, T.
AU  - Tamura, K.
AU  - et al.
DO  - 10.1158/1538-7445.SABCS16-P4-07-04
IS  - 4
KW  - *breast cancer
*disease duration
*neoadjuvant chemotherapy
*prediction
*remission
Adult
Aged
Animal model
Breast density
California
Cancer risk
Cancer screening
Controlled clinical trial
Controlled study
Disease model
Ethnicity
E‐mail
Female
Gene mutation
Genetic screening
Genetic susceptibility
Hispanic
Human
Human tissue
Information processing
Interview
Major clinical study
Mammography
Middle aged
Nomenclature
Nuclear magnetic resonance imaging
Pilot study
Randomization
Randomized controlled trial
Risk factor
Satisfaction
Study design
University
Workflow
M3  - Journal: Conference Abstract
PY  - 2017
ST  - Detecting early breast cancer by the combination of five serum microRNAs and its possibility of prediction of pathological complete response in neoadjuvant chemotherapy
T2  - Cancer research
TI  - Detecting early breast cancer by the combination of five serum microRNAs and its possibility of prediction of pathological complete response in neoadjuvant chemotherapy
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01377831/full
VL  - 77
ID  - 1658
ER  - 

TY  - JOUR
AB  - Pilot screening clinics were conducted in two Los Angeles County health districts where cervical cancer incidence and mortality rates were high. Results are of interest because they provide information on planning and operating community-based clinics in low-income areas where there are women who are unlikely to seek or are ineligible for available health services.
AN  - 763008
AU  - Misczynski, M.
AU  - Stern, E.
DA  - Mar
DO  - 10.1097/00005650-197903000-00008
DP  - NLM
ET  - 1979/03/01
IS  - 3
KW  - Adult
African Americans
Breast Neoplasms/*prevention & control
California
Community Health Centers/organization & administration
Community Health Workers/education
*Community Participation
Female
Hispanic Americans
Humans
Mass Screening/*organization & administration/statistics & numerical data
Middle Aged
Patient Compliance
Pilot Projects
Poverty
Urban Population
Uterine Cervical Neoplasms/*prevention & control
LA  - eng
N1  - Misczynski, M
Stern, E
Journal Article
Research Support, U.S. Gov't, P.H.S.
United States
Med Care. 1979 Mar;17(3):304-13. doi: 10.1097/00005650-197903000-00008.
PY  - 1979
SN  - 0025-7079 (Print)
0025-7079
SP  - 304-13
ST  - Detection of cervical and breast cancer: a community-based pilot study
T2  - Med Care
TI  - Detection of cervical and breast cancer: a community-based pilot study
VL  - 17
ID  - 752
ER  - 

TY  - JOUR
AB  - Objectives To analyze prospectively whether prostate cancer (CaP) incidence differs between Japanese men with a prostate-specific antigen (PSA) level of 2.0 to 4.0 ng/mL and those with a PSA level of 4.1 to 10.0 ng/mL. Methods Men 79 years old or younger who were referred to our clinic were screened for CaP. Individuals with PSA levels of 2.0 ng/mL or greater were recommended for transrectal prostate biopsy. The prebiopsy clinical characteristics, cancer detection rate, and pathologic findings from the needle biopsy and prostatectomy specimen were compared between the low (2.0 to 4.0 ng/mL) and intermediate (4.1 to 10.0 ng/mL) PSA groups. Results Of 858 patients screened for CaP, 440 with benign findings on digital rectal examination met the criteria, and 274 (62.3%) underwent biopsy. Of those undergoing biopsy, 110 and 123 patients had a low or an intermediate PSA level, respectively. Men in the low PSA group had a higher free/total PSA ratio, smaller prostate volume, and lower PSA density compared with those in the intermediate PSA group. CaP was diagnosed in 26 (23.6%) of 110 in the low and 29 (23.6%) of 123 in the intermediate PSA group. No statistically significant difference was found between the two groups in the pathologic findings of needle biopsy, including Gleason score, number of cores per biopsy, percentage of positive cores, and cancer length in the positive cores. Conclusions No statistically significant difference was found in the incidence of CaP (23.6%) between men with low and intermediate PSA levels in a Japanese population. The diagnostic yield was comparable to that reported for both white and black men. © 2004 Elsevier Inc.
AD  - T. Kobayashi, Department of Urology, Hamamatsu Rosai Hospital, Shogen-cho 25, Hamamatsu, Shizuoka 430-8525, Japan
AU  - Kobayashi, T.
AU  - Nishizawa, K.
AU  - Ogura, K.
AU  - Mitsumori, K.
AU  - Ide, Y.
DB  - Embase
Medline
DO  - 10.1016/j.urology.2003.11.025
IS  - 4
KW  - prostate specific antigen
adult
aged
article
cancer diagnosis
cancer incidence
cancer localization
cancer screening
comparative study
concentration response
controlled study
disease marker
human
Japan
laboratory test
major clinical study
male
medical assessment
needle biopsy
patient selection
population research
priority journal
prostate biopsy
prostate cancer
relative density
scoring system
statistical significance
LA  - English
M3  - Article
N1  - L38479418
2004-04-29
PY  - 2004
SN  - 0090-4295
SP  - 727-731
ST  - Detection of prostate cancer in men with prostate-specific antigen levels of 2.0 to 4.0 ng/mL equivalent to that in men with 4.1 to 10.0 ng/mL in a Japanese population
T2  - Urology
TI  - Detection of prostate cancer in men with prostate-specific antigen levels of 2.0 to 4.0 ng/mL equivalent to that in men with 4.1 to 10.0 ng/mL in a Japanese population
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L38479418&from=export
http://dx.doi.org/10.1016/j.urology.2003.11.025
VL  - 63
ID  - 1284
ER  - 

TY  - JOUR
AB  - Objective: Early and accurate diagnosis of small metastatic brain tumors may affect outcomes and treatment strategies. For this reason, 3-dimensional (3D) thin-section imaging is preferred. However, with conventional contrast-enhanced (CE) 3D imaging, such as magnetization-prepared rapid gradient echo (MP-RAGE), many visually enhanced vessels may mimic small metastatic tumors, hindering tumor detection. CE black-blood single-slab 3D turbo-spin echo imaging (BB-ssTSE) was recently developed, which uses variable refocusing flip angles and flow-sensitizing gradient schemes, to enhance metastatic brain tumors while selectively suppressing blood vessels. The purpose of this work was to investigate the efficiency of the proposed CE BB-ssTSE in detecting small metastatic brain tumors as compared with conventional MP-RAGE. Materials and Methods: Numerical comparisons of MP-RAGE and BB-ssTSE were performed by simulation studies to investigate the signal/contrast behaviors of flowing blood and stationary CE tumors. For in vivo studies, we enrolled 35 patients (18 women; mean age, 58.1 years) with breast or lung cancer who underwent brain magnetic resonance imaging. After administering a double dose of contrast medium, whole-brain 2-dimensional T1-weighted imaging followed by high-resolution isotropic 3D BB-ssTSE and MP-RAGE was performed at 3.0 T. Two reviewers independently evaluated the presence of metastatic brain tumors using: (1) MP-RAGE; (2) BB-ssTSE; and (3) MP-RAGE + BB-ssTSE sequentially in 3 review sessions, 2 weeks apart. The lesions were classified by size into 2 groups: large (<5 mm) and small (<5 mm). Both reviewers marked all tumors detected at each session. Another reviewer combined the results of the 2 reviewers and compared the detection rates of metastatic brain tumors between BB-ssTSE and MP-RAGE by using follow-up imaging. Intraclass correlation coefficients between the 2 reviewers were measured. Results: Numerical simulations showed that the proposed BB-ssTSE effectively attenuated the signal intensity of flowing blood over the entire echo train, resulting in CE tumor-to-white matter contrast comparable with conventional MP-RAGE. The combined evaluation of MP-RAGE + BB-ssTSE showed 242 tumors in 28 patients. Of these, 153 lesions were <5 mm. MP-RAGE found 111 small metastatic brain tumors, BB-ssTSE found 150, and MP-RAGE + BB-ssTSE found 153. Significantly, more small tumors were detected by BB-ssTSE than MP-RAGE (P = 0.001, Wilcoxon signed-rank test). All large tumors were detected similarly by both MP-RAGE and BB-ssTSE. By combined results for MP-RAGE + BB-ssTSE, sensitivities for detection of small metastatic tumors were 72.5% for MP-RAGE and 98.0% for BB-ssTSE (P < 0.0001, McNemar test). Intraclass correlation coefficients between the 2 reviewers were 0.826 for MP-RAGE and 0.954 for BB-ssTSE. Conclusion: Compared with conventional MP-RAGE, the proposed CE BB-ssTSE imaging, which enhances tumors while selectively suppressing blood vessels, leads to significantly better detection of small metastatic brain tumors <5 mm. © 2012 by Lippincott Williams & Wilkins.
AD  - J. Kim, Department of Radiology, Research Institute of Radiological Science, Yonsei University, 250 Yonsei-ro, Seodaemun-gu, Seoul, 120-752, South Korea
AU  - Park, J.
AU  - Kim, J.
AU  - Yoo, E.
AU  - Lee, H.
AU  - Chang, J. H.
AU  - Kim, E. Y.
DB  - Embase
Medline
DO  - 10.1097/RLI.0b013e3182319704
IS  - 2
KW  - gadolinium pentetate meglumine
adult
aged
article
brain blood flow
brain metastasis
breast cancer
cancer diagnosis
clinical article
clinical trial
contrast enhanced black blood single slab three dimensional turbo spin echo imaging
contrast enhancement
diagnostic accuracy
female
follow up
human
image analysis
intermethod comparison
lung cancer
magnetization prepared rapid gradient echo
male
mathematical computing
nuclear magnetic resonance imaging
priority journal
small metastatic brain tumor
tumor localization
tumor volume
white matter
LA  - English
M3  - Article
N1  - L51725894
2011-11-24
2012-01-25
PY  - 2012
SN  - 0020-9996
1536-0210
SP  - 136-141
ST  - Detection of small metastatic brain tumors: Comparison of 3D contrast-enhanced whole-brain black-blood imaging and MP-RAGE imaging
T2  - Investigative Radiology
TI  - Detection of small metastatic brain tumors: Comparison of 3D contrast-enhanced whole-brain black-blood imaging and MP-RAGE imaging
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L51725894&from=export
http://dx.doi.org/10.1097/RLI.0b013e3182319704
VL  - 47
ID  - 1126
ER  - 

TY  - JOUR
AB  - This descriptive/cross-sectional study assessed determinants of prostate cancer screening in a sample of African American military servicemen who were age 45 years and older. Data were collected using the Edwards Prostate Perception Survey, a 52-item questionnaire that assessed knowledge, beliefs, self-efficacy, health-related practices, and demographic variables. Despite reporting high knowledge and positive belief about prostate cancer and screening, 43% of the respondents indicated they had never been screened with the prostate-specific antigen blood test, and 27% reported that health care providers had not recommended screening. Respondents were more likely to be screened if they had more knowledge of the prostate-specific antigen test, were retired, older, and when health care providers recommended it. The younger active duty servicemen in the 45 to 50 age group reported the lowest rates of screening.
AD  - Tripler Army Medical Center, Honolulu, HI 96859, USA
Tripler Army Medical Center, 1 Jarrett White Road, Honolulu, HI 96859
AN  - 106319415. Language: English. Entry Date: 20060818. Revision Date: 20200423. Publication Type: journal article
AU  - Joseph, H. J.
AU  - Joseph, Hyacinth J.
DB  - CINAHL Complete
DO  - 10.7205/milmed.171.5.430
DP  - EBSCOhost
IS  - 5
KW  - Black Persons
Cancer Screening
Military Personnel -- United States
Prostatic Neoplasms -- Prevention and Control
Coefficient Alpha
Cross Sectional Studies
Data Analysis Software
Demography
Descriptive Research
Hawaii
Middle Age
Questionnaires
Reliability
Research Question
Research Subject Recruitment
Scales
Summated Rating Scaling
Surveys
United States
Funding Source
Human
N1  - research; tables/charts. Journal Subset: Biomedical; Expert Peer Reviewed; Peer Reviewed; USA. Grant Information: Funded by the TriService Nursing Research Program (Grant NO3-017). NLM UID: 2984771R.
PMID: NLM16761895.
PY  - 2006
SN  - 0026-4075
SP  - 430-435
ST  - Determinants of prostate cancer screening in a sample of African American military servicemen
T2  - Military Medicine
TI  - Determinants of prostate cancer screening in a sample of African American military servicemen
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106319415&site=ehost-live&scope=site
VL  - 171
ID  - 1907
ER  - 

TY  - JOUR
AB  - Background: African Americans are often diagnosed with advanced stage cancer and experience higher mortality compared with whites in the United States. Contributing factors, like differences in access to medical care and the prevalence of comorbidities, do not entirely explain racial differences in outcomes. Methods: The Detroit Research on Cancer Survivors (ROCS) pilot study was conducted to investigate factors related to short- and long-term outcomes among patients with cancer. Participants completed web-based surveys, and mailed saliva specimens were collected for future genetic studies. Results: We recruited 1,000 participants with an overall response rate of 68%. Thirty-one percent completed the survey without any interviewer support and the remaining participated in an interviewer-administered survey. Seventy-four percent provided a saliva specimen and 64% consented for tumor tissue retrieval. African American survivors required more interviewer support (P < 0.001); however, their response rate (69.6%) was higher than non-Hispanic whites (65.4%). African Americans reported poorer overall cancer-related quality of life compared with non-Hispanic whites, measured by FACT-G score (P < 0.001), however, this relationship was reversed after controlling for socioeconomic factors, marital status, and the presence of comorbidities. Conclusions: In this pilot study, we demonstrated that a web-based survey supplemented with telephone interviews and mailed saliva kits are cost-effective methods to collect patient-reported data and DNA for large studies of cancer survivors with a high proportion of minority patients. The preliminary data collected reinforces differences by race in factors affecting cancer outcomes. Our efforts continue as we expand this unique cohort to include more than 5,000 African American cancer survivors. Impact: Formal investigation of factors influencing adverse outcomes among African American cancer survivors will be critical in closing the racial gap in morbidity and mortality.
AD  - J.L. Beebe-Dimmer, Population Studies and Disparities Research Program, Barbara Ann Karmanos Cancer Institute, Detroit, MI, United States
AU  - Beebe-Dimmer, J. L.
AU  - Albrecht, T. L.
AU  - Baird, T. E.
AU  - Ruterbusch, J. J.
AU  - Hastert, T.
AU  - Harper, F. W. K.
AU  - Simon, M. S.
AU  - Abrams, J.
AU  - Schwartz, K. L.
AU  - Schwartz, A. G.
DB  - Embase
Medline
DO  - 10.1158/1055-9965.EPI-18-0123
IS  - 4
KW  - adult
African American
aged
ancestry group
arthritis
article
body mass
breast cancer
cancer diagnosis
cancer localization
cancer patient
cancer registry
cancer screening
cancer staging
cancer survivor
cancer therapy
cerebrovascular accident
chronic obstructive lung disease
clinical outcome
clinical protocol
cohort analysis
colorectal cancer
comorbidity
congestive heart failure
cost effectiveness analysis
depression
diabetes mellitus
disease severity
family history
female
Functional Assessment of Cancer Therapy
Functional Assessment of Cancer Therapy General
health behavior
human
human cell
human tissue
hypercholesterolemia
hypertension
long term care
lung cancer
major clinical study
male
marriage
medical history
obesity
osteoporosis
patient-reported outcome
physical activity
pilot study
priority journal
prostate cancer
quality of life
race difference
refusal to participate
risk factor
saliva
socioeconomics
thyroid disease
underweight
LA  - English
M3  - Article
N1  - L2001776296
2019-04-10
2019-04-15
PY  - 2019
SN  - 1055-9965
SP  - 666-674
ST  - The Detroit research on cancer survivors (ROCS) pilot study: A focus on outcomes after cancer in a racially diverse patient population
T2  - Cancer Epidemiology Biomarkers and Prevention
TI  - The Detroit research on cancer survivors (ROCS) pilot study: A focus on outcomes after cancer in a racially diverse patient population
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L2001776296&from=export
http://dx.doi.org/10.1158/1055-9965.EPI-18-0123
VL  - 28
ID  - 851
ER  - 

TY  - JOUR
AB  - African Americans are disproportionately affected by diabetes and colorectal cancer. Although studies have shown the effectiveness of spiritually based health interventions delivered by community health workers to African Americans, few have described the development of the capacity-building component. This article describes this process. The development of the Healthy Congregations Healthy Communities Program (HCHC) was guided through a community-based participatory research lens and included: 1) establishment of a community coalition; 2) identification by coalition members of churches as the best venues for health promotion strategies among African Americans; 3) recruitment of churches; 4) development of a training manual; 5) recruitment and training of congregational health leaden (CHLs); and 6) "Passing of the torch" from the coalition to the CHLs who implemented the intervention in their congregations. We trained 35 CHLs to promote awareness about diabetes and colorectal cancer using a culturally relevant, spiritually based curriculum. Pre- and post-test paired t-tests showed significant increases in CHLs' knowledge of wellness (P<.001), colorectal cancer (P<.002)., nutrition (P<.004), and lifestyle changes (P<.005). The community-academic partnership was successful in developing a culturally relevant, spiritually based capacity-building program for African American CHLs to implement health promotion strategies in their congregations and communities.
AN  - WOS:000438472200003
AU  - Morales-Aleman, M. M.
AU  - Moore, A.
AU  - Scarinci, I. C.
DA  - Win
DO  - 10.18865/ed.28.1.11
IS  - 1
N1  - 29467561
PY  - 2018
SN  - 1049-510X
SP  - 11-18
ST  - Develoment of a Participatory Capacity-Building Program for Congregational Health Leaders in African American Churches in the Us South
T2  - Ethnicity & Disease
TI  - Develoment of a Participatory Capacity-Building Program for Congregational Health Leaders in African American Churches in the Us South
VL  - 28
ID  - 2838
ER  - 

TY  - JOUR
AB  - Community-based participatory research (CBPR) is an important strategy for reducing racial disparities in health outcomes. Academic-community partnerships are central to CBPR; however, there are few examples of how to develop these partnerships for prostate cancer research. This report describes the methods used to develop an academic-community partnership between investigators at the University of Pennsylvania and members of the Philadelphia chapter of the National Black Leadership Initiative on Cancer for CBPR on quality of life following prostate cancer diagnosis. Our experiences demonstrate that a significant investment of time is needed to identify a community partner for prostate cancer research and develop an effective partnership.
AD  - Department of Psychiatry and Abramson Cancer Center, University of Pynnsylvania, Philadelphia, PA 19104, USA. chanita@mail.med.upenn.edu
AN  - 17020523
AU  - Hughes Halbert, C.
AU  - Weathers, B.
AU  - Delmoor, E.
DA  - Summer
DO  - 10.1207/s15430154jce2102_13
DP  - NLM
ET  - 2006/10/06
IS  - 2
KW  - Academic Medical Centers/*organization & administration
*African Americans
Biomedical Research/*organization & administration
Community Health Planning/organization & administration
Community Participation
Health Education/organization & administration
Health Services Research/methods/*organization & administration
Humans
*Interinstitutional Relations
Male
Patient Selection
Philadelphia
Program Development
*Prostatic Neoplasms
LA  - eng
N1  - Hughes Halbert, Chanita
Weathers, Benita
Delmoor, Ernestine
P50-CA105641-010004/CA/NCI NIH HHS/United States
R24MD001594/MD/NIMHD NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, P.H.S.
England
J Cancer Educ. 2006 Summer;21(2):99-103. doi: 10.1207/s15430154jce2102_13.
PY  - 2006
SN  - 0885-8195 (Print)
0885-8195
SP  - 99-103
ST  - Developing an academic-community partnership for research in prostate cancer
T2  - J Cancer Educ
TI  - Developing an academic-community partnership for research in prostate cancer
VL  - 21
ID  - 546
ER  - 

TY  - JOUR
AB  - BACKGROUND: In developing cancer diagnostic studies, there is a particular need for the population of patients with symptoms of possible oncological significance who consult the GP in 'real life' to be comparable with the group of individuals with symptoms constructed as part of a research project. OBJECTIVES: The objective of this study was to seek to assess whether a community-based symptom survey can be harnessed in order to produce clinically relevant and reproducible populations within which studies of more detailed indicants could be undertaken. METHOD: A total of 3629 patients registered with a general practice at Winterton, UK, were sent a questionnaire enquiring about 10 symptoms of possible oncological significance together with their consultation intention in relation to these symptoms. Up to 1 month later, an identical questionnaire was applied to all patients reporting at least one symptom, and more detailed information was obtained by research nurses on each symptom. RESULTS: The overall response rate was 64.4%, and 850 patients reported one or more symptoms. For the majority of symptom reports, there was moderate to substantial agreement between the two applications of the questionnaire. The question on blood in the motions/toilet pan or on the toilet paper demonstrated almost perfect agreement. Slight agreement was found for abdominal pain for longer than 4 weeks and for black/tarry motions. In relation to the reliability of the patient consultation intention, there was substantial/moderate agreement for actions related to the majority of symptoms. For all symptoms, there was also a greater level of agreement for past activity than future intent. CONCLUSION: The results of the study provide some support for a community survey as a mechanism to develop 'clinically relevant' populations for the iatrotropic symptoms rectal bleeding or indigestion/heartburn within which studies of more detailed indicants could be undertaken. There is also consistency with the work of others in relation to the numbers and characteristics of patients within the 'clinically relevant' population.
AD  - The Surgery, Manlake Avenue, Winterton, Scunthorpe DN15 9TA, UK. N.Summerton@hull.ac.uk
AN  - 12738705
AU  - Summerton, N.
AU  - Mann, S.
AU  - Sutton, J.
AU  - Rigby, A.
AU  - Theakston, A.
AU  - Clark, J.
AU  - Williams-Hardy, H.
AU  - Summerton, A.
DA  - Jun
DO  - 10.1093/fampra/cmg317
DP  - NLM
ET  - 2003/05/10
IS  - 3
KW  - Aged
England/epidemiology
Epidemiologic Methods
*Epidemiologic Research Design
Family Practice/*statistics & numerical data
Humans
Middle Aged
Neoplasms/*diagnosis/epidemiology
*Patient Selection
Population Surveillance/*methods
Prevalence
Reproducibility of Results
Research/standards
Risk Factors
LA  - eng
N1  - Summerton, N
Mann, S
Sutton, J
Rigby, A
Theakston, A
Clark, J
Williams-Hardy, H
Summerton, A
Journal Article
England
Fam Pract. 2003 Jun;20(3):340-6. doi: 10.1093/fampra/cmg317.
PY  - 2003
SN  - 0263-2136 (Print)
0263-2136
SP  - 340-6
ST  - Developing clinically relevant and reproducible symptom-defined populations for cancer diagnostic research in general practice using a community survey
T2  - Fam Pract
TI  - Developing clinically relevant and reproducible symptom-defined populations for cancer diagnostic research in general practice using a community survey
VL  - 20
ID  - 649
ER  - 

TY  - JOUR
AB  - Prostate cancer (PrCA) is the most commonly diagnosed non-skin cancer among men. PrCA mortality in African-American (AA) men in South Carolina is ~50% higher than for AAs in the U.S as a whole. AA men also have low rates of participation in cancer research. This paper describes partnership development and recruitment efforts of a Community-Academic-Clinical research team for a PrCA education intervention with AA men and women that was designed to address the discordance between high rates of PrCA mortality and limited participation in cancer research. Guided by Vesey's framework on recruitment and retention of minority groups in research, recruitment strategies were selected and implemented following multiple brainstorming sessions with partners having established community relationships. Based on findings from these sessions culturally appropriate strategies are recommended for recruiting AA men and women for PrCA education research. Community-based research recruitment challenges and lessons learned are presented.
AD  - Arnold School of Public Health, Department of Health Promotion, Education, and Behavior, University of South Carolina, Columbia, SC 29208, USA. dbfriedman@sc.du
AN  - 22528633
AU  - Friedman, D. B.
AU  - Johnson, K. M.
AU  - Owens, O. L.
AU  - Thomas, T. L.
AU  - Dawkins, D. S.
AU  - Gansauer, L.
AU  - Bartelt, S.
AU  - Waddell, N. M.
AU  - Talley, P. J.
AU  - Bearden, J. D., 3rd
AU  - Hébert, J. R.
C2  - PMC3352970
C6  - NIHMS368832
DA  - Jun
DO  - 10.1007/s13187-012-0353-0
DP  - NLM
ET  - 2012/04/25
IS  - 2
KW  - *Academic Medical Centers
African Americans/*psychology
*Decision Making
Female
Focus Groups
Health Education/*organization & administration
Health Knowledge, Attitudes, Practice
Humans
Male
Middle Aged
*Patient Selection
Pilot Projects
Prostatic Neoplasms/*diagnosis/prevention & control
*Residence Characteristics
South Carolina
LA  - eng
N1  - 1543-0154
Friedman, Daniela B
Johnson, Kim M
Owens, Otis L
Thomas, Tracey L
Dawkins, Delisa S
Gansauer, Lucy
Bartelt, Sharon
Waddell, Nancy M
Talley, Pastor J
Bearden, James D 3rd
Hébert, James R
K05 CA136975-03/CA/NCI NIH HHS/United States
U54 CA153461-01/CA/NCI NIH HHS/United States
K05 CA136975/CA/NCI NIH HHS/United States
U54 CA153461-02/CA/NCI NIH HHS/United States
U54 CA153461/CA/NCI NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
J Cancer Educ. 2012 Jun;27(2):243-9. doi: 10.1007/s13187-012-0353-0.
PY  - 2012
SN  - 0885-8195 (Print)
0885-8195
SP  - 243-9
ST  - Developing partnerships and recruiting dyads for a prostate cancer informed decision making program: lessons learned from a community-academic-clinical team
T2  - J Cancer Educ
TI  - Developing partnerships and recruiting dyads for a prostate cancer informed decision making program: lessons learned from a community-academic-clinical team
VL  - 27
ID  - 368
ER  - 

TY  - JOUR
AB  - Background: Navigators have the potential to help overcome barriers that interfere with cancer treatment adherence, but their widespread use is economically challenging, especially in rural and low-resource communities. A centrally located interdisciplinary navigator team using technology to extend the navigators' reach holds promise to efficiently improve treatment outcomes. Objectives: To develop and evaluate a centralized "virtual" navigation program to support breast cancer patients through their adjuvant treatment. Methods: The technology-enhanced navigator program was developed in collaboration with patient advisors and evaluated in a randomized clinical trial comparing use of the web-based navigation application with and without a navigator team (N = 98). A usability assessment was conducted at 3 months after enrollment. Comparisons by study arm were conducted using independent samples t tests for continuous measures and chi-square tests for proportions. Results: Of the participants, 67% were minorities, mostly African American. Slightly more of the group randomized to the navigator team reported that the application was easy to use (77.6% vs 71.4%) and with higher confidence (71.4% vs 67.3%), but these differences were not statistically significant. Discussion: A web-based interactive navigation program was developed in collaboration with breast cancer patients. Evaluation of the program demonstrated ease of use even among those with no prior computer experience. Conclusions: A "virtual" interdisciplinary navigator program was confidently and easily used by low-income breast cancer patients who had a wide range in age, education levels, and prior computer experience.
AD  - Prevention and Research Center, Mercy Medical Center, Baltimore, MD
Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD
Johns Hopkins University School of Nursing, Baltimore, MD
Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, MD
Center for Cancer Prevention and Control, Maryland Department of Health and Mental Hygiene, Baltimore, MD
Advancing Synergy, LLC, Baltimore, MD
AN  - 115259997. Language: English. Entry Date: 20180412. Revision Date: 20180412. Publication Type: Article
AU  - Helzlsouer, Kathy J.
AU  - Appling, Susan E.
AU  - Scarvalone, Susan
AU  - Manocheh, Shannon
AU  - MacDonald, Ryan
AU  - Gallicchio, Lisa
AU  - Henninger, Dawn
AU  - Varanasi, Arti P.
DB  - CINAHL Complete
DP  - EBSCOhost
IS  - 4
KW  - Breast Neoplasms
Program Development
Cancer Patients
Patient Navigation
Multidisciplinary Care Team
Socioeconomic Factors
Program Evaluation
Internet
Human
Randomized Controlled Trials
Random Assignment
Patient Compliance
Female
Adult
Middle Age
T-Tests
Chi Square Test
N1  - pictorial; research; tables/charts; randomized controlled trial. Journal Subset: Nursing; Peer Reviewed; USA. Special Interest: Oncologic Care; Women's Health.
PY  - 2016
SN  - 2166-0999
SP  - 10-18
ST  - Development and Evaluation of a Technology-Enhanced Interdisciplinary Navigation Program for Low-Income Breast Cancer Patients
T2  - Journal of Oncology Navigation & Survivorship
TI  - Development and Evaluation of a Technology-Enhanced Interdisciplinary Navigation Program for Low-Income Breast Cancer Patients
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=115259997&site=ehost-live&scope=site
VL  - 7
ID  - 1909
ER  - 

TY  - JOUR
AB  - Underserved minority communities have few resources for addressing comorbidity risk reduction among long-term cancer survivors. To address this community need, we developed and piloted the Bronx Oncology Living Daily (BOLD) Healthy Living program, the first known diabetes prevention and control program to target cancer survivors and co-survivors in Bronx County, NY. The program aimed to facilitate lifestyle change and improve health-related quality of life (HRQoL) through weekly group nutrition education (60-90 min) and exercise (60 min) classes. We examined baseline characteristics of participants using simple descriptive statistics and evaluated program implementation and impact using the Reach, Efficacy, Adoption, Implementation and Maintenance (RE-AIM) framework. The curriculum, which drew from the social-ecological framework and motivational and cognitive behavioral strategies, consisted of 12 culturally and medically tailored modules with options for implementation as a 12- or 4-week program. Seven programs (four 12 weeks and three 4 weeks in length, respectively) were implemented at five community site locations. Sixty-six cancer survivors and 17 cancer co-survivors (mean age 60.5 +/- 10.2 years) enrolled in one of the programs. Most participants were female (95.2 %) minority (55.4 % black, 26.5 % Hispanic/Latino) breast cancer survivors (75.7 %). Median program attendance was 62.5 % and did not significantly differ by program length; however, 67.3 % of participants achieved a parts per thousand yen60 % attendance among the 12-week programs, compared to 41.9 % among the 4-week programs, and this difference was statistically significant (p = 0.02). Overall, participants reported significant pre/post improvements in perceived health as good/excellent (66.0 to 75.5 %; p = 0.001) and borderline significant decreases in perceived pain as moderate/severe (45.5 to 38.2 %; p = 0.05). More than 90 % of participants reported that the program helped them to achieve their short-term goals, motivated them to engage in healthier behaviors, and felt that the nutrition and exercise classes were relevant to their needs. These results indicate that a short-term lifestyle intervention program for adult cancer survivors was acceptable in our community and motivated cancer survivors to improve their HRQoL. The curriculum can be used as a tool to facilitate development of similar programs in the future.
AN  - WOS:000360918700022
AU  - Conlon, B. A.
AU  - Kahan, M.
AU  - Martinez, M.
AU  - Isaac, K.
AU  - Rossi, A.
AU  - Skyhart, R.
AU  - Wylie-Rosett, J.
AU  - Moadel-Robblee, A.
DA  - Sep
DO  - 10.1007/s13187-014-0750-7
IS  - 3
N1  - 25394834
PY  - 2015
SN  - 0885-8195
SP  - 535-545
ST  - Development and Evaluation of the Curriculum for BOLD (Bronx Oncology Living Daily) Healthy Living: a Diabetes Prevention and Control Program for Underserved Cancer Survivors
T2  - Journal of Cancer Education
TI  - Development and Evaluation of the Curriculum for BOLD (Bronx Oncology Living Daily) Healthy Living: a Diabetes Prevention and Control Program for Underserved Cancer Survivors
VL  - 30
ID  - 2968
ER  - 

TY  - JOUR
AB  - Background: For selected locally advanced prostate cancer (PCa) patients, radical prostatectomy (RP) is one of the first-line treatments. We aimed to develop a preoperative nomogram to identify what kinds of patients can get the most survival benefits after RP. Methods: We conducted analyses with data from the Surveillance, Epidemiology, and End Results (SEER) database. Covariates used for analyses included age at diagnosis, marital status, race, American Joint Committee on Cancer (AJCC) 7th TNM stage, Prostate specific antigen, Gleason biopsy score (GS), percent of positive cores. We estimated the cumulative incidence function for cause-specific death. The Fine and Gray's proportional subdistribution hazard approach was used to perform multivariable competing risk analyses and reveal prognostic factors. A nomogram was built by these factors (including GS, percent of positive cores and N stage) and validated by concordance index and calibration curves. Risk stratification was established based on the nomogram. Results: We studied 14,185 patients. N stage, GS, and percent of positive cores were the independent prognostic factors used to construct the nomogram. For validating, in the training cohort, the C-index was 0.779 (95% CI 0.736-0.822), and in the validation cohort, the C-index was 0.773 (95% CI 0.710-0.836). Calibration curves showed that the predicted survival and actual survival were very close. The nomogram performed better over the AJCC staging system (C-index 0.779 versus 0.764 for training cohort, and 0.773 versus 0.744 for validation cohort). The new stratification of risk groups based on the nomogram also showed better discrimination than the AJCC staging system. Conclusions: The preoperative nomogram can provide favorable prognosis stratification ability to help clinicians identify patients who are suitable for surgery.
AD  - X. Ma, Department of Biotherapy, West China Hospital, State Key Laboratory of Biotherapy, Sichuan University, Chengdu, China
AU  - Zhou, X.
AU  - Ning, Q.
AU  - Jin, K.
AU  - Zhang, T.
AU  - Ma, X.
DB  - Embase
Medline
DO  - 10.1186/s12885-020-6565-5
IS  - 1
KW  - adult
age
aged
article
Black person
cancer prognosis
cancer staging
cancer survival
Caucasian
cause of death
Gleason score
human
incidence
intermethod comparison
major clinical study
male
marriage
middle aged
nomogram
patient selection
prediction
preoperative evaluation
proportional hazards model
prostate biopsy
prostate cancer
prostatectomy
race difference
risk assessment
LA  - English
M3  - Article
N1  - L630939804
2020-02-25
2020-02-27
PY  - 2020
SN  - 1471-2407
ST  - Development and validation of a preoperative nomogram for predicting survival of patients with locally advanced prostate cancer after radical prostatectomy
T2  - BMC Cancer
TI  - Development and validation of a preoperative nomogram for predicting survival of patients with locally advanced prostate cancer after radical prostatectomy
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L630939804&from=export
http://dx.doi.org/10.1186/s12885-020-6565-5
VL  - 20
ID  - 815
ER  - 

TY  - JOUR
AB  - Since prostate cancer incidence, prevalence and mortality are still highest among Black men in the United States, it is important to effectively address the factors that contribute to prostate cancer disparities in this at-risk population as well as their low participation in biomedical research/clinical trials. An effective communication strategy that can be used to disseminate information with high public health impact to Black men is one way to combat prostate cancer disparities. The objective of this study was to develop a Minority Prostate Cancer (MiCaP) research communication strategy using focus group methodology and expert in-depth interviews. The communication strategy statement developed in this study provides a guide for message concepts and materials for Black men, including communication content, source, channel, and location. Specifically, it provides recommendations on how to deliver information, how to choose the language and relevant images, how to gain attention, who is preferred to deliver messages, and other ways to engage Black men in health communication strategies. The communication strategy statement was used to develop the MiCaP Research Digest, a research communication program that is currently being tested in Orange County, Duval County, Leon County, Gadsden County, and the Tampa Bay area of Florida.
AN  - WOS:000546274400001
AU  - Odedina, F. T.
AU  - Walsh-Childers, K.
AU  - Young, M. E.
AU  - Kaninjing, E.
AU  - Krieger, J. L.
AU  - Pereira, D.
AU  - Dagne, G.
AU  - Askins, N.
AU  - Fathi, P.
DO  - 10.1007/s13187-020-01815-0
N1  - 32638289
SN  - 0885-8195
ST  - Development of a Minority Prostate Cancer Research Digest: Communication Strategy Statement for Black Men
T2  - Journal of Cancer Education
TI  - Development of a Minority Prostate Cancer Research Digest: Communication Strategy Statement for Black Men
ID  - 2773
ER  - 

TY  - JOUR
AB  - Despite the promise of clinical trials for improving cancer care, less than 5% of all cancer patients participate. Racial/ethnic minorities continue to be underrepresented in cancer clinical trials (CCTs). To address this gap, we developed a plain language, web-based decision support tool (CHOICES DST) in English and Spanish to support decision-making about CCTs among Blacks and Hispanics. In phase 1 (information collection), we conducted qualitative interviews with 45 cancer patients, completed a thorough literature review, and reviewed results from a telephone survey of 1100 cancer patients. In phase 2 (content generation), we created the first iteration of the CHOICES DST. In phase 3 (usability testing), we gathered user experience and acceptability data from a small sample of cancer survivors (n = 9). The Knowledge, Empowerment, and Values Clarification (KEV) model of decision-making was developed based on data from phase 1. The KEV model and other phase 1 data allowed us to create the CHOICES DST platform. Usability testing of the CHOICES DST showed highly favorable responses from users, satisfaction with content, ease of navigation, and a desire to use the tool. Qualitative results identified addressable points that would benefit from content and navigation-related alterations. The final version of the CHOICES DST was well received and understood by Black and Hispanic participants, and adheres to the mandates for plain language communication. This research provides preliminary data that CHOICES DST holds promise for improving knowledge of CCTs and potentially improving informed decision-making about participation in trials.
AN  - WOS:000534960600005
AU  - Langford, A. T.
AU  - Hawley, S. T.
AU  - Stableford, S.
AU  - Studts, J. L.
AU  - Byrne, M. M.
DA  - Jun
DO  - 10.1007/s13187-019-1482-5
IS  - 3
N1  - 30739270
PY  - 2020
SN  - 0885-8195
SP  - 454-461
ST  - Development of a Plain Language Decision Support Tool for Cancer Clinical Trials: Blending Health Literacy, Academic Research, and Minority Patient Perspectives
T2  - Journal of Cancer Education
TI  - Development of a Plain Language Decision Support Tool for Cancer Clinical Trials: Blending Health Literacy, Academic Research, and Minority Patient Perspectives
VL  - 35
ID  - 2777
ER  - 

TY  - JOUR
AB  - Racial disparities have been found in the use of chemotherapy as cancer treatment. These disparities may be, in part, due to well-documented differences in the quality of communication during clinical interactions with oncologists and Black versus White patients. In this study using a community-based participatory research approach, academic researchers, community members, and oncologists formed a partnership to develop a communication intervention to address racial disparities in cancer care. Partners developed a question prompt list (QPL), a simple tool that can be used to improve communication, and thus treatment, during clinical interactions in which oncologists and Black patients discuss chemotherapy. Partners endorsed the use of a QPL, provided specific suggestions for content and format, conducted and analyzed qualitative interviews with Black patients receiving chemotherapy, and approved the final version. The feasibility and effectiveness of the QPL that resulted from this research process are currently under evaluation in a separate study.
AD  - Department of Oncology, Wayne State University/Karmanos Cancer Institute, 4100 John R, MM03CB, Detroit, 48201, MI, USA. egglys@karmanos.org
AN  - 23440665
AU  - Eggly, S.
AU  - Tkatch, R.
AU  - Penner, L. A.
AU  - Mabunda, L.
AU  - Hudson, J.
AU  - Chapman, R.
AU  - Griggs, J. J.
AU  - Brown, R.
AU  - Albrecht, T.
C2  - PMC3665702
C6  - NIHMS449638
DA  - Jun
DO  - 10.1007/s13187-013-0456-2
DP  - NLM
ET  - 2013/02/27
IS  - 2
KW  - Adult
African Americans/*psychology
Aged
Breast Neoplasms/drug therapy/ethnology/psychology
Chemotherapy, Adjuvant
Colonic Neoplasms/drug therapy/ethnology/psychology
*Communication
Community-Based Participatory Research
Female
Healthcare Disparities/*ethnology
Humans
Interview, Psychological
Male
Middle Aged
Neoadjuvant Therapy
Neoplasms/*drug therapy/*ethnology/psychology
*Patient Education as Topic
Patient Participation
Patient Satisfaction
*Physician-Patient Relations
Rectal Neoplasms/drug therapy/ethnology/psychology
*Surveys and Questionnaires
LA  - eng
N1  - 1543-0154
Eggly, Susan
Tkatch, Rifky
Penner, Louis A
Mabunda, Lorna
Hudson, Janella
Chapman, Robert
Griggs, Jennifer J
Brown, Richard
Albrecht, Terrance
U54 CA 153606/CA/NCI NIH HHS/United States
P30CA22453/CA/NCI NIH HHS/United States
U54 CA153606/CA/NCI NIH HHS/United States
P30 CA022453/CA/NCI NIH HHS/United States
P30 AG015281/AG/NIA NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
J Cancer Educ. 2013 Jun;28(2):282-9. doi: 10.1007/s13187-013-0456-2.
PY  - 2013
SN  - 0885-8195 (Print)
0885-8195
SP  - 282-9
ST  - Development of a question prompt list as a communication intervention to reduce racial disparities in cancer treatment
T2  - J Cancer Educ
TI  - Development of a question prompt list as a communication intervention to reduce racial disparities in cancer treatment
VL  - 28
ID  - 337
ER  - 

TY  - JOUR
AB  - African American women have a lower rate of regular mammography screening, resulting in higher incidence of advanced-stage breast cancer at diagnosis and a lower 5-year survival rate as compared with white women. Researchers have demonstrated that several health beliefs relate to mammography screening in African American women, but little attention has been paid to the importance of religiousness. Although some authors have attempted to determine a link between religiousness and health, we lack a valid and reliable instrument to measure religiousness that can be found in the context of health behaviors. The purpose of this article is to describe the development and psychometric testing of the Wagle Health-Specific Religiousness (WHSR) scale, an instrument used to measure religious beliefs and the influence of those beliefs on mammography screening for African American women. A sample of 344 low-income African American women who were nonadherent to mammography at accrual participating in a randomized trial completed the WHSR. Data from this trial were used to determine the validity and reliability of the WHSR. The 19-item WHSR scale had a Cronbach alpha of. 94. Construct validity was supported via factor analysis and analysis of theoretical relationships. Although further testing is warranted, this analysis indicates that the concept of religiousness is an important component of mammography behavior in African American women.
AD  - Department of Veterans Affairs, Illiana Health Care System, 1900 East Main St, Danville, IL 61832, USA. ann.wagle@va.gov
AN  - 19661792
AU  - Wagle, A. M.
AU  - Champion, V. L.
AU  - Russell, K. M.
AU  - Rawl, S. M.
DA  - Sep-Oct
DO  - 10.1097/NCC.0b013e3181aaf0dd
DP  - NLM
ET  - 2009/08/08
IS  - 5
KW  - Adult
African Americans/*statistics & numerical data
Aged
Breast Neoplasms/*diagnosis
Female
*Health Knowledge, Attitudes, Practice
Humans
Linear Models
Mammography/*statistics & numerical data
*Mass Screening
Middle Aged
Patient Acceptance of Health Care/*statistics & numerical data
Poverty
*Program Development
Psychometrics
*Religion
Reproducibility of Results
Socioeconomic Factors
United States
LA  - eng
N1  - 1538-9804
Wagle, Ann M
Champion, Victoria L
Russell, Kathleen M
Rawl, Susan M
Journal Article
Validation Study
United States
Cancer Nurs. 2009 Sep-Oct;32(5):418-25. doi: 10.1097/NCC.0b013e3181aaf0dd.
PY  - 2009
SN  - 0162-220x
SP  - 418-25
ST  - Development of Wagle Health-Specific Religiousness scale
T2  - Cancer Nurs
TI  - Development of Wagle Health-Specific Religiousness scale
VL  - 32
ID  - 451
ER  - 

TY  - JOUR
AB  - PURPOSE: Cancer of the prostate (CaP) is the leading cancer among men in sub-Saharan Africa (SSA). A substantial proportion of these men with CaP are diagnosed at late (usually incurable) stages, yet little is known about the etiology of CaP in SSA. METHODS: We established the Men of African Descent and Carcinoma of the Prostate Network, which includes seven SSA centers partnering with five US centers to study the genetics and epidemiology of CaP in SSA. We developed common data elements and instruments, regulatory infrastructure, and biosample collection, processing, and shipping protocols. We tested this infrastructure by collecting epidemiologic, medical record, and genomic data from a total of 311 patients with CaP and 218 matched controls recruited at the seven SSA centers. We extracted genomic DNA from whole blood, buffy coat, or buccal swabs from 265 participants and shipped it to the Center for Inherited Disease Research (Baltimore, MD) and the Centre for Proteomics and Genomics Research (Cape Town, South Africa), where genotypes were generated using the UK Biobank Axiom Array. RESULTS: We used common instruments for data collection and entered data into the shared database. Double-entered data from pilot participants showed a 95% to 98% concordance rate, suggesting that data can be collected, entered, and stored with a high degree of accuracy. Genotypes were obtained from 95% of tested DNA samples (100% from blood-derived DNA samples) with high concordance across laboratories. CONCLUSION: We provide approaches that can produce high-quality epidemiologic and genomic data in multicenter studies of cancer in SSA.
AD  - Caroline Andrews, Brian Fortier, Amy Hayward, Ruth Lederman, and Timothy R. Rebbeck; Dana-Farber Cancer Institute; Alex Orfanos and Yuri Quintana, Beth Israel Deaconess Medical Center; Timothy R. Rebbeck, Harvard T.H. Chan School of Public Health, Boston, MA; Lindsay Petersen, Jo McBride, Desiree C. Petersen, Olabode Ajayi, Paidamoyo Kachambwa, Moleboheng Seutloali, Aubrey Shoko, Mamokhosana Mokhosi, and Reinhard Hiller, Centre for Proteomic and Genomic Research; Pedro Fernandez and Hayley Irusen, Stellenbosch University and Tygerberg Hospital, Cape Town; Wenlong C. Chen and Elvira Singh, National Cancer Registry, National Health Laboratory Service; Wenlong C. Chen, Elvira Singh, Maureen Joffe, Audrey Pentz, and Cassandra Claire Soo, University of Witwatersrand, Johannesburg, South Africa; Marcia Adams, Chrissie Ongaco, Elizabeth Pugh, Jane Romm, and Tameka Shelford, Center for Inherited Disease Research, Baltimore; Michael B. Cook, National Cancer Institute, National Institutes of Health, Bethesda, MD; Frank Chinegwundoh, Bart's Health National Health Services Trust, London, United Kingdom; Ben Adusei, Sunny Mante, and Nana Yaa Snyper, 37 Military Hospital; Andrew A. Adjei, Richard Biritwum, Richard Gyasi, Mathew Kyei, James E. Mensah, Julian Okine, Vicky Okyne, Isabella Rockson, Evelyn Tay, Yao Tettey, and Edward Yeboah, Korle-Bu Teaching Hospital, Accra, Ghana; Ilir Agalliu, David W. Lounsbury, and Thomas Rohan, Albert Einstein College of Medicine, Bronx; Judith S. Jacobson, Alfred I. Neugut, and Edward Gelmann, Columbia University, New York, NY; Joseph Lachance, Georgia Institute of Technology, Atlanta, GA; Cristine N. Duffy and Ann Hsing, Stanford University, Stanford Cancer Institute, Stanford, CA; Cherif Dial, Thierno Amadou Diallo, Mohamed Jalloh, Serigne Magueye Gueye, and Papa Moussa Sène Kane, Hôpital Général de Grand Yoff, Institute de Formation et de la Recherche en Urologie et de la Santé de la Famillie; Halimatou Diop, Anna Julienne Ndiaye, Amina Sow Sall, and Ndeye Coumba Toure-Kane, Hôpital Aristide Le Dantec, Dakar, Senegal; Ezenwa Onyemata and Alash'le Abimiku, Institute of Human Virology, H3 African Biorepository Initiative; Oseremen Aisuodionoe-Shadrach, Abubakar Mustapha Jamda, Peter Oluwole Olabode, Maxwell Madueke Nwegbu, and Olalekan Hafees Ajibola, University of Abuja; Oseremen Aisuodionoe-Shadrach, Abubakar Mustapha Jamda, Peter Oluwole Olabode, and Maxwell Madueke Nwegbu, University of Abuja Teaching Hospital, Abuja; Olushola Jeremiah Ajamu and Yakubu Garba Ambuwa, Federal Medical Center, Keffi; Akindele Olupelumi Adebiyi, Michael Asuzu, Olufemi Ogunbiyi, Olufemi Popoola, Olayiwola Shittu, Olukemi Amodu, Emeka Odiaka, and Ifeoluwa Makinde, University College Hospital, Ibadan, Nigeria.
AN  - 30260755
AU  - Andrews, C.
AU  - Fortier, B.
AU  - Hayward, A.
AU  - Lederman, R.
AU  - Petersen, L.
AU  - McBride, J.
AU  - Petersen, D. C.
AU  - Ajayi, O.
AU  - Kachambwa, P.
AU  - Seutloali, M.
AU  - Shoko, A.
AU  - Mokhosi, M.
AU  - Hiller, R.
AU  - Adams, M.
AU  - Ongaco, C.
AU  - Pugh, E.
AU  - Romm, J.
AU  - Shelford, T.
AU  - Chinegwundoh, F.
AU  - Adusei, B.
AU  - Mante, S.
AU  - Snyper, N. Y.
AU  - Agalliu, I.
AU  - Lounsbury, D. W.
AU  - Rohan, T.
AU  - Orfanos, A.
AU  - Quintana, Y.
AU  - Jacobson, J. S.
AU  - Neugut, A. I.
AU  - Gelmann, E.
AU  - Lachance, J.
AU  - Dial, C.
AU  - Diallo, T. A.
AU  - Jalloh, M.
AU  - Gueye, S. M.
AU  - Kane, P. M. S.
AU  - Diop, H.
AU  - Ndiaye, A. J.
AU  - Sall, A. S.
AU  - Toure-Kane, N. C.
AU  - Onyemata, E.
AU  - Abimiku, A.
AU  - Adjei, A. A.
AU  - Biritwum, R.
AU  - Gyasi, R.
AU  - Kyei, M.
AU  - Mensah, J. E.
AU  - Okine, J.
AU  - Okyne, V.
AU  - Rockson, I.
AU  - Tay, E.
AU  - Tettey, Y.
AU  - Yeboah, E.
AU  - Chen, W. C.
AU  - Singh, E.
AU  - Cook, M. B.
AU  - Duffy, C. N.
AU  - Hsing, A.
AU  - Soo, C. C.
AU  - Fernandez, P.
AU  - Irusen, H.
AU  - Aisuodionoe-Shadrach, O.
AU  - Jamda, A. M.
AU  - Olabode, P. O.
AU  - Nwegbu, M. M.
AU  - Ajibola, O. H.
AU  - Ajamu, O. J.
AU  - Ambuwa, Y. G.
AU  - Adebiyi, A. O.
AU  - Asuzu, M.
AU  - Ogunbiyi, O.
AU  - Popoola, O.
AU  - Shittu, O.
AU  - Amodu, O.
AU  - Odiaka, E.
AU  - Makinde, I.
AU  - Joffe, M.
AU  - Pentz, A.
AU  - Rebbeck, T. R.
C2  - PMC6223491
DA  - Sep
DO  - 10.1200/jgo.18.00063
DP  - NLM
ET  - 2018/09/28
KW  - African Continental Ancestry Group
Baltimore
Carcinoma/*epidemiology/*genetics/pathology
Genomics
Genotype
Humans
Male
Prostate/pathology
Prostatic Neoplasms/*epidemiology/*genetics/pathology
South Africa/epidemiology
LA  - eng
N1  - 2378-9506
Andrews, Caroline
Fortier, Brian
Hayward, Amy
Lederman, Ruth
Petersen, Lindsay
McBride, Jo
Petersen, Desiree C
Ajayi, Olabode
Kachambwa, Paidamoyo
Seutloali, Moleboheng
Shoko, Aubrey
Mokhosi, Mamokhosana
Hiller, Reinhard
Adams, Marcia
Ongaco, Chrissie
Pugh, Elizabeth
Romm, Jane
Shelford, Tameka
Chinegwundoh, Frank
Adusei, Ben
Mante, Sunny
Snyper, Nana Yaa
Agalliu, Ilir
Lounsbury, David W
Rohan, Thomas
Orfanos, Alex
Quintana, Yuri
Jacobson, Judith S
Neugut, Alfred I
Gelmann, Edward
Lachance, Joseph
Dial, Cherif
Diallo, Thierno Amadou
Jalloh, Mohamed
Gueye, Serigne Magueye
Kane, Papa Moussa Sène
Diop, Halimatou
Ndiaye, Anna Julienne
Sall, Amina Sow
Toure-Kane, Ndeye Coumba
Onyemata, Ezenwa
Abimiku, Alash'le
Adjei, Andrew A
Biritwum, Richard
Gyasi, Richard
Kyei, Mathew
Mensah, James E
Okine, Julian
Okyne, Vicky
Rockson, Isabella
Tay, Evelyn
Tettey, Yao
Yeboah, Edward
Chen, Wenlong C
Singh, Elvira
Cook, Michael B
Duffy, Christine N
Hsing, Ann
Soo, Cassandra Claire
Fernandez, Pedro
Irusen, Hayley
Aisuodionoe-Shadrach, Oseremen
Jamda, Abubakar Mustapha
Olabode, Peter Oluwole
Nwegbu, Maxwell Madueke
Ajibola, Olalekan Hafees
Ajamu, Olushola Jeremiah
Ambuwa, Yakubu Garba
Adebiyi, Akindele Olupelumi
Asuzu, Michael
Ogunbiyi, Olufemi
Popoola, Olufemi
Shittu, Olayiwola
Amodu, Olukemi
Odiaka, Emeka
Makinde, Ifeoluwa
Joffe, Maureen
Pentz, Audrey
Rebbeck, Timothy R
U01 CA184374/CA/NCI NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
J Glob Oncol. 2018 Sep;4:1-14. doi: 10.1200/JGO.18.00063.
PY  - 2018
SN  - 2378-9506
SP  - 1-14
ST  - Development, Evaluation, and Implementation of a Pan-African Cancer Research Network: Men of African Descent and Carcinoma of the Prostate
T2  - J Glob Oncol
TI  - Development, Evaluation, and Implementation of a Pan-African Cancer Research Network: Men of African Descent and Carcinoma of the Prostate
VL  - 4
ID  - 100
ER  - 

TY  - JOUR
AB  - BACKGROUND: Subjective memory complaints (SMCs) are associated with increased risk of dementia in older adults, but the role of comorbidities in modifying this risk is unknown. OBJECTIVES: To assess whether comorbidities modify estimated dementia risk based on SMCs. DESIGN: The Prevention of Alzheimer's Disease with Vitamin E and Selenium Study (PREADVISE) was designed as an ancillary study to the Selenium and Vitamin E Cancer Prevention Trial (SELECT), a randomized, multi-center prostate cancer prevention trial with sites in the Unites States, Puerto Rico, and Canada. In 2009, PREADVISE and SELECT were changed into cohort studies. SETTING: Secondary analysis of PREADVISE data. PARTICIPANTS: PREADVISE recruited 7,540 non-demented male volunteers from participating SELECT sites from 2002 to 2009. SMCs, demographics, and comorbidities including hypertension, diabetes, coronary artery bypass graft (CABG), stroke, sleep apnea, and head injury were ascertained by participant interview. MEASUREMENTS: Cox models were used to investigate whether baseline comorbidities modified hazard ratios (HR) for SMC-associated dementia risk using two methods: (1) we included one interaction term between SMC and a comorbidity in the model at a time, and (2) we included all two-way interactions between SMC and covariates of interest and reduced the model by "backward" selection. SMC was operationalized as any complaint vs. no complaint. RESULTS: Baseline SMCs were common (23.6%). In the first analyses, with the exception of stroke, presence of self-reported comorbidities was associated with lower estimated HR for dementia based on SMC status (complaint vs. no complaint), but this difference was only significant for diabetes. In the second analysis, the two-way interactions between SMC and race as well as SMC and diabetes were significant. Here, black men without diabetes who reported SMC had the highest estimated dementia risk (HR=5.05, 95% CI 2.55-10.00), while non-black men with diabetes who reported SMC had the lowest estimated risk (HR=0.71, 95% CI 0.35-1.41). CONCLUSIONS: SMCs were more common among men with comorbidities, but these complaints appeared to be less predictive of dementia risk than those originating from men without comorbidities, suggesting that medical conditions such as diabetes may explain SMCs that are unrelated to an underlying neurodegenerative process.
AD  - Sanders-Brown Center on Aging, University of Kentucky, Lexington KY 40536, USA.
Department of Epidemiology, College of Public Health, University of Kentucky, Lexington KY 40536, USA.
Department of Neurology, College of Medicine, University of Kentucky, Lexington KY 40356, USA.
Department of Behavioral Science, College of Medicine, University of Kentucky, Lexington KY 40536, USA.
Department of Public Health, Western Kentucky University, Bowling Green KY 42101, USA.
Department of Statistics, College of Arts and Sciences, University of Kentucky, Lexington KY 40536, USA.
Department of Biostatistics, College of Public Health, University of Kentucky, Lexington KY 40536, USA.
AN  - 28944218
AU  - Zhang, X.
AU  - Schmitt, F. A.
AU  - Caban-Holt, A. M.
AU  - Ding, X.
AU  - Kryscio, R. J.
AU  - Abner, E.
C2  - PMC5607951
C6  - NIHMS848398
DO  - 10.14283/jpad.2017.7
DP  - NLM
ET  - 2017/09/26
IS  - 3
KW  - Alzheimer’s disease
Subjective memory complaints (SMCs)
comorbidities
dementia
effect measure modification
LA  - eng
N1  - Zhang, X
Schmitt, F A
Caban-Holt, A M
Ding, X
Kryscio, R J
Abner, E
R01 AG019241/AG/NIA NIH HHS/United States
U10 CA037429/CA/NCI NIH HHS/United States
UG1 CA189974/CA/NCI NIH HHS/United States
UM1 CA182883/CA/NCI NIH HHS/United States
Journal Article
J Prev Alzheimers Dis. 2017;4(3):143-148. doi: 10.14283/jpad.2017.7. Epub 2017 Mar 7.
PY  - 2017
SN  - 2274-5807 (Print)
2274-5807
SP  - 143-148
ST  - Diabetes mitigates the role of memory complaint in predicting dementia risk: Results from the Prevention of Alzheimer's Disease with Vitamin E and Selenium Study
T2  - J Prev Alzheimers Dis
TI  - Diabetes mitigates the role of memory complaint in predicting dementia risk: Results from the Prevention of Alzheimer's Disease with Vitamin E and Selenium Study
VL  - 4
ID  - 156
ER  - 

TY  - JOUR
AB  - The Gail model is used to predict the risk of breast cancer in women of diverse race/ethnic groups for clinical trial protocols. However, this model has only been validated in US white women. Using a nested case-control study design, we evaluated the diagnostic accuracy of the original Gail model (GM) and that of the revised Gail model algorithm for blacks/African-Americans (GM-B) in the Black Women's Health Study (BWHS). Risk profiles were derived via a self reported questionnaire at the time of enrollment into the BWHS in 1995. Biennial questionnaires were obtained from the participants to determine the incident cases of breast cancer. The study of 725 breast cancer cases and 725 controls revealed that the 5-year risk of breast cancer based on the GM ranged from 0.2% to 15.4% among cases and 0.2% to 13.6% among the controls. Based on the GM-B, the 5-year risk of breast cancer ranged from 0.2% to 8.7% among cases and 0.2% to 7.2% among the controls. The sensitivities of the GM and GM-B model with the standard cutoff of 1.7% were 17.9% (95% CI: 15.9-19.9%) and 4.1% (95% CI: 3.0-5.2), respectively. Both the original and the modified version of the Gail model underestimate the risk of developing breast cancer in African-American women. More importantly, the modified Gail Model (GM-B) does a worse job at predicting the development of breast cancer for blacks than the original model (GM).
AD  - Howard University Cancer Center, Washington, DC 20060, USA. ladams-campbell@howard.edu
AN  - 17593036
AU  - Adams-Campbell, L. L.
AU  - Makambi, K. H.
AU  - Palmer, J. R.
AU  - Rosenberg, L.
DA  - Jul-Aug
DO  - 10.1111/j.1524-4741.2007.00439.x
DP  - NLM
ET  - 2007/06/27
IS  - 4
KW  - Adult
*African Americans
Aged
Algorithms
Breast Neoplasms/*etiology/genetics
Case-Control Studies
Female
Humans
Maternal Age
Middle Aged
*Models, Statistical
Postmenopause
Predictive Value of Tests
Premenopause
ROC Curve
Risk Assessment/*methods/standards
*Women's Health
LA  - eng
N1  - Adams-Campbell, Lucile L
Makambi, Kepher H
Palmer, Julie R
Rosenberg, Lynn
R01 CA58420/CA/NCI NIH HHS/United States
Evaluation Study
Journal Article
Research Support, N.I.H., Extramural
United States
Breast J. 2007 Jul-Aug;13(4):332-6. doi: 10.1111/j.1524-4741.2007.00439.x.
PY  - 2007
SN  - 1075-122X (Print)
1075-122x
SP  - 332-6
ST  - Diagnostic accuracy of the Gail model in the Black Women's Health Study
T2  - Breast J
TI  - Diagnostic accuracy of the Gail model in the Black Women's Health Study
VL  - 13
ID  - 524
ER  - 

TY  - JOUR
AB  - In the United States, colorectal cancer (CRC) is the third leading cause of cancer-related death and third most commonly diagnosed cancer among adults. This study is the first to examine the relationship between diet-related beliefs for colorectal cancer prevention and dietary intake among an urban, predominantly Black population (n = 169). More than two-thirds reported diet-related CRC prevention beliefs. Those with diet-related CRC prevention beliefs had healthier intakes for dietary fiber ( p = .005), fruit, vegetable, bean ( p = .027), red meat ( p = .032), vitamin C ( p = .039), and cholesterol ( p = .045). Most people may already have diet-related CRC prevention beliefs and having them is associated with a more healthful dietary intake.
AD  - Department of Health and Natural Sciences, Goodwin College, East Hartford USA
Department of Health and Behavior Studies, Teachers College, Columbia University, New York USA
Department of Public Health, William Paterson University, Wayne USA
Department of Health and Behavior Studies, Teachers College, Columbia University, New York 10027 USA
AN  - 109816283. Language: English. Entry Date: 20150708. Revision Date: 20200708. Publication Type: Journal Article
AU  - Zaharek-Girgasky, Margot
AU  - Wolf, Randi
AU  - Zybert, Patricia
AU  - Basch, Corey
AU  - Basch, Charles
DB  - CINAHL Complete
DO  - 10.1007/s10900-014-9984-x
DP  - EBSCOhost
IS  - 4
KW  - Minority Groups
Diet -- Evaluation
Colorectal Neoplasms -- Prevention and Control
Health Beliefs
Food Intake -- Evaluation
Community Health Services
Human
United States
Colorectal Neoplasms -- Mortality
Colorectal Neoplasms -- Diagnosis
Life Style, Sedentary
Urban Areas
Black Persons
Race Factors
Insurance Coverage
Data Collection
Language
Colonoscopy
Patient Selection -- Methods
Crohn Disease -- Diagnosis
Crohn Disease -- Complications
Colitis, Ulcerative -- Diagnosis
Colitis, Ulcerative -- Complications
Male
Female
West Indies
Obesity -- Diagnosis
Middle Age
Ethnic Groups
Income
Education
Birth Place
Body Mass Index
Data Analysis
Data Analysis Software
Vegetables
Dietary Fiber
Fruit
Meat
Water
Fish
Alcohol Drinking
Dairy Products
N1  - research; tables/charts. Journal Subset: Biomedical; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; Public Health; USA. Special Interest: Public Health. NLM UID: 7600747.
PY  - 2015
SN  - 0094-5145
SP  - 680-685
ST  - Diet-Related Colorectal Cancer Prevention Beliefs and Dietary Intakes in an Urban Minority Population
T2  - Journal of Community Health
TI  - Diet-Related Colorectal Cancer Prevention Beliefs and Dietary Intakes in an Urban Minority Population
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=109816283&site=ehost-live&scope=site
VL  - 40
ID  - 1912
ER  - 

TY  - JOUR
AB  - INTRODUCTION Advanced glycation end‐products (AGEs) are implicated in the pathogenesis of chronic diseasesand cancer. AGEs are produced endogenously but can also be consumed in foods. High amounts of AGEs arefound in animal products and processed foods, and AGE formation is accelerated during cooking at hightemperatures. Existing disparities in dietary practices could result from limited access to healthy foods among manyother factors, further contributing to racial health disparities. The objective of the study was to investigate theassociation between dAGE intake and breast cancer risk among different racial/ethnic groups of women using theProstate, Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO). METHODS The PLCO enrolled womenaged 55 to 74 years into a randomized controlled trial examining various cancer screening modalities. In thisprospective analysis, the study sample included only women enrolled in the intervention arm who were cancer‐freeat baseline and completed a baseline questionnaire and food frequency questionnaire (DQX) [non‐Hispanic White(NHW): 25,096; non‐Hispanic Black (NHB): 1,179 and Other race/ethnicity: 1,300]. dAGE values were assigned andquantified to foods in the DQX using a published AGE database. Descriptive analysis was used to obtain means andpercentages while Cox proportional hazards model estimated the hazard ratios (HR) and 95% CIs of breast cancerby tertiles of dAGE intake with adjustment for multiple potential confounders. RESULTS After a median 11.5 years offollow‐up, 1,599 women were diagnosed with breast cancer, including 1,472 NHW, 51 NHB, and 76 Other race/ethnicity. The average dAGE consumption among all the women was 6,106 KU/1000kcal per day (SD: 2691 KU/1000kcal per day) and was highest among NHB (6765 ± 3353 KU/1000kcal per day) compared to NHW (6101 ± 2648 KU/1000kcal per day) and Other race/ethnicity (5604 ± 2723 KU/1000kcal per day). There was an increased risk of breast cancer across the tertiles of dAGE intake (HRT2 VS T1:1.14, 95% CI: 1.00, 1.31 and HRT3 VS T1:1.20, 95% CI: 1.02, 1.42). In stratified analyses, increased risk of breast cancer was observed in all races but was significant only in NHW women (HRT2 VS T1: 1.15, 95% CI: 1.00, 1.32 and HRT3 VS T1: 1.22, 95% CI: 1.02, 1.45). For NHB the association for the highest tertile compared to the lowest tertile was HRT3 VS T1: 1.20, 95% CI: 0.48, 3.01, and for Other race/ethnicity the association was HRT3 VS T1: 1.70, 95% CI: 0.78, 3.73. CONCLUSION Among all women in the study, high intake of dAGE increased the risk of breast cancer. Overall the association appeared to be more prominent among NHW women, though small sample sizes resulted in imprecise estimates for other racial/ethnic groups.
AN  - CN-02213315
AU  - Omofuma, O. O.
AU  - Turner, D. P.
AU  - Peterson, L. L.
AU  - Merchant, A. T.
AU  - Zhang, J.
AU  - Steck, S. E.
DO  - 10.1158/1538-7755.DISP19-C033
IS  - 6 SUPPL 2
KW  - *breast cancer
*cancer screening
*colorectal cancer
*diet
*lung cancer
*ovary cancer
*prostate cancer
*race
Adult
Cancer risk
Clinical trial
Conference abstract
Controlled study
Drug combination
Ethnic group
Ethnicity
Female
Food frequency questionnaire
Health disparity
Human
Human tissue
Major clinical study
Male
Randomized controlled trial
Sample size
M3  - Journal: Conference Abstract
PY  - 2020
ST  - Dietary advanced glycation end products(dAGEs) and breast cancer by race in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO)
T2  - Cancer epidemiology biomarkers and prevention
TI  - Dietary advanced glycation end products(dAGEs) and breast cancer by race in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO)
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02213315/full
VL  - 29
ID  - 1620
ER  - 

TY  - JOUR
AB  - OBJECTIVES: To examine whether a diet low in fat and high in fiber, fruits, and vegetables and ethnicity had any influence on serum prostate-specific antigen (PSA) levels, because serum PSA is a marker for the presence of prostate cancer. The incidence of prostate cancer increases with age, varies by ethnicity, and is greater among men with a first-degree relative who has had the disease. Large international variations in the rates of prostate cancer incidence and mortality, as well as the incidence changes in migrants and their offspring, also suggest that exogenous factors, including diet, have a strong influence on the development of this disease. METHODS: We used data and blood samples from the Polyp Prevention Trial, a multicenter randomized trial designed to evaluate the impact of a diet low in fat and high in fiber, fruits, and vegetables on the recurrence of colorectal adenomas. Recruitment was from 1991 through 1994. Participants were followed up from their baseline recruitment date for 4 years. From this group, we identified 1100 white men and 97 black men who were 35 years of age or older, did not have prostate cancer, and had serum samples available for study. RESULTS: At baseline, no difference was present in the fat intake for the black and white men (mean +/- SE, 90 +/- 3.6 g/day and 84 +/- 1.0 g/day, respectively; P = 0.15). The baseline serum PSA levels did not vary by ethnicity. For black men, the mean serum PSA level was 2.2 +/- 0.36 ng/mL compared with 2.0 +/- 0.07 ng/mL for white men (P = 0.64). Although all men assigned to the intervention group markedly reduced their fat intake by approximately 15% and increased their fruit and vegetable intake by approximately 2.25 servings per day, no difference was noted in the kinetics of the serum PSA levels by dietary intervention or race. CONCLUSIONS: Although ethnic differences in the incidence of prostate cancer are well defined, we found no difference in the baseline fat intake among black and white men that might have contributed to this difference. Serum PSA, a marker often used in early detection programs for prostate cancer, was not associated with manipulation of the amount of fat in the diet, regardless of ethnicity.
AD  - Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.
AN  - 14550442
AU  - Eastham, J. A.
AU  - Riedel, E.
AU  - Latkany, L.
AU  - Fleisher, M.
AU  - Schatzkin, A.
AU  - Lanza, E.
AU  - Shike, M.
DA  - Oct
DO  - 10.1016/s0090-4295(03)00576-4
DP  - NLM
ET  - 2003/10/11
IS  - 4
KW  - Adult
African Continental Ancestry Group
Aged
Biomarkers, Tumor/blood
Cohort Studies
*Diet, Fat-Restricted
Dietary Fats/adverse effects
*Dietary Fiber/administration & dosage
*Ethnic Groups
European Continental Ancestry Group
Feeding Behavior
Follow-Up Studies
Fruit
Humans
Male
Middle Aged
Prostate-Specific Antigen/*blood
Prostatic Neoplasms/blood/*epidemiology/prevention & control
United States/epidemiology
Vegetables
LA  - eng
N1  - 1527-9995
Eastham, James A
Riedel, Elyn
Latkany, Lianne
Fleisher, Martin
Schatzkin, Arthur
Lanza, Elaine
Shike, Moshe
Polyp Prevention Trial Study Group
Clinical Trial
Journal Article
Multicenter Study
Randomized Controlled Trial
United States
Urology. 2003 Oct;62(4):677-82. doi: 10.1016/s0090-4295(03)00576-4.
PY  - 2003
SN  - 0090-4295
SP  - 677-82
ST  - Dietary manipulation, ethnicity, and serum PSA levels
T2  - Urology
TI  - Dietary manipulation, ethnicity, and serum PSA levels
VL  - 62
ID  - 641
ER  - 

TY  - JOUR
AB  - Colorectal cancer (CRC) remains a major cause of cancer death worldwide. Over 70% of CRC cases are sporadic and related to lifestyle. Epidemiological studies inversely correlate CRC incidence with the intake of fruits and vegetables but not with their phenolic content. Preclinical studies using in vitro (cell lines) and animal models of CRC have reported anticancer effects for dietary phenolics through the regulation of different markers and signaling pathways. Herein, we review and contrast the evidence between preclinical studies and clinical trials (patients with CRC or at risk, familial adenopolyposis or aberrant crypt foci) investigating the protective effects of curcumin, resveratrol, isoflavones, green tea extracts (epigallocatechin gallate), black raspberry powder (anthocyanins and ellagitannins), bilberry extract (anthocyanins), ginger extracts (gingerol derivatives), and pomegranate extracts (ellagitannins and ellagic acid). To date, curcumin is the most promising polyphenol as possible future adjuvant in CRC management. Overall, the clinical evidence of dietary phenolics against CRC is still weak and the amounts needed to exert some effects largely exceed common dietary doses. We discuss here the possible reasons behind the gap between preclinical and clinical research (inconsistence of results, lack of clinical endpoints, etc.), and provide an outlook and a roadmap to approach this topic.
AD  - Research Group on Quality, Safety and Bioactivity of Plant Foods, Department of Food Science and Technology, CEBAS-CSIC, Murcia, Spain.
AN  - 25693744
AU  - Núñez-Sánchez, M. A.
AU  - González-Sarrías, A.
AU  - Romo-Vaquero, M.
AU  - García-Villalba, R.
AU  - Selma, M. V.
AU  - Tomás-Barberán, F. A.
AU  - García-Conesa, M. T.
AU  - Espín, J. C.
DA  - Jul
DO  - 10.1002/mnfr.201400866
DP  - NLM
ET  - 2015/02/20
IS  - 7
KW  - Animals
Antineoplastic Agents, Phytogenic/*pharmacology
Clinical Trials as Topic
Colorectal Neoplasms/*drug therapy/epidemiology/pathology
Curcumin/pharmacology
Diet
Drug Screening Assays, Antitumor/methods
Gastrointestinal Microbiome
Ginger
Humans
Lythraceae
Phenols/*pharmacology
Resveratrol
Stilbenes/pharmacology
Tea
Animal models
Clinical trials
Colon cancer
In vitro
Polyphenol
LA  - eng
N1  - 1613-4133
Núñez-Sánchez, María A
González-Sarrías, Antonio
Romo-Vaquero, María
García-Villalba, Rocío
Selma, María V
Tomás-Barberán, Francisco A
García-Conesa, María-Teresa
Espín, Juan Carlos
Journal Article
Research Support, Non-U.S. Gov't
Review
Germany
Mol Nutr Food Res. 2015 Jul;59(7):1274-91. doi: 10.1002/mnfr.201400866. Epub 2015 Mar 31.
PY  - 2015
SN  - 1613-4125
SP  - 1274-91
ST  - Dietary phenolics against colorectal cancer--From promising preclinical results to poor translation into clinical trials: Pitfalls and future needs
T2  - Mol Nutr Food Res
TI  - Dietary phenolics against colorectal cancer--From promising preclinical results to poor translation into clinical trials: Pitfalls and future needs
VL  - 59
ID  - 257
ER  - 

TY  - JOUR
AB  - This review explores factors potentially contributing to the disparity in survival after breast cancer between African-American and Caucasian women in the United States. A number of factors have been implicated as the cause of poorer survival for black women, including clinical and pathologic features of the disease that are indicative of poor prognosis, economic resource inequities, and differences in treatment access and efficacy. The latter is explored in detail using data from the National Surgical Adjuvant Breast and Bowel Project (NSABP), a nationwide multicenter clinical trials group for breast and colorectal cancers. Key studies into the disparity in breast cancer survival are reviewed according to proposed principal determinants of poorer outcome for black women. Results among black and white women participating in several randomized NSABP clinical trials are also presented. Primary endpoints in those studies were clinical and pathologic disease characteristics at study entry, time to disease progression or new cancers, and total survival time after breast cancer diagnosis and treatment. In most studies reported in the literature, the primary explanatory factor alone, such as stage of disease at diagnosis, did not fully account for differences in outcome between groups; when additional factors were taken into account, however, prognoses became more similar. Results from the NSABP clinical trials similarly indicated that when stage of disease and treatment were comparable, outcomes for blacks did not differ markedly from those of whites. In summary, black women, diagnosed at comparable disease stage as white women and treated appropriately, tend to experience similar breast cancer prognoses and survival. However, important clinical and pathologic disease characteristics may continue to place certain women at increased risk of poorer outcome, and warrant continued study. The opportunity for increased clinical trial participation by black women is encouraged.
AD  - Department of Biostatistics, Graduate School of Public Health, University of Pittsburgh, PA, USA.
AN  - 10735015
AU  - Dignam, J. J.
DA  - Jan-Feb
DO  - 10.3322/canjclin.50.1.50
DP  - NLM
ET  - 2000/03/29
IS  - 1
KW  - *African Continental Ancestry Group
Breast Neoplasms/*mortality/pathology
Clinical Trials as Topic
Disease Progression
*European Continental Ancestry Group
Female
Health Services Accessibility
Humans
Multicenter Studies as Topic
Neoplasm Staging
Neoplasms, Second Primary/epidemiology
Prognosis
Risk Factors
Socioeconomic Factors
Survival Rate
Treatment Outcome
United States/epidemiology
LA  - eng
N1  - Dignam, J J
Comparative Study
Journal Article
Review
United States
CA Cancer J Clin. 2000 Jan-Feb;50(1):50-64. doi: 10.3322/canjclin.50.1.50.
PY  - 2000
SN  - 0007-9235 (Print)
0007-9235
SP  - 50-64
ST  - Differences in breast cancer prognosis among African-American and Caucasian women
T2  - CA Cancer J Clin
TI  - Differences in breast cancer prognosis among African-American and Caucasian women
VL  - 50
ID  - 703
ER  - 

TY  - THES
AB  - Prostate cancer (PCa) affects Blacks disproportionately when compared to other groups. PCa is the primary cancer and second cause of cancer mortality among Black men. Some researchers have declared that the high PCa incidence and mortality rates in the Black population are a result of poor screening rates. PCa screening perceptions are reasonably known among African American men; however, limited documentation is available for the ever-expanding population of ethnic Black Caribbean men in the United States. Ethnic Blacks from the Caribbean are at high risk for PCa, with PCa incidence and mortality rates comparable to, or exceeding those of African American men. This quantitative non-experimental comparative analysis study examined differences in the perception of ethnic Blacks toward PCa and PCa screening. Also being examined was the extent and manner in which these PCa perceptions among ethnic Black men differ with respect to specific ethnic groups within the Black population and varied with respect to demographic factors of age, education, marital status, health insurance coverage, and income. The Health Belief Model – Prostate Cancer Scale (HBM-PCS) was theoretical framework used in this study. The HBM-PCS and a Demographic survey were provided to 167 participants (40 to 80 years), recruited via flyers at grocers, shopping malls, plazas, restaurants, and barbershops frequented by ethnic Black men residing in Broward County, Florida. There was a statistically significant difference in Perceived PCa Seriousness with respect to ethnic identity, F(4, 162) = 4.54, MSE = .531, p = .002, η 2 = 0.10. There was also a statistically significant difference in Perceived PCa Screening Barriers with respect to ethnic identity, F(4,162) = 4.08, MSE = .226, p = .004, η2 = 0.09. There was no statistically significant difference in Perceived PCa Screening Benefits with respect to ethnic identity, F(4, 162) = .80, MSE = .188, p= .526, η2 = 0.02. The interaction effect between ethnicity and age F(8, 152) = 2.08, MSE = .180, p= .041, partial eta = .099 and ethnicity and income F(14, 142) = 1.79, MSE = .177, p= .045, partial eta = .150 on perceived PCa screening Benefits were of statistical significance. Perceived PCa Screening Barriers also statistically significantly differed with respect to education level [F(5, 160) = 4.48, MSE = .221, p= .001, η2p = 0.12], income level [F(4, 160) = 6.21, MSE = .216, p < .001, η2p = 0.13], and health insurance coverage [t(165) = 3.22, p < .001]. Future studies should take into consideration additional ethnic Black groups, which should consist of larger samples that are more equally weighted among each ethnic group being examined. Additionally, future studies should focus on how ethnic Black men perceived the benefits of PCa, and how their perceptions of the benefits of screening contribute to, or prevent them from screening for PCa disease. Of interest should also be studies on PCa trajectory in ethnic Black immigrants in the United States, as to whether PCa incidences and mortalities become lessened upon migration from their country of origin. (PsycINFO Database Record (c) 2016 APA, all rights reserved)
AN  - 2015-99240-059
AU  - McFarlane, Debrah
DB  - psyh
DP  - EBSCOhost
KW  - black men
ethnic identity
African American men
partial eta
Neoplasms
Ideology
At Risk Populations
Blacks
Cancer Screening
Prostate
Marginalization
N1  - Accession Number: 2015-99240-059. Other Journal Title: Dissertation Abstracts International. Partial author list: First Author & Affiliation: McFarlane, Debrah; Northcentral U., US. Release Date: 20160222. Publication Type: Dissertation Abstract (0400). Format Covered: Electronic. Document Type: Dissertation. Dissertation Number: AAI3682234. ISBN: 978-1-321-55490-8. Language: English. Major Descriptor: Neoplasms; Ideology. Minor Descriptor: At Risk Populations; Blacks; Cancer Screening; Prostate; Marginalization. Classification: General Psychology (2100); Social Processes & Social Issues (2900). Population: Human (10). Methodology: Empirical Study; Quantitative Study.
PB  - ProQuest Information & Learning
PY  - 2015
SN  - 0419-4217
978-1-321-55490-8
ST  - Differences in perceptions of prostate cancer screening among multiethnic black men
TI  - Differences in perceptions of prostate cancer screening among multiethnic black men
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2015-99240-059&site=ehost-live&scope=site
VL  - 76
ID  - 1697
ER  - 

TY  - JOUR
AB  - Purpose: The purpose of this report was to identify the relationship of mammography adoption with perceived susceptibility to breast cancer and perceived benefits and barriers to mammography. Methods: Stage of mammography adoption was based on the Transtheoretical Model. Previously validated scales for susceptibility, benefits, and barriers were administered. The sample included 694 women who were recruited from a large Health Maintenance Organization and general medicine clinic. The mean age was 61.2 years; 30% were African American and 67% were Caucasian. Results: Women who were currently compliant (action) had lower perceived barriers than other groups. Precontemplators and Relapse Precontemplators had lower perceived benefits scores than those who were currently compliant or those who were thinking of having a mammogram. Women who had never received a mammogram were more likely to feel they were too old for the procedure. Stage matched interventions are discussed. Conclusions: Beliefs differ among women in various stages of mammography adoption. These differences may inform interventions to increase mammography use.
AN  - WOS:000182903700009
AU  - Champion, V. L.
AU  - Skinner, C. S.
DA  - Apr
DO  - 10.1089/154099903321667618
IS  - 3
N1  - 59
12804358
PY  - 2003
SN  - 1524-6094
SP  - 277-286
ST  - Differences in perceptions of risk, benefits, and barriers by stage of mammography adoption
T2  - Journal of Womens Health & Gender-Based Medicine
TI  - Differences in perceptions of risk, benefits, and barriers by stage of mammography adoption
VL  - 12
ID  - 2697
ER  - 

TY  - JOUR
AB  - Key Points: Question: Do stage of cancer at diagnosis, use of definitive therapy, and survival differ by race/ethnicity among patients with 1 of the most common cancers? Findings: In this cohort study of 950 377 patients with cancer, stage at diagnosis, treatment, and survival varied by race and ethnicity. Overall, compared with Asian patients, black patients were more likely to have metastatic disease at diagnosis, black and Hispanic patients were less likely to receive definitive treatment, and white, black, and Hispanic patients had worse odds of cancer-specific and overall survival. Meaning: The findings of this study may lead to different management strategies based on race and ethnicity to improve outcomes. This cohort study assesses the stage of cancer at diagnosis, use of therapy, overall survival, and cancer-specific survival among patients with cancer from different racial/ethnic groups. Importance: Information about stage of cancer at diagnosis, use of therapy, and survival among patients from different racial/ethnic groups with 1 of the most common cancers is lacking. Objective: To assess stage of cancer at diagnosis, use of therapy, overall survival (OS), and cancer-specific survival (CSS) in patients with cancer from different racial/ethnic groups. Design, Setting, and Participants: This cohort study included 950 377 Asian, black, white, and Hispanic patients who were diagnosed with prostate, ovarian, breast, stomach, pancreatic, lung, liver, esophageal, or colorectal cancers from January 2004 to December 2010. Data were collected using the Surveillance, Epidemiology, and End Results (SEER) database, and patients were observed for more than 5 years. Data analysis was conducted in July 2018. Main Outcomes and Measures: Multivariable logistic and Cox regression were used to evaluate the differences in stage of cancer at diagnosis, treatment, and survival among patients from different racial/ethnic groups. Results: A total of 950 377 patients (499 070 [52.5%] men) were included in the study, with 681 251 white patients (71.7%; mean [SD] age, 65 [12] years), 116 015 black patients (12.2%; mean [SD] age, 62 [12] years), 65 718 Asian patients (6.9%; mean [SD] age, 63 [13] years), and 87 393 Hispanic patients (9.2%; mean [SD] age, 61 [13] years). Compared with Asian patients, black patients were more likely to have metastatic disease at diagnosis (odds ratio [OR], 1.144; 95% CI, 1.109-1.180; P <.001). Black and Hispanic patients were less likely to receive definitive treatment than Asian patients (black: adjusted OR, 0.630; 95% CI, 0.609-0.653; P <.001; Hispanic: adjusted OR, 0.751; 95% CI, 0.724-0.780; P <.001). White, black, and Hispanic patients were more likely to have poorer CSS and OS than Asian patients (CSS, white: adjusted HR, 1.310; 95% CI, 1.283-1.338; P <.001; black: adjusted HR, 1.645; 95% CI, 1.605-1.685; P <.001; Hispanic: adjusted HR, 1.300; 95% CI, 1.266-1.334; P <.001; OS, white: adjusted HR, 1.333; 95% CI, 1.310-1.357; P <.001; black: adjusted HR, 1.754; 95% CI, 1.719-1.789; P <.001; Hispanic: adjusted HR, 1.279; 95% CI, 1.269-1.326; P <.001). Conclusions and Relevance: In this study of patients with 1 of 9 leading cancers, stage at diagnosis, treatment, and survival were different by race and ethnicity. These findings may help to optimize treatment and improve outcomes.
AD  - Department of Integrated Therapy, Fudan University Shanghai Cancer Center, Shanghai Medical College, Shanghai, China
Department of Nephrology, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Department of Medical Affairs, Qilu Hospital of Shandong University, Jinan, China
Department of Internal Medicine–Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China
AN  - 142666474. Language: English. Entry Date: 20200414. Revision Date: 20200508. Publication Type: Article
AU  - Zhang, Chenyue
AU  - Zhang, Chenxing
AU  - Wang, Qingliang
AU  - Li, Zhenxiang
AU  - Lin, Jiamao
AU  - Wang, Haiyong
DB  - CINAHL Complete
DO  - 10.1001/jamanetworkopen.2020.2950
DP  - EBSCOhost
IS  - 4
KW  - Neoplasm Staging -- Evaluation
Neoplasms -- Therapy
Survival Analysis -- Evaluation
Cancer Patients -- Psychosocial Factors
Ethnic Groups
Human
Prospective Studies
Asians
Black Persons
White Persons
Hispanic Americans
Databases
Multivariate Analysis
Logistic Regression
Cox Proportional Hazards Model
Male
Female
Middle Age
Aged
Odds Ratio
Confidence Intervals
Descriptive Statistics
Patient Selection
Data Analysis Software
T-Tests
Chi Square Test
Neoplasm Metastasis
N1  - research; tables/charts.
PY  - 2020
SP  - e202950-e202950
ST  - Differences in Stage of Cancer at Diagnosis, Treatment, and Survival by Race and Ethnicity Among Leading Cancer Types
T2  - JAMA Network Open
TI  - Differences in Stage of Cancer at Diagnosis, Treatment, and Survival by Race and Ethnicity Among Leading Cancer Types
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=142666474&site=ehost-live&scope=site
VL  - 3
ID  - 1913
ER  - 

TY  - JOUR
AB  - Introduction: Malignant breast tumors are often hormone-dependent, and to this end, both estrogen and progesterone receptors are good prognostic markers for evaluation of the outcomes after therapy. In addition, HER-2/neu, whose expression is increasingly being associated with poor prognosis of breast cancer, has predictive potential after immunotherapy. Cytochrome P450 3A4 is highly involved in the metabolism of steroids. Thus, we investigated the impact of CYP 3A4 gene variants in association with clinical outcomes in African American (AFAM) versus Caucasian (CAU) patients with breast cancer diagnosis. Methods: Patients who had undergone biopsy procedures for diagnosis or for partial or radical mastectomy were recruited. The CYP 3A4 genotypes (A or G) were detected using polymerase chain reaction amplification and primers designed for a single nucleotide polymorphism. The messenger RNA (mRNA) transcriptswere screened by reverse transcription- polymerase chain reaction. Clinical data including tumor staging, pathology grades, and family history were evaluated. Results: Frequency of the CYP 3A4-G (mutated variant) was significantly increased in AFAMpatients as compared with controls (P < 0.001). No statistically significant difference was observed between the genotypes comparing the benign versus ductal carcinomas in situ (DCIS) or infiltrating ductal carcinomas (IDCAs). In AFAM patients, GG alleles were increased in IDCA with stage III tumors, and in CAU patients, the AA alleles were increased with stage III tumors. The mRNA expression was reduced in patients with IDCA versus DCIS or benign tumors (benign vs IDCA, P < 0.0009; DCIS vs IDCA, P G 0.005), as well in HER-2/ neuYpositive tumors versus samples negative for receptors (P < 0.0024). Conclusions: Genotype association was affected by race. Expression levels of total CYP 3A4 mRNA were inversely correlated with clinical diagnosis. This may suggest mRNA testing as an additional tool that accelerates improvement in the diagnosis of the onsets of breast cancer. Copyright © 2011 by The American Federation for Medical Research.
AD  - D.O. McDaniel, School of Medicine, University of MS Medical Center, 2500 N State St, CSB L-126, Jackson, MS 39216-4505, United States
AU  - McDaniel, D. O.
AU  - Thurber, T.
AU  - Lewis-Traylor, A.
AU  - Berry, C.
AU  - Barber, W. H.
AU  - Zhou, X.
AU  - Bigler, S.
AU  - Vance, R.
DB  - Embase
Medline
DO  - 10.231/JIM.0b013e3182277e3b
IS  - 7
KW  - cytochrome P450 3A4
estrogen receptor
messenger RNA
progesterone receptor
adult
African American
article
breast tumor
Caucasian
controlled study
disease association
female
gene expression
genotype
human
human tissue
immunohistochemistry
major clinical study
polymerase chain reaction
race difference
reverse transcription polymerase chain reaction
single nucleotide polymorphism
LA  - English
M3  - Article
N1  - L364212046
2012-02-15
2012-02-17
PY  - 2011
SN  - 1708-8267
SP  - 1096-1103
ST  - Differential association of cytochrome p450 3a4 genotypes with onsets of breast tumors in african american versus caucasian patients
T2  - Journal of Investigative Medicine
TI  - Differential association of cytochrome p450 3a4 genotypes with onsets of breast tumors in african american versus caucasian patients
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L364212046&from=export
http://dx.doi.org/10.231/JIM.0b013e3182277e3b
VL  - 59
ID  - 1149
ER  - 

TY  - JOUR
AB  - BACKGROUND: Diffusion of new cancer treatments can be both inefficient and incomplete. The uptake of new treatments over time (diffusion) has not been well studied. We analyzed the diffusion of docetaxel in metastatic prostate cancer. METHODS: We identified metastatic prostate cancer patients diagnosed from 1995 to 2007 using the Surveillance, Epidemiology, and End Results Program (SEER)-Medicare database. Medicare claims through 2008 were analyzed. We assessed cumulative incidence of docetaxel by socioeconomic, demographic, and comorbidity variables, and compared diffusion patterns to landmark events including release of phase III results and FDA approval dates. We compared docetaxel diffusion patterns in prostate cancer to those in metastatic breast, lung, ovarian, and gastric cancers. To model docetaxel use over time, we used the classic "mixed influence" deterministic diffusion model. All statistical tests were two-sided. RESULTS: We identified 6561 metastatic prostate cancer patients; 1350 subsequently received chemotherapy. Among patients who received chemotherapy, docetaxel use was 95% by 2008. Docetaxel uptake was statistically significantly slower (P < .01) for patients older than 65 years, blacks, patients in lower income areas, and those who experienced poverty. Eighty percent of docetaxel diffusion occurred prior to the May, 2004 release of phase III results showing superiority of docetaxel over standard-of-care. The maximum increase in the rate of use of docetaxel occurred nearly simultaneously for prostate cancer as for all other cancers combined (in 2000). CONCLUSION: Efforts to increase the diffusion of treatments with proven survival benefits among disadvantaged populations could lead to cancer population survival gains. Docetaxel diffusion mostly preceded phase III evidence for its efficacy in castration-resistant prostate cancer, and appeared to be a cancer-wide-rather than a disease-specific-phenomenon. Diffusion prior to definitive evidence indicates the prevalence of off-label chemotherapy use.
AD  - Affiliations of authors: SWOG Statistical Center, Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA (JMU, WEB, ML); University of Washington, Department of Health Services Research, Seattle, WA (DM); Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA (SRR, RBE); Division of Hematology/Oncology, Columbia University, New York, NY (DLH). junger@fredhutch.org.
Affiliations of authors: SWOG Statistical Center, Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA (JMU, WEB, ML); University of Washington, Department of Health Services Research, Seattle, WA (DM); Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA (SRR, RBE); Division of Hematology/Oncology, Columbia University, New York, NY (DLH).
AN  - 25540245
AU  - Unger, J. M.
AU  - Hershman, D. L.
AU  - Martin, D.
AU  - Etzioni, R. B.
AU  - Barlow, W. E.
AU  - LeBlanc, M.
AU  - Ramsey, S. R.
C2  - PMC4326312
DA  - Feb
DO  - 10.1093/jnci/dju412
DP  - NLM
ET  - 2014/12/30
IS  - 2
KW  - Aged
Aged, 80 and over
Antineoplastic Agents/*therapeutic use
Clinical Trials, Phase II as Topic
Comorbidity
Docetaxel
Drug Approval
Humans
Male
Medicare
Middle Aged
Practice Patterns, Physicians'/*statistics & numerical data
Prostatic Neoplasms/*drug therapy/epidemiology/*pathology
Prostatic Neoplasms, Castration-Resistant/drug therapy
SEER Program
Taxoids/*therapeutic use
United States/epidemiology
LA  - eng
N1  - 1460-2105
Unger, Joseph M
Hershman, Dawn L
Martin, Diane
Etzioni, Ruth B
Barlow, William E
LeBlanc, Michael
Ramsey, Scott R
U10 CA037429/CA/NCI NIH HHS/United States
U10 CA180819/CA/NCI NIH HHS/United States
UG1 CA189974/CA/NCI NIH HHS/United States
CA37429/CA/NCI NIH HHS/United States
Comparative Study
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
J Natl Cancer Inst. 2014 Dec 24;107(2):dju412. doi: 10.1093/jnci/dju412. Print 2015 Feb.
PY  - 2015
SN  - 0027-8874 (Print)
0027-8874
ST  - The diffusion of docetaxel in patients with metastatic prostate cancer
T2  - J Natl Cancer Inst
TI  - The diffusion of docetaxel in patients with metastatic prostate cancer
VL  - 107
ID  - 264
ER  - 

TY  - JOUR
AB  - African American (AA) men are significantly more likely to die of prostate cancer (PrCA) than other racial groups, and there is a critical need to identify strategies for providing information about PrCA screening and the importance of informed decision making (IDM). To assess whether a computer-based IDM intervention for PrCA screening would be appropriate for AA men, this formative evaluation study examined their (1) PrCA risk and screening knowledge; (2) decision-making processes for PrCA screening; (3) usage of, attitudes toward, and access to interactive communication technologies (ICTs); and (4) perceptions regarding a future, novel, computer-based PrCA education intervention. A purposive convenience sample of 39 AA men aged 37 to 66 years in the Southeastern United States was recruited through faith-based organizations to participate in one of six 90-minute focus groups and complete a 45-item descriptive survey. Participants were generally knowledgeable about PrCA. However, few engaged in IDM with their doctor and few were informed about the associated risks and uncertainties of PrCA screening. Most participants used ICTs on a daily basis for various purposes including health information seeking. Most participants were open to a novel, computer-based intervention if the system was easy to use and its animated avatars were culturally appropriate. Because study participants had low exposure to IDM for PrCA, but frequently used ICTs, IDM interventions using ICTs (e.g., computers) hold promise for AA men and should be explored for feasibility and effectiveness. These interventions should aim to increase PrCA screening knowledge and stress the importance of participating in IDM with doctors.
AN  - WOS:000374234000005
AU  - Owens, O. L.
AU  - Friedman, D. B.
AU  - Brandt, H. M.
AU  - Bernhardt, J. M.
AU  - Hebert, J. R.
DA  - May
DO  - 10.1177/1557988314564178
IS  - 3
N1  - 25563381
PY  - 2016
SN  - 1557-9883
SP  - 207-219
ST  - Digital Solutions for Informed Decision Making: An Academic-Community Partnership for the Development of a Prostate Cancer Decision Aid for African American Men
T2  - American Journal of Mens Health
TI  - Digital Solutions for Informed Decision Making: An Academic-Community Partnership for the Development of a Prostate Cancer Decision Aid for African American Men
VL  - 10
ID  - 2946
ER  - 

TY  - JOUR
AB  - BACKGROUND: A resect and discard strategy for diminutive (≤5 mm) colon polyps has been proposed to save costs of screening colonoscopy (SC). Prior studies on neoplasia prevalence based on polyp size have involved mostly white patients. OBJECTIVE: To determine the prevalence of adenomas and advanced histologic features by size among primarily black and Latino patients enrolled in a prospective SC study. DESIGN: Retrospective analysis of data from a prospective clinical trial. SETTING: Urban academic medical center. PATIENTS: Average risk, asymptomatic, minority patients aged ≥50 years undergoing SC. INTERVENTIONS: Screening colonoscopy. MAIN OUTCOME MEASUREMENTS: Rates of neoplasia and advanced histologic features (villous histology, high-grade dysplasia, or cancer) by polyp size and location. RESULTS: A total of 566 polyps from 295 patients were analyzed. Diminutive polyps and small (6-9 mm) polyps had lower prevalence of ≥1 advanced feature compared with large (≥10 mm) polyps (0.9% and 2.7%, respectively, vs 13.6%; P < .001 for both comparisons). Distal polyps were less likely to be neoplastic (31.7% vs 61.4%; P < .001) than proximal polyps in all size categories (P < .001 for all comparisons). After adjusting for sex, ethnicity, age, and location, large polyps were more likely to have ≥1 advanced feature than diminutive polyps (adjusted odds ratio [OR] 19.5; 95% CI, 4.4-85.6) or small polyps (adjusted OR 6.1; 95% CI, 2.2-16.9). LIMITATIONS: Use of pathology reports for polyp size. CONCLUSION: Among a cohort of minority patients, advanced histologic features were very rare in diminutive polyps. Distal polyps were less likely to be neoplastic than proximal polyps in all size categories. This supports a resect and discard strategy for diminutive polyps, especially in the distal colon.
AD  - Division of Gastroenterology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Division of Cancer Prevention and Control, Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
AN  - 25708761
AU  - Lee, K. K.
AU  - Jandorf, L.
AU  - Itzkowitz, S. H.
DA  - Mar
DO  - 10.1016/j.gie.2014.11.036
DP  - NLM
ET  - 2015/02/25
IS  - 3
KW  - Adenocarcinoma/*ethnology/pathology/surgery
Adenoma/*ethnology/pathology/surgery
Adult
*African Americans
Aged
Colonic Neoplasms/*ethnology/pathology/surgery
Colonic Polyps/*ethnology/pathology/surgery
*Colonoscopy
Early Detection of Cancer
Female
*Hispanic Americans
Humans
Male
Middle Aged
Prevalence
Retrospective Studies
LA  - eng
N1  - 1097-6779
Lee, Kristen K
Jandorf, Lina
Itzkowitz, Steven H
Journal Article
United States
Gastrointest Endosc. 2015 Mar;81(3):728-32. doi: 10.1016/j.gie.2014.11.036.
PY  - 2015
SN  - 0016-5107
SP  - 728-32
ST  - Diminutive polyps among black and Latino populations undergoing screening colonoscopy: evidence supporting a resect and discard approach
T2  - Gastrointest Endosc
TI  - Diminutive polyps among black and Latino populations undergoing screening colonoscopy: evidence supporting a resect and discard approach
VL  - 81
ID  - 256
ER  - 

TY  - JOUR
AB  - OBJECTIVE: To analyze advertising, recruitment methods, and study participant demographics for the National Lung Screening Trial (NLST) site at Wake Forest University School of Medicine to define efficient ways to recruit participants for general clinical trials. STUDY DESIGN AND SETTING: Recruitment method data, demographics, geographic location, and date of enrollment were collected from all 1,112 NLST participants. Marketing data and financial records were analyzed to determine the effectiveness of each recruitment method. RESULTS: The total amount spent on advertising was $144,668, with the cost of enrollment per participant averaging $130. For black participants, the recruitment cost per person was $406, whereas for white and other race participants, the cost was $122 (P<0.0001). To encourage minority enrollment, $13,192 was spent on television advertising geared toward black viewers, resulting in eight black participants at an average cost per person of $1,649. Direct mailing cost $143 per participant recruited, whereas TV ads cost $382 per participant. CONCLUSION: Direct mailing to a targeted group was the most efficient way to recruit participants. Printed advertising methods, that is, newspaper ads and brochures, were quite effective, whereas television ads were expensive. Appropriate minority recruitment needs sufficient attention and resources to ensure census groups are adequately represented.
AD  - Department of Radiology, Wake Forest University School of Medicine, Winston-Salem, NC 27157, USA. lhinshaw@wfubmc.edu
AN  - 17606183
AU  - Hinshaw, L. B.
AU  - Jackson, S. A.
AU  - Chen, M. Y.
DA  - Aug
DO  - 10.1016/j.jclinepi.2006.11.005
DP  - NLM
ET  - 2007/07/04
IS  - 8
KW  - Advertising/economics
African Continental Ancestry Group
Clinical Trials as Topic
Costs and Cost Analysis
Demography
European Continental Ancestry Group
Geography
Humans
Lung Neoplasms/*diagnosis
Mass Screening/methods
*Patient Selection
Postal Service/economics
Sample Size
Television/economics
LA  - eng
N1  - Hinshaw, Lisa B
Jackson, Sharon A
Chen, Michael Y
Journal Article
United States
J Clin Epidemiol. 2007 Aug;60(8):853-7. doi: 10.1016/j.jclinepi.2006.11.005. Epub 2007 Mar 26.
PY  - 2007
SN  - 0895-4356 (Print)
0895-4356
SP  - 853-7
ST  - Direct mailing was a successful recruitment strategy for a lung-cancer screening trial
T2  - J Clin Epidemiol
TI  - Direct mailing was a successful recruitment strategy for a lung-cancer screening trial
VL  - 60
ID  - 520
ER  - 

TY  - JOUR
AB  - PURPOSE: Reduction mammaplasty is one of the most common procedures performed by plastic surgeons. Previous studies demonstrated that most plastic surgeons do not require preoperative mammography prior to reduction mammaplasty. The incidental discovery of malignant or high-risk lesions in breast reduction specimens may preclude the possibility of breast-conserving surgery. The purpose of this study was to examine the factors associated with discussion of preoperative mammography with reduction mammaplasty patients. METHODS: About 638 consecutive patients were identified between January 2000 and December 2010 who underwent reduction mammaplasty. Clinicopathologic and treatment information was collected. Factors associated with discussion of preoperative mammography prior to surgery were compared. RESULTS: Of 638 patients, the median age was 36 (range 18-77) with 44% ≥40. Approximately half (56.0%) were White and 37.5% were African-American. The use of mammography was discussed in 43.3% of patients and completed in 41.5%. On final pathology, eight patients (1.3%) had high-risk lesions and two (0.3%) demonstrated malignancy (1 DCIS, 1 invasive). Of these 10 patients, two were under the age of 40 and four had preoperative mammograms. Factors associated with mammography discussion were age ≥40, White race, the presence of comorbidities, family history of breast cancer, prior breast surgery, prior breast biopsy, history of breast cancer (all P < 0.0001) and tobacco use (P = 0.04). CONCLUSIONS: Due to the potential risk of invasive cancer and high-risk lesions in the final surgical specimen, preoperative mammography should be discussed with selected patients by plastic surgeons, particularly those who fall within national screening guidelines.
AD  - Department of Plastic Surgery, Medical College of Wisconsin, Milwaukee, Wisconsin.
Intermountain Healthcare, Salt Lake City, Utah.
Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin.
Department of Surgery, Medical College of Wisconsin, Milwaukee, Wisconsin.
AN  - 30924231
AU  - Klement, K. A.
AU  - Hijjawi, J. B.
AU  - Neuner, J.
AU  - Kelley, K.
AU  - Kong, A. L.
DA  - May
DO  - 10.1111/tbj.13237
DP  - NLM
ET  - 2019/03/30
IS  - 3
KW  - Adolescent
Adult
Aged
Breast/abnormalities/surgery
Breast Neoplasms/*diagnostic imaging
Female
Humans
Hypertrophy/surgery
Mammaplasty/*methods
*Mammography
Middle Aged
Patient Selection
*Preoperative Care
Retrospective Studies
Young Adult
*preoperative screening
*reduction mammoplasty
LA  - eng
N1  - 1524-4741
Klement, Kristen A
Orcid: 0000-0002-4068-3008
Hijjawi, John B
Neuner, Joan
Kelley, Katherine
Kong, Amanda L
Journal Article
United States
Breast J. 2019 May;25(3):439-443. doi: 10.1111/tbj.13237. Epub 2019 Mar 28.
PY  - 2019
SN  - 1075-122x
SP  - 439-443
ST  - Discussion of preoperative mammography in women undergoing reduction mammaplasty
T2  - Breast J
TI  - Discussion of preoperative mammography in women undergoing reduction mammaplasty
VL  - 25
ID  - 79
ER  - 

TY  - JOUR
AB  - BACKGROUND: Clinical trials are essential to establish the effectiveness of new cancer therapies, but less than 5% of adults with cancer enroll in trials. In addition to ineligibility or lack of available trials, barriers to enrollment may include limited patient awareness about the option of participation. METHODS: We surveyed a multiregional cohort of patients with lung or colorectal cancer (or their surrogates) three to six months after diagnosis. We assessed whether respondents reported learning that clinical trial participation might be an option, and, if so, with whom they discussed trials. We used logistic regression to assess the association of patient characteristics with discussing trial participation and enrolling in trials. All statistical tests were two-sided. RESULTS: Of 7887 respondents, 1114 (14.1%) reported discussing the possibility of clinical trial participation; most learned about trials from their physicians, and 287 patients (3.6% of all patients, 25.8% of trial discussants) enrolled. Among 2173 patients who received chemotherapy for advanced (stage III/IV lung or stage IV colorectal) cancer, 25.7% discussed trials, and 7.6% (29.5% of trial discussants) enrolled. Discussions were less frequent among older patients, African American or Asian vs white patients, and those with lower incomes and more comorbidity. Enrollment was higher among patients reporting shared vs physician-driven decisions (all P < .05). CONCLUSIONS: In this population-based cohort, only 14% of patients discussed participation in clinical trials. Discussions were more frequent among advanced cancer patients but were still reported by a minority of patients. Strategies to expand access to trials and facilitate patient-provider communication about participation may accelerate development of better cancer therapeutics.
AD  - Division of General Internal Medicine, Brigham and Women's Hospital, Boston, MA (KLK, NLK); Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD (NKA, SBC, CNK); Division of Population Sciences, Dana-Farber Cancer Institute, Boston, MA (DS); Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor, MI (JZA); University of California, Los Angeles and RAND Corporation, Santa Monica, CA (KK); Department of Population Medicine (RHF) and Department of Health Care Policy (NLK, JZA), Harvard Medical School, Boston, MA.
Division of General Internal Medicine, Brigham and Women's Hospital, Boston, MA (KLK, NLK); Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD (NKA, SBC, CNK); Division of Population Sciences, Dana-Farber Cancer Institute, Boston, MA (DS); Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor, MI (JZA); University of California, Los Angeles and RAND Corporation, Santa Monica, CA (KK); Department of Population Medicine (RHF) and Department of Health Care Policy (NLK, JZA), Harvard Medical School, Boston, MA. keating@hcp.med.harvard.edu.
AN  - 25217775
AU  - Kehl, K. L.
AU  - Arora, N. K.
AU  - Schrag, D.
AU  - Ayanian, J. Z.
AU  - Clauser, S. B.
AU  - Klabunde, C. N.
AU  - Kahn, K. L.
AU  - Fletcher, R. H.
AU  - Keating, N. L.
C2  - PMC4168309
DA  - Oct
DO  - 10.1093/jnci/dju216
DP  - NLM
ET  - 2014/09/14
IS  - 10
KW  - African Americans/statistics & numerical data
Age Factors
Aged
Aged, 80 and over
Asian Americans/statistics & numerical data
Choice Behavior
Clinical Trials as Topic
Cohort Studies
Colorectal Neoplasms/*diagnosis/pathology/therapy
*Communication
Comorbidity
*Decision Making
European Continental Ancestry Group/statistics & numerical data
Female
Humans
Income
Information Seeking Behavior
Lung Neoplasms/*diagnosis/pathology/therapy
Male
Middle Aged
Neoplasm Staging
Patient Participation
*Patient Selection
Surveys and Questionnaires
United States
LA  - eng
N1  - 1460-2105
Kehl, Kenneth L
Arora, Neeraj K
Schrag, Deborah
Ayanian, John Z
Clauser, Steven B
Klabunde, Carrie N
Kahn, Katherine L
Fletcher, Robert H
Keating, Nancy L
U01 CA093348/CA/NCI NIH HHS/United States
U01 CA093344/CA/NCI NIH HHS/United States
U01 CA093324/CA/NCI NIH HHS/United States
U01 CA093326/CA/NCI NIH HHS/United States
U01 CA093329/CA/NCI NIH HHS/United States
U01 CA093332/CA/NCI NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
J Natl Cancer Inst. 2014 Sep 13;106(10):dju216. doi: 10.1093/jnci/dju216. Print 2014 Oct.
PY  - 2014
SN  - 0027-8874 (Print)
0027-8874
ST  - Discussions about clinical trials among patients with newly diagnosed lung and colorectal cancer
T2  - J Natl Cancer Inst
TI  - Discussions about clinical trials among patients with newly diagnosed lung and colorectal cancer
VL  - 106
ID  - 275
ER  - 

TY  - JOUR
AB  - Clinical trials are essential for the development of new and effective treatments for cancer; however, participation rates are low. One reason for this is lack of knowledge about clinical trials. This study assessed how often clinical trials are discussed on calls to National Cancer Institute's Cancer Information Service (CIS). The authors quantitatively analyzed 283,094 calls to the CIS (1-800-4-CANCER) over 3 years (2006-2008). They calculated descriptive statistics and multivariate regressions to determine whether specific caller characteristics are associated with the presence of a clinical trials discussion. In addition, 2 focus groups were conducted with CIS information specialists (n = 12) to provide insight into the findings. The authors found that approximately 9.3% of CIS calls discussed clinical trials, with higher percentages for patients (12.5%) and family members (15.4%). Calls with Hispanics, Blacks, and Spanish speakers were less likely to include a conversation. For all cancers, patients who are in treatment or experiencing a recurrence were statistically significantly more likely to discuss clinical trials. CIS information specialists reported callers' limited knowledge of clinical trials. The CIS has the unique ability to make a substantial effect in educating patients about clinical trials as an option in cancer treatment and care.
AN  - WOS:000304480800006
AU  - Byrne, M. M.
AU  - Kornfeld, J.
AU  - Vanderpool, R.
AU  - Belanger, M.
DO  - 10.1080/10810730.2011.626500
IS  - 3
N1  - 22150169
PY  - 2012
SN  - 1081-0730
SP  - 319-337
ST  - Discussions of Cancer Clinical Trials with the National Cancer Institute's Cancer Information Service
T2  - Journal of Health Communication
TI  - Discussions of Cancer Clinical Trials with the National Cancer Institute's Cancer Information Service
VL  - 17
ID  - 3077
ER  - 

TY  - JOUR
AB  - Background: Many terminally ill patients enroll in hospice only in the final days before death or not at all. Discussing hospice with a health care provider could increase awareness of hospice and possibly result in earlier use. Methods: We used data on 1517 patients diagnosed as having stage IV lung cancer from a multiregional study. We estimated logistic regression models for the probability that a patient discussed hospice with a physician or other health care provider before an interview 4 to 7 months after diagnosis as reported by either the patient or surrogate or documented in the medical record. Results: Half (53%) of the patients had discussed hospice with a provider. Patients who were black, Hispanic, non-English speaking, married or living with a partner, Medicaid beneficiaries, or had received chemotherapy were less likely to have discussed hospice. Only 53% of individuals who died within 2 months after the interview had discussed hospice, and rates were lower among those who lived longer. Patients who reported that they expected to live less than 2 years had much higher rates of discussion than those expecting to live longer. Patients reporting the most severe pain or dyspnea were no more likely to have discussed hospice than those reporting less severe or no symptoms. A third of patients who reported discussing do-not-resuscitate preferences with a physician had also discussed hospice. Conclusions: Many patients diagnosed as having metastatic lung cancer had not discussed hospice with a provider within 4 to 7 months after diagnosis. Increased communication with physicians could address patients' lack of awareness about hospice and misunderstandings about prognosis. Arch Intern Med. 2009; 169(10): 954-962
AN  - WOS:000266304500009
AU  - Huskamp, H. A.
AU  - Keating, N. L.
AU  - Malin, J. L.
AU  - Zaslavsky, A. M.
AU  - Weeks, J. C.
AU  - Earle, C. C.
AU  - Teno, J. M.
AU  - Virnig, B. A.
AU  - Kahn, K. L.
AU  - He, Y. L.
AU  - Ayanian, J. Z.
DA  - May
DO  - 10.1001/archinternmed.2009.127
IS  - 10
N1  - 19468089
PY  - 2009
SN  - 0003-9926
SP  - 954-962
ST  - Discussions With Physicians About Hospice Among Patients With Metastatic Lung Cancer
T2  - Archives of Internal Medicine
TI  - Discussions With Physicians About Hospice Among Patients With Metastatic Lung Cancer
VL  - 169
ID  - 3148
ER  - 

TY  - JOUR
AB  - Multiple myeloma (MM) is an incurable hematologic malignancy with disparities in outcomes noted among racial-ethnic subgroups, likely due to disparities in access to effective treatment modalities. Clinical trials can provide access to evidence-based medicine but representation of minorities on therapeutic clinical trials has been dismal. We evaluated the impact of patient race-ethnicity in pooled data from nine large national cooperative group clinical trials in newly diagnosed MM. Among 2896 patients enrolled over more than two decades, only 18% were non-White and enrollment of minorities actually decreased in most recent years (2002-2011). African-Americans were younger and had more frequent poor-risk markers, including anemia and increased lactate dehydrogenase. Hispanics had the smallest proportion of patients on trials utilizing novel therapeutic agents. While adverse demographic (increased age) and clinical (performance status, stage, anemia, kidney dysfunction) factors were associated with inferior survival, patient race-ethnicity did not have an effect on objective response rates, progression-free, or overall survival. While there are significant disparities in MM incidence and outcomes among patients of different racial-ethnic groups, this disparity seems to be mitigated by access to appropriate therapeutic options, for example, as offered by clinical trials. Improved minority accrual in therapeutic clinical trials needs to be a priority.
AD  - Mayo Clinic, Jacksonville, FL, USA. ailawadhi.sikander@mayo.edu.
Dana Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA, USA.
South West Oncology Group (SWOG) Statistical Center, Seattle, WA, USA.
Mayo Clinic, Scottsdale, AZ, USA.
Mayo Clinic, Rochester, MN, USA.
Celgene Corporation, Summit, NJ, USA.
Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA.
Mount Sinai Medical Center, New York, NY, USA.
MD Anderson Cancer Center, The University of Texas, Houston, TX, USA.
AN  - 29980678
AU  - Ailawadhi, S.
AU  - Jacobus, S.
AU  - Sexton, R.
AU  - Stewart, A. K.
AU  - Dispenzieri, A.
AU  - Hussein, M. A.
AU  - Zonder, J. A.
AU  - Crowley, J.
AU  - Hoering, A.
AU  - Barlogie, B.
AU  - Orlowski, R. Z.
AU  - Rajkumar, S. V.
C2  - PMC6035273
DA  - Jul 6
DO  - 10.1038/s41408-018-0102-7
DP  - NLM
ET  - 2018/07/08
IS  - 7
KW  - Adult
Aged
Aged, 80 and over
Clinical Trials as Topic
Combined Modality Therapy
Ethnic Groups
European Continental Ancestry Group
Female
*Healthcare Disparities
Humans
Male
Middle Aged
Multiple Myeloma/diagnosis/*epidemiology/mortality/therapy
Neoplasm Staging
Outcome Assessment, Health Care
Prognosis
LA  - eng
N1  - 2044-5385
Ailawadhi, Sikander
Jacobus, Susanna
Sexton, Rachael
Stewart, Alexander K
Dispenzieri, Angela
Hussein, Mohamad A
Zonder, Jeffrey A
Crowley, John
Hoering, Antje
Barlogie, Bart
Orlowski, Robert Z
Rajkumar, S Vincent
N01 CA004919/CA/NCI NIH HHS/United States
U10 CA037981/CA/NCI NIH HHS/United States
U10 CA004919/CA/NCI NIH HHS/United States
U10 CA013650/CA/NCI NIH HHS/United States
U10 CA021115/CA/NCI NIH HHS/United States
U10 CA180835/CA/NCI NIH HHS/United States
UG1 CA189974/CA/NCI NIH HHS/United States
U10 CA180858/CA/NCI NIH HHS/United States
U10 CA066636/CA/NCI NIH HHS/United States
P50 CA186781/CA/NCI NIH HHS/United States
UG1 CA189828/CA/NCI NIH HHS/United States
U10 CA180790/CA/NCI NIH HHS/United States
U10 CA180820/CA/NCI NIH HHS/United States
U10 CA023318/CA/NCI NIH HHS/United States
U10 CA180794/CA/NCI NIH HHS/United States
U10 CA180888/CA/NCI NIH HHS/United States
U10 CA180819/CA/NCI NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
Blood Cancer J. 2018 Jul 6;8(7):67. doi: 10.1038/s41408-018-0102-7.
PY  - 2018
SN  - 2044-5385
SP  - 67
ST  - Disease and outcome disparities in multiple myeloma: exploring the role of race/ethnicity in the Cooperative Group clinical trials
T2  - Blood Cancer J
TI  - Disease and outcome disparities in multiple myeloma: exploring the role of race/ethnicity in the Cooperative Group clinical trials
VL  - 8
ID  - 113
ER  - 

TY  - JOUR
AB  - IMPORTANCE: Pathologic complete response rate (pCR), the primary end point of the ACOSOG (American College of Surgeons Oncology Group) Z1041 (Alliance) trial, and disease-free survival (DFS) and overall survival (OS) in women with operable HER2-positive breast cancer are similar between treatment regimens. OBJECTIVE: To assess DFS and OS for patients treated with sequential vs concurrent anthracycline plus trastuzumab. DESIGN, SETTING, AND PARTICIPANTS: Phase 3 randomized clinical trial conducted at 36 centers in the continental United States and Puerto Rico. Women 18 years or older with invasive operable HER2-positive breast cancer were enrolled from September 15, 2007, to December 15, 2011, and randomized to 1 of 2 treatment arms. The analysis data set was locked on October 15, 2017, and analysis was completed on December 15, 2017. INTERVENTIONS: Patients randomized to arm 1 received 500 mg/m2 of fluorouracil, 75 mg/m2 of epirubicin, and 500 mg/m2 of cyclophosphamide (FEC) every 3 weeks for 12 weeks followed by the combination of 80 mg/m2 of paclitaxel and 2 mg/kg (except initial dose of 4 mg/kg) of trastuzumab weekly for 12 weeks. Patients randomized to arm 2 received the same combination of paclitaxel with trastuzumab weekly for 12 weeks followed by FEC every 3 weeks with weekly trastuzumab for 12 weeks. Women with hormone receptor-positive disease received endocrine therapy, and radiotherapy was delivered at physician discretion. MAIN OUTCOMES AND MEASURES: The primary outcomes were DFS and OS and pCR in the breast and nodes. RESULTS: Two hundred eighty-two women with HER2-positive breast cancer were enrolled in the trial, and 2 withdrew consent before treatment. Among the remaining 280 women, the median age was 50 years (range, 28-76 years), 232 (82.9%) were white, 29 (10.3%) were black, 8 (2.9%) were Asian, 4 (1.4%) were American Indian or Alaskan Native, and 7 (2.5%) did not report race/ethnicity. There were 22 disease events in arm 1 and 27 in arm 2. Disease-free survival rates did not differ with respect to treatment arm (stratified log-rank P = .96; stratified hazard ratio [HR] [arm 2 to arm 1], 1.02; 95% CI, 0.56-1.83). Overall survival did not differ with respect to treatment arm (stratified log-rank P = .73; stratified HR [arm 2 to arm 1], 1.17; 95% CI, 0.48-2.88). CONCLUSIONS AND RELEVANCE: Across a median follow-up of 5.1 years (range, 26 days to 6.2 years), pCR, DFS, and OS did not differ with respect to sequential or concurrent administration of FEC with trastuzumab. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT00513292.
AD  - Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston.
Department of Health Sciences Research, Alliance Statistics and Data Center, Mayo Clinic, Rochester, Minnesota.
Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston.
Department of Surgery, University of Texas Southwestern Medical Center, Dallas.
Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.
Department of Surgery, Mayo Clinic, Rochester, Minnesota.
Doctor's Hospital of Laredo, Laredo, Texas.
Department of Medical Oncology, University of New Mexico School of Medicine, Albuquerque.
Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston.
AN  - 30193295
AU  - Buzdar, A. U.
AU  - Suman, V. J.
AU  - Meric-Bernstam, F.
AU  - Leitch, A. M.
AU  - Ellis, M. J.
AU  - Boughey, J. C.
AU  - Unzeitig, G. W.
AU  - Royce, M. E.
AU  - Hunt, K. K.
C2  - PMC6331049 sponsorship from Genentech, Novartis, Puma Biotechnology, Taiho Oncology, Pfizer, Pieris Pharmaceuticals Inc, and Zymeworks and serving as a consultant for Genentech and Pieris Pharmaceuticals Inc. Dr Royce reported receiving travel and consultancy fees from Syndax; consultancy fees from CellTrion; travel and consultancy fees from Novartis; and grant support to her institution from Novartis. Dr Hunt reported receiving research funding to her institution from Endomagnetics. She serves on advisory boards for Merck and Armada Health. No other disclosures are reported.
DA  - Jan 1
DO  - 10.1001/jamaoncol.2018.3691
DP  - NLM
ET  - 2018/09/08
IS  - 1
KW  - Adult
Aged
Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use
Biomarkers, Tumor/*analysis
Breast Neoplasms/chemistry/*drug therapy/mortality/pathology
Chemotherapy, Adjuvant
Cyclophosphamide/administration & dosage
Disease Progression
Drug Administration Schedule
Epirubicin/administration & dosage
Female
Fluorouracil/administration & dosage
Humans
Middle Aged
*Neoadjuvant Therapy/adverse effects/mortality
Paclitaxel/administration & dosage
Progression-Free Survival
Puerto Rico
Receptor, ErbB-2/*analysis
Risk Factors
Time Factors
Trastuzumab/administration & dosage
United States
LA  - eng
N1  - 2374-2445
Buzdar, Aman U
Suman, Vera J
Meric-Bernstam, Funda
Leitch, Ann Marilyn
Ellis, Matthew J
Boughey, Judy C
Unzeitig, Gary W
Royce, Melanie E
Hunt, Kelly K
P30 CA016672/CA/NCI NIH HHS/United States
UG1 CA233329/CA/NCI NIH HHS/United States
U10 CA180821/CA/NCI NIH HHS/United States
U10 CA180858/CA/NCI NIH HHS/United States
UG1 CA232760/CA/NCI NIH HHS/United States
UG1 CA233302/CA/NCI NIH HHS/United States
U10 CA180790/CA/NCI NIH HHS/United States
U10 CA180882/CA/NCI NIH HHS/United States
U10 CA180870/CA/NCI NIH HHS/United States
Clinical Trial, Phase III
Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
JAMA Oncol. 2019 Jan 1;5(1):45-50. doi: 10.1001/jamaoncol.2018.3691.
PY  - 2019
SN  - 2374-2437 (Print)
2374-2437
SP  - 45-50
ST  - Disease-Free and Overall Survival Among Patients With Operable HER2-Positive Breast Cancer Treated With Sequential vs Concurrent Chemotherapy: The ACOSOG Z1041 (Alliance) Randomized Clinical Trial
T2  - JAMA Oncol
TI  - Disease-Free and Overall Survival Among Patients With Operable HER2-Positive Breast Cancer Treated With Sequential vs Concurrent Chemotherapy: The ACOSOG Z1041 (Alliance) Randomized Clinical Trial
VL  - 5
ID  - 106
ER  - 

TY  - JOUR
AN  - 144269786. Language: English. Entry Date: 20200708. Revision Date: 20200708. Publication Type: Article
AU  - Newitt, Valerie Neff
DB  - CINAHL Complete
DO  - 10.1097/01.cot.0000654700.58384.e2
DP  - EBSCOhost
IS  - 3
KW  - Healthcare Disparities
Cancer Patients
Clinical Trials
Research Subject Recruitment
Black Persons -- Psychosocial Factors
Prostatic Neoplasms
Socioeconomic Factors
Health Services Accessibility
Financial Support
Abiraterone Acetate -- Therapeutic Use
Career Planning and Development
N1  - pictorial. Journal Subset: Biomedical; Peer Reviewed; USA. NLM UID: 8100849.
PY  - 2020
SN  - 0276-2234
SP  - 1-11
ST  - Disparities among Cancer Patients Seen in gaps in Clinical Trial Participation
T2  - Oncology Times
TI  - Disparities among Cancer Patients Seen in gaps in Clinical Trial Participation
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=144269786&site=ehost-live&scope=site
VL  - 42
ID  - 1917
ER  - 

TY  - JOUR
AD  - Memorial Sloan Kettering Cancer Center, New York, NY.
Memorial Sloan Kettering Cancer Center, New York, NY osbornej@mskcc.org.
AN  - 25691679
AU  - Spratt, D. E.
AU  - Osborne, J. R.
C2  - PMC4372848
DA  - Apr 1
DO  - 10.1200/jco.2014.58.1751
DP  - NLM
ET  - 2015/02/19
IS  - 10
KW  - African Americans/statistics & numerical data
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Clinical Trials, Phase III as Topic
European Continental Ancestry Group/statistics & numerical data
Healthcare Disparities/ethnology/*statistics & numerical data
Humans
Male
Prostatic Neoplasms, Castration-Resistant/*drug therapy/ethnology/*radiotherapy
Radioisotopes
Radium/*therapeutic use
Randomized Controlled Trials as Topic
United States
LA  - eng
N1  - 1527-7755
Spratt, Daniel E
Osborne, Joseph R
P30 CA008748/CA/NCI NIH HHS/United States
R21 CA153177/CA/NCI NIH HHS/United States
U54 CA132378/CA/NCI NIH HHS/United States
U54 CA137788/CA/NCI NIH HHS/United States
Journal Article
J Clin Oncol. 2015 Apr 1;33(10):1101-3. doi: 10.1200/JCO.2014.58.1751. Epub 2015 Feb 17.
PY  - 2015
SN  - 0732-183X (Print)
0732-183x
SP  - 1101-3
ST  - Disparities in castration-resistant prostate cancer trials
T2  - J Clin Oncol
TI  - Disparities in castration-resistant prostate cancer trials
VL  - 33
ID  - 259
ER  - 

TY  - JOUR
AB  - PURPOSE: To examine whether and how distrust of the health system and predisposition to use healthcare services influence frequency of mammograms and Clinical Breast Exams (CBEs). METHODS: A community-based survey recruited 184 women (age 47+/-12); 49% were college-educated, 77% had health insurance, and 57% were non-white. Distrust was measured with a four-item scale (Cronbach alpha=0.71); predisposition to use health services with an 11-item scale (Cronbach alpha=0.84). Ordinal regression analysis was used to test two models examining 'time since last mammogram' and 'time since last CBE.' The later model had a better goodness-of-fit, as indicated by a non-significant, Pearson coefficient. FINDINGS: Distrust to the health system was significantly correlated with age (r=-0.19*), income (r=-0.16*), and predisposition to use health services (r=-0.26**). Distrust predicted time since last CBE (B: 0.37, SE: 0.19*), which in turn was significantly correlated with time since last mammogram (r=0.44**). Predisposition to use health services predicted time since last CBE (B: -0.78, SE: 0.19**) and time since last mammogram (B: -0.47, SE: 0.22**). Insurance predicted time since last CBE (B: -0.94, SE: 0.44*), while age (B: -0.21, SE: 0.03**) and income (B: -0.19, SE: 0.09*) predicted time since last mammogram. CONCLUSION: Distrust of the healthcare system and predisposition to use health services influence breast cancer screening directly. Distrust interferes with behavioral patterns that favor recurrent breast cancer screening. PRACTICE IMPLICATIONS: Trustworthiness in the healthcare system and positive attitudes for the use of, health services enhance routine breast cancer screening. *p<0.05, **p<0.001.
AD  - Division of Acute, Critical, and Long Term Care, University of Michigan School of Nursing, 400 N. Ingalls Building, Room 2158, Ann Arbor, MI 48109, United States. mkatapo@umich.edu
AN  - 105060567. Language: English. Entry Date: 20100917. Revision Date: 20150820. Publication Type: Journal Article
AU  - Katapodi, M. C.
AU  - Pierce, P. F.
AU  - Facione, N. C.
DB  - CINAHL Complete
DO  - 10.1016/j.ijnurstu.2009.12.014
DP  - EBSCOhost
IS  - 8
KW  - Breast Neoplasms -- Prevention and Control
Cancer Screening
Consumer Attitudes
Health Resource Utilization
Trust
Adult
Age Factors
Asians
Black Persons
Breast Examination
Coefficient Alpha
Consumer Attitudes -- Evaluation
Convenience Sample
Cross Sectional Studies
Descriptive Research
Descriptive Statistics
Female
Funding Source
Hispanic Americans
Human
Income
Middle Age
Pearson's Correlation Coefficient
Questionnaires
Regression
Research Subject Recruitment
Scales
Summated Rating Scaling
United States
White Persons
N1  - research; tables/charts. Journal Subset: Core Nursing; Europe; Nursing; Peer Reviewed; UK & Ireland. Instrumentation: Distrust of the Healthcare System Scale (DHS); Habit of Health Services Utilization scale (HHSU). Grant Information: Department of Defense Medical Research, Breast Cancer Research Program, Clinical Nurse Research Grant, Award No. DAMD17-03-1-0356. NLM UID: 0400675.
PMID: NLM20089252.
PY  - 2010
SN  - 0020-7489
SP  - 975-983
ST  - Distrust, predisposition to use health services and breast cancer screening: results from a multicultural community-based survey
T2  - International Journal of Nursing Studies
TI  - Distrust, predisposition to use health services and breast cancer screening: results from a multicultural community-based survey
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105060567&site=ehost-live&scope=site
VL  - 47
ID  - 1918
ER  - 

TY  - JOUR
AB  - Background: Although there are considerable racial and ethnic disparities in prostate cancer incidence and mortality in the United States and globally, clinical trials often do not reflect disease incidence across racial and ethnic subgroups. This study aims to comprehensively review the reporting of race and ethnicity data and the representation of race and ethnicity across prostate cancer treatment-, prevention-, and screening-based clinical trials. Methods: Seventy-two global phase III and IV prevention, screening, and treatment prostate cancer clinical trials with enrollment start dates between 1987 and 2016 were analyzed in this study, representing a total of 893,378 individual trial participants. Availability and representation of race and ethnicity data by trial funding type, temporal changes in the racial/ethnic diversity of participants, and geographic representation of countries were assessed. Results: Of the 72 trials analyzed, 59 (81.9%) had available race data, and 11 (15.3%) of these trials additionally reported ethnicity. Of the trials reporting data, participants were overwhelmingly white men (with the highest proportion in U.S. nonpublicly funded trials), comprising over 96% of the study population. The proportion of white participants in prostate cancer clinical trials has remained at over 80% since 1990. Geographically, Africa and the Caribbean were particularly underrepresented with only 3% of countries included. Conclusions: Trial participants continue to be majority white despite the known racial disparities in prostate cancer clinical outcomes. Impact: Current and future trials must use novel recruitment strategies to ensure enrollment of underrepresented men. Targeting the inclusion of African and Caribbean medical centers is crucial to achieve equity in representation.
AD  - E.M. Rencsok, Harvard T.H. Chan School of Public Health, 677 Huntington Avenue, Boston, MA, United States
AU  - Rencsok, E. M.
AU  - Bazzi, L. A.
AU  - McKay, R. R.
AU  - Huang, F. W.
AU  - Friedant, A.
AU  - Vinson, J.
AU  - Peisch, S.
AU  - Zarif, J. C.
AU  - Simmons, S.
AU  - Hawthorne, K.
AU  - Villanti, P.
AU  - Kantoff, P. W.
AU  - Heath, E.
AU  - George, D. J.
AU  - Mucci, L. A.
DB  - Embase
Medline
DO  - 10.1158/1055-9965.EPI-19-1616
IS  - 7
KW  - Africa
African American
Alaska Native
American Indian
article
Asian
Black person
cancer prevention
cancer screening
cancer therapy
Caribbean
Caucasian
clinical outcome
ethnic difference
funding
Hispanic
human
major clinical study
male
multiracial person
patient information
patient selection
phase 3 clinical trial (topic)
phase 4 clinical trial (topic)
prevention study
priority journal
prostate cancer
race difference
systematic review
LA  - English
M3  - Article
N1  - L2010900008
2021-02-10
2021-02-18
PY  - 2020
SN  - 1538-7755
1055-9965
SP  - 1374-1380
ST  - Diversity of enrollment in prostate cancer clinical trials: current status and future directions
T2  - Cancer Epidemiology Biomarkers and Prevention
TI  - Diversity of enrollment in prostate cancer clinical trials: current status and future directions
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L2010900008&from=export
http://dx.doi.org/10.1158/1055-9965.EPI-19-1616
VL  - 29
ID  - 800
ER  - 

TY  - JOUR
AD  - J. Adolfsson, Oncologic Center, Karolinska University Hospital, 171 76 Stockholm, Sweden
AU  - Adolfsson, J.
DB  - Embase
DO  - 10.1038/ncpuro0205
IS  - 6
KW  - prostate specific antigen
academic achievement
African American
cancer diagnosis
cancer screening
Caucasian
digital rectal examination
ethnic difference
ethnology
follow up
human
laboratory diagnosis
male
patient care
patient compliance
priority journal
prostate cancer
refusal to participate
short survey
LA  - English
M3  - Short Survey
N1  - L40903180
2005-07-12
PY  - 2005
SN  - 1743-4270
SP  - 272-273
ST  - Do false-positive screening results affect screening behavior for prostate cancer?
T2  - Nature Clinical Practice Urology
TI  - Do false-positive screening results affect screening behavior for prostate cancer?
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L40903180&from=export
http://dx.doi.org/10.1038/ncpuro0205
VL  - 2
ID  - 1266
ER  - 

TY  - JOUR
AB  - Background: Black patients have higher lung cancer risk despite lower pack years of smoking. We assessed lung cancer risk by race, ethnicity, and sex among a nationally representative population eligible for lung cancer screening based on Medicare criteria. Methods: We used data from the National Health and Nutrition Examination Survey, 2007-2012 to assess lung cancer risk by sex, race and ethnicity among persons satisfying Medicare age and pack-year smoking eligibility criteria for lung cancer screening. We assessed Medicare eligibility based on age (55-77 years) and pack-years (>30). We assessed 6-year lung cancer risk using a risk prediction model from Prostate, Lung, Colorectal and Ovarian Cancer Screening trial that was modified in 2012 (PLCOm2012). We compared the proportions of eligible persons by sex, race and ethnicity using Medicare criteria with a risk cut-point that was adjusted to achieve comparable total number of persons eligible for screening. Results: Among the 29.7 million persons aged 55-77 years who ever smoked, we found that 7.3 million (24.5%) were eligible for lung cancer screening under Medicare criteria. Among those eligible, Blacks had statistically significant higher (4.4%) and Hispanics lower lung cancer risk (1.2%) than non-Hispanic Whites (3.2%). At a cut-point of 2.12% risk for lung screening eligibility, the percentage of Blacks and Hispanics showed statistically significant changes. Blacks eligible rose by 48% and Hispanics eligible declined by 63%. Black men and Hispanic women were affected the most. There was little change in eligibility among Whites. Conclusion: Medicare eligibility criteria for lung cancer screening do not align with estimated risk for lung cancer among Blacks and Hispanics. Data are urgently needed to determine whether use of risk-based eligibility screening improves lung cancer outcomes among minority patients.
AU  - Fiscella, K.
AU  - Winters, P.
AU  - Farah, S.
AU  - Sanders, M.
AU  - Mohile, S. G.
DB  - Embase
Medline
DO  - 10.1371/journal.pone.0143789
IS  - 11
KW  - adult
aged
article
Black person
cancer risk
cancer screening
controlled study
ethnic difference
female
health care delivery
health survey
high risk population
Hispanic
human
lung cancer
major clinical study
male
medicare
minority group
outcome assessment
patient selection
population research
race difference
risk assessment
sex difference
smoking
United States
LA  - English
M3  - Article
N1  - L608067742
2016-02-12
2016-02-17
PY  - 2015
SN  - 1932-6203
ST  - Do lung cancer eligibility criteria align with risk among blacks and hispanics?
T2  - PLoS ONE
TI  - Do lung cancer eligibility criteria align with risk among blacks and hispanics?
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L608067742&from=export
http://dx.doi.org/10.1371/journal.pone.0143789
VL  - 10
ID  - 993
ER  - 

TY  - JOUR
AB  - Most professional organizations, including the American College of Physicians and U.S. Preventive Services Task Force, emphasize that screening for prostate cancer with the prostate-specific antigen (PSA) test should only occur after a detailed discussion between the health-care provider and patient about the known risks and potential benefits of the test. In fact, guidelines strongly advise health-care providers to involve patients, particularly those at elevated risk of prostate cancer, in a "shared decision making" (SDM) process about PSA testing. We analyzed data from the National Cancer Institute's Health Information National Trends Survey 2011-2012-a nationally representative, cross-sectional survey-to examine the extent to which health professionals provided men with information critical to SDM prior to PSA testing, including (1) that patients had a choice about whether or not to undergo PSA testing, (2) that not all doctors recommend PSA testing, and (3) that no one is sure if PSA testing saves lives. Over half (55 %) of men between the ages of 50 and 74 reported ever having had a PSA test. However, only 10 % of men, regardless of screening status, reported receiving all three pieces of information: 55 % reported being informed that they could choose whether or not to undergo testing, 22 % reported being informed that some doctors recommend PSA testing and others do not, and 14 % reported being informed that no one is sure if PSA testing actually saves lives. Black men and men with lower levels of education were less likely to be provided this information. There is a need to improve patient-provider communication about the uncertainties associated with the PSA test. Interventions directed at patients, providers, and practice settings should be considered.
AD  - Process of Care Research Branch, Behavioral Research Program, National Cancer Institute, National Institutes of Health, 9609 Medical Center Dr. 3E230, Bethesda, MD, 20892, USA. leyvabryan@gmail.com.
Basic Biobehavioral and Psychological Sciences Branch, Behavioral Research Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Science of Research and Technology Branch, Behavioral Research Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Department of Public Health and Community Medicine, Tufts University, Boston, MA, USA.
Process of Care Research Branch, Behavioral Research Program, National Cancer Institute, National Institutes of Health, 9609 Medical Center Dr. 3E230, Bethesda, MD, 20892, USA.
AN  - 26498649
AU  - Leyva, B.
AU  - Persoskie, A.
AU  - Ottenbacher, A.
AU  - Hamilton, J. G.
AU  - Allen, J. D.
AU  - Kobrin, S. C.
AU  - Taplin, S. H.
C2  - PMC5515087
C6  - NIHMS875215
DA  - Dec
DO  - 10.1007/s13187-015-0870-8
DP  - NLM
ET  - 2016/10/21
IS  - 4
KW  - Aged
Biomarkers, Tumor/blood
Communication
Cross-Sectional Studies
*Decision Making
Early Detection of Cancer/*methods/psychology
*Health Knowledge, Attitudes, Practice
Humans
Male
Middle Aged
*Patient Navigation
Patient Participation
Physicians/psychology
Prostate-Specific Antigen/*blood
Prostatic Neoplasms/blood/*diagnosis/prevention & control/psychology
Risk Factors
Surveys and Questionnaires
United States/epidemiology
*PSA testing
*Patient-provider communication
*Prostate cancer screening
*Shared decision making
*Uncertainty
disclose.
LA  - eng
N1  - 1543-0154
Leyva, Bryan
Persoskie, Alexander
Ottenbacher, Allison
Hamilton, Jada G
Allen, Jennifer D
Kobrin, Sarah C
Taplin, Stephen H
P30 CA008748/CA/NCI NIH HHS/United States
Journal Article
J Cancer Educ. 2016 Dec;31(4):693-701. doi: 10.1007/s13187-015-0870-8.
PY  - 2016
SN  - 0885-8195 (Print)
0885-8195
SP  - 693-701
ST  - Do Men Receive Information Required for Shared Decision Making About PSA Testing? Results from a National Survey
T2  - J Cancer Educ
TI  - Do Men Receive Information Required for Shared Decision Making About PSA Testing? Results from a National Survey
VL  - 31
ID  - 199
ER  - 

TY  - JOUR
AB  - Purpose Financial toxicity negatively affects patients with cancer, especially racial/ethnic minorities. Patient-oncologist discussions about treatment-related costs may reduce financial toxicity by factoring costs into treatment decisions. This study investigated the frequency and nature of cost discussions during clinical interactions between African American patients and oncologists and examined whether cost discussions were affected by patient sociodemographic characteristics and social support, a known buffer to perceived financial stress. Methods Video recorded patient-oncologist clinical interactions (n = 103) from outpatient clinics of two urban cancer hospitals (including a National Cancer Institute-designated comprehensive cancer center) were analyzed. Coders studied the videos for the presence and duration of cost discussions and then determined the initiator, topic, oncologist response to the patient's concerns, and the patient's reaction to the oncologist's response. Results Cost discussions occurred in 45% of clinical interactions. Patients initiated 63% of discussions; oncologists initiated 36%. The most frequent topics were concern about time off from work for treatment (initiated by patients) and insurance (initiated by oncologists). Younger patients and patients with more perceived social support satisfaction were more likely to discuss cost. Patient age interacted with amount of social support to affect frequency of cost discussions within interactions. Younger patients with more social support had more cost discussions; older patients with more social support had fewer cost discussions. Conclusion Cost discussions occurred in fewer than one half of the interactions and most commonly focused on the impact of the diagnosis on patients' opportunity costs rather than treatment costs. Implications for ASCO's Value Framework and design of interventions to improve cost discussions are discussed.
AD  - Karmanos Cancer Institute, Wayne State University
Josephine Ford Cancer Institute, Henry Ford Health System, Detroit, MI
AN  - 121734396. Language: English. Entry Date: 20170315. Revision Date: 20190711. Publication Type: Article
AU  - Hamel, Lauren M.
AU  - Penner, Louis A.
AU  - Eggly, Susan
AU  - Chapman, Robert
AU  - Klamerus, Justin F.
AU  - Simon, MichaelS
AU  - Stanton, Sarah C. E.
AU  - Albrecht, Terrance L.
DB  - CINAHL Complete
DO  - 10.1200/JOP.2016.015859
DP  - EBSCOhost
IS  - 3
KW  - Health Care Costs
Oncologists
Physician-Patient Relations -- Evaluation
Cancer Care Facilities
Human
Minority Groups
National Cancer Institute (U.S.)
Neoplasms
Oncology
Physicians
Support, Psychosocial
United States
Videorecording
Black Persons
Race Factors
Cancer Patients -- Evaluation
Ethnic Groups
Health Services Accessibility -- Evaluation
Outpatient Service
Patient Satisfaction
Neoplasms -- Economics
Data Collection
Communication
Research Subject Recruitment
Socioeconomic Factors
Multivariate Analysis
Regression
Data Analysis Software
Male
Female
Education
Income
Breast Neoplasms -- Diagnosis
Colorectal Neoplasms
Lung Neoplasms
N1  - research; tables/charts. Journal Subset: Biomedical; Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; USA. NLM UID: 101261852.
PY  - 2017
SN  - 1554-7477
SP  - e249-e258
ST  - Do Patients and Oncologists Discuss the Cost of Cancer Treatment? An Observational Study of Clinical Interactions Between African American Patients and Their Oncologists
T2  - Journal of Oncology Practice
TI  - Do Patients and Oncologists Discuss the Cost of Cancer Treatment? An Observational Study of Clinical Interactions Between African American Patients and Their Oncologists
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=121734396&site=ehost-live&scope=site
VL  - 13
ID  - 1919
ER  - 

TY  - JOUR
AB  - BACKGROUND: Significant palliative care intervention has focused on physical pain and symptom control; yet less empirical evidence supports efforts to address the psychosocial and spiritual dimensions of experience. OBJECTIVE: To evaluate the impact of an intervention (Outlook) that promotes discussions of end-of-life preparation and completion on health outcomes in dying persons, including pain and symptoms, physical function, emotional function (anxiety and depression), spiritual well-being, and quality of life at the end of life. DESIGN: A three-arm pilot randomized control trial. Subjects were recruited from inpatient and outpatient hospital, palliative care, and hospice settings. Intervention subjects met with a facilitator three times and discussed issues related to life review, forgiveness, and heritage and legacy. Attention control subjects met with a facilitator three times and listened to a nonguided relaxation CD. True control subjects received no intervention. MEASUREMENTS: Preoutcomes and postoutcomes included the Memorial Symptom Assessment Scale, QUAL-E, Rosow-Breslau ADL Scale, Profile of Mood States anxiety sub-scale, the CESD short version, and the Daily Spiritual Experience Scale. RESULTS: Eighty-two hospice eligible patients enrolled in the study; 38 were women, 35 were African American. Participants' primary diagnoses included cancer (48), heart disease (5) lung disease (10), and other (19) Ages ranged from 28-96. Participants in the active discussion intervention showed improvements in functional status, anxiety, depression, and preparation for end of life. CONCLUSIONS: The Outlook intervention was acceptable to patients from a variety of educational and ethnic backgrounds and offers a brief, manualized, intervention for emotional and spiritual concerns.
AD  - Center for Health Services Research in Primary Care, Durham VA Medical Center, Durham, North Carolina 27705, USA. Karen.steinhauser@duke.edu
AN  - 19021487
AU  - Steinhauser, K. E.
AU  - Alexander, S. C.
AU  - Byock, I. R.
AU  - George, L. K.
AU  - Olsen, M. K.
AU  - Tulsky, J. A.
DA  - Nov
DO  - 10.1089/jpm.2008.0078
DP  - NLM
ET  - 2008/11/22
IS  - 9
KW  - *Activities of Daily Living
Adult
Aged
Aged, 80 and over
Female
Humans
Interviews as Topic
Male
Middle Aged
North Carolina
Palliative Care/*methods
Quality of Life/*psychology
*Severity of Illness Index
Spirituality
Terminal Care/psychology
LA  - eng
N1  - 1557-7740
Steinhauser, Karen E
Alexander, Stewart C
Byock, Ira R
George, Linda K
Olsen, Maren K
Tulsky, James A
Journal Article
Randomized Controlled Trial
United States
J Palliat Med. 2008 Nov;11(9):1234-40. doi: 10.1089/jpm.2008.0078.
PY  - 2008
SN  - 1557-7740
SP  - 1234-40
ST  - Do preparation and life completion discussions improve functioning and quality of life in seriously ill patients? Pilot randomized control trial
T2  - J Palliat Med
TI  - Do preparation and life completion discussions improve functioning and quality of life in seriously ill patients? Pilot randomized control trial
VL  - 11
ID  - 483
ER  - 

TY  - JOUR
AB  - BACKGROUND: In this randomized trial, Project CARE, we examined whether participation in a cognitive-behavioral stress management and breast cancer wellness and education program improved psychological outcomes among a sample of underserved black breast cancer survivors. METHODS: Both complementary medicine interventions were 10-sessions, manualized, group-based, and were culturally adapted for black women in the community from evidence-based interventions. Participants were 114 black women (mean age = 51.1, 27-77 years) who had completed breast cancer treatment 0-12 months before enrollment (stages 0-IV, mean time since cancer diagnosis = 14.1 months). Women were enrolled upon completion of curative treatment (ie, surgical, chemotherapy, radiation oncology) and randomized to receive cognitive-behavioral stress management or cancer wellness and education program. RESULTS: There was a remarkable 95% retention rate from baseline to 6-month follow-up. Participants in both conditions showed statistically significant improvement on indices of psychological well-being, including overall quality of life (Functional Assessment of Cancer Therapy-Breast), intrusive thoughts (Impact of Event Scale-Revised), depressive symptoms (Center for Epidemiologic Studies-Depression), and stress levels (Perceived Stress Scale) over the 6-month postintervention follow-up (all repeated measures analysis of variance within-subjects time effects: P < .05, except for overall mood; Profile of Mood States-Short Version). Contrary to hypotheses, however, condition × time effects were not statistically significant. CONCLUSIONS: Findings suggest that improvements in multiple measures over time may have been due to intensive training in stress management, extensive provision of breast cancer information, or participation in an ongoing supportive group of individuals from a similar racial background. Implications bear on decisions about appropriate control groups, the timing of intervention delivery during the treatment trajectory, and perceived support from the research team.
AD  - Department of Psychiatry and Behavioral Sciences (SCL, BRR, MHA), Sylvester Comprehensive Cancer Center (SCL, DWA, CSC, EK, MHA), and Department of Public Health Sciences (EK), University of Miami Miller School of Medicine, Miami, FL; Department of Clinical and Health Psychology, University of Florida, Gainesville, FL (NEW); The Miriam Hospital, The Warren Alpert Medical School of Brown University, Providence, RI (SV); Department of Psychology, University of Miami, Coral Gables, FL (MHA, CSC). SLechner@med.miami.edu.
Department of Psychiatry and Behavioral Sciences (SCL, BRR, MHA), Sylvester Comprehensive Cancer Center (SCL, DWA, CSC, EK, MHA), and Department of Public Health Sciences (EK), University of Miami Miller School of Medicine, Miami, FL; Department of Clinical and Health Psychology, University of Florida, Gainesville, FL (NEW); The Miriam Hospital, The Warren Alpert Medical School of Brown University, Providence, RI (SV); Department of Psychology, University of Miami, Coral Gables, FL (MHA, CSC).
AN  - 25749598
AU  - Lechner, S. C.
AU  - Whitehead, N. E.
AU  - Vargas, S.
AU  - Annane, D. W.
AU  - Robertson, B. R.
AU  - Carver, C. S.
AU  - Kobetz, E.
AU  - Antoni, M. H.
C2  - PMC4411537
DA  - Nov
DO  - 10.1093/jncimonographs/lgu032
DP  - NLM
ET  - 2015/03/10
IS  - 50
KW  - Adaptation, Psychological
Adult
African Americans/*psychology
Breast Neoplasms/*psychology
Cognitive Behavioral Therapy
Community Mental Health Services
*Complementary Therapies
Depression/psychology
Female
Humans
Middle Aged
Patient Education as Topic
Psychiatric Status Rating Scales
Psychotherapy, Group
Quality of Life
Stress, Psychological/*therapy
Survivors/*psychology
Vulnerable Populations/*psychology
LA  - eng
N1  - 1745-6614
Lechner, Suzanne C
Whitehead, Nicole E
Vargas, Sara
Annane, Debra W
Robertson, Belinda R
Carver, Charles S
Kobetz, Erin
Antoni, Michael H
UL1 TR000460/TR/NCATS NIH HHS/United States
R01CA131451/CA/NCI NIH HHS/United States
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
J Natl Cancer Inst Monogr. 2014 Nov;2014(50):315-22. doi: 10.1093/jncimonographs/lgu032.
PY  - 2014
SN  - 1052-6773 (Print)
1052-6773
SP  - 315-22
ST  - Does a community-based stress management intervention affect psychological adaptation among underserved black breast cancer survivors?
T2  - J Natl Cancer Inst Monogr
TI  - Does a community-based stress management intervention affect psychological adaptation among underserved black breast cancer survivors?
VL  - 2014
ID  - 253
ER  - 

TY  - JOUR
AB  - BACKGROUND: Breast cancer patients' informational, psychosocial and access needs may affect receipt of post‐surgical adjuvant treatment. High quality community‐based patient assistance programs which address such barriers are often underutilized presumably b/c pts are unaware of such programs. We conducted a RCT to inform and enable women to connect with programs that can address underlying needs that might interfere with care delivery. METHODS: Women were recruited w/in 2‐4 wks of their surgical Rx of BC. We assessed informational, psychosocial, and practical needs and randomized women to Intervention (INT) vs usual care (UC). The INT consisted of educating women about existing programs by creating an action plan and mailing it to them with related materials. UC patients received a pamphlet about breast cancer and its treatment. All were called 2 wks later to ascertain packet receipt, and for INT patients, ongoing needs and connection to a Patient Assistance Program. Treatment data is based on chart abstraction >6 months after surgery. Analyses were intent to treat. RESULTS: 370 women with a new primary, early‐stage breast cancer operated at 1 of 8 participating NYC hospitals consented to participate: 189 in the INT and 180 in UC. 186 were Black or Hispanic and evenly divided between INT and UC. Rates of need did not differ between trial or racial groups: 234 had informational needs; 200 had psychosocial and 193, practical‐access needs; 78 had 1 need, 66 had 2 needs, 139 had 3 needs. At 2 wks, 107 of INT pts had an ongoing need yet only 89 had connected to a program. Rates of treatment in INT vs UC were: 84% vs 89% RT post BCS (p=.28); 93% vs 86% chemo for ER negative tumors >1 cm (p=.28); and 87% vs 88% for hormonal therapy for ER + tumors >1 cm. Treatment underuse was higher in older women (mean: 61y vs 56y; p<0.01). Race, education, insurance, stage, type or number of needs was not related to underuse. CONCLUSION: Post‐surgical adjuvant treatment rates are high; there is no racial disparity in treatment. Some needs expressed <1 month after surgery appear to resolve without apparent external intervention and some require more intensive involvement to enable connection to a patient assistance program. This finding suggests that future interventions take into account the dynamic changing needs of women with a new breast cancer diagnosis and more intensive efforts be made to connect those with ongoing needs to best target resources to those with unresolved needs that can interfere with treatment receipt.
AN  - CN-01035229
AU  - Bickell, N. A.
AU  - Oluwole, S.
AU  - Joseph, K. A.
AU  - Menes, T.
AU  - Srinivasan, A.
AU  - Kemeny, M.
AU  - J, A. Sparano
AU  - Franco, R.
AU  - Fei, K.
AU  - Leventhal, H.
DO  - 10.1007/s11606-011-1730-9
KW  - *breast
*human
*internal medicine
*patient
*society
Adjuvant therapy
Breast cancer
Cancer diagnosis
Cancer patient
Community
Education
Female
Hispanic
Hormonal therapy
Hospital
Insurance
Intention to treat analysis
Race
Surgery
Tumor
M3  - Journal: Conference Abstract
PY  - 2011
SP  - S328
ST  - Does patient assistance reduce racial disparities in quality of breast cancercare?
T2  - Journal of general internal medicine
TI  - Does patient assistance reduce racial disparities in quality of breast cancercare?
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01035229/full
VL  - 26
ID  - 1617
ER  - 

TY  - JOUR
AB  - LESSONS LEARNED: Despite U.S. Food and Drug Administration approval to reduce alopecia, data on efficacy of scalp cooling in Black patients with cancer are limited by lack of minority representation in prior clinical trials. Scalp cooling devices may have less efficacy in Black patients; additional studies are required to explore the possible causes for this, including hair texture and cap design. BACKGROUND: The Paxman scalp cooling (SC) device is U.S. Food and Drug Administration (FDA)-approved for prevention of chemotherapy-induced alopecia. Studies report 50%-80% success rates and high patient satisfaction, yet there have been no studies of SC in Black patients. We conducted a phase II feasibility study of Paxman SC with a planned enrollment of 30 Black patients receiving chemotherapy for stage I-III breast cancer. METHODS: Black patients who planned to receive at least four cycles of chemotherapy with non-anthracycline (NAC) or anthracycline (AC) regimens were eligible. Alopecia was assessed by trained oncology providers using the modified Dean scale (MDS) prior to each chemotherapy session. Distress related to alopecia was measured by the Chemotherapy Alopecia Distress Scale (CADS). RESULTS: Fifteen patients enrolled in the intervention before the study was closed early because of lack of efficacy. Median MDS and CADS increased after SC, suggesting increased hair loss (p < .001) and alopecia distress (p = .04). Only one participant was successful in preventing significant hair loss; the majority stopped SC before chemotherapy completion because of grade 3 alopecia (>50% hair loss). CONCLUSION: SC may not be efficacious in preventing alopecia in Black women. Differences in hair thickness, hair volume, and limitations of cooling cap design are possible contributing factors.
AD  - MedStar Washington Hospital Center, Washington Cancer Institute, Lombardi Comprehensive Cancer Center, Washington, DC, USA.
MedStar Health Research Institute, Washington Cancer Institute, Washington, DC, USA.
Paxman Scalp Cooling, Huddersfield, United Kingdom.
Georgetown University, Office of Minority Health and Cancer Prevention and Control, Washington, DC, USA.
AN  - 33512741
AU  - Dilawari, A.
AU  - Gallagher, C.
AU  - Alintah, P.
AU  - Chitalia, A.
AU  - Tiwari, S.
AU  - Paxman, R.
AU  - Adams-Campbell, L.
AU  - Dash, C.
DA  - Jan 29
DO  - 10.1002/onco.13690
DP  - NLM
ET  - 2021/01/30
KW  - Breast cancer
Chemotherapy-induced alopecia
Paxman scalp cooling device
LA  - eng
N1  - 1549-490x
Dilawari, Asma
Gallagher, Christopher
Alintah, Princess
Chitalia, Ami
Tiwari, Shruti
Paxman, Richard
Adams-Campbell, Lucile
Dash, Chiranjeev
Journal Article
United States
Oncologist. 2021 Jan 29. doi: 10.1002/onco.13690.
PY  - 2021
SN  - 1083-7159
ST  - Does Scalp Cooling Have the Same Efficacy in Black Patients Receiving Chemotherapy for Breast Cancer?
T2  - Oncologist
TI  - Does Scalp Cooling Have the Same Efficacy in Black Patients Receiving Chemotherapy for Breast Cancer?
ID  - 9
ER  - 

TY  - JOUR
AB  - Background: Association studies have suggested that lower circulating 25-hydroxyvitamin D [25(OH)D] in African Americans may partially underlie higher rates of cardiovascular disease and cancer in this population. Nonetheless, the relation between vitamin D supplementation and 25(OH)D concentrations in African Americans remains undefined. Objective: Our primary objective was to determine the doseresponse relation between vitamin D and plasma 25(OH)D. Design: A total of 328 African Americans in Boston, MA, were enrolled over 3 winters from 2007 to 2010 and randomly assigned to receive a placebo or 1000, 2000, or 4000 IU vitamin D3/d for 3 mo. Subjects completed sociodemographic and dietary questionnaires, and plasma samples were drawn at baseline and 3 and 6 mo. Results: Median plasma 25(OH)D concentrations at baseline were 15.1, 16.2, 13.9, and 15.7 ng/mL for subjects randomly assigned to receive the placebo or 1000, 2000, or 4000 IU/d, respectively (P = 0.63). The median plasma 25(OH)D concentration at 3 mo differed significantly between supplementation arms at 13.7, 29.7, 34.8, and 45.9 ng/mL, respectively (P < 0.001). An estimated 1640 IU vitamin D3/d was needed to raise the plasma 25(OH)D concentration to ≥20 ng/mL in ≥97.5% of participants, whereas a dose of 4000 IU/d was needed to achieve concentrations ≥33 ng/mL in ≥80% of subjects. No significant hypercalcemia was seen in a subset of participants. Conclusions: Within African Americans, an estimated 1640 IU vitamin D3/d was required to achieve concentrations of plasma 25(OH)D recommended by the Institute of Medicine, whereas 4000 IU/d was needed to reach concentrations predicted to reduce cancer and cardio-vascular disease risk in prospective observational studies. These results may be helpful for informing future trials of disease prevention. This trial was registered at clinicaltrials.gov as NCT00585637. © 2014 American Society for Nutrition.
AD  - K. Ng, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States
AU  - Ng, K.
AU  - Scott, J. B.
AU  - Drake, B. F.
AU  - Chan, A. T.
AU  - Hollis, B. W.
AU  - Chandler, P. D.
AU  - Bennett, G. G.
AU  - Giovannucci, E. L.
AU  - Gonzalez-Suarez, E.
AU  - Meyerhardt, J. A.
AU  - Emmons, K. M.
AU  - Fuchs, C. S.
DB  - Embase
Medline
DO  - 10.3945/ajcn.113.067777
IS  - 3
KW  - NCT00585637
25 hydroxyvitamin D
calcium
colecalciferol
placebo
absence of side effects
adult
African American
aged
article
calcium blood level
cancer prevention
colorectal cancer
controlled study
correlational study
demography
dietary compliance
dose response
double blind procedure
drug eruption
drug withdrawal
female
human
hypercalcemia
major clinical study
male
middle aged
polydipsia
questionnaire
randomized controlled trial
side effect
socioeconomics
treatment response
very elderly
vitamin blood level
vitamin supplementation
winter
L1  - internal-pdf://3862120563/587.pdf
LA  - English
M3  - Article
N1  - L372485404
2014-03-06
2014-03-11
PY  - 2014
SN  - 0002-9165
1938-3207
SP  - 587-598
ST  - Dose response to vitamin D supplementation in African Americans: Results of a 4-arm, randomized, placebo-controlled trial
T2  - American Journal of Clinical Nutrition
TI  - Dose response to vitamin D supplementation in African Americans: Results of a 4-arm, randomized, placebo-controlled trial
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L372485404&from=export
http://dx.doi.org/10.3945/ajcn.113.067777
VL  - 99
ID  - 1035
ER  - 

TY  - JOUR
AB  - SCOPE: Black raspberry (BRB) phytochemicals demonstrate anti-carcinogenic properties in experimental models, including prostate cancer. Two BRB foods, a confection and nectar, providing a consistent and reproducible product for human clinical studies are designed and characterized. METHODS AND RESULTS: Men with clinically localized prostate cancer are sequentially enrolled to a control group or one of four intervention groups (confection or nectar, 10 or 20 g dose; n = 8 per group) for 4 weeks prior to prostatectomy. Primary outcomes include: safety, adherence, and ellagitannin metabolism. Adherence to the intervention is >96%. No significant (≥grade II) toxicities are detected. Urinary urolithins (A, B, C, and D) and dimethyl ellagic acid (DMEA) quantified by Ultra high performance liquid chromatography tandem mass spectroscopy (UPLC/MS/MS) indicate a dose-dependent excretion yet heterogeneous patterns among men. Men in the BRB confection groups have greater urinary excretion of the microbial urinary metabolites urolithin A and DMEA, suggesting that this food matrix provides greater colonic microflora exposure. CONCLUSION: Fully characterized BRB confections and nectar are ideal for food-based large phase III human clinical studies. BRB products provide a bioavailable source of BRB phytochemicals, however large inter individual variation in polyphenol metabolism suggests that host genetics, microflora, and other factors are critical to understanding bioactivity and metabolism.
AD  - Department of Human Sciences, The Ohio State University, Columbus, OH, USA.
Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
Division of Biostatistics, The Ohio State University, Columbus, OH, USA.
Department of Food Science and Technology, The Ohio State University, Columbus, OH, USA.
Nutrient and Phytochemical Analytic Shared Resource, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
Department of Urology, The Ohio State University, Columbus, OH, USA.
Ohio Health Physician Group Robotic Urologic and Cancer Surgery, Dublin Methodist Hospital, 7450 Hospital Drive, Suite 300, Dublin, OH, 8518 43016, USA.
Department of Internal Medicine, Division of Medical Oncology, The Ohio State University, Columbus, OH, USA.
AN  - 32112501
AU  - Roberts, K. M.
AU  - Grainger, E. M.
AU  - Thomas-Ahner, J. M.
AU  - Hinton, A.
AU  - Gu, J.
AU  - Riedl, K.
AU  - Vodovotz, Y.
AU  - Abaza, R.
AU  - Schwartz, S. J.
AU  - Clinton, S. K.
DA  - May
DO  - 10.1002/mnfr.201900800
DP  - NLM
ET  - 2020/03/01
IS  - 10
KW  - *black raspberries
*ellagitannins
*polyphenol explorer database
*polyphenols
*urolithins
LA  - eng
N1  - 1613-4133
Roberts, Kristen M
Orcid: 0000-0001-5619-990x
Grainger, Elizabeth M
Thomas-Ahner, Jennifer M
Hinton, Alice
Gu, Junnan
Riedl, Ken
Vodovotz, Yael
Abaza, Ronney
Schwartz, Steven J
Clinton, Steven K
UL1 TR001070/TR/NCATS NIH HHS/United States
KL2 RR025754/RR/NCRR NIH HHS/United States
P30 CA016058/CA/NCI NIH HHS/United States
U01 CA188250/CA/NCI NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Germany
Mol Nutr Food Res. 2020 May;64(10):e1900800. doi: 10.1002/mnfr.201900800. Epub 2020 Mar 17.
PY  - 2020
SN  - 1613-4125
SP  - e1900800
ST  - Dose-Dependent Increases in Ellagitannin Metabolites as Biomarkers of Intake in Humans Consuming Standardized Black Raspberry Food Products Designed for Clinical Trials
T2  - Mol Nutr Food Res
TI  - Dose-Dependent Increases in Ellagitannin Metabolites as Biomarkers of Intake in Humans Consuming Standardized Black Raspberry Food Products Designed for Clinical Trials
VL  - 64
ID  - 52
ER  - 

TY  - JOUR
AB  - Background: Chinese herbal medicine (CHM) is a common complementary therapy used by patients with cancer for reduction of chemotherapy-induced toxic effects. This study applied the highest standard of clinical trial methodology to examine the role of CHM in reducing chemotherapy-induced toxicity, while maintaining a tailored approach to therapy. Patients and methods: Patients with early-stage breast or colon cancer who required postoperative adjuvant chemotherapy were eligible for the study. Enrolled patients were randomly assigned to one of three Chinese herbalists who evaluated and prescribed a combination of single-item packaged herbal extract granules. Patients received either CHM or placebo packages with a corresponding serial number. The placebo package contained nontherapeutic herbs with an artificial smell and taste similar to a typical herbal tea. The primary end points were hematologic and non-hematologic toxicity according to the National Cancer Institute Common Toxicity Criteria Version 2. Results: One hundred and twenty patients were accrued at the time of premature study termination. Patient characteristics of the two groups were similar. The incidence of grade 3/4 anemia, leukopenia, neutropenia, and thrombocytopenia for the CHM and placebo groups were 5.4%, 47.3%, 52.7%, and 1.8% and 1.8%, 32.2%, 44.7%, and 3.6%, respectively (P = 0.27, 0.37, 0.63, and 0.13, respectively). Incidence of grade 2 nausea was the only non-hematologic toxicity that was significantly reduced in the CHM group (14.6% versus 35.7%, P = 0.04). Conclusions: Traditional CHM does not reduce the hematologic toxicity associated with chemotherapy. CHM, however, does have a significant impact on control of nausea. © 2007 Oxford University Press.
AD  - T.S.K. Mok, Department of Clinical Oncology, Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong
AU  - Mok, T. S. K.
AU  - Yeo, W.
AU  - Johnson, P. J.
AU  - Hui, P.
AU  - Ho, W. M.
AU  - Lam, K. C.
AU  - Xu, M.
AU  - Chak, K.
AU  - Chan, A.
AU  - Wong, H.
AU  - Mo, F.
AU  - Zee, B.
C1  - adriamycin(Ebewe,Austria)
C2  - Baxter(Netherlands)
E Fong(China)
Ebewe(Austria)
DB  - Embase
Medline
DO  - 10.1093/annonc/mdl465
IS  - 4
KW  - antineoplastic agent
black bean extract
Chinese drug
cyclophosphamide
dexamethasone
doxorubicin
fluorouracil
folinic acid
granisetron
herbaceous agent
maltose
metoclopramide
placebo
plant extract
unclassified drug
adjuvant therapy
adult
aged
alopecia
anemia
anorexia
article
blood toxicity
breast cancer
cancer adjuvant therapy
cancer chemotherapy
chemotherapy induced emesis
Chinese medicine
clinical trial
colon cancer
constipation
controlled clinical trial
controlled study
diarrhea
disease severity
dizziness
double blind procedure
drug granule
drug induced disease
drug induced headache
drug manufacture
drug toxicity
early cancer
fatigue
febrile neutropenia
female
herbal medicine
human
incidence
insomnia
leukopenia
major clinical study
male
multiple cycle treatment
nausea
neutropenia
odor
pain
patient compliance
pigment disorder
postoperative care
prescription
priority journal
randomized controlled trial
side effect
skin manifestation
stomatitis
tea
thrombocytopenia
adriamycin
LA  - English
M3  - Article
N1  - L46523283
2007-04-01
PY  - 2007
SN  - 0923-7534
1569-8041
SP  - 768-774
ST  - A double-blind placebo-controlled randomized study of Chinese herbal medicine as complementary therapy for reduction of chemotherapy-induced toxicity
T2  - Annals of Oncology
TI  - A double-blind placebo-controlled randomized study of Chinese herbal medicine as complementary therapy for reduction of chemotherapy-induced toxicity
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L46523283&from=export
http://dx.doi.org/10.1093/annonc/mdl465
VL  - 18
ID  - 1234
ER  - 

TY  - JOUR
AB  - Background Adenoma detection rate (ADR) is an increasingly utilized core quality measure for colonoscopies. Rate of adenomas can be as high as 30% and missed lesions are particularly in right‐side of the colon. Careful examination of the right colon is recommended but the ideal withdrawal time for the right colon is unknown. We enrolled patients above the age of 50, undergoing colonoscopy for screening for colon ADR was compared when 30 seconds were spent during retroflexion in the right colon, from cecum up to the hepatic flexure, with <30 seconds were spent in the right colon up the hepatic flexure. 141 patients were randomized but randomization was flexible at the discretion of the endoscopist if the maneuver was challenging. 101 patients (71%) were included in the <30 second group and 40 patients (29%) in the ≥ 30 second group. Mean age was 60 years SD ± 8.5years. 76% patients were Caucasian and 20% were African American. 54% patients were female and 46% were male. 70% patients were average risk for colorectal cancer screening, 16% had family history of colon cancer and 27% had history of polyps. Median ASA score was 2, Median time to reach cecum was 360seconds (6mins), median withdrawal time was 660seconds (11mins), median right colon withdrawal time was 165 seconds. There was no differences between the groups in indication p=0.4, family history of colon cancer p=0.7. Overall adenoma detection rate was 50%. Adult colonoscope (12.8mm) was used in 82% of patients while a pediatric colonoscope (11.5mm) was used in 18%. There was a significantly higher rate of adenoma detection in the right colon 45% when retroflexion was performed for ≥30 seconds compared to 23% in the group where it was performed for < 30 seconds p=0.009. Polyps that were seen only on retroflexion, which could not be seen on forward view, were significantly more likely to be found in the ≥ 30 second group (22%, n =8) compared to the <30 second group 3%, p<0.001. GI fellows were successful in retroflexion in 58% of cases vs. 74% with attending physicians p=0.027. Retroflexion success was 90% when there was no looping, vs. 89% with mild and only 25% with severe looping, p<0.001. Retroflexion was successful in 54% with Boston bowel prep score of 2 compared to 72% with score of 3 in the right colon p=0.005 and success was 81% when no abdominal pressure was required vs. 58% with pressure p=0.001. Patients in whom retroflexion failed had a higher BMI (mean 3.16 vs. 29.8 when retroflexion failed, p=0.04). Conclusion Adenoma detection rate in the right colon was significantly improved when retroflexion was performed. Barriers to successful retroflexion included looping of the colonoscopy during the procedure, abdominal pressure, BMI, fellow participation and bowel prep quality.
AN  - CN-01964867
AU  - Faisal, M. F.
AU  - Hasan, B.
AU  - Shafiq, M.
AU  - Varghese, J.
AU  - Clarkston, W. K.
AU  - Campbell, D.
AU  - Chhabra, R.
AU  - Hamid, F.
AU  - Escalante, S.
AU  - Kim, J.
AU  - et al.
DO  - 10.1016/S0016-5085(18)31466-5
IS  - 6
KW  - Abdominal pressure
Adult
African American
Body mass
Cancer patient
Cancer screening
Caucasian
Cecum
Child
Colon adenoma
Colonoscope
Colonoscopy
Colorectal cancer
Conference abstract
Controlled study
Drug withdrawal
Endoscopist
Family history
Female
Human
Liver
Major clinical study
Male
Massachusetts
Middle aged
Physician
Polyp
Randomization
Randomized controlled trial
Treatment failure
M3  - Journal: Conference Abstract
PY  - 2018
SP  - S‐339‐
ST  - DURATION OF RETROFLEXION SIGNIFICANTLY INFLUENCES ADENOMA DETECTION RATE IN THE RIGHT COLON: a RANDOMIZED CONTROLLED TRIAL
T2  - Gastroenterology
TI  - DURATION OF RETROFLEXION SIGNIFICANTLY INFLUENCES ADENOMA DETECTION RATE IN THE RIGHT COLON: a RANDOMIZED CONTROLLED TRIAL
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01964867/full
VL  - 154
ID  - 1549
ER  - 

TY  - JOUR
AB  - Patient navigators (PNs) coordinate medical services and connect patients with resources to improve outcomes, satisfaction, and reduce costs. Little national information is available to inform workforce development. We analyzed 819 responses from an online PN survey conducted in 2009-2010. Study variables were mapped to the five Consolidated Framework for Implementation Research (CFIR) constructs to explore program variations by type of PN. Five logistic regression models compared each PN type to all others while adjusting for covariates. Thirty-five percent of respondents were nurse navigators, 28% lay navigators, 20% social work (SW)/counselor navigators, 7% allied health navigators, and 10% were "other" types of PNs. Most were non-Hispanic White (71%), female (94%), and at least college educated (70%). The primary differences were observed among: the core intervention tasks; position structure; work setting; health conditions navigated; navigator race/ethnicity; personal cancer experiences; navigation training; and patient populations served. Lay PNs had fewer odds of identifying as Hispanic, work in rural settings and assist underserved populations compared to others. Nurse navigators showed greater odds of clinical responsibilities, work in hospital or government settings and fewer odds of navigating minority populations compared to others. SW/counselor navigators also had additional duties, provided greater assistance to Medicare patient populations, and less odds of navigating underserved populations than others. In summary, our survey indicates that the type of PN utilized is an indicator of other substantial differences in program implementation. CFIR provides a robust method to compare differences and should incorporate care coordination outcomes in future PN research.
AD  - P.A. Valverde, Department of Community and Behavioral Health, School of Public Health, 12477 E 19th Ave, MS B119-406, Aurora, CO, United States
AU  - Valverde, P. A.
AU  - Calhoun, E.
AU  - Esparza, A.
AU  - Wells, K. J.
AU  - Risendal, B. C.
DB  - Embase
Medline
DO  - 10.1093/tbm/ibx080
IS  - 3
KW  - adult
African American
article
Asian
breast cancer
cancer survivor
caregiver support
Caucasian
community participation
comparative study
cooperation
counseling
counselor
cross-sectional study
early intervention
educational status
English (language)
ethnicity
female
government
health care disparity
health care organization
Hispanic
human
Human immunodeficiency virus infection
major clinical study
male
medically underserved
medicare
nurse
online system
paramedical personnel
patient care
peer group
personal experience
priority journal
responsibility
rural area
social work
social worker
treatment outcome
urban area
uterine cervix cancer
volunteer
LA  - English
M3  - Article
N1  - L622347136
2018-06-06
2018-06-08
PY  - 2018
SN  - 1613-9860
1869-6716
SP  - 456-467
ST  - The early dissemination of patient navigation interventions: Results of a respondent-driven sample survey
T2  - Translational Behavioral Medicine
TI  - The early dissemination of patient navigation interventions: Results of a respondent-driven sample survey
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L622347136&from=export
http://dx.doi.org/10.1093/tbm/ibx080
VL  - 8
ID  - 897
ER  - 

TY  - JOUR
AB  - BACKGROUND: Although cancer survivors are more likely to be unemployed than individuals without a cancer history, employment participation after treatment of early-stage breast cancer has not been widely studied to date. The objectives of the current study were to evaluate employment trajectories in a cohort of patients with early-stage breast cancer and age-matched controls from the time of diagnosis to the 2-year follow-up, and identify factors associated with diminished and emerging employment participation. METHODS: As part of a larger cohort study of 1096 patients with early-stage breast cancer and same-aged women without breast cancer, data from 723 working-age (aged 40-64 years) women (347 patients and 376 controls) were analyzed to evaluate 4 employment trajectories (sustained unemployment, diminished employment, emerging employment, and sustained employment). Multivariable logistic regression models were used to identify factors associated with diminished employment versus sustained employment, and emerging employment versus sustained unemployment. RESULTS: Lower percentages of patients (71%) compared with controls (79%) reported full-time or part-time employment at enrollment (P<.01). Fatigue was a significant predictor of diminished employment for both patients (odds ratio [OR], 5.71; 95% confidence interval [95% CI], 2.48-13.15) and controls (OR, 2.38; 95% CI, 1.21-4.68). Among patients, African American race (OR, 4.02; 95% CI, 1.57-10.28) and public/uninsured insurance status (OR, 4.76; 95% CI, 1.34-12.38) were found to be associated with diminished employment. Among controls, high social support was associated with emerging employment (OR, 3.12; 95% CI, 1.25-7.79). CONCLUSIONS: Fatigued patients, African American patients, and publicly insured/uninsured patients with cancer were more likely to experience diminished employment after 2 years of follow-up. Further investigation with longer follow-up is warranted to identify factors associated with these disparities in employment participation after treatment of early-stage breast cancer. Cancer 2018;124:2026-35. © 2018 American Cancer Society. © 2018 American Cancer Society
AD  - Brown School, Washington University in St. Louis, St. Louis, MO, United States
Department of Medicine, Washington University School of Medicine, Washington University in St. Louis, St. Louis, MO, United States
Department of Surgery, Washington University School of Medicine, Washington University in St. Louis, St. Louis, MO, United States
AU  - Ekenga, C. C.
AU  - Pérez, M.
AU  - Margenthaler, J. A.
AU  - Jeffe, D. B.
DB  - Scopus
DO  - 10.1002/cncr.31270
IS  - 9
KW  - breast cancer
employment
fatigue
return to work
survivorship
M3  - Article
N1  - Cited By :17
Export Date: 22 March 2021
PY  - 2018
SP  - 2026-2035
ST  - Early-stage breast cancer and employment participation after 2 years of follow-up: A comparison with age-matched controls
T2  - Cancer
TI  - Early-stage breast cancer and employment participation after 2 years of follow-up: A comparison with age-matched controls
UR  - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85042030520&doi=10.1002%2fcncr.31270&partnerID=40&md5=cd2c4155650078f6c945008aecc4fe4b
VL  - 124
ID  - 2273
ER  - 

TY  - JOUR
AD  - Loyola University Medical Center, Maywood, IL.
AN  - 25623716
AU  - Ellimoottil, C.
AU  - Gupta, G. N.
AU  - Quek, M. L.
DA  - Feb
DO  - 10.1016/j.urology.2014.09.066
DP  - NLM
ET  - 2015/01/28
IS  - 2
KW  - *African Americans
*European Continental Ancestry Group
Humans
Male
*Patient Selection
*Prostatectomy
Prostatic Neoplasms/*surgery
*Watchful Waiting
LA  - eng
N1  - 1527-9995
Ellimoottil, Chandy
Gupta, Gopal N
Quek, Marcus L
Comment
Editorial
United States
Urology. 2015 Feb;85(2):441. doi: 10.1016/j.urology.2014.09.066.
PY  - 2015
SN  - 0090-4295
SP  - 441
ST  - Editorial comment
T2  - Urology
TI  - Editorial comment
VL  - 85
ID  - 261
ER  - 

TY  - JOUR
AN  - 19758632
AU  - Friedman, D. B.
DA  - Nov
DO  - 10.1016/j.juro.2009.07.101
DP  - NLM
ET  - 2009/09/18
IS  - 5
KW  - *African Americans
*Early Detection of Cancer
Humans
Male
Patient Compliance/*statistics & numerical data
*Patient Selection
Prostatic Neoplasms/*diagnosis
Risk Factors
LA  - eng
N1  - 1527-3792
Friedman, Daniela B
Comment
Editorial
United States
J Urol. 2009 Nov;182(5):2217-8. doi: 10.1016/j.juro.2009.07.101. Epub 2009 Sep 16.
PY  - 2009
SN  - 0022-5347
SP  - 2217-8
ST  - Editorial comment
T2  - J Urol
TI  - Editorial comment
VL  - 182
ID  - 446
ER  - 

TY  - JOUR
AB  - BACKGROUND: Quality of bowel preparation and patient knowledge remains a major barrier for completing colorectal cancer screening. Few studies have tested unique ways to impact patient understanding centering on interactive computer programs, pictures, and brochures. Two studies explored instructional videos but focused on patient compliance and anxiety as endpoints. Furthermore, excessive video length and content may limit their impact on a broad patient population. No study so far has studied a video's impact on preparation quality and patient understanding of the colonoscopy procedure. METHODS: We conducted a single blinded prospective study of inner city patients presenting for a first time screening colonoscopy. During their initial visit patients were randomized to watch an instructional colonoscopy video or a video discussing gastroesophageal reflux disease (GERD). All patients watched a 6 minutes long video with the same spokesperson, completed a demographic questionnaire (Supplemental Digital Content 1, http://links.lww.com/JCG/A352) and were enrolled only if screened within 30 days of their visit. On the day of the colonoscopy, patients completed a 14 question quiz of their knowledge. Blinded endoscopist graded patient preparations based on the Ottawa scale. All authors had access to the study data and reviewed and approved the final manuscript. RESULTS: Among the 104 subjects enrolled in the study, 56 were in the colonoscopy video group, 48 were in GERD video group, and 12 were excluded. Overall, 48% were male and 52% female; 90% of patients had less than a high school education, 76% were African American, and 67% used a 4 L split-dose preparation. There were no differences between either video group with regard to any of the above categories. Comparisons between the 2 groups revealed that the colonoscopy video group had significantly better Ottawa bowel preparation score (4.77 vs. 6.85; P=0.01) than the GERD video group. The colonoscopy video group also had less-inadequate repeat bowel preparations versus the GERD video group (9% vs. 23%; P<0.01). The overall score on the knowledge questionnaire (Supplemental Digital Content 1, http://links.lww.com/JCG/A352) was significantly higher in the colonoscopy video group as compared with the GERD video group (12.77 vs. 11.08; P<0.001. In all patients the overall quiz score positively correlated with preparation quality (odds ratio, 2.31; confidence interval, 1.35-3.94; P<0.001). CONCLUSIONS: Our unique population represented an overwhelmingly under-educated (85% had a high school education or less) and minority group (76% African American). They are one of the most at risk of having multiple barriers such as comprehension and reading difficulties resulting in poor preparation examinations and no shows to procedures. Our instructional video proved to be high yield in this population. The patients assigned to watch the colonoscopy video showed a significant increase in "excellent" grade adequate bowel preparation quality by >23% and a significant decrease in "inadequate" bowel preparations by almost 50%. Our study proves that an educational video can improve both comprehension with regard to all aspects of colonoscopy. ClinicalTrials.gov number, NCT02906969.
AD  - Division of Gastroenterology and Hepatology, Drexel University College of Medicine, Philadelphia, PA.
AN  - 28742732
AU  - Pillai, A.
AU  - Menon, R.
AU  - Oustecky, D.
AU  - Ahmad, A.
DA  - Jul
DO  - 10.1097/mcg.0000000000000893
DP  - NLM
ET  - 2017/07/26
IS  - 6
KW  - Cathartics/adverse effects/*therapeutic use
Colonoscopy/*education/*methods
Colorectal Neoplasms/*pathology
Comprehension
Early Detection of Cancer/*methods
Health Communication
*Health Knowledge, Attitudes, Practice
Humans
Patient Education as Topic/*methods
Philadelphia
Prospective Studies
Single-Blind Method
Surveys and Questionnaires
Therapeutic Irrigation/*methods
*Urban Health Services
*Video Recording
LA  - eng
N1  - 1539-2031
Pillai, Ajish
Menon, Radha
Oustecky, David
Ahmad, Asyia
Journal Article
Randomized Controlled Trial
United States
J Clin Gastroenterol. 2018 Jul;52(6):515-518. doi: 10.1097/MCG.0000000000000893.
PY  - 2018
SN  - 0192-0790
SP  - 515-518
ST  - Educational Colonoscopy Video Enhances Bowel Preparation Quality and Comprehension in an Inner City Population
T2  - J Clin Gastroenterol
TI  - Educational Colonoscopy Video Enhances Bowel Preparation Quality and Comprehension in an Inner City Population
VL  - 52
ID  - 161
ER  - 

TY  - JOUR
AB  - Socioeconomic inequalities cause different tobacco consumption patterns. The purpose of this study was to examine the relationship between educational level and smoking behaviour, including type of tobacco consumption, in lung cancer patients. To this end, epidemiological analyses of 801 lung cancer patients recruited for a case-control study in four public hospitals in Asturias, Spain, between October 2000 and April 2006 were carried out. Smoking behaviour and educational level data were obtained through personal interview. Analyses indicated that the probability of heavy smoking among low educational-level patients was approximately twice as high as for high educational-level patients (RRR>31.2packs/years = 2.04; CI 95%= 1.15-3.62; RRR>52packs/years= 2.14; CI 95%= 0.98-4.64). Low-educated patients were more than three times as likely to be long-time smokers (RRR>40years = 3.30; CI 95%= 1.43-7.62). The probability of smoking exclusively black tobacco was almost four times greater in low educational-level patients (RRRblack only= 3.72; CI 95%= 1.23-11.19). The results show that there are broad educational inequalities with regard to the quantity, duration and type of tobacco consumption among lung cancer patients in Northern Spain. © 2010 Psicothema.
AD  - A. Tardón, Facultad de Medicina, Universidad de Oviedo, 33006 Oviedo, Spain
AU  - Leader, A.
AU  - Fernández-Somoano, A.
AU  - López-Cima, M. F.
AU  - González-Arriaga, P.
AU  - Pascual, T.
AU  - Marrón, M. G.
AU  - Tardón, A.
DB  - Medline
IS  - 4
KW  - aged
article
case control study
clinical trial
comparative study
educational status
female
human
lung tumor
male
middle aged
multicenter study
smoking
smoking cessation
socioeconomics
Spain
statistics
time
L1  - internal-pdf://1350490027/3778.pdf
LA  - English
Spanish
M3  - Article
N1  - L359998938
2011-03-09
PY  - 2010
SN  - 0214-9915
SP  - 634-640
ST  - Educational inequalities in quantity, duration and type of tobacco consumption among lung cancer patients in Asturias: Epidemiological analyses
T2  - Psicothema
TI  - Educational inequalities in quantity, duration and type of tobacco consumption among lung cancer patients in Asturias: Epidemiological analyses
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L359998938&from=export
VL  - 22
ID  - 1151
ER  - 

TY  - JOUR
AB  - Only 3% of women with breast cancer participate in cancer clinical trials nationwide. The lack of awareness about clinical trials is a significant barrier towards clinical trials participation. A study was conducted at a large urban Comprehensive Cancer Center to test (1) the effectiveness of an 18-min educational video on improving attitudes toward clinical trials and trials enrollment among new breast cancer patients seen at the Karmanos Cancer Institute, and (2) to assess racial differences in attitudes regarding clinical trials. Participants were randomized to either the educational intervention prior to their first oncology clinic appointment or to standard care. A baseline and 2-week post-intervention survey to assess attitudes toward clinical trials participation was completed by participants. Of 218 subjects recruited, 196 (55% white vs. 45% African American (AA)) eligible patients were included in the analysis. A small increase in therapeutic clinical trial enrollment was observed in the intervention arm but was not statistically significant (10.4% vs. 6.1%; P = 0.277). The intervention also did not result in a clear improvement in patients' attitudes toward clinical trials at posttest. However, a lower enrollment rate for the AA women was noted after adjusting for stage (OR = 0.282, P = 0.049). Significantly more negative scores were noted in 3 out of the 5 baseline attitudinal scales for AA women. The educational video did not significantly increase enrollment in breast cancer clinical trials. The findings that AA women had significantly more negative attitudes toward clinical trials than white women may partially explain the racial disparity in enrollment. An educational video remains a simple and cost-effective way to educate patients. Future studies should focus on designing a new educational video to specifically target cultural and attitudinal barriers in the AA population to more effectively change attitudes and increase trial enrollment.
AD  - Carman and Ann Adams Department of Pediatrics, Wayne State University, Detroit, MI, USA. duw@med.wayne.edu
AN  - 19152024
AU  - Du, W.
AU  - Mood, D.
AU  - Gadgeel, S.
AU  - Simon, M. S.
C2  - PMC3799768
C6  - NIHMS515459
DA  - Sep
DO  - 10.1007/s10549-009-0311-7
DP  - NLM
ET  - 2009/01/20
IS  - 2
KW  - Attitude to Health/ethnology
Breast Neoplasms/pathology/*therapy
*Clinical Trials as Topic
Continental Population Groups
Female
Humans
Middle Aged
Neoplasm Staging
Patient Education as Topic/*methods
*Patient Selection
*Video Recording
LA  - eng
N1  - 1573-7217
Du, Wei
Mood, Darlene
Gadgeel, Shirish
Simon, Michael S
P30 CA022453/CA/NCI NIH HHS/United States
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Breast Cancer Res Treat. 2009 Sep;117(2):339-47. doi: 10.1007/s10549-009-0311-7. Epub 2009 Jan 17.
PY  - 2009
SN  - 0167-6806 (Print)
0167-6806
SP  - 339-47
ST  - An educational video to increase clinical trials enrollment among breast cancer patients
T2  - Breast Cancer Res Treat
TI  - An educational video to increase clinical trials enrollment among breast cancer patients
VL  - 117
ID  - 479
ER  - 

TY  - JOUR
AB  - INTRODUCTION: Only 3 to 5% of new adult cancer patients participate in clinical trials nationwide. The lack of knowledge and awareness about clinical trials is a significant barrier to clinical trials participation. A randomized trial was conducted to test the effect of an educational video on positively changing patients' knowledge and attitudes regarding clinical trials and thereby increasing enrollment rates. METHODS: Lung cancer patients were randomized to viewing either an 18-minute video about clinical trials before first clinic appointment or to standard care. Participants completed a baseline and 2-week postintervention survey to assess their knowledge and attitudes toward trials participation. Fisher's exact test tests, t tests, and regression were used to compare patient characteristics and outcomes between arms. RESULTS: Of 145 subjects randomized, 126 (63/arm) satisfied all inclusion criteria and were included in the analysis. A linear regression showed that the video intervention was significantly associated with patients' self-assessed likelihood to enroll score measured at 2-week follow-up (p = 0.019). Although statistically insignificant, enrollment rates were found to be higher in the intervention arm for therapeutic trials alone (17.5% versus 11.1%) and for therapeutic and nontherapeutic trials combined (25.4% versus 15.9%). CONCLUSIONS: The brief educational video seems to be effective in positively changing lung cancer patients' attitudes about participation in clinical trials. Higher enrollment rates were also observed in the intervention group but the differences did not reach statistical significance. These findings suggest a potential impact of the educational video on clinical trial enrollment; however, larger studies are needed to confirm these findings.
AD  - Carman and Ann Adams Department of Pediatrics, Wayne State University, Children's Hospital of Michigan, 3901 Beaubien, Room 3N47, Detroit, MI 48201, USA. duw@med.wayne.edu
AN  - 18166837
AU  - Du, W.
AU  - Mood, D.
AU  - Gadgeel, S.
AU  - Simon, M. S.
DA  - Jan
DO  - 10.1097/JTO.0b013e31815e8bb2
DP  - NLM
ET  - 2008/01/02
IS  - 1
KW  - African Americans/statistics & numerical data
Carcinoma, Non-Small-Cell Lung/pathology/*therapy
*Educational Technology
European Continental Ancestry Group/statistics & numerical data
Female
Health Knowledge, Attitudes, Practice
Humans
Linear Models
Lung Neoplasms/pathology/*therapy
Male
Middle Aged
Patient Education as Topic/*methods
Surveys and Questionnaires
*Videotape Recording
LA  - eng
N1  - 1556-1380
Du, Wei
Mood, Darlene
Gadgeel, Shirish
Simon, Michael S
R03 CA096437-01A1/CA/NCI NIH HHS/United States
Clinical Trial
Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
United States
J Thorac Oncol. 2008 Jan;3(1):23-9. doi: 10.1097/JTO.0b013e31815e8bb2.
PY  - 2008
SN  - 1556-0864
SP  - 23-9
ST  - An educational video to increase clinical trials enrollment among lung cancer patients
T2  - J Thorac Oncol
TI  - An educational video to increase clinical trials enrollment among lung cancer patients
VL  - 3
ID  - 510
ER  - 

TY  - JOUR
AB  - INTRODUCTION: We conducted a randomized controlled trial to determine if an in-home educational intervention conducted by lay health workers (LHWs) could increase adherence among low-income, inner-city, African-American women to breast and cervical cancer screening schedules. METHODS: We recruited 321 African-American women from diverse inner-city sources. After baseline interviews, they were randomly assigned to either the intervention (n = 163) or the control (n = 158) group. Those in the intervention group were visited in their homes up to three times by LHWs who provided a culturally sensitive educational program that emphasized the need for screening. RESULTS: Ninety-three (93) women in the intervention group and 102 in the control group completed the postintervention interview. For Pap smears, the increase in screening was similar in both groups. For clinical breast exams (CBEs), however, there was a modest increase in the intervention group. The improvement was greatest for mammography, for which there was a 10% to 12% increase. Among women who were not on recommended schedules at baseline, the improvement was substantial and greater in the intervention group. CONCLUSIONS: LHWs' intervention appeared to improve the rate at which inner-city women obtained CBEs and mammograms, but had no effect on Pap smears. A high attrition rate weakened our ability to make conclusive statements about the exact impact of the intervention.
AD  - Department of Community Health and Preventive Medicine, Morehouse School of Medicine, Morehouse College, Atlanta, Georgia, USA.
AN  - 9037342
AU  - Sung, J. F.
AU  - Blumenthal, D. S.
AU  - Coates, R. J.
AU  - Williams, J. E.
AU  - Alema-Mensah, E.
AU  - Liff, J. M.
DA  - Jan-Feb
DP  - NLM
ET  - 1997/01/01
IS  - 1
KW  - Adolescent
Adult
*African Americans
Aged
Aged, 80 and over
Breast Neoplasms/ethnology/*prevention & control
Breast Self-Examination
*Community Health Workers
Community Participation/statistics & numerical data
Female
Follow-Up Studies
Georgia
Health Education/*methods
Humans
Mass Screening
Middle Aged
Poverty
Urban Population
Uterine Cervical Neoplasms/ethnology/*prevention & control
LA  - eng
N1  - Sung, J F
Blumenthal, D S
Coates, R J
Williams, J E
Alema-Mensah, E
Liff, J M
U54 CA118638/CA/NCI NIH HHS/United States
CA49095-05/CA/NCI NIH HHS/United States
N0 1-CN-65032/CN/NCI NIH HHS/United States
Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, U.S. Gov't, P.H.S.
Netherlands
Am J Prev Med. 1997 Jan-Feb;13(1):51-7.
PY  - 1997
SN  - 0749-3797 (Print)
0749-3797
SP  - 51-7
ST  - Effect of a cancer screening intervention conducted by lay health workers among inner-city women
T2  - Am J Prev Med
TI  - Effect of a cancer screening intervention conducted by lay health workers among inner-city women
VL  - 13
ID  - 735
ER  - 

TY  - JOUR
AB  - Background: Colorectal cancer is the second leading cause of cancer-related death in the United States, in part, because one third of Americans fail to get screened. In a prior randomized controlled trial, we found that an iPad patient decision aid called Mobile Patient Technology for Health-CRC (mPATH-CRC) doubled the proportion of patients who completed colorectal cancer screening. Methods: All data for the current analysis were collected as part of a randomized controlled trial to determine the impact of mPATH-CRC on receipt of colorectal cancer screening within 24 weeks. Participants were enrolled from six community-based primary care practices between June 2014 and May 2016 and randomized to either usual care or mPATH-CRC. Six potential mediators of the intervention effect on screening were considered. The Iacobucci method was used to assess the significance of the mediation. Results: A total of 408 patients had complete data for all potential mediators. Overall, the potential mediators accounted for approximately three fourths (76.3%) of the effect of the program on screening completion. Perceived benefits, self-efficacy, ability to state a screening decision, and patient–provider discussion were statistically significant mediators. Patient–provider discussion accounted for the largest proportion of the effect of mPATH-CRC (70.7%). Conclusions: mPATH-CRC increased completion of colorectal cancer screening by affecting patient-level and system-level mediators. However, the most powerful mediator was the occurrence of a patient–provider discussion about screening. Digital interventions like mPATH-CRC are an important adjunct to the patient–provider encounter. Impact: Understanding the factors that mediated mPATH-CRC's success is paramount to developing other effective interventions.
AD  - N.M. Denizard-Thompson, Wake Forest School of Medicine, 1 Medical Center Boulevard, Winston-Salem, NC, United States
AU  - Denizard-Thompson, N. M.
AU  - Miller, D. P.
AU  - Snavely, A. C.
AU  - Spangler, J. G.
AU  - Doug Case, L.
AU  - Weaver, K. E.
DB  - Embase
Medline
DO  - 10.1158/1055-9965.EPI-19-1199
IS  - 8
KW  - adult
African American
aged
article
cancer screening
colonoscopy
colorectal cancer
controlled study
female
health care delivery
health disparity
health literacy
health program
human
income
major clinical study
male
occult blood test
patient care
practice guideline
primary medical care
priority journal
randomized controlled trial
self concept
telephone interview
unemployment
vulnerable population
LA  - English
M3  - Article
N1  - L2010900030
2021-02-10
2021-02-19
PY  - 2020
SN  - 1538-7755
1055-9965
SP  - 1564-1569
ST  - Effect of a digital health intervention on decreasing barriers and increasing facilitators for colorectal cancer screening in vulnerable patients
T2  - Cancer Epidemiology Biomarkers and Prevention
TI  - Effect of a digital health intervention on decreasing barriers and increasing facilitators for colorectal cancer screening in vulnerable patients
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L2010900030&from=export
http://dx.doi.org/10.1158/1055-9965.EPI-19-1199
VL  - 29
ID  - 794
ER  - 

TY  - JOUR
AB  - IMPORTANCE: Lung cancer screening with low-dose computed tomography lowers lung cancer mortality but has potential harms. Current guidelines support patients receiving information about the benefits and harms of lung cancer screening during decision-making. OBJECTIVE: To examine the effect of a patient decision aid (PDA) about lung cancer screening compared with a standard educational material (EDU) on decision-making outcomes among smokers. DESIGN, SETTING, AND PARTICIPANTS: This randomized clinical trial was conducted using 13 state tobacco quitlines. Current and recent tobacco quitline clients who met age and smoking history eligibility for lung cancer screening were enrolled from March 30, 2015, to September 12, 2016, and followed up for 6 months until May 5, 2017. Data analysis was conducted between May 5, 2017, and September 30, 2018. INTERVENTIONS: Participants were randomized to the PDA video Lung Cancer Screening: Is It Right for Me? (n = 259) or to EDU (n = 257). MAIN OUTCOMES AND MEASURES: The primary outcomes were preparation for decision-making and decisional conflict measured at 1 week. Secondary outcomes included knowledge, intentions, and completion of screening within 6 months of receiving the intervention measured by patient report. RESULTS: Of 516 quit line clients enrolled, 370 (71.7%) were younger than 65 years, 320 (62.0%) were female, 138 (26.7%) identified as black, 47 (9.1%) did not have health insurance, and 226 (43.8%) had a high school or lower educational level. Of participants using the PDA, 153 of 227 (67.4%) were well prepared to make a screening decision compared with 108 of 224 participants (48.2%) using EDU (odds ratio [OR], 2.31; 95% CI, 1.56-3.44; P < .001). Feeling informed about their screening choice was reported by 117 of 234 participants (50.0%) using a PDA compared with 66 of 233 participants (28.3%) using EDU (OR, 2.56; 95% CI, 1.72-3.79; P < .001); 159 of 234 participants (68.0%) using a PDA compared with 110 of 232 (47.4%) participants using EDU reported being clear about their values related to the harms and benefits of screening (OR, 2.37; 95% CI, 1.60-3.51; P < .001). Participants using a PDA were more knowledgeable about lung cancer screening than participants using EDU at each follow-up assessment. Intentions to be screened and screening behaviors did not differ between groups. CONCLUSIONS AND RELEVANCE: In this study, a PDA delivered to clients of tobacco quit lines improved informed decision-making about lung cancer screening. Many smokers eligible for lung cancer screening can be reached through tobacco quit lines. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT02286713.
AD  - Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston.
Department of Health Disparities Research, The University of Texas MD Anderson Cancer Center, Houston.
Department of Radiology, Wake Forest School of Medicine, Winston-Salem, North Carolina.
Department of Behavioral Science, The University of Texas MD Anderson Cancer Center, Houston.
North American Quitline Consortium, Phoenix, Arizona.
Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston.
Information & Quality Healthcare Inc, Ridgeland, Mississippi.
Houston Department for Health and Human Services, Houston, Texas.
Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston.
Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston.
AN  - 32003822
AU  - Volk, R. J.
AU  - Lowenstein, L. M.
AU  - Leal, V. B.
AU  - Escoto, K. H.
AU  - Cantor, S. B.
AU  - Munden, R. F.
AU  - Rabius, V. A.
AU  - Bailey, L.
AU  - Cinciripini, P. M.
AU  - Lin, H.
AU  - Housten, A. J.
AU  - Luckett, P. G.
AU  - Esparza, A.
AU  - Godoy, M. C.
AU  - Bevers, T. B.
C2  - PMC7042872 the Patient-Centered Outcomes Research Institute (PCORI) and receiving grants from the National Institutes of Health and The University of Texas MD Anderson Cancer Center during the conduct of the study. Dr Lowenstein reported receiving grants from PCORI, The University of Texas MD Anderson Cancer Center Duncan Family Institute, and the National Institutes of Health during the conduct of the study. Ms Leal reported receiving grants from PCORI, the National Cancer Institute, and The University of Texas MD Anderson Cancer Center Duncan Family Institute during the conduct of the study. Dr Munden reported receiving stock options from Optellum Ltd and preferred stock from TheraBionic outside the submitted work.
DA  - Jan 3
DO  - 10.1001/jamanetworkopen.2019.20362
DP  - NLM
ET  - 2020/02/01
IS  - 1
KW  - Adult
Aged
Aged, 80 and over
Decision Support Techniques
Early Detection of Cancer/*methods/*psychology
Female
Humans
Lung Neoplasms/*diagnosis
Male
Mass Screening/*psychology/statistics & numerical data
Middle Aged
Patient Participation/*psychology/statistics & numerical data
Smokers/*psychology/*statistics & numerical data
Tomography, X-Ray Computed/*psychology/statistics & numerical data
United States
LA  - eng
N1  - 2574-3805
Volk, Robert J
Lowenstein, Lisa M
Leal, Viola B
Escoto, Kamisha H
Cantor, Scott B
Munden, Reginald F
Rabius, Vance A
Bailey, Linda
Cinciripini, Paul M
Lin, Heather
Housten, Ashley J
Luckett, Pamela Graef
Esparza, Angelina
Godoy, Myrna C
Bevers, Therese B
P30 CA016672/CA/NCI NIH HHS/United States
Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
JAMA Netw Open. 2020 Jan 3;3(1):e1920362. doi: 10.1001/jamanetworkopen.2019.20362.
PY  - 2020
SN  - 2574-3805
SP  - e1920362
ST  - Effect of a Patient Decision Aid on Lung Cancer Screening Decision-Making by Persons Who Smoke: A Randomized Clinical Trial
T2  - JAMA Netw Open
TI  - Effect of a Patient Decision Aid on Lung Cancer Screening Decision-Making by Persons Who Smoke: A Randomized Clinical Trial
VL  - 3
ID  - 54
ER  - 

TY  - JOUR
AB  - PURPOSE: African-American women (AAW) are more likely to be metabolically unhealthy than White women (WW). Metabolic syndrome (MetS) is associated with increased breast cancer risk and mortality from breast cancer is greater in AAW compared to WW. Data show MetS affects health-related quality of life (HRQoL). Exercise studies report improvements in MetS, however, no study to date has examined HRQoL in metabolically unhealthy AAW enrolled in an exercise trial. METHODS: This report examined the effect of a 6-month, 3-arm (supervised exercise, home-based exercise, control) randomized exercise controlled trial on HRQoL among 213 obese, metabolically unhealthy, postmenopausal AAW at high risk for breast cancer. RESULTS: Certain baseline participant characteristics were related to baseline HRQoL dimensions. The "exercise group" (supervised group combined with the home-based group) showed significantly greater improvement in health change scores (M = 13.6, SD = 3.1) compared to the control group (M = 0.7, SD = 4.4) (p = 0.02) over the 6-month study period. There were no significant differences in HRQoL change scores between the 3 study groups, however, although non-significant, data indicated most HRQoL change scores were more favorable in the supervised group. CONCLUSION: While significant improvement occurred in health change scores in the combined supervised and home-based group compared to the control group, we did not observe any significant differences on HRQoL change scores between all three study groups. However, while non-significant, there was a trend for more favorable HRQoL change scores in the supervised group versus the home-based and control groups. Additional research is needed to further explore this topic.
AD  - Howard University Cancer Center, Howard University, Washington, DC, United States.
Georgetown Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, United States.
Department of Health Behavior and Policy, School of Medicine, Virginia Commonwealth University, Richmond, VA, United States.
Department of Biostatistics, Bioinformatics, and Biomathematics, Georgetown University Medical Center, Washington, DC, United States.
Georgetown Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, United States. Electronic address: lla9@georgetown.edu.
AN  - 29428830
AU  - Taylor, T. R.
AU  - Dash, C.
AU  - Sheppard, V.
AU  - Makambi, K.
AU  - Ma, X.
AU  - Adams-Campbell, L. L.
C2  - PMC5871580
C6  - NIHMS950260
DA  - Apr
DO  - 10.1016/j.cct.2018.02.005
DP  - NLM
ET  - 2018/02/13
KW  - African Americans/psychology/statistics & numerical data
Breast Neoplasms/prevention & control
Diet, Reducing/*methods
Exercise/*psychology
Exercise Therapy/*methods
Female
Health Status Disparities
Humans
*Metabolic Syndrome/psychology/therapy
Middle Aged
*Obesity/metabolism/psychology/therapy
Outcome Assessment, Health Care
Postmenopause/metabolism/psychology
*Quality of Life
Weight Reduction Programs/methods
*Blacks
*Exercise
*Metabolic syndrome
*Women
LA  - eng
N1  - 1559-2030
Taylor, Teletia R
Dash, Chiranjeev
Sheppard, Vanessa
Makambi, Kepher
Ma, Xiaoyang
Adams-Campbell, Lucile L
K07 CA197112/CA/NCI NIH HHS/United States
P30 CA051008/CA/NCI NIH HHS/United States
P60 MD006920/MD/NIMHD NIH HHS/United States
UL1 TR001409/TR/NCATS NIH HHS/United States
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Contemp Clin Trials. 2018 Apr;67:121-128. doi: 10.1016/j.cct.2018.02.005. Epub 2018 Feb 8.
PY  - 2018
SN  - 1551-7144 (Print)
1551-7144
SP  - 121-128
ST  - The effect of a randomized controlled physical activity trial on health related quality of life in metabolically unhealthy African-American women: FIERCE STUDY
T2  - Contemp Clin Trials
TI  - The effect of a randomized controlled physical activity trial on health related quality of life in metabolically unhealthy African-American women: FIERCE STUDY
VL  - 67
ID  - 133
ER  - 

TY  - JOUR
AB  - BACKGROUND In the primary analysis of the Aspirin in Reducing Events in the Elderly (ASPREE) trial, now published in the Journal, we report that the daily use of aspirin did not provide a benefit with regard to the primary end point of disability-free survival among older adults. A numerically higher rate of the secondary end point of death from any cause was observed with aspirin than with placebo. METHODS From 2010 through 2014, we enrolled community-dwelling persons in Australia and the United States who were 70 years of age or older (or >= 65 years of age among blacks and Hispanics in the United States) and did not have cardiovascular disease, dementia, or disability. Participants were randomly assigned to receive 100 mg of enteric-coated aspirin or placebo. Deaths were classified according to the underlying cause by adjudicators who were unaware of trial-group assignments. Hazard ratios were calculated to compare mortality between the aspirin group and the placebo group, and post hoc exploratory analyses of specific causes of death were performed. RESULTS Of the 19,114 persons who were enrolled, 9525 were assigned to receive aspirin and 9589 to receive placebo. A total of 1052 deaths occurred during a median of 4.7 years of follow-up. The risk of death from any cause was 12.7 events per 1000 person-years in the aspirin group and 11.1 events per 1000 person-years in the placebo group (hazard ratio, 1.14; 95% confidence interval [CI], 1.01 to 1.29). Cancer was the major contributor to the higher mortality in the aspirin group, accounting for 1.6 excess deaths per 1000 person-years. Cancer-related death occurred in 3.1% of the participants in the aspirin group and in 2.3% of those in the placebo group (hazard ratio, 1.31; 95% CI, 1.10 to 1.56). CONCLUSIONS Higher all-cause mortality was observed among apparently healthy older adults who received daily aspirin than among those who received placebo and was attributed primarily to cancer-related death. In the context of previous studies, this result was unexpected and should be interpreted with caution. (Funded by the National Institute on Aging and others; ASPREE ClinicalTrials.gov number, NCT01038583.)
AN  - WOS:000447679900007
AU  - McNeil, J. J.
AU  - Nelson, M. R.
AU  - Woods, R. L.
AU  - Lockery, J. E.
AU  - Wolfe, R.
AU  - Reid, C. M.
AU  - Kirpach, B.
AU  - Shah, R. C.
AU  - Ives, D. G.
AU  - Storey, E.
AU  - Ryan, J.
AU  - Tonkin, A. M.
AU  - Newman, A. B.
AU  - Williamson, J. D.
AU  - Margolis, K. L.
AU  - Ernst, M. E.
AU  - Abhayaratna, W. P.
AU  - Stocks, N.
AU  - Fitzgerald, S. M.
AU  - Orchard, S. G.
AU  - Trevaks, R. E.
AU  - Beilin, L. J.
AU  - Donnan, G. A.
AU  - Gibbs, P.
AU  - Johnston, C. I.
AU  - Radziszewska, B.
AU  - Grimm, R.
AU  - Murray, A. M.
DA  - Oct
DO  - 10.1056/NEJMoa1803955
IS  - 16
N1  - 30221595
PY  - 2018
SN  - 0028-4793
SP  - 1519-1528
ST  - Effect of Aspirin on All-Cause Mortality in the Healthy Elderly
T2  - New England Journal of Medicine
TI  - Effect of Aspirin on All-Cause Mortality in the Healthy Elderly
VL  - 379
ID  - 2843
ER  - 

TY  - JOUR
AB  - Objective: The aim of this study was to explore the effect of a defined formula of Chinese medicinal herbs, GengNianAn (GNA, also called menopausal symptom-relieving formula) formula in relieving menopausal symptoms in ovariectomized women. Design: A double-blind randomized placebo-controlled trial. Method: Between May 2003 and June 2006, 69 ovariectomized Chinese women were recruited to complete 12 weeks of intervention with either a defined formula of GNA (n = 36) or placebo (n = 33) taken twice daily as a beverage. Clinical symptoms were assessed by the modified Kupperman scale. The levels of venous blood serum follicle stimulating hormone (FSH), luteinizing hormone (LH), estradiol (E-2), and the maturation index (Ml) of vaginal epithelial cells were respectively measured. Results: There existed significant differences between the two groups in the total Kupperman scoring, MI of vaginal exfoliative cells, and the levels of FSH, LH, and E2 after treatment (P < .05). Conclusion: Chinese herbs may be a useful alternative treatment for ovariectomized women suffering from menopausal symptoms, who are unable or do not want to receive hormone replacement therapy (HRT).
AN  - WOS:000250294500011
AU  - Zhou, J.
AU  - Qu, F.
AU  - Nan, R.
AU  - Tang, D.
DA  - Sep-Oct
DO  - 10.1016/j.explore.2007.06.002
IS  - 5
N1  - 17905357
PY  - 2007
SN  - 1550-8307
SP  - 478-484
ST  - The effect of Chinese medicinal herbs in relieving menopausal symptoms in ovariectomized Chinese women
T2  - Explore-the Journal of Science and Healing
TI  - The effect of Chinese medicinal herbs in relieving menopausal symptoms in ovariectomized Chinese women
VL  - 3
ID  - 3186
ER  - 

TY  - JOUR
AB  - Ethnopharmacological relevance: Cimicifuga racemose is previously proved effective on nature menopausal syndrome (MPS). However, its clinical value in treating with MPS induced by luteinizing-hormone releasing hormone analogue (LHRH-a) therapy of pre-/peri-menopausal breast cancer patients is still unknown. Aim of study: This perspective randomised-design study is to investigate the effect and safety of cimicifuga racemosa on MPS induced by LHRH-a in breast cancer (clinical trial registered: NCT03339882). Materials and methods: Breast cancer patients planning for LHRH-a treatment were randomly divided into 2 groups. The control group which was being treated with the standard treatment of LHRH-a. The other group was being treated with Remifemin, the commercialized product of cimicifuga racemose extract, combined with LHRH-a, called Remifemin group. Our main endpoint was Kupperman menopause index (KMI). Hormone levels in peripheral blood and gynecological complications were also evaluated. Results: Totally, 85 patients (42 in Remifemin group and 43 in control group) were enrolled in Zhejiang Cancer Hospital. At the 4th, 8th and 12th week after using LHRH-a, the KMI were all significantly lower in Remifemin group than in control group (P < 0.01), while the hormone levels, including estradiol (E-2), follicle-stimulating hormone (FSH) and luteinizing hormone (LH) were similar in the two groups. In addition, the incidence of cervical cyst in Remifemin group was higher than that in control group (P = 0.02), and there was no significant difference in the other gynecological complications, including endometrial thickening, ovarian cyst or uterine fibroid (P > 0.05) Conclusions: Cimicifuga racemose is effective, oncological safe and reliable for treatment of MPS caused by LHRH-a in breast cancer.
AN  - WOS:000476964300010
AU  - Wang, C.
AU  - Huang, Q.
AU  - Liang, C. L.
AU  - Zhang, Y. W.
AU  - Deng, D. H.
AU  - Yu, Y.
AU  - Chen, D. B.
AU  - Yang, H. J.
AU  - Yu, X. F.
DA  - Jun
DO  - 10.1016/j.jep.2019.111840
N1  - 111840
30935866
PY  - 2019
SN  - 0378-8741
ST  - Effect of cimicifuga racemosa on menopausal syndrome caused by LHRH-a in breast cancer
T2  - Journal of Ethnopharmacology
TI  - Effect of cimicifuga racemosa on menopausal syndrome caused by LHRH-a in breast cancer
VL  - 238
ID  - 2818
ER  - 

TY  - JOUR
AB  - IMPORTANCE: Colorectal cancer (CRC) screening is underused, especially among vulnerable populations. Decision aids and patient navigation are potentially complementary interventions for improving CRC screening rates, but their combined effect on screening completion is unknown. OBJECTIVE: To determine the combined effect of a CRC screening decision aid and patient navigation compared with usual care on CRC screening completion. DESIGN, SETTING, AND PARTICIPANTS: In this randomized clinical trial, data were collected from January 2014 to March 2016 at 2 community health center practices, 1 in North Carolina and 1 in New Mexico, serving vulnerable populations. Patients ages 50 to 75 years who had average CRC risk, spoke English or Spanish, were not current with recommended CRC screening, and were attending primary care visits were recruited and randomized 1:1 to intervention or control arms. INTERVENTIONS: Intervention participants viewed a CRC screening decision aid in English or Spanish immediately before their clinician encounter. The decision aid promoted screening and presented colonoscopy and fecal occult blood testing as screening options. After the clinician encounter, intervention patients received support for screening completion from a bilingual patient navigator. Control participants viewed a food safety video before the encounter and otherwise received usual care. MAIN OUTCOMES AND MEASURES: The primary outcome was CRC screening completion within 6 months of the index study visit assessed by blinded medical record review. RESULTS: Characteristics of the 265 participants were as follows: their mean age was 58 years; 173 (65%) were female, 164 (62%) were Latino; 40 (15%) were white non-Latino; 61 (23%) were black or of mixed race; 191 (78%) had a household income of less than $20 000; 101 (38%) had low literacy; 75 (28%) were on Medicaid; and 91 (34%) were uninsured. Intervention participants were more likely to complete CRC screening within 6 months (68% vs 27%); adjusted-difference, 40 percentage points (95% CI, 29-51 percentage points). The intervention was more effective in women than in men (50 vs 21 percentage point increase, interaction P = .02). No effect modification was observed across other subgroups. CONCLUSIONS AND RELEVANCE: A patient decision aid plus patient navigation increased the rate of CRC screening completion in compared with usual care invulnerable primary care patients. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT02054598.
AD  - Cecil G. Sheps Center for Health Services Research, University of North Carolina, Chapel Hill2Division of General Medicine & Clinical Epidemiology, University of North Carolina School of Medicine, Chapel Hill3Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill.
Department of Medicine, University of Iowa Carver College of Medicine, Iowa City5University of Iowa Holden Comprehensive Cancer Center, University of Iowa, Iowa City6Department of Family and Community Medicine, University of New Mexico School of Medicine, Albuquerque.
Department of Family Medicine, Carolinas HealthCare System, Charlotte, North Carolina.
Department of Family and Community Medicine, University of New Mexico School of Medicine, Albuquerque8University of New Mexico Comprehensive Cancer Center, Albuquerque.
Department of Family and Community Medicine, University of New Mexico School of Medicine, Albuquerque9Department of Anthropology, University of Maryland, College Park.
Division of General Medicine & Clinical Epidemiology, University of North Carolina School of Medicine, Chapel Hill10Department of Biostatistics, University of North Carolina, Chapel Hill.
University of New Mexico Comprehensive Cancer Center, Albuquerque.
Cecil G. Sheps Center for Health Services Research, University of North Carolina, Chapel Hill.
Cecil G. Sheps Center for Health Services Research, University of North Carolina, Chapel Hill2Division of General Medicine & Clinical Epidemiology, University of North Carolina School of Medicine, Chapel Hill3Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill11Department of Internal Medicine, University of Texas Dell Medical School, Austin.
AN  - 28505217
AU  - Reuland, D. S.
AU  - Brenner, A. T.
AU  - Hoffman, R.
AU  - McWilliams, A.
AU  - Rhyne, R. L.
AU  - Getrich, C.
AU  - Tapp, H.
AU  - Weaver, M. A.
AU  - Callan, D.
AU  - Cubillos, L.
AU  - Urquieta de Hernandez, B.
AU  - Pignone, M. P.
C2  - PMC5710456
DA  - Jul 1
DO  - 10.1001/jamainternmed.2017.1294
DP  - NLM
ET  - 2017/05/16
IS  - 7
KW  - African Americans
Aged
Colonoscopy/methods/psychology
*Colorectal Neoplasms/diagnosis/epidemiology/psychology
Decision Making
*Decision Support Techniques
*Early Detection of Cancer/methods/psychology
Female
Hispanic Americans
Humans
Male
Medical Records, Problem-Oriented/statistics & numerical data
Middle Aged
New Mexico/epidemiology
North Carolina/epidemiology
Occult Blood
Patient Navigation/*methods
Primary Health Care/methods/statistics & numerical data
Vulnerable Populations/ethnology/statistics & numerical data
LA  - eng
N1  - 2168-6114
Reuland, Daniel S
Brenner, Alison T
Hoffman, Richard
McWilliams, Andrew
Rhyne, Robert L
Getrich, Christina
Tapp, Hazel
Weaver, Mark A
Callan, Danelle
Cubillos, Laura
Urquieta de Hernandez, Brisa
Pignone, Michael P
P30 CA086862/CA/NCI NIH HHS/United States
P30 DK056350/DK/NIDDK NIH HHS/United States
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, P.H.S.
JAMA Intern Med. 2017 Jul 1;177(7):967-974. doi: 10.1001/jamainternmed.2017.1294.
PY  - 2017
SN  - 2168-6106 (Print)
2168-6106
SP  - 967-974
ST  - Effect of Combined Patient Decision Aid and Patient Navigation vs Usual Care for Colorectal Cancer Screening in a Vulnerable Patient Population: A Randomized Clinical Trial
T2  - JAMA Intern Med
TI  - Effect of Combined Patient Decision Aid and Patient Navigation vs Usual Care for Colorectal Cancer Screening in a Vulnerable Patient Population: A Randomized Clinical Trial
VL  - 177
ID  - 166
ER  - 

TY  - JOUR
AB  - Potential barriers to colorectal cancer (CRC) screening include preexisting medical conditions (comorbidities), physician recommendation, psychosocial factors, and screening preparedness. This study's purpose was to investigate the impact of comorbid conditions on CRC screening among African Americans. A stage-matched randomized clinical trial was performed. Asymptomatic African Americans over age 50, with a primary care physician, and eligible for CRC screening were recruited at The Mount Sinai Hospital from 2005 to 2008. One hundred sixty-one patients were assessed for referral for, and completion of, CRC screening, comorbid conditions, "readiness to change," and number of physician visits within the observation period. Data was compared to a pretrial index to predict the likely effect of comorbid conditions on CRC screening. One hundred fifty-nine patients completed the study; 108 (68.9%) were referred for and 34 (21.2%) completed CRC screening. No demographic characteristics were associated with CRC screening completion. CRC screening referrals were similar for all patients, regardless of comorbidities or clinical visits. Comorbidities rated as having extreme influence on CRC screening showed a trend toward lower screening rates. There was a significant increase in screening rates among participants in advanced stages of readiness at enrollment. These data suggest that while comorbidities did not predict colonoscopy completion, they may play a role in concert with other factors. This is the only study to assess the effect of screening colonoscopy in an African American primary care setting. We must continue to explore interventions to narrow the disparate gap in screening and mortality rates.
AD  - Department of Medicine, Mount Sinai School of Medicine, New York, NY 10029, USA.
AN  - 22351374
AU  - Lukin, D. J.
AU  - Jandorf, L. H.
AU  - Dhulkifl, R. J.
AU  - Thélémaque, L. D.
AU  - Christie, J. A.
AU  - Itzkowitz, S. H.
AU  - Duhamel, K. N.
C2  - PMC3778660
C6  - NIHMS509663
DA  - Jun
DO  - 10.1007/s13187-011-0303-2
DP  - NLM
ET  - 2012/02/22
IS  - 2
KW  - Colorectal Neoplasms/*diagnosis/*prevention & control
*Comorbidity
Early Detection of Cancer/methods
Female
Humans
Male
*Mass Screening
Middle Aged
*Patient Compliance
Prospective Studies
Risk Factors
LA  - eng
N1  - 1543-0154
Lukin, Dana J
Jandorf, Lina H
Dhulkifl, Rayhana J
Thélémaque, Linda D
Christie, Jennifer A
Itzkowitz, Steven H
Duhamel, Katherine N
P30 CA008748/CA/NCI NIH HHS/United States
R01 CA104130/CA/NCI NIH HHS/United States
5R01CA104130-4/CA/NCI NIH HHS/United States
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
J Cancer Educ. 2012 Jun;27(2):269-76. doi: 10.1007/s13187-011-0303-2.
PY  - 2012
SN  - 0885-8195 (Print)
0885-8195
SP  - 269-76
ST  - Effect of comorbid conditions on adherence to colorectal cancer screening
T2  - J Cancer Educ
TI  - Effect of comorbid conditions on adherence to colorectal cancer screening
VL  - 27
ID  - 374
ER  - 

TY  - JOUR
AB  - OBJECTIVE: Assess impact of a computer-based patient support system on quality of life in younger women with breast cancer, with particular emphasis on assisting the underserved. DESIGN: Randomized controlled trial conducted between 1995 and 1998. SETTING: Five sites: two teaching hospitals (Madison, Wis, and Chicago, Ill), two nonteaching hospitals (Chicago), and a cancer resource center (Indianapolis, Ill). The latter three sites treat many underserved patients. PARTICIPANTS: Newly diagnosed breast cancer patients (N = 246) under age 60. INTERVENTIONS: Experimental group received Comprehensive Health Enhancement Support System (CHESS), a home-based computer system providing information, decision-making, and emotional support. MEASUREMENTS AND MAIN RESULTS: Pretest and two post-test surveys (at two- and five-month follow-up) measured aspects of participation in care, social/information support, and quality of life. At two-month follow-up, the CHESS group was significantly more competent at seeking information, more comfortable participating in care, and had greater confidence in doctor(s). At five-month follow-up, the CHESS group had significantly better social support and also greater information competence. In addition, experimental assignment interacted with several indicators of medical underservice (race, education, and lack of insurance), such that CHESS benefits were greater for the disadvantaged than the advantaged group. CONCLUSIONS: Computer-based patient support systems such as CHESS may benefit patients by providing information and social support, and increasing their participation in health care. These benefits may be largest for currently underserved populations.
AD  - Department of Industrial Engineering, University of Wisconsin-Madison, Madison, WI 53705, USA. dhgustaf@facstaff.wisc.edu
AN  - 11520380
AU  - Gustafson, D. H.
AU  - Hawkins, R.
AU  - Pingree, S.
AU  - McTavish, F.
AU  - Arora, N. K.
AU  - Mendenhall, J.
AU  - Cella, D. F.
AU  - Serlin, R. C.
AU  - Apantaku, F. M.
AU  - Stewart, J.
AU  - Salner, A.
C2  - PMC1495237
DA  - Jul
DO  - 10.1046/j.1525-1497.2001.016007435.x
DP  - NLM
ET  - 2001/08/25
IS  - 7
KW  - Adult
African Americans
Breast Neoplasms/ethnology/*psychology
Female
Follow-Up Studies
Humans
*Information Services
Linear Models
*Medically Underserved Area
Middle Aged
Multivariate Analysis
Patient Education as Topic/*methods
Patient Participation
*Quality of Life
Social Support
LA  - eng
N1  - 1525-1497
Gustafson, D H
Hawkins, R
Pingree, S
McTavish, F
Arora, N K
Mendenhall, J
Cella, D F
Serlin, R C
Apantaku, F M
Stewart, J
Salner, A
5R01HD32922/HD/NICHD NIH HHS/United States
Clinical Trial
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, U.S. Gov't, P.H.S.
J Gen Intern Med. 2001 Jul;16(7):435-45. doi: 10.1046/j.1525-1497.2001.016007435.x.
PY  - 2001
SN  - 0884-8734 (Print)
0884-8734
SP  - 435-45
ST  - Effect of computer support on younger women with breast cancer
T2  - J Gen Intern Med
TI  - Effect of computer support on younger women with breast cancer
VL  - 16
ID  - 681
ER  - 

TY  - JOUR
AB  - OBJECTIVE: Outcome of acute respiratory distress syndrome (ARDS) in relation to age, gender, race, pre-Intensive Care Unit (ICU) location, and type of ICU. METHODS: Retrospective cohort study of patients enrolled in the ARDS network randomized controlled trials. RESULTS: A total of 2914 patients were included in these trials. Outcomes were adjusted to baseline covariates including APACHE III score, vasopressor use, cause of lung injury, lung injury score, diabetes, cancer status, body mass index, and study ID. Older patients had significantly higher mortality at both 28- and 60-day (odds ratio [OR] 2.59 [95% confidence interval [CI]: 2.12-3.18] P < 0.001 and 2.79, 95% CI: 2.29-3.39, P < 0.001, respectively); less ICU and ventilator free days (relative risk [RR] 0.92, 95% CI: 0.87-0.96, P < 0.001 and 0.92, 95% CI: 0.88-0.96, P < 0.001, respectively). For preadmission location, the 28- and 60-day mortality were lower if the patient was admitted from the operating room (OR)/recovery room (OR 0.65, 95% CI: 0.44-0.95, P = 0.026; and OR = 0.66, 95% CI: 0.46-0.95, P = 0.025, respectively) or emergency department (OR = 0.78, 95% CI: 0.61-0.99, P = 0.039; and OR = 0.71, 95% CI: 0.56-0.89, P = 0.004, respectively), but no statistical differences in ICU and ventilator free days between different preadmission locations. Races other than white and black had a statistically higher mortality (28- and 60-day mortality: OR = 1.47, 95% CI: 1.09-1.98, P = 0.011; and OR 1.53, 95% CI: 1.15-2.04, P = 0.004, respectively). Between whites and blacks, females and males there were no statistically significant differences in all outcomes. CONCLUSION: Older patients and races other than blacks and whites have higher mortality associated with ARDS. Mortality is affected by patients preadmission location. There are no differences in outcome in relation to the type of ICU, gender, or between blacks and whites.
AD  - Division of Pulmonary, Critical Care and Sleep Medicine, Wayne State University School of Medicine, Detroit, MI, USA.
Department of Oncology, Wayne State University School of Medicine, Detroit, MI, USA.
AN  - 28197217
AU  - El-Haddad, H.
AU  - Jang, H.
AU  - Chen, W.
AU  - Haider, S.
AU  - Soubani, A. O.
C2  - PMC5264167
DA  - Jan-Mar
DO  - 10.4103/1817-1737.197767
DP  - NLM
ET  - 2017/02/16
IS  - 1
KW  - Acute respiratory distress syndrome
demographics
outcome
LA  - eng
N1  - 1998-3557
El-Haddad, Haitham
Jang, Hyejeong
Chen, Wei
Haider, Samran
Soubani, Ayman O
Journal Article
Ann Thorac Med. 2017 Jan-Mar;12(1):17-24. doi: 10.4103/1817-1737.197767.
PY  - 2017
SN  - 1817-1737 (Print)
1998-3557
SP  - 17-24
ST  - The effect of demographics and patient location on the outcome of patients with acute respiratory distress syndrome
T2  - Ann Thorac Med
TI  - The effect of demographics and patient location on the outcome of patients with acute respiratory distress syndrome
VL  - 12
ID  - 183
ER  - 

TY  - JOUR
AB  - Women with inadequate health insurance have lower mammography rates than the general population. Finding successful strategies to enroll eligible women is an ongoing challenge for the National Breast and Cervical Cancer Early Detection Program. To test the effectiveness of a population-based strategy to increase mammography utilization among low-income underinsured women ages 40 to 64 years, a randomized trial was conducted to assess the effect of two mailed interventions on mammography utilization through Sage, the National Breast and Cervical Cancer Early Detection Program in Minnesota. Women (N = 145,467) ages 40 to 63 years [mean (SD), 49.7 (6.8)] with estimated household incomes below $50,000 (47.9% were <$35,000) from a commercial database were randomized to three groups: Mail, Mail Plus Incentive, or Control. Both the Mail and the Mail Plus Incentive groups received two simple mailings prompting them to call a toll-free number to access free mammography services. The Mail Plus Incentive intervention offered a small monetary incentive for a completed mammogram. After 1 year, both intervention groups had significantly higher Sage mammography rates than the Controls, and the Mail Plus Incentive group had a significantly higher rate than the Mail group. The Mail and Mail Plus Incentive interventions were estimated to produce increases in Sage screening rates of 0.23% and 0.75%, respectively, beyond the composite Control rate of 0.83%. Direct mail is an effective strategy for increasing mammography use through Sage. Coupling direct mail with an incentive significantly enhances the intervention's effectiveness. Direct mail should be considered as a strategy to increase mammography use among low-income, medically under-served women.
AN  - WOS:000232473400011
AU  - Slater, J. S.
AU  - Henly, G. A.
AU  - Ha, C. N.
AU  - Malone, M. E.
AU  - Nyman, J. A.
AU  - Diaz, S.
AU  - McGovern, P. G.
DA  - Oct
DO  - 10.1158/1055-9965.EPI-05-0034
IS  - 10
N1  - 16214915
PY  - 2005
SN  - 1055-9965
SP  - 2346-2352
ST  - Effect of direct mail as a population-based strategy to increase mammography use among low-income underinsured women ages 40 to 64 years
T2  - Cancer Epidemiology Biomarkers & Prevention
TI  - Effect of direct mail as a population-based strategy to increase mammography use among low-income underinsured women ages 40 to 64 years
VL  - 14
ID  - 3234
ER  - 

TY  - JOUR
AB  - IMPORTANCE: Erlotinib is a standard first-line therapy for patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC). Median progression-free survival (PFS) with erlotinib is approximately 10 months. OBJECTIVE: To determine whether adding bevacizumab to erlotinib treatment results in superior progression-free survival compared with erlotinib alone. DESIGN, SETTING, AND PARTICIPANTS: This phase 2 randomized clinical trial compared erlotinib plus bevacizumab with erlotinib alone in EGFR-mutant NSCLC. The trial was conducted in 17 US academic and community medical centers among 88 patients with EGFR exon 19 deletion or exon 21 L858R mutation based on local testing and stage 4 NSCLC who were eligible for bevacizumab. Patients were enrolled between November 2, 2012, and August 22, 2016, and followed up for a median (range) of 33 (0.7-62.5) months. Data were analyzed on August 28, 2018, and included data from November 2, 2012, to August 20, 2018. INTERVENTIONS: Patients were randomized with equal allocation to 150 mg of oral erlotinib daily alone or with 15 mg/kg of intravenous bevacizumab every 3 weeks. Study therapy continued until disease progression, unacceptable adverse event, or withdrawal of consent. MAIN OUTCOMES AND MEASURES: The primary outcome was PFS as assessed by the investigator; secondary outcomes were objective response rate (ORR), adverse events, and overall survival (OS). Analysis was designed to detect a hazard ratio (HR) of 0.667 for PFS (an improvement from a median PFS of 10 to 15 months). RESULTS: Among 88 patients enrolled, the median (range) age was 63 (31-84) years; 62 patients (70%) were female; 75 (85%) were white, 8 (9%) were African American, 3 (3%) were Asian, and for 2 (2%), data on race were not available. Forty-eight patients (55%) were never smokers, 45 patients (51%) were of Eastern Cooperative Oncology Group performance status 1, and 59 patients (67%) had EGFR exon 19 deletion. Compared with erlotinib, the combination did not result in a significant difference in PFS (HR, 0.81; 95% CI, 0.50-1.31; P = .39; median PFS 17.9 [combination] and 13.5 months [erlotinib]), ORR (81% vs 83%; P = .81), and OS (HR, 1.41; 95% CI, 0.71-2.81; P = .33; median OS, 32.4 months [combination] and 50.6 months [erlotinib]). Adverse events of grade 3 or higher observed in 5 or more patients in the combination and erlotinib arms were skin eruption in 11 (26%) vs 7 (16%) patients, diarrhea in 4 (9%) vs 6 (13%) patients, hypertension in 17 (40%) vs 9 (20%) patients, and proteinuria in 5 (12%) vs 0 (0%) patients. CONCLUSIONS AND RELEVANCE: Erlotinib plus bevacizumab compared with erlotinib did not result in a significant improvement in PFS in EGFR-mutant NSCLC. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT01532089.
AD  - Duke Cancer Institute, Durham, North Carolina.
Dana Farber Cancer Institute, Boston, Massachusetts.
Alliance Data and Statistical Center, Department of Biostatistics and Bioinformatics, Duke University, Durham, North Carolina.
The Ohio State University Comprehensive Cancer Center, Columbus.
University of North Carolina Lineberger Cancer Center at Chapel Hill.
Moores Cancer Center, University of California, San Diego.
Saint Vincent Hospital Cancer Center, Green Bay, Wisconsin.
Illinois Cancer Care-Peoria, Peoria, Illinois.
Division of Medical Oncology, Washington University School of Medicine in St Louis, Missouri.
Division of Hematology and Oncology, State University of New York Upstate Medical University, Syracuse.
Spartanburg Regional Health, Spartanburg, South Carolina.
Biological Sciences Division, University of Chicago Medicine, Chicago, Illinois.
AN  - 31393548
AU  - Stinchcombe, T. E.
AU  - Jänne, P. A.
AU  - Wang, X.
AU  - Bertino, E. M.
AU  - Weiss, J.
AU  - Bazhenova, L.
AU  - Gu, L.
AU  - Lau, C.
AU  - Paweletz, C.
AU  - Jaslowski, A.
AU  - Gerstner, G. J.
AU  - Baggstrom, M. Q.
AU  - Graziano, S.
AU  - Bearden, J., 3rd
AU  - Vokes, E. E.
C2  - PMC6692685 fees from AstraZeneca, grants and personal fees from Boehringer Ingelheim, personal fees from Pfizer, personal fees from Merrimack Pharmaceuticals, personal fees from Roche/Genentech, personal fees from Chugai Pharmaceuticals, personal fees from ACEA Biosciences, personal fees from Novartis Oncology, grants and personal fees from Takeda Oncology, and grants and personal fees from Daiichi Sankyo during the conduct of the study; personal fees from LOXO Onxology, grants and personal fees from Eli Lilly, personal fees from Araxes Pharmaceuticals, personal fees from Ignyta, personal fees from SFJ Pharmaceuticals, personal fees from Voronoi, and personal fees from Biocartis, personal fees from Mirati, outside the submitted work; and receiving postmarketing royalties from a Dana Farber Cancer Institute–owned patent on EGFR Mutations licensed to LabCorp. Dr Stinchcombe reported receiving grants from Genentech/Roche and AstraZeneca during the conduct of the study; personal fees from Regneron, Takeda, AstraZeneca, Novartis, Genentech/Roche, and G1 Therapeutics outside the submitted work. Dr Weiss reported receiving personal fees from Genentech, grants and personal fees from AstraZeneca, grants and personal fees from Celgene, personal fees from Nanobiotix, grants and personal fees from Pfizer, personal fees from Boston Biomedical, personal fees from Boehringer Ingelheim, grants and personal fees from G1 Therapeutics, personal fees from EMD Serono, personal fees from Regeneron, grants from Merck, personal fees from Immunicum, personal fees from Biomarck, grants and personal fees from Pfizer, and grants from Astellas outside the submitted work. Dr Bazhenova reported receiving personal fees from Astra Zeneca, personal fees from Genentech, personal fees from Takeda, Pfizer, and Novartis outside the submitted work. Dr Vokes reported receiving personal fees from AbbVie, Amgen, AstraZeneca, Biolumina, BMS, Celgene, Eli Lilly, EMD Serono, Genentech, Merck, Novartis, and Regeneron outside the submitted work. Dr Paweletz reported receiving personal fees and travel support from AstraZeneca Korea, and personal fees and travel support from BioRad outside the submitted work and having a patent EGFR plasma genotyping pending to the Dana Farber Cancer Institute. Dr Bertino reported receiving personal fees from Takeda Oncology outside the submitted work. No other disclosures were reported.
DA  - Aug 8
DO  - 10.1001/jamaoncol.2019.1847
DP  - NLM
ET  - 2019/08/09
IS  - 10
LA  - eng
N1  - 2374-2445
Stinchcombe, Thomas E
Jänne, Pasi A
Wang, Xiaofei
Bertino, Erin M
Weiss, Jared
Bazhenova, Lyudmila
Gu, Lin
Lau, Christie
Paweletz, Cloud
Jaslowski, Anthony
Gerstner, Gregory J
Baggstrom, Maria Q
Graziano, Stephen
Bearden, James 3rd
Vokes, Everett E
Journal Article
JAMA Oncol. 2019 Aug 8;5(10):1448-55. doi: 10.1001/jamaoncol.2019.1847.
PY  - 2019
SN  - 2374-2437 (Print)
2374-2437
SP  - 1448-55
ST  - Effect of Erlotinib Plus Bevacizumab vs Erlotinib Alone on Progression-Free Survival in Patients With Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Phase 2 Randomized Clinical Trial
T2  - JAMA Oncol
TI  - Effect of Erlotinib Plus Bevacizumab vs Erlotinib Alone on Progression-Free Survival in Patients With Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Phase 2 Randomized Clinical Trial
VL  - 5
ID  - 67
ER  - 

TY  - JOUR
AB  - Key Points: Question: Is the combination of erlotinib and bevacizumab superior to erlotinib alone to treat epidermal growth factor receptor (EGFR)–mutant non–small cell lung cancer? Findings: This phase 2 randomized clinical trial found that compared with erlotinib alone, the combination of erlotinib and bevacizumab did not result in superior progression-free survival. Meaning: The combination of erlotinib and bevacizumab does not have superior efficacy compared with erlotinib alone. This phase 2 multicenter randomized clinical trial including 88 patients compares progression-free survival, and secondarily overall survival, overall response rate, and adverse events, in patients with stage 4 EGFR-mutant non–small cell lung cancer treated with erlotinib plus bevacizumab vs erlotinib alone. Importance: Erlotinib is a standard first-line therapy for patients with epidermal growth factor receptor (EGFR)–mutant non–small cell lung cancer (NSCLC). Median progression-free survival (PFS) with erlotinib is approximately 10 months. Objective: To determine whether adding bevacizumab to erlotinib treatment results in superior progression-free survival compared with erlotinib alone. Design, Setting, and Participants: This phase 2 randomized clinical trial compared erlotinib plus bevacizumab with erlotinib alone in EGFR-mutant NSCLC. The trial was conducted in 17 US academic and community medical centers among 88 patients with EGFR exon 19 deletion or exon 21 L858R mutation based on local testing and stage 4 NSCLC who were eligible for bevacizumab. Patients were enrolled between November 2, 2012, and August 22, 2016, and followed up for a median (range) of 33 (0.7-62.5) months. Data were analyzed on August 28, 2018, and included data from November 2, 2012, to August 20, 2018. Interventions: Patients were randomized with equal allocation to 150 mg of oral erlotinib daily alone or with 15 mg/kg of intravenous bevacizumab every 3 weeks. Study therapy continued until disease progression, unacceptable adverse event, or withdrawal of consent. Main Outcomes and Measures: The primary outcome was PFS as assessed by the investigator; secondary outcomes were objective response rate (ORR), adverse events, and overall survival (OS). Analysis was designed to detect a hazard ratio (HR) of 0.667 for PFS (an improvement from a median PFS of 10 to 15 months). Results: Among 88 patients enrolled, the median (range) age was 63 (31-84) years; 62 patients (70%) were female; 75 (85%) were white, 8 (9%) were African American, 3 (3%) were Asian, and for 2 (2%), data on race were not available. Forty-eight patients (55%) were never smokers, 45 patients (51%) were of Eastern Cooperative Oncology Group performance status 1, and 59 patients (67%) had EGFR exon 19 deletion. Compared with erlotinib, the combination did not result in a significant difference in PFS (HR, 0.81; 95% CI, 0.50-1.31; P =.39; median PFS 17.9 [combination] and 13.5 months [erlotinib]), ORR (81% vs 83%; P =.81), and OS (HR, 1.41; 95% CI, 0.71-2.81; P =.33; median OS, 32.4 months [combination] and 50.6 months [erlotinib]). Adverse events of grade 3 or higher observed in 5 or more patients in the combination and erlotinib arms were skin eruption in 11 (26%) vs 7 (16%) patients, diarrhea in 4 (9%) vs 6 (13%) patients, hypertension in 17 (40%) vs 9 (20%) patients, and proteinuria in 5 (12%) vs 0 (0%) patients. Conclusions and Relevance: Erlotinib plus bevacizumab compared with erlotinib did not result in a significant improvement in PFS in EGFR-mutant NSCLC. Trial Registration: ClinicalTrials.gov identifier: NCT01532089.
AD  - Duke Cancer Institute, Durham, North Carolina
Dana Farber Cancer Institute, Boston, Massachusetts
Alliance Data and Statistical Center, Department of Biostatistics and Bioinformatics, Duke University, Durham, North Carolina
The Ohio State University Comprehensive Cancer Center, Columbus
University of North Carolina Lineberger Cancer Center at Chapel Hill
Moores Cancer Center, University of California, San Diego
Saint Vincent Hospital Cancer Center, Green Bay, Wisconsin
Illinois Cancer Care-Peoria, Peoria, Illinois
Division of Medical Oncology, Washington University School of Medicine in St Louis, Missouri
Division of Hematology and Oncology, State University of New York Upstate Medical University, Syracuse
Spartanburg Regional Health, Spartanburg, South Carolina
Biological Sciences Division, University of Chicago Medicine, Chicago, Illinois
AN  - 139077399. Language: English. Entry Date: 20191026. Revision Date: 20191029. Publication Type: Article
AU  - Stinchcombe, Thomas E.
AU  - Jänne, Pasi A.
AU  - Wang, Xiaofei
AU  - Bertino, Erin M.
AU  - Weiss, Jared
AU  - Bazhenova, Lyudmila
AU  - Gu, Lin
AU  - Lau, Christie
AU  - Paweletz, Cloud
AU  - Jaslowski, Anthony
AU  - Gerstner, Gregory J.
AU  - Baggstrom, Maria Q.
AU  - Graziano, Stephen
AU  - Bearden Iii, James
AU  - Vokes, Everett E.
DB  - CINAHL Complete
DO  - 10.1001/jamaoncol.2019.1847
DP  - EBSCOhost
IS  - 10
KW  - Carcinoma, Non-Small-Cell Lung -- Drug Therapy
Erlotinib -- Therapeutic Use
Bevacizumab -- Therapeutic Use
Antineoplastic Agents, Combined -- Therapeutic Use
Epidermal Growth Factors
Mutation
Treatment Outcomes -- Evaluation
Survival
Human
Male
Female
Adult
Middle Age
Aged
Aged, 80 and Over
Randomized Controlled Trials
Random Assignment
Multicenter Studies
Antineoplastic Agents, Combined -- Adverse Effects
Confidence Intervals
Kaplan-Meier Estimator
Chi Square Test
Data Analysis Software
Cox Proportional Hazards Model
Erlotinib -- Administration and Dosage
Bevacizumab -- Administration and Dosage
Cell-Free Nucleic Acids -- Analysis
Sex Factors
Functional Status
Clinical Assessment Tools
Funding Source
N1  - research; tables/charts; randomized controlled trial. Journal Subset: Peer Reviewed; USA. Instrumentation: Eastern Cooperative Oncology Group (ECOG) Performance Status Scale. Grant Information: This study was funded by Genentech/Roche..
PY  - 2019
SN  - 2374-2437
SP  - 1448-1455
ST  - Effect of Erlotinib Plus Bevacizumab vs Erlotinib Alone on Progression-Free Survival in Patients With Advanced EGFR-Mutant Non–Small Cell Lung Cancer: A Phase 2 Randomized Clinical Trial
T2  - JAMA Oncology
TI  - Effect of Erlotinib Plus Bevacizumab vs Erlotinib Alone on Progression-Free Survival in Patients With Advanced EGFR-Mutant Non–Small Cell Lung Cancer: A Phase 2 Randomized Clinical Trial
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=139077399&site=ehost-live&scope=site
VL  - 5
ID  - 1927
ER  - 

TY  - JOUR
AB  - BACKGROUND: This study examined the effects of supervised and home-based exercise interventions on changes in metabolic syndrome (MetS) according to breast cancer risk (high vs low) in black women enrolled in the Focused Intervention on Exercise to Reduce Cancer (FIERCE) trial. METHODS: Postmenopausal, obese, metabolically unhealthy black women, 45 to 65 years old, were randomized to supervised aerobic exercise (73 women), home-based walking-based exercise (69 women), or a control arm (71 women). Participants in the exercise arms underwent a 6-month intervention with study assessments conducted at the baseline and 6 months. The primary outcome measure was MetS (fasting glucose, waist circumference, blood pressure, serum triglycerides, and high-density lipoprotein [HDL]). The intervention effects on MetS, stratified by breast cancer risk as measured by the family history of breast cancer and model-based projected breast cancer risk, were examined with intent-to-treat analyses using generalized estimating equation models. RESULTS: Among women with a family history of breast cancer, the exercise arms had lower mean MetS z scores, which suggested an improvement in the metabolic profile, than controls at 6 months (controls, + 0.55; home-based arm, -0.97, P < .01; supervised arm, -0.89, P < .01). Stratified analyses by projected breast cancer risk suggested similar but statistically nonsignificant findings, with those at high risk having more favorable changes in the MetS z score in the exercise arms versus the control arm. These changes were primarily attributable to changes in blood pressure, triglycerides, and HDL. CONCLUSIONS: Short-term aerobic activity regimens may improve the metabolic profile and thereby reduce breast cancer risk in obese, metabolically unhealthy black women at high risk for cancer. © 2018 American Cancer Society.
AD  - Department of Oncology, Georgetown Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, District of Columbia.
Department of Medicine, Howard University Cancer Center, Howard University, Washington, District of Columbia.
Department of Biostatistics, Bioinformatics & Biomathematics, Georgetown Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, District of Columbia.
Office of Minority Health and Health Disparities Research, Georgetown Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, District of Columbia.
Department of Kinesiology, University of Maryland School of Public Health, College Park, Maryland.
AN  - 29975403
AU  - Dash, C.
AU  - Taylor, T. R.
AU  - Makambi, K. H.
AU  - Hicks, J.
AU  - Hagberg, J. M.
AU  - Adams-Campbell, L. L.
C2  - PMC6108932
C6  - NIHMS966799
DA  - Aug
DO  - 10.1002/cncr.31569
DP  - NLM
ET  - 2018/07/06
IS  - 16
KW  - Blood Glucose
Breast Neoplasms/blood/complications/pathology/*therapy
Cholesterol, HDL/blood
*Exercise
Fasting
Female
Humans
Metabolic Syndrome/blood/complications/pathology/*therapy
Middle Aged
Triglycerides/blood
*black
*breast cancer
*clinical trial
*metabolic syndrome
authors.
LA  - eng
N1  - 1097-0142
Dash, Chiranjeev
Orcid: 0000-0002-3314-8461
Taylor, Teletia R
Makambi, Kepher H
Hicks, Jennifer
Hagberg, James M
Adams-Campbell, Lucile L
K07 CA197112/CA/NCI NIH HHS/United States
P30 CA051008/CA/NCI NIH HHS/United States
P60 MD006920/MD/NIMHD NIH HHS/United States
UL1 TR001409/TR/NCATS NIH HHS/United States
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Cancer. 2018 Aug;124(16):3355-3363. doi: 10.1002/cncr.31569. Epub 2018 Jul 5.
PY  - 2018
SN  - 0008-543X (Print)
0008-543x
SP  - 3355-3363
ST  - Effect of exercise on metabolic syndrome in black women by family history and predicted risk of breast cancer: The FIERCE Study
T2  - Cancer
TI  - Effect of exercise on metabolic syndrome in black women by family history and predicted risk of breast cancer: The FIERCE Study
VL  - 124
ID  - 114
ER  - 

TY  - JOUR
AB  - Background and study objective: Several studies suggest a protective role of green tea catechins against prostate cancer(PCa). In order to evaluate the efficacy of green tea catechins for chemoprevention of PCa in patients with high-grade prostate intraepithelial neoplasia (HG-PIN) we performed a phase II clinical trial. Methods: Sixty volunteers with HG-PIN were enrolled to carry out a double-blind randomized placebo-controlled phase II clinical trial. Treated group took daily 600 mg of green tea catechins(Categ Plus (R)) for 1 year. Patients were screened at 6 and 12 months through prostatic biopsy and measurements of prostate-specific antigen(PSA). Results: Despite the statistically significant reduction of PSA observed in subjects who received green tea catechins for 6 and 12 months, we did not find any statistical difference in PCa incidence between the experimental groups neither after 6 nor after 12 months. However, throughout the one-year follow-up we observed very limited adverse effects induced by green tea catechins and a not significant improvement in lower urinary tract symptoms and quality of life. Conclusions: Although the small number of patients enrolled in our study and the relatively short duration of intervention, our findings seems to deny the efficacy of green tea catechins. However, results of our clinical study, mainly for its low statistical strength, suggest that the effectiveness of green tea catechins should be evaluated in both a larger cohort of men and longer trial.
AN  - WOS:000418562800006
AU  - Micali, S.
AU  - Territo, A.
AU  - Pirola, G. M.
AU  - Ferrari, N.
AU  - Sighinolfi, M. C.
AU  - Martorana, E.
AU  - Navarra, M.
AU  - Bianchi, G.
DO  - 10.4081/aiua.2017.3.197
IS  - 3
N1  - 28969404
PY  - 2017
SN  - 1124-3562
SP  - 197-202
ST  - Effect of green tea catechins in patients with high-grade prostatic intraepithelial neoplasia: Results of a short-term double-blind placebo controlled phase II clinical trial
T2  - Archivio Italiano Di Urologia E Andrologia
TI  - Effect of green tea catechins in patients with high-grade prostatic intraepithelial neoplasia: Results of a short-term double-blind placebo controlled phase II clinical trial
VL  - 89
ID  - 2912
ER  - 

TY  - JOUR
AB  - BACKGROUND: Ethnic disparities in access to health care is a persistent problem in the US. Despite the broad implementation of managed care, there is little information that specifically addresses how this type of coverage may affect ethnic disparities. OBJECTIVES: To examine the effect of managed care insurance on the use of preventive care for different ethnic groups. RESEARCH DESIGN: Observational cohort using the 1996 Medical Expenditure Panel Survey. SUBJECTS: Adults with health insurance who report their ethnicity as white, black, Hispanic, or Asian/Pacific Islander. MAIN OUTCOME MEASURES: (1) Mammography within the past 2 years for women between 50 and 75 years of age; (2) clinical breast exam within the past 2 years for women between 40 and 75 years; (3) Papanicolaou smear within the past 2 years for women between 18 and 65 years; and (4) cholesterol screening within the past 5 years for men and women older than the age of 20 years. RESULTS: Hispanic people enrolled in a managed care plan report higher rates of mammography, breast exam, and Papanicolaou smear compared with Hispanic people with fee-for-service insurance. For example, the adjusted predicted probability of a mammogram for Hispanic women with managed care was 85.6% compared with 72.4% for Hispanic women with fee-for-service coverage (risk difference: 13.2%; 95% CI for the risk difference 0.7%-25.7%). White persons with managed care are also more likely than white persons with fee-for-service coverage to receive mammography and cholesterol screening. Managed care is not associated with less preventive care for any ethnic group. CONCLUSIONS: In this nationally representative household survey, it was found that managed care is associated with greater use of some preventive care for Hispanic persons and white persons than fee-for-service insurance. Despite a focus on prevention, the benefits of managed care are not apparent for black persons or Asian/Pacific Islanders.
AD  - Institute for Health Policy Studies, Division of General Internal Medicine, San Francisco General Hospital, CA, USA. jhaas@itsa.ucsf.edu
AN  - 12218765
AU  - Haas, J. S.
AU  - Phillips, K. A.
AU  - Sonneborn, D.
AU  - McCulloch, C. E.
AU  - Liang, S. Y.
DA  - Sep
DO  - 10.1097/00005650-200209000-00004
DP  - NLM
ET  - 2002/09/10
IS  - 9
KW  - Adult
Breast Neoplasms/diagnosis
Chi-Square Distribution
Cohort Studies
*Ethnic Groups
Fee-for-Service Plans
Female
*Health Services Accessibility
Health Services Research
Humans
Hypercholesterolemia/diagnosis
Male
Mammography/statistics & numerical data
*Managed Care Programs
Middle Aged
Papanicolaou Test
Preventive Health Services/*statistics & numerical data
United States
Vaginal Smears/statistics & numerical data
LA  - eng
N1  - Haas, Jennifer S
Phillips, Kathryn A
Sonneborn, Dean
McCulloch, Charles E
Liang, Su-Ying
P01 HS10771/HS/AHRQ HHS/United States
P01HS10856/HS/AHRQ HHS/United States
R01 CA81130/CA/NCI NIH HHS/United States
Comparative Study
Journal Article
Research Support, U.S. Gov't, P.H.S.
United States
Med Care. 2002 Sep;40(9):743-51. doi: 10.1097/00005650-200209000-00004.
PY  - 2002
SN  - 0025-7079 (Print)
0025-7079
SP  - 743-51
ST  - Effect of managed care insurance on the use of preventive care for specific ethnic groups in the United States
T2  - Med Care
TI  - Effect of managed care insurance on the use of preventive care for specific ethnic groups in the United States
VL  - 40
ID  - 663
ER  - 

TY  - JOUR
AB  - BACKGROUND: Decision aids can improve decision making processes, but the amount and type of information that they should attempt to communicate is controversial. We sought to compare, in a pilot randomized trial, two colorectal cancer (CRC) screening decision aids that differed in the number of screening options presented. METHODS: Adults ages 48-75 not currently up to date with screening were recruited from the community and randomized to view one of two versions of our previously tested CRC screening decision aid. The first version included five screening options: fecal occult blood test (FOBT), sigmoidoscopy, a combination of FOBT and sigmoidoscopy, colonoscopy, and barium enema. The second discussed only the two most frequently selected screening options, FOBT and colonoscopy. Main outcomes were differences in screening interest and test preferences between groups after decision aid viewing. Patient test preference was elicited first without any associated out-of-pocket costs (OPC), and then with the following costs: FOBT-$10, sigmoidoscopy-$50, barium enema-$50, and colonoscopy-$200. RESULTS: 62 adults participated: 25 viewed the 5-option decision aid, and 37 viewed the 2-option version. Mean age was 54 (range 48-72), 58% were women, 71% were White, 24% African-American; 58% had completed at least a 4-year college degree. Comparing participants that viewed the 5-option version with participants who viewed the 2-option version, there were no differences in screening interest after viewing (1.8 vs. 1.9, t-test p = 0.76). Those viewing the 2-option version were somewhat more likely to choose colonoscopy than those viewing the 5-option version when no out of pocket costs were assumed (68% vs. 46%, p = 0.11), but not when such costs were imposed (41% vs. 42%, p = 1.00). CONCLUSION: The number of screening options available does not appear to have a large effect on interest in colorectal cancer screening. The effect of offering differing numbers of options may affect test choice when out-of-pocket costs are not considered.
AD  - Center for Decision Making Research, Cecil Sheps Center for Health Services Research, University of North Carolina-Chapel Hill, Chapel Hill, North Carolina, USA. jgriffith@unc.edu
AN  - 18218084
AU  - Griffith, J. M.
AU  - Lewis, C. L.
AU  - Brenner, A. R.
AU  - Pignone, M. P.
C2  - PMC2259331
DA  - Jan 24
DO  - 10.1186/1472-6947-8-4
DP  - NLM
ET  - 2008/01/26
KW  - Aged
Barium
Choice Behavior
Colonoscopy/economics/statistics & numerical data
Colorectal Neoplasms/*diagnosis
*Decision Support Techniques
Enema/economics/statistics & numerical data
Female
Financing, Personal
Humans
Male
Mass Screening/economics/*methods
Middle Aged
North Carolina
Occult Blood
Patient Participation/economics/*statistics & numerical data
Patient Satisfaction/economics/*statistics & numerical data
Sigmoidoscopy/economics/statistics & numerical data
Surveys and Questionnaires
LA  - eng
N1  - 1472-6947
Griffith, Jennifer M
Lewis, Carmen L
Brenner, Alison R T
Pignone, Michael P
K07 CA104128/CA/NCI NIH HHS/United States
K07 CA104128-01A2/CA/NCI NIH HHS/United States
P30 CD000138/CD/ODCDC CDC HHS/United States
5K07CA104128/CA/NCI NIH HHS/United States
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
BMC Med Inform Decis Mak. 2008 Jan 24;8:4. doi: 10.1186/1472-6947-8-4.
PY  - 2008
SN  - 1472-6947
SP  - 4
ST  - The effect of offering different numbers of colorectal cancer screening test options in a decision aid: a pilot randomized trial
T2  - BMC Med Inform Decis Mak
TI  - The effect of offering different numbers of colorectal cancer screening test options in a decision aid: a pilot randomized trial
VL  - 8
ID  - 506
ER  - 

TY  - JOUR
AB  - BACKGROUND: There is growing evidence that patient navigation improves breast cancer screening rates; however, there are limited efficacy studies of its effect among African American older adult women. OBJECTIVE: To evaluate the effect of patient navigation on screening mammography among African American female Medicare beneficiaries in Baltimore, MD. DESIGN: The Cancer Prevention and Treatment Demonstration (CPTD), a multi-site study, was a randomized controlled trial conducted from April 2006 through December 2010. SETTING: Community-based and clinical setting. PARTICIPANTS: The CPTD Screening Trial enrolled 1905 community-dwelling African American female Medicare beneficiaries who were ≥65 years of age and resided in Baltimore, MD. Participants were recruited from health clinics, community centers, health fairs, mailings using Medicare rosters, and phone calls. INTERVENTIONS: Participants were randomized to either: printed educational materials on cancer screening (control group) or printed educational materials + patient navigation services designed to help participants overcome barriers to cancer screening (intervention group). MAIN MEASURE: Self-reported receipt of mammography screening within 2 years of the end of the study. KEY RESULTS: The median follow-up period for participants in this analysis was 17.8 months. In weighted multivariable logistic regression analyses, women in the intervention group had significantly higher odds of being up to date on mammography screening at the end of the follow-up period compared to women in the control group (odds ratio [OR] 2.26, 95 % confidence interval [CI]1.59-3.22). The effect of the intervention was stronger among women who were not up to date with mammography screening at enrollment (OR 3.63, 95 % CI 2.09-6.38). CONCLUSION: Patient navigation among urban African American Medicare beneficiaries increased self-reported mammography utilization. The results suggest that patient navigation for mammography screening should focus on women who are not up to date on their screening.
AD  - Division of General Medicine, University of Michigan Health System, Ann Arbor, MI, USA.
Department of Oncology, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Department of Medicine, The Brooklyn Hospital Center, Brooklyn, NY, USA. jgf9001@nyp.org.
Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Department of Population, Family and Reproductive Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Department of Health, Behavior and Society, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Department of Acute and Chronic Care, Johns Hopkins School of Nursing, Baltimore, MD, USA.
Health Partners Cancer Program and Institute for Education and Research, Minneapolis, MN, USA.
Centers for Medicare and Medicaid Services, Baltimore, MD, USA.
Park West Health Systems, Baltimore, MD, USA.
TVCOFA Corporation, Baltimore, MD, USA.
Formerly of the Department of Health, Behavior and Society, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA.
AN  - 26259762
AU  - Marshall, J. K.
AU  - Mbah, O. M.
AU  - Ford, J. G.
AU  - Phelan-Emrick, D.
AU  - Ahmed, S.
AU  - Bone, L.
AU  - Wenzel, J.
AU  - Shapiro, G. R.
AU  - Howerton, M.
AU  - Johnson, L.
AU  - Brown, Q.
AU  - Ewing, A.
AU  - Pollack, C. E.
C2  - PMC4700012
DA  - Jan
DO  - 10.1007/s11606-015-3484-2
DP  - NLM
ET  - 2015/08/12
IS  - 1
KW  - *African Americans
Aged
Breast Neoplasms/economics/*ethnology/prevention & control
Early Detection of Cancer/*economics
Female
*Guideline Adherence
Health Knowledge, Attitudes, Practice
Humans
Mammography/economics
Medicare/*economics
Patient Education as Topic/*methods
Patient Navigation/*economics
Surveys and Questionnaires
United States/epidemiology
African American
mammography
patient navigation
LA  - eng
N1  - 1525-1497
Marshall, Jessie Kimbrough
Mbah, Olive M
Ford, Jean G
Phelan-Emrick, Darcy
Ahmed, Saifuddin
Bone, Lee
Wenzel, Jennifer
Shapiro, Gary R
Howerton, Mollie
Johnson, Lawrence
Brown, Qiana
Ewing, Altovise
Pollack, Craig Evan
U54 CA153710/CA/NCI NIH HHS/United States
UL1 TR001079/TR/NCATS NIH HHS/United States
5 T32 HL007180-340/HL/NHLBI NIH HHS/United States
1UL1TR001079/TR/NCATS NIH HHS/United States
T32 HL007180/HL/NHLBI NIH HHS/United States
K07 CA151910/CA/NCI NIH HHS/United States
U54CA153710/CA/NCI NIH HHS/United States
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
J Gen Intern Med. 2016 Jan;31(1):68-76. doi: 10.1007/s11606-015-3484-2. Epub 2015 Aug 11.
PY  - 2016
SN  - 0884-8734 (Print)
0884-8734
SP  - 68-76
ST  - Effect of Patient Navigation on Breast Cancer Screening Among African American Medicare Beneficiaries: A Randomized Controlled Trial
T2  - J Gen Intern Med
TI  - Effect of Patient Navigation on Breast Cancer Screening Among African American Medicare Beneficiaries: A Randomized Controlled Trial
VL  - 31
ID  - 236
ER  - 

TY  - JOUR
AB  - OBJECTIVES: To determine individuals' perceptions concerning dementia screening and to evaluate the possibility of an association between their perceptions and their willingness to undergo screening. DESIGN: Cross-sectional study of primary care patients aged 65 and older. SETTING: Urban primary care clinics in Indianapolis, Indiana, in 2008 to 2009. PARTICIPANTS: Five hundred fifty-four primary care patients without a documented diagnosis of dementia. MEASUREMENTS: The Perceptions Regarding Investigational Screening for Memory in Primary Care Questionnaire (PRISM-PC) and agreement or refusal to undergo dementia screening. RESULTS: Of the 554 study participants who completed the PRISM-PC, 65.5% were aged 70 and older, 70.0% were female, and 56.5% were African American; 57 (10.3%) refused screening for dementia. Of the 497 (89.7%) who agreed to screening, 63 (12.7%) screened positive. After adjusting for age, perception of depression screening, perception of colon cancer screening, and belief that no treatment is currently available for Alzheimer's disease, the odds of refusing screening were significantly lower in participants who had higher PRISM-PC domain scores for benefits of dementia screening (odds ratio (OR) = 0.85, 95% confidence interval (CI) = 0.75-0.97; P = .02). In the same regression model, the odds of refusing screening were significantly higher in participants aged 70 to 74 (OR = 5.65, 95% CI = 2.27-14.09; P < .001) and those aged 75 to 79 (OR = 3.63, 95% CI = 1.32-9.99; P = .01) than in the reference group of patients aged 65 to 69. CONCLUSION: Age and perceived benefit of screening are associated with acceptance of dementia screening in primary care. © 2012, Copyright the Authors Journal compilation © 2012, The American Geriatrics Society.
AD  - M.A. Boustani, Regenstrief Institute, Inc., Indiana University, Indianapolis, IN, United States
AU  - Fowler, N. R.
AU  - Boustani, M. A.
AU  - Frame, A.
AU  - Perkins, A. J.
AU  - Monahan, P.
AU  - Gao, S.
AU  - Sachs, G. A.
AU  - Hendrie, H. C.
DB  - Embase
Medline
DO  - 10.1111/j.1532-5415.2012.03991.x
IS  - 6
KW  - African American
aged
Alzheimer disease
article
attitude to illness
colon cancer
cross-sectional study
dementia
depression
female
human
major clinical study
male
mass screening
perception
primary medical care
questionnaire
refusal to participate
sex difference
statistical significance
United States
urban population
LA  - English
M3  - Article
N1  - L364992985
2012-06-21
2012-06-25
PY  - 2012
SN  - 0002-8614
1532-5415
SP  - 1037-1043
ST  - Effect of patient perceptions on dementia screening in primary care
T2  - Journal of the American Geriatrics Society
TI  - Effect of patient perceptions on dementia screening in primary care
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L364992985&from=export
http://dx.doi.org/10.1111/j.1532-5415.2012.03991.x
VL  - 60
ID  - 1115
ER  - 

TY  - JOUR
AB  - Mammography screening continues to be under-utilized, especially among women from lower socioeconomic groups. In order to determine whether having direct access to health care services has an effect on mammography use among low income women, we conducted a randomized trial of two alternative letter reminders among 1,717 women who were enrolled at two locations of a multi-site inner city health department in Detroit. All participants were 39(1/2) years of age and older and were due for a screening mammogram at randomization. A physician-directed reminder form was placed in each of the participant's medical records at the beginning of the study. In addition participants were randomized to receive either a letter directing them to visit their primary care physician, a letter directing them to contact the clinic directly to schedule a mammogram, or no letter. Study participants were predominantly African-American, two-thirds of whom were over age 50, and who had minimal health insurance coverage. During the intervention year, mammograms were completed by 179 out of 967 study women at site one (18.5%), and 90 out of 750 study women at site two (12%). A multivariate model controlling for the simultaneous effect of age, insurance type, visit history and past mammography use, showed no significant independent effect of either type of letter reminder on mammography completion during the study year. In conclusion, letters targeted at women due for screening mammograms did not have a beneficial effect on mammography utilization above and beyond that of a physician medical record reminder.
AD  - Barbara Ann Karmanos Cancer Institute at Wayne State University, Detroit, MI 48201, USA.
AN  - 11245341
AU  - Simon, M. S.
AU  - Gimotty, P. A.
AU  - Moncrease, A.
AU  - Dews, P.
AU  - Burack, R. C.
DA  - Jan
DO  - 10.1023/a:1006410711370
DP  - NLM
ET  - 2001/03/14
IS  - 1
KW  - Adult
Aged
Breast Neoplasms/*diagnostic imaging
Female
*Health Services Accessibility
Humans
Mammography/*statistics & numerical data
*Mass Screening
Medical Records
Middle Aged
*Patient Compliance
*Patient Education as Topic
Physician-Patient Relations
Poverty
Primary Health Care
*Reminder Systems
Urban Population
LA  - eng
N1  - Simon, M S
Gimotty, P A
Moncrease, A
Dews, P
Burack, R C
CA-54578/CA/NCI NIH HHS/United States
Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, U.S. Gov't, P.H.S.
Netherlands
Breast Cancer Res Treat. 2001 Jan;65(1):63-70. doi: 10.1023/a:1006410711370.
PY  - 2001
SN  - 0167-6806 (Print)
0167-6806
SP  - 63-70
ST  - The effect of patient reminders on the use of screening mammography in an urban health department primary care setting
T2  - Breast Cancer Res Treat
TI  - The effect of patient reminders on the use of screening mammography in an urban health department primary care setting
VL  - 65
ID  - 688
ER  - 

TY  - JOUR
AB  - Purpose: The increase in mortality noted in African Americans with colon cancer is attributed to advanced stage at presentation and disparities in treatment received. The aim of this study was to assess the influence of race on the treatments and survival of colon cancer patients in an equal-access healthcare system. Methods: This retrospective cohort study included African American and white patients with colon cancer treated at Department of Defense facilities. Disease stage, surgery performed, chemotherapy used, and overall survival were evaluated. Results: Of the 6958 colon cancer patients identified, 1115 were African American. African Americans presented more frequently with stage IV disease, 23% vs 17% for whites (P <.001). There was no difference in surgical resection rates for African American or whites (85.8% vs 85.5%, respectively; x2, P >.05). There was no difference in the use of systemic chemotherapy for stage III colon cancer (73.5% for African Americans vs 72.2% for whites; x2, P >.05) or stage IV colon cancer (56.3% for African Americans vs 54.4% for whites; x2, P >.05). The overall 5-year survival rate was similar for African American and white patients (56.1% vs 58.5%, respectively; log-rank, P >.05). After adjusting for gender, age, tumor grade, and stage, African American race was not a risk factor for survival in Cox proportional hazard analysis (hazard ratio, 0.981; 95% confidence interval, 0.888 -1.084). Conclusions: In an equal-access healthcare system, African American race is not associated with an increase in mortality. African American patients undergo surgery and chemotherapy is administered at rates equal to whites for all stages of colon cancer. © 2009 The ASCRS.
AD  - L. J. Hofmann, Department of Surgery, William Beaumont Army Medical Center, 5005 N. Piedras St, El Paso, TX 79920, United States
AU  - Hofmann, L. J.
AU  - Lee, S.
AU  - WaddelL, B.
AU  - Davis, K. G.
DB  - Embase
Medline
DO  - 10.1007/DCR.0b013e3181bdcdb2
IS  - 1
KW  - adult
African American
article
cancer chemotherapy
cancer mortality
cancer surgery
cancer survival
cohort analysis
colon cancer
controlled study
economic aspect
female
health care access
health care system
human
major clinical study
male
outcome assessment
overall survival
patient selection
race difference
retrospective study
risk factor
statistical significance
survival rate
LA  - English
M3  - Article
N1  - L358428081
2010-03-18
2010-04-13
PY  - 2010
SN  - 0012-3706
1530-0358
SP  - 9-15
ST  - Effect of race on colon cancer treatment and outcomes in the department of defense healthcare system
T2  - Diseases of the Colon and Rectum
TI  - Effect of race on colon cancer treatment and outcomes in the department of defense healthcare system
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L358428081&from=export
http://dx.doi.org/10.1007/DCR.0b013e3181bdcdb2
VL  - 53
ID  - 1174
ER  - 

TY  - JOUR
AB  - Background: Cardiac toxicity (CT) is a rare late effect of anthracycline therapy for breast cancer (BC). Statins may attenuate the CT of anthracyclines. Myocardial strain can detect subclinical CT before ejection fraction (EF) declines. Global longitudinal strain (GLS) ≥‐19% and relative change (RelΔ) in GLS≥11% predict future decline in EF. We conducted a pilot study to evaluate the effect of simvastatin on GLS in BC patients receiving anthracyclines. Methods: We enrolled women with stage I‐III BC planning doxorubicin/cyclophosphamide (AC) x 4. Women with heart disease or taking a statin were excluded. Participants were randomized 1:1 to simvastatin 40 mg daily x 24 weeks (wk) + AC or to AC alone. We performed echo with strain 5 times: baseline (BL), pre‐AC#2, 1‐3 wk after AC#4, 24 wk after AC #1 and 52 wk after AC#1. The primary endpoint was the mean absolute change (Δ) in GLS from BL to 1‐3 wk after AC#4. Secondary endpoints included RelΔ in GLS, feasibility and safety. We used two‐sample t‐tests to compare mean changes in GLS and Fisher's exact test to compare dichotomized GLS values. The study closed early due to loss of staff. Results: Of 31 patients, 15 (48%) received simvastatin+AC. Mean age was 46 years; 71% pre‐menopausal, 61% white and 32% black. There were no significant differences in BL cardiovascular risk factors between the arms. After AC, 3 HER2+ patients received trastuzumab. There were no grade 3‐4 AEs with simvastatin. Common grade 1‐2 AEs included myalgia (20%), elevated AST (27%) and elevated ALT (53%). One patient in the AC arm died from heart failure with low EF 2 months after having a normal echo 1‐3 wk after AC#4. The rate of missing echos was 14%. Of 133 completed echos, 124 (93%) were evaluable for GLS. Mean GLS was <‐19% at all times in the simvastatin+AC arm. Mean GLS was <‐19% at BL and pre‐AC#2 in the AC arm, but >‐19% at post‐AC times in the AC arm. Mean EF was >60% at all times in both arms. Among 27 patients evaluable for the primary endpoint, there was no significant difference in mean Δ in GLS from BL to 1‐3 wk after AC#4 between the arms (Simvastatin+AC: 0.42%; AC: 1.11%, p=0.57). In addition, there were no differences in the meanΔ in GLS from BL to any other time between the arms (all p>0.1). The proportion of patients with GLS<‐19% was higher in the simvastatin+AC arm than in the AC arm pre‐AC#2 (73% vs 44%), 1‐3 wk after AC#4 (67% vs 38%), 24 wk after AC #1 (53% vs 25%) and 52 wk after AC#1 (53% vs 25%) (all p>0.05). The proportion of patients with RelΔ in GLS≥11% from BL was lower in the simvastatin+AC arm than in the AC arm pre‐AC#2 (13% vs 19%), 1‐3 wk after AC#4 (20% vs 44%) and 24 wk after AC#1(27% vs 31%) (all p>0.05). Conclusion: Simvastatin did not result in a statistically significant difference in the mean Δ in GLS from BL to 1‐3 wk after AC#4. However, the study was underpowered due to small sample size and there was a suggestion of reduced CT with simvastatin. Co‐administration of simvastatin and AC was safe and serial echocardiographic strain monitoring was feasible. Further studies are needed to evaluate the cardioprotective effect of statins on strain in BC patients receiving anthracyclines.
AN  - CN-01942239
AU  - Smith, K. L.
AU  - Griffin, J. M.
AU  - Tsai, H. L.
AU  - Leathers, M.
AU  - Hays, A.
AU  - Lu, D. Y.
AU  - Zhang, Z.
AU  - Rosner, G. L.
AU  - Russell, S. D.
AU  - Connolly, R. M.
AU  - et al.
DO  - 10.1158/1538-7445.SABCS18-P4-16-09
IS  - 4
KW  - *breast cancer
*cancer patient
*cardiotoxicity
Adult
Adverse drug reaction
Aspartate aminotransferase level
Cancer staging
Cardiovascular risk
Clinical article
Conference abstract
Controlled study
Drug safety
Drug therapy
Feasibility study
Female
Heart ejection fraction
Heart failure
Human
Middle aged
Monitoring
Myalgia
Pilot study
Randomized controlled trial
Sample size
Side effect
Staff
M3  - Journal: Conference Abstract
PY  - 2019
ST  - Effect of simvastatin on cardiac strain in breast cancer patients receiving anthracycline therapy
T2  - Cancer research
TI  - Effect of simvastatin on cardiac strain in breast cancer patients receiving anthracycline therapy
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01942239/full
VL  - 79
ID  - 1660
ER  - 

TY  - JOUR
AB  - 1517 Background: When used in the adjuvant setting, aromatase inhibitors (AIs) reduce the incidence of contralateral breast cancer and are therefore under investigation for primary breast cancer prevention. Statins hold promise for chemoprevention based on preclinical and epidemiological data. Adding statin to AI has the potential to enhance breast cancer prevention and to protect women from AI-related side effects. Prior to initiating a chemoprevention trial of combination therapy, we evaluated the potential for pharmacokinetic drug-drug interaction between anastrozole and simvastatin in postmenopausal women taking adjuvant anastrozole to ensure that the combination will not influence anastrozole concentration or affect its ability to reduce estrogen.Methods: Postmenopausal women with hormone receptor-positive, stage 0-III breast cancer who had been on adjuvant anastrozole (1 mg/day) for at least 30 days were prescribed 14 days of simvastatin (40 mg/day). We collected serum at baseline (anastrozole alone) and after 14 days of simvastatin initiation (combination therapy). Anastrozole and hydroxyanastrozole, its hydroxylated metabolite, concentrations were determined using liquid chromatography-tandem mass spectrometry assay. Estrogen concentrations will be determined using radio-immunoassay. Significant change in anastrozole was predetermined to be greater than a 30% decrease in concentrations. Percent changes from baseline in anastrozole and hydroxyanastrozole were evaluated using Wilcoxon signed-rank tests.Results: From December 2006 to September 2008, 11 women (10 Caucasian, 1 Black, all reported non-Hispanic with a mean age of 60 yrs [range 51-69]) were enrolled in the study. Of these women, nine had evaluable anastrozole concentrations. After 14 days of simvastatin, there were nonsignificant changes in anastrozole (median percentage difference = 10.1% [-13.5%, 38.4%], p = 0.36) and hydroxyanastrozole (median percentage difference = -3.0% [-19.1%, 11.2%], p = 0.65). Estrogen data will be available for presentation.Conclusions: Simvastatin is unlikely to alter the pharmacokinetics of anastrozole in a clinically meaningful way. Combination studies to assess chemopreventive properties of the combination are planned. [Table: see text].
AD  - Johns Hopkins Kimmel Cancer Center, Baltimore, MD; University of Colorado, Denver, CO; Indiana University, Bloomington, IN
AN  - 120352865. Language: English. Entry Date: In Process. Revision Date: 20161223. Publication Type: journal article. Supplement Title: 5/21/2009 Supplement Part 1 of 2. Journal Subset: Biomedical
AU  - Bao, T.
AU  - Slater, S. A.
AU  - Blackford, A.
AU  - Jeter, S. C.
AU  - Wright, L.
AU  - Rudek, M. A.
AU  - Desta, Z.
AU  - Stearns, V.
DB  - CINAHL Complete
DP  - EBSCOhost
N1  - Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA. NLM UID: 8309333.
PMID: NLM27964328.
PY  - 2009
SN  - 0732-183X
SP  - 1517-1517
ST  - Effect of simvastatin on the pharmacokinetics of anastrozole
T2  - Journal of Clinical Oncology
TI  - Effect of simvastatin on the pharmacokinetics of anastrozole
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=120352865&site=ehost-live&scope=site
VL  - 27
ID  - 1929
ER  - 

TY  - JOUR
AB  - OBJECTIVES: This paper aims to investigate the effect of socioeconomic status, as measured by education, on the survival of breast cancer patients treated on 10 studies conducted by the Cancer and Leukemia Group B. METHODS: Sociodemographic data, including education, were reported by the patient at trial enrollment. Cox proportional hazards model stratified by treatment arm/study was used to examine the effect of education on survival among patients with early stage and metastatic breast cancer, after adjustment for known prognostic factors. RESULTS: The patient population included 1020 patients with metastatic disease and 5146 patients with early stage disease. Among metastatic patients, factors associated with poorer survival in the final multivariable model included African American race, never married, negative estrogen receptor status, prior hormonal therapy, visceral involvement, and bone involvement. Among early stage patients, significant factors associated with poorer survival included African American race, separated/widowed, post/perimenopausal, negative/unknown estrogen receptor status, negative progesterone receptor status, >4 positive nodes, tumor diameter >2 cm, and education. Having not completed high school was associated with poorer survival among early stage patients. Among metastatic patients, non-African American women who lacked a high school degree had poorer survival than other non-African American women, and African American women who lacked a high school education had better survival than educated African American women. CONCLUSIONS: Having less than a high school education is a risk factor for death among patients with early stage breast cancer who participated in a clinical trial, with its impact among metastatic patients being less clear. Post-trial survivorship plans need to focus on women with low social status, as measured by education.
AD  - Department of Biostatistics & Bioinformatics, Duke University Medical Center, Durham, NC 27710, USA. james.herndon@duke.edu
AN  - 22021121
AU  - Herndon, J. E., 2nd
AU  - Kornblith, A. B.
AU  - Holland, J. C.
AU  - Paskett, E. D.
C2  - PMC3920288
C6  - NIHMS547394
DA  - Feb
DO  - 10.1002/pon.2094
DP  - NLM
ET  - 2011/10/25
IS  - 2
KW  - Adult
African Americans/statistics & numerical data
Aged
Breast Neoplasms/ethnology/*mortality
Clinical Trials as Topic
Educational Status
Female
Humans
Middle Aged
Multivariate Analysis
Proportional Hazards Models
Risk Factors
*Social Class
Survival Rate
United States/epidemiology
LA  - eng
N1  - 1099-1611
Herndon, James E 2nd
Kornblith, Alice B
Holland, Jimmie C
Paskett, Electra D
U10 CA032291/CA/NCI NIH HHS/United States
CA33601/CA/NCI NIH HHS/United States
U10 CA077658/CA/NCI NIH HHS/United States
CA32291/CA/NCI NIH HHS/United States
U10 CA031946/CA/NCI NIH HHS/United States
CA77651/CA/NCI NIH HHS/United States
U10 CA033601/CA/NCI NIH HHS/United States
U10 CA077651/CA/NCI NIH HHS/United States
CA77658/CA/NCI NIH HHS/United States
CA31946/CA/NCI NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
Psychooncology. 2013 Feb;22(2):315-23. doi: 10.1002/pon.2094. Epub 2011 Oct 20.
PY  - 2013
SN  - 1057-9249 (Print)
1057-9249
SP  - 315-23
ST  - Effect of socioeconomic status as measured by education level on survival in breast cancer clinical trials
T2  - Psychooncology
TI  - Effect of socioeconomic status as measured by education level on survival in breast cancer clinical trials
VL  - 22
ID  - 383
ER  - 

TY  - JOUR
AB  - This prespecified ancillary study of a randomized clinical trial compares the effects of daily marine omega-3 fatty acid supplementation vs placebo on risk of colorectal cancer precursors, including conventional adenomas and serrated polyps, in an average-risk US population. Importance Marine omega-3 fatty acid has been suggested to protect against colorectal cancer. Objective To assess the effect of daily marine omega-3 fatty acid supplementation on the risk of colorectal cancer precursors, including conventional adenomas and serrated polyps. Design, Setting, and Participants This study was a prespecified ancillary study of the placebo-controlled randomized clinical trial VITAL (Vitamin D and Omega-3 Trial). An intention-to-treat analysis was used to examine the effect of daily marine omega-3 supplements among 25871 adults in the US general population (including 5106 African American persons) free of cancer and cardiovascular disease at enrollment. Randomization was from November 2011 to March 2014, and intervention ended as planned on December 31, 2017. Interventions Marine omega-3 fatty acid, 1 g daily (which included eicosapentaenoic acid, 460 mg, and docosahexaenoic acid, 380 mg) and vitamin D3 (2000 IU daily) supplements. Main Outcomes and Measures Risk of conventional adenomas (including tubular adenoma, tubulovillous adenoma, villous adenoma, and adenoma with high-grade dysplasia) or serrated polyps (including hyperplastic polyp, traditional serrated adenoma, and sessile serrated polyp). In a subset of participants who reported receiving a diagnosis of polyp on follow-up questionnaires, endoscopic and pathologic records were obtained to confirm the diagnosis. Odds ratios (ORs) and 95% CIs were calculated using logistic regression, after adjusting for age, sex, vitamin D treatment assignment, and use of endoscopy. Secondary analyses were performed according to polyp features and participants' characteristics. Results The demographic characteristics of participants at randomization were well balanced between the treatment and placebo groups; for example, 50.6% vs 50.5% were women, and 19.7% vs 19.8% were African American persons were included in each group. The mean (SD) age was 67.1 (7.1) years in the placebo group and 67.2 (7.1) in the omega-3 treatment group. During a median follow-up of 5.3 years (range, 3.8-6.1 years), 294 cases of conventional adenomas were documented in the omega-3 group and 301 in the control group (multivariable OR, 0.98; 95% CI, 0.83-1.15) (1:1 ratio between number of cases and number of participants). In addition, 174 cases of serrated polyps were documented in the omega-3 group and 167 in the control group (OR, 1.05; 95% CI, 0.84-1.29). Null associations were found for polyp subgroups according to size, location, multiplicity, or histology. In secondary analyses, marine omega-3 treatment appeared to be associated with lower risk of conventional adenomas among individuals with low plasma levels of omega-3 index at baseline (OR, 0.76; 95% CI, 0.57-1.02; P = .03 for interaction by omega-3 index). A beneficial association of supplementation was also noted in the African American population (OR, 0.59; 95% CI, 0.35-1.00) but not in other racial/ethnic groups (P = .11 for interaction). Conclusions and Relevance Supplementation with marine omega-3 fatty acids, 1 g per day, was not associated with reduced risk of colorectal cancer precursors. A potential benefit of this supplementation for individuals with low baseline omega-3 levels or for African American persons requires further confirmation. Question Does marine omega-3 fatty acid supplementation reduce risk of colorectal cancer precursors in the US general population? Findings In this randomized clinical trial that included 25871 adults, daily supplementation of marine omega-3 fatty acid, 1 g, did not reduce risk of conventional adenomas or serrated polyps. A suggestive beneficial association was observed among individuals with low plasma levels of omega-3 fatty acid at baseline and among African American persons. Meaning Daily supplementation with marine omega-3 fatty acids, 1 g, appears not to reduce the risk of colorectal premalignant lesions in the average-risk US population; however, individuals with low plasma levels of omega-3 or African American persons may benefit.
AN  - WOS:000506583600016
AU  - Song, M. Y.
AU  - Lee, I. M.
AU  - Manson, J. E.
AU  - Buring, J. E.
AU  - Dushkes, R.
AU  - Gordon, D.
AU  - Walter, J.
AU  - Wu, K.
AU  - Chan, A. T.
AU  - Ogino, S.
AU  - Fuchs, C. S.
AU  - Meyerhardt, J. A.
AU  - Giovannucci, E. L.
AU  - Manson, J. E.
AU  - Buring, J. E.
AU  - Cook, N. R.
AU  - Lee, I. M.
AU  - Christen, W.
AU  - Bassuk, S. S.
AU  - Mora, S.
AU  - Gibson, H.
AU  - Gordon, D.
AU  - Copeland, T.
AU  - D'Agostino, D.
AU  - Friedenberg, G.
AU  - Ridge, C.
AU  - Bubes, V.
AU  - Giovannucci, E. L.
AU  - Willett, W. C.
AU  - Baron, J.
AU  - Holick, M.
AU  - Hollis, B.
AU  - Albert, C. M.
AU  - Gold, D.
AU  - LeBoff, M.
AU  - Okereke, O.
AU  - Pradhan, A.
AU  - Sesso, H.
AU  - Chen, W.
AU  - Chandler, P.
AU  - Gaziano, J. M.
AU  - Demler, O.
AU  - Rexrode, K.
AU  - Costenbader, K.
AU  - Forman, J.
AU  - Alexander, E.
AU  - Friedman, S.
AU  - Katz, J.
AU  - Zhang, S. M.
AU  - Lin, J.
AU  - Walter, J.
AU  - Duszlak, J.
AU  - Kalan, K.
AU  - MacFadyen, J.
AU  - Gomelskaya, N.
AU  - Bates, D.
AU  - Sarkissian, A.
AU  - Breen, M.
AU  - Andrade, Y.
AU  - Vinayagamoorthy, M.
AU  - Li, C. Y.
AU  - Kim, E.
AU  - Giulianini, F.
AU  - Kotler, G.
AU  - Van Denburgh, M.
AU  - Dushkes, R.
AU  - Liu, Y. Y.
AU  - Pereira, E.
AU  - Fields-Johnson, L.
AU  - Menjin, G.
AU  - Liu, L.
AU  - Girard, L.
AU  - Zeller, S.
AU  - Riches, N.
AU  - Hasson, K.
AU  - Bhang, E.
AU  - Revilla, M.
AU  - McCarthy, E.
AU  - Moran, A.
AU  - Haise, K.
AU  - Arsenault, L.
AU  - Quinn, P.
AU  - Grimes, S.
AU  - Fitchorov, I.
AU  - Schwerin, K.
AU  - Curry, S.
AU  - Murray, A.
AU  - Zhang, A.
AU  - Walrond-Williams, D.
AU  - Weinberg, A.
AU  - Pfeffer, C.
AU  - Haubourg, M.
AU  - Nguyen, V.
AU  - Ouellette, H.
AU  - Rodriguez, R.
AU  - Montgomery, T.
AU  - Morse, K.
AU  - Guzman, V.
AU  - Perry, M.
AU  - Weekes, S.
AU  - Smith, D.
AU  - Clar, A.
AU  - Curran, S.
AU  - Fonge, Y.
AU  - Hibbert, D.
AU  - Paine, L.
AU  - Royce, K.
AU  - Splaine, C.
AU  - McMahon, J.
AU  - Eldridge, D.
AU  - Hand, L.
AU  - Inandan, K.
AU  - Werden, M. R.
AU  - Samuelson, H.
AU  - Hrbek, A.
AU  - Mele, M.
AU  - Bowes, E.
AU  - Ryan, M. A.
AU  - Camargo, C.
AU  - Danik, J.
AU  - Thadhani, R.
AU  - Wang, T.
AU  - Shah, R. C.
AU  - Albert, M. A.
AU  - Kase, C.
AU  - Vesper, H.
AU  - Botelho, J.
AU  - Cohen, L. S.
AU  - Colton, T.
AU  - Espeland, M. A.
AU  - Henderson, C.
AU  - Lichtenstein, A. H.
AU  - Silliman, R. A.
AU  - Wenger, N.
AU  - Boyington, J.
AU  - Costello, R.
AU  - Davis, C.
AU  - Greenwald, P.
AU  - Riscuta, G.
AU  - Seifried, H.
DA  - Jan
DO  - 10.1001/jamaoncol.2019.4587
IS  - 1
N1  - 31750855
PY  - 2020
SN  - 2374-2437
SP  - 108-115
ST  - Effect of Supplementation With Marine omega-3 Fatty Acid on Risk of Colorectal Adenomas and Serrated Polyps in the US General Population A Prespecified Ancillary Study of a Randomized Clinical Trial
T2  - Jama Oncology
TI  - Effect of Supplementation With Marine omega-3 Fatty Acid on Risk of Colorectal Adenomas and Serrated Polyps in the US General Population A Prespecified Ancillary Study of a Randomized Clinical Trial
VL  - 6
ID  - 2800
ER  - 

TY  - JOUR
AB  - IMPORTANCE: Marine ω-3 fatty acid has been suggested to protect against colorectal cancer. OBJECTIVE: To assess the effect of daily marine ω-3 fatty acid supplementation on the risk of colorectal cancer precursors, including conventional adenomas and serrated polyps. DESIGN, SETTING, AND PARTICIPANTS: This study was a prespecified ancillary study of the placebo-controlled randomized clinical trial VITAL (Vitamin D and Omega-3 Trial). An intention-to-treat analysis was used to examine the effect of daily marine ω-3 supplements among 25 871 adults in the US general population (including 5106 African American persons) free of cancer and cardiovascular disease at enrollment. Randomization was from November 2011 to March 2014, and intervention ended as planned on December 31, 2017. INTERVENTIONS: Marine ω-3 fatty acid, 1 g daily (which included eicosapentaenoic acid, 460 mg, and docosahexaenoic acid, 380 mg) and vitamin D3 (2000 IU daily) supplements. MAIN OUTCOMES AND MEASURES: Risk of conventional adenomas (including tubular adenoma, tubulovillous adenoma, villous adenoma, and adenoma with high-grade dysplasia) or serrated polyps (including hyperplastic polyp, traditional serrated adenoma, and sessile serrated polyp). In a subset of participants who reported receiving a diagnosis of polyp on follow-up questionnaires, endoscopic and pathologic records were obtained to confirm the diagnosis. Odds ratios (ORs) and 95% CIs were calculated using logistic regression, after adjusting for age, sex, vitamin D treatment assignment, and use of endoscopy. Secondary analyses were performed according to polyp features and participants' characteristics. RESULTS: The demographic characteristics of participants at randomization were well balanced between the treatment and placebo groups; for example, 50.6% vs 50.5% were women, and 19.7% vs 19.8% were African American persons were included in each group. The mean (SD) age was 67.1 (7.1) years in the placebo group and 67.2 (7.1) in the ω-3 treatment group. During a median follow-up of 5.3 years (range, 3.8-6.1 years), 294 cases of conventional adenomas were documented in the ω-3 group and 301 in the control group (multivariable OR, 0.98; 95% CI, 0.83-1.15) (1:1 ratio between number of cases and number of participants). In addition, 174 cases of serrated polyps were documented in the ω-3 group and 167 in the control group (OR, 1.05; 95% CI, 0.84-1.29). Null associations were found for polyp subgroups according to size, location, multiplicity, or histology. In secondary analyses, marine ω-3 treatment appeared to be associated with lower risk of conventional adenomas among individuals with low plasma levels of ω-3 index at baseline (OR, 0.76; 95% CI, 0.57-1.02; P = .03 for interaction by ω-3 index). A beneficial association of supplementation was also noted in the African American population (OR, 0.59; 95% CI, 0.35-1.00) but not in other racial/ethnic groups (P = .11 for interaction). CONCLUSIONS AND RELEVANCE: Supplementation with marine ω-3 fatty acids, 1 g per day, was not associated with reduced risk of colorectal cancer precursors. A potential benefit of this supplementation for individuals with low baseline ω-3 levels or for African American persons requires further confirmation. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT01169259.
AD  - Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Clinical and Translational Epidemiology Unit, Mongan Institute, Massachusetts General Hospital, Harvard Medical School, Boston.
Division of Gastroenterology, Massachusetts General Hospital, Harvard Medical School, Boston.
Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge.
Department of Oncologic Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Yale Cancer Center, New Haven, Connecticut.
Department of Medicine, Yale School of Medicine, New Haven, Connecticut.
Smilow Cancer Hospital, New Haven, Connecticut.
Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
AN  - 31750855
AU  - Song, M.
AU  - Lee, I. M.
AU  - Manson, J. E.
AU  - Buring, J. E.
AU  - Dushkes, R.
AU  - Gordon, D.
AU  - Walter, J.
AU  - Wu, K.
AU  - Chan, A. T.
AU  - Ogino, S.
AU  - Fuchs, C. S.
AU  - Meyerhardt, J. A.
AU  - Giovannucci, E. L.
C2  - PMC6902220 American Cancer Society. Dr Lee reported receiving grants from the National Institutes of Health (NIH) during the conduct of the study. Dr Manson reported receiving grants from the NIH and receiving nonfinancial support from Pronova BioPharma/BASF and from Pharmavite during the conduct of the study. Dr Buring reported receiving grants from NIH during the conduct of the study and having a family member (spouse) on the Scientific Advisory Board of Pharmavite, which provided pills and packaging for the parent VITAL trial. Drs Dushkes, Gordon, and Walter reported receiving grants from the NIH during the conduct of the study. Dr Chan reported being on the data and safety monitoring board of Pfizer; grants and consulting fees from Bayer Pharma AG; and consulting fees from Janssen Pharmaceuticals outside the submitted work. Dr Ogino reported receiving grants from the NIH and from the Dana-Farber Harvard Cancer Center during the conduct of the study, and receiving a honorarium from Kaishi Professional University through Lighthouse. Dr Fuchs reported receiving consulting fees from Agios, Bain Capital, Bayer, Celgene, Dicerna Pharmaceuticals, Five Prime Therapeutics, Inc, Gilead Sciences, Inc, Eli Lilly and Company, Entrinsic Health Solutions, Genentech, KEW, Inc, Merck & Co, Merrimack Pharmaceuticals, Pfizer, Sanofi, Taiho Pharmaceutical, Unum Therapeutics, and CytomX Therapeutics outside the submitted work; serving as a director for CytomX Therapeutics; and owning unexercised stock options for CytomX Therapeutics and Entrinsic Health. Dr Meyerhardt reported receiving consulting fees from Taiho Pharmaceutical, Ignyta, and Cota Healthcare outside the submitted work. No other disclosures were reported.
DA  - Nov 21
DO  - 10.1001/jamaoncol.2019.4587
DP  - NLM
ET  - 2019/11/22
IS  - 1
LA  - eng
N1  - 2374-2445
Song, Mingyang
Lee, I-Min
Manson, JoAnn E
Buring, Julie E
Dushkes, Rimma
Gordon, David
Walter, Joseph
Wu, Kana
Chan, Andrew T
Ogino, Shuji
Fuchs, Charles S
Meyerhardt, Jeffrey A
Giovannucci, Edward L
VITAL Research Group
R00 CA215314/CA/NCI NIH HHS/United States
Journal Article
JAMA Oncol. 2019 Nov 21;6(1):108-15. doi: 10.1001/jamaoncol.2019.4587.
PY  - 2019
SN  - 2374-2437 (Print)
2374-2437
SP  - 108-15
ST  - Effect of Supplementation With Marine ω-3 Fatty Acid on Risk of Colorectal Adenomas and Serrated Polyps in the US General Population: A Prespecified Ancillary Study of a Randomized Clinical Trial
T2  - JAMA Oncol
TI  - Effect of Supplementation With Marine ω-3 Fatty Acid on Risk of Colorectal Adenomas and Serrated Polyps in the US General Population: A Prespecified Ancillary Study of a Randomized Clinical Trial
VL  - 6
ID  - 58
ER  - 

TY  - JOUR
AB  - IMPORTANCE: Outpatient colonoscopy is important for colorectal cancer screening. However, nonadherence and poor bowel preparation are common. OBJECTIVE: To determine if an automated text messaging intervention with a focus on informational and reminder functions could improve attendance rates and bowel preparation quality for outpatient colonoscopy. DESIGN, SETTING, AND PARTICIPANTS: This randomized clinical trial was conducted in an endoscopy center at an urban academic medical center. Adult patients scheduled for outpatient colonoscopy between January and September 2019 were enrolled by telephone call (early phase) or by automated text message (late phase). Data were analyzed from October 2019 to January 2020. INTERVENTIONS: After enrollment, patients were randomized in a 1:1 ratio to usual care (ie, written instructions and nurse telephone call) or to the intervention (ie, usual care plus an automated series of 9 educational or reminder text messages in the week prior to scheduled colonoscopy). MAIN OUTCOMES AND MEASURES: The primary outcome was appointment attendance rate with good or excellent bowel preparation. Secondary outcomes included appointment attendance rate, bowel preparation quality (poor or inadequate, fair or adequate, and good or excellent), and cancellation lead time (in days). RESULTS: Among 753 patients included and randomized in the trial (median [interquartile range] age, 56 [49-64] years; 364 [48.3%] men; 429 [57.2%] Black), 367 patients were randomized to the intervention group and 386 patients were randomized to the control group. There was no significant difference in the primary outcome between groups (patients attending appointments with good or excellent bowel preparation: intervention, 195 patients [53.1%]; control, 210 patients [54.4%]; P = .73), including when stratified by early or late phase enrollment groups. Similarly, there were no significant differences in secondary outcomes. CONCLUSIONS AND RELEVANCE: This randomized clinical trial found no significant difference in appointment attendance or bowel preparation quality with an automated text messaging intervention compared with the usual care control. Future work could optimize the content and delivery of text message interventions or identify patient subgroups that may benefit from this approach. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03710213.
AD  - Division of Gastroenterology and Hepatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia.
Leonard David Institute of Health Economics, University of Pennsylvania, Philadelphia.
Center for Clinical Epidemiology and Biostatistics, Department of Biostatistics, Epidemiology & Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia.
Corporal Michael J. Crescenz VA Medical Center, Philadelphia, Pennsylvania.
Center for Health Care Innovation, University of Pennsylvania, Philadelphia.
AN  - 33492374
AU  - Mahmud, N.
AU  - Asch, D. A.
AU  - Sung, J.
AU  - Reitz, C.
AU  - Coniglio, M. S.
AU  - McDonald, C.
AU  - Bernard, D.
AU  - Mehta, S. J.
C2  - PMC7835713 Hathaway, serving as a partner in and part owner of VAL Health, and receiving compensation and/or travel support for speaking, writing, or consulting for Salzburg Global Seminars, GlaxoSmithKline, JFK Health System, Cosmetic Boot Camp, Meeting Designs, Capital Consulting, Healthcare Financial Management Association, Joslin Diabetes Center, National Academy of Medicine, the Commonwealth Fund, Massachusetts Medical Society, Endocrine Society, Osteoarthritis Research Society International, Baystate Medical Center, Weill-Cornell Medical College, Association of American Medical Colleges, TEDMED, National Alliance of Health Care Purchaser Coalitions, Deloitte, Harvard University, American Association for Physician Leadership, Brandeis University, University of Rochester, Partner’s Health Care System, Virginia Medical Center, Johns Hopkins University, The MITRE Corporation, and University of Chicago. No other disclosures were reported.
DA  - Jan 4
DO  - 10.1001/jamanetworkopen.2020.34553
DP  - NLM
ET  - 2021/01/26
IS  - 1
KW  - *Ambulatory Care
*Appointments and Schedules
Cathartics/*administration & dosage
*Colonoscopy
Female
Humans
Male
Middle Aged
*Patient Compliance
Reminder Systems
*Text Messaging
LA  - eng
N1  - 2574-3805
Mahmud, Nadim
Asch, David A
Sung, Jessica
Reitz, Catherine
Coniglio, Mary S
McDonald, Caitlin
Bernard, Donna
Mehta, Shivan J
K08 CA234326/CA/NCI NIH HHS/United States
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
JAMA Netw Open. 2021 Jan 4;4(1):e2034553. doi: 10.1001/jamanetworkopen.2020.34553.
PY  - 2021
SN  - 2574-3805
SP  - e2034553
ST  - Effect of Text Messaging on Bowel Preparation and Appointment Attendance for Outpatient Colonoscopy: A Randomized Clinical Trial
T2  - JAMA Netw Open
TI  - Effect of Text Messaging on Bowel Preparation and Appointment Attendance for Outpatient Colonoscopy: A Randomized Clinical Trial
VL  - 4
ID  - 12
ER  - 

TY  - JOUR
AB  - The recruitment and retention of African Americans into cancer control studies presents a formidable task to the scientific and policy communities as well as patient and advocacy communities. The purpose of this investigation was to assess the role of a timed incentive schedule on response rates in a study of African American and white breast cancer survivors. A mailed quality-of-life survey battery was sent to 583 breast cancer survivors (50% African American, 50% white). Half of the participants received payment in advance, whereas the other half was promised payment. The overall response rate was 54% (n = 278). The timing of incentives did not affect participation rates in either ethnic group. About 51% of the respondents were from the payment-in-advance condition and 49% were from the paid-on-completion condition. Therefore, we conclude that payment on completion may be the more cost-effective approach in studies with higher socioeconomic status patients, such as this sample of breast cancer survivors.
AD  - Department of Psychiatry and Biobehavioral Sceinces, University of California, Los Angeles 90024, USA.
AN  - 11152085
AU  - Ashing-Giwa, K.
AU  - Ganz, P. A.
C2  - PMC2568330
DA  - Nov
DP  - NLM
ET  - 2001/01/11
IS  - 11
KW  - Adult
*African Americans
Aged
Aged, 80 and over
Breast Neoplasms/*ethnology/psychology
Data Collection/*methods
Female
Humans
Middle Aged
*Patient Selection
Postal Service
Quality of Life
*Reward
Time Factors
United States
LA  - eng
N1  - Ashing-Giwa, K
Ganz, P A
CA63028/CA/NCI NIH HHS/United States
Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, U.S. Gov't, P.H.S.
J Natl Med Assoc. 2000 Nov;92(11):528-32.
PY  - 2000
SN  - 0027-9684 (Print)
0027-9684
SP  - 528-32
ST  - Effect of timed incentives on subject participation in a study of long-term breast cancer survivors: are there ethnic differences?
T2  - J Natl Med Assoc
TI  - Effect of timed incentives on subject participation in a study of long-term breast cancer survivors: are there ethnic differences?
VL  - 92
ID  - 696
ER  - 

TY  - JOUR
AB  - One in eight women will develop breast cancer over their lifetime with 230,000 women diagnosed in 2015. For this reason, breast cancer prevention efforts are essential. Vitamin D, with anticancer properties, may have a role in prevention of some cancers, including breast cancer. This report discusses the rationale, study protocol, and baseline data for a clinical trial of vitamin D and its effects on breast cancer biomarkers. This study was a randomized controlled trial designed to evaluate the effect of a fixed dose of vitamin D on specfic breast cancer biomarkers. Study participants were randomized to take either vitamin D or placebo for a period of 1 year. All participants had mammograms and blood drawn for serum biomarkers. A subset of participants underwent random periareolar fine needle aspiration to draw tissue for biomarkers. From January 2011 to December 2013, 300 premenopausal women, aged 59 or younger, were recruited from 41 institutions across the United States. A total of 102 women underwent random periareolar fine needle aspiration. The last subject completed the trial in January 2015. Baseline vitamin D levels for all participants ranged from 4-72 ng/mL, with 62% of participants being vitamin D deficient at enrollment (≥30 ng/mL or ≥75 nmo-l/L). The mean body mass index was 27.0 kg/m(2) (range 15.1-53.6 kg/m(2)). 14% and 11.7% of participants were Hispanic or African American, respectively. Accrual and enrollment of participants is feasible for this type of multi-center prevention trial, and it can readily be carried out in a cooperative group setting.
AD  - Division of Hematology and Oncology, Department of Medicine, University of Vermont, Burlington VT.
Alliance Statistics and Data Center, Duke University, Durham, NC.
Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN.
State University of New York Upstate Medical University, Syracuse, NY.
Novant Health Forsyth Medical Center, Winston-Salem, NC.
Contra Costa Regional Medical Center, Martinez, CA.
Doctor's Hospital of Laredo, Laredo, TX.
Dana-Farber/Partners CancerCare, Boston, MA.
Roswell Park Cancer Institute, Buffalo, NY.
AN  - 29081880
AU  - Apoe, O.
AU  - Jung, S. H.
AU  - Liu, H.
AU  - Seisler, D. K.
AU  - Charlamb, J.
AU  - Zekan, P.
AU  - Wang, L. X.
AU  - Unzeitig, G. W.
AU  - Garber, J.
AU  - Marshall, J.
AU  - Wood, M.
C2  - PMC5656380
C6  - NIHMS870350
DA  - Jul
DP  - NLM
ET  - 2016/07/01
IS  - 7
KW  - biomarkers
breast cancer
breast cancer prevention
chemoprevention
mammographic density
vitamin D
LA  - eng
N1  - Apoe, Ogheneruona
Jung, Sin-Ho
Liu, Heshan
Seisler, Drew K
Charlamb, Jayne
Zekan, Patricia
Wang, Lili X
Unzeitig, Gary W
Garber, Judy
Marshall, James
Wood, Marie
U10 CA086726/CA/NCI NIH HHS/United States
U10 CA045564/CA/NCI NIH HHS/United States
U10 CA021115/CA/NCI NIH HHS/United States
U10 CA045389/CA/NCI NIH HHS/United States
U10 CA021060/CA/NCI NIH HHS/United States
U10 CA077597/CA/NCI NIH HHS/United States
UG1 CA189858/CA/NCI NIH HHS/United States
U10 CA180857/CA/NCI NIH HHS/United States
U10 CA180850/CA/NCI NIH HHS/United States
U10 CA180798/CA/NCI NIH HHS/United States
UG1 CA189817/CA/NCI NIH HHS/United States
UG1 CA189830/CA/NCI NIH HHS/United States
UG1 CA189823/CA/NCI NIH HHS/United States
U10 CA035113/CA/NCI NIH HHS/United States
U10 CA180790/CA/NCI NIH HHS/United States
U10 CA180820/CA/NCI NIH HHS/United States
U10 CA180870/CA/NCI NIH HHS/United States
U10 CA180867/CA/NCI NIH HHS/United States
U10 CA180838/CA/NCI NIH HHS/United States
U10 CA180888/CA/NCI NIH HHS/United States
R21 CA137650/CA/NCI NIH HHS/United States
U10 CA180866/CA/NCI NIH HHS/United States
Journal Article
Am J Hematol Oncol. 2016 Jul;12(7):4-9.
PY  - 2016
SN  - 1939-6163 (Print)
1939-6163
SP  - 4-9
ST  - Effect of Vitamin D Supplementation on Breast Cancer Biomarkers: CALGB 70806 (Alliance) Study Design and Baseline Data
T2  - Am J Hematol Oncol
TI  - Effect of Vitamin D Supplementation on Breast Cancer Biomarkers: CALGB 70806 (Alliance) Study Design and Baseline Data
VL  - 12
ID  - 210
ER  - 

TY  - JOUR
AB  - PURPOSE: Health research in low- and middle-income countries can generate novel scientific knowledge and improve clinical care, fostering population health improvements to prevent premature death. Project management is a critical part of the success of this research, applying knowledge, skills, tools, and techniques to accomplish required goals. Here, we describe the development and implementation of tools to support a multifaceted study of prostate cancer in Africa, focusing on building strategic and operational capacity. METHODS: Applying a learning organizational framework, we developed and implemented a project management toolkit (PMT) that includes a management process flowchart, a cyclical center-specific schedule of activities, periodic reporting and communication, and center-specific monitoring and evaluation metrics. RESULTS: The PMT was successfully deployed during year one of the project with effective component implementation occurring through periodic cycles of dissemination and feedback to local center project managers. A specific evaluation was conducted 1 year after study initiation to obtain enrollment data, evaluate individual quality control management plans, and undertake risk log assessments and follow-up. Pilot data obtained identified areas in which centers required mentoring, strengthening, and capacity development. Strategies were implemented to improve project goals and operational capacity through local problem solving, conducting quality control checks and following compliancy with study aims. Moving forward, centers will perform quarterly evaluations and initiate strengthening measures as required. CONCLUSION: The PMT has fostered the development of both strategic and operational capacity across project centers. Investment in project management resources is essential to ensuring high-quality, impactful health research in low- and middle-income countries.
AD  - Emeka Odiaka, Ifeoluwa Makinde, Akindele Olupelumi Adebiyi, and Olufemi Popoola, University College Hospital, Ibadan; Olalekan Hafees Ajibola and Oseremen Aisuodionoe-Shadrach, University of Abuja; Oseremen Aisuodionoe-Shadrach, University of Abuja Teaching Hospital, Abuja, Nigeria; David W. Lounsbury and Ilir Agalliu, Albert Einstein College of Medicine, Bronx, NY; Mohamed Jalloh, Thierno Amadou Diallo, Papa Moussa Sene Kane, and Serigne Magueye Gueye, Hôpital Général de Grand Yoff, Institut de Formation et de la Recherche en Urologie et de la Santé de la Familliale, Dakar, Senegal; Ben Adusei and Sunny Mante, 37 Military Hospital, Ghana; Isabella Rockson, Vicky Okyne, Edward Yeboah, and James E. Mensah, Korle-Bu Teaching Hospital, and University of Ghana, Accra, Ghana; Hayley Irusen and Pedro Fernandez, Stellenbosch University and Tygerberg Hospital; Lindsay Petersen, Jo McBride, and Desiree C. Petersen, Centre for Proteomic and Genomic Research, Cape Town; Audrey Pentz, Elvira Singh, and Maureen Joffe, University of the Witwatersrand, Johannesburg, South Africa; Ann Hsing, Stanford University, Stanford, CA; Yuri Quintana, Beth Israel Deaconess Medical Center; Brian Fortier, Timothy R. Rebbeck, and Caroline Andrews, Dana-Farber Cancer Institute; and Timothy R. Rebbeck, Harvard TH Chan School of Public Health, Boston, MA.
AN  - 30260756
AU  - Odiaka, E.
AU  - Lounsbury, D. W.
AU  - Jalloh, M.
AU  - Adusei, B.
AU  - Diallo, T. A.
AU  - Kane, P. M. S.
AU  - Rockson, I.
AU  - Okyne, V.
AU  - Irusen, H.
AU  - Pentz, A.
AU  - Makinde, I.
AU  - Ajibola, O. H.
AU  - Petersen, L.
AU  - McBride, J.
AU  - Petersen, D. C.
AU  - Mante, S.
AU  - Agalliu, I.
AU  - Adebiyi, A. O.
AU  - Popoola, O.
AU  - Yeboah, E.
AU  - Mensah, J. E.
AU  - Hsing, A.
AU  - Fernandez, P.
AU  - Aisuodionoe-Shadrach, O.
AU  - Joffe, M.
AU  - Singh, E.
AU  - Gueye, S. M.
AU  - Quintana, Y.
AU  - Fortier, B.
AU  - Rebbeck, T. R.
AU  - Andrews, C.
C2  - PMC6223501
DA  - Sep
DO  - 10.1200/jgo.18.00062
DP  - NLM
ET  - 2018/09/28
KW  - African Continental Ancestry Group
Carcinoma/*epidemiology/pathology
Developing Countries
Humans
Income
Male
Prostate/pathology
Prostatic Neoplasms/*epidemiology/pathology
South Africa/epidemiology
LA  - eng
N1  - 2378-9506
Odiaka, Emeka
Lounsbury, David W
Jalloh, Mohamed
Adusei, Ben
Diallo, Thierno Amadou
Kane, Papa Moussa Sene
Rockson, Isabella
Okyne, Vicky
Irusen, Hayley
Pentz, Audrey
Makinde, Ifeoluwa
Ajibola, Olalekan Hafees
Petersen, Lindsay
McBride, Jo
Petersen, Desiree C
Mante, Sunny
Agalliu, Ilir
Adebiyi, Akindele Olupelumi
Popoola, Olufemi
Yeboah, Edward
Mensah, James E
Hsing, Ann
Fernandez, Pedro
Aisuodionoe-Shadrach, Oseremen
Joffe, Maureen
Singh, Elvira
Gueye, Serigne Magueye
Quintana, Yuri
Fortier, Brian
Rebbeck, Timothy R
Andrews, Caroline
P30 CA006516/CA/NCI NIH HHS/United States
U01 CA184374/CA/NCI NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
J Glob Oncol. 2018 Sep;4:1-12. doi: 10.1200/JGO.18.00062.
PY  - 2018
SN  - 2378-9506
SP  - 1-12
ST  - Effective Project Management of a Pan-African Cancer Research Network: Men of African Descent and Carcinoma of the Prostate (MADCaP)
T2  - J Glob Oncol
TI  - Effective Project Management of a Pan-African Cancer Research Network: Men of African Descent and Carcinoma of the Prostate (MADCaP)
VL  - 4
ID  - 99
ER  - 

TY  - JOUR
AB  - Background: Community-based participatory research (CBPR) approaches that involve community and academic partners in activities ranging from protocol design through dissemination of study findings can increase recruitment of medically underserved and underrepresented racial/ethnic minority populations into biomedical research. Methods: Five cancer screening and prevention trials in three National Cancer Institute (Bethesda, MD)-funded Community Networks Program Centers (CNPC), in Florida, Kansas, and South Carolina, were conducted across diverse populations. Data were collected on total time period of recruitment, ratios of participants enrolled over potential participants approached, selected CBPR strategies, capacity-building development, and systematic procedures for community stakeholder involvement. Results: Community-engaged approaches used included establishing colearning opportunities, participatory procedures for community-Academic involvement, and community and clinical capacity building. A relatively large proportion of individuals identified for recruitment was actually approached (between 50% and 100%). The proportion of subjects who were eligible among all those approached ranged from 25% to more than 70% (in the community setting). Recruitment rates were very high (78%-100% of eligible individuals approached) and the proportion who refused or who were not interested among those approached was very low (5%-11%). Conclusions: Recruitment strategies used by the CNPCs were associated with low refusal and high enrollment ratios of potential subjects. Adherence to CBPR principles in the spectrum of research activities, from strategic planning to project implementation, has significant potential to increase involvement in biomedical research and improve our ability to make appropriate recommendations for cancer prevention and control programming in underrepresented diverse populations. Impact: CBPR strategies should be more widely implemented to enhance study recruitment. © 2014 American Association for Cancer Research.
AD  - K.A. Greiner, University of Kansas Medical Center, 4125 Rainbow Boulevard, Kansas KS 66160, United States
AU  - Greiner, K. A.
AU  - Friedman, D. B.
AU  - Adams, S. A.
AU  - Gwede, C. K.
AU  - Cupertino, P.
AU  - Engelman, K. K.
AU  - Meade, C. D.
AU  - Hebert, J. R.
DB  - Embase
Medline
DO  - 10.1158/1055-9965.EPI-13-0760
IS  - 3
KW  - African American
article
breast cancer
cancer prevention
cancer screening
community
community care
controlled study
ethnic group
female
follow up
health program
human
major clinical study
male
national health organization
participatory research
pilot study
priority journal
prostate cancer
randomized controlled trial
social network
strategic planning
United States
LA  - English
M3  - Article
N1  - L372645292
2014-03-27
2014-04-02
PY  - 2014
SN  - 1055-9965
SP  - 416-423
ST  - Effective recruitment strategies and community-based participatory research: Community networks program centers' recruitment in cancer prevention studies
T2  - Cancer Epidemiology Biomarkers and Prevention
TI  - Effective recruitment strategies and community-based participatory research: Community networks program centers' recruitment in cancer prevention studies
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L372645292&from=export
http://dx.doi.org/10.1158/1055-9965.EPI-13-0760
VL  - 23
ID  - 1043
ER  - 

TY  - JOUR
AB  - BACKGROUND: Physician recommendation of colorectal cancer (CRC) screening is a critical facilitator of screening completion. Providing patients a choice of screening options may increase CRC screening completion, particularly among racial and ethnic minorities. OBJECTIVE: Our purpose was to assess the effectiveness of physician-only and physician-patient interventions on increasing rates of CRC screening discussions as compared to usual care. DESIGN: This study was quasi-experimental. Clinics were allocated to intervention or usual care; patients in intervention clinics were randomized to receipt of patient intervention. PARTICIPANTS: Patients aged 50 to 75 years, due for CRC screening, receiving care at either a federally qualified health care center or an academic health center participated in the study. INTERVENTION: Intervention physicians received continuous quality improvement and communication skills training. Intervention patients watched an educational video immediately before their appointment. MAIN MEASURES: Rates of patient-reported 1) CRC screening discussions, and 2) discussions of more than one screening test. KEY RESULTS: The physician-patient intervention (n = 167) resulted in higher rates of CRC screening discussions compared to both physician-only intervention (n = 183; 61.1 % vs.50.3 %, p = 0.008) and usual care (n = 153; 61.1 % vs. 34.0 % p = 0.03). More discussions of specific CRC screening tests and discussions of more than one test occurred in the intervention arms than in usual care (44.6 % vs. 22.9 %,p = 0.03) and (5.1 % vs. 2.0 %, p = 0.036), respectively, but discussion of more than one test was uncommon. Across all arms, 143 patients (28.4 %) reported discussion of colonoscopy only; 21 (4.2 %) reported discussion of both colonoscopy and stool tests. CONCLUSIONS: Compared to usual care and a physician-only intervention, a physician-patient intervention increased rates of CRC screening discussions, yet discussions overwhelmingly focused solely on colonoscopy. In underserved patient populations where access to colonoscopy may be limited, interventions encouraging discussions of both stool tests and colonoscopy may be needed.
AD  - Division of General Internal Medicine and Geriatrics, Department of Medicine, Northwestern University Feinberg School of Medicine, 675 N. St. Clair St. Suite 18-200, Chicago, IL, 60611, USA. ndolan@nmff.org.
Division of General Internal Medicine and Geriatrics, Department of Medicine, Northwestern University Feinberg School of Medicine, 675 N. St. Clair St. Suite 18-200, Chicago, IL, 60611, USA.
Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Evanston, IL, USA.
Division of Gastroenterology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Division of General Internal Medicine, Department of Medicine, University of Illinois Hospital & Health Sciences System, Chicago, IL, USA.
Department of Family Medicine and Community Health, University of Minnesota, Minneapolis, MN, USA.
Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
AN  - 25986137
AU  - Dolan, N. C.
AU  - Ramirez-Zohfeld, V.
AU  - Rademaker, A. W.
AU  - Ferreira, M. R.
AU  - Galanter, W. L.
AU  - Radosta, J.
AU  - Eder, M. M.
AU  - Cameron, K. A.
C2  - PMC4636583
DA  - Dec
DO  - 10.1007/s11606-015-3381-8
DP  - NLM
ET  - 2015/05/20
IS  - 12
KW  - African Americans/*psychology/statistics & numerical data
Aged
Colonoscopy/psychology/statistics & numerical data
Colorectal Neoplasms/*diagnosis/*ethnology
Communication
Early Detection of Cancer/methods/*psychology/statistics & numerical data
Female
Follow-Up Studies
Hispanic Americans/*psychology/statistics & numerical data
Humans
Illinois
Male
Middle Aged
Occult Blood
Patient Education as Topic/methods
Patient Selection
*Physician-Patient Relations
colorectal cancer screening
health literacy
physician communication of preventive care
randomized trial
LA  - eng
N1  - 1525-1497
Dolan, Nancy C
Ramirez-Zohfeld, Vanessa
Rademaker, Alfred W
Ferreira, M Rosario
Galanter, William L
Radosta, Jonathan
Eder, Milton Mickey
Cameron, Kenzie A
P30 CA060553/CA/NCI NIH HHS/United States
R01 CA140177/CA/NCI NIH HHS/United States
UL1 TR001422/TR/NCATS NIH HHS/United States
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, N.I.H., Extramural
J Gen Intern Med. 2015 Dec;30(12):1780-7. doi: 10.1007/s11606-015-3381-8. Epub 2015 May 19.
PY  - 2015
SN  - 0884-8734 (Print)
0884-8734
SP  - 1780-7
ST  - The Effectiveness of a Physician-Only and Physician-Patient Intervention on Colorectal Cancer Screening Discussions Between Providers and African American and Latino Patients
T2  - J Gen Intern Med
TI  - The Effectiveness of a Physician-Only and Physician-Patient Intervention on Colorectal Cancer Screening Discussions Between Providers and African American and Latino Patients
VL  - 30
ID  - 240
ER  - 

TY  - JOUR
AB  - BACKGROUND: Colorectal cancer (CRC) screening reduces mortality yet remains underutilized. Low health literacy may contribute to this underutilization by interfering with patients' ability to understand and receive preventive health services. PURPOSE: To determine if a web-based multimedia CRC screening patient decision aid, developed for a mixed-literacy audience, could increase CRC screening. DESIGN: RCT. Patients aged 50-74 years and overdue for CRC screening were randomized to the web-based decision aid or a control program seen immediately before a scheduled primary care appointment. SETTING/PARTICIPANTS: A large community-based, university-affiliated internal medicine practice serving a socioeconomically disadvantaged population. MAIN OUTCOME MEASURES: Patients completed surveys to determine their ability to state a screening test preference and their readiness to receive screening. Charts were abstracted by masked observers to determine if screening tests were ordered and completed. RESULTS: Between November 2007 and September 2008, a total of 264 patients enrolled in the study. Data collection was completed in 2009, and data analysis was completed in 2010. A majority of participants (mean age=57.8 years) were female (67%), African-American (74%), had annual household incomes of <$20,000 (76%), and had limited health literacy (56%). When compared to control participants, more decision-aid participants had a CRC screening preference (84% vs 55%, p<0.0001) and an increase in readiness to receive screening (52% vs 20%, p=0.0001). More decision-aid participants had CRC screening tests ordered (30% vs 21%) and completed (19% vs 14%), but no statistically significant differences were seen (AOR=1.6, 95% CI=0.97, 2.8, and AOR=1.7, 95% CI=0.88, 3.2, respectively). Similar results were found across literacy levels. CONCLUSIONS: The web-based decision aid increased patients' ability to form a test preference and their intent to receive screening, regardless of literacy level. Further study should examine ways the decision aid can be combined with additional system changes to increase CRC screening.
AD  - General Internal Medicine, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157, USA. dmiller@wakehealth.edu
AN  - 21565651
AU  - Miller, D. P., Jr.
AU  - Spangler, J. G.
AU  - Case, L. D.
AU  - Goff, D. C., Jr.
AU  - Singh, S.
AU  - Pignone, M. P.
C2  - PMC3480321
C6  - NIHMS310119
DA  - Jun
DO  - 10.1016/j.amepre.2011.02.019
DP  - NLM
ET  - 2011/05/14
IS  - 6
KW  - Aged
Colorectal Neoplasms/*diagnosis
*Decision Support Techniques
Female
Health Literacy
Humans
*Internet
Male
Mass Screening/*methods
Middle Aged
Patient Preference
Primary Health Care/methods
Socioeconomic Factors
LA  - eng
N1  - 1873-2607
Miller, David P Jr
Spangler, John G
Case, L Doug
Goff, David C Jr
Singh, Sonal
Pignone, Michael P
K05 CA129166/CA/NCI NIH HHS/United States
K05 CA129166-04/CA/NCI NIH HHS/United States
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Am J Prev Med. 2011 Jun;40(6):608-15. doi: 10.1016/j.amepre.2011.02.019.
PY  - 2011
SN  - 0749-3797 (Print)
0749-3797
SP  - 608-15
ST  - Effectiveness of a web-based colorectal cancer screening patient decision aid: a randomized controlled trial in a mixed-literacy population
T2  - Am J Prev Med
TI  - Effectiveness of a web-based colorectal cancer screening patient decision aid: a randomized controlled trial in a mixed-literacy population
VL  - 40
ID  - 394
ER  - 

TY  - JOUR
AB  - Objectives: Evaluate an advance notice letter for enhancing patient satisfaction survey response rates in African Americans and Whites. Methods: Randomized trial of an advance notice letter (versus no letter) mailed two weeks prior to a mail satisfaction survey in a random sample of 600 African American and White patients ages 50 and older, stratified by ethnicity, sex, and age. Results: The advance letter was independently associated with a completed survey in Whites (odds ratio = 2.73; 95% confidence interval [CI] 1.66, 4.50), but not in African Americans (odds ratio = 1.24; 95% CI 0.76, 2.02). Being male was independently associated with returning a survey in Whites (odds ratio = 1.86; 95% CI 1.13, 3.06). Younger age (odds ratio = 0.98; 95% CI 0.96, 0.99) was independently associated with a completed survey in African Americans. Discussion: An advance letter prior to a satisfaction survey is associated with increased response rates in Whites, but not in African Americans.
AN  - WOS:000224424800008
AU  - Napoles-Springer, A. M.
AU  - Fongwa, M. N.
AU  - Stewart, A. L.
AU  - Gildengorin, G.
AU  - Perez-Stable, E. J.
DA  - Nov
DO  - 10.1177/0898264304269724
IS  - 5
N1  - S
15
15448290
PY  - 2004
SN  - 0898-2643
SP  - 124S-136S
ST  - The effectiveness of an advance notice letter on the recruitment of African Americans and whites for a mailed patient satisfaction survey
T2  - Journal of Aging and Health
TI  - The effectiveness of an advance notice letter on the recruitment of African Americans and whites for a mailed patient satisfaction survey
VL  - 16
ID  - 2674
ER  - 

TY  - JOUR
AB  - OBJECTIVE: The purpose of this study was to report the results of a meta-analysis conducted on the effects of clinical trials in breast cancer screening for African American women between 1997 and 2017. DATA SOURCES: Articles published in English and in the United States, between January 1997 and March 2017, were eligible for inclusion if they (1) conducted psychosocial, behavioral, or educational interventions designed to increase screening mammography rates in predominantly African American women of all ages; (2) utilized a randomized, controlled trial (RCT) design; and (3) reported quantitative screening rates following the intervention. STUDY DESIGN: Randomized clinical trials on breast cancer screening in African American women, published between January 1997 and March 2017, were selected from database searches. DATA COLLECTION METHODS: Data collected included effect size of screening versus comparison interventions, intervention characteristics, and a number of study characteristics to explore potential moderators. Search results yielded 327 articles, of which 14 met inclusion criteria and were included in analyses. PRINCIPAL FINDINGS: Findings indicated that screening interventions for African American women were significantly more likely to result in mammography than control (OR = 1.56 [95 percent CI = 1.27-1.93], p < .0001). Although no patient or study characteristics significantly moderated screening efficacy, the most effective interventions were those specifically tailored to meet the perceived risk of African American women. CONCLUSIONS: Screening interventions are at least minimally effective for promoting mammography among African American women, but research in this area is limited to a small number of studies. More research is needed to enhance the efficacy of existing interventions and reduce the high morbidity and mortality rate of this underserved population.
AD  - School of Social Work, University of Pittsburgh, Pittsburgh, PA.
Center on Race and Social Problems, University of Pittsburgh, Pittsburgh, PA.
Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA.
AN  - 29159815
AU  - Copeland, V. C.
AU  - Kim, Y. J.
AU  - Eack, S. M.
C2  - PMC6056582
DA  - Aug
DO  - 10.1111/1475-6773.12806
DP  - NLM
ET  - 2017/11/22
IS  - Suppl Suppl 1
KW  - African Americans/*psychology/*statistics & numerical data
Breast Neoplasms/diagnosis/*ethnology
Cultural Competency
Early Detection of Cancer/methods/*statistics & numerical data
Female
Health Knowledge, Attitudes, Practice
Health Promotion/methods
Health Services Research/organization & administration/statistics & numerical data
Humans
Mammography/statistics & numerical data
Program Evaluation
Randomized Controlled Trials as Topic
United States
*African Americans
*Health disparities
*breast cancer
*meta-analysis
*screening
*women
LA  - eng
N1  - 1475-6773
Copeland, Valire Carr
Orcid: 0000-0002-6925-6800
Kim, Yoo Jung
Eack, Shaun M
Orcid: 0000-0001-6368-7004
Journal Article
Meta-Analysis
Research Support, Non-U.S. Gov't
Health Serv Res. 2018 Aug;53 Suppl 1(Suppl Suppl 1):3170-3188. doi: 10.1111/1475-6773.12806. Epub 2017 Nov 21.
PY  - 2018
SN  - 0017-9124 (Print)
0017-9124
SP  - 3170-3188
ST  - Effectiveness of Interventions for Breast Cancer Screening in African American Women: A Meta-Analysis
T2  - Health Serv Res
TI  - Effectiveness of Interventions for Breast Cancer Screening in African American Women: A Meta-Analysis
VL  - 53 Suppl 1
ID  - 147
ER  - 

TY  - JOUR
AB  - BACKGROUND: Prostate cancer incidence and mortality in the United States in African Americans (AA) are higher than in Caucasians. Eastern Cuyahoga County in Ohio is majority AA and is considered an underserved population particularly vulnerable to healthcare disparities. There is a paucity of data about shared decision making among high-risk AA men with regard to prostate cancer screening. This study aims to examine shared versus informed decision making (SDM versus IDM) in a randomized, control trial among a large, high-risk AA population. METHODS: Patients were included in annual one-day outreach events, each held over 3 years (2017-2019), and were randomized at each event into IDM (control) and SDM (investigational) groups and then were offered screening via prostate specific antigen (PSA) and digital rectal exam (DRE). The primary endpoints were proportion of participants over 40 who did not demonstrate decisional conflict about prostate cancer screening measured by the SURE score, as well as change of knowledge score about prostate cancer screening. RESULTS: Overall, 175 patients were enrolled in the trial; 79 in the SDM arm and 96 in the IDM arm. The investigational (SDM) arm had 3/79 (3.9%) conflict versus 6/96 (6.4%) in the control (IDM) arm (p = 0.74). With regard to knowledge improvement, the SDM cohort demonstrated improvement following educational tools for 66/79 (81%) of participants versus 76/96 (79%) in the IDM cohort (p = 0.85). There was no difference in the proportion (63%) of participants in either group who found the information very helpful (using a Likert scale). CONCLUSIONS: Our education-based study showed no significant difference between SDM and IDM with regard to decisional conflict about prostate cancer screening. The study also demonstrated significant improvement in knowledge about prostate cancer screening in a high-risk AA population in both groups. Our results should be interpreted with caution due to several limitations; however, the study can serve as a benchmark for future studies in this very important topic.
AD  - Department of Hematology and Medical Oncology, Geisinger Cancer Institute, Geisinger Medical Center, Danville, PA, USA.
Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA, USA.
Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
Department of Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
Texas Oncology, Oklahoma, TX, USA.
Department of Hematology and Medical Oncology, South Pointe Hospital, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
AN  - 33410359
AU  - Carlson, D. S.
AU  - Grivas, P.
AU  - Wei, W.
AU  - Dhillon, P. K.
AU  - Abraksia, S.
DA  - Feb
DO  - 10.1080/07357907.2020.1855441
DP  - NLM
ET  - 2021/01/08
IS  - 2
KW  - African Americans/*statistics & numerical data
Decision Making
Decision Making, Shared
Digital Rectal Examination/*methods
Early Detection of Cancer
Feasibility Studies
Humans
Kallikreins/*metabolism
Male
Patient Education as Topic
Prostate-Specific Antigen/*metabolism
Prostatic Neoplasms/*diagnosis/ethnology/metabolism
Sensitivity and Specificity
United States/ethnology
African American
Prostate cancer screening
education
high-risk population
randomized controlled trial
shared decision making informed decision making
LA  - eng
N1  - 1532-4192
Carlson, Daniel S
Grivas, Petros
Orcid: 0000-0003-3965-3394
Wei, Wei
Dhillon, Puneet K
Abraksia, Samir
Journal Article
Randomized Controlled Trial
England
Cancer Invest. 2021 Feb;39(2):124-132. doi: 10.1080/07357907.2020.1855441. Epub 2021 Jan 7.
PY  - 2021
SN  - 0735-7907
SP  - 124-132
ST  - The Effectiveness of Shared Compared to Informed Decision Making for Prostate Cancer Screening in a High-Risk African American Population: A Randomized Control Trial
T2  - Cancer Invest
TI  - The Effectiveness of Shared Compared to Informed Decision Making for Prostate Cancer Screening in a High-Risk African American Population: A Randomized Control Trial
VL  - 39
ID  - 18
ER  - 

TY  - JOUR
AB  - PURPOSE/HYPOTHESIS: Chemotherapy‐induced peripheral neuropathy (CIPN) causes significant pain and is an adverse effect of cancer treatment. Yoga is a popular movement therapy used by cancer survivors, with prior studies representing Caucasian, suburban, femalemiddle‐aged breast cancer survivors.1‐5 Minorities and other populations are definitively underrepresented in the existing research on yoga for cancer survivors, with notable barriers.6‐8 This study explored a somatic yoga and meditation (SYM) intervention on functional outcomes and quality of life (QOL) in a predominantly minority population with CIPN in an urban setting. The goals of this single‐arm feasibility study are to describe recruitment strategies, test feasibility, and determine preliminary effectiveness of an 8‐week protocol for CIPN. NUMBER OF SUBJECTS: Eight individuals diagnosed with CIPN self‐reported as 63% African American and 37% Caucasian. Mean age was 65.0 years (49‐73) with 81% attendance and no adverse events. MATERIALS AND METHODS: SYM was provided once a week for 8 weeks × 1.5 hours, with home program, journaling, and group debriefing at mid‐and end‐study. Primary outcomes: Sit and Reach (SR), Functional Reach (FR), and Timed Up and Go (TUG). Self‐reported secondary outcomes: Patient Neurotoxicity Questionnaire (PNQ), FACT‐GOG‐Ntx, Brief Pain Inventory (BPI), Perceived Stress Scale (PSS), Pittsburgh Sleep Quality Index (PSQI), and Falls Efficacy Scale (FES). Vibration sensation measured via biothesiometer. Results: Quantitative Findings: Improvement trended in flexibility (SR) (mean reduction 3.20, SD 5.33, p=0.133) and balance (FR) (mean reduction 1.45, SD 7.41, p=0.597). TUG showed reduced fall risk (mean reduction 1.16, SD 1.84, p=0.119). CIPN symptoms (FACT‐GOG‐Ntx) improved significantly (88.88 to 106.88, SD 20.03, p=.039), with improvement in sensory symptoms and muscular weakness (PNQ) (3.56 to 3.31, p=.316). Decreased fear of falling (FES) approached significance (39.26 to 34.38, SD 6.081 p=.058). Stress (PSS) reduced (15.75 to 15.00 p=0.608), with sleep quality (PSQI) improved (9.75 to 9.38 p=0.644). Spirituality (FACIT‐SP) improved (101.75 to 115.63 p=.496). Participants experienced slight increase in BPI pain severity (3.50 to 3.75, p=0.041) which may reflect musculoskeletal co‐morbidities. QUALITATIVE FINDINGS: Four themes emerged: 1) Variation of CIPN symptoms, with musculoskeletal pain, 2) Utility of learned skills, 3) Improvement in self‐confidence, balance, and stability, 4) Social support, with CIPN experience validation and increased health literacy. CONCLUSIONS: Recruitment challenges require specific outreach, community level trust, and health literacy assistance. Preliminary data suggests SYMforCIPNmay reduce fear of falling and CIPN symptoms, and improve QOL. CLINICAL RELEVANCE: Rehab professionals may choose components of yoga (e.g. balance poses, breath work) for intervention, including referral to gentle community yoga programs. An inclusive randomized controlled trial, utilizing methods of representative recruitment, is needed to establish efficacy of SYM for CIPN for cancer survivors.
AN  - CN-02086311
AU  - Galantino, M. L.
AU  - Brooks, J.
AU  - Tiger, R.
AU  - Jang, S.
AU  - Wilson, K. A.
DO  - 10.1097/01.REO.0000000000000202
IS  - 1
KW  - *chemotherapy‐induced peripheral neuropathy
*pilot study
*yoga
African American
Aged
Biothesiometer
Breast cancer
Breathing
Brief Pain Inventory
Cancer patient
Cancer survival
Cancer survivor
Case report
Caucasian
Clinical article
Comorbidity
Conference abstract
Fall risk
Falls Efficacy Scale
Fear of falling
Feasibility study
Female
Health literacy
Human
Movement therapy
Muscle weakness
Musculoskeletal pain
Neurotoxicity
Pain severity
Patient referral
Perceived Stress Scale
Pittsburgh Sleep Quality Index
Preliminary data
Quality of life
Quantitative analysis
Questionnaire
Randomized controlled trial
Religion
Sensation
Skill
Sleep quality
Social support
Stress
Timed up and go test
Trust
Vibration
M3  - Journal: Conference Abstract
PY  - 2020
SP  - E15‐E16
ST  - Effectiveness of yoga and meditation for chemotherapy-induced peripheral neuropathy: a pilot study featuring minority recruitment
T2  - Rehabilitation oncology
TI  - Effectiveness of yoga and meditation for chemotherapy-induced peripheral neuropathy: a pilot study featuring minority recruitment
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02086311/full
VL  - 38
ID  - 1588
ER  - 

TY  - JOUR
AB  - INTERVENTION: 1. Group 1 (n = 30) will be given a placebo and serve as the control group 2. Group 2 (n = 30) will be given 500 mg of Nigella sativa 3. Group 3 (n = 30) will be given 1 g Nigella sativa 4. Group 4 (n = 30) will be given 2 g Nigella sativa Nigella sativa will be given in the form of 500 mg powder capsules (Bio Extracts, Sri Lanka). A single capsule in the morning for group 2 and in divided doses (morning and evening) for groups 3 and 4. The control group will be given capsules similar to those given to the test group but filled with a placebo. The patients will be assigned to the control and test groups' randomly, by using table of random numbers. The ongoing conventional treatment of the patients will not be interrupted or modified. The study subjects will be evaluated four times during the course of the study; at the time of recruitment (baseline) and monthly thereafter for 3 months. CONDITION: Asthma (partly controlled) ; Respiratory ; Asthma PRIMARY OUTCOME: The following assessments will be made during all the four visits to determine the effect of treatment with Nigella: ; 1. Anthropometric measurements including weight (measured using a digital Holtain electronic scale [150 ± 0.1 kg]) and height (measured with a Holtain stadiometer to the nearest millimetre). These measurements will be used for interpretation of lung function tests.; 2. Clinical assessment, performed by pulmonologists in the research team at King Fahad Hospital of the University in Al‐Khobar. It will be carried out according to the criteria adopted by the Global Initiative for Asthma (GINA 2008) to determine level of control of the patients. The asthma control test questionnaire will be filled for every patient. The type of medication used will also be recorded and any modifications needed will be noted and recorded. ; 3. Lung function tests: Peak expiratory flow (PEF), Forced Expiratory Volume in First second (FEV1) and forced vital capacity (FVC) will be measured during each visit for the sake of evaluating control. FEV1 and FVC will be measured using Vitalograph Pneumotrac® model 6800. Wright peak flow meter will be used for measurement of PEF. In addition, another independent indicator of asthma control; variability in airflow limitation will be evaluated. For this sake a hand held portable Peak Expiratory Flow meter will be given to every patient in the study. The patients will be asked to measure their PEF twice every day. This will be preceded by careful explanation of the procedure to the patients. These measurements will be performed during the week preceding the start of the trial to establish baseline data and will be repeated during the week preceding every visit. The patients will be reminded in due time. PEF is measured first thing in the morning before treatment is taken, when values are often close to their lowest and last thing at night. PEF variability will be evaluated by obtaining the difference between the maximum and minimum over the week and dividing this by the mean value over that week. FEV1, forced expiratory volume during the mid‐part of vital capacity (FEF25‐75%) and FVC will be measured on the day of each of the four visits.; 4. Exhaled Nitric Oxide (FeNO) levels will be measured at all the visits by using Niox Mino® (Aerocrine AB, Sweden). The results will be managed by software Niox Mino Data Manager®.; 5. Immune cells and inflammatory mediators: Total and differential count of the white blood cells will be done for all patients in all the four visits including the recruitment visit. Th1 and Th2 counts will also be performed. In addition eosinophil count will be done in a sample of induced sputum. Interleukins 4, 5, 8, 10, 13 and Tumour Necrosis Factor (TNF) will be measured in blood and sputum. Leukotrienes, LTB4, LTC4, LTD4 and LTE4 will also be measured in blood as well as in the induced sputum. T helper‐1 (Th1) and T helper‐2 (Th2) will be evaluated by flow cytometry. The leukotrienes and interleukins and other cytokines will be done by Enzyme Linked Immunosorbent Assay (ELISA) ith Quantikines kits purchased from RD systems using the original method described by Yalo and Berson. Sputum induction will be performed using a method previously described. In brief, the procedure will be started 10 minutes after the administration of 400 µg of inhaled salbutamol. Hypertonic saline (3%) will be inhaled using a nebuliser for 15 minute or until enough sputum is obtained for analysis. The procedure will be terminated if there is a decrease in FEV1 20% in relation to the baseline value occurs. Saline nebulisation will be performed using a Fisoneb ultrasonic nebulizer (Fisons, Pickering, Ontario, Canada), with an output rate of 0.87 mL/min and particles presenting a median aerodynamic mass diameter of 5.58 µm. During the inhalation period, FEV1 will be measured every three minutes to ensure the safety of the test. Sputum samples will be processed and analysed within two hours. An induced sputum sample appropriate for analysis will be defined as that containing expectorated material with cellular viability greater than 50% and contamination by oropharyngeal squamous cells lower than 20%, as well as being of a quantity sufficient for differential counts of 400 cells. The standard protocol presented by Lacy and colleagues will be used (Lacy et al 2005). In the induced sputum specimen collected the following will be measured:; 5.1. Total and differential white cell count; 5.2. IgE; 5.3. Interleukins 4, 5, 8, 10, 13 and TNF‐alpha; 5.4. Leukotriens LTB4, LTC4, LTD4 and LTE4; 5.5. Eosinophil cationic protein; 5.6. Eotaxin; ; All related information and results for each patient will be recorded in a separate proforma for regular follow up and quick reference. SECONDARY OUTCOME: No secondary outcome measures INCLUSION CRITERIA: 1. Established diagnosis of partly controlled asthma 2. Aged 18 ‐ 60 years old, either sex 3. Willingness to participate in the study
AN  - CN-01857373
AU  - Isrctn
PY  - 2009
ST  - Effects of ?Black Seed? supplementation on management outcome of partially controlled asthma
T2  - http://www.who.int/trialsearch/Trial2.aspx?TrialID=ISRCTN48853858
TI  - Effects of ?Black Seed? supplementation on management outcome of partially controlled asthma
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01857373/full
ID  - 1526
ER  - 

TY  - JOUR
AB  - Objectives Despite the Advisory Committee on Immunization Practices (ACIP) recommendations for young adult females and males to receive the three-dose human papillomavirus (HPV) vaccine, most recent findings show that only 30% of the U.S. females aged 19-26, 2.8% of males aged 19-21, and only 1.7% of males aged 22-26 are initiating vaccination. This study evaluates the effects of a brief (5-10 min) group HPV educational intervention on knowledge and intent to vaccinate among young adults. Methods A sample of 131 18-26 year old females and males was recruited from the 2012 INShape Black and Minority Health Fair in Indiana. We randomized participants into one of two groups: (1) survey completion prior to education (control group) or (2) survey completion following education (intervention group). Written surveys assessed HPV knowledge, vaccination history, and vaccination intent (for unvaccinated participants). Results Respondents were primarily female (70%), single (85%), and the majority self-identified as non-Hispanic Black (77%). Thirty-seven percent had initiated HPV vaccination (≥ 1 dose) and 19% had completed the series. The intervention group had higher HPV knowledge scores (M = 9.1; SD = 1.8) than the control group (M = 7.0; SD = 2.9; F = 22.53). Among unvaccinated individuals (n = 79), the intervention group had higher HPV vaccination intent (86%) compared to the control group (67%) (OR = 3.09; 95%CI = 1.02-9.36). Conclusions Despite ACIP recommendations, young adults continue to have low awareness of vaccine benefits and low vaccination rates. This study suggests that educational interventions to increase HPV awareness and vaccination may help to boost vaccination rates. © 2013 Published by Elsevier Inc.
AD  - L.M. Kester, Department of Pediatrics, Indiana University, 410 W. 10th Street, Indianapolis, IN 46202, United States
AU  - Kester, L. M.
AU  - Shedd-Steele, R. B.
AU  - Dotson-Roberts, C. A.
AU  - Smith, J.
AU  - Zimet, G. D.
DB  - Embase
Medline
DO  - 10.1016/j.ygyno.2013.12.033
IS  - SUPPL1
KW  - Wart virus vaccine
adult
anus cancer
article
awareness
condyloma acuminatum
controlled study
female
Hispanic
human
major clinical study
male
Black person
patient attitude
patient education
priority journal
randomized controlled trial
uterine cervix cancer
vaccination
young adult
LA  - English
M3  - Article
N1  - L52951645
2014-01-15
2014-04-02
PY  - 2014
SN  - 1095-6859
0090-8258
SP  - S9-S12
ST  - The effects of a brief educational intervention on human papillomavirus knowledge and intention to initiate HPV vaccination in 18-26 year old young adults
T2  - Gynecologic Oncology
TI  - The effects of a brief educational intervention on human papillomavirus knowledge and intention to initiate HPV vaccination in 18-26 year old young adults
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L52951645&from=export
http://dx.doi.org/10.1016/j.ygyno.2013.12.033
VL  - 132
ID  - 1055
ER  - 

TY  - JOUR
AB  - Number: 1038 Background: Hispanic and black women with breast cancer have poorer survival and are more likely to be obese and sedentary than non‐Hispanic whites. Regular physical activity, high intake of fruits and vegetables, and lean body mass may improve survival. We report the initial results of a randomized wait‐list controlled pilot study to test the effects of 6 months of the community‐based Curves© exercise and nutrition program on weight loss among minority BC survivors.Methods: Hispanic/black women with stage 0‐IIIa breast cancer who were 6 months post‐treatment, sedentary and had a BMI25kg/m2 were enrolled. Eligible participants were randomized to the Immediate Arm (IA): 6 months of the Curves© exercise and dietary change weight loss program, followed by 6 months of observation; or the Delayed Arm (DA): 6 months of a waitlist control period, followed by 6 months of the Curves© program. The intervention entailed recommending exercise 5 times/wk using the 30‐minute Curves© circuit‐based exercise program and attending a series of 6 weekly nutrition sessions that promoted a high‐vegetable/low‐fat diet. All study materials were available in Spanish and English. Participants underwent clinic visits at baseline, 3, 6, 9, and 12 months and were followed with monthly telephone calls during the intervention. Month 6 results are reported here.Results: Forty‐two women enrolled in the study (IA, n=22; DA, n=20). Baseline characteristics: mean (ñSD) age, 50.7 (ñ8.9) years; 78.6% Hispanic/21.4% black; breast cancer stage, stage 0 9.5%, stage I 42.9%, stage II 33.3%, stage III 14.2%; mean body mass index (BMI), 33.2 (ñ5.9) kg/m2; mean % body fat as measured by DEXA, 41.6 (ñ4.9) %; and mean VO2 max, 18.4 (ñ3.6). Six month data were collected from 39 women; 2 women were removed from the study due to medical conditions (1 recurrent disease, 1 previously undiagnosed cardiac condition) and 1 women dropped from the study due to being too busy. In the IA, the average number of exercise sessions attended over the 6 month period was 1.1(ñ0.8) per week (range: 0.04 to 2.9/wk), and all participants attended all 6 nutrition classes either in‐person or via phone make‐up sessions. After 6 months, women in the IA lost an average of 2.7 (ñ3.2) kg (range: loss of 9.9 kg to gain of 1.7 kg), had a decrease in percent body fat of 1.5 (ñ1.5)% (range: loss of 5.9% to gain of 0.2%), and a decrease in VO2max of 1.0 (ñ3.4) ml/kg/min (range: decrease of 8.6 ml/kg/min to increase of 2.5 ml/kg/min) (within‐subject measures p<0.05 for change in weight and percent body fat; all between‐arm measures p>0.05). Twelve month data collection will be completed in July 2009 and will be presented at the conference.Conclusions: This 6 month pilot physical activity and dietary change intervention resulted in decreased in body weight and percent body fat among Hispanic and black BC survivors, although this decline was not significantly different than the wait‐list control group. Though adherence to the exercise intervention was less than the targeted 5 exercise sessions per week, those that did adhere lost up to 9.9 kg. Further research on barriers to participation, optimal dose, and duration are necessary for future intervention trials.
AN  - CN-00990645
AU  - Greenlee, H.
AU  - Greenlee, H.
AU  - Greenlee, H.
AU  - Crew, K.
AU  - Crew, K.
AU  - Crew, K.
DO  - 10.1158/0008-5472.SABCS-09-1038
IS  - 24 Supplement
PY  - 2010
ST  - Effects of a Combined Physical Activity and Dietary Change Intervention on Weight Loss in Minority Breast Cancer Survivors
TI  - Effects of a Combined Physical Activity and Dietary Change Intervention on Weight Loss in Minority Breast Cancer Survivors
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00990645/full
VL  - 69
ID  - 1627
ER  - 

TY  - JOUR
AB  - Despite conflicting guidelines, a significant subset of high-risk men decide to undergo routine prostate cancer screening. Yet, there is a scarcity of available programs, and no studies evaluating interventions to support men in dealing with the psychosocial impact of screening. In this study, one of the first to explore the responses of high-risk men enrolling in a Prostate Cancer Risk Assessment Program (N = 128), patients underwent a prostate cancer risk counseling visit immediately followed by either a cognitive-affective preparation session designed to help them process the information they received or a general health education session. All men in this self-selected sample chose to participate in prostate cancer screening. Men were assessed 3 weeks and 6 months post-counseling. The impact of the enhanced counseling condition on knowledge, perceived risk, expectancies, and intrusive ideation was a function of racial and coping style group. Implications for tailored interventions to maximize preparedness for risk and screening counseling are discussed.
AN  - WOS:000453104800004
AU  - Roussi, P.
AU  - Miller, S. M.
AU  - Giri, V. N.
AU  - Obeid, E.
AU  - Wen, K. Y.
AU  - Tagai, E. K.
AU  - Scarpato, J.
AU  - Gross, L.
AU  - Roy, G.
DA  - Dec
DO  - 10.1177/1359105316671188
IS  - 14
N1  - 28810355
PY  - 2018
SN  - 1359-1053
SP  - 1800-1809
ST  - Effects of a randomized trial comparing standard and enhanced counseling for men at high risk of prostate cancer as a function of race and monitoring style
T2  - Journal of Health Psychology
TI  - Effects of a randomized trial comparing standard and enhanced counseling for men at high risk of prostate cancer as a function of race and monitoring style
VL  - 23
ID  - 2835
ER  - 

TY  - JOUR
AB  - Purpose: The purpose of this cohort study was to investigate the association of adjuvant chemotherapy with quality of life (QoL), survival, and recurrence over the 24 months following diagnosis in stage II colon cancer patients. Methods: Overall, 453 patients were recruited from North Carolina from 2009 to 2011 and interviewed with a closed-ended survey detailing quality of life, health behaviors, treatment, and cancer recurrence at three times points: diagnosis, 12-, and 24-months post-diagnosis; mortality was obtained via the National Death Index. Results: In sum, 265 patients received chemotherapy. Receipt of chemotherapy exhibited an inverse association with total Functional Assessment of Cancer Treatment (FACT)-General (P < 0.01), FACT-Colorectal (P < 0.01), physical (P < 0.01), emotional (P = 0.02), and functional (P < 0.01) well-being; the inverse association between receiving chemotherapy and emotional well-being persisted for Caucasians but not African Americans (Pinteraction = 0.049). Those who received chemotherapy demonstrated significantly higher odds of cancer recurrence (odds ratio (OR) 2.74; 95 % confidence interval (CI) 1.18, 6.35) and all-cause mortality (OR: 1.95; 95 % CI: 1.05, 3.62). Conclusions: In this study, stage II colon cancer patients who received chemotherapy treatment were more likely to have poor QoL, recurrence, and all-cause mortality after 24 months compared to those who did not receive chemotherapy. Future research focusing on subtypes of chemotherapy treatment, as well as a longer follow-up period, is needed.
AD  - K. He, Department of Epidemiology and Biostatistics, School of Public Health, Indiana University, 1025 E. Seventh Street, SPH C032, Bloomington, IN, United States
AU  - Lewis, C.
AU  - Xun, P.
AU  - He, K.
DB  - Embase
Medline
DO  - 10.1007/s00520-015-2931-2
IS  - 4
KW  - adjuvant chemotherapy
adult
African American
aged
article
cancer mortality
cancer patient
cancer prognosis
cancer recurrence
cancer survival
Caucasian
clinical assessment tool
cohort analysis
colon cancer
Colorectal Cancer Subscale
confidence interval
controlled study
correlation analysis
emotion
female
follow up
Functional Assessment of Cancer Therapy Colorectal
Functional Assessment of Cancer Therapy General
functional status
health behavior
human
major clinical study
male
Mental Component Score
Physical Component Score
Physical Social Emotional and Functional Wellbeing scale
priority journal
prospective study
quality of life
Short Form 12
treatment outcome
Trial Outcome Index Physical Functional Colorectal score
United States
LA  - English
M3  - Article
N1  - L606001296
2015-09-18
2016-03-14
PY  - 2016
SN  - 1433-7339
0941-4355
SP  - 1463-1471
ST  - Effects of adjuvant chemotherapy on recurrence, survival, and quality of life in stage II colon cancer patients: a 24-month follow-up
T2  - Supportive Care in Cancer
TI  - Effects of adjuvant chemotherapy on recurrence, survival, and quality of life in stage II colon cancer patients: a 24-month follow-up
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L606001296&from=export
http://dx.doi.org/10.1007/s00520-015-2931-2
VL  - 24
ID  - 975
ER  - 

TY  - JOUR
AB  - BACKGROUND: The purpose of this study was to examine the effects of baseline comorbidities on screening adherence in a sample of older African American men (ages >or=55 years) enrolled in a case management intervention in a cancer screening trial. METHODS: Baseline comorbidity data were obtained from 683 African American men who were randomly assigned to a case management intervention group (n = 344) or to a case management control group (n = 339). The effects of comorbidities on the screening adherence rates of each group were then assessed. RESULTS: No statistically significant interactions were found between each health history characteristic and the intervention. Therefore, analyses were not stratified by intervention status. In general, participants with comorbidities were no less likely to adhere to trial screening than participants without comorbidities. Exceptions were current smokers and participants with chronic bronchitis. Current smokers were less likely than others to adhere to the prostate-specific antigen test (P = 0.02) and the digital rectal examination for prostate cancer screening (P = 0.01), to the chest X-ray for lung cancer screening (P < 0.01), and to the flexible sigmoidoscopy for colorectal cancer screening (P = 0.04). Participants with chronic bronchitis had lower rates of adherence to the chest X-ray (P = 0.06). Having a relative with cancer positively influenced adherence to the digital rectal examination (P = 0.05). CONCLUSIONS: Overall, older African American men with comorbidities appear to be very good candidates for participation in longitudinal cancer screening trials. However, smoking had a statistically significant and deleterious effect on adherence to all types of screening.
AD  - Department of Biostatistics, Bioinformatics, and Epidemiology, Medical University of South Carolina, PO Box 250955, Charleston, SC 29425, USA. fordmar@musc.edu
AN  - 18463399
AU  - Ford, M. E.
AU  - Havstad, S. L.
AU  - Fields, M. E.
AU  - Manigo, B.
AU  - McClary, B.
AU  - Lamerato, L.
C2  - PMC3424636
C6  - NIHMS394238 were disclosed.
DA  - May
DO  - 10.1158/1055-9965.Epi-08-0118
DP  - NLM
ET  - 2008/05/09
IS  - 5
KW  - African Americans/*statistics & numerical data
Colorectal Neoplasms/*prevention & control
Comorbidity
Humans
Lung Neoplasms/*prevention & control
Male
*Mass Screening
Middle Aged
*Patient Compliance
Prostatic Neoplasms/*prevention & control
Risk Factors
LA  - eng
N1  - 1538-7755
Ford, Marvella E
Havstad, Suzanne L
Fields, Maya E
Manigo, Brandy
McClary, Beth
Lamerato, Lois
N01-CN-25512/CN/NCI NIH HHS/United States
N01 CN25512/CA/NCI NIH HHS/United States
1 P30 AG 21677/AG/NIA NIH HHS/United States
R24 MD001116/MD/NIMHD NIH HHS/United States
R24 MD-04-002/MD/NIMHD NIH HHS/United States
P30 AG021677/AG/NIA NIH HHS/United States
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.
Cancer Epidemiol Biomarkers Prev. 2008 May;17(5):1234-9. doi: 10.1158/1055-9965.EPI-08-0118. Epub 2008 May 7.
PY  - 2008
SN  - 1055-9965 (Print)
1055-9965
SP  - 1234-9
ST  - Effects of baseline comorbidities on cancer screening trial adherence among older African American men
T2  - Cancer Epidemiol Biomarkers Prev
TI  - Effects of baseline comorbidities on cancer screening trial adherence among older African American men
VL  - 17
ID  - 496
ER  - 

TY  - THES
AB  - The Breast and Cervical Cancer Prevention and Treatment Act (BCCPTA) of 2000 allowed states to extend Medicaid coverage to uninsured women under 65, diagnosed with breast and cervical cancers (including pre-cervical condition) through the National Breast and Cervical Cancer Early Detection Program providers, or in Georgia any provider, and found in need of cancer treatment. The first article examined whether BCCPTA helped uninsured breast cancer patients enroll in Medicaid more quickly to start treatment at early stage. I conducted a quasi-experimental study that compared the stage of cancer of the women aged 19-64 diagnosed with breast cancer who were eligible for BCCPTA with those in the same age spectrum diagnosed with one of five other cancers when they enrolled in Medicaid. There were 8.0 more breast cancer patients enrolling in Medicaid at early stage than control cancer patients per month. The marginal effect of BCCPTA increased 9.5% breast cancer cases enrolling in Medicaid at early stage (p<.1). The second article examined how BCCPTA affected the patterns of disenrollment from Medicaid for women diagnosed with breast, cervical and control cancers. The post-BCCPTA period analyzed here was one in which Georgia women could self-report that they were in active treatment and hence, still eligible. The unadjusted disenrollment rate declined 50% for breast and cervical cancer cases while it increased 30% for control cancer cases post-BCCPTA. The direction and magnitude of results held after adjusting for covariates that could affect disenrollment rates. The third article investigated cervical cancer treatment of patients enrolled in Medicaid under BCCPTA. In terms of treatment combination, 75% of pre-invasive patients had a precancerous procedure, with about 21%, versus 34% of invasive cases receiving surgery. Those more likely to receive surgery among pre-invasive cases were those with more advanced stage and a co-morbidity. Among invasive cases, later stage was associated with higher odds of radiation/chemo but not surgery. Non-Hispanic black were significantly less likely to have surgery than those non-Hispanic white in both pre-invasive (p < .01) and invasive cases (p = .05). (PsycINFO Database Record (c) 2016 APA, all rights reserved)
AN  - 2011-99120-323
AU  - Chien, Li-Nien
DB  - psyh
DP  - EBSCOhost
KW  - breast cancer
cervical cancer
treatment act
uninsured patients
Cancer Screening
Health Care Policy
Uninsured (Health Insurance)
Uterus
N1  - Accession Number: 2011-99120-323. Other Journal Title: Dissertation Abstracts International. Partial author list: First Author & Affiliation: Chien, Li-Nien; Emory U., US. Release Date: 20110808. Publication Type: Dissertation Abstract (0400). Format Covered: Electronic. Document Type: Dissertation. Dissertation Number: AAI3431975. ISBN: 978-1-124-33220-8. Language: English. Major Descriptor: Cancer Screening; Health Care Policy; Uninsured (Health Insurance). Minor Descriptor: Uterus. Classification: Health & Mental Health Treatment & Prevention (3300). Population: Human (10); Female (40). Location: Georgia. Age Group: Adulthood (18 yrs & older) (300); Young Adulthood (18-29 yrs) (320); Thirties (30-39 yrs) (340); Middle Age (40-64 yrs) (360). Methodology: Empirical Study; Quantitative Study. Page Count: 1.
PB  - ProQuest Information & Learning
PY  - 2011
SN  - 0419-4217
978-1-124-33220-8
SP  - 7385-7385
ST  - The effects of Breast and Cervical Cancer Prevention and Treatment Act (BCCPTA) in Georgia
TI  - The effects of Breast and Cervical Cancer Prevention and Treatment Act (BCCPTA) in Georgia
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2011-99120-323&site=ehost-live&scope=site
VL  - 71
ID  - 1809
ER  - 

TY  - JOUR
AB  - Background: Asthma is the most common pediatric illness in the United States, burdening low-income and minority families disproportionately and contributing to high health care costs. Clinic-based asthma education and telephone case management have had mixed results on asthma control, as have eHealth programs and online games. Objectives: To test the effects of (1) CHESS+CM, a system for parents and children ages 4-12 years with poorly controlled asthma, on asthma control and medication adherence, and (2) competence, self-efficacy, and social support as mediators. CHESS+CM included a fully automated eHealth component (Comprehensive Health Enhancement Support System [ CHESS]) plus monthly nurse case management (CM) via phone. CHESS, based on self-determination theory, was designed to improve competence, social support, and intrinsic motivation of parents and children. Methods: We identified eligible parent-child dyads from files of managed care organizations in Madison and Milwaukee, Wisconsin, USA, sent them recruitment letters, and randomly assigned them (unblinded) to a control group of treatment as usual plus asthma information or to CHESS+CM. Asthma control was measured by the Asthma Control Questionnaire (ACQ) and self-reported symptom-free days. Medication adherence was a composite of pharmacy refill data and medication taking. Social support, information competence, and self-efficacy were self-assessed in questionnaires. All data were collected at 0, 3, 6, 9, and 12 months. Asthma diaries kept during a 3-week run-in period before randomization provided baseline data. Results: Of 305 parent-child dyads enrolled, 301 were randomly assigned, 153 to the control group and 148 to CHESS+CM. Most parents were female (283/301, 94%), African American (150/301, 49.8%), and had a low income as indicated by child's Medicaid status (154/301, 51.2%); 146 (48.5%) were single and 96 of 301 (31.9%) had a high school education or less. Completion rates were 127 of 153 control group dyads (83.0%) and 132 of 148 CHESS+CM group dyads (89.2%). CHESS+CM group children had significantly better asthma control on the ACQ (d = -0.31, 95% confidence limits [CL] -0.56, -0.06, P = .011), but not as measured by symptom-free days (d = 0.18, 95% CL -0.88, 1.60, P = 1.00). The composite adherence scores did not differ significantly between groups (d = 1.48%, 95% CL -8.15, 11.11, P = .76). Social support was a significant mediator for CHESS+CM's effect on asthma control (alpha = .200, P = .01; beta = .210, P = .03). Self-efficacy was not significant (alpha = .080, P = .14; beta = .476, P = .01); neither was information competence (alpha = .079, P = .09; beta = .063, P = .64). Conclusions: Integrating telephone case management with eHealth benefited pediatric asthma control, though not medication adherence. Improved methods of measuring medication adherence are needed. Social support appears to be more effective than information in improving pediatric asthma control.
AN  - WOS:000308609600004
AU  - Gustafson, D.
AU  - Wise, M.
AU  - Bhattacharya, A.
AU  - Pulvermacher, A.
AU  - Shanovich, K.
AU  - Phillips, B.
AU  - Lehman, E.
AU  - Chinchilli, V.
AU  - Hawkins, R.
AU  - Kim, J. S.
DA  - Jul-Aug
DO  - 10.2196/jmir.1964
IS  - 4
N1  - 22835804
PY  - 2012
SN  - 1438-8871
SP  - 41-59
ST  - The Effects of Combining Web-Based eHealth With Telephone Nurse Case Management for Pediatric Asthma Control: A Randomized Controlled Trial
T2  - Journal of Medical Internet Research
TI  - The Effects of Combining Web-Based eHealth With Telephone Nurse Case Management for Pediatric Asthma Control: A Randomized Controlled Trial
VL  - 14
ID  - 3065
ER  - 

TY  - JOUR
AB  - Improving breast screening behaviors in African American women is an important public health goal. To increase participation in screening, it is necessary to identify factors that contribute to reduced screening, including perceived risk and cancer worry. This paper presents predictors of changes perceived in risk and worry among 113 African American women (aged 20–72 yrs) of differing ethnic identities as they undergo breast cancer risk counseling. Participants were recruited from community sources to a study of counseling for breast cancer risk They completed a baseline assessment, randomly received breast cancer risk counseling or served as a control group, and completed a follow-up assessment. Counseling produced significant differences in perceived risk and cancer worry. Predictors of risk and worry changes, as a result of counseling, included income and ethnic identity. It is suggested that these data can guide better services for African American women and research into the complexity of the effects of ethnic identity on health. (PsycINFO Database Record (c) 2016 APA, all rights reserved)
AN  - 1998-12576-009
AU  - Bowen, Deborah J.
AU  - Christensen, Catherine L.
AU  - Powers, Diane
AU  - Graves, Diane R.
AU  - Anderson, Cheryl A. M.
DB  - psyh
DO  - 10.1023/A:1026262321756
DP  - EBSCOhost
IS  - 3
KW  - counseling & ethnic identity
perceived risk & cancer worry
20–72 yr old African American females undergoing breast cancer risk counseling
Anxiety
Breast Neoplasms
Counseling
Ethnic Identity
Risk Perception
Blacks
Human Females
Neoplasms
N1  - Fred Hutchinson Cancer Research Ctr, Div of Public Health Sciences, Seattle, WA, US. Release Date: 19981101. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Print. Document Type: Journal Article. Language: English. Major Descriptor: Anxiety; Breast Neoplasms; Counseling; Ethnic Identity; Risk Perception. Minor Descriptor: Blacks; Human Females; Neoplasms. Classification: Cancer (3293). Population: Human (10); Female (40). Age Group: Adulthood (18 yrs & older) (300); Aged (65 yrs & older) (380). Methodology: Empirical Study. Page Count: 15. Issue Publication Date: Sep, 1998.
PY  - 1998
SN  - 1068-9583
1573-3572
SP  - 365-379
ST  - Effects of counseling and ethnic identity on perceived risk and cancer worry in African American women
T2  - Journal of Clinical Psychology in Medical Settings
T3  - Race and ethnicity in the medical setting: Psychological implications
TI  - Effects of counseling and ethnic identity on perceived risk and cancer worry in African American women
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=1998-12576-009&site=ehost-live&scope=site
VL  - 5
ID  - 1791
ER  - 

TY  - JOUR
AB  - PURPOSE/OBJECTIVES: To obtain preliminary data and determine the feasibility of a large-scale experimental study to test the efficacy of the Rogerian Science of Unitary Human Beings-based intervention of dialogue and therapeutic touch (TT) on pre- and postoperative anxiety and mood and postoperative pain from breast cancer surgery. DESIGN: Experimental. SETTING: Mid-Atlantic region; ambulatory. SAMPLE: 29 Caucasian and 2 African American English-speaking women with positive breast cancer biopsy (experimental, n = 14; control, n = 17), ranging in age from 31-84 years old (F = 55.6). METHODS: Treatments administered in subjects' homes within seven days prior to surgery and 24 hours after hospital discharge. Experimental treatment consisted of 10 minutes of TT and 20 minutes of dialogue. Control treatment consisted of 10 minutes of quiet time and 20 minutes of dialogue. Data (Spielberger State-Trait Anxiety Inventory. Affects Balance Scale, and Visual Analog Scale-Pain) were collected at the conclusion of each home visit. MAIN RESEARCH VARIABLES: Anxiety, mood, and pain. FINDINGS: The experimental group had lower preoperative state anxiety than the control groups (p = 0.008). No difference was found for preoperative mood. No differences were found for any postoperative measure. CONCLUSIONS: A large-scale study of dialogue and TT would require changes in design and recruitment strategies. IMPLICATIONS FOR NURSING PRACTICE: Nurses may provide more comprehensive care by incorporating dialogue and TT or quiet time into their pre- and postoperative care. Additional research, however, is recommended to determine the differential effects of dialogue, TT, and quiet time on women's experiences with breast cancer prior to incorporating these noninvasive modalities into clinical practice.
AD  - William Paterson University, Wayne, NJ, USA.
AN  - 9766290
AU  - Samarel, N.
AU  - Fawcett, J.
AU  - Davis, M. M.
AU  - Ryan, F. M.
DA  - Sep
DP  - NLM
ET  - 1998/10/10
IS  - 8
KW  - Adult
*Affect
Aged
Aged, 80 and over
Anxiety/*prevention & control
Breast Neoplasms/*surgery
*Communication
Female
Humans
Middle Aged
*Nurse-Patient Relations
Nursing Methodology Research
Postoperative Care/*nursing/*psychology
Preoperative Care/*nursing/*psychology
Therapeutic Touch/*nursing/*psychology
LA  - eng
N1  - Samarel, N
Fawcett, J
Davis, M M
Ryan, F M
Clinical Trial
Controlled Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't
United States
Oncol Nurs Forum. 1998 Sep;25(8):1369-76.
PY  - 1998
SN  - 0190-535X (Print)
0190-535x
SP  - 1369-76
ST  - Effects of dialogue and therapeutic touch on preoperative and postoperative experiences of breast cancer surgery: an exploratory study
T2  - Oncol Nurs Forum
TI  - Effects of dialogue and therapeutic touch on preoperative and postoperative experiences of breast cancer surgery: an exploratory study
VL  - 25
ID  - 727
ER  - 

TY  - JOUR
AB  - The authors examined the effects that differently framed and targeted health messages have on persuading low-income women to obtain screening mammograms. The authors recruited 752 women over 40 years of age from community health clinics and public housing developments and assigned the women randomly to view videos that were either gain or loss framed and either targeted specifically to their ethnic groups or multicultural. Loss-framed, multicultural messages were most persuasive. The advantage of loss-framed, multicultural messages was especially apparent for Anglo women and Latinas but not for African American women. These effects were stronger after 6 months than after 12 months.
AD  - Department of Psychology, Yale University, New Haven, Connecticut 06520-8205, USA.
AN  - 11515737
AU  - Schneider, T. R.
AU  - Salovey, P.
AU  - Apanovitch, A. M.
AU  - Pizarro, J.
AU  - McCarthy, D.
AU  - Zullo, J.
AU  - Rothman, A. J.
DA  - Jul
DO  - 10.1037//0278-6133.20.4.256
DP  - NLM
ET  - 2001/08/23
IS  - 4
KW  - Adult
Breast Neoplasms/diagnosis/epidemiology
Culture
*Ethnic Groups
Female
Health Behavior
*Health Promotion
Humans
Mammography/*psychology/statistics & numerical data
Mass Screening
Middle Aged
Random Allocation
Socioeconomic Factors
Videotape Recording
LA  - eng
N1  - Schneider, T R
Salovey, P
Apanovitch, A M
Pizarro, J
McCarthy, D
Zullo, J
Rothman, A J
P01-MH/DA56826/MH/NIMH NIH HHS/United States
R01-CA68427/CA/NCI NIH HHS/United States
Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.
United States
Health Psychol. 2001 Jul;20(4):256-66. doi: 10.1037//0278-6133.20.4.256.
PY  - 2001
SN  - 0278-6133 (Print)
0278-6133
SP  - 256-66
ST  - The effects of message framing and ethnic targeting on mammography use among low-income women
T2  - Health Psychol
TI  - The effects of message framing and ethnic targeting on mammography use among low-income women
VL  - 20
ID  - 682
ER  - 

TY  - JOUR
AB  - Aim Approximately 50% of African American smokers are light smokers (smoke <= 10 cigarettes a day). The prevalence of light smoking in the United States is increasing, yet there has not been a single smoking cessation clinical trial targeting light smokers. The purpose of this 2 x 2 factorial, randomized clinical trial was to evaluate the efficacy of nicotine gum (2 mg versus placebo) and counseling (motivational interviewing versus health education) for African American light smokers. Design Participants were assigned randomly to one of four study arms: 2 mg nicotine gum plus health education (HE); 2 mg nicotine gum plus motivational interviewing (MI); placebo gum plus HE; and placebo gum plus MI. Participants and setting A total of 755 African American light smokers (66% female, mean age = 45) were enrolled at a community health center over a 16-month period.Participants received an 8-week supply of nicotine gum and six counseling sessions during the course of the 26-week study. Biochemical measures included expired carbon monoxide (CO) and serum and salivary cotinine. Findings Seven-day quit rates for nicotine gum were no better than for the placebo group (14.2% versus 11.1%, P = 0.232) at 6 months. However, a counseling effect emerged, with HE performing significantly better than MI (16.7% versus 8.5%, P < 0.001). These results were consistent across outcome time-points (weeks 1, 8, and 26). Conclusions Results highlight the potential positive impact of directive information and advice-oriented counseling on smoking cessation. Studies are needed to assess other interventions that may further improve quit rates among African American light smokers who are motivated to quit.
AN  - WOS:000237516100019
AU  - Ahluwalia, J. S.
AU  - Okuyemi, K.
AU  - Nollen, N.
AU  - Choi, W. S.
AU  - Kaur, H.
AU  - Pulvers, K.
AU  - Mayo, M. S.
DA  - Jun
DO  - 10.1111/j.1360-0443.2006.01461.x
IS  - 6
N1  - 16696632
PY  - 2006
SN  - 0965-2140
SP  - 883-891
ST  - The effects of nicotine gum and counseling among African American light smokers: a 2 x 2 factorial design
T2  - Addiction
TI  - The effects of nicotine gum and counseling among African American light smokers: a 2 x 2 factorial design
VL  - 101
ID  - 3218
ER  - 

TY  - JOUR
AB  - BACKGROUND: Several factors may contribute to poorer prognosis for obese breast cancer patients, including unfavorable disease features, the influence of fat on estrogen availability, co-morbidity, and socio-demographic factors. Both obesity and estrogen receptor negative (ER-) tumors are more prevalent in black women than in whites in North America. We evaluated obesity and race in relation to outcomes in women with ER-breast cancer. METHODS: Among 4,077 women from National Surgical Adjuvant Breast and Bowel Project clinical trials for node-negative, ER-breast cancer, we evaluated disease-free survival (DFS) and its constituents (tumor recurrence, contralateral breast cancer (CBC), second primary cancers, deaths prior to these events) and mortality in relation to body mass index (BMI) and race, using statistical modeling to account for other prognostic factors. RESULTS: Compared to those of normal weight (BMI< or =24.9), DFS hazard was greater for obese (BMI > or = 30) women [hazard ratio (HR)=1.16, 95% confidence interval (CI)=1.01-1.33]. Obesity did not increase recurrence hazard, but did influence CBC (HR=2.08, 95% CI=1.22-3.55 in postmenopausal women) and second cancers (HR=1.49, 95% CI=1.06-2.10). Mortality increased with obesity; when partitioned by likely cause, those with BMI > or = 35.0 had greater risk of non-breast cancer mortality (HR=1.86, 95% CI=1.21-2.84). Relative to whites and adjusted for BMI, black women had greater hazard for DFS (HR=1.17, 95% CI=1.00-1.38), CBC (HR=1.37, 95% CI=0.94-1.99), and non-breast cancer deaths (HR=2.10, 95% CI=1.45-3.03); risk for deaths likely due to breast cancer was closer to that in whites (HR=1.18; 95% CI=0.93-1.50). CONCLUSIONS: For women with node-negative, ER-breast cancer from clinical trials, obesity did not increase recurrence risk, but was associated with greater risk for second cancers, CBC, and mortality, particularly non-breast cancer deaths. Less favorable prognosis for black women persists in clinical trials, and is in part attributable to non-breast cancer outcomes.
AD  - Department of Health Studies, The University of Chicago, Chicago, IL 60637, USA. jdignam@health.bsd.uchicago.edu
AN  - 16331345
AU  - Dignam, J. J.
AU  - Wieand, K.
AU  - Johnson, K. A.
AU  - Raich, P.
AU  - Anderson, S. J.
AU  - Somkin, C.
AU  - Wickerham, D. L.
DA  - Jun
DO  - 10.1007/s10549-005-9118-3
DP  - NLM
ET  - 2005/12/07
IS  - 3
KW  - Adult
African Americans/*statistics & numerical data
Antineoplastic Agents/therapeutic use
Body Mass Index
Breast Neoplasms/*complications/*ethnology/mortality
Disease-Free Survival
European Continental Ancestry Group/*statistics & numerical data
Female
Humans
Lymph Nodes/pathology
Middle Aged
Multicenter Studies as Topic
North America/epidemiology
Obesity/*complications
Odds Ratio
Prognosis
Proportional Hazards Models
Randomized Controlled Trials as Topic
Receptors, Estrogen/analysis
Retrospective Studies
Survival Analysis
LA  - eng
N1  - Dignam, James J
Wieand, Kelly
Johnson, Karen A
Raich, Peter
Anderson, Stewart J
Somkin, Carol
Wickerham, D Lawrence
NCI P30-CA-14599/CA/NCI NIH HHS/United States
NCI-R03-CA-99508/CA/NCI NIH HHS/United States
NCI-U10-CA-12027/CA/NCI NIH HHS/United States
NCI-U10-CA-69651/CA/NCI NIH HHS/United States
Comparative Study
Journal Article
Research Support, N.I.H., Extramural
Netherlands
Breast Cancer Res Treat. 2006 Jun;97(3):245-54. doi: 10.1007/s10549-005-9118-3. Epub 2005 Dec 6.
PY  - 2006
SN  - 0167-6806 (Print)
0167-6806
SP  - 245-54
ST  - Effects of obesity and race on prognosis in lymph node-negative, estrogen receptor-negative breast cancer
T2  - Breast Cancer Res Treat
TI  - Effects of obesity and race on prognosis in lymph node-negative, estrogen receptor-negative breast cancer
VL  - 97
ID  - 580
ER  - 

TY  - JOUR
AB  - Disodium disuccinate astaxanthin ('rac'-dAST; Cardax™) is a water-dispersible C40 carotenoid derivative under development for oral and parenteral administration for cardioprotection of the at-risk ischemic cardiovascular patient. In experimental infarction models in animals (rats, rabbits, and dogs), significant myocardial salvage has been obtained, up to 100% at the appropriate dose in dogs. The documented mechanism of action in vitro includes direct scavenging of biologically produced superoxide anion; in vivo in rabbits, modulation of the complement activity of serum has also been shown. A direct correlation between administration of the test compound in animals and reductions of multiple, independent markers of oxidative stress in serum was recently obtained in a rat experimental infarction model. For the current study, it was hypothesized that oral Cardax™ administration would inhibit oxidative damage of multiple relevant biological targets in a representative, well-characterized murine peritoneal inflammation model. A previously developed mass spectrometry-based (LC/ESI/MS/MS) approach was used to interrogate multiple distinct pathways of oxidation in a black mouse (C57/BL6) model system. In vivo markers of oxidant stress from peritoneal lavage samples (supernatants) were evaluated in mice on day eight (8) after treatment with either Cardax™ or vehicle (lipophilic emulsion without drug) orally by gavage at 500 mg/kg once per day for seven (7) days at five (5) time points: (1) baseline prior to treatment (t = 0); (2) 16 h following intraperitoneal (i.p.) injection with thioglycollate to elicit a neutrophilic infiltrate; (3) 4 h following i.p. injection of yeast cell wall (zymosan; t = 16 h/4 h thioglycollate + zymosan); (4) 72 h following i.p. injection with thioglycollate to elicit monocyte/macrophage infiltration; and (5) 72 h/4 h thioglycollate + zymosan. A statistically significant sparing effect on the arachidonic acid (AA) and linoleic acid (LA) substrates was observed at time points two and five. When normalized to the concentration of the oxidative substrates, statistically significant reductions of 8-isoprostane-F2α (8-iso-F2α) at time point three (maximal neutrophil recruitment/activation), and 5-HETE, 5-oxo-EET, 11-HETE, 9-HODE, and PGF2α at time point five (maximal monocyte/macrophage recruitment/activation) were observed. Subsequently, the direct interaction of the optically inactive stereoisomer of Cardax™ (meso-dAST) with human 5-lipoxygenase (5-LOX) was evaluated in vitro with circular dichroism (CD) and electronic absorption (UV/Vis) spectroscopy, and subsequent molecular docking calculations were made using mammalian 15-LOX as a surrogate (for which XRC data has been reported). The results suggested that the meso-compound was capable of interaction with, and binding to, the solvent-exposed surface of the enzyme. These preliminary studies provide the foundation for more detailed evaluation of the therapeutic effects of this compound on the 5-LOX enzyme, important in chronic diseases such as atherosclerosis, asthma, and prostate cancer in humans. © 2006 Elsevier Inc. All rights reserved.
AD  - Hawaii Biotech, Inc., 99-193 Aiea Heights Drive, Suite 200, Aiea, HI 96701, United States
Departments of Cell Biology, Cardiovascular Medicine, Center for Cardiovascular Diagnostics and Prevention, Cleveland, OH 44195, United States
Department of Molecular Pharmacology, Institute of Biomolecular Chemistry, Chemical Research Center, P.O. Box 17, Budapest, H-1525, Hungary
AU  - Lockwood, S. F.
AU  - Penn, M. S.
AU  - Hazen, S. L.
AU  - Bikádi, Z.
AU  - Zsila, F.
DB  - Scopus
DO  - 10.1016/j.lfs.2005.12.052
IS  - 2
KW  - 5-Lipoxygenase
Astaxanthin
Cardax™
Carotenoids
Disodium disuccinate astaxanthin
HETEs
HODEs
Inflammation
LC/ESI/MS/MS
Oxidative stress
M3  - Article
N1  - Cited By :17
Export Date: 22 March 2021
PY  - 2006
SP  - 162-174
ST  - The effects of oral Cardax™ (disodium disuccinate astaxanthin) on multiple independent oxidative stress markers in a mouse peritoneal inflammation model: influence on 5-lipoxygenase in vitro and in vivo
T2  - Life Sciences
TI  - The effects of oral Cardax™ (disodium disuccinate astaxanthin) on multiple independent oxidative stress markers in a mouse peritoneal inflammation model: influence on 5-lipoxygenase in vitro and in vivo
UR  - https://www.scopus.com/inward/record.uri?eid=2-s2.0-33646709465&doi=10.1016%2fj.lfs.2005.12.052&partnerID=40&md5=8c243a10563aaa97184f898da600529f
VL  - 79
ID  - 2574
ER  - 

TY  - JOUR
AB  - OBJECTIVES: To determine the effects of online narrative and didactic information on breast cancer patients' healthcare participation and the interaction effects of race. SAMPLE: 353 breast cancer patients (111 African Americans) using an eHealth program with narratives (audiovisual and text) and didactic information (text only). MEASURES: healthcare participation scale (0, 4 months), online information use. ANALYSES: hierarchical regression. RESULTS: Narrative (beta=0.123, p<0.01) and didactic (beta=0.104, p<0.05) information use had independent and positive effects on healthcare participation. Effects of both were significantly greater for African Americans. CONCLUSIONS: Findings are consistent with and advance prior research on online learning processes and outcomes for breast cancer patients: (1) benefits accrue with using a variety of online learning tools; (2) African Americans use and benefit more from online narrative and didactic information than do Caucasians. PRACTICE IMPLICATIONS: eHealth programs should provide both didactic and narrative information-especially for African Americans and might consider making greater use of interactive and audiovisual formats. As patients increasingly use of the web for cancer information, clinicians should provide lists of web high quality resources that provide both narrative and didactic information.
AD  - Center for Health Enhancement Systems Studies, University of Wisconsin, Madison, WI 53726, United States. mewise@wisc.edu
AN  - 18201859
AU  - Wise, M.
AU  - Han, J. Y.
AU  - Shaw, B.
AU  - McTavish, F.
AU  - Gustafson, D. H.
C2  - PMC2367096
C6  - NIHMS41904
DA  - Mar
DO  - 10.1016/j.pec.2007.11.009
DP  - NLM
ET  - 2008/01/19
IS  - 3
KW  - Adaptation, Psychological
*African Americans/education/ethnology/statistics & numerical data
Breast Neoplasms/*ethnology
*European Continental Ancestry Group/education/ethnology/statistics & numerical data
Female
Humans
Internet/*organization & administration
Middle Aged
Narration
Patient Education as Topic/*organization & administration
Patient Participation/*psychology/statistics & numerical data
Program Evaluation
Regression Analysis
Social Support
Surveys and Questionnaires
LA  - eng
N1  - Wise, Meg
Han, Jeong Yeob
Shaw, Bret
McTavish, Fiona
Gustafson, David H
R01 LM006533-03/LM/NLM NIH HHS/United States
R01 LM006533-03S1/LM/NLM NIH HHS/United States
P50 CA095817-01A1/CA/NCI NIH HHS/United States
P50 CA095817/CA/NCI NIH HHS/United States
P50 CA095817-04/CA/NCI NIH HHS/United States
P50 CA095817-03/CA/NCI NIH HHS/United States
P50 CA095817-05/CA/NCI NIH HHS/United States
R01 LM006533-02/LM/NLM NIH HHS/United States
P50 CA095817-02/CA/NCI NIH HHS/United States
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Patient Educ Couns. 2008 Mar;70(3):348-56. doi: 10.1016/j.pec.2007.11.009. Epub 2008 Jan 16.
PY  - 2008
SN  - 0738-3991 (Print)
0738-3991
SP  - 348-56
ST  - Effects of using online narrative and didactic information on healthcare participation for breast cancer patients
T2  - Patient Educ Couns
TI  - Effects of using online narrative and didactic information on healthcare participation for breast cancer patients
VL  - 70
ID  - 509
ER  - 

TY  - JOUR
AB  - The efficacy and tolerability of dutasteride (0.5 mg daily for 2 years) in African-Americans (n = 161), compared with Caucasians ( n = 3961), was assessed in a post hoc analysis of data from three Phase III clinical trials. Dutasteride significantly reduced serum dihydrotestosterone levels by >90% and significantly improved subjective ( symptom score) and objective ( prostate volume, peak urinary flow rate, risk of benign prostatic hyperplasia-related surgery and acute urinary retention) outcomes in both African-Americans and Caucasians. For all efficacy measures, there was no statistically significant treatment-by-race interaction and dutasteride was well tolerated in both racial groups. Therefore, dutasteride demonstrated similar efficacy and safety profiles in African-Americans and Caucasians.
AN  - WOS:000242795100022
AU  - Roehrborn, C. G.
AU  - Ray, P.
DA  - Dec
DO  - 10.1038/sj.pcan.4500911
IS  - 4
N1  - 16983393
PY  - 2006
SN  - 1365-7852
SP  - 432-438
ST  - Efficacy and tolerability of the dual 5 alpha-reductase inhibitor, dutasteride, in the treatment of benign prostatic hyperplasia in African-American men
T2  - Prostate Cancer and Prostatic Diseases
TI  - Efficacy and tolerability of the dual 5 alpha-reductase inhibitor, dutasteride, in the treatment of benign prostatic hyperplasia in African-American men
VL  - 9
ID  - 3207
ER  - 

TY  - JOUR
AB  - Observed variations in breast cancer survival by racial/ethnic background have been attributed to many factors, including differences in clinical and pathologic disease features at diagnosis and economic resource inequities that may affect treatment access and quality. In this report, we examine outcomes for African-American and Caucasian breast cancer patients participating in selected randomized clinical trials of the National Surgical Adjuvant Breast and Bowel Project (NSABP) to determine whether prognosis or efficacy of systemic adjuvant therapy differed between these groups. Randomized clinical trials offer the advantages of a similar disease stage and a uniform treatment plan for all participants. Patients from four NSABP trials enrolling patients from 1982 through 1994 with axillary lymph node-negative disease (543 African-American and 7582 Caucasian) and three trials enrolling patients from 1984 through 1991 with axillary lymph node-positive disease (548 African-American and 4986 Caucasian) were included. Disease-free survival (DFS), which was defined as time on study free of breast cancer recurrence, second primary cancer, or death preceding these events, and survival risk ratios (RRs) with two-sided 95% confidence intervals (CIs) for African-Americans versus Caucasians were computed from Cox proportional hazards models that included relevant prognostic covariates. Treatment benefits for the therapies evaluated in these trials were estimated separately for African-Americans and for Caucasians. Among patients with lymph node-negative disease, African-Americans had similar DFS rates to Caucasians (African-American/Caucasian RR = 1.06, 95% CI = 0.92 to 1.23) but had modestly greater mortality rates (RR = 1.21, 95% CI = 1.01 to 1.46). Among lymph node-positive patients, DFS was similar (RR = 1.04, 95% CI = 0.93 to 1.17) and survival was again less favorable for African-Americans (RR = 1.18 95% CI = 1.03 to 1.34). Survival excluding deaths most likely attributable to causes other than cancer was similar between African-Americans and Caucasians (RR = 1.08 [95% CI = 0.88 to 1.33] for lymph node-negative patients and RR = 1.09 [95% CI = 0.96 to 1.25] for lymph node-positive patients). Among lymph node-negative and lymph node-positive patients, African-Americans and Caucasians realized comparable benefit from either the addition of chemotherapy or tamoxifen to surgery alone or the addition of chemotherapy to tamoxifen. In summary, African-American women and Caucasian women who were diagnosed at a comparable disease stage and were similarly treated tended to experience similar breast cancer prognosis. However, a mortality deficit persisted for African-American women relative to Caucasian women, which may be in part due to greater mortality from noncancer causes among African-Americans. Benefit from systemic adjuvant therapy for recurrence and mortality reduction was comparable between African-Americans and Caucasians. This study and investigations in other health-care settings suggest that African-American women and Caucasian women with breast cancer derive a similar benefit from systemic adjuvant therapy when it is administered in accordance with their clinical and pathologic disease presentation.
AD  - Biostatistical Center, National Surgical Adjuvant Breast and Bowel Project (NSABP), 1 Sterling Plaza, 230 N. Craig St., Pittsburgh, PA 15213, USA. jdignam@health.bsd.uchicago.edu
AN  - 11773290
AU  - Dignam, J. J.
DO  - 10.1093/oxfordjournals.jncimonographs.a003458
DP  - NLM
ET  - 2002/01/05
IS  - 30
KW  - *African Continental Ancestry Group
Aged
Antineoplastic Agents/*therapeutic use
Breast Neoplasms/*drug therapy
Chemotherapy, Adjuvant/*statistics & numerical data
Disease-Free Survival
*European Continental Ancestry Group
Female
Humans
Lymphatic Metastasis
Middle Aged
Odds Ratio
Outcome and Process Assessment, Health Care
Randomized Controlled Trials as Topic
Receptors, Estrogen/metabolism
Survival Rate
LA  - eng
N1  - Dignam, J J
U10 CA 69651/CA/NCI NIH HHS/United States
Journal Article
Research Support, U.S. Gov't, P.H.S.
United States
J Natl Cancer Inst Monogr. 2001;(30):36-43. doi: 10.1093/oxfordjournals.jncimonographs.a003458.
PY  - 2001
SN  - 1052-6773 (Print)
1052-6773
SP  - 36-43
ST  - Efficacy of systemic adjuvant therapy for breast cancer in African-American and Caucasian women
T2  - J Natl Cancer Inst Monogr
TI  - Efficacy of systemic adjuvant therapy for breast cancer in African-American and Caucasian women
ID  - 675
ER  - 

TY  - JOUR
AB  - BACKGROUND: Upfront docetaxel (UD) with androgen deprivation therapy (ADT) has been demonstrated to improve survival outcomes in metastatic castration-sensitive prostate cancer (mCSPC). However, existing studies have included predominantly Caucasian patients. STUDY QUESTION: To compare the efficacy of addition of UD to ADT in mCSPC to ADT alone among minority patients. STUDY DESIGN: Retrospective study of mCSPC patients. MEASURES AND OUTCOMES: Patients treated with UD and ADT between January 2014 and December 2017 (UD + ADT, n = 44) were compared with those treated with ADT alone between January 2008 and January 2017 (ADT, n = 38); patients of Caucasian ethnicity were excluded. The outcome of interest was progression-free survival (PFS), which was estimated using Kaplan-Meier analysis and Cox proportional hazard analysis. RESULTS: Overall, 63 (76.8%) patients were African American and 16 (19.5%) were Hispanic. Fifty-five (67%) patients had high-volume mCSPC. The median follow-up was 14 months [95% confidence interval (CI): 10.4-16.5] for UD + ADT and 42 months (95% CI: 17-66.9) for ADT. Median PFS did not differ between groups: UD + ADT: 16 versus ADT: 18 months [hazard ratio (HR) for UD + ADT = 0.88, 95% CI: 0.48-1.62; P = 0.70]. In patients with high-volume disease, median PFS remained similar (UD + ADT: 16 vs. ADT: 14 months (HR for UD + ADT = 0.64, 95% CI: 0.33-1.25; P = 0.19). On multivariable analysis, prolonged time to nadir PSA, HR = 0.83 (95% CI: 0.76-0.90), was independently associated with PFS. The most common toxicities in UD + ADT were anemia and fatigue. Major limitations include small sample size and potential for selection bias due to the retrospective study design. CONCLUSIONS: In this retrospective review of a minority mCSPC cohort, UD + ADT was not associated with improved PFS compared with ADT alone. Although further study with larger sample size is needed, these results underscore the importance of ensuring accrual of minorities in clinical trials, reflective of the real-world setting.
AD  - Division of Hematology-Oncology, Department of Medicine, John H. Stroger, Jr. Hospital of Cook County, Chicago, IL.
Division of Cardiology, Department of Medicine, New York Medical College at Westchester Medical Center, Valhalla, NY.
Department of Urology, University of Washington School of Medicine, Seattle, WA.
Seattle Cancer Care Alliance, Seattle, WA.
AN  - 32384317
AU  - Pathak, S.
AU  - Thekkekara, R.
AU  - Yadav, U.
AU  - Ahmed, A. T.
AU  - Yim, B.
AU  - Lad, T. E.
AU  - Mullane, M.
AU  - Batra, K. K.
AU  - Aronow, W. S.
AU  - Psutka, S. P.
DA  - May 5
DO  - 10.1097/mjt.0000000000001085
DP  - NLM
ET  - 2020/05/10
LA  - eng
N1  - 1536-3686
Pathak, Surabhi
Thekkekara, Romy
Yadav, Udit
Ahmed, Ahmed Tarig
Yim, Barbara
Lad, Thomas E
Mullane, Michael
Batra, Kumar Kunnal
Aronow, Wilbert S
Psutka, Sarah P
Journal Article
United States
Am J Ther. 2020 May 5. doi: 10.1097/MJT.0000000000001085.
PY  - 2020
SN  - 1075-2765
ST  - Efficacy of Upfront Docetaxel With Androgen Deprivation Therapy for Castration-Sensitive Metastatic Prostate Cancer Among Minority Patients
T2  - Am J Ther
TI  - Efficacy of Upfront Docetaxel With Androgen Deprivation Therapy for Castration-Sensitive Metastatic Prostate Cancer Among Minority Patients
ID  - 36
ER  - 

TY  - JOUR
AB  - BACKGROUND: African Americans have the highest incidence and mortality and are less likely than whites to have been screened for colorectal cancer (CRC). Many interventions have been shown to increase CRC screening in research settings, but few have been evaluated specifically for use in African-American communities in real world settings. This study aims to identify the most efficacious approach to disseminate an evidence-based intervention in promoting colorectal screening in African Americans and to identify the factors associated with its efficacy. METHODS/DESIGN: In this study, investigators will recruit 20 community coalitions and 7,200 African-Americans age 50 to 74 to test passive and active approaches to disseminating the Educational Program to Increase Colorectal Cancer Screening (EPICS); to measure the extent to which EPICS is accepted and the fidelity of implementation in various settings and to estimate the potential translatability and public health impact of EPICS. This four-arm cluster randomized trial compares the following implementation strategies: passive arms, (web access to facilitator training materials and toolkits without technical assistance (TA) and (web access, but with technical assistance (TA); active arms, (in-person access to facilitator training materials and toolkits without TA and (in-person access with TA). Primary outcome measures are the reach (the proportion of representative community coalitions and individuals participating) and efficacy (post-intervention changes in CRC screening rates). Secondary outcomes include adoption (percentage of community coalitions implementing the EPICS sessions) and implementation (quality and consistency of the intervention delivery). The extent to which community coalitions continue to implement EPICS post-implementation (maintenance) will also be measured. Cost-effectiveness analysis will be conducted. DISCUSSION: Implementing EPICS in partnership with community coalitions, we hypothesized, will result in more rapid adoption than traditional top-down approaches, and resulting changes in community CRC screening practices are more likely to be sustainable over time. With its national reach, this study has the potential to enhance our understanding of barriers and enablers to the uptake of educational programs aimed at eliminating cancer disparities. TRIAL REGISTRATION: http://www.ClinicalTrials.gov NCT01805622.
AD  - Department of Community Health and Preventive Medicine, Morehouse School of Medicine, Atlanta, GA, USA. ssmith@msm.edu
AN  - 23924263
AU  - Smith, S. A.
AU  - Blumenthal, D. S.
C2  - PMC3750535
DA  - Aug 7
DO  - 10.1186/1748-5908-8-86
DP  - NLM
ET  - 2013/08/09
KW  - African Americans/ethnology
Aged
Cluster Analysis
Colorectal Neoplasms/ethnology/*prevention & control
Early Detection of Cancer
Female
Health Promotion/organization & administration
Health Status Disparities
Humans
Male
Middle Aged
Patient Education as Topic/*methods
Treatment Outcome
LA  - eng
N1  - 1748-5908
Smith, Selina A
Blumenthal, Daniel S
1R01CA166785-01/CA/NCI NIH HHS/United States
U54 CA118623/CA/NCI NIH HHS/United States
5U54CA118638-07/CA/NCI NIH HHS/United States
U54 CA118638/CA/NCI NIH HHS/United States
UL1 TR000454/TR/NCATS NIH HHS/United States
U54 CA118948/CA/NCI NIH HHS/United States
G12 MD007585/MD/NIMHD NIH HHS/United States
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Implement Sci. 2013 Aug 7;8:86. doi: 10.1186/1748-5908-8-86.
PY  - 2013
SN  - 1748-5908
SP  - 86
ST  - Efficacy to effectiveness transition of an Educational Program to Increase Colorectal Cancer Screening (EPICS): study protocol of a cluster randomized controlled trial
T2  - Implement Sci
TI  - Efficacy to effectiveness transition of an Educational Program to Increase Colorectal Cancer Screening (EPICS): study protocol of a cluster randomized controlled trial
VL  - 8
ID  - 321
ER  - 

TY  - GEN
AB  - Black Americans are under‐represented in cancer clinical trials because of myriad factors. Minority under‐representation in clinical trials likely contributes to the disparate cancer outcomes among minorities and the poor. This Commentary, in light of a clinical trial that was prematurely terminated because of poor accrual of black men, discusses strategies to identify and overcome barriers to enrollment for this particularly vulnerable population.
AD  - Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA
Laboratory of Epidemiology and Population Sciences, National Institute on Aging, National Institutes of Health, Baltimore, Maryland, USA
AU  - Jackson, Jonathan D.
AU  - Moy, Beverly
AU  - Evans, Michele K.
CY  - Durham, North Carolina
DB  - CINAHL Complete
DO  - 10.1634/theoncologist.2016-0327
DP  - EBSCOhost
J2  - Oncologist
KW  - Prostatic Neoplasms -- Drug Therapy
Neoplasm Metastasis -- Drug Therapy
Abiraterone Acetate -- Therapeutic Use
Prednisone -- Therapeutic Use
Black Persons
Drug Therapy
Androgens -- Metabolism
Polymorphism, Genetic
Male
Prostatic Neoplasms -- Mortality
N1  - Accession Number: 120270065. Language: English. Entry Date: 20161223. Revision Date: 20191029. Publication Type: Opinion; commentary; letter. Journal Subset: Biomedical; Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA. NLM UID: 9607837.
PB  - AlphaMed Company, Inc., dba AlphaMed Press
PY  - 2016
SN  - 1083-7159
SP  - 1411-1413
ST  - The Elimination of Cancer Health Disparities: Are We Ready to Do the Heavy Lifting?...Tsao CK, Sfakianos J, Liaw B et al. Phase II clinical trial of abiraterone acetate plus prednisone in black men with metastatic prostate cancer. Oncologist. 2016 Dec; 21(12):1414-e9
TI  - The Elimination of Cancer Health Disparities: Are We Ready to Do the Heavy Lifting?...Tsao CK, Sfakianos J, Liaw B et al. Phase II clinical trial of abiraterone acetate plus prednisone in black men with metastatic prostate cancer. Oncologist. 2016 Dec; 21(12):1414-e9
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=120270065&site=ehost-live&scope=site
VL  - 21
ID  - 2121
ER  - 

TY  - JOUR
AB  - A study in hamsters of the distribution and elimination of radioactivity after a single intratracheal instillation of a suspension of [3H]3,4-benzopyrene (BP) in aminosol vitrum 100%, or of mixtures of BP and asbestos or of BP and carbon black in the same suspending medium, is reported. During the first 3 weeks of the experiment, radioactivity disappeared rapidly from the lungs irrespective of the presence or absence of carbon black. After 21 days, however, both asbestos and carbon black significantly increased retention of radioactivity. More macrophages could be recovered by use of a standard washing technique after the administration of BP + carbon black or BP + asbestos, than after the administration of BP alone, but the radioactivity per macrophage was highest in the group treated with benzopyrene only. The levels of radioactivity found in liver, kidneys, blood and urine were similar in the 3 groups of animals. In the faeces there was an earlier fall of radioactivity after treatment with BP + carbon black (between 14 and 21 days) than after treatment with BP alone (between 21 and 28 days. The significance of the results in relation to the causation of lung cancer in man is briefly discussed. © 1969, The British Empire Cancer Campaign for Research. All rights reserved.
AD  - Laboratory of Cancer Prevention, Institute of Experimental and Clinical Oncology AM.S. U.S.S.R, 6 Kashirskoye Shosse, Moscow, Russian Federation
Chester Beatty Research Institute, Fulham Road, London, S.W.3, United Kingdom
AU  - Pylev, L. N.
AU  - Roe, F. J.
AU  - Warwick, G. P.
DB  - Scopus
DO  - 10.1038/bjc.1969.16
IS  - 1
M3  - Article
N1  - Cited By :35
Export Date: 22 March 2021
PY  - 1969
SP  - 103-115
ST  - Elimination of radioactivity after intratracheal instillation of tritiated 3,4-benzopyrene in hamsters
T2  - British Journal of Cancer
TI  - Elimination of radioactivity after intratracheal instillation of tritiated 3,4-benzopyrene in hamsters
UR  - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0014483703&doi=10.1038%2fbjc.1969.16&partnerID=40&md5=d7fc11358a4aa720e650436658fc083c
VL  - 23
ID  - 2663
ER  - 

TY  - JOUR
AB  - I. Background and Significance: Several exploratory and major controlled studies conducted on the mainland US have shown intimate partner violence (IPV) or intimate partner abuse (IPA) to be risk factors for a variety of physical, reproductive and mental health problems, including HIV/AIDS, many of which are areas of known health disparity for African American and Latina women. The current investigators recently completed the first in‐depth prevalence study of violence and abuse of women in the US Virgin islands (USVI) and associated health consequences. This seminal study showed 1) Lifetime prevalence of IPV of 32.8% in the USVI and past two year prevalence of 37.2%%.in a sample of 1059 women aged 18‐55 who self‐identified as African Caribbean or from African descent and who had an intimate partner during the past two years 2) Past two year physical and/or sexual abuse ranged from 4 % on the island of St Croix to 9% on St Thomas 3) Abused women had significantly more risk factors for Sexually Transmitted Infections (STIs) and HIV/AIDS than did women not abused, and 4) Risk factors for STIs and HIV/AIDS included being forced into vaginal or anal sex, women having concurrent partners or their partners having multiple partners, having a STI, lack of consistent condom use, and exchange sex (trading sex for material goods) This study also found women amenable to being asked about IPV in health care settings where a brief intervention could be feasibly implemented. Preliminary qualitative work illuminated women's perceptions of community and cultural perspectives on IPV in the USVI. The proposed randomized clinical trial (RCT) builds on findings from the prior study. II. Research Strategy: A RCT will provide a preliminary test of an intervention designed to reduce IPV and IPA and the concurrent risk of STIs and HIV in abused USVI women by empowering their use of safety behaviors and increasing their use of resources... IPV and IPA have been linked to high‐risk sexual behaviors, the inability to negotiate safer sex behaviors, and negative sexual health outcomes. The research plan is to deliver a structured intervention to reduce the devastating impact of IPV and IPA for abused women in the USVI. Time I: Women will respond to baseline data measures using computer assisted self‐reports. Data collected include socio‐demographic and cultural characteristics of women and their partners, past and recent intimate partner physical, sexual and emotional abuse (SVAWS), Danger Assessment (DA), baseline HIV/STD status and risks for infection, including condom use. To minimize attrition contact information for each participant and for three contact persons (family, friends, and neighbors) will also be collected. Abused women will be randomized by the computer to either the Healthy Relationships Risk Reduction experimental intervention group or the Healthy Lifestyles comparison control group A. Session 1‐ Risk Reduction Intervention Group. Women in the Experimental Intervention will complete this session following initial assessment and group assignment. The ESP‐DOVE IPV Empowerment Intervention is an individualized (60 minute) protocol following the initial enrollment session. Abused women will view a video developed in the US Virgin Islands, using local actors, depicting various experiences of abused Virgin Island. The abused women will participate in a one on one structured, brochure‐based intervention with a trained interventionist that addresses information about the cycle of violence, risk factors that may increase a woman's danger of homicide (the Danger Assessment), choices or options (leaving, using local shelter resources, accessing resources in the criminal justice system), safety planning, and specific local and national phone numbers for IPV resources. The intervention provides the woman with information, emphasizing that she has options or The structured ESP‐ DOVE intervention is interactive and encourages the woman to describe her experiences and choose her options as they proceed. The intervention as been modified to be culturally appropriate for abused women of African Caribbean or African American background living in the US Virgin Islands. Since the context of IPV varies considerably, this approach allows individualization, client input and choice, all thought to enhance intervention success with battered women and other "hard to reach" populations At the same time, the brochure gives the nurse and other interventionists a script to increase uniformity of the intervention across women and interventionists. Four major intervention components: a) IPV information, b) Danger Assessment, c) Safety Planning, and d) Resources are explored. At the end of Session I, the woman in the risk reduction intervention group will provide contact information for Session 2 which will be scheduled one week later. Time 2: Session 2‐ Women will assess their needs associated with IPV, safety behaviors and feelings about how their situation is evolving. The need for resources and services will be explored. The session will also focus on helping the women learn how to reduce their risk for HIV/STD infections. This one‐on‐one behavioral intervention has been found to reduce HIV/STD risk behaviors and STD morbidity among inner‐city African American women in primary care settings in a NINR funded randomized controlled trial. The intervention has been modified and culturally tailored for abused women in the US Virgin Islands and involves a skill‐building one‐on‐one session that the facilitator tailors to the specific needs of each participant after conducting an HIV/STD risk assessment interview. It involves STD prevention behavioral skills, video clips, condom demonstration, practice with an anatomical model, and role‐playing. Curriculum activities are also designed to help women recognize that faulty reasoning and decision‐making can increase their risk of HIV infection. The activities help the women understand the adverse consequences of participating in unsafe sexual activity and the positive consequences of safer sexual practices. Contact information for Session 3 will be validated and a follow up group session scheduled. Time 3: Session 3: The third session will consist of small groups (8‐10) of women in a supportive/educational session led by an interventionist and investigator. Sessions held in each district in the USVI and will be scheduled two weeks following Session 2. Women in the experimental intervention group will have another opportunity to integrate issues related to their IPV experiences. . They will interact with other abused women in a setting conducive to sharing attitudes and beliefs about IPV prevention, cultural beliefs about IPV, the need for support, assertiveness training, stress and affect management, safety enhancement strategies and effective behaviors to reduce the risk of HIV and sexually transmitted disease and personal vulnerability. Session three will be offered twice each week in each district until all participants have had an opportunity to complete the intervention. At the end of session 3, the women will be scheduled for a three month follow‐up to assess outcomes. Contact information will be reconfirmed. B. Healthy Living Comparison Control Group Session 1: Women in the Healthy Living comparison control group will complete the baseline assessment using the computer assisted tablets for self‐report. Women who report a history of intimate partner abuse will be will be yoked on age (>25 or <below 25) and ethnicity (Hispanic or Non‐Hispanic and education (HS grad vs < high school graduation). During Session one, if randomly assigned to the Healthy Living Comparison Control intervention group, they will be focus on Breast Health Education and how to develop a breast health care plan aimed at reducing the risk of breast cancer in women of African heritage. Obesity as a risk factor for breast cancer will be introduced. Booklets on breast health and developing a breast health plan will be provided as well as general resource information on women and child health services. Contact inf rmation for the one week follow up will be obtained and the woman given an appointment for Session II. Session 2: At time two women in the comparison control health promotion group will be involved in a session on Healthy Lifestyles for African Caribbean Women: Reducing Obesity Risks. The one on one interactive session will discuss the association between breast cancer and obesity as well as other major health problems associated with obesity. They learn how to assess their Body Mass Index and measure waist conference to determine whether or not they are at risk for obesity related health problems. The session will last approximately one hour. They will also be briefly reassessed for abuse to determine if abuse is escalating and the need for a referral. Participant contact information will be confirmed and Session 3 scheduled two weeks later. Session 3: At time three participants in the comparison control health promotion group control will engage in a follow up group session of 6‐8 women that will include sharing progress made on developing breast health plans as well as planned choices to reduce obesity and promote healthy lifestyles including diet and exercise. The group discussion will be facilitated by the original facilitator as well as one of the study investigators. Contact information for the final follow up will be will be validated. Participants will complete a post interview on the computer and a 3 month follow‐up outcome assessment will be scheduled. C. Outcome Measures Time 4: Intervention outcomes will be measured at three months to assess effectiveness and safety of the Integrated Risk Reduction Intervention for Women Experiencing IPA. Participants will include women who completed all three sessions of the Risk Reduction intervention or three sessions of the Health Education Comparison Control group. The outcome measures will be completed on computer tablets and will include the same measures that were used at the initial assessment in addition to an assessment of changes in safety and prevention behaviors. Participants will be scheduled for a six month follow‐up for final outcome measures. Time 5: Final post intervention outcome measures will be obtained six months after the participant completes the 3 month outcome measures. The women will again be contacted at least two weeks prior to the scheduled outcomes measures by Caribbean Exploratory NIMHD Research Center Staff to re‐confirm the scheduled follow‐up and will repeat the same process on computer tablets including outcome measures used at the three month assessment. D. Data management 1. Preliminary Analyses: Microsoft Access and Excel will be used for record keeping, tracking, and initial data processing. The latest versions of SAS and SPSS computer programs will be used for data management and analysis. Access to the computers and data CDs will be limited both physically and electronically. Computers and data will be stored in an office that is locked when not in use. Access to databases will be restricted with read and write protection. Data analysis will begin with preparatory activities such as the treatment of missing data, identification of outliers and other such data cleaning tasks. A detailed descriptive analysis of all quantitative data will be performed, involving the summarization of data and the use of inferential and graphical exploratory data analytic techniques. 2. Analysis: To conduct a preliminary test of the integrated intervention as described in the brief description, analysis of covariance, frequency and logistic regression will be used to explore potential differences in predictor variables between the two groups.
AN  - CN-01546297
AU  - Nct
PY  - 2014
ST  - Empowered Sisters Project Making Choices Reducing Risks
T2  - https://clinicaltrials.gov/show/NCT02158962
TI  - Empowered Sisters Project Making Choices Reducing Risks
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01546297/full
ID  - 1633
ER  - 

TY  - JOUR
AB  - Minority representation in clinical trials is vital for researchers to assess differential effects in outcomes of therapies on biological and genetic characteristics among groups. This study assessed the effect of Choices, a bilingual multi-component intervention, on perceived understanding of clinical trials, agreement with stages of decision readiness and consideration of clinical trials as a treatment option, among Latina breast cancer patients. This randomized controlled pilot study compared Choices with a control condition providing general clinical trial information to eligible patients. Seventy-seven Latina breast cancer patients were randomly assigned to either Choices (n = 38) or the control (n = 39). Choices included three components: an educational interactive video, a low-literacy booklet, and care coordination by patient navigation (i.e., educational and psychosocial support, coordinating appointments, translating, interacting with the medical team). Choices was more effective than the control in improving perceived understanding of clinical trials (p=.033) and increasing consideration of clinical trials as a treatment option (p=.008). Additionally, intervention participants showed significant changes between baseline and post-intervention on agreement with stages of decision readiness statements (p<.002) than control participants (p>.05); the percentage of intervention women in agreement with preparation to action statements increased from 52.8% at baseline to 86.1% at post-intervention, and those in agreement with ready to action stages rose from 50.0% to 88.9%. Computer-based videos and care coordination provided by patient navigation-specifically tailored to Latinos-are effective strategies to successfully address awareness, and improved decision-making skills to make informed decisions about clinical trial participation.
AN  - WOS:000433218200014
AU  - Chalela, P.
AU  - Munoz, E.
AU  - Gallion, K. J.
AU  - Kaklamani, V.
AU  - Ramirez, A. G.
DA  - Jun
DO  - 10.1093/tbm/ibx083
IS  - 3
N1  - SI
29800408
PY  - 2018
SN  - 1869-6716
SP  - 439-449
ST  - Empowering Latina breast cancer patients to make informed decisions about clinical trials: a pilot study
T2  - Translational Behavioral Medicine
TI  - Empowering Latina breast cancer patients to make informed decisions about clinical trials: a pilot study
VL  - 8
ID  - 2857
ER  - 

TY  - JOUR
AB  - The investigator proposes a three‐phase project to improve awareness of use of advance directives, palliative care and hospice services among patients with metastatic cancer by creating and evaluating a multifaceted culturally sensitive intervention that targets specific previously identified barriers to EOL care for AAs, including: knowledge, attitudes, and awareness of options for care, conflict between patients' spiritual beliefs, and the general hospice and palliative medicine philosophy of care, and medical mistrust. Aim 1 will refine and validate the e‐EOL computerized algorithm to identify persons with stage III and IV breast, lung, colorectal, or other serious cancer who are appropriate candidates for discussions about advance care planning, palliative care, and hospice in the outpatient setting. The work in Aim 1 seeks to overcome the upstream barrier that physicians often have difficulty with prognostication and are reluctant to discuss prognosis and EOL care options with patients. Aim 2 will involve continued stakeholder engagement and the conduct of focus groups with oncologists and primary care providers at Parkland Hospital and its affiliated clinics to determine how to make the intervention feasible and acceptable to patients, caregivers, and providers. The investigator also will obtain feedback on our newly developed video and written educational materials that communicate key messages about EOL care options and overcome common barriers. In Aim 3, the investigator will test the preliminary feasibility, acceptability, and efficacy of the intervention that uses the e‐EOL algorithm to identify AA patients with advanced cancer who are eligible for care discussions and then deploy a culturally concordant behavior change intervention that combines a Lay Health Advisor (LHA) and video and written materials. Use of an LHA will help overcome the providers' reluctance or lack of time to discuss EOL care issues and mitigate medical mistrust. The three linked studies provide the necessary sequence of research projects and multidisciplinary learning experiences needed to accomplish the PI's scientific and training goals. It will also lay the groundwork for a fully powered RCT to test the efficacy of a multifaceted EOL care counseling intervention vs. usual care. Details of Research Design and Methods for Aim 1: Refine an e‐EOL algorithm to identify patients with metastatic cancer in the outpatient setting. Aim 1 will expand and validate the e‐EOL algorithm to identify patients with advanced cancer who are appropriate candidates for discussions about EOL care options in the outpatient setting. The e‐EOL algorithm will assist physicians with determining prognosis more accurately and will provide a mechanism for systematically identifying candidates for a subsequent EOL care counseling intervention outlined in Aim 3. Details of Research Design and Methods for Aim 2: The investigator will refine components of a culturally sensitive intervention to improve knowledge of and intent to consider EOL care options. Use of decision aids, educational videos, and LHAs has been shown to be effective in improving medical knowledge and shared decision making and reducing racial disparities for several clinical conditions. Though there have been few applications of these promising approaches to palliative and EOL care, recent use of decision aids in improving knowledge about the goals of care for persons with advanced dementia, have shown promise. Aim 2 will iteratively refine the intervention messages delivered through a combination of novel DVD segments that we have developed, print materials, and guided discussions by a culturally concordant LHA. Through qualitative methods, the team will test the language, framing, and communication strategies for conveying intervention messages and obtain feedback from primary care and oncology providers at Parkland Hospital to verify the appropriateness of these messages as intended by investigators. Details of Research Design and Methods for Aim 3: Assess the feasibility and a ceptability of a multifaceted EOL care behavior change pilot intervention. The pilot intervention will combine the refined elements from Aims 1 and 2, to conduct a small pilot RCT comparing the intervention group to a usual care control group. All of these aims taken together lay the groundwork for a future, fully powered RCT. Description of the Pilot Intervention: The EOL LHA will meet with eligible patients and their caregivers to tell them their doctor approved of them receiving more information about their treatment options. The LHA will then assist the eligible patients and caregivers in watching the EOL care DVD segments (the video modules described in Aim 2 targeted to their pre‐intervention survey needs assessment). After the patients and caregivers watch the DVD, the LHA will answer questions and provide additional information. They will then use counseling scripts created by the PI and research team to probe in more depth the patient's goals of care, and understanding of their clinical condition, prognosis, and treatment options. They will tailor the discussion to the patient's values, preferences, concerns, and clinical circumstances. Those who express interest in hearing more about EOL care options will be encouraged to discuss this with their doctor. The counselor will offer to update their physician on their discussion and help communicate the patient's desire for a palliative care consult or advance directive (if that is something they wanted). Specific questions about prognosis will be referred to the treating physician. Formal palliative care referrals will be ordered and performed in the usual fashion with the exception that the patient may ask the LHA to update the palliative care team on their prior discussions, concerns, and preferences. The LHA will follow up with patients the day after they view the educational video to answer any additional questions and again within one week to assist patients with advance care planning questions and referrals. All intervention sessions will be audiotaped to ensure intervention fidelity. Usual Care: Participants randomized to usual care will proceed with clinical care as already routinely implemented by their physicians. At the time of recruitment, they will be asked to identify their primary caregiver who will also be contacted. Patient‐caregiver pairs who are randomized to usual care will also be asked if they would be willing to be contacted at 1, 3 and 6‐month intervals to complete the post‐study assessment. All participants will be mailed a reminder letter that study staff will be contacting them to participate in follow‐up surveys a couple of weeks prior to the 1‐month surveys. The reminder letter will include an informational brochure that briefly and simply summarizes advance care planning options. Primary Outcomes: Feasibility and acceptability are the main process outcomes. Feasibility is success in accurately identifying eligible patients via the e‐EOL algorithm (number flagged, specificity, positive predictive value), and numbers and rates of patients completing the pilot intervention and follow‐up interviews. Acceptability will be measured with Likert scale items rating "understandability, informativeness, balance, right amount of information, helpfulness, and "recommending this to others" used in published trials of decision aids. The LHA will also ask open‐ended questions on things patients did or did not like about the intervention. The primary decision making outcome is change in intent to discuss EOL care options based on the Transtheoretical Stages of Change Model, an approach used in many other realms. The investigator will categorize patients into the following stages: 1) Pre‐contemplation: is unaware of EOL care options/has not thought about discussing this with a provider; 2) Contemplation: is aware of EOL care options/thinking about discussing options; 3) Preparation: intends to discuss EOL care issues with the doctor/has a plan for talking about it; 4) Action: has a discussion with the provider about EOL care. The comp etion stage is not applicable in this medical situation because the goal of the intervention is for the patient to have an informed discussion about benefits and harms of all treatment options including EOL care. The intent is NOT to get all patients to choose palliative care or hospice, or complete and an advance directive, but for them to understand how palliative care may benefit them now or in the future, and how it can be combined with curative care. The goal is for the patient to make "the right decision for them" based on knowing all of the facts and options. Secondary Outcomes will measure: 1) Knowledge of prognosis and EOL care options: will be measured by a questionnaire from prior NCI‐funded palliative care studies; 2) Decisional conflict will be assessed by the Decisional Conflict Scale, a validated 16 item scale measuring uncertainty about the best course of action and factors contributing to uncertainty. Scores <25 (on this 100‐point scale) are associated with implementing decisions, and scores >38 with decisional delay; 3) Quality of life (QOL): will be assessed with the McGill QOL Questionnaire, a well‐validated 20‐item scale developed to measure QOL at the EOL; 4) Healthcare utilization will include: outpatient visits (incl. palliative care), ED visits, hospitalizations, total hospital days, and use of hospice services (type and time to hospice initiation); 5) Date and place (hospital, hospice, home) of deaths within a 6 month follow‐up period will also be recorded.
AN  - CN-01662091
AU  - Nct
PY  - 2018
ST  - End-of-Life Care for African Americans: an Outpatient Intervention
T2  - https://clinicaltrials.gov/show/NCT03626402
TI  - End-of-Life Care for African Americans: an Outpatient Intervention
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01662091/full
ID  - 1446
ER  - 

TY  - JOUR
AB  - Background/Objective: Patients with metastatic nonsmall cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations benefit from improved survival and quality of life with EGFR-directed therapy. We sought to explore if these improvements in cancer care impacted the delivery of end-of-life (EOL) care in this population. Design: We retrospectively reviewed medical records of patients cared for at our institution with the diagnosis of metastatic EGFR-mutant NSCLC who died by January 2015. Results: Sixty-one patients were included. The majority of patients were female (68%), white or Asian (97%), and never or minimal smokers (76%). Forty-two out of fifty-eight patients (72%) received chemotherapy within 30 days of death. Forty-one out of sixty-one patients (67%) had a hospital admission within 30 days of death. EOL outcomes were known for 53 patients. Of these, 34 (64%) patients enrolled on hospice. The median length of stay on hospice was 6 days (range 0-206). Thirty-three (62%) patients died at home with hospice services or at an inpatient hospice facility. Eighteen patients (34%) died in the hospital. Conclusion: Patients with metastatic NSCLC harboring EGFR mutations had high rates of chemotherapy use and hospital admissions in the last month of life, and many died in the hospital. Hospital admissions near the EOL and short admissions to hospice are indicators of poor quality EOL care and are likely a result of prolonged chemotherapy administration in this population. Thus, current healthcare delivery models may be insufficient to provide comprehensive EOL care for patients with EGFR mutations.
AD  - Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Massachusetts General Hospital Cancer Center, Boston, Massachusetts.
AN  - 119806384. Language: English. Entry Date: 20161206. Revision Date: 20190513. Publication Type: Article
AU  - Bauman, Jessica R.
AU  - Piotrowska, Zofia
AU  - Muzikansky, Alona
AU  - Gallagher, Emily
AU  - Scribner, Emily
AU  - Temel, Brandon
AU  - Sequist, Lecia V.
AU  - Heist, Rebecca S.
AU  - Temel, Jennifer S.
DB  - CINAHL Complete
DO  - 10.1089/jpm.2016.0180
DP  - EBSCOhost
IS  - 12
KW  - Terminally Ill Patients
Lung Neoplasms -- Diagnosis
Neoplasm Metastasis
Epidermal Growth Factors -- Physiology
Mutation
Human
Carcinoma, Non-Small-Cell Lung -- Mortality
Cancer Patients -- Evaluation
Survival
Patient Selection
Male
Female
Race Factors
Ethnic Groups
White Persons
Asians
Chemotherapy, Cancer
Patient Admission
Death -- Evaluation
Hospice Care
Length of Stay
Health Care Delivery
Quality of Health Care -- Evaluation
Retrospective Design
Record Review
Descriptive Statistics
Data Analysis Software
Black Persons
Smoking -- Evaluation
N1  - research; tables/charts. Journal Subset: Biomedical; Peer Reviewed; USA. NLM UID: 9808462.
PY  - 2016
SN  - 1096-6218
SP  - 1316-1319
ST  - End-of-Life Care in Patients with Metastatic Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations
T2  - Journal of Palliative Medicine
TI  - End-of-Life Care in Patients with Metastatic Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=119806384&site=ehost-live&scope=site
VL  - 19
ID  - 1937
ER  - 

TY  - JOUR
AB  - BACKGROUND: Diets high in fat have been proposed as one cause of obesity, primarily because fat is more energy-dense than other macronutrients. However, the literature on fat consumption and human obesity is inconclusive. This research examines associations between dietary fat intake and obesity in men participating in the Prostate Cancer Prevention Trial. METHODS: Data in this cross-sectional study are from 15,266 men (55-79 years) who completed questionnaires on usual diet, physical activity, and health-related characteristics. Height and weight were collected by clinic personnel. Obesity was defined as body mass index (BMI) greater than or equal to 30 kg/m2. RESULTS: In this healthy cohort, 23.3% were obese. Younger age, a sedentary lifestyle, lower education, and black race were positively associated with obesity (all P < 0.001). Using two statistical approaches, both total energy and energy from fat, but not total energy from other macronutrients, increased linearly and significantly with increasing BMI. Mean fat intake increased from 691 kcal (31.4% energy) among normal-BMI men to 797 kcal (34.3% energy) among the obese (P for trend <0.001). After controlling for demographic and health-related characteristics in regression models, BMI increased by 0.53 and 0.14 kg/m(2) for every 500 kcal of fat and total energy consumed, respectively. Energy underreporting, based on estimated basal metabolic rate and physical activity, was fourfold higher among obese compared to normal-weight men. CONCLUSIONS: In this large cohort of healthy older men, energy from fat was associated with obesity, suggesting that high-fat dietary patterns are contributing to the high rates of obesity in U.S. men.
AD  - Fred Hutchinson Cancer Research Center, Cancer Prevention Research Program, 1100 Fairview Avenue N., MP-702, Seattle, Washington, 98109, USA. jabouta@unc.edu
AN  - 11969348
AU  - Satia-Abouta, J.
AU  - Patterson, R. E.
AU  - Schiller, R. N.
AU  - Kristal, A. R.
DA  - May
DO  - 10.1006/pmed.2002.1018
DP  - NLM
ET  - 2002/04/24
IS  - 5
KW  - Aged
*Body Mass Index
Clinical Trials as Topic
Cohort Studies
Cross-Sectional Studies
Data Collection
Diet
Dietary Fats/*administration & dosage
Energy Intake/*physiology
Exercise
Humans
Male
Middle Aged
*Obesity/metabolism
Prostatic Neoplasms/*prevention & control
Smoking
LA  - eng
N1  - Satia-Abouta, Jessie
Patterson, Ruth E
Schiller, Rebecca N
Kristal, Alan R
5 R01 CA63164/CA/NCI NIH HHS/United States
5 U10 CA37429/CA/NCI NIH HHS/United States
Journal Article
Research Support, U.S. Gov't, P.H.S.
United States
Prev Med. 2002 May;34(5):493-501. doi: 10.1006/pmed.2002.1018.
PY  - 2002
SN  - 0091-7435 (Print)
0091-7435
SP  - 493-501
ST  - Energy from fat is associated with obesity in U.S. men: results from the Prostate Cancer Prevention Trial
T2  - Prev Med
TI  - Energy from fat is associated with obesity in U.S. men: results from the Prostate Cancer Prevention Trial
VL  - 34
ID  - 671
ER  - 

TY  - JOUR
AB  - INTRODUCTION: Younger breast cancer survivors often lead extremely busy lives with multiple demands and responsibilities, making them difficult to recruit into clinical trials. African American women are even more difficult to recruit because of additional historical and cultural barriers. In a randomized clinical trial of an intervention, we successfully used culturally informed, population-specific recruitment and retention strategies to engage younger African-American breast cancer survivors. METHODS: Caucasian and African American breast cancer survivors were recruited from multiple communities and sites. A variety of planned recruitment and retention strategies addressed cultural and population-specific barriers and were guided by three key principals: increasing familiarity with the study in the communities of interest; increasing the availability and accessibility of study information and study participation; and using cultural brokers. RESULTS: Accrual of younger African-American breast cancer survivors increased by 373% in 11 months. The steepest rise in the numbers of African-American women recruited came when all strategies were in place and operating simultaneously. Retention rates were 87% for both Caucasian and African American women. DISCUSSSION/CONCLUSIONS: To successfully recruit busy, younger African American cancer survivors, it is important to use a multifaceted approach, addressing cultural and racial/ethnic barriers to research participation; bridging gaps across cultures and communities; including the role of faith and beliefs in considering research participation; recognizing the demands of different life stages and economic situations and the place of research in the larger picture of peoples' lives. Designs for recruitment and retention need to be broadly conceptualized and specifically applied. IMPLICATIONS FOR CANCER SURVIVORS: For busy cancer survivors, willingness to participate in and complete research participation is enhanced by strategies that address barriers but also acknowledge the many demands on their time by making research familiar, available, accessible and credible.
AD  - School of Nursing, University of North Carolina at Chapel Hill, CB# 7460, Chapel Hill, NC 27599, USA. germino@email.unc.edu
AN  - 20886374
AU  - Germino, B. B.
AU  - Mishel, M. H.
AU  - Alexander, G. R.
AU  - Jenerette, C.
AU  - Blyler, D.
AU  - Baker, C.
AU  - Vines, A. I.
AU  - Green, M.
AU  - Long, D. G.
C2  - PMC3041858
C6  - NIHMS255249
DA  - Mar
DO  - 10.1007/s11764-010-0150-x
DP  - NLM
ET  - 2010/10/05
IS  - 1
KW  - African Americans/*psychology/statistics & numerical data
Breast Neoplasms/ethnology/psychology/rehabilitation/*therapy
Carcinoma/ethnology/psychology/rehabilitation/*therapy
Communication Barriers
Counseling/methods
*Culture
Fear/physiology
Female
Health Services Accessibility
Humans
Patient Acceptance of Health Care/psychology/statistics & numerical data
*Patient Selection
Psychotherapy/methods
*Randomized Controlled Trials as Topic/psychology
Recurrence
Residence Characteristics
*Survivors/psychology
LA  - eng
N1  - 1932-2267
Germino, Barbara B
Mishel, Merle H
Alexander, G Rumay
Jenerette, Coretta
Blyler, Diane
Baker, Carol
Vines, Anissa I
Green, Melissa
Long, Debra G
R01 NR010190/NR/NINR NIH HHS/United States
R01 NR010190-09/NR/NINR NIH HHS/United States
U01 CA114629/CA/NCI NIH HHS/United States
Evaluation Study
Journal Article
J Cancer Surviv. 2011 Mar;5(1):82-91. doi: 10.1007/s11764-010-0150-x. Epub 2010 Oct 1.
PY  - 2011
SN  - 1932-2259 (Print)
1932-2259
SP  - 82-91
ST  - Engaging African American breast cancer survivors in an intervention trial: culture, responsiveness and community
T2  - J Cancer Surviv
TI  - Engaging African American breast cancer survivors in an intervention trial: culture, responsiveness and community
VL  - 5
ID  - 412
ER  - 

TY  - JOUR
AB  - BACKGROUND: African American men (AAM) are under-represented in prostate cancer (PCa) research despite known disparities. Screening with prostate-specific antigen (PSA) has low specificity for high-grade PCa leading to PCa over diagnosis. The Prostate Health Index (PHI) has higher specificity for lethal PCa but needs validation in AAM. Engaging AAM as citizen scientists (CSs) may improve participation of AAM in PCa research.Results and Lessons Learned: Eight CSs completed all training modules and 139 AAM were recruited. Challenges included equity in research leadership among multiple principal investigators (PIs) and coordinating CSs trainings. CONCLUSIONS: Engaging AAM CSs can support engaging/recruiting AAM in PCa biomarker validation research. Equity among multiple stakeholders can be challenging, but proves beneficial in engaging AAM in research. OBJECTIVES: Assess feasibility of mobilizing CSs to recruit AAM as controls for PHI PCa validation biomarker study. METHODS: We highlight social networks/assets of stakeholders, CSs curriculum development/implementation, and recruitment of healthy controls for PHI validation.
AN  - 31378740
AU  - Watson, K. S.
AU  - Henderson, V.
AU  - Murray, M.
AU  - Murphy, A. B.
AU  - Levi, J. B.
AU  - McDowell, T.
AU  - Holloway-Beth, A.
AU  - Gogana, P.
AU  - Dixon, M. A.
AU  - Moore, L.
AU  - Hall, I.
AU  - Kimbrough, A.
AU  - Molina, Y.
AU  - Winn, R. A.
C2  - PMC6693518
C6  - NIHMS1045039
DO  - 10.1353/cpr.2019.0043
DP  - NLM
ET  - 2019/08/06
IS  - 5
KW  - Adult
*African Americans
Age Factors
Community Participation
Community-Based Participatory Research/*organization & administration
Early Detection of Cancer/*methods
Humans
Male
Middle Aged
Motivation
*Patient Selection
Prostate-Specific Antigen/blood
Prostatic Neoplasms/*diagnosis
Social Networking
Socioeconomic Factors
LA  - eng
N1  - 1557-055x
Watson, Karriem S
Henderson, Vida
Murray, Marcus
Murphy, Adam B
Levi, Josef Ben
McDowell, Tiffany
Holloway-Beth, Alfreda
Gogana, Pooja
Dixon, Michael A
Moore, LeAndre
Hall, Ivanhoe
Kimbrough, Alexander
Molina, Yamilé
Winn, Robert A
U54 MD012523/MD/NIMHD NIH HHS/United States
U54 CA202995/CA/NCI NIH HHS/United States
U54 CA202997/CA/NCI NIH HHS/United States
P20 CA202908/CA/NCI NIH HHS/United States
U54 CA203000/CA/NCI NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Prog Community Health Partnersh. 2019;13(5):103-112. doi: 10.1353/cpr.2019.0043.
PY  - 2019
SN  - 1557-0541 (Print)
1557-0541
SP  - 103-112
ST  - Engaging African American Men as Citizen Scientists to Validate a Prostate Cancer Biomarker: Work-in-Progress
T2  - Prog Community Health Partnersh
TI  - Engaging African American Men as Citizen Scientists to Validate a Prostate Cancer Biomarker: Work-in-Progress
VL  - 13
ID  - 69
ER  - 

TY  - JOUR
AB  - PURPOSE: The purpose of this study was to enhance adherence among older (aged 55 years and older) African American men enrolled in a cancer screening trial for prostate, lung, and colorectal cancer. For this study, we defined adherence as completing the trial screenings. DESIGN AND METHODS: We used a randomized trial design. Case managers contacted intervention group participants (n=352) at least monthly by telephone and provided information and referral services. The control group included 351 participants. RESULTS: Among participants with low income, those in the intervention group had higher screening adherence rates than did participants in the control group for (a) prostate-specific antigen test for prostate cancer (74.3% vs 53.0%, p=.001), (b) digital rectal exam for prostate cancer (66.2% vs 46.1%, p=.011), and (c) chest x-ray for lung cancer (70.9% vs 51.3%, p=.012). We found no statistically significant differences in adherence rates for flexible sigmoidoscopy screening for colorectal cancer. In contrast, among participants with moderate-to-high income, we found no statistically significant differences in adherence rates between intervention and control group participants for any of the screening tests. IMPLICATIONS: The case management intervention was effective in enhancing adherence among participants with the lowest income, who in many studies are the most difficult to retain.
AD  - Department of Biostatistics, Bioinformatics, and Epidemiology, Medical University of South Carolina, 135 Cannon Street, Suite 303, P.O. Box 250835, Charleston, SC 29425, USA. fordmar@musc.edu
AN  - 16921009
AU  - Ford, M. E.
AU  - Havstad, S.
AU  - Vernon, S. W.
AU  - Davis, S. D.
AU  - Kroll, D.
AU  - Lamerato, L.
AU  - Swanson, G. M.
DA  - Aug
DO  - 10.1093/geront/46.4.545
DP  - NLM
ET  - 2006/08/22
IS  - 4
KW  - *African Americans
Aged
Aged, 80 and over
*Case Management
*Clinical Trials as Topic
Culture
Humans
Male
*Mass Screening
Middle Aged
Neoplasms/*prevention & control
Patient Compliance/*psychology
Patient Dropouts/*psychology
*Patient Selection
Poverty
Social Support
Social Work
Telephone
LA  - eng
N1  - Ford, Marvella E
Havstad, Suzanne
Vernon, Sally W
Davis, Shawna D
Kroll, David
Lamerato, Lois
Swanson, G Marie
1 P30 AG 21677/AG/NIA NIH HHS/United States
N01-CN-25512/CN/NCI NIH HHS/United States
R24 RFA-MD-04-002/MD/NIMHD NIH HHS/United States
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, U.S. Gov't, P.H.S.
United States
Gerontologist. 2006 Aug;46(4):545-50. doi: 10.1093/geront/46.4.545.
PY  - 2006
SN  - 0016-9013 (Print)
0016-9013
SP  - 545-50
ST  - Enhancing adherence among older African American men enrolled in a longitudinal cancer screening trial
T2  - Gerontologist
TI  - Enhancing adherence among older African American men enrolled in a longitudinal cancer screening trial
VL  - 46
ID  - 555
ER  - 

TY  - JOUR
AB  - Background: We describe the expansion of the Atherosclerosis Risk in Communities (ARIC) Study into a cancer cohort. In 1987 to 1989, ARIC recruited 15,792 participants 45 to 64 years old to be sex (55% female), race (27% black), and geographically diverse. ARIC has exceptional data collected during 6 clinical visits and calls every 6 months, repeated biospecimens, and linkage to Medicare claims data. Methods: We established a Cancer Coordinating Center to implement infrastructure activities, convened a Working Group for data use, leveraged ARIC staff and procedures, and developed protocols. We initiated a cancer-specific participant contact, added questions to existing contacts, obtained permission to collect medical records and tissue, abstracted records, linked with state cancer registries, and adjudicated cases and characterizing data. Results: Through 2012, we ascertained and characterized 4,743 incident invasive, first, and subsequent primary cancers among 4,107 participants and 1,660 cancer-related deaths. We generated a total cancer incidence and mortality analytic case file, and analytic case files for bladder, breast, colorectal, liver, lung, pancreas, and prostate cancer incidence, mortality, and case fatality. Adjudication of multiple data sources improved case records and identified cancers not identified via registries. From 2013 onward, we ascertain cases from self-report coupled with medical records. Additional cancer registry linkages are planned. Conclusions: Compared with starting a new cohort, expanding a cardiovascular cohort into ARIC Cancer was an efficient strategy. Our efforts yielded enhanced case files with 25 years of follow-up. Impact: Now that the cancer infrastructure is established, ARIC is contributing its unique features to modern cancer epidemiology research. © 2017 American Association for Cancer Research.
AD  - Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 615 N. Wolfe Street, Rm. E6148, Baltimore, MD 21205, United States
Department of Oncology, Johns Hopkins University, School of Medicine, Baltimore, MD, United States
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, United States
Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins University, Baltimore, MD, United States
Department of Biostatistics, University of North Carolina at Chapel Hill, School of Global Public Health, Chapel Hill, NC, United States
Division of Geriatrics, University of Mississippi Medical Center, Jackson, MI, United States
Division of Neurology, University of Mississippi Medical Center, Jackson, MI, United States
Department of Epidemiology and Prevention, Wake Forest School of Medicine, Winston-Salem, NC, United States
Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, MN, United States
Department of Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, NC, United States
James Buchanan Brady Urological Institute, Johns Hopkins University, School of Medicine, Baltimore, MD, United States
AU  - Joshu, C. E.
AU  - Barber, J. R.
AU  - Coresh, J.
AU  - Couper, D. J.
AU  - Mosley, T. H.
AU  - Vitolins, M. Z.
AU  - Butler, K. R.
AU  - Nelson, H. H.
AU  - Prizment, A. E.
AU  - Selvin, E.
AU  - Tooze, J. A.
AU  - Visvanathan, K.
AU  - Folsom, A. R.
AU  - Platz, E. A.
DB  - Scopus
DO  - 10.1158/1055-9965.EPI-17-0696
IS  - 3
M3  - Article
N1  - Cited By :14
Export Date: 22 March 2021
PY  - 2018
SP  - 295-305
ST  - Enhancing the infrastructure of the atherosclerosis risk in Communities (ARIC) study for cancer epidemiology research: Aric cancer
T2  - Cancer Epidemiology Biomarkers and Prevention
TI  - Enhancing the infrastructure of the atherosclerosis risk in Communities (ARIC) study for cancer epidemiology research: Aric cancer
UR  - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85045505535&doi=10.1158%2f1055-9965.EPI-17-0696&partnerID=40&md5=52b57dcfac6d60680b6dd6339fe59d51
VL  - 27
ID  - 2283
ER  - 

TY  - JOUR
AB  - Research suggests that community involvement is integral to solving public health problems, including involvement in clinical trials - a gold standard. Significant racial/ethnic disparities exist in the accrual of participants for clinical trials. Location and cultural aspects of clinical trials influence recruitment and accrual to clinical trials. It is increasingly necessary to be aware of defining characteristics, such as location and culture of the populations from which research participants are enrolled. Little research has examined the effect of location and cultural competency in adapting clinical trial research for minority and underserved communities on accrual for clinical trials. Utilizing embedded community academic sites, the authors applied cultural competency frameworks to adapt clinical trial research in order to increase minority participation in nontherapeutic cancer clinical trials. This strategy resulted in successful accrual of participants to new clinical research trials, specifically targeting participation from minority and underserved communities in metropolitan Washington, DC. From 2012 to 2014, a total of 559 participants enrolled across six nontherapeutic clinical trials, representing a 62% increase in the enrollment of blacks in clinical research. Embedding cancer prevention programs and research in the community was shown to be yet another important strategy in the arsenal of approaches that can potentially enhance clinical research enrollment and capacity. The analyses showed that the capacity to acquire cultural knowledge about patients - their physical locales, cultural values, and environments in which they live - is essential to recruiting culturally and ethnically diverse population samples.
AD  - S.F. Wallington, GeorgetownLombardi Comprehensive Cancer Center, Research Building, E501, 3970 Reservoir Road, N.W., Washington, DC, United States
AU  - Wallington, S. F.
AU  - Dash, C.
AU  - Sheppard, V. B.
AU  - Goode, T. D.
AU  - Oppong, B. A.
AU  - Dodson, E. E.
AU  - Hamilton, R. N.
AU  - Adams-Campbell, L. L.
DB  - Embase
Medline
DO  - 10.1016/j.amepre.2015.07.036
IS  - 1
KW  - African American
article
breast cancer
cancer prevention
cancer research
clinical research
cultural competence
cultural value
environmental factor
gold standard
human
knowledge
minority group
population
public health problem
smoking cessation
LA  - English
M3  - Article
N1  - L607379444
2015-12-30
2016-01-11
PY  - 2016
SN  - 1873-2607
0749-3797
SP  - 111-117
ST  - Enrolling Minority and Underserved Populations in Cancer Clinical Research
T2  - American Journal of Preventive Medicine
TI  - Enrolling Minority and Underserved Populations in Cancer Clinical Research
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L607379444&from=export
http://dx.doi.org/10.1016/j.amepre.2015.07.036
VL  - 50
ID  - 985
ER  - 

TY  - JOUR
AB  - PURPOSE: To determine the effect of patient, protocol, geographic, and institutional factors on enrollment of older persons onto cancer trials. METHODS: We conducted a cross-sectional analysis of patients enrolled onto National Cancer Institute-sponsored lung, breast, colorectal, and prostate cancer trials during 1996 to 2002. We used a cross-classified logistic multilevel model to examine the associations between patient, hospital, county, and protocol characteristics, and the likelihood of participants being elderly (>or= 65 years old). RESULTS: The final study sample consisted of 36,167 patients enrolled onto 33 trials. After accounting for cancer type, only 6% of the variation in elderly enrollment onto cancer trials was at the protocol level. In contrast, more than 55% of the variation in elderly enrollment was attributable to patient level variation. In multivariate analysis, nonwhite patients were significantly less likely to be elderly than whites (odds ratio [OR] for blacks, 0.51; 95% CI, 0.44 to 0.58; and OR for Hispanics, 0.49; 95% CI, 0.40 to 0.59 v whites). Participants living less than 7 miles from their recruitment center were significantly more likely to be elderly (OR, 1.31; 95% CI, 1.24 to 1.38). Among the 910 recruitment centers, the median adjusted proportion of patients who were elderly was 24.9% (interquartile range, 24.0% to 26.9%). There were a significantly higher number of outlier centers (<or= 20.8% or >or= 29.3% elderly) than would be expected by a normal distribution (68 observed v six expected; P < .0001). CONCLUSION: Race and proximity to trial enrollment centers were significantly related to age of trial participants after adjusting for protocol factors. Additional work should explore why some recruitment centers were outliers regarding enrollment of older persons.
AD  - Section of General Internal Medicine, Yale University School of Medicine, New Haven, CT 06520, USA. cary.gross@yale.edu
AN  - 16034051
AU  - Gross, C. P.
AU  - Herrin, J.
AU  - Wong, N.
AU  - Krumholz, H. M.
DA  - Jul 20
DO  - 10.1200/jco.2005.14.365
DP  - NLM
ET  - 2005/07/22
IS  - 21
KW  - African Continental Ancestry Group
Aged/*psychology
*Clinical Trials as Topic/methods
Cross-Sectional Studies
European Continental Ancestry Group
Hispanic Americans
Humans
Logistic Models
Multivariate Analysis
Neoplasms/therapy
Odds Ratio
Patient Selection
Residence Characteristics
United States
LA  - eng
N1  - Gross, Cary P
Herrin, Jeph
Wong, Natalie
Krumholz, Harlan M
1 K08 AG24842/AG/NIA NIH HHS/United States
1K07CA-90402/CA/NCI NIH HHS/United States
P30AG21342/AG/NIA NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.
United States
J Clin Oncol. 2005 Jul 20;23(21):4755-63. doi: 10.1200/JCO.2005.14.365.
PY  - 2005
SN  - 0732-183X (Print)
0732-183x
SP  - 4755-63
ST  - Enrolling older persons in cancer trials: the effect of sociodemographic, protocol, and recruitment center characteristics
T2  - J Clin Oncol
TI  - Enrolling older persons in cancer trials: the effect of sociodemographic, protocol, and recruitment center characteristics
VL  - 23
ID  - 595
ER  - 

TY  - JOUR
AB  - PURPOSE: Racial/ethnic minorities are often assumed to be less willing to participate in and provide biospecimens for biomedical research. We examined racial/ethnic differences in enrollment of women with breast cancer (probands) and their first-degree relatives in the Northern California site of the Breast Cancer Family Registry from 1996 to 2011. METHODS: We evaluated participation in several study components, including biospecimen collection, for probands and relatives by race/ethnicity, cancer history, and other factors. RESULTS: Of 4,780 eligible probands, 76% enrolled in the family registry by completing the family history and risk factor questionnaires and 68% also provided a blood or mouthwash sample. Enrollment was highest (81%) for non-Hispanic whites (NHWs) and intermediate (73-76%) for Hispanics, African Americans, and all Asian American subgroups, except Filipina women (66%). Of 4,279 eligible relatives, 77% enrolled in the family registry, and 65% also provided a biospecimen sample. Enrollment was highest for NHWs (87%) and lowest for Chinese (68%) and Filipinas (67%). Among those enrolled, biospecimen collection rates were similar for NHW, Hispanic, and African American women, both for probands (92-95%) and relatives (82-87%), but lower for some Asian-American subgroups (probands: 72-88%; relatives: 71-88%), foreign-born Asian Americans, and probands those who were more recent immigrants or had low English language proficiency. CONCLUSIONS: These results show that racial/ethnic minority populations are willing to provide biospecimen samples for research, although some Asian American subgroups in particular may need more directed recruitment methods. To address long-standing and well-documented cancer health disparities, minority populations need equal opportunities to contribute to biomedical research.
AD  - Cancer Prevention Institute of California, Fremont, CA, 94358, USA. emjohn@stanford.edu.
Department of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, CA, 94304, USA. emjohn@stanford.edu.
Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, 94304, USA. emjohn@stanford.edu.
Stanford Cancer Institute, 780 Welch Road, Suite CJ250C, Stanford, CA, 94304-5769, USA. emjohn@stanford.edu.
Cancer Prevention Institute of California, Fremont, CA, 94358, USA.
Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, 94304, USA.
Department of Health Research and Policy, Stanford University of School of Medicine, Stanford, CA, 94305, USA.
Department of Biomedical Data Science, Stanford University of School of Medicine, 94305, Stanford, CA, USA.
AN  - 30835011
AU  - John, E. M.
AU  - Sangaramoorthy, M.
AU  - Koo, J.
AU  - Whittemore, A. S.
AU  - West, D. W.
C2  - PMC6548459
C6  - NIHMS1523191
DA  - Apr
DO  - 10.1007/s10552-019-01154-6
DP  - NLM
ET  - 2019/03/06
IS  - 4
KW  - Adolescent
Adult
African Americans/statistics & numerical data
Asian Americans/statistics & numerical data
Breast Neoplasms/*epidemiology/ethnology
California/epidemiology
Continental Population Groups/*statistics & numerical data
European Continental Ancestry Group/statistics & numerical data
Female
Hispanic Americans/statistics & numerical data
Humans
Middle Aged
Registries
Risk Factors
Young Adult
African Americans
Asian Americans
Biospecimen collection
Breast cancer
Epidemiology
Hispanics
Race/ethnicity
Study participation
LA  - eng
N1  - 1573-7225
John, Esther M
Orcid: 0000-0003-3259-8003
Sangaramoorthy, Meera
Koo, Jocelyn
Whittemore, Alice S
West, Dee W
HHSN261201000036C/CA/NCI NIH HHS/United States
U58 DP000807/DP/NCCDPHP CDC HHS/United States
UM1 CA164920/CA/NCI NIH HHS/United States
UM1 CA164920/Division of Cancer Epidemiology and Genetics, National Cancer Institute/
Journal Article
Cancer Causes Control. 2019 Apr;30(4):395-408. doi: 10.1007/s10552-019-01154-6. Epub 2019 Mar 5.
PY  - 2019
SN  - 0957-5243 (Print)
0957-5243
SP  - 395-408
ST  - Enrollment and biospecimen collection in a multiethnic family cohort: the Northern California site of the Breast Cancer Family Registry
T2  - Cancer Causes Control
TI  - Enrollment and biospecimen collection in a multiethnic family cohort: the Northern California site of the Breast Cancer Family Registry
VL  - 30
ID  - 80
ER  - 

TY  - JOUR
AB  - 6633 Background: Enrollment of cancer patients (pt) in clinical trials is considered essential in order to improve cancer care. However, cancer clinical trials participation remains low. Understanding barriers to pt enrollment is necessary to overcome this problem. Previous reports have identified pt age, race, and ethnicity, disease stage, performance status (PS) and relationship with their health care provider as factors that can influence the enrollment of pts in clinical trials.Methods: We conducted a retrospective review of the charts of all lung cancer pts seen in the Thoracic Oncology Clinic at Vanderbilt Ingram Cancer Center between November 2005 and November 2008. A total of 1075 lung cancer pts were seen.Results: 577 charts (of a planned 1075) have been audited to date. Pt demographics: median age = 64 yrs; male = 54%; Caucasian = 92%, African American = 4%, and Asian = 1%; NSCLC = 80%, SCLC = 17%. Male pts were more likely than females to be eligible for a clinical trial (p = 0.056). A study protocol was available for 57% of pts; 52% of pts proved eligible; 36% were entered into a study (11% total population). Significantly more protocols were available for NSCLC pts compared to pts with SCLC (p ≤ 0.001); there was also a non-significant trend towards higher enrollment of eligible NSCLC pts. There was no difference in eligibility between ethnicity; the percentage of eligible pts enrolling on trials was similar between Caucasian & African American pts (46% and 43%); no Asian pts were enrolled. The most common reasons for not enrolling included a preference for treatment closer to home (29%), patient refusal (19%), PS (19%), and co-morbidities (17%). The distance pts traveled was inversely correlated with likelihood of study participation.Conclusions: A total of 11% of lung cancer pt evaluated in our Thoracic Oncology Clinic were enrolled in clinical trials. Our data suggest additional strategies are needed to attract minority groups, increase enrollment of women and pts with comorbidities and poor PS. Travel distances influence pt willingness to participate in clinical trials. Strategies are needed to overcome this factor. No significant financial relationships to disclose.
AD  - Vanderbilt-Ingram Cancer Center, Nashville, TN
AN  - 120350353. Language: English. Entry Date: In Process. Revision Date: 20161223. Publication Type: journal article. Supplement Title: 5/21/2009 Supplement Part 1 of 2. Journal Subset: Biomedical
AU  - Keedy, V. L.
AU  - Horn, L.
AU  - Hayes, A.
AU  - Spencer, B.
AU  - Garcia, G.
AU  - Campbell, N.
AU  - Sandler, A.
AU  - Carbone, D.
AU  - Johnson, D. H.
DB  - CINAHL Complete
DP  - EBSCOhost
N1  - Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA. NLM UID: 8309333.
PMID: NLM27961814.
PY  - 2009
SN  - 0732-183X
SP  - 6633-6633
ST  - Enrollment of lung cancer patients on clinical trials at an NCI comprehensive cancer center
T2  - Journal of Clinical Oncology
TI  - Enrollment of lung cancer patients on clinical trials at an NCI comprehensive cancer center
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=120350353&site=ehost-live&scope=site
VL  - 27
ID  - 1941
ER  - 

TY  - JOUR
AB  - BACKGROUND: Minority populations in the United States, especially blacks and Hispanics, are generally underrepresented among participants in clinical trials. Here, we report the experience of enrolling ethnic minorities in a large cancer screening trial. METHODS: The Prostate, Colorectal, Lung and Ovarian (PLCO) Cancer Screening Trial is a multicenter randomized trial designed to evaluate the effectiveness of screening for the PLCO cancers. Subjects were recruited at 10 U.S. centers between 1993 and 2001. One screening center had a major special recruitment effort for blacks and another center had a major special recruitment effort for Hispanics. RESULTS: Among almost 155,000 subjects enrolled in PLCO, minority enrollment was as follows: black (5.0%), Hispanic (1.8%) and Asian (3.6%). This compares to an age-eligible population in the combined catchment areas of the PLCO centers that was 14.0% black, 2.9% Hispanic and 5.4% Asian, and an age-eligible population across the U.S. that was 9.5% black, 6.5% Hispanic and 3.0% Asian. About half (45%) of Hispanics were recruited at the center with the special Hispanic recruitment effort. Seventy percent of blacks were recruited at two centers; the one with the major special recruitment effort and a center in Detroit whose catchment area was 20% black among age-eligibles. Blacks, Hispanics and (non-Hispanic) whites were all more highly educated, less likely to currently smoke and more likely to get regular exercise than their counterparts in the general population. CONCLUSION: Significant efforts were made to recruit racial/ ethnic minorities into PLCO, and these efforts resulted in enrollment levels that were comparable to those seen in many recent cancer screening or prevention trials. Blacks and Hispanics were nonetheless underrepresented in PLCO compared to their levels among age-eligibles in the overall U.S. population or in the aggregate PLCO catchment areas.
AD  - Division of Cancer Prevention, National Cancer Institute, Bethesda, MD 20892, USA. pp4f@nih.gov
AN  - 18390022
AU  - Pinsky, P. F.
AU  - Ford, M.
AU  - Gamito, E.
AU  - Higgins, D.
AU  - Jenkins, V.
AU  - Lamerato, L.
AU  - Tenorio, S.
AU  - Marcus, P. M.
AU  - Gohagan, J. K.
DA  - Mar
DO  - 10.1016/s0027-9684(15)31241-4
DP  - NLM
ET  - 2008/04/09
IS  - 3
KW  - African Americans/statistics & numerical data
Aged
Asian Americans/statistics & numerical data
Attitude to Health
Colorectal Neoplasms/*diagnosis/epidemiology
Ethnic Groups/*statistics & numerical data
European Continental Ancestry Group/statistics & numerical data
Female
Hispanic Americans/statistics & numerical data
Humans
Lung Neoplasms/*diagnosis/epidemiology
Male
*Mass Screening
Middle Aged
Minority Health
Ovarian Neoplasms/*diagnosis/epidemiology
Patient Acceptance of Health Care
Patient Satisfaction
*Patient Selection
Prostatic Neoplasms/*diagnosis/epidemiology
United States/epidemiology
LA  - eng
N1  - Pinsky, Paul F
Ford, Marvella
Gamito, Eduard
Higgins, Darlene
Jenkins, Victoria
Lamerato, Lois
Tenorio, Sally
Marcus, Pamela M
Gohagan, John K
Clinical Trial
Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial
United States
J Natl Med Assoc. 2008 Mar;100(3):291-8. doi: 10.1016/s0027-9684(15)31241-4.
PY  - 2008
SN  - 0027-9684 (Print)
0027-9684
SP  - 291-8
ST  - Enrollment of racial and ethnic minorities in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial
T2  - J Natl Med Assoc
TI  - Enrollment of racial and ethnic minorities in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial
VL  - 100
ID  - 501
ER  - 

TY  - JOUR
AB  - Minority U.S. populations are underrepresented in cancer clinical trials. This review appraises the impact of the disparity in clinical trial participation by minority patients in the current era of cancer immunotherapy. Enrollment on pivotal trials leading to U.S. regulatory approval of immune checkpoint inhibitors showed poor representation of minority ethnic groups. Specifically, we found that black patients constitute less than 4% of all patients enrolled across multiple trials that supported the approval of immune checkpoint inhibitors for the treatment of lung cancer. Similar underrepresentation was observed for trials conducted in renal cell carcinoma and other tumor types. Since efficacy of immunotherapy is only observed in a subset of patients, the use of predictive biomarkers to identify responders along with new strategies to expand the benefit to a larger subset of patients are current areas of active investigation. The inadequate representation of minority patients on immunotherapy clinical trials could perpetuate outcome disparity because the unique biology of the host and the tumors from this subpopulation is not accounted for as new treatment algorithms to guide optimal use of immunotherapy are developed for use in the real world.
AD  - 1 Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA.
2 Department of Biology, Alabama State University, Montgomery, AL.
AN  - 31099618
AU  - Nazha, B.
AU  - Mishra, M.
AU  - Pentz, R.
AU  - Owonikoko, T. K.
DA  - Jan
DO  - 10.1200/edbk_100021
DP  - NLM
ET  - 2019/05/18
KW  - *Clinical Trials as Topic
Health Care Surveys
Humans
Immunotherapy
*Minority Groups
Neoplasms/diagnosis/epidemiology/therapy
Patient Participation
*Patient Selection
United States/epidemiology
LA  - eng
N1  - 1548-8756
Nazha, Bassel
Mishra, Manoj
Pentz, Rebecca
Owonikoko, Taofeek K
Journal Article
Review
United States
Am Soc Clin Oncol Educ Book. 2019 Jan;39:3-10. doi: 10.1200/EDBK_100021. Epub 2019 May 17.
PY  - 2019
SN  - 1548-8748
SP  - 3-10
ST  - Enrollment of Racial Minorities in Clinical Trials: Old Problem Assumes New Urgency in the Age of Immunotherapy
T2  - Am Soc Clin Oncol Educ Book
TI  - Enrollment of Racial Minorities in Clinical Trials: Old Problem Assumes New Urgency in the Age of Immunotherapy
VL  - 39
ID  - 74
ER  - 

TY  - JOUR
AB  - Purpose Under-representation of elderly, women, and racial/ethnic minority patients with cancer in clinical trials is of national concern. The goal of this study was to characterize enrollment trends and disparities by age, sex, and race/ethnicity in lung cancer trials. Methods We analyzed data for 23,006 National Cancer Institute cooperative group lung cancer trial participants and 578,476 patients with lung cancer from the SEER registry from 1990 to 2012. The enrollment disparity difference (EDD) and enrollment disparity ratio (EDR) were calculated on the basis of the proportion of each subgroup in the trial population and the US lung cancer population. Annual percentage changes (APCs) in the subgroup proportions in each population were compared over time. Results Enrollment disparity for patients ≥ 70 years of age with non-small-cell lung cancer improved from 1990 to 2012 (test of parallelism, P = .020), with a remaining EDD of 0.22 (95% CI, 0.19 to 0.25) and EDR of 1.65 (95% CI, 1.51 to 1.82) in 2010 to 2012. No improvement was seen for elderly patients with small-cell lung cancer (SCLC), with an APC of 0.20 ( P = .714) among trial participants, despite a rising proportion of elderly patients with SCLC in the US population (APC, 0.32; P = .020). Enrollment disparity for women with lung cancer improved overall, with the gap closing by 2012 (EDD, 0.03 [95% CI, 0.00 to 0.06]; EDR, 1.07 [95% CI, 1.00 to 1.16]). Enrollment disparities persisted without significant improvement for elderly women, blacks, Asians/Pacific Islanders, and Hispanics. Conclusion Under-representation in lung cancer trials improved significantly from 1990 to 2012 for elderly patients with non-small-cell lung cancer and for women, but ongoing efforts to improve the enrollment of elderly patients with SCLC and minorities are needed. Our study highlights the importance of addressing enrollment disparities by demographic and disease subgroups to better target under-represented groups of patients with lung cancer.
AD  - Herbert H. Pang and Perry Cheng, School of Public Health, Li Ka Shing Faculty of Medicine, Hong Kong, Special Administrative Region, People's Republic of China; Herbert H. Pang, Xiaofei Wang, Ying Zhang, Thomas E. Stinchcombe, and Harvey J. Cohen, Duke University School of Medicine, Durham, NC; Melisa L. Wong, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco; David Gandara, University of California, Davis Comprehensive Cancer Center, Sacramento, CA; Apar Kishor Ganti, Veterans Affairs Nebraska Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE; Daniel J. Sargent and Sumithra J. Mandrekar, Mayo Clinic, Rochester, MN; Chen Hu, NRG Oncology Statistics and Data Management Center, Philadelphia, PA; Chen Hu, Johns Hopkins University School of Medicine, Baltimore, MD; Mary W. Redman, Fred Hutchinson Cancer Research Center, Seattle, WA; Judith B. Manola, Dana-Farber Cancer Institute, Boston, MA; Richard L. Schilsky, ASCO, Alexandria, VA; Jeffrey D. Bradley, Washington University School of Medicine, St Louis, MO; Alex A. Adjei, Roswell Park Cancer Institute, Buffalo, NY; Suresh S. Ramalingam, The Winship Cancer Institute of Emory University, Atlanta, GA; and Everett E. Vokes, University of Chicago, Chicago, IL.
AN  - 27646951
AU  - Pang, H. H.
AU  - Wang, X.
AU  - Stinchcombe, T. E.
AU  - Wong, M. L.
AU  - Cheng, P.
AU  - Ganti, A. K.
AU  - Sargent, D. J.
AU  - Zhang, Y.
AU  - Hu, C.
AU  - Mandrekar, S. J.
AU  - Redman, M. W.
AU  - Manola, J. B.
AU  - Schilsky, R. L.
AU  - Cohen, H. J.
AU  - Bradley, J. D.
AU  - Adjei, A. A.
AU  - Gandara, D.
AU  - Ramalingam, S. S.
AU  - Vokes, E. E.
C2  - PMC5477832 online at www.jco.org. Author contributions are found at the end of this article.
DA  - Nov 20
DO  - 10.1200/jco.2016.67.7088
DP  - NLM
ET  - 2016/09/21
IS  - 33
KW  - Age Factors
Aged
Carcinoma, Non-Small-Cell Lung/*epidemiology/*therapy
Clinical Trials as Topic/*statistics & numerical data
Female
Healthcare Disparities/*statistics & numerical data
Humans
Lung Neoplasms/*epidemiology/ethnology/*therapy
Male
Patient Selection
SEER Program
Sex Factors
Socioeconomic Factors
United States/epidemiology
LA  - eng
N1  - 1527-7755
Pang, Herbert H
Wang, Xiaofei
Stinchcombe, Thomas E
Wong, Melisa L
Cheng, Perry
Ganti, Apar Kishor
Sargent, Daniel J
Zhang, Ying
Hu, Chen
Mandrekar, Sumithra J
Redman, Mary W
Manola, Judith B
Schilsky, Richard L
Cohen, Harvey J
Bradley, Jeffrey D
Adjei, Alex A
Gandara, David
Ramalingam, Suresh S
Vokes, Everett E
R21 AG042894/AG/NIA NIH HHS/United States
U10 CA180846/CA/NCI NIH HHS/United States
T32 AG000212/AG/NIA NIH HHS/United States
U10 CA180833/CA/NCI NIH HHS/United States
P01 CA142538/CA/NCI NIH HHS/United States
U10 CA180838/CA/NCI NIH HHS/United States
U10 CA180888/CA/NCI NIH HHS/United States
U10 CA180819/CA/NCI NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
J Clin Oncol. 2016 Nov 20;34(33):3992-3999. doi: 10.1200/JCO.2016.67.7088. Epub 2016 Sep 30.
PY  - 2016
SN  - 0732-183X (Print)
0732-183x
SP  - 3992-3999
ST  - Enrollment Trends and Disparity Among Patients With Lung Cancer in National Clinical Trials, 1990 to 2012
T2  - J Clin Oncol
TI  - Enrollment Trends and Disparity Among Patients With Lung Cancer in National Clinical Trials, 1990 to 2012
VL  - 34
ID  - 203
ER  - 

TY  - JOUR
AB  - INTRODUCTION: The incidence of pancreatic cancer worldwide appears to correlate with increasing age, and it is slightly more common among men and Jewish people. There is evidence that the incidence rate is higher among blacks than among whites. METHODS: The published literature was reviewed for preparation of an overview on epidemiology of pancreatic cancer. RESULTS: A possible role of diabetes in the etiology of pancreatic cancer has been suggested by different epidemiological studies. Several investigations indicate that a history of pancreatitis may increase the risk of pancreas cancer, and it appears that people with a history of pernicious anemia or partial gastrectomy for ulcer as well as cholecystectomy may be at higher risk. Individuals with familial adenomatous polyposis (FAP) also have a high risk of developing this cancer. Pancreatic cancer is seen in some breast cancer families with BRCA1 and BRCA2 mutations. Epidemiological studies have confirmed that relatives of individuals with pancreatic cancer have an increased risk of this malignancy. Affected family members of the familial atypical multiple-mole melanoma (FAMMM) as well as those with a positive family history of ataxia-telangiectasia (AT) have much higher risk of developing pancreatic cancer, compared with the general population. A positive association has been reported between pancreatic cancer risk and dietary intake such as fat and oil, meat, and dairy products, as well as with high intake of energy, fried foods, carbohydrates, cholesterol, and salt. The risk is found to decrease with increased consumption of fresh fruits and vegetables, fiber, natural foods, and Vitamin C. Cigarette smoking has shown the strongest positive association with risk of pancreatic cancer. CONCLUSION: Some diseases and medical conditions such as diabetes, chronic pancreatitis, AP, family aggregation of pancreatic cancer, FAMMM, AT, as well as nutrition and lifestyle factors, like smoking may play important role in the etiology of pancreatic cancer.
AD  - Epidemiology Research Unit, Centre hospitalier de l'Université de Montréal (CHUM), Pav. Masson, Hôtel-Dieu, Faculty of Medicine, Université de Montréal, 3850 St. Urbain Street, Montreal, Que., Canada H2W 1T7. parvis.ghadirian@umontreal.ca
AN  - 12670518
AU  - Ghadirian, P.
AU  - Lynch, H. T.
AU  - Krewski, D.
DO  - 10.1016/s0361-090x(03)00002-3
DP  - NLM
ET  - 2003/04/03
IS  - 2
KW  - Clinical Trials as Topic
Female
Humans
Incidence
Male
Pancreatic Neoplasms/*epidemiology/etiology/genetics
Pedigree
Risk Factors
LA  - eng
N1  - Ghadirian, P
Lynch, H T
Krewski, D
Journal Article
Review
England
Cancer Detect Prev. 2003;27(2):87-93. doi: 10.1016/s0361-090x(03)00002-3.
PY  - 2003
SN  - 0361-090X (Print)
0361-090x
SP  - 87-93
ST  - Epidemiology of pancreatic cancer: an overview
T2  - Cancer Detect Prev
TI  - Epidemiology of pancreatic cancer: an overview
VL  - 27
ID  - 651
ER  - 

TY  - JOUR
AN  - 20392157
AU  - Grann, V. R.
DA  - May
DO  - 10.1089/jwh.2010.1985
DP  - NLM
ET  - 2010/04/16
IS  - 5
KW  - African Continental Ancestry Group/*psychology
Breast Neoplasms/*prevention & control
Female
Humans
Patient Acceptance of Health Care/*ethnology
*Patient Selection
Premenopause/*psychology
*Women's Health
LA  - eng
N1  - 1931-843x
Grann, Victor R
Comment
Editorial
United States
J Womens Health (Larchmt). 2010 May;19(5):837-8. doi: 10.1089/jwh.2010.1985.
PY  - 2010
SN  - 1540-9996
SP  - 837-8
ST  - Erasing barriers to minority participation in cancer research
T2  - J Womens Health (Larchmt)
TI  - Erasing barriers to minority participation in cancer research
VL  - 19
ID  - 424
ER  - 

TY  - JOUR
AB  - Declaration of Competing Interest statements were not included in the published version of the following articles that appeared in previous issues of Contemporary Clinical Trials Communications. The appropriate Declaration/Competing Interest statements, provided by the Authors, are included below. 1. “Intestinal-level anti-inflammatory bioactivities of catechin-rich green tea: Rationale, design, and methods of a double-blind, randomized, placebo-controlled crossover trial in metabolic syndrome and healthy adults” [Contemporary Clinical Trials Communications, 2019; 17: 100495] https://doi.org/10.1016/j.conctc.2019.100495 Declaration of competing interest: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.2. “Trauma Management Therapy and Prolonged Exposure Therapy for PTSD in an active duty sample: Design and methodology of a randomized clinical trial” [Contemporary Clinical Trials Communications, 2019; 17: 100491] https://doi.org/10.1016/j.conctc.2019.100491 Declaration of competing interest: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.3. “Virtual reality for pain management in patients with heart failure: Study rationale and design” [Contemporary Clinical Trials Communications, 2019; 16: 100470] https://doi.org/10.1016/j.conctc.2019.100470 Declaration of competing interest: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.4. “Recruitment and retention of families interested in a parent-based pediatric obesity intervention” [Contemporary Clinical Trials Communications, 2019; 16: 100467] https://doi.org/10.1016/j.conctc.2019.100467 Declaration of competing interest: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.5. “2D (2 Dimensional) TEQR design for Determining the optimal Dose for safety and efficacy” [Contemporary Clinical Trials Communications, 2019; 16: 100461] https://doi.org/10.1016/j.conctc.2019.100461 Declaration of competing interest: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.6. “Design of a novel digital intervention to promote healthy weight management among postpartum African American women” [Contemporary Clinical Trials Communications, 2019; 16: 100460] https://doi.org/10.1016/j.conctc.2019.100460 Declaration of competing interest: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.7. “Integrating smartphone technology, social support and the outdoor built environment to promote community-based aerobic and resistance-based physical activity: Rationale and study protocol for the ‘ecofit’ randomized controlled trial” [Contemporary Clinical Trials Communications, 2019; 16: 100457] https://doi.org/10.1016/j.conctc.2019.100457 Declaration of competing interest: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.8. “Qualitative analysis of COACH: A community-based behavioral intervention to reduce obesity health disparities within a marginalized community” [Contemporary Clinical Trials Communications, 2019; 16: 100452] https://doi.org/10.1016/j.conctc.2019.100452 Declaration of competing interest: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.9. “Statistical considerations for testing an AI algorithm used for rescreening lung CT images” [Contemporary Clinical Trials Communications, 2019; 16: 100434] https://doi.org/10.1016/j.conctc.2019.100434 Declaration of competing interest: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.10. “Study protocol: Randomized controlled trial of web-based decision support tools for high-risk women and healthcare providers to increase breast cancer chemoprevention” [Contemporary Clinical Trials Communications, 2019; 16: 100433] https://doi.org/10.1016/j.conctc.2019.100433 Declaration of competing interest: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.11. “Bayesian adaptive randomization trial of intravenous ketamine for veterans with late-life, treatment-resistant depression” [Contemporary Clinical Trials Communications, 2019; 16: 100432] https://doi.org/10.1016/j.conctc.2019.100432 Declaration of competing interest: The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Dr. Sanjay Mathew has served as a consultant to Allergan, Alkermes, Bracket, Clexio Biosciences, Janssen, Perception Neurosciences, and Sage Therapeutics. He has served as a co-investigator for clinical trials funded by NeuroRx and Janssen and has received research support from Biohaven Pharmaceuticals and VistaGen Therapeutics. Dr. Marijn Lijffijt has served as principal investigator for trials funded by NeuroRx and Vistagen Therapeutics.12. “A descriptive research: Exclusion from submitted clinical data package in the review process of new drug approval due to GCP violation in Japan” [Contemporary Clinical Trials Communications, 2019; 15: 100416] https://doi.org/10.1016/j.conctc.2019.100416 Declaration of competing interest: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.13. “Ultrafiltration-profiled hemodialysis to reduce dialysis-related cardiovascular stress: Study protocol for a randomized controlled trial” [Contemporary Clinical Trials Communications, 2019; 15: 100415] https://doi.org/10.1016/j.conctc.2019.100415 Declaration of competing interest: In the last 3 years, JEF has received speaking honoraria from American Renal Associates, the American Society of Nephrology, Dialysis Clinic, Inc., the National Kidney Foundation, and multiple universities. JEF is on the medical advisory board of NxStage Medical, Inc. and has received consulting fees from Fresenius Medical Care, North America and AstraZeneca. In the last 3 years, MMA has received investigator-initiated research funding from the Renal Research Institute, a subsidiary of Fresenius Medical Care, North America and honoraria from the International Society of Nephrology. The remaining authors have no competing interests.14. “Efficacy of smoking cessation with varenicline plus counselling for e-cigarettes users (VAREVAPE): A protocol for a randomized controlled trial” [Contemporary Clinical Trials Communications, 2019; 15: 100412] https://doi.org/10.1016/j.conctc.2019.100412 Declaration of competing interest: “The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: PC is fixed-term researcher at University of Catania, Italy and won the 2015 unrestricted grant from Pfizer,GRAND, Global Research Award for Nicotine Dependence, that as declared in the text support this study. MM is fixed-term researcher at Centro per la Prevenzione e Cura del Tabagismo, University of Catania. In relation to his work in the area of tobacco control and respiratory diseases, P has received lecture fees and research funding from Pfizer, Inc., GlaxoSmithKline plc, CV Therapeutics, NeuroSearch A/S, Sandoz, MSD, Boehringer Ingelheim, Novartis, Duska Thera eutics, and Forest Laboratories. He has also served as a consultant for Pfizer, Inc., Global Health Alliance for treatment of tobacco dependence, CV Therapeutics, NeuroSearch A/S, Boehringer Ingelheim, Duska Therapeutics, Forest Laboratories, ECITA (Electronic Cigarette Industry Trade Association, in the UK), and Health Diplomat (consulting company that delivers solutions to global health problems with special emphasis on harm minimization). Lecture fees from a number of European EC industry and trade associations (including Fédération Interprofessionnelle de la VAPE in France and Federazione Italiana Esercenti Svapo Elettronico in Italy) were directly donated to vaper advocacy no-profit organizations. He is currently Head of the European Technical Committee for standardization on “Requirements and test methods for emissions of electronic cigarettes” (CEN/TC 437; WG4). He is also founder of the Center of Excellence for the acceleration of Harm Reduction at the University of Catania (CoEHAR), which has received a grant from the Foundation for a Smoke Free World to support 8 independent investigator-initiated research projects on tobacco harm reduction, and scientific advisor for LIAF, Lega Italiana Anti Fumo (Italian acronym for Italian Anti- Smoking League). The other authors have no conflict of interests to declare.15. “Recruitment challenges in stroke neurorecovery clinical trials” [Contemporary Clinical Trials Communications, 2019; 15: 100404] https://doi.org/10.1016/j.conctc.2019.100404 Declaration of competing interest: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
DB  - Embase
DO  - 10.1016/j.conctc.2020.100689
KW  - erratum
LA  - English
M3  - Erratum
N1  - L2010331825
2020-12-22
PY  - 2020
SN  - 2451-8654
ST  - Erratum regarding missing Declaration of Competing Interest statements in previously published articles (Contemporary Clinical Trials Communications (2019) 16, (S2451865419302236), (10.1016/j.conctc.2019.100461))
T2  - Contemporary Clinical Trials Communications
TI  - Erratum regarding missing Declaration of Competing Interest statements in previously published articles (Contemporary Clinical Trials Communications (2019) 16, (S2451865419302236), (10.1016/j.conctc.2019.100461))
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L2010331825&from=export
http://dx.doi.org/10.1016/j.conctc.2020.100689
VL  - 20
ID  - 776
ER  - 

TY  - JOUR
AB  - The Minority-Based Community Clinical Oncology Program (MB-CCOP) at University of Medicine and Dentistry of New Jersey, New Jersey Medical School-University Hospital Cancer Center was established to serve an unmet need in a medically, educationally, and socioeconomically underserved community of primarily African American and Latino patients in Newark and Essex County, New Jersey. The MB-CCOP was built on an existing infrastructure of multidisciplinary teams of cancer specialists who collaborated in patient care and an existing clinical research program, which included multilingual staff and a breast cancer navigator. This article highlights some of the unique opportunities and challenges involved in the startup of an MB-CCOP specifically relevant to an academic setting. We present a guide to the necessary infrastructure and institutional support that must be in place before considering such a program and some of the steps an institution can take to overcome barriers preventing successful enrollment of patients onto clinical trials.
AD  - University of Medicine and Dentistry of New Jersey, New Jersey Medical School-University Hospital Cancer Center, Newark, NJ, USA.
AN  - 23814524
AU  - Wieder, R.
AU  - Teal, R.
AU  - Saunders, T.
AU  - Weiner, B. J.
C2  - PMC3595450
DA  - Mar
DO  - 10.1200/jop.2012.000648
DP  - NLM
ET  - 2013/07/03
IS  - 2
KW  - Cancer Care Facilities/*organization & administration
Clinical Trials as Topic
Community Health Services/*organization & administration
*Government Programs
*Health Services Accessibility
Hospitals, University/organization & administration
Humans
Medical Oncology
*Minority Groups
National Cancer Institute (U.S.)
New Jersey
Program Evaluation
Schools, Medical/organization & administration
United States
LA  - eng
N1  - 1935-469x
Wieder, Robert
Teal, Randall
Saunders, Tracie
Weiner, Bryan J
U10 CA128506/CA/NCI NIH HHS/United States
1U10CA128506-01A1/CA/NCI NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
J Oncol Pract. 2013 Mar;9(2):e48-54. doi: 10.1200/JOP.2012.000648.
PY  - 2013
SN  - 1554-7477 (Print)
1554-7477
SP  - e48-54
ST  - Establishing a minority-based community clinical oncology program: the University of Medicine and Dentistry of New Jersey, New Jersey Medical School-university Hospital Cancer Center experience
T2  - J Oncol Pract
TI  - Establishing a minority-based community clinical oncology program: the University of Medicine and Dentistry of New Jersey, New Jersey Medical School-university Hospital Cancer Center experience
VL  - 9
ID  - 327
ER  - 

TY  - JOUR
AB  - Breast cancer continues to be among the most common cancers affecting women in the United States. Researchers investigating the area are turning their attention to novel prevention, detection, and treatment options. Recent molecular epidemiology research has highlighted the effects of both genetic and environmental exposures on an individual's risk of developing breast cancer and predicted response to treatment. Cohort designs are a potentially powerful tool that researchers can utilize to investigate the genetic and environmental factors affecting breast cancer risk and treatment options. This paper describes the recruitment of a community-based cohort of women in a southern state. The Spit for the Cure Cohort (SFCC), being developed by researchers at the University of Arkansas for Medical Sciences (Little Rock, AR), is designed to be representative of the female population of the state with oversampling of women with a history of breast cancer and women of color. To date, the SFCC includes more than 14,000 women recruited from all 75 counties of Arkansas and six neighboring states. Methods used to recruit and maintain the cohort and collect both questionnaire data and genetic material are described, as are the demographic characteristics of the cohort as it currently exists. The recruitment methods utilized for the SFCC are rapidly building a breast cancer cohort and providing a large biorepository for molecular epidemiology research.
AD  - Department of Epidemiology, Fay W. Boozman College of Public Health, University of Arkansas for Medical Sciences, Little Rock, Arkansas
Epidemiology Branch, Center for Public Health Practice, Arkansas Department of Health, Little Rock, Arkansas
Division of Breast Surgical Oncology, Department of Surgery, College of Medicine, University of Arkansas for Medical Sciences, Arkansas
Department of Medical Genetics, College of Medicine, University of Arkansas for Medical Sciences, Arkansas
Department of Epidemiology, Fay W. Boozman College of Public Health, University of Arkansas for Medical Sciences, Little Rock, Arkansas; Department of Psychiatry, College of Medicine, University of Arkansas for Medical Sciences, Arkansas
AN  - 104895964. Language: English. Entry Date: 20110510. Revision Date: 20200708. Publication Type: Journal Article
AU  - Bondurant, Kristina L.
AU  - Harvey, Sarah
AU  - Klimberg, Suzanne
AU  - Kadlubar, Susan
AU  - Phillips, Martha M.
DB  - CINAHL Complete
DO  - 10.1111/j.1524-4741.2011.01082.x
DP  - EBSCOhost
IS  - 3
KW  - Breast Neoplasms -- Epidemiology
Research Subject Recruitment
Funding Source
Human
Female
Prospective Studies
Arkansas
Breast Neoplasms -- Familial and Genetic
Adult
Middle Age
Aged
Aged, 80 and Over
Questionnaires
Black Persons
White Persons
Descriptive Statistics
N1  - research; tables/charts. Journal Subset: Biomedical; Blind Peer Reviewed; Editorial Board Reviewed; Peer Reviewed; USA. Special Interest: Oncologic Care; Women's Health. Grant Information: This work is funded by the Arkansas Breast Cancer Research Program (ABCRP) of the Winthrop P. Rockefeller Cancer Institute at UAMS.. NLM UID: 9505539.
PMID: NLM21489034.
PY  - 2011
SN  - 1075-122X
SP  - 281-288
ST  - Establishment of a Southern Breast Cancer Cohort
T2  - Breast Journal
TI  - Establishment of a Southern Breast Cancer Cohort
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104895964&site=ehost-live&scope=site
VL  - 17
ID  - 1945
ER  - 

TY  - JOUR
AB  - BACKGROUND: Historically, groups that are most susceptible to health and healthcare disparities have been underrepresented in medical research. It is imperative to explore approaches that can facilitate the recruitment of underrepresented individuals into research studies. METHODS: Two approaches, hospital and community-based recruitment (CBR), were developed and implemented over 36 months to study the genetics of hereditary breast cancer and associated cancers in Alabama, a medically underserved state with double the national percentage of self-identifying African Americans, establishing the Alabama Hereditary Cancer Cohort. RESULTS: Overall, 242 individuals enrolled. This included 84 cancer probands through hospital recruitment, as well as 76 probands and 82 family members through CBR. Eighty-one percent of the study participants' counties of residence are completely medically underserved. Furthermore, African Americans represent 26% of the hospital probands compared to 49% and 70% of the probands and family members who, respectively, enrolled through CBR. CONCLUSION: Although both recruitment mechanisms were instrumental, the unique trust building, educational, and traveling components of CBR facilitated the enrollment of African Americans resulting in large families for genetic analyses. The ultimate goal is to gain insight from these rudimentary efforts in order to expand recruitment and accrue a unique resource for cancer genetics research.
AD  - Department of Drug Discovery and Development, Harrison School of Pharmacy, Auburn University, Auburn, Alabama.
Department of Pathobiology, College of Veterinary Medicine, Auburn University, Auburn, Alabama.
East Alabama Medical Center, Cancer Center, Opelika, Alabama.
Department of Human Development and Family Studies, College of Human Sciences, Auburn University, Auburn, Alabama.
AN  - 29962060
AU  - Bishop, M. R.
AU  - Shah, A.
AU  - Shively, M.
AU  - Huskey, A. L. W.
AU  - Omeler, S. M.
AU  - Bilgili, E. P.
AU  - Jackson, E.
AU  - Daniell, K.
AU  - Stallworth, E.
AU  - Spina, S.
AU  - Shepp, K.
AU  - Bergstresser, S.
AU  - Davis, A.
AU  - Dean, H.
AU  - Gibson, J.
AU  - Johnson, B.
AU  - Merner, N. D.
C2  - PMC6160710
DA  - Sep
DO  - 10.1002/mgg3.443
DP  - NLM
ET  - 2018/07/03
IS  - 5
KW  - Adult
Aged
Alabama/epidemiology
Cohort Studies
*Family
Female
*Genetics, Medical
Humans
Male
Middle Aged
Neoplasms/epidemiology/*genetics
*African American
*biobank
*hereditary breast cancer
*recruitment
*underrepresented individuals
LA  - eng
N1  - 2324-9269
Bishop, Madison R
Shah, Amit
Shively, Melissa
Huskey, Anna L W
Omeler, Sophonie M
Bilgili, Erin P
Jackson, Ebony
Daniell, Kathleen
Stallworth, Elizabeth
Spina, Stephanie
Shepp, Kasey
Bergstresser, Sydney
Davis, Amber
Dean, Holly
Gibson, Jantunn
Johnson, Brandon
Merner, Nancy D
Orcid: 0000-0002-8954-0155
American Association of Colleges of Pharmacy New Investigator Award/International
Auburn University Research Initiative in Cancer Seed Grant/International
Auburn University Innovative Research Grant through the Internal Grant Program/International
Joy to Life Foundation Grant/International
Clinical Trial
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Mol Genet Genomic Med. 2018 Sep;6(5):766-778. doi: 10.1002/mgg3.443. Epub 2018 Jul 1.
PY  - 2018
SN  - 2324-9269
SP  - 766-778
ST  - Establishment of the Alabama Hereditary Cancer Cohort - strategies for the inclusion of underrepresented populations in cancer genetics research
T2  - Mol Genet Genomic Med
TI  - Establishment of the Alabama Hereditary Cancer Cohort - strategies for the inclusion of underrepresented populations in cancer genetics research
VL  - 6
ID  - 115
ER  - 

TY  - JOUR
AB  - Background: The Breast Cancer Prevention Trial demonstrated that tamoxifen treatment produced a 49% reduction in the risk of invasive breast cancer among women at elevated risk for the disease. The U.S. Food and Drug Administration (FDA) subsequently approved tamoxifen for women aged 35 years or older with a 5-year breast cancer risk of 1.67% or higher for breast cancer chemoprevention. However, tamoxifen use has been associated with adverse outcomes, and not all eligible women have a positive benefit/risk ratio. Methods: We used weighted data from the year 2000 National Health Interview Survey Cancer Control Module to estimate the total number of U.S. women, aged 35-79 years, who were eligible for tamoxifen chemoprevention based on the FDA eligibility criteria. We also estimated the numbers of white and black women who would benefit from tamoxifen chemoprevention on the basis of a positive benefit/risk index developed by Gail et al. Results: Of the 65826074 women aged 35-79 years without reported breast cancer in the United States in 2000, 10232816 women (15.5%, 95% confidence interval [CI] = 14.7% to 16.3%) would be eligible for tamoxifen chemoprevention. The percentage of U.S. women who would be eligible varied dramatically by race, with 18.7% (95% CI = 17.8% to 19.7%) of white women, 5.7% (95% CI = 4.3% to 7.5%) of black women, and 2.9% (95% CI = 2.1% to 3.9%) of Hispanic women being eligible. Of the 50 104829 white U.S. women aged 35-79 years, 2 431 911 (4.9%, 95% CI = 4.3% to 5.4%) would have a positive benefit/risk index for tamoxifen chemoprevention. Of the 7 481 779 black U.S. women aged 35-79 years, only 42 768 (0.6%, 95% CI = 0.2% to 1.3%) would have a positive benefit/risk index. Among white women, 28 492 (95% CI = 24 693 to 32 292) breast cancers would be prevented or deferred if those women who have a positive net benefit index took tamoxifen over the next 5 years. Conclusion: A substantial percentage of U.S. women would be eligible for tamoxifen chemoprevention according to FDA criteria, but a much smaller percentage would have an estimated net benefit. Nevertheless, this latter percentage corresponds to more than two million women.
AD  - A.N. Freedman, National Cancer Institute, Div. of Cancer Control/Pop. Sciences, 6130 Executive Blvd., Bethesda, MD 20892-7344, United States
AU  - Freedman, A. N.
AU  - Graubard, B. I.
AU  - Rao, S. R.
AU  - McCaskill-Stevens, W.
AU  - Ballard-Barbash, R.
AU  - Gail, M. H.
DB  - Embase
Medline
DO  - 10.1093/jnci/95.7.526
IS  - 7
KW  - tamoxifen
adult
age
aged
article
breast cancer
tumor invasion
cancer risk
Caucasian
chemoprophylaxis
controlled study
deep vein thrombosis
drug approval
drug indication
drug use
endometrium cancer
female
Food and Drug Administration
frequency analysis
gender
health survey
high risk patient
human
human tissue
lung embolism
major clinical study
Black person
patient selection
priority journal
race difference
risk assessment
risk benefit analysis
treatment outcome
United States
LA  - English
M3  - Article
N1  - L36511623
2003-05-09
PY  - 2003
SN  - 0027-8874
SP  - 526-532
ST  - Estimates of the number of U.S. women who could benefit from tamoxifen for breast cancer chemoprevention
T2  - Journal of the National Cancer Institute
TI  - Estimates of the number of U.S. women who could benefit from tamoxifen for breast cancer chemoprevention
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L36511623&from=export
http://dx.doi.org/10.1093/jnci/95.7.526
VL  - 95
ID  - 1294
ER  - 

TY  - JOUR
AB  - Purpose: Healthy or unhealthy lifestyle behaviors are often adopted together. We aimed to investigate the combined effect of estrogen-related lifestyle factors on postmenopausal breast cancer risk. Methods: Data from 27,153 women enrolled in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial were used. We created an estrogen-related lifestyle score (ERLS) by incorporating a previously developed measure of estrogenic diet, alcohol intake, body mass index (BMI), and physical activity. The scores ranged from 0 to 6 with alcohol and BMI accounting for higher weights than the other factors. To evaluate the preventive possibilities of a low estrogen-related lifestyle and to be consistent with other published lifestyle scores, higher scores were set to correspond with potentially lower estrogenic lifestyle. The association between the ERLS and incident breast cancer was examined using Cox proportional hazards models. Results: Participants with an ERLS of 4 or ≥ 5 had a 23% (HR 0.77; 95% CI 0.67–0.89) and 34% (HR 0.66; 95% CI 0.56–0.78) lower risk of breast cancer, respectively, compared to those with an ERLS ≤ 2 after multivariable adjustment. Estimates were similar when restricting to invasive cases or estrogen receptor-positive subtypes. No single lifestyle component appeared to drive the association. Conclusions: Our findings suggest that the combined effect of a lifestyle characterized by a low estrogenic diet, low alcohol consumption, low body weight, and high levels of physical activity are associated with a reduction in postmenopausal breast cancer risk, possibly through an influence on estrogen metabolism.
AD  - S.E. Steck, Cancer Prevention and Control Program, University of South Carolina, Columbia, SC, United States
AU  - Guinter, M. A.
AU  - McLain, A. C.
AU  - Merchant, A. T.
AU  - Sandler, D. P.
AU  - Steck, S. E.
DB  - Embase
Medline
DO  - 10.1007/s10549-018-4784-0
IS  - 3
KW  - CA 125 antigen
adult
alcohol consumption
article
Asian
Black person
body mass
body weight
breast cancer
breast carcinoma
caloric intake
cancer incidence
cancer screening
Caucasian
cohort analysis
controlled study
diet
diet therapy
dietary questionnaire
estrogen metabolism
estrogen receptor positive breast cancer
estrogen related lifestyle score
estrogenic diet
family history
female
food frequency questionnaire
healthy lifestyle
Hispanic
human
lifestyle
lifestyle modification
liquid chromatography
major clinical study
menopause
obesity
ovariectomy
parity
physical activity
postmenopausal breast cancer
postmenopause
priority journal
questionnaire
risk factor
scoring system
sigmoidoscopy
smoking
tandem mass spectrometry
LA  - English
M3  - Article
N1  - L621664896
2018-04-18
PY  - 2018
SN  - 1573-7217
0167-6806
SP  - 613-622
ST  - An estrogen-related lifestyle score is associated with risk of postmenopausal breast cancer in the PLCO cohort
T2  - Breast Cancer Research and Treatment
TI  - An estrogen-related lifestyle score is associated with risk of postmenopausal breast cancer in the PLCO cohort
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L621664896&from=export
http://dx.doi.org/10.1007/s10549-018-4784-0
VL  - 170
ID  - 887
ER  - 

TY  - JOUR
AB  - Critical illness trials involving genetic data collection are increasingly commonplace and pose challenges not encountered in less acute settings, related in part to the precipitous, severe and incapacitating nature of the diseases involved. We performed a systematic literature review to understand the nature of such studies conducted to date, and to consider, from an ethical perspective, potential barriers to future investigations. We identified 79 trials enrolling 24 499 subjects. Median (interquartile range) number of participants per study was 263 (116.75-430.75). Of these individuals, 16 269 (66.4%) were Caucasian, 1327 (5.4%) were African American, 1707 (7.0%) were Asian Pacific Islanders and 139 (0.6%) were Latino. For 5020 participants (20.5%), ethnicity was not reported. Forty-eight studies (60.8%) recruited subjects from single centers and all studies examined a relatively small number of genetic markers. Technological advances have rendered it feasible to conduct clinical studies using high-density genome-wide scanning. It will be necessary for future critical illness trials using these approaches to be of greater scope and complexity than those so far reported. Empirical research into issues related to greater ethnic inclusivity, accuracy of substituted judgment and specimen stewardship may be essential for enabling the conduct of such trials. The Pharmacogenomics Journal (2010) 10, 77-85; doi:10.1038/tpj.2009.61; published online 8 December 2009
AN  - WOS:000275933100001
AU  - Freeman, B. D.
AU  - Kennedy, C. R.
AU  - Frankel, H. L.
AU  - Clarridge, B.
AU  - Bolcic-Jankovic, D.
AU  - Iverson, E.
AU  - Shehane, E.
AU  - Celious, A.
AU  - Zehnbauer, B. A.
AU  - Buchman, T. G.
DA  - Apr
DO  - 10.1038/tpj.2009.61
IS  - 2
N1  - 19997084
PY  - 2010
SN  - 1470-269X
SP  - 77-85
ST  - Ethical considerations in the collection of genetic data from critically ill patients: What do published studies reveal about potential directions for empirical ethics research?
T2  - Pharmacogenomics Journal
TI  - Ethical considerations in the collection of genetic data from critically ill patients: What do published studies reveal about potential directions for empirical ethics research?
VL  - 10
ID  - 3118
ER  - 

TY  - THES
AB  - Colon cancer prognosis largely depends on factors related to the patient, treatment, and tumor. The expertise of the cancer care team is also an important determinant of outcome. NIH Consensus conferences and other authorities recommended adjuvant chemotherapy for all colon cancer patients with stage III (node-positive). This recommendation was initially based on a clinical trial showing a 41% lower recurrence rate and a 33% lower mortality rate with 5-FU treatment of patients found to have disease spread to lymph nodes on surgical resection. Colon cancer, like virtually all solid tumors, has traditionally been viewed as a 'surgical disease'; that is, the primary therapy for localized cancers is surgical resection. However, chemotherapy is usually given by a medical oncologist. Thus almost all patients with stage III colon cancer are seen by a surgeon and surgeons need to refer patients to medical oncologists because medical oncologists are often best suited to address the informational needs of a newly diagnosed cancer patient and to provide adjuvant chemotherapy to their patients. The purpose of this study is to examine differences in oncology care among four ethnic groups: Non-Hispanic Whites, Blacks, Asians, and Hispanics. Data for this study come from the Surveillance Epidemiology and End Results (SEER) -Medicare linked database. The sample is comprised of older colon cancer patients diagnosed between 1992 and 1999 in 11 SEER areas. Five hypotheses were tested: (1) patients who see a medical oncologist are more likely to receive chemotherapy; (2) patients in minority groups (Blacks, Hispanics, and Asian) will be less likely to receive chemotherapy than those in the majority group (non-Hispanic whites), after controlling for other patient characteristics and tumor features; (3) patients in minority groups will be less likely to see a medical oncologists than those in the majority group (non-Hispanic whites) after controlling for other patient characteristics; (4) seeing a medical oncologist is not likely to diminish the relative differences in the receipt of chemotherapy among all groups; (5) patients treated by a younger surgeon (fewer years since graduation) are more likely to see a medical oncologist, controlling for cancer and other characteristics. Results suggest that patients with older age, who are unmarried, have state buy-in coverage (a marker for low income), have more comorbidities and live in certain SEER areas (Detroit, Connecticut, San Francisco, Hawaii, Iowa, New Mexico, Seattle and Utah) were less likely to see a medical oncologist. Patients of black ethnicity, of older age, who are unmarried, have state buy-in coverage, have more comorbidities and live in certain SEER areas (New Mexico, Seattle and Utah) were significantly less likely to receive chemotherapy. Surgeon characteristics (years since graduation) impact on whether their patients see a medical oncologist. Patients seeing a medical oncologist were 9 times more likely to receive chemotherapy, after controlling for demographic and tumor characteristics. Seeing a medical oncologist and receiving chemotherapy have increased over time and are strongly associated with each other. This study demonstrates that the major reason why older black patients with stage III colon cancer do not receive chemotherapy is that they are more likely to be unmarried, have low income, and have more comorbidities. However, seeing a medical oncologist does not eliminate the disparities in chemotherapy use by age, ethnicity, or marital status. It reduces the absolute differences, just not the relative differences. Further work is required to explore the role of patient knowledge and attitudes, organizational factors, and factors involving access to chemotherapy services in maintaining those differences. (PsycINFO Database Record (c) 2016 APA, all rights reserved)
AN  - 2007-99018-112
AU  - Luo, Ruili
DB  - psyh
DP  - EBSCOhost
KW  - ethnic difference
oncology care
older patients
stage III colon cancer
chemotherapy
Blacks
Clinical Trials
Medicare
Neoplasms
Latinos/Latinas
Oncology
N1  - Accession Number: 2007-99018-112. Other Journal Title: Dissertation Abstracts International. Partial author list: First Author & Affiliation: Luo, Ruili; U Texas Medical Branch Graduate School Of Biomedical Sciences, US. Release Date: 20071022. Publication Type: Dissertation Abstract (0400). Format Covered: Electronic. Document Type: Dissertation. Dissertation Number: AAI3256827. Language: English. Major Descriptor: Blacks; Clinical Trials; Medicare; Neoplasms; Latinos/Latinas. Minor Descriptor: Oncology. Classification: Health & Mental Health Treatment & Prevention (3300). Population: Human (10). Age Group: Adulthood (18 yrs & older) (300); Aged (65 yrs & older) (380). Methodology: Empirical Study; Quantitative Study. Page Count: 1.
PB  - ProQuest Information & Learning
PY  - 2007
SN  - 0419-4217
SP  - 1592-1592
ST  - Ethnic difference in oncology care among older patients with stage III colon cancer
TI  - Ethnic difference in oncology care among older patients with stage III colon cancer
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2007-99018-112&site=ehost-live&scope=site
VL  - 68
ID  - 1806
ER  - 

TY  - JOUR
AB  - Behavioral theories developed through research with mainstream, English-speaking populations have been applied to ethnically diverse and underserved communities in the effort to eliminate disparities in early breast cancer detection. This study tests the validity of the transtheoretical model (TTM) decisional balance measure and the application of the TTM stages of change in a multiethnic, multilingual sample. A random sample of 1,463 Filipino, Latino, African American, Chinese, and White women aged 40 to 74 completed a phone survey of mammography beliefs and practices. Consistent with the TTM and independent of ethnicity, decisional balance was associated with mammography stage in all five ethnic groups when controlling for socioeconomic and other factors. In addition, having private insurance and a regular physician and being a long-time resident in the United States were positively associated with mammography maintenance. The application of the TTM for mammography is supported in a multiethnic and multilingual sample.
AD  - Institute for Health and Aging, University of California-San Francisco, CA 94143-0646, USA. reginas@itsa.ucsf.edu
AN  - 16891624
AU  - Otero-Sabogal, R.
AU  - Stewart, S.
AU  - Shema, S. J.
AU  - Pasick, R. J.
C2  - PMC2939724
C6  - NIHMS230739
DA  - Apr
DO  - 10.1177/1090198105277854
DP  - NLM
ET  - 2006/08/08
IS  - 2
KW  - Adult
Aged
Attitude to Health
Data Collection
*Ethnic Groups
Female
Humans
Interviews as Topic
Mammography/*statistics & numerical data
Middle Aged
Models, Theoretical
Patient Acceptance of Health Care
*Patient Participation
San Francisco
LA  - eng
N1  - 1552-6127
Otero-Sabogal, Regina
Stewart, Susan
Shema, Sarah J
Pasick, Rena J
P01 CA055112-09S3/CA/NCI NIH HHS/United States
5P01 CA 55112/CA/NCI NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
Validation Study
Health Educ Behav. 2007 Apr;34(2):278-96. doi: 10.1177/1090198105277854. Epub 2006 Aug 4.
PY  - 2007
SN  - 1090-1981 (Print)
1090-1981
SP  - 278-96
ST  - Ethnic differences in decisional balance and stages of mammography adoption
T2  - Health Educ Behav
TI  - Ethnic differences in decisional balance and stages of mammography adoption
VL  - 34
ID  - 558
ER  - 

TY  - JOUR
AB  - The aim of this study was to determine whether there are racial/ethnic differences in initiation and timing of adjuvant endocrine therapy (AET) after Medicare Part D drug coverage. We conducted a retrospective cohort study using data from the Surveillance, Epidemiology, and End Results-Medicare-linked data to assess ethnic, socio-demographic, and tumor characteristic variations in the initiation of AET among patients >= 65 with hormone receptor-positive breast cancer in 2007-2009 enrolled in Medicare Part D through 2010. Logistic regression models were performed to assess the association between race/ethnicity and the initiation of tamoxifen, aromatase inhibitors (AIs), and overall AET (tamoxifen or AIs) within the first 12 months of diagnosis. Of the 12,198 women with hormone receptor-positive breast cancer, 74.8 % received AET within 12 months of diagnosis, of which 17.3 % received tamoxifen and 82.8 % received AIs. After controlling for all variables, only Asian women were found to have a greater odds of initiation of overall AET compared to non-Hispanic white women (odds ratio (OR): 1.28, 95 % CI: 1.03-1.58). Hispanic Mexicans and non-Hispanic black patients had a significantly lower odds of tamoxifen initiation (0.70, 0.54-0.91; 0.25, 0.10-0.62). For AI initiation, Hispanic Mexicans and Asians had a higher odds compared to non-Hispanic white women (2.06, 1.34-3.10; 1.33, 1.11-1.61). A suboptimal proportion of women (25.2 %) did not initiate AET within 12 months of diagnosis and therefore did not receive the full benefits of treatment to reduce the risk of breast cancer recurrence and mortality. Racial/ethnic differences in the initiation of tamoxifen and AIs have important implications that require further investigation.
AN  - WOS:000368699100009
AU  - Farias, A. J.
AU  - Du, X. L. L.
DA  - Feb
DO  - 10.1007/s12032-016-0732-1
IS  - 2
N1  - 19
26786154
PY  - 2016
SN  - 1357-0560
ST  - Ethnic differences in initiation and timing of adjuvant endocrine therapy among older women with hormone receptor-positive breast cancer enrolled in Medicare Part D
T2  - Medical Oncology
TI  - Ethnic differences in initiation and timing of adjuvant endocrine therapy among older women with hormone receptor-positive breast cancer enrolled in Medicare Part D
VL  - 33
ID  - 2955
ER  - 

TY  - JOUR
AB  - OBJECTIVES: The aim of the study was to examine ethnic differences in participation in colorectal cancer screening by flexible sigmoidoscopy (FS). It assessed both intentions to be screened and actual screening uptake, and considered whether demographic, health and psychosocial factors mediated the ethnic differences. The setting of this study follows a subset of participants from the UK FS Trial. METHODS: A postal questionnaire assessed ethnicity, demographic characteristics, health, attitudes to screening and FS screening intentions. Data on screening intentions were available for 17,333 adults aged 55-64 years (Sample 1). Screening uptake was recorded in a subsample of 4303 respondents who were subsequently randomized to receive an invitation to screening (Sample 2). RESULTS: Screening intentions in Sample 1 were equally high across all the ethnic groups (>80% [13,724/17,042] reported they were interested). In contrast, attendance (Sample 2) was considerably lower among Asians (54% [43/79]) compared with White (69% [2843/4123]) or Black (80% [33/41]) respondents. Multivariate analysis showed that potential explanatory factors, including socioeconomic deprivation, poor health and fearful and fatalistic attitudes did not account for the lower screening attendance among Asians. CONCLUSION: Further research is required to identify explanations for the gap between intentions and behaviour in UK Asians if any future FS screening programme is to be introduced equitably.
AD  - Department of Epidemiology and Public Health, University College of London, Gower Street, London WC1E 6BT, UK. k.robb@ucl.ac.uk
AN  - 18927095
AU  - Robb, K. A.
AU  - Power, E.
AU  - Atkin, W.
AU  - Wardle, J.
DO  - 10.1258/jms.2008.007112
DP  - NLM
ET  - 2008/10/18
IS  - 3
KW  - Attitude to Health
*Ethnic Groups
Female
Health Status
Humans
Male
Middle Aged
Patient Selection
Perception
Psychology
Sigmoidoscopy/*methods/psychology
United Kingdom
LA  - eng
N1  - Robb, Kathryn A
Power, Emily
Atkin, Wendy
Wardle, Jane
8933/Cancer Research UK/United Kingdom
G9615910/Medical Research Council/United Kingdom
Journal Article
Research Support, Non-U.S. Gov't
England
J Med Screen. 2008;15(3):130-6. doi: 10.1258/jms.2008.007112.
PY  - 2008
SN  - 0969-1413 (Print)
0969-1413
SP  - 130-6
ST  - Ethnic differences in participation in flexible sigmoidoscopy screening in the UK
T2  - J Med Screen
TI  - Ethnic differences in participation in flexible sigmoidoscopy screening in the UK
VL  - 15
ID  - 486
ER  - 

TY  - JOUR
AB  - Objectives: We examine access to and type of social support after initial receipt of an abnormal mammogram across non-Latina White (NLW), African American, and Latina women. Method: This cross-sectional study used a mixed method design, with quantitative and qualitative measures. Women were recruited through 2 community advocates and 3 breast-health-related care organizations. Results: With regard to access, African American women were less likely to access social support relative to NLW counterparts. Similar nonsignificant differences were found for Latinas. Women did not discuss results with family and friends to avoid burdening social networks and negative reactions. Networks’ geographic constraints and medical mistrust influenced Latina and African American women’s decisions to discuss results. With regard to type of social support, women reported emotional support across ethnicity. Latina and African American women reported more instrumental support, whereas NLW women reported more informational support in the context of their well-being. Conclusions: There are shared and culturally unique aspects of women’s experiences with social support after initially receiving an abnormal mammogram. Latina and African American women may particularly benefit from informational support from health care professionals. Communitywide efforts to mitigate mistrust and encourage active communication about cancer may improve ethnic disparities in emotional well-being and diagnostic resolution during initial receipt of an abnormal mammogram. (PsycINFO Database Record (c) 2016 APA, all rights reserved)
AD  - Molina, Yamile, School of Public Health, University of Illinois at Chicago, 1603 West Taylor Street, Chicago, IL, US, 60612
AN  - 2016-25495-001
AU  - Molina, Yamile
AU  - Hohl, Sarah D.
AU  - Nguyen, Michelle
AU  - Hempstead, Bridgette H.
AU  - Weatherby, Shauna Rae
AU  - Dunbar, Claire
AU  - Beresford, Shirley A. A.
AU  - Ceballos, Rachel M.
DB  - psyh
DO  - 10.1037/cdp0000098
DP  - EBSCOhost
IS  - 4
KW  - race/ethnicity
disparities
social support
abnormal mammogram
breast health
Health
Mammography
Racial and Ethnic Differences
Health Disparities
Cancer Screening
N1  - School of Public Health, University of Illinois at Chicago, Chicago, IL, US. Other Publishers: John Wiley & Sons, Inc. Release Date: 20160523. Correction Date: 20161006. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: English. Major Descriptor: Health; Mammography; Racial and Ethnic Differences; Social Support; Health Disparities. Minor Descriptor: Cancer Screening. Classification: Health & Mental Health Treatment & Prevention (3300). Population: Human (10); Female (40). Location: US. Age Group: Adulthood (18 yrs & older) (300); Thirties (30-39 yrs) (340); Middle Age (40-64 yrs) (360); Aged (65 yrs & older) (380). Tests & Measures: Abnormal Mammogram Stressors, Coping Strategies, and Family and Friend Dynamics Semistructured Interview Guide; Psychological Consequences Questionnaire DOI: 10.1037/t12460-000. Methodology: Empirical Study; Longitudinal Study; Qualitative Study; Quantitative Study. Page Count: 6. Issue Publication Date: Oct, 2016. Publication History: First Posted Date: May 23, 2016. Copyright Statement: American Psychological Association. 2016.
Sponsor: National Cancer Institute, US. Grant: P50CA148143, R25CA92408, K01CA154938-01A1, U54CA203000-01, U54CA202995-01, and U54CA202997-01. Recipients: No recipient indicated
PY  - 2016
SN  - 1099-9809
1939-0106
SP  - 588-593
ST  - Ethnic differences in social support after initial receipt of an abnormal mammogram
T2  - Cultural Diversity and Ethnic Minority Psychology
TI  - Ethnic differences in social support after initial receipt of an abnormal mammogram
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2016-25495-001&site=ehost-live&scope=site
ymolin2@uic.edu
VL  - 22
ID  - 1746
ER  - 

TY  - JOUR
AB  - Background: Prior research demonstrated statistically significant racial disparities related to lung cancer treatment and outcomes. We examined differences in initial imaging and survival between blacks, Hispanics, and non-Hispanic whites. Methods: The linked Surveillance, Epidemiology, and End Results-Medicare database between 2007 and 2015 was used to compare initial imaging modality for patients with lung cancer. Participants included 28 881 non-Hispanic whites, 3123 black, and 1907 Hispanics, patients age 66 years and older who were enrolled in Medicare fee-for-service and diagnosed with lung cancer. The primary outcome was comparison of positron emission tomography (PET) imaging with computerized tomography (CT) imaging use between groups. A secondary outcome was 12-month cancer-specific survival. Information on stage, treatment, and treatment facility was included in the analysis. Chi-square test and logistic regression were used to evaluate factors associated with imaging use. Kaplan-Meier method and Cox proportional hazards regression were used to calculate adjusted hazard ratios and survival. All statistical tests were two-sided. Results: After adjusting for demographic, community, and facility characteristics, blacks were less likely to undergo PET or CT imaging at diagnosis compared with non-Hispanic whites odds ratio (OR) = 0.54 (95% confidence interval [CI] = 0.50 to 0.59; P < .001). Hispanics were also less likely to receive PET with CT imaging (OR = 0.72, 95% CI = 0.65 to 0.81; P < .001). PET with CT was associated with improved survival (HR = 0.61, 95% CI = 0.57 to 0.65; P < .001). Conclusions: Blacks and Hispanics are less likely to undergo guidelinerecommended PET with CT imaging at diagnosis of lung cancer, which may partially explain differences in survival. Awareness of this issue will allow for future interventions aimed at reducing this disparity.
AN  - WOS:000606177900006
AU  - Morgan, R. L.
AU  - Karam, S. D.
AU  - Bradley, C. J.
DA  - Dec
DO  - 10.1093/jnci/djaa034
IS  - 12
N1  - djaa034
32134453
PY  - 2020
SN  - 0027-8874
SP  - 1204-1212
ST  - Ethnic Disparities in Imaging Utilization at Diagnosis of Non-Small Cell Lung Cancer
T2  - Jnci-Journal of the National Cancer Institute
TI  - Ethnic Disparities in Imaging Utilization at Diagnosis of Non-Small Cell Lung Cancer
VL  - 112
ID  - 2755
ER  - 

TY  - JOUR
AB  - Ethnic variations that may influence the preferences and outcomes associated with prostate cancer treatment are not well delineated. Our objective was to evaluate prospectively preferences, optimism, involvement in care, and quality of life (QOL) in black and white veterans newly diagnosed with localized prostate cancer. A total of 95 men who identified themselves as black/African-American or white who had newly diagnosed, localized prostate cancer completed a "time trade-off" task to assess utilities for current health and mild, moderate, and severe functional impairment; importance rankings for attributes associated with prostate cancer (eg, urinary function); and baseline and follow-up measures of optimism, involvement in care, and QOL. Interviews were scheduled before treatment, and at 3 and 12 months after treatment. At baseline, both blacks and whites ranked pain, bowel, and bladder function as their most important concerns. Optimism, involvement in care, and QOL were similar. Utilities for mild impairment were lower for blacks than whites, but were similar for moderate and severe problems. Decline in QOL at 3 and 12 months compared to baseline occurred for both groups. However, even with adjustment for marital status, education level, and treatment, blacks had less increase in nausea and vomiting and more increase in difficulty with sexual interest and weight gain compared with whites. Black and white veterans entered localized prostate cancer treatment with similar priorities, optimism, and involvement in care. Quality-of-life declines were common to both groups during the first year after diagnosis, but ethnic variation occurred with respect to nausea and vomiting, sexual interest, and weight gain.
AD  - Mental Health Service, Research and Development, Department of Veterans Affairs Medical Center, San Francisco 94121, USA. sknight@itsa.ucsf.edu
AN  - 15279688
AU  - Knight, S. J.
AU  - Siston, A. K.
AU  - Chmiel, J. S.
AU  - Slimack, N.
AU  - Elstein, A. S.
AU  - Chapman, G. B.
AU  - Nadler, R. B.
AU  - Bennett, C. L.
DA  - Jun
DO  - 10.3816/cgc.2004.n.010
DP  - NLM
ET  - 2004/07/29
IS  - 1
KW  - *African Continental Ancestry Group
Aged
Attitude to Health
Cross-Sectional Studies
*European Continental Ancestry Group
Humans
Male
Middle Aged
Nausea/etiology
Patient Participation
Prostatic Neoplasms/*ethnology/pathology/*therapy
*Quality of Life
Sexuality
*Veterans
Vomiting/etiology
Weight Gain
LA  - eng
N1  - Knight, Sara J
Siston, Amy K
Chmiel, Joan S
Slimack, Nicholas
Elstein, Arthur S
Chapman, Gretchen B
Nadler, Robert B
Bennett, Charles L
Comparative Study
Journal Article
Research Support, U.S. Gov't, Non-P.H.S.
United States
Clin Prostate Cancer. 2004 Jun;3(1):31-7. doi: 10.3816/cgc.2004.n.010.
PY  - 2004
SN  - 1540-0352 (Print)
1540-0352
SP  - 31-7
ST  - Ethnic variation in localized prostate cancer: a pilot study of preferences, optimism, and quality of life among black and white veterans
T2  - Clin Prostate Cancer
TI  - Ethnic variation in localized prostate cancer: a pilot study of preferences, optimism, and quality of life among black and white veterans
VL  - 3
ID  - 624
ER  - 

TY  - JOUR
AB  - BACKGROUND: Ethnic variation in patient-reported outcomes such as health-related quality of life (HRQoL) and satisfaction with care are understudied areas in the management of elderly prostate cancer (PCa) patients. METHODS: In this prospective cohort study, between the years 2002 and 2004, the authors recruited 214 older (>or=65 years) men with newly diagnosed PCa from an urban academic hospital and a Veterans Administration hospital. Participants completed generic (SF-36), prostate-specific (UCLA-PCI) HRQoL, and satisfaction with care (CSQ-8) surveys at baseline and at 3, 6, and 12-months follow-up. Clinically significant difference was used to compute return to baseline. The authors compared time to return to baseline HRQoL after controlling for confounding variables by using ANOVA and log-linear models. Survival curves were used to compare time to return to baseline across ethnicity. RESULTS: Regression analysis revealed that age and marital status, not ethnicity, were independent predictors of radical prostatectomy, rather than radiation treatment. African Americans reported lower HRQoL scores at diagnosis and required a longer time to return to baseline. Log-linear analysis indicated that African-American ethnicity was associated with lower 12-month scores for role physical (odds ratio [OR], 0.46; standard error [SE], 0.40), role emotional (OR, 0.37; SE, 0.43), bodily pain (OR, 0.74; SE, 0.10), urinary function (OR, 0.90; SE, 0.11), and urinary bother (OR, 0.72; SE, 0.17). Both groups reported comparably high levels of satisfaction with care. CONCLUSIONS: African-American elderly exhibited poorer outcomes and required a longer time to return to baseline HRQoL. These differences highlight the need for discussion with patients and families prior to treatment about expectations and the need for support services post-treatment.
AD  - Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104-2676, USA. jravi@mail.med.upenn.edu
AN  - 17443664
AU  - Jayadevappa, R.
AU  - Johnson, J. C.
AU  - Chhatre, S.
AU  - Wein, A. J.
AU  - Malkowicz, S. B.
DA  - Jun 1
DO  - 10.1002/cncr.22675
DP  - NLM
ET  - 2007/04/20
IS  - 11
KW  - Activities of Daily Living
African Americans/*statistics & numerical data
Aged
Cohort Studies
Ethnic Groups
European Continental Ancestry Group/*statistics & numerical data
Health Status
Humans
Male
Outcome Assessment, Health Care
Prospective Studies
Prostatectomy
Prostatic Neoplasms/*ethnology/psychology/therapy
*Quality of Life
*Self Disclosure
Surveys and Questionnaires
LA  - eng
N1  - Jayadevappa, Ravishankar
Johnson, Jerry C
Chhatre, Sumedha
Wein, Alan J
Malkowicz, S Bruce
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
United States
Cancer. 2007 Jun 1;109(11):2229-38. doi: 10.1002/cncr.22675.
PY  - 2007
SN  - 0008-543X (Print)
0008-543x
SP  - 2229-38
ST  - Ethnic variation in return to baseline values of patient-reported outcomes in older prostate cancer patients
T2  - Cancer
TI  - Ethnic variation in return to baseline values of patient-reported outcomes in older prostate cancer patients
VL  - 109
ID  - 528
ER  - 

TY  - JOUR
AB  - BACKGROUND: Ethnic/racial minorities experience poorer outcomes from lung cancer than non-Hispanic whites. Higher hospital procedure volume is associated with better survival from lung resection for lung cancer. OBJECTIVES: We examined whether (1) ethnic/racial minorities are more likely to obtain lung resections at lower volume hospitals, (2) ethnicity/race is associated with inpatient mortality, (3) hospital volume mediates this association, and (4) hospital selection is mediated by racial/ethnic segregation, differences in insurance coverage, or limited hospital choice. METHODS: Six years of data from the Nationwide Inpatient Sample (NIS 1998-2003, unweighted n = 50,245, weighted n = 129,506) were used in multivariate models controlling for sociodemographic factors, case complexity, and hospital characteristics. Additional analyses were conducted using the Area Resource File, which provided data on ethnic density and number of surgical hospitals in the hospital region. RESULTS: Blacks/African Americans (odds ratio [OR] = 0.45; 0.34-0.58) and Latinos (OR = 0.44; 0.32-0.63) had lower odds of obtaining lung resection at a high-volume hospital than non-Hispanic whites. Blacks/African Americans (OR = 1.30; 1.01-1.67), Latinos (OR = 1.41; 1.02-1.94), and other racial/ethnic minorities (OR = 1.46; 1.04-2.06) also had higher odds of dying in hospital, but this association was statistically nonsignificant after controlling for hospital volume. Hospital location was not associated with lung resection procedure volume, nor did location mediate the association between ethnicity/race and hospital volume. CONCLUSIONS: Ethnic/racial minorities are obtaining lung resection in lower volume hospitals and are more likely to die in hospital. Hospital volume is associated with higher mortality, but health insurance, segregation, and number of surgical hospitals within a county do not account for observed disparities.
AD  - National Center on Addiction and Substance Abuse at Columbia University, 633 Third Avenue, New York, NY 10017, USA. cneighbors@casacolumbia.edu
AN  - 17571014
AU  - Neighbors, C. J.
AU  - Rogers, M. L.
AU  - Shenassa, E. D.
AU  - Sciamanna, C. N.
AU  - Clark, M. A.
AU  - Novak, S. P.
DA  - Jul
DO  - 10.1097/MLR.0b013e3180326110
DP  - NLM
ET  - 2007/06/16
IS  - 7
KW  - *African Americans
Aged
Community Participation
*European Continental Ancestry Group
Female
Health Services Accessibility
*Hispanic Americans
*Hospital Administration
Hospital Bed Capacity
Hospital Mortality
Humans
Insurance Coverage
Insurance, Health
Lung Neoplasms/*ethnology/*surgery
Male
Quality of Health Care
Rural Population
Urban Population
LA  - eng
N1  - Neighbors, Charles J
Rogers, Michelle L
Shenassa, Edmond D
Sciamanna, Christopher N
Clark, Melissa A
Novak, Scott P
K07 CA 909961/CA/NCI NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
United States
Med Care. 2007 Jul;45(7):655-63. doi: 10.1097/MLR.0b013e3180326110.
PY  - 2007
SN  - 0025-7079 (Print)
0025-7079
SP  - 655-63
ST  - Ethnic/racial disparities in hospital procedure volume for lung resection for lung cancer
T2  - Med Care
TI  - Ethnic/racial disparities in hospital procedure volume for lung resection for lung cancer
VL  - 45
ID  - 526
ER  - 

TY  - JOUR
AB  - Background:Black ethnic groups have a higher breast cancer mortality than Whites. American studies have identified variations in tumour biology and unequal health-care access as causative factors. We compared tumour pathology, treatment and outcomes in three ethnic groups in young breast cancer patients treated in the United Kingdom.Methods:Women aged ≤40 years at breast cancer diagnosis were recruited to the POSH national cohort study (MREC: 00/06/69). Personal characteristics, tumour pathology and treatment data were collected at diagnosis. Follow-up data were collected annually. Overall survival (OS) and distant relapse-free survival (DRFS) were assessed using Kaplan-Meier curves, and multivariate analyses were performed using Cox regression.Results:Ethnicity data were available for 2915 patients including 2690 (91.0%) Whites, 118 (4.0%) Blacks and 87 (2.9%) Asians. Median tumour diameter at presentation was greater in Blacks than Whites (26.0 mm vs 22.0 mm, P=0.0103), and multifocal tumours were more frequent in both Blacks (43.4%) and Asians (37.0%) than Whites (28.9%). ER/PR/HER2-negative tumours were significantly more frequent in Blacks (26.1%) than Whites (18.6%, P=0.043). Use of chemotherapy was similarly high in all ethnic groups (89% B vs 88.6% W vs 89.7% A). A 5-year DRFS was significantly lower in Blacks than Asians (62.8% B vs 77.0% A, P=0.0473) or Whites (62.8 B% vs 77.0% W, P=0.0053) and a 5-year OS for Black patients, 71.1% (95% CI: 61.0-79.1%), was significantly lower than that of Whites (82.4%, 95% CI: 80.8-83.9%, W vs B: P=0.0160). In multivariate analysis, Black ethnicity had an effect on DRFS in oestrogen receptor (ER)-positive patients that is independent of body mass index, tumour size, grade or nodal status, HR: 1.60 (95% CI: 1.03-2.47, P=0.035).Conclusion:Despite equal access to health care, young Black women in the United Kingdom have a significantly poorer outcome than White patients. Black ethnicity is an independent risk factor for reduced DRFS particularly in ER-positive patients. © 2014 Cancer Research UK.
AD  - E. Copson, Cancer Sciences Academic Unit, University of Southampton Clinical Trials Unit, University Hospital Southampton Foundation Trust, Tremona Road, Southampton SO16 6YA, United Kingdom
AU  - Copson, E.
AU  - Maishman, T.
AU  - Gerty, S.
AU  - Eccles, B.
AU  - Stanton, L.
AU  - Cutress, R. I.
AU  - Altman, D. G.
AU  - Durcan, L.
AU  - Simmonds, P.
AU  - Jones, L.
AU  - Tapper, W.
AU  - Eccles, D.
DB  - Embase
Medline
DO  - 10.1038/bjc.2013.650
IS  - 1
KW  - antineoplastic agent
estrogen receptor
article
Asian
body mass
breast cancer
cancer adjuvant therapy
cancer chemotherapy
cancer grading
cancer recurrence
cancer risk
cancer surgery
cancer survival
Caucasian
cohort analysis
distant recurrence free survival
estrogen receptor positive breast cancer
ethnic group
ethnicity
female
follow up
human
major clinical study
Black person
outcome assessment
overall survival
partial mastectomy
priority journal
recurrence free survival
survival rate
tumor volume
United Kingdom
LA  - English
M3  - Article
N1  - L52827872
2013-10-28
2014-01-20
PY  - 2014
SN  - 0007-0920
1532-1827
SP  - 230-241
ST  - Ethnicity and outcome of young breast cancer patients in the United Kingdom: The POSH study
T2  - British Journal of Cancer
TI  - Ethnicity and outcome of young breast cancer patients in the United Kingdom: The POSH study
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L52827872&from=export
http://dx.doi.org/10.1038/bjc.2013.650
VL  - 110
ID  - 1039
ER  - 

TY  - JOUR
AB  - BACKGROUND: Social inequalities in breast cancer survival are smaller when the cancer is screen-detected. We examined survival from screen-detected and non screen-detected breast cancer by ethnicity and deprivation. METHODS: Cancer registry data for 20 283 women aged 50-70 years, diagnosed between 1989-2011 and invited for screening, were linked with screening and ethnicity data. We examined Asian, Black and White groups, less deprived and middle/more deprived women. Net survival was estimated using ethnic- and deprivation-specific life tables. Estimates were corrected for lead-time bias and over-diagnosis. RESULTS: Net survival varied by screening history. No significant differences in survival were found by ethnicity. Five-year net survival was 90.0% (95% CI, 89.3-90.8%) in less deprived groups and 86.7% (85.9-87.4%) among middle/more deprived women. Screening benefitted all ethnic and both deprivation groups. Whether screen-detected or not, more deprived women had significantly poorer outcomes: 5-year net survival was 78.0% (76.7-79.2%) for deprived women who were not screen-detected compared with 94.0% (93.1-95.1%) for less deprived women who were screen-detected. CONCLUSIONS: The three ethnic groups differed little in their breast cancer survival. Although screening confers a survival benefit to all, there are still wide disparities in survival by deprivation. More needs to be done to determine what underlies these differences and tackle them.
AD  - Cancer Research UK Cancer Survival Group, Department of Non-Communicable Disease Epidemiology, Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, Keppel St, London WC1E 7HT, UK.
West Midlands Breast Screening Quality Assurance Reference Centre, Public Health England, 5 St Philip's Place, Birmingham B3 2PW, UK.
AN  - 26079301
AU  - Morris, M.
AU  - Woods, L. M.
AU  - Rogers, N.
AU  - O'Sullivan, E.
AU  - Kearins, O.
AU  - Rachet, B.
C2  - PMC4522622
DA  - Jul 28
DO  - 10.1038/bjc.2015.204
DP  - NLM
ET  - 2015/06/17
IS  - 3
KW  - Aged
Breast Neoplasms/diagnosis/*mortality
Early Detection of Cancer/*statistics & numerical data
Ethnic Groups/*statistics & numerical data
Female
Health Services Accessibility/statistics & numerical data
Humans
Mammography/*statistics & numerical data
Middle Aged
Patient Participation/statistics & numerical data
*Psychosocial Deprivation
Socioeconomic Factors
Survival Analysis
United Kingdom/epidemiology
LA  - eng
N1  - 1532-1827
Morris, M
Woods, L M
Rogers, N
O'Sullivan, E
Kearins, O
Rachet, B
14031/CRUK_/Cancer Research UK/United Kingdom
C23409/A14031/CRUK_/Cancer Research UK/United Kingdom
Journal Article
Research Support, Non-U.S. Gov't
Br J Cancer. 2015 Jul 28;113(3):548-55. doi: 10.1038/bjc.2015.204. Epub 2015 Jun 16.
PY  - 2015
SN  - 0007-0920 (Print)
0007-0920
SP  - 548-55
ST  - Ethnicity, deprivation and screening: survival from breast cancer among screening-eligible women in the West Midlands diagnosed from 1989 to 2011
T2  - Br J Cancer
TI  - Ethnicity, deprivation and screening: survival from breast cancer among screening-eligible women in the West Midlands diagnosed from 1989 to 2011
VL  - 113
ID  - 238
ER  - 

TY  - JOUR
AB  - Cancer clinical trial (CCT) accrual and retention rates remain disproportionately low among African Americans. Awarenesss and access to trials are crucial facilitators of trial participation. Strategies developed within a community-based participatory framework (CBPR) are potential solutions to increase awareness and access to CCTs. In this study, we describe the pilot phase of three innovative community-centered modules to improve basic CCT knowledge, awareness of locations to access CCT information, and opportunities to participate in CCTs. Four community organizations completed Community Bridges to CCT training-of-the-trainer and recruited adult African American volunteers to participate in one of three CCT education modules: a workshop about CCTs, a role play describing one person's experience with CCTs, or a call and response session reviewing myths and facts about CCTs. Pre- and post-test surveys were collected and analyzed using McNemar agreement statistic to evaluate changes in knowledge and attitudes regarding trials. Trainers enrolled 125 participants in the call and response (n = 22), role play (n = 60), and workshop (n = 43) modules. Module participants were mostly African American, female, and with a mean age of 53 years. Comparison of pre- and post-test responses demonstrates favorable changes in awareness of CCTs and where to access CCTs across the sample. Analysis by module type indicates significant increases for participants in the call and response (p < 0.01) and role play modules (p < 0.001), but not the workshop module. Despite measures taken to increase the participation and retention rate of African Americans in clinical trials, little advancement has been made. Developing tailored community education modules on CCTs within the CBPR framework is a promising innovation to increase knowledge about CCTs and favorable attitudes about participation that are known precursors to trial enrollment.
AN  - WOS:000349759300024
AU  - Green, M. A.
AU  - Michaels, M.
AU  - Blakeney, N.
AU  - Odulana, A. A.
AU  - Isler, M. R.
AU  - Richmond, A.
AU  - Long, D. G.
AU  - Robinson, W. S.
AU  - Taylor, Y. J.
AU  - Corbie-Smith, G.
DA  - Mar
DO  - 10.1007/s13187-014-0764-1
IS  - 1
N1  - 25564207
PY  - 2015
SN  - 0885-8195
SP  - 158-166
ST  - Evaluating a Community-Partnered Cancer Clinical Trials Pilot Intervention with African American Communities
T2  - Journal of Cancer Education
TI  - Evaluating a Community-Partnered Cancer Clinical Trials Pilot Intervention with African American Communities
VL  - 30
ID  - 2985
ER  - 

TY  - JOUR
AB  - This mixed methods study will occur in three phases: (Aim 1) a formative exploratory phase involving in‐depth qualitative interviews that will inform Aims 2 and 3; (Aim 2) development and pilot testing of all COACH research protocols, including coach training curriculum, quantitative surveys, recruitment protocols among 50 participants and 50 coaches; and (Aim 3) a full‐size randomized trial involving recruitment of total 550 study participants and 550 coaches, randomization, and longitudinal data collection. Aim 1: Implement formative research to inform COACH intervention (IRB Number 00003825): As of June 2012, we have conducted in‐depth interviews reaching saturation with twelve stakeholders; six healthcare providers and six community leaders. The interviews were transcribed and analyzed providing crucial information for the development of the research in Aims 2 and 3. Aim 2: Development and pilot testing of all COACH protocols among 50 index participants and 50 participant‐designated coaches: Using convenience sampling, we will recruit and enroll African American residents of Baltimore City and Prince George's County who are aged 50‐74 years. We will conduct a pilot study to assess the coaches' effect (versus traditional health education using an educational brochure) on overcoming the participants' barriers to discussing cancer screening with their primary care providers and, if needed, to getting screened for breast, cervical, and/or colorectal cancers. Aim 3: Implementation of full randomized COACH trial among 550 total participants and 550 total coaches: Using convenience sampling and other sampling methods, we will recruit and enroll African American residents of Baltimore City and Prince George's County who are aged 50‐74 years. We will utilize our study's IRB‐approved flyer to recruit potential study participants in medical centers, senior housing, neighborhood development centers, markets, and community centers in various neighborhoods in our study's catchment areas. Eligible and interested participants will complete an in‐person baseline interview administered by a trained interviewer. The participant will then be randomized, stratifying by county and gender, to one of the following two interventions: (1) printed educational materials only (PEM) or (2) printed educational material plus specialized training for his/her health coach to help the participant overcome his/her barriers to cancer screening (COACH). The coach will then complete a short interviewer‐administered questionnaire. If the participant is randomized to COACH, then the coach will be invited to participate in a 40‐minute in‐person training. Participants and coaches will then be queried at 6‐months and one year to assess their cancer screening status and other outcomes of interest. The primary outcome variable of the COACH intervention will be the change in the proportion of participants completing at least one of the recommended screenings, comparing the COACH group to the PEM group during follow up. Another primary outcome will be the change in the proportion of participants who report talking with their healthcare provider regarding at least one of the recommended cancer screening(s) during follow up. Secondary outcome variables will include between‐group changes in the time to completion of screenings, changes in cancer screening barriers, and changes in the reported levels of stress for both the participants and coaches.
AN  - CN-02040216
AU  - Nct
KW  - Colorectal Neoplasms
Uterine Cervical Neoplasms
PY  - 2012
ST  - Evaluating Coaches of Older Adults for Cancer Care and Health Behaviors
T2  - https://clinicaltrials.gov/show/NCT01613430
TI  - Evaluating Coaches of Older Adults for Cancer Care and Health Behaviors
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02040216/full
ID  - 1612
ER  - 

TY  - THES
AB  - This study involved a cross-sectional analysis of baseline dietary intake data from African American breast cancer survivors (AABCS) enrolled in 'Moving Forward,' a randomized controlled weight management intervention study. Analyses examined: 1) habitual dietary intake; 2) adherence to the general United States (US) population 2010 Dietary Guidelines for Americans (2010 DGAs); and 3) adherence to the American Cancer Society/American Institute of Cancer Research (ACS/AICR) dietary recommendations. We used the Healthy Eating Index-2010 (HEI 2010) to assess adherence to the 2010 DGAs and a 24-point dietary quality scoring system adapted from Berdan et al. 2014 and Hastert et al. 2013 to assess adherence to the combined ACS/AICR dietary recommendations. We also examined predictors of dietary quality including demographics, self-efficacy, social support, and perceived barriers to healthy foods. In this cohort of AABCS, dietary quality was sub-optimal. However, the dietary quality scores were higher than reported for AA women in the general population and some studies targeting white breast cancer survivors. Dietary components with optimal and poor adherence should be acknowledged when developing interventions, as well as the relationship between education, self-efficacy, and lifestyle factors on dietary adherence. Self-efficacy and perceived barriers to healthy foods play a significant role in dietary adherence. This relationship seems to be modified by lifestyle factors. Greater attention is needed to understand how social, cultural, and environmental factors may work together and be leveraged to strengthen intervention and improve dietary outcomes in AABCS. (PsycINFO Database Record (c) 2018 APA, all rights reserved)
AN  - 2017-54457-090
AU  - Springfield, Sparkle
DB  - psyh
DP  - EBSCOhost
KW  - diet quality
African Americans
breast cancer survivors
Blacks
Breast Neoplasms
Diets
Survivors
N1  - Accession Number: 2017-54457-090. Other Journal Title: Dissertation Abstracts International. Partial author list: First Author & Affiliation: Springfield, Sparkle; University of Illinois at Chicago, Kinesiology and Nutrition, US. Release Date: 20180212. Publication Type: Dissertation Abstract (0400). Format Covered: Electronic. Document Type: Dissertation. Dissertation Number: AAI10644561. ISBN: 978-0355177954. Language: English. Major Descriptor: Blacks; Breast Neoplasms; Diets; Survivors. Classification: Health & Mental Health Treatment & Prevention (3300). Population: Human (10). Location: US. Methodology: Empirical Study; Quantitative Study.
PB  - ProQuest Information & Learning
PY  - 2018
SN  - 0419-4217
978-0355177954
ST  - Evaluating diet quality in African American breast cancer survivors
TI  - Evaluating diet quality in African American breast cancer survivors
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2017-54457-090&site=ehost-live&scope=site
VL  - 79
ID  - 1686
ER  - 

TY  - JOUR
AB  - PURPOSE: There has been much publicized concern about difficulty with minority recruitment into research studies, particularly since minority inclusion in randomized clinical trials was mandated by the 1993 National Institutes of Health Revitalization Act. We reviewed recruitment data in published reports from clinical studies to assess the actual degree of success in recruiting minorities versus whites and to identify barriers to recruitment. METHODS: We abstracted articles published between September 1993 and February 1995 that reported detailed results of participant recruitment for studies conducted in the United States. RESULTS: Of 65 articles meeting our eligibility criteria (median sample size, 1323), only one (1.5%) reported the racial/ethnic composition of potential study participants. Only two articles (3.1%) provided information about the racial/ethnic composition of eligible subjects, and only one (1.5%) provided information about the racial/ethnic composition of refusing subjects. For enrolled subjects, race/ethnicity was less likely to be reported (58.5%) than were age (90.8%) or gender (80.0%). CONCLUSIONS: The published literature currently contains insubstantial data to either refute or prove that there are differential recruitment rates among minorities as compared with whites. Changes in reporting will be needed in order to track progress in this area. (C) 1997 Elsevier Science Inc.
AN  - WOS:A1997YC85900008
AU  - Ness, R. B.
AU  - Nelson, D. B.
AU  - Kumanyika, S. K.
AU  - Grisso, J. A.
DA  - Oct
DO  - 10.1016/S1047-2797(97)00080-X
IS  - 7
N1  - 59
9349914
PY  - 1997
SN  - 1047-2797
SP  - 472-478
ST  - Evaluating minority recruitment into clinical studies: How good are the data?
T2  - Annals of Epidemiology
TI  - Evaluating minority recruitment into clinical studies: How good are the data?
VL  - 7
ID  - 2732
ER  - 

TY  - JOUR
AB  - BACKGROUND: Associations between optimal use of a tailored decision-aid and levels of accuracy of perceived breast cancer risk, confidence in decision-making, and satisfaction with decisions about HRT were evaluated in a randomized intervention trial with a community sample of women aged 45-54. METHODS: Data are from 289 women randomized to receive a computer-tailored three-step decision-aid. RESULTS: Forty-seven percent of participants reported optimal use of the intervention materials. African American women and those with low confidence in decision-making were less likely to use the intervention optimally than white women and those with higher confidence (P<0.05). Optimal use of the decision-aid was associated with increased accuracy of perceived risk and confidence to make a decision. DISCUSSION: When used optimally, self-directed decision-aids can improve women's ability to make decisions about HRT. Additional refinement of these aids is needed. For some subgroups of women, adjuncts such as telephone counseling also might be considered.
AD  - Center for Health Services Research in Primary Care, Durham Veterans Affairs Medical Center, 508 Fulton Street (152), Durham, NC 27705, USA. basti001@mc.duke.edu
AN  - 12477613
AU  - Bastian, L. A.
AU  - McBride, C. M.
AU  - Fish, L.
AU  - Lyna, P.
AU  - Farrell, D.
AU  - Lipkus, I. M.
AU  - Rimer, B. K.
AU  - Siegler, I. C.
DA  - Dec
DO  - 10.1016/s0738-3991(02)00048-4
DP  - NLM
ET  - 2002/12/13
IS  - 3
KW  - African Americans/education/psychology
Computer-Assisted Instruction/standards
Counseling
*Decision Making, Computer-Assisted
*Decision Support Techniques
Estrogen Replacement Therapy/adverse effects/*psychology
European Continental Ancestry Group/education/psychology
Female
Humans
Middle Aged
North Carolina
Patient Education as Topic/standards
Patient Participation
Postmenopause/*psychology
Self Efficacy
Women/education/*psychology
LA  - eng
N1  - Bastian, Lori A
McBride, Colleen M
Fish, Laura
Lyna, Pauline
Farrell, David
Lipkus, Isaac M
Rimer, Barbara K
Siegler, Ilene C
P01-CA-72099-05/CA/NCI NIH HHS/United States
Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, U.S. Gov't, P.H.S.
Ireland
Patient Educ Couns. 2002 Dec;48(3):283-91. doi: 10.1016/s0738-3991(02)00048-4.
PY  - 2002
SN  - 0738-3991 (Print)
0738-3991
SP  - 283-91
ST  - Evaluating participants' use of a hormone replacement therapy decision-making intervention
T2  - Patient Educ Couns
TI  - Evaluating participants' use of a hormone replacement therapy decision-making intervention
VL  - 48
ID  - 660
ER  - 

TY  - JOUR
AB  - Objective: In an effort to evaluate the effectiveness of faith-based health promotion programmes in educating African American women about breast cancer knowledge and risks, the local affiliate of a national breast cancer research foundation funded the Genesis Health Project (GHP) Network, a community-designed, culturally competent intervention, to develop, implement and evaluate the Breast Cancer Awareness and Education Program. This article reports on the faith-based education model used and uses evaluation data to determine whether the intervention improved awareness of breast cancer risk, methods for reducing risk, the importance of early detection and the availability of low-cost or free mammograms. Design: Pastoral health messaging and culturally appropriate strategies were used to heighten awareness of breast cancer risks and prevention, promote mammography and early detection, increase awareness of free/low-cost mammography and encourage the adoption of healthier behaviours. Setting: African American churches and collaborators targeting African American women in a mid-sized city in the northeastern USA. Method: Summative evaluations used paper and pencil pre- and post-event surveys, with measures for objectives targeted by the programme to evaluate the impact of activities. Results: Overall, participants in the Breast Cancer Awareness and Education Program showed improvements in general knowledge about breast cancer, higher breast cancer mortality among African American women, warning signs, risks and ways to mitigate risk, and the availability of low-cost or free mammograms. Conclusion: Findings confirm that faith-based health promotion programmes can be effective in helping to educate inner-city African American women about breast cancer and associated risk factors.
AD  - M.T. Brown, School of Social Work, David B. Falk College, Syracuse University, 320D Lyman Hall, Syracuse, NY, United States
AU  - Brown, M. T.
AU  - Cowart, L. W.
DB  - Embase
DO  - 10.1177/0017896918778308
IS  - 5
KW  - adult
African American
aged
article
breast cancer
cancer mortality
community participation
cultural sensitivity
early cancer diagnosis
faith-based organization
female
health behavior
health care availability
health education
health promotion
human
male
mammography
priority journal
risk reduction
United States
LA  - English
M3  - Article
N1  - L622435993
2018-06-08
2018-08-27
PY  - 2018
SN  - 1748-8176
0017-8969
SP  - 571-585
ST  - Evaluating the effectiveness of faith-based breast health education
T2  - Health Education Journal
TI  - Evaluating the effectiveness of faith-based breast health education
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L622435993&from=export
http://dx.doi.org/10.1177/0017896918778308
VL  - 77
ID  - 888
ER  - 

TY  - JOUR
AB  - Background: The WISDOM Study (Women Informed to Screen Depending on Measures of risk) aims to examine the effectiveness of personalized breast cancer screening and to bring objective recommendations to the current mammography screening debate. The WISDOM Study is a 100,000 woman randomized trial with a preference‐tolerant design that will determine if risk‐based screening (RBS) vs. annual screening, is as safe, less morbid, enables prevention and is preferred by women. A pilot was conducted to test the logistics of online participation and examine the acceptance of the study design and approach. Methods: Women were recruited from the UCSF site of the Athena Breast Health Network, a clinical care‐research cohort of 110,000 women from the 5 University of California Medical Centers and Sanford Health. The pilot recruited women via email who were 40‐74 years of age with no history of breast cancer and a normal mammogram in the past year. Those interested visited the WISDOM Study website (wisdomstudy.org), signed up, elected randomization or self‐selection, provided electronic consent using DocuSign (eConsent), and completed genetic testing (RBS arm). The Breast Cancer Surveillance Consortium (BCSC) model (standard risk factors, ethnicity, and breast density) in addition to genetic testing (9 genes and 75 SNPs) was used to calculate breast cancer risks that informed the start and frequency of screening for women in the RBS arm. BCSC was also used in the annual screening arm but did not inform mammography screening recommendations. The pilot used a mixed method approach (using enrollment data, Exit Survey data, individual interviews and focus groups) to assess enrollment preferences, randomization acceptance and overall study workflow. Results: The online electronic enrollment process and patient engagement portal was successfully implemented. In total, 639 women were invited, 235 registered (34%), and 171 (27%) consented to the pilot. Of these, 74% (127) elected to be randomized, and 26% chose to self‐assign (66% chose annual screening (29)). Mean age was 56 years and the ethnic breakdown of the cohort was: 79% White, 10% Asian, 7% Latino, 3% Black, 1% other. 92% of those in the risk‐based arm of the study completed genetic testing and were given results; only one genetic mutation was identified and occurred in CHEK2. Within the RBS arm (78), mammography recommendations were: 61% no further mammography until the age of 50, 22% biennial, 11% annual, and 6% every 6 month alternating MRI and mammogram. Exit Survey data illuminated confusion in study arm names (risk‐based vs. annual), randomization acceptance (74%), annual arm preference in the self‐selection group (66%), eConsent satisfaction (90%), enrollment process ease of use (88%), and website content, navigation and appearance satisfaction (66%). The pilot concluded in May 2016 to allow for refinements prior to the full trial. Conclusion: Our pilot demonstrates that the majority of women are willing to be randomized and participate in an online screening study to answer the important question on optimal breast cancer screening. The pilot study results will inform implementation of the 100,000 women WISDOM Study which launches in fall of 2016.
AN  - CN-01378057
AU  - Stover Fiscalini, A.
AU  - Theiner, S.
AU  - Kaplan, C.
AU  - Sarrafan, S.
AU  - Sawyer, S.
AU  - Liang, A.
AU  - Rosenberg-Wohl, S.
AU  - Gordon, D.
AU  - Frick, M.
AU  - Borowsky, A.
AU  - et al.
DO  - 10.1158/1538-7445.SABCS16-P5-02-03
IS  - 4
KW  - *breast cancer
*cancer screening
*feasibility study
Adult
Aged
Animal model
Breast density
California
Cancer risk
Controlled clinical trial
Controlled study
Disease model
Ethnicity
E‐mail
Female
Gene mutation
Genetic screening
Genetic susceptibility
Hispanic
Human
Information processing
Interview
Major clinical study
Mammography
Middle aged
Nomenclature
Nuclear magnetic resonance imaging
Pilot study
Randomization
Randomized controlled trial
Risk factor
Satisfaction
Study design
University
Workflow
M3  - Journal: Conference Abstract
PY  - 2017
ST  - Evaluating the feasibility of a web-based preference-tolerant randomized trial of risk-based vs. annual breast cancer screening: WISDOM study pilot
T2  - Cancer research
TI  - Evaluating the feasibility of a web-based preference-tolerant randomized trial of risk-based vs. annual breast cancer screening: WISDOM study pilot
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01378057/full
VL  - 77
ID  - 1656
ER  - 

TY  - JOUR
AB  - Objective: Psychological distress impairs the cognitive function involved in planning and decision-making (executive cognitive function), and hinders engagement in health promoting behaviors. This study examined the relationship among distress, executive cognitive function (ECF) and mammography use in African American women at risk for breast cancer. Design: A cross-sectional sample of mammography screening adherers (n=44) and nonadherers (n=16) completed measures of psychological distress (Brief Symptom Inventory) and executive cognitive function, (Wisconsin Card Sort Task and Stroop Color Word Test). Results: More than one-quarter of the high-risk sample had high levels of distress. Distress scores explained 12% of the variance in two ECF components (abstract concept formation and cognitive flexibility), suggesting a significant relationship between psychological distress and cognitive function. Distress scores and ECF measures did not predict mammography use; employment status emerged as the strongest predictor of mammography screening (OR=4.36, 95% CI: 1.18-16.07). Conclusion: Elevated psychological distress is evident in high-risk African American women and appears to have an effect on the cognitive function involved in behavioral regulation and planning. Results also support the role of socioeconomic status as a significant predictor of mammography use.
AD  - S.S. Laing, Department of Psychology, Howard University, United States
AU  - Laing, S. S.
AU  - Ocampo, C.
AU  - Harris, J. R.
DB  - Embase
Medline
IS  - 4
KW  - adult
African American
article
breast cancer
Brief Symptom Inventory
cancer risk
cancer screening
controlled study
correlation analysis
distress syndrome
employment status
executive function
female
health care utilization
human
major clinical study
mammography
patient participation
psychological aspect
socioeconomics
wisconsin card sort task and stroop color word test
LA  - English
M3  - Article
N1  - L362515889
2011-09-16
2011-09-21
PY  - 2010
SN  - 1049-510X
SP  - 467-473
ST  - Evaluating the relationships among psychological distress, executive cognitive function and economic factors on mammography use in unaffected African American women at risk for breast cancer
T2  - Ethnicity and Disease
TI  - Evaluating the relationships among psychological distress, executive cognitive function and economic factors on mammography use in unaffected African American women at risk for breast cancer
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L362515889&from=export
http://www.ishib.org/journal/20-4/ethn-20-04-467.pdf
VL  - 20
ID  - 1157
ER  - 

TY  - JOUR
AB  - Engaging partners in the planning, implementation, and evaluation of cancer education programs is critical for improving the health of our communities. A 2-year pilot education intervention on prostate cancer decision making and participation in medical research was funded by the National Cancer Institute. The partnership involving community members and clinical staff at a cancer center was used to develop recruitment strategies and plan for the implementation of the intervention with African-American middle-age and older men and female family members. We assessed partners' perceptions of this community-academic-clinical research collaboration. In year 2, eight project advisory council members were selected among existing partners and year 1 participants to serve as a formal committee. Council members were required to participate in telephone and in person meetings and actively support recruitment/implementation efforts. At the conclusion of the project, 20 individuals (all clinical and community partners, including the eight advisory council members) were invited to complete a survey to assess their perceived impact of the collaboration on the community and provide suggestions for future collaborations. Most partners agreed that their organization benefitted from the collaboration and that various aspects of the advisory council process (e.g., both formal and informal communication) worked well. The most noted accomplishment of the partnership related to leveraging the collaboration to make men more knowledgeable about prostate cancer decision making. Suggested improvements for future collaborations included distributing more frequent updates regarding project successes. Evaluating partners' perceptions of this collaboration provided important recommendations for future planning, implementation, and evaluation of community-based cancer education programs.
AN  - 24078315
AU  - Friedman, D. B.
AU  - Owens, O. L.
AU  - Jackson, D. D.
AU  - Johnson, K. M.
AU  - Gansauer, L.
AU  - Dickey, J.
AU  - Miller, R.
AU  - Payne, J.
AU  - Bearden, J. D.
AU  - Hebert, J. R.
C2  - PMC3968180
C6  - NIHMS528314
DA  - Mar
DO  - 10.1007/s13187-013-0550-5
DP  - NLM
ET  - 2013/10/01
IS  - 1
KW  - Academic Medical Centers/*organization & administration
Community Networks/*organization & administration
*Cooperative Behavior
*Health Education
*Health Services Accessibility
*Healthcare Disparities
Humans
Male
Pilot Projects
Prognosis
Prostatic Neoplasms/ethnology/*prevention & control
South Carolina
LA  - eng
N1  - 1543-0154
Friedman, Daniela B
Owens, Otis L
Jackson, Dawnyea D
Johnson, Kim M
Gansauer, Lucy
Dickey, Joe
Miller, Ron
Payne, Johnny
Bearden, James D
Hebert, James R
K05 CA136975/CA/NCI NIH HHS/United States
U54 CA153461/CA/NCI NIH HHS/United States
Evaluation Study
Journal Article
Research Support, N.I.H., Extramural
J Cancer Educ. 2014 Mar;29(1):80-5. doi: 10.1007/s13187-013-0550-5.
PY  - 2014
SN  - 0885-8195 (Print)
0885-8195
SP  - 80-5
ST  - An evaluation of a community-academic-clinical partnership to reduce prostate cancer disparities in the South
T2  - J Cancer Educ
TI  - An evaluation of a community-academic-clinical partnership to reduce prostate cancer disparities in the South
VL  - 29
ID  - 314
ER  - 

TY  - JOUR
AB  - Engaging partners in the planning, implementation, and evaluation of cancer education programs is critical for improving the health of our communities. A 2-year pilot education intervention on prostate cancer decision making and participation in medical research was funded by the National Cancer Institute. The partnership involving community members and clinical staff at a cancer center was used to develop recruitment strategies and plan for the implementation of the intervention with African-American middle-age and older men and female family members. We assessed partners’ perceptions of this community–academic–clinical research collaboration. In year 2, eight project advisory council members were selected among existing partners and year 1 participants to serve as a formal committee. Council members were required to participate in telephone and in person meetings and actively support recruitment/implementation efforts. At the conclusion of the project, 20 individuals (all clinical and community partners, including the eight advisory council members) were invited to complete a survey to assess their perceived impact of the collaboration on the community and provide suggestions for future collaborations. Most partners agreed that their organization benefitted from the collaboration and that various aspects of the advisory council process (e.g., both formal and informal communication) worked well. The most noted accomplishment of the partnership related to leveraging the collaboration to make men more knowledgeable about prostate cancer decision making. Suggested improvements for future collaborations included distributing more frequent updates regarding project successes. Evaluating partners’ perceptions of this collaboration provided important recommendations for future planning, implementation, and evaluation of community-based cancer education programs. (PsycINFO Database Record (c) 2016 APA, all rights reserved)
AD  - Friedman, Daniela B., Arnold School of Public Health, Cancer Prevention and Control Program, University of South Carolina, 915 Greene Street, Suite 235, Columbia, SC, US
AN  - 2014-36570-017
AU  - Friedman, Daniela B.
AU  - Owens, Otis L.
AU  - Jackson, Dawnyea D.
AU  - Johnson, Kim M.
AU  - Gansauer, Lucy
AU  - Dickey, Joe
AU  - Miller, Ron
AU  - Payne, Johnny
AU  - Bearden, James D.
AU  - Hebert, James R.
DB  - psyh
DO  - 10.1007/s13187-013-0550-5
DP  - EBSCOhost
IS  - 1
KW  - evaluation
community
academic and clinical partnership
prostate cancer disparities
south
cancer education programs
decision making
interventions
Academic Medical Centers
Community Networks
Cooperative Behavior
Health Education
Health Services Accessibility
Healthcare Disparities
Humans
Male
Pilot Projects
Prognosis
Prostatic Neoplasms
South Carolina
Client Education
Neoplasms
Prostate
Geography
Intervention
N1  - Department of Health Promotion, Education, and Behavior, University of South Carolina, Columbia, SC, US. Other Publishers: Lawrence Erlbaum; Taylor & Francis. Release Date: 20140929. Correction Date: 20141103. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: English. Grant Information: Friedman, Daniela B. Major Descriptor: Client Education; Decision Making; Neoplasms; Prostate. Minor Descriptor: Geography; Intervention. Classification: Promotion & Maintenance of Health & Wellness (3365). Population: Human (10); Male (30); Female (40). Location: US. Age Group: Adulthood (18 yrs & older) (300); Middle Age (40-64 yrs) (360). Tests & Measures: Telephone Survey; online survey; Wilder Foundation Collaboration Factors Inventory. Methodology: Empirical Study; Interview; Qualitative Study; Quantitative Study. References Available: Y. Page Count: 6. Issue Publication Date: Mar, 2014. Publication History: First Posted Date: Sep 28, 2013. Copyright Statement: Springer Science+Business Media New York. 2013.
Sponsor: National Cancer Institute, Community Networks Program Centers, US. Grant: U54 CA153461. Other Details: Pilot Project Leader. Recipients: Friedman, Daniela B.; Hebert, James R. (Prin Inv)
Sponsor: National Cancer Institute, Cancer Training Branch, Cancer Prevention and Control, US. Grant: K05 CA136975. Other Details: Established Investigator Award. Recipients: Hebert, James R.
PY  - 2014
SN  - 0885-8195
1543-0154
SP  - 80-85
ST  - An evaluation of a community–academic–clinical partnership to reduce prostate cancer disparities in the south
T2  - Journal of Cancer Education
TI  - An evaluation of a community–academic–clinical partnership to reduce prostate cancer disparities in the south
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2014-36570-017&site=ehost-live&scope=site
dbfriedman@sc.edu
VL  - 29
ID  - 1732
ER  - 

TY  - JOUR
AB  - PURPOSE: To evaluate the effects of iDecide on prostate cancer knowledge, informed decision-making self-efficacy, technology use self-efficacy, and intention to engage in informed decision-making among African American men. DESIGN: One-group, pretest/posttest. SETTING: Community settings in South Carolina. PARTICIPANTS: African American men, ages 40 years +, without a prior prostate cancer diagnosis (n = 354). INTERVENTION: iDecide, an embodied conversational agent-led, computer-based prostate cancer screening decision aid. MEASURES: Prostate cancer knowledge, informed decision-making self-efficacy, technology use self-efficacy, and intention to engage in informed decision-making. ANALYSIS: Descriptive statistics, paired t tests, general linear modeling, Spearman correlations. RESULTS: On average, participants experienced significant improvements in their prostate cancer knowledge ( P ≤ .001), informed decision-making self-efficacy ( P ≤ .001), and technology use self-efficacy ( P ≤ .001), postintervention. Additionally, 67% of participants reported an intention to engage in informed decision-making. CONCLUSION: Given the significant improvements across all measures, this research demonstrates that embodied conversational agent-led decision aids can be used to enhance the capacity for making informed prostate cancer screening decisions among African American men and increase their technology use self-efficacy. One critical limitation of this study is that most men had received prostate cancer screening prior to engaging in our intervention, so the implications of this intervention may be different for men who do not have a history of screening. Additionally, actual engagement in informed decision-making postintervention was not assessed.
AD  - 1 College of Social Work, University of South Carolina, Columbia, SC, USA.
2 Statewide Cancer Prevention and Control Program, University of South Carolina, Columbia, SC, USA.
3 College of Nursing, University of South Carolina, Columbia, SC, USA.
4 Department of Health Promotion, Education and Behavior, Arnold School of Public Health, University of South Carolina, Columbia, SC, USA.
5 Department of Psychiatry and Behavioral Sciences, Hollings Cancer Center Medical University of South Carolina, Columbia, SC, USA.
AN  - 29996666
AU  - Owens, O. L.
AU  - Felder, T.
AU  - Tavakoli, A. S.
AU  - Revels, A. A.
AU  - Friedman, D. B.
AU  - Hughes-Halbert, C.
AU  - Hébert, J. R.
DA  - Feb
DO  - 10.1177/0890117118786866
DP  - NLM
ET  - 2018/07/13
IS  - 2
KW  - Adult
*African Americans
Age Factors
Aged
Attitude to Computers
*Decision Support Techniques
Early Detection of Cancer/*methods
Health Knowledge, Attitudes, Practice
Health Promotion/*methods
Humans
Male
Middle Aged
Patient Participation
Prostate-Specific Antigen
Prostatic Neoplasms/diagnosis/*ethnology
Self Efficacy
Socioeconomic Factors
South Carolina
*African American
*cancer screening
*decision-making
*prostate cancer
*technology
LA  - eng
N1  - 2168-6602
Owens, Otis L
Felder, Tisha
Tavakoli, Abbas S
Revels, Asa A
Friedman, Daniela B
Hughes-Halbert, Chanita
Hébert, James R
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
United States
Am J Health Promot. 2019 Feb;33(2):267-278. doi: 10.1177/0890117118786866. Epub 2018 Jul 11.
PY  - 2019
SN  - 0890-1171
SP  - 267-278
ST  - Evaluation of a Computer-Based Decision Aid for Promoting Informed Prostate Cancer Screening Decisions Among African American Men: iDecide
T2  - Am J Health Promot
TI  - Evaluation of a Computer-Based Decision Aid for Promoting Informed Prostate Cancer Screening Decisions Among African American Men: iDecide
VL  - 33
ID  - 112
ER  - 

TY  - JOUR
AB  - Mammography screenings have the potential to reduce mortality; unfortunately, participation rates remain below federally established targets. To increase screening, the Ontario Breast Screening Program (OBSP) implemented a mammography recruitment intervention that involved a locally designed postcard. The first phase of this descriptive study involved the distribution of a questionnaire to determine how attendees became aware of the OBSP. Semistructured telephone interviews were conducted in the study's second phase to describe breast screening attendees' perceptions of the postcard campaign. Although the participants positively appraised the postcard initiative, it played a minor role in comparison to typical OBSP recruitment methods.
AN  - WOS:000294608800002
AU  - Hanson, K.
AU  - Montgomery, P.
AU  - Bakker, D.
AU  - Conlon, M.
DO  - 10.1080/07370016.2011.589230
IS  - 3
N1  - 21809929
PY  - 2011
SN  - 0737-0016
SP  - 130-143
ST  - Evaluation of an Intervention Designed to Recruit Canadian Women to Mammography Screening
T2  - Journal of Community Health Nursing
TI  - Evaluation of an Intervention Designed to Recruit Canadian Women to Mammography Screening
VL  - 28
ID  - 3104
ER  - 

TY  - JOUR
AB  - PURPOSE/OBJECTIVES: To describe the Heiney-Adams Recruitment Framework (H-ARF); to delineate a recruitment plan for a randomized, behavioral trial (RBT) based on H-ARF; and to provide evaluation data on its implementation. DATA SOURCES: All data for this investigation originated from a recruitment database created for an RBT designed to test the effectiveness of a therapeutic group convened via teleconference for African American women with breast cancer. DATA SYNTHESIS: Major H-ARF concepts include social marketing and relationship building. The majority of social marketing strategies yielded 100% participant recruitment. Greater absolute numbers were recruited via Health Insurance Portability and Accountability Act waivers. Using H-ARF yielded a high recruitment rate (66%). CONCLUSIONS: Application of H-ARF led to successful recruitment in an RBT. The findings highlight three areas that researchers should consider when devising recruitment plans: absolute numbers versus recruitment rate, cost, and efficiency with institutional review board-approved access to protected health information. IMPLICATIONS FOR NURSING: H-ARF may be applied to any clinical or population-based research setting because it provides direction for researchers to develop a recruitment plan based on the target audience and cultural attributes that may hinder or help recruitment.
AD  - Cancer Prevention and Control Program, University of South Carolina, Columbia, SC, USA. heineys@mailbox.sc.edu
AN  - 20439201
AU  - Heiney, S. P.
AU  - Adams, S. A.
AU  - Wells, L. M.
AU  - Johnson, H.
C2  - PMC2946071
C6  - NIHMS232054
DA  - May
DO  - 10.1188/10.Onf.E160-e167
DP  - NLM
ET  - 2010/05/05
IS  - 3
KW  - African Americans/education/*ethnology
Audiovisual Aids
Breast Neoplasms/*ethnology
Cultural Competency
Female
Humans
Models, Nursing
*Models, Psychological
Nursing Evaluation Research
Patient Acceptance of Health Care/ethnology
*Patient Selection
Program Development
Program Evaluation
Randomized Controlled Trials as Topic
Researcher-Subject Relations/psychology
Self-Help Groups
*Social Marketing
Telecommunications
Trust
Women/education/*psychology
LA  - eng
N1  - 1538-0688
Heiney, Sue P
Adams, Swann Arp
Wells, Linda M
Johnson, Hiluv
R01 CA107305/CA/NCI NIH HHS/United States
R01 CA107305-05/CA/NCI NIH HHS/United States
R01 CA107305-04/CA/NCI NIH HHS/United States
R01 CA107305-01A1/CA/NCI NIH HHS/United States
R01CA107305/CA/NCI NIH HHS/United States
R01 CA107305-03/CA/NCI NIH HHS/United States
R01 CA107305-02/CA/NCI NIH HHS/United States
R01 CA107305-05S1/CA/NCI NIH HHS/United States
Evaluation Study
Journal Article
Research Support, N.I.H., Extramural
Oncol Nurs Forum. 2010 May;37(3):E160-7. doi: 10.1188/10.ONF.E160-E167.
PY  - 2010
SN  - 0190-535X (Print)
0190-535x
SP  - E160-7
ST  - Evaluation of conceptual framework for recruitment of African American patients with breast cancer
T2  - Oncol Nurs Forum
TI  - Evaluation of conceptual framework for recruitment of African American patients with breast cancer
VL  - 37
ID  - 421
ER  - 

TY  - JOUR
AB  - Objectives: •Present results of a pilot‐intervention designed to increase advance care planning (ACP) engagement within an African American cancer population.•Describe an investigation into health literacy and religious coping in the context of ACP, with the intention of assessing barriers that impact the completion of advance directives. Original Research Background: Prior investigations into disparities in advance care planning (ACP) among African Americans (AAs) suggest that there is a need to develop interventions to increase engagement in the ACP process. Research Objectives: To test an intervention designed to increase awareness of and intention to complete advance directives (AD) and medical power of attorney (MPOA) among a cohort of AA cancer patients. Methods: AA breast, lung, colon, and prostate cancer patients (Stage II, III, or IV) were randomized to an intervention versus a usual care control group. Intervention participants met with an AA lay health advisor (LHA) who facilitated viewing of a video that addressed barriers to completion of ACP and subsequent discussion. Change in stage of intent to complete AD/MPOA was measured by Transtheoretical Stages of Change Model. Linear regression was conducted to evaluate whether the intervention was associated with a change in stage of intent to complete ACP from baseline to 1‐month assessment. Cancer health literacy and religious coping were analyzed as potential moderators. Results: Fifty‐six patients were enrolled (28 intervention group, 28 control group). The majority of patients (71%) were found to have high cancer‐related health literacy and high religious coping (53%). The intervention was associated with a progression in stage of intent to complete ADs at one month (B = ‐0.83, t(47) = ‐2.79) p = 0.007) versus controls. Increased intent to appoint an MPOA at 1 month was not statistically significant. Health literacy and religious coping were not associated with change in intention. Conclusion: This culturally sensitive intervention was associated with progression in stage of intent to complete ADs at 1‐month follow‐up assessment. Health literacy and religious coping were not considered moderators. Implications for Research, Policy, or Practice: This work highlights the possible utility of a culturally sensitive intervention designed to improve engagement in ACP among African Americans. Future research should continue to address barriers in this area.
AN  - CN-01787130
AU  - Rhodes, R.
AU  - Knox-Rice, T.
DO  - 10.1016/j.jpainsymman.2018.12.124
IS  - 2
KW  - *African American
*advance care planning
*cancer patient
*health literacy
Adult
Breast cancer
Cancer staging
Cohort analysis
Colon cancer
Conference abstract
Controlled study
Female
Follow up
Human
Lay health worker
Linear regression analysis
Living will
Lung cancer
Major clinical study
Male
Power of attorney
Prostate cancer
Randomized controlled trial
Tumor‐related gene
Videorecording
M3  - Journal: Conference Abstract
PY  - 2019
SP  - 411‐
ST  - The Evaluation of Health Literacy, Spiritual Coping, and Advance Care Planning Following a Culturally Sensitive Intervention for African American Cancer Patients (FR421A)
T2  - Journal of pain and symptom management
TI  - The Evaluation of Health Literacy, Spiritual Coping, and Advance Care Planning Following a Culturally Sensitive Intervention for African American Cancer Patients (FR421A)
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01787130/full
VL  - 57
ID  - 1412
ER  - 

TY  - JOUR
AB  - PURPOSE: The objective of this investigation was to assess the impact of race (black v white) on the survival of patients with multiple myeloma treated within the context of a large clinical trial. PATIENTS AND METHODS: A cohort of patients randomized to receive one of two treatment regimens and monitored for at least 10 years was studied to assess the impact of race as a prognostic factor, after adjusting for other known factors such as stage of disease. Patients were recruited from the referral network of the Southwest Oncology Group (SWOG), a national multiinstitutional consortium that includes both academic and community treatment centers. Patients had a diagnosis of multiple myeloma and had not previously been treated for this disease. They were carefully characterized as to demographic and clinical features, and were randomized to receive one of two treatment regimens, which proved to have virtually identical outcomes. The outcome measure was survival, measured from the date of randomization to the date of last contact. Patients still alive at last contact date were treated as censored observation. RESULTS: Survival for black myeloma patients was similar to that for white patients, both overall and adjusted for prognostic factors such as stage. CONCLUSION: Observed differences in mortality between blacks and whites cannot be attributed to differences in survival after diagnosis, given comparable treatment.
AD  - Arizona Cancer Center, University of Arizona, Tucson, USA.
AN  - 8622048
AU  - Modiano, M. R.
AU  - Villar-Werstler, P.
AU  - Crowley, J.
AU  - Salmon, S. E.
DA  - Mar
DO  - 10.1200/jco.1996.14.3.974
DP  - NLM
ET  - 1996/03/01
IS  - 3
KW  - *African Continental Ancestry Group
Antineoplastic Combined Chemotherapy Protocols/therapeutic use
Carmustine/administration & dosage
Cohort Studies
Cyclophosphamide/administration & dosage
Doxorubicin/administration & dosage
*European Continental Ancestry Group
Female
Humans
Male
Melphalan/administration & dosage
Middle Aged
Multiple Myeloma/drug therapy/*genetics/*mortality
Prednisone/administration & dosage
Retrospective Studies
Survival Analysis
Vincristine/administration & dosage
LA  - eng
N1  - Modiano, M R
Villar-Werstler, P
Crowley, J
Salmon, S E
CA-13612/CA/NCI NIH HHS/United States
CA-23074/CA/NCI NIH HHS/United States
Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, U.S. Gov't, P.H.S.
United States
J Clin Oncol. 1996 Mar;14(3):974-7. doi: 10.1200/JCO.1996.14.3.974.
PY  - 1996
SN  - 0732-183X (Print)
0732-183x
SP  - 974-7
ST  - Evaluation of race as a prognostic factor in multiple myeloma. An ancillary of Southwest Oncology Group Study 8229
T2  - J Clin Oncol
TI  - Evaluation of race as a prognostic factor in multiple myeloma. An ancillary of Southwest Oncology Group Study 8229
VL  - 14
ID  - 742
ER  - 

TY  - JOUR
AB  - The purpose of this study was to determine in healthy humans whether First Leaf (FL; composed of blackcurrant extract powder, lactoferrin and lutein) and Cassis Anthomix 30 (CAM30; blackcurrant extract powder) can positively modify the colonic microbiota by enhancing the growth of the beneficial bacteria and inactivating the toxic bacterial enzymes which are known to be involved in colonic carcinogenesis. Thirty healthy adult male and female volunteers were recruited for this study. Fluorescent in situ hybridization was carried out to analyse the populations of fecal microbiota. Consumption of FL and CAM30 led to significant increases (P < 0.0001) in the population sizes of lactobacilli and bifidobacteria whereas the population sizes of Clostridium spp. and Bacteroides spp were decreased significantly (P < 0.0001). In addition, feeding of FL and CAM30 decreases the activity of β-glucuronidase (bacterial enzyme which is considered to be one of the enzymes that increases risk for colorectal cancer) and significantly decreased (P < 0.05) the fecal pH. In conclusion, the results of this study open up the possibility that consumption of FL and CAM30 can offer various benefits to human health through acting as novel prebiotic agents via increasing the numbers of beneficial bacteria (lactobacilli and bifidobacteria) in the gut. © 2013 John Wiley & Sons, Ltd.
AD  - A.-L. Molan, Institute of Food, Nutrition and Human Health, College of Health, Massey University, Palmerston North, New Zealand
AU  - Molan, A. L.
AU  - Liu, Z.
AU  - Plimmer, G.
C2  - Four Leaf(Japan)
Just the Berries(New Zealand)
DB  - Embase
Medline
DO  - 10.1002/ptr.5009
IS  - 3
KW  - bacterial enzyme
beta glucuronidase
black currant extract
lactoferrin
prebiotic agent
xanthophyll
adult
antimicrobial activity
article
bacterial growth
Bifidobacteriales
cancer risk
colorectal cancer
controlled study
diet supplementation
drug dosage form comparison
enzyme activity
feces microflora
female
fluorescence in situ hybridization
human
human experiment
intestine flora
Lactobacillus casei
male
normal human
pH
randomized controlled trial
risk benefit analysis
LA  - English
M3  - Article
N1  - L52587863
2013-05-20
2014-03-27
PY  - 2014
SN  - 0951-418X
1099-1573
SP  - 416-422
ST  - Evaluation of the effect of blackcurrant products on gut microbiota and on markers of risk for colon cancer in humans
T2  - Phytotherapy Research
TI  - Evaluation of the effect of blackcurrant products on gut microbiota and on markers of risk for colon cancer in humans
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L52587863&from=export
http://dx.doi.org/10.1002/ptr.5009
VL  - 28
ID  - 1036
ER  - 

TY  - JOUR
AB  - INTRODUCTION: The NCI developed the print-based educational brochure, Facing Forward, to fill a gap in helping cancer patients meet the challenges of transitioning from active treatment to survivorship; however, little research has been conducted on its efficacy. PURPOSE: The aims of this study were to evaluate the efficacy of Facing Forward in promoting the uptake of recommended behaviors (e.g., ways to manage physical changes) and to explore its usability. METHODS: At the last treatment appointment, early-stage breast, prostate, colorectal, and thoracic cancer patients (N = 340) recruited from community clinical oncology practices and an academic medical center completed a baseline assessment and were randomized to receive either Facing Forward (n = 175) or an attention control booklet about the NCI's Cancer Information Service (n = 165). Patients completed follow-up assessments at 8 weeks and 6 months post-baseline. RESULTS: The reported uptake of recommended stress management behaviors was greater among intervention than control participants at both 8 weeks post-baseline (p = 0.016) and 6 months post-baseline (p = 0.017). At 8 weeks post-baseline, the intervention control group difference was greater among African-American than Caucasian participants (p < 0.03) and significant only among the former (p < 0.003); attendance at a cancer support group was also greater among the intervention than control group participants (p < 0.02). There were no significant intervention control group differences in the reported uptake of recommended behaviors in three other categories (p > 0.025). Intervention participants rated Facing Forward as understandable and helpful and indicated a high level of intention to try the behaviors recommended. CONCLUSIONS: Facing Forward can enhance early-stage survivors' reported ability to manage stress and increase support group use during the reentry period. IMPLICATIONS FOR CANCER SURVIVORS: Facing Forward can help survivors meet the challenges of the reentry period.
AD  - Research & Training Institute, Cancer Support Community, Philadelphia, PA 19131, USA.
AN  - 23229087
AU  - Buzaglo, J. S.
AU  - Miller, S. M.
AU  - Kendall, J.
AU  - Stanton, A. L.
AU  - Wen, K. Y.
AU  - Scarpato, J.
AU  - Zhu, F.
AU  - Lyle, J.
AU  - Rowland, J.
C2  - PMC3626437
C6  - NIHMS444951
DA  - Mar
DO  - 10.1007/s11764-012-0245-7
DP  - NLM
ET  - 2012/12/12
IS  - 1
KW  - African Americans
Counseling
European Continental Ancestry Group
Female
Health Information Systems/*statistics & numerical data
Humans
Male
Middle Aged
National Cancer Institute (U.S.)
Neoplasms/*rehabilitation
*Pamphlets
*Quality of Life
*Survivors
United States
LA  - eng
N1  - 1932-2267
Buzaglo, Joanne S
Miller, Suzanne M
Kendall, Jeffery
Stanton, Annette L
Wen, Kuang-Yi
Scarpato, John
Zhu, Fang
Lyle, Jennifer
Rowland, Julia
P30 CA06927/CA/NCI NIH HHS/United States
R01 CA104979/CA/NCI NIH HHS/United States
P01 CA057586/CA/NCI NIH HHS/United States
5P01 CA057586/CA/NCI NIH HHS/United States
P30 CA006927/CA/NCI NIH HHS/United States
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.
J Cancer Surviv. 2013 Mar;7(1):63-73. doi: 10.1007/s11764-012-0245-7. Epub 2012 Dec 11.
PY  - 2013
SN  - 1932-2259 (Print)
1932-2259
SP  - 63-73
ST  - Evaluation of the efficacy and usability of NCI's Facing Forward booklet in the cancer community setting
T2  - J Cancer Surviv
TI  - Evaluation of the efficacy and usability of NCI's Facing Forward booklet in the cancer community setting
VL  - 7
ID  - 347
ER  - 

TY  - JOUR
AB  - STUDY TYPE: Diagnostic (exploratory cohort). LEVEL OF EVIDENCE: 2b. OBJECTIVE: To evaluate the Prostate Cancer Prevention Trial (PCPT) risk calculator in a screening cohort of young, racially diverse, high-risk men with a low baseline prostate-specific antigen (PSA) level and enrolled in the Prostate Cancer Risk Assessment Program (PRAP). The PCPT calculator provides an assessment of prostate cancer risk based on age, PSA level, race, previous biopsy, and family history. PATIENTS AND METHODS: Eligibility for PRAP includes men aged 35-69 years who are African-American, have a family history of prostate cancer, or have a known BRCA1/2 mutation. PCPT risk scores were determined for PRAP participants, and were compared to observed prostate cancer rates. RESULTS: In all, 624 participants were evaluated, including 382 (61.2%) African-American men and 242 (38.7%) men with a family history of prostate cancer; the median (range) age was 49.0 (34.0-69.0) years and the median PSA level 0.9 (0.1-27.2) ng/mL. The PCPT risk score correlated with prostate cancer diagnosis, as the median baseline risk score in patients diagnosed with prostate cancer was 31.3%, vs 14.2% in patients not diagnosed with prostate cancer (P < 0.001). The PCPT calculator similarly stratified the risk of diagnosis of Gleason score > or =7 disease, as the median risk score was 36.2% in patients diagnosed with Gleason > or =7 prostate cancer vs 15.2% in all other participants (P < 0.001). CONCLUSION: The PCPT risk calculator score was found to stratify prostate cancer risk in a cohort of young, primarily African-American men with a low baseline PSA level. These results support further evaluation of this predictive tool for assessing the risk of prostate cancer in high-risk men.
AD  - Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, USA.
AN  - 19709072
AU  - Kaplan, D. J.
AU  - Boorjian, S. A.
AU  - Ruth, K.
AU  - Egleston, B. L.
AU  - Chen, D. Y.
AU  - Viterbo, R.
AU  - Uzzo, R. G.
AU  - Buyyounouski, M. K.
AU  - Raysor, S.
AU  - Giri, V. N.
C2  - PMC2809782
C6  - NIHMS143534
DA  - Feb
DO  - 10.1111/j.1464-410X.2009.08793.x
DP  - NLM
ET  - 2009/08/28
IS  - 3
KW  - Adult
*African Americans
Aged
Early Detection of Cancer/*methods
Humans
Kaplan-Meier Estimate
Male
Mass Screening/standards
Middle Aged
Pedigree
Prostate-Specific Antigen/blood
Prostatic Neoplasms/genetics/*prevention & control
Risk Assessment/methods
LA  - eng
N1  - 1464-410x
Kaplan, David J
Boorjian, Stephen A
Ruth, Karen
Egleston, Brian L
Chen, David Y T
Viterbo, Rosalia
Uzzo, Robert G
Buyyounouski, Mark K
Raysor, Susan
Giri, Veda N
P30 CA006927/CA/NCI NIH HHS/United States
P30 CA006927-46/CA/NCI NIH HHS/United States
Evaluation Study
Journal Article
Research Support, N.I.H., Extramural
BJU Int. 2010 Feb;105(3):334-7. doi: 10.1111/j.1464-410X.2009.08793.x. Epub 2009 Aug 25.
PY  - 2010
SN  - 1464-4096 (Print)
1464-4096
SP  - 334-7
ST  - Evaluation of the Prostate Cancer Prevention Trial Risk calculator in a high-risk screening population
T2  - BJU Int
TI  - Evaluation of the Prostate Cancer Prevention Trial Risk calculator in a high-risk screening population
VL  - 105
ID  - 449
ER  - 

TY  - JOUR
AB  - PURPOSE: A number of factors have been identified as being associated with the documented low accrual rate of minorities into cancer-related clinical trials in the USA. An important issue is the fundamental interest, or lack thereof, of these specific patient populations in actually considering study participation. METHODS: To examine this issue, aggregate data were analyzed from a proprietary Internet-based decision support program (NexProfiler Treatment Option Tools for Cancer, NexCura, Seattle, WA, USA) embedded into approximately 100 cancer-associated Web sites where responding patients (or their families) were asked, but not required, to identify their race/ethnicity (African-American, Asian-American, Caucasian and Hispanic) and to also respond to the question, "Are you interested in learning about clinical trials?". RESULTS: Of the > 60,000 patients who both self-identified their race/ethnicity and responded to the question regarding their desire to learn about clinical trials, approximately 10% were from the minority (non-Caucasian) groups. Of note, in all four malignancies analyzed (breast, colorectal, lung, and prostate) and in both patients < or = 60 and > 60 years of age, each of the three non-Caucasian populations expressed an interest in learning about such studies that was equal to, if not greater than, that observed in the Caucasian respondents. CONCLUSION: Assuming these provocative results regarding self-declared desire to learn about clinical trials can be confirmed by others with similar Internet-associated databases, this analysis suggests Web-based recruitment strategies may be an effective method to communicate with minority populations in the US (and, perhaps, elsewhere) with a specific interest in considering participation in cancer clinical trials.
AD  - The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Mail Box #121, Houston, TX 77030, USA. mmarkman@mdanderson.org
AN  - 17598129
AU  - Markman, M.
AU  - Petersen, J.
AU  - Montgomery, R.
DA  - Jan
DO  - 10.1007/s00432-007-0263-4
DP  - NLM
ET  - 2007/06/29
IS  - 1
KW  - African Americans
Asian Americans
Breast Neoplasms/*ethnology/psychology/therapy
Clinical Trials as Topic/*statistics & numerical data
Colorectal Neoplasms/*ethnology/psychology/therapy
*Continental Population Groups
Ethnic Groups
European Continental Ancestry Group
Female
Hispanic Americans
Humans
Internet
Lung Neoplasms/*ethnology/psychology/therapy
Male
Middle Aged
Minority Groups
*Patient Participation
Prostatic Neoplasms/*ethnology/psychology/therapy
LA  - eng
N1  - 1432-1335
Markman, Maurie
Petersen, Judy
Montgomery, Robert
Journal Article
Germany
J Cancer Res Clin Oncol. 2008 Jan;134(1):115-8. doi: 10.1007/s00432-007-0263-4. Epub 2007 Jun 28.
PY  - 2008
SN  - 0171-5216
SP  - 115-8
ST  - An examination of the influence of patient race and ethnicity on expressed interest in learning about cancer clinical trials
T2  - J Cancer Res Clin Oncol
TI  - An examination of the influence of patient race and ethnicity on expressed interest in learning about cancer clinical trials
VL  - 134
ID  - 522
ER  - 

TY  - THES
AB  - Recent evidence suggests racial/ethnic minorities, older adults and the economically disadvantaged are willing to participate in cancer clinical trials (CCTs) but may lack the opportunity to do so. We define opportunity for participation as an offer from a healthcare provider or researcher for screening and/or enrollment in a CCT. A barrier/promoter of opportunity for participation is eligibility, or the key attributes/characteristics a person must have in order to participate in a CCT. We have limited understanding of the roles of opportunity and eligibility for participation in CCTs and how this may contribute to under-representation. The primary objective of this dissertation was to examine whether opportunity and eligibility for cancer clinical trial participation differs between under-represented and well-represented groups based on socio-demographic and disease characteristics. Using Ford's conceptual framework for examining participation of under-represented groups in CCTs, we performed a cross-sectional matched cohort study in a large academic comprehensive cancer center. We enrolled 88 new cancer patients (44 Black or Hispanic, 44 Non-Hispanic White), matched on age (+/- 5 years) and cancer type (breast, lung, kidney or leukemia). We collected information on opportunity, eligibility, socio-demographic/disease characteristics and reasons for exclusion via a participant questionnaire, and with participant permission, a retrospective electronic medical record (EMR) review. We examined differences using Fisher's exact tests, t-tests and ANOVA. Most of the sample reported no opportunity for CCT participation (79%) and were ineligible for accruing trials (84%). Those with Stage III/IV disease were significantly more likely to have opportunity (p=.001) and be eligible for participation (p=<.001). Differences in opportunity and eligibility were predominantly associated with disease characteristics, as opposed to socio-demographic characteristics. Common reasons for exclusion included 'other' (a combination of categories primarily suggesting advanced disease), prior therapy, and lack of required therapy (per study eligibility criteria). Results suggest lack of available trials, poor patient-trial fit and stringent eligibility criteria limit opportunity across populations. Opportunity and eligibility likely vary based on complex intersections between race, ethnicity, age, SES and disease characteristics, as well as differences in the healthcare setting. Future research should explore these intersections and how they influence under-representation in opportunity for CCT participation.
AU  - Rearden, Jessica Rose
DB  - CINAHL Complete
DP  - EBSCOhost
KW  - Clinical Trials
Ethnic Groups
Minority Groups
Oncology
Research Subjects
Analysis of Variance
Black Persons
Cancer Care Facilities
Cross Sectional Studies
Descriptive Statistics
Fisher's Exact Test
Hispanic Americans
Human
Matched Case Control
Neoplasm Staging
Prospective Studies
Questionnaires
Record Review
T-Tests
White Persons
M1  - Ph.D.
N1  - Accession Number: 109774689. Language: English. Entry Date: 20150206. Revision Date: 20150923. Publication Type: Doctoral Dissertation; research. Special Interest: Oncologic Care.
UMI Order AAI3635540
PB  - University of Pennsylvania
PY  - 2014
SN  - 9781321166453
SP  - 168 p-168 p
ST  - Examining opportunity for cancer clinical trial participation among under-represented groups
TI  - Examining opportunity for cancer clinical trial participation among under-represented groups
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=109774689&site=ehost-live&scope=site
ID  - 1947
ER  - 

TY  - JOUR
AB  - The current study examines changes in awareness and health beliefs from baseline to 12 months post-intervention following receipt of one of two colorectal cancer (CRC) educational interventions that aimed to promote CRC screening among a racially and ethnically diverse and medically underserved population. Participants (N = 270) were enrolled in a randomized controlled trial to increase CRC screening and completed both baseline and 12-month follow-up assessments. Participants were aged 50-75, at average CRC risk, not up-to-date with CRC screening guidelines, and receiving care at one of three community-based clinics. Participants were randomized to receive either a targeted, low-literacy intervention informed by the Preventive Health Model [PHM] (photonovella and DVD plus fecal immunochemical test [FIT]) or a non-targeted intervention (standard educational brochure plus FIT). Changes in CRC awareness and health beliefs from baseline to 12 months were examined both within and between intervention groups using Student's t tests. Participants in both intervention conditions demonstrated an increase in CRC awareness, PHM social influence, and trust in the healthcare system (all p's < .0001), with no significant between-group differences. Among those receiving the targeted intervention, there also was an increase in PHM salience (p < .05). Among individuals receiving the non-targeted intervention, there was an increase in PHM response efficacy (p < .01) and PHM self-efficacy (p < .0001). Both CRC screening interventions promoted positive changes in awareness and several health beliefs from baseline to 12 months, suggesting important benefits of CRC education. Regardless of whether education was targeted or non-targeted, providing CRC screening education successfully promoted durable changes in awareness and health beliefs.
AN  - WOS:000466345600014
AU  - Christy, S. M.
AU  - Sutton, S. K.
AU  - Gwede, C. K.
AU  - Chavarria, E. A.
AU  - Davis, S. N.
AU  - Abdulla, R.
AU  - Schultz, I.
AU  - Roetzheim, R.
AU  - Shibata, D.
AU  - Meade, C. D.
DA  - Apr
DO  - 10.1007/s13187-017-1301-9
IS  - 2
N1  - 29177920
PY  - 2019
SN  - 0885-8195
SP  - 297-303
ST  - Examining the Durability of Colorectal Cancer Screening Awareness and Health Beliefs Among Medically Underserved Patients: Baseline to 12 months Post-Intervention
T2  - Journal of Cancer Education
TI  - Examining the Durability of Colorectal Cancer Screening Awareness and Health Beliefs Among Medically Underserved Patients: Baseline to 12 months Post-Intervention
VL  - 34
ID  - 2825
ER  - 

TY  - JOUR
AB  - BACKGROUND: Margin status is an important prognostic factor for local recurrence after breast conserving surgery (BCS) for breast cancer. We designed a prospective randomized trial to evaluate the effect of shave margins on positive margins and locoregional recurrence (LRR). METHODS: Patients were randomized to BCS or BCS with resection of 5 additional margins (BCS + M). Tumor margins were classified as negative [>2 mm for ductal carcinoma in situ (DCIS); >1 mm for invasive carcinoma] based on guidelines at the time of accrual. RESULTS: A total of 75 patients with stage 0-III breast cancer (76 samples) were randomized, mean age 59.6 years with median follow-up 39.5 months. Overall, 21 patients (27.6 %) had positive margins: 14 had undergone BCS and 7 BCS + M (p = 0.005). Of the 21 patients with positive margins, 19 had DCIS on final pathology (OR 7.56; 95 % CI 1.52-37.51).All patients with positive margins were offered re-excision; 11 had negative final margins after re-excision surgery. Overall, 6 patients (8.3 %) developed LRR with recurrence being more common in the BCS group when compared with the BCS + M group (17.2 vs 2.3 %; p = 0.025). CONCLUSIONS: Taking additional cavity shave margins at the time of initial excision resulted in a reduction in positive margin rate, a decrease in return to operating room for re-excision, and lower LRR.
AD  - Grady Memorial Hospital, Winship Cancer Institute, Emory University, Atlanta, GA, USA. veronica.c.jones@emory.edu.
Winship Cancer Institute, Emory University, Atlanta, GA, USA. veronica.c.jones@emory.edu.
Department of Surgery, Gundersen Health System, La Crosse, WI, USA.
Winship Cancer Institute, Emory University, Atlanta, GA, USA.
Grady Memorial Hospital, Winship Cancer Institute, Emory University, Atlanta, GA, USA.
Morehouse School of Medicine, Grady Memorial Hospital, Atlanta, GA, USA.
Department of Surgery, Michigan State University, Lansing, MI, USA.
Department of Pathology, Grady Memorial Hospital, Emory University, Atlanta, GA, USA.
AN  - 26254169
AU  - Jones, V.
AU  - Linebarger, J.
AU  - Perez, S.
AU  - Gabram, S.
AU  - Okoli, J.
AU  - Bumpers, H.
AU  - Burns, B.
AU  - Mosunjac, M.
AU  - Rizzo, M.
DA  - Feb
DO  - 10.1245/s10434-015-4789-4
DP  - NLM
ET  - 2015/08/09
IS  - 2
KW  - Adult
African Americans/*statistics & numerical data
Aged
Aged, 80 and over
Breast Neoplasms/ethnology/pathology/*surgery
Carcinoma, Ductal, Breast/ethnology/pathology/*surgery
Carcinoma, Intraductal, Noninfiltrating/ethnology/pathology/*surgery
Female
Follow-Up Studies
Hospitals, Public
Humans
*Mastectomy, Segmental
Middle Aged
Neoplasm Invasiveness
Neoplasm Recurrence, Local/*diagnosis
Neoplasm Staging
Neoplasm, Residual/ethnology/pathology/*surgery
Prognosis
Prospective Studies
LA  - eng
N1  - 1534-4681
Jones, Veronica
Linebarger, Jared
Perez, Sebastian
Gabram, Sheryl
Okoli, Joel
Bumpers, Harvey
Burns, Brian
Mosunjac, Marina
Rizzo, Monica
Clinical Trial
Journal Article
Randomized Controlled Trial
United States
Ann Surg Oncol. 2016 Feb;23(2):456-64. doi: 10.1245/s10434-015-4789-4. Epub 2015 Aug 8.
PY  - 2016
SN  - 1068-9265
SP  - 456-64
ST  - Excising Additional Margins at Initial Breast-Conserving Surgery (BCS) Reduces the Need for Re-excision in a Predominantly African American Population: A Report of a Randomized Prospective Study in a Public Hospital
T2  - Ann Surg Oncol
TI  - Excising Additional Margins at Initial Breast-Conserving Surgery (BCS) Reduces the Need for Re-excision in a Predominantly African American Population: A Report of a Randomized Prospective Study in a Public Hospital
VL  - 23
ID  - 237
ER  - 

TY  - JOUR
AB  - Background: African American (AA) colorectal cancer (CRC) survivors tend to be more obese and less physically active than white survivors. Purpose/Objective: To test the feasibility of an aerobic exercise program as well as explore perceptions about supervised exercise among AA CRC survivors. Methods: A prospective supervised exercise intervention performed on a cycle ergometer 2 d/wk for 12 weeks. Peak (o2peak) and submaximal exercise (Six-Minute Walk Test [6MWT]) along with questionnaires (36-Item Short Form Health Survey [SF-36], Memorial Sloan Kettering Cancer Center Bowel Function Instrument [BFI], Functional Assessment of Cancer Therapy-Colorectal (FACT-C) and Fatigue (FACIT-F), and Brief Symptom Inventory [BSI]). A second group of survivors participated in an interview evaluating perceptions regarding exercise. Design: Prospective case series and qualitative interview. Setting: Research university and academic medical center. Patients: AA and white CRC survivors. Results: Quantitative: A total of 237 letters were mailed to CRC survivors (112 whites, 126 AAs). From the letters, 25 whites and 15 AAs expressed interest; only 5 whites (4.5%) and 4 AAs (3.2%) enrolled. Two AA and 5 white survivors (7/9) finished the program. There was an improvement in peak exercise (P =.011) and quality of life (QOL) (SF-36 total, P =.035) posttraining. Qualitative: 30 CRC survivors (12 AAs and 18 whites) participated in qualitative interviews and selected comorbidity, motivation, and location as primary barriers to exercise. Limitations: Small sample size. Conclusions: Recruiting CRC survivors (regardless of race) into an exercise program is challenging; however, there are exercise and QOL benefits associated with participation. Barriers to exercise are similar between AA and white CRC survivors.
AD  - A.D. Ray, Department of Rehabilitation Science, State University at Buffalo, 3435 Main St, Buffalo, NY, United States
AU  - Ray, A. D.
AU  - Masucci Twarozek, A.
AU  - Williams, B. T.
AU  - Erwin, D. O.
AU  - Underwood, W.
AU  - Mahoney, M. C.
DB  - Embase
DO  - 10.1097/01.REO.0000000000000125
IS  - 4
KW  - bicycle ergometer
Ergoselect 100
adult
aerobic exercise
African American
aged
article
Bowel Function Instrument
Brief Symptom Inventory
cancer center
cancer survivor
cardiopulmonary exercise test
case study
Caucasian
colorectal cancer
comorbidity
digestive system disease assessment
exploratory research
female
Functional Assessment of Cancer Therapy Colorectal
Functional Assessment of Cancer Therapy Fatigue
functional status assessment
human
intervention study
major clinical study
male
middle aged
motivation
multicenter study
patient participation
perception
program feasibility
prospective study
qualitative research
quality of life
quality of life assessment
quantitative study
race difference
self report
semi structured interview
Short Form 36
six minute walk test
university hospital
LA  - English
M3  - Article
N1  - L625229064
2018-12-04
2018-12-07
PY  - 2018
SN  - 2381-2427
2168-3808
SP  - 188-197
ST  - Exercise in african American and white colorectal cancer survivors: A mixed-methods approach
T2  - Rehabilitation Oncology
TI  - Exercise in african American and white colorectal cancer survivors: A mixed-methods approach
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L625229064&from=export
http://dx.doi.org/10.1097/01.REO.0000000000000125
VL  - 36
ID  - 883
ER  - 

TY  - JOUR
AB  - BACKGROUND: Colorectal cancer screening (CRCS) in the United States is inadequate in minority communities and particularly among those who lack insurance. Finding ways to increase screenings in these minorities presents a healthcare challenge. The authors sought to determine whether offering CRCS at the time of mammography is an effective way to increase CRCS among minority women. METHODS: This study was offered to women attending the Breast Examination Center of Harlem (BECH), a community outreach program of Memorial Sloan-Kettering serving the primarily black and Hispanic Harlem Community. Screening was explained, medical fitness was determined, and colonoscopies were performed. Barriers to screening and ways to overcome them were ascertained. Participants had to be at least 50 years of age without a history of colorectal cancer or screening within the last 10 years. RESULTS: There were 2616 women eligible for CRCS, of these women 2005 (77%) refused to participate in the study, and 611 (23%) women were enrolled. There was a high interest in CRCS including among those who declined to participate in the study. The major barrier was lack of medical insurance, which was partially overcome by alternative funding. Of the 611 women enrolled, 337 (55%) went on to have screening colonoscopy. Forty-nine (15%) women had adenomatous polyps. CONCLUSIONS: Offering CRCS to minority women at the time of mammography and without a physician's referral is an effective way to expand screening. Screening colonoscopy findings are similar to those in the general population. Alternatives to traditional medical insurance are needed for the uninsured. © 2010 American Cancer Society.
AD  - M. Shike, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, United States
AU  - Shike, M.
AU  - Schattner, M.
AU  - Genao, A.
AU  - Grant, W.
AU  - Burke, M.
AU  - Zauber, A.
AU  - Russo, L.
AU  - Cuyjet, V.
DB  - Embase
Medline
DO  - 10.1002/cncr.25566
IS  - 1
KW  - NCT00613873
adenomatous polyp
adult
African American
aged
article
cancer screening
colonoscopy
colorectal cancer
controlled study
family history
female
gastrointestinal symptom
health insurance
Hispanic
human
mammography
minority group
patient referral
patient satisfaction
priority journal
refusal to participate
United States
women's health
LA  - English
M3  - Article
N1  - L361009992
2011-02-04
PY  - 2011
SN  - 0008-543X
1097-0142
SP  - 70-76
ST  - Expanding colorectal cancer screening among minority women
T2  - Cancer
TI  - Expanding colorectal cancer screening among minority women
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L361009992&from=export
http://dx.doi.org/10.1002/cncr.25566
VL  - 117
ID  - 1147
ER  - 

TY  - JOUR
AB  - BACKGROUND: Optimizing participant response rates is important for obtaining representative samples and the timely completion of studies. It is a common practice to use participant incentives to boost response rates, but few studies have systematically examined their effectiveness, particularly among minority groups. METHODS: We experimentally tested three incentive strategies for their effectiveness in improving response rates among colorectal cancer cases (n = 3,816) and their relatives (n = 2,353). A 2 x 2 x 2 factorial design compared (a) registered versus first class mail, (b) $5 cash with the initial mailing (yes/no), and (c) $20 promise (yes/no) upon completion of the information form (for cases) or $10 promise (yes/no) upon completion of the baseline survey (for relatives). Outcome measures were provision of contact information on first-degree relatives for cases and completion of the baseline survey for relatives. RESULTS: The response rate among cases was low in all ethnic groups (28-37%) and incentive strategies did not have an effect. Among relatives, the overall baseline survey response rate was 71%, ranging from 66% among Asians to 76% among Whites. Modest absolute increases were observed for payment schedules that included a $5 cash enclosure with the initial mailing in the total sample [odds ratio (OR), 1.65 and 1.47] and among Latinos (OR, 1.94 and 1.74) but not among Asians (OR, 1.61 and 1.55) or African Americans (OR, 1.19 and 1.02). Response rates were not influenced by registered versus first-class mailing. CONCLUSION: The effects of incentives in this study were modest with some suggestion of differences by ethnic group and type of incentive.
AD  - School of Public Health and Jonsson Comprehensive Cancer Center, University of California, Los Angeles, USA. amaxwell@ucla.edu
AN  - 19755646
AU  - Maxwell, A. E.
AU  - Bastani, R.
AU  - Glenn, B. A.
AU  - Mojica, C. M.
AU  - Chang, L. C.
C2  - PMC2759859
C6  - NIHMS140207
DA  - Oct
DO  - 10.1158/1055-9965.Epi-09-0299
DP  - NLM
ET  - 2009/09/17
IS  - 10
KW  - Colorectal Neoplasms/*ethnology
Ethnic Groups
Health Care Surveys/*methods
Humans
*Motivation
Multivariate Analysis
Postal Service
Reproducibility of Results
Research Design
Surveys and Questionnaires
Telephone
LA  - eng
N1  - 1538-7755
Maxwell, Annette E
Bastani, Roshan
Glenn, Beth A
Mojica, Cynthia M
Chang, L Cindy
R01 CA075367/CA/NCI NIH HHS/United States
R01 CA075367-04/CA/NCI NIH HHS/United States
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Cancer Epidemiol Biomarkers Prev. 2009 Oct;18(10):2620-5. doi: 10.1158/1055-9965.EPI-09-0299. Epub 2009 Sep 15.
PY  - 2009
SN  - 1055-9965 (Print)
1055-9965
SP  - 2620-5
ST  - An experimental test of the effect of incentives on recruitment of ethnically diverse colorectal cancer cases and their first-degree relatives into a research study
T2  - Cancer Epidemiol Biomarkers Prev
TI  - An experimental test of the effect of incentives on recruitment of ethnically diverse colorectal cancer cases and their first-degree relatives into a research study
VL  - 18
ID  - 447
ER  - 

TY  - JOUR
AB  - Background: African Americans (AA) have a higher rate of lung cancer than Caucasians per 100,000 population (74.7 versus 64.4) but are underrepresented in randomized clinical trials. In the Point‐ Break study, AAs were enrolled at the same rate as the US incidence of non‐small cell lung cancer (NSCLC) for AAs in 2011 (13%; now 15% in 2013). Post‐hoc analyses of the AA subgroup were conducted from this study to evaluate efficacy and safety, as well as these outcomes by treatment center. Methods: All patients (N=939) were chemonaive with an ECOG performance status (PS) of 0/1. AAs were analyzed against Caucasians for efficacy/safety in the pemetrexed (Pem) arm only. Subgroup analyses of AAs alone were conducted for efficacy/safety (between arm comparisons) as well as academic versus community settings (pooled two treatment arms). Hazard ratios and p‐values were derived from a multivariate Cox‐PH model, adjusting for disease stage, gender, PS and measurable/nonmeasurable disease. Response rates and adverse events (AEs) were compared using the exact test. Results: Patients had stage IIIb (with pleural effusion)/IV nonsquamous NSCLC, according to AJCC edition 6. There were 94 AAs (42 = Pem arm; 52 = Paclitaxel [Pac] arm) and 805 Caucasians in the treated population. Demographics were statistically comparable between AAs and Caucasians in the Pem Arm, respectively: 62%/53% male, 71%/53% <65 years, 98%/89% ever smokers, 81%/90% Stage IV disease, with ECOG PS of 0/1, 33%/67%, versus 44%/56%. Median OS was similar between AAs and Caucasians in the Pem arm at 12.4 versus 12.3 months. Median PFS for AAs and Caucasians was 4.6 months versus 6.0 months (HR 1.229 (0.864 ‐ 1.749; p=0.251). Overall response rate (ORR) for AAs was higher, though not statistically, at 38.1% versus 33.3% (p=0.607). Efficacy among AAs was fairly similar with median OS for Pem arm at 12.4 versus 13.7 months for Pac arm (p=0.1208). Median PFS by arm was 4.6 versus 5.1 months (p=0.6699). ORR among AAs was 38% in both arms. AAs showed a heavy trend (80%) for enrollment in community centers (n=74) versus academic center (n=20). Efficacy among AAs by setting showed a higher median OS at academic sites at 16.5 months versus 11.4 months, p=0.1906 (HR=0.6605; 95% CI: 0.355 ‐ 1.229). Median PFS was also higher at academic sites at 6.9 months versus 4.6 months, p=0.9149 (HR =0.9690; 95% CI: 0.544 ‐ 1.726). Drug‐related grade 3/4 AEs in the Pem arm showed higher percentages for Caucasians with the exception of neutropenia, as follows: anemia (7.3%/15.9%), thrombocytopenia (9.8%/25.5%), fatigue (4.9%/11.5%), neutropenia (31.7%/25.3%), febrile neutropenia (0%/1.6%). Among AAs in the Pem/Pac Arm respectively, drug‐related grade 3/4 AEs were: anemia (7.3%/0%), thrombocytopenia (9.8%/4.0%), fatigue (4.9%/4.0%), neutropenia (31.7%/44.0%), and febrile neutropenia (0%/4.0%). Conclusion: There were no significant differences between AAs and Caucasians for OS, PFS, and ORR. Among AAs, median OS was not superior for either arm. PFS and OS were similar for academic and community settings among AAs. Caucasians had a significantly higher incidence of Grade 3/4 thrombocytopenia (p=0.0217), but this should be interpreted with caution due to the sample size for the AAs.
AN  - CN-01059010
AU  - Reynolds, C.
AU  - Patel, J. D.
AU  - Garon, E.
AU  - Olsen, M. R.
AU  - Bonomi, P.
AU  - Govindan, R.
AU  - Obasaju, C.
AU  - Pennella, E. J.
AU  - Liu, J.
AU  - Guba, S. C.
AU  - et al.
DO  - 10.1097/01.JTO.0000438438.14562.c8
KW  - *African American
*bevacizumab
*carboplatin
*human
*lung cancer
*lung non small cell cancer
*paclitaxel
*patient
*pemetrexed
Anemia
Arm
Clinical trial (topic)
Community
Electrocorticography
Fatigue
Febrile neutropenia
Gender
Hazard ratio
Male
Model
Neutropenia
PH
Pleura effusion
Population
Post hoc analysis
Safety
Sample size
Smoking
Statistical significance
Thrombocytopenia
M3  - Journal: Conference Abstract
PY  - 2013
SP  - S562
ST  - Exploratory subset analysis in african americans from the pointbreak study (randomized phase 3 pemetrexed + carboplatin + bevacizumab followed by maintenance pemetrexed + bevacizumab versus paclitaxel + carboplatin + bevacizumab followed by maintenance bevacizumab in patients with stage IIIB/ IV nonsquamous non-small cell lung cancer)
T2  - Journal of thoracic oncology.
TI  - Exploratory subset analysis in african americans from the pointbreak study (randomized phase 3 pemetrexed + carboplatin + bevacizumab followed by maintenance pemetrexed + bevacizumab versus paclitaxel + carboplatin + bevacizumab followed by maintenance bevacizumab in patients with stage IIIB/ IV nonsquamous non-small cell lung cancer)
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01059010/full
VL  - 8
ID  - 1413
ER  - 

TY  - JOUR
AB  - INTRODUCTION: African Americans have a greater incidence of lung cancer than whites and have been underrepresented in clinical trials. In the PointBreak trial (pemetrexed-carboplatin-bevacizumab and maintenance pemetrexed-bevacizumab [PemCBev] vs. paclitaxel-carboplatin-bevacizumab and maintenance bevacizumab [PacCBev]), 10% of the patients were African American. PointBreak had negative findings; PemCBev did not demonstrate superior overall survival (OS). MATERIALS AND METHODS: PointBreak subgroup efficacy and safety data were retrospectively analyzed: African Americans versus whites for PemCBev; PemCBev versus PacCBev in African Americans; and academic versus community settings for African Americans. Hazard ratios (HRs) and P values were derived from a multivariate Cox proportional hazards model after adjusting for covariates. RESULTS: Of 939 intent-to-treat (ITT) patients, 94 were African American and 805 were white. African-American enrollment was uniform across the study sites (median, 1 African American per site). In the PemCBev arm, OS (HR, 1.125; P = .525), progression-free survival (PFS) (HR, 1.229; P = .251), response (P = .607), and toxicity profiles were similar in African Americans versus whites. For African Americans, OS (HR, 1.375; P = .209), PFS (HR, 0.902; P = .670), response (P = 1.000), and toxicity profiles were similar in the PemCBev versus PacCBev arm. For African Americans, no significant differences were seen in OS (HR, 0.661; P = .191) or PFS (HR, 0.969; P = .915) in academic versus community practice settings. CONCLUSION: In the PemCBev arm, this exploratory analysis showed no significant differences between African Americans and whites for the efficacy outcomes or toxicity profiles. Consistent with the ITT population negative trial result, for African Americans, the median OS was not superior for either arm. For African Americans, PFS and OS were similar in the academic and community settings. Additional outcomes data for African Americans should be collected in lung cancer studies.
AD  - US Oncology Research, Ocala, FL. Electronic address: craig.reynolds@usoncology.com.
Northwestern University Feinberg School of Medicine, Chicago, IL.
University of California, Los Angeles, David Geffen School of Medicine, Translational Research in Oncology-United States, Los Angeles, CA.
Tulsa Cancer Institute, Tulsa, OK.
Rush University Medical Center, Chicago, IL.
Washington University School of Medicine, St Louis, MO.
Eli Lilly and Company, Indianapolis, IN.
Sarah Cannon Research Institute, Nashville, TN and Tennessee Oncology, PLLC, Nashville, TN.
Northwest Georgia Oncology Centers, PC, Marietta, GA.
Division of Hematology/Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, PA.
AN  - 25516338
AU  - Reynolds, C. H.
AU  - Patel, J. D.
AU  - Garon, E. B.
AU  - Olsen, M. R.
AU  - Bonomi, P.
AU  - Govindan, R.
AU  - Pennella, E. J.
AU  - Liu, J.
AU  - Guba, S. C.
AU  - Li, S.
AU  - Spigel, D. R.
AU  - Hermann, R. C.
AU  - Socinski, M. A.
AU  - Obasaju, C. K.
DA  - May
DO  - 10.1016/j.cllc.2014.11.004
DP  - NLM
ET  - 2014/12/18
IS  - 3
KW  - Adult
African Americans/*ethnology
Aged
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Bevacizumab/administration & dosage
Carboplatin/administration & dosage
Carcinoma, Non-Small-Cell Lung/*drug therapy/ethnology/pathology
Disease-Free Survival
Drug Administration Schedule
Female
Humans
Lung Neoplasms/*drug therapy/ethnology/pathology
Male
Middle Aged
Neoplasm Staging
Paclitaxel/administration & dosage
Pemetrexed/administration & dosage
Retrospective Studies
Survival Analysis
Treatment Outcome
Alimta
Avastin
Minority groups
LA  - eng
N1  - 1938-0690
Reynolds, Craig H
Patel, Jyoti D
Garon, Edward B
Olsen, Mark R
Bonomi, Philip
Govindan, Ramaswamy
Pennella, Eduardo J
Liu, Jingyi
Guba, Susan C
Li, Shi
Spigel, David R
Hermann, Robert C
Socinski, Mark A
Obasaju, Coleman K
Clinical Trial, Phase III
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
United States
Clin Lung Cancer. 2015 May;16(3):200-8. doi: 10.1016/j.cllc.2014.11.004. Epub 2014 Nov 18.
PY  - 2015
SN  - 1525-7304
SP  - 200-8
ST  - Exploratory Subset Analysis of African Americans From the PointBreak Study: Pemetrexed-Carboplatin-Bevacizumab Followed by Maintenance Pemetrexed-Bevacizumab Versus Paclitaxel-Carboplatin-Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB/IV Nonsquamous Non-Small-Cell Lung Cancer
T2  - Clin Lung Cancer
TI  - Exploratory Subset Analysis of African Americans From the PointBreak Study: Pemetrexed-Carboplatin-Bevacizumab Followed by Maintenance Pemetrexed-Bevacizumab Versus Paclitaxel-Carboplatin-Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB/IV Nonsquamous Non-Small-Cell Lung Cancer
VL  - 16
ID  - 266
ER  - 

TY  - JOUR
AB  - Introduction African Americans have a greater incidence of lung cancer than whites and have been underrepresented in clinical trials. In the PointBreak trial (pemetrexed-carboplatin-bevacizumab and maintenance pemetrexed-bevacizumab [PemCBev] vs. paclitaxel-carboplatin-bevacizumab and maintenance bevacizumab [PacCBev]), 10% of the patients were African American. PointBreak had negative findings; PemCBev did not demonstrate superior overall survival (OS). Materials and Methods PointBreak subgroup efficacy and safety data were retrospectively analyzed: African Americans versus whites for PemCBev; PemCBev versus PacCBev in African Americans; and academic versus community settings for African Americans. Hazard ratios (HRs) and P values were derived from a multivariate Cox proportional hazards model after adjusting for covariates. Results Of 939 intent-to-treat (ITT) patients, 94 were African American and 805 were white. African-American enrollment was uniform across the study sites (median, 1 African American per site). In the PemCBev arm, OS (HR, 1.125; P =.525), progression-free survival (PFS) (HR, 1.229; P =.251), response (P =.607), and toxicity profiles were similar in African Americans versus whites. For African Americans, OS (HR, 1.375; P =.209), PFS (HR, 0.902; P =.670), response (P = 1.000), and toxicity profiles were similar in the PemCBev versus PacCBev arm. For African Americans, no significant differences were seen in OS (HR, 0.661; P =.191) or PFS (HR, 0.969; P =.915) in academic versus community practice settings. Conclusion In the PemCBev arm, this exploratory analysis showed no significant differences between African Americans and whites for the efficacy outcomes or toxicity profiles. Consistent with the ITT population negative trial result, for African Americans, the median OS was not superior for either arm. For African Americans, PFS and OS were similar in the academic and community settings. Additional outcomes data for African Americans should be collected in lung cancer studies.
AD  - C.H. Reynolds, US Oncology Research, 433 SW 10 Street, Ocala, FL, United States
AU  - Reynolds, C. H.
AU  - Patel, J. D.
AU  - Garon, E. B.
AU  - Olsen, M. R.
AU  - Bonomi, P.
AU  - Govindan, R.
AU  - Pennella, E. J.
AU  - Liu, J.
AU  - Guba, S. C.
AU  - Li, S.
AU  - Spigel, D. R.
AU  - Hermann, R. C.
AU  - Socinski, M. A.
AU  - Obasaju, C. K.
C1  - alimta(Lilly)
avastin(Genentech)
C2  - Genentech
Lilly
DB  - Embase
Medline
DO  - 10.1016/j.cllc.2014.11.004
IS  - 3
KW  - NCT00762034
bevacizumab
carboplatin
paclitaxel
pemetrexed
adult
African American
aged
alopecia
area under the curve
article
bleeding
cancer combination chemotherapy
cancer incidence
cancer staging
cancer survival
Caucasian
drug delivery system
drug efficacy
drug safety
fatigue
febrile neutropenia
female
gastrointestinal toxicity
hazard ratio
human
induction chemotherapy
intention to treat analysis
maintenance therapy
major clinical study
male
non small cell lung cancer
open study
overall survival
premedication
progression free survival
pulmonary hypertension
race difference
retrospective study
sensory neuropathy
thrombosis
treatment response
alimta
avastin
LA  - English
M3  - Article
N1  - L600982571
2014-12-25
2015-05-25
PY  - 2015
SN  - 1938-0690
1525-7304
SP  - 200-208
ST  - Exploratory subset analysis of African Americans from the PointBreak study: Pemetrexed-carboplatin-bevacizumab followed by maintenance pemetrexed-bevacizumab versus paclitaxel-carboplatin-bevacizumab followed by maintenance bevacizumab in patients with stage IIIB/IV nonsquamous non-small-cell lung cancer
T2  - Clinical Lung Cancer
TI  - Exploratory subset analysis of African Americans from the PointBreak study: Pemetrexed-carboplatin-bevacizumab followed by maintenance pemetrexed-bevacizumab versus paclitaxel-carboplatin-bevacizumab followed by maintenance bevacizumab in patients with stage IIIB/IV nonsquamous non-small-cell lung cancer
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L600982571&from=export
http://dx.doi.org/10.1016/j.cllc.2014.11.004
VL  - 16
ID  - 1011
ER  - 

TY  - JOUR
AB  - BACKGROUND: African Americans are more likely to be diagnosed with metastatic colorectal cancer than whites and have shorter survival once they are diagnosed. In this analysis, the authors examined racial differences in clinical outcomes among patients with metastatic colorectal cancer (mCRC) who received bevacizumab. METHODS: The study cohort consisted of 1589 white patients (81.4%) and 227 African American patients (11.6%) with mCRC who received front-line bevacizumab therapy and who were enrolled in a large, predominantly community-based, prospective, observational cohort study. Differences in time-to-event endpoints and response rates were examined by race. Differences in the incidence of baseline and treatment-related toxicities associated with bevacizumab also were examined. Finally, differences in patterns of care by race were explored. RESULTS: The median overall survival was 22.6 months for African Americans and 22.9 months for whites, and the median progression-free survival was 9.5 months for African Americans and 9.8 months for whites. Response rates (complete responses plus partial responses) were 37.5% for African Americans and 46.3% for whites (adjusted odds ratio, 0.67; 95% confidence interval, 0.50-0.90). African Americans had higher rates of baseline diabetes (18.9% vs 11%; P = .002), higher rates of hypertension (52.9% vs 41.4%; P = .001), and worsening hypertension while on therapy (13.7% vs 8.9%; P = .02), but no differences in on-treatment arterial thromboembolic events were observed. CONCLUSIONS: This large observational cohort study of patients with mCRC demonstrated that, when treated in a similar fashion with modern chemotherapy, African Americans and whites had equivalent cancer outcomes. No significant differences in bevacizumab-related toxicity or patterns of care were observed between African Americans and whites. The lower response rate among African Americans deserves further study.
AD  - Section of Hematology-Oncology, Department of Medicine, University of Chicago, Chicago, Illinois 60637-1470, USA. bpolite@medicine.bsd.uchicago.edu
AN  - 21800287
AU  - Polite, B. N.
AU  - Sing, A.
AU  - Sargent, D. J.
AU  - Grothey, A.
AU  - Berlin, J.
AU  - Kozloff, M.
AU  - Feng, S.
DA  - Feb 15
DO  - 10.1002/cncr.26394
DP  - NLM
ET  - 2011/07/30
IS  - 4
KW  - *African Continental Ancestry Group
Aged
Angiogenesis Inhibitors/adverse effects/*therapeutic use
Antibodies, Monoclonal, Humanized/adverse effects/*therapeutic use
Antineoplastic Agents/adverse effects/*therapeutic use
Antineoplastic Combined Chemotherapy Protocols
Bevacizumab
Cohort Studies
Colorectal Neoplasms/*drug therapy/*ethnology/mortality
Drug Therapy, Combination
*European Continental Ancestry Group
Female
Follow-Up Studies
Humans
Kaplan-Meier Estimate
Male
Middle Aged
Neoplasm Metastasis
Outcome Assessment, Health Care
Prospective Studies
Survival Rate
Treatment Outcome
United States
LA  - eng
N1  - 1097-0142
Polite, Blase N
Sing, Amy
Sargent, Daniel J
Grothey, Axel
Berlin, Jordan
Kozloff, Mark
Feng, Shibao
Comparative Study
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
United States
Cancer. 2012 Feb 15;118(4):1083-90. doi: 10.1002/cncr.26394. Epub 2011 Jul 28.
PY  - 2012
SN  - 0008-543x
SP  - 1083-90
ST  - Exploring racial differences in outcome and treatment for metastatic colorectal cancer: results from a large prospective observational cohort study (BRiTE)
T2  - Cancer
TI  - Exploring racial differences in outcome and treatment for metastatic colorectal cancer: results from a large prospective observational cohort study (BRiTE)
VL  - 118
ID  - 388
ER  - 

TY  - JOUR
AB  - BACKGROUND: Inequalities in cancer research participation are thought to exist with certain groups under-represented in research populations; however, much of the evidence is based on small-scale studies. The aim of this study was to explore data from in-depth interviews with cancer patients and a large national survey to investigate variation in who is asked to participate in research and who takes part. METHODS: Factors associated with research discussion and participation were explored in National Cancer Patient Experience Survey data using multivariate logistic regression and during in-depth interviews with 25 breast cancer patients. RESULTS: Survey data were available for 66,953 cancer patients; 30.4% reported having discussions about, and 18.9% took part in, research. Barriers to participation at staff, patient and trust level were evident; for example, staff were less likely to discuss research with older patients, Asian and black patients were less likely to take part and patients treated at specialist or teaching trusts had higher levels of discussion and participation. Interviews showed that patients' willingness to participate changed over time and was not synonymous with participation as some were ineligible. CONCLUSION: Some patient groups were less likely to have discussions about or participate in research. Analysis of this variation vis-à-vis the composition of the patient population may be useful to ensure that there is equity regarding the potential benefits of research participation and that research findings are applicable to target populations in the translational model.
AD  - Patient Experience Research Centre, Department of Infectious Disease Epidemiology, School of Public Health, Imperial College London, St. Mary's Campus, Norfolk Place, Paddington, London, W2 1PG, UK. louise.mc-grath-lone@imperial.ac.uk.
Patient Experience Research Centre, Department of Infectious Disease Epidemiology, School of Public Health, Imperial College London, St. Mary's Campus, Norfolk Place, Paddington, London, W2 1PG, UK. s.day@imperial.ac.uk.
Patient Experience Research Centre, Department of Infectious Disease Epidemiology, School of Public Health, Imperial College London, St. Mary's Campus, Norfolk Place, Paddington, London, W2 1PG, UK. c.schoenborn@imperial.ac.uk.
Patient Experience Research Centre, Department of Infectious Disease Epidemiology, School of Public Health, Imperial College London, St. Mary's Campus, Norfolk Place, Paddington, London, W2 1PG, UK. h.ward@imperial.ac.uk.
AN  - 26341736
AU  - Mc Grath-Lone, L.
AU  - Day, S.
AU  - Schoenborn, C.
AU  - Ward, H.
C2  - PMC4560870
DA  - Sep 4
DO  - 10.1186/s12885-015-1628-8
DP  - NLM
ET  - 2015/09/06
KW  - Adolescent
Adult
Aged
Aged, 80 and over
Breast Neoplasms/*pathology
Clinical Trials as Topic/*methods/statistics & numerical data
Cross-Sectional Studies
Female
Health Services Accessibility/*statistics & numerical data
Health Surveys
Healthcare Disparities/statistics & numerical data
Humans
Interviews as Topic
Male
Middle Aged
Patient Participation/*statistics & numerical data
*Patient Selection
Young Adult
LA  - eng
N1  - 1471-2407
Mc Grath-Lone, Louise
Day, Sophie
Schoenborn, Claudia
Ward, Helen
Journal Article
Research Support, Non-U.S. Gov't
BMC Cancer. 2015 Sep 4;15:618. doi: 10.1186/s12885-015-1628-8.
PY  - 2015
SN  - 1471-2407
SP  - 618
ST  - Exploring research participation among cancer patients: analysis of a national survey and an in-depth interview study
T2  - BMC Cancer
TI  - Exploring research participation among cancer patients: analysis of a national survey and an in-depth interview study
VL  - 15
ID  - 234
ER  - 

TY  - JOUR
AB  - Cervical cancer is the most frequent cancer among women aged between 15 years and 44 years in Kenya, resulting in an estimated 4,802 women being diagnosed with cervical cancer and 2,451 dying from the disease annually. It is often detected at its advanced invasive stages, resulting in a protracted illness upon diagnosis. This qualitative study looked at the illness trajectories of women living with cervical cancer enrolled for follow-up care at Kenyatta National Hospital cancer treatment center and the Nairobi Hospice, both in Nairobi county, Kenya. Using the qualitative phenomenological approach, data were collected through 18 in-depth interviews with women living with cervical cancer between April and July 2011. In-depth interviews with their caregivers, key informant interviews with health care workers, and participant observation field notes were used to provide additional qualitative data. These data were analyzed based on grounded theory's inductive approach. Two key themes on which the data analysis was then anchored were identified, namely, psychosocial challenges of cervical cancer and structural barriers to quality health care. Findings indicated a prolonged illness trajectory with psychosocial challenges, fueled by structural barriers that women were faced with after a cervical cancer diagnosis. To address issues relevant to the increasing numbers of women with cervical cancer, research studies need to include larger samples of these women. Also important are studies that allow in-depth understanding of the experiences of women living with cervical cancer.
AN  - WOS:000214750800083
AU  - Ngutu, M.
AU  - Nyamongo, I. K.
DO  - 10.2147/IJWH.S88668
N1  - 26346001
PY  - 2015
SN  - 1179-1411
SP  - 791-798
ST  - Exploring the barriers to health care and psychosocial challenges in cervical cancer management in Kenya
T2  - International Journal of Womens Health
TI  - Exploring the barriers to health care and psychosocial challenges in cervical cancer management in Kenya
VL  - 7
ID  - 2989
ER  - 

TY  - JOUR
AB  - OBJECTIVE: It is thought that patients fare better when they participate in treatment decision-making, and when they have more control over the amount and type of information they receive. To facilitate informed decision-making, interactive decision aids have been introduced in health care. This article describes how much, and which information patients select from an interactive decision aid on breast cancer. To explore whether the interactive system facilitates that different patients receive different information, associations between patients' characteristics and information selection are inspected. METHODS: The interactive decision aid was provided to 106 patients after an initial discussion with their surgeon about their diagnosis and treatment options. Information regarding patients' age, completed education, treatment preference, psychological functioning, decision uncertainty and decision style was collected with a written, structured questionnaire. The questionnaire was completed before patients used the interactive decision aid. To create categories, a median-split procedure was employed on the scores of the continuous background variables. The information patients selected from the interactive decision aid were registered into logfiles. Associations between patients' background variables and information selection were investigated by means of univariate statistics. RESULTS: Patients (n=97; 92%) used the interactive decision aid intensively. On average, patients spent almost 70min searching for information and selected 21 information topics. Overall, treatment related information was clearly more selected than other types of information. Age, education, and decision style factors were associated with information selection. CONCLUSION: The interactive breast cancer decision aid was utilized intensively. The interactive system was found to facilitate that different patients received different amounts and types of information. PRACTICE IMPLICATIONS: Interactive decision aids may improve information giving to patients, and as a result, the quality of care. To safeguard informed-choice, decision aids should be used in conjunction with other communication strategies. Decision aids should be available continuously and throughout the patients' disease journey. The Internet may help to achieve broad dissemination and enduring access.
AD  - Academic Medical Center, University of Amsterdam, Department of Medical Psychology (Room J3-401), P.O. Box 22 660, 1100 DD Amsterdam, The Netherlands. J.Molenaar@AMC.UvA.NL
AN  - 16945498
AU  - Molenaar, S.
AU  - Sprangers, M.
AU  - Oort, F.
AU  - Rutgers, E.
AU  - Luiten, E.
AU  - Mulder, J.
AU  - van Meeteren, M.
AU  - de Haes, H.
DA  - Jan
DO  - 10.1016/j.pec.2006.06.022
DP  - NLM
ET  - 2006/09/02
IS  - 1
KW  - Adaptation, Psychological
Adult
Aged
Aged, 80 and over
Avoidance Learning
Breast Neoplasms/*psychology/surgery
*CD-ROM/standards
Choice Behavior
Communication
Computer-Assisted Instruction/*methods
*Decision Support Techniques
Female
Health Services Needs and Demand
Humans
Informed Consent
Internal-External Control
Mastectomy/education/psychology
Mastectomy, Segmental/education/psychology
Middle Aged
Netherlands
Patient Education as Topic/*methods
Patient Participation/methods/psychology
Surveys and Questionnaires
Uncertainty
User-Computer Interface
LA  - eng
N1  - Molenaar, Sjaak
Sprangers, Mirjam
Oort, Frans
Rutgers, Emiel
Luiten, Ernest
Mulder, Jan
van Meeteren, Marjolijn
de Haes, Hanneke
Journal Article
Ireland
Patient Educ Couns. 2007 Jan;65(1):122-30. doi: 10.1016/j.pec.2006.06.022. Epub 2006 Sep 1.
PY  - 2007
SN  - 0738-3991 (Print)
0738-3991
SP  - 122-30
ST  - Exploring the black box of a decision aid: what information do patients select from an interactive Cd-Rom on treatment options in breast cancer?
T2  - Patient Educ Couns
TI  - Exploring the black box of a decision aid: what information do patients select from an interactive Cd-Rom on treatment options in breast cancer?
VL  - 65
ID  - 554
ER  - 

TY  - JOUR
AB  - In addition to the physical suffering experienced by cancer survivors, there are considerable financial hardships and access barriers to quality health care. The current study explored the financial burden of breast cancer on African American medically underserved women. Four focus groups were conducted in three major cities across Tennessee. Research participants (N=36) were recruited by the staff of cancer support and treatment programs in the area. Findings revealed that participants' lack of insurance or inadequate insurance resulted in missed, delayed, or fewer treatment opportunities. The financial burden of cancer was not limited to the acute treatment phase. The women in the current study reported extreme economic hardship resulting from this disease into long-term survivorship. This exploratory study confirms the importance of providing care across the continuum to address the complex needs of low-income cancer survivors.
AD  - Middle Tennessee State University, TN, USA.
AN  - 19648700
AU  - Darby, K.
AU  - Davis, C.
AU  - Likes, W.
AU  - Bell, J.
DA  - Aug
DO  - 10.1353/hpu.0.0176
DP  - NLM
ET  - 2009/08/04
IS  - 3
KW  - Adult
*African Americans
Breast Neoplasms/*economics/*ethnology
Female
Focus Groups
*Health Expenditures
Health Services Accessibility/economics
Humans
*Medically Underserved Area
Middle Aged
Qualitative Research
Tennessee
LA  - eng
N1  - Darby, Kathleen
Davis, Cindy
Likes, Wendy
Bell, John
Journal Article
Research Support, Non-U.S. Gov't
United States
J Health Care Poor Underserved. 2009 Aug;20(3):721-8. doi: 10.1353/hpu.0.0176.
PY  - 2009
SN  - 1049-2089 (Print)
1049-2089
SP  - 721-8
ST  - Exploring the financial impact of breast cancer for African American medically underserved women: a qualitative study
T2  - J Health Care Poor Underserved
TI  - Exploring the financial impact of breast cancer for African American medically underserved women: a qualitative study
VL  - 20
ID  - 453
ER  - 

TY  - JOUR
AB  - PURPOSE: To better understand research participation among hard-to-reach populations, this exploratory investigation examined characteristics of enrollees and non-enrollees from a population-based longitudinal study with African-American and Latina-American breast cancer survivors. METHODS: A mixed-method recruitment approach was utilized to enroll participants from cancer registries and community groups who were 1-6 years post-diagnosis. RESULTS: Four hundred and sixty-eight participants agreed to participate constituting an 81% participation rate; 65 and 55% completed Time-1, and both Time-1 and Time-2 assessments, respectively. African-Americans were more likely to agree to participate and complete the T1 assessment (73%) than Latinas (62%) (p < 0.05). Participation was influenced by educational attainment and comorbidities (p < 0.05) for African-Americans. Among Latinas, language proficiency, comorbidities and psychological difficulties (p < 0.01) influenced participation. CONCLUSIONS: Our findings suggest that enrollment in research studies may be influenced by complex and multi-dimensional factors stemming from subjects' characteristics including ethnicity, culture, language proficiency and literary, and socioeconomic status, as well as medical characteristics including co-occurring chronic illness and psychological status. Thus, comprehensive, multi-method research studies are urgently needed to better understand and address the challenge of minority recruitment in biomedical research. To increase research participation among cancer survivors, it is imperative to implement focused strategies that will support and encourage individuals' enrollment and continued participation in studies.
AD  - Center of Community Alliance for Research and Education (CCARE), Department of Population Sciences, City of Hope, 1500 E Duarte Road, Duarte, CA, 91010-3000, USA, kashing@coh.org.
AN  - 25037246
AU  - Ashing, K.
AU  - Rosales, M.
AU  - Fernandez, A.
DA  - Feb
DO  - 10.1007/s11136-014-0758-9
DP  - NLM
ET  - 2014/07/20
IS  - 2
KW  - Adult
African Americans/*psychology
Aged
Breast Neoplasms/*ethnology/psychology/therapy
Comorbidity
Culture
Female
Health Behavior/*ethnology
Hispanic Americans/*psychology
Humans
Logistic Models
Longitudinal Studies
Middle Aged
*Patient Selection
Surveys and Questionnaires
Survivors/*psychology
United States
LA  - eng
N1  - 1573-2649
Ashing, Kimlin
Rosales, Monica
Fernandez, Alejandro
Journal Article
Research Support, Non-U.S. Gov't
Netherlands
Qual Life Res. 2015 Feb;24(2):445-54. doi: 10.1007/s11136-014-0758-9. Epub 2014 Jul 19.
PY  - 2015
SN  - 0962-9343
SP  - 445-54
ST  - Exploring the influence of demographic and medical characteristics of African-American and Latinas on enrollment in a behavioral intervention study for breast cancer survivors
T2  - Qual Life Res
TI  - Exploring the influence of demographic and medical characteristics of African-American and Latinas on enrollment in a behavioral intervention study for breast cancer survivors
VL  - 24
ID  - 283
ER  - 

TY  - JOUR
AB  - Genetic counseling (GC) for hereditary breast and ovarian cancer is available mainly in academic settings. Despiteequal risk, most low income public hospital patients remain unaware and untested. Remote counseling may be asolution, but research has been limited to phone counseling for insured patients. Our study compares in‐person,phone, and video conference GC among high‐risk patients in 3 public hospitals to determine the comparativeeffectiveness of GC delivered across modes with regard to patients' knowledge, cancer distress, decisional conflict,perceived stress, risk perception, satisfaction, and recall. We also assessed whether patients have a preference forcounseling mode and how that affects outcomes. This report describes the study design and lessons learnedregarding recruitment. We conducted a multicenter partially randomized preference noninferiority trial with English‐,Spanish‐, and Cantonese‐speaking patients assigned by randomization or patients” preference to one of the threeGC modes. High‐risk patients were identified using a family history screener in clinics or by physician referral. Studystaff verified risk by phone, invited participation, conducted informed consent, and administered a baseline survey.Enrollees were asked whether they could be randomized or if they preferred one GC mode. They were then given aGC appointment and called again within 2 weeks of counseling for a follow‐up survey. Power calculations required270 randomized patients. A total of 23,401 screener forms yielded 824 likely to be high‐risk; 656 completed baseline surveys. Race/ethnic composition was 40% Latinx, 25% white, 19% African American, and 8% Asian. Of these, 531were counseled, and 505 completed final surveys (283 from randomized patients). The majority (64%) of non‐randomized patients chose counseling by phone, 33% chose in person, 3% chose video. • At every step,participation exceeded our projections, showing that diverse low‐income patients were interested in participating inresearch that they deemed relevant. • Our greatest recruitment challenges were due more to settings than topatients. Collection of screeners varied greatly by month and/or clinic. Oncologists valued the risk services offeredby the study, but intensive engagement was necessary with front‐line staff/supervisors because of their jobdemands. • Partial randomization functioned well. Prior studies showed that many high‐risk women refuserandomization for GC. Adding a preference arm necessitated a larger sample, but greater inclusiveness yields moregeneralizable findings. • Recruitment of Chinese‐speaking patients was low (2.5%) due largely to structural barrierswhich we continue to explore. Practice‐based safety net research presents numerous challenges that require closepartnerships, extensive planning, and highly skilled staff capable of sensitive personnel engagement. The work isrewarded by real‐world findings, the sine qua non in efforts to eliminate cancer disparities.
AN  - CN-02213305
AU  - Guerra, C.
AU  - Lee, R.
AU  - Stewart, S. L.
AU  - Kaplan, C.
AU  - Joseph, G.
AU  - Tsoh, J.
AU  - Dixit, N.
AU  - Cedermaz, H.
AU  - Kim, J.
AU  - Campbell, J.
AU  - et al.
DO  - 10.1158/1538-7755.DISP19-A034
IS  - 6 SUPPL 2
KW  - Adult
African American
Calculation
Conference abstract
Controlled study
Distress syndrome
Family history
Female
Follow up
Genetic counseling
High risk patient
Human
Informed consent
Lowest income group
Major clinical study
Multicenter study
Non‐inferiority trial
Oncologist
Patient referral
Perception
Race
Randomization
Randomized controlled trial
Recall
Risk assessment
Satisfaction
Speech
Stress
Videoconferencing
M3  - Journal: Conference Abstract
PY  - 2020
ST  - Extending the reach of genetic counselingto the safety net: study design and recruitment challengesof a randomized trial
T2  - Cancer epidemiology biomarkers and prevention
TI  - Extending the reach of genetic counselingto the safety net: study design and recruitment challengesof a randomized trial
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02213305/full
VL  - 29
ID  - 1564
ER  - 

TY  - JOUR
AB  - OBJECTIVES: To evaluate the recently developed Prostate Cancer Prevention Trial (PCPT) prostate cancer risk calculator in the San Antonio Center of Biomarkers of Risk for Prostate Cancer (SABOR) cohort of the Early Detection Research Network, a younger and more ethnically diverse population than that in the PCPT. METHODS: From 3488 SABOR participants, we identified 446 who had undergone prostate biopsy and had undergone prostate-specific antigen measurement and digital rectal examination before biopsy. Most biopsies were performed for abnormal digital rectal examination findings, a prostate-specific antigen level of more than 2.5 ng/mL, or elevated risk because of a first-degree relative with prostate cancer. We evaluated the operating characteristics of the PCPT calculator for detecting prostate cancer in this cohort of SABOR participants. Of the 446 men in this cohort, 24% were younger than 55 years of age. RESULTS: Of the 446 men who had undergone biopsy, 148 (33.2%) had prostate cancer. The observed SABOR prostate cancer rates increased with increasing PCPT risk: 15.7%, 39.0%, 48.8%, and 100.0% for a PCPT risk calculator value of less than 25%, 25% to 50%, 50% to 75%, and greater than 75%, respectively. The PCPT risk calculator had an area under the receiver operating characteristic curve of 65.5% (95% confidence interval 60.2% to 70.8%, P < 0.0001), was greater in African-American men (area under curve of 80.0%, 95% confidence interval 67.8% to 92.2%) than in other races (P = 0.02), and was not different in Hispanic men (P > 0.05). CONCLUSIONS: The results of our study have shown that the PCPT risk calculator, available from the Internet and incorporating the current best panel of risk factors, is valid in other, more diverse, populations.
AD  - Department of Urology, University of Texas Health Science Center, San Antonio, Texas 78229, USA. parekhd@uthscsa.edu
AN  - 17169636
AU  - Parekh, D. J.
AU  - Ankerst, D. P.
AU  - Higgins, B. A.
AU  - Hernandez, J.
AU  - Canby-Hagino, E.
AU  - Brand, T.
AU  - Troyer, D. A.
AU  - Leach, R. J.
AU  - Thompson, I. M.
DA  - Dec
DO  - 10.1016/j.urology.2006.10.022
DP  - NLM
ET  - 2006/12/16
IS  - 6
KW  - Aged
Biopsy
Clinical Trials as Topic/*methods
Follow-Up Studies
Humans
Male
Middle Aged
Population Surveillance
Prostate-Specific Antigen/blood
Prostatic Neoplasms/blood/*diagnosis/*prevention & control
Risk Assessment/*methods
LA  - eng
N1  - 1527-9995
Parekh, Dipen J
Ankerst, Donna Pauler
Higgins, Betsy A
Hernandez, Javier
Canby-Hagino, Edith
Brand, Timothy
Troyer, Dean A
Leach, Robin J
Thompson, Ian M
U01-CA86402/CA/NCI NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Validation Study
United States
Urology. 2006 Dec;68(6):1152-5. doi: 10.1016/j.urology.2006.10.022.
PY  - 2006
SN  - 0090-4295
SP  - 1152-5
ST  - External validation of the Prostate Cancer Prevention Trial risk calculator in a screened population
T2  - Urology
TI  - External validation of the Prostate Cancer Prevention Trial risk calculator in a screened population
VL  - 68
ID  - 540
ER  - 

TY  - JOUR
AB  - Minority women are grossly underserved and suffer poorer quality of life during and after treatment for breast cancer. Despite this greater need, interventions designed to foster adaptation to disease among such women are scarce. Our recent randomized trial tested the efficacy of a 10‐week multi‐modal, group‐based, cognitive behavioral stress management (CBSM) intervention delivered in a university setting among women with breast cancer who recently completed adjuvant treatment. Using a panel of psychological, physiological, and physical indicators of adaptation, the investigators examined whether the intervention facilitated "recovery" or adaptation after adjuvant therapy for breast cancer had been completed. CBSM intervention participants showed improvements in multiple indicators of psychosocial adaptation (fewer intrusive thoughts, lower anxiety, less social disruption, less negative affect, more positive affect, greater benefit finding, and higher levels of positive states of mind), physiological adaptation (decreased cortisol and increased cellular immune function and Th1 cytokine production) and physical adaptation to disease (less fatigue and improved sleep quality). Many of these findings held at 3 and 9 month follow‐ups. As with most psychosocial oncology research, participants in the randomized trial were mostly non‐Hispanic White women. Whether or not the results of that trial are generalizable to the larger population that includes minority women needs to be tested. The proposed research aims to translate this University‐based, CBSM intervention into a format that will be acceptable and effective in a community setting. The investigators will target our efforts toward low‐income African American women, (n=120 after attrition) diagnosed with breast cancer (all stages of disease). Participants will be randomized to 10‐week CBSM intervention or an attention time‐matched Enhanced Breast Cancer Wellness and Education (CW) active comparison‐control condition and monitored for 6 months afterward. Outcomes include: (a) acceptability of the intervention, (b) psychosocial adaptation, (c) physical symptom clusters, (d) economic implications and (e) an objective indicator of stress (diurnal salivary cortisol). The main goal is to test whether a successful stress‐management intervention can be effectively implemented in natural settings in the community and will be acceptable to a community‐dwelling, low‐income population of African American women with breast cancer. Specific Aim 1: To examine the acceptability of an empirically‐validated stress management intervention in community‐dwelling low‐income African American women with breast cancer. Specific Aim 2: To test the prediction that participants randomized to CBSM intervention show significant improvements in indices of psychosocial adaptation (i.e., cancer‐specific distress, quality of life) relative to women randomized to a CW attention control condition across the study period. Specific Aim 3: To test the prediction that participants randomized to CBSM intervention show significant improvements in indices of physical symptom clusters relative to women randomized to a CW attention control condition across the study period (physical symptom clusters include pain, sleep, fatigue). Specific Aim 4: To test the prediction that women randomized to a CBSM intervention versus CW attention control condition have better economic outcomes across the study period (as measured by faster return to work, fewer sick days, fewer health care visits). Specific Aim 5: To test the prediction that participants randomized to CBSM intervention show significant improvements in indices of physiological adaptation relative to women randomized to a CW attention control condition across the study period by examining diurnal salivary cortisol as objective measure of stress.
AN  - CN-01549665
AU  - Nct
KW  - Breast Neoplasms
PY  - 2014
ST  - Facilitating Adjustment in Low Income Black Women With Breast Cancer
T2  - https://clinicaltrials.gov/show/NCT02272335
TI  - Facilitating Adjustment in Low Income Black Women With Breast Cancer
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01549665/full
ID  - 1409
ER  - 

TY  - JOUR
AB  - African American men experience worse prostate cancer outcomes compared with those of Caucasian men, not only in incidence and mortality rates, but also in coping with the side effects of treatment. Unfortunately, African American men have been significantly under-represented in research evaluating the efficacy of psychosocial interventions for improving coping in prostate cancer survivors. This pilot study explored the feasibility and efficacy of coping skills training (CST), an intervention developed to enhance coping with treatment side effects in a sample of African American prostate cancer survivors and their intimate partners. The intervention was delivered in a telephone-based format designed to facilitate research participation. A total of 40 couples were randomized to either 6 sessions of CST or usual care. Survivors completed measures of disease-specific quality of life (QOL) related to urinary, sexual, bowel, and hormonal symptom domains, as well as measures of global QOL (i.e., physical functioning and mental health). Partners completed measures of caregiver strain, mood, and vigor. Analysis of data from 30 couples (12 couples in CST, 18 couples in usual care) indicated that CST produced moderate to large treatment effects for QOL related to bowel, urinary, sexual, and hormonal symptoms. Partners who underwent CST reported less caregiver strain, depression, and fatigue, and more vigor, with moderate effect sizes observed that approached conventional levels of statistical significance. These preliminary findings suggest that telephone-based CST is a feasible approach that can successfully enhance coping inAfrican American prostate cancer survivors and their intimate partners. Cancer 2007. (c) 2006 American Cancer Society.
AD  - Pain Prevention and Treatment Research, Department of Psychiatry and Behavioral Medicine, Duke University Medical Center, Durham, North Carolina 27704, USA. dcampb069@mc.duke.edu
AN  - 17173280
AU  - Campbell, L. C.
AU  - Keefe, F. J.
AU  - Scipio, C.
AU  - McKee, D. C.
AU  - Edwards, C. L.
AU  - Herman, S. H.
AU  - Johnson, L. E.
AU  - Colvin, O. M.
AU  - McBride, C. M.
AU  - Donatucci, C.
DA  - Jan 15
DO  - 10.1002/cncr.22355
DP  - NLM
ET  - 2006/12/19
IS  - 2 Suppl
KW  - *Adaptation, Psychological
African Americans/*psychology
Biomedical Research/ethics/statistics & numerical data
Caregivers
Humans
Male
Middle Aged
Patient Participation/*psychology
Pilot Projects
Prostatic Neoplasms/ethnology/*psychology
*Quality of Life
Survivors/*psychology
Telephone
LA  - eng
N1  - Campbell, Lisa C
Keefe, Francis J
Scipio, Cindy
McKee, Daphne C
Edwards, Christopher L
Herman, Steven H
Johnson, Lawrence E
Colvin, O Michael
McBride, Colleen M
Donatucci, Craig
CA14236-2853/CA/NCI NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
United States
Cancer. 2007 Jan 15;109(2 Suppl):414-24. doi: 10.1002/cncr.22355.
PY  - 2007
SN  - 0008-543X (Print)
0008-543x
SP  - 414-24
ST  - Facilitating research participation and improving quality of life for African American prostate cancer survivors and their intimate partners. A pilot study of telephone-based coping skills training
T2  - Cancer
TI  - Facilitating research participation and improving quality of life for African American prostate cancer survivors and their intimate partners. A pilot study of telephone-based coping skills training
VL  - 109
ID  - 539
ER  - 

TY  - JOUR
AB  - PURPOSE: The purpose of this study is to describe the factors associated with the decisions of older African American women to join the PLCO (Prostate, Lung, Colorectal and Ovarian) Cancer Screening Trial when recruited. METHODS: African American women between ages 55 and 74 years who were never diagnosed with a PLCO cancer were eligible for our study. Two methods of recruitment were used. First, mailings were sent to a random sample of women describing the PLCO followed by a telephone call to determine interest in the PLCO. If women were not interested in PLCO but consented to participate in our study, they were interviewed immediately. Second, we followed up with African American women who responded to mass mailings sent out before the start of our study by the Pittsburgh PLCO office. Women completed an interview about their cancer and clinical trial knowledge, attitudes, beliefs, and behaviors. The responses of women who joined the PLCO Trial are contrasted with the responses of women who did not join. RESULTS: Numerous factors were associated with the decision of older African American women to join the PLCO, including perceptions of cancer prevention and detection, the experience of having a loved one with cancer, knowledge of and experience with clinical trials, and beliefs regarding the benefits and risks of clinical trial participation. CONCLUSION: Minority recruitment to cancer clinical trials could be increased by designing interventions focused on individual, organizational, and community needs.
AD  - Graduate School of Public Health, 217 Parran Hall, University of Pittsburgh, Pittsburgh, PA 15261, USA. trauth@pitt.edu
AN  - 16314633
AU  - Trauth, J. M.
AU  - Jernigan, J. C.
AU  - Siminoff, L. A.
AU  - Musa, D.
AU  - Neal-Ferguson, D.
AU  - Weissfeld, J.
DA  - Dec 1
DO  - 10.1200/jco.2004.00.9571
DP  - NLM
ET  - 2005/11/30
IS  - 34
KW  - African Americans/*psychology
Aged
Colorectal Neoplasms/diagnosis/ethnology/prevention & control
*Decision Making
Female
Health Knowledge, Attitudes, Practice
Humans
Lung Neoplasms/diagnosis/ethnology/prevention & control
Male
Mass Screening/methods/*psychology
Middle Aged
Multicenter Studies as Topic/*psychology
Neoplasms/*diagnosis/ethnology/prevention & control
Ovarian Neoplasms/diagnosis/ethnology/prevention & control
Pennsylvania
Prostatic Neoplasms/diagnosis/ethnology/prevention & control
Randomized Controlled Trials as Topic/*psychology
Research Design
LA  - eng
N1  - Trauth, Jeanette M
Jernigan, Jan C
Siminoff, Laura A
Musa, Donald
Neal-Ferguson, Derietra
Weissfeld, Joel
5 RO3CA73340/CA/NCI NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
United States
J Clin Oncol. 2005 Dec 1;23(34):8730-8. doi: 10.1200/JCO.2004.00.9571.
PY  - 2005
SN  - 0732-183X (Print)
0732-183x
SP  - 8730-8
ST  - Factors affecting older african american women's decisions to join the PLCO Cancer Screening Trial
T2  - J Clin Oncol
TI  - Factors affecting older african american women's decisions to join the PLCO Cancer Screening Trial
VL  - 23
ID  - 583
ER  - 

TY  - JOUR
AB  - BACKGROUND: Little is known about the participation of minorities in health behavior research. This manuscript assesses factors associated with participation among women in four racial/ethnic groups. METHODS: A total of 2800 Asian/Pacific Islander (API), Black, Latina, and non-Latina White women recruited through the San Francisco Mammography Registry was invited in 2002 and 2003 to participate in a telephone survey about breast cancer prevention. RESULTS: Minorities participated at lower rates (49% for APIs, 60% for Latinas, and 64% for Blacks) than Whites (77%). Increased participation was associated with younger age for Latinas (OR = 1.90, 95% CI 1.05-3.44) and Whites (OR = 1.77, CI 1.08-2.91), and with a family history of breast cancer for APIs (OR = 2.09, CI 1.24-3.52). Decreased participation was associated with having less than a high school education for APIs (OR = 0.47, CI 0.26-0.86), Blacks (OR = 0.29, CI 0.11-0.78), and Latinas (OR = 0.51, CI 0.28-0.94). CONCLUSIONS: Results suggest minorities' participation in health behavior research does not match Whites' and should be enhanced.
AD  - Department of Medicine, Division of General Internal Medicine, Medical Effectiveness Research Center, University of California, 3333 California Street, Suite 335, San Francisco, CA 94143-0856, USA.
AN  - 15936066
AU  - Des Jarlais, G.
AU  - Kaplan, C. P.
AU  - Haas, J. S.
AU  - Gregorich, S. E.
AU  - Pérez-Stable, E. J.
AU  - Kerlikowske, K.
DA  - Sep-Oct
DO  - 10.1016/j.ypmed.2005.04.001
DP  - NLM
ET  - 2005/06/07
IS  - 3-4
KW  - Adult
Aged
Breast Neoplasms/*prevention & control
*Community Participation
Data Collection
*Ethnic Groups
Female
Humans
Middle Aged
*Risk Reduction Behavior
San Francisco
LA  - eng
N1  - Des Jarlais, Genevieve
Kaplan, Celia Patricia
Haas, Jennifer S
Gregorich, Steven E
Pérez-Stable, Eliseo J
Kerlikowske, Karla
P30-AG15272/AG/NIA NIH HHS/United States
U01CA63740/CA/NCI NIH HHS/United States
U01CA86117/CA/NCI NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.
United States
Prev Med. 2005 Sep-Oct;41(3-4):720-7. doi: 10.1016/j.ypmed.2005.04.001. Epub 2005 Jun 3.
PY  - 2005
SN  - 0091-7435 (Print)
0091-7435
SP  - 720-7
ST  - Factors affecting participation in a breast cancer risk reduction telephone survey among women from four racial/ethnic groups
T2  - Prev Med
TI  - Factors affecting participation in a breast cancer risk reduction telephone survey among women from four racial/ethnic groups
VL  - 41
ID  - 600
ER  - 

TY  - JOUR
AB  - PURPOSE: This paper examines factors associated with attendance in a National Cancer Institute-funded randomized trial of nutrition education to increase fruit and vegetable consumption among women served by the Special Supplemental Nutrition Program for Women, Infants, and Children (WIC). SETTING: The study took place at 16 WIC sites in Maryland. SUBJECTS: The participants were 1528 women who were enrolled in WIC or who had children enrolled in WIC, were > or = 18 years of age, and planned to continue enrollment at that WIC site for at least 6 months (68% of eligible women approached agreed to participate). INTERVENTION: Women received personal invitations, letters, and telephone reminders from peer educators encouraging their attendance at three bimonthly nutrition sessions. MEASURES: Demographic data were collected in a baseline survey. Attendance data and telephone and address changes were also collected. The postintervention survey included a question regarding reasons for nonattendance. Focus groups were also held to ascertain reasons for attendance or nonattendance. Chi-square tests of trend and multiple logistic regression, adjusted for within-site correlation, were used in statistical analyses. RESULTS: Fifty-four percent of enrollees attended at least one session. Multiple logistic regression analysis showed increased odds of attending with higher age, breast-feeding, and/or knowledge of the recommendation to eat five or more servings of fruits and vegetables daily. There were decreased odds of attending for pregnant women who already had children. There were nonsignificant trends toward decreased attendance among unmarried women compared with married women and among blacks compared with nonblacks. Reasons given for nonattendance included withdrawal from WIC, moving, conflicting activities, negative feelings about nutrition education, and lack of transportation or child care. CONCLUSIONS: The results suggest that numerous barriers hinder participation in nutrition programs aimed at low-income women. These barriers should be considered by health care professionals when planning intervention programs. Overcoming these barriers presents a major challenge.
AD  - Department of Epidemiology and Preventive Medicine, University of Maryland School of Medicine, Baltimore 21201, USA.
AN  - 10538640
AU  - Damron, D.
AU  - Langenberg, P.
AU  - Anliker, J.
AU  - Ballesteros, M.
AU  - Feldman, R.
AU  - Havas, S.
DA  - May-Jun
DO  - 10.4278/0890-1171-13.5.268
DP  - NLM
ET  - 1999/10/28
IS  - 5
KW  - Adolescent
Adult
Aged
Chi-Square Distribution
*Community Participation
Educational Status
Female
*Fruit
Health Promotion/*methods
Humans
Logistic Models
Maryland
Middle Aged
Nutritional Sciences/*education
*Vegetables
Women's Health Services
LA  - eng
N1  - Damron, D
Langenberg, P
Anliker, J
Ballesteros, M
Feldman, R
Havas, S
R01CA59725/CA/NCI NIH HHS/United States
Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.
United States
Am J Health Promot. 1999 May-Jun;13(5):268-75. doi: 10.4278/0890-1171-13.5.268.
PY  - 1999
SN  - 0890-1171 (Print)
0890-1171
SP  - 268-75
ST  - Factors associated with attendance in a voluntary nutrition education program
T2  - Am J Health Promot
TI  - Factors associated with attendance in a voluntary nutrition education program
VL  - 13
ID  - 712
ER  - 

TY  - JOUR
AB  - Purpose: This paper examines factors associated with attendance in a National Cancer Institute-funded randomized trial of nutrition education to increase fruit and vegetable consumption among women served by the Special Supplemental Nutrition Program for Women, Infants, and Children (WIC).Setting: The study took place at 16 WIC sites in Maryland.Subjects: The participants were 1528 women who were enrolled in WIC or who had children enrolled in WIC, were > or = 18 years of age, and planned to continue enrollment at that WIC site for at least 6 months (68% of eligible women approached agreed to participate).Intervention: Women received personal invitations, letters, and telephone reminders from peer educators encouraging their attendance at three bimonthly nutrition sessions.Measures: Demographic data were collected in a baseline survey. Attendance data and telephone and address changes were also collected. The postintervention survey included a question regarding reasons for nonattendance. Focus groups were also held to ascertain reasons for attendance or nonattendance. Chi-square tests of trend and multiple logistic regression, adjusted for within-site correlation, were used in statistical analyses.Results: Fifty-four percent of enrollees attended at least one session. Multiple logistic regression analysis showed increased odds of attending with higher age, breast-feeding, and/or knowledge of the recommendation to eat five or more servings of fruits and vegetables daily. There were decreased odds of attending for pregnant women who already had children. There were nonsignificant trends toward decreased attendance among unmarried women compared with married women and among blacks compared with nonblacks. Reasons given for nonattendance included withdrawal from WIC, moving, conflicting activities, negative feelings about nutrition education, and lack of transportation or child care.Conclusions: The results suggest that numerous barriers hinder participation in nutrition programs aimed at low-income women. These barriers should be considered by health care professionals when planning intervention programs. Overcoming these barriers presents a major challenge.
AD  - Department of Epidemiology and Preventive Medicine, University of Maryland School of Medicine, Baltimore 21201, USA
Department of Epidemiology and Preventive Medicine, University of Maryland School of Medicine, Baltimore, MD 21201
AN  - 107226773. Language: English. Entry Date: 19991201. Revision Date: 20180220. Publication Type: journal article
AU  - Damron, D.
AU  - Langenberg, P.
AU  - Anliker, J.
AU  - Ballesteros, M.
AU  - Feldman, R.
AU  - Havas, S.
AU  - Damron, D.
AU  - Langenberg, P.
AU  - Anliker, J.
AU  - Ballesteros, M.
AU  - Feldman, R.
AU  - Havas, S.
DB  - CINAHL Complete
DP  - EBSCOhost
IS  - 5
KW  - Nutrition Education -- In Adulthood
Infant Nutrition
Child Nutrition
Nutrition Education -- In Infancy and Childhood
Consumer Participation
Child
Funding Source
Focus Groups
Fruit
Vegetables
Survey Research
Questionnaires
Pretest-Posttest Design
Mantel-Haenszel Test
Multiple Logistic Regression
P-Value
Odds Ratio
Confidence Intervals
Data Analysis, Statistical
Data Analysis Software
Prospective Studies
Adolescence
Adult
Middle Age
Aged
Female
Human
N1  - commentary; research; tables/charts. Commentary: Glanz K. Participation, retention, and adherence: implications for health promotion research and practice. (AM J HEALTH PROMOT) 1999 May-Jun; 13 (5): 276-277. Journal Subset: Blind Peer Reviewed; Double Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Health Promotion/Education; Peer Reviewed; USA. Grant Information: R01CA59725/CA/NCI NIH HHS/United States. NLM UID: 8701680.
PMID: NLM10538640.
PY  - 1999
SN  - 0890-1171
SP  - 268-277
ST  - Factors associated with attendance in a voluntary nutrition education program...including commentary by Glanz K
T2  - American Journal of Health Promotion
TI  - Factors associated with attendance in a voluntary nutrition education program...including commentary by Glanz K
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=107226773&site=ehost-live&scope=site
VL  - 13
ID  - 1953
ER  - 

TY  - JOUR
AB  - PURPOSE: The practice patterns of medical oncologists at a large National Cancer Institute Comprehensive Cancer Center in Detroit, MI were evaluated to better understand factors associated with accrual to breast cancer clinical trials. PATIENTS AND METHODS: From 1996 to 1997, physicians completed surveys on 319 of 344 newly evaluated female breast cancer patients. The 19-item survey included clinical data, whether patients were offered clinical trial (CT) participation and enrollment, and when applicable, reasons why they were not. Multivariate analyses using logistic regression were performed to evaluate predictors of an offer and enrollment. RESULTS: The patients were 57% white, 32% black, and 11% other/unknown race. One hundred six (33%) were offered participation and 36 (34%) were enrolled. In multivariate analysis, CTs were less likely offered to older women (mean age, 52 years for those offered v 57 years for those not offered; P =.0005) and black women (21% of blacks offered v 42% of whites; P =.0009). Women with stage 1 disease, poor performance status, and those who were previously diagnosed were also less likely to be offered trials. None of these factors were significant predictors of enrollment. Women were not offered trials because of ineligibility (57%), lack of available trials (41%), and noncompliance (2%). Reasons for failed enrollment included patient refusal (88%) and failed eligibility (12%). CONCLUSION: It is important for cooperative groups to design studies that will accommodate a broader spectrum of patients. Further work is needed to assess ways to improve communication about breast cancer CT participation to all eligible women.
AD  - Hudson Webber Cancer Research Building, 4th floor, 4100 John R. St, Detroit, MI 48201, USA. Simonm@karmanos.org
AN  - 15082724
AU  - Simon, M. S.
AU  - Du, W.
AU  - Flaherty, L.
AU  - Philip, P. A.
AU  - Lorusso, P.
AU  - Miree, C.
AU  - Smith, D.
AU  - Brown, D. R.
DA  - Jun 1
DO  - 10.1200/jco.2004.03.005
DP  - NLM
ET  - 2004/04/15
IS  - 11
KW  - African Americans/statistics & numerical data
Age Factors
*Breast Neoplasms
*Clinical Trials as Topic
European Continental Ancestry Group/statistics & numerical data
Female
Health Care Surveys
*Health Services Accessibility
Humans
Logistic Models
Michigan
Middle Aged
*Minority Groups/statistics & numerical data
Multivariate Analysis
*Patient Selection
LA  - eng
N1  - Simon, Michael S
Du, Wei
Flaherty, Lawrence
Philip, Philip A
Lorusso, Patricia
Miree, Cheryl
Smith, Daryn
Brown, Diane R
CA 59-016/CA/NCI NIH HHS/United States
CA-22453/CA/NCI NIH HHS/United States
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.
United States
J Clin Oncol. 2004 Jun 1;22(11):2046-52. doi: 10.1200/JCO.2004.03.005. Epub 2004 Apr 13.
PY  - 2004
SN  - 0732-183X (Print)
0732-183x
SP  - 2046-52
ST  - Factors associated with breast cancer clinical trials participation and enrollment at a large academic medical center
T2  - J Clin Oncol
TI  - Factors associated with breast cancer clinical trials participation and enrollment at a large academic medical center
VL  - 22
ID  - 633
ER  - 

TY  - JOUR
AB  - Objectives: To identify patient, hospital, and central venous catheter factors that may influence the use of low-dose heparin infusion for central venous catheter patency in critically ill children. Design: Secondary analysis of an international multicenter observational study. Setting: Fifty-nine PICUs over four study dates in 2012, involving seven countries. Patients: Children less than 18 years old with a central venous catheter who were admitted to a participating unit and enrolled in the completed Prophylaxis against Thrombosis Practice study were included. All overflow patients were excluded. Interventions: None. Measurements and Main Results: Of the 2,484 patients in the Prophylaxis against Thrombosis Practice study, 1,312 patients had a central venous catheter. Five hundred seven of those patients used low-dose heparin infusion. The frequency of low-dose heparin infusion was compared across various patient, hospital, and central venous catheter factors using chi-square, Mann-Whitney U, and Fisher exact tests. In the multivariate analysis, age was not a significant factor for low-dose heparin infusion use. Patients with pulmonary hypertension had decreased low-dose heparin infusion use, whereas those with active surgical or trauma diagnoses had increased low-dose heparin infusion use. All centrally inserted central venous catheters were more likely to use low-dose heparin infusion when compared with peripherally inserted central venous catheters. The Asia-Pacific region showed increased low-dose heparin infusion use, along with community hospitals and smaller ICUs (< 10 beds). Conclusions: Patient, central venous catheter, and hospital factors are associated with the use of low-dose heparin infusion in critically ill children. Further study is needed to evaluate the efficacy and persistence of low-dose heparin infusion use.
AD  - S.J. Hanson, Department of Pediatrics, Medical College of Wisconsin, United States
AU  - Onyeama, S. J. N.
AU  - Hanson, S. J.
AU  - Dasgupta, M.
AU  - Hoffmann, R. G.
AU  - Faustino, E. V. S.
DB  - Embase
Medline
DO  - 10.1097/PCC.0000000000000854
IS  - 8
KW  - central venous catheter
peripherally inserted central venous catheter
acetylsalicylic acid
antivitamin K
heparin
low molecular weight heparin
adolescent
age
article
Asia
Asian
Australia
Black person
bleeding tendency
brain hemorrhage
Canada
catheter thrombosis
Caucasian
cavopulmonary connection
cerebrovascular accident
child
childhood cancer
community hospital
continuous infusion
craniotomy
critically ill patient
femoral vein
heart catheterization
heart surgery
heparinization
Hispanic
home care
hospitalized child
human
infant
intensive care unit
internal jugular vein
low drug dose
major clinical study
multicenter study (topic)
New Zealand
newborn
parenteral nutrition
peripheral vascular system
Portugal
priority journal
pulmonary hypertension
race difference
retrospective study
secondary analysis
sickle cell anemia
Spain
subclavian vein
thorax
thrombosis prevention
umbilical cord
United States
LA  - English
M3  - Article
N1  - L611065367
2016-07-08
2016-08-19
PY  - 2016
SN  - 1947-3893
1529-7535
SP  - e352-e361
ST  - Factors associated with continuous low-dose heparin infusion for central venous catheter patency in critically ill children worldwide
T2  - Pediatric Critical Care Medicine
TI  - Factors associated with continuous low-dose heparin infusion for central venous catheter patency in critically ill children worldwide
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L611065367&from=export
http://dx.doi.org/10.1097/PCC.0000000000000854
VL  - 17
ID  - 966
ER  - 

TY  - JOUR
AB  - Context: Lung cancer is the leading cause of cancer death in the United States. Surgical resection for stage I or II non-small cell cancer remains the only reliable treatment for cure. Patients who do not undergo surgery have a median survival of less than 1 year. Despite the survival disadvantage, many patients with early-stage disease do not receive surgical care and rates are even lower for black patients. Objectives: To identify potentially modifiable factors regarding surgery in patients newly diagnosed with early-stage lung cancer and to explore why blacks undergo surgery less often than whites. Design, Setting, and Patients: Prospective cohort study with patients identified by pulmonary, oncology, thoracic surgery, and generalist practices in 5 communities through study referral or computerized tomography review protocol. A total of 437 patients with biopsy-proven or probable early-stage lung cancer were enrolled between December 2005 and December 2008. Before establishment of treatment plans, patients were administered a survey including questions about trust, patient-physician communication, attitudes toward cancer, and functional status. Information about comorbid illnesses was obtained through chart audits. Main Outcome Measure: Lung cancer surgery within 4 months of diagnosis. Results: A total of 386 patients met full eligibility criteria for lung resection surgery. The median age was 66 years (range, 26-90 years) and 29% of patients were black. The surgical rate was 66% for white patients (n=179/273) compared with 55% for black patients (n=62/113; P=.05). Negative perceptions of patient-physician communication manifested by a 5-point decrement on a 25-point communication scale (odds ratio [OR], 0.42; 95% confidence interval [CI], 0.32-0.74) and negative perception of 1-year prognosis postsurgery (OR, 0.27; 95% CI, 0.14-0.50; absolute risk, 34%) were associated with decisions against surgery. Surgical rates for blacks were particularly low when they had 2 or more comorbid illnesses (13% vs 62% for <2 comorbidities; OR, 0.04 [95% CI, 0.01-0.25]; absolute risk, 49%) and when blacks lacked a regular source of care (42% with no regular care vs 57% with regular care; OR, 0.20 [95% CI, 0.10-0.43]; absolute risk, 15%). Conclusions: A decision not to undergo surgery by patients with newly diagnosed lung cancer was independently associated with perceptions of communication and prognosis, older age, multiple comorbidities, and black race. Interventions to optimize surgery should consider these factors. ©2010 American Medical Association. All rights reserved.
AD  - S. Cykert, Internal Medicine Program, Moses Cone Health System, Greensboro Area Health Education Center, Greensboro, NC, United States
AU  - Cykert, S.
AU  - Dilworth-Anderson, P.
AU  - Monroe, M. H.
AU  - Walker, P.
AU  - McGuire, F. R.
AU  - Corbie-Smith, G.
AU  - Edwards, L. J.
AU  - Bunton, A. J.
DB  - Embase
Medline
DO  - 10.1001/jama.2010.793
IS  - 23
KW  - adult
aged
article
cancer diagnosis
cancer staging
clinical trial
comorbidity
computer assisted tomography
controlled clinical trial
controlled study
doctor patient relationship
female
functional status
general practice
health survey
human
lung cancer
lung resection
lung surgery
major clinical study
male
clinical audit
medical decision making
medical record review
patient attitude
patient referral
priority journal
prognosis
race difference
surgical risk
thorax surgery
treatment planning
LA  - English
M3  - Article
N1  - L359019040
2010-06-24
2010-07-01
PY  - 2010
SN  - 0098-7484
1538-3598
SP  - 2368-2376
ST  - Factors associated with decisions to undergo surgery among patients with newly diagnosed early-stage lung cancer
T2  - JAMA - Journal of the American Medical Association
TI  - Factors associated with decisions to undergo surgery among patients with newly diagnosed early-stage lung cancer
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L359019040&from=export
http://dx.doi.org/10.1001/jama.2010.793
http://jama.ama-assn.org/cgi/reprint/303/23/2368
VL  - 303
ID  - 1162
ER  - 

TY  - JOUR
AB  - BACKGROUND: Because of the lack of results from randomized clinical trials comparing the efficacy of aggressive therapies with that of more conservative therapies for clinically localized prostate cancer, men and their physicians may select treatments based on other criteria. We examined the association of sociodemographic and clinical characteristics with four management options: radical prostatectomy, radiation therapy, hormonal therapy, and watchful waiting. METHODS: We studied 3073 participants of the Prostate Cancer Outcomes Study diagnosed from October 1, 1994, through October 31, 1995, with clinically localized disease (T1 or T2). Participants completed a baseline survey, and diagnostic and treatment information was abstracted from medical records. Multiple logistic regression analysis identified factors associated with initial treatment. All statistical tests were two-sided. RESULTS: Patients with clinically localized disease received the following treatments: radical prostatectomy (47.6%), radiation therapy (23.4%), hormonal therapy (10.5%), or watchful waiting (18.5%). Men aged 75 years or older more often received conservative treatment (i.e., hormonal therapy alone or watchful waiting; 57.9% of men aged 75-79 years and 82.1% of men aged 80 years and older) than aggressive treatment (i.e., radical prostatectomy or radiation therapy) (for all age groups, P</=.001). After adjustment for age, clinical stage, baseline prostate-specific antigen level, and histologic grade, the following factors were associated with conservative treatment: history of a heart attack, being unmarried, geographic region, poor pretreatment bladder control, and impotence. In men younger than 60 years, use of aggressive treatment was similar by race/ethnicity (adjusted percentages = 85.5%, 88.1%, and 85.3% for white, African-American, and Hispanic men, respectively). However, among men 60 years old and older, African-American men underwent aggressive treatment less often than did white men or Hispanic men (adjusted percentages for men aged 60-64 years = 67.1%, 84.7%, and 79.2%, respectively; 65-74 years = 64.8%, 73.4%, and 79.5%, respectively; and 75 years old and older = 25.2%, 45.7%, and 36.6%, respectively). CONCLUSIONS: The association of nonclinical factors with treatment suggests that, in the absence of definitive information regarding treatment effectiveness, men diagnosed with prostate cancer should be better informed of the risks and benefits of all treatment options.
AD  - Applied Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA. lh50w@nih.gov
AN  - 11752011
AU  - Harlan, L. C.
AU  - Potosky, A.
AU  - Gilliland, F. D.
AU  - Hoffman, R.
AU  - Albertsen, P. C.
AU  - Hamilton, A. S.
AU  - Eley, J. W.
AU  - Stanford, J. L.
AU  - Stephenson, R. A.
DA  - Dec 19
DO  - 10.1093/jnci/93.24.1864
DP  - NLM
ET  - 2001/12/26
IS  - 24
KW  - Adult
Age Factors
Aged
Aged, 80 and over
Clinical Trials as Topic
Hormones/therapeutic use
Humans
Logistic Models
Male
Middle Aged
Prostate-Specific Antigen/blood
Prostatic Neoplasms/*drug therapy/*radiotherapy/*surgery
Treatment Outcome
LA  - eng
N1  - Harlan, L C
Potosky, A
Gilliland, F D
Hoffman, R
Albertsen, P C
Hamilton, A S
Eley, J W
Stanford, J L
Stephenson, R A
N01PC67000/PC/NCI NIH HHS/United States
N01PC67005/PC/NCI NIH HHS/United States
N01PC67006/PC/NCI NIH HHS/United States
N01PC67007/PC/NCI NIH HHS/United States
N01PC67009/PC/NCI NIH HHS/United States
N01PC67010/PC/NCI NIH HHS/United States
Comparative Study
Journal Article
Research Support, U.S. Gov't, P.H.S.
United States
J Natl Cancer Inst. 2001 Dec 19;93(24):1864-71. doi: 10.1093/jnci/93.24.1864.
PY  - 2001
SN  - 0027-8874 (Print)
0027-8874
SP  - 1864-71
ST  - Factors associated with initial therapy for clinically localized prostate cancer: prostate cancer outcomes study
T2  - J Natl Cancer Inst
TI  - Factors associated with initial therapy for clinically localized prostate cancer: prostate cancer outcomes study
VL  - 93
ID  - 677
ER  - 

TY  - JOUR
AB  - BACKGROUND: Despite the large number of men diagnosed with localized prostate cancer, there is as yet no consensus concerning appropriate treatment. The purpose of this study was to describe the initial treatment patterns for localized prostate cancer in a population-based sample and to determine the clinical and patient characteristics associated with initial treatment and overall survival. METHODS: The analysis included 3,300 patients from seven states, diagnosed with clinically localized prostate cancer in 1997. We examined the association of sociodemographic and clinical characteristics with four treatment options: radical prostatectomy, radiation therapy, hormone therapy, and watchful waiting. Diagnostic and treatment information was abstracted from medical records. Socioeconomic measures were derived from the 2000 Census based on the patient's residence at time of diagnosis. Vital status through December 31, 2002, was obtained from medical records and linkages to state vital statistics files and the National Death Index. Multiple logistic regression analysis and Cox proportional hazards models identified factors associated with initial treatment and overall survival, respectively. RESULTS: Patients with clinically localized prostate cancer received the following treatments: radical prostatectomy (39.7%), radiation therapy (31.4%), hormone therapy (10.3%), or watchful waiting (18.6%). After multivariable adjustment, the following variables were associated with conservative treatment (hormone therapy or watchful waiting): older age, black race, being unmarried, having public insurance, having non-screen detected cancer, having normal digital rectal exam results, PSA values above 20, low Gleason score (2-4), comorbidity, and state of residence. Among patients receiving definitive treatment (radical prostatectomy or radiation therapy), older age, being unmarried, PSA values above 10, unknown Gleason score, state of residence, as well as black race in patients under 60 years of age, were associated with receipt of radiation therapy. Overall survival was related to younger age, being married, Gleason score under 8, radical prostatectomy, and state of residence. Comorbidity was only associated with risk of death within the first three years of diagnosis. CONCLUSIONS: In the absence of clear-cut evidence favoring one treatment modality over another, it is important to understand the factors that inform treatment selection. Since state of residence was a significant predictor of both treatment as well as overall survival, true regional differences probably exist in how physicians and patients select treatment options. Factors affecting treatment choice and treatment effectiveness need to be further explored in future population-based studies.
AD  - New York State Cancer Registry, New York State Department of Health, 150 Broadway, Suite 361, Menands, NY 12204-2719, USA. mjs08@health.state.ny.us
AN  - 20403178
AU  - Schymura, M. J.
AU  - Kahn, A. R.
AU  - German, R. R.
AU  - Hsieh, M. C.
AU  - Cress, R. D.
AU  - Finch, J. L.
AU  - Fulton, J. P.
AU  - Shen, T.
AU  - Stuckart, E.
C2  - PMC2876077
DA  - Apr 19
DO  - 10.1186/1471-2407-10-152
DP  - NLM
ET  - 2010/04/21
KW  - Adenocarcinoma/*mortality/pathology/*therapy
Aged
Aged, 80 and over
Antineoplastic Agents, Hormonal/*therapeutic use
Humans
Logistic Models
Male
Middle Aged
Neoplasm Invasiveness
Observation
Odds Ratio
Patient Selection
Practice Patterns, Physicians'/*statistics & numerical data
Proportional Hazards Models
Prostatectomy/*statistics & numerical data
Prostatic Neoplasms/*mortality/pathology/*therapy
Radiotherapy/statistics & numerical data
Registries
Residence Characteristics
Risk Assessment
Risk Factors
Socioeconomic Factors
Survival Analysis
Time Factors
Treatment Outcome
United States/epidemiology
LA  - eng
N1  - 1471-2407
Schymura, Maria J
Kahn, Amy R
German, Robert R
Hsieh, Mei-Chin
Cress, Rosemary D
Finch, Jack L
Fulton, John P
Shen, Tiefu
Stuckart, Erik
Journal Article
Multicenter Study
BMC Cancer. 2010 Apr 19;10:152. doi: 10.1186/1471-2407-10-152.
PY  - 2010
SN  - 1471-2407
SP  - 152
ST  - Factors associated with initial treatment and survival for clinically localized prostate cancer: results from the CDC-NPCR Patterns of Care Study (PoC1)
T2  - BMC Cancer
TI  - Factors associated with initial treatment and survival for clinically localized prostate cancer: results from the CDC-NPCR Patterns of Care Study (PoC1)
VL  - 10
ID  - 423
ER  - 

TY  - JOUR
AB  - BACKGROUND & AIMS: Endoscopists do not routinely follow guidelines to survey individuals with low-risk adenomas (LRAs; 1-2 small tubular adenomas, < 1 cm) every 5-10 years for colorectal cancer; many recommend shorter surveillance intervals for these individuals. We aimed to identify the reasons that endoscopists recommend shorter surveillance intervals for some individuals with LRAs and determine whether timing affects outcomes at follow-up examinations. METHODS: We collected data from 1560 individuals (45-75 years old) who participated in a prospective chemoprevention trial (of vitamin D and calcium) from 2004 through 2008. Participants in the trial had at least 1 adenoma, detected at their index colonoscopy, and were recommended to receive follow-up colonoscopy examinations at 3 or 5 years after adenoma identification, as recommended by the endoscopist. For this analysis we collected data from only participants with LRAs. These data included characteristics of participants and endoscopists and findings from index and follow-up colonoscopies. Primary endpoints were frequency of recommending shorter (3-year) vs longer (5-year) surveillance intervals, factors associated with these recommendations, and effect on outcome, determined at the follow-up colonoscopy. RESULTS: A 3-year surveillance interval was recommended for 594 of the subjects (38.1%). Factors most significantly associated with recommendation of 3-year vs a 5-year surveillance interval included African American race (relative risk [RR] to white, 1.41; 95% confidence interval [CI], 1.14-1.75), Asian/Pacific Islander ethnicity (RR to white, 1.7; 95% CI, 1.22-2.43), detection of 2 adenomas at the index examination (RR vs 1 adenoma, 1.47; 95% CI, 1.27-1.71), more than 3 serrated polyps at the index examination (RR=2.16, 95% CI, 1.59-2.93), or index examination with fair or poor quality bowel preparation (RR vs excellent quality, 2.16; 95% CI, 1.66-2.83). Other factors that had a significant association with recommendation for a 3-year surveillance interval included family history of colorectal cancer and detection of 1-2 serrated polyps at the index examination. In comparisons of outcomes, we found no significant differences between the 3-year vs 5-year recommendation groups in proportions of subjects found to have 1 or more adenomas (38.8% vs 41.7% respectively; P = .27), advanced adenomas (7.7% vs 8.2%; P = .73) or clinically significant serrated polyps (10.0% vs 10.3%; P = .82) at the follow-up colonoscopy. CONCLUSIONS: Possibly influenced by patients' family history, race, quality of bowel preparation, or number or size of polyps, endoscopists frequently recommend 3-year surveillance intervals instead of guideline-recommended intervals of 5 years or longer for individuals with LRAs. However, at the follow-up colonoscopy, similar proportions of participants have 1 or more adenomas, advanced adenomas, or serrated polyps. These findings support the current guideline recommendations of performing follow-up examinations of individuals with LRAs at least 5 years after the index colonoscopy.
AD  - Department of Medicine, Department of Veterans Affairs Medical Center, White River Junction, Vermont; Department of Epidemiology for ELB, JAB, and LM and Department of Medicine in the Division of Gastroenterology and Hepatology for JCA and DJR, The Geisel School of Medicine at Dartmouth, Hanover, New Hampshire. Electronic address: joseph.anderson@dartmouth.edu.
Department of Epidemiology for ELB, JAB, and LM and Department of Medicine in the Division of Gastroenterology and Hepatology for JCA and DJR, The Geisel School of Medicine at Dartmouth, Hanover, New Hampshire; Department of Medicine in the Division of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Department of Medicine in the Division of Gastroenterology and Hepatology, University of Colorado School of Medicine and Gastroenterology of the Rockies, Denver and Boulder, Colorado.
Department of Epidemiology for ELB, JAB, and LM and Department of Medicine in the Division of Gastroenterology and Hepatology for JCA and DJR, The Geisel School of Medicine at Dartmouth, Hanover, New Hampshire.
Department of Epidemiology, Rollins School of Public Health, and Winship Cancer Institute, Emory University, Atlanta, Georgia.
Department of Gastroenterology and Hepatology, Cleveland Clinic, Cleveland, Ohio.
Department of Medicine in the Division of Gastroenterology and Hepatology, University of Texas MD Anderson Cancer Center, Houston, Texas.
Division of Environmental Health Sciences, University of Minnesota School of Public Health, Minneapolis, Minnesota.
Interim Dean and Professor of Statistics in the College of Engineering and Mathematical Sciences, University of Vermont, Burlington, Vermont.
Department of Medicine in the Division of Gastroenterology and Hepatology, University of Puerto Rico, San Juan, Puerto Rico.
Minnesota Gastroenterology, P.A., Minneapolis, Minnesota.
Department of Medicine in the Division of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Department of Medicine, Department of Veterans Affairs Medical Center, White River Junction, Vermont; Department of Epidemiology for ELB, JAB, and LM and Department of Medicine in the Division of Gastroenterology and Hepatology for JCA and DJR, The Geisel School of Medicine at Dartmouth, Hanover, New Hampshire.
AN  - 28219690
AU  - Anderson, J. C.
AU  - Baron, J. A.
AU  - Ahnen, D. J.
AU  - Barry, E. L.
AU  - Bostick, R. M.
AU  - Burke, C. A.
AU  - Bresalier, R. S.
AU  - Church, T. R.
AU  - Cole, B. F.
AU  - Cruz-Correa, M.
AU  - Kim, A. S.
AU  - Mott, L. A.
AU  - Sandler, R. S.
AU  - Robertson, D. J.
C2  - PMC6251057
C6  - NIHMS996463
DA  - Jun
DO  - 10.1053/j.gastro.2017.02.010
DP  - NLM
ET  - 2017/02/22
IS  - 8
KW  - Adenoma/*diagnosis/pathology/prevention & control
Aged
Anticarcinogenic Agents/therapeutic use
Calcium/therapeutic use
Carcinoma/*diagnosis/pathology/prevention & control
Colon/*pathology
Colonic Neoplasms/*diagnosis/pathology/prevention & control
*Colonoscopy/standards/trends
Dietary Supplements
Disease Progression
Early Detection of Cancer/*methods/standards/trends
Female
*Gastroenterologists/standards/trends
Guideline Adherence
Humans
Male
Middle Aged
Multivariate Analysis
North America
Odds Ratio
Patient Selection
Practice Guidelines as Topic
*Practice Patterns, Physicians'/standards/trends
Predictive Value of Tests
Prospective Studies
Risk Assessment
Risk Factors
Time Factors
Tumor Burden
Vitamin D/therapeutic use
*Colon Cancer
*Detection
*Progression
*Tumor Development
LA  - eng
N1  - 1528-0012
Anderson, Joseph C
Baron, John A
Ahnen, Dennis J
Barry, Elizabeth L
Bostick, Roberd M
Burke, Carol A
Bresalier, Robert S
Church, Timothy R
Cole, Bernard F
Cruz-Correa, Marcia
Kim, Adam S
Mott, Leila A
Sandler, Robert S
Robertson, Douglas J
R01 CA059005/CA/NCI NIH HHS/United States
R01 CA098286/CA/NCI NIH HHS/United States
U01 CA046927/CA/NCI NIH HHS/United States
Journal Article
Multicenter Study
Randomized Controlled Trial
Gastroenterology. 2017 Jun;152(8):1933-1943.e5. doi: 10.1053/j.gastro.2017.02.010. Epub 2017 Feb 20.
PY  - 2017
SN  - 0016-5085 (Print)
0016-5085
SP  - 1933-1943.e5
ST  - Factors Associated With Shorter Colonoscopy Surveillance Intervals for Patients With Low-Risk Colorectal Adenomas and Effects on Outcome
T2  - Gastroenterology
TI  - Factors Associated With Shorter Colonoscopy Surveillance Intervals for Patients With Low-Risk Colorectal Adenomas and Effects on Outcome
VL  - 152
ID  - 180
ER  - 

TY  - JOUR
AB  - Objective: To identify the factors associated with weight gain after diagnosis of breast cancer in a heterogeneous population of women. Design: Descriptive cross-sectional study. Subjects: 1,116 patients who had been diagnosed with stage I, stage II, or stage IIIA primary, operable breast cancer within the previous 4 years. Patients were recruited during enrollment into a diet intervention trial to reduce risk for breast cancer recurrence. Analysis Demographic data, weight history, and physical activity information obtained by questionnaire and medical information obtained by chart review; dietary assessment based on four 24-hour dietary recalls collected by telephone. Associations between weight change after the diagnosis of breast cancer and prediction variables were examined using univariate and multiple linear regression analyses. Results: Overall, 60% of the subjects reported weight gain, 26% reported weight loss, and 14% reported no change in weight after the diagnosis of breast cancer. The overall mean weight change was a gain of 2.7 kg (6 lb). Factors positively and independently associated with weight gain were time since diagnosis of breast cancer, adjuvant chemotherapy, African-American ethnicity, current energy intake, and postmenopausal status at time of study entry. Factors inversely and independently associated with weight gain were prediagnosis body mass index, age at diagnosis, education level, and exercise index score. Applications: Higher energy intake and lower level of physical activity are independently associated with increased risk for weight gain after the diagnosis of breast cancer. Strategies to modify these behaviors are likely to influence the long-term pattern of weight change.
AD  - C.L. Rock, University of California, Can. Prevention and Control Program, Dept. 0901, 9500 Gilman Dr, San Diego, CA 92093-0901, United States
AU  - Rock, C. L.
AU  - Flatt, S. W.
AU  - Newman, V.
AU  - Caan, B. J.
AU  - Haan, M. N.
AU  - Stefanick, M. L.
AU  - Faerber, S.
AU  - Pierce, J. P.
DB  - Embase
Medline
DO  - 10.1016/S0002-8223(99)00298-9
IS  - 10
KW  - cyclophosphamide
doxorubicin
fluorouracil
methotrexate
adjuvant chemotherapy
adult
aged
article
breast cancer
caloric intake
demography
disease association
female
human
major clinical study
nutrition
physical activity
postmenopause
recurrence risk
risk factor
body weight gain
LA  - English
M3  - Article
N1  - L29480611
1999-10-24
PY  - 1999
SN  - 0002-8223
SP  - 1212-1218
ST  - Factors associated with weight gain in women after diagnosis of breast cancer
T2  - Journal of the American Dietetic Association
TI  - Factors associated with weight gain in women after diagnosis of breast cancer
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L29480611&from=export
http://dx.doi.org/10.1016/S0002-8223(99)00298-9
VL  - 99
ID  - 1326
ER  - 

TY  - JOUR
AB  - OBJECTIVE: To identify the factors associated with weight gain after diagnosis of breast cancer in a heterogeneous population of women. DESIGN: Descriptive cross-sectional study. SUBJECTS: 1,116 patients who had been diagnosed with stage I, stage II, or stage IIIA primary, operable breast cancer within the previous 4 years. Patients were recruited during enrollment into a diet intervention trial to reduce risk for breast cancer recurrence. Analysis Demographic data, weight history, and physical activity information obtained by questionnaire and medical information obtained by chart review; dietary assessment based on four 24-hour dietary recalls collected by telephone. Associations between weight change after the diagnosis of breast cancer and prediction variables were examined using univariate and multiple linear regression analyses. RESULTS: Overall, 60% of the subjects reported weight gain, 26% reported weight loss, and 14% reported no change in weight after the diagnosis of breast cancer. The overall mean weight change was a gain of 2.7 kg (6 lb). Factors positively and independently associated with weight gain were time since diagnosis of breast cancer, adjuvant chemotherapy, African-American ethnicity, current energy intake, and postmenopausal status at time of study entry. Factors inversely and independently associated with weight gain were prediagnosis body mass index, age at diagnosis, education level, and exercise index score. APPLICATIONS: Higher energy intake and lower level of physical activity are independently associated with increased risk for weight gain after the diagnosis of breast cancer. Strategies to modify these behaviors are likely to influence the long-term pattern of weight change.
AD  - Department of Family and Preventive Medicine, University of California, San Diego, La Jolla 92093-0901, USA.
AN  - 10524383
AU  - Rock, C. L.
AU  - Flatt, S. W.
AU  - Newman, V.
AU  - Caan, B. J.
AU  - Haan, M. N.
AU  - Stefanick, M. L.
AU  - Faerber, S.
AU  - Pierce, J. P.
DA  - Oct
DO  - 10.1016/s0002-8223(99)00298-9
DP  - NLM
ET  - 1999/10/19
IS  - 10
KW  - Adult
Aged
Body Mass Index
Breast Neoplasms/diagnosis/diet therapy/*physiopathology
Cross-Sectional Studies
Diet Surveys
Educational Status
Energy Intake
Exercise
Female
Humans
Logistic Models
Mental Recall
Middle Aged
Multicenter Studies as Topic
Neoplasm Recurrence, Local/prevention & control
Randomized Controlled Trials as Topic
Surveys and Questionnaires
Time Factors
*Weight Gain
LA  - eng
N1  - Rock, C L
Flatt, S W
Newman, V
Caan, B J
Haan, M N
Stefanick, M L
Faerber, S
Pierce, J P
R01 CA069375/CA/NCI NIH HHS/United States
CA69375/CA/NCI NIH HHS/United States
M01-R00070/PHS HHS/United States
M01-RR00827/RR/NCRR NIH HHS/United States
Journal Article
Research Support, U.S. Gov't, P.H.S.
United States
J Am Diet Assoc. 1999 Oct;99(10):1212-21. doi: 10.1016/s0002-8223(99)00298-9.
PY  - 1999
SN  - 0002-8223 (Print)
0002-8223
SP  - 1212-21
ST  - Factors associated with weight gain in women after diagnosis of breast cancer. Women's Healthy Eating and Living Study Group
T2  - J Am Diet Assoc
TI  - Factors associated with weight gain in women after diagnosis of breast cancer. Women's Healthy Eating and Living Study Group
VL  - 99
ID  - 713
ER  - 

TY  - JOUR
AB  - This study evaluated factors associated with willingness to provide biospecimens for cancer genetic research among African American cancer survivors. A total of 200 African American adults diagnosed with breast, colon, and/or prostate cancers completed a self-administered survey. Family history information, beliefs about cancer research, cancer genetics and disparities knowledge, willingness to provide a biospecimen, and demographics were obtained. Chi-square, independent samples t tests, and logistic regression analyses were performed. Overall, 79% of this sample was willing to provide a biospecimen for cancer genetics research. Independent associations of willingness to provide a biospecimen existed among demographics (males (p = 0.041)), those who believed in the importance of genetic causes of cancer (p < 0.001), individuals who believe it is important to participate in genetics research (p < 0.001), and those who indicated they would participate in genetics research to help future generations (p = 0.026). Overall, 12.5–56% of participants demonstrated some level of genetics and cancer disparities. This study identified factors that may be incorporated into future research interventions to engage the African American cancer population in cancer genetics biobanking research.
AD  - A.T. Ewing, 23andMe Inc., Mountain View, CA, United States
AU  - Ewing, A. T.
AU  - Kalu, N.
AU  - Cain, G.
AU  - Erby, L. H.
AU  - Ricks-Santi, L. J.
AU  - Tetteyfio-Kidd Telemaque, E.
AU  - Scott, D. M.
DB  - Embase
DO  - 10.1007/s12687-019-00411-0
IS  - 4
KW  - adult
African American
anatomical concepts
article
biospecimen
breast cancer
cancer genetics
cancer survivor
chi square test
cohort analysis
colon cancer
controlled study
demography
disease association
family history
female
health behavior
health disparity
health survey
human
knowledge
logistic regression analysis
major clinical study
male
patient participation
population research
priority journal
prostate cancer
risk factor
Student t test
LA  - English
M3  - Article
N1  - L626832159
2019-03-26
2019-11-01
PY  - 2019
SN  - 1868-6001
1868-310X
SP  - 471-480
ST  - Factors associated with willingness to provide biospecimens for genetics research among African American cancer survivors
T2  - Journal of Community Genetics
TI  - Factors associated with willingness to provide biospecimens for genetics research among African American cancer survivors
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L626832159&from=export
http://dx.doi.org/10.1007/s12687-019-00411-0
VL  - 10
ID  - 839
ER  - 

TY  - JOUR
AB  - Background: Ethnic and socio-economic inequalities have been reported in the uptake of colorectal cancer (CRC) screening. This study aimed to explore the factors affecting CRC screening participation in an ethnically and socio-economically diverse inner city population. Methods: Semi-structured interviews were undertaken with 50 people aged 55–74 years, recruited from GP practices in south-east London. Participants were from Black African (n = 13), Black Caribbean (n = 15), White British (n = 17), Black other (n = 2) and White other (n = 3) backgrounds. Participants’ socio-economic status (SES) was assessed using a combined measure of educational attainment, housing tenure and car ownership. Participants’ SES varied although there were more participants from less deprived backgrounds than those from more deprived backgrounds. The interview topic guide was informed by the Theoretical Domains Framework. Interviews were recorded, transcribed and analysed using framework analysis. Findings: Lack of awareness of CRC screening was a barrier for all participants. There were also some notable group differences by ethnicity and SES. Cancer fear was a barrier for White British participants of varying SES. Misunderstanding instructions for completing the guaiac faecal occult blood test (gFOBt) was a barrier for people of low SES regardless of ethnicity. For Black African and Black Caribbean participants, of any SES, religious faith and a perceived civic duty to participate in screening encouraged participation. Discussion and conclusions: This is the first study to provide detailed information on the separate views of Black African and Black Caribbean participants about screening. Consideration of ethnicity and SES together also allowed us to identify pertinent barriers for particular groups that can be targeted to improve access to screening for those who wish to take part. (PsycINFO Database Record (c) 2018 APA, all rights reserved)
AD  - Dharni, Nimarta, Bradford Institute for Health Research, Bradford Teaching Hospitals NHS Trust, Bradford Royal Infirmary, Bradford, United Kingdom
AN  - 2016-41109-001
AU  - Dharni, Nimarta
AU  - Armstrong, David
AU  - Chung‐Faye, Guy
AU  - Wright, Alison J.
DB  - psyh
DO  - 10.1111/hex.12489
DP  - EBSCOhost
IS  - 4
KW  - bowel cancer screening
colorectal cancer screening
ethnicity
FOBt
psychological beliefs
socio‐economic status
Adult Attitudes
Cancer Screening
Ethnic Identity
Socioeconomic Status
Urban Environments
N1  - Bradford Institute for Health Research, Bradford Teaching Hospitals NHS Foundation Trust, Bradford, United Kingdom. Other Publishers: Blackwell Publishing. Release Date: 20160825. Correction Date: 20180208. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: English. Grant Information: Dharni, Nimarta. Major Descriptor: Adult Attitudes; Cancer Screening; Ethnic Identity; Socioeconomic Status. Minor Descriptor: Urban Environments. Classification: Cancer (3293). Population: Human (10); Male (30); Female (40). Location: United Kingdom. Age Group: Adulthood (18 yrs & older) (300); Middle Age (40-64 yrs) (360); Aged (65 yrs & older) (380). Methodology: Empirical Study; Interview; Qualitative Study. Page Count: 10. Issue Publication Date: Aug, 2017. Publication History: Accepted Date: Jul 14, 2016. Copyright Statement: Published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. The Authors—Health Expectations. 2016.
Sponsor: Kings College London, Department of Primary Care & Public Health Sciences, United Kingdom. Other Details: Doctoral studentship. Recipients: Dharni, Nimarta
Sponsor: King’s College Hospital Charity. Recipients: No recipient indicated
PY  - 2017
SN  - 1369-6513
1369-7625
SP  - 608-617
ST  - Factors influencing participation in colorectal cancer screening—A qualitative study in an ethnic and socio‐economically diverse inner city population
T2  - Health Expectations: An International Journal of Public Participation in Health Care & Health Policy
TI  - Factors influencing participation in colorectal cancer screening—A qualitative study in an ethnic and socio‐economically diverse inner city population
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2016-41109-001&site=ehost-live&scope=site
nimarta.dharni@bthft.nhs.uk
VL  - 20
ID  - 1715
ER  - 

TY  - JOUR
AB  - Purpose: We evaluated the survival time of patients with stage D cancer of the prostate (CaP) in Yaounde, Cameroon, so as to lay the groundwork for evaluating patient management and outcomes in such communities in sub-Saharan Africa. Patients and Materials: A cohort of 200 patients was recruited at diagnosis and followed over a 171 month period. They had a standard work-up and staging protocol except for the absence of bone scan. Treatment was offered after they were staged following the Whitemore ABCD-system. Standard statistical analysis was performed for quantitative variables and graphs developed for continuous variables. Pearson correlation and Chi-square tests were used to evaluate associations between variables. The Kaplan-Meier product-limit method was used to estimate survival functions and log-rank test to compare data from complete survival curves. The statistical significance level was fixed at p values less than or equal to 0.05. Results: The mean age of our patients was 67 years and 41.5% of them were in the 60-69 year-bracket. Survival was worse for those 66 years and older (p = 0.013). Patient survival correlated with tumor differentiation such that a Gleason score of 6 or greater meant diminished survival time (p = 0.014). For the entire group, median overall survival was 40.5 months, 44% at 5 years and 17% at 10 years. Patients who received multi-modal therapy (complete androgen ablation by surgical and medical means, and radiation to the pelvis and metastatic sites) seemed to have the best survival (p < 0.001) although patient stratification into treatment groups was not randomized. A comparison of survival of African-American cohorts and this group showed no statistical significance (p = 0.1). Conclusion: Survival of patients with prostate cancer in Yaounde is just as low as in African-Americans. Survival is worse however, for men older than 66 years in Yaounde. A call for comparative and collaborative clinical trials is made.
AD  - F.F. Angwafo III, Department of Surgery, Section of Urology, University of Yaounde I, Yaounde, Cameroon
AU  - Angwafo Iii, F. F.
AU  - Atanga, P. N.
AU  - Minkoulou, E.
AU  - Fouda, P. J.
AU  - Kim, K. S.
AU  - Adams-Campbell, L.
AU  - Zoung-Kanyi, J.
DB  - Embase
DO  - 10.1080/1561095031000101269
IS  - 1
KW  - androgen
adult
age
aged
article
bone scintiscanning
Cameroon
cancer staging
cancer survival
cohort analysis
controlled study
correlation analysis
disease association
human
major clinical study
male
Black person
priority journal
prostate cancer
prostatectomy
race difference
survival time
LA  - English
M3  - Article
N1  - L36830391
2003-07-23
PY  - 2003
SN  - 1561-0950
SP  - 7-11
ST  - Factors influencing patient survival in a group of men with prostate cancer in Yaoundé, Cameroon
T2  - UroOncology
TI  - Factors influencing patient survival in a group of men with prostate cancer in Yaoundé, Cameroon
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L36830391&from=export
http://dx.doi.org/10.1080/1561095031000101269
VL  - 3
ID  - 1295
ER  - 

TY  - JOUR
AB  - Objectives: to examine predictors of use of complementary therapies reported by women who had also received standard medical treatment for early-stage breast cancer. Methods: A volunteer sample of 231 black, Hispanic, and non-Hispanic white patients with early-stage breast cancer (diagnosed within the preceding year) reported their use of complementary therapies. We examined predictors of the use of each therapy from among a set of demographic and quality of life measures. Results: Most women reported using 1 complementary therapy or more, most commonly psychotherapy, support groups, meditation, and spiritual healing. Use of psychotherapy related to age, education, and elevated distress. Use of other complementary therapies was not related to distress. More black than Hispanic or nonHispanic white patients used herbal therapies and spiritual healing. Use of complementary therapies did not relate to expectation of recurrence, dissatisfaction with medical care, or (among relevant patients) concerns about the consequences of chemotherapy. Conclusions: Use of healing therapies that do not replace medical treatment should be viewed as attempts to increase potential benefit and not as signs of distress or dissatisfaction. Use of complementary therapies also varies across racial and ethnic groups.
AN  - 107052093. Language: English. Entry Date: 20010914. Revision Date: 20150711. Publication Type: Journal Article
AU  - Alferi, S. M.
AU  - Antoni, M. H.
AU  - Ironson, G.
AU  - Kilbourn, K. M.
AU  - Carver, C. S.
DA  - 2001 Summer
DB  - CINAHL Complete
DP  - EBSCOhost
IS  - 3
KW  - Breast Neoplasms -- Therapy
Combined Modality Therapy
Alternative Therapies
Attitude to Illness
Black Persons
Hispanic Americans
White Persons
Demography
Adult
Middle Age
Aged
Chi Square Test
T-Tests
Logistic Regression
Center for Epidemiological Studies Depression Scale
Psychological Tests
Psychosocial Adjustment to Illness Scale
Research Subject Recruitment
Attitude Measures
Scales
Descriptive Statistics
Religion and Religions
Time Factors
Funding Source
Human
N1  - research; tables/charts. Journal Subset: Biomedical; Peer Reviewed; USA. Instrumentation: Profile of Mood States (POMS); Psychosocial Adjustment to Illness Scale (PAIS); Center for Epidemiologic Studies Depression Scale (CES-D); Profile of Concerns about Breast Cancer (PCBC). Grant Information: Supported by National Cancer Institute grant CA-64710 and Department of Defense training grant J4236-DAMD1794. NLM UID: 7503064.
PMID: NLM11506149.
PY  - 2001
SN  - 0098-8421
SP  - 120-126
ST  - Factors predicting the use of complementary therapies in a multi-ethnic sample of early-stage breast cancer patients
T2  - Journal of the American Medical Women's Association
TI  - Factors predicting the use of complementary therapies in a multi-ethnic sample of early-stage breast cancer patients
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=107052093&site=ehost-live&scope=site
VL  - 56
ID  - 1955
ER  - 

TY  - JOUR
AB  - BACKGROUND: Understanding how low-income, uninsured African American/black men use faith to cope with prostate cancer provides a foundation for the design of culturally appropriate interventions to assist underserved men cope with the disease and its treatment. Previous studies have shown spirituality to be a factor related to health and quality of life, but the process by which faith, as a promoter of action, supports coping merits exploration. OBJECTIVE: Our purpose was to describe the use of faith by low-income, uninsured African American/black men in coping with prostate cancer and its treatment and adverse effects. METHODS: We analyzed data from a qualitative study that used in-depth individual interviews involving 18 African American men ranging in ages from 53 to 81 years. Our analysis used grounded theory techniques. RESULTS: Faith was used by African American men to overcome fear and shock engendered by their initial perceptions of cancer. Faith was placed in God, health care providers, self, and family. Men came to see their prostate cancer experience a new beginning that was achieved through purposeful acceptance or resignation. CONCLUSIONS: Faith was a motivator of and source for action. Faith empowered men to be active participants in their treatment and incorporate treatment outcomes into their lives meaningfully. IMPLICATION: By understanding faith as a source of empowerment for active participation in care, oncology nurses can use men's faith to facilitate reframing of cancer perceptions and to acknowledge the role of men's higher being as part of the team. Studies are needed to determine if this model is relevant across various beliefs and cultures.
AD  - UCLA School of Nursing, David Geffen School of Medicine at UCLA, University of California-Los Angeles, CA 90095, USA. smaliski@sonnet.ucla.edu
AN  - 104945356. Language: English. Entry Date: 20110121. Revision Date: 20150820. Publication Type: Journal Article
AU  - Maliski, Sally L.
AU  - Connor, Sarah E.
AU  - Williams, Lindsay
AU  - Litwin, Mark S.
DB  - CINAHL Complete
DO  - 10.1097/NCC.0b013e3181e1f7ff
DP  - EBSCOhost
IS  - 6
KW  - Black Persons -- Psychosocial Factors -- California
Cancer Patients -- Psychosocial Factors
Coping
Poverty
Spirituality
Aged
Aged, 80 and Over
Attitude to Illness -- Evaluation
Audiorecording
California
Culture
Descriptive Research
Empowerment
Funding Source
Grounded Theory
Human
Male
Medically Uninsured
Middle Age
Patient Attitudes -- Evaluation
Research Subject Recruitment
Semi-Structured Interview
Socioeconomic Factors
Thematic Analysis
N1  - research; tables/charts. Commentary: Ward-Smith Peggy. Faith among Low-Income, African-American/Black Men Treated for Prostate Cancer. (UROL NURS) Jul/Aug2011; 31 (4): 244-244. Journal Subset: Core Nursing; Double Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Nursing; Peer Reviewed; USA. Grant Information: Department of Defense (PC030104 and IMSD GM55052). NLM UID: 7805358.
PMID: NLM20555257.
PY  - 2010
SN  - 0162-220X
SP  - 470-478
ST  - Faith among low-income, African American/Black men treated for prostate cancer
T2  - Cancer Nursing
TI  - Faith among low-income, African American/Black men treated for prostate cancer
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104945356&site=ehost-live&scope=site
VL  - 33
ID  - 1956
ER  - 

TY  - JOUR
AB  - BACKGROUND: Evidence suggests that the risk of breast and prostate cancer is increased among those with a family history of the same disease and particularly among first-degree relatives. However, less is known about the relationship between breast and prostate cancer within families and particularly among minority populations. METHODS: Analyses of participants in the Women's Health Initiative observational cohort who were free of breast cancer at the time of their baseline examination were conducted. Subjects were followed for breast cancer through August 31, 2009. A Cox proportional hazards regression modeling approach was used to estimate the risk of breast cancer associated with a family history of prostate cancer, breast cancer, and both among first-degree relatives. RESULTS: There were 78,171 eligible participants, and 3506 breast cancer cases were diagnosed during the study period. A family history of prostate cancer was associated with a modest increase in breast cancer risk after adjustments for confounders (adjusted hazard ratio [aHR], 1.14; 95% confidence interval [CI], 1.02-1.26). In a separate analysis examining the joint impact of both cancers, a family history of both breast and prostate cancer was associated with a 78% increase in breast cancer risk (aHR, 1.78; 95% CI, 1.45-2.19). Risk estimates associated with a family history of both breast and prostate cancer were higher among African American women (aHR, 2.34; 95% CI, 1.09-5.02) versus white women (aHR, 1.66; 95% CI, 1.33-2.08). CONCLUSIONS: These findings suggest that prostate cancer diagnosed among first-degree family members increases a woman's risk of developing breast cancer. Future studies are needed to determine the relative contributions of genes and a shared environment to the risk for both cancers.
AD  - Karmanos Cancer Institute, Detroit, Michigan; Department of Oncology, Wayne State University School of Medicine, Detroit, Michigan.
AN  - 25754547
AU  - Beebe-Dimmer, J. L.
AU  - Yee, C.
AU  - Cote, M. L.
AU  - Petrucelli, N.
AU  - Palmer, N.
AU  - Bock, C.
AU  - Lane, D.
AU  - Agalliu, I.
AU  - Stefanick, M. L.
AU  - Simon, M. S.
C2  - PMC4457314
C6  - NIHMS675278
DA  - Apr 15
DO  - 10.1002/cncr.29075
DP  - NLM
ET  - 2015/03/11
IS  - 8
KW  - African Americans/statistics & numerical data
Aged
Aged, 80 and over
Breast Neoplasms/*epidemiology/ethnology/genetics
Clinical Trials as Topic
Cluster Analysis
Family
Female
Humans
Male
Middle Aged
*Postmenopause
Proportional Hazards Models
Prostatic Neoplasms/*epidemiology
Risk Factors
African American
aggregation
epidemiology
family history
genetics
LA  - eng
N1  - 1097-0142
Beebe-Dimmer, Jennifer L
Yee, Cecilia
Cote, Michele L
Petrucelli, Nancie
Palmer, Nynikka
Bock, Cathryn
Lane, Dorothy
Agalliu, Ilir
Stefanick, Marcia L
Simon, Michael S
HHSN268201100001I/HL/NHLBI NIH HHS/United States
HHSN271201100004C/PHS HHS/United States
HHSN268201100004I/HL/NHLBI NIH HHS/United States
HHSN268201100046C/HL/NHLBI NIH HHS/United States
HHSN268201100003C/WH/WHI NIH HHS/United States
HHSN268201100003C/PHS HHS/United States
R25 CA122061/CA/NCI NIH HHS/United States
HHSN268201100004C/PHS HHS/United States
HHSN271201100004C/AG/NIA NIH HHS/United States
HHSN268201100002C/WH/WHI NIH HHS/United States
P30 CA022453/CA/NCI NIH HHS/United States
HHSN68201100001C/PHS HHS/United States
HHSN268201100046C/PHS HHS/United States
HHSN268201100002I/HL/NHLBI NIH HHS/United States
R01 CA140314/CA/NCI NIH HHS/United States
HHSN268201100002C/PHS HHS/United States
HHSN268201100001C/WH/WHI NIH HHS/United States
HHSN268201100004C/WH/WHI NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Cancer. 2015 Apr 15;121(8):1265-72. doi: 10.1002/cncr.29075. Epub 2015 Mar 9.
PY  - 2015
SN  - 0008-543X (Print)
0008-543x
SP  - 1265-72
ST  - Familial clustering of breast and prostate cancer and risk of postmenopausal breast cancer in the Women's Health Initiative Study
T2  - Cancer
TI  - Familial clustering of breast and prostate cancer and risk of postmenopausal breast cancer in the Women's Health Initiative Study
VL  - 121
ID  - 251
ER  - 

TY  - JOUR
AB  - Previous researchers have found high mortality and incidence rates for pancreatic cancer in the Acadiana region of southern Louisiana. While lifestyle practices such as pork and alcohol consumption and a familial trend have been linked to pancreatic cancer, cigarette smoking is the only established risk factor for pancreatic cancer. Therefore, a retrospective, descriptive study was conducted to explore lifestyle risk factors and the familial trend in pancreatic cancer. The Familial Pancreatic Cancer Questionnaire (FPCQ) was used to collect data on demographics, tobacco and alcohol use, dietary history, and medical history. A surrogate respondent (family member) for 3I pancreatic cancer subjects completed the FPCQ. Race and gender specific incidence rates (IR) for pancreatic cancer in Acadiana were calculated. Results showed that mean IRs for pancreatic cancer for Caucasian and African-American males and females were higher than national SEER rates. Pancreatic cancer and lung cancer were the most frequently reported cancers among subjects' first degree relatives. The majority (65%) of the subjects smoked. A positive family history for pancreatic cancer was found in this study with five (16%) of the pancreatic cancer subjects having one or more first degree relatives with pancreatic cancer. This percent is twice that found by previous researchers.
AD  - USL College of Nursing, PO Box 43810, Lafayette, LA 70504-3810
AN  - 107383600. Language: English. Entry Date: 19961001. Revision Date: 20150820. Publication Type: Journal Article
AU  - Price, T. F.
AU  - Payne, R. L.
AU  - Oberleitner, M. G.
DB  - CINAHL Complete
DP  - EBSCOhost
IS  - 4
KW  - Pancreatic Neoplasms -- Epidemiology
Ethnic Groups -- Louisiana
Family Health
Louisiana
Retrospective Design
Descriptive Research
Race Factors
Sex Factors
Descriptive Statistics
Risk Factors
Questionnaires
Content Validity
Research Subject Recruitment
Data Analysis Software
Research Instruments
Demography
Health Behavior
Male
Female
Human
N1  - research; tables/charts. Journal Subset: Core Nursing; Double Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Nursing; Peer Reviewed; USA. Instrumentation: Familial Pancreatic Cancer Questionnaire (FPCQ). NLM UID: 7805358.
PMID: NLM8768685.
PY  - 1996
SN  - 0162-220X
SP  - 275-282
ST  - Familial pancreatic cancer in South Louisiana
T2  - Cancer Nursing
TI  - Familial pancreatic cancer in South Louisiana
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=107383600&site=ehost-live&scope=site
VL  - 19
ID  - 1957
ER  - 

TY  - JOUR
AB  - Background: Many African American men have two major risk factors for prostate cancer. By ethnicity alone, they have twice the risk of Euro-American men of developing prostate cancer. Having a family history (brother or father with prostate cancer) also doubles their risk. The major hypotheses tested in this study are that men with a family history perceive their risk to be higher, are more worried about getting prostate cancer, and are more likely to have used cancer screening tests than men without such a history. Methods: A sample of 208 African American men, ages 40 to 74 years, were recruited through relatives or friends whose prostate cancer diagnosis was reported to the California Cancer Registry during the years 1997 to 2001 and from churches and African American social groups. Following a screening interview to determine eligibility, 88 men with self-reported, first-degree family history of prostate cancer and 120 without such history were interviewed by telephone. Logistic regression was used to create models of perceived risk, prostate cancer worries, receipt of a digital rectal exam, and/or prostate-specific antigen (PSA) testing. Results: Men with a self-reported family history of prostate cancer did not perceive their risk as higher than men without a family history, nor did they report more cancer worries. They were more likely to report having a recent PSA test, but not a digital rectal exam. Having a higher than average perceived risk was associated with younger age, a college education, and lower mental well-being, and reporting more prostate cancer worries and being more likely to have had a recent PSA test. Conclusions: Although there continues to be controversy about PSA testing, these data suggest that African American men at above-average risk are inclined to be screened. Copyright © 2006 American Association for Cancer Research.
AD  - J.R. Bloom, School of Public Health, University of California, 409 Warren Hall, Berkeley, CA 94720-7360, United States
AU  - Bloom, J. R.
AU  - Stewart, S. L.
AU  - Oakley-Girvans, I.
AU  - Banks, P. J.
AU  - Chang, S.
DB  - Embase
Medline
DO  - 10.1158/1055-9965.EPI-05-0738
IS  - 11
KW  - prostate specific antigen
adult
African American
aged
article
cancer diagnosis
cancer registry
cancer risk
cancer screening
controlled study
demography
digital rectal examination
family history
human
interview
major clinical study
male
priority journal
prostate cancer
self report
socioeconomics
telephone
United States
LA  - English
M3  - Article
N1  - L44877042
2007-01-11
PY  - 2006
SN  - 1055-9965
SP  - 2167-2173
ST  - Family history, perceived risk, and prostate cancer screening among African American men
T2  - Cancer Epidemiology Biomarkers and Prevention
TI  - Family history, perceived risk, and prostate cancer screening among African American men
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L44877042&from=export
http://dx.doi.org/10.1158/1055-9965.EPI-05-0738
VL  - 15
ID  - 1237
ER  - 

TY  - JOUR
AB  - Family health history about cancer is an important prevention and health promotion tool. Yet few studies have identified family context factors that promote such discussions. We explored relations among family context (cohesion, flexibility, and openness), self-efficacy, and cancer communication (gathering family history, sharing cancer risk information, and frequency) in a diverse group of women enrolled in a randomized control trial. Baseline survey data for 472 women were analyzed. The women's average age was 34 years, 59% identified as Black, 31% had graduated high school, and 75% reported a family history of any cancer. Results showed that greater family cohesion and flexibility were related to higher communication frequency and sharing cancer information. Women who reported greater self-efficacy were more likely to have gathered family history, shared cancer risk information, and communicated more frequently with relatives. Openness was not associated with communication but was related to greater family cohesion and flexibility. Adjusting for demographic variables, self-efficacy, and family cohesion significantly predicted communication frequency. Women with higher self-efficacy were also more likely to have gathered family health history about cancer and shared cancer risk information. Future research may benefit from considering family organization and self-efficacy when developing psychosocial theories that in turn inform cancer prevention interventions.
AN  - WOS:000371811900009
AU  - Rodriguez, V. M.
AU  - Corona, R.
AU  - Bodurtha, J. N.
AU  - Quillin, J. M.
DA  - Mar
DO  - 10.1080/10810730.2015.1080328
IS  - 3
N1  - 26735646
PY  - 2016
SN  - 1081-0730
SP  - 346-355
ST  - Family Ties: The Role of Family Context in Family Health History Communication About Cancer
T2  - Journal of Health Communication
TI  - Family Ties: The Role of Family Context in Family Health History Communication About Cancer
VL  - 21
ID  - 2951
ER  - 

TY  - JOUR
AB  - Rates of colon cancer are much higher in African Americans (65:100,000) than in rural South Africans (<5:100,000). The higher rates are associated with higher animal protein and fat, and lower fibre consumption, higher colonic secondary bile acids, lower colonic short-chain fatty acid quantities and higher mucosal proliferative biomarkers of cancer risk in otherwise healthy middle-aged volunteers. Here we investigate further the role of fat and fibre in this association. We performed 2-week food exchanges in subjects from the same populations, where African Americans were fed a high-fibre, low-fat African-style diet and rural Africans a high-fat, low-fibre western-style diet, under close supervision. In comparison with their usual diets, the food changes resulted in remarkable reciprocal changes in mucosal biomarkers of cancer risk and in aspects of the microbiota and metabolome known to affect cancer risk, best illustrated by increased saccharolytic fermentation and butyrogenesis, and suppressed secondary bile acid synthesis in the African Americans.
AD  - Division of Gastroenterology, Hepatology and Nutrition, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania 15213, USA.
Department of Surgery and Cancer and Centre for Digestive and Gut Health, Institution of Global Health Innovation, Imperial College, London SW7 2AZ, UK.
1] Laboratory of Microbiology, Wageningen University, Wageningen 6703 HB, The Netherlands [2] Department of Veterinary Bioscience, University of Helsinki, Helsinki, Finland.
University of Illinois at Urbana-Champaign, Champaign, Illinois 61801, USA.
Division of Sports Medicine and Nutrition, School of Health and Rehabilitation Sciences, University of Pittsburgh, Pittsburgh, Pennsylvania 15213, USA.
University of KwaZulu-Natal, Durban, South Africa.
Laboratory of Microbiology, Wageningen University, Wageningen 6703 HB, The Netherlands.
Division of Endocrinology, University of Pittsburgh, Pittsburgh, Pennsylvania 15213, USA.
Division of Pathology, University of Pittsburgh, Pittsburgh, Pennsylvania 15213, USA.
1] Laboratory of Microbiology, Wageningen University, Wageningen 6703 HB, The Netherlands [2] Department of Veterinary Bioscience, University of Helsinki, Helsinki, Finland [3] RPU Immunolbiology, Department of Bacteriology and Immunology, University of Helsinki, Helsinki 00014, Finland.
AN  - 25919227
AU  - O'Keefe, S. J.
AU  - Li, J. V.
AU  - Lahti, L.
AU  - Ou, J.
AU  - Carbonero, F.
AU  - Mohammed, K.
AU  - Posma, J. M.
AU  - Kinross, J.
AU  - Wahl, E.
AU  - Ruder, E.
AU  - Vipperla, K.
AU  - Naidoo, V.
AU  - Mtshali, L.
AU  - Tims, S.
AU  - Puylaert, P. G.
AU  - DeLany, J.
AU  - Krasinskas, A.
AU  - Benefiel, A. C.
AU  - Kaseb, H. O.
AU  - Newton, K.
AU  - Nicholson, J. K.
AU  - de Vos, W. M.
AU  - Gaskins, H. R.
AU  - Zoetendal, E. G.
C2  - PMC4415091
C6  - NIHMS657331
DA  - Apr 28
DO  - 10.1038/ncomms7342
DP  - NLM
ET  - 2015/04/29
KW  - African Americans/statistics & numerical data
Aged
Biomarkers/metabolism
Colon/metabolism/*microbiology
Colonic Neoplasms/*etiology
Diet, Fat-Restricted
Diet, High-Fat/*adverse effects/statistics & numerical data
Dietary Fiber/*statistics & numerical data
Feces/chemistry
Healthy Volunteers
Humans
Inflammation/etiology/metabolism
*Intestinal Mucosa
Metabolome
Microbiota
Middle Aged
Rural Population/statistics & numerical data
South Africa
Urine/chemistry
LA  - eng
N1  - 2041-1723
O'Keefe, Stephen J D
Li, Jia V
Lahti, Leo
Orcid: 000000015537637x
Ou, Junhai
Carbonero, Franck
Mohammed, Khaled
Posma, Joram M
Kinross, James
Wahl, Elaine
Ruder, Elizabeth
Vipperla, Kishore
Naidoo, Vasudevan
Mtshali, Lungile
Tims, Sebastian
Puylaert, Philippe G B
DeLany, James
Krasinskas, Alyssa
Benefiel, Ann C
Kaseb, Hatem O
Newton, Keith
Nicholson, Jeremy K
de Vos, Willem M
Orcid: 0000000202733166
Gaskins, H Rex
Zoetendal, Erwin G
UL1 TR000005/TR/NCATS NIH HHS/United States
UL1 RR024153/RR/NCRR NIH HHS/United States
UL1TR000005/TR/NCATS NIH HHS/United States
250172/ERC_/European Research Council/International
R01 CA135379/CA/NCI NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Nat Commun. 2015 Apr 28;6:6342. doi: 10.1038/ncomms7342.
PY  - 2015
SN  - 2041-1723
SP  - 6342
ST  - Fat, fibre and cancer risk in African Americans and rural Africans
T2  - Nat Commun
TI  - Fat, fibre and cancer risk in African Americans and rural Africans
VL  - 6
ID  - 248
ER  - 

TY  - JOUR
AB  - The goal of increasing participation in fecal occult blood testing (FOBT) for elderly African Americans is a national priority. Fatalism is believed to be a barrier to screening among this population. Fatalism is the belief that death is inevitable when cancer is present. The Powe Fatalism Model guided this descriptive, correlational study that reports on the relationship between race and fatalism, as well as the relationship between fatalism and participation in FOBT. Participants (N = 192) were recruited from randomly selected congregate meal sites. The majority of participants were African American, female, had minimal education, and minimal incomes. Elderly African Americans were significantly more fatalistic than elderly white participants and less likely to participate in FOBT. Not only was fatalism a significant predictor of FOBT, but it remained the only significant predictor of FOBT, but it remained the only significant predictor even when factors such as age, poverty, and education were controlled. Nursing science must accept the challenges of promptly identifying fatalistic individuals and the development of interventions to counteract its influence.
AD  - College of Nursing, Medical University of South Carolina, Charleston, USA.
AN  - 7585493
AU  - Powe, B. D.
DA  - Oct
DP  - NLM
ET  - 1995/10/01
IS  - 5
KW  - African Americans/*psychology/statistics & numerical data
Aged
*Attitude to Death
Colorectal Neoplasms/prevention & control/*psychology
Female
Humans
Logistic Models
Male
Mass Screening/psychology/statistics & numerical data
Middle Aged
Occult Blood
Patient Compliance/psychology
Socioeconomic Factors
South Carolina
LA  - eng
N1  - Powe, B D
NR-02259-03/NR/NINR NIH HHS/United States
Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, U.S. Gov't, P.H.S.
United States
Cancer Nurs. 1995 Oct;18(5):385-92.
PY  - 1995
SN  - 0162-220X (Print)
0162-220x
SP  - 385-92
ST  - Fatalism among elderly African Americans. Effects on colorectal cancer screening
T2  - Cancer Nurs
TI  - Fatalism among elderly African Americans. Effects on colorectal cancer screening
VL  - 18
ID  - 743
ER  - 

TY  - THES
AB  - Introduction: Fear of recurrence (FOR) has been studied in various populations of patients with cancer e.g. colon, prostate, and breast. Breast cancer survivors are often faced with the lingering fear that the cancer may reoccur. It is estimated over 232,000 women diagnosed with breast cancer in 2014 FOR has the possibility to impact the lives of thousands of women. Yet, little is known about FOR in women diagnosed with breast cancer at a young age and are young breast cancer survivors (YBCS). These cancer survivors need additional support, as the probability they will develop another cancer is high.Purpose: The purposes of this study were to 1) describe FOR in a large, statewide sample of YBCS 2) to explore predictors of FOR and 3) to determine if FOR is a mediator for breast cancer surveillance, namely mammograms and clinical breast exams (CBE).Methods: This secondary data analysis examines baseline data collected for an efficacy trial, aiming to increase breast cancer surveillance and use of cancer genetic services among YBCS and their high risk family members. Fear of recurrence was examined in 863 YBCS identified and recruited through the Michigan cancer registry. Participants completed a survey including instruments that measured FOR, quality of life (mental and physical), self-efficacy in managing breast cancer, perceived breast cancer risk, knowledge of breast cancer risk factors, family support, and current breast cancer surveillance practices.Findings: Results of this study suggest predictors of FOR in young breast cancer survivors include African American race, lower level of education, belief that cancer development is by chance, and increased level of anxiety. The strongest predictor of FOR was low level of self-efficacy in managing breast cancer. Being negative for the BRCA1 genetic marker was found not to be associated with FOR in this population. FOR did not mediate surveillance mammograms or clinical breast exams.Conclusion: Knowing what predicts young breast cancer survivors to experience FOR is important in lessening FOR. Employing screening measures to determine patients at risk for experiencing FOR may lessen this problem.
AU  - Pattison, Kelley Hempsall
DB  - CINAHL Complete
DP  - EBSCOhost
KW  - Breast Neoplasms -- Psychosocial Factors
Cancer Survivors -- Psychosocial Factors
Health Behavior
Neoplasm Recurrence, Local -- Psychosocial Factors
Breast Examination
Clinical Trials
Fear
Human
Mammography
Michigan
Quality of Life
Secondary Analysis
Self-Efficacy
M1  - Ph.D.
N1  - Accession Number: 109774695. Language: English. Entry Date: 20150206. Revision Date: 20150923. Publication Type: Doctoral Dissertation; clinical trial; research. Special Interest: Oncologic Care.
UMI Order AAI3636586
PB  - University of Michigan
PY  - 2014
SN  - 9781321182392
SP  - 69 p-69 p
ST  - Fear of Cancer Recurrence in Young Breast Cancer Survivors: Impact on Surveillance Behaviors
TI  - Fear of Cancer Recurrence in Young Breast Cancer Survivors: Impact on Surveillance Behaviors
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=109774695&site=ehost-live&scope=site
ID  - 1958
ER  - 

TY  - JOUR
AB  - Content: Introduction: The American College of Surgeons mandates that all accredited cancer programs fully implement psychosocial distress screening and survivorship programs for all patients by 2015 and 2019, respectively. The VA health‐care system provides cancer care for over 524,000 veterans annually with approximately 41% receiving care for prostate cancer (PC). However, the VA‐ well‐known for its technological advances and innovative evidence‐based health education and promotion programs‐offers fewer resources for low‐literacy veterans who have been diagnosed and treated for cancer. Aim: To describe predictors of psychological distress within baseline data collected from a cohort of participants in a randomized controlled trial of a symptom management intervention for low‐health literacy veterans. Methods: The PC‐PEP (Prostate Cancer‐Patient Education Program) was developed specifically for lower‐literacy men recently treated for PC. Modules focus specifically on PC‐specific topics such as sexual and urinary functioning, as well as more general health education materials on patient‐provider communication, physical exercise, and stress reduction. A cohort of Englishspeaking US veterans diagnosed with PC <4 years was screened and enrolled in the study via telephone (n D 90). Data were analyzed using bivariate analyses and stepwise multivariate models. Main Outcome Measure: We measured distress using a validated measure of fear of cancer recurrence (FoR). Results: Ninety veterans (61 White, 29 African American) completed baseline questionnaires. Most participants had spouses/significant relationships (66%), completed college/graduate coursework or degrees (70%), were retired (46%), and reported being treated for PC via surgery vs radiotherapy (58%). Bivariate analyses: Scores from the EPIC urinary (UB) and sexual bother (SB); EPIC urinary (UF) and sexual function (SF); Chew et al. 3‐item health literacy measure (HL); and a self‐efficacy (SE) measure for prostate self‐management were compared using Pearson's correlation coefficients. FoR was significantly and negatively correlated with UB and UF, and SE (all p < 0.01). Thus, participants reporting worse UB, UF, or SE had greater FoR. When participants who were treated with surgery or radiotherapy were compared directly, those completing surgery had significantly lower SB, SF, UF, and SE scores indicating worse functioning, more bother, less self‐efficacy), on average, than those completing radiotherapy (all p<0.05); however, their FoR was also significantly lower (M D 38.4 vs M D 45.9, p<0.05). Stepwise multivariate: When symptom, clinical demographic, treatment, HL, and SE variables were considered, greater FoR was associated with lower SE for symptom management and with having radiation rather than surgery (both p < 0.001). Conclusion: Our baseline findings support those of other studies linking patient experiences of higher numbers of symptoms, symptom‐related distress, and FoR dependent on treatment type. Men typically report fewer discussions and visits with providers, which might alleviate these issues. This trend is mirrored in the VA, a hypermasculine setting, where veterans typically report worse overall health status and greater symptomology. Oncology social workers should tailor educational and counseling interventions to reduce FoR and enrich the survivorship experience of this unique population.
AN  - CN-01406309
AU  - Goltz, H.
DO  - 10.1080/07347332.2016.1147913
IS  - 1‐2
KW  - *cancer recurrence
*distress syndrome
*fear
*health literacy
*prostate cancer
*veteran
African American
Bivariate analysis
Cancer epidemiology
Cancer patient
Clinical study
College
Controlled clinical trial
Controlled study
Correlation coefficient
Counseling
Diagnosis
Doctor patient relation
Education program
Exercise
Health status
Human
Male
Mental stress
Model
Oncology
Questionnaire
Radiation
Radiotherapy
Randomized controlled trial
Self care
Sexual function
Social worker
Spouse
Surgery
Symptom
Telephone
M3  - Journal: Conference Abstract
PY  - 2016
SP  - 150‐151
ST  - Fear of recurrence among low-health literacy veterans with prostate cancer
T2  - Journal of psychosocial oncology
TI  - Fear of recurrence among low-health literacy veterans with prostate cancer
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01406309/full
VL  - 34
ID  - 1540
ER  - 

TY  - JOUR
AB  - African Americans' greater access to mobile phones makes short messaging service technology a promising complement to health promotion interventions. Short messaging service text messages were added to the Men's Prostate Awareness Church Training project, a men's health intervention for African American men. We report on the feasibility and acceptability of the use of short messaging service text messages in the intervention. Short messaging service text messages served as (1) workshop reminders; (2) post-workshop message reinforcement; (3) spiritual/motivational messages; and (4) participant retention. At workshop 4, over 65percent of participants wished to continue receiving the messages. While there was an increase in recall over time, more than one-third of the participants did not recall receiving the 53 text messages. However, recall was considerably greater among men who attended the Men's Prostate Awareness Church Training workshops. Overall, the inclusion of text messages in health promotion interventions targeting mature African American men was found to be feasible and acceptable.
AN  - WOS:000389055600011
AU  - Le, D.
AU  - Holt, C. L.
AU  - Saunders, D. R.
AU  - Wang, M. Q.
AU  - Coriolan, A.
AU  - Savoy, A. D.
AU  - Slade, J. L.
AU  - Muwwakkil, B.
AU  - Atkinson, N. L.
DA  - Dec
DO  - 10.1177/1460458215598636
IS  - 4
N1  - 26324051
PY  - 2016
SN  - 1460-4582
SP  - 932-947
ST  - Feasibility and acceptability of SMS text messaging in a prostate cancer educational intervention for African American men
T2  - Health Informatics Journal
TI  - Feasibility and acceptability of SMS text messaging in a prostate cancer educational intervention for African American men
VL  - 22
ID  - 2927
ER  - 

TY  - JOUR
AB  - Background: Clinicians can miss up to half of patients’ symptomatic toxicities in cancer clinical trials and routine practice. Although patient-reported outcome questionnaires have been developed to capture this information, it is unclear whether clinicians will make use of patient-reported outcomes to inform their own toxicity documentation, or to prompt symptom management activities. Methods: 44 lung cancer patients that participated in a phase 2 treatment trial self-reported 13 symptomatic toxicities derived from the National Cancer Institute’s Common Terminology Criteria for Adverse Events and Karnofsky Performance Status via tablet computers in waiting areas immediately preceding scheduled visits. During visits, clinicians viewed patients’ self-reported toxicity and performance status ratings on a computer interface and could agree or disagree/reassign grades (“shared” reporting). Agreement of clinicians with patient-reported grades was tabulated, and compared using weighted kappa statistics. Clinical actions in response to patient-reported severe (grade 3/4) toxicities were measured (e.g. treatment discontinuation, dose reduction, supportive medications). For comparison, 45 non-trial patients with lung cancer being treated in the same clinic by the same physicians were simultaneously enrolled in a parallel cohort study in which patients also self-reported toxicity grades but reports were not shared with clinicians (“non-shared” reporting). Results: Toxicities and performance status were reported by patients and reviewed by clinicians at (780/782) 99.7% of study visits in the phase 2 trial which used “shared” reporting. Clinicians agreed with patients 93% of the time with kappas 0.82–0.92. Clinical actions were taken in response to 67% of severe patient-reported toxicities. In the “non-shared” reporting comparison group, clinicians agreed with patients 56% of the time with kappas 0.04–0.48 (significantly worse than shared reporting for all symptoms), and clinical actions were taken in response to 44% of severe patient-reported toxicities. Conclusion: Clinicians will frequently agree with patient-reported symptoms and performance status, and will use this information to guide documentation and symptom management. (ClinicalTrials.gov: NCT00807573).
AD  - Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Cancer Outcomes Research Program, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
Dana-Farber/Harvard Cancer Center, Boston, MA, USA
Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA
Department of Psychiatry & Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, NY, USA
AN  - 115184470. Language: English. Entry Date: 20160513. Revision Date: 20180530. Publication Type: Article
AU  - Basch, Ethan
AU  - Wood, William A.
AU  - Schrag, Deborah
AU  - Sima, Camelia S.
AU  - Shaw, Mary
AU  - Rogak, Lauren J.
AU  - Kris, Mark G.
AU  - Shouery, Marwan
AU  - Bennett, Antonia
AU  - Atkinson, Thomas
AU  - Pietanza, M. Catherine
DB  - CINAHL Complete
DO  - 10.1177/1740774515615540
DP  - EBSCOhost
IS  - 3
KW  - Adverse Drug Event
Cancer Patients
Randomized Controlled Trials
Access to Information
Human
Lung Neoplasms
Self Report
Treatment Outcomes
Antineoplastic Agents -- Adverse Effects
Kappa Statistic
Female
Male
Adult
Middle Age
Aged
Aged, 80 and Over
White Persons
Black Persons
Pilot Studies
Funding Source
N1  - pictorial; research; tables/charts. Journal Subset: Biomedical; Europe; UK & Ireland. Grant Information: Funding for this research was provided by the Societyof Memorial Sloan Kettering Cancer Center.. NLM UID: 101285473.
PY  - 2016
SN  - 1740-7745
SP  - 331-337
ST  - Feasibility and clinical impact of sharing patient-reported symptom toxicities and performance status with clinical investigators during a phase 2 cancer treatment trial
T2  - Clinical Trials
TI  - Feasibility and clinical impact of sharing patient-reported symptom toxicities and performance status with clinical investigators during a phase 2 cancer treatment trial
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=115184470&site=ehost-live&scope=site
VL  - 13
ID  - 1959
ER  - 

TY  - JOUR
AB  - Weight management after breast cancer (BC) treatment in African American (AA) women is crucial to reduce comorbid conditions and health disparities. We examined feasibility and potential efficacy of commercial eHealth/mHealth tools for weight management in AA BC survivors in New Jersey. Participants (N = 35) were randomized to an intervention (SparkPeople) plus activity tracker, Fitbit Charge (n = 18), or wait-list active control group (Fitbit only, n = 17). Anthropometric, behavioral, and quality of life (QOL) outcomes were collected at baseline, 3, 6, and 12 months. Differences in outcomes were assessed using intent-to-treat analysis. Retention was 97.1%. Both groups lost weight, with no significant differences between groups. At month 6, mean weight change was: intervention: -1.71 kg (SD 2.33; p = .006), 33.3% lost ≥3% of baseline weight; control: -2.54 kg (SD 4.00, p = .002), 23.5% lost ≥3% weight. Intervention participants achieved significant improvements in waist circumference (-3.56 cm, SD 4.70, p = .005), QOL (p = .030), and use of strategies for healthy eating (p = .025) and decreasing calories (p < .001). Number of days logged food per week was associated with decreases in waist circumference at 6 months (β -0.79, 95% CI, -1.49, -0.09, p = .030) and 12 months (β -2.16, 95% CI, -4.17, -0.15, p = .038). Weight loss was maintained at 12 months. This is the first study to demonstrate potential efficacy of commercial eHealth/mHealth tools for weight loss in AA BC survivors, without additional counseling from the research team. If effective, they may be convenient weight loss tools that can be easily and widely disseminated. Clinical Trials registration: ClinicalTrials.gov NCT02699983.
AD  - Department of Family Medicine and Community Health, Rutgers Robert Wood Johnson Medical School, New Brunswick, USA.
Institute for Health, Health Care Policy and Aging Research, New Brunswick, USA.
Cancer Prevention, Control and Population Research, Rutgers Cancer Institute of New Jersey, New Brunswick, USA.
Department of Biostatistics & Epidemiology, Rutgers School of Public Health, Piscataway, USA.
Department of Internal Medicine, University of Texas Health Science Center at Houston, Houston, USA.
AN  - 30535101
AU  - Ferrante, J. M.
AU  - Devine, K. A.
AU  - Bator, A.
AU  - Rodgers, A.
AU  - Ohman-Strickland, P. A.
AU  - Bandera, E. V.
AU  - Hwang, K. O.
C2  - PMC7543085
DA  - Oct 8
DO  - 10.1093/tbm/iby124
DP  - NLM
ET  - 2018/12/12
IS  - 4
KW  - *African Americans
*Breast cancer survivors
*Fitness trackers
*Health status disparities
*Internet
*Weight loss programs
LA  - eng
N1  - 1613-9860
Ferrante, Jeanne M
Devine, Katie A
Bator, Alicja
Rodgers, Ashley
Ohman-Strickland, Pamela A
Bandera, Elisa V
Hwang, Kevin O
P30 CA072720/CA/NCI NIH HHS/United States
R01 CA185623/CA/NCI NIH HHS/United States
R21 CA191431/CA/NCI NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Transl Behav Med. 2020 Oct 8;10(4):938-948. doi: 10.1093/tbm/iby124.
PY  - 2020
SN  - 1869-6716 (Print)
1613-9860
SP  - 938-948
ST  - Feasibility and potential efficacy of commercial mHealth/eHealth tools for weight loss in African American breast cancer survivors: pilot randomized controlled trial
T2  - Transl Behav Med
TI  - Feasibility and potential efficacy of commercial mHealth/eHealth tools for weight loss in African American breast cancer survivors: pilot randomized controlled trial
VL  - 10
ID  - 94
ER  - 

TY  - JOUR
AB  - Background: Prior data have indicated that minority breast cancer survivors are receptive to participating in lifestyle interventions delivered via email or the Web. In this study, we examined the feasibility and preliminary results of A Lifestyle Intervention via Email (ALIVE) in a sample of racial and ethnic minority cancer survivors. Methods: Survivors (Mean age = 52, 83% African American) were recruited and randomized to either a 3‐month physical activity or a dietary condition. Descriptive statistics and mixed‐effects models were computed to examine the behavioral and evaluation outcomes. Results: Forty‐four of 71 survivors who participated in the baseline assessment completed the study. Survivors in the physical activity condition compared to the diet condition made greater improvements in leisure time physical activity (+272 vs. +120 Metabolic equivalent minutes per week; P < 0.01) and greater reductions in sedentary time (‐304 vs. ‐59 minutes/week; P < 0.01). No signi‐cant time‐by‐group interactions were observed for our diet variables; however, positive trends among survivors in fruit and vegetables (+0.7 cup servings/day, P < 0.01) were observed in the dietary condition. Feasibility data from survivors indicated that most survivors would recommend ALIVE to other cancer survivors (97%), were satis‐ed with ALIVE (82%), and felt that ALIVE was effective (73%). Survivors expressed concerns about the automated calls and functionality of the ALIVE e‐mails. Conclusions: ALIVE appears to be feasible for racial and ethnic minority cancer survivors and shows promising results for implementation in larger and ethnically diverse cohorts. Functionality changes are warranted to boost adherence rates.
AN  - CN-01398152
AU  - Paxton, R.
AU  - Hajek, R.
AU  - Newcomb, P.
AU  - Taylor, W.
AU  - Chang, S.
AU  - Courneya, K. S.
AU  - Parra-Medina, D.
AU  - Jones, L.
IS  - 15
KW  - *breast cancer
*cancer survivor
*clinical study
*e‐mail
*feasibility study
*female
*lifestyle
*male
Adult
African American
Controlled clinical trial
Controlled study
Diet
Ethnic group
Fruit
Group dynamics
Human
Metabolic equivalent
Middle aged
Model
Physical activity
Randomized controlled trial
Statistics
M3  - Journal: Conference Abstract
PY  - 2017
ST  - Feasibility and preliminary results of A Lifestyle Intervention via Email (ALIVE) in minority breast cancer survivors
T2  - Journal of clinical oncology
TI  - Feasibility and preliminary results of A Lifestyle Intervention via Email (ALIVE) in minority breast cancer survivors
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01398152/full
VL  - 35
ID  - 1529
ER  - 

TY  - JOUR
AB  - Background/Objective: Accelerated partial‐breast irradiation (APBI) is becoming a popular choice as an alternative to whole‐breast irradiation in patients with early‐stage breast cancer. Intraoperative radiation therapy (IORT) is a form of APBI that allows for the delivery of a single fraction of radiation at the time of breast‐conserving surgery (BCS). Currently available methods of IORT have been criticized due to lack of image‐guided treatment planning and poor dosimetry resulting from the use of lowenergy photons. At another institution that has an HDR brachytherapy suite and in‐room computed tomography (CT), a novel form of breast IORT was developed. This allows for customized treatment planning and delivery of a higher prescription dose. The procedure and IORT treatment all take place in a fully integrated brachytherapy suite. We sought to test the feasibility of this method of IORT at our institution that does not have a fully integrated brachytherapy suite. Methods: A feasibility study at a second site was designed to be incorporated into an ongoing prospective Phase II trial. Eligibility criteria included patients 45 years or older with invasive or situ breast cancer with a tumor size < 3 cm and N0 disease. Patients were eligible before (pre‐pathology) or within 30 days (post‐pathology) of their BCS. BCS was performed in a same‐day procedure unit. A multilumen brachytherapy balloon was placed in the lumpectomy cavity and filled to an appropriate volume. Cavity conformance was assessed using ultrasound. Following discharge from the same‐day procedure unit, the patients walked to the radiation oncology department and underwent CT imaging, treatment planning, and HDR brachytherapy to a dose of 12.5 Gy (to 1‐cm depth from the balloon surface) was delivered. Following treatment, the balloon was deflated, and the catheter was removed. The primary endpoints were feasibility and acute toxicity. Feasibility was defined as being able to deliver protocol treatment in 12 of the first 15 patients accrued to the study. Results: Sixteen patients were consented for the study, and 1 was found to be ineligible. Fifteen patients were enrolled in the study. The median age of patients enrolled was 64 (range 49 to 72 years old). There were 7 Caucasian patients, 9 African American patients, and 2 Hispanic patients. Fourteen of the patients were treated in the pre‐pathology cohort, and 1 was treated in the post‐pathology cohort. All patients were able to receive protocol‐directed therapy (95% CI 78, 100%), and thus the study was deemed feasible. Two patients had adverse events; 1 patient developed a seroma after surgery requiring oral antibiotics and aspiration, and 1 patient developed wound breakdown requiring local wound care. Conclusions: For patients with early‐stage breast cancer, HDR brachytherapy with CT guidance is feasible and safe in a setting without an integrated brachytherapy suite. Our novel approach to breast IORT incorporates image guidance and allows for a higher radiation dose than conventional IORT and is currently being evaluated in a prospective phase 2 trial.
AN  - CN-01376139
AU  - Lazar, M.
AU  - Berger, A.
AU  - Petroni, G.
AU  - Tsangaris, T.
AU  - Anne, P.
AU  - Simone, N.
AU  - Libby, B.
AU  - Showalter, T.
AU  - Showalter, S.
DO  - 10.1245/s10434-017-5854-y
IS  - 2 Supplement 1
KW  - *brachytherapy
*feasibility study
*intraoperative radiotherapy
Acute toxicity
Adult
African American
Antibiotic agent
Aspiration
Balloon
Breast cancer
Catheter
Caucasian
Clinical article
Computer assisted tomography
Controlled clinical trial
Controlled study
Drug megadose
Drug toxicity
Female
Hispanic
Human
Lumpectomy
Male
Middle aged
Partial mastectomy
Pathology
Phase 2 clinical trial
Prescription
Radiation dose
Radiation oncology
Seroma
Surgery
Treatment planning
Tumor volume
Ultrasound
Wound
M3  - Conference Abstract
PY  - 2017
SP  - 260‐261
ST  - Feasibility of intraoperative radiation therapy using CT-guided high-dose-rate brachytherapy without a fully integrated brachytherapy suite
T2  - Annals of surgical oncology. Conference: 18th annual meeting of the american society of breast surgeons, ASBS 2017. United states
TI  - Feasibility of intraoperative radiation therapy using CT-guided high-dose-rate brachytherapy without a fully integrated brachytherapy suite
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01376139/full
VL  - 24
ID  - 1546
ER  - 

TY  - JOUR
AB  - Objective: The purpose of this pilot study was to test the feasibility of delivering the mobile mindfulness-based stress reduction for breast cancer (mMBSR(BC)) program using an iPad and to evaluate its impact on symptom improvement. Methods: A single group, pre-posttest design was implemented among female stages 0-III breast cancer survivors (BCS) who completed treatment. Data were collected at baseline and week 6 on measures of psychological and physical symptoms and quality of life. The mMBSR(BC) program is a standardized, stress-reducing intervention that combines sitting and walking meditation, body scan, and yoga and is designed to deliver weekly 2-hour sessions for 6 weeks using an iPad. Results: The mean age of the 15 enrolled BCS was 57 years; one participant was non-Hispanic black, and 14 were non-Hispanic white. Of the 13 who completed the study, there were significant improvements from baseline to 6 weeks post-mMBSR(BC) in psychological and physical symptoms of depression, state anxiety, stress, fear of recurrence, sleep quality, fatigue, and quality of life (P's <.05). Effect sizes for improvements of multiple symptoms ranged from medium to large. Conclusions: These results provide preliminary support that the mMBSR(BC) program may be feasible and acceptable, showing a clinical impact on decreasing psychological and physical symptoms. This mobile-based program offers a delivery of a standardized MBSR(BC) intervention to BCS that is convenient for their own schedule while decreasing symptom burden in the survivorship phase after treatment for breast cancer.
AD  - C.A. Lengacher, College of Nursing, University of South Florida, Tampa, FL, United States
AU  - Lengacher, C. A.
AU  - Reich, R. R.
AU  - Ramesar, S.
AU  - Alinat, C. B.
AU  - Moscoso, M.
AU  - Cousin, L.
AU  - Marino, V. R.
AU  - Elias, M. N.
AU  - Paterson, C. L.
AU  - Pleasant, M. L.
AU  - Rodriguez, C. S.
AU  - Wang, H. L.
AU  - Kip, K. E.
AU  - Meng, H.
AU  - Park, J. Y.
DB  - Embase
Medline
DO  - 10.1002/pon.4491
IS  - 2
KW  - tablet computer
mobile phone
adult
anxiety disorder
article
breast cancer
cancer pain
cancer survivor
clinical article
cognition
controlled study
depression
fatigue
fear
feasibility study
female
human
meditation
mindfulness
mobile application
outcome assessment
patient compliance
quality of life
randomized controlled trial
sleep quality
physiological stress
stress management
walking
yoga
iPad
LA  - English
M3  - Article
N1  - L620585556
2018-02-15
2018-02-21
PY  - 2018
SN  - 1099-1611
1057-9249
SP  - 524-531
ST  - Feasibility of the mobile mindfulness-based stress reduction for breast cancer (mMBSR(BC)) program for symptom improvement among breast cancer survivors
T2  - Psycho-Oncology
TI  - Feasibility of the mobile mindfulness-based stress reduction for breast cancer (mMBSR(BC)) program for symptom improvement among breast cancer survivors
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L620585556&from=export
http://dx.doi.org/10.1002/pon.4491
VL  - 27
ID  - 911
ER  - 

TY  - JOUR
AB  - The purpose of this study was to assess the feasibility of using ethnic beauty salons to reach out to Vietnamese and Korean American women for cervical cancer screening education. Participants (N = 62) were conveniently recruited from ethnic beauty salons located in Albuquerque, New Mexico. Two feasibility questionnaires were separately administered to cosmetologists and their customers. Findings support the view that ethnic beauty salons can be used as a gateway to reach out to these populations, and cosmetologists have the potential to operate as community lay health workers to deliver cervical cancer screening education aimed at reducing disparities in cervical cancer and screening to their ethnic customers.
AN  - WOS:000362727700008
AU  - Lee, J.
AU  - Carvallo, M.
AU  - Lee, E.
DA  - Nov
DO  - 10.1177/0193945914529025
IS  - 11
N1  - 24698810
PY  - 2015
SN  - 0193-9459
SP  - 1489-1509
ST  - Feasibility of Utilizing Ethnic Beauty Salons for Cervical Cancer Screening Education
T2  - Western Journal of Nursing Research
TI  - Feasibility of Utilizing Ethnic Beauty Salons for Cervical Cancer Screening Education
VL  - 37
ID  - 2966
ER  - 

TY  - JOUR
AB  - Background: Obesity is associated with tumor aggressiveness and disease-specific mortality for more than 15 defined malignancies, including prostate cancer. Preclinical studies suggest that weight loss from caloric restriction and increased physical activity may suppress hormonal, energy-sensing, and inflammatory factors that drive neoplastic progression; however, exact mechanisms are yet to be determined, and experiments in humans are limited. Methods: We conducted a randomized controlled trial among 40 overweight or obese, newly-diagnosed prostate cancer patients who elected prostatectomy to explore feasibility of a presurgical weight loss intervention that promoted a weight loss of roughly one kg. week-1 via caloric restriction and physical activity, as well as to assess effects on tumor biology and circulating biomarkers. Measures of feasibility (accrual, retention, adherence, and safety) were primary endpoints. Exploratory aims were directed at the intervention's effect on tumor proliferation (Ki-67) and other tumor markers (activated caspase-3, insulin and androgen receptors, VEGF, TNFβ, NFκB, and 4E-BP1), circulating biomarkers (PSA, insulin, glucose, VEGF, TNFβ, leptin, SHBG, and testosterone), lymphocytic gene expression of corresponding factors and cellular bioenergetics in neutrophils, and effects on the gut microbiome. Consenting patients were randomized in a 1:1 ratio to either: 1) weight loss via a healthful, guidelines-based diet and exercise regimen; or 2) a wait-list control. While biological testing is currently ongoing, this paper details our methods and feasibility outcomes. Results: The accrual target was met after screening 101 cases (enrollment rate: 39.6 %). Other outcomes included a retention rate of 85 %, excellent adherence (95 %), and no serious reported adverse events. No significant differences by age, race, or weight status were noted between enrollees vs. non-enrollees. The most common reasons for non-participation were "too busy" (30 %), medical exclusions (21 %), and "distance" (16 %). Conclusions: Presurgical trials offer a means to study the impact of diet and exercise interventions directly on tumor tissue, and other host factors that are feasible and safe, though modifications are needed to conduct trials within an abbreviated period of time and via distance medicine-based approaches. Pre-surgical trials are critical to elucidate the impact of lifestyle interventions on specific mechanisms that mediate carcinogenesis and which can be used subsequently as therapeutic targets. Trial registration: NCT01886677.
AD  - W. Demark-Wahnefried, University of Alabama at Birmingham (UAB), Department of Nutrition Sciences, 346 Webb Nutrition Sciences Bldg., 1675 University Blvd, Birmingham, AL, United States
AU  - Demark-Wahnefried, W.
AU  - Nix, J. W.
AU  - Hunter, G. R.
AU  - Rais-Bahrami, S.
AU  - Desmond, R. A.
AU  - Chacko, B.
AU  - Morrow, C. D.
AU  - Azrad, M.
AU  - Frugé, A. D.
AU  - Tsuruta, Y.
AU  - Ptacek, T.
AU  - Tully, S. A.
AU  - Segal, R.
AU  - Grizzle, W. E.
DB  - Embase
Medline
DO  - 10.1186/s12885-016-2075-x
IS  - 1
KW  - NCT01886677
androgen receptor
biological marker
caspase 3
glucose
immunoglobulin enhancer binding protein
initiation factor 4E binding protein 1
insulin
insulin receptor
Ki 67 antigen
leptin
lymphotoxin
phosphatidylinositol 3 kinase
phosphatidylinositol 3,4,5 trisphosphate 3 phosphatase
prostate specific antigen
protein kinase B
sex hormone binding globulin
testosterone
vasculotropin
adult
African American
article
bioenergy
body composition
body fat
body mass
caloric intake
caloric restriction
cancer growth
cancer mortality
cancer patient
cardiorespiratory fitness
Caucasian
clinical article
controlled study
feasibility study
hospital admission
human
male
obesity
physical activity
prostate cancer
prostatectomy
quality of life
randomized controlled trial
risk factor
tumor growth
waist circumference
body weight gain
body weight loss
LA  - English
M3  - Article
N1  - L608079320
2016-02-16
2016-02-23
PY  - 2016
SN  - 1471-2407
ST  - Feasibility outcomes of a presurgical randomized controlled trial exploring the impact of caloric restriction and increased physical activity versus a wait-list control on tumor characteristics and circulating biomarkers in men electing prostatectomy for prostate cancer
T2  - BMC Cancer
TI  - Feasibility outcomes of a presurgical randomized controlled trial exploring the impact of caloric restriction and increased physical activity versus a wait-list control on tumor characteristics and circulating biomarkers in men electing prostatectomy for prostate cancer
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L608079320&from=export
http://dx.doi.org/10.1186/s12885-016-2075-x
VL  - 16
ID  - 981
ER  - 

TY  - JOUR
AB  - OBJECTIVES: Employment following illness is associated with better physical and psychological functioning. This study aimed to assess the feasibility and acceptability of a theoretically led workbook intervention designed to support patients with cancer returning to work. DESIGN: Parallel-group randomised controlled trial with embedded qualitative interviews. SETTING: Oncology clinics within four English National Health Service Trusts. PARTICIPANTS: Patients who had received a diagnosis of breast, gynaecological, prostate or colorectal cancer and who had been receiving treatment for a minimum of two weeks. INTERVENTION: A self-guided WorkPlan workbook designed to support patients with cancer to return to work with fortnightly telephone support calls to discuss progress. The control group received treatment as usual and was offered the workbook at the end of their 12-month follow-up. OUTCOME MEASURES: We assessed aspects of feasibility including eligibility, recruitment, data collection, attrition, feasibility of the methodology, acceptability of the intervention and potential to calculate cost-effectiveness. RESULTS: The recruitment rate of eligible patients was 44%; 68 participants consented and 58 (85%) completed baseline measures. Randomisation procedures were acceptable, data collection methods (including cost-effectiveness data) were feasible and the intervention was acceptable to participants. Retention rates at 6-month and 12-month follow-up were 72% and 69%, respectively. At 6-month follow-up, 30% of the usual care group had returned to full-time or part-time work (including phased return to work) compared with 43% of the intervention group. At 12 months, the percentages were 47% (usual care) and 68% (intervention). CONCLUSIONS: The findings confirm the feasibility of a definitive trial, although further consideration needs to be given to increasing the participation rates among men and black and ethnic minority patients diagnosed with cancer. TRIAL REGISTRATION NUMBER: ISRCTN56342476; Pre-results.
AD  - Department of Psychological Sciences, Birkbeck University of London, London, UK.
Faculty of Health and Life Sciences, Coventry University, Coventry, UK.
Leeds Institute of Health Sciences, University of Leeds, Leeds, UK.
Oncology Department, Queen Elizabeth Hospital, University Hospitals Birmingham National Health Service Foundation Trust, Birmingham, UK.
Occupational and Environmental Medicine, Institute of Clinical Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.
AN  - 30670507
AU  - Grunfeld, E. A.
AU  - Schumacher, L.
AU  - Armaou, M.
AU  - Woods, P. L.
AU  - Rolf, P.
AU  - Sutton, A. J.
AU  - Zarkar, A.
AU  - Sadhra, S. S.
C2  - PMC6347862
DA  - Jan 21
DO  - 10.1136/bmjopen-2018-022746
DP  - NLM
ET  - 2019/01/24
IS  - 1
KW  - Adult
Aged
Cancer Survivors/*psychology
Cost-Benefit Analysis
Feasibility Studies
Female
*Goals
Humans
Male
Middle Aged
Neoplasms/economics/therapy
Return to Work/*statistics & numerical data
State Medicine
Time Factors
United Kingdom
*cancer
*employment
*feasibility
*intervention
*randomised controlled trial
LA  - eng
N1  - 2044-6055
Grunfeld, Elizabeth A
Orcid: 0000-0003-3358-7517
Schumacher, Lauren
Armaou, Maria
Woods, Pernille L
Rolf, Pauline
Sutton, Andrew John
Orcid: 0000-0001-7008-4770
Zarkar, Anjali
Sadhra, Steven S
PB-PG-0613-31088/DH_/Department of Health/United Kingdom
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
BMJ Open. 2019 Jan 21;9(1):e022746. doi: 10.1136/bmjopen-2018-022746.
PY  - 2019
SN  - 2044-6055
SP  - e022746
ST  - Feasibility randomised controlled trial of a guided workbook intervention to support work-related goals among cancer survivors in the UK
T2  - BMJ Open
TI  - Feasibility randomised controlled trial of a guided workbook intervention to support work-related goals among cancer survivors in the UK
VL  - 9
ID  - 82
ER  - 

TY  - JOUR
AB  - OBJECTIVES: To examine the feasibility, acceptability, and effects of a dyad-based uncertainty management intervention for breast cancer, including tailored information and coping skills training. SAMPLE & SETTING: 16 patient-partner dyads experiencing breast cancer were enrolled from a midwestern comprehensive cancer center. METHODS & VARIABLES: A single-group pre-/posttest design was used, and descriptive statistics and Cohen's d were calculated. Measures were completed before the intervention and during each treatment cycle. Feasibility, acceptability, fidelity, uptake, and outcome variables (uncertainty, dyadic coping, family functioning) were included. RESULTS: 16 dyads were enrolled during a 13-month period; 15 dyads completed the training for the study, and 13 dyads completed all study activities. Overall, participants reported satisfaction with the intervention. Small to medium effect sizes were observed across the outcomes. IMPLICATIONS FOR NURSING: This study highlights the need for nurses to help couples manage uncertainty related to new cancer treatment. Tailored interventions can allow nurses to use their time efficiently by focusing on individuals actual needs.
AN  - WOS:000569153100014
AU  - Zhang, Y. Z.
AU  - Kwekkeboom, K. L.
DA  - Sep
DO  - 10.1188/20.ONF.595-608
IS  - 5
N1  - 32830807
PY  - 2020
SN  - 0190-535X
SP  - 595-608
ST  - A Feasibility Study of an Uncertainty Management Intervention for Patient-Partner Dyads Experiencing Breast Cancer
T2  - Oncology Nursing Forum
TI  - A Feasibility Study of an Uncertainty Management Intervention for Patient-Partner Dyads Experiencing Breast Cancer
VL  - 47
ID  - 2768
ER  - 

TY  - JOUR
AB  - The barbershop is a promising setting where African-American men might receive information and education about prostate cancer. In this study, we assessed the feasibility of engaging rural barbershops as venues for barbers to deliver a prostate cancer education intervention to increase informed decision-making for prostate cancer screening among customers. Twelve barbershops were recruited from two separate micropolitan areas in Georgia as intervention and control sites. Structured interviews were conducted with 11 barbers in both sites about customer characteristics as well as their willingness to participate in the study. The interviews were audio recorded and transcribed for analysis. In the intervention site, six barbers completed a survey and a pre-/posttest prostate cancer knowledge instrument following training classes. Barbers reported a wide average range of customers served per week (50 to 300). African-American men made up an average of 87 % of customers. Barbers thought prostate cancer was an important discussion topic, felt they would be comfortable discussing it, and supported the participation of their barbershop in the study. For intervention group barbers, there was a statistically significant difference between the average pretest knowledge score of 72 % (mean 12.2, SD = 3.2) and the posttest knowledge score of 89 % (mean 15.2, SD = 1.1) (P = 0.03) on the 17-item prostate cancer knowledge instrument. Based on the multiple interactions with the barbers, there was high receptivity to the topic and consensus about the importance of addressing prostate cancer with their customers. Rural barbershops represent feasible venues for delivering a prostate cancer education intervention. (PsycINFO Database Record (c) 2016 APA, all rights reserved)
AD  - Luque, John S., Jiann-Ping Hsu College of Public Health, Georgia Southern University, P.O. Box 8015, Hendricks Hall, Statesboro, GA, US, 30460-8015
AN  - 2016-24279-004
AU  - Luque, John S.
AU  - Roy, Siddhartha
AU  - Tarasenko, Yelena N.
AU  - Ross, Levi
AU  - Johnson, Jarrett
AU  - Gwede, Clement K.
DB  - psyh
DO  - 10.1007/s13187-014-0739-2
DP  - EBSCOhost
IS  - 4
KW  - African American
Barbershop
Prostate cancer
Cancer education
Blacks
Cancer Screening
Community Involvement
Health Education
Prevention
Prostate
Rural Environments
N1  - Jiann-Ping Hsu College of Public Health, Georgia Southern University, Statesboro, GA, US. Other Publishers: Lawrence Erlbaum; Taylor & Francis. Release Date: 20160905. Correction Date: 20160908. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: English. Conference Information: International Cancer Education Conference, Oct, 2014, Clearwater, FL, US. Conference Note: A prior version of this paper was presented at the aforementioned conference. Major Descriptor: Blacks; Cancer Screening; Community Involvement; Health Education; Prevention. Minor Descriptor: Prostate; Rural Environments. Classification: Promotion & Maintenance of Health & Wellness (3365). Population: Human (10); Male (30); Female (40). Location: US. Age Group: Adulthood (18 yrs & older) (300); Thirties (30-39 yrs) (340); Middle Age (40-64 yrs) (360). Tests & Measures: Prostate Cancer Knowledge Instrument; Decision Self-Efficacy Scale DOI: 10.1037/t23888-000. Methodology: Empirical Study; Interview; Quantitative Study. Page Count: 6. Issue Publication Date: Dec, 2015. Publication History: First Posted Date: Oct 8, 2014. Copyright Statement: Springer Science+Business Media New York. 2014.
Sponsor: National Institute on Minority Health and Health Disparities, US. Grant: P20MD006901. Recipients: No recipient indicated
PY  - 2015
SN  - 0885-8195
1543-0154
SP  - 623-628
ST  - Feasibility study of engaging barbershops for prostate cancer education in rural African-American communities
T2  - Journal of Cancer Education
TI  - Feasibility study of engaging barbershops for prostate cancer education in rural African-American communities
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2016-24279-004&site=ehost-live&scope=site
ORCID: 0000-0002-3833-0836
ORCID: 0000-0002-8085-4641
jluque@georgiasouthern.edu
VL  - 30
ID  - 1751
ER  - 

TY  - JOUR
AB  - There are marked racial differences in breast cancer, the second leading cause of death among US women. Understanding the causes of these differences is essential to eliminate breast cancer inequities. More prevalent in African American than in Caucasian women, metabolic syndrome has been associated with breast cancer outcomes. Further research is needed to understand metabolic syndrome's role in breast cancer disparities, thus novel strategies to increase minority participation in research are important. We embedded two approaches (comprehensive, focused) to increase African American participation in breast cancer research in a state-wide service program and pilot tested both approaches in rural African American women. We conducted three comprehensive and three focused outreach programs (n = 48) and assessed research participation through consent and actual provision of data for four types of data: survey, anthropometric, blood, and mammography records. The majority of participants provided written consent for all data collection procedures (96 % survey; 92 % anthropometric; 94 %, blood; 100 % mammography). There were no between group differences in consent rates. There was variation in the overall proportion of participants who provided data (96 % survey; 92 % anthropometric; 73 % blood; 40 % mammography). Women in the comprehensive approach were less likely to return for a scheduled mammogram than women in the focused approach (19 % vs 64 %, p = 0.0236). Both outreach programs promoted African American engagement in research. Differences in the provision of data by type may have been due to participant burden (i.e., time required to provide data). Study designs that embed research in service programs have promise to increase minority research participation.
AD  - University of Arkansas for Medical Sciences, Little Rock, AR, USA. khk@uams.edu.
University of Arkansas for Medical Sciences, Little Rock, AR, USA.
AN  - 27085550
AU  - Yeary, K. H. K.
AU  - Moore, P.
AU  - Turner, J.
AU  - Dawson, L.
AU  - Heo, S.
AU  - Greene, P.
C2  - PMC5065933
C6  - NIHMS779151
DA  - Feb
DO  - 10.1007/s13187-016-1032-3
DP  - NLM
ET  - 2016/04/18
IS  - 1
KW  - Adult
*African Americans
Aged
Attitude to Health/*ethnology
Biomedical Research
Breast Neoplasms/*ethnology
Feasibility Studies
Female
Health Promotion
*Health Status Disparities
Humans
Mammography/statistics & numerical data
Middle Aged
Minority Groups
*Patient Selection
Rural Population
Surveys and Questionnaires
United States
*African American
*Breast cancer
*Disparities
*Metabolic syndrome
*Minority
*Research participation
LA  - eng
N1  - 1543-0154
Yeary, Karen Hye-Cheon Kim
Moore, Page
Turner, Jerome
Dawson, Leah
Heo, Seongkum
Greene, Paul
P20 MD002329/MD/NIMHD NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
J Cancer Educ. 2018 Feb;33(1):29-36. doi: 10.1007/s13187-016-1032-3.
PY  - 2018
SN  - 0885-8195 (Print)
0885-8195
SP  - 29-36
ST  - Feasibility Test of a Community-Relevant Intervention Designed to Promote African American Participation in Translational, Breast Cancer Disparities Research: Know About Health Options for Women (Know HOW)
T2  - J Cancer Educ
TI  - Feasibility Test of a Community-Relevant Intervention Designed to Promote African American Participation in Translational, Breast Cancer Disparities Research: Know About Health Options for Women (Know HOW)
VL  - 33
ID  - 214
ER  - 

TY  - JOUR
AB  - BACKGROUND: The utility of psychosocial interventions in reducing symptom burden and improving health-related quality of life (HRQOL) for men with localized prostate cancer has been demonstrated. However, studies have yet to demonstrate the efficacy of interventions in advanced prostate cancer (APC). This study examined the feasibility, acceptability, and preliminary efficacy of a technology-assisted, 10-week, group-based psychosocial intervention for diverse men with APC. METHODS: The participants were 74 men (mean age, 68.84 years; non-Hispanic white, 57%; black, 40.5%) who were randomized to a cognitive-behavioral stress management (CBSM) treatment or health promotion (HP) attention-control condition. The participants were assessed at the baseline, weekly throughout the 10-week program, and 6 months after the baseline. Outcomes were assessed with the Patient-Reported Outcomes Measurement Information System along with established measures of HRQOL, CBSM intervention targets (eg, relaxation skills), and patient-reported acceptability. RESULTS: Feasibility was demonstrated through good retention rates (>85%) and acceptable average attendance rates (>70%), and acceptability was demonstrated through very favorable weekly session evaluations (mean score, 4/5) and exit surveys (mean score, 3.6/4). Men randomized to the CBSM condition reported significant reductions (P < .05) in depressive symptoms and improvements in relaxation self-efficacy (P < .05) at the 6-month follow-up. CBSM participants reported trends for improvement in distress and functional well-being (P < .08) in comparison with those in the HP condition. Effect sizes ranged from medium (0.54) to large (1.87) and, in some instances, were clinically meaningful. CONCLUSIONS: Technology-based CBSM interventions among diverse men with APC may be feasible, acceptable, and efficacious.
AD  - Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Mental Health and Behavioral Sciences Service, Miami Veterans Affairs Healthcare System, Miami, Florida.
Department of Urology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
AN  - 26348661
AU  - Yanez, B.
AU  - McGinty, H. L.
AU  - Mohr, D. C.
AU  - Begale, M. J.
AU  - Dahn, J. R.
AU  - Flury, S. C.
AU  - Perry, K. T.
AU  - Penedo, F. J.
C2  - PMC4670576
C6  - NIHMS714605
DA  - Dec 15
DO  - 10.1002/cncr.29658
DP  - NLM
ET  - 2015/09/09
IS  - 24
KW  - African Americans/psychology
Aged
Aged, 80 and over
Cognitive Behavioral Therapy/*methods
Depression/psychology/*therapy
European Continental Ancestry Group/psychology
Feasibility Studies
Humans
Male
Middle Aged
Neoplasm Staging
*Patient Acceptance of Health Care
Patient Satisfaction
Prostatic Neoplasms/pathology/*psychology
*Quality of Life
Self Efficacy
Stress, Psychological/psychology/*therapy
Therapy, Computer-Assisted/*methods
Treatment Outcome
eHealth
prostate cancer
psychosocial aspects
quality of life
randomized trial
LA  - eng
N1  - 1097-0142
Yanez, Betina
McGinty, Heather L
Mohr, David C
Begale, Mark J
Dahn, Jason R
Flury, Sarah C
Perry, Kent T
Penedo, Frank J
P30 CA060553/CA/NCI NIH HHS/United States
R01 CA157809/CA/NCI NIH HHS/United States
R01CA157809/CA/NCI NIH HHS/United States
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Cancer. 2015 Dec 15;121(24):4407-15. doi: 10.1002/cncr.29658. Epub 2015 Sep 8.
PY  - 2015
SN  - 0008-543X (Print)
0008-543x
SP  - 4407-15
ST  - Feasibility, acceptability, and preliminary efficacy of a technology-assisted psychosocial intervention for racially diverse men with advanced prostate cancer
T2  - Cancer
TI  - Feasibility, acceptability, and preliminary efficacy of a technology-assisted psychosocial intervention for racially diverse men with advanced prostate cancer
VL  - 121
ID  - 232
ER  - 

TY  - JOUR
AB  - The clinical trials mechanism of standardized treatment and follow-up for cancer patients with similar stages and patterns of disease is the most powerful approach available for evaluating the efficacy of novel therapies, and clinical trial participation should protect against delivery of care variations associated with racial/ethnic identity and/or socioeconomic status. Unfortunately, disparities in clinical trial accrual persist, with African Americans (AA) and Hispanic/Latino Americans (HA) underrepresented in most studies. We evaluated the accrual patterns for 10 clinical trials conducted by the American College of Surgeons Oncology Group (ACOSOG) 1999-2009, and analyzed results by race/ethnicity as well as by study design. Eight of 10 protocols were successful in recruiting AA and/or HA participants; three of four randomized trials were successful. Features that were present among all of the successfully recruiting protocols were: (1) studies designed to recruit patients with regional or advanced-stage disease (2 of 2 protocols); and (2) studies that involved some investigational systemic therapy (3 of 3 protocols). AA and HA cancer patients can be successfully accrued onto randomized clinical trials, but study design affects recruitment patterns. Increased socioeconomic disadvantages observed within minority-ethnicity communities results in barriers to screening and more advanced cancer stage distribution. Improving cancer early detection is critical in the effort to eliminate outcome disparities but existing differences in disease burden results in diminished eligibility for early-stage cancer clinical trials among minority-ethnicity patients.
AN  - WOS:000297358900005
AU  - Diehl, K. M.
AU  - Green, E. M.
AU  - Weinberg, A.
AU  - Frederick, W. A.
AU  - Holmes, D. R.
AU  - Green, B.
AU  - Morris, A.
AU  - Kuerer, H. M.
AU  - Beltran, R. A.
AU  - Mendez, J.
AU  - Gines, V.
AU  - Ota, D. M.
AU  - Nelson, H.
AU  - Newman, L. A.
DA  - Dec
DO  - 10.1245/s10434-011-1818-9
IS  - 13
N1  - 21681382
PY  - 2011
SN  - 1068-9265
SP  - 3544-3550
ST  - Features Associated with Successful Recruitment of Diverse Patients onto Cancer Clinical Trials: Report from the American College of Surgeons Oncology Group
T2  - Annals of Surgical Oncology
TI  - Features Associated with Successful Recruitment of Diverse Patients onto Cancer Clinical Trials: Report from the American College of Surgeons Oncology Group
VL  - 18
ID  - 3080
ER  - 

TY  - JOUR
AB  - Diagnosis with breast cancer is not an automatic cause for discharge from the military. Therefore, it is important to know how this disease impacts enlisted women in the military. This study describes how enlisted women manage diagnosis and treatment within the context of their military careers. Grounded theory guided the study methodology. Audiotaped semistructured interviews were conducted three times over 9 months to learn how treatment impacted work demands. Data saturation was attained after 46 interviews were conducted. Participants had to balance demands and expectations among the Military Career and Military Medical Subsystems and their Social Support Subsystem. Support from the chain of command was critical in women's ability to balance demands and expectations of career, family, and illness. Military nurses are in a unique position to create strategies that will assist enlisted women in coping with breast cancer.
AD  - School of Nursing, College of Health & Human Services, University of North Carolina, Charlotte, Charlotte, NC 28223, USA
School of Nursing, College of Health & Human Services, University of North Carolina, Charlotte, NC 28223
AN  - 106692368. Language: English. Entry Date: 20040116. Revision Date: 20171209. Publication Type: journal article
AU  - Wilmoth, M. C.
AU  - Wilmoth, Margaret Chamberlain
DB  - CINAHL Complete
DP  - EBSCOhost
IS  - 7
KW  - Adaptation, Psychological
Breast Neoplasms -- Psychosocial Factors
Military Personnel -- Psychosocial Factors
Women, Working -- Psychosocial Factors
Workload
Activities of Daily Living
Adult
Audiorecording
Black Persons
Breast Neoplasms -- Surgery
Chemotherapy, Cancer -- Adverse Effects
Coding
Demography
Female
Funding Source
Grounded Theory
Interviews
Life Change Events
Literature Review
Middle Age
Negotiation
Phenomenological Research
Purposive Sample
Questionnaires
Research Subject Recruitment
Research, Nursing
Self Care -- Psychosocial Factors
Telephone
United States
United States Air Force
United States Army
United States Navy
White Persons
Human
N1  - research; tables/charts. Journal Subset: Biomedical; Expert Peer Reviewed; Peer Reviewed; USA. Grant Information: Funded by a grant from the TriService Nursing Research Program, MDA-905-97-Z-0018. NLM UID: 2984771R.
PMID: NLM12901457.
PY  - 2003
SN  - 0026-4075
SP  - 514-519
ST  - The Federal Nursing Services Award. Enlisted women with breast cancer: balancing demands and expectations
T2  - Military Medicine
TI  - The Federal Nursing Services Award. Enlisted women with breast cancer: balancing demands and expectations
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106692368&site=ehost-live&scope=site
VL  - 168
ID  - 2122
ER  - 

TY  - JOUR
AB  - PURPOSE OF REVIEW: Fibroadenomas are the most common breast masses in adolescent women, therefore it is important that health providers understand their assessment and management. This review discusses an approach to investigation and management of fibroadenomas in adolescents. RECENT FINDINGS: Fibroadenomas are benign tumors which commonly present in late adolescence. They are classified according to their histology and size. Simple fibroadenomas are the most common type and usually present as smooth mobile masses up to 3 cm in diameter. Giant fibroadenomas are more uncommon but typically present in adolescence. Fibroadenomas associated with other soft-tissue masses should raise the possibility of an inherited syndrome. Assessment of breast masses in this age group generally involves clinical assessment through history and physical examination and, when imaging is needed, ultrasonography. As the incidence of primary breast malignancy is very low in this age group, core biopsy is not routinely recommended. Large or rapidly growing tumors, or those associated with suspicious features, warrant surgical excision. New minimally invasive excision techniques are being introduced which are associated with high initial success rates. SUMMARY: Whereas the vast majority of fibroadenomas in teenagers may be monitored with surveillance alone, new minimally invasive techniques may play an important role in the management of selected patients.
AD  - Division of Pediatric and Adolescent Gynecology, Mayo Clinic, Rochester, Minnesota, USA.
AN  - 19606032
AU  - Jayasinghe, Y.
AU  - Simmons, P. S.
DA  - Oct
DO  - 10.1097/GCO.0b013e32832fa06b
DP  - NLM
ET  - 2009/07/17
IS  - 5
KW  - Adolescent
African Americans
Biopsy, Needle
Breast Neoplasms/*diagnostic imaging/ethnology/pathology
Female
Fibroadenoma/*diagnostic imaging/ethnology/pathology
Humans
Patient Participation
Physical Examination
Ultrasonography
LA  - eng
N1  - 1473-656x
Jayasinghe, Yasmin
Simmons, Patricia S
Journal Article
Review
England
Curr Opin Obstet Gynecol. 2009 Oct;21(5):402-6. doi: 10.1097/GCO.0b013e32832fa06b.
PY  - 2009
SN  - 1040-872x
SP  - 402-6
ST  - Fibroadenomas in adolescence
T2  - Curr Opin Obstet Gynecol
TI  - Fibroadenomas in adolescence
VL  - 21
ID  - 456
ER  - 

TY  - JOUR
AB  - Background: Achievement of pathologic complete response (pCR) to preoperative therapy is a predictor of improved disease‐free and overall survival. Sequential and concurrent regimens of D and C were evaluated in patients with Her2‐negative breast cancers who were candidates for preoperative chemotherapy. Methods: Patients with Stage I (>1.0 cm), II or III, Her‐negative breast cancer from Georgia‐based oncology network were randomized between Arm A: sequential therapy with D 100 mg/m2 every 3 weeks for 4 cycles followed by C 1000 mg/m2 PO BID on days 1‐14 of 3 week cycle for 4 cycles; Arm B: concurrent therapy with with D 50 mg/m2 on day 1 and C 1000 mg/m2 PO BID on days 1‐7 of 2 week cycle for 8 cycles. Primary endpoint was pCR rate; secondary endpoints included response rate and toxicity. Results: 51 patients were accrued (4/2007‐7/2009), Arm A (n=25) Arm B (n=26) and are evaluable for primary endpoint. Patients were accrued at academic center (45%), county hospital (33%), and community sites (22%). Median age was 50.3 years. Median tumor size was 6.1 cm. 35 of 51 (68.6%) were clinically node‐positive at study entry. 57% of patients were African American, 35% Caucasian, and 8% other. 30 of 51 (58.8%) of patients had ER and/or PR‐positive tumors; 21 of 51 (41.2%) had ER/PR‐negative tumors (triple negative). Treatment was well‐tolerated with expected grade 3‐4 toxicities: neutropenia 15.7%; hand‐foot syndrome 5.9%; neuropathy 3.9%. On Arm A, clinical complete response (CR) rate was 32%. Partial response (PR) rate was 28%. Stable disease (SD) rate was 12 %. Progressive disease (PD) rate was 28%. On Arm B, clinical CR rate was 46.2%. PR rate was 42.3%. SD rate was 3.8%. PD rate was 7.7%. pCR rate was 8% for Arm A and 11.5% for Arm B. Among triple negative breast cancer subjects, pCR rate was 19%. Conclusions: This is the first clinical trial to accrue patients through a Georgia‐based oncology trial network and more than half of enrolled patients were African American. The final results from this phase II trial of D and C show that both regimens were well‐tolerated and had modest clinical activity, with greater activity in the concurrent therapy arm and among triple negative patients.
AN  - CN-01034317
AU  - Zelnak, A. B.
AU  - Harichand-Herdt, S.
AU  - Styblo, T. M.
AU  - Rizzo, M.
AU  - Gabram, S. G. A.
AU  - Bumpers, H. L.
AU  - Hermann, R. C.
AU  - Srinivasiah, J.
AU  - Schnell, F. M.
AU  - O'Regan, R.
IS  - 15 SUPPL. 1
KW  - *breast cancer
*capecitabine
*docetaxel
*human
*phase 2 clinical trial
Achievement
African American
Arm
Caucasian
Chemotherapy
Clinical trial
Community
Hand foot syndrome
Neuropathy
Neutropenia
Oncology
Overall survival
Patient
Public hospital
Pyrazinamide
Therapy
Toxicity
Triple negative breast cancer
Tumor
Tumor volume
M3  - Journal: Conference Abstract
PY  - 2011
ST  - Final results from randomized phase II trial of preoperative docetaxel (D) and capecitabine (C) given sequentially or concurrently for HER2-negative breast cancers
T2  - Journal of clinical oncology
TI  - Final results from randomized phase II trial of preoperative docetaxel (D) and capecitabine (C) given sequentially or concurrently for HER2-negative breast cancers
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01034317/full
VL  - 29
ID  - 1473
ER  - 

TY  - JOUR
AB  - Background Clinical trials test new ways to prevent, detect, diagnose, or treat diseases. Researchers have found that minority patients are willing to participate in clinical trials, yet these patients have barriers which hinder their access to trials. Methods To explore African American women's participation in breast cancer clinical trials, eight focus groups were conducted with breast cancer patients, family members/care givers, religious leaders, and healthcare providers to gather information on the perspectives and opinions on the topic. The focus group conversations were transcribed, and transcripts were imported into QSR International's NVivo 10 software. The transcripts were organized into folders based on four categories. The content analysis performed was based on recordings and notes. Results The following themes were generated as a result of conducting these focus groups and gathering information on the perspectives and opinions about participating in clinical trials, based on the groups who participated: Promoting participation in research; Personal experience with cancer; Support and support services; Awareness, knowledge, and experience with clinical trials; Providers' roles in clinical trials. Conclusion The data collected in this study present several actionable themes that, if addressed by individual researchers and the medical community at large, could increase participation in clinical trials by African American patients. They also provide a deeper and more nuanced understanding of the factors influencing African American patients' decisions around participating in clinical trials.
AD  - S.M. Swain, Georgetown University Medical Center, 4000 Reservoir Road NW, 120 Building D, Washington DC, United States
AU  - Robinson, B. N.
AU  - Newman, A. F.
AU  - Wallington, S. F.
AU  - Swain, S. M.
DB  - Embase
DO  - 10.1016/j.conctc.2016.09.004
KW  - African American
article
awareness
breast cancer
cancer patient
cancer research
caregiver
clergy
clinical trial (topic)
content analysis
family
health care personnel
human
information processing
information seeking
knowledge
medical information
patient participation
personal experience
priority journal
LA  - English
M3  - Article
N1  - L612320985
2016-10-03
2016-10-12
PY  - 2016
SN  - 2451-8654
SP  - 170-178
ST  - Focus on You: Cancer clinical trials perspectives
T2  - Contemporary Clinical Trials Communications
TI  - Focus on You: Cancer clinical trials perspectives
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L612320985&from=export
http://dx.doi.org/10.1016/j.conctc.2016.09.004
VL  - 4
ID  - 952
ER  - 

TY  - JOUR
AB  - Background: We evaluated the efficacy of a Chicago-based cancer patient navigation program developed to increase the proportion of patients reaching diagnostic resolution and reduce the time from abnormal screening test to definitive diagnostic resolution. Methods: Women with an abnormal breast (n = 352) or cervical (n = 545) cancer screening test were recruited for the quasi-experimental study. Navigation subjects originated from five federally qualified health center sites and one safety net hospital. Records-based concurrent control subjects were selected from 20 sites. Control sites had similar characteristics to the navigated sites in terms of patient volume, racial/ethnic composition, and payor mix. Mixed-effects logistic regression and Cox proportional hazard regression analyses were conducted to compare navigation and control patients reaching diagnostic resolution by 60 days and time to resolution, adjusting for demographic covariates and site. Results: Compared with controls, the breast navigation group had shorter time to diagnostic resolution (aHR = 1.65, CI = 1.20-2.28) and the cervical navigation group had shorter time to diagnostic resolution for those who resolved after 30 days (aHR = 2.31, CI = 1.75-3.06), with no difference before 30 days (aHR = 1.42, CI = 0.83-2.43). Variables significantly associated with longer time to resolution for breast cancer screening abnormalities were being older, never partnered, abnormal mammogram and BI-RADS 3, and being younger and Black for cervical abnormalities. Conclusions: Patient navigation reduces time from abnormal cancer finding to definitive diagnosis in underserved women. Impact: Results support efforts to use patient navigation as a strategy to reduce cancer disparities among socioeconomically disadvantaged women. ©2012 AACR.
AD  - Health Policy and Management, Jiann-Ping Hsu College of Public Health, Georgia Southern University, Statesboro, GA, United States
Division of Health Policy and Administration, School of Public Health, University of Illinois at Chicago, Chicago, IL, United States
AU  - Markossian, T. W.
AU  - Darnell, J. S.
AU  - Calhoun, E. A.
DB  - Scopus
DO  - 10.1158/1055-9965.EPI-12-0535
IS  - 10
M3  - Article
N1  - Cited By :58
Export Date: 22 March 2021
PY  - 2012
SP  - 1691-1700
ST  - Follow-up and timeliness after an abnormal cancer screening among underserved, urban women in a patient navigation program
T2  - Cancer Epidemiology Biomarkers and Prevention
TI  - Follow-up and timeliness after an abnormal cancer screening among underserved, urban women in a patient navigation program
UR  - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84867319979&doi=10.1158%2f1055-9965.EPI-12-0535&partnerID=40&md5=39a17f3695b0ccf081e8e445d24a41dd
VL  - 21
ID  - 2452
ER  - 

TY  - JOUR
AB  - BACKGROUND: Significant disparities exist in colorectal cancer (CRC) screening rates among those of low socioeconomic status, with fewer years of education, lacking health insurance, or living in rural areas. METHODS: A randomized controlled trial was conducted to compare the effectiveness of 2 follow-up approaches to a health literacy intervention to improve CRC screening: automated telephone call or personal call. Patients aged 50 to 75 years residing in 4 rural community clinics in Louisiana were given a structured interview that assessed demographic, health literacy and CRC screening barriers, knowledge, and attitudes. All were given health literacy-informed CRC education, a patient-friendly CRC screening pamphlet, simplified fecal immunochemical test (FIT) instructions, and a FIT kit, and a "teach-back" method was used to confirm understanding. Patients were randomized to 1 of 2 telephone follow-up arms. If they did not mail their FIT kit within 4 weeks, they received a reminder call and were called again at 8 weeks if the test still was not received. RESULTS: A total of 620 patients were enrolled. Approximately 55% were female, 66% were African American, and 40% had limited literacy. The overall FIT completion rate was 68%: 69.2% in the automated telephone call arm and 67% in the personal call arm. Greater than one-half of the patients (range, 58%-60%) returned the FIT kit without receiving a telephone call. There was no difference noted with regard to the effectiveness of the follow-up calls; each increased the return rate by 9%. CONCLUSIONS: Providing FIT kits and literacy-appropriate education at regularly scheduled clinic visits with a follow-up telephone call when needed was found to increase CRC screening among low-income, rural patients. The lower cost automated call was just as effective as the personal call.
AD  - Department of Medicine, Louisiana State University Health Sciences Center-Shreveport, Shreveport, Louisiana.
Department of Preventive Medicine, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois.
College of Nursing and Health, Loyola University New Orleans, New Orleans, Louisiana.
Teche Action Clinic, Franklin, Louisiana.
AN  - 31355924
AU  - Arnold, C. L.
AU  - Rademaker, A. W.
AU  - Morris, J. D.
AU  - Ferguson, L. A.
AU  - Wiltz, G.
AU  - Davis, T. C.
C2  - PMC6763382
C6  - NIHMS1038105
DA  - Oct 15
DO  - 10.1002/cncr.32398
DP  - NLM
ET  - 2019/07/30
IS  - 20
KW  - Aged
Ambulatory Care Facilities
Colorectal Neoplasms/blood/*diagnosis/epidemiology/pathology
*Early Detection of Cancer
Feces/chemistry
Female
Follow-Up Studies
Health Education/statistics & numerical data
Health Literacy
Humans
Louisiana/epidemiology
Male
Mass Screening/*methods
Middle Aged
Occult Blood
Rural Population/*statistics & numerical data
Telephone
*colorectal cancer screening
*disparities
*health literacy
*prevention
*randomized controlled trial
*rural community clinics
LA  - eng
N1  - 1097-0142
Arnold, Connie L
Orcid: 0000-0001-8961-2342
Rademaker, Alfred W
Morris, James D
Ferguson, Laurie Anne
Wiltz, Gary
Davis, Terry C
U54 GM104940/GM/NIGMS NIH HHS/United States
RSG-13-021-01-CPPB/American Cancer Society/International
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Cancer. 2019 Oct 15;125(20):3615-3622. doi: 10.1002/cncr.32398. Epub 2019 Jul 29.
PY  - 2019
SN  - 0008-543X (Print)
0008-543x
SP  - 3615-3622
ST  - Follow-up approaches to a health literacy intervention to increase colorectal cancer screening in rural community clinics: A randomized controlled trial
T2  - Cancer
TI  - Follow-up approaches to a health literacy intervention to increase colorectal cancer screening in rural community clinics: A randomized controlled trial
VL  - 125
ID  - 70
ER  - 

TY  - JOUR
AN  - 14632278
AU  - Hoyo, C.
AU  - Reid, M. L.
AU  - Godley, P. A.
AU  - Parrish, T.
AU  - Smith, L.
AU  - Gammon, M.
DA  - Fall
DP  - NLM
ET  - 2003/11/25
IS  - 4
KW  - Adult
*African Continental Ancestry Group
Aged
Cohort Studies
Humans
Male
Middle Aged
North Carolina
Patient Acceptance of Health Care/*ethnology
*Patient Selection
Prostatic Neoplasms/diagnosis/*ethnology/therapy
Surveys and Questionnaires
Treatment Refusal
Trust
LA  - eng
N1  - Hoyo, Cathrine
Reid, M LaVerne
Godley, Paul A
Parrish, Theodore
Smith, Lenora
Gammon, Marilie
Journal Article
Patient Education Handout
United States
Ethn Dis. 2003 Fall;13(4):547-8.
PY  - 2003
SN  - 1049-510X (Print)
1049-510x
SP  - 547-8
ST  - For the patient. Improving participation of African-American men in research studies
T2  - Ethn Dis
TI  - For the patient. Improving participation of African-American men in research studies
VL  - 13
ID  - 638
ER  - 

TY  - JOUR
AB  - The author discusses a successful, nurse-coordinated collaborative community-based breast health program that targeted older African American women from the state of South Carolina. Over 16 community organizations and health care partners supported the four-phase program that was funded by the South Carolina Breast and Cervical Risk Reduction Program and the South Carolina Chapter of the American Cancer Society.
AD  - Clemson University School of Nursing, College of Health, Education, and Human Development, USA. lynetteG@aol.com
AN  - 11760311
AU  - Gibson, L. M.
DA  - Jul-Aug
DP  - NLM
ET  - 2002/01/05
IS  - 4
KW  - African Americans/education/*psychology
Aged
Attitude to Health/ethnology
Breast Neoplasms/nursing/*prevention & control
*Community-Institutional Relations
Female
Feminism
Health Education/*organization & administration
Health Knowledge, Attitudes, Practice
Health Promotion/*organization & administration
Humans
Mass Screening/*organization & administration
Middle Aged
*Patient Selection
Poverty
Program Development
South Carolina
Women/education/*psychology
Women's Health Services/*organization & administration
LA  - eng
N1  - Gibson, L M
Journal Article
United States
ABNF J. 2000 Jul-Aug;11(4):94-6.
PY  - 2000
SN  - 1046-7041 (Print)
1046-7041
SP  - 94-6
ST  - A four-phase program to recruit African American women into breast cancer promotion programs
T2  - Abnf j
TI  - A four-phase program to recruit African American women into breast cancer promotion programs
VL  - 11
ID  - 676
ER  - 

TY  - JOUR
AB  - Objectives. Uncertainty exists regarding optimal prostate cancer screening parameters for high-risk populations. The purpose of this study is to report the use of percent free prostate-specific antigen (PSA) as an indication for biopsy in men at increased risk for developing prostate cancer who have a normal digital rectal examination (DRE) and total PSA level between 2 and 4 ng/mL. Methods. African-American men and men with at least one first-degree relative with prostate cancer are eligible for enrollment into the Prostate Cancer Risk Assessment Program (PRAP) at our institution. Between October 1996 and April 2002, 310 asymptomatic high-risk men with no history of prostate cancer, benign prostatic hyperplasia (BPH), or prostatic intraepithelial neoplasia (PIN) were screened in the PRAP with DRE and total PSA. Percent free PSA was obtained in men with a total PSA between 2 and 10 ng/mL. Men with a normal DRE and total PSA between 2 and 4 ng/mL were advised to undergo transrectal ultrasound-guided (TRUS) biopsies of the prostate if the percent free PSA was less than 27%. Other indications for biopsy included an abnormal DRE or a total PSA greater than 4 ng/mL. The primary endpoint evaluated was prostate cancer detection in high-risk men with a benign prostate examination, a normal total PSA between 2 and 4 ng/mL, and percent free PSA less than 27%. Results. Of the 310 men, 174 (56%) were African American and 202 (65%) had at least one first-degree relative with prostate cancer. Sixty-two of the 310 men were referred for prostate biopsy, and 40 of 62 had biopsy performed. Twenty-one of 40 men were diagnosed with prostate canter for a cancer detection rate of 53% in all men undergoing biopsy and an overall cancer detection rate of 6.8% in this high-risk population. Thirty-seven high-risk men (median age 54 years) with a total PSA level between 2 and 4 ng/mL (median 2.7 ng/mL and a normal DRE were found to have a percent free PSA level of less than 27% (median 16%, range 8% to 25%). Twenty-three of these 37 men (62%) proceeded with the recommended prostate biopsy. Prostatic adenocarcinoma was diagnosed in 12 of 23 men for a cancer detection rate of 52% in men undergoing biopsy and 32% in all men with a normal DRE, a total PSA between 2 and 4 ng/mL, and a percent free PSA less than 27%. All positive biopsies demonstrated clinically significant Gleason score 6 or 7 disease. In all men electing radical prostatectomy, bilateral organ-confined disease (pT2bN0M0) was confirmed. Conclusions. In this unique population of men at high risk for prostate cancer, a percent free PSA of less than 27% was found to be useful for detecting early-stage but clinically significant cancers in men with a total PSA value between 2 and 4 ng/mL and normal DRE findings. (C) 2003, Elsevier Science Inc.
AN  - WOS:000182193500018
AU  - Uzzo, R. G.
AU  - Pinover, W. H.
AU  - Horwitz, E. M.
AU  - Parlanti, A.
AU  - Mazzoni, S.
AU  - Raysor, S.
AU  - Mirchandani, I.
AU  - Greenberg, R. E.
AU  - Pollack, A.
AU  - Hanks, G. E.
AU  - Watkins-Bruner, D.
DA  - Apr
DO  - 10.1016/S0090-4295(02)02524-4
IS  - 4
N1  - 28
12670560
PY  - 2003
SN  - 0090-4295
SP  - 754-759
ST  - Free prostate-specific antigen improves prostate cancer detection in a high-risk population of men with a normal total PSA and digital rectal examination
T2  - Urology
TI  - Free prostate-specific antigen improves prostate cancer detection in a high-risk population of men with a normal total PSA and digital rectal examination
VL  - 61
ID  - 2698
ER  - 

TY  - JOUR
AB  - Objectives: To describe the complete history of major opportunistic events experienced by 1883 HIV-infected persons prior to and specifically within 6 months of death, and to determine whether the frequency of specific events varies according to demographic characteristics, risk behaviors or geographic location. Design: Descriptive case series. Methods: Of 6682 HIV-infected individuals enrolled in studies sponsored by the Community Programs for Clinical Research on AIDS between September 1990 and June 1994, 1883 died during follow-up. A complete history of AIDS-defining events was determined for these patients by combining medical history data obtained at the time of enrollment, new events that occurred during follow-up, and causes of death. Results: The most common opportunistic AIDS-defining events these 1883 patients experienced before death were Pneumocystis carinii pneumonia (PCP; 45%), Mycobacterium avium complex (MAC; 25%), wasting syndrome (25%), bacterial pneumonia (24%), cytomegalovirus (CMV) disease (23%) and candidiasis (esophageal or pulmonary; 22%). In addition, 47% of patients experienced two or three AIDS-defining events before death, and 22% experienced four or more events. In the 6 months prior to death, 22% of patients had PCP, 21% had MAC, and 20% had CMV disease. Significant sex and ethnic differences were found: bacterial pneumonia occurred more often before death in women compared with men; fewer blacks and Latinos than whites experienced Kaposi's sarcoma (KS); and fewer blacks than whites had CMV disease before death. The percentage of patients with KS and CMV also varied by risk behavior. The frequency of 10 opportunistic diseases varied by geographic region after adjustment for demographic characteristics and risk behavior. Of note, many more patients in northeastern USA had tuberculosis and fewer had MAC. Conclusion: A large percentage of individuals with HIV infection experienced multiple AIDS-defining opportunistic diseases before death. PCP, MAC, wasting syndrome, bacterial pneumonia, CMV disease, and candidiasis (esophageal or pulmonary) account for a substantial proportion of morbidity associated with HIV infection. More diseases varied by geographic location than by demographic characteristics or risk behavior of patients. Continued research on the etiology and prevention of these diseases and how they relate to one another should be a high priority.
AD  - J.D. Neaton, Division of Biostatistics, School of Public Health, University of Minnesota, 2221 University Avenue SE, Minneapolis, MN 55414-1380, United States
AU  - Chan, I. S. F.
AU  - Neaton, J. D.
AU  - Saravolatz, L. D.
AU  - Crane, L. R.
AU  - Osterberger, J.
DB  - Embase
Medline
DO  - 10.1097/00002030-199510000-00005
IS  - 10
KW  - article
bacterial pneumonia
behavior
candidiasis
cause of death
clinical research
cytomegalovirus infection
death
demography
ethnic difference
female
follow up
gender
human
Human immunodeficiency virus infection
Kaposi sarcoma
major clinical study
male
medical record
muscle atrophy
Mycobacterium avium complex
opportunistic infection
Pneumocystis pneumonia
priority journal
tuberculosis
LA  - English
M3  - Article
N1  - L25280007
1995-10-02
PY  - 1995
SN  - 0269-9370
SP  - 1145-1151
ST  - Frequencies of opportunistic diseases prior to death among HIV-infected persons
T2  - AIDS
TI  - Frequencies of opportunistic diseases prior to death among HIV-infected persons
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L25280007&from=export
http://dx.doi.org/10.1097/00002030-199510000-00005
VL  - 9
ID  - 1340
ER  - 

TY  - JOUR
AB  - The authors prospectively examined the relation of fruit and vegetable intake to breast cancer risk among 51,928 women aged 21-69 years at enrollment in 1995 in the Black Women's Health Study. Dietary intake was assessed by using a validated food frequency questionnaire. Cox proportional hazards models were used to estimate incidence rate ratios and 95% confidence intervals, adjusted for breast cancer risk factors. During 12 years of follow-up, there were 1,268 incident cases of breast cancer. Total fruit, total vegetable, and total fruit and vegetable intakes were not significantly associated with overall risk of breast cancer. However, total vegetable consumption was associated with a decreased risk of estrogen receptor-negative/progesterone receptor-negative breast cancer (incidence rate ratio = 0.57, 95% confidence interval: 0.38, 0.85, for ≥2 servings/day relative to <4/week; Ptrend = 0.02). In addition, there was some evidence of inverse associations with breast cancer risk overall for cruciferous vegetable intake (Ptrend = 0.06) and for carrot intake (Ptrend = 0.02). Study findings suggest that frequent consumption of vegetables is inversely associated with risk of estrogen receptor-negative/progesterone receptor-negative breast cancer, and that specific vegetables may be associated with a decreased risk of breast cancer overall. © 2010 The Author.
AD  - D. A. Boggs, Slone Epidemiology Center, Boston University, 1010 Commonwealth Avenue, Boston, MA 02215, United States
AU  - Boggs, D. A.
AU  - Palmer, J. R.
AU  - Wise, L. A.
AU  - Spiegelman, D.
AU  - Stampfer, M. J.
AU  - Adams-Campbell, L. L.
AU  - Rosenberg, L.
DB  - Embase
Medline
DO  - 10.1093/aje/kwq293
IS  - 11
KW  - estrogen receptor
progesterone receptor
adult
African American
aged
article
breast cancer
cancer risk
clinical evaluation
clinical trial
dietary intake
female
food frequency questionnaire
fruit
health food
human
incidence
major clinical study
nutritional assessment
portion size
proportional hazards model
prospective study
vegetable
LA  - English
M3  - Article
N1  - L360073532
2010-12-09
2010-12-14
PY  - 2010
SN  - 0002-9262
1476-6256
SP  - 1268-1279
ST  - Fruit and vegetable intake in relation to risk of breast cancer in the black women's health study
T2  - American Journal of Epidemiology
TI  - Fruit and vegetable intake in relation to risk of breast cancer in the black women's health study
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L360073532&from=export
http://dx.doi.org/10.1093/aje/kwq293
VL  - 172
ID  - 1152
ER  - 

TY  - JOUR
AB  - Women of minority race/ethnicity have been underrepresented in United States-based breast cancer chemoprevention trials. Searches of Medline between 1966 and 2004 were done with priority given to recent reports (1996-2004), and references from bibliographies of relevant articles. Large chemoprevention trials have reported significant breast cancer risk reduction and increased risk of serious adverse events in tamoxifen-treated, high-risk women, which illustrates the need to carefully assess the risk/benefits of this therapy. The mathematical model used for this purpose in the United States-based trials has resulted in the inclusion of very few women of minority racial/ethnic backgrounds. The continued use of this risk assessment that has not been adequately validated for its usefulness in non-Caucasian populations, should be reviewed, especially given that adequate alternative nonmathematical models exist. Current and future chemoprevention trials should also use nonmathematical selection criteria to ensure that eligible underrepresented minorities are adequately included in these trials.
AD  - Chronic Disease Prevention and Control Research Center, Baylor College of Medicine, 1709 Dryden Road, Suite 1025, Houston, TX 77030, USA. mfonc@bcm.tmc.edu
AN  - 16599373
AU  - Cyrus-David, M. S.
DA  - Winter
DP  - NLM
ET  - 2006/04/08
IS  - 1
KW  - Adult
African Americans
Antineoplastic Agents, Hormonal/therapeutic use
Breast Neoplasms/*prevention & control
*Chemoprevention
Clinical Trials as Topic
Estrogen Antagonists/therapeutic use
Female
Humans
Raloxifene Hydrochloride/therapeutic use
Tamoxifen/therapeutic use
United States
LA  - eng
N1  - Cyrus-David, Mfon S
K22 CA 100137-02/CA/NCI NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
United States
Ethn Dis. 2006 Winter;16(1):216-22.
PY  - 2006
SN  - 1049-510X (Print)
1049-510x
SP  - 216-22
ST  - The future of women of minority race/ethnicity in breast cancer chemoprevention therapy
T2  - Ethn Dis
TI  - The future of women of minority race/ethnicity in breast cancer chemoprevention therapy
VL  - 16
ID  - 572
ER  - 

TY  - JOUR
AB  - BACKGROUND: Previous research has shown colorectal cancer (CRC) screening disparities by gender. Little research has focused primarily on gender differences among older Black individuals, and reasons for existing gender differences remain poorly understood. METHODS: We used baseline data from the Cancer Prevention and Treatment Demonstration Screening Trial. Participants were recruited from November 2006 to March 2010. In-person interviews were used to assess self-reported CRC screening behavior. Up-to-date CRC screening was defined as self-reported colonoscopy or sigmoidoscopy in the past 10 years or fecal occult blood testing in the past year. We used multivariable logistic regression to examine the association between gender and self-reported screening, adjusting for covariates. The final model was stratified by gender to examine factors differentially associated with screening outcomes for males and females. RESULTS: The final sample consisted of 1,552 female and 586 male Black Medicare beneficiaries in Baltimore, Maryland. Males were significantly less likely than females to report being up-to-date with screening (77.5% vs. 81.6%, P = 0.030), and this difference was significant in the fully adjusted model (OR: 0.72; 95% confidence interval, 0.52-0.99). The association between having a usual source of care and receipt of cancer screening was stronger among males compared with females. CONCLUSIONS: Although observed differences in CRC screening were small, several factors suggest that gender-specific approaches may be used to promote screening adherence among Black Medicare beneficiaries. IMPACT: Given disproportionate CRC mortality between White and Black Medicare beneficiaries, gender-specific interventions aimed at increasing CRC screening may be warranted among older Black patients.
AD  - North Campus Research Complex, 2800 Plymouth Road, Building 16, 4th Floor, Ann Arbor, MI 48109, USA. makathry@med.umich.edu
AN  - 23629519
AU  - Martinez, K. A.
AU  - Pollack, C. E.
AU  - Phelan, D. F.
AU  - Markakis, D.
AU  - Bone, L.
AU  - Shapiro, G.
AU  - Wenzel, J.
AU  - Howerton, M.
AU  - Johnson, L.
AU  - Garza, M. A.
AU  - Ford, J. G.
C2  - PMC3681887
C6  - NIHMS472927 disclose.
DA  - Jun
DO  - 10.1158/1055-9965.Epi-12-1215
DP  - NLM
ET  - 2013/05/01
IS  - 6
KW  - Adenocarcinoma/*diagnosis/prevention & control
African Americans/*statistics & numerical data
Aged
Aged, 80 and over
Baltimore
Colonoscopy
Colorectal Neoplasms/*diagnosis/prevention & control
*Early Detection of Cancer
European Continental Ancestry Group/*statistics & numerical data
Female
Follow-Up Studies
Humans
Male
Medicare
Occult Blood
Prognosis
Sex Factors
Sigmoidoscopy
United States
LA  - eng
N1  - 1538-7755
Martinez, Kathryn A
Pollack, Craig E
Phelan, Darcy F
Markakis, Diane
Bone, Lee
Shapiro, Gary
Wenzel, Jennifer
Howerton, Mollie
Johnson, Lawrence
Garza, Mary A
Ford, Jean G
U54 CA153710/CA/NCI NIH HHS/United States
5T32HS000029-25/HS/AHRQ HHS/United States
K01 CA140358/CA/NCI NIH HHS/United States
U54 CA091409/CA/NCI NIH HHS/United States
K07CA151910/CA/NCI NIH HHS/United States
K07 CA151910/CA/NCI NIH HHS/United States
K01CA140358/CA/NCI NIH HHS/United States
T32 HS000029/HS/AHRQ HHS/United States
P20 MD006737/MD/NIMHD NIH HHS/United States
5U54CA091409-10/CA/NCI NIH HHS/United States
U54CA153710/CA/NCI NIH HHS/United States
Comparative Study
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.
Cancer Epidemiol Biomarkers Prev. 2013 Jun;22(6):1037-42. doi: 10.1158/1055-9965.EPI-12-1215. Epub 2013 Apr 29.
PY  - 2013
SN  - 1055-9965 (Print)
1055-9965
SP  - 1037-42
ST  - Gender differences in correlates of colorectal cancer screening among Black Medicare beneficiaries in Baltimore
T2  - Cancer Epidemiol Biomarkers Prev
TI  - Gender differences in correlates of colorectal cancer screening among Black Medicare beneficiaries in Baltimore
VL  - 22
ID  - 331
ER  - 

TY  - JOUR
AB  - BACKGROUND: Black women are more likely to be diagnosed at a later stage of breast cancer in part due to barriers to timely screening mammography, resulting in poorer mortality and survival outcomes. Patient navigation that helps to overcome barriers to the early detection of breast cancer is an effective intervention for reducing breast cancer disparity. However, the ability to recognize and seek help to overcome barriers may be affected by gendered and racialized social expectations of women. METHODS: Data from a randomized controlled trial, the Patient Navigation in Medically Underserved Areas study, were used. The likelihood of obtaining a follow-up screening mammogram was compared between women who identified ≥1 barriers and those who did not. RESULTS: Of the 3754 women who received the Patient Navigation in Medically Underserved Areas navigation intervention, approximately 14% identified ≥ 1 barriers, which led to additional navigator contacts. Consequently, those women who reported barriers were more likely to obtain a subsequent screening mammogram. Black women, women living in poverty, and women with a higher level of distrust were less likely to report barriers. CONCLUSIONS: Minority women living in poverty have always been the source of social support for others. However, gendered and racialized social expectations may affect the ways in which women seek help for their own health needs. A way to improve the effectiveness of navigation would be to recognize how minority women's gender images and expectations could shape how they seek help and support. A report of no barriers does not always translate into no problems. Proactive approaches to identify potential barriers may be beneficial.
AD  - Division of Health Policy and Administration, School of Public Health, University of Illinois at Chicago, Chicago, Illinois.
College of Medicine, Department of Pediatrics, University of Illinois at Chicago, Chicago, Illinois.
University of Illinois Cancer Center, Chicago, Illinois.
Division of Community Health Science, School of Public Health, University of Illinois at Chicago, Chicago, Illinois.
Center for Population Science and Discovery, University of Arizona Health Sciences, Tucson, Arizona.
AN  - 30246241
AU  - Kim, S. J.
AU  - Glassgow, A. E.
AU  - Watson, K. S.
AU  - Molina, Y.
AU  - Calhoun, E. A.
C2  - PMC6487877
C6  - NIHMS974207
DA  - Nov 15
DO  - 10.1002/cncr.31636
DP  - NLM
ET  - 2018/09/25
IS  - 22
KW  - African Americans/statistics & numerical data
Breast Neoplasms/*diagnostic imaging/*ethnology
Chicago/ethnology
*Delayed Diagnosis/statistics & numerical data
Early Detection of Cancer
Female
Health Services Accessibility
Humans
Mammography/statistics & numerical data
Mass Screening
Medically Underserved Area
Middle Aged
Patient Navigation/*methods
Program Evaluation
Randomized Controlled Trials as Topic
Socioeconomic Factors
*barriers
*breast cancer
*diagnostic mammography
*distrust
*gendered social norms
*health disparity
LA  - eng
N1  - 1097-0142
Kim, Sage J
Glassgow, Anne Elizabeth
Watson, Karriem S
Molina, Yamile
Calhoun, Elizabeth A
P20 CA202908/CA/NCI NIH HHS/United States
3P60 MD003424-03S1/MD/NIMHD NIH HHS/United States
K01 CA193918/CA/NCI NIH HHS/United States
U54 CA202995/CA/NCI NIH HHS/United States
P60 MD003424/MD/NIMHD NIH HHS/United States
U54 CA202997/CA/NCI NIH HHS/United States
U54 CA203000/CA/NCI NIH HHS/United States
Comparative Study
Journal Article
Research Support, N.I.H., Extramural
Cancer. 2018 Nov 15;124(22):4350-4357. doi: 10.1002/cncr.31636. Epub 2018 Sep 24.
PY  - 2018
SN  - 0008-543X (Print)
0008-543x
SP  - 4350-4357
ST  - Gendered and racialized social expectations, barriers, and delayed breast cancer diagnosis
T2  - Cancer
TI  - Gendered and racialized social expectations, barriers, and delayed breast cancer diagnosis
VL  - 124
ID  - 102
ER  - 

TY  - JOUR
AB  - Colorectal cancer rates in Latin American countries are less than half of those observed in the United States. Latin Americans are the resultant of generations of an admixture of Native American, European, and African individuals. The potential role of genetic admixture in colorectal carcinogenesis has not been examined. We evaluate the association of genetic ancestry with colorectal neoplasms in 190 adenocarcinomas, 113 sporadic adenomas and 243 age- and sex-matched controls enrolled in a multicentric case-control study in Colombia. Individual ancestral genetic fractions were estimated using the STRUCTURE software, based on allele frequencies and assuming three distinct population origins. We used the Illumina Cancer Panel to genotype 1,421 sparse single-nucleotide polymorphisms (SNPs), and Northern and Western European ancestry, LWJ and Han Chinese in Beijing, China populations from the HapMap project as references. A total of 678 autosomal SNPs overlapped with the HapMap data set SNPs and were used for ancestry estimations. African mean ancestry fraction was higher in adenomas (0.13, 95% confidence interval (95% CI)=0.11-0.15) and cancer cases (0.14, 95% CI=0.12-0.16) compared with controls (0.11, 95% CI=0.10-0.12). Conditional logistic regression analysis, controlling for known risk factors, showed a positive association of African ancestry per 10% increase with both colorectal adenoma (odds ratio (OR)=1.12, 95% CI=0.97-1.30) and adenocarcinoma (OR=1.19, 95% CI=1.05-1.35). In conclusion, increased African ancestry (or variants linked to it) contributes to the increased susceptibility of colorectal cancer in admixed Latin American population.
AD  - 1] Grupo de Investigacion Epidemiologica, Instituto Nacional de Cancerologia de Colombia, Bogota, Colombia [2] The Roslin Institute, The University of Edinburgh, Edinburgh, UK.
1] Grupo de Investigacion Epidemiologica, Instituto Nacional de Cancerologia de Colombia, Bogota, Colombia [2] Departamento de Quimica, Universidad Nacional de Colombia, Cundinamarca, Colombia.
Facultad de Medicina, Universidad Industrial de Santander, Bucaramanga, Colombia.
Facultad de Medicina, Universidad Libre, Barranquilla, Colombia.
Fundacion Oftalmologica de Santander, Bucaramanga, Colombia.
Department of Pediatrics and Stanley S. Scott Cancer Center, Louisiana State University Health Sciences Center, New Orleans, LA, USA.
1] The Roslin Institute, The University of Edinburgh, Edinburgh, UK [2] MRC-Human Genetics Unit at the MRC IGMM, University of Edinburgh, Edinburgh, UK.
AN  - 24518838
AU  - Hernandez-Suarez, G.
AU  - Sanabria, M. C.
AU  - Serrano, M.
AU  - Herran, O. F.
AU  - Perez, J.
AU  - Plata, J. L.
AU  - Zabaleta, J.
AU  - Tenesa, A.
C2  - PMC4169534
DA  - Oct
DO  - 10.1038/ejhg.2013.310
DP  - NLM
ET  - 2014/02/13
IS  - 10
KW  - Adenocarcinoma/*genetics
African Americans/genetics
Body Mass Index
Case-Control Studies
China
Colorectal Neoplasms/*genetics
Energy Intake
European Continental Ancestry Group/genetics
Female
Gene Frequency
Genetic Predisposition to Disease
Genetics, Population
Genotype
Genotyping Techniques
HapMap Project
Hispanic Americans/*genetics
Humans
Logistic Models
Male
Middle Aged
Polymorphism, Single Nucleotide
Risk Factors
LA  - eng
N1  - 1476-5438
Hernandez-Suarez, Gustavo
Sanabria, Maria Carolina
Serrano, Marta
Herran, Oscar F
Perez, Jesus
Plata, Jose L
Zabaleta, Jovanny
Tenesa, Albert
P20GM103501/GM/NIGMS NIH HHS/United States
Biotechnology and Biological Sciences Research Council/United Kingdom
C12229/A13154/Cancer Research UK/United Kingdom
13154/Cancer Research UK/United Kingdom
P20 RR021970/RR/NCRR NIH HHS/United States
P20 GM103501/GM/NIGMS NIH HHS/United States
Journal Article
Multicenter Study
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Eur J Hum Genet. 2014 Oct;22(10):1208-16. doi: 10.1038/ejhg.2013.310. Epub 2014 Feb 12.
PY  - 2014
SN  - 1018-4813 (Print)
1018-4813
SP  - 1208-16
ST  - Genetic ancestry is associated with colorectal adenomas and adenocarcinomas in Latino populations
T2  - Eur J Hum Genet
TI  - Genetic ancestry is associated with colorectal adenomas and adenocarcinomas in Latino populations
VL  - 22
ID  - 295
ER  - 

TY  - JOUR
AB  - We compared a tailored and a targeted intervention designed to increase genetic testing, clinical breast exam (CBE), and mammography in young breast cancer survivors (YBCS) (diagnosed <45 years old) and their blood relatives. A two-arm cluster randomized trial recruited a random sample of YBCS from the Michigan cancer registry and up to two of their blood relatives. Participants were stratified according to race and randomly assigned as family units to the tailored (n = 637) or the targeted (n = 595) intervention. Approximately 40% of participants were Black. Based on intention-to-treat analyses, YBCS in the tailored arm reported higher self-efficacy for genetic services (p = 0.0205) at 8-months follow-up. Genetic testing increased approximately 5% for YBCS in the tailored and the targeted arm (p ≤ 0.001; p < 0.001) and for Black and White/Other YBCS (p < 0.001; p < 0.001). CBEs and mammograms increased significantly in both arms, 5% for YBCS and 10% for relatives and were similar for Blacks and White/Others. YBCS and relatives needing less support from providers reported significantly higher self-efficacy and intention for genetic testing and surveillance. Black participants reported significantly higher satisfaction and acceptability. Effects of these two low-resource interventions were comparable to previous studies. Materials are suitable for Black women at risk for hereditary breast/ovarian cancer (HBOC).
AD  - Department of Clinical Research, Faculty of Medicine, University of Basel, 4055 Basel, Switzerland.
School of Nursing, University of Michigan, Ann Arbor, MI 48109-5482, USA.
College of Nursing, Ohio State University, Columbus, OH 43210, USA.
Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.
Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI 48109-5618, USA.
School of Public Health, University of Michigan, Ann Arbor, MI 48109-5618, USA.
Statistics Online Computational Resource, School of Nursing, University of Michigan, Ann Arbor, MI 48109-2003, USA.
AN  - 32899538
AU  - Katapodi, M. C.
AU  - Ming, C.
AU  - Northouse, L. L.
AU  - Duffy, S. A.
AU  - Duquette, D.
AU  - Mendelsohn-Victor, K. E.
AU  - Milliron, K. J.
AU  - Merajver, S. D.
AU  - Dinov, I. D.
AU  - Janz, N. K.
C2  - PMC7563571
DA  - Sep 5
DO  - 10.3390/cancers12092526
DP  - NLM
ET  - 2020/09/10
IS  - 9
KW  - Black participants
Hboc
cancer survivorship
cascade genetic testing in families
family recruitment
statewide random sampling
tailored intervention
targeted intervention
LA  - eng
N1  - 2072-6694
Katapodi, Maria C
Orcid: 0000-0003-3903-3750
Ming, Chang
Orcid: 0000-0002-2817-3865
Northouse, Laurel L
Duffy, Sonia A
Duquette, Debra
Orcid: 0000-0003-4664-0495
Mendelsohn-Victor, Kari E
Milliron, Kara J
Merajver, Sofia D
Dinov, Ivo D
Orcid: 0000-0003-3825-4375
Janz, Nancy K
68039/Robert Wood Johnson Foundation Nurse Faculty Scholars Awards/
5U48DP001901-03/CC/CDC HHS/United States
Journal Article
Cancers (Basel). 2020 Sep 5;12(9):2526. doi: 10.3390/cancers12092526.
PY  - 2020
SN  - 2072-6694 (Print)
2072-6694
ST  - Genetic Testing and Surveillance of Young Breast Cancer Survivors and Blood Relatives: A Cluster Randomized Trial
T2  - Cancers (Basel)
TI  - Genetic Testing and Surveillance of Young Breast Cancer Survivors and Blood Relatives: A Cluster Randomized Trial
VL  - 12
ID  - 27
ER  - 

TY  - JOUR
AB  - BACKGROUND: Breast cancer is the most common cancer in women worldwide. Around 50% of breast cancer familial risk has been so far explained by known susceptibility alleles with variable levels of risk and prevalence. The vast majority of these breast cancer associated variations reported to date are from populations of European ancestry. In spite of its heterogeneity and genetic wealth, North-African populations have not been studied by the HapMap and the 1000Genomes projects. Thus, very little is known about the genetic architecture of these populations. METHODS: This study aimed to investigate a subset of common breast cancer loci in the general Tunisian population and to compare their genetic composition to those of other ethnic groups. We undertook a genome-wide haplotype study by genotyping 135 Tunisian subjects using the Affymetrix 6.0-Array. We compared Tunisian allele frequencies and linkage disequilibrium patterns to those of HapMap populations and we performed a comprehensive assessment of the functional effects of several selected variants. RESULTS: Haplotype analyses showed that at risk haplotypes on 2p24, 4q21, 6q25, 9q31, 10q26, 11p15, 11q13 and 14q32 loci are considerably frequent in the Tunisian population (> 20%). Allele frequency comparison showed that the frequency of rs13329835 is significantly different between Tunisian and all other HapMap populations. LD-blocks and Principle Component Analysis revealed that the genetic characteristics of breast cancer variants in the Tunisian, and so probably the North-African populations, are more similar to those of Europeans than Africans. Using eQTl analysis, we characterized rs9911630 as the most strongly expression-associated SNP that seems to affect the expression levels of BRCA1 and two long non coding RNAs (NBR2 and LINC008854). Additional in-silico analysis also suggested a potential functional significance of this variant. CONCLUSIONS: We illustrated the utility of combining haplotype analysis in diverse ethnic groups with functional analysis to explore breast cancer genetic architecture in Tunisia. Results presented in this study provide the first report on a large number of common breast cancer genetic polymorphisms in the Tunisian population which may establish a baseline database to guide future association studies in North Africa.
AD  - Laboratory of biomedical genomics and oncogenetics, Institut Pasteur de Tunis, Université Tunis El Manar, 13, Place Pasteur BP 74, 1002, Tunis, Belvédère, Tunisie. yosr.hamdi.82@gmail.com.
Laboratory of biomedical genomics and oncogenetics, Institut Pasteur de Tunis, Université Tunis El Manar, 13, Place Pasteur BP 74, 1002, Tunis, Belvédère, Tunisie.
Department of Genetic Medicine, Weill Cornell Medical College-Qatar, Doha, Qatar.
Laboratory of Genetics, Immunology and Human Pathology, Department of Biology, Faculty of Sciences of Tunis, University of Tunis El Manar, Tunis, Tunisia.
Department of Human Genetics, Charles Nicolle Hospital, Tunis, Tunisia.
Medical Oncology Department, Abderrahmen Mami Hospital, Ariana, Tunisia.
Department of Biology, Faculty of Science of Bizerte, Université Tunis Carthage, Tunis, Tunisia.
AN  - 30594178
AU  - Hamdi, Y.
AU  - Ben Rekaya, M.
AU  - Jingxuan, S.
AU  - Nagara, M.
AU  - Messaoud, O.
AU  - Benammar Elgaaied, A.
AU  - Mrad, R.
AU  - Chouchane, L.
AU  - Boubaker, M. S.
AU  - Abdelhak, S.
AU  - Boussen, H.
AU  - Romdhane, L.
C2  - PMC6310952
DA  - Dec 29
DO  - 10.1186/s12885-018-5133-8
DP  - NLM
ET  - 2018/12/31
IS  - 1
KW  - Adult
African Continental Ancestry Group/*genetics
Breast Neoplasms/*genetics
Computer Simulation
Female
Gene Frequency/genetics
Genetic Loci/*genetics
*Genetic Predisposition to Disease
*Genome-Wide Association Study
Haplotypes/genetics
Healthy Volunteers
Humans
Linkage Disequilibrium/genetics
Male
Middle Aged
Polymorphism, Single Nucleotide
Tunisia
Breast cancer susceptibility
Functional analysis
Haplotype analysis
Population genetics
institutional review board of Pasteur Institute of Tunis
registration number
(IRB00005445, WA00010074). All patients gave their written informed consent. CONSENT
FOR PUBLICATION: Not applicable. COMPETING INTERESTS: The authors declare that they
have no competing interests. PUBLISHER’S NOTE: Springer Nature remains neutral with
regard to jurisdictional claims in published maps and institutional affiliations.
LA  - eng
N1  - 1471-2407
Hamdi, Yosr
Ben Rekaya, Mariem
Jingxuan, Shan
Nagara, Majdi
Messaoud, Olfa
Benammar Elgaaied, Amel
Mrad, Ridha
Chouchane, Lotfi
Boubaker, Mohamed Samir
Abdelhak, Sonia
Boussen, Hamouda
Romdhane, Lilia
NPRP 08-083-3-031/Qatar National Research Fund/
Comparative Study
Journal Article
BMC Cancer. 2018 Dec 29;18(1):1295. doi: 10.1186/s12885-018-5133-8.
PY  - 2018
SN  - 1471-2407
SP  - 1295
ST  - A genome wide SNP genotyping study in the Tunisian population: specific reporting on a subset of common breast cancer risk loci
T2  - BMC Cancer
TI  - A genome wide SNP genotyping study in the Tunisian population: specific reporting on a subset of common breast cancer risk loci
VL  - 18
ID  - 89
ER  - 

TY  - JOUR
AB  - OBJECTIVE: Taxane containing chemotherapy extends survival for breast cancer patients. However, taxane-induced peripheral neuropathy (TIPN) cannot be predicted, prevented or effectively treated. Using genome-wide analyses, we sought to identify common risk variants for TIPN. PATIENTS AND METHODS: Women with high-risk breast cancer enrolled in SWOG 0221 were genotyped using the Illumina 1M chip. Genome-wide analyses were performed in relation to ≥grade 3 Common Terminology Criteria for Adverse Events (CTCAE) neuropathy in European and African Americans. Data were meta-analyzed with GW associations of CTCAE ≥grade 3 versus <grade 3 in CALGB 40101 assuming a fixed effects model. RESULTS: The percentage of ≥grade 3 TIPN in 1269 European Americans and 139 African Americans in S0221, was 11.6 and 22.3%, respectively. CALGB 40101 ≥grade 3 TOPN was 7.2%. The most significant association with ≥grade 3 TIPN was the G allele of rs1858826 in GNGT1 (Pmeta=1.1×10), which showed a decrease in risk of ≥grade 3 TIPN (odds ratio=0.29, 95% confidence interval: 0.18-0.46). CONCLUSION: The genetic variants associated with ≥grade 3 TIPN are hypothesized to have biochemical functions and reside in and near genes involved in diabetes and diabetic neuropathy. This finding is consistent with results from CALGB 40101 pathway analyses. Larger homogeneous trials with similar dosing and criteria for defining neuropathy are needed to properly assess the relationship of genomics with the neuropathy spectrum.
AD  - The Ohio State University, Columbus.
Mayo Clinic, Rochester, Minnesota.
SWOG Statistical Center.
Cleveland Clinic, Cleveland, Ohio.
University of Southern California, Los Angeles.
Roswell Park Cancer Institute, Buffalo.
Alliance Statistics and Data Center, Duke University Medical Center.
Duke University, Durham, North Carolina.
Columbia University, New York, New York.
Loyola University Chicago Cardinal Bernardin Cancer Center, Maywood, Illinois.
University of Michigan, Ann Arbor, Michigan.
Baystate Medical Center, Springfield, Massachusetts.
Georgetown University, Washington, District of Columbia.
Allan Blair Cancer Centre, Regina, Saskatchewan, Canada.
Seattle Cancer Care Alliance, Seattle.
MD Anderson Cancer Center, Houston, Texas.
Arizona Cancer Center, Tucson, Arizona, USA.
University of California San Francisco, San Francisco, California.
AN  - 29278617
AU  - Sucheston-Campbell, L. E.
AU  - Clay-Gilmour, A. I.
AU  - Barlow, W. E.
AU  - Budd, G. T.
AU  - Stram, D. O.
AU  - Haiman, C. A.
AU  - Sheng, X.
AU  - Yan, L.
AU  - Zirpoli, G.
AU  - Yao, S.
AU  - Jiang, C.
AU  - Owzar, K.
AU  - Hershman, D.
AU  - Albain, K. S.
AU  - Hayes, D. F.
AU  - Moore, H. C.
AU  - Hobday, T. J.
AU  - Stewart, J. A.
AU  - Rizvi, A.
AU  - Isaacs, C.
AU  - Salim, M.
AU  - Gralow, J. R.
AU  - Hortobagyi, G. N.
AU  - Livingston, R. B.
AU  - Kroetz, D. L.
AU  - Ambrosone, C. B.
C2  - PMC5824720
C6  - NIHMS913836
DA  - Feb
DO  - 10.1097/fpc.0000000000000318
DP  - NLM
ET  - 2017/12/27
IS  - 2
KW  - African Americans/genetics
Breast Neoplasms/complications/*drug therapy/genetics/pathology
Bridged-Ring Compounds/*adverse effects/therapeutic use
European Continental Ancestry Group/genetics
Female
*Genetic Predisposition to Disease
Genome-Wide Association Study
Genomics
Genotype
Humans
Peripheral Nervous System Diseases/*genetics/pathology
Polymorphism, Single Nucleotide
Taxoids/*adverse effects/therapeutic use
LA  - eng
N1  - 1744-6880
Sucheston-Campbell, Lara E
Clay-Gilmour, Alyssa I
Barlow, William E
Budd, G Thomas
Stram, Daniel O
Haiman, Christopher A
Sheng, Xin
Yan, Li
Zirpoli, Gary
Yao, Song
Jiang, Chen
Owzar, Kouros
Hershman, Dawn
Albain, Kathy S
Hayes, Daniel F
Moore, Halle C
Hobday, Timothy J
Stewart, James A
Rizvi, Abbas
Isaacs, Claudine
Salim, Muhammad
Gralow, Jule R
Hortobagyi, Gabriel N
Livingston, Robert B
Kroetz, Deanna L
Ambrosone, Christine B
R25 CA092049/CA/NCI NIH HHS/United States
UG1 CA189974/CA/NCI NIH HHS/United States
U10 CA180821/CA/NCI NIH HHS/United States
U10 CA180801/CA/NCI NIH HHS/United States
R01 CA095222/CA/NCI NIH HHS/United States
S10 OD018164/OD/NIH HHS/United States
U10 CA180888/CA/NCI NIH HHS/United States
U10 CA180819/CA/NCI NIH HHS/United States
U24 CA114748/CA/NCI NIH HHS/United States
U10 CA180866/CA/NCI NIH HHS/United States
Journal Article
Meta-Analysis
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Pharmacogenet Genomics. 2018 Feb;28(2):49-55. doi: 10.1097/FPC.0000000000000318.
PY  - 2018
SN  - 1744-6872 (Print)
1744-6872
SP  - 49-55
ST  - Genome-wide meta-analyses identifies novel taxane-induced peripheral neuropathy-associated loci
T2  - Pharmacogenet Genomics
TI  - Genome-wide meta-analyses identifies novel taxane-induced peripheral neuropathy-associated loci
VL  - 28
ID  - 139
ER  - 

TY  - JOUR
AB  - Background: Prostate cancer incidence rates vary, 25-fold worldwide. Differences in PSA screening are largely, but not entirely, responsible. We examined geographic differences in prevalence of histologic prostate inflammation and subsequent prostate cancer risk. Methods: Seven thousand nonHispanic white men were enrolled in the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial from Europe (n - 4,644), North America (n - 1,746), South America (n 466), and Australia/New Zealand (n - 144). Histologic inflammation in baseline negative prostate biopsies was classified as chronic (lymphocytes/macrophages ) acute (neutrophils). Multivariable logistic regression was used to examine associations between region and prostate inflammation, and between region and prostate cancer risk at 2-year biopsy. Results: Prevalence of prostate inflammation varied across region, with broadly similar patterns for acute and chronic inflammation. Relative to Europe, prevalence of acute inflammation was higher in North America [odds ratio (OR), 1.77; 95% confidence interval (CI), 1.51-2.08] and Australia, 'New Zealand (OR, 2.07; 95% CI, 1.40-3,06). Men front these regions had lower prostate cancer risk than Europeans at biopsy. Among North Americans, prevalence of acute inflammation was higher in Canada versus the United States (OR, 1.40; 95% CI, 1.07-1.83), but prostate cancer risk did not differ between these regions. Among Europeans, prevalence of acute inflammation was lower in Northern and Eastern (OR, 0.79; 95% CI, 0.65-0.9 7 and OR 0.62; 95% CI, 0.45-0.87, respectively), relative t o Western Europe, and these men had higher prostate cancer risk at biopsy. Conclusions: Prevalence of histologic prostate inflammation varied by region. Geographic differences in prostate inflammation tracked inversely with geographic differences in prostate cancer risk. Impact: Characterization of premalignant prostate biology and the relationship with subsequent prostate cancer risk could inform prostate cancer prevention efforts. (C)2018 AACR.
AN  - WOS:000437461100009
AU  - Allott, E. H.
AU  - Markt, S. C.
AU  - Howard, L. E.
AU  - Vidal, A. C.
AU  - Moreira, D. M.
AU  - Castro-Santamaria, R.
AU  - Andriole, G. L.
AU  - Mucci, L. A.
AU  - Freedland, S. J.
DA  - Jul
DO  - 10.1158/1055-9965.EPI-18-0076
IS  - 7
N1  - 29669727
PY  - 2018
SN  - 1055-9965
SP  - 783-789
ST  - Geographic Differences in Baseline Prostate Inflammation and Relationship with Subsequent Prostate Cancer Risk: Results from the Multinational REDUCE Trial
T2  - Cancer Epidemiology Biomarkers & Prevention
TI  - Geographic Differences in Baseline Prostate Inflammation and Relationship with Subsequent Prostate Cancer Risk: Results from the Multinational REDUCE Trial
VL  - 27
ID  - 2852
ER  - 

TY  - JOUR
AB  - IMPORTANCE: Studies showing that patients with cancer from rural areas have worse outcomes than their urban counterparts have relied on cancer population data and did not account for differences in access to care. Clinical trial patients receive protocol-directed care by design, so large clinical trial databases are ideal for examining the impact of rural vs urban residency on outcomes. OBJECTIVE: To compare the geographic distribution and survival outcomes for rural vs urban patients with cancer treated in clinical trials. DESIGN, SETTING, AND PARTICIPANTS: In this comparative effectiveness retrospective cohort analysis, 36 995 patients from all 50 states enrolled in 44 phase 3 and phase 2/3 SWOG (formerly the Southwest Oncology Group) treatment trials from January 1, 1986, to December 31, 2012, were examined. Seventeen different cancer-specific analysis cohorts were constructed. Data through January 30, 2018, were analyzed. MAIN OUTCOMES AND MEASURES: Rural vs urban residency was defined using the Rural-Urban Continuum Codes developed by the US Department of Agriculture. Multivariate Cox regression was used to estimate the association of residency with overall survival, progression-free survival, and cancer-specific survival, controlling for major disease-specific prognostic factors and demographic variables and stratifying by study. Different definitions of rurality were examined. The distribution of rural vs urban patients by geographic region was described. RESULTS: Overall, 27.7% of patients were 65 years or older (range across 17 cohort analyses, 7.8%-74.5%), 40.3% were female in the non-sex-specific analyses (range across 17 cohort analyses, 28.1%-45.9%), and 10.8% were black (range across 17 cohort analyses, 1.9%-22.4%). Overall, 19.4% of patients (7184 of 36 995) were from rural locations. Rural patients were more likely to be aged 65 years or older (rural, 30.7% aged ≥65 years vs urban, 27.0% aged ≥65 years; difference, 3.7%; 95% CI, 2.5%-4.9%; P < .001), were less likely to be black (rural, 5.4% vs urban, 12.1%; difference, 6.7%; 95% CI, 6.1%-7.3%; P < .001), were similar with respect to sex (rural, 40.4% female vs urban, 39.7% female; difference, 0.6%; 95% CI, -1.4% to 2.6%; P = .53), and were well represented within major US geographic regions (West, Midwest, South, and Northeast). Clinical prognostic factors were similar. In multivariable regression, rural patients with adjuvant-stage estrogen receptor-negative and progesterone receptor-negative breast cancer had worse overall survival (hazard ratio, 1.27; 95% CI, 1.06-1.51; P = .008) and cancer-specific survival (hazard ratio, 1.26; 95% CI, 1.04-1.52; P = .02). No other statistically significant differences for overall, progression-free, or cancer-specific survival were found. Results were consistent regardless of the definition of rurality. CONCLUSIONS AND RELEVANCE: Rural and urban patients with uniform access to cancer care through participation in a SWOG clinical trial had similar outcomes. This finding suggests that improving access to uniform treatment strategies for patients with cancer may help resolve the disparity in cancer outcomes between rural and urban patients.
AD  - SWOG Statistics and Data Management Center, Seattle, Washington.
Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Sweetwater Regional Cancer Center, Memorial Hospital of Sweetwater County, Rock Springs, Wyoming.
Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston.
Columbia University Medical Center, New York, New York.
AN  - 30646114
AU  - Unger, J. M.
AU  - Moseley, A.
AU  - Symington, B.
AU  - Chavez-MacGregor, M.
AU  - Ramsey, S. D.
AU  - Hershman, D. L.
C2  - PMC6324281 and the National Cancer Institute during the conduct of the study. Ms Moseley reported other support from the National Cancer Institute during the conduct of the study. Dr Chavez-MacGregor reported employment in MD Anderson Physician’s Network, consulting or advisory roles for Pfizer and Roche/Genentech, research funding from Novartis, and travel funding from Pfizer. Dr Ramsey reported consulting or advisory roles for Bayer, Bristol-Myers Squibb, Genentech, Kite Pharma, and Seattle Genetics; research funding from Bayer and Bristol-Myers Squibb; and travel funding from Bayer Schering Pharma, Bristol-Myers Squibb, and Flatiron Health. No other disclosures were reported.
DA  - Aug 3
DO  - 10.1001/jamanetworkopen.2018.1235
DP  - NLM
ET  - 2019/01/16
IS  - 4
KW  - Aged
Clinical Trials as Topic
Cohort Studies
Female
Geography
Health Status Disparities
Healthcare Disparities/statistics & numerical data
Humans
Male
Middle Aged
Neoplasms/*mortality/*therapy
Retrospective Studies
Rural Health
Survival Rate
United States
Urban Health
LA  - eng
N1  - 2574-3805
Unger, Joseph M
Moseley, Anna
Symington, Banu
Chavez-MacGregor, Mariana
Ramsey, Scott D
Hershman, Dawn L
U10 CA180819/CA/NCI NIH HHS/United States
UG1 CA189974/CA/NCI NIH HHS/United States
Comparative Study
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
JAMA Netw Open. 2018 Aug 3;1(4):e181235. doi: 10.1001/jamanetworkopen.2018.1235.
PY  - 2018
SN  - 2574-3805
SP  - e181235
ST  - Geographic Distribution and Survival Outcomes for Rural Patients With Cancer Treated in Clinical Trials
T2  - JAMA Netw Open
TI  - Geographic Distribution and Survival Outcomes for Rural Patients With Cancer Treated in Clinical Trials
VL  - 1
ID  - 84
ER  - 

TY  - JOUR
AB  - PURPOSE: There is increased interest in developing and disseminating health behavior interventions for cancer survivors. Challenges in these efforts include participant burden in traveling to central intervention sites and sustainability. The purpose of this article is to report various methods used to recruit breast cancer survivors into an exercise intervention that attempts to address both of these challenges. METHODS: Letters were mailed within specific zip codes near community-based intervention sites in cooperation with state cancer registries. Additional recruitment methods included flyers at breast care clinics and support groups, mass media, and conferences. RESULTS: Of the 3200 women who responded, 82% (n = 2625) identified having heard about the study through state or hospital registry and 8% (n = 243) through print and broadcast media. Thirty-five percent (n = 103) of randomized women self-identified as having a minority racial background and 31.9% (n = 94) self-identified as African American. Comparisons of participant age and racial distribution to state cancer registries indicate similar age distribution but greater racial diversity among participants. CONCLUSION: These results support the use of population-based cancer registries to recruit survivors into community-based interventions and clinical trials.
AD  - Center for Clinical Epidemiology and Biostatistics, School of Medicine, University of Pennsylvania, Philadelphia, PA 19104-6021, USA.
AN  - 19516160
AU  - Rogerino, A.
AU  - Grant, L. L.
AU  - Wilcox, H., 3rd
AU  - Schmitz, K. H.
DA  - Jul
DO  - 10.1249/MSS.0b013e31819af871
DP  - NLM
ET  - 2009/06/12
IS  - 7
KW  - Adult
Aged
Aged, 80 and over
Breast Neoplasms/*drug therapy/epidemiology/therapy
*Community-Based Participatory Research
Data Collection
*Exercise
*Exercise Therapy
Female
Geography
*Health Behavior
Humans
Middle Aged
New Jersey/epidemiology
Pennsylvania/epidemiology
Physical Fitness
Registries
Survival Analysis
Time Factors
United States/epidemiology
LA  - eng
N1  - 1530-0315
Rogerino, Amy
Grant, Lorita L
Wilcox, Homer 3rd
Schmitz, Kathryn H
R01 CA106851/CA/NCI NIH HHS/United States
UL1 RR024134/RR/NCRR NIH HHS/United States
R01-CA106851/CA/NCI NIH HHS/United States
RR024134/RR/NCRR NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
United States
Med Sci Sports Exerc. 2009 Jul;41(7):1413-20. doi: 10.1249/MSS.0b013e31819af871.
PY  - 2009
SN  - 0195-9131
SP  - 1413-20
ST  - Geographic recruitment of breast cancer survivors into community-based exercise interventions
T2  - Med Sci Sports Exerc
TI  - Geographic recruitment of breast cancer survivors into community-based exercise interventions
VL  - 41
ID  - 466
ER  - 

TY  - JOUR
AB  - Introduction: Multiple myeloma (MM) is a disease of older adults, yet standard baseline assessments do not include assessment of physiologic age or frailty. In older adults with cancer, geriatric assessment (GA) predicts treatment toxicity and survival. In MM, frailty is associated with treatment discontinuation, toxicity and survival (Palumbo Blood 201 5). Studies of patient preferences have shown that maintenance of independence in daily activities is a high priority in older adults with serious medical conditions (Fried NEJM2002) We sought to examine GA factors associated with 1) autologous stem cell transplant (ASCT) eligibility and 2) increased functional dependence over follow‐up. Methods: Patients (pts) with newly diagnosed MM aged 65 and older were enrolled in a prospective cohort study at 2 institutions. Pts underwent a brief, primarily self‐administered geriatric assessment (GA) at baseline, 3‐and 6‐months of follow‐up. GA included functional status (instrumental activities of daily living/IADLs), medications, cognition (Short Blessed Test), psychological state (Mental Health Inventory), the Timed Up and Go physical performance test (TUG) and the Charlson comorbidity index (CCI). Analyses were performed using SAS v9.4/Stata 14.1. Descriptive and inferential statistics were used to summarize and compare groups, as appropriate. Results: 40 pts enrolled, with a median age of 69.5 (range 65‐84). 77.5% were white, 12.5% black and 10% other/unknown. 62.5% were male. Median MD‐rated Karnofsky performance status (KPS) was 80 (range 50‐100). Geriatric syndromes were common, with 62.5% of patients reporting dependence in one or more IADLs, 47.5% with one or more comorbidities, 28.5% reported one or more falls in the prior 6 months and 10% screened positive for cognitive impairment. Median number of medications was 9 (range 1‐23). 26 pts (65%) were felt to be ASCT candidates by the treating physician, who was blinded to the GA. Factors associated with MD‐determined ASCT candidacy were: fewer comorbidities (mean CCI 0.6 vs. 1.9. p=0.0065), higher MD‐rated KPS (71% MDKPS >80 vs 47%, p=0.021) and faster TUG (mean 11.9 seconds vs 15.8, p=0.013). While 26 were considered eligible, only 21 pts (52.5%) ultimately underwent ASCT [attrition due to pt preference (2), progression (1), failed mobilization (1) and unknown (1)]. Increasing age (OR 0.77/year, 95%CI 0.601‐0.988) and IADL dependence (OR 0.043, 95% CI 0.004‐0.464), but not KPS or comorbidities, were independently associated with decreased odds of actually undergoing ASCT. We also examined factors associated with changes in functional status in the 36 patients who completed 6‐month follow‐up. 6 pts (16.7%) had a 2 point increase in dependence in IADLs. In a generalized linear model, undergoing ASCT and baseline comorbidities were independently associated with higher IADL scores at 6‐months (p=0.036, p=0.033 respectively). All patients with an increase in IADL scores (increased functional dependence) had a change in treatment regimen due to toxicity. Age, International Staging System Stage, gender, deletion 17p and disease progression were not associated with increased functional dependence. Development of peripheral neuropathy was not associated with IADL dependence or falls. Conclusions: GA reveals that geriatric syndromes are common in older adults with multiple myeloma. GA may provide a framework to objectively define transplant eligibility. Increased functional dependence is associated with baseline comorbidities and undergoing ASCT. Further study is needed to examine the utility of GA in predicting treatment toxicity and survival.
AN  - CN-01334746
AU  - Wildes, T. M.
AU  - Tuchman, S.
AU  - Trinkaus, K. M.
AU  - Colditz, G.
IS  - 22) (no pagination
KW  - *geriatric assessment
*multiple myeloma
Adult
Aged
Charlson Comorbidity Index
Clinical article
Clinical trial
Cognitive defect
Cohort analysis
Controlled clinical trial
Controlled study
Daily life activity
Diagnosis
Disease course
Female
Follow up
Functional status
Gender
Gene deletion
Human
Inferential statistics
Karnofsky Performance Status
Male
Mental health
Patient preference
Peripheral neuropathy
Physical performance
Physician
Single blind procedure
Staging
Statistical model
Stem cell
Syndrome
Timed Up and Go Test
Toxicity
M3  - Journal: Conference Abstract
PY  - 2016
ST  - Geriatric assessment in older adults with multiple myeloma
T2  - Blood. Conference: 58th annual meeting of the american society of hematology, ASH 2016. United states. Conference start: 20161203. Conference end: 20161206
TI  - Geriatric assessment in older adults with multiple myeloma
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01334746/full
VL  - 128
ID  - 1471
ER  - 

TY  - JOUR
AB  - Despite higher rates of prostate cancer-related mortality and later stage of prostate cancer diagnosis, Black/African American men are significantly less likely than non-Hispanic White men to use early detection screening tools, like prostate-specific antigen (PSA) testing for prostate cancer. Lower screening rates may be due, in part, to controversy over the value of prostate cancer screenings as part of routine preventive care for men, but Black men represent a high-risk group for prostate cancer that may still benefit from PSA testing. Exploring the role of social factors that might be associated with PSA testing can increase knowledge of what might promote screening behaviors for prostate cancer and other health conditions for which Black men are at high risk. Using multilevel logistic regression, this study analyzed self-report lifetime use of PSA test for 829 Black men older than 45 years across 381 Philadelphia census tracts. This study included individual demographic and aggregated social capital data from the Public Health Management Corporation's 2004, 2006, and 2008 waves of the Community Health Database, and sociodemographic characteristics from the 2000 U.S. Census. Each unit increase in community participation was associated with a 3 to 3.5 times greater likelihood of having had a PSA test (odds ratio = 3.35). Findings suggest that structural forms of social capital may play a role in screening behaviors for Black men in Philadelphia. A better understanding of the mechanism underlying the link between social capital and screening behaviors can inform how researchers and interventionists develop tools to promote screening for those who need it.
AD  - School of Medicine, University of Pennsylvania, Philadelphia, PA, USA ldean@post.harvard.edu.
Harvard School of Public Health, Boston, MA, USA.
Massachusetts General Hospital, Boston, MA, USA.
School of Arts and Sciences, University of Pennsylvania, Philadelphia, PA, USA.
AN  - 25117538
AU  - Dean, L. T.
AU  - Subramanian, S. V.
AU  - Williams, D. R.
AU  - Armstrong, K.
AU  - Zubrinsky Charles, C.
AU  - Kawachi, I.
C2  - PMC4472568
C6  - NIHMS697212
DA  - Sep
DO  - 10.1177/1557988314546491
DP  - NLM
ET  - 2014/08/15
IS  - 5
KW  - *African Continental Ancestry Group
Age Factors
*Community Participation
Health Surveys
Humans
Income
Insurance Coverage
Insurance, Health
Male
Mass Screening/*statistics & numerical data
Middle Aged
Multivariate Analysis
Philadelphia/epidemiology
Prostate-Specific Antigen/blood
Prostatic Neoplasms/blood/*prevention & control
*Social Capital
Black/African American men
Philadelphia
community participation
prostate cancer
prostate-specific antigen (PSA)
screening
social capital
of interest with respect to the research, authorship, and/or publication of this
article.
LA  - eng
N1  - 1557-9891
Dean, Lorraine T
Subramanian, S V
Williams, David R
Armstrong, Katrina
Zubrinsky Charles, Camille
Kawachi, Ichiro
F31 CA136236/CA/NCI NIH HHS/United States
K01 CA184288/CA/NCI NIH HHS/United States
1F31CA136236/CA/NCI NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
Am J Mens Health. 2015 Sep;9(5):385-96. doi: 10.1177/1557988314546491. Epub 2014 Aug 12.
PY  - 2015
SN  - 1557-9883 (Print)
1557-9883
SP  - 385-96
ST  - Getting Black Men to Undergo Prostate Cancer Screening: The Role of Social Capital
T2  - Am J Mens Health
TI  - Getting Black Men to Undergo Prostate Cancer Screening: The Role of Social Capital
VL  - 9
ID  - 279
ER  - 

TY  - JOUR
AB  - BACKGROUND: There is increasing evidence that both green and black tea are beneficial for cardiovascular disease (CVD) prevention. OBJECTIVES: To determine the effects of green and black tea on the primary prevention of CVD. SEARCH METHODS: We searched the following databases on 12 October 2012 without language restrictions: CENTRAL in The Cochrane Library, MEDLINE (OVID), EMBASE (OVID) and Web of Science (Thomson Reuters). We also searched trial registers, screened reference lists and contacted authors for additional information where necessary. SELECTION CRITERIA: Randomised controlled trials (RCTs) lasting at least three months involving healthy adults or those at high risk of CVD. Trials investigated the intake of green tea, black tea or tea extracts. The comparison group was no intervention, placebo or minimal intervention. The outcomes of interest were CVD clinical events and major CVD risk factors. Any trials involving multifactorial lifestyle interventions or focusing on weight loss were excluded to avoid confounding. DATA COLLECTION AND ANALYSIS: Two review authors independently selected trials for inclusion, abstracted data and assessed the risk of bias. Trials of green tea were analysed separately from trials of black tea. MAIN RESULTS: We identified 11 RCTs with a total of 821 participants, two trials awaiting classification and one ongoing trial. Seven trials examined a green tea intervention and four examined a black tea intervention. Dosage and form of both green and black tea differed between trials. The ongoing trial is examining the effects of green tea powder capsules.No studies reported cardiovascular events.Black tea was found to produce statistically significant reductions in low-density lipoprotein (LDL) cholesterol (mean difference (MD) -0.43 mmol/L, 95% confidence interval (CI) -0.56 to -0.31) and blood pressure (systolic blood pressure (SBP): MD -1.85 mmHg, 95% CI -3.21 to -0.48. Diastolic blood pressure (DBP): MD -1.27 mmHg, 95% CI -3.06 to 0.53) over six months, stable to sensitivity analysis, but only a small number of trials contributed to each analysis and studies were at risk of bias.Green tea was also found to produce statistically significant reductions in total cholesterol (MD -0.62 mmol/L, 95% CI -0.77 to -0.46), LDL cholesterol (MD -0.64 mmol/L, 95% CI -0.77 to -0.52) and blood pressure (SBP: MD -3.18 mmHg, 95% CI -5.25 to -1.11; DBP: MD -3.42, 95% CI -4.54 to -2.30), but only a small number of studies contributed to each analysis, and results were not stable to sensitivity analysis. When both tea types were analysed together they showed favourable effects on LDL cholesterol (MD -0.48 mmol/L, 95% CI -0.61 to -0.35) and blood pressure (SBP: MD -2.25 mmHg, 95% CI -3.39 to -1.11; DBP: MD -2.81 mmHg, 95% CI -3.77 to -1.86). Adverse events were measured in five trials and included a diagnosis of prostate cancer, hospitalisation for influenza, appendicitis and retinal detachment but these are unlikely to be directly attributable to the intervention. AUTHORS' CONCLUSIONS: There are very few long-term studies to date examining green or black tea for the primary prevention of CVD. The limited evidence suggests that tea has favourable effects on CVD risk factors, but due to the small number of trials contributing to each analysis the results should be treated with some caution and further high quality trials with longer-term follow-up are needed to confirm this.
AD  - Division of Health Sciences, Warwick Medical School, University of Warwick, Coventry, UK.
AN  - 23780706
AU  - Hartley, L.
AU  - Flowers, N.
AU  - Holmes, J.
AU  - Clarke, A.
AU  - Stranges, S.
AU  - Hooper, L.
AU  - Rees, K.
C2  - PMC7433290
DA  - Jun 18
DO  - 10.1002/14651858.CD009934.pub2
DP  - NLM
ET  - 2013/06/20
IS  - 6
KW  - *Beverages
Blood Pressure/physiology
*Camellia sinensis
Cardiovascular Diseases/*prevention & control
Cholesterol/blood
Humans
Phytotherapy/*methods
Primary Prevention/*methods
Randomized Controlled Trials as Topic
Tea
LA  - eng
N1  - 1469-493x
Hartley, Louise
Flowers, Nadine
Holmes, Jennifer
Clarke, Aileen
Stranges, Saverio
Hooper, Lee
Rees, Karen
10/4001/13/Department of Health/United Kingdom
SRP/10/4001/13/Department of Health/United Kingdom
Journal Article
Meta-Analysis
Research Support, Non-U.S. Gov't
Review
Systematic Review
Cochrane Database Syst Rev. 2013 Jun 18;2013(6):CD009934. doi: 10.1002/14651858.CD009934.pub2.
PY  - 2013
SN  - 1361-6137
SP  - Cd009934
ST  - Green and black tea for the primary prevention of cardiovascular disease
T2  - Cochrane Database Syst Rev
TI  - Green and black tea for the primary prevention of cardiovascular disease
VL  - 2013
ID  - 328
ER  - 

TY  - JOUR
AB  - BACKGROUND: This review is an update of a previously published review in the Cochrane Database of Systematic Reviews (2009, Issue 3).Tea is one of the most commonly consumed beverages worldwide. Teas from the plant Camellia sinensis can be grouped into green, black and oolong tea, and drinking habits vary cross-culturally. C sinensis contains polyphenols, one subgroup being catechins. Catechins are powerful antioxidants, and laboratory studies have suggested that these compounds may inhibit cancer cell proliferation. Some experimental and nonexperimental epidemiological studies have suggested that green tea may have cancer-preventative effects. OBJECTIVES: To assess possible associations between green tea consumption and the risk of cancer incidence and mortality as primary outcomes, and safety data and quality of life as secondary outcomes. SEARCH METHODS: We searched eligible studies up to January 2019 in CENTRAL, MEDLINE, Embase, ClinicalTrials.gov, and reference lists of previous reviews and included studies. SELECTION CRITERIA: We included all epidemiological studies, experimental (i.e. randomised controlled trials (RCTs)) and nonexperimental (non-randomised studies, i.e. observational studies with both cohort and case-control design) that investigated the association of green tea consumption with cancer risk or quality of life, or both. DATA COLLECTION AND ANALYSIS: Two or more review authors independently applied the study criteria, extracted data and assessed methodological quality of studies. We summarised the results according to diagnosis of cancer type. MAIN RESULTS: In this review update, we included in total 142 completed studies (11 experimental and 131 nonexperimental) and two ongoing studies. This is an additional 10 experimental and 85 nonexperimental studies from those included in the previous version of the review. Eleven experimental studies allocated a total of 1795 participants to either green tea extract or placebo, all demonstrating an overall high methodological quality based on 'Risk of bias' assessment. For incident prostate cancer, the summary risk ratio (RR) in the green tea-supplemented participants was 0.50 (95% confidence interval (CI) 0.18 to 1.36), based on three studies and involving 201 participants (low-certainty evidence). The summary RR for gynaecological cancer was 1.50 (95% CI 0.41 to 5.48; 2 studies, 1157 participants; low-certainty evidence). No evidence of effect of non-melanoma skin cancer emerged (summary RR 1.00, 95% CI 0.06 to 15.92; 1 study, 1075 participants; low-certainty evidence). In addition, adverse effects of green tea extract intake were reported, including gastrointestinal disorders, elevation of liver enzymes, and, more rarely, insomnia, raised blood pressure and skin/subcutaneous reactions. Consumption of green tea extracts induced a slight improvement in quality of life, compared with placebo, based on three experimental studies. In nonexperimental studies, we included over 1,100,000 participants from 46 cohort studies and 85 case-control studies, which were on average of intermediate to high methodological quality based on Newcastle-Ottawa Scale 'Risk of bias' assessment. When comparing the highest intake of green tea with the lowest, we found a lower overall cancer incidence (summary RR 0.83, 95% CI 0.65 to 1.07), based on three studies, involving 52,479 participants (low-certainty evidence). Conversely, we found no association between green tea consumption and cancer-related mortality (summary RR 0.99, 95% CI 0.91 to 1.07), based on eight studies and 504,366 participants (low-certainty evidence). For most of the site-specific cancers we observed a decreased RR in the highest category of green tea consumption compared with the lowest one. After stratifying the analysis according to study design, we found strongly conflicting results for some cancer sites: oesophageal, prostate and urinary tract cancer, and leukaemia showed an increased RR in cohort studies and a decreased RR or no difference in case-control studies. AUTHORS' CONCLUSIONS: Overall, findings from experimental and nonexperimental epidemiological studies yielded inconsistent results, thus providing limited evidence for the beneficial effect of green tea consumption on the overall risk of cancer or on specific cancer sites. Some evidence of a beneficial effect of green tea at some cancer sites emerged from the RCTs and from case-control studies, but their methodological limitations, such as the low number and size of the studies, and the inconsistencies with the results of cohort studies, limit the interpretability of the RR estimates. The studies also indicated the occurrence of several side effects associated with high intakes of green tea. In addition, the majority of included studies were carried out in Asian populations characterised by a high intake of green tea, thus limiting the generalisability of the findings to other populations. Well conducted and adequately powered RCTs would be needed to draw conclusions on the possible beneficial effects of green tea consumption on cancer risk.
AD  - University of Modena and Reggio Emilia, Research Center in Environmental, Nutritional and Genetic Epidemiology (CREAGEN), Department of Biomedical, Metabolic and Neural Sciences, Via Campi 287, Modena, Italy, 41125.
University of Naples 'Federico II', Department of Pharmacy, School of Medicine and Surgery, Via D Montesano 49, Naples, Italy, 80131.
University of East Anglia, Norwich Medical School, Earlham Road, Norwich, Norfolk, UK, NR4 7TJ.
Paracelsus Medical University, Klinikum Nuremberg, Department of Internal Medicine, Division of Oncology and Hematology, Prof.-Ernst-Nathan-Str. 1, Nuremberg, Germany, D-90419.
Boston University School of Public Health, Department of Epidemiology, 715 Albany Street, Boston, USA, MA 02118.
AN  - 32118296
AU  - Filippini, T.
AU  - Malavolti, M.
AU  - Borrelli, F.
AU  - Izzo, A. A.
AU  - Fairweather-Tait, S. J.
AU  - Horneber, M.
AU  - Vinceti, M.
C2  - PMC7059963 none known
 MV: none known
DA  - Mar 2
DO  - 10.1002/14651858.CD005004.pub3
DP  - NLM
ET  - 2020/03/03
IS  - 3
KW  - Breast Neoplasms/prevention & control
*Camellia sinensis/chemistry
Case-Control Studies
Female
Flavonoids/pharmacology
Gastrointestinal Neoplasms/epidemiology/prevention & control
Humans
Incidence
Liver Neoplasms/epidemiology/prevention & control
Lung Neoplasms/epidemiology/prevention & control
Male
Mouth Neoplasms/epidemiology/prevention & control
Neoplasms/epidemiology/mortality/*prevention & control
Phenols/pharmacology
Phytotherapy/*methods
Plant Extracts/adverse effects/*therapeutic use
Polyphenols
Randomized Controlled Trials as Topic
Skin Neoplasms/epidemiology/prevention & control
*Tea/adverse effects
Urogenital Neoplasms/epidemiology/prevention & control
LA  - eng
N1  - 1469-493x
Filippini, Tommaso
Malavolti, Marcella
Borrelli, Francesca
Izzo, Angelo A
Fairweather-Tait, Susan J
Horneber, Markus
Vinceti, Marco
Journal Article
Meta-Analysis
Research Support, Non-U.S. Gov't
Systematic Review
Cochrane Database Syst Rev. 2020 Mar 2;3(3):CD005004. doi: 10.1002/14651858.CD005004.pub3.
PY  - 2020
SN  - 1361-6137
SP  - Cd005004
ST  - Green tea (Camellia sinensis) for the prevention of cancer
T2  - Cochrane Database Syst Rev
TI  - Green tea (Camellia sinensis) for the prevention of cancer
VL  - 3
ID  - 51
ER  - 

TY  - JOUR
AB  - Breast cancer is the most common malignancy in women worldwide. Tea has anticarcinogenic effects against breast cancer in experimental studies. However, epidemiologic evidence that tea protects against breast cancer has been inconsistent. A case-control study was conducted in Southeast China between 2004 and 2005. The incidence cases were 1009 female patients aged 20-87 years with histologically confirmed breast cancer. The 1009 age-matched controls were healthy women randomly recruited from breast disease clinics. Information on duration, frequency, quantity, preparation, type of tea consumption, diet and lifestyle were collected by face-to-face interview using a validated and reliable questionnaire. Conditional logistic regression analyses were used to estimate odds ratios (ORs) and associated 95% confidence intervals. Compared with non-tea drinkers, green tea drinkers tended to reside in urban, have better education and have higher consumption of coffee, alcohol, soy, vegetables and fruits. After adjusting established and potential confounders, green tea consumption was associated with a reduced risk of breast cancer. The ORs were 0.87 (0.73-1.04) in women consuming 1-249 g of dried green tea leaves per annum, 0.68 (0.54-0.86) for 250-499 g per annum, 0.59 (0.45-0.77) for 500-749 g per annum and 0.61 (0.48-0.78) for >= 750 g per annum, with a statistically significant test for trend (P < 0.001). Similar dose-response relationships were observed for duration of drinking green tea, number of cups consumed and new batches prepared per day. We conclude that regular consumption of green tea can protect against breast cancer. More research to closely examine the relationship between tea consumption and breast cancer risk is warranted.
AN  - WOS:000246121300023
AU  - Zhang, M.
AU  - Holman, C. D. J.
AU  - Huang, J. P.
AU  - Xie, X.
DA  - May
DO  - 10.1093/carcin/bgl252
IS  - 5
N1  - 17183063
PY  - 2007
SN  - 0143-3334
SP  - 1074-1078
ST  - Green tea and the prevention of breast cancer: a case-control study in Southeast China
T2  - Carcinogenesis
TI  - Green tea and the prevention of breast cancer: a case-control study in Southeast China
VL  - 28
ID  - 3196
ER  - 

TY  - JOUR
AB  - Background. There is little research on medical mistrust as a barrier to breast cancer screening. This study investigated the psychometric properties of a new scale, the Group-Based Medical Mistrust Scale (GBMMS), and its association with cancer screening attitudes and breast cancer screening practices among African American and Latina women. Methods. Participants were 168 African American and Latina urban women who completed the GBMMS and measures of sociodemographics, cancer screening pros and cons, acculturation, breast cancer screening practices and physician recommendation of such screening. Results. A principal components analysis of GBMMS items revealed three factors that were analyzed as subscales: (1) suspicion, (2) group disparities in health care, and (3) lack of support from health care providers. Convergent validity of the GBMMS was supported by its negative association with perceived benefits of cancer screening and acculturation and positive association with perceived disadvantages of cancer screening. Results further showed that women who reported no previous mammogram or a long-term lapse in mammography participation (>5 years) had significantly higher total GBMMS scores (P < 0.04) compared to women who were either adherent to mammography guidelines or nonadherent but reported a mammogram within the past 5 years. This analysis controlled for physician recommendation. Conclusions: Results support the validity of the GBMMS and its association with breast cancer screening adherence. The GBMMS may be used to further investigate medical mistrust as a barrier to screening for cancers for which ethnic group disparities have been observed. (C) 2003 The Institute For Cancer Prevention and Elsevier Inc. All rights reserved.
AN  - WOS:000188319200012
AU  - Thompson, H. S.
AU  - Valdimarsdottir, H. B.
AU  - Winkel, G.
AU  - Jandorf, L.
AU  - Redd, W.
DA  - Feb
DO  - 10.1016/j.ypmed.2003.09.041
IS  - 2
N1  - 195
14715214
PY  - 2004
SN  - 0091-7435
SP  - 209-218
ST  - The Group-Based Medical Mistrust Scale: psychometric properties and association with breast cancer screening
T2  - Preventive Medicine
TI  - The Group-Based Medical Mistrust Scale: psychometric properties and association with breast cancer screening
VL  - 38
ID  - 2686
ER  - 

TY  - JOUR
AB  - Access and recruitment barriers may have contributed to the underrepresentation of Black African/Caribbean men and their partners in current psychosocial research related to prostate cancer survivors. Whilst some studies have explored recruitment barriers and facilitators from participants' perspectives, little is known from researchers' point of view. This paper aimed to address this gap in the literature. Recruitment strategies included the following: cancer support groups, researchers' networks, media advertisement, religious organisations, National Health Service hospitals and snowball sampling. Thirty-six eligible participants (men = 25, partners = 11) were recruited into the study. Recruitment barriers comprised of gate-keeping and advertisement issues and the stigma associated with prostate cancer disclosure. Facilitators which aided recruitment included collaborating with National Health Service hospitals, snowball sampling, flexible data collection, building rapport with participants to gain their trust and researcher's attributes. Findings highlight that "hard to reach" Black African/Caribbean populations may be more accessible if researchers adopt flexible but strategic and culturally sensitive recruitment approaches. Such approaches should consider perceptions of stigma associated with prostate cancer within these communities and the influence gatekeepers can have in controlling access to potential participants. Increased engagement with healthcare professionals and gatekeepers could facilitate better access to Black African/Caribbean populations so that their voices can be heard and their specific needs addressed within the healthcare agenda.
AD  - Institute of Nursing and Health Research, Ulster University, Jordanstown, UK.
School of Nursing, Ulster University, Londonderry, UK.
Barts Health NHS Trust, London, UK.
School of Health Sciences: City, University of London, London, UK.
Institute for Health Research, University of Bedfordshire, Luton, UK.
Institute of Nursing and Health Research, Ulster University, Coleraine, UK.
AN  - 30548713
AU  - Bamidele, O. O.
AU  - H, E. McGarvey
AU  - Lagan, B. M.
AU  - Chinegwundoh, F.
AU  - Ali, N.
AU  - McCaughan, E.
DA  - Mar
DO  - 10.1111/ecc.12977
DP  - NLM
ET  - 2018/12/15
IS  - 2
KW  - Adolescent
Adult
Advertising
African Americans/ethnology/psychology
African Continental Ancestry Group/*ethnology/psychology
Aged
Disclosure
Female
Gatekeeping
Health Services Accessibility
Humans
Interinstitutional Relations
Male
Middle Aged
Patient Acceptance of Health Care/ethnology/psychology
*Patient Selection
Prostatic Neoplasms/*ethnology/psychology
Qualitative Research
Sexual Partners
Stereotyping
West Indies/ethnology
Young Adult
African caribbean
Black African
men
partners
prostate cancer
recruitment
LA  - eng
N1  - 1365-2354
Bamidele, Olufikayo O
Orcid: 0000-0003-2235-9463
E McGarvey, Helen
Orcid: 0000-0001-9145-8778
Lagan, Briege M
Orcid: 0000-0001-5536-394x
Chinegwundoh, Frank
Ali, Nasreen
McCaughan, Eilis
Ulster University/
Journal Article
England
Eur J Cancer Care (Engl). 2019 Mar;28(2):e12977. doi: 10.1111/ecc.12977. Epub 2018 Dec 12.
PY  - 2019
SN  - 0961-5423
SP  - e12977
ST  - "Hard to reach, but not out of reach": Barriers and facilitators to recruiting Black African and Black Caribbean men with prostate cancer and their partners into qualitative research
T2  - Eur J Cancer Care (Engl)
TI  - "Hard to reach, but not out of reach": Barriers and facilitators to recruiting Black African and Black Caribbean men with prostate cancer and their partners into qualitative research
VL  - 28
ID  - 93
ER  - 

TY  - JOUR
AB  - Purpose: We describe the translation of K. R. Lorig and colleagues' Chronic Disease Self-Management Program (CDSMP) for delivery in a senior center and evaluate pre-post benefits for African American participants. Design and Methods: Modifications to the CDSMP included a name change; an additional introductory session; and course augmentations involving culturally relevant foods, stress reduction techniques, and communicating with racially/ethnically diverse physicians. We recruited participants from senior center members, area churches, and word of mouth. We conducted baseline and 4-month post-interviews. Results: A total of 569 African American elders attended an introductory session, with 519 (91%) enrolling in the 6-session program. Of the 519, 444 (86%) completed ≥4 sessions and 414 (79%) completed pre-post interviews. We found small but statistically significant improvements for exercise (p = .001), use of cognitive management strategies (p = .001), energy/fatigue (p = .001), self-efficacy (p = .001), health distress (p = .001), and illness intrusiveness in different life domains (probabilities from .001-.021). We found no changes for health utilization. Outcomes did not differ by gender, number of sessions attended, number and type of chronic conditions, facilitator, leader, or recruitment site. Implications: The CDSMP can be translated for delivery by trained senior center personnel to African American elders. Participant benefits compare favorably to original trial outcomes. The translated program is replicable and may help to address health disparities.
AD  - L.N. Gitlin, Center for Applied Research on Aging and Health, Thomas Jefferson University, 130 South 9th Street, Philadelphia, PA 19107, United States
AU  - Gitlin, L. N.
AU  - Chernett, N. L.
AU  - Harris, L. F.
AU  - Palmer, D.
AU  - Hopkins, P.
AU  - Dennis, M. P.
DB  - Embase
Medline
DO  - 10.1093/geront/48.5.698
IS  - 5
KW  - adult
African American
aged
arthritis
article
asthma
chronic disease self management program
chronic obstructive lung disease
cognition
cultural factor
diabetes mellitus
distress syndrome
energy
ethnic difference
exercise
fatigue
female
food
health care delivery
health care utilization
health program
health status
heart disease
human
hypertension
interpersonal communication
interview
male
neoplasm
outcome assessment
physical activity
probability
race difference
self concept
sex difference
social stress
physiological stress
LA  - English
M3  - Article
N1  - L352773148
2009-01-15
PY  - 2008
SN  - 0016-9013
SP  - 698-705
ST  - Harvest health: Translation of the chronic disease self-management program for older African Americans in a senior setting
T2  - Gerontologist
TI  - Harvest health: Translation of the chronic disease self-management program for older African Americans in a senior setting
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L352773148&from=export
http://dx.doi.org/10.1093/geront/48.5.698
VL  - 48
ID  - 1205
ER  - 

TY  - JOUR
AB  - Abstract: Purpose: Investigate the relationship between African American women''s health beliefs in regard to breast cancer screening behaviors. Data sources: A sample of 131 African American women, age 20–65, from a family practice clinic and 3 rural churches in Southeast. Conclusions: One-hundred and nine of the participants reported practicing breast self-exam (BSE) within the past 12 months. However, 21 women had never practiced BSE. Fear of not doing it correctly was a main barrier. Implication for practice: Steps should be taken to increase confidence and resolve barriers of African American women through the development of culturally sensitive educational training on BSE and cancer prevention.
AN  - 104456379. Language: English. Entry Date: 20120622. Revision Date: 20200708. Publication Type: Journal Article
AU  - Registe, Marlaine
AU  - Porterfield, Susan Padham
DB  - CINAHL Complete
DO  - 10.1016/j.nurpra.2011.09.025
DP  - EBSCOhost
IS  - 6
KW  - Health Beliefs
Black Persons -- United States
Breast Self-Examination
Human
United States
Health Beliefs -- Evaluation
Female
Adult
Middle Age
Southeastern United States
Descriptive Research
Correlational Studies
Health Knowledge -- Evaluation
Research Subject Recruitment
Convenience Sample
Scales
Summated Rating Scaling
Correlation Coefficient
N1  - research; tables/charts. Journal Subset: Blind Peer Reviewed; Core Nursing; Double Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Nursing; Peer Reviewed; USA. Special Interest: Advanced Nursing Practice. Instrumentation: Champion's Breast Cancer Screening Instrument Scale; Champion's Breast Cancer Screening Beliefs Instrument. NLM UID: 101264817.
PY  - 2012
SN  - 1555-4155
SP  - 446-451
ST  - Health Beliefs of African American Women on Breast Self-Exam
T2  - Journal for Nurse Practitioners
TI  - Health Beliefs of African American Women on Breast Self-Exam
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104456379&site=ehost-live&scope=site
VL  - 8
ID  - 1966
ER  - 

TY  - JOUR
AB  - African Americans are more likely than any other racial or ethnic group to develop colorectal cancer (CRC) and to die as a result. Factors such as age, family history, income, knowledge, attitudes and beliefs regarding screening are important predictors of risk, and multiple factors may contribute to poor CRC outcomes for African Americans. Although screening is not the only factor associated with CRC outcomes, it may be one of the more important and modifiable risk factors for African Americans. Few programs have utilized narrative approaches to promote cancer screening among African Americans. None have focused on CRC screening. The purpose of this discussion is to review factors associated with CRC incidence, late detection and mortality among African Americans with emphasis on screening to improve CRC-related outcomes, and to discuss narrative health promotion as a culturally appropriate means for eliminating the disparities in CRC-related outcomes between African Americans and other racial/ethnic groups.
AD  - Department of African & African American Studies, Arizona State University, Wilson Hall Suite 140, PO Box 870903, Tempe, AZ 85287-0903; alyssa.robillard@asu.edu
AN  - 105365294. Language: English. Entry Date: 20090807. Revision Date: 20200708. Publication Type: Journal Article
AU  - Robillard, A. G.
AU  - Larkey, L.
DB  - CINAHL Complete
DO  - 10.1353/hpu.0.0161
DP  - EBSCOhost
IS  - 2
KW  - Black Persons
Cancer Screening
Colorectal Neoplasms -- Prevention and Control
Colorectal Neoplasms -- Risk Factors
American Cancer Society
Clinical Trials
Colorectal Neoplasms -- Epidemiology
Culture
Family History
Female
Health Beliefs
Health Knowledge
Health Promotion
Incidence
Male
Morbidity
Narratives
Nutrition
Physical Activity
Practice Guidelines
Research Subject Recruitment
Socioeconomic Factors
N1  - review; tables/charts. Supplement Title: 2009 Supplement. Journal Subset: Health Services Administration; Peer Reviewed; Public Health; USA. NLM UID: 9103800.
PMID: NLM19711496.
PY  - 2009
SN  - 1049-2089
SP  - 102-119
ST  - Health disadvantages in colorectal cancer screening among African Americans: considering the cultural context of narrative health promotion
T2  - Journal of Health Care for the Poor & Underserved
TI  - Health disadvantages in colorectal cancer screening among African Americans: considering the cultural context of narrative health promotion
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105365294&site=ehost-live&scope=site
VL  - 20
ID  - 1967
ER  - 

TY  - JOUR
AB  - Background: Primary care physician (PCP) recommendation for cancer screening is a strong predictor of adherence to screening; however, patients with limited health literacy (HL) may have difficulty understanding information about screening. We implemented a continuing medical education program to train PCPs in cancer risk communication with limited HL patients. Our main study objective is to determine whether changes in PCP communication improve patients' adherence to cancer screening. We examined baseline patient characteristics to assess whether patients' cancer screening information needs vary across levels of limited HL and determine which factors may influence adherence to different types of cancer screening tests. Methods: This study is part of a 4‐year randomized controlled trial of a communication skills training program targeting PCPs (11 intervention vs. 8 control) who practice in safety‐net clinics in New Orleans, LA and their patients with limited HL (Rapid Estimate of Adult Literacy in Medicine [REALM] score < 60). For each PCP, we recruited 10 patients (men [age 50‐75]; women [age 40‐75]) who were overdue for at least one cancer screening test (mammography; pap smears; FOBT/ endoscopy/barium enema). We conducted baseline interviews to obtain socio‐demographics, cancer knowledge, cancer screening status and ratings of physician communication style (Perceived Involvement in Care Scale). We conducted baseline chart reviews to confirm cancer screening status. Results: Of 871 clinic patients screened to date, 164 met eligibility criteria (target sample size: 180). The most common reasons for exclusion were HL too high (37%), up‐to‐date on cancer screening (20%), or new patients to the PCP (12%). Most eligible patients are African American (90%), female (77%), insured (61%) and read at the 7th‐8th grade level (67%). Only 35% of the study sample was up‐to‐date by chart review on mammography, 34% on pap smears, and 29% on colorectal cancer screening. Patient ratings of the level of information exchange with their PCPs varied by level of HL with patients with < 3rd grade reading level rating their PCPs significantly lower (mean [SD]: 2.9 [1.4]) than patients with higher reading levels (7th‐8th grade: 3.4 [1.0]; 5th‐6th grade: 3.7 [0.6]). Overall, less than 1/3 of patients knew the age at which to start breast/cervical/CRC screening. Knowledge about the cancer screened for by mammography and the tests available for CRC screening varied significantly by level of HL (7th‐8th grade vs. 5th‐6th grade vs. <3rd grade: Breast, 83% vs. 69% vs. 41%; CRC, 51% vs. 32% vs. 12%). Only 10% of patients knew that pap smears screen for cervical cancer. There was no significant difference in cancer screening status by level of HL, cancer screening knowledge or perceptions of involvement in care. For mammography, the odds of being up‐to‐date increased with having insurance (OR, 95% CI: 3.2 [1.4‐7.5]) and emotional/informational support (1.6 [1.2‐2.2]) whereas receiving care in a community health center reduced the odds (0.42 [0.2‐0.9]). For CRC screening, family history of CRC increased the odds of being up‐to‐date (5.7 [1.3‐23.8]) whereas emotional/informational support reduced the odds (0.63 [0.5‐0.9]). There were no significant factors that influenced cervical cancer screening status. Although patients' perceptions of health information exchange and cancer screening knowledge may depend on their level of health literacy, psychosocial, familial and health system related factors may ultimately influence adherence to cancer screening. Message framing for cancer risk communication should take these factors into consideration.
AN  - CN-00980592
AU  - Price-Haywood, E. G.
AU  - Harden-Barrios, J.
AU  - Cooper, L. A.
DO  - 10.1158/1055-9965.DISP-11-A11
IS  - 10
KW  - *cancer research
*cancer screening
*health disparity
*health literacy
*human
*medical information
*neoplasm
*patient
Adult
African American
Breast
Cancer risk
Colorectal cancer
Communication skill
Education program
Family history
Female
General practitioner
Health care
Health center
Hospital
Insurance
Interpersonal communication
Interview
Male
Mammography
Medical education
Medical record review
Papanicolaou test
Physician
Randomized controlled trial
Reading
Safety
Sample size
Screening
Screening test
Training
United States
Uterine cervix cancer
M3  - Journal: Conference Abstract
PY  - 2011
ST  - Health information needs and predictors of cancer screening status among patients with limited health literacy
T2  - Cancer epidemiology biomarkers and prevention
TI  - Health information needs and predictors of cancer screening status among patients with limited health literacy
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00980592/full
VL  - 20
ID  - 1568
ER  - 

TY  - JOUR
AB  - The current study examined the sociodemographic and psychosocial variables that predicted being at risk for low health literacy among a population of racially and ethnically diverse patients accessing primary care services at community-based clinics. Participants (N=416) were aged 50-75 years, currently not up-to-date with colorectal cancer (CRC) screening, at average CRC risk, and enrolled in a randomized controlled trial (RCT) aimed at promoting CRC screening. Participants completed a baseline interview that assessed health literacy as measured by Rapid Estimate of Adult Literacy in Medicine-Revised, sociodemographic factors, and psychosocial variables (e.g., health beliefs) prior to randomization and receipt of an intervention. Thirty-six percent of the participants were found to be at risk for low health literacy. Sociodemographic and psychosocial variables were assessed as predictors of being at risk for low health literacy using logistic regression. In the final model, predictors were male gender, being from a racial/ethnic minority group, being unable to work, having higher social influence scores, and having higher religious belief scores. These findings suggest several patient characteristics that may be associated with low health literacy, and highlight the importance of supporting all patients through simplified and clear communications and information to improve understanding of CRC screening information.
AN  - WOS:000418940500007
AU  - Christy, S. M.
AU  - Gwede, C. K.
AU  - Sutton, S. K.
AU  - Chavarria, E.
AU  - Davis, S. N.
AU  - Abdulla, R.
AU  - Ravindra, C.
AU  - Schultz, I.
AU  - Roetzheim, R.
AU  - Meade, C. D.
DO  - 10.1080/10810730.2017.1377322
IS  - 11
N1  - 29125435
PY  - 2017
SN  - 1081-0730
SP  - 923-931
ST  - Health Literacy among Medically Underserved: The Role of Demographic Factors, Social Influence, and Religious Beliefs
T2  - Journal of Health Communication
TI  - Health Literacy among Medically Underserved: The Role of Demographic Factors, Social Influence, and Religious Beliefs
VL  - 22
ID  - 2915
ER  - 

TY  - JOUR
AB  - Innovative strategies are needed to increase minorities' research participation. Using existing social networks within the African American community, "home health parties" were tested as a way to recruit African American women to a breast cancer control study. Parties included social, educational, and recruitment components. All women attending health parties consented, completed a survey, and received the study's preliminary breast cancer risk assessment. There were no differences in rates of participation for subsequent study components between women recruited via parties versus other methods. Health parties are viable recruitment strategies, reduce barriers to participation, provide a supportive environment, and are relatively inexpensive.
AD  - UCSD Cancer Center, Department of Surgery, UCSD School of Medicine, La Jolla, California 92093-0850, USA. gsadler@ucsd.edu
AN  - 17020516
AU  - Sadler, G. R.
AU  - York, C.
AU  - Madlensky, L.
AU  - Gibson, K.
AU  - Wasserman, L.
AU  - Rosenthal, E.
AU  - Barbier, L.
AU  - Newman, V. A.
AU  - Tso, C.
DA  - Summer
DO  - 10.1207/s15430154jce2102_6
DP  - NLM
ET  - 2006/10/06
IS  - 2
KW  - Adult
*African Americans
Attitude to Health
Biomedical Research/education/*methods
Breast Neoplasms/prevention & control/therapy
Clinical Trials as Topic
Female
Health Education/*methods
Health Promotion/*methods
Humans
Interpersonal Relations
Middle Aged
*Patient Selection
Risk Assessment
Social Support
LA  - eng
N1  - Sadler, Georgia Robins
York, Crystal
Madlensky, Lisa
Gibson, Kathi
Wasserman, Linda
Rosenthal, Eric
Barbier, Leslie
Newman, Vicky A
Tso, Cindy
5 P30 CA023100-22/CA/NCI NIH HHS/United States
P60MD00220/MD/NIMHD NIH HHS/United States
R25CA65745/CA/NCI NIH HHS/United States
U56 CA92079/CA/NCI NIH HHS/United States
U56 CA92081/CA/NCI NIH HHS/United States
Evaluation Study
Journal Article
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, P.H.S.
England
J Cancer Educ. 2006 Summer;21(2):71-6. doi: 10.1207/s15430154jce2102_6.
PY  - 2006
SN  - 0885-8195 (Print)
0885-8195
SP  - 71-6
ST  - Health parties for African American study recruitment
T2  - J Cancer Educ
TI  - Health parties for African American study recruitment
VL  - 21
ID  - 547
ER  - 

TY  - JOUR
AB  - Purpose: Understanding the potential consequences of racial differences in prostate cancer outcomes, from survival rates to quality of life considerations, is important for the clinician and patient. We examined demographic, clinical and health related quality of life data comparing black with white patients just after treatment of prostate cancer and 1 year later. Materials and Methods: We analyzed data on 1,178 patients who were newly diagnosed with prostate cancer in the Cancer of the Prostate Strategic Urologic Research Endeavor, a national observational database of men recruited from 35 community and academic urology practices throughout the United States. Patient demographics, clinical characteristics and validated health related quality of life questionnaires were reviewed. A total of 958 white and 161 black patients with prostate cancer who completed at least 2 surveys were compared. Results: The black patients were younger, and had lower income and education levels than white patients. Controlling for age, education and income differences, black patients generally had worse clinical characteristics at presentation and lower baseline health related quality of life data scores in most generic and disease specific categories at treatment. The most notable exception was sexual function, which was the only score that was higher in black patients at treatment. With time, health related quality of life improved in both groups but black patients had slower rates of improvement for general health, bodily pain, physical function, role function, disease worry and bowel function. They continued to have higher sexual function. Conclusions: Significant differences exist in clinical presentation, sociodemographic characteristics, and health related quality of life between black and white men with prostate cancer. These health related quality of life differences remain after treatment. Physicians should not assume that outcomes in black men would be similar to other patients.
AD  - D.P. Lubeck, Department of Urology, UCSF/Mt. Zion Compreh. Can. Ctr., Univ. of California, San Francisco, San Francisco, CA, United States
AU  - Lubeck, D. P.
AU  - Kim, H.
AU  - Grossfeld, G.
AU  - Ray, P.
AU  - Penson, D. F.
AU  - Flanders, S. C.
AU  - Carroll, P. R.
DB  - Embase
Medline
DO  - 10.1016/S0022-5347(05)65551-6
IS  - 6
KW  - adult
aged
anxiety
article
cancer research
Caucasian
data base
demography
human
intestine function
major clinical study
male
Black person
pain
priority journal
prostate cancer
quality of life
questionnaire
race difference
sexual function
United States
urology
validation process
LA  - English
M3  - Article
N1  - L33065274
2001-11-28
PY  - 2001
SN  - 0022-5347
SP  - 2281-2285
ST  - Health related quality of life differences between black and white men with prostate cancer: Data from the cancer of the prostate strategic urologic research endeavor
T2  - Journal of Urology
TI  - Health related quality of life differences between black and white men with prostate cancer: Data from the cancer of the prostate strategic urologic research endeavor
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L33065274&from=export
http://dx.doi.org/10.1016/S0022-5347(05)65551-6
VL  - 166
ID  - 1305
ER  - 

TY  - JOUR
AB  - BACKGROUND: The diagnosis and treatment of breast cancer can result in an array of late cancer-specific side effects and changes in general well-being. Research has focused on white samples, limiting our understanding of the unique health-related quality of life outcomes of African American breast cancer survivors (BCSs). Even when African American BCSs have been targeted, research is limited by small samples and failure to include comparisons of peers without a history of breast cancer. OBJECTIVE: The purpose of this study was to compare health-related quality of life of African American female BCSs with that of African American women with no history of breast cancer (control group). METHODS: A total of 140 women (62 BCSs and 78 controls), 18 years or older and 2 to 10 years postdiagnosis, were recruited from a breast cancer clinic and cancer support groups. Participants provided informed consent and completed a 1-time survey based on the proximal-distal health-related quality of life model of Brenner et al (1995). RESULTS: After adjusting for age, education, income, and body mass index, results show that African American BCSs experienced more fatigue (P = .001), worse hot flashes (P < .001), and worse sleep quality (P < .001) but more social support from their partner (P = .028) and more positive change (P = .001) compared with African American female controls. CONCLUSIONS: Our results suggest that African American female BCSs may experience unique health-related outcomes that transcend age, education, socioeconomic status, and body mass index. IMPLICATIONS FOR PRACTICE: Findings suggest the importance of understanding the survivorship experience for particular racial and ethnic subgroups to proactively assess difficulties and plan interventions.
AD  - School of Nursing, Indiana University, Indianapolis, 46202, USA. dvonah@iupui.edu
AN  - 22228394
AU  - Von Ah, D. M.
AU  - Russell, K. M.
AU  - Carpenter, J.
AU  - Monahan, P. O.
AU  - Qianqian, Z.
AU  - Tallman, E.
AU  - Ziner, K. W.
AU  - Storniolo, A. M.
AU  - Miller, K. D.
AU  - Giesler, R. B.
AU  - Haase, J.
AU  - Otte, J.
AU  - Champion, V. L.
C2  - PMC3326198
C6  - NIHMS340029
DA  - Sep-Oct
DO  - 10.1097/NCC.0b013e3182393de3
DP  - NLM
ET  - 2012/01/10
IS  - 5
KW  - African Americans/*psychology/statistics & numerical data
Aged
Breast Neoplasms/*ethnology/therapy
Case-Control Studies
Cross-Sectional Studies
Female
Health Surveys
Humans
Middle Aged
Nursing Methodology Research
Quality of Life/*psychology
Survivors/*psychology/statistics & numerical data
LA  - eng
N1  - 1538-9804
Von Ah, Diane M
Russell, Kathleen M
Carpenter, Janet
Monahan, Patrick O
Qianqian, Zhao
Tallman, Eileen
Ziner, Kim Wagler
Storniolo, Anna Maria
Miller, Kathy D
Giesler, R Brian
Haase, Joan
Otte, Julie
Champion, Victoria L
P30 CA082709/CA/NCI NIH HHS/United States
R03 CA097737/CA/NCI NIH HHS/United States
R03 CA097737-02/CA/NCI NIH HHS/United States
R03-CA97737/CA/NCI NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Cancer Nurs. 2012 Sep-Oct;35(5):337-46. doi: 10.1097/NCC.0b013e3182393de3.
PY  - 2012
SN  - 0162-220X (Print)
0162-220x
SP  - 337-46
ST  - Health-related quality of life of african american breast cancer survivors compared with healthy African American women
T2  - Cancer Nurs
TI  - Health-related quality of life of african american breast cancer survivors compared with healthy African American women
VL  - 35
ID  - 377
ER  - 

TY  - JOUR
AB  - BACKGROUND: Lymphedema is an adverse effect of breast cancer treatment that causes swelling and pain in the arm and hand. We tested 2 lymphedema prevention interventions and their impact on health-related quality of life (HRQOL) in a group-randomized trial at 38 cooperative group sites within the United States. METHODS: Patients were recruited before breast surgery. Sites were randomly assigned to education-only (EO) lymphedema prevention or education plus exercise and physical therapy (LEAP). Lymphedema was defined as a ≥10% difference in arm volume at any time from baseline to 18 months postsurgery. HRQOL was assessed using the Functional Assessment of Cancer Therapy-Breast plus 4 lymphedema items (FACT-B+4). Longitudinal mixed model regression analysis, adjusting for key demographic and clinical variables, examined participants' HRQOL by intervention group and lymphedema status. RESULTS: A total of 547 patients (56% LEAP) were enrolled and completed HRQOL assessments. The results revealed no differences between the interventions in preventing lymphedema (P = .37) or HRQOL (FACT-B+4 total score; P = .8777). At 18 months, the presence of lymphedema was associated with HRQOL at borderline significance (P = .0825). However, African American patients reported greater lymphedema symptoms (P = .0002) and better emotional functioning (P = .0335) than patients of other races or ethnicities. Lower HRQOL during the intervention was associated with younger age (P ≤ .0001), Eastern Cooperative Oncology Group performance status >0 (P = .0002), ≥1 positive lymph nodes (P = .0009), having no education beyond high school (P < .0001), having undergone chemotherapy (P = .0242), and having had only axillary node dissection or sentinel node biopsy versus both (P = .0007). CONCLUSION: The tested interventions did not differ in preventing lymphedema or in HRQOL outcomes. African American women reported greater HRQOL impacts due to lymphedema symptoms than women of other races or ethnicities.
AD  - Department of Internal Medicine, The Ohio State University, Columbus, Ohio.
Mayo Clinic, Rochester, Minnesota.
Department of Health Sciences, Mayo Clinic, Rochester, Minnesota.
Department of Nursing Research, University of Missouri, Columbia, Missouri.
Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio.
Division of Oncology & Health Sciences Research, Mayo Clinic College of Medicine, Rochester, Minnesota.
Mount Sinai Medical Center, Miami Beach, Florida.
City of Laredo, Laredo, Texas.
Cancer Research Consortium of West Michigan, Grand Rapids, Michigan.
Division of Surgical Oncology, City of Hope, Duarte, California.
Department of Hematology/Oncology, University of Chicago, Chicago, Illinois.
Alliance for Clinical Trials in Oncology Foundation, Protocol Operations Program Office, Chicago, Illinois.
North Central Cancer Treatment Group, Mayo Clinic, Rochester, Minnesota.
Department of Medicine, The Ohio State University, Columbus, Ohio.
AN  - 33079393
AU  - Naughton, M. J.
AU  - Liu, H.
AU  - Seisler, D. K.
AU  - Le-Rademacher, J.
AU  - Armer, J. M.
AU  - Oliveri, J. M.
AU  - Sloan, J. A.
AU  - Hock, K.
AU  - Schwartz, M.
AU  - Unzeitig, G.
AU  - Melnik, M.
AU  - Yee, L. D.
AU  - Fleming, G. F.
AU  - Taylor, J. R.
AU  - Loprinzi, C.
AU  - Paskett, E. D.
C2  - PMC7790999
C6  - NIHMS1630495
DA  - Jan 15
DO  - 10.1002/cncr.33184
DP  - NLM
ET  - 2020/10/21
IS  - 2
KW  - breast cancer
lymphedema
quality of life
race
symptoms
conduct of the study. Dr. Paskett reports grants from Merck Foundation and Pfizer
during the conduct of the study.
LA  - eng
N1  - 1097-0142
Naughton, Michelle J
Liu, Heshan
Seisler, Drew K
Le-Rademacher, Jennifer
Orcid: 0000-0002-2234-7430
Armer, Jane M
Oliveri, Jill M
Orcid: 0000-0002-6222-8217
Sloan, Jeffrey A
Hock, Karen
Schwartz, Michael
Unzeitig, Gary
Melnik, Marianne
Yee, Lisa D
Fleming, Gini F
Taylor, John R
Loprinzi, Charles
Orcid: 0000-0001-8044-5752
Paskett, Electra D
Orcid: 0000-0002-8247-8299
UG1 CA233331/CA/NCI NIH HHS/United States
UL1 TR001409/TR/NCATS NIH HHS/United States
UG1 CA232760/CA/NCI NIH HHS/United States
UG1 CA189817/CA/NCI NIH HHS/United States
U10 CA180790/CA/NCI NIH HHS/United States
UG1 CA189819/CA/NCI NIH HHS/United States
U10CA180850/CA/NCI NIH HHS/United States
UG1CA189817/CA/NCI NIH HHS/United States
66426/Lance Armstrong Foundation/
POP0600316/KOMEN/Susan G. Komen/United States
UL1TR001409/CA/NCI NIH HHS/United States
U10CA180836/CA/NCI NIH HHS/United States
UG1CA189823/CA/NCI NIH HHS/United States
U10 CA180836/CA/NCI NIH HHS/United States
U10CA180790/CA/NCI NIH HHS/United States
U10 CA180850/CA/NCI NIH HHS/United States
UG1CA189819/CA/NCI NIH HHS/United States
UG1 CA189823/CA/NCI NIH HHS/United States
Journal Article
Cancer. 2021 Jan 15;127(2):300-309. doi: 10.1002/cncr.33184. Epub 2020 Oct 20.
PY  - 2021
SN  - 0008-543X (Print)
0008-543x
SP  - 300-309
ST  - Health-related quality of life outcomes for the LEAP study-CALGB 70305 (Alliance): A lymphedema prevention intervention trial for newly diagnosed breast cancer patients
T2  - Cancer
TI  - Health-related quality of life outcomes for the LEAP study-CALGB 70305 (Alliance): A lymphedema prevention intervention trial for newly diagnosed breast cancer patients
VL  - 127
ID  - 20
ER  - 

TY  - JOUR
AB  - Background: Lymphedema is an adverse effect of breast cancer treatment that causes swelling and pain in the arm and hand. We tested 2 lymphedema prevention interventions and their impact on health-related quality of life (HRQOL) in a group-randomized trial at 38 cooperative group sites within the United States. Methods: Patients were recruited before breast surgery. Sites were randomly assigned to education-only (EO) lymphedema prevention or education plus exercise and physical therapy (LEAP). Lymphedema was defined as a ≥10% difference in arm volume at any time from baseline to 18 months postsurgery. HRQOL was assessed using the Functional Assessment of Cancer Therapy–Breast plus 4 lymphedema items (FACT-B+4). Longitudinal mixed model regression analysis, adjusting for key demographic and clinical variables, examined participants' HRQOL by intervention group and lymphedema status. Results: A total of 547 patients (56% LEAP) were enrolled and completed HRQOL assessments. The results revealed no differences between the interventions in preventing lymphedema (P =.37) or HRQOL (FACT-B+4 total score; P =.8777). At 18 months, the presence of lymphedema was associated with HRQOL at borderline significance (P =.0825). However, African American patients reported greater lymphedema symptoms (P =.0002) and better emotional functioning (P =.0335) than patients of other races or ethnicities. Lower HRQOL during the intervention was associated with younger age (P ≤.0001), Eastern Cooperative Oncology Group performance status >0 (P =.0002), ≥1 positive lymph nodes (P =.0009), having no education beyond high school (P <.0001), having undergone chemotherapy (P =.0242), and having had only axillary node dissection or sentinel node biopsy versus both (P =.0007). Conclusion: The tested interventions did not differ in preventing lymphedema or in HRQOL outcomes. African American women reported greater HRQOL impacts due to lymphedema symptoms than women of other races or ethnicities.
AD  - M.J. Naughton, Department of Internal Medicine, The Ohio State University, Columbus, OH, United States
AU  - Naughton, M. J.
AU  - Liu, H.
AU  - Seisler, D. K.
AU  - Le-Rademacher, J.
AU  - Armer, J. M.
AU  - Oliveri, J. M.
AU  - Sloan, J. A.
AU  - Hock, K.
AU  - Schwartz, M.
AU  - Unzeitig, G.
AU  - Melnik, M.
AU  - Yee, L. D.
AU  - Fleming, G. F.
AU  - Taylor, J. R.
AU  - Loprinzi, C.
AU  - Paskett, E. D.
DB  - Embase
Medline
DO  - 10.1002/cncr.33184
KW  - adult
African American
age
article
axillary lymph node
breast cancer
breast surgery
cancer chemotherapy
cancer patient
cancer surgery
controlled study
demography
dissection
ethnicity
exercise
female
Functional Assessment of Cancer Therapy Breast
high school
human
intervention study
lymphedema
major clinical study
physiotherapy
prevention
quality of life
race
randomized controlled trial
sentinel lymph node
surgery
United States
LA  - English
M3  - Article in Press
N1  - L2007015361
2020-10-22
PY  - 2020
SN  - 1097-0142
0008-543X
ST  - Health-related quality of life outcomes for the LEAP study—CALGB 70305 (Alliance): A lymphedema prevention intervention trial for newly diagnosed breast cancer patients
T2  - Cancer
TI  - Health-related quality of life outcomes for the LEAP study—CALGB 70305 (Alliance): A lymphedema prevention intervention trial for newly diagnosed breast cancer patients
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L2007015361&from=export
http://dx.doi.org/10.1002/cncr.33184
ID  - 822
ER  - 

TY  - JOUR
AB  - IMPORTANCE: Patients with cancer are at risk for unplanned hospitalizations during treatment which can increase the cost of care. OBJECTIVES: To determine demographic and clinical factors associated with healthcare utilization and costs among clinical trial participants. DESIGN, SETTING, AND PATIENTS: We conducted a retrospective analysis among breast cancer patients over the age of 65 treated on SWOG clinical trials from 1999 to 2011 with trial data linked to Medicare claims. MAIN OUTCOMES AND MEASURES: The outcomes were healthcare utilization (emergency room visits (ER), hospitalizations) and costs from Medicare Claims. Demographic, clinical, and prognostic factors were captured from clinical trial records. We identified cardiovascular comorbidities/risk factors (CVD-RFs) of diabetes, hypertension, hypercholesterolemia, and coronary artery disease (CAD) from Medicare claims. Multivariable logistic and linear regression were used to assess the association between CVD-RFs and outcomes. RESULTS: Among the 708 patients included in the analysis, 160 (22.6%) experienced 234 separate hospitalizations, and 193 (27.3%) experienced 311 separate ER visits. Black race was associated with an increase in hospitalizations (OR [95% CI], 2.52 [1.10-5.79], p = 0.03), but not emergency room visits compared to white race. Diabetes, hypertension, hypercholesterolemia, and CAD were all independently associated with increased risk of both hospitalizations and ER visit. Hypertension had the strongest association, with more than a threefold risk of hospitalization for those with hypertension compared to those without (OR [95% CI], 3.16 [1.85-5.40], p < 0.001). For those with ≥ 3 RFs, the risk of hospitalization was nearly 3 times greater compared to 0 or 1 CVD-RFs (OR [95% CI], 2.74 [1.71-4.38], p < 0.001). Similar results were seen for ER visits. In the first 12 months after trial registration, patients with diabetes ($38,324 vs $30,923, 23.9% increase, p = 0.05), hypercholesterolemia ($34,168 vs $30,661, 11.4% increase, p = 0.02), and CAD ($37,781 vs $31,698, 19.2% increase, p = 0.04) had statistically significantly higher total healthcare costs. Additionally, those with ≥ 2 significant CVD-RFs ($35,353 vs. $28,899, 22.3% increase, p = 0.005) had statistically significantly higher total healthcare costs. CONCLUSIONS: Among participants treated on clinical trials, black race and presence of multiple cardiovascular comorbidities was associated with a substantial increase in ER visits, hospitalizations and healthcare costs. Efforts to reduce unplanned hospitalizations should focus on this high-risk group.
AD  - Columbia University Medical Center and the Herbert Irving Comprehensive Cancer Center, 161 Fort Washington Avenue, 10-1068, New York, NY, 10032, USA. dlh23@columbia.edu.
SWOG Statistics and Data Management Center, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Columbia University Medical Center and the Herbert Irving Comprehensive Cancer Center, 161 Fort Washington Avenue, 10-1068, New York, NY, 10032, USA.
Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
AN  - 32306168
AU  - Hershman, D. L.
AU  - Till, C.
AU  - Wright, J. D.
AU  - Accordino, M.
AU  - Vaidya, R.
AU  - Barlow, W. E.
AU  - Ramsey, S.
AU  - Unger, J. M.
DA  - Jun
DO  - 10.1007/s10549-020-05634-1
DP  - NLM
ET  - 2020/04/20
IS  - 2
KW  - Aged
Aged, 80 and over
Breast Neoplasms/*economics/epidemiology/therapy
Clinical Trials, Phase II as Topic
Clinical Trials, Phase III as Topic
Comorbidity
Ethnic Groups/*statistics & numerical data
Female
Follow-Up Studies
Health Care Costs/*statistics & numerical data
Hospitalization/*statistics & numerical data
Humans
Medicare
Patient Acceptance of Health Care/*statistics & numerical data
Prognosis
Retrospective Studies
United States/epidemiology
*Breast cancer
*Elderly
*Hospitalizations
*Resource utilization
LA  - eng
N1  - 1573-7217
Hershman, Dawn L
Orcid: 0000-0001-8807-153x
Till, Cathee
Wright, Jason D
Accordino, Melissa
Vaidya, Riha
Barlow, William E
Ramsey, Scott
Unger, Joseph M
1UG1CA189974-01/CA/NCI NIH HHS/United States
Journal Article
Netherlands
Breast Cancer Res Treat. 2020 Jun;181(2):455-463. doi: 10.1007/s10549-020-05634-1. Epub 2020 Apr 18.
PY  - 2020
SN  - 0167-6806
SP  - 455-463
ST  - Healthcare utilization and cost of care in elderly breast cancer patients enrolled in SWOG clinical trials
T2  - Breast Cancer Res Treat
TI  - Healthcare utilization and cost of care in elderly breast cancer patients enrolled in SWOG clinical trials
VL  - 181
ID  - 39
ER  - 

TY  - JOUR
AB  - Background and rationale: East Asian adults are known to have higher levels of visceral adiposity than whites, African Americans, and Hispanic adults in the US. This visceral fat deposition, because of its close proximity to the portal vein, has greater metabolic activity and is associated with a greater risk of cardiometabolic diseases and possibly certain cancers (e.g., breast and colorectal cancers). Newly introduced weight loss interventions, specifically, intermittent energy restriction (IER), have been proposed to be as effective as continuous energy restriction, achieve higher and long‐term compliance, and may predominantly result in a decrease in visceral fat. Thus, implementing this novel weight loss intervention among East Asian Americans with high visceral fat deposition would be particularly beneficial . Goal: This study aims to demonstrate the feasibility to conduct an intermittent energy restriction (IER) nutritional intervention aimed at reducing visceral adiposity in overweight Asian Americans middle‐aged adults. 1. To finalize and implement a protocol for an IER intervention plus exercise with the goal of reducing visceral fat in overweight adult East Asian Americans (EAA). The protocol will include an intensive dietary intervention and an exercise program administered by a dietitian through individual meetings and the use of new technologies to monitor dietary compliance. 2. After eligibility screening, 70 individuals will be randomized to either the intensive intervention diet group or to a non‐intensive intervention (active comparator) diet group for 12 weeks. The intensive intervention group will follow a low carbohydrate‐ low energy IER diet for two consecutive days, and the Mediterranean (MED) diet for the other five days and meet estimated energy requirements (IER + MED group). The active comparator group will follow the Dietary Approaches to Stop Hypertension (DASH) diet for all seven days and meet estimated energy requirements (DASH group). With an expected attrition rate of ~25%, the investigators expect ~50 participants to complete the study. 3. To evaluate study retention, protocol adherence, effect size of the intervention on body weight, total adiposity, DXA measured visceral fat (main outcome), estimated visceral adipose tissue area, and selected clinical measures (e.g., waist circumference, hip circumference). Design: Randomized lifestyle intervention trial to compare the effects of two twelve‐week diets ‐ (i) an IER + MED diet versus (ii) DASH diet‐ on DXA quantified visceral fat deposition distribution in overweight/obese men and women. Both intervention groups will be asked to follow a moderate exercise program (1 hour of walking five days a week). The research will be carried out in the University of Hawaii Cancer Center (UHCC). The investigators will determine and compare the primary and secondary endpoints at least five days after the last 2 energy‐restricted days to a corresponding day of the week in the DASH group at the completion of the 12th week of IER+MED or DASH diets. Assessing dietary intervention adherence: Dietary intake of energy, fat (monounsaturated fatty acids (MUFA), Polyunsaturated fatty acids (PUFA) and saturated fat), carbohydrate, protein, dietary fiber and alcohol will be assessed prior to the first week of intervention, the 5‐6th week, and the 12th week. Participants will capture images of foods eaten and consumed over four days (i.e., before and after images of each eating occasion). A mobile app designed to seamlessly take images of foods/beverages will be loaded to onto each participant's mobile telephones for free and removed at the end of the study. Physical activity level will be assessed at baseline using a physical activity questionnaire. Advice, support and monitoring in both diet groups Foods eaten for the IER+MED and DASH diets will be self‐selected by the participants and not provided by the study team. The IER+MED and DASH groups will receive clear instructions on how to follow the allocated diet in a face‐to‐face die ary consultation with one of the trial dietitians (45‐ 60 minute appointment) at the UHCC. Both groups will receive comprehensive written instructions of how to follow the diets at home, including recommended portion sizes and recipes and suggested meal plans. Both groups will receive appropriate behavioral techniques to promote adherence to diets (i.e., self‐monitoring of diet and goal setting). Participants will be contacted by telephone by an allocated dietitian one week after randomization to check that they have started the diet, to assess understanding of the diet and to provide any trouble shooting advice. Participants will be contacted by an allocated dietitian with weekly phone calls in weeks 1 to 4 to discuss adherence and any problems with the diet; and with every other week phone calls in weeks 5 to 12. Both groups will be asked to record 4‐day dietary records with the mobile food record at Week 6 and Week 11. This will allow assessment to adherence of the allocated diets and better tailor dietary advice. Participants will be asked to report overall compliance to the diet and physical activity plans using a scale of 0‐10 for each, on the weekly and fortnightly phone calls with the dietitian. The IER+MED group will also be asked to record adherence to the 2‐day IER using a scale of 0‐2. All participants will also be advised to become more active, walking at least one hour per day five days per week. The intermittent energy restriction (IER) group will be encouraged to walk on the non‐IER days. Post‐Study At the end of the study all participants will be offered advice on continued weight loss and/or weight loss maintenance if they have reached a target weight and this is appropriate. This will include advice regarding preferred diet, i.e., IER+MED or DASH. If resources permit, the investigators will recontact participants six and twelve months after the end of the intervention to assess dietary intake, physical activity and body weight. Statistical Considerations Statistical analysis will be conducted within Epidemiology Program, UHCC. The primary aim is to determine changes in percentage visceral fat between the IER+MED diet and the DASH diet over a 3 months period. The sample size of 25 participants per group has been chosen to detect a difference of 15 percentage points in the reduction in visceral fat between the two different diets, assuming an estimated 25% drop‐out rate. Calculations assume a two‐sided t‐test with estimated standard deviation of 10% and the conventional 5% significance level. The primary analysis will be performed on an intent‐to‐treat principle, where all participants will be analyzed by randomization group, regardless of compliance. The primary endpoints of visceral fat measurements will be regressed on randomization group and time point, as well as potential confounders, using a mixed model approach accounting for the repeated measures at baseline, and 6 and 12 weeks. The primary hypothesis will be tested by a contrast F test comparing the difference between groups in the change from baseline to 12 weeks. The 6 month assessment will be similarly tested to understand the trend over time. If there is evidence of a linear change in fat over time, time will be entered as a continuous variable and the slope will be compared between groups. Visceral fat will be modelled as an absolute area and as percentage of total area. The secondary analysis will analyze relationship between the IER+MED intervention and total adiposity. Ethical Considerations The study will be performed in accordance with the ethical principles in the Declaration of Helsinki and the University of Hawaii operational and ethical guidelines for research and other applicable regulatory requirements. Participant information and consent Consent to enter the study will be sought from each participant only after a full explanation has been given, information has been provided and time allowed for consideration. The right of the participant to refuse to participate without giving reasons will be respecte . Discontinuation and withdrawal Participants are free to withdraw from the study at any time, without prejudice to further treatment. Participants may also be discontinued from the study at any time, at the discretion of the investigator. Requests by the participant to be withdrawn from the study should be made through the principal investigator. Confidentiality After the participant has consented, any information from the study will be stored on a secure password‐protected computer that will be accessible only to the research team. Trial data on anthropometry and activity meter data will be kept in a secure computer at the UHCC. The food & beverage images from the 4‐day mobile food records will be kept on a secure server. Data Handling and Record Keeping All data will be kept strictly confidential. Any individual volunteering to participate will be assigned a code number, with the link to identifying information only available to the few study staff that require this information. Identifying information will be maintained in separate secure computer files from the remainder of the data. All forms will be stored in locked file cabinets, and those with identifying information will be stored separately from the other forms. No analysis will ever identify participants individually.
AN  - CN-01662431
AU  - Nct
PY  - 2018
ST  - The Healthy Diet and Lifestyle Study
T2  - https://clinicaltrials.gov/show/NCT03639350
TI  - The Healthy Diet and Lifestyle Study
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01662431/full
ID  - 1614
ER  - 

TY  - JOUR
AB  - Complementary and alternative medicines (CAM) such as isoflavones and black cohosh are commonly used to deal with menopausal symptoms, but benefit a limited proportion of women. The aim of this minireview is to summarize the evidence of the efficacy and safety of other herbal preparations. Randomized controlled trials (RCTs) find that the extracts of Mediterranean pine bark (Pycnogenol(®)), linseed, and Lepididium meyenii (Maca) reduce vasomotor symptoms. The results of RCTs of the hop flavonoid 8-prenylnaringenin are conflicting. Animal and human studies suggest that Dioscorea villosa (Wild yam),and Broccoli may protect against osteoporosis and breast and gynecological cancers but further evidence is required. Linseed may protect against breast cancer but the results are conflicting.
AD  - Menopause Clinic, Department of Obstetrics and Gynecology, University Hospital of Ghent, De Pintelaan, 185, 9000 Gent, Belgium. Electronic address: herman.depypere@ugent.be.
Emeritus, Department of Endocrinology and Metabolic Diseases, University Hospital of Ghent, De Pintelaan, 185, 9000 Gent, Belgium.
AN  - 24314619
AU  - Depypere, H. T.
AU  - Comhaire, F. H.
DA  - Feb
DO  - 10.1016/j.maturitas.2013.11.001
DP  - NLM
ET  - 2013/12/10
IS  - 2
KW  - Animals
Brassicaceae
Cimicifuga
Dioscorea
Drugs, Chinese Herbal/therapeutic use
Female
Flavonoids/therapeutic use
Flax
Hot Flashes/*drug therapy
Humans
Humulus
Isoflavones
Lepidium
*Menopause
Osteoporosis/prevention & control
*Phytotherapy
Plant Extracts
Plant Preparations/*therapeutic use
Randomized Controlled Trials as Topic
Herbal medicine
Menopause
Nutraceutical
Treatment
LA  - eng
N1  - 1873-4111
Depypere, Herman T
Comhaire, Frank H
Journal Article
Review
Ireland
Maturitas. 2014 Feb;77(2):191-4. doi: 10.1016/j.maturitas.2013.11.001. Epub 2013 Nov 19.
PY  - 2014
SN  - 0378-5122
SP  - 191-4
ST  - Herbal preparations for the menopause: beyond isoflavones and black cohosh
T2  - Maturitas
TI  - Herbal preparations for the menopause: beyond isoflavones and black cohosh
VL  - 77
ID  - 304
ER  - 

TY  - JOUR
AB  - Background: The quadrivalent human papillomavirus (HPV) vaccine (qHPV; types 6, 11, 16, 18) is indicated for men and women 9-26 years to prevent HPV associated anogenital high grade squamous intraepithelial lesions (HSIL) and cancer. ACTG 5298 was a randomized placebo controlled Phase 3 study in HIV-infected men who have sex with men (MSM), and women of qHPV to prevent persistent anal HPV infection. Baseline data is presented here.Methods: HIV-infected MSM, and women ≥ 27 years without previous anogenital or oral cancer were enrolled. Baseline anal cytology, high resolution anoscopy and collection of anal, oral, and vaginal specimens for HPV genotyping were performed and acceptability assessed.Results: 575 participants were enrolled (82% male and 18% female). Median age was 47 years. Race/ethnicity was 46% White, 31% Black, and 20% Hispanic. Plasma HIV-1 RNA was <50 copies/mL in 83% and median CD4 T count was 602 cells/μL. Abnormal anal cytology was detected in 62%, with corresponding HSIL on biopsy (bHSIL) in 33%. Anal HPV 6, 11, 16 and 18 were detected in 25%, 13%, 32%, and 18% of participants respectively. Prevalence of 0, 1, 2, 3, and 4 qHPV types was 40%, 38%, 17%, 4%, and 1%, respectively. Oral infection with ≥ 1 qHPV type was detected in 10% of participants. Study procedures were generally acceptable.Conclusions: At study baseline, there was a high prevalence of abnormal anal cytology, bHSIL, and HPV infection. Sixty percent of participants had anal infection with preventable qHPV types.
AD  - Department of Medicine, University of Pittsburgh, Pittsburgh, PN
Icahn School of Medicine at Mount Sinai, New York City, NY
Center for Biostatistics in AIDS Research, Harvard T.H. Chan School of Public Health, Boston, MA
Department of Laboratory Medicine, University of Washington, Seattle, WA
Department of Medicine, University of Washington, Seattle, WA
Merck and Co Inc. Kenilworth, NJ
Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD
University of North Carolina, Chapel Hill, NC
Baylor College of Medicine, Waco, TX
Social and Scientific Systems Inc. Silver Spring, MD
Weill Cornell Medicine, New York City, NY
AN  - 128623258. Corporate Author: ACTG 5298 Study Team. Language: English. Entry Date: 20190426. Revision Date: 20180324. Publication Type: journal article. Journal Subset: Biomedical
AU  - Cranston, Ross D.
AU  - Cespedes, Michelle S.
AU  - Paczuski, Pawel
AU  - Ming, Yang
AU  - Coombs, Robert W.
AU  - Dragavon, Joan
AU  - Saah, Alfred
AU  - Godfrey, Catherine
AU  - Webster-Cyriaque, Jennifer Y.
AU  - Chiao, Elizabeth Y.
AU  - Bastow, Barbara
AU  - Wilkin, Timothy
AU  - Yang, Ming
DB  - CINAHL Complete
DO  - 10.1097/OLQ.0000000000000745
DP  - EBSCOhost
IS  - 4
N1  - Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA. Grant Information: U01 AI068636/AI/NIAID NIH HHS/United States. NLM UID: 7705941.
PMID: NLM29465697.
PY  - 2018
SN  - 0148-5717
SP  - 266-271
ST  - High Baseline Anal HPV and Abnormal Anal Cytology in a Phase 3 Trial of the Quadrivalent HPV Vaccine in HIV-infected individuals over 26 years old: ACTG 5298
T2  - Sexually Transmitted Diseases
TI  - High Baseline Anal HPV and Abnormal Anal Cytology in a Phase 3 Trial of the Quadrivalent HPV Vaccine in HIV-infected individuals over 26 years old: ACTG 5298
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=128623258&site=ehost-live&scope=site
VL  - 45
ID  - 1969
ER  - 

TY  - JOUR
AB  - BACKGROUND: The quadrivalent human papillomavirus (HPV) vaccine (qHPV; types 6, 11, 16, 18) is indicated for men and women aged 9 to 26 years to prevent HPV associated anogenital high-grade squamous intraepithelial lesions (HSIL) and cancer. ACTG 5298 was a randomized placebo controlled Phase 3 study in human immunodeficiency virus (HIV)-infected men who have sex with men, and women of qHPV to prevent persistent anal HPV infection. Baseline data are presented here. METHODS: Human immunodeficiency virus-infected men who have sex with men, and women 27 years or older without previous anogenital or oral cancer were enrolled. Baseline anal cytology, high-resolution anoscopy and collection of anal, oral, and vaginal specimens for HPV genotyping were performed and acceptability assessed. RESULTS: Five hundred seventy-five (575) participants were enrolled (82% men and 18% women). Median age was 47 years. Race/ethnicity was 46% white, 31% black, and 20% Hispanic. Plasma HIV-1 RNA was less than 50 copies/mL in 83% and median CD4 T count was 602 cells/μL. Abnormal anal cytology was detected in 62%, with corresponding HSIL on biopsy (bHSIL) in 33%. Anal HPV 6, 11, 16, and 18 were detected in 25%, 13%, 32%, and 18% of the participants, respectively. Prevalence of 0, 1, 2, 3, and 4 qHPV types was 40%, 38%, 17%, 4%, and 1%, respectively. Oral infection with 1 or more qHPV type was detected in 10% of the participants. Study procedures were generally acceptable. CONCLUSIONS: At study baseline, there was a high prevalence of abnormal anal cytology, bHSIL, and HPV infection. Sixty percent of the participants had anal infection with preventable qHPV types.
AN  - 29528986
AU  - Cranston, R. D.
AU  - Cespedes, M. S.
AU  - Paczuski, P.
AU  - Yang, M.
AU  - Coombs, R. W.
AU  - Dragavon, J.
AU  - Saah, A.
AU  - Godfrey, C.
AU  - Webster-Cyriaque, J. Y.
AU  - Chiao, E. Y.
AU  - Bastow, B.
AU  - Wilkin, T.
C2  - PMC5868482
C6  - NIHMS912471 Merck and Co. T Wilkin has received institutional grant support from Gilead, BMS and GlaxoSmithKline/ViiV, and consulting support from GlaxoSmithKline/ViiV. M Cespedes has received institutional grant support from GlaxoSmithKline and consulting support from Gilead.
DA  - Apr
DO  - 10.1097/olq.0000000000000745
DP  - NLM
ET  - 2018/03/13
IS  - 4
KW  - Anal Canal/cytology/*pathology/*virology
Anus Neoplasms/epidemiology/virology
CD4 Lymphocyte Count
Double-Blind Method
Female
HIV Infections/complications/epidemiology/*virology
Homosexuality, Male
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16,
18/*administration & dosage
Humans
Male
Middle Aged
Papillomaviridae/genetics/isolation & purification
Papillomavirus Infections/epidemiology
Squamous Intraepithelial Lesions of the Cervix/epidemiology/pathology/virology
LA  - eng
N1  - 1537-4521
Cranston, Ross D
Cespedes, Michelle S
Paczuski, Pawel
Yang, Ming
Coombs, Robert W
Dragavon, Joan
Saah, Alfred
Godfrey, Catherine
Webster-Cyriaque, Jennifer Y
Chiao, Elizabeth Y
Bastow, Barbara
Wilkin, Timothy
ACTG 5298 Study Team
UM1 AI069494/AI/NIAID NIH HHS/United States
P30 CA016086/CA/NCI NIH HHS/United States
UM1 AI069415/AI/NIAID NIH HHS/United States
UM1 AI068634/AI/NIAID NIH HHS/United States
U01 AI068636/AI/NIAID NIH HHS/United States
UM1 AI106701/AI/NIAID NIH HHS/United States
U01 AI068634/AI/NIAID NIH HHS/United States
P30 AI050410/AI/NIAID NIH HHS/United States
Clinical Trial, Phase III
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Sex Transm Dis. 2018 Apr;45(4):266-271. doi: 10.1097/OLQ.0000000000000745.
PY  - 2018
SN  - 0148-5717 (Print)
0148-5717
SP  - 266-271
ST  - High Baseline Anal Human Papillomavirus and Abnormal Anal Cytology in a Phase 3 Trial of the Quadrivalent Human Papillomavirus Vaccine in Human Immunodeficiency Virus-Infected Individuals Older Than 26 Years: ACTG 5298
T2  - Sex Transm Dis
TI  - High Baseline Anal Human Papillomavirus and Abnormal Anal Cytology in a Phase 3 Trial of the Quadrivalent Human Papillomavirus Vaccine in Human Immunodeficiency Virus-Infected Individuals Older Than 26 Years: ACTG 5298
VL  - 45
ID  - 130
ER  - 

TY  - JOUR
AB  - Introduction: Altered serum microRNA (miRNA) levels may be correlated with a dysregulated expression pattern in parental tumor tissue and reflect the clinical evolution of disease. The overexpression of miR-21, miR-10b, and miR-19a is associated with the acquisition of malignant characteristics (increased tumor cell proliferation, migration, invasion, dissemination, and metastasis); thus, we determined their utility as serum biomarkers for aggressive breast cancer (HER2-overexpressed or -amplified [HER2+] and inflammatory breast cancer [IBC]). Experimental Design: In this prospective study, we measured miR-21, miR-10b, and miR-19a levels using quantitative reverse transcriptase-polymerase chain reaction in the serum of 113 breast cancer patients and determined their association with clinicopathologic factors and clinical outcome. Thirty healthy donors with no history of cancer were enrolled as controls. Results: Patients with non-metastatic HER2+ breast cancer had higher serum miR-21 median levels than patients with nonmetastatic HER2- disease (p = 0.044); whereas patients with metastatic HER2+ breast cancer had higher serum miR-10b median levels than patients with metastatic HER2- disease (p = 0.0004). There were no significant differences in serum miR- 19a median levels between HER2+ and HER22 groups, regardless of the presence of metastases. High serum miR-19a levels were associated with IBC (p = 0.039). Patients with metastatic IBC had significantly higher serum miR-19a median levels than patients with metastatic non-IBC (p = 0.019). Finally, high serum miR-19a levels were associated with longer progression-free survival time (10.3 vs. 3.2 months; p = 0.022) and longer overall survival time (median not reached vs. 11.2 months; p = 0.003) in patients with metastatic HER2+ IBC. Conclusion: High levels of miR-21 and miR-10b were present in the serum of patients with non-metastatic and metastatic HER2+ breast cancer, respectively. High levels of serum miR-19a may represent a biomarker for IBC that is predictive for favorable clinical outcome in patients with metastatic HER2+ IBC. © 2014 Anfossi et al.
AD  - Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, TX, United States
Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, University of Texas MD Anderson Cancer Center, Houston, TX, United States
Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, United States
Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, United States
Department of Experimental Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX, United States
University of Texas Graduate School of Biomedical Sciences at Houston, University of Texas MD Anderson Cancer Center, Houston, TX, United States
AU  - Anfossi, S.
AU  - Giordano, A.
AU  - Gao, H.
AU  - Cohen, E. N.
AU  - Tin, S.
AU  - Wu, Q.
AU  - Garza, R. J.
AU  - Debeb, B. G.
AU  - Alvarez, R. H.
AU  - Valero, V.
AU  - Hortobagyi, G. N.
AU  - Calin, G. A.
AU  - Ueno, N. T.
AU  - Woodward, W. A.
AU  - Reuben, J. M.
C7  - e83113
DB  - Scopus
DO  - 10.1371/journal.pone.0083113
IS  - 1
M3  - Article
N1  - Cited By :57
Export Date: 22 March 2021
PY  - 2014
ST  - High serum miR-19a levels are associated with inflammatory breast cancer and are predictive of favorable clinical outcome in patients with metastatic HER2+ inflammatory breast cancer
T2  - PLoS ONE
TI  - High serum miR-19a levels are associated with inflammatory breast cancer and are predictive of favorable clinical outcome in patients with metastatic HER2+ inflammatory breast cancer
UR  - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84897375137&doi=10.1371%2fjournal.pone.0083113&partnerID=40&md5=aa70200818767134b0f5d0f60b11a0f0
VL  - 9
ID  - 2401
ER  - 

TY  - JOUR
AB  - PURPOSE: Diabetes is common, increases with age, and may affect outcomes among people with cancer. Understanding the association between diabetes and cancer outcome is challenging, because patients with diabetes have increased all-cause mortality compared with patients without diabetes. METHODS: We systematically examined the phase III trial database of SWOG to identify patients enrolled in trials during the period from 1999 to 2011. We linked the SWOG clinical records to Medicare claims data according to Social Security number, sex, and date of birth. Medicare claims were used to identify diabetes with at least 6 months of continuous Medicare coverage immediately before registration. Multivariable Cox regression was used to compare survival outcomes between patients with and without diabetes for each of 10 tumor cohorts. The primary outcome was overall survival. We also examined progression-free survival and cancer-free survival. RESULTS: In total, 6,422 patients from 15 trials were ≥ 65.5 years of age, of whom 3,173 patients (49%) met the criteria for linkage to Medicare claims. Thirty percent (n = 952) had claims for diabetes before registration. Patients with diabetes were more likely to be black ( P < .001), but no other differences in demographic characteristics were observed. In multivariable Cox regression, no association was found between baseline diabetes and overall or progression-free survival; in one case, patients with diabetes had marginally worse cancer-free survival (advanced non-small-cell lung cancer; P = .05). A global test found that baseline diabetes was associated with worse overall survival ( P = .03) across the entire panel of analyses. CONCLUSION: Diabetes is common among elderly patients enrolled in clinical trials. Unlike prior observational studies, among patients treated with uniform treatment regimens, and controlling for known prognostic factors, we did not observe an association between diabetes and progression-free or cancer-free survival.
AD  - Dawn L. Hershman and Jason D. Wright, Columbia University Medical Center, New York, NY; Cathee Till, William E. Barlow, and Joseph M. Unger, SWOG Statistical Center, Fred Hutchinson Cancer Research Center; and Scott Ramsey, Fred Hutchinson Cancer Research Center, Seattle, WA.
AN  - 30657402
AU  - Hershman, D. L.
AU  - Till, C.
AU  - Wright, J. D.
AU  - Ramsey, S.
AU  - Barlow, W. E.
AU  - Unger, J. M.
C2  - PMC6640843
C6  - NIHMS1037377 manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/site/ifc. DAWN L. HERSHMAN: No relationship to disclose CATHEE TILL: Research Funding: Genentech (I) Patents, Royalties, Other Intellectual Property: Provisional patent application for CD20-targeted CAR T cells (I) JASON D. WRIGHT: Consulting or Advisory Role: Clovis Oncology, Tesaro SCOTT RAMSEY: Consulting or Advisory Role: Bayer, Seattle Genetics, Genentech, Bristol-Myers Squibb Research Funding: Bayer Travel, Accommodations, Expenses: Bayer Schering Pharma WILLIAM E. BARLOW: Research Funding: AstraZeneca (Inst), Merck (Inst) JOSEPH M. UNGER: No relationship to disclose
DA  - Nov
DO  - 10.1200/cci.17.00040
DP  - NLM
ET  - 2017/11/01
KW  - Age Factors
Aged
Aged, 80 and over
Cause of Death
Clinical Trials, Phase III as Topic
Databases, Factual
*Diabetes Complications/epidemiology
*Diabetes Mellitus/epidemiology
Female
Humans
Male
Medicare
Neoplasms/*complications/epidemiology/*mortality
Proportional Hazards Models
Risk Factors
Survival Analysis
United States/epidemiology
LA  - eng
N1  - 2473-4276
Hershman, Dawn L
Till, Cathee
Wright, Jason D
Ramsey, Scott
Barlow, William E
Unger, Joseph M
R01 CA134964/CA/NCI NIH HHS/United States
R01 CA169121/CA/NCI NIH HHS/United States
UG1 CA189974/CA/NCI NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
JCO Clin Cancer Inform. 2017 Nov;1:1-12. doi: 10.1200/CCI.17.00040.
PY  - 2017
SN  - 2473-4276
SP  - 1-12
ST  - History of Diabetes and Survival Outcome Among Participants 65 Years or Older in SWOG Clinical Trials
T2  - JCO Clin Cancer Inform
TI  - History of Diabetes and Survival Outcome Among Participants 65 Years or Older in SWOG Clinical Trials
VL  - 1
ID  - 152
ER  - 

TY  - JOUR
AB  - Background: In the United States, 5-year survival rates of 69% and 84%, respectively, have recently been reported for African-American and Caucasian women diagnosed with breast cancer. Differences in the levels of endogenous sex hormones in these populations could explain some of the variation in survival rates, since estrogen is recognized as a risk factor for this type of cancer. Purpose: Dietary factors are known to affect endogenous hormone levels; therefore, our study was designed to determine the serum hormone levels of African-American women consuming a typical North American diet, to determine the effect of a low-fat and high-fiber diet on their serum hormone levels, and to compare the base-line serum hormone levels in the African- American women with hormone data from our study of Caucasian women (n = 68) consuming the same control diet. Methods: Twenty-one healthy, premenopausal, African-American women who agreed to eat only food prepared in a clinical study unit were recruited into the study. The control diet was similar to their usual diet, being high in fat (40% of calories from fat) and low in fiber (12 g/day), and was consumed on average for 3 weeks. The concentrations of estrone (E1), estrone sulfate (E1SO4), estradiol (E2), free E2, androstenedione, and sex hormone-binding globulin (SHBG) in serum samples obtained from the participants during the last week of the control diet and during the follicular phase of their menstrual cycle were determined. The women were then switched to a diet low in fat (20% of calories as fat) and high in fiber (40 g/day); they consumed this diet for two menstrual cycles before blood samples were collected for determination of serum hormone levels. Repeated-measures regression modeling was used to investigate the relationship between diet and hormone levels in African-American and Caucasian women. All P values resulted from two-sided statistical tests. Results: Analysis of serum hormone levels in the African-American women indicated that the change in diet caused a significant decrease in E2 (-8.5 %; 95 % confidence interval [CI] = -16.1% to -0.3%;P-&lt;.03) and E1SO4 (- 16.2%; 95% CI = -22.1% to -9.8%; P&lt;.0001) and a significant increase in androstenedione levels (+18.3%; 95% CI = +10.3% to +26.8%; P&lt;.0001). SHBG levels of the African-American women were 5.6% (95% CI = -14.0% to +3.7%) lower for those on the experimental diet compared with those on the control diet, but the difference was not statistically significant. Comparison of control serum hormone values in the African-American women in this study with those in Caucasian women previously studied indicated that the Caucasian women had statistically significant lower levels of E1 (-37%; 95% CI = - 61.2% to-16.4%; P≤.0002), E2 (-54.5%; 95% CI = -90.9% to-25.1%; P≤.0001), free E2 (-30.2%; 95% CI = -65.7% to -2.3%; P&lt;.03), and androstenedione (- 48.3%; 95% CI = -83.7% to -19.7%; P≤.0004). Conclusion: African-American women appear to have higher levels of serum hormones than Caucasian women, and dietary modification can result in a lowering of serum estrogens.
AD  - Dept. of Fam. Med. and Comm. Health, Tufts University, School of Medicine, Boston, MA, United States
Department of Biostatistics, Harvard School of Public Health, Boston, MA, United States
Department of Epidemiology, Harvard School of Public Health, Boston, MA, United States
Dept. Obstet. and Gynecol. and Med., Univ. of Massachussetts Med. School, Worcester, MA, United States
Nutrition Unit, Dept. of Fam. Med. and Comm. Health, Tufts University School of Medicine, 136 Harrison Ave., Boston, MA 02111, United States
AU  - Woods, M. N.
AU  - Barnett, J. B.
AU  - Spiegelman, D.
AU  - Trail, N.
AU  - Hertzmark, E.
AU  - Longcope, C.
AU  - Gorbach, S. L.
DB  - Scopus
DO  - 10.1093/jnci/88.19.1369
IS  - 19
M3  - Article
N1  - Cited By :77
Export Date: 22 March 2021
PY  - 1996
SP  - 1369-1374
ST  - Hormone levels during dietary changes in premenopausal African-American women
T2  - Journal of the National Cancer Institute
TI  - Hormone levels during dietary changes in premenopausal African-American women
UR  - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0029762816&doi=10.1093%2fjnci%2f88.19.1369&partnerID=40&md5=67e4337d50177a2946b3c626c781251a
VL  - 88
ID  - 2647
ER  - 

TY  - JOUR
AB  - OBJECTIVES: Because of the potential benefits and risks of hormone replacement therapy (HRT), information about the efficacy of HRT in different groups of women is important to patients and providers. The objectives of this study were to review the evidence on the benefits and risks of HRT in African American women and to present a quantitative analysis of the potential reduction in mortality from osteoporotic fractures and coronary heart disease and the potential increase in risk of breast and endometrial cancer. METHODS: A MEDLINE search of English-language observational studies and clinical trials on the effects of HRT on osteoporotic fractures and coronary heart disease (CHD) was conducted for the time period from 1966 to September 1998. Using available CHD mortality data for African American women and white women, potential reductions in mortality with HRT were explored for African American and white women. RESULTS: In the 30 studies on CHD and HRT, African American women were known to comprise only 173 (0.1%) of 148,437 participants. In 11 studies of HRT and osteoporotic fractures, only 128 (0.4%) of 40,299 participants were known to be African American women. An analysis of CHD mortality by decade intervals indicated that African American women, aged 55 to 64, are more likely to die from CHD each year than white women. Despite a lower incidence of breast and endometrial cancer among African American women, the mortality rates of African American women with these cancers is higher compared with white women. CONCLUSIONS: With the higher underlying CHD mortality rate among African American women, HRT is an important potential preventive therapy. The absence of African American women and other non-white women from clinical studies of HRT makes it difficult to fully assess the risks and benefits of HRT in this group of women.
AD  - Department of Gynecology and Obstetrics, Johns Hopkins Medical Institutions, Baltimore, MD 21202, USA.
AN  - 10374222
AU  - Nicholson, W. K.
AU  - Brown, A. F.
AU  - Gathe, J.
AU  - Grumbach, K.
AU  - Washington, A. E.
AU  - Pérez-Stable, E. J.
DA  - Summer
DP  - NLM
ET  - 1999/06/22
IS  - 2
KW  - African Americans/*statistics & numerical data
Aged
Attitude to Health
Cardiovascular Diseases/*ethnology/prevention & control
Clinical Trials as Topic/statistics & numerical data
Data Collection
Female
Genital Neoplasms, Female/*ethnology/prevention & control
Hormone Replacement Therapy/*methods
Humans
Incidence
Middle Aged
Osteoporosis, Postmenopausal/*ethnology/prevention & control
Patient Selection
Policy Making
Postmenopause/drug effects/*ethnology
Risk Factors
Survival Rate
United States/epidemiology
LA  - eng
N1  - Nicholson, W K
Brown, A F
Gathe, J
Grumbach, K
Washington, A E
Pérez-Stable, E J
HS 07373/HS/AHRQ HHS/United States
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.
Review
United States
Menopause. 1999 Summer;6(2):147-55.
PY  - 1999
SN  - 1072-3714 (Print)
1072-3714
SP  - 147-55
ST  - Hormone replacement therapy for African American women: missed opportunities for effective intervention
T2  - Menopause
TI  - Hormone replacement therapy for African American women: missed opportunities for effective intervention
VL  - 6
ID  - 718
ER  - 

TY  - JOUR
AB  - Interleukin-6 modulates immune response, estrogen production, and growth pathways in breast cancer. We evaluated the effect of several common, functional interleukin-6 promoter variants in node-positive breast cancer patients enrolled on a multicenter, cooperative group, adjuvant chemotherapy trial to determine whether these variants were associated with clinical outcome overall and by estrogen receptor tumor phenotype. Genomic DNA and clinical data were collected from a clinical trial of adjuvant anthracycline-based chemotherapy followed by randomization to high-dose cyclophosphamide/thiotepa or observation (Intergroup Trial 0121). Genotyping for -174G>C (rs1800795), -597G>A (rs1800797), and -572G>C (rs1800796) was done by site-specific PCR and PyroSequencing, whereas the -373A(n)T(n) repeat was directly sequenced. Log-rank tests and Cox modeling were used to compare outcomes by genotype/haplotype and other factors. Three hundred forty-six patients (64% of trial) had corresponding genotype/clinical data available and did not differ from overall trial participants. After adjustment, patients with estrogen receptor-positive tumors and genotypes 597 GG or 174 GG had significantly worse disease-free survival [hazard ratio (HR), 1.6; P = 0.02 and HR, 1.71; P = 0.007, respectively], whereas the 373 8A12T repeat appeared to be protective (HR, 0.62; P = 0.02). The presence of at least one copy of the haplotype ([-597G, -572G, -373[10A/11T], -174G]) was associated with worse disease-free survival (HR, 1.46; P = 0.04). Kaplan-Meier plots show that all patients in this group relapsed by 24 months from diagnosis. This poor-risk haplotype was quite common overall (estimated frequency, 0.20) and twice as frequent among Blacks (estimated frequency, 0.41).
AD  - Department of Medicine (Hematology/Oncology), University of Pennsylvania School of Medicine, Philadelphia, PA, USA. Angela.Demichele@uphs.upenn.edu
AN  - 19435922
AU  - DeMichele, A.
AU  - Gray, R.
AU  - Horn, M.
AU  - Chen, J.
AU  - Aplenc, R.
AU  - Vaughan, W. P.
AU  - Tallman, M. S.
C2  - PMC4304767
C6  - NIHMS433959
DA  - May 15
DO  - 10.1158/0008-5472.Can-08-2989
DP  - NLM
ET  - 2009/05/14
IS  - 10
KW  - Adult
Antineoplastic Combined Chemotherapy Protocols/therapeutic use
Breast Neoplasms/drug therapy/*genetics/mortality/pathology
Cell Division
Disease-Free Survival
Female
*Genetic Variation
Humans
Interleukin-6/*genetics
Lymphatic Metastasis
Middle Aged
*Polymorphism, Single Nucleotide
*Promoter Regions, Genetic
Receptors, Estrogen/*analysis
Receptors, Progesterone/analysis
Retrospective Studies
Survival Analysis
Survivors
LA  - eng
N1  - 1538-7445
DeMichele, Angela
Gray, Robert
Horn, Michelle
Chen, Jinbo
Aplenc, Richard
Vaughan, William P
Tallman, Martin S
U10 CA021115/CA/NCI NIH HHS/United States
U10 CA017145/CA/NCI NIH HHS/United States
U10 CA066636/CA/NCI NIH HHS/United States
R01 CA104581/CA/NCI NIH HHS/United States
U10 CA023318/CA/NCI NIH HHS/United States
U10 CA015488/CA/NCI NIH HHS/United States
Journal Article
Cancer Res. 2009 May 15;69(10):4184-91. doi: 10.1158/0008-5472.CAN-08-2989. Epub 2009 May 12.
PY  - 2009
SN  - 0008-5472 (Print)
0008-5472
SP  - 4184-91
ST  - Host genetic variants in the interleukin-6 promoter predict poor outcome in patients with estrogen receptor-positive, node-positive breast cancer
T2  - Cancer Res
TI  - Host genetic variants in the interleukin-6 promoter predict poor outcome in patients with estrogen receptor-positive, node-positive breast cancer
VL  - 69
ID  - 471
ER  - 

TY  - JOUR
AB  - Prostate cancer is the most commonly diagnosed cancer in men in the United States and affects African Americans disproportionately when compared to other ethnic groups. There are unclear reasons for this disparity, but several factors may include race, nutrition, family history of cancer, and screening. With early detection of prostate cancer, survival is much better; thus, screening may be helpful, especially for high-risk individuals. Prostate cancer screening continues to be controversial. A paucity of data exists on what prostate cancer screening means to African Americans, particularly in rural areas, and how they make the decision whether or not to undergo prostate cancer screening. This study interviewed 17 African American men to explore how and when they decided about prostate cancer screening. Most of the men (n = 9) said that they had prostate cancer screening. Three themes emerged from the data: (1) these men had information on prostate cancer; (2) family and friends played an important role in the men's decision-making process; and (3) for screening, it was necessary for the men to have a trusting relationship with their healthcare provider. These findings confirm that the decision-making process is not a simple process. The study's results can help healthcare providers understand some of the important decision-making factors in prostate cancer screening for African American men.
AD  - School of Nursing, University of Virginia, Charlottesville, VA 22908-0782, USA. raj9c@virginia.edu
AN  - 105475381. Language: English. Entry Date: 20090424. Revision Date: 20150820. Publication Type: Journal Article
AU  - Jones, R. A.
AU  - Steeves, R.
AU  - Williams, I.
DB  - CINAHL Complete
DO  - 10.1097/NCC.0b013e3181982c6e
DP  - EBSCOhost
IS  - 2
KW  - Black Persons -- United States
Cancer Screening
Decision Making
Prostatic Neoplasms -- Prevention and Control
Adult
Aged
Audiorecording
Constant Comparative Method
Convenience Sample
Descriptive Statistics
Family Role
Field Notes
Funding Source
Health Education
Male
Middle Age
Patient Attitudes -- Evaluation
Phenomenological Research
Professional-Patient Relations
Research Subject Recruitment
Rural Areas
Semi-Structured Interview
Thematic Analysis
Trust
United States
Human
N1  - research; tables/charts. Journal Subset: Core Nursing; Double Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Nursing; Peer Reviewed; USA. Grant Information: NIH/National Institute of Nursing Research--P-20, with additional funding by the Rural Health Care Research Center at the University of Virginia School of Nursing. NLM UID: 7805358.
PMID: NLM19258830.
PY  - 2009
SN  - 0162-220X
SP  - 166-172
ST  - How African American men decide whether or not to get prostate cancer screening
T2  - Cancer Nursing
TI  - How African American men decide whether or not to get prostate cancer screening
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105475381&site=ehost-live&scope=site
VL  - 32
ID  - 1970
ER  - 

TY  - JOUR
AB  - Clinical trials (CTs) are important for advancing public health and medical research, however, CT recruitment is challenging. The high reading level of CT information and the technical language of providers or researchers can serve as barriers to recruitment. Prior studies on the informed consent process found that consent documents often contain complicated terms. Limited research has examined resources specifically used to recruit individuals into CTs. The purpose of this study was to examine the content and readability of CT recruitment education resources in one U.S. state. Convenience sampling was employed for the collection of CT recruitment materials. A codebook was developed based on previous content analyses and emergent themes from statewide focus groups about CTs. A total of 127 materials were collected and analyzed (37.8% print; 62.2% Web). Most content was focused on treatment-related CTs (60.6%). Inclusion criteria related to specific disease conditions (88.9%) and age (73.6%) were described most often. Only 30% of resources had an explicit call to action. Overall mean readability level was Grade 11.7. Web-based materials were significantly more likely to be written at a higher grade level than print materials (p <= .0001). Readability also differed significantly according to resource distributor/creator, CT type, person quoted, and presence or absence of inclusion criteria and an explicit call to action. Our study provides insight into the content and difficulty level of recruitment materials intended to provide initial information about a CT. Future studies should examine individuals' comprehension of recruitment materials and how participation intentions are associated with recruitment messages. (C) 2014 Elsevier Inc. All rights reserved.
AN  - WOS:000340301400015
AU  - Friedman, D. B.
AU  - Kim, S. H.
AU  - Tanner, A.
AU  - Bergeron, C. D.
AU  - Foster, C.
AU  - General, K.
DA  - Jul
DO  - 10.1016/j.cct.2014.05.004
IS  - 2
N1  - 24836075
PY  - 2014
SN  - 1551-7144
SP  - 275-283
ST  - How are we communicating about clinical trials? An assessment of the content and readability of recruitment resources
T2  - Contemporary Clinical Trials
TI  - How are we communicating about clinical trials? An assessment of the content and readability of recruitment resources
VL  - 38
ID  - 3005
ER  - 

TY  - JOUR
AB  - RATIONALE: Radiographic lung cancer screening guidelines and coverage requirements warrant a shared decision-making process. Guidance is needed regarding how to conduct shared decision making effectively. A useful organizing theme should include consideration of a patient's response to and tolerance of uncertainty associated with lung cancer screening. OBJECTIVES: The objectives of this study are to: (1) describe how patients respond to specific categories of uncertainty in the context of lung cancer screening, and (2) inform strategies for addressing concerns about uncertainty as part of the shared decision making. METHODS: We performed two series of structured interviews on participants in a convenience sample of current or former cigarette smokers recruited from primary care and pulmonary practices in Philadelphia. An interview guide included prompts related to benefits, harms, and responses to general and specific types of uncertainty (stochastic, statistical, and evidentiary) associated with lung cancer screening. Interviews were audio-recorded, transcribed, and independently coded by two investigators. An inductive analysis was conducted, and major themes were identified. MEASUREMENTS AND MAIN RESULTS: Twenty-two adults participated in the study. Sixty-eight percent were men, 72% were black or African American, and 50% met U.S. Preventive Services Task Force criteria for lung cancer screening. The primary themes to emerge from our study were: (1) the desire to decrease uncertainty may motivate lung cancer screening decisions; (2) uncertainty is an attribute of health states that impacts how patients weigh benefits and harms of lung cancer screening; (3) patient understanding and tolerance of uncertainty varies across stochastic, statistical, and evidentiary uncertainty; and (4) provider-patient communication may mitigate intolerance of uncertainty in the context of lung cancer screening. CONCLUSIONS: A systematic approach to understanding and addressing patients' concerns about uncertainty in the context of lung cancer screening can guide a patient-centered approach to shared decision making. The results of this study can inform provider-patient communication strategies regarding the decision to perform radiographic lung cancer screening.
AD  - 1 Division of General Internal Medicine.
2 Center for Health Equity Research and Promotion.
3 Division of Hematology and Oncology, and.
5 Department of Radiology, and.
4 Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, Pennsylvania.
6 Department of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
7 Division of Pulmonary, Allergy, and Critical Care, Department of Medicine, and.
8 Veterans Affairs Connecticut Healthcare System, West Haven, Connecticut; and.
9 Department of Medicine, Yale University, New Haven, Connecticut.
AN  - 27676595
AU  - Schapira, M. M.
AU  - Aggarwal, C.
AU  - Akers, S.
AU  - Aysola, J.
AU  - Imbert, D.
AU  - Langer, C.
AU  - Simone, C. B., 2nd
AU  - Strittmatter, E.
AU  - Vachani, A.
AU  - Fraenkel, L.
C2  - PMC5122480
DA  - Nov
DO  - 10.1513/AnnalsATS.201604-290OC
DP  - NLM
ET  - 2016/09/28
IS  - 11
KW  - Aged
*Communication
*Decision Making
Early Detection of Cancer/methods
Female
Humans
Interviews as Topic
Lung Neoplasms/*diagnosis/*psychology
Male
Middle Aged
*Patient Participation
Philadelphia
Physician-Patient Relations
Practice Guidelines as Topic
Radiography
*Uncertainty
*ambiguity
*lung cancer screening
LA  - eng
N1  - 2325-6621
Schapira, Marilyn M
Aggarwal, Charu
Akers, Scott
Aysola, Jaya
Imbert, Diana
Langer, Corey
Simone, Charlie B 2nd
Strittmatter, Emily
Vachani, Anil
Fraenkel, Liana
I21 HX001334/HX/HSRD VA/United States
P30 CA016520/CA/NCI NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.
Ann Am Thorac Soc. 2016 Nov;13(11):1969-1976. doi: 10.1513/AnnalsATS.201604-290OC.
PY  - 2016
SN  - 2329-6933 (Print)
2325-6621
SP  - 1969-1976
ST  - How Patients View Lung Cancer Screening. The Role of Uncertainty in Medical Decision Making
T2  - Ann Am Thorac Soc
TI  - How Patients View Lung Cancer Screening. The Role of Uncertainty in Medical Decision Making
VL  - 13
ID  - 201
ER  - 

TY  - JOUR
AB  - Purpose : We chose to examine the impact of socioeconomic factors an accrual to National Cancer Institute (NCI)-sponsored cancer treatment trials. Patients and Methods: We estimated the geographic and demographic cancer burden in the United States and then identified 24,332 patients accrued to NCI-sponsored cancer treatment trials during a 12-month period. Next, we examined accrual by age, sex, geographic residence, health insurance status, health maintenance organization market penetration, several proxy measures of socioeconomic status, the availability of an oncologist, and the presence of a hospital with an approved multidisciplinary cancer program. Results: Pediatric patients were accrued to clinical trials at high levels, whereas after adolescence, only a small percentage of cancer patients were enrolled onto clinical trials. There were few differences by sex. Black males as well as Asian-American and Hispanic adults were accrued to clinical trials at lower rates than white cancer patients of the same age. Overall, the highest observed accrual was in suburban counties. Compared with the United States population, patients enrolled onto clinical trials were significantly less likely to be uninsured and more like to have Medicare health insurance. Geographic areas with higher socioeconomic levels had higher levels of clinical trial accruals. The number of oncologists and the presence of approved cancer programs both were significantly associated with increased accrual to clinical trials. Conclusion: We must work to increase the number of adults who enroll onto trials, especially among the elderly. Ongoing partnership with professional societies may be an effective approach to strengthen accrual to clinical trials. (C) 2002 by American Society of Clinical Oncology.
AN  - WOS:000175154900023
AU  - Sateren, W. B.
AU  - Trimble, E. L.
AU  - Abrams, J.
AU  - Brawley, O.
AU  - Breen, N.
AU  - Ford, L.
AU  - McCabe, M.
AU  - Kaplan, R.
AU  - Smith, M.
AU  - Ungerleider, R.
AU  - Christian, M. C.
DA  - Apr 15
DO  - 10.1200/JCO.2002.08.056
IS  - 8
N1  - 351
11956272
PY  - 2002
SN  - 0732-183X
SP  - 2109-2117
ST  - How sociodemographics, presence of oncology specialists, and hospital cancer programs affect accrual to cancer treatment trials
T2  - Journal of Clinical Oncology
TI  - How sociodemographics, presence of oncology specialists, and hospital cancer programs affect accrual to cancer treatment trials
VL  - 20
ID  - 2703
ER  - 

TY  - JOUR
AB  - Elevated serum phosphorus is associated with higher death risk in hemodialysis patients. Previous studies have suggested that both higher serum parathyroid hormone (PTH) level and higher dietary protein intake may contribute to higher serum phosphorus levels. However, it is not well known how these two factors simultaneously contribute to the combined risk of hyperphosphatemia in real patient-care scenarios. We hypothesized that the likelihood of hyperphosphatemia increases across higher serum PTH and higher normalized protein catabolic rate (nPCR) levels, a surrogate of protein intake. Over an 8-year period (July 2001-June 2009), we identified 69,355 maintenance hemodialysis patients with PTH, nPCR, and phosphorus data in a large dialysis provider. Logistic regression models were examined to assess the association between likelihood of hyperphosphatemia (serum phosphorus >5.5mg/dl) and serum PTH and nPCR increments. Patients were 61±15 years old and included 46% women, 33% blacks, and 57% diabetics. Both higher serum PTH level and higher protein intake were associated with higher risk of hyperphosphatemia in dialysis patients. Compared with patients with PTH level 150-<300 pg/ml and nPCR level 1.0-<1.2 g/kg/day, patients with iPTH4600 pg/ml and nPCR>1.2 g/kg/day had a threefold higher risk of hyperphosphatemia (OR: 3.17, 95% CI: 2.69-3.75). Hyperphosphatemia is associated with both higher dietary protein intake and higher serum PTH level in maintenance hemodialysis patients. Worsening or resistant hyperphosphatemia may be an under-appreciated consequence of secondary hyperparathyroidism independent of dietary phosphorus load. Management of hyperphosphatemia should include diligent correction of hyper-parathyroidism while maintaining adequate intake of high protein foods with low phosphorus content. © 2013 International Society of Nephrology.
AD  - K. Kalantar-Zadeh, Harold Simmons Center for Kidney Disease Research and Epidemiology, Division of Nephrology and Hypertension, University of California, 101 The City Drive South, City Tower, Orange, CA 92868-3217, United States
AU  - Streja, E.
AU  - Lau, W. L.
AU  - Goldstein, L.
AU  - Sim, J. J.
AU  - Molnar, M. Z.
AU  - Nissenson, A. R.
AU  - Kovesdy, C. P.
AU  - Kalantar-Zadeh, K.
DB  - Embase
DO  - 10.1038/kisup.2013.96
IS  - 5
KW  - albumin
alkaline phosphatase
bicarbonate
calcium
creatinine
ferritin
hemoglobin
parathyroid hormone
phosphorus
acquired immune deficiency syndrome
adult
aged
albumin blood level
alkaline phosphatase blood level
article
atherosclerosis
coronary artery atherosclerosis
bicarbonate blood level
calcium blood level
cardiovascular disease
case mix
catabolism
cerebrovascular disease
chronic obstructive lung disease
comorbidity
congestive heart failure
creatinine blood level
diabetes mellitus
disease association
female
ferritin blood level
hemodialysis patient
hemoglobin blood level
human
Human immunodeficiency virus infection
hyperparathyroidism
hyperphosphatemia
hypertension
hypothesis
insurance
iron binding capacity
leukocyte count
lymphocyte count
maintenance therapy
major clinical study
male
malignant neoplasm
marriage
middle aged
parathyroid hormone blood level
patient selection
peripheral vascular disease
phosphate blood level
prevalence
protein intake
renal replacement therapy
secondary hyperparathyroidism
treatment duration
LA  - English
M3  - Article
N1  - L370392703
2014-03-06
2014-03-12
PY  - 2013
SN  - 2157-1716
2157-1724
SP  - 462-468
ST  - Hyperphosphatemia is a combined function of high serum PTH and high dietary protein intake in dialysis patients
T2  - Kidney International Supplements
TI  - Hyperphosphatemia is a combined function of high serum PTH and high dietary protein intake in dialysis patients
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L370392703&from=export
http://dx.doi.org/10.1038/kisup.2013.96
VL  - 3
ID  - 1064
ER  - 

TY  - JOUR
AB  - Background: Hematopoietic cell transplants (HCTs) are associated with high morbidity and mortality, which complicate the decision-making process for people considering HCT clinical trials. There is a lack of research examining longitudinally how patients make clinical trial participation decisions in US cancer referral centers. Objective: A qualitative study was conducted to examine how patients and their family caregivers decide to participate in HCT research at a US cancer referral center. Methods: Semistructured interviews were conducted with 25 patients enrolled in early-stage phase 2 HCT research studies and with 20 family caregivers. Interviews were conducted before HCT and approximately days 80 and 365 after HCT. Results: Most patients (92%) and their caregivers (75%) decided to participate in research well before consent conferences at the cancer referral center. Patients' reasons for deciding to participate included having "no other option," seeking a cure, and following their home oncologists' recommendations. Conclusion: Currently, US researchers are primarily guided by Federal regulations that view the decision-making process as a cognitive one. Findings confirmed cognition was a part of consent; however, most patients made the decision to participate in high-risk clinical trials long before they had been apprised of the specific information about the study and before the consent conference. Implications for Practice: The high risk of death from the disease and/or the HCT underscored the emotional component of decision making and affirmed that researchers need to acknowledge this emotional component to meet the ethical imperative of providing "informed consent. © 2011 Lippincott Williams & Wilkins.
AD  - K. Shannon-Dorcy, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, 1100 Fairview Ave N, Seattle, WA 98109-1024, United States
AU  - Shannon-Dorcy, K.
AU  - Drevdahl, D. J.
DB  - Embase
Medline
DO  - 10.1097/NCC.0b013e318207cb03
IS  - 6
KW  - adult
African American
aged
American Indian
article
cancer research
caregiver
chronic lymphatic leukemia
clinical article
clinical decision making
clinical trial (topic)
controlled clinical trial
controlled study
engraftment
female
follow up
government regulation
graft versus host reaction
hematopoietic stem cell transplantation
high risk patient
Hispanic
Hodgkin disease
human
informed consent
male
medical ethics
medical information
multiple myeloma
phase 2 clinical trial
priority journal
promyelocytic leukemia
qualitative research
refractory anemia
semi structured interview
United States
LA  - English
M3  - Article
N1  - L51234092
2011-01-21
2011-11-11
PY  - 2011
SN  - 0162-220X
1538-9804
SP  - 428-433
ST  - I had already made up my mind: Patients and caregivers' perspectives on making the decision to participate in research at a us cancer referral center
T2  - Cancer Nursing
TI  - I had already made up my mind: Patients and caregivers' perspectives on making the decision to participate in research at a us cancer referral center
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L51234092&from=export
http://dx.doi.org/10.1097/NCC.0b013e318207cb03
VL  - 34
ID  - 1131
ER  - 

TY  - JOUR
AB  - This article describes common experiences of African American women breast cancer survivors through poetic analysis. Group-as-a-whole theory and empirical and interpretive phenomenology guided analysis of transcripts from three focus groups (n = 21) of African American breast cancer survivors. Familiarity with transcripts and themes led to awareness of poetic ways in which African American women described experiences. Black feminist literature and African American historical references contextualized survivors' experiences. Poetic interpretations of African American women's breast cancer experiences, from diagnosis to survivorship, were created from transcript dialogues. Verbatim words were used to construct the poems, as often as possible. Eleven poems describe the journey from diagnosis to survivorship as experienced by African American women. The poetry may raise levels of awareness of African American women's breast cancer survivorship experiences. Attention to subtleties that underpin culture within the context of health care environments may help health care providers to improve cultural competence.
AN  - 105918292. Language: English. Entry Date: 20080104. Revision Date: 20200623. Publication Type: Journal Article
AU  - Kooken, W. C.
AU  - Haase, J. E.
AU  - Russell, K. M.
DB  - CINAHL Complete
DO  - 10.1177/0193945907302968
DP  - EBSCOhost
IS  - 7
KW  - Black Persons -- United States
Breast Neoplasms
Cancer Survivors
Poetry
Adult
Aged
Audiorecording
Breast Neoplasms -- Diagnosis
Coping
Cultural Competence
Female
Focus Groups
Funding Source
Middle Age
Phenomenological Research
Professional-Patient Relations
Quality of Life -- Evaluation
Research Subject Recruitment
Secondary Analysis
Thematic Analysis
Theory
United States
Human
N1  - poetry; research; tables/charts. Commentary: Chiu L. Commentary by Chiu. (WEST J NURS RES) Nov2007; 29 (7): 924-926; Thomas-MacLean R. Commentary by Thomas-MacLean. (WEST J NURS RES) Nov2007; 29 (7): 920-921; Sinding C. Commentary by Sinding. (WEST J NURS RES) Nov2007; 29 (7): 922-923. Journal Subset: Core Nursing; Expert Peer Reviewed; Nursing; Peer Reviewed; USA. Grant Information: National Institutes of Health/National Institute of Nursing Research; University School of Nursing T 32 Training Grant, NR 07066 National Institute of Nursing Research. NLM UID: 7905435.
PMID: NLM17895427.
PY  - 2007
SN  - 0193-9459
SP  - 896-919
ST  - 'I've been through something': poetic explorations of African American women's cancer survivorship
T2  - Western Journal of Nursing Research
TI  - 'I've been through something': poetic explorations of African American women's cancer survivorship
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105918292&site=ehost-live&scope=site
VL  - 29
ID  - 1988
ER  - 

TY  - JOUR
AB  - It is estimated that the lifetime risk of being diagnosed with prostate cancer is 1 in 5. The identification of risk factors, including age, African-American ancestry, family history, and possibly diet and environmental factors, has allowed health care professionals the opportunity to identify, screen, and study men at the greatest risk of developing prostate cancer. The risk factors, current screening tools, and the informed consent process for men participating in a prostate cancer screening program are outlined.
AD  - Englewood-Mount Sinai Cancer Risk Assessment and Counselling Program, Mount Sinai School of Medicine/Englewood Hospital and Medical Center, Englewood, NJ, USA.
AN  - 11998038
AU  - Grumet, S. C.
AU  - Bruner, D. W.
DA  - Feb
DP  - NLM
ET  - 2002/05/10
IS  - 1
KW  - Aged
Humans
Male
Mass Screening/*methods
Medical History Taking
Middle Aged
Patient Selection
Physical Examination
Prostate-Specific Antigen/blood
Prostatic Neoplasms/diagnostic imaging/epidemiology/*prevention & control
Risk Factors
Ultrasonography
LA  - eng
N1  - Grumet, S C
Bruner, D W
Journal Article
Review
United States
Urol Nurs. 2000 Feb;20(1):15-8, 23-4, 46.
PY  - 2000
SN  - 1053-816X (Print)
1053-816x
SP  - 15-8, 23-4, 46
ST  - The identification and screening of men at high risk for developing prostate cancer
T2  - Urol Nurs
TI  - The identification and screening of men at high risk for developing prostate cancer
VL  - 20
ID  - 668
ER  - 

TY  - JOUR
AB  - PURPOSE OF REVIEW: The clinical value of active surveillance may still be limited due to acceptance and considerable misclassification rates, and inadequate follow-up criteria. This review focuses on the most recent developments in the use of active surveillance and patient-specific factors that may be used to identify patients suitable for this strategy. RECENT FINDINGS: The number of patients diagnosed with low-risk prostate cancer has risen. Active surveillance acceptance rates are increasing, but still limited and varying importantly (2-49%). Misclassification is inevitable in all currently used protocols, although most of these patients still have relatively favorable-risk prostate cancer. African-American race, obese, and older-aged patients show more unfavorable intermediate results in an active surveillance situation. These are unlikely to be explained by the small differences in preoperative characteristics only. Psychological profiling may also be added to the selection process. Most studies report intermediate endpoints only. SUMMARY: Patient-specific factors may be incorporated when identifying patients for active surveillance. This does not imply that active surveillance is not justified in specific groups, but may suggest the need for an intensified and personalized selection, instead of a one-size-fits-all approach.
AD  - aUtrecht University Medical Centre, Utrecht, The Netherlands bPeter MacCallum Cancer Centre cRoyal Melbourne Hospital, Melbourne, Australia.
AN  - 25692721
AU  - van den Bergh, R. C.
AU  - Murphy, D. G.
AU  - Costello, A. J.
DA  - May
DO  - 10.1097/mou.0000000000000159
DP  - NLM
ET  - 2015/02/19
IS  - 3
KW  - Clinical Protocols
Disease Progression
Humans
Male
Neoplasm Staging
Patient Selection
Precision Medicine/*trends
Prostate-Specific Antigen/*blood
Prostatic Neoplasms/*diagnosis/pathology
Quality of Life
Risk Assessment
Risk Factors
*Watchful Waiting
LA  - eng
N1  - 1473-6586
van den Bergh, Roderick C N
Murphy, Declan G
Costello, Anthony J
Journal Article
Review
United States
Curr Opin Urol. 2015 May;25(3):252-7. doi: 10.1097/MOU.0000000000000159.
PY  - 2015
SN  - 0963-0643
SP  - 252-7
ST  - Identification of candidates for observation
T2  - Curr Opin Urol
TI  - Identification of candidates for observation
VL  - 25
ID  - 258
ER  - 

TY  - JOUR
AB  - PURPOSE/OBJECTIVES: To describe problems chosen as targets of problem-solving therapy by spouses and partners of patients with prostate cancer. DESIGN: Descriptive, cross-sectional. SETTING: Spouses' and partners' homes. SAMPLE: Spouses and partners (N = 66) aged 32-79 years (mean = 60 years). The sample was predominantly Caucasian (82%) and African American (8%). METHODS: As part of a randomized clinical trial, women received problem-solving therapy to help manage issues related to their husbands' or partners' prostate cancer. The issues they chose to address during therapy and the categorization of the issues fell into four groups: treatment and side-effect issues, patient issues, family issues, and spouse issues. Scores on the Social Problem-Solving Inventory-Revised, which measures everyday problem-solving skills, and the Profile of Mood States, which measures mood disturbance, were contrasted with the problems women chose to address. MAIN RESEARCH VARIABLES: Problems faced by spouses and partners of patients with prostate cancer. FINDINGS: The most frequently reported categories were spouse issues (e.g., women's emotional wellness, balancing their medical concerns with their husbands' condition) and patient issues (e.g., men's lack of communication, fear, or depression). CONCLUSIONS: Findings of this study alert nurses to a variety of key problem areas for spouses and partners of patients with prostate cancer. IMPLICATIONS FOR NURSING: Spouses and partners play a critical role when their loved ones have cancer. Understanding the problems spouses and partners face can help nurses design optimal supportive care interventions.
AD  - Rebecca and John Moores University of California, San Diego (UCSD), Cancer Center, USA.
AN  - 16858462
AU  - Hawes, S.
AU  - Malcarne, V.
AU  - Ko, C.
AU  - Sadler, G.
AU  - Banthuia, R.
AU  - Sherman, S.
AU  - Varni, J.
AU  - Schmidt, J.
DA  - Jul 1
DO  - 10.1188/06.Onf.807-814
DP  - NLM
ET  - 2006/07/22
IS  - 4
KW  - Adult
Aged
Aged, 80 and over
Communication
Cross-Sectional Studies
Family Therapy
Female
Humans
Male
Mental Health
Middle Aged
Mood Disorders
*Problem Solving
Prostatic Neoplasms/*complications
Randomized Controlled Trials as Topic
*Spouses
LA  - eng
N1  - 1538-0688
Hawes, Starlyn
Malcarne, Vanessa
Ko, Celine
Sadler, Georgia
Banthuia, Rajni
Sherman, Sandra
Varni, James
Schmidt, Joseph
R25 CA 65745/CA/NCI NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
United States
Oncol Nurs Forum. 2006 Jul 1;33(4):807-14. doi: 10.1188/06.ONF.807-814.
PY  - 2006
SN  - 0190-535x
SP  - 807-14
ST  - Identifying problems faced by spouses and partners of patients with prostate cancer
T2  - Oncol Nurs Forum
TI  - Identifying problems faced by spouses and partners of patients with prostate cancer
VL  - 33
ID  - 559
ER  - 

TY  - THES
AB  - Rationale: Breast cancer is the most commonly diagnosed cancer, excluding skin cancers, and is the second leading cause of cancer death among women in the United States. Despite advancements in screening, early detection, and cancer treatments, not all women have benefited equally. Racial and ethnic minorities, particularly African American women, and those of low income have higher breast cancer mortality rates compared to the general population. Previous research has identified a number of demographic (e.g., race/ethnicity, age, health insurance, income), medical (e.g., comorbidities with other illnesses, family medical history), environmental (e.g., geographic area), and health system (e.g., type of cancer-related services available) factors associated with breast cancer disparities. However, these factors have largely been examined individually, and no study has comprehensively evaluated how multiple individual and contextual factors impact breast cancer outcomes. Therefore, this dissertation project had two primary aims: 1) to identify distinct subgroups of breast cancer patients based on demographic, medical, environmental, and health system factors that have been shown to influence timeliness of breast cancer care, and 2) to examine differences among emergent classes in timely initiation of breast cancer treatment. Design: The proposed study used archival data from the control arm of the Patient Navigation Research Project (PNRP), a five-year 10-site clinical trial of adult patients from medically underserved populations with an abnormal cancer screening or a new diagnosis of breast, cervical, colorectal, or prostate cancer. For this study, the sample included 198 patients with newly diagnosed Stage I-III breast cancer who received usual standard of care (control arm) from four PNRP sites, and who received a treatment for breast cancer (e.g., surgery, chemotherapy, radiation, hormonal therapy). Control participants were primarily recruited via medical record abstraction for which informed consent was waived. Exploratory Latent Class Analysis (LCA) was used to identify subgroups of breast cancer patients based on demographic (race/ethnicity, age at diagnosis, health insurance status, annual household income), medical (comorbidities [Charlson Comorbidity Index], family history of cancer), environmental (geographic residence [urban vs. rural], and health system (cancer-related services available onsite) factors associated with timeliness of breast cancer care. For the second aim, the study conducted logistic regression analyses to examine if class membership significantly predicted timely breast cancer treatment initiation, defined as initiation of any treatment for breast cancer (e.g., surgery, chemotherapy, radiation, hormonal therapy) within 30 or 60 days of diagnosis, controlling for type of breast cancer treatment. Results: Three classes of breast cancer patients were identified with varying patterns of patient demographic, medical, and health system characteristics. The first class was distinguished by its high endorsement of indicators associated with timely breast cancer care; patients in this class were most likely to be White, have private health insurance, and have a family history of cancer. The second class was characterized by individual and contextual factors associated with treatment delays, including having public health insurance, not having a family history of cancer, and receiving care at a facility with the least amount of breast cancer services available onsite. The third class represented breast cancer patients with the oldest average age at diagnosis and the greatest number of medical comorbidities. Binomial logistic regression analyses demonstrated that the emergent classes did not significantly differ in the likelihood of initiating breast cancer treatment within 30 days or 60 days from breast cancer… (PsycINFO Database Record (c) 2018 APA, all rights reserved)
AN  - 2018-52509-265
AU  - Baik, Sharon Hyun
DB  - psyh
DP  - EBSCOhost
KW  - breast cancer
treatment
Cancer Screening
Neoplasms
N1  - Accession Number: 2018-52509-265. Other Journal Title: Dissertation Abstracts International. Partial author list: First Author & Affiliation: Baik, Sharon Hyun; San Diego State University, Psychology, US. Release Date: 20181129. Publication Type: Dissertation Abstract (0400). Format Covered: Electronic. Document Type: Dissertation. Dissertation Number: AAI10931886. ISBN: 978-0438305113. Language: English. Major Descriptor: Treatment. Minor Descriptor: Cancer Screening; Neoplasms. Classification: Health & Mental Health Treatment & Prevention (3300). Population: Human (10); Female (40). Location: US. Methodology: Empirical Study; Quantitative Study.
PB  - ProQuest Information & Learning
PY  - 2019
SN  - 0419-4217
978-0438305113
ST  - Identifying typologies of breast cancer patients based on multiple individual and contextual factors for timely treatment initiation
TI  - Identifying typologies of breast cancer patients based on multiple individual and contextual factors for timely treatment initiation
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2018-52509-265&site=ehost-live&scope=site
VL  - 80
ID  - 1679
ER  - 

TY  - JOUR
AB  - PURPOSE: We evaluated the use of abiraterone acetate (1,000 mg) plus prednisone (5 mg) in patients with high risk, nonmetastatic, castration resistant prostate cancer. MATERIALS AND METHODS: Patients considered at high risk for progression to metastatic disease (prostate specific antigen 10 ng/ml or greater, or prostate specific antigen doubling time 10 months or less) received abiraterone acetate plus prednisone daily in 28-day cycles. The primary study end point was the proportion of patients in whom a 50% or greater prostate specific antigen reduction was achieved during cycles 1 to 6. Secondary end points included time to prostate specific antigen progression, time to radiographic evidence of disease progression and safety. RESULTS: Of the 131 enrolled patients 44 (34%) remained on treatment with a median followup of 40.0 months. Median age was 72 years (range 48 to 90). Of the patients 82.4% were white and 14.5% were black. Median screening prostate specific antigen was 11.9 ng/dl and median prostate specific antigen doubling time was 3.4 months. Prostate specific antigen was significantly reduced (p <0.0001) with a 50% or greater prostate specific antigen reduction in 86.9% of cases and a 90% or greater reduction in 59.8%. Median time to prostate specific antigen progression was 28.7 months (95% CI 21.2-38.2). Median time to radiographic evidence of disease progression was not reached but on sensitivity analysis in 15 patients it was estimated to be 41.4 months (95% CI 27.6-not estimable). Baseline testosterone 12.5 ng/dl or greater and a 90% or greater prostate specific antigen reduction at cycle 3 were associated with longer time to prostate specific antigen progression and radiographic evidence of disease progression. Outcomes in black patients were similar to those in other patients. Adverse events, grade 3 or greater adverse events and serious adverse events were reported in 96.2%, 61.1% and 43.5% of patients, respectively. CONCLUSIONS: In patients with high risk, nonmetastatic, castration resistant prostate cancer treatment with abiraterone acetate plus prednisone demonstrated a significant 50% or greater prostate specific antigen reduction with encouraging results for the secondary end points, including the safety of 5 mg prednisone.
AD  - Helen Diller Family Comprehensive Cancer Center, University of California-San Francisco, San Francisco, California. Electronic address: ryan@umn.edu.
University of Colorado Cancer Center, Aurora, Colorado.
Carolina Urologic Research Center, Myrtle Beach, South Carolina.
Roswell Park Cancer Institute, Buffalo, New York.
Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
Janssen Scientific Affairs, LLC, Horsham, Pennsylvania.
Memorial Sloan Kettering Cancer Center, New York, New York.
AN  - 29630978
AU  - Ryan, C. J.
AU  - Crawford, E. D.
AU  - Shore, N. D.
AU  - Underwood, W., 3rd
AU  - Taplin, M. E.
AU  - Londhe, A.
AU  - Francis, P. S. J.
AU  - Phillips, J.
AU  - McGowan, T.
AU  - Kantoff, P. W.
C2  - PMC6429921
C6  - NIHMS981897
DA  - Aug
DO  - 10.1016/j.juro.2018.03.125
DP  - NLM
ET  - 2018/04/10
IS  - 2
KW  - Abiraterone Acetate/*therapeutic use
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Bone Neoplasms/*diagnostic imaging/secondary
Disease Progression
Disease-Free Survival
Drug Administration Schedule
Humans
Kallikreins/*blood
Kaplan-Meier Estimate
Magnetic Resonance Imaging
Male
Middle Aged
Prednisone/*therapeutic use
Prostate/diagnostic imaging/pathology
Prostate-Specific Antigen/*blood
Prostatic Neoplasms, Castration-Resistant/blood/diagnostic imaging/*drug
therapy/pathology
*abiraterone acetate
*adverse events
*prednisone
*prostate-specific antigen
*prostatic neoplasms
LA  - eng
N1  - 1527-3792
Ryan, Charles J
Crawford, E David
Shore, Neal D
Underwood, Willie 3rd
Taplin, Mary-Ellen
Londhe, Anil
Francis, Peter St John
Phillips, Jennifer
McGowan, Tracy
Kantoff, Philip W
P30 CA008748/CA/NCI NIH HHS/United States
Clinical Trial, Phase II
Journal Article
Multicenter Study
J Urol. 2018 Aug;200(2):344-352. doi: 10.1016/j.juro.2018.03.125. Epub 2018 Apr 6.
PY  - 2018
SN  - 0022-5347 (Print)
0022-5347
SP  - 344-352
ST  - The IMAAGEN Study: Effect of Abiraterone Acetate and Prednisone on Prostate Specific Antigen and Radiographic Disease Progression in Patients with Nonmetastatic Castration Resistant Prostate Cancer
T2  - J Urol
TI  - The IMAAGEN Study: Effect of Abiraterone Acetate and Prednisone on Prostate Specific Antigen and Radiographic Disease Progression in Patients with Nonmetastatic Castration Resistant Prostate Cancer
VL  - 200
ID  - 128
ER  - 

TY  - JOUR
AB  - Human papillomavirus (HPV) infection can lead to significant disease in males, including anogenital warts, intraepithelial neoplasias, and several types of oral and anogenital cancers. The quadrivalent HPV (type 6/11/16/18) L1 virus-like particle (VLP) vaccine (qHPV vaccine; Gardasil) has recently been demonstrated to prevent persistent infection and associated disease related to vaccine HPV types in males. We report the overall immunogenicity results from a trial of the quadrivalent HPV vaccine in males. Overall, 3,463 heterosexual men and 602 men who had sex with men were enrolled into a randomized, placebo-controlled, double-blind safety, immunogenicity, and efficacy study. Serum samples were collected prior to vaccination at day 1 and at months 7, 24, and 36 postvaccination. Immunogenicity was evaluated with a multiplex, competitive Luminex immunoassay. Almost all subjects (97.4 to 99.2%) seroconverted for vaccine HPV types by month 7. At month 36, 88.9%, 94.0%, 97.9%, and 57.0% of subjects were still seropositive for HPV-6, -11, -16, and -18, respectively. For all vaccine HPV types, black subjects had significantly higher antibody titers at month 7 than did both Caucasian and Asian subjects. An anamnestic antibody response was seen in men seropositive before vaccination. The vaccine was highly immunogenic in males 16 to 23 years of age; responses were comparable to those observed in women. Furthermore, the immune responses were consistent with the established efficacy of the vaccine in the prevention of incident and persistent HPV infection, anogenital warts, and anal intraepithelial neoplasia.
AD  - STI Research Centre, University of Sydney, Sydney, Australia. richard.hillman@sydney.edu.au
AN  - 22155768
AU  - Hillman, R. J.
AU  - Giuliano, A. R.
AU  - Palefsky, J. M.
AU  - Goldstone, S.
AU  - Moreira, E. D., Jr.
AU  - Vardas, E.
AU  - Aranda, C.
AU  - Jessen, H.
AU  - Ferris, D. G.
AU  - Coutlee, F.
AU  - Marshall, J. B.
AU  - Vuocolo, S.
AU  - Haupt, R. M.
AU  - Guris, D.
AU  - Garner, E. I.
C2  - PMC3272915
DA  - Feb
DO  - 10.1128/cvi.05208-11
DP  - NLM
ET  - 2011/12/14
IS  - 2
KW  - Adolescent
Adult
Antibodies, Viral/blood
Carcinoma in Situ/*prevention & control/virology
Condylomata Acuminata/immunology/*prevention & control/virology
Double-Blind Method
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
Human papillomavirus 11/immunology
Human papillomavirus 16/immunology
Human papillomavirus 18/immunology
Human papillomavirus 6/immunology
Humans
Male
Papillomavirus Infections/immunology/*prevention & control
Papillomavirus Vaccines/*immunology
Young Adult
LA  - eng
N1  - 1556-679x
Hillman, Richard J
Giuliano, Anna R
Palefsky, Joel M
Goldstone, Stephen
Moreira, Edson D Jr
Vardas, Eftyhia
Aranda, Carlos
Jessen, Heiko
Ferris, Daron G
Coutlee, Francois
Marshall, J Brooke
Vuocolo, Scott
Haupt, Richard M
Guris, Dalya
Garner, Elizabeth I O
M01 RR000079/RR/NCRR NIH HHS/United States
UL1 RR024131/RR/NCRR NIH HHS/United States
M01-RR-00079/RR/NCRR NIH HHS/United States
UL1RR024131/RR/NCRR NIH HHS/United States
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Clin Vaccine Immunol. 2012 Feb;19(2):261-7. doi: 10.1128/CVI.05208-11. Epub 2011 Dec 7.
PY  - 2012
SN  - 1556-6811 (Print)
1556-679x
SP  - 261-7
ST  - Immunogenicity of the quadrivalent human papillomavirus (type 6/11/16/18) vaccine in males 16 to 26 years old
T2  - Clin Vaccine Immunol
TI  - Immunogenicity of the quadrivalent human papillomavirus (type 6/11/16/18) vaccine in males 16 to 26 years old
VL  - 19
ID  - 379
ER  - 

TY  - JOUR
AB  - Lung cancer is one of the leading causes of death worldwide. Cell death pathways such as autophagy, apoptosis, and necrosis can provide useful clinical and immunological insights that can assist in the design of personalized therapeutics. In this study, variations in the expression of genes involved in cell death pathways and resulting infiltration of immune cells were explored in lung adenocarcinoma (The Cancer Genome Atlas: TCGA, lung adenocarcinoma (LUAD), 510 patients). Firstly, genes involved in autophagy (n = 34 genes), apoptosis (n = 66 genes), and necrosis (n = 32 genes) were analyzed to assess the prognostic significance in lung cancer. The significant genes were used to develop the cell death index (CDI) of 21 genes which clustered patients based on high risk (high CDI) and low risk (low CDI). The survival analysis using the Kaplan–Meier curve differentiated patients based on overall survival (40.4 months vs. 76.2 months), progression-free survival (26.2 months vs. 48.6 months), and disease-free survival (62.2 months vs. 158.2 months) (Log-rank test, p < 0.01). Cox proportional hazard model significantly associated patients in high CDI group with a higher risk of mortality (Hazard Ratio: H.R 1.75, 95% CI: 1.28–2.45, p < 0.001). Differential gene expression analysis using principal component analysis (PCA) identified genes with the highest fold change forming distinct clusters. To analyze the immune parameters in two risk groups, cytokines expression (n = 265 genes) analysis revealed the highest association of IL-15RA and IL 15 (> 1.5-fold, p < 0.01) with the high-risk group. The microenvironment cell-population (MCP)-counter algorithm identified the higher infiltration of CD8+ T cells, macrophages, and lower infiltration of neutrophils with the high-risk group. Interestingly, this group also showed a higher expression of immune checkpoint molecules CD-274 (PD-L1), CTLA-4, and T cell exhaustion genes (HAVCR2, TIGIT, LAG3, PDCD1, CXCL13, and LYN) (p < 0.01). Furthermore, functional enrichment analysis identified significant perturbations in immune pathways in the higher risk group. This study highlights the presence of an immunocompromised microenvironment indicated by the higher infiltration of cytotoxic T cells along with the presence of checkpoint molecules and T cell exhaustion genes. These patients at higher risk might be more suitable to benefit from PD-L1 blockade or other checkpoint blockade immunotherapies.
AD  - R. Kolhe, Department of Pathology, Medical College of Georgia, Augusta University, Augusta, GA, United States
AU  - Ahluwalia, P.
AU  - Ahluwalia, M.
AU  - Mondal, A. K.
AU  - Sahajpal, N.
AU  - Kota, V.
AU  - Rojiani, M. V.
AU  - Rojiani, A. M.
AU  - Kolhe, R.
DB  - Embase
DO  - 10.3390/cancers13010155
IS  - 1
KW  - CD8 antigen
CXCL13 chemokine
cytotoxic T lymphocyte antigen 4
hepatitis A virus cellular receptor 2
interleukin 15
interleukin 15 receptor alpha
programmed death 1 ligand 1
protein kinase Lyn
T lymphocyte receptor
adult
African American
aged
aneuploidy
apoptosis
article
autophagy (cellular)
cancer immunotherapy
cancer prognosis
cancer radiotherapy
cancer staging
Caucasian
CD8+ T lymphocyte
cell death
cell fate
cell infiltration
cell population
CXCL13 gene
disease free survival
disease specific survival
distant metastasis
female
gene
gene expression
genetic association
genetic variability
HAVCR2 gene
high risk patient
high risk population
human
immune response
immunocompetent cell
immunocompromised patient
immunogenomics
Kaplan Meier method
LAG3 gene
low risk patient
lung adenocarcinoma
lung cancer
lymph node metastasis
lymphocytic infiltration
LYN gene
macrophage
major clinical study
male
middle aged
mortality risk
neutrophil chemotaxis
overall survival
patient selection
PDCD1 gene
principal component analysis
progression free survival
proportional hazards model
survival analysis
TIGIT gene
tumor microenvironment
LA  - English
M3  - Article
N1  - L2005866828
2021-02-02
2021-02-05
PY  - 2021
SN  - 2072-6694
SP  - 1-18
ST  - Immunogenomic gene signature of cell-death associated genes with prognostic implications in lung cancer
T2  - Cancers
TI  - Immunogenomic gene signature of cell-death associated genes with prognostic implications in lung cancer
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L2005866828&from=export
http://dx.doi.org/10.3390/cancers13010155
VL  - 13
ID  - 760
ER  - 

TY  - THES
AB  - African American women with breast cancer face a higher risk of dying from their disease compared to women of other racial/ethnic groups. Experts suggest that this excess mortality would be significantly reduced if screening were more effectively utilized. The recognition of the relationship between culture, community and cancer has resulted in the proposition of a variety of community-based breast cancer education programs for African American women. Much is assumed about the receptivity of African American women to community based breast education programs, yet few studies have been conducted to validate if and or to what degree this is so. This research project was undertaken to determine the impact of a culturally appropriate education video on beliefs about breast cancer and screening in African American women ages 35-65. Sixty-seven women were recruited from metropolitan churches in Columbus, Georgia and one local sorority, namely Alpha Kappa Alpha Sorority, Inc. In addition to Columbus, Georgia, there were women recruited from rural churches in Montezuma, Georgia. Fifty-seven women completed both pre-post tests.The Champion Health Belief Model Scales (CHBMS) was used as a pre-test/post-test to determine if there is a significant change in any of the subscales of the CHMBS in African American women who view the Witness ProjectRTM education video. Demographic characteristics were analyzed using descriptive statistics. A non-parametric equivalent of the paired sample t-test called the Wilcoxin Signed Ranks Test was used to examine change in the CHBMS over time. Changes over time in perceived susceptibility to breast cancer and seriousness of breast cancer were examined. There were no significant changes in perceived susceptibility, but there was a significant change in seriousness, with participants having significantly lower perceptions of seriousness of breast cancer at post-test than at pre-test (p=0.01).The remaining subscales were examined for changes over time. Results indicated that participants reported significantly greater perceptions of benefits of self breast examination and benefits of mammography at the post-test with p values of 0.03 and 0.05 respectively. There were no significant changes over time in confidence in performing self breast examination, health motivation, and barriers to self examination and barriers to mammography.
AU  - Frazier, Linda M.
DB  - CINAHL Complete
DP  - EBSCOhost
KW  - Black Persons
Breast Neoplasms -- Education
Cultural Sensitivity -- Evaluation
Teaching Methods -- Evaluation
Videorecording -- Evaluation
Adult
Aged
Descriptive Statistics
Female
Georgia
Human
Middle Age
P-Value
Pretest-Posttest Design
T-Tests
Wilcoxon Signed Rank Test
M1  - D.N.P.
N1  - Accession Number: 109860755. Language: English. Entry Date: 20130920. Revision Date: 20150923. Publication Type: Doctoral Dissertation; research.
UMI Order AAI3538761
PB  - Georgia Health Sciences University
PY  - 2008
SN  - 9781303015342
SP  - 64 p-64 p
ST  - The impact of a culturally appropriate education video on beliefs about breast cancer in African American women ages 35-65
TI  - The impact of a culturally appropriate education video on beliefs about breast cancer in African American women ages 35-65
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=109860755&site=ehost-live&scope=site
ID  - 2123
ER  - 

TY  - JOUR
AB  - Background: Eliciting patients’ preferences within a framework of shared decision making (SDM) has been advocated as a strategy for increasing colorectal cancer (CRC) screening adherence. Our objective was to assess the effectiveness of a novel decision aid on SDM in the primary care setting. Methods: An interactive, computer-based decision aid for CRC screening was developed and evaluated within the context of a randomized controlled trial. A total of 665 average-risk patients (mean age, 57 years; 60% female; 63% black, 6% Hispanic) were allocated to 1 of 2 intervention arms (decision aid alone, decision aid plus personalized risk assessment) or a control arm. The interventions were delivered just prior to a scheduled primary care visit. Outcome measures (patient preferences, knowledge, satisfaction with the decision-making process [SDMP], concordance between patient preference and test ordered, and intentions) were evaluated using prestudy/poststudy visit questionnaires and electronic scheduling. Results: Overall, 95% of patients in the intervention arms identified a preferred screening option based on values placed on individual test features. Mean cumulative knowledge, SDMP, and intention scores were significantly higher for both intervention groups compared with the control group. Concordance between patient preference and test ordered was 59%. Patients who preferred colonoscopy were more likely to have a test ordered than those who preferred an alternative option (83% v. 70%; P < 0.01). Intention scores were significantly higher when the test ordered reflected patient preferences. Conclusions: Our interactive computer-based decision aid facilitates SDM, but overall effectiveness is determined by the extent to which providers comply with patient preferences. (PsycINFO Database Record (c) 2016 APA, all rights reserved)
AD  - Schroy, Paul C. III, Boston Medical Center, 85 East Concord Street, Suite 7715, Boston, MA, US, 02118
AN  - 2011-09417-009
AU  - Schroy, Paul C., III
AU  - Emmons, Karen
AU  - Peters, Ellen
AU  - Glick, Julie T.
AU  - Robinson, Patricia A.
AU  - Lydotes, Maria A.
AU  - Mylvanaman, Shamini
AU  - Evans, Stephen
AU  - Chaisson, Christine
AU  - Pignone, Michael
AU  - Prout, Marianne
AU  - Davidson, Peter
AU  - Heeren, Timothy C.
DB  - psyh
DO  - 10.1177/0272989X10369007
DP  - EBSCOhost
IS  - 1
KW  - shared decision making
colorectal cancer screening
computer-based decision aid
primary health care
patient satisfaction
Aged
Analysis of Variance
Colonoscopy
Colorectal Neoplasms
Decision Making, Computer-Assisted
Decision Support Techniques
Early Detection of Cancer
Female
Focus Groups
Health Knowledge, Attitudes, Practice
Humans
Male
Middle Aged
Physician-Patient Relations
Psychometrics
Risk Assessment
Surveys and Questionnaires
Cancer Screening
Client Participation
Colon Disorders
Decision Making
Decision Support Systems
Client Satisfaction
Computer Assisted Diagnosis
Neoplasms
Therapeutic Processes
N1  - Department of Medicine, Boston University School of Medicine, Boston, MA, US. Release Date: 20110822. Correction Date: 20120618. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: English. Conference Information: Annual Meeting of the Society for Medical Decision Making, 2008, Philadelphia, PA, US. Grant Information: Schroy, Paul C. III. Conference Note: Portions of this paper were presented at the aforementioned conference. Major Descriptor: Cancer Screening; Client Participation; Colon Disorders; Decision Making; Decision Support Systems. Minor Descriptor: Client Satisfaction; Computer Assisted Diagnosis; Neoplasms; Primary Health Care; Therapeutic Processes. Classification: Cancer (3293); Health & Mental Health Services (3370). Population: Human (10); Male (30); Female (40). Location: US. Age Group: Adulthood (18 yrs & older) (300); Middle Age (40-64 yrs) (360); Aged (65 yrs & older) (380). Tests & Measures: Satisfaction with the Decision-Making Process Scale [Appended]. Methodology: Empirical Study; Quantitative Study; Treatment Outcome. References Available: Y. Page Count: 15. Issue Publication Date: Jan-Feb, 2011. Publication History: Accepted Date: Jan 27, 2010; First Submitted Date: Jul 14, 2009.
Sponsor: Agency for Healthcare Research and Quality. Grant: R01HS013912. Recipients: Schroy, Paul C. III
PY  - 2011
SN  - 0272-989X
1552-681X
SP  - 93-107
ST  - The impact of a novel computer-based decision aid on shared decision making for colorectal cancer screening: A randomized trial
T2  - Medical Decision Making
TI  - The impact of a novel computer-based decision aid on shared decision making for colorectal cancer screening: A randomized trial
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2011-09417-009&site=ehost-live&scope=site
ORCID: 0000-0001-5643-3559
ORCID: 0000-0001-8747-6199
ORCID: 0000-0002-6657-7342
ORCID: 0000-0002-3207-9257
paul.schroy@bmc.org
VL  - 31
ID  - 1771
ER  - 

TY  - JOUR
AB  - Background: Based on cohort studies and a limited number of prospective studies, physical activity (PA) can improve quality of life (QoL) in non‐Hodgkin lymphoma (NHL), multiple myeloma (MM), and patients (pts) undergoing autologous stem cell transplant (ASCT). There are also data to suggest that survival (Pophali et al, ASH 2017) is improved with increased PA in NHL pts. After ASCT, it is known that QoL and physical function will decrease. PA has been linked to improved QoL outcomes for pts undergoing ASCT. Recently, evidence shows fitness trackers can help monitor and improve adherence to PA in cancer pts. We aim to study the feasibility of a PA intervention in NHL/MM patients undergoing ASCT and to assess the use of smart watches in this setting to monitor PA. Methods: We included MM and NHL pts undergoing ASCT. Key inclusion criteria included ECOG < 2 and ability to complete a 6 minute walk test (6MWT). Pts were asked to adhere to a PA program of 150 minutes a week on a stationary bicycle or by walking, recording data in a diary and by wearing a smart watch provided to them. Data were collected from date of hospitalization to discharge, with research staff checking on pts at least twice a week to ensure adequate data collection and adherence. Feasibility of the intervention was assessed by average weekly minutes of PA performed by self‐report. Validation of moderate intensity PA was attempted by heart rate (HR) monitoring (goal 40% of HR reserve) by the smart watch. QoL was assessed from FACT‐lymphoma and FACT‐MM surveys prior to transplant and around day 30 post ASCT. Clinical outcomes measured include time to neutrophil engraftment (≥0.5 10E3/mcL) and physical function (6MWT). Survey scores and 6MWT distances were compared using Wilcoxson rank sum tests. Historical controls at Emory matched for age, disease status, conditioning, stem cells infused, and use of stimulating factor were used to compare median time to neutrophil engraftment. Results: Since April 2018, 10 pts have enrolled and completed the PA intervention. Median age was 62, 70% were males, 40% had NHL, 50% were African American, and 50% were Caucasian. All pts were chemotherapy sensitive at time of transplant. Conditioning regimens included BEAM (30%), Melphalan (60%) and Busulfan/cyclophosphamide/etoposide (10%). Granulocyte colony stimulating factor was used in 60% of pts. Median follow up was 22 days. Six of 9 (67%) patients were able to adhere to a PA regimen while hospitalized by self‐report, with one patient having incomplete PA data. Eight of ten patients wore their watch regularly for HR analysis. Six of these eight patients (75%) consistently reached HR goal during their PA. Of the 6 patients who met PA goal by self‐report, 4 (67%) consistently met HR goals during PA (sample data, figure 1). QoL scores measured by FACT‐lymphoma and FACT‐MM showed no significant decrease in total score from pre‐intervention to post‐discharge follow up (median score difference‐2.5 points, p‐value=0.72, table 1). Individual sections of FACT surveys showed no significant differences except emotional well‐being (median score difference, ‐3 points, p=0.008, table 1). Physical function by 6MWT decreased by a median of 97 meters (pre‐test median of 435 meters, post‐test median of 333.5 meters, p‐value=0.016, table 1). Compared to 20 historical controls, median time to engraftment was similar (12 days vs 12.5 days). Conclusion: Our findings support the feasibility of studying an inpatient PA intervention for ASCT pts using traditional and novel methods. Nearly 70% of pts who participated were successful in adhering to a PA regimen of 150 minutes of exercise. Ongoing assessment by research staff to encourage pts to adhere to prescribed exercise, as well as use of a smart watch to validate PA by HR data was feasible. QoL results are consistent with prior PA studies in ASCT pts, with no significant decrease in overall QoL by day +30. Additional analyses from this study, including a flow‐based panel to measure the impact of PA o immune reconstitution post ASCT, will be presented at the meeting. We plan to utilize the findings from this feasibility study to construct a randomized study of PA in ASCT assessing QoL as a primary outcome.
AN  - CN-01791907
AU  - Ip, A.
AU  - Churnetski, M. C.
AU  - Calzada, O.
AU  - Chang, A.
AU  - Liu, Y.
AU  - Bumpers, N.
AU  - Leeson, D.
AU  - Mahar, E.
AU  - Hesaroieh, I.
AU  - Crain, M.
AU  - et al.
DO  - 10.1182/blood-2018-99-119757
KW  - *autologous stem cell transplantation
*cancer patient
*feasibility study
*multiple myeloma
*nonhodgkin lymphoma
*walk test
Activity tracker
Adult
African American
Bicycle
Cancer chemotherapy
Caucasian
Clinical article
Clinical outcome
Cohort analysis
Conference abstract
Controlled study
Disease course
Engraftment
Exercise
Female
Follow up
Heart rate
Hospital patient
Hospitalization
Human
Human cell
Immune reconstitution
Male
Middle aged
Monitoring
Neutrophil
Outcome assessment
Pretest posttest design
Prospective study
Quality of life
Randomized controlled trial
Rank sum test
Self report
Staff
Statistical significance
Validation process
Wellbeing
M3  - Journal: Conference Abstract
PY  - 2018
ST  - The impact of a physical activity intervention can be accurately assessed by smart watches in patients completing autologous stem cell transplantation for lymphoma or multiple myeloma: results of a feasibility study
T2  - Blood
TI  - The impact of a physical activity intervention can be accurately assessed by smart watches in patients completing autologous stem cell transplantation for lymphoma or multiple myeloma: results of a feasibility study
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01791907/full
VL  - 132
ID  - 1491
ER  - 

TY  - JOUR
AB  - Lifestyle interventions may reduce inflammation and lower breast cancer (BrCa) risk. This randomized trial assessed the impact of the Sistas Inspiring Sistas Through Activity and Support (SISTAS) study on plasma C-reactive protein (CRP), interleukin-6 (IL-6) and Dietary Inflammatory Index (DII). This unblinded, dietary and physical activity trial was implemented in 337 obese (body mass index [BMI] ≥30 kg/m(2)) African American (AA) women recruited between 2011 and 2015 in South Carolina through a community-based participatory approach with measurements at baseline, 3 months, and 12 months. Participants were randomized into either intervention (n = 176) or wait-list control group (n = 161). Linear mixed-effect models were used for analyses of CRP and IL-6. Baseline CRP was significantly higher in those with greater obesity, body fat percentage, and waist circumference (all p <.01). No difference was observed between groups for CRP or IL-6 at 3 or 12 months; however, improvements in diet were observed in the intervention group compared to the control group (p = .02) at 3 months but were not sustained at 12 months. Although the intervention was not successful at reducing levels of CRP or IL-6, a significant decrease was observed in DII score for the intervention group, indicating short-term positive dietary change.
AD  - Cancer Prevention and Control Program, University of South Carolina , Columbia, South Carolina, USA.
Department of Epidemiology and Biostatistics, Arnold School of Public Health, University of South Carolina , Columbia, South Carolina, USA.
Department of Psychiatry & Behavioral Sciences, Medical University of South Carolina , Charleston, South Carolina, USA.
College of Nursing, University of South Carolina , Columbia, South Carolina, USA.
Department of Pathology, Microbiology and Immunology, School of Medicine, University of South Carolina , Columbia, South Carolina, USA.
Connecting Health Innovations LLC , Columbia, South Carolina, USA.
Department of Health Promotion, Education, and Behavior, Arnold School of Public Health, University of South Carolina , Columbia, South Carolina, USA.
AN  - 32248760
AU  - Babatunde, O. A.
AU  - Arp Adams, S.
AU  - Truman, S.
AU  - Sercy, E. Msph
AU  - Murphy, A. E.
AU  - Khan, S. Msw
AU  - Hurley, Tg Ms
AU  - Wirth, M. D.
AU  - Choi, S. K.
AU  - Johnson, H. Ba
AU  - Hebert, J. R. ScD
C2  - PMC7332405
C6  - NIHMS1595005
DA  - Aug
DO  - 10.1080/03630242.2020.1746950
DP  - NLM
ET  - 2020/04/07
IS  - 7
KW  - *African Americans
*breast cancer
*c-reactive protein
*dietary Inflammatory Index
*inflammation
LA  - eng
N1  - 1541-0331
Babatunde, Oluwole Adeyemi
Arp Adams, Swann
Truman, Samantha
Sercy, Erica MSPH
Murphy, Angela E
Khan, Samira MSW
Hurley, Thomas G MS
Wirth, Michael D
Choi, Seul Ki
Johnson, Hiluv BA
Hebert, James R ScD
Orcid: 0000-0002-0677-2672
K00 CA222722/CA/NCI NIH HHS/United States
K05 CA136975/CA/NCI NIH HHS/United States
R15 CA179355/CA/NCI NIH HHS/United States
F99 CA222722/CA/NCI NIH HHS/United States
R44 DK103377/DK/NIDDK NIH HHS/United States
U54 CA153461/CA/NCI NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
Women Health. 2020 Aug;60(7):792-805. doi: 10.1080/03630242.2020.1746950. Epub 2020 Apr 5.
PY  - 2020
SN  - 0363-0242 (Print)
0363-0242
SP  - 792-805
ST  - The impact of a randomized dietary and physical activity intervention on chronic inflammation among obese African-American women
T2  - Women Health
TI  - The impact of a randomized dietary and physical activity intervention on chronic inflammation among obese African-American women
VL  - 60
ID  - 44
ER  - 

TY  - JOUR
AB  - We report the first multisite, multicomponent community intervention trial to focus on cancer prevention in African Americans. The project explored the potential of historically black medical schools to deliver health information to their local communities and used a community-based participatory research approach. The intervention consisted of culturally sensitive messages at appropriate educational levels delivered over an 18-month period and tested in predominantly black census tracts in Nashville, TN and Atlanta, GA. Chattanooga, TN and Decatur, GA served as comparison cities. Results were evaluated by pre- and postintervention random-digit dial telephone surveys. The intervention cities showed an increase in reported contact with or knowledge of the project. There was little or no effect on knowledge or attitudes in the intervention cities. Compared to Chattanooga, Nashville showed an increase in percentage of women receiving Pap smears. Compared to Decatur, Atlanta showed an increase in percentage of age-appropriate populations receiving digital rectal exams, colorectal cancer screenings and mammograms. The results of this community intervention trial demonstrated modest success and are encouraging for future efforts of longer duration.
AD  - Morehouse Prevention Research Center and Department of Community Health and Preventive Medicine, Morehouse School of Medicine, Atlanta GA 30310-1495, USA. dblumenthal@msm.edu
AN  - 16334495
AU  - Blumenthal, D. S.
AU  - Fort, J. G.
AU  - Ahmed, N. U.
AU  - Semenya, K. A.
AU  - Schreiber, G. B.
AU  - Perry, S.
AU  - Guillory, J.
C2  - PMC2594915
DA  - Nov
DP  - NLM
ET  - 2005/12/13
IS  - 11
KW  - Adult
African Americans/*education/statistics & numerical data
Female
Georgia
Health Behavior
Health Care Surveys
Health Education/*methods/statistics & numerical data
*Health Knowledge, Attitudes, Practice
Humans
Interviews as Topic
Male
Mass Screening/statistics & numerical data
Neoplasms/*prevention & control
Patient Participation/statistics & numerical data
Primary Prevention/*methods/statistics & numerical data
Program Evaluation
Regression Analysis
Socioeconomic Factors
Tennessee
LA  - eng
N1  - Blumenthal, Daniel S
Fort, Jane G
Ahmed, Nasar U
Semenya, Kofi A
Schreiber, George B
Perry, Shelley
Guillory, Joyce
N01-CO94394/CO/NCI NIH HHS/United States
U48/CCU415794/CC/ODCDC CDC HHS/United States
Evaluation Study
Journal Article
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, P.H.S.
J Natl Med Assoc. 2005 Nov;97(11):1479-88.
PY  - 2005
SN  - 0027-9684 (Print)
0027-9684
SP  - 1479-88
ST  - Impact of a two-city community cancer prevention intervention on African Americans
T2  - J Natl Med Assoc
TI  - Impact of a two-city community cancer prevention intervention on African Americans
VL  - 97
ID  - 578
ER  - 

TY  - JOUR
AB  - Introduction: Innovative methods to increase awareness about clinical trials and address barriers associated with low participation among racial/ethnic minorities are desperately needed. African Americans comprise 5% of all clinical trial participants, and Hispanics make up 1%. Use of multimedia educational material has shown promise as an effective strategy to increase minority clinical trial enrollment. However, this approach has not been broadly implemented. We tested the effect of a video educational program on clinical trial knowledge and enrollment in a sample of oncology outpatients. Methods: A randomized controlled trial was conducted with 63 oncology patients without previous history of clinical trial participation. Participants were randomly assigned to the intervention, to watch a clinical trial educational video in the office, or to the control group which did not receive in-office education. The Clinical Trial Knowledge survey was administered before the intervention and 1 week after the intervention. Participation in clinical trials was assessed 1-year post study participation. Results for white participants and ethnic minorities were compared. Ethnicity was self-reported through the electronic health record and confirmed by self-reporting on questionnaire. Results: Sixty-three participants were recruited in this study. At 1-year follow-up, 3 participants enrolled in clinical trials in the study group which had received office-based video intervention and 2 participants enrolled in the control group (Z = 0.39, p = 0.69). These results were not statistically significant. Impact of the intervention by ethnicity could not be assessed due to low total clinical trial enrollment. The video intervention did not change knowledge, attitudes, or barriers as measured by the Clinical Trial Knowledge Survey. Minority participants did report significantly more negative beliefs and barriers to participation than white participants. Conclusions: Increasing awareness and knowledge about clinical trials in underrepresented communities is an important step to providing opportunities for participation. Future studies should focus on how to address the negative expectations of clinical trials and the greater information needs in minority populations. Tailored or personalized messaging may address negative perceptions of clinical trial participation.
AN  - WOS:000466971000001
AU  - Skinner, J. S.
AU  - Fair, A. M.
AU  - Holman, A. S.
AU  - Boyer, A. P.
AU  - Wilkins, C. H.
DA  - Apr
DO  - 10.3389/fpubh.2019.00104
N1  - 104
31106188
PY  - 2019
SN  - 2296-2565
ST  - The Impact of an Educational Video on Clinical Trial Enrollment and Knowledge in Ethnic Minorities: A Randomized Control Trial
T2  - Frontiers in Public Health
TI  - The Impact of an Educational Video on Clinical Trial Enrollment and Knowledge in Ethnic Minorities: A Randomized Control Trial
VL  - 7
ID  - 2824
ER  - 

TY  - JOUR
AB  - BACKGROUND: The Cancer and Leukemia Group B (CALGB) 9343 trial demonstrated that adjuvant radiation therapy (RT) can be omitted in women 70 years or older, with small (≤2 cm), negative lymph nodes, estrogen receptor (ER)-positive breast cancer. We examined whether RT usage following the CALGB publication had decreased over time and evaluated sociodemographic and clinical factors associated with RT omission. MATERIALS AND METHODS: From the National Cancer Data Base, we analyzed a cohort of 120,308 women aged 70 years or older with stage I, ER-positive breast cancer who underwent lumpectomy. Patients were classified into two groups based on the time of CALGB 9343 publication: (i) pre-CALGB (up to 2004), and (ii) post-CALGB (2005-2012). Clinicopathological and sociodemographic variables were compared between pre- and post-CALGB groups. Chi-square and multivariable logistic regression were employed, with the omission of adjuvant RT as the primary outcome in the regression analysis. RESULTS: Radiation therapy usage decreased by 4.1% after CALGB publication (on average 71.6% pre-CALGB vs. 67.5% post-CALGB; p<0.0001). Almost one-third of women aged ≥85 years received RT in the post-CALGB group. In a multivariable model, the variables significantly associated with increased odds for omission of RT in the post-CALGB group were: advanced age, African-American, increased great circle distance, therapy under academic research program, residents of East South-Central region, living in a rural population <2,500 not adjacent to a metropolitan area, low income level, Medicaid recipients, high comorbidity index, small tumor, well-differentiated histology, residual tumor, and lack of receipt of chemotherapy and anti-hormonal therapy. CONCLUSION: During the study period, the CALGB trial publication had a minimal impact on the rate of adjuvant RT use among elderly women with small, ER-positive breast cancers. Significant variation in RT usage existed across sociodemographic strata.
AD  - Department of Surgery, Louisiana State University Health Sciences Center in Shreveport, Shreveport, Louisiana, LA, U.S.A.
Feist-Weiller Cancer Center, Shreveport, LA, U.S.A.
School of Public Health, Louisiana State University Health Sciences Center, New Orleans, LA, U.S.A.
Feist-Weiller Cancer Center, Shreveport, LA, U.S.A. ppeddi@lsuhsc.edu.
Department of Medicine, Louisiana State University Health Sciences Center in Shreveport, Shreveport, Louisiana, LA, U.S.A.
AN  - 28982874
AU  - Chu, Q. D.
AU  - Zhou, M.
AU  - Medeiros, K. L.
AU  - Peddi, P.
AU  - Wu, X. C.
DA  - Oct
DO  - 10.21873/anticanres.11992
DP  - NLM
ET  - 2017/10/07
IS  - 10
KW  - Age Factors
Aged
Aged, 80 and over
Biomarkers, Tumor/*analysis
Breast Neoplasms/chemistry/epidemiology/pathology/*radiotherapy
Chi-Square Distribution
*Clinical Trials, Phase III as Topic
Databases, Factual
Evidence-Based Medicine/trends
Female
Healthcare Disparities/*trends
Humans
Logistic Models
Mastectomy, Segmental
Multivariate Analysis
Neoplasm Staging
Odds Ratio
Practice Patterns, Physicians'/*trends
Radiation Oncologists/*trends
Radiotherapy, Adjuvant/trends
Receptors, Estrogen/*analysis
Risk Factors
*Socioeconomic Factors
Time Factors
Treatment Outcome
United States/epidemiology
*er+
*Elderly
*adherence
*breast cancer
*hormone-positive breast cancer
*radiation therapy
*small breast cancer
*stage I breast cancer
LA  - eng
N1  - 1791-7530
Chu, Quyen D
Zhou, Meijiao
Medeiros, Kaelen L
Peddi, Prakash
Wu, Xiao Cheng
Journal Article
Greece
Anticancer Res. 2017 Oct;37(10):5585-5594. doi: 10.21873/anticanres.11992.
PY  - 2017
SN  - 0250-7005
SP  - 5585-5594
ST  - Impact of CALGB 9343 Trial and Sociodemographic Variation on Patterns of Adjuvant Radiation Therapy Practice for Elderly Women (≥70 Years) with Stage I, Estrogen Receptor-positive Breast Cancer: Analysis of the National Cancer Data Base
T2  - Anticancer Res
TI  - Impact of CALGB 9343 Trial and Sociodemographic Variation on Patterns of Adjuvant Radiation Therapy Practice for Elderly Women (≥70 Years) with Stage I, Estrogen Receptor-positive Breast Cancer: Analysis of the National Cancer Data Base
VL  - 37
ID  - 153
ER  - 

TY  - THES
AB  - Populations of Black-African descent have slower rates of nicotine and cotinine metabolism, smoke fewer cigarettes (∼10 cigarettes/day), and have higher incidences of tobacco-related illnesses compared to Caucasians. Cytochrome P450 2A6 (CYP2A6) is the main enzyme involved in the metabolism of nicotine and its proximal metabolite cotinine, as well as tobacco-specific nitrosamines. Genetic polymorphisms in CYP2A6 contribute to the large variability observed in rates of nicotine metabolism. Reduced CYP2A6 activity has been associated with fewer cigarettes smoked, higher quit rates, and lower lung cancer risk in predominantly moderate to heavy-smoking (∼20–30 cigarettes/day) Caucasians. CYP2A6 genetic variants and their impact on smoking behaviours have not been well studied among individuals of Black-African descent. The main objectives herein were to identify and characterize new CYP2A6 variants that may explain the slower rates of metabolism, and determine whether CYP2A6 variation is a predictor of smoking phenotypes in this population. Furthermore, we examined whether previously validated biomarkers of tobacco exposure have limitations among individuals of Black-African descent given their low and sporadic smoking patterns. A new CYP2A6 variant (CYP2A623) was found in individuals of Black-African descent recruited for a nicotine pharmacogenetic-pharmacokinetic study. CYP2A623 reduced activity towards nicotine and coumarin in vitro and was associated with slower rates of CYP2A6 kinetics in vivo. In a clinical trial of African-American light smokers, CYP2A6 slow metabolizers were more successful at smoking cessation compared to normal metabolizers, although no differences in cigarette consumption were found. Two common biochemical markers of tobacco smoke exposure, cotinine and exhaled carbon monoxide, were weakly correlated with self-reported cigarette consumption. These biomarkers were not substantially affected by variables previously shown to alter amount smoked and/or rates of cotinine metabolism such as gender, age, body mass index or smoking menthol cigarettes. However, CYP2A6 slow metabolizers had significantly higher cotinine without smoking more cigarettes. Identification and characterization of novel variants adds to our understanding of nicotine pharmacokinetic differences between racial/ethnic minority groups and improves accuracy of CYP2A6 genotype groupings for genetic association studies. Furthermore, better insight into the biological factors associated with smoking behaviours will aid in the development of more efficacious targeted treatments for this understudied population. (PsycINFO Database Record (c) 2016 APA, all rights reserved)
AN  - 2014-99040-145
AU  - Ho, Man Ki
DB  - psyh
DP  - EBSCOhost
KW  - Genetic polymorphisms
alter amount
biochemical markers
biological factors
black-african descent
cigarette consumption
clinical trial
cotinine metabolism
exhaled carbon monoxide
genetic association studies
genetic variants
genetic variation
genotype groupings
light smokers
Blacks
Nicotine
Genetics
Metabolism
Polymorphism
Tobacco Smoking
N1  - Accession Number: 2014-99040-145. Other Journal Title: Dissertation Abstracts International. Partial author list: First Author & Affiliation: Ho, Man Ki; U Toronto, Canada. Release Date: 20140317. Publication Type: Dissertation Abstract (0400). Format Covered: Electronic. Document Type: Dissertation. Dissertation Number: AAINR97691. ISBN: 978-0-494-97691-3. Language: English. Major Descriptor: Blacks; Nicotine. Minor Descriptor: Genetics; Metabolism; Polymorphism; Tobacco Smoking. Classification: Health & Mental Health Treatment & Prevention (3300). Population: Human (10). Location: US. Methodology: Empirical Study; Quantitative Study.
PB  - ProQuest Information & Learning
PY  - 2014
SN  - 0419-4217
978-0-494-97691-3
ST  - Impact of CYP2A6 genetic variation on nicotine metabolism and smoking behaviours in light smoking populations of Black-African descent
TI  - Impact of CYP2A6 genetic variation on nicotine metabolism and smoking behaviours in light smoking populations of Black-African descent
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2014-99040-145&site=ehost-live&scope=site
VL  - 74
ID  - 1740
ER  - 

TY  - JOUR
AB  - BACKGROUND: Patient navigation is a promising intervention to address cancer disparities but requires a multisite controlled trial to assess its effectiveness. METHODS: The Patient Navigation Research Program compared patient navigation with usual care on time to diagnosis or treatment for participants with breast, cervical, colorectal, or prostate screening abnormalities and/or cancers between 2007 and 2010. Patient navigators developed individualized strategies to address barriers to care, with the focus on preventing delays in care. To assess timeliness of diagnostic resolution, we conducted a meta-analysis of center- and cancer-specific adjusted hazard ratios (aHRs) comparing patient navigation vs usual care. To assess initiation of cancer therapy, we calculated a single aHR, pooling data across all centers and cancer types. We conducted a metaregression to evaluate variability across centers. All statistical tests were two-sided. RESULTS: The 10521 participants with abnormal screening tests and 2105 with a cancer or precancer diagnosis were predominantly from racial/ethnic minority groups (73%) and publically insured (40%) or uninsured (31%). There was no benefit during the first 90 days of care, but a benefit of navigation was seen from 91 to 365 days for both diagnostic resolution (aHR = 1.51; 95% confidence interval [CI] = 1.23 to 1.84; P < .001)) and treatment initiation (aHR = 1.43; 95% CI = 1.10 to 1.86; P < .007). Metaregression revealed that navigation had its greatest benefits within centers with the greatest delays in follow-up under usual care. CONCLUSIONS: Patient navigation demonstrated a moderate benefit in improving timely cancer care. These results support adoption of patient navigation in settings that serve populations at risk of being lost to follow-up.
AD  - Affiliations of authors: Division of Cancer Prevention and Control, Department of Internal Medicine, College of Medicine, Comprehensive Cancer Center (EDP), and Center for Biostatistics (GSY), The Ohio State University, Columbus, OH; Institute for Clinical Research and Health Policy Studies, Tufts Medical Center and Tufts University School of Medicine, Boston, MA (KMF); Women's Health Unit, Section of General Internal Medicine, Evans Department of Medicine, Boston Medical Center and Women's Health Interdisciplinary Research Center, Boston University School of Medicine, Boston, MA (TAB); Division of Health Policy and Administration, School of Public Health, University of Illinois at Chicago, Chicago, IL (EC, JSD); Department of Obstetrics and Gynecology, University of Texas Health Science Center, San Antonio, TX (DLD); Department of Family Medicine and Public Health Sciences and Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY (KF); Center to Reduce Cancer Health Disparities, National Cancer Institute (MLH), and Biostatistics and Bioinformatics Branch, Division of Epidemiology, Statistics, and Prevention Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health (DMM), Rockville, MD (MLH); George Washington University School of Public Health and Health Services, Washington, DC (NL, PL); H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL (J-HL, RGR); George Washington Cancer Institute, Washington, DC (PL. SRP); Duke Cancer Institute, Durham, NC (SRP); Denver Health, Denver, CO (PCR, EMW); University of Colorado Denver, Aurora, CO (PCR); Department of Family Medicine, University of South Florida, Tampa, FL (RGR); Department of Obstetrics and Gynecology and Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL (MS); Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL (MS); Clinical Research Ser
AN  - 24938303
AU  - Freund, K. M.
AU  - Battaglia, T. A.
AU  - Calhoun, E.
AU  - Darnell, J. S.
AU  - Dudley, D. J.
AU  - Fiscella, K.
AU  - Hare, M. L.
AU  - LaVerda, N.
AU  - Lee, J. H.
AU  - Levine, P.
AU  - Murray, D. M.
AU  - Patierno, S. R.
AU  - Raich, P. C.
AU  - Roetzheim, R. G.
AU  - Simon, M.
AU  - Snyder, F. R.
AU  - Warren-Mears, V.
AU  - Whitley, E. M.
AU  - Winters, P.
AU  - Young, G. S.
AU  - Paskett, E. D.
C2  - PMC4072900
DA  - Jun
DO  - 10.1093/jnci/dju115
DP  - NLM
ET  - 2014/06/19
IS  - 6
KW  - Adult
African Americans/statistics & numerical data
Aged
Breast Neoplasms/diagnosis/therapy
Colorectal Neoplasms/diagnosis/therapy
Communication Barriers
Confounding Factors, Epidemiologic
Controlled Clinical Trials as Topic
*Early Detection of Cancer
European Continental Ancestry Group/statistics & numerical data
Female
*Healthcare Disparities
Hispanic Americans/statistics & numerical data
Humans
Male
Middle Aged
Neoplasms/*diagnosis/*therapy
Odds Ratio
*Patient Navigation
Prostatic Neoplasms/diagnosis/therapy
Randomized Controlled Trials as Topic
Time-to-Treatment/*statistics & numerical data
United States
Uterine Cervical Neoplasms/diagnosis/therapy
LA  - eng
N1  - 1460-2105
Freund, Karen M
Battaglia, Tracy A
Calhoun, Elizabeth
Darnell, Julie S
Dudley, Donald J
Fiscella, Kevin
Hare, Martha L
LaVerda, Nancy
Lee, Ji-Hyun
Levine, Paul
Murray, David M
Patierno, Steven R
Raich, Peter C
Roetzheim, Richard G
Simon, Melissa
Snyder, Frederick R
Warren-Mears, Victoria
Whitley, Elizabeth M
Winters, Paul
Young, Gregory S
Paskett, Electra D
Writing Group of the Patient Navigation Research Program
01CA116937/CA/NCI NIH HHS/United States
U01CA116925/CA/NCI NIH HHS/United States
UL1 TR000150/TR/NCATS NIH HHS/United States
U01CA116903/CA/NCI NIH HHS/United States
U01CA116924/CA/NCI NIH HHS/United States
P30 CA076292/CA/NCI NIH HHS/United States
P30 CA016058/CA/NCI NIH HHS/United States
U01 CA116892/CA/NCI NIH HHS/United States
U01CA116885/CA/NCI NIH HHS/United States
U01CA116875/CA/NCI NIH HHS/United States
U01 CA117281/CA/NCI NIH HHS/United States
Journal Article
Meta-Analysis
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
J Natl Cancer Inst. 2014 Jun 17;106(6):dju115. doi: 10.1093/jnci/dju115. Print 2014 Jun.
PY  - 2014
SN  - 0027-8874 (Print)
0027-8874
SP  - dju115
ST  - Impact of patient navigation on timely cancer care: the Patient Navigation Research Program
T2  - J Natl Cancer Inst
TI  - Impact of patient navigation on timely cancer care: the Patient Navigation Research Program
VL  - 106
ID  - 284
ER  - 

TY  - JOUR
AB  - There is a paucity of research on the effects of pretest measurement with prostate cancer screening. What effect does a pretest measurement have on posttest outcomes? This research reports knowledge of prostate cancer screening among men randomized to an Enhanced decision aid versus an Usual Care decision aid. Using a Solomon Four research design, there were a total of 198 men in 4 groups. Most of the sample was African American (78%), with a mean age of 52 years. The greatest posttest knowledge occurred with the Enhanced decision aid in contrast to the Usual Care. The Enhanced/Usual Care groups that had both a pretest and posttest and had received a previous digital rectal examination had the highest means (P = .015), with means of 9.1 and 7.0, respectively. Among men who had a previous digital rectal examination, the greatest increase in score occurred among men randomized to the Enhanced decision aid in contrast to the Usual Care decision aid, 2.9 versus 0.4 (P = .008). The outcome varied based on the status of (1) random group assignment of the Solomon Four design and (2) status of previous digital rectal examination. Implications for nurses include consideration 1 of a pretest to increase posttest knowledge scores.
AD  - School of Nursing, Medical College of Georgia, Augusta 30912, USA. sweinrich@mcg.edu
AN  - 106200503. Language: English. Entry Date: 20071130. Revision Date: 20150711. Publication Type: Journal Article
AU  - Weinrich, S. P.
AU  - Seger, R.
AU  - Curtsinger, T.
AU  - Pumphrey, G.
AU  - NeSmith, E. G.
AU  - Weinrich, M. C.
DB  - CINAHL Complete
DP  - EBSCOhost
IS  - 5
KW  - Cancer Screening -- Education
Decision Making -- Education
Health Knowledge -- Evaluation
Prostatic Neoplasms -- Prevention and Control
Study Design
Adult
Aged
Analysis of Covariance
Bivariate Statistics
Black Persons
Chi Square Test
Descriptive Statistics
Digital Rectal Examination
Family History
Funding Source
Kentucky
Logistic Regression
Male
Mantel-Haenszel Test
Middle Age
Multivariate Analysis
Pamphlets
Pretest-Posttest Design
Questionnaires
Random Assignment
Research Subject Recruitment
Socioeconomic Factors
T-Tests
Teaching Methods
White Persons
Human
N1  - consumer/patient teaching materials; research; tables/charts. Journal Subset: Core Nursing; Double Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Nursing; Peer Reviewed; USA. Instrumentation: Knowledge About Prostate Cancer Screening Questionnaire. Grant Information: Supported by the American Cancer Society grant TURSG-01-074-01-PBP, and the Commonwealth of Kentucky Resarch Challenge Fund. NLM UID: 7805358.
PMID: NLM17876174.
PY  - 2007
SN  - 0162-220X
SP  - E16-28
ST  - Impact of pretest on posttest knowledge scores with a Solomon Four research design
T2  - Cancer Nursing
TI  - Impact of pretest on posttest knowledge scores with a Solomon Four research design
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106200503&site=ehost-live&scope=site
VL  - 30
ID  - 1972
ER  - 

TY  - JOUR
AB  - Objective: We sought to examine the impact of primary tumor resection on survival in HER2+ stage IV breast cancer patients in the era of HER2 targeted therapy. Methods: We conducted a retrospective cohort study of women with HER2+ stage IV breast cancer in the National Cancer Database from 2010 to 2012 comparing those who did and did not undergo definitive breast surgery. Results: Of 3231 patients, treatment included primary site surgery in 35.0%; chemo/targeted therapy in 89.4%; endocrine therapy in 37.7%; and radiation in 31.8%. Surgery was associated with Medicare/other government (OR 1.36, 95% CI 1.03–1.81) or private insurance (OR 1.93, 95% CI 1.53–2.42) versus none/Medicaid, radiation (OR 2.10, 95% CI 1.76–2.51), chemo/targeted therapy (OR 1.99, 95% CI 1.47–2.70), and endocrine therapy (OR 1.73, 95% CI 1.40–2.14). Non-Hispanic Black versus White patients (OR 0.68, 95% CI 0.53–0.87) were less likely to have surgery. Overall mortality was associated with insurance (Medicare/other government versus none/Medicaid, HR 0.36, p < 0.0001), receipt of chemo/targeted therapy (HR 0.76, p = 0.008), endocrine therapy (HR 0.70, p = 0.0006), and radiation therapy (HR 1.33, p = 0.0009), NH Black versus White race/ethnicity (HR 1.39, p = 0.002), visceral versus bone-only metastases (HR 1.44, p = 0.0003), and lowest versus highest income quartile (HR 1.36, p = 0.01). Propensity score analysis showed surgery was associated with improved survival versus no surgery (HR 0.56, 95% CI 0.40–0.77). Conclusions: Surgery of the primary site for metastatic HER2+ breast cancer is associated with improved overall survival in selected patients.
AD  - S.S. Lum, Department of Surgery, Division of Surgical Oncology, School of Medicine, Loma Linda University, Loma Linda, CA, United States
AU  - Mudgway, R.
AU  - Chavez de Paz Villanueva, C.
AU  - Lin, A. C.
AU  - Senthil, M.
AU  - Garberoglio, C. A.
AU  - Lum, S. S.
DB  - Embase
Medline
DO  - 10.1245/s10434-020-08310-2
IS  - 8
KW  - NCT00941759
pertuzumab
trastuzumab
adult
article
bone metastasis
breast surgery
cancer hormone therapy
cancer mortality
cancer radiotherapy
cancer staging
cancer surgery
cancer survival
cancer therapy
cohort analysis
controlled study
female
health care quality
health insurance
human
human epidermal growth factor receptor 2 positive breast cancer
major clinical study
mastectomy
medicaid
medicare
modified radical mastectomy
patient selection
primary tumor
propensity score
prospective study
race difference
radical mastectomy
randomized controlled trial
retrospective study
simple mastectomy
systemic therapy
LA  - English
M3  - Article
N1  - L2004442666
2020-03-24
2020-07-17
PY  - 2020
SN  - 1534-4681
1068-9265
SP  - 2711-2720
ST  - The Impact of Primary Tumor Surgery on Survival in HER2 Positive Stage IV Breast Cancer Patients in the Current Era of Targeted Therapy
T2  - Annals of Surgical Oncology
TI  - The Impact of Primary Tumor Surgery on Survival in HER2 Positive Stage IV Breast Cancer Patients in the Current Era of Targeted Therapy
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L2004442666&from=export
http://dx.doi.org/10.1245/s10434-020-08310-2
VL  - 27
ID  - 791
ER  - 

TY  - JOUR
AB  - OBJECTIVE: To evaluate active surveillance (AS) criteria on their ability to predict favorable pathology at prostatectomy within a low-risk African American (AA) cohort. METHODS: The sensitivity, specificity, positive predictive value, receiver operator curve, and area under the curve (AUC) were compared for 6 published AS criteria (National Comprehensive Cancer Network; Memorial Sloan-Kettering Cancer Center; Prostate Cancer Research International: Active Surveillance Study; Johns Hopkins-Epstein; University of California at San Francisco; and University of Miami) to predict organ-confined Gleason score 6 disease at prostatectomy in AAs and white Americans (WAs) with low-risk cancer. We also compared clinical parameters for AAs with favorable prostatectomy pathology with those for AAs with unfavorable pathology, and then used preoperative variables associated with unfavorable pathology as an additional exclusion criteria for AS. RESULTS: Of 468 patients with low-risk disease, 308 of 402 (76.6%) WAs and 55 of 66 (83.3%) AAs were eligible for AS by one or more criteria (P = .23). For WAs, Prostate Cancer Research International: Active Surveillance Study criteria had the highest rate of favorable pathology (81.7%) and the best performance (AUC = 0.70) in determining appropriate candidates for AS. However, all 6 AS criteria performed poorly for AA patients, with all AUCs ≤0.52. When comparing AAs with favorable pathology with AAs with unfavorable pathology, only family history of prostate cancer was statistically significant (11 of 25 [47.8%] vs. 8 of 41 [22.2%]; P = .04). When adjusting AS criteria in AAs to exclude those with a positive family history, the AUC increased most for the University of California at San Francisco (from 0.52 to 0.6) and Memorial Sloan-Kettering Cancer Center criteria (from 0.50 to 0.58). CONCLUSION: Current criteria underperform in appropriately selecting AAs for AS. AAs considering AS should be counseled about their increased risk for occult adverse pathology, particularly if a family history of prostate cancer is present.
AD  - Division of Urology, Department of Surgery, Hospital of University of Pennsylvania, Philadelphia, PA. Electronic address: Eugene.pietzak@uphs.upenn.edu.
Division of Urology, Department of Surgery, Hospital of University of Pennsylvania, Philadelphia, PA.
AN  - 25623715
AU  - Pietzak, E. J.
AU  - Van Arsdalen, K.
AU  - Patel, K.
AU  - Malkowicz, S. B.
AU  - Wein, A. J.
AU  - Guzzo, T. J.
DA  - Feb
DO  - 10.1016/j.urology.2014.09.065
DP  - NLM
ET  - 2015/01/28
IS  - 2
KW  - *African Americans
*European Continental Ancestry Group
Humans
Male
Middle Aged
*Patient Selection
*Prostatectomy
Prostatic Neoplasms/*surgery
Retrospective Studies
Risk Assessment
*Watchful Waiting
LA  - eng
N1  - 1527-9995
Pietzak, Eugene J
Van Arsdalen, Keith
Patel, Kinnari
Malkowicz, S Bruce
Wein, Alan J
Guzzo, Thomas J
Comparative Study
Journal Article
Research Support, Non-U.S. Gov't
United States
Urology. 2015 Feb;85(2):436-40. doi: 10.1016/j.urology.2014.09.065.
PY  - 2015
SN  - 0090-4295
SP  - 436-40
ST  - Impact of race on selecting appropriate patients for active surveillance with seemingly low-risk prostate cancer
T2  - Urology
TI  - Impact of race on selecting appropriate patients for active surveillance with seemingly low-risk prostate cancer
VL  - 85
ID  - 262
ER  - 

TY  - JOUR
AB  - OBJECTIVES: To determine whether blacks with hormone-refractory prostate cancer have shorter survival compared with whites with the same disease. METHODS: Data from eight multicenter trials (four Phase II and four randomized Phase III studies) conducted by the Cancer and Leukemia Group B were combined. Eligible patients had progressive prostate cancer after androgen deprivation therapy (with documented castration levels of testosterone), an Eastern Cooperative Oncology Group performance status of 0 to 2, and adequate hematologic, renal, and hepatic function. The proportional hazards model was used to assess the prognostic importance of race, adjusting for important factors. All statistical tests were two-sided. RESULTS: Of the 1183 patients, 15% were blacks, 45% of patients had a Gleason sum of 8 or greater, and the median age was 71 years. Of the 1183 patients, 35% had measurable disease and 89% had an Eastern Cooperative Oncology Group performance status of 0 to 1. Blacks were younger, had a shorter interval between diagnosis and study entry, and had greater prostate-specific antigen levels, lower hemoglobin levels, and a lower likelihood of prior prostatectomy than whites. The median survival was 15 months (95% confidence interval 12 to 18) for blacks compared with 14 months (95% confidence interval 13 to 15) for whites. In a multivariate analysis, adjusting for age, performance status, presence of visceral disease, hemoglobin, Gleason sum, prostate-specific antigen level, alkaline phosphatase, lactate dehydrogenase, and years since diagnosis, the hazard ratio was 0.85 (95% confidence interval 0.71 to 1.02, P = 0.08) for blacks compared with whites. CONCLUSIONS: No statistically significant difference was found in overall survival between blacks and whites with metastatic hormone-refractory prostate cancer.
AD  - Department of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, North Carolina 27710, USA.
AN  - 15302462
AU  - Halabi, S.
AU  - Small, E. J.
AU  - Vogelzang, N. J.
AU  - Barrier, R. C., Jr.
AU  - George, S. L.
AU  - Gilligan, T. D.
DA  - Aug
DO  - 10.1016/j.urology.2004.04.014
DP  - NLM
ET  - 2004/08/11
IS  - 2
KW  - Adenocarcinoma/drug therapy/genetics/*mortality/radiotherapy/surgery
Adult
African Continental Ancestry Group/genetics
Aged
Aged, 80 and over
Androgen Antagonists/therapeutic use
Antineoplastic Agents, Hormonal/therapeutic use
Clinical Trials, Phase II as Topic/statistics & numerical data
Clinical Trials, Phase III as Topic/statistics & numerical data
Combined Modality Therapy
*Continental Population Groups/genetics
Drug Resistance, Neoplasm
European Continental Ancestry Group/genetics
Genetic Predisposition to Disease
Hemoglobins/analysis
Humans
Male
Middle Aged
Multicenter Studies as Topic/statistics & numerical data
Neoplasm Metastasis
Proportional Hazards Models
Prostatectomy
Prostatic Neoplasms/drug therapy/genetics/*mortality/radiotherapy/surgery
Randomized Controlled Trials as Topic/statistics & numerical data
Salvage Therapy
Socioeconomic Factors
Survival Analysis
United States/epidemiology
LA  - eng
N1  - 1527-9995
Halabi, Susan
Small, Eric J
Vogelzang, Nicholas J
Barrier, Robert C Jr
George, Stephen L
Gilligan, Timothy D
CA33601/CA/NCI NIH HHS/United States
Journal Article
Meta-Analysis
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, U.S. Gov't, P.H.S.
United States
Urology. 2004 Aug;64(2):212-7. doi: 10.1016/j.urology.2004.04.014.
PY  - 2004
SN  - 0090-4295
SP  - 212-7
ST  - Impact of race on survival in men with metastatic hormone-refractory prostate cancer
T2  - Urology
TI  - Impact of race on survival in men with metastatic hormone-refractory prostate cancer
VL  - 64
ID  - 622
ER  - 

TY  - JOUR
AB  - Objectives: Over 18 years, 7 phase 2 trials in advanced pancreatic cancer (APC) were conducted at Karmanos Cancer Institute (KCI). We sought factors that influenced the selection of patients for clinical trials and explored differences in overall survival (OS) of patients treated on clinical trials versus standard of care. Methods: The target population was patients with APC diagnosed between January 1, 1986, and December 31, 2003. Patients were divided into 3 mutually exclusive groups: treated on clinical trials at KCI (t-KCI), treated at KCI but not on a clinical trial (KCI), or treated at non-KCI institutions (n-KCI). Results: Eight thousand two hundred thirty patients met study criteria: 6470 n-KCI, 1642 KCI, and 118 t-KCI. Significant differences were observed across the 3 groups with respect to age, race, stage, grade, and socioeconomic status. Median OS was higher in t-KCI (8.5 months) than in KCI (5.0 months) or n-KCI (2.8 months) and could not be accounted for by variations in baseline characteristics. Conclusions: Patients enrolled on clinical trials were younger, had better socioeconomic status, and were less often African American. Patients with APC treated at academic institutions may have longer OS than patients treated in the community. Clinical trials seem to offer a survival advantage for patients with APC.
AN  - WOS:000282098200005
AU  - El-Rayes, B. F.
AU  - Jasti, P.
AU  - Severson, R. K.
AU  - Almhanna, K.
AU  - Philip, P. A.
AU  - Shields, A.
AU  - Zalupski, M.
AU  - Heilbrun, L. K.
DA  - Oct
DO  - 10.1097/MPA.0b013e3181da91dd
IS  - 7
N1  - 20467351
PY  - 2010
SN  - 0885-3177
SP  - 967-971
ST  - Impact of Race, Age, and Socioeconomic Status on Participation in Pancreatic Cancer Clinical Trials
T2  - Pancreas
TI  - Impact of Race, Age, and Socioeconomic Status on Participation in Pancreatic Cancer Clinical Trials
VL  - 39
ID  - 3109
ER  - 

TY  - JOUR
AB  - Previous studies demonstrated poor response to neoadjuvant systemic therapy (NST) for breast cancer among black women and women who are overweight or obese, but this may be due to chemotherapy underdosing. We assessed associations of race, ethnicity, and body mass index (BMI) with pathologic complete response (pCR) in clinical trial populations. 1797 women enrolled in four NST trials (CALGB 40601, 40603; ACOSOG Z1041, Z1071) were included. Tumor subtypes were defined by estrogen receptor (ER) and HER2 status. Logistic regression generated odds ratios (OR) and 95 % confidence intervals (CI) for the associations of race, ethnicity, and BMI with in-breast pCR adjusting for subtype, study arm, lymph node status, tumor size, and tumor grade. 253 (14.1 %) were black, 199 (11.1 %) Hispanic, 520 (28.9 %) overweight, and 743 (41.4 %) obese. Compared to whites, Blacks and Hispanics were more likely to be obese and Blacks were more likely to have triple-negative cancer. pCR rates differed significantly by tumor subtype. In multivariate analyses, neither race (black vs white: OR 1.18, 95 % CI 0.85-1.62) nor ethnicity (Hispanic vs non-Hispanic; OR 1.30, 95 % CI 0.67-2.53) were significant predictors of pCR overall or by subtype. Overweight and obese women had lower pCR rates in ER+/HER2+, but higher pCR rates in ER-/HER2+ cancers. There was no difference in pCR according to race or ethnicity. Overall, there was no major difference in pCR rates by BMI. These findings suggest that pCR with optimally dosed NST is a function of tumor, rather than patient, biology.
AD  - Massachusetts General Hospital, 55 Fruit Street, Boston, MA, 02114, USA. ewarner@mgh.harvard.edu.
Weill Cornell Medical College, 402 East 67th Street, New York, NY, 10065, USA.
Alliance Statistics and Data Center, 1216 Second St. SW, Rochester, MN, 55902, USA.
Mayo Clinic, 200 1st St SW, Rochester, MN, 55905, USA.
University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA.
University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center, 101 Manning Drive, Chapel Hill, NC, 27514, USA.
Women and Infants Hospital of Rhode Island and Alpert Medical School of Brown University, 101 Dudley Street, Providence, RI, 02905, USA.
Brigham and Women's Hospital, 75 Francis Street, Boston, MA, 02115, USA.
Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA.
AN  - 27449492
AU  - Warner, E. T.
AU  - Ballman, K. V.
AU  - Strand, C.
AU  - Boughey, J. C.
AU  - Buzdar, A. U.
AU  - Carey, L. A.
AU  - Sikov, W. M.
AU  - Partridge, A. H.
C2  - PMC5011019
C6  - NIHMS805454
DA  - Aug
DO  - 10.1007/s10549-016-3918-5
DP  - NLM
ET  - 2016/07/28
IS  - 1
KW  - Adult
Body Mass Index
Breast Neoplasms/*drug therapy/*ethnology/metabolism
Clinical Trials as Topic
Continental Population Groups
Disease-Free Survival
Female
Humans
Middle Aged
Neoadjuvant Therapy
Obesity/*epidemiology
Odds Ratio
Overweight/*epidemiology
Prospective Studies
Receptor, ErbB-2/metabolism
Receptors, Estrogen/metabolism
Survival Analysis
Treatment Outcome
*Body mass index
*Breast cancer
*Ethnicity
*Pathologic complete response
*Race
LA  - eng
N1  - 1573-7217
Warner, Erica T
Ballman, Karla V
Strand, Carrie
Boughey, Judy C
Buzdar, Aman U
Carey, Lisa A
Sikov, William M
Partridge, Ann H
UG1 CA233329/CA/NCI NIH HHS/United States
U10 CA180858/CA/NCI NIH HHS/United States
UG1 CA232760/CA/NCI NIH HHS/United States
K01 CA188075/CA/NCI NIH HHS/United States
UG1 CA189823/CA/NCI NIH HHS/United States
U10 CA180790/CA/NCI NIH HHS/United States
U10 CA180867/CA/NCI NIH HHS/United States
U10 CA180838/CA/NCI NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Breast Cancer Res Treat. 2016 Aug;159(1):109-18. doi: 10.1007/s10549-016-3918-5. Epub 2016 Jul 22.
PY  - 2016
SN  - 0167-6806 (Print)
0167-6806
SP  - 109-18
ST  - Impact of race, ethnicity, and BMI on achievement of pathologic complete response following neoadjuvant chemotherapy for breast cancer: a pooled analysis of four prospective Alliance clinical trials (A151426)
T2  - Breast Cancer Res Treat
TI  - Impact of race, ethnicity, and BMI on achievement of pathologic complete response following neoadjuvant chemotherapy for breast cancer: a pooled analysis of four prospective Alliance clinical trials (A151426)
VL  - 159
ID  - 207
ER  - 

TY  - JOUR
AB  - BACKGROUND: Older women, and older minorities in particular, are under represented in breast cancer trials. Although socioeconomic status (SES) is associated with both race and age, to the authors' knowledge little is known regarding the impact of SES on trial enrollment among older women with breast cancer. METHODS: The authors performed a case-control study comparing women who were participants in National Cancer Institute cooperative group breast cancer trials (cases) with a population-based sample of breast cancer patients (controls) obtained from the linked Surveillance, Epidemiology, and End Results (SEER)-Medicare data base. The sample was restricted to women age >/= 65 years who were living in SEER areas. Proxies for SES included the proportion of the population below poverty level (by zip code) and unemployed (by county) as well those with Medicaid insurance coverage. A multivariable logistic regression model was used to test the association of SES with trial participation after accounting for other patient and county characteristics. RESULTS: In bivariate analysis, trial participants were significantly less likely than community cancer patients to reside in high-poverty zip codes (20.9% vs. 24.9%, respectively; P < 0.001) or to have Medicaid insurance (2.0% vs. 10.0%; P < 0.0001). After adjusting for race, age, and county, trial participation remained inversely related to residing in areas with high poverty (odds ratio [OR] vs. residents of remaining counties, 0.78; 95% confidence interval [95% CI], 0.62-0.98), high unemployment rates (OR vs. residents of residents of counties in the lowest quartile, 0.50; 95% CI, 0.35-0.71), and having Medicaid insurance (OR vs. women without Medicaid, 0.22; 95% CI, 0.13-0.37); black race was not found to be related to trial participation (OR for black vs. white, 1.0; 95% CI, 0.67-1.47). CONCLUSIONS: Low SES was associated inversely with trial enrollment for older women with breast cancer and appeared to account for the enrollment disparities between black patients and white patients. Future efforts to enhance enrollment of elderly women in cancer research should identify specific barriers related to SES that may be amenable to intervention.
AD  - Section of General Internal Medicine, Department of Medicine, Robert Wood Johnson Clinical Scholars Program, New Haven, Connecticut, USA.
AN  - 15597407
AU  - Gross, C. P.
AU  - Filardo, G.
AU  - Mayne, S. T.
AU  - Krumholz, H. M.
DA  - Feb 1
DO  - 10.1002/cncr.20792
DP  - NLM
ET  - 2004/12/15
IS  - 3
KW  - African Americans/*statistics & numerical data
Aged
Asian Americans/statistics & numerical data
Breast Neoplasms/*therapy
Case-Control Studies
Clinical Trials as Topic/*statistics & numerical data
European Continental Ancestry Group/*statistics & numerical data
Female
Hispanic Americans/statistics & numerical data
Humans
Logistic Models
Medicaid
Multivariate Analysis
National Institutes of Health (U.S.)
Odds Ratio
*Patient Selection
*Poverty
SEER Program
Unemployment
United States
LA  - eng
N1  - Gross, Cary P
Filardo, Giovanni
Mayne, Susan T
Krumholz, Harlan M
1K07CA-90402/CA/NCI NIH HHS/United States
P30AG21342/AG/NIA NIH HHS/United States
Journal Article
Research Support, U.S. Gov't, P.H.S.
United States
Cancer. 2005 Feb 1;103(3):483-91. doi: 10.1002/cncr.20792.
PY  - 2005
SN  - 0008-543X (Print)
0008-543x
SP  - 483-91
ST  - The impact of socioeconomic status and race on trial participation for older women with breast cancer
T2  - Cancer
TI  - The impact of socioeconomic status and race on trial participation for older women with breast cancer
VL  - 103
ID  - 612
ER  - 

TY  - JOUR
AB  - BACKGROUND: African American accrual to prevention trials at rates representative of the disease burden experienced by this population requires additional resources and focused efforts. PURPOSE: To describe the rationale, context, and criteria for selection of sites that received Minority Recruitment Enhancement Grants (MREGs) to increase African American recruitment to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). To determine if African American accrual was higher among the 15 MREG sites when compared with similar nonawarded sites. METHODS: Changes in African American accrual at sites that received MREGs are compared with changes in a group of 15, frequency-matched, nonawarded sites using a quasi-experimental, post hoc analysis. Successful and unsuccessful recruitment strategies reported by the MREG sites are described. RESULTS: The increased number of African American participants accrued per month at MREG sites post-funding was higher than the change at comparison sites by a factor of 3.38 (p = 0.004, 95% CI: 1.51-7.57). An estimated 602 additional African American participants were recruited at MREG sites due to MREG funding, contributing to the overall 14.9% African American recruitment. Successful recruitment strategies most reported by MREG sites included increasing staff, transportation resources, recruiting through the media, mailings, and prostate cancer screening clinics during off-hours. LIMITATIONS: Comparison sites were chosen retrospectively, not by randomization. Although comparison sites were selected to be similar to MREG sites with regard to potential confounding factors, it is possible that unknown factors could have biased results. Cost-effective analyses were not conducted. CONCLUSIONS: MREG sites increased African American accrual in the post-funding period more than comparison sites, indicating MREG funding enhanced the sites' abilities to accrue African American participants. Targeted grants early in the accrual period may be a useful multi-site intervention to increase African American accrual for a prevention study where adequate African American representation is essential.
AD  - MD Anderson Cancer Center, University of Texas, Houston, TX 77230-1439, USA. edcook@mdanderson.org
AN  - 20156960
AU  - Cook, E. D.
AU  - Arnold, K. B.
AU  - Hermos, J. A.
AU  - McCaskill-Stevens, W.
AU  - Moody-Thomas, S.
AU  - Probstfield, J. L.
AU  - Hamilton, S. J.
AU  - Campbell, R. D.
AU  - Anderson, K. B.
AU  - Minasian, L. M.
C2  - PMC3956599
C6  - NIHMS551233
DA  - Feb
DO  - 10.1177/1740774509357227
DP  - NLM
ET  - 2010/02/17
IS  - 1
KW  - *African Americans
Antioxidants/*therapeutic use
Humans
Male
Middle Aged
Multicenter Studies as Topic
Neoplasms/ethnology/*prevention & control
*Patient Selection
Prostatic Neoplasms/ethnology/*prevention & control
Randomized Controlled Trials as Topic
Research Support as Topic/*economics
Selenium/*therapeutic use
United States
Vitamin E/*therapeutic use
LA  - eng
N1  - 1740-7753
Cook, Elise D
Arnold, Kathryn B
Hermos, John A
McCaskill-Stevens, Worta
Moody-Thomas, Sarah
Probstfield, Jeffrey L
Hamilton, Sandra J
Campbell, Russell D
Anderson, Karen B
Minasian, Lori M
P30-CA015704/CA/NCI NIH HHS/United States
U10 CA037429/CA/NCI NIH HHS/United States
P30 CA015704/CA/NCI NIH HHS/United States
CA37429/CA/NCI NIH HHS/United States
5-U10-CA-37429/CA/NCI NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
Clin Trials. 2010 Feb;7(1):90-9. doi: 10.1177/1740774509357227.
PY  - 2010
SN  - 1740-7745 (Print)
1740-7745
SP  - 90-9
ST  - Impact of supplemental site grants to increase African American accrual for the Selenium and Vitamin E Cancer Prevention Trial
T2  - Clin Trials
TI  - Impact of supplemental site grants to increase African American accrual for the Selenium and Vitamin E Cancer Prevention Trial
VL  - 7
ID  - 431
ER  - 

TY  - JOUR
AB  - BACKGROUND: The Z0011 trial showed similar outcomes between sentinel node biopsy (SNB) alone and axillary node dissection (ALND) for early-stage breast cancer, but few studies have examined Z0011's impact on practice patterns. STUDY DESIGN: Using the National Cancer Data Base, we examined use of SNB alone in patients who did and did not fulfill Z0011 eligibility criteria from 1998 to 2011. Because the National Cancer Data Base does not specifically identify SNB vs ALND, we categorized removal of ≤4 nodes as SNB only and ≥10 nodes as ALND. RESULTS: Of 74,309 lumpectomy patients who fulfilled Z0011 criteria; 17,630 (23.7%) had a ≤4 nodes removed, 15,619 (21.0%) had 5 to 9 nodes removed, and 41,060 (55.3%) had ≥10 nodes removed. The proportion of lumpectomy patients receiving SNB increased from 6.1% in 1998 to 23.0% in 2009 to 56.0% in 2011 (p < 0.001). Independent predictors of ALND in lumpectomy patients were triple-negative tumors, younger than 50 years old, African-American race, size ≥3.0 cm, ≥2 positive nodes, invasive lobular carcinoma, grade III disease, and lymph node macrometastases. Patients outside of Z0011 criteria also underwent SNB alone: 54% of patients with tumors >5 cm, 52.5% who received no radiation therapy or accelerated partial breast irradiation, 35.9% with clinically positive nodes, 22.3% who underwent mastectomy, and 12.9% who had >3 tumor-positive nodes. CONCLUSIONS: The use of SNB alone for patients fulfilling Z0011 criteria has increased substantially from 2009 to 2011. A considerable proportion of patients falling outside of Z0011 eligibility criteria were also treated with SNB alone.
AD  - Department of Surgery, Evanston Hospital, Evanston, IL; Department of Surgery, NorthShore University HealthSystem, University of Chicago, Pritzker School of Medicine, Chicago, IL. Electronic address: kyao@northshore.org.
Department of Surgery, Evanston Hospital, Evanston, IL.
Department of Surgery, Evanston Hospital, Evanston, IL; Department of Surgery, NorthShore University HealthSystem, University of Chicago, Pritzker School of Medicine, Chicago, IL.
Center for Biomedical Research Informatics, Evanston Hospital, Evanston, IL.
AN  - 25899731
AU  - Yao, K.
AU  - Liederbach, E.
AU  - Pesce, C.
AU  - Wang, C. H.
AU  - Winchester, D. J.
DA  - Jul
DO  - 10.1016/j.jamcollsurg.2015.02.035
DP  - NLM
ET  - 2015/04/23
IS  - 1
KW  - Adult
Aged
Aged, 80 and over
Axilla
Breast Neoplasms/pathology/*surgery
Carcinoma, Ductal, Breast/pathology/*surgery
Carcinoma, Lobular/pathology/*surgery
Databases, Factual
Female
Guideline Adherence/*statistics & numerical data
Humans
Logistic Models
Lymph Node Excision/methods/*statistics & numerical data
*Mastectomy, Segmental
Middle Aged
Practice Guidelines as Topic
Practice Patterns, Physicians'/*statistics & numerical data
Randomized Controlled Trials as Topic
Sentinel Lymph Node Biopsy/statistics & numerical data
United States
LA  - eng
N1  - 1879-1190
Yao, Katharine
Liederbach, Erik
Pesce, Catherine
Wang, Chi-Hsiung
Winchester, David J
Evaluation Study
Journal Article
United States
J Am Coll Surg. 2015 Jul;221(1):71-81. doi: 10.1016/j.jamcollsurg.2015.02.035. Epub 2015 Mar 26.
PY  - 2015
SN  - 1072-7515
SP  - 71-81
ST  - Impact of the American College of Surgeons Oncology Group Z0011 Randomized Trial on the Number of Axillary Nodes Removed for Patients with Early-Stage Breast Cancer
T2  - J Am Coll Surg
TI  - Impact of the American College of Surgeons Oncology Group Z0011 Randomized Trial on the Number of Axillary Nodes Removed for Patients with Early-Stage Breast Cancer
VL  - 221
ID  - 249
ER  - 

TY  - JOUR
AB  - BACKGROUND: Observational studies suggest that hormone replacement therapy (HRT) reduces women's risk of cardiovascular disease (CVD). However the Women's Health Initiative (WHI) HRT arm was stopped early because of increased risk of CVD, stroke, pulmonary embolism, and breast cancer. Evaluating HRT-prescribing patterns in relation to the release of the WHI will help determine if these study results have influenced the use of HRT. METHODS: This is a descriptive time series analysis to primarily evaluate utilization trends of HRT in women > or =50 years enrolled in the Pennsylvania Medicaid Program. HRT was categorized as follows: conjugated equine estrogen (CEE) plus medroxyprogesterone acetate (MPA), CEE only, and other estrogens/progesterone combinations. RESULTS: The overall prevalence of HRT decreased significantly post-WHI study release for all age and racial groups. The prevalence of CEE plus MPA decreased throughout the study; however, the prevalence of HRT declined at a faster rate after the WHI study release among women in their 50s and 60s compared with women in their 70s and 80s. There was a statistically significant reduction in all types of HRT use. CONCLUSIONS: The WHI influenced all types of HRT use among postmenopausal women in a Medicaid program. Administrative claims data can be a useful tool for monitoring an immediate impact of national guidelines or a national level outcomes trial.
AD  - Loma Linda University School of Pharmacy, Loma Linda, CA; jhillman@rx.llu.edu
AN  - 106622657. Language: English. Entry Date: 20050429. Revision Date: 20200708. Publication Type: Journal Article
AU  - Hillman, J. J.
AU  - Zuckerman, I. H.
AU  - Lee, E.
DB  - CINAHL Complete
DO  - 10.1089/jwh.2004.13.986
DP  - EBSCOhost
IS  - 9
KW  - Hormone Replacement Therapy -- Utilization
Estrogens, Conjugated -- Administration and Dosage
Women's Health
Aged
Attitude to Health
Black Persons
Comparative Studies
Descriptive Research
Epidemiological Research
Female
Funding Source
Linear Regression
Medicaid
Middle Age
Pennsylvania
Prescriptions, Drug
Prevalence
Prospective Studies
Risk Factors
Statistical Significance
T-Tests
Time Factors
White Persons
Human
N1  - research; tables/charts. Journal Subset: Biomedical; Peer Reviewed; USA. Grant Information: Supported in part by the Commonwealth of Pennsylvania, Dept of Public Welfare, Office of Medical Assistance Programs, and the Agency for Healthcare Research and Quality grant 1 R24 HS11673. NLM UID: 101159262.
PMID: NLM15665655.
PY  - 2004
SN  - 1540-9996
SP  - 986-992
ST  - The impact of the Women's Health Initiative on hormone replacement therapy in a Medicaid program
T2  - Journal of Women's Health (15409996)
TI  - The impact of the Women's Health Initiative on hormone replacement therapy in a Medicaid program
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106622657&site=ehost-live&scope=site
VL  - 13
ID  - 2125
ER  - 

TY  - JOUR
AB  - Purpose: A prior analysis by the Southwest Oncology Group (SWOG) showed that women and African American patients were adequately represented on cancer clinical treatment trials but that older patients were substantially underrepresented. Twenty-five percent of patients ≥ 65 years old were enrolled onto SWOG trials from 1993 to 1996, whereas 63% of all patients with cancer were ≥ 65 years old. Recognition of this under-representation led to a change in Medicare policy in 2000 to include coverage of routine patient care costs of clinical trials. We conducted an updated analysis of accrual trends. Methods: The proportions of enrollment onto SWOG treatment trials by sex, race/ethnicity, and age (≥ 65 years) were computed for the years 1997 to 2000; corresponding rates in the United States were derived from US Census and National Cancer Institute Surveillance, Epidemiology, and End Results data. Additionally, method of payment data were analyzed over time (1993 to 2003) to assess whether patterns in method of payment changed with the new Year 2000 Medicare policy on clinical trials coverage. Results: The results showed continued adequate representation by sex and race/ethnicity. Older patient accrual on SWOG trials increased significantly since 2000, with 31 % of patients ≥ 65 years old enrolled from 1997 to 2000 and 38% enrolled from 2001 to 2003 (v 25% from 1993 to 1996). The percentage of patients using Medicare plus supplemental insurance also increased beginning in 2000, whereas the percentage of patients using Medicare alone remained the same. Conclusion: Method of payment analyses provided evidence that the Year 2000 Medicare policy change had a positive impact, but only for those patients with supplemental private coverage of coinsurance costs. Improvements in the Medicare payment structure could further increase older patient participation in clinical trials. © 2006 by American Society of Clinical Oncology.
AD  - J.M. Unger, Southwest Oncology Group, Operations Office, 14980 Omicron Dr, San Antonio, TX 78245-3217, United States
AU  - Unger, J. M.
AU  - Coltman Jr, C. A.
AU  - Crowley, J. J.
AU  - Hutchins, L. F.
AU  - Martino, S.
AU  - Livingston, R. B.
AU  - Macdonald, J. S.
AU  - Blanke, C. D.
AU  - Gandara, D. R.
AU  - Crawford, E. D.
AU  - Albain, K. S.
DB  - Embase
Medline
DO  - 10.1200/JCO.2005.02.8928
IS  - 1
KW  - adolescent
adult
aged
article
breast cancer
cancer patient
child
colorectal cancer
demography
ethnicity
female
health care cost
health care policy
health service
hospital admission
human
lung cancer
major clinical study
male
medicare
patient care
patient participation
priority journal
prospective payment
prostate cancer
race difference
sex ratio
United States
LA  - English
M3  - Article
N1  - L46630505
2006-01-01
PY  - 2006
SN  - 0732-183X
SP  - 141-144
ST  - Impact of the year 2000 medicare policy change on older patient enrollment to cancer clinical trials
T2  - Journal of Clinical Oncology
TI  - Impact of the year 2000 medicare policy change on older patient enrollment to cancer clinical trials
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L46630505&from=export
http://dx.doi.org/10.1200/JCO.2005.02.8928
VL  - 24
ID  - 1257
ER  - 

TY  - JOUR
AB  - CONTEXT: Low-income and racial/ethnic minority populations experience disproportionate colorectal cancer (CRC) burden and poorer survival. Novel behavioral strategies are needed to improve screening rates in these groups. BACKGROUND: The study aimed to test a theoretically based "implementation intentions" intervention for improving CRC screening among unscreened adults in urban safety-net clinics. DESIGN: Randomized controlled trial. SETTING/PARTICIPANTS: Adults (N=470) aged ≥50 years, due for CRC screening, from urban safety-net clinics were recruited. INTERVENTION: The intervention (conducted in 2009-2011) was delivered via touchscreen computers that tailored informational messages to decisional stage and screening barriers. The computer then randomized participants to generic health information on diet and exercise (Comparison group) or "implementation intentions" questions and planning (Experimental group) specific to the CRC screening test chosen (fecal immunochemical test or colonoscopy). MAIN OUTCOME MEASURES: The primary study outcome was completion of CRC screening at 26 weeks based on test reports (analysis conducted in 2012-2013). RESULTS: The study population had a mean age of 57 years and was 42% non-Hispanic African American, 28% non-Hispanic white, and 27% Hispanic. Those receiving the implementation intentions-based intervention had higher odds (AOR=1.83, 95% CI=1.23, 2.73) of completing CRC screening than the Comparison group. Those with higher self-efficacy for screening (AOR=1.57, 95% CI=1.03, 2.39), history of asthma (AOR=2.20, 95% CI=1.26, 3.84), no history of diabetes (AOR=1.86, 95% CI=1.21, 2.86), and reporting they had never heard that "cutting on cancer" makes it spread (AOR=1.78, 95% CI=1.16, 2.72) were more likely to complete CRC screening. CONCLUSIONS: The results of this study suggest that programs incorporating an implementation intentions approach can contribute to successful completion of CRC screening even among very low-income and diverse primary care populations. Future initiatives to reduce CRC incidence and mortality disparities may be able to employ implementation intentions in large-scale efforts to encourage screening and prevention behaviors.
AD  - Department of Family Medicine; University of Kansas Cancer Center. Electronic address: agreiner@kumc.edu.
Department of Family Medicine; Center for American Indian Community Health; Department of Preventive Medicine; University of Kansas Cancer Center.
Department of Family Medicine.
Siteman Cancer Center, Washington University, St. Louis, Missouri.
Department of Biostatistics; University of Kansas Cancer Center.
Department of Family Medicine; University of Kansas Cancer Center; Center of Excellence for Health Communications to Underserved Populations, William Allen White School of Journalism and Mass Communications.
Department of Preventive Medicine; University of Kansas Cancer Center.
School of Architecture Design and Planning, University of Kansas, Kansas City, Kansas.
Department of Family Medicine; University of Kansas Cancer Center.
Department of Internal Medicine, University of Kansas Medical Center.
AN  - 25455115
AU  - Greiner, K. A.
AU  - Daley, C. M.
AU  - Epp, A.
AU  - James, A.
AU  - Yeh, H. W.
AU  - Geana, M.
AU  - Born, W.
AU  - Engelman, K. K.
AU  - Shellhorn, J.
AU  - Hester, C. M.
AU  - LeMaster, J.
AU  - Buckles, D. C.
AU  - Ellerbeck, E. F.
C2  - PMC4311575
C6  - NIHMS658433
DA  - Dec
DO  - 10.1016/j.amepre.2014.08.005
DP  - NLM
ET  - 2014/12/03
IS  - 6
KW  - African Americans
Colonoscopy/*statistics & numerical data
*Colorectal Neoplasms/diagnosis/ethnology/psychology
Computer-Assisted Instruction/methods/statistics & numerical data
Diagnosis, Computer-Assisted/methods/psychology/statistics & numerical data
*Early Detection of Cancer/methods/psychology/statistics & numerical data
European Continental Ancestry Group
Female
Hispanic Americans
Humans
*Intention
Male
Mass Screening/methods
Middle Aged
*Occult Blood
Outcome Assessment, Health Care
Poverty
Safety-net Providers/methods
United States
LA  - eng
N1  - 1873-2607
Greiner, K Allen
Daley, Christine M
Epp, Aaron
James, Aimee
Yeh, Hung-Wen
Geana, Mugur
Born, Wendi
Engelman, Kimberly K
Shellhorn, Jeremy
Hester, Christina M
LeMaster, Joseph
Buckles, Daniel C
Ellerbeck, Edward F
R01 CA123245/CA/NCI NIH HHS/United States
CA123245/CA/NCI NIH HHS/United States
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Am J Prev Med. 2014 Dec;47(6):703-14. doi: 10.1016/j.amepre.2014.08.005. Epub 2014 Nov 18.
PY  - 2014
SN  - 0749-3797 (Print)
0749-3797
SP  - 703-14
ST  - Implementation intentions and colorectal screening: a randomized trial in safety-net clinics
T2  - Am J Prev Med
TI  - Implementation intentions and colorectal screening: a randomized trial in safety-net clinics
VL  - 47
ID  - 269
ER  - 

TY  - JOUR
AB  - Reports an error in 'Implementation intentions and colorectal screening: A randomized trial in safety-net clinics' by K. Allen Greiner, Christine M. Daley, Aaron Epp, Aimee James, Hung-Wen Yeh, Mugur Geana, Wendi Born, Kimberly K. Engelman, Jeremy Shellhorn, Christina M. Hester, Joseph LeMaster, Daniel C. Buckles and Edward F. Ellerbeck (American Journal of Preventive Medicine, 2014[Dec], Vol 47[6], 703-714). In the original article, there is an error in results section. The correction is given in the erratum. (The following abstract of the original article appeared in record [rid]2014-49474-005[/rid]). Context: Low-income and racial/ethnic minority populations experience disproportionate colorectal cancer (CRC) burden and poorer survival. Novel behavioral strategies are needed to improve screening rates in these groups. Background: The study aimed to test a theoretically based 'implementation intentions' intervention for improving CRC screening among unscreened adults in urban safety-net clinics. Design: Randomized controlled trial. Setting/participants: Adults (N = 470) aged ≥ 50 years, due for CRC screening, from urban safety-net clinics were recruited. Intervention: The intervention (conducted in 2009−2011) was delivered via touchscreen computers that tailored informational messages to decisional stage and screening barriers. The computer then randomized participants to generic health information on diet and exercise (Comparison group) or 'implementation intentions' questions and planning (Experimental group) specific to the CRC screening test chosen (fecal immunochemical test or colonoscopy). Main outcome measures: The primary study outcome was completion of CRC screening at 26 weeks based on test reports (analysis conducted in 2012−2013). Results: The study population had a mean age of 57 years and was 42% non-Hispanic African American, 28% non-Hispanic white, and 27% Hispanic. Those receiving the implementation intentions−based intervention had higher odds (AOR = 1.83, 95% CI = 1.23, 2.73) of completing CRC screening than the Comparison group. Those with higher self-efficacy for screening (AOR = 1.57, 95% CI = 1.03, 2.39), history of asthma (AOR = 2.20, 95% CI = 1.26, 3.84), no history of diabetes (AOR = 1.86, 95% CI = 1.21, 2.86), and reporting they had never heard that 'cutting on cancer' makes it spread (AOR = 1.78, 95% CI = 1.16, 2.72) were more likely to complete CRC screening. Conclusions: The results of this study suggest that programs incorporating an implementation intentions approach can contribute to successful completion of CRC screening even among very low-income and diverse primary care populations. Future initiatives to reduce CRC incidence and mortality disparities may be able to employ implementation intentions in large-scale efforts to encourage screening and prevention behaviors. (PsycINFO Database Record (c) 2016 APA, all rights reserved)
AD  - Greiner, K. Allen, Department of Family Medicine, University of Kansas Medical Center, Mailstop 3064, 4125 Rainbow Boulevard, Kansas City, KS, US, 66160
AN  - 2015-33753-027
AU  - Greiner, K. Allen
AU  - Daley, Christine M.
AU  - Epp, Aaron
AU  - James, Aimee
AU  - Yeh, Hung-Wen
AU  - Geana, Mugur
AU  - Born, Wendi
AU  - Engelman, Kimberly K.
AU  - Shellhorn, Jeremy
AU  - Hester, Christina M.
AU  - LeMaster, Joseph
AU  - Buckles, Daniel C.
AU  - Ellerbeck, Edward F.
DB  - psyh
DP  - EBSCOhost
IS  - 2
KW  - colorectal screening
screening barriers
racial ethnic minority populations
randomized trial
Cancer Screening
Clinics
Colon Disorders
Intention
Intervention
Minority Groups
Treatment Barriers
Health Disparities
N1  - Department of Family Medicine, University of Kansas Medical Center, Kansas City, KS, US. Release Date: 20150907. Correction Date: 20160512. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Erratum/Correction. Language: English. Major Descriptor: Cancer Screening; Clinics; Colon Disorders; Intention; Intervention. Minor Descriptor: Minority Groups; Treatment Barriers; Health Disparities. Classification: Health & Mental Health Services (3370). Population: Human (10). Page Count: 1. Issue Publication Date: Aug, 2015. Copyright Statement: Published by Elsevier Inc. American Journal of Preventive Medicine. 2015.
PY  - 2015
SN  - 0749-3797
1873-2607
SP  - 322-322
ST  - 'Implementation intentions and colorectal screening: A randomized trial in safety-net clinics': Correction
T2  - American Journal of Preventive Medicine
TI  - 'Implementation intentions and colorectal screening: A randomized trial in safety-net clinics': Correction
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2015-33753-027&site=ehost-live&scope=site
agreiner@kumc.edu
VL  - 49
ID  - 1779
ER  - 

TY  - JOUR
AB  - Study objective: To assess the feasibility and yields of screening for breast and cervical cancer in an urban public hospital emergency department. Methods: Women who presented to the ED of a large, urban public hospital during the study period with nonurgent conditions were eligible for a Papanicolaou test (Pap smear) and a clinical breast examination (CBE) if they were 18 years of age or older, and for a mammogram if they were 40 years of age or older, provided they had not had the screening examination within the past year. The Pap smear and CBE were performed by a nurse, and mammography was scheduled for a later date. Women with gynecologic complaints were excluded. Results: On the basis of screening history, medical status, and age, 1,850 (32%) of the 5,830 women seen in the ER during the 23-month study period were eligible for both mammography and CBE, and 2,361 (41%) were eligible for Pap smears. Of these women, 116 (6%) completed mammography and CBE, and 644 (27%) received Pap smears. Among screened women, 10 (9%) and 20 (3%), respectively, had results that were suspicious or positive for breast or cervical cancer. Follow-up rates were low: 20% for breast screening and 50% for Pap smears. Among those receiving follow-up, 1 woman was found to have breast cancer and 8 were found to have cervical neoplasia. Conclusion: ED cancer screening was feasible and yielded a high rate of cancer detection. Program efficiency was hampered by low volume and high numbers of patients lost to follow-up after abnormal screening results. Greater integration into the acute care setting and more intensive recruitment and follow-up strategies are needed to maximize the potential yield and cost-effectiveness of such programs.
AN  - WOS:A1996VQ47600005
AU  - Mandelblatt, J.
AU  - Freeman, H.
AU  - Winczewski, D.
AU  - Cagney, K.
AU  - Williams, S.
AU  - Trowers, R.
AU  - Tang, J.
AU  - Kerner, J.
AU  - Baird, M.
AU  - Bennett, S.
AU  - Godfrey, D.
AU  - Kelly, D.
AU  - Murdock, L.
AU  - Nelson, E.
AU  - Nixon, A.
AU  - Smith, D.
AU  - Rios, S.
DA  - Nov
DO  - 10.1016/S0196-0644(96)70111-7
IS  - 5
N1  - 27
8909269
PY  - 1996
SN  - 0196-0644
SP  - 493-498
ST  - Implementation of a breast and cervical cancer screening program in a public hospital emergency department
T2  - Annals of Emergency Medicine
TI  - Implementation of a breast and cervical cancer screening program in a public hospital emergency department
VL  - 28
ID  - 2734
ER  - 

TY  - JOUR
AB  - Low-income minorities often face system-based and personal barriers to screening colonoscopy (SC). Culturally targeted patient navigation (CTPN) programs employing professional navigators (Pro-PNs) or community-based peer navigators (Peer-PNs) can help overcome barriers but are not widely implemented. In East Harlem, NY, USA, where approximately half the residents participate in SC, 315 African American patients referred for SC at a primary care clinic with a Direct Endoscopic Referral System were recruited between May 2008 and May 2010. After medical clearance, 240 were randomized to receive CTPN delivered by a Pro-PN (n = 106) or Peer-PN (n = 134). Successful navigation was measured by SC adherence rate, patient satisfaction and navigator trust. Study enrollment was 91.4% with no significant differences in SC adherence rates between Pro-PN (80.0%) and Peer-PN (71.3%) (P = 0.178). Participants in both groups reported high levels of satisfaction and trust. These findings suggest that CTPN Pro-PN and Peer-PN programs are effective in this urban primary care setting. We detail how we recruited and trained navigators, how CTPN was implemented and provide a preliminary answer to our questions of the study aims: can peer navigators be as effective as professionals and what is the potential impact of patient navigation on screening adherence?
AD  - Mount Sinai School of Medicine, One Gustave L. Levy Place, New York, NY 10029-6574, USA, Population Studies and Disparities Research Program, Department of Oncology, School of Medicine, Karmanos Cancer Institute, Wayne State University, 4100 John R, MM03CB Detroit, MI 48201, USA and Mailman School of Public Health, Columbia University, 722 West, 168th Street, New York, NY 10032, USA.
AN  - 23393099
AU  - Jandorf, L.
AU  - Cooperman, J. L.
AU  - Stossel, L. M.
AU  - Itzkowitz, S.
AU  - Thompson, H. S.
AU  - Villagra, C.
AU  - Thélémaque, L. D.
AU  - McGinn, T.
AU  - Winkel, G.
AU  - Valdimarsdottir, H.
AU  - Shelton, R. C.
AU  - Redd, W.
C2  - PMC3772329
DA  - Oct
DO  - 10.1093/her/cyt003
DP  - NLM
ET  - 2013/02/09
IS  - 5
KW  - African Americans
Colonoscopy/*psychology
Colorectal Neoplasms/diagnosis/mortality/*prevention & control
*Cultural Competency
Humans
New York City/epidemiology
Patient Compliance
Patient Navigation/*organization & administration
Patient Satisfaction
Peer Group
Poverty
Program Development
*Referral and Consultation
Trust
LA  - eng
N1  - 1465-3648
Jandorf, Lina
Cooperman, Julia L
Stossel, Lauren M
Itzkowitz, Steven
Thompson, Hayley S
Villagra, Cristina
Thélémaque, Linda D
McGinn, Thomas
Winkel, Gary
Valdimarsdottir, Heiddis
Shelton, Rachel C
Redd, William
K05 CA108955/CA/NCI NIH HHS/United States
R01 CA120658/CA/NCI NIH HHS/United States
5R01CA120658-02/CA/NCI NIH HHS/United States
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Health Educ Res. 2013 Oct;28(5):803-15. doi: 10.1093/her/cyt003. Epub 2013 Feb 7.
PY  - 2013
SN  - 0268-1153 (Print)
0268-1153
SP  - 803-15
ST  - Implementation of culturally targeted patient navigation system for screening colonoscopy in a direct referral system
T2  - Health Educ Res
TI  - Implementation of culturally targeted patient navigation system for screening colonoscopy in a direct referral system
VL  - 28
ID  - 338
ER  - 

TY  - JOUR
AB  - BACKGROUND: Population-based genomic screening has the predicted ability to reduce morbidity and mortality associated with medically actionable conditions. However, much research is needed to develop standards for genomic screening and to understand the perspectives of people offered this new testing modality. This is particularly true for non-European ancestry populations who are vastly underrepresented in genomic medicine research. Therefore, we implemented a pilot genomic screening program in the BioMe Biobank in New York City, where the majority of participants are of non-European ancestry. METHODS: We initiated genomic screening for well-established genes associated with hereditary breast and ovarian cancer syndrome (HBOC), Lynch syndrome (LS), and familial hypercholesterolemia (FH). We evaluated and included an additional gene (TTR) associated with hereditary transthyretin amyloidosis (hATTR), which has a common founder variant in African ancestry populations. We evaluated the characteristics of 74 participants who received results associated with these conditions. We also assessed the preferences of 7461 newly enrolled BioMe participants to receive genomic results. RESULTS: In the pilot genomic screening program, 74 consented participants received results related to HBOC (N = 26), LS (N = 6), FH (N = 8), and hATTR (N = 34). Thirty-three of 34 (97.1%) participants who received a result related to hATTR were self-reported African American/African (AA) or Hispanic/Latinx (HL), compared to 14 of 40 (35.0%) participants who received a result related to HBOC, LS, or FH. Among the 7461 participants enrolled after the BioMe protocol modification to allow the return of genomic results, 93.4% indicated that they would want to receive results. Younger participants, women, and HL participants were more likely to opt to receive results. CONCLUSIONS: The addition of TTR to a pilot genomic screening program meant that we returned results to a higher proportion of AA and HL participants, in comparison with genes traditionally included in genomic screening programs in the USA. We found that the majority of participants in a multi-ethnic biobank are interested in receiving genomic results for medically actionable conditions. These findings increase knowledge about the perspectives of diverse research participants on receiving genomic results and inform the broader implementation of genomic medicine in underrepresented patient populations.
AD  - The Institute for Genomic Health, Icahn School of Medicine at Mount Sinai, New York, NY, USA. noura.abul-husn@mssm.edu.
Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA. noura.abul-husn@mssm.edu.
Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA. noura.abul-husn@mssm.edu.
The Institute for Genomic Health, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Cardiogenetics, GeneDx Inc., Gaithersburg, MD, USA.
The Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
AN  - 33546753
AU  - Abul-Husn, N. S.
AU  - Soper, E. R.
AU  - Braganza, G. T.
AU  - Rodriguez, J. E.
AU  - Zeid, N.
AU  - Cullina, S.
AU  - Bobo, D.
AU  - Moscati, A.
AU  - Merkelson, A.
AU  - Loos, R. J. F.
AU  - Cho, J. H.
AU  - Belbin, G. M.
AU  - Suckiel, S. A.
AU  - Kenny, E. E.
C2  - PMC7863616 speaker honorarium from Genentech. E.E.K. has received speaker honoraria from Illumina and Regeneron Pharmaceuticals. The remaining authors declare no competing interests.
DA  - Feb 5
DO  - 10.1186/s13073-021-00832-y
DP  - NLM
ET  - 2021/02/07
IS  - 1
LA  - eng
N1  - 1756-994x
Abul-Husn, Noura S
Orcid: 0000-0002-5179-1944
Soper, Emily R
Braganza, Giovanna T
Rodriguez, Jessica E
Zeid, Natasha
Cullina, Sinead
Bobo, Dean
Moscati, Arden
Merkelson, Amanda
Loos, Ruth J F
Cho, Judy H
Belbin, Gillian M
Suckiel, Sabrina A
Kenny, Eimear E
Journal Article
Genome Med. 2021 Feb 5;13(1):17. doi: 10.1186/s13073-021-00832-y.
PY  - 2021
SN  - 1756-994x
SP  - 17
ST  - Implementing genomic screening in diverse populations
T2  - Genome Med
TI  - Implementing genomic screening in diverse populations
VL  - 13
ID  - 7
ER  - 

TY  - JOUR
AD  - Department of Health and Human Services National Institutes of Health Scientific Workshop on Menopausal Hormone Therapy, JNMA, 1012 Tenth St, NW, Washington, DC 20001, USA.
AN  - 12749614
AU  - Carroll, L. N.
C2  - PMC2594604
DA  - Apr
DP  - NLM
ET  - 2003/05/17
IS  - 4
KW  - African Americans
*African Continental Ancestry Group
Breast Neoplasms/ethnology
Cardiovascular Diseases/ethnology
Clinical Trials as Topic/methods
Colorectal Neoplasms/ethnology
*Estrogen Replacement Therapy/*statistics & numerical data
*European Continental Ancestry Group
Female
Hispanic Americans
Humans
Incidence
Osteoporosis/ethnology
Postmenopause/drug effects
Risk Assessment
United States/epidemiology
*Women's Health
LA  - eng
N1  - Carroll, L Natalie
Address
J Natl Med Assoc. 2003 Apr;95(4):253-6.
PY  - 2003
SN  - 0027-9684 (Print)
0027-9684
SP  - 253-6
ST  - Implications of menopausal hormonal therapy for African-American and Hispanic women
T2  - J Natl Med Assoc
TI  - Implications of menopausal hormonal therapy for African-American and Hispanic women
VL  - 95
ID  - 648
ER  - 

TY  - JOUR
AB  - OBJECTIVES: Limited research exists on correlates of psychosocial distress in Black breast cancer patients. The goals of the study were to describe the prevalence of distress (anxiety and depression) in Black women with breast cancer and to examine the influence of demographic, clinical, contextual (e.g., self-efficacy, medical mistrust), and process of care factors (e.g., patient satisfaction) on women's level of anxiety and depression. METHODS: Eighty-two Black women diagnosed with invasive non-metastatic breast cancer were interviewed by phone. Collected data included demographic, clinical, contextual, and process of care factors. Bivariate correlations were used to examine relationships between those variables. Multiple linear regressions were used to examine predictors of anxiety and depression. RESULTS: About one-third of the women (32%) met cut-off thresholds for distress. Medical mistrust and positive attitude had significant influences on anxiety levels, whereas age and positive attitude were determinants of levels of depression. Participants with higher medical mistrust reported more anxiety (r = .379; p < .001) and depression (r = .337; p = .002), whereas women with higher self-efficacy reported less anxiety (r = -.401; p < .001) and depression (r = -.427; p < .001). Age was inversely related to both anxiety and depression (r = -.224; r = -.296, respectively; p < .05). CONCLUSIONS: Findings support national recommendations for routine distress screening in the delivery of cancer care particularly in younger Black patients. Interventions targeted to boost self-efficacy or reduce medical mistrust through enhanced patient-provider interactions may decrease psychological distress. Psychosocial needs of younger patients warrant particular attention.
AD  - Department of Oncology, Georgetown University Medical Center and Georgetown-Lombardi Comprehensive Cancer Center, Breast Cancer Program, Washington, DC, USA.
AN  - 24150907
AU  - Sheppard, V. B.
AU  - Harper, F. W.
AU  - Davis, K.
AU  - Hirpa, F.
AU  - Makambi, K.
C2  - PMC4144019
C6  - NIHMS558796
DA  - Feb
DO  - 10.1002/pon.3382
DP  - NLM
ET  - 2013/10/24
IS  - 2
KW  - Adaptation, Psychological
Adult
African Americans/*psychology
Age Factors
Anxiety/*psychology
Attitude to Health
Breast Neoplasms/*psychology
Depression/*psychology
Female
Humans
Linear Models
Middle Aged
Multivariate Analysis
Patient Participation
*Religion and Psychology
Risk Factors
*Self Efficacy
Stress, Psychological/*psychology
Trust
LA  - eng
N1  - 1099-1611
Sheppard, Vanessa B
Harper, Felicity W K
Davis, Kimberly
Hirpa, Fikru
Makambi, Kepher
R01CA154848/CA/NCI NIH HHS/United States
2L60MD000291-02/MD/NIMHD NIH HHS/United States
UL1 TR000101/TR/NCATS NIH HHS/United States
P30 CA051008/CA/NCI NIH HHS/United States
P30 CA022453/CA/NCI NIH HHS/United States
L60 MD000291/MD/NIMHD NIH HHS/United States
R01 CA154848/CA/NCI NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
Psychooncology. 2014 Feb;23(2):143-50. doi: 10.1002/pon.3382. Epub 2013 Oct 22.
PY  - 2014
SN  - 1057-9249 (Print)
1057-9249
SP  - 143-50
ST  - The importance of contextual factors and age in association with anxiety and depression in Black breast cancer patients
T2  - Psychooncology
TI  - The importance of contextual factors and age in association with anxiety and depression in Black breast cancer patients
VL  - 23
ID  - 309
ER  - 

TY  - JOUR
AB  - This study examined the relationship between demographic factors and other correlates of fatalism, and assessed the impact of fatalistic beliefs on the participation in breast cancer screening in rural women. The subjects were 220 women aged 50 and over recruited from 6 large rural counties in South Carolina. Data were collected using a demographic questionnaire and the revised Powe Fatalism Inventory. Results show significant associations between fatalism and increased age (p = 0.005), race (p = 0.0001), doctor recommendation (p = .0034) and decreased educational level (p = 0.001). Fatalism was associated with noncompliance with mammography screening in univariate analysis among African-American women (OR = .362; 95% CI: 1.11, 11.8). After adjusting for possible confounders (age, education, and doctor recommendation), fatalism was not significantly associated with noncompliance with screening. These results illustrate age, race, and education may be important predictors of fatalism and that fatalism may be one barrier that has previously gone unmeasured and unchallenged in understanding screening behavior in older women.
AD  - Department of Public Health Sciences, 524 Edwards Hall, Clemson University, Clemson, SC 29634, USA.
AN  - 11217186
AU  - Mayo, R. M.
AU  - Ureda, J. R.
AU  - Parker, V. G.
DO  - 10.1300/J074v13n01_05
DP  - NLM
ET  - 2001/02/24
IS  - 1
KW  - Aged
Breast Neoplasms/*prevention & control/*psychology
Female
Health Services for the Aged
Humans
Mammography/*psychology
Mass Screening/*psychology
Middle Aged
*Patient Participation
Rural Health
Rural Population
South Carolina
Women's Health
LA  - eng
N1  - Mayo, R M
Ureda, J R
Parker, V G
Journal Article
England
J Women Aging. 2001;13(1):57-72. doi: 10.1300/J074v13n01_05.
PY  - 2001
SN  - 0895-2841 (Print)
0895-2841
SP  - 57-72
ST  - Importance of fatalism in understanding mammography screening in rural elderly women
T2  - J Women Aging
TI  - Importance of fatalism in understanding mammography screening in rural elderly women
VL  - 13
ID  - 689
ER  - 

TY  - JOUR
AD  - M.B. Fisher, Discovery Pharmacokinetics/Dynamics, Pfizer Inc., PGRD, Eastern Point Road, Groton, CT 06340, United States
AU  - Foti, R. S.
AU  - Fisher, M. B.
DB  - Embase
Medline
DO  - 10.1038/sj.tpj.6500286
IS  - 6
KW  - alprazolam
antiestrogen
azathioprine
benzodiazepine derivative
benzothiazepine derivative
corticosteroid
cyclosporine
cytochrome P450 3A1
cytochrome P450 3A4
cytochrome P450 3A5
diltiazem
everolimus
immunosuppressive agent
midazolam
multidrug resistance protein 1
vinorelbine tartrate
nifedipine
rapamycin
tacrolimus
tamoxifen
triazolam
African American
article
breast cancer
Caucasian
dose response
drug clearance
drug hydroxylation
drug metabolism
enzyme substrate
ethnic difference
gene frequency
genetic polymorphism
genotype
heterozygote
homozygosity
human
patient selection
population genetics
priority journal
LA  - English
M3  - Article
N1  - L39600052
2004-12-20
PY  - 2004
SN  - 1470-269X
SP  - 362-364
ST  - Importance of patient selection when determining the significance of the CYP3A5 polymorphism in clinical trials
T2  - Pharmacogenomics Journal
TI  - Importance of patient selection when determining the significance of the CYP3A5 polymorphism in clinical trials
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L39600052&from=export
http://dx.doi.org/10.1038/sj.tpj.6500286
VL  - 4
ID  - 1276
ER  - 

TY  - JOUR
AB  - BACKGROUND: African Americans (AA) and socioeconomic status (SES) disadvantaged older breast cancer survivors (BCS) are more likely to experience poor functional and health outcomes. However, few studies have evaluated the putative beneficial effects of exercise on these outcomes in older racial minority and SES-disadvantaged BCS. METHODS: This is a mixed-methods study that includes a randomized-controlled trial, "IMPROVE", to evaluate a group-based exercise intervention compared to a support group program in older BCS, followed by post-intervention semi-structured interviews to evaluate the intervention. The trial aims to recruit 220 BCS with 55 in each of four strata defined by race (AA versus Non-Hispanic Whites) and SES (disadvantaged vs. non-disadvantaged). Participants are ≥65 years old and within five years of treatment completion for stage I-III breast cancer. Participants are randomized to a 52-week, three sessions/week, one-hour/session, moderate intensity aerobic and resistance group exercise intervention, (n = 110) or a 52-week, one hour/week, support group intervention [attention-control arm], (n = 110). The first 20 weeks of both programs are supervised and the last 32 weeks, unsupervised. The primary outcome is the change in Short Physical Performance Battery (SPPB) Scores at 20 weeks from baseline, between the two arms. Secondary outcomes include change in SPPB scores at 52 weeks, change in body composition and biomarkers, at 20 and 52 weeks from baseline, between arms. DISCUSSION: Results of the trial may contribute to a better understanding of factors associated with recruitment, and acceptability, and will inform future exercise programs to optimally improve health outcomes for older BCS.
AD  - Division of Hematology/Oncology, Department of Medicine, Case Western Reserve University (CWRU) School of Medicine, Cleveland, OH, United States of America; Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH, United States of America. Electronic address: Cynthia.owusu@case.edu.
Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH, United States of America; Department of Population and Quantitative Health Sciences, CWRU, Cleveland, OH, United States of America.
Department of Medicine, Division of Hematology/Oncology, MetroHealth Medical Center, Cleveland, OH, United States of America.
The Gathering Place, Beachwood, OH, United States of America.
Cleveland Clinic, Department of Hematology/Oncology, Cleveland, OH, United States of America.
University Hospitals of Cleveland, Cleveland, OH, United States of America.
Penn State University College of Medicine, Hershey, PA, United States of America.
Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH, United States of America.
California Baptist University, Riverside, CA, United States of America.
West Virginia University School of Medicine, Morgantown, WV, United States of America.
Division of Hematology/Oncology, Department of Medicine, Case Western Reserve University (CWRU) School of Medicine, Cleveland, OH, United States of America.
AN  - 32304828
AU  - Owusu, C.
AU  - Nock, N. L.
AU  - Hergenroeder, P.
AU  - Austin, K.
AU  - Bennet, E.
AU  - Cerne, S.
AU  - Moore, H.
AU  - Petkac, J.
AU  - Schluchter, M.
AU  - Schmitz, K. H.
AU  - Webb Hooper, M.
AU  - Atkins, L.
AU  - Asagba, O.
AU  - Wimbley, L.
AU  - Berger, N. A.
C2  - PMC7325580
C6  - NIHMS1585824
DA  - May
DO  - 10.1016/j.cct.2020.106001
DP  - NLM
ET  - 2020/04/19
KW  - *African American
*Cancer exercise
*Older breast
*socioeconomic status-disadvantaged
LA  - eng
N1  - 1559-2030
Owusu, Cynthia
Nock, Nora L
Hergenroeder, Paul
Austin, Kristina
Bennet, Elizabeth
Cerne, Stephen
Moore, Halle
Petkac, Jean
Schluchter, Mark
Schmitz, Kathryn H
Webb Hooper, Monica
Atkins, Lindsay
Asagba, Oghenerukeme
Wimbley, Leonard
Berger, Nathan A
R01 MD009699/MD/NIMHD NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
Contemp Clin Trials. 2020 May;92:106001. doi: 10.1016/j.cct.2020.106001. Epub 2020 Apr 15.
PY  - 2020
SN  - 1551-7144 (Print)
1551-7144
SP  - 106001
ST  - IMPROVE, a community-based exercise intervention versus support group to improve functional and health outcomes among older African American and non-Hispanic White breast cancer survivors from diverse socioeconomic backgrounds: Rationale, design and methods
T2  - Contemp Clin Trials
TI  - IMPROVE, a community-based exercise intervention versus support group to improve functional and health outcomes among older African American and non-Hispanic White breast cancer survivors from diverse socioeconomic backgrounds: Rationale, design and methods
VL  - 92
ID  - 40
ER  - 

TY  - JOUR
AB  - BACKGROUND: Behavioral intervention studies in older breast cancer survivors, particularly older African American (AA) and socioeconomic status-disadvantaged breast cancer survivors, are lacking. To inform future studies, the authors examined recruitment strategies in older breast cancer survivors who participated in an exercise intervention study. METHODS: IMPROVE is a randomized trial designed to evaluate a group-based exercise intervention versus a support group (ClinicalTrials.gov identifier, NCT02763228). Participants were aged ≥65 years who had survived stage I through III breast cancer and were within 5 years of treatment completion. Participants were recruited through multiple approaches, including peripheral, linguistic, and constituent-involving strategies that incorporated the identification of potentially eligible patients from 3 local hospitals and from State of Ohio registries and through direct clinician and community organization referrals. RESULTS: Between October 2016 and November 2019, 7487 patients were screened, 4790 were potentially eligible, and 213 were randomized into the study. The eligible:randomization rates were 4.4% overall and 84%, 8%, and 2% for recruitment using direct referrals, hospital registries, and state registries, respectively. The median age of the randomized cohort was 70 years (range, 65-88 years) and included 44% AA and 44% socioeconomic status-disadvantaged breast cancer survivors. Compared with all registry-eligible patients, directly referred-eligible patients were more likely to be AA versus Non-Hispanic White (41% vs 19%; P = .006), to be contacted successfully (100% vs 33%; P < .0001), and to accept study participation (88% vs 16%; P < .0001). CONCLUSIONS: Direct referrals appeared to be the most efficient strategy for recruiting AA survivors. Behavioral intervention studies seeking to target older AA and socioeconomic status-disadvantaged breast cancer survivors should include strategies that foster direct referrals to study participation.
AD  - Division of Hematology/Oncology, Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, Ohio.
Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, Ohio.
Department of Population and Quantitative Health Sciences, Case Western Reserve University, Cleveland, Ohio.
Washington University School of Medicine, St Louis, Missouri.
Hospice of Western Reserve, Cleveland, Ohio.
The Gathering Place, Beachwood, Ohio.
Department of Hematology/Oncology, Cleveland Clinic, Cleveland, Ohio.
Physical Medicine and Rehabilitation, University Hospitals of Cleveland, Cleveland, Ohio.
Penn State University College of Medicine, Hershey, Pennsylvania.
AN  - 33539554
AU  - Owusu, C.
AU  - Nock, N. L.
AU  - Feuntes, V.
AU  - Margevicius, S.
AU  - Hergenroeder, P.
AU  - Austin, K.
AU  - Bennet, E.
AU  - Cerne, S.
AU  - Moore, H. C. F.
AU  - Petkac, J.
AU  - Schluchter, M.
AU  - Schmitz, K. H.
AU  - Webb Hooper, M.
AU  - Coccia, S.
AU  - Nagy, C.
AU  - Wimbley, L.
AU  - Berger, N. A.
DA  - Feb 4
DO  - 10.1002/cncr.33430
DP  - NLM
ET  - 2021/02/05
KW  - African American (AA)
exercise
older breast cancer
socioeconomic status-disadvantaged
LA  - eng
N1  - 1097-0142
Owusu, Cynthia
Orcid: 0000-0003-2045-4336
Nock, Nora L
Feuntes, Vanessa
Margevicius, Seunghee
Orcid: 0000-0001-5663-8319
Hergenroeder, Paul
Austin, Kristina
Bennet, Elizabeth
Cerne, Stephen
Moore, Halle C F
Petkac, Jean
Schluchter, Mark
Schmitz, Kathryn H
Orcid: 0000-0003-2400-2935
Webb Hooper, Monica
Coccia, Sarah
Nagy, Caitlin
Wimbley, Leonard
Berger, Nathan A
R01MD009699/MD/NIMHD NIH HHS/United States
Journal Article
United States
Cancer. 2021 Feb 4. doi: 10.1002/cncr.33430.
PY  - 2021
SN  - 0008-543x
ST  - IMPROVE, a community-based exercise intervention versus support group to improve functional and health outcomes among older African American and Non-Hispanic White breast cancer survivors from diverse socioeconomic backgrounds: Recruitment strategies and baseline characteristics
T2  - Cancer
TI  - IMPROVE, a community-based exercise intervention versus support group to improve functional and health outcomes among older African American and Non-Hispanic White breast cancer survivors from diverse socioeconomic backgrounds: Recruitment strategies and baseline characteristics
ID  - 8
ER  - 

TY  - JOUR
AB  - Background: African‐Americans (AA) and lower socioeconomic status (SES) older breast cancer survivors (BCS) are more likely to experience poor functional and health outcomes. Promotion of healthy behaviors, such as physical activity (PA), is critical to addressing these health disparities. Here we describe the rationale, design and methods of a randomized controlled trial testing the effectiveness of a physical activity intervention among older BCS from diverse racial and SES backgrounds.Methods: The IMPROVE Study is a community‐based randomized‐controlled trial designed to recruit 320 BCS, 80 in each of four strata defined by race (AA vs. Non‐Hispanic Whites [NHW]) and SES (low vs. high). Participants are aged > 65 years, AA or NHW and are within five years from treatment completion for stage I‐III breast cancer. Participants are recruited utilizing the Ohio Cancer Incidence and Surveillance System database or directly from three area hospitals in Cleveland, Ohio and randomized to one of two arms: a 52‐week moderate intensity aerobic and resistance group training intervention (n = 160) versus attention‐control (support group sessions), (n = 160). The first 20 weeks of the PA intervention includes 3x per week 60‐minute supervised sessions. The last 32 weeks of the PA intervention are unsupervised. Each of the 60‐minute supervised PA sessions include 30 minutes of moderate intensity aerobic activity at 50%‐70% of HRmax (maximum heart rate) and 30 minutes of resistance training based on 1‐RM (repetition maximum) for chest and leg press. The attention‐control group attend a once per week 60‐minute support group session for the first 20 weeks and have unsupervised group sessions during the last 32 weeks. Exit interviews are being conducted at 52 weeks. The primary outcome is change in Short Physical Performance Battery (SPPB) Scores at 20 weeks. Secondary outcomes include change in SPPB scores at 52 weeks, and change in body composition and biomarkers of breast cancer prognosis at 20 and 52 weeks. One hundred and seventy‐four participants have been enrolled as of 02/07/2019. Discussion: This study includes three underserved populations, (older BCS in general, older AA BCS and older low SES BCS) in one study. Results may contribute to a better understanding of factors associated with recruitment, sustained participation and acceptability, and will inform physical activity programs that will optimally improve the functional and health outcomes for older women during breast cancer survivorship.
AN  - CN-01985534
AU  - Owusu, C.
AU  - Nock, N.
AU  - Hergenroeder, P.
AU  - Austin, K.
AU  - Bennett, B.
AU  - Cerne, S.
AU  - Moore, H. C. F.
AU  - Petkac, J.
AU  - Schluchter, M. D.
AU  - Schmitz, K. H.
AU  - et al.
DO  - 10.1200/JCO.2019.37.15_suppl.TPS11629
KW  - *breast cancer
*cancer survival
*cancer survivor
*physical activity
Adult
African American
Attention
Body composition
Cancer incidence
Cancer prognosis
Cancer staging
Caucasian
Conference abstract
Controlled study
Female
Heart rate
Human
Interview
Leg
Major clinical study
Multicenter study
Ohio
Physical performance
Randomized controlled trial
Resistance training
Social status
Support group
Survivorship
Thorax
M3  - Journal: Conference Abstract
PY  - 2019
ST  - Improve: a community-based physical activity intervention to improve functional and health outcomes in older breast cancer survivors: rationale, design, and methods
T2  - Journal of clinical oncology
TI  - Improve: a community-based physical activity intervention to improve functional and health outcomes in older breast cancer survivors: rationale, design, and methods
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01985534/full
VL  - 37
ID  - 1455
ER  - 

TY  - JOUR
AB  - Background and Aim. Inadequate bowel preparation is a major impediment in colonoscopy quality outcomes. Aim of this study was to evaluate the role of multimedia education (MME) in improving bowel preparation quality and adenoma detection rate. Methods. This was an IRB-approved prospective randomized study that enrolled 111 adult patients undergoing outpatient screening or surveillance colonoscopy. After receiving standard colonoscopy instructions, the patients were randomized into MME group (n = 48) and control group (n = 46). The MME group received comprehensive multimedia education including an audio-visual program, a visual aid, and a brochure. Demographics, quality of bowel preparation, and colonoscopy findings were recorded. Results. MME group had a significantly better bowel preparation in the entire colon (OR 2.65, 95% CI 1.16-6.09) and on the right side of the colon (OR 2.74, 95% CI 1.12-6.71) as compared to control group (p < 0.05). Large polyps (>1 cm) were found more frequently in the MME group (11/31, 35.5% versus 0/13; p < 0.05). More polyps and adenomas were detected in MME group (57 versus 39 and 31 versus 13, resp.) but the difference failed to reach statistical significance. Conclusion. MME can lead to significant improvement in the quality of bowel preparation and large adenoma detection in a predominantly African-American population.
AD  - S. Garg, Division of Gastroenterology, Department of Medicine, Sinai Hospital of Baltimore, Baltimore, MD, United States
AU  - Garg, S.
AU  - Girotra, M.
AU  - Chandra, L.
AU  - Verma, V.
AU  - Kaur, S.
AU  - Allawy, A.
AU  - Secco, A.
AU  - Anand, R.
AU  - Dutta, S. K.
DB  - Embase
DO  - 10.1155/2016/2072401
KW  - bicarbonate plus macrogol 3350 plus potassium chloride plus sodium chloride plus sodium sulfate
adult
African American
article
audiovisual aid
colon adenoma
colon carcinoma
colon polyp
colonoscopy
controlled study
demography
female
groups by age
human
intestine preparation
major clinical study
male
middle aged
multimedia
multimedia education
outpatient
patient education
prospective study
race difference
randomized controlled trial
sex difference
single blind procedure
statistical significance
visual aid
LA  - English
M3  - Article
N1  - L608950004
2016-03-24
2016-04-05
PY  - 2016
SN  - 1029-0516
1070-3608
ST  - Improved Bowel Preparation with Multimedia Education in a Predominantly African-American Population: A Randomized Study
T2  - Diagnostic and Therapeutic Endoscopy
TI  - Improved Bowel Preparation with Multimedia Education in a Predominantly African-American Population: A Randomized Study
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L608950004&from=export
http://dx.doi.org/10.1155/2016/2072401
VL  - 2016
ID  - 986
ER  - 

TY  - JOUR
AB  - PURPOSE: Frequent prostate specific antigen testing for screening and monitoring prostate cancer has led to significant stage migration. We evaluated whether overall survival in hormone naïve patients with metastatic prostate cancer has improved during the era of prostate specific antigen use. We also assessed whether any patient subsets benefited differentially during this period. MATERIALS AND METHODS: We compared overall survival in 3 sequential phase III trials of 3,096 men with hormone naïve, metastatic prostate cancer who received similar androgen deprivation therapy, including 2 trials performed before the prostate specific antigen era (S8494 and S8894) and the other done during this era (S9346). Overall survival was adjusted for patient and disease risk factors in the latter 2 trials. Subgroups were evaluated by interactions of risk factors with trial. RESULTS: Median overall survival was 30 months in S8494, 33 months in S8894 and 49 months in S9346. Adjusting for risk factors, there was a 22% lower risk of death in S9346 than in S8894 (HR 0.78, 95% CI 0.70, 0.87, p <0.001). The improvement in overall survival was greater in black American men (test of interaction p = 0.008). In S8494 and S8894 median survival for black men was 27 months, and 34 and 35 months for nonblack men, respectively. This racial difference disappeared in S9346 with overall survival of 48 and 49 months in black and nonblack men, respectively. CONCLUSIONS: Adjusting for risk factors, overall survival was significantly improved in the post-prostate specific antigen era trial. However, it cannot be concluded that this was attributable only to prostate specific antigen monitoring. Black men now have overall survival comparable to that of white men. Current estimates of survival should be used to design new trials in this population.
AD  - Fred Hutchinson Cancer Research Center, Seattle, Washington 98109-1024, USA. ctangen@fhcrc.org
AN  - 22921015
AU  - Tangen, C. M.
AU  - Hussain, M. H.
AU  - Higano, C. S.
AU  - Eisenberger, M. A.
AU  - Small, E. J.
AU  - Wilding, G.
AU  - Donnelly, B. J.
AU  - Schelhammer, P. F.
AU  - Crawford, E. D.
AU  - Vogelzang, N. J.
AU  - Powell, I. J.
AU  - Thompson, I. M., Jr.
C2  - PMC3481164
C6  - NIHMS410786
DA  - Oct
DO  - 10.1016/j.juro.2012.06.046
DP  - NLM
ET  - 2012/08/28
IS  - 4
KW  - Aged
Clinical Trials, Phase III as Topic
Humans
Male
Middle Aged
Neoplasm Metastasis
Prostatic Neoplasms/*mortality/*pathology
Survival Rate/trends
LA  - eng
N1  - 1527-3792
Tangen, Catherine M
Hussain, Maha H A
Higano, Celestia S
Eisenberger, Mario A
Small, Eric J
Wilding, George
Donnelly, Bryan J
Schelhammer, Paul F
Crawford, E David
Vogelzang, Nicholas J
Powell, Isaac J
Thompson, Ian M Jr
CA63848/CA/NCI NIH HHS/United States
CA86780/CA/NCI NIH HHS/United States
CA37981/CA/NCI NIH HHS/United States
CA58416/CA/NCI NIH HHS/United States
CA76462/CA/NCI NIH HHS/United States
CA45466/CA/NCI NIH HHS/United States
CA28862/CA/NCI NIH HHS/United States
CA46136/CA/NCI NIH HHS/United States
CA35128/CA/NCI NIH HHS/United States
CA35261/CA/NCI NIH HHS/United States
CA35117/CA/NCI NIH HHS/United States
CA22433/CA/NCI NIH HHS/United States
CA12213/CA/NCI NIH HHS/United States
CA12644/CA/NCI NIH HHS/United States
CA20319/CA/NCI NIH HHS/United States
CA52650/CA/NCI NIH HHS/United States
CA35283/CA/NCI NIH HHS/United States
CA35200/CA/NCI NIH HHS/United States
CA68183/CA/NCI NIH HHS/United States
CA35281/CA/NCI NIH HHS/United States
P30 CA014520/CA/NCI NIH HHS/United States
CA128567/CA/NCI NIH HHS/United States
CA63845/CA/NCI NIH HHS/United States
CA45808/CA/NCI NIH HHS/United States
CA35262/CA/NCI NIH HHS/United States
CA14028/CA/NCI NIH HHS/United States
CA58882/CA/NCI NIH HHS/United States
CA45377/CA/NCI NIH HHS/United States
CA11083/CA/NCI NIH HHS/United States
CA58861/CA/NCI NIH HHS/United States
CA52772/CA/NCI NIH HHS/United States
CA35090/CA/NCI NIH HHS/United States
CA76132/CA/NCI NIH HHS/United States
CA46282/CA/NCI NIH HHS/United States
CA16385/CA/NCI NIH HHS/United States
CA76447/CA/NCI NIH HHS/United States
U10 CA032102/CA/NCI NIH HHS/United States
CA46368/CA/NCI NIH HHS/United States
CA67663/CA/NCI NIH HHS/United States
CA45461/CA/NCI NIH HHS/United States
CA35192/CA/NCI NIH HHS/United States
CA74647/CA/NCI NIH HHS/United States
CA46113/CA/NCI NIH HHS/United States
CA32734/CA/NCI NIH HHS/United States
CA58686/CA/NCI NIH HHS/United States
CA52386/CA/NCI NIH HHS/United States
CA42777/CA/NCI NIH HHS/United States
CA52654/CA/NCI NIH HHS/United States
CA58723/CA/NCI NIH HHS/United States
CA95860/CA/NCI NIH HHS/United States
CA76492/CA/NCI NIH HHS/United States
Comparative Study
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
J Urol. 2012 Oct;188(4):1164-9. doi: 10.1016/j.juro.2012.06.046. Epub 2012 Aug 22.
PY  - 2012
SN  - 0022-5347 (Print)
0022-5347
SP  - 1164-9
ST  - Improved overall survival trends of men with newly diagnosed M1 prostate cancer: a SWOG phase III trial experience (S8494, S8894 and S9346)
T2  - J Urol
TI  - Improved overall survival trends of men with newly diagnosed M1 prostate cancer: a SWOG phase III trial experience (S8494, S8894 and S9346)
VL  - 188
ID  - 357
ER  - 

TY  - JOUR
AB  - Background: Prostate cancer (PCa) is a major public health concern among African American (A.A.) men. A.A. men have the highest PCa incidences nationally and internationally. Objective: The goal of this pilot study was to evaluate the effectiveness of an evidence-based PCa awareness intervention designed to positively affect the knowledge, attitudes, and beliefs of A.A. men regarding PCa screening. Method: A quantitative pre/post survey research design was utilized. A convenience sample of 11 subjects were recruited. The intervention consisted of a pre-survey, video presentation, oral presentation, question and answer session, and post-survey. The Thomas Jefferson University Prostate Cancer Screening Survey was used as the survey instrument. Results: The findings revealed a strong positive correlation between age of participants and pre-test scores. As education level increased among the participants so did knowledge, attitudes, and beliefs. Conclusions: The study's goal was met by increasing awareness and changing knowledge, attitudes, and beliefs in A.A. men regarding PCa screening. Implications for Nursing: Nurses and healthcare providers should encourage discussions with A.A. men regarding advantages and disadvantages of PCa screening that embraces cultural awareness. PCa knowledge is important for shared decision-making with healthcare providers.
AD  - Troy University School of Nursing, Troy, Alabama
AN  - 141937558. Language: English. Entry Date: 20200302. Revision Date: 20210311. Publication Type: Article
AU  - Adams, Carlos D.
AU  - Forehand, Jeffery Wade
AU  - Pines, Eula W.
DB  - CINAHL Complete
DO  - 10.1891/2380-9418.13.1.84
DP  - EBSCOhost
IS  - 1
KW  - Prostatic Neoplasms -- Education
Cancer Screening
Health Education
Black Persons -- Education
Attitude to Illness -- Evaluation
Health Knowledge -- Evaluation
Health Beliefs -- Evaluation
Outcomes of Education
Human
Southeastern United States
Male
Clinical Trials
Quantitative Studies
Pretest-Posttest Design
Convenience Sample
Videorecording
Questionnaires
Age Factors
Pilot Studies
Adult
Middle Age
Data Analysis Software
Descriptive Statistics
Decision Making, Shared
N1  - clinical trial; research; tables/charts. Journal Subset: Nursing. Special Interest: Men's Health. Instrumentation: Thomas Jefferson University Prostate Cancer Screening Survey.
PY  - 2020
SN  - 2380-9418
SP  - 84-89
ST  - Improvement of Knowledge, Attitudes, and Beliefs of African American Men Toward Prostate Cancer Screening
T2  - Journal of Doctoral Nursing Practice
TI  - Improvement of Knowledge, Attitudes, and Beliefs of African American Men Toward Prostate Cancer Screening
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=141937558&site=ehost-live&scope=site
VL  - 13
ID  - 1974
ER  - 

TY  - JOUR
AB  - INTRODUCTION AND OBJECTIVES: Salvage prostate bed radiotherapy (PBRT) results in about 70% 5 yr freedom from progression (FFP). A three arm randomized trial was designed to determine whether there are incremental gains in FFP by adding (i) 4‐6 mo of short term androgen deprivation therapy (STAD) to PBRT and (ii) the combination of STAD and pelvic lymph node treatment (PLNRT) to PBRT. METHODS: Patients were randomized to PBRT alone (Arm 1), PBRT + STAD (Arm 2), and PLNRT + PBRT + STAD (Arm 3). The FFP primary endpoint included PSA nadir+2, clinical failure, or death from any cause. The sample size provided 90% power to detect a 10% absolute FFP improvement at 5 yr in Arm 2 compared to Arm 1 and another 10% improvement in Arm 3 compared to Arm 2 (overall alpha of 0.025). Based on 1191 eligible patents with 5 yr minimum follow‐up on the third planned interim analysis for efficacy and futility, stepwise comparisons were made to determine if the Haybittle‐Peto (HP) threshold boundary of p < 0.001 (one sided) was crossed. Futility evaluation tested the alternative hypotheses at p < 0.001. Adverse events were graded using CTCAEv3.0. RESULTS: From 2008‐2015, 1792 patients were enrolled. Of these, 1736 were eligible with a median age of 64 yr, black in 13%, baseline Zubrod status of 0 in 93%, seminal vesicle involvement in 15%, pre‐radiotherapy PSA of <1.0 ng/ml in 89%, Gleason score <8 in 83%, and pT2 margin positive or pT3 in 72%. Median follow‐up for those living is 5.4 yr. For the 1191 patients in the interim analysis cohort, the 5 yr FFP rates for Arms 1, 2, and 3 were 71%, 83% and 89%. When compared to Arm 1, Arm 3 exceeded the HP boundary with a hazard ratio (HR) 0.44 (95% CI: 0.32‐0.59). Arm 3 was then compared to Arm 2, yielding a difference of 6% (p = 0.0063) and an HR of 0.71 (95% CI: 0.51‐0.98). In all eligible patients followed for up to 8 years, there were 45, 38 and 25 patients who developed distant metastasis (DM) in Arms 1, 2 and 3. The HR was 0.52 (95% CI: 0.32‐0.85) for Arm 3 vs Arm 1 and 0.64 (95% CI: 0.39‐1.06) for Arm 3 vs. Arm 2. With IMRT use in 87% of cases, there were no significant differences in late grade 2+ or 3+ renal/GU or GI events; only grade 2+ blood/bone marrow events attributable to PLNRT were significant (p<0.044). CONCLUSIONS: These are the first randomized findings to demonstrate that extending salvage radiotherapy to cover the pelvic lymph nodes results in early, meaningful, reductions in progression when combined with STAD. Follow‐up of patients will further elucidate the magnitude of the differences in DM and in FFP between arms 2 and 3.
AN  - CN-01998436
AU  - Pollack, A.
AU  - Karrison, T.
AU  - Balogh, A. G.
AU  - Low, D.
AU  - Bruner, D. W.
AU  - Wefel, J. S.
AU  - Gomella, L. G.
AU  - Martin, A. G.
AU  - Michalski, J. M.
AU  - Angyalfi, S. J.
AU  - et al.
DO  - 10.1097/01.JU.0000557133.04919.da
IS  - 4
KW  - *androgen deprivation therapy
*cancer radiotherapy
*pelvis lymph node
*prostate
Adult
All cause mortality
Alternative hypothesis
Bone marrow
Cancer patient
Cohort analysis
Conference abstract
Controlled study
Disease course
Distant metastasis
Follow up
Gleason score
Human
Kidney
Major clinical study
Male
Middle aged
Patent
Radiotherapy
Randomized controlled trial
Sample size
Seminal vesicle
Treatment failure
M3  - Journal: Conference Abstract
PY  - 2019
SP  - e1054‐e1055
ST  - Improvements in freedom from progression with short term androgen deprivation therapy and pelvic lymph node treatment added to prostate bed salvage radiotherapy: the NRG oncology/rtog 0534 spport trial
T2  - Journal of urology
TI  - Improvements in freedom from progression with short term androgen deprivation therapy and pelvic lymph node treatment added to prostate bed salvage radiotherapy: the NRG oncology/rtog 0534 spport trial
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01998436/full
VL  - 201
ID  - 1640
ER  - 

TY  - JOUR
AB  - Background: The goal of the Carolinas Cancer Education and Screening (CARES) Project was to improve colorectal cancer (CRC) screening among low-income women in subsidized housing communities in 11 cities in North and South Carolina who were traditionally underserved by cancer control efforts. Methods: Cross-sectional samples were randomly selected from housing authority lists at 5 timepoints in this nonrandomized community-based intervention study. Face-to-face interviews focused on CRC knowledge, beliefs, barriers to screening, and screening behaviors. The intervention components were based on a previous evidence-based program. Results: A total of 2098 surveys were completed. Seventy-eight percent of the respondents were African American, 62% were 651 years, and 4% were married. At baseline, the rate of CRC screening within guidelines was 49.3% and physician recommendation was the strongest predictor (odds ratio [OR] = 21.9) of being within guidelines. There was an increase in positive beliefs about CRC screening (P =.010) and in the intention to complete CRC screening in the next 12 months (P =.053) after the intervention. The odds of being within CRC screening guidelines for women living in a city that had received the intervention were not significantly different from women living in a city that had not received the intervention (P =.496). Conclusions: Although CRC screening rates were not significantly better after the intervention, there was a positive change in beliefs about screening and intention to be screened. The results suggest that the dissemination of an evidence- based behavioral intervention may require a longer duration to engage hard-to-reach populations and change behaviors. (PsycINFO Database Record (c) 2016 APA, all rights reserved)
AD  - Katz, Mira L., College of Public Health, A-352 Starling Loving Hall, 320 West 10th Ave., Columbus, OH, US, 43210
AN  - 2008-13358-009
AU  - Katz, Mira L.
AU  - Tatum, Cathy
AU  - Dickinson, Stephanie L.
AU  - Murray, David M.
AU  - Long-Foley, Kristie
AU  - Cooper, M. Robert
AU  - Daven, Morgan
AU  - Paskett, Electra D.
DB  - psyh
DO  - 10.1002/cncr.22930
DP  - EBSCOhost
IS  - 7
KW  - colorectal cancer screening
community volunteers
Carolinas Cancer Education and Screening Project
low income women
African Americans
Aged
Aged, 80 and over
Colorectal Neoplasms
Cross-Sectional Studies
Female
Health Behavior
Health Education
Humans
Mass Screening
Middle Aged
North Carolina
Odds Ratio
Poverty
Preventive Health Services
South Carolina
Volunteers
Women's Health
Cancer Screening
Community Involvement
Gastrointestinal System
Neoplasms
Human Females
Lower Income Level
N1  - Health Behavior and Health Promotion, College of Public Health, Ohio State University, Columbus, OH, US. Release Date: 20090803. Correction Date: 20130128. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: English. Major Descriptor: Cancer Screening; Community Involvement; Gastrointestinal System; Neoplasms; Volunteers. Minor Descriptor: Human Females; Lower Income Level. Classification: Cancer (3293); Promotion & Maintenance of Health & Wellness (3365). Population: Human (10); Female (40). Location: US. Age Group: Adulthood (18 yrs & older) (300); Middle Age (40-64 yrs) (360); Aged (65 yrs & older) (380); Very Old (85 yrs & older) (390). Methodology: Empirical Study; Quantitative Study. References Available: Y. Page Count: 9. Issue Publication Date: Oct, 2007.
Sponsor: American Cancer Society, US. Grant: TIOG-99-361-02. Recipients: No recipient indicated
Sponsor: National Cancer Institute, US. Grant: 1 K07 CA107079. Recipients: No recipient indicated
PY  - 2007
SN  - 0008-543X
1097-0142
SP  - 1602-1610
ST  - Improving colorectal cancer screening by using community volunteers: Results of the Carolinas Cancer Education and Screening (CARES) Project
T2  - Cancer
TI  - Improving colorectal cancer screening by using community volunteers: Results of the Carolinas Cancer Education and Screening (CARES) Project
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2008-13358-009&site=ehost-live&scope=site
mira.katz@osumc.edu
VL  - 110
ID  - 1801
ER  - 

TY  - JOUR
AB  - OBJECTIVES: To determine the efficacy of the Power Over Pain-Coaching (POP-C) intervention to improve functional status among African American outpatients with cancer pain. SAMPLE & SETTING: 310 African American patients were recruited from an urban comprehensive cancer center. The study took place in the patients' homes. METHODS & VARIABLES: A two-group randomized design with repeated measures was used. Data were analyzed with linear mixed effects regression analysis and structural equation change score models. Variables were pain, pain-related distress, functional status, perceived control over pain, and the following antecedents to control: medication management, pain advocacy, and living with pain. RESULTS: Functional status was improved in POP-C participants relative to control group participants (p < 0.05). Distress also was differentially decreased (p < 0.05). Pain intensity ratings decreased significantly in all patients (p <0.05). The largest intervention effects were observed in the living with pain component. IMPLICATIONS FOR NURSING: Perceived control over pain was strongly related to functional status and is amenable to interventions using the POP-C intervention components described in this article.
AN  - WOS:000459359400597
AU  - Vallerand, A. H.
AU  - Hasenau, S. M.
AU  - Robinson-Lane, S. G.
AU  - Templin, T. N.
DA  - Mar
DO  - 10.1188/18.ONF.260-272
IS  - 2
N1  - 29466352
PY  - 2018
SN  - 0190-535X
SP  - 260-272
ST  - Improving Functional Status in African Americans With Cancer Pain: A Randomized Clinical Trial
T2  - Oncology Nursing Forum
TI  - Improving Functional Status in African Americans With Cancer Pain: A Randomized Clinical Trial
VL  - 45
ID  - 2870
ER  - 

TY  - JOUR
AB  - BACKGROUND: Randomized clinical trials provide the evidence base for new advances in treating and preventing cancer. The representation of racial and ethnic minorities in clinical trials remains persistently low, ranging from 1.5 to 5 %. This lack of ethnic and racial diversity among study participants hinders the ability to generalize findings and deliver the best care possible. Studies without adequate minority representation may diminish opportunities for identifying the health needs of minority groups, and may contribute to the disproportional burden of cancer in these populations. It is essential to include a diverse sample of participants in clinical trials. This study describes best practices for engaging diverse populations in clinical trials METHODS: Project SUPPORT is a randomized controlled clinical trial that seeks to recruit 374 low‐income and racially and ethnically diverse breast cancer patients at Boston Medical Center (BMC), an urban academic safety net hospital. The Project SUPPORT study objective is to determine whether patient navigation supported by medical‐legal partnership improves timely cancer treatment. Participants randomized to the control arm receive a patient navigator, who coordinates patient care and addresses barriers to care. Participants randomized to the intervention arm receive a patient navigator who systematically consults with lawyers from Medical‐Legal Partnership| Boston (MLP) to address socio‐legal barriers to care such as housing insecurity. This descriptive study aims to explore how enrollment of a diverse patient population into a randomized controlled trial is achieved with bilingual research assistants who recruit patients in their primary language: English, Spanish or Haitian Creole. Recruitment protocols required that primary spoken language be determined at the time of eligibility, so that all eligible participants were matched with a research assistant who spoke their primary language at the time of recruitment. We report here retention and enrollment rates by both race and primary spoken language. RESULTS: Of the 186 eligible women approached for enrollment, 39 declined participation and 147 (79 %) enrolled. The median age of those enrolled was 56 years, 77 (52 %) were Black, 32 (22 %) Hispanic, 30 (20 %) White, and 8 (6 %) other. Primary spoken language among participants: 31 (21 %) Spanish, 14 (10 %) Haitian Creole and 102 (69 %) English. The majority (73 %) of subjects had public health insurance. Enrollment rates by race/ethnicity were: 77 out of 91 (84 %) Black, 32 out of 38 (84 %) Hispanic, and 30 out of 44 (70 %) White patients. Enrollment rates by primary spoken language include: 31 out of 37 (84 %) Spanish, 14 out of 20 (70 %) Haitian Creole and 102 out of 128 (80 %) English speakers. Research assistants survey patients at enrollment, 3, 6 and 12 months post‐enrollment. Retention rates are high with 94 % at 3 months, 91 % at 6 months and 82 % at 12 months. CONCLUSIONS: These preliminary data suggest that having culturally diverse research staff who can communicate with study participants in their primary language aids in the successful recruitment and retention of historically underrepresented populations and should be a topic of further investigation.
AN  - CN-01160480
AU  - Bak, S.
AU  - Battaglia, T. A.
AU  - Castano, M.
AU  - Festa, K.
AU  - Flacks, J. H.
AU  - Gunn, C. M.
AU  - Ko, N. Y.
AU  - Morton, S.
AU  - Pamphile, J.
IS  - 2
KW  - *clinical trial
*ethnic group
*human
*internal medicine
*neoplasm
*society
*tongue
Arm
Breast cancer
Cancer patient
Cancer therapy
Clinical trial (topic)
Controlled clinical trial
Controlled clinical trial (topic)
Female
Haitian
Health
Hispanic
Housing
Language
Lawyer
Lowest income group
Minority group
Patient
Patient care
Population
Public health insurance
Randomized controlled trial
Randomized controlled trial (topic)
Safety net hospital
Scientist
United States
M3  - Journal: Conference Abstract
PY  - 2016
SP  - S271‐
ST  - Improving inclusion of racial and ethnic minorities in a randomized cancer clinical trial using a diverse and multi-lingual research team
T2  - Journal of general internal medicine
TI  - Improving inclusion of racial and ethnic minorities in a randomized cancer clinical trial using a diverse and multi-lingual research team
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01160480/full
VL  - 31
ID  - 1613
ER  - 

TY  - JOUR
AB  - BACKGROUND: Little is known about the effect of health professionals' advice on promoting healthy lifestyle behaviors (diet and exercise) among breast cancer patients. PURPOSE: To identify predictors of receiving lifestyle advice from health professionals and its impact on healthy lifestyle behaviors. METHODS: We used data from a randomized controlled trial of an interactive, cancer-communication video program using African American breast cancer survivor stories for newly diagnosed African American breast cancer patients (Stages 0-III). Participants completed five interviews over 2 years. This intervention did not significantly affect changes in quality-of-life outcomes. In secondary analysis, we examined differences in baseline variables between women with and without diabetes. Logistic regression models identified independent predictors of receiving advice from "a doctor or other health professional" to improve diet and exercise and of self-reported change in diet and exercise habits at 2 year follow-up. RESULTS: Of 193 patients included (85% of 228 enrolled), 53 (28%) had diabetes. At 2 year follow-up, a greater proportion of women with (vs. without) diabetes reported receiving advice by a doctor/health professional to improve their diet (73% vs. 57%, p = .04,). Predictors of receiving dietary advice were obesity, diabetes, and breast-conserving surgery (each p < .05). Women receiving dietary advice were 2.75 times more likely to report improving their diet (95% confidence interval: 1.17, 6.46) at follow-up, but receiving physical activity advice was not significantly associated with patients reporting an increase in exercise. CONCLUSIONS: Although receiving dietary advice predicted dietary improvements, receiving exercise advice did not lead to an increase in physical activity. CLINICAL TRIAL REGISTRATION: Trial Number NCT00929084.
AD  - Department of Family and Consumer Sciences, University of Tennessee, Knoxville, TN, USA.
Department of Medicine, School of Medicine, Washington University in St. Louis, St. Louis, MO, USA.
Department of Surgery, School of Medicine, Washington University in St. Louis, St. Louis, MO, USA.
Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, St. Louis, MO, USA.
Brown School of Social Work, Washington University in St. Louis, St. Louis, MO, USA.
AN  - 32298407
AU  - Jarvandi, S.
AU  - Pérez, M.
AU  - Margenthaler, J.
AU  - Colditz, G. A.
AU  - Kreuter, M. W.
AU  - Jeffe, D. B.
C2  - PMC7880224
DA  - Feb 12
DO  - 10.1093/abm/kaaa020
DP  - NLM
ET  - 2020/04/17
IS  - 1
KW  - *Advice
*Breast cancer
*Diabetes
*Diet
*Exercise
*Healthcare professionals
LA  - eng
N1  - 1532-4796
Jarvandi, Soghra
Pérez, Maria
Margenthaler, Julie
Colditz, Graham A
Kreuter, Matthew W
Jeffe, Donna B
P30 CA091842/CA/NCI NIH HHS/United States
P50 CA095815/CA/NCI NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
Ann Behav Med. 2021 Feb 12;55(1):1-13. doi: 10.1093/abm/kaaa020.
PY  - 2021
SN  - 0883-6612 (Print)
0883-6612
SP  - 1-13
ST  - Improving Lifestyle Behaviors After Breast Cancer Treatment Among African American Women With and Without Diabetes: Role of Health Care Professionals
T2  - Ann Behav Med
TI  - Improving Lifestyle Behaviors After Breast Cancer Treatment Among African American Women With and Without Diabetes: Role of Health Care Professionals
VL  - 55
ID  - 41
ER  - 

TY  - JOUR
AU  - Ibraheem, A.
AU  - Polite, B.
DB  - Embase
Medline
DO  - 10.1002/cncr.31073
IS  - 24
KW  - advanced cancer
article
Asian
basal like breast cancer
Black person
breast cancer
cancer diagnosis
cancer incidence
cancer mortality
Caucasian
clinical trial (topic)
colon cancer
ethnic group
gender
health care disparity
Hispanic
human
mortality rate
outcome assessment
Pacific Islander
patient attitude
patient participation
patient preference
priority journal
prostate cancer
quality of life
social status
study design
triple negative breast cancer
LA  - English
M3  - Article
N1  - L618986837
2017-11-01
2017-12-20
PY  - 2017
SN  - 1097-0142
0008-543X
SP  - 4752-4756
ST  - Improving the accrual of racial and ethnic minority patients in clinical trials: Time to raise the stakes
T2  - Cancer
TI  - Improving the accrual of racial and ethnic minority patients in clinical trials: Time to raise the stakes
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L618986837&from=export
http://dx.doi.org/10.1002/cncr.31073
VL  - 123
ID  - 919
ER  - 

TY  - JOUR
AB  - Despite recent advances in the treatment of prostate cancer, the death rate in the UK is continuing to rise. This article examines how improvements in screening and management could have an impact on survival rates in the future.
AD  - K. Stewart, Prostate Cancer UK, United Kingdom
AU  - Stewart, K.
DB  - Embase
DO  - 10.1002/psb.1449
IS  - 4
KW  - abiraterone
antiandrogen
docetaxel
enzalutamide
gonadorelin agonist
gonadorelin antagonist
nicotinamide adenine dinucleotide adenosine diphosphate ribosyltransferase inhibitor
olaparib
prostate specific antigen
radioisotope
radium 223
sipuleucel T
unclassified drug
African Caribbean
age distribution
article
brachytherapy
cancer classification
cancer hormone therapy
cancer mortality
cancer screening
cancer staging
clinical competence
clinical trial (topic)
ethnic difference
family history
general practitioner
health care access
health care quality
high risk population
human
male sexual dysfunction
national health service
nuclear magnetic resonance imaging
orchiectomy
outcome assessment
patient selection
personalized medicine
prostate cancer
prostatectomy
quality of life
survival rate
survival time
treatment planning
United Kingdom
LA  - English
M3  - Article
N1  - L610447290
2016-05-27
2016-05-31
PY  - 2016
SN  - 1931-2253
0959-6682
SP  - 14-20
ST  - Improving the detection and management of prostate cancer
T2  - Prescriber
TI  - Improving the detection and management of prostate cancer
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L610447290&from=export
http://dx.doi.org/10.1002/psb.1449
VL  - 27
ID  - 977
ER  - 

TY  - JOUR
AB  - ObjectivesTo evaluate the performance of multiparametric magnetic resonance imaging (mpMRI) in predicting prostate cancer on repeat biopsy; and to compare the cancer detection rates (CDRs) of MRI/transrectal ultrasonography (TRUS) fusion-guided biopsy with standard 12-core biopsy in men with at least one previous negative biopsy. Patients and Methods We prospectively enrolled men with elevated or rising PSA levels and/or abnormal digital rectal examination into our MRI/TRUS fusion-guided prostate biopsy trial. Participants underwent a 3 T mpMRI with an endorectal coil. Three radiologists graded all suspicious lesions on a 5-point Likert scale. MRI/TRUS fusion-guided biopsies of suspicious prostate lesions and standard TRUS-guided 12-core biopsies were performed. Analysis of 140 eligible men with at least one previous negative biopsy was performed. We calculated CDRs and estimated area under the receiver operating characteristic curves (AUCs) of mpMRI in predicting any cancer and clinically significant prostate cancer. Results The overall CDR was 65.0% (91/140). Higher level of suspicion on mpMRI was significantly associated with prostate cancer detection (P < 0.001) with an AUC of 0.744 compared with 0.653 and 0.680 for PSA level and PSA density, respectively. The CDRs of MRI/TRUS fusion-guided and standard 12-core biopsy were 52.1% (73/140) and 48.6% (68/140), respectively (P = 0.435). However, fusion biopsy was more likely to detect clinically significant prostate cancer when compared with the 12-core biopsy (47.9% vs 30.7%; P < 0.001). Of the cancers missed by 12-core biopsy, 20.9% (19/91) were clinically significant. Most cancers missed by 12-core biopsy (69.6%) were located in the anterior fibromuscular stroma and transition zone. Using a fusion-biopsy-only approach in men with an MRI suspicion score of ≥4 would have missed only 3.5% of clinically significant prostate cancers. Conclusions Using mpMRI and subsequent MRI/TRUS fusion-guided biopsy platform may improve detection of clinically significant prostate cancer in men with previous negative biopsies. Addition of a 12-core biopsy may be needed to avoid missing some clinically significant prostate cancers.
AD  - A.R. Rastinehad, Arthur Smith Institute for Urology, Hofstra North Shore-LIJ School of Medicine, 450 Lakeville Rd, New Hyde Park, NY, United States
AU  - Salami, S. S.
AU  - Ben-Levi, E.
AU  - Yaskiv, O.
AU  - Ryniker, L.
AU  - Turkbey, B.
AU  - Kavoussi, L. R.
AU  - Villani, R.
AU  - Rastinehad, A. R.
DB  - Embase
Medline
DO  - 10.1111/bju.12938
IS  - 4
KW  - NCT01566045
prostate specific antigen
12 core prostate biopsy
adult
African American
aged
article
cancer prognosis
cancer screening
controlled study
diagnostic test accuracy study
diffusion coefficient
digital rectal examination
false negative result
false positive result
family history
Gleason score
human
image guided biopsy
intermethod comparison
major clinical study
male
nuclear magnetic resonance imaging
priority journal
prospective study
prostate biopsy
prostate cancer
prostate fusion biopsy
protein blood level
receiver operating characteristic
risk assessment
transrectal ultrasonography
LA  - English
M3  - Article
N1  - L603428296
2015-04-01
2015-04-08
PY  - 2015
SN  - 1464-410X
1464-4096
SP  - 562-570
ST  - In patients with a previous negative prostate biopsy and a suspicious lesion on magnetic resonance imaging, is a 12-core biopsy still necessary in addition to a targeted biopsy?
T2  - BJU International
TI  - In patients with a previous negative prostate biopsy and a suspicious lesion on magnetic resonance imaging, is a 12-core biopsy still necessary in addition to a targeted biopsy?
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L603428296&from=export
http://dx.doi.org/10.1111/bju.12938
VL  - 115
ID  - 1004
ER  - 

TY  - JOUR
AB  - Metastasis is a major cause of cancer-related death and liver metastasis (LM) is a distinct type for its relatively good prognosis after timely treatment for selected patients. However, a generalizable estimation of incidence and prognosis of LM is lacking. Cancer patients with known LM status in the Surveillance, Epidemiology and End Results database were enrolled in the present study. The incidence and prognosis of LM were calculated by primary cancer type and clinicopathological factors. Among 1,630,725 cases, 105,329 (6.46%) cases present LM at diagnosis, with a median survival of 4 months. LM presents at diagnosis in 39.96% of pancreatic cancer, 16.00% of colorectal cancer (CRC) and 12.68% of lung cancer. Of all LM cases, 25.58% originated from lung cancer, with 24.76% from CRC and 17.55% from pancreatic cancer. LM originated from small intestine cancer shows the best prognosis (median survival: 30 months), followed by testis cancer (25 months) and breast cancer (15 months). Subgroup analyses demonstrated disparities in incidence and prognosis of LM, with higher incidence and poorer prognosis in the older population, African American, male, and patients with inferior socioeconomic status. The current study provides a generalizable data resource for the epidemiology of LM, which may help tailor screening protocol, design clinical trials and estimate disease burden.
AD  - KU Leuven, Campus Gasthuisberg, Faculty of Medicine Leuven 3000, Belgium.
Shanghai Key Laboratory of Molecular Imaging, Shanghai University of Medicine and Health Sciences Shanghai 201318, China.
AN  - 32509393
AU  - Wang, S.
AU  - Feng, Y.
AU  - Swinnen, J.
AU  - Oyen, R.
AU  - Li, Y.
AU  - Ni, Y.
C2  - PMC7269791
DP  - NLM
ET  - 2020/06/09
IS  - 5
KW  - Metastasis
Seer
epidemiology
liver
LA  - eng
N1  - 2156-6976
Wang, Shuncong
Feng, Yuanbo
Swinnen, Johan
Oyen, Raymond
Li, Yue
Ni, Yicheng
Journal Article
Am J Cancer Res. 2020 May 1;10(5):1477-1517. eCollection 2020.
PY  - 2020
SN  - 2156-6976 (Print)
2156-6976
SP  - 1477-1517
ST  - Incidence and prognosis of liver metastasis at diagnosis: a pan-cancer population-based study
T2  - Am J Cancer Res
TI  - Incidence and prognosis of liver metastasis at diagnosis: a pan-cancer population-based study
VL  - 10
ID  - 35
ER  - 

TY  - JOUR
AB  - In order to elucidate the dose-response relationship between ingested inorganic arsenic and internal cancers, a total of 263 patients with black-foot disease and 2293 healthy residents in the endemic area of arseniasis were recruited and followed up for 7 years. The information on consumption of high-arsenic artesian well water, sociodemographic characteristics, life-style and dietary habits, and personal and family history of cancers was obtained through standardized interviews. The occurrence of internal cancers among study subjects was determined through annual health examinations, home visit personal interviews, household registration data checks, and national death certification and cancer registry profile linkages. A dose-response relationship was observed between the long-term arsenic exposure from drinking artesian well water and the incidence of lung cancer, bladder cancer, and cancers of all sites combined after adjustment for age, sex, and cigarette smoking through Cox's proportional hazards regression analysis. Blackfoot disease patients had a significantly increased cancer incidence after adjustment for cumulative arsenic exposure. © 1995, American Association for Cancer Research. All rights reserved.
AD  - Institute of Epidemiology, College of Public Health, National Taiwan University, Jen-Ai Road Section 1, Taipei 10018, Taiwan
School of Public Health, Taipei Medical College, Taipei 110, Taiwan
Department of Oncology, National Taiwan University Hospital, Taipei 100, Taiwan
Department of Urology, National Cheng-Kung University, Tainan 704, Taiwan
Department of Urology, Kaohsiung Medical College, Kaohsiung 807, Taiwan
Institute of Biomedical Sciences, Academia Sinica, Taipei 115, Taiwan
AU  - Chiou, H. Y.
AU  - Hsueh, Y. M.
AU  - Liaw, K. F.
AU  - Horng, S. F.
AU  - Chiang, M. H.
AU  - Pu, Y. S.
AU  - Lin, J. S. N.
AU  - Huang, C. H.
AU  - Chen, C. J.
DB  - Scopus
IS  - 6
M3  - Article
N1  - Cited By :398
Export Date: 22 March 2021
PY  - 1995
SP  - 1296-1300
ST  - Incidence of Internal Cancers and Ingested Inorganic Arsenic: A Seven-Year Follow-up Study in Taiwan
T2  - Cancer Research
TI  - Incidence of Internal Cancers and Ingested Inorganic Arsenic: A Seven-Year Follow-up Study in Taiwan
UR  - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0028919048&partnerID=40&md5=4c0e3772aedb3e6ba4e90581598f5365
VL  - 55
ID  - 2653
ER  - 

TY  - JOUR
AB  - BACKGROUND: Chest imaging is performed for a variety of reasons in HIV-infected adults. There are limited data on the prevalence of incidental findings, progression of these findings over time and the relationship with inflammation in antiretroviral therapy (ART)-treated HIV-infected adults. METHODS: This study utilized data from a randomized clinical trial of rosuvastatin in HIV-infected adults on ART. Incidental findings were reported from chest computed tomography (CT) scans obtained for coronary artery calcium score at entry, week 48 and 96. Markers of immune activation and inflammation were measured concurrently. Poisson regression and generalized estimating equations were used. RESULTS: A total of 147 participants were enrolled. Median age was 46 years, 78% were male, 68% African American and 63% current smokers. At baseline, 57% of participants had at least one incidental lung finding (ILF) and four additional participants had at least one ILF by week 96. At baseline, older age, current smoking, lower nadir CD4(+) T-cell count and low-density lipoprotein and higher lipoprotein-associated phospholipase A2 (Lp-PLA2) were independently associated with having a greater number of ILFs. In the longitudinal analyses, older age, lower nadir CD4(+) T-cell count and higher baseline soluble tumour necrosis factor α-receptor I (sTNF-RI) were independently associated with having a greater number of ILFs over 96 weeks. CONCLUSIONS: Over half of participants had at least one incidental finding on chest CT. Beyond traditional factors of older age and smoking, lower nadir CD4(+) T-cell count and higher markers of inflammation were associated with having a greater number of ILFs in HIV-infected adults on ART.
AD  - Case Western Reserve University School of Medicine, Cleveland, OH, USA.
MetroHealth Medical Center, Cleveland, OH, USA.
University Hospitals Case Medical Center, Cleveland, OH, USA.
AN  - 27647021
AU  - Park, M. S.
AU  - Hileman, C. O.
AU  - Sattar, A.
AU  - Gilkeson, R.
AU  - McComsey, G. A.
C2  - PMC5484045
C6  - NIHMS866770
DO  - 10.3851/imp3090
DP  - NLM
ET  - 2016/09/21
IS  - 2
KW  - 1-Alkyl-2-acetylglycerophosphocholine Esterase/blood
Adult
Age Factors
Anticholesteremic Agents/therapeutic use
*Antiretroviral Therapy, Highly Active
CD4 Lymphocyte Count
Calcinosis/*diagnostic imaging/pathology
Coronary Vessels/*diagnostic imaging/pathology
Female
HIV Infections/*diagnostic imaging/drug therapy/virology
HIV-1/drug effects/physiology
Humans
*Incidental Findings
Lipoproteins, LDL/blood
Lung/*diagnostic imaging/pathology
Male
Middle Aged
Receptors, Tumor Necrosis Factor, Type I/blood
Risk Factors
Rosuvastatin Calcium/therapeutic use
Smoking/physiopathology
Tomography, X-Ray Computed
LA  - eng
N1  - 2040-2058
Park, Michelle S
Hileman, Corrilynn O
Sattar, Abdus
Gilkeson, Robert
McComsey, Grace A
K23 HL116209/HL/NHLBI NIH HHS/United States
R56 HL126526/HL/NHLBI NIH HHS/United States
UL1 TR000439/TR/NCATS NIH HHS/United States
P30 AI036219/AI/NIAID NIH HHS/United States
R01 NR012642/NR/NINR NIH HHS/United States
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Antivir Ther. 2017;22(2):127-133. doi: 10.3851/IMP3090. Epub 2016 Sep 24.
PY  - 2017
SN  - 1359-6535 (Print)
1359-6535
SP  - 127-133
ST  - Incidental findings on chest computed tomography are common and linked to inflammation in HIV-infected adults
T2  - Antivir Ther
TI  - Incidental findings on chest computed tomography are common and linked to inflammation in HIV-infected adults
VL  - 22
ID  - 202
ER  - 

TY  - JOUR
AB  - BACKGROUND Inclusion of diverse groups of participants in cancer clinical trials is an important methodological and clinical issue. The quality of the science and generalizability of results depends on the inclusion of study participants who represent all populations among whom these treatment and prevention approaches will be used. METHODS We conducted a systematic review using OVID as the primary source of reports included. Based on 304 peer-reviewed publications, diversity in the inclusion and reporting of study participants during a decade of cancer treatment and prevention trials (2001-2010) is summarized. Recommendations are made for improvements in the science and reporting of cancer clinical trials. RESULTS Of the 277 treatment trials and 27 prevention trials included in this report, more than 80% of participants were white and 59.8% were male. In the recent decade, race and sex are rarely used as selection criteria unless the trial is focused on a sex-specific cancer. CONCLUSIONS Women and racial/ethnic minorities remain severely underrepresented in cancer clinical trials, thus limiting the generalizability of cancer clinical research. © 2013 American Cancer Society.
AD  - G.M. Swanson, Richard M. Fairbanks School of Public Health, Indiana University-Purdue University Indianapolis, 714 N. Senate Avenue, Indianapolis, IN 46202, United States
AU  - Kwiatkowski, K.
AU  - Coe, K.
AU  - Bailar, J. C.
AU  - Swanson, G. M.
DB  - Embase
Medline
DO  - 10.1002/cncr.28168
IS  - 16
KW  - African American
American Indian
article
Asian
breast carcinoma
cancer mortality
cancer prevention
cancer recurrence
cancer research
cancer risk
cancer survival
cancer therapy
Caucasian
clinical trial (topic)
endometrium carcinoma
ethnic difference
ethnic group
gender
Hispanic
human
ovary carcinoma
patient selection
priority journal
prostate carcinoma
publication
quality of life
race difference
risk reduction
sex difference
systematic review
testis carcinoma
uterine cervix carcinoma
LA  - English
M3  - Article
N1  - L52590762
2013-05-21
2013-09-04
PY  - 2013
SN  - 0008-543X
1097-0142
SP  - 2956-2963
ST  - Inclusion of minorities and women in cancer clinical trials, a decade later: Have we improved?
T2  - Cancer
TI  - Inclusion of minorities and women in cancer clinical trials, a decade later: Have we improved?
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L52590762&from=export
http://dx.doi.org/10.1002/cncr.28168
VL  - 119
ID  - 1073
ER  - 

TY  - JOUR
AB  - Background Although general trends in cancer outcomes are improving, racial/ethnic disparities in patient outcomes continue to widen, suggesting disparity-related shortcomings in cancer research designs. Methods Using convenience sampling, a total of 24 data sources, representing several research designs and 5 high-burden tumor types, were included for analyses. The percentages of races/ethnicities across each design/tumor type were compared with those of the 2017 US Census data. The authors used a framework based on the Belmont principles to evaluate the ethical strengths and/or weaknesses of each design. Results In all designs, white individuals were found to be overrepresented. African American and Asian individuals were underrepresented, and Native Americans had consistently poor or no representation. In general, ethical concerns varied according to the study design. Clinical trials were high with regard to respect for persons and beneficence but low for equitable subject selection related to the inclusion of race/ethnicity. Observational study designs were more inclusive for race/ethnicity compared with clinical and translational studies, but their clinical usefulness was less. Conclusions The authors proposed that ethical concerns should vary according to the study design. Because observational designs have strengths in inclusiveness for race/ethnicity, their clinical usefulness can be improved by extending the Learning Health System in hospital catchment populations, the use of health records linked to biospecimens, and minority oversampling. Likewise, minority enrollment into clinical trials can be improved through Learning Health System linking and by using National Cancer Institute-mandated Community Outreach and Engagement Cores. This will allow precision medicine for otherwise overlooked minority subgroups.
AN  - WOS:000486035700001
AU  - Behring, M.
AU  - Hale, K.
AU  - Ozaydin, B.
AU  - Grizzle, W. E.
AU  - Sodeke, S. O.
AU  - Manne, U.
DA  - Dec
DO  - 10.1002/cncr.32495
IS  - 24
N1  - 31502259
PY  - 2019
SN  - 0008-543X
SP  - 4452-4461
ST  - Inclusiveness and ethical considerations for observational, translational, and clinical cancer health disparity research
T2  - Cancer
TI  - Inclusiveness and ethical considerations for observational, translational, and clinical cancer health disparity research
VL  - 125
ID  - 2809
ER  - 

TY  - JOUR
AB  - Purpose: To describe how investigators in a multisite randomized clinical trial addressed scientific and ethical issues involved in creating risk models based on genetic testing for African American participants. Methods: The following informed our decision whether to stratify risk assessment by ethnicity: evaluation of epidemiological data, appraisal of benefits and risks of incorporating ethnicity into calculations, and feasibility of creating ethnicity-specific risk curves. Once the decision was made, risk curves were created based on data from a large, diverse study of first-degree relatives of patients with Alzheimer disease. Results: Review of epidemiological data suggested notable differences in risk between African Americans and whites and that Apolipoprotein E genotype predicts risk in both groups. Discussions about the benefits and risks of stratified risk assessments reached consensus that estimates based on data from whites should not preclude enrolling African Americans, but population-specific risk curves should be created if feasible. Risk models specific to ethnicity, gender, and Apolipoprotein E genotype were subsequently developed for the randomized clinical trial that oversampled African Americans. Conclusion: The Risk Evaluation and Education for Alzheimer Disease study provides an instructive example of a process to develop risk assessment protocols that are sensitive to the implications of genetic testing for multiple ethnic groups with differing levels of risk.
AN  - WOS:000254239600008
AU  - Christensen, K. D.
AU  - Roberts, J. S.
AU  - Royal, C. D. M.
AU  - Fasaye, G. A.
AU  - Obisesan, T.
AU  - Cupples, L. A.
AU  - Whitehouse, P. J.
AU  - Butson, M. B.
AU  - Linnenbringer, E.
AU  - Relkin, N. R.
AU  - Farrer, L.
AU  - Cook-Deegan, R.
AU  - Green, R. C.
DA  - Mar
DO  - 10.1097/GIM.0b013e318164e4cf
IS  - 3
N1  - 18344711
PY  - 2008
SN  - 1098-3600
SP  - 207-214
ST  - Incorporating ethnicity into genetic risk assessment for Alzheimer disease: the REVEAL study experience
T2  - Genetics in Medicine
TI  - Incorporating ethnicity into genetic risk assessment for Alzheimer disease: the REVEAL study experience
VL  - 10
ID  - 3173
ER  - 

TY  - JOUR
AB  - BACKGROUND: Black and Hispanic patients participate in clinical trials at lower rates than white patients nationally; lack of diversity in clinical trials prevents appropriate safety and efficacy testing of new treatments in these populations. METHODS: The Oncology Welcomes New Haven into Trials (OWN IT) initiative at the Yale Cancer Center used a multi-tiered approach to improve breast cancer minority clinical trial accrual through community focus groups, ongoing community outreach, institutional executive council representation, grand rounds presentation, and didactic lectures with healthcare providers. Eligibility criteria of breast cancer trials at Smilow Cancer Center were reviewed using clinicaltrials.gov. Also, an anonymous, 5-min survey was conducted at regular visits with Smilow Breast Center patients to gauge awareness of and access to clinical trials. Survey data were compared to the Yale Cancer Center Clinical Trials Office, Connecticut Tumor Registry, and U.S. Census records. Two-tailed Fisher's tests were used for all analyses. RESULTS: There was a significant increase in the number of minority patients who participated in clinical trials at Smilow Cancer Center from 2016 (95/750) to 2018 (155/944) (p = 0.0325). Two hundred patients participated in the survey; response rate 92%. There was no significant difference in the rate at which patients were invited to participate in clinical trials or the rate at which they declined to participate based on race or ethnicity. Black and Hispanic patients were significantly less likely to be aware of clinical trials than white patients (p < .001). The review of eligibility criteria showed that over half of the studies reviewed had restrictions regarding increased liver function tests, and many restricted the participation of patients with other chronic conditions. CONCLUSIONS: Low participation in clinical trials among black and Hispanic patients is likely multifaceted. This study indicated that there are likely structural factors at work which can be modified with institutional effort. The role of patient education regarding clinical trials and accrual should be studied further as should eligibility criteria as a potential barrier to participation.
AD  - Yale Cancer Center, 300 George Street, Suite 120, New Haven, CT, 06511, USA. amelia.trant@yale.edu.
Yale Cancer Center, 300 George Street, Suite 120, New Haven, CT, 06511, USA.
AN  - 32840699
AU  - Trant, A. A.
AU  - Walz, L.
AU  - Allen, W.
AU  - DeJesus, J.
AU  - Hatzis, C.
AU  - Silber, A.
DA  - Nov
DO  - 10.1007/s10549-020-05873-2
DP  - NLM
ET  - 2020/08/26
IS  - 2
KW  - Breast cancer
Clinical trials
Eligibility criteria
Health disparities
LA  - eng
N1  - 1573-7217
Trant, Amelia A
Orcid: 0000-0002-9945-3696
Walz, Lucas
Allen, Whitney
DeJesus, Jose
Hatzis, Christos
Silber, Andrea
Journal Article
Netherlands
Breast Cancer Res Treat. 2020 Nov;184(2):499-505. doi: 10.1007/s10549-020-05873-2. Epub 2020 Aug 25.
PY  - 2020
SN  - 0167-6806
SP  - 499-505
ST  - Increasing accrual of minority patients in breast cancer clinical trials
T2  - Breast Cancer Res Treat
TI  - Increasing accrual of minority patients in breast cancer clinical trials
VL  - 184
ID  - 29
ER  - 

TY  - JOUR
AB  - The objective of this study was to evaluate the effectiveness of a church-based breast cancer screening education program on mammography attainment by African American women 40 years old and older in rural Alabama. The sample consisted of 192 women who volunteered to participate in the study through 13 African American churches in a rural, economically-depressed Alabama county. The design was quasi-experimental and had some features of community-based participatory research. Churches were randomly assigned to three groups (full program, partial program and control). The full program (group educational session plus an in-home visit from a Home Health Educator) positively affected mammography attainment (38% increase from baseline to Time 2). In addition, barriers to mammography attainment were reduced for women who had not obtained a mammogram by follow-up. Community-based participatory projects in collaboration with churches and cooperative extension programs have the potential to reduce racial disparities in breast cancer in rural areas.
AD  - University of Alabasma, Birmingham, AL, USA. powell@tuskegee.edu
AN  - 16327093
AU  - Powell, M. E.
AU  - Carter, V.
AU  - Bonsi, E.
AU  - Johnson, G.
AU  - Williams, L.
AU  - Taylor-Smith, L.
AU  - Hayes, Q.
AU  - Hull, P. C.
AU  - Cain, V. A.
AU  - Husaini, B. A.
DA  - Nov
DO  - 10.1353/hpu.2005.0129
DP  - NLM
ET  - 2005/12/06
IS  - 4 Suppl A
KW  - Adult
African Americans/*education
Aged
Alabama/epidemiology
Breast Neoplasms/*diagnostic imaging/*ethnology
Community Participation
Female
Health Education
Health Services Accessibility
Humans
Mammography/*statistics & numerical data
Middle Aged
Religion
*Rural Population
Socioeconomic Factors
LA  - eng
N1  - Powell, Mary Edith
Carter, Vivian
Bonsi, Eunice
Johnson, Gwendolyn
Williams, Licia
Taylor-Smith, Lucile
Hayes, Quanita
Hull, Pamela C
Cain, Van A
Husaini, Baqar A
Journal Article
Research Support, U.S. Gov't, P.H.S.
United States
J Health Care Poor Underserved. 2005 Nov;16(4 Suppl A):11-21. doi: 10.1353/hpu.2005.0129.
PY  - 2005
SN  - 1049-2089 (Print)
1049-2089
SP  - 11-21
ST  - Increasing mammography screening among African American women in rural areas
T2  - J Health Care Poor Underserved
TI  - Increasing mammography screening among African American women in rural areas
VL  - 16
ID  - 581
ER  - 

TY  - JOUR
AB  - BACKGROUND: A randomized trial was conducted to test the effectiveness of a videotape for increasing mammography screening among a multiethnic sample of older women. METHODS: A multiethnic sample of Caucasian, African-American, and Hispanic women between the ages of 50 and 70 was recruited from Resident Lists compiled by the State of Massachusetts. After completing a baseline questionnaire, women were randomized to receive either a videotape or pamphlet about mammography and recontacted at 2 and 12 months after baseline to assess attitudes, beliefs, and mammography screening. A total of 581 women completed questionnaires at all three time points. RESULTS: At baseline, approximately 75% of women reported having a mammogram in the past year and 90% reported having one in the past 2 years. Rates did not differ between groups. At the 12-month follow-up, mammography rates, adjusted for baseline screening, were 80.4% in the video and 74.8% in the pamphlet group. Logistic regression analysis of mammography at 12 months (within past year vs. >1 year ago) controlling for baseline mammogram produced an odds ratio of 1.48 for the video group that was not significantly different from unity (95% CI = 0.95-2.28). CONCLUSIONS: The videotape had a small effect on increasing mammography screening. Although the effect was smaller than more intensive interventions, the video is a convenient, low cost, and easily implemented method to increase mammography screening.
AD  - Department of Public Health Sciences, Wake Forest University School of Medicine, Winston-Salem, NC 27157, USA. navis@wfubmc.edu
AN  - 15313089
AU  - Avis, N. E.
AU  - Smith, K. W.
AU  - Link, C. L.
AU  - Goldman, M. B.
DA  - Sep
DO  - 10.1016/j.ypmed.2004.05.024
DP  - NLM
ET  - 2004/08/18
IS  - 3
KW  - African Americans/statistics & numerical data
Age Distribution
Aged
Asian Americans/statistics & numerical data
Attitude to Health/*ethnology
Breast Neoplasms/ethnology/*prevention & control
European Continental Ancestry Group/statistics & numerical data
Female
Humans
Incidence
Logistic Models
Mammography/*statistics & numerical data
Mass Screening/statistics & numerical data
Middle Aged
Pamphlets
Patient Acceptance of Health Care/*ethnology
Patient Compliance
Patient Education as Topic/methods
Probability
Prospective Studies
United States
*Video Recording
LA  - eng
N1  - Avis, Nancy E
Smith, Kevin W
Link, Carol L
Goldman, Marlene B
RR CA76756/RR/NCRR NIH HHS/United States
Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, U.S. Gov't, P.H.S.
United States
Prev Med. 2004 Sep;39(3):498-506. doi: 10.1016/j.ypmed.2004.05.024.
PY  - 2004
SN  - 0091-7435 (Print)
0091-7435
SP  - 498-506
ST  - Increasing mammography screening among women over age 50 with a videotape intervention
T2  - Prev Med
TI  - Increasing mammography screening among women over age 50 with a videotape intervention
VL  - 39
ID  - 621
ER  - 

TY  - JOUR
AB  - BACKGROUND: Residential distance from an academic or cancer center is a significant barrier to minority patient participation in cancer research. Most cancer clinical trials (CTs) are only accessible at academic and cancer centers, yet most cancer patients receive treatment in their home communities where access to CTs may be limited. Oncology nurse navigation is an innovative approach for increasing minority CT participation by facilitating access to cancer CTs in communities where minority patients live. The purpose of this study was to evaluate the impact of oncology nurse navigation on community-based recruitment of black patients to breast cancer CTs at a major cancer center. METHODS: We merged the roles of a traditional oncology research nurse and a professional patient navigator to create a novel health care provider role, the oncology nurse navigator. The primary duties of the oncology nurse navigator were to engage black cancer patients in the offices of their community physicians and to collaborate with community physicians to increase black patient participation in cancer research. The oncology nurse navigator played a key role in all phases of the CT participation process (e.g., screening for eligibility and completion of informed consent and clinical research forms) and guided each patient around barriers in the health care system. The accrual of eligible patients to breast cancer CTs was used to assess the impact of oncology nurse navigation on community-based recruitment of blacks to cancer CTs. RESULTS: Between January 2007 and December 2008, a total of 132 black breast cancer patients were screened by a single oncology nurse navigator for eligibility to University of Southern California-sponsored breast cancer CTs. Fifty-nine patients were eligible for CTs, and each was invited to participate in 1 or more CTs for which they were eligible. Fifty-one of 59 eligible black patients (86% of eligible patients) were enrolled to 1 or more research protocols. The estimated cost per enrolled patient was $5,677, nearly half the expected per patient cost of treating patients on CT at an academic or cancer center. CONCLUSIONS: Oncology nurse navigation is an effective outreach strategy for increasing black patient participation in cancer research and may be achieved at nearly half the cost of traditional methods of enrolling patients in CTs at cancer centers.
AD  - University of Southern California Kenneth Norris Jr. Comprehensive Cancer Center, Los Angeles, CA 90033, USA. dholmes@usc.edu
AN  - 21996347
AU  - Holmes, D. R.
AU  - Major, J.
AU  - Lyonga, D. E.
AU  - Alleyne, R. S.
AU  - Clayton, S. M.
DA  - Apr
DO  - 10.1016/j.amjsurg.2011.02.005
DP  - NLM
ET  - 2011/10/15
IS  - 4
KW  - Academic Medical Centers
Breast Neoplasms/diagnosis/ethnology/*therapy
California
*Clinical Trials as Topic
Female
Health Services Accessibility/*organization & administration
Humans
Minority Groups/*statistics & numerical data
*Nurse's Role
Nurse-Patient Relations
Oncology Nursing/*methods
Patient Participation/statistics & numerical data
Patient Selection
LA  - eng
N1  - 1879-1883
Holmes, Dennis Ricky
Major, Jacquelyn
Lyonga, Doris Efosi
Alleyne, Rebecca Simone
Clayton, Sheilah Marie
Comparative Study
Journal Article
Research Support, Non-U.S. Gov't
United States
Am J Surg. 2012 Apr;203(4):415-22. doi: 10.1016/j.amjsurg.2011.02.005. Epub 2011 Oct 13.
PY  - 2012
SN  - 0002-9610
SP  - 415-22
ST  - Increasing minority patient participation in cancer clinical trials using oncology nurse navigation
T2  - Am J Surg
TI  - Increasing minority patient participation in cancer clinical trials using oncology nurse navigation
VL  - 203
ID  - 385
ER  - 

TY  - JOUR
AB  - PURPOSE/OBJECTIVES: To describe the knowledge base of African American men regarding prostate cancer and evaluate the immediate effects of an educational intervention on short-term knowledge acquisition. DESIGN: Prospective one group pretest/post-test. SETTING: Church meetings, Salvation Army senior meetings, health fairs, and senior citizens' meetings in the African American community of a large midwestern city. SAMPLE: Convenience sample of 75 African American men (ages 23-88) who completed a pre- and postintervention questionnaire regarding knowledge and awareness of prostate cancer. METHOD: The questionnaire was based on patient education material from the American Cancer Society. The instrument consisted of seven statements related to prostate cancer incidence, risk factors, and detection. Following completion of the preintervention questionnaire, the investigator provided subjects with information on prostate cancer. Subjects were retested. MAIN RESEARCH VARIABLES: Knowledge and awareness of prostate cancer including incidence, risk factors, and detection in African American men. FINDINGS: Correct responses increased from 23% (preeducation) to 64% (posteducation). The three most frequently missed questions on the pretest related to urinary frequency as an early sign of prostate cancer incidence of prostate cancer in African American men, and increased risk among African American men for prostate cancer when compared to Caucasian men. These items remained the three most frequently missed questions on the post-test. CONCLUSIONS: An educational intervention had a positive effect on short-term knowledge and awareness of prostate cancer in African American men. Additional research is necessary to assess long-term retention of information and what effect, if any, increased knowledge has on health behavior. IMPLICATIONS FOR NURSING PRACTICE: Continued efforts are warranted to encourage this high-risk group to participate in prostate screenings. To influence health behavior, patient education and information regarding the incidence and mortality of prostate cancer is critical in this high-risk population.
AD  - Urology/Oncology Department, Indiana University Medical Center, USA.
AN  - 9007911
AU  - Collins, M.
DA  - Jan-Feb
DP  - NLM
ET  - 1997/01/01
IS  - 1
KW  - Adult
African Americans/*psychology
Aged
Aged, 80 and over
*Health Knowledge, Attitudes, Practice
Humans
Male
Middle Aged
Nursing Evaluation Research
Patient Education as Topic/methods
Prospective Studies
Prostatic Neoplasms/ethnology/*psychology
Risk Factors
Sampling Studies
Surveys and Questionnaires
LA  - eng
N1  - Collins, M
Journal Article
United States
Oncol Nurs Forum. 1997 Jan-Feb;24(1):91-5.
PY  - 1997
SN  - 0190-535X (Print)
0190-535x
SP  - 91-5
ST  - Increasing prostate cancer awareness in African American men
T2  - Oncol Nurs Forum
TI  - Increasing prostate cancer awareness in African American men
VL  - 24
ID  - 736
ER  - 

TY  - JOUR
AB  - OBJECTIVE: Colorectal cancer could be prevented through regular screening. Individuals age 50 and older are recommended to get screened via colonoscopy. Because physician referral is a major predictor of colonoscopy completion, two low-cost, evidence-based interventions were tested to increase referrals by activating patients to self-advocate. METHODS: This study compared the impact of a pre-visit educational handout that prompts patients to discuss colonoscopy with their physician with the handout plus brief counseling through exit interviews and chart reviews. The main outcome was physician referral. RESULTS: Medical charts were reviewed for eligibility: 130 control patients (Arm 1), 45 patients who received the educational handout and health counseling (Arm 2), and 50 patients who received only the handout (Arm 3). Colonoscopy referral rates increased from 24.6% in Arm 1 to 44.4% and 52.0% in Arms 2 and 3, respectively (p=0.001). The proportion of exit interview participants who discussed colonoscopy with their doctor increased from 68.8% in Arm 1 to 76.5% and 88.9% in Arms 2 and 3, respectively. CONCLUSIONS: Results indicate that both interventions are effective at increasing colonoscopy referrals. PRACTICAL IMPLICATIONS: Results suggest that an educational handout alone is sufficient in prompting patient-initiated discussions about colonoscopy.
AD  - Division of Cancer Prevention and Control, Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Electronic address: pathu.sriphanlop@mssm.edu.
Division of Cancer Prevention and Control, Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
AN  - 26996052
AU  - Sriphanlop, P.
AU  - Hennelly, M. O.
AU  - Sperling, D.
AU  - Villagra, C.
AU  - Jandorf, L.
DA  - Aug
DO  - 10.1016/j.pec.2016.03.005
DP  - NLM
ET  - 2016/03/22
IS  - 8
KW  - African Americans/statistics & numerical data
Aged
Colonoscopy/*statistics & numerical data
Colorectal Neoplasms/*diagnosis/ethnology/prevention & control
*Counseling
Early Detection of Cancer/methods
Female
Hispanic Americans/statistics & numerical data
Humans
Male
Mass Screening/*statistics & numerical data
Middle Aged
New York City/epidemiology
*Patient Education as Topic
*Patient Participation
Physician-Patient Relations
Poverty Areas
Primary Health Care/organization & administration
Quality Improvement
Referral and Consultation/*statistics & numerical data
*Cancer
*Cancer screening
*Colonoscopy
*Colorectal cancer screening
*Patient activation
*Patient education
*Quality improvement
LA  - eng
N1  - 1873-5134
Sriphanlop, Pathu
Hennelly, Marie Oliva
Sperling, Dylan
Villagra, Cristina
Jandorf, Lina
Comparative Study
Journal Article
Ireland
Patient Educ Couns. 2016 Aug;99(8):1427-31. doi: 10.1016/j.pec.2016.03.005. Epub 2016 Mar 7.
PY  - 2016
SN  - 0738-3991
SP  - 1427-31
ST  - Increasing referral rate for screening colonoscopy through patient education and activation at a primary care clinic in New York City
T2  - Patient Educ Couns
TI  - Increasing referral rate for screening colonoscopy through patient education and activation at a primary care clinic in New York City
VL  - 99
ID  - 217
ER  - 

TY  - JOUR
AB  - With the growing burden of cancer in minority populations and limited progress in eliminating cancer disparities, it has become important to develop a diverse oncology workforce in basic, clinical, and behavioral research who will address cancer disparities and increase the participation of minority populations in clinical trials. To address the lack of well-trained underrepresented minority cancer scientists in Florida, the University of Florida collaborated with Florida A&M University in 2012 to establish the Florida Prostate Cancer Research Training Opportunities for Outstanding Leaders (ReTOOL) Program. Since 2012, the ReTOOL program has expanded to (1) cover all areas of cancer disparities; (2) offer training opportunities to minority students from all historically Black colleges and universities (HBCUs) in Florida; and (3) successfully secure both intramural and extramural federal funding to continuously provide research training opportunities for minority students in Florida. Focusing primarily on training Black students, the ReTOOL model includes culturally sensitive recruitment, mentorship, didactic curriculum, networking, and hands on experience in cancer research. This paper discusses the lessons learned from administering the ReTOOL program for 5 years, which includes having the right inputs (such as majority-minority institutions partnership, funding, faculty advisors, committed mentors, culturally competent staff, and standardized program requirements) and processes (such as pipeline approach, structured applications system, didactic curriculum, research experience, and continuous mentoring) for an effective research training program. The program impact is an increase in the pool of underrepresented minority candidates with scientific and academic career progression paths focused on reducing cancer health disparities.
AD  - College of Pharmacy, University of Florida, Orlando, FL, USA. fodedina@cop.ufl.edu.
College of Medicine, University of Florida, Gainesville, FL, USA. fodedina@cop.ufl.edu.
Florida A&M University, Tallahassee, FL, USA.
College of Pharmacy, University of Florida, Orlando, FL, USA.
College of Nursing, University of Florida, Gainesville, FL, USA.
Colleges of Dentistry, University of Florida, Gainesville, FL, USA.
College of Education, University of Florida, Gainesville, FL, USA.
AN  - 29542061
AU  - Odedina, F. T.
AU  - Reams, R. R.
AU  - Kaninjing, E.
AU  - Nguyen, J.
AU  - Mochona, B.
AU  - Lyon, D. E.
AU  - Askins, N.
AU  - Behar-Horenstein, L. S.
C2  - PMC7247618
C6  - NIHMS951434
DA  - Jun
DO  - 10.1007/s13187-018-1344-6
DP  - NLM
ET  - 2018/03/16
IS  - 3
KW  - Biomedical Research/*education
Career Choice
Curriculum
Female
Florida
Humans
Male
Medical Oncology/education
Mentoring
*Minority Groups
Program Evaluation
Research Personnel/*education
Students
Workforce
*Biomedical research workforce
*Cancer research training
*Minority undergraduate research
*ReTOOL program
*Summer research training program
*Underrepresented minorities
LA  - eng
N1  - 1543-0154
Odedina, Folakemi T
Orcid: 0000-0003-3796-1385
Reams, R R
Kaninjing, E
Nguyen, J
Mochona, B
Lyon, D E
Askins, N
Behar-Horenstein, L S
R25 CA214225/CA/NCI NIH HHS/United States
P20 CA192992/CA/NCI NIH HHS/United States
P20 CA192990/CA/NCI NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.
J Cancer Educ. 2019 Jun;34(3):577-583. doi: 10.1007/s13187-018-1344-6.
PY  - 2019
SN  - 0885-8195 (Print)
0885-8195
SP  - 577-583
ST  - Increasing the Representation of Minority Students in the Biomedical Workforce: the ReTOOL Program
T2  - J Cancer Educ
TI  - Increasing the Representation of Minority Students in the Biomedical Workforce: the ReTOOL Program
VL  - 34
ID  - 129
ER  - 

TY  - JOUR
AB  - BACKGROUND: Underserved ethnic minority populations experience significant disparities in HIV, hepatitis C virus (HCV), colorectal cancer (CRC), and cervical cancer incidence and mortality. Much of the excess burden of these diseases among underserved communities is due to lack of preventive care, including screening. Barriers to disease screening include low awareness, lack of access to care and health insurance, and cultural beliefs regarding disease prevention. Our current trial aims to examine community health worker (CHW)-delivered, home-based multi-modality screening for HIV, HCV, CRC, and cervical cancer simultaneously. DESIGN: We are conducting a randomized pragmatic trial among 900 Haitian, Hispanic, and African-American participants from diverse underserved communities in South Florida. People between the ages of 50 and 65 who have not had appropriate HIV, HCV, CRC, and cervical cancer screening per United States Preventive Services Task Force (USPSTF) recommendations are eligible for the study. Participants are recruited by CHWs and complete a structured interview to assess multilevel determinants of disease risk. Participants are then randomized to receive HIV, HCV, CRC, and cervical cancer screening via navigation to care by a CHW (Group 1) or via CHW-delivered home-based screening (Group 2). The primary outcome is completion of screening for each of these diseases within 6 months post-enrollment. DISCUSSION: Our trial is among the first to examine the effectiveness of a CHW-delivered, multimodality, home-based disease-screening approach. If found to be effective, this approach may represent a cost-effective strategy for disease screening within underserved and underscreened minority groups. TRIAL REGISTRATION: Clinical Trials.gov # NCT02970136, registered November 21, 2016.
AD  - Sylvester Comprehensive Cancer Center, Clinical Research Building, University of Miami, Miller School of Medicine, 1120 NW 14th Street, Miami, FL, 33136, USA. OCarrasquillo@med.miami.edu.
Department of Medicine, University of Miami Miller School of Medicine, 1120 NW 14th Street, Miami, FL, 33136, USA. OCarrasquillo@med.miami.edu.
Department of Public Health Sciences, University of Miami Miller School of Medicine, 1120 NW 14th Street, Miami, FL, 33136, USA. OCarrasquillo@med.miami.edu.
Sylvester Comprehensive Cancer Center, Clinical Research Building, University of Miami, Miller School of Medicine, 1120 NW 14th Street, Miami, FL, 33136, USA.
Department of Medicine, University of Miami Miller School of Medicine, 1120 NW 14th Street, Miami, FL, 33136, USA.
Health Choice Network, 9064 N.W. 13 Terrace, Miami, FL, 33172, USA.
Department of Public Health Sciences, University of Miami Miller School of Medicine, 1120 NW 14th Street, Miami, FL, 33136, USA.
AN  - 32349789
AU  - Carrasquillo, O.
AU  - Seay, J.
AU  - Jhaveri, V.
AU  - Long, T.
AU  - Kenya, S.
AU  - Thomas, E.
AU  - Sussman, D.
AU  - Trevil, D.
AU  - Koru-Sengul, T.
AU  - Kobetz, E.
C2  - PMC7191705
DA  - Apr 29
DO  - 10.1186/s13063-020-4213-7
DP  - NLM
ET  - 2020/05/01
IS  - 1
KW  - African Americans
Aged
Awareness
Colorectal Neoplasms/*diagnosis/epidemiology/ethnology
*Community Health Workers
Female
Florida/epidemiology
HIV/*immunology
HIV Infections/*diagnosis/epidemiology/ethnology/virology
Haiti/ethnology
Health Services Accessibility
Healthcare Disparities
Hepacivirus/*immunology
Hepatitis C/*diagnosis/epidemiology/ethnology
Hispanic Americans
Humans
Male
Mass Screening/*methods
Middle Aged
*Minority Groups
Pragmatic Clinical Trials as Topic
Uterine Cervical Neoplasms/*diagnosis/epidemiology/ethnology
Cervical cancer
Colorectal cancer
Hiv
Hpv
Haitian
Hepatitis C
Hispanic
Immigrant
Screening
LA  - eng
N1  - 1745-6215
Carrasquillo, Olveen
Seay, Julia
Jhaveri, Vasanti
Long, Timothy
Kenya, Sonjia
Thomas, Emmanuel
Sussman, Daniel
Trevil, Dinah
Koru-Sengul, Tulay
Kobetz, Erin
1U01MD010614-01/MD/NIMHD NIH HHS/United States
Clinical Trial Protocol
Journal Article
Trials. 2020 Apr 29;21(1):368. doi: 10.1186/s13063-020-4213-7.
PY  - 2020
SN  - 1745-6215
SP  - 368
ST  - Increasing uptake of evidence-based screening services though a community health worker-delivered multimodality program: study protocol for a randomized pragmatic trial
T2  - Trials
TI  - Increasing uptake of evidence-based screening services though a community health worker-delivered multimodality program: study protocol for a randomized pragmatic trial
VL  - 21
ID  - 38
ER  - 

TY  - JOUR
AB  - BACKGROUND: Population data suggest that black men have a higher risk of dying from prostate cancer (PCa) than other racial ethnicities. OBJECTIVE: To examine the impact of black race on progression-free survival (PFS) and overall survival (OS) among men with metastatic castration-resistant PCa (mCRPC) enrolled in randomized controlled trials (RCTs). DESIGN, SETTING, AND PARTICIPANTS: A pooled analysis was performed on individual patient data from five modern PCa RCTs available from Project Data Sphere. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Adjusted hazard ratios (HRs) were calculated to compare black and white race regarding PFS and OS. Subgroup analyses of mCRPC trials were performed based on the control arm treatments (mitoxantrone or docetaxel). Relevant covariates were used for adjustment in all analyses. RESULTS AND LIMITATIONS: A total of 1613 patients were included; 77 were black (4.7%). No significant differences between black and white men's baseline characteristics were noted regarding age, performance status, or pretreatment prostate-specific antigen. The pooled HRs for black race for OS and PFS were 1.01 (95% confidence interval [CI], 0.73-1.35) and 1.29 (95% CI, 0.95-1.76), respectively. The median OS for black compared with white men was 254 versus 238 d (p=0.92), respectively, with mitoxantrone and 581 versus 546 d (p=0.53), respectively, with docetaxel. The primary limitation was the relatively small number of black men enrolled in mCRPC clinical trials. CONCLUSIONS: In the context of RCTs, in which patients receive generally uniform treatment, a significant difference in OS for black men could not be detected in mCRPC. Black men continue to be dramatically underrepresented in RCTs, and efforts are needed to increase minority accrual to these trials. PATIENT SUMMARY: We looked at the outcomes of men treated in randomized controlled trials to determine the impact of black race on survival. We found that in the context of modern clinical trials, there does not appear to be a significant difference in survival between black and white races; however, a trend for greater progression in black men was noted.
AD  - Department of Radiation Oncology, University of Michigan Medical Center, Ann Arbor, MI, USA. Electronic address: sprattda@med.umich.edu.
Department of Radiation Oncology, Brigham and Women's Hospital, Boston, MA, USA.
Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Department of Radiation Oncology, University of Michigan Medical Center, Ann Arbor, MI, USA.
Department of Urology, University of Michigan Medical Center, Ann Arbor, MI, USA.
AN  - 28723519
AU  - Spratt, D. E.
AU  - Chen, Y. W.
AU  - Mahal, B. A.
AU  - Osborne, J. R.
AU  - Zhao, S. G.
AU  - Morgan, T. M.
AU  - Palapattu, G.
AU  - Feng, F. Y.
AU  - Nguyen, P. L.
DA  - Dec
DO  - 10.1016/j.euf.2016.03.010
DP  - NLM
ET  - 2017/07/21
IS  - 5
KW  - Disparity
Prostate cancer
Randomized controlled trial
LA  - eng
N1  - 2405-4569
Spratt, Daniel E
Chen, Yu-Wei
Mahal, Brandon A
Osborne, Joseph R
Zhao, Shuang G
Morgan, Todd M
Palapattu, Ganesh
Feng, Felix Y
Nguyen, Paul L
Journal Article
Netherlands
Eur Urol Focus. 2016 Dec;2(5):532-539. doi: 10.1016/j.euf.2016.03.010. Epub 2016 Apr 1.
PY  - 2016
SN  - 2405-4569
SP  - 532-539
ST  - Individual Patient Data Analysis of Randomized Clinical Trials: Impact of Black Race on Castration-resistant Prostate Cancer Outcomes
T2  - Eur Urol Focus
TI  - Individual Patient Data Analysis of Randomized Clinical Trials: Impact of Black Race on Castration-resistant Prostate Cancer Outcomes
VL  - 2
ID  - 163
ER  - 

TY  - JOUR
AB  - BACKGROUND: Socioeconomic and racial/ethnic disparities in breast and cervical cancer screening persist. An exploratory study was conducted to better understand co-occurring risk factors in underserved groups that could inform interventions to improve screening adherence. The objective of this study was to examine associations between breast and cervical cancer screening adherence and co-occurring risk factors in three racial/ethnic groups of underserved women. METHODS: Black, Latina, and Arab women (N=514), ages 21 to 70 years, were enrolled into the Kin Keeper(SM) randomized controlled trial in communities around Detroit, Michigan. We used participant baseline assessments (e.g., demographic characteristics, health literacy) to explore screening risks using an additive approach and multivariate logistic analyses. RESULTS: For black women, having more health literacy risks were associated with reduced odds of a clinical breast exam (CBE), mammogram, and Papanicolaou (Pap) test; more competing priorities were associated with reduced odds of a Pap test; lack of doctor mammogram recommendation was significantly associated with decreased odds of CBE. For Latina women, lack of doctor recommendations were significantly associated with decreased odds of CBE, mammogram, and Pap test. For Arab women, lack of doctor recommendations were significantly associated with decreased odds of CBE, mammogram, and Pap test; more competing priorities were significantly associated with reduced odds of CBE and Pap test. All results were significant at p<0.05. CONCLUSIONS: Characteristics associated with breast and cervical screening adherence differs among Black, Latina, and Arab underserved women. Interventions to improve screening should be tailored for racial/ethnic groups with particular attention to competing survival priorities, health literacy risks factors, and provider recommendations.
AD  - 1 Obstetrics, Gynecology, and Reproductive Biology, Michigan State University , East Lansing, Michigan.
AN  - 24283674
AU  - Roman, L.
AU  - Meghea, C.
AU  - Ford, S.
AU  - Penner, L.
AU  - Hamade, H.
AU  - Estes, T.
AU  - Williams, K. P.
C2  - PMC4056454
DA  - Jan
DO  - 10.1089/jwh.2013.4397
DP  - NLM
ET  - 2013/11/29
IS  - 1
KW  - Adult
African Americans/*statistics & numerical data
Aged
Arabs/*statistics & numerical data
Breast Neoplasms/*diagnosis/ethnology/prevention & control
Early Detection of Cancer/*statistics & numerical data
Female
Health Behavior/ethnology
Health Knowledge, Attitudes, Practice
Health Literacy
Health Services Accessibility
Health Services Needs and Demand
Healthcare Disparities
Hispanic Americans/*statistics & numerical data
Humans
Logistic Models
Mammography
Medically Underserved Area
Michigan/epidemiology
Middle Aged
Multivariate Analysis
Papanicolaou Test
Risk Factors
Socioeconomic Factors
Surveys and Questionnaires
Uterine Cervical Neoplasms/*diagnosis/ethnology/prevention & control
Vaginal Smears
Women/education/*psychology
LA  - eng
N1  - 1931-843x
Roman, Leeanne
Meghea, Cristian
Ford, Sabrina
Penner, Louis
Hamade, Hiam
Estes, Tamika
Williams, Karen Patricia
P30 AG015281/AG/NIA NIH HHS/United States
R01 NR011323/NR/NINR NIH HHS/United States
Journal Article
J Womens Health (Larchmt). 2014 Jan;23(1):57-64. doi: 10.1089/jwh.2013.4397. Epub 2013 Nov 27.
PY  - 2014
SN  - 1540-9996 (Print)
1540-9996
SP  - 57-64
ST  - Individual, provider, and system risk factors for breast and cervical cancer screening among underserved Black, Latina, and Arab women
T2  - J Womens Health (Larchmt)
TI  - Individual, provider, and system risk factors for breast and cervical cancer screening among underserved Black, Latina, and Arab women
VL  - 23
ID  - 306
ER  - 

TY  - JOUR
AB  - BACKGROUND: There is increasing discussion whether colorectal cancer (CRC) screening guidelines should be individualized by sex and race. OBJECTIVES: To determine individualized colonoscopic screening guidelines by sex and race for the average-risk population and to compare the cost-effectiveness of this approach with that of uniform guidelines for all. DESIGN: We used the MISCAN-Colon microsimulation model to estimate life expectancy and lifetime CRC screening and treatment costs in a U.S. cohort of black and white men and women at average risk for CRC. We compared the base-case strategy of no screening and 3 competing colonoscopy strategies: (1) the currently recommended 'uniform 10-yearly colonoscopy from age 50 years,' (2) a shorter interval 'uniform 8-yearly colonoscopy from age 51 years,' and (3) 'individualized screening according to sex and race.' RESULTS: The base-case strategy of no screening was the least expensive, yet least effective. The uniform 10-yearly colonoscopy strategy was dominated. The uniform 8-yearly colonoscopy and individualized strategies both increased life expectancy by 0.0433 to 0.0435 years per individual, at a cost of $15,565 to $15,837 per life-year gained. In the individualized strategy, blacks began screening 6 years earlier, with a 1-year shorter interval compared with whites. The individualized policies were essentially the same for men and women, because the higher CRC risk in men was offset by their shorter life expectancy. The results were robust for changes in model assumptions. CONCLUSIONS: The improvements in costs and effects of individualizing CRC screening on a population level were only marginal. Individualized guidelines, however, could contribute to decreasing disparities between blacks and whites. The acceptability and feasibility of individualized guidelines, therefore, should be explored.
AD  - Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands. i.vogelaar@erasmusmc.nl
AN  - 105367571. Language: English. Entry Date: 20090814. Revision Date: 20200708. Publication Type: Journal Article
AU  - Lansdorp-Vogelaar, I.
AU  - van Ballegooijen, M.
AU  - Zauber, A. G.
AU  - Boer, R.
AU  - Wilschut, J.
AU  - Winawer, S. J.
AU  - Habbema, J. D. F.
DB  - CINAHL Complete
DO  - 10.1016/j.gie.2008.08.040
DP  - EBSCOhost
IS  - 1
KW  - Colonoscopy
Ethnology
Health Screening
Patient Selection
Sex Factors
Cost Benefit Analysis
Data Analysis Software
Funding Source
Multivariate Analysis
Neoplasms -- Prevention and Control
Netherlands
Sensitivity and Specificity
Human
N1  - research; tables/charts. Commentary: Schmitt CM. Customization and the cost of eliminating disparities in colon cancer. (GASTROINTEST ENDOSC) Jul2009; 70 (1): 109-111. Journal Subset: Biomedical; Double Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA. Grant Information: Cancer Intervention and Surveillance Modeling Network. NLM UID: 0010505.
PMID: NLM19467539.
PY  - 2009
SN  - 0016-5107
SP  - 96-24
ST  - Individualizing colonoscopy screening by sex and race
T2  - Gastrointestinal Endoscopy
TI  - Individualizing colonoscopy screening by sex and race
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105367571&site=ehost-live&scope=site
VL  - 70
ID  - 1981
ER  - 

TY  - JOUR
AB  - BACKGROUND: Black Americans have higher mortality from breast cancer than white Americans. This study explores the influence of socioeconomic factors and black race on treatment and mortality for early-stage breast cancer. METHODS: A cohort of 21,848 female black and white, non-Hispanic subjects from the Massachusetts Cancer Registry diagnosed with stage I or II breast cancer between 1999-2004 was studied. Subjects with tumors larger than 5 cm were excluded. We used mixed modeling methods to assess the impact of race on guideline concordant care (GCC), defined as receipt of mastectomy or breast conserving surgery plus radiation. Cox proportional hazard regression was used to assess disease-specific mortality. RESULTS: Blacks were less likely to receive GCC after adjusting for age and clinical variables (OR: 0.75; 95% CI: 0.61, 0.92). Marital status and insurance were predictors of receipt of GCC. After adjustment for all covariates, there were no longer significant differences between black and white women regarding the receipt of GCC. Nevertheless, black women were more likely to die of early-stage breast cancer than white women after adjusting for clinical, treatment, socioeconomic variables, and reporting hospital (HR: 1.6; 95% CI: 1.1-2.1). CONCLUSIONS: Socioeconomic factors are mediators of racial differences in treatment outcomes. Significant racial differences exist in disease-specific mortality for women with early-stage breast cancer. Attention to reducing socioeconomic barriers to care may influence racial differences in breast cancer treatment and mortality. © 2009 Lippincott Williams & Wilkins, Inc.
AD  - J. P. B. Berz, Section of General Internal Medicine, Boston University Medical Center, Crosstown Building, 801 Massachusetts Ave., Boston, MA 02118, United States
AU  - Berz, J. P. B.
AU  - Johnston, K.
AU  - Backus, B.
AU  - Doros, G.
AU  - Rose, A. J.
AU  - Pierre, S.
AU  - Battaglia, T. A.
DB  - Embase
Medline
IS  - 9
KW  - adult
African American
aged
article
breast carcinoma
cancer mortality
cancer radiotherapy
cancer registry
cancer staging
controlled study
European American
female
health insurance
human
major clinical study
mastectomy
patient selection
practice guideline
race difference
socioeconomics
United States
LA  - English
M3  - Article
N1  - L355177947
2009-10-21
PY  - 2009
SN  - 0025-7079
SP  - 986-992
ST  - The influence of black race on treatment and mortality for early-stage breast cancer
T2  - Medical Care
TI  - The influence of black race on treatment and mortality for early-stage breast cancer
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L355177947&from=export
VL  - 47
ID  - 1197
ER  - 

TY  - JOUR
AB  - Background The influence of church attendance and spirituality on mammography use was studied among Native American, White, and African American women living in a rural county. Methods A randomized trial was conducted to increase mammography use. Women (n = 851) were randomly assigned to receive either an educational program delivered by a lay health advisor or a physician letter and brochure about cervical cancer screening (control group). Church attendance and spirituality were measured at baseline and mammography use was evaluated 12 months after enrollment using medical record review. Results Almost two-thirds of the women reported that they attended church at least once a week, and less than 4% were classified as having low spirituality. Church attendance (P = 0.299) or spirituality (P = 0.401) did not have a significant impact on mammography use. Conclusions Church attendance and spirituality did not impact mammography use.
AD  - The College of Public Health, The Ohio State University, A-352 Starling Loving Hall, 320 West 10th Avenue, Columbus, OH 43210, USA. mira.katz@osumc.edu
AN  - 19105013
AU  - Katz, M. L.
AU  - Kauffman, R. M.
AU  - Tatum, C. M.
AU  - Paskett, E. D.
C2  - PMC3895452
C6  - NIHMS543845
DA  - Jun
DO  - 10.1007/s10943-008-9159-0
DP  - NLM
ET  - 2008/12/24
IS  - 2
KW  - Adult
African Americans
Aged
Aged, 80 and over
Breast Neoplasms/diagnosis/ethnology
European Continental Ancestry Group
Female
Humans
Indians, North American
Mammography/*statistics & numerical data
Middle Aged
North Carolina
Poverty
Rural Population
*Spirituality
LA  - eng
N1  - 1573-6571
Katz, Mira L
Kauffman, Ross M
Tatum, Cathy M
Paskett, Electra D
K07 CA107079/CA/NCI NIH HHS/United States
R01 CA072022/CA/NCI NIH HHS/United States
K07CA107079/CA/NCI NIH HHS/United States
CA57707-08/CA/NCI NIH HHS/United States
R25 CA057707/CA/NCI NIH HHS/United States
CA72022-04/CA/NCI NIH HHS/United States
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
J Relig Health. 2008 Jun;47(2):227-36. doi: 10.1007/s10943-008-9159-0. Epub 2008 Jan 19.
PY  - 2008
SN  - 0022-4197 (Print)
0022-4197
SP  - 227-36
ST  - Influence of church attendance and spirituality in a randomized controlled trial to increase mammography use among a low-income, tri-racial, rural community
T2  - J Relig Health
TI  - Influence of church attendance and spirituality in a randomized controlled trial to increase mammography use among a low-income, tri-racial, rural community
VL  - 47
ID  - 480
ER  - 

TY  - JOUR
AB  - PURPOSE: It is unclear why racial differences exist in the frequency of surgery for lung cancer treatment. Comorbidity is an important consideration in selection of patients for lung cancer treatment, including surgery. To assess whether comorbidity contributes to the observed racial differences, we evaluated racial differences in the prevalence of comorbidity and their impact on receipt of surgery. PATIENTS AND METHODS: A total of 1,314 patients (1,135 white, 179 black) in the Veterans Health Administration diagnosed with early-stage non-small-cell lung cancer in 2007 were included. The effect of comorbidity on surgery was determined by using generalized linear models with a logit link accounting for patient clustering within Veterans Administration Medical Centers. RESULTS: Compared with whites, blacks had greater prevalence of hypertension, liver disease, renal disease, illicit drug abuse, and poor performance status, but lower prevalence of respiratory disease. The impact of most individual comorbidities on receipt of surgery was similar between blacks and whites, and comorbidity did not influence the race-surgery association in a multivariable analysis. The proportion of blacks not receiving surgery as well as refusing surgery was greater than that among whites. CONCLUSION: Blacks had a greater prevalence of several comorbid conditions and poor performance status; however, the overall comorbidity score did not differ by race. In general, the effect of comorbidity on receipt of surgery was similar in blacks and whites. Racial differences in comorbidity do not fully explain why blacks undergo lung cancer surgery less often than whites.
AD  - Durham VA Medical Center, Durham, NC 27705, USA. Christina.Williams4@va.gov
AN  - 23269988
AU  - Williams, C. D.
AU  - Stechuchak, K. M.
AU  - Zullig, L. L.
AU  - Provenzale, D.
AU  - Kelley, M. J.
C2  - PMC3731921 found at the end of this article.
DA  - Feb 1
DO  - 10.1200/jco.2012.44.1170
DP  - NLM
ET  - 2012/12/28
IS  - 4
KW  - African Americans/*statistics & numerical data
Aged
Aged, 80 and over
Carcinoma, Non-Small-Cell Lung/*ethnology/pathology/*surgery
*Comorbidity
European Continental Ancestry Group/*statistics & numerical data
Female
Healthcare Disparities/*ethnology/statistics & numerical data
Humans
Hypertension/epidemiology
Karnofsky Performance Status
Kidney Diseases/epidemiology
Linear Models
Liver Diseases/epidemiology
Lung Neoplasms/*ethnology/pathology/*surgery
Male
Middle Aged
Multivariate Analysis
Neoplasm Staging
*Patient Selection
Pneumonectomy/statistics & numerical data
Prevalence
Retrospective Studies
Substance-Related Disorders/epidemiology
United States/epidemiology
Veterans/*statistics & numerical data
LA  - eng
N1  - 1527-7755
Williams, Christina D
Stechuchak, Karen M
Zullig, Leah L
Provenzale, Dawn
Kelley, Michael J
R25 CA116339/CA/NCI NIH HHS/United States
T32 HS000079/HS/AHRQ HHS/United States
5R25CA116339/CA/NCI NIH HHS/United States
T32-HS00079/HS/AHRQ HHS/United States
Journal Article
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, P.H.S.
J Clin Oncol. 2013 Feb 1;31(4):475-81. doi: 10.1200/JCO.2012.44.1170. Epub 2012 Dec 26.
PY  - 2013
SN  - 0732-183X (Print)
0732-183x
SP  - 475-81
ST  - Influence of comorbidity on racial differences in receipt of surgery among US veterans with early-stage non-small-cell lung cancer
T2  - J Clin Oncol
TI  - Influence of comorbidity on racial differences in receipt of surgery among US veterans with early-stage non-small-cell lung cancer
VL  - 31
ID  - 346
ER  - 

TY  - JOUR
AB  - Research has suggested that race, gender, and menthol cigarette use influence tobacco-smoke exposure measures and smoking-related disease risk. For example, a high proportion of Black smokers prefer menthol cigarettes and, despite smoking fewer cigarettes per day (CPD) than do Whites, tend to have higher cotinine levels. Additionally, Black males are more at risk for smoking-related lung cancer. High cotinine levels and smoking menthol cigarettes may lead to higher toxin intake, which contributes to increased disease risk. We explored the relationship between tobacco exposure variables (i.e., cotinine, CPD, carbon monoxide [CO], nicotine content, and nicotine dependence) with respect to race, gender, and menthol content in a sample of 307 smokers recruited from the greater Boston area to participate in a smoking cessation treatment trial. The pattern of correlations between tobacco exposure measures and cotinine showed a consistently positive correlation between cotinine and CO in all smokers and a correlation between cotinine and CPD in those who smoked nonmenthol cigarettes. Cotinine and CPD correlations varied by gender and race among menthol cigarette smokers. Consistently, we found a significant gender x race x menthol interaction on salivary cotinine level as well as cotinine/CPD ratio. These findings suggest that the relationship between number of cigarettes consumed and salivary cotinine is more complex than previously believed. It is not sufficient to look at race alone; researchers and clinicians need to look at race and gender concurrently, as well as type of cigarette consumed.
AD  - Harvard School of Dental Medicine, Boston, MA 02115, USA. taru_mustonen@hsdm.harvard.edu
AN  - 16085529
AU  - Mustonen, T. K.
AU  - Spencer, S. M.
AU  - Hoskinson, R. A.
AU  - Sachs, D. P.
AU  - Garvey, A. J.
DA  - Aug
DO  - 10.1080/14622200500185199
DP  - NLM
ET  - 2005/08/09
IS  - 4
KW  - Adult
African Americans/psychology/*statistics & numerical data
Analysis of Variance
Attitude to Health/ethnology
Biomarkers/analysis
Carbon Monoxide/analysis
Cotinine/analysis
European Continental Ancestry Group/psychology/*statistics & numerical data
Female
Flavoring Agents/adverse effects/*analysis
Humans
Male
Menthol/adverse effects/*analysis
Middle Aged
Saliva/chemistry
Sex Distribution
Smoking/adverse effects/*epidemiology/*metabolism
Smoking Cessation/statistics & numerical data
United States/epidemiology
LA  - eng
N1  - Mustonen, Taru Kinnunen
Spencer, Stacie M
Hoskinson, Randall A
Sachs, David P L
Garvey, Arthur J
DA12165/DA/NIDA NIH HHS/United States
Comparative Study
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.
England
Nicotine Tob Res. 2005 Aug;7(4):581-90. doi: 10.1080/14622200500185199.
PY  - 2005
SN  - 1462-2203 (Print)
1462-2203
SP  - 581-90
ST  - The influence of gender, race, and menthol content on tobacco exposure measures
T2  - Nicotine Tob Res
TI  - The influence of gender, race, and menthol content on tobacco exposure measures
VL  - 7
ID  - 592
ER  - 

TY  - JOUR
AB  - BACKGROUND: Several reports have shown that obesity is associated with increased risk of biochemical failure after radical prostatectomy. However, limited information is available regarding the impact of obesity on prostate cancer progression after radiotherapy. The current study sought to determine whether obesity was an independent predictor of biochemical failure (BF) and clinical recurrence (CF) among patients treated with external-beam radiotherapy (EBRT). METHODS: A retrospective analysis was performed on 873 patients receiving EBRT as the sole treatment for localized prostate cancer between 1988 and 2001. The Kaplan-Meier method, log-rank test, and Cox proportional hazards analyses were performed. RESULTS: Of the 873 patients, 18% were mildly obese and 5% were moderately to severely obese. Obesity was related to younger age at diagnosis (P < .001), more recent year of diagnosis (P = .03), and race (P = .03), with African-American men having the highest obesity rates. During a mean follow-up of 96 months, 295 patients experienced BF and 127 had CF. On multivariate analysis, controlling for clinical and treatment characteristics, increased body mass index (BMI) significantly predicted BF (hazards ratio [HR] = 1.04; 95% confidence interval [95% CI], 1.02-1.07) with a positive trend by BMI category (P = .001). Similar results were found when the outcome was CF; BMI remained an independent predictor of progression (HR = 1.05; 95% CI, 1.01-1.09), with a statistically significant trend by increased BMI category (P = .03). CONCLUSIONS: The current findings validate the important role of obesity, not only on BF but also on CF, and suggest a link to the biologic basis of tumor progression that can be therapeutically exploited.
AD  - Department of Epidemiology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA. sstrom@manderson.org
AN  - 16802288
AU  - Strom, S. S.
AU  - Kamat, A. M.
AU  - Gruschkus, S. K.
AU  - Gu, Y.
AU  - Wen, S.
AU  - Cheung, M. R.
AU  - Pisters, L. L.
AU  - Lee, A. K.
AU  - Rosser, C. J.
AU  - Kuban, D. A.
DA  - Aug 1
DO  - 10.1002/cncr.22025
DP  - NLM
ET  - 2006/06/28
IS  - 3
KW  - Adult
Aged
Aged, 80 and over
Body Mass Index
Demography
Diabetes Complications/*blood
Disease Progression
Humans
Male
Middle Aged
*Obesity
Patient Selection
Predictive Value of Tests
Prostate-Specific Antigen/*blood
Prostatic Neoplasms/*etiology/*radiotherapy
Retrospective Studies
Treatment Failure
LA  - eng
N1  - Strom, Sara S
Kamat, Ashish M
Gruschkus, Stephen K
Gu, Yun
Wen, Sijin
Cheung, Min Rex
Pisters, Louis L
Lee, Andrew K
Rosser, Charles J
Kuban, Deborah A
CA84964/CA/NCI NIH HHS/United States
CA90270/CA/NCI NIH HHS/United States
ES07784/ES/NIEHS NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
United States
Cancer. 2006 Aug 1;107(3):631-9. doi: 10.1002/cncr.22025.
PY  - 2006
SN  - 0008-543X (Print)
0008-543x
SP  - 631-9
ST  - Influence of obesity on biochemical and clinical failure after external-beam radiotherapy for localized prostate cancer
T2  - Cancer
TI  - Influence of obesity on biochemical and clinical failure after external-beam radiotherapy for localized prostate cancer
VL  - 107
ID  - 562
ER  - 

TY  - JOUR
AB  - BACKGROUND: Pain management racial disparities exist, yet it is unclear whether disparities exist in pain management in advanced cancer. OBJECTIVE: To examine the effect of race on physicians' pain assessment and treatment in advanced lung cancer and the moderating effect of patient activation. DESIGN: Randomized field experiment. Physicians consented to see two unannounced standardized patients (SPs) over 18 months. SPs portrayed 4 identical roles-a 62-year-old man with advanced lung cancer and uncontrolled pain-differing by race (black or white) and role (activated or typical). Activated SPs asked questions, interrupted when necessary, made requests, and expressed opinions. PARTICIPANTS: Ninety-six primary care physicians (PCPs) and oncologists from small cities, and suburban and rural areas of New York, Indiana, and Michigan. Physicians' mean age was 52 years (SD = 27.17), 59% male, and 64% white. MAIN MEASURES: Opioids prescribed (or not), total daily opioid doses (in oral morphine equivalents), guideline-concordant pain management, and pain assessment. KEY RESULTS: SPs completed 181 covertly audio-recorded visits that had complete data for the model covariates. Physicians detected SPs in 15% of visits. Physicians prescribed opioids in 71% of visits; 38% received guideline-concordant doses. Neither race nor activation was associated with total opioid dose or guideline-concordant pain management, and there were no interaction effects (p > 0.05). Activation, but not race, was associated with improved pain assessment (ẞ, 0.46, 95% CI 0.18, 0.74). In post hoc analyses, oncologists (but not PCPs) were less likely to prescribe opioids to black SPs (OR 0.24, 95% CI 0.07, 0.81). CONCLUSIONS: Neither race nor activation was associated with opioid prescribing; activation was associated with better pain assessment. In post hoc analyses, oncologists were less likely to prescribe opioids to black male SPs than white male SPs; PCPs had no racial disparities. In general, physicians may be under-prescribing opioids for cancer pain. TRIAL REGISTRATION: NCT01501006.
AD  - Center for Cancer Research, Purdue University, West Lafayette, IN, USA.
Regenstrief Center for Healthcare Engineering, Purdue University, West Lafayette, IN, USA.
Human Development & Family Studies, Purdue University, West Lafayette, IN, USA.
Department of Internal Medicine, Hematology/ Oncology Division, and Health Management and Policy, University of Michigan School of Medicine, Ann Arbor, MI, USA.
Department of Health Management & Policy, University of Michigan School of Medicine, Ann Arbor, MI, USA.
Center for Communication and Disparities Research, University of Rochester School of Medicine, Rochester, NY, USA.
Department of Family Medicine, University of Rochester School of Medicine, Rochester, NY, USA.
Department of Public Health Sciences, University of Rochester School of Medicine, Rochester, NY, USA.
Department of Statistics, Purdue University, West Lafayette, IN, USA.
Department of Biostatistics, University of Michigan School of Medicine, Ann Arbor, MI, USA.
Department of Internal Medicine, University of California Davis School of Medicine, Sacramento, CA, USA.
Department of Psychiatry, University of Rochester School of Medicine, Rochester, NY, USA.
School of Public Health, Department of Social and Behavioral Sciences, West Virginia University, Morgantown, WV, USA.
James P Wilmot Cancer Center, University of Rochester School of Medicine, Rochester, NY, USA.
Center for Communication and Disparities Research, University of Rochester School of Medicine, Rochester, NY, USA. ronald_epstein@urmc.rochester.edu.
Department of Family Medicine, University of Rochester School of Medicine, Rochester, NY, USA. ronald_epstein@urmc.rochester.edu.
Department of Psychiatry, University of Rochester School of Medicine, Rochester, NY, USA. ronald_epstein@urmc.rochester.edu.
James P Wilmot Cancer Center, University of Rochester School of Medicine, Rochester, NY, USA. ronald_epstein@urmc.rochester.edu.
Department of Medicine, University of Rochester School of Medicine, Rochester, NY, USA. ronald_epstein@urmc.rochester.edu.
Family Medicine Research Programs, University of Rochester, Rochester, NY, USA. ronald_epstein@urmc.rochester.edu.
AN  - 30632104
AU  - Shields, C. G.
AU  - Griggs, J. J.
AU  - Fiscella, K.
AU  - Elias, C. M.
AU  - Christ, S. L.
AU  - Colbert, J.
AU  - Henry, S. G.
AU  - Hoh, B. G.
AU  - Hunte, H. E. R.
AU  - Marshall, M.
AU  - Mohile, S. G.
AU  - Plumb, S.
AU  - Tejani, M. A.
AU  - Venuti, A.
AU  - Epstein, R. M.
C2  - PMC6420510
DA  - Mar
DO  - 10.1007/s11606-018-4785-z
DP  - NLM
ET  - 2019/01/12
IS  - 3
KW  - Adult
Aged
Analgesics, Opioid/therapeutic use
Cancer Pain/*drug therapy
Continental Population Groups/*psychology
Drug Prescriptions
Female
Humans
Lung Neoplasms/*drug therapy
Male
Middle Aged
Pain Management/methods/*psychology
Patient Participation/methods/*psychology
Physicians/*psychology
*communication
*doctor-patient relations
*lung cancer
*pain management
*racial disparities
LA  - eng
N1  - 1525-1497
Shields, Cleveland G
Griggs, Jennifer J
Fiscella, Kevin
Elias, Cezanne M
Christ, Sharon L
Colbert, Joseph
Henry, Stephen G
Hoh, Beth G
Hunte, Haslyn E R
Marshall, Mary
Mohile, Supriya Gupta
Plumb, Sandy
Tejani, Mohamedtaki A
Venuti, Alison
Epstein, Ronald M
K23 DA043052/DA/NIDA NIH HHS/United States
K24 AG056589/AG/NIA NIH HHS/United States
R01 CA155376/CA/NCI NIH HHS/United States
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
J Gen Intern Med. 2019 Mar;34(3):435-442. doi: 10.1007/s11606-018-4785-z. Epub 2019 Jan 10.
PY  - 2019
SN  - 0884-8734 (Print)
0884-8734
SP  - 435-442
ST  - The Influence of Patient Race and Activation on Pain Management in Advanced Lung Cancer: a Randomized Field Experiment
T2  - J Gen Intern Med
TI  - The Influence of Patient Race and Activation on Pain Management in Advanced Lung Cancer: a Randomized Field Experiment
VL  - 34
ID  - 85
ER  - 

TY  - JOUR
AB  - OBJECTIVES: Enrollment of adult cancer patients in clinical trials remains low, particularly in the minority population. Understanding patient attitudes towards clinical trials during the recruitment process may enhance accrual. Unfortunately, data describing patient attitudes towards clinical trials are limited, particularly in the radiation oncology clinic setting. METHODS: A piloted questionnaire assessing basic demographics and attitudes toward clinical trials was offered in 2 radiation oncology clinics between April 2003 and October 2003. The questionnaire was completed by 166 patients. The mean age of the patients completing the questionnaire was 56 years (range, 15-84 years). Of the 166 patients included in the analysis, 108 (65%) were White. The most common cancer diagnoses included prostate (19%), head and neck (16%), and breast (14%). RESULTS: There was no statistical difference between Whites and non-Whites regarding their interest in learning about clinical trials (84.3% versus 84.9%, P = 0.92); nor was there a significant difference in the rate of previous or current trial enrollment (21.3% versus 34.0%, P = 0.08). White patients were more likely to gather information about clinical trials from the Internet (30.6% versus 11.3%, P = 0.007), and they were more likely to use physicians as a source of this information (50.0% versus 34.0%, P = 0.05). Non-White patients were more likely to obtain information about clinical trials from other patients (24.5% versus 12.0%, P = 0.04). In addition, more non-White patients believed they had been treated on clinical trials without their knowledge (21.6% versus 9.3%, P = 0.032). Patients differed somewhat in their expectations of clinical trials. More non-Whites indicated that they would need a >50% chance of benefiting from a trial (64.4% versus 45.0%, P = 0.03) to enroll on that trial, though there were no statistical differences in outlook towards potential toxicities associated with treatment on a clinical trial. CONCLUSIONS: Minority patients historically enroll in clinical trials at a significantly lower rate. Our study of radiation oncology patients documents significant differences in attitudes towards clinical trials between Whites and non-Whites. Understanding the differences in attitudes may allow physicians to overcome barriers that would otherwise hinder the enrollment of non-White patients into clinical trials.
AD  - Department of Radiation Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA. wood@xrt.upenn.edu
AN  - 17148997
AU  - Wood, C. G.
AU  - Wei, S. J.
AU  - Hampshire, M. K.
AU  - Devine, P. A.
AU  - Metz, J. M.
DA  - Dec
DO  - 10.1097/01.coc.0000236213.61427.84
DP  - NLM
ET  - 2006/12/07
IS  - 6
KW  - Adolescent
Adult
African Americans/*psychology
Aged
Aged, 80 and over
Asian Americans/*psychology
*Attitude to Health
*Clinical Trials as Topic
Demography
European Continental Ancestry Group/*psychology
Female
Health Surveys
Hispanic Americans/*psychology
Humans
Male
Middle Aged
Patient Selection
Radiation Oncology
LA  - eng
N1  - 1537-453x
Wood, Charles G
Wei, S Jack
Hampshire, Margaret K
Devine, Pamela A
Metz, James M
Journal Article
United States
Am J Clin Oncol. 2006 Dec;29(6):593-9. doi: 10.1097/01.coc.0000236213.61427.84.
PY  - 2006
SN  - 0277-3732
SP  - 593-9
ST  - The influence of race on the attitudes of radiation oncology patients towards clinical trial enrollment
T2  - Am J Clin Oncol
TI  - The influence of race on the attitudes of radiation oncology patients towards clinical trial enrollment
VL  - 29
ID  - 541
ER  - 

TY  - JOUR
AB  - PURPOSE/OBJECTIVES: To examine the relationship between women's reported social support and their adherence to recommended breast cancer screening guidelines. DESIGN: Descriptive, cross-sectional survey. SETTING: Community women's organizations throughout the San Francisco Bay Area. SAMPLE: 833 mostly low-income women with a mean age of 46.2 years from three racial or ethnic groups (i.e., Latina, Caucasian, and African American) who were not breast cancer survivors. METHODS: Social support was measured with a five-item, four-point, Likert scale developed for the study (Cronbach's alpha = 0.7248). Adherence to screening guidelines was measured by asking frequency of performing breast self-examination (BSE) and frequency of obtaining a clinical breast examination (CBE) and a mammogram. Research assistants and leaders of women's organizations conducted the survey in work and community settings. MAIN RESEARCH VARIABLES: Social support, performance of BSE, obtaining a CBE and a mammogram, income, education, spoken language, and level of acculturation. FINDINGS: Higher levels of social support were related to higher income and higher education. Lower levels of social support were associated with being Latina, completing the survey in Spanish, and being born abroad. Women who did not adhere to screening guidelines (for BSE or CBE) reported less social support. CONCLUSIONS: Social support is associated with adherence to breast cancer screening guidelines. IMPLICATIONS FOR NURSING: Nurses should assess women's levels of social support as a factor when evaluating adherence to breast cancer screening guidelines.
AN  - 106942370. Language: English. Entry Date: 20050817. Revision Date: 20200708. Publication Type: Journal Article
AU  - Katapodi, M. C.
AU  - Facione, N. C.
AU  - Miaskowski, C.
AU  - Dodd, M. J.
AU  - Waters, C.
DB  - CINAHL Complete
DO  - 10.1188/02.ONF.845-852
DP  - EBSCOhost
IS  - 5
KW  - Support, Psychosocial
Cancer Screening
Breast Neoplasms -- Diagnosis
Cultural Diversity
World Wide Web
Information Resources
Descriptive Research
Cross Sectional Studies
California
Conceptual Framework
Research Subject Recruitment
Analysis of Variance
Acculturation
Data Analysis Software
T-Tests
Pearson's Correlation Coefficient
Mammography
Breast Self-Examination
Breast Examination
Research Instruments
Descriptive Statistics
Adult
Middle Age
Aged
Aged, 80 and Over
Female
Funding Source
Human
N1  - research; tables/charts. Journal Subset: Core Nursing; Double Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Nursing; Peer Reviewed; USA. Grant Information: Funded by the California Breast Cancer Research Program Grant 1-KB-0045, Alpha Eta Chapter of Sigma Theta Tau International Honor Society of Nursing, and the University of California, San Francisco Research Center for Symptom Management. NLM UID: 7809033.
PMID: NLM12058159.
PY  - 2002
SN  - 0190-535X
SP  - 845-852
ST  - The influence of social support on breast cancer screening in a multicultural community sample
T2  - Oncology Nursing Forum
TI  - The influence of social support on breast cancer screening in a multicultural community sample
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106942370&site=ehost-live&scope=site
VL  - 29
ID  - 2126
ER  - 

TY  - JOUR
AB  - Purpose/Objective(s): The immuno‐inflammatory state has been shown in several retrospective series to be associated with poor outcomes following radiation therapy (RT) for high risk prostate cancer (PCA). We conducted an a priori designed validation study using prospectively banked serum specimens from the phase III clinical trial RTOG 0521. It was hypothesized the pre‐treatment inflammatory state would correlate with clinical outcomes. Materials/Methods: Patients enrolled on RTOG 0521 had serum samples banked for future biomarker validation. This study was designed to validate previous findings (Hall 2013) showing an association between elevations in CRP levels and shorter biochemical failure‐free survival after RT. CRP levels were measured in pre‐treatment samples using a widely available, clinical grade assay. A panel of serum inflammatory cytokines were also measured including: monocyte chemotactic protein‐1 (MCP‐1), granulocyte‐macrophage colony‐stimulating factor (GM‐CSF), interferon gamma (IFN‐γ), IL‐1b, IL‐2, IL‐4, IL‐5, IL‐6, IL‐8, IL‐10, IL‐12, IL‐13, IL‐17A, IL‐23, and tumor necrosis factor (TNFα). The primary endpoint examined in this a priori designed validation study was disease‐free survival (DFS), defined as the time from randomization to the development of biochemical failure, local progression, distant metastases, or death from PCA, whichever occurred first. Additional endpoints included correlation with cytokine levels and toxicity events attributed to RT, namely: pollakiuria ≥grade (g) 2, cystitis ≥g 2, diarrhea ≥g 2, erectile dysfunction (ED) ≥g 2, proctitis≥g 2. Results: Of 563 patients who enrolled in RTOG 0521, 202 had banked serum samples available. In the subsample, median age was 66 years (range 48‐83), 90% of patients were white and 10% African‐American. There was not an association between CRP and DFS ([HR] = 1.07 per one log increase in CRP, 95% CI: 0.84 ‐ 1.38, p = 0.58). Pre‐treatment IL‐10 was significantly associated with worse DFS, both unadjusted (HR = 1.60 per log increase, p = 0.0029) and following co‐variate adjustment (HR = 1.44 per log increase, p = 0.019). IL‐10 was also associated with increased distant metastases (HR = 1.55 per log increase, p = 0.028). Pretreatment levels of IFN‐γ, IL‐1b, IL‐2, IL‐13, IL‐23 were negatively associated with g 2 or higher pollakiuria (adjusted OR = 0.64, 0.65, 0.71, 0.72, and 0.74, respectively, all p<0.05) and IL‐6 was negatively associated with g 2 or higher ED (OR = 0.62, p = 0.027). Conclusion: Pretreatment CRP was not associated with a poorer DFS following RT. Higher baseline levels of IL‐10 were significantly associated with lower rates of DFS and higher rates of distant metastases, a novel finding that warrants further exploration. Multiple cytokines were associated with the development of RT‐specific toxicities, which may help with the design of precision strategies to mitigate RT‐induced toxicities.
AN  - CN-02175382
AU  - Hall, W. A.
AU  - Karrison, T. G.
AU  - Rosenthal, S. A.
AU  - Amin, M.
AU  - Gomella, L. G.
AU  - Purdy, J. A.
AU  - Sartor, O.
AU  - Michalski, J. M.
AU  - Garzotto, M.
AU  - Bergom, C.
AU  - et al.
DO  - 10.1016/j.ijrobp.2020.07.1740
IS  - 3
KW  - *cancer radiotherapy
*prostate adenocarcinoma
*validation study
African American
Aged
Biochemical failure free survival
Cancer growth
Cancer survival
Clinical outcome
Clinical trial
Conference abstract
Controlled study
Cystitis
Diarrhea
Disease free survival
Distant metastasis
Erectile dysfunction
Gene expression
Human
Human tissue
Major clinical study
Male
Phase 3 clinical trial
Pollakisuria
Protein blood level
Protein expression
Radiotherapy
Randomization
Randomized controlled trial
Retrospective study
M3  - Journal: Conference Abstract
PY  - 2020
SP  - e562‐e563
ST  - The Influence of the Pretreatment Host Immune State on Response to Radiation Therapy in High Risk Adenocarcinoma of the Prostate: a Validation Study from NRG Oncology/RTOG 0521 (Updated)
T2  - International journal of radiation oncology biology physics
TI  - The Influence of the Pretreatment Host Immune State on Response to Radiation Therapy in High Risk Adenocarcinoma of the Prostate: a Validation Study from NRG Oncology/RTOG 0521 (Updated)
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02175382/full
VL  - 108
ID  - 1536
ER  - 

TY  - JOUR
AB  - Background: Vitamin D is safe and has breast cancer prevention properties. CALGB 70806 was a randomized phase II trial evaluating the effect of vit D on several breast cancer biomarkers (including MD and serum IGF1). Methods: Premenopausal women were assigned to receive either 2000IU of Vit D or placebo for 12 months, stratified by baseline (BL) vit D level (sufficient vs insufficient). Eligible women were premenopausal, age < 55, with at least 25% dense breast tissue. Biomarker specimens were collected at baseline and 12 months. MD was determined using the Breast Imaging Reporting and Data System (BIRADS), semiautomated and automated methods. Serum IGF1 was determined by ELISA. Biomarkers were compared between arms using Wilcoxon and t‐tests. Results: 300 women were recruited from 41 institutions across the US between 1/11 ‐12/13. The mean age was 42.6 years with 14% Hispanic, 12% African American, 74% European. 62% of participants were vitamin D deficient at enrollment and 49% of women had MD between 25‐50% with only 12% over 50% dense. 216 (72%) of participants completed treatment, 8 withdrew due to side effects, and 76 for other reasons (28% withdrawal rate). A significant increase in Vit D was seen with treatment with 99% and 72% of experimental and control subjects having sufficient levels at 12 months(P < 0.0001)). MD decreased 2.2% over 1 year for the entire cohort, with no significant difference between arms (Table 1). Similarly, no significant change in IGF1 levels was seen with Vit D. Conclusions: Vit D supplementation resulted in a significant increase in serum Vit D (from a mean of 35.5 to 49.7 ng/mL, p = < 0.0001). However, no significant change in MD was observed with treatment; potentially due to small change in MD seen at 1 year, the low percentage of high MD or that Vit D works by another mechanism. Further study with longer Vit D exposure is warranted.
AN  - CN-01792152
AU  - Wood, M.
AU  - Seisler, D. K.
AU  - Hsieh, M. K.
AU  - Kontos, D.
AU  - Ambaye, A. B.
AU  - Le-Petross, H. T.
AU  - Jung, S. H.
AU  - Liu, H.
AU  - Zekan, P. J.
AU  - Cardinal, L.
AU  - et al.
DO  - 10.1200/JCO.2018.36.15_suppl.1549
IS  - 15
KW  - *breast density
Adult
African American
Breast cancer
Breast tissue
Conference abstract
Controlled study
Data system
Drug therapy
Drug withdrawal
Enzyme linked immunosorbent assay
Female
Gene expression
Hispanic
Human
Human tissue
Major clinical study
Phase 2 clinical trial
Premenopause
Protein expression
Randomized controlled trial
Side effect
M3  - Journal: Conference Abstract
PY  - 2018
ST  - Influence of vitamin D (Vit D) on mammographic density (MD) and insulin like growth factor 1 (IGF1): results of CALGB (Alliance) 70806
T2  - Journal of clinical oncology
TI  - Influence of vitamin D (Vit D) on mammographic density (MD) and insulin like growth factor 1 (IGF1): results of CALGB (Alliance) 70806
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01792152/full
VL  - 36
ID  - 1562
ER  - 

TY  - JOUR
AB  - BACKGROUND: Informed decision making regarding screening mammography is recommended for women in their 40s; however, what information women want and how much involvement in decision making they prefer are not known. METHODS: Surveys were mailed to women aged 40 to 44 scheduled for their first screening mammogram. Women were members of a large New England health maintenance organization and received medical care at a multispecialty practice in the greater Boston area. Outcome measures included information needs and decisional control preferences. RESULTS: Ninety-six women responded. Of 93 identifying their ethnicity, 62 (67%) were white, 18 (19%) were black, 10 (11%) were Asian, 2 (2%) were Hispanic, and 1 (1%) was other. Most (91% [85/93]) wanted their primary care provider to be the source of information regarding screening mammography. Information needs included the next steps to take if the mammogram result was abnormal (89%), how the woman would be contacted (75%), and how quickly (71%). Women also wanted to know about the harms of false-positive (84%) and false-negative (82%) results, benefits of screening in prolonging life (73%), and risk of getting breast cancer (69%). Most women preferred to make the screening decision after considering their medical provider's opinion (38%) or together with their medical provider (46%); fewer than 10% preferred that the decision be made by the woman or her provider alone. CONCLUSIONS: Women cited specific information needs before initiating screening mammography, including screening logistics and potential harms and benefits of screening. They also wanted to participate in the decision-making process. Effective methods should be developed for communicating desired information before screening.
AD  - Department of Ambulatory Care and Prevention, Harvard Medical School and Harvard Pilgrim Health Care, Boston, MA 02215, USA. larissa_nekhlyudov@harvardpilgrim.org
AN  - 15983285
AU  - Nekhlyudov, L.
AU  - Li, R.
AU  - Fletcher, S. W.
DA  - Jun 27
DO  - 10.1001/archinte.165.12.1370
DP  - NLM
ET  - 2005/06/29
IS  - 12
KW  - Adult/*psychology
Breast Neoplasms/diagnosis/etiology/psychology
Female
Health Surveys
Humans
Mammography/*psychology
Needs Assessment
Patient Education as Topic
Patient Participation/*psychology
*Patient Satisfaction
Risk Assessment
Socioeconomic Factors
Women/*psychology
Empirical Approach
Health Care and Public Health
LA  - eng
N1  - Nekhlyudov, Larissa
Li, Rong
Fletcher, Suzanne W
5-R25-CA57711-10/CA/NCI NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, P.H.S.
United States
Arch Intern Med. 2005 Jun 27;165(12):1370-4. doi: 10.1001/archinte.165.12.1370.
PY  - 2005
SN  - 0003-9926 (Print)
0003-9926
SP  - 1370-4
ST  - Information and involvement preferences of women in their 40s before their first screening mammogram
T2  - Arch Intern Med
TI  - Information and involvement preferences of women in their 40s before their first screening mammogram
VL  - 165
ID  - 598
ER  - 

TY  - JOUR
AB  - BACKGROUND: First degree relatives (FDRs) of men diagnosed with prostate cancer (PCa) are at increased risk for developing the disease, due in part to multiple concurrent risk factors. There is a lack of innovative targeted decision aids to help FDRs make an informed decision about whether or not to undergo PCa screening. PURPOSE: This randomized pilot trial evaluated the efficacy of a targeted PCa screening decision aid in unaffected FDRs of PCa survivors. METHODS: Seventy-eight Black and White FDRs were randomized to one of two decision aid groups; 39 to a FDR-targeted decision aid and 39 to a general decision aid. The targeted decision aid group received a general PCa decision aid booklet plus a newly developed decision aid DVD targeted specifically for FDRs. PCa screening decision outcomes included knowledge, decisional conflict, distress, and satisfaction with screening decision. Outcomes were assessed at baseline and 4 weeks after baseline. RESULTS: There were no differences by intervention group for knowledge, decisional conflict, distress, or satisfaction with screening decision (p>0.05). However, men in both groups had significant increases in knowledge and decreases in decisional conflict (p<0.001). These changes were most pronounced (p<0.05) for younger men compared to older men. CONCLUSION: Results suggest that general and targeted information can play an important role in increasing knowledge and decreasing decisional conflict among FDRs. Additional research is needed to identify subgroups of men who benefit the most and better understand the outcomes of a screening decision aid among diverse samples of FDRs.
AD  - 1902 Magnolia Drive, MRC-CANCONT, Moffitt Cancer Center, Tampa, FL 33612, United States. Electronic address: stacy.davis@moffitt.org.
1902 Magnolia Drive, MRC-CANCONT, Moffitt Cancer Center, Tampa, FL 33612, United States; Department of Oncologic Sciences, University of South Florida College of Medicine, 12901 Bruce B. Downs Blvd., MDC 44, Tampa, FL 33612, United States. Electronic address: steve.sutton@moffitt.org.
1902 Magnolia Drive, MRC-CANCONT, Moffitt Cancer Center, Tampa, FL 33612, United States; Department of Oncologic Sciences, University of South Florida College of Medicine, 12901 Bruce B. Downs Blvd., MDC 44, Tampa, FL 33612, United States. Electronic address: susan.vadaparampil@moffitt.org.
1902 Magnolia Drive, MRC-CANCONT, Moffitt Cancer Center, Tampa, FL 33612, United States; Department of Oncologic Sciences, University of South Florida College of Medicine, 12901 Bruce B. Downs Blvd., MDC 44, Tampa, FL 33612, United States. Electronic address: cathy.meade@moffitt.org.
1902 Magnolia Drive, MRC-CANCONT, Moffitt Cancer Center, Tampa, FL 33612, United States; Department of Oncologic Sciences, University of South Florida College of Medicine, 12901 Bruce B. Downs Blvd., MDC 44, Tampa, FL 33612, United States. Electronic address: brian.rivers@moffitt.org.
1902 Magnolia Drive, MRC-CANCONT, Moffitt Cancer Center, Tampa, FL 33612, United States. Electronic address: Mitul.patel@moffitt.org.
1902 Magnolia Drive, MRC-CANCONT, Moffitt Cancer Center, Tampa, FL 33612, United States; Department of Oncologic Sciences, University of South Florida College of Medicine, 12901 Bruce B. Downs Blvd., MDC 44, Tampa, FL 33612, United States. Electronic address: javier.torresroca@moffitt.org.
1902 Magnolia Drive, MRC-CANCONT, Moffitt Cancer Center, Tampa, FL 33612, United States; Department of Oncologic Sciences, University of South Florida College of Medicine, 12901 Bruce B. Downs Blvd., MDC 44, Tampa, FL 33612, United States. Electronic address: randy.heysek@moffitt.org.
1902 Magnolia Drive, MRC-CANCONT, Moffitt Cancer Center, Tampa, FL 33612, United States; Department of Oncologic Sciences, University of South Florida College of Medicine, 12901 Bruce B. Downs Blvd., MDC 44, Tampa, FL 33612, United States. Electronic address: philippe.spiess@moffitt.org.
1902 Magnolia Drive, MRC-CANCONT, Moffitt Cancer Center, Tampa, FL 33612, United States; Department of Oncologic Sciences, University of South Florida College of Medicine, 12901 Bruce B. Downs Blvd., MDC 44, Tampa, FL 33612, United States. Electronic address: julio.powsang@moffitt.org.
1902 Magnolia Drive, MRC-CANCONT, Moffitt Cancer Center, Tampa, FL 33612, United States; Department of Oncologic Sciences, University of South Florida College of Medicine, 12901 Bruce B. Downs Blvd., MDC 44, Tampa, FL 33612, United States. Electronic address: paul.jacobsen@moffitt.org.
1902 Magnolia Drive, MRC-CANCONT, Moffitt Cancer Center, Tampa, FL 33612, United States; Department of Oncologic Sciences, University of South Florida College of Medicine, 12901 Bruce B. Downs Blvd., MDC 44, Tampa, FL 33612, United States. Electronic address: clement.gwede@moffitt.org.
AN  - 25465497
AU  - Davis, S. N.
AU  - Sutton, S. K.
AU  - Vadaparampil, S. T.
AU  - Meade, C. D.
AU  - Rivers, B. M.
AU  - Patel, M. V.
AU  - Torres-Roca, J. F.
AU  - Heysek, R. V.
AU  - Spiess, P.
AU  - Pow-Sang, J.
AU  - Jacobsen, P. B.
AU  - Gwede, C. K.
C2  - PMC4274628
C6  - NIHMS642782
DA  - Nov
DO  - 10.1016/j.cct.2014.10.007
DP  - NLM
ET  - 2014/12/04
IS  - 2
KW  - Adult
African Americans
Aged
*Decision Making
*Decision Support Techniques
Early Detection of Cancer
European Continental Ancestry Group
Health Knowledge, Attitudes, Practice
Humans
Male
Middle Aged
Pamphlets
Patient Participation/*methods
Pilot Projects
Prostatic Neoplasms/*diagnosis/ethnology/*psychology
Socioeconomic Factors
Cancer education
Cancer prevention and control
First degree relatives
Informed decision making
Prostate cancer
Screening decision making
LA  - eng
N1  - 1559-2030
Davis, Stacy N
Sutton, Steven K
Vadaparampil, Susan T
Meade, Cathy D
Rivers, Brian M
Patel, Mitul V
Torres-Roca, Javier F
Heysek, Randy V
Spiess, Philippe
Pow-Sang, Julio
Jacobsen, Paul B
Gwede, Clement K
P30 CA076292/CA/NCI NIH HHS/United States
R21 CA125428/CA/NCI NIH HHS/United States
R25 CA090314/CA/NCI NIH HHS/United States
P30-CA76292/CA/NCI NIH HHS/United States
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Contemp Clin Trials. 2014 Nov;39(2):327-34. doi: 10.1016/j.cct.2014.10.007. Epub 2014 Oct 23.
PY  - 2014
SN  - 1551-7144 (Print)
1551-7144
SP  - 327-34
ST  - Informed decision making among first-degree relatives of prostate cancer survivors: a pilot randomized trial
T2  - Contemp Clin Trials
TI  - Informed decision making among first-degree relatives of prostate cancer survivors: a pilot randomized trial
VL  - 39
ID  - 268
ER  - 

TY  - JOUR
AB  - Prostate cancer incidence and mortality are highest among African-American men, and coupled with the controversy around routine prostate cancer screening, reaching African-American men with interventions to help them make an informed decision about whether or not to be screened is critical. This study compares two approaches to delivering a church-based peer community health advisor intervention consisting of a series of four men's health workshops on informed decision-making for prostate cancer screening. In the men-only group, male community health advisors teach group workshops consisting only of men. In the health partner group, male-female pairs of community health advisors teach workshops in a mixed-gender format in which enrolled men are asked to invite a significant woman in their lives (e.g., wife/partner, sister, daughter, friend) with them to the workshops. Eighteen African-American churches were randomized to receive one of the two approaches, and 283 eligible men enrolled in the intervention. Main findings suggested that the workshops had an impact on stage of decision-making, and this increased significantly over time in the health partner group only. The intervention was highly rated by men in both groups, and these ratings increased over time, with some study group differences. Within-workshop study group differences favored the health partner group in some instances; however, men in the men-only groups reported greater increases in their ratings of trust in the workshops over time. The health partner intervention strategy appears to be promising for reaching men of color with health information.
AD  - Department of Behavioral and Community Health, School of Public Health, University of Maryland, 2369 School of Public Health Building (255), College Park, MD, 20742, USA, cholt14@umd.edu.
AN  - 25330866
AU  - Holt, C. L.
AU  - Le, D.
AU  - Saunders, D. R.
AU  - Wang, M. Q.
AU  - Slade, J. L.
AU  - Muwwakkil, B.
AU  - Williams, R.
AU  - Atkinson, N. L.
AU  - Whitehead, T. L.
AU  - Naslund, M.
DA  - Sep
DO  - 10.1007/s13187-014-0731-x
DP  - NLM
ET  - 2014/10/22
IS  - 3
KW  - African Americans/*psychology
Aged
*Decision Making
Early Detection of Cancer
Female
Focus Groups
Health Education/*organization & administration
Health Knowledge, Attitudes, Practice
Humans
Male
Men's Health
Middle Aged
Patient Acceptance of Health Care
*Personal Satisfaction
Prostatic Neoplasms/*diagnosis/ethnology/*prevention & control
Religion
Sex Factors
United States
LA  - eng
N1  - 1543-0154
Holt, Cheryl L
Le, Daisy
Saunders, Darlene R
Wang, Min Qi
Slade, Jimmie L
Muwwakkil, Bettye
Williams, Ralph
Atkinson, Nancy L
Whitehead, Tony L
Naslund, Michael
R01 CA105202/CA/NCI NIH HHS/United States
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
England
J Cancer Educ. 2015 Sep;30(3):530-4. doi: 10.1007/s13187-014-0731-x.
PY  - 2015
SN  - 0885-8195
SP  - 530-4
ST  - Informed Decision-Making and Satisfaction with a Church-Based Men's Health Workshop Series for African-American Men: Men-Only vs. Mixed-Gender Format
T2  - J Cancer Educ
TI  - Informed Decision-Making and Satisfaction with a Church-Based Men's Health Workshop Series for African-American Men: Men-Only vs. Mixed-Gender Format
VL  - 30
ID  - 272
ER  - 

TY  - JOUR
AB  - IMPORTANCE: Germline mutations in BRCA1 and BRCA2 are relatively common in women with ovarian, fallopian tube, and peritoneal carcinoma (OC) causing a greatly increased lifetime risk of these cancers, but the frequency and relevance of inherited mutations in other genes is less well characterized. OBJECTIVE: To determine the frequency and importance of germline mutations in cancer-associated genes in OC. DESIGN, SETTING, AND PARTICIPANTS: A study population of 1915 woman with OC and available germline DNA were identified from the University of Washington (UW) gynecologic tissue bank (n = 570) and from Gynecologic Oncology Group (GOG) phase III clinical trials 218 (n = 788) and 262 (n = 557). Patients were enrolled at diagnosis and were not selected for age or family history. Germline DNA was sequenced from women with OC using a targeted capture and multiplex sequencing assay. MAIN OUTCOMES AND MEASURES: Mutation frequencies in OC were compared with the National Heart, Lung, and Blood Institute GO Exome Sequencing Project (ESP) and the Exome Aggregation Consortium (ExAC). Clinical characteristics and survival were assessed by mutation status. RESULTS: Overall, the median (range) age at diagnosis was 60 (28-91) years in patients recruited from UW and 61 (23-87) years in patients recruited from the GOG trials. A higher number of black women were recruited from the GOG trials (4.3% vs 1.4%; P = .009); but in patients recruited from UW, there was a higher proportion of fallopian tube carcinomas (13.3% vs 5.7%; P < .001); stage I and II disease (14.6% vs 0% [GOG trials were restricted to advanced-stage cancer]); and nonserous carcinomas (29.9% vs 13.1%, P < .001). Of 1915 patients, 280 (15%) had mutations in BRCA1 (n = 182), or BRCA2 (n = 98), and 8 (0.4%) had mutations in DNA mismatch repair genes. Mutations in BRIP1 (n = 26), RAD51C (n = 11), RAD51D (n = 11), PALB2 (n = 12), and BARD1 (n = 4) were significantly more common in patients with OC than in the ESP or ExAC, present in 3.3%. Race, histologic subtype, and disease site were not predictive of mutation frequency. Patients with a BRCA2 mutation from the GOG trials had longer progression-free survival (hazard ratio [HR], 0.60; 95% CI, 0.45-0.79; P < .001) and overall survival (HR, 0.39; 95% CI, 0.25-0.60; P < .001) compared with those without mutations. CONCLUSIONS AND RELEVANCE: Of 1915 patients with OC, 347 (18%) carried pathogenic germline mutations in genes associated with OC risk. PALB2 and BARD1 are suspected OC genes and together with established OC genes (BRCA1, BRCA2, BRIP1, RAD51C, RAD51D, MSH2, MLH1, PMS2, and MSH6) bring the total number of genes suspected to cause hereditary OC to 11.
AD  - Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Washington, Seattle.
The NRG Oncology Statistical and Data Center, Roswell Park Cancer Center Institute, Buffalo, New York.
Division of Medical Genetics, Department of Medicine, University of Washington, Seattle4Department of Genome Sciences, University of Washington, Seattle.
Department of Genome Sciences, University of Washington, Seattle.
Division of Gynecologic Oncology, University of Pennsylvania, Philadelphia.
Division of Gynecologic Oncology, Sutter Health California Pacific Medical Center, San Francisco, California.
Division of Gynecologic Oncology, University of Colorado, Denver.
Division of Gynecologic Oncology, University of Oklahoma, Oklahoma City.
Division of Gynecologic Oncology, Women and Infants Hospital, Providence, Rhode Island.
Department of Pathology and Laboratory Medicine, The Research Institute at Nationwide Children's Hospital, Columbus, Ohio.
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Washington, Seattle3Division of Medical Genetics, Department of Medicine, University of Washington, Seattle.
Massachusetts General Hospital, Department of Medicine, Harvard Medical School, Boston.
AN  - 26720728
AU  - Norquist, B. M.
AU  - Harrell, M. I.
AU  - Brady, M. F.
AU  - Walsh, T.
AU  - Lee, M. K.
AU  - Gulsuner, S.
AU  - Bernards, S. S.
AU  - Casadei, S.
AU  - Yi, Q.
AU  - Burger, R. A.
AU  - Chan, J. K.
AU  - Davidson, S. A.
AU  - Mannel, R. S.
AU  - DiSilvestro, P. A.
AU  - Lankes, H. A.
AU  - Ramirez, N. C.
AU  - King, M. C.
AU  - Swisher, E. M.
AU  - Birrer, M. J.
C2  - PMC4845939
C6  - NIHMS778753 boards for Endocyte, Astra Zeneca, MedImmune, Oxigene, Advaxis, and Amgen; and his institution was reimbursed for his time. Dr. Burger reports that he previously participated as a consultant to Genentech/Roche during advisory board meetings. No other disclosures are reported.
DA  - Apr
DO  - 10.1001/jamaoncol.2015.5495
DP  - NLM
ET  - 2016/01/01
IS  - 4
KW  - Adult
Aged
Aged, 80 and over
DNA Mutational Analysis
Disease-Free Survival
Female
Genetic Predisposition to Disease/*genetics
Germ-Line Mutation/*genetics
Humans
Middle Aged
Ovarian Neoplasms/*genetics/mortality
Prognosis
Proportional Hazards Models
LA  - eng
N1  - 2374-2445
Norquist, Barbara M
Harrell, Maria I
Brady, Mark F
Walsh, Tom
Lee, Ming K
Gulsuner, Suleyman
Bernards, Sarah S
Casadei, Silvia
Yi, Qian
Burger, Robert A
Chan, John K
Davidson, Susan A
Mannel, Robert S
DiSilvestro, Paul A
Lankes, Heather A
Ramirez, Nilsa C
King, Mary Claire
Swisher, Elizabeth M
Birrer, Michael J
U10 CA180868/CA/NCI NIH HHS/United States
P20 CA097943/CA/NCI NIH HHS/United States
RC2 HL102923/HL/NHLBI NIH HHS/United States
UC2 HL102926/HL/NHLBI NIH HHS/United States
UC2 HL103010/HL/NHLBI NIH HHS/United States
1 U10 CA180822/CA/NCI NIH HHS/United States
U24 CA114793/CA/NCI NIH HHS/United States
R01CA131965/CA/NCI NIH HHS/United States
RC2 HL102926/HL/NHLBI NIH HHS/United States
U10 CA27469/CA/NCI NIH HHS/United States
R01 CA175716/CA/NCI NIH HHS/United States
CA 27469/CA/NCI NIH HHS/United States
U10 CA027469/CA/NCI NIH HHS/United States
P50 CA083636/CA/NCI NIH HHS/United States
U10 CA180798/CA/NCI NIH HHS/United States
5K12HD001264-13/HD/NICHD NIH HHS/United States
RC2 HL102924/HL/NHLBI NIH HHS/United States
U10 CA037517/CA/NCI NIH HHS/United States
R01CA157744/CA/NCI NIH HHS/United States
R35 CA197458/CA/NCI NIH HHS/United States
R01 CA142832/CA/NCI NIH HHS/United States
L30 CA179780/CA/NCI NIH HHS/United States
UC2 HL102923/HL/NHLBI NIH HHS/United States
R01CA142834/CA/NCI NIH HHS/United States
UC2 HL102924/HL/NHLBI NIH HHS/United States
U24 CA196067/CA/NCI NIH HHS/United States
K12 HD001264/HD/NICHD NIH HHS/United States
R01CA175716/CA/NCI NIH HHS/United States
CA 37517/CA/NCI NIH HHS/United States
RC2 HL103010/HL/NHLBI NIH HHS/United States
R01 CA157744/CA/NCI NIH HHS/United States
P50CA083636/CA/NCI NIH HHS/United States
RC4 CA156551/CA/NCI NIH HHS/United States
R01 CA131965/CA/NCI NIH HHS/United States
RC4CA156551/CA/NCI NIH HHS/United States
U10 CA180822/CA/NCI NIH HHS/United States
RC2 HL102925/HL/NHLBI NIH HHS/United States
UC2 HL102925/HL/NHLBI NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
JAMA Oncol. 2016 Apr;2(4):482-90. doi: 10.1001/jamaoncol.2015.5495.
PY  - 2016
SN  - 2374-2437 (Print)
2374-2437
SP  - 482-90
ST  - Inherited Mutations in Women With Ovarian Carcinoma
T2  - JAMA Oncol
TI  - Inherited Mutations in Women With Ovarian Carcinoma
VL  - 2
ID  - 223
ER  - 

TY  - JOUR
AB  - e17504 Methods: Data from CTMS constituents and follow-up information describing enrollment status and barriers to trial participation are reviewed.Results: During 15 months of operation the CTMS provided information to 10,997 individuals; 7,521 (68.39%) used the website only, and 3,476 (31.61%) also contacted the ACS call center. Among 981 of the 3,476 (28.22% the basis of analyses below) who consented to and could be reached for follow-up and who answered the question on enrollment status, 119 (12.13%) enrolled in a CT. Trial phase was known for 74 enrollees (phase I: 17 [22.97%]; II: 36 [48.65%]; III: 21 [28.38%]; IV: 0 [0%]). Enrollment was negatively (p < 0.05) associated with poor ECOG functional status and black race, and was positively related to disease stage. Among the 757 individuals with available disease site and enrollment information, those with stomach cancer accounted for the most enrollments (25, 24.75% of all enrollments); followed by melanoma (12, 11.88%) and kidney, renal pelvis, bladder, ureter and urethra (also 12, 11.88%), and breast cancer (11, 10.89%). The highest enrollment rates (% enrollees among individuals with available follow-up) were for multiple myeloma/plasma cell disorders (4/14, 28.57%), melanoma (12/49, 24.49%), primary CNS malignancy (5/31, 16.13%), and soft tissue sarcoma (6/45, 13.33%). The following barriers were significantly associated with non-enrollment: 'I cannot travel to clinical trial site,' 'I cannot find a clinical trial using the modality or treatment I want,' 'My physical activity level is too low,' and 'I do not have measurable disease or am cancer-free.'Conclusions: 12% of CTMS participants with available follow-up data for enrollment status participated in a CT. Several determinants of CT participation were identified. Strategies for eliminating racial disparities, facilitating transportation, and increasing participation among patients with earlier stage disease and more common tumor types must be developed and implemented. No significant financial relationships to disclose.
AD  - American Cancer Society, Atlanta, GA; Coalition of Cancer Cooperative Groups, Philadelphia, PA
AN  - 120351777. Language: English. Entry Date: In Process. Revision Date: 20161223. Publication Type: journal article. Supplement Title: 5/21/2009 Supplement Part 1 of 2. Journal Subset: Biomedical
AU  - Gansler, T.
AU  - Comis, R.
AU  - Sharpe, K.
AU  - Tis, L.
AU  - Jin, M.
AU  - Dahlquist, K.
AU  - Kepner, J.
AU  - Hao, Y.
AU  - Cressman, G.
AU  - Naples, K.
DB  - CINAHL Complete
DP  - EBSCOhost
N1  - Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA. NLM UID: 8309333.
PMID: NLM27963240.
PY  - 2009
SN  - 0732-183X
SP  - e17504-e17504
ST  - Initial results of a new clinical trial matching service to increase patient participation
T2  - Journal of Clinical Oncology
TI  - Initial results of a new clinical trial matching service to increase patient participation
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=120351777&site=ehost-live&scope=site
VL  - 27
ID  - 1983
ER  - 

TY  - JOUR
AB  - BACKGROUND: Thymoquinone (TQ) is a bioactive phytoconstituent obtained from Nigella sativa (black seeds). It has promising potential in cancer prevention. OBJECTIVE: Previous studies have shown that TQ can modulate signaling pathways responsible for cancer progression, thus enhancing the efficacy and improving the safety profile of clinically used anticancer drugs. METHOD: TQ acts on cell cycle and inhibits progression from G1 to S phase by targeting various proteins (cyclin D1, cyclin E, and p27). It also exhibits histone deacetylase (HDAC) inhibitory effects, targets p21 and Maspin, and induces pro-apoptotic gene, Bax and downregulates anti-apoptotic gene Bcl-2. Breast cancer (BC) is reported as one of the most common malignancies in women. RESULTS: Despite the research and advancement, it remains one of the most common causes of cancer related deaths among women. Recent advancements in molecular screening of BC led to the identification of clinically challenging condition of triple negative breast cancer (TNBC). TNBC is characterized by the absence of targetable receptors viz. estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) expressions. It is also characterized by reduced or absence of phosphatase and tensin homolog (PTEN) expression, a tumor suppressor gene having diverse functions including regulation of apoptosis, cell cycle, and metastasis. CONCLUSION: Since TQ has been reported to up-regulate several growth factors such as vascular endothelial growth factor (VEGF), EGF and PTEN expression, the present review article discusses the targeting potential of TQ for therapeutic intervention against such types of breast cancer.
AD  - Department of Pharmaceutics, Faculty of Pharmacy, Integral University, Kursi Road, Lucknow, India.
School of Medical & Allied Sciences, Department of Pharmaceutics, K.R. Mangalam University, Gurgaon, India.
Department of Pharmaceutics, College of Pharmacy, Najran University, Najran, Saudi Arabia.
Department of Pharmacology, Central Research Institute of Unani Medicine (CRIUM), Hyderabad-500038, India.
Product Development Research, Jubilant Generics Limited, Noida, U.P., India.
Nanomedicine Research Lab, Department of Pharmaceutics, Faculty of Pharmacy, Jamia Hamdard, New Delhi, India.
AN  - 28606050
AU  - Barkat, M. A.
AU  - Harshita
AU  - Ahmad, J.
AU  - Khan, M. A.
AU  - Beg, S.
AU  - Ahmad, F. J.
DO  - 10.2174/1389450118666170612095959
DP  - NLM
ET  - 2017/06/14
IS  - 1
KW  - Antineoplastic Agents, Phytogenic/adverse effects/isolation &
purification/*therapeutic use
Benzoquinones/adverse effects/isolation & purification/*therapeutic use
Clinical Trials as Topic
Female
Humans
Molecular Targeted Therapy
Nigella sativa/chemistry
Seeds/chemistry
Triple Negative Breast Neoplasms/*drug therapy/metabolism/pathology
*hdac
*tnbc
*Thymoquinone
*vegf
*apoptosis
*black seeds
*breast cancer
LA  - eng
N1  - 1873-5592
Barkat, Md Abul
Harshita
Ahmad, Javed
Khan, Mohammad Ahmed
Beg, Sarwar
Ahmad, Farhan Jalees
Journal Article
Research Support, Non-U.S. Gov't
Review
United Arab Emirates
Curr Drug Targets. 2018;19(1):70-80. doi: 10.2174/1389450118666170612095959.
PY  - 2018
SN  - 1389-4501
SP  - 70-80
ST  - Insights into the Targeting Potential of Thymoquinone for Therapeutic Intervention Against Triple-negative Breast Cancer
T2  - Curr Drug Targets
TI  - Insights into the Targeting Potential of Thymoquinone for Therapeutic Intervention Against Triple-negative Breast Cancer
VL  - 19
ID  - 165
ER  - 

TY  - JOUR
AB  - Background: Racial disparities in breast cancer survival between Black and White women persist across all stages of breast cancer. The metabolic syndrome (MetS) of insulin resistance disproportionately affects more Black than White women. It has not been discerned if insulin resistance mediates the link between race and poor prognosis in breast cancer. We aimed to determine whether insulin resistance mediates in part the association between race and breast cancer prognosis, and if insulin receptor (IR) and insulin-like growth factor receptor (IGF-1R) expression differs between tumors from Black and White women. Methods: We conducted a cross-sectional, multi-center study across ten hospitals. Self-identified Black women and White women with newly diagnosed invasive breast cancer were recruited. The primary outcome was to determine if insulin resistance, which was calculated using the homeostatic model assessment of insulin resistance (HOMA-IR), mediated the effect of race on prognosis using the multivariate linear mediation model. Demographic data, anthropometric measurements, and fasting blood were collected. Poor prognosis was defined as a Nottingham Prognostic Index (NPI) > 4.4. Breast cancer pathology specimens were evaluated for IR and IGF-1R expression by immunohistochemistry (IHC). Results: Five hundred fifteen women were recruited (83% White, 17% Black). The MetS was more prevalent in Black women than in White women (40% vs 20%, p < 0.0001). HOMA-IR was higher in Black women than in White women (1.9 ± 1.2 vs 1.3 ± 1.4, p = 0.0005). Poor breast cancer prognosis was more prevalent in Black women than in White women (28% vs 15%. p = 0.004). HOMA-IR was positively associated with NPI score (r = 0.1, p = 0.02). The mediation model, adjusted for age, revealed that HOMA-IR significantly mediated the association between Black race and poor prognosis (β = 0.04, 95% CI 0.005-0.009, p = 0.002). IR expression was higher in tumors from Black women than in those from White women (79% vs 52%, p = 0.004), and greater IR/IGF-1R ratio was also associated with higher NPI score (IR/IGF-1R > 1: 4.2 ± 0.8 vs IR/IGF-1R = 1: 3.9 ± 0.8 vs IR/IGF-1R < 1: 3.5 ± 1.0, p < 0.0001). Conclusions: In this multi-center, cross-sectional study of US women with newly diagnosed invasive breast cancer, insulin resistance is one factor mediating part of the association between race and poor prognosis in breast cancer. © 2020 The Author(s).
AD  - Division of Endocrinology, Diabetes and Bone Disease, Icahn School of Medicine at Mount Sinai, 1428 Madison Avenue, New York, NY 10029, United States
Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, United States
Tisch Cancer Institute at Mount Sinai, Icahn School of Medicine at Mount Sinai, New York, NY, United States
Department of Population Health Science and Policy, Center for Health Equity and Community Engaged Research, Icahn School of Medicine at Mount Sinai, New York, NY 10029, United States
Center for Health Equity and Community Engaged Research, Icahn School of Medicine at Mount Sinai, New York, United States
Department of Surgery, Columbia University Medical Center, New York, NY, United States
Department of Surgery, Icahn School of Medicine at Mount Sinai, New York, NY, United States
Department of Surgery, Mercy Medical Center, Baltimore, MD, United States
Department of Surgery, Mount Sinai Beth Israel, New York, NY, United States
Department of Surgery, Yale School of Medicine, New Haven, CT, United States
Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, United States
Department of Surgery, Wayne State University School of Medicine, Detroit, MI, United States
Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, United States
AU  - Gallagher, E. J.
AU  - Fei, K.
AU  - Feldman, S. M.
AU  - Port, E.
AU  - Friedman, N. B.
AU  - Boolbol, S. K.
AU  - Killelea, B.
AU  - Pilewskie, M.
AU  - Choi, L.
AU  - King, T.
AU  - Nayak, A.
AU  - Franco, R.
AU  - Cruz, D.
AU  - Antoniou, I. M.
AU  - Leroith, D.
AU  - Bickell, N. A.
C7  - 40
DB  - Scopus
DO  - 10.1186/s13058-020-01281-y
IS  - 1
KW  - Breast cancer
Cross-sectional study
Disparities
Insulin receptor
Insulin resistance
Insulin-like growth factor receptor
Prognosis
M3  - Article
N1  - Cited By :1
Export Date: 22 March 2021
PY  - 2020
ST  - Insulin resistance contributes to racial disparities in breast cancer prognosis in US women
T2  - Breast Cancer Research
TI  - Insulin resistance contributes to racial disparities in breast cancer prognosis in US women
UR  - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85084606046&doi=10.1186%2fs13058-020-01281-y&partnerID=40&md5=a20f16798507f4962af3e73465bbd432
VL  - 22
ID  - 2195
ER  - 

TY  - JOUR
AB  - Plant foods and associated nutrients may impact prostate cancer (PC) risk and survival. Therefore, we compared dietary intake, mainly plant food groups among 382 controls and 478 PC cases (373 incident and 105 prevalent cases). Caucasian controls had significantly higher daily servings of vegetables (3.4 vs. 2.5, P= 0.002) and fruits and/or fruit juices (1.6 vs. 1.3, P = 0.02) compared to African American controls. In Caucasians, incident cases reported lower intake of fiber, vitamin C, vitamin A, alpha -carotene, beta -carotene, cryptoxanthin, folate, genistein, daidzein, and fruits and/or fruit juice than controls and/or prevalent cases. In African Americans, incident cases had lower intake of alpha -carotene compared to controls and prevalent cases. Reduced PC risk was associated with the highest tertile of cryptoxanthin (OR = 0.51; 95% CI = 0.35-0.75), fiber (OR = 0.56; 95% CI = 0.35-0.89), vitamin C (OR = 0.60; 95% CI = 0.41-0.88), and fruits and/or fruit juices (OR = 0.46; 95% CI = 0.31-0.68), with significant linear trends. Increased risk of PC was associated with the highest tertile of protein (OR = 1.99; 95% CI = 1.05-3.79) and daily servings of grains (OR = 1.99; 95% CI = 1.23-3.22) with significant linear trends. In summary, we demonstrate racial/ethnic differences in dietary intake of plant foods. The significantly higher consumption of protective dietary constituents among prevalent cases compared to incident cases suggests that PC survivors may be amenable to dietary change.
AD  - Department of Psychiatry and Behavioral Sciences, University of Miami Miller School of Medicine, 1120 NW 14th Street, Miami, FL 33136, USA.
AN  - 105470219. Language: English. Entry Date: 20090522. Revision Date: 20200708. Publication Type: Journal Article
AU  - Lewis, J. E.
AU  - Soler-Vilá, H.
AU  - Clark, P. E.
AU  - Kresty, L. A.
AU  - Allen, G. O.
AU  - Hu, J. J.
DB  - CINAHL Complete
DO  - 10.1080/01635580802419756
DP  - EBSCOhost
IS  - 2
KW  - Nutrients
Plants, Edible
Prostatic Neoplasms -- Risk Factors
Analysis of Variance
Black Persons
Body Mass Index
Descriptive Statistics
Funding Source
Prostatic Neoplasms -- Mortality
Race Factors
Research Subject Recruitment -- Methods
White Persons
Human
N1  - research; tables/charts. Journal Subset: Biomedical; Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA. Grant Information: American Cancer Society (CNE-101119), Comprehensive Cancer Center of Wake Forest University (CA12197), and National Research Foundation to the Wake Forest University's General Clinical Research Center (M01-RR07122). NLM UID: 7905040.
PMID: NLM19235037.
PY  - 2009
SN  - 0163-5581
SP  - 216-224
ST  - Intake of plant foods and associated nutrients in prostate cancer risk
T2  - Nutrition & Cancer
TI  - Intake of plant foods and associated nutrients in prostate cancer risk
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105470219&site=ehost-live&scope=site
VL  - 61
ID  - 1984
ER  - 

TY  - JOUR
AB  - Background: Despite ASCO recommendations that tobacco use be assessed and managed, most cancer patients who smoke do not receive tobacco treatment. Evidence‐based tobacco treatment has not yet been integrated into routine oncology care, and the optimal tobacco treatment strategy in this context is unknown. Methods: We conducted a two‐arm, two‐site RCT to compare sustained counseling plus medication (Intervention Group; IG) to standard tobacco counseling (comparison group; CG) to assist newly diagnosed cancer patients to quit smoking. Both treatment groups received 4 weekly telephone‐delivered motivational counseling sessions. The IG additionally received 4 biweekly plus 3 monthly counseling sessions (total 11) and 12‐weeks of free FDAapproved cessation medication (nicotine replacement therapy (NRT; patch/lozenge), varenicline, or bupropion). Eligibility criteria included a recent cancer diagnosis (breast, GI/GU, gyn, head & neck, lymphoma, lung, melanoma), cigarette use in the past 30 days, and English/Spanish speaking. The primary outcome was 6‐ month biochemically verified abstinence. Results: 303 (70% of confirmed eligibles) patients were enrolled and randomized to a treatment group. Participants were 56% female; 82% white non‐ Hispanic and 10% black; mean age = 58.3 (sd = 9.7); 40% had a nonsmoking related tumor. 86% completed the 6‐month surveys. 80% of IG patients used a smoking cessation medication, among which 83% selected NRT. Using intention‐to‐treat, 6‐month quit rates were 33% in the IG group vs. 19% in the CG group (p < .02). Using intention‐to‐treat, 57% of IG patients were adherent to sustained counseling (≥7 sessions), which was associated with increased 6‐ month quit rates (p < .0001). Cost per patient was $1,273 (IG) vs. $838 (CG). Conclusions: Among newly‐diagnosed cancer patients, a treatment program of sustained telephone‐delivered counseling and free medication produced a higher 6‐month quit rate vs. a briefer counseling program. The cost‐per‐quit compared favorably to other cessation interventions. Findings provide strong support for the benefit of sustained tobacco treatment and a model for effective implementation of tobacco treatment into oncology care settings nationwide.
AN  - CN-01789220
AU  - Park, E. R.
AU  - Perez, G. K.
AU  - Regan, S.
AU  - Muzikanksy, A.
AU  - Rigotti, N.
AU  - Levy, D. E.
AU  - Temel, J. S.
AU  - Cooley, M. E.
AU  - Partridge, A. H.
AU  - Pirl, W. F.
AU  - et al.
DO  - 10.1200/JCO.2018.36.15-suppl.6505
IS  - 15
KW  - *lymphoma
*smoking cessation
Adult
Breast
Cancer diagnosis
Cancer model
Cancer patient
Cigarette smoking
Conference abstract
Controlled study
Counseling
Female
Head
Hispanic
Human
Lozenge
Lung
Male
Melanoma
Middle aged
Neck
Nicotine replacement therapy
Oncology
Outcome assessment
Randomized controlled trial
Speech
Telephone
M3  - Journal: Conference Abstract
PY  - 2018
ST  - Integrating tobacco treatment into cancer care: a first snapshot of RCT findings
T2  - Journal of clinical oncology
TI  - Integrating tobacco treatment into cancer care: a first snapshot of RCT findings
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01789220/full
VL  - 36
ID  - 1629
ER  - 

TY  - JOUR
AB  - INTRODUCTION: Racial/ethnic diversity in prostate cancer (CaP) clinical trials (CTs) is essential to address CaP disparities. California Cancer Registry mandated electronic reporting (e-path) of structured data elements from pathologists diagnosing cancer thereby creating an opportunity to identify and approach patients rapidly. This study tested the utility of an online CT matching tool (called Trial Library) used in combination with e-path to improve matching of underrepresented CaP patients into CTs at time of diagnosis. METHODS: This was a nonrandomized, single-arm feasibility study among patients with a new pathologic diagnosis of high-risk CaP (Gleason Score ≥8). Eligible patients were sent recruitment materials and enrolled patients were introduced to Trial Library. RESULTS: A total of 419 case listings were assessed. Patients were excluded due to physician contraindication, not meeting baseline eligibility, or unable to be reached. Final participants (N = 52) completed a baseline survey. Among study participants, 77% were White, 10% were Black/Hispanic/Missing, and 14% were Asian. The majority of the study participants were over 65 years of age (81%) and Medicare insured (62%). Additionally, 81% of participants reported using the Internet to learn about CaP. The majority (62%) of participants reported that Trial Library increased their interest in CT participation. CONCLUSIONS: The current study demonstrated that leveraging structured e-path data reporting to a population-based cancer registry to recruit men with high risk CaP to clinical research is feasible and acceptable. We observed that e-path may be linked with an online CT matching tool, Trial Library. Future studies will prioritize recruitment from reporting facilities that serve more racially/ethnically diverse patient populations.
AD  - Department of Medicine, Division of Hematology/Oncology, University of California San Francisco, San Francisco, CA; Helen Diller Family Comprehensive Cancer Center, San Francisco, CA. Electronic address: Hala.borno@ucsf.edu.
Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA; Greater Bay Area Cancer Registry, University of California San Francisco, San Francisco, CA.
Helen Diller Family Comprehensive Cancer Center, San Francisco, CA.
Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA.
Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Department of Urology, University of California San Francisco, San Francisco, CA; Center for Digital Health Innovation, University of California, San Francisco, CA.
Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA; Greater Bay Area Cancer Registry, University of California San Francisco, San Francisco, CA.
AN  - 33419644
AU  - Borno, H. T.
AU  - Duffy, C.
AU  - Zhang, S.
AU  - Canchola, A. J.
AU  - Loya, Z.
AU  - Golden, T.
AU  - Oh, D. L.
AU  - Odisho, A. Y.
AU  - Gomez, S.
DA  - Jan 5
DO  - 10.1016/j.urolonc.2020.12.010
DP  - NLM
ET  - 2021/01/10
KW  - Cancer disparities
Clinical trials
Early case ascertainment
Electronic pathology
Prostate cancer
LA  - eng
N1  - 1873-2496
Borno, Hala T
Duffy, Christine
Zhang, Sylvia
Canchola, Alison J
Loya, Zinnia
Golden, Todd
Oh, Debora L
Odisho, Anobel Y
Gomez, Scarlett
Journal Article
United States
Urol Oncol. 2021 Jan 5:S1078-1439(20)30639-6. doi: 10.1016/j.urolonc.2020.12.010.
PY  - 2021
SN  - 1078-1439
ST  - Integration of electronic pathology reporting with clinical trial matching for advanced prostate cancer
T2  - Urol Oncol
TI  - Integration of electronic pathology reporting with clinical trial matching for advanced prostate cancer
ID  - 16
ER  - 

TY  - JOUR
AB  - Although prior studies have shown that African American smokers are likely to carry some of the genetic variants associated with smoking risk, additional research with African American smokers is needed to replicate these findings. Limited information is available on interest in participating in research to identify genetic risk factors for smoking among African American smokers; therefore, the goals of the present study were to describe intentions to participate in smoking and genetics research, and to determine factors that are associated with participation intentions. Subjects were 128 African American male and female adult smokers. Sociodemographic characteristics, clinical factors, attitudes about genetic testing, and intentions to participate in genetics research were evaluated during a structured telephone interview. Overall, 58% of respondents reported that they would be very likely to participate in research to identify genetic risk factors for smoking. Greater beliefs about the benefits of participating in medical research (odds ratio, 3.17; 95% confidence interval, 1.45-6.94; P = 0.004) and fewer perceptions of the limitations and risks of genetic testing (odds ratio, 0.90; 95% confidence interval, 0.82-0.98; P = 0.01) had significant independent associations with reporting a high likelihood of participating in this type of research. Recruitment messages and protocols that address the benefits of research participation, as well as concerns about the limitations and risks of genetic testing, may enhance African American participation in research on genetics and smoking. Copyright © 2006 American Association for Cancer Research.
AD  - C.H. Halbert, University of Pennsylvania, 3535 Market Street, Philadelphia, PA 19104, United States
AU  - Halbert, C. H.
AU  - Gandy Jr, O. H.
AU  - Collier, A.
AU  - Shaker, L.
DB  - Embase
Medline
DO  - 10.1158/1055-9965.EPI-05-0437
IS  - 1
KW  - adult
African American
article
cancer risk
carcinogenesis
clinical protocol
correlation analysis
demography
family history
female
genetic predisposition
genetic screening
genetic variability
high risk behavior
human
interview
lung cancer
lung carcinogenesis
major clinical study
male
medical research
priority journal
race difference
risk factor
smoking habit
telephone
LA  - English
M3  - Article
N1  - L43498767
2006-04-20
PY  - 2006
SN  - 1055-9965
SP  - 150-153
ST  - Intentions to participate in genetics research among African American smokers
T2  - Cancer Epidemiology Biomarkers and Prevention
TI  - Intentions to participate in genetics research among African American smokers
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L43498767&from=export
http://dx.doi.org/10.1158/1055-9965.EPI-05-0437
VL  - 15
ID  - 1256
ER  - 

TY  - JOUR
AB  - Six regions for prostate cancer genes have been identified, and it is anticipated that prostate cancer susceptibility testing will be available in the future. This correlational study identified predictors for interest in prostate cancer susceptibility testing among African American men. Participants were 320 African American men from the African American Hereditary Prostate Cancer Study and the South Carolina Prostate Cancer Education and Screening Study participated. Two questions measured interest in genetic prostate cancer susceptibility testing and family history of prostate cancer. Chi-square analyses by family history as well as demographics (age, education, marital status) were performed. Most of the men (277 [87%]) indicated an interest in genetic prostate cancer susceptibility testing. Interest in undergoing testing did not vary by family history, age, or education. Marital status was the only significant demographic predictor. Men who were married were significantly more likely to respond with a "yes" to interest in prostate cancer susceptibility testing than were men who were not married. The high "yes" response rate and the men's confusion between the genetic prostate cancer susceptibility testing and prostate cancer screening highlight the need for public education once prostate cancer genes are identified and available for public testing.
AD  - School of Nursing, University of Louisville, KY 40292, USA. sally.weinrich@louisville.edu
AN  - 11838717
AU  - Weinrich, S.
AU  - Royal, C.
AU  - Pettaway, C. A.
AU  - Dunston, G.
AU  - Faison-Smith, L.
AU  - Priest, J. H.
AU  - Roberson-Smith, P.
AU  - Frost, J.
AU  - Jenkins, J.
AU  - Brooks, K. A.
AU  - Powell, I.
DA  - Feb
DO  - 10.1097/00002820-200202000-00007
DP  - NLM
ET  - 2002/02/13
IS  - 1
KW  - Adult
African Americans/psychology/*statistics & numerical data
African Continental Ancestry Group/genetics
Aged
Aged, 80 and over
Genetic Predisposition to Disease
Genetic Testing/*psychology
Humans
Male
Middle Aged
Patient Participation/statistics & numerical data
Prostatic Neoplasms/*genetics/nursing/prevention & control
South Carolina/ethnology
Surveys and Questionnaires
Texas/ethnology
LA  - eng
N1  - Weinrich, Sally
Royal, Charmaine
Pettaway, Curtis A
Dunston, Georgia
Faison-Smith, Louise
Priest, Julie Hudson
Roberson-Smith, Pamela
Frost, Jacqueline
Jenkins, Jean
Brooks, Karen Albiez
Powell, Isaac
Journal Article
United States
Cancer Nurs. 2002 Feb;25(1):28-34. doi: 10.1097/00002820-200202000-00007.
PY  - 2002
SN  - 0162-220X (Print)
0162-220x
SP  - 28-34
ST  - Interest in genetic prostate cancer susceptibility testing among african American men
T2  - Cancer Nurs
TI  - Interest in genetic prostate cancer susceptibility testing among african American men
VL  - 25
ID  - 672
ER  - 

TY  - JOUR
AD  - B.C. Goh, Department of Hematology-Oncology, National University Health System, Singapore
AU  - Goh, B. C.
C1  - s 1(Taiho,Japan)
taxotere(Sanofi Aventis)
C2  - Sanofi Aventis
Taiho(Japan)
DB  - Embase
Medline
IS  - 8
KW  - gimeracil plus oteracil potassium plus tegafur
antineoplastic agent
carboplatin
cytochrome P450 3A4
docetaxel
doxorubicin
drug metabolizing enzyme
African American
American Indian
article
Asian
breast cancer
cancer research
Caucasian
Chinese
clinical trial
cultural factor
dosimetry
drug determination
drug disposition
drug industry
drug labeling
drug manufacture
drug metabolism
drug research
drug safety
ethnic difference
ethnicity
Food and Drug Administration
genetic polymorphism
hematologic disease
Hispanic
human
Indian
individualization
international cooperation
non small cell lung cancer
malignant neoplasm
metastasis potential
methodology
Black person
Pacific Islander
patient selection
population genetics
practice guideline
race difference
sample size
Singapore
social aspect
standardization
treatment outcome
United States
s 1
taxotere
LA  - English
M3  - Article
N1  - L352450445
2008-10-23
PY  - 2008
SN  - 1543-0790
SP  - 559-561
ST  - Interethnic differences in drug metabolism
T2  - Clinical Advances in Hematology and Oncology
TI  - Interethnic differences in drug metabolism
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L352450445&from=export
http://www.clinicaladvances.com/article_pdfs/ho-article-200808-drug.pdf
VL  - 6
ID  - 1207
ER  - 

TY  - JOUR
AB  - Background: Enrollment of early stage lung cancer patients to randomized trials has historically been challenging. The STARS Trial enrolled 36 of 1,030 intended patients from 28 sites, while the ROSEL Trial recruited 22 of 960 intended patients from 10 sites. Unfortunately, evidence shows African Americans with early stage, NSCLC are significantly less likely than their European American counterparts to undergo resection and may also be less likely to participate in lung cancer trials as well. PURPOSE: The purpose of this research is to describe interim recruitment results from an NIMHD‐funded, NCI NCORP‐based patient navigation trial conducted with African Americans with early stage, probable/proven nonsmall cell lung cancer (NSCLC). DESIGN: The protocol‐driven, barriers‐focused patient navigation intervention is being conducted in the context of a two‐arm cluster‐randomized trial testing the effectiveness of the intervention in increasing rates of lungdirected curative‐intent therapy (surgery and SBRT) in African Americans with Stage I‐II NSCLC. The 2 study arms consist of the protocol‐driven, intensive navigation intervention vs. usual care. The trial includes 24 study sites in 13 US states. Specific activities to enhance recruitment in the present trial include reaching out to referring physicians (e.g., primary care, pulmonologists, radiologists) to increase referrals of African American patients to the participating NCORP sites, and partnering with the leaders of community engagement activities at the sites to raise community‐level awareness of the trial. RESULTS/CONCLUSIONS: To date, 64 African American patients have been recruited and the trial is now on target to meet its expected accrual goal of 200 patients. The majority of potential participants were ineligible due to receipt of surgical resection or radiation therapy prior to enrollment (32%), not having been told that they had probable/proven NSCLC prior to study contact (13%) or a previous history of lung cancer (13%). Only 9 potential participants have refused trial participation. The median age of the 64 participants is 64 years (range 37‐86 years). Most are unmarried (64%) and have a high school diploma or less (72%). Only 13 of the participants (20%) have no comorbidities. The number of enrolled‐to‐date African American participants in this ongoing trial exceeds the total number of participants recruited to the STARS Trial or to the ROSEL Trial.
AN  - CN-01743527
AU  - Ford, M. E.
AU  - Bryant, D. C.
AU  - Cartmell, K. B.
AU  - Sterba, K.
AU  - Burshell, D. R.
AU  - Hill, E. G.
AU  - De Toma, A.
AU  - Knight, K. D.
AU  - Weaver, K.
AU  - Calhoun, E.
AU  - et al.
DO  - 10.1158/1538-7755.DISP16-A72
IS  - 2
KW  - *African American
*non small cell lung cancer
Adult
Awareness
Clinical trial
Comorbidity
Controlled clinical trial
Controlled study
High school
Human
Leadership
Major clinical study
Middle aged
Primary medical care
Pulmonologist
Radiologist
Radiotherapy
Randomized controlled trial
Single (marital status)
Stereotactic body radiation therapy
Surgery
M3  - Journal: Conference Abstract
PY  - 2017
ST  - Interim recruitment outcomes in an NCORP-based patient navigation trial for African Americans with early stage lung cancer
T2  - Cancer epidemiology biomarkers and prevention
TI  - Interim recruitment outcomes in an NCORP-based patient navigation trial for African Americans with early stage lung cancer
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01743527/full
VL  - 26
ID  - 1392
ER  - 

TY  - JOUR
AB  - Background: Enrollment of early‐stage lung cancer patients to randomized trials has historically been challenging. The STARS Trial enrolled 36 of 1,030 intended patients from 28 sites, while the ROSEL Trial recruited 22 of 960 intended patients from 10 sites. Unfortunately, evidence shows African Americans with early‐stage non‐small cell lung cancer (NSCLC) are significantly less likely than their European American counterparts to undergo resection and may also be less likely to participate in lung cancer trials as well. Purpose: The purpose of this research is to describe interim recruitment results from an NIMHD‐funded, NCI NCORP‐based patient navigation trial conducted with African Americans with early‐stage, probable/proven NSCLC. Design: The protocol‐driven, barriers‐focused patient navigation intervention is being conducted in the context of a two‐arm cluster‐randomized trial testing the effectiveness of the intervention in increasing rates of lung‐directed curative‐intent therapy (surgery and SBRT) in African Americans with Stage I‐II NSCLC. The two study arms consist of the protocol‐driven, intensive navigation intervention vs. usual care. The trial includes 24 study sites in 13 U.S. states. Specific activities to enhance recruitment in the present trial include reaching out to referring physicians (e.g., primary care, pulmonologists, radiologists) to increase referrals of African American patients to the participating NCORP sites, and partnering with the leaders of community‐engagement activities at the sites to raise community‐level awareness of the trial. Results/Conclusions: To date, 90 African American patients have been recruited and the trial is now on target to meet its expected accrual goal of 200 patients. The majority of potential participants were ineligible due to receipt of surgical resection or radiation therapy prior to enrollment (27%), not having been told that they had probable/proven NSCLC prior to study contact (32%), or a previous history of lung cancer (10%). Only 13 potential participants have refused trial participation. The median age of the 90 participants is 66 years (range 51‐86 years). Most are unmarried (64%) and have a high school diploma or less (73%). Only 10 of the participants (24%) have no comorbidities. The number of enrolled‐to‐date African American participants in this ongoing trial exceeds the total number of participants recruited to the STARS Trial or to the ROSEL Trial.
AN  - CN-01653940
AU  - Ford, M. E.
AU  - Bryant, D. C.
AU  - Cartmell, K. B.
AU  - Sterba, K.
AU  - Burshell, D. R.
AU  - Hill, E. G.
AU  - De Toma, A.
AU  - Knight, K. D.
AU  - Weaver, K.
AU  - Calhoun, E.
AU  - et al.
DO  - 10.1158/1538-7755.DISP17-A23
IS  - 7
KW  - *African American
*cancer patient
*cancer staging
*non small cell lung cancer
Adult
Aged
Awareness
Cancer radiotherapy
Cancer surgery
Comorbidity
Conference abstract
Controlled study
Female
High school
Human
Leadership
Major clinical study
Male
Primary medical care
Pulmonologist
Radiologist
Radiotherapy
Randomized controlled trial
Single (marital status)
Stereotactic body radiation therapy
Surgery
M3  - Journal: Conference Abstract
PY  - 2018
ST  - Interim Recruitment Outcomes in an NCORP-Based Patient Navigation Trial for African Americans with Early Stage Lung Cancer1,2
T2  - Cancer epidemiology biomarkers and prevention
TI  - Interim Recruitment Outcomes in an NCORP-Based Patient Navigation Trial for African Americans with Early Stage Lung Cancer1,2
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01653940/full
VL  - 27
ID  - 1391
ER  - 

TY  - JOUR
AB  - OBJECTIVES: African-American women suffer disproportionately from HIV, breast cancer, and other illnesses. Little is known about the relationship between internalized HIV-related stigma and health beliefs related to other illnesses, including breast cancer. Our study examined (1) the relationship between internalized HIV-related stigma and breast health beliefs over time and (2) the moderating effects of participating in a stigma reduction intervention and/or social support. METHODS: Data from 239 African-American women receiving care for HIV in Chicago, IL, or Birmingham, AL, enrolled in the Unity randomized controlled trial, were used in this secondary analysis. Threat of breast cancer was measured in terms of perceived susceptibility, fear, and adverse consequences as well as an overall perceived threat of breast cancer. We used multivariate models with generalized estimating equations to examine the relationship between internalized HIV-related stigma and breast health beliefs across three time points (baseline, immediately post-workshop, and at 12-month follow-up) and to examine if the study arm (HIV stigma reduction vs. breast cancer education) or social support moderated the relationship. RESULTS: Internalized HIV-related stigma was associated with greater overall perceived threat (p < 0.001), susceptibility (p = 0.03), fear (p < 0.001), and perceived adverse consequences (p < 0.001) of breast cancer. These associations remained consistent across study arms and across all levels of social support. CONCLUSIONS: Future studies that examine co-morbid health conditions among African-American women living with HIV should consider the impact of HIV-related stigma on attitudes and beliefs related to co-morbid conditions.
AD  - Department of Global Health, University of Washington, Seattle, WA, USA.
Community Health Sciences Division, University of Illinois at Chicago, 1601 West Taylor Street, Chicago, IL, 60612, USA. Ymolin2@uic.edu.
School of Nursing & Health Studies, University of Washington Bothell, Bothell, WA, USA.
Department of Psychology, University of Washington, Seattle, WA, USA.
Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Department of Medicine, Northwestern University, Chicago, IL, USA.
CORE Center/Division of Infectious Diseases, Stroger Hospital of Cook County, Chicago, IL, USA.
Department of Psychiatry, University of Washington, Seattle, WA, USA.
AN  - 31452148
AU  - Fabian, K.
AU  - Molina, Y.
AU  - Kemp, C. G.
AU  - Nevin, P. E.
AU  - McCoy, K.
AU  - Simoni, J. M.
AU  - Andrasik, M.
AU  - Cohn, S. E.
AU  - Micci, S.
AU  - Rao, D.
C2  - PMC6980483
C6  - NIHMS1538294
DA  - Feb
DO  - 10.1007/s40615-019-00632-6
DP  - NLM
ET  - 2019/08/28
IS  - 1
KW  - *African–American women
*Breast cancer
*hiv
*Stigma
Simoni, Dr. Andrasik, Dr. Cohn, Dr. Micci, and Dr. Rao declare no conflicts of
interest.
LA  - eng
N1  - 2196-8837
Fabian, Katrin
Molina, Yamilé
Kemp, Christopher G
Nevin, Paul E
McCoy, Katryna
Simoni, Jane M
Andrasik, Michele
Cohn, Susan E
Micci, Sandy
Rao, Deepa
R25 CA092408/CA/NCI NIH HHS/United States
R01 MH098675/MH/NIMH NIH HHS/United States
P30 AI027757/AI/NIAID NIH HHS/United States
K01 CA193918/CA/NCI NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
J Racial Ethn Health Disparities. 2020 Feb;7(1):45-51. doi: 10.1007/s40615-019-00632-6. Epub 2019 Aug 26.
PY  - 2020
SN  - 2197-3792 (Print)
2196-8837
SP  - 45-51
ST  - Internalized HIV-Related Stigma and Breast Health Beliefs Among African-American Women Receiving Care for HIV in the USA
T2  - J Racial Ethn Health Disparities
TI  - Internalized HIV-Related Stigma and Breast Health Beliefs Among African-American Women Receiving Care for HIV in the USA
VL  - 7
ID  - 65
ER  - 

TY  - JOUR
AB  - Background: Many patients are now accessing the Internet to obtain cancer clinical trials information. However, services offering clinical trials recruitment information have not been well defined. Objectives: This study describes one of the first Web-based cancer clinical trials matching resources and the demographics of users who were successfully matched. Methods: OncoLink is the Internet-based educational resource managed by the University of Pennsylvania Cancer Center (UPCC) and serves between 1 and 2 million pages per month to over 385000 unique IP addresses. OncoLink launched one of the first clinical trials matching resources on the Internet that allowed patients to enter demographic data through a secure connection and be matched to clinical trials. For patients with matches to potential trials, appointments were facilitated with the principal investigators. Results: While we did not keep track of patients who could not be matched, 627 patients who submitted online applications between January 2002 and April 2003 were successfully matched for potential enrollment in clinical trials. The mean age of the patient population was 56 years (range 18-88 years). Males represented 60% of the patient population, and over 90% of users were Caucasian. Most of the applications were from patients with colorectal cancer (13%), lung cancer (14%), melanoma (10%), and non-Hodgkin's lymphoma (9%). Conclusions: This report shows that a significant number of patients are willing to use the Internet for enrolling in clinical trials. Care must be taken to reach patients from a variety of socioeconomic and racial backgrounds. This Internet resource helps to facilitate a consultation with a cancer patient who is prescreened and motivated to enroll in clinical trials.
AN  - WOS:000232304600003
AU  - Metz, J. M.
AU  - Coyle, C.
AU  - Hudson, C.
AU  - Hampshire, M.
DA  - 2005
DO  - 10.2196/jmir.7.3.e24
IS  - 3
N1  - 17
PY  - 2005
SN  - 1438-8871
ST  - An Internet-based cancer clinical trials matching resource
T2  - Journal of Medical Internet Research
TI  - An Internet-based cancer clinical trials matching resource
VL  - 7
ID  - 2669
ER  - 

TY  - JOUR
AB  - Background: AA men often present with more aggressive prostate cancer and are less likely to receive treatment, negatively affecting quality‐of‐life and overall survival (OS). Sipuleucel‐T is an autologous cellular immunotherapy approved for asymptomatic or minimally symptomatic mCRPC. Data from the PROCEED registry showed that OS for AA pts treated with SIP‐T was 9.3 mo longer than OS for Caucasian pts. In a prior subgroup analysis of Phase III data, AA pts realized a 30.7‐mo difference in OS with SIP‐T vs. placebo (PBO). We calculated the NNTB to further interpret the OS benefit in AA pts. Methods:Data were pooled from 3 Phase III mCRPC SIP‐T trials (D9901, D9902A, and IMPACT). The absolute risk reduction (ARR) is calculated from Kaplan‐Meier estimates at 12‐, 24‐, and 36‐mo for all SIP‐T subjects, and an AA cohort, receiving >1 infusion. NNTB, the inverse of the ARR, represents the number of pts needed to be treated with SIP‐T to prevent 1 additional death compared to PBO. All NNTB values are rounded up. Results: Of the 737 pooled mCRPC pts enrolled, 488 men were randomized to SIP‐T (n=33 AA), and 249 to PBO. Baseline clinical characteristics between the SIP‐T and PBO groups were well balanced; however, compared to overall SIP‐T and PBO, AA SIP‐T pts were more likely to have received prior chemotherapy, lower hemoglobin, and better performance status. The NNTB at 12‐mo was the same (13) for both the pooled SIP‐T and AA treated cohort. At 24‐mo, the NNTB values were 10 for pooled and 5 for AA. At 36‐mo, an NNTB of 8 (pooled) and 3 (AA) SIP‐T treatments prevented 1 additional death (Table). Conclusions: This NNTB analysis shows a favorable survival benefit for AA men treated with SIP‐T and all treated SIP‐T subjects. NNTB values declined over 3‐years, suggesting durability of clinical benefit with SIP‐T, and that it may address a known survival disparity in AA with prostate cancer. Studies with larger sample sizes may confirm if AA pts derive a greater OS benefit from SIP‐T. (Table Presented).
AN  - CN-01940746
AU  - Moses, K. A.
AU  - Flanders, S. C.
AU  - Harmon, M.
AU  - Chang, N. N.
AU  - Rayford, W.
AU  - Quinn, D. I.
AU  - Sartor, A. O.
KW  - *African American
*cancer patient
*cancer survival
*castration resistant prostate cancer
*overall survival
Adult
Clinical feature
Cohort analysis
Conference abstract
Controlled study
Death
Drug therapy
Female
Human
Human tissue
Infusion
Kaplan Meier method
Major clinical study
Male
Patient history of chemotherapy
Phase 3 clinical trial
Prevention
Randomized controlled trial
Risk reduction
Sample size
M3  - Journal: Conference Abstract
PY  - 2019
ST  - Interpreting survival outcomes for African-American (AA) patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with sipuleucel-T (SIP-T) with number needed to treat to benefit (NNTB)
T2  - Journal of clinical oncology
TI  - Interpreting survival outcomes for African-American (AA) patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with sipuleucel-T (SIP-T) with number needed to treat to benefit (NNTB)
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01940746/full
VL  - 37
ID  - 1518
ER  - 

TY  - JOUR
AB  - BACKGROUND: Older African-American women with single marital status are least likely to use screening procedures. This study aimed to evaluate a breast screening intervention program conducted in this population. METHODS: Ten public housing complexes were randomly assigned to either the intervention or the control group. African-American women aged 65 and over were recruited into the study if they were widowed, divorced, separated, or never married and did not have a history of breast cancer (n = 325). The intervention program was delivered by lay health educators at the participant's apartment and was designed to increase knowledge about breast screening, reduce psychological problems, and increase support from significant others. Breast-screening-related cognition and behavior were measured at baseline and at 1 and 2 years postintervention. RESULTS: Comparisons of the preintervention and postintervention measurements showed that while the proportion of women who had a clinical breast examination or mammogram in the preceding year was decreased at 1 year postintervention in the control group, it was increased in the intervention group. However, the differences did not reach a significant level. No consistent patterns could be found in changes of breast self-examination and variables in knowledge, attitudes, and beliefs. When analyses were restricted to women whose significant others had provided information or help on breast screening, results were better, but the differences between the intervention and control groups still did not reach statistical significance. CONCLUSIONS: These results did not suggest significant effects of an intervention program that used lay health educators to promote breast cancer screening in older single African-American women.
AD  - Pennsylvania State University College of Medicine, Hershey 17033, USA. kzhu@hes.hmc.psu.edu
AN  - 11969355
AU  - Zhu, K.
AU  - Hunter, S.
AU  - Bernard, L. J.
AU  - Payne-Wilks, K.
AU  - Roland, C. L.
AU  - Elam, L. C.
AU  - Feng, Z.
AU  - Levine, R. S.
DA  - May
DO  - 10.1006/pmed.2002.1016
DP  - NLM
ET  - 2002/04/24
IS  - 5
KW  - African Americans/*psychology
Aged
Aged, 80 and over
Breast Neoplasms/ethnology/*prevention & control
Breast Self-Examination
Data Collection
Female
Health Knowledge, Attitudes, Practice
Humans
Mammography
*Mass Screening
Women's Health
LA  - eng
N1  - Zhu, Kangmin
Hunter, Sandra
Bernard, Louis J
Payne-Wilks, Kathleen
Roland, Chanel L
Elam, Lloyd C
Feng, Ziding
Levine, Robert S
Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, U.S. Gov't, Non-P.H.S.
United States
Prev Med. 2002 May;34(5):536-45. doi: 10.1006/pmed.2002.1016.
PY  - 2002
SN  - 0091-7435 (Print)
0091-7435
SP  - 536-45
ST  - An intervention study on screening for breast cancer among single African-American women aged 65 and older
T2  - Prev Med
TI  - An intervention study on screening for breast cancer among single African-American women aged 65 and older
VL  - 34
ID  - 670
ER  - 

TY  - JOUR
AB  - Racial disparities in the treatment of non‐small lung cancer (NSCLC) continue to exist leading to poorer outcomes in African‐Americans (AA) compared to Caucasians (C). Our previous multi‐institutional prospective cohort study of 386 patients identified a surgical rate in early stage NSCLC of 66% C but only 55% AA (p = 0.05; OR 0.75; 95% CI 0.57‐0.99). An identified potentially reversible factor associated with omitting surgery in first our study was a patient's perception of lower‐quality cancer communication manifested by a 5‐point decrement on a 25‐point communication scale; OR for AA 0.27 (0.15‐0.51) compared C 0.47 (0.24‐0.93). (Cykert et al JAMA 2010) An additional 714 baseline patients were identified from a 3 year retrospective chart review of all patients with early stage NSCLC at the 3 academic institutions involved in this current intervention study. Baseline surgical rates 69% for C and 66% for AA. Combined stereotactic body radiation therapy (SBRT) with surgery C 80% and AA 76%. Controlling for co‐morbidities, COPD, age and other demographic data, the OR for surgery AA compared to C 0.64 (95% CI 0.43‐0.96) and for combined surgery or SBRT AA compared to C 0.61 (95% CI 0.43‐0.96). Methods: Patients with a stage I or II NSCLC were identified and randomized to each institution's standard of care approach or to an 'intervention' component utilizing a trained navigator to enhance patient communication and treatment understanding focusing on our observed potentially reversible factor. Results: 244 patients were prospectively recruited into this intervention study. Mean age 65.7 years; 54% women; 89 (34%) AA. The intervention group showed an overall surgical rate of 74% (74.8% C, 71.4% AA; p = 0.6). Combined treatment of either surgery or SBRT increased an ablative treatment to 91.9% for C and 94.1% AA patients (p = 0.5). Logistic regression was performed comparing the intervention group to the baseline group. Results showed that overall treatment improved for both C and AA and the surgical and overall treatment disparity between C and AA was no longer present, while age, COPD, and clinical stage remained significant predictors of treatment. Conclusion: A multifaceted intervention designed to enhance patient communication and treatment understanding removed the surgical and overall early lung cancer treatment disparity between AA and C. Clinical trial information: NCT01687738.
AN  - CN-01428351
AU  - Walker, P. R.
AU  - Cykert, S.
AU  - Edwards, L.
AU  - Arya, R.
AU  - Dilworth-Anderson, P.
IS  - 11
KW  - *cancer staging
*intervention study
*non small cell lung cancer
Ablation therapy
African American
Aged
Cancer surgery
Cancer therapy
Chronic obstructive lung disease
Comorbidity
Controlled study
Demography
Disease course
Drug combination
Female
Health care quality
Human
Major clinical study
Male
Medical record review
Multicenter study
Perception
Prospective study
Randomized controlled trial
Stereotactic body radiation therapy
Surgery
M3  - Journal: Conference Abstract
PY  - 2017
SP  - S1553‐
ST  - An intervention study to reduce black-white treatment disparities in early stage non-small cell lung cancer
T2  - Journal of thoracic oncology
TI  - An intervention study to reduce black-white treatment disparities in early stage non-small cell lung cancer
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01428351/full
VL  - 12
ID  - 1389
ER  - 

TY  - JOUR
AB  - This paper reports the results of a practice-based intervention program to increase mammography screening among women 65 and older who receive their health care in the private sector. Forty-three primary-care practices and 2147 women in central and western North Carolina were enrolled in the study, and 1911 women completed all phases of the study. The intervention was a three-stage educational and counseling program designed to become progressively more intensive at each stage. The interventions included provider education in the form of current information on issues in mammography for older women, simply written educational materials on breast cancer and screening mailed to women, and a brief telephone counseling session for the women. While the analysis revealed no overall effect across all three stages of the intervention program, tests for interaction indicated a significant program effect for women who were 80 or older, had less than 9 years of education, were black, or had no private insurance to supplement Medicare. The results suggested that providing primary-care physicians with information on screening older women and providing the women with useful educational materials can increase participation in screening mammography among subgroups of women currently least likely to receive mammography screening.
AD  - Department of Family and Community Medicine, Wake Forest University School of Medicine, Winston-Salem, NC 27157; bmichiel@wfubmc.edu
AN  - 106473154. Language: English. Entry Date: 20050624. Revision Date: 20170831. Publication Type: Journal Article
AU  - Michielutte, R.
AU  - Sharp, P. C.
AU  - Foley, K. L.
AU  - Cunningham, L. E.
AU  - Spangler, J. G.
AU  - Paskett, E. D.
AU  - Case, L. D.
DB  - CINAHL Complete
DP  - EBSCOhost
IS  - 2
KW  - Behavioral Changes -- In Old Age
Breast Neoplasms -- Prevention and Control -- In Old Age
Gerontologic Care
Mammography -- Trends -- In Old Age
Aged
Aged, 80 and Over
Conceptual Framework
Counseling
Descriptive Statistics
Female
Funding Source
Interviews
North Carolina
P-Value
Pretest-Posttest Design
Record Review
Regression
Two-Tailed Test
Human
N1  - research; tables/charts. Journal Subset: Europe; Health Promotion/Education; Peer Reviewed; UK & Ireland. Grant Information: National Cancer Institute (R01-CA79746). NLM UID: 8608459.
PMID: NLM15254001.
PY  - 2005
SN  - 0268-1153
SP  - 149-162
ST  - Intervention to increase screening mammography among women 65 and older
T2  - Health Education Research
TI  - Intervention to increase screening mammography among women 65 and older
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106473154&site=ehost-live&scope=site
VL  - 20
ID  - 1986
ER  - 

TY  - JOUR
AB  - BACKGROUND: African-American men have the lowest 5-year survival rate in the U.S. for colorectal cancer (CRC) of any racial group, which may partly stem from low screening adherence. It is imperative to synthesize the literature evaluating the effectiveness of interventions on CRC screening uptake in this population. MATERIALS AND METHODS: In this systematic review and meta-analysis, Medline, CINAHL, Embase, and Cochrane CENTRAL were searched for U.S.-based interventions that: were published after 1998-January 2020; included African-American men; and evaluated CRC screening uptake explicitly. Checklist by Cochrane Collaboration and Joanna Brigg were utilized to assess risk of bias, and meta-regression and sensitivity analyses were employed to identify the most effective interventions. RESULTS: Our final sample comprised 41 studies with 2 focused exclusively on African-American men. The most frequently adopted interventions were educational materials (39%), stool-based screening kits (14%), and patient navigation (11%). Most randomized controlled trials failed to provide details about the blinding of the participant recruitment method, allocation concealment method, and/or the outcome assessment. Due to high heterogeneity, meta-analysis was conducted among 17 eligible studies. Interventions utilizing stool-based kits or patient navigation were most effective at increasing CRC screening completion, with odds ratios of 9.60 (95% CI 2.89-31.82, p = 0.0002) and 2.84 (95% CI 1.23-6.49, p = 0.01). No evidence of publication bias was present for this study registered with the International Prospective Registry of Systematic Reviews (PROSPERO 2019 CRD42019119510). CONCLUSIONS: Additional research is warranted to uncover effective, affordable interventions focused on increasing CRC screening completion among African-American men. When designing and implementing future multicomponent interventions, employing 4 or fewer interventions types may reduce bias risk. Since only 5% of the interventions solely focused on African-American men, future theory-driven interventions should consider recruiting samples comprised solely of this population.
AD  - Department of Family & Preventive Medicine, University of Utah School of Medicine, Salt Lake City, Utah, United States of America.
Department of Health Education and Promotion, East Carolina University, Greenville, NC, United States of America.
Cancer Biostatistics Shared Resource, Huntsman Cancer Institute, Salt Lake City, UT, United States of America.
Medical Sciences Library, Texas A&M University, College Station, TX, United States of America.
AN  - 32936812
AU  - Rogers, C. R.
AU  - Matthews, P.
AU  - Xu, L.
AU  - Boucher, K.
AU  - Riley, C.
AU  - Huntington, M.
AU  - Le Duc, N.
AU  - Okuyemi, K. S.
AU  - Foster, M. J.
C2  - PMC7494124
DO  - 10.1371/journal.pone.0238354
DP  - NLM
ET  - 2020/09/17
IS  - 9
KW  - African Americans/*psychology/statistics & numerical data
Colorectal Neoplasms/*diagnosis/prevention & control/psychology
Early Detection of Cancer/*psychology/statistics & numerical data
*Health Knowledge, Attitudes, Practice
Humans
Male
Patient Acceptance of Health Care/*psychology
Patient Education as Topic/*methods
Prognosis
LA  - eng
N1  - 1932-6203
Rogers, Charles R
Orcid: 0000-0002-3571-8229
Matthews, Phung
Xu, Lei
Boucher, Kenneth
Riley, Colin
Huntington, Matthew
Le Duc, Nathan
Okuyemi, Kola S
Foster, Margaret J
K01 CA234319/CA/NCI NIH HHS/United States
P30 CA042014/CA/NCI NIH HHS/United States
Journal Article
Meta-Analysis
Research Support, N.I.H., Extramural
Systematic Review
PLoS One. 2020 Sep 16;15(9):e0238354. doi: 10.1371/journal.pone.0238354. eCollection 2020.
PY  - 2020
SN  - 1932-6203
SP  - e0238354
ST  - Interventions for increasing colorectal cancer screening uptake among African-American men: A systematic review and meta-analysis
T2  - PLoS One
TI  - Interventions for increasing colorectal cancer screening uptake among African-American men: A systematic review and meta-analysis
VL  - 15
ID  - 25
ER  - 

TY  - JOUR
AB  - OBJECTIVES: Ethnic minorities are disproportionately impacted by prostate cancer (PCa) and are at risk for not receiving informed decision making (IDM). We conducted a systematic literature review on interventions to improve: (1) IDM about PCa in screening-eligible minority men, and (2) quality of life (QOL) in minority PCa survivors. DATA SOURCES: MeSH headings for PCa, ethnic minorities, and interventions were searched in MEDLINE, Cochrane Database of Systematic Reviews, Cochrane Central Register of Controlled Trials, CINAHL, and PsycINFO. SUBJECT ELIGIBILITY CRITERIA: We identified U.S.-based, English-language articles (1985 - 2010) on interventions to improve PCa IDM and QOL that included 50% or more minority patients or analyses stratified by race/ethnicity. STUDY APPRAISAL AND SYNTHESIS METHODS: Articles (n = 19) were evaluated and scored for quality using a Downs and Black (DB) system. Interventions were organized by those enhancing 1) IDM about PCa screening and 2) improving QOL and symptom among PCa survivors. Outcomes were reported by intervention type (educational seminar, printed material, telephone-based, video and web-based). RESULTS: Fourteen studies evaluated interventions for enhancing IDM about PCa screening and five evaluated programs to improve outcomes for PCa survivors. Knowledge scores were statistically significantly increased in 12 of 13 screening studies that measured knowledge, with ranges of effect varying across intervention types: educational programs (13% - 48% increase), print (11% - 18%), videotape/DVD (16%), and web-based (7% - 20%). In the final screening study, an intervention to improve decision-making about screening increased decisional self-efficacy by 9%. Five cognitive-behavioral interventions improved QOL among minority men being treated for localized PCa through enhancing problem solving and coping skills. LIMITATIONS: Weak study designs, small sample sizes, selection biases, and variation in follow-up intervals across studies. CONCLUSIONS: Educational programs were the most effective intervention for improving knowledge among screening-eligible minority men. Cognitive behavioral strategies improved QOL for minority men treated for localized PCa.
AD  - Department of Medicine, Section of Geriatrics & Palliative Medicine, University of Chicago Medical Center, 5841 S. Maryland Avenue, Chicago, IL 60637, USA.
AN  - 22798216
AU  - Sajid, S.
AU  - Kotwal, A. A.
AU  - Dale, W.
C2  - PMC3403148
DA  - Aug
DO  - 10.1007/s11606-012-2086-5
DP  - NLM
ET  - 2012/07/17
IS  - 8
KW  - Continental Population Groups/ethnology
*Decision Making
Disease Management
Ethnic Groups/ethnology
Healthcare Disparities/*ethnology
Humans
Male
*Patient Participation/methods
Prostatic Neoplasms/diagnosis/*ethnology/*therapy
Randomized Controlled Trials as Topic/methods
LA  - eng
N1  - 1525-1497
Sajid, Saleha
Kotwal, Ashwin A
Dale, William
Journal Article
Research Support, Non-U.S. Gov't
Review
Systematic Review
J Gen Intern Med. 2012 Aug;27(8):1068-78. doi: 10.1007/s11606-012-2086-5.
PY  - 2012
SN  - 0884-8734 (Print)
0884-8734
SP  - 1068-78
ST  - Interventions to improve decision making and reduce racial and ethnic disparities in the management of prostate cancer: a systematic review
T2  - J Gen Intern Med
TI  - Interventions to improve decision making and reduce racial and ethnic disparities in the management of prostate cancer: a systematic review
VL  - 27
ID  - 359
ER  - 

TY  - JOUR
AB  - AIM: The aim of this article was to determine sentinel lymph node (SLN) identification rate (IR) using Patent Blue V in patients with non-small cell lung cancer (NSCLC) and to evaluate the accuracy of SLN for the presence of mediastinal metastasis. METHODS: Between 2004 and 2006 the data from 32 patients with clinical stage IA to IIB, who underwent lung resection for NSCLC, were prospectively analyzed. Patent blue V dye was injected in the peritumoral tissue, and the first lymph node to stain was identified as a sentinel node. RESULTS: SLN was identified in fifteen patients (IR=46.9%). SLN with metastatic involvement was observed in four patients. Accuracy, sensitivity and specificity of the sentinel lymph node in predicting the status of other mediastinal lymph node stations were respectively 86.7%, 100%, and 84.6%. In 63.1% patients, the SLNs corresponded to the lymph node stations 10 and 11. In seven patients (36.9%), the SLNs were located in the N2 stations. CONCLUSION: Although the use of Patent Blue V for SLN identification is feasible, this technique presents relatively low identification rate. The major difficulty on the detection of SLNs was the black coloration of the lymph node, which interfered with the visualization of the dye.
AD  - Department of Thoracic Surgery, Pavilhão Pereira Filho Hospital, Santa Casa de Porto Alegre, Porto Alegre, Brazil.
AN  - 18212725
AU  - Bustos, M. E.
AU  - Camargo, J. J.
AU  - Resin Geyer, G.
AU  - Feijó Andrade, C.
DA  - Feb
DP  - NLM
ET  - 2008/01/24
IS  - 1
KW  - Adult
Aged
Aged, 80 and over
Carcinoma, Non-Small-Cell Lung/pathology/secondary/*surgery
*Coloring Agents
Feasibility Studies
Female
Humans
*Intraoperative Care
Lung/pathology
Lung Neoplasms/pathology/secondary/*surgery
Lymphatic Metastasis/*diagnosis
Male
Mediastinum
Middle Aged
Neoplasm Staging
Patient Selection
Prospective Studies
Sensitivity and Specificity
*Sentinel Lymph Node Biopsy
LA  - eng
N1  - Bustos, M E F
Camargo, J J P
Resin Geyer, G
Feijó Andrade, C
Comparative Study
Evaluation Study
Journal Article
Research Support, Non-U.S. Gov't
Italy
Minerva Chir. 2008 Feb;63(1):29-36.
PY  - 2008
SN  - 0026-4733 (Print)
0026-4733
SP  - 29-36
ST  - Intraoperative detection of sentinel lymph nodes using Patent Blue V in non-small cell lung cancer
T2  - Minerva Chir
TI  - Intraoperative detection of sentinel lymph nodes using Patent Blue V in non-small cell lung cancer
VL  - 63
ID  - 507
ER  - 

TY  - JOUR
AB  - BACKGROUND: Obesity has a variety of adverse health outcomes, but to the authors' knowledge, the effect of obesity on outcome in patients with advanced prostate cancer is not known. For this reason, the correlation between an elevated body mass index (BMI) and clinical outcomes in patients with metastatic, castration-recurrent prostate cancer (CRPC) was evaluated. METHODS: A total of 1226 men with CRPC who were enrolled in 9 prospective clinical trials conducted by the Cancer and Leukemia Group B (CALGB) for the treatment of metastatic disease were considered. Eligible patients had progressive prostate cancer during androgen deprivation therapy (with documented castrate levels of testosterone); an Eastern Cooperative Oncology Group performance status of 0 to 2; and adequate hematologic, renal, and hepatic function. Patients were classified based on BMI as normal (18.5-24.9 kg/m(2)), overweight (25-29.9 kg/m(2)), and mildly to severely obese (> or =30 kg/m(2)). RESULTS: Approximately 24% of the patients had a normal BMI, 43% were overweight, and 33% were mildly to severely obese. On multivariable analysis, BMI was found to be a statistically significant predictor of overall survival and prostate cancer-specific mortality. Compared with men with normal BMIs, the hazard ratios for death for overweight men and mildly to severely obese men were 0.80 (95% confidence interval [95% CI], 0.68-0.93; P = .001) and 0.80 (95% CI, 0.68-0.94; P = .010), respectively. CONCLUSIONS: In patients with metastatic CRPC, obesity (as defined by an elevated BMI) appears to have a protective effect against overall mortality and prostate cancer-specific mortality. Alternatively, a higher BMI may reflect different cancer biology (ie, the lack of cachexia-producing substances). Further studies to gain a more comprehensive understanding of the mechanisms behind these clinical observations are needed.
AD  - Department of Biostatistics and Bioinformatics, Duke University, Durham, North Carolina 27705, USA. susan.halabi@duke.edu
AN  - 17665494
AU  - Halabi, S.
AU  - Ou, S. S.
AU  - Vogelzang, N. J.
AU  - Small, E. J.
DA  - Oct 1
DO  - 10.1002/cncr.22932
DP  - NLM
ET  - 2007/08/01
IS  - 7
KW  - African Americans/statistics & numerical data
Aged
Androgen Antagonists/*therapeutic use
Antineoplastic Agents, Hormonal/*therapeutic use
*Body Mass Index
Clinical Trials as Topic
Disease-Free Survival
European Continental Ancestry Group/statistics & numerical data
Humans
Kaplan-Meier Estimate
Male
Middle Aged
Multivariate Analysis
Neoplasm Recurrence, Local/blood/drug therapy/*therapy
Obesity/blood/*physiopathology
Predictive Value of Tests
Prospective Studies
Prostate-Specific Antigen/blood
Prostatic Neoplasms/blood/drug therapy/ethnology/*pathology/*therapy
Severity of Illness Index
Testosterone/blood
United States/epidemiology
LA  - eng
N1  - Halabi, Susan
Ou, San-San
Vogelzang, Nicholas J
Small, Eric J
CA 36601/CA/NCI NIH HHS/United States
Comparative Study
Journal Article
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.
United States
Cancer. 2007 Oct 1;110(7):1478-84. doi: 10.1002/cncr.22932.
PY  - 2007
SN  - 0008-543X (Print)
0008-543x
SP  - 1478-84
ST  - Inverse correlation between body mass index and clinical outcomes in men with advanced castration-recurrent prostate cancer
T2  - Cancer
TI  - Inverse correlation between body mass index and clinical outcomes in men with advanced castration-recurrent prostate cancer
VL  - 110
ID  - 518
ER  - 

TY  - JOUR
AB  - OBJECTIVE: To discuss the complexities facing the researcher in attempting to determine reasons for the high rate of absconding from biomedical treatments by black African women diagnosed with breast cancer. DESIGN: Qualitative study based on in-depth interviews and participant observations of the informants, to ascertain attitudes, beliefs and practices of black African breast cancer patients with regard to the choice of healer. PARTICIPANTS: 10 black breast cancer patients, 4 African indigenous healers, 4 black lay persons, and 8 Groote Schuur Hospital members. SETTING: Radiation Oncology Department, Groote Schuur Hospital, Cape Town. RESULTS: The study revealed that various determinants affect black women's decision to abscond from biomedical breast cancer treatments. These determinants were based on social and cultural peculiarities. However, these findings did not explain the difference in absconding rates between black cervical (30%) and breast cancer (80%) patients. Although the two patient groups shared social, economic, and cultural backgrounds, their decisions with regard to biomedical treatments of cancer were remarkably different. CONCLUSIONS: The methods chosen for the research project provided a framework for a qualitative study of one ethnic group of breast cancer patients. However, the research framework failed to allow comparisons between breast and cervical cancer patients from the same ethnic backgrounds. Therefore, although the research findings revealed determinants affecting black breast cancer treatments, they do not explain the discrepancy between absconding rates of black cervical and breast cancer patients.
AN  - 9472279
AU  - Wright, S. V.
DA  - Nov
DP  - NLM
ET  - 1998/02/24
IS  - 11
KW  - African Americans/psychology
African Continental Ancestry Group
Breast Neoplasms/ethnology/*therapy
Female
*Health Knowledge, Attitudes, Practice
Humans
*Medicine, African Traditional
*Patient Dropouts
Perception
South Africa
LA  - eng
N1  - Wright, S V
Case Reports
Journal Article
South Africa
S Afr Med J. 1997 Nov;87(11):1540-3.
PY  - 1997
SN  - 0256-9574 (Print)
SP  - 1540-3
ST  - An investigation into the causes of absconding among black African breast cancer patients
T2  - S Afr Med J
TI  - An investigation into the causes of absconding among black African breast cancer patients
VL  - 87
ID  - 732
ER  - 

TY  - JOUR
AB  - AIM: Preoperative anaemia is associated with increased morbidity and mortality. The aim of this systematic review is to evaluate the efficacy of preoperative iron supplementation in the treatment of anaemia, and its effect on the postoperative recovery of patients undergoing surgery for colorectal carcinoma. METHOD: This systematic review was performed using MEDLINE, EMBASE and the Cochrane library to assess current evidence on the role of iron supplementation in the treatment of preoperative anaemia. Our main outcomes were absolute increase in haemoglobin, blood transfusion rate and postoperative morbidity. Main inclusion criteria were: preoperative iron supplementation, presence of colorectal carcinoma and elective surgery. The Downs-Black questionnaire was used for quality assessment of the included studies. RESULTS: Of the 605 studies analysed, seven, three randomized controlled trials and four cohort studies, were included. Despite iron supplementation, the three randomized controlled trials showed a decrease in haemoglobin level. This was contrary to the four cohort studies which all showed a significant increase. All studies showed a decreased blood transfusion rate following iron supplementation. None of the included studies assessed postoperative morbidity. Due to heterogeneity in study design, duration of treatment, dosages and variation in iron substrates, we were unable to perform a meta-analysis. CONCLUSION: In anaemic patients who require surgery for colorectal carcinoma, current evidence is of inadequate quality to draw a definitive conclusion on the efficacy of the various measures to treat preoperative anaemia.
AD  - Department of Surgery, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands.
Department of Surgery, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa.
AN  - 26342151
AU  - Borstlap, W. A.
AU  - Stellingwerf, M. E.
AU  - Moolla, Z.
AU  - Musters, G. D.
AU  - Buskens, C. J.
AU  - Tanis, P. J.
AU  - Bemelman, W. A.
DA  - Dec
DO  - 10.1111/codi.13110
DP  - NLM
ET  - 2015/09/06
IS  - 12
KW  - Adult
Aged
Aged, 80 and over
Anemia, Iron-Deficiency/*drug therapy/etiology
Blood Transfusion/statistics & numerical data
Cohort Studies
Colorectal Neoplasms/blood/*complications/surgery
Dietary Supplements
Female
Humans
Iron/*therapeutic use
Male
Middle Aged
Postoperative Complications/prevention & control
*Preoperative Period
Randomized Controlled Trials as Topic
Trace Elements/*therapeutic use
Preoperative anaemia
colorectal carcinoma
iron therapy
LA  - eng
N1  - 1463-1318
Borstlap, W A A
Stellingwerf, M E
Moolla, Z
Musters, G D
Buskens, C J
Tanis, P J
Bemelman, W A
Journal Article
Review
Systematic Review
England
Colorectal Dis. 2015 Dec;17(12):1044-54. doi: 10.1111/codi.13110.
PY  - 2015
SN  - 1462-8910
SP  - 1044-54
ST  - Iron therapy for the treatment of preoperative anaemia in patients with colorectal carcinoma: a systematic review
T2  - Colorectal Dis
TI  - Iron therapy for the treatment of preoperative anaemia in patients with colorectal carcinoma: a systematic review
VL  - 17
ID  - 233
ER  - 

TY  - JOUR
AD  - Department of Radiation Medicine, Oregon Health & Science University, Portland, Oregon. Electronic address: drwood@post.harvard.edu.
Department of Radiation Medicine, Oregon Health & Science University, Portland, Oregon.
AN  - 29165281
AU  - McClelland, S., 3rd
AU  - Jaboin, J. J.
AU  - Mitin, T.
DA  - Dec 1
DO  - 10.1016/j.ijrobp.2017.08.017
DP  - NLM
ET  - 2017/11/23
IS  - 5
KW  - *African Americans
Aged
Health Promotion
Humans
Male
Middle Aged
*Population Surveillance
Prostatectomy
Prostatic Neoplasms/ethnology/mortality/*radiotherapy
Randomized Controlled Trials as Topic
Risk
Scandinavian and Nordic Countries
United States
*Watchful Waiting
LA  - eng
N1  - 1879-355x
McClelland, Shearwood 3rd
Jaboin, Jerry J
Mitin, Timur
Editorial
United States
Int J Radiat Oncol Biol Phys. 2017 Dec 1;99(5):1076-1077. doi: 10.1016/j.ijrobp.2017.08.017.
PY  - 2017
SN  - 0360-3016
SP  - 1076-1077
ST  - Is Advocacy for Active Surveillance Over Definitive Intervention in Low-Risk Prostate Cancer Applicable to African American Patients?
T2  - Int J Radiat Oncol Biol Phys
TI  - Is Advocacy for Active Surveillance Over Definitive Intervention in Low-Risk Prostate Cancer Applicable to African American Patients?
VL  - 99
ID  - 146
ER  - 

TY  - JOUR
AB  - BACKGROUND: In 1991, Medicare began covering screening mammograms subject to copayment and deductible. This study evaluated the effectiveness of Medicare in removing financial barriers to screening mammography among low-income older women. METHODS: In an inner-city public hospital's General Medicine Clinic, 119 consecutive, eligible, and consenting Medicare-enrolled women without known risk factors for breast cancer other than age, and no mammogram in the previous 2 years, were entered into a randomized controlled trial with follow-up after 2 months. The mean age was 71 years; 77% were black, 92% had an annual income below $10,000, and 52% had had a previous mammogram. All patients were counseled concerning indications for screening mammograms and Medicare coverage, and all were referred to a low-cost mammography facility. Sixty-one subjects were randomly assigned a voucher for a free screening mammogram at the referral facility. Obtaining a mammogram within 60 days of study entry was the main outcome measure. RESULTS: Of the women given vouchers, 27 (44%) obtained screening mammograms, compared with six (10%) of those without vouchers (P < .001). Adjustment by multiple logistic regression confirmed this association, yielding an adjusted odds ratio of 7.4 (95% confidence interval, 2.5 to 21.4). Knowledge concerning mammography and breast cancer increased significantly overall (and within randomization groups) between initial interview and follow-up; fear did not change. For women without the voucher, the main reason for not obtaining a mammogram was financial; the main reason for women with the voucher was transportation. CONCLUSION: In a low-income, inner-city population of older women, financial barriers to screening mammography persist despite Medicare coverage.
AD  - Department of Medicine, Baylor College of Medicine, Ben Taub General Hospital, Houston, Tex.
AN  - 8203989
AU  - Kiefe, C. I.
AU  - McKay, S. V.
AU  - Halevy, A.
AU  - Brody, B. A.
DA  - Jun 13
DP  - NLM
ET  - 1994/06/13
IS  - 11
KW  - Aged
Aged, 80 and over
Costs and Cost Analysis
Federal Government
Female
Health Behavior
Health Knowledge, Attitudes, Practice
*Health Services Accessibility
Humans
Mammography/*economics
*Medicare
Middle Aged
Patient Compliance
*Patient Selection
*Poverty
Socioeconomic Factors
United States
Urban Health
Empirical Approach
Health Care and Public Health
LA  - eng
N1  - Kiefe, C I
McKay, S V
Halevy, A
Brody, B A
Clinical Trial
Controlled Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
United States
Arch Intern Med. 1994 Jun 13;154(11):1217-24.
PY  - 1994
SN  - 0003-9926 (Print)
0003-9926
SP  - 1217-24
ST  - Is cost a barrier to screening mammography for low-income women receiving Medicare benefits? A randomized trial
T2  - Arch Intern Med
TI  - Is cost a barrier to screening mammography for low-income women receiving Medicare benefits? A randomized trial
VL  - 154
ID  - 746
ER  - 

TY  - JOUR
AD  - Department of Radiation and Medical Oncology, University of California, San Francisco, USA.
AN  - 9828588
AU  - Roach, M., 3rd
C2  - PMC2653096
DA  - Nov
DP  - NLM
ET  - 1998/11/26
IS  - 11 Suppl
KW  - *African Continental Ancestry Group
Humans
Male
Prognosis
Prostatic Neoplasms/diagnosis/*ethnology/mortality
Randomized Controlled Trials as Topic
Retrospective Studies
Survival Rate
United States/epidemiology
LA  - eng
N1  - Roach, M 3rd
Journal Article
Review
J Natl Med Assoc. 1998 Nov;90(11 Suppl):S713-9.
PY  - 1998
SN  - 0027-9684 (Print)
0027-9684
SP  - S713-9
ST  - Is race an independent prognostic factor for survival from prostate cancer?
T2  - J Natl Med Assoc
TI  - Is race an independent prognostic factor for survival from prostate cancer?
VL  - 90
ID  - 724
ER  - 

TY  - JOUR
AN  - 19567421
AU  - Brawley, O. W.
DA  - Jul 15
DO  - 10.1093/jnci/djp185
DP  - NLM
ET  - 2009/07/02
IS  - 14
KW  - African Americans/*statistics & numerical data
African Continental Ancestry Group/statistics & numerical data
Breast Neoplasms/mortality
Clinical Trials, Phase III as Topic
European Continental Ancestry Group/*statistics & numerical data
Female
*Health Status Disparities
*Healthcare Disparities
Humans
Incidence
Male
Neoplasms/diagnosis/epidemiology/*mortality/pathology/therapy
Predictive Value of Tests
Prevalence
Prognosis
Randomized Controlled Trials as Topic
Risk Factors
LA  - eng
N1  - 1460-2105
Brawley, Otis W
Comment
Editorial
United States
J Natl Cancer Inst. 2009 Jul 15;101(14):970-1. doi: 10.1093/jnci/djp185. Epub 2009 Jun 30.
PY  - 2009
SN  - 0027-8874
SP  - 970-1
ST  - Is race really a negative prognostic factor for cancer?
T2  - J Natl Cancer Inst
TI  - Is race really a negative prognostic factor for cancer?
VL  - 101
ID  - 460
ER  - 

TY  - JOUR
AB  - BACKGROUND: Self-reported cancer screening behaviors are often overreported and may lead to biased estimates of prevalence and of subgroup differences in screening. We examined whether the tendency to give socially desirable responses was associated with concordance between self-reported colorectal cancer (CRC) screening behaviors and medical records. METHODS: Primary care patients (n = 857) age 50 to 74 years completed a mail, face-to-face, or telephone survey that assessed CRC screening and social desirability measured by a short version of the Marlowe-Crowne scale. We used medical records to verify self-reports of fecal occult blood testing (FOBT), sigmoidoscopy, colonoscopy, and barium enema. RESULTS: Social desirability scores were lower for whites versus African Americans, college graduates, and patients reporting no prior screening tests; they were higher for telephone versus mail or face-to-face survey respondents. In univariable logistic regression analysis, social desirability scores were not associated with concordance for FOBT (OR = 1.03, 95% CI = 0.94-1.13), sigmoidoscopy (OR = 0.95, 95% CI = 0.86-1.04), or colonoscopy (OR = 0.99, 95% CI = 0.88-1.11); however, lower social desirability scores were associated with increased concordance for barium enema (OR = 0.87, 95% CI = 0.77-0.99). In multivariable analyses, no associations were statistically significant. CONCLUSION: Social desirability as measured by the Marlowe-Crowne scale was not associated with accuracy of self-reported CRC tests in our sample, suggesting that other explanations for overreporting need to be explored. IMPACT: By understanding sources of response bias, we can improve the accuracy of self-report measures.
AD  - University of Texas-Houston School of Public Health, Division of Health Promotion and Behavioral Sciences, 7000 Fannin Street, Suite 2560, Houston, TX 77030, USA. sally.w.vernon@uth.tmc.edu
AN  - 22144501
AU  - Vernon, S. W.
AU  - Abotchie, P. N.
AU  - McQueen, A.
AU  - White, A.
AU  - Eberth, J. M.
AU  - Coan, S. P.
C2  - PMC3268255
C6  - NIHMS349120 responsibility of the authors and does not necessarily represent the official views of the Centers for Disease Control and Prevention.
DA  - Jan
DO  - 10.1158/1055-9965.Epi-11-0552
DP  - NLM
ET  - 2011/12/07
IS  - 1
KW  - African Americans
Aged
Colorectal Neoplasms/diagnosis/ethnology/*psychology
Early Detection of Cancer/*psychology/statistics & numerical data
European Continental Ancestry Group
Female
Humans
Male
Medical Records
Middle Aged
Randomized Controlled Trials as Topic
*Self Report
*Social Desirability
Surveys and Questionnaires
LA  - eng
N1  - 1538-7755
Vernon, Sally W
Abotchie, Peter N
McQueen, Amy
White, Arica
Eberth, Jan M
Coan, Sharon P
R25 CA057712/CA/NCI NIH HHS/United States
R25 CA057712-12/CA/NCI NIH HHS/United States
U48 DP000057/DP/NCCDPHP CDC HHS/United States
R25CA57712/CA/NCI NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.
Cancer Epidemiol Biomarkers Prev. 2012 Jan;21(1):61-5. doi: 10.1158/1055-9965.EPI-11-0552. Epub 2011 Dec 5.
PY  - 2012
SN  - 1055-9965 (Print)
1055-9965
SP  - 61-5
ST  - Is the accuracy of self-reported colorectal cancer screening associated with social desirability?
T2  - Cancer Epidemiol Biomarkers Prev
TI  - Is the accuracy of self-reported colorectal cancer screening associated with social desirability?
VL  - 21
ID  - 380
ER  - 

TY  - JOUR
AB  - Background Difficulties in recruiting and retaining Asian Americans in traditional research have been well documented. Despite an increasing number of technology-based cancer studies among racial/ethnic minorities, little is still known about potential issues in recruiting and retaining racial/ethnic minority cancer survivors for technology-based intervention research. Objective This discussion article aims to examine issues in recruiting and retaining a group of racial/ethnic minorities-Asian American breast cancer survivors-for a technology-based intervention study. Methods The parent study is an ongoing large-scale, national-scope, technology-based intervention study among a target number of 330 Asian American breast cancer survivors. During the recruitment and retention process, research diaries were written by research team members, and the written records of weekly research team meetings were kept. The written records were analyzed using a content analysis. Then, the themes were used to support the discussion points made in the article. Results There existed subethnic differences in research participation; it was easier to recruit Chinese participants compared with other subethnic groups. The use of culturally matched research team members and multiple languages was essential. Gatekeepers were also elemental for recruitment and retention. Various motivation strategies were needed to retain the participants. Each subethnic group used different communication apps. Finally, trust building was essential to retain the participants in the intervention. Conclusions Researchers need to consider these practical issues in future technology-based intervention research.
AN  - WOS:000503281800006
AU  - Im, E. O.
AU  - Kim, S.
AU  - Xu, S.
AU  - Lee, C.
AU  - Hamajima, Y.
AU  - Inohara, A.
AU  - Chang, K.
AU  - Chee, E.
AU  - Chee, W.
DA  - Jan-Feb
DO  - 10.1097/NCC.0000000000000657
IS  - 1
N1  - 30346330
PY  - 2020
SN  - 0162-220X
SP  - E22-E29
ST  - Issues in Recruiting and Retaining Asian American Breast Cancer Survivors in a Technology-Based Intervention Study
T2  - Cancer Nursing
TI  - Issues in Recruiting and Retaining Asian American Breast Cancer Survivors in a Technology-Based Intervention Study
VL  - 43
ID  - 2801
ER  - 

TY  - JOUR
AB  - Given high rates of smoking among cancer patients, smoking cessation treatment is crucial; yet limited data exist to guide integration of such trials into the oncologic context. In order to determine the feasibility of conducting smoking cessation clinical trials with cancer patients, screening and baseline data from a large randomized placebo-controlled pharmacotherapy trial were analyzed. Descriptive statistics and regression analyses were used to compare enrollees to decliners, describe program enrollees, and assess correlates of confidence in quitting smoking. Out of 14,514 screened patients, 263 (<2%) were eligible; 43 (16%) refused enrollment. Among the eligible patients, 220 (84%) enrolled. Enrollment barriers included smoking rate, medical history/contraindicated medication, lack of interest, and language. Compared to enrollees, decliners were more likely to have advanced cancer. The trial enrolled a sample of 67 (>30%) African Americans; participants had extensive smoking histories; many were highly nicotine dependent; and participants consumed about seven alcoholic beverages/week on average. Head and neck and breast cancer were the most common tumors. About 52 (25%) reported depressive symptoms. A higher level of confidence to quit smoking was related to lower depression and lower tumor stage. Integrating a smoking cessation clinical trial into the oncologic setting is challenging, yet feasible. Recruitment strategies are needed for patients with advanced disease and specific cancers. Once enrolled, addressing participant's depressive symptoms is critical for promoting cessation.
AD  - Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA. elisa.martinez@fccc.edu
AN  - 18758971
AU  - Martinez, E.
AU  - Tatum, K. L.
AU  - Weber, D. M.
AU  - Kuzla, N.
AU  - Pendley, A.
AU  - Campbell, K.
AU  - Ridge, J. A.
AU  - Langer, C.
AU  - Miyamoto, C.
AU  - Schnoll, R. A.
C2  - PMC2628415
C6  - NIHMS66385
DA  - Feb
DO  - 10.1007/s10552-008-9222-x
DP  - NLM
ET  - 2008/09/02
IS  - 1
KW  - Adult
Aged
Aged, 80 and over
Double-Blind Method
Female
Health Promotion
Humans
Male
Middle Aged
Neoplasms/complications/epidemiology/*therapy
*Smoking Cessation
Treatment Outcome
LA  - eng
N1  - 1573-7225
Martinez, Elisa
Tatum, Kristina L
Weber, Dorothy M
Kuzla, Natalie
Pendley, Anna
Campbell, Kirsten
Ridge, John A
Langer, Corey
Miyamoto, Curtis
Schnoll, Robert A
R01 CA095678/CA/NCI NIH HHS/United States
R01 CA095678-06/CA/NCI NIH HHS/United States
P30 CA006927-45/CA/NCI NIH HHS/United States
R01 CA95678/CA/NCI NIH HHS/United States
P30 CA006927/CA/NCI NIH HHS/United States
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Cancer Causes Control. 2009 Feb;20(1):97-104. doi: 10.1007/s10552-008-9222-x. Epub 2008 Aug 29.
PY  - 2009
SN  - 0957-5243 (Print)
0957-5243
SP  - 97-104
ST  - Issues related to implementing a smoking cessation clinical trial for cancer patients
T2  - Cancer Causes Control
TI  - Issues related to implementing a smoking cessation clinical trial for cancer patients
VL  - 20
ID  - 490
ER  - 

TY  - JOUR
AB  - The incidence of prostate cancer among African-Caribbean men in the UK is three times that among men from the majority population. Little attention, however, has been given to the perceptions and experiences of treatment and care of men from these communities with prostate cancer. This qualitative study is the first such investigation, situating men’s accounts within the context of their personal history and social environment. Using a community-based, snowball sampling method, 16 first generation African-Caribbean men living in Central England were recruited. Similarities and divergence in men’s experience were identified through thematic analysis of interview transcripts. Men’s responses to their situation were influenced by aspects of migration and historical context as well as culture. While medical treatment was highly valued, common difficulties were compounded by problems of health professional–patient communication, stereotyping and insensitivity of some staff. Lack of coordination between services and agencies adversely affected the wellbeing of frail men and widowers. Findings suggest the need for a more proactive approach to giving and eliciting information combined with cultural diversity training. More systematic referral procedures and information exchange between African- Caribbean men with prostate cancer and their general practitioner, hospital, social care and voluntary agencies, churches and community organisations are indicated. (PsycINFO Database Record (c) 2016 APA, all rights reserved)
AD  - Nanton, V., Health Sciences Research Institute, Warwick Medical School University of Warwick, Coventry, United Kingdom, CV47AL
AN  - 2011-00912-008
AU  - Nanton, V.
AU  - Dale, J.
DB  - psyh
DO  - 10.1111/j.1365-2354.2009.01155.x
DP  - EBSCOhost
IS  - 1
KW  - prostate cancer
United Kingdom
cancer incidence
patient experiences
African-Caribbean cancer patients
Africa
African Continental Ancestry Group
Aged
Aged, 80 and over
Attitude to Health
Caribbean Region
Communication
Cultural Characteristics
Great Britain
Health Knowledge, Attitudes, Practice
Humans
Male
Middle Aged
Physician-Patient Relations
Prostatic Neoplasms
Qualitative Research
Religion
Social Support
Epidemiology
Neoplasms
Prostate
Blacks
N1  - Health Sciences Research Institute, Warwick Medical School, University of Warwick, Coventry, United Kingdom. Other Publishers: Blackwell Publishing. Release Date: 20110725. Correction Date: 20120618. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: English. Major Descriptor: Epidemiology; Neoplasms; Prostate. Minor Descriptor: Blacks. Classification: Cancer (3293). Population: Human (10); Male (30). Location: England. Age Group: Adulthood (18 yrs & older) (300); Middle Age (40-64 yrs) (360); Aged (65 yrs & older) (380). Methodology: Empirical Study; Interview; Qualitative Study. References Available: Y. Page Count: 10. Issue Publication Date: Jan, 2011. Publication History: Accepted Date: May 20, 2009. Copyright Statement: Blackwell Publishing Ltd. 2009.
Sponsor: Cancer Research UK, United Kingdom. Other Details: Small project award. Recipients: No recipient indicated
PY  - 2011
SN  - 0961-5423
1365-2354
SP  - 62-71
ST  - ‘It don't make sense to worry too much’: The experience of prostate cancer in African‐Caribbean men in the UK
T2  - European Journal of Cancer Care
TI  - ‘It don't make sense to worry too much’: The experience of prostate cancer in African‐Caribbean men in the UK
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2011-00912-008&site=ehost-live&scope=site
ORCID: 0000-0001-9256-3553
v.nanton@warwick.ac.uk
VL  - 20
ID  - 1780
ER  - 

TY  - JOUR
AB  - Randomised controlled trials (RCTs) represent the gold standard methodology for determining effectiveness of healthcare interventions. Poor recruitment to RCTs can threaten external validity and waste resources. An inherent tension exists between safeguarding informed decision-making by participants and maximising numbers enrolled. This study investigated what occurs during informed consent appointments in an ongoing multi-centre RCT in the UK. Objectives were to investigate: 1] how study staff presented study information to participants; 2] what evidence emerged as to how well-informed participants were when proceeding to randomisation or treatment selection; and 3] what aspects of the communication process may facilitate improvements in providing evidence of informed consent. Qualitative analysis of a purposive sample of 23 recruitment appointments from three study centres and involving several recruitment staff applied techniques of thematic, content and conversation analysis (CA). Thematic analysis and CA revealed variation in appointment content and structure. Appointments were mostly recruiter-led or participant-led, and this structure was associated with what evidence emerged as to how participants understood information provided and whether they were in equipoise. Participant-led appointments provided this evidence more consistently. Detailed CA identified communication techniques which, when employed by recruiters, provided evidence as to how participants understood the choices before them. Strategic use of open questions, pauses and ceding the floor in the interaction facilitated detailed and systematic exploration of each participant's concerns and position regarding equipoise. We conclude that the current focus on content to be provided to achieve informed consent should be broadened to encompass consideration of how information is best conveyed to potential participants. A model of tailored information provision using the communication techniques identified and centred on eliciting and addressing participants' concerns is proposed. Use of these techniques is necessary to make potential participants' understanding of key issues and their position regarding equipoise explicit in order to facilitate truly informed consent.
AD  - Department of Social Medicine, University of Bristol, 39 Whatley Road, Clifton, Bristol BS8 2PS, United Kingdom. julia.wade@bristol.ac.uk
AN  - 19364625
AU  - Wade, J.
AU  - Donovan, J. L.
AU  - Lane, J. A.
AU  - Neal, D. E.
AU  - Hamdy, F. C.
DA  - Jun
DO  - 10.1016/j.socscimed.2009.02.023
DP  - NLM
ET  - 2009/04/15
IS  - 11
KW  - Aged
*Communication
Humans
*Informed Consent
Male
Middle Aged
Multicenter Studies as Topic
*Patient Participation
*Patient Selection
Prostatic Neoplasms
*Randomized Controlled Trials as Topic
Tape Recording
United Kingdom
LA  - eng
N1  - 1873-5347
Wade, Julia
Donovan, Jenny L
Lane, J Athene
Neal, David E
Hamdy, Freddie C
G0800800/Medical Research Council/United Kingdom
MC_U145079312/Medical Research Council/United Kingdom
Journal Article
Research Support, Non-U.S. Gov't
England
Soc Sci Med. 2009 Jun;68(11):2018-28. doi: 10.1016/j.socscimed.2009.02.023. Epub 2009 Apr 11.
PY  - 2009
SN  - 0277-9536
SP  - 2018-28
ST  - It's not just what you say, it's also how you say it: opening the 'black box' of informed consent appointments in randomised controlled trials
T2  - Soc Sci Med
TI  - It's not just what you say, it's also how you say it: opening the 'black box' of informed consent appointments in randomised controlled trials
VL  - 68
ID  - 472
ER  - 

TY  - JOUR
AB  - Beginning in the 20th century and continuing into the new millennia, vaccines against numerous diseases have had an unquestioned principal role of both enhancing the quality of life and increasing life expectancy (Rappuoli R, Mandl CW, Black S, De Gregorio E: Vaccines for the twenty-first century society. Nat Rev Immunol 2011, 11:865-872). Despite this success and the development of sophisticated new vaccine technologies, there remain multiple infectious diseases including tuberculosis, malaria and AIDS that await an effective prophylactic vaccine. In addition, there have been recent clinical successes among individuals with cancer using vaccine treatment strategies-so-called therapeutic vaccines-that stimulate tumor specific immunity and increase survival (Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, et al.: Sipuleucel-T immunotherapy for castration-resistant prostate cancer. New Engl J Med 2010, 363:411-422). Here we summarize a new class of vaccines termed Killed But Metabolically Active (KBMA). KBMA vaccines are whole pathogenic or attenuated organisms killed through photochemical inactivation and cannot cause disease, yet retain sufficient metabolic activity to initiate a potent immune response. KBMA vaccines have two broad applications. First, recombinant KBMA vaccines encoding selected antigens relevant to infectious disease or cancer can be used to elicit a desired immune response. In the second application, KBMA vaccines can be derived from attenuated forms of a targeted pathogen, allowing for the presentation of the entire antigenic repertoire to the immune system, of particular importance when the correlates of protection are unknown.
AD  - Aduro BioTech, Inc., Berkeley, CA 94710, United States. tdubensky@adurobiotech.com
AN  - 22608846
AU  - Dubensky, T. W., Jr.
AU  - Skoble, J.
AU  - Lauer, P.
AU  - Brockstedt, D. G.
DA  - Dec
DO  - 10.1016/j.copbio.2012.04.005
DP  - NLM
ET  - 2012/05/23
IS  - 6
KW  - Animals
Cancer Vaccines/immunology
Clinical Trials as Topic
DNA Repair
Ficusin
Humans
Leishmania/immunology
Listeria monocytogenes/genetics/immunology
Ultraviolet Rays
Vaccines, Attenuated/immunology
Vaccines, Inactivated/*immunology/radiation effects/supply & distribution
Vaccines, Synthetic/genetics/immunology
LA  - eng
N1  - 1879-0429
Dubensky, Thomas W Jr
Skoble, Justin
Lauer, Peter
Brockstedt, Dirk G
Journal Article
Review
England
Curr Opin Biotechnol. 2012 Dec;23(6):917-23. doi: 10.1016/j.copbio.2012.04.005. Epub 2012 May 18.
PY  - 2012
SN  - 0958-1669
SP  - 917-23
ST  - Killed but metabolically active vaccines
T2  - Curr Opin Biotechnol
TI  - Killed but metabolically active vaccines
VL  - 23
ID  - 367
ER  - 

TY  - JOUR
AB  - BACKGROUND: Although breast and cervical cancer deaths have declined due to early screening, detection, and more effective treatment, racial and ethnic disparities persist. This paper describes the study design and baseline characteristics of a randomized controlled trial (RCT) evaluating the effectiveness of the Kin Keeper(SM) Cancer Prevention Intervention, a family-focused educational intervention for underserved women applied in a community-based setting to promote health literacy and screening adherence to address cancer disparities. METHODS: Female public health community health workers (CHWs) were trained to administer the intervention. They recruited female clients from their public health program caseload and asked each to assemble two to four adult female family members for the breast and cervical cancer home-based education sessions the CHWs would deliver in English, Spanish or Arabic. We randomized the clients into the kin keeper group (treatment) or the participant client group (control). RESULTS: Complete data were obtained on 514 Black, Latina, and Arab women. Close to half were unemployed and had yearly family income below $20,000. Thirty-four percent had no medical insurance, and 21% had diabetes. Almost 40% had no mammography in the last year. Treatment and control groups were similar on most sociodemographics but showed differences in breast and cervical screening history. CONCLUSIONS: This innovative study demonstrates the implementation of an RCT using community-based participatory research, while delivering cancer prevention education across woman's life span with women not connected to the health care system.
AD  - Department of Obstetrics, Gynecology & Reproductive Biology, College of Human Medicine Michigan State University, East Lansing, MI 48824, USA. Karen.Williams@ht.msu.edu
AN  - 23274402
AU  - Williams, K. P.
AU  - Roman, L.
AU  - Meghea, C. I.
AU  - Penner, L.
AU  - Hammad, A.
AU  - Gardiner, J.
C2  - PMC3594085
C6  - NIHMS431768
DA  - Mar
DO  - 10.1016/j.cct.2012.12.005
DP  - NLM
ET  - 2013/01/01
IS  - 2
KW  - Adult
African Americans
Aged
Arabs
Breast Neoplasms/*diagnosis
*Community Health Workers
Community-Based Participatory Research/methods
Early Detection of Cancer/*methods
*Family
Female
Health Knowledge, Attitudes, Practice/ethnology
Health Literacy
Hispanic Americans
House Calls
Humans
Mammography
Middle Aged
Patient Education as Topic/*methods
United States
Uterine Cervical Neoplasms/*diagnosis
LA  - eng
N1  - 1559-2030
Williams, Karen Patricia
Roman, LeeAnne
Meghea, Cristian Ioan
Penner, Louis
Hammad, Adnan
Gardiner, Joseph
R01 NR011323/NR/NINR NIH HHS/United States
1R01011323/PHS HHS/United States
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Contemp Clin Trials. 2013 Mar;34(2):312-9. doi: 10.1016/j.cct.2012.12.005. Epub 2012 Dec 28.
PY  - 2013
SN  - 1551-7144 (Print)
1551-7144
SP  - 312-9
ST  - Kin KeeperSM: design and baseline characteristics of a community-based randomized controlled trial promoting cancer screening in Black, Latina, and Arab women
T2  - Contemp Clin Trials
TI  - Kin KeeperSM: design and baseline characteristics of a community-based randomized controlled trial promoting cancer screening in Black, Latina, and Arab women
VL  - 34
ID  - 344
ER  - 

TY  - JOUR
AB  - This article assessed the impact of knowledge of breast cancer and type and intensity of participation in a church-based breast cancer education program and other factors on mammography screening among African Americans and Latinas. Logistic regression was used to assess the impact of these factors on self-reported mammography utilization. Passive participation in church-sponsored activities, measured by breast cancer information that was heard, seen, or read, was found to be significantly associated with the likelihood of mammography use among African Americans. Moreover, African Americans who reported hearing, seeing, or reading about mammograms at their churches four or more times were 15 times more likely to report mammography use within the past year than were those who encountered information only once. Messages from pastors and church bulletin announcements were the most significant predictors. An increase in knowledge was not associated with higher mammography use. For Latinas, none of the hypothesized knowledge or participation variables was found to be significant. The results suggest that faith-based breast cancer programs can be effective by adopting tailored strategies to raise awareness about the importance of early detection.
AD  - School of Public Health, University of Illinois at Chicago, Illinois, USA.
AN  - 16760248
AU  - Darnell, J. S.
AU  - Chang, C. H.
AU  - Calhoun, E. A.
DA  - Jul
DO  - 10.1177/1524839906288693
DP  - NLM
ET  - 2006/06/09
IS  - 3 Suppl
KW  - Adult
African Americans
Aged
Aged, 80 and over
Breast Neoplasms/*diagnosis/*ethnology
Community Participation
Cross-Sectional Studies
Female
*Health Knowledge, Attitudes, Practice
Health Promotion/*methods
Hispanic Americans
Humans
Mammography/*statistics & numerical data
Mass Screening
Middle Aged
Prospective Studies
*Religion
LA  - eng
N1  - Darnell, Julie S
Chang, Chih-Hung
Calhoun, Elizabeth A
U50CCU517370/PHS HHS/United States
Journal Article
Research Support, U.S. Gov't, P.H.S.
United States
Health Promot Pract. 2006 Jul;7(3 Suppl):201S-12S. doi: 10.1177/1524839906288693. Epub 2006 Jun 7.
PY  - 2006
SN  - 1524-8399 (Print)
1524-8399
SP  - 201s-12s
ST  - Knowledge about breast cancer and participation in a faith-based breast cancer program and other predictors of mammography screening among African American women and Latinas
T2  - Health Promot Pract
TI  - Knowledge about breast cancer and participation in a faith-based breast cancer program and other predictors of mammography screening among African American women and Latinas
VL  - 7
ID  - 564
ER  - 

TY  - JOUR
AB  - BACKGROUND: Enrollment of minorities in clinical trials remains low. Through a California population-based study of men with early stage prostate cancer, we examined the relationships between race/ethnicity and 1) attitudes, 2) knowledge and 3) willingness to participate in clinical trials. METHODS: From November 2011-November 2012, we identified all incident cases of prostate cancer in African American, Latino, and Asian American men ages 18-75 years, and a random sample of white men diagnosed in 2008, through the California Cancer Registry, living within 60 miles of a site offering ≥ 1 clinical trial. Participants completed a 30-min telephone interview in English, Spanish, or Chinese. In this cross-sectional population-based study, multivariable logistic regression was used to estimate associations between race/ethnicity and 1) attitudes, 2) knowledge and 3) willingness to participate. RESULTS: Of 855 participants, 52% were ≥ 65 years, 42% were white, 24% Latino, 19% African American and 15% Asian American. The majority (81%) had medium-to-high health literacy. Compared to non-Latino white men, African American men were less likely to have above average knowledge of clinical trials (OR=0.55; CI=0.35-0.86), as were Asian American (OR=0.55; CI=0.33-0.93) and Latino men (OR=0.30; CI=0.18-0.48). There were no racial/ethnic differences in willingness to participate. The attitude that "researchers are the main beneficiaries" was negatively associated with willingness (OR=0.63; CI=0.43-0.93); the attitude that "patients are the main beneficiaries" was positively associated with willingness to participate (OR=1.57; CI=1.07-2.29). CONCLUSIONS: Men with early stage prostate cancer are willing to take part in clinical trials and this willingness does not vary by race/ethnicity.
AD  - Department of Medicine, Division of General Internal Medicine,University of CaliforniaSan Francisco, USA; Helen Diller Family Comprehensive Cancer Center,University of CaliforniaSan Francisco, USA. Electronic address: celia.kaplan@ucsf.edu.
Department of Medicine, Division of General Internal Medicine,University of CaliforniaSan Francisco, USA; Helen Diller Family Comprehensive Cancer Center,University of CaliforniaSan Francisco, USA.
Helen Diller Family Comprehensive Cancer Center,University of CaliforniaSan Francisco, USA.
Department of Medicine, Division of General Internal Medicine,University of CaliforniaSan Francisco, USA.
Department of Psychiatry,University of CaliforniaSan Francisco, USA.
Radiation Oncology, University of California, San Francisco, USA.
Helen Diller Family Comprehensive Cancer Center,University of CaliforniaSan Francisco, USA; Department of Medicine, Division of Hematology and Oncology,University of CaliforniaSan Francisco, USA.
AN  - 26435199
AU  - Kaplan, C. P.
AU  - Nápoles, A. M.
AU  - Narine, S.
AU  - Gregorich, S.
AU  - Livaudais-Toman, J.
AU  - Nguyen, T.
AU  - Leykin, Y.
AU  - Roach, M.
AU  - Small, E. J.
DA  - Nov
DO  - 10.1016/j.cct.2015.09.023
DP  - NLM
ET  - 2015/10/06
IS  - Pt B
KW  - African Americans/psychology
Aged
Asian Americans/psychology
California
Continental Population Groups/*psychology
Cross-Sectional Studies
European Continental Ancestry Group/psychology
*Health Knowledge, Attitudes, Practice
Health Literacy
Hispanic Americans/psychology
Humans
Interviews as Topic
Male
Middle Aged
Patient Participation/*psychology
Prostatic Neoplasms/ethnology/*therapy
Research Subjects/*psychology
Socioeconomic Factors
Clinical trials participation
Prostate cancer
LA  - eng
N1  - 1559-2030
Kaplan, Celia P
Nápoles, Anna Maria
Narine, Steven
Gregorich, Steven
Livaudais-Toman, Jennifer
Nguyen, Tung
Leykin, Yan
Roach, Mack
Small, Eric J
Journal Article
Research Support, U.S. Gov't, Non-P.H.S.
United States
Contemp Clin Trials. 2015 Nov;45(Pt B):443-448. doi: 10.1016/j.cct.2015.09.023. Epub 2015 Oct 3.
PY  - 2015
SN  - 1551-7144
SP  - 443-448
ST  - Knowledge and attitudes regarding clinical trials and willingness to participate among prostate cancer patients
T2  - Contemp Clin Trials
TI  - Knowledge and attitudes regarding clinical trials and willingness to participate among prostate cancer patients
VL  - 45
ID  - 230
ER  - 

TY  - JOUR
AB  - The vast majority of (BRCA1/2) genetic testing has been conducted in White women, in particular Ashkenazi Jewish women, with limited information available for Black and Hispanic women. Understanding perspectives of those who are underserved is critical to developing interventions to support inclusive approaches to genetic testing. This qualitative study explored knowledge and perceptions of BRCA1/2 genetic testing among diverse women in South Florida. We also explored participants' information needs. Convenience sampling was used to recruit a diverse group of 15 women with a personal or family history of breast cancer. We conducted semi-structured interviews and used grounded theory method to analyze the data. Five themes were identified: (1) lacking awareness and knowledge of BRCA1/2 genetic testing and results among Black women, (2) perceiving BRCA1/2 genetic testing as beneficial to themselves and a way to be proactive about cancer risk, (3) perceiving BRCA1/2 genetic testing as beneficial to family members, (4) interactions with healthcare providers and the healthcare system that shape genetic testing experiences, and (5) information needs for reducing cancer risk and promoting health. Our findings suggest that diverse underserved women perceived genetic testing as beneficial to themselves and family members. Women needed more information about the BRCA genes and genetic testing, prevention strategies, and the latest breast cancer research. Healthcare providers, particularly nurse practitioners, need to engage diverse high-risk women in discussions about their cancer risk, address unmet information needs, and, in particular, educate Black women about the benefits of pursuing genetic testing.
AD  - Christine E. Lynn College of Nursing, Florida Atlantic University, 777 Glades Road, Boca Raton, FL, 33431, USA. Jonest@health.fau.edu.
College for Design and Social Inquiry, Florida Atlantic University, Boca Raton, Florida, 33431, USA.
Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton, Florida, 33431, USA.
Christine E. Lynn College of Nursing, Florida Atlantic University, 777 Glades Road, Boca Raton, FL, 33431, USA.
School of Nursing, University of Rochester, Rochester, NY, 14642, USA.
Dana Farber Cancer Institute, Boston, Massachusetts, 02215, USA.
AN  - 33555545
AU  - Jones, T.
AU  - Howard, H.
AU  - Freeman-Costin, K.
AU  - Creighton, A.
AU  - Wisdom-Chambers, K.
AU  - Underhill-Blazey, M.
DA  - Feb 8
DO  - 10.1007/s12687-021-00507-6
DP  - NLM
ET  - 2021/02/09
KW  - BRCA1 and BRCA2
Breast cancer
Diverse women
Genetic testing
Personal or family history
Qualitative research
LA  - eng
N1  - Jones, Tarsha
Orcid: 0000-0003-2118-5780
Howard, Heather
Freeman-Costin, Katherine
Creighton, Ana
Wisdom-Chambers, Karen
Underhill-Blazey, Meghan
Journal Article
Germany
J Community Genet. 2021 Feb 8. doi: 10.1007/s12687-021-00507-6.
PY  - 2021
SN  - 1868-310X (Print)
1868-310x
ST  - Knowledge and perceptions of BRCA1/2 genetic testing and needs of diverse women with a personal or family history of breast cancer in South Florida
T2  - J Community Genet
TI  - Knowledge and perceptions of BRCA1/2 genetic testing and needs of diverse women with a personal or family history of breast cancer in South Florida
ID  - 6
ER  - 

TY  - JOUR
AB  - Disparities exist in breast cancer knowledge and education, which tend to influence symptom interpretation and decision to seek screening/care. The present project describes a cohort of women's experiences, knowledge, and health behavior prior to and after a diagnosis of breast cancer. It also studies how knowledge and demographic factors are associated with level of involvement participants had in the treatment of their breast cancer. Women >18 years who have been diagnosed and treated for breast cancer within 10 years were recruited in Pittsburgh, PA, through the Healthy People Cohort Registry, a database of volunteers from the community, and Brooklyn, NY, through the American Cancer Society breast cancer survivor database. Subsequent to institutional ethics approval, a questionnaire was administered by mail and through an electronic interactive format. The study included 124 breast cancer survivors, one-quarter of whom were of African ancestry. Roughly half of the women indicated that their overall knowledge of breast cancer was limited before diagnosis; no significant association between overall knowledge before diagnosis and stage at diagnosis or an active role of the patient in treatment choices was observed. Two-third of the women reported using personal research on internet, books, and other media to increase knowledge on breast cancer after diagnosis; the improvement of knowledge was associated with an active role in therapy choice. White women's self report of breast cancer knowledge prior to diagnosis was higher than that of women of African origin (p = 0.03); the latter experienced more delays in getting results about the diagnosis (p = 0.002), in starting treatment (p = 0.03), and in having treatment available at local facilities (p = 0.007) than white women. White women were more likely to improve their knowledge through their own research (p = 0.08) and through the contribution of their physician (p = 0.06) than women of African origin.There is still a need for addressing breast cancer knowledge among black women, and improvement in physician emotional support and in their contribution to the patient's knowledge is necessary. These efforts may have a positive impact on breast cancer knowledge among black women in the US.
AN  - 24022520
AU  - Taioli, E.
AU  - Joseph, G. R.
AU  - Robertson, L.
AU  - Eckstein, S.
AU  - Ragin, C.
C2  - PMC3952028
C6  - NIHMS523534
DA  - Mar
DO  - 10.1007/s13187-013-0540-7
DP  - NLM
ET  - 2013/09/12
IS  - 1
KW  - Adult
Aged
Breast Neoplasms/*diagnosis/*prevention & control/psychology
Cross-Sectional Studies
*Decision Making
Female
Follow-Up Studies
*Health Behavior
*Health Knowledge, Attitudes, Practice
Humans
Mammography
Middle Aged
Patient Participation
Surveys and Questionnaires
Survivors/*psychology
LA  - eng
N1  - 1543-0154
Taioli, Emanuela
Joseph, Gail R
Robertson, Linda
Eckstein, Stacy
Ragin, Camille
KL2 TR000146/TR/NCATS NIH HHS/United States
R13 CA130596/CA/NCI NIH HHS/United States
R13 MD007156/MD/NIMHD NIH HHS/United States
UL1 TR000005/TR/NCATS NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
J Cancer Educ. 2014 Mar;29(1):44-9. doi: 10.1007/s13187-013-0540-7.
PY  - 2014
SN  - 0885-8195 (Print)
0885-8195
SP  - 44-9
ST  - Knowledge and prevention practices before breast cancer diagnosis in a cross-sectional study among survivors: impact on patients' involvement in the decision making process
T2  - J Cancer Educ
TI  - Knowledge and prevention practices before breast cancer diagnosis in a cross-sectional study among survivors: impact on patients' involvement in the decision making process
VL  - 29
ID  - 318
ER  - 

TY  - JOUR
AB  - This correlational pilot study measured limitations of prostate cancer screening, using a revised Knowledge of Prostate Cancer Questionnaire. Knowledge in 81 low-income men is reported. The Knowledge About Prostate Cancer Screening Questionnaire consists of 12 questions, with scores ranging from 0 to 12. Concepts measured include limitations, symptoms, risk factors, and screening age guidelines. The Total Knowledge Score had a mean of 6.60, with a standard deviation of 3.00, indicating that knowledge was low. Half of the men knew that 'some treatments for prostate cancer can make it harder for men to control their urine. 'More than half of the men knew that, 'some treatments for prostate cancer can cause problems with a man's ability to have sex.' Married men, low-income men, and Caucasian men had significantly lower Total Knowledge Scores than unmarried, higher income, and African American men. Implications for practice and research are discussed.
AD  - University of Louisville School of Nursing, 555 S. Floyd St., K Wing, Louisville, KY 40202; sally.weinrich@louisville.edu
AN  - 106599678. Language: English. Entry Date: 20050401. Revision Date: 20150820. Publication Type: Journal Article
AU  - Weinrich, S. P.
AU  - Seger, R.
AU  - Miller, B. L.
AU  - Davis, C.
AU  - Kim, S.
AU  - Wheeler, C.
AU  - Weinrich, M.
DB  - CINAHL Complete
DP  - EBSCOhost
IS  - 6
KW  - Cancer Screening
Health Knowledge -- Evaluation
Prostatic Neoplasms -- Prevention and Control
Adult
Bivariate Statistics
Chi Square Test
Coefficient Alpha
Confidence Intervals
Construct Validity
Content Validity
Correlational Studies
Descriptive Statistics
Education, Continuing (Credit)
Funding Source
Kentucky
Male
Marital Status
Middle Age
Multiple Regression
Multivariate Analysis
Pilot Studies
Poverty
Prostatic Neoplasms -- Education
Questionnaires
Race Factors
Research Subject Recruitment
T-Tests
Test-Retest Reliability
Human
N1  - CEU; exam questions; questionnaire/scale; research; tables/charts. Journal Subset: Core Nursing; Double Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Nursing; Peer Reviewed; USA. Grant Information: American Cancer Society grant TURSG-01-074-01-PBP; and the Commonwealth of Kentucky Research Challenge Trust Fund. NLM UID: 7805358.
PMID: NLM15632783.
PY  - 2004
SN  - 0162-220X
SP  - 442-453
ST  - Knowledge of the limitations associated with prostate cancer screening among low-income men
T2  - Cancer Nursing
TI  - Knowledge of the limitations associated with prostate cancer screening among low-income men
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106599678&site=ehost-live&scope=site
VL  - 27
ID  - 1989
ER  - 

TY  - JOUR
AB  - The goal of this study was to understand the unique needs and barriers to breast cancer control among African American women in the rural South. This population experiences barriers that surpass that of other minorities. Researchers conducted 6 focus groups to assess barriers of minority women in Mississippi toward breast cancer prevention and clinical trials. These women had little knowledge of treatment options and negative perceptions of screening and clinical trial participation. This research equips others to identify new health education strategies. Conclusions also provide insight into prevention for other minority populations, such as Latina, Asian, and American Indian women.
AD  - Mississippi Department of Education, Jackson, USA. alwilliams@mde.k12.ms.us
AN  - 19525705
AU  - Avis-Williams, A.
AU  - Khoury, A.
AU  - Lisovicz, N.
AU  - Graham-Kresge, S.
DA  - Jul-Sep
DO  - 10.1097/FCH.0b013e3181ab3bbb
DP  - NLM
ET  - 2009/06/16
IS  - 3
KW  - Adult
Breast Neoplasms/*diagnosis/*prevention & control
Clinical Trials as Topic
Female
Focus Groups
*Health Knowledge, Attitudes, Practice
Health Services Accessibility
Humans
Mass Screening
*Medically Underserved Area
Middle Aged
Mississippi
Patient Participation
Risk Factors
Rural Population
LA  - eng
N1  - 1550-5057
Avis-Williams, Amanda
Khoury, Amal
Lisovicz, Nedra
Graham-Kresge, Susan
Journal Article
Research Support, Non-U.S. Gov't
United States
Fam Community Health. 2009 Jul-Sep;32(3):238-46. doi: 10.1097/FCH.0b013e3181ab3bbb.
PY  - 2009
SN  - 0160-6379
SP  - 238-46
ST  - Knowledge, attitudes, and practices of underserved women in the rural South toward breast cancer prevention and detection
T2  - Fam Community Health
TI  - Knowledge, attitudes, and practices of underserved women in the rural South toward breast cancer prevention and detection
VL  - 32
ID  - 465
ER  - 

TY  - JOUR
AB  - Background Effective strategies are needed to actively encourage Black women in Canada to adhere to breast and cervical cancer screening and follow-up. In this study, we describe "Ko-Pamoja," a pilot peer education program for breast and cervical cancer screening targeted specifically at Black women in Toronto, Canada. Methods We used an Afrocentric lens to design the program, whose purpose was to increase awareness of cancer susceptibility and the benefits of screening for breast and cervical cancer for Black women. Participants were recruited through three Black-predominant churches. We used pre- and post-session questionnaires to assess changes in participant awareness of cancer susceptibility and screening guidelines, and changes in screening self-efficacy. Results 30 women attended sessions. Ko-Pamoja was able to increase awareness of cancer susceptibility, awareness of screening guidelines, and screening self-efficacy. Two months after the last session, four women had been screened for breast cancer at a participating mammogram site. Conclusions Building on the successes of Ko-Pamoja, future versions are being developed in the region. These versions will be adapted to take into account our lessons learned while maintaining the Afrocentric lens and community-focussed approach, in order to promote cancer screening and ultimately improve outcomes.
AN  - WOS:000415211000005
AU  - Lofters, A.
AU  - Jain, A.
AU  - Siu, W. N.
AU  - Kyte, M.
AU  - Lee-Foon, N.
AU  - Scott, F.
AU  - Nnorom, O.
DA  - Nov
DO  - 10.1007/s10552-017-0920-0
IS  - 11
N1  - SI
28685277
PY  - 2017
SN  - 0957-5243
SP  - 1207-1218
ST  - Ko-Pamoja: the feasibility of a lay health educator-led breast and cervical screening program for Black women in Ontario, Canada (short report)
T2  - Cancer Causes & Control
TI  - Ko-Pamoja: the feasibility of a lay health educator-led breast and cervical screening program for Black women in Ontario, Canada (short report)
VL  - 28
ID  - 2884
ER  - 

TY  - JOUR
AN  - 19211449
AU  - Schmidt, C.
DA  - Feb 18
DO  - 10.1093/jnci/djp015
DP  - NLM
ET  - 2009/02/13
IS  - 4
KW  - African Americans/statistics & numerical data
Breast Neoplasms/mortality
Clinical Trials as Topic
Colorectal Neoplasms/mortality
Community-Institutional Relations
Education, Medical, Graduate/economics/trends
Exercise
Female
*Health Status Disparities
*Healthcare Disparities
Humans
Male
*Medical Oncology
*Medically Underserved Area
Minority Groups/*statistics & numerical data
Obesity/prevention & control
Patient Participation
Prostatic Neoplasms/mortality
Societies, Medical
Socioeconomic Factors
United States/epidemiology
Workforce
LA  - eng
N1  - 1460-2105
Schmidt, Charlie
News
United States
J Natl Cancer Inst. 2009 Feb 18;101(4):224-5, 227. doi: 10.1093/jnci/djp015. Epub 2009 Feb 10.
PY  - 2009
SN  - 0027-8874
SP  - 224-5, 227
ST  - Komen/ASCO program aims to swell ranks of minority oncologists
T2  - J Natl Cancer Inst
TI  - Komen/ASCO program aims to swell ranks of minority oncologists
VL  - 101
ID  - 478
ER  - 

TY  - JOUR
AB  - The KEEPS trial is a randomized, double‐blind, controlled trial designed to test whether menopausal hormone therapy initiated within 3 years of menopause can delay progression of atherosclerosis, as assessed by common carotid artery intirna media thickness (CIMT, primary outcome)and coronary artery calcium (CAC, secondary outcome) over 4 years of treatment. Additional outcomes of interest include cognitive function, menopausal symptoms, quality of life, lipids/CVD biomarker status, and mammographic breast density. Women (n = 727) were randomized to the following regimens: 0.45 mg/d oral conjugated estrogen (CEE), 0.05 mg/d transdermal estradiol, both with cyclic oral micronized progesterone (200 mg/d xl2 days/month), or placebo. Women 42‐58 years old and 6‐36 months from final menses were eligible. Exclusion criteria included: hysterectomy, body mass index (BMI) >35 kg2, LDL cholesterol >160 mg/dL, CAC >50 Agatston Units at baseline, smoking >10 cigarettes/day, and history of diabetes, myocardial infarction, stroke, thromboembolic disease or cancer. Mean age (SD) at enrollment was 52.7 (2.6) years and mean years (SD) from onset of menopause were 1.8 (0.8). About 15% of participants self‐identified as African American or Hispanic, and ~80% were Caucasian. More than two‐thirds had a college education, a similar percentage had moderate‐to‐severe vasomotor symptoms, and mean BMI was 26.2 kg/m2. KEEPS participants were at overall lower risk of CVD than Women's Health Initiative (WHI) participants: lower mean systolic BP, lower mean BMI, more favorable lipid parameters (all P values <0.01). At baseline, CVD risk factors, as well as CIMT and CAC values, were comparable across groups. Mean baseline CIMT for all groups was 0.712 +/‐ 0.09 mm. Thus, KEEPS has several design features that are distinctly different from the WHI design, including: enrollment of younger and generally healthier perimenopausal and recently menopausal women; administration of a lower dose of CEE (0.45 mg daily) versus 0.625 mg administered in WHI; one arm that includes estradiol and a transdermal route of delivery; cyclic administration of natural progesterone versus continuous therapy with synthetic medroxyprogesterone acetate in WHI; and inclusion of only those women undergoing natural and non‐surgical menopause. KEEPS findings that will be presented at this plenary session include the effects of the interventions on atherosclerosis progression by CIMT and CAC and effects on cognitive function assessed by a comprehensive and detailed battery of cognitive tests.
AN  - CN-01067858
AU  - Manson, J. E.
DO  - 10.1097/gme.0b013e3182739e2f
IS  - 12
KW  - *estrogen
*menopause
*population
*prevention study
*society
African American
Arm
Atherosclerosis
Biological marker
Body mass
Breast
Calcium
Caucasian
Cerebrovascular accident
Cognition
College
Common carotid artery
Conjugated estrogen
Controlled study
Coronary artery
Density
Diabetes mellitus
Education
Estradiol
Female
Health
Heart infarction
Hispanic
Hormonal therapy
Human
Hysterectomy
Lipid
Low density lipoprotein
Low density lipoprotein cholesterol
Medroxyprogesterone acetate
Menstruation
Neoplasm
Parameters
Placebo
Progesterone
Quality of life
Risk
Risk factor
Smoking
Statistical significance
Therapy
Thickness
Thromboembolism
Transdermal drug administration
M3  - Journal: Conference Abstract
PY  - 2012
SP  - 1365
ST  - The kronos early estrogen prevention study (KEEPS): rationale, design & baseline characteristics of the study population
T2  - Menopause.
TI  - The kronos early estrogen prevention study (KEEPS): rationale, design & baseline characteristics of the study population
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01067858/full
VL  - 19
ID  - 1575
ER  - 

TY  - JOUR
AB  - Purpose/Objective(s): Sexual dysfunction is common in prostate cancer survivors after radiation therapy. Preclinical and small studies suggested benefit of L‐arginine based nutritional supplementation (LAS) to improve erectile dysfunction(ED). We completed a placebo‐controlled trial evaluating a commercially available LAS. Materials/Methods: Eight‐week, randomized, placebo‐controlled double‐ blinded trial. Eligibility: prostate cancer survivors > 6 months after active treatment, no active cancer, successful sexual activity prior to radiation therapy, self‐identified concern with sexual quality of life, and agree to one intercourse attempt weekly during study. Serum testosterone normal range if prior androgen suppression. Patients randomized to two dose levels of LAS or placebo (Arm 1: 6 capsules placebo bid; Arm 2: 3 capsules LAS and 3 capsules placebo BID; Arm 3: 6 capsules LAS bid). Each capsule contains L‐arginine (500 mg), gingko biloba (8.3 mg), ginseng (33.3 mg), and multivitamins. Stratification by age (>/< 65 years) and current usage PDE‐5I. Third party analysis verified LAS contents. Primary outcome: erectile function score from International Index Erectile Function (IIEF) at 8 weeks. Secondary outcomes: other subscale scores from IIEF, Expanded Prostate Cancer Index Composite (EPIC‐26), a Sexual Encounter Profile, general efficacy questions (GEQ) for successful intercourse and improved erections (yes/ no), FACT‐Prostate, and retention, adherence, and toxicity measures. Assessments made at baseline, 4 and 8 weeks. Results: One hundred forty patients between October 2010 and November 2013; Arm 1 ‐ 48 patients, Arm 2 ‐ 45 patients, and Arm 3 ‐ 47 patients. Ages ranged from 48 to 80 with a median of 68 years. Sixty‐four percent of the patients were white, 34% black, 1% Hispanic, and 1% Asian. Eighty‐five percent were married. Forty‐nine (35%) used concurrent PDE‐5I. Median BMI was 29.6 overweight). Overall retention was 79% at 8 weeks and not different between arms (p = 0.85). Self‐reported compliance through returned diaries was 96%. No SAE possibly or definitely related to LAS occurred. The most common toxicity: grade 1 to 2 dyspepsia in 8 cases total. Mean IIEF baseline score of avg 13.2 across 3 arms suggesting moderate ED. No difference in IIEF erectile function domain (primary end‐point) was seen in LAS treatment arms at 8 wks (p = 0.12). No benefit was seen at high or low dose levels compared to placebo for EPIC‐26, IIEF all domains, and all FACT scales (all p > 0.1). For the GEQ, no difference with placebo; approximately 20‐30% of patients on all 3 arms felt improvement with the LAS or placebo suggesting placebo effect. Conclusions: In a post‐radiation therapy prostate cancer population with moderate erectile dysfunction, L‐arginine based supplementation did not show benefit versus placebo. Toxicity was minimal. Based on these results, further study of this supplement is not warranted in this population.
AN  - CN-01056719
AU  - Urbanic, J. J.
AU  - Case, D.
AU  - Lesser, G.
AU  - Enevold, G.
AU  - Naughton, M.
AU  - Danhauer, S.
AU  - Rapp, S.
AU  - Vitolins, M.
AU  - Johnson, S.
AU  - McCollough, M.
AU  - et al.
IS  - 1 SUPPL. 1
KW  - *cancer survivor
*dose calculation
*human
*oncology
*prostate cancer
*quality of life
*radiotherapy
*society
Androgen
Arginine
Arm
Asian
Controlled study
Diet supplementation
Dyspepsia
Erectile dysfunction
Ginkgo biloba
Ginseng
Hispanic
Implantable cardioverter defibrillator
International Index of Erectile Function
Low drug dose
Male
Married person
Multivitamin
Neoplasm
Obesity
Patient
Phosphodiesterase V
Placebo
Placebo effect
Population
Prostate
Sexual behavior
Sexual dysfunction
Sexual intercourse
Stratification
Supplementation
Testosterone blood level
Toxicity
M3  - Journal: Conference Abstract
PY  - 2014
SP  - S86‐S87
ST  - L-argininee based nutritional supplement did not improve erectile function or quality of life in prostate cancer survivors previously treated with radiation therapy: results of CCOP research base protocol 98110-A randomized phase 2 dose finding study
T2  - International journal of radiation oncology biology physics.
TI  - L-argininee based nutritional supplement did not improve erectile function or quality of life in prostate cancer survivors previously treated with radiation therapy: results of CCOP research base protocol 98110-A randomized phase 2 dose finding study
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01056719/full
VL  - 90
ID  - 1630
ER  - 

TY  - JOUR
AB  - This study examines the lack of race-adjusted measurements for renal function in eligibility criteria for participation of black men in prostate cancer trials.
AD  - Dana-Farber/Brigham and Women's Cancer Center and Harvard Medical School, Boston, Massachusetts.
Harvard Radiation Oncology Program, Boston, Massachusetts.
AN  - 29423505
AU  - Vastola, M. E.
AU  - Yang, D. D.
AU  - Muralidhar, V.
AU  - Mahal, B. A.
AU  - Lathan, C. S.
AU  - McGregor, B. A.
AU  - Nguyen, P. L.
C2  - PMC5885818 Bristol-Myers Squibb and Eli Lilly and Company and has received a philanthropic grant from CVS, all outside the submitted work. Dr McGregor reports receiving personal fees from Seattle Genetics, Bayer, Astellas, Astra-Zeneca, Genetech, and Exelixis, all outside the submitted work. Dr Nguyen reports receiving personal fees from Ferring Pharmaceuticals, Medivation/Astellas, GenomeDx Biosciences, Dendreon, Nanobiotix, Augmenix, Blue Earth, and Bayer and received research support for clinical trials from Astellas Pharma and Janssen Pharmaceuticals for his affiliated institutions, all outside the submitted work. No other conflicts were reported.
DA  - Mar 1
DO  - 10.1001/jamaoncol.2017.4658
DP  - NLM
ET  - 2018/02/10
IS  - 3
KW  - *African Americans/statistics & numerical data
Artifacts
*Clinical Laboratory Techniques/standards
*Clinical Trials as Topic/methods/statistics & numerical data
Creatinine/analysis/blood
Eligibility Determination/*methods
Humans
Kidney Function Tests/standards
Leukocyte Count/standards
Male
Neutropenia/blood/diagnosis/ethnology
Neutrophils/pathology
*Patient Participation/methods/statistics & numerical data
Patient Selection
*Prostatic Neoplasms/blood/ethnology/physiopathology
LA  - eng
N1  - 2374-2445
Vastola, Marie E
Yang, David D
Muralidhar, Vinayak
Mahal, Brandon A
Lathan, Christopher S
McGregor, Bradley A
Nguyen, Paul L
Letter
JAMA Oncol. 2018 Mar 1;4(3):413-414. doi: 10.1001/jamaoncol.2017.4658.
PY  - 2018
SN  - 2374-2437 (Print)
2374-2437
SP  - 413-414
ST  - Laboratory Eligibility Criteria as Potential Barriers to Participation by Black Men in Prostate Cancer Clinical Trials
T2  - JAMA Oncol
TI  - Laboratory Eligibility Criteria as Potential Barriers to Participation by Black Men in Prostate Cancer Clinical Trials
VL  - 4
ID  - 135
ER  - 

TY  - JOUR
AB  - A convenience sample of Jamaican and Haitian men completed the translated versions of the Prostate Health Questionnaire. The findings support that the translated survey is comprehensive, has internal consistency, and is reliable over time when used for these populations.
AD  - Associate Professor, Barry University School of Nursing, Miami Shores, FL
AN  - 106365730. Language: English. Entry Date: 20061124. Revision Date: 20150819. Publication Type: Journal Article
AU  - Kleier, J. A.
DB  - CINAHL Complete
DP  - EBSCOhost
IS  - 4
KW  - Black Persons -- Florida
Health Promotion
Instrument Construction
Instrument Validation
Prostatic Neoplasms -- Prevention and Control
Questionnaires
Translations
Aged
Coefficient Alpha
Descriptive Statistics
Florida
Funding Source
Immigrants
Middle Age
Pearson's Correlation Coefficient
Post Hoc Analysis
Research Subject Recruitment
Summated Rating Scaling
Test-Retest Reliability
Validation Studies
West Indies
Human
N1  - research; tables/charts. Commentary: Sublett CM. Translating evidence into clinical practice. Critique of 'language adaptation and testing of the Prostate Health Questionnaire for Jamaican and Haitian men'. (UROL NURS) Aug2006; 26 (4): 311-313. Journal Subset: Core Nursing; Double Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Nursing; Peer Reviewed; USA. Instrumentation: Prostate Health Questionnaire (Fearing et al). Grant Information: Supported by a grant from the Society of Urologic Nurses and Associates. NLM UID: 8812256.
PMID: NLM16939048.
PY  - 2006
SN  - 1053-816X
SP  - 304-310
ST  - Language adaptation and testing of the Prostate Health Questionnaire for Jamaican and Haitian men
T2  - Urologic Nursing
TI  - Language adaptation and testing of the Prostate Health Questionnaire for Jamaican and Haitian men
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106365730&site=ehost-live&scope=site
VL  - 26
ID  - 1990
ER  - 

TY  - JOUR
AB  - Background and aims: Breast cancer-related death is attributable mainly to metastasis. Inflammatory breast cancer (IBC) is an infrequent subtype of breast cancer that shows a relatively high rate of metastasis. In this study, we aimed to compare the metastatic patterns and prognostic outcomes of IBC and non-inflammatory breast cancer (non-IBC). Methods: We extracted data between 2010 and 2014 from the Surveillance, Epidemiology and End Results (SEER) database. The Chi-square test and Fisher’s exact test were used to compare the categorical parameters among different groups. Logistic regression was applied for multivariate analysis. The Kaplan–Meier method and multivariate Cox regression models were performed to analyze prognosis. Results: We enrolled 233,686 breast cancer patients between 2010 and 2014 in our research, including 2806 IBC and 230,880 non-IBC patients. Compared with the non-IBC group, the IBC group tended to have a higher incidence of the human epidermal growth factor receptor 2 positive (HER2+) and triple-negative breast cancer (TNBC) subtypes, older age, a higher rate of unmarried status, a lower incidence of black race, poorer tumor differentiation, larger tumor sizes, and a higher frequency of regional lymph node invasion. IBC and non-IBC shared similar trends in molecular subtypes among different metastatic organs. The percentage of the hormone receptor positive (HR+)/human epidermal growth factor receptor 2 negative (HER2–) subtype decreased gradually in patients with lung (IBC 42.5%, non-IBC 55.7%), distant lymph node (IBC 41.5%, non-IBC 54.6%), liver (IBC 31.1%, non-IBC 46.7%), and brain (IBC 30.6%, non-IBC 47.9%) metastases compared with that in patients with bone (IBC 50.8%, non-IBC 69.0%) metastasis in both cohorts. In both the IBC and non-IBC cases, the proportion of visceral metastases increased in the TNBC subtype, especially brain metastasis (IBC 26.4%, non-IBC 21.2%), which had the largest increase. The frequencies of all sites (bone, lung, liver, brain, and distant lymph node) in IBC were much higher than those in non-IBC (bone: IBC 21.1%, non-IBC 3.0%; lung: IBC 11.4%, non-IBC 1.4%; liver: IBC 9.6%, non-IBC 1.2%; brain: IBC 2.6%, non-IBC 0.3%; distant lymph node: IBC 12.9%, non-IBC 1.0%). The most frequent bi-site metastasis was the bone and liver (IBC 2.5%, non-IBC 0.3%), and the most frequent tri-site combination was the bone, lung, and liver (IBC 1.1%, non-IBC 0.2%). Kaplan–Meier curves and multivariate Cox regression models suggested that the IBC cohort had poorer overall survival [hazard ratio (HR) 1.602, 95% confidence interval (CI) 1.496–1.716, p < 0.001] and breast cancer-specific survival (HR 1.511, 95% CI 1.402–1.628, p < 0.001) than the non-IBC cohort. Furthermore, univariate and multivariate analyses indicated that IBC was an independent prognostic factor in patients with different metastatic sites. Conclusion: IBC and non-IBC patients presented with different metastatic frequencies, clinical features and prognostic outcomes. Our findings provide more information for therapeutic decision making and clinical study designs.
AD  - Z. Wang, Department of General Surgery, Comprehensive Breast Health Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Ruijin Er Road, Shanghai, China
AU  - Wang, Z.
AU  - Wang, H.
AU  - Ding, X.
AU  - Chen, X.
AU  - Shen, K.
DB  - Embase
DO  - 10.1177/1758835920932674
KW  - epidermal growth factor receptor 2
adult
aged
article
Black person
bone metastasis
brain metastasis
cancer patient
cancer prognosis
cancer registry
cancer research
cancer specific survival
cohort analysis
female
human
human epidermal growth factor receptor 2 negative breast cancer
human epidermal growth factor receptor 2 positive breast cancer
inflammatory breast cancer
liver metastasis
lung metastasis
lymph node
lymph node metastasis
major clinical study
male
outcome assessment
overall survival
retrospective study
trend study
triple negative breast cancer
tumor differentiation
tumor volume
LA  - English
M3  - Article
N1  - L2005171374
2020-07-01
2020-07-14
PY  - 2020
SN  - 1758-8359
1758-8340
ST  - A large-cohort retrospective study of metastatic patterns and prognostic outcomes between inflammatory and non-inflammatory breast cancer
T2  - Therapeutic Advances in Medical Oncology
TI  - A large-cohort retrospective study of metastatic patterns and prognostic outcomes between inflammatory and non-inflammatory breast cancer
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L2005171374&from=export
http://dx.doi.org/10.1177/1758835920932674
VL  - 12
ID  - 820
ER  - 

TY  - JOUR
AB  - Increasing minority participation in cancer research is an ethical and statistical necessity for gaining population-specific knowledge of cancer prevention, screening, and treatment. Locating and recruiting eligible and willing minority participants presents unique structural and cultural/ linguistic challenges. Community Based Participatory Research provides a viable set of principles for facilitating recruitment in hard-to-recruit communities. We focus on the specific challenge of recruiting and engaging low-income and underinsured Latina women in cancer prevention education research, and present community-based strategies used to recruit women into a recently completed study in Arizona, Juntas en la Salud (Together in Health). Community representatives and promotoras' (Latino community health educators) involvement in site identification, individual recruitment, and development of strategies and materials for the interventions built engagement and trust. These strategies resulted in enrollment of an especially low-income, underinsured population. To emphasize the degree to which a particularly underserved population was recruited, we present data comparing demographic and screening profiles of enrollees to the general population of Latinos in Arizona. (C) 2008 Published by Elsevier Inc.
AN  - WOS:000262603800009
AU  - Larkey, L. K.
AU  - Gonzalez, J. A.
AU  - Mar, L. E.
AU  - Glantz, N.
DA  - Jan
DO  - 10.1016/j.cct.2008.08.003
IS  - 1
N1  - 18775798
PY  - 2009
SN  - 1551-7144
SP  - 47-54
ST  - Latina recruitment for cancer prevention education via Community Based Participatory Research strategies
T2  - Contemporary Clinical Trials
TI  - Latina recruitment for cancer prevention education via Community Based Participatory Research strategies
VL  - 30
ID  - 3157
ER  - 

TY  - JOUR
AB  - PURPOSE: Latinas and African-Americans with breast cancer, especially those of lower socioeconomic status and acculturation, have been underrepresented in studies assessing treatment satisfaction, decision-making, and quality of life. A study was designed to recruit a large and representative sample of these subgroups. MATERIALS AND METHODS: Incident cases were selected by rapid case ascertainment (RCA) in the Los Angeles Surveillance, Epidemiology, and End Results Registry from 2005 to 2006, with oversampling of Latinas and African-Americans. Patients were mailed a questionnaire and $10 incentive 5 to 6 months after diagnosis; nonrespondents were contacted by telephone. Multivariate analysis was used to assess possible response bias. The RCA definition of Hispanic origin was validated by self-reports. The Short Acculturation Scale for Hispanics index for Latina respondents was used. RESULTS: One thousand six hundred and ninety-eight eligible breast cancer cases were selected and 1,223 participated, for a response rate of 72.0%, which varied little by race/ethnicity. Age, race/ethnicity, and clinical factors were not associated with response; however, respondents were slightly more likely to be married and from higher socioeconomic status census tracts than nonrespondents. The RCA definition of Hispanic identity was highly sensitive (94.6%) and specific (90.0%). Lower acculturation was associated with lower education and literacy among Latinas. DISCUSSION: High response rates among all subgroups were achieved due to the use of RCA, an incentive, extensive telephone follow-up, a native Spanish-speaking interviewer, and a focused questionnaire. The low acculturation index category identified a highly vulnerable subgroup. This large sample representing subgroups with greater problems will provide a basis for developing better interventions to assist these women.
AD  - Department of Preventive Medicine, Keck School of Medicine, University of Southern California, USC/Norris Comprehensive Cancer Center, Los Angeles, CA 90089-9175, USA. ahamilt@usc.edu
AN  - 19549806
AU  - Hamilton, A. S.
AU  - Hofer, T. P.
AU  - Hawley, S. T.
AU  - Morrell, D.
AU  - Leventhal, M.
AU  - Deapen, D.
AU  - Salem, B.
AU  - Katz, S. J.
C2  - PMC4147726
C6  - NIHMS589868
DA  - Jul
DO  - 10.1158/1055-9965.Epi-09-0238
DP  - NLM
ET  - 2009/06/25
IS  - 7
KW  - *Acculturation
Adult
Aged
Breast Neoplasms/epidemiology/*ethnology/psychology/therapy
Educational Status
Female
Hispanic Americans/psychology/*statistics & numerical data
Humans
Logistic Models
Los Angeles/epidemiology
Middle Aged
Outcome Assessment, Health Care
Population Surveillance/*methods
Psychological Tests
Registries
SEER Program
*Social Identification
Surveys and Questionnaires
Young Adult
LA  - eng
N1  - 1538-7755
Hamilton, Ann S
Hofer, Timothy P
Hawley, Sarah T
Morrell, Donna
Leventhal, Meryl
Deapen, Dennis
Salem, Barbara
Katz, Steven J
R01 CA088370/CA/NCI NIH HHS/United States
N01-PC-35139/PC/NCI NIH HHS/United States
K05 CA111340/CA/NCI NIH HHS/United States
N02 PC015105/PC/NCI NIH HHS/United States
U55/CCR921930/PHS HHS/United States
N01PC35136/CA/NCI NIH HHS/United States
N01PC35139/CA/NCI NIH HHS/United States
N01-PC-35136/PC/NCI NIH HHS/United States
R01 CA109696/CA/NCI NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.
Cancer Epidemiol Biomarkers Prev. 2009 Jul;18(7):2022-9. doi: 10.1158/1055-9965.EPI-09-0238. Epub 2009 Jun 23.
PY  - 2009
SN  - 1055-9965 (Print)
1055-9965
SP  - 2022-9
ST  - Latinas and breast cancer outcomes: population-based sampling, ethnic identity, and acculturation assessment
T2  - Cancer Epidemiol Biomarkers Prev
TI  - Latinas and breast cancer outcomes: population-based sampling, ethnic identity, and acculturation assessment
VL  - 18
ID  - 461
ER  - 

TY  - JOUR
AB  - Examples of cancer prevention and screening trials in the Southwest are reviewed as a platform for highlighting gaps in research on Latino recruitment. Three trials are described, using "message/source/channel" categories as a framework. Each trial engaged community members to facilitate recruitment and developed tailored strategies to meet challenges emerging after recruitment began. Although we affirm that culturally relevant messages, community member referral networks, and adjustment to community realities seem important to Latino recruitment, current anecdotal and research findings do not allow evidence-based recommendations to be made. We suggest a research agenda to further illuminate critical factors for successful Latino recruitment. Published by Elsevier Inc.
AN  - WOS:000253329700006
AU  - Larkey, L. K.
AU  - Ogden, S. L.
AU  - Tenorio, S.
AU  - Ewell, T.
DA  - Feb
DO  - 10.1016/j.apnr.2006.09.003
IS  - 1
N1  - 18226761
PY  - 2008
SN  - 0897-1897
SP  - 30-39
ST  - Latino recruitment to cancer prevention/screening trials in the Southwest: setting a research agenda
T2  - Applied Nursing Research
TI  - Latino recruitment to cancer prevention/screening trials in the Southwest: setting a research agenda
VL  - 21
ID  - 3175
ER  - 

TY  - JOUR
AB  - African-Americans experience a disproportionate share of thoracic cancer burden compared to Whites. Low socioeconomic status (SES) and race are factors in low clinical trial enrollment, accounting for the disparities between African-Americans and Whites. Less than 3% of newly diagnosed cancer patients enroll in clinical trials, and of that number, only 10% represent ethnic minorities. The value of clinical trials research is not generalizable without sufficient representation by ethnic minorities. Patient navigation, an intervention designed to ensure timely and efficient access to healthcare, may improve clinical trial enrollment among African-Americans in lung and esophageal trials by influencing a patient's perception of clinical trials. The lack of navigation programs and training may negatively influence standardization of navigation techniques. The purpose of this project was to deliver and evaluate an evidence-based navigation-training curriculum for "lay" navigators. The primary outcomes measured were confidence in the role as navigator, understanding a navigator's role, and knowledge and perception of clinical trials. The results revealed overall confidence in the role as lay navigators increased from pre-to-post test. Lessons learned included the need for preparatory classes to build the navigator's confidence, and additional training components in death and dying. A larger study is warranted to confirm the findings.
AD  - Hollings Cancer Center, Medical University of South Carolina, PO BX 250955, 86 Jonathan Lucas Street, Charleston, SC 29425, USA. bryantdc@musc.edu
AN  - 23061182
AU  - Bryant, D. C.
AU  - Williamson, D.
AU  - Cartmell, K.
AU  - Jefferson, M.
DA  - Dec
DP  - NLM
ET  - 2012/10/16
IS  - 2
KW  - *African Americans
*Clinical Trials as Topic
Community Health Workers/*education
*Curriculum
Female
Health Services Accessibility
Healthcare Disparities/ethnology
Humans
Male
Models, Educational
Neoplasms/ethnology/*therapy
Patient Acceptance of Health Care/ethnology
*Patient Selection
Pilot Projects
Social Support
Southeastern United States
LA  - eng
N1  - Bryant, Debbie Chatman
Williamson, Deborah
Cartmell, Kathleen
Jefferson, Melanie
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
United States
J Natl Black Nurses Assoc. 2011 Dec;22(2):68-75.
PY  - 2011
SN  - 0885-6028 (Print)
0885-6028
SP  - 68-75
ST  - A lay patient navigation training curriculum targeting disparities in cancer clinical trials
T2  - J Natl Black Nurses Assoc
TI  - A lay patient navigation training curriculum targeting disparities in cancer clinical trials
VL  - 22
ID  - 352
ER  - 

TY  - JOUR
AB  - Introduction: The protective effects of breastfeeding against developing breast cancer are well known; however, it is unknown whether women are aware of this breastfeeding benefit. Research Aim/Questions: The aim of this investigation was to determine whether mothers received information about breast cancer risk reduction during breastfeeding counseling and whether this knowledge affected their decision to initiate and sustain breastfeeding. Materials and Methods: The survey was conducted at The Ohio State University Comprehensive Cancer Center with women aged 18-50 who had at least one live birth. Participants were recruited through primary care practice and a national clinical research registry. Results: Six hundred sixty-seven (92%) of the 724 respondents breastfed. Over half of them (56%), that is, 407 women (60.4% Caucasian, 46.9% African American), were aware before their most recent childbirth that breastfeeding reduced the risk of breast cancer. Of the 407 women, 36.4% said this knowledge affected their decision to breastfeed. Of the 39 who did not breastfeed, 23 women (59.0%) responded that awareness of risk reduction would have influenced their decision to breastfeed. Only 120 of 724 respondents (16.6%) received this information from healthcare providers. Women with this knowledge breastfed longer than those without this knowledge (13.2 versus 9.3 months; p < 0.001). More Caucasian women (76.4%) breastfed any one child for more than 6 months compared with African American women (63.2%; p = 0.011; chi-squared test). Conclusion: While several factors affect the initiation and duration of breastfeeding, this study demonstrates that knowledge of association between breastfeeding and breast cancer risk reduction may influence breastfeeding practices. Our study illustrates the need for improved counseling for mothers by healthcare providers regarding this benefit.
AU  - Ganju, A.
AU  - Suresh, A.
AU  - Stephens, J.
AU  - Palettas, M.
AU  - Burke, D.
AU  - Miles, L.
AU  - Lehman, K.
AU  - Rudesill, R.
AU  - Lustberg, M.
AU  - Bose-Brill, S.
AU  - Ramaswamy, B.
DB  - Medline
DO  - 10.1089/bfm.2018.0170
IS  - 10
KW  - adult
African American
article
awareness
breast cancer
breast feeding
cancer center
cancer risk
Caucasian
child
childbirth
clinical research
controlled study
counseling
female
health care personnel
human
human experiment
lactation
learning
live birth
major clinical study
mother
Ohio
primary medical care
risk reduction
young adult
LA  - English
M3  - Article
N1  - L631800473
2020-05-26
PY  - 2018
SN  - 1556-8342
SP  - 651-656
ST  - Learning, Life, and Lactation: Knowledge of Breastfeeding's Impact on Breast Cancer Risk Reduction and Its Influence on Breastfeeding Practices
T2  - Breastfeeding medicine : the official journal of the Academy of Breastfeeding Medicine
TI  - Learning, Life, and Lactation: Knowledge of Breastfeeding's Impact on Breast Cancer Risk Reduction and Its Influence on Breastfeeding Practices
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L631800473&from=export
http://dx.doi.org/10.1089/bfm.2018.0170
VL  - 13
ID  - 874
ER  - 

TY  - JOUR
AB  - Prostate cancer disproportionately affects Black men, who may also encounter barriers to participation in prostate cancer risk assessment. The Prostate Risk, Education and Assessment in the Community with Help (REACH) project was a community-based extension of a comprehensive prostate cancer risk assessment program at a comprehensive cancer center. The goals of the REACH project were the following: (1) establish a community prostate cancer risk assessment clinic, (2) conduct targeted recruitment, and (3) provide navigation services including follow-up for uninsured men. Key implementation steps included the following: (1) choosing a clinic site, (2) establishing patient access procedures, (3) establishing navigator services, (4) developing subsidy fund use guidelines, and (5) designing recruitment and promotion. Through community-based promotion, 64 men inquired about the program and 26 (41 %) participated. Of those screened, 46 % had abnormal results, and 2 men were diagnosed with prostate cancer. Here, we describe a unique demonstration project to implement a comprehensive prostate cancer risk assessment program in an underserved Black community and describe successes and challenges to inform future efforts to promote access to underserved men.
AD  - Center for Injury Research and Prevention, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Office of Health Communications and Health Disparities, Fox Chase Cancer Center, Philadelphia, PA, USA.
Department of Health Outcomes and Behavior, Division of Population Sciences, H. Lee Moffitt Cancer Center, Tampa, FL, USA.
Division of Population Science, Department of Medical Oncology, Thomas Jefferson University, 1025 Walnut Street, Room 1015, Philadelphia, PA, 19107, USA.
Department of Clinical Genetics, Fox Chase Cancer Center, Philadelphia, PA, USA.
National Comprehensive Cancer Center, Fort Washington, PA, USA.
Division of Population Science, Department of Medical Oncology, Thomas Jefferson University, 1025 Walnut Street, Room 1015, Philadelphia, PA, 19107, USA. Veda.Giri@jefferson.edu.
AN  - 25971432
AU  - Fleisher, L.
AU  - Davis, S. N.
AU  - Gross, L.
AU  - Bagden, L.
AU  - Zakrzewski, D.
AU  - González, E.
AU  - Kandadai, V.
AU  - Rusten, C.
AU  - Baskett, J.
AU  - Obeid, E.
AU  - Giri, V. N.
DA  - Mar
DO  - 10.1007/s13187-015-0854-8
DP  - NLM
ET  - 2015/05/15
IS  - 1
KW  - Adult
Aged
Early Detection of Cancer/*psychology
Ethnic Groups/*education
Follow-Up Studies
Humans
Learning
Male
Middle Aged
*Patient Education as Topic
Patient Navigation
Patient Selection
Prognosis
Program Evaluation
Prostatic Neoplasms/diagnosis/*prevention & control/psychology
Risk Assessment
Vulnerable Populations/*psychology
African American
Community screening
Prostate cancer screening
LA  - eng
N1  - 1543-0154
Fleisher, Linda
Davis, Stacy N
Gross, Laura
Bagden, Loretta
Zakrzewski, Debra
González, Evelyn
Kandadai, Venk
Rusten, Cheryl
Baskett, Jerilyn
Obeid, Elias
Giri, Veda N
Journal Article
Research Support, Non-U.S. Gov't
England
J Cancer Educ. 2016 Mar;31(1):191-7. doi: 10.1007/s13187-015-0854-8.
PY  - 2016
SN  - 0885-8195
SP  - 191-7
ST  - Lessons Learned from Implementing a Prostate Cancer Risk Assessment Program for Underserved High-Risk Men in the Community: the Prostate REACH Project
T2  - J Cancer Educ
TI  - Lessons Learned from Implementing a Prostate Cancer Risk Assessment Program for Underserved High-Risk Men in the Community: the Prostate REACH Project
VL  - 31
ID  - 243
ER  - 

TY  - JOUR
AB  - Prior clinical research supports the effectiveness of cancer support groups for cancer patients and their families, yet African-American families continue to be underrepresented in cancer support groups and in cancer clinical research studies. In order to fill this gap, we developed and evaluated a culturally adapted family support group for African-American families coping with parental cancer. We encountered unexpected challenges in overcoming barriers to recruitment, partnering with oncology providers, and building trust with the African-American community and African-American families coping with parental cancer. We describe actions taken during the two phases of this study and lessons learned along the way about recruiting and engaging African-American families in cancer support group studies, partnering with oncology providers, networking with the African-American community, and the importance of demonstrating cultural sensitivity to overcome the understandable historical legacy of mistrust.
AN  - WOS:000312328000023
AU  - Davey, M. P.
AU  - Kissil, K.
AU  - Lynch, L.
AU  - Harmon, L. R.
AU  - Hodgson, N.
DA  - Sep
DO  - 10.1007/s13187-012-0398-0
IS  - 4
N1  - 22791545
PY  - 2012
SN  - 0885-8195
SP  - 744-751
ST  - Lessons Learned in Developing a Culturally Adapted Intervention for African-American Families Coping with Parental Cancer
T2  - Journal of Cancer Education
TI  - Lessons Learned in Developing a Culturally Adapted Intervention for African-American Families Coping with Parental Cancer
VL  - 27
ID  - 3061
ER  - 

TY  - JOUR
AB  - PURPOSE/OBJECTIVES: To describe the process of planning a theory-based support group project for African American women with breast cancer. DATA SOURCES: A needs assessment and recruitment strategies consistent with the Oncology Nursing Society's Multicultural Outcomes: Guidelines for Cultural Competence were used to adapt a support group intervention for newly diagnosed African American women in urban central Texas. DATA SYNTHESIS: The reviewed literature and local cancer survivor leaders indicated the need for education and support of newly diagnosed women. Although researchers worked for several years with lay leaders to gain legitimacy and trust, not enough participants were recruited to test an intervention specifically for African American women. CONCLUSIONS: Recruiting support group research participants from a relatively small minority population is problematic even when collaborating with population leaders. IMPLICATIONS FOR NURSING: Nurses may encounter barriers to conducting research in minority populations. Starting early to build credibility with that population, being flexible with eligibility criteria, beginning with pre-experimental studies, and paying participants may be required.
AD  - School of Nursing, University of Texas, Austin, TX, USA. dcoward@mail.utexas.edu
AN  - 15759064
AU  - Coward, D. D.
DA  - Mar 5
DO  - 10.1188/05.Onf.261-266
DP  - NLM
ET  - 2005/03/11
IS  - 2
KW  - Adult
African Americans/*psychology
Breast Neoplasms/*ethnology/*nursing
Cultural Characteristics
Female
Humans
Interprofessional Relations
Needs Assessment
Nurse's Role
Patient Advocacy
Program Development
*Self-Help Groups
LA  - eng
N1  - 1538-0688
Coward, Doris D
5R29NR004434-05/NR/NINR NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.
United States
Oncol Nurs Forum. 2005 Mar 5;32(2):261-6. doi: 10.1188/05.ONF.261-266.
PY  - 2005
SN  - 0190-535x
SP  - 261-6
ST  - Lessons learned in developing a support intervention for African American women with breast cancer
T2  - Oncol Nurs Forum
TI  - Lessons learned in developing a support intervention for African American women with breast cancer
VL  - 32
ID  - 607
ER  - 

TY  - JOUR
AB  - In a randomized, double-blind trial for metastatic prostate cancer (Stage D2), 603 men received leuprolide, a gonadotropin-releasing hormone analog that inhibits the release of gonadotropins, coupled with either placebo or flutamide, a nonsteroidal antiandrogen that inhibits the binding of androgens to the cell nucleus. The 303 men receiving androgen blockade with leuprolide and flutamide demonstrated a longer progression-free survival (16.9 vs. 13.9 months, P = 0.039) and an increased median length of survival (35.0 vs. 27.9 months, P = 0.035). In the subgroup of men with minimal disease and good performance status, the advantages of maximal androgen blockade were more pronounced. It is concluded that combined androgen blockade with leuprolide and flutamide was more effective than leuprolide alone for patients with metastatic cancer of the prostate. The therapeutic benefits, although greatest in patients with minimum disease, need to be evaluated in a prospective, randomized fashion in trials specifically designed for men with minimal disease and good performance status. Exploratory analyses using the black race as an explanatory variable were also performed. Black race is associated with shorter survival times and is also associated with other prognostic factors, including recent weight loss, anemia, elevated phosphatase levels, and pain. These findings suggest the need for future studies of the relationship of black race and response to prostate cancer therapy.
AD  - Division of Urology, University of Colorado Health Sciences Center, Denver 80262.
AN  - 2118417
AU  - Crawford, E. D.
AU  - Blumenstein, B. A.
AU  - Goodman, P. J.
AU  - Davis, M. A.
AU  - Eisenberger, M. A.
AU  - McLeod, D. G.
AU  - Spaulding, J. T.
AU  - Benson, R.
AU  - Dorr, F. A.
DA  - Sep 1
DO  - 10.1002/cncr.1990.66.s5.1039
DP  - NLM
ET  - 1990/09/01
IS  - 5 Suppl
KW  - Adult
African Continental Ancestry Group
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use
Double-Blind Method
Flutamide/administration & dosage
Gonadotropin-Releasing Hormone/administration & dosage/*analogs & derivatives
Humans
Leuprolide
Male
Middle Aged
Neoplasm Staging
Prostatic Neoplasms/*drug therapy/ethnology/mortality/pathology
Randomized Controlled Trials as Topic
Survival Rate
LA  - eng
N1  - Crawford, E D
Blumenstein, B A
Goodman, P J
Davis, M A
Eisenberger, M A
McLeod, D G
Spaulding, J T
Benson, R
Dorr, F A
Clinical Trial
Journal Article
Randomized Controlled Trial
United States
Cancer. 1990 Sep 1;66(5 Suppl):1039-44. doi: 10.1002/cncr.1990.66.s5.1039.
PY  - 1990
SN  - 0008-543X (Print)
0008-543x
SP  - 1039-44
ST  - Leuprolide with and without flutamide in advanced prostate cancer
T2  - Cancer
TI  - Leuprolide with and without flutamide in advanced prostate cancer
VL  - 66
ID  - 749
ER  - 

TY  - JOUR
AB  - Objectives: To examine lifestyle behaviors among non-Hispanic Black and White women with a family history of breast cancer and determine the extent to which they meet American Cancer Society (ACS) Nutrition and Physical Activity Recommendations for Breast Cancer Prevention. Method: Cross-sectional data from 44,364 women enrolled in the Sister Study (2009), a study of sisters of women with breast cancer within the U.S., were analyzed. Descriptive statistics and chi-square analyses were used to examine body mass index and lifestyle behaviors (e.g., exercise, diet, and smoking) and to determine percentages of women meeting ACS recommendations. Results: Black women consumed a lower percentage of calories from fat (mean 36.90% vs. 37.17%) and were more likely to meet ACS alcohol recommendations than Whites. White women consumed more fruits and vegetables/day (mean 4.81 vs. 4.41) than Black women and were more likely to meet ACS guidelines for physical activity (26.4% vs. 18.2%) and body mass index (42.5% vs. 16.7%). Conclusion: Despite an elevated risk for breast cancer due to a family history of breast cancer, the majority of women were no more likely than women in the general population to engage in healthy lifestyle behaviors. These women may benefit from lifestyle behavior risk-reduction counseling. (PsycINFO Database Record (c) 2016 APA, all rights reserved)
AD  - Spector, Denise, Gillings School of Global Public Health, Get REAL & HEEL Breast Cancer Program, University of North Carolina at Chapel Hill, CB #8615, 3433 Country Club Drive, Chapel Hill, NC, US, 27599
AN  - 2011-08133-022
AU  - Spector, Denise
AU  - DeRoo, Lisa A.
AU  - Sandler, Dale P.
DB  - psyh
DO  - 10.1016/j.ypmed.2011.03.001
DP  - EBSCOhost
IS  - 5
KW  - women's lifestyle behavior
family history
breast cancer
Black women
White women
risk
Adult
African Americans
Aged
Breast Neoplasms
Cross-Sectional Studies
European Continental Ancestry Group
Female
Genetic Predisposition to Disease
Health Behavior
Humans
Middle Aged
Motor Activity
Obesity
United States
Family Background
Lifestyle
Blacks
Human Females
Risk Factors
Whites
N1  - Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, US. Release Date: 20110829. Correction Date: 20151214. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: English. Grant Information: Spector, Denise. Major Descriptor: Breast Neoplasms; Family Background; Lifestyle. Minor Descriptor: Blacks; Human Females; Risk Factors; Whites. Classification: Cancer (3293). Population: Human (10); Female (40). Location: US. Age Group: Adulthood (18 yrs & older) (300); Thirties (30-39 yrs) (340); Middle Age (40-64 yrs) (360); Aged (65 yrs & older) (380). Tests & Measures: Food Frequency Questionnaire. Methodology: Empirical Study; Longitudinal Study; Prospective Study; Interview; Quantitative Study. References Available: Y. Page Count: 4. Issue Publication Date: May 1, 2011. Publication History: First Posted Date: Mar 9, 2011. Copyright Statement: All rights reserved. Elsevier Inc. 2011.
Sponsor: American Cancer Society, US. Grant: DSCN-07-132-01. Other Details: Through a Doctoral Degree Scholarship in Cancer Nursing. Recipients: Spector, Denise
Sponsor: National Institutes of Health, National Institute of Environmental Health Sciences, Intramural Research Program, US. Grant: Z01 ES0044005. Recipients: No recipient indicated
PY  - 2011
SN  - 0091-7435
SP  - 394-397
ST  - Lifestyle behaviors in Black and White women with a family history of breast cancer
T2  - Preventive Medicine: An International Journal Devoted to Practice and Theory
TI  - Lifestyle behaviors in Black and White women with a family history of breast cancer
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2011-08133-022&site=ehost-live&scope=site
sandler@niehs.nih.gov
DerooL@niehs.nih.gov
dspector@email.unc.edu
VL  - 52
ID  - 1722
ER  - 

TY  - JOUR
AB  - BACKGROUND: Our data have indicated that minority breast cancer survivors are receptive to participating in lifestyle interventions delivered via email or the Web, yet few Web-based studies exist in this population. OBJECTIVE: The aim of this study was to examine the feasibility and preliminary results of an email-delivered diet and activity intervention program, "A Lifestyle Intervention Via Email (ALIVE)," delivered to a sample of racial and ethnic minority breast cancer survivors. METHODS: Survivors (mean age: 52 years, 83% [59/71] African American) were recruited and randomized to receive either the ALIVE program's 3-month physical activity track or its 3-month dietary track. The fully automated system provided tools for self-monitoring and goal setting, tailored content, and automated phone calls. Descriptive statistics and mixed-effects models were computed to examine the outcomes of the study. RESULTS: Upon completion, 44 of 71 survivors completed the study. Our "intention-to-treat" analysis revealed that participants in the physical activity track made greater improvements in moderate to vigorous activity than those in the dietary track (+97 vs. +49 min/week, P<.001). Similarly, reductions in total sedentary time among those in the physical activity track (-304 vs. -59 min/week, P<.001) was nearly 5 times greater than that for participants in the dietary track. Our completers case analysis indicated that participants in the dietary track made improvements in the intake of fiber (+4.4 g/day), fruits and vegetables (+1.0 cup equivalents/day), and reductions in saturated fat (-2.3 g/day) and trans fat (-0.3 g/day) (all P<.05). However, these improvements in dietary intake were not significantly different from the changes observed by participants in the physical activity track (all P>.05). Process evaluation data indicated that most survivors would recommend ALIVE to other cancer survivors (97%), were satisfied with ALIVE (82%), and felt that ALIVE was effective (73%). However, survivors expressed concerns about the functionality of the interactive emails. CONCLUSIONS: ALIVE appears to be feasible for racial and ethnic minority cancer survivors and showed promising results for larger implementation. Although survivors favored the educational content, a mobile phone app and interactive emails that work on multiple email domains may help to boost adherence rates and to improve satisfaction with the Web-based platform. TRIAL REGISTRATION: ClinicalTrials.gov NCT02722850; https://clinicaltrials.gov/ct2/show/NCT02722850 (Archived by WebCite at http://www.webcitation.org/6tHN9VsPh).
AD  - Department of Community Medicine and Population Health, The University of Alabama, Tuscaloosa, AL, United States.
Center for Health Equity and Evaluation Research, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Texas Health Resources, Texas Health Harris Methodist Hospital, Fort Worth, TX, United States.
School of Public Health, University of North Texas Health Science Center, Fort Worth, TX, United States.
Institute of Healthy Aging, University of North Texas Health Science Center, Forth Worth, TX, United States.
Department of Health Promotion and Behavior Sciences, The University of Texas Health Science Center at Houston, Houston, TX, United States.
Department of Mexican American & Latina/o Studies, The University of Texas at Austin, Austin, TX, United States.
Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Faculty of Physical Education and Recreation, University of Alberta, Edmonton, AB, Canada.
Turnaround Health, a division of NutritionQuest, Berkeley, CA, United States.
School of Public Health, University of California at Berkeley, Berkeley, CA, United States.
School of Public Health, Texas A&M Health Science Center, Bryan, TX, United States.
AN  - 28935620
AU  - Paxton, R. J.
AU  - Hajek, R.
AU  - Newcomb, P.
AU  - Dobhal, M.
AU  - Borra, S.
AU  - Taylor, W. C.
AU  - Parra-Medina, D.
AU  - Chang, S.
AU  - Courneya, K. S.
AU  - Block, G.
AU  - Block, T.
AU  - Jones, L. A.
C2  - PMC5629346
DA  - Sep 21
DO  - 10.2196/cancer.7495
DP  - NLM
ET  - 2017/09/25
IS  - 2
KW  - African Americans
Internet
breast neoplasm
computer tailoring
diet
email
feasibility study
physical activity
posture
program evaluation
interest in ALIVE.
LA  - eng
N1  - 2369-1999
Paxton, Raheem J
Orcid: 0000-0001-9430-7051
Hajek, Richard
Orcid: 0000-0001-6248-5283
Newcomb, Patricia
Orcid: 0000-0002-5306-8899
Dobhal, Megha
Orcid: 0000-0002-6447-0648
Borra, Sujana
Orcid: 0000-0003-3433-3981
Taylor, Wendell C
Orcid: 0000-0002-6196-3025
Parra-Medina, Deborah
Orcid: 0000-0002-5505-524x
Chang, Shine
Orcid: 0000-0003-3804-9697
Courneya, Kerry S
Orcid: 0000-0002-9677-3918
Block, Gladys
Orcid: 0000-0001-6722-930x
Block, Torin
Orcid: 0000-0001-5399-1950
Jones, Lovell A
Orcid: 0000-0001-8914-9896
K01 CA158000/CA/NCI NIH HHS/United States
Journal Article
JMIR Cancer. 2017 Sep 21;3(2):e13. doi: 10.2196/cancer.7495.
PY  - 2017
SN  - 2369-1999 (Print)
2369-1999
SP  - e13
ST  - A Lifestyle Intervention via Email in Minority Breast Cancer Survivors: Randomized Parallel-Group Feasibility Study
T2  - JMIR Cancer
TI  - A Lifestyle Intervention via Email in Minority Breast Cancer Survivors: Randomized Parallel-Group Feasibility Study
VL  - 3
ID  - 157
ER  - 

TY  - JOUR
AB  - The majority of smoking cessation research has focused on heavy smokers. African Americans (AA) are less likely than the general population to be heavy smokers. Thus, little is known about the smoking and psychosocial characteristics of lighter AA smokers. The present study compared the baseline demographic, smoking, and psychosocial characteristics of light (5-10 cigarettes per day; n = 86) and moderate to heavy (> 10 cigarettes per day; n = 286) AA smokers enrolled in a smoking cessation clinical trial. Results indicated no differences between groups on demographic variables. However, light smokers (LS) were less dependent on smoking, reported more previous quit attempts, and had higher self-efficacy to quit than moderate to heavy smokers (MHS). Oil a Measure of withdrawal, LS reported less pre-quit craving and less difficulty concentrating thin MHS. In addition, LS reported lower perceived stress, fewer symptoms of depression, and greater positive affect than AA MHS. These findings highlight important similarities and differences between AA LS and MHS, and have implications for the treatment of AA smokers. (C) 2008 Elsevier Ltd. All rights reserved.
AN  - WOS:000262197200010
AU  - Businelle, M. S.
AU  - Kendzor, D. E.
AU  - Costello, T. J.
AU  - Cofta-Woerpel, L.
AU  - Li, Y. S.
AU  - Mazas, C. A.
AU  - Vidrine, J. I.
AU  - Reitzel, L. R.
AU  - Cinciripini, P. M.
AU  - Ahluwalia, J. S.
AU  - Wetter, D. W.
DA  - Feb
DO  - 10.1016/j.addbeh.2008.10.009
IS  - 2
N1  - 18976867
PY  - 2009
SN  - 0306-4603
SP  - 197-203
ST  - Light versus heavy smoking among African American men and women
T2  - Addictive Behaviors
TI  - Light versus heavy smoking among African American men and women
VL  - 34
ID  - 3154
ER  - 

TY  - JOUR
AB  - OBJECTIVE: The Healthy Aging Partnerships in Prevention Initiative (HAPPI) aims to increase the use of clinical preventive services (CPS) among underserved Latinos and African Americans in South Los Angeles who are 50+ years old. MATERIALS AND METHODS: HAPPI uses an evidencebased model, SPARC, to leverage existing resources and link community resources. HAPPI's multi-sectoral partnerships include local non-governmental organizations (NGOs), community health centers (CHCs), aging and public health agencies serving the City and County of Los Angeles, and a university. Activities include CHC capacity assessment and training, and community capacity-building that included a small grants program. RESULTS: We engaged five CHCs in quality improvement activities and eight NGOs in networking and programming to increase awareness and receipt of CPS. We discuss barriers and facilitators including the success of trainings conducted with CHC providers and NGO re- presentatives. CONCLUSIONS: Multi-sectoral collaborations hold promise for increasing awareness and use of CPS in underserved communities.
AD  - Center for Health Policy Research, The University of California. California, USA.
Fielding School of Public Health, The University of California. California, USA.
Division of General Internal Medicine and Health Services Research, Geffen School of Medicine, The University of California. California, USA.
AN  - 31430085
AU  - Bravo, R. L.
AU  - Kietzman, K. G.
AU  - Toy, P.
AU  - Duru, O. K.
AU  - Wallace, S. P.
DA  - Jul-Ago
DO  - 10.21149/9450
DP  - NLM
ET  - 2019/08/21
IS  - 4
KW  - African Americans
Aged
*Capacity Building
Colorectal Neoplasms/*diagnosis/prevention & control
Community Health Services/*organization & administration
Community Participation
Financing, Organized
*Healthy Aging
Hispanic Americans
Humans
Inservice Training
Interinstitutional Relations
Los Angeles
Middle Aged
Patient-Centered Care/organization & administration
Preventive Health Services/*organization & administration
Primary Health Care/*organization & administration
intersectoral collaboration
preventive health services
public health
of interests.
LA  - eng
N1  - 1606-7916
Bravo, Rosana L
Kietzman, Kathryn G
Toy, Peggy
Duru, O Kenrik
Wallace, Steven P
P01 HS010858/HS/AHRQ HHS/United States
Journal Article
Mexico
Salud Publica Mex. 2019 Jul-Ago;61(4):427-435. doi: 10.21149/9450.
OP  - Promover una alianza entre la atención primaria y las organizaciones comunitarias para aumentar las pruebas de detección de cáncer colorrectal: el proyecto HAPPI.
PY  - 2019
SN  - 0036-3634
SP  - 427-435
ST  - Linking primary care and community organizations to increase colorectal cancer screening rates: the HAPPI project
T2  - Salud Publica Mex
TI  - Linking primary care and community organizations to increase colorectal cancer screening rates: the HAPPI project
VL  - 61
ID  - 66
ER  - 

TY  - JOUR
AB  - Colorectal cancer frustrates with high relapse after the traditional treatment including surgery and chemotherapy. Neoantigen-based therapeutic vaccine has achieved high response rate in the clinical trials rising the immunotherapy as a promising alternative for colorectal cancer. Herein, colon cancer cells derived neoantigen peptide Adpgk were employed to be co-encapsulated with black phosphorus quantum dots into liposome (Adpgk-BPQDs-liposome) as therapeutic vaccine. Adpgk-BPQDs-liposome were dispersed in F127 gel containing GM-CSF. The heat generated by black phosphorus (BP) under 808 nm near-infrared laser irradiation accelerates the F127 gel ablation and the release of GM-CSF, which recruit APC cells and prime the native T cells. The tumor bearing mice received the programmed cell death protein 1 (PD-1) checkpoint blockade antibody combined with photo-thermal gel intensively prevented the tumor progress. Furthermore, the tumor infiltrating CD8+ T cells were significantly increased which lead to the elimination of the tumor.
AN  - 33419493
AU  - Zhang, J.
AU  - Chen, X.
AU  - Xue, T.
AU  - Cheng, Q.
AU  - Ye, X.
AU  - Wang, C.
AU  - Yu, Y.
AU  - Ji, X.
AU  - Wu, M.
AU  - Zhang, X.
AU  - Zheng, Y.
AU  - Wu, B.
AU  - Liang, X.
AU  - Mei, L.
DA  - Sep 1
DO  - 10.1166/jbn.2020.2977
DP  - NLM
ET  - 2021/01/10
IS  - 9
KW  - Animals
*Antigens
CD8-Positive T-Lymphocytes
*Immunotherapy
Liposomes
Mice
Neoplasm Recurrence, Local
*Peptides
Phosphorus
*Quantum Dots
Vaccines
LA  - eng
N1  - Zhang, Jinxie
Chen, Xiuli
Xue, Tianyuan
Cheng, Qinzhen
Ye, Xinyu
Wang, Changshan
Yu, Yongkang
Ji, Xiaoyuan
Wu, Meiying
Zhang, Xudong
Zheng, Yi
Wu, Benqing
Liang, Xin
Mei, Lin
Journal Article
United States
J Biomed Nanotechnol. 2020 Sep 1;16(9):1394-1405. doi: 10.1166/jbn.2020.2977.
PY  - 2020
SN  - 1550-7033 (Print)
1550-7033
SP  - 1394-1405
ST  - Liposomes Encapsulating Neoantigens and Black Phosphorus Quantum Dots for Enhancing Photothermal Immunotherapy
T2  - J Biomed Nanotechnol
TI  - Liposomes Encapsulating Neoantigens and Black Phosphorus Quantum Dots for Enhancing Photothermal Immunotherapy
VL  - 16
ID  - 17
ER  - 

TY  - JOUR
AB  - Context: Barbershops and beauty salons are located in all communities and frequented by diverse groups of people, making them key settings for addressing health disparities. No studies have reviewed the growing body of literature describing studies promoting health in these settings. This review summarized the literature related to promoting health within barbershops and beauty salons to inform future approaches that target diverse populations in similar settings. Evidence acquisition: We identified and reviewed published research articles describing formative research, recruitment, and health-related interventions set in beauty salons and barber-shops. Pub Med and other secondary search engines were searched in 2010 and again in 2013 for English-language papers indexed from 1990 through August 2013. The search yielded 113 articles, 71 of which were formerly reviewed, and 54 were eligible for inclusion. Evidence synthesis: Included articles were categorized as formative research (n=27); recruitment (n=7); or intervention (n=20). Formative research studies showed that owners, barbers/stylists, and their customers were willing participants, clarifying the feasibility of promoting health in these settings. Recruitment studies demonstrated that salon/shop owners will join research studies and can enroll customers. Among intervention studies, level of stylist/barber involvement was categorized. More than 73.3% of intervention studies demonstrated statistically significant results, targeted mostly racial/ethnic minority groups and focused on a variety of health topics. Conclusions: Barbershops and beauty salons are promising settings for reaching populations most at risk for health disparities. Although these results are encouraging, more rigorous research and evaluation of future salon- and barbershop-based interventions are needed. (C) 2014 American Journal of Preventive Medicine
AN  - WOS:000337657800010
AU  - Linnan, L. A.
AU  - D'Angelo, H.
AU  - Harrington, C. B.
DA  - Jul
DO  - 10.1016/j.amepre.2014.02.007
IS  - 1
N1  - 24768037
PY  - 2014
SN  - 0749-3797
SP  - 77-85
ST  - A Literature Synthesis of Health Promotion Research in, Salons and Barbershops
T2  - American Journal of Preventive Medicine
TI  - A Literature Synthesis of Health Promotion Research in, Salons and Barbershops
VL  - 47
ID  - 3004
ER  - 

TY  - JOUR
AB  - Background: The number of breast cancer survivors has increased since 1990 due to advances in biomedical technology that lead to an increase in early diagnosis and treatment. Research on survivorship has focused on the psychological and treatment aspects of the disease. The goal of this study was focused on exploring the lived experiences of breast cancer survivors from diagnosis, treatment and beyond. Objective: To understand the lived experiences of women who are breast cancer survivors. Design, Setting and Participants: A purposive sampling strategy was used to recruit participants from two Missouri cancer centres. A total of 15 women breast cancer survivors were interviewed. Findings: Three major themes emerged that described the lived experiences of the women. These were factors from the diagnosis and treatment management impacting survivorship, relationship and support system and implication of survivorship. Participants noted that coping with the diagnosis and treatment was a stressful journey and required lots of adjustment and changes. Some developed various techniques such as journaling their activities which provided comfort. In addition, support from family was shared as the key which gave them strength and courage through the different stages of treatment. However, they found it difficult to articulate what survivorship meant. Conclusion: Using in ‐ depth interview techniques, this study shed light on the experiences of women who were diagnosed with breast cancer and have completed treatment. They acknowledged frustration with their diagnosis and body changes. Support received from family and friends helped them cope through their treatment. However, they felt abandoned once the treatment phase was over and were uncertain what survivorhood meant to them.
AD  - Division of Public Health Sciences, Department of Surgery, Washington University in St. Louis School of Medicine, St. Louis MO, USA
Department of Rural Sociology, Community Development Program, University of Missouri Extension, University of Missouri, Columbia MO, USA
AN  - 114888064. Language: English. Entry Date: 20160502. Revision Date: 20180813. Publication Type: Article
AU  - Williams, Faustine
AU  - Jeanetta, Stephen C.
DB  - CINAHL Complete
DO  - 10.1111/hex.12372
DP  - EBSCOhost
IS  - 3
KW  - Life Experiences
Breast Neoplasms -- Diagnosis
Cancer Survivors
Breast Neoplasms -- Therapy
Treatment Outcomes
Health
Human
Female
Qualitative Studies
Technology, Medical
Interviews
Breast Neoplasms -- Psychosocial Factors
Ethnic Groups
Race Factors
Research Subject Recruitment
Data Collection
Data Analysis
Reliability and Validity
White Persons
Black Persons
Neoplasm Staging
Disease Duration
N1  - research; tables/charts. Journal Subset: Europe; Health Services Administration; Peer Reviewed; UK & Ireland. NLM UID: 9815926.
PY  - 2016
SN  - 1369-6513
SP  - 631-642
ST  - Lived experiences of breast cancer survivors after diagnosis, treatment and beyond: qualitative study
T2  - Health Expectations
TI  - Lived experiences of breast cancer survivors after diagnosis, treatment and beyond: qualitative study
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=114888064&site=ehost-live&scope=site
VL  - 19
ID  - 1993
ER  - 

TY  - JOUR
AB  - PURPOSE: Weekly paclitaxel, concurrent radiation, and androgen deprivation (ADT) were evaluated in patients with high-risk prostate cancer (PC) with or without prior prostatectomy (RP). METHODS AND MATERIALS: Eligible post-RP patients included: pathological T3 disease, or rising prostate-specific antigen (PSA) ≥ 0.5 ng/mL post-RP. Eligible locally advanced PC (LAPC) patients included: 1) cT2b-4N0N+, M0; 2) Gleason score (GS) 8-10; 3) GS 7 + PSA 10-20 ng/mL; or 4) PSA 20-150 ng/mL. Treatment included ADT (4 or 24 months), weekly paclitaxel (40, 50, or 60 mg/m(2)/wk), and pelvic radiation therapy (total dose: RP = 64.8 Gy; LAPC = 70.2 Gy). RESULTS: Fifty-nine patients were enrolled (LAPC, n = 29; RP, n = 30; ADT 4 months, n = 29; 24 months, n = 30; whites n = 29, African Americans [AA], n = 28). Baseline characteristics (median [range]) were: age 67 (45-86 years), PSA 5.9 (0.1-92.1 ng/mL), GS 8 (6-9). At escalating doses of paclitaxel, 99%, 98%, and 95% of doses were given with radiation and ADT, respectively, with dose modifications required primarily in RP patients. No acute Grade 4 toxicities occurred. Grade 3 toxicities were diarrhea 15%, urinary urgency/incontinence 10%, tenesmus 5%, and leukopenia 3%. Median follow-up was 75.3 months (95% CI: 66.8-82.3). Biochemical progression occurred in 24 (41%) patients and clinical progression in 11 (19%) patients. The 5- and 7-year OS rates were 83% and 67%. There were no differences in OS between RP and LAPC, 4- and 24-month ADT, white and AA patient categories. CONCLUSIONS: In addition to LAPC, to our knowledge, this is the first study to evaluate concurrent chemoradiation with ADT in high-risk RP patients. With a median follow-up of 75.3 months, this trial also represents the longest follow-up of patients treated with taxane-based chemotherapy with EBRT in high-risk prostate cancer. Concurrent ADT, radiation, and weekly paclitaxel at 40 mg/m(2)/week in RP patients and 60 mg/m(2)/week in LAPC patients is feasible and well-tolerated.
AD  - Department of Medicine, University of Maryland School of Medicine, University of Maryland Greenebaum Cancer Center, Baltimore, MD 21201, USA. ahussain@som.umaryland.edu
AN  - 21036487
AU  - Hussain, A.
AU  - Wu, Y.
AU  - Mirmiran, A.
AU  - DiBiase, S.
AU  - Goloubeva, O.
AU  - Bridges, B.
AU  - Mannuel, H.
AU  - Engstrom, C.
AU  - Dawson, N.
AU  - Amin, P.
AU  - Kwok, Y.
DA  - Jan 1
DO  - 10.1016/j.ijrobp.2010.09.009
DP  - NLM
ET  - 2010/11/03
IS  - 1
KW  - Aged
Aged, 80 and over
Androgen Antagonists/*therapeutic use
Antineoplastic Agents, Phytogenic/*administration & dosage
Chemoradiotherapy/adverse effects/*methods
Diarrhea/etiology
Drug Administration Schedule
Humans
Leukopenia/etiology
Male
Middle Aged
Neoplasm Grading
Paclitaxel/*administration & dosage
Prospective Studies
Prostate-Specific Antigen/blood
Prostatectomy
Prostatic Neoplasms/blood/mortality/pathology/*therapy
Radiotherapy Dosage
Survival Analysis
Urination Disorders/etiology
LA  - eng
N1  - 1879-355x
Hussain, Arif
Wu, Yin
Mirmiran, Alireza
DiBiase, Steven
Goloubeva, Olga
Bridges, Benjamin
Mannuel, Heather
Engstrom, Christine
Dawson, Nancy
Amin, Pradip
Kwok, Young
Clinical Trial, Phase I
Journal Article
Research Support, Non-U.S. Gov't
United States
Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):167-74. doi: 10.1016/j.ijrobp.2010.09.009. Epub 2010 Oct 30.
PY  - 2012
SN  - 0360-3016
SP  - 167-74
ST  - Long-term follow-up of a prospective trial of trimodality therapy of weekly paclitaxel, radiation, and androgen deprivation in high-risk prostate cancer with or without prior prostatectomy
T2  - Int J Radiat Oncol Biol Phys
TI  - Long-term follow-up of a prospective trial of trimodality therapy of weekly paclitaxel, radiation, and androgen deprivation in high-risk prostate cancer with or without prior prostatectomy
VL  - 82
ID  - 408
ER  - 

TY  - JOUR
AB  - Purpose/Objective: High-grade glioma is the most common primary malignant tumor of the CNS, with death often resulting from uncontrollable intracranial disease. Radiation dose may be limited by the tolerance of critical structures, such as the brainstem and optic apparatus. In this report, long-term outcomes in patients treated with conventionally fractionated stereotactic boost for tumors in close proximity to critical structures are presented. Materials/Methods: Patients eligible for inclusion in this single institution retrospective review had a pathologically confirmed high-grade glioma status post-surgical resection. Inclusion criteria required tumor location within one centimeter of a critical structure, including the optic chiasm, optic nerve, and brainstem. Radiation therapy consisted of external beam radiation followed by a conventionally fractionated stereotactic boost. Oncologic outcomes and toxicity were assessed. Results: Thirty patients eligible for study inclusion underwent resection of a high-grade glioma. The median initial adjuvant EBRT dose was 50 Gy with a median conventionally fractionated stereotactic boost of 10 Gy. All stereotactic treatments were given in 2 Gy daily fractions. Median follow-up time for the entire cohort was 38 months with a median overall survival of 45 months and 5-year overall survival of 32.5%. The median freedom from local progression was 45 months, and the 5-year freedom from local progression was 29.7%. Two cases of radiation retinopathy were identified following treatment. No patient experienced toxicity attributable to the optic chiasm, optic nerve, or brainstem and no grade 3+ radionecrosis was observed. Conclusions: Oncologic and toxicity outcomes in high-grade glioma patients with tumors in unfavorable locations treated with conventionally fractionated stereotactic boost are comparable to those reported in the literature. This treatment strategy is appropriate for those patients with resected high-grade glioma in close proximity to critical structures.
AD  - M.C. Repka, Department of Radiation Medicine, MedStar Georgetown University Hospital, Washington, DC, United States
AU  - Repka, M. C.
AU  - Lei, S.
AU  - Campbell, L.
AU  - Suy, S.
AU  - Voyadzis, J. M.
AU  - Kalhorn, C.
AU  - McGrail, K.
AU  - Jean, W.
AU  - Subramaniam, D. S.
AU  - Lischalk, J. W.
AU  - Collins, S. P.
AU  - Collins, B. T.
DB  - Embase
DO  - 10.3389/fonc.2018.00373
IS  - SEP
KW  - lomustine
procarbazine
temozolomide
vincristine
adjuvant chemotherapy
adjuvant radiotherapy
adolescent
adult
African American
aged
article
brain stem
cancer chemotherapy
cancer patient
cancer radiotherapy
cancer survival
Caucasian
cause of death
cerebrovascular accident
clinical article
clinical outcome
conformal radiotherapy
disease exacerbation
electrocorticography
external beam radiotherapy
female
follow up
glioma
histology
human
intensity modulated radiation therapy
laser coagulation
lung embolism
male
middle aged
occipital lobe
optic chiasm
optic nerve
organs at risk
overall survival
parietal lobe
patient selection
prescription
radiation dose fractionation
radiation field
radiation injury
radiation necrosis
radiation retinopathy
retinopathy
stereotactic radiosurgery
stereotactic treatment
temporal lobe
tumor growth
tumor localization
tumor recurrence
visual acuity
x-ray computed tomography
LA  - English
M3  - Article
N1  - L623822196
2018-09-18
2018-10-16
PY  - 2018
SN  - 2234-943X
ST  - Long-term outcomes following conventionally fractionated stereotactic boost for high-grade gliomas in close proximity to critical organs at risk
T2  - Frontiers in Oncology
TI  - Long-term outcomes following conventionally fractionated stereotactic boost for high-grade gliomas in close proximity to critical organs at risk
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L623822196&from=export
http://dx.doi.org/10.3389/fonc.2018.00373
VL  - 8
ID  - 884
ER  - 

TY  - JOUR
AB  - Lifestyle changes in persons diagnosed with cancer are important because they may impact prognosis, co-morbidities, and survival. This report describes longitudinal changes in lifestyle behaviors and health status among colon cancer survivors (n = 278) and population-based controls (n = 459) in North Carolina (39% African American), and examines demographic and psychosocial correlates of healthy lifestyle changes following a colon cancer diagnosis. Data are from surveys of a population-based cohort of colon cancer patients on diagnosis (the North Carolina Colon Cancer Study, NCCCS) and approximately 2 years post-diagnosis [the North Carolina Strategies to Improve Diet, Exercise, and Screening Study (NC STRIDES)], and population-based controls. Both studies collected information on demographic/lifestyle characteristics and medical history. The NCCCS reflects pre-diagnosis or pre-interview patterns, whereas NC STRIDES queried on current practices. Between the NCCCS and NC STRIDES, colon cancer survivors reported significant increases in vegetable intake, physical activity, and supplement use (all P <0.01) and a non-statistically significant increase in fruit/juice consumption (0.1 serving), with larger fruit/vegetable changes in African Americans than Whites. Controls increased physical activity and supplement use and fewer reported arthritic symptoms (P < 0.05). Survivors who were older and female had an almost 3 times higher likelihood of having used at least one new dietary supplement post-diagnosis, whereas being retired correlated with increased vegetable intake, all P < 0.05. Having more barriers to increasing fruit/vegetable intake was inversely associated with taking a new supplement (P < 0.05 only in controls). Colon cancer survivors reported making significant improvements in multiple health-related behaviors. Health care providers should communicate with persons diagnosed with colon cancer to ensure that they are making healthy lifestyle changes.
AD  - Department of Nutrition and Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, USA. jessie.satia@amgen.com
AN  - 15184259
AU  - Satia, J. A.
AU  - Campbell, M. K.
AU  - Galanko, J. A.
AU  - James, A.
AU  - Carr, C.
AU  - Sandler, R. S.
DA  - Jun
DP  - NLM
ET  - 2004/06/09
IS  - 6
KW  - Adenocarcinoma/ethnology/prevention & control/*psychology
Adult
African Americans/psychology
Aged
Aged, 80 and over
Colonic Neoplasms/ethnology/prevention & control/*psychology
European Continental Ancestry Group/psychology
Feeding Behavior
Female
*Health Behavior/ethnology
*Health Status
Humans
Life Change Events
*Life Style/ethnology
Longitudinal Studies
Male
Middle Aged
North Carolina
Randomized Controlled Trials as Topic
Registries
Risk Factors
Survivors/*psychology
LA  - eng
N1  - Satia, Jessie A
Campbell, Marci K
Galanko, Joseph A
James, Aimee
Carr, Carol
Sandler, Robert S
K22 CA96556/CA/NCI NIH HHS/United States
P30 DK34987/DK/NIDDK NIH HHS/United States
R01 CA66635/CA/NCI NIH HHS/United States
R01 CA81914/CA/NCI NIH HHS/United States
Journal Article
Research Support, U.S. Gov't, P.H.S.
United States
Cancer Epidemiol Biomarkers Prev. 2004 Jun;13(6):1022-31.
PY  - 2004
SN  - 1055-9965 (Print)
1055-9965
SP  - 1022-31
ST  - Longitudinal changes in lifestyle behaviors and health status in colon cancer survivors
T2  - Cancer Epidemiol Biomarkers Prev
TI  - Longitudinal changes in lifestyle behaviors and health status in colon cancer survivors
VL  - 13
ID  - 627
ER  - 

TY  - JOUR
AB  - Background: Racial breast cancer survival disparity is attributed, in part, to disparity in cancer treatment. Changes in HRQOL influencing treatment adherence over the chemotherapy course may be under recognized as a potential etiology of racial disparity in breast cancer treatment. Objective: To describe African American breast cancer women's HRQOL and the relationship of HRQOL with adherence (dose prescribed without delay) rates to prescribed chemotherapy over three time points of chemotherapy (baseline, midpoint and completion). Methods: Descriptive analysis of an ongoing randomized controlled trial of a psycho‐educational intervention to encourage acceptance and adherence to chemotherapy for African American women with breast cancer. The present study used HRQOL data from the parent study and descriptively reported change of quality of life over three time points: baseline ‐ pre chemotherapy (Time 1); at midpoint of chemotherapy (Time 2) and at completion of chemotherapy (Time 3). A further analysis of HRQOL and its role as a potential mediator with treatment adherence was assessed. Descriptive analysis of secondary aim of the parent study, The Attitudes, Communication, Treatment and Support (ACTS) intervention. The Functional Assessment of Cancer Therapy (FACT) was used to measure HRQOL including physical, social, functional and emotional subscales. Adherence data were extracted from medical records. Linear mixed modeling analysis method was used. Results: One hundred and twenty six African American patients were included from the ongoing parent study for this analysis, 67 from the intervention group and 69 from the usual care group. Subjects were recruited from four cancer centers in western Pennsylvania and one from Western Ohio. Subjects were diagnosed with any stage invasive breast cancer and were undergoing chemotherapy. Overall HRQOL decreased significantly over three time points (p<0.01) primarily driven from the physical subscale. Adherence to prescribed chemotherapy was significantly correlated with HRQOL (r=0.32, p<0.01). Physical well‐being subscales decreased significantly over time. Energy, treatment side effects, feeling ill and spending time in bed during chemotherapy were items that decreased in score (increased in severity) most over three time points (decreased score >0.5 from time1 to time3). Energy and pain were the items with the lowest scores for the physical well‐being subscale at baseline and the two follow up assessments (mean score<3.0 out of 4). Conclusions: Worsening in physical symptoms and functional status was demonstrated over time among African American women receiving breast cancer chemotherapy. Lack of adherence to prescribed chemotherapy was significantly correlated with declining HRQOL. Implications for Practice: The influence of HRQOL on chemotherapy dose reduction and early treatment cessation was primarily from physical factors during chemotherapy for African American women. Clinically this emphasizes the importance of close QOL and symptom screening, encouraging symptom reporting and the need to exhaust symptom management options before early treatment termination.
AN  - CN-01142542
AU  - Rosenzweig, M. Q.
AU  - Liang, Z.
DO  - 10.1158/1538-7445.SABCS15-PD4-01
IS  - 4
KW  - *African American
*breast cancer
*cancer chemotherapy
*female
*human
*quality of life
Cancer center
Cancer survival
Cancer therapy
Chemotherapy
Drug dose reduction
Etiology
Follow up
Functional assessment
Functional status
Interpersonal communication
Medical record
Model
Pain
Parent
Patient
Patient compliance
Randomized controlled trial
Screening
Side effect
United States
Wellbeing
M3  - Journal: Conference Abstract
PY  - 2016
ST  - Longitudinal health related quality of life (HRQOL) and subsequent adherence to breast cancer chemotherapy among African American women
T2  - Cancer research
TI  - Longitudinal health related quality of life (HRQOL) and subsequent adherence to breast cancer chemotherapy among African American women
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01142542/full
VL  - 76
ID  - 1493
ER  - 

TY  - JOUR
AB  - Background: Regular adherence to screening mammography, also known as maintenance of mammography, reduces breast cancer morbidity and mortality. However, mammography maintenance is uncommon and little is know about why women do not maintain regular screening schedules. We investigated longitudinal predictors of women not maintaining adherence. Methods: Participants were insured women enrolled in an intervention trial who had screening mammograms 8 to 9 months before study enrollment (n = 1,493). Data were collected from 2003 to 2008. We used discrete event history analysis to model nonadherence to mammography maintenance over three successive annual screening intervals (+ 2 months). Results: Most (54%) women did not maintain screening adherence over 3 years. Women who did not maintain adherence were more likely to be ages 40 to 49 years, rate their health fair or poor, be less satisfied with their last mammography experiences, report one or more barriers to getting mammograms, be less than completely confident about getting their next mammograms (lower self-efficacy), or have weaker behavioral intentions. The odds of not maintaining adherence decreased over time. Discussion: Although great strides have been achieved in increasing the proportion of women who have received mammograms, most women still are not maintaining regular mammography use over time. Our findings provide insights into targets for future mammography maintenance interventions. Cancer Epidemiol Biomarkers Prev; 19(4); 1103-11. (C) 2010 AACR.
AN  - WOS:000278484400031
AU  - Gierisch, J. M.
AU  - Earp, J. A.
AU  - Brewer, N. T.
AU  - Rimer, B. K.
DA  - Apr
DO  - 10.1158/1055-9965.EPI-09-1120
IS  - 4
N1  - 20354125
PY  - 2010
SN  - 1055-9965
SP  - 1103-1111
ST  - Longitudinal Predictors of Nonadherence to Maintenance of Mammography
T2  - Cancer Epidemiology Biomarkers & Prevention
TI  - Longitudinal Predictors of Nonadherence to Maintenance of Mammography
VL  - 19
ID  - 3116
ER  - 

TY  - JOUR
AB  - Breast cancer patients' perceived risk of recurrence has been associated with psychological distress. Little is known about the change of patients' perceived risk of recurrence over time and factors associated with their recurrence-risk perceptions. We prospectively recruited 549 newly diagnosed early-stage breast cancer patients; patients completed interviews at 6 weeks, 6 months, 1 year, and 2 years after definitive surgical treatment. A random-effects regression model with repeated ordinal measurements was used to estimate the relationship between perceived risk of recurrence and demographic, medical, and psychosocial factors. We analyzed data from 535 patients [34% ductal carcinoma in situ (DCIS); 20% non-white] who reported their perceived risk at one or more interviews. At the first interview, 16% reported having no lifetime risk of recurrence, and another 16% reported >= 50% risk of recurrence, including 15% of DCIS patients. Patients who were white (OR = 5.88, 95% Cl 3.39-10.19) and had greater state anxiety (OR = 1.04, 95% CI 1.02-1.07) were more likely, while patients who received radiotherapy (OR = 0.72, 95% CI 0.54-0.96) and had more social support (OR = 0.59, 95% CI 0.46-0.75) were less likely to report higher risk of recurrence. Cancer stage was not significantly associated with perceived risk of recurrence. Perceived risk of recurrence did not change significantly over time. Educating early-stage breast cancer patients about their actual risk could result in more realistic recurrence-risk perceptions, and increasing social support could help alleviate anxiety associated with exaggerated risk perceptions.
AN  - WOS:000284508300028
AU  - Liu, Y.
AU  - Perez, M.
AU  - Schootman, M.
AU  - Aft, R. L.
AU  - Gillanders, W. E.
AU  - Ellis, M. J.
AU  - Jeffe, D. B.
DA  - Dec
DO  - 10.1007/s10549-010-0912-1
IS  - 3
N1  - 20446031
PY  - 2010
SN  - 0167-6806
SP  - 835-844
ST  - A longitudinal study of factors associated with perceived risk of recurrence in women with ductal carcinoma in situ and early-stage invasive breast cancer
T2  - Breast Cancer Research and Treatment
TI  - A longitudinal study of factors associated with perceived risk of recurrence in women with ductal carcinoma in situ and early-stage invasive breast cancer
VL  - 124
ID  - 3106
ER  - 

TY  - JOUR
AB  - Low-dose computed tomography (LDCT) screening may be a teachable moment for smoking cessation among African Americans. African Americans have been understudied within the context of LDCT and smoking cessation. The study objective was to evaluate the feasibility of recruiting African Americans to a future longitudinal trial and to obtain sample size estimates for that trial. Participants (N = 18) were African Americans eligible for LDCT screening who completed a questionnaire at three time points. Self-efficacy and intention to quit smoking were compared. The results of the current study show that it is feasible to recruit African Americans eligible for LDCT.
AD  - a Icahn School of Medicine at Mount Sinai , New York , New York , USA.
b Memorial Sloan Kettering Cancer Center , New York , New York , USA.
AN  - 30252615
AU  - Sly, J. R.
AU  - Miller, S. J.
AU  - Li, Y.
AU  - Bolutayo, K.
AU  - Jandorf, L.
C2  - PMC6433542
C6  - NIHMS982909
DA  - Nov-Dec
DO  - 10.1080/07347332.2018.1499693
DP  - NLM
ET  - 2018/09/27
IS  - 6
KW  - African Americans/*psychology/statistics & numerical data
Aged
Early Detection of Cancer/*methods
Feasibility Studies
Female
Humans
Intention
Lung Neoplasms/*ethnology/prevention & control
Male
Middle Aged
Self Efficacy
Smokers/*psychology/statistics & numerical data
Smoking Cessation/*ethnology/psychology
Surveys and Questionnaires
Tomography, X-Ray Computed
*African Americans
*cancer prevention
*lung cancer screening
*smoking cessation
*teachable moment
LA  - eng
N1  - 1540-7586
Sly, Jamilia R
Orcid: 0000-0002-0504-0728
Miller, Sarah J
Li, Yaqi
Bolutayo, Kemi
Jandorf, Lina
K01 CA204456/CA/NCI NIH HHS/United States
K07 CA190726/CA/NCI NIH HHS/United States
P30 CA008748/CA/NCI NIH HHS/United States
P30 CA196521/CA/NCI NIH HHS/United States
Journal Article
J Psychosoc Oncol. 2018 Nov-Dec;36(6):784-792. doi: 10.1080/07347332.2018.1499693. Epub 2018 Sep 25.
PY  - 2018
SN  - 0734-7332 (Print)
0734-7332
SP  - 784-792
ST  - Low-dose computed tomography lung cancer screening as a teachable moment for smoking cessation among African American smokers: A feasibility study
T2  - J Psychosoc Oncol
TI  - Low-dose computed tomography lung cancer screening as a teachable moment for smoking cessation among African American smokers: A feasibility study
VL  - 36
ID  - 101
ER  - 

TY  - JOUR
AB  - Objectives: To investigate the frequency and etiology of lower gastrointestinal hemorrhage (LGIH) in African-American and Hispanic elderly patients and to determine its natural history and the risks and benefits of therapeutic interventions. Setting: Inner-city community teaching hospital serving predominantly African-American and Hispanic populations. Methods: Records of 236 patients, 65 to 103 years of age, with a diagnosis of LGIH were reviewed retrospectively, over a period of 7 years, (9 White and 6 Asian patients were excluded). Results: In 21 patients, the source of bleeding was located in the upper gastrointestinal tract, and these patients were excluded from the study. The source of bleeding remained unidentified in 16 of 200 patients, and they were also excluded. Bleeding was so profuse in 19 patients that satisfactory endoscopy could not be performed and emergency angiography and/or surgery was required. Endoscopic results were available in 165 patients and included: internal hemorrhoids in 60 (active bleeding in 23) patients, diverticular bleeding in 55, angiodysplasia in 50, polyps in 37, cancer in 23, drug-induced (anti-coagulants, non-steroidal anti-inflammatory drugs) lesions in 20, ischemic colitis in 15, ulcerative colitis in 10, solitary rectal ulcer in 9, Crohn's disease in 8, and colonic varices in 6 patients. Forty-eight patients had more than one lesion. Endoscopic therapy was given to 101 patients and was helpful in stopping bleeding and/or delaying surgery in 69 patients. Overall, there were 43 deaths, mostly due to underlying multiple system disease. Mortality rates did not differ by race/ethnicity or gender. Older elderly (76-85 yrs.; P<0.01) and (>85 yrs.; P<0.001) had higher mortality rates. None of the deaths were directly due to endoscopy. Conclusions: Despite the small number of patients, our study suggests that acute LGIH in African-American and Hispanic elderly patients is a common condition, with the potential to become a life-threatening event. All such patients should be offered the benefits of early endoscopy and therapeutic interventions, unless contraindicated by their advanced directives. A patient's advanced age should not be a deterrent to any of the diagnostic or therapeutic interventions.
AD  - A.J. Akhtar, Department of Internal Medicine, King-Drew Medical Center, Division of Gastroenterology, 12021 South Wilmington Avenue, Los Angeles, CA 90059, United States
AU  - Akhtar, A. J.
C1  - aspirin
DB  - Embase
Medline
IS  - 3
KW  - acetylsalicylic acid
alcohol
anticoagulant agent
antiinflammatory agent
nonsteroid antiinflammatory agent
abdominal angiography
age
aged
alcohol abuse
angiodysplasia
article
colon Crohn disease
colon diverticulosis
colon polyp
community hospital
controlled study
death
diagnostic procedure
disease severity
drug induced disease
early diagnosis
elderly care
emergency surgery
endoscopic surgery
ethnology
female
frequency analysis
gastrointestinal endoscopy
gastrointestinal hemorrhage
gender
hemorrhoid
human
human tissue
intestine cancer
intestine injury
ischemic colitis
major clinical study
male
medical record
mortality
patient selection
race difference
rectum ulcer
retrospective study
risk benefit analysis
treatment contraindication
ulcerative colitis
upper gastrointestinal tract
varicosis
aspirin
LA  - English
M3  - Article
N1  - L34893390
2002-08-27
PY  - 2002
SN  - 1049-510X
SP  - 379-382
ST  - Lower gastrointestinal hemorrhage in African-American and hispanic elderly patients
T2  - Ethnicity and Disease
TI  - Lower gastrointestinal hemorrhage in African-American and hispanic elderly patients
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L34893390&from=export
VL  - 12
ID  - 1299
ER  - 

TY  - JOUR
AB  - Objective: The study examined whether vitamin D insufficiency is a predictor of prevalent and/or incident common chronic conditions in African American men (AAM) and Caucasian American men (CAM). Methods: A total of 1,017 men were recruited at an urban VA medical center and followed prospectively for a mean of 5.4 years. Prevalent and incident chronic conditions evaluated were: obesity, type 2 diabetes, cancer, depression, dementia, and cardiovascular disease (CVD, including coronary artery disease [CAD], cerebrovascular accident [CVA], and congestive heart failure [CHF]). Univariate and multivariate regressions were performed to examine the association between 25-hydroxyvitamin D (25[OH]D) and these chronic illnesses. Results: This analysis was limited to 955 men (65.5% AAM, 27.2% CAM, 6.4% Hispanic) who had at least 1 year of follow-up (range, 1.0 to 7.1 years). Univariate analysis of the entire group showed that 25(OH)D correlated negatively with body mass index (BMI). There was no correlation between 25(OH) D and prevalent CVD (including separate analyses for CAD, CVA, and CHF), cancer, depression, dementia, all-cause mortality, or incident cancer, CAD, or CVA. Independent predictors of prevalent common conditions included increasing age, BMI, smoking, alcohol and polysubstance use, but not 25(OH)D levels. Conclusion: The study does not support previously suggested associations of low vitamin D levels with prevalent common chronic conditions or increased risk for cancer, CAD, and CVA in a population of men with high burden of chronic disease. The finding that smoking and alcohol and polysubstance use are predictors of chronic conditions is an important reminder for addressing these risks during patient encounters.
AN  - WOS:000397863200004
AU  - Cartier, J. L.
AU  - Kukreja, S. C.
AU  - Barengolts, E.
DA  - Mar
DO  - 10.4158/EP161456.OR
IS  - 3
N1  - 27849379
PY  - 2017
SN  - 1530-891X
SP  - 271-278
ST  - Lower Serum 25-Hydroxyvitamin D Is Associated with Obesity but Not Common Chronic Conditions: An Observational Study of African American and Caucasian Male Veterans
T2  - Endocrine Practice
TI  - Lower Serum 25-Hydroxyvitamin D Is Associated with Obesity but Not Common Chronic Conditions: An Observational Study of African American and Caucasian Male Veterans
VL  - 23
ID  - 2907
ER  - 

TY  - JOUR
AB  - Background: The 15‐year Women's Health Initiative (WHI) sponsored by the NIH has provided a robust dataset on health risks for post‐menopausal black women (BW), including the impact of hormone therapy (HRT) on cancer risk. Women enrolled in the WHI randomized, placebo‐controlled trial and taking HRT demonstrated no increase in lung cancer incidence, but a statistically significant increase in mortality. However, effects of estrogen plus progestin on non‐small cell lung cancer (NSCLC) incidence and outcomes has not been extensively examined, especially in African Ancestry (AA) and smoking history. Methods: Study participants were identified who met WHI clinical trial entry criteria. Cox regression models and Kaplan‐Meier method plots were utilized. Analyses adjusted for age, BMI, education, smoking status, alcohol use, health status, and physical activity. A secondary analysis was performed on BW based on AA via Affymetrix Human SNP Array. Results: 161, 808 pts were enrolled from October 1993 to December 1998 (after exclusions total analytic cohort = 142,503). 128,682 (90%) were white (WW) and 13,821 (10%) were BW. BW had lower incidence of NSCLC compared to WW (HR 0.68; P <.0001). HRT participants had a 55% increase in incidence of NSCLC (p <.0001). Former alcohol users had highest risk of NSCLC incidence (HR 2.72; p < 0.0001). Age groups (55‐59 years; 60‐69 years; 70‐79 years) were significantly less associated with BW compared to the youngest(50‐54 years; P <.0001). HRT participants were more likely BW (OR 1.17; p <.0001). More current smokers were BW compared to WW (OR 1.75; p <.0001). HRT participants had increased risk of death to NSCLC (HR 1.29; p <.001). There was a trend for survival (p = 0.3667) in WW participants compared to BW (32 vs 28.0 months, respectively). BW who had > 80% AA had a decreased incidence NSCLC trend compared to BW with < 80% AA (HR 0.81; p = 0.2806). Conclusions: BW, especially those with high levels of AA had decreased incidence of NSCLC. Those patients who received HRT had higher incidence and death from NSCLC. Further investigations are required to understand the mechanisms that AA and HRT alter risks associated with NSCLC.
AN  - CN-02011135
DO  - 10.1200/JCO.2019.37.15_suppl.e18258
KW  - *African American
*non small cell lung cancer
Adult
Alcohol consumption
Body mass
Cancer incidence
Cancer patient
Cancer survival
Cohort analysis
Conference abstract
Controlled study
Current smoker
Education
Female
Groups by age
Health status
Hormonal therapy
Human
Kaplan Meier method
Major clinical study
Male
Middle aged
Mortality
Physical activity
Secondary analysis
Single nucleotide polymorphism
Women's health
M3  - Journal: Conference Abstract
PY  - 2019
ST  - Lung cancer in African-Americans and analysis of estrogen plus progestin use
T2  - Journal of clinical oncology
TI  - Lung cancer in African-Americans and analysis of estrogen plus progestin use
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02011135/full
VL  - 37
ID  - 1362
ER  - 

TY  - JOUR
AB  - Lung cancer is the leading cause of cancer morbidity and mortality in the U.S. and racial/ethnic minorities carry the greatest burden of lung cancer disparities with African Americans (AAs) impacted disproportionately. Inequities in lung cancer health disparities are often associated with multiple bio-behavioral and socio-cultural factors among racial/ethnic minorities. Epigenetic research has advanced the understanding of the intersectionality between biological and socio-cultural factors in lung cancer disparities among AAs. However, gaps exist in the engagement of diverse populations in epigenetic lung cancer research, which poses a challenge in ensuring the generalizability and implementation of epigenetic research in populations that carry an unequal cancer burden. Grounding epigenetic lung cancer research within a socio-ecological framework may prove promising in implementing a multi-level approach to community engagement, screening, navigation, and research participation among AAs. The University of Illinois Cancer Center (UI Cancer Center) is employing an evidence-based (EB) model of community/patient engagement utilizing the socio-ecological model (SEM) to develop a culturally sensitive epigenetic lung cancer research program that addresses multiple factors that impact lung cancer outcomes in AAs. By implementing epigenetic research within a group of Federally Qualified Health Centers (FQHCs) guided by the SEM, the UI Cancer Center is proposing a new pathway in mitigating lung cancer disparities in underserved communities. At the individual level, the framework examines tobacco use among patients at FQHCs (the organizational level) and also tailors epigenetic research to explore innovative biomarkers in high risk populations. Interpersonal interventions use Patient Navigators to support navigation to EB tobacco cessation resources and lung cancer screening. Community level support within the SEM is developed by ongoing partnerships with local and national partners such as the American Lung Association (ALA) and the American Cancer Society (ACS). Lastly, at the policy level, the UI Cancer Center acknowledges the role of policy implications in lung cancer screening and advocates for policies and screening recommendations that examine the current guidelines from the United States Preventive Services Task Force (USPTF).
AN  - WOS:000460956100001
AU  - Watson, K. S.
AU  - Hulbert, A.
AU  - Henderson, V.
AU  - Chukwudozie, I. B.
AU  - Aponte-Soto, L.
AU  - Lerner, L.
AU  - Martinez, E.
AU  - Kim, S.
AU  - Winn, R. A.
DA  - Mar
DO  - 10.3389/fonc.2019.00087
N1  - 87
30915271
PY  - 2019
SN  - 2234-943X
ST  - Lung Cancer Screening and Epigenetics in African Americans: The Role of the Socioecological Framework
T2  - Frontiers in Oncology
TI  - Lung Cancer Screening and Epigenetics in African Americans: The Role of the Socioecological Framework
VL  - 9
ID  - 2828
ER  - 

TY  - JOUR
AB  - Purpose: Overall lung surgery rates and black/white disparities have not improved during a decade of documentation. The goal of this study is to incorporate lessons from the previous prospective cohort study to optimize lung cancer surgery rates and narrow black‐white disparities for patients diagnosed with stage I or II, non‐small cell lung cancer. Participants: Stage I and II, non‐small cell lung cancer at 3 participating sites. Procedures: Phase I of the study has been completed. Phase I was a deidentified 3‐year, retrospective chart review, used to establish the baseline surgical rates for the intervention. The patient enrollment phase of the study will move forward that will include use of a real time registry to follow patient progression through clinical follow up, diagnostic testing and treatment for biopsy proven or highly probable early stage, non‐small cell lung cancer. The patient enrollment portion of the study will start, September 2012. All patients with Stage I or II non‐small cell lung cancer who enroll in the study will be entered into real time registries at every site. Patients' progress through the registries including follow‐up provider visits, diagnostic tests, and procedures will be transparent and any missed appointments will be flagged. Feedback will be given to lung cancer providers in both arms. The randomized trial will compare patients who receive usual care plus the registry to those who receive the registry plus visits and calls from a trained cancer communicator ‐educator (CCE) who is well versed in issues specific to lung cancer and trained in active listening and communication that accounts for patients' limitations in health literacy. The CCE will also use Kleinman's Patient Model to identify attitudes or beliefs that represent barriers to recommended care that could potentially be addressed through negotiation and more targeted communication. The hypothesis is that an electronic warning system, data transparency, and enhanced communication will optimize lung surgery rates and reduce racial gaps.
AN  - CN-01581340
AU  - Nct
KW  - Carcinoma, Non‐Small‐Cell Lung
Lung Neoplasms
PY  - 2012
ST  - Lung Cancer Surgery: decisions Against Life Saving Care - The Intervention
T2  - https://clinicaltrials.gov/show/NCT01687738
TI  - Lung Cancer Surgery: decisions Against Life Saving Care - The Intervention
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01581340/full
ID  - 1411
ER  - 

TY  - JOUR
AB  - Background: LVI and black race are associated with poorer prognosis in early breast cancer (BCA). The Oncotype DX 21‐gene Recurrence Score (RS) is both prognostic for recurrence and predictive of chemotherapy benefit in estrogen‐receptor positive (ER+), HER2‐negative (HER2‐) early BCA. Black women enrolled on the TAILORx trial, which assigned or randomized women with hormone receptor‐positive, HER2‐, node‐negative (N0) BCA to adjuvant therapy based on RS, had a 1.4‐fold higher risk of recurrence than white women, despite similar RS distribution, treatment, and reported adherence to endocrine therapy. No prior studies have evaluated the impact of LVI, RS, and race in the same population, to assess whether LVI contributes to racial disparities or adds prognostic information to RS. Methods: Female patients diagnosed between 1/1/2010 (the first year LVI was collected by NCDB) and 1/1/2014 with ER+ HER2‐BCA, measuring up to 5 cm, with 0‐3 involved axillary nodes, treated with definitive surgery as first treatment, and with numeric RS available, were identified from the 2005‐2016 NCDB database. Bivariate associations between two categorical variables were examined using the chi‐square test. Multivariate Cox proportional hazards model were used to assess association between LVI, chemotherapy and RS on overall survival (OS), while adjusting age, race, tumor size, grade, LN status, median income, and education level. The estimated HR for each variable in the model, along with its 95% CI, was reported. All tests are two‐sided with significance level =5%. All analyses were conducted using SAS 9.4. Results: 77,425 women met inclusion criteria, 65,018 N0 and 12,407 node‐positive (N+). 2870 deaths were seen. LVI was present in 12.7% of cases, and associated with poor tumor grade, high RS =26, and N+ (all p<0.0001), but not black race. Black race was associated with with larger tumor size, poorer tumor grade, high RS =26, and N+ (all p<0.0001). Tumor‐related factors associated with poorer OS included LVI (p<0.0001), larger tumor size (21‐50 vs 0‐20 mm, p<0.0001), higher RS (11‐25 vs 0‐10, p=0.039, =26 vs 0‐10, p<0.0001), poor histologic grade (3 vs 1, p<0.0001) and N+ (p<0.0001). Demographic factors associated with worse OS were older age (p<0.0001) and black race (p<0.0001). Median income was inversely associated with OS (p<0.0001). LVI correlated with poor grade and higher RS, and with N+ (p<0.0001). LVI was associated with worse OS in the entire cohort [HR 1.241 (95% CI 1.120, 1.375, p<0.0001)] and in N0 patients [HR 1.355 (95% CI 1.195, 1.536, p<0.0001)], but not in N+. LVI was associated with worse OS in N0 patients with RS 11‐25 [HR 1.292 (95% CI 1.074, 1.555)] and =26 [HR 1.553 (95% CI 1.277, 1.888)], but not in patients with RS 0‐10. Test for interaction between RS and LVI was not significant. Conclusion: LVI adds prognostic information in ER+, HER2‐, N0 BCA with RS 11‐100. Black race is associated with worse OS, and with adverse prognostic factors such as high grade and high RS, but not with LVI.
AN  - CN-02146614
DO  - 10.1158/1538-7445.SABCS19-P3-08-06
IS  - 4
KW  - *Black person
*cancer recurrence
*human epidermal growth factor receptor 2 negative breast cancer
*lymph vessel metastasis
Aged
Axillary lymph node
Cancer chemotherapy
Cancer grading
Cancer patient
Cancer prognosis
Cancer size
Cancer staging
Cancer surgery
Cancer survival
Cohort analysis
Conference abstract
Controlled study
Demography
Education
Female
Histology
Human
Human epidermal growth factor receptor 2 positive breast cancer
Major clinical study
Overall survival
Tumor‐related gene
M3  - Journal: Conference Abstract
PY  - 2020
ST  - Lymphovascular invasion (LVI), the 21-gene recurrence score, and race in early estrogen receptor-positive, HER2-negative breast cancer: a national cancer database (NCDB) analysis
T2  - Cancer research
TI  - Lymphovascular invasion (LVI), the 21-gene recurrence score, and race in early estrogen receptor-positive, HER2-negative breast cancer: a national cancer database (NCDB) analysis
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02146614/full
VL  - 80
ID  - 1580
ER  - 

TY  - JOUR
AB  - BACKGROUND: Various methods are reported as aids to cecal intubation for cases in which colonoscopy is difficult. This study aimed to investigate prospectively whether a gastroscope with magnification function, narrow-band imaging (NBI), and a soft black hood can aid insertion in cases of difficult colonoscopy and facilitate both accurate diagnosis and safe treatment. METHODS: This prospective study recruited 177 patients. All were examined with a magnifying gastroscope. A commercially available soft black hood was attached to the gastroscope during insertion and magnification. Difficult colonoscopy was anticipated before colonoscopy in cases of patients with at least one of the following factors: low BMI (<20 kg/m(2)), adhesion due to previous surgery, or previous colonoscopy that could not reach to the cecum. The success rate and duration of cecal intubation then were assessed. All detected lesions were evaluated by magnifying NBI and then classified as non-neoplastic or neoplastic for endoscopic diagnosis. Subsequently, all the lesions were removed and examined histologically for comparison. RESULTS: The overall success rate of cecal intubation was 100% (177/177), and the mean time taken to reach the cecum was 5.9 min. A total of 156 lesions were detected endoscopically, and the overall diagnostic accuracy of NBI with magnification was 98.7%. No associated complications occurred. CONCLUSION: Magnifying gastroscopy using a soft black hood and NBI is useful for cecal intubation in cases wherein colonoscopy is difficult, facilitating accurate diagnosis and safe treatment.
AD  - Department of Gastroenterology, Chofu Surgical Clinic, Tokyo, Japan.
AN  - 21487877
AU  - Nakamura, H.
AU  - Fu, K.
AU  - Yamamura, A.
DA  - Sep
DO  - 10.1007/s00464-011-1662-9
DP  - NLM
ET  - 2011/04/14
IS  - 9
KW  - Adenocarcinoma/diagnosis
Adenoma/diagnosis
Adult
Aged
Aged, 80 and over
Carcinoid Tumor/diagnosis
Cecum
Colonic Neoplasms/diagnosis
Colonic Polyps/diagnosis
Colonoscopy/*instrumentation/methods
Equipment Design
Female
*Gastroscopes
Humans
Male
Middle Aged
Prospective Studies
Video Recording
Young Adult
LA  - eng
N1  - 1432-2218
Nakamura, Hisashi
Fu, Kuangi
Yamamura, Akihiko
Clinical Trial
Journal Article
Germany
Surg Endosc. 2011 Sep;25(9):3016-21. doi: 10.1007/s00464-011-1662-9. Epub 2011 Apr 13.
PY  - 2011
SN  - 0930-2794
SP  - 3016-21
ST  - Magnifying gastroscopy using a soft black hood for difficult colonoscopy
T2  - Surg Endosc
TI  - Magnifying gastroscopy using a soft black hood for difficult colonoscopy
VL  - 25
ID  - 396
ER  - 

TY  - JOUR
AB  - Edith Joyner, 61, won't personally benefit from participating in the Sister Study, but it was important for her to join, she says, not only to honor her two sisters who battled the disease, but to help the next generation of females in her family avoid the same fate.
AN  - 105802558. Language: English. Entry Date: 20080829. Revision Date: 20150711. Publication Type: Journal Article
AU  - Cavallo, J.
DA  - 2008 Spring
DB  - CINAHL Complete
DP  - EBSCOhost
IS  - 1
KW  - Black Persons
Breast Neoplasms -- Prevention and Control
Clinical Trials
Female
Middle Age
Research Subject Recruitment
N1  - brief item; pictorial. Journal Subset: Consumer Health; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA. NLM UID: 101145998.
PY  - 2008
SN  - 1534-7664
SP  - 37-37
ST  - Making a difference
T2  - CURE: Cancer Updates, Research & Education
TI  - Making a difference
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105802558&site=ehost-live&scope=site
VL  - 7
ID  - 1996
ER  - 

TY  - JOUR
AB  - BACKGROUND: Ongoing debate about mammography screening for women in their 40s has brought awareness to the opportunities and challenges for achieving optimal breast health in young African American women and in battling health inequities that place them at greater risk for mortality from breast cancer. Despite the screening controversy, a need exists to understand the complex issues related to mammography knowledge, attitudes, and behaviors of young minority women, while empowering them to take an active role in their breast health care. OBJECTIVES: The purpose of this article is to describe the complicated issues related to screening in young African American women within the context of the uncertainty about the evidence surrounding screening practices. METHODS: Literature was reviewed to garner a comprehensive update of the mammography screening controversy and its impact on mammography practices. FINDINGS: Nurses should be aware of the mammography screening controversy and breast cancer risk assessment and how they affect young women's participation in mammography screening. Mammography screening should be a shared decision between the patient and healthcare provider. A better understanding of breast health and its effect on young minority women is needed. Nurses have a prominent role to advocate for, empower, and educate patients as they face the task of deciding whether to begin or continue mammography in their 40s.
AD  - U.S. Public Health Service Commissioned Corps.
Duquesne University in Pittsburgh, PA.
University of Texas Health Science Center in San Antonio.
AN  - 26000591
AU  - Kidd, A. D.
AU  - Colbert, A. M.
AU  - Jatoi, I.
DA  - Jun
DO  - 10.1188/15.Cjon.E52-e58
DP  - NLM
ET  - 2015/05/23
IS  - 3
KW  - Adult
*African Americans
Breast Neoplasms/*diagnosis
Decision Making
Early Detection of Cancer
Female
Health Status Disparities
Humans
*Mammography
*Patient Participation
African American women
Patient education
breast cancer
health disparities
individual risk
mammography
LA  - eng
N1  - 1538-067x
Kidd, April D
Colbert, Alison M
Jatoi, Ismail
Journal Article
Review
United States
Clin J Oncol Nurs. 2015 Jun;19(3):E52-8. doi: 10.1188/15.CJON.E52-E58.
PY  - 2015
SN  - 1092-1095
SP  - E52-8
ST  - Mammography: review of the controversy, health disparities, and impact on young african american women
T2  - Clin J Oncol Nurs
TI  - Mammography: review of the controversy, health disparities, and impact on young african american women
VL  - 19
ID  - 239
ER  - 

TY  - JOUR
AB  - Objective: Evidence suggests that treatment side‐effects of prostate cancer (CaP) substantially affect the psychosocial well‐being of affected men and their partners. However, this phenomenon is poorly understood among high risk (1 in 4) Black African (BA)/Black Caribbean (BC) men and their partners, as they are currently under‐represented in global research on CaP survivorship. This study explored the psychosocial experiences of BA/BC men with CaP and their partners in the United Kingdom as they lived through the side effects of CaP treatment within their own sociocultural and marital contexts. Methods: Using constructivist grounded theory methodology, interviews and focus groups were conducted with eligible men (n = 25), partners (n = 11), and health care professionals (HCPs) (n = 11) recruited in England. Data were iteratively analysed using constant comparison following the key stages of initial, focused, and theoretical coding until saturation was achieved. Results: Data analysis culminated in the development of a substantive theory 'man in the driving seat,' which describes the experiences of BA/BC men with CaP and their partners within their context. Culturally informed gender roles and identities influenced how men and partners responded and coped with the side effects of CaP treatment. There was a hierarchy of power within the BA/BC relationship, in which men were dominantly positioned as leaders, whilst partners mostly operated from a supportive but 'accepting' position. Conclusion: Inclusive and culturally sensitive individual and couple‐focused psychosocial support, which is devoid of stereotyping and recognises the experiences of both BA/BC men and their partners is recommended. (PsycINFO Database Record (c) 2020 APA, all rights reserved)
AD  - Bamidele, Olufikayo, Institute of Nursing and Health Research, Ulster University, Jordanstown, Northern Ireland
AN  - 2019-37007-001
AU  - Bamidele, Olufikayo
AU  - McGarvey, Helen
AU  - Lagan, Briege M.
AU  - Parahoo, Kader
AU  - Chinegwundoh Mbe, Frank
AU  - McCaughan, Eilís
DB  - psyh
DO  - 10.1002/pon.5150
DP  - EBSCOhost
IS  - 8
KW  - Black African
Black Caribbean
experiences
grounded theory
men
partners
prostate cancer
oncology
psychosocial
Blacks
Neoplasms
Prostate
African Cultural Groups
Psychosocial Factors
N1  - Institute of Nursing and Health Research, Ulster University, Jordanstown, Northern Ireland. Release Date: 20190708. Correction Date: 20200123. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: English. Grant Information: Bamidele, Olufikayo. Major Descriptor: Blacks; Grounded Theory; Neoplasms; Prostate; Partners. Minor Descriptor: African Cultural Groups; Psychosocial Factors. Classification: Cancer (3293). Population: Human (10); Male (30); Female (40). Location: England. Age Group: Adulthood (18 yrs & older) (300). Methodology: Empirical Study; Interview; Focus Group; Qualitative Study. Supplemental Data: Tables and Figures Internet. Page Count: 9. Issue Publication Date: Aug, 2019. Publication History: Accepted Date: Jun 2, 2019; Revised Date: May 30, 2019; First Submitted Date: Mar 8, 2019. Copyright Statement: John Wiley & Sons, Ltd. 2019.
Sponsor: Ulster University, Northern Ireland. Other Details: Vice Chancellor's Research Scholarship. Recipients: Bamidele, Olufikayo
PY  - 2019
SN  - 1057-9249
1099-1611
SP  - 1712-1720
ST  - 'Man in the driving seat': A grounded theory study of the psychosocial experiences of Black African and Black Caribbean men treated for prostate cancer and their partners
T2  - Psycho-Oncology
TI  - 'Man in the driving seat': A grounded theory study of the psychosocial experiences of Black African and Black Caribbean men treated for prostate cancer and their partners
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2019-37007-001&site=ehost-live&scope=site
ORCID: 0000-0001-5536-394X
ORCID: 0000-0001-9145-8778
ORCID: 0000-0003-2235-9463
bamidele-o@ulster.ac.uk
VL  - 28
ID  - 1673
ER  - 

TY  - JOUR
AN  - 8866197
AU  - Haynes, M. A.
DA  - Jul
DP  - NLM
ET  - 1996/07/01
IS  - 7
KW  - *African Americans
*African Continental Ancestry Group
Humans
Male
Mass Screening
Neoplasm Staging
Patient Participation
Prevalence
Prostatic Neoplasms/diagnosis/*ethnology/mortality/*therapy
United States/epidemiology
LA  - eng
N1  - Haynes, M A
Journal Article
Review
United States
Compr Ther. 1996 Jul;22(7):449-53.
PY  - 1996
SN  - 0098-8243 (Print)
0098-8243
SP  - 449-53
ST  - The management of prostate cancer in blacks: the physician's dilemma intensified
T2  - Compr Ther
TI  - The management of prostate cancer in blacks: the physician's dilemma intensified
VL  - 22
ID  - 739
ER  - 

TY  - JOUR
AB  - Uterine fibroids occur in approximately 50% of women over the age of 40 years, and an estimated 50% of those are symptomatic. Menorrhagia is the most common symptom and the primary indication for treatment, although bulk symptoms often occur and can be treated. Pharmacotherapy is typically inadequate unless it can be expected to successfully bridge to menopause or allow for a less-invasive intervention. However, hormonal therapies have risks. Hysterectomy is still the most commonly performed procedure for symptomatic fibroids and has the lowest rate of reintervention (compared with myomectomy or uterine artery embolization [UAE]), but rates of more serious complications are higher and patient satisfaction and ability to return to normal activities may also be less favorable. Myomectomy is not necessarily less morbid than hysterectomy and may have a greater failure rate than UAE. Techniques and devices vary with little standardization, and operator experience is crucial to success. The largest studies of UAE show very low rates of serious complications and rapid recovery. UAE significantly improves symptoms related to uterine fibroids in 85%-90% of patients. Herein, this article will discuss the nature of fibroids and their diagnosis, pharmacotherapy, surgical treatment, and nonsurgical interventional treatment, including UAE and magnetic resonance-guided focused ultrasound.
AD  - D.K. Powell, West Cancer Center, University of Tennessee Health Science Center, 7945 Wolf River Boulevard, Germantown, TN, United States
AU  - Silberzweig, J. E.
AU  - Powell, D. K.
AU  - Matsumoto, A. H.
AU  - Spies, J. B.
C1  - eligard(Sanofi Aventis,Canada)
C2  - Sanofi Aventis(Canada)
DB  - Embase
Medline
DO  - 10.1148/radiol.2016141693
IS  - 3
KW  - chemokine
cytokine
growth factor
leuprorelin
levonorgestrel
oral contraceptive agent
progesterone receptor
acne
adenomyosis
African American
anemia
aortography
arterial embolization
article
Asian
body weight disorder
breast tenderness
Caucasian
cerebrovascular accident
connective tissue
conservative treatment
diabetes mellitus
extracellular matrix
female
fluid retention
gallstone
high intensity focused ultrasound
Hispanic
hormonal therapy
human
hypertension
hysterectomy
liver adenoma
menopausal syndrome
menopause
menorrhagia
menstruation
mood disorder
myomectomy
nuclear magnetic resonance
nuclear magnetic resonance imaging
pathogenesis
patient satisfaction
patient selection
priority journal
risk reduction
sexual dysfunction
sexual function
standardization
symptomatology
treatment indication
ultrasound therapy
uterine artery
uterine artery embolization
uterus myoma
venous thromboembolism
eligard
LA  - English
M3  - Article
N1  - L612077518
2016-09-14
2016-09-20
PY  - 2016
SN  - 1527-1315
0033-8419
SP  - 675-692
ST  - Management of uterine fibroids: A focus on uterine-sparing interventional techniques
T2  - Radiology
TI  - Management of uterine fibroids: A focus on uterine-sparing interventional techniques
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L612077518&from=export
http://dx.doi.org/10.1148/radiol.2016141693
VL  - 280
ID  - 965
ER  - 

TY  - JOUR
AB  - Objective: The purpose of this study was to examine the effects of a theory-based decision-making uncertainty management intervention (DMUMI) providing newly diagnosed prostate cancer patients with information, communication skills and personally designed prompts. Methods: A randomized clinical trial was conducted using a 3 × 2 design with intervention and control groups including both Caucasian and African-American men. General linear mixed models were used to compare intervention groups over time. Results: Significant main effects for the treatment groups were found for uncertainty management (cancer knowledge, problem-solving, and patient–provider communication), medical communication competence, number and helpfulness of resources for information, and decisional regret. Conclusion: The intervention was effective in uncertainty management for Caucasian and African-American men, specifically in preparing competent patients with improved knowledge, problem-solving skills, information resources, and communication skills. Using the Uncertainty in Illness Theory, specific skills were selected with a focus on the antecedents of uncertainty. Practice implications: In the treatment decision-making context, patients and supportive others need information about disease, treatment options and side effects but they also need communication skills training prior to the treatment decision consultation. (PsycInfo Database Record (c) 2020 APA, all rights reserved)
AD  - Mishel, Merle H., University of North Carolina at Chapel Hill, CB# 7460, Chapel Hill, NC, US, 27599
AN  - 2009-23096-008
AU  - Mishel, Merle H.
AU  - Germino, Barbara B.
AU  - Lin, Lin
AU  - Pruthi, Raj S.
AU  - Wallen, Eric M.
AU  - Crandell, Jaime
AU  - Blyler, Diane
DB  - psyh
DO  - 10.1016/j.pec.2009.09.009
DP  - EBSCOhost
IS  - 3
KW  - uncertainty management intervention
treatment decision making
prostate cancer
clinical trials
medical communication
Communication
Decision Making
Humans
Linear Models
Male
Middle Aged
Models, Psychological
Patient Satisfaction
Physician-Patient Relations
Prostatic Neoplasms
Psychometrics
Uncertainty
Intervention
Neoplasms
Therapeutic Processes
Impression Management
Prostate
N1  - School of Nursing, University of NC at Chapel Hill, Chapel Hill, NC, US. Release Date: 20100215. Correction Date: 20201005. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: English. Major Descriptor: Clinical Trials; Decision Making; Intervention; Neoplasms; Therapeutic Processes. Minor Descriptor: Impression Management; Prostate; Uncertainty. Classification: Medical Treatment of Physical Illness (3363). Population: Human (10); Male (30). Location: US. Age Group: Adulthood (18 yrs & older) (300). Tests & Measures: Self-control Schedule—Problem Solving Subscale; Types of Information Checklist; Quality of Life Scale—Decisional Regret Subscale; Profile of Mood States--Short Form DOI: 10.1037/t20023-000; Patient-Provider Communication Scale [Appended] DOI: 10.1037/t22797-000; Prostate Cancer Knowledge Scale [Appended] DOI: 10.1037/t22799-000; Medical Communication Competence Scale DOI: 10.1037/t07804-000; Mini Mental State Examination. Methodology: Empirical Study; Quantitative Study. References Available: Y. Page Count: 11. Issue Publication Date: Dec, 2009. Publication History: Accepted Date: Sep 9, 2009; Revised Date: Sep 2, 2009; First Submitted Date: Sep 30, 2008. Copyright Statement: All rights reserved. Elsevier Ireland Ltd. 2009.
Sponsor: National Institutes of Health, National Institute of Nursing Research, US. Grant: 5RO1 NR08144. Recipients: No recipient indicated
PY  - 2009
SN  - 0738-3991
1873-5134
SP  - 349-359
ST  - Managing uncertainty about treatment decision making in early stage prostate cancer: A randomized clinical trial
T2  - Patient Education and Counseling
TI  - Managing uncertainty about treatment decision making in early stage prostate cancer: A randomized clinical trial
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2009-23096-008&site=ehost-live&scope=site
mishel@email.unc.edu
VL  - 77
ID  - 1792
ER  - 

TY  - JOUR
AB  - Background: While CBGT has been found effective in treating VMS for women with breast cancer (MENOS1), CBGT has not been studied comparing outcomes among women of differing race and psychiatric diagnoses. This preliminary study evaluated effects of a CBGT treatment developed by Hunter & Smith (2015)on primary outcomes of hot flash frequency and problem rating (HFF‐PR), hot flash daily interference (HFDIS)and quality of life (QOL). Secondary outcomes included depression, anxiety, perceived stress (PS), anhedonia, and hot flash beliefs (HFBS). Methods: This cross‐cultural, non‐randomized, clinical trial (NCT02860910)enrolled 59 black and white peri‐ and postmenopausal women with chronic, remitting and relapsing major depression (MDD)or bipolar disorder (BD)with or without anxiety disorder. The intervention was delivered in groups of 4 to 7 participants for 6 consecutive weeks. Participants were recruited from a University Hospital outpatient setting in the Midwest‐USA. All participants had ≥ 7 problematic VMS per week, were not taking HT, were stable on psychotropic medications for ≥ 8 weeks, and were 40–65 years old. Menopause had been naturally or surgically induced. Assessments were collected at baseline (BL)and at 6 weeks/end of study (EOS). The main analysis examined change from baseline to 6 weeks in the intent‐to‐treat (ITT)population. Results: Mean age was 53 (SD 5.4), 57.6% (N = 34)black; 55 (SD 5.8), 42.4% (N = 25)white; 81.4% (N = 48)with MDD; 18.6% (N = 11)with BD and other psychiatric diagnoses; and 64.4% (N = 38)with generalized anxiety. Significantly more white women were married, had more education, and a lower BMI compared to black women. Four women terminated the study prematurely. The sample improved significantly on HF problem rating and HFDIS p <.001, and QOL p =.0015, but not on HFF. Depression, anxiety, and PS significantly reduced from BL to EOS at p ≤.001. Pleasure in life and positive beliefs about coping with HF significantly increased from BL to EOS at p ≤.001. There were no significant racial differences or differences based on psychiatric diagnoses in primary outcomes. Conclusions: Manualized CBGT appears to be an effective treatment for women with bothersome VMS and mood disorders. Randomized controlled trials are needed to further study this treatment with this population.
AN  - CN-01937592
AU  - Conklin, D.
AU  - Ganocy, S.
AU  - Goto, T.
AU  - Lagrotta, C.
AU  - D'Arcangelo, N.
AU  - Sajatovic, M.
DO  - 10.1016/j.maturitas.2019.04.106
KW  - *DSM‐5
*bipolar disorder
*group therapy
Adult
Aged
Anhedonia
Anxiety disorder
Body mass
Breast cancer
Cancer recurrence
Clinical article
Conference abstract
Controlled study
Female
Hot flush
Human
Major depression
Male
Married person
Middle aged
Outcome assessment
Outpatient
Pleasure
Postmenopause
Psychiatric diagnosis
Quality of life
Race difference
Randomized controlled trial
Remission
Stress
University hospital
M3  - Journal: Conference Abstract
PY  - 2019
SP  - 146‐
ST  - Manualized cognitive behavioral group therapy (CBGT)to treat vasomotor symptoms (VMS)for black and white women diagnosed with DSM-V mood disorders
T2  - Maturitas
TI  - Manualized cognitive behavioral group therapy (CBGT)to treat vasomotor symptoms (VMS)for black and white women diagnosed with DSM-V mood disorders
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01937592/full
VL  - 124
ID  - 1556
ER  - 

TY  - JOUR
AB  - OBJECTIVE: This project was designed to provide an overview of hot flash studies conducted over the past two decades at the Mayo Clinic and in the North Central Cancer Treatment Group. DESIGN: Prospective clinical trials performed by these investigators are illustrated, described, and discussed. RESULTS: Ten randomized, controlled (eight placebo controlled), double-blind clinical trials were conducted involving a total of 1,581 women and three placebo-controlled, double-blind clinical trials involving a total of 329 men were conducted. In addition, 14 pilot trials, having involved more than 325 participants to date, were conducted. CONCLUSIONS: Data from the pilot trials have given direction for substances that ought to be further explored in more definitive studies. In men, randomized studies demonstrate that hot flashes are markedly decreased by low doses of megestrol acetate, moderately decreased by gabapentin, but not substantially decreased by clonidine. Results from the randomized trials in women demonstrate that hot flashes are markedly decreased by relatively low doses of progestational agents (megestrol acetate and medroxyprogesterone acetate), moderately decreased by venlafaxine, mildly to moderately decreased by fluoxetine, mildly decreased by clonidine, but not substantially decreased by vitamin E, a soy phytoestrogen product, or black cohosh. Last, the data investigated in these studies support the hypothesis that, for the treatment of hot flashes in women, the results of therapeutic maneuvers are similar regardless of whether the patient has a history of breast cancer and/or is taking tamoxifen.
AD  - Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA. cloprinzi@mayo.edu
AN  - 18427355
AU  - Loprinzi, C. L.
AU  - Barton, D. L.
AU  - Sloan, J. A.
AU  - Novotny, P. J.
AU  - Dakhil, S. R.
AU  - Verdirame, J. D.
AU  - Knutson, W. H.
AU  - Kelaghan, J.
AU  - Christensen, B.
DA  - Jul-Aug
DO  - 10.1097/gme.0b013e3181679150
DP  - NLM
ET  - 2008/04/23
IS  - 4 Pt 1
KW  - Female
Hot Flashes/*drug therapy/etiology
Humans
Male
Randomized Controlled Trials as Topic
LA  - eng
N1  - Loprinzi, Charles L
Barton, Debra L
Sloan, Jeff A
Novotny, Paul J
Dakhil, Shaker R
Verdirame, Joseph D
Knutson, Wilma H
Kelaghan, Joseph
Christensen, Brad
Journal Article
United States
Menopause. 2008 Jul-Aug;15(4 Pt 1):655-60. doi: 10.1097/gme.0b013e3181679150.
PY  - 2008
SN  - 1072-3714 (Print)
1072-3714
SP  - 655-60
ST  - Mayo Clinic and North Central Cancer Treatment Group hot flash studies: a 20-year experience
T2  - Menopause
TI  - Mayo Clinic and North Central Cancer Treatment Group hot flash studies: a 20-year experience
VL  - 15
ID  - 498
ER  - 

TY  - JOUR
AB  - Purpose: To describe African American women's experience of being at high risk for breast cancer. Design: A hermeneutic phenomenological approach was used to guide in-depth interviews and analysis. Methods to ensure trustworthiness and rigor were included. Methods: Open interviews were conducted with 20 African American women who were at high risk for breast cancer (family history, personal history, genetic mutation). They were recruited from a cancer risk clinic and community-based settings. Data were transcribed verbatim, and themes were labeled among and between all interviews. Findings: Five themes were identified: (a) life-changing experience; (b) relationships: fears, support, and concerns; (c) the healthcare experience; (d) raising awareness; and (e) strong faith. Conclusions: Young women at high risk for breast cancer have unique emotional and support needs that are shaped by stage in life, relationships with significant others, their faith, and interactions with the healthcare delivery system. Clinical Relevance: Breast cancer does occur in young women. This highlights the need for timely and sensitive approaches to care when young women present with breast health concerns or abnormal breast findings.
AD  - Alpha Lambda, Former Manager-Nursing Research, Research Associate, Center for Clinical Cancer Genetics and Global Health, University of Chicago Medical Center, Chicago, IL
Gamma Pi at Large, Professor and Kenneth E. Morehead Endowed Chair in Nursing, Associate Dean for Research, University of Nebraska Medical Center, College of Nursing, Omaha, NE
AN  - 104679300. Language: English. Entry Date: 20110923. Revision Date: 20200708. Publication Type: Journal Article
AU  - Phillips, Janice
AU  - Cohen, Marlene Z.
DA  - 2011 3rd Quarter
DB  - CINAHL Complete
DO  - 10.1111/j.1547-5069.2011.01399.x
DP  - EBSCOhost
IS  - 3
KW  - Breast Neoplasms
Black Persons -- United States
Attitude to Illness
Cancer Patients
Family History
Human
Attitude to Illness -- Evaluation
Female
Phenomenological Research
Information Resources
World Wide Web
Descriptive Research
Interviews
Thematic Analysis
Adult
Audiorecording
Questionnaires
Family Relations
Professional-Patient Relations
Health Services Accessibility
Cross Sectional Studies
United States
Research Subject Recruitment
Purposive Sample
Funding Source
N1  - research. Supplement Title: 2011 3rd Quarter. Journal Subset: Core Nursing; Double Blind Peer Reviewed; Expert Peer Reviewed; Nursing; Peer Reviewed; USA. Grant Information: National Institute of Nursing Research and the University of Illinois Center for Reducing Risks in Vulnerable Populations (CCRVP) 5 P30 NR009014.. NLM UID: 100911591.
PMID: NLM21884369.
PY  - 2011
SN  - 1527-6546
SP  - 239-247
ST  - The Meaning of Breast Cancer Risk for African American Women
T2  - Journal of Nursing Scholarship
TI  - The Meaning of Breast Cancer Risk for African American Women
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104679300&site=ehost-live&scope=site
VL  - 43
ID  - 2127
ER  - 

TY  - SER
AB  - In this section, the general principles of inhalation, deposition, clearance and retention of poorly soluble particles that have low toxicity are discussed. This information is also relevant to the monographs on titanium dioxide and talc in this volume.
DB  - Scopus
M3  - Article
N1  - Export Date: 22 March 2021
PY  - 2010
SP  - 125-184
ST  - Mechanistic and other relevant data
T2  - IARC Monographs on the Evaluation of Carcinogenic Risks to Humans
TI  - Mechanistic and other relevant data
UR  - https://www.scopus.com/inward/record.uri?eid=2-s2.0-78449292710&partnerID=40&md5=31137d567b9d63231bb11b378403436a
VL  - 93
ID  - 2493
ER  - 

TY  - JOUR
AB  - African-American women experience disproportionately adverse outcomes relative to non-Latina White women after an abnormal mammogram result. Research has suggested medical advocacy and staff support may improve outcomes among this population. The purpose of the study was to understand reasons African-American women believe medical advocacy to be important and examine if and how staff can encourage and be supportive of medical advocacy. A convenience-based sample of 30–74-year-old women who self-identified as African-American/Black/of African descent and who had received an abnormal mammogram result was recruited from community-based organizations, mobile mammography services, and the local department of health. This qualitative study included semi-structured interviews. Patients perceived medical advocacy to be particularly important for African-Americans, given mistrust and discrimination present in medical settings and their own familiarity with their bodies and symptoms. Respondents emphasized that staff can encourage medical advocacy through offering information in general in a clear, informative, and empathic style. Cultural competency interventions that train staff how to foster medical advocacy may be a strategy to improve racial disparities following an abnormal mammogram. (PsycINFO Database Record (c) 2016 APA, all rights reserved)
AD  - Molina, Yamile, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N., M3-B232, Seattle, WA, US, 98109
AN  - 2016-24278-009
AU  - Molina, Yamile
AU  - Hempstead, Bridgette H.
AU  - Thompson-Dodd, Jacci
AU  - Weatherby, Shauna Rae
AU  - Dunbar, Claire
AU  - Hohl, Sarah D.
AU  - Malen, Rachel C.
AU  - Ceballos, Rachel M.
DB  - psyh
DO  - 10.1007/s13187-014-0732-9
DP  - EBSCOhost
IS  - 3
KW  - Abnormal mammogram disparities
African-American
Communication
Breast cancer screening
Follow-up
Qualitative
Medical advocacy
Advocacy
Blacks
Cancer Screening
Human Females
Mammography
Environment
N1  - Fred Hutchinson Cancer Research Center, Seattle, WA, US. Other Publishers: Lawrence Erlbaum; Taylor & Francis. Release Date: 20160606. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: English. Major Descriptor: Advocacy; Blacks; Cancer Screening; Human Females; Mammography. Minor Descriptor: Environment. Classification: Promotion & Maintenance of Health & Wellness (3365). Population: Human (10); Female (40). Location: US. Age Group: Adulthood (18 yrs & older) (300); Thirties (30-39 yrs) (340); Middle Age (40-64 yrs) (360); Aged (65 yrs & older) (380). Tests & Measures: Semi-Structured Interview Guide. Methodology: Empirical Study; Interview; Qualitative Study. References Available: Y. Page Count: 6. Issue Publication Date: Sep, 2015. Publication History: First Posted Date: Oct 2, 2014. Copyright Statement: Springer Science+Business Media New York. 2014.
Sponsor: National Cancer Institute, US. Grant: P50CA148143; R25CA92408; K01CA154938-01A1. Recipients: No recipient indicated
PY  - 2015
SN  - 0885-8195
1543-0154
SP  - 447-452
ST  - Medical advocacy and supportive environments for African-Americans following abnormal mammograms
T2  - Journal of Cancer Education
TI  - Medical advocacy and supportive environments for African-Americans following abnormal mammograms
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2016-24278-009&site=ehost-live&scope=site
ymolina@fhcrc.org
VL  - 30
ID  - 1749
ER  - 

TY  - JOUR
AD  - New York University, New York, NY 10003, USA. troy.duster@nyu.edu
AN  - 17321318
AU  - Duster, T.
DA  - Feb 24
DO  - 10.1016/s0140-6736(07)60320-1
DP  - NLM
ET  - 2007/02/27
IS  - 9562
KW  - African Americans/*genetics
Age Distribution
Aged
Antineoplastic Agents/therapeutic use
Clinical Trials as Topic
*Drug Approval
Drug Combinations
Gefitinib
Heart Failure/*drug therapy/*genetics/mortality
Humans
Hydralazine/*therapeutic use
Isosorbide Dinitrate/*therapeutic use
Lung Neoplasms/drug therapy
Middle Aged
Patents as Topic/legislation & jurisprudence
Quinazolines/therapeutic use
United States
United States Food and Drug Administration
LA  - eng
N1  - 1474-547x
Duster, Troy
Journal Article
Review
England
Lancet. 2007 Feb 24;369(9562):702-4. doi: 10.1016/S0140-6736(07)60320-1.
PY  - 2007
SN  - 0140-6736
SP  - 702-4
ST  - Medicalisation of race
T2  - Lancet
TI  - Medicalisation of race
VL  - 369
ID  - 535
ER  - 

TY  - JOUR
AN  - CN-01492843
AU  - Nct
KW  - Cardiovascular Diseases
PY  - 2015
ST  - Men Together Making a Difference: health Promotion for Black Men
T2  - https://clinicaltrials.gov/show/NCT02572414
TI  - Men Together Making a Difference: health Promotion for Black Men
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01492843/full
ID  - 1388
ER  - 

TY  - JOUR
AB  - Objective: To assess the feasibility of performing national, randomized trials of dietary interventions for localized prostate cancer. Methods: The Men's Eating and Living (MEAL) study (CALGB 70807 [Alliance]) is a phase III clinical trial testing the efficacy of a high‐vegetable diet to prevent progression in patients with prostate cancer on active surveillance (AS). Participants were randomized to a validated diet counselling intervention or to a control condition. Chi‐squared and Kruskal‐Wallis analyses were used to assess between‐group differences at baseline. Results: Between 2011 and 2015, 478 (103%) of a targeted 464 patients were randomized at 91 study sites. At baseline, the mean (sd) age was 64 (6) years and mean (sd) PSA concentration was 4.9 (2.1) ng/mL. Fifty‐six (12%) participants were African‐American, 17 (4%) were Hispanic/Latino, and 16 (3%) were Asian‐American. There were no significant between‐group differences for age (P = 0.98), race/ethnicity (P = 0.52), geographic region (P = 0.60), time since prostate cancer diagnosis (P = 0.85), PSA concentration (P = 0.96), clinical stage (T1c or T2a; P = 0.27), or Gleason sum (Gleason 6 or 3+4 = 7; P = 0.76). In a pre‐planned analysis, the baseline prostate biopsy samples of the first 50 participants underwent central pathology review to confirm eligibility, with an expectation that <10% would become ineligible. One of 50 participants (2%) became ineligible. Conclusion: The MEAL study shows the feasibility of implementing national, multi‐institutional phase III clinical trials of diet for prostate cancer and of testing interventions to prevent disease progression in AS. Copyright © 2017 BJU International.
AN  - CN-01372980
AU  - Parsons, J. K.
AU  - Pierce, J. P.
AU  - Mohler, J.
AU  - Paskett, E.
AU  - Jung, S. H.
AU  - Morris, M. J.
AU  - Small, E.
AU  - Hahn, O.
AU  - Humphrey, P.
AU  - Taylor, J.
AU  - et al.
DO  - 10.1111/bju.13890
KW  - *carotenoid
*diet
*eating
*feasibility study
*prostate cancer
Adult
African American
Asian American
Cancer staging
Clinical trial
Controlled clinical trial
Controlled study
Counseling
Disease course
Endogenous compound
Ethnicity
Expectation
Gleason score
Hispanic
Human
Human tissue
Kruskal Wallis test
Major clinical study
Male
Middle aged
Pathology
Prevention
Prostate biopsy
Prostate specific antigen
Race
Randomized controlled trial
Vegetable
M3  - Article In Press
PY  - 2017
ST  - Men's Eating and Living (MEAL) study (CALGB 70807 ): recruitment feasibility and baseline demographics of a randomized trial of diet in men on active surveillance for prostate cancer
T2  - BJU international
TI  - Men's Eating and Living (MEAL) study (CALGB 70807 ): recruitment feasibility and baseline demographics of a randomized trial of diet in men on active surveillance for prostate cancer
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01372980/full
VL  - (no pagination)
ID  - 1538
ER  - 

TY  - JOUR
AB  - OBJECTIVE: To assess the feasibility of performing national, randomized trials of dietary interventions for localized prostate cancer. METHODS: The Men's Eating and Living (MEAL) study (CALGB 70807 [Alliance]) is a phase III clinical trial testing the efficacy of a high-vegetable diet to prevent progression in patients with prostate cancer on active surveillance (AS). Participants were randomized to a validated diet counselling intervention or to a control condition. Chi-squared and Kruskal-Wallis analyses were used to assess between-group differences at baseline. RESULTS: Between 2011 and 2015, 478 (103%) of a targeted 464 patients were randomized at 91 study sites. At baseline, the mean (sd) age was 64 (6) years and mean (sd) PSA concentration was 4.9 (2.1) ng/mL. Fifty-six (12%) participants were African-American, 17 (4%) were Hispanic/Latino, and 16 (3%) were Asian-American. There were no significant between-group differences for age (P = 0.98), race/ethnicity (P = 0.52), geographic region (P = 0.60), time since prostate cancer diagnosis (P = 0.85), PSA concentration (P = 0.96), clinical stage (T1c or T2a; P = 0.27), or Gleason sum (Gleason 6 or 3+4 = 7; P = 0.76). In a pre-planned analysis, the baseline prostate biopsy samples of the first 50 participants underwent central pathology review to confirm eligibility, with an expectation that <10% would become ineligible. One of 50 participants (2%) became ineligible. CONCLUSION: The MEAL study shows the feasibility of implementing national, multi-institutional phase III clinical trials of diet for prostate cancer and of testing interventions to prevent disease progression in AS.
AD  - Division of Urologic Oncology, UC San Diego Moores Comprehensive Cancer Center, La Jolla, CA, USA.
Department of Urology, UC San Diego Health System, La Jolla, CA, USA.
VA San Diego Healthcare System, La Jolla, CA, USA.
Department of Family Medicine and Public Health and Moores Cancer Center, University of California, San Diego, La Jolla, CA, USA.
Department of Urology, Roswell Park Cancer Institute, Buffalo, NY, USA.
Department of Medicine, College of Medicine, Comprehensive Cancer Center, Ohio State University, Columbus, OH, USA.
Alliance Statistics and Data Center, Duke University, Durham, NC, USA.
Memorial Sloan Kettering Cancer Center, New York, NY, USA.
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA.
Alliance Central Protocol Operations, University of Chicago, Chicago, IL, USA.
Department of Pathology, Yale University Medical School, New Haven, CT, USA.
Department of Prevention and Population Sciences, Roswell Park Cancer Institute, Buffalo, NY, USA.
AN  - 28437029
AU  - Parsons, J. K.
AU  - Pierce, J. P.
AU  - Mohler, J.
AU  - Paskett, E.
AU  - Jung, S. H.
AU  - Morris, M. J.
AU  - Small, E.
AU  - Hahn, O.
AU  - Humphrey, P.
AU  - Taylor, J.
AU  - Marshall, J.
C2  - PMC5654696
C6  - NIHMS871013
DA  - Apr
DO  - 10.1111/bju.13890
DP  - NLM
ET  - 2017/04/25
IS  - 4
KW  - Aged
Aged, 80 and over
Biopsy
Diet/*methods/*statistics & numerical data
Disease Progression
Humans
Male
Middle Aged
Prostate-Specific Antigen/blood
Prostatic Neoplasms/*diet therapy/epidemiology/pathology/*prevention & control
Vegetables
*#pcsm
*#ProstateCancer
*active surveillance
*carotenoids
*diet
*outcomes
*prevention
LA  - eng
N1  - 1464-410x
Parsons, J Kellogg
Orcid: 0000-0002-3676-9730
Pierce, John P
Mohler, James
Paskett, Electra
Jung, Sin-Ho
Morris, Michael J
Small, Eric
Hahn, Olwen
Humphrey, Peter
Taylor, John
Marshall, James
U10 CA077658/CA/NCI NIH HHS/United States
U10 CA031946/CA/NCI NIH HHS/United States
UG1 CA189974/CA/NCI NIH HHS/United States
U10 CA033601/CA/NCI NIH HHS/United States
U10 CA059518/CA/NCI NIH HHS/United States
P30 CA008748/CA/NCI NIH HHS/United States
U10 CA180791/CA/NCI NIH HHS/United States
U10 CA037447/CA/NCI NIH HHS/United States
U10 CA180850/CA/NCI NIH HHS/United States
U10 CA041287/CA/NCI NIH HHS/United States
UG1 CA189823/CA/NCI NIH HHS/United States
U10 CA077651/CA/NCI NIH HHS/United States
R01 CA132951/CA/NCI NIH HHS/United States
U10 CA180866/CA/NCI NIH HHS/United States
U10 CA138561/CA/NCI NIH HHS/United States
Clinical Trial, Phase III
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.
BJU Int. 2018 Apr;121(4):534-539. doi: 10.1111/bju.13890. Epub 2017 May 21.
PY  - 2018
SN  - 1464-4096 (Print)
1464-4096
SP  - 534-539
ST  - Men's Eating and Living (MEAL) study (CALGB 70807 [Alliance]): recruitment feasibility and baseline demographics of a randomized trial of diet in men on active surveillance for prostate cancer
T2  - BJU Int
TI  - Men's Eating and Living (MEAL) study (CALGB 70807 [Alliance]): recruitment feasibility and baseline demographics of a randomized trial of diet in men on active surveillance for prostate cancer
VL  - 121
ID  - 169
ER  - 

TY  - JOUR
AB  - OBJECTIVE: In the context of scientific uncertainty, treatment choices for localized prostate cancer vary, but reasons for this variation are unclear. We explored how black and white American men made their treatment decision. METHODS: Guided by conceptual model, we conducted semistructured interviews of 21 American (14 black and 7 white) men with recently diagnosed localized prostate cancer. RESULTS: Physician recommendation was very important in the treatment decision, but patient self-perception/values and attitudes/beliefs about prostate cancer were also influential. Patients who chose surgery believed it offered the best chance of cure and were more concerned that the cancer might spread if not surgically removed. Patients who chose radiation therapy believed it offered equal efficacy of cure but fewer side effects than surgery. Fear of future consequences was the most common reason to reject watchful waiting. Anecdotal experiences of family and friends were also important, especially in deciding "what not to do." The new technology of robotic-assisted prostatectomy provided optimism for men who wanted surgery but feared morbidity associated with traditional open surgery. Few men seemed aware that treatment did not guarantee improved survival. CONCLUSION: Most men reported making "the best choice for me" by taking into account medical information and personal factors. Perceptions of treatment efficacy and side effects, which derived mainly from physicians' descriptions and/or anecdotal experiences of family and friends, were the most influential factors in men's treatment decision. By understanding factors that influence patients' treatment decisions, clinicians may be more sensitive to individual patients' preferences/concerns and provide more patient-centered care.
AD  - Department of Family Medicine, Sciences, Karmanos Cancer Institute, Wayne State University, Detroit, Michigan, USA. jxu@med.wayne.edu
AN  - 21830629
AU  - Xu, J.
AU  - Dailey, R. K.
AU  - Eggly, S.
AU  - Neale, A. V.
AU  - Schwartz, K. L.
C2  - PMC4283563
C6  - NIHMS651516
DA  - Jun
DO  - 10.1016/s0027-9684(15)30359-x
DP  - NLM
ET  - 2011/08/13
IS  - 6
KW  - African Americans
Aged
Biomedical Technology
*Choice Behavior
Culture
Directive Counseling/standards
European Continental Ancestry Group
Humans
Male
Middle Aged
Patient Participation/*psychology
Patient-Centered Care/*standards
Physician's Role/*psychology
Physician-Patient Relations
Prostate/pathology/radiation effects/surgery
Prostatectomy/psychology/trends
Prostatic Neoplasms/ethnology/*psychology/*therapy
Radiotherapy/psychology
Self Concept
Social Support
United States
LA  - eng
N1  - Xu, Jinping
Dailey, Rhonda K
Eggly, Susan
Neale, Anne Victoria
Schwartz, Kendra L
P30 CA022453/CA/NCI NIH HHS/United States
Journal Article
Research Support, Non-U.S. Gov't
J Natl Med Assoc. 2011 Jun;103(6):468-78. doi: 10.1016/s0027-9684(15)30359-x.
PY  - 2011
SN  - 0027-9684 (Print)
0027-9684
SP  - 468-78
ST  - Men's perspectives on selecting their prostate cancer treatment
T2  - J Natl Med Assoc
TI  - Men's perspectives on selecting their prostate cancer treatment
VL  - 103
ID  - 387
ER  - 

TY  - JOUR
AB  - Whether menthol cigarettes confer a higher risk of death than plain cigarettes is not known. The Lung Health Study (LHS) enrolled 5,887 adult smokers in a clinical trial of smoking cessation and ipratropium in the prevention of chronic obstructive pulmonary disease. LHS participants have been subjected to surveillance for mortality from all causes for 14 years. We examined these data for differences between self-reported smokers of menthol cigarettes versus plain cigarettes. Using proportional hazards regression methods, we found no differences in hazard ratios for coronary heart disease, cardiovascular disease, lung cancer, or death from any cause. Contrary to expectations about nicotine dependence, we found that users of menthol cigarettes had smoked fewer pack-years at baseline. We found no difference in success at smoking cessation with or without menthol. We conclude that our data contain no evidence that mentholation of cigarettes increases the hazards of smoking.
AD  - Department of Community Health Sciences, University of Manitoba. Winnipeg, MB, Canada. rmurray@hsc.mb.ca
AN  - 17365741
AU  - Murray, R. P.
AU  - Connett, J. E.
AU  - Skeans, M. A.
AU  - Tashkin, D. P.
DA  - Jan
DO  - 10.1080/14622200601078418
DP  - NLM
ET  - 2007/03/17
IS  - 1
KW  - Adult
African Americans/statistics & numerical data
Bronchodilator Agents/therapeutic use
Female
*Health Behavior
Humans
Ipratropium/therapeutic use
Lung Diseases/*chemically induced/epidemiology
Male
Menthol/*adverse effects
Middle Aged
Risk Factors
Smoking/*epidemiology
Smoking Cessation/statistics & numerical data
*Smoking Prevention
*Tobacco
LA  - eng
N1  - Murray, Robert P
Connett, John E
Skeans, Melissa A
Tashkin, Donald P
HR 46002/HR/NHLBI NIH HHS/United States
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
England
Nicotine Tob Res. 2007 Jan;9(1):101-7. doi: 10.1080/14622200601078418.
PY  - 2007
SN  - 1462-2203 (Print)
1462-2203
SP  - 101-7
ST  - Menthol cigarettes and health risks in Lung Health Study data
T2  - Nicotine Tob Res
TI  - Menthol cigarettes and health risks in Lung Health Study data
VL  - 9
ID  - 533
ER  - 

TY  - JOUR
AB  - Given concerns about survey nonresponse bias as well as the need to plan resources for participant recruitment, this study tracked each step of the recruitment process (location, response, consent, and completion) of sociodemographically diverse older women for a survey concerning mammography experience. Younger, less educated poor women were likely to be lost due to inability to locate them, while older middle- and upper-economic-group women were more likely to be lost due to refusal to participate. Hispanic and Black women were significantly more likely to respond on successive attempts to recruit them than were White, non-Hispanic women. There was no significant difference in refusal rates by minority women over the successive contacts, as contrasted with White women, who refused at significantly higher rates with each attempt.
AD  - University of Massachusetts Medical Center.
AN  - 10138810
AU  - Zapka, J. G.
AU  - Chasan-Taber, L.
AU  - Bigelow, C.
AU  - Hurley, T.
DA  - Dec
DO  - 10.1177/016327879401700408
DP  - NLM
ET  - 1994/11/04
IS  - 4
KW  - Aged
Bias
Breast Neoplasms/prevention & control
Chi-Square Distribution
Community Participation
Data Collection/methods
Ethnic Groups/*statistics & numerical data
Female
Health Services Research/*methods
Humans
Mammography/statistics & numerical data
Massachusetts
Middle Aged
Socioeconomic Factors
*Women's Health
LA  - eng
N1  - Zapka, J G
Chasan-Taber, L
Bigelow, C
Hurley, T
R01-506874/PHS HHS/United States
Journal Article
Research Support, U.S. Gov't, P.H.S.
United States
Eval Health Prof. 1994 Dec;17(4):485-500. doi: 10.1177/016327879401700408.
PY  - 1994
SN  - 0163-2787 (Print)
0163-2787
SP  - 485-500
ST  - Methodological issues for health-related surveys of multicultural older women
T2  - Eval Health Prof
TI  - Methodological issues for health-related surveys of multicultural older women
VL  - 17
ID  - 745
ER  - 

TY  - JOUR
AB  - PURPOSE: The goal of the Metropolitan NY Registry, and five other international collaborating sites of the Cooperative Family Registry for Breast Cancer Studies [CFRBCS], has been the development of a comprehensive resource for interdisciplinary genetic epidemiology studies addressing breast cancer risk and prognostic factors.METHODS: Family recruitment has been conducted in clinical and community settings by a multidisciplinary team of collaborators affiliated at six major metropolitan NY medical centers. Families meeting one of the following criteria were invited to join: a male with breast cancer; a female with breast or ovarian cancer diagnosed at age </=45; a female with breast and ovarian cancer; or two or more first and second degree relatives diagnosed at any ages. Participants are asked to complete an epidemiology questionnaire, dietary history form, extensive family history, and donate biospecimens including blood and urine. Pathology reports and tissue samples are obtained for breast and ovarian cancer cases; pathology reports are requested to confirm the history of other cancers.RESULTS: Of the 1102 families (3,252 participants), 28 males and 1,304 females had been treated for breast cancer. More than 2,400 blood samples are banked and >3,000 epidemiology questionnaires completed. Ethnic/racial data indicates 14% are of African American or Hispanic heritage and 509 families (46%) are of Ashkenazi descent. One or more DNA samples from 400 Ashkenazi families have been tested for the three BRCA1/2 founder mutations. Of 331 Ashkenazi participants with a history of breast and/or ovarian cancer, 19% were found to be mutation carriers. Thirty-six (7 men/29 women) mutation carriers are free of cancer.CONCLUSIONS: The families participating in the NY Registry reflect a spectrum of breast cancer risk. The extensive NY and CFRBCS databases and banked biospecimens provide a unique resource for multidisciplinary genetic epidemiologic studies that may identify avenues for prevention.
AD  - Divisions of Sociomedical Sciences, Environmental Health Sciences, and Epidemiology, Mailman School of Public Health of Columbia University, New York, NY, USA
AN  - 11018378
AU  - Senie, R.
AU  - Santella, R.
AU  - Ahsan, H.
DA  - Oct 1
DO  - 10.1016/s1047-2797(00)00148-4
DP  - NLM
ET  - 2000/10/06
IS  - 7
LA  - eng
N1  - 1873-2585
Senie, R
Santella, R
Ahsan, H
Journal Article
United States
Ann Epidemiol. 2000 Oct 1;10(7):462. doi: 10.1016/s1047-2797(00)00148-4.
PY  - 2000
SN  - 1047-2797
SP  - 462
ST  - The metropolitan new york registry & cfrbcs. Unique resources for breast cancer research
T2  - Ann Epidemiol
TI  - The metropolitan new york registry & cfrbcs. Unique resources for breast cancer research
VL  - 10
ID  - 699
ER  - 

TY  - JOUR
AB  - Lepidic adenocarcinoma previously known as bronchioloalveolar carcinoma (BAC) is a non-small cell lung cancer with an indolent presentation. Bronchial anthracofibrosis (BAF) is caused by long-standing exposure to biomass fuel smoke often in poorly ventilated kitchen. Middle lobe syndrome (MLS) due to BAF is not uncommon however, lepidic adenocarcinoma then known as BAC, presenting as MLS has been documented only once before in the Polish literature. A 68-year-old never-smoker female with biomass fuel smoke exposure presented with cough and breathlessness. Imaging revealed MLS. Fiberoptic bronchoscopy visualised bluish-black hyperpigmentation with narrowing and distortion of right middle lobe bronchus suggestive of BAF. Transbronchial biopsy confirmed presence of lepidic adenocarcinoma. To our knowledge, this is the first detailed description of lepidic adenocarcinoma and BAF presenting as MLS.
AD  - University of Delhi, Department of Pulmonary Medicine. kunalrocks89@gmail.com.
AN  - 29424200
AU  - Kunal, S.
AU  - Jain, S.
AU  - Shah, A.
DA  - Dec 19
DO  - 10.4081/monaldi.2017.864
DP  - NLM
ET  - 2018/02/10
IS  - 3
KW  - Adenocarcinoma, Bronchiolo-Alveolar/complications/*pathology
Aged
Anthracosis/complications/*pathology
Biomass
Bronchial Diseases/pathology
Bronchoscopy/methods
Dyspnea/diagnosis/etiology
Female
Humans
Lost to Follow-Up
Middle Lobe Syndrome/diagnostic imaging/*pathology
Smoke/*adverse effects
Tomography, X-Ray Computed/methods
*Biomass fuel smoke exposure
*bronchial anthracofibrosis: lepidic adenocarcinoma
*fibreoptic bronchoscopy
*high resolution computed tomography.
LA  - eng
N1  - Kunal, Shekhar
Jain, Sudhir
Shah, Ashok
Case Reports
Journal Article
Italy
Monaldi Arch Chest Dis. 2017 Dec 19;87(3):864. doi: 10.4081/monaldi.2017.864.
PY  - 2017
SN  - 1122-0643 (Print)
1122-0643
SP  - 864
ST  - Middle lobe syndrome: An exceptional presentation of concomitant lepidic adenocarcinoma and bronchial anthracofibrosis
T2  - Monaldi Arch Chest Dis
TI  - Middle lobe syndrome: An exceptional presentation of concomitant lepidic adenocarcinoma and bronchial anthracofibrosis
VL  - 87
ID  - 134
ER  - 

TY  - JOUR
AB  - Objectives • List at least three characteristics of a comprehensive yoga intervention. • List at least two ways that yoga can help with pain and symptom management. Original Research Background. Women with metastatic breast cancer (MBC) often report high levels of pain and other disease‐related symptoms including fatigue, sleep disturbance, psychological distress, and functional impairment. Yoga and mindfulness interventions have shown promise for improving the management of pain and related symptoms, however they have rarely been tested in patients with advanced disease. We developed a mindful yoga intervention that specifically targets pain and related symptoms and are currently testing its feasibility and preliminary efficacy in women with MBC. Research Objectives. Study aims are to test the feasibility and acceptability of the yoga intervention along with its effects onpain, fatigue, sleepdisturbance, psychological distress, and functional impairment. This presentation will include an overview of the yoga intervention along with preliminary data on feasibility outcomes. Methods. Approximately 70 patients will be recruited and randomized to either the yoga intervention or a comparison condition (social support group). Assessments occur at baseline, post‐treatment, and 3‐ and 6‐month follow‐ups. Currently 51 patients have been enrolled and completed baseline and post‐treatment assessments. Results. The mean age of the sample is 56.5; 24% are African American and 72% are White. At baseline, patients reported mild levels of pain (mean=2.0, SD=1.5 on Brief Pain Inventory) and fatigue (mean=3.4, SD=2.5 onBrief Fatigue Inventory), andmoderate levels of psychological distress (mean=11.8, SD=7.0 onHospital Anxiety&Depression Scale). Retention is 84%which contrasts favorably with prior behavioral studies in MBC (retention ≤ 74%). 71% of patients have attended at least 4 of the 8 sessions. There have been no adverse events associated with the yoga intervention. Conclusion. Mindful yoga appears to be a feasible and acceptable approach for symptom management for women with MBC. Implications for research, policy or practice. Further research is warranted on yoga interventions for pain and symptom management in patients with advanced cancer.
AN  - CN-01717442
AU  - Porter, L.
AU  - Carson, J.
AU  - Carson, K.
AU  - Olsen, M.
AU  - Sanders, L.
AU  - Keefe, F.
DO  - 10.1016/j.jpainsymman.2016.12.248
IS  - 2
KW  - *depression
*metastatic breast cancer
Adult
Advanced cancer
Adverse drug reaction
African American
Anxiety
Brief Pain Inventory
Controlled clinical trial
Controlled study
Fatigue
Feasibility study
Female
Functional disease
Human
Major clinical study
Mental stress
Middle aged
Mindfulness
Pain
Randomized controlled trial
Side effect
Social support
M3  - Journal: Conference Abstract
PY  - 2017
SP  - 430‐431
ST  - Mindful yoga for symptom management in metastatic breast cancer
T2  - Journal of pain and symptom management
TI  - Mindful yoga for symptom management in metastatic breast cancer
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01717442/full
VL  - 53
ID  - 1543
ER  - 

TY  - JOUR
AB  - Purpose: Women with metastatic breast cancer (MBC) report poor quality of life and high levels of pain and other disease related symptoms including fatigue, sleep disturbance, psychological distress, and functional impairment. As MBC is a terminal illness for which major treatment advances are slow to appear, it is critical to develop effective interventions to enhance the quality of the remaining years of these women's lives. Yoga interventions and mindfulness interventions have shown promise for improving the management of pain and related symptoms, however prior studies testing such interventions with cancer patients have been limited to patients with early stage disease. Methods: We previously developed an 8‐week mindful yoga intervention (“Yoga of Awareness”) specifically designed to address pain and related symptoms. Data from a small randomized controlled trial (RCT) supported the mindful yoga intervention in improving pain, fatigue, and emotional distress in survivors of early stage breast cancer. This presentation will focus on a new RCT, funded by the National Center for Complementary and Integrative Health, for 60 women with MBC who are receiving treatment at Duke Cancer Institute. Data will be collected at baseline, post‐treatment, and 3‐ and 6‐month follow‐ups. An overview of the mindful yoga intervention will be presented along with demographics, baseline data (pain, fatigue, sleep quality, psychological distress, functional capacity, mindfulness) and feasibility outcomes (eligibility, accrual, retention, attendance). Results: At present 38 of the targeted 60 patients have been enrolled; by May 2016 enrollment will be complete. Thus far the mean age of the sample is 56.4; 32.4% are African American and 67.6% are White. Retention = 89% which contrasts favorably with the few prior behavioral studies in MBC (retention ≤74%). Mean attendance at intervention sessions has been 69% vs. 75% in our early stage breast cancer trial. Conclusion: Challenges in implementing the study and lessons learned will be discussed.
AN  - CN-01743708
AU  - Carson, J.
AU  - Carson, K.
DO  - 10.1089/acm.2016.29003.abstracts
IS  - 6
KW  - *metastatic breast cancer
Adult
African American
Cancer center
Controlled clinical trial
Emotional stress
Fatigue
Feasibility study
Female
Functional status
Human
Major clinical study
Mental stress
Mindfulness
Pain
Randomized controlled trial
Sleep quality
Survivor
Symptom
M3  - Journal: Conference Abstract
PY  - 2016
SP  - A70‐A71
ST  - Mindful yoga for women with metastatic breast cancer
T2  - Journal of alternative and complementary medicine (New York, N.Y.)
TI  - Mindful yoga for women with metastatic breast cancer
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01743708/full
VL  - 22
ID  - 1470
ER  - 

TY  - JOUR
AB  - The Minnesota Green Tea Trial (MGTT) was a randomized, placebo-controlled, double-blinded trial investigating the effect of daily green tea extract consumption for 12 months on biomarkers of breast cancer risk. Participants were healthy postmenopausal women at high risk of breast cancer due to dense breast tissue with differing catechol-O-methyltransferase (COMT) genotypes. The intervention was a green tea catechin extract containing 843.0 +/- A 44.0 mg/day epigallocatechin gallate or placebo capsules for 1 year. Annual digital screening mammograms were obtained at baseline and month 12, and fasting blood and 24-h urine samples were provided at baseline and at months 6 and 12. Primary endpoints included changes in percent mammographic density, circulating endogenous sex hormones, and insulin-like growth factor axis proteins; secondary endpoints were changes in urinary estrogens and estrogen metabolites and circulating F2-isoprostanes, a biomarker of oxidative stress. The MGTT screened more than 100,000 mammograms and randomized 1,075 participants based on treatment (green tea extract vs. placebo), stratified by COMT genotype activity (high COMT vs. low/intermediate COMT genotype activity). A total of 937 women successfully completed the study and 138 dropped out (overall dropout rate = 12.8 %). In this paper we report the rationale, design, recruitment, participant characteristics, and methods for biomarker and statistical analyses.
AN  - WOS:000361068800004
AU  - Samavat, H.
AU  - Dostal, A. M.
AU  - Wang, R. W.
AU  - Bedell, S.
AU  - Emory, T. H.
AU  - Ursin, G.
AU  - Torkelson, C. J.
AU  - Gross, M. D.
AU  - Le, C. T.
AU  - Yu, M. C.
AU  - Yang, C. S.
AU  - Yee, D.
AU  - Wu, A. H.
AU  - Yuan, J. M.
AU  - Kurzer, M. S.
DA  - Oct
DO  - 10.1007/s10552-015-0632-2
IS  - 10
N1  - 26206423
PY  - 2015
SN  - 0957-5243
SP  - 1405-1419
ST  - The Minnesota Green Tea Trial (MGTT), a randomized controlled trial of the efficacy of green tea extract on biomarkers of breast cancer risk: study rationale, design, methods, and participant characteristics
T2  - Cancer Causes & Control
TI  - The Minnesota Green Tea Trial (MGTT), a randomized controlled trial of the efficacy of green tea extract on biomarkers of breast cancer risk: study rationale, design, methods, and participant characteristics
VL  - 26
ID  - 2967
ER  - 

TY  - JOUR
AB  - Significant progress has been made since the war against cancer was launched. Discoveries in molecular medicine, genetics, and epidemiology have led to the recognition that certain cancers are potentially preventable and that elements of lifestyle, along with genetic, hormonal, and metabolic factors can be altered to reduce cancer risk. Advances in medical technology have led to the development of new imaging methods and computer technologies that can aid in efforts to detect, diagnosis, and treat cancer. Since the offensive against cancer was initiated, cancer treatments have become more powerful, more precise, less drastic, and safer. As a result, cancer incidence and mortality have begun to decline. Yet, while the nation boasts of the progress being achieved relative to cancer incidence and mortality, and federal research agencies retort that research applies to all populations, it is apparent that the declines do not translate to all populations in the United States. Clinical research is essential to cancer prevention and control. Within the oncology community, clinical cancer research trials are viewed as an efficient and economical way for patients to secure state of-the-science medical care. Recognizing the need to improve access to state-of-the-science cancer treatment and control programs, minority and female participation in clinical cancer research trials has been encouraged, This recommendation is based on the belief that increased participation in well-designed clinical cancer research trials adhering to strict protocols and quality controls will, not only help validate the application of research findings to minority and female populations, but also result in better patient outcomes. Born out of a commitment to social equity, justice, beneficence, and the desire to ensure that data relevant to cancer prevention and control are both valid and generarizable to populations across the United States, several programs of research aimed toward increasing the representation of women and minorities in clinical cancer research have been pursued by the National Cancer Institute. This issue of the Annals of Epidemiology Minorities, Women, and Clinical Cancer Research presents issues and challenges that face the research community and descriptions of effective models, strategies, and practices that may be used to increase the participation of minorities and women in clinical cancer research trials and facilitate the conduct of research directed toward reducing the cancer burden within the United States. (C) 2000 Elsevier Science Inc. All rights reserved.
AN  - WOS:000165950000002
AU  - Underwood, S. M.
DA  - Nov
DO  - 10.1016/S1047-2797(00)00200-3
IS  - 8
N1  - S
Workshop on Participation of Minorities and Women in Clinical Cancer Research
FEB 26-27, 1999
WASHINGTON, D.C.
NCI
32
11189090
PY  - 2000
SN  - 1047-2797
SP  - S3-S12
ST  - Minorities, women, and clinical cancer research: The charge, promise, and challenge
T2  - Annals of Epidemiology
TI  - Minorities, women, and clinical cancer research: The charge, promise, and challenge
VL  - 10
ID  - 2717
ER  - 

TY  - JOUR
AB  - This article has discussed the increased incidence and disproportionately increased mortality of prostate cancer among African American men.Although the exact reasons are unknown, genetics may play a role, in addition to health care practices. Morbidity from other disease states, such as diabetes, obesity, or hypertension, may influence the overall survival of patients with prostate cancer. Current research tools will continue to explore biologic differences between the races; however, socioeconomic status and access to health care must not be overlooked. Several studies have demonstrated that similar disease stages and equal access to health care will result in similar outcomes. It is recognized that screening for prostate cancer will remain a controversial topic. Several influential professional societies recommend against screening and other professional societies endorse screening. Large-scale trials are currently underway hoping to answer this critical question. Since the advent of current screening tools, however, it seems that the overall mortality for prostate cancer has decreased and this cannot be ignored. Certainly, screening programs and clinical trials have traditionally had difficulty in recruiting minority participants, although more recent trials seem to be finding success. A primary care physician who is viewed as competent by their patients can certainly have a positive impact on their African American patients' willingness to participate in studies and screening programs. Most importantly, on the individual level, primary care physicians can provide a great service to their minority patients by offering educational materials on prostate cancer and by offering screening to qualified patients. The current American Urologic Association and National Cancer Institute guidelines recommend offering screening to all men age 50 and above. African American men or men with a first-degree relative with prostate cancer should be offered screening beginning at age 40. Proper screening consists of both a digital rectal examination to assess for asymmetry or nodules of the prostate and a serum PSA. Current recommendations are that individuals with a serum PSA greater than 4 ng/mL ora prostate nodule or asymmetric prostate should be referred to an urologist,where a biopsy can be performed easily in the office setting.The PSA cutoff of 4 has recently been questioned. A study by Thompson et al [31] evaluated 2950 men with a PSA of 4 or less with prostate biopsy.They found that the risk of prostate cancer in men with a PSA between 3.1 and 4 was 26.9% and that 25% of these men with prostate cancer had high-grade disease. All men found to have cancer had T1 disease. The clinical relevance of this surprisingly high rate of prostate cancer in men with a normal PSA is yet to be determined and is pending in studies on the ultimate effect of screening on mortality from prostate cancer. This information is not intended to confuse the issue, but intended to provide the most up-to-date information and allow for the best clinical decision making by the primary care physician. What can currently be recommended is if a patient is concerned about his possibility of having prostate cancer despite a normal PSA, a referral to an urologist to at least further discuss the issue may be in order. This may be especially true if the patient is African American or has a family history of prostate cancer at an early age.
AD  - Department of Urology, University of Texas Health Science Center at San Antonio, MC 7845, 7703 Floyd Curl Drive, San Antonio, TX 78229-3900, USA.
AN  - 15925651
AU  - French, D. B.
AU  - Jones, L. A.
DA  - Jul
DO  - 10.1016/j.mcna.2005.02.003
DP  - NLM
ET  - 2005/06/01
IS  - 4
KW  - Humans
Male
Minority Groups/*statistics & numerical data
Patient Selection
Prostatic Diseases/*epidemiology/physiopathology/therapy
Socioeconomic Factors
United States/epidemiology
LA  - eng
N1  - French, Dan B
Jones, LeRoy A
Journal Article
Review
United States
Med Clin North Am. 2005 Jul;89(4):805-16. doi: 10.1016/j.mcna.2005.02.003.
PY  - 2005
SN  - 0025-7125 (Print)
0025-7125
SP  - 805-16
ST  - Minority issues in prostate disease
T2  - Med Clin North Am
TI  - Minority issues in prostate disease
VL  - 89
ID  - 601
ER  - 

TY  - JOUR
AB  - Although recruitment of ethnic and racial minorities in medical research has been evaluated in several studies, much less is known about the methods used to recruit these populations to participate in cancer genetics research. This report reviews the resources that have been used to identify and recruit ethnic and racial minorities to participate in hereditary breast cancer research. Overall, hospital-based resources were used most often to identify potential subjects, and active recruitment methods were used most frequently to enroll eligible subjects. This review suggests that there appears to be a finite number of resources and strategies to identify and recruit potential subjects to participate in cancer genetics research; however, options for improving awareness about cancer genetics research among ethnic and racial minorities have not been extensively evaluated. To study ethnic and racial minority participation in cancer genetics research, stronger evaluation components will need to be integrated into research methods. Both observational and experimental studies are needed to determine resources that are most effective for identifying potential subjects who are ethnic and racial minorities and to evaluate the effects of different recruitment strategies on enrollment decisions among these populations.
AN  - WOS:000222539400009
AU  - Hughes, C.
AU  - Peterson, S. K.
AU  - Ramirez, A.
AU  - Gallion, K. J.
AU  - McDonald, P. G.
AU  - Skinner, C. S.
AU  - Bowen, D.
DA  - Jul
IS  - 7
N1  - 44
15247125
PY  - 2004
SN  - 1055-9965
SP  - 1146-+
ST  - Minority recruitment in hereditary breast cancer research
T2  - Cancer Epidemiology Biomarkers & Prevention
TI  - Minority recruitment in hereditary breast cancer research
VL  - 13
ID  - 2679
ER  - 

TY  - JOUR
AB  - PURPOSE: African American men have a higher prostate cancer risk profile than that of other men in the United States. The purpose of this manuscript is to summarize the challenges associated with enrolling and randomizing African American and other minority participants in the Prostate Cancer Prevention Trial (PCPT). METHODS: The PCPT is a randomized trial of finasteride versus placebo for preventing prostate cancer in healthy men age 55 years and older; it is coordinated by the Southwest Oncology Group. The manuscript describes demographic and lifestyle characteristics of the PCPT randomized sample (18,882 men) by four racial and ethnic groups (Caucasian, African American, Hispanic, and other). African American men comprised 4% of the total randomized sample compared to our goal of 8%. Minority recruitment was emphasized through the Study Manual and training that occurred at trial activation. Supplemental minority recruitment activities were initiated a year after study activation and continued through the end of the accrual period. Minority recruitment was emphasized as follows: minority recruitment presentations at PCPT training seminars (held during twice yearly Southwest Oncology Group meetings); distribution of additional minority recruitment materials; engagement of four consultants for minority recruitment; production of a Minority Recruitment Manual; and a small pilot study involving minority outreach recruiters at five PCPT sites. RESULTS: The consultants were helpful in implementing the pilot project and in suggesting and reviewing materials for minority recruitment. The five-site pilot project did not increase either enrollment or randomization of minorities (with a possible exception at one site). CONCLUSIONS: We suggest that a long-term perspective is required for successful recruitment of minority participants in clinical trials. Likewise, extensive minority recruitment efforts must be ready to implement at trial activation.
AD  - From the Southwest Oncology Group Statistical Center/Fred Hutchinson Cancer Research Center, Seattle, WA 98109-1024, USA.
AN  - 11189097
AU  - Moinpour, C. M.
AU  - Atkinson, J. O.
AU  - Thomas, S. M.
AU  - Underwood, S. M.
AU  - Harvey, C.
AU  - Parzuchowski, J.
AU  - Lovato, L. C.
AU  - Ryan, A. M.
AU  - Hill, M. S.
AU  - Deantoni, E.
AU  - Gritz, E. R.
AU  - Thompson, I. M., Jr.
AU  - Coltman, C. A., Jr.
DA  - Nov
DO  - 10.1016/s1047-2797(00)00185-x
DP  - NLM
ET  - 2001/02/24
IS  - 8 Suppl
KW  - Aged
Continental Population Groups
Demography
Finasteride/therapeutic use
Humans
Life Style/ethnology
Male
Middle Aged
Minority Groups/*statistics & numerical data
*Patient Selection
Pilot Projects
Placebos
Prostatic Neoplasms/*ethnology/*prevention & control
Randomized Controlled Trials as Topic/*statistics & numerical data
LA  - eng
N1  - Moinpour, C M
Atkinson, J O
Thomas, S M
Underwood, S M
Harvey, C
Parzuchowski, J
Lovato, L C
Ryan, A M
Hill, M S
Deantoni, E
Gritz, E R
Thompson, I M Jr
Coltman, C A Jr
2 U10 CA37429-09/CA/NCI NIH HHS/United States
5 U10 CA37429/CA/NCI NIH HHS/United States
Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.
United States
Ann Epidemiol. 2000 Nov;10(8 Suppl):S85-91. doi: 10.1016/s1047-2797(00)00185-x.
PY  - 2000
SN  - 1047-2797 (Print)
1047-2797
SP  - S85-91
ST  - Minority recruitment in the prostate cancer prevention trial
T2  - Ann Epidemiol
TI  - Minority recruitment in the prostate cancer prevention trial
VL  - 10
ID  - 693
ER  - 

TY  - JOUR
AB  - BACKGROUND: Previous large chemoprevention studies have not recruited significant numbers of minorities. The Selenium and Vitamin E Cancer Prevention Trial (SELECT) is a large phase III study evaluating the impact of selenium and vitamin E on the clinical incidence of prostate cancer. Over 400 SELECT study sites in the USA, Canada, and Puerto Rico recruited men to this trial. The SELECT recruitment goal was 24% minorities, with 20% black, 3% Hispanic, and 1% Asian participants. The goal for black participants was set at 20% because of their proportion in the United States population and their prevalence of prostate cancer. METHODS: The minority recruitment strategies in SELECT were to: 1) consider minority recruitment during site selection; 2) expand the eligibility criteria by lowering the age criterion for black men and including men with controlled co-morbid illnesses; 3) develop a national infrastructure; 4) give additional funds to sites with the potential to increase black enrollment; and 5) provide resources to maximize free media opportunities to promote SELECT. RESULTS: SELECT recruitment began in August 2001 and was intended to last five years, but concluded two years ahead of schedule in June 2004. Of the 35 534 participants enrolled, 21% were minorities, with 15% black, 5% Hispanic, and 1% Asian. CONCLUSIONS: Careful planning, recruitment of large numbers of clinical centers and adequate resources accomplished by the combined efforts of the National Cancer Institute (NCI), Southwest Oncology Group (SWOG), SELECT Recruitment and Adherence Committee (RAC), SELECT Minority and Medically Underserved Subcommittee (MMUS), and the local SELECT sites resulted in attainment of the estimated sample size ahead of schedule and recruitment of the largest percentage of black participants ever randomized to a cancer prevention trial.
AD  - Department of Clinical Cancer Prevention, Unit 1360, The University of Texas M D Anderson Cancer Center, Houston 77230-1439, USA. edcook@mdanderson.org
AN  - 16315648
AU  - Cook, E. D.
AU  - Moody-Thomas, S.
AU  - Anderson, K. B.
AU  - Campbell, R.
AU  - Hamilton, S. J.
AU  - Harrington, J. M.
AU  - Lippman, S. M.
AU  - Minasian, L. M.
AU  - Paskett, E. D.
AU  - Craine, S.
AU  - Arnold, K. B.
AU  - Probstfield, J. L.
DO  - 10.1191/1740774505cn111oa
DP  - NLM
ET  - 2005/12/01
IS  - 5
KW  - African Americans
Aged
Antioxidants/therapeutic use
*Clinical Trials, Phase III as Topic
Humans
Male
Middle Aged
*Patient Selection
Prostatic Neoplasms/*drug therapy/ethnology
Randomized Controlled Trials as Topic
Research Design
Vitamin E/therapeutic use
LA  - eng
N1  - Cook, Elise D
Moody-Thomas, Sarah
Anderson, Karen B
Campbell, Russell
Hamilton, Sandra J
Harrington, Joseph M
Lippman, Scott M
Minasian, Lori M
Paskett, Electra D
Craine, Stephen
Arnold, Kathryn B
Probstfield, Jeffrey L
5-U10-CA-37429/CA/NCI NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, P.H.S.
England
Clin Trials. 2005;2(5):436-42. doi: 10.1191/1740774505cn111oa.
PY  - 2005
SN  - 1740-7745 (Print)
1740-7745
SP  - 436-42
ST  - Minority recruitment to the Selenium and Vitamin E Cancer Prevention Trial (SELECT)
T2  - Clin Trials
TI  - Minority recruitment to the Selenium and Vitamin E Cancer Prevention Trial (SELECT)
VL  - 2
ID  - 582
ER  - 

TY  - JOUR
AB  - PURPOSE: American minority groups have been historically underrepresented in phase III prostate cancer clinical trials despite often having higher risk disease. We analyzed enrollment trends of major racial/ethnic groups in the United States in phase III prostate cancer trials between 2003 and 2014 compared to SEER (Surveillance, Epidemiology and End Results) incidence data. MATERIALS AND METHODS: Phase III prostate cancer trials primarily enrolling patients from the United States were identified in the ClinicalTrials.gov database. Enrollment trends were analyzed for major racial/ethnic groups. Prostate cancer incidence data from the SEER registry were used to identify enrollment targets. The enrollment difference was determined by calculating the absolute difference between the percent of a racial/ethnic subgroup in the SEER registry population and the percent of that subgroup in the phase III prostate cancer trial population. RESULTS: Among 39 studies identified African American enrollment in therapeutic trials increased across the study period (p <0.001). The enrollment difference for African Americans was -9.0% (95% CI -7.6- -10.5, p <0.001) in 2003 to 2005 and 1.4% (95% CI 0.2-2.6, p = 0.020) in 2012 to 2014. However, African American men were under enrolled in metastatic disease trials (enrollment difference -5.8%, 95% CI -4.8- -6.8, p <0.001). Latino and Asian American men were consistently under enrolled in all trial types. CONCLUSIONS: Minority groups in the United States were largely under enrolled in phase III prostate cancer trials between 2003 and 2014. While recruitment efforts may have had an impact, as demonstrated by increased enrollment of African American men, there remains a need to expand recruitment efforts to achieve diversity in trials.
AD  - Department of Urology, Zuckerberg San Francisco General Hospital, University of California-San Francisco, San Francisco, California.
Division of General Internal Medicine, Department of Medicine, Zuckerberg San Francisco General Hospital, University of California-San Francisco, San Francisco, California.
AN  - 30218761
AU  - Balakrishnan, A. S.
AU  - Palmer, N. R.
AU  - Fergus, K. B.
AU  - Gaither, T. W.
AU  - Baradaran, N.
AU  - Ndoye, M.
AU  - Breyer, B. N.
DA  - Feb
DO  - 10.1016/j.juro.2018.09.029
DP  - NLM
ET  - 2018/09/16
IS  - 2
KW  - African Americans/statistics & numerical data
Asian Americans/statistics & numerical data
Clinical Trials, Phase III as Topic/*statistics & numerical data
European Continental Ancestry Group/statistics & numerical data
Hispanic Americans/statistics & numerical data
Humans
Male
*Minority Health
*Patient Selection
*Prostatic Neoplasms/therapy
SEER Program
Time Factors
United States
LA  - eng
N1  - 1527-3792
Balakrishnan, Ashwin S
Palmer, Nynikka R
Fergus, Kirkpatrick B
Gaither, Thomas W
Baradaran, Nima
Ndoye, Medina
Breyer, Benjamin N
Comparative Study
Journal Article
United States
J Urol. 2019 Feb;201(2):259-267. doi: 10.1016/j.juro.2018.09.029.
PY  - 2019
SN  - 0022-5347
SP  - 259-267
ST  - Minority Recruitment Trends in Phase III Prostate Cancer Clinical Trials (2003 to 2014): Progress and Critical Areas for Improvement
T2  - J Urol
TI  - Minority Recruitment Trends in Phase III Prostate Cancer Clinical Trials (2003 to 2014): Progress and Critical Areas for Improvement
VL  - 201
ID  - 104
ER  - 

TY  - JOUR
AN  - 105970189. Language: English. Entry Date: 20080215. Revision Date: 20150711. Publication Type: Journal Article
AU  - Long, K.
DB  - CINAHL Complete
DP  - EBSCOhost
IS  - 21
KW  - Beauty
Cancer Survivors
Lymphedema
Black Persons
Breast Neoplasms
Female
Research Subject Recruitment
N1  - brief item. Note: Published in multiple journals. Journal Subset: Nursing; USA.
PY  - 2007
SN  - 1547-5131
SP  - 27-27
ST  - Mixing beauty and health: lymphedema study looks for participants at beauty shops
T2  - NurseWeek (15475131)
TI  - Mixing beauty and health: lymphedema study looks for participants at beauty shops
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105970189&site=ehost-live&scope=site
VL  - 14
ID  - 1998
ER  - 

TY  - JOUR
AB  - Context: To optimize treatment of Black pts with multiple myeloma, a greater understanding of differences in outcomes in Black pts vs. White pts is needed. In GRIFFIN, DARA plus RVd (D‐RVd) improved rates and depth of response in autologous stem cell transplant (ASCT)‐eligible NDMM pts. Here, we report a subgroup analysis of Black pts from GRIFFIN. Design: Between 2016 and 2018, pts in the United States were randomized 1:1 to RVd ± DARA and received 4 induction cycles, high‐dose therapy, ASCT, 2 consolidation cycles, and maintenance with R ± DARA for 24 mo. The pre‐specified primary endpoint was stringent complete response (sCR) rate by end of consolidation, which occurred at a median follow‐up of 13.5 mo. Results below are based on longer follow‐up (22.1 mo). Results: Two hundred seven pts (D‐RVd, n=104; RVd, n=103) were randomized; 32 (15%) pts were Black (D‐RVd, n=14; RVd, n=18), and 161 (78%) pts were White (D‐RVd, n=85; RVd, n=76). Baseline demographics were generally similar between treatment arms in Black and White pts. D‐RVd vs RVd improved the sCR rate by end of consolidation in Black (10 [71%]; 6 [33%]) and White pts (35 [43%]; 24 [34%]). Including post‐consolidation data, sCR with D‐RVd vs. RVd was achieved by 12 (86%) and 7 (39%) Black pts and 50 (61%) and 33 (46%) White pts. ORR by end of consolidation was improved for D‐RVd vs. RVd in Black pts (14 [100%] vs. 17 [94%]), as were rates of ≥CR (12 [86%] vs. 7 [39%]) and minimal residual disease at 10−5 (5 [36%] vs. 3 [17%]). Grade 3/4 TEAEs (≥25%) with D‐RVd/RVd included neutropenia (Black pts, 50%/22%; White pts, 41%/16%), lymphopenia (29%/39%; 23%/16%), and thrombocytopenia (29%/11%; 14%/8%). Grade 3/4 infections for D‐RVd/RVd occurred in 36%/17% of Black and 20%/23% of White pts. IRRs occurred in 29% of Black and 45% of White pts. Conclusions: GRIFFIN demonstrated that D‐RVd improved responses in the Black NDMM pt subgroup, but larger studies are needed to better define the magnitude of DARA benefit in Black pts. Improved recruitment of Black pts in clinical trials is needed to understand disease biology and response to therapy among racial groups.
AN  - CN-02212698
AU  - Nooka, A. K.
AU  - Kaufman, J. L.
AU  - Rodriguez, C.
AU  - Jakubowiak, A.
AU  - Shune, L.
AU  - Badros, A.
AU  - Chari, A.
AU  - Richardson, P. G.
AU  - Pei, H.
AU  - Ukropec, J.
AU  - et al.
DO  - 10.1016/S2152-2650(20)30956-3
KW  - *African American
*cancer patient
*multiple myeloma
Adult
Clinical trial
Conference abstract
Controlled study
Demography
Drug combination
Drug megadose
Drug therapy
Female
Follow up
Human
Human cell
Lymphocytopenia
Major clinical study
Male
Minimal residual disease
Neutropenia
Race
Randomized controlled trial
Remission
Stem cell
Thrombocytopenia
Treatment response
United States
M3  - Journal: Conference Abstract
PY  - 2020
SP  - S308‐S309
ST  - MM-350: daratumumab (DARA) + Lenalidomide/Bortezomib/Dexamethasone (RVd) in African American/Black Patients (Pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): subgroup Analysis of GRIFFIN
T2  - Clinical lymphoma, myeloma & leukemia
TI  - MM-350: daratumumab (DARA) + Lenalidomide/Bortezomib/Dexamethasone (RVd) in African American/Black Patients (Pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): subgroup Analysis of GRIFFIN
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02212698/full
VL  - 20
ID  - 1402
ER  - 

TY  - JOUR
AB  - Objectives: Rural women are underrepresented in cancer research. We hypothesized that providing access to a research study to rural, medically underserved women who were receiving their breast cancer screening using a mobile mammography unit would increase the representation of rural women in a cancer cohort study. Design: This study is a cross-sectional study using a cohort of women who have been recruited to a breast cancer study in Arkansas. Setting: Recruiters accompanied a mobile mammography unit, the MammoVan, to implement a novel method for reaching and recruiting underrepresented rural Arkansas women into the study. Participants include 5850 women recruited from 2010 through 2012 as part of the Arkansas Rural Community Health (ARCH) study. Results: Participants recruited during their mammography screening on the MammoVan tended to be more rural, less educated, and more likely to be non-Hispanic than those recruited in other venues. A significant difference was not noted for race or age. Conclusion: Collaboration with the MammoVan greatly aided the recruitment of rural participants. These strategies can facilitate the representation of this historically underserved and understudied rural population in future research studies.
AD  - P.A. McElfish, Department of Internal Medicine, College of Medicine, University of Arkansas for Medical Sciences Northwest, Fayetteville, AR, United States
AU  - McElfish, P. A.
AU  - Su, L. J.
AU  - Lee, J. Y.
AU  - Runnells, G.
AU  - Henry-Tillman, R.
AU  - Kadlubar, S. A.
DB  - Embase
DO  - 10.1177/1178223419876296
KW  - MammoVan
mobile mammography unit
adult
African American
Arkansas
article
breast cancer
cancer research
cancer screening
Caucasian
clinical effectiveness
cohort analysis
education
female
health care access
Hispanic
human
major clinical study
mammography
medically underserved
rural area
LA  - English
M3  - Article
N1  - L2003195495
2019-10-25
2019-11-04
PY  - 2019
SN  - 1178-2234
ST  - Mobile Mammography Screening as an Opportunity to Increase Access of Rural Women to Breast Cancer Research Studies
T2  - Breast Cancer: Basic and Clinical Research
TI  - Mobile Mammography Screening as an Opportunity to Increase Access of Rural Women to Breast Cancer Research Studies
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L2003195495&from=export
http://dx.doi.org/10.1177/1178223419876296
VL  - 13
ID  - 861
ER  - 

TY  - JOUR
AB  - BACKGROUND: Clinical trials are critical to advancing cancer treatment. Minority populations are underrepresented among trial participants, and there is limited understanding of their decision-making process and key determinants of decision outcomes regarding trial participation. METHODS: To understand research decision-making among clinical trial-eligible African-American cancer patients at Johns Hopkins, we conducted seven focus groups (n=32) with trial-offered patients ≥ 18 years diagnosed with lung, breast, prostate, or colorectal cancer ≤ 5 years. Three "acceptor" and four "decliner" focus groups were conducted. Questions addressed: attitudes towards clinical trials, reasons for accepting or declining participation, and recommendations to improve minority recruitment and enrollment. Data were transcribed and analyzed using traditional approaches to content and thematic analysis in NVivo 9.0. Data coding resulted in themes that supported model construction. RESULTS: Participant experiences revealed the following themes when describing the decision-making process: Information gathering, Intrapersonal perspectives, and Interpersonal influences. Decision outcomes included the presence or absence of decision regret and satisfaction. From these themes, we generated a Model of Cancer Clinical Trial Decision-making. CONCLUSION: Our model should be tested in hypothesis-driven research to elucidate factors and processes influencing decision balance and outcomes of trial-related decision-making. The model should also be tested in other disparities populations and for diagnoses other than cancer.
AD  - Johns Hopkins School of Nursing, 525 N. Wolfe St, Baltimore, MD 21205-2110, USA.
Bloomberg School of Public Health, Baltimore, MD, USA.
AN  - 25960945
AU  - Wenzel, J. A.
AU  - Mbah, O.
AU  - Xu, J.
AU  - Moscou-Jackson, G.
AU  - Saleem, H.
AU  - Sakyi, K.
AU  - Ford, J. G.
C2  - PMC4420720
C6  - NIHMS679521
DA  - Jun
DO  - 10.1007/s40615-014-0063-x
DP  - NLM
ET  - 2015/05/12
IS  - 2
KW  - Adult
African Americans/*psychology/statistics & numerical data
Aged
Clinical Trials as Topic/*psychology/statistics & numerical data
*Decision Making
Female
Focus Groups
Health Status Disparities
Humans
Male
Middle Aged
*Models, Psychological
Neoplasms/*ethnology/therapy
African-Americans
Cancer disparities
Clinical trials
Decision balance
Decision regret
LA  - eng
N1  - 2196-8837
Wenzel, Jennifer A
Mbah, Olive
Xu, Jiayun
Moscou-Jackson, Gyasi
Saleem, Haneefa
Sakyi, Kwame
Ford, Jean G
U54 CA153710/CA/NCI NIH HHS/United States
T32 NR012704/NR/NINR NIH HHS/United States
RC2 MD004797/MD/NIMHD NIH HHS/United States
F31 NR014598/NR/NINR NIH HHS/United States
U24MD006970/MD/NIMHD NIH HHS/United States
F31 NR014750/NR/NINR NIH HHS/United States
U54CA153710/CA/NCI NIH HHS/United States
U24 MD006970/MD/NIMHD NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
J Racial Ethn Health Disparities. 2015 Jun;2(2):192-9. doi: 10.1007/s40615-014-0063-x.
PY  - 2015
SN  - 2197-3792 (Print)
2196-8837
SP  - 192-9
ST  - A Model of Cancer Clinical Trial Decision-making Informed by African-American Cancer Patients
T2  - J Racial Ethn Health Disparities
TI  - A Model of Cancer Clinical Trial Decision-making Informed by African-American Cancer Patients
VL  - 2
ID  - 244
ER  - 

TY  - JOUR
AB  - The application of the POCK model of pulmonary clearance and retention to new experimental results of chronic inhalation studies with rats exposed for 2 yr to diesel exhaust or carbon black is reported. For the first time in lifetime studies with these carbonaceous aerosols, experimental data became available for paniculate mass burdens in the lung-associated lymph nodes. Furthermore, seven out of eight lifetime runs used exposure rate indices causing lung overload and lung tumors. The simulations of the POCK model were consistent with previous POCK representations of diesel soot and carbon black exposure studies. The new data on lifetime patterns of lymph node loads, however, required an adjustment of the interstitial kinetics in order to account for the apparent lymph-node load stagnation after about 1 yr of chronic exposures leading to lung overload. The consistently observed coincidence of lymph-node load stagnation and tumor induction in the new exposure studies occurred always in a situation where overload caused a pronounced increase of the interstitial particle burden. These observations were thought to support a hypothesis that assumed the time integral of the interstitial burden as an effective relative dose for a rat-specific overload carcinogenesis. Depending on aerosol material and rat strain, common critical values of this dose relating to both lymph-node load stagnation and tumor induction were postulated and calculated by using the model-inferred simulation data. The low precision of the experimental data indicating lymph-node load stagnation rendered the results semiquantitative. However, a plausible evaluation of the sparse empirical dose-response data of overload carcinogenesis for the two carbonaceous aerosols yielded no-effect thresholds commensurable and compatible with the critical dose values. © 1994 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted.
AD  - Chemical Industry Institute of Toxicology, Research Triangle Park, NC, United States
Inhalation Toxicology Research Institute, Albuquerque, NM, United States
AU  - Stöber, W.
AU  - Mauderly, J. L.
DB  - Scopus
DO  - 10.3109/08958379409040504
IS  - 5
M3  - Article
N1  - Cited By :17
Export Date: 22 March 2021
PY  - 1994
SP  - 427-457
ST  - Model-inferred hypothesis of a critical dose for overload tumor induction by diesel soot and carbon black
T2  - Inhalation Toxicology
TI  - Model-inferred hypothesis of a critical dose for overload tumor induction by diesel soot and carbon black
UR  - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0028002829&doi=10.3109%2f08958379409040504&partnerID=40&md5=216b62bdad7a30a10e6caef1c6c83fcb
VL  - 6
ID  - 2659
ER  - 

TY  - JOUR
AB  - BACKGROUND: Attrition occurs when a participant fails to respond to one or more study waves. The accumulation of attrition over several waves can lower the sample size and power and create a final sample that could differ in characteristics than those who drop out. The main reason to conduct a longitudinal study is to analyze repeated measures; research subjects who drop out cannot be replaced easily. Our group recently investigated factors affecting nonparticipation (refusal) in the first wave of a population-based study of prostate cancer. In this study we assess factors affecting attrition in the second wave of the same study. We compare factors affecting nonparticipation in the second wave to the ones affecting nonparticipation in the first wave. METHODS: Information available on participants in the first wave was used to model attrition. Different sources of attrition were investigated separately. The overall and race-stratified factors affecting attrition were assessed. Kaplan-Meier survival curve estimates were calculated to assess the impact of follow-up time on participation. RESULTS: High cancer aggressiveness was the main predictor of attrition due to death or frailty. Higher Charlson Comorbidity Index increased the odds of attrition due to death or frailty only in African Americans (AAs). Young age at diagnosis for AAs and low income for European Americans (EAs) were predictors for attrition due to lost to follow-up. High cancer aggressiveness for AAs, low income for EAs, and lower patient provider communication scores for EAs were predictors for attrition due to refusal. These predictors of nonparticipation were not the same as those in wave 1. For short follow-up time, the participation probability of EAs was higher than that of AAs. CONCLUSIONS: Predictors of attrition can vary depending on the attrition source. Examining overall attrition (combining all sources of attrition under one category) instead of distinguishing among its different sources should be avoided. The factors affecting attrition in one wave can be different in a later wave and should be studied separately.
AD  - LSUHSC, School of Public Health, Biostatistics Program, New Orleans, USA.
LSUHSC, School of Public Health, Biostatistics Program, New Orleans, USA. eoral@lsuhsc.edu.
LSUHSC, School of Public Health, Epidemiology Program, New Orleans, USA.
Department of Urology, Roswell Park Cancer Institute, Buffalo, USA.
Lineberger Comprehensive Cancer Center, UNC-Chapel Hill, Chapel Hill, USA.
LSUHSC, School of Public Health, Health Policy and Systems Management Program, New Orleans, USA.
AN  - 29925318
AU  - Spiers, S.
AU  - Oral, E.
AU  - Fontham, E. T. H.
AU  - Peters, E. S.
AU  - Mohler, J. L.
AU  - Bensen, J. T.
AU  - Brennan, C. S.
C2  - PMC6011525
DA  - Jun 20
DO  - 10.1186/s12874-018-0518-6
DP  - NLM
ET  - 2018/06/22
IS  - 1
KW  - Adult
African Americans/statistics & numerical data
Aged
European Continental Ancestry Group/statistics & numerical data
Follow-Up Studies
Humans
Kaplan-Meier Estimate
*Logistic Models
Longitudinal Studies
Male
Middle Aged
Patient Participation/psychology/*statistics & numerical data
Prostatic Neoplasms/*diagnosis/ethnology/*therapy
Risk Factors
United States
*Attrition
*Longitudinal study
*Nonresponse bias
*Prostate cancer
*Unit nonresponse
from all PCaP study research subjects prior to participation and all study protocols
were approved by participating institutions’ Institutional Review Boards. The
current study that included an analysis of a sub-set of PCaP research subjects was
also approved by the Louisiana State Health Sciences University-New Orleans
Institutional Review Board (IRB #7971). It was exempted from additional consent
requirements as minimal risk research utilizing secondary data. COMPETING INTERESTS:
The authors declare that they have no competing interests. PUBLISHER’S NOTE:
Springer Nature remains neutral with regard to jurisdictional claims in published
maps and institutional affiliations.
LA  - eng
N1  - 1471-2288
Spiers, Samantha
Oral, Evrim
Fontham, Elizabeth T H
Peters, Edward S
Mohler, James L
Bensen, Jeannette T
Brennan, Christine S
R15 CA151031/CA/NCI NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.
BMC Med Res Methodol. 2018 Jun 20;18(1):60. doi: 10.1186/s12874-018-0518-6.
PY  - 2018
SN  - 1471-2288
SP  - 60
ST  - Modelling attrition and nonparticipation in a longitudinal study of prostate cancer
T2  - BMC Med Res Methodol
TI  - Modelling attrition and nonparticipation in a longitudinal study of prostate cancer
VL  - 18
ID  - 118
ER  - 

TY  - JOUR
AB  - OBJECTIVE: To conduct timely epidemiologic investigations of molecular/genetic markers that may contribute to the development of prostate, lung, colorectal, or other cancers within the Selenium and Vitamin E Cancer Prevention Trial (SELECT), and to evaluate interactions between these markers and the study interventions. METHODS: The epidemiologic studies within SELECT will be based on 32,400 men aged 55 years or older (age 50 or older for the African-American men) enrolled into an intergroup, randomized, placebo-controlled, double-blind, phase III prevention trial of supplemental selenium and vitamin E developed and funded by the National Cancer Institute, and coordinated by the Southwest Oncology Group. During the 12-year study period approximately 1500-2000 cases of prostate cancer, 800 lung cancers, and 500 colon cancers are estimated to be diagnosed, based on data from the ongoing Prostate Cancer Prevention Trial of finasteride. A modified fasting blood sample will be processed to collect plasma for analysis of micronutrients, hormones, cytokines, and other proteins. Buffy-coat derived white blood cells collected at baseline will be used for isolation of DNA and establishment of immortalized cell lines. Red blood cells will be stored for analysis of hemoglobin adducts and other components. RESULTS: Specific results anticipated from these molecular studies will provide information on factors hypothesized to contribute to prostate cancer risk and that may modify the efficacy of either trial supplement, including: steroid sex hormones and several polymorphic genes that encode proteins affecting androgenic stimulation of the prostate, including the androgen receptor, steroid 5alpha-reductase type II, CYP17, and beta-hydroxysteroid dehydrogenase; polymorphisms of DNA repair genes and carcinogen metabolism genes, including those involved in the activation of chemical carcinogens to reactive intermediates (e.g., CYP1A1) or the detoxification of reactive intermediates (e.g., glutathione S-transferase M1); DNA and protein adducts; and insulin-like growth factors and leptin. CONCLUSION: SELECT offers an excellent opportunity to conduct molecular epidemiologic investigations to assess gene-environment interactions and their role in prostate, lung, and colon carcinogenesis.
AD  - Department of Clinical Cancer Prevention, University of Texas M. D. Anderson Cancer Center, Houston 77030, USA.
AN  - 11552710
AU  - Hoque, A.
AU  - Albanes, D.
AU  - Lippman, S. M.
AU  - Spitz, M. R.
AU  - Taylor, P. R.
AU  - Klein, E. A.
AU  - Thompson, I. M.
AU  - Goodman, P.
AU  - Stanford, J. L.
AU  - Crowley, J. J.
AU  - Coltman, C. A.
AU  - Santella, R. M.
DA  - Sep
DO  - 10.1023/a:1011277600059
DP  - NLM
ET  - 2001/09/13
IS  - 7
KW  - *Colorectal Neoplasms/epidemiology/genetics/prevention & control
Double-Blind Method
Epidemiologic Studies
Genetic Markers
Gonadal Steroid Hormones/blood
Humans
Leptin/blood
*Lung Neoplasms/epidemiology/genetics/prevention & control
Male
Middle Aged
Prospective Studies
*Prostatic Neoplasms/epidemiology/genetics/prevention & control
Risk Factors
Selenium/therapeutic use
United States/epidemiology
Vitamin E/therapeutic use
LA  - eng
N1  - Hoque, A
Albanes, D
Lippman, S M
Spitz, M R
Taylor, P R
Klein, E A
Thompson, I M
Goodman, P
Stanford, J L
Crowley, J J
Coltman, C A
Santella, R M
1 U 10 CA 37429/CA/NCI NIH HHS/United States
Clinical Trial
Clinical Trial, Phase III
Journal Article
Randomized Controlled Trial
Research Support, U.S. Gov't, P.H.S.
Netherlands
Cancer Causes Control. 2001 Sep;12(7):627-33. doi: 10.1023/a:1011277600059.
PY  - 2001
SN  - 0957-5243 (Print)
0957-5243
SP  - 627-33
ST  - Molecular epidemiologic studies within the Selenium and Vitamin E Cancer Prevention Trial (SELECT)
T2  - Cancer Causes Control
TI  - Molecular epidemiologic studies within the Selenium and Vitamin E Cancer Prevention Trial (SELECT)
VL  - 12
ID  - 680
ER  - 

TY  - JOUR
AB  - Epithelial ovarian cancer (EOC) accounts for 5% of all cancer deaths and is the fifth leading cause of cancer death in women in the United States. While the incidence is slightly higher in European Americans (EA) than in African American (AA) women, five‐year relative survival is much worse for AA women at 36.4% compared to 44.3% for EA women. AA women also have a poorer survival for breast cancer and for both ovarian and breast cancer access to appropriate treatment is a major contributor. Additionally poorer breast cancer survival among AA women has been attributed to aggressive subtypes being more common in AA women compared to EA women. Although the definition of ovarian cancer subtypes has lagged behind that of breast cancer, there have been major changes in the understanding of EOC over the past decade where EOC is not seen as a single disease but as a heterogeneous group of distinct diseases with different morphologic, protein and gene expression profiles. There is now strong evidence that the diverse histologic types comprising ovarian cancer arise not primarily from the ovarian surface epithelium but from various extra‐ovarian Systematic molecular characterization of the most common and lethal morphologic disease subgroup, high grade serous ovarian cancer (HGOSC), provides evidence that subtypes of HGSOC exist and are definable based on gene expression patterns. Four subtypes appear to have robust definitions across different datasets and populations, which resemble the TCGA subtypes labeled as mesenchymal, proliferative, differentiated, and immunoreactive. Most of the molecular profiles of HGSOC in AA women have been based on white cases, with only 24 AA cases available in the TCGA dataset and 29 AA cases in the North Carolina Ovarian Cancer Study. In our recent study which included 164 EA and 29 AA women enrolled in the North Carolina Ovarian Cancer Study, we reported differences in the relative proportion of the four HGOSC gene expression subtypes by race. Preliminary results of HGSOC gene expression patterns in a larger sample of cases enrolled in the African American Cancer Epidemiology Study (AACES), an ongoing multi‐center population‐based study, support the existence of similar and novel subtypes as reported in EA women with ovarian cancer. Additionally, intrinsic mutational subtypes have been described using the TCGA data of which four have been found to predict survival. However, these mutational subtypes were not found to correspond to the gene expression subtypes. The majority of the ovarian cancer cases were EA and further work in this area which specifically addresses AAs with ovarian cancer is warranted. Although there are over 20 known genome‐wide ovarian cancer risk associated SNPs, none have yet been evaluated in AAs and most were determined among EA women. Evaluation of association with these susceptibility variants is currently underway in AA ovarian cancer cases and controls within the NCI‐funded GAME‐ON consortium. Nearly all EOC research has been performed in EA women with limited focus on racially diverse populations. Comparisons across populations will aid in precisely defining genetic association, molecular subtypes and identify subtype‐specific features for future functional characterization with implications for improving treatment and understanding the etiology of one of the most deadly cancers. Below are research objectives that will address important gaps in the molecular epidemiology of ovarian cancer in African American women: * Determine molecular subtypes among African‐American women * Evaluate genetic risk variants for ovarian cancer susceptibility and survival in African‐American women * Incorporate assessment of ovarian cancer risk of African Americans in risk prediction models * Develop evidence‐based interventions to reduce risk and increase survival.
AN  - CN-01250215
AU  - Schildkraut, J. M.
DO  - 10.1158/1538-7755.DISP15-IA31
IS  - 3 Supplement) (no pagination
KW  - *molecular epidemiology
*ovary carcinoma
African American
Breast cancer
Cancer epidemiology
Cancer research
Cancer risk
Cancer survival
Cancer susceptibility
Clinical article
Clinical trial
Controlled clinical trial
Controlled study
Endogenous compound
Epithelium
European American
Female
Gene expression profiling
Genetic association
Genetic risk
Human
Human tissue
Model
Multicenter study
North Carolina
Population based case control study
Prediction
Race
Tumor gene
M3  - Journal: Conference Abstract
PY  - 2016
ST  - Molecular epidemiology of ovarian cancer
T2  - Cancer epidemiology biomarkers and prevention. Conference: 8th AACR conference on the science of health disparities in racial/ethnic minorities and the medically underserved. United states. Conference start: 20151113. Conference end: 20151116
TI  - Molecular epidemiology of ovarian cancer
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01250215/full
VL  - 25
ID  - 1420
ER  - 

TY  - JOUR
AB  - OBJECTIVE: To examine mortality and morbidity after prostate biopsy in the intervention arm of the Prostate, Lung, Colorectal and Ovarian Cancer Screening (PLCO) trial. SUBJECTS AND METHODS: Abstractors from the PLCO trial recorded the types and dates of diagnostic follow-up procedures after positive screens and documented the types and dates of resultant complications. Cancers and deaths among the participants were tracked. The mortality rate in the 120-day period after prostate biopsy was compared with a control rate of deaths in the 120-day period after a negative screen in men without biopsy. Multivariate analysis was performed to control for potential confounders, including age, comorbidities and smoking. Rates of any complication, infectious and non-infectious complications were computed among men with a negative biopsy. Multivariate analysis was used to examine the risk factors for complications. RESULTS: Of the 37,345 men enrolled in the PLCO trial (intervention arm), 4861 had at least one biopsy after a positive screen and 28,661 had a negative screen and no biopsy. The 120-day mortality rate after biopsy was 0.95 (per 1000), compared with the control group rate of 1.8; the multivariate relative risk was 0.49 (95% CI: 0.2-1.1). Among 3706 negative biopsies, the rates (per 1000) of any complication, infectious and non-infections complications were 20.2, 7.8 and 13.0, respectively. A history of prostate enlargement or inflammation was significantly associated with higher rates of both infectious (odds ratio [OR] = 3.7) and non-infectious (OR = 2.2) complications. Black race was associated with a higher infectious complications rate (OR = 7.1) and repeat biopsy was associated with lower rates of non-infectious complications (OR = 0.3). CONCLUSION: Mortality rates were not found to be higher after prostate biopsy in the PLCO trial and complications were relatively infrequent, with several risk factors identified.
AD  - Division of Cancer Prevention, National Cancer Institute, Bethesda, MD, USA.
AN  - 24053621
AU  - Pinsky, P. F.
AU  - Parnes, H. L.
AU  - Andriole, G.
C2  - PMC3873374
C6  - NIHMS512075
DA  - Feb
DO  - 10.1111/bju.12368
DP  - NLM
ET  - 2013/09/24
IS  - 2
KW  - Aged
Biomarkers, Tumor/blood
Biopsy/*adverse effects
*Early Detection of Cancer
Humans
Hypertrophy/epidemiology/etiology
Male
*Mass Screening/methods
Middle Aged
Prostate/*pathology
Prostate-Specific Antigen/blood
Prostatic Neoplasms/blood/complications/*diagnosis/*mortality
Prostatitis/epidemiology/etiology
Surveys and Questionnaires
United States/epidemiology
Psa
complications
mortality
prostate biopsy
prostate-specific antigen
LA  - eng
N1  - 1464-410x
Pinsky, Paul F
Parnes, Howard L
Andriole, Gerald
Z99 CA999999/Intramural NIH HHS/United States
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, N.I.H., Extramural
BJU Int. 2014 Feb;113(2):254-9. doi: 10.1111/bju.12368. Epub 2013 Nov 21.
PY  - 2014
SN  - 1464-4096 (Print)
1464-4096
SP  - 254-9
ST  - Mortality and complications after prostate biopsy in the Prostate, Lung, Colorectal and Ovarian Cancer Screening (PLCO) trial
T2  - BJU Int
TI  - Mortality and complications after prostate biopsy in the Prostate, Lung, Colorectal and Ovarian Cancer Screening (PLCO) trial
VL  - 113
ID  - 315
ER  - 

TY  - JOUR
AB  - This paper presents the rationale and findings of a feasibility and process study of the Kin Keeper(SM) Cancer Prevention Intervention. An observational cohort study design was implemented with African-American women in synergistic female family relationships. Community health workers (CHWs) from two Michigan public health programs recruited women to serve as 'kin keepers' who in turn recruited their female family members. In total, 161 kin keepers and female family members were sampled. Trained CHWs led kin keepers and family members in learning about breast cancer. Data methods included baseline and post-training administration of a breast cancer literacy assessment, post-training focus groups and review of personal action plans. To validate the feasibility of the process, a linear mixed-effects regression with 97% power was identified and differences in pre-post scores were detected at 5% significance level. Adjusting for family random effects, breast cancer literacy scores increased for all participants recruited (P-value = 0.0004) suggesting that the process was feasible. Analysis of focus groups and action plans indicated that participants valued the instruction and planned to act upon it. This experience with kin keepers and their families offers encouragement that the theoretical model and its community-based delivery can continue to enhance scholarship dedicated to ameliorating health care disparities.
AN  - WOS:000264190800013
AU  - Williams, K. P.
AU  - Mullan, P. B.
AU  - Todem, D.
DA  - Apr
DO  - 10.1093/her/cyn026
IS  - 2
N1  - 18515265
PY  - 2009
SN  - 0268-1153
SP  - 343-356
ST  - Moving from theory to practice: implementing the Kin Keeper(SM) Cancer Prevention Model
T2  - Health Education Research
TI  - Moving from theory to practice: implementing the Kin Keeper(SM) Cancer Prevention Model
VL  - 24
ID  - 3152
ER  - 

TY  - JOUR
AB  - Role of Biomarkers in Lung Cancer Screening As a part of ongoing research to understand the etiology and early detection of lung cancer, the Integrative Analysis of Lung Cancer Etiology and Risk (INTEGRAL) consortium has been genotyping large numbers of lung cancer cases and controls and analyzing biomarkers from case cohort members prior to their diagnosis with lung cancer and matched controls. We are also assembling knowledge about predictors of lung cancer risk to identify biomarkers that will be applied along with radiomic features to select individuals at highest risk for lung cancer to enroll in screening studies and to assist in resolution of cancer risk among those found to have small nodules. To date we have analyzed genetic data from 29,266 patients and 56,450 controls of European descent(1) and curated genotyping information from 20 studies conducted in European descent, 14 from Asian descent and 1 study in African‐American Populations(2). Ongoing imputation is allowing us to integrate most of these data for a further analysis that brings together world populations for genetic discovery. Results of these studies have identified 12 strongly replicated loci and an additional 38 loci that are highly significant in some studies but less well replicated. Among the variants that we identified, a variant in BRCA2 (1) is remarkable for conferring over 2 fold increased risk for lung cancer development independent of smoking behavior and thereby indicating a small subset of high risk individuals based on genotype. Further studies to identify rare variants that confer a high risk of lung cancer have identified mutations in ATM and KIAA0930 with odds ratios well over 2. The ATM variant is associated with loss of heterozygosity in tumors but does not cause Ataxia Telangiectasia in homozygotes. We have used genetic information to develop polygenic risk scores and a model that included 221 variants yielded the most improvement in accuracy. Results comparing models to identify individuals at high risk for lung cancer development based on risk scores compared with models based on demographic, clinical and smoking information show a modest increase in prediction accuracy, but identify selected individuals who are at high risk and for whom lung screening would be particularly indicated. The genetic information we have developed and curated can also be used with additional approaches to identify predictors of lung cancer risk using shared heritability and Mendelian randomization analyses. Shared heritability analysis identifies strong genetic correlations with all measures of smoking behavior and also with primary biliary cirrhosis and schizophrenia. Mendelian randomization, which removes concerns about change in BMI during cancer development, shows that increased BMI is associated with squamous and small cell lung cancer and not associated with adenocarcinoma(3). Mendelian randomization studies found association of increased lung cancer risk with longer germline telomere length and increased risk associated with higher levels of vitamin B12(4). Further Mendelian randomization studies are underway to evaluate other biochemical factors that may associate with increased lung cancer risk. Cohort studies to identify biomarker signatures of risk have identified a reliable panel(5) comprising CEA125, CEA, CYFRA 21‐1 and pro‐SFTB that along with smoking behavior provide an area under the receiver operator curve of 83%, indicating that a strategy that seeks to identify high risk individuals using data from questionnaires about smoking along with biomarker analysis could substantially improve the yield of low dose spiral CT screening. Further studies of panels of biomarkers including microRNA and circulating cell‐free DNA are underway to evaluate the utility of adding additional biomarkers to further identify higher risk individuals. 1. McKay JD, et al. (2017) Large‐scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes. Nature gen tics 49(7):1126‐1132. 2. Bosse Y & Amos CI (2018) A Decade of GWAS Results in Lung Cancer. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 27(4):363‐379. 3. Carreras‐Torres R, et al. (2017) Obesity, metabolic factors and risk of different histological types of lung cancer: A Mendelian randomization study. PloS one 12(6):e0177875. 4. Fanidi A, et al. (2018) Is high vitamin B12 status a cause of lung cancer? International journal of cancer. Journal international du cancer. 5. Integrative Analysis of Lung Cancer E, et al. (2018) Assessment of Lung Cancer Risk on the Basis of a Biomarker Panel of Circulating Proteins. JAMA oncology 4(10):e182078. Keywords: Genetics, Biomarkers, Early Detection
AN  - CN-01995934
AU  - Brennan, P.
AU  - Amos, C.
DO  - 10.1016/j.jtho.2019.08.384
IS  - 10
KW  - *genome‐wide association study
Adenocarcinoma
Adult
African American
Ataxia telangiectasia
Body mass
Cancer risk
Cohort analysis
Conference abstract
Controlled study
Diagnosis
Disease course
Female
Gene mutation
Genetic association
Genetic correlation
Genetic marker
Genetic risk score
Genetic susceptibility
Germ line
Heritability
Heterozygosity loss
Histopathology
Homozygote
Human
Human cell
Low drug dose
Major clinical study
Male
Mendelian randomization analysis
Obesity
Prediction
Primary biliary cirrhosis
Questionnaire
Randomized controlled trial
Schizophrenia
Small cell lung cancer
Smoking
Spiral computer assisted tomography
Squamous cell carcinoma
Telomere length
M3  - Journal: Conference Abstract
PY  - 2019
SP  - S193‐
ST  - MS18.03 Amolecular Diagnostics, Incorporating GWAS and Risk Models: future Approaches to the Identification of High-Risk Individuals
T2  - Journal of thoracic oncology
TI  - MS18.03 Amolecular Diagnostics, Incorporating GWAS and Risk Models: future Approaches to the Identification of High-Risk Individuals
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01995934/full
VL  - 14
ID  - 1502
ER  - 

TY  - JOUR
AB  - Background: Aromatase inhibitors (AIs) are recommended as first‐line adjuvant hormonal therapy in postmenopausal women with hormone‐receptor‐positive breast cancer, as monotherapy or sequential therapy after tamoxifen. AI‐associated musculoskeletal symptoms (AIMSS) occur in approximately 50% of women receiving AIs and in some may result in discontinuation of treatment. Symptom management is essential to ensure that breast cancer patients receive the full recommended duration of AI therapy. We conducted a randomized, placebo‐controlled trial to evaluate the effect of acupuncture on AIMSS and report the first interim analysis. Method: Postmenopausal women with early stage breast cancer, experiencing AIMSS, who had not had acupuncture in the year prior to the study, were eligible. Patients were randomized to 8 weekly acupuncture or sham acupuncture. Health assessment questionnaire disability index (HAQ‐DI ranging 0‐3.0) and pain visual analog scale (VAS ranging 0‐100) were used to assess clinical musculoskeletal disorder severity at weeks 0, 4, 8, and 12 or 24. Change in HAQ‐DI (HAQ‐DI) and VAS scores (VAS) from baseline were compared between patients receiving acupuncture versus sham acupuncture using exact Wilcoxon rank sum test. Serum samples were collected for measurements of estrogens and beta endorphin concentrations and cytokine profile before and after the intervention to evaluate the etiology of AIMSS and the mechanism of acupuncture in treating AIMSS. Results: Between May 2008 and June 2011, 48 patients were enrolled, 2 patients were not evaluable due to noncompliance to treatment and lost to follow up, 10 were still receiving treatment and therefore not evaluable. Thirty‐six were evaluable, and were equally distributed between the real and sham acupuncture groups. Baseline characteristics were balanced between the two groups with regard to age, race, and body mass index (BMI) with the exception that baseline mean HAQ‐DI was higher in the acupuncture group (0.9 vs 0.55, p=0.04). White/Black/Asian: 26/7/3, Median (range): age: 61 (45‐82); BMI (kg/m2): 31.1 (22.9‐59.6). At week 8, both groups showed a wide range of HAQ‐DI (HAQ‐DI =HAQ‐DIweek8‐HAQ‐DIbaseline): from ‐1.38 to 0.5 in the acupuncture group versus from ‐1 to 0.12 in sham acupuncture group. There was no statistically significant difference in mean HAQ‐DI between the real and sham acupuncture groups (‐0.33 vs ‐0.33, p=0.87). Eleven patients in each group (61%) reported decreased HAQ‐DI scores, which correlated with improved function. There was no difference in mean VAS between the real and sham acupuncture groups (‐9.27 vs ‐13.82, p=0.67). No significant side effects were reported. Changes in other time points and in serum biomarkers will be presented at the meeting. Conclusions: The majority of breast cancer patients experiencing AIMSS who participated in our study reported a reduced HAQ‐DI score both from acupuncture and sham acupuncture. We did not observe significant differences between responses to real versus sham acupuncture after 8 weekly treatments. The study remains open to accrual to reach 50 evaluable patients.
AN  - CN-01026972
AU  - Bao, T.
AU  - Tarpinian, K.
AU  - Medeiros, M.
AU  - Gould, J.
AU  - Jeter, S.
AU  - Cai, L.
AU  - Tait, N.
AU  - Shetty, J.
AU  - Lewis, J.
AU  - Gitten, L.
AU  - et al.
DO  - 10.1158/0008-5472.SABCS11-P4-12-13
IS  - 24 SUPPL. 3
KW  - *acupuncture
*aromatase inhibitor
*breast cancer
*cancer patient
*double blind procedure
*human
*musculoskeletal disease
Adjuvant
Ametantrone diacetate
Beta endorphin
Body mass
Controlled study
Cytokine
Disability
Estrogen
Etiology
Female
Follow up
Health Assessment Questionnaire
Hormonal therapy
Hormone receptor
Monotherapy
Pain
Patient
Placebo
Postmenopause
Rank sum test
Serum
Side effect
Tamoxifen
Therapy
Visual analog scale
M3  - Journal: Conference Abstract
PY  - 2011
ST  - A multi-center randomized controlled double blind trial assessing the effect of acupuncture in reducing musculoskeletal symptoms in breast cancer patients taking aromatase inhibitors: first interim analysis
T2  - Cancer research
TI  - A multi-center randomized controlled double blind trial assessing the effect of acupuncture in reducing musculoskeletal symptoms in breast cancer patients taking aromatase inhibitors: first interim analysis
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01026972/full
VL  - 71
ID  - 1582
ER  - 

TY  - JOUR
AB  - BACKGROUND: How to identify whether T1-2 colorectal cancers have lymph nodes metastases pre-op or intra-op is a crucial problem in clinic. The purpose of this study was to evaluate the feasibility of using carbon nanoparticles to track lymph nodes metastases in T1-2 colorectal cancers. METHODS: A multi-center study was performed between July 2012 and January 2014. Seventy-three patients with T1-2 colorectal cancer identified by pre-op endoscopic ultrasonography (EUS) were recruited. 1 ml carbon nanoparticles suspension was endoscopically injected into the submucosal layer at four points around the site of the primary tumor 1 day before surgery. Laparoscopic radical resection with lymphadenectomy was performed. Sentinel lymph nodes (SLNs) were defined as nodes that were black-dyed by carbon nanoparticles. Pathology confirmed whether lymph nodes have cancer metastases and the SLNs accuracy. RESULTS: SLNs were easily found under laparoscopy. The mean number of SLNs was 3 (range 1-5). All patients had SLNs lying alongside the mesenteric vessel or main arterial vessel. After pathological analysis, 2 patients (9.52%) had lymph node metastasis in 21 patients with EUS T1 cancers, and 10 patients (19.23%) had lymph node metastasis in 52 patients with EUS T2 cancers. In two T1 cases with lymph node metastasis, SLNs were positive with 100% accuracy. In ten T2 cases with lymph node metastasis, SLNs were positive in nine cases. In pathology, carbon nanoparticles were seen in lymphatic vessels, and lymphoid sinus and macrophages in negative SLNs. When SLNs were positive, carbon nanoparticles were seen around cancer cells in lymph nodes. The overall sensitivity, specificity, accuracy of SLNs in T1-2 colorectal cancers were 91.67, 100, 98.63%, respectively. CONCLUSIONS: We demonstrated the feasibility of using carbon nanoparticles to track lymph nodes metastases in T1-2 colorectal cancers. Carbon nanoparticles black-dyed lymph nodes play a role as SLNs in T1-2 colorectal cancers.
AD  - Department of General Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, Guangdong, People's Republic of China, ynjun@yahoo.com.
AN  - 24935202
AU  - Yan, J.
AU  - Xue, F.
AU  - Chen, H.
AU  - Wu, X.
AU  - Zhang, H.
AU  - Chen, G.
AU  - Lu, J.
AU  - Cai, L.
AU  - Xiang, G.
AU  - Deng, Z.
AU  - Zheng, Y.
AU  - Zheng, X.
AU  - Li, G.
DA  - Dec
DO  - 10.1007/s00464-014-3608-5
DP  - NLM
ET  - 2014/06/18
IS  - 12
KW  - Adolescent
Adult
Aged
*Carbon
Colectomy
Colorectal Neoplasms/*pathology/surgery
*Coloring Agents
Feasibility Studies
Female
Humans
Laparoscopy
Lymph Node Excision
Lymph Nodes/*pathology/surgery
Lymphatic Metastasis
Male
Mesentery
Middle Aged
*Nanoparticles
Rectum/surgery
Sensitivity and Specificity
Young Adult
LA  - eng
N1  - 1432-2218
Yan, Jun
Xue, Fangqin
Chen, Hongyuan
Wu, Xiufeng
Zhang, Hui
Chen, Gang
Lu, Jianping
Cai, Lisheng
Xiang, Gao
Deng, Zhenwei
Zheng, Yu
Zheng, Xiaoling
Li, Guoxin
Clinical Trial
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Germany
Surg Endosc. 2014 Dec;28(12):3315-21. doi: 10.1007/s00464-014-3608-5. Epub 2014 Jun 17.
PY  - 2014
SN  - 0930-2794
SP  - 3315-21
ST  - A multi-center study of using carbon nanoparticles to track lymph node metastasis in T1-2 colorectal cancer
T2  - Surg Endosc
TI  - A multi-center study of using carbon nanoparticles to track lymph node metastasis in T1-2 colorectal cancer
VL  - 28
ID  - 285
ER  - 

TY  - JOUR
AB  - BACKGROUND: Reports continue to show that Blacks with curable lung or breast cancer complete treatment less often than similar Whites contributing to worse survival. ACCURE is an intervention trial designed to address this problem. PATIENTS AND METHODS: A pragmatic, quality improvement trial comparing an intervention group to retrospective and concurrent controls. Patients with early stage breast or lung cancer aged 18 to 85 were enrolled (N = 302) at 2 cancer centers between April 2013 and March 2015 for the intervention component. Data from patients seen between January 2007 and December 2012 with these diagnoses were obtained to establish control completion rates. Concurrent data for non-study patients were used to identify secular trends. The intervention included: a real time registry derived from electronic health records of participants to signal missed appointments or unmet care milestones, a navigator, and clinical feedback. The primary outcome was "Treatment Complete", a composite variable representing completion of surgery, recommended radiation and chemotherapy for each patient. RESULTS: The mean age in the intervention group was 63.1 years; 37.1% of patients were Black. Treatment completion in retrospective and concurrent controls showed significant Black-White differences (Blacks (B) 79.8% vs. Whites (W) 87.3%, p < 0.001; 83.1% B vs. 90.1% W, p < 0.001, respectively). The disparity lessened within the intervention (B 88.4% and W 89.5%, p = 0.77). Multivariate analyses confirmed disparities reduction. OR for Black-White disparity within the intervention was 0.98 (95% CI 0.46-2.1); Black completion in the intervention compared favorably to Whites in retrospective (OR 1.6; 95% CI 0.90-2.9) and concurrent (OR 1.1; 95% CI 0.59-2.0) controls. CONCLUSION: A real time registry combined with feedback and navigation improved completion of treatment for all breast and lung cancer patients and narrowed disparities. Similar multi-faceted interventions could mitigate disparities in the treatment of other cancers and chronic conditions.
AD  - The University of North Carolina School of Medicine, 145 N Medical Drive CB# 7165, Chapel Hill, NC 27599, USA. Electronic address: samuel_cykert@med.unc.edu.
Department of Health Behavior, The Gilling's School of Global Public Health, 360 Rosenau Hall, CB# 7440, Chapel Hill, NC 27599, USA.
Cone Health Cancer Center, 501 N Elam Ave, Greensboro, NC 27403, USA.
UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine 5150 Centre Avenue POB2 Cancer Pavilion, Room 438 Pittsburgh, PA 15232, USA.
Department of Radiation Oncology UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine5230 Centre Ave. Pittsburgh, PA 15232, USA.
The Partnership Project, 301 S. Elm Street, Suite 414 Greensboro, NC 27401, USA.
Department of Health Behavior, The Gilling's School of Global Public Health 1700 Martin Luther King, Jr. Boulevard CB #7426, Chapel Hill, NC 27599, USA.
Department of Biostatistics, The Gilling's School of Global Public Health, The University of North Carolina at Chapel Hill, 3104C McGavran-Greenberg Hall, CB #7420, Chapel Hill, NC 27599, USA.
Department of Public Health Education, University of North Carolina at Greensboro, P.O. Box 26170, Greensboro, NC 27402-6170, USA.
Biostatistical Support Unit, The Center for Health Promotion and Disease Prevention, The University of North Carolina at Chapel Hill, 1700 Martin Luther King Jr. Boulevard, CB# 7426, Chapel Hill NC 27599, USA.
AN  - 30928088
AU  - Cykert, S.
AU  - Eng, E.
AU  - Manning, M. A.
AU  - Robertson, L. B.
AU  - Heron, D. E.
AU  - Jones, N. S.
AU  - Schaal, J. C.
AU  - Lightfoot, A.
AU  - Zhou, H.
AU  - Yongue, C.
AU  - Gizlice, Z.
DA  - Oct
DO  - 10.1016/j.jnma.2019.03.001
DP  - NLM
ET  - 2019/04/01
IS  - 5
KW  - Cancer disparities
Institutional racism
Intervention
Quality improvement
LA  - eng
N1  - 1943-4693
Cykert, Samuel
Eng, Eugenia
Manning, Matthew A
Robertson, Linda B
Heron, Dwight E
Jones, Nora S
Schaal, Jennifer C
Lightfoot, Alexandra
Zhou, Haibo
Yongue, Christina
Gizlice, Ziya
R01 CA150980/CA/NCI NIH HHS/United States
Journal Article
United States
J Natl Med Assoc. 2020 Oct;112(5):468-477. doi: 10.1016/j.jnma.2019.03.001. Epub 2019 Mar 28.
PY  - 2020
SN  - 0027-9684
SP  - 468-477
ST  - A Multi-faceted Intervention Aimed at Black-White Disparities in the Treatment of Early Stage Cancers: The ACCURE Pragmatic Quality Improvement trial
T2  - J Natl Med Assoc
TI  - A Multi-faceted Intervention Aimed at Black-White Disparities in the Treatment of Early Stage Cancers: The ACCURE Pragmatic Quality Improvement trial
VL  - 112
ID  - 78
ER  - 

TY  - JOUR
AB  - PURPOSE: The 4Kscore® test accurately detects aggressive prostate cancer and reduces unnecessary biopsies. However, its performance in African American men has been unknown. We assessed test performance in a cohort of men with a large African American representation. MATERIALS AND METHODS: Men referred for prostate biopsy at 8 Veterans Affairs medical centers were prospectively enrolled in the study. All men underwent phlebotomy for 4Kscore test assessment prior to prostate biopsy. The primary outcome was the detection of Grade Group 2 or higher cancer on biopsy. We assessed the discrimination, calibration and clinical usefulness of 4Kscore to predict Grade Group 2 or higher prostate cancer and compared it to a base model consisting of age, digital rectal examination and prostate specific antigen. Additionally, we compared test performance in African American and nonAfrican American men. RESULTS: Of the 366 enrolled men 205 (56%) were African American and 131 (36%) had Grade Group 2 or higher prostate cancer. The 4Kscore test showed better discrimination (AUC 0.81 vs 0.74, p <0.01) and higher clinical usefulness on decision curve analysis than the base model. Test prediction closely approximated the observed risk of Grade Group 2 or higher prostate cancer. There was no difference in test performance in African American and nonAfrican American men (0.80 vs 0.84, p = 0.32), The test outperformed the base model in each group. CONCLUSIONS: The 4Kscore test accurately predicts aggressive prostate cancer for biopsy decision making in African American and nonAfrican American men.
AD  - Department of Urology, University of Miami and Miami Veterans Affairs Medical Center, Miami, Florida. Electronic address: s.punnen@miami.edu.
Cedars-Sinai Medical Center, Los Angeles, California; Durham Veterans Affairs Medical Center, Durham, North Carolina.
Durham Veterans Affairs Medical Center, Durham, North Carolina; Duke Cancer Institute, Durham, North Carolina.
Department of Urology and Population Health, New York University and Manhattan Veterans Affairs Medical Center, New York, New York.
Department of Urology, University of Minnesota and Minneapolis Veterans Affairs Medical Center, Minneapolis, Minnesota.
Medical University of South Carolina and Ralph H. Johnson Veterans Affairs Medical Center, Charleston, South Carolina.
Pathology and Laboratory Medicine Service, Kansas City Veterans Affairs Medical Center, Kansas City, Missouri.
Department of Urology, University of California-Irvine, Irvine, California; Veterans Affairs Long Beach Health System, Long Beach, California.
OPKO Diagnostics, Woburn, Massachusetts.
Tulane University School of Medicine and Southeast Louisiana Veterans Health Care Center, New Orleans, Louisiana.
AN  - 29223389
AU  - Punnen, S.
AU  - Freedland, S. J.
AU  - Polascik, T. J.
AU  - Loeb, S.
AU  - Risk, M. C.
AU  - Savage, S.
AU  - Mathur, S. C.
AU  - Uchio, E.
AU  - Dong, Y.
AU  - Silberstein, J. L.
DA  - Jun
DO  - 10.1016/j.juro.2017.11.113
DP  - NLM
ET  - 2017/12/11
IS  - 6
KW  - Adenocarcinoma/blood/*diagnosis/pathology
African Americans/*statistics & numerical data
Aged
Biomarkers, Tumor/*blood
Biopsy
Clinical Decision-Making
Hospitals, Veterans/statistics & numerical data
Humans
Male
Middle Aged
Neoplasm Grading
Patient Selection
Predictive Value of Tests
Prognosis
Prospective Studies
Prostate/*pathology
Prostatic Neoplasms/blood/*diagnosis/pathology
Risk Assessment/methods
United States
United States Department of Veterans Affairs
*African Americans
*biomarkers
*kallikreins
*neoplasm grading
*prostatic neoplasms
*tumor
LA  - eng
N1  - 1527-3792
Punnen, Sanoj
Freedland, Stephen J
Polascik, Thomas J
Loeb, Stacy
Risk, Michael C
Savage, Stephen
Mathur, Sharad C
Uchio, Edward
Dong, Yan
Silberstein, Jonathan L
Clinical Trial
Journal Article
Multicenter Study
United States
J Urol. 2018 Jun;199(6):1459-1463. doi: 10.1016/j.juro.2017.11.113. Epub 2017 Dec 6.
PY  - 2018
SN  - 0022-5347
SP  - 1459-1463
ST  - A Multi-Institutional Prospective Trial Confirms Noninvasive Blood Test Maintains Predictive Value in African American Men
T2  - J Urol
TI  - A Multi-Institutional Prospective Trial Confirms Noninvasive Blood Test Maintains Predictive Value in African American Men
VL  - 199
ID  - 140
ER  - 

TY  - JOUR
AB  - OBJECTIVE: Colon capsule endoscopy (CCE) has shown promise for colorectal neoplasia detection compared with optical colonoscopy (OC), but has not been compared with other screening tests in average risk screening patients. DESIGN: Patients 50 to 75 years of age (African Americans, 45-75 years) were randomised to CCE or CT colonography (CTC) and subsequent blinded OC. The primary endpoint was diagnostic yield of polyps ≥6 mm with CCE or CTC. Secondary endpoints included accuracy for size and histology, examination completeness, number/proportion of subjects with polyps and adenomas ≥6 mm and ≥10 mm, subject satisfaction and safety. RESULTS: From 320 enrolled subjects, data from 286 (89.4%) were evaluable. The proportion of subjects with any polyp ≥6 mm confirmed by OC was 31.6% for CCE versus 8.6% for CTC (pPr non-inferiority and superiority=0.999). The diagnostic yield of polyps ≥10 mm was 13.5% with CCE versus 6.3% with CTC (pPr non-inferiority=0.9954). The sensitivity and specificity of CCE for polyps ≥6 mm was 79.2% and 96.3% while that of CTC was 26.8% and 98.9%. The sensitivity and specificity of CCE for polyps ≥10 mm was 85.7% and 98.2% compared with 50% and 99.1% for CTC. Both tests were well tolerated/safe. CONCLUSION: CCE was superior to CTC for detection of polyps ≥6 mm and non-inferior for identification of polyps ≥10 mm. CCE should be considered comparable or superior to CTC as a colorectal neoplasia screening test, although neither test is as effective as OC. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov no: NCT02754661.
AD  - Gastroenterology, University of Texas Health Science Center at Houston, Houston, Texas, USA brooks.d.cash@uth.tmc.edu.
Gastroenterology, Borland Groover Clinic, Jacksonville, Florida, USA.
Specialists in Gastroenterology, Clinical Research Professionals, Saint Louis, Missouri, USA.
Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
MultiCare Medical Division Gastroenterology, Clinical Research Professionals, Chesterfield, Missouri, USA.
Gastroenterology, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, USA.
Indianapolis Gastroenterology and Hepatology, Indianapolis, Indiana, USA.
Gastroenterology, American Medical Center, Nicosia, Cyprus.
Department of Gastroenterology and Hepatology, Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain.
Gastroenterology, Baystate Medical Center, Springfield, Massachusetts, USA.
Indiana University School of Medicine, Indiana University Hospital, Indianapolis, Indiana, USA.
AN  - 33443017
AU  - Cash, B. D.
AU  - Fleisher, M. R.
AU  - Fern, S.
AU  - Rajan, E.
AU  - Haithcock, R.
AU  - Kastenberg, D. M.
AU  - Pound, D.
AU  - Papageorgiou, N. P.
AU  - Fernández-Urién, I.
AU  - Schmelkin, I. J.
AU  - Rex, D. K.
DA  - Dec 18
DO  - 10.1136/gutjnl-2020-322578
DP  - NLM
ET  - 2021/01/15
KW  - colonic adenomas
colonic polyps
colorectal cancer screening
endoscopic procedures
Medtronic, Salix, Allergan, Takeda
Speakers’ Bureau for Salix, Allergan, Takeda,
AlfaSigma, RedHill, QOL. ER: Consultant to Olympus
IP with Medtronic. DMK:
Consultant to Medtronic, Ferring, Salix, MotusGI
Research support from Medtronic,
MotusGI. DP: Speakers’ Bureau: Gilead Life Sciences, Merck
Advisory Boards: Gilead,
Novartis, Intercept. NPP: Consultant to Medtronic. IF-U received honorarium from
Medtronic. IJS: Consultant to Medtronic. DKR: Consultant to Olympus Corporation,
Boston Scientific, Medtronic, Aries Pharmaceutical, Braintree Laboratories, Lumendi
Ltd, Norgine, Endokey, GI Supply
Research support: EndoAid, Olympus Corporation,
Medivators, Erbe USA Inc.
Ownership: Satisfai Health.
LA  - eng
N1  - 1468-3288
Cash, Brooks D
Orcid: 0000-0002-8497-3349
Fleisher, Mark R
Fern, Steven
Rajan, Elizabeth
Haithcock, Robyn
Kastenberg, David M
Pound, David
Papageorgiou, Neofytos P
Fernández-Urién, Ignacio
Schmelkin, Ira J
Rex, Douglas K
Journal Article
England
Gut. 2020 Dec 18:gutjnl-2020-322578. doi: 10.1136/gutjnl-2020-322578.
PY  - 2020
SN  - 0017-5749
ST  - Multicentre, prospective, randomised study comparing the diagnostic yield of colon capsule endoscopy versus CT colonography in a screening population (the TOPAZ study)
T2  - Gut
TI  - Multicentre, prospective, randomised study comparing the diagnostic yield of colon capsule endoscopy versus CT colonography in a screening population (the TOPAZ study)
ID  - 14
ER  - 

TY  - JOUR
AB  - BACKGROUND: There are limited data regarding interventions designed to improve cancer screening rates in safety-net practices with "real world" patients. OBJECTIVE: To examine the impact of a multimodal intervention on mammography and colorectal cancer (CRC) screening rates in a safety-net practice caring for underserved patients. METHODS: At an inner-city family medicine practice, all patients past due for mammography or CRC screening were assigned to receive or not receive a screening promotion intervention based on their medical record number. The 12-month intervention included outreach to patients (tailored letters, automated and personal phone calls) and point-of-care patient and clinician prompts. The trial was registered at clinicaltrials.gov, NCT00818857. RESULTS: We enrolled 469 participants aged 40 to 74 years, including 28% African Americans, 5% Latinos, 25% with Medicaid, and 10% without any form of insurance. Participants in the intervention group showed statistically significantly higher rates of cancer screening; rates were 41% vs 16.8% for mammography and 28.8% vs 10% for CRC screening. These findings were confirmed in multivariable analysis. Similar relative improvements in screening were seen across race, ethnicity, socioeconomic status, and insurance groups. DISCUSSION: A multimodal intervention shows promise for improving rates of mammography and colorectal cancer screening within a safety-net practice. Further study will identify the most cost-effective components of the intervention.
AD  - Department of Family Medicine, University of Rochester School of Medicine and Dentistry, New York, USA. kevin_fiscella@urmc.rochester.edu
AN  - 22046855
AU  - Fiscella, K.
AU  - Humiston, S.
AU  - Hendren, S.
AU  - Winters, P.
AU  - Idris, A.
AU  - Li, S. X.
AU  - Ford, P.
AU  - Specht, R.
AU  - Marcus, S.
DA  - Aug
DO  - 10.1016/s0027-9684(15)30417-x
DP  - NLM
ET  - 2011/11/04
IS  - 8
KW  - Adult
Aged
Breast Neoplasms/prevention & control
Colonoscopy/*statistics & numerical data
Female
Health Promotion/*organization & administration/*statistics & numerical data
Humans
Male
Mammography/*statistics & numerical data
Middle Aged
Multivariate Analysis
*Occult Blood
Sigmoidoscopy/*statistics & numerical data
Urban Population
LA  - eng
N1  - Fiscella, Kevin
Humiston, Sharon
Hendren, Samantha
Winters, Paul
Idris, Amna
Li, Shirley X L
Ford, Patricia
Specht, Raymond
Marcus, Steven
Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't
United States
J Natl Med Assoc. 2011 Aug;103(8):762-8. doi: 10.1016/s0027-9684(15)30417-x.
PY  - 2011
SN  - 0027-9684 (Print)
0027-9684
SP  - 762-8
ST  - A multimodal intervention to promote mammography and colorectal cancer screening in a safety-net practice
T2  - J Natl Med Assoc
TI  - A multimodal intervention to promote mammography and colorectal cancer screening in a safety-net practice
VL  - 103
ID  - 382
ER  - 

TY  - JOUR
AB  - This article reviews mushrooms with anti-breast cancer activity. The mushrooms covered which are better known include the following: button mushroom Agaricus bisporus, Brazilian mushroom Agaricus blazei, Amauroderma rugosum, stout camphor fungus Antrodia camphorata, Jew's ear (black) fungus or black wood ear fungus Auricularia auricula-judae, reishi mushroom or Lingzhi Ganoderma lucidum, Ganoderma sinense, maitake mushroom or sheep's head mushroom Grifola frondosa, lion's mane mushroom or monkey head mushroom Hericium erinaceum, brown beech mushroom Hypsizigus marmoreus, sulfur polypore mushroom Laetiporus sulphureus, Lentinula edodes (shiitake mushroom), Phellinus linteus (Japanese "meshimakobu," Chinese "song gen," Korean "sanghwang," American "black hoof mushroom"), abalone mushroom Pleurotus abalonus, king oyster mushroom Pleurotus eryngii, oyster mushroom Pleurotus ostreatus, tuckahoe or Fu Ling Poria cocos, and split gill mushroom Schizophyllum commune. Antineoplastic effectiveness in human clinical trials and mechanism of anticancer action have been reported for Antrodia camphorata, Cordyceps sinensis, Coriolus versicolor, Ganoderma lucidum, Grifola frondosa, and Lentinula edodes.
AD  - State Key Laboratory of Respiratory Disease for Allergy, School of Medicine, Shenzhen University, Shenzhen, Guangdong, China. jack1993@yahoo.com.
School of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China. tzibunng@cuhk.edu.hk.
The Chinese University of Hong Kong (CUHK) Shenzhen Research Institute, Shenzhen, China. tzibunng@cuhk.edu.hk.
Vita Green Pharmaceuticals (Hong Kong) Limited, Hong Kong, China. helen.chan@vitagreen.com.
Institute of Plant Nutrition, Agricultural Resources and Environmental Science, Henan Academy of Agricultural Sciences, Zhengzhou, China.
Department of Orthopedics and Traumatology, The Chinese University of Hong Kong, Hong Kong, China.
State Key Laboratory of Oncology in Southern China, Sun Yat-Sen University Cancer Center and Department of Pathology, Sun Yat-Sen University Cancer Center, Guangzhou, China.
Department of Social Medicine, College of Public Health, Xinjiang Medical University, Urumqi, China.
School of Medicine, King's College London, London, UK.
Department of Clinical Molecular Biology, University of Oslo and Akershus University Hospital, Lørenskog, Norway.
The Norwegian Centre on Healthy Ageing (NO-Age), Oslo, Norway.
Department of Microbiology, China Agricultural University, Beijing, China.
Department of Microbiology, The Key Laboratory of Molecular Microbiology and Technology, Ministry of Education, Nankai University, Tianjin, China.
Fujian Key Laboratory of Marine Enzyme Engineering, Fuzhou University, Fuzhou, Fujian, China.
Department of Molecular Biochemistry, Faculty of Chemistry, University of Gdańsk, Wita Stwosza 63, Gdańsk, Poland.
Department of Biochemistry and Microbiology, Nelson Mandela University, Port Elizabeth, 6031, South Africa.
Key Laboratory of Vegetable Postharvest Processing, Institute of Plant and Environment Protection, Beijing Academy of Agriculture and Forestry Sciences, and Beijing Key Laboratory of Fruits and Vegetable Storage and Processing, Ministry of Agriculture, Beijing, China.
State Key Laboratory of Respiratory Disease for Allergy, School of Medicine, Shenzhen University, Shenzhen, Guangdong, China.
State Key Laboratory of Respiratory Disease for Allergy, School of Medicine, Shenzhen University, Shenzhen, Guangdong, China. lichunman@szu.edu.cn.
State Key Laboratory of Respiratory Disease for Allergy, School of Medicine, Shenzhen University, Shenzhen, Guangdong, China. xialixin@szu.edu.cn.
AN  - 32274562
AU  - Wong, J. H.
AU  - Ng, T. B.
AU  - Chan, H. H. L.
AU  - Liu, Q.
AU  - Man, G. C. W.
AU  - Zhang, C. Z.
AU  - Guan, S.
AU  - Ng, C. C. W.
AU  - Fang, E. F.
AU  - Wang, H.
AU  - Liu, F.
AU  - Ye, X.
AU  - Rolka, K.
AU  - Naude, R.
AU  - Zhao, S.
AU  - Sha, O.
AU  - Li, C.
AU  - Xia, L.
DA  - Jun
DO  - 10.1007/s00253-020-10476-4
DP  - NLM
ET  - 2020/04/11
IS  - 11
KW  - Agaricales/*chemistry/*classification
Animals
Antineoplastic Agents/*therapeutic use
Breast Neoplasms/*drug therapy
Cell Line, Tumor
Clinical Trials as Topic
Complex Mixtures/chemistry/pharmacology
Disease Models, Animal
Female
Humans
Mice
Rats
Apoptosis
Breast cancer
Clinical trials
Mushrooms
Xenograft
LA  - eng
N1  - 1432-0614
Wong, Jack Ho
Ng, Tzi Bun
Orcid: 0000-0001-7951-8838
Chan, Helen Hei Ling
Liu, Qin
Man, Gene Chi Wai
Zhang, Chris Zhiyi
Guan, Suzhen
Ng, Charlene Cheuk Wing
Fang, Evandro Fei
Wang, Hexiang
Liu, Fang
Ye, Xiuyun
Rolka, Krzysztof
Naude, Ryno
Zhao, Shuang
Sha, Ou
Li, Chunman
Xia, Lixin
12131221/Health and Medical Research Fund/
81471927/nsfc/
JCYJ20170818094217688/Science and Technology Innovation Commission of Shenzhen/
85629-000001/National Development and Reform Commission/
Journal Article
Review
Germany
Appl Microbiol Biotechnol. 2020 Jun;104(11):4675-4703. doi: 10.1007/s00253-020-10476-4. Epub 2020 Apr 9.
PY  - 2020
SN  - 0175-7598
SP  - 4675-4703
ST  - Mushroom extracts and compounds with suppressive action on breast cancer: evidence from studies using cultured cancer cells, tumor-bearing animals, and clinical trials
T2  - Appl Microbiol Biotechnol
TI  - Mushroom extracts and compounds with suppressive action on breast cancer: evidence from studies using cultured cancer cells, tumor-bearing animals, and clinical trials
VL  - 104
ID  - 43
ER  - 

TY  - JOUR
AB  - Cigarette smoking is the major determinant of lung cancer. However, only a fraction of smokers develops lung cancer; genetically determined susceptibility factors seem to play an important role also. Previous case-control studies have shown that in vitro bleomycin-induced mutagen sensitivity is an independent risk factor for head-and-neck cancers, and preliminary data suggest a similar association with lung cancer. However, these studies were almost exclusively performed on Caucasian populations. To test whether ethnic differences in cancer risk are due to differences in mutagen sensitivity, we are using the in vitro mutagen sensitivity assay to conduct a case-control study of mutagen sensitivity and lung cancer risk in low-risk (Mexican-American) and high-risk (African-American) groups. Here we report the results of our ongoing study of 209 African-Americans (90 cases and 119 controls) in the Houston-Galveston area. Mexican-American data will be reported separately as case accrual increases. Predictably, all measures of cigarette smoking status (including intensity, duration, tar content, depth of inhalation, and type of cigarette) were significant predictors of risk. In addition, 55.3% of the cases were mutagen sensitive (defined as >1 break/ cell), compared with 24.6% of the controls, with an age-, sex-, and smoking-adjusted odds ratio (OR) of 3.7 (95% confidence limits = 1.4, 9.4). Of interest, higher risks were noted for former smokers (OR = 5.4) compared with current smokers (OR = 3.1) and especially for younger former smokers (<55 years). By histologic-specific analysis, mutagen sensitivity was significantly associated with risk for adenocarcinoma (OR = 4.8) and squamous cell carcinoma (OR = 8.5). Stratified analysis showed that there was an interaction between mutagen sensitivity and current and former smoking and heavy smoking (≥20 pack-years) that appeared to be greater than multiplicative. These risk estimates are generally higher than those we reported for head-and-neck cancer in Caucasian populations. Further research should focus on the cytogenetic and molecular evaluation of whether the break sites are random or occur at specific sites and on comparisons with DNA repair assay systems. © 1995, American Association for Cancer Research. All rights reserved.
AD  - Departments of Epidemiology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, United States
Cell Biology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, United States
Thoracic and Cardiovascular Surgery, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, United States
AU  - Spitz, M. R.
AU  - Hsu, T. C.
AU  - Wu, X.
AU  - Fueger, J. J.
AU  - Amos, C. I.
AU  - Roth, J. A.
DB  - Scopus
IS  - 2
M3  - Article
N1  - Cited By :101
Export Date: 22 March 2021
PY  - 1995
SP  - 99-103
ST  - Mutagen Sensitivity as a Biological Marker of Lung Cancer Risk in African Americans
T2  - Cancer Epidemiology Biomarkers and Prevention
TI  - Mutagen Sensitivity as a Biological Marker of Lung Cancer Risk in African Americans
UR  - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0028924121&partnerID=40&md5=9858cf48585b7056343dc48ef8a4101e
VL  - 4
ID  - 2654
ER  - 

TY  - JOUR
AB  - Background: Cancers related to tobacco use and African-American ancestry are under-characterized by genomics. This gap in precision oncology research represents a major challenge in the health disparities in the United States. Methods: The Precision Oncology trial at the Wake Forest Baptist Comprehensive Cancer Center enrolled 431 cancer patients from March 2015 to May 2016. The composition of these patients consists of a high representation of tobacco-related cancers (e.g., lung, colorectal, and bladder) and African-American ancestry (13.5%). Tumors were sequenced to identify mutations to gain insight into genetic alterations associated with smoking and/or African-American ancestry. Results: Tobacco-related cancers exhibit a high mutational load. These tumors are characterized by high-frequency mutations in TP53, DNA damage repair genes (BRCA2 and ATM), and chromatin remodeling genes (the lysine methyltransferases KMT2D or MLL2, and KMT2C or MLL3). These tobacco-related cancers also exhibit augmented tumor heterogeneities. Smoking related genetic mutations were validated by The Cancer Genome Atlas dataset that includes 2,821 cases with known smoking status. The Wake Forest and The Cancer Genome Atlas cohorts (431 and 7,991 cases, respectively) revealed a significantly increased mutation rate in the TP53 gene in the African-American subgroup studied. Both cohorts also revealed 5 genes (e.g. CDK8) significantly amplified in the African-American population. Conclusions: These results provide strong evidence that tobacco is a major cause of genomic instability and heterogeneity in cancer. TP53 mutations and key oncogene amplifications emerge as key factors contributing to cancer outcome disparities among different racial/ethnic groups.
AD  - Wake Forest Baptist Comprehensive Cancer Center, Wake Forest Baptist Medical Center, Winston Salem, NC, USA 27157.
Department of Cancer Biology, Wake Forest School of Medicine, Winston Salem, NC, USA 27157.
Institute for Biosciences and Medical Technology, University of Tampere, Tampere, Finland 33520.
Department of Internal Medicine-Section of Hematology and Oncology, Wake Forest School of Medicine, Winston Salem, NC, USA 27157.
Department of Biostatistical Sciences, Wake Forest School of Medicine, Winston Salem, NC, USA 27157.
Department of Laboratory Medicine and Pathology, Wake Forest School of Medicine, Winston Salem, NC, USA 27157.
Institute for Systems Biology, Seattle, WA, USA 98109.
Department of Epidemiology and Biostatistics, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China 300060.
Department of Radiology, Wake Forest School of Medicine, Winston Salem, NC, USA 27157.
Center for Genomics and Personalized Medicine Research, Wake Forest School of Medicine, Winston Salem, NC, USA 27157.
Department of General Surgery-Section of Surgical Oncology, Wake Forest School of Medicine, Winston Salem, NC, USA 27157.
Foundation Medicine, Cambridge, MA, USA 02141.
Department of Radiation Oncology, Wake Forest School of Medicine, Winston Salem, NC, USA 27157.
Department of Social Sciences and Health Policy, Wake Forest School of Medicine, Winston Salem, NC, USA 27157.
Wake Forest School of Medicine, Winston Salem, NC, USA 27157.
AN  - 28824725
AU  - Kytola, V.
AU  - Topaloglu, U.
AU  - Miller, L. D.
AU  - Bitting, R. L.
AU  - Goodman, M. M.
AU  - D. Agostino RB, Jr.
AU  - Desnoyers, R. J.
AU  - Albright, C.
AU  - Yacoub, G.
AU  - Qasem, S. A.
AU  - DeYoung, B.
AU  - Thorsson, V.
AU  - Shmulevich, I.
AU  - Yang, M.
AU  - Shcherban, A.
AU  - Pagni, M.
AU  - Liu, L.
AU  - Nykter, M.
AU  - Chen, K.
AU  - Hawkins, G. A.
AU  - Grant, S. C.
AU  - Petty, W. J.
AU  - Alistar, A. T.
AU  - Levine, E. A.
AU  - Staren, E. D.
AU  - Langefeld, C. D.
AU  - Miller, V.
AU  - Singal, G.
AU  - Petro, R. M.
AU  - Robinson, M.
AU  - Blackstock, W.
AU  - Powell, B. L.
AU  - Wagner, L. I.
AU  - Foley, K. L.
AU  - Abraham, E.
AU  - Pasche, B.
AU  - Zhang, W.
C2  - PMC5562225 Medicine. No other authors declared Conflicts of Interest.
DO  - 10.7150/thno.20355
DP  - NLM
ET  - 2017/08/22
IS  - 11
KW  - African Americans
Colorectal Neoplasms/*pathology
European Continental Ancestry Group
Humans
Lung Neoplasms/*pathology
*Mutation
Pathology, Molecular
Sequence Analysis, DNA
Tobacco Smoking/*adverse effects
Tumor Suppressor Protein p53/genetics
Urinary Bladder Neoplasms/*pathology
LA  - eng
N1  - 1838-7640
Kytola, Ville
Topaloglu, Umit
Miller, Lance D
Bitting, Rhonda L
Goodman, Michael M
D Agostino, Ralph B Jr
Desnoyers, Rodwige J
Albright, Carol
Yacoub, George
Qasem, Shadi A
DeYoung, Barry
Thorsson, Vesteinn
Shmulevich, Ilya
Yang, Meng
Shcherban, Anastasia
Pagni, Matthew
Liu, Liang
Nykter, Matti
Chen, Kexin
Hawkins, Gregory A
Grant, Stefan C
Petty, W Jeffrey
Alistar, Angela Tatiana
Levine, Edward A
Staren, Edgar D
Langefeld, Carl D
Miller, Vincent
Singal, Gaurav
Petro, Robin M
Robinson, Mac
Blackstock, William
Powell, Bayard L
Wagner, Lynne I
Foley, Kristie L
Abraham, Edward
Pasche, Boris
Zhang, Wei
P30 CA012197/CA/NCI NIH HHS/United States
U24 CA143835/CA/NCI NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Theranostics. 2017 Jul 12;7(11):2914-2923. doi: 10.7150/thno.20355. eCollection 2017.
PY  - 2017
SN  - 1838-7640
SP  - 2914-2923
ST  - Mutational Landscapes of Smoking-Related Cancers in Caucasians and African Americans: Precision Oncology Perspectives at Wake Forest Baptist Comprehensive Cancer Center
T2  - Theranostics
TI  - Mutational Landscapes of Smoking-Related Cancers in Caucasians and African Americans: Precision Oncology Perspectives at Wake Forest Baptist Comprehensive Cancer Center
VL  - 7
ID  - 159
ER  - 

TY  - JOUR
AB  - In spite of cancer screening programs, women continue to present with advanced breast cancer. How do women decide whether and when to seek an evaluation for self-discovered symptoms? This study examined 104 narratives told by 80 Anglo-, Latina-, and African-American women who participated in 1 of 16 community-based focus groups. The women's narratives contained powerful thematic messages about breast cancer and their expected behavior in the event of a self-discovered breast symptom. Narrative explanations that predicted an increased likelihood of advanced disease at diagnosis included these factors: incorrect symptom attributions and risk estimations; reluctance to consider the threat posed by the symptom; failure to tell another person about the symptom; and expectations of abandonment by male partners, deportation, prejudice, and refusal of treatment due to poverty. Stories of advanced breast cancer also told of reliance on alternative healing, concerns about overwhelming family resources, and extreme modesty that inhibited obtaining a physical examination. Interventions aimed at earlier detection of breast cancer must connect with the beliefs and assumptions embedded in these narratives, provide pragmatic solutions for perceived constraints on seeking evaluations of self-discovered symptoms, and explore the use of community narratives to confirm the value of early detection of breast cancer.
AD  - Box 0610, School of Nursing, University of California, San Francisco, CA 94143-0610
AN  - 107159518. Language: English. Entry Date: 19990201. Revision Date: 20150820. Publication Type: Journal Article
AU  - Facione, N. C.
AU  - Giancarlo, C. A.
DB  - CINAHL Complete
DP  - EBSCOhost
IS  - 6
KW  - Breast Neoplasms -- Psychosocial Factors
Breast Neoplasms -- Diagnosis
Patient Attitudes
Help Seeking Behavior
Symptoms
Funding Source
Research Subject Recruitment
Focus Groups
California
Patient Attitudes -- Evaluation
Narratives
Thematic Analysis
Qualitative Studies
Adult
Middle Age
Female
Human
N1  - research; tables/charts. Journal Subset: Core Nursing; Double Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Nursing; Peer Reviewed; USA. Grant Information: Funding was provided by the California Breast Cancer Research Program 1KB-0045, National American Cancer Society MPCN-24-2, NINR 1F31NR06851, Sigma Theta Tau Alpha Eta Chapter, and the University of California Alumni and Friends Fund. NLM UID: 7805358.
PMID: NLM9849001.
PY  - 1998
SN  - 0162-220X
SP  - 430-440
ST  - Narratives of breast symptom discovery and cancer diagnosis: psychologic risk for advanced cancer at diagnosis
T2  - Cancer Nursing
TI  - Narratives of breast symptom discovery and cancer diagnosis: psychologic risk for advanced cancer at diagnosis
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=107159518&site=ehost-live&scope=site
VL  - 21
ID  - 2002
ER  - 

TY  - JOUR
AB  - PURPOSE: Recent clinical practice guidelines on prostate cancer screening using the prostate-specific antigen (PSA) test (PSA screening) have recommended that clinicians practice shared decision making-a process involving clinician-patient discussion of the pros, cons, and uncertainties of screening. We undertook a study to determine the prevalence of shared decision making in both PSA screening and nonscreening, as well as patient characteristics associated with shared decision making. METHODS: A nationally representative sample of 3,427 men aged 50 to 74 years participating in the 2010 National Health Interview Survey responded to questions on the extent of shared decision making (past physician-patient discussion of advantages, disadvantages, and scientific uncertainty associated with PSA screening), PSA screening intensity (tests in past 5 years), and sociodemographic and health-related characteristics. RESULTS: Nearly two-thirds (64.3%) of men reported no past physician-patient discussion of advantages, disadvantages, or scientific uncertainty (no shared decision making); 27.8% reported discussion of 1 to 2 elements only (partial shared decision making); 8.0% reported discussion of all 3 elements (full shared decision making). Nearly one-half (44.2%) reported no PSA screening, 27.8% reported low-intensity (less-than-annual) screening, and 25.1% reported high-intensity (nearly annual) screening. Absence of shared decision making was more prevalent in men who were not screened; 88% (95% CI, 86.2%-90.1%) of nonscreened men reported no shared decision making compared with 39% (95% CI, 35.0%-43.3%) of men undergoing high-intensity screening. Extent of shared decision making was associated with black race, Hispanic ethnicity, higher education, health insurance, and physician recommendation. Screening intensity was associated with older age, higher education, usual source of medical care, and physician recommendation, as well as with partial vs no or full shared decision making. CONCLUSIONS: Most US men report little shared decision making in PSA screening, and the lack of shared decision making is more prevalent in nonscreened than in screened men. Screening intensity is greatest with partial shared decision making, and different elements of shared decision making are associated with distinct patient characteristics. Shared decision making needs to be improved in decisions for and against PSA screening.
AD  - Maine Medical Center Research Institute, Portland, ME 04101, USA. hanp@mmc.org
AN  - 23835816
AU  - Han, P. K.
AU  - Kobrin, S.
AU  - Breen, N.
AU  - Joseph, D. A.
AU  - Li, J.
AU  - Frosch, D. L.
AU  - Klabunde, C. N.
C2  - PMC3704490
DA  - Jul-Aug
DO  - 10.1370/afm.1539
DP  - NLM
ET  - 2013/07/10
IS  - 4
KW  - Adult
Aged
*Attitude to Health
Biomarkers, Tumor/blood
Decision Making
Early Detection of Cancer/*methods/psychology
Humans
Male
Mass Screening/*methods/psychology
Middle Aged
Patient Navigation
Patient Participation/*methods/psychology
Prevalence
Prostate-Specific Antigen/*blood
Prostatic Neoplasms/diagnosis/*prevention & control/psychology
Risk Factors
United States/epidemiology
mass screening
prostate-specific antigen
LA  - eng
N1  - 1544-1717
Han, Paul K J
Kobrin, Sarah
Breen, Nancy
Joseph, Djenaba A
Li, Jun
Frosch, Dominick L
Klabunde, Carrie N
Journal Article
Ann Fam Med. 2013 Jul-Aug;11(4):306-14. doi: 10.1370/afm.1539.
PY  - 2013
SN  - 1544-1709 (Print)
1544-1709
SP  - 306-14
ST  - National evidence on the use of shared decision making in prostate-specific antigen screening
T2  - Ann Fam Med
TI  - National evidence on the use of shared decision making in prostate-specific antigen screening
VL  - 11
ID  - 326
ER  - 

TY  - JOUR
AB  - BACKGROUND: One of the first chemoprevention trials conducted in the western hemisphere, the National Surgical Adjuvant Breast and Bowel Project's (NSABP) Breast Cancer Prevention Trial (BCPT), demonstrated the need to evaluate all aspects of recruitment in real time and to implement strategies to enroll racial and ethnic minority women. PURPOSE: The purpose of this report is to review various patient recruitment efforts the NSABP developed to enhance the participation of racial and ethnic minority women in the Study of Tamoxifen and Raloxifene (STAR) trial and to describe the role that the recruitment process played in the implementation and understanding of breast cancer risk assessment in minority communities. METHODS: The NSABP STAR trial was a randomized, double-blinded study comparing the use of tamoxifen 20 mg/day to raloxifene 60 mg/day, for a 5-year period, to reduce the risk of developing invasive breast cancer. Eligible postmenopausal women were required to have a 5-year predicted breast cancer risk of 1.66% based on the modified Gail Model. For the current report, eligibility and enrollment data were tabulated by race/ethnicity for women who submitted STAR risk assessment forms (RAFs). RESULTS: A total of 184,460 RAFs were received, 145,550 (78.9%) from white women and 38,910 (21.1%) from minority women. Of the latter group, 21,444 (11.6%) were from African Americans/blacks, 7913 (4.5%) from Hispanics/Latinas, and 9553 (5.2%) from other racial or ethnic groups. The percentages of risk-eligible women among African Americans, Hispanics/Latinas, others, and whites were 14.2%, 23.3%, 13.7%, and 57.4%, respectively. Programs targeting minority enrollment submitted large numbers of RAFs, but the eligibility rates of the women referred from those groups tended to be lower than the rates among women referred outside of those programs. The average number of completed risk assessments increased among minority women over the course of the recruitment period compared to those from whites. LIMITATIONS: We have not addressed all identified barriers to the recruitment of minorities in clinical research. Our risk assessments and recruitment results do not reflect the modified Gail Model for African Americans. CONCLUSIONS: Recruitment strategies used in STAR for racial and ethnic minorities contributed to doubling the minority enrollment compared to that in the BCPT and increased the awareness of breast cancer risk assessment in minority communities. Incorporation of new information into models to improve the risk estimation of diverse populations should prove beneficial.
AD  - Community Oncology & Prevention Trials Research Group, Division of Cancer Prevention, National Cancer Institute, NIH, Bethesda, MD 20892, USA. wm57h@nih.gov
AN  - 23335675
AU  - McCaskill-Stevens, W.
AU  - Wilson, J. W.
AU  - Cook, E. D.
AU  - Edwards, C. L.
AU  - Gibson, R. V.
AU  - McElwain, D. L.
AU  - Figueroa-Moseley, C. D.
AU  - Paskett, E. D.
AU  - Roberson, N. L.
AU  - Wickerham, D. L.
AU  - Wolmark, N.
C2  - PMC4059676
C6  - NIHMS592719
DA  - Apr
DO  - 10.1177/1740774512470315
DP  - NLM
ET  - 2013/01/22
IS  - 2
KW  - African Americans
Antineoplastic Agents/*administration & dosage/therapeutic use
Breast Neoplasms/ethnology/*prevention & control
Chemoprevention
Community-Based Participatory Research/methods
Continental Population Groups/*statistics & numerical data
Double-Blind Method
European Continental Ancestry Group
Female
Hispanic Americans
Humans
Patient Education as Topic
Patient Selection
Raloxifene Hydrochloride/*administration & dosage/therapeutic use
Randomized Controlled Trials as Topic/*methods
Risk Assessment
Tamoxifen/*administration & dosage/therapeutic use
LA  - eng
N1  - 1740-7753
McCaskill-Stevens, Worta
Wilson, John W
Cook, Elise D
Edwards, Cora L
Gibson, Regina V
McElwain, Diane L
Figueroa-Moseley, Colmar D
Paskett, Electra D
Roberson, Noma L
Wickerham, D Lawrence
Wolmark, Norman
U10-CA-69651/CA/NCI NIH HHS/United States
U10-CA-37377/CA/NCI NIH HHS/United States
U10 CA012027/CA/NCI NIH HHS/United States
U10-CA-69974/CA/NCI NIH HHS/United States
U10-CA-12027/CA/NCI NIH HHS/United States
U10 CA069651/CA/NCI NIH HHS/United States
U10 CA069974/CA/NCI NIH HHS/United States
U10 CA037377/CA/NCI NIH HHS/United States
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Clin Trials. 2013 Apr;10(2):280-91. doi: 10.1177/1740774512470315. Epub 2013 Jan 18.
PY  - 2013
SN  - 1740-7745 (Print)
1740-7745
SP  - 280-91
ST  - National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene trial: advancing the science of recruitment and breast cancer risk assessment in minority communities
T2  - Clin Trials
TI  - National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene trial: advancing the science of recruitment and breast cancer risk assessment in minority communities
VL  - 10
ID  - 341
ER  - 

TY  - JOUR
AB  - PURPOSE: Neoadjuvant chemoradiation for stage II/III rectal cancer results in up to 49% of patients with a clinical complete response. As a result, many have questioned whether surgery can be omitted for this group of patients. Currently, there is insufficient evidence for chemoradiation only, or nonoperative management (NOM), to support its adoption. Despite this, anecdotal evidence suggests there is a trend toward increased use of NOM. Our objective was to examine the use of NOM for rectal cancer over time, as well as the patient- and facility-level factors associated with its use. METHODS: We included all incident cases of invasive, nonmetastatic rectal adenocarcinoma reported to the National Cancer Database from 1998 to 2010. We performed univariate and multivariate analyses to assess for NOM use over time, as well as associated patient- and facility-level factors. RESULTS: A total of 146,135 patients met the inclusion criteria: 5,741 had NOM and 140,394 had surgery with or without additional therapy. From 1998 to 2010, NOM doubled, from 2.4% to 5% of all cases annually. Patients who were black (adjusted odds ratio [AOR], 1.71; 95% CI, 1.57 to 1.86), uninsured (AOR, 2.35; 95% CI, 2.08 to 2.65) or enrolled in Medicaid (AOR, 2.10; 95% CI, 1.90 to 2.33), or treated at low-volume facilities (AOR, 1.53; 95% CI, 1.42 to 1.64) were more likely to receive NOM than were patients who were white, privately insured, and treated at a high-volume facility, respectively. CONCLUSION: NOM demonstrates promise for the treatment of rectal cancer; currently, however, the most appropriate strategy is to pursue this approach with well-informed patients in the context of a clinical trial. We observed evidence of increasing NOM use, with this increase occurring more frequently in black and uninsured/Medicaid patients, raising concern that increased NOM use may actually represent increasing disparities in rectal cancer care rather than innovation. Further studies are needed to assess survival differences by treatment strategy.
AD  - All authors: University of North Carolina, Chapel Hill, NC. clayton.ellis@unchealth.unc.edu.
All authors: University of North Carolina, Chapel Hill, NC.
AN  - 27022115
AU  - Ellis, C. T.
AU  - Samuel, C. A.
AU  - Stitzenberg, K. B.
DA  - May 10
DO  - 10.1200/jco.2015.64.2066
DP  - NLM
ET  - 2016/03/30
IS  - 14
KW  - Adenocarcinoma/epidemiology/pathology/*therapy
Adult
Aged
Aged, 80 and over
Chemoradiotherapy/trends
Cohort Studies
Databases, Factual
Female
Humans
Kidney Neoplasms/epidemiology/pathology/*therapy
Male
Middle Aged
Neoadjuvant Therapy/trends
Neoplasm Staging
United States/epidemiology
LA  - eng
N1  - 1527-7755
Ellis, Clayton Tyler
Samuel, Cleo A
Stitzenberg, Karyn B
T32 HS000032/HS/AHRQ HHS/United States
Journal Article
Research Support, U.S. Gov't, P.H.S.
United States
J Clin Oncol. 2016 May 10;34(14):1644-51. doi: 10.1200/JCO.2015.64.2066. Epub 2016 Mar 28.
PY  - 2016
SN  - 0732-183x
SP  - 1644-51
ST  - National Trends in Nonoperative Management of Rectal Adenocarcinoma
T2  - J Clin Oncol
TI  - National Trends in Nonoperative Management of Rectal Adenocarcinoma
VL  - 34
ID  - 215
ER  - 

TY  - JOUR
AB  - The purpose of this study was to identify important sociodemographic factors affecting the utilization of immediate and early delayed postmastectomy breast reconstruction in the United States. Using the Surveillance, Epidemiology, and End Results (SEER) program, all cases of mastectomy-treated breast cancer that were reported to a SEER registry in 1998 were identified. Data were limited to reconstructions within the first 4 months postmastectomy, and logistic regression was used to analyze the effects of sociodemographic variables on reconstruction rates. Of the 10,406 mastectomy-treated breast cancer patients, 1607 (15 percent) underwent reconstruction within the first 4 months postmastectomy. Compared with women 45 to 54 years old, those 35 to 44 years old were significantly more likely to have breast reconstruction (OR = 1.52, p < 0.001), but women 55 to 64, 65 to 74, and 75 years and older were significantly less likely to have reconstruction (OR = 0.42, p < 0.001; OR = 0.16, p < 0.001; OR = 0.04, p < 0.001, respectively). Compared with Caucasian women, African American, Hispanic, and Asian women were significantly less likely to have reconstruction (OR = 0.48, p < 0.001; OR = 0.45, p < 0.001; OR = 0.29, p < 0.001, respectively). In addition, a four-fold difference in reconstruction rates existed in high-use versus low-use regions. With regard to the type of reconstruction, patients younger than 35 and 65 to 74 years old were significantly less likely to receive autogenous tissue reconstruction compared with women 45 to 54 years old (OR = 0.47, p = 0.047; OR = 0.61, p = 0.031, respectively). However, African Americans were significantly more likely to receive autogenous tissue reconstructions compared with Caucasians (OR = 2.03, p = 0.021). According to these data, the utilization of immediate and early delayed breast reconstruction in the United States is low and is significantly influenced by patients' age, race, and geographic location. Further research is needed to evaluate the impact of provider bias, patient preference, and barriers to care on the utilization of breast reconstruction in the United States.
AD  - A.K. Alderman, R. Wood Johnson Clin. Scholars Prog., Univ. of Michigan Medical Center, 6312 Medical Science Building I, 1150 W. Medical Center Drive, Ann Arbor, MI 48109-0604, United States
AU  - Alderman, A. K.
AU  - McMahon Jr, L.
AU  - Wilkins, E. G.
DB  - Embase
Medline
DO  - 10.1097/01.PRS.0000041438.50018.02
IS  - 2
KW  - adult
age distribution
aged
article
Asian
autograft
breast carcinoma
breast reconstruction
Caucasian
controlled study
ethnic difference
female
geographic distribution
health care utilization
human
logistic regression analysis
major clinical study
mastectomy
Black person
patient selection
postoperative period
priority journal
race difference
self concept
surgical technique
United States
LA  - English
M3  - Article
N1  - L36182312
2003-02-20
PY  - 2003
SN  - 0032-1052
SP  - 695-703
ST  - The national utilization of immediate and early delayed breast reconstruction and the effect of sociodemographic factors
T2  - Plastic and Reconstructive Surgery
TI  - The national utilization of immediate and early delayed breast reconstruction and the effect of sociodemographic factors
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L36182312&from=export
http://dx.doi.org/10.1097/01.PRS.0000041438.50018.02
VL  - 111
ID  - 1296
ER  - 

TY  - JOUR
AB  - BACKGROUND: In 2006, the National Health Service Bowel Cancer Screening Programme in England (NHSBCSP) began offering routine population-based biennial faecal occult blood testing (FOBt) at ages 60-69. There is, however, limited information on how characteristics of individuals affect participation and outcomes of screening, and we studied this association by linking NHSBCSP data to a large prospective cohort of women. METHODS: Electronic linkage of the NHSBCSP and Million Women Study records identified 899 166 women in the study cohort with at least one invitation for screening. NHSBCSP provided information on screening acceptance, FOBt results, screen-detected colorectal cancer and other outcomes. The Million Women Study provided prospectively collected information on personal and lifestyle factors. Multiple regression was used to estimate relative risks (RRs) of factors associated with acceptance and outcomes of screening. RESULTS: Overall, 70% of women (628 976/899 166) accepted their first invitation for bowel cancer screening, of whom 9133 (1.5%) were FOBt-positive, 743 (0.1%) had screen-detected colorectal cancer and 3056 (0.5%) had screen-detected colorectal adenoma. Acceptance was lower in women from the most than the least deprived tertile, in South Asians and in Blacks than in Whites, in current than in never smokers and in obese than in normal weight women: adjusted RRs (95% confidence interval) for acceptance vs not, 0.90 (0.90-0.90); 0.77 (0.75-79); 0.94 (0.92-0.96); 0.78 (0.77-0.78); and 0.88 (0.88-0.89), respectively: P<0.001 for each. These factors were also associated with an increased risk of being FOBt-positive and of having screen-detected adenoma, but were not strongly associated with the risk of screen-detected colorectal cancer. Relative risks for screen-detected adenoma were 1.22 (1.12-1.34), 2.46 (1.75-3.45), 1.61 (1.05-2.48), 1.53 (1.38-1.68) and 1.77 (1.60-1.95), respectively (P<0.001 for all, except for Blacks vs Whites P=0.03). Use of hormone therapy for menopause was associated with reduced risk of screen-detected adenoma, RR ever vs never use, 0.87 (0.81-0.93), P<0.001 and colorectal cancer, 0.78 (0.68-0.91), P=0.001. INTERPRETATION: Among women in England, socioeconomic and lifestyle factors strongly affect participation in routine bowel cancer screening, risk of being FOBt-positive and risk of having screen-detected colorectal adenoma. However, screen-detected colorectal cancer risk is not strongly related to these factors.
AD  - Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
1] Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK [2] NHS Cancer Screening Programmes, Public Health England, Fulwood House, Old Fulwood Road, Sheffield S10 3TH, UK.
AN  - 25742470
AU  - Blanks, R. G.
AU  - Benson, V. S.
AU  - Alison, R.
AU  - Brown, A.
AU  - Reeves, G. K.
AU  - Beral, V.
AU  - Patnick, J.
AU  - Green, J.
C2  - PMC4453681
DA  - Apr 28
DO  - 10.1038/bjc.2015.69
DP  - NLM
ET  - 2015/03/06
IS  - 9
KW  - Aged
*Colonoscopy
Colorectal Neoplasms/*diagnosis
Early Detection of Cancer/*statistics & numerical data
England
Female
Follow-Up Studies
Humans
*Life Style
Middle Aged
National Health Programs/*organization & administration
Occult Blood
Patient Acceptance of Health Care
*Patient Participation
Prognosis
Prospective Studies
LA  - eng
N1  - 1532-1827
Blanks, R G
Benson, V S
Alison, R
Brown, A
Reeves, G K
Beral, V
Patnick, J
Green, J
Cancer Research UK/United Kingdom
Medical Research Council/United Kingdom
Journal Article
Research Support, Non-U.S. Gov't
Br J Cancer. 2015 Apr 28;112(9):1562-7. doi: 10.1038/bjc.2015.69. Epub 2015 Mar 5.
PY  - 2015
SN  - 0007-0920 (Print)
0007-0920
SP  - 1562-7
ST  - Nationwide bowel cancer screening programme in England: cohort study of lifestyle factors affecting participation and outcomes in women
T2  - Br J Cancer
TI  - Nationwide bowel cancer screening programme in England: cohort study of lifestyle factors affecting participation and outcomes in women
VL  - 112
ID  - 254
ER  - 

TY  - JOUR
AB  - BACKGROUND: Consumers are increasingly looking to natural health products to manage specific diseases such as osteoporosis. As a result, healthcare providers need evidence‐based information on which to base recommendations regarding use and efficacy. OBJECTIVE: To identify natural health products (NHPs, ie, dietary supplements) advocated for the prevention and treatment of osteoporosis and systematically review the evidence from randomized controlled trials for the effect of NHPs on bone mineral density (BMD)/fracture rate in women. METHODS: MEDLINE, Natural Medicines Comprehensive Database, and the Internet were initially searched to identify NHPs advocated for prevention and treatment of osteoporosis. For NHPs having evidence to support their claim, the aforementioned sources, along with International Pharmaceutical Abstracts, the Cochrane Library, the International Bibliographic Information on Dietary Supplements, the Cumulative Index to Nursing & Allied Health, and HerbMed, were searched to locate randomized controlled trials published in English between 1966 and October 2004. Bibliographies of identified articles were also searched. Randomized controlled trials were selected if they evaluated the use of a single NHP in women, using BMD/fracture rate as the outcome measure. NHPs were excluded from further evaluation if a review had already been published. Data were extracted using predetermined criteria and studies appraised using the Jadad scale. Forty‐five NHPs were identified that the authors claimed to be beneficial in prevention and treatment of osteoporosis, with 15 having evidence to support their claim. Calcium; copper; evening primrose oil; fish oils; fluoride; magnesium; manganese; strontium; vitamin D; and black, green, and oolong tea did not meet study criteria. RESULTS: Results from randomized controlled trials evaluating dehydroepiandrosterone (DHEA), phytoestrogens, and vitamin K2 (menaquinone or menatetrenone) were promising; however, study limitations suggest the need for confirmatory evidence. CONCLUSIONS: Although no definitive conclusions can be drawn, the relative safety of phytoestrogens, DHEA, and vitamin K2 at the studied doses, as well as preliminary positive results from randomized controlled trials, provides some initial support for the use of these NHPs in the prevention and treatment of osteoporosis in women.
AN  - CN-01749885
AU  - Whelan, A. M.
AU  - Jurgens, T. M.
AU  - Bowles, S. K.
DO  - 10.1345/aph.1G226
IS  - 5
KW  - *diet supplementation
*osteoporosis /drug therapy /prevention
Abdominal distension /side effect
Acne /side effect
Actaea racemosa
Alfalfa
Althaea
Angelica sinensis
Arthralgia /side effect
Avocado
Black pepper
Bone density
Bone mineral
Bone pain /side effect
Breast cancer /side effect
Breast disease /side effect
Cabbage
Clinical trial
Constipation /side effect
Controlled clinical trial
Dandelion
Diarrhea /side effect
Drug efficacy
Drug safety
Dyspnea /side effect
Edema /side effect
Equisetum
Fatigue /side effect
Flatulence /side effect
Fluid retention
Ginseng
Glycyrrhiza
Headache /side effect
Herbal medicine
Hirsutism /side effect
Human
Hypertension /side effect
Malaise /side effect
Menopausal syndrome /drug therapy
Menstruation disorder /side effect
Nausea /side effect
Neoplasm /side effect
Papaya
Phytotherapy
Postmenopause osteoporosis /drug therapy /prevention
Priority journal
Pruritus /side effect
Randomized controlled trial
Review
Rumex
Skin irritation /side effect
Sleep disorder /side effect
Stomach irritation /side effect
Systematic review
Tea
Thorax pain /side effect
Treatment outcome
Vomiting /side effect
M3  - Journal: Review
PY  - 2006
SP  - 836‐849
ST  - Natural health products in the prevention and treatment of osteoporosis: systematic review of randomized controlled trials
T2  - Annals of pharmacotherapy
TI  - Natural health products in the prevention and treatment of osteoporosis: systematic review of randomized controlled trials
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01749885/full
VL  - 40
ID  - 1598
ER  - 

TY  - JOUR
AB  - OBJECTIVES: To systematically review the literature on the impact of patient navigators on cancer screening for limited English proficient (LEP) patients. DATA SOURCES: Electronic databases (PubMed, PsycINFO via OVID, Web of Science, Cochrane, EMBASE, and Scopus) through 8 May 2015. ELIGIBILITY CRITERIA: Articles in this review had: (1) a study population of LEP patients eligible for breast, cervical or colorectal cancer screenings, (2) a patient navigator intervention to provide services prior to or during cancer screening, (3) a comparison of the patient navigator intervention to either a control group or another intervention, and (4) language-specific outcomes related to the patient navigator intervention. STUDY APPRAISAL: We assessed the quality of the articles using the Downs and Black Scale. RESULTS: Fifteen studies met the inclusion criteria and evaluated the screening rates for breast, colorectal, and cervical cancer in 15 language populations. Fourteen studies resulted in improved screening rates for LEP patients between 7 and 60%. There was great variability in the patient navigation interventions evaluated. Training received by navigators was not reported in nine of the studies and no studies assessed the language skills of the patient navigators in English or the target language. LIMITATIONS: This study is limited by the variability in study designs and limited reporting on patient navigator interventions, which reduces the ability to draw conclusions on the full effect of patient navigators. CONCLUSIONS: Overall, we found evidence that navigators improved screening rates for breast, cervical and colorectal cancer screening for LEP patients. Future studies should systematically collect data on the training curricula for navigators and assess their English and non-English language skills in order to identify ways to reduce disparities for LEP patients.
AD  - Department of Psychiatry and Behavioral Sciences, Immigrant Health and Cancer Disparities Service, Memorial Sloan-Kettering Cancer Center, New York City, NY, USA.
Department of Psychology, New School for Social Research, New York, NY, USA.
University of Washington School of Medicine, Seattle, WA, USA.
Medical Library, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Department of Psychiatry and Behavioral Sciences, Immigrant Health and Cancer Disparities Service, Memorial Sloan-Kettering Cancer Center, New York City, NY, USA. diamondl@mskcc.org.
AN  - 26786875
AU  - Genoff, M. C.
AU  - Zaballa, A.
AU  - Gany, F.
AU  - Gonzalez, J.
AU  - Ramirez, J.
AU  - Jewell, S. T.
AU  - Diamond, L. C.
C2  - PMC4803699
DA  - Apr
DO  - 10.1007/s11606-015-3572-3
DP  - NLM
ET  - 2016/01/21
IS  - 4
KW  - Clinical Trials as Topic/methods
*Communication Barriers
Early Detection of Cancer/*methods/trends
Health Services Accessibility/trends
Humans
Patient Navigation/*methods/trends
communication barriers
language
limited English proficiency
patient navigators
LA  - eng
N1  - 1525-1497
Genoff, Margaux C
Zaballa, Alexandra
Gany, Francesca
Gonzalez, Javier
Ramirez, Julia
Jewell, Sarah T
Diamond, Lisa C
P30 CA008748/CA/NCI NIH HHS/United States
Journal Article
Review
Systematic Review
J Gen Intern Med. 2016 Apr;31(4):426-34. doi: 10.1007/s11606-015-3572-3. Epub 2016 Jan 19.
PY  - 2016
SN  - 0884-8734 (Print)
0884-8734
SP  - 426-34
ST  - Navigating Language Barriers: A Systematic Review of Patient Navigators' Impact on Cancer Screening for Limited English Proficient Patients
T2  - J Gen Intern Med
TI  - Navigating Language Barriers: A Systematic Review of Patient Navigators' Impact on Cancer Screening for Limited English Proficient Patients
VL  - 31
ID  - 221
ER  - 

TY  - JOUR
AB  - BACKGROUND: Prostate cancer disproportionately affects low-income and minority men. This study evaluates the impact of a patient navigation intervention on timeliness of diagnostic resolution and treatment initiation among veterans with an abnormal prostate cancer screen. METHODS: Participants were enrolled between 2006 and 2010. The intervention involved a social worker and lay health worker navigation team that assisted patients in overcoming barriers to care. For navigated (n = 245) versus control (n = 245) participants, we evaluated rates of diagnostic resolution and treatment and adjusted for race, age, and Gleason score. RESULTS: Of 490 participants, 68% were African American, 47% were ≥ 65 years old, and 35% had cancer. Among those with an abnormal screen, navigation did not have a significant effect on time to diagnostic resolution compared to controls (median days of 97 versus 111; adj. HR 1.17, 95% CI, 0.96-1.43, p = 0.12). On analysis of the period beyond 80 days, navigated men reached resolution faster than controls (median of 151 days versus 190 days; adj. HR 1.41, 95% CI, 1.07-1.86, p = 0.01). Among those with cancer, navigation did not have a significant effect on time to treatment initiation compared to controls (median of 93 days versus 87 days; adj. HR 1.15, 95% CI, 0.82-1.62, p = 0.41). CONCLUSION: Our navigation program did not significantly impact the overall time to resolution or treatment for men with prostate cancer compared to controls. The utility of navigation programs may extend beyond targeted navigation times, however, and future studies focusing on other outcomes measures are therefore needed.
AD  - Robert H, Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA. m-simon2@northwestern.edu.
AN  - 23947435
AU  - Simon, M. A.
AU  - Nonzee, N. J.
AU  - McKoy, J. M.
AU  - Liu, D.
AU  - Luu, T. H.
AU  - Byer, P.
AU  - Eklund, E. A.
AU  - Richey, E. A.
AU  - Wu, Z.
AU  - Dong, X.
AU  - Rademaker, A. W.
C2  - PMC3844412
DA  - Aug 15
DO  - 10.1186/1472-6963-13-314
DP  - NLM
ET  - 2013/08/21
KW  - Adult
Aged
Aged, 80 and over
*Early Detection of Cancer
Hospitals, Veterans/organization & administration
Humans
Male
Middle Aged
Patient Navigation/*methods
Prostate-Specific Antigen/blood
Prostatic Neoplasms/*diagnosis/therapy
Social Work/methods
Time Factors
United States
*Veterans
LA  - eng
N1  - 1472-6963
Simon, Melissa A
Nonzee, Narissa J
McKoy, June M
Liu, Dachao
Luu, Thanh Ha
Byer, Peter
Eklund, Elizabeth A
Richey, Elizabeth A
Wu, Zhigang
Dong, XinQi
Rademaker, Alfred W
UL1 TR000150/TR/NCATS NIH HHS/United States
K12 HD050121/HD/NICHD NIH HHS/United States
K01 CA134554/CA/NCI NIH HHS/United States
P30 CA060553/CA/NCI NIH HHS/United States
U01 CA116875/CA/NCI NIH HHS/United States
Clinical Trial
Journal Article
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.
BMC Health Serv Res. 2013 Aug 15;13:314. doi: 10.1186/1472-6963-13-314.
PY  - 2013
SN  - 1472-6963
SP  - 314
ST  - Navigating veterans with an abnormal prostate cancer screening test: a quasi-experimental study
T2  - BMC Health Serv Res
TI  - Navigating veterans with an abnormal prostate cancer screening test: a quasi-experimental study
VL  - 13
ID  - 320
ER  - 

TY  - JOUR
AB  - Most cancer care is delivered in the community, while most clinical trials exist in academic centers. We analyzed clinical trial accrual of a tertiary care cancer center and its affiliated community sites to better understand what types of trials accrued at the community sites and whether community accrual increased ethnic diversity. The institutional clinical trial database was searched for solid tumor accruals during 2018–2019. Patient’s race was abstracted, and trial’s funding source, phase, and disease type/stage were tabulated. Of 3689 accruals, 133 were at community sites, representing 26 unique trials while the main campus accrued to 93 unique trials. Community site accruals were highest for breast and colorectal cancer, but patients with less common cancers such as renal, nasopharyngeal, and gastric cancer were also accrued at community sites. Accruals occurred to randomized trials, as well as phase Ib and translational biomarker studies. Minority patients constituted 20.0% and 32.5% of community site accruals for therapeutic and non-therapeutic trials respectively, compared to 20.6% and 29.8% of main campus accruals for therapeutic and non-therapeutic trials, respectively. We conclude that community sites affiliated with an academic cancer center can accrue to a broad spectrum of clinical trials while enhancing racial diversity in participation of clinical trials. Further expansion of access to clinical trials in community sites is necessary to broaden patient access to state-of-the-art and next-generation treatment options.
AD  - T. Dorff, City of Hope Comprehensive Cancer Center, Department of Medical Oncology and Developmental Therapeutics, Duarte, CA, United States
AU  - Kim, D. J.
AU  - Otap, D.
AU  - Ruel, N.
AU  - Gupta, N.
AU  - Khan, N.
AU  - Dorff, T.
DB  - Embase
DO  - 10.3390/jcm9061970
IS  - 6
KW  - adjuvant
tumor marker
adult
African American
aged
American Indian
article
Asian
bioaccumulation
breast cancer
cancer center
Caucasian
chimeric antigen receptor T-cell immunotherapy
clinical trial
colorectal cancer
community care
controlled study
estimated glomerular filtration rate
ethnicity
female genital tract cancer
gastroesophageal junction
head and neck cancer
health auxiliary
hematologic malignancy
human
investigator sponsored trial
kidney cancer
liver cell carcinoma
major clinical study
melanoma
metastasis
nasopharynx cancer
national health organization
Native Hawaiian
neoadjuvant chemotherapy
non small cell lung cancer
pancreas cancer
phase 1 clinical trial
race
randomized controlled trial
sarcoma
solid malignant neoplasm
stereotactic body radiation therapy
stomach cancer
tertiary care center
toxicity
urogenital tract cancer
LA  - English
M3  - Article
N1  - L2004595684
2020-07-27
2020-09-15
PY  - 2020
SN  - 2077-0383
SP  - 1-7
ST  - NCI–clinical trial accrual in a community network affiliated with a designated cancer center
T2  - Journal of Clinical Medicine
TI  - NCI–clinical trial accrual in a community network affiliated with a designated cancer center
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L2004595684&from=export
http://dx.doi.org/10.3390/jcm9061970
VL  - 9
ID  - 819
ER  - 

TY  - JOUR
AB  - Objective. To assess osteoporosis knowledge, beliefs, and preventive behaviors among young adult women and to identify sources that they would mostly likely utilize to learn more about the disease. Methods. Information was gathered through a cross-sectional survey of 321 women (mean age 21.6 years; 63.5% were white, 29.2% were black) enrolled in a required undergraduate health course at a southeastern state university. Results. Two hundred seventy-seven (86%) of the survey participants had heard about osteoporosis, but only 3.8% of respondents reported getting both adequate exercise and the recommended 1,200 mg of calcium per day. Respondents believed that they were unlikely to develop osteoporosis and that osteoporosis is less serious than other common causes of morbidity and mortality in women, such as heart disease and breast cancer (P < 0.0001). Brochures, magazines, and short counseling sessions were preferred information sources for learning about osteoporosis. Conclusions. The majority of young women studied are at risk for developing premature osteoporosis. They prefer brochures, magazines, and short counseling sessions during medical office visits to learn about osteoporosis. © 2001 by the American College of Rheumatology.
AD  - M.J. Kasper, Department of Kinesiology, Valdosta State University, Valdosta, GA 31698, United States
AU  - Kasper, M. J.
AU  - Peterson, M. G. E.
AU  - Allegrante, J. P.
DB  - Embase
Medline
DO  - 10.1002/1529-0131(200102)45:1<28::aid-anr80>3.0.co;2-g
IS  - 1
KW  - calcium
adult
article
clinical trial
education program
female
health survey
human
human experiment
human tissue
morbidity
normal human
osteoporosis
patient counseling
patient information
risk assessment
LA  - English
M3  - Article
N1  - L32280400
2001-04-24
PY  - 2001
SN  - 2151-4658
SP  - 28-34
ST  - The need for comprehensive educational osteoporosis prevention programs for young women: Results from a second osteoporosis prevention survey
T2  - Arthritis Care and Research
TI  - The need for comprehensive educational osteoporosis prevention programs for young women: Results from a second osteoporosis prevention survey
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L32280400&from=export
http://dx.doi.org/10.1002/1529-0131(200102)45:1<28::aid-anr80>3.0.co;2-g
VL  - 45
ID  - 1314
ER  - 

TY  - JOUR
AB  - This article describes a shared model of the breast cancer experience negotiated by the members of a spontaneously organized breast cancer self-help group in eastern North Carolina. In the course of sharing their personal experience narratives with one another, these women worked to negotiate points of agreement among the varying sources of knowledge and oftentimes conflicting belief systems they held about breast cancer. The synthetic model they created rejected many of the assumptions underlying the dominant biomedical view of cancer "survivorship," particularly its emphasis on the autonomous individual as decision maker and its attendant male-gendered sports and military imagery--assumptions that often implicitly structured the agendas and topics discussed in the formal, medically sanctioned support groups these women found unappealing. The implications for theories about the construction of shared cultural models and for continuing efforts to design support groups to meet the needs of a diverse patient population are explored.
AD  - Department of Anthropology, East Carolina University, USA.
AN  - 11036585
AU  - Mathews, H. F.
DA  - Sep
DO  - 10.1525/maq.2000.14.3.394
DP  - NLM
ET  - 2000/10/19
IS  - 3
KW  - African Americans/psychology
Anthropology, Cultural
Breast Neoplasms/*psychology/therapy
Cognitive Dissonance
European Continental Ancestry Group/psychology
Female
Group Processes
*Health Knowledge, Attitudes, Practice
Humans
Models, Psychological
Negotiating
North Carolina
Patient Participation
*Self-Help Groups
Social Support
*Sociology, Medical
LA  - eng
N1  - Mathews, H F
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
United States
Med Anthropol Q. 2000 Sep;14(3):394-413. doi: 10.1525/maq.2000.14.3.394.
PY  - 2000
SN  - 0745-5194 (Print)
0745-5194
SP  - 394-413
ST  - Negotiating cultural consensus in a breast cancer self-help group
T2  - Med Anthropol Q
TI  - Negotiating cultural consensus in a breast cancer self-help group
VL  - 14
ID  - 698
ER  - 

TY  - JOUR
AB  - Background: The effect of neighborhood and healthcare access factors on cancer outcomes among patients enrolled in navigator programs is not clearly understood. This study assessed associations between: (i) neighborhood factors and diagnostic time to resolution (TTR) and (ii) geographic access and TTR following an abnormal breast or cervical cancer screening test among women participating in the Ohio Patient Navigator Research Program (OPNRP). Methods: Patient (demographic, socioeconomic status, home-to-clinic distance) and neighborhood (deprivation, racial segregation) characteristics of 801 women living in one of 285 census tracts (CT) in greater Columbus, Ohio were examined. Randomization to receive navigation occurred at the clinic level. Multilevel Cox regression and spatial analysis were used to estimate effects of various factors on TTR and assess model assumptions, respectively. Results: TTR increased as neighborhood deprivation increased. After adjustment for age, friend social support, education, and healthcare status, the TTR among women living in a neighborhood with a moderate median household income (between $36,147 and $53,099) was shorter compared with women living in low median household income neighborhoods (<$36,147; P < 0.05). There is little evidence that unmeasured confounders are geographically patterned. Conclusions: Increased neighborhood socioeconomic deprivation was associated with longer TTR following an abnormal breast or cervical cancer screening test. Impact: These results highlight the need for addressing patient- and neighborhood-level factors to reduce cancer disparities among underserved populations.
AD  - J.J. Plascak, Department of Health Services, School of Public Health, University of Washington, Box 359455, Seattle, WA, United States
AU  - Plascak, J. J.
AU  - Llanos, A. A.
AU  - Pennell, M. L.
AU  - Weier, R. C.
AU  - Paskett, E. D.
DB  - Embase
Medline
DO  - 10.1158/1055-9965.EPI-14-0348
IS  - 12
KW  - adult
African American
age
article
breast cancer
cancer screening
educational status
European American
female
health care concepts
health care disparity
human
income
major clinical study
medical record review
medically uninsured
multicenter study (topic)
neighborhood
private health insurance
public health insurance
randomized controlled trial (topic)
social status
social support
time to resolution
uterine cervix cancer
LA  - English
M3  - Article
N1  - L600988173
2014-12-25
2015-06-12
PY  - 2014
SN  - 1055-9965
SP  - 2819-2828
ST  - Neighborhood factors associated with time to resolution following an abnormal breast or cervical cancer screening test
T2  - Cancer Epidemiology Biomarkers and Prevention
TI  - Neighborhood factors associated with time to resolution following an abnormal breast or cervical cancer screening test
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L600988173&from=export
http://dx.doi.org/10.1158/1055-9965.EPI-14-0348
VL  - 23
ID  - 1021
ER  - 

TY  - JOUR
AB  - The Neighborhood Voice is a vehicle customized for conducting health research in community settings. It brings research studies into neighborhoods affected most by health disparities and reaches groups often underrepresented in research samples. This paper reports on the experience and satisfaction of 599 African American women who participated in research on board the Neighborhood Voice. Using bivariate, psychometric, and logistic regression analyses, we examined responses to a brief post-research survey. Most women (71%) reported that they had never previously participated in research, and two-thirds (68%) rated their Neighborhood Voice experience as excellent. Satisfaction scores were highest among first-time research participants (p < .05). Women's ratings of the Neighborhood Voice on Comfort (OR = 4.9; 95% CI = 3.0, 7.9) and Convenience (OR = 1.8; 95% CI = 1.2, 2.9) significantly predicted having an excellent experience. Mobile research facilities may increase participation among disadvantaged and minority populations. Our brief survey instrument is a model for evaluating such outreach.
AD  - Health Communication Research Laboratory, George Warren Brown School of Social Work, Washington University in St. Louis, St. Louis, MO 63112, USA. kalcaraz@wustl.edu
AN  - 21411475
AU  - Alcaraz, K. I.
AU  - Weaver, N. L.
AU  - Andresen, E. M.
AU  - Christopher, K.
AU  - Kreuter, M. W.
C2  - PMC3955197
C6  - NIHMS450388
DA  - Sep
DO  - 10.1177/0163278710395933
DP  - NLM
ET  - 2011/03/18
IS  - 3
KW  - *African Americans
*Automobiles
Biomedical Research/*methods
Breast Neoplasms/*ethnology
Female
Health Status Disparities
Humans
Middle Aged
Missouri
*Patient Selection
LA  - eng
N1  - 1552-3918
Alcaraz, Kassandra I
Weaver, Nancy L
Andresen, Elena M
Christopher, Kara
Kreuter, Matthew W
P30 AG028740/AG/NIA NIH HHS/United States
P50 CA095815/CA/NCI NIH HHS/United States
CA-095815/CA/NCI NIH HHS/United States
Evaluation Study
Journal Article
Research Support, N.I.H., Extramural
Eval Health Prof. 2011 Sep;34(3):336-48. doi: 10.1177/0163278710395933. Epub 2011 Mar 16.
PY  - 2011
SN  - 0163-2787 (Print)
0163-2787
SP  - 336-48
ST  - The Neighborhood Voice: evaluating a mobile research vehicle for recruiting African Americans to participate in cancer control studies
T2  - Eval Health Prof
TI  - The Neighborhood Voice: evaluating a mobile research vehicle for recruiting African Americans to participate in cancer control studies
VL  - 34
ID  - 397
ER  - 

TY  - JOUR
AB  - As neighborhood context is increasingly recognized as an important predictor of health outcomes and health behaviors, this analysis sought to determine the relationship between neighborhood-level socioeconomic status (SES) and regular mammography screening behavior. One thousand four hundred fifty-one women ages 40 to 79 years who obtained an "index" screening mammogram at one of five urban hospitals in Connecticut between October 1996 and January 1998 were enrolled in this prospective study. The logistic regression analysis includes the 1,229 women [484 African-American (39%) and 745 White (61%)] who completed telephone interviews at baseline and follow-up (average 29.4 months later) and for whom the study outcome, nonadherence to age-specific mammography screening guidelines, was ascertained. Neighborhood-level SES was determined using 1990 census tract information. Neighborhood-level SES variables (quartiles) were associated with nonadherence for African-American women [neighborhood-level education and composite socioeconomic position index (SEP Index)] and White women (neighborhood-level crowding and neighborhood-level assets). Using race-specific categorizations reflective of individual-level SES distributions, the SEP Index and neighborhood-level education were associated with nonadherence to mammography screening guidelines for African-American women (marginally significant for White women), independent of individual-level SES and other known predictors of mammography screening use [African-American women: SEP Index odds ratio (OR), 3.55; 95% confidence interval (95% CI), 1.33-9.51; neighborhood-level education OR, 3.21; 95% CI, 1.25-8.26; White women: SEP Index OR, 2.13; 95% CI, 0.97-4.67; neighborhood-level education OR, 2.31; 95% CI, 0.93-5.76]. The results of this analysis underscore the importance of examining neighborhood social context as well as individual factors in the study of mammography screening behavior. Copyright © 2007 American Association for Cancer Research.
AD  - Department of Epidemiology and Biostatistics, University of Florida College of Public Health and Health Professions, Gainesville, FL, United States
Department of Epidemiology and Public Health, Yale University School of Medicine, New Haven, CT, United States
Department of Epidemiology and Biostatistics, University of Florida School of Public Health and Health Professions, P. O. Box 100231, Gainesville, FL 32610, United States
AU  - Dailey, A. B.
AU  - Kasl, S. V.
AU  - Holford, T. R.
AU  - Calvocoressi, L.
AU  - Jones, B. A.
DB  - Scopus
DO  - 10.1158/1055-9965.EPI-06-1076
IS  - 11
M3  - Article
N1  - Cited By :58
Export Date: 22 March 2021
PY  - 2007
SP  - 2293-2303
ST  - Neighborhood-level socioeconomic predictors of nonadherence to mammography screening guidelines
T2  - Cancer Epidemiology Biomarkers and Prevention
TI  - Neighborhood-level socioeconomic predictors of nonadherence to mammography screening guidelines
UR  - https://www.scopus.com/inward/record.uri?eid=2-s2.0-38949138135&doi=10.1158%2f1055-9965.EPI-06-1076&partnerID=40&md5=a6d2e144a484b4cc4ce51f4c9e86de36
VL  - 16
ID  - 2549
ER  - 

TY  - JOUR
AB  - Purpose of Review: Although the use of neoadjuvant chemotherapy (NCT) in breast cancer was once reserved for patients with locally advanced disease or inflammatory breast cancers, it is increasingly used in patients with early-stage tumors. This review outlines the pertinent research in the field over the last year and discusses the clinical implications. Recent Findings: The present review will focus on three evolving areas in the neoadjuvant research field: factors determining response, use of endocrine and biologic therapies, and how to manage patients following response. Summary: NCT in breast cancer is a remarkable research platform providing insight into tumor biology and treatment efficacy in an expedited timeframe. Refining patient selection based on tumor and patient characteristics allows clinicians to limit potentially toxic therapy to those patients expected to receive the greatest benefit. Additionally, exploring new agents and sequencing of regimens based on these characteristics has great potential for impacting local-regional and systemic outcomes. Lastly, as the population of patients undergoing NCT grows, we must constantly adjust our treatment paradigms. We need to monitor them carefully and accurately, understand the implication of a treated tumor for future therapy, and determine how much additional therapy is necessary. © 2011 Wolters Kluwer Health | Lippincott Williams & Wilkins.
AD  - K. K. Hunt, Department of Surgical Oncology, University of Texas, MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, United States
AU  - Caudle, A. S.
AU  - Hunt, K. K.
C1  - herceptin
DB  - Embase
Medline
DO  - 10.1097/GCO.0b013e3283416477
IS  - 1
KW  - doxorubicin
epidermal growth factor receptor 2
estrogen receptor
fluorodeoxyglucose
letrozole
metformin
nicotinamide adenine dinucleotide adenosine diphosphate ribosyltransferase inhibitor
progesterone receptor
trastuzumab
adjuvant chemotherapy
advanced cancer
African American
article
axillary lymph node
breast cancer
breast carcinoma
breast conservation therapy
cancer chemotherapy
cancer hormone therapy
cancer patient
cancer radiotherapy
cancer research
cancer therapy
diabetes mellitus
drug efficacy
event free survival
heart failure
human
lobular carcinoma
lymph node dissection
mammography
mastectomy
nuclear magnetic resonance imaging
patient monitoring
patient selection
phase 2 clinical trial (topic)
positron emission tomography
postoperative care
priority journal
risk factor
sentinel lymph node biopsy
treatment response
tumor volume
herceptin
LA  - English
M3  - Article
N1  - L361110066
2011-01-24
2011-02-04
PY  - 2011
SN  - 1040-872X
SP  - 31-36
ST  - The neoadjuvant approach in breast cancer treatment: It is not just about chemotherapy anymore
T2  - Current Opinion in Obstetrics and Gynecology
TI  - The neoadjuvant approach in breast cancer treatment: It is not just about chemotherapy anymore
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L361110066&from=export
http://dx.doi.org/10.1097/GCO.0b013e3283416477
VL  - 23
ID  - 1146
ER  - 

TY  - JOUR
AB  - Background: Breast cancer surgery is usually performed under general anaesthesia (GA) and is frequently associated with postoperative nausea, vomiting and painful restricted movement of the shoulder. GA, with the exception of large doses of opioids, does not eliminate the surgical stress response. Paravertebral nerve blockade (PVB) may be an alternative to GA for this type of surgery especially in those patients with coexisting morbid diseases. However, PVB is associated with an incidence of failed black in 5-10% of cases. The aim of this study was to detect the success rate and the safety of PVB when guided by nerve stimulator and to compare the efficacy of this technique vs. GA for inhibition of surgical stress response during breast cancer surgery. Methods: Forty women were enrolled in this prospective randomized study, to receive GA (GA group; n = 20) or PVB (PVB group; n = 20) at T1-T6, using ropivacaine 0.5 % with epinephrine 1:200,000. In the PVB group, success rate and incidence of complications were recorded. In both groups, blood samples for measurement of glucose and cortisol concentrations were obtained before skin incision; 1 hour after skin incision; and at 3 and 24 hours postoperatively. Postoperative visual analogue pain scores (VAS) at rest and on moving the ipsilateral arm at predetermined time intervals postoperatively (1, 2, 6, 12 and 24 h) as well as the incidence of postoperative nausea and vomiting (PONV) throughout the 24 hours postoperatively were recorded in both groups. Results: All PVBs were successful and inadvertent complications other than hypotension (10% incidence) were not reported. There were no significant differences in the plasma glucose or cortisol concentrations between the two groups before skin incision. They were significantly lower in the PVB group 1 h after skin incision and at 3 h postoperatively. However, there were no significant differences in glucose or cortisol concentrations, between the 2 groups, at 24 h postoperatively. Patients in the PVB group had significantly lower VAS scores both at rest and on moving the arm at all the predetermined time intervals postoperatively as well as significantly lower incidence of PONV throughout the 24 h postoperatively. Conclusion: Nerve stimulator-guided PVB at the level of T1-T6 with ropivacaine represents a suitable alternative to GA for breast cancer surgery. Important benefits of PVB include reduced surgical stress response, as evidenced by lower plasma cortisol and glucose concentrations, superior postoperative analgesia and lower incidence of PONV.
AD  - A.F. Omran, Department of Anaesthesiology, National Cancer Institute, Cairo, Egypt
AU  - Omran, A. F.
AU  - El-Sisi, A. H.
DB  - Embase
IS  - 4
KW  - epinephrine
atracurium besilate
fentanyl
lidocaine
propofol
ropivacaine
adult
arm movement
article
blood sampling
breast cancer
clinical article
clinical trial
controlled study
drug safety
female
general anesthesia
glucose blood level
human
hydrocortisone blood level
hypotension
nausea and vomiting
nerve block
nerve stimulation
postoperative pain
postoperative period
skin incision
physiological stress
visual analog scale
LA  - English
M3  - Article
N1  - L44783613
2006-12-07
PY  - 2005
SN  - 1110-1849
SP  - 295-300
ST  - Nerve stimulator-guided thoracic paravertebral ropivacaine versus general anaesthesia: Effect on stress response to breast cancer surgery
T2  - Egyptian Journal of Anaesthesia
TI  - Nerve stimulator-guided thoracic paravertebral ropivacaine versus general anaesthesia: Effect on stress response to breast cancer surgery
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L44783613&from=export
VL  - 21
ID  - 1258
ER  - 

TY  - JOUR
AB  - Context Few studies have examined the prevalence and severity of treatment-induced neuropathic symptoms in patients across different cancer types. Objectives This study aimed to report the prevalence of numbness/tingling (N/T) and neuropathic pain in patients with colorectal cancer (CRC) vs. other cancers, describe the prevalence of moderate-to-severe N/T by specific clinical variables, and examine factors associated with the presence of these symptoms. Methods A total of 3106 outpatients with colorectal (n = 718), breast (n = 1544), lung (n = 524), or prostate (n = 320) cancer were enrolled at any point in their treatment. Assessments were conducted at the initial visit and 28-35 days later. Patients reported pain and N/T; clinicians reported mechanism of pain and ranked the top three symptoms causing difficulties. Results Moderate-to-severe N/T was higher in patients with CRC relative to other cancer types (25.8% vs. 17.1%, P < 0.001); 25% vs. 10.5% of clinicians rated N/T as a top three symptom for patients with CRC relative to other cancers (P < 0.001). The prevalence of neuropathic pain was comparable between patients with CRC and other cancers (P = 0.654). Patients with CRC, longer duration of cancer, prior therapy, on current therapy, older patients, and patients of black race experienced worse N/T. Conclusion Patients with CRC experience significantly higher rates of N/T but comparable neuropathic pain, relative to patients with other cancers. Awareness of the prevalence and severity of neuropathic symptoms and their associated risk factors in this patient population is critical for both clinicians and patients. © 2015 American Academy of Hospice and Palliative Medicine.
AD  - Department of General Oncology, University of Texas M. D. Anderson Cancer Center, Unit 410, 1515 Holcombe Boulevard, Houston, TX 77030, United States
Department of Biostatistics and Computational Biology, Dana Farber Cancer Institute, Boston, MA, United States
Breast and Oncology Departments, Mayo Clinic, Rochester, MN, United States
National Cancer Institute, Rockville, MD, United States
Marshfield Clinic, Marshfield, WI, United States
AU  - Lewis, M. A.
AU  - Zhao, F.
AU  - Jones, D.
AU  - Loprinzi, C. L.
AU  - Brell, J.
AU  - Weiss, M.
AU  - Fisch, M. J.
DB  - Scopus
DO  - 10.1016/j.jpainsymman.2014.11.300
IS  - 6
KW  - Colorectal cancer
neuropathic pain
neuropathy
numbness/tingling
oxaliplatin
M3  - Article
N1  - Cited By :12
Export Date: 22 March 2021
PY  - 2015
SP  - 1016-1024
ST  - Neuropathic symptoms and their risk factors in medical oncology outpatients with colorectal vs. breast, lung, or prostate cancer: Results from a prospective multicenter study
T2  - Journal of Pain and Symptom Management
TI  - Neuropathic symptoms and their risk factors in medical oncology outpatients with colorectal vs. breast, lung, or prostate cancer: Results from a prospective multicenter study
UR  - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84931957205&doi=10.1016%2fj.jpainsymman.2014.11.300&partnerID=40&md5=4ff3d3e1c99b7cb4564324f3f3d7e6d3
VL  - 49
ID  - 2373
ER  - 

TY  - JOUR
AN  - 16705120
AU  - Whitworth, A.
DA  - May 17
DO  - 10.1093/jnci/djj223
DP  - NLM
ET  - 2006/05/18
IS  - 10
KW  - African Americans/*genetics/*statistics & numerical data
Breast Neoplasms/mortality/pathology
Clinical Trials as Topic
Colorectal Neoplasms/drug therapy
Female
*Health Services Accessibility
Humans
Male
Minority Groups/*statistics & numerical data
Neoplasms/*genetics/*mortality/therapy
Patient Selection
*Poverty
Trust
United States/epidemiology
LA  - eng
N1  - 1460-2105
Whitworth, Ariel
News
United States
J Natl Cancer Inst. 2006 May 17;98(10):669. doi: 10.1093/jnci/djj223.
PY  - 2006
SN  - 0027-8874
SP  - 669
ST  - New research suggests access, genetic differences play role in high minority cancer death rate
T2  - J Natl Cancer Inst
TI  - New research suggests access, genetic differences play role in high minority cancer death rate
VL  - 98
ID  - 568
ER  - 

TY  - JOUR
AN  - 106170747. Language: English. Entry Date: 20071012. Revision Date: 20150711. Publication Type: Journal Article. Journal Subset: Biomedical
DB  - CINAHL Complete
DP  - EBSCOhost
IS  - 9
KW  - Adolescence
Aged -- Legislation and Jurisprudence
Antibodies, Monoclonal -- Therapeutic Use
Black Persons
Breast Neoplasms -- Risk Factors
Cancer Screening -- Trends
Capecitabine -- Therapeutic Use
Cervix Neoplasms -- Prevention and Control
Child
Child, Preschool
Childhood Neoplasms -- Complications
Colonography, Computed Tomographic -- Utilization
Colorectal Neoplasms -- Drug Therapy
Cryptorchidism -- Therapy
Drug Design
Erythropoietin -- Adverse Effects
Female
Great Britain
Infant
Infant, Newborn
Male
Medical Organizations
Neoplasms -- Drug Therapy
Neoplasms, Second Primary -- Risk Factors
Prostatic Neoplasms -- Prevention and Control
Research Subject Recruitment
Resuscitation Orders -- Legislation and Jurisprudence
Stomach Neoplasms -- Drug Therapy
Testicular Neoplasms -- Risk Factors
Tumor Markers, Biological
United Kingdom
N1  - Blind Peer Reviewed; Editorial Board Reviewed; Europe; Expert Peer Reviewed; Peer Reviewed; UK & Ireland. NLM UID: 9005373.
PY  - 2007
SN  - 0959-8049
SP  - 1337-1340
ST  - News... news... news
T2  - European Journal of Cancer
TI  - News... news... news
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106170747&site=ehost-live&scope=site
VL  - 43
ID  - 2007
ER  - 

TY  - JOUR
AB  - Approximately 50% of African American (AA) smokers are light smokers (smoke <= 10 cigarettes a day), yet this group is understudied despite being at-risk of smoking-related death and disease. This study is a secondary analysis of data from a clinical trial that assessed the efficacy of nicotine gum and counseling for smoking cessation among African American light smokers. The purpose of the current paper was to assess nicotine dependence among participants enrolled in the clinical trial using three measures of nicotine dependence. The Cigarette Dependence Scale (CDS), the Fagerstrom Test for Nicotine Dependence Scale (FTND), and the Nicotine Dependence Syndrome Scale (NDSS) were administered to 700 participants (67% female; mean age=45 years). Exhaled carbon monoxide (CO) and serum cotinine were assessed. The CDS showed the strongest association with biochemical markers (r=0.28 for cotinine and 0.25 for CO). Factor analysis of the NDSS revealed five factors: drive, priority, tolerance, continuity, and stereotypy. Compared to those who smoked 1-5 CPD, smokers who averaged 6-10 CPD scored higher on all three dependence (p < 0.001) and two biochemical measures (p < 0.001), and on three of the five NDSS subscales (Drive, p < 0.001; Stereotypy, p < 0.01; and Tolerance, p < 0.01). Given the different domains tapped by each instrument, the use of multiple measures might yield the most comprehensive assessment of nicotine dependence. Results suggest the validity of these scales for African American light smokers and point to the need for sensitivity to differential levels of nicotine dependence among subgroups of light smokers. (C) 2007 Published by Elsevier Ltd.
AN  - WOS:000249279000002
AU  - Okuyemi, K. S.
AU  - Pulvers, K. M.
AU  - Cox, L. S.
AU  - Thomas, J. L.
AU  - Kaur, H.
AU  - Mayo, M. S.
AU  - Nazir, N.
AU  - Etter, J. F.
AU  - Ahluwalia, J. S.
DA  - Oct
DO  - 10.1016/j.addbeh.2007.01.002
IS  - 10
N1  - 17307303
PY  - 2007
SN  - 0306-4603
SP  - 1989-2002
ST  - Nicotine dependence among African American light smokers: A comparison of three scales
T2  - Addictive Behaviors
TI  - Nicotine dependence among African American light smokers: A comparison of three scales
VL  - 32
ID  - 3183
ER  - 

TY  - JOUR
AB  - Poor compliance with conventional asthma medications remains a major problem in achieving asthma control. Nigella sativa oil (NSO) is used traditionally for many inflammatory conditions such as asthma. We aimed to investigate the benefits of NSO supplementation on clinical and inflammatory parameters of asthma. NSO capsules 500 mg twice daily for 4 weeks were used as a supplementary treatment in a randomized, double-blind, placebo-controlled trial in asthmatics (clinicaltrials.gov: NCT02407262). The primary outcome was Asthma Control Test score. The secondary outcomes were pulmonary function test, blood eosinophils and total serum Immunoglobulin E. Between 1 June and 30 December 2015, 80 asthmatics were enrolled, with 40 patients in each treatment and placebo groups. After 4 weeks, ten patients had withdrawn from each group. Compared with placebo, NSO group showed a significant improvement in mean Asthma Control Test score 21.1 (standard deviation = 2.6) versus 19.6 (standard deviation = 3.7) (p = 0.044) and a significant reduction in blood eosinophils by −50 (−155 to −1) versus 15 (−60 to 87) cells/μL (p = 0.013). NSO improved forced expiratory volume in 1 second as percentage of predicted value by 4 (−1.25 to 8.75) versus 1 (−2 to 5) but non-significant (p = 0.170). This randomized, double-blind, placebo-controlled trial demonstrated that NSO supplementation improves asthma control with a trend in pulmonary function improvement. This was associated with a remarkable normalization of blood eosinophlia. Future studies should follow asthmatics for longer periods in a multicentre trial. Copyright © 2017 John Wiley & Sons, Ltd. Copyright © 2017 John Wiley & Sons, Ltd.
AD  - Research Cluster Biodiversity and Medicines, UCL School of Pharmacy, University College London, London, United Kingdom
Department of Natural Products & Alternative Medicine, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia
Department of Practice and Policy, UCL School of Pharmacy, University College London, London, United Kingdom
Allergy and Clinical Immunology Division, Department of Internal Medicine, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia
Respiratory Unit, Department of Internal Medicine, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia
Department of Medicine, King Abdulaziz University Hospital, Jeddah, Saudi Arabia
Department of Family and Community Medicine, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia
Centre of Excellence in Genomic Medicine Research, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia
AU  - Koshak, A.
AU  - Wei, L.
AU  - Koshak, E.
AU  - Wali, S.
AU  - Alamoudi, O.
AU  - Demerdash, A.
AU  - Qutub, M.
AU  - Pushparaj, P. N.
AU  - Heinrich, M.
DB  - Scopus
DO  - 10.1002/ptr.5761
IS  - 3
KW  - allergy
asthma
black seed
clinical trial
eosinophils
Nigella sativa
M3  - Article
N1  - Cited By :20
Export Date: 22 March 2021
PY  - 2017
SP  - 403-409
ST  - Nigella sativa Supplementation Improves Asthma Control and Biomarkers: A Randomized, Double-Blind, Placebo-Controlled Trial
T2  - Phytotherapy Research
TI  - Nigella sativa Supplementation Improves Asthma Control and Biomarkers: A Randomized, Double-Blind, Placebo-Controlled Trial
UR  - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85014361264&doi=10.1002%2fptr.5761&partnerID=40&md5=ea488f45ab665dcfc648bfb60a851cd3
VL  - 31
ID  - 2320
ER  - 

TY  - JOUR
AB  - Background: Mild‐to‐moderate bone pain is the most commonly reported adverse event (AE) associated with PEG. Both N (an NSAID) and L (an antihistamine) are used in the clinic to reduce this AE, but data on the efficacy of these interventions are limited.Methods: In this openlabel study (NCT01712009 ), women ≥ 18 years of age with newly diagnosed stage I‐III breast cancer and ECOG performance status ≤ 2 who were planning ≥ 4 cycles of adjuvant or neoadjuvant chemo with PEG support starting in cycle 1 were randomized 1:1:1 to receive prophylactic N, L, or no prophylaxis (NP). Pts received N (500 mg BID) or L (10 mg QD) for 5 days beginning the day of PEG administration in each of the first 4 chemo cycles. PEG (6 mg) was administered in each cycle 24‐72 hours after chemo. Primary endpoint: all‐grade bone pain in cycle 1 from AE reporting. Results: Pts enrolled: 600. White 83.0%, black 14.1%, Asian 1.2%. Mean (SD) age: 54.2 (11.1) years. Stage I/II/III: 25.6%/50.1%/24.4%. Difference (95% CI) in all‐grade bone pain in cycle 1: NP vs N ‐6.3% (‐16.7%, 4.1%), NP vs L ‐4.1% (‐14.5%, 6.3%), N vs L 2.2% (‐8.0%, 12.4%). See table for additional results. Conclusions: Levels of allgrade and grade 3/4 bone pain were comparable in the N, L, and NP groups, but there was a trend toward lower pain with N and L. Both N and L had tolerable toxicity; L was associated. (Table Presented).
AN  - CN-01780673
AU  - Kirshner, J. J.
AU  - Guinigundo, A. S.
AU  - Vanni, L.
AU  - Maxwell, C. L.
AU  - Reiner, M.
AU  - Garcia, J.
AU  - Morrow, P. K. H.
KW  - *bone pain
*breast cancer
*chemotherapy
*drug therapy
Adult
Adverse drug reaction
Clinical trial
Controlled clinical trial
Controlled study
Diagnosis
Hospital
Human
Major clinical study
Neoadjuvant therapy
Prophylaxis
Randomized controlled trial
Toxicity
M3  - Journal: Conference Abstract
PY  - 2016
ST  - Nolan: a randomized, phase II study to estimate the effect of prophylactic naproxen (N) or loratadine (L) vs no intervention on bone pain in 600 patients (pts) with earlystage breast cancer receiving chemotherapy (chemo) and pegfilgrastim (PEG)
T2  - Journal of clinical oncology
TI  - Nolan: a randomized, phase II study to estimate the effect of prophylactic naproxen (N) or loratadine (L) vs no intervention on bone pain in 600 patients (pts) with earlystage breast cancer receiving chemotherapy (chemo) and pegfilgrastim (PEG)
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01780673/full
VL  - 34
ID  - 1642
ER  - 

TY  - JOUR
AB  - In postmenopausal women estrogens in combination with progestins have beneficial effects on climacteric complaints and on osteoporosis but this hormone replacement therapy (HRT) bears the risk of increased mammary carcinomas and cardiovascular diseases. Phytoestrogens at low doses have little or no effects on climacteric complaints, at high doses they mimic the effects of estrogens. Therefore other plant derived substances are currently intensively investigated. Extracts of the rhizome of black cohosh (Cimicifuga racemosa=CR) did not bind to estrogen receptors and were shown to be devoid of estrogenic effects on mammary cancer cells in vitro and on mammary gland and uterine histology in ovariectomized rats. In addition in this rat model the special extract CR BNO 1055 inhibited the occurrence of hot flushes and development of osteoporosis. In postmenopausal women CR BNO 1055 reduced major climacteric complaints as effectively as conjugated estrogens and significantly more than placebo. Similar data were published for other European CR preparations whereas 2 US American preparations were ineffective. This was most likely due to the too high doses or due to the adulteration with Asian Cimicifuga preparations. In all European studies neither effects in the uterus nor in mammary glands were observed. The effective compounds in CR are most likely neurotransmitter-mimetic in nature: dopaminergic, noradrenergic, serotoninergic and GABAergic effects were demonstrated and some have been structurally identified. We conclude that CR extracts at low doses are effective to ameliorate climacteric complaints but are devoid of adverse estrogenic effects. These finding strengthens the role of CR extracts as substitutes for HRT. This article is part of a special issue entitled: Special Issue on Phytoestrogens.
AD  - Hormone and Obesity Center Goettingen, Bahnhofsallee 1d, 37081 Göttingen, Germany. Electronic address: w.wuttke@verdevital.de.
AN  - 23459142
AU  - Wuttke, W.
AU  - Jarry, H.
AU  - Haunschild, J.
AU  - Stecher, G.
AU  - Schuh, M.
AU  - Seidlova-Wuttke, D.
DA  - Jan
DO  - 10.1016/j.jsbmb.2013.02.007
DP  - NLM
ET  - 2013/03/06
KW  - Animals
Cimicifuga
Clinical Trials as Topic
Endometrium/drug effects
Estrogen Replacement Therapy
Female
Hot Flashes/drug therapy
Humans
Mammary Glands, Human/drug effects
Phytoestrogens/*pharmacology
Plant Extracts/*pharmacology
Postmenopause
Black cohosh
Climacteric complaints
Estrogen
Mammary gland
Neurotransmitters
Uterus
LA  - eng
N1  - 1879-1220
Wuttke, Wolfgang
Jarry, Hubertus
Haunschild, Jutta
Stecher, Guenter
Schuh, Markus
Seidlova-Wuttke, Dana
Journal Article
Review
England
J Steroid Biochem Mol Biol. 2014 Jan;139:302-10. doi: 10.1016/j.jsbmb.2013.02.007. Epub 2013 Feb 28.
PY  - 2014
SN  - 0960-0760
SP  - 302-10
ST  - The non-estrogenic alternative for the treatment of climacteric complaints: Black cohosh (Cimicifuga or Actaea racemosa)
T2  - J Steroid Biochem Mol Biol
TI  - The non-estrogenic alternative for the treatment of climacteric complaints: Black cohosh (Cimicifuga or Actaea racemosa)
VL  - 139
ID  - 336
ER  - 

TY  - JOUR
AB  - BACKGROUND: Interest in non-hormonal therapies for the treatment of menopausal symptoms has increased since the publication of adverse effects of estrogen replacement therapy. OBJECTIVE: To provide information on the efficacy of non-hormonal therapies for menopausal vasomotor symptoms based on evidence from published randomised controlled studies. METHODS: The Cochrane Database of Systematic Reviews (CDSR), MEDLINE, Alternative Therapies in Health and Medicine database (ATHMD) and Allied and Complementary Medicine database (AMED) were searched for randomised controlled trials in the English language reporting data on treatment of menopausal vasomotor symptoms. Trials including cancer breast patients were included. RESULTS: Our search identified 58 randomised controlled trials of which 11 involved the use of clonidine, six for SSRIs, four for gabapentin, seven for black cohosh, seven for red clover, 18 for phytoestrogens, two for ginseng, one for evening primrose, one for dong quai and one for vitamin E. Most trials had methodological deficiencies. CONCLUSION: There is evidence that clonidine, paroxetine, venlafaxine, gabapentin and black cohosh may be beneficial in the treatment of menopausal vasomotor symptoms in some women. Current evidence does not support the use of fluoxetine, red clover, phytoestrogens, Ginseng, evening primrose, dong quai and vitamin E. The side effects profile of these therapies should be considered.
AD  - Royal Worcestershire Hospital, Worcester, UK.
AN  - 17593379
AU  - Cheema, D.
AU  - Coomarasamy, A.
AU  - El-Toukhy, T.
DA  - Nov
DO  - 10.1007/s00404-007-0390-9
DP  - NLM
ET  - 2007/06/27
IS  - 5
KW  - Amines/therapeutic use
Cimicifuga
Clonidine/therapeutic use
Cyclohexanecarboxylic Acids/therapeutic use
Female
Gabapentin
Hot Flashes/*therapy
Humans
Menopause
Middle Aged
Phytoestrogens/*therapeutic use
*Phytotherapy
*Plants, Medicinal
Randomized Controlled Trials as Topic
Trifolium
gamma-Aminobutyric Acid/therapeutic use
LA  - eng
N1  - Cheema, Deepti
Coomarasamy, Arri
El-Toukhy, Tarek
Journal Article
Review
Germany
Arch Gynecol Obstet. 2007 Nov;276(5):463-9. doi: 10.1007/s00404-007-0390-9. Epub 2007 Jun 26.
PY  - 2007
SN  - 0932-0067 (Print)
0932-0067
SP  - 463-9
ST  - Non-hormonal therapy of post-menopausal vasomotor symptoms: a structured evidence-based review
T2  - Arch Gynecol Obstet
TI  - Non-hormonal therapy of post-menopausal vasomotor symptoms: a structured evidence-based review
VL  - 276
ID  - 523
ER  - 

TY  - JOUR
AB  - Background & Aims: Although hepatitis B and C have been the main drivers of hepatocellular carcinoma (HCC), nonalcoholic steatohepatitis (NASH) has recently become an important cause of HCC. The aim of this study was to assess the causes of HCC among liver transplant (LT) candidates in the United States. Methods: The Scientific Registry of Transplant Recipients (2002–2016) was used to estimate the trends in prevalence of HCC in LT candidates with the most common types of chronic liver disease: alcoholic liver disease (ALD), chronic hepatitis B (CHB), chronic hepatitis C, and NASH. Results: 158,347 adult LT candidates were included. Of these, 26,121 (16.5%) had HCC; this proportion increased from 6.4% (2002) to 23.0% (2016) (trend P <.0001). Over the study period, CHC remained the most common etiology for HCC (65%). The proportions of HCC accounted for by CHC and ALD remained stable (both trend P >.10), the proportion of CHB decreased 3.1-fold (P <.0001), while the proportion of NASH in HCC increased 7.7-fold (from 2.1% to 16.2%; P <.0001). Furthermore, since 2002, the prevalence of HCC in LT candidates with NASH increased 11.8-fold, while this rate increased 6.0-fold in CHB, 3.4-fold in ALD, and 2.3-fold in CHC (all P <.0001); the increasing trend in NASH was steeper than that for any other etiology (P <.0001 in a trend regression model). The proportion of LT candidates with HCC who ultimately received a transplant or died while waiting did not differ between etiologies (P >.05). Conclusions: Nonalcoholic steatohepatitis is the most rapidly growing cause of HCC among US patients listed for liver transplantation.
AD  - Z. Younossi, Betty and Guy Beatty Center for Integrated Research, Inova Health System, Claude Moore Health Education and Research Building, 3300 Gallows Road, Falls Church, VA, United States
AU  - Younossi, Z.
AU  - Stepanova, M.
AU  - Ong, J. P.
AU  - Jacobson, I. M.
AU  - Bugianesi, E.
AU  - Duseja, A.
AU  - Eguchi, Y.
AU  - Wong, V. W.
AU  - Negro, F.
AU  - Yilmaz, Y.
AU  - Romero-Gomez, M.
AU  - George, J.
AU  - Ahmed, A.
AU  - Wong, R.
AU  - Younossi, I.
AU  - Ziayee, M.
AU  - Afendy, A.
DB  - Embase
Medline
DO  - 10.1016/j.cgh.2018.05.057
IS  - 4
KW  - adult
age distribution
alcohol liver disease
article
ascites
bacterial peritonitis
Black person
bleeding
cancer mortality
cancer prognosis
cancer recurrence
cancer staging
cancer surgery
cardiovascular disease
cause of death
cerebrovascular accident
chronic hepatitis B
chronic hepatitis C
chronic obstructive lung disease
comorbidity
coronary artery disease
deterioration
female
follow up
graft failure
graft recipient
hepatic encephalopathy
hospital admission
hospital discharge
human
hypertension
infection
kidney failure
liver cell carcinoma
liver cirrhosis
liver graft
liver transplantation
longitudinal study
major clinical study
male
malignant neoplasm
Model For End Stage Liver Disease Score
mortality risk
multiple organ failure
non insulin dependent diabetes mellitus
nonalcoholic fatty liver
obesity
patient dropout
postoperative complication
prevalence
respiratory failure
risk assessment
risk factor
sex ratio
surgical mortality
surgical risk
trend study
United States
variceal bleeding
LA  - English
M3  - Article
N1  - L2001507716
2019-02-01
2019-02-27
PY  - 2019
SN  - 1542-7714
1542-3565
SP  - 748-755.e3
ST  - Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates
T2  - Clinical Gastroenterology and Hepatology
TI  - Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L2001507716&from=export
http://dx.doi.org/10.1016/j.cgh.2018.05.057
VL  - 17
ID  - 854
ER  - 

TY  - JOUR
AB  - Purpose: To apply our convolutional neural network (CNN) algorithm to predict neoadjuvant chemotherapy (NAC) response using the I-SPY TRIAL breast MRI dataset. Methods: From the I-SPY TRIAL breast MRI database, 131 patients from 9 institutions were successfully downloaded for analysis. First post-contrast MRI images were used for 3D segmentation using 3D slicer. Our CNN was implemented entirely of 3 × 3 convolutional kernels and linear layers. The convolutional kernels consisted of 6 residual layers, totaling 12 convolutional layers. Dropout with a 0.5 keep probability and L2 normalization was utilized. Training was implemented by using the Adam optimizer. A 5-fold cross validation was used for performance evaluation. Software code was written in Python using the TensorFlow module on a Linux workstation with one NVidia Titan X GPU. Results: Of 131 patients, 40 patients achieved pCR following NAC (group 1) and 91 patients did not achieve pCR following NAC (group 2). Diagnostic accuracy of our CNN two classification model distinguishing patients with pCR vs non-pCR was 72.5 (SD ± 8.4), with sensitivity 65.5% (SD ± 28.1) and specificity of 78.9% (SD ± 15.2). The area under a ROC Curve (AUC) was 0.72 (SD ± 0.08). Conclusion: It is feasible to use our CNN algorithm to predict NAC response in patients using a multi-institution dataset.
AD  - R. Ha, Breast Imaging Section, New York Presbyterian Hospital, Columbia University Medical Center, 622 West 168th Street, PB-1-301, New York, NY, United States
AU  - Liu, M. Z.
AU  - Mutasa, S.
AU  - Chang, P.
AU  - Siddique, M.
AU  - Jambawalikar, S.
AU  - Ha, R.
DB  - Embase
Medline
DO  - 10.1016/j.mri.2020.08.021
KW  - laboratory software
NVidia Titan X GPU
Pythonidae
radiology workstation
TensorFlow module
adult
African American
Alaska Native
American Indian
area under the curve
article
Asian
brain size
breast cancer
Caucasian
controlled study
convolutional neural network
diagnostic accuracy
diagnostic test accuracy study
dynamic contrast-enhanced magnetic resonance imaging
histogram
human
institutional review
learning algorithm
major clinical study
middle aged
nuclear magnetic resonance imaging
Pacific Islander
prediction
priority journal
probability
Python
LA  - English
M3  - Article
N1  - L2007704030
2020-09-09
2020-10-28
PY  - 2020
SN  - 1873-5894
0730-725X
SP  - 148-151
ST  - A novel CNN algorithm for pathological complete response prediction using an I-SPY TRIAL breast MRI database
T2  - Magnetic Resonance Imaging
TI  - A novel CNN algorithm for pathological complete response prediction using an I-SPY TRIAL breast MRI database
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L2007704030&from=export
http://dx.doi.org/10.1016/j.mri.2020.08.021
VL  - 73
ID  - 782
ER  - 

TY  - JOUR
AB  - BACKGROUND: Black men have the greatest burden of premature death and disability from hypertension (HTN) in the United States, and the highest incidence and mortality from colorectal cancer (CRC). While several clinical trials have reported beneficial effects of lifestyle changes on blood pressure (BP) reduction, and improved CRC screening with patient navigation (PN), the effectiveness of these approaches in community-based settings remains understudied, particularly among Black men. METHODS/DESIGN: MISTER B is a two-parallel-arm randomized controlled trial that will compare the effect of a motivational interviewing tailored lifestyle intervention (MINT) versus a culturally targeted PN intervention on improvement of BP and CRC screening among black men aged ≥50 with uncontrolled HTN who are eligible for CRC screening. Approximately 480 self-identified black men will be randomly assigned to one of the two study conditions. This innovative research design allows each intervention to serve as the control for the other. Specifically, the MINT arm is the control condition for the PN arm, and vice-versa. This novel, simultaneous testing of two community-based interventions in a randomized fashion is an economical and yet rigorous strategy that also enhances the acceptability of the project. Participants will be recruited during scheduled screening events at barbershops in New York City. Trained research assistants will conduct the lifestyle intervention, while trained community health workers will deliver the PN intervention. The primary outcomes will be 1) within-patient change in systolic and diastolic BP from baseline to six months and 2) CRC screening rates at six months. DISCUSSION: This innovative study will provide a unique opportunity to test two interventions for two health disparities simultaneously in community-based settings. Our study is one of the first to test culturally targeted patient navigation for CRC screening among black men in barbershops. Thus, our study has the potential to improve the reach of hypertension control and cancer prevention efforts within a high-risk population that is under-represented in primary care settings. TRIAL REGISTRATION: ClinicalTrials.gov, NCT01092078.
AD  - Center for Healthful Behavior Change, New York University School of Medicine, 227 E, 30th St,, 6th Floor, Room 637, New York, NY 10016, USA. Joseph.ravenell@nyumc.org.
AN  - 24011142
AU  - Ravenell, J.
AU  - Thompson, H.
AU  - Cole, H.
AU  - Plumhoff, J.
AU  - Cobb, G.
AU  - Afolabi, L.
AU  - Boutin-Foster, C.
AU  - Wells, M.
AU  - Scott, M.
AU  - Ogedegbe, G.
C2  - PMC3844539
DA  - Sep 8
DO  - 10.1186/1745-6215-14-287
DP  - NLM
ET  - 2013/09/10
KW  - African Americans/*psychology
Age Factors
Barbering
Blood Pressure
Clinical Protocols
Colorectal Neoplasms/diagnosis/ethnology/*prevention & control/psychology
Community Health Services
Cultural Characteristics
*Early Detection of Cancer
Health Knowledge, Attitudes, Practice/*ethnology
Health Promotion
Health Status Disparities
Healthcare Disparities/ethnology
Humans
Hypertension/diagnosis/ethnology/physiopathology/psychology/*therapy
Male
Middle Aged
*Motivational Interviewing
New York City
Patient Navigation
Patient Selection
Predictive Value of Tests
*Research Design
Risk Factors
*Risk Reduction Behavior
Sex Factors
Time Factors
Treatment Outcome
LA  - eng
N1  - 1745-6215
Ravenell, Joseph
Thompson, Hayley
Cole, Helen
Plumhoff, Jordan
Cobb, Gia
Afolabi, Lola
Boutin-Foster, Carla
Wells, Martin
Scott, Marian
Ogedegbe, Gbenga
P60 MD003421/MD/NIMHD NIH HHS/United States
R01 HL096946/HL/NHLBI NIH HHS/United States
5P60MD003421/MD/NIMHD NIH HHS/United States
Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Trials. 2013 Sep 8;14:287. doi: 10.1186/1745-6215-14-287.
PY  - 2013
SN  - 1745-6215
SP  - 287
ST  - A novel community-based study to address disparities in hypertension and colorectal cancer: a study protocol for a randomized control trial
T2  - Trials
TI  - A novel community-based study to address disparities in hypertension and colorectal cancer: a study protocol for a randomized control trial
VL  - 14
ID  - 319
ER  - 

TY  - JOUR
AB  - PURPOSE: There has been a paucity of interventions developed for African American women to address persistent health disparities between African American and Caucasian breast cancer patients. We developed and piloted a technologically innovative, culturally targeted, cancer-communication intervention for African American breast cancer patients using African American breast cancer survivor stories. METHODS: We rated 917 clips from a video library of survivors' stories for likability, clarity and length, and emotional impact (scaled responses) and categorized each clip by theme (Coping, Support and Relationships, Healthcare Experiences, Follow-up Care, Quality of Life, and Treatment Side Effects). We selected 207 clips told by 35 survivors (32-68 years old; 4-30 years after diagnosis), fitting one of 12 story topics, for inclusion in the interactive video program loaded onto a touch-screen computer. Videos can be searched by storyteller or story topics; stories with the strongest emotional impact were displayed first in the video program. RESULTS: We pilot tested the video program with ten African American breast cancer survivors (mean age, 54; range 39-68 years), who, after training, watched videos and then evaluated the stories and video-program usability. Survivor stories were found to be "interesting and informative," and usability was rated highly. Participants identified with storytellers (e.g., they "think a lot like me," "have values like mine") and agreed that the stories convinced them to receive recommended surveillance mammograms. CONCLUSIONS: This novel, cancer-communication technology using survivor stories was very favorably evaluated by breast cancer survivors and is now being tested in a randomized controlled clinical trial. IMPLICATIONS FOR CANCER SURVIVORS: Breast cancer survivors can draw support and information from a variety of sources, including from other breast cancer survivors. We developed the survivor stories video program specifically for African American survivors to help improve their quality of life and adherence to follow-up care. Breast cancer survivors' experiences with treatment and living with cancer make them especially credible messengers of cancer information. Our novel, interactive technology is being tested in a randomized controlled trial and will be more broadly disseminated to reach a wider audience.
AD  - Washington University School of Medicine, 660 S. Euclid, Saint Louis, MO, 63110, USA, mperez@dom.wustl.edu.
AN  - 24030573
AU  - Pérez, M.
AU  - Sefko, J. A.
AU  - Ksiazek, D.
AU  - Golla, B.
AU  - Casey, C.
AU  - Margenthaler, J. A.
AU  - Colditz, G.
AU  - Kreuter, M. W.
AU  - Jeffe, D. B.
C2  - PMC3945406
C6  - NIHMS524265
DA  - Mar
DO  - 10.1007/s11764-013-0308-4
DP  - NLM
ET  - 2013/09/14
IS  - 1
KW  - Adult
African Americans/*psychology
Aged
Attitude to Health
Early Diagnosis
Emotions
Female
Health Promotion/*methods
*Healthcare Disparities
Humans
Mammography/psychology
Middle Aged
*Narration
Neoplasms/*psychology
Patient Acceptance of Health Care
Patient Compliance
Patient Education as Topic/*methods
Pilot Projects
Randomized Controlled Trials as Topic/methods
Research Design
Socioeconomic Factors
Survivors/*psychology
Video Recording
LA  - eng
N1  - 1932-2267
Pérez, Maria
Sefko, Julianne A
Ksiazek, Deb
Golla, Balaji
Casey, Chris
Margenthaler, Julie A
Colditz, Graham
Kreuter, Matthew W
Jeffe, Donna B
P30 CA091842/CA/NCI NIH HHS/United States
P50 CA095815/CA/NCI NIH HHS/United States
2P50 CA095815/CA/NCI NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
J Cancer Surviv. 2014 Mar;8(1):21-30. doi: 10.1007/s11764-013-0308-4. Epub 2013 Sep 13.
PY  - 2014
SN  - 1932-2259 (Print)
1932-2259
SP  - 21-30
ST  - A novel intervention using interactive technology and personal narratives to reduce cancer disparities: African American breast cancer survivor stories
T2  - J Cancer Surviv
TI  - A novel intervention using interactive technology and personal narratives to reduce cancer disparities: African American breast cancer survivor stories
VL  - 8
ID  - 317
ER  - 

TY  - JOUR
AB  - The Selenium and Vitamin E Cancer Prevention Trial (SELECT) randomized 35,533 healthy men, >55 yr old (>50 yr if African American), with normal digital rectal exams and prostate specific antigens <4 ng/ml to 1) 200 μg/day l-selenomethionine, 2) 400 IU/day all-rac-alpha-tocopheryl acetate (vitamin E), 3) both supplements, or 4) placebo for 7 to 12 yr. The hypotheses underlying SELECT, that selenium and vitamin E individually and together decrease prostate cancer incidence, derived from epidemiologic and laboratory evidence and significant secondary endpoints in the Nutritional Prevention of Cancer (selenium) and Alpha-Tocopherol Beta-Carotene (vitamin E) trials. In SELECT, prostate cancer incidence did not differ among the 4 arms: hazard ratios [99% confidence intervals (CIs)] for prostate cancer were 1.13 (99% CI = 0.95-1.35, P = 0.06; n = 473) for vitamin E, 1.04 (99% CI = 0.87-1.24, P = 0.62; n = 432) for selenium, and 1.05 (99% CI = 0.88-1.25, P = 0.52; n = 437) for selenium + vitamin E vs. 1.00 (n = 416) for placebo. Statistically nonsignificant increased risks of prostate cancer with vitamin E alone [relative risk (RR) = 1.13, P = 0.06) and newly diagnosed Type 2 diabetes mellitus with selenium alone (RR = 1.07, P = 0.16) were observed. SELECT data show that neither selenium nor vitamin E, alone or together, in the doses and formulations used, prevented prostate cancer in this heterogeneous population of healthy men.
AD  - Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland 20892, USA. dunnb@mail.nih.gov
AN  - 20924966
AU  - Dunn, B. K.
AU  - Richmond, E. S.
AU  - Minasian, L. M.
AU  - Ryan, A. M.
AU  - Ford, L. G.
DO  - 10.1080/01635581.2010.509833
DP  - NLM
ET  - 2010/10/07
IS  - 7
KW  - Aged
Animals
Humans
Male
Middle Aged
Prostatic Neoplasms/*prevention & control
Randomized Controlled Trials as Topic
Selenomethionine/*administration & dosage
Vitamin E/*administration & dosage
LA  - eng
N1  - 1532-7914
Dunn, Barbara K
Richmond, Ellen S
Minasian, Lori M
Ryan, Anne M
Ford, Leslie G
Journal Article
Review
United States
Nutr Cancer. 2010;62(7):896-918. doi: 10.1080/01635581.2010.509833.
PY  - 2010
SN  - 0163-5581
SP  - 896-918
ST  - A nutrient approach to prostate cancer prevention: The Selenium and Vitamin E Cancer Prevention Trial (SELECT)
T2  - Nutr Cancer
TI  - A nutrient approach to prostate cancer prevention: The Selenium and Vitamin E Cancer Prevention Trial (SELECT)
VL  - 62
ID  - 411
ER  - 

TY  - JOUR
AB  - Healthy lifestyle behaviors are recommended to reduce cancer risk and overall mortality. Adherence to cancer-preventive health behaviors and subsequent cancer risk has not been evaluated in a diverse sample of postmenopausal women. We examined the association between the American Cancer Society (ACS) Nutrition and Physical Activity Cancer Prevention Guidelines score and risk of incident cancer, cancer-specific mortality, and all-cause mortality in 65,838 postmenopausal women enrolled in the Women's Health Initiative Observational Study. ACS guidelines scores (0-8 points) were determined from a combined measure of diet, physical activity, body mass index (current and at age 18 years), and alcohol consumption. After a mean follow-up of 12.6 years, 8,632 incident cancers and 2,356 cancer deaths were identified. The highest ACS guidelines scores compared with the lowest were associated with a 17% lower risk of any cancer [HR, 0.83; 95% confidence interval (CI), 0.75-0.92], 22% lower risk of breast cancer (HR, 0.78; 95% CI, 0.67-0.92), 52% lower risk of colorectal cancer (HR, 0.48; 95% CI, 0.32-0.73), 27% lower risk of all-cause mortality, and 20% lower risk of cancer-specific mortality (HR, 0.80; 95% CI, 0.71-0.90). Associations with lower cancer incidence and mortality were generally strongest among Asian, black, and Hispanic women and weakest among non-Hispanic whites. Behaviors concordant with Nutrition and Physical Activity Cancer Prevention Guidelines were associated with lower risk of total, breast, and colorectal cancers and lower cancer-specific mortality in postmenopausal women. ©2013 American Association for Cancer Research.
AD  - C.A. Thomson, Health Promotion Sciences, Canyon Ranch Center for Prevention and Health Promotion, Mel and Enid Zuckerman College of Public Health, 1295 N. Martin Street, Tucson, AZ 85721, United States
AU  - Thomson, C. A.
AU  - McCullough, M. L.
AU  - Wertheim, B. C.
AU  - Chlebowski, R. T.
AU  - Martinez, M. E.
AU  - Stefanick, M. L.
AU  - Rohan, T. E.
AU  - Manson, J. E.
AU  - Tindle, H. A.
AU  - Ockene, J.
AU  - Vitolins, M. Z.
AU  - Wactawski-Wende, J.
AU  - Sarto, G. E.
AU  - Lane, D. S.
AU  - Neuhouser, M. L.
DB  - Embase
Medline
DO  - 10.1158/1940-6207.CAPR-13-0258
IS  - 1
KW  - estrogen
gestagen
nonsteroid antiinflammatory agent
adult
alcohol consumption
american cancer society physical activity cancer prevention guidelines score
article
Asian
breast cancer
cancer incidence
cancer mortality
cancer prevention
cancer risk
cause of death
colonoscopy
colorectal cancer
endometrium cancer
female
follow up
health behavior
Hispanic
human
lifestyle
lung cancer
middle aged
Black person
non profit organization
nutrition
observational study
ovary cancer
physical activity
postmenopause
practice guideline
priority journal
scoring system
body weight gain
women's health
LA  - English
M3  - Article
N1  - L372114176
2014-01-22
2014-01-27
PY  - 2014
SN  - 1940-6207
1940-6215
SP  - 42-53
ST  - Nutrition and physical activity cancer prevention guidelines, cancer risk, and mortality in the women's health initiative
T2  - Cancer Prevention Research
TI  - Nutrition and physical activity cancer prevention guidelines, cancer risk, and mortality in the women's health initiative
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L372114176&from=export
http://dx.doi.org/10.1158/1940-6207.CAPR-13-0258
http://cancerpreventionresearch.aacrjournals.org/content/7/1/42.full.pdf+html
VL  - 7
ID  - 1042
ER  - 

TY  - JOUR
AB  - BACKGROUND: Differential prostate-specific antigen (PSA) testing practices according to obesity-related comorbid conditions may contribute to inconsistent results in studies of obesity and prostate cancer. We investigated the relationship between obesity and PSA testing, and evaluated the role of prior diagnoses and disease screening on PSA testing patterns. METHODS: Men, 40 and 79 years old and without prior prostate cancer were recruited from 25 health centers in the Southern US (n = 11,558, 85% African-American). An extensive in-person interview measured medical and other characteristics of study participants, including PSA test histories, weight, height, demographics, and disease history. Odds ratios (OR) and (95% confidence intervals) from logistic regression summarized the body mass index (BMI) and PSA test association while adjusting for socio-economic status (SES). RESULTS: BMI between 25 and 40 was significantly associated with recent PSA testing (past 12 months) (OR(25.0-29.9) = 1.23 (1.09, 1.39); OR(30-34.9) = 1.36 (1.18, 1.57); OR(35.0-39.9) = 1.44 (1.18, 1.76); OR(> or =40) = 1.15 (0.87, 1.51)). Prior severe disease diagnoses, such as heart disease, did not influence the obesity and PSA test association. However, adjustment for prior high blood pressure or high cholesterol diagnoses reduced the BMI-PSA testing associations. Physician PSA test recommendations were not associated with BMI, and results did not appreciably vary by race. CONCLUSIONS: Overweight and obese men were preferentially PSA tested within the past 12 months. BMI was not associated with physician screening recommendations. Data suggest that clinical diagnoses related to obesity increase clinical encounters that lead to preferential selection of obese men for prostate cancer diagnosis. This detection effect may bias epidemiologic investigations of obesity and prostate cancer incidence.
AD  - Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, Tennessee, USA. jay.fowke@vanderbilt.edu
AN  - 16752375
AU  - Fowke, J. H.
AU  - Signorello, L. B.
AU  - Underwood, W., 3rd
AU  - Ukoli, F. A.
AU  - Blot, W. J.
DA  - Sep 15
DO  - 10.1002/pros.20377
DP  - NLM
ET  - 2006/06/06
IS  - 13
KW  - Adult
*African Americans
Aged
Body Mass Index
Cohort Studies
*European Continental Ancestry Group
Humans
Hypercholesterolemia/diagnosis/epidemiology
Hypertension/diagnosis/epidemiology
Male
Mass Screening/statistics & numerical data/*trends
Middle Aged
Obesity/*diagnosis/epidemiology
Odds Ratio
Patient Selection
Prostate-Specific Antigen/*blood
Prostatic Neoplasms/blood/*diagnosis/epidemiology
Risk Factors
Selection Bias
Socioeconomic Factors
Southeastern United States/epidemiology
LA  - eng
N1  - Fowke, Jay H
Signorello, Lisa B
Underwood, Willie 3rd
Ukoli, Flora A M
Blot, William J
R01 CA092447/CA/NCI NIH HHS/United States
R01 CA 92447/CA/NCI NIH HHS/United States
Comparative Study
Journal Article
Multicenter Study
Research Support, N.I.H., Extramural
United States
Prostate. 2006 Sep 15;66(13):1371-80. doi: 10.1002/pros.20377.
PY  - 2006
SN  - 0270-4137 (Print)
0270-4137
SP  - 1371-80
ST  - Obesity and prostate cancer screening among African-American and Caucasian men
T2  - Prostate
TI  - Obesity and prostate cancer screening among African-American and Caucasian men
VL  - 66
ID  - 566
ER  - 

TY  - JOUR
AB  - Historically, African Americans have resisted participation in clinical trials and other research projects because of distrust of the mostly white research establishment. Although there are legitimate reasons for refusing to join clinical trials, most notably the abuses of the Tuskegee Syphilis Study, African Americans may be passing up opportunities to obtain needed medications years before they reach the market. This article analyzes 29 empirical articles from medical and mental health journals for their findings on recruiting and maintaining African Americans in clinical trials. Reasons for declining and accepting opportunities to participate are organized into themes that represent the salient findings of these reports. Suggestions for social work interventions and changes in research designs are intended to make the research process more welcoming to African Americans. Interventions are linked to the themes and incorporate social work ethics and values. The premise of this study is that African Americans should be offered realistic opportunities supported by sufficient resources to increase participation.
AN  - WOS:000233323100004
AU  - Mason, S. E.
DA  - Nov
DO  - 10.1093/hsw/30.4.296
IS  - 4
N1  - 16323721
PY  - 2005
SN  - 0360-7283
SP  - 296-304
ST  - Offering African Americans opportunities to participate in clinical trials research: How social workers can help
T2  - Health & Social Work
TI  - Offering African Americans opportunities to participate in clinical trials research: How social workers can help
VL  - 30
ID  - 3232
ER  - 

TY  - JOUR
AB  - BACKGROUND Colorectal cancer (CRC) is the second leading cause of all cancer related deaths in the United States and Europe. Although the incidence has been decreasing for individuals' = 50, it has been on the rise for individuals < 50. AIM To identify potential risk factors for early-onset CRC. METHODS A population-based cohort analysis using a national database, Explorys, screened all patients with an active electronic medical record from January 2012 to December 2016 with a diagnosis of CRC. Subgroups were stratified based on age (25 - 49 years vs = 50 years). Demographics, comorbidities, and symptom profiles were recorded and compared between both age groups. Furthermore, the younger group was also compared with a control group consisting of individuals aged 25-49 years within the same timeframe without a diagnosis of CRC. Twentydata points for CRC related factors were analyzed to identify potential risk factors specific to early-onset CRC. RESULTS A total of 68860 patients were identified with CRC, of which 5710 (8.3%) were younger than 50 years old, with 4140 (73%) between 40-49 years of age. Multivariable analysis was reported using odds ratio (OR) with 95%CI and demonstrated that several factors were associated with an increased risk of CRC in the early-onset group versus the later-onset group. These factors included: African-American race (OR 1.18, 95%CI: 1.09-1.27, P < 0.001), presenting symptoms of abdominal pain (OR 1.82, 95%CI: 1.72-1.92, P <0.001), rectal pain (OR 1.50, 95%CI: 1.28-1.77, P < 0.001), altered bowel function (OR 1.12, 95%CI: 1.05-1.19, P = 0.0005), having a family history of any cancer (OR 1.78, 95%CI: 1.67- 1.90, P < 0.001), gastrointestinal (GI) malignancy (OR 2.36, 95%CI: 2.18-2.55, P < 0.001), polyps (OR 1.41, 95%CI: 1.08-1.20, P < 0.001), and obesity (OR 1.14, 95%CI: 1.08-1.20, P < 0.001). Comparing the early-onset cohort versus the control group, factors that were associated with an increased risk of CRC were: male gender (OR 1.34, 95%CI: 1.27-1.41), P < 0.001), Caucasian (OR 1.48, 95%CI: 1.40-1.57, P < 0.001) and African-American race (OR 1.25, 95%CI: 1.17-1.35, P < 0.001), presenting symptoms of abdominal pain (OR 4.73, 95%CI: 4.49-4.98, P < 0.001), rectal pain (OR 7.48, 95%CI: 6.42-8.72, P < 0.001), altered bowel function (OR 5.51, 95%CI: 5.19-5.85, P < 0.001), rectal bleeding (OR 9.83, 95%CI: 9.12-10.6, P < 0.001), weight loss (OR 7.43, 95%CI: 6.77-8.15, P < 0.001), having a family history of cancer (OR 11.66, 95%CI: 10.97-12.39, P < 0.001), GI malignancy (OR 28.67, 95%CI: 26.64-30.86, P < 0.001), polyps (OR 8.15, 95%CI: 6.31-10.52, P < 0.001), tobacco use (OR 2.46, 95%CI: 2.33-2.59, P < 0.001), alcohol use (OR 1.71, 95%CI: 1.62-1.80, P < 0.001), presence of colitis (OR 4.10, 95%CI: 3.79-4.43, P < 0.001), and obesity (OR 2.88, 95%CI: 2.74-3.04, P < 0.001). CONCLUSION Pending further investigation, these potential risk factors should lower the threshold of suspicion for early CRC and potentially be used to optimize guidelines for early screening.
AD  - S. Thakkar, Division of Gastroenterology and Hepatology, Allegheny Health Network, 1307 Federal Street, Suite 301, Pittsburgh, PA, United States
AU  - Syed, A. R.
AU  - Thakkar, P.
AU  - Horne, Z. D.
AU  - Abdul-Baki, H.
AU  - Kochhar, G.
AU  - Farah, K.
AU  - Thakkar, S.
DB  - Embase
DO  - 10.4251/wjgo.v11.i11.1011
IS  - 11
KW  - abdominal pain
adult
African American
aged
alcohol consumption
article
cancer diagnosis
cancer risk
cancer screening
Caucasian
cohort analysis
colitis
colorectal cancer
comparative study
controlled study
early cancer
electronic medical record
female
gastrointestinal tumor
groups by age
human
hyperlipidemia
hypertension
intestine function disorder
major clinical study
male
middle aged
obesity
patient selection
rectum hemorrhage
risk factor
stomach polyp
very elderly
LA  - English
M3  - Article
N1  - L630284295
2019-12-27
2020-01-01
PY  - 2019
SN  - 1948-5204
SP  - 1011-1020
ST  - Old vs new: Risk factors predicting early onset colorectal cancer
T2  - World Journal of Gastrointestinal Oncology
TI  - Old vs new: Risk factors predicting early onset colorectal cancer
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L630284295&from=export
http://dx.doi.org/10.4251/wjgo.v11.i11.1011
VL  - 11
ID  - 835
ER  - 

TY  - JOUR
AD  - Internal Medicine, Pennsylvania Hospital, University of Pennsylvania Health System, Philadelphia, PA, USA; ohadoren@gmail.com ohad.oren@uphs.upenn.edu.
Internal Medicine, Wolfson Medical Center, Tel Aviv University, Tel Aviv, Israel.
Hematology and Oncology Division, Pennsylvania Hospital, University of Pennsylvania Health System, Philadelphia, PA, USA.
AN  - 27573566
AU  - Oren, O.
AU  - Oren, M.
AU  - Beach, D.
DA  - Dec
DO  - 10.1093/annonc/mdw409
DP  - NLM
ET  - 2016/08/31
IS  - 12
KW  - African Americans/*ethnology/genetics
Clinical Trials as Topic/methods
Humans
Male
Prostate-Specific Antigen/analysis/genetics
Prostatic Neoplasms/*diagnosis/*ethnology/genetics
LA  - eng
N1  - 1569-8041
Oren, O
Oren, M
Beach, D
Editorial
England
Ann Oncol. 2016 Dec;27(12):2146-2148. doi: 10.1093/annonc/mdw409. Epub 2016 Aug 29.
PY  - 2016
SN  - 0923-7534
SP  - 2146-2148
ST  - On the generalizability of prostate cancer studies: why race matters
T2  - Ann Oncol
TI  - On the generalizability of prostate cancer studies: why race matters
VL  - 27
ID  - 205
ER  - 

TY  - JOUR
AB  - Background: Delivering personal narratives and peer support for CRC screening in an online weight-loss community could be an efficient approach to engaging individuals at increased risk, because obesity is associated with excess colorectal cancer (CRC) mortality and lower screening rates. Purpose: Evaluate user engagement and impact of narratives and peer support for promoting CRC screening in an online weight-loss community. Design: Pilot randomized trial. Setting/participants: Members of an online weight-loss community who were not up-to-date with CRC screening were enrolled in the study in 2011. Intervention: Basic and Enhanced groups (n=153 each) both received education. The Enhanced group also received narratives and peer support for CRC screening in online forums. Main outcome measures: The main measures were user engagement, psychosocial outcomes, and self-report CRC screening at 6 months. Analyses were conducted with (1) the full sample of participants and (2) a minimum dose sample of those who participated in their assigned intervention to a minimum degree. Analyses were completed in 2012. Results: Participants were mostly female (92%) with a mean age of 56 years. More than 90% in both groups viewed the educational information. Only 57% in the Enhanced group joined the online team. The Enhanced group had greater improvement in motivation for screening than the Basic group at 1 month (p=0.03). In the full sample, there was no difference in CRC screening at 6 months (Enhanced 19% vs Basic 16%, adjusted OR=1.33, 95% CI=0.73, 2.42). In the minimum dose sample, fecal Occult blood testing was higher in the Enhanced (14%) vs Basic (7%) group (adjusted OR=2.49, 95% CI=1.01, 6.17). Conclusions: Although no between-group differences in CRC screening were seen at 6 months, this study did demonstrate that it is feasible to deploy a narrative and peer support intervention for CRC screening in a randomized trial among members of an online community. However, modifications are needed to improve user engagement.
AN  - WOS:000320827500012
AU  - Hwang, K. O.
AU  - Ottenbacher, A. J.
AU  - Graham, A. L.
AU  - Thomas, E. J.
AU  - Street, R. L.
AU  - Vernon, S. W.
DA  - Jul
DO  - 10.1016/j.amepre.2013.02.024
IS  - 1
N1  - 23790994
PY  - 2013
SN  - 0749-3797
SP  - 98-107
ST  - Online Narratives and Peer Support for Colorectal Cancer Screening A Pilot Randomized Trial
T2  - American Journal of Preventive Medicine
TI  - Online Narratives and Peer Support for Colorectal Cancer Screening A Pilot Randomized Trial
VL  - 45
ID  - 3041
ER  - 

TY  - JOUR
AB  - BACKGROUND: Poly (ADP-ribose)-polymerase inhibitors (PARPi) have been approved for cancer patients with germline BRCA1/2 (gBRCA1/2) mutations, and efforts to expand the utility of PARPi beyond BRCA1/2 are ongoing. In preclinical models of triple-negative breast cancer (TNBC) with intact DNA repair, we have previously shown an induced synthetic lethality with combined EGFR inhibition and PARPi. Here, we report the safety and clinical activity of lapatinib and veliparib in patients with metastatic TNBC. METHODS: A first-in-human, pilot study of lapatinib and veliparib was conducted in metastatic TNBC (NCT02158507). The primary endpoint was safety and tolerability. Secondary endpoints were objective response rates and pharmacokinetic evaluation. Gene expression analysis of pre-treatment tumor biopsies was performed. Key eligibility included TNBC patients with measurable disease and prior anthracycline-based and taxane chemotherapy. Patients with gBRCA1/2 mutations were excluded. RESULTS: Twenty patients were enrolled, of which 17 were evaluable for response. The median number of prior therapies in the metastatic setting was 1 (range 0-2). Fifty percent of patients were Caucasian, 45% African-American, and 5% Hispanic. Of evaluable patients, 4 demonstrated a partial response and 2 had stable disease. There were no dose-limiting toxicities. Most AEs were limited to grade 1 or 2 and no drug-drug interactions noted. Exploratory gene expression analysis suggested baseline DNA repair pathway score was lower and baseline immunogenicity was higher in the responders compared to non-responders. CONCLUSIONS: Lapatinib plus veliparib therapy has a manageable safety profile and promising antitumor activity in advanced TNBC. Further investigation of dual therapy with EGFR inhibition and PARP inhibition is needed. TRIAL REGISTRATION: ClinicalTrials.gov , NCT02158507 . Registered on 12 September 2014.
AD  - Department of Medicine, Division of Hematology Oncology, University of Alabama at Birmingham, Birmingham, AL, USA.
Department of Medicine, Brookwood Baptist Health, Birmingham, AL, USA.
Department of Radiation Oncology, University of Alabama at Birmingham, Birmingham, AL, USA.
Department of Pharmacology/Toxicology, University of Alabama at Birmingham, Birmingham, AL, USA.
Department of Radiation Oncology, University of Alabama at Birmingham, Birmingham, AL, USA. shyang@uabmc.edu.
O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, 1700 6th Avenue South, HSROC Suite 2232 (176F), Birmingham, AL, 35249, USA. shyang@uabmc.edu.
AN  - 33663560
AU  - Stringer-Reasor, E. M.
AU  - May, J. E.
AU  - Olariu, E.
AU  - Caterinicchia, V.
AU  - Li, Y.
AU  - Chen, D.
AU  - Della Manna, D. L.
AU  - Rocque, G. B.
AU  - Vaklavas, C.
AU  - Falkson, C. I.
AU  - Nabell, L. M.
AU  - Acosta, E. P.
AU  - Forero-Torres, A.
AU  - Yang, E. S.
C2  - PMC7934554
DA  - Mar 4
DO  - 10.1186/s13058-021-01408-9
DP  - NLM
ET  - 2021/03/06
IS  - 1
KW  - *DNA repair
*PARP inhibitors
*Synthetic lethality
*Targeted therapy
*Triple-negative breast cancer
Oncology, Bayer, and Lilly
research funding from Tesaro/Janssen. E.
Stringer-Reasor: involved in clinical trials with money paid directly to UAB from
Seattle Genetics, Pfizer, Novartis, TESARO, and GSK
on advisory boards for Mylan
Institutional and Lilly
grants provided by Susan G. Komen and Victory Foundation.
C. Falkson: advisory boards for Agendia, Biotheranostics, and Oncotype Dx. G.
Rocque: grants from Genetech, Pfizer, and Carevive
consult for Pfizer. C. Vaklavas:
consulting/advisory role: Daiichi-Sankyo (one time)
research funding paid to my
institution: Seattle Genetics, Genentech, Roche, Pfizer, Incyte, Pharmacyclics,
Novartis, TRACON Pharmaceuticals, Innocrin Pharmaceuticals, Zymeworks, and H3
Biomedicine
other relationships: Puma Biotechnology, Takeda, Daiichi Sankyo
uncompensated relationship: Genentech (unpaid thought leader). E. Acosta, L, Yufeng,
L. Nabell, J. May, E. Olariu, D. Della Manna, and V. Caterinicchia have no conflicts
to disclose.
LA  - eng
N1  - 1465-542x
Stringer-Reasor, Erica M
May, Jori E
Olariu, Eva
Caterinicchia, Valerie
Li, Yufeng
Chen, Dongquan
Della Manna, Deborah L
Rocque, Gabrielle B
Vaklavas, Christos
Falkson, Carla I
Nabell, Lisle M
Acosta, Edward P
Forero-Torres, Andres
Yang, Eddy S
Orcid: 0000-0002-6450-2638
15-20-43/AACR-TNBC Foundation Grant/
NA/Scariot Foundation/
Journal Article
Breast Cancer Res. 2021 Mar 4;23(1):30. doi: 10.1186/s13058-021-01408-9.
PY  - 2021
SN  - 1465-5411 (Print)
1465-5411
SP  - 30
ST  - An open-label, pilot study of veliparib and lapatinib in patients with metastatic, triple-negative breast cancer
T2  - Breast Cancer Res
TI  - An open-label, pilot study of veliparib and lapatinib in patients with metastatic, triple-negative breast cancer
VL  - 23
ID  - 3
ER  - 

TY  - JOUR
AB  - Purpose: Inclusion of women in biomedical cancer research have the potential to close gaps in cancer health disparities and improve adjuvant therapies for women; yet samples needed to advance this area of science are lacking. We developed low-cost educational recruitment strategies to increase our collection of biospecimens from women. Materials and Methods: Women diagnosed with hormone receptor positive (HR+) breast cancer that initiated hormonal therapy were recruited from three integrated health systems. The analytical sample (n = 144) consisted of women who consented but did not return a saliva sample within 1 year of the initial assessment (baseline). Brief informational recruitment materials were developed via published literature and preliminary data. Women received recruitment materials, which included a personalized information letter, a colorful low-literacy instruction sheet, a postage-paid envelope, and collection kits. We evaluated intervention materials and performed descriptive and bivariate statistics to describe factors associated with biospecimen donation. Results: Of the total sample, 61% were white and 34% were black. Overall, 29 surveys (20%) and 25 (17%) saliva kits were returned. Women found the materials helpful and easy to read and understand. Women with higher levels of functional well-being and lower ratings of religiosity were more likely to return biospecimens (p < 0.005) after receiving enhanced materials. Conclusion: This article provides recruitment strategies to enhance biospecimen samples among women. Receipt of brief informational print materials inclusive of personalized messages enhanced our outreach strategies and increased our overall biospecimen provision rate by 17%. The inclusion of messages with a focus on spirituality and other cultural messages may further increase biospecimen provision in racial/ethnic diverse groups of women; however, further study is needed to support this claim. Clinical Trail Registration Number: NCT02992730.
AD  - Department of Health Behavior and Policy, Virginia Commonwealth University School of Medicine, Richmond, Virginia, USA.
VCU Massey Cancer Center Office of Health Equity and Disparities Research, Richmond, Virginia, USA.
AN  - 33428522
AU  - Edmonds, M. C.
AU  - Sutton, A. L.
AU  - Cummings, Y.
AU  - Sheppard, V. B.
DA  - Jan 11
DO  - 10.1089/jwh.2020.8502
DP  - NLM
ET  - 2021/01/12
KW  - breast cancer survivors
women in biospecimen samples
women's health research
LA  - eng
N1  - 1931-843x
Edmonds, Megan C
Sutton, Arnethea L
Cummings, Yvonne
Sheppard, Vanessa B
Journal Article
United States
J Womens Health (Larchmt). 2021 Jan 11. doi: 10.1089/jwh.2020.8502.
PY  - 2021
SN  - 1540-9996
ST  - Opportunities to Improve Women's Health: Engaging Racial/Ethnic Diverse Women to Provide Biospecimens for Research
T2  - J Womens Health (Larchmt)
TI  - Opportunities to Improve Women's Health: Engaging Racial/Ethnic Diverse Women to Provide Biospecimens for Research
ID  - 15
ER  - 

TY  - JOUR
AB  - Objective. Standard surgical treatment for CIN may impair fertility generating a need for alternative treatment options. We tested the efficacy and toxicity of oral DIM in the treatment of CIN 2 or 3 lesions. Methods. Patients with biopsy-proven cervical intraepithelial neoplasia (CIN) 2 or 3 scheduled for loop electrosurgical excision procedure (LEEP) were randomized 2:1 to receive diindolylmethane (DIM) (BioResponse-DIM (R), BioResponse, Boulder, CO) orally at approximately 2 mg/kg/day for 12 weeks or placebo (defatted rice bran, BioResponse). Subjects were evaluated every 3-4 months for I year. Analysis of data LIP to I year was assessed including Pap smear, HPV, colposcopy, biopsy and physical examination were performed at follow-up. Central pathology review confirmed all histology diagnoses. Results. To date, 64 subjects (mean age 28 years, range 18-61) have been enrolled (45 in the DIM arm, 19 in the placebo arm), with 60 available for analysis. Average follow-up was 6 months. At enrollment, 58% were diagnosed with CIN 2 and 42% with CIN 3, 57% of subjects were Caucasian, 15% African American, 12% Hispanic and 17% Asian. During treatment 2 Subjects (3%) complained of nausea (grade 2) at the 3- to 4-month visit. No systemic toxicities were observed (normal CBC, LFFs, Comprehensive metabolic). Forty-six subjects had biopsies at first follow-up (77%), Twenty-one Subjects (47%) in the DIM group had improved CIN with a decrease by 1-2 grades or a normal result. Median time to improvement was 5 months. Improved Pap smear was seen in 49% (22/45) with either a less severe abnormality or normal result. Colposcopy improved in twenty-five subjects in the DIM group (56%). Of these 25 Subjects, 21 (84%) had improved colposcopic impression, 13 (52%) had a decrease in involved quadrants and 18 (72%) had a decrease in lesion number. Complete colposcopic response was observed in 4 subjects (9%). Stratifying by level of dysplasia, age, race, HPV status, tobacco use, contraceptive used did not alter the results. At median follow-up of 6 months, 85% of subjects have not required LEEP based on routine clinical triage of improving global assessment. There was no statistically significant difference in any outcome between the DIM and placebo group. Conclusion. Oral DIM at 2 mg/kg/day is well tolerated with no significant toxicity. We observed a high rate of clinically significant improvement in confirmed CIN 2 or 3 lesions among both treatment groups in this randomized clinical trial. (C) 2009 Elsevier Inc. All rights reserved.
AN  - WOS:000275360000035
AU  - Del Priore, G.
AU  - Gudipudi, D. K.
AU  - Montemarano, N.
AU  - Restivo, A. M.
AU  - Malanowska-Stega, J.
AU  - Arslan, A. A.
DA  - Mar
DO  - 10.1016/j.ygyno.2009.10.060
IS  - 3
N1  - 19939441
PY  - 2010
SN  - 0090-8258
SP  - 464-467
ST  - Oral diindolyl methane (DIM): Pilot evaluation of a nonsurgical treatment for cervical dysplasia
T2  - Gynecologic Oncology
TI  - Oral diindolyl methane (DIM): Pilot evaluation of a nonsurgical treatment for cervical dysplasia
VL  - 116
ID  - 3120
ER  - 

TY  - JOUR
AB  - Objective: The aim of this study was to compare oral micronized progesterone (progesterone) with placebo as therapy for postmenopausal hot flushes and night sweats (vasomotor symptoms [VMS]). Methods: Healthy volunteer community women 1 to 10 years since final menstruation were recruited for a randomized double-blind placebo-controlled trial of progesterone (300 mg daily at bedtime) between 2003 and 2009 and were screened for clinical, physical, or laboratory evidence of cardiovascular risks (nonsmoking, moderate body mass index [< 35 kg/m(2)], normal lipids, electrocardiogram, nondiabetic). Women recorded daily frequency and severity (1-4) of VMS in the Daily Menopause Diary during run-in (4 wk) and intervention (12 wk). Average daily VMS score (day frequency x day severity x night frequency x night severity) during final 28 therapy days was the primary outcome, analyzed by therapy, with run-in score as covariate. Results: Randomized participants were 133 healthy community women with VMS, ages 44 to 62 years, with a mean (SD) VMS score of 17.0 (10.4) at run-in (VMS frequency 6.8 [3.2] episodes/d). Women were randomized to progesterone (n = 75) or placebo (n = 58); analysis included all with VMS data at run-in and on therapy (n = 68 and 46, respectively). The VMS scores of women taking progesterone were better than placebo (mean adjusted difference, -4.3 (95% CI, -6.6 to -1.9), with mean reductions of 10.0 (95% CI, -12.0 to -8.1) and 4.4 (95% CI, -6.6 to -2.2) in the progesterone and placebo arms, respectively. Discontinuation with adverse events was 9% (progesterone, 8; placebo, 4), with no serious cases. Conclusions: Oral micronized progesterone is effective for treatment of hot flushes and night sweats in healthy women early in postmenopause.
AN  - WOS:000306844000010
AU  - Hitchcock, C. L.
AU  - Prior, J. C.
DA  - Aug
DO  - 10.1097/gme.0b013e318247f07a
IS  - 8
N1  - 22453200
PY  - 2012
SN  - 1072-3714
SP  - 886-893
ST  - Oral micronized progesterone for vasomotor symptoms-a placebo-controlled randomized trial in healthy postmenopausal women
T2  - Menopause-the Journal of the North American Menopause Society
TI  - Oral micronized progesterone for vasomotor symptoms-a placebo-controlled randomized trial in healthy postmenopausal women
VL  - 19
ID  - 3063
ER  - 

TY  - JOUR
AB  - Objective: To assess barriers to physician participation in cancer clinical trials among oncologists, oncology leaders, and health plan leaders. Study Design: Mail survey of 221 oncologists combined with semistructured telephone interviews with oncology and plan leaders at 10 integrated healthcare systems, Methods: The survey instrument examined physicians' involvement in clinical trials; their perception of the value of trials to them, their patients, and their organization; and the presence of infrastructure support for trials and associated resource constraints. The interviews investigated similar issues from the leaders' perspective. We used linear regression to model trial enrollment and standard qualitative techniques to analyze the interviews. Results: Oncologists estimated they enrolled 7% of patients in trials. They expressed extremely favorable attitudes toward trials as, patient care and a benefit to themselves a source of high-quality professionally. While positive attitudes toward trials were common, and were significant bivariate predictors of enrollment, organizational factors were the predominant predictors in multivariate analysis. The best combination of factors independently predicting enrollment related to organizational support for trials, subspecialty of the oncologist, and limitations of trial eligibility requirements. Conclusions: To increase trial participation, there is a critical need for infrastructure to support trials, especially additional support staff and research nurses. In addition, there is a need for better intra-organizational communication and consideration of the impact of trial design on internal health plan resources. This research supports the need to continue a national dialogue about the broadly defined benefits and costs of clinical trials to patients, physicians, and health plans.
AN  - WOS:000230472900001
AU  - Somkin, C. P.
AU  - Altschuler, A.
AU  - Ackerson, L.
AU  - Geiger, A. M.
AU  - Greene, S. M.
AU  - Mouchawar, J.
AU  - Holup, J.
AU  - Fehrenbacher, L.
AU  - Nelson, A.
AU  - Glass, A.
AU  - Polikoff, J.
AU  - Tishler, S.
AU  - Schmidt, C.
AU  - Field, T.
AU  - Wagner, E.
DA  - Jul
IS  - 7
N1  - 16044978
PY  - 2005
SN  - 1088-0224
SP  - 413-421
ST  - Organizational barriers to physician participation in cancer clinical trials
T2  - American Journal of Managed Care
TI  - Organizational barriers to physician participation in cancer clinical trials
VL  - 11
ID  - 3239
ER  - 

TY  - JOUR
AB  - This article describes the process and results associated with the organizational-level recruitment of Black barbershops into Fitness in the Shop (FITShop), a 6-month barbershop-based intervention study designed to promote physical activity among Black men. Organizational-level recruitment activities included (1) a telephone call to prospective barbershop owners to assess their interest and eligibility for participation, (2) an organizational eligibility letter sent to all interested and eligible barbershops, (3) a visit to interested and eligible barbershops, where a culturally sensitive informational video was shown to barbershop owners to describe the study activities and share testimonies from trusted community stakeholders, and (4) a signed agreement with barbershop owners and barbers, which formalized the organizational partnership. Structured interviews were conducted with owners of a total of 14 enrolled barbershops, representing 30% of those determined to be eligible and interested. Most enrolled shops were located in urban settings and strip malls. Barbershop owners were motivated to enroll in the study based on commitment to their community, perceived client benefits, personal interest in physical activity, and a perception that the study had potential to make a positive impact on the barbershop and on reducing health disparities. Results offer important insights about recruiting barbershops into intervention trials.
AN  - WOS:000432068800009
AU  - Hood, S.
AU  - Hall, M.
AU  - Dixon, C.
AU  - Jolly, D.
AU  - Linnan, L.
DA  - May
DO  - 10.1177/1524839917696715
IS  - 3
N1  - 29161902
PY  - 2018
SN  - 1524-8399
SP  - 377-389
ST  - Organizational-Level Recruitment of Barbershops as Health Promotion Intervention Study Sites: Addressing Health Disparities Among Black Men
T2  - Health Promotion Practice
TI  - Organizational-Level Recruitment of Barbershops as Health Promotion Intervention Study Sites: Addressing Health Disparities Among Black Men
VL  - 19
ID  - 2863
ER  - 

TY  - JOUR
AB  - BACKGROUND: Osteoporotic fractures are associated with high morbidity, mortality, and cost. METHODS: We performed a post hoc analysis of the Women's Health Initiative (WHI) clinical trials data to assess osteoporosis treatment and identify participant characteristics associated with utilization of osteoporosis medication(s) after new diagnoses of osteoporosis or fracture. Information from visits prior to and immediately subsequent to the first fracture event or osteoporosis diagnosis were evaluated for medication use. A full logistic regression model was used to identify factors predictive of osteoporosis medication use after a fracture or a diagnosis of osteoporosis. RESULTS: The median length of follow-up from enrollment to the last WHI clinic visit for the study cohort was 13.9 years. Among the 13,990 women who reported new diagnoses of osteoporosis or fracture between enrollment and their final WHI visit, and also had medication data available, 21.6% reported taking an osteoporosis medication other than estrogen. Higher daily calcium intake, diagnosis of osteoporosis alone or both osteoporosis and fracture (compared with diagnosis of fracture alone), Asian or Pacific Islander race/ethnicity (compared with White/Caucasian), higher income, and hormone therapy use (past or present) were associated with significantly higher likelihood of osteoporosis pharmacotherapy. Women with Black/African American race/ethnicity (compared with White/Caucasian), body mass index >= 30 (compared with body mass index of 18.5-24.9), current tobacco use (compared with past use or lifetime nonusers), and history of arthritis were less likely to use osteoporosis treatment. CONCLUSION: Despite well-established treatment guidelines in postmenopausal women with osteoporosis or history of fractures, pharmacotherapy use was suboptimal in this study. Initiation of osteoporosis treatment after fragility fracture may represent an opportunity to improve later outcomes in these high-risk women. Specific attention needs to be paid to increasing treatment among women with fragility fractures, obesity, current tobacco use, history of arthritis, or of Black race/ethnicity. (C) 2017 Elsevier Inc. All rights reserved.
AN  - WOS:000405852200039
AU  - Sattari, M.
AU  - Cauley, J. A.
AU  - Garvan, C.
AU  - Johnson, K. C.
AU  - LaMonte, M. J.
AU  - Li, W. J.
AU  - Limacher, M.
AU  - Manini, T.
AU  - Sarto, G. E.
AU  - Sullivan, S. D.
AU  - Wactawski-Wende, J.
AU  - Beyth, R. J.
DA  - Aug
DO  - 10.1016/j.amjmed.2017.02.042
IS  - 8
N1  - 28366425
PY  - 2017
SN  - 0002-9343
SP  - 937-948
ST  - Osteoporosis in the Women's Health Initiative: Another Treatment Gap?
T2  - American Journal of Medicine
TI  - Osteoporosis in the Women's Health Initiative: Another Treatment Gap?
VL  - 130
ID  - 2893
ER  - 

TY  - JOUR
AB  - Objective: To describe the knowledge of, and attitudes toward, out-of-pocket expenses (OOPE) associated with prostate cancer treatment and the influence of OOPE on the treatment choices of patients with prostate cancer. Materials and Methods: We undertook a qualitative research study for which we recruited patients with clinically localized prostate cancer. Patients answered a series of open-ended questions during a semistructured interview and completed a questionnaire about the physician's role in discussing OOPE, the burden of OOPE, the effect of OOPE on treatment decisions, and previous knowledge of OOPE. Results: A total of 41 (26 white and 15 black) eligible patients were enrolled from the urology and radiation oncology practices of the University of Pennsylvania. Qualitative assessment revealed 5 major themes: (a) "my insurance takes care of it"; (b) "health is more important than cost"; (c) "I did not look into it"; (d) "I cannot afford it but would have chosen the same treatment"; and (e) "It is not my doctor's business." Most patients (38 of 41, 93%) reported that they would not have chosen a different treatment even if they had known the actual OOPE of their treatment. Patients who reported feeling burdened by OOPE were socioeconomically heterogeneous, and their treatment choices remained unaffected. Only 2 patients stated they knew "a lot" about the likely OOPE for different prostate cancer treatments before choosing their treatment. Conclusion: Among insured patients with prostate cancer treated at a large academic medical center, few had knowledge of OOPE before making treatment choices. © 2012 Elsevier Inc. All Rights Reserved.
AD  - J.E. Bekelman, Department of Radiation Oncology, Hospital of the University of Pennsylvania, Perelman School of Medicine, 3400 Civic Center Boulevard, Philadelphia, PA 19104, United States
AU  - Jung, O. S.
AU  - Guzzo, T.
AU  - Lee, D.
AU  - Mehler, M.
AU  - Christodouleas, J.
AU  - Deville, C.
AU  - Hollis, G.
AU  - Shah, A.
AU  - Vapiwala, N.
AU  - Wein, A.
AU  - Pauly, M.
AU  - Bekelman, J. E.
DB  - Embase
Medline
DO  - 10.1016/j.urology.2012.08.027
IS  - 6
KW  - adult
aged
article
clinical article
clinical trial
cost
external beam radiotherapy
health
health care cost
human
male
out of pocket expense
priority journal
prospective study
prostate cancer
prostatectomy
qualitative research
questionnaire
semi structured interview
LA  - English
M3  - Article
N1  - L52269276
2012-10-26
2012-12-21
PY  - 2012
SN  - 0090-4295
1527-9995
SP  - 1252-1257
ST  - Out-of-pocket expenses and treatment choice for men with prostate cancer
T2  - Urology
TI  - Out-of-pocket expenses and treatment choice for men with prostate cancer
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L52269276&from=export
http://dx.doi.org/10.1016/j.urology.2012.08.027
VL  - 80
ID  - 1106
ER  - 

TY  - JOUR
AB  - The recently completed Selenium and Vitamin E Cancer Prevention Trial (SELECT) was one of the largest human cancer prevention trials ever undertaken. Its purpose was to assess the role of selenium and vitamin E in prostate cancer prevention, but SELECT found no decline in prostate cancer. Comparison of this study to other clinical trials involving selenium and to the results of animal studies suggests that the source of the selenium supplement, L-selenomethionine, and the relatively high initial levels of selenium in the enrolled men may have contributed to this outcome. Further analysis of the clinical and animal data highlights the need for mechanistic studies to better understand selenium biology in order to target dietary selenium to appropriate subsets of the human population: those individuals most likely to benefit from this micronutrient.
AD  - Molecular Biology of Selenium Section, Laboratory of Cancer Prevention, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
AN  - 19299660
AU  - Hatfield, D. L.
AU  - Gladyshev, V. N.
C2  - PMC2718722
C6  - NIHMS131622
DA  - Feb
DO  - 10.1124/mi.9.1.6
DP  - NLM
ET  - 2009/03/21
IS  - 1
KW  - African Americans
Animals
*Chemoprevention
Dietary Supplements/analysis
Double-Blind Method
Humans
Male
Middle Aged
Neoplasms/genetics/*prevention & control
Prostatic Neoplasms/genetics/prevention & control
*Randomized Controlled Trials as Topic
Selenium/*administration & dosage/metabolism
Selenoproteins/chemistry/metabolism
Treatment Outcome
Vitamin E/*administration & dosage/metabolism
LA  - eng
N1  - 1543-2548
Hatfield, Dolph L
Gladyshev, Vadim N
R01 CA080946/CA/NCI NIH HHS/United States
R01 CA080946-09/CA/NCI NIH HHS/United States
Z01 BC005317-24/Intramural NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
Research Support, N.I.H., Intramural
Mol Interv. 2009 Feb;9(1):18-21. doi: 10.1124/mi.9.1.6.
PY  - 2009
SN  - 1534-0384 (Print)
1534-0384
SP  - 18-21
ST  - The Outcome of Selenium and Vitamin E Cancer Prevention Trial (SELECT) reveals the need for better understanding of selenium biology
T2  - Mol Interv
TI  - The Outcome of Selenium and Vitamin E Cancer Prevention Trial (SELECT) reveals the need for better understanding of selenium biology
VL  - 9
ID  - 474
ER  - 

TY  - JOUR
AB  - Objective.-To determine whether there is a racial difference in prognosis among childhood cancers. Design.-An overall (30-year) survival analysis by race was followed by separate studies for ''early'' and ''recent'' treatment eras, defined by time points at which significantly improved outcome was demonstrated for specific tumor types, Stratified analyses were performed to adjust for recognized prognostic features. Setting.-Pediatric oncology research and treatment center. Patients.-The study included 798 black and 4507 white children with newly diagnosed malignancies treated from January 1962 through June 1992. These patients were accepted for treatment regardless of their financial status and were enrolled on disease-specific protocols. Results.-Across the 30-year study period, black children had a significantly poorer rate of survival than white children (P<.,001, log-rank test). In the early treatment era, a significant difference was seen for all forms of cancer combined (P<.001), with 10-year Kaplan-Meier estimates (+/-SE) of 37%+/-3% for black children and 50%+/-1% for white children. This difference largely reflected the poorer prognosis of black children with the most common childhood cancer, acute lymphoblastic leukemia. In the recent treatment era, there were no significant differences in treatment outcome by race for specific disease categories or for all forms of cancer combined, Ten-year survival rates were 67%+/-6% for black children and 66%+/-3% for white children, indicating a significantly greater improvement in the former group. Conclusion.-With equal access to effective contemporary treatment, black children with cancer fare as well as white children when treated with protocol-based therapy at a pediatric oncology research center.
AN  - WOS:A1995QG74800028
AU  - Pui, C. H.
AU  - Boyett, J. M.
AU  - Hancock, M. L.
AU  - Pratt, C. B.
AU  - Meyer, W. H.
AU  - Crist, W. M.
DA  - Feb 22
DO  - 10.1001/jama.273.8.633
IS  - 8
N1  - 71
7844873
PY  - 1995
SN  - 0098-7484
SP  - 633-637
ST  - Outcome of Treatment for Childhood-Cancer in Black as Compared with White-Children - the St-Jude-Childrens-Research-Hospital Experience, 1962 through 1992
T2  - Jama-Journal of the American Medical Association
TI  - Outcome of Treatment for Childhood-Cancer in Black as Compared with White-Children - the St-Jude-Childrens-Research-Hospital Experience, 1962 through 1992
VL  - 273
ID  - 2740
ER  - 

TY  - JOUR
AB  - BACKGROUND: African-Americans generally have lower survival rates from colon cancer than Caucasian Americans. This disparity has been attributed to many sources, including diagnosis at later disease stage and other unfavorable disease features, inadequate treatment, and socioeconomic factors. The randomized clinical trial setting ensures similarity in disease stage and a uniform treatment plan between blacks and whites. In this study, we evaluated survival and related end points for African-American and Caucasian patients with colon cancer participating in randomized clinical trials of the National Surgical Adjuvant Breast and Bowel Project (NSABP) to determine whether outcomes were less favorable for African-Americans. METHODS: The study included African-American (n = 663) or Caucasian (n = 5969) patients from five serially conducted, randomized clinical trials of the NSABP. We compared recurrence-free survival, disease-free survival (recurrence, new primary cancer, or death), and survival (death from any cause) between blacks and whites by using statistical modeling to account for differences in patient and disease characteristics between the groups. Statistical tests were two-sided. RESULTS: Dukes' stage and number of positive lymph nodes were remarkably similar between African-American and Caucasian patients in each trial. Over all trials combined, an 8% (95% confidence interval [CI] = -6% to 25%; P =.27) excess risk of colon cancer recurrence that was not statistically significant was observed for blacks. A greater disparity in survival was seen, with blacks experiencing a statistically significant 21% (95% CI = 6%-37%; P =.004) greater risk of death. Treatment efficacy appeared similar between the groups. CONCLUSIONS: While the overall survival prognosis was less favorable for African-Americans compared with Caucasians in these trials, other outcomes measured were considerably more similar than those seen in the population at large, suggesting that earlier detection and adjuvant therapy could appreciably improve colon cancer prognosis for African-Americans. Continued investigations into causes of the deficits noted are warranted.
AD  - J. J. Dignam, L. Colangelo, W. Tian, J. Jones, National Surgical Adjuvant Breast and Bowel Project (NSABP) and University of Pittsburgh, PA 15213, USA. dignam@vms.cis.pitt.edu
AN  - 10564677
AU  - Dignam, J. J.
AU  - Colangelo, L.
AU  - Tian, W.
AU  - Jones, J.
AU  - Smith, R.
AU  - Wickerham, D. L.
AU  - Wolmark, N.
DA  - Nov 17
DO  - 10.1093/jnci/91.22.1933
DP  - NLM
ET  - 1999/11/24
IS  - 22
KW  - Adult
African Americans/*statistics & numerical data
Aged
Colonic Neoplasms/pathology/*therapy
Combined Modality Therapy
Disease-Free Survival
European Continental Ancestry Group/*statistics & numerical data
Female
Follow-Up Studies
Humans
Male
Middle Aged
Neoplasm Staging
Randomized Controlled Trials as Topic
Survival Analysis
Treatment Outcome
United States
LA  - eng
N1  - Dignam, J J
Colangelo, L
Tian, W
Jones, J
Smith, R
Wickerham, D L
Wolmark, N
U10CA12027/CA/NCI NIH HHS/United States
U10CA69651/CA/NCI NIH HHS/United States
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.
United States
J Natl Cancer Inst. 1999 Nov 17;91(22):1933-40. doi: 10.1093/jnci/91.22.1933.
PY  - 1999
SN  - 0027-8874 (Print)
0027-8874
SP  - 1933-40
ST  - Outcomes among African-Americans and Caucasians in colon cancer adjuvant therapy trials: findings from the National Surgical Adjuvant Breast and Bowel Project
T2  - J Natl Cancer Inst
TI  - Outcomes among African-Americans and Caucasians in colon cancer adjuvant therapy trials: findings from the National Surgical Adjuvant Breast and Bowel Project
VL  - 91
ID  - 708
ER  - 

TY  - JOUR
AB  - BACKGROUND: Among patients with resected colon cancer, black patients have worse survival than whites. We investigated whether disparities in survival and related endpoints would persist when patients were treated with identical therapies in controlled clinical trials. METHODS: We assessed 14,611 patients (1218 black and 13,393 white) who received standardized adjuvant treatment in 12 randomized controlled clinical trials conducted in North America for resected stage II and stage III colon cancer between 1977 and 2002. Individual patient data on covariates and outcomes were extracted from the Adjuvant Colon Cancer ENdpoinTs (ACCENT) database. The endpoints examined in this meta-analysis were overall survival (time to death), recurrence-free survival (time to recurrence or death), and recurrence-free interval (time to recurrence). Cox models were stratified by study and controlled for sex, stage, age, and treatment to determine the effect of race. Kaplan-Meier estimates were adjusted for similar covariates to control for confounding. All statistical tests were two-sided. RESULTS: Black patients were younger than whites (median age, 58 vs 61 years, respectively; P < .001) and more likely to be female (55% vs 45%, respectively; P < .001). Overall survival was worse in black patients than whites (hazard ratio [HR] of death = 1.22, 95% confidence interval [CI] = 1.11 to 1.34, P < .001). Five-year overall survival rates for blacks and whites were 68.2% and 72.8%, respectively. When subsets defined by sex, stage, and age were analyzed, overall survival was consistently worse in black patients. Recurrence-free survival was worse in black patients than whites (HR of recurrence or death = 1.14, 95% CI = 1.04 to 1.24, P = .0045). Three-year recurrence-free survival rates in blacks and whites were 68.4% and 72.1%, respectively. In contrast, recurrence-free interval was similar in black and white patients (HR of recurrence = 1.08, 95% CI = 0.97 to 1.19, P = .15). Three-year recurrence-free interval rates in blacks and whites were 71.3% and 74.2%, respectively. CONCLUSIONS: Black patients with resected stage II and stage III colon cancer who were treated with the same therapy as white patients experienced worse overall and recurrence-free survival, but similar recurrence-free interval, compared with white patients. The differences in survival may be mostly because of factors unrelated to the patients' adjuvant colon cancer treatment.
AD  - National Surgical Adjuvant Breast and Bowel Project Biostatistical Center, One Sterling Plaza, 201 N Craig St, Pittsburgh, PA 15213, USA. yothers@nsabp.pitt.edu
AN  - 21997132
AU  - Yothers, G.
AU  - Sargent, D. J.
AU  - Wolmark, N.
AU  - Goldberg, R. M.
AU  - O'Connell, M. J.
AU  - Benedetti, J. K.
AU  - Saltz, L. B.
AU  - Dignam, J. J.
AU  - Blackstock, A. W.
C2  - PMC3196480
DA  - Oct 19
DO  - 10.1093/jnci/djr310
DP  - NLM
ET  - 2011/10/15
IS  - 20
KW  - Adult
African Americans/*statistics & numerical data
Aged
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Chemotherapy, Adjuvant
Clinical Trials, Phase III as Topic
Colonic Neoplasms/*drug therapy/ethnology/*mortality/pathology/surgery
Confounding Factors, Epidemiologic
Disease-Free Survival
European Continental Ancestry Group/statistics & numerical data
Female
Fluorouracil/administration & dosage
Health Status Disparities
Healthcare Disparities
Humans
Kaplan-Meier Estimate
Leucovorin/administration & dosage
Levamisole/administration & dosage
Lomustine/administration & dosage
Male
Middle Aged
Multivariate Analysis
Neoplasm Staging
Odds Ratio
Proportional Hazards Models
Randomized Controlled Trials as Topic
Treatment Outcome
United States/epidemiology
Vincristine/administration & dosage
LA  - eng
N1  - 1460-2105
Yothers, Greg
Sargent, Daniel J
Wolmark, Norman
Goldberg, Richard M
O'Connell, Michael J
Benedetti, Jacqueline K
Saltz, Leonard B
Dignam, James J
Blackstock, A William
ACCENT Collaborative Group
U10CA-69974/CA/NCI NIH HHS/United States
U24-CA-114732/CA/NCI NIH HHS/United States
CA 25224/CA/NCI NIH HHS/United States
U10CA-37377/CA/NCI NIH HHS/United States
U10CA-12027/CA/NCI NIH HHS/United States
U10CA-69651/CA/NCI NIH HHS/United States
Journal Article
Meta-Analysis
Research Support, N.I.H., Extramural
J Natl Cancer Inst. 2011 Oct 19;103(20):1498-506. doi: 10.1093/jnci/djr310. Epub 2011 Oct 12.
PY  - 2011
SN  - 0027-8874 (Print)
0027-8874
SP  - 1498-506
ST  - Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials
T2  - J Natl Cancer Inst
TI  - Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials
VL  - 103
ID  - 384
ER  - 

TY  - JOUR
AB  - BACKGROUND: Metastatic colorectal cancer (CRC) outcomes continue to improve, but they vary significantly by race and ethnicity. We hypothesize that these disparities arise from unequal access to care. MATERIALS AND METHODS: The Harris Health System (HHS) is an integrated health delivery network that provides medical care to the underserved, predominantly minority population of Harris County, Texas. As the largest HHS facility and an affiliate of Baylor College of Medicine's Dan L. Duncan Comprehensive Cancer Center, Ben Taub Hospital (BTH) delivers cancer care through multidisciplinary subspecialty that prioritize access to care, adherence to evidence-based clinical pathways, integration of supportive services, and mitigation of financial toxicity. We performed a retrospective analysis of minority patients diagnosed with and treated for metastatic CRC at BTH between January 2010 and December 2012. Kaplan-Meier survival curves were compared with survival curves from randomized control trials reported during that time period. RESULTS: We identified 103 patients; 40% were black, 49% were Hispanic, and 12% were Asian or Middle Eastern. Thirty-five percent reported a language other than English as their preferred language. Seventy-four percent of patients with documented coverage status were uninsured. Eighty-four percent of patients received standard chemotherapy with a clinician-reported response rate of 63%. Overall survival for BTH patients undergoing chemotherapy was superior to that of subjects enrolled in the CRYSTAL (Cetuximab Combined with Irinotecan in First-Line Therapy for Metastatic Colorectal Cancer) trial (median, 24.0 vs. 19.9 months; P = .014). CONCLUSION: HHS provides a health delivery infrastructure through which minority patients with socioeconomic challenges experience clinical outcomes comparable with highly selected patients enrolled in randomized control trials. Efforts to resolve CRC disparities should focus on improving access of at-risk populations to high-quality comprehensive cancer care.
AD  - Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA.
Department of Medicine, Baylor College of Medicine, Houston, TX.
Department of Medicine, Baylor College of Medicine, Houston, TX; Department of Medicine, Dan L. Duncan Comprehensive Cancer Center, Houston, TX.
Department of Medicine, Baylor College of Medicine, Houston, TX; Department of Medicine, Dan L. Duncan Comprehensive Cancer Center, Houston, TX. Electronic address: blmusher@bcm.edu.
AN  - 32165040
AU  - Lau-Min, K.
AU  - Prakash, P.
AU  - Jo, E.
AU  - Thrift, A. P.
AU  - Hilsenbeck, S.
AU  - Musher, B. L.
C2  - PMC7261246
C6  - NIHMS1547897
DA  - Jun
DO  - 10.1016/j.clcc.2019.09.002
DP  - NLM
ET  - 2020/03/14
IS  - 2
KW  - *Black
*Disparities
*Hispanic
*Stage 4
*Survival
*Underserved
pharma for serving as principal investigator for a Phase I trial in pancreatic
cancer and receives consultation fees from Ipsen pharmaceuticals for Onivyde
(FDA-approved for pancreatic cancer). Since both of these relationships pertain to
pancreatic cancer rather than colorectal cancer, neither poses a conflict of
interest in relation to the current study. The other authors have no potential
conflicts of interest to disclose.
LA  - eng
N1  - 1938-0674
Lau-Min, Kelsey
Prakash, Preeti
Jo, Eunji
Thrift, Aaron P
Hilsenbeck, Susan
Musher, Benjamin L
P30 CA125123/CA/NCI NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
Clin Colorectal Cancer. 2020 Jun;19(2):e49-e57. doi: 10.1016/j.clcc.2019.09.002. Epub 2020 Jan 2.
PY  - 2020
SN  - 1533-0028 (Print)
1533-0028
SP  - e49-e57
ST  - Outcomes Among Minority Patients With Metastatic Colorectal Cancer in a Safety-net Health Care System
T2  - Clin Colorectal Cancer
TI  - Outcomes Among Minority Patients With Metastatic Colorectal Cancer in a Safety-net Health Care System
VL  - 19
ID  - 49
ER  - 

TY  - JOUR
AB  - BACKGROUND: Previous studies have demonstrated that African-Americans with colon cancer have worse overall and stage-specific survival rates than Caucasians. Such differences could reflect variation in access to health care, in tumor biology, or in treatment efficacy. Little is known about potential differences in chemotherapy-related toxicities between African-Americans and Caucasians. In this study, we examined survival and toxic effects among African-American and Caucasian patients enrolled in a large, randomized phase III trial of adjuvant chemotherapy for resected colon cancer. METHODS: We analyzed data on 3380 patients (344 African-Americans and 3036 Caucasians) enrolled in a randomized trial of adjuvant 5-fluorouracil-based chemotherapy in patients with stage II (high risk) and stage III colon cancer to evaluate differences in outcomes and toxicity. We compared disease-free survival (DFS) and overall survival (OS) between African-Americans and Caucasians by the Kaplan-Meier method, computed Cox proportional hazards by multivariable analysis, and compared treatment-related toxicity rates by Fisher's exact test. All statistical tests were two-sided. RESULTS: We found no differences in DFS or OS between African-American and Caucasian patients. Five-year DFS was 57% (95% confidence interval [CI] = 52% to 62%) for African-Americans and 58% (95% CI = 56% to 60%) for Caucasians (P =.15), and 5-year OS was 65% (95% CI = 60% to 70%) for African-Americans and 66% (95% CI = 64% to 68%) for Caucasians (P =.38). On multivariable analysis, no statistically significant difference in disease recurrence or death was detected between the racial/ethnic groups (hazard ratios for African-Americans versus Caucasians: disease recurrence = 1.1, 95% CI = 0.9 to 1.3; death = 1.1, 95% CI = 0.9 to 1.3). Treatment-related toxicity differed between the African-American and Caucasian patients, with African-Americans experiencing statistically significantly lower rates of diarrhea (P<.001), nausea (P<.001), vomiting (P =.01), stomatitis (P<.001), and overall toxicity (P =.005). CONCLUSIONS: In this study of patients with similar access to health care resources and treatment with adjuvant chemotherapy, we found similar 5-year DFS and OS in African-Americans and Caucasians with stage II and III colon cancer. The two groups derived similar benefits from adjuvant chemotherapy. Moreover, African-Americans appeared to experience less treatment-related toxicity.
AD  - A. D. McCollum, R. J. Mayer, C. S. Fuchs, Dana-Farber Cancer Institute, Boston, MA, USA. amccollum@partners.org
AN  - 12165641
AU  - McCollum, A. D.
AU  - Catalano, P. J.
AU  - Haller, D. G.
AU  - Mayer, R. J.
AU  - Macdonald, J. S.
AU  - Benson, A. B., 3rd
AU  - Fuchs, C. S.
DA  - Aug 7
DO  - 10.1093/jnci/94.15.1160
DP  - NLM
ET  - 2002/08/08
IS  - 15
KW  - African Continental Ancestry Group
Antimetabolites, Antineoplastic/*therapeutic use
Chemotherapy, Adjuvant
Colonic Neoplasms/*drug therapy/*ethnology/mortality
European Continental Ancestry Group
Fluorouracil/adverse effects/*therapeutic use
Humans
Treatment Outcome
LA  - eng
N1  - McCollum, A David
Catalano, Paul J
Haller, Daniel G
Mayer, Robert J
Macdonald, John S
Benson, Al B 3rd
Fuchs, Charles S
CA15488/CA/NCI NIH HHS/United States
CA21115/CA/NCI NIH HHS/United States
CA23318/CA/NCI NIH HHS/United States
CA32291/CA/NCI NIH HHS/United States
CA58415/CA/NCI NIH HHS/United States
Clinical Trial
Clinical Trial, Phase III
Journal Article
Randomized Controlled Trial
Research Support, U.S. Gov't, P.H.S.
United States
J Natl Cancer Inst. 2002 Aug 7;94(15):1160-7. doi: 10.1093/jnci/94.15.1160.
PY  - 2002
SN  - 0027-8874 (Print)
0027-8874
SP  - 1160-7
ST  - Outcomes and toxicity in african-american and caucasian patients in a randomized adjuvant chemotherapy trial for colon cancer
T2  - J Natl Cancer Inst
TI  - Outcomes and toxicity in african-american and caucasian patients in a randomized adjuvant chemotherapy trial for colon cancer
VL  - 94
ID  - 666
ER  - 

TY  - JOUR
AB  - Background: Previous studies have demonstrated that African-Americans with colon cancer have worse overall and stage-specific survival rates than Caucasians. Such differences could reflect variation in access to health care, in tumor biology, or in treatment efficacy. Little is known about potential differences in chemotherapy-related toxicities between African-Americans and Caucasians. In this study, we examined survival and toxic effects among African-American and Caucasian patients enrolled in a large, randomized phase III trial of adjuvant chemotherapy for resected colon cancer. Methods: We analyzed data on 3380 patients (344 African-Americans and 3036 Caucasians) enrolled in a randomized trial of adjuvant 5-fluorouracil-based chemotherapy in patients with stage II (high risk) and stage III colon cancer to evaluate differences in outcomes and toxicity. We compared disease-free survival (DFS) and overall survival (OS) between African-Americans and Caucasians by the Kaplan-Meier method, computed Cox proportional hazards by multivariable analysis, and compared treatment-related toxicity rates by Fisher's exact test. All statistical tests were two-sided. Results: We found no differences in DFS or OS between African-American and Caucasian patients. Five-year DFS was 57% (95% confidence interval [CI] = 52% to 62%) for African-Americans and 58% (95% CI = 56% to 60%) for Caucasians (P = .15), and 5-year OS was 65% (95% CI = 60% to 70%) for African-Americans and 66% (95% CI= 64% to 68%) for Caucasians (P = .38). On multivariable analysis, no statistically significant difference in disease recurrence or death was detected between the racial/ethnic groups (hazard ratios for African-Americans versus Caucasians: disease recurrence = 1.1, 95% CI = 0.9 to 1.3; death = 1.1, 95% CI = 0.9 to 1.3). Treatment-related toxicity differed between the African-American and Caucasian patients, with African-Americans experiencing statistically significantly lower rates of diarrhea (P<.001), nausea (P<.001), vomiting (P = .01), stomatitis (P<.001), and overall toxicity (P = .005). Conclusions: In this study of patients with similar access to health care resources and treatment with adjuvant chemotherapy, we found similar 5-year DFS and OS in African-Americans and Caucasians with stage II and III colon cancer. The two groups derived similar benefits from adjuvant chemotherapy. Moreover, African-Americans appeared to experience less treatment-related toxicity.
AD  - A.D. McCollum, Dana-Farber Cancer Institute, 44 Binney St., Boston, MA, United States
AU  - McCollum, A. D.
AU  - Catalano, P. J.
AU  - Haller, D. G.
AU  - Mayer, R. J.
AU  - Macdonald, J. S.
AU  - Benson Iii, A. B.
AU  - Fuchs, C. S.
DB  - Embase
Medline
IS  - 15
KW  - fluorouracil
folinic acid
levamisole
adult
aged
anemia
article
cancer adjuvant therapy
cancer mortality
cancer recurrence
cancer staging
cancer survival
Caucasian
clinical trial
colon cancer
confidence interval
controlled clinical trial
controlled study
data analysis
diarrhea
ethnic group
female
fever
Fisher exact test
gastrointestinal toxicity
hazard assessment
health care access
high risk patient
human
infection
Kaplan Meier method
leukopenia
major clinical study
male
multivariate analysis
nausea
Black person
phase 3 clinical trial
priority journal
race difference
randomized controlled trial
skin toxicity
statistical analysis
stomatitis
survival rate
thrombocytopenia
treatment outcome
vomiting
LA  - English
M3  - Article
N1  - L34919053
2002-09-02
PY  - 2002
SN  - 0027-8874
SP  - 1160-1167
ST  - Outcomes and toxicity in African-American and Caucasians patients in a randomized adjuvant chemotherapy trial for colon cancer
T2  - Journal of the National Cancer Institute
TI  - Outcomes and toxicity in African-American and Caucasians patients in a randomized adjuvant chemotherapy trial for colon cancer
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L34919053&from=export
VL  - 94
ID  - 1301
ER  - 

TY  - JOUR
AB  - African American men continue to bear a disproportionate share of the burden of disease. Engaging these men in health research and health promotion programsespecially lower-income, African American men who are vulnerable to chronic disease conditions such as obesity and heart diseasehas historically proven quite difficult for researchers and public health practitioners. The few effective outreach strategies identified in the literature to date are largely limited to recruiting through hospital clinics, churches, and barbershops. The Men of Color Health Awareness (MOCHA) project is a grassroots, community-driven initiative that has developed a number of innovative outreach strategies. After describing these strategies, we present data on the demographic and health characteristics of the population reached using these methods, which indicate that MOCHA has been highly effective in reaching this population of men.
AN  - WOS:000441714200012
AU  - Graham, L. F.
AU  - Scott, L.
AU  - Lopeyok, E.
AU  - Douglas, H.
AU  - Gubrium, A.
AU  - Buchanan, D.
DA  - Sep
DO  - 10.1177/1557988318768602
IS  - 5
N1  - 29695204
PY  - 2018
SN  - 1557-9883
SP  - 1307-1316
ST  - Outreach Strategies to Recruit Low-Income African American Men to Participate in Health Promotion Programs and Research: Lessons From the Men of Color Health Awareness (MOCHA) Project
T2  - American Journal of Mens Health
TI  - Outreach Strategies to Recruit Low-Income African American Men to Participate in Health Promotion Programs and Research: Lessons From the Men of Color Health Awareness (MOCHA) Project
VL  - 12
ID  - 2848
ER  - 

TY  - JOUR
AB  - Clinical studies have reported associations between ovarian stromal hyperplasia and the diagnosis of hormonally related tumors such as endometrial cancer. To assess the hypothesis that characteristics of benign ovaries among postmenopausal women are related to risk for breast, endometrial, and colon cancer, we analyzed systematically collected transvaginal ultrasound data for participants enrolled in the screening arm of the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. Among women without cancer, median ovarian volume declined with age from 1.25 cm3 for women between ages 55 and 59 years to 1.0 cm3 for those between ages 65 and 69 years. African American and Caucasian women had larger median ovarian volumes than Asians. Larger ovarian volume was also associated with the highest quartiles of height and weight and ever having smoked. After adjusting for race, age, parity, body mass, smoking, and hormone use, women with median ovarian volumes >or=3.0 cm3 were at increased risk for breast cancer [odds ratio (OR), 1.42; 95% confidence interval (95% CI), 1.11-1.70], endometrial cancer (OR, 1.97; 95% CI, 1.12-3.48), and colon cancer (OR, 2.00; 95% CI, 1.25-3.21). Significant trends of risk with increasing volume were found only for breast and endometrial cancers. We conclude that large ovaries among postmenopausal women may represent a marker of risk for hormonally related tumors. Confirmation of these findings in future studies, including analyses of serum hormone levels and tissues, may provide insights into hormonal carcinogenesis among older women.
AD  - Hormonal and Reproductive Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, 6120 Executive Boulevard, Rockville, MD 20892, USA. shermanm@mail.nih.gov
AN  - 16896048
AU  - Sherman, M. E.
AU  - Lacey, J. V.
AU  - Buys, S. S.
AU  - Reding, D. J.
AU  - Berg, C. D.
AU  - Williams, C.
AU  - Hartge, P.
DA  - Aug
DO  - 10.1158/1055-9965.Epi-05-0847
DP  - NLM
ET  - 2006/08/10
IS  - 8
KW  - Aged
Case-Control Studies
Colonic Neoplasms/etiology/pathology
Endometrial Neoplasms/etiology/pathology
Female
Humans
Middle Aged
Ovarian Neoplasms/*etiology/pathology
Ovary/*pathology
*Postmenopause
LA  - eng
N1  - Sherman, Mark E
Lacey, James V
Buys, Saundra S
Reding, Douglas J
Berg, Christine D
Williams, Craig
Hartge, Patricia
Intramural NIH HHS/United States
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, N.I.H., Intramural
United States
Cancer Epidemiol Biomarkers Prev. 2006 Aug;15(8):1550-4. doi: 10.1158/1055-9965.EPI-05-0847.
PY  - 2006
SN  - 1055-9965 (Print)
1055-9965
SP  - 1550-4
ST  - Ovarian volume: determinants and associations with cancer among postmenopausal women
T2  - Cancer Epidemiol Biomarkers Prev
TI  - Ovarian volume: determinants and associations with cancer among postmenopausal women
VL  - 15
ID  - 557
ER  - 

TY  - JOUR
AB  - INTRODUCTION AND OBJECTIVES: Sipuleucel‐T (sip‐T) is an FDA‐approved autologous cellular immunotherapy targeting prostatic acid phosphatase in select men with metastatic castration‐resistant prostate cancer (mCRPC). Previous retrospective analyses of three sip‐T phase 3 trials showed a 30.7‐mo overall survival (OS) advantage for African American (AA) patients (pts) vs control pts while in the IMPACT trial, sip‐T extended median OS by 4.1 mo vs control (McLeod AUA 2012 #P953). The PROCEED registry provides a prospective opportunity to confirm these observations in a larger group of AA pts. METHODS: PROCEED (NCT01306890) enrolled men with mCRPC. In this analysis, two Caucasian (CAU) pts were matched to each AA pt by baseline prostate‐specific antigen (PSA), as PSA correlates with OS in pts receiving sip‐T (Schellhammer 2013). OS and time to first anticancer intervention (tACI) post‐sip‐T were examined; univariate and multivariate analyses evaluated independent factors associated with OS. RESULTS: 420 CAU pts were matched to 210 AA pts; all received >=1 sip‐T infusion. CAU pts had significantly higher baseline median hemoglobin levels (p<0.001; 13.0 g/dL vs 12.1 g/dL for AA pts) and were more likely to receive prior local therapy (p=0.02) or prior chemotherapy (p<0.001). CAU pts had a longer tACI of 9.3 mo vs 7.6 mo for AA pts. However, AA pts had a significantly longer median OS of 39.5 mo vs 28.1 mo for CAU pts (p<0.001; HR 0.665, 95% CI 0.530‐ 0.835). After univariate and multivariate analyses, six baseline characteristics were significantly associated with OS (Table). Younger age, lower PSA or alkaline phosphatase, and higher hemoglobin levels were independently associated with longer OS. No prior chemotherapy and the AA race were also independent predictors of extended OS. CONCLUSIONS: Post‐sip‐T, median OS for AA pts was significantly extended by nearly 1 year compared with matched CAU pts. In this large prospective analysis, AA race emerged as an independent predictor of longer OS in multivariate analyses, confirming observations of prior retrospective analysis of phase 3 trial data. These results should stimulate additional studies on the biologic basis for AA men's enhanced response to sip‐T and potentially other immunotherapies. (Table presented).
AN  - CN-01376092
AU  - Sartor, A. O.
AU  - Armstrong, A.
AU  - Ahaghotu, C.
AU  - McLeod, D.
AU  - Cooperberg, M.
AU  - Penson, D.
AU  - Kantoff, P.
AU  - Vogelzang, N.
AU  - Hussain, A.
AU  - Pieczonka, C.
AU  - et al.
IS  - 4 Supplement 1
KW  - *African American
*Caucasian
*overall survival
*register
*sipuleucel T
Alkaline phosphatase
Castration resistant prostate cancer
Clinical trial
Controlled clinical trial
Controlled study
Drug therapy
Endogenous compound
Hemoglobin blood level
Human
Immunotherapy
Infusion
Local therapy
Major clinical study
Male
Multivariate analysis
Patient history of chemotherapy
Phase 3 clinical trial
Prostate specific antigen
Retrospective study
M3  - Conference Abstract
PY  - 2017
SP  - e456‐e457
ST  - Overall survival analysis of african american and caucasian patients receiving Sipuleucel-T: preliminary data from the proceed registry
T2  - Journal of urology. Conference: 112th annual meeting of the american urological association, AUA 2017. United states
TI  - Overall survival analysis of african american and caucasian patients receiving Sipuleucel-T: preliminary data from the proceed registry
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01376092/full
VL  - 197
ID  - 1483
ER  - 

TY  - JOUR
AB  - Background: Reports have suggested that African‐American (AA) men with metastatic castration‐resistant prostate cancer (mCRPC) have shorter overall survival (OS) than Caucasian (C) men. Prior reports have been limited by small sample size. The primary goal of this analysis was to compare OS in AA men to Caucasian men treated with docetaxel/prednisone or a docetaxel/prednisone containing regimen. Methods: Individual patient data from 8,871 mCRPC men randomized on nine phase III trials to docetaxel/prednisone (DP) or a DP containing regimen were combined. Race used in the analysis was based on self‐report. The primary endpoint is OS, defined as the time between randomization and death or date of last follow‐up if patients were alive. The proportional hazards model was used to assess the prognostic importance of race (AA vs. C) adjusting for established risk factors that were common across the trials (age, PSA, performance status, alkaline phosphatase, hemoglobin, and sites of metastases). Results: Of 8,871 patients, 7,528 (85%) were C, 500 (6%) were AA, 424 were Asian (5%) and 419 (4%) had race unspecified. The last two groups were deleted from the analysis leaving 8,452 pts. Median age was 69 years and 94% had performance status 0‐1. Median hemoglobin, PSA and alkaline phosphatase were 12.9 g/dL, 86 ng/mL and 139 U/L, respectively. Pattern of metastatic spread were: 72% bone disease with or without lymph nodes, 9% lung disease, 9% liver disease and 7% lymph nodes only. Median OS were 21.0 (95% CI = 19.4‐22.5) vs. 21.2 months (95% CI = 20.8‐21.7) in AAs and C, respectively. In multivariable analysis adjusting for established risk factors, the pooled hazard ratio (HR) for AAs vs. Caucasians was 0.81 (95% CI = 0.72‐0.92, p‐value = 0.001) in all patients. Similar results were observed in 4,172 of patients who were treated with DP. Conclusions: We observed a statistically significant increased OS in AA vs. C men with mCRPC who were eligible to be enrolled on these clinical trials. Further understanding the biological variation by race in men with mCRPC treated with DP is warranted.
AN  - CN-01785287
AU  - Halabi, S.
AU  - Dutta, S.
AU  - Tangen, C. M.
AU  - Rosenthal, M.
AU  - Petrylak, D. P.
AU  - Thompson, I. M.
AU  - Chi, K. N.
AU  - De Bono, J. S.
AU  - Fandi, A.
AU  - Araujo, J. C.
AU  - et al.
DO  - 10.1200/JCO.2018.36.18-suppl.LBA5005
IS  - 18
KW  - *African American
*Caucasian
*cancer survival
*castration resistant prostate cancer
*overall survival
Aged
Biological variation
Bone disease
Cancer patient
Cancer prognosis
Conference abstract
Controlled study
Death
Drug combination
Drug therapy
Follow up
Human
Liver disease
Lung disease
Lymph node
Major clinical study
Male
Metastasis
Patient coding
Phase 3 clinical trial
Randomization
Randomized controlled trial
Risk assessment
Risk factor
Self report
Statistical significance
M3  - Journal: Conference Abstract
PY  - 2018
ST  - Overall survival between African-American (AA) and Caucasian (C) men with metastatic castration-resistant prostate cancer (mCRPC)
T2  - Journal of clinical oncology
TI  - Overall survival between African-American (AA) and Caucasian (C) men with metastatic castration-resistant prostate cancer (mCRPC)
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01785287/full
VL  - 36
ID  - 1499
ER  - 

TY  - JOUR
AB  - PURPOSE: Several studies have reported that among patients with localized prostate cancer, black men have a shorter overall survival (OS) time than white men, but few data exist for men with advanced prostate cancer. The primary goal of this analysis was to compare the OS in black and white men with metastatic castration-resistant prostate cancer (mCRPC) who were treated in phase III clinical trials with docetaxel plus prednisone (DP) or a DP-containing regimen. METHODS: Individual participant data from 8,820 men with mCRPC randomly assigned in nine phase III trials to DP or a DP-containing regimen were combined. Race was based on self-report. The primary end point was OS. The Cox proportional hazards regression model was used to assess the prognostic importance of race (black v white) adjusted for established risk factors common across the trials (age, prostate-specific antigen, performance status, alkaline phosphatase, hemoglobin, and sites of metastases). RESULTS: Of 8,820 men, 7,528 (85%) were white, 500 (6%) were black, 424 (5%) were Asian, and 368 (4%) were of unknown race. Black men were younger and had worse performance status, higher testosterone and prostate-specific antigen, and lower hemoglobin than white men. Despite these differences, the median OS was 21.0 months (95% CI, 19.4 to 22.5 months) versus 21.2 months (95% CI, 20.8 to 21.7 months) in black and white men, respectively. The pooled multivariable hazard ratio of 0.81 (95% CI, 0.72 to 0.91) demonstrates that overall, black men have a statistically significant decreased risk of death compared with white men ( P < .001). CONCLUSION: When adjusted for known prognostic factors, we observed a statistically significant increased OS in black versus white men with mCRPC who were enrolled in these clinical trials. The mechanism for these differences is not known.
AD  - 1 Duke University Medical Center, Durham, NC.
2 Fred Hutchinson Cancer Research Center, Seattle, WA.
3 The Royal Melbourne Hospital, Parkville, VIC, Australia.
4 Yale University School of Medicine, New Haven, CT.
5 UT Health Science Center, San Antonio, TX.
6 BC Cancer Agency Vancouver Centre, Vancouver, BC.
7 The University of Texas MD Anderson Cancer Center, Houston, TX.
8 University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA.
9 Gustave Roussy, Villejuif, France.
10 Memorial Sloan Kettering Cancer Center, New York, NY.
11 The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD.
12 The Institute of Cancer Research and The Royal Marsden National Health Service Foundation Trust, Sutton, United Kingdom.
13 Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada.
14 University of California San Francisco, San Francisco, CA.
15 Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, PA.
AN  - 30576268
AU  - Halabi, S.
AU  - Dutta, S.
AU  - Tangen, C. M.
AU  - Rosenthal, M.
AU  - Petrylak, D. P.
AU  - Thompson, I. M., Jr.
AU  - Chi, K. N.
AU  - Araujo, J. C.
AU  - Logothetis, C.
AU  - Quinn, D. I.
AU  - Fizazi, K.
AU  - Morris, M. J.
AU  - Eisenberger, M. A.
AU  - George, D. J.
AU  - De Bono, J. S.
AU  - Higano, C. S.
AU  - Tannock, I. F.
AU  - Small, E. J.
AU  - Kelly, W. K.
C2  - PMC6804881
DA  - Feb 10
DO  - 10.1200/jco.18.01279
DP  - NLM
ET  - 2018/12/24
IS  - 5
KW  - African Continental Ancestry Group/*statistics & numerical data
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Clinical Trials, Phase III as Topic
Docetaxel/administration & dosage
European Continental Ancestry Group/*statistics & numerical data
Humans
Male
Mitoxantrone/administration & dosage
Neoplasm Metastasis
Prednisone/administration & dosage
Prostatic Neoplasms, Castration-Resistant/*drug
therapy/*ethnology/mortality/pathology
Randomized Controlled Trials as Topic
LA  - eng
N1  - 1527-7755
Halabi, Susan
Dutta, Sandipan
Tangen, Catherine M
Rosenthal, Mark
Petrylak, Daniel P
Thompson, Ian M Jr
Chi, Kim N
Araujo, John C
Logothetis, Christopher
Quinn, David I
Fizazi, Karim
Morris, Michael J
Eisenberger, Mario A
George, Daniel J
De Bono, Johann S
Higano, Celestia S
Tannock, Ian F
Small, Eric J
Kelly, William Kevin
P30 CA016672/CA/NCI NIH HHS/United States
UG1 CA189974/CA/NCI NIH HHS/United States
P30 CA008748/CA/NCI NIH HHS/United States
P30 CA014089/CA/NCI NIH HHS/United States
U10 CA180888/CA/NCI NIH HHS/United States
U10 CA180819/CA/NCI NIH HHS/United States
U10 CA180830/CA/NCI NIH HHS/United States
Journal Article
Meta-Analysis
Research Support, U.S. Gov't, Non-P.H.S.
Systematic Review
J Clin Oncol. 2019 Feb 10;37(5):403-410. doi: 10.1200/JCO.18.01279. Epub 2018 Dec 21.
PY  - 2019
SN  - 0732-183X (Print)
0732-183x
SP  - 403-410
ST  - Overall Survival of Black and White Men With Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel
T2  - J Clin Oncol
TI  - Overall Survival of Black and White Men With Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel
VL  - 37
ID  - 91
ER  - 

TY  - JOUR
AB  - Background: Fragmented care, limited psychosocial support, and poor symptom management plague some women with breast cancer, especially those with low income, leading to poor health outcomes among disadvantaged groups. To address these disparities a “virtual” navigator system was developed. The efficacy of patient navigation delivered via a web‐based knowledge and communication portal to improve adherence, symptom management and quality of life among low‐income women undergoing adjuvant breast cancer treatment is being evaluated in a randomized clinical trial with a recruitment goal of 100 patients. Methods: All subjects receive a netbook computer with access to the web‐based portal, wireless Internet connectivity, and computer training. The application provides direct links to vetted reliable websites and, for the intervention arm, access to tailored documents, short instructional videos by the study team and at least biweekly navigator (nurse and/or social worker) visits via Skype™ or telephone. Assessments are conducted at baseline, 6 and 12 months after enrollment. Study outcomes include treatment adherence (appointments kept, relative dose intensity and medication possession ratio), fatigue (10 point Visual Analog Scale), distress (Impact of Events Scale) and quality of life (FACT‐B.) Results: Barriers to implementation include inadequate connectivity in some rural areas, delivery of computers by supplier, and monthly data limits (5GB) for the wireless service resulting in temporary suspension of service when limits are exceeded (4 control participants to date.) Mean age of the 35 women enrolled as of November 2012 is 47.5 years (SD 9.7); range 24‐68. All have incomes < 300% of poverty level and 59% are African American. 44% have a high school education or less. 40% have co‐morbid psychiatric diagnoses. About a quarter of participants have little or no computer experience. Compared to control patients, those on the intervention arm are more likely to agree or strongly agree (73% versus 29%) that the portal is easy to use, that they use it frequently and that they have confidence in their ability to use it. Conclusion: Women randomized to the navigational support intervention arm are more likely than control women to use the portal to access information and to feel more confident in their use of the portal. The study will determine if increased access to educational materials and virtual support translates into improved health outcomes.
AN  - CN-01011419
AU  - Helzlsouer, K. J.
AU  - Appling, S.
AU  - Scarvalone, S.
AU  - MacDonald, R.
AU  - Price, A.
AU  - Wolf, B.
AU  - Snyder, I.
AU  - Varanasi, A.
DO  - 10.1158/1538-7445.AM2013-1382
IS  - 8
KW  - *cancer research
*human
*patient care
*randomized controlled trial
*technology
African American
Arm
Breast cancer
Cancer therapy
Clinical trial
Computer
Drug therapy
Education
Fatigue
Female
Health
High school
Impact of Events Scale
Income
Internet
Interpersonal communication
Lowest income group
Nurse
Patient
Patient compliance
Plague
Poverty
Psychiatric diagnosis
Psychosocial care
Quality of life
Rural area
Social worker
Telephone
Videorecording
Visual analog scale
M3  - Journal: Conference Abstract
PY  - 2013
ST  - Overcoming disparities with technology-enhanced patient navigation: implementation of a randomized controlled trial
T2  - Cancer research
TI  - Overcoming disparities with technology-enhanced patient navigation: implementation of a randomized controlled trial
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01011419/full
VL  - 73
ID  - 1555
ER  - 

TY  - JOUR
AB  - Culturally appropriate recruiting strategies will increase the number of African-American men consenting to participate in prostate cancer research. This article describes the complexity of recruitment issues and highlights strategies that enhance research participation.
AD  - Assistant Professor, College of Social Work, University of South Carolina, Columbia, SC
Core Faculty Member, Statewide Cancer Prevention and Control Program, University of South Carolina, Columbia, SC
Deputy Director, C & J Consulting, Columbia, SC
Professor and Chair, Statewide Cancer Prevention and Control Program, University of South Carolina, Columbia, SC
Professor and Chair, the Department of Health Promotion, Education, and Behavior, University of South Carolina, Columbia, SC
AN  - 126845386. Language: English. Entry Date: 20171220. Revision Date: 20191111. Publication Type: Article
AU  - Owens, Otis L.
AU  - James, Calvin
AU  - Friedman, Daniela B.
DB  - CINAHL Complete
DO  - 10.7257/1053-816X.2017.37.6.293
DP  - EBSCOhost
IS  - 6
KW  - Research Subject Recruitment -- Methods
Health Status Disparities
Prostatic Neoplasms -- Prevention and Control
Human
Conceptual Framework
Churches
Culture
Public Spaces
Organizations
Purposive Sample
Practitioner's Office
Male
Adult
Descriptive Research
Descriptive Statistics
Snowball Sample
South Carolina
N1  - research; tables/charts. Journal Subset: Core Nursing; Double Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Nursing; Peer Reviewed; USA. Special Interest: Oncologic Care. NLM UID: 8812256.
PY  - 2017
SN  - 1053-816X
SP  - 293-315
ST  - Overcoming the Challenges Of African-American Recruitment In Health Sciences Research: Strategies and Recommendations
T2  - Urologic Nursing
TI  - Overcoming the Challenges Of African-American Recruitment In Health Sciences Research: Strategies and Recommendations
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=126845386&site=ehost-live&scope=site
VL  - 37
ID  - 2011
ER  - 

TY  - JOUR
AB  - Large, long term research studies present recruitment challenges that can be met with collaborative approaches to identify and enroll participants. The Osteoporotic Fractures in Men Study (MrOS), a multi-center observational study designed to determine risk factors for osteoporosis, fractures and prostate cancer in older men, recruited 5995 participants over a 25-month period. Enrolling a cohort that represented the race and age distribution of each community, and developing interest in an older male cohort about a condition commonly thought of as a "women's disease," were major recruitment challenges. During the start-up phase, recruitment challenges and strategies were analyzed and collective approaches were developed to address ways to motivate the target population. Key methods included mailings using community and provider contact lists; regional and senior newspaper advertisements; and presentations targeted to seniors. Sites used a centrally developed recruitment brochure. Response to mass mailings at some sites surpassed 10-15% and appointment show rates averaged above 85%. The final number enrolled in MrOS was 5% more than the original recruitment goal of 5700. Minority recruitment was enhanced through the use of the Health Care Financing Administration and other databases that allowed for targeted recruitment. Overall, minority enrollment was approximately 10.56% of the cohort (244 African American, 191 Asian). Men age>80 were enthusiastic and represent about 18% of enrollees. Through a coordinated approach of developing and refining recruitment strategies and materials, sites were able to adapt their original strategies and complete recruitment ahead of schedule.
AD  - Oregon Health and Science University, 3181 SW Sam Jackson Park Road CR107, Portland, OR 97239, USA. blankj@ohsu.edu
AN  - 16085466
AU  - Blank, J. B.
AU  - Cawthon, P. M.
AU  - Carrion-Petersen, M. L.
AU  - Harper, L.
AU  - Johnson, J. P.
AU  - Mitson, E.
AU  - Delay, R. R.
DA  - Oct
DO  - 10.1016/j.cct.2005.05.005
DP  - NLM
ET  - 2005/08/09
IS  - 5
KW  - Aged
Aged, 80 and over
Fractures, Bone/*epidemiology/etiology
Humans
Longitudinal Studies
Male
Minority Groups/statistics & numerical data
Osteoporosis/*epidemiology
*Patient Selection
Prospective Studies
Prostatic Diseases/epidemiology
Risk Factors
United States/epidemiology
LA  - eng
N1  - Blank, Janet Babich
Cawthon, Peggy Mannen
Carrion-Petersen, Mary Lou
Harper, Loretta
Johnson, J Phillip
Mitson, Eileen
Delay, Romelia Ramírez
AG18197/AG/NIA NIH HHS/United States
AR45580/AR/NIAMS NIH HHS/United States
AR45583/AR/NIAMS NIH HHS/United States
AR45614/AR/NIAMS NIH HHS/United States
AR45632/AR/NIAMS NIH HHS/United States
AR45654/AR/NIAMS NIH HHS/United States
U01-AR45647/AR/NIAMS NIH HHS/United States
Journal Article
Multicenter Study
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, P.H.S.
United States
Contemp Clin Trials. 2005 Oct;26(5):557-68. doi: 10.1016/j.cct.2005.05.005.
PY  - 2005
SN  - 1551-7144 (Print)
1551-7144
SP  - 557-68
ST  - Overview of recruitment for the osteoporotic fractures in men study (MrOS)
T2  - Contemp Clin Trials
TI  - Overview of recruitment for the osteoporotic fractures in men study (MrOS)
VL  - 26
ID  - 593
ER  - 

TY  - JOUR
AB  - OBJECTIVE: Encourage older African-American women to participate in breast cancer detection. Breast cancer deaths for older African-American women are higher than for Caucasian counterparts. Effective outreach education about mammography and breast exam is one method to reduce the disparity by encouraging women to enter treatment earlier through earlier diagnosis. Traditional outreach strategies have proven ineffective with this cohort. METHOD: In this study we utilized the trust placed in known community leaders to recruit older African-American women to participate in breast health education leading to completion of a mammogram. One hundred sixty-two women were identified as participants. RESULTS: Seventy-nine percent of the women who completed the project obtained mammograms and 9% had mammograms scheduled at 1-month follow-up, whereas 22% of the individuals who received only mailed educational materials completed mammograms and none had scheduled mammograms pending. DISCUSSION: Health education for difficult-to-reach populations can be effective but requires greater inclusion of community partners to offset issues related to trust, health beliefs, and access.
AD  - Aging Resource Center, Agency on Aging of South Central CT, One Long Wharf, New Haven, CT 06511, USA. CHOICESsccaa@snet.net
AN  - 18956513
AU  - Kidder, B.
DO  - 10.1080/00981380801970830
DP  - NLM
ET  - 2008/10/30
IS  - 1
KW  - *African Americans
Aged
Attitude to Health/ethnology
Breast Neoplasms/diagnosis/*ethnology/*prevention & control
Community Participation/methods
Community-Institutional Relations
Female
Health Education/*methods
Humans
Mammography
Middle Aged
North Carolina
Patient Acceptance of Health Care/ethnology
Program Evaluation
United States
Women's Health
LA  - eng
N1  - Kidder, Beverly
Journal Article
Research Support, Non-U.S. Gov't
United States
Soc Work Health Care. 2008;47(1):60-72. doi: 10.1080/00981380801970830.
PY  - 2008
SN  - 0098-1389 (Print)
0098-1389
SP  - 60-72
ST  - P.O.W. (protect our women): results of a breast cancer prevention project targeted to older African-American women
T2  - Soc Work Health Care
TI  - P.O.W. (protect our women): results of a breast cancer prevention project targeted to older African-American women
VL  - 47
ID  - 484
ER  - 

TY  - JOUR
AB  - Background:Insufficient data exist to describe the hematological safety of palbociclib in African American women (AAW) who are known to have a high incidence of benign ethnic neutropenia (BEN). The studies that led to the FDA approval of palbociclib (PALOMA 1 and 3) only included participants with baseline absolute neutrophil count (ANC) of >1500/mm3. The standard lower limit of ANC of 1500/mm3 for initiation of treatment in those with BEN has been previously challenged. In this current study, we propose to lower the ANC cutoff for enrollment to 1000/mm3. Trial design: PALINA is a phase II study evaluating the hematological safety of palbociclib with letrozole in 35 AAW with hormone receptor (HR) positive HER2 negative advanced breast cancer and ANC >1000/mm3. Patients enrolled will receive palbociclib 125mg daily for 21 days followed by 7 days off and letrozole 2.5mg daily. For patients enrolled with baseline ANC between 1000‐1499/mm3, initial dose of palbociclib will be 100mg daily for 21 days followed by 7 days off. Presence of Duffy Null Polymorphism (SNP rs2814778) as a predictive marker for neutrophil count will be assessed at baseline. Metabolite and exosomal signature (proteins and RNA) of drug resistance will be evaluated at different time points. Main eligibility criteria: Self‐identified Black, African or AAW of > 18 years of age with proven diagnosis of advanced HR‐positive, HER2‐negative breast cancer; ECOG performance status 0‐2; ANC > 1,000/mm3 and no prior receipt of CDK4/6 inhibitors. Specific aims: The primary endpoint is the proportion of patients who complete planned oncologic therapy without the development of a hematological event defined as episodes of febrile neutropenia and treatment discontinuation due to neutropenia. Additional endpoints include: number of patients who required dose delays or dose reductions in palbociclib attributed to neutropenia; rate of grade 3/4 neutropenia; clinical benefit rate at 24 weeks; correlations between metabolite and exosomal signature with disease response; correlations between baseline ANC prior to cancer diagnosis and the Duffy Null polymorphism with hematological safety. Statistical methods: The study is designed to assess the rate of completion of planned therapy in the absence of a hematological event defined as episodes of febrile neutropenia and treatment discontinuation due to neutropenia. Simon's two‐stage design with a maximum of 35 patients is used. The null hypothesis that the true completion rate is 60% will be tested against a one‐sided alternative. This design yields a type I error rate of 0.05 and power of 80% when the true completion rate is 80%.
AN  - CN-01363841
AU  - Lynce, F.
AU  - Shajahan-Haq, A.
AU  - Cai, L.
AU  - Graham, D.
AU  - Gallagher, C.
AU  - Mohebtash, M.
AU  - Kamugisha, L.
AU  - Novielli, N.
AU  - Castle, J.
AU  - Forero, A.
AU  - et al.
DO  - 10.1158/1538-7445.SABCS16-OT2-01-09
IS  - 4 Supplement 1) (no pagination
KW  - *African American
*breast cancer
*controlled study
*epidermal growth factor receptor 2
*hormone receptor
*letrozole
*palbociclib
*safety
Adult
Cancer diagnosis
Clinical article
Clinical trial
Controlled clinical trial
Cyclin dependent kinase 4
Cyclin dependent kinase 6
Diagnosis
Disease course
Drug combination
Drug resistance
Drug therapy
Drug withdrawal
Endogenous compound
Febrile neutropenia
Female
Genetic marker
Genetic susceptibility
Human
Metabolite
Neutrophil count
Null hypothesis
Pharmacokinetics
Phase 2 clinical trial
Single nucleotide polymorphism
Statistical analysis
Study design
Young adult
M3  - Conference Abstract
PY  - 2017
ST  - PALINA: a phase II safety study of palbociclib in combination with letrozole in African American women with hormone receptor positive HER2 negative advanced breast cancer
T2  - Cancer research. Conference: 39th annual CTRC-AACR san antonio breast cancer symposium. United states
TI  - PALINA: a phase II safety study of palbociclib in combination with letrozole in African American women with hormone receptor positive HER2 negative advanced breast cancer
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01363841/full
VL  - 77
ID  - 1438
ER  - 

TY  - JOUR
AB  - Palbociclib has been shown to be a highly effective therapy in hormone receptor positive metastatic breast cancer when used in combination with letrozole or fulvestrant. Grade 3/4 neutropenia is a common side effect although febrile neutropenia is relatively uncommon. Insufficient data exist to describe the hematological safety of palbociclib in African American women (AAW) known to have a high incidence of benign ethnic neutropenia (BEN). PALOMA 1, 2 and 3, the initial phase II/III studies that led to the U.S. Food and Drug Administration (FDA) approval of palbociclib in metastatic breast cancer, only included participants with baseline absolute neutrophil count (ANC) of 1500/mm(3) or higher. African American women (AAW) were underrepresented in the PALOMA trials and this may be partially explained by strict requirements for minimal ANC ≥1500/mm(3). The ANC of 1500/mm(3) for initiation of treatment in those with BEN has been previously challenged. In this study, we propose to lower the ANC cutoff for enrollment to 1000/mm(3). PALINA (NCT02692755) is a phase II, single arm, multicenter clinical trial that will enroll 35 patients. The primary endpoint is to assess the proportion of patients who complete therapy without the development of febrile neutropenia or treatment discontinuation due to neutropenia. The secondary endpoints include number of patients who required dose delays or dose reductions in palbociclib attributed to neutropenia, rate of grade 3/4 neutropenia, clinical benefit rate at 24 weeks, the association between metabolite and exosomal signature with disease response and the association between baseline ANC prior to cancer diagnosis and the Duffy Null polymorphism (SNP rs2814778) with hematological safety. PALINA will provide important information about the hematologic safety of palbociclib in AAW with advanced breast cancer.
AD  - MedStar Georgetown University Hospital, Lombardi Comprehensive Cancer Center, USA.
MedStar Washington Hospital Center, USA.
Georgetown University, Lombardi Comprehensive Cancer Center, USA.
University of Chicago, USA.
Thomas Jefferson University, USA.
MedStar Union Memorial Hospital, USA.
MedStar Good Samaritan Hospital, USA.
AN  - 30009277
AU  - Lynce, F.
AU  - Saleh, M.
AU  - Shajahan-Haq, A.
AU  - Gallagher, C.
AU  - Dilawari, A.
AU  - Hahn, O.
AU  - Abu-Khalaf, M.
AU  - Cai, L.
AU  - Pohlmann, P.
AU  - Mohebtash, M.
AU  - Kamugisha, L.
AU  - Isaacs, C.
C2  - PMC6042467
DA  - Jun
DO  - 10.1016/j.conctc.2018.05.012
DP  - NLM
ET  - 2018/07/17
KW  - *African-American
*Fulvestrant
*Letrozole
*Palbociclib
LA  - eng
N1  - 2451-8654
Lynce, Filipa
Saleh, Mervat
Shajahan-Haq, Ayesha
Gallagher, Christopher
Dilawari, Asma
Hahn, Olwen
Abu-Khalaf, Maysa
Cai, Ling
Pohlmann, Paula
Mohebtash, Mahsa
Kamugisha, Lois
Isaacs, Claudine
R01 CA201092/CA/NCI NIH HHS/United States
Journal Article
Contemp Clin Trials Commun. 2018 May 7;10:190-192. doi: 10.1016/j.conctc.2018.05.012. eCollection 2018 Jun.
PY  - 2018
SN  - 2451-8654
SP  - 190-192
ST  - PALINA: A phase II safety study of palbociclib in combination with letrozole or fulvestrant in African American women with hormone receptor positive HER2 negative advanced breast cancer
T2  - Contemp Clin Trials Commun
TI  - PALINA: A phase II safety study of palbociclib in combination with letrozole or fulvestrant in African American women with hormone receptor positive HER2 negative advanced breast cancer
VL  - 10
ID  - 111
ER  - 

TY  - JOUR
AB  - Background: Latinos are underrepresented in biomedical research, particularly biomarker research, yet they constitute the nation's largest ethnic/racial minority. Optimal methods for obtaining biospecimens for biomarker research among Latinos need to be identified. To minimize barriers and enhance participation, this study developed and tested tailored strategies for collecting biomarkers of chronic stress and premature aging among Spanish-speaking Latina breast cancer survivors. Methods: This study used a community-based participatory approach and selected hair and saliva as noninvasive biospecimens to assess telomere length, the cortisol awakening response (CAR), and hair cortisol concentration. We developed bilingual multimedia instructional materials, and community health workers assisted in collections. Telephone surveys assessed willingness to participate in future studies, barriers to sample collection, and recommendations for improving the strategies. Results: A total of 103 participants were recruited over 18 months from two rural sites in California, and 88 were retained at 6-month follow-up. At baseline, rates of donating salivary DNA for telomere length measurement, saliva for CAR analysis, and hair for cortisol concentration were 98%, 89%, and 52%, respectively. At follow-up, rates were 83%, 76%, and 55%, respectively. The majority of participants reported being very willing to provide hair (72%) or saliva (74%) for future studies. Conclusions: Our results support the feasibility of including minorities in biomedical research. We report excellent rates of saliva collection when community partners are engaged in the process, and when patient-centered and culturally tailored recruitment methods are implemented. Impact: The development of methods to facilitate the inclusion of minorities in biomedical research is critical to eliminate racial/ethnic health disparities.
AN  - WOS:000521288000010
AU  - Samayoa, C.
AU  - Santoyo-Olsson, J.
AU  - Escalera, C.
AU  - Stewart, A. L.
AU  - Ortiz, C.
AU  - Marquez-Magana, L.
AU  - Urias, A.
AU  - Gonzalez, N.
AU  - Cervantes, S. A.
AU  - Torres-Nguyen, A.
AU  - Parada-Ampudia, L.
AU  - Napoles, A. M.
DA  - Mar
DO  - 10.1158/1055-9965.EPI-19-0942
IS  - 3
N1  - 32132128
PY  - 2020
SN  - 1055-9965
SP  - 606-615
ST  - Participant-Centered Strategies for Overcoming Barriers to Biospecimen Collection among Spanish-Speaking Latina Breast Cancer Survivors
T2  - Cancer Epidemiology Biomarkers & Prevention
TI  - Participant-Centered Strategies for Overcoming Barriers to Biospecimen Collection among Spanish-Speaking Latina Breast Cancer Survivors
VL  - 29
ID  - 2790
ER  - 

TY  - JOUR
AB  - Context Despite the importance of diversity of cancer trial participants with regard to race, ethnicity, age, and sex, there is little recent information about the representation of these groups in clinical trials. Objective To characterize the representation of racial and ethnic minorities, the elderly, and women in cancer trials sponsored by the National Cancer Institute. Design, Setting, and Patients Cross-sectional population-based analysis of all participants in therapeutic nonsurgical National Cancer Institute Clinical Trial Cooperative Group breast, colorectal, lung, and prostate cancer clinical trials in 2000 through 2002. In a separate analysis, the ethnic distribution of patients enrolled in 2000 through 2002 was compared with those enrolled in 1 996 through 1998, using logistic regression models to estimate the relative risk ratio of enrollment for racial and ethnic minorities to that of white patients during these time periods. Main Outcome Measure Enrollment fraction, defined as the number of trial enrollees divided by the estimated US cancer cases in each race and age subgroup. Results Cancer research participation varied significantly across racial/ethnic and age groups. Compared with a 1.8% enrollment fraction among white patients, lower enrollment fractions were noted in Hispanic (1.3 %; odds ratio [OR] vs whites, 0.72; 95% confidence interval [CI], 0.68-0.77; P<.001) and black (1.3%; OR, 0.71; 95% Cl, 0.68-0.74; P<001) patients. There was a strong relationship between age and enrollment fraction, with trial participants 30 to 64 years of age representing 3.0% of incident cancer patients in that age group, in comparison to 1.3% of 65- to 74-year-old patients and 0.5% of patients 75 years of age and older. This inverse relationship between age and trial enrollment fraction was consistent across racial and ethnic groups. Although the total number of trial participants increased during our study period, the representation of racial and ethnic minorities decreased. in comparison to whites, after adjusting for age, cancer type, and sex, patients enrolled in 2000 through 2002 were 24% less likely to be black (adjusted relative risk ratio, 0.76; 95% Cl, 0.65-0.89; P<.001). Men were more likely than women to enroll in colorectal cancer trials (enrollment fractions: 2.1 % vs 1.6%, respectively; OR, 1.30; 95% Cl, 1.24-1,35; P<.001) and lung cancer trials (enrollment fractions: 0.9% vs 0.7%, respectively; OR, 1.23; 95% Cl, 1.16-1.31; P<001). Conclusions Enrollment in cancer trials is low for all patient groups. Racial and ethnic minorities, women, and the elderly were less likely to enroll in cooperative group cancer trials than were whites, men, and younger patients, respectively. The proportion of trial participants who are black has declined in recent years.
AN  - WOS:000221862300026
AU  - Murthy, V. H.
AU  - Krumholz, H. M.
AU  - Gross, C. P.
DA  - Jun 9
DO  - 10.1001/jama.291.22.2720
IS  - 22
N1  - 1161
15187053
PY  - 2004
SN  - 0098-7484
SP  - 2720-2726
ST  - Participation in cancer clinical trials - Race-, sex-, and age-based disparities
T2  - Jama-Journal of the American Medical Association
TI  - Participation in cancer clinical trials - Race-, sex-, and age-based disparities
VL  - 291
ID  - 2682
ER  - 

TY  - JOUR
AB  - CONTEXT: Despite the importance of diversity of cancer trial participants with regard to race, ethnicity, age, and sex, there is little recent information about the representation of these groups in clinical trials. OBJECTIVE: To characterize the representation of racial and ethnic minorities, the elderly, and women in cancer trials sponsored by the National Cancer Institute. DESIGN, SETTING, AND PATIENTS: Cross-sectional population-based analysis of all participants in therapeutic nonsurgical National Cancer Institute Clinical Trial Cooperative Group breast, colorectal, lung, and prostate cancer clinical trials in 2000 through 2002. In a separate analysis, the ethnic distribution of patients enrolled in 2000 through 2002 was compared with those enrolled in 1996 through 1998, using logistic regression models to estimate the relative risk ratio of enrollment for racial and ethnic minorities to that of white patients during these time periods. MAIN OUTCOME MEASURE: Enrollment fraction, defined as the number of trial enrollees divided by the estimated US cancer cases in each race and age subgroup. RESULTS: Cancer research participation varied significantly across racial/ethnic and age groups. Compared with a 1.8% enrollment fraction among white patients, lower enrollment fractions were noted in Hispanic (1.3%; odds ratio [OR] vs whites, 0.72; 95% confidence interval [CI], 0.68-0.77; P<.001) and black (1.3%; OR, 0.71; 95% CI, 0.68-0.74; P<.001) patients. There was a strong relationship between age and enrollment fraction, with trial participants 30 to 64 years of age representing 3.0% of incident cancer patients in that age group, in comparison to 1.3% of 65- to 74-year-old patients and 0.5% of patients 75 years of age and older. This inverse relationship between age and trial enrollment fraction was consistent across racial and ethnic groups. Although the total number of trial participants increased during our study period, the representation of racial and ethnic minorities decreased. In comparison to whites, after adjusting for age, cancer type, and sex, patients enrolled in 2000 through 2002 were 24% less likely to be black (adjusted relative risk ratio, 0.76; 95% CI, 0.65-0.89; P<.001). Men were more likely than women to enroll in colorectal cancer trials (enrollment fractions: 2.1% vs 1.6%, respectively; OR, 1.30; 95% CI, 1.24-1.35; P<.001) and lung cancer trials (enrollment fractions: 0.9% vs 0.7%, respectively; OR, 1.23; 95% CI, 1.16-1.31; P<.001). CONCLUSIONS: Enrollment in cancer trials is low for all patient groups. Racial and ethnic minorities, women, and the elderly were less likely to enroll in cooperative group cancer trials than were whites, men, and younger patients, respectively. The proportion of trial participants who are black has declined in recent years.
AD  - Section of General Internal Medicine, Department of Medicine, Yale University School of Medicine, New Haven, Conn 06520, USA.
AN  - 15187053
AU  - Murthy, V. H.
AU  - Krumholz, H. M.
AU  - Gross, C. P.
DA  - Jun 9
DO  - 10.1001/jama.291.22.2720
DP  - NLM
ET  - 2004/06/10
IS  - 22
KW  - Adult
Age Distribution
Aged
Clinical Trials as Topic/*statistics & numerical data
Cross-Sectional Studies
European Continental Ancestry Group/statistics & numerical data
Female
*Health Services Accessibility
Humans
Logistic Models
Male
Middle Aged
Minority Groups/statistics & numerical data
National Institutes of Health (U.S.)
*Neoplasms/epidemiology/therapy
Sex Distribution
United States
Biomedical and Behavioral Research
Empirical Approach
LA  - eng
N1  - 1538-3598
Murthy, Vivek H
Krumholz, Harlan M
Gross, Cary P
1K07CA-90402/CA/NCI NIH HHS/United States
P30AG21342/AG/NIA NIH HHS/United States
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.
United States
JAMA. 2004 Jun 9;291(22):2720-6. doi: 10.1001/jama.291.22.2720.
PY  - 2004
SN  - 0098-7484
SP  - 2720-6
ST  - Participation in cancer clinical trials: race-, sex-, and age-based disparities
T2  - Jama
TI  - Participation in cancer clinical trials: race-, sex-, and age-based disparities
VL  - 291
ID  - 626
ER  - 

TY  - JOUR
AB  - BACKGROUND: Participation in cancer clinical trials is low, particularly in racial and ethnic minorities in some cases, which has negative consequences for the generalizability for study findings. The objective of this study was to determine what factors are associated with patients' participation or willingness to participate and whether these factors vary by race/ethnicity. DESIGN: or METHODS: . White, Hispanic, and black participants were obtained through the Florida cancer registry and who were diagnosed with breast, lung, colorectal, or prostate cancer (N = 1100). Participants were surveyed via telephone to obtain demographic information, past participation, and willingness to participate in clinical trials, as well as barriers and facilitators to participation. Logistic and Poisson regressions were performed. RESULTS: . Respondents were on average 67.4 years old, 42.7% were male, and 50.1% were married. In this population, 7.7% of respondents had participated in a clinical trial, and 36.5% stated that they would be willing to participate. In multivariate models, blacks and Hispanics were equally likely as whites to be willing to participate in cancer trials, but Hispanics were less likely to have participated, and this was especially more likely in non-English-speaking Hispanics compared with English-speaking Hispanics. Notable barriers across race/ethnicity were mistrust and lack of knowledge of clinical trials. Limitations. Cross-sectional design limits cause-and-effect conclusions. CONCLUSIONS: . There are racial differences in participation rates but not in willingness to participate. We hypothesize that willingness to participate is not very high because people are uninformed about participating, particularly in non-English-speaking Hispanics. Barriers and facilitators to participation vary by race. Improved understanding of cultural differences that can be addressed by physicians may restore faith, comprehension, and acceptability of clinical trials by all patients.
AD  - Department of Public Health Sciences (MMB), University of Miami Miller School of Medicine, Miami, Florida.
Sylvester Comprehensive Cancer Center (MMB, SLT), University of Miami Miller School of Medicine, Miami, Florida.
Department of Medicine (SG, JH), University of Miami Miller School of Medicine, Miami, Florida.
Department of Psychology, Universityof Miami, Miami, Florida (MA)
AN  - 23897588
AU  - Byrne, M. M.
AU  - Tannenbaum, S. L.
AU  - Glück, S.
AU  - Hurley, J.
AU  - Antoni, M.
DA  - Jan
DO  - 10.1177/0272989x13497264
DP  - NLM
ET  - 2013/07/31
IS  - 1
KW  - Aged
*Clinical Trials as Topic
Cross-Sectional Studies
Female
Florida
Humans
Male
Middle Aged
Neoplasms/*psychology/therapy
*Patient Participation
*cohort studies
*patient decision making
*population-based studies
LA  - eng
N1  - 1552-681x
Byrne, Margaret M
Tannenbaum, Stacey L
Glück, Stefan
Hurley, Judith
Antoni, Michael
U54 CA153705/CA/NCI NIH HHS/United States
Journal Article
Research Support, Non-U.S. Gov't
United States
Med Decis Making. 2014 Jan;34(1):116-26. doi: 10.1177/0272989X13497264. Epub 2013 Jul 29.
PY  - 2014
SN  - 0272-989x
SP  - 116-26
ST  - Participation in cancer clinical trials: why are patients not participating?
T2  - Med Decis Making
TI  - Participation in cancer clinical trials: why are patients not participating?
VL  - 34
ID  - 322
ER  - 

TY  - JOUR
AB  - PURPOSE: To determine the recruitment goals that investigators set for racial/ethnic minorities and the factors associated with failure to meet those goals. METHODS: Four hundred forty principal investigators (PIS) conducting clinical research funded by the National Heart, Lung, and Blood Institute (NHLBI) in 2001 completed a mailed survey providing their minority recruitment goals and enrollment data for their most recent NHLBI-funded study. RESULTS: Ninety-two percent of PIS set goals for African Americans, 68% for Hispanics, 55% for Asian Americans, 35% for Native Hawaiians/Pacific Islanders, and 23% of PIS set recruitment goals for American Indians/Native Alaskans. Among those PIS who did set minority recruitment goals, the mean goal for the recruitment of African Americans was 31%, 16% for Hispanics, and 9% for Asian Americans. Twenty-seven percent of PIS failed to meet their recruitment goals for African Americans, 23% for Asian Americans, and 23% for Hispanics. After adjusting for multiple investigator and trial characteristics, the type of study (odds ratio [OR] 1.8; 95% confidence interval [CI] 1.2, 3.4 for observational vs. phase III trial) completion of study enrollment (OR 2.0; 95% CI 1.2, 3.4), and PI identification of a larger number of major barriers to participation (OR 1.8; 95% CI 1.1, 3.0) were all associated with failure to meet recruitment goals for African Americans. However, no factors were consistently associated with failure to meet recruitment goals across different racial/ethnic groups. CONCLUSIONS: Investigators often do not set recruitment goals for some racial/ethnic groups. Factors associated with failure to meet recruitment goals vary in the recruitment of different minority groups.
AN  - WOS:000248672900010
AU  - Durant, R. W.
AU  - Davis, R. B.
AU  - George, Dmms
AU  - Williams, I. C.
AU  - Blumenthal, C.
AU  - Corbie-Smith, G. M.
DA  - Aug
DO  - 10.1016/j.annepidem.2007.02.003
IS  - 8
N1  - 17531504
PY  - 2007
SN  - 1047-2797
SP  - 634-642
ST  - Participation in research studies: Factors associated with failing to meet minority recruitment goals
T2  - Annals of Epidemiology
TI  - Participation in research studies: Factors associated with failing to meet minority recruitment goals
VL  - 17
ID  - 3187
ER  - 

TY  - JOUR
AB  - OBJECTIVE: To characterize the representation of racial/ethnic minorities, women, and older persons among participants in surgical trials sponsored by the National Cancer Institute (NCI). METHODS: The NCI Clinical Trial Cooperative Group surgical oncology trials database was queried for breast, colorectal, lung, and prostate cancers treated during the period 2000-2002 (n=13,991). Data from the SEER program and the Census were used to estimate age-, gender-, and race/ethnicity-specific incidence of the same cancers among U.S. adults during the same period. Enrollment fraction (EF), defined as the number of trial enrollees divided by the estimated U.S. cancer cases in each demographic group, was the primary outcome measure. Logistic regression was used to compare the enrollment of racial/ethnic, gender and age subgroups in this analysis. RESULTS: Relative to white patients (EF=0.72%), lower EFs were noted in African-American (0.48%, odds ratio [OR] vs whites 0.67, P<0.001), Hispanic (0.54%, OR 0.76, P<0.001), and Asian/Pacific islander (0.59%, OR 0.82, P=0.001) patients. Overall, women were more likely to enroll in surgical trials (1.12%) than men (0.22%, OR 5.06, P<0.001). Patients 65-74 years of age (EF 0.45%) were less likely to be enrolled than those 20-44 years of age (EF=2.28%, OR 0.20, P=0.001). CONCLUSIONS: The enrollment in surgical oncology trials is very low across all demographics. However, racial/ethnic minorities and older persons are less likely to be enrolled in cooperative group surgical oncology trials than are whites and younger patients. The high EF for women is due to the high availability of trials for women with breast cancer. Strategies to increase accrual to surgical trials and ameliorate disparities related to race/ethnicity, gender, and age are needed.
AD  - Department of General Surgery, Section on Surgical Oncology, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157, USA. jhstewar@wfubmc.edu
AN  - 17682824
AU  - Stewart, J. H.
AU  - Bertoni, A. G.
AU  - Staten, J. L.
AU  - Levine, E. A.
AU  - Gross, C. P.
DA  - Dec
DO  - 10.1245/s10434-007-9500-y
DP  - NLM
ET  - 2007/08/09
IS  - 12
KW  - Adult
Age Distribution
Aged
Clinical Trials as Topic/*statistics & numerical data
Continental Population Groups/*statistics & numerical data
Ethnic Groups/*statistics & numerical data
Female
Gender Identity
Health Services Accessibility
Humans
Male
Middle Aged
National Institutes of Health (U.S.)
Neoplasms/epidemiology/*surgery/therapy
Patient Participation/*statistics & numerical data
SEER Program
Sex Distribution
United States
LA  - eng
N1  - 1534-4681
Stewart, John H
Bertoni, Alain G
Staten, Jennifer L
Levine, Edward A
Gross, Cary P
K08 CA131482/CA/NCI NIH HHS/United States
Journal Article
United States
Ann Surg Oncol. 2007 Dec;14(12):3328-34. doi: 10.1245/s10434-007-9500-y. Epub 2007 Aug 8.
PY  - 2007
SN  - 1068-9265
SP  - 3328-34
ST  - Participation in surgical oncology clinical trials: gender-, race/ethnicity-, and age-based disparities
T2  - Ann Surg Oncol
TI  - Participation in surgical oncology clinical trials: gender-, race/ethnicity-, and age-based disparities
VL  - 14
ID  - 516
ER  - 

TY  - JOUR
AB  - To the authors' knowledge, little is known regarding the participation of Asian Americans in cancer prevention research. In 2002, the authors mailed surveys to primary care physicians in Northern California to assess their knowledge, attitudes, behaviors, and barriers concerning the participation of Asian-American women in breast cancer chemoprevention research. The response rate was 52.3% (n = 306 physicians). For physician barriers, most respondents selected lack of study knowledge (73%) and effort required to establish eligibility (75%) and to explain risks and benefits (68%). For patient barriers, most physicians chose the following: physicians did not inform patients about trials (76%), limited English proficiency (78%), researcher-participant language discordance (74%), and complex protocols (69%). Significantly more Asian-American physicians than non-Asian-American physicians (but a majority of each) selected as patient barriers a lack of culturally relevant information on breast cancer, a lack of knowledge about research concepts, and fear of experimentation. A majority of Asian-American physicians also selected the following patient barriers: lack of knowledge of preventive care or breast cancer, work concern, misperception that experimental treatment is inferior, personal modesty, and lack of personal benefit. In multivariate analyses, physicians who were in practice longer, who spent more time with patients, or who knew of tools to estimate breast cancer risk were more likely to discuss such trials with Asian-American women; whereas male physicians and those who believed that Asian-American women's deference to physicians was a barrier were less likely to have discussed such trials with Asian-American women. Efforts to increase research participation among Asian Americans should include physician education and linguistically appropriate recruitment efforts.
AN  - WOS:000233974300023
AU  - Nguyen, T. T.
AU  - Somkin, C. P.
AU  - Ma, Y. F.
DA  - Dec
DO  - 10.1002/cncr.21519
IS  - 12
N1  - AANCART 5th Asian-American-Cancer-Control-Academy Conference
OCT 22-23, 2004
Sacramento, CA
Asian Amer Network Canc Awareness , Res & Training, Asian Amer Canc Control Acad
S
16247807
PY  - 2005
SN  - 0008-543X
SP  - 3006-3014
ST  - Participation of Asian-American women in cancer chemoprevention research - Physician perspectives
T2  - Cancer
TI  - Participation of Asian-American women in cancer chemoprevention research - Physician perspectives
VL  - 104
ID  - 3229
ER  - 

TY  - JOUR
AB  - Overall, participation rates in cancer clinical trials are very low, ranging from 3 to 20% of eligible participants. However, participation rates are especially low among the socially disadvantaged and racial/ethnic minority groups that have been historically underrepresented in clinical research. Structural factors such as study duration, treatment or intervention schedule, cost, time, followup visits, and side effects represent more of a barrier to participation among these groups compared with white, non-Hispanics. Attitudes, beliefs, perceptions, and knowledge regarding clinical research, and cultural characteristics of underrepresented minorities pose additional barriers to participation. This article focuses on the structural, cultural, and linguistic factors that affect participation in clinical cancer research for each major U.S. racial/ethnic group. Low socioeconomic status, speaking a primary language other than English, differences in communication styles, mistrust of research and the medical system, fear, embarrassment, and lack of knowledge about the origin of cancer appear to have a negative impact on clinical cancer research participation rates. Much of the information about these factors comes from studies of cancer screening because little data is available on the factors that prevent and facilitate participation of minorities in clinical cancer trials specifically. Such research is needed, and, given the heterogeneity within and between minority populations, should occur in several different geographic settings and with as many different minority subpopulations as possible. (C) 2000 Elsevier Science Inc. All rights reserved.
AN  - WOS:000165950000004
AU  - Giuliano, A. R.
AU  - Mokuau, N.
AU  - Hughes, C.
AU  - Tortolero-Luna, G.
AU  - Risendal, B.
AU  - Ho, R. C. S.
AU  - Prewitt, T. E.
AU  - McCaskill-Stevens, W. J.
DA  - Nov
DO  - 10.1016/S1047-2797(00)00195-2
IS  - 8
N1  - S
Workshop on Participation of Minorities and Women in Clinical Cancer Research
FEB 26-27, 1999
WASHINGTON, D.C.
NCI
210
11189089
PY  - 2000
SN  - 1047-2797
SP  - S22-S34
ST  - Participation of minorities in cancer research: The influence of structural, cultural, and linguistic factors
T2  - Annals of Epidemiology
TI  - Participation of minorities in cancer research: The influence of structural, cultural, and linguistic factors
VL  - 10
ID  - 2714
ER  - 

TY  - JOUR
AB  - Purpose: On June 7, 2000 President Clinton issued an executive memorandum directing Medicare payment for routine patient care in qualifying clinical trials. We estimated the proportion of older patients with prostate cancer who were examined as part of a qualifying clinical trial, and the association between participation and patient characteristics. Materials and Methods: We performed an observational study using the Surveillance, Epidemiology and End Results Medicare database to determine participation in qualifying clinical trials in a sample of 37,216 men 66 years old or older who were enrolled in Medicare and diagnosed with prostate cancer between September 2000 and December 2002. Results: Within 3 years of diagnosis 211 men (0.567%) received routine patient care in a qualifying clinical trial. These participants were more likely to be younger than 70 years (OR 1.687, 95% CI 1.27-2.24) and less likely to be less educated and reside in low income, metropolitan neighborhoods. White men were more likely to participate in clinical trials than nonwhite men but this association was not statistically significant (OR 1.426, CI 0.97-2.09). Participation varied significantly by registry site (0% to 1.2%) but not by tumor grade or stage, or prostate specific antigen status. Conclusions: Few older patients with prostate cancer participated in qualifying trials between 2000 and 2002. Those who participated were not representative of the general population of older patients with prostate cancer. Greater efforts are required to expand trial enrollment and decrease disparities in research participation. © 2010 American Urological Association Education and Research, Inc.
AD  - B. M. Craig, MRC-CANCONT, 12902 Magnolia Dr., Tampa, FL 33612-9416, United States
AU  - Craig, B. M.
AU  - Gilbert, S. M.
AU  - Herndon, J. B.
AU  - Vogel, B.
AU  - Quinn, G. P.
DB  - Embase
Medline
DO  - 10.1016/j.juro.2010.04.076
IS  - 3
KW  - prostate specific antigen
African American
aged
article
cancer grading
cancer patient
cancer staging
educational status
European American
Hispanic
human
income
major clinical study
male
medicare
observational study
patient care
priority journal
prostate cancer
research subject
LA  - English
M3  - Article
N1  - L50997063
2010-07-21
2010-11-18
PY  - 2010
SN  - 0022-5347
SP  - 901-906
ST  - Participation of older patients with prostate cancer in medicare eligible trials
T2  - Journal of Urology
TI  - Participation of older patients with prostate cancer in medicare eligible trials
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L50997063&from=export
http://dx.doi.org/10.1016/j.juro.2010.04.076
VL  - 184
ID  - 1158
ER  - 

TY  - JOUR
AB  - PURPOSE: Despite concerns about declining participation rates in epidemiologic studies in recent years, relatively few papers have discussed obstacles to recruiting study participants or strategies for optimizing response rates. This report describes factors associated with nonparticipation in a population-based, case-control study of breast cancer and discusses ways to overcome barriers to participation. METHODS: Contact and cooperation rates were calculated for participants in the Carolina Breast Cancer Study (CBCS), stratified by case status, age, race, and race of interviewer. Demographic and breast cancer risk factor characteristics of partial and full responders also were compared. RESULTS: Contact rates and cooperation rates varied by case/control status and demographic characteristics. Contact rates were lower among controls, younger women, and black women. Cooperation rates were lower among controls, older women, and black cases. Cooperation rates were higher among both black and nonblack women when participants and interviewers were concordant on race. CONCLUSIONS: Obstacles to recruitment seem to differ among race and age subgroups, suggesting chat recruitment strategies may need to be tailored to potential participants based upon demographic characteristics. Strategies have been implemented to improve response rates in this and other epidemiologic studies; however, additional research and innovation in this area are needed. Ann Epidemiol 1999;9:188-195. (C) 1999 Elsevier Science Inc. All rights reserved.
AN  - WOS:000079205200007
AU  - Moorman, P. G.
AU  - Newman, B.
AU  - Millikan, R. C.
AU  - Tse, C. K. J.
AU  - Sandler, D. P.
DA  - Apr
DO  - 10.1016/S1047-2797(98)00057-X
IS  - 3
N1  - 156
10192651
PY  - 1999
SN  - 1047-2797
SP  - 188-195
ST  - Participation rates in a case control study: The impact of age, race, and race of interviewer
T2  - Annals of Epidemiology
TI  - Participation rates in a case control study: The impact of age, race, and race of interviewer
VL  - 9
ID  - 2728
ER  - 

TY  - JOUR
AB  - PURPOSE: Despite concerns about declining participation rates in epidemiologic studies in recent years, relatively few papers have discussed obstacles to recruiting study participants or strategies for optimizing response rates. This report describes factors associated with nonparticipation in a population-based, case-control study of breast cancer and discusses ways to overcome barriers to participation. METHODS: Contact and cooperation rates were calculated for participants in the Carolina Breast Cancer Study (CBCS), stratified by case status, age, race, and race of interviewer. Demographic and breast cancer risk factor characteristics of partial and full responders also were compared. RESULTS: Contact rates and cooperation rates varied by case/control status and demographic characteristics. Contact rates were lower among controls, younger women, and black women. Cooperation rates were lower among controls, older women, and black cases. Cooperation rates were higher among both black and nonblack women when participants and interviewers were concordant on race. CONCLUSIONS: Obstacles to recruitment seem to differ among race and age subgroups, suggesting that recruitment strategies may need to be tailored to potential participants based upon demographic characteristics. Strategies have been implemented to improve response rates in this and other epidemiologic studies; however, additional research and innovation in this area are needed.
AD  - Department of Epidemiology and Public Health, Yale University School of Medicine, New Haven, CT 06520-8034, USA.
AN  - 10192651
AU  - Moorman, P. G.
AU  - Newman, B.
AU  - Millikan, R. C.
AU  - Tse, C. K.
AU  - Sandler, D. P.
DA  - Apr
DO  - 10.1016/s1047-2797(98)00057-x
DP  - NLM
ET  - 1999/04/07
IS  - 3
KW  - Adult
African Americans/statistics & numerical data
Breast Neoplasms/*epidemiology
*Case-Control Studies
Demography
European Continental Ancestry Group/statistics & numerical data
Female
Humans
Middle Aged
North Carolina/epidemiology
*Patient Compliance/statistics & numerical data
*Patient Participation/statistics & numerical data
LA  - eng
N1  - Moorman, P G
Newman, B
Millikan, R C
Tse, C K
Sandler, D P
P50-CA58223/CA/NCI NIH HHS/United States
R29-CA67285/CA/NCI NIH HHS/United States
Journal Article
Research Support, U.S. Gov't, P.H.S.
United States
Ann Epidemiol. 1999 Apr;9(3):188-95. doi: 10.1016/s1047-2797(98)00057-x.
PY  - 1999
SN  - 1047-2797 (Print)
1047-2797
SP  - 188-95
ST  - Participation rates in a case-control study: the impact of age, race, and race of interviewer
T2  - Ann Epidemiol
TI  - Participation rates in a case-control study: the impact of age, race, and race of interviewer
VL  - 9
ID  - 720
ER  - 

TY  - JOUR
AB  - BACKGROUND: Cancer clinical trials are essential for testing new treatments and represent state-of-the-art cancer treatment, but only a small percentage of patients ever enroll in a trial. Under-enrollment is an even greater problem among minorities, particularly African Americans, representing a racial/ethnic disparity in cancer care. One understudied cause is patient-physician communication, which is often of poor quality during clinical interactions between African-American patients and non-African-American physicians. Partnering Around Cancer Clinical Trials (PACCT) involves a transdisciplinary theoretical model proposing that patient and physician individual attitudes and beliefs and their interpersonal communication during racially discordant clinical interactions influence outcomes related to patients' decisions to participate in a trial. The overall goal of the study is to test a multilevel intervention designed to increase rates at which African-American and White men with prostate cancer make an informed decision to participate in a clinical trial. METHODS/DESIGN: Data collection will occur at two NCI-designated comprehensive cancer centers. Participants include physicians who treat men with prostate cancer and their African-American and White patients who are potentially eligible for a clinical trial. The study uses two distinct research designs to evaluate the effects of two behavioral interventions, one focused on patients and the other on physicians. The primary goal is to increase the number of patients who decide to enroll in a trial; secondary goals include increasing rates of physician trial offers, improving the quality of patient-physician communication during video recorded clinical interactions in which trials may be discussed, improving patients' understanding of trials offered, and increasing the number of patients who actually enroll. Aims are to 1) determine the independent and combined effects of the two interventions on outcomes; 2) compare the effects of the interventions on African-American versus White men; and 3) examine the extent to which patient-physician communication mediates the effect of the interventions on the outcomes. DISCUSSION: PACCT has the potential to identify ways to increase clinical trial rates in a diverse patient population. The research can also improve access to high quality clinical care for African American men bearing the disproportionate burden of disparities in prostate and other cancers. TRIAL REGISTRATION: Clinical Trials.gov registration number: NCT02906241 (September 8, 2016).
AD  - Department of Oncology, Wayne State University/Karmanos Cancer Institute, 4100 John R, Detroit, MI, 48201, USA.
Department of Oncology, Wayne State University/Karmanos Cancer Institute, 4100 John R, Detroit, MI, 48201, USA. hamell@karmanos.org.
Department of English, Wayne State University, 5057 Woodward Suite 9408, Detroit, MI, 48202, USA.
Johns Hopkins School of Medicine/Sidney Kimmel Comprehensive Cancer Center, 1M59 Bunting -Blaustein Cancer Research Building, 1650 Orleans Street, Baltimore, MD, 21287, USA.
Johns Hopkins School of Medicine/Sidney Kimmel Comprehensive Cancer Center, 550 North Broadway, 1003-G, Baltimore, MD, 21205, USA.
AN  - 29197371
AU  - Eggly, S.
AU  - Hamel, L. M.
AU  - Heath, E.
AU  - Manning, M. A.
AU  - Albrecht, T. L.
AU  - Barton, E.
AU  - Wojda, M.
AU  - Foster, T.
AU  - Carducci, M.
AU  - Lansey, D.
AU  - Wang, T.
AU  - Abdallah, R.
AU  - Abrahamian, N.
AU  - Kim, S.
AU  - Senft, N.
AU  - Penner, L. A.
C2  - PMC5712160
DA  - Dec 2
DO  - 10.1186/s12885-017-3804-5
DP  - NLM
ET  - 2017/12/05
IS  - 1
KW  - African Americans/psychology
Communication
European Continental Ancestry Group/psychology
Humans
Male
Minority Groups/psychology
*Minority Health
Models, Theoretical
Patient Participation
Patient Selection
*Physician-Patient Relations
Prostatic Neoplasms/*drug therapy/ethnology
Clinical trials
Health disparities
Patient-physician communication
Prostate cancer
approved by the Institutional Review Boards of Wayne State University and Johns
Hopkins University. This is a report of a study protcol, and thus human subject
consent was not necessary. In order to participate, all participants will provide
written informed consent. CONSENT FOR PUBLICATION: Not applicable. COMPETING
INTERESTS: The authors declare that they have no competing interests. PUBLISHER’S
NOTE: Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
LA  - eng
N1  - 1471-2407
Eggly, Susan
Hamel, Lauren M
Heath, Elisabeth
Manning, Mark A
Albrecht, Terrance L
Barton, Ellen
Wojda, Mark
Foster, Tanina
Carducci, Michael
Lansey, Dina
Wang, Ting
Abdallah, Rehab
Abrahamian, Narineh
Kim, Seongho
Senft, Nicole
Penner, Louis A
R01 CA200718/CA/NCI NIH HHS/United States
R01CA200718-01/National Cancer Institute/
Journal Article
Randomized Controlled Trial
BMC Cancer. 2017 Dec 2;17(1):807. doi: 10.1186/s12885-017-3804-5.
PY  - 2017
SN  - 1471-2407
SP  - 807
ST  - Partnering around cancer clinical trials (PACCT): study protocol for a randomized trial of a patient and physician communication intervention to increase minority accrual to prostate cancer clinical trials
T2  - BMC Cancer
TI  - Partnering around cancer clinical trials (PACCT): study protocol for a randomized trial of a patient and physician communication intervention to increase minority accrual to prostate cancer clinical trials
VL  - 17
ID  - 142
ER  - 

TY  - JOUR
AB  - BACKGROUND/AIMS: Reduced minority participation in clinical research challenges researchers to consider novel recruitment modalities. This study describes a formal partnership between the National Educational Foundation of the Zeta Phi Beta Sorority and the Mid-Atlantic Cancer Genetics Network. The goal was to enhance awareness about inherited breast cancer and to increase enrollment in the national Cancer Genetics Network. METHODS: In this descriptive, pilot study, two recruitment strategies across four states were undertaken: an onsite educational session at four Annual State Leadership Conferences and a 2-tiered direct mail campaign to the sorority membership. RESULTS: Recruitment methods targeted over 1,200 well-educated African American women. Of the 279 attendees at the state conference educational sessions, only 3 women meeting the high risk eligibility requirement enrolled. Direct mail recruitment elicited 24 eligible women. Lessons learned are described. CONCLUSION: Despite low accrual, the partnership laid a foundation for broader collaboration with the Zeta Phi Beta Sorority. In the future, collaboration with minority sororities and fraternities as part of standard registry recruitment should be explored.
AD  - Mid-Atlantic Cancer Genetics Network, the Johns Hopkins University, Baltimore, MD 21205, USA. olsen@son.jhmi.edu
AN  - 18417967
AU  - Olsen, S. J.
AU  - Malvern, K. T.
AU  - May, B. J.
AU  - Jenkins, I. L.
AU  - Griffin, C. A.
DO  - 10.1159/000116880
DP  - NLM
ET  - 2008/04/18
IS  - 4
KW  - Adult
African Americans/*genetics/psychology
Aged
Female
*Genetic Research
Humans
*Medical Oncology
Middle Aged
Neoplasms/genetics/*psychology
*Patient Participation
*Peer Group
Registries
Students/*psychology
Surveys and Questionnaires
LA  - eng
N1  - 1422-2833
Olsen, Sharon J
Malvern, Kathryn T
May, Betty J
Jenkins, Issie L
Griffin, Constance A
5U24CA78148/CA/NCI NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
Switzerland
Community Genet. 2008;11(4):201-7. doi: 10.1159/000116880. Epub 2008 Apr 14.
PY  - 2008
SN  - 1422-2795
SP  - 201-7
ST  - Partnership with an African American sorority to enhance participation in cancer genetics research
T2  - Community Genet
TI  - Partnership with an African American sorority to enhance participation in cancer genetics research
VL  - 11
ID  - 499
ER  - 

TY  - JOUR
AB  - This paper describes a community-based approach, including a partnership of an academic medical institution and a high-risk, urban, African-American population, directed at decreasing premature morbidity and mortality and enhancing health and functional status. The intervention approach is based on a model of community-based leadership and "ownership" of interventions and programs to enhance sustainability of effective approaches, and it follows specific stages to assure appropriate assessment and evaluation. Initial efforts were directed at the control of hypertension and were coordinated through decentralized mayor's stations in Baltimore, Maryland. This approach was successful in significantly enhancing control of hypertension and reducing related morbidity and mortality. Over time, an enhanced partnership has been coordinated through churches in the community and organized around a program entitled "Heart, Body, and Soul." Current efforts are directed at the major risk factors and preventable and/or controllable problems in the population, such as hypertension, smoking, obesity, diabetes, hyperlipidemia, and cervical and breast cancer. Key components include the training of neighborhood health workers to provide screening, counseling, monitoring, support, and follow-up; enhanced access to care; training of high school students as health counselors; and use of media to promote healthier life-styles.
AD  - Johns Hopkins Center for Health Promotion, Baltimore, Maryland.
AN  - 1467764
AU  - Levine, D. M.
AU  - Becker, D. M.
AU  - Bone, L. R.
AU  - Stillman, F. A.
AU  - Tuggle, M. B., 2nd
AU  - Prentice, M.
AU  - Carter, J.
AU  - Filippeli, J.
DA  - Summer
DP  - NLM
ET  - 1992/01/01
IS  - 3
KW  - *Academic Medical Centers
African Americans
Baltimore
*Community Participation
Health Behavior
Health Promotion/*organization & administration/standards
Health Services Research
Humans
*Interinstitutional Relations
*Minority Groups
Models, Organizational
Outcome Assessment, Health Care
Program Development
Program Evaluation
LA  - eng
N1  - Levine, D M
Becker, D M
Bone, L R
Stillman, F A
Tuggle, M B 2nd
Prentice, M
Carter, J
Filippeli, J
Journal Article
United States
Ethn Dis. 1992 Summer;2(3):296-305.
PY  - 1992
SN  - 1049-510X (Print)
1049-510x
SP  - 296-305
ST  - A partnership with minority populations: a community model of effectiveness research
T2  - Ethn Dis
TI  - A partnership with minority populations: a community model of effectiveness research
VL  - 2
ID  - 748
ER  - 

TY  - JOUR
AB  - Medical guidelines do not recommend prostate cancer screening, particularly without informed and shared decision making. This study investigates undisclosed opportunistic screening using prostate specific antigen (PSA) testing in black immigrant and African American men. Participants (N = 142) were insured urban men, 45- to 70-years old. Patients' reports of testing were compared with medical claims to assess undisclosed PSA testing. Most (94.4 %) men preferred to share in screening decisions, but few (46.5 %) were aware PSA testing was performed. Four factors predicted being unaware of testing: low formal education, low knowledge about prostate cancer, no intention to screen, and no physician recommendation (all p's < .05). Undisclosed PSA testing was common. Both patient and provider factors increased risk of being uninformed about prostate cancer screening. Interventions combining patient education and physician engagement in shared decision making may better align practice with current prostate cancer screening guidelines.
AD  - Department of Social and Behavioral Sciences, College of Public Health, Temple University, 957 Ritter Annex, 1301 Cecil B. Moore Ave, Philadelphia, PA, 19122, USA. slepore@temple.edu.
Department of Biostatistics and Epidemiology, College of Public Health, Temple University, 1301 Cecil B. Moore Ave, Philadelphia, PA, 19122, USA.
Department of Health Outcomes and Behaviors, Moffitt Cancer Center, Tampa, FL, 33612, USA.
Department of Health and Behavioral Studies, Teachers College, Columbia University, 525 West 120th Street, New York, NY, 10027, USA.
1199SEIU Benefit and Pension Funds, 330 W. 42nd Street, New York, NY, 10036, USA.
AN  - 27449217
AU  - Lepore, S. J.
AU  - Nair, R. G.
AU  - Davis, S. N.
AU  - Wolf, R. L.
AU  - Basch, C. E.
AU  - Thomas, N.
AU  - Shmukler, C.
AU  - Ullman, R.
C2  - PMC5407941
C6  - NIHMS855687
DA  - Dec
DO  - 10.1007/s10903-016-0468-1
DP  - NLM
ET  - 2016/07/28
IS  - 6
KW  - African Americans/*statistics & numerical data
Aged
Decision Making
Early Detection of Cancer/*methods
Emigrants and Immigrants/*statistics & numerical data
Health Knowledge, Attitudes, Practice
Humans
Male
Middle Aged
Patient Participation
Prostate-Specific Antigen/*analysis
Prostatic Neoplasms/diagnosis/*ethnology
Socioeconomic Factors
*Informed decision making
*Minority health
*Patient preferences
*Prostate cancer screening
*Shared decision making
LA  - eng
N1  - 1557-1920
Lepore, Stephen J
Nair, Rasmi G
Davis, Stacy N
Wolf, Randi L
Basch, Charles E
Thomas, Nigel
Shmukler, Celia
Ullman, Ralph
P30 CA006927/CA/NCI NIH HHS/United States
R01 CA104223/CA/NCI NIH HHS/United States
R01CA104223/CA/NCI NIH HHS/United States
Journal Article
Observational Study
Research Support, N.I.H., Extramural
J Immigr Minor Health. 2017 Dec;19(6):1343-1350. doi: 10.1007/s10903-016-0468-1.
PY  - 2017
SN  - 1557-1912 (Print)
1557-1912
SP  - 1343-1350
ST  - Patient and Physician Factors Associated with Undisclosed Prostate Cancer Screening in a Sample of Predominantly Immigrant Black Men
T2  - J Immigr Minor Health
TI  - Patient and Physician Factors Associated with Undisclosed Prostate Cancer Screening in a Sample of Predominantly Immigrant Black Men
VL  - 19
ID  - 208
ER  - 

TY  - JOUR
AB  - The objective of this study was to determine whether assertive patient behavior influences physician decision-making in the treatment of older breast cancer patients. One hundred and twenty-eight physicians saw videotapes depicting women seeking care for breast cancer and then recommended evaluation and treatment plans. Identical scripts were used, but the age, race, socioeconomic status, mobility, general health, and assertive behavior of the patients were experimentally varied along with the physician's specialty and length of practice. No direct effects of assertive patient behavior were seen. However, black, comorbid, and lower SES women were more likely to have full staging of their tumors ordered when they made an assertive request. Treatment recommendations also showed an interaction of assertiveness with patient's age and social class as well as physicians' specialty. The results indicate that a moderately assertive patient request may change provider behavior, although the effects of assertiveness vary most by what type of patient demonstrates this behavior. In particular, assertiveness led to more careful diagnostic testing for patients who came from groups that are "disadvantaged."
AD  - The School of Arts and Sciences, Massachusetts College of Pharmacy and Health Sciences, Boston, USA.
AN  - 10414805
AU  - Krupat, E.
AU  - Irish, J. T.
AU  - Kasten, L. E.
AU  - Freund, K. M.
AU  - Burns, R. B.
AU  - Moskowitz, M. A.
AU  - McKinlay, J. B.
DA  - Aug
DO  - 10.1016/s0277-9536(99)00106-9
DP  - NLM
ET  - 1999/07/22
IS  - 4
KW  - Aged
Aged, 80 and over
Breast Neoplasms/*psychology/therapy
*Decision Making
Factor Analysis, Statistical
Female
Humans
Logistic Models
Monte Carlo Method
*Patient Participation
*Physician-Patient Relations
Socioeconomic Factors
LA  - eng
N1  - Krupat, E
Irish, J T
Kasten, L E
Freund, K M
Burns, R B
Moskowitz, M A
McKinlay, J B
AG11352/AG/NIA NIH HHS/United States
Journal Article
Research Support, U.S. Gov't, P.H.S.
England
Soc Sci Med. 1999 Aug;49(4):449-57. doi: 10.1016/s0277-9536(99)00106-9.
PY  - 1999
SN  - 0277-9536 (Print)
0277-9536
SP  - 449-57
ST  - Patient assertiveness and physician decision-making among older breast cancer patients
T2  - Soc Sci Med
TI  - Patient assertiveness and physician decision-making among older breast cancer patients
VL  - 49
ID  - 716
ER  - 

TY  - JOUR
AB  - Attitudes of patients toward the necessity of physician consent in epidemiologic studies were assessed. Questionnaires were mailed to women with breast, endometrial and ovarian cancers who had previously participated in a personal interview study (N = 692). Of respondents (N = 514), only 2 per cent would have preferred their physician to have withheld approval, and half considered physician permission necessary. Thirty-five per cent reported that their doctor talked to them about the study prior to the interview. Implications of including physician consent in study protocols are discussed.
The initiation of contact with a patient for an epidemiologic study is usually contingent upon the prior consent of the attending physician. To assess the attitudes of patients toward the necessity of physician consent, questionnaires were mailed to 692 women with breast, endometrial, or ovarian cancers who had previously participated in a personal interview study. Only 2% of the 514 respondents would have preferred that their physicians withhold approval; half considered physician permission necessary. One-third of the patients--most frequently black women and women of lower educational levels--reported that their doctors had talked to them about the study prior to the interview.
eng
AN  - 6507697
AU  - Boring, C. C.
AU  - Brockman, E.
AU  - Causey, N.
AU  - Gregory, H. R.
AU  - Greenberg, R. S.
C2  - PMC1652685
DA  - Dec
DO  - 10.2105/ajph.74.12.1406
DP  - NLM
ET  - 1984/12/01
IS  - 12
KW  - Adult
Attitude
Breast Neoplasms
Educational Status
*Epidemiologic Methods
Female
Humans
*Informed Consent
Middle Aged
Ovarian Neoplasms
*Patient Selection
*Physician-Patient Relations
*Research Subjects
Uterine Neoplasms
Biomedical and Behavioral Research
Empirical Approach
Professional Patient Relationship
LA  - eng
N1  - 1541-0048
Boring, C C
Brockman, E
Causey, N
Gregory, H R
Greenberg, R S
N01 CN 61027/CN/NCI NIH HHS/United States
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.
Am J Public Health. 1984 Dec;74(12):1406-8. doi: 10.2105/ajph.74.12.1406.
PY  - 1984
SN  - 0090-0036 (Print)
0090-0036
SP  - 1406-8
ST  - Patient attitudes toward physician consent in epidemiologic research
T2  - Am J Public Health
TI  - Patient attitudes toward physician consent in epidemiologic research
VL  - 74
ID  - 750
ER  - 

TY  - JOUR
AB  - Background: Women with breast or cervical cancer abnormalities can experience barriers to timely follow-up care, resulting in delays in cancer diagnosis. Patient navigation programs that identify and remove barriers to ensure timely receipt of care are proliferating nationally. The study used a systematic framework to describe barriers, including differences between African American and Latina women; to determine recurrence of barriers; and to examine factors associated with barriers to follow-up care. Methods: Data originated from 250 women in the intervention arm of the Chicago Patient Navigation Research Program (PNRP). The women had abnormal cancer screening findings and navigator encounters. Women were recruited from a community health center and a publicly owned medical center. After describing proportions of African American and Latina women experiencing particular barriers, logistic regression was used to explore associations between patient characteristics, such as race/ethnicity, and type of barriers. Results: The most frequent barriers occurred at the intrapersonal level (e.g., insurance issues and fear), while institutional-level barriers such as system problems with scheduling care were the most commonly recurring over time (29%). The majority of barriers (58%) were reported in the first navigator encounter. Latinas (81%) reported barriers more often than African American women (19%). Differences in race/ethnicity and employment status were associated with types of barriers. Compared to African American women, Latinas were more likely to report an intrapersonal level barrier. Unemployed women were more likely to report an institutional level barrier. Conclusion: In a sample of highly vulnerable women, there is no single characteristic (e.g., uninsured) that predicts what kinds of barriers a woman is likely to have. Nevertheless, navigators appear able to easily resolve intrapersonal-level barriers, but ongoing navigation is needed to address system-level barriers. Patient navigation programs can adopt the PNRP barriers framework to assist their efforts in assuring timely follow-up care. (PsycINFO Database Record (c) 2016 APA, all rights reserved)
AD  - Tejeda, Silvia, Institute for Health Research and Policy, School of Public Health, University of Illinois at Chicago, 1747 West Roosevelt Road (MC275), Chicago, IL, US, 60608
AN  - 2013-20778-007
AU  - Tejeda, Silvia
AU  - Darnell, Julie S.
AU  - Cho, Young I.
AU  - Stolley, Melinda R.
AU  - Markossian, Talar W.
AU  - Calhoun, Elizabeth A.
DB  - psyh
DO  - 10.1089/jwh.2012.3590
DP  - EBSCOhost
IS  - 6
KW  - patient barriers
breast cancer
cervical cancer abnormalities
follow up care
clinical diagnosis
Adult
African Americans
Breast Neoplasms
Delayed Diagnosis
Female
Health Services Accessibility
Hispanic Americans
Humans
Middle Aged
Patient Navigation
Uterine Cervical Neoplasms
Young Adult
Cervix
Medical Diagnosis
Quality of Care
Treatment Barriers
Human Females
N1  - Institute for Health Research and Policy, School of Public Health, University of Illinois at Chicago, Chicago, IL, US. Release Date: 20140331. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: English. Major Descriptor: Breast Neoplasms; Cervix; Medical Diagnosis; Quality of Care; Treatment Barriers. Minor Descriptor: Human Females. Classification: Health & Mental Health Services (3370). Population: Human (10); Female (40). Location: US. Age Group: Adulthood (18 yrs & older) (300). Methodology: Empirical Study; Quantitative Study. References Available: Y. Page Count: 11. Issue Publication Date: Jun, 2013. Copyright Statement: Mary Ann Liebert, Inc.
Sponsor: National Institutes of Health, US. Grant: P50 CA106743-07S1; R25 CA057699; U01 CAI 16875. Recipients: No recipient indicated
PY  - 2013
SN  - 1540-9996
1931-843X
SP  - 507-517
ST  - Patient barriers to follow-up care for breast and cervical cancer abnormalities
T2  - Journal of Women's Health
TI  - Patient barriers to follow-up care for breast and cervical cancer abnormalities
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2013-20778-007&site=ehost-live&scope=site
stejeda@uic.edu
VL  - 22
ID  - 1735
ER  - 

TY  - JOUR
AB  - OBJECTIVE: To assess associations of patient characteristics with quality-related characteristics of the hospitals where they were treated for colorectal cancer and the role of these associations in disparities in treatment quality affecting vulnerable patient groups or variations across health plans. SETTING: Population-based cancer registry in California. PARTICIPANTS: A total of 38 237 patients diagnosed with stage I-III (non-metastatic) colorectal cancer in California between 1994 and 1998. METHODS: Registry data were linked with hospital discharge abstracts, US census data, and Medicare enrollment data. The associations of patients' sociodemographic, clinical, and geographic covariates with treatment at high-volume institutions were assessed with logistic regression. The associations of patients' covariates with the risk-adjusted 30-day mortality rates of the hospitals where they received surgery were tested with linear regression. RESULTS: Patients with more advanced tumor stage or more extensive comorbidity, those of Hispanic or Asian race/ethnicity, and those from less affluent communities were less likely to undergo surgery at high-volume institutions and were treated at hospitals with higher risk-adjusted 30-day postoperative mortality rates than those who were less severely ill, white, or more affluent, respectively (all P < 0.05). Black patients also received surgery at hospitals with above-average mortality. Among patients 65 years and older, Medicare managed-care enrollees underwent surgery in higher-volume hospitals than Medicare fee-for-service enrollees, and there was substantial variation in hospital volume and adjusted hospital mortality among Medicare managed-care plans. CONCLUSION: Improving access of sicker, poorer, and minority patients to high-quality hospitals for cancer surgery may improve their outcomes. Further study of processes affecting hospital referral is warranted.
AD  - Department of Health Care Policy, Harvard Medical School, 180 Longwood Avenue, Boston, MA 02115, USA.
AN  - 17000710
AU  - Zhang, W.
AU  - Ayanian, J. Z.
AU  - Zaslavsky, A. M.
DA  - Feb
DO  - 10.1093/intqhc/mzl047
DP  - NLM
ET  - 2006/09/27
IS  - 1
KW  - Adult
Aged
California
Colorectal Neoplasms/*surgery
Female
Health Services Accessibility
Humans
*Inpatients
Male
Middle Aged
Outcome Assessment, Health Care
*Quality of Health Care
Registries
Risk Adjustment
Severity of Illness Index
Surgery Department, Hospital/*standards
LA  - eng
N1  - Zhang, Wei
Ayanian, John Z
Zaslavsky, Alan M
R01 HS09869/HS/AHRQ HHS/United States
U01 CA93324/CA/NCI NIH HHS/United States
U55/CCR921930/PHS HHS/United States
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.
England
Int J Qual Health Care. 2007 Feb;19(1):11-20. doi: 10.1093/intqhc/mzl047. Epub 2006 Sep 25.
PY  - 2007
SN  - 1353-4505 (Print)
1353-4505
SP  - 11-20
ST  - Patient characteristics and hospital quality for colorectal cancer surgery
T2  - Int J Qual Health Care
TI  - Patient characteristics and hospital quality for colorectal cancer surgery
VL  - 19
ID  - 551
ER  - 

TY  - JOUR
AB  - Purpose To evaluate usage trends and identify factors associated with proton beam therapy (PBT) compared to alternative forms of external beam radiation therapy (RT) (EBRT) for localized prostate cancer. Patients and Methods The National Cancer Database was queried for men with localized (N0, M0) prostate cancer diagnosed between 2004 and 2013, treated with EBRT, with available data on EBRT modality (photon vs. PBT). Binary multiple logistic regression identified variables associated with EBRT modality. Results In total, 143,702 patients were evaluated with relatively few men receiving PBT (5,709 [4.0%]). Significant differences in patient and clinical characteristics were identified between those men treated with PBT compared to those treated with photon (odds ratio [OR]; 95% CI). Patients treated with PBT were generally younger (OR = 0.73; CI: 0.67–0.82), National Comprehensive Cancer Network low-risk compared to intermediate (0.71; 0.65–0.78) or high (0.44; 0.38–0.5) risk, white vs. black race (0.66; 0.58–0.77), with less comorbidity (Charlson-Deyo 0 vs. 2+; 0.70; 0.50–0.98), live in higher income counties (1.55; 1.36–1.78), and live in metropolitan areas compared to urban (0.21; 0.18–0.23) or rural (0.14; 0.10–0.19) areas. Most patients treated with PBT travelled more than 100 miles to the treatment facility. Annual PBT utilization significantly increased in both total number and percentage of EBRT over time (2.7%–5.6%; P<0.001). PBT utilization increased mostly in men classified as National Comprehensive Cancer Network low-risk (4%–10.2%). Conclusion PBT for men with localized prostate cancer significantly increased in the United States from 2004 to 2013. Significant demographic and prognostic differences between those men treated with photons and protons were identified.
AD  - T.J. Pugh, Department of Radiation Oncology, University of Colorado School of Medicine, Aurora, CO, United States
AU  - Amini, A.
AU  - Raben, D.
AU  - Crawford, E. D.
AU  - Flaig, T. W.
AU  - Kessler, E. R.
AU  - Lam, E. T.
AU  - Maroni, P.
AU  - Pugh, T. J.
DB  - Embase
Medline
DO  - 10.1016/j.urolonc.2017.01.013
IS  - 6
KW  - prostate specific antigen
aged
androgen deprivation therapy
article
brachytherapy
cancer radiotherapy
cancer staging
comorbidity
data base
demography
Gleason score
high income country
human
major clinical study
male
patient selection
priority journal
prostate cancer
proton therapy
radiation dose
United States
urban area
LA  - English
M3  - Article
N1  - L614459419
2017-02-21
2017-06-13
PY  - 2017
SN  - 1873-2496
1078-1439
SP  - 438-446
ST  - Patient characterization and usage trends of proton beam therapy for localized prostate cancer in the United States: A study of the National Cancer Database
T2  - Urologic Oncology: Seminars and Original Investigations
TI  - Patient characterization and usage trends of proton beam therapy for localized prostate cancer in the United States: A study of the National Cancer Database
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L614459419&from=export
http://dx.doi.org/10.1016/j.urolonc.2017.01.013
VL  - 35
ID  - 934
ER  - 

TY  - JOUR
AB  - PURPOSE: The efficacy of prostate cancer screening is uncertain, and professional organizations recommend educating patients about potential harms and benefits. We evaluated the effect of a videotape decision aid on promoting informed decision making about prostate cancer screening among primary care patients. METHODS: A group of 160 men, 45 to 70 years of age, with no history of prostate cancer, were randomized to view or not to view a 20-minute educational videotape before a routine office visit at a university-based family medicine clinic. The subjects were contacted again 1 year after their visit to assess their receipt of prostate cancer screening (digital rectal examination [DRE] or prostate-specific antigen [PSA] testing), their satisfaction with their screening decision, and knowledge retention since the baseline assessment. RESULTS: Follow-up assessments were completed for 87.5% of the intervention subjects and 83.8% of the control subjects. The rate of DRE did not differ between the 2 groups. Prostate-specific antigen testing was reported by 24 of 70 (34.3%) intervention subjects and 37 of 67 (55.2%) control subjects (P = .01). African American men were more likely to have had PSA testing (9 of 16, 56.3%) than were white men (13 of 46, 28.3%) (P = .044). Satisfaction with the screening decision did not differ between the study groups. Intervention subjects were more knowledgeable of prostate cancer screening than were control subjects, although these differences declined within 1 year (P < .001). CONCLUSIONS: Decision aids for prostate cancer screening can have a long-term effect on screening behavior and appear to promote informed decision making.
AD  - Department of Family and Community Medicine, Baylor College of Medicine, Houston, Tex 77098-3915, USA. bvolk@bcm.tmc.edu
AN  - 15043176
AU  - Volk, R. J.
AU  - Spann, S. J.
AU  - Cass, A. R.
AU  - Hawley, S. T.
C2  - PMC1466553
DA  - May-Jun
DO  - 10.1370/afm.7
DP  - NLM
ET  - 2004/03/27
IS  - 1
KW  - Aged
*Decision Making
Follow-Up Studies
Humans
Male
Mass Screening/methods
Middle Aged
Patient Education as Topic/*methods
Physical Examination/methods
Prostate-Specific Antigen/blood
Prostatic Neoplasms/blood/*diagnosis
Rectum
Videotape Recording
LA  - eng
N1  - 1544-1717
Volk, Robert J
Spann, Stephen J
Cass, Alvab R
Hawley, Sarah T
K02 HS000007/HS/AHRQ HHS/United States
D32-PE10158-01/PE/BHP HRSA HHS/United States
K02-HS00007-02/HS/AHRQ HHS/United States
Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.
Ann Fam Med. 2003 May-Jun;1(1):22-8. doi: 10.1370/afm.7.
PY  - 2003
SN  - 1544-1709 (Print)
1544-1709
SP  - 22-8
ST  - Patient education for informed decision making about prostate cancer screening: a randomized controlled trial with 1-year follow-up
T2  - Ann Fam Med
TI  - Patient education for informed decision making about prostate cancer screening: a randomized controlled trial with 1-year follow-up
VL  - 1
ID  - 634
ER  - 

TY  - JOUR
AB  - Purpose To investigate the effect of socioeconomic status, as measured by education, on the survival of 1,577 lung cancer patients treated on 11 studies conducted by the Cancer and Leukemia Group B. Patients and Methods Sociodemographic data, including education, was reported by the patient at the time of clinical trial accrual. Cox proportional hazards model stratified by treatment arm/ study was used to examine the effect of education on survival after adjustment for known prognostic factors. Results The patient population included 1,177 patients diagnosed with non-small-cell lung cancer (NSCLC; stage III or IV) and 400 patients diagnosed with small-cell lung cancer (SCLC; extensive or limited). Patients with less than an eighth grade education (13% of patients) were significantly more likely to be male, nonwhite, and older; have a performance status (PS) of 1 or 2; and have chest pain. Significant predictors of poor survival in the final model included male sex, PS of 1 or 2, dyspnea, weight loss, liver or bone metastases, unmarried, presence of adrenal metastases and high alkaline phosphatase levels among patients with NSCLC, and high WBC levels among patients with advanced disease. Education was not predictive of survival. Conclusion The physical condition of patients with low education who enroll onto clinical trials is worse than patients with higher education. Once enrolled onto a clinical trial, education does not affect the survival of patients with SCLC or stage III or IV NSCLC. The standardization of treatment and follow-up within a clinical trial, regardless of education, is one possible explanation for this lack of effect.
AN  - WOS:000259350200010
AU  - Herndon, J. E.
AU  - Kornblith, A. B.
AU  - Holland, J. C.
AU  - Paskett, E. D.
DA  - Sep
DO  - 10.1200/JCO.2008.16.7460
IS  - 25
N1  - 18757325
PY  - 2008
SN  - 0732-183X
SP  - 4116-4123
ST  - Patient education level as a predictor of survival in lung cancer clinical trials
T2  - Journal of Clinical Oncology
TI  - Patient education level as a predictor of survival in lung cancer clinical trials
VL  - 26
ID  - 3165
ER  - 

TY  - JOUR
AB  - Purpose Studies have shown an association between socioeconomic status (SES) and quality of oncology care, but less is known about the impact of patient SES on clinical trial participation. Patients and Methods We assessed clinical trial participation patterns according to important SES (income, education) and demographic factors in a large sample of patients surveyed via an Internet-based treatment decision tool. Logistic regression, conditioning on type of cancer, was used. Attitudes toward clinical trials were assessed using prespecified items about treatment, treatment tolerability, convenience, and cost. Results From 2007 to 2011, 5,499 patients were successfully surveyed. Forty percent discussed clinical trials with their physician, 45% of discussions led to physician offers of clinical trial participation, and 51% of offers led to clinical trial participation. The overall clinical trial participation rate was 9%. In univariate models, older patients (P = .002) and patients with lower income (P = .001) and education (P = .02) were less likely to participate in clinical trials. In a multivariable model, income remained a statistically significant predictor of clinical trial participation (odds ratio, 0.73; 95% CI, 0.57 to 0.94; P = .01). Even in patients age >= 65 years, who have universal access to Medicare, lower income predicted lower trial participation. Cost concerns were much more evident among lower-income patients (P = .001). Conclusion Lower-income patients were less likely to participate in clinical trials, even when considering age group. A better understanding of why income is a barrier may help identify ways to make clinical trials better available to all patients and would increase the generalizability of clinical trial results across all income levels. J Clin Oncol 31:536-542. (C) 2013 by American Society of Clinical Oncology
AN  - WOS:000314820400010
AU  - Unger, J. M.
AU  - Hershman, D. L.
AU  - Albain, K. S.
AU  - Moinpour, C. M.
AU  - Petersen, J. A.
AU  - Burg, K.
AU  - Crowley, J. J.
DA  - Feb
DO  - 10.1200/JCO.2012.45.4553
IS  - 5
N1  - 18th Annual National Research Services Award Conference / Annual Research Meeting of the Academy-Health
JUN 23-26, 2012
Orlando, FL
Acad Hlth
23295802
PY  - 2013
SN  - 0732-183X
SP  - 536-542
ST  - Patient Income Level and Cancer Clinical Trial Participation
T2  - Journal of Clinical Oncology
TI  - Patient Income Level and Cancer Clinical Trial Participation
VL  - 31
ID  - 3049
ER  - 

TY  - JOUR
AB  - PURPOSE: High rates of mastectomy and marked regional variations have motivated lingering concerns about overtreatment and failure to involve women in treatment decisions. We examined the relationship between patient involvement in decision making and type of surgical treatment for women with breast cancer. METHODS: All women with ductal carcinoma-in-situ and a 20% random sample of women with invasive breast cancer aged 79 years and younger who were diagnosed in 2002 and reported to the Detroit and Los Angeles Surveillance, Epidemiology, and End Results registries were identified and surveyed shortly after receipt of surgical treatment (response rate, 77.4%; n = 1,844). RESULTS: Mean age was 60.1 years; 70.2% of the women were white, 18.0% were African American, and 11.8% were from other ethnic groups. Overall, 30.2% of women received mastectomy as initial treatment. Most women reported that they made the surgical decision (41.0%) or that the decision was shared (37.1%); 21.9% of patients reported that their surgeon made the decision with or without their input. Among white women, only 5.3% of patients whose surgeon made the decision received mastectomy compared with 16.8% of women who shared the decision and 27.0% of women who made the decision (P < .001, adjusted for clinical factors, predisposing factors, and number of surgeons visited). However, this association was not observed for African American women (Wald test 10.0, P = .041). CONCLUSION: Most women reported that they made or shared the decision about surgical treatment. More patient involvement in decision making was associated with greater use of mastectomy. Racial differences in the association of involvement with receipt of treatment suggest that the decision-making process varies by racial groups.
AD  - Division of General Medicine, Department of Internal Medicine, University of Michigan, 300 N Ingalls, Ste 7E12, Box 0429, Ann Arbor, MI 48109-0429, USA. skatz@umich.edu
AN  - 16110013
AU  - Katz, S. J.
AU  - Lantz, P. M.
AU  - Janz, N. K.
AU  - Fagerlin, A.
AU  - Schwartz, K.
AU  - Liu, L.
AU  - Deapen, D.
AU  - Salem, B.
AU  - Lakhani, I.
AU  - Morrow, M.
DA  - Aug 20
DO  - 10.1200/jco.2005.06.217
DP  - NLM
ET  - 2005/08/20
IS  - 24
KW  - Adult
Aged
Breast Neoplasms/*surgery
Carcinoma, Intraductal, Noninfiltrating/*surgery
*Decision Making
Female
Humans
Logistic Models
*Mastectomy
*Mastectomy, Segmental
Middle Aged
*Patient Participation
Physician-Patient Relations
SEER Program
LA  - eng
N1  - Katz, Steven J
Lantz, Paula M
Janz, Nancy K
Fagerlin, Angela
Schwartz, Kendra
Liu, Lihua
Deapen, Dennis
Salem, Barbara
Lakhani, Indu
Morrow, Monica
N01-PC-35139/PC/NCI NIH HHS/United States
N01-PC-65064/PC/NCI NIH HHS/United States
R01 CA8837-A1/CA/NCI NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.
United States
J Clin Oncol. 2005 Aug 20;23(24):5526-33. doi: 10.1200/JCO.2005.06.217.
PY  - 2005
SN  - 0732-183X (Print)
0732-183x
SP  - 5526-33
ST  - Patient involvement in surgery treatment decisions for breast cancer
T2  - J Clin Oncol
TI  - Patient involvement in surgery treatment decisions for breast cancer
VL  - 23
ID  - 590
ER  - 

TY  - JOUR
AB  - BACKGROUND: Controversy surrounds treatment for localized prostate cancer (LPC). OBJECTIVES: To assess men's localized prostate cancer (LPC) knowledge and its association with decision-making difficulty, satisfaction and regret. METHODS: Population-based sample of 201 men (104 white, 97 black), ≤ 75 years with newly diagnosed LPC completed a self-administered survey. RESULTS: Mean age was 61(±7.6) years; two-thirds had less than a Bachelor's degree. Mean LPC knowledge was low, 5.87 (±2.53, maximum score 11). More than a third of men who received surgery or radiation did not know about serious long-term treatment side effects. Fewer than half of the men correctly answered comparative side effect and survival benefit questions between surgery and radiation. Knowledge gaps were greatest among black men, men with lower education, single men. Tumor aggressiveness (i.e. PSA level, Gleason score) and treatment choice were not associated with knowledge. Knowledge was not associated with decisional satisfaction or regret. However, greater knowledge was associated with greater decision-making difficulty (P = .018). CONCLUSIONS: Significant LPC knowledge gaps existed across groups, with greater knowledge gaps among black men. The association of decision-making difficulty with knowledge was independent of race. Better patient education is needed, but may not alleviate men's decision-making difficulty due to inherent scientific uncertainty.
AD  - From the Department of Family Medicine and Public Health Sciences (ENR, JX), Department of Oncology (JJR), and Department of Anesthesiology (JL), Wayne State University School of Medicine (LMD), Detroit, MI; and the Department of Medicine, Michigan State University, East Lansing (MH-R).
From the Department of Family Medicine and Public Health Sciences (ENR, JX), Department of Oncology (JJR), and Department of Anesthesiology (JL), Wayne State University School of Medicine (LMD), Detroit, MI; and the Department of Medicine, Michigan State University, East Lansing (MH-R). jxu@med.wayne.edu.
AN  - 28484061
AU  - Daum, L. M.
AU  - Reamer, E. N.
AU  - Ruterbusch, J. J.
AU  - Liu, J.
AU  - Holmes-Rovner, M.
AU  - Xu, J.
DA  - May-Jun
DO  - 10.3122/jabfm.2017.03.160298
DP  - NLM
ET  - 2017/05/10
IS  - 3
KW  - Adult
African Americans/psychology
Aged
Clinical Decision-Making
Cross-Sectional Studies
*Decision Making
Emotions
European Continental Ancestry Group/psychology
Health Care Surveys
*Health Knowledge, Attitudes, Practice
Humans
Logistic Models
Male
Michigan
Middle Aged
Patient Participation/*psychology
Patient Preference/*psychology
Patient Satisfaction
Prostatic Neoplasms/ethnology/psychology/*therapy
Uncertainty
Decision Making
Prostate Cancer
LA  - eng
N1  - 1558-7118
Daum, Lisa M
Reamer, Elyse N
Ruterbusch, Julie J
Liu, Joe
Holmes-Rovner, Margaret
Xu, Jinping
Journal Article
United States
J Am Board Fam Med. 2017 May-Jun;30(3):288-297. doi: 10.3122/jabfm.2017.03.160298.
PY  - 2017
SN  - 1557-2625
SP  - 288-297
ST  - Patient Knowledge and Qualities of Treatment Decisions for Localized Prostate Cancer
T2  - J Am Board Fam Med
TI  - Patient Knowledge and Qualities of Treatment Decisions for Localized Prostate Cancer
VL  - 30
ID  - 168
ER  - 

TY  - JOUR
AB  - Purpose Less than 10% of patients enrolled in clinical trials are minorities. The patient navigation model has been used to improve access to medical care but has not been evaluated as a tool to increase the participation of minorities in clinical trials. The Increasing Minority Participation in Clinical Trials project used patient navigators (PNs) to enhance the recruitment of African Americans for and their retention in therapeutic cancer clinical trials in a National Cancer Institute-designated comprehensive cancer center. Methods Lay individuals were hired and trained to serve as PNs for clinical trials. African American patients potentially eligible for clinical trials were identified through chart review or referrals by clinic nurses, physicians, and social workers. PNs provided two levels of services: education about clinical trials and tailored support for patients who enrolled in clinical trials. Results Between 2007 and 2014, 424 African American patients with cancer were referred to the Increasing Minority Participation in Clinical Trials project. Of those eligible for a clinical trial (N = 378), 304 (80.4%) enrolled in a trial and 272 (72%) consented to receive patient navigation support. Of those receiving patient navigation support, 74.5% completed the trial, compared with 37.5% of those not receiving patient navigation support. The difference in retention rates between the two groups was statistically significant (P < .001). Participation of African Americans in therapeutic cancer clinical trials increased from 9% to 16%. Conclusion Patient navigation for clinical trials successfully retained African Americans in therapeutic trials compared with non-patient navigation trial participation. The model holds promise as a strategy to reduce disparities in cancer clinical trial participation. Future studies should evaluate it with racial/ ethnic minorities across cancer centers.
AN  - WOS:000377821100026
AU  - Fouad, M. N.
AU  - Acemgil, A.
AU  - Bae, S.
AU  - Forero, A.
AU  - Lisovicz, N.
AU  - Martin, M. Y.
AU  - Oates, G. R.
AU  - Partridge, E. E.
AU  - Vickers, S. M.
DA  - Jun
DO  - 10.1200/JOP.2015.008946
IS  - 6
N1  - 27189356
PY  - 2016
SN  - 1554-7477
SP  - 554-U303
ST  - Patient Navigation As a Model to Increase Participation of African Americans in Cancer Clinical Trials
T2  - Journal of Oncology Practice
TI  - Patient Navigation As a Model to Increase Participation of African Americans in Cancer Clinical Trials
VL  - 12
ID  - 2943
ER  - 

TY  - JOUR
AB  - INTRODUCTION: Colorectal cancer is a leading cause of cancer-related death in the U.S. Although screening reduces colorectal cancer incidence and mortality, screening rates among U.S. adults remain less than optimal, especially among disadvantaged populations. This study examined the efficacy of patient navigation to increase colonoscopy screening. STUDY DESIGN: RCT. SETTING/PARTICIPANTS: A total of 843 low-income adults, primarily Hispanic and non-Hispanic blacks, aged 50-75 years referred for colonoscopy at Boston Medical Center were randomized into the intervention (n=429) or control (n=427) groups. Participants were enrolled between September 2012 and December 2014, with analysis following through 2015. INTERVENTION: Two bilingual lay navigators provided individualized education and support to reduce patient barriers and facilitate colonoscopy completion. The intervention was delivered largely by telephone. MAIN OUTCOME MEASURE: Colonoscopy completion within 6 months of study enrollment. RESULTS: Colonoscopy completion was significantly higher for navigated patients (61.1%) than control group patients receiving usual care (53.2%, p=0.021). Based on regression analysis, the odds of completing a colonoscopy for navigated patients was one and a half times greater than for controls (95% CI=1.12, 2.03, p=0.007). There were no differences between navigated and control groups in regard to adequacy of bowel preparation (95.3% vs 97.3%, respectively). CONCLUSIONS: Navigation significantly improved colonoscopy screening completion among a racially diverse, low-income population. Results contribute to mounting evidence demonstrating the efficacy of patient navigation in increasing colorectal cancer screening. Screening can be further enhanced when navigation is combined with other evidence-based practices implemented in healthcare systems and the community.
AD  - Division of Cancer Prevention and Control, Centers for Disease Control and Prevention, Atlanta, Georgia. Electronic address: adegroff@cdc.gov.
Boston Medical Center, Gastroenterology, Boston, Massachusetts.
Westat, Rockville, Maryland.
Division of Cancer Prevention and Control, Centers for Disease Control and Prevention, Atlanta, Georgia.
AN  - 28676254
AU  - DeGroff, A.
AU  - Schroy, P. C., 3rd
AU  - Morrissey, K. G.
AU  - Slotman, B.
AU  - Rohan, E. A.
AU  - Bethel, J.
AU  - Murillo, J.
AU  - Ren, W.
AU  - Niwa, S.
AU  - Leadbetter, S.
AU  - Joseph, D.
DA  - Sep
DO  - 10.1016/j.amepre.2017.05.010
DP  - NLM
ET  - 2017/07/06
IS  - 3
KW  - Academic Medical Centers/statistics & numerical data
Aged
Boston
Colonoscopy/statistics & numerical data
Colorectal Neoplasms/*diagnostic imaging/epidemiology/prevention & control
Early Detection of Cancer/*methods/statistics & numerical data
Female
Healthcare Disparities/statistics & numerical data
Humans
Incidence
Male
Mass Screening/*methods/statistics & numerical data
Middle Aged
Occult Blood
Patient Navigation/*methods/statistics & numerical data
Poverty/statistics & numerical data
Program Evaluation
Referral and Consultation/statistics & numerical data
Self Report
Socioeconomic Factors
LA  - eng
N1  - 1873-2607
DeGroff, Amy
Schroy, Paul C 3rd
Morrissey, Kerry Grace
Slotman, Beth
Rohan, Elizabeth A
Bethel, James
Murillo, Jennifer
Ren, Weijia
Niwa, Shelley
Leadbetter, Steven
Joseph, Djenaba
Journal Article
Randomized Controlled Trial
Netherlands
Am J Prev Med. 2017 Sep;53(3):363-372. doi: 10.1016/j.amepre.2017.05.010. Epub 2017 Jul 1.
PY  - 2017
SN  - 0749-3797
SP  - 363-372
ST  - Patient Navigation for Colonoscopy Completion: Results of an RCT
T2  - Am J Prev Med
TI  - Patient Navigation for Colonoscopy Completion: Results of an RCT
VL  - 53
ID  - 164
ER  - 

TY  - JOUR
AB  - To facilitate access to care and to ensure adherence to diagnostic follow-up of positive breast cancer screening or prescribed treatment for confirmed cancer, community volunteers were used as patient navigators (PNs) for a population of low-income, medically underserved women, primarily African Americans. Partnerships were established with local healthcare facilities, residents from the targeted areas were hired as county coordinators, and community volunteers were trained to serve as PNs. Patients who had a suspicious mammogram or confirmed diagnosis of breast cancer were recruited from 23 Alabama counties. For these patients, barriers to diagnostic follow-up or treatment were identified by PNs, who assisted in overcoming these barriers by referring patients to appropriate treatment facilities, guiding them through the healthcare system, and providing the necessary logistical, social, or emotional support. With this intervention, patients kept 93% of their appointments. Thus, for medically underserved patients with breast cancer or a suspicious mammogram, intervention by a network of community volunteers serving as PNs improves adherence to follow-up diagnostic procedures and treatment. PNs can help close the gap between development and delivery of cancer treatments to those who are medically underserved. (Ethn Dis. 2010;20:155-161)
AN  - WOS:000277815700012
AU  - Fouad, M.
AU  - Wynn, T.
AU  - Martin, M.
AU  - Partridge, E.
DA  - Spr
IS  - 2
N1  - 20503896
PY  - 2010
SN  - 1049-510X
SP  - 155-161
ST  - Patient Navigation Pilot Project: Results from the Community Health Advisors in Action Program (Chaap)
T2  - Ethnicity & Disease
TI  - Patient Navigation Pilot Project: Results from the Community Health Advisors in Action Program (Chaap)
VL  - 20
ID  - 3119
ER  - 

TY  - JOUR
AB  - BACKGROUND: Profound advances in biomedical science have contributed to increased longevity and improved quality of life for many Americans. Despite this progress, a heavier burden of disease is borne by some population groups in the United States, particularly the poor and underserved. Landmark reports published since 1973 have highlighted these health disparities, explored their causal factors, and outlined strategies to reduce them. More recent research studies underscore the results of these early reports that identify social position, economic status, culture, and environment as critical determinants of who develops and survives cancer and of the quality of life of cancer survivors. METHODS: The Patient Navigation Program was established in Harlem, New York, in 1990 to address the dramatic disparities in breast cancer mortality among minority women in the community. RESULTS AND CONCLUSIONS: The success of the Harlem Patient Navigation Program has provided the impetus for the development of many similar patient navigation programs across the country and for federal support for Patient Navigation research to address the critical need for effective interventions to eliminate cancer health disparities, particularly among minorities and the underserved.
AD  - National Cancer Institute, National Institutes of Health, Rockville, MD 20852, USA.
AN  - 17020496
AU  - Freeman, H. P.
DA  - Spring
DO  - 10.1207/s15430154jce2101s_4
DP  - NLM
ET  - 2006/10/06
IS  - 1 Suppl
KW  - African Americans/statistics & numerical data
Breast Neoplasms/diagnosis/ethnology/*mortality/*prevention & control
*Community Health Centers
Community-Institutional Relations
Delivery of Health Care
Female
Follow-Up Studies
Hispanic Americans/statistics & numerical data
Hospitals, Community
Humans
Mass Screening
Medically Uninsured/statistics & numerical data
Minority Groups/statistics & numerical data
Neoplasm Staging
New York City/epidemiology
*Patient Selection
Poverty
Primary Prevention
Program Evaluation
Survival Rate
LA  - eng
N1  - Freeman, Harold P
Journal Article
England
J Cancer Educ. 2006 Spring;21(1 Suppl):S11-4. doi: 10.1207/s15430154jce2101s_4.
PY  - 2006
SN  - 0885-8195 (Print)
0885-8195
SP  - S11-4
ST  - Patient navigation: a community centered approach to reducing cancer mortality
T2  - J Cancer Educ
TI  - Patient navigation: a community centered approach to reducing cancer mortality
VL  - 21
ID  - 549
ER  - 

TY  - JOUR
AB  - OBJECTIVE: To gain preliminary insight into patients' levels of awareness and preferences about research recruitment through cancer registries. METHODS: We developed four questions about the North Carolina Central Cancer Registry's educational brochure and about patient preferences regarding physician involvement in research recruitment. These questions were included in the baseline interview conducted among 100 consecutively enrolled participants in the North Carolina Colorectal Cancer Care Outcomes Research Study, an ongoing observational study. RESULTS: Patients who read the Registry's educational brochure generally reported that it helped them understand that a researcher could contact them, but only about one-fourth of patients recalled receiving and reading the brochure. Over two-thirds of patients said they preferred that researchers contact them directly about their interest in research participation, rather than checking with their physician first. Among patients who wanted their physician involved, most preferred a physician notification rather than a physician permission approach. CONCLUSIONS: Registry policies about patient education and physician involvement can have an important impact on researchers' ability to conduct population-based studies. Understanding patient perspectives is key to developing balanced policies that protect patients' privacy, as well as facilitate their opportunities to make autonomous decisions about participating in research.
AD  - Department of Health Policy and Administration, School of Public Health, University of North Carolina, CB# 7411, McGavran-Greenberg Hall, Chapel Hill, NC 27599-7411, USA. laura_beskow@unc.edu
AN  - 16215867
AU  - Beskow, L. M.
AU  - Sandler, R. S.
AU  - Millikan, R. C.
AU  - Weinberger, M.
DA  - Dec
DO  - 10.1007/s10552-005-0407-2
DP  - NLM
ET  - 2005/10/11
IS  - 10
KW  - African Continental Ancestry Group
Age Factors
Aged
Clinical Trials as Topic
Colorectal Neoplasms/*therapy
European Continental Ancestry Group
Female
Humans
Interviews as Topic
Male
Middle Aged
North Carolina
Pamphlets
*Patient Satisfaction
*Patient Selection
Physician-Patient Relations
Pilot Projects
*Registries
Research Design
LA  - eng
N1  - Beskow, Laura M
Sandler, Robert S
Millikan, Robert C
Weinberger, Morris
P30 DK34987/DK/NIDDK NIH HHS/United States
R25 CA57726/CA/NCI NIH HHS/United States
U01 CA93326/CA/NCI NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
Netherlands
Cancer Causes Control. 2005 Dec;16(10):1171-5. doi: 10.1007/s10552-005-0407-2.
PY  - 2005
SN  - 0957-5243 (Print)
0957-5243
SP  - 1171-5
ST  - Patient perspectives on research recruitment through cancer registries
T2  - Cancer Causes Control
TI  - Patient perspectives on research recruitment through cancer registries
VL  - 16
ID  - 587
ER  - 

TY  - JOUR
AB  - Introduction A rapid learning system (RLS) of health care harnesses data generated from routine patient care to create a virtuous cycle of data collection and analysis for quality improvement and research. The success of such systems depends on understanding patient perspectives regarding the ethical issues that arise from the ongoing implementation of this transformative concept. Methods An interview guide was designed to evaluate patient perspectives to inform the ethical implementation of an oncology RLS. A purposively selected, diverse sample of 32 patients with cancer was recruited from two institutions to participate in semistructured, in-depth interviews for formal qualitative analysis. Results The extent to which respondents expressed discomfort with more permissive system features (less formal notification/consent, broader uses/users, inclusion of sensitive data) reflected their trust, which in turn seemed to vary by sociodemographic features. It was also influenced by their familiarity with technology and their attitudes and beliefs regarding privacy and the use of electronic medical records more generally. Distrust of insurers and the pharmaceutical industry led subjects to desire greater oversight and restriction of these potential users of the system. Subjects were most comfortable when doctors were the primary users, engaged patients directly in the notification and consent discussion, and oversaw the system. Conclusion Those actively developing RLSs should recognize the critical importance of trust and the key role that doctors will need to play in order for such systems to be successful and to ensure that their implementation is ethically palatable to the patients whose data are being included.
AD  - University of Michigan, Ann Arbor, MI
American Society of Clinical Oncology, Alexandria, VA
University of Pennsylvania, Philadelphia, PA
AN  - 121734400. Language: English. Entry Date: 20170315. Revision Date: 20181205. Publication Type: Article
AU  - Jones, Rochelle D.
AU  - Sabolch, Aaron N.
AU  - Aakhus, Erin
AU  - Spence, Rebecca A.
AU  - Bradbury, Angela R.
AU  - Jagsi, Reshma
DB  - CINAHL Complete
DO  - 10.1200/JOP.2016.016782
DP  - EBSCOhost
IS  - 3
KW  - Patient Care -- Methods
Ethics
Oncologic Care -- Education
Attitude of Health Personnel
Electronic Health Records
Human
Physicians -- Evaluation
Privacy and Confidentiality
Quality Improvement
Trust
Data Collection
Interviews
Patient Satisfaction -- Evaluation
Cancer Patients
Michigan
Geographic Locations
Research Subject Recruitment
Qualitative Studies
Data Analysis
Data Analysis Software
Health Beliefs
Male
Female
Middle Age
Aged
Aged, 80 and Over
White Persons
Black Persons
Hispanic Americans
Asians
Neoplasms -- Classification
Breast Neoplasms
Prostatic Neoplasms
Lung Neoplasms
Genetics
N1  - research; tables/charts. Journal Subset: Biomedical; Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; USA. NLM UID: 101261852.
PY  - 2017
SN  - 1554-7477
SP  - e163-e175
ST  - Patient Perspectives on the Ethical Implementation of a Rapid Learning System for Oncology Care
T2  - Journal of Oncology Practice
TI  - Patient Perspectives on the Ethical Implementation of a Rapid Learning System for Oncology Care
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=121734400&site=ehost-live&scope=site
VL  - 13
ID  - 2016
ER  - 

TY  - JOUR
AB  - Background: The purpose of this article is to describe the background, design, and patient populations of the Patient Safety in Surgery Study, as a preliminary to the articles in this journal that will report the results of the Study. Study Design: The Patient Safety in Surgery Study was a prospective cohort study. Trained nurses collected preoperative risk factors, operative variables, and 30-day postoperative mortality and morbidity outcomes in patients undergoing major general and vascular operations at 128 Veterans Affairs (VA) medical centers and 14 selected university medical centers between October 1, 2001 and September 30, 2004. An Internet-based data collection system was used to input data from the different private medical centers. Semiannual feedback of observed to expected mortality and morbidity ratios was provided to the participating medical centers. Results: During the 3-year study, total accrual in general surgery was 145,618 patients, including 68.5% from the VA and 31.5% from the private sector. Accrual in vascular surgery totaled 39,225 patients, including 77.8% from the VA and 22.2% from the private sector. VA patients were older and included a larger proportion of male patients and African Americans and Hispanics. The VA population included more inguinal, umbilical, and ventral hernia repairs, although the private-sector population included more thyroid and parathyroid, appendectomy, and operations for breast cancer. Preoperative comorbidities were similar in the two populations, but the rates of comorbidities were higher in the VA. American Society of Anesthesiologists classification tended to be higher in the VA. Conclusions: The National Surgical Quality Improvement Program methodology was successfully implemented in the 14 university medical centers. The data from the study provided the basis for the articles in this issue of the Journal of the American College of Surgeons. © 2007 American College of Surgeons.
AD  - S.F. Khuri, VA Boston Healthcare System, West, Roxbury, MA, United States
AU  - Khuri, S. F.
AU  - Henderson, W. G.
AU  - Daley, J.
AU  - Jonasson, O.
AU  - Jones, R. S.
AU  - Campbell Jr, D. A.
AU  - Fink, A. S.
AU  - Mentzer Jr, R. M.
AU  - Steeger, J. E.
DB  - Embase
Medline
DO  - 10.1016/j.jamcollsurg.2007.03.028
IS  - 6
KW  - adult
aged
appendectomy
article
cancer surgery
clinical trial
comorbidity
controlled clinical trial
controlled study
female
general surgery
human
major clinical study
male
methodology
morbidity
mortality
multicenter study
outcome assessment
patient safety
patient selection
postoperative complication
priority journal
risk factor
surgery
thyroid surgery
treatment outcome
vascular surgery
LA  - English
M3  - Article
N1  - L46819102
2007-06-01
PY  - 2007
SN  - 1072-7515
SP  - 1089-1102
ST  - The Patient Safety in Surgery Study: Background, Study Design, and Patient Populations
T2  - Journal of the American College of Surgeons
TI  - The Patient Safety in Surgery Study: Background, Study Design, and Patient Populations
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L46819102&from=export
http://dx.doi.org/10.1016/j.jamcollsurg.2007.03.028
VL  - 204
ID  - 1231
ER  - 

TY  - JOUR
AB  - BACKGROUND: Colorectal cancer (CRC) screening is effective but underutilized. Although physician recommendation is an important predictor of screening, considerable variation in CRC screening completion remains. PURPOSE: To characterize the influence of patient trust in care providers on CRC screening behavior. METHODS: Data were collected as part of a cluster-randomized CRC screening intervention trial performed in the San Francisco Community Health Network from March 2007 to January 2012 (analysis, Spring 2012). All study participants received a recommendation to complete CRC screening from their primary care provider (PCP). Included participants were aged 50-79 years, not current with screening, and completed the Wake Forest Trust Scale (WFTS) measuring trust in PCPs and doctors in general. Primary outcome was CRC screening completion (colonoscopy or fecal occult blood testing) within 12 months following enrollment. Multivariable association adjusted for race/ethnicity, language, and other sociodemographics was estimated using generalized estimating equations with logit link and binomial distribution. RESULTS: WFTS response was 70.3% (701). Most participants (83%) were Latino, Asian, or black. Most had income <$30,000 (96%) and public health insurance (86%). Higher trust in PCP was associated with screening completion (OR=1.11, 95% CI=1.03, 1.17), but trust in doctors was not (OR=1.02, 95% CI=0.82, 1.28). Race, language, and other sociodemographic factors were not significant in multivariable analysis. CONCLUSIONS: After controlling for traditional factors, trust in PCP remained the only significant driver of CRC screening completion in low-income patients. Interventions to promote CRC screening may be improved by including efforts to enhance patient trust in PCP.
AD  - Emory University School of Medicine, Atlanta, Georgia.
Department of Health Services, University of Washington School of Public Health and Division of Gastroenterology, University of Washington School of Medicine, Seattle, Washington.
Division of General Internal Medicine and Center for Vulnerable Populations, University of California, San Francisco, San Francisco, California.
Department of Health Services, University of Washington School of Public Health and Division of Gastroenterology, University of Washington School of Medicine, Seattle, Washington. Electronic address: jinadomi@medicine.washington.edu.
AN  - 25084682
AU  - Gupta, S.
AU  - Brenner, A. T.
AU  - Ratanawongsa, N.
AU  - Inadomi, J. M.
C2  - PMC4171139
C6  - NIHMS598611
DA  - Oct
DO  - 10.1016/j.amepre.2014.04.020
DP  - NLM
ET  - 2014/08/03
IS  - 4
KW  - Aged
Colonoscopy/statistics & numerical data
Colorectal Neoplasms/*diagnosis/psychology
Female
Humans
Male
Mass Screening/*methods/psychology
Middle Aged
Occult Blood
Patient Acceptance of Health Care
*Physician-Patient Relations
Poverty
San Francisco
Trust/*psychology
LA  - eng
N1  - 1873-2607
Gupta, Shivani
Brenner, Alison T
Ratanawongsa, Neda
Inadomi, John M
K24 DK080941/DK/NIDDK NIH HHS/United States
K24DK080941/DK/NIDDK NIH HHS/United States
R01 CA106773/CA/NCI NIH HHS/United States
UL1 RR024131/RR/NCRR NIH HHS/United States
5T32-HS000032/HS/AHRQ HHS/United States
R01CA106773/CA/NCI NIH HHS/United States
5T32 HS 13853-9/HS/AHRQ HHS/United States
K08 HS022561/HS/AHRQ HHS/United States
UL1 TR000004/TR/NCATS NIH HHS/United States
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, P.H.S.
Am J Prev Med. 2014 Oct;47(4):417-23. doi: 10.1016/j.amepre.2014.04.020. Epub 2014 Jul 29.
PY  - 2014
SN  - 0749-3797 (Print)
0749-3797
SP  - 417-23
ST  - Patient trust in physician influences colorectal cancer screening in low-income patients
T2  - Am J Prev Med
TI  - Patient trust in physician influences colorectal cancer screening in low-income patients
VL  - 47
ID  - 281
ER  - 

TY  - JOUR
AB  - Background/Purpose: African American women are diagnosed with breast cancer at later stages and have higher mortality rates than white women. The Patient Voices Network (PVN), a community group whose vision is “a community of educated and involved patients working hand in hand with physicians in making decisions about their own health care,” conceived of and implemented a walk to raise awareness of breast cancer and link women to screening resources in a low-income, urban community Objectives: To describe the planning and implementation of the Concerned About You: Breast Cancer Awareness Walk & Wellness Event and its impact on an academic community partnership. Methods: A narrative approach was used. Meeting minutes and event planning notes were reviewed. Community participation rates and participant satisfaction were tracked using registration records and a survey administered at the event. Results: 328 community members registered and 194 attended. Responses to a satisfaction survey indicated community buy-in and interest in future events. Two women were screened at the event and 78 were screened at a follow-up opportunity at their primary care practices. The process was driven by participatory guidelines and laid the foundation for future activities. Conclusions: Community input addressed the need for screening mammography in an underserved community. The partnership approach featured complementary strengths of both patients and University staff, fostered skill building and co-learning, and ultimately strengthened our partnership. A partnered approach may be effective in engaging hard-to-reach populations to address health disparities.
AD  - L. Tumiel Berhalter, Department of Family Medicine, University at Buffalo, 77 Goodell St., Room 220N, Buffalo, NY, United States
AU  - Reilly, S. M.
AU  - Wilson Crowley, M.
AU  - Harold, P.
AU  - Hemphill, D.
AU  - Tumiel Berhalter, L.
DB  - Embase
Medline
DO  - 10.1016/j.jnma.2017.10.008
IS  - 5
KW  - adult
aged
article
breast cancer
breast cancer awareness
cancer patient
cancer screening
community care
community participation
female
follow up
health care organization
health care planning
health program
health survey
human
major clinical study
medically underserved
middle aged
narrative
patient satisfaction
practice guideline
primary medical care
priority journal
skill
wellbeing
young adult
LA  - English
M3  - Article
N1  - L619411749
2017-11-29
2019-10-07
PY  - 2018
SN  - 1943-4693
0027-9684
SP  - 448-454
ST  - Patient Voices Network: Bringing Breast Cancer Awareness and Action into Underserved Communities
T2  - Journal of the National Medical Association
TI  - Patient Voices Network: Bringing Breast Cancer Awareness and Action into Underserved Communities
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L619411749&from=export
http://dx.doi.org/10.1016/j.jnma.2017.10.008
VL  - 110
ID  - 879
ER  - 

TY  - JOUR
AB  - Objectives: Endocrine therapy is part of standard adjuvant therapy for patients with hormone receptor-positive breast cancer and has been shown to improve recurrence-free and overall survival. However, adherence to endocrine therapy is suboptimal and is difficult to measure. In this study we evaluate the feasibility of using the Morisky Medication Adherence Scale (MMAS) to assess patient adherence to aromatase inhibitor (AI) therapy. Methods: Patients with stage 1 to 3, hormone receptor-positive breast cancer receiving adjuvant AI therapy were prospectively enrolled on an Institutional Review Board approved protocol. The MMAS questionnaire was administered to each patient and adherence was measured. Information on duration of AI therapy, patient and tumor characteristics, and treatment was collected. A multivariable logit model approach was utilized to evaluate potential barriers to adherence. Results: Between 2011 and 2014, 100 patients were enrolled. The distribution of adherence levels was 13% low, 37% medium, and 50% high. High adherence was reported more frequently in white women (58%), patients with stage 2 and 3 disease (54%), and patients who did not receive chemotherapy (62%). Multivariable analysis demonstrated that higher adherence was more likely in white women compared with African American women (estimated odds ratio=2.8). Conclusions: Using the MMAS, only 50% of women with stage 1 to 3 breast cancer reported high adherence to AI therapy, consistent with other reports showing suboptimal adherence to adjuvant endocrine therapy. The MMAS allows for the rapid assessment of adherence to oral adjuvant endocrine therapy and is valuable in a busy clinical setting.
AD  - S.B. Kesmodel, Departments of Surgery, Division of General and Oncologic Surgery, University of Maryland School of Medicine, 29 S. Greene St., Baltimore, MD, United States
AU  - Kesmodel, S. B.
AU  - Goloubeva, O. G.
AU  - Rosenblatt, P. Y.
AU  - Heiss, B.
AU  - Bellavance, E. C.
AU  - Chumsri, S.
AU  - Bao, T.
AU  - Thompson, J.
AU  - Nightingale, G.
AU  - Tait, N. S.
AU  - Nichols, E. M.
AU  - Feigenberg, S. J.
AU  - Tkaczuk, K. H.
DB  - Embase
Medline
DO  - 10.1097/COC.0000000000000314
IS  - 5
KW  - aromatase inhibitor
adjuvant therapy
adult
African American
aged
article
breast cancer
cancer adjuvant therapy
cancer patient
Caucasian
clinical trial
early cancer
female
human
major clinical study
medication compliance
Morisky Medication Adherence Scale
patient-reported outcome
postmenopause
prospective study
questionnaire
LA  - English
M3  - Article
N1  - L610940644
2016-06-30
2018-05-22
PY  - 2018
SN  - 1537-453X
0277-3732
SP  - 508-512
ST  - Patient-reported Adherence to Adjuvant Aromatase Inhibitor Therapy Using the Morisky Medication Adherence Scale: An Evaluation of Predictors
T2  - American Journal of Clinical Oncology: Cancer Clinical Trials
TI  - Patient-reported Adherence to Adjuvant Aromatase Inhibitor Therapy Using the Morisky Medication Adherence Scale: An Evaluation of Predictors
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L610940644&from=export
http://dx.doi.org/10.1097/COC.0000000000000314
VL  - 41
ID  - 914
ER  - 

TY  - JOUR
AB  - BACKGROUND: Aromatase inhibitors (AIs) have been associated with decrements in patient-reported outcomes (PROs). The objective of this study was to assess whether real acupuncture (RA), compared with sham acupuncture (SA), improves PROs in patients with breast cancer who are receiving an adjuvant AI. METHODS: Postmenopausal women with a stage 0 through III breast cancer who received an AI and had treatment-associated musculoskeletal symptoms were randomized to receive 8 weekly RA versus SA in a dual-center, randomized controlled trial. The National Surgical Adjuvant Breast and Bowel Project (NSABP) menopausal symptoms questionnaire, the Center for Epidemiological Studies Depression (CESD) scale, the Hospital Anxiety and Depression Scale (HADS), the Pittsburgh Sleep Quality Index (PSQI), the hot flash daily diary, the Hot Flash-Related Daily Interference Scale (HFRDI), and the European quality-of-life survey (EuroQol) were used to assess PROs at baseline and at 4weeks, 8 weeks, and 12 weeks. RESULTS: The intention-to-treat analysis included 23 patients in the RA arm and 24 patients in the SA arm. There were no significant differences in baseline characteristics between the 2 groups. Compared with baseline, scores in the RA arm improved significantly at week 8 on the CESD (P = .022), hot flash severity (P = .006), hot flash frequency (P = .011), the HFRDI (P = .014), and NSABP menopausal symptoms (P = .022); scores in the SA arm improved significantly on the EuroQol (P = .022),the HFRDI (P = .043), and NSABP menopausal symptoms (P = .005). Post-hoc analysis indicated that African American patients (n = 9) benefited more from RA than SA compared with non-African American patients (n = 38) in reducing hot flash severity (P < .001) and frequency (P < .001) scores. CONCLUSIONS: Both RA and SA were associated with improvement in PROs among patients with breast cancer who were receiving AIs, and no significant difference was detected between arms. Racial differences in response to acupuncture warrant further study.
AD  - University of Maryland Greenebaum Cancer Center, Baltimore, Maryland.
AN  - 24375332
AU  - Bao, T.
AU  - Cai, L.
AU  - Snyder, C.
AU  - Betts, K.
AU  - Tarpinian, K.
AU  - Gould, J.
AU  - Jeter, S.
AU  - Medeiros, M.
AU  - Chumsri, S.
AU  - Bardia, A.
AU  - Tan, M.
AU  - Singh, H.
AU  - Tkaczuk, K. H.
AU  - Stearns, V.
C2  - PMC3946917
C6  - NIHMS516679
DA  - Feb 1
DO  - 10.1002/cncr.28352
DP  - NLM
ET  - 2014/01/01
IS  - 3
KW  - *Acupuncture Therapy
Adult
Aged
Aged, 80 and over
Aromatase Inhibitors/*adverse effects
Bone Diseases/chemically induced/*prevention & control
Breast Neoplasms/psychology/*therapy
Double-Blind Method
Female
Humans
Middle Aged
Muscular Diseases/chemically induced/*prevention & control
Quality of Life
acupuncture
aromatase inhibitor
musculoskeletal symptoms
patient-reported outcomes
role in Novartis, and receives research funding from Novartis, GSK, Merck
Dr. Vered
Stearns receives research funding from Pfizer, Novartis.
LA  - eng
N1  - 1097-0142
Bao, Ting
Cai, Ling
Snyder, Claire
Betts, Kelly
Tarpinian, Karineh
Gould, Jeff
Jeter, Stacie
Medeiros, Michelle
Chumsri, Saranya
Bardia, Aditya
Tan, Ming
Singh, Harvinder
Tkaczuk, Katherin H R
Stearns, Vered
P30CA006973/CA/NCI NIH HHS/United States
P30 CA006973/CA/NCI NIH HHS/United States
P30 CA134274/CA/NCI NIH HHS/United States
R21 CA173263/CA/NCI NIH HHS/United States
K12 CA126849/CA/NCI NIH HHS/United States
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Cancer. 2014 Feb 1;120(3):381-9. doi: 10.1002/cncr.28352. Epub 2013 Dec 23.
PY  - 2014
SN  - 0008-543X (Print)
0008-543x
SP  - 381-9
ST  - Patient-reported outcomes in women with breast cancer enrolled in a dual-center, double-blind, randomized controlled trial assessing the effect of acupuncture in reducing aromatase inhibitor-induced musculoskeletal symptoms
T2  - Cancer
TI  - Patient-reported outcomes in women with breast cancer enrolled in a dual-center, double-blind, randomized controlled trial assessing the effect of acupuncture in reducing aromatase inhibitor-induced musculoskeletal symptoms
VL  - 120
ID  - 298
ER  - 

TY  - JOUR
AB  - BACKGROUND: To make informed decisions, patients must have adequate knowledge of key decision-relevant facts. OBJECTIVE: To determine adults' knowledge about information relevant to common types of medication, screening, or surgery decisions they recently made. SETTING: National sample of US adults identified by random-digit dialing. DESIGN: Cross-sectional survey conducted between November 2006 and May 2007. PARTICIPANTS: A total of 2575 English-speaking adults aged 40 y or older who reported having discussed the following medical decisions with a health care provider within the previous 2 y: prescription medications for hypertension, hypercholesterolemia, or depression; screening tests for colorectal, breast, or prostate cancer; or surgeries for knee/hip replacement, cataracts, or lower back pain. MEASUREMENTS: Participants answered knowledge questions and rated the importance of their health care provider, family/friends, and the media as sources of information. RESULTS: Accuracy rates varied widely across questions and decision contexts. For example, patients considering cataract surgery were more likely to correctly estimate recovery time than those patients considering lower back pain or knee/hip replacement (78% v. 29% and 39%, P < 0.001). Similarly, participants were more knowledgeable of facts about colorectal cancer screening than those who were asked about breast or prostate cancer. Finally, respondents were consistently more knowledgeable on comparable questions about blood pressure medication than cholesterol medication or antidepressants. The impact of demographic characteristics and sources of information also varied substantially. For example, blacks had lower knowledge than whites about cancer screening decisions (odds ratio [OR] = 0.57; 95% confidence interval [CI] = 0.43, 0.75; P = 0.001) and medication (OR = 0.77; 95% CI = 0.60, 0.97; P = 0.03) even after we controlled for other demographic factors. The same was not true for surgical decisions. LIMITATIONS: The questions did not measure all knowledge relevant to informed decision making, were subject to recall biases, and may have assessed numeracy more than knowledge. CONCLUSIONS: Patient knowledge of key facts relevant to recently made medical decisions is often poor and varies systematically by decision type and patient characteristics. Improving patient knowledge about risks, benefits, and characteristics of medical procedures is essential to support informed decision making.
AD  - VA Health Services Research & Development Center of Excellence, VA Ann Arbor Healthcare System, Ann Arbor, MI, USA. fagerlin@med.umich.edu
AN  - 20881153
AU  - Fagerlin, A.
AU  - Sepucha, K. R.
AU  - Couper, M. P.
AU  - Levin, C. A.
AU  - Singer, E.
AU  - Zikmund-Fisher, B. J.
DA  - Sep-Oct
DO  - 10.1177/0272989x10378700
DP  - NLM
ET  - 2010/10/15
IS  - 5 Suppl
KW  - Adult
Aged
Confidence Intervals
Cross-Sectional Studies
Decision Making
Early Detection of Cancer
Educational Measurement
Educational Status
Female
General Surgery
*Health Knowledge, Attitudes, Practice
Humans
Logistic Models
Male
Middle Aged
Multivariate Analysis
Neoplasms/diagnosis/drug therapy/surgery
Odds Ratio
*Patient Education as Topic
*Patient Participation
Prescription Drugs
Risk
LA  - eng
N1  - 1552-681x
Fagerlin, Angela
Sepucha, Karen R
Couper, Mick P
Levin, Carrie A
Singer, Eleanor
Zikmund-Fisher, Brian J
Journal Article
Research Support, Non-U.S. Gov't
United States
Med Decis Making. 2010 Sep-Oct;30(5 Suppl):35S-52S. doi: 10.1177/0272989X10378700.
PY  - 2010
SN  - 0272-989x
SP  - 35s-52s
ST  - Patients' knowledge about 9 common health conditions: the DECISIONS survey
T2  - Med Decis Making
TI  - Patients' knowledge about 9 common health conditions: the DECISIONS survey
VL  - 30
ID  - 410
ER  - 

TY  - JOUR
AB  - Background Fewer than 5 % of cancer patients participate in clinical research. Although this paltry rate has led to extensive research on this topic, previous studies have not sought verbatim comments in a real-time, comprehensive manner to understand why patients decline. Methods This study used a low-risk, non-interventional parent study that focused on cancer-associated weight loss to understand patients' reasons for declining research participation. A research assistant wrote down the name and verbatim reason of all patients who declined to participate. These comments with accompanying patient demographic data are the subject of this report. Results Of the 334 patients, 51 (15 %) declined parent study enrollment; three comment-related themes emerged: (1) a repelling sense of too much institutional research, (2) overwhelming personal health issues, and (3) a low likelihood of returning to the institution. In univariate and multivariate analyses, only age (older) and gender (female) were associated with non-enrollment. Interestingly, 41 patients with fatigue scores of 7 or worse and 26 with pain scores of 7 or worse were enrolled. Conclusions Although many factors were associated with declining to participate in research, symptom severity was not. Upfront education might help cancer patients better prioritize their participation in research, particularly as some patients felt overwhelmed by too much research in the institution; and for now, investigators should continue to keep asking patients for their participation.
AN  - WOS:000337088900006
AU  - Wanger, T.
AU  - Foster, N. R.
AU  - Nguyen, P. L.
AU  - Jatoi, A.
DA  - Jun
DO  - 10.1007/s13539-014-0128-z
IS  - 2
N1  - 24622952
PY  - 2014
SN  - 2190-5991
SP  - 121-125
ST  - Patients' rationale for declining participation in a cancer-associated weight loss study
T2  - Journal of Cachexia Sarcopenia and Muscle
TI  - Patients' rationale for declining participation in a cancer-associated weight loss study
VL  - 5
ID  - 3006
ER  - 

TY  - JOUR
AB  - To characterize patients' willingness to donate a biospecimen for future research as part of a breast cancer-related biobank involving a general screening population. We performed a prospective cross-sectional study of 4,217 women aged 21-89 years presenting to our facilities for screening mammogram between December 2010 and October 2011. This HIPAA-compliant study was approved by our institutional review board. We collected data on patients' interest in and actual donation of a biospecimen, motivators and barriers to donating, demographic information, and personal breast cancer risk factors. A multivariate logistic regression analysis was performed to identify patient-level characteristics associated with an increased likelihood to donate. Mean patient age was 57.8 years (SD 11.1 years). While 66.0 % (2,785/4,217) of patients were willing to donate blood or saliva during their visit, only 56.4 % (2,378/4,217) actually donated. Women with a college education (OR = 1.27, p = 0.003), older age (OR = 1.02, p < 0.001), previous breast biopsy (OR = 1.23, p = 0.012), family history of breast cancer (OR = 1.23, p = 0.004), or a comorbidity (OR = 1.22, p = 0.014) were more likely to donate. Asian-American women were significantly less likely to donate (OR = 0.74, p = 0.005). The major reason for donating was to help all future patients (42.3 %) and the major reason for declining donation was privacy concerns (22.3 %). A large proportion of women participating in a breast cancer screening registry are willing to donate blood or saliva to a biobank. Among minority participants, Asian-American women are less likely to donate and further qualitative research is required to identify novel active recruitment strategies to insure their involvement. © 2012 Springer Science+Business Media New York.
AD  - C.I. Lee, Department of Radiology, University of Washington School of Medicine, 825 Eastlake Avenue East, G3-200, Seattle, WA 98109-1023, United States
AU  - Lee, C. I.
AU  - Bassett, L. W.
AU  - Leng, M.
AU  - Maliski, S. L.
AU  - Pezeshki, B. B.
AU  - Wells, C. J.
AU  - Mangione, C. M.
AU  - Naeim, A.
DB  - Embase
Medline
DO  - 10.1007/s10549-012-2324-x
IS  - 3
KW  - adult
African American
aged
article
Asian American
attitude to health
biobank
blood donor
breast biopsy
breast cancer
cancer screening
Caucasian
cerebrovascular accident
cohort analysis
comorbidity
controlled study
cross-sectional study
diabetes mellitus
educational status
ethnicity
family history
female
health care facility
heart disease
Hispanic
human
human tissue
hypertension
kidney disease
liver disease
major clinical study
mammography
medical history
patient participation
priority journal
prospective study
LA  - English
M3  - Article
N1  - L52289264
2012-11-10
2013-10-28
PY  - 2012
SN  - 0167-6806
1573-7217
SP  - 899-906
ST  - Patients' willingness to participate in a breast cancer biobank at screening mammogram
T2  - Breast Cancer Research and Treatment
TI  - Patients' willingness to participate in a breast cancer biobank at screening mammogram
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L52289264&from=export
http://dx.doi.org/10.1007/s10549-012-2324-x
VL  - 136
ID  - 1107
ER  - 

TY  - JOUR
AB  - BACKGROUND: Population-based overall patterns of surgical management of the axilla in women with operable breast cancer during the era of adoption of sentinel lymph node biopsy (SLNB) were studied. METHODS: Women with operable breast carcinoma residing in 14 geographic areas of the Surveillance, Epidemiology, and End Results (SEER) cancer registries (1998-2004, n=239,661) were assessed for axillary surgical patterns of care. RESULTS: Use of SLNB increased from 11 to 59%. Use of no axillary surgery decreased from 14 to 6.6%. In pathologic node-negative women, use of axillary lymph node dissection (ALND) decreased from 94 to 36%. Independent factors most associated with failure to receive SLNB included diagnosis year (2000: 62%; 2004: 29%), surgery (mastectomy: 64%; breast-conserving surgery: 36%), tumor size (T3: 71%; T2: 56%; T1: 40%), age (>or= 70 years: 50%; <70 years: 45%), grade (high: 42%; low: 38%), urbanity (non-large metropolitan area: 49%; large metropolitan area: 42%), and, by quartile, poverty (highest: 47%; lowest: 35%), and white-collar employment (lowest: 56%; highest: 47%). In pathologic node-positive women who had SLNB, failure to undergo completion ALND increased from 20% in 1998 to 32% in 2004. Patients with smaller, lower-grade tumors, and those with smaller size of nodal metastasis, lack of extracapsular extension, age >or= 70 years, increased linguistic isolation, African-American or Hispanic race/ethnicity, and white-collar employment were less likely to undergo completion ALND. CONCLUSIONS: Management of the axilla changed dramatically during the period of rapid adoption of SLNB. Patterns of care suggest both appropriate and inappropriate selection for SLNB and ALND.
AD  - Department of Radiation Oncology, St. Vincent's Cancer Center, New York, NY 10011, USA. jrescigno@aptiumoncology.com
AN  - 19101768
AU  - Rescigno, J.
AU  - Zampell, J. C.
AU  - Axelrod, D.
DA  - Mar
DO  - 10.1245/s10434-008-0195-5
DP  - NLM
ET  - 2008/12/23
IS  - 3
KW  - African Americans
Aged
Axilla
Breast Neoplasms/pathology/*surgery
Carcinoma, Ductal, Breast/secondary/*surgery
Carcinoma, Lobular/secondary/*surgery
Carcinoma, Medullary/secondary/*surgery
European Continental Ancestry Group
Female
Follow-Up Studies
Hispanic Americans
Humans
Lymph Node Excision
Lymph Nodes/pathology
Lymphatic Metastasis
Middle Aged
Neoplasm Staging
Patient Selection
Prognosis
Registries
Risk Factors
SEER Program
Sentinel Lymph Node Biopsy
Survival Rate
Treatment Outcome
LA  - eng
N1  - 1534-4681
Rescigno, John
Zampell, Jamie C
Axelrod, Deborah
Journal Article
United States
Ann Surg Oncol. 2009 Mar;16(3):687-96. doi: 10.1245/s10434-008-0195-5. Epub 2008 Dec 20.
PY  - 2009
SN  - 1068-9265
SP  - 687-96
ST  - Patterns of axillary surgical care for breast cancer in the era of sentinel lymph node biopsy
T2  - Ann Surg Oncol
TI  - Patterns of axillary surgical care for breast cancer in the era of sentinel lymph node biopsy
VL  - 16
ID  - 482
ER  - 

TY  - JOUR
AB  - BACKGROUND: Older women have high rates of breast carcinoma, and there are substantial variations in the patterns of care for this population group. METHODS: The authors studied 718 breast carcinoma patients age 67 years and older who were diagnosed with localized disease between 1995 and 1997 from 29 hospitals in 5 regions. Data were collected from patients, charts, and surgeons. Logistic regression analysis was used to evaluate determinants of treatment. RESULTS: Women who were concerned about body image were 1.8 times more likely (95% confidence interval [95% CI], 1.1-2.8) to receive breast conservation surgery and radiotherapy than women without this preference, controlling for other factors. In contrast, women who preferred receiving no therapy beyond surgery were 3.9 times more likely (95% CI, 2.9-6.1) to undergo mastectomy than other women, after considering other factors. Radiotherapy was omitted after breast conservation 3.4 times more often (95% CI, 2.0-5.6) among women age 80 years and older than among women ages 67-79 years, controlling for covariates. Black women tended to have radiotherapy omitted after breast conservation surgery 2.0 times more often (95% CI, 0.9-4.4) than white women (P = 0.09). Women age 80 years and older also were 70% less likely (odds ratio = 0.3; 95% CI, 0.1-0.8) to receive chemotherapy than women ages 67-79 years, controlling for health, functional status, and other covariates. CONCLUSIONS: After considering other factors, patient preferences and age were found to be associated with breast carcinoma treatment patterns in older women. Further research and training are needed to provide care for the growing population of older women that is both clinically appropriate and consonant with a woman's preferences.
AD  - Departments of Oncology and Medicine, Lombardi Cancer Center, Georgetown University School of Medicine, Washington, DC, USA.
AN  - 10931455
AU  - Mandelblatt, J. S.
AU  - Hadley, J.
AU  - Kerner, J. F.
AU  - Schulman, K. A.
AU  - Gold, K.
AU  - Dunmore-Griffith, J.
AU  - Edge, S.
AU  - Guadagnoli, E.
AU  - Lynch, J. J.
AU  - Meropol, N. J.
AU  - Weeks, J. C.
AU  - Winn, R.
DA  - Aug 1
DP  - NLM
ET  - 2000/08/10
IS  - 3
KW  - Aged
Analysis of Variance
Breast Neoplasms/psychology/*therapy
Cohort Studies
Female
Humans
Logistic Models
*Patient Participation
*Practice Patterns, Physicians'
LA  - eng
N1  - Mandelblatt, J S
Hadley, J
Kerner, J F
Schulman, K A
Gold, K
Dunmore-Griffith, J
Edge, S
Guadagnoli, E
Lynch, J J
Meropol, N J
Weeks, J C
Winn, R
R01HS08395/HS/AHRQ HHS/United States
Journal Article
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, U.S. Gov't, P.H.S.
United States
Cancer. 2000 Aug 1;89(3):561-73.
PY  - 2000
SN  - 0008-543X (Print)
0008-543x
SP  - 561-73
ST  - Patterns of breast carcinoma treatment in older women: patient preference and clinical and physical influences
T2  - Cancer
TI  - Patterns of breast carcinoma treatment in older women: patient preference and clinical and physical influences
VL  - 89
ID  - 701
ER  - 

TY  - JOUR
AB  - Racial disparities in breast cancer survivorship are a major concern nationally. How survivors cope with cancer and re-frame their lives is a critical part of survivorship. Community-academic research partnerships may facilitate access to much-needed psychosocial support for African American survivors and caregivers in rural areas, but drivers of successful intervention implementation are not well understood. The purpose of this study was to describe the training and evaluation of Community Coaches and Guides (i.e., peer supporters) using the Peer Connect program for African American breast cancer survivors and caregivers. Community engagement strategies were used to implement the training component of Peer Connect, an evidence-based program grounded in the Diffusion of Innovation Theory utilizing motivational interviewing techniques (MI) and a "train-the-trainer" model. Quantitative and qualitative methods examined implementation outcomes of feasibility, MI fidelity, and acceptability-precursor outcomes that must be achieved before examining intervention impact vis-à-vis changes in support care. Training was feasible to implement and replicable by the trained Community Coaches. Beyond feasibility and replicability, success was modest regarding MI fidelity. Benefits (e.g., serving as role models and having safe sources of support) and lessons learned (e.g., need for additional quality control) were identified as both facilitators and barriers to implementation and as factors that could impact the effectiveness of community-engaged programs to improve survivorship outcomes. Peer Connect, like other programs that employ community-engagement strategies, holds promise to meet the psychosocial support needs of diverse rural cancer survivor populations.
AD  - School of Public Health, Department of Health Promotion and Behavioral Sciences, The University of Texas, 5323 Harry Hines, V8.112, Dallas, TX, 75390-9128, USA. Marlyn.A.Allicock@uth.tmc.edu.
Department of Youth, Family, and Community Sciences College of Agriculture and Life Sciences, North Carolina State University, Raleigh, NC, 27695, USA.
Center for Health Promotion and Disease Prevention, University of North Carolina at Chapel Hill, Chapel Hill, USA.
University of North Carolina at Chapel Hill, Chapel Hill, USA.
Rural Health Group, Inc, 500 Jackson St, Roanoke Rapids, NC, 27870, USA.
Vidant Edgecombe Hospital, 111 Hospital Dr a, Tarboro, NC, 27886, USA.
AN  - 28425087
AU  - Allicock, M.
AU  - Haynes-Maslow, L.
AU  - Johnson, L. S.
AU  - Carpenter, W. R.
AU  - Vines, A. I.
AU  - Belle, D. G.
AU  - Phillips, R.
AU  - Cherry, M. W.
C2  - PMC5645281
DA  - Sep
DO  - 10.1007/s13142-017-0490-4
DP  - NLM
ET  - 2017/04/21
IS  - 3
KW  - Adult
*African Americans
Aged
*Breast Neoplasms/therapy
*Cancer Survivors/education
*Caregivers
Community Health Workers/*education
Community Participation
Evidence-Based Practice
Feasibility Studies
Female
Healthcare Disparities
Humans
Information Dissemination/methods
Mentoring
Middle Aged
Patient Acceptance of Health Care
*Peer Group
Qualitative Research
Self Efficacy
Social Support
*African American
*Breast cancer
*Cancer survivors
*Community engagement
*Peer support
*Training
THEIR INVOLVEMENT. ᅟ CONFLICT OF INTEREST: The authors declare that they have no
conflicts of interest. STATEMENT OF HUMAN RIGHTS: ᅟ ETHICAL APPROVAL: All procedures
performed in studies involving human participants were in accordance with the
ethical standards of the institutional and/or national research committee and with
the 1975 Helsinki declaration and its later amendments or comparable ethical
standards. STATEMENT ON THE WELFARE OF ANIMALS: This article does not contain any
studies with animals performed by any of the authors. Informed consent was obtained
by all individual participants included in the study (University of North Carolina
at Chapel Hill, IRB #12-1941.
LA  - eng
N1  - 1613-9860
Allicock, Marlyn
Orcid: 0000-0002-2114-6768
Haynes-Maslow, Lindsey
Johnson, La-Shell
Carpenter, William R
Vines, Anissa I
Belle, Denise G
Phillips, Ray
Cherry, Michele W
P30 DK056350/DK/NIDDK NIH HHS/United States
U01 CA114629/CA/NCI NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Transl Behav Med. 2017 Sep;7(3):495-505. doi: 10.1007/s13142-017-0490-4.
PY  - 2017
SN  - 1869-6716 (Print)
1613-9860
SP  - 495-505
ST  - Peer Connect for African American breast cancer survivors and caregivers: a train-the-trainer approach for peer support
T2  - Transl Behav Med
TI  - Peer Connect for African American breast cancer survivors and caregivers: a train-the-trainer approach for peer support
VL  - 7
ID  - 170
ER  - 

TY  - JOUR
AB  - PURPOSE: The purpose of this study was to explore the feasibility and acceptability of a peer navigation survivorship program for African American (AA) breast cancer survivors (BCS) and its potential effects on selected short-term outcomes according to the Quality of Life Model Applied to Cancer Survivors. METHODS: An AA BCS who completed treatment over 1 year prior to the study was trained as a peer navigator (PN), and then paired with AA women completing primary breast cancer treatment (n=4) for 2 months. This mixed-methods, proof of concept study utilized a convergent parallel approach to explore feasibility and investigate whether changes in scores are favorable using interviews and self-administered questionnaires. RESULTS: Results indicate that the PN intervention was acceptable by both PN and BCS, and was feasible in outcomes of recruitment, cost, and time requirements. Improvements in symptom distress, perceived support from God, and preparedness for recovery outcomes were observed over time. Qualitative analysis revealed six themes emerging from BCS interviews: "learning to ask the right questions", "start living life again", "shifting my perspective", "wanting to give back", "home visits are powerful", and "we both have a journey": support from someone who has been there. CONCLUSION: Results support current literature indicating that AA women who have survived breast cancer can be an important source of support, knowledge, and motivation for those completing breast cancer treatment. Areas for future research include standardization of training and larger randomized trials of PN intervention. IMPLICATIONS FOR CANCER SURVIVORS: The transition from breast cancer patient to survivor is a period when there can be a loss of safety net concurrent with persistent support needs. AA cancer survivors can benefit from culturally tailored support and services after treatment for breast cancer. With further testing, this PN intervention may aid in decreasing general symptom distress and increase readiness for recovery post-treatment.
AD  - College of Nursing, Medical University of South Carolina, Charleston, SC, USA.
South Carolina Clinical and Translation Research Center for Community Health Partnerships, College of Nursing, Medical University of South Carolina, Charleston, SC, USA.
Department of Public Health Sciences, Medical University of South Carolina, Charleston, SC, USA.
AN  - 25404863
AU  - Mollica, M. A.
AU  - Nemeth, L. S.
AU  - Newman, S. D.
AU  - Mueller, M.
AU  - Sterba, K.
C2  - PMC4230185
DO  - 10.2147/prom.S69744
DP  - NLM
ET  - 2014/11/19
KW  - African American
breast cancer
peer support
survivor
LA  - eng
N1  - 1179-271x
Mollica, Michelle A
Nemeth, Lynne S
Newman, Susan D
Mueller, Martina
Sterba, Katherine
UL1 TR000062/TR/NCATS NIH HHS/United States
Journal Article
Patient Relat Outcome Meas. 2014 Nov 7;5:131-44. doi: 10.2147/PROM.S69744. eCollection 2014.
PY  - 2014
SN  - 1179-271X (Print)
1179-271x
SP  - 131-44
ST  - Peer navigation in African American breast cancer survivors
T2  - Patient Relat Outcome Meas
TI  - Peer navigation in African American breast cancer survivors
VL  - 5
ID  - 270
ER  - 

TY  - JOUR
AB  - Prostate cancer is the most frequently diagnosed major cancer and the second cause of cancer-related deaths among men. With early detection through screening and timely treatment, 9 out of 10 men will survive a minimum of 5 years. However, with late diagnoses, only 3 out of 10 men will have a 5-year minimum survival rate. Guided by a conceptual map, this correlational research examined perceived benefits as a predictor of participation in free prostate cancer screening. Perceived benefits are the personal belief and valuing of screening for early detection of prostate cancer. All subjects received one of four educational interventions: traditional, peer educator, client navigator, or combination. Participation in prostate cancer screening was measured by compliance with the American Cancer Society's Guidelines, which included a digital rectal exam (DRE) and/or a prostate-specific antigen (PSA) blood test. The purposive sample (n = 1,522) of men, ages 40 to 70 years, was recruited from randomly selected churches, barbershops, industries, housing projects, and car dealerships in a southeastern state. Seventy-two percent of the sample was African American. Predictors of participation in free prostate cancer screening were these: perceived benefits, being white, having at least a high school education, being married, and receiving the client navigator or combination educational intervention. The Benefits Scale was significant (p = 0.013, odds ratio (OR) = 1.059) as a predictor for participation in screening when all demographic variables and educational interventions were controlled. Practice implications for nursing are discussed and recommendations for future research are presented.
AD  - Medical College of Georgia, School of Nursing, Augusta 30912, USA.
AN  - 9775485
AU  - Tingen, M. S.
AU  - Weinrich, S. P.
AU  - Heydt, D. D.
AU  - Boyd, M. D.
AU  - Weinrich, M. C.
DA  - Oct
DO  - 10.1097/00002820-199810000-00006
DP  - NLM
ET  - 1998/10/17
IS  - 5
KW  - Adult
Aged
*Attitude to Health
Humans
Male
*Mass Screening
Middle Aged
*Oncology Nursing
*Patient Participation
Prostatic Neoplasms/*nursing/*prevention & control
Socioeconomic Factors
LA  - eng
N1  - Tingen, M S
Weinrich, S P
Heydt, D D
Boyd, M D
Weinrich, M C
R01 CA60561-01/CA/NCI NIH HHS/United States
Journal Article
Research Support, U.S. Gov't, P.H.S.
United States
Cancer Nurs. 1998 Oct;21(5):349-57. doi: 10.1097/00002820-199810000-00006.
PY  - 1998
SN  - 0162-220X (Print)
0162-220x
SP  - 349-57
ST  - Perceived benefits: a predictor of participation in prostate cancer screening
T2  - Cancer Nurs
TI  - Perceived benefits: a predictor of participation in prostate cancer screening
VL  - 21
ID  - 726
ER  - 

TY  - JOUR
AB  - The study objective was to determine whether perceived racial discrimination influenced nonadherence to screening mammography guidelines. Enrolled in this prospective study were 1,451 women aged 40-79 years who obtained an "index" screening mammogram at one of five urban hospitals in Connecticut between October 1996 and January 1998. This logistic regression analysis included 1,229 women (484 African American (39%), 745 White (61%)) who completed telephone interviews at baseline and follow-up (on average 29 months later). Perceived racial discrimination was measured as lifetime experience in seven possible situations. Approximately 42% of African-American women and 10% of White women reported lifetime racial discrimination. Perceived racial discrimination was not associated with nonadherence to age-specific mammography screening guidelines in unadjusted or multivariate-adjusted analyses. Although these negative findings may reflect the well-recognized problems associated with measurement of perceived discrimination, it is possible that women who recognize and report racial discrimination develop compensatory characteristics that enable positive health prevention behavior, in spite of their past experiences. Copyright © 2007 by the Johns Hopkins Bloomberg School of Public Health All rights reserved.
AD  - Department of Epidemiology and Public Health, Yale University School of Medicine, New Haven, CT, United States
Department of Epidemiology and Biostatistics, University of Florida College of Public Health and Health Professions, Gainesville, FL, United States
Department of Epidemiology and Biostatistics, University of Florida School of Public Health and Health Professions, P.O. Box 100231, Gainesville, FL 32610, United States
AU  - Dailey, A. B.
AU  - Kasl, S. V.
AU  - Holford, T. R.
AU  - Jones, B. A.
DB  - Scopus
DO  - 10.1093/aje/kwm004
IS  - 11
KW  - African Americans
Breast neoplasms
Discrimination (psychology)
Ethnic groups
Mammography
Prejudice
Risk factors
M3  - Article
N1  - Cited By :31
Export Date: 22 March 2021
PY  - 2007
SP  - 1287-1295
ST  - Perceived racial discrimination and nonadherence to screening mammography guidelines: Results from the race differences in the screening mammography process study
T2  - American Journal of Epidemiology
TI  - Perceived racial discrimination and nonadherence to screening mammography guidelines: Results from the race differences in the screening mammography process study
UR  - https://www.scopus.com/inward/record.uri?eid=2-s2.0-34447267207&doi=10.1093%2faje%2fkwm004&partnerID=40&md5=1a61e26635887a7683974b1931a9b647
VL  - 165
ID  - 2560
ER  - 

TY  - JOUR
AB  - OBJECTIVES: In predominately white populations, measurement of the percentage of free prostate-specific antigen (%fPSA) has been shown to enhance the specificity of total PSA testing for prostate cancer while maintaining high sensitivity and to aid in prostate cancer staging. This study evaluated whether the %fPSA cutoff that maintained a 95% sensitivity in a white population yielded the same sensitivity and specificity in a black population and whether %fPSA was useful in predicting postoperative pathologic features in blacks. METHODS: We evaluated 647 white and 79 black men, prospectively enrolled at prostate cancer screening and surgical referral centers. Subjects were 50 to 75 years old with digital rectal examination findings that were not suspicious for prostate cancer and total PSA values between 4.0 and 10.0 ng/mL. All had undergone needle biopsy of the prostate. Hybritech's Tandem total and free PSA assays were used. RESULTS: Ninety-five percent sensitivity was attained with a %fPSA cutoff of 25% in both races. Use of this cutoff could have avoided unnecessary biopsies in 20% of white and 17% of black subjects (P = 0.69). In receiver operating characteristic (ROC) curve analysis, the area under the curve (AUC) for %fPSA was significantly higher than for total PSA in both blacks (0.76 versus 0.56, P <0.01) and whites (0.70 versus 0.54, P <0.001). In both races, higher %fPSA values indicated a lower risk of cancer and also predicted favorable pathologic features in radical prostatectomy specimens. CONCLUSIONS: A 25% fPSA cutoff detected 95% of cancers and reduced unnecessary biopsies in both races. Higher %fPSA values were associated with favorable postoperative histopathologic findings in both races.
AD  - Division of Urologic Surgery, Department of Surgery, Washington University School of Medicine, St. Louis, Missouri 63110, USA.
AN  - 10699613
AU  - Catalona, W. J.
AU  - Partin, A. W.
AU  - Slawin, K. M.
AU  - Naughton, C. K.
AU  - Brawer, M. K.
AU  - Flanigan, R. C.
AU  - Richie, J. P.
AU  - Patel, A.
AU  - Walsh, P. C.
AU  - Scardino, P. T.
AU  - Lange, P. H.
AU  - deKernion, J. B.
AU  - Southwick, P. C.
AU  - Loveland, K. G.
AU  - Parson, R. E.
AU  - Gasior, G. H.
DA  - Mar
DO  - 10.1016/s0090-4295(99)00547-6
DP  - NLM
ET  - 2000/03/04
IS  - 3
KW  - *African Continental Ancestry Group
Aged
Area Under Curve
Biopsy
*European Continental Ancestry Group
Humans
Male
Middle Aged
Neoplasm Staging
Prospective Studies
Prostate/pathology
Prostate-Specific Antigen/*blood
Prostatectomy
Prostatic Neoplasms/*diagnosis/ethnology/pathology/surgery
ROC Curve
Retrospective Studies
Sensitivity and Specificity
LA  - eng
N1  - 1527-9995
Catalona, W J
Partin, A W
Slawin, K M
Naughton, C K
Brawer, M K
Flanigan, R C
Richie, J P
Patel, A
Walsh, P C
Scardino, P T
Lange, P H
deKernion, J B
Southwick, P C
Loveland, K G
Parson, R E
Gasior, G H
Clinical Trial
Comparative Study
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
United States
Urology. 2000 Mar;55(3):372-6. doi: 10.1016/s0090-4295(99)00547-6.
PY  - 2000
SN  - 0090-4295
SP  - 372-6
ST  - Percentage of free PSA in black versus white men for detection and staging of prostate cancer: a prospective multicenter clinical trial
T2  - Urology
TI  - Percentage of free PSA in black versus white men for detection and staging of prostate cancer: a prospective multicenter clinical trial
VL  - 55
ID  - 705
ER  - 

TY  - JOUR
AB  - Objective: The problem of cancer health disparities is substantial. Clinical trials are widely advocated as a means of reducing disparities and bringing state-of-the-art care to the broader community, where most cancer care is delivered. This study sought to develop a better understanding of why disproportionately few African American men enroll in clinical trials given their substantial cancer burden. Design: This study applied community-based participatory research (CBPR) methods to design and conduct four focus groups of African American male cancer survivors and their caregivers in North Carolina. Results: Among major themes, participants expressed confusion about the relationship between clinical trials, treatment, and research; signifying patient confusion and misinterpretation of common clinical trial terminology. Social norms including gender barriers and generational differences remain problematic; participants often reported that men do not talk about health issues, are unwilling to go to the doctor, and exhibit misapprehension and distrust regarding trials. Participants perceived this misunderstanding as detrimental to community health and expressed the need for more clarity in clinical trials information and a more fundamental social openness and communication about cancer detection and treatment. Conclusion: Findings indicate the importance of clinical trial education in both traditional provider referral to trials and also in general patient navigation. To dispel pervasive misapprehension regarding placebos, clinical trial information should emphasize the role of standard care in modern cancer treatment trials. Many participants described willingness to participate in a trial upon physician recommendation, suggesting merit in improving patient-physician communication through culturally competent terminology and trial referral systems.
AN  - WOS:000351259300006
AU  - Trantham, L. C.
AU  - Carpenter, W. R.
AU  - DiMartino, L. D.
AU  - White, B.
AU  - Green, M.
AU  - Teal, R.
AU  - Corbie-Smith, G.
AU  - Godley, P. A.
DA  - Feb
DO  - 10.1016/S0027-9684(15)30007-9
IS  - 1
N1  - 26113749
PY  - 2015
SN  - 0027-9684
SP  - 33-41
ST  - Perceptions of Cancer Clinical Research Among African American Men in North Carolina
T2  - Journal of the National Medical Association
TI  - Perceptions of Cancer Clinical Research Among African American Men in North Carolina
VL  - 107
ID  - 2987
ER  - 

TY  - JOUR
AB  - Hypothesis/aims of study Incontinence can be extremely burdensome and is common after prostate cancer surgery. Although incontinence improves or resolves over the first several months following prostatectomy, even transient incontinence can deter the return to employment and resumption of beneficial activity, since activity worsens stress incontinence. Also, studies show that a significant number of men have long‐term post‐prostatectomy incontinence sufficient to warrant wearing a pad [1]. At least six adequately powered, randomized controlled trials have shown that perioperative outpatient pelvic floor muscle training can hasten postoperative recovery of bladder control and reduce the severity of incontinence following radical prostatectomy [2,3]. However, most men undergoing prostatectomy do not receive this training. One reason is a lack of providers trained in male pelvic floor muscle rehabilitation. Also, men may have difficulty getting time off from work or not want to travel long distances to attend this training if it is available. To provide more men with perioperative pelvic floor rehabilitation, we developed a home telehealth program, based on an evidence‐based in‐clinic protocol that reduced post‐prostatectomy incontinence. The program was then pilot tested to demonstrate feasibility and patient acceptance. The aims of the innovative study were to convert a successful, clinic‐based, perioperative rehabilitation program, including pelvic floor muscle training, progressive exercises, and bladder control techniques, to a home telehealth format and to do feasibility and pilot testing. The hypothesis was that men would use the program and find it beneficial. Study design, materials and methods This innovative study used a panel of experts including a urologist, geriatricians, and health educators with input from patients to develop a story‐based series of lessons to assist the patients to master the evidence‐based content which is shown in the Table. (Table presented) Each daily session is 5‐10 minutes in length, written on a 6th grade reading level, and accessed on a telehealth device. There were 2‐4 weeks of daily sessions pre‐operatively depending on how close to surgery the patient was enrolled. There were 60 sessions post‐operatively, started as soon as their urinary catheter was removed. Adherence was monitored remotely via the telehealth device and patients were telephoned if they missed more than 3 daily sessions in a row. Inclusion criteria: 1) men with prostate cancer scheduled to undergo a radical prostatectomy and 2) ability to read English (later versions in other languages are planned). Exclusion Criterion: self‐reported incontinence prior to prostatectomy. Evaluation of the home telehealth program was done with mixed quantitative and qualitative methods. The primary outcome was feasibility defined a priori as enrollment of at least 75% of men undergoing radical prostatectomy who met the inclusion criteria and then at least 75% of those men enrolled completing 90% or more telehealth sessions. Qualitative evaluation of the program included a semi‐structured telephone interview after completion of the program. Interviews were taped for determination of themes by 2 coder analysts. Results Of 31 men scheduled to undergo radical prostatectomy and meeting inclusion/exclusion criteria, 30 (97%) were enrolled. Age ranged 53‐70 years with a mean age of 62 years; 58% African American, 42% CaucAsian. Of the 30 enrollees, 4 did not have surgery due to change in treatment plan to radiation therapy, leaving 26 who were eligible and participated in the home telehealth program. Of the 26 participants, only 1 declined to continue doing the sessions and dropped out of the study; 1 died of postoperative complications. Thus, 92% of participants completed the program. Three of the men needed telephone reminders to start using the device. All 24 completers did 100% of the sessions. The qualitative data were very informative with themes of ease of use, usefulness of knowledge provided, elpfulness of the story format, and appreciation of the home setting for acquiring the information. Quotes highlighting the themes follow. Asked “What did you think about the information you received in the telehealth program?”‐“Once I started [the program] I couldn't believe that all the questions I should have asked the doctor were right there in the program and with answers. I didn't know what to ask so I just made the doctor think I had enough information. He [the urologist] asked me several times if I had any questions, but really, I would never have thought of those questions.” “Doing the program made it a lot easier and quicker to get back to normal.” Asked about the exercises: “At first, it was quite difficult, because I didn't realize or understand what they meant by it. But once I kept doing and doing it, and I figured out how to really do it, it was a piece of cake.” Asked about the stories: “They make you want to use the machine more. It made you look forward to using it.” “I learned about different people having prostate cancer and they survived it and they are doing well.” Asked about the overall program: “I liked the how the program was set up, the way they told me to do it. Nobody disturbs you, nobody watches you, it is private.” Interpretation of results This evidence‐based, home telehealth program including pelvic floor muscle training, progressive exercises, and bladder control techniques, met our benchmarks for feasibility during this pilot study: 97% of men scheduled for radical prostatectomy enrolled and 92% completed the program. Qualitative findings supported benefits of the program before and after prostatectomy. Concluding message Home telehealth is a feasible venue to teach pelvic floor muscle exercises and behavioral strategies to control urine leakage to men undergoing radical prostatectomy. A randomized, controlled trial of this home telehealth program is in progress.
AN  - CN-01409521
AU  - Goode, P.
AU  - Markland, A.
AU  - Barnacastle, S.
AU  - Wright, M. K.
AU  - Redden, D.
AU  - Echt, K.
AU  - Colli, J.
AU  - Burgio, K.
KW  - *prostatectomy
*stress incontinence
*telehealth
Adult
African American
Cancer surgery
Caucasian
Clinical article
Controlled clinical trial
Controlled study
Cooperation
Doctor patient relation
Employment
Evidence based practice center
Feasibility study
Geriatrician
Health educator
Human
Language
Machine
Male
Middle aged
Normal human
Outpatient
Pelvic floor muscle training
Pilot study
Postoperative complication
Prostate cancer
Qualitative analysis
Radiotherapy
Randomized controlled trial
Rehabilitation
Remission
Structured interview
Study design
Surgery
Telephone
Thinking
Travel
Urinary catheter
Urologist
M3  - Journal: Conference Abstract
PY  - 2017
SP  - S167‐S168
ST  - Perioperative home telehealth program for post-prostatectomy incontinence
T2  - Neurourology and urodynamics
TI  - Perioperative home telehealth program for post-prostatectomy incontinence
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01409521/full
VL  - 36
ID  - 1572
ER  - 

TY  - JOUR
AB  - Background: WISDOM is a 100,000 healthy women preference‐tolerant, pragmatic study comparing annual to personalized risk‐based breast screening. The novelty of WISDOM personalized screening is the integration of previously validated genetic and clinical risk factors (age, family history, breast biopsy results, ethnicity, mammographic density) into a single risk assessment model that directs the starting age, timing, and frequency of screening. The goal of WISDOM is to determine if personalized screening, compared to annual screening, is as safe, less morbid, enables prevention, and is preferred by women. The study is registered on ClinicalTrials.gov, NCT02620852. Methods: Women aged 40‐74 years with no history of breast cancer or DCIS, and no previous double mastectomy can join the study online at wisdomstudy.org. Participants can elect randomization or self‐select a study arm, and provide electronic consent and Release for Medical Information using DocuSign. For all participants, 5‐year risk of developing breast cancer is calculated according to the Breast Cancer Screening Consortium (BCSC) model. Participants in the personalized arm undergo panel‐based mutation testing, and their 5‐year risk is calculated using the BCSC score combined with a Polygenic Risk Score (BCSC‐PRS) that includes 75 single nucleotide polymorphisms (SNPs, increase to 229) known to increase breast cancer risk. SNPs and mutations (BRCA1, BRCA2, TP53, PTEN, STK11, CDH1, ATM, PALB2, and CHEK2) are assessed by saliva‐based testing through Color Genomics. 5‐year risk level thresholds are used to stratify for low‐, moderate‐and high risk. Risk stratification determines age to start, stop, and frequency of screening. Enrollment: As of July 2018, the WISDOM study is open to all eligible women in California, North Dakota, South Dakota, Minnesota and Iowa. To date, 23,329 eligible women have registered and 14,393 women have consented to participate in the trial. We analyzed 3,255 participants who have completed risk assessment in the personalized arm. The median age was 56 years. 82% were Caucasian, 1% African‐American, and 6% Asian. 9% self‐reported as Hispanic. We are partnering with health insurers and self‐insured companies using coverage with evidence progression. To strengthen generalizability, we are expanding to other states. WISDOM enrollment will continue past 2019. Feasibility: To evaluate the addition of PRS, we used paired statistical tests (McNemar) to compare the distributions of BCSC, and BCSC‐PRS risk estimates around low‐risk (<1.3%), and very‐high risk (>6%) thresholds, the latter corresponding to 5‐year risk of a BRCA mutation carrier. The median 5‐year risk was 1.5% (IQR 1.0‐2.1%) using the BCSC model, and 1.4% (IQR 0.8‐2.5%) using the BCSC‐PRS model. The BCSC‐PRS model classified more women into the low (<1%) and very high (≥6%) risk categories compared to the BCSC model (p < 0.001). Conclusions: Our findings demonstrate that incorporating genetic variants into a validated clinical model is feasible and impacts risk classification compared to a model without genetic risk factors. Results at 5 years will reveal if this classification improves healthcare value by reducing screen volumes and costs without jeopardizing outcomes.
AN  - CN-01936382
AU  - Acerbi, I.
AU  - Shieh, Y.
AU  - Madlensky, L.
AU  - Tice, J.
AU  - Ziv, E.
AU  - Eklund, M.
AU  - Blanco, A.
AU  - DeRosa, D.
AU  - Tong, B.
AU  - Goodman, D.
AU  - et al.
DO  - 10.1158/15387445.SABCS18-OT2-08-01
IS  - 4
KW  - *cancer screening
*intraductal carcinoma
Adult
African American
Age
Aged
Breast biopsy
Breast density
California
Cancer risk
Cancer surgery
Caucasian
Conference abstract
Controlled study
Ethnicity
Family history
Feasibility study
Female
Gene mutation
Genetic association
Genetic risk
Genetic susceptibility
Genetic variability
Genomics
Hispanic
Human
Iowa
Major clinical study
Mastectomy
Medical information
Middle aged
Minnesota
North Dakota
Randomization
Randomized controlled trial
Risk assessment
Risk factor
Saliva
Single nucleotide polymorphism
South Dakota
Stratification
Surgery
M3  - Journal: Conference Abstract
PY  - 2019
ST  - Personalized breast cancer screening in a population based study: women Informed to Screen Depending on Measures of risk (WISDOM)
T2  - Cancer research
TI  - Personalized breast cancer screening in a population based study: women Informed to Screen Depending on Measures of risk (WISDOM)
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01936382/full
VL  - 79
ID  - 1504
ER  - 

TY  - JOUR
AB  - BACKGROUND: This article discusses the sometimes unique presentation and course of breast cancer in African-American women and the impact these differences have on the perception of breast disease among African-American women. METHODS: The project described represents the thoughts of many African-American breast cancer survivors, as summarized by three breast cancer survivor-advocates who work through very different national organizations, each of whom has vast experience working directly with African-American breast cancer survivors and their families. RESULTS: In addition to discussions of compelling considerations that have an impact on survivor access, such as agency, culture, and class, other important access questions are raised for research scientists and clinicians that have an impact on the prevention, screening, and detection and treatment of breast cancer in African-American women as well as their accrual to clinical trials. CONCLUSIONS: To eradicate ethnicity-related disparities in breast cancer outcomes for African-American women, it is important for the medical community (clinicians and research scientists) to develop active partnerships with African-American and other breast cancer survivor-advocates in order to establish effective breast health awareness and breast cancer treatment programs and to develop meaningful breast cancer research programs.
AD  - Breast Cancer Liaison, National Black Women's Health Project, Mailman School of Public Health, Columbia University, 722 West 168 Street, Suite 1030, New York City, NY 10032, USA. nl227@columbia.edu
AN  - 12491496
AU  - Lythcott, N.
AU  - Green, B. L.
AU  - Kramer Brown, Z.
DA  - Jan 1
DO  - 10.1002/cncr.11013
DP  - NLM
ET  - 2002/12/20
IS  - 1 Suppl
KW  - *African Americans
Breast Neoplasms/diagnosis/*ethnology/*psychology/therapy
Clinical Trials as Topic
Female
*Health Care Coalitions
Health Knowledge, Attitudes, Practice
Health Services Accessibility
Humans
Minority Groups
*Patient Advocacy
Research
Social Support
Survivors/*psychology
Women's Health
LA  - eng
N1  - Lythcott, Ngina
Green, Bettye L
Kramer Brown, Zora
Journal Article
United States
Cancer. 2003 Jan 1;97(1 Suppl):324-8. doi: 10.1002/cncr.11013.
PY  - 2003
SN  - 0008-543X (Print)
0008-543x
SP  - 324-8
ST  - The perspective of African-American breast cancer survivor-advocates
T2  - Cancer
TI  - The perspective of African-American breast cancer survivor-advocates
VL  - 97
ID  - 658
ER  - 

TY  - JOUR
AB  - Community-academic partnerships play a vital role in ensuring the engagement of African American (AA) men in research. Project Brotherhood (PB) is a community organization that has played an integral role in advancing prostate cancer (PCa) research within two pilot projects supported by the Chicago Cancer Health Equity Collaborative (ChicagoCHEC).Community Perspective: It is rare to see community organizations led by AA men acknowledged for their role in advancing health equity research. We provide a community perspective of PB as a model in engaging AA men in research. PB has been recognized nationally by the Centers for Disease Control and Prevention (CDC) and others demonstrating their national footprint in advancing the inclusion of AA men in all aspects of research. We hope to demonstrate that engagement of AA men in research is important and feasible and to highlight PB as a national model in engaging AA men in research.
AN  - 31378744
AU  - Murray, M.
AU  - Campbell, C.
AU  - Kendall, L.
AU  - Whitt-Glover, M. C.
AU  - Watson, K. S.
C2  - PMC6954669
C6  - NIHMS1063238
DO  - 10.1353/cpr.2019.0047
DP  - NLM
ET  - 2019/08/06
IS  - 5
KW  - *African Americans
Chicago
Community Participation
Community-Based Participatory Research/*organization & administration
Community-Institutional Relations
Humans
Male
*Patient Selection
Prostatic Neoplasms/*ethnology
United States
LA  - eng
N1  - 1557-055x
Murray, Marcus
Campbell, Christian
Kendall, LeChaun
Whitt-Glover, Melicia C
Watson, Karriem S
P30 DK092950/DK/NIDDK NIH HHS/United States
U54 CA202995/CA/NCI NIH HHS/United States
U54 CA202997/CA/NCI NIH HHS/United States
U54 CA203000/CA/NCI NIH HHS/United States
Journal Article
Prog Community Health Partnersh. 2019;13(5):137-142. doi: 10.1353/cpr.2019.0047.
PY  - 2019
SN  - 1557-0541 (Print)
1557-0541
SP  - 137-142
ST  - Perspectives from Project Brotherhood: Facilitating Engagement of African American Men in Research
T2  - Prog Community Health Partnersh
TI  - Perspectives from Project Brotherhood: Facilitating Engagement of African American Men in Research
VL  - 13
ID  - 68
ER  - 

TY  - JOUR
AB  - OBJECTIVES: To assess the novel approach of using the community pharmacist as the primary health care team member to facilitate colorectal cancer (CRC) risk counseling and screening in socioeconomically disadvantaged populations. SETTING: A collaborative effort between the UConn Health Colon Cancer Prevention Program and UConn School of Pharmacy in conjunction with large independent chain pharmacies (medium to medium-high volume) located in metropolitan areas of Connecticut, including Hartford, Bridgeport, New Haven, and Stamford. Pharmacies located in hospitals, across the street from a large physician practice, or within the community. PRACTICE DESCRIPTION: The study involved 2 phases. The first phase involved education and training for community pharmacists regarding counseling approaches for patients on the topic of CRC. The second phase of the study involved patient recruitment and counseling with subsequent fecal immunohistochemical testing (FIT). PRACTICE INNOVATION: A community pharmacist provided face-to-face counseling on CRC risk factor reduction and provided CRC screening to patients who were without insurance or underinsured. No CRC screening or education program existed beforehand. EVALUATION: A target sample size of 60 participants was needed with a type 1 error rate of 5% and a power of 80%. Exploration of variables using multivariate logistic regression model included any variable with a univariate P < 0.2. Multivariate P values < 0.05 were considered independent predictors. RESULTS: After approaching 312 consumers, 16 of them consented to the study. The majority of participants (88%) were African American or Latino, and 69% were currently unemployed. Eight participants agreed to complete FIT, and 88% of participants completed FIT correctly. Only 1 positive FIT result was observed, but a subsequent colonoscopy was negative. Of the 12 questions that assessed baseline CRC knowledge in the initial survey, 16 participants answered an average of 2.6 (range, 0-6, SD, 1.6) questions incorrectly. Only 4 participants completed the follow-up survey of CRC knowledge and program satisfaction; thus, exploration of variables was not conducted. Patients indicated high satisfaction with the program of education and FIT dispensing. CONCLUSION: This study faced difficulty in recruiting pharmacists to participate, with the main reason being lack of compensation and disruption to workflow. Patient participation in the trial was also low because of a lack of time or interest in participation. Of the patients who did participate, the level of satisfaction in having the pharmacist speak to them about CRC screening was high. This service is an excellent example of how the pharmacist can provide a more accessible, convenient, and responsive approach to patients' needs while improving health equity. Future studies that employ a revenue model to build the infrastructure and capacity necessary to offer this service efficiently and consistently are needed.
AN  - 32197754
AU  - Holle, L. M.
AU  - Levine, J.
AU  - Buckley, T.
AU  - White, C. M.
AU  - White, C.
AU  - Hadfield, M. J.
DA  - Jul-Aug
DO  - 10.1016/j.japh.2020.02.014
DP  - NLM
ET  - 2020/03/22
IS  - 4
LA  - eng
N1  - 1544-3450
Holle, Lisa M
Levine, Joel
Buckley, Thomas
White, C Michael
White, Cedric
Hadfield, Matthew J
Journal Article
Research Support, Non-U.S. Gov't
United States
J Am Pharm Assoc (2003). 2020 Jul-Aug;60(4):e109-e116. doi: 10.1016/j.japh.2020.02.014. Epub 2020 Mar 18.
PY  - 2020
SN  - 1086-5802
SP  - e109-e116
ST  - Pharmacist intervention in colorectal cancer screening initiative
T2  - J Am Pharm Assoc (2003)
TI  - Pharmacist intervention in colorectal cancer screening initiative
VL  - 60
ID  - 46
ER  - 

TY  - JOUR
AB  - Background and rationale Many comments have been issued about similarities and differences between 2003 American and European guidelines for the management of arterial hypertension (1,2), especially after the publication of the Antihypertensive and Lipid‐Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) study (3‐5). Both guidelines agree that the majority of hypertensive patients require more than one medication to achieve optimal blood pressure control and, consistent with the most recent findings, the need of expensive, large clinical trials to demonstrate the superiority of one medication on another is probably over (3,6). What is clear now is that blood pressure must be optimally controlled to reduce risk of cardiovascular mortality and morbidity in population, no matter which combination of medications is used. Comparison between single medications is substantially academic and conceals the reality: in all trials, in most circumstances comparison is between combinations, more than single medications. In the Losartan Intervention for Endpoint Reduction Study (LIFE study) (6), for instance, there has been a comparison between the combination of losartan with low dose hydrochlorothiazide versus the combination of atenolol with the same diuretic. The difference between the seventh Joint National Committee (USA) on Prevention, Diagnosis and Management of Hypertension (JNC VII) and European Society of Cardiology (ESC) and European Society of Hypertension (ESH) 2003 guidelines, often presented as substantial, is in the priority that Americans still give to the diuretic therapy, consistent with the most waited results of the ALLHAT (3). The ALLHAT was a randomized, double‐blind, multicenter clinical institutional trial, entirely sponsored by the National Heart, Lung, and Blood Institute (NHLBI) (3), and designed to determine whether occurrence of fatal or nonfatal coronary heart disease is lower for high risk hypertensive patients treated with amlodipine, lisinopril, doxazosin, or chlorthalidone. The protocol was also approved by an independent Review Committee external to the NHLBI (7). The ALLHAT recruited 9,000‐15,000 participants/intervention arm (total: 33,357), and the follow‐up was quite long (4‐8 years). The doxazosin arm was closed prematurely because of higher mortality (8). Despite a number of important limitations of this study (4,9), the overall impact of its findings remains very high. The baseline characteristics of the ALLHAT participants were substantially similar in the 3 arms completing the study. Chlortalidone was significantly more effective than both amlodipine and lisinopril in achieving optimal control of blood pressure at year 1 and year 2 and more effective than lisinopril in blood pressure control at year 3, 4 and 5 (all p<0.001). Consistent with the better control of blood pressure, chlortalidone tended to provide a 10% more protection for combined fatal and non fatal coronary heart disease than lisinopril whereas protection was similar for amlodipine, though this protection was less evident than the superiority in controlling blood pressure. In fact, the difference in risk profile versus the lisinopril arm achieved statistical significance only for elderly and African‐American participants. Another relevant finding from the ALLHAT concerns the incidence of congestive heart failure that was substantially less with chlortalidone than with either amlodipine or lisinopril. There are many recurrent criticisms to all trials showing the superiority of diuretics over other medications in controlling blood pressure. First of all, worsening of glucose metabolism, due to thiazide effects, is matter of concern (4,14‐18). Also the ALLHAT authors report a higher incidence of diabetes in the diuretic group which, however, did not affect the outcome results (3). However, this concern is also sustained by recent evidence of the dangerous effect of incident diabetes in patients with arterial hypertension (15). One factor that might aggravate glucose metabolism during therapy with di retics is the underestimated effect of hypokalemia, which interferes with glucose‐stimulated insulin release, a condition that might be aggravated by association with beta‐adrenergic block (19,20). Among other beneficial effects, including improvement in blood pressure control, correction of hypokalemia prevents or significantly reduces thiazide‐induced hyperglycemia (21‐24). It is possible that low‐dose potassium‐sparing diuretics by preventing hypokaleemia might also prevent metabolic effects of thiazide, at the same time enhancing the antihypertensive effects of thiazide (25), but, this hypothesis has never been tested in ad hoc trials. The second concern about the use of diuretics is the risk of low therapeutic compliance of hypertensive patients, due to the diuretic effect and other hypokalemia‐related side‐effects (26,27). These few reports, however, contrast with the evidence that quality of life is improved by long term therapy with diuretics (28‐30). The effort, therefore, should probably be direct toward persistence of initial treatment with diuretics, a goal that might be reached by improving the procedures of follow‐up, for instance, as we have recently proposed, by implementing internet‐based digital networks, connecting hypertension specialists with general practitioners (31). The Campania Salute (CS)network is a system that was set up in 1995 by us (31). It is an italian regional network system aimed at improving the management of essential hypertension by integrating the activity of general practitioners (GPs) with hypertension specialists. This network includes about 12.000 hypertensive patients followed by 23 outpatient hypertensive clinics allocated in different Community Hospitals in the Campania Region and 60 GPs, homogeneously allocated in the regional area, referring to the Hypertension Clinic of Federico II University Hospital in Naples (coordinating centre). GPs were randomly selected among a pool of physicians referring their patients to the Hypertension Clinic at Federico II University. Through the CS system clinical data detected at each visit can be shared between the coordinating center and the peripheral units.Low‐risk hypertensive patients continue their follow up in the peripheral units, whereas high‐risk hypertensive patients are more closely followed up by the coordinating centre, which also evaluates target organ damage and associated diseases. Patients' information is shared through on‐line access to the remote database, integrated by smartcards. The smartcard belongs to patients and contains his/her personal identification number (PIN). This PIN allows users to access the file of the patient stored in the database. Each physician has also his own PIN to access into the database, limited to his/her own patient files. Clinical data are upgraded at each visit by GPs and physicians of both peripheral centres and coordinator centre. Access to the remote database allows users to read all clinical and laboratory data, as well as tracking electrocardiography (ECG) and cardiac and vascular ultrasound images. In addition, the smartcard also works as portable database in which identification and clinical data are reported. By virtue of a central database, data of individual patients can be stored, updated and retrieved directly on‐line by participants in the project. The restricted access to individual data requires the pre‐assigned identification code of both the patient and the relevant remote units. The central database uses Wincare software (TSD Projects, Milan, Italy) which contains separate sheets for medical history, physical examination, biochemistry electrocardiography, cardiovascular ultrasound, other imaging tests and ambulatory blood pressure monitoring. The last update of an individual patient's record can also be downloaded and stored in the patient's personal smartcard. We started the CS project with the aim of obtaining a stronger interaction between GPs and hypertension clinics, by providing a direct link and accessible patients' records. Blood p essure control was improved with our referral system, since better overall results were obtained if the patient was followed within the network. Indeed, at the end of the observation period, 51% of patients in the CS group had a blood pressure below 140/90 mmHg, a percentage comparable to that of patients included in clinical trials. This follow‐up strategy also allowed an active pharmacovigilance procedure, with side effects promptly reported to the GPs, which prevented the occurrence of difference in compliance among the various antihypertensive treatments. In addition, this kind of follow‐up allowed by means of pharmacogenetic studies to demonstrate that the occurrence of side effects may be predicted from individual genotype (32). Indeed, we have recently reported that in patients bearing β2AR gene Glu27 variant or the β3AR gene Arg64 variant there was a larger occurrence of hypertriglyceridemia, alone or in combination with elevated cholesterol levels. Furthermore, the β2AR Glu27variant significantly associates with hypetriglyceridemia in a cumulative fashion. The risk of developing this side effect after β‐blockade was four‐fold higher in patients homozygous for the β2AR Glu27 variant than in β2AR27Gln allele. This result not only allowed the identification of patients at high risk to develop metabolic complications to chronic β‐blockade treatment, but also contributed to elucidate the pathophysiological mechanisms which mediate these side effects, raising the possibility to prevent them. Objectives of the study This study has been designed to assess whether a follow‐up strategy based on a strict cooperation between GPs and hypertension specialists allows the use of diuretics as first‐line antihypertensive treatment with a persistence on assigned therapy equivalent to that achieved by using any other first line antihypertensive therapy. Assessment of safety and efficacy for controlling cardiovascular risk will be also performed as secondary endpoint. In fact, in contrast with trials comparing single‐drug effects, this study compares two strategies of antihypertensive management, based on either real‐word prescriptions or a regimen in which thiazide diuretics represent a forced first line antihypertensive therapy. If our hypothesis will be demonstrated diuretics might be suggested as an efficient and economic first line antihypertensive treatment, on which build up optimal antihypertensive therapy by adding other class drugs, in all patients, provided that the follow‐up procedure is based on the proposed organization. This approach will be of great utility for the National Health Care System to reduce costs, since, a large part of the economic burden is related to the use of antihypertensive medications more expensive than thiazides, as first line agents, in particular so far only 40% of the hypertensive patients receive diuretics in their therapy. Finally, the pharmacogenetic study is focused on characterization of polymorphisms of candidate genes associated to development of metabolic side effects of diuretics, to help understanding of mechanisms underlying these adverse events. This kind of information will help to prevent the occurrence of adverse events by the use of adeguate combination treatment, thus resulting in the further reduction of the cost of antihypertensive treatment due to the reduction of the number of patients that discontinue therapy for occurrence of adverse events. Study design This is a multicenter, open label, randomized study to compare the effects of an antihypertensive strategy using a thiazide diuretic as first‐line, versus the use as initial therapy of other antihypertensive treatments. All the analyses will be performed by personel blinded to treatment. The study will be performed in collaboration with the Società Italiana Medicina Generale (SIMG), Sezione Campania, and the Società Italiana Ipertensione Arteriosa (SIIA), Sezione Campania. Study population. The recruitment phase will last 8 months. During this period 2600 patients will be enrolled, in the ffices of 260 GPs' with documented previous experience in controlled studies, performed according to recommendations of Good Clinical Practice, and availability to access to Internet. Selected GPs will be trained to the use of the web‐based database on which they will store the required information of patients participating into the study. This training period will last a week and will be supervised by the coordinator's center. Exemplificative print outs of the web‐based CRF are available for evaluation on the web site www.campaniasalute.it. GPs are required: 1) to record a full medical history, including smoking and drinking habits, based on a pre‐defined clinical record; 2) to collect demographic and anthropometric measures (height, weight, waist circumference at the iliac crest); 3) to perform a complete physical exam. At baseline and at each visit thereafter, seated office blood pressure will be measured in triplicate using a manual sphygmomanometer according to international guidelines. Measurements will be rounded to the closest 2 mmHg interval. Inclusion criteria: Hypertensive patients will be 18 to 75‐year old. Eligible patients are required to have stage Ic or II essential hypertension, and to be previously untreated or poorly controlled. They will be selected by GPs participating into the study. Similar to untreated patients, those with poor control of blood pressure under multiple‐drug therapy will start treatment with one single drug, which will be titrated to the highest dose before adding subsequent medications, based on the GP's judgement. Hypertension will be defined according to 2003 ESH/ESC guidelines (1). Blood and urine tests will be performed, according to guidelines for Hypertension Management For General Practitioners (GP) of the Regione Campania (see Bollettino Ufficiale Regione Campania, number 11, 18/02/2002, allegato A). This screening includes cell blood counts (CBCs), serum creatinine, sodium, potassium, uric acid, total cholesterol, triglycerides, HDL‐cholesterol, glucose, urine analysis and EKG. LDL will be calculated starting from the total cholesterol, triglyceride and HDL‐cholesterol. Exclusion criteria. Women in fertile age not using recognized contraceptive methods, or pregnant or nursing will be excluded from the protocol, since the use of many antihypertensive drugs is contraindicated in pregnancy and lactation. Patients will be excluded when presenting with documented coronary or cerebrovascular events in the previous 6 months, NYHA class higher than 1, history of congestive heart failure, secondary hypertension, cancer disease, renal disease (serum creatinine >2 mg/dl), liver cirrhosis or severe dysfunction, or any other health problem that may interfere with the projected 2 year follow‐up. Data will be stored in an electronic database located in the Coordinating Centre, to which GPs may have access for uploading data on a daily base, using personal, encrypted, login and password. Eligible patients will be asked for written informed consent and thereafter referred to the identified Hypertension Specialist Centre located in their areas, for end‐organ damage evaluation by echocardiography, carotid ultrasound and urine dip‐stick. These data will be stored in the central database. After local echocardiographic evaluation, patients showing left ventricular Ejection Fraction < 45% will be excluded from the study. Eligible patients will be asked for blood sampling for genomic DNA analysis and then randomised by the coordinating centre to either diuretics or other treatment. This latter will be decided by the GPs. Randomization will be organized in permuted blocks of 10 patients for each GP, half of which will be assigned to diuretics. The randomization code will be communicated to the referring GP by e‐mail. Blood samples for genetic analysis and signed informed consents will be sent to the coordinating centre for storage. Blood samples will be coded and anonymously processed for genetic analysis by the Department of Pharmacology of FEDERICO II University of Naples. he data resulting from this analysis will be stored in the patient CRF page. Intervention: Drugs will be administered orally. GPs should use chlortalidone (12.5‐25 mg daily) in the arm with compulsive thiazide diuretic as first line. In the alternative arm, GPs may choose any appropriate single‐drug (excluding thiazide diuretic) or combination therapy, as first‐line, at the tolerated dose. After randomization, patients will be evaluated monthly at the GPs' office, for therapy adjustment, to achieve blood pressure normalization (i.e Systolic Blood pressure >140 mmHg, and Diastolic Blood pressure >90 mmHg). In the thiazide arm, if blood pressure normalization is not achieved not even with the maximal dose, it will be possible to add any other classes of antihypertensive drugs. Once blood pressure normalization is achieved, GPs will monitor blood pressure once every 2 months, at the renewal of the drug prescription. Blood pressure values will be stored in the central database. At each visit, GPs will record drug therapy, including concomitant medications, evaluate the compliance to assigned antihypertensive regimen, and monitor and record adverse events by reporting all data in the CRF. After two years from randomization, patients will be checked for blood and urine tests and referred to the Hypertension Specialist Centre for echocardiography, carotid ultrasounds and urine dip‐stick. This data will be stored in the central database. Information retrieval: At each visit, the GPs will record drug therapy, including concomitant medications, will evaluate the compliance to the assigned antihypertensive medications by pill count, and will monitor and record adverse events by reporting all data in the CRF. Pre clinical cardiovascular disease will be assessed by echocardiography and carotid ultrasonography. All ultrasound exams will be sent to the Reading Center at Federico II University Hospital and will be processed, according to procedures described in the annex. Monitoring of the study: All data will be reported on a specifically designed electronic clinical research form (CRF) (see web site: www.campaniasalute.com), and will be transferred to the Coordinating Center for data storage and analysis. The Steering Committee will appoint a Data Coordinating Committee to evaluate all CRFs on a continuous way to ensure quality and objectivity of the analysis performed by trained professionals. In order to monitor for patient security, GPs will be asked to actively monitor periodically for adverse events, by asking patients at the time of drug prescription renewal for the occurrence of symptoms or signs that can be related to aggravation of their condition or adverse events of therapy. In selected cases, GPs can refer the patients to the Hypertension Specialist Centre for eventual instrumental and or blood and urinary analyses. Adverse events will be reported in the digital CRF. Sample size estimate: The main outcome to be tested is whether persitance on therapy of an antihypertensive regimen based on diuretics as first choice is equivalent to that obtained in a free regimen using any other antihypertensive medication as first choice (equivalence study). As secondary outcomes, reduction of left ventricle (LV) mass and carotid intima‐media thickness will be evaluated as markers of preclinical cardiovascular disease, under the hypothesis that improvement of end‐organ damage under diuretic‐based treatment will not be different from the treatment based on other antihypertensive medications (equivalence). The reduction of the ESH/ESC risk‐score will also be evaluated, under the same equivalence hypothesis. Sample size was primarily estimated for the primary outcome, but afterward tested on power also on secondary outcomes. See Annex for details Organizational characteristics: The study will be governed by a Steering Committee chaired by the Principal Investigator (Prof. Bruno Trimarco). The study will be performed as a collaborative effort of 260 general practitioners (with previous experience in scientific initiatives), sp cialist centers (Community Hospitals and University Hospitals in which specialized evaluation of hypertension related organ damage is routinely evaluated). The Department of Medicina Clinica, Scienze Cardiovascolari ed Immunologiche, division of Coronary Intensive Care Unit and High Blood Pressure Center will act as a Coordinating Center, run by Professor Trimarco, PI. The central database will be stored at this center, and the other specialist centers and GPs will have remote access to it through encrypted login and password. The web‐based access to the database has already been implemented at the Coordinating Center, within the Campania Salute Project, a regional network of Community Hospitals and GPs. Echocardiograms and carotid ultrasounds will be performed at the Federico II University Hospital or in peripheral centers, under a standardized protocol, which will be distributed in an electronic format (CD‐ROM). All studies will be directly transmitted through the Internet to the Reading Center. Feasibility: The Principal Investigator, Bruno Trimarco, has a long and extensive experience in running trials of antihypertensive treatment and management of hypertension (see CV). As Director of the Coordinating Institution he will personally assure full support of the institution facilities, and of professional help in monitoring and statistics. The Ultrasound Reading Center has wide experience in centralized reading of studies on LV hypertrophy and function as well as in studies on arterial structure and has been involved in a number of international multicenter trials (35,40). The Reading Center is provided of 4 work stations for echocardiographic reading and 2 for carotid ultrasound, with high level of security for preservation of data and privacy. All echocardiograms will be classified with a reception number which will join the recruitment number of the participant (every participants will have 2 identification numbers in addition to the number of identification document). Timing: The study will last 3 years. The first eigth months will be spent for recruitment and randomization. The follow‐up will last 2 years. Analysis of data will be performed ad interim, as soon as the last recruited patient completes the intermediate evaluation after one year of follow‐up. Final main analysis will be performed right after the conclusion of follow‐up of the last recruited patient. A number of analysis concerning secondary end‐points and including every ancillary study that might be proposed from the Steering Committee or the participating Hypertension Specialist Centres, will be implemented thereafter. Ethical aspects. We have tried to minimize possible therapy related side effects to those that are usually observed in the practical clinic. Indeed, all treatments and dosages are those that are usually adopted by general practitioner for the daily practice. Therefore, we do not expect any additional risk for patients that are enrolled in the study. The complications that are associated to thiazide treatment will be prevented by the use of maximal doses that are in the low range of therapeutic effect, and close to the regimen that currently used in daily practice. As for intromission in the private sphere of the patients, the data will be nominally entered in the database by the physician using a login/password protected web‐based 32bit encrypted connection, and available only for this research purposes after given informed consent by the patients.
AN  - CN-02017979
AU  - Nct
KW  - Diuretics
Hypertension
PY  - 2006
ST  - Pharmacosurveillance and Pharmacogenetics of First-line Diuretics in Hypertension: the StayOnDiur Study
T2  - https://clinicaltrials.gov/show/NCT00408512
TI  - Pharmacosurveillance and Pharmacogenetics of First-line Diuretics in Hypertension: the StayOnDiur Study
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02017979/full
ID  - 1664
ER  - 

TY  - JOUR
AB  - OBJECTIVES: Veliparib (V) potentiated therapeutic efficacy of cisplatin (C) and etoposide (E) in preclinical models of SCLC. We conducted this phase 1 study to establish the safety of the combination in human subjects. MATERIALS AND METHODS: The study employed the 3+3 dose escalation design to establish the safety and recommended phase 2 dose (RP2D) of V when combined with fixed doses of C (75 mg/m(2) on day 1) and E (100mg/m(2) on days 1-3) in a 21-day cycle. The starting dose of V was 60 mg (bid days 1-7) with plan to escalate to 100mg (days 1-7) or de-escalate to 40 mg (days 1-7) depending on the dose limiting toxicity (DLT) experience during cycle 1. Patients with treatment-naïve, extensive stage SCLC were included. RESULTS: The study enrolled 9 patients: M/F (4/5); median age (60); White/African American (8/1). V was tolerated at the 60 mg (DLT in 0 of 3 patients) and 100mg dose (DLT in 1 of 6 patients; grade 5 cardiac failure). Veliparib at 100mg in combination with standard doses of C and E was established as the RP2D. Grades 3-5 adverse events irrespective of attribution during cycle 1 included: dehydration (1), diarrhea (1), fatigue (1), febrile neutropenia (1), heart failure (1), leukopenia (6), lymphopenia (1), nausea (2), neutropenia (8), respiratory failure (1), and thrombocytopenia (2). Investigator-assessed efficacy outcome in 7 evaluable patients were stable disease in 2/7 (28.6%), partial response in 4/7 (57.1%), and complete response in 1/7 (14.3%) patients. CONCLUSIONS: This study demonstrated the safety of combining veliparib with cisplatin and etoposide in previously untreated SCLC patients.
AD  - The Winship Cancer Institute of Emory University, Atlanta, GA, United States. Electronic address: towonik@emory.edu.
Dana-Farber Cancer Institute, Boston, MA, United States.
University of Texas Southwestern Medical Center, Dallas, TX, United States.
Rutgers Cancer Institute of New Jersey and Robert Wood Johnson Medical School, Rutgers, The State University of New Jersey, New Brunswick, NJ 08903-2681, United States.
Penn State Hershey Cancer Institute, Hershey, PA, United States.
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, United States.
Abramson Cancer Center at the University of Pennsylvania, Philadelphia, PA, United States.
The Winship Cancer Institute of Emory University, Atlanta, GA, United States.
AN  - 25985977
AU  - Owonikoko, T. K.
AU  - Dahlberg, S. E.
AU  - Khan, S. A.
AU  - Gerber, D. E.
AU  - Dowell, J.
AU  - Moss, R. A.
AU  - Belani, C. P.
AU  - Hann, C. L.
AU  - Aggarwal, C.
AU  - Ramalingam, S. S.
C2  - PMC4539011
C6  - NIHMS693760
DA  - Jul
DO  - 10.1016/j.lungcan.2015.04.015
DP  - NLM
ET  - 2015/05/20
IS  - 1
KW  - Aged
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage/*adverse
effects
Benzimidazoles/administration & dosage/adverse effects
Chemotherapy-Induced Febrile Neutropenia/etiology
Cisplatin/administration & dosage
Etoposide/administration & dosage
Fatigue/chemically induced
Female
Heart Failure/chemically induced
Humans
Lung Neoplasms/*drug therapy/pathology
Male
Middle Aged
Small Cell Lung Carcinoma/*drug therapy/pathology
Thrombocytopenia/chemically induced
Parp
Phase I
Small cell
Veliparib
LA  - eng
N1  - 1872-8332
Owonikoko, Taofeek K
Dahlberg, Suzanne E
Khan, Saad A
Gerber, David E
Dowell, Jonathan
Moss, Rebecca A
Belani, Chandra P
Hann, Christine L
Aggarwal, Charu
Ramalingam, Suresh S
K23 CA164015/CA/NCI NIH HHS/United States
U10 CA021115/CA/NCI NIH HHS/United States
CA180820/CA/NCI NIH HHS/United States
CA180802/CA/NCI NIH HHS/United States
CA180870/CA/NCI NIH HHS/United States
CA180794/CA/NCI NIH HHS/United States
U10 CA180820/CA/NCI NIH HHS/United States
U10 CA180794/CA/NCI NIH HHS/United States
U10 CA180870/CA/NCI NIH HHS/United States
CA180864/CA/NCI NIH HHS/United States
5K23CA164015/CA/NCI NIH HHS/United States
Clinical Trial, Phase I
Journal Article
Research Support, N.I.H., Extramural
Lung Cancer. 2015 Jul;89(1):66-70. doi: 10.1016/j.lungcan.2015.04.015. Epub 2015 May 8.
PY  - 2015
SN  - 0169-5002 (Print)
0169-5002
SP  - 66-70
ST  - A phase 1 safety study of veliparib combined with cisplatin and etoposide in extensive stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E2511)
T2  - Lung Cancer
TI  - A phase 1 safety study of veliparib combined with cisplatin and etoposide in extensive stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E2511)
VL  - 89
ID  - 241
ER  - 

TY  - JOUR
AB  - Background: Ixazomib citrate is an oral proteasome inhibitor under phase 3 investigation in patients (pts) with multiple myeloma (MM) and amyloidosis. Ixazomib citrate immediately hydrolyzes to the active moiety ixazomib in aqueous solutions or plasma. In ongoing clinical studies, ixazomib citrate is taken on an empty stomach. Aims: To characterize the effect of a high‐fat meal on the single‐dose pharmacokinetics (PK) of ixazomib. Methods: This is a phase 1, single‐dose, open‐label, randomized, multicenter, two‐period, two‐sequence, cross‐over study (NCT01454076). Pts were randomized to receive a single 4 mg dose of ixazomib citrate with or without a standard highfat breakfast on Day 1, followed by administration under the respective alternate food intake condition (fasted to fed, or fed to fasted) on Day 15 of Cycle 1. Serial blood samples were collected over 0‐216 hr after ixazomib citrate dosing on Days 1 and 15 for PK characterization. From Cycle 2, ixazomib citrate 4 mg was administered on an empty stomach on Days 1, 8, and 15 of a 28‐day cycle. Plasma PK parameters were estimated by non‐compartmental methods using Phoenix WinNonlin version 6.2. Effects of the high fat‐meal on ixazomib AUC0‐216 and Cmax were evaluated by analyses of variance on log‐transformed values. Safety and response data after multiple dosing were also collected. Results: 24 pts (19 Caucasian, 4 African American, 1 Hispanic; 13 M, 11 F; 22 solid tumor, 2 lymphoma) were enrolled. Mean age was 62 years (range 46‐85), mean weight 74 kg (range 43‐112), and mean body surface area 1.9 m2 (range 1.4‐2.4). Final data from 15 PK‐evaluable pts were used to assess the impact of food on ixazomib PK. Following a single dose of ixazomib citrate, median Tmax was 1 and 4 hr for fasted and fed treatment, respectively. Administration of ixazomib citrate with food resulted in an approximately 28% decrease in AUC and 69% decrease in Cmax (Table). Although relatively modest, the observed decrease in AUC is inferred to be of potential clinical significance as, when dosed at 4 mg with a high‐fat meal, ixazomib exposures would be expected to approximate those achieved at 3 mg (the first dose level reduction for pts experiencing drug‐related toxicity). As of January 2014, 19 (79%) pts experienced drug‐related adverse events (AEs) in Cycle 2 and beyond following multiple dosing with ixazomib citrate on a weekly schedule, including 6 drug‐related grade 3 AEs in 5 pts (anemia, n=2; dehydration, fatigue, peripheral edema, and vomiting, each n=1); no drug‐related grade 4 AEs were reported. Summary and Conclusion: Administration of ixazomib citrate 4 mg after a high‐fat meal resulted in a decrease in the rate and extent of oral absorption, with an approximately 30% reduction in total systemic exposure. These results support the continued administration of ixazomib citrate on an empty stomach (no food for 2 hr before and 1 hr post dose) in ongoing phase 3 studies in relapsed/refractory MM, newly diagnosed MM, and amyloidosis.
AN  - CN-01057870
AU  - Gupta, N.
AU  - Hanley, M. J.
AU  - Venkatakrishnan, K.
AU  - Wang, B.
AU  - Kinley, J.
AU  - Sharma, S.
AU  - Bessudo, A.
AU  - Shou, Y.
AU  - Nemunaitis, J.
KW  - *hematology
*human
*ixazomib citrate
*lipid diet
*lymphoma
*patient
*pharmacokinetics
*phase 1 clinical trial
*proteasome inhibitor
*solid tumor
Absorption
African American
Amyloidosis
Anemia
Aqueous solution
Blood sampling
Body surface
Caucasian
Clinical study
Crossover procedure
Dehydration
Exposure
Fatigue
Food
Food intake
Hispanic
Ixazomib
Maximum plasma concentration
Meal
Multiple myeloma
Parameters
Peripheral edema
Phase 3 clinical trial
Plasma
Safety
Single drug dose
Stomach
Toxicity
Vomiting
Weight
M3  - Journal: Conference Abstract
PY  - 2014
SP  - 376
ST  - A phase 1 study of the effect of a high-fat meal on the pharmacokinetics of ixazomib citrate (MLN9708), an investigational oral proteasome inhibitor, in patients with advanced solid tumors or lymphoma
T2  - Haematologica
TI  - A phase 1 study of the effect of a high-fat meal on the pharmacokinetics of ixazomib citrate (MLN9708), an investigational oral proteasome inhibitor, in patients with advanced solid tumors or lymphoma
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01057870/full
VL  - 99
ID  - 1486
ER  - 

TY  - JOUR
AB  - Background: Treatment with once‐daily E/C/F/TAF in HIV‐1‐infected therapy‐naïve patients was shown to be effective and safe through 144 weeks in two randomised, double‐blinded trials, which excluded participants whose HIV‐1 harboured the M184V and/or M184I mutation. Materials and methods: This ongoing, prospective open‐label, single arm, multicentre, 48‐week trial is evaluating the efficacy and safety of switching suppressed participants to E/C/F/TAF from a stable regimen (≥6 months) of a third agent plus either F/tenofovir disoproxil fumarate or abacavir/lamivudine. Participants had a historical genotype report showing M184V and/or M184I and no evidence of previous virologic failure (VF) or resistance to boosted PIs or INSTIs. At screening, HIV‐1 RNA <50 c/mL was required as well as the absence of additional NRTI or PI resistance mutations based on sequencing of integrated HIV DNA (GenoSure Archive, Monogram Biosciences). The primary objective is to evaluate the efficacy of switching to E/C/F/ TAF in maintaining HIV‐1 RNA <50 c/mL at Week 12 using pure virologic response (PVR). Participants with discontinuation or missing values were considered responders if they never had HIV‐1 RNA >50 c/ mL at 2 consecutive visits and the last HIV‐1 RNA was <50 c/mL. This report presents the Week 24 data. Results: Thirty‐seven participants were enrolled and switched to E/C/ F/TAF. The mean age was 50 years (range 22 to 76), 73% White, 19% Black, 22% women, median CD4 count 724 cells/lL and 100% HIVRNA <50 c/mL at baseline. Through Week 24, all 37 participants (100%) had HIV‐1 RNA <50 c/mL based on PVR. Three participants who discontinued prior to Week 24 with last recorded HIV‐1 RNA <50 c/mL were not considered VF. Four serious adverse events occurred (none were study drug‐related): one each of squamous cell carcinoma, acute kidney injury (with poorly controlled hypertension and diabetes), transient proteinuria (resolved on study drug) and pulmonary embolism. Twenty‐two per cent (8/37) of participants experienced a study drug‐related AE (grade 1 or 2); one participant discontinued due to grade 2 muscle spasms (Table 1). Conclusions: E/C/F/TAF offers an effective, well‐tolerated switch option for patients with pre‐existing M184V and/or M184I mutations. These data on continued virologic suppression despite resistance are encouraging though longer term data are needed.
AN  - CN-01941252
AU  - Perez-Valero, I.
AU  - Llibre, J.
AU  - Lazzarin, A.
AU  - Molina, J.
AU  - Margot, N.
AU  - Piontkowsky, D.
AU  - Das, M.
AU  - Espinoza, L.
AU  - Haubrich, R.
DO  - 10.1002/jia2.25263
KW  - *Human immunodeficiency virus 1
*gene mutation
*pilot study
Acute kidney failure
Adult
Adverse event
CD4 lymphocyte count
Clinical article
Comparative effectiveness
Conference abstract
Controlled study
Diabetes mellitus
Double blind procedure
Drug efficacy
Drug safety
Drug therapy
Drug withdrawal
Female
Genotype
Human
Hypertension
Information center
Lung embolism
Male
Middle aged
Multicenter study
Muscle spasm
Nonhuman
Pharmacokinetics
Phase 3 clinical trial
Prospective study
Proteinuria
Randomized controlled trial
Squamous cell carcinoma
M3  - Journal: Conference Abstract
PY  - 2019
ST  - A phase 3b, open-label, pilot study to evaluate switching to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) in virologically suppressed HIV-1 infected adult subjects harbouring the NRTI resistance mutation M184V and/or M184I (GS-US-292-1824)
T2  - Journal of the international AIDS society
TI  - A phase 3b, open-label, pilot study to evaluate switching to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) in virologically suppressed HIV-1 infected adult subjects harbouring the NRTI resistance mutation M184V and/or M184I (GS-US-292-1824)
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01941252/full
VL  - 22
ID  - 1607
ER  - 

TY  - JOUR
AB  - Background: Treatment with once‐daily E/C/F/TAF in HIV‐1‐infected therapy‐naïve patients was shown to be effective and safe through 144 weeks in two randomized, double‐blinded trials, which excluded participants whose HIV‐1 harbored the M184V and/or M184I mutation. Methods: This ongoing, prospective open‐label, single arm, multicenter, 48‐week trial is evaluating the efficacy and safety of switching suppressed participants to E/C/F/TAF from a stable regimen (≥6 months) of a third agent plus either F/tenofovir disoproxil fumarate or abacavir/lamivudine. Participants had a historical genotype report showing M184V and/or M184I and no evidence of previous virologic failure (VF) or resistance to boosted PIs or INSTIs. At screening, HIV‐1 RNA <50 copies/mL was required as well as absence of additional NRTI or PI resistance mutations based on sequencing of integrated HIV DNA (GenoSure Archive, Monogram Biosciences). The primary objective is to evaluate the efficacy of switching to E/C/F/ TAF in maintaining HIV‐1 RNA <50 copies/mL at Week 12 using pure virologic response (PVR). Participants with discontinuation or missing values were considered responders if they never had HIV‐1 RNA ≥50 copies/mL at two consecutive visits and the last HIV‐1 RNA was <50 copies/mL. This report presents the Week 24 data. Results: Thirty‐seven participants were enrolled and switched to E/C/ F/TAF. Mean age was 50 years (range 22 to 76), 73% White, 19% Black, 22% women, median CD4 count 724 cells/μL and 100% HIV RNA <50 copies/mL at baseline. Through Week 24, all 37 participants (100%) had HIV‐1 RNA <50 copies/mL based on PVR (Table 1). Three participants who discontinued prior to Week 24 with last recorded HIV‐1 RNA <50 copies/mL were not considered VF. Four serious adverse events occurred (none were study drug‐related): 1 each of squamous cell carcinoma, acute kidney injury (with poorly controlled hypertension and diabetes), transient proteinuria (resolved on study drug) and pulmonary embolism. Twenty‐two percent (8/37) of participants experienced a study drug‐related AE (grade 1 or 2) one participant discontinued due to grade 2 muscle spasms. Conclusions: E/C/F/TAF offers an effective, well tolerated switch option for patients with pre‐existing M184V and/or M184I mutations. These data on continued virologic suppression despite resistance are encouraging though longer term data are needed. (Table Presented) .
AN  - CN-01631633
AU  - Perez Valero, I.
AU  - Llibre, J. M.
AU  - Lazzarin, A.
AU  - Di Perri, G.
AU  - Pulido, F.
AU  - Molina, J. M.
AU  - Esser, S.
AU  - McNicholl, I.
AU  - Lorgeoux, R. P.
AU  - Margot, N.
AU  - et al.
DO  - 10.1002/jia2.25148
KW  - *Human immunodeficiency virus 1
*gene mutation
*pilot study
Acute kidney failure
Adult
Adverse event
CD4 lymphocyte count
Clinical article
Comparative effectiveness
Conference abstract
Controlled study
Diabetes mellitus
Double blind procedure
Drug efficacy
Drug resistance
Drug safety
Drug therapy
Drug withdrawal
Female
Genotype
Human
Hypertension
Information center
Lung embolism
Male
Middle aged
Multicenter study
Muscle spasm
Nonhuman
Pharmacokinetics
Phase 3 clinical trial
Prospective study
Proteinuria
Randomized controlled trial
Squamous cell carcinoma
M3  - Journal: Conference Abstract
PY  - 2018
ST  - A phase 3b, open-label, pilot study to evaluate switching to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) in virologically-suppressed HIV-1 infected adult subjects harboring the NRTI resistance mutation M184V and/or M184I (GS-US-292-1824)
T2  - Journal of the international AIDS society
TI  - A phase 3b, open-label, pilot study to evaluate switching to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) in virologically-suppressed HIV-1 infected adult subjects harboring the NRTI resistance mutation M184V and/or M184I (GS-US-292-1824)
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01631633/full
VL  - 21
ID  - 1606
ER  - 

TY  - JOUR
AB  - Purpose: Concurrent inhibition of mTOR and PI3K led to improved efficacy in preclinical models and provided the rationale for this phase I study of everolimus and buparlisib (BKM120) in patients with advanced solid tumor. Patients and Methods: We used the Bayesian Escalation with Overdose Control design to test escalating doses of everolimus (5 or 10 mg) and buparlisib (20, 40, 60, 80, and 100 mg) in eligible patients. Pharmacokinetic assessment was conducted using blood samples collected on cycle 1, days 8 and 15. Pharmacodynamic impact on mTOR/PI3K pathway modulation evaluated in paired skin biopsies collected at baseline and end of cycle 1. Results: We enrolled 43 patients, median age of 63 (range, 39–78) years; 25 (58.1%) females, 35 (81.4%) Caucasians, and 8 (18.6%) Blacks. The most frequent toxicities were hyperglycemia, diarrhea, nausea, fatigue, and aspartate aminotransferase elevation. Dose-limiting toxicities observed in 7 patients were fatigue (3), hyperglycemia (2), mucositis (1), acute kidney injury (1), and urinary tract infection (1). The recommended phase II dose (RP2D) for the combination was established as everolimus (5 mg) and buparlisib (60 mg). The best response in 27 evaluable patients was progressive disease and stable disease in 3 (11%) and 24 (89%), respectively. The median progression-free survival and overall survival were 2.7 (1.8–4.2) and 9 (6.4–13.2) months. Steady-state pharmacokinetic analysis showed dose-normalized maximum concentrations and AUC values for everolimus and buparlisib in combination to be comparable with single-agent pharmacokinetic. Conclusions: The combination of everolimus and buparlisib is safe and well-tolerated at the RP2D of 5 and 60 mg on a continuous daily schedule.
AD  - T.K. Owonikoko, Emory University School of Medicine, 1365 Clifton Road, NE, Atlanta, GA, United States
AU  - Owonikoko, T. K.
AU  - Harvey, R. D.
AU  - Carthon, B.
AU  - Chen, Z.
AU  - Lewis, C.
AU  - Collins, H.
AU  - Zhang, C.
AU  - Lawson, D. H.
AU  - Alese, O. B.
AU  - Bilen, M. A.
AU  - Sica, G. L.
AU  - Steuer, C. E.
AU  - Shaib, W. L.
AU  - Wu, C.
AU  - Harris, W. B.
AU  - Akce, M.
AU  - Kudchagkar, R. R.
AU  - El-Rayes, B. F.
AU  - Lonial, S.
AU  - Ramalingam, S. S.
AU  - Khuri, F. R.
DB  - Embase
Medline
DO  - 10.1158/1078-0432.CCR-19-2697
IS  - 11
KW  - NCT01470209
buparlisib
everolimus
mammalian target of rapamycin
phosphatidylinositol 3 kinase
acute kidney failure
adult
aged
Akt signaling
anemia
anorexia
anxiety disorder
area under the curve
article
Black person
bladder cancer
blood analysis
body weight loss
breast cancer
cancer chemotherapy
cancer growth
cancer patient
cancer survival
Caucasian
cellulitis
clinical article
cohort analysis
colorectal cancer
concentration at steady-state
constipation
coughing
dehydration
diarrhea
dizziness
drug safety
dry eye
dyspepsia
dyspnea
dysuria
ear infection
edema
erectile dysfunction
fatigue
female
fever
gastroenteropancreatic neuroendocrine tumor
headache
human
human tissue
hyperbilirubinemia
hypercholesterolemia
hyperglycemia
hypertension
hypertransaminasemia
hypertriglyceridemia
hyperuricemia
hypoalbuminemia
hypocalcemia
hypokalemia
hypomagnesemia
hyponatremia
hypophosphatemia
hypotension
insomnia
leukopenia
lung cancer
lung embolism
male
maximum concentration
memory disorder
mucosa inflammation
multiple cycle treatment
musculoskeletal pain
nausea
neuropathy
neutropenia
nocturia
nose obstruction
oral mucositis
ovary cancer
overall survival
Parainfluenza virus infection
pharmacokinetic parameters
phase 1 clinical trial
phase 2 clinical trial
pneumonia
priority journal
progression free survival
pruritus
rash
rectum hemorrhage
respiratory failure
salivary gland cancer
sepsis
side effect
skin biopsy
soft tissue sarcoma
solid malignant neoplasm
survival rate
thrombocytopenia
thymus cancer
thyroid cancer
tongue swelling
treatment response
upper respiratory tract infection
urinary tract infection
vagina bleeding
LA  - English
M3  - Article
N1  - L2006839383
2020-07-28
2020-08-04
PY  - 2020
SN  - 1557-3265
1078-0432
SP  - 2497-2505
ST  - A Phase I Study of Safety, Pharmacokinetics, and Pharmacodynamics of Concurrent Everolimus and Buparlisib Treatment in Advanced Solid Tumors
T2  - Clinical Cancer Research
TI  - A Phase I Study of Safety, Pharmacokinetics, and Pharmacodynamics of Concurrent Everolimus and Buparlisib Treatment in Advanced Solid Tumors
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L2006839383&from=export
http://dx.doi.org/10.1158/1078-0432.CCR-19-2697
VL  - 26
ID  - 804
ER  - 

TY  - JOUR
AB  - Taxanes and anthracyclines have been among the best-studied chemotherapy classes in castration-resistant prostate cancer (CRPC). Docetaxel (D) 75 mg/m2 every 3 weeks has been the standard first line chemotherapy for CRPC. Encapsulation of doxorubicin in polyethylene glycol-coated liposomes (PLD) was developed to enhance the safety and efficacy of conventional doxorubicin. We hypothesize that the combination of weekly low dose-D and PLD would result in a high response rate and low toxicity. Eligibility criteria included metastatic progressive CRPC, no prior D or PLD and good organ function. After a short phase I with no dose-limiting toxicity, D 30 mg/m2 was administered on days 1, 8 and 15; and PLD 30 mg/m2 on day 1 only, every 28 days. Thirty-seven patients were enrolled. The PSA response rate was 53%. Twenty-two subjects had measurable disease; one (5%) achieved complete response, five (23%) partial response, and twelve (54%) stable disease. Twenty-seven patients (73%) manifested pain relief. The median time to progression was 3.7 months for all patients and 7.9 months for responders. Median overall survival was 16.3 months. Grade 4 neutropenia without infection and anemia occurred in 1 patient each. Grade 3 treatment-related toxicities included: 15% fatigue; 9% neutropenia, anemia and nausea; 6% dehydration and hand-foot syndrome; and 3% infection, febrile neutropenia, thrombosis, stomatitis, headache, vomiting, weight loss and weakness. In this non-comparative study D-PLD demonstrated a higher activity than previously reported with single agent D with favorable side effect profile. A phase 3 study would be needed to evaluate the true benefit of this combination. ClinicalTrials.gov Identifier: NCT00456989.
AD  - D.A. Laber, Section of Satellite Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, United States
AU  - Laber, D. A.
AU  - Eatrides, J.
AU  - Jaglal, M. V.
AU  - Haider, M.
AU  - Visweshwar, N.
AU  - Patel, A.
DB  - Embase
Medline
DO  - 10.1007/s12032-020-01420-7
IS  - 10
KW  - NCT00456989
docetaxel
doxorubicin
prostate specific antigen
adult
African American
aged
alopecia
analgesia
anemia
anorexia
article
bleeding
body weight disorder
body weight loss
cancer radiotherapy
cancer surgery
castration resistant prostate cancer
Caucasian
clinical article
confusion
dehydration
disease exacerbation
drug efficacy
drug safety
edema
fatigue
febrile neutropenia
fever
follow up
hand foot syndrome
headache
human
infection
low drug dose
male
metastasis
nail disease
nausea
neutropenia
orchiectomy
overall survival
peripheral neuropathy
phase 1 clinical trial
phase 2 clinical trial
priority journal
prostate adenocarcinoma
prostatectomy
stomatitis
thrombocytopenia
thrombosis
vomiting
weakness
LA  - English
M3  - Article
N1  - L2006798747
2020-09-30
2020-10-07
PY  - 2020
SN  - 1559-131X
1357-0560
ST  - A phase I/II study of docetaxel in combination with pegylated liposomal doxorubicin in metastatic castration-resistant prostate cancer
T2  - Medical Oncology
TI  - A phase I/II study of docetaxel in combination with pegylated liposomal doxorubicin in metastatic castration-resistant prostate cancer
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L2006798747&from=export
http://dx.doi.org/10.1007/s12032-020-01420-7
VL  - 37
ID  - 787
ER  - 

TY  - JOUR
AB  - Background: Priorities in breast cancer chemoprevention include developing safe and tolerable agents for potential chronic use that are effective against hormone receptor (HR)‐negative breast cancer and validating intermediate biomarkers which correlate with breast cancer risk. Various epidemiologic studies have demonstrated an inverse association between green tea consumption and breast cancer risk. The primary polyphenol of green tea, epigallocatechin gallate (EGCG), is a potent antioxidant that acts on multiple stages of carcinogenesis. The primary objective of this phase IB trial was to demonstrate the safety of using an oral green tea extract, Polyphenon E (Poly E), over a 6‐month period in patients with a history of HR‐negative breast cancer. Secondary exploratory objectives were to investigate the dose‐related biologic effects of Poly E on breast tissue, radiographic, serum and urine‐based biomarkers. Methods: Forty women with stage I‐III HR‐negative breast cancer who completed adjuvant treatment were randomized to oral Poly E: (1) 400mg, (2) 600mg, or (3) 800mg (2‐4 capsules) bid or matching placebo for 6 months. The primary endpoint of this dose escalation study was to determine the maximum tolerated dose (MTD) of Poly E in this patient population, defined as the dose that causes 25% dose limiting toxicity (DLT, grade 2 or higher). Assignment to dose level was based upon an adaptive clinical trial design called the time‐to‐event continual reassessment method, such that more participants were assigned to the MTD. Safety was assessed by monitoring clinical and laboratory parameters during monthly visits. At baseline and 6 months, a mammogram and random core biopsy of the contralateral breast and serial blood and urine collections were obtained for biomarker analyses. Secondary exploratory endpoints included breast tissue‐based biomarkers (Ki‐67, ER), mammographic density, serum hormone metabolites (estradiol, testosterone, IGF‐I, IGFBP‐3, SHBG), inflammatory and oxidative stress biomarkers (serum CRP, urine PGE‐M, 8‐OHdG, isoprostane). Results: From July 2007 to Sept 2009, 40 women were enrolled from 4 sites. Baseline characteristics included median age: 55 (39‐65); pre/postmenopausal: 10/30; White/Hispanic/Black/Asian: 23/9/7/1; stage I/II/III: 16/15/9; median time since diagnosis: 33 months (10‐170). Eighteen participants were each assigned to dose levels 1 and 2, four participants to dose level 3. There was 1 DLT at dose level 1 (grade 3 rectal bleeding), 3 DLTs at dose level 2 (grade 2 weight gain and indigestion, grade 3 insomnia), and 1 DLT at dose level 3 (grade 3 liver function abnormality). As a result, 600mg bid was found to be the MTD for Poly E. Biomarker analyses are currently ongoing. Conclusions: Using a novel clinical trial design for phase I testing which evaluates long‐term toxicity, we determined the MTD for Poly E that will serve as the upper safety limit in future breast cancer chemoprevention trials. We also obtained preliminary data on the biological effects of Poly E on biomarkers of breast cancer risk, which can elucidate potential mechanisms of action and possibly serve as surrogate endpoints in future clinical efficacy trials.
AN  - CN-01061915
AU  - Crew, K. D.
AU  - Lippman, S.
AU  - Hershman, D. L.
AU  - Brown, P.
AU  - Greenlee, H.
AU  - Bevers, T.
AU  - Arun, B.
AU  - Hudis, C.
AU  - McArthur, H.
AU  - Vornik, L.
AU  - et al.
DO  - 10.1158/1940-6207.PREV-11-CN06-02
IS  - 10 SUPPL. 1
KW  - *breast cancer
*cancer prevention
*female
*hormone receptor
*human
*placebo
*polyphenon E
Adjuvant therapy
Antioxidant
Biological activity
Biological marker
Biopsy
Blood
Breast
C reactive protein
Cancer risk
Carcinogenesis
Chemoprophylaxis
Clinical trial
Density
Diagnosis
Epidemiology
Epigallocatechin gallate
Estradiol
Green tea extract
Hormone blood level
Indigestion
Insomnia
Isoprostane derivative
Laboratory
Liver function
Maximum tolerated dose
Metabolite
Monitoring
Oxidative stress
Parameters
Patient
Polyphenol
Population
Rectum hemorrhage
Safety
Serum
Study design
Tea
Testosterone
Toxicity
Urine
Weight gain
M3  - Journal: Conference Abstract
PY  - 2011
ST  - Phase IB randomized, double-blinded, placebo-controlled, dose escalation study of Polyphenon E in women with a history of hormone receptor-negative breast cancer
T2  - Cancer prevention research (philadelphia, pa.)
TI  - Phase IB randomized, double-blinded, placebo-controlled, dose escalation study of Polyphenon E in women with a history of hormone receptor-negative breast cancer
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01061915/full
VL  - 4
ID  - 1659
ER  - 

TY  - JOUR
AB  - BACKGROUND: Tasquinimod is an immunomodulating and anti-antiangiogenic oral agent with anti-prostate cancer activity in preclinical studies and in clinical trials of men with metastatic castration resistant prostate cancer (mCRPC), including single agent activity and in combination with taxanes. We sought to identify the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of tasquinimod in combination with cabazitaxel and prednisone in men with chemorefractory mCRPC. METHODS: Men with mCRPC who had failed prior docetaxel chemotherapy received cabazitaxel 25 mg/m2 every 3 weeks with oral tasquinimod at 1 of 3 escalating dose levels (0.25, 0.5, and 1.0 mg once daily) with prednisone and PEG-filgastrim support, using a 3 + 3 dose escalation design. Treatment continued until progressive disease or unacceptable toxicity. RESULTS: We enrolled 25 men with chemorefractory mCRPC. The RP2D was 0.5 mg tasquinimod based on excess DLTs (two of three men) observed at dose level 3 (1.0 mg) including grade 3 sensory neuropathy and grade 3 atrial fibrillation. Dose level 2 was expanded to 14 men, where 3 DLTs were observed: grade 3 fatigue, grade 4 febrile neutropenia, and grade 3 liver function abnormalities. The proportion of men with a ≥30% PSA decline was 63% and the median composite progression-free survival (PFS) was 8.5 months (95% CI 4.2–16.4 months) based on 12 PFS events. The median number of cycles of cabazitaxel was 6 (range 1–13), with six men receiving >10 cycles. Best overall RECIST responses (CR + PR) were observed in three men (12%), with stable disease in 12 (48%). No pharmacokinetic interactions were observed. CONCLUSIONS: We determined the RP2D of tasquinimod combined with cabazitaxel to be 0.5 mg daily following a 3 week lead-in of tasquinimod 0.25 mg with growth factor support. No unexpected toxicities occurred. Prostate 77: 385–395, 2017. © 2016 Wiley Periodicals, Inc.
AD  - A.J. Armstrong, Divisions of Medical Oncology and Urology, Departments of Medicine and Surgery, Duke Cancer Institute, Durham, NC, United States
AU  - Armstrong, A. J.
AU  - Humeniuk, M. S.
AU  - Healy, P.
AU  - Szmulewitz, R.
AU  - Winters, C.
AU  - Kephart, J.
AU  - Harrison, M. R.
AU  - Martinez, E.
AU  - Mundy, K.
AU  - Halabi, S.
AU  - George, D.
DB  - Embase
Medline
DO  - 10.1002/pros.23277
IS  - 4
KW  - NCT01513733
abiraterone acetate
cabazitaxel
docetaxel
enzalutamide
opiate
pegfilgrastim
prednisone
prostate specific antigen
tasquinimod
abdominal pain
adult
African American
aged
alopecia
anemia
anorexia
antineoplastic activity
area under the curve
article
atrial fibrillation
bleeding
bone metastasis
cancer immunotherapy
cancer pain
cancer survival
castration resistant prostate cancer
Caucasian
circulating tumor cell
clinical article
colon perforation
constipation
controlled study
diarrhea
dizziness
drug clearance
drug dose escalation
drug response
drug safety
drug tolerability
lack of drug effect
dysgeusia
dyspepsia
electrolyte disturbance
fatigue
febrile neutropenia
gastritis
headache
human
hypertransaminasemia
hypotension
insomnia
Karnofsky Performance Status
leg swelling
liver dysfunction
liver metastasis
lung metastasis
lymph node metastasis
male
maximum tolerated dose
metastasis potential
multiple cycle treatment
musculoskeletal pain
nausea
oral mucositis
overall survival
pain
peripheral edema
phase 1 clinical trial
progression free survival
prostate adenocarcinoma
rash
recommended drug dose
sensory neuropathy
sepsis
stomach ulcer
taste disorder
thrombocytopenia
urinary tract infection
visceral metastasis
volume of distribution
vomiting
LA  - English
M3  - Article
N1  - L613714116
2016-12-20
2017-02-23
PY  - 2017
SN  - 1097-0045
0270-4137
SP  - 385-395
ST  - Phase Ib Trial of Cabazitaxel and Tasquinimod in Men With Heavily Pretreated Metastatic Castration Resistant Prostate Cancer (mCRPC): The CATCH Trial
T2  - Prostate
TI  - Phase Ib Trial of Cabazitaxel and Tasquinimod in Men With Heavily Pretreated Metastatic Castration Resistant Prostate Cancer (mCRPC): The CATCH Trial
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L613714116&from=export
http://dx.doi.org/10.1002/pros.23277
VL  - 77
ID  - 942
ER  - 

TY  - JOUR
AB  - BACKGROUND: Patients with advanced non-small cell lung cancer (NSCLC) have no curative treatment options; therefore, improving their quality of life (QOL) is an important goal. Gefitinib, an epidermal growth factor receptor (EGFR) inhibitor, is a safe oral agent that may be of benefit to a specific population of NSCLC. PATIENTS AND METHODS: A Phase II clinical trial included chemonaïve patients with advanced NSCLC and poor performance status (PS). Response rate, progression-free survival, overall survival, QOL using the Functional Assessment of Cancer Therapy - Lung (FACT-L) questionnaire, and Trial Outcome Index (TOI) were evaluated. RESULTS: Twelve out of 19 enrolled patients were evaluable. The median age for the evaluable patients was 68.8 years (59.7-74.6). Out of all the patients, 7 (58.3%) had adenocarcinoma and 5 (41.7%) had squamous cell carcinoma. The median duration of treatment was 62.5 days (26.5-115.0) in the evaluable patients. Grade 3/4 toxicities included fatigue, rash, diarrhea, and nausea. One patient had partial response, eight patients had stable disease (SD), and three patients progressed. The median overall survival for the evaluable population was 4.9 months (2.3-16). The median progression-free survival was 3.7 months (1.9-6.6). TOI was marginally associated with the overall survival, with a hazard ratio of 0.92 (95% confidence interval: 0.84, 1.0) (P = 0.061). FACT-L score and the TOI were highly correlated (r = 0.96, P < 0.0001). TOI scores were higher in African Americans compared to Caucasians and increased with age. CONCLUSION: Our results suggest that gefitinib use in patients with NSCLC and poor PS may improve the QOL of older patients and African American patients.
AD  - University of Cincinnati, Cincinnati, OH, USA.
University of Illinois at Urbana-Champaign, IL, USA.
Cleveland Clinic Foundation, Cleveland, OH, USA.
University of Tennessee Cancer Institute, Memphis, TN, USA.
King Saud bin Abdul-Aziz University for Health Sciences, King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia.
AN  - 25520566
AU  - Karim, N. A.
AU  - Musaad, S.
AU  - Zarzour, A.
AU  - Patil, S.
AU  - Jazieh, A. R.
C2  - PMC4245085
DO  - 10.4137/cmo.S15172
DP  - NLM
ET  - 2014/12/19
KW  - advanced non-small cell lung cancer
gefitinib
poor performance status
quality of life
LA  - eng
N1  - 1179-5549
Karim, Nagla Abdel
Musaad, Salma
Zarzour, Ahmad
Patil, Sadanand
Jazieh, Abdul Rahman
Journal Article
Clin Med Insights Oncol. 2014 Nov 25;8:121-8. doi: 10.4137/CMO.S15172. eCollection 2014.
PY  - 2014
SN  - 1179-5549 (Print)
1179-5549
SP  - 121-8
ST  - Phase II Clinical Trial of Gefitinib for the Treatment of Chemonaïve Patients with Advanced Non-small Cell Lung Cancer with Poor Performance Status
T2  - Clin Med Insights Oncol
TI  - Phase II Clinical Trial of Gefitinib for the Treatment of Chemonaïve Patients with Advanced Non-small Cell Lung Cancer with Poor Performance Status
VL  - 8
ID  - 265
ER  - 

TY  - JOUR
AB  - PURPOSE: Women with metastatic triple negative breast cancer (TNBC) can have a poor prognosis with treatment limited to cytotoxic chemotherapy. The identification of effective therapies that may limit exposure to cytotoxic chemotherapy and lead to prolonged survival is an unmet medical need. We tested an inhibitor of the epidermal growth factor receptor, panitumumab in combination with chemotherapy. METHODS: We conducted a single arm clinical trial in women with metastatic or locally advanced TNBC to paclitaxel 80 mg/m2 and carboplatin AUC of 2 on days 1, 8, and 15 and panitumumab 6 mg/kg on days 1 and 15 for a cycle length of 28 days. The objectives were to evaluate the response rate and safety of the combination in comparison to historical controls. RESULTS: Fourteen patients with TNBC were enrolled with a median age of 53 years. The majority of women were African American (64.3%) with visceral metastasis (64.2%). Hematologic toxicities, particularly neutropenia and thrombocytopenia, were a major cause of missed chemotherapy and delayed treatment in this study. The overall response rate (complete and partial response) of the 13 evaluable patients was 46%. The median time to best response was 2.4 months and the median time to disease progression was 3.6 months. We were able to perform the PAM50 analysis on tumors from 7 of our subjects. All the samples tested clustered within the basal-like subtype. CONCLUSIONS: In our experience the response rate of carboplatin, paclitaxel and panitumumab was consistent with other reports of response for cytotoxic chemotherapy in metastatic TNBC.
AD  - a Wake Forest University Baptist Medical Center ; Winston-Salem , NC USA.
AN  - 25928118
AU  - Cowherd, S.
AU  - Miller, L. D.
AU  - Melin, S. A.
AU  - Akman, S.
AU  - Isom, S.
AU  - Cole, J.
AU  - Pullikuth, A.
AU  - Lawrence, J. A.
C2  - PMC4622683
DO  - 10.1080/15384047.2015.1026481
DP  - NLM
ET  - 2015/05/01
IS  - 5
KW  - Adult
Aged
Antibodies, Monoclonal/administration & dosage/*therapeutic use
Antineoplastic Combined Chemotherapy Protocols/administration & dosage/*therapeutic
use
Carboplatin/administration & dosage/*therapeutic use
ErbB Receptors/*antagonists & inhibitors
Female
Gene Expression
Gene Expression Profiling
Humans
Middle Aged
Paclitaxel/administration & dosage/*therapeutic use
Panitumumab
Triple Negative Breast Neoplasms/*drug therapy/genetics/pathology
AUC, area under the curve
CR, complete response
EGFR, Epidermal growth factor inhibitor
FISH, Fluorescence in situ hybridization
Hgb, hemoglobin
IHC, immunohistochemistry
IRB, Institutional Review Board
Mg/dl, milligram/deciliter
Mg/kg, milligram/kilogram
PD, progressive disease
PR, partial response
RECIST, response evaluation in sold tumors
TNBC, triple negative breast cancer
epidermal growth factor inhibitor
g/dl, grams/deciliter
metastatic breast cancer
pacliataxel carboplatin
triple negative breast cancer
LA  - eng
N1  - 1555-8576
Cowherd, S
Miller, L D
Melin, S A
Akman, S
Isom, S
Cole, J
Pullikuth, A
Lawrence, J A
P30 CA012197/CA/NCI NIH HHS/United States
Clinical Trial, Phase II
Journal Article
Research Support, Non-U.S. Gov't
Cancer Biol Ther. 2015;16(5):678-83. doi: 10.1080/15384047.2015.1026481.
PY  - 2015
SN  - 1538-4047 (Print)
1538-4047
SP  - 678-83
ST  - A phase II clinical trial of weekly paclitaxel and carboplatin in combination with panitumumab in metastatic triple negative breast cancer
T2  - Cancer Biol Ther
TI  - A phase II clinical trial of weekly paclitaxel and carboplatin in combination with panitumumab in metastatic triple negative breast cancer
VL  - 16
ID  - 246
ER  - 

TY  - JOUR
AB  - EW02, a polysaccharide-enriched crude extract from black soybean, has been shown to assist hematopoiesis in chemotherapy-treated animals. The present study aimed to clarify the safety, quality of life (QOL) and efficacy for myelopoiesis of EW02 administration in early breast cancer (EBC) patients receiving adjuvant chemotherapy. A total of 60 eligible EBC patients were enrolled in a randomized, double-blinded trial, 40 of whom were prescribed 700 mg oral EW02 three times daily for 15 days in chemotherapy cycle (C)2. The remainder were prescribed a placebo. All subjects took EW02 in C3 for 15 days. Blood samples were collected at different time-points for determining the blood cell count, and the serum level of granulocyte colony-stimulating factor (G-CSF) and interleukin (IL)-6. All patients tolerated EW02 well without severe side-effects. QOL evaluation showed that only the score of one questionnaire section (QLQ-C30) was significantly increased at C1 day (D)8 to C2D8 when the EW02 and placebo groups were compared (P=0.045). No significant myelopoiesis recovery, and no incremental change in IL-6 and G-CSF levels were found in C2. Subgroup analysis showed a slightly lower decrease in absolute neutrophil count (ANC) in the EW02 patients who underwent Adriamycin + cyclophosphamide treatment compared with the placebo group. Although EW02 failed to show efficacy for myelopoiesis in the present study, EW02 was still well tolerated in EBC patients who underwent adjuvant chemotherapy.
AD  - Division of Hematology and Oncology, Department of Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, R.O.C. ; Graduate Institute of Life Sciences, National Defense Medical Center, Taipei, Taiwan, R.O.C.
Division of Hematology and Oncology, Department of Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, R.O.C.
Division of Hematology and Oncology, Department of Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, R.O.C. ; Institute of Clinical Medicine, Taipei Medical University, Shuang-Ho Hospital, New Taipei, Taiwan, R.O.C.
Graduate Institute of Life Sciences, National Defense Medical Center, Taipei, Taiwan, R.O.C. ; Institute of Clinical Medicine, Taipei Medical University, Shuang-Ho Hospital, New Taipei, Taiwan, R.O.C. ; Division of Hematology and Oncology, Department of Medicine, Taipei Medical University, Shuang-Ho Hospital, New Taipei, Taiwan, R.O.C.
AN  - 26622752
AU  - Wu, Y. Y.
AU  - Liu, H. Y.
AU  - Huang, T. C.
AU  - Chen, J. H.
AU  - Chang, P. Y.
AU  - Ho, C. L.
AU  - Chao, T. Y.
C2  - PMC4533740
DA  - Sep
DO  - 10.3892/ol.2015.3492
DP  - NLM
ET  - 2015/12/02
IS  - 3
KW  - black soybean
breast cancer
chemotherapy
myelopoiesis
LA  - eng
N1  - 1792-1082
Wu, Yi-Ying
Liu, Hsin-Yi
Huang, Tzu-Chuan
Chen, Jia-Hong
Chang, Ping-Ying
Ho, Ching-Liang
Chao, Tsu-Yi
Journal Article
Oncol Lett. 2015 Sep;10(3):1793-1798. doi: 10.3892/ol.2015.3492. Epub 2015 Jul 14.
PY  - 2015
SN  - 1792-1074 (Print)
1792-1074
SP  - 1793-1798
ST  - A phase II double-blinded study to evaluate the efficacy of EW02 in reducing chemotherapy-induced neutropenia in breast cancer
T2  - Oncol Lett
TI  - A phase II double-blinded study to evaluate the efficacy of EW02 in reducing chemotherapy-induced neutropenia in breast cancer
VL  - 10
ID  - 225
ER  - 

TY  - JOUR
AB  - Purpose: A multicenter, open-label, phase II trial was conducted to evaluate the efficacy, safety, and tolerability of selumetinib in iodine-refractory papillary thyroid cancer (IRPTC). Experimental Design: Patients with advanced IRPTC with or without follicular elements and documented disease progression within the preceding 12 months were eligible to receive selumetinib at a dose of 100 mg twice daily. The primary endpoint was objective response rate using Response Evaluation Criteria in Solid Tumors. Secondary endpoints were safety, overall survival, and progression-free survival (PFS). Tumor genotype including mutations in BRAF, NRAS, and HRAS was assessed. Results: Best responses in 32 evaluable patients out of 39 enrolled were 1 partial response (3%), 21 stable disease (54%), and 11 progressive disease (28%). Disease stability maintenance occurred for 16 weeks in 49%, 24 weeks in 36%. Median PFS was 32 weeks. BRAF V600E mutants (12 of 26 evaluated, 46%) had a longer median PFS compared with patients with BRAF wild-type (WT) tumors (33 versus 11 weeks, respectively, HR = 0.6, not significant, P = 0.3). The mostcommonadverse events and grades 3 to 4 toxicities included rash, fatigue, diarrhea, and peripheral edema. Two pulmonary deaths occurred in the study and were judged unlikely to be related to the study drug. Conclusions: Selumetinib was well tolerated but the study was negative with regard to the primary outcome. Secondary analyses suggest that future studies of selumetinib and other mitogen-activated protein (MAP)/extracellular signal-regulated kinase (ERK; MEK) inhibitors in IRPTC should consider BRAF V600E mutation status in the trial design based on differential trends in outcome. ©2012 AACR.
AD  - D.N. Hayes, UNC Chapel Hill, CB# 7295, 450 West Drive, Chapel Hill, NC 27599, United States
AU  - Hayes, D. N.
AU  - Lucas, A. S.
AU  - Tanvetyanon, T.
AU  - Krzyzanowska, M. K.
AU  - Chung, C. H.
AU  - Murphy, B. A.
AU  - Gilbert, J.
AU  - Mehra, R.
AU  - Moore, D. T.
AU  - Sheikh, A.
AU  - Hoskins, J.
AU  - Hayward, M. C.
AU  - Zhao, N.
AU  - O'Connor, W.
AU  - Weck, K. E.
AU  - Cohen, R. B.
AU  - Cohen, E. E. W.
C1  - arry 142886
azd 6244
DB  - Embase
Medline
DO  - 10.1158/1078-0432.CCR-11-0563
IS  - 7
KW  - axitinib
iodine 131
motesanib
selumetinib
sorafenib
adult
African American
aged
article
Asian
BRAF gene
cancer grading
Caucasian
clinical article
controlled study
diarrhea
disease course
drug dose reduction
drug efficacy
drug eruption
drug fatality
drug half life
drug safety
drug tolerability
drug withdrawal
fatigue
female
gene mutation
genotype
genotyping technique
HRAS gene
human
human cell
human tissue
iodine refractory papillary thyroid cancer
male
multicenter study
multiple cycle treatment
NRAS gene
oncogene
onset age
open study
overall survival
peripheral edema
pharmacogenomics
phase 2 clinical trial
priority journal
progression free survival
takotsubo cardiomyopathy
thyroid follicular carcinoma
thyroid papillary carcinoma
treatment outcome
treatment response
arry 142886
azd 6244
LA  - English
M3  - Article
N1  - L364574551
2012-04-12
2012-04-20
PY  - 2012
SN  - 1078-0432
1557-3265
SP  - 2056-2065
ST  - Phase II efficacy and pharmacogenomic study of selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements
T2  - Clinical Cancer Research
TI  - Phase II efficacy and pharmacogenomic study of selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L364574551&from=export
http://dx.doi.org/10.1158/1078-0432.CCR-11-0563
http://clincancerres.aacrjournals.org/content/18/7/2056.full.pdf+html
VL  - 18
ID  - 1122
ER  - 

TY  - JOUR
AB  - BACKGROUND: We hypothesized that thalidomide would improve the response and toxicity profile of chemotherapy with carboplatin and irinotecan. METHODS: The key eligibility criteria were stage IIIB (malignant pleural effusion) and IV non-small cell lung cancer, measurable disease, no prior chemotherapy, prior radiation only for brain metastasis, performance status 0 or 1, and adequate hematologic, hepatic, and renal function. Treatment consisted of carboplatin at a calculated area under the curve of 5 and infused intravenously for 30 min on day 1 and irinotecan (50 mg/m2 intravenously for 90 min on days 1 and 8 every 21 days). Thalidomide was given orally every evening starting on day 1 until progressive disease; the starting dose was 200 mg per day, which was escalated by 100 mg per week if tolerated (maximum 1000 mg per day). The objectives were to determine the response rate, time to progression, overall survival, and toxicity profile. RESULTS: In all, 46 patients were enrolled, but three who never received protocol treatment were excluded from the analysis. The characteristics of the 43 eligible and treated patients included median age 63 (47-79), female/male 13/30, black/white 3/40, PS 0/1 in 10/33, and stage 3/4 in 6/37. The objective response rates were complete response 1 (2%), partial response 5 (12%), stable disease 24 (56%), progressive disease 9 (21%), and unevaluable for response 4 (9%). The median time to progression was 3.7 months (95% confidence interval [CI], 2.5-4.9). The median survival time was 8.1 months (95% CI, 5.0-12.9). Frequent toxicities were neutropenia, fatigue/malaise, and nausea/vomiting. Diarrhea was uncommon and mild. CONCLUSIONS: This treatment regimen of carboplatin, irinotecan, and thalidomide was tolerable, with reversible neutropenia as the major toxicity and only minor diarrhea. The overall response rate did not meet our predetermined level of efficacy to merit further investigation.
AD  - Comprehensive Cancer Center, Wake Forest University, Winston-Salem, North Carolina, USA. aamiller@wfubmc.edu
AN  - 17409967
AU  - Miller, A. A.
AU  - Case, D.
AU  - Atkins, J. N.
AU  - Giguere, J. K.
AU  - Bearden, J. D.
DA  - Oct
DP  - NLM
ET  - 2007/04/06
IS  - 8
KW  - Aged
Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use
Camptothecin/administration & dosage/adverse effects/analogs & derivatives
Carboplatin/administration & dosage/adverse effects
Carcinoma, Non-Small-Cell Lung/*drug therapy/mortality
Disease-Free Survival
Female
Humans
Irinotecan
Lung Neoplasms/*drug therapy/mortality
Male
Middle Aged
Survival Rate
Thalidomide/administration & dosage
LA  - eng
N1  - 1556-1380
Miller, Antonius A
Case, Doug
Atkins, James N
Giguere, Jeffrey K
Bearden, James D
U10CA81851/CA/NCI NIH HHS/United States
Clinical Trial, Phase II
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
United States
J Thorac Oncol. 2006 Oct;1(8):832-6.
PY  - 2006
SN  - 1556-0864
SP  - 832-6
ST  - Phase II study of carboplatin, irinotecan, and thalidomide in patients with advanced non-small cell lung cancer
T2  - J Thorac Oncol
TI  - Phase II study of carboplatin, irinotecan, and thalidomide in patients with advanced non-small cell lung cancer
VL  - 1
ID  - 530
ER  - 

TY  - JOUR
AB  - INTRODUCTION: SRC is an oncogene with an essential role in the invasiveness and metastasis of solid tumors including small cell lung cancer. Dasatinib is a potent inhibitor of SRC as well as other tyrosine kinases. The primary objective of this study was to determine the efficacy of second-line dasatinib in patients with chemosensitive (relapse or progression > or =90 days after completing first-line therapy) small cell lung cancer. METHODS: Patients with measurable disease; performance status 0 to 1; no more than one prior platinum-based chemotherapy regimen; and adequate hematologic, hepatic, and renal function were eligible. Dasatinib was administered orally at 70 mg twice daily continuously (1 cycle = 21 days) until disease progression or unacceptable toxicity. Response was determined after every two cycles. Patients were followed until disease progression or death. The study was prospectively designed to simultaneously discriminate between complete plus partial response rates of 5% versus 20% and progression-free survival (PFS) rates at 6 weeks of 50% versus 70.7% in 53 evaluable patients with at least 92% power. The study was to be terminated early and declared negative if 1 or less objective response and 14 or fewer instances of PFS > or =6 weeks were observed among the initial 27 patients; however, patient accrual continued while the initial 27 patients were evaluated. RESULTS: Between April 2007 and December 2008, 45 patients were enrolled, but one patient never received any protocol therapy and one patient was ineligible: male/female, 17/26; white/black/unknown, 40/2/1; median age, 64 years (range, 35-84 years); and performance status 0/1, 12/31. No objective response was recorded among the 43 eligible and treated patients. Among the initial 27 patients, only 13 instances of PFS > or =6 weeks were observed. With a median follow-up time of 7.1 months, median estimated overall survival and PFS times for the 43 eligible and treated patients were 17.0 and 5.9 weeks, respectively. Common reasons for removal of patients from protocol treatment were progressive disease (65%) and adverse events (26%). Toxicity was generally mild to moderate: grade 3 events of >5% frequency included fatigue and pleural and pericardial effusions; and no grade 4 or 5 events were encountered. CONCLUSIONS: Dasatinib did not reach our specified efficacy criteria in this clinical setting, and the study was terminated.
AD  - Comprehensive Cancer Center of Wake Forest University, Medical Center Blvd., WinstonSalem, NC 27157, USA. aamiller@wfubmc.edu
AN  - 20087228
AU  - Miller, A. A.
AU  - Pang, H.
AU  - Hodgson, L.
AU  - Ramnath, N.
AU  - Otterson, G. A.
AU  - Kelley, M. J.
AU  - Kratzke, R. A.
AU  - Vokes, E. E.
C2  - PMC2853764
C6  - NIHMS181118
DA  - Mar
DO  - 10.1097/JTO.0b013e3181cee36e
DP  - NLM
ET  - 2010/01/21
IS  - 3
KW  - Adult
Aged
Aged, 80 and over
Antineoplastic Agents/therapeutic use
Dasatinib
Drug Resistance, Neoplasm
Female
Humans
Lung Neoplasms/*drug therapy/pathology
Male
Middle Aged
Neoplasm Recurrence, Local/*drug therapy/pathology
Neoplasm Staging
Protein Kinase Inhibitors/*therapeutic use
Pyrimidines/*therapeutic use
Salvage Therapy
Small Cell Lung Carcinoma/*drug therapy/pathology
Survival Rate
Thiazoles/*therapeutic use
Treatment Outcome
Young Adult
LA  - eng
N1  - 1556-1380
Miller, Antonius A
Pang, Herbert
Hodgson, Lydia
Ramnath, Nithya
Otterson, Gregory A
Kelley, Michael J
Kratzke, Robert A
Vokes, Everett E
Cancer and Leukemia Group B (CALGB)
U10 CA032291/CA/NCI NIH HHS/United States
CA33601/CA/NCI NIH HHS/United States
CA77597/CA/NCI NIH HHS/United States
CA11789/CA/NCI NIH HHS/United States
U10 CA077658/CA/NCI NIH HHS/United States
CA77406/CA/NCI NIH HHS/United States
CA35113/CA/NCI NIH HHS/United States
CA32291/CA/NCI NIH HHS/United States
U10 CA086726/CA/NCI NIH HHS/United States
CA41287/CA/NCI NIH HHS/United States
U10 CA035279/CA/NCI NIH HHS/United States
U10 CA045808/CA/NCI NIH HHS/United States
CA03927/CA/NCI NIH HHS/United States
U10 CA031946/CA/NCI NIH HHS/United States
U10 CA033601/CA/NCI NIH HHS/United States
U10 CA077597/CA/NCI NIH HHS/United States
CA45808/CA/NCI NIH HHS/United States
CA35279/CA/NCI NIH HHS/United States
U10 CA114558/CA/NCI NIH HHS/United States
U10 CA045418/CA/NCI NIH HHS/United States
CA86726/CA/NCI NIH HHS/United States
U10 CA041287/CA/NCI NIH HHS/United States
U10 CA035113/CA/NCI NIH HHS/United States
U10 CA031946-28/CA/NCI NIH HHS/United States
CA114558-02/CA/NCI NIH HHS/United States
CA47642/CA/NCI NIH HHS/United States
CA45418/CA/NCI NIH HHS/United States
CA77658/CA/NCI NIH HHS/United States
CA77298/CA/NCI NIH HHS/United States
U10 CA047642/CA/NCI NIH HHS/United States
CA31983/CA/NCI NIH HHS/United States
CA31946/CA/NCI NIH HHS/United States
U10 CA003927/CA/NCI NIH HHS/United States
Clinical Trial, Phase II
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
J Thorac Oncol. 2010 Mar;5(3):380-4. doi: 10.1097/JTO.0b013e3181cee36e.
PY  - 2010
SN  - 1556-0864 (Print)
1556-0864
SP  - 380-4
ST  - A phase II study of dasatinib in patients with chemosensitive relapsed small cell lung cancer (Cancer and Leukemia Group B 30602)
T2  - J Thorac Oncol
TI  - A phase II study of dasatinib in patients with chemosensitive relapsed small cell lung cancer (Cancer and Leukemia Group B 30602)
VL  - 5
ID  - 434
ER  - 

TY  - JOUR
AB  - Dolastatin-10 is a natural, cytotoxic peptide with microtubule-inhibitory and apoptotic effects. It has demonstrated in vitro and in vivo efficacy in the DU-145 human prostate cancer model. A Phase II clinical trial was designed in patients with hormone-refractory prostate cancer. Dolastatin-10 was administered at a dose of 400 microg/m2 i.v. every 3 weeks. Dose escalation to 450 microg/m2 was permitted. Toxicity evaluation was conducted every 2 weeks, and assessment of response was done at the end of every two cycles. Sixteen patients were enrolled between October 1998 to December 1999. The median age was 71 years (range, 59-79 years). Median prostate-specific antigen value was 108 ng/ml (range, 15.3-1672 ng/ml). Of the 15 eligible patients, 7 were Caucasian and 8 were African-American. Eight patients had bone-only metastases, and seven had measurable disease with or without bone metastases. A total of 56 cycles have been administered. Only 2 patients required dose adjustment because of toxicity, and in 5 patients, dose escalation was feasible to 450 microg/m2. The major toxicities observed were grade 3 and 4 neutropenia in 8 patients and grade 3 neuropathy in 1 patient. All 15 patients are evaluable for response. Three patients demonstrated stable disease; 2 of these had bone disease, and 1 had nodal metastasis. All others had disease progression. Dolastatin-10 is very well tolerated in this elderly, pretreated population but lacks significant clinical activity as a single agent.
AD  - Department of Medicine, Wayne State University, and Barbara Ann Karmanos Cancer Institute, Detroit, Michigan 48201, USA.
AN  - 11106233
AU  - Vaishampayan, U.
AU  - Glode, M.
AU  - Du, W.
AU  - Kraft, A.
AU  - Hudes, G.
AU  - Wright, J.
AU  - Hussain, M.
DA  - Nov
DP  - NLM
ET  - 2000/12/06
IS  - 11
KW  - Adenocarcinoma/*drug therapy
Aged
Antineoplastic Agents/*therapeutic use
Depsipeptides
Humans
Male
Middle Aged
Neoplasm Metastasis
Oligopeptides/*therapeutic use
Prostatic Neoplasms/*drug therapy
LA  - eng
N1  - Vaishampayan, U
Glode, M
Du, W
Kraft, A
Hudes, G
Wright, J
Hussain, M
Clinical Trial
Clinical Trial, Phase II
Journal Article
United States
Clin Cancer Res. 2000 Nov;6(11):4205-8.
PY  - 2000
SN  - 1078-0432 (Print)
1078-0432
SP  - 4205-8
ST  - Phase II study of dolastatin-10 in patients with hormone-refractory metastatic prostate adenocarcinoma
T2  - Clin Cancer Res
TI  - Phase II study of dolastatin-10 in patients with hormone-refractory metastatic prostate adenocarcinoma
VL  - 6
ID  - 697
ER  - 

TY  - JOUR
AB  - OBJECTIVE: The tolerability and efficacy of targeted therapy in older adults with cancer has not been adequately studied. Neratinib is a novel HER1, HER2, HER4 tyrosine kinase inhibitor that has recently been granted FDA approval for treatment of breast cancer. The major toxicity of neratinib is diarrhea, which affects up to 90% of patients. This phase II trial evaluates the safety and tolerability of neratinib in adults ≥60. METHODS: Patients aged 60 or older with histologically proven metastatic breast cancer and HER2 amplification (defined by ASCO/CAP guideline) or HER2/HER3 activating mutation were enrolled to receive neratinib at 240 mg daily in 28-day cycles. The association between tolerability, defined as dose reduction and number of completed courses, and log(2) Cancer and Aging Research Group (CARG) toxicity risk score was assessed using a Student's t-test and linear regression, respectively. Response rate, progression free survival, and overall survival were also evaluated. RESULTS: 25 patients were enrolled with median age of 66 (range 60-79). Seventy-six percent of patients were white, 16% Asian, and 8% African-American. Seventy-six percent were patients with hormone receptor (HR) positive metastatic breast cancer (MBC) and 24% were patients with HR negative MBC. Median number of prior lines of metastatic therapy were 3 (range 0-11). 20/25 (80%) had worst grade toxicities ≥2. A total of 9/25 (36%) had grade 3 toxicities including 5/20 (20%) diarrhea, 2/20 (8%) vomiting, and 2/20 (8%) abdominal pain. There were no grade 4 or 5 toxicities. A total of 9/25 (36%) had dose reduction, and 2/25 (8%) discontinued therapy due to toxicity. The association between dose reductions and CARG toxicity score reached borderline statistical significance suggesting a trend with participants with higher CARG toxicity risk scores being more likely to require a dose modification (p = 0.054). 1/25 (4%) had a partial response, 11/25 (44%) had stable disease, 12/25 (48%) had progression of disease, and 1/25 (4%) was not assessed. Median progression free survival (PFS) was 2.6 months (95% CI [2.56-5.26]), and median overall survival (OS) was 17.4 months (95% CI [10.3, NA]). CONCLUSIONS: Neratinib was safe in this population of older adults with HER2 amplified or HER2/3 mutated metastatic breast cancer (BC). Higher CARG toxicity risk score may be associated with greater need for dose adjustments. Future studies are needed to confirm this finding.
AD  - Department of Medical Oncology & Therapeutics Research, City of Hope National Medical Center, Duarte, CA, United States of America. Electronic address: yuyuan@coh.org.
Department of Medical Oncology & Therapeutics Research, City of Hope National Medical Center, Duarte, CA, United States of America.
Department of Biostatistics, City of Hope National Medical Center, Duarte, CA, United States of America.
City of Hope National Medical Center, Mission Hills, CA, United States of America.
City of Hope National Medical Center, West Covina, CA, United States of America.
AN  - 33663941
AU  - Yuan, Y.
AU  - Lee, J. S.
AU  - Yost, S. E.
AU  - Stiller, T.
AU  - Blanchard, M. S.
AU  - Padam, S.
AU  - Katheria, V.
AU  - Kim, H.
AU  - Sun, C.
AU  - Tang, A.
AU  - Martinez, N.
AU  - Patel, N. D.
AU  - Sedrak, M. S.
AU  - Waisman, J.
AU  - Li, D.
AU  - Sanani, S.
AU  - Presant, C. A.
AU  - Mortimer, J.
DA  - Mar 1
DO  - 10.1016/j.jgo.2021.02.020
DP  - NLM
ET  - 2021/03/06
KW  - CARG toxicity risk score
Metastatic breast cancer
Neratinib
Phase II trial
Merck, Eisai, Novartis, Puma, Genentech, and Pfizer
is a consultant for Puma, and
is on the Speakers Bureau for Eisai. The other authors declare that they have no
competing interests.
LA  - eng
N1  - 1879-4076
Yuan, Yuan
Lee, Jin Sun
Yost, Susan E
Stiller, Tracey
Blanchard, M Suzette
Padam, Simran
Katheria, Vani
Kim, Heeyoung
Sun, Canlan
Tang, Aileen
Martinez, Norma
Patel, Niki Dipesh
Sedrak, Mina S
Waisman, James
Li, Daneng
Sanani, Shamel
Presant, Cary A
Mortimer, Joanne
Journal Article
Netherlands
J Geriatr Oncol. 2021 Mar 1:S1879-4068(21)00044-8. doi: 10.1016/j.jgo.2021.02.020.
PY  - 2021
SN  - 1879-4068
ST  - Phase II study of neratinib in older adults with HER2 amplified or HER2/3 mutated metastatic breast cancer
T2  - J Geriatr Oncol
TI  - Phase II study of neratinib in older adults with HER2 amplified or HER2/3 mutated metastatic breast cancer
ID  - 2
ER  - 

TY  - JOUR
AB  - LESSONS LEARNED: The safety and activity findings of abiraterone acetate plus prednisone treatment in black men with mCRPC were similar to results from previously conducted studies with largely white populations.Poor trial accrual continues to be a challenge in black men with mCRPC and further efforts are needed to address such underrepresentation. BACKGROUND: Self-identified black men have higher incidence and mortality from prostate cancer in the United States compared with white men but are dramatically underrepresented in clinical trials exploring novel therapies for metastatic castration-resistant prostate cancer (mCRPC). METHODS: Black men with mCRPC were treated with abiraterone acetate (AA), 1,000 mg daily, and prednisone (P), 5 mg twice daily. The primary objective was to determine antitumor activity (defined by a ≥30% decline in prostate-specific antigen [PSA] level) and to correlate germline polymorphisms in androgen metabolism genes with antitumor activity. Secondary objectives included determining safety, post-treatment changes in measurable disease, and time to disease progression. RESULTS: From April 2013 to March 2016, a total of 11 black men were enrolled and received AA plus P (AA+P); 7 of 10 evaluable patients were docetaxel naive. Post-treatment declines in PSA level of ≥30% were achieved in 90% of patients. The side effect profile was consistent with prior clinical trials exploring AA+P in mCRPC. Due to poor accrual, the study was closed prematurely with insufficient sample size for the planned pharmacogenetic analyses. CONCLUSION: In this small prospective study terminated for poor accrual, the safety and activity of AA+P in black men with mCRPC was similar to that reported in prior studies exploring AA in largely white populations. Further efforts are needed to address underrepresentation of black men in mCRPC trials.
Publisher: Abstract available from the publisher.
chi
AD  - Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA matthew.galsky@mssm.edu.
Department of Urology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Queens Hospital Center, Jamaica, New York, USA.
AN  - 27742908
AU  - Tsao, C. K.
AU  - Sfakianos, J.
AU  - Liaw, B.
AU  - Gimpel-Tetra, K.
AU  - Kemeny, M.
AU  - Bulone, L.
AU  - Shahin, M.
AU  - Oh, W. K.
AU  - Galsky, M. D.
C2  - PMC5153336
DA  - Dec
DO  - 10.1634/theoncologist.2016-0026
DP  - NLM
ET  - 2016/10/16
IS  - 12
KW  - Abiraterone Acetate/administration & dosage/adverse effects
African Continental Ancestry Group
Aged
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Humans
Male
Middle Aged
Neoplasm Metastasis
Prednisone/administration & dosage/adverse effects
Prospective Studies
Prostatic Neoplasms, Castration-Resistant/*drug therapy/ethnology/pathology
LA  - eng
N1  - 1549-490x
Tsao, Che-Kai
Sfakianos, John
Liaw, Bobby
Gimpel-Tetra, Kiev
Kemeny, Margaret
Bulone, Linda
Shahin, Mohammad
Oh, William Kyu
Galsky, Matthew David
Clinical Trial, Phase II
Journal Article
Research Support, Non-U.S. Gov't
Oncologist. 2016 Dec;21(12):1414-e9. doi: 10.1634/theoncologist.2016-0026. Epub 2016 Oct 14.
PY  - 2016
SN  - 1083-7159 (Print)
1083-7159
SP  - 1414-e9
ST  - Phase II Trial of Abiraterone Acetate Plus Prednisone in Black Men With Metastatic Prostate Cancer
T2  - Oncologist
TI  - Phase II Trial of Abiraterone Acetate Plus Prednisone in Black Men With Metastatic Prostate Cancer
VL  - 21
ID  - 200
ER  - 

TY  - JOUR
AB  - e16028 Background: In metastatic CRPC, second line therapy after docetaxel, remains a currently unmet need. Based on the efficacy and tolerability of S and B in prostate cancer, and the clinical synergy noted between chemotherapy and B, a phase II trial of the combination was conducted.Methods: Metastatic CRPC patients, with prior docetaxel based chemotherapy were eligible to receive S 80 mg/m2 orally for days 1-5, and B 10 mg/kg on day 1, and 15mg/kg on day 15 of each 35 day cycle. Prednisone was administered at a dose of 5 mg twice daily. Response was assessed every 2 cycles. Toxicity was assessed weekly during cycle 1 and on days 1 and 15 of each subsequent cycle. Primary endpoint was time to progression defined as a skeletal event, new areas of metastases on bone scans or per RECIST criteria for measurable disease.Results: 19 of 28 patients have been enrolled to date; 7 African American and 12 Caucasian,, with median age of 68.5 years and median pretherapy PSA of 137.8 ng/mL (range 16.8-994 ng/mL). 7 (44%) had bone pain, Gleason score of 7 and ≥ 8 in 7 and 12 patients respectively. Measurable disease progression was noted in 5 patients, bone scan progression in 6 patients, progression of both in 3 patients, and PSA only progression in 5 patients. 76 cycles have been administered; 7 patients continued on therapy beyond 6 cycles. The only grade 4 toxicity noted was pulmonary embolism in 2 patients, after 2 and 6 cycles of therapy. Grade 3 neutropenia, gastrointestinal toxicity, and electrolyte abnormalities were noted in 1 patient each. There were no treatment related deaths. 16/19 patients are response evaluable. 7 patients had a PSA decline of which 4 patients had a ≥30% PSA decline. 3 of 6 patients had a measurable disease response. 11 of 16 patients have progressed to date after median of 6 cycles of therapy. Time to progression and survival data will be reported.Conclusions: The combination was well tolerated, and revealed preliminary evidence of clinical efficacy in docetaxel pretreated metastatic CRPC. [Table: see text].
AD  - Wayne State University/Karmanos Cancer Institute, Detroit, MI; Wayne State University, Detroit, MI
AN  - 120351504. Language: English. Entry Date: In Process. Revision Date: 20161223. Publication Type: journal article. Supplement Title: 5/21/2009 Supplement Part 1 of 2. Journal Subset: Biomedical
AU  - Vaishampayan, U. N.
AU  - Heilbrun, L. K.
AU  - Heath, E. I.
AU  - Smith, D. W.
AU  - Dickow, B.
AU  - Baranowski, K.
AU  - Powell, I.
AU  - Fontana, J.
DB  - CINAHL Complete
DP  - EBSCOhost
N1  - Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA. NLM UID: 8309333.
PMID: NLM27962967.
PY  - 2009
SN  - 0732-183X
SP  - e16028-e16028
ST  - Phase II trial of bevacizumab (B) and oral satraplatin (S) and prednisone in docetaxel pretreated metastatic castrate resistant prostate cancer (CRPC)
T2  - Journal of Clinical Oncology
TI  - Phase II trial of bevacizumab (B) and oral satraplatin (S) and prednisone in docetaxel pretreated metastatic castrate resistant prostate cancer (CRPC)
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=120351504&site=ehost-live&scope=site
VL  - 27
ID  - 2021
ER  - 

TY  - JOUR
AB  - Current chemotherapy for patients with advanced colorectal cancer is relatively ineffective and may be associated with significant toxicity. Bryostatin 1 (bryo 1) influences cell proliferation, intracellular metabolism and signaling, differentiation, and apoptosis in human cancer cell lines via modulation of protein kinase C (PKC) activity. This trial investigates the efficacy and toxicity of bryo 1 as a novel therapeutic agent for patients with advanced colorectal cancer who have had previous 5-fluorouracil therapy. The primary end point was tumor response to bryo 1. Toxicity was also assessed. Twenty-eight patients with advanced colorectal cancer were enrolled. The mean age was 59 years (range, 38-76), with 16 men and 12 women, and good minority representation (11 African-Americans). The first 10 patients initially received 25 microg/m2 of bryo 1 weekly as a 24-h infusion for 3 weeks of every 4-week cycle, with dose escalation to 35 microg/m2 starting with the second cycle. The remaining patients were started at 35 microg/m2 and escalated to 40 microg/m2, if toxicity was minimal. Twenty-five patients were evaluable for objective tumor response, and complete data on toxicity were collected on 26 patients. No partial or complete tumor responses were observed. All 25 patients had disease progression within four cycles. Myalgia was the most common toxicity. Myelosuppression was not seen. bryo 1 as a weekly 24-h continuous infusion lacks single-agent antitumor activity in advanced colorectal cancer. Toxicity differs from that of traditional chemotherapeutic drugs.
AD  - Division of Hematology and Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan 48201, USA.
AN  - 11205915
AU  - Zonder, J. A.
AU  - Shields, A. F.
AU  - Zalupski, M.
AU  - Chaplen, R.
AU  - Heilbrun, L. K.
AU  - Arlauskas, P.
AU  - Philip, P. A.
DA  - Jan
DP  - NLM
ET  - 2001/02/24
IS  - 1
KW  - Adult
Aged
Antineoplastic Agents/adverse effects/*therapeutic use
Bryostatins
Colorectal Neoplasms/*drug therapy/pathology
Female
Humans
Infusions, Intravenous
Lactones/adverse effects/*therapeutic use
Macrolides
Male
Middle Aged
Neoplasm Metastasis
Treatment Outcome
LA  - eng
N1  - Zonder, J A
Shields, A F
Zalupski, M
Chaplen, R
Heilbrun, L K
Arlauskas, P
Philip, P A
CA-22453/CA/NCI NIH HHS/United States
Clinical Trial
Clinical Trial, Phase II
Journal Article
Research Support, U.S. Gov't, P.H.S.
United States
Clin Cancer Res. 2001 Jan;7(1):38-42.
PY  - 2001
SN  - 1078-0432 (Print)
1078-0432
SP  - 38-42
ST  - A phase II trial of bryostatin 1 in the treatment of metastatic colorectal cancer
T2  - Clin Cancer Res
TI  - A phase II trial of bryostatin 1 in the treatment of metastatic colorectal cancer
VL  - 7
ID  - 690
ER  - 

TY  - JOUR
AB  - OBJECTIVE: To conduct a phase II trial of the combination of carboplatin, prednisone, and everolimus in metastatic castrate-resistant prostate cancer (mCRPC) as mTOR inhibition can overcome resistance to chemotherapy in prostate cancer. METHODS: Patients with progressive mCRPC pretreated with docetaxel-based regimen were eligible. Performance status of 0-1 and adequate bone marrow, renal, and liver function were required. Primary end point was time to progression. Treatment consisted of carboplatin (starting dose equal to area under the curve (AUC of 5) intravenously every 21 days along with oral everolimus 5 mg once daily and prednisone 5 mg twice daily. RESULTS: Twenty-six patients were enrolled with median age of 69 years with 8 patients of African American origin. Grade 3 or 4 thrombocytopenia or neutropenia in 4 of 6 initial patients required dose adjustment of carboplatin to AUC of 4 for subsequent patients. There were no pharmacokinetic interactions between carboplatin and everolimus. The median time to progression was 2.5 months (90% confidence interval [CI], 1.8-4.3 months), and median overall survival was 12.5 months (90% CI, 7.7-18.7 months). Of 10 patients, 8 that demonstrated positive nuclear phosphorylated AKT (pAKT) staining on immunohistochemistry progressed within 9 weeks, whereas 2 patients with negative staining continued without progression for prolonged durations of 30 and 48 weeks. TSC1 gene mutations did not correlate with clinical outcome. CONCLUSION: The addition of the mTOR inhibitor everolimus to carboplatin demonstrated minimal clinical efficacy in metastatic prostate cancer. pAKT testing warrants further evaluation as a predictive marker of response to everolimus therapy.
AD  - Department of Oncology, Department of Medicine, Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, MI. Electronic address: vaishamu@karmanos.org.
Department of Oncology, Northshore University Health System, Evanston, IL.
Department of Oncology, Cancer Institute of New Jersey, New Brunswick, NJ.
Department of Oncology, Biostatistics Core, Barbara Ann Karmanos Cancer Institute, Detroit, MI.
Department of Oncology, John D. Dingell Veterans Medical Center, Detroit, MI.
Department of Oncology, Department of Medicine, Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, MI.
AN  - 26375845
AU  - Vaishampayan, U.
AU  - Shevrin, D.
AU  - Stein, M.
AU  - Heilbrun, L.
AU  - Land, S.
AU  - Stark, K.
AU  - Li, J.
AU  - Dickow, B.
AU  - Heath, E.
AU  - Smith, D.
AU  - Fontana, J.
C2  - PMC6902637
C6  - NIHMS1061562
DA  - Dec
DO  - 10.1016/j.urology.2015.08.008
DP  - NLM
ET  - 2015/09/17
IS  - 6
KW  - Adenocarcinoma/*drug therapy/*secondary
Aged
Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use
Carboplatin/administration & dosage/pharmacokinetics
Disease Progression
Docetaxel
Everolimus/administration & dosage/pharmacokinetics
Humans
Male
Neoplastic Cells, Circulating
Phosphorylation
Prednisone/administration & dosage
Prostate-Specific Antigen/blood
Prostatic Neoplasms, Castration-Resistant/chemistry/*drug therapy/*pathology
Proto-Oncogene Proteins c-akt/analysis/metabolism
Survival Rate
TOR Serine-Threonine Kinases/analysis
Taxoids/administration & dosage
Tuberous Sclerosis Complex 1 Protein
Tumor Suppressor Proteins/genetics
LA  - eng
N1  - 1527-9995
Vaishampayan, Ulka
Shevrin, Daniel
Stein, Mark
Heilbrun, Lance
Land, Susan
Stark, Karri
Li, Jing
Dickow, Brenda
Heath, Elisabeth
Smith, Daryn
Fontana, Joseph
P30 CA022453/CA/NCI NIH HHS/United States
CA-22453/CA/NCI NIH HHS/United States
Clinical Trial, Phase II
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Urology. 2015 Dec;86(6):1206-11. doi: 10.1016/j.urology.2015.08.008. Epub 2015 Sep 12.
PY  - 2015
SN  - 0090-4295 (Print)
0090-4295
SP  - 1206-11
ST  - Phase II Trial of Carboplatin, Everolimus, and Prednisone in Metastatic Castration-resistant Prostate Cancer Pretreated With Docetaxel Chemotherapy: A Prostate Cancer Clinical Trial Consortium Study
T2  - Urology
TI  - Phase II Trial of Carboplatin, Everolimus, and Prednisone in Metastatic Castration-resistant Prostate Cancer Pretreated With Docetaxel Chemotherapy: A Prostate Cancer Clinical Trial Consortium Study
VL  - 86
ID  - 231
ER  - 

TY  - JOUR
AB  - BACKGROUND: Early chemohormonal therapy in metastatic prostate cancer may offer an advantage by simultaneously targeting androgen-dependent and -independent clones. Hence, a phase II trial was conducted to evaluate the efficacy and toxicity of estramustine and etoposide in hormone-sensitive metastatic prostate cancer. PATIENT AND METHODS: Eligibility consisted of untreated metastatic prostate cancer, adequate organ function, and a performance status of 0 to 2 by Zubrod criteria. A 21-day schedule of oral estramustine (10 mg/kg/day) and etoposide (50 mg/m2/day) was administered every 28 days. Hormonal therapy was allowed at the end of the protocol therapy. Toxicity was assessed weekly, PSA levels were assessed with each cycle, and objective response was evaluated every 3 cycles. RESULTS: Twenty-one patients were enrolled (10 white, 11 black) with a median age of 59.5 years (range, 42-79 years), a median PSA of 338 ng/mL (range, 0.9-20,000 ng/mL), and a median Gleason score of 8 points. Ten patients had bone-only metastases, 11 had measurable disease, of whom 4 had visceral metastases. A total of 128 cycles were administered (median, 6 cycles). No dose reductions were required. Nineteen patients were able to be evaluated for response. Severe toxicities included thromboembolic events and anemia in 2 patients each and fatigue in 1 patient. There were no episodes of febrile neutropenia. Response was observed in 8 of 11 patients (73%) with measurable disease. Median PSA nadir after therapy was 0.45 ng/mL, and undetectable PSA (<0.1 ng/mL) was achieved in 4 patients. Median time to PSA progression was 16.65 months. At a median follow-up of 34 months, 18 patients were alive. The 1-, 2-, and 3-year overall survival rates were 90%, 82%, and 72% respectively. Median survival has not yet been reached. CONCLUSION: The combination of estramustine and etoposide is well tolerated, and has promising activity in newly diagnosed metastatic prostate cancer.
AD  - Division of Hematology/Oncology, Barbara Ann Karmanos Cancer Institute and Wayne State University, Detroit, Michiga, USA.
AN  - 15577431
AU  - Vaishampayan, U.
AU  - Fontana, J.
AU  - Du, W.
AU  - Hussain, M.
DA  - Dec
DO  - 10.1097/01.coc.0000135922.12198.e4
DP  - NLM
ET  - 2004/12/04
IS  - 6
KW  - Adult
Aged
Antineoplastic Agents, Hormonal/administration & dosage
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Estramustine/administration & dosage
Etoposide/administration & dosage
Humans
Male
Middle Aged
Neoplasm Metastasis
Neoplasms, Hormone-Dependent/*drug therapy/pathology
Prostatic Neoplasms/*drug therapy/pathology
Survival Rate
LA  - eng
N1  - 1537-453x
Vaishampayan, Ulka
Fontana, Joseph
Du, Wei
Hussain, Maha
Clinical Trial
Clinical Trial, Phase II
Journal Article
Research Support, Non-U.S. Gov't
United States
Am J Clin Oncol. 2004 Dec;27(6):550-4. doi: 10.1097/01.coc.0000135922.12198.e4.
PY  - 2004
SN  - 0277-3732
SP  - 550-4
ST  - Phase II trial of estramustine and etoposide in androgen-sensitive metastatic prostate carcinoma
T2  - Am J Clin Oncol
TI  - Phase II trial of estramustine and etoposide in androgen-sensitive metastatic prostate carcinoma
VL  - 27
ID  - 613
ER  - 

TY  - JOUR
AB  - PURPOSE: We sought to evaluate the activity and tolerance of the rationally designed sequence of paclitaxel-topotecan-etoposide, a nonplatinum regimen, as induction therapy for limited-stage small-cell lung cancer before combined chemo- and radiotherapy. PATIENTS AND METHODS: Patients with measurable disease, performance status 0 to 2, no prior therapy, and adequate organ function were eligible. Paclitaxel (110 mg/m2, administered intravenously on day 1), topotecan (1.5 mg/m2, administered orally on days 2 to 4), and etoposide (160 mg/m2, administered orally on days 5 to 7 every 21 days), with filgrastim for two cycles, were followed by chest irradiation to 70 Gy (to postinduction tumor volume) concurrent with carboplatin (area under the curve of 5, administered intravenously on day 1) and etoposide (100 mg/m2 on days 1 to 3 every 21 days) without filgrastim for three cycles (five chemotherapy cycles total). We aimed to determine the response rates to induction and overall therapy, overall and failure-free survival, and toxicity. The primary statistical endpoint was to differentiate between complete response rates of 50 and 70% for the overall treatment program. RESULTS: Between June 2001 and January 2003, 65 patients were enrolled, but one never started therapy, and one was ineligible. Patient characteristics included male/female, 27/36; white/black/other/unknown, 58/3/1/1; median age 62 (range, 38-78); performance status 0/1/2, 27/33/3. Induction chemotherapy resulted in six (10%) complete responses and 35 (56%) partial responses. Overall response to chemoradiotherapy included 27 (43%; 95% confidence interval [CI] 30-56%) complete responses and 24 (38%) partial responses. Median progression-free survival is 12 months (95% CI, 9-15 months). Median overall survival is 20 months (95% CI, 16-24 months). Frequent (>20%) grade 3/4 toxicities during all therapy included neutropenia, febrile neutropenia, anemia, thrombocytopenia, fatigue, and dysphagia. One patient died of febrile neutropenia, one died of febrile neutropenia and typhlitis, and one patient who declined transfusion for anemia died of cardiac ischemia. CONCLUSIONS: This treatment regimen has significant activity in limited-stage small-cell lung cancer but did not meet our prospectively defined criteria for further investigation in this setting. The addition of etoposide and the use of a sequenced administration schedule did not seem to improve overall activity beyond our prior experience with a topotecan-paclitaxel doublet.
AD  - Comprehensive Cancer Center, Wake Forest University, Winston-Salem, North Carolina, USA. aamiller@wfubmc.edu
AN  - 17607121
AU  - Miller, A. A.
AU  - Wang, X. F.
AU  - Bogart, J. A.
AU  - Hodgson, L. D.
AU  - Rocha Lima, C. M.
AU  - Radford, J. E.
AU  - Vokes, E. E.
AU  - Green, M. R.
DA  - Jul
DO  - 10.1097/JTO.0b013e318074bbf5
DP  - NLM
ET  - 2007/07/04
IS  - 7
KW  - Adult
Aged
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Carcinoma, Small Cell/drug therapy/radiotherapy/*therapy
Combined Modality Therapy
Dose-Response Relationship, Drug
Etoposide/administration & dosage
Female
Follow-Up Studies
Humans
Lung Neoplasms/drug therapy/radiotherapy/*therapy
Male
Middle Aged
Paclitaxel/administration & dosage
Retrospective Studies
Severity of Illness Index
Survival Rate
Topotecan/administration & dosage
Treatment Outcome
LA  - eng
N1  - 1556-1380
Miller, Antonius A
Wang, Xiaofei F
Bogart, Jeffrey A
Hodgson, Lydia D
Rocha Lima, Caio M S
Radford, James E
Vokes, Everett E
Green, Mark R
Cancer and Leukemia Group B (CALGB)
CA31946/CA/NCI NIH HHS/United States
CA33601/CA/NCI NIH HHS/United States
Clinical Trial, Phase II
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
United States
J Thorac Oncol. 2007 Jul;2(7):645-51. doi: 10.1097/JTO.0b013e318074bbf5.
PY  - 2007
SN  - 1556-0864
SP  - 645-51
ST  - Phase II trial of paclitaxel-topotecan-etoposide followed by consolidation chemoradiotherapy for limited-stage small cell lung cancer: CALGB 30002
T2  - J Thorac Oncol
TI  - Phase II trial of paclitaxel-topotecan-etoposide followed by consolidation chemoradiotherapy for limited-stage small cell lung cancer: CALGB 30002
VL  - 2
ID  - 519
ER  - 

TY  - JOUR
AB  - No effective therapy has been demonstrated for hormone refractory prostate cancer (HRPC). Pyrazine diazohydroxide (PZDH) is a novel antineoplastic agent with a broad range of activity in preclinical studies and a moderate toxicity profile in Phase I trials. We undertook a Phase II study of PZDH in HRPC utilizing decline in PSA as the primary end point. Fifteen patients were enrolled, median age of 70 (55-86), median pretherapy PSA 206 ng/ml (range 42-10,000). Four patients were African American. Sites of disease: bone only 7, soft tissue only 2, both 6. All were evaluable for toxicity and response. PZDH was administered at 250 mg/m2 i.v. every three weeks. The median number of cycles administered was two (range 1-6). Toxicity was mild, with only one patient manifesting serious (grade 3-4) toxicity. Unfortunately, activity was minimal with only a single patient demonstrating a >75% decline in PSA. As this patient's PSA began to rise almost immediately the response was considered transient and not felt to justify pursuing a second stage of the trial. Supporting this conclusion was the disappointing median survival of 220 days. In summary, we conclude that PZDH, while well tolerated at this dose and schedule has only minimal activity in HRPC.
AD  - Division of Hematology/Oncology, UC Davis School of Medicine, Sacramento, CA, USA.
AN  - 9848583
AU  - Edelman, M. J.
AU  - Meyers, F. J.
AU  - Grennan, T.
AU  - Lauder, J.
AU  - Doroshow, J.
DO  - 10.1023/a:1006097109088
DP  - NLM
ET  - 1998/12/16
IS  - 2
KW  - Aged
Androgens/*physiology
Antineoplastic Agents/therapeutic use
Drug Resistance, Neoplasm
Humans
Male
Middle Aged
Prostatic Neoplasms/*drug therapy
Pyrazines/*therapeutic use/toxicity
Survival Rate
LA  - eng
N1  - Edelman, M J
Meyers, F J
Grennan, T
Lauder, J
Doroshow, J
CA 63265/CA/NCI NIH HHS/United States
Clinical Trial
Clinical Trial, Phase II
Journal Article
Research Support, U.S. Gov't, P.H.S.
United States
Invest New Drugs. 1998;16(2):179-82. doi: 10.1023/a:1006097109088.
PY  - 1998
SN  - 0167-6997 (Print)
0167-6997
SP  - 179-82
ST  - Phase II trial of pyrazine diazohydroxide in androgen-independent prostate cancer
T2  - Invest New Drugs
TI  - Phase II trial of pyrazine diazohydroxide in androgen-independent prostate cancer
VL  - 16
ID  - 723
ER  - 

TY  - JOUR
AB  - Background: Rigosertib (ON 01910.Na), a first-in-class Ras mimetic and small-molecule inhibitor of multiple signaling pathways including polo-like kinase 1 (PLK1) and phosphoinositide 3-kinase (PI3K), has shown efficacy in preclinical pancreatic cancer models. In this study, rigosertib was assessed in combination with gemcitabine in patients with treatment-naïve metastatic pancreatic adenocarcinoma. Materials and methods: Patients with metastatic pancreatic adenocarcinoma were randomized in a 2:1 fashion to gemcitabine 1000 mg/m2 weekly for 3 weeks of a 4-week cycle plus rigosertib 1800 mg/m2 via 2-h continuous IV infusions given twice weekly for 3 weeks of a 4-week cycle (RIG + GEM) versus gemcitabine 1000 mg/m2 weekly for 3 weeks in a 4-week cycle (GEM). Results: A total of 160 patients were enrolled globally and randomly assigned to RIG + GEM (106 patients) or GEM (54). The most common grade 3 or higher adverse events were neutropenia (8% in the RIG + GEM group versus 6% in the GEM group), hyponatremia (17% versus 4%), and anemia (8% versus 4%). The median overall survival was 6.1 months for RIG + GEM versus 6.4 months for GEM [hazard ratio (HR), 1.24; 95% confidence interval (CI) 0.85-1.81]. The median progression-free survival was 3.4 months for both groups (HR = 0.96; 95% CI 0.68-1.36). The partial response rate was 19% versus 13% for RIG + GEM versus GEM, respectively. Of 64 tumor samples sent for molecular analysis, 47 were adequate for multiplex genetic testing and 41 were positive for mutations. The majority of cases had KRAS gene mutations (40 cases). Other mutations detected included TP53 (13 cases) and PIK3CA (1 case). No correlation between mutational status and efficacy was detected. Conclusions: The combination of RIG + GEM failed to demonstrate an improvement in survival or response compared with GEM in patients with metastatic pancreatic adenocarcinoma. Rigosertib showed a similar safety profile to that seen in previous trials using the IV formulation.
AD  - W.A. Messersmith, Division of Medical Oncology, GI Medical Oncology Program, Developmental Therapeutics Program, University of Colorado Cancer Center, University of Colorado School of Medicine, Mailstop 8117, 12801 East 17th Ave., L18-8124, Aurora, CO, United States
AU  - O'Neil, B. H.
AU  - Scott, A. J.
AU  - Ma, W. W.
AU  - Cohen, S. J.
AU  - Aisner, D. L.
AU  - Menter, A. R.
AU  - Tejani, M. A.
AU  - Cho, J. K.
AU  - Granfortuna, J.
AU  - Coveler, L.
AU  - Olowokure, O. O.
AU  - Baranda, J. C.
AU  - Cusnir, M.
AU  - Phillip, P.
AU  - Boles, J.
AU  - Nazemzadeh, R.
AU  - Rarick, M.
AU  - Cohen, D. J.
AU  - Radford, J.
AU  - Fehrenbacher, L.
AU  - Bajaj, R.
AU  - Bathini, V.
AU  - Fanta, P.
AU  - Berlin, J.
AU  - McRee, A. J.
AU  - Maguire, R.
AU  - Wilhelm, F.
AU  - Maniar, M.
AU  - Jimeno, A.
AU  - Gomes, C. L.
AU  - Messersmith, W. A.
C1  - on 01910
DB  - Embase
Medline
DO  - 10.1093/annonc/mdv264
IS  - 9
KW  - gemcitabine
rigosertib
adult
African American
aged
anemia
article
Asian
Black person
Caucasian
continuous infusion
controlled study
correlation analysis
decreased appetite
diarrhea
drug efficacy
drug safety
drug withdrawal
fatigue
female
gene
gene mutation
genetic analysis
hazard ratio
Hispanic
human
human tissue
hypertransaminasemia
hypoalbuminemia
hyponatremia
liver metastasis
lung metastasis
major clinical study
male
multicenter study
multiple cycle treatment
nausea
neutropenia
oncogene K ras
overall survival
pancreas adenocarcinoma
peritoneum metastasis
phase 2 clinical trial
phase 3 clinical trial
PIK3CA gene
priority journal
progression free survival
randomized controlled trial
retroperitoneal cancer
thrombocytopenia
treatment response
tumor suppressor gene
very elderly
vomiting
on 01910
LA  - English
M3  - Article
N1  - L606045592
2015-09-22
2020-03-23
PY  - 2015
SN  - 1569-8041
0923-7534
SP  - 1923-1929
ST  - A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer
T2  - Annals of Oncology
TI  - A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L606045592&from=export
http://dx.doi.org/10.1093/annonc/mdv264
VL  - 26
ID  - 996
ER  - 

TY  - JOUR
AB  - Purpose This trial was conducted to determine the optimal duration of chemotherapy in Korean patients with advanced non - small-cell lung cancer (NSCLC). Patients and Methods Patients with stages IIIB to IV NSCLC who had not progressed after two cycles of chemotherapy were randomly assigned to receive either four (arm A) or two (arm B) more cycles of third-generation, platinum-doublet treatment. Results Of the 452 enrolled patients, 314 were randomly assigned to the groups. One-year survival rates were 59.0% in arm A and 62.4% in arm B, and the difference of 3.4% (95% Cl, -8.0 to 4.8) met the predefined criteria for noninferiority. The median time to progression (TTP), however, was 6.2 months (95% Cl, 5.7 to 6.7 months) in arm A and 4.6 months (95% Cl, 4.4 to 4.8 months) in arm B, the difference of which is statistically significant (P = .001). The frequencies of hematologic and nonhematologic toxicities were similar in the two arms. Conclusion This study confirms the noninferiority of overall survival with four cycles compared with six cycles of chemotherapy for the first-line treatment of advanced NSCLC and supports the current American Society of Clinical Oncology guidelines. Notably, patients receiving six cycles of chemotherapy compared with four cycles showed a favorable TTP, suggesting that further investigation of the new strategies of maintenance therapy with less toxic agents after three to four cycles of induction chemotherapy might be warranted to improve survival, with consideration of both ethnicity and pharmacogenomic signatures.
AN  - WOS:000251074400016
AU  - Park, J. O.
AU  - Kim, S. W.
AU  - Ahn, J. S.
AU  - Suh, C.
AU  - Lee, J. S.
AU  - Jang, J. S.
AU  - Cho, E. K.
AU  - Yang, S. H.
AU  - Choi, J. H.
AU  - Heo, D. S.
AU  - Park, S. Y.
AU  - Shin, S. W.
AU  - Ahn, M. J.
AU  - Lee, J. S.
AU  - Yun, Y. H.
AU  - Lee, J. W.
AU  - Park, K.
DA  - Nov
DO  - 10.1200/JCO.2007.10.8134
IS  - 33
N1  - 18024869
PY  - 2007
SN  - 0732-183X
SP  - 5233-5239
ST  - Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non-small-cell lung cancer
T2  - Journal of Clinical Oncology
TI  - Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non-small-cell lung cancer
VL  - 25
ID  - 3182
ER  - 

TY  - JOUR
AB  - Filipino women (N = 530, mean age 63 years, predominantly low income) were recruited through various community based organizations and churches in Los Angeles County. All women were randomly invited to attend a single group session with a Filipino health educator to discuss breast and cervical cancer screening or the health benefits of exercise. At 3 months after the group session, the exercise assessment tool used in the National Health and Nutrition Examination Survey III was completed by 487 women (92 percent retention rate). This paper describes the pattern of physical activity among older Filipino-American women and a physical activity intervention specifically designed for this group. (C) 2002 by The Haworth Press, Inc. All rights reserved.
AN  - WOS:000177660000005
AU  - Maxwell, A. E.
AU  - Bastani, R.
AU  - Vida, P.
AU  - Warda, U. S.
DA  - 2002
DO  - 10.1300/J013v36n01_05
IS  - 1
N1  - 17
12215004
PY  - 2002
SN  - 0363-0242
SP  - 67-79
ST  - Physical activity among older Filipino-American women
T2  - Women & Health
TI  - Physical activity among older Filipino-American women
VL  - 36
ID  - 2705
ER  - 

TY  - JOUR
AB  - Physical activity has been associated with a lower risk of colorectal cancer. However, data is lacking on whether the association is consistent between sexes and across different races/ethnicities and anatomic subsites of tumors. We analyzed data from the Multiethnic Cohort in Hawaii and California, consisting of mostly African Americans, Native Hawaiians, Japanese Americans, Latinos, and whites ages 45–75 years at recruitment. During a mean follow-up of 16.8 years, 4,430 invasive adenocarcinoma cases of the colorectum were identified among 172,502 eligible participants. Cox proportional hazards models were used to estimate the HR and 95% confidence interval (CI). The multivariate-adjusted HR (95% CI) for the highest versus lowest quintiles of physical activity (metabolic equivalent hours of moderate or vigorous activities per day) was 0.76 (0.66–0.87) in men (Ptrend &lt; 0.001) and 0.94 (0.80–1.11) in women (Ptrend ¼ 0.53, Pheterogeneity by sex ¼ 0.07). Sleeping and sitting hours were not associated with colorectal cancer risk both in men and women. In men, the inverse association was statistically significant among African Americans and Japanese Americans, for right colon and rectal cancer, and in all body mass index groups, although heterogeneity tests were not significant across race/ethnicity or anatomic subsite of tumors. The findings confirm the inverse association between physical activity and colorectal cancer, which appears to be stronger in men, and suggest possible differences in the strength of the association by race/ethnicity and anatomic subsite of tumors. © 2019 American Association for Cancer Research.
AD  - Cancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, HI, United States
Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States
AU  - Park, S. Y.
AU  - Wilkens, L. R.
AU  - Haiman, C. A.
AU  - Marchand, L. L.
DB  - Scopus
DO  - 10.1158/1940-6207.CAPR-18-0452
IS  - 5
M3  - Article
N1  - Cited By :5
Export Date: 22 March 2021
PY  - 2019
SP  - 315-325
ST  - Physical activity and colorectal cancer risk by sex, race/ethnicity, and subsite: The multiethnic cohort study
T2  - Cancer Prevention Research
TI  - Physical activity and colorectal cancer risk by sex, race/ethnicity, and subsite: The multiethnic cohort study
UR  - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85065510192&doi=10.1158%2f1940-6207.CAPR-18-0452&partnerID=40&md5=9d8ec8cc5e6c73cf001f4a9617a9fcb7
VL  - 12
ID  - 2231
ER  - 

TY  - JOUR
AB  - Background: The present study sought to examine the influence of physical activity on quality of life and negative mood in a sample of Black breast cancer survivors to determine if physical activity (dichotomized) predicted mean differences in negative mood and quality of life in this population. Methods: Study participants include 114 women diagnosed with breast cancer (any stage of disease, any type of breast cancer) recruited to participate in an adaptive cognitive-behavioral stress management intervention. The mean body mass index of the sample at baseline was 31.39 (standard deviation = 7.17). Results: A multivariate analysis of covariance (MANCOVA) was conducted to determine if baseline physical activity predicted mean differences in negative mood and quality of life at baseline and at follow ups while controlling for relevant covariates. A one-way MANCOVA revealed a significant multivariate effect by physical activity group for the combined dependent variables at Time 2 (post 10-week intervention), p = .039. The second one-way MANCOVA revealed a significant multivariate effect at Time 3 (6 months after Time 2), p = .034. Specifically, Black breast cancer survivors who engaged in physical activity experienced significantly lower negative mood and higher social/family well-being at Time 2 and higher spiritual and functional well-being at Times 2 and 3. Conclusions: Results show that baseline physical activity served protective functions for breast cancer survivors over time. Developing culturally relevant physical activity interventions specifically for Black breast cancer survivors may prove vital to improving quality of life and mood in this population. Copyright (C) 2016 John Wiley & Sons, Ltd.
AN  - WOS:000405228100014
AU  - Diggins, A. D.
AU  - Hearn, L. E.
AU  - Lechner, S. C.
AU  - Annane, D.
AU  - Antoni, M. H.
AU  - Whitehead, N. E.
DA  - Jun
DO  - 10.1002/pon.4095
IS  - 6
N1  - 26923090
PY  - 2017
SN  - 1057-9249
SP  - 822-828
ST  - Physical activity in Black breast cancer survivors: implications for quality of life and mood at baseline and 6-month follow-up
T2  - Psycho-Oncology
TI  - Physical activity in Black breast cancer survivors: implications for quality of life and mood at baseline and 6-month follow-up
VL  - 26
ID  - 2897
ER  - 

TY  - JOUR
AB  - Self-reported health status in cancer patients is an independent predictor of medical outcomes. This study investigated the association between changes in recreational physical activity in colon cancer survivors and quality of life (QoL) across a 24-month follow-up beginning at diagnosis. Patients (n = 453) diagnosed with stage II colon cancer were recruited from the North Carolina Central Cancer Registry from 2009 to 2011. Patients were interviewed annually about health behaviors (e.g., dietary intake, physical activity, alcohol and tobacco use), socioeconomic variables, and treatment. To index QoL, the Functional Assessment of Cancer Therapy-Colorectal (FACT-C) and Short Form-12 (SF-12) were utilized. Baseline vigorous exercise showed a positive correlation with the Functional Assessment of Cancer Therapy-General (FACT-G) Colorectal Cancer Scale (CCS) (beta = 0.15, 95 % CI 0.07-0.23), FACT-C (beta = 0.39, 95 % CI 0.06-0.72), and Trial Outcome Index (TOI) (beta = 0.28, 95 % CI 0.01-0.55). Race modified the association between vigorous activity and the FACT-G (P (interaction) = 0.010), FACT-C (P (interaction) = 0.020), TOI (P (interaction) < 0.010), and the PCS (P (interaction) < 0.010). As compared to no change, increasing physical activity over a 24-month period following diagnosis significantly improved scores from the FACT-G (beta = 3.13, 95 % CI 0.48-5.77, P (trend) = 0.054), FACT-C (beta = 3.51, 95 % CI 0.35-6.68, P (trend) = 0.08) TOI (beta = 2.46, 95 % CI 0.16-4.75, P (trend) = 0.04), and PCS of the SF-12 (beta = 3.28, 95 % CI 0.93-5.63, P (trend) < 0.01). Vigorous exercise is a significant predictor of higher QoL in stage II colon cancer patients. Patients with increased recreational physical activity have significantly improved QoL over 24 months following diagnosis.
AN  - WOS:000341820000008
AU  - Lewis, C.
AU  - Xun, P. C.
AU  - He, K.
DA  - Oct
DO  - 10.1007/s11136-014-0679-7
IS  - 8
N1  - 24706291
PY  - 2014
SN  - 0962-9343
SP  - 2235-2246
ST  - Physical activity in relation to quality of life in newly diagnosed colon cancer patients: a 24-month follow-up
T2  - Quality of Life Research
TI  - Physical activity in relation to quality of life in newly diagnosed colon cancer patients: a 24-month follow-up
VL  - 23
ID  - 2997
ER  - 

TY  - JOUR
AB  - African American women report low participation in physical activity and are disproportionately burdened by related conditions (obesity, breast, and colon cancer). Physical activity interventions have shown promising results among African American women, but most studies in this area have focused on short-term increases. More enduring changes in health behavior will be needed to eliminate existing health disparities. Thus, the current study examined 12-month physical activity and psychosocial outcomes from a pilot randomized controlled trial (N = 84) of a Home-based Individually tailored Physical activity Print (HIPP) intervention for African American women in the Deep South. Retention was 77.4% at 12 months. HIPP participants increased self-reported moderate-to-vigorous physical activity from 35.1 minutes/week (standard deviation [SD] = 47.8) at baseline to 124 minutes/week (SD = 95.5) at 12 months, compared with the wellness contact control participants who reported increases from 48.2 minutes/week (SD = 51.3) to 102.5 minutes/week (SD = 94.5) over 12 months (between-group p > .05). Results indicate that modest improvements in moderate-to-vigorous physical activity and related psychosocial variables occurred during the active intervention phase (months 0-6) and were sustained during the tapered maintenance period (months 6-12). Low-cost, high-reach, home-based strategies have great potential for supporting sustained participation in physical activity and achieving long-term health benefits among African American women in the Deep South.
AD  - University of Alabama at Birmingham, Birmingham, AL, USA.
Brown University, Providence, RI, USA.
AN  - 30203677
AU  - Pekmezi, D.
AU  - Ainsworth, C.
AU  - Desmond, R.
AU  - Pisu, M.
AU  - Williams, V.
AU  - Wang, K.
AU  - Holly, T.
AU  - Meneses, K.
AU  - Marcus, B.
AU  - Demark-Wahnefried, W.
DA  - Mar
DO  - 10.1177/1524839918798819
DP  - NLM
ET  - 2018/09/12
IS  - 2
KW  - *Black/African American
*behavior change
*cancer prevention and control
*health disparities
*health promotion
*minority health
*physical activity/exercise
*women’s health
LA  - eng
N1  - Pekmezi, Dori
Ainsworth, Cole
Desmond, Renee
Pisu, Maria
Williams, Victoria
Wang, Kaiying
Holly, Taylor
Meneses, Karen
Marcus, Bess
Demark-Wahnefried, Wendy
UL1 TR001417/TR/NCATS NIH HHS/United States
T32 HL105349/HL/NHLBI NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
United States
Health Promot Pract. 2020 Mar;21(2):268-276. doi: 10.1177/1524839918798819. Epub 2018 Sep 11.
PY  - 2020
SN  - 1524-8399 (Print)
1524-8399
SP  - 268-276
ST  - Physical Activity Maintenance Following Home-Based, Individually Tailored Print Interventions for African American Women
T2  - Health Promot Pract
TI  - Physical Activity Maintenance Following Home-Based, Individually Tailored Print Interventions for African American Women
VL  - 21
ID  - 105
ER  - 

TY  - JOUR
AB  - BACKGROUND: Identifying modifiable factors that influence the epidemiology of colorectal cancer incidence among multiethnic groups might be informative for the development of public health strategies targeting the disease. Minimal data exists describing the impact of physical activity on colorectal polyp risk in United States minority populations. The aim of this study is to evaluate the relationship of exercise on the prevalence of polyps in a multiethnic colorectal cancer screening population. RESULTS: We enrolled 982 patients: 558 Hispanic, 202 Asian,149 Black, and 69 White. Patients who reported exercising one or more hours weekly had a lower prevalence of any polyps (25.3% vs 33.2%, P = 0.008) as well as adenomas (13.8 vs. 18.9%, P = 0.03) compared to those who did not exercise. Black and Hispanic patients and those who were overweight or obese also had lower prevalence of polyps if they led an active lifestyle. Multivariate analysis revealed that age >55, male sex, and Black race/ethnicity were positively associated with the presence of adenomas, while a history of exercising one hour or more weekly was an independent negative predictor for the presence of adenomas anywhere in the colon (OR 0.67; 95% CI 0.4 - 0.9, P = 0.03). CONCLUSIONS: Exercising one hour per week was associated with a lower prevalence of polyps and adenomas when compared to those who exercised less or not at all. An active lifestyle provides benefits to groups who are at risk for colorectal cancer, such as Blacks. It also provides significant protection to overweight and obese individuals. Public health initiatives should promote physical activity as a cancer prevention tool in multiethnic populations. TRIAL REGISTRATION: none.
AD  - Memorial Sloan Kettering Cancer Center, New York, NY, USA. sanchezn@mskcc.org
AN  - 22715975
AU  - Sanchez, N. F.
AU  - Stierman, B.
AU  - Saab, S.
AU  - Mahajan, D.
AU  - Yeung, H.
AU  - Francois, F.
C2  - PMC3437999
DA  - Jun 20
DO  - 10.1186/1756-0500-5-312
DP  - NLM
ET  - 2012/06/22
KW  - Adenoma/*ethnology/*prevention & control
African Americans/statistics & numerical data
Age Factors
Asian Americans/statistics & numerical data
Chi-Square Distribution
Colonic Polyps/*ethnology/*prevention & control
Colonoscopy
Colorectal Neoplasms/*ethnology/*prevention & control
Ethnic Groups/*statistics & numerical data
European Continental Ancestry Group/statistics & numerical data
*Exercise
Female
Hispanic Americans/statistics & numerical data
Humans
Logistic Models
Male
*Mass Screening/methods
Middle Aged
Multivariate Analysis
New York City/epidemiology
Obesity/ethnology
Odds Ratio
Overweight/ethnology
Prevalence
Prospective Studies
Risk Assessment
Risk Factors
*Risk Reduction Behavior
Sex Factors
Urban Health/ethnology
LA  - eng
N1  - 1756-0500
Sanchez, Nelson F
Stierman, Bryan
Saab, Said
Mahajan, Divya
Yeung, Howa
Francois, Fritz
1UL1RR029893/RR/NCRR NIH HHS/United States
Comparative Study
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
BMC Res Notes. 2012 Jun 20;5:312. doi: 10.1186/1756-0500-5-312.
PY  - 2012
SN  - 1756-0500
SP  - 312
ST  - Physical activity reduces risk for colon polyps in a multiethnic colorectal cancer screening population
T2  - BMC Res Notes
TI  - Physical activity reduces risk for colon polyps in a multiethnic colorectal cancer screening population
VL  - 5
ID  - 364
ER  - 

TY  - JOUR
AB  - Background: The purpose of this study was to examine the associations between physician-patient discussions, demographic and health-related variables, and PSA test use. Of the previous studies that examined physician-patient discussions about PSA test use, none focused on African-American men. Methods: Using a sample of African-American men (N=739) aged ≥40 years who had participated in the National Health Interview Survey (NHIS) 2000, we assessed demographic, health status and other variables related to two PSA test use outcomes: 1) had a PSA test within the past year, and 2) had ≥3 PSA tests within the past five years. Results: More than three-fourths (76.6%) of our sample reported that their doctors had discussed with them the advantages and disadvantages of the PSA test before administering it. The bivariate analysis showed a number of variables positively associated with PSA test use including men aged ≥50, having health insurance coverage and having participated in physician-patient discussions about the test. Discussion: Despite the high percentage of men who had discussions with their doctor, there was a large number of men who had neither heard of nor undergone a PSA test. More efforts should be made by the healthcare community to promote prostate cancer screening education and physician-patient discussions.
AD  - B.B. Tannor, Division of Cancer Prevention and Control, Centers for Disease Control and Prevention, 4770 Buford Highway, NE (K-55), Atlanta, GA 30341-3717, United States
AU  - Tannor, B. B.
AU  - Ross, L.
DB  - Embase
Medline
IS  - 4
KW  - prostate specific antigen
adult
aged
antigen detection
article
cancer screening
community care
demography
disease association
doctor patient relationship
education program
funding
health insurance
human
interview
major clinical study
male
multivariate analysis
patient participation
priority journal
prostate cancer
LA  - English
M3  - Article
N1  - L43535362
2006-04-27
PY  - 2006
SN  - 0027-9684
SP  - 532-538
ST  - Physician-patient discussions about prostate-specific antigen test use among African-American men
T2  - Journal of the National Medical Association
TI  - Physician-patient discussions about prostate-specific antigen test use among African-American men
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L43535362&from=export
VL  - 98
ID  - 1249
ER  - 

TY  - JOUR
AB  - OBJECTIVE: Vasomotor symptoms (VMS), sleep disturbance, and cognitive complaints are common among women with a history of breast cancer and contribute to decreased quality of life. Studies in healthy women showed an association between verbal memory performance and physiologic VMS measured with ambulatory skin conductance monitors but not with VMS by self-report. We hypothesized that we would find a similar association in women with breast cancer. METHODS: Participants included 30 female breast cancer survivors (mean age 52.7 y; 26.7% African-American) with moderate-to-severe VMS enrolled in a larger clinical trial of a nonhormonal intervention for VMS. At baseline, participants completed assessments of physiologic VMS, actigraphy-based assessments of sleep, questionnaires about mood, and two tests of verbal memory - Logical Memory (LM) and the California Verbal Learning Test (CVLT). Using baseline data, we conducted multivariate regression analyses to examine the association between VMS and memory, controlling for sleep and other factors. RESULTS: On average, women reported 46% of total physiologic VMS. A higher frequency of physiologic VMS - but not reported VMS - was significantly associated with lower scores on the California Verbal Learning Test short-delay free recall (r[28] = -0.41, P = 0.03), long-delay free recall (r[28] = -0.42, P = 0.03), and total clustering, (r[28] = -0.39, P = 0.04). These associations were independent of sleep, mood, and other factors. CONCLUSIONS: Independent of their effect on sleep, VMS may be a modifiable contributor to memory difficulties in women with breast cancer. These findings underscore the importance of objective measurement of VMS in cognitive studies. : Video Summary:http://links.lww.com/MENO/A623.
AD  - Department of Psychology, University of Illinois, Chicago, IL.
Department of Neurology and Psychiatry, Johns Hopkins School of Medicine, Baltimore, MD.
Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.
Department of Anesthesiology, Northwestern University Feinberg School of Medicine, Chicago, IL.
Department of Psychiatry, University of Illinois at Chicago, Chicago, IL.
Department of Obstetrics & Gynecology, University of Illinois at Chicago, Chicago, IL.
AN  - 33110036
AU  - Fogel, J.
AU  - Rubin, L. H.
AU  - Kilic, E.
AU  - Walega, D. R.
AU  - Maki, P. M.
DA  - Nov
DO  - 10.1097/gme.0000000000001608
DP  - NLM
ET  - 2020/10/29
IS  - 11
LA  - eng
N1  - 1530-0374
Fogel, Jessica
Rubin, Leah H
Kilic, Ece
Walega, David R
Maki, Pauline M
Journal Article
Research Support, Non-U.S. Gov't
United States
Menopause. 2020 Nov;27(11):1209-1219. doi: 10.1097/GME.0000000000001608.
PY  - 2020
SN  - 1072-3714
SP  - 1209-1219
ST  - Physiologic vasomotor symptoms are associated with verbal memory dysfunction in breast cancer survivors
T2  - Menopause
TI  - Physiologic vasomotor symptoms are associated with verbal memory dysfunction in breast cancer survivors
VL  - 27
ID  - 19
ER  - 

TY  - JOUR
AB  - BACKGROUND: Hot flashes cause significant morbidity in postmenopausal women, including women with breast cancer. We undertook a pilot study to estimate the effectiveness of black cohosh to reduce hot flashes. METHODS: Women who reported significant hot flashes (> or = 14 per week) were enrolled. Black cohosh was given in the form of the commercial product Remifemin. The first week was a no-treatment baseline period, and therapy was given for the subsequent 4 weeks. Hot flash data were collected by daily questionnaires during baseline and treatment weeks. Adverse effects were recorded. RESULTS: Twenty-one women completed the study. Their mean age was 56 years (range, 38-80). Thirteen patients had a history of breast cancer. Six patients were taking tamoxifen or raloxifene. Patients reported an average of 8.3 hot flashes per day during the baseline week. The reduction in mean daily hot flash frequency was 50% (95% CI, 34%-65%), while weekly hot flash scores were reduced 56% (95% CI, 40%-71%) at completion of the study. Overall, patients reported less trouble with sleeping, less fatigue, and less abnormal sweating. No patients stopped therapy because of adverse effects. CONCLUSIONS: Black cohosh appeared to reduce hot flashes and had a low toxicity. The efficacy found in this trial seems to be more than would be expected by a placebo effect (20%-30% hot flash reduction in previous trials). These results suggest that further evaluation of this black cohosh preparation with a phase III randomized trial is indicated.
AD  - Department of Surgery, Mayo Clinic, Scottsdale, Arizona 85259, USA. pockaj.barbara@mayo.edu
AN  - 15565808
AU  - Pockaj, B. A.
AU  - Loprinzi, C. L.
AU  - Sloan, J. A.
AU  - Novotny, P. J.
AU  - Barton, D. L.
AU  - Hagenmaier, A.
AU  - Zhang, H.
AU  - Lambert, G. H.
AU  - Reeser, K. A.
AU  - Wisbey, J. A.
DO  - 10.1081/cnv-200026394
DP  - NLM
ET  - 2004/11/30
IS  - 4
KW  - Adolescent
Adult
Breast Neoplasms/therapy
*Cimicifuga
Drug Administration Schedule
Female
Hot Flashes/*drug therapy
Humans
Middle Aged
Pilot Projects
Plant Extracts/adverse effects/*therapeutic use
Postmenopause
LA  - eng
N1  - Pockaj, Barbara A
Loprinzi, Charles L
Sloan, Jeff A
Novotny, Paul J
Barton, Debra L
Hagenmaier, Andrea
Zhang, Huayan
Lambert, George H
Reeser, Kristine A
Wisbey, Joyce A
Clinical Trial
Journal Article
England
Cancer Invest. 2004;22(4):515-21. doi: 10.1081/cnv-200026394.
PY  - 2004
SN  - 0735-7907 (Print)
0735-7907
SP  - 515-21
ST  - Pilot evaluation of black cohosh for the treatment of hot flashes in women
T2  - Cancer Invest
TI  - Pilot evaluation of black cohosh for the treatment of hot flashes in women
VL  - 22
ID  - 614
ER  - 

TY  - JOUR
AB  - The purpose of this project was to develop and test the feasibility and preliminary efficacy of a video about cancer clinical trials (CCTs) developed for breast cancer patients. We developed 2 brief 7-min videos that focused on breast cancer patients describing their experiences participating in CCTs, supplemented with doctors and research staff explaining key research concepts. One video was culturally tailored to Black patients and the other to White patients. To assess feasibility study, participants and their care providers completed a survey to evaluate their satisfaction with the video. Eligibility criteria for the study included ≥ 21 years of age, English-speaking, no prior experience participating in a CCT, and being potentially eligible for breast CCT enrollment. Preliminary efficacy was evaluated with a pretest-posttest design using a single item asking about intent to enroll in a clinical trial. The mean age of the patient sample (n = 50) was 53.0 years, and 50.0% were Black. Participants reported that the video was in the right length, useful, and easy to understand. Providers' evaluation (n = 5) revealed that viewing the video helped prepare patients for further CCT discussion. Preliminary efficacy showed no statistically significant difference in participant interest in CCT enrollment pre- and post-video. Changes in patients' intent in enrollment were associated with age and education. Culturally adapted video interventions can be helpful in supporting both patients and providers throughout the CCT education process but additional work is needed to improve enrollment into clinical trials.
AD  - Nell Hodgson Woodruff School of Nursing, Emory University, 1520 Clifton Road, Atlanta, GA, 30322, USA. kyeager@emory.edu.
Winship Cancer Institute, Emory University, 1365-C Clifton Road NE, Atlanta, GA, 30322-4207, USA. kyeager@emory.edu.
Nell Hodgson Woodruff School of Nursing, Emory University, 1520 Clifton Road, Atlanta, GA, 30322, USA.
Winship Cancer Institute, Emory University, 1365-C Clifton Road NE, Atlanta, GA, 30322-4207, USA.
School of Medicine, Emory University, 100 Woodruff Circle, Atlanta, GA, 30322, USA.
AN  - 32654039
AU  - Yeager, K. A.
AU  - Bai, J.
AU  - Gogineni, K.
AU  - Meisel, J. L.
AU  - Kweon, J.
AU  - Bruner, D. W.
AU  - Waldrop-Valverde, D.
DA  - Jul 11
DO  - 10.1007/s13187-020-01826-x
DP  - NLM
ET  - 2020/07/13
KW  - Breast cancer
Clinical trial
Education
Video intervention
LA  - eng
N1  - 1543-0154
Yeager, Katherine A
Orcid: 0000-0001-5076-3151
Bai, Jinbing
Gogineni, Keerthi
Meisel, Jane Lowe
Kweon, Jaime
Bruner, Deborah W
Waldrop-Valverde, Drenna
D2015-012/V Foundation for Cancer Research/
Journal Article
England
J Cancer Educ. 2020 Jul 11. doi: 10.1007/s13187-020-01826-x.
PY  - 2020
SN  - 0885-8195
ST  - Pilot Feasibility Study of a Video Intervention to Educate Patients with Breast Cancer About Clinical Trials
T2  - J Cancer Educ
TI  - Pilot Feasibility Study of a Video Intervention to Educate Patients with Breast Cancer About Clinical Trials
ID  - 33
ER  - 

TY  - JOUR
AB  - OBJECTIVE: Interventions for fear of recurrence (FOR) of cancer have nominal effects, perhaps due to limited integration of empirically supported skills. This pilot trial tested the acceptability and feasibility of a multimodal, mind-body resiliency intervention targeting FOR among survivors of various cancers. METHODS: Early stage cancer survivors 3-30 months post-treatment were recruited to participate in an eight-session in-person mind-body resiliency group intervention that taught relaxation skills, cognitive - behavioral techniques, healthy lifestyle behaviors, mindfulness meditation, and positive psychology skills all targeted for FOR. Primary outcomes were feasibility (enrollment rate, session attendance, survey completion, skills practice) and acceptability (enjoyableness, convenience, helpfulness, relevance). Patient-reported outcomes (FOR, uncertainty intolerance, cancer-related uncertainty, perceived stress, resiliency, positive affect, and coping skills) were collected at baseline, post-intervention, +1 month, and +3 months. Exit interviews assessed survivors' reported benefits. RESULTS: Participants (N = 4 groups, 23 survivors, enrollment response rate = 58%) included survivors of seven common cancer types who were on average 12 months post-treatment. Attendance was high (M = 6.1 sessions), and 96% of survivors completed all surveys. Sustained increases in relaxation skills practice 3+ days/week were reported (baseline = 16%, post-intervention = 76%, +3 months = 71%). Most sessions (87%) were rated as highly or very highly acceptable. Moderate-to-large (d = 0.87) improvements in FOR severity were observed post-intervention (p < .01) and across assessments (p < .01), with similar changes observed in other patient-reported outcomes. Exit interviews revealed behavioral, cognitive, emotional, and existential benefits. CONCLUSIONS: The targeted mind-body resiliency intervention shows promising acceptability, feasibility, and favorable changes in FOR and coping skills practice. Further adaptation and testing in a randomized trial are warranted.
AN  - WOS:000570288000001
AU  - Hall, D. L.
AU  - Park, E. R.
AU  - Cheung, T.
AU  - Davis, R. B.
AU  - Yeh, G. Y.
DA  - Oct
DO  - 10.1016/j.jpsychores.2020.110215
N1  - 110215
32818720
PY  - 2020
SN  - 0022-3999
ST  - A Pilot Mind-Body Resiliency Intervention Targeting Fear of Recurrence among Cancer Survivors
T2  - Journal of Psychosomatic Research
TI  - A Pilot Mind-Body Resiliency Intervention Targeting Fear of Recurrence among Cancer Survivors
VL  - 137
ID  - 2761
ER  - 

TY  - JOUR
AB  - PURPOSE: We investigated a combination therapy with weekly paclitaxel and all trans-retinoic acid (ATRA) for tolerability, response to treatment, time to progression and survival in previously treated patients with metastatic or recurrent breast cancer. Our rationale was based on preclinical studies demonstrating potentiation of the cytotoxic effects of taxanes and induction of differentiation by ATRA. PATIENTS AND METHODS: Seventeen patients with previously treated metastatic or recurrent breast cancer were enrolled to a regimen of all-trans retinoic acid (Vesanoid, tretinoin, Hoffman-La Roche, Inc.) 45 mg/m(2) PO daily for 4 days starting 2 days before a 1 h treatment with paclitaxel (Taxol, Bristol-Myers Squibb, Plainsboro, NJ) 80 mg/m(2) IV administered weekly for 3 weeks, repeated in 28 day cycles until disease progression or until no longer tolerated. Patients were evaluated for toxicity, response, time to progression and survival. Patients were primarily African American and Latino, representative of the population served by our Cancer Center. RESULTS: The regimen was relatively well tolerated. There were nine grade 3 and one grade 4 toxic events. We administered 162 treatment cycles with a mean of 7.5 per patient (range 1-22, median 5). Three patients had a partial response (17.6%) and ten patients had stable disease (58.8%), with an overall clinical benefit of 76.4%. Median time to progression was 6.0 months (range 1-21, mean 7.7 months). Fourteen evaluable patients had a median survival of 16 months (range 1-68 months, mean 25.2 months). CONCLUSIONS: The data suggest this is a well tolerated regimen with modest response rates but with time to progression and survival rates similar to those reported for paclitaxel alone and relatively high rates of stable disease in this sample of patients.
AD  - Department of Medicine, UMDNJ-New Jersey Medical School/University Hospital Cancer Center, Newark, NJ, USA.
AN  - 20596747
AU  - Bryan, M.
AU  - Pulte, E. D.
AU  - Toomey, K. C.
AU  - Pliner, L.
AU  - Pavlick, A. C.
AU  - Saunders, T.
AU  - Wieder, R.
DA  - Dec
DO  - 10.1007/s10637-010-9478-3
DP  - NLM
ET  - 2010/07/03
IS  - 6
KW  - African Americans
Aged
Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use
Breast Neoplasms/*drug therapy/pathology
Disease Progression
Female
Hispanic Americans
Humans
Middle Aged
Neoplasm Metastasis
Neoplasm Recurrence, Local
Paclitaxel/administration & dosage
Pilot Projects
Survival Rate
Treatment Outcome
Tretinoin/administration & dosage
LA  - eng
N1  - 1573-0646
Bryan, Margarette
Pulte, E Dianne
Toomey, Kathleen C
Pliner, Lillian
Pavlick, Anna C
Saunders, Tracie
Wieder, Robert
Clinical Trial, Phase II
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
United States
Invest New Drugs. 2011 Dec;29(6):1482-7. doi: 10.1007/s10637-010-9478-3. Epub 2010 Jul 2.
PY  - 2011
SN  - 0167-6997
SP  - 1482-7
ST  - A pilot phase II trial of all-trans retinoic acid (Vesanoid) and paclitaxel (Taxol) in patients with recurrent or metastatic breast cancer
T2  - Invest New Drugs
TI  - A pilot phase II trial of all-trans retinoic acid (Vesanoid) and paclitaxel (Taxol) in patients with recurrent or metastatic breast cancer
VL  - 29
ID  - 416
ER  - 

TY  - JOUR
AB  - BACKGROUND: We tested if magnesium would diminish bothersome hot flashes in breast cancer patients. METHODS: Breast cancer patients with at least 14 hot flashes a week received magnesium oxide 400 mg for 4 weeks, escalating to 800 mg if needed. Hot flash score (frequency × severity) at baseline was compared to the end of treatment. RESULTS: Of 29 who enrolled, 25 women completed treatment. The average age was 53.5 years; six African American, the rest Caucasian; eight were on tamoxifen, nine were on aromatase inhibitors, and 14 were on anti-depressants. Seventeen patients escalated the magnesium dose. Hot flash frequency/week was reduced from 52.2 (standard error (SE), 13.7) to 27.7 (SE, 5.7), a 41.4% reduction, p = 0.02, two-sided paired t test. Hot flash score was reduced from 109.8 (SE, 40.9) to 47.8 (SE, 13.8), a 50.4% reduction, p = 0.04. Of 25 patients, 14 (56%) had a >50% reduction in hot flash score, and 19 (76%) had a >25% reduction. Fatigue, sweating, and distress were all significantly reduced. Side effects were minor: two women stopped the drug including one each with headache and nausea, and two women had grade 1 diarrhea. Compliance was excellent, and many patients continued treatment after the trial. CONCLUSIONS: Oral magnesium appears to have helped more than half of the patients and was well tolerated. Side effects and cost ($0.02/tablet) were minimal. A randomized placebo-controlled trial is planned.
AD  - Department of Internal Medicine Residency Program, Virginia Commonwealth University Health System, Richmond, VA, USA.
AN  - 21271347
AU  - Park, H.
AU  - Parker, G. L.
AU  - Boardman, C. H.
AU  - Morris, M. M.
AU  - Smith, T. J.
C2  - PMC3085555
C6  - NIHMS277868 relationship with any organization that sponsored the research. Research support for the investigators comes from the Massey Cancer Center NCI Core Grant 5 P30 CA16059 (TJS, GLP, MM, and CHB); salary support for TJS comes from GO8 LM0095259 from the National Library of Medicine and R01CA116227-01 from the National Cancer Institute. The pilot trial research was sponsored by the VCU-Massey Cancer Center, which has no financial interest in the publication or the results. Indeed, the low cost of oral magnesium (US $0.02 per tablet) precludes any commercial interest and was one of the attractive features of the therapy. The authors note that they have full control of all primary data, which is stored in the secure VCU-Massey ONCOR system, and that they agree to allow the journal to review their data if requested. All authors meet standards for authorship and have made important contributions to the study.
DA  - Jun
DO  - 10.1007/s00520-011-1099-7
DP  - NLM
ET  - 2011/01/29
IS  - 6
KW  - Adult
Aged
Breast Neoplasms/complications/*drug therapy
Drug Costs
Female
Follow-Up Studies
Hot Flashes/*drug therapy/etiology
Humans
Magnesium Oxide/adverse effects/economics/*therapeutic use
Medication Adherence
*Menopause
Middle Aged
Pilot Projects
Severity of Illness Index
LA  - eng
N1  - 1433-7339
Park, Haeseong
Parker, Gwendolyn L
Boardman, Cecelia H
Morris, Monica M
Smith, Thomas J
G08 LM009525-01/LM/NLM NIH HHS/United States
G08 LM009525/LM/NLM NIH HHS/United States
5 P30 CA16059/CA/NCI NIH HHS/United States
G08 LM009525-02/LM/NLM NIH HHS/United States
G08 LM0095259/LM/NLM NIH HHS/United States
P30 CA016059/CA/NCI NIH HHS/United States
R01 CA116227/CA/NCI NIH HHS/United States
R01CA116227-01/CA/NCI NIH HHS/United States
Clinical Trial, Phase II
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Support Care Cancer. 2011 Jun;19(6):859-63. doi: 10.1007/s00520-011-1099-7. Epub 2011 Jan 27.
PY  - 2011
SN  - 0941-4355 (Print)
0941-4355
SP  - 859-63
ST  - A pilot phase II trial of magnesium supplements to reduce menopausal hot flashes in breast cancer patients
T2  - Support Care Cancer
TI  - A pilot phase II trial of magnesium supplements to reduce menopausal hot flashes in breast cancer patients
VL  - 19
ID  - 400
ER  - 

TY  - JOUR
AB  - African Americans are underrepresented in cancer research. We evaluate whether collaboration with African American churches can improve cancer awareness and increase participation in translational research protocols among African Americans. From February to April 2010, the Mayo Clinic partnered with African American Jacksonville churches to provide educational programs focused on cancer research and healthy behaviors. Education on multiple myeloma and on-site access to a translational cancer research pilot project evaluating the prevalence of monoclonal gammopathies and t(14,18) in African Americans was offered. Seventy-four percent, 236 out of 318 participants, returned the questionnaires. The majority of participants had never received information on multiple myeloma (67%), had never received clinical research study information (57%), and were enrolled in the translational research studies (55%). Partnerships with African American churches in community education projects that bring research to church venues are effective in improving cancer awareness and in increasing research participation among African Americans.
AD  - Division of Hematology and Oncology, Mayo Clinic, Jacksonville, FL 32224, USA. gcolonotero@mayo.edu
AN  - 22072126
AU  - Colon-Otero, G.
AU  - Albertie, M.
AU  - Lesperance, M.
AU  - Weis, J. A.
AU  - Coles, A.
AU  - Smith, N.
AU  - Mills, L.
AU  - Woodward, T.
AU  - Aspitia, A. M.
AU  - Vishnu, P.
AU  - Willis, F.
AU  - Isley, A.
AU  - Fonseca, R.
AU  - Vachon, C.
AU  - Rajkumar, S. V.
C2  - PMC3736846
C6  - NIHMS498197
DA  - Jun
DO  - 10.1007/s13187-011-0288-x
DP  - NLM
ET  - 2011/11/11
IS  - 2
KW  - Adult
*African Americans
Aged
Awareness
*Community-Based Participatory Research
Female
*Health Education
Health Knowledge, Attitudes, Practice
Humans
Male
Mass Screening
Middle Aged
Multiple Myeloma/*diagnosis/ethnology/prevention & control
Patient Education as Topic/*organization & administration
Pilot Projects
*Translational Medical Research
LA  - eng
N1  - 1543-0154
Colon-Otero, Gerardo
Albertie, Monica
Lesperance, Mary
Weis, Jennifer A
Coles, Alton
Smith, Nina
Mills, Lynette
Woodward, Timothy
Aspitia, Alvaro Moreno
Vishnu, Prakash
Willis, Floyd
Isley, Amber
Fonseca, Rafael
Vachon, Celine
Rajkumar, S Vincent
R01 CA083724/CA/NCI NIH HHS/United States
1 UL1 RR024150/RR/NCRR NIH HHS/United States
CA 90297052/CA/NCI NIH HHS/United States
P50-CA01508/CA/NCI NIH HHS/United States
UL1 RR024150/RR/NCRR NIH HHS/United States
R01 CA107476/CA/NCI NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
J Cancer Educ. 2012 Jun;27(2):294-8. doi: 10.1007/s13187-011-0288-x.
PY  - 2012
SN  - 0885-8195 (Print)
0885-8195
SP  - 294-8
ST  - A pilot program in collaboration with African American churches successfully increases awareness of the importance of cancer research and participation in cancer translational research studies among African Americans
T2  - J Cancer Educ
TI  - A pilot program in collaboration with African American churches successfully increases awareness of the importance of cancer research and participation in cancer translational research studies among African Americans
VL  - 27
ID  - 381
ER  - 

TY  - JOUR
AB  - OBJECTIVE: Obesity is associated with poorer breast cancer outcomes and losing weight postdiagnosis may improve survival. As Hispanic and black women have poorer breast cancer prognosis than non-Hispanic whites diagnosed at similar age and stage, and have higher rates of obesity, effective weight loss strategies are needed. We piloted a randomized, waitlist-controlled, crossover study to examine the effects and feasibility of the commercial Curves weight loss program among Hispanic, African American and Afro-Caribbean breast cancer survivors. DESIGN AND METHODS: Women with stage 0-IIIa breast cancer ≥ 6 months posttreatment, sedentary, and BMI ≥ 25 kg/m(2) were randomized to the immediate arm (IA): 6 months of the Curves program followed by 6 months of observation; or the waitlist control arm (WCA): 6 months of observation followed by 6 months of the Curves program. The Curves program uses a 30-min exercise circuit and a high-vegetable/low-fat/calorie-restricted diet. RESULTS: A total of 42 women enrolled (79% Hispanic, 21% black), mean age 51 (range 32-69) and mean BMI 33.2(± 5.9) kg/m(2); 91% were retained at month 12. At month 6, women in the IA lost an average 3.3% (± 3.5%) of body weight (range: 1.7% gain to 10.6% loss), as compared with 1.8% (± 2.9%) weight loss in the WCA (P = 0.04). At month 12, on average women in the IA regained some but not all of the weight lost during the first 6 months (P = 0.02). CONCLUSIONS: Minority breast cancer survivors were recruited and retained in a weight loss study. Six months of the Curves program resulted in moderate weight loss, but weight loss was not maintained postintervention. Future interventions should identify methods to increase uptake and maintenance of weight loss behaviors.
AD  - Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, New York, USA. hg2120@columbia.edu
AN  - 23505170
AU  - Greenlee, H. A.
AU  - Crew, K. D.
AU  - Mata, J. M.
AU  - McKinley, P. S.
AU  - Rundle, A. G.
AU  - Zhang, W.
AU  - Liao, Y.
AU  - Tsai, W. Y.
AU  - Hershman, D. L.
C2  - PMC4705911
C6  - NIHMS704496 Conflict of Interest Forms for this article.
DA  - Jan
DO  - 10.1002/oby.20245
DP  - NLM
ET  - 2013/03/19
IS  - 1
KW  - Adult
African Continental Ancestry Group
Aged
Body Mass Index
Breast Neoplasms/*complications/ethnology
Caloric Restriction
*Diet, Reducing
Dietary Fats/administration & dosage
*Exercise
Female
Hispanic Americans
Humans
Middle Aged
*Minority Groups
Obesity/complications/diet therapy/ethnology/*therapy
Pilot Projects
*Survivors
Weight Gain
*Weight Reduction Programs
LA  - eng
N1  - 1930-739x
Greenlee, Heather A
Crew, Katherine D
Mata, Jennie M
McKinley, Paula S
Rundle, Andrew G
Zhang, Wenfei
Liao, Yuyan
Tsai, Wei Y
Hershman, Dawn L
UL1 RR024156/RR/NCRR NIH HHS/United States
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Obesity (Silver Spring). 2013 Jan;21(1):65-76. doi: 10.1002/oby.20245.
PY  - 2013
SN  - 1930-7381 (Print)
1930-7381
SP  - 65-76
ST  - A pilot randomized controlled trial of a commercial diet and exercise weight loss program in minority breast cancer survivors
T2  - Obesity (Silver Spring)
TI  - A pilot randomized controlled trial of a commercial diet and exercise weight loss program in minority breast cancer survivors
VL  - 21
ID  - 334
ER  - 

TY  - JOUR
AB  - Background: Interventions addressing cancer survivors' posttreatment concerns can be time-intensive and require specialized staff. Research is needed to identify feasible minimal intervention strategies to improve survivors' quality of life after treatment. Objectives: The objective of this study was to evaluate the feasibility and short-term impact of a minimal clinic intervention on breast cancer survivors' quality of life, unmet needs, distress, and cancer worry. Interventions/Methods: In this randomized controlled pilot trial, we enrolled breast cancer survivors at the end of treatment and administered baseline surveys. Participants were randomized to study arm (4-week video plus educational booklet intervention group and usual care group) and completed follow-up surveys at 10 weeks. Linear regression was used to examine intervention effects on quality of life outcomes controlling for clinical and demographic factors. Open-ended questions were used to examine program satisfaction and obtain feedback to improve the intervention. Results: We enrolled 92 survivors in the trial. Participants rated the intervention highly and reported feeling less isolated and having more realistic expectations about their recovery after completing the program. Despite positive qualitative findings, no significant intervention effects were observed for quality of life, unmet needs, distress, or cancer worry in unadjusted or adjusted analyses. Conclusions: Future research is needed to define optimal intervention elements to prepare breast cancer survivors for the posttreatment period. Implications for Practice: Effective survivorship interventions may require more intensive components such as clinical input and longer follow-up periods.
AD  - K.R. Sterba, Department of Public Health Sciences, Medical University of South Carolina, Charleston, SC, United States
AU  - Sterba, K. R.
AU  - Armeson, K.
AU  - Franco, R.
AU  - Harper, J.
AU  - Patten, R.
AU  - Kindall, S.
AU  - Bearden, J.
AU  - Zapka, J.
DB  - Embase
Medline
DO  - 10.1097/NCC.0000000000000152
IS  - 2
KW  - antineoplastic agent
adult
African American
aged
article
breast cancer
cancer chemotherapy
cancer hormone therapy
cancer survivor
caregiver
Caucasian
controlled study
convalescence
depression
distress syndrome
expectation
feasibility study
female
follow up
health care survey
health program
human
human needs
intervention study
minimal clinic intervention
nutrition education
open-ended questionnaire
patient attitude
patient education
patient satisfaction
patient worry
pilot study
priority journal
program feasibility
quality of life
randomized controlled trial
treatment outcome
LA  - English
M3  - Article
N1  - L53136817
2014-05-22
2015-03-18
PY  - 2015
SN  - 1538-9804
0162-220X
SP  - E48-E56
ST  - A pilot randomized controlled trial testing a minimal intervention to prepare breast cancer survivors for recovery
T2  - Cancer Nursing
TI  - A pilot randomized controlled trial testing a minimal intervention to prepare breast cancer survivors for recovery
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L53136817&from=export
http://dx.doi.org/10.1097/NCC.0000000000000152
VL  - 38
ID  - 1010
ER  - 

TY  - JOUR
AB  - Most cancer patients do not have an explicit discussion about prognosis and treatment despite documented adverse outcomes. Few decision aids have been developed to assist the difficult discussions of palliative management. We developed decision aids for people with advanced in curable breast, colorectal, lung, and hormone-refractory prostate cancers facing first-, second-, third-, and fourth-line chemotherapy. We recruited patients from our urban oncology clinic after gaining the permission of their treating oncologist. We measured knowledge of curability and treatment benefit before and after the intervention. Twenty-six of 27 (96%) patients completed the aids, with ameanage of 63, 56% female, 56% married, 56% African American, and 67% with a high school education or more. Most patients (14/27, 52%) thought a person with their advanced cancer could be cured, which was reduced (to 8/26, 31%, P = 0.15) after the decision aid. Nearly all overestimated the effect of palliative chemotherapy. No distress was noted, and hope did not change. The majority (20/27, 74%) found the information helpful to them, and almost all (25/27, 93%) wanted to share the information with their family and physicians. It is possible to give incurable patients their prognosis, treatment options, and options for improving end-of-life care without causing distress or lack of hope. Almost all find the information helpful and want to share it with doctors and family. Research is needed to test the findings in a larger sample and measure the outcomes of truthful information on quality of life, quality of care, and costs.
AD  - Massey Cancer Center of Virginia Commonwealth University, School of Education, VCU School of Medicine, Department of Social and Behavioral Health, and the Virginia Cancer Institute, Richmond, Virginia 23298-0230, USA. tsmith5@mcvh-vcu.edu
AN  - 21542415
AU  - Smith, T. J.
AU  - Dow, L. A.
AU  - Virago, E. A.
AU  - Khatcheressian, J.
AU  - Matsuyama, R.
AU  - Lyckholm, L. J.
C2  - PMC3589716
C6  - NIHMS447553
DA  - Mar-Apr
DO  - 10.1016/j.suponc.2010.12.005
DP  - NLM
ET  - 2011/05/06
IS  - 2
KW  - Aged
*Decision Support Techniques
Female
Humans
Male
Middle Aged
Neoplasms/*drug therapy
Pilot Projects
Prognosis
LA  - eng
N1  - 1879-596x
Smith, Thomas J
Dow, Lindsay A
Virago, Enid A
Khatcheressian, James
Matsuyama, Robin
Lyckholm, Laurel J
G08 LM009525/LM/NLM NIH HHS/United States
R01 CA116227/CA/NCI NIH HHS/United States
G08 LM0095259/LM/NLM NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
J Support Oncol. 2011 Mar-Apr;9(2):79-86. doi: 10.1016/j.suponc.2010.12.005.
PY  - 2011
SN  - 1544-6794 (Print)
1544-6794
SP  - 79-86
ST  - A pilot trial of decision aids to give truthful prognostic and treatment information to chemotherapy patients with advanced cancer
T2  - J Support Oncol
TI  - A pilot trial of decision aids to give truthful prognostic and treatment information to chemotherapy patients with advanced cancer
VL  - 9
ID  - 395
ER  - 

TY  - JOUR
AB  - A continuing challenge in weight loss treatment is attaining maintenance of weight loss. The goal of this study was to develop a counseling method that would assist African American breast cancer survivors with weight loss maintenance. In this pilot study, 31 obese breast cancer survivors were recruited. Individualized, dietitian-led counseling by telephone and free Weight Watchers coupons were provided to all participants for 18 months. At the 6-month time point, women were randomized to receive spirituality counseling or not in addition to the standard program. The spirituality counseling was delivered via telephone using an 8-step framework. Subjects were asked to utilize daily meditation or prayer, daily readings, and the recording of thoughts in a journal. Mean weight loss from baseline to 6 months was a modest 2.0% of baseline weight. From 6 to 18 months, there was no further weight change in the spirituality arm and a gain of 0.7% in the dietitian-only arm. Despite little effect on weight loss, it did appear that spirituality counseling positively affected spiritual well-being (FACIT-Sp) scores and dietary quality. The spirituality counseling framework therefore may be further refined and useful for other health promotion studies with African American populations.
AD  - Department of Family Medicine, University of Michigan, Ann Arbor, Michigan 48109-5930, USA. zoralong@umich.edu
AN  - 19585923
AU  - Djuric, Z.
AU  - Mirasolo, J.
AU  - Kimbrough, L.
AU  - Brown, D. R.
AU  - Heilbrun, L. K.
AU  - Canar, L.
AU  - Venkatranamamoorthy, R.
AU  - Simon, M. S.
C2  - PMC2719839
C6  - NIHMS126904
DA  - Jun
DO  - 10.1016/s0027-9684(15)30940-8
DP  - NLM
ET  - 2009/07/10
IS  - 6
KW  - *African Americans
Body Mass Index
Breast Neoplasms/mortality/*psychology
Diet Records
*Directive Counseling
Female
Humans
Middle Aged
Motor Activity
Obesity/complications/diet therapy/psychology
Pilot Projects
Quality of Life
*Religion and Psychology
Surveys and Questionnaires
Survival Analysis
Survivors
United States
*Weight Loss
LA  - eng
N1  - Djuric, Zora
Mirasolo, Josephine
Kimbrough, LaVern
Brown, Diane R
Heilbrun, Lance K
Canar, Lisa
Venkatranamamoorthy, Raghu
Simon, Michael S
R21 CA100720-01A1/CA/NCI NIH HHS/United States
1R21 CA100720/CA/NCI NIH HHS/United States
R21 CA100720/CA/NCI NIH HHS/United States
P30 CA022453-229020/CA/NCI NIH HHS/United States
P30 CA022453/CA/NCI NIH HHS/United States
R21 CA100720-02/CA/NCI NIH HHS/United States
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
J Natl Med Assoc. 2009 Jun;101(6):552-64. doi: 10.1016/s0027-9684(15)30940-8.
PY  - 2009
SN  - 0027-9684 (Print)
0027-9684
SP  - 552-64
ST  - A pilot trial of spirituality counseling for weight loss maintenance in African American breast cancer survivors
T2  - J Natl Med Assoc
TI  - A pilot trial of spirituality counseling for weight loss maintenance in African American breast cancer survivors
VL  - 101
ID  - 457
ER  - 

TY  - JOUR
AB  - In recent years, a physiology-oriented multicompartmental kinetics (POCK) model was developed to simulate pulmonary retention data of biopersistent, noncytotoxic aerosols in long-term inhalation exposures of rats. Experimental data were successfully simulated for submicrometer-sized aerosols like carbon black, diesel soot and titanium dioxide and for a micrometer-sized xerographic toner aerosol (Stober et al., 1994, 1995). This article describes for various rat strains successful POCK model simulations of experimental pulmonary retention data of micrometer-sized aerosols of biopersistent cytotoxic SiO2 modifications like quartz and quartzite. In the past, the POCK model was not applied to cytotoxic aerosols and dusts. Cytotoxicity was considered incompatible with the model assumption of a constant macrophage lifetime independent of the macrophage aerosol load. The few relevant experimental retention studies with biopersistent silica found in the open literature showed particulate lung burdens up to some 15 mg per rat lung. Apparently, at these loads, pulmonary burdens could be simulated because the fraction of alveolar macrophages killed by the cytotoxic particles was possibly still small compared to the total number of viable macrophages. Of necessity, however, the classical alveolar clearance in these studies was exclusively performed by alveolar macrophages that were burdened with cytotoxic particles, and the cells appeared to suffer from a substantial initial decrease of their inherent mobility. Thus a sizeable reduction of the alveolar clearance rate coefficient in comparison to nontoxic aerosol was found. The results for the model parameters of several different exposure studies are shown and interpreted in comparison to nontoxic titanium dioxide retention parameters.
AN  - WOS:000079908500001
AU  - Stober, W.
DA  - Apr
DO  - 10.1080/089583799197096
IS  - 4
N1  - 11
10380170
PY  - 1999
SN  - 0895-8378
SP  - 269-292
ST  - Pock model simulations of pulmonary quartz dust retention data in extended inhalation exposures of rats
T2  - Inhalation Toxicology
TI  - Pock model simulations of pulmonary quartz dust retention data in extended inhalation exposures of rats
VL  - 11
ID  - 2729
ER  - 

TY  - JOUR
AB  - Tamoxifen (TAM) is widely used for treatment and prevention of breast cancer. TAM is metabolized by cytochrome P450 (CYP450) enzymes, including CYP3A5. Although two genetic polymorphisms in CYP3A5 are known (CYP3A5*3 and CYP3A5*6), the effects of these polymorphisms on TAM metabolism, TAM side effects, and tumor characteristics are unknown. Thus, this work tested the hypothesis that CYP3A5 polymorphisms are associated with differential TAM levels, TAM side effects, and tumor characteristics in breast cancer patients. Postmenopausal women with breast cancer (n=98) were recruited from a single cancer center. Polymorphic status was established using polymerase chain reactions (PCR). The associations between polymorphic status, race, TAM levels, side effects, and tumor characteristics were assessed using t-tests and logistic regression models. The data indicate that 40.7% of the breast cancer patients had the CYP3A5*3 polymorphism, and 9.1% had the CYP3A5*6 polymorphism. In addition, Caucasian women were 26 times more likely to carry the CYP3A5*3 polymorphism than African American (AA) women, whereas AA women were nine times more likely to carry the CYP3A5*6 polymorphism than Caucasian women. No significant differences were seen in TAM or TAM metabolite levels or TAM side effects by polymorphic status. There was a significant difference, however, in mean tumor size in women with the CYP3A5*6 polymorphism (3.6±0.98 cm) compared to those without the polymorphism (2.0±0.18 cm) (P<0.02). Taken together, these data suggest that racial differences in CYP3A5 polymorphisms exist although the polymorphisms do not appear to be associated with levels of TAM metabolites and side effects. © 2004 Elsevier Ireland Ltd. All rights reserved.
AD  - Dept. of Epidemiol. and Prev. Med., School of Medicine, Univ. Maryland, 600 W. Redwood S.
AU  - Tucker, A. N.
AU  - Tkaczuk, K. A.
AU  - Lewis, L. M.
AU  - Tomic, D.
AU  - Lim, C. K.
AU  - Flaws, J. A.
DB  - Embase
Medline
DO  - 10.1016/j.canlet.2004.08.027
IS  - 1
KW  - cytochrome P450 3A5
tamoxifen
African American
article
breast carcinoma
Caucasian
clinical trial
depression
disease association
genetic polymorphism
hot flush
human
insomnia
irritability
migraine
nausea
polymerase chain reaction
postmenopause
priority journal
race
tumor volume
vaginal dryness
LA  - English
M3  - Article
N1  - L39642867
2004-12-28
PY  - 2005
SN  - 0304-3835
SP  - 61-72
ST  - Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients
T2  - Cancer Letters
TI  - Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L39642867&from=export
http://dx.doi.org/10.1016/j.canlet.2004.08.027
VL  - 217
ID  - 1273
ER  - 

TY  - JOUR
AB  - Background: The epidermal growth factor receptor (EGFR) gene is the prototype member of the type I receptor tyrosine kinase (TK) family and plays a pivotal role in cell proliferation and differentiation. There are three well described polymorphisms that are associated with increased protein production in experimental systems: a polymorphic dinucleotide repeat (CA simple sequence repeat 1 [CA-SSR1]) in intron one (lower number of repeats) and two single nucleotide polymorphisms (SNPs) in the promoter region, -216 (G/T or T/T) and -191 (C/A or A/A). The objective of this study was to examine distributions of these three polymorphisms and their relationships to each other and to EGFR gene mutations and allelic imbalance (AI) in non-small cell lung cancers. Methods and Findings: We examined the frequencies of the three polymorphisms of EGFR in 556 resected lung cancers and corresponding non-malignant lung tissues from 336 East Asians, 213 individuals of Northern European descent, and seven of other ethnicities. We also studied the EGFR gene in 93 corresponding non-malignant lung tissue samples from European-descent patients from Italy and in peripheral blood mononuclear cells from 250 normal healthy US individuals enrolled in epidemiological studies including individuals of European descent, African-Americans, and Mexican-Americans. We sequenced the four exons (18-21) of the TK domain known to harbor activating mutations in tumors and examined the status of the CA-SSR1 alleles (presence of heterozygosity, repeat number of the alleles, and relative amplification of one allele) and allele-specific amplification of mutant tumors as determined by a standardized semiautomated method of microsatellite analysis. Variant forms of SNP -216 (G/T or T/T) and SNP -191 (C/A or A/A) (associated with higher protein production in experimental systems) were less frequent in East Asians than in individuals of other ethnicities (p < 0.001). Both alleles of CA-SSR1 were significantly longer in East Asians than in individuals of other ethnicities (p < 0.001). Expression studies using bronchial epithelial cultures demonstrated a trend towards increased mRNA expression in cultures having the variant SNP -216 G/T or T/T genotypes. Monoallelic amplification of the CA-SSR1 locus was present in 30.6% of the informative cases and occurred more often in individuals of East Asian ethnicity. AI was present in 44.4% (95% confidence interval: 34.1%-54.7%) of mutant tumors compared with 25.9% (20.6%-31.2%) of wild-type tumors (p = 0.002). The shorter allele in tumors with AI in East Asian individuals was selectively amplified (shorter allele dominant) more often in mutant tumors (75.0%, 61.6%-88.4%) than in wild-type tumors (43.5%, 31.8%-55.2%, p = 0.003). In addition, there was a strong positive association between AI ratios of CA-SSR1 alleles and AI of mutant alleles. Conclusions: The three polymorphisms associated with increased EGFR protein production (shorter CA-SSR1 length and variant forms of SNPs -216 and -191) were found to be rare in East Asians as compared to other ethnicities, suggesting that the cells of East Asians may make relatively less intrinsic EGFR protein. Interestingly, especially in tumors from patients of East Asian ethnicity, EGFR mutations were found to favor the shorter allele of CA-SSR1, and selective amplification of the shorter allele of CA-SSR1 occurred frequently in tumors harboring a mutation. These distinct molecular events targeting the same allele would both be predicted to result in greater EGFR protein production and/or activity. Our findings may help explain to some of the ethnic differences observed in mutational frequencies and responses to TK inhibitors. © 2007 Nomura et al.
AD  - Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, TX, United States
Cancer Prevention Research, Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, United States
Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX, United States
First Department of Surgery, Tokyo Medical University, Tokyo, Japan
Pathology Unit, Center of Excellence on Aging, University Foundation, Chieti, Italy
Department of Cell Biology, University of Texas Southwestern Medical Center, Dallas, TX, United States
Department of Epidemiology, University of Texas M. D. Anderson Cancer Center, Houston, TX, United States
Department of Pathology, University of Texas M. D. Anderson Cancer Center, Houston, TX, United States
Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, United States
Department of Pharmacology, University of Texas Southwestern Medical Center, Dallas, TX, United States
AU  - Nomura, M.
AU  - Shigematsu, H.
AU  - Li, L.
AU  - Suzuki, M.
AU  - Takahashi, T.
AU  - Estess, P.
AU  - Siegelman, M.
AU  - Feng, Z.
AU  - Kato, H.
AU  - Marchetti, A.
AU  - Shay, J. W.
AU  - Spitz, M. R.
AU  - Wistuba, I. I.
AU  - Minna, J. D.
AU  - Gazdar, A. F.
DB  - Scopus
DO  - 10.1371/journal.pmed.0040125
IS  - 4
M3  - Article
N1  - Cited By :115
Export Date: 22 March 2021
PY  - 2007
SP  - 715-727
ST  - Polymorphisms, mutations, and amplification of the EGFR gene in non-small cell lung cancers
T2  - PLoS Medicine
TI  - Polymorphisms, mutations, and amplification of the EGFR gene in non-small cell lung cancers
UR  - https://www.scopus.com/inward/record.uri?eid=2-s2.0-34247477205&doi=10.1371%2fjournal.pmed.0040125&partnerID=40&md5=9e0a4ae8a3dfac9235c9958161e355ef
VL  - 4
ID  - 2562
ER  - 

TY  - JOUR
AB  - Background: Outcomes after nonelective surgery for gastric cancer (GC) are poorly defined. Our objective was to compare outcomes of patients undergoing nonelective GC surgery after admission through the emergency department (EDSx) with patients receiving elective surgery or surgery after planned admission (non-EDSx) nationally. Methods: The Nationwide Inpatient Sample (NIS) database was used to examine patients undergoing GC surgery between 2008 and 2012. Demographics and outcomes were compared between EDSx and non-EDSx. Multivariable logistic regression was used to examine predictors of discharge to home. Results: Of 9279 patients, 1143 (12%) underwent EDSx. They were more likely to be female (42 vs. 35%), nonwhite (56 vs. 33%), aged ≥75 years (40 vs. 26%), in the lowest quartile for household income (31 vs. 25%), have one or more comorbidities (87 vs. 70%), treated at a nonteaching hospital (46 vs. 25%), and have a concomitant diagnosis of obstruction, perforation, or bleeding (30 vs. 6%). They had longer total length of stay (LOS; 16 vs. 9 days), longer median postoperative stays (10 vs. 9 days), higher in-hospital mortality (8 vs. 3%), and were less likely to be discharged home (63 vs. 82%). EDSx was more expensive ($125,300 vs. $83,604). EDSx was associated with a lower likelihood of discharge to home (odds ratio 0.52, 95% CI 0.43–0.62). Conclusions: Nationally, 12% of GC surgeries are performed after emergency department admission, which occurs more frequently in vulnerable populations and results in worse outcomes. Understanding factors leading to increased EDSx and developing strategies to decrease EDSx may improve GC surgery outcomes.
AD  - I. Solsky, Department of Surgery, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY, United States
AU  - Solsky, I.
AU  - Friedmann, P.
AU  - Muscarella, P.
AU  - In, H.
DB  - Embase
Medline
DO  - 10.1245/s10434-016-5696-z
IS  - 5
KW  - adult
aged
article
Black person
cancer surgery
Caucasian
central nervous system disease
comorbidity
controlled study
deep vein thrombosis
elective surgery
emergency ward
ethnic difference
female
heart disease
Hispanic
hospital admission
hospital discharge
hospital mortality
hospitalization
household income
human
length of stay
lung disease
lung embolism
major clinical study
male
obstruction
outcome assessment
patient selection
perforation
postoperative complication
postoperative hemorrhage
postoperative period
sepsis
stomach cancer
stomach surgery
surgical infection
vulnerable population
LA  - English
M3  - Article
N1  - L613562038
2016-12-13
2017-04-28
PY  - 2017
SN  - 1534-4681
1068-9265
SP  - 1180-1187
ST  - Poor Outcomes of Gastric Cancer Surgery After Admission Through the Emergency Department
T2  - Annals of Surgical Oncology
TI  - Poor Outcomes of Gastric Cancer Surgery After Admission Through the Emergency Department
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L613562038&from=export
http://dx.doi.org/10.1245/s10434-016-5696-z
VL  - 24
ID  - 935
ER  - 

TY  - JOUR
AB  - Empiric data on recruitment of minorities into clinical or population studies are limited. The authors evaluated population- and community-based recruitment methods in a 1998-2001 case-control study of lung cancer among African Americans and Latinos. For lung cancer cases in the San Francisco Bay Area of California, rapid case ascertainment by the tumor registry combined with telephone screening identified 470 (9%) African Americans and 262 (5%) Latinos. When random digit dialing (RDD) and Health Care Financing Administration (HCFA) records failed to yield adequate numbers of controls in appropriate age-gender-ethnicity groups, community-based recruitment methods were used. Demographic characteristics and behavioral and occupational risk factors for controls, by recruitment method, were compared with those for lung cancer cases to evaluate potential bias. The average numbers of hours spent per control recruited were 18.6 for RDD, 11.4 for HCFA, and less than 1 for the community-based methods. The prevalence of smoking-related lung cancer risk factors was significantly higher among African-American community-based controls than for those identified through RDD (p < 0.005). Compared with HCFA controls, Latino RDD controls reported significantly higher cumulative smoking exposure (p < 0.05). Further assessment of strategies for successful recruitment of minority participants into epidemiologic studies is warranted.
AD  - Northern California Cancer Center, Union City, CA 94587, USA. dcabral@nccc.org
AN  - 12882950
AU  - Cabral, D. N.
AU  - Nápoles-Springer, A. M.
AU  - Miike, R.
AU  - McMillan, A.
AU  - Sison, J. D.
AU  - Wrensch, M. R.
AU  - Pérez-Stable, E. J.
AU  - Wiencke, J. K.
DA  - Aug 1
DO  - 10.1093/aje/kwg138
DP  - NLM
ET  - 2003/07/29
IS  - 3
KW  - Adult
*African Americans
Aged
Case-Control Studies
Female
Genetic Predisposition to Disease
*Hispanic Americans
Humans
Lung Neoplasms/*epidemiology/*ethnology/genetics
Male
Middle Aged
Occupations
*Patient Selection
Registries/*statistics & numerical data
Risk Factors
San Francisco/epidemiology/ethnology
Smoking/*adverse effects
LA  - eng
N1  - Cabral, Daramöla N
Nápoles-Springer, Anna M
Miike, Rei
McMillan, Alex
Sison, Jennette D
Wrensch, Margaret R
Pérez-Stable, Eliseo J
Wiencke, John K
San Francisco Bay Area Lung Cancer Study
ES06717/ES/NIEHS NIH HHS/United States
P30 AG15272/AG/NIA NIH HHS/United States
Journal Article
Research Support, U.S. Gov't, P.H.S.
United States
Am J Epidemiol. 2003 Aug 1;158(3):272-9. doi: 10.1093/aje/kwg138.
PY  - 2003
SN  - 0002-9262 (Print)
0002-9262
SP  - 272-9
ST  - Population- and community-based recruitment of African Americans and Latinos: the San Francisco Bay Area Lung Cancer Study
T2  - Am J Epidemiol
TI  - Population- and community-based recruitment of African Americans and Latinos: the San Francisco Bay Area Lung Cancer Study
VL  - 158
ID  - 643
ER  - 

TY  - JOUR
AB  - PURPOSE: Although many studies clearly demonstrate disparities in cancer clinical trial enrollment, there is a lack of consensus on potential causes. Furthermore, virtually nothing is known about associations between patients' decision-making style and their participation in clinical trials. METHODS: Women with newly diagnosed, stage 0-II breast cancer reported to the Georgia and Los Angeles County Surveillance, Epidemiology, and End Results (SEER) registries in 2013-2014 were surveyed approximately seven months after diagnosis. We investigated two primary outcome variables: (1) invitation to participate in a clinical trial, (2) participation in a clinical trial. We evaluated bivariate associations using Chi-squared tests and used multivariable logistic regression models to investigate associations between patient variables, including decision-making style, and the primary outcomes. RESULTS: 2578 patients responded (71% response rate); 30% were > age 65, 18% were black, 18% were Latina, 29% had ≤ high school education. 10% of patients reported invitation to participate in a clinical trial; 5% reported participation in a clinical trial. After adjustment younger age, receipt of chemotherapy or radiation, disease stage, and a more rational (versus more intuitive) decision-making style were associated with a higher odds of invitation to participate. Being married was associated with a higher odds of participation; having an annual family income ≥ $40,000 was associated with a lower odds of participation. CONCLUSIONS: 10% of patients reported invitation to participate in a clinical trial, and half of these reported participation. Invitation to participate varied by age and decision-making style, and participation varied by marital status and income.
AD  - Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan, Ann Arbor, MI, USA.
Department of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA.
Center for Bioethics and Social Sciences in Medicine, University of Michigan, Ann Arbor, MI, USA.
Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor, MI, USA.
Department of Biostatistics, University of Michigan, Ann Arbor, MI, USA.
Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.
Department of Health Management and Policy, University of Michigan, Ann Arbor, MI, USA.
US Department of Veterans Affairs Health Services Research and Development, University of Michigan, Ann Arbor, MI, USA.
Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan, Ann Arbor, MI, USA. cveenstr@med.umich.edu.
Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor, MI, USA. cveenstr@med.umich.edu.
AN  - 32757135
AU  - Patel, M. A.
AU  - Shah, J. L.
AU  - Abrahamse, P. H.
AU  - Jagsi, R.
AU  - Katz, S. J.
AU  - Hawley, S. T.
AU  - Veenstra, C. M.
C2  - PMC7606336
C6  - NIHMS1618239
DA  - Nov
DO  - 10.1007/s10549-020-05844-7
DP  - NLM
ET  - 2020/08/07
IS  - 2
KW  - Breast cancer
Clinical trial
Disparities
Enrollment
Participation
Shah declares that she has no conflict of interest. Mr. Abrahamse declares that he
has no conflict of interest. Dr. Katz declares that he has no conflict of interest.
Dr. Hawley declares that she has no conflict of interest. Dr. Veenstra declares that
she has no conflict of interest.
LA  - eng
N1  - 1573-7217
Patel, Monica A
Shah, Jennifer L
Abrahamse, Paul H
Jagsi, Reshma
Katz, Steven J
Hawley, Sarah T
Veenstra, Christine M
Orcid: 0000-0001-9947-7156
HHSN261201000140C/CA/NCI NIH HHS/United States
HHSN261201000035C/CA/NCI NIH HHS/United States
K07 CA19675201/National Cancer Institute (US)/
HHSN261201000035I/CA/NCI NIH HHS/United States
HHSN261201300015C/CA/NCI NIH HHS/United States
HHSN261201000034C/CA/NCI NIH HHS/United States
T32 CA009357/CA/NCI NIH HHS/United States
U58 DP003862/DP/NCCDPHP CDC HHS/United States
K07 CA196752/CA/NCI NIH HHS/United States
P01 CA163233/CA/NCI NIH HHS/United States
U58 DP003875/DP/NCCDPHP CDC HHS/United States
Journal Article
Breast Cancer Res Treat. 2020 Nov;184(2):507-518. doi: 10.1007/s10549-020-05844-7. Epub 2020 Aug 5.
PY  - 2020
SN  - 0167-6806 (Print)
0167-6806
SP  - 507-518
ST  - A population-based study of invitation to and participation in clinical trials among women with early-stage breast cancer
T2  - Breast Cancer Res Treat
TI  - A population-based study of invitation to and participation in clinical trials among women with early-stage breast cancer
VL  - 184
ID  - 31
ER  - 

TY  - JOUR
AB  - PURPOSE/OBJECTIVES: To determine racial and ethnic differences in the range and number of post-treatment symptoms among women who have undergone surgical and postsurgical treatment for breast cancer. DESIGN: Retrospective study. SETTING: Community-based social services agency and public health clinic. Methods: Face-to-face interview of 116 women who had undergone breast cancer surgery. SAMPLE: Primarily low-income women in an urban area in northern California. Participants were recruited via posted flyers regarding the study. MAIN RESEARCH VARIABLES: Outcomes (depression, fatigue, pain, and swelling from lymphedema) and demographics (ethnicity, age, income, insurance, education, and marital status). FINDINGS: The typical participant was 47 years old, had 12 years of education, and was a parent (74%), unmarried (67%), heterosexual (88%), uninsured (68%), and employed (66%). Thirty percent were Caucasian, 30% African American, 25% Latina, and 15% women of other ethnic backgrounds. African American women and Latinas reported increased rates of pain and an increased number of symptoms. Latinas also reported higher rates of fatigue and depression. In multivariate analyses, an increased number of symptoms were associated with decreased income, with receiving chemotherapy, with having a mastectomy, and with Latina ethnicity. CONCLUSIONS: These data suggest an increased rate of post-treatment symptoms experienced by low-income and ethnic minority women. IMPLICATIONS FOR NURSING: A need exists for affordable, culturally appropriate symptom management interventions. Nursing will have a vital role in designing, testing, and offering such interventions.
AD  - Adjunct Assistant Professor, Department of Social and Behavioral Sciences, University of California, San Francisco; devers@itsa.ucsf.edu
AN  - 106606014. Language: English. Entry Date: 20050415. Revision Date: 20200708. Publication Type: Journal Article
AU  - Eversley, R.
AU  - Estrin, D.
AU  - Dibble, S.
AU  - Wardlaw, L.
AU  - Pedrosa, M.
AU  - Favila-Penney, W.
DB  - CINAHL Complete
DO  - 10.1188/05.ONF.250-256
DP  - EBSCOhost
IS  - 2
KW  - Breast Neoplasms
Cancer Survivors
Minority Groups
Treatment Outcomes -- Evaluation
Analysis of Variance
Black Persons
Breast Neoplasms -- Drug Therapy
Breast Neoplasms -- Radiotherapy
Breast Neoplasms -- Surgery
Brief Pain Inventory
California
Cancer Fatigue
Center for Epidemiological Studies Depression Scale
Chi Square Test
Clinical Assessment Tools
Coefficient Alpha
Convenience Sample
Data Analysis Software
Depression
Descriptive Research
Education, Continuing (Credit)
Female
Funding Source
Hispanic Americans
Interviews
Middle Age
Postoperative Pain
Psychological Tests
Regression
Research Subject Recruitment
Retrospective Design
White Persons
Human
N1  - CEU; exam questions; research; tables/charts. Journal Subset: Core Nursing; Double Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Nursing; Peer Reviewed; USA. Instrumentation: Brief Pain Inventory (BPI); Center for Epidemiologic Studies Depression Scale (CES-D); Piper Fatigue Scale. Grant Information: Funded by a California Breast Cancer Research Project Community Research Collaborative Award (Project # 7BB-1500). NLM UID: 7809033.
PMID: NLM15759063.
PY  - 2005
SN  - 0190-535X
SP  - 250-256
ST  - Post-treatment symptoms among ethnic minority breast cancer survivors
T2  - Oncology Nursing Forum
TI  - Post-treatment symptoms among ethnic minority breast cancer survivors
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106606014&site=ehost-live&scope=site
VL  - 32
ID  - 2026
ER  - 

TY  - JOUR
AB  - Objective: Despite numerous clinical trials, it is unknown whether ethnicity affects treatment response to cognitive enhancers in Alzheimer's disease (AD). There is convincing evidence of ethnic and genetic variability in drug metabolism. This article reviews the available data on ethnicity in clinical trials for AD to answer two questions: (1) what are the challenges to diagnose and treat AD across different ethnic groups, and (2) are there differences in response to pharmacologic interventions for AD across these different ethnic groups? Method: Available data from Alzheimer's Disease Cooperative Study (ADCS) randomized controlled clinical trials and from randomized controlled industry-sponsored trials for four cognitive enhancers (donepezil, galantamine, rivastigmine and sabeluzole) were pooled to assess the numbers of non-Caucasian participants. Results: The participation of ethnic minority subjects in clinical trials for AD was dependent on the funding source, although Caucasian participants were over-represented and non-Caucasian participants were under-represented in the clinical trials. Because of the low participation rate of ethnic minorities, there were insufficient data to assess any differences in treatment outcome among different ethnic groups. Strategies to improve diversity in clinical trials are discussed. Conclusion: Greater participation of ethnically diverse participants in clinical trials for AD would generate additional information on possible differences in metabolism, treatment response, adverse events to therapeutic agents, and could foster the investigation of genetic variability among ethnic groups.
AN  - WOS:000246984800016
AU  - Faison, W. E.
AU  - Schultz, S. K.
AU  - Aerssens, J.
AU  - Alvidrez, J.
AU  - Anand, R.
AU  - Farrer, L. A.
AU  - Jarvik, L.
AU  - Manly, J.
AU  - McRae, T.
AU  - Murphy, G. M.
AU  - Olin, J. T.
AU  - Regier, D.
AU  - Son, M.
AU  - Mintzer, J. E.
DA  - Jun
DO  - 10.1017/S104161020700511X
IS  - 3
N1  - 17451614
PY  - 2007
SN  - 1041-6102
SP  - 539-558
ST  - Potential ethnic modifiers in the assessment and treatment of Alzheimer's disease: challenges for the future
T2  - International Psychogeriatrics
TI  - Potential ethnic modifiers in the assessment and treatment of Alzheimer's disease: challenges for the future
VL  - 19
ID  - 3195
ER  - 

TY  - JOUR
AN  - 12625318
AU  - Levenson, D.
DA  - Nov 1
DP  - HSR
ET  - 2003/03/11
IS  - 21
KW  - African Americans/*statistics & numerical data
Breast Neoplasms/ethnology/*mortality
Clinical Trials as Topic
European Continental Ancestry Group/statistics & numerical data
Female
Humans
Outcome Assessment, Health Care
Poverty/*statistics & numerical data
Prognosis
Risk Factors
Survival
United States/epidemiology
LA  - eng
N1  - Levenson, Deborah
News
United States
Rep Med Guidel Outcomes Res. 2002 Nov 1;13(21):9-10, 12.
PY  - 2002
SN  - 1050-5636 (Print)
1050-5636
SP  - 9-10, 12
ST  - Poverty is a major factor in African American breast cancer deaths
T2  - Rep Med Guidel Outcomes Res
TI  - Poverty is a major factor in African American breast cancer deaths
VL  - 13
ID  - 654
ER  - 

TY  - JOUR
AB  - Background: The majority of women diagnosed with breast cancer are overweight or obese, and gain weight after diagnosis. The Practice‐based Opportunities for Weight Reduction (POWER) study reported that, in an obese population with cardiovascular risk factors, a scalable remote weight loss intervention with web support was equally effective to an in‐person intervention (Appel NEJM 2011). We adapted the remote intervention for breast cancer survivors. Methods: We conducted a phase II single‐blind trial in which women with stage 0‐III breast cancer and a BMI ≥25 were randomized to a remotely‐delivered weight loss intervention with a study specific website (POWER‐remote) or to self‐directed weight loss. Participants were stratified by menopausal status and concomitant hormone therapy use. Weight was assessed at baseline, 6 and 12 months. The primary objective was to compare the proportion of women who lost ≥5% of their baseline body weight after 6 months in the POWER‐remote and the self‐directed arms. A sample size of 80 patients yielded approximately 93.6% power to detect a difference in weight loss response of 19.0% in the self‐directed arm and 38.2% in the POWER‐remote arm with a one‐sided type I error of 10%. We obtained blood samples for correlative studies including inflammatory biomarkers and assessment of telomere length at baseline and 6 months. Results: From 2013‐2015 we enrolled 96 women; 84 were evaluable for the primary analysis. Both cohorts had similar baseline characteristics including menopausal status, race (77% Caucasian and 20% African American in entire cohort), and BMI (average mean 32 kg/m2). The majority (93%) of patients received endocrine therapy, and 55% had completed chemotherapy. At 6 months 43.1% (95% CI 29.3‐57.8) of women randomized to POWER‐remote had lost ≥5% of their baseline body weight, compared to 11.1% (95% CI 3.7‐24.1) in the self‐directed arm, p<0.001. A significant difference continued at 12 months, and was observed in all subgroups (Table 1). Biomarker analysis will be presented at the meeting. Conclusions: Sustained weight loss over 1 year is feasible in breast cancer survivors who undergo a remotely delivered weight loss intervention. Weight loss was observed irrespective of endocrine therapy or chemotherapy. These data will be used to design a new trial with a physical activity component.
AN  - CN-01377939
AU  - Santa-Maria, C. A.
AU  - Coughlin, J.
AU  - Blackford, A.
AU  - Carpenter, A.
AU  - Dalcin, A.
AU  - Huang, C. Y.
AU  - Luber, B.
AU  - Schreyer, C.
AU  - Armanios, M.
AU  - Sharma, D.
AU  - et al.
DO  - 10.1158/1538-7445.SABCS16-P4-14-01
IS  - 4
KW  - *breast cancer
*weight loss program
African American
Blood
Body mass
Cancer survivor
Caucasian
Chemotherapy
Controlled clinical trial
Controlled study
Female
Hormonal therapy
Human
Human tissue
Major clinical study
Phase 2 clinical trial
Physical activity
Randomized controlled trial
Sample size
Telomere length
M3  - Journal: Conference Abstract
PY  - 2017
ST  - POWER-remote: a randomized study evaluating the effect of a remote-based weight loss program in women with early stage breast cancer
T2  - Cancer research
TI  - POWER-remote: a randomized study evaluating the effect of a remote-based weight loss program in women with early stage breast cancer
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01377939/full
VL  - 77
ID  - 1560
ER  - 

TY  - JOUR
AB  - PURPOSE: To determine the association of pre-diagnostic allostatic load (AL) with health-related quality of life (HRQOL) among Black women with breast cancer. METHODS: In a sample of 409 Black women with non-metastatic breast cancer enrolled in the Women's Circle of Health Follow-Up Study (WCHFS), two pre-diagnostic AL measures were estimated using medical records data from up to 12 months prior to breast cancer diagnosis: AL-lipid/metabolic profile-based measure and AL-inflammatory profile-based measure. HRQOL was assessed approximately 24 months post diagnosis, using the Functional Assessment of Cancer Therapy-Breast Cancer (FACT-B) instrument, including 5 subscale scores [presented by physical well-being (PWB), social & family well-being (SFWB), emotional well-being (EWB), functional well-being (FWB), and breast cancer-specific scale (BCS)] and 3 derived total scores [presented by trial outcome index (TOI), Functional Assessment of Cancer Therapy-General (FACT-G) and FACT-B]. We used multivariable logistic regression models, using dichotomized AL scores (lower AL: 0-3 points, higher AL: 4-8 points), to assess the associations between the two pre-diagnostic AL measures and HRQOL. RESULTS: Higher pre-diagnostic AL was associated with poorer FWB and lower FACT-G, but these associations were statistically significant for the AL-inflammatory profile-based measure (FWB: OR 1.63, 95% CI 1.04, 2.56; FACT-G: OR 1.62, 95% CI 1.04, 2.54), but not the AL-lipid/metabolic profile-based measure (FWB: OR 1.45, 95% CI 0.81, 2.59; FACT-G: OR 1.33, 95% CI 0.75, 2.37). CONCLUSION: These findings suggest that higher AL, particularly when measured using the inflammatory profile-based measure, was associated with poorer HRQOL, namely FWB and FACT-G, among Black breast cancer survivors.
AD  - Department of Biostatistics and Epidemiology, Rutgers School of Public Health, Piscataway, NJ, USA.
Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
Department of Medicine, Robert Wood Johnson Medical School, New Brunswick, NJ, USA.
Division of Preventive Medicine, University of Alabama at Birmingham School of Medicine, Birmingham, AL, USA.
Department of Epidemiology and Biostatistics, SUNY Downstate Health Sciences University School of Public Health, Brooklyn, NY, USA.
Department of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Department of Biostatistics and Epidemiology, Rutgers School of Public Health, Piscataway, NJ, USA. Adana.Llanos@Rutgers.edu.
Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA. Adana.Llanos@Rutgers.edu.
AN  - 32914357
AU  - Xing, C. Y.
AU  - Doose, M.
AU  - Qin, B.
AU  - Lin, Y.
AU  - Carson, T. L.
AU  - Plascak, J. J.
AU  - Demissie, K.
AU  - Hong, C. C.
AU  - Bandera, E. V.
AU  - Llanos, A. A. M.
C2  - PMC7657984
C6  - NIHMS1628006
DA  - Dec
DO  - 10.1007/s10549-020-05901-1
DP  - NLM
ET  - 2020/09/12
IS  - 3
KW  - Allostatic load
Black women
Breast cancer survivorship
Health-related quality of life
Longitudinal study
LA  - eng
N1  - 1573-7217
Xing, Cathleen Y
Doose, Michelle
Qin, Bo
Lin, Yong
Carson, Tiffany L
Plascak, Jesse J
Demissie, Kitaw
Hong, Chi-Chen
Bandera, Elisa V
Llanos, Adana A M
Orcid: 0000-0001-9954-9121
K01 CA193527/CA/NCI NIH HHS/United States
P30 CA072720/CA/NCI NIH HHS/United States
R00 MD013300/MD/NIMHD NIH HHS/United States
P01 CA151135/CA/NCI NIH HHS/United States
K99 MD013300/MD/NIMHD NIH HHS/United States
K99MD013300/MD/NIMHD NIH HHS/United States
K07 CA222158/CA/NCI NIH HHS/United States
P01CA151135/Division of Cancer Prevention, National Cancer Institute/
K01CA193527/Division of Cancer Prevention, National Cancer Institute/
HHSN261201300021C/CA/NCI NIH HHS/United States
P30CA072720/Division of Cancer Prevention, National Cancer Institute/
K07CA222158/Division of Cancer Prevention, National Cancer Institute/
R01 CA185623/CA/NCI NIH HHS/United States
R01 CA100598/CA/NCI NIH HHS/United States
R01CA100598/Division of Cancer Prevention, National Cancer Institute/
R01CA185623/Division of Cancer Prevention, National Cancer Institute/
Journal Article
Breast Cancer Res Treat. 2020 Dec;184(3):901-914. doi: 10.1007/s10549-020-05901-1. Epub 2020 Sep 10.
PY  - 2020
SN  - 0167-6806 (Print)
0167-6806
SP  - 901-914
ST  - Pre-diagnostic allostatic load and health-related quality of life in a cohort of Black breast cancer survivors
T2  - Breast Cancer Res Treat
TI  - Pre-diagnostic allostatic load and health-related quality of life in a cohort of Black breast cancer survivors
VL  - 184
ID  - 26
ER  - 

TY  - JOUR
AB  - The aims of this study were to: 1) determine prevalence of anogenital and oral HPV, 2) determine concordance between HPV at anal, perianal, scrotal/penile, and oral sites; and 3) describe factors associated with anogenital HPV types targeted by the 9-valent vaccine. Data were collected from 2012 to 2015 among men who have sex with men 18-26 years of age enrolled in a vaccine trial (N = 145). Penile/scrotal, perianal, anal, and oral samples were tested for 61 HPV types. Logistic regression was used to identify factors associated with types in the 9-valent vaccine. Participants' mean age was 23.0 years, 55.2% were African-American, and 26.2% were Hispanic; 93% had anal, 40% penile, and 6% oral HPV. Among those with anogenital infection, 18% had HPV16. Concordance was low between anogenital and oral sites. Factors independently associated with a 9-valent vaccine-type HPV were: race (African-American vs. White, OR= 2.67, 95% CI =1.11-6.42), current smoking (yes vs. no, OR = 2.37, 95% CI =1.03-5.48), and number of recent receptive anal sex partners (2 + vs. 0, OR = 3.47, 95% CI =1.16-10.4). Most MSM were not infected with HPV16 or HPV18, suggesting that they may still benefit from HPV vaccination, but anogenital HPV was very common, highlighting the importance of vaccinating men before sexual initiation.
AN  - WOS:000469800500008
AU  - Kahn, J. A.
AU  - Belzer, M.
AU  - Chi, X. F.
AU  - Lee, J.
AU  - Gaur, A. H.
AU  - Mayer, K.
AU  - Martinez, J.
AU  - Futterman, D. C.
AU  - Stier, E. A.
AU  - Paul, M. E.
AU  - Chiao, E. Y.
AU  - Reirden, D.
AU  - Goldstone, S. E.
AU  - Martinez, A. P. O.
AU  - Cachay, E. R.
AU  - Barroso, L. F.
AU  - Da Costa, M.
AU  - Wilson, C. M.
AU  - Palefsky, J. M.
AU  - Stier, E.
AU  - Ratner, L.
AU  - Bucher, G.
AU  - Wachsman, W.
AU  - Cachay, E.
AU  - Sitapati, A.
AU  - Goldstone, S.
AU  - Worrall, D.
AU  - Kaplan, L.
AU  - Berry, M.
AU  - Jay, N.
AU  - Palefsky, J.
AU  - Rubin, M.
AU  - Chiao, E.
AU  - Barroso, L.
AU  - Bachmann, L.
AU  - Tirado-Gomez, M.
AU  - Guiot, H.
AU  - Kapogiannis, B.
AU  - Serchuck, L.
AU  - Borek, N.
AU  - Brouwers, P.
AU  - Allison, S.
AU  - Vena, D.
AU  - Lynne, J.
AU  - Wilson, C.
AU  - Partlow, C.
AU  - Lee, J.
AU  - Korelitz, J.
AU  - Driver, B.
AU  - Bojan
AU  - Campos
AU  - Dillard
AU  - Tucker
AU  - Head
AU  - Dormitzer
AU  - Chambers
DA  - Jun
DO  - 10.1016/j.pvr.2019.01.002
N1  - 30658128
PY  - 2019
SN  - 2405-8521
SP  - 52-61
ST  - Pre-vaccination prevalence of anogenital and oral human papillomavirus in young HIV-infected men who have sex with men
T2  - Papillomavirus Research
TI  - Pre-vaccination prevalence of anogenital and oral human papillomavirus in young HIV-infected men who have sex with men
VL  - 7
ID  - 2821
ER  - 

TY  - JOUR
AB  - Background: Few studies have empirically tested the association of allostatic load (AL) with breast cancer clinicopathology. The aim of this study was to examine the association of AL, measured using relevant biomarkers recorded in medical records before breast cancer diagnosis, with unfavorable tumor clinicopathologic features among Black women. Methods: In a sample of 409 Black women with nonmetastatic breast cancer who are enrolled in the Women's Circle of Health Follow-Up Study, we estimated prediagnostic AL using two measures: AL measure 1 [lipid profile–based—assessed by systolic and diastolic blood pressure (SBP, DBP), high-density lipoprotein, low-density lipoprotein, total cholesterol, triglycerides, and glucose levels; waist circumference; and use of diabetes, hypertension, or hypercholesterolemia medication] and AL measure 2 (inflammatory index–based—assessed by SBP, DBP, glucose, and albumin levels; estimated glomerular filtration rate; body mass index; waist circumference; and use of medications previously described). We used Cohen's statistic to assess agreement between the two AL measures and multivariable logistic models to assess the associations of interest. Results: AL measures 1 and 2 moderately agreed (k = 0.504). Higher prediagnostic AL predicted higher grade (poorly differentiated vs. well/moderately differentiated) using AL measure 1 [OR = 2.16; 95% confidence interval (CI), 1.18–3.94] and AL measure 2 (OR = 1.60; 95% CI, 1.02–2.51), and larger tumor size (≥2 cm vs. <2 cm; OR = 1.58; 95% CI, 1.01–2.46) using AL measure 2 only. Conclusions: Elevated prediagnostic AL might contribute to more unfavorable breast cancer clinicopathology. Impact: Addressing elevated prediagnostic levels of AL has potentially important clinical implications. ©2019 American Association for Cancer Research.
AD  - Department of Biostatistics and Epidemiology, Rutgers School of Public Health, Piscataway, NJ, United States
Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, United States
Department of Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, United States
Division of Medical Oncology, Department of Internal Medicine, University of Kentucky College of Medicine, Lexington, KY, United States
Markey Cancer Center, University of Kentucky, Lexington, KY, United States
Department of Epidemiology and Biostatistics, SUNY Downstate Health Sciences, University School of Public Health, Brooklyn, NY, United States
Department of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States
AU  - Xing, C. Y.
AU  - Doose, M.
AU  - Qin, B.
AU  - Lin, Y.
AU  - Plascak, J. J.
AU  - Omene, C.
AU  - He, C.
AU  - Demissie, K.
AU  - Hong, C. C.
AU  - Bandera, E. V.
AU  - Llanos, A. A. M.
DB  - Scopus
DO  - 10.1158/1055-9965.EPI-19-0712
M3  - Article
N1  - Cited By :5
Export Date: 22 March 2021
PY  - 2020
SP  - 216-224
ST  - Prediagnostic allostatic load as a predictor of poorly differentiated and larger sized breast cancers among black women in the Women's Circle of health follow-up study
T2  - Cancer Epidemiology Biomarkers and Prevention
TI  - Prediagnostic allostatic load as a predictor of poorly differentiated and larger sized breast cancers among black women in the Women's Circle of health follow-up study
UR  - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85077913490&doi=10.1158%2f1055-9965.EPI-19-0712&partnerID=40&md5=0a0de0f2a43d517f2af948ff59fc21b4
VL  - 29
ID  - 2212
ER  - 

TY  - JOUR
AB  - OBJECTIVES • To investigate baseline demographic and clinicopathological characteristics of men who participate in our penile rehabilitation programme after radical prostatectomy (RP). • To determine predictors for participation in rehabilitation, as well as successful rehabilitation outcome using multivariable logistic regression analyses. PATIENTS AND METHODS • We analysed data on 2345 consecutive patients who underwent RP between 2001 and 2009 in our institution. • The decision to participate in penile rehabilitation using phosphodiesterase type 5 inhibitor (PDE5i) with a vacuum erection device (VED) was based on the patient's choice after post-RP discussions. • Rehabilitation success was defined using the following criteria: (i) patients who continued the penile rehabilitation programme and did not switch treatment from PDE5i to other erectile aids, (ii) success was noted in men who had an Expanded Prostate Cancer Index Composite (EPIC) sexual function (SF) score of > 75% of the patient's baseline EPIC score, and (iii) patients who answered that they achieved adequate erections with a PDE5i. • Logistic regression analysis was used to identify factors associated with treatment participation and its success. RESULTS • Of 676 patients, 354 (53.2%) men participated in a penile rehabilitation programme. Among 329 rehabilitation participants with available data, 96 (29.2%) had treatment success. • In multivariable regression analysis, African-Americans (odds ratio [ OR ] 3.47, P < 0.001), and higher preoperative SF (OR 1.02, P < 0.001) were associated with participation in rehabilitation. • Higher preoperative PSA concentration (OR 0.50, P =0.004) and presence of positive surgical margins (OR 0.68, P =0.042) were found to be independent predictors for non-participation in the rehabilitation. • For rehabilitation outcomes, being older at surgery (OR 0.93, P =0.001) and adjuvant therapy (OR 0.34, P =0.047) had a negative association with successful outcome. • There was a trend in the relationship between primary surgeon and rehabilitation success (OR 1.05, P =0.053) CONCLUSIONS • Those patients who have risk factors, e.g. adverse prostate cancer features, need to be carefully counselled and encouraged to participate in the penile rehabilitation programme. • Clinicians could lead patients toward successful outcomes if appropriate surgical techniques and rehabilitation are provided. © 2012 THE AUTHORS.
AD  - M. Kimura, Duke University Medical Center, PO Box 2804, Yellow Zone, Durham, NC 27710, United States
AU  - Kimura, M.
AU  - Caso, J. R.
AU  - Bañez, L. L.
AU  - Koontz, B. F.
AU  - Gerber, L.
AU  - Senocak, C.
AU  - Donatucci, C. F.
AU  - Vujaskovic, Z.
AU  - Moul, J. W.
AU  - Polascik, T. J.
DB  - Embase
Medline
DO  - 10.1111/j.1464-410X.2012.11168.x
IS  - 11 C
KW  - phosphodiesterase V inhibitor
prostate specific antigen
adjuvant therapy
adult
African American
age
article
clinical feature
controlled study
demography
human
major clinical study
male
outcome assessment
patient assessment
patient decision making
patient participation
penile rehabilitation program
penis erection
postoperative care
priority journal
prostate cancer
prostatectomy
protein blood level
rehabilitation care
scoring system
sexual function
urological therapeutic device
vacuum erection assistance device
LA  - English
M3  - Article
N1  - L51980017
2012-04-25
2013-06-12
PY  - 2012
SN  - 1464-4096
1464-410X
SP  - E931-E938
ST  - Predicting participation in and successful outcome of a penile rehabilitation programme using a phosphodiesterase type 5 inhibitor with a vacuum erection device after radical prostatectomy
T2  - BJU International
TI  - Predicting participation in and successful outcome of a penile rehabilitation programme using a phosphodiesterase type 5 inhibitor with a vacuum erection device after radical prostatectomy
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L51980017&from=export
http://dx.doi.org/10.1111/j.1464-410X.2012.11168.x
VL  - 110
ID  - 1104
ER  - 

TY  - JOUR
AB  - Background: Cortisol, a stress-related hormone, has been measured in many psychoimmunological studies via collection of saliva; however, patterns of participant adherence to protocol procedures are rarely described in the literature. Objectives: In this paper we examine adherence to a cortisol morning rise collection protocol and explore its associations with demographic predictors and fatigue. Method: Participants included 262 breast cancer survivors enrolled in a National Institute of Nursing Research funded longitudinal intervention study (5R01NR010190, M. Mishel, P.I.). Self-reported times of salivary cortisol collection were recorded for each of 12 saliva samples. Adherence was assessed with respect to various demographic factors and fatigue. Participants were categorized as having high, moderate, or low adherence to the saliva collection protocol. Results: Overall, 117 (45%) participants had high adherence to the protocol, 117 (45%) participants had moderate adherence, and 28 (∼11%) participants had low adherence. Tests for proportionality for the polytomous logistic regression indicated that demographic predictors in our model had a similar association with each level of participant adherence. Women who did not adhere to the saliva collection were more likely to be African American (OR .50, CI .29–.88) and to report a high impact of fatigue on their behaviors (OR .88, CI .79–.98). Though other predictors in the model were not statistically significant (working full-time and living with at least one child under 18 years of age), the overall model was significant (χ²(4) = 17.35, p < .01). Discussion: To our knowledge, this is the first study to examine profiles of participant adherence to a cortisol sampling protocol over multiple timepoints. By conceptualizing adherence as a polytomous outcome, future studies may give us insights into adherence trends in other populations with the aim of promoting adherence and designing more informed saliva collection protocols. (PsycINFO Database Record (c) 2016 APA, all rights reserved)
AD  - Mishel, Merle H., School of Nursing, University of North Carolina at Chapel Hill, CB# 7460, Chapel Hill, NC, US, 27599
AN  - 2010-20107-001
AU  - Hall, Daniel L.
AU  - Blyler, Diane
AU  - Allen, Deborah
AU  - Mishel, Merle H.
AU  - Crandell, Jamie
AU  - Germino, Barbara B.
AU  - Porter, Laura S.
DB  - psyh
DO  - 10.1016/j.psyneuen.2010.08.008
DP  - EBSCOhost
IS  - 4
KW  - participant adherence
cortisol collection protocol
breast cancer survivors
demographic factors
fatigue
Adult
Arousal
Circadian Rhythm
Female
Forecasting
Humans
Hydrocortisone
Longitudinal Studies
Middle Aged
Patient Compliance
Saliva
Specimen Handling
Wakefulness
Young Adult
Breast Neoplasms
Data Collection
Demographic Characteristics
Experimental Subjects
Survivors
N1  - School of Nursing, University of North Carolina at Chapel Hill, Chapel Hill, NC, US. Release Date: 20100927. Correction Date: 20150615. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: English. Major Descriptor: Breast Neoplasms; Data Collection; Demographic Characteristics; Fatigue; Hydrocortisone. Minor Descriptor: Experimental Subjects; Survivors. Classification: Research Methods & Experimental Design (2260); Cancer (3293). Population: Human (10); Female (40). Location: US. Age Group: Adulthood (18 yrs & older) (300); Young Adulthood (18-29 yrs) (320); Thirties (30-39 yrs) (340); Middle Age (40-64 yrs) (360). Tests & Measures: Piper Fatigue Scale—Revised DOI: 10.1037/t18854-000. Methodology: Empirical Study; Longitudinal Study; Quantitative Study. References Available: Y. Page Count: 7. Issue Publication Date: May, 2011. Publication History: Accepted Date: Aug 23, 2010; Revised Date: Aug 5, 2010; First Submitted Date: May 24, 2010. Copyright Statement: All rights reserved. Elsevier Ltd. 2010.
Sponsor: National Institute of Nursing Research, US. Grant: 5R01NR010190. Recipients: No recipient indicated
PY  - 2011
SN  - 0306-4530
1873-3360
SP  - 540-546
ST  - Predictors and patterns of participant adherence to a cortisol collection protocol
T2  - Psychoneuroendocrinology
TI  - Predictors and patterns of participant adherence to a cortisol collection protocol
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2010-20107-001&site=ehost-live&scope=site
mishel@email.unc.edu
VL  - 36
ID  - 1770
ER  - 

TY  - JOUR
AB  - Background: Lay health advisor (LHA) programs are increasingly being implemented in the USA and globally in the context of health promotion and disease prevention. LHAs are effective in addressing health disparities when used to reach medically underserved populations, with strong evidence among African American and Hispanic women. Despite their success and the evidence supporting implementation of LHA programs in community settings, there are tremendous barriers to sustaining LHA programs and little is understood about their implementation and sustainability in "real-world" settings. The purpose of this study was to (1) propose a conceptual framework to investigate factors at individual, social, and organizational levels that impact LHA activity and retention; and (2) use prospective data to investigate the individual, social, and organizational factors that predict activity level and retention among a community-based sample of African American LHAs participating in an effective, evidence-based LHA program (National Witness Project; NWP). Methods: Seventy-six LHAs were recruited from eight NWP sites across the USA. Baseline predictor data was collected from LHAs during a telephone questionnaire administered between 2010 and 2011. Outcome data on LHA participation and program activity levels were collected in the fall of 2012 from NWP program directors. Chi-square and ANOVA tests were used to identify differences between retained and completely inactive LHAs, and LHAs with high/moderate vs. low/no activity levels. Multivariable logistic regression models were conducted to identify variables that predicted LHA retention and activity levels. Results: In multivariable models, LHAs based at sites with academic partnerships had increased odds of retention and high/moderate activity levels, even after adjusting for baseline LHA activity level. Higher religiosity among LHAs was associated with decreased odds of being highly/moderately active. LHA role clarity and self-efficacy were associated with retention and high/moderate activity in multivariable models unadjusted for baseline LHA activity level. Conclusions: Organizational and role-related factors are critical in influencing the retention and activity levels of LHAs. Developing and fostering partnerships with academic institutions will be important strategies to promote successful implementation and sustainability of LHA programs. Clarifying role expectations and building self-efficacy during LHA recruitment and training should be further explored to promote LHA retention and participation.
AN  - WOS:000373181400002
AU  - Shelton, R. C.
AU  - Dunston, S. K.
AU  - Leoce, N.
AU  - Jandorf, L.
AU  - Thompson, H. S.
AU  - Crookes, D. M.
AU  - Erwin, D. O.
DA  - Mar
DO  - 10.1186/s13012-016-0403-9
N1  - 41
27000149
PY  - 2016
SN  - 1748-5908
ST  - Predictors of activity level and retention among African American lay health advisors (LHAs) from The National Witness Project: Implications for the implementation and sustainability of community-based LHA programs from a longitudinal study
T2  - Implementation Science
TI  - Predictors of activity level and retention among African American lay health advisors (LHAs) from The National Witness Project: Implications for the implementation and sustainability of community-based LHA programs from a longitudinal study
VL  - 11
ID  - 2950
ER  - 

TY  - JOUR
AB  - PURPOSE: Although African-Americans experience higher cancer morbidity and mortality rates compared to their White counterparts, their participation in biospecimen research is lower than that of their white peers. This study investigated the prevalence and predictors of biospecimen donation in a large, cohort study of Black women. METHODS: The BWHS is a follow-up study of U.S. Black women aged 21-69 years enrolled through postal health questionnaires. Between January 2004 and December 2007, participants were sent a consent form with a postage-paid return envelope, and a mouthwash collection kit. Univariate and age- and educational status-adjusted logistic regression models were used to estimate the association of socio-demographic, lifestyle and medical factors with donation of biospecimens. RESULTS: Buccal cells with consent forms were obtained from 26,790 women, for a response rate of 51 %. The strongest predictors of biospecimen donation were age: response increased from 48.6 % among those aged <40 to 63.1 % among those aged 60 and older [RR 1.30 (95 % CI 1.27, 1.34)]; multivitamin use [RR (95 % CI) 1.32 (1.30, 1.34)]; physician visit in the previous 2 years [RR (95 % CI) 1.61 (1.58, 1.65)], and a history of breast [RR (95 % CI) 1.59 (1.56, 1.63)], colon [RR (95 % CI) 1.18 (1.16, 1.20)], and cervical [RR (95 % CI) 1.63 (1.60, 1.67)] cancer screening. CONCLUSIONS: We found that 51 % of women in the geographically-dispersed Black Women's Health Study cohort were willing to provide mouthwash samples to be used for genetic analyses. The response in this study is encouraging given published findings of low overall participation rates of African-Americans in genetic studies.
AD  - Georgetown-Lombardi Comprehensive Cancer Center, 3970 Reservoir Road, N.W., E501, Washington, DC, 20057, USA. lla9@georgetown.edu.
Georgetown-Lombardi Comprehensive Cancer Center, 3970 Reservoir Road, N.W., E501, Washington, DC, 20057, USA.
Slone Epidemiology Center, Boston University, Boston, MA, USA.
AN  - 27106577
AU  - Adams-Campbell, L. L.
AU  - Dash, C.
AU  - Palmer, J. R.
AU  - Wiedemeier, M. V.
AU  - Russell, C. W.
AU  - Rosenberg, L.
AU  - Cozier, Y. C.
C2  - PMC5089698
C6  - NIHMS824709
DA  - Jun
DO  - 10.1007/s10552-016-0747-0
DP  - NLM
ET  - 2016/04/24
IS  - 6
KW  - Adult
African Americans/*statistics & numerical data
Age Factors
Aged
Biological Specimen Banks
Breast Neoplasms/diagnosis
Cohort Studies
Colonic Neoplasms/diagnosis
Early Detection of Cancer/*statistics & numerical data
Female
Follow-Up Studies
*Health Behavior
Humans
Logistic Models
Middle Aged
*Patient Selection
Sequence Analysis, DNA
Specimen Handling
Surveys and Questionnaires
Uterine Cervical Neoplasms/diagnosis
Vitamins/therapeutic use
Women's Health
Young Adult
Biospecimens
Blacks
Buccal cells
DNA
Genetics
Women
LA  - eng
N1  - 1573-7225
Adams-Campbell, Lucile L
Dash, Chiranjeev
Palmer, Julie R
Wiedemeier, Manuela V
Russell, Cordelia W
Rosenberg, Lynn
Cozier, Yvette C
R01 CA098663/CA/NCI NIH HHS/United States
K07 CA197112/CA/NCI NIH HHS/United States
U01 CA182898/CA/NCI NIH HHS/United States
R01 CA058420/CA/NCI NIH HHS/United States
UM1 CA164974/CA/NCI NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
Cancer Causes Control. 2016 Jun;27(6):797-803. doi: 10.1007/s10552-016-0747-0. Epub 2016 Apr 22.
PY  - 2016
SN  - 0957-5243 (Print)
0957-5243
SP  - 797-803
ST  - Predictors of biospecimen donation in the Black Women's Health Study
T2  - Cancer Causes Control
TI  - Predictors of biospecimen donation in the Black Women's Health Study
VL  - 27
ID  - 213
ER  - 

TY  - JOUR
AB  - BACKGROUND: Death in the absence of disease recurrence (competing mortality) is an important determinant of disease-free survival (DFS) in early breast cancer. The authors sought to identify predictors of this event using competing risks modeling. METHODS: A cohort study was made of 1231 consecutive women with stage I to II invasive breast cancer diagnosed between 1986 and 2004, treated with breast conservation therapy. Median follow-up was 82 months. The authors used a parametric competing risks regression model to analyze factors associated with the cumulative incidence of competing mortality. They generated a risk score from the model coefficient estimates and stratified patients according to low and high risk score for analysis. RESULTS: Ten-year DFS was 69.7% (95% confidence interval [CI], 66.2%-72.9%). The 10-year cumulative incidence of locoregional recurrence (LRR) was 4.4% (95% CI, 3.0%-5.8%), distant recurrence was 7.1% (95% CI, 5.4%-8.9%), and competing mortality was 18.7% (95% CI, 15.9%-21.6%). On multivariate analysis, competing mortality was associated with increasing age (hazard ratio [HR], 1.83 per 10 years; 95% CI, 1.58-2.12), black race (HR, 1.71; 95% CI, 1.17-2.51), and comorbid disease (HR, 1.93, 95% CI, 1.40-2.65). Ten-year cumulative incidences of competing mortality, locoregional recurrence, and distant recurrence for patients at low (n=638) versus high (n=593) risk of competing mortality were 7.2% versus 30.6% (P<.001), 4.4% versus 4.4% (P=.97), and 8.6% versus 5.6% (P=.12), respectively. CONCLUSIONS: Competing mortality is an important event influencing 10-year DFS in early breast cancer and is associated with increasing age, black race, and comorbid disease. Stratifying patients according to competing mortality risk may be useful in designing clinical trials.
AD  - Department of Radiation Oncology, University of California San Diego/Moores Cancer Center, La Jolla, California 92129, USA. lmell@ucsd.edu
AN  - 20737562
AU  - Mell, L. K.
AU  - Jeong, J. H.
AU  - Nichols, M. A.
AU  - Polite, B. N.
AU  - Weichselbaum, R. R.
AU  - Chmura, S. J.
DA  - Dec 1
DO  - 10.1002/cncr.25370
DP  - NLM
ET  - 2010/08/26
IS  - 23
KW  - Adult
Age Factors
Aged
Aged, 80 and over
Breast Neoplasms/complications/*mortality
Clinical Trials as Topic
Cohort Studies
*Comorbidity
Continental Population Groups
*Disease-Free Survival
Female
Humans
Middle Aged
Models, Statistical
Neoplasm Metastasis
Neoplasm Recurrence, Local/mortality
Recurrence
Risk Factors
*Statistics as Topic
LA  - eng
N1  - Mell, Loren K
Jeong, Jong-Hyeon
Nichols, Michael A
Polite, Blase N
Weichselbaum, Ralph R
Chmura, Steven J
Journal Article
United States
Cancer. 2010 Dec 1;116(23):5365-73. doi: 10.1002/cncr.25370. Epub 2010 Aug 24.
PY  - 2010
SN  - 0008-543X (Print)
0008-543x
SP  - 5365-73
ST  - Predictors of competing mortality in early breast cancer
T2  - Cancer
TI  - Predictors of competing mortality in early breast cancer
VL  - 116
ID  - 414
ER  - 

TY  - JOUR
AB  - Purpose: A fraction of smokers considered eligible for pharmacotherapy treatment trials for nicotine dependence enrolled. Little is known about smokers not enrolling in a treatment trial or how these smokers differ from those who have enrolled. Procedures: We screened 2257 individuals for a smoking cessation trial involving behavioral counseling and a novel medication. Findings: Of those screened, 33% of callers were eligible for enrollment (N=753). Of those eligible for the trial, 37% attended the subsequent enrollment session (N=282). We compared the 282 attendees to the 471 smokers who were eligible for the trial but did not attend. Logistic regression indicated that African American smokers were about half as likely to enroll in the trial (odds ratio [OR], 0.55; 95% CI, 0.36-0.84); for every year increase in age, participants were 4% more likely to enroll (OR, 1.04; 95% CI, 1.02-1.06); and participants who were motivated to enroll in the trial for financial incentives were 42% less likely to enroll in the trial (OR, 0.58; 95% CI, 0.45-0.76). Conclusions: These findings suggest the need to devise and test recruitment strategies directed toward African Americans and younger smokers to increase enrollment among eligible smokers to smoking cessation treatment trials. (PsycINFO Database Record (c) 2016 APA, all rights reserved)
AD  - Schnoll, Robert A., Department of Psychiatry, University of Pennsylvania, 3535 Market St, 4th Floor, Philadelphia, PA, US, 19104
AN  - 2009-07617-003
AU  - Dahm, Jamie Lyn
AU  - Cook, Elaina
AU  - Baugh, Kaylene
AU  - Wileyto, E. Paul
AU  - Pinto, Angela
AU  - Leone, Frank
AU  - Halbert, Chanita Hughes
AU  - Schnoll, Robert A.
DB  - psyh
DO  - 10.1016/S0027-9684(15)30931-7
DP  - EBSCOhost
IS  - 5
KW  - smokers
pharmacotherapy treatment trials
nicotine dependence
smoking cessation
African Americans
Adolescent
Adult
Aged
Aged, 80 and over
Behavior Therapy
Confidence Intervals
Female
Humans
Logistic Models
Male
Mass Screening
Middle Aged
Multivariate Analysis
Odds Ratio
Patient Acceptance of Health Care
Pennsylvania
Smoking
Surveys and Questionnaires
Young Adult
Blacks
Clinical Trials
Nicotine
Tobacco Smoking
Drug Therapy
N1  - Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, US. Other Publishers: Elsevier Science. Release Date: 20091214. Correction Date: 20160502. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Print. Document Type: Journal Article. Language: English. Major Descriptor: Blacks; Clinical Trials; Nicotine; Smoking Cessation; Tobacco Smoking. Minor Descriptor: Drug Therapy. Classification: Drug & Alcohol Rehabilitation (3383). Population: Human (10); Male (30); Female (40). Location: US. Age Group: Adulthood (18 yrs & older) (300); Young Adulthood (18-29 yrs) (320). Tests & Measures: Mini International Neuropsychiatric Interview DOI: 10.1037/t18597-000. Methodology: Clinical Trial; Empirical Study; Quantitative Study. References Available: Y. Page Count: 6. Issue Publication Date: May, 2009.
Sponsor: Commonwealth of Pennsylvania, Department of Health, US. Grant: SAP 4100027297. Recipients: No recipient indicated
Sponsor: National Cancer Institute, US. Grant: ROI CAI26969; ROI CA95678. Other Details: Transdisciplinary Tobacco Use Research Center Grant. Recipients: No recipient indicated
Sponsor: National Institute on Drug Abuse, US. Grant: P50 CA84718. Recipients: No recipient indicated
Sponsor: National Human Genome Research Institute. Grant: ROI HG004346. Recipients: No recipient indicated
Sponsor: American Cancer Society, US. Grant: RSGPB-05-240-01-CPPB. Recipients: No recipient indicated
Sponsor: Cephalon. Other Details: Company that manufactures modafinil, provided the study medication and financial support for follow-up interviews. Recipients: No recipient indicated
PY  - 2009
SN  - 0027-9684
1943-4693
SP  - 450-455
ST  - Predictors of enrollment in a smoking cessation clinical trial after eligibility screening
T2  - Journal of the National Medical Association
TI  - Predictors of enrollment in a smoking cessation clinical trial after eligibility screening
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2009-07617-003&site=ehost-live&scope=site
schnoll@mail.med.upenn.edu
VL  - 101
ID  - 1796
ER  - 

TY  - JOUR
AB  - BACKGROUND: Clinical trials may offer patients innovative therapeutic options with potentially better outcomes, which are particularly relevant for patients afflicted with lung carcinoma, because current therapies provide only modest survival benefits. Only approximately 5% of patients with newly diagnosed cancer participate in clinical trials nationwide, and African-American (AA) patients are particularly under-represented. METHODS: To determine predictors of clinical trials enrollment, the authors reviewed the medical records of 427 patients with lung carcinoma (175 AA patients and 252 non-AA patients) who were eligible for clinical trials between 1994 and 1998 at the Karmanos Cancer Institute in Detroit, Michigan. Logistic regression analysis was used to assess the association of patient demographic characteristics and clinical trial enrollment. RESULTS: Ninety-one patients (21%) were enrolled onto a lung cancer clinical trial during the period of the current study. Enrollment was associated significantly with race (P < 0.001), gender (P = 0.048), age (P = 0.005), and insurance type (P = 0.024). After multivariable adjustment, only race and gender remained significant predictors of enrollment. AA patients were less likely to enroll than non-AA patients (odds ratio [OR], 0.485; 95% confidence interval [95% CI], 0.243-0.966), and men were more likely than women to enroll (OR, 1.812; 95% CI, 1.033-3.178). CONCLUSIONS: The current results suggest disparities by race and gender in the enrollment of patients onto lung cancer clinical trials and support the need to improve educational and outreach endeavors that would make clinical trials available to a wider range of eligible patients.
AD  - Department of Pediatrics, Wayne State University, Detroit, Michigan 48201, USA. duw@med.wayne.edu
AN  - 16342295
AU  - Du, W.
AU  - Gadgeel, S. M.
AU  - Simon, M. S.
DA  - Jan 15
DO  - 10.1002/cncr.21638
DP  - NLM
ET  - 2005/12/13
IS  - 2
KW  - Aged
Carcinoma/*therapy
Clinical Trials as Topic/*standards
Continental Population Groups
Female
Humans
Lung Neoplasms/*therapy
Male
Middle Aged
*Patient Selection
Sex Factors
LA  - eng
N1  - Du, Wei
Gadgeel, Shirish M
Simon, Michael S
Journal Article
United States
Cancer. 2006 Jan 15;106(2):420-5. doi: 10.1002/cncr.21638.
PY  - 2006
SN  - 0008-543X (Print)
0008-543x
SP  - 420-5
ST  - Predictors of enrollment in lung cancer clinical trials
T2  - Cancer
TI  - Predictors of enrollment in lung cancer clinical trials
VL  - 106
ID  - 577
ER  - 

TY  - JOUR
AB  - African American (AA) men have a higher incidence of and a higher mortality rate for prostate cancer than White men but are less likely to participate in prostate cancer screening. This study identifies predictors for participation in a free prostate cancer screening in 179 men, 64% of whom are AA. Each man was invited to see his personal physician for a free prostate cancer screening following a prostate cancer educational program given at his worksite. 47% of the AA men went to their personal physician following the educational program and received a digital rectal examination (DRE) and a prostate specific antigen (PSA) screening. 16% of the AA men had obtained a DRE in the previous 12 mo. However, 44% subsequently participated in free DRE screening. Similarly, only 6% of the AA men had received a PSA screening in the previous 12 mo, yet 42% obtained a PSA screening after the educational program. Implications for allocating limited resources for education and screening to the high-risk group of AA men are discussed. This study's model of a prostate cancer educational program at worksites followed by attendees visiting their personal physician for screening could be replicated throughout the US to increase AA men's participation in prostate cancer screening. (PsycINFO Database Record (c) 2016 APA, all rights reserved)
AN  - 1998-04138-004
AU  - Weinrich, Sally P.
AU  - Greiner, Ellen
AU  - Reis-Starr, Carol
AU  - Yoon, Stephen
AU  - Weinrich, Martin
DB  - psyh
DO  - 10.1207/s15327655jchn1502_5
DP  - EBSCOhost
IS  - 2
KW  - predictors of participating in prostate screening
40–70 yr old African American vs White males
Adult
African Americans
Aged
Humans
Logistic Models
Male
Mass Screening
Middle Aged
Multivariate Analysis
Occupational Health Services
Odds Ratio
Prostatic Neoplasms
South Carolina
Cancer Screening
Client Participation
Human Males
Prediction
Racial and Ethnic Differences
Blacks
Whites
N1  - U South Carolina, Coll of Nursing, Columbia, SC, US. Other Publishers: Taylor & Francis. Release Date: 19980901. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Print. Document Type: Journal Article. Language: English. Major Descriptor: Cancer Screening; Client Participation; Human Males; Prediction; Racial and Ethnic Differences. Minor Descriptor: Blacks; Whites. Classification: Promotion & Maintenance of Health & Wellness (3365). Population: Human (10); Male (30). Location: US. Age Group: Adulthood (18 yrs & older) (300); Middle Age (40-64 yrs) (360); Aged (65 yrs & older) (380). Methodology: Empirical Study. Page Count: 17. Issue Publication Date: 1998.
PY  - 1998
SN  - 0737-0016
1532-7655
SP  - 113-129
ST  - Predictors of participation in prostate cancer screening at worksites
T2  - Journal of Community Health Nursing
TI  - Predictors of participation in prostate cancer screening at worksites
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=1998-04138-004&site=ehost-live&scope=site
VL  - 15
ID  - 1802
ER  - 

TY  - JOUR
AB  - Blacks who smoke have increased tobacco-related health risks. Cessation decreases the likelihood of many health problems. Smoking reduction may be important in the cessation process and potentially reduce health risks. Because little is known about specific predictors of smoking reduction, we investigated factors predicting reduction among Black light smokers enrolled in a 26-week cessation trial. Specifically, we compared (a) reducers (reduced cigarettes per day [cpd] >= 50%) with nonreducers and (b) reducers with quitters. Baseline demographic, smoking-related, and psychosocial variables were collected, and Week 26 smoking status was assessed. Among 539 participants, 41.0% (n = 221) reduced their smoking, 17.6% (n = 95) quit, and 41.4% (n = 223) did not reduce their smoking by >= 50%. In comparison with reducers, nonreducers were more likely to have their first cigarette within 30 min of waking (odds ratio [OR] = 2.4, 95% CI = 1.47-3.93), lower baseline cpd (OR = 0.84, 95% CI = 0.77-0.93), higher baseline cotinine levels (OR = 1.002, 95% CI = 1.000-1.003), lower perceived stress (OR = 0.86, 95% CI = 0.78-0.95), and higher Smoking Consequences Questionnaire (SCQ) negative social impression scores (OR = 1.04, 95% CI = 1.01-1.06), after controlling for treatment arm, gender, and age. Significant predictors of smoking cessation versus reduction included lower baseline cpd (OR = 0.85, 95% CI = 0.75-0.95), higher nicotine dependence (OR = 1.47, 95% CI = 1.09-1.98), lower baseline cotinine levels (OR = 0.996, 95% CI = 0.994-0.998), higher body mass index (OR = 1.05, 95% CI = 1.01-1.08), lower perceived stress (OR = 0.82, 95% CI = 0.72-0.95), and higher SCQ negative social impression scores (OR = 1.05, 95% CI = 1.01-1.08). Distinct predictors are associated with different trajectories of smoking behavior change (i.e., reduction vs. cessation vs. no change).
AN  - WOS:000276304800013
AU  - Berg, C. J.
AU  - Thomas, J. L.
AU  - Guo, H. F.
AU  - An, L. C.
AU  - Okuyemi, K. S.
AU  - Collins, T. C.
AU  - Ahluwalia, J. S.
DA  - Apr
DO  - 10.1093/ntr/ntq019
IS  - 4
N1  - 20194521
PY  - 2010
SN  - 1462-2203
SP  - 423-431
ST  - Predictors of smoking reduction among Blacks
T2  - Nicotine & Tobacco Research
TI  - Predictors of smoking reduction among Blacks
VL  - 12
ID  - 3117
ER  - 

TY  - JOUR
AB  - BACKGROUND: Disparities in breast cancer care are a worsening problem, requiring effective interventions that seek to address the delivery of high quality cancer care. Evidence from interventions designed to improve timeliness of care routinely identify lack of social support as one of the biggest barriers to care. And, the presence of social support is associated with adherence to treatment and survival. This study explores predictors of social support in a diverse population of newly diagnosed cancer patients seeking care at an urban safety net medical center. METHODS: This is a descriptive analysis of baseline preliminary data from participants enrolled in Project SUPPORT, a randomized controlled comparative effectiveness trial designed to evaluate the impact of patient navigation with or without legal support and services, among women diagnosed with Stages 0‐4 breast cancer between 2014‐2016. Upon enrollment (within one month of a cancer diagnosis) we administered theMedical Outcomes Survey (MOS) of social support to all participants. This validated survey measures functional support, including an overall score (range 0‐95) and 4 distinct domains: Emotional/ Informational, Tangible, Affectionate and Positive Social Interaction. Using chisquared and t‐testswe comparedMOS scores across socio‐demographic variables: age, race, language, insurance, health literacy and marital status. RESULTS: Of the 139 participants, mean age is 54.5 (SD = 10.6); 54%Black, 23%White, 21% Hispanic, and 2% identified as other; the majority had public insurance 76%; 65% speak English, 21% Spanish and 14% Haitian Creole. Only 35% have adequate health literacy as measured by the BRIEF. Only 32% are currently partnered. The overall mean total score for social support is 75.3 (+/‐ 25), median of 81.6 (range 60.5 ‐ 98.7). Participants scored lowest in tangible support (mean score 67.4 +/‐ 34.1) and highest in affective support (mean score 82.7 +/‐ 26.3). Non‐White participants scored lower across all domains (mean overall MOS score 73.5 +/‐ 2.4) when compared withWhites (mean overall MOS score 81.4 +/‐ 4.4). There were no significant differences in MOS scores by language, insurance, literacy or marital status. CONCLUSIONS: This is the first study to describe social support scores (overall and specific domains) from the validated MOS survey tool among a racially diverse, low income urban cancer patient population. Preliminary findings suggest non‐white women are most at risk for low social support, and can thus benefit from targeted interventions.
AN  - CN-01474373
AU  - Ko, N. Y.
AU  - Gunn, C.
AU  - Bak, S.
AU  - Wang, N.
AU  - Nelson, K.
AU  - Flacks, J. H.
AU  - Morton, S.
AU  - Battaglia, T. A.
IS  - 2 Supplement 1
KW  - *breast cancer
*cancer patient
*safety
Adult
Cancer diagnosis
Clinical trial
Comparative effectiveness
Diagnosis
Female
Haitian Creole
Health literacy
Hispanic
Human
Instrument validation
Insurance
Lowest income group
Major clinical study
Marriage
Middle aged
Race
Social interaction
Social support
M3  - Conference Abstract
PY  - 2017
SP  - S283
ST  - Predictors of social supportamongnewly diagnosed breast cancer patients seeking care at an urban safety net academic medical center
T2  - Journal of general internal medicine. Conference: 40th annual meeting of the society of general internal medicine, SGIM 2017. United states
TI  - Predictors of social supportamongnewly diagnosed breast cancer patients seeking care at an urban safety net academic medical center
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01474373/full
VL  - 32
ID  - 1641
ER  - 

TY  - JOUR
AB  - BACKGROUND: Compared with other racial groups, African Americans have the highest colorectal cancer (CRC) incidence and mortality rates coupled with lower screening rates. OBJECTIVE: Our study examined the predictors of stage of adoption for fecal occult blood testing (FOBT) and colonoscopy among African American primary care patients who were nonadherent to published screening guidelines. METHODS: Baseline data (N = 815) in a randomized clinical trial were analyzed. Participants were categorized into precontemplation, contemplation, and preparation stages for FOBT and colonoscopy. Predictor variables were demographics, clinical variables, CRC health beliefs and knowledge, and social support. Hierarchical modeling was to identify significant predictors of stage of adoption. RESULTS: Older, male, Veterans Affairs participants and those with higher perceived self-efficacy, family/friend encouragement, and a provider recommendation had higher odds of being at a more advanced stage of adoption for FOBT. Patients with a history of cancer and higher perceived barriers had higher odds of being at an earlier stage of adoption for FOBT. Predictors of more advanced stage of adoption for colonoscopy included higher perceived benefits, higher perceived self-efficacy, family/friend encouragement, and a provider recommendation for colonoscopy. Higher income (>30 000 vs <15 000) was predictive of earlier stage of adoption for colonoscopy. CONCLUSIONS: Enhancing self-efficacy, encouragement from family and friends, and provider recommendations are important components of interventions to promote CRC screening. IMPLICATIONS FOR PRACTICE: Nurses can use knowledge of the characteristics associated with stage of adoption to educate and motivate their African American primary care patients to complete CRC screening tests.
AD  - Author Affiliations: University of South Florida College of Nursing, Tampa (Dr Wang); Department of Psychology, Purdue University School of Science, Indiana University-Purdue University, Indianapolis (Ms Christy); University of Texas Southwestern Medical Center, Harold C. Simmons Cancer Center, Dallas (Dr Skinner); Indiana University School of Nursing, Indianapolis (Drs Champion and Rawl and Ms Krier); Indiana University Simon Cancer Center, Indianapolis (Drs Champion, Perkins, and Rawl); Grady College of Journalism and Mass Communication, University of Georgia, Athens (Dr Springston); Indiana University School of Medicine, Indianapolis (Drs Perkins and Tong and Ms Gebregziabher).
AN  - 24145250
AU  - Wang, H. L.
AU  - Christy, S. M.
AU  - Skinner, C. S.
AU  - Champion, V. L.
AU  - Springston, J. K.
AU  - Perkins, S. M.
AU  - Tong, Y.
AU  - Krier, C.
AU  - Gebregziabher, N.
AU  - Rawl, S. M.
C2  - PMC3991768
C6  - NIHMS514583
DA  - Jul-Aug
DO  - 10.1097/NCC.0b013e3182a40d8d
DP  - NLM
ET  - 2013/10/23
IS  - 4
KW  - *African Americans/statistics & numerical data
Aged
Aged, 80 and over
Colonoscopy/*nursing
Colorectal Neoplasms/diagnosis/ethnology/mortality/*nursing
Early Detection of Cancer/*nursing
Female
Guideline Adherence
Guidelines as Topic
Health Knowledge, Attitudes, Practice/ethnology
Humans
Incidence
Male
Middle Aged
Nursing Research
*Occult Blood
*Patient Acceptance of Health Care/ethnology
*Patient Compliance/statistics & numerical data
Predictive Value of Tests
*Primary Health Care/statistics & numerical data
Randomized Controlled Trials as Topic
Risk Factors
Self Efficacy
Sensitivity and Specificity
Social Support
United States/epidemiology
Veterans/statistics & numerical data
LA  - eng
N1  - 1538-9804
Wang, Hsiao-Lan
Christy, Shannon M
Skinner, Celette S
Champion, Victoria L
Springston, Jeffrey K
Perkins, Susan M
Tong, Yan
Krier, Connie
Gebregziabher, Netsanet
Rawl, Susan M
R25 CA117865-06/CA/NCI NIH HHS/United States
R01 CA115983/CA/NCI NIH HHS/United States
R25 CA117865/CA/NCI NIH HHS/United States
T32 CA117865/CA/NCI NIH HHS/United States
P30 CA082709/CA/NCI NIH HHS/United States
UL1 TR001108/TR/NCATS NIH HHS/United States
T32 NR007066/NR/NINR NIH HHS/United States
Journal Article
Multicenter Study
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Cancer Nurs. 2014 Jul-Aug;37(4):241-51. doi: 10.1097/NCC.0b013e3182a40d8d.
PY  - 2014
SN  - 0162-220X (Print)
0162-220x
SP  - 241-51
ST  - Predictors of stage of adoption for colorectal cancer screening among African American primary care patients
T2  - Cancer Nurs
TI  - Predictors of stage of adoption for colorectal cancer screening among African American primary care patients
VL  - 37
ID  - 310
ER  - 

TY  - JOUR
AB  - PURPOSE: This paper examines the relationship between race, religiousness, spiritual well-being, antitumor treatment and preference for aggressive care among Black and White patients with advanced stage lung cancer receiving ambulatory cancer care in an urban setting. METHODS: A cross-sectional exploration of patients enrolled in a Cleveland-based longitudinal study after initial diagnosis of advanced lung cancer were interviewed in Cleveland regarding religiousness, spiritual well-being, preferences for cardiopulmonary resuscitation (CPR), goals of aggressive care, and willingness to tolerate adverse health states. Receipt of antitumor treatment was identified from medical records. RESULTS: We analyzed data from 67 Black and 129 White patients (N=196). Regression analysis for CPR showed that race was not associated with preference for CPR (OR=1.12, CI 0.44-2.85). The odds of choosing CPR were three times higher among patients receiving antitumor treatment (OR=3.26, CI 1.12-9.44). Greater willingness to endure adverse health states was associated with higher spiritual well-being scores (b=0.12, CI 0.01-0.25). Choosing goals to extend life versus relieve pain was higher among persons with higher spiritual well-being as well (RRR=1.08, CI 1.01-1.16), yet the relationship with religiousness was negative (RRR=0.46, CI 0.22-0.98). CONCLUSIONS: After controlling for multiple factors, race was associated only with CPR, but not with other measures of preference for aggressive care. In addition, receipt of active antitumor treatment was positively associated with preference for CPR and spiritual well-being was important to setting end-of-life care goals and perspectives. Future directions for tailoring end-of-life care decision-making initiatives should move beyond race and discussions of CPR alone and focus on a full spectrum of patient beliefs and preferences at the end of life.
AD  - Mandel School of Applied Social Sciences, Case Western Reserve University, Cleveland, OH, 44106, USA, gxk56@case.edu.
AN  - 24317850
AU  - Kypriotakis, G.
AU  - Francis, L. E.
AU  - O'Toole, E.
AU  - Towe, T. P.
AU  - Rose, J. H.
DA  - May
DO  - 10.1007/s00520-013-2079-x
DP  - NLM
ET  - 2013/12/10
IS  - 5
KW  - Adult
African Americans/*psychology
Aged
Cardiopulmonary Resuscitation/*psychology
Cross-Sectional Studies
Decision Making
European Continental Ancestry Group/*psychology
Female
Hospice Care/methods/psychology
Humans
Longitudinal Studies
Lung Neoplasms/*ethnology/pathology/psychology/*therapy
Male
Middle Aged
Neoplasm Staging
Religion and Medicine
Spirituality
Terminal Care/methods/*psychology
Vulnerable Populations/ethnology/*psychology
LA  - eng
N1  - 1433-7339
Kypriotakis, George
Francis, Linda E
O'Toole, Elizabeth
Towe, Tanyanika Phillips
Rose, Julia Hannum
Journal Article
Randomized Controlled Trial
Germany
Support Care Cancer. 2014 May;22(5):1251-9. doi: 10.1007/s00520-013-2079-x. Epub 2013 Dec 7.
PY  - 2014
SN  - 0941-4355
SP  - 1251-9
ST  - Preferences for aggressive care in underserved populations with advanced-stage lung cancer: looking beyond race and resuscitation
T2  - Support Care Cancer
TI  - Preferences for aggressive care in underserved populations with advanced-stage lung cancer: looking beyond race and resuscitation
VL  - 22
ID  - 303
ER  - 

TY  - JOUR
AB  - BACKGROUND: Incorporating patients' preferences into colorectal cancer (CRC) screening recommendations has been identified as a potential mechanism for increasing adherence. This study used conjoint analysis to describe variation in CRC screening preferences among racially/ethnically diverse primary care patients. METHODS: We recruited patients ages 50-80 of a large practice-based research network stratified by white, African American, or Hispanic race/ethnicity to complete a preference assessment instrument. Participants were asked to rate 8 hypothetical CRC screening test scenarios comprised of different combinations of 5 attributes and 6 scenarios designed to depict guideline-recommended CRC screening tests (eg, fecal occult blood test, flexible sigmoidoscopy, colonoscopy, and double contrast barium enema) including new technology (eg, virtual colonoscopy, fecal immunochemical test). Responses were used to calculate the overall importance of test attributes, the relative importance of attribute levels, and to identify factors associated with preferences. RESULTS: Two hundred twelve primary care patients were recruited to the study (74 white, 60 African American, 78 Hispanic). Of the guideline-recommended tests, 37% preferred COL, 31% FOBT, 15% BE, and 9% SIG. Ratings of new technology tests were significantly (P < 0.05) higher than ratings of guideline-recommended tests. The order of the importance of attributes was: what the test involved (37%), accuracy (19%), frequency (17%), discomfort (15%), and preparation (13%). Part-worth utilities for 1 attribute showed that collecting a stool sample was most preferable and endoscopy without sedation least preferable. Multivariate regression found that race/ethnicity and specific test attributes were independently associated (P < 0.05) with test preferences. CONCLUSIONS: Primary care patients have distinct preferences for CRC screening tests that can be linked to test attributes. Racial/ethnic variations in test preferences persist when controlling for attributes. Tailoring screening recommendations to patients' preferences may increase screening adherence.
AD  - Department of Internal Medicine, Division of General Medicine and Ann Arbor VA Healthcare System, University of Michigan, Ann Arbor, Michigan 48109, USA. sarahawl@umich.edu
AN  - 18725820
AU  - Hawley, S. T.
AU  - Volk, R. J.
AU  - Krishnamurthy, P.
AU  - Jibaja-Weiss, M.
AU  - Vernon, S. W.
AU  - Kneuper, S.
DA  - Sep
DO  - 10.1097/MLR.0b013e31817d932e
DP  - NLM
ET  - 2008/09/09
IS  - 9 Suppl 1
KW  - African Americans/statistics & numerical data
Aged
Attitude to Health/*ethnology
Colorectal Neoplasms/*diagnosis/*ethnology/psychology
Ethnic Groups/*statistics & numerical data
European Continental Ancestry Group/statistics & numerical data
Female
Hispanic Americans/statistics & numerical data
Humans
Male
Mass Screening/statistics & numerical data
Middle Aged
Multivariate Analysis
Outcome Assessment, Health Care
Patient Acceptance of Health Care/*ethnology
Patient Education as Topic
Patient Satisfaction/*statistics & numerical data
Predictive Value of Tests
Primary Health Care/statistics & numerical data
Surveys and Questionnaires
United States/epidemiology
LA  - eng
N1  - 1537-1948
Hawley, Sarah T
Volk, Robert J
Krishnamurthy, Partha
Jibaja-Weiss, Maria
Vernon, Sally W
Kneuper, Suzanne
P20 HS11187/HS/AHRQ HHS/United States
R21 CA100589/CA/NCI NIH HHS/United States
Comparative Study
Journal Article
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, P.H.S.
United States
Med Care. 2008 Sep;46(9 Suppl 1):S10-6. doi: 10.1097/MLR.0b013e31817d932e.
PY  - 2008
SN  - 0025-7079
SP  - S10-6
ST  - Preferences for colorectal cancer screening among racially/ethnically diverse primary care patients
T2  - Med Care
TI  - Preferences for colorectal cancer screening among racially/ethnically diverse primary care patients
VL  - 46
ID  - 489
ER  - 

TY  - JOUR
AB  - Background: Parenthood after cancer is a critical concern for many cancer patients (pts). Pregnancy (prg) during cancer is an emotional time for about 1/1000 pregnant women. No randomized controlled studies exist examining the impact of cancer treatment (tx) on the developing fetus nor on the woman with cancer. Methods: From 2002‐2011, women presenting for cancer tx during prg were approached for this IRB‐approved prospective database study. All pts provided written consent. Results: To date 143 pts are evaluable. The median age at diagnosis was 32.1 years and median gestational age (GA) at enrollment was 18.2 weeks. 95/143 (66.4%) are White, 19 (13.3%) are African American, 17 (11.9%) are Hispanic and 12 (8.4%) are Asian/Other. Primary cancers included breast (n=59, 41.3%), hematologic (n=29, 20.3%), melanoma (n=13, 9%), GYN (n=11, 8%), GI (n=8, 5.6%), head/neck (n=7, 6%) and other (n=16, 11%) (brain=4, GU=1, thyroid=3, head/neck=7, thoracic=1, sarcoma=6, unknown primary=1). 111/143 (77.6%) of prgs resulted in live births. Median birth weight was 6.5 lbs. Median follow‐up time for pts was 32.3 months. To date, 3/19 pts who terminated prgs have died (1.6%). Most terminations occurred in the 1st trimester. To date, 79 pts (55.2%) are NED and 23 pts have died; of these 19 (1.7%) had live births. No major malformations were observed in the 74/143 (52%) of pts who received chemotherapy (CTx) during pregnancy. 57% received FAC/FEC; other regimens included ABVD (n=5), cytarabine (n=5), CHOP/R‐CHOP, and platinum‐based regimens. Median GA at the start of CTx was 19.7 wks. Median number of CTx cycles during prg was 4. Other pts underwent surgery (n=32), no tx (n=14), deferred tx until after delivery (n=17), radiation (2), transplant (3), other (1). Conclusions: Cancer diagnosis during prg is compatible with successful tx and prg outcome. Cancer tx during the 2nd and 3rd trimester can be safely given and in our pts did not result in adverse prg outcomes. Tx during the 1st trimester is usually not recommended. Thus cancer pts in their 1st trimester need to be extensively counseled about their disease as well as about the risks to the prg. In our pts continuation or termination of prg were not associated with an increased risk of death.
AN  - CN-01008198
AU  - Milbourne, A.
AU  - Sun, C. C.
AU  - Fanale, M. A.
AU  - Theriault, R. L.
AU  - Rimes, S. A.
AU  - Litton, J. K.
AU  - Ramirez, M. M.
IS  - 15
KW  - *female
*human
*neoplasm
*oncology
*pregnancy outcome
*society
African American
Birth weight
Brain
Breast
Cancer diagnosis
Cancer of unknown primary site
Cancer patient
Cancer therapy
Chemotherapy
Congenital malformation
Data base
Death
Diagnosis
Fetus
Follow up
Gestational age
Hispanic
Live birth
Melanoma
Parenthood
Pregnancy
Pregnant woman
Primary tumor
Radiation
Randomized controlled trial
Risk
Sarcoma
Surgery
Thyroid gland
Transplantation
M3  - Journal: Conference Abstract
PY  - 2012
ST  - Pregnancy outcomes in women with cancer
T2  - Journal of clinical oncology
TI  - Pregnancy outcomes in women with cancer
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01008198/full
VL  - 30
ID  - 1509
ER  - 

TY  - JOUR
AB  - BACKGROUND: Sepsis is characterized by metabolic disturbances, and previous data suggest a relative carnitine deficiency may contribute to metabolic dysfunction. Studies regarding safety and patient‐centered efficacy of carnitine during septic shock are lacking. METHODS: This was a double‐blind randomized control trial of levocarnitine (L‐carnitine) infusion vs normal saline for the treatment of vasopressor‐dependent septic shock. Patients meeting consensus definition for septic shock with a cumulative vasopressor index ≥ 3 and sequential organ failure assessment (SOFA) score ≥ 5 enrolled within 16 hours of the recognition of septic shock were eligible. The primary safety outcome was difference in serious adverse events (SAEs) per patient between groups. Efficacy outcomes included proportion of patients demonstrating a decrease in SOFA score of 2 or more points at 24 hours and short‐ and long‐term survival. RESULTS: Of the 31 patients enrolled, 16 were in the L‐carnitine and 15 were in the placebo arm. There was no difference in SAEs between placebo and intervention (2.1 vs 1.8 SAEs per patient, P = .44). There was no difference in the proportion of patients achieving a decrease in SOFA score of 2 or more points at 24 hours between placebo and treatment (53% vs 44%, P = .59). Mortality was significantly lower at 28 days in the L‐carnitine group (4/16 vs 9/15, P = .048), with a nonsignificant improved survival at 1 year (P = .06). CONCLUSION: L‐carnitine infusion appears safe in vasopressor‐dependent septic shock. Preliminary efficacy data suggest potential benefit of L‐carnitine treatment, and further testing is indicated.
AN  - CN-00999396
AU  - Puskarich, M. A.
AU  - Kline, J. A.
AU  - Krabill, V.
AU  - Claremont, H.
AU  - Jones, A. E.
DO  - 10.1177/0148607113495414
IS  - 6
KW  - *carnitine/ae [Adverse Drug Reaction]
*carnitine/ct [Clinical Trial]
*carnitine/dt [Drug Therapy]
*carnitine/iv [Intravenous Drug Administration]
*hypertensive factor/dt [Drug Therapy]
*septic shock/dt [Drug Therapy]
*septic shock/th [Therapy]
Acute kidney failure/si [Side Effect]
Acute respiratory failure/si [Side Effect]
Adrenalin/dt [Drug Therapy]
Adult
African Americans
Aged
Anemia/si [Side Effect]
Article
Artificial ventilation
Body Mass Index
Brain disease/si [Side Effect]
Cardiomyopathies [drug therapy]
Carnitine [deficiency, *pharmacology]
Central cord syndrome/si [Side Effect]
Cerebrovascular accident/si [Side Effect]
Chronic kidney failure/si [Side Effect]
Chronic obstructive lung disease/si [Side Effect]
Clinical article
Consensus
Controlled study
Deep vein thrombosis/si [Side Effect]
Diarrhea/si [Side Effect]
Disease exacerbation/si [Side Effect]
Disseminated intravascular clotting/si [Side Effect]
Dopamine/dt [Drug Therapy]
Dose‐Response Relationship, Drug
Double blind procedure
Double‐Blind Method
Drug efficacy
Drug fatality/si [Side Effect]
Drug infusion
Drug safety
End stage renal disease/si [Side Effect]
Erythrocyte transfusion
European Continental Ancestry Group
Female
Follow up
Gastrointestinal hemorrhage/si [Side Effect]
Heart arrest/si [Side Effect]
Heart atrium fibrillation/si [Side Effect]
Heparin induced thrombocytopenia/si [Side Effect]
Heparin/ae [Adverse Drug Reaction]
Human
Humans
Hyperammonemia [drug therapy]
Hypoglycemia/si [Side Effect]
Hypokalemia/si [Side Effect]
Hypomagnesemia/si [Side Effect]
Infection/si [Side Effect]
Infestation/si [Side Effect]
Liver dysfunction/si [Side Effect]
Long term survival
Lung embolism/si [Side Effect]
Male
Middle Aged
Mortality
Muscular Diseases [drug therapy]
Myopathy/si [Side Effect]
Nausea and vomiting/si [Side Effect]
Neoplasm/si [Side Effect]
Noradrenalin/dt [Drug Therapy]
Obstructive jaundice/si [Side Effect]
Outcome assessment
Patent foramen ovale/si [Side Effect]
Phenylephrine/dt [Drug Therapy]
Placebo
Pneumonia/si [Side Effect]
Pneumothorax/si [Side Effect]
Priority journal
Prospective Studies
Prospective study
Randomized controlled trial
Return of spontaneous circulation
Seizure/si [Side Effect]
Sequential Organ Failure Assessment Score
Shock, Septic [*drug therapy]
Short term survival
Skin abscess/si [Side Effect]
Sodium chloride
Steroid
Survival time
Thrombocytopenia/si [Side Effect]
Treatment Outcome
Vasoconstrictor Agents [*pharmacology]
Vasopressin/dt [Drug Therapy]
M3  - Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non‐U.S. Gov't
PY  - 2014
SP  - 736‐743
ST  - Preliminary safety and efficacy of L-carnitine infusion for the treatment of vasopressor-dependent septic shock: a randomized control trial
T2  - JPEN. Journal of parenteral and enteral nutrition
TI  - Preliminary safety and efficacy of L-carnitine infusion for the treatment of vasopressor-dependent septic shock: a randomized control trial
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00999396/full
VL  - 38
ID  - 1442
ER  - 

TY  - JOUR
AB  - BACKGROUND: African American men are at a higher risk of developing and dying from prostate cancer compared to white men. The serum prostate-specific antigen (PSA) screening test has a high risk of false-positive results and overdiagnosis; therefore, it is not routinely recommended. Rather, men are encouraged to make individualized decisions with their medical providers, after being fully informed about its potential benefits, limitations, and risks. OBJECTIVE: This study aimed to describe the development and pilot testing of an interactive Web-based decision aid (DA; Prostate Cancer Screening Preparation [PCSPrep]) for African American men, designed to promote informed decision making for prostate cancer screening. METHODS: Four focus groups (n=33) were conducted to assess men's reactions to DAs developed in prior studies and gather information to modify the content and format. The pilot test employed a pre-posttest evaluation design. A convenience sample of 41 men aged 45-70 years with no history of prostate cancer was recruited from community settings. Participants completed online surveys before and after using PCSPrep that assessed prostate cancer screening knowledge, decision self-efficacy, decisional conflict, and preparation for decision making. RESULTS: Use of PCSPrep was associated with a significant increase in prostate cancer knowledge (49% vs 62% correct responses; P<.001), and men also experienced less decisional conflict (24 vs 15 on a scale of 0-100; P=.008). No changes in self-efficacy about decision making or screening preferences were observed. Most men (81%) reported that using PCSPrep prepared them to make informed decisions in partnership with their provider. CONCLUSIONS: PCSPrep was an acceptable DA that improved men's knowledge, reduced decisional conflict, and promoted the perception of being prepared for shared decision making. Further research is needed to test the DA in a larger randomized trial.
AD  - Department of Community Health, Tufts University, Medford, MA, United States.
AN  - 32369032
AU  - Allen, J. D.
AU  - Reich, A.
AU  - Cuevas, A. G.
AU  - Ladin, K.
C2  - PMC7238086
DA  - May 5
DO  - 10.2196/15502
DP  - NLM
ET  - 2020/05/06
IS  - 5
KW  - African Americans
Aged
Decision Making
Decision Support Techniques
Early Detection of Cancer
Humans
Male
Middle Aged
Pilot Projects
Prostate-Specific Antigen
*Prostatic Neoplasms/diagnosis
*decision making (shared)
*decision support techniques
*early detection of cancer
*men’s health
*minority health
*prostate neoplasms
LA  - eng
N1  - 2291-5222
Allen, Jennifer Dacey
Orcid: 0000-0002-5888-7930
Reich, Amanda
Orcid: 0000-0001-5922-4154
Cuevas, Adolfo G
Orcid: 0000-0001-9875-3825
Ladin, Keren
Orcid: 0000-0002-4310-8260
Journal Article
JMIR Mhealth Uhealth. 2020 May 5;8(5):e15502. doi: 10.2196/15502.
PY  - 2020
SN  - 2291-5222
SP  - e15502
ST  - Preparing African American Men to Make Informed Prostate Cancer Screening Decisions: Development and Pilot Testing of an Interactive Online Decision Aid
T2  - JMIR Mhealth Uhealth
TI  - Preparing African American Men to Make Informed Prostate Cancer Screening Decisions: Development and Pilot Testing of an Interactive Online Decision Aid
VL  - 8
ID  - 37
ER  - 

TY  - JOUR
AB  - OBJECTIVE: To define the prevalence and patterns of self-initiated herbal and vitamin supplementation among men at high risk of developing prostate cancer, as there is increasing public awareness of prostate cancer screening, risk-factor assessment and prevention, leading to increasing interest in the use and systematic study of nutritional therapies for prostate cancer prevention. SUBJECTS AND METHODS: Since 1996 our institution has prospectively maintained a prostate cancer-risk registry through its Prostate Cancer Risk Assessment Program (PRAP). Eligibility includes African-American men, any man with at least one first-degree relative or two or more second-degree relatives with prostate cancer, or men who tested positively for the BRCA1 gene mutation. A 420-item self-administered questionnaire was completed and included the use of nutritional supplements and complementary therapies. We divided men into groups who used supplements to lessen their cancer risk and those who did not. The prevalence and patterns of use were evaluated and the two groups then compared for differences in demographic, socio-economic and risk-perception variables. RESULTS: In all, 345 high-risk men were enrolled in the PRAP over a 5-year period. Data on the use of dietary or herbal supplements were available on 333 men (97%), of whom over half (170) reported taking one or more supplements to prevent prostate cancer. Supplement use was divided into eight categories, including vitamins, minerals, extracts from fruits/seeds, organic compounds, flowers/bulbs, leaves/bark, roots, or animal products. Most commonly used for self-initiated chemoprevention were vitamins (95%), minerals (28%), and fruit/seed extracts (18%). More than a quarter of men (27%) took three or more agents. Men taking proactive preventative measures were statistically more likely to be Caucasian and aged > 60 years (P < 0.05). African-Americans were less likely to self-initiate preventative steps. Men taking supplements tended to return more often for follow-up and participate in PRAP longer, while those not taking supplements tended to earn less and report less self-perceived risk. CONCLUSIONS: A significant proportion of men at risk of developing prostate cancer initiate measures they perceive to reduce their risk. Although the chemopreventative efficacy of many of these supplements remains unsubstantiated, they are widely perceived by the public to reduce the risk of developing prostate cancer. These data provide an insight into patient perceptions and misconceptions of chemopreventative strategies, and may help to refine recruitment efforts in multi-institutional prostate cancer prevention trials.
AD  - The Department of Urology, Fox Chase Cancer Centre, Temple University School of Medicine, 333 Cottman Avenue, Philadelphia, PA 19111-2497, USA. r_uzzo@fccc.edu
AN  - 15142142
AU  - Uzzo, R. G.
AU  - Brown, J. G.
AU  - Horwitz, E. M.
AU  - Hanlon, A.
AU  - Mazzoni, S.
AU  - Konski, A.
AU  - Greenberg, R. E.
AU  - Pollack, A.
AU  - Kolenko, V.
AU  - Watkins-Bruner, D.
DA  - May
DO  - 10.1111/j.1464-410X.2004.04759.x
DP  - NLM
ET  - 2004/05/15
IS  - 7
KW  - Adult
Aged
*Dietary Supplements
Herbal Medicine
Humans
Male
Middle Aged
Prostatic Neoplasms/*prevention & control
Risk Factors
Self Care
Vitamins/administration & dosage
LA  - eng
N1  - Uzzo, R G
Brown, J G
Horwitz, E M
Hanlon, A
Mazzoni, S
Konski, A
Greenberg, R E
Pollack, A
Kolenko, V
Watkins-Bruner, D
Journal Article
England
BJU Int. 2004 May;93(7):955-60. doi: 10.1111/j.1464-410X.2004.04759.x.
PY  - 2004
SN  - 1464-4096 (Print)
1464-4096
SP  - 955-60
ST  - Prevalence and patterns of self-initiated nutritional supplementation in men at high risk of prostate cancer
T2  - BJU Int
TI  - Prevalence and patterns of self-initiated nutritional supplementation in men at high risk of prostate cancer
VL  - 93
ID  - 630
ER  - 

TY  - JOUR
AB  - BACKGROUND: African-American breast cancer survivors commonly demonstrate low serum 25-hydroxyvitamin D (25(OH)D). Decreased cutaneous conversion, high levels of adiposity, and even breast cancer treatment may influence vitamin D status. Previous investigations have analyzed African-American women in aggregate with other breast cancer survivors and have not comprehensively addressed these influential factors. OBJECTIVES: To determine the prevalence of low serum 25(OH)D in an exclusively African-American cohort of female breast cancer survivors with overweight/obesity and to evaluate the role of ultraviolet (UV) light exposure, body composition, and dietary sources of vitamin D on serum 25(OH)D levels. DESIGN: Cross-sectional. PARTICIPANTS: Pre- and postmenopausal African-American breast cancer survivors (n=244) were recruited from various neighborhoods in the city of Chicago, IL, between September 2011 and September 2014 for a larger weight loss trial. MAIN OUTCOME MEASURES: Demographic, clinical, anthropometric (body mass index [calculated as kg/m(2)], waist circumference, and hip circumference), blood specimen, dietary intake (food frequency questionnaire), and sun behavior data were collected by trained study personnel before trial participation. Dual-energy x-ray absorptiometry was used to quantify adiposity (total, percentage, regional, visceral) and lean mass. Serum 25(OH)D was used as the biomarker reflective of vitamin D status. STATISTICAL ANALYSES: Mean (±standard deviation), frequencies, and multivariate linear regression modeling. RESULTS: The average participant was 57.4 years old (±10.0), 6.9 years (±5.2) from initial breast cancer diagnosis with a body mass index of 36.2 (±6.2). The majority of participants (60%) reported habitual oral vitamin D supplementation with mean intake of 327 IU (±169). Vitamin D deficiency was prevalent in 81% and 43%, when the cut points of the Endocrine Society (<30 ng/mL or <75 nmol/L) and the Institute of Medicine (<20 ng/mL or <50 nmol/L) were applied, respectively. A multivariate model adjusting for age, seasonality of blood draw, total energy intake, use of supplemental vitamin D, darker skin pigmentation, breast cancer stage, and waist-to-hip ratio was able to explain 28.8% of the observed variance in serum 25(OH)D concentrations. No significant associations were detected for body mass index or any dual-energy x-ray absorptiometry measures of body composition. CONCLUSIONS: Considering the number of women who endorsed use of vitamin D supplementation, the prevalence of vitamin D deficiency among these African-American breast cancer survivors was high. Vitamin D supplementation, sun behavior, and waist-to-hip ratio may serve as future points of intervention to improve the vitamin D status of this minority survivor population.
AN  - 29305131
AU  - Sheean, P.
AU  - Arroyo, C.
AU  - Woo, J.
AU  - Schiffer, L.
AU  - Stolley, M.
C2  - PMC5869090
C6  - NIHMS917984
DA  - Apr
DO  - 10.1016/j.jand.2017.10.009
DP  - NLM
ET  - 2018/01/07
IS  - 4
KW  - Adult
African Americans/*statistics & numerical data
Breast Neoplasms/*blood/complications
Cancer Survivors/*statistics & numerical data
Chicago/epidemiology
Cross-Sectional Studies
Dietary Supplements/statistics & numerical data
Female
Humans
Middle Aged
Nutritional Status
Prevalence
Vitamin D/administration & dosage/*analogs & derivatives/blood
Vitamin D Deficiency/*epidemiology/etiology
*African American
*Breast cancer
*Obesity
*Serum 25(OH)D
*Vitamin D
disclose regarding the conduct and reporting of this work.
LA  - eng
N1  - Sheean, Patricia
Arroyo, Claudia
Woo, Jennifer
Schiffer, Linda
Stolley, Melinda
P30 AG022849/AG/NIA NIH HHS/United States
R01 CA154406/CA/NCI NIH HHS/United States
R25 CA057699/CA/NCI NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
J Acad Nutr Diet. 2018 Apr;118(4):568-577. doi: 10.1016/j.jand.2017.10.009. Epub 2018 Jan 2.
PY  - 2018
SN  - 2212-2672 (Print)
2212-2672
SP  - 568-577
ST  - Prevalence and Predictors of Low Serum 25-Hydroxyvitamin D among Female African-American Breast Cancer Survivors
T2  - J Acad Nutr Diet
TI  - Prevalence and Predictors of Low Serum 25-Hydroxyvitamin D among Female African-American Breast Cancer Survivors
VL  - 118
ID  - 138
ER  - 

TY  - JOUR
AB  - BACKGROUND: Women living with human immunodeficiency virus (WLHIV) have disproportionately high rates of squamous cell carcinoma of the anus compared with the general population of women. Anal high-grade squamous intraepithelial lesions (HSILs) precede anal cancer, and accurate studies of HSIL prevalence among WLHIV in the United States are lacking. METHODS: The AIDS Malignancy Consortium 084 study was a multicenter national trial to evaluate the prevalence of and risk factors for anal HSIL in a US cohort. Eligible participants were WLHIV aged ≥18 years with no history of anal HSIL. Study participants had an examination including collection of cervical/vaginal and anal specimens, followed by high-resolution anoscopy with biopsy. RESULTS: We enrolled 256 women with evaluable anal pathology. The mean age was 49.4 years, 64% women were non-Hispanic black, 67% were former or current smokers, and 56% reported ever having anal sex with a man. The median CD4 T-cell count was 664 cells/μL. The prevalence of anal histologic HSIL (hHSIL) was 27% (95% confidence interval [CI], 22%-33%). There was a strong concordance (240/254) between local and consensus pathologists for hHSIL vs less than hHSIL (κ = 0.86 [95% CI, .79-.93]). Current CD4 count of ≤200 cells/μL was the strongest predictor of consensus anal hHSIL diagnosis (adjusted odds ratio [aOR], 10.34 [95% CI, 3.47-30.87]). History of anoreceptive intercourse was also associated with hHSIL (aOR, 2.44 [95% CI, 1.22-4.76]). CONCLUSIONS: The prevalence of anal hHSIL in WLHIV in the United States was 27% in this study where all participants received high-resolution anoscopy and biopsy.
AD  - Obstetrics and Gynecology, Boston University School of Medicine, Massachusetts.
Department of Biostatistics, University of Arkansas for Medical Sciences, Little Rock.
Department of Pathology, Mount Zion Medical Center, University of California, San Francisco (UCSF).
Department of Management Policy and Community Health, School of Public Health, University of Texas Health Science Center at Houston.
Department of Obstetrics/Gynecology and Women's Health, Rutgers-New Jersey Medical School, Newark.
Department of Medicine, UCSF.
Anal Neoplasia Clinic, Research, and Education Center, San Francisco, California.
Division of Hematology Oncology, UCSF.
Clinical Trials Unit, Department of Medicine, Cornell University, New York, New York.
School of Nursing, University of California, Los Angeles.
Department of Internal Medicine, Infectious Diseases, Wake Forest University Health Sciences, Winston-Salem, North Carolina.
University of Vic, Hospital Germans Trias i Pujol, Badalona, Spain.
Department of Surgery, Montefiore Medical Center, Bronx, New York.
Department of Medicine and Department of Microbiology and Medical Zoology, University of Puerto Rico School of Medicine, San Juan.
Division of Infectious Diseases, CORE Center/Stroger Hospital of Cook County, Chicago, Illinois.
Department of Pathology, Baylor College of Medicine, Houston, Texas.
Department of Pathology, George Washington University, Washington, District of Columbia.
Icahn School of Medicine at Mount Sinai, New York, New York.
Section of Infectious Diseases, Department of Medicine, Baylor College of Medicine.
Center for Innovations in Quality, Effectiveness, and Safety, Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas.
AN  - 31292602
AU  - Stier, E. A.
AU  - Lensing, S. Y.
AU  - Darragh, T. M.
AU  - Deshmukh, A. A.
AU  - Einstein, M. H.
AU  - Palefsky, J. M.
AU  - Jay, N.
AU  - Berry-Lawhorn, J. M.
AU  - Wilkin, T.
AU  - Wiley, D. J.
AU  - Barroso, L. F.
AU  - Cranston, R. D.
AU  - Levine, R.
AU  - Guiot, H. M.
AU  - French, A. L.
AU  - Citron, D.
AU  - Rezaei, M. K.
AU  - Goldstone, S. E.
AU  - Chiao, E.
C2  - PMC7146000
DA  - Apr 10
DO  - 10.1093/cid/ciz408
DP  - NLM
ET  - 2019/07/12
IS  - 8
KW  - Anal Canal
*Anus Neoplasms/epidemiology
Female
Hiv
*HIV Infections/complications/epidemiology
Humans
Male
Middle Aged
*Papillomavirus Infections/complications/epidemiology
Prevalence
Risk Factors
Squamous Intraepithelial Lesions
*hiv
*hpv
*hsil
*epidemiology
*women’s health
LA  - eng
N1  - 1537-6591
Stier, Elizabeth A
Lensing, Shelly Y
Darragh, Teresa M
Deshmukh, Ashish A
Einstein, Mark H
Palefsky, Joel M
Jay, Naomi
Berry-Lawhorn, J Michael
Wilkin, Timothy
Wiley, Dorothy J
Barroso, Luis F
Cranston, Ross D
Levine, Rebecca
Guiot, Humberto M
French, Audrey L
Citron, Deborah
Rezaei, M Katayoon
Goldstone, Stephen E
Chiao, Elizabeth
R01 CA163103/CA/NCI NIH HHS/United States
UM1 CA121947/CA/NCI NIH HHS/United States
Journal Article
Multicenter Study
Research Support, N.I.H., Extramural
Clin Infect Dis. 2020 Apr 10;70(8):1701-1707. doi: 10.1093/cid/ciz408.
PY  - 2020
SN  - 1058-4838 (Print)
1058-4838
SP  - 1701-1707
ST  - Prevalence of and Risk Factors for Anal High-grade Squamous Intraepithelial Lesions in Women Living with Human Immunodeficiency Virus
T2  - Clin Infect Dis
TI  - Prevalence of and Risk Factors for Anal High-grade Squamous Intraepithelial Lesions in Women Living with Human Immunodeficiency Virus
VL  - 70
ID  - 73
ER  - 

TY  - JOUR
AB  - Colorectal cancer (CRC) screening is strongly supported by evidence and widely recommended, but remains underutilized. This study reports the prevalence of CRC diagnostic testing and CRC screening in three racial/ethnic groups attending the same primary care clinic. A cross-sectional survey was conducted to elicit past history of CRC testing, including test type, indication and timing. A comparable number of African American, Hispanic and non-Hispanic white patients aged 50-80 were recruited. 560 surveys were completed: mean age was 63.4 years, 64% reported minority race/ethnicity, and 96.8% had insurance. Overall, 62.5% [95% CI: 58.5%, 66.5%] of patients were current with any type of CRC test, when diagnostic and screening procedures were included. However, 48.6% [95% CI: 44.5%, 52.7%] of the sample was current with CRC screening, when only procedures performed for screening in asymptomatic patients were included. Patients least likely to be current with testing were those of minority race/ethnicity (48.2% of Hispanics, 56.7% of African Americans and 67.5% of non Hispanic whites, p < 0.05), younger age, (57.6% of those aged 50-64, and 71.4% of those aged 65-80, p < 0.005), and those with private insurance alone (56.0% private, 67.7% public and 68.1% mixed, p < 0.05). Our findings indicate that racial/ethnic and age related disparities in CRC screening exist even in a patient population that has the same source of health care and no differences in insurance status. These results underline the need for providers to emphasize CRC screening in their practices to minority patients and those younger than 65 years of age.
AN  - WOS:000249792300002
AU  - Shokar, N. K.
AU  - Carlson, C. A.
AU  - Weller, S. C.
DA  - Oct
DO  - 10.1007/s10900-007-9052-x
IS  - 5
N1  - 17922203
PY  - 2007
SN  - 0094-5145
SP  - 311-323
ST  - Prevalence of colorectal cancer testing and screening in a multiethnic primary care population
T2  - Journal of Community Health
TI  - Prevalence of colorectal cancer testing and screening in a multiethnic primary care population
VL  - 32
ID  - 3185
ER  - 

TY  - JOUR
AB  - Importance: Universal screening of patients with newly diagnosed cancer for hepatitis B virus (HBV), hepatitis C virus (HCV), and HIV is not routine in oncology practice, and experts disagree about whether universal screening should be performed. Objective: To estimate the prevalence of HBV, HCV, and HIV infection among persons with newly diagnosed cancer. Design, Setting, and Participants: Multicenter prospective cohort study of patients with newly diagnosed cancer (ie, identified within 120 days of cancer diagnosis) at 9 academic and 9 community oncology institutions affiliated with SWOG (formerly the Southwest Oncology Group) Cancer Research Network, a member of the National Clinical Trials Network, with enrollment from August 29, 2013, through February 15, 2017. The data analysis was conducted using data available through August 17, 2017. Main Outcomes and Measures: The accrual goal was 3000 patients and the primary end point was the presence of HBV infection (previous or chronic), HCV infection, or HIV infection at enrollment. Patients with previous knowledge of infection as well as patients with unknown viral viral status were evaluated. Results: Of 3092 registered patients, 3051 were eligible and evaluable. Median (range) age was 60.6 (18.2-93.7) years, 1842 (60.4%) were female, 553 (18.1%) were black, and 558 (18.3%) were Hispanic ethnicity. Screened patients had similar clinical and demographic characteristics compared with those registered. The observed infection rate for previous HBV infection was 6.5% (95% CI, 5.6%-7.4%; n = 197 of 3050 patients); chronic HBV, 0.6% (95% CI, 0.4%-1.0%; n = 19 of 3050 patients); HCV, 2.4% (95% CI, 1.9%-3.0%; n = 71 of 2990 patients); and HIV, 1.1% (95% CI, 0.8%-1.6%; n = 34 of 3045). Among those with viral infections, 8 patients with chronic HBV (42.1%; 95% CI, 20.3%-66.5%), 22 patients with HCV (31.0%; 95% CI, 20.5%-43.1%), and 2 patients with HIV (5.9%; 95% CI, 0.7%-19.7%) were newly diagnosed through the study. Among patients with infections, 4 patients with chronic HBV (21.1%; 95% CI, 6.1%-45.6%), 23 patients with HCV (32.4%; 95% CI, 21.8%-44.5%), and 7 patients with HIV (20.6%; 95% CI, 8.7%-37.9%) had no identifiable risk factors. Conclusions and Relevance: Results of this study found that a substantial proportion of patients with newly diagnosed cancer and concurrent HBV or HCV are unaware of their viral infection at the time of cancer diagnosis, and many had no identifiable risk factors for infection. Screening patients with cancer to identify HBV and HCV infection before starting treatment may be warranted to prevent viral reactivation and adverse clinical outcomes. The low rate of undiagnosed HIV infection may not support universal screening of newly diagnosed cancer patients.
AD  - S.D. Ramsey, Hutchinson Institute for Cancer Outcomes Research, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, M3-B232, Seattle, WA, United States
AU  - Ramsey, S. D.
AU  - Unger, J. M.
AU  - Baker, L. H.
AU  - Little, R. F.
AU  - Loomba, R.
AU  - Hwang, J. P.
AU  - Chugh, R.
AU  - Konerman, M. A.
AU  - Arnold, K.
AU  - Menter, A. R.
AU  - Thomas, E.
AU  - Michels, R. M.
AU  - Jorgensen, C. W.
AU  - Burton, G. V.
AU  - Bhadkamkar, N. A.
AU  - Hershman, D. L.
DB  - Embase
Medline
DO  - 10.1001/jamaoncol.2018.6437
IS  - 4
KW  - hepatitis B vaccine
adult
age
aged
article
Black person
blood analysis
blood transfusion
breast cancer
cancer center
cohort analysis
colorectal cancer
contact examination
demography
digestive system cancer
female
gender
head and neck cancer
hematologic malignancy
hepatitis B
Hepatitis B virus
hepatitis C
Hepatitis C virus
Hispanic
human
Human immunodeficiency virus
Human immunodeficiency virus infection
intravenous drug abuse
liver cancer
lung cancer
major clinical study
male
malignant neoplasm
medical history
middle aged
needlestick injury
occupational exposure
prevalence
prospective study
prostate cancer
risk factor
sexual behavior
teaching hospital
unprotected sex
very elderly
virus load
young adult
LA  - English
M3  - Article
N1  - L626047362
2019-01-28
2019-05-14
PY  - 2019
SN  - 2374-2445
2374-2437
SP  - 497-505
ST  - Prevalence of Hepatitis B Virus, Hepatitis C Virus, and HIV Infection among Patients with Newly Diagnosed Cancer from Academic and Community Oncology Practices
T2  - JAMA Oncology
TI  - Prevalence of Hepatitis B Virus, Hepatitis C Virus, and HIV Infection among Patients with Newly Diagnosed Cancer from Academic and Community Oncology Practices
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L626047362&from=export
http://dx.doi.org/10.1001/jamaoncol.2018.6437
VL  - 5
ID  - 852
ER  - 

TY  - JOUR
AB  - BACKGROUND: Professional medical organizations recommend individualized patient decision making about prostate cancer screening. Little is known about primary care physicians' use of pre-screening discussions to promote informed decision making for prostate cancer screening. The aim of this study is to explore physicians' use of pre-screening discussions and reasons why physicians would or would not try to persuade patients to be screened if they initially refuse testing. METHODS: Primary care physicians completed a self-administered survey about prostate cancer screening practices for informed decision making. RESULTS: Sixty-six physicians (75.9%) completed the survey, and 63 were used in the analysis. Thirteen physicians (20.6%) reported not using prescreening discussions, 45 (71.4%) reported the use of prescreening discussions, and 3 (4.8%) reported neither ordering the PSA test nor discussing it with patients. Sixty-nine percent of physicians who reported not having discussions indicated they were more likely to screen African American patients for prostate cancer, compared to 50% of physicians who reported the use of discussions (Chi-square(1) = 1.62, p = .20). Similarly, 91% of physicians who reported not having discussions indicated they are more likely to screen patients with a family history of prostate cancer, compared to 46% of those who reported the use of discussion (Chi-square(1) = 13.27, p < .001). Beliefs about the scientific evidence and efficacy of screening, ethical concerns regarding patient autonomy, and concerns about time constraints differed between physicians who would and would not try to persuade a patient to be tested. CONCLUSION: Although guidelines recommend discussing the risks and benefits of prostate cancer screening, physicians report varying practice styles. Future research needs to consider the nature of discussions and the degree to which informed decision making is being achieved in clinical practice.
AD  - Department of Family and Community Medicine, Baylor College of Medicine, Houston, USA. skneuper@bcm.edu
AN  - 19296843
AU  - Linder, S. K.
AU  - Hawley, S. T.
AU  - Cooper, C. P.
AU  - Scholl, L. E.
AU  - Jibaja-Weiss, M.
AU  - Volk, R. J.
C2  - PMC2666644
DA  - Mar 18
DO  - 10.1186/1471-2296-10-19
DP  - NLM
ET  - 2009/03/20
KW  - Attitude of Health Personnel
Cross-Sectional Studies
Guideline Adherence
Health Care Surveys
Humans
Male
Mass Screening
Patient Participation
Physicians, Family/*statistics & numerical data
Practice Guidelines as Topic
Practice Patterns, Physicians'/*statistics & numerical data
Prostate-Specific Antigen/blood
Prostatic Neoplasms/*diagnosis/ethnology
Surveys and Questionnaires
LA  - eng
N1  - 1471-2296
Linder, Suzanne K
Hawley, Sarah T
Cooper, Crystale P
Scholl, Lawrence E
Jibaja-Weiss, Maria
Volk, Robert J
R01 HS010612/HS/AHRQ HHS/United States
R25 CA057712/CA/NCI NIH HHS/United States
R01 HS10612/HS/AHRQ HHS/United States
R25CA057712/CA/NCI NIH HHS/United States
Comparative Study
Journal Article
Research Support, U.S. Gov't, P.H.S.
BMC Fam Pract. 2009 Mar 18;10:19. doi: 10.1186/1471-2296-10-19.
PY  - 2009
SN  - 1471-2296
SP  - 19
ST  - Primary care physicians' reported use of pre-screening discussions for prostate cancer screening: a cross-sectional survey
T2  - BMC Fam Pract
TI  - Primary care physicians' reported use of pre-screening discussions for prostate cancer screening: a cross-sectional survey
VL  - 10
ID  - 475
ER  - 

TY  - JOUR
AD  - Department of Psychiatry and Human Behavior, Alpert Medical School of Brown University, Providence, RI, USA
Department of Behavioral and Social Sciences, Brown University, Providence, RI, USA, Centers for Behavioral and Preventive Medicine, The Miriam Hospital, Providence, RI, USA
Department of Psychiatry and Human Behavior, Alpert Medical School of Brown University, Providence, RI, USA, Centers for Behavioral and Preventive Medicine, The Miriam Hospital, Providence, RI, USA
AN  - 104202665. Language: English. Entry Date: 20130807. Revision Date: 20200708. Publication Type: Journal Article
AU  - Zhou, Eric S.
AU  - Dunsiger, Shira I.
AU  - Pinto, Bernardine M.
DB  - CINAHL Complete
DO  - 10.1177/1740774513480004
DP  - EBSCOhost
IS  - 4
KW  - Research Subject Recruitment -- Methods
Cancer Survivors
Breast Neoplasms
Physical Activity
Clinical Trials
Human
Female
Socioeconomic Factors
Center for Epidemiological Studies Depression Scale
Clinical Assessment Tools
Psychological Tests
Data Analysis Software
T-Tests
Middle Age
White Persons
Black Persons
Education
Funding Source
N1  - research; tables/charts; randomized controlled trial. Journal Subset: Biomedical; Europe; UK & Ireland. Instrumentation: Center for Epidemiologic Studies Depression Scale (CES-D); Functional Assessment of Cancer Therapy-Breast (FACT-B); Stage of motivational readiness for physical activity. Grant Information: This work was supported by the American Cancer Society Research Scholar Grant (03-243-01-PBP).. NLM UID: 101285473.
PMID: NLM23515464.
PY  - 2013
SN  - 1740-7745
SP  - 587-592
ST  - Proactive versus reactive recruitment to a physical activity intervention for breast cancer survivors: Does it matter?
T2  - Clinical Trials
TI  - Proactive versus reactive recruitment to a physical activity intervention for breast cancer survivors: Does it matter?
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104202665&site=ehost-live&scope=site
VL  - 10
ID  - 2030
ER  - 

TY  - JOUR
AB  - INTRODUCTION: Healthy lifestyle behaviors are an essential component of prostate cancer survivorship; however, it is unknown whether Black participants are adequately represented in randomized controlled trials (RCTs) on lifestyle interventions. The goal of this study was to identify types of lifestyle RCTs that may require improved recruitment resources to enhance generalizability of lifestyle recommendations to Black patients. MATERIALS AND METHODS: ClinicalTrials.gov was used to identify lifestyle RCTs among patients with prostate cancer. Using racial distribution data from the Surveillance, Epidemiology, and End Results (SEER) program as a reference, one-sample proportion tests were performed to assess adequate recruitment of Black participants. RESULTS: Of 31 lifestyle trials, one trial reported race-specific results. Proportion of Black participants was acquired from 26 trials. Compared to the US population, Black participants were overrepresented in the overall study population (17% versus 15%, p = 0.019). Black participants were underrepresented in trials exploring exercise interventions (9% versus 15%, p = 0.041), trials among patients with advanced disease (9% versus 16%, p < 0.001), and in university-funded trials (12% versus 15%, p = 0.026). CONCLUSIONS: The reporting of race data, and race-specific results when feasible, is essential for clinicians to accurately generalize findings from lifestyle trials. Additional resources may be necessary to aid in strategic recruitment of Black participants for trials on exercise interventions, trials among patients with advanced disease, and in university-funded trials.
AD  - UCSF Osher Center for Integrative Medicine, University of California, San Francisco, UCSF Box 1726, 1545 Divisadero Street, Suite 301, San Francisco, CA, 94143, USA. kbz2102@columbia.edu.
College of Physicians and Surgeons, Columbia University Medical Center, 630 W 168th Street, New York, NY, 10032, USA. kbz2102@columbia.edu.
Division of Hematology and Medical Oncology, University of California, San Francisco, San Francisco, CA, USA.
Department of Urology, University of California, San Francisco, San Francisco, CA, USA.
Department of Epidemiology & Biostatistics, University of California, San Francisco, San Francisco, CA, USA.
Division of Hematology-Oncology, San Francisco VA Health Care System, San Francisco, CA, USA.
AN  - 32078741
AU  - Zuniga, K. B.
AU  - Borno, H.
AU  - Chan, J. M.
AU  - Van Blarigan, E. L.
AU  - Friedlander, T. W.
AU  - Wang, S.
AU  - Zhang, L.
AU  - Kenfield, S. A.
DA  - Oct
DO  - 10.1007/s40615-020-00724-8
DP  - NLM
ET  - 2020/02/23
IS  - 5
KW  - *African Americans
*Diet
*Exercise
*Prostatic neoplasms
*Randomized controlled trial
LA  - eng
N1  - 2196-8837
Zuniga, Kyle B
Orcid: 0000-0003-3759-3658
Borno, Hala
Chan, June M
Van Blarigan, Erin L
Friedlander, Terence W
Wang, Sunny
Zhang, Li
Kenfield, Stacey A
T32AT003997/AT/NCCIH NIH HHS/United States
R01CA207749/CA/NCI NIH HHS/United States
R21CA184605/CA/NCI NIH HHS/United States
R01CA181802/CA/NCI NIH HHS/United States
K07CA197077/CA/NCI NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Switzerland
J Racial Ethn Health Disparities. 2020 Oct;7(5):996-1002. doi: 10.1007/s40615-020-00724-8. Epub 2020 Feb 20.
PY  - 2020
SN  - 2196-8837
SP  - 996-1002
ST  - The Problem of Underrepresentation: Black Participants in Lifestyle Trials Among Patients with Prostate Cancer
T2  - J Racial Ethn Health Disparities
TI  - The Problem of Underrepresentation: Black Participants in Lifestyle Trials Among Patients with Prostate Cancer
VL  - 7
ID  - 53
ER  - 

TY  - JOUR
AB  - A1 Introduction to the 8(th) Annual Conference on the Science of Dissemination and Implementation: Optimizing Personal and Population Health David Chambers, Lisa Simpson D1 Discussion forum: Population health D&I research Felicia Hill-Briggs D2 Discussion forum: Global health D&I research Gila Neta, Cynthia Vinson D3 Discussion forum: Precision medicine and D&I research David Chambers S1 Predictors of community therapists’ use of therapy techniques in a large public mental health system Rinad Beidas, Steven Marcus, Gregory Aarons, Kimberly Hoagwood, Sonja Schoenwald, Arthur Evans, Matthew Hurford, Ronnie Rubin, Trevor Hadley, Frances Barg, Lucia Walsh, Danielle Adams, David Mandell S2 Implementing brief cognitive behavioral therapy (CBT) in primary care: Clinicians' experiences from the field Lindsey Martin, Joseph Mignogna, Juliette Mott, Natalie Hundt, Michael Kauth, Mark Kunik, Aanand Naik, Jeffrey Cully S3 Clinician competence: Natural variation, factors affecting, and effect on patient outcomes Alan McGuire, Dominique White, Tom Bartholomew, John McGrew, Lauren Luther, Angie Rollins, Michelle Salyers S4 Exploring the multifaceted nature of sustainability in community-based prevention: A mixed-method approach Brittany Cooper, Angie Funaiole S5 Theory informed behavioral health integration in primary care: Mixed methods evaluation of the implementation of routine depression and alcohol screening and assessment Julie Richards, Amy Lee, Gwen Lapham, Ryan Caldeiro, Paula Lozano, Tory Gildred, Carol Achtmeyer, Evette Ludman, Megan Addis, Larry Marx, Katharine Bradley S6 Enhancing the evidence for specialty mental health probation through a hybrid efficacy and implementation study Tonya VanDeinse, Amy Blank Wilson, Burgin Stacey, Byron Powell, Alicia Bunger, Gary Cuddeback S7 Personalizing evidence-based child mental health care within a fiscally mandated policy reform Miya Barnett, Nicole Stadnick, Lauren Brookman-Frazee, Anna Lau S8 Leveraging an existing resource for technical assistance: Community-based supervisors in public mental health Shannon Dorsey, Michael Pullmann S9 SBIRT implementation for adolescents in urban federally qualified health centers: Implementation outcomes Shannon Mitchell, Robert Schwartz, Arethusa Kirk, Kristi Dusek, Marla Oros, Colleen Hosler, Jan Gryczynski, Carolina Barbosa, Laura Dunlap, David Lounsbury, Kevin O'Grady, Barry Brown S10 PANEL: Tailoring Implementation Strategies to Context - Expert recommendations for tailoring strategies to context Laura Damschroder, Thomas Waltz, Byron Powell S11 PANEL: Tailoring Implementation Strategies to Context - Extreme facilitation: Helping challenged healthcare settings implement complex programs Mona Ritchie S12 PANEL: Tailoring Implementation Strategies to Context - Using menu-based choice tasks to obtain expert recommendations for implementing three high-priority practices in the VA Thomas Waltz S13 PANEL: The Use of Technology to Improve Efficient Monitoring of Implementation of Evidence-based Programs - Siri, rate my therapist: Using technology to automate fidelity ratings of motivational interviewing David Atkins, Zac E. Imel, Bo Xiao, Doğan Can, Panayiotis Georgiou, Shrikanth Narayanan S14 PANEL: The Use of Technology to Improve Efficient Monitoring of Implementation of Evidence-based Programs - Identifying indicators of implementation quality for computer-based ratings Cady Berkel, Carlos Gallo, Irwin Sandler, C. Hendricks Brown, Sharlene Wolchik, Anne Marie Mauricio S15 PANEL: The Use of Technology to Improve Efficient Monitoring of Implementation of Evidence-based Programs - Improving implementation of behavioral interventions by monitoring emotion in spoken speech Carlos Gallo, C. Hendricks Brown, Sanjay Mehrotra S16 Scorecards and dashboards to assure data quality of health management information system (HMIS) using R Dharmendra Chandurkar, Siddhartha Bora, Arup Das, Anand Tripathi, Niranjan Saggurti, Anita Raj S17 A big data approach for discovering and implementing patient safety insights Eric Hughes, Brian Jacobs, Eric Kirkendall S18 Improving the efficacy of a depression registry for use in a collaborative care model Danielle Loeb, Katy Trinkley, Michael Yang, Andrew Sprowell, Donald Nease S19 Measurement feedback systems as a strategy to support implementation of measurement-based care in behavioral health Aaron Lyon, Cara Lewis, Meredith Boyd, Abigail Melvin, Semret Nicodimos, Freda Liu, Nathanial Jungbluth S20 PANEL: Implementation Science and Learning Health Systems: Intersections and Commonalities - Common loop assay: Methods of supporting learning collaboratives Allen Flynn S21 PANEL: Implementation Science and Learning Health Systems: Intersections and Commonalities - Innovating audit and feedback using message tailoring models for learning health systems Zach Landis-Lewis S22 PANEL: Implementation Science and Learning Health Systems: Intersections and Commonalities - Implementation science and learning health systems: Connecting the dots Anne Sales S23 Facilitation activities of Critical Access Hospitals during TeamSTEPPS implementation Jure Baloh, Marcia Ward, Xi Zhu S24 Organizational and social context of federally qualified health centers and variation in maternal depression outcomes Ian Bennett, Jurgen Unutzer, Johnny Mao, Enola Proctor, Mindy Vredevoogd, Ya-Fen Chan, Nathaniel Williams, Phillip Green S25 Decision support to enhance treatment of hospitalized smokers: A randomized trial Steven Bernstein, June-Marie Rosner, Michelle DeWitt, Jeanette Tetrault, James Dziura, Allen Hsiao, Scott Sussman, Patrick O’Connor, Benjamin Toll S26 PANEL: Developing Sustainable Strategies for the Implementation of Patient-Centered Care across Diverse US Healthcare Systems - A patient-centered approach to successful community transition after catastrophic injury Michael Jones, Julie Gassaway S27 PANEL: Developing Sustainable Strategies for the Implementation of Patient-Centered Care across Diverse US Healthcare Systems - Conducting PCOR to integrate mental health and cancer screening services in primary care Jonathan Tobin S28 PANEL: Developing Sustainable Strategies for the Implementation of Patient-Centered Care across Diverse US Healthcare Systems - A comparative effectiveness trial of optimal patient-centered care for US trauma care systems Douglas Zatzick S29 Preferences for in-person communication among patients in a multi-center randomized study of in-person versus telephone communication of genetic test results for cancer susceptibility Angela R Bradbury, Linda Patrick-Miller, Brian Egleston, Olufunmilayo I Olopade, Michael J Hall, Mary B Daly, Linda Fleisher, Generosa Grana, Pamela Ganschow, Dominique Fetzer, Amanda Brandt, Dana Farengo-Clark, Andrea Forman, Rikki S Gaber, Cassandra Gulden, Janice Horte, Jessica Long, Rachelle Lorenz Chambers, Terra Lucas, Shreshtha Madaan, Kristin Mattie, Danielle McKenna, Susan Montgomery, Sarah Nielsen, Jacquelyn Powers, Kim Rainey, Christina Rybak, Michelle Savage, Christina Seelaus, Jessica Stoll, Jill Stopfer, Shirley Yao and Susan Domchek S30 Working towards de-implementation: A mixed methods study in breast cancer surveillance care Erin Hahn, Corrine Munoz-Plaza, Jianjin Wang, Jazmine Garcia Delgadillo, Brian Mittman Michael Gould S31Integrating evidence-based practices for increasing cancer screenings in safety-net primary care systems: A multiple case study using the consolidated framework for implementation research Shuting (Lily) Liang, Michelle C. Kegler, Megan Cotter, Emily Phillips, April Hermstad, Rentonia Morton, Derrick Beasley, Jeremy Martinez, Kara Riehman S32 Observations from implementing an mHealth intervention in an FQHC David Gustafson, Lisa Marsch, Louise Mares, Andrew Quanbeck, Fiona McTavish, Helene McDowell, Randall Brown, Chantelle Thomas, Joseph Glass, Joseph Isham, Dhavan Shah S33 A multicomponent intervention to improve primary care provider adherence to chronic opioid therapy guidelines and reduce opioid misuse: A cluster randomized controlled trial protocol Jane Liebschutz, Karen Lasser S34 Implementing collaborative care for substance use disorders in primary care: Preliminary findings from the summit study Katherine Watkins, Allison Ober, Sarah Hunter, Karen Lamp, Brett Ewing S35 Sustaining a task-shifting strategy for blood pressure control in Ghana: A stakeholder analysis Juliet Iwelunmor, Joyce Gyamfi, Sarah Blackstone, Nana Kofi Quakyi, Jacob Plange-Rhule, Gbenga Ogedegbe S36 Contextual adaptation of the consolidated framework for implementation research (CFIR) in a tobacco cessation study in Vietnam Pritika Kumar, Nancy Van Devanter, Nam Nguyen, Linh Nguyen, Trang Nguyen, Nguyet Phuong, Donna Shelley S37 Evidence check: A knowledge brokering approach to systematic reviews for policy Sian Rudge S38 Using Evidence Synthesis to Strengthen Complex Health Systems in Low- and Middle-Income Countries Etienne Langlois S39 Does it matter: timeliness or accuracy of results? The choice of rapid reviews or systematic reviews to inform decision-making Andrea Tricco S40 Evaluation of the veterans choice program using lean six sigma at a VA medical center to identify benefits and overcome obstacles Sherry Ball, Anne Lambert-Kerzner, Christine Sulc, Carol Simmons, Jeneen Shell-Boyd, Taryn Oestreich, Ashley O'Connor, Emily Neely, Marina McCreight, Amy Labebue, Doreen DiFiore, Diana Brostow, P. Michael Ho, David Aron S41 The influence of local context on multi-stakeholder alliance quality improvement activities: A multiple case study Jillian Harvey, Megan McHugh, Dennis Scanlon S42 Increasing physical activity in early care and education: Sustainability via active garden education (SAGE) Rebecca Lee, Erica Soltero, Nathan Parker, Lorna McNeill, Tracey Ledoux S43 Marking a decade of policy implementation: The successes and continuing challenges of a provincial school food and nutrition policy in Canada Jessie-Lee McIsaac, Kate MacLeod, Nicole Ata, Sherry Jarvis, Sara Kirk S44 Use of research evidence among state legislators who prioritize mental health and substance abuse issues Jonathan Purtle, Elizabeth Dodson, Ross Brownson S45 PANEL: Effectiveness-Implementation Hybrid Designs: Clarifications, Refinements, and Additional Guidance Based on a Systematic Review and Reports from the Field - Hybrid type 1 designs Brian Mittman, Geoffrey Curran S46 PANEL: Effectiveness-Implementation Hybrid Designs: Clarifications, Refinements, and Additional Guidance Based on a Systematic Review and Reports from the Field - Hybrid type 2 designs Geoffrey Curran S47 PANEL: Effectiveness-Implementation Hybrid Designs: Clarifications, Refinements, and Additional Guidance Based on a Systematic Review and Reports from the Field - Hybrid type 3 designs Jeffrey Pyne S48 Linking team level implementation leadership and implementation climate to individual level attitudes, behaviors, and implementation outcomes Gregory Aarons, Mark Ehrhart, Elisa Torres S49 Pinpointing the specific elements of local context that matter most to implementation outcomes: Findings from qualitative comparative analysis in the RE-inspire study of VA acute stroke care Edward Miech S50 The GO score: A new context-sensitive instrument to measure group organization level for providing and improving care Edward Miech S51 A research network approach for boosting implementation and improvement Kathleen Stevens, I.S.R.N. Steering Council S52 PANEL: Qualitative methods in D&I Research: Value, rigor and challenge - The value of qualitative methods in implementation research Alison Hamilton S53 PANEL: Qualitative methods in D&I Research: Value, rigor and challenge - Learning evaluation: The role of qualitative methods in dissemination and implementation research Deborah Cohen S54 PANEL: Qualitative methods in D&I Research: Value, rigor and challenge - Qualitative methods in D&I research Deborah Padgett S55 PANEL: Maps & models: The promise of network science for clinical D&I - Hospital network of sharing patients with acute and chronic diseases in California Alexandra Morshed S56 PANEL: Maps & models: The promise of network science for clinical D&I - The use of social network analysis to identify dissemination targets and enhance D&I research study recruitment for pre-exposure prophylaxis for HIV (PrEP) among men who have sex with men Rupa Patel S57 PANEL: Maps & models: The promise of network science for clinical D&I - Network and organizational factors related to the adoption of patient navigation services among rural breast cancer care providers Beth Prusaczyk S58 A theory of de-implementation based on the theory of healthcare professionals’ behavior and intention (THPBI) and the becker model of unlearning David C. Aron, Divya Gupta, Sherry Ball S59 Observation of registered dietitian nutritionist-patient encounters by dietetic interns highlights low awareness and implementation of evidence-based nutrition practice guidelines Rosa Hand, Jenica Abram, Taylor Wolfram S60 Program sustainability action planning: Building capacity for program sustainability using the program sustainability assessment tool Molly Hastings, Sarah Moreland-Russell S61 A review of D&I study designs in published study protocols Rachel Tabak, Alex Ramsey, Ana Baumann, Emily Kryzer, Katherine Montgomery, Ericka Lewis, Margaret Padek, Byron Powell, Ross Brownson S62 PANEL: Geographic variation in the implementation of public health services: Economic, organizational, and network determinants - Model simulation techniques to estimate the cost of implementing foundational public health services Cezar Brian Mamaril, Glen Mays, Keith Branham, Lava Timsina S63 PANEL: Geographic variation in the implementation of public health services: Economic, organizational, and network determinants - Inter-organizational network effects on the implementation of public health services Glen Mays, Rachel Hogg S64 PANEL: Building capacity for implementation and dissemination of the communities that care prevention system at scale to promote evidence-based practices in behavioral health - Implementation fidelity, coalition functioning, and community prevention system transformation using communities that care Abigail Fagan, Valerie Shapiro, Eric Brown S65 PANEL: Building capacity for implementation and dissemination of the communities that care prevention system at scale to promote evidence-based practices in behavioral health - Expanding capacity for implementation of communities that care at scale using a web-based, video-assisted training system Kevin Haggerty, David Hawkins S66 PANEL: Building capacity for implementation and dissemination of the communities that care prevention system at scale to promote evidence-based practices in behavioral health - Effects of communities that care on reducing youth behavioral health problems Sabrina Oesterle, David Hawkins, Richard Catalano S68 When interventions end: the dynamics of intervention de-adoption and replacement Virginia McKay, M. Margaret Dolcini, Lee Hoffer S69 Results from next-d: can a disease specific health plan reduce incident diabetes development among a national sample of working-age adults with pre-diabetes? Tannaz Moin, Jinnan Li, O. Kenrik Duru, Susan Ettner, Norman Turk, Charles Chan, Abigail Keckhafer, Robert Luchs, Sam Ho, Carol Mangione S70 Implementing smoking cessation interventions in primary care settings (STOP): using the interactive systems framework Peter Selby, Laurie Zawertailo, Nadia Minian, Dolly Balliunas, Rosa Dragonetti, Sarwar Hussain, Julia Lecce S71 Testing the Getting To Outcomes implementation support intervention in prevention-oriented, community-based settings Matthew Chinman, Joie Acosta, Patricia Ebener, Patrick S Malone, Mary Slaughter S72 Examining the reach of a multi-component farmers’ market implementation approach among low-income consumers in an urban context Darcy Freedman, Susan Flocke, Eunlye Lee, Kristen Matlack, Erika Trapl, Punam Ohri-Vachaspati, Morgan Taggart, Elaine Borawski S73 Increasing implementation of evidence-based health promotion practices at large workplaces: The CEOs Challenge Amanda Parrish, Jeffrey Harris, Marlana Kohn, Kristen Hammerback, Becca McMillan, Peggy Hannon S74 A qualitative assessment of barriers to nutrition promotion and obesity prevention in childcare Taren Swindle, Geoffrey Curran, Leanne Whiteside-Mansell, Wendy Ward S75 Documenting institutionalization of a health communication intervention in African American churches Cheryl Holt, Sheri Lou Santos, Erin Tagai, Mary Ann Scheirer, Roxanne Carter, Janice Bowie, Muhiuddin Haider, Jimmie Slade, Min Qi Wang S76 Reduction in hospital utilization by underserved patients through use of a community-medical home Andrew Masica, Gerald Ogola, Candice Berryman, Kathleen Richter S77 Sustainability of evidence-based lay health advisor programs in African American communities: A mixed methods investigation of the National Witness Project Rachel Shelton, Lina Jandorf, Deborah Erwin S78 Predicting the long-term uninsured population and analyzing their gaps in physical access to healthcare in South Carolina Khoa Truong S79 Using an evidence-based parenting intervention in churches to prevent behavioral problems among Filipino youth: A randomized pilot study Joyce R. Javier, Dean Coffey, Sheree M. Schrager, Lawrence Palinkas, Jeanne Miranda S80 Sustainability of elementary school-based health centers in three health-disparate southern communities Veda Johnson, Valerie Hutcherson, Ruth Ellis S81 Childhood obesity prevention partnership in Louisville: creative opportunities to engage families in a multifaceted approach to obesity prevention Anna Kharmats, Sandra Marshall-King, Monica LaPradd, Fannie Fonseca-Becker S82 Improvements in cervical cancer prevention found after implementation of evidence-based Latina prevention care management program Deanna Kepka, Julia Bodson, Echo Warner, Brynn Fowler S83 The OneFlorida data trust: Achieving health equity through research & training capacity building Elizabeth Shenkman, William Hogan, Folakami Odedina, Jessica De Leon, Monica Hooper, Olveen Carrasquillo, Renee Reams, Myra Hurt, Steven Smith, Jose Szapocznik, David Nelson, Prabir Mandal S84 Disseminating and sustaining medical-legal partnerships: Shared value and social return on investment James Teufel
AD  - Division of Cancer Control and Population Sciences, National Cancer Institute, National Institutes of Health, Rockville, MD 20850 USA
AcademyHealth, Washington, DC 20036 USA
Department of Medicine and Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins Medical Institutions, Baltimore, MD 21287 USA
Psychiatry, University of Pennsylvania, Philadelphia, PA 19104 USA
Family Medicine and Community Health, University of Pennsylvania, Philadelphia, PA 19104 USA
School of Social Policy and Practice, University of Pennsylvania, Philadelphia, PA 19103 USA
Psychiatry, UC San Diego, La Jolla, CA 92083-0812 USA
Child & Adolescent Psychiatry, The Child Study Center at NYU Langone Medical Center, New York, NY, New York, NY 10016 USA
Psychiatry and Behavioral Sciences, MUSC, Charleston, SC 29425 USA
DBHIDS, City of Philadelphia, Philadelphia, PA 19104 USA
CBH, City of Philadelphia, Philadelphia, PA 19104 USA
Psychiatry, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19107 USA
Health Services Research & Development, Department of Veterans Affairs & Baylor College of Medicine, Houston, TX 77030 USA
Treatment Core, Department of Veterans Affairs, Waco, TX 76711 USA
National Center for PTSD, Executive Division, Department of Veterans Affairs, White River Junction, VT 05009 USA
HSR&D, HSR&D Center for Health Information and Communication, Roudebush VA Medical Center, Indianapolis, IN 46202 USA
Psychology, Indiana University Purdue University Indianapolis, Indianapolis, IN 46202 USA
Department of Psychiatric Rehabilitation and Counseling, Rutgers University, Newark, NJ 07107 USA
Health Services Research & Development, Richard L. Roudebush VAMC, Indianapolis, IN 46202 USA
IUPUI Department of Psychology, ACT Center of Indiana, Indianapolis, IN 46202 USA
Human Development, Washington State University, Pullman, WA 99164 USA
Prevention Science, Washington State University, Pullman, WA 99164 USA
Group Health Research Institute, Group Health, Seattle, WA 98101 USA
Behavioral Health Services, Group Health, Seattle, WA 98101 USA
Preventive Care, Group Health, Seattle, WA 98101 USA
Health Services Research & Development, Primary and Specialty Medical Care Service, VA Puget Sound, Seattle, WA 98108 USA
School of Social Work, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 USA
Health Policy & Management, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27566-7411 USA
College of Social Work, Ohio State University, Columbus, OH 43210 USA
Psychology, University of California, Los Angeles, Los Angeles, CA 90095 USA
Psychiatry, University of California, San Diego, La Jolla, CA 92093 USA
Psychology, University of Washington, Seattle, WA 98195 USA
Department of Psychiatry and Behavioral Sciences, Division of Public Behavioral Health, University of Washington, Seattle, WA 98102 USA
Social Research Center, Friends Research Institute, Baltimore, MD 21201 USA
Pediatrics, Total Health Care, Baltimore, MD 21217 USA
The Mosaic Group, The Mosaic Group, Baltimore, MD 21210 USA
Behavioral Health Economics Program, RTI International, Chicago, IL 60606-4901 USA
Center for Interdisciplinary Substance Abuse Research, Research Triangle Institute, Rockville, MD 20852 USA
Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY 10467 USA
Division of Community Collaboration and Implementation Science, Albert Einstein College of Medicine of Yeshiva University, Bronx, NY 10467 USA
Department of Psychology, University of Maryland, College Park, College Park, MD 20742 USA
Psychology, University of North Carolina at Wilmington, Wilmington, NC 28403 USA
Department of Veterans Affairs, VA Center for Clinical Management Research, Ann Arbor, MI 48105 USA
Psychology, Eastern Michigan University, Ypsilanti, MI 48197 USA
Health Policy & Management, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27566 USA
VA QUERI Program for Team-Based Behavioral Health, Department of Veterans Affairs, North Little Rock, AR 72114 USA
Health Services Research & Development, VA Center for Clinical Management Research, Ann Arbor, MI 48105 USA
Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, WA 98105 USA
Educational Psychology, University of Utah, Salt Lake City, UT 84112 USA
Electrical Engineering, University of Southern California, Los Angeles, CA 90089 USA
Computer Science, University of Southern California, Los Angeles, CA 90089 USA
Electrical Engineering & Computer Science, University of Southern California, Los Angeles, CA 90089 USA
REACH Institute, Arizona State University, Tempe, AZ 85284 USA
Center for Prevention Implementation Methodology, Northwestern University, Chicago, IL 60611 USA
Psychology, Arizona State University, Tempe, AZ 85287 USA
Industrial Engineering, Northwestern University, Chicago, IL 60611 USA
Research, Sambodhi Research and Communications Private Limited, Noida, 201301 India
Monitoring and Evaluation, India Health Action Trust, Lucknow, 226001 India
Monitoring, Learning and Evaluation, Bill and Melinda Gates Foundation, New Delhi, 110057 India
Division of Global Public Health, Department of Medicine, University of California, San Diego, San Diego, CA 92093 USA
Information Technology, MITRE, Bedford, MA 01730 USA
VP, CMIO, CIO, Children’s National Health System, Washington, DC, 20010 USA
Association CMIO, Cincinnati Children’s Hospital and Medical Center, Cincinnati, OH 45229 USA
Department of Medicine/Division of General Internal Medicine, University of Colorado School of Medicine, Aurora, CO 80045 USA
Department of Clinical Pharmacy, University of Colorado School of Pharmacy, Aurora, CO 80045 USA
University of Colorado School of Medicine, Aurora, CO 80045 USA
Department of Family Medicine, University of Colorado School of Medicine, Aurora, CO 80238 USA
Psychiatry and Behavioral Sciences, University of Washington, Seattle, WA 98115 USA
Psychological and Brain Sciences, Indiana University, Bloomington, IN 47405 USA
Psychology, University of Washington, Seattle, WA 98115 USA
Learning Health Sciences, Medical School, University of Michigan, Ann Arbor, MI 48109 USA
Learning Health Sciences, University of Michigan Medical School, Ann Arbor, MI 48109 USA
Learning Health Sciences, University of Michigan, Ann Arbor, MI 48109 USA
Center for Clinical Management Research, VA Ann Arbor Health Care System, Ann Arbor, MI 48109 USA
Department of Health Management and Policy, University of Iowa, Iowa City, IA 52242 USA
Family Medicine, University of Washington, Seattle, WA 98105-6099 USA
Psychiatry & Behavioral Sciences, University of Washington, Seattle, WA 98195 USA
Center for Clinical and Epidemiological Research, University of Washington, Seattle, WA 98101 USA
George Warren Brown School of Social Work, Washington University in St. Louis, Saint Louis, MO 63130 USA
Social Work, Boise State University, Boise, ID 83725 USA
School of Social Work, University of Tennessee, Knoxville, TN 37996 USA
Emergency Medicine, Yale University School of Medicine, New Haven, CT 06519 USA
Cancer Prevention and Control, Yale Cancer Center, New Haven, CT 06519 USA
Information Technology Services, Yale-New Haven Hospital, New Haven, CT 06510 USA
Medicine, Yale School of Medicine, New Haven, CT 06519 USA
Pediatrics and Emergency Medicine, Yale-New Haven Hospital, New Haven, CT 06510 USA
Medicine, Yale-New Haven Hospital, New Haven, CT 06510 USA
Internal Medicine, Yale University School of Medicine, New Haven, CT 06520 USA
Public Health Sciences, Medical University of South Carolina, Charleston, SC 29425 USA
Research, Shepherd Center, Atlanta, GA 30312 USA
Virginia C. Crawford Research Institute, Atlanta, GA 30309 USA
Community Engaged Research, Clinical Directors Network, Inc. & The Rockefeller University, New York, NY 10018 USA
Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, WA 98104 USA
Division of Hematology-Oncology, Department of Medicine, The University of Pennsylvania, Philadelphia, PA 19104 USA
Department of Medical Ethics and Health Policy, The University of Pennsylvania, Philadelphia, PA 19104 USA
Center for Clinical Cancer Genetics Department of Medicine, Hematology/Oncology, The University of Chicago, Chicago, IL 60637 USA
Biostatistics and Bioinformatics Facility, The Fox Chase Cancer Center, Philadelphia, PA 19111 USA
Center for Clinical Cancer Genetics, The University of Chicago, Chicago, IL 60637 USA
Clinical Genetics/Gastrointestinal Risk Assessment, The Fox Chase Cancer Center, Philadelphia, PA 19111 USA
Department of Clinical Genetics, The Fox Chase Cancer Center, Philadelphia, PA 19111 USA
Center for Injury Research and Prevention, The Children’s Hospital of Philadelphia, Philadelphia, PA 19104 USA
Hematology and Medical Oncology, MD Anderson Cancer Center at Cooper, Camden, NJ 08043 USA
Internal Medicine, John H. Stroger, Jr. Hospital, Chicago, IL 60612 USA
Mariann and Robert MacDonald Women’s Cancer Risk Evaluation Program, The University of Pennsylvania, Philadelphia, PA 19104 USA
Cancer Genetics Program, MD Anderson Cancer Center at Cooper, Camden, NJ 08043 USA
Breast and Cervical Cancer Screening Program, John H. Stroger, Jr. Hospital, Chicago, IL 60612 USA
Cancer Screening Program, John H. Stroger, Jr. Hospital, Chicago, IL 60612 USA
Comprehensive Cancer Risk and Prevention Clinic, The University of Chicago, Chicago, IL 60637 USA
Emory Prevention Research Center, Emory University Rollins School of Public Health, Atlanta, GA 30322 USA
Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA 91101 USA
Research Institute, Palo Alto Medical Foundation, Palo Alto, CA 94301 USA
Department of Behavioral Sciences and Health Education, Emory University Rollins School of Public Health, Atlanta, GA 30322 USA
Behavioral Sciences and Health Education, Rollins School of Public Health, Emory Prevention Research Center, Atlanta, GA 30322 USA
Statistics and Evaluation Center, American Cancer Society, Atlanta, GA 30303 USA
Center for Health Enhancement Systems Studies, University of Wisconsin – Madison, Madison, WI 53706 USA
Center for Technology and Behavioral Health, Dartmouth College, Dartmouth, NH 03755 USA
Communication Arts, University of Wisconsin – Madison, Madison, WI 53706 USA
Industrial and Systems Engineering, University of Wisconsin – Madison, Madison, WI 53706 USA
Family Medicine, Population Health Sciences, University of Wisconsin School of Medicine & Public Health, Madison, WI 53715 USA
Access Community Health Center, Access Community Health Center, Madison, WI 53706 USA
School of Social Work, University of Wisconsin – Madison, Madison, WI 54706 USA
Communication Sciences, University of Wisconsin – Madison, Madison, WI 53706 USA
Clinical Addiction Research and Education (CARE) Unit, Boston Medical Center/Boston University School of Medicine, Boston, MA 02118 USA
Boston University School of Public Health, Boston, MA 02118 USA
RAND Corporation, RAND Corporation, Santa Monica, CA 90407 USA
Venice Family Clinic, Venice Family Clinic, Venice, CA 90291 USA
Kinesiology and Community Health, University of Illinois at Urbana Champaign, Champaign, IL 61822 USA
Center for Healthful Behavior Change, New York University, New York, NY 10016 USA
Global Institute of Public Health, New York University, New York, NY 10003 USA
Physiology, Kwame Nkrumah University of Science and Technology, Kumasi, 00000 Ghana
Population Health and Medicine, New York University, New York, NY 10016 USA
Department of Population Health, New York University School of Medicine, New York, NY 10016 USA
College of Nursing, New York University, New York, NY 10075 USA
Institute of Social and Medical Sciences, Institute of Social and Medical Sciences, Hanoi, Vietnam
Knowledge Exchange Division, Sax Institute, Ultimo, NSW 2007 Australia
Alliance for Health Policy and Systems Research, World Health Organization, Geneva, 1211 Switzerland
Dalla Lana School of Public Health/St Michael’s Hospital, University of Toronto, Toronto, ON M5B 1W8 Canada
Research, Department of Veterans Affairs, Cleveland, OH 44106 USA
Research, Eastern Colorado Health Care System, Department of Veterans Affairs, Denver, CO 80220 USA
University of Colorado, Denver, CO 80204 USA
Center of Innovation for Veteran-Centered and Value-Driven Care, VA Puget Sound Health Care System, Seattle, WA 98108 USA
Research Service, Cleveland VA Medical Center, Cleveland, OH 44106 USA
Denver-Seattle Center of Innovation, Eastern Colorado Health Care System, Aurora, CO 80045 USA
Research, Cleveland VA Medical Center, Cleveland, OH 44106 USA
Denver-Seattle Center of Innovation, VA Eastern Colorado Health Care System, Denver, CO 80220 USA
Education Department, Louis Stokes Cleveland VA Medical Center, Cleveland, OH 44106 USA
Medicine, Case Western Reserve University School of Medicine, Cleveland, OH USA
Health Professions, Medical University of South Carolina, Charleston, SC 29425 USA
Healthcare Leadership and Management, Medical University of South Carolina, Charleston, SC 29425 USA
Center for Healthcare Studies, Northwestern University, Chicago, IL 60611 USA
Department of Health Policy and Administration, Pennsylvania State University, University Park, PA 16802 USA
College of Nursing and Health Innovation, Arizona State University, Phoenix, AZ 85004 USA
Health & Human Performance, University of Houston, Houston, TX 77204 USA
Health Disparities Research, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 USA
School of Health and Human Performance, Dalhousie University, Halifax, NS B3H4R2 Canada
Health Management &Policy, Drexel University School of Public Health, Philadelphia, PA 19130 USA
Institute for Public Health, Washington University, St. Louis, MO 63112 USA
Brown School and Prevention Research Center in St. Louis, Washington University in St. Louis, Saint Louis, MO 63130 USA
Research and Evaluation, Kaiser Permanente Southern Calif/US Dept of Veterans Affairs, Pasadena, CA 91101 USA
Department of Pharmacy Practice, University of Arkansas for Medical Sciences, Little Rock, AR 72205 USA
Psychiatry and Behavioral Sciences, University of Arkansas for Medical Sciences, Little Rock, AR 72205 USA
Department of Psychology, San Diego State University, San Diego, CA 92182-4611 USA
HSR&D, Richard L. Roudebush VA Medical Center, Indianapolis, IN 46202 USA
Improvement Science Research Network, University of Texas Health Science Center San Antonio, San Antonio, TX 78229 USA
HSR&D Center for the Study of Healthcare Innovation, Implementation and Policy, Department of Veterans Affairs, Los Angeles, CA 90073 USA
UCLA Department of Psychiatry and Biobehavioral Sciences, UCLA, Los Angeles, CA 90024 USA
Family Medicine, Oregon Health & Science University, Portland, OR 97239 USA
Silver School of Social Work, New York University, New York, NY 10003 USA
Brown School, Washington University in St. Louis, Saint Louis, MO 63130 USA
Division of Infectious Diseases, Washington University School of Medicine, St. Louis, MO 63110 USA
Brown School, Washington University in St. Louis, Saint Louis, MO 63110 USA
Case Western Reserve University, Cleveland, OH USA
Department of Veterans Affairs, Medicine, Louis Stokes Cleveland Medical Center, Cleveland, OH 44106 USA
Research, International, and Scientific Affairs, Academy of Nutrition and Dietetics, Chicago, IL 60606 USA
Web Strategy, Academy of Nutrition and Dietetics, Chicago, IL 60606 USA
Center for Public Health Systems Science, Washington University in St. Louis, St. Louis, MO 63112 USA
School of Medicine, Washington University in St. Louis, St. Louis, MO 63110 USA
Brown School, Washington University in St. Louis, St. Louis, MO 63110 USA
Health Management and Policy, University of Kentucky, College of Public Health, Lexington, KY 40536 USA
Department of Health Services Management, University of Kentucky, College of Public Health, Lexington, KY 40536 USA
Systems for Action National Program Office, University of Kentucky, College of Public Health, Lexington, KY 40536 USA
College of Health Sciences, University of Kentucky, Lexington, KY 40536 USA
Department of Sociology and Criminology & Law, University of Florida, Gainesville, FL 32611 USA
School of Social Welfare, UC Berkeley, Berkeley, CA 94720 USA
Department of Public Health Sciences, University of Miami, Miami, FL 33136 USA
School of Social Work, University of Washington, Seattle, WA 98115 USA
College of Public Health and Human Sciences, Oregon State University, Corvallis, OR 97331 USA
School of Social and Behavioral Health Sciences, Oregon State University, Corvallis, OR 97331 USA
Department of Anthropology, Case Western Reserve University, Cleveland, OH 44106 USA
Division of General Internal Medicine and Health Services Research, David Geffen School of Medicine at University of California, Los Angeles, CA 90024 USA
HSR&D Center for the Study of Healthcare Innovation, Implementation, and Policy, VA Greater Los Angeles Healthcare System, Los Angeles, CA 90073 USA
Department of Health Policy and Management, Fielding School of Public Health, University of California, Los Angeles, CA 90095 USA
Actuarial Pricing, UnitedHealthcare, Minneapolis, MN 55343 USA
Actuarial Pricing, UnitedHealthcare, Minneapolis, MN 55369 USA
Innovations, UnitedHealthcare, Minneapolis, MN 55343 USA
Addictions Program, Centre for Addiction and Mental Health, Toronto, ON M5T1P7 Canada
Family and Community Medicine, University of Toronto, Toronto, ON M5T1P7 Canada
Psychiatry, Dalla Lana School of Public Health, University of Toronto, Toronto, ON M5T1P7 Canada
Pharmacology and Toxicology, University of Toronto, Toronto, ON M5T1P7 Canada
Addictions Medicine, Centre for Addiction and Mental Health, Toronto, ON M5S 3E3 Canada
Nicotine Dependence Service, Centre for Addiction and Mental Health, Toronto, ON M5T 1P7 Canada
Health, RAND Corporation, Pittsburgh, PA 15213 USA
VISN 4 MIRECC, VA Pittsburgh Healthcare Center, Pittsburgh, PA 15206 USA
Health, RAND Corporation, Arlington, VA 22202-5050 USA
Health, RAND Corporation, Santa Monica, CA 90407 USA
Epidemiology and Biostatistics, Case Western Reserve University, Cleveland, OH 44106 USA
Prevention Research Center for Healthy Neighborhoods, Case Western Reserve University, Cleveland, OH 44106 USA
Family Medicine, Case Western Reserve University, Cleveland, OH 44106 USA
Mandel School of Applied Social Sciences, Case Western Reserve University, Cleveland, OH 44106 USA
School of Nutrition and Health Promotion, Arizona State University, Phoenix, AZ 85004 USA
Agreculture, St. Clair Superior Development Corporation, Cleveland, OH 44103 USA
Department of Health Services, University of Washington, Health Promotion Research Center, Seattle, WA 98105 USA
Health Promotion Research Center, University of Washington, Seattle, WA 98105 USA
Partner Relationships, American Cancer Society, Seattle, WA 98109 USA
Health Services, University of Washington, Seattle, WA 98105 USA
Family and Preventive Medicine, University of Arkansas for Medical Sciences, Little Rock, AR 72205 USA
Pediatrics, University of Arkansas for Medical Sciences, Little Rock, AR 72205 USA
Behavioral and Community Health, University of Maryland, College Park, MD 20742 USA
Program Evaluation, Scheirer Consulting, Princeton, NJ 8540 USA
Community Ministry of Prince George’s County, Upper Marlboro, MD 20772 USA
Health Behavior and Society, Johns Hopkins University, Baltimore, MD 21205 USA
Maryland Institute for Applied Environmental Health, University of Maryland, College Park, MD 20742 USA
Center for Clinical Effectiveness, Baylor Scott & White Health, Dallas, TX 75206 USA
Department of Sociomedical Sciences, Columbia University Mailman School of Public Health, New York, NY 10032 USA
Oncological Sciences, Mount Sinai School of Medicine, New York, NY 10029 USA
Division of Cancer Prevention and Population Sciences, Roswell Park Cancer Institute, Buffalo, NY 14263 USA
Public Health Sciences, Clemson University, Clemson, SC 29634 USA
Department of Pediatrics, Division of General Pediatrics, Chidren’s Hospital Los Angeles/USC Keck School of Medicine, Los Angeles, CA 90027 USA
Division of Hospital Medicine, Chidren’s Hospital Los Angeles, Los Angeles, CA 90027 USA
Social Work, University of Southern California, Los Angeles, CA 90089-0411 USA
Semel Institute for Neuroscience and Human Behavior, UCLA Center for Health Services and Society, Los Angeles, CA 90024 USA
Pediatrics, Emory University, Atlanta, GA 30303 USA
Pediatrics, PARTNERS for Equity in Child and Adolescent Health, Atlanta, GA 30303 USA
Johns Creek, GA 30022 USA
International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205 USA
International Health, Global Obesity Prevention Center, Baltimore, MD 21205 USA
Shawnee Christian Health Care Center, Louisville, KY 40212 USA
Health, Behavior, & Society, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21202 USA
Huntsman Cancer Institute, University of Utah, College of Nursing and Huntsman Cancer Institute, Salt Lake City, UT 84112 USA
Cancer Control and Population Sciences, Huntsman Cancer Institute & University of Utah, Salt Lake City, UT 84112 USA
Department of Health Outcomes and Policy, University of Florida College of Medicine, Gainesville, FL 32606 USA
Department of Pharmaceutical Outcomes and Policy, University of Florida, Gainesville, FL 32606 USA
Clinical and Translational Science Institute, Florida State University College of Medicine, Tallahassee, FL 32308 USA
Psychology, University of Miami, Miami, FL 33136 USA
Department of Medicine, University of Miami, Miami, FL 33136 USA
Department of Pharmaceutical Sciences, Florida A & M University, Tallahassee, FL 32308 USA
College of Medicine, Florida State University, Tallahassee, FL 32308 USA
Translational Research Institute, Florida Hospital, Orlando, FL 32804 USA
Clinical and Translational Science Institute, University of Miami, Miami, FL 33136 USA
Clinical and Translational Science Institute, University of Florida, Gainesville, FL 32606 USA
Biology, Edward Waters College, Jacksonville, FL 32309 USA
Public Health, Mercyhurst University, Erie, PA 16504 USA
AN  - 27490260
AU  - Chambers, D.
AU  - Simpson, L.
AU  - Hill-Briggs, F.
AU  - Neta, G.
AU  - Vinson, C.
AU  - Chambers, D.
AU  - Beidas, R.
AU  - Marcus, S.
AU  - Aarons, G.
AU  - Hoagwood, K.
AU  - Schoenwald, S.
AU  - Evans, A.
AU  - Hurford, M.
AU  - Rubin, R.
AU  - Hadley, T.
AU  - Barg, F.
AU  - Walsh, L.
AU  - Adams, D.
AU  - Mandell, D.
AU  - Martin, L.
AU  - Mignogna, J.
AU  - Mott, J.
AU  - Hundt, N.
AU  - Kauth, M.
AU  - Kunik, M.
AU  - Naik, A.
AU  - Cully, J.
AU  - McGuire, A.
AU  - White, D.
AU  - Bartholomew, T.
AU  - McGrew, J.
AU  - Luther, L.
AU  - Rollins, A.
AU  - Salyers, M.
AU  - Cooper, B.
AU  - Funaiole, A.
AU  - Richards, J.
AU  - Lee, A.
AU  - Lapham, G.
AU  - Caldeiro, R.
AU  - Lozano, P.
AU  - Gildred, T.
AU  - Achtmeyer, C.
AU  - Ludman, E.
AU  - Addis, M.
AU  - Marx, L.
AU  - Bradley, K.
AU  - VanDeinse, T.
AU  - Wilson, A. B.
AU  - Stacey, B.
AU  - Powell, B.
AU  - Bunger, A.
AU  - Cuddeback, G.
AU  - Barnett, M.
AU  - Stadnick, N.
AU  - Brookman-Frazee, L.
AU  - Lau, A.
AU  - Dorsey, S.
AU  - Pullmann, M.
AU  - Mitchell, S.
AU  - Schwartz, R.
AU  - Kirk, A.
AU  - Dusek, K.
AU  - Oros, M.
AU  - Hosler, C.
AU  - Gryczynski, J.
AU  - Barbosa, C.
AU  - Dunlap, L.
AU  - Lounsbury, D.
AU  - O’Grady, K.
AU  - Brown, B.
AU  - Damschroder, L.
AU  - Waltz, T.
AU  - Powell, B.
AU  - Ritchie, M.
AU  - Waltz, T.
AU  - Atkins, D.
AU  - Imel, Z. E.
AU  - Xiao, B.
AU  - Can, D.
AU  - Georgiou, P.
AU  - Narayanan, S.
AU  - Berkel, C.
AU  - Gallo, C.
AU  - Sandler, I.
AU  - Brown, C. H.
AU  - Wolchik, S.
AU  - Mauricio, A. M.
AU  - Gallo, C.
AU  - Brown, C. H.
AU  - Mehrotra, S.
AU  - Chandurkar, D.
AU  - Bora, S.
AU  - Das, A.
AU  - Tripathi, A.
AU  - Saggurti, N.
AU  - Raj, A.
AU  - Hughes, E.
AU  - Jacobs, B.
AU  - Kirkendall, E.
AU  - Loeb, D.
AU  - Trinkley, K.
AU  - Yang, M.
AU  - Sprowell, A.
AU  - Nease, D.
AU  - Lyon, A.
AU  - Lewis, C.
AU  - Boyd, M.
AU  - Melvin, A.
AU  - Nicodimos, S.
AU  - Liu, F.
AU  - Jungbluth, N.
AU  - Lyon, A.
AU  - Lewis, C.
AU  - Boyd, M.
AU  - Melvin, A.
AU  - Nicodimos, S.
AU  - Liu, F.
AU  - Jungbluth, N.
AU  - Flynn, A.
AU  - Landis-Lewis, Z.
AU  - Sales, A.
AU  - Baloh, J.
AU  - Ward, M.
AU  - Zhu, X.
AU  - Bennett, I.
AU  - Unutzer, J.
AU  - Mao, J.
AU  - Proctor, E.
AU  - Vredevoogd, M.
AU  - Chan, Y. F.
AU  - Williams, N.
AU  - Green, P.
AU  - Bernstein, S.
AU  - Rosner, J. M.
AU  - DeWitt, M.
AU  - Tetrault, J.
AU  - Dziura, J.
AU  - Hsiao, A.
AU  - Sussman, S.
AU  - O’Connor, P.
AU  - Toll, B.
AU  - Jones, M.
AU  - Gassaway, J.
AU  - Tobin, J.
AU  - Zatzick, D.
AU  - Bradbury, A. R.
AU  - Patrick-Miller, L.
AU  - Egleston, B.
AU  - Olopade, O. I.
AU  - Hall, M. J.
AU  - Daly, M. B.
AU  - Fleisher, L.
AU  - Grana, G.
AU  - Ganschow, P.
AU  - Fetzer, D.
AU  - Brandt, A.
AU  - Farengo-Clark, D.
AU  - Forman, A.
AU  - Gaber, R. S.
AU  - Gulden, C.
AU  - Horte, J.
AU  - Long, J.
AU  - Chambers, R. L.
AU  - Lucas, T.
AU  - Madaan, S.
AU  - Mattie, K.
AU  - McKenna, D.
AU  - Montgomery, S.
AU  - Nielsen, S.
AU  - Powers, J.
AU  - Rainey, K.
AU  - Rybak, C.
AU  - Savage, M.
AU  - Seelaus, C.
AU  - Stoll, J.
AU  - Stopfer, J.
AU  - Yao, S.
AU  - Domchek, S.
AU  - Hahn, E.
AU  - Munoz-Plaza, C.
AU  - Wang, J.
AU  - Delgadillo, J. G.
AU  - Mittman, B.
AU  - Gould, M.
AU  - Liang, S.
AU  - Kegler, M. C.
AU  - Cotter, M.
AU  - Phillips, E.
AU  - Hermstad, A.
AU  - Morton, R.
AU  - Beasley, D.
AU  - Martinez, J.
AU  - Riehman, K.
AU  - Gustafson, D.
AU  - Marsch, L.
AU  - Mares, L.
AU  - Quanbeck, A.
AU  - McTavish, F.
AU  - McDowell, H.
AU  - Brown, R.
AU  - Thomas, C.
AU  - Glass, J.
AU  - Isham, J.
AU  - Shah, D.
AU  - Liebschutz, J.
AU  - Lasser, K.
AU  - Watkins, K.
AU  - Ober, A.
AU  - Hunter, S.
AU  - Lamp, K.
AU  - Ewing, B.
AU  - Iwelunmor, J.
AU  - Gyamfi, J.
AU  - Blackstone, S.
AU  - Quakyi, N. K.
AU  - Plange-Rhule, J.
AU  - Ogedegbe, G.
AU  - Kumar, P.
AU  - Van Devanter, N.
AU  - Nguyen, N.
AU  - Nguyen, L.
AU  - Nguyen, T.
AU  - Phuong, N.
AU  - Shelley, D.
AU  - Rudge, S.
AU  - Langlois, E.
AU  - Tricco, A.
AU  - Ball, S.
AU  - Lambert-Kerzner, A.
AU  - Sulc, C.
AU  - Simmons, C.
AU  - Shell-Boyd, J.
AU  - Oestreich, T.
AU  - O’Connor, A.
AU  - Neely, E.
AU  - McCreight, M.
AU  - Labebue, A.
AU  - DiFiore, D.
AU  - Brostow, D.
AU  - Ho, P. M.
AU  - Aron, D.
AU  - Harvey, J.
AU  - McHugh, M.
AU  - Scanlon, D.
AU  - Lee, R.
AU  - Soltero, E.
AU  - Parker, N.
AU  - McNeill, L.
AU  - Ledoux, T.
AU  - McIsaac, J. L.
AU  - MacLeod, K.
AU  - Ata, N.
AU  - Jarvis, S.
AU  - Kirk, S.
AU  - Purtle, J.
AU  - Dodson, E.
AU  - Brownson, R.
AU  - Mittman, B.
AU  - Curran, G.
AU  - Curran, G.
AU  - Pyne, J.
AU  - Aarons, G.
AU  - Ehrhart, M.
AU  - Torres, E.
AU  - Miech, E.
AU  - Miech, E.
AU  - Stevens, K.
AU  - Hamilton, A.
AU  - Cohen, D.
AU  - Padgett, D.
AU  - Morshed, A.
AU  - Patel, R.
AU  - Prusaczyk, B.
AU  - Aron, D. C.
AU  - Gupta, D.
AU  - Ball, S.
AU  - Hand, R.
AU  - Abram, J.
AU  - Wolfram, T.
AU  - Hastings, M.
AU  - Moreland-Russell, S.
AU  - Tabak, R.
AU  - Ramsey, A.
AU  - Baumann, A.
AU  - Kryzer, E.
AU  - Montgomery, K.
AU  - Lewis, E.
AU  - Padek, M.
AU  - Powell, B.
AU  - Brownson, R.
AU  - Mamaril, C. B.
AU  - Mays, G.
AU  - Branham, K.
AU  - Timsina, L.
AU  - Mays, G.
AU  - Hogg, R.
AU  - Fagan, A.
AU  - Shapiro, V.
AU  - Brown, E.
AU  - Haggerty, K.
AU  - Hawkins, D.
AU  - Oesterle, S.
AU  - Hawkins, D.
AU  - Catalano, R.
AU  - McKay, V.
AU  - Dolcini, M. M.
AU  - Hoffer, L.
AU  - Moin, T.
AU  - Li, J.
AU  - Duru, O. K.
AU  - Ettner, S.
AU  - Turk, N.
AU  - Chan, C.
AU  - Keckhafer, A.
AU  - Luchs, R.
AU  - Ho, S.
AU  - Mangione, C.
AU  - Selby, P.
AU  - Zawertailo, L.
AU  - Minian, N.
AU  - Balliunas, D.
AU  - Dragonetti, R.
AU  - Hussain, S.
AU  - Lecce, J.
AU  - Chinman, M.
AU  - Acosta, J.
AU  - Ebener, P.
AU  - Malone, P. S.
AU  - Slaughter, M.
AU  - Freedman, D.
AU  - Flocke, S.
AU  - Lee, E.
AU  - Matlack, K.
AU  - Trapl, E.
AU  - Ohri-Vachaspati, P.
AU  - Taggart, M.
AU  - Borawski, E.
AU  - Parrish, A.
AU  - Harris, J.
AU  - Kohn, M.
AU  - Hammerback, K.
AU  - McMillan, B.
AU  - Hannon, P.
AU  - Swindle, T.
AU  - Curran, G.
AU  - Whiteside-Mansell, L.
AU  - Ward, W.
AU  - Holt, C.
AU  - Santos, S. L.
AU  - Tagai, E.
AU  - Scheirer, M. A.
AU  - Carter, R.
AU  - Bowie, J.
AU  - Haider, M.
AU  - Slade, J.
AU  - Wang, M. Q.
AU  - Masica, A.
AU  - Ogola, G.
AU  - Berryman, C.
AU  - Richter, K.
AU  - Shelton, R.
AU  - Jandorf, L.
AU  - Erwin, D.
AU  - Truong, K.
AU  - Javier, J. R.
AU  - Coffey, D.
AU  - Schrager, S. M.
AU  - Palinkas, L.
AU  - Miranda, J.
AU  - Johnson, V.
AU  - Hutcherson, V.
AU  - Ellis, R.
AU  - Kharmats, A.
AU  - Marshall-King, S.
AU  - LaPradd, M.
AU  - Fonseca-Becker, F.
AU  - Kepka, D.
AU  - Bodson, J.
AU  - Warner, E.
AU  - Fowler, B.
AU  - Shenkman, E.
AU  - Hogan, W.
AU  - Odedina, F.
AU  - De Leon, J.
AU  - Hooper, M.
AU  - Carrasquillo, O.
AU  - Reams, R.
AU  - Hurt, M.
AU  - Smith, S.
AU  - Szapocznik, J.
AU  - Nelson, D.
AU  - Mandal, P.
AU  - Teufel, J.
C2  - PMC4977475
DA  - Aug 1
DO  - 10.1186/s13012-016-0452-0
DP  - NLM
ET  - 2016/08/05
IS  - Suppl 2
LA  - eng
N1  - 1748-5908
Chambers, David
Simpson, Lisa
Hill-Briggs, Felicia
Neta, Gila
Vinson, Cynthia
Beidas, Rinad
Marcus, Steven
Aarons, Gregory
Hoagwood, Kimberly
Schoenwald, Sonja
Evans, Arthur
Hurford, Matthew
Rubin, Ronnie
Hadley, Trevor
Barg, Frances
Walsh, Lucia
Adams, Danielle
Mandell, David
Martin, Lindsey
Mignogna, Joseph
Mott, Juliette
Hundt, Natalie
Kauth, Michael
Kunik, Mark
Naik, Aanand
Cully, Jeffrey
McGuire, Alan
White, Dominique
Bartholomew, Tom
McGrew, John
Luther, Lauren
Rollins, Angie
Salyers, Michelle
Cooper, Brittany
Funaiole, Angie
Richards, Julie
Lee, Amy
Lapham, Gwen
Caldeiro, Ryan
Lozano, Paula
Gildred, Tory
Achtmeyer, Carol
Ludman, Evette
Addis, Megan
Marx, Larry
Bradley, Katharine
VanDeinse, Tonya
Wilson, Amy Blank
Stacey, Burgin
Powell, Byron
Bunger, Alicia
Cuddeback, Gary
Barnett, Miya
Stadnick, Nicole
Brookman-Frazee, Lauren
Lau, Anna
Dorsey, Shannon
Pullmann, Michael
Mitchell, Shannon
Schwartz, Robert
Kirk, Arethusa
Dusek, Kristi
Oros, Marla
Hosler, Colleen
Gryczynski, Jan
Barbosa, Carolina
Dunlap, Laura
Lounsbury, David
O’Grady, Kevin
Brown, Barry
Damschroder, Laura
Waltz, Thomas
Ritchie, Mona
Atkins, David
Imel, Zac E
Xiao, Bo
Can, Doğan
Georgiou, Panayiotis
Narayanan, Shrikanth
Berkel, Cady
Gallo, Carlos
Sandler, Irwin
Brown, C Hendricks
Wolchik, Sharlene
Mauricio, Anne Marie
Mehrotra, Sanjay
Chandurkar, Dharmendra
Bora, Siddhartha
Das, Arup
Tripathi, Anand
Saggurti, Niranjan
Raj, Anita
Hughes, Eric
Jacobs, Brian
Kirkendall, Eric
Loeb, Danielle
Trinkley, Katy
Yang, Michael
Sprowell, Andrew
Nease, Donald
Lyon, Aaron
Lewis, Cara
Boyd, Meredith
Melvin, Abigail
Nicodimos, Semret
Liu, Freda
Jungbluth, Nathanial
Flynn, Allen
Landis-Lewis, Zach
Sales, Anne
Baloh, Jure
Ward, Marcia
Zhu, Xi
Bennett, Ian
Unutzer, Jurgen
Mao, Johnny
Proctor, Enola
Vredevoogd, Mindy
Chan, Ya-Fen
Williams, Nathaniel
Green, Phillip
Bernstein, Steven
Rosner, June-Marie
DeWitt, Michelle
Tetrault, Jeanette
Dziura, James
Hsiao, Allen
Sussman, Scott
O’Connor, Patrick
Toll, Benjamin
Jones, Michael
Gassaway, Julie
Tobin, Jonathan
Zatzick, Douglas
Bradbury, Angela R
Patrick-Miller, Linda
Egleston, Brian
Olopade, Olufunmilayo I
Hall, Michael J
Daly, Mary B
Fleisher, Linda
Grana, Generosa
Ganschow, Pamela
Fetzer, Dominique
Brandt, Amanda
Farengo-Clark, Dana
Forman, Andrea
Gaber, Rikki S
Gulden, Cassandra
Horte, Janice
Long, Jessica
Chambers, Rachelle Lorenz
Lucas, Terra
Madaan, Shreshtha
Mattie, Kristin
McKenna, Danielle
Montgomery, Susan
Nielsen, Sarah
Powers, Jacquelyn
Rainey, Kim
Rybak, Christina
Savage, Michelle
Seelaus, Christina
Stoll, Jessica
Stopfer, Jill
Yao, Shirley
Domchek, Susan
Hahn, Erin
Munoz-Plaza, Corrine
Wang, Jianjin
Delgadillo, Jazmine Garcia
Mittman, Brian
Gould, Michael
Liang, Shuting (Lily)
Kegler, Michelle C
Cotter, Megan
Phillips, Emily
Hermstad, April
Morton, Rentonia
Beasley, Derrick
Martinez, Jeremy
Riehman, Kara
Gustafson, David
Marsch, Lisa
Mares, Louise
Quanbeck, Andrew
McTavish, Fiona
McDowell, Helene
Brown, Randall
Thomas, Chantelle
Glass, Joseph
Isham, Joseph
Shah, Dhavan
Liebschutz, Jane
Lasser, Karen
Watkins, Katherine
Ober, Allison
Hunter, Sarah
Lamp, Karen
Ewing, Brett
Iwelunmor, Juliet
Gyamfi, Joyce
Blackstone, Sarah
Quakyi, Nana Kofi
Plange-Rhule, Jacob
Ogedegbe, Gbenga
Kumar, Pritika
Van Devanter, Nancy
Nguyen, Nam
Nguyen, Linh
Nguyen, Trang
Phuong, Nguyet
Shelley, Donna
Rudge, Sian
Langlois, Etienne
Tricco, Andrea
Ball, Sherry
Lambert-Kerzner, Anne
Sulc, Christine
Simmons, Carol
Shell-Boyd, Jeneen
Oestreich, Taryn
O’Connor, Ashley
Neely, Emily
McCreight, Marina
Labebue, Amy
DiFiore, Doreen
Brostow, Diana
Ho, P Michael
Aron, David
Harvey, Jillian
McHugh, Megan
Scanlon, Dennis
Lee, Rebecca
Soltero, Erica
Parker, Nathan
McNeill, Lorna
Ledoux, Tracey
McIsaac, Jessie-Lee
MacLeod, Kate
Ata, Nicole
Jarvis, Sherry
Kirk, Sara
Purtle, Jonathan
Dodson, Elizabeth
Brownson, Ross
Curran, Geoffrey
Pyne, Jeffrey
Ehrhart, Mark
Torres, Elisa
Miech, Edward
Stevens, Kathleen
I.S.R.N. Steering Council
Hamilton, Alison
Cohen, Deborah
Padgett, Deborah
Morshed, Alexandra
Patel, Rupa
Prusaczyk, Beth
Aron, David C
Gupta, Divya
Hand, Rosa
Abram, Jenica
Wolfram, Taylor
Hastings, Molly
Moreland-Russell, Sarah
Tabak, Rachel
Ramsey, Alex
Baumann, Ana
Kryzer, Emily
Montgomery, Katherine
Lewis, Ericka
Padek, Margaret
Mamaril, Cezar Brian
Mays, Glen
Branham, Keith
Timsina, Lava
Hogg, Rachel
Fagan, Abigail
Shapiro, Valerie
Brown, Eric
Haggerty, Kevin
Hawkins, David
Oesterle, Sabrina
Catalano, Richard
McKay, Virginia
Dolcini, M Margaret
Hoffer, Lee
Moin, Tannaz
Li, Jinnan
Duru, O Kenrik
Ettner, Susan
Turk, Norman
Chan, Charles
Keckhafer, Abigail
Luchs, Robert
Ho, Sam
Mangione, Carol
Selby, Peter
Zawertailo, Laurie
Minian, Nadia
Balliunas, Dolly
Dragonetti, Rosa
Hussain, Sarwar
Lecce, Julia
Chinman, Matthew
Acosta, Joie
Ebener, Patricia
Malone, Patrick S
Slaughter, Mary
Freedman, Darcy
Flocke, Susan
Lee, Eunlye
Matlack, Kristen
Trapl, Erika
Ohri-Vachaspati, Punam
Taggart, Morgan
Borawski, Elaine
Parrish, Amanda
Harris, Jeffrey
Kohn, Marlana
Hammerback, Kristen
McMillan, Becca
Hannon, Peggy
Swindle, Taren
Whiteside-Mansell, Leanne
Ward, Wendy
Holt, Cheryl
Santos, Sheri Lou
Tagai, Erin
Scheirer, Mary Ann
Carter, Roxanne
Bowie, Janice
Haider, Muhiuddin
Slade, Jimmie
Wang, Min Qi
Masica, Andrew
Ogola, Gerald
Berryman, Candice
Richter, Kathleen
Shelton, Rachel
Jandorf, Lina
Erwin, Deborah
Truong, Khoa
Javier, Joyce R
Coffey, Dean
Schrager, Sheree M
Palinkas, Lawrence
Miranda, Jeanne
Johnson, Veda
Hutcherson, Valerie
Ellis, Ruth
Kharmats, Anna
Marshall-King, Sandra
LaPradd, Monica
Fonseca-Becker, Fannie
Kepka, Deanna
Bodson, Julia
Warner, Echo
Fowler, Brynn
Shenkman, Elizabeth
Hogan, William
Odedina, Folakami
De Leon, Jessica
Hooper, Monica
Carrasquillo, Olveen
Reams, Renee
Hurt, Myra
Smith, Steven
Szapocznik, Jose
Nelson, David
Mandal, Prabir
Teufel, James
001/World Health Organization/International
Journal Article
Implement Sci. 2016 Aug 1;11 Suppl 2(Suppl 2):100. doi: 10.1186/s13012-016-0452-0.
PY  - 2016
SN  - 1748-5908
SP  - 100
ST  - Proceedings of the 8th Annual Conference on the Science of Dissemination and Implementation : Washington, DC, USA. 14-15 December 2015
T2  - Implement Sci
TI  - Proceedings of the 8th Annual Conference on the Science of Dissemination and Implementation : Washington, DC, USA. 14-15 December 2015
VL  - 11 Suppl 2
ID  - 206
ER  - 

TY  - JOUR
AB  - 1. Effect of chronic haloperidol treatment on D‐2 receptors labelled by (3H)‐spiperone in homogenates of rat corpus striatum. A. L. Gundlach, D. J. de Vries and P. M. Beart 2. The effects of haloperidol and apomorphine on behavioural responses in rats with modified thyroid status. M. A. Joschko, A. D. Crocker and D. H. Overstreet 3. Dopamine (DA) and dihydroxyphenylacetic acid (DOPAC) distribution within the brain and spinal cord of spontaneously hypertensive (SHR) and Wistar‐Kyoto (WK) rats at various ages. L. G. Howes, P. R. Rowe, R. J. Summers and W. J. Louis 4. Dopamine administration into the nucleus accumbens and the retention of conditioned avoidance learning by rats. P. U. Braes, P. M. Gregory and D. M. Jackson 5. Ketanserin, a serotonin‐2 antagonist, inhibits the vasoconstriction but not the vasodilation produced by serotonin. P. L. McLennan and D. A. Taylor 6. A clinical pharmacological study on ketanserin, a new serotonin antagonist. R. W. Bury, A. T. Kacprowicz, V. Iwanov, P. G. Shaw, R. F. W. Moulds 7. The differentiation of receptor activity of leu5‐ and met5‐enkephalin utilizing in vivo pA2 analysis. M. J. Quinn and M. R. Fennessy 9. The bioavailability of propantheline bromide. D. K. Moses, B. G. Charles, and P. J. Ravenscroft 10. Elimination of amphotericin B in patients with impaired renal function. M. S. Ching, D. J. Morgan, K. Raymond, R. W. Bury, M. L. Mashford, F. W. Gurr and A. A. Somogyif 11. A renal mechanism for the cloflbric acid‐probenecid interaction. P. J. Meffin and D. M. Zilm 12. pH‐Dependent rearrangement of the biosynthetic ester glucuronide of valproic acid (Epilim) to β‐glucuronidase‐resistant forms. R. G. Dickinson and M. J. Eadie 13. Interaction of purines with GABA‐independent ‘central’ but not ‘peripheral’ benzodiazepine binding sites. L. P. Davies, J. H. Skerritt, S. Chen Chow and G. A. R. Johnston 14. Benzodiazepine stimulation of GABA binding–studies with agonists and antagonists. J. H. Skerritt and G. A. R. Johnston 15. Inhibition of binding of [3H]‐batrachotoxinin A 20‐α‐benzoate to sodium channels by the anticonvulsant drugs diphenylhydantoin and carbamazepine. M. Willow and W. A. Catterall 16. Effects of mianserin on noradrenergic mechanisms. A. Rose, M. W. McCulloch and C. Sarantos‐Laska 17. The effect of olfactory bulbectomy (OB) and antidepressant drugs on circadian rhythm and pineal function in the rat. Doreen H. Leigh and K. D. Cairncross 18. Narcotic potency of the n‐alkanes. Janet De Silva, A. J. Christophers and M. W. Nott 19. Hyperactivity following fetal ethanol exposure is due to a delay in the development of the cholinergic neuro‐transmitter system. N. W. Bond 20. Prevention by aminophylline of the renal effects of both hypertonic saline and amphotericin B; possible linkage of tubuloglomerular feedback and nephrotoxicity. J. F. Gerkens and R. A. Branch (introduced by A. J. Smith) 21. Paracetamol toxicity in hamster hepatocytes: Studies with inhibitors of drug metabolism. A. W. Harman and L. J. Fischer (introduced by K. F. Ilett) 22. The mechanism of action of paracetamol protective agents in the mouse. J. O. Miners, R. Drew, J. Attwood, J. Adams and D. J. Birkett 23. Measurement of formation of reactive metabolites of phenacetin in man. M. Veronese, S. McLean and N. Davies 24. Liver injury due to chronic halothane inhalation. J. L. Plummer, P. de la M. Hall, M. J. Cousins, F. N. Bastin and A. H. Ilsley 25. Changes in rat hepatic microsomal mixed function oxidase activity following exposure to halothane. K. M. Knights, G. K. Gourlay and M. J. Cousins 26. Testicular effects of 2,4,5‐trichlorophenoxy‐acetic acid (2,4,5‐T). R. Drew and J. Rowell 27. Plasma concentrations of unbound phenytoin in the management of epilepsy. C. Kilpatrick, S. Wanwimolruk and L. M. H. Wing 28. Double‐blind comparison of ranitidine and cimetidine in the treatment of chronic gastric ulcer. J. E. Kellow, G. D. Barr, A. E. Cowen, M. Ward, L. Wood and D. W. Piper 29. Comparative evaluation of cimetidine and ranitidine for stress ulce prophylaxis in the critically ill. D. G. More, R. F. Raper, I. Munro, J. Boutagy and G. M. Shenfield 30. The pharmacokinetics and effect on platelet aggregation of dipyridamole in humans. A. Jenkins, S. Watts, D. Imhoff, B. Duncan, F. Bochner and J. Lloyd 31. A crossover trial of combination α‐ and β‐adrenergic blockade in hypertension. G. S. Stokes, B. A. Mennie and R. Gellatly 32. Different determinants of compliance in epilepsy and hypertension. G. M. Peterson, S. McLean and K. S. Millingen 33. Positive chronotropic responses produced by cardiac α1‐adrenoceptors in the pithed rat. L.‐H. Tung, O. H. Drummer, W. J. Louis and M. J. Rand 34. Effects of partial β‐agonists and phosphodiesterase inhibition on β‐adrenoceptor responsiveness of cultured cardiac cells. A. Bobik, P. Little, J. Campbell and S. Minasian 35. In vitro cardiac activity of isoquinoline derivatives related to papaverine. P. Goadby, R. Foulkes and A. A. Anderson (introduced by C. Raper) 36. Peripheral inhibition of cardiac vagal action by sympathetic adrenergic stimulation. E. K. Potter and D. I. McCloskey (introduced by W. E. Glover) 37. Prostaglandins and the pericardial pressor chemoreflex in dogs. P. N. Nolan, D. E. Luk and J. Staszewska‐Barczak 38. Effect of capsaicin on the Bezold‐Jarisch reflex in the rabbit. Y‐M. Wang, M. L. Mashford and P. J. Harman 39. Correlations between pharmacological responses and structure of human lung parenchyma strips. R. G. Goldie, J. F. Bertram, J. M. Papadimitriou and J. W. Paterson 40. Cholinergic responses in human lung–a structure/function correlation. M. J. B. Finney, N. Berend and J. L. Black 41. Comparisons ofin vivoandin vitroresponses to histamine in human airways. K. Vincenc, J. Black, A. Woolcock and J. Shaw 42. An interaction betwen leukotriene D4 and histamine on airways resistance in anaesthetized guinea‐pigs. A. G. Stewart, D. C. Thompson and M. R. Fennessy 43. Inhaled prazosin and histamine induced bronchoconstriction. C. R. Jenkins, G. J. Hart, A. B. X. Breslin and G. E. Marlin 44. Prednisolone disposition as a function of dose and oral contraceptive use. B. C. Sallustio, P. J. Meffin, P. M. Brooks and L. M. H. Wing 45. The influence of fatty acids on the binding of prednisolone to albumin. J. M. Potter and D. M. Offerman 46. Midazolam pharmacokinetics in the elderly. M. T. Smith, V. Heazlewood, M. J. Eadie and T. O'R. Brophy 47. Temazepam pharmacokinetics in healthy adults. H. Ghabrial, P. V. Desmond, P. J. Har‐man, M. L. Mashford, B. Westwood, K. J. Breen and A. J. Gijsbers 48. The absorption of aspirin in migraine, and the effect of metoclopramide. L. M. Ross‐Lee, M. J. Eadie, V. Heazlewood and J. H. Tyrer 49. Gastric and intestinal absorption of captopril in the rat. P. J. Worland, O. H. Drummer and B. Jarrott 50. In vivoevidence of presnyaptic a‐adrenoceptors modulating inotropic responses to sympathetic stimulation. R. A. Jarvis, R. Einstein and A. H. Goodman 51. Clonidine fails to inhibit vagal bradycardia: evidence against presynaptic α‐adrenoceptors on cardiac vagal varicosities. M. J. Lew and J. A. Angus 52. Facilitation of sympathetic neuroeffector transmission in guinea‐pig isolated atria by angiotensin I and angiotensin II. J. Ziogas, D. F. Story and M. J. Rand 53. Effect of α‐adrenoreceptor antagonists and neuronal uptake inhibitors on dimethylphenyl‐piperazinium (DMPP)‐induced release of adrenaline from the rabbit adrenal gland. A. R. Collett and D. F. Story 54. Is the carrier system for extraneuronal uptake of catecholamines the same in different cell types? J. J. Cole and S. R. O'Donnell 55. Sites of extraneuronal o‐methylation of isoprenaline in guinea‐pig trachea. L. J. Bryan and S. R. O'Donnell 56. Anti‐inflammatory/anti‐arthritic activity of some copper‐D‐penicillamine complexes. I. R. Garrett and M. W. Whitehouse 57. Determination of response of individual patients with rheumatoid arthritis to auranofin. G. D. Champion, D. Bieri, C. D. Browne, D. Cairns, R. O. Day, G. G. Graham, G. Harris and P. N. Sambrook 58. Studies on the mechanism by which smoking increases the uptake of gold by red blood cells. G. G. Graham, H. M. Jones, T. M. Macpherson and G. D. Champion 59. Anti‐inflammatory drugs in a model of chronic inflammation. R. S. Hirsch and B. Vernon‐Roberts 60. Heavy metal (Au, Pt) nephropathy: studies in normal and inflamed rats. M. W. Whitehouse, I. R. Garrett and B. Vernon‐Roberts 61. Renal function and lithium treatment: a two year prospective study. G. F. S. Johnson, G. E. Hunt and G. G. Duggin 62. Extra‐visceral drug clearance. W. B. Runciman, R. N. Upton, A. H. Ilsley, R. Carapetis, T. M. Shepherd, C. Nancarrow and L. E. Mather 63. β‐Adrenoceptor antagonists as possible inhibitors of drug metabolism in man. L. M. H. Wing, J. O. Miners, B. J. Harrington, K. Lillywhite and K. J. Smith 64. Comparison of β‐adrenoceptor antagonists as modulators of drug metabolism. J. T. Ahokas, C. Davies and P. J. Ravenscroft 65. Guanethidine N‐oxide formation as a measure of flavin‐containing mono‐oxygenase enzyme activity in rat hepatocytes. M. E. McManus, P. H. Grantham, P. J. Wirth, P. P. Roller and S. S. Thorgeirsson 66. Interaction of imidazole drugs with hepatic cytochrome P‐450 dependent enzymes. J. Scott and R. Drew 67. Captopril disulphide conjugates can be reduced back to captopril in vivo. O. H. Drummer and B. Jarrott 68. The rat costo‐uterine muscle: an isolated preparation of potential use for screening drugs acting at β2‐adrenoceptors. J. N. Pennefather and M. L. Hartley 69. Dose‐related effects of ovarian steroid hormones on guinea‐pig myometrial adrenoceptors. M. E. Story, M. L. Hartley and J. N. Pennefather 70. Evidence from binding studies for alpha and beta adrenoceptors associated with rat glomeruli. G. A. McPherson and R. J. Summers 71. A comparison of the effects of phenoxybenzamine and RX781094 in the vas deferens. M. Papanicolaou, M. W. McCulloch and M. J. Rand 72. Ketanserin lowers blood pressure in rats by a‐adrenoceptor blockade. J. F. Marwood and G. S. Stokes 73. Hypotensive response to ketanserin in conscious rabbits: role of α‐adrenoceptors. C. E. Wright, J. A. Angus and G. P. Jackman 74. The influence of platelets on prostanoid release from rat hearts perfused in vitro. M. Purchase and G. J. Dusting 75. The antagonism of the effects of platelet products on a human blood vessel by verapamil, nifedipine and sodium nitrite. R. F. W. Moulds, V. Iwanov and R. L. Medcalf 76. Antagonists of endothelial cell‐mediated relaxation of arterial smooth muscle. T. M. Cocks and J. A. Angus 77. Differences in the mechanism of the endothelium‐dependent relaxing action of acetylcholine in rabbit aorta and dog femoral artery. D. Tang and W. E. Glover 78. Actions of leukotrienes C4, D4 and E, on rat isolated hearts. W. J. Hum, O. L. Woodman and G. J. Dusting 79. Study of the acute toxicity, kinetics and pharmacological action of digitoxigenin glucoside (Dt‐O‐Glu) using the guinea‐pig left atria, mouse, rabbit and open‐chest anaesthetized dog. P. M. Altaian and R. E. Thomas 80. The effect of pH on the inhibitory effect of verapamil, nifedipine and diltiazem on the ATP dependent and DTP independent Ca2+ binding activity of isolated rat cardiac carcolemmal preparation. J. S. Dillon and W. G. Nayler 81. Theobromine metabolism in man: effects of cimetidine and sulphinpyrazone. D. J. Birkett, J. O. Miners, L. M. H. Wing and J. Attwood 82. Decreased clearance of warfarin after treatment with cimetidine or ranitidine. P. V. Desmond, K. J. Breen, P. J. Harman, M. L. Mashford and B. J. Morphett 83. The influence of chemical structure on the route of metabolism of barbiturates. A. Treston, W. D. Hooper and M. J. Eadie 84. Conjugation of benzoic acid in seven species of marsupial. Almah Awaluddin and S. McLean 85. 25‐Hydroxylation of vitamin D in patients on long‐term anticonvulsant therapy and with parenchymal liver disease. A. Boroky, H. Morris C. Nordin, J. LaBrooy, and F. Bochner 86. Metabolism of tritiated glyceryl trinitrate by human erythrocytes. P. A. Cossum and M. S. Roberts 87. Metronidazol metabolism in the premature neonate. J. Baird‐Lambert, P. E. Doyle, E. Jager‐Roman and N. Buchanan 88. The measurement of motor performance in Parkinson's disease and the evaluation of a sustained release formulation of L‐dopa with benserazide. P. Paull, D. Madden, J. Morris and D. Wade 89. Modulation of dopamine responses by activation of β‐hydroxy phenethylamine receptors. D. F. H. Dougan and D. N. Wade 90. Effect of α‐methyltyrosine on the concentrations of m‐tyramine and α‐methyl m‐tyramine in rat striatum. P. H. Duffield, D. F. H. Dougan, D. N. Wade and A. M. Duffield 91. Radioreceptor assay of the pharmacokinetics of midazolam and chlordiazepoxide. K. M. Taylor, D. M. Paton and R. A. Boas 92. Properties of fentanyl binding to the μ opiate receptor. K. M. Taylor and J. W. Villiger 93. Problems with propranolol as a displacer of [3H)‐dihydroalprenolol for defining β‐receptors in the rat cerebral cortex. E. J. Begg and D. N. Wade 94. The modulation of high affinity (3H)‐spiperone binding by manganese in homogenates of the rat corpus striatum. D. J. de Vries and P. M. Beart 95. The anticonvulsant, carbamazepine, interacts with brain benzodiazepine receptors. J. H. Skerritt and S. Chen Chow 96. Potent theophylline‐like activity of some novel pyrazolopyrimidines. S. Chen Chow, J. H. Skerritt, L. P. Davies, G. A. R. Johnston and D. J. Brown 97. Modification of hypothermic effects of physostigmine by ovariectomy. R. A. Netherton and D. H. Overstreet 98. Design and activity of a new oxygen heterocyclic analogue of GABA. R. D. Allan, G. A. R. Johnston and R. Kazlauskas 99. Selectivity of antidepressants to inhibit amine uptake following in vivo administration. B. Manias and D. A. Taylor 100. Parallel cross‐tolerance to stress and morphine antinociception: no change in endogenous opioid activity following chronic opiate treatment. M. J. Christie, G. B. Chesher, and K. D. Bird 101. Mesenteric vessels from hypertensive rats exhibit an increased responsiveness to serotonin that is inhibited by ketanserin. D. A. Taylor and P. L. McLennan 102. Inhibition of 5‐hydroxytryptophan‐induced wet‐shakes by serotonin‐2 receptor antagonists. C. Y. Yap and D. A. Taylor 103. Neurally‐mediated relaxant effect of serotonin in guinea‐pig distal ileum. E.J. Mylecharane and R. McD. Sutherland 104. Antagonist activity of ketanserin in smooth muscle preparations. R. McD. Sutherland and E. J. Mylecharane 105. Metabolic profile of [3H]‐noradrenaline released by isoprenaline from rabbit atria. C. Sarantos‐Laska, M. W. McCulloch and M. J. Rand 106. Binding of (3H)‐rauwolscine to intact human blood platelets. A. J. Smith and L. M. Stewart 107. Action of opioid‐ and α‐adrenoceptor agonists on neurogenic oedema. R. Lew, G. A. Bentley and I. W. Copeland 108. Sympathetic function in the epididymal and prostatic halves of the rat vas deferens after vasectomy. R. M. DeGaris, M. L. Hartley, J. A. Leedham and J. N. Pennefather 109. Thyroid status and α‐adrenoceptors in rat mesenteric arterioles. G. J. Mammen, E. J. N. Ishac and J. N. Pennefather 110. In vivoandin vitroeffects of propylene glycol in human airways. J. Black, K. Yan, C. Salome and J. Shaw 111. Responses of guinea‐pig lung parenchymal strips to drugs affecting adrenoceptors. P. Goad‐by and M. Vadher (introduced by C. Raper) 112. The functional antagonism of carbachol‐induced contractions by β‐adrenoceptor agonists in guinea‐pig isolated tracheal smooth muscle. P. J. Henry, K. M. Lulich and J. W. Paterson 113. Verapamil inhibits thromboxane A2 release from guinea‐pig isolated perfused lungs. S. Ozols and J. P. Seale 114. The effects of fenoterol and selective β‐adrenoceptor antagonists on the release of SRS‐A leukotrienes from human lung fragments. J. M. Hughes, J. P. Seale and D. M. Temple 115. Effect of a new antiallergic compound, SM857, on the release of slow‐reacting substance (leukotrienes) from lung tissue. J. G. Kench, J. P. Seale and D. M. Temple 116. Age‐related changes in responses of human isolated arteries an veins. M. J. Stevens, S. Lipe and R. F. W. Moulds 117. Hyperventilation potentiates the nicotine‐induced depressor chemoreflex in the dog. Denise E. Luk, P. N. Nolan and Janina Staszewska‐Barczak 118. Cardiac sarcolemma during ischaemia and reperfusion: influence of verapamil. M. J. Daly, J. Elz, and W. G. Nayler 119. Structure‐activity relations at peripheral adenosine receptors. D. M. Paton 120. Computer‐assisted anticonvulsant therapy. G. M. Peterson 121. Assessment of efficacy of oral dihydroergotamine in severe orthostatic hypotension from Australian case studies. P. F. Isaac, S. A. Genge, A. Barnes and G. L. Couch 122. The influence of some different antihypertensive drugs on the cardiovascular reaction to isometric exercise. G. Nyberg 123. Comparison of colloidal bismuth subcitrate tablets and liquid in duodenal ulcer healing. J. E. Kellow, G. D. Barr, W. R. J. Middleton and D. W. Piper 124. Effects on β‐blockade on performance in competitive swimming. G. Nyberg and B. Furberg 125. Pharmacokinetic optimization of aminophylline infusion requirements in critically ill asthmatic patients. K. F. Ilett, R. L. Nation, T. E. Oh and B. Silbert 126. Utilization of drug level monitoring in a district hospital. M. Kennedy and W. Beshaw 127. Use of prophylactic antibiotics in children undergoing operations. N. Anderson, D. Cohen, D. Dorman and J. Shaw 128. Drug usage in a coronary care unit. P. Raymond, G. Hale, M. L. Mashford, K. Raymond, J. Roberts, M. Robertson and P. Seo 129. Survey of drug abuse patterns in a casualty department population. J. E. Ray, D. K. Reilly, T. Haavisto, P. D. Paull and R. O. Day 130. Structure‐activity relationships for protein binding of radiocontrast agents. S. Wan‐wimolruk and D. J. Birkett 131. Preliminary pharmacokinetic and pharmacodynamic studies with tizanidine in patients with spasticity. P. Symoniw, V. Heazlewood, P. Maruff and M. J. Eadie 132. Aspirin glucocorticosteroid interaction in man. R. O. Day, G. Harris, M. Brown and G. Graham 133. Analysis and pharmacokinetics of the β‐adrenoceptor agonist ICI 118,587 (Corwin). G. P. Jackman, C. J. Oddie, A. Bobik and G. Jennings 134. Disposition and cardiovascular effects of cimetidine in critically ill patients. R. L. Nation, K. F. Ilett, R. Tjokrosetio, T. E. Oh, P. Cameron and W. Thompson 135. The effect of cimetidine and metoclopramide on the elimination of misonidazole (Ro 07–0582) in man. K. M. Williams, E. J. Begg, D. N. Wade and K. O'Shea 136. Purification of UDP glucuronosyltransferase from mouse liver. P. I. Mackenzie and I. S. Owens (introduced by M. E. McManus) 137. Metabolism of primidone in man. W. D. Hooper, A. Treston, N. W. Jacobsent and M. J. Eadie 138. Influence of cimetidine on procainamide pharmacokinetics in man. A. Somogyi, A. McLean and B. Heinzow 139. Differential effects of hypoxia on the disposition of propranolol and sodium taurocholate by the rat isolated perfused liver. B. Jones, G. Mihaly, R. Smallwood, L. Webster, D. Morgan and M. Madsen 140. Intra‐ and extra‐hepatic carcinomas impair drug metabolism in the rat. P. J. Harman, S. E. Doig, P. V. Desmond, M. L. Mashford, K. J. Breen and B. Gray 141. Kinetic evidence for the involvement of multiple forms of human liver cytochrome P‐450 in the metabolism of acetylaminofluorene. M. E. McManus, R. F. Minchin, P. J. Wirth and S. S. Thorgeirsson 142. Dose‐response curves for the effects of enteric‐coated aspirin on platelet function. P. A. Cossum, J. H. Vial, L. J. McLeodf and M. S. Roberts 143. Converting enzyme inhibition in the rat is accompanied by potentiation of inflammation. A. P. Svolmanis and A. L. A. Boura 144. The effect of route of administration on the distribution and severity of lesions due to a compound whose toxic action is cytochrome P‐450 associated. A. A. Seawright, A. R. Mattocks and J. Hrdlicka 145. Peroxidation of rat liver microsomal membrane lipids induced by methyl mercury. M. Hicks, J. M. Gebicki and K. D. Cairncross 146. Some toxicological and behavioural effects of in utero methyl mercury exposure in the rat. Ann A. Parks, Robyn Can, M. Hicks, J. M. Gebicki and K. D. Cairncross 147. Effects of cimetidine and ranitidine on halothane metabolism and hepatotoxicity. J. L. Plummer, S. Wanwimolruk, M. A. Jenner, P. de la M. Hallt, and M. J. Cousins 148. Cardiovascular and hepatic effects of halothane and isoflurane in a guinea‐pig model of ‘halothane hepatitis'. C. A. Lunam, P. de la M. Hall and M. J. Cousins. (Introduced by M. J. Cousins.) 149. HPLC assays for β‐lactam antibiotics in body fluids. P.J. Harman, Y. M. Wang and M. L. Mashford 150. Comparison of three methods for the routine measurement of phenytoin free fraction during therapeutic drug monitoring. S. Wanwimolruk, D. J. Birkett and L. M. H. Wing 151. Measurement of propantheline bromide in serum by high performance liquid chromatography. B. G. Charles, D. K. Moses and P. J. Ravenscroft 152. The use of 2,5‐diphenyloxazole as a substrate in the assay of AAH. A. Philippides, J. Ahokas. C. Davies, N. Jacobsen and N. Kärki 153. Simultaneous HPLC assay for cimetidine and ranitidine. J. Boutagy, I. A. Munro, D. G. More and G. M. Shenfield 154. The analysis of D‐penicillamine in plasma using fluorescence derivatisation and high performance liquid chromatography. J. O. Miners, I. Fearnley, D. Smith, M. W. Whitehouse, P. Brooks, and D. J. Birkett Copyright © 1983, Wiley Blackwell. All rights reserved
DB  - Scopus
DO  - 10.1111/j.1440-1681.1983.tb00851.x
IS  - 6
M3  - Article
N1  - Export Date: 22 March 2021
PY  - 1983
SP  - 641-730
ST  - PROCEEDINGS OF THE AUSTRALASIAN SOCIETY OF CLINICAL AND EXPERIMENTAL PHARMACOLOGISTS
T2  - Clinical and Experimental Pharmacology and Physiology
TI  - PROCEEDINGS OF THE AUSTRALASIAN SOCIETY OF CLINICAL AND EXPERIMENTAL PHARMACOLOGISTS
UR  - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84981021636&doi=10.1111%2fj.1440-1681.1983.tb00851.x&partnerID=40&md5=7f92656db31aa4f2ea53c69dd1d0285f
VL  - 10
ID  - 2662
ER  - 

TY  - JOUR
AB  - PURPOSE: National health statistics indicate that blacks have lower survival rates from colorectal cancer than do whites. This disparity has been attributed to differences in stage at diagnosis and other disease features, extent and quality of treatment, and socioeconomic factors. We evaluated outcomes for blacks and whites with rectal cancer who participated in randomized clinical trials of the National Surgical Adjuvant Breast and Bowel Project (NSABP). The randomized trial setting enhances uniformity in disease stage and treatment plan among all participants. PATIENTS AND METHODS: The study included black (N = 104) or white (N = 1,070) patients from two serially conducted NSABP randomized trials for operable rectal cancer. Recurrence-free survival and survival were compared using statistical modeling to account for differences in patient and disease characteristics between the groups. RESULTS: Blacks and whites had largely similar disease features at diagnosis. After adjustment for patient and tumor prognostic covariates, the black/white recurrence hazard ratio (HR) was 1.25 (95% confidence interval [CI], 0.94 to 1.66). The mortality HR was somewhat larger at 1.45 (95% CI = 1.09 to 1.93). Outcomes were improved for both groups in the more recent trial, which employed systemic adjuvant chemotherapy in all treatment arms. CONCLUSION: Recurrence-free survival was modestly less favorable for blacks, whereas overall survival was more disparate. Outcomes between groups were more comparable than those noted in national health statistics surveys and other studies. Adequate treatment access and the identification of new prognostic factors that can identify patients at high risk of recurrence are needed to ensure optimal outcomes for rectal cancer patients of all racial/ethnic backgrounds.
AD  - Department of Health Studies, University of Chicago and University of Chicago Cancer Research Center, Chicago, IL 60637, USA. jdignam@health.bsd.uchicago.edu
AN  - 12560428
AU  - Dignam, J. J.
AU  - Ye, Y.
AU  - Colangelo, L.
AU  - Smith, R.
AU  - Mamounas, E. P.
AU  - Wieand, H. S.
AU  - Wolmark, N.
DA  - Feb 1
DO  - 10.1200/jco.2003.02.004
DP  - NLM
ET  - 2003/02/01
IS  - 3
KW  - *African Continental Ancestry Group
Aged
Disease Progression
Disease-Free Survival
*European Continental Ancestry Group
Female
Health Services Accessibility
Humans
Male
Middle Aged
*Neoplasm Recurrence, Local
Odds Ratio
Prognosis
Randomized Controlled Trials as Topic
Rectal Neoplasms/*ethnology/*pathology/therapy
Risk Factors
Treatment Outcome
LA  - eng
N1  - Dignam, James J
Ye, Yunrong
Colangelo, Linda
Smith, Roy
Mamounas, Eleftherios P
Wieand, H Samuel
Wolmark, Norman
P30-CA-14599/CA/NCI NIH HHS/United States
U10-CA-12027/CA/NCI NIH HHS/United States
U10-CA-69651/CA/NCI NIH HHS/United States
Clinical Trial
Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, U.S. Gov't, P.H.S.
United States
J Clin Oncol. 2003 Feb 1;21(3):413-20. doi: 10.1200/JCO.2003.02.004.
PY  - 2003
SN  - 0732-183X (Print)
0732-183x
SP  - 413-20
ST  - Prognosis after rectal cancer in blacks and whites participating in adjuvant therapy randomized trials
T2  - J Clin Oncol
TI  - Prognosis after rectal cancer in blacks and whites participating in adjuvant therapy randomized trials
VL  - 21
ID  - 656
ER  - 

TY  - JOUR
AB  - Numerous advances in the treatment of patients who have metastatic disease have improved colorectal cancer management, including new chemotherapeutic agents and combinations and targeted agents that modulate the efficacy of chemotherapy. Recent advances in the administration of irinotecan and oxaliplatin, in combination with 5-FU/LV, plus the addition of targeted agents bevacizumab and cetuximab have afforded steady increases in response rates and survival. Ongoing studies are evaluating the optimal sequencing and combinations of the agents described and the efficacy of new combinations in metastatic and adjuvant settings. Because the number of African-American patients in most clinical trials in colorectal cancer has been low, it is imperative that method increase participation so that new research developments reach all segments of the population.
AD  - Division of Medical Oncology, Kimmel Cancer Center, Thomas Jefferson University, Gibbon Building, Suite 4240, Philadelphia, PA 19107, USA. edith.mitchell@jefferson.edu
AN  - 16129111
AU  - Mitchell, E. P.
DA  - Sep
DO  - 10.1016/j.mcna.2005.05.007
DP  - NLM
ET  - 2005/09/01
IS  - 5
KW  - *African Americans
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Clinical Trials as Topic
Colorectal Neoplasms/*drug therapy/*ethnology/pathology
Humans
Liver Neoplasms/drug therapy/ethnology/secondary
SEER Program
Survival Rate
United States/epidemiology
LA  - eng
N1  - Mitchell, Edith P
Journal Article
Review
United States
Med Clin North Am. 2005 Sep;89(5):1045-57, 1054. doi: 10.1016/j.mcna.2005.05.007.
PY  - 2005
SN  - 0025-7125 (Print)
0025-7125
SP  - 1045-57, 1054
ST  - Prognostic impact of race and ethnicity in the treatment of colorectal cancer
T2  - Med Clin North Am
TI  - Prognostic impact of race and ethnicity in the treatment of colorectal cancer
VL  - 89
ID  - 589
ER  - 

TY  - JOUR
AB  - Purpose To our knowledge the optimal treatment of patients following a negative prostate biopsy is unknown. Consequently, resources are increasingly being directed toward risk stratification in this cohort. However, the risk of prostate cancer mortality in this group before the introduction of supplemental biomarkers and imaging techniques is unclear. Materials and Methods The PLCO (Prostate, Lung, Colorectal and Ovarian Cancer) Screening Trial provides survival data prior to the implementation of new diagnostic interventions. We divided men with an initial positive screen and a subsequent prostate biopsy into cohorts based on positive or negative results. Prostate cancer specific mortality was then compared to that in the trial control arm to estimate the prognostic significance of biopsy results relative to the general population. Results A total of 36,525 and 36,560 patients comprised the screening and control arms, respectively. Of 4,064 subjects with a positive first screen 1,233 underwent a linked biopsy, of which 473 were positive and 760 were negative. At a median followup of 12.9 years, 1.1% of men in the negative biopsy cohort had died of prostate cancer. The difference in mortality rates between the negative biopsy and control arms was 0.734 deaths per 1,000 person-years. The proportional subhazard ratios of prostate cancer specific mortality for negative biopsy and positive biopsy relative to the control arm were 2.93 (95% CI 1.44–5.99) and 18.77 (95% CI 12.62–27.93), respectively. Conclusions After a negative prostate biopsy, men face a relatively low risk of death from prostate cancer when followed with traditional markers and biopsy techniques. This suggests limited potential for new diagnostic interventions to improve survival in this group.
AD  - D.M. Golombos, Weill Cornell Medicine, 525 East 68th St., Starr 900, New York, United States
AU  - Lewicki, P.
AU  - Shoag, J.
AU  - Golombos, D. M.
AU  - Oromendia, C.
AU  - Ballman, K. V.
AU  - Halpern, J. A.
AU  - Stone, B. V.
AU  - O'Malley, P.
AU  - Barbieri, C. E.
AU  - Scherr, D. S.
DB  - Embase
Medline
DO  - 10.1016/j.juro.2016.11.002
IS  - 4
KW  - adult
African American
aged
article
cancer incidence
cancer mortality
cancer prognosis
cancer risk
cancer screening
cancer survival
Caucasian
controlled study
family history
follow up
Gleason score
human
major clinical study
male
medical record review
mortality rate
priority journal
prognostic assessment
prostate biopsy
prostate cancer
prostate cancer prognostic test
randomized controlled trial (topic)
tumor biopsy
LA  - English
M3  - Article
N1  - L614646915
2017-03-07
2017-04-13
PY  - 2017
SN  - 1527-3792
0022-5347
SP  - 1014-1019
ST  - Prognostic Significance of a Negative Prostate Biopsy: An Analysis of Subjects Enrolled in a Prostate Cancer Screening Trial
T2  - Journal of Urology
TI  - Prognostic Significance of a Negative Prostate Biopsy: An Analysis of Subjects Enrolled in a Prostate Cancer Screening Trial
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L614646915&from=export
http://dx.doi.org/10.1016/j.juro.2016.11.002
VL  - 197
ID  - 940
ER  - 

TY  - JOUR
AB  - Objective To determine the importance of perineural invasion (PNI) on diagnostic biopsy in men enrolled in active surveillance (AS). Patients and Methods Eligibility criteria for AS included clinical stage ≤ T2a and Gleason score ≤6, ≤3 cores positive, maximum single core involvement <50%, and total tumour volume ≤5% on diagnostic biopsy. All men received 12-core confirmation biopsy at ≤6 months. AS 'failure' on confirmatory biopsy was defined as failure to meet one or more eligibility criteria. Risk of AS failure was compared in men with and without PNI. Results For the 165 men comprising the study population, the mean (sd) age was 66.9 (6.5) years and the median (interquartile, IQR) PSA level of men at study entry was 4.4 (3.2-6.0) ng/mL. The median (IQR) follow-up was 5.5 (1.1-9.9) months. In all, 8.5% (14/165 men) had PNI on diagnostic biopsy. Compared with those without PNI, men with PNI tended to have more cores involved with cancer, at a mean (sd) of 2.0 (0.7) vs 1.6 (0.8) cores (P = 0.08) but did not have significantly a greater mean (sd) total tumour length on diagnostic biopsy, at 3.0 (2.1) vs 2.3 (3.6) mm (P = 0.27). Men with PNI on diagnostic biopsy were significantly more likely to meet criteria for disease progression on confirmatory biopsy (57% [8/14] vs 21% [32/151]; P = 0.006). PNI remained a significant predictor for AS failure after adjustment for number of positive cores, maximum percentage core involvement, and total tumour length (odds ratio 4.4, 95% confidence interval 1.4-14.2). Conclusions PNI on diagnostic biopsy is associated with disease progression on confirmatory biopsy. The presence of PNI should factor into appropriate patient selection and counselling in AS. © 2013 BJU International.
AD  - B.T. Helfand, Department of Surgery, John and CarolWalter Center for Urological Health, NorthShore University Health System, 2650 Ridge Avenue Walgreen Building, Suite 2507, Evanston, IL, United States
AU  - Cohn, J. A.
AU  - Dangle, P. P.
AU  - Wang, C. E.
AU  - Brendler, C. B.
AU  - Novakovic, K. R.
AU  - McGuire, M. S.
AU  - Helfand, B. T.
DB  - Embase
Medline
DO  - 10.1111/bju.12463
IS  - 1
KW  - African American
aged
article
cancer growth
cancer prognosis
cancer staging
Caucasian
disease association
disease surveillance
follow up
human
major clinical study
male
men's health
patient counseling
patient selection
perineural invasion
population research
prediction
priority journal
prostate biopsy
prostate cancer
prostate volume
race difference
risk assessment
tumor volume
LA  - English
M3  - Article
N1  - L52974161
2014-01-29
2014-07-08
PY  - 2014
SN  - 1464-410X
1464-4096
SP  - 75-80
ST  - The prognostic significance of perineural invasion and race in men considering active surveillance
T2  - BJU International
TI  - The prognostic significance of perineural invasion and race in men considering active surveillance
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L52974161&from=export
http://dx.doi.org/10.1111/bju.12463
VL  - 114
ID  - 1057
ER  - 

TY  - JOUR
AB  - Objectives: Lactate clearance (LC) and central venous oxygen saturation (ScvO2) have been proposed as goals of early sepsis resuscitation. The authors sought to determine the agreement and prognostic value of achieving ScvO2 or LC goals in septic shock patients undergoing emergency department (ED)-based early resuscitation. Methods: This was a preplanned analysis of a multicenter ED randomized controlled trial of early sepsis resuscitation targeting three variables: central venous pressure, mean arterial pressure, and either ScvO2 or LC. Inclusion criteria included suspected infection, two or more systemic inflammation criteria, and either systolic blood pressure of <90 mm Hg after intravenous fluid bolus or lactate level of >4 mmol/L. Both ScvO2 and LC were measured simultaneously. The ScvO2 goal was defined as ≥70%. Lactate was measured at enrollment and every 2 hours until the goal was reached or up to 6 hours. LC goal was defined as a decrease of ≥10% from initial measurement. The primary outcome was in-hospital mortality. Results: A total of 203 subjects were included, with an overall mortality of 19.7%. Achievement of the ScvO 2 goal only was associated with a mortality rate of 41% (9/22), while achievement of the LC goal only was associated with a mortality rate of 8% (2/25; proportion difference = 33%; 95% confidence interval [CI] = 9% to 55%). No agreement was found between goal achievement (κ = -0.02), and exact test for matched pairs demonstrated no significant difference between discordant pairs (p = 0.78). Conclusions: No agreement was found between LC and ScvO 2 goal achievement in early sepsis resuscitation. Achievement of a ScvO2≥ 70% without LC ≥ 10% was more strongly associated with mortality than achievement of LC ≥ 10% with failure to achieve ScvO 2≥ 70%. © 2012 by the Society for Academic Emergency Medicine.
AD  - A.E. Jones, Department of Emergency Medicine, University of Mississippi Medical Center, Jackson, MS, United States
AU  - Puskarich, M. A.
AU  - Trzeciak, S.
AU  - Shapiro, N. I.
AU  - Arnold, R. C.
AU  - Heffner, A. C.
AU  - Kline, J. A.
AU  - Jones, A. E.
DB  - Embase
Medline
DO  - 10.1111/j.1553-2712.2012.01292.x
IS  - 3
KW  - NCT00372502
activated protein C
dobutamine
infusion fluid
lactic acid
abdominal infection
adult
African American
antibiotic therapy
article
artificial ventilation
bloodstream infection
breathing rate
Caucasian
central vein
central venous oxygen saturation
central venous pressure
chronic obstructive lung disease
comorbidity
controlled study
corticosteroid therapy
crystalloid
diabetes mellitus
disease severity
early intervention
emergency treatment
erythrocyte transfusion
female
Glasgow coma scale
heart rate
Hispanic
human
Human immunodeficiency virus infection
kidney failure
lactate blood level
lung infection
major clinical study
male
malignant neoplasm
mean arterial pressure
mortality
multicenter study
multiple organ failure
nursing home patient
organ transplantation
outcome assessment
oxygen saturation
priority journal
prognosis
prospective study
randomized controlled trial
resuscitation
septic shock
skin infection
systolic blood pressure
urinary tract infection
LA  - English
M3  - Article
N1  - L364510442
2012-04-03
PY  - 2012
SN  - 1069-6563
1553-2712
SP  - 252-258
ST  - Prognostic value and agreement of achieving lactate clearance or central venous oxygen saturation goals during early sepsis resuscitation
T2  - Academic Emergency Medicine
TI  - Prognostic value and agreement of achieving lactate clearance or central venous oxygen saturation goals during early sepsis resuscitation
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L364510442&from=export
http://dx.doi.org/10.1111/j.1553-2712.2012.01292.x
VL  - 19
ID  - 1124
ER  - 

TY  - JOUR
AB  - PURPOSE: We investigated the prognostic value of distant metastasis sites among patients with metastatic colorectal cancer (CRC) and the significance of metastasectomy and resection of the primary CRC. METHODS: Between 2010 and 2014, patients diagnosed with metastatic colorectal adenocarcinoma were selected using the surveillance, epidemiology, and end results (SEER) database. The prognosis of these patients was compared according to the site of metastasis (liver, lung, bone, and brain). A total of 15,133 patients suffered from isolated organ involvement, while 5135 patients experienced multiple organ metastases. RESULTS: In the isolated organ metastasis cohort, median overall survival (OS) for patients with liver, lung, bone, and brain metastases was 16, 20, 7, and 5 months, respectively. Patients with isolated lung metastases had better cancer-specific survival (CSS) and OS as compared to patients with metastases at any other sites (p < 0.0001 for both CSS and OS). Patients with isolated liver metastases had better prognosis as compared to patients with isolated bone or brain metastases (p < 0.0001 for both CSS and OS). Moreover, patients with a single metastatic site had better prognosis than patients with multiple organs involved (p < 0.0001 for both CSS and OS). Multivariate analysis in patients with isolated organ metastases demonstrated that age ≤ 60 years, rectal cancer, being married, non-black race, N0 stage, and surgery of the primary and distant lesions showed more favorable prognosis. CONCLUSIONS: The metastatic site was an independent prognostic factor in stage IV colorectal cancer. Also, carefully chosen patients may benefit from surgery.
AD  - Department of Colorectal Surgery, Fudan University Shanghai Cancer Center, No. 270, Dong'an Road, Xuhui District, Shanghai, 200032, China.
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Department of Colorectal Surgery, Fudan University Shanghai Cancer Center, No. 270, Dong'an Road, Xuhui District, Shanghai, 200032, China. oncosurgeonli@sohu.com.
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China. oncosurgeonli@sohu.com.
Department of Colorectal Surgery, Fudan University Shanghai Cancer Center, No. 270, Dong'an Road, Xuhui District, Shanghai, 200032, China. 1149lxx@sina.com.
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China. 1149lxx@sina.com.
AN  - 29931408
AU  - Luo, D.
AU  - Liu, Q.
AU  - Yu, W.
AU  - Ma, Y.
AU  - Zhu, J.
AU  - Lian, P.
AU  - Cai, S.
AU  - Li, Q.
AU  - Li, X.
DA  - Sep
DO  - 10.1007/s00384-018-3091-x
DP  - NLM
ET  - 2018/06/23
IS  - 9
KW  - Adenocarcinoma/mortality/*secondary/*surgery
Clinical Decision-Making
*Colectomy/adverse effects/mortality
Colorectal Neoplasms/mortality/*pathology/*surgery
Disease-Free Survival
Female
Humans
Male
*Metastasectomy/adverse effects/mortality
Middle Aged
Neoplasm Staging
Patient Selection
Retrospective Studies
Risk Assessment
Risk Factors
SEER Program
Time Factors
United States/epidemiology
Colorectal cancer
Distant metastatic site
Prognosis
LA  - eng
N1  - 1432-1262
Luo, Dakui
Liu, Qi
Yu, Wencheng
Ma, Yanlei
Zhu, Ji
Lian, Peng
Cai, Sanjun
Li, Qingguo
Li, Xinxiang
Orcid: 0000-0002-5902-3659
81772599/National Natural Science Foundation of China/
81702353/National Natural Science Foundation of China/
17ZR1406400/Shanghai Municipal Natural Science Foundation/
Journal Article
Germany
Int J Colorectal Dis. 2018 Sep;33(9):1241-1249. doi: 10.1007/s00384-018-3091-x. Epub 2018 Jun 21.
PY  - 2018
SN  - 0179-1958
SP  - 1241-1249
ST  - Prognostic value of distant metastasis sites and surgery in stage IV colorectal cancer: a population-based study
T2  - Int J Colorectal Dis
TI  - Prognostic value of distant metastasis sites and surgery in stage IV colorectal cancer: a population-based study
VL  - 33
ID  - 117
ER  - 

TY  - JOUR
AB  - BACKGROUND. The objective of this study was to characterize changes in hemoglobin (HGB) levels after the initiation of androgen-deprivation therapy (ADT) in patients with previously untreated, metastatic prostate cancer who were enrolled in a large clinical trial. METHODS. The multivariate associations between 3-month change in HGB and baseline characteristics were evaluated with a linear regression model. The associations between 3-month change in HGB level and time-to-event outcomes, including overall survival and progression-free survival, were evaluated by using proportional hazards regression models. RESULTS. Quartiles of baseline HGB levels were <= 12.0 g/dL, from 12.1 to 13.7 g/dL, from 13.8 to 14.7 g/dL, and > 14.7 g/dL. Overall, 3 months after initiating ADT, the mean HGB level declined 0.54 g/dL (standard deviation [SD], 1.68 g/dL); however, the mean HGB level increased by 0.99 g/dL (SD, 1.83 g/dL) in patients who had baseline HGB levels < 12 g/dL and decreased 1.04 g/dL (SD, 1.28 g/dL) in patients who had baseline HGB levels >= 12 g/dL. After adjusting for potential confounders, including baseline HGB level, a decline in HGB after 3 months of ADT was associated independently with shorter survival (hazards ratio [HR], 1.10 per 1 g/dL decline; P = .0035) and shorter progression-free survival (HR, 1.08 per 1 g/dL decline; P = .013). An unexpected finding was that the effect of baseline HGB on overall and progression-free survival varied significantly by race. CONCLUSIONS. in a sample of men with newly diagnosed, metastatic prostate cancer, a decline in HGB level after 3 months of ADT was associated with shorter survival and progression-free survival after adjusting for disease status and other baseline covariates. Although race alone was not a strong predictor of death or disease progression, the effect of the baseline HGB level on overall and progression-free survival varied significantly by race.
AN  - WOS:000239157800007
AU  - Beer, T. M.
AU  - Tangen, C. M.
AU  - Bland, L. B.
AU  - Hussain, M.
AU  - Goldman, B. H.
AU  - DeLoughery, T. G.
AU  - Crawford, E. D.
DA  - Aug
DO  - 10.1002/cncr.22029
IS  - 3
N1  - 16804926
PY  - 2006
SN  - 0008-543X
SP  - 489-496
ST  - The prognostic value of hemoglobin change after initiating androgen-deprivation therapy for newly diagnosed metastatic prostate cancer - A multivariate analysis of Southwest Oncology Group Study 8894
T2  - Cancer
TI  - The prognostic value of hemoglobin change after initiating androgen-deprivation therapy for newly diagnosed metastatic prostate cancer - A multivariate analysis of Southwest Oncology Group Study 8894
VL  - 107
ID  - 3212
ER  - 

TY  - JOUR
AB  - To examine the prognostic significance of lifestyle factors in urinary bladder cancer, we conducted a follow-up study of 258 incident bladder cancer patients, who were originally recruited in a case-control study in metropolitan Nagoya. Information on individual survivals was obtained from the computer data-file of the tumor registry of the Nagoya Bladder Cancer Research Group. Univariate analyses revealed significant associations of 5-year survivorship with educational attainment, marital status, drinking habits and consumption of green tea in males, and age at first consultation, histological type and grade of tumor, stage and distant metastasis in both sexes. After adjustment for age, stage, histology (histological type and grade) and distant metastasis by means of a proportional hazards model, drinking of alcoholic beverages was significantly associated with the prognosis of bladder cancer in males. Its adjusted hazard ratio was 0.46 (95% confidence interval: 0.26-0.79), favoring patients who had taken alcoholic beverages. In detailed analysis, ex-drinkers and all levels of current drinkers demonstrated hazard ratios smaller than unity, although no clear dose-response relationship was detected. No prognostic significance was found for such lifestyle factors as smoking habit, uses of artificial sweeteners and hairdye, and consumption of coffee, black tea, matcha (powdered green tea) and cola.
AN  - WOS:A1993MN95100004
AU  - Wakai, K.
AU  - Ohno, Y.
AU  - Obata, K.
AU  - Aoki, K.
DA  - Dec
DO  - 10.1111/j.1349-7006.1993.tb02826.x
IS  - 12
N1  - 21
8294212
PY  - 1993
SN  - 0910-5050
SP  - 1223-1229
ST  - Prognostic-Significance of Selected Life-Style Factors in Urinary-Bladder Cancer
T2  - Japanese Journal of Cancer Research
TI  - Prognostic-Significance of Selected Life-Style Factors in Urinary-Bladder Cancer
VL  - 84
ID  - 2743
ER  - 

TY  - JOUR
AB  - Tested the effectiveness of a multiphasic culturally relevant intervention, delivered over a 1-yr period to increase the rates of participation in fecal occult blood testing (FOBT) at the initial screening opportunity and at the 1-yr follow-up screening opportunity among rural African American women. The study used a pretest/post-test design among African American women (N=106; aged 50-94 yrs) who attended senior citizen centers in a rural southern state. The centers were randomly assigned to the cultural and self-empowerment group, who received the 5-phased intervention, the modified cultural group, who received phase I of the intervention only, or the traditional group, who served as the control group. Women in the cultural and self-empowerment group had a significantly higher rate of participation in FOBT than did those in the modified cultural group and the traditional group. The modified cultural group had a significantly higher rate of participation in FOBT than the did the traditional group. Predictors of participation in FOBT were the women's family history of colorectal cancer and the average number of visits to their healthcare provider. (PsycINFO Database Record (c) 2016 APA, all rights reserved)
AD  - Powe, Barbara D., American Cancer Society, Behavioral Research Ctr, Special Populations Research, 1599 Clifton Road, NE, Atlanta, GA, US, 30329
AN  - 2002-18809-002
AU  - Powe, Barbara D.
DB  - psyh
DO  - 10.1046/j.1523-5394.2002.103008.x
DP  - EBSCOhost
IS  - 3
KW  - culturally relevant intervention
rural African American women
fecal occult blood testing participation
self empowerment
African Americans
Aged
Aged, 80 and over
Colonic Neoplasms
Colonoscopy
Female
Humans
Mass Screening
Middle Aged
Occult Blood
Rural Population
Cancer Screening
Client Participation
Culture (Anthropological)
Empowerment
Health Promotion
Blacks
Blood
Human Females
Rural Environments
Self-Determination
N1  - American Cancer Society, Behavioral Research Ctr, Special Populations Research, Atlanta, GA, US. Release Date: 20021211. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Print. Document Type: Journal Article. Language: English. Major Descriptor: Cancer Screening; Client Participation; Culture (Anthropological); Empowerment; Health Promotion. Minor Descriptor: Blacks; Blood; Human Females; Rural Environments; Self-Determination. Classification: Promotion & Maintenance of Health & Wellness (3365). Population: Human (10); Female (40). Location: US. Age Group: Adulthood (18 yrs & older) (300); Middle Age (40-64 yrs) (360); Aged (65 yrs & older) (380); Very Old (85 yrs & older) (390). Methodology: Empirical Study; Followup Study. References Available: Y. Page Count: 8. Issue Publication Date: May, 2002.
PY  - 2002
SN  - 1065-4704
SP  - 139-146
ST  - Promoting fecal occult blood testing in rural African American women
T2  - Cancer Practice
TI  - Promoting fecal occult blood testing in rural African American women
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2002-18809-002&site=ehost-live&scope=site
VL  - 10
ID  - 1803
ER  - 

TY  - JOUR
AB  - INTRODUCTION: Evidence-based health promotion programs that are disseminated in community settings can improve population health. However, little is known about how effective such programs are when they are implemented in communities. We examined community implementation of an evidence-based program, Body and Soul, to promote consumption of fruits and vegetables. METHODS: We randomly assigned 19 churches to 1 of 2 arms, a colon cancer screening intervention or Body and Soul. We conducted our study from 2008 through 2010. We used the RE-AIM (reach, effectiveness, adoption, implementation, and maintenance) framework to evaluate the program and collected data via participant surveys, on-site observations, and interviews with church coordinators and pastors. RESULTS: Members of 8 churches in Michigan and North Carolina participated in the Body and Soul program. Mean fruit and vegetable consumption increased from baseline (3.9 servings/d) to follow-up (+0.35, P = .04). The program reached 41.4% of the eligible congregation. Six of the 8 churches partially or fully completed at least 3 of the 4 program components. Six churches expressed intention to maintain the program. Church coordinators reported limited time and help to plan and implement activities, competing church events, and lack of motivation among congregation members as barriers to implementation. CONCLUSIONS: The RE-AIM framework provided an effective approach to evaluating the dissemination of an evidence-based program to promote health. Stronger emphasis should be placed on providing technical assistance as a way to improve other community-based translational efforts.
AD  - The University of Texas, School of Public Health, Division of Health Promotion and Behavioral Sciences, 5323 Harry Hines, V8.112, Dallas, TX 75390-9128, USA. Marlyn.A.Allicock@uth.tmc.edu
AN  - 23489638
AU  - Allicock, M.
AU  - Johnson, L. S.
AU  - Leone, L.
AU  - Carr, C.
AU  - Walsh, J.
AU  - Ni, A.
AU  - Resnicow, K.
AU  - Pignone, M.
AU  - Campbell, M.
C2  - PMC3600872
DO  - 10.5888/pcd10.120161
DP  - NLM
ET  - 2013/03/16
KW  - African Americans
Colonic Neoplasms/*diagnosis/ethnology
Community Participation
Counseling
*Diet/ethnology
Female
*Fruit
Health Knowledge, Attitudes, Practice
*Health Promotion
Humans
Male
Michigan
Middle Aged
Motor Activity
North Carolina
Program Evaluation
Religion and Medicine
*Vegetables
LA  - eng
N1  - 1545-1151
Allicock, Marlyn
Johnson, La-Shell
Leone, Lucia
Carr, Carol
Walsh, Joan
Ni, Andi
Resnicow, Ken
Pignone, Michael
Campbell, Marci
U01 CA114629/CA/NCI NIH HHS/United States
U48 DP000059/DP/NCCDPHP CDC HHS/United States
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.
Prev Chronic Dis. 2013;10:E33. doi: 10.5888/pcd10.120161.
PY  - 2013
SN  - 1545-1151
SP  - E33
ST  - Promoting fruit and vegetable consumption among members of black churches, Michigan and North Carolina, 2008-2010
T2  - Prev Chronic Dis
TI  - Promoting fruit and vegetable consumption among members of black churches, Michigan and North Carolina, 2008-2010
VL  - 10
ID  - 335
ER  - 

TY  - JOUR
AB  - BACKGROUND: For health educators, the controversy surrounding routine prostate cancer screening provides curriculum development and delivery challenges. The purpose of this study was to evaluate a community-based prostate health awareness program. METHODS: Using a pretest-posttest design, participants were recruited from community-based organizations to assess the effectiveness of the program in the areas of knowledge gain, short-term intentions, and changing prostate health behaviors. RESULTS: Many of the participants reported having been tested for prostate cancer, yet there was a lower than expected pretest knowledge base. There were significant increases in knowledge on the posttest and some impact on short-term intentions and behavior. DISCUSSION: A community-based prostate health awareness program prior to the patient-physician encounter can assist health-care professionals in the education process and give men the tools to make an informed decision.
AD  - Department of Family Medicine, Wayne State University, 101 East Alexandrine, 2nd Floor, Detroit, MI 48201; pbridge@med.wayne.edu
AN  - 106498916. Language: English. Entry Date: 20050812. Revision Date: 20200708. Publication Type: Journal Article
AU  - Bridge, P. D.
AU  - Berry-Bobovski, L. C.
AU  - Gallagher, R. E.
DA  - Fall2004
DB  - CINAHL Complete
DO  - 10.1207/s15430154jce1903_13
DP  - EBSCOhost
IS  - 3
KW  - Cancer Screening
Health Behavior
Health Education
Health Knowledge
Prostatic Neoplasms -- Prevention and Control
Asians
Behavioral Changes
Black Persons
Coefficient Alpha
Convenience Sample
Curriculum
Descriptive Statistics
Educational Status
Evaluation Research
Funding Source
Health Promotion
Hispanic Americans
Internal Consistency
Male
Middle Age
P-Value
Pretest-Posttest Design
Program Evaluation
Research Instruments
Suburban Areas
Surveys
Urban Areas
White Persons
Wilcoxon Signed Rank Test
Human
N1  - questionnaire/scale; research; tables/charts. Journal Subset: Biomedical; Blind Peer Reviewed; Double Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Health Promotion/Education; Peer Reviewed; USA. Instrumentation: Basic Prostate Cancer Concepts subscale; Controversial Aspects of Prostate Cancer Screening subscale. Grant Information: Michigan Department of Community Health. NLM UID: 8610343.
PMID: NLM15458874.
PY  - 2004
SN  - 0885-8195
SP  - 174-179
ST  - Promoting informed decision making: evaluating a community-based Prostate Health Awareness program
T2  - Journal of Cancer Education
TI  - Promoting informed decision making: evaluating a community-based Prostate Health Awareness program
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106498916&site=ehost-live&scope=site
VL  - 19
ID  - 2031
ER  - 

TY  - JOUR
AB  - The objective of this study was to test the efficacy of a pilot intervention to increase mammography utilization among African-American women recruited from those waiting in the emergency department (ED)for non-urgent complaints. In a 3-armed pilot of a randomized controlled trial we compared the effects of a brief motivational interview delivered by a lay health worker with those of a culturally targeted brochure and a usual care control group. The results showed that one quarter (23%) of the sample reported having never had a mammogram prior to the study. There was no group difference by mammography status at the 3-month interview. More than one quarter of those retained in the study indicated they had received a mammogram during the study (27.4%). The conclusions from the study were that lay health workers are a valuable asset and may be used in innovative settings such as the ED to increase screening among vulnerable populations.
AN  - 29932542
AU  - Hatcher, J.
AU  - Schoenberg, N. E.
AU  - Dignan, M.
AU  - Rayens, M. K.
DA  - Jul
DP  - NLM
ET  - 2016/07/01
IS  - 1
KW  - Adult
African Americans/*psychology
Aged
Aged, 80 and over
Breast Neoplasms/*diagnosis/*psychology
Emergency Medical Services/methods
Female
Health Personnel/psychology
Health Promotion/*methods
Humans
Interpersonal Relations
Mammography/*psychology
Middle Aged
*Pamphlets
Patient Education as Topic/*methods
Pilot Projects
United States
LA  - eng
N1  - Hatcher, Jennifer
Schoenberg, Nancy E
Dignan, Mark
Rayens, Mary Kay
Comparative Study
Journal Article
United States
J Natl Black Nurses Assoc. 2016 Jul;27(1):38-44.
PY  - 2016
SN  - 0885-6028 (Print)
0885-6028
SP  - 38-44
ST  - Promoting Mammography with African-American Women in the Emergency Department Using Lay Health Workers
T2  - J Natl Black Nurses Assoc
TI  - Promoting Mammography with African-American Women in the Emergency Department Using Lay Health Workers
VL  - 27
ID  - 209
ER  - 

TY  - JOUR
AU  - Bravo, R. L.
AU  - Kietzman, K. G.
AU  - Toy, P.
AU  - Duru, O. K.
AU  - Wallace, S. P.
DB  - Medline
DO  - 10.21149/9450
IS  - 4
KW  - African American
aged
California
capacity building
colorectal tumor
community care
community participation
financial management
healthy aging
Hispanic
human
in service training
middle aged
organization and management
patient care
preventive health service
primary health care
public relations
LA  - English
M3  - Article
N1  - L629138661
2019-09-04
2020-02-10
PY  - 2019
SN  - 1606-7916
SP  - 427-435
ST  - Promover una alianza entre la atención primaria y las organizaciones comunitarias para aumentar las pruebas de detección de cáncer colorrectal: el proyecto HAPPI
T2  - Salud publica de Mexico
TI  - Promover una alianza entre la atención primaria y las organizaciones comunitarias para aumentar las pruebas de detección de cáncer colorrectal: el proyecto HAPPI
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L629138661&from=export
http://dx.doi.org/10.21149/9450
VL  - 61
ID  - 846
ER  - 

TY  - JOUR
AB  - BACKGROUND: Discriminating indolent from clinically significant prostate cancer (PCa) in the initial biopsy setting remains an important issue. Prospectively evaluated diagnostic assays are necessary to ensure efficacy and clinical adoption. OBJECTIVE: Performance and utility assessment of ExoDx Prostate (IntelliScore) (EPI) urine exosome gene expression assay versus standard clinical parameters for discriminating Grade Group (GG) ≥2 PCa from GG1 PCa and benign disease on initial biopsy. DESIGN, SETTING, AND PARTICIPANTS: A two-phase adaptive clinical utility study (NCT03031418) comparing EPI results with biopsy outcomes in men, with age ≥50 yr and prostate-specific antigen (PSA) 2-10ng/ml, scheduled for initial prostate biopsy. After EPI performance assessment during phase I, a clinical implementation document (ie, CarePath) was developed for utilizing the EPI test in phase II, where the biopsy decision is uncertain. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Performance evaluation of the EPI test in patients enrolled in phase I and publication of a consensus CarePath for phase II. RESULTS AND LIMITATIONS: In a total of 503 patients, with median age of 64 yr, median PSA 5.4ng/ml, 14% African American, 70% Caucasian, 53% positive biopsy rate (22% GG1, 17% GG2, and 15% ≥ GG3), EPI was superior to an optimized model of standard clinical parameters with an area under the curve (AUC) 0.70 versus 0.62, respectively, comparable with previously published results (n=519 patients, EPI AUC 0.71). Validated cut-point 15.6 would avoid 26% of unnecessary prostate biopsies and 20% of total biopsies, with negative predictive value (NPV) 89% and missing 7% of ≥GG2 PCa. Alternative cut-point 20 would avoid 40% of unnecessary biopsies and 31% of total biopsies, with NPV 89% and missing 11% of ≥GG2 PCa. The clinical investigators reached consensus recommending use of the 15.6 cut-point for phase II. Outcome of the decision impact cohort in phase II will be reported separately. CONCLUSIONS: EPI is a noninvasive, easy-to-use, gene expression urine assay, which has now been successfully validated in over 1000 patients across two prospective validation trials to stratify risk of ≥GG2 from GG1 cancer and benign disease. The test improves identification of patients with higher grade disease and would reduce the total number of unnecessary biopsies. PATIENT SUMMARY: It is challenging to predict which men are likely to have high-grade prostate cancer (PCa) at initial biopsy with prostate-specific antigen 2-10ng/ml. This study further demonstrates that the ExoDx Prostate (IntelliScore) test can predict ≥GG2 PCa at initial biopsy and defer unnecessary biopsies better than existing risk calculator's and standard clinical data.
AD  - Department of Urology, Columbia University Medical Center, New York City, NY, USA.
Icahn School of Medicine at Mt. Sinai, New York City, NY, USA. Electronic address: michael.donovan@mssm.edu.
Urology Center of Englewood, Englewood, NJ, USA.
The James Buchanan Brady Urological Institute and Department of Urology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Delaware Valley Urology, Vorhees, NJ, USA.
Exosome Diagnostics GmbH, Martinsried, Germany.
Exosome Diagnostics Inc, Waltham, MA, USA.
Atlantic Urology Clinics, Myrtle Beach, SC, USA.
Division of Urologic Surgery, Department of Surgery and the Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, USA.
UT Health Science Center, San Antonio, TX, USA.
Department of Urology, University of California at San Francisco, CA, USA.
AN  - 30237023
AU  - McKiernan, J.
AU  - Donovan, M. J.
AU  - Margolis, E.
AU  - Partin, A.
AU  - Carter, B.
AU  - Brown, G.
AU  - Torkler, P.
AU  - Noerholm, M.
AU  - Skog, J.
AU  - Shore, N.
AU  - Andriole, G.
AU  - Thompson, I.
AU  - Carroll, P.
DA  - Dec
DO  - 10.1016/j.eururo.2018.08.019
DP  - NLM
ET  - 2018/09/22
IS  - 6
KW  - Aged
Biomarkers, Tumor/*blood/*genetics/urine
Biopsy
Clinical Decision-Making
Exosomes/*genetics
Gene Expression Profiling/*methods
Genetic Predisposition to Disease
Humans
Kallikreins/*blood
Male
Middle Aged
Neoplasm Grading
Phenotype
Predictive Value of Tests
Prospective Studies
Prostate-Specific Antigen/*blood
Prostatic Neoplasms/blood/*genetics/pathology/urine
Reproducibility of Results
United States
Urinalysis
*Exosomes
*Extended validation study
*High grade prostate cancer
*Initial biopsy
*Prostate cancer
*Risk assessment tools
LA  - eng
N1  - 1873-7560
McKiernan, James
Donovan, Michael J
Margolis, Eric
Partin, Alan
Carter, Ballentine
Brown, Gordon
Torkler, Phillipp
Noerholm, Mikkel
Skog, Johan
Shore, Neal
Andriole, Gerry
Thompson, Ian
Carroll, Peter
Clinical Trial
Comparative Study
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Switzerland
Eur Urol. 2018 Dec;74(6):731-738. doi: 10.1016/j.eururo.2018.08.019. Epub 2018 Sep 17.
PY  - 2018
SN  - 0302-2838
SP  - 731-738
ST  - A Prospective Adaptive Utility Trial to Validate Performance of a Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer in Patients with Prostate-specific Antigen 2-10ng/ml at Initial Biopsy
T2  - Eur Urol
TI  - A Prospective Adaptive Utility Trial to Validate Performance of a Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer in Patients with Prostate-specific Antigen 2-10ng/ml at Initial Biopsy
VL  - 74
ID  - 103
ER  - 

TY  - JOUR
AB  - Background: Discriminating indolent from clinically significant prostate cancer (PCa) in the initial biopsy setting remains an important issue. Prospectively evaluated diagnostic assays are necessary to ensure efficacy and clinical adoption. Objective: Performance and utility assessment of ExoDx Prostate (IntelliScore) (EPI) urine exosome gene expression assay versus standard clinical parameters for discriminating Grade Group (GG) ≥2 PCa from GG1 PCa and benign disease on initial biopsy. Design, setting, and participants: A two-phase adaptive clinical utility study (NCT03031418) comparing EPI results with biopsy outcomes in men, with age ≥50 yr and prostate-specific antigen (PSA) 2–10 ng/ml, scheduled for initial prostate biopsy. After EPI performance assessment during phase I, a clinical implementation document (ie, CarePath) was developed for utilizing the EPI test in phase II, where the biopsy decision is uncertain. Outcome measurements and statistical analysis: Performance evaluation of the EPI test in patients enrolled in phase I and publication of a consensus CarePath for phase II. Results and limitations: In a total of 503 patients, with median age of 64 yr, median PSA 5.4 ng/ml, 14% African American, 70% Caucasian, 53% positive biopsy rate (22% GG1, 17% GG2, and 15% ≥ GG3), EPI was superior to an optimized model of standard clinical parameters with an area under the curve (AUC) 0.70 versus 0.62, respectively, comparable with previously published results (n = 519 patients, EPI AUC 0.71). Validated cut-point 15.6 would avoid 26% of unnecessary prostate biopsies and 20% of total biopsies, with negative predictive value (NPV) 89% and missing 7% of ≥GG2 PCa. Alternative cut-point 20 would avoid 40% of unnecessary biopsies and 31% of total biopsies, with NPV 89% and missing 11% of ≥GG2 PCa. The clinical investigators reached consensus recommending use of the 15.6 cut-point for phase II. Outcome of the decision impact cohort in phase II will be reported separately. Conclusions: EPI is a noninvasive, easy-to-use, gene expression urine assay, which has now been successfully validated in over 1000 patients across two prospective validation trials to stratify risk of ≥GG2 from GG1 cancer and benign disease. The test improves identification of patients with higher grade disease and would reduce the total number of unnecessary biopsies. Patient summary: It is challenging to predict which men are likely to have high-grade prostate cancer (PCa) at initial biopsy with prostate-specific antigen 2–10 ng/ml. This study further demonstrates that the ExoDx Prostate (IntelliScore) test can predict ≥GG2 PCa at initial biopsy and defer unnecessary biopsies better than existing risk calculator's and standard clinical data. ExoDx Prostate (IntelliScore) is a urine-based test that relies solely on a three-gene signature to predict high-grade prostate cancer at initial biopsy for men with prostate-specific antigen 2–10 ng/ml. The test has been prospectively validated on over 1000 men from two multisite trials.
AD  - M.J. Donovan, Icahn School of Medicine at Mt. Sinai, Pathology, 1468 Madison Avenue, New York City, NY, United States
AU  - McKiernan, J.
AU  - Donovan, M. J.
AU  - Margolis, E.
AU  - Partin, A.
AU  - Carter, B.
AU  - Brown, G.
AU  - Torkler, P.
AU  - Noerholm, M.
AU  - Skog, J.
AU  - Shore, N.
AU  - Andriole, G.
AU  - Thompson, I.
AU  - Carroll, P.
DB  - Embase
Medline
DO  - 10.1016/j.eururo.2018.08.019
IS  - 6
KW  - NCT03031418
adult
African American
aged
area under the curve
article
Asian
cancer diagnosis
Caucasian
clinical outcome
cohort analysis
consensus
controlled clinical trial
controlled study
diagnostic value
exosome
false negative result
gene expression assay
health care quality
Hispanic
human
human tissue
major clinical study
male
needle biopsy
phase 1 clinical trial
phase 2 clinical trial
predictive value
priority journal
prospective study
prostate biopsy
prostate cancer
shared decision making
transrectal ultrasonography
tumor biopsy
urine
urine volume
validation study
LA  - English
M3  - Article
N1  - L2001106346
2018-09-21
2018-11-15
PY  - 2018
SN  - 1873-7560
0302-2838
SP  - 731-738
ST  - A Prospective Adaptive Utility Trial to Validate Performance of a Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer in Patients with Prostate-specific Antigen 2–10 ng/ml at Initial Biopsy
T2  - European Urology
TI  - A Prospective Adaptive Utility Trial to Validate Performance of a Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer in Patients with Prostate-specific Antigen 2–10 ng/ml at Initial Biopsy
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L2001106346&from=export
http://dx.doi.org/10.1016/j.eururo.2018.08.019
VL  - 74
ID  - 872
ER  - 

TY  - JOUR
AB  - PURPOSE: Breast cancer risk prediction models have underestimated risk for African American women, contributing to lower recruitment rates in prevention trials. A model previously developed for African American women was found to underestimate risk in the Black Women's Health Study (BWHS). METHODS: We developed a breast cancer risk model for African American women using relative risks derived from 10 years of follow-up of BWHS participants age 30 to 69 years at baseline. Using the subsequent 5 years of follow-up data, we evaluated calibration as the ratio of expected to observed number of breast cancers and assessed discriminatory accuracy using the concordance statistic. RESULTS: The BWHS model included family history, previous biopsy, body mass index at age 18 years, age at menarche, age at first birth, oral contraceptive use, bilateral oophorectomy, estrogen plus progestin use, and height. There was good agreement between predicted and observed number of breast cancers overall (expected-to-observed ratio, 0.96; 95% CI, 0.88 to 1.05) and in most risk factor categories. Discriminatory accuracy was higher for women younger than age 50 years (area under the curve [AUC], 0.62; 95% CI, 0.58 to 0.65) than for women age ≥ 50 years (AUC, 0.56; 95% CI, 0.53 to 0.59). Using a 5-year predicted risk of 1.66% or greater as a cut point, 2.8% of women younger than 50 years old and 32.2% of women ≥ 50 years old were classified as being at elevated risk of invasive breast cancer. CONCLUSION: The BWHS model was well calibrated overall, and the predictive ability was best for younger women. The proportion of women predicted to meet the 1.66% cut point commonly used to determine eligibility for breast cancer prevention trials was greatly increased relative to previous models.
AD  - Deborah A. Boggs, Lynn Rosenberg, and Julie R. Palmer, Slone Epidemiology Center at Boston University, Boston, MA; and Lucile L. Adams-Campbell, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC.
Deborah A. Boggs, Lynn Rosenberg, and Julie R. Palmer, Slone Epidemiology Center at Boston University, Boston, MA; and Lucile L. Adams-Campbell, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC. jpalmer@bu.edu.
AN  - 25624428
AU  - Boggs, D. A.
AU  - Rosenberg, L.
AU  - Adams-Campbell, L. L.
AU  - Palmer, J. R.
C2  - PMC4356712 online at www.jco.org. Author contributions are found at the end of this article.
DA  - Mar 20
DO  - 10.1200/jco.2014.57.2750
DP  - NLM
ET  - 2015/01/28
IS  - 9
KW  - Adult
African Americans
African Continental Ancestry Group
Aged
Area Under Curve
Breast Neoplasms/diagnosis/*epidemiology/*ethnology
Calibration
Data Interpretation, Statistical
Female
Humans
Incidence
Middle Aged
Models, Theoretical
Prospective Studies
Reproducibility of Results
Risk Assessment
Women's Health
LA  - eng
N1  - 1527-7755
Boggs, Deborah A
Rosenberg, Lynn
Adams-Campbell, Lucile L
Palmer, Julie R
R01 CA058420/CA/NCI NIH HHS/United States
U01 CA182898/CA/NCI NIH HHS/United States
UM1 CA164974/CA/NCI NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
J Clin Oncol. 2015 Mar 20;33(9):1038-44. doi: 10.1200/JCO.2014.57.2750. Epub 2015 Jan 26.
PY  - 2015
SN  - 0732-183X (Print)
0732-183x
SP  - 1038-44
ST  - Prospective approach to breast cancer risk prediction in African American women: the black women's health study model
T2  - J Clin Oncol
TI  - Prospective approach to breast cancer risk prediction in African American women: the black women's health study model
VL  - 33
ID  - 260
ER  - 

TY  - JOUR
AB  - BACKGROUND: The purpose of this study was to evaluate baseline demographic characteristics which may be associated with worse health related quality of life (HRQOL) for patients with locally advanced non-small cell lung cancer (NSCLC) receiving definitive chemoradiation (CRT). MATERIALS: Patients with NSCLC were prospectively enrolled on an Institutional Review Board-approved clinical trial between 2009 and 2012. HRQOL assessments were collected pre-radiation therapy (RT), during RT, and within 3 months post-RT using Euroqol (EQ-5D), MD Anderson Symptom Inventory (MDASI), and Functional Assessment of Cancer Therapy General (FACT-G). HRQOL correlation was assessed with categorical variables by Wilcoxon rank sum tests and with continuous variables by Pearson correlation. P<0.05 was defined as statistically significant. RESULTS: Forty-three consecutive patients received definitive concurrent CRT and completed assessments at one or more time-points. Patients most commonly had stage IIIB disease (72%), were married or with a partner (70%) and Caucasian (91%). Median patient age was 65 (range: 39-79) years and Charlson comorbidity index (CCI) was 0 (range: 0-5). Female gender, African-American ethnicity, age, chemotherapy type, baseline hemoglobin, and CCI were associated with worse post-treatment HRQOL measures. CONCLUSIONS: We have identified novel characteristics associated with worse quality of life following definitive CRT for lung cancer. Patients at risk for worse post-treatment quality of life may benefit from earlier follow-up and greater supportive measures following treatment.
AD  - Department of Radiation Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
AN  - 31555509
AU  - Vogel, J.
AU  - Wang, X.
AU  - Troxel, A. B.
AU  - Simone, C. B., 2nd
AU  - Rengan, R.
AU  - Lin, L. L.
C2  - PMC6749111
DA  - Aug
DO  - 10.21037/tlcr.2019.08.21
DP  - NLM
ET  - 2019/09/27
IS  - 4
KW  - Chemoradiation (CRT)
non-small cell lung cancer (NSCLC)
quality of life
LA  - eng
N1  - 2226-4477
Vogel, Jennifer
Wang, Xingmei
Troxel, Andrea B
Simone, Charles B 2nd
Rengan, Ramesh
Lin, Lilie L
Journal Article
Transl Lung Cancer Res. 2019 Aug;8(4):332-339. doi: 10.21037/tlcr.2019.08.21.
PY  - 2019
SN  - 2218-6751 (Print)
2218-6751
SP  - 332-339
ST  - Prospective assessment of demographic characteristics associated with worse health related quality of life measures following definitive chemoradiation in patients with locally advanced non-small cell lung cancer
T2  - Transl Lung Cancer Res
TI  - Prospective assessment of demographic characteristics associated with worse health related quality of life measures following definitive chemoradiation in patients with locally advanced non-small cell lung cancer
VL  - 8
ID  - 61
ER  - 

TY  - JOUR
AB  - AIM: To investigate biological prevention with flavonoids the recurrence risk of neoplasia was studied in patients with resected colorectal cancer and after adenoma polypectomy. METHODS: Eighty-seven patients, 36 patients with resected colon cancer and 51 patients after polypectomy, were divided into 2 groups: one group was treated with a flavonoid mixture (daily standard dose 20 mg apigenin and 20 mg epigallocathechin-gallat, n = 31) and compared with a matched control group (n = 56). Both groups were observed for 3-4 years by surveillance colonoscopy and by questionnaire. RESULTS: Of 87 patients enrolled in this study, 36 had resected colon cancer and 29 of these patients had surveillance colonoscopy. Among the flavonoid-treated patients with resected colon cancer (n = 14), there was no cancer recurrence and one adenoma developed. In contrast the cancer recurrence rate of the 15 matched untreated controls was 20% (3 of 15) and adenomas evolved in 4 of those patients (27%). The combined recurrence rate for neoplasia was 7% (1 of 14) in the treated patients and 47% (7 of 15) in the controls (P = 0.027). CONCLUSION: Sustained long-term treatment with a flavonoid mixture could reduce the recurrence rate of colon neoplasia in patients with resected colon cancer. (C) 2008 WJG. All rights reserved.
AN  - WOS:000255720400008
AU  - Hoensch, H.
AU  - Groh, B.
AU  - Edler, L.
AU  - Kirch, W.
DA  - Apr
DO  - 10.3748/wjg.14.2187
IS  - 14
N1  - 18407592
PY  - 2008
SN  - 1007-9327
SP  - 2187-2193
ST  - Prospective cohort comparison of flavonoid treatment in patients with resected colorectal cancer to prevent recurrence
T2  - World Journal of Gastroenterology
TI  - Prospective cohort comparison of flavonoid treatment in patients with resected colorectal cancer to prevent recurrence
VL  - 14
ID  - 3171
ER  - 

TY  - JOUR
AB  - Background: Patients diagnosed with prostate cancer (PCa) are presented with several treatment options of similar efficacy but varying side effects. Understanding how and why patients make their treatment decisions, as well as the effect of treatment choice on long-term outcomes, is critical to ensuring effective, patient-centered care. This study examined treatment decision-making in a racially diverse, equal-access, contemporary cohort of patients with PCa counseled on treatment options at a multidisciplinary clinic. Methods: A prospective cohort study was initiated at the Walter Reed National Military Medical Center (formerly Walter Reed Army Medical Center) in 2006. Newly diagnosed patients with PCa were enrolled before attending a multidisciplinary clinic. Patients completed surveys preclinic and postclinic to assess treatment preferences, reasons for treatment choice, and decisional regret. Results: As of January 2014, 925 patients with PCa enrolled in this study. Surgery (54%), external radiation (20%), and active surveillance (12%) were the most common primary treatments for patients with low- and intermediate-risk PCa, whereas patients with high-risk PCa chose surgery (34%) or external radiation with neoadjuvant hormones (57%). Treatment choice differed by age at diagnosis, race, comorbidity status, and calendar year in both univariable and multivariable analyses. Patients preferred to play an active role in the decision-making process and cited doctors at the clinic as the most helpful source of treatment-related information. Almost all patients reported satisfaction with their decision. Conclusions: This is one of the first prospective cohort studies to examine treatment decision-making in an equal-access, multidisciplinary clinic setting. Studies of this cohort would aid in understanding and improving the PCa decision-making process.
AD  - I.L. Rosner, Department of Defense, Center for Prostate Disease Research, Rockville, MD, United States
AU  - Hurwitz, L. M.
AU  - Cullen, J.
AU  - Elsamanoudi, S.
AU  - Kim, D. J.
AU  - Hudak, J.
AU  - Colston, M.
AU  - Travis, J.
AU  - Kuo, H. C.
AU  - Porter, C. R.
AU  - Rosner, I. L.
DB  - Embase
Medline
DO  - 10.1016/j.urolonc.2015.11.014
IS  - 5
KW  - adult
African American
age distribution
article
cancer adjuvant therapy
cancer center
cancer epidemiology
cancer surgery
cancer therapy
cohort analysis
comorbidity
educational status
hormonal therapy
human
intermediate risk patient
low risk patient
major clinical study
male
middle aged
patient care
patient decision making
patient participation
patient preference
priority journal
prospective study
prostate cancer
quality of life
race difference
LA  - English
M3  - Article
N1  - L607328554
2015-12-25
2016-05-03
PY  - 2016
SN  - 1873-2496
1078-1439
SP  - 233.e17-233.e25
ST  - A prospective cohort study of treatment decision-making for prostate cancer following participation in a multidisciplinary clinic
T2  - Urologic Oncology: Seminars and Original Investigations
TI  - A prospective cohort study of treatment decision-making for prostate cancer following participation in a multidisciplinary clinic
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L607328554&from=export
http://dx.doi.org/10.1016/j.urolonc.2015.11.014
VL  - 34
ID  - 974
ER  - 

TY  - JOUR
AB  - Background: Prostate cancer is the most common cancer in British men but its aetiology is not well understood. We aimed to identify risk factors for prostate cancer in British males. Methods: We studied 219 335 men from the UK Biobank study who were free from cancer at baseline. Exposure data were collected at recruitment. Prostate cancer risk by the different exposures was estimated using multivariable-adjusted Cox proportional hazards models. Results: In all, 4575 incident cases of prostate cancer occurred during 5.6 years of follow-up. Prostate cancer risk was positively associated with the following: black ethnicity (hazard ratio black vs white = 2.61, 95% confidence interval = 2.10-3.24); having ever had a prostate-specific antigen test (1.31, 1.23-1.40); being diagnosed with an enlarged prostate (1.54, 1.38-1.71); and having a family history of prostate cancer (1.94, 1.77-2.13). Conversely, Asian ethnicity (Asian vs white hazard ratio = 0.62, 0.47-0.83), excess adiposity (body mass index (>= 35 vs <25 kgm(-2) = 0.75, 0.64-0.88) and body fat (>= 30.1 vs <20.5% = 0.81, 0.73-0.89)), cigarette smoking (current vs never smokers = 0.85, 0.77-0.95), having diabetes (0.70, 0.62-0.80), and never having had children (0.89, 0.81-0.97) or sexual intercourse (0.53, 0.33-0.84) were related to a lower risk. Conclusions: In this new large British prospective study, we identified associations with already-established, putative and possible novel risk factors for being diagnosed with prostate cancer. Future research will examine associations by tumour characteristics.
AN  - WOS:000414550300020
AU  - Perez-Cornago, A.
AU  - Key, T. J.
AU  - Allen, N. E.
AU  - Fensom, G. K.
AU  - Bradbury, K. E.
AU  - Martin, R. M.
AU  - Travis, R. C.
DA  - Nov
DO  - 10.1038/bjc.2017.312
IS  - 10
N1  - 28910820
PY  - 2017
SN  - 0007-0920
SP  - 1562-1571
ST  - Prospective investigation of risk factors for prostate cancer in the UK Biobank cohort study
T2  - British Journal of Cancer
TI  - Prospective investigation of risk factors for prostate cancer in the UK Biobank cohort study
VL  - 117
ID  - 2883
ER  - 

TY  - JOUR
AB  - Background: There are no prospective studies that define best therapy for DHL (presence of c‐MYC and BCL‐2 translocations) or DEL (co‐expression of c‐MYC 40% and BCL‐2 50% by IHC). Retrospective data for both entities show suboptimal outcomes with R‐CHOP and perhaps improved outcomes with intensified regimens such as DA‐EPOCH‐R. We conducted a phase I prospective multicenter study adding escalating doses of LEN to DA‐EPOCH‐R in pts with DHL or DEL. Herein, we report the final results of the dose‐finding portion of this ongoing clinical trial. Patients and Methods: Eligible pts had DHL or DEL as defined above. They were allowed to receive radiotherapy for neurologic compromise or one cycle of R‐CHOP prior to enrollment at the investigator's discretion. Pts had measurable disease, ECOG PS 0‐2, and adequate liver, kidney, and marrow function and no known HIV or CNS involvement. Either aspirin or warfarin prophylaxis was required. Primary objective was to determine the maximum‐tolerated dose (MTD) of LEN when added to DA‐EPOCH‐R. We utilized a standard (3+3 design) where LEN was started at 10mg (days 1‐14, Q21‐days) with each cycle of DA‐EPOCH‐R, and escalated to a maximum of 25 mg unless a MTD was reached at an earlier dose. Dose‐limiting toxicities (DLTs) were assessed during cycle 1; DA‐EPOCH‐R administration and dose modifications were conducted as per usual protocol. Cycles were repeated every 3‐weeks for a maximum of 6 cycles and were followed by an end of therapy PET scan. CNS prophylaxis was strongly encouraged with 12.5 mg IT‐methotrexate for 4 doses during induction. Patients attaining PET negativity after induction were continued on maintenance LEN 10 mg (days 1‐14 Q21 days) for 12 cycles. During the LEN dose escalation portion of the study, a hematologic toxicity did not count as a DLT to allow DA‐EPOCH‐R dose adjustments. Results: 15 pts (6: DHL and 9: DEL; 13 DLBCL and 2 BCL‐U) were enrolled; median age was 62 years (range: 26‐83). There were 5 males and 10 females (11 whites, 3 African Americans, and 1 Asian pts). Two pts had ECOG PS 2 while all others were 0‐1. All pts (100%) had stage III/IV disease, 13 pts (86%) had high‐risk IPI score, and median LDH was 673 (range: 193‐1, 835). All ptsare assessable for toxicity. Serious adverse events (SAEs) per dose levels are summarized in the Table. DA‐EPOCH‐R dose escalation was feasible in 10 pts (67%), one pt (6.7%) maintained the same dose throughout, and another (6.7%) required dose de‐escalation. Two DLTs were observed (grade 4 sepsis and hypotension for both) at dose‐level 20 mg of LEN leading to 15 mg being the MTD and RP2D. Most common grade 1 and/or 2 non‐hematologic toxicities were fatigue (70%), constipation (47%), alopecia (53%), nausea (47%), peripheral sensory neuropathy (40%), diarrhea (33%), and hypokalemia (33%). The only grade 3 and/or 4 non‐hematologic toxicity occurring in 2 pts (13%) was hypokalemia. All others occurred in 1 pt (6%) and were: constipation, fever, hyperglycemia, hypertension, mucositis, and hypoalbumenemia. One pt (6%) developed treatment‐related myelodysplasia, (T‐MDS), 18 months after treatment initiation. Twelve patients are evaluable for response at time of analysis, (1 patient lost to follow‐up, and 2 with ongoing therapy). Best responses at completion of induction based on PET were 6 complete responses (CR: 50%), 3 partial responses (PR: 25%) and 1 pt with progressive disease (8%). All CR pts received LEN maintenance but only 1 completed 12 cycles to date (1 came off due to cytopenias found later to have T‐MDS, 1 due to AE, 1 due to finding of unrelated colon cancer, 2 on active maintenance). With median follow up 10.7 months (range: 1.3‐18.6 months), 14 pts remain alive and one pt has died for an OS of 93%. Conclusions: LEN can safely be added to DA‐EPOCH‐R in DHL and DEL patients at a dose of 15 mg (days 1‐14 Q21 days). Chemotherapy dose escalation was not compromised and preliminary safety/efficacy data appear promising. A phase II study in this pt population with LEN+DA‐EPOCH‐R is underway.
AN  - CN-01334682
AU  - Nabhan, C.
AU  - Karrison, T.
AU  - Kline, J.
AU  - Cohen, K.
AU  - Bishop, M. R.
AU  - Karmali, R.
AU  - Rapoport, A. P.
AU  - Venugopal, P.
AU  - Wade, J.
AU  - Fishkin, P.
AU  - et al.
IS  - 22) (no pagination
KW  - *diffuse large B‐cell lymphoma
*lenalidomide
*recombinant erythropoietin
*rituximab
Acetylsalicylic acid
Adult
Adverse drug reaction
African American
Aged
Alopecia
Blood toxicity
Caucasian
Central nervous system
Chemotherapy
Clinical article
Clinical trial
Colon cancer
Constipation
Controlled clinical trial
Controlled study
Cytopenia
Diarrhea
Dose calculation
Drug therapy
Fatigue
Female
Fever
Follow up
Human
Human immunodeficiency virus
Hyperglycemia
Hypertension
Hypokalemia
Hypotension
Kidney function
Kidney medulla
Liver function
Male
Maximum tolerated dose
Methotrexate
Mucosa inflammation
Myelodysplastic syndrome
Nausea
Nonhuman
Phase 1 clinical trial
Phase 2 clinical trial
Positron emission tomography
Prophylaxis
Radiotherapy
Remission
Safety
Sensory neuropathy
Sepsis
Side effect
Warfarin
M3  - Journal: Conference Abstract
PY  - 2016
ST  - Prospective phase i multi-center trial incorporating lenalidomide (LEN) into dose-adjusted EPOCH plus rituximab (DA-EPOCH-R) in patients with double hit (DHL) or double expressing (DEL) lymphomas: final results
T2  - Blood. Conference: 58th annual meeting of the american society of hematology, ASH 2016. United states. Conference start: 20161203. Conference end: 20161206
TI  - Prospective phase i multi-center trial incorporating lenalidomide (LEN) into dose-adjusted EPOCH plus rituximab (DA-EPOCH-R) in patients with double hit (DHL) or double expressing (DEL) lymphomas: final results
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01334682/full
VL  - 128
ID  - 1488
ER  - 

TY  - JOUR
AB  - Objective: Symptom burden remains a distressing problem for survivors with non-small-cell lung cancer (stages I-IIIa). This pilot study evaluated feasibility and preliminary effects of a tailored mindfulness-based intervention, Breathe Easier, which encompasses meditation, 2 levels of mindful hatha yoga, breathing exercises, and participant interaction. Methods: Participants were recruited from 2 cancer programs in the US Southeast. A family member was required for participation. Sixty-two participants enrolled (20% recruitment) and 49 completed the intervention (79% retention). Participants chose level 1 yoga (basic) or level 2 (more advanced). Of the completers, survivors were 39% male and 65% Black. A community-based participatory research framework helped identify the specific needs and interests of potential participants and foreseeable barriers to implementation. A 2-month prospective, 1-group, pre-post design evaluated feasibility. Intervention dosage was measured using written protocols. Attendance and completion of daily home assignments measured adherence. Acceptability was assessed using a 10-item questionnaire, completed at three time points. Preliminary outcome data collected pre- and post-intervention tested the hypothesis that participants who received the 8-week intervention Breathe Easier would, post-intervention, demonstrate (a) less dyspnea, (b) less fatigue, (c) less stress, (d) improved sleep, (e) improved anxiety and depression, and (f) improved functional exercise capacity. Exit interviews were conducted, transcribed verbatim, and analyzed for content using descriptive statistics. Results: Quantitative and qualitative measures indicated strong feasibility. Over time, level 1 participants had statistically less dyspnea, fatigue and improved exercise capacity, as well as improved sleep, and stress scores. Level 2 participants experienced slightly increased dyspnea and fatigue but improved sleep, stress, and exercise capacity. All participants experienced anxiety and depression within normal limits pre- and post-intervention. Five major themes emerged out of exit interviews: Learning to Breathe Easier; Interacting with Others as a Personal Benefit; Stretching, Releasing Tension, and Feeling Energized; Enhancing Closeness with Committed Partners; Refocusing on Living; and Sustaining New Skills as a Decision. Conclusions: The study offers insight into the feasibility of an 8-week in-person mindfulness-based intervention with a unique subset of understudied survivors of lung cancer and family members. Outcome data interpretation is limited by the 1-group design and sample size.
AD  - K.K. McDonnell, University of South Carolina, Columbia, SC, United States
AU  - McDonnell, K. K.
AU  - Gallerani, D. G.
AU  - Newsome, B. R.
AU  - Owens, O. L.
AU  - Beer, J.
AU  - Myren-Bennett, A. R.
AU  - Regan, E.
AU  - Hardin, J. W.
AU  - Webb, L. A.
DB  - Embase
Medline
DO  - 10.1177/1534735420969829
KW  - adult
aged
anxiety
article
Black person
breathing exercise
cancer family
cancer survivor
clinical outcome
depression
dyspnea
evidence based practice
exercise
family therapy
fatigue
female
Functional Assessment of Chronic Illness Therapy
Functional Assessment of Chronic Illness Therapy Dyspnea Scale
Functional Assessment of Chronic Illness Therapy Fatigue Scale
hatha yoga
health care need
home mental health care
Hospital Anxiety and Depression Scale
human
intervention study
interview
intimacy
major clinical study
male
meditation
middle aged
mindfulness
non small cell lung cancer
outcome assessment
participatory research
patient attendance
patient compliance
patient participation
Perceived Stress Scale
pilot study
Pittsburgh Sleep Quality Index
preliminary data
pretest posttest design
priority journal
program evaluation
program feasibility
prospective study
qualitative research
quantitative study
six minute walk test
skill
sleep disorder
sleep quality
social interaction
physiological stress
stress management
stretching
thematic analysis
LA  - English
M3  - Article
N1  - L2007114066
2020-11-04
2020-12-10
PY  - 2020
SN  - 1552-695X
1534-7354
ST  - A Prospective Pilot Study Evaluating Feasibility and Preliminary Effects of Breathe Easier: A Mindfulness-based Intervention for Survivors of Lung Cancer and Their Family Members (Dyads)
T2  - Integrative Cancer Therapies
TI  - A Prospective Pilot Study Evaluating Feasibility and Preliminary Effects of Breathe Easier: A Mindfulness-based Intervention for Survivors of Lung Cancer and Their Family Members (Dyads)
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L2007114066&from=export
http://dx.doi.org/10.1177/1534735420969829
VL  - 19
ID  - 823
ER  - 

TY  - JOUR
AB  - Purpose/Objective(s): Patient recruitment is a challenge for randomized controlled trials (RCTs). There is considerable debate whether a RCT comparing intensity‐modulated radiotherapy (IMRT) and proton beam therapy (PBT) for prostate cancer (PCa) can be practically conducted. We therefore investigated patients' willingness to participate (WTP) in such a RCT. Materials/Methods: We undertook a qualitative research study in which we prospectively enrolled patients with clinically localized PCa seen at the University of Pennsylvania and Massachusetts General Hospital between October 2010 and March 2011. Only those patients who met the following Gleason score (GS) and PSA criteria were eligible: GS 6 or 3+4 = 7 if PSA <10 or GS ≤ 6 if PSA 10 ‐<20. We used purposive sampling to ensure a diverse sample based on age, race, travel distance, and physician. Immediately after consultation with a genitourinary radiation oncologist, patients participated in a semi‐structured interview in which they reviewed a description of a hypothetical RCT comparing IMRT and PBT, were asked both open‐ended and focused follow‐up questions regarding their motivations for and concerns about enrollment, and completed a written questionnaire assessing characteristics such as demographics and prior knowledge of IMRT or PBT. Patients' stated WTP in the hypothetical RCT was assessed using a 6‐point Likert scale (1 = definitely not, 6 = definitely). A sample size was not determined a priori as enrollment was continued until theoretical saturation was achieved, i.e. when additional interviews yielded no new information. Interview transcripts were analyzed using qualitative research techniques including thematic data analysis and constant comparison techniques. Results: Forty (30 white, 10 black) patients were enrolled from the practices of 8 physicians. We identified 28 factors that impacted patients' WTP, which largely centered on five major themes: 1) altruism, 2) randomization, 3) prior knowledge of therapies 4) physician recommendation, and 5) financial incentives. Most (24/40, 60%) patients, including 7/10 black patients, stated they would either “definitely” or “probably” participate. Eighteen percent (7/40) stated they would “definitely not” or “probably not” enroll, most of whom (5/7) preferred PBT prior to their physician visit.
AN  - CN-01005985
AU  - Shah, A.
AU  - Efstathiou, J. A.
AU  - Paly, J. J.
AU  - Halpern, S. D.
AU  - Christodouleas, J. P.
AU  - Deville, C.
AU  - Vapiwala, N.
AU  - Zietman, A. L.
AU  - Hahn, S. M.
AU  - Bekelman, J. E.
IS  - 2
KW  - *human
*intensity modulated radiation therapy
*oncology
*patient
*prostate cancer
*proton therapy
*randomized controlled trial
*society
Altruism
Consultation
Data analysis
Follow up
General hospital
Gleason score
Interview
Motivation
Physician
Qualitative research
Questionnaire
Radiation
Randomization
Randomized controlled trial (topic)
Sample size
Sampling
Semi structured interview
Therapy
Travel
United States
University
M3  - Journal: Conference Abstract
PY  - 2011
SP  - S442‐S443
ST  - Prospective preference assessment of patients' willingness to participate in a randomized controlled trial of intensity modulated radiotherapy versus proton therapy for localized prostate cancer
T2  - International journal of radiation oncology biology physics
TI  - Prospective preference assessment of patients' willingness to participate in a randomized controlled trial of intensity modulated radiotherapy versus proton therapy for localized prostate cancer
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01005985/full
VL  - 81
ID  - 1619
ER  - 

TY  - JOUR
AB  - PURPOSE: To investigate patients' willingness to participate (WTP) in a randomized controlled trial (RCT) comparing intensity-modulated radiotherapy (IMRT) with proton beam therapy (PBT) for prostate cancer (PCa). METHODS AND MATERIALS: We undertook a qualitative research study in which we prospectively enrolled patients with clinically localized PCa. We used purposive sampling to ensure a diverse sample based on age, race, travel distance, and physician. Patients participated in a semi-structured interview in which they reviewed a description of a hypothetical RCT, were asked open-ended and focused follow-up questions regarding their motivations for and concerns about enrollment, and completed a questionnaire assessing characteristics such as demographics and prior knowledge of IMRT or PBT. Patients' stated WTP was assessed using a 6-point Likert scale. RESULTS: Forty-six eligible patients (33 white, 13 black) were enrolled from the practices of eight physicians. We identified 21 factors that impacted patients' WTP, which largely centered on five major themes: altruism/desire to compare treatments, randomization, deference to physician opinion, financial incentives, and time demands/scheduling. Most patients (27 of 46, 59%) stated they would either "definitely" or "probably" participate. Seventeen percent (8 of 46) stated they would "definitely not" or "probably not" enroll, most of whom (6 of 8) preferred PBT before their physician visit. CONCLUSIONS: A substantial proportion of patients indicated high WTP in a RCT comparing IMRT and PBT for PCa.
AD  - Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA, USA.
AN  - 22381899
AU  - Shah, A.
AU  - Efstathiou, J. A.
AU  - Paly, J. J.
AU  - Halpern, S. D.
AU  - Bruner, D. W.
AU  - Christodouleas, J. P.
AU  - Coen, J. J.
AU  - Deville, C., Jr.
AU  - Vapiwala, N.
AU  - Shipley, W. U.
AU  - Zietman, A. L.
AU  - Hahn, S. M.
AU  - Bekelman, J. E.
DA  - May 1
DO  - 10.1016/j.ijrobp.2011.11.072
DP  - NLM
ET  - 2012/03/03
IS  - 1
KW  - African Continental Ancestry Group/psychology
Aged
Altruism
European Continental Ancestry Group/psychology
Humans
Male
Middle Aged
Motivation
Patient Compliance/*psychology
Patient Education as Topic
Patient Participation/*psychology
Patient Preference/psychology
Prospective Studies
Prostatic Neoplasms/*psychology/*radiotherapy
*Proton Therapy
Qualitative Research
Radiotherapy, Intensity-Modulated/*psychology
Randomized Controlled Trials as Topic/*psychology
Reimbursement, Incentive
Time Factors
LA  - eng
N1  - 1879-355x
Shah, Anand
Efstathiou, Jason A
Paly, Jonathan J
Halpern, Scott D
Bruner, Deborah W
Christodouleas, John P
Coen, John J
Deville, Curtiland Jr
Vapiwala, Neha
Shipley, William U
Zietman, Anthony L
Hahn, Stephen M
Bekelman, Justin E
Journal Article
Research Support, Non-U.S. Gov't
United States
Int J Radiat Oncol Biol Phys. 2012 May 1;83(1):e13-9. doi: 10.1016/j.ijrobp.2011.11.072. Epub 2012 Feb 28.
PY  - 2012
SN  - 0360-3016
SP  - e13-9
ST  - Prospective preference assessment of patients' willingness to participate in a randomized controlled trial of intensity-modulated radiotherapy versus proton therapy for localized prostate cancer
T2  - Int J Radiat Oncol Biol Phys
TI  - Prospective preference assessment of patients' willingness to participate in a randomized controlled trial of intensity-modulated radiotherapy versus proton therapy for localized prostate cancer
VL  - 83
ID  - 373
ER  - 

TY  - JOUR
AB  - The relation of body mass index (BMI) and weight gain to breast cancer risk is complex, and little information is available on Black women, among whom the prevalence of obesity is high. We assessed BMI and weight gain in relation to breast cancer risk in prospective data from the Black Women's Health Study. In 1995, 59,000 African American women enrolled in the Black Women's Health Study by completing mailed questionnaires. Data on anthropometric factors were obtained at baseline and every 2 years afterwards. In 10 years of follow-up, 1,062 incident cases of breast cancer occurred. Incidence rate ratios (IRR) were computed in multivariable Cox proportional hazards regression. BMI at age 18 years of ≥25 relative to <20 was associated with a reduced risk of breast cancer among both premenopausal women (IRR, 0.68; 95% confidence interval, 0.46-0.98) and postmenopausal women (IRR, 0.53; 95% confidence interval, 0.35-0.81). There was an inverse association of current BMI with premenopausal breast cancer but no association with postmenopausal breast cancer, either overall or among never-users of hormone therapy. Weight gain was not associated with postmenopausal breast cancer risk. In analyses restricted to breast cancers that were estrogen and progesterone receptor positive, IRRs for current BMI and weight gain were elevated but not statistically significant. The findings indicate that being overweight at age 18 years is associated with a reduced risk of both premenopausal and postmenopausal breast cancer in African American women. Understanding the reasons for the association may help elucidate the pathways through which adolescent exposures influence breast cancer risk. The lack of association of obesity with receptor-negative tumors in postmenopausal African American women may partially explain why breast cancer incidence in older Black women is not high relative to other ethnic groups in spite of the high prevalence of obesity in Black women. Copyright © 2007 American Association for Cancer Research.
AD  - J.R. Palmer, Slone Epidemiology Center, Boston University, 1010 Commonwealth Avenue, Boston, MA 02215, United States
AU  - Palmer, J. R.
AU  - Adams-Campbell, L. L.
AU  - Boggs, D. A.
AU  - Wise, L. A.
AU  - Rosenberg, L.
DB  - Embase
Medline
DO  - 10.1158/1055-9965.EPI-07-0336
IS  - 9
KW  - adult
aged
anthropometry
article
body mass
body size
breast cancer
cancer incidence
cancer risk
confidence interval
controlled study
disease association
female
follow up
human
major clinical study
obesity
postmenopause
premenopause
priority journal
waist hip ratio
body weight gain
L1  - internal-pdf://2381148771/1795.full.pdf
LA  - English
M3  - Article
N1  - L47450509
2007-09-01
PY  - 2007
SN  - 1055-9965
SP  - 1795-1802
ST  - A prospective study of body size and breast cancer in black women
T2  - Cancer Epidemiology Biomarkers and Prevention
TI  - A prospective study of body size and breast cancer in black women
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L47450509&from=export
http://dx.doi.org/10.1158/1055-9965.EPI-07-0336
VL  - 16
ID  - 1222
ER  - 

TY  - JOUR
AB  - Introduction: Patients with low‐risk prostate cancer (PCa) often have excellent oncologic outcomes. However, treatment with curative intent can lead to decrements in health‐related quality of life (HRQoL). Patients treated with radical prostatectomy have been shown to suffer declines in urinary and sexual HRQoL as compared to those managed with active surveillance (AS). Similarly, patients treated with external‐beam radiation therapy (EBRT) are hypothesized to experience greater declines in bowel HRQoL. As health‐related quality‐of‐life (HRQoL) concerns are paramount when selecting among treatment options for low‐risk PCa, this study examined HRQoL outcomes in men undergoing EBRT as compared to AS in a prospective, racially diverse cohort. Methods: A prospective study of HRQoL in patients with PCa enrolled in the Center for Prostate Disease Research (CPDR) Multicenter National Database was initiated in 2007. The current study included patients diagnosed through April 2014. HRQoL was assessed with the Expanded Prostate Cancer Index Composite (EPIC) and the Medical Outcomes Study Short Form (SF‐36). Temporal changes in HRQoL were compared for patients with low‐risk PCa managed on AS vs. EBRT at baseline, 1‐, 2‐, and 3 years post‐PCa diagnosis. Longitudinal patterns were modeled using linear regression models fitted with generalized estimating equations (GEE), adjusting for baseline HRQoL, demographic, and clinical patient characteristics. Results: Of the 499 eligible patients with low‐risk PCa, 103 (21%) selected AS and 60 (12%) were treated with EBRT. Demographic characteristics of the treatment groups were similar, though a greater proportion of patients in the EBRT group were African American (P = 0.0003). At baseline, both treatment groups reported comparable HRQoL. EBRT patients experienced significantly worse bowel function and bother at 1 year (adjusted mean score: 87 vs. 95, P = 0.001 and 89 vs. 95, P = 0.008, respectively) and 2 years (87 vs. 93, P = 0.007 and 87 vs. 96, P = 0.002, respectively) compared to patients managed on AS. In contrast to those on AS, more than half the number of patients who received EBRT experienced a decline in bowel function (52% vs. 17%, p=0.003) and bother (52% vs. 15%, P = 0.002) from baseline to 1 year. Patients who received EBRT were significantly more likely to experience a decrease in more than one functional domain (urinary, sexual, bowel, or hormonal) at 1 year when compared with those on AS (60% vs. 28%, P = 0.004). Conclusions: Patients receiving EBRT for low‐risk prostate cancer suffer declines in bowel HRQoL. These declines are not experienced by patients on AS, suggesting that management of low‐risk prostate cancer with AS may offer a means for preserving HRQoL following prostate cancer diagnosis. Copyright © 2017 Elsevier Inc.
AN  - CN-01299622
AU  - Banerji, J. S.
AU  - Hurwitz, L. M.
AU  - Cullen, J.
AU  - Wolff, E. M.
AU  - Levie, K. E.
AU  - Rosner, I. L.
AU  - Brand, T. C.
AU  - L'Esperance, J. O.
AU  - Sterbis, J. R.
AU  - Porter, C. R.
DO  - 10.1016/j.urolonc.2016.12.015
KW  - *Short Form 36
*prospective study
*prostate cancer
African American
Cancer diagnosis
Clinical trial
Controlled clinical trial
Controlled study
Data base
Diagnosis
External beam radiotherapy
Human
Intestine function
Linear regression analysis
Major clinical study
Male
Multicenter study
Population model
Radiotherapy
M3  - Journal: Article In Press
PY  - 2017
ST  - A prospective study of health-related quality-of-life outcomes for patients with low-risk prostate cancer managed by active surveillance or radiation therapy
T2  - Urologic oncology: seminars and original investigations. (no pagination), 2017
TI  - A prospective study of health-related quality-of-life outcomes for patients with low-risk prostate cancer managed by active surveillance or radiation therapy
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01299622/full
VL  - Date of Publication: July 18
ID  - 1522
ER  - 

TY  - JOUR
AB  - Purpose/Objective(s): TGF‐β plays a central role in mediating postradiation fibrosis. Prior literature posits that single nucleotide polymorphisms in the TGF‐β gene may account for differences in fibrosis risk, but prospective validation is lacking. The C509T polymorphism in the promotor region of the TGF‐β gene is associated with increased expression and elevated circulating levels of TGF‐β. We sought to prospectively validate the C509T variant allele as a predictor of breast fibrosis. Materials/Methods: Patients were recruited from a prospective randomized trial comparing two whole breast irradiation dosing schedules. The trial was prospectively designed to yield 83% power to test the hypothesis that C509T is associated with a fourfold increase in grade 2+ breast fibrosis assessed at 3 years post‐radiation using the SOMA scale, assuming 150 participants and aZ0.05. Exploratory, pre‐specified analyses tested the association of C509T with patient‐reported cosmetic and functional outcomes assessed using the Breast Cancer Treatment Outcomes Scale (BCTOS), cosmetic outcome graded on the RTOG scale by a threephysician panel blinded to randomization arm, and NCI CTCAEv4. Hypotheses were tested using Fisher's exact, Chi‐square, or Student's t‐test as appropriate. Multivariable logistic regression identified predictors of grade 2+ breast fibrosis. Results: TGF‐β genotype and 3‐year follow‐up were available for 174 of 287 patients enrolled in the trial, of whom 89 (51%) had at least one copy of C509T. C509T was present in 75% of Hispanics compared to 48% of whites and 35% of blacks (PZ.01), but it was not associated with other baseline covariables. The primary outcome, grade 2+ breast fibrosis, was present in 14% of patients with C509T compared to 4% of patients without it (PZ.02). In multivariable analysis, only C509T (ORZ5.2, 95% CI 1.3‐20.7, PZ.02) and post‐operative cosmetic outcome (ORZ7.7, 95% CI 2.5‐23.4, P<.001) predicted breast fibrosis risk. The randomization arm did not predict breast fibrosis (PZ.98) and did not interact with TGF‐β genotype (PZ.94). C509T was also associated with adverse patient‐reported functional outcome (PZ.04), with a trend toward increased risk of moderate to large shoulder stiffness (11% vs 4%; PZ.08). C509T was also associated with greater risk of grade 2 NCI CTC breast atrophy (17% vs 7%; PZ.047). C509T was not associated with patient‐reported (PZ.52) or panel‐assessed (PZ.51) cosmetic Conclusion: This study prospectively validates the C509T allele of TGF‐β as a key predictor of breast fibrosis risk and other adverse outcomes. TGFb genotype may be helpful for patient selection, risk stratification, and radiation mitigation strategies. outcome.
AN  - CN-01437670
AU  - Grossberg, A.
AU  - Lei, X.
AU  - Xu, T.
AU  - Shaitelman, S. F.
AU  - Hoffman, K. E.
AU  - Bloom, E.
AU  - Stauder, M. C.
AU  - Tereffe, W.
AU  - Schlembach, P. J.
AU  - Woodward, W. A.
AU  - et al.
IS  - 5
KW  - *DNA polymorphism
*breast cancer
*breast fibrosis
*cancer patient
*cancer staging
*gene mutation
*radiation
*validation process
Adult
Adverse outcome
Black person
Breast atrophy
Breast radiotherapy
Cancer surgery
Cancer therapy
Caucasian
Controlled study
Exploratory research
Female
Follow up
Frozen shoulder
Gene frequency
Genetic susceptibility
Genotype
Human
Major clinical study
Male
Patient selection
Prospective study
Randomization
Randomized controlled trial
Stratification
Student
Student t test
M3  - Journal: Conference Abstract
PY  - 2017
SP  - 1318‐
ST  - Prospective validation of transforming growth factor-beta (TGF-β) polymorphism C509T as a predictor of radiation-induced fibrosis in early stage breast cancer patients
T2  - International journal of radiation oncology biology physics
TI  - Prospective validation of transforming growth factor-beta (TGF-β) polymorphism C509T as a predictor of radiation-induced fibrosis in early stage breast cancer patients
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01437670/full
VL  - 99
ID  - 1460
ER  - 

TY  - JOUR
AB  - Prostate cancer is a significant cause of death among men of all races in the United States, and it does disproportionately affect Black men. This disease poses a number of questions that desperately need answers. These questions involve not just the cause and prevention of the prostate cancer, but a very real and valid question is "does screening for and aggressive treatment of prostate cancer save lives." Almost all questions in prostate cancer are not questions unique to blacks or whites, or any specific population. These questions can only be answered through well-designed basic and clinical research studies. This research must be supported by both physician and patient participation. Conveying truthful, accurate information in this disease in which so much is unanswered is imperative. In American medical history, black men have often been misled or misinformed oftentimes by well-meaning paternalistic individuals. Physicians and laymen teaching about this disease must themselves realize and then truthfully convey "what is known, what is not known, and what is believed." This will allow the layman to make educated decisions regarding screening, treatment, and participation in clinical studies.
AD  - Office of Special Populations Research, National Cancer Institute, Bethesda, MD 20892, USA.
AN  - 9858323
AU  - Brawley, O. W.
DA  - Nov
DP  - NLM
ET  - 1998/12/19
IS  - 4
KW  - *African Americans
African Continental Ancestry Group
Clinical Trials as Topic
Ethics, Medical
Humans
Male
*Mass Screening/standards
*Prostatic Neoplasms/ethnology/genetics/prevention & control/therapy
*Research Design
Socioeconomic Factors
United States
LA  - eng
N1  - Brawley, O W
Journal Article
Review
United States
Semin Urol Oncol. 1998 Nov;16(4):184-6.
PY  - 1998
SN  - 1081-0943 (Print)
1081-0943
SP  - 184-6
ST  - Prostate cancer and black men
T2  - Semin Urol Oncol
TI  - Prostate cancer and black men
VL  - 16
ID  - 722
ER  - 

TY  - JOUR
AB  - Prostate cancer is a significant health problem for African-American men intensified by low participation in screenings, clinical trials, and prospective cohort studies. Ten focus groups were conducted with African-American males and their female partners/spouses. Perceptions and knowledge about prostate cancer, as well as willingness to participate in screening and research studies were measured. Participants had a basic level of knowledge about prostate cancer, and the importance of education was a unified theme. Dialogue with targeted African-American men and their partners/spouses may increase awareness and retention in medical research, while influencing health promotion, education and behavior.
AD  - University of Mississippi Medical Center, 2500 North State Street, Jackson, MS 39216, USA. gdhughes@prevmed.umsmed.edu
AN  - 19175246
AU  - Hughes, G. D.
AU  - Sellers, D. B.
AU  - Fraser, L., Jr.
AU  - Teague, R.
AU  - Knight, B.
DA  - Summer
DP  - NLM
ET  - 2007/07/01
IS  - 2
KW  - African Americans/education/*ethnology
Aged
Attitude to Health/*ethnology
Awareness
Community Participation/methods/*psychology
*Community-Institutional Relations
*Cooperative Behavior
Female
Focus Groups
Health Education/organization & administration
Health Knowledge, Attitudes, Practice
Health Services Needs and Demand
Humans
Information Dissemination
Male
Mass Screening
Middle Aged
Mississippi
Nursing Methodology Research
Prostatic Neoplasms/diagnosis/*ethnology/prevention & control
Trust
LA  - eng
N1  - Hughes, Gail D
Sellers, Denethia B
Fraser, Lionel Jr
Teague, Robert
Knight, Bern'Nadette
Journal Article
Research Support, Non-U.S. Gov't
United States
J Cult Divers. 2007 Summer;14(2):68-73.
PY  - 2007
SN  - 1071-5568 (Print)
1071-5568
SP  - 68-73
ST  - Prostate cancer community collaboration and partnership: education, awareness, recruitment, and outreach to southern African-American males
T2  - J Cult Divers
TI  - Prostate cancer community collaboration and partnership: education, awareness, recruitment, and outreach to southern African-American males
VL  - 14
ID  - 521
ER  - 

TY  - JOUR
AB  - PURPOSE: Men with a family history of prostate cancer and black men are at higher risk for prostate cancer. Recruitment and retention of these men at high risk into early detection programs is challenging. We report a comprehensive analysis of recruitment methods, show rates and participant factors from the Prostate Cancer Risk Assessment Program, a prospective, longitudinal prostate cancer screening study. MATERIALS AND METHODS: Men 35 to 69 years old were eligible for recruitment if they had a family history of prostate cancer, were black or had a BRCA1/2 mutation. Recruitment methods were analyzed using standard statistical methods with respect to participant demographics and presentation to the first program appointment. RESULTS: Of 707 men recruited 64.9% presented to the initial program appointment. More men were recruited via radio than via referral or other methods (chi-square = 298.13, p <0.0001). Men recruited by radio were more likely to be black (p <0.001), less educated (p = 0.003) and not married or partnered (p = 0.007), and have no prostate cancer family history (p <0.001). Men recruited by referral had a higher income (p = 0.007) and were more likely to attend the initial program visit than those recruited by radio or other methods (chi-square = 27.08, p <0.0001). CONCLUSIONS: This comprehensive analysis shows that radio led to higher recruitment of black men with lower socioeconomic status. However, these men at high risk have a lower presentation rate for prostate cancer screening. Targeted motivational measures must be studied to improve the show rate for prostate cancer risk assessment in these men at high risk.
AD  - Cancer Screening Cancer Prevention and Control Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA. Veda.Giri@fccc.edu
AN  - 19758657
AU  - Giri, V. N.
AU  - Coups, E. J.
AU  - Ruth, K.
AU  - Goplerud, J.
AU  - Raysor, S.
AU  - Kim, T. Y.
AU  - Bagden, L.
AU  - Mastalski, K.
AU  - Zakrzewski, D.
AU  - Leimkuhler, S.
AU  - Watkins-Bruner, D.
C2  - PMC2760660
C6  - NIHMS115254
DA  - Nov
DO  - 10.1016/j.juro.2009.07.021
DP  - NLM
ET  - 2009/09/18
IS  - 5
KW  - Adult
*African Americans
Aged
*Early Detection of Cancer
Humans
Male
Middle Aged
Patient Compliance/*statistics & numerical data
*Patient Selection
Prostatic Neoplasms/*diagnosis
Risk Factors
LA  - eng
N1  - 1527-3792
Giri, Veda N
Coups, Elliot J
Ruth, Karen
Goplerud, Julia
Raysor, Susan
Kim, Taylor Y
Bagden, Loretta
Mastalski, Kathleen
Zakrzewski, Debra
Leimkuhler, Suzanne
Watkins-Bruner, Deborah
P30 CA006927/CA/NCI NIH HHS/United States
P30 CA006927-46S2/CA/NCI NIH HHS/United States
Journal Article
Research Support, Non-U.S. Gov't
J Urol. 2009 Nov;182(5):2212-7. doi: 10.1016/j.juro.2009.07.021. Epub 2009 Sep 16.
PY  - 2009
SN  - 0022-5347 (Print)
0022-5347
SP  - 2212-7
ST  - Prostate cancer early detection program recruitment methods and show rates in men at high risk
T2  - J Urol
TI  - Prostate cancer early detection program recruitment methods and show rates in men at high risk
VL  - 182
ID  - 445
ER  - 

TY  - JOUR
AB  - The use of churches as recruitment sites of African Americans into health promotion activities is a popular theme in the 1990s literature. This research measured the impact of previous exposure to cancer on participation in an educational program and a free prostate cancer screening. Cues to action from the Health Belief Model provided the conceptual framework. Over 500 men attended a prostate cancer educational program at their church. Men who participated in the educational program and completed the questionnaire were given a voucher that they could take to their doctor of choice for a free prostate cancer examination. Having a member of the congregation who was previously diagnosed with cancer was a significant cue to attendance at the educational program (P = 0.03). Recommendations for future cancer screening in churches are given.
AD  - College of Nursing, University of South Carolina, Columbia 29208, USA.
AN  - 9629032
AU  - Weinrich, S.
AU  - Holdford, D.
AU  - Boyd, M.
AU  - Creanga, D.
AU  - Cover, K.
AU  - Johnson, A.
AU  - Frank-Stromborg, M.
AU  - Weinrich, M.
DA  - Jun
DO  - 10.1111/j.1525-1446.1998.tb00338.x
DP  - NLM
ET  - 1998/06/18
IS  - 3
KW  - *African Americans
Health Education/*organization & administration
Health Promotion
Humans
Male
Mass Screening/*organization & administration
Middle Aged
*Pastoral Care
Patient Selection
Program Evaluation
Prostatic Neoplasms/ethnology/*prevention & control
Public Health Nursing
South Carolina
Surveys and Questionnaires
LA  - eng
N1  - Weinrich, S
Holdford, D
Boyd, M
Creanga, D
Cover, K
Johnson, A
Frank-Stromborg, M
Weinrich, M
R01 CA60561/CA/NCI NIH HHS/United States
Journal Article
Research Support, U.S. Gov't, P.H.S.
United States
Public Health Nurs. 1998 Jun;15(3):188-95. doi: 10.1111/j.1525-1446.1998.tb00338.x.
PY  - 1998
SN  - 0737-1209 (Print)
0737-1209
SP  - 188-95
ST  - Prostate cancer education in African American churches
T2  - Public Health Nurs
TI  - Prostate cancer education in African American churches
VL  - 15
ID  - 731
ER  - 

TY  - JOUR
AB  - Active surveillance (AS) is an increasingly prevalent treatment choice for low grade prostate cancer. Eligibility criteria for AS are varied and it is unclear if family history of prostate cancer should be used as an exclusion criterion when considering men for AS. To determine whether family history plays a significant role in the progression of prostate cancer for men undergoing active surveillance, PubMed searches of 'family history and prostate cancer', 'family history and prostate cancer progression' and 'factors of prostate cancer progression' were used to identify research publications about the relationship between family history and prostate cancer progression. These searches generated 536 papers that were screened and reviewed. Six publications were ultimately included in this analysis. Review of the six publications suggests that family history does not increase the risk of prostate cancer progression, whilst a subgroup analysis in one study found that family history increases the risk of prostate cancer progression only in African-Americans. A family history of prostate cancer does not appear to increase a patient's risk of having more aggressive prostate cancer and is therefore unlikely to be an important factor in determining eligibility for AS. Further studies are needed to better understand the relationship between race, family history, and eligibility for AS.
AD  - Department of Urology, University of Michigan, Ann Arbor, MI, USA.
Spectrum Health Medical Center, Grand Rapids, MI, USA.
Department of Urology, Wayne State University, Detroit, MI, USA.
AN  - 28371016
AU  - Telang, J. M.
AU  - Lane, B. R.
AU  - Cher, M. L.
AU  - Miller, D. C.
AU  - Dupree, J. M.
DA  - Oct
DO  - 10.1111/bju.13862
DP  - NLM
ET  - 2017/04/04
IS  - 4
KW  - Aged
Early Detection of Cancer/*methods
Genetic Predisposition to Disease/*epidemiology
Humans
Incidence
Male
Middle Aged
Observational Studies as Topic
Patient Selection
Pedigree
Prostate-Specific Antigen/blood
Prostatic Neoplasms/*diagnosis/*genetics/therapy
Risk Assessment
United States/epidemiology
*Watchful Waiting
*#pcsm
*#ProstateCancer
*active surveillance
*family history
LA  - eng
N1  - 1464-410x
Telang, Jaya M
Orcid: 0000-0002-3322-8832
Lane, Brian R
Cher, Michael L
Miller, David C
Dupree, James M
Journal Article
Meta-Analysis
Review
Systematic Review
England
BJU Int. 2017 Oct;120(4):464-467. doi: 10.1111/bju.13862. Epub 2017 May 3.
PY  - 2017
SN  - 1464-4096
SP  - 464-467
ST  - Prostate cancer family history and eligibility for active surveillance: a systematic review of the literature
T2  - BJU Int
TI  - Prostate cancer family history and eligibility for active surveillance: a systematic review of the literature
VL  - 120
ID  - 175
ER  - 

TY  - JOUR
AB  - Prostate cancer is the most common noncutaneous malignancy and the second leading cause of cancer death in men. In the United States, 90% of men with prostate cancer are more than age 60 years, diagnosed by early detection with the prostate-specific antigen (PSA) blood test, and have disease believed confined to the prostate gland (clinically localized). Common treatments for clinically localized prostate cancer include watchful waiting (WW), surgery to remove the prostate gland (radical prostatectomy), external-beam radiation therapy and interstitial radiation therapy (brachytherapy), and androgen deprivation. Little is known about the relative effectiveness and harms of treatments because of the paucity of randomized controlled trials. The Department of Veterans Affairs/National Cancer Institute/Agency for Healthcare Research and Quality Cooperative Studies Program Study #407:Prostate Cancer Intervention Versus Observation Trial (PIVOT), initiated in 1994, is a multicenter randomized controlled trial comparing radical prostatectomy with WW in men with clinically localized prostate cancer. We describe the study rationale, design, recruitment methods, and baseline characteristics of PIVOT enrollees. We provide comparisons with eligible men declining enrollment and men participating in another recently reported randomized trial of radical prostatectomy vs WW conducted in Scandinavia. We screened 13 022 men with prostate cancer at 52 US medical centers for potential enrollment. From these, 5023 met initial age, comorbidity, and disease eligibility criteria, and a total of 731 men agreed to participate and were randomized. The mean age of enrollees was 67 years. Nearly one-third were African American. Approximately 85% reported that they were fully active. The median PSA was 7.8ng/mL (mean 10.2ng/mL). In three-fourths of men, the primary reason for biopsy leading to a diagnosis of prostate cancer was a PSA elevation or rise. Using previously developed tumor risk categorizations incorporating PSA levels, Gleason histologic grade, and tumor stage, it was found that approximately 40% had low-risk, 34% had medium-risk, and 21% had high-risk prostate cancer based on local histopathology. Comparison to our national sample of eligible men declining PIVOT participation as well as to men enrolled in the Scandinavian trial indicated that PIVOT enrollees are representative of men being diagnosed and treated in the United States and quite different from men in the Scandinavian trial. PIVOT enrolled an ethnically diverse population representative of men diagnosed with prostate cancer in the United States. Results will yield important information regarding the relative effectiveness and harms of surgery compared with WW for men with predominately PSA-detected clinically localized prostate cancer.
AD  - Minneapolis VA Center for Chronic Disease Outcomes Research, 1 Veterans Drive (111-0), Minneapolis, MN 55417, USA. tim.wilt@med.va.gov
AN  - 23271771
AU  - Wilt, T. J.
C2  - PMC3540866
DA  - Dec
DO  - 10.1093/jncimonographs/lgs041
DP  - NLM
ET  - 2012/12/29
IS  - 45
KW  - Adult
Aged
Biopsy, Needle
Disease Progression
Humans
Male
Middle Aged
Neoplasm Grading
Prostate/pathology/surgery
Prostate-Specific Antigen/blood
*Prostatectomy
*Prostatic Neoplasms/diagnosis/surgery/therapy
Treatment Outcome
*Watchful Waiting
LA  - eng
N1  - 1745-6614
Wilt, Timothy J
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.
J Natl Cancer Inst Monogr. 2012 Dec;2012(45):184-90. doi: 10.1093/jncimonographs/lgs041.
PY  - 2012
SN  - 1052-6773 (Print)
1052-6773
SP  - 184-90
ST  - The Prostate Cancer Intervention Versus Observation Trial: VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy with watchful waiting for men with clinically localized prostate cancer
T2  - J Natl Cancer Inst Monogr
TI  - The Prostate Cancer Intervention Versus Observation Trial: VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy with watchful waiting for men with clinically localized prostate cancer
VL  - 2012
ID  - 345
ER  - 

TY  - JOUR
AB  - BACKGROUND: Prostate cancer is the most common noncutaneous malignancy and the second leading cause of cancer death in men. Ninety percent of men with prostate cancer are over aged 60 years, diagnosed by early detection with the prostate specific antigen (PSA) blood test and have disease believed confined to the prostate gland (clinically localized). Common treatments for clinically localized prostate cancer include watchful waiting surgery to remove the prostate gland (radical prostatectomy), external beam radiation therapy and interstitial radiation therapy (brachytherapy) and androgen deprivation. Little is known about the relative effectiveness and harms of treatments due to the paucity of randomized controlled trials. The VA/NCI/AHRQ Cooperative Studies Program Study #407: Prostate cancer Intervention Versus Observation Trial (PIVOT), initiated in 1994, is a multicenter randomized controlled trial comparing radical prostatectomy to watchful waiting in men with clinically localized prostate cancer. METHODS: We describe the study rationale, design, recruitment methods and baseline characteristics of PIVOT enrollees. We provide comparisons with eligible men declining enrollment and men participating in another recently reported randomized trial of radical prostatectomy versus watchful waiting conducted in Scandinavia. RESULTS: We screened 13,022 men with prostate cancer at 52 United States medical centers for potential enrollment. From these, 5023 met initial age, comorbidity and disease eligibility criteria and a total of 731 men agreed to participate and were randomized. The mean age of enrollees was 67 years. Nearly one-third were African-American. Approximately 85% reported they were fully active. The median prostate specific antigen (PSA) was 7.8 ng/mL (mean 10.2 ng/mL). In three-fourths of men the primary reason for biopsy leading to a diagnosis of prostate cancer was a PSA elevation or rise. Using previously developed tumor risk categorizations incorporating PSA levels, Gleason histologic grade and tumor stage, approximately 43% had low risk, 36% had medium risk and 20% had high-risk prostate cancer. Comparison to our national sample of eligible men declining PIVOT participation as well as to men enrolled in the Scandinavian trial indicated that PIVOT enrollees are representative of men being diagnosed and treated in the U.S. and quite different from men in the Scandinavian trial. CONCLUSIONS: PIVOT enrolled an ethnically diverse population representative of men diagnosed with prostate cancer in the United States. Results will yield important information regarding the relative effectiveness and harms of surgery compared to watchful waiting for men with predominately PSA detected clinically localized prostate cancer.
AD  - Minneapolis VA Center for Chronic Disease Outcomes Research, Minneapolis, MN 55417, United States. tim.wilt@med.va.gov
AN  - 18783735
AU  - Wilt, T. J.
AU  - Brawer, M. K.
AU  - Barry, M. J.
AU  - Jones, K. M.
AU  - Kwon, Y.
AU  - Gingrich, J. R.
AU  - Aronson, W. J.
AU  - Nsouli, I.
AU  - Iyer, P.
AU  - Cartagena, R.
AU  - Snider, G.
AU  - Roehrborn, C.
AU  - Fox, S.
DA  - Jan
DO  - 10.1016/j.cct.2008.08.002
DP  - NLM
ET  - 2008/09/12
IS  - 1
KW  - Adult
Aged
Comorbidity
Disease Progression
Humans
Male
Middle Aged
Prostate-Specific Antigen/blood
Prostatectomy
Prostatic Neoplasms/mortality/*surgery
Research Design
Socioeconomic Factors
LA  - eng
N1  - 1559-2030
Wilt, Timothy J
Brawer, Michael K
Barry, Michael J
Jones, Karen M
Kwon, Young
Gingrich, Jeffrey R
Aronson, William J
Nsouli, Imad
Iyer, Padmini
Cartagena, Ruben
Snider, Glenn
Roehrborn, Claus
Fox, Steven
Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, U.S. Gov't, Non-P.H.S.
United States
Contemp Clin Trials. 2009 Jan;30(1):81-7. doi: 10.1016/j.cct.2008.08.002. Epub 2008 Aug 23.
PY  - 2009
SN  - 1551-7144
SP  - 81-7
ST  - The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer
T2  - Contemp Clin Trials
TI  - The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer
VL  - 30
ID  - 488
ER  - 

TY  - JOUR
AB  - BACKGROUND. Early detection of small-volume prostate cancer (PCa) has led to the concept of focal therapy to treat PCa as an organ-sparing, minimally invasive procedure. The authors sought to determine the frequency of unilateral cancers in the contemporary prostate-specific antigen (PSA) era to determine the percentage of patients who would be candidates for hemiablation of the prostate by using focal therapy while preserving the contralateral lobe. METHODS. Paraffin-embedded radical prostatectomy specimens (1184 specimens) from consecutive patients between 2002 and 2006 with pathologic organ confined PCa were analyzed. Pathologic assessment focused on tumor laterality and percentage of tumor involvement (PTI) along with other routine parameters such as pathological T-classification (pT), pathological Gleason Score (pGS), extracapsular extension (ECE), and surgical margins (SM). Clinical and pathologic parameters were analyzed by univariate and multivariate methods. RESULTS. Completely unilateral cancers were identified in 227 (19.2%) of 1184 patients. Of these patients, 164 (72.2%) had PTI of ≤5%, 40 (17.6%) had a PTI of 5.01%-10%, 9 (4.0%) had a PTI of 10.01%-15%, and 14 (6.2%) had a PTI of > 15%, respectively (P < .0005). African-American men had bilateral cancers more commonly that non-African-American men, eg, 90.8% versus 79.2%, respectively (P < .0005). Race, PTI, pGS, and SM were independent predictors by multivariate logistic regression (P ≤ .05). CONCLUSIONS. This study suggests that 1 in 5 men diagnosed with PCa have small volume, completely unilateral cancers that may be amenable to hemiablation of the prostate. Further study is needed to develop predictive models to select candidates for focal therapy. © 2007 American Cancer Society.
AD  - T.J. Polascik, Department of Urology, Duke University Medical Center, Box 2804, Yellow Zone, Durham, NC 27710, United States
AU  - Mouraviev, V.
AU  - Mayes, J. M.
AU  - Sun, L.
AU  - Madden, J. F.
AU  - Moul, J. W.
AU  - Polascik, T. J.
DB  - Embase
Medline
DO  - 10.1002/cncr.22858
IS  - 4
KW  - paraffin
prostate specific antigen
adult
African American
aged
article
cancer classification
cancer localization
catheter ablation
controlled study
disease severity
Gleason score
histopathology
human
human cell
human tissue
major clinical study
male
multivariate analysis
multivariate logistic regression analysis
patient selection
prediction
priority journal
prostate cancer
race difference
LA  - English
M3  - Article
N1  - L47257670
2007-08-15
PY  - 2007
SN  - 0008-543X
1097-0142
SP  - 906-910
ST  - Prostate cancer laterality as a rationale of focal ablative therapy for the treatment of clinically localized prostate cancer
T2  - Cancer
TI  - Prostate cancer laterality as a rationale of focal ablative therapy for the treatment of clinically localized prostate cancer
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L47257670&from=export
http://dx.doi.org/10.1002/cncr.22858
VL  - 110
ID  - 1223
ER  - 

TY  - JOUR
AB  - Background: A disproportionate burden of prostate cancer (CaP) incidence and mortality is observed for African American (AA) versus Caucasian (CA) patients in the US. Potential underlying reasons for racial disparity include biology, comorbidity profiles, access to health care, adherence to follow‐up care and/or treatment aggressiveness. This study examined CaP progression and overall survival (OS) among AA and CA patients undergoing radical prostatectomy (RP). Methods: This retrospective cohort study examined men enrolled in the Center for Prostate Disease Research (CPDR) Multi‐Center National Database between January 1, 1990 and December 31, 2014. Patients with biopsydetected CaP without metastasis and treated with RP within 12 months of CaP diagnosis were eligible. Biochemical recurrence (BCR) was defined as a PSA value of > = 0.4 ng/mL followed by a subsequent increase. PSADT was categorized as < 3, 3‐8.99, 9‐14.99, and > = 15 months. Kaplan‐Meier estimation curves and multivariable Cox proportional hazards analysis were used to examine BCR and OS. Results: A total of 6,785 patients were eligible; 21.5% self‐reported as AA and 78.5% self‐reported as CA. Median follow‐up time was 6.1 years. Comparable distributions of pathologic features at RP and adjuvant treatment over time were observed across race but several comorbid conditions were more common in AA patients including cardiovascular disease, hypertension, diabetes, and other cancer types. In race‐specific unadjusted Kaplan Meier analyses, PSADT was an important predictor of BCR and OS for both AA and CA patients (Log rank p < 0.0001 for all KM models). In multivariable analysis, a greater odds of BCR over time was observed for AA versus CA patients (HR = 1.28, CI = 1.11, 1.48, p = 0.0009) after adjustment for D'Amico risk stratum, comorbidity, pathological features, and PSADT. PSADT was a critical predictor of BCR, with worst outcomes at extreme comparison of PSADT categories: HR < 3 vs. > = 15 months= 41.5, CI = 33.6, 51.3, p < 0.0001). Conclusions: In a large racially diverse, longitudinal cohort with equal health care access, there was a striking relationship between PSADT and time to BCR for each racial group and poorer outcomes for AA versus CA patients.
AN  - CN-01407277
AU  - Cullen, J.
AU  - Kuo, H. C.
AU  - Chen, Y.
AU  - Hurwitz, L.
AU  - Rosner, I. L.
AU  - Porter, C.
AU  - Brand, T. C.
AU  - Sterbis, J.
AU  - Stroup, S.
AU  - Rebbeck, T.
AU  - et al.
IS  - 6 Supplement 1) (no pagination
KW  - *African American
*Caucasian
*prostate cancer
*prostatectomy
Adjuvant
Biochemical recurrence
Clinical trial
Cohort analysis
Comorbidity
Controlled clinical trial
Controlled study
Data base
Diabetes mellitus
Diagnosis
Endogenous compound
Follow up
Health care access
Human
Hypertension
Kaplan Meier method
Major clinical study
Male
Metastasis
Model
Multicenter study
Overall survival
M3  - Conference Abstract
PY  - 2017
ST  - Prostate cancer outcomes for African American and caucasian patients undergoing radical prostatectomy
T2  - Journal of clinical oncology. Conference: 2017 genitourinary cancers symposium. United states
TI  - Prostate cancer outcomes for African American and caucasian patients undergoing radical prostatectomy
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01407277/full
VL  - 35
ID  - 1475
ER  - 

TY  - JOUR
AB  - PURPOSE OF REVIEW: We review the concepts surrounding prostate cancer prevention strategies with 5-alpha reductase inhibitors (5-ARIs) and the controversies associated with their use. RECENT FINDINGS: Updated data have shown no increased risk of death from the diagnosis of higher risk cancer; however, 5-ARIs remain controversial and not approved for prostate cancer prevention. SUMMARY: The main theme of the review identifies the success of reducing insignificant prostate cancer and the controversy with the increased association of higher risk prostate cancer by approximately 20%. The reduction was shown to be most significant reduction in low-grade prostate cancer. The initial concern about 5-ARI use was that it could potentially increase high-risk prostate cancer leading to higher mortality in those men. Higher mortality has not been seen in follow-up data; however, 5-ARIs continue to have a black box warning and are not approved for prostate cancer prevention.
AD  - Department of Urology (liss), University of Texas Health San Antonio.
CHRISTUS Santa Rosa Medical Center Hospital, CHRISTUS Research Institute, San Antonio, Texas, USA.
AN  - 29095730
AU  - Liss, M. A.
AU  - Thompson, I. M.
DA  - Jan
DO  - 10.1097/mou.0000000000000464
DP  - NLM
ET  - 2017/11/03
IS  - 1
KW  - 3-Oxo-5-alpha-Steroid 4-Dehydrogenase/metabolism
5-alpha Reductase Inhibitors/pharmacology/*therapeutic use
Dihydrotestosterone/metabolism
Dutasteride/pharmacology/therapeutic use
Early Detection of Cancer
Finasteride/pharmacology/therapeutic use
Humans
Male
Organ Size/drug effects
Prostate/*drug effects/metabolism/pathology
Prostatic Hyperplasia/diagnosis/*drug therapy/pathology
Prostatic Neoplasms/diagnosis/pathology/*prevention & control
Randomized Controlled Trials as Topic
Receptors, Androgen/metabolism
Risk Factors
LA  - eng
N1  - 1473-6586
Liss, Michael A
Thompson, Ian M
Journal Article
Review
United States
Curr Opin Urol. 2018 Jan;28(1):42-45. doi: 10.1097/MOU.0000000000000464.
PY  - 2018
SN  - 0963-0643
SP  - 42-45
ST  - Prostate cancer prevention with 5-alpha reductase inhibitors: concepts and controversies
T2  - Curr Opin Urol
TI  - Prostate cancer prevention with 5-alpha reductase inhibitors: concepts and controversies
VL  - 28
ID  - 151
ER  - 

TY  - JOUR
AB  - The National Cancer Institute (NCI) is the largest funder of prostate cancer research in the United States and indeed the world. It is sponsoring a number of studies to answer the significant questions pertinent to prostate cancer and pertinent to black men. These include studies of epidemiology; cancer prevention, screening, and control; clinical treatment; and basic science. In addition, the NCI is charged with dissemination of research findings to physicians and the lay public. The following is a description of the NCI prostate cancer research portfolio including the scientific questions being addressed and how are they being addressed.
AD  - Office of Special Populations Research, National Cancer Institute, Bethesda, MD 20892, USA.
AN  - 9858332
AU  - Brawley, O. W.
AU  - Figueroa-Valles, N.
DA  - Nov
DP  - NLM
ET  - 1998/12/19
IS  - 4
KW  - *African Americans
Clinical Trials as Topic
Humans
*Information Services
Male
National Institutes of Health (U.S.)/*organization & administration
Prostatic Neoplasms/*epidemiology/ethnology/etiology
*Research Support as Topic
*SEER Program
United States/epidemiology
LA  - eng
N1  - Brawley, O W
Figueroa-Valles, N
Journal Article
Review
United States
Semin Urol Oncol. 1998 Nov;16(4):235-40.
PY  - 1998
SN  - 1081-0943 (Print)
1081-0943
SP  - 235-40
ST  - Prostate cancer research and the National Cancer Institute
T2  - Semin Urol Oncol
TI  - Prostate cancer research and the National Cancer Institute
VL  - 16
ID  - 721
ER  - 

TY  - JOUR
AB  - Men of the African diaspora are diagnosed with prostate cancer much later than Caucasians and the mortality rate is significantly higher in these groups than among Caucasians. This study investigates health beliefs surrounding prostate health in a sample of African American and Caribbean men and identifies reasons men have for delaying or avoiding prostate screenings. One hundred African American and Caribbean men recruited from three churches, aged 37-89, were surveyed about their health seeking behaviors and knowledge of prostate cancer. Forty-five of these men also attended a seminar on the importance of early detection. Eighty percent of the men revealed they were embarrassed to have digital rectal examinations. Sixty percent feared impotence and incontinence after treatment if diagnosed with cancer. Findings reveal that attention to cultural realities may assist healthcare professionals in planning culturally sensitive educational interventions in the community that may narrow the health disparities gap in this population.
AD  - Florida International University, School of Nursing, North Miami Beach, Miami, Florida 33181, USA.
AN  - 18399361
AU  - Parchment, Y. D.
DA  - Nov-Dec
DP  - NLM
ET  - 2008/04/11
IS  - 6
KW  - Adult
Africa/ethnology
African Americans/education/*ethnology
Aged
Aged, 80 and over
Cultural Competency
Digital Rectal Examination/psychology
Fear
Florida/epidemiology
*Health Knowledge, Attitudes, Practice
Health Services Accessibility
Healthcare Disparities
Humans
Male
Mass Screening/*psychology
Men/education/*psychology
Middle Aged
Needs Assessment/organization & administration
Nursing Methodology Research
Patient Acceptance of Health Care/*ethnology
Patient Education as Topic/organization & administration
*Prostatic Neoplasms/diagnosis/ethnology
Psychological Theory
Socioeconomic Factors
Surveys and Questionnaires
West Indies/ethnology
LA  - eng
N1  - Parchment, Yvonne D
Journal Article
United States
ABNF J. 2004 Nov-Dec;15(6):116-20.
PY  - 2004
SN  - 1046-7041 (Print)
1046-7041
SP  - 116-20
ST  - Prostate cancer screening in African American and Caribbean males: detriment in delay
T2  - Abnf j
TI  - Prostate cancer screening in African American and Caribbean males: detriment in delay
VL  - 15
ID  - 500
ER  - 

TY  - JOUR
AB  - Background: The benefit of screening for prostate cancer using prostate-specific antigen (PSA) testing and digital rectal examination (DRE) is uncertain and is under evaluation in a randomized prospective trial, the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Although the final results are several years away, the initial round of screening is complete. We describe the population enrolled in the PLCO trial, their baseline PSA and DRE screening results, and diagnostic follow-up results during the first year of follow-up. Methods: A total of 38350 men were randomly assigned to the screening arm of the PLCO trial from November 1993 through June 2001. Men were advised to seek diagnostic follow-up from their primary care provider if their DRE was suspicious for cancer and/or if their serum PSA level was higher than 4 ng/mL. PLCO trial staff obtained records related to diagnostic follow-up. Results: Compliance with both screening tests was high (more than 89%). At screening, 7.5% of men had a positive DRE (i.e., suspicious for cancer) and 7.9% had a PSA level higher than 4 ng/mL. Of the men with positive screening tests, 74.2% underwent additional diagnostic testing, and 31.5% underwent a prostatic biopsy within 1 year. Overall, 1.4% of the men in the screening arm were diagnosed with prostate cancer, the majority of whom had clinically localized cancer. These compliance, biopsy, and cancer detection rates appear to be representative of contemporary practice patterns. Conclusion: The PLCO trial is evaluating PSA- and DRE-based screening for prostate cancer in a clinically valid manner. Whether such screening will result in a reduction of prostate cancer mortality cannot be answered until the randomized comparison is completed.
AN  - WOS:000227710600009
AU  - Andriole, G. L.
AU  - Levin, D. L.
AU  - Crawford, E. D.
AU  - Gelmann, E. R.
AU  - Pinsky, P. F.
AU  - Chia, D.
AU  - Kramer, B. S.
AU  - Reding, D.
AU  - Church, T. R.
AU  - Grubb, R. L.
AU  - Izmirlian, G.
AU  - Ragard, L. R.
AU  - Clapp, J. D.
AU  - Prorok, P. C.
AU  - Gohagan, J. K.
DA  - Mar 16
DO  - 10.1093/jnci/dji065
IS  - 6
N1  - 160
15770007
PY  - 2005
SN  - 0027-8874
SP  - 433-438
ST  - Prostate cancer screening in the prostate, lung, colorectal and Ovarian (PLCO) Cancer Screening Trial: Findings from the initial screening round of a randomized trial
T2  - Jnci-Journal of the National Cancer Institute
TI  - Prostate cancer screening in the prostate, lung, colorectal and Ovarian (PLCO) Cancer Screening Trial: Findings from the initial screening round of a randomized trial
VL  - 97
ID  - 2664
ER  - 

TY  - THES
AB  - Problem and Significance: Prostate cancer (PC) is a potentially deadly disease that causes increased mortality rates in African-Americans. According to the American Cancer Society, prostate cancer occurs more frequently in African-American men than in men of other races. African-American men are also more likely to be diagnosed at an advanced stage, and are more than twice as likely to die of PC as White men. Purpose: The purpose of this translational research project was to survey adult African-Americans and their partners to explore inhibitors and facilitators to PC screening. Methods: A total of 125 adult participants were recruited onsite at community health fairs in Los Angeles County to participate in a PC screening survey. Survey questions elicited information about age, gender, educational background, and personal and family PC screening history. The project used a cross-sectional design. Data Analysis: All data were entered in Statistical Package for the Social Sciences (SPSS) Version 20. First, univariate descriptive statistics were used to describe the sample of AA and partners; means and standard deviations for continuous variables such as age and education; and percentages for categorical variables such as gender. Second, bivariate analysis was used to answer research questions 1 and 2. For research question 1, chi-square-test was used to compare male and female survey question responses. For research question 2, individual chi-square tests were used for the variables (age, years of education, prior personal and family PCS history; and prior personal and family history of PC diagnosis) to assess the effect of these variables on the responses to the PC screening survey. Results: The mean age of participants was 52.44 years (SD=12.36 years); 76% were AA; 39% had college/technical graduate school. Among the AA men, two (3%) had prostate cancer, 22% had family member/friend with PC, and 31% received PC screening education. Both AA and their partners had similar screening-related behavior and beliefs about its myths (p>0.05). Significant difference was found between AA and their partners in emotional concerns (people doing prostate exams are rude, having a prostate cancer screening is embarrassing for my loved one) (p<0.05). Implications for Nursing: AA men and their partners had similar PC screening-related behavior, but differ in their emotional concerns. Participants need supplementary PC screening-related education to make an informed decision regarding follow-up and treatment. A culturally and linguistically appropriate education program to increase awareness/participation in PC screening and clinical trials is needed for AA. (PsycINFO Database Record (c) 2019 APA, all rights reserved)
AN  - 2016-17134-232
AU  - James, Angela
DB  - psyh
DP  - EBSCOhost
KW  - prostate cancer screening
African-Americans
mortality rates
healthsurvey
Blacks
Cancer Screening
Prostate
Surveys
Partners
Mortality Rate
N1  - Accession Number: 2016-17134-232. Other Journal Title: Dissertation Abstracts International. Partial author list: First Author & Affiliation: James, Angela; Azusa Pacific University, Nursing, US. Release Date: 20160623. Correction Date: 20190211. Publication Type: Dissertation Abstract (0400). Format Covered: Electronic. Document Type: Dissertation. Dissertation Number: AAI3712467. ISBN: 978-1321893236. Language: English. Major Descriptor: Blacks; Cancer Screening; Prostate; Surveys; Partners. Minor Descriptor: Mortality Rate. Classification: Health & Mental Health Treatment & Prevention (3300). Population: Human (10); Male (30). Location: US. Age Group: Adulthood (18 yrs & older) (300). Methodology: Empirical Study; Quantitative Study.
PB  - ProQuest Information & Learning
PY  - 2016
SN  - 0419-4217
978-1321893236
ST  - Prostate cancer screening survey among African-Americans and their partners
TI  - Prostate cancer screening survey among African-Americans and their partners
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2016-17134-232&site=ehost-live&scope=site
VL  - 76
ID  - 1719
ER  - 

TY  - JOUR
AB  - Cancer survivors are at an increased risk of bone loss due to previous cancer treatments and are at increased risk of obesity and other cardiometabolic diseases. Therefore it is important for cancer survivors to adhere to an active lifestyle and good nutrition. The study proposes a single site, pilot, randomized clinical trial to examine the efficacy of a lifestyle program that includes recreational soccer (RS) and nutrition education compared to mobile health lifestyle program to improve bone density and bone turnover. It proposes that leveraging the growing enthusiasm around soccer in Atlanta and the U.S. may lead to increased interest, participation, retention and engagement in lifestyle change programming among prostate cancer (PCa) survivors. Therefore, this study seeks to directly test the implementation feasibility of a lifestyle change intervention in combination with RS and determine its effects in bone health, body composition, mental health, functional and cardiometabolic status among PCa survivors. A comparison group will receive usual care plus a low cost, mobile‐health (mHealth) enabled lifestyle intervention, without supervised physical activity (PA) programming. The aim is to recruit 40 men (50% African American or Latino) that have been in survivor status for at least 6 months from several Winship Cancer Institute clinical sites. The trial will exclude those with metastatic disease, already too active, and with any contraindications to exercise. The participants will be randomized after eligibility screening and will be scheduled for baseline assessments. The intervention group will be offered twice/week 60‐minute soccer conditioning sessions using an evidence‐based Football Fitness curriculum, delivered by trained soccer coaches. They will also receive lifestyle education including nutrition and other American Heart Association (AHA) Life's Simple 7 core messages after soccer sessions for 15 minutes. The comparison group will receive weekly educational and motivational text messages, aimed at improving physical activity (PA) and lifestyles. Both intervention and comparison groups will receive a wearable Garmin device to objectively monitor PA volume (steps) and intensity (minutes of moderate and vigorous) PA, as well as sedentary and sleep time. The study will assess pre and post differences in bone mineral density (primary outcome), body composition (DXA), bone turnover biomarkers, anthropometrics, diet, physical fitness, blood pressure and patient‐reported outcomes including PA and diet self‐efficacy, quality of life and depression. The trial will also compare the compliance with the federal recommendations of 150 weekly minutes of moderate‐to‐vigorous PA between the recreational soccer‐based intervention and the comparison group, as a marker of program adherence. All study assessments will be conducted at the Emory Clinical Research Center on the Clifton Campus and the intervention group will have their soccer sessions on a soccer field in the Atlanta area that is convenient for the participants. All participants will be given gift cards for each assessment visit. The investigators anticipate the RS program will be more efficacious in preventing bone loss and increasing weight loss in PCa survivors. This study will engage men in a lifestyle program that has the potential to sustain healthy behaviors beyond the term of the study.
AN  - CN-02001486
AU  - Nct
KW  - Prostatic Neoplasms
PY  - 2019
ST  - Prostate Cancer Soccer
T2  - https://clinicaltrials.gov/show/NCT04144127
TI  - Prostate Cancer Soccer
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02001486/full
ID  - 1421
ER  - 

TY  - JOUR
AB  - Prostate cancer has recently surpassed lung cancer to become the most common cancer of American men. The estimated number of new prostate cancer cases in 2005 is expected to be 232,090, up from 198,000 in 2002. Prostate cancer represents 29% of all new cancer diagnoses in men and is comparable to the incidence of breast cancer in women. Prostate cancer continues to disproportionately affect minority men. For patients with early, localized prostate cancer, there are a number of treatment options, including surgical removal of the prostate, radiation therapy (external beam or implantation of radioactive "seeds"), hormonal therapy, cryoablation, or expectant monitoring ("watchful waiting"). Most of these currently available treatments for localized prostate cancer carry the risk of a number of iatrogenic symptoms, including urinary incontinence, ED, and others that vary depending on the treatment received. The need for symptom management education is greater for men with lower health literacy. Health literacy ‐ "the ability to which individuals have the capacity to obtain, process, and understand health information services needed to make appropriate health decisions" ‐ has been shown to be strongly related to health status and health outcomes. Persons with lower health literacy skills are significantly less likely to take preventive actions to improve their health. Health literacy is a particular concern for men with prostate cancer because African‐American men, a group with a significantly higher prevalence of prostate cancer, are over‐represented among lower literacy men with prostate cancer.3 The study proposed here will develop and evaluate in a randomized controlled trial (RCT) an empirically‐derived symptom management intervention for lower literacy men with prostate cancer. The intervention will be based on a biopsychosocial model of prostate cancer symptom management developed from the more general the UCSF Symptom Management Model (SMM) and Bandura's Self‐Efficacy Theory. The efficacy of the intervention will be evaluated with 200 men with localized prostate cancer randomized to receive either the new tailored symptom management program or usual care. Participants in both the intervention and control groups will receive a booklet on coping with cancer available to all patients treated at the UCSF Comprehensive Cancer Center. Intervention group participants also will receive a new symptom management intervention tailored to their individual symptom profile. Both groups will be followed for 6 months after enrollment, with assessments at enrollment and 5 additional timepoints. The proposed research project includes the following specific aims: 1. Conduct an RCT to evaluate a tailored symptom management intervention targeted to lower literacy men with localized prostate cancer. The investigators hypothesize men who receive the tailored symptom management intervention (N=100) will report significantly less symptom distress at the 6‐month follow‐up than men in the control condition (N=100). Symptom distress will be measured by the Expanded Prostate Cancer Index Composite (EPIC) Urinary Bother and Sexual Bother sub‐scales. The intervention and control groups will be stratified by literacy level and type of prostate cancer treatment. 2. Complete a planned training experience that will include courses in responsible conduct of research, symptom management, cancer care, cancer prevention, cancer epidemiology, clinical research with diverse communities, and longitudinal analysis methods that will provide the knowledge and skills necessary to successfully conduct the RCT. 3. Assemble a group of key personnel with expertise necessary to guide the training experience and RCT. The primary mentor will be Leslie Schover, PhD, an expert in cancer symptom management. Other key personnel will include Stephen J. Lepore, PhD, Principal Investigator of a previous prostate cancer psychosocial intervention study; Brian J. Miles, MD, an expert in prostate cancer treatment; and Robert Morgan, PhD, a senior methodolo ist.
AN  - CN-01525990
AU  - Nct
KW  - Prostatic Neoplasms
PY  - 2009
ST  - Prostate Cancer Symptom Management for Low Literacy Men
T2  - https://clinicaltrials.gov/show/NCT00983710
TI  - Prostate Cancer Symptom Management for Low Literacy Men
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01525990/full
ID  - 1416
ER  - 

TY  - JOUR
AB  - OBJECTIVE: To estimate contemporary population-based patterns of the relative burden of prostate cancer-specific mortality (PCSM) attributable to each N0M0 prostate cancer risk-group, that may guide prioritization in research, trial design, and clinical practice. METHODS: We categorized 2004-2015 Surveillance, Epidemiology, and End Results database patients by risk group (low, favorable intermediate, unfavorable intermediate, high, and very highrisk). Using the Fine-Gray method, we calculated the relative burden of 10-year PCSM attributable to each risk group. RESULTS: Among N = 337 162 men (6.8-year median follow-up; median age 65 years), the relative proportion of low-, favorable intermediate-, unfavorable intermediate-, high-, and very high-risk diagnoses were 29.9% (N = 100 969), 31.1% (N = 104 696), 17.9% (N = 60 360), 18.1% (N = 61 023), and 3.0% (N = 10 114). Within 10 years of diagnosis, among patients who died of prostate cancer (N = 15 064), 5.0% (N = 746) had low-risk, 13.7% (N = 2060) had favorable intermediate-risk, 16.1% (N = 2429) had unfavorable intermediate-risk, 47.8% (N = 7196) had high-risk, and 17.5% (N = 2633) had very high-risk disease at diagnosis. Patients aged 65 and older accounted for 51.9% of all diagnoses and 72.3% of 10-year PCSM. Although black patients accounted for 15.0% of low-risk diagnoses, they accounted for 20.6% of 10-year PCSM. White patients accounted for 80.3% of low-risk diagnoses and 75.7% of 10-year PCSM. CONCLUSION: Although high-risk and very high-risk disease account for one-fifth of diagnoses, they account for two-thirds of 10-year PCSM. Older patients and black patients with low-risk disease accounted for a disproportionately large proportion of deaths. These findings support targeting research toward high-risk disease and ensuring adequate representation of older and black men in clinical trials.
AD  - Dana-Farber Cancer Institute/Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Harvard Medical School, Boston, Massachusetts.
Geisel School of Medicine at Dartmouth, Hanover, New Hampshire.
Department of Radiation Oncology, University of Miami Miller School of Medicine, Miami, Florida.
Office of Community Outreach and Engagement, Sylvester Comprehensive Cancer Center, Florida.
AN  - 32659024
AU  - Dee, E. C.
AU  - Nezolosky, M. D.
AU  - Chipidza, F. E.
AU  - Arega, M. A.
AU  - Butler, S. S.
AU  - Sha, S. T.
AU  - Mahal, B. A.
AU  - Nguyen, P. L.
AU  - Yang, D. D.
AU  - Muralidhar, V.
DA  - Sep
DO  - 10.1002/pros.24041
DP  - NLM
ET  - 2020/07/14
IS  - 13
KW  - Age Factors
Aged
Clinical Trials as Topic
Humans
Incidence
Male
Middle Aged
Needs Assessment
Prostatic Neoplasms/epidemiology/*mortality/pathology
Risk
SEER Program
United States/epidemiology
*Gleason score
*cancer-specific mortality
*high-risk prostate cancer
*prognostication
*prostate cancer
*prostate cancer risk group
LA  - eng
N1  - 1097-0045
Dee, Edward Christopher
Orcid: 0000-0001-6119-0889
Nezolosky, Michelle D
Chipidza, Fallon E
Arega, Melaku A
Butler, Santino S
Orcid: 0000-0003-4157-9437
Sha, Sybil T
Mahal, Brandon A
Orcid: 0000-0003-3036-334x
Nguyen, Paul L
Yang, David D
Muralidhar, Vinayak
R01-CA240582/NH/NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
United States
Prostate. 2020 Sep;80(13):1128-1133. doi: 10.1002/pros.24041. Epub 2020 Jul 13.
PY  - 2020
SN  - 0270-4137
SP  - 1128-1133
ST  - Prostate cancer-specific mortality burden by risk group among men with localized disease: Implications for research and clinical trial priorities
T2  - Prostate
TI  - Prostate cancer-specific mortality burden by risk group among men with localized disease: Implications for research and clinical trial priorities
VL  - 80
ID  - 32
ER  - 

TY  - JOUR
AB  - PURPOSE: Evidence suggests differences in androgen receptor AR signaling between black (B) and white (W) patients with prostate cancer, but pivotal trials of abiraterone acetate (AA) for patients with metastatic castration-resistant prostate cancer (mCRPC) enrolled few black patients, a population with a higher mortality from prostate cancer. Our primary objective was to determine differences in response to AA between B and W patients. METHODS: We performed a retrospective case-control study of B vs. W patients treated with AA between May 1, 2008 and June 16, 2015 at Duke University Medical Center. Patients were identified (W control patients were matched 2:1 to B patients stratified based on previous docetaxel exposure) through pharmacy records and were eligible if treated with AA for metastatic castration-resistant prostate cancer. Patients with previous enzalutamide use were excluded. The primary objective was to compare the rate of≥90% prostate-specific antigen (PSA) decline from baseline between B vs. W patients. Secondary outcomes included comparing time on therapy, time to PSA progression, and overall survival among groups. RESULTS: Baseline characteristics among patients (n = 45 B, n = 90 W) were identified; these included Karnofsky performance status, PSA, Gleason score, alkaline phosphatase, albumin, hemoglobin, lactate dehydrogenase, opiate use for pain, and metastatic sites. Baseline characteristics among groups were similar except for median hemoglobin (B = 11.4g/dl, W = 12.3g/dl). The proportion of B patients achieving a≥90% PSA level decline was 37.8% vs. 28.9% for W patients (P = 0.296). Statistically significant differences were found in the proportion of patients achieving a≥50% PSA level decline (B = 68.9%, W = 48.9% [P = 0.028]) and≥30% PSA level decline (B = 77.8%, W = 54.4% [P = 0.008]). Rates of primary abiraterone-refractory disease (PSA increase as best response) trended higher in W (31.1%) than in B (15.6%) patients (P = 0.052). Median treatment duration (B = 9.4 mo, W = 8.3 mo) did not differ (Wilcoxon P = 0.444). Median overall survival (B = 27.3 mo [95% CI: 13.9, not estimable], W = 24.8 mo [95% CI: 19, 31.6] [P = 0.669]) and median time to PSA progression (B = 11.0 mo [95% CI: 4.3, 18.0], W = 9.4 mo [95% CI: 6.2, 13.0] [P = 0.917]) did not differ. CONCLUSIONS: Black patients may have a higher PSA response to AA than white patients. An ongoing prospective clinical study (NCT01940276) is evaluating outcomes between black and white patients treated with AA.
AD  - Duke University Medical Center, Durham, NC; Department of Biostatistics and Bioinformatics, Duke University, Durham, NC. Electronic address: sundhar.ramalingam@dm.duke.edu.
Duke University Medical Center, Durham, NC.
Duke University Medical Center, Durham, NC; Department of Biostatistics and Bioinformatics, Duke University, Durham, NC.
Duke University Medical Center, Durham, NC; Duke Cancer Institute, Durham, NC.
AN  - 28126272
AU  - Ramalingam, S.
AU  - Humeniuk, M. S.
AU  - Hu, R.
AU  - Rasmussen, J.
AU  - Healy, P.
AU  - Wu, Y.
AU  - Harrison, M. R.
AU  - Armstrong, A. J.
AU  - George, D. J.
AU  - Zhang, T.
DA  - Jun
DO  - 10.1016/j.urolonc.2016.12.016
DP  - NLM
ET  - 2017/01/28
IS  - 6
KW  - Abiraterone Acetate/*therapeutic use
African Continental Ancestry Group
Case-Control Studies
Disease Progression
European Continental Ancestry Group
Humans
Kallikreins/*blood
Male
Neoplasm Metastasis
Prospective Studies
Prostate-Specific Antigen/*blood
Prostatic Neoplasms, Castration-Resistant/blood/*drug therapy/ethnology/pathology
Retrospective Studies
*Abirterone acetate
*Castration-resistant
*Prostate-specific antigen
*Prostatic neoplasms
*Race
LA  - eng
N1  - 1873-2496
Ramalingam, Sundhar
Humeniuk, Michael S
Hu, Rachel
Rasmussen, Julia
Healy, Patrick
Wu, Yuan
Harrison, Michael R
Armstrong, Andrew J
George, Daniel J
Zhang, Tian
Journal Article
United States
Urol Oncol. 2017 Jun;35(6):418-424. doi: 10.1016/j.urolonc.2016.12.016. Epub 2017 Jan 23.
PY  - 2017
SN  - 1078-1439
SP  - 418-424
ST  - Prostate-specific antigen response in black and white patients treated with abiraterone acetate for metastatic castrate-resistant prostate cancer
T2  - Urol Oncol
TI  - Prostate-specific antigen response in black and white patients treated with abiraterone acetate for metastatic castrate-resistant prostate cancer
VL  - 35
ID  - 187
ER  - 

TY  - JOUR
AB  - Purpose Evidence suggests differences in androgen receptor AR signaling between black (B) and white (W) patients with prostate cancer, but pivotal trials of abiraterone acetate (AA) for patients with metastatic castration–resistant prostate cancer (mCRPC) enrolled few black patients, a population with a higher mortality from prostate cancer. Our primary objective was to determine differences in response to AA between B and W patients. Methods We performed a retrospective case-control study of B vs. W patients treated with AA between May 1, 2008 and June 16, 2015 at Duke University Medical Center. Patients were identified (W control patients were matched 2:1 to B patients stratified based on previous docetaxel exposure) through pharmacy records and were eligible if treated with AA for metastatic castration–resistant prostate cancer. Patients with previous enzalutamide use were excluded. The primary objective was to compare the rate of≥90% prostate-specific antigen (PSA) decline from baseline between B vs. W patients. Secondary outcomes included comparing time on therapy, time to PSA progression, and overall survival among groups. Results Baseline characteristics among patients (n = 45 B, n = 90 W) were identified; these included Karnofsky performance status, PSA, Gleason score, alkaline phosphatase, albumin, hemoglobin, lactate dehydrogenase, opiate use for pain, and metastatic sites. Baseline characteristics among groups were similar except for median hemoglobin (B = 11.4 g/dl, W = 12.3 g/dl). The proportion of B patients achieving a≥90% PSA level decline was 37.8% vs. 28.9% for W patients (P = 0.296). Statistically significant differences were found in the proportion of patients achieving a≥50% PSA level decline (B = 68.9%, W = 48.9% [P = 0.028]) and≥30% PSA level decline (B = 77.8%, W = 54.4% [P = 0.008]). Rates of primary abiraterone-refractory disease (PSA increase as best response) trended higher in W (31.1%) than in B (15.6%) patients (P = 0.052). Median treatment duration (B = 9.4 mo, W = 8.3 mo) did not differ (Wilcoxon P = 0.444). Median overall survival (B = 27.3 mo [95% CI: 13.9, not estimable], W = 24.8 mo [95% CI: 19, 31.6] [P = 0.669]) and median time to PSA progression (B = 11.0 mo [95% CI: 4.3, 18.0], W = 9.4 mo [95% CI: 6.2, 13.0] [P = 0.917]) did not differ. Conclusions Black patients may have a higher PSA response to AA than white patients. An ongoing prospective clinical study (NCT01940276) is evaluating outcomes between black and white patients treated with AA.
AD  - S. Ramalingam, 3404 Wake Forest Road, Medical Office Building 7, Raleigh, NC, United States
AU  - Ramalingam, S.
AU  - Humeniuk, M. S.
AU  - Hu, R.
AU  - Rasmussen, J.
AU  - Healy, P.
AU  - Wu, Y.
AU  - Harrison, M. R.
AU  - Armstrong, A. J.
AU  - George, D. J.
AU  - Zhang, T.
DB  - Embase
Medline
DO  - 10.1016/j.urolonc.2016.12.016
IS  - 6
KW  - NCT01940276
abiraterone acetate
albumin
alkaline phosphatase
hemoglobin
lactate dehydrogenase
opiate
prostate specific antigen
albumin blood level
alkaline phosphatase blood level
article
Black person
cancer chemotherapy
cancer patient
castration resistant prostate cancer
Caucasian
clinical trial (topic)
controlled study
Gleason score
hemoglobin blood level
human
Karnofsky Performance Status
lactate dehydrogenase blood level
major clinical study
male
metastasis
overall survival
pain
post treatment survival
priority journal
race difference
retrospective study
time to treatment
treatment duration
treatment response
LA  - English
M3  - Article
N1  - L614168973
2017-01-26
2017-06-13
PY  - 2017
SN  - 1873-2496
1078-1439
SP  - 418-424
ST  - Prostate-specific antigen response in black and white patients treated with abiraterone acetate for metastatic castrate–resistant prostate cancer
T2  - Urologic Oncology: Seminars and Original Investigations
TI  - Prostate-specific antigen response in black and white patients treated with abiraterone acetate for metastatic castrate–resistant prostate cancer
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L614168973&from=export
http://dx.doi.org/10.1016/j.urolonc.2016.12.016
VL  - 35
ID  - 933
ER  - 

TY  - JOUR
AB  - OBJECTIVES: To estimate the incidence of prostate cancer among African-American men and Caribbean immigrants to the United States, to assess the applicability of large-scale prostate screening trials to a community screening program, and to recruit unscreened men. METHODS: African-American and Caribbean-American men were targeted with a community-based prostate cancer screening program in Jamaica, New York. Serum prostate-specific antigen determination and digital rectal examination were used to determine abnormal findings. The incidence of an abnormal screening examination was used to project the incidence of prostate cancer, which was compared with that in other reported trials. RESULTS: The projected incidence of prostate cancer among African-Americans and Caribbean-Americans older than 50 years was 8% and 7%, respectively, similar to that reported in other trials of African-American men. The projected incidence of prostate cancer in Caribbean-American men aged 40 to 49 years was 1%, the same as the high rate reported among Caribbean men. As in other trials, a family history of prostate cancer and age were strong predictors of abnormal findings. Of the recruited men older than 50 years, 58% had never been screened compared with 42% nationally. CONCLUSIONS: Large population-based screening trials have identified ethnic groups at high risk of prostate cancer. This trial detected high rates of abnormal screening findings by targeting ethnicity. The incidence of an abnormal examination was high in Caribbean-American men younger than 50 years old. Finally, this trial successfully recruited underscreened men.
AD  - Department of Urology, Cornell University Weill Medical College and New York Presbyterian Hospital, New York, New York 10021, USA.
AN  - 15882726
AU  - Shelton, J. B.
AU  - Barocas, D. A.
AU  - Conway, F.
AU  - Hart, K.
AU  - Nelson, K.
AU  - Richstone, L.
AU  - Gonzalez, R. R.
AU  - Raman, J. D.
AU  - Scherr, D. S.
DA  - May
DO  - 10.1016/j.urology.2004.11.047
DP  - NLM
ET  - 2005/05/11
IS  - 5
KW  - Adult
African Americans/*statistics & numerical data
Aged
Aged, 80 and over
Caribbean Region/ethnology
Ethnic Groups/*statistics & numerical data
Humans
Incidence
Male
Mass Screening
Middle Aged
New York/epidemiology
Palpation
Predictive Value of Tests
Prostate-Specific Antigen/*blood
Prostatic Neoplasms/epidemiology/*ethnology
LA  - eng
N1  - 1527-9995
Shelton, Jeremy B
Barocas, Daniel A
Conway, Frances
Hart, Kathleen
Nelson, Kinloch
Richstone, Lee
Gonzalez, Ricardo R
Raman, Jay D
Scherr, Douglas S
Journal Article
United States
Urology. 2005 May;65(5):931-6. doi: 10.1016/j.urology.2004.11.047.
PY  - 2005
SN  - 0090-4295
SP  - 931-6
ST  - Prostate-specific antigen screening in a high-risk population: lessons from the community and how they relate to large-scale population-based studies
T2  - Urology
TI  - Prostate-specific antigen screening in a high-risk population: lessons from the community and how they relate to large-scale population-based studies
VL  - 65
ID  - 604
ER  - 

TY  - JOUR
AB  - BACKGROUND: The U.S. Preventive Services Task Force (USPSTF) released a draft recommendation advising against prostate-specific antigen (PSA) testing in October 2011, a major shift from previous years of recommending neither for or against PSA testing due to insufficient evidence. PURPOSE: The purpose of this study was to assess men's awareness of the new recommendation, and their responses to it. METHODS: This study comprised a web survey of men aged 40-74 years that was conducted through GfK Custom Research, LLC's Knowledge Panel® from November 22 to December 2, 2011. Chi-square tests and logistic regression analyses were conducted to identify factors associated with disagreement with and intention to follow the recommendation. Data were analyzed in March 2012. RESULTS: The survey sample included 1089 men without a history of prostate cancer. After reviewing the recommendation, 62% agreed with the recommendation. Age and worry about getting prostate cancer were significantly related to disagreement with the recommendation. Only 13% of respondents were intenders (they planned to follow the U.S. Preventive Services Task Force recommendation and not get a prostate-specific antigen test in the future); 54% were non-intenders (they planned to not follow the U.S. Preventive Services Task Force recommendation and get a prostate-specific antigen test in the future; and 33% were undecided. Black race, higher income, having a PSA test in the past 2 years, and being somewhat/very worried about getting prostate cancer were all positively associated with being a non-intender. CONCLUSIONS: Study findings suggest that consumers are favorably disposed to PSA testing, despite new evidence suggesting that the harms outweigh the benefits. The new USPSTF recommendation against PSA testing in all men may be met with resistance.
AD  - Health Communication Program, RTI International, Rockville, MD 20852, USA. lsquiers@rti.org
AN  - 23867025
AU  - Squiers, L. B.
AU  - Bann, C. M.
AU  - Dolina, S. E.
AU  - Tzeng, J.
AU  - McCormack, L.
AU  - Kamerow, D.
DA  - Aug
DO  - 10.1016/j.amepre.2013.04.005
DP  - NLM
ET  - 2013/07/23
IS  - 2
KW  - Adult
*Advisory Committees
Age Factors
Aged
Attitude to Health
Chi-Square Distribution
Health Surveys
Humans
Male
*Mass Screening/methods/psychology
Middle Aged
Patient Participation
Preventive Health Services/*methods
Prostate-Specific Antigen/*blood
*Prostatic Neoplasms/blood/diagnosis/prevention & control/psychology
Regression Analysis
Risk Assessment
United States
LA  - eng
N1  - 1873-2607
Squiers, Linda B
Bann, Carla M
Dolina, Suzanne E
Tzeng, Janice
McCormack, Lauren
Kamerow, Douglas
Journal Article
Netherlands
Am J Prev Med. 2013 Aug;45(2):182-9. doi: 10.1016/j.amepre.2013.04.005.
PY  - 2013
SN  - 0749-3797
SP  - 182-9
ST  - Prostate-specific antigen testing: men's responses to 2012 recommendation against screening
T2  - Am J Prev Med
TI  - Prostate-specific antigen testing: men's responses to 2012 recommendation against screening
VL  - 45
ID  - 324
ER  - 

TY  - JOUR
AB  - Prostate-specific antigen (PSA) testing could be used to identify men who are at higher future risk of developing clinical prostate cancer or to diagnose prostate cancer earlier in high-risk groups, such as black men or those with a family history of the disease. These cohorts then could be offered chemopreventive clinical trial participation opportunities. The Physicians' Health Study and other longitudinal studies have shown that even between a PSA level of 1.0 and 4.0 ng/mL, the risk of future prostate cancer is incrementally increased. Department of Defense Studies of young men between 15 and 45 show that normal men have very low PSA values. Using a threshold PSA even as low as 1.5 ng/mL for men in their fifth decade is well beyond the 95th percentile of "normal" PSA. Young black men between 40 and 49 years old have a higher risk of prostate cancer than white men and should be pursued for chemoprevention studies. PSA is not perfect. Benign prostatic hyperplasia and inflammation (and, perhaps, other factors) can confound the use of PSA thresholds to identify men for chemoprevention or early detection. Certain chemopreventive agents may affect PSA physiology without affecting the disease process itself creating a meaningless epiphenomenon. Young black men may not generally be receptive to PSA testing or chemopreventive trials.
AD  - Urology Service, Department of Surgery, Walter Reed Army Medical Center, Washington, DC, USA. Jmoul@cpdr.org
AN  - 11295620
AU  - Moul, J. W.
DA  - Apr
DO  - 10.1016/s0090-4295(00)00967-5
DP  - NLM
ET  - 2001/04/11
IS  - 4 Suppl 1
KW  - Adult
African Continental Ancestry Group
Age Factors
Aged
Case-Control Studies
Clinical Trials as Topic
European Continental Ancestry Group
Forecasting
Humans
Male
Middle Aged
*Military Personnel
Prostate-Specific Antigen/*blood
Prostatic Hyperplasia/blood
Prostatic Neoplasms/*blood/ethnology/*prevention & control
Reference Values
Risk
United States
LA  - eng
N1  - 1527-9995
Moul, J W
Journal Article
United States
Urology. 2001 Apr;57(4 Suppl 1):174-7. doi: 10.1016/s0090-4295(00)00967-5.
PY  - 2001
SN  - 0090-4295
SP  - 174-7
ST  - Prostate-specific antigen-enhanced testing and risk stratification for chemoprevention trials
T2  - Urology
TI  - Prostate-specific antigen-enhanced testing and risk stratification for chemoprevention trials
VL  - 57
ID  - 687
ER  - 

TY  - JOUR
AB  - OBJECTIVES: African-Caribbean men have a risk of prostate cancer comparable to that of African-American men. To begin exploring potential risk factors for prostate cancer in these high-risk black subgroups, we conducted a pilot study in Brooklyn, New York, a community with large numbers of African-Americans and immigrants from Jamaica and Haiti. METHODS: Black men, 35 to 65 years of age, who were born in the United States, Jamaica, or Haiti were recruited in Brooklyn. The subjects' serum samples were analyzed for prostate-specific antigen (PSA) and the following hormones, which may be related to prostate cancer: testosterone, sex hormone-binding globulin, 3alpha-androstanediol glucuronide, insulin-like growth factor-1 (IGF-1), and IGF-binding protein-3 (IGFBP-3). Subgroup differences in PSA and hormonal levels, adjusted for relevant covariates, were explored using analysis of variance techniques. RESULTS: For 3 months, we recruited 21 U.S.-born, 20 Jamaican-born, and 24 Haitian-born black men using various methods. The mean age-adjusted PSA level was 1.04 ng/mL in the U.S.-born men, 1.09 ng/mL in the Jamaican-born men, and 0.85 ng/mL in the Haitian-born men (P = 0.55). The mean age-adjusted hormone levels, as well as testosterone/sex hormone-binding globulin and IGF-1/IGFBP-3 ratios, also were not significantly different statistically across the subgroups. CONCLUSIONS: It is feasible to conduct epidemiologic studies of prostate cancer in these high-risk black subgroups in Brooklyn. Our preliminary data suggest that the serum levels of PSA and potential hormonal risk factors are similar among U.S.-born, Jamaican-born, and Haitian-born black men. Larger follow-up studies are being planned to confirm these findings.
AD  - Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York 10032, USA.
AN  - 15351583
AU  - Chen, A. C.
AU  - MacChia, R. J.
AU  - Conway, F.
AU  - Magai, C.
AU  - Desai, M.
AU  - Neugut, A. I.
DA  - Sep
DO  - 10.1016/j.urology.2004.04.004
DP  - NLM
ET  - 2004/09/08
IS  - 3
KW  - Adult
*African Americans/statistics & numerical data
Aged
Androstane-3,17-diol/*analogs & derivatives/blood
Emigration and Immigration
*Ethnic Groups/statistics & numerical data
Feasibility Studies
Genetic Predisposition to Disease
Gonadal Steroid Hormones/*blood
Haiti/ethnology
Humans
Insulin-Like Growth Factor Binding Protein 3/*blood
Insulin-Like Growth Factor I/*analysis
Jamaica/ethnology
Male
Middle Aged
New York City/epidemiology
Patient Selection
Pilot Projects
Prostate-Specific Antigen/blood
Prostatic Neoplasms/*epidemiology
Risk Factors
Sex Hormone-Binding Globulin/analysis
Testosterone/blood
United States/ethnology
LA  - eng
N1  - 1527-9995
Chen, Allen C
MacChia, Richard J
Conway, Francine
Magai, Carol
Desai, Manisha
Neugut, Alfred I
P20 CA91372/CA/NCI NIH HHS/United States
Comparative Study
Evaluation Study
Journal Article
Research Support, U.S. Gov't, P.H.S.
United States
Urology. 2004 Sep;64(3):522-7. doi: 10.1016/j.urology.2004.04.004.
PY  - 2004
SN  - 0090-4295
SP  - 522-7
ST  - Prostate-specific antigen, sex steroid hormones, and the insulin-like growth factor axis in U.S.-born, Jamaican, and Haitian black men: a pilot study
T2  - Urology
TI  - Prostate-specific antigen, sex steroid hormones, and the insulin-like growth factor axis in U.S.-born, Jamaican, and Haitian black men: a pilot study
VL  - 64
ID  - 620
ER  - 

TY  - JOUR
AB  - The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial is enrolling 148,000 men and women ages 55-74 at ten screening centers nationwide with balanced randomization to intervention and control arms. For prostate cancer, men receive a digital rectal examination and a blood test for prostate-specific antigen. For lung cancer, men and women receive a posteroanterior view chest X-ray. For colorectal cancer, men and women undergo a 60-cm flexible sigmoidoscopy. For ovarian cancer, women receive a blood test for the CA125 tumor marker and transvaginal ultrasound. Members of the control arm continue with their usual care. Follow-up in both groups will continue for at least 13 years from randomization to assess health status and cause of death. The primary endpoint is mortality from the four PLCO cancers, which accounts for about 53% of all cancer deaths in men and 41% of cancer deaths in women in the United States each year. Blood specimens are collected from screened participants, buccal cell DNA from controls, and histology slides from cases; these are maintained in a biorepository. Participants complete a baseline questionnaire (covering health status and risk factors) and a dietary questionnaire. More than 12,000 participants were enrolled in the pilot phase (concluded in September 1994). Changes in the eligibility criteria followed. As of April 2000, enrollment exceeded 144,500. Data are scanned into designated on-site computers for uploading by participant identification number to the coordinating center for quality checks, archival storage, and preparation of analysis datasets for use by the National Cancer Institute (NCI). Scientific direction is provided by NCI scientists, trial investigators, external consultants, and an independent data safety and monitoring board. Performance and data quality are monitored via data edits, site visits, random record audits, and teleconferences. The PLCO trial is formally endorsed by the American Cancer Society and has been ranked by the American Urological Association as one of the most important prostate cancer studies being conducted. Special efforts to enroll black participants are cosponsored by the U.S. Centers for Disease Control and Prevention.
AD  - Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland 29892-7346, USA.
AN  - 11189683
AU  - Gohagan, J. K.
AU  - Prorok, P. C.
AU  - Hayes, R. B.
AU  - Kramer, B. S.
DA  - Dec
DO  - 10.1016/s0197-2456(00)00097-0
DP  - NLM
ET  - 2001/02/24
IS  - 6 Suppl
KW  - Aged
Colorectal Neoplasms/*diagnosis/prevention & control
Data Collection
Female
Humans
International Cooperation
Lung Neoplasms/*diagnosis/prevention & control
Male
*Mass Screening
Middle Aged
Multicenter Studies as Topic
Ovarian Neoplasms/*diagnosis/prevention & control
Patient Selection
Prostatic Neoplasms/*diagnosis/prevention & control
*Randomized Controlled Trials as Topic
LA  - eng
N1  - Gohagan, J K
Prorok, P C
Hayes, R B
Kramer, B S
Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial Project Team
Journal Article
United States
Control Clin Trials. 2000 Dec;21(6 Suppl):251S-272S. doi: 10.1016/s0197-2456(00)00097-0.
PY  - 2000
SN  - 0197-2456 (Print)
0197-2456
SP  - 251s-272s
ST  - The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status
T2  - Control Clin Trials
TI  - The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status
VL  - 21
ID  - 692
ER  - 

TY  - JOUR
AB  - The pathogenesis and treatment of ulcerative colitis remain poorly understood. The aim of the present study is to investigate the effects of black cumin (Nigella sativa) oil on rats with colitis. Experimental colitis was induced with 1 mL trinitrobenzene sulfonic acid (TNBS) in 40% ethanol by intracolonic administration with 8-cm-long cannula under ether anesthesia to rats in colitis group and colitis + black cumin oil group. Rats in the control group were given saline at the same volume by intracolonic administration. Black cumin oil (BCO, Origo "100% natural Black Cumin Seed Oil," Turkey) was given to colitis + black cumin oil group by oral administration during 3 days, 5 min after colitis induction. Saline was given to control and colitis groups at the same volume by oral administration. At the end of the experiment, macroscopic lesions were scored and the degree of oxidant damage was evaluated by colonic total protein, sialic acid, malondialdehyde, and glutathione levels, collagen content, and tissue factor, superoxide dismutase, and myeloperoxidase activities. Tissues were also examined by histological and cytological analysis. Proinflammatory cytokines [tumor necrosis factor-alpha (TNF-alpha), interleukin (IL)-1 beta, and IL-6], lactate dehydrogenase activity, and triglyceride and cholesterol levels were analyzed in blood samples. We found that black cumin oil decreased the proinflammatory cytokines, lactate dehydrogenase, triglyceride, and cholesterol, which were increased in colitis. BCO, by preventing inflammatory status in the blood, partly protected colonic tissue against experimental ulcerative colitis.
AN  - WOS:000287501500015
AU  - Isik, F.
AU  - Akbay, T. T.
AU  - Yarat, A.
AU  - Genc, Z.
AU  - Pisiriciler, R.
AU  - Caliskan-Ak, E.
AU  - Cetinel, S.
AU  - Altintas, A.
AU  - Sener, G.
DA  - Mar
DO  - 10.1007/s10620-010-1333-z
IS  - 3
N1  - 20658190
PY  - 2011
SN  - 0163-2116
SP  - 721-730
ST  - Protective Effects of Black Cumin (Nigella sativa) Oil on TNBS-Induced Experimental Colitis in Rats
T2  - Digestive Diseases and Sciences
TI  - Protective Effects of Black Cumin (Nigella sativa) Oil on TNBS-Induced Experimental Colitis in Rats
VL  - 56
ID  - 3098
ER  - 

TY  - JOUR
AB  - Medical decision making in the context of serious illness ideally involves a patient who understands his or her condition and prognosis and can effectively formulate and communicate his or her care preferences. To understand the relationships among these care processes, we analyzed baseline into-view data from veterans enrolled in a randomized controlled trial of a palliative care intervention. Participants were 400 inpatient veterans admitted with a physician-estimated risk of one-year mortality more than, 25 %; 260 (65 %) had cancer as the primary diagnosis. Patients who believed that they had a illness (89% sample) reported that their provider had communicated this to them more frequently than those who did not share that belief (78% vs. 22%, P < 0.001). Over half (53%) of the participants reported discussing their cam preferences with their providers and 66% reported such discussions with their family; 35% had a living will. In multivariate analysis, greater functional impairment was associated with patients having discussed their care preferences with providers (P < 0.05), whereas patient understanding of prognosis (P < 0.05), better quality of life (P < 0.01), and not being African American (P < 0.05) were associated with patients having discussed their care preferences with family higher education (P < 0.001), and not being African American (P < 0.01) were associated with having a living will. Patients with poor understanding of prognosis are less likely to discuss care preferences with family members, suggesting the importance of provider communication with patients regarding prognosis. Because functional decline may prompt physicians to discuss prognosis with patients, patients with relatively preserved function may particularly need such communication. J Pain Symptom Manage 2010;39:527-534. (C) 2010 U.S. Cancer Pain Relief Committee. Published by Elsevier Inc. All rights reserved.
AN  - WOS:000276578500006
AU  - Wagner, G. J.
AU  - Riopelle, D.
AU  - Steckart, J.
AU  - Lorenz, K. A.
AU  - Rosenfeld, K. E.
DA  - Mar
DO  - 10.1016/j.jpainsymman.2009.07.012
IS  - 3
N1  - 20171827
PY  - 2010
SN  - 0885-3924
SP  - 527-534
ST  - Provider Communication and Patient Understanding of Life-Limiting Illness and Their Relationship to Patient Communication of Treatment Preferences
T2  - Journal of Pain and Symptom Management
TI  - Provider Communication and Patient Understanding of Life-Limiting Illness and Their Relationship to Patient Communication of Treatment Preferences
VL  - 39
ID  - 3121
ER  - 

TY  - JOUR
AB  - PURPOSE: The Community Clinical Oncology Program (CCOP) and Minority-Based Community Clinical Oncology Program (MBCCOP) are provider-based research networks (PBRN) that improve minority enrollment in cancer-focused clinical trials. We hypothesized that affiliation with a PBRN may also mitigate racial differences in hospice enrollment for patients with lung cancer. METHODS: We used the SEER-Medicare data, linked to the National Cancer Institute's CCOP program data, to identify all patients (≥ age 65 years) with lung cancer, diagnosed from 2001 to 2007. We defined clinical treatment settings as CCOP, MBCCOP, academic, or community-affiliated and used multivariable logistic regression analysis to determine factors associated with hospice enrollment. RESULTS: Forty-one thousand eight hundred eighty-five (55.1%) patients with lung cancer enrolled in hospice before death. Approximately 55% of CCOP, 57% of MBCCOP, 57% of academic, and 52% of community patients enrolled. Patients who were more likely to enroll were female (odds ratio [OR], 1.36; 95% CI, 1.31 to 1.40); ≥ age 79 years (OR, 1.11; 95%CI, 1.06 to 1.16); white; lived in more educated areas; had minimal comorbidities; and had distant disease. Asian and black patients in academic (41.1% and 50.4%, respectively) and community practices (35.2% and 43.4%, respectively) were less likely to enroll in hospice compared with white patients (academic, 58.8%; community, 53.1%). However, hospice enrollment was equivalent for black and white patients in MBCCOP (59.5% v 57.2%) and CCOP (52.2% v 56.3%) practices. CONCLUSION: Minority patients with lung cancer receiving treatment in cancer-focused PBRN- affiliated practices have greater hospice enrollment than those treated in academic and community practices.
AD  - University of North Carolina School of Medicine; and University of North Carolina, Lineberger Comprehensive Cancer Center, Chapel, Hill, NC dopenn@unch.unc.edu.
University of North Carolina School of Medicine; and University of North Carolina, Lineberger Comprehensive Cancer Center, Chapel, Hill, NC.
AN  - 24781367
AU  - Penn, D. C.
AU  - Stitzenberg, K. B.
AU  - Cobran, E. K.
AU  - Godley, P. A.
C2  - PMC4094645
DA  - Jul
DO  - 10.1200/jop.2013.001268
DP  - NLM
ET  - 2014/05/02
IS  - 4
KW  - Aged
Aged, 80 and over
Cohort Studies
Community Health Services
Female
Hospices/*statistics & numerical data
Humans
Lung Neoplasms/*ethnology/*therapy
Male
Minority Groups/*statistics & numerical data
Palliative Care/statistics & numerical data
Primary Health Care
SEER Program
United States
LA  - eng
N1  - 1935-469x
Penn, Dolly C
Stitzenberg, Karyn B
Cobran, Ewan K
Godley, Paul A
U55/CCR921930-02/PHS HHS/United States
T32 CA128590/CA/NCI NIH HHS/United States
UL1TR000083/TR/NCATS NIH HHS/United States
N02 PC015105/PC/NCI NIH HHS/United States
T32 5T32CA128582-043/CA/NCI NIH HHS/United States
5R01CA124402/CA/NCI NIH HHS/United States
HHSN261200800726P/CO/NCI NIH HHS/United States
UL1 TR000083/TR/NCATS NIH HHS/United States
T325T32CA128590-04/CA/NCI NIH HHS/United States
R01 CA124402/CA/NCI NIH HHS/United States
N01PC35136/CA/NCI NIH HHS/United States
N01PC35139/CA/NCI NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.
J Oncol Pract. 2014 Jul;10(4):e182-90. doi: 10.1200/JOP.2013.001268. Epub 2014 Apr 29.
PY  - 2014
SN  - 1554-7477 (Print)
1554-7477
SP  - e182-90
ST  - Provider-based research networks demonstrate greater hospice use for minority patients with lung cancer
T2  - J Oncol Pract
TI  - Provider-based research networks demonstrate greater hospice use for minority patients with lung cancer
VL  - 10
ID  - 290
ER  - 

TY  - JOUR
AB  - Background: We have shown previously in multivariable analysis that AA men had 19% lower risk of death than C men with metastatic castration resistant prostate cancer (mCRPC) treated with a docetaxel (D) and prednisone (P) based regimen. The primary goal of this analysis was to compare ≥50%PSA decline and objective response rate (ORR) in C men, AA men, and Asian men with mCRPC treated with a DP based regimen. Methods:Individual patient data from 8,151 mCRPC men randomized on eight phase III trials to a D containing regimen were combined. Race used in the analysis was based on self‐report. The endpoints were ≥50% PSA decline from baseline defined by the PSA working group 2 and ORR (defined as complete or partial response). The logistic regression model was employed to assess the prognostic importance of race in predicting ≥50% PSA decline and ORR adjusting for treatment arm, performance status, and site of metastases. Results: Of 8,151, 7,687 (94%) patients had evaluable PSA data. Of 7,687 men, 6,535 (85%) were W, 445 (6%) were B, 395 (5%) were Asian and 312 (4%) had race unspecified. Men with race unspecified were excluded from the analysis, leaving 7,375 men. Percentage of patients who experienced PSA decline from baseline were: 64%, 58% and 62% in W, B and Asian men, respectively. In multivariable analysis adjusting for risk factors, the pooled odds ratios for PSA decline for AA vs. W were 0.9 (95% CI = 0.7‐1.1, p = 0.16) and 1.0 (95% CI = 0.8‐1.2, p = 0.92) for Asian vs. W. In 2,760 patients with measurable disease, the percentage of patients who had ORR were: 39%, 31% and 34% in W, B and Asian men, respectively. In multivariable analysis, the pooled odds ratios for ORR were 1.0 (95% CI = 0.7‐1.4) for B vs. W and 0.9 (95% CI = 0.6‐1.4) for Asian vs. W. Conclusions: There were no differences in PSA decline and ORR outcomes in W, B, or Asian men with mCRPC enrolled on these phase III clinical trials with DP.
AN  - CN-02011056
DO  - 10.1200/JCO.2019.37.15_suppl.5021
KW  - *Asian
*castration resistant prostate cancer
Adult
Cancer model
Cancer patient
Cancer prognosis
Conference abstract
Controlled study
Disease course
Drug therapy
Human
Male
Meta analysis
Metastasis
Patient coding
Phase 3 clinical trial (topic)
Race
Randomized controlled trial (topic)
Risk factor
Self report
M3  - Journal: Conference Abstract
PY  - 2019
ST  - PSA decline and objective response rates in White (W), Black (B), and Asian men with metastatic castration-resistant prostate cancer (mCRPC)
T2  - Journal of clinical oncology
TI  - PSA decline and objective response rates in White (W), Black (B), and Asian men with metastatic castration-resistant prostate cancer (mCRPC)
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02011056/full
VL  - 37
ID  - 1539
ER  - 

TY  - JOUR
AB  - Background: Enzalutamideis ahighly effective treatment in patients with metastatic castration resistant prostate cancer (mCRPC). Although Prostate Cancer Working Group Guidelines (PCWG) recommend continuing treatment until radiographic progression of disease (rPD) or clinical progression (cPD), many patients discontinue therapy for rising PSA alone. Methods: We conducted an open label, randomized phase 2 clinical trial in mCRPC patients (on testosterone suppression therapy) previously untreated with docetaxel, abiraterone, or enzalutamide, comparing enzalutamide alone or in combination with PROSTVAC, a therapeutic cancer vaccine designed to induce an anti‐tumor immune response. The study discontinued accrual after a planned interim analysis indicated no difference in progression between the two arms. Patients were followed beyond PSA progression (first of three confirmed PSA rises, evaluated monthly) until rPD per PCWG (scans done every 3 months per protocol). Results: A total of 57 patients were enrolled with a median follow up time of 55.4 months. Of those, 47 (82%) patients were Caucasian and seven (12%) patients were African American. The median age of patients on enrollment was 67.2 years. 49/57 (86%) patients had PSA progression and the median time to first PSA rise for all 57 patients combined was 6.4 months (95% CI: 3.7‐11.0 months) after starting enzalutamide. 38/57 (67%) patients experienced progressive disease (majority with rPD and 1/38 (3%) with cPD), with the median time to progression for all 57 patients of 23.3 months (95% CI: 16.1‐27.8 months). Conclusions: Consistent with PCWG recommendations, these data suggest that a rising PSA may not be a warning of near‐term clinically significant disease progression in mCRPC patients given the nearly 17‐month difference between the first rise in PSA and ultimate rPD or cPD seen in this analysis. These data highlight the need to continue to educate patients and providers on PCWG criteria for progression, which were also used in original trials that led to the FDA approval of enzalutamide, so as not to substantially limit the potential efficacy of mCRPC therapies such as enzalutamide.
AN  - CN-02097936
AU  - Gandhy, S. U.
AU  - Karzai, F.
AU  - Marte, J. L.
AU  - Bilusic, M.
AU  - McMahon, S.
AU  - Strauss, J.
AU  - Couvillon, A.
AU  - Williams, M.
AU  - Hankin, A.
AU  - Steinberg, S. M.
AU  - et al.
DO  - 10.1200/JCO.2020.38.6_suppl.105
IS  - 6
KW  - *cancer growth
*cancer patient
*castration resistant prostate cancer
African American
Aged
Cancer therapy
Caucasian
Clinical trial
Conference abstract
Controlled study
Disease free interval
Drug combination
Drug therapy
Follow up
Human
Immune response
Major clinical study
Male
Phase 2 clinical trial
Randomized controlled trial
M3  - Journal: Conference Abstract
PY  - 2020
ST  - PSA progression compared to radiographic or clinical progression in metastatic castration-resistant prostate cancer patients treated with enzalutamide
T2  - Journal of clinical oncology
TI  - PSA progression compared to radiographic or clinical progression in metastatic castration-resistant prostate cancer patients treated with enzalutamide
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02097936/full
VL  - 38
ID  - 1487
ER  - 

TY  - JOUR
AB  - The effectiveness of support group interventions for cancer patients has been established among White patients but has been virtually unstudied among minority patients. The current study represents the 1st randomized support group intervention targeted to African American women with breast cancer. Participants (N = 73) with nonmetastatic breast cancer were randomly assigned to an 8-week group intervention or an assessment-only control condition At 12 months, the intervention resulted in improved mood as well as improved general and cancer-specific psychological functioning among women with greater baseline distress or lower income. Subsequent research is needed to address effective methods of enrolling and following women with fewer psychosocial and financial resources, as they were the most likely to benefit from this particular intervention.
AN  - WOS:000182881000011
AU  - Taylor, K. L.
AU  - Lamdan, R. M.
AU  - Siegel, J. E.
AU  - Shelby, R.
AU  - Moran-Klimi, K.
AU  - Hrywna, M.
DA  - May
DO  - 10.1037/0278-6133.22.3.316
IS  - 3
N1  - 64
12790260
PY  - 2003
SN  - 0278-6133
SP  - 316-323
ST  - Psychological adjustment among African American breast cancer patients: One-year follow-up results of a randomized psychoeducational group intervention
T2  - Health Psychology
TI  - Psychological adjustment among African American breast cancer patients: One-year follow-up results of a randomized psychoeducational group intervention
VL  - 22
ID  - 2696
ER  - 

TY  - JOUR
AB  - Despite a decline in cigarette smoking over the past few decades, rates remain unacceptably high for certain segments of the population, such as urban African Americans (AAs). AA smokers, on average, smoke fewer cigarettes per day than European American samples; however, AA smokers are less likely to achieve abstinence during a quit attempt. Outcome expectancies have previously been association with cessation outcomes, but prior research has not examined expectancies among treatment-seeking AA light smokers. The 33-item Smoking Consequences Questionnaire-Adult (SCQ-A) was evaluated among 751 AA light smokers (i.e., <= 10 cigarettes per day) enrolled in a cessation trial. Exploratory factor analyses replicated the original 10-factor solution. Factors were significantly correlated (r = -.06-51, P < .001) and associated with expected demographic, psychosocial, and tobacco-related variables. Results provide initial validation of the SCQ-A among AA light smokers seeking cessation treatment and highlight the association of smoking expectancies with other tobacco-related and psychosocial factors in this sample.
AN  - WOS:000283304800002
AU  - Thomas, J. L.
AU  - Bronars, C. A.
AU  - Stewart, D. W.
AU  - Okuyemi, K. S.
AU  - Befort, C. A.
AU  - Nazir, N.
AU  - Mayo, M. S.
AU  - Jeffries, S. K.
AU  - Ahluwalia, J. S.
DO  - 10.1080/08897070802606345
IS  - 1
N1  - 19197778
PY  - 2009
SN  - 0889-7077
SP  - 14-25
ST  - Psychometric Properties of a Brief Smoking Consequences Questionnaire for Adults (SCQ-A) Among African American Light Smokers
T2  - Substance Abuse
TI  - Psychometric Properties of a Brief Smoking Consequences Questionnaire for Adults (SCQ-A) Among African American Light Smokers
VL  - 30
ID  - 3161
ER  - 

TY  - JOUR
AB  - Objective. In a randomized trial of women with early stage breast cancer undergoing adjuvant chemotherapy, two stress management interventions, tai chi training and spiritual growth groups, were compared to a usual care control group, to evaluate psychosocial functioning, quality of life (QOL), and biological markers thought to reflect cancer- and treatment-specific mechanisms. Method. The sample consisted of 145 women aged 27-75 years; 75% were Caucasian and 25% African American. A total of 109 participants completed the study, yielding a 75% retention rate. Grounded in a psychoneuroimmunology framework, the overarching hypothesis was that both interventions would reduce perceived stress, enhance QOL and psychosocial functioning, normalize levels of stress-related neuroendocrine mediators, and attenuate immunosuppression. Results. While interesting patterns were seen across the sample and over time, the interventions had no appreciable effects when delivered during the period of chemotherapy. Conclusions. Findings highlight the complex nature of biobehavioral interventions in relation to treatment trajectories and potential outcomes. Psychosocial interventions like these may lack sufficient power to overcome the psychosocial or physiological stress experienced during the chemotherapy treatment period. It may be that interventions requiring less activity and/or group attendance would have enhanced therapeutic effects, and more active interventions need to be tested prior to and following recovery from chemotherapy.
AD  - Virginia Commonwealth University School of Nursing, Richmond, VA 23298, USA.
AN  - 23762127
AU  - Robins, J. L.
AU  - McCain, N. L.
AU  - Elswick, R. K., Jr.
AU  - Walter, J. M.
AU  - Gray, D. P.
AU  - Tuck, I.
C2  - PMC3666296
DO  - 10.1155/2013/372908
DP  - NLM
ET  - 2013/06/14
LA  - eng
N1  - 1741-4288
Robins, Jo Lynne W
McCain, Nancy L
Elswick, R K Jr
Walter, Jeanne M
Gray, D Patricia
Tuck, Inez
M01 RR000065/RR/NCRR NIH HHS/United States
R01 CA114718/CA/NCI NIH HHS/United States
Journal Article
Evid Based Complement Alternat Med. 2013;2013:372908. doi: 10.1155/2013/372908. Epub 2013 May 14.
PY  - 2013
SN  - 1741-427X (Print)
1741-427x
SP  - 372908
ST  - Psychoneuroimmunology-Based Stress Management during Adjuvant Chemotherapy for Early Breast Cancer
T2  - Evid Based Complement Alternat Med
TI  - Psychoneuroimmunology-Based Stress Management during Adjuvant Chemotherapy for Early Breast Cancer
VL  - 2013
ID  - 329
ER  - 

TY  - JOUR
AB  - OBJECTIVE: It is well documented that stress is associated with negative health outcomes in cancer patients. The purpose of this study was to assess the effects of a novel mindfulness intervention called mindfulness-based art therapy (MBAT) versus standard educational support, on indices of stress and quality of life in breast cancer patients with high stress levels. METHODS: A total of 191 women were enrolled, stratified by age and stress level, and randomized to receive either an 8-week MBAT intervention or a breast cancer educational support program of equal time and duration. Psychosocial stress was measured using the Symptoms Checklist-90-Revised, and quality of life was measured using the Medical Outcomes Study Short-Form Health Survey at baseline, immediately post-intervention, and at 6 months. RESULTS: Results showed overall significant improvements in psychosocial stress and quality of life in both the MBAT and educational support groups immediately post-intervention; however, participants with high stress levels at baseline had significantly improved overall outcomes only in the MBAT group, both immediately post-intervention and at 6 months. In addition, at 6 months follow-up, participants attending five or more sessions trended toward retaining treatment effects better in the MBAT than in the control group. Finally, black women and white women were similar in terms of how they benefited from the MBAT intervention, even though white participants tended to have higher educational level and marital status. CONCLUSIONS: In conclusion, MBAT is associated with significant, sustained benefits across a diverse range of breast cancer patients, particularly those with high stress levels.
AD  - Jefferson-Myrna Brind Center of Integrative Medicine, Thomas Jefferson University, Philadelphia, PA, USA.
AN  - 23873790
AU  - Monti, D. A.
AU  - Kash, K. M.
AU  - Kunkel, E. J.
AU  - Moss, A.
AU  - Mathews, M.
AU  - Brainard, G.
AU  - Anne, R.
AU  - Leiby, B. E.
AU  - Pequinot, E.
AU  - Newberg, A. B.
DA  - Nov
DO  - 10.1002/pon.3320
DP  - NLM
ET  - 2013/07/23
IS  - 11
KW  - Adaptation, Psychological
Adult
Aged
Aged, 80 and over
Art Therapy/*methods
Breast Neoplasms/psychology/*therapy
Female
Follow-Up Studies
Health Status
Humans
Middle Aged
Mindfulness/*methods
Patient Education as Topic/*methods
Quality of Life/*psychology
Socioeconomic Factors
Stress, Psychological/diagnosis/psychology/*therapy
Treatment Outcome
LA  - eng
N1  - 1099-1611
Monti, Daniel A
Kash, Kathryn M
Kunkel, Elisabeth J
Moss, Aleeze
Mathews, Michael
Brainard, George
Anne, Ranni
Leiby, Benjamin E
Pequinot, Edward
Newberg, Andrew B
R01 CA111832/CA/NCI NIH HHS/United States
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
England
Psychooncology. 2013 Nov;22(11):2565-75. doi: 10.1002/pon.3320. Epub 2013 Jul 21.
PY  - 2013
SN  - 1057-9249
SP  - 2565-75
ST  - Psychosocial benefits of a novel mindfulness intervention versus standard support in distressed women with breast cancer
T2  - Psychooncology
TI  - Psychosocial benefits of a novel mindfulness intervention versus standard support in distressed women with breast cancer
VL  - 22
ID  - 323
ER  - 

TY  - JOUR
AB  - Background: Although colorectal cancer (CRC) is one of the most commonly diagnosed cancers and a major cause of cancer related mortality, very little is known about why screening adherence rates are low. First-degree relatives of CRC patients are the largest group of individuals at increased risk of CRC. Psychosocial factors related to CRC screening adherence were examined in a sample of siblings of individuals diagnosed with CRC. Method: To identify psychosocial factors related with participation in cancer screening examinations, 90 siblings of CRC patients were recruited. Adherence to screening by fecal occult blood test, flexible sigmoidoscopy and colonoscopy was the relevant factor. Sociodemographic variables, health locus of control (HLOC), perceived social support, knowledge about CRC and coping strategies were independent measures. Results: Significant differences were found in age, gender, retirement status, knowledge of sibling's illness, HLOC-powerful others, coping strategies (positive thinking, blaming others, seeking social support), perceived social support types (listening, affective, material) and social support sources (friends, work colleagues and health staff). Using stepwise logistic regression, the strongest predictor of adherence was knowledge of sibling's illness. Conclusions: The findings suggest that effective strategies to increase participation in CRC screening may include efforts to improve knowledge of sibling's illness, material social support and advice from health staff. (c) 2006 International Society for Preventive Oncology. Published by Elsevier Ltd. All rights reserved.
AN  - WOS:000241211500007
AU  - Gili, M.
AU  - Roca, M.
AU  - Ferrer, V.
AU  - Obrador, A.
AU  - Cabeza, E.
DO  - 10.1016/j.cdp.2006.06.005
IS  - 4
N1  - 16963195
PY  - 2006
SN  - 0361-090X
SP  - 354-360
ST  - Psychosocial factors associated with the adherence to a colorectal cancer screening program
T2  - Cancer Detection and Prevention
TI  - Psychosocial factors associated with the adherence to a colorectal cancer screening program
VL  - 30
ID  - 3227
ER  - 

TY  - JOUR
AB  - The purpose of this study was to investigate health beliefs associated with repeat mammography screening in African American women 51 years or older over a 5-year period. Long-term repeat mammography screening is inconsistent in African American women; therefore, this study measured demographic, knowledge, and health belief predictors of repeat screening. The theoretical framework for this study was the health belief model. Baseline data from a larger randomized controlled trial were analyzed using descriptive statistics and logistic regression. The sample consisted of 602 African American women with no breast cancer history and at least 1 reported screening mammogram in the past 5 years. They were recruited from 3 primary care health settings. Having been screened 4 to 5 times in the past 5 years was associated with more knowledge about screening guidelines and fewer perceived barriers to screening. Results point to the importance of collaborating with African American communities to promote life-long mammography screening by increasing access to culturally appropriate information on screening guidelines and ameliorating barriers to screening within the context of the African American experience.
AD  - Indiana University School of Nursing, Indianapolis, IN 46202-5107, USA. katrusse@iupui.edu
AN  - 16783125
AU  - Russell, K. M.
AU  - Champion, V. L.
AU  - Skinner, C. S.
DA  - May-Jun
DO  - 10.1097/00002820-200605000-00012
DP  - NLM
ET  - 2006/06/20
IS  - 3
KW  - African Americans/education/*ethnology
Aged
Aged, 80 and over
Educational Status
Female
Guideline Adherence
Health Behavior/ethnology
Health Knowledge, Attitudes, Practice
Health Services Accessibility
Health Services Needs and Demand
Humans
Logistic Models
Mammography/psychology/*statistics & numerical data
Mass Screening/psychology/*statistics & numerical data
Middle Aged
Midwestern United States
Nursing Methodology Research
Patient Acceptance of Health Care/*ethnology/statistics & numerical data
Practice Guidelines as Topic
Risk Assessment
Self Efficacy
Surveys and Questionnaires
Time Factors
Women/education/*psychology
LA  - eng
N1  - Russell, Kathleen M
Champion, Victoria L
Skinner, Celette Sugg
R01NR04081/NR/NINR NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
United States
Cancer Nurs. 2006 May-Jun;29(3):236-43. doi: 10.1097/00002820-200605000-00012.
PY  - 2006
SN  - 0162-220X (Print)
0162-220x
SP  - 236-43
ST  - Psychosocial factors related to repeat mammography screening over 5 years in African American women
T2  - Cancer Nurs
TI  - Psychosocial factors related to repeat mammography screening over 5 years in African American women
VL  - 29
ID  - 563
ER  - 

TY  - JOUR
AB  - Objective: Prior studies demonstrating minimal psychological consequences for women receiving genetic counseling/genetic testing (GC/GT) for hereditary breast and ovarian cancer rely on predominantly Caucasian women. We conducted a prospective follow-up of a subset of participants from a population-based study of Black breast cancer (BC) survivors receiving GC/GT for BRCA1 and BRCA2 mutations. Methods: Black women with invasive BC at age <= 50 years diagnosed between 2009 and 2012 were recruited through the Florida Cancer Registry. Participants (n= 215, age M= 44.7, SD= 6.2) were offered telephone pre- and post-test GC, a subset completed questionnaires assessing sociodemographic, clinical, and psychosocial variables. Results: There were no baseline differences in cancer-related distress, psychological distress, or quality of life between test result groups. Social well-being improved in women receiving negative results (P=.01), but no other outcomes demonstrated significant changes over time between groups. Conclusions: Our study is among the first to demonstrate minimal negative psychosocial outcomes following GC/GT among young Black BC survivors, irrespective of test results.
AN  - WOS:000452440800014
AU  - Gonzalez, B. D.
AU  - Hoogland, A. I.
AU  - Kasting, M. L.
AU  - Cragun, D.
AU  - Kim, J.
AU  - Ashing, K.
AU  - Holt, C. L.
AU  - Halbert, C. H.
AU  - Pal, T.
AU  - Vadaparampil, S. T.
DA  - Dec
DO  - 10.1002/pon.4887
IS  - 12
N1  - 30207419
PY  - 2018
SN  - 1057-9249
SP  - 2778-2785
ST  - Psychosocial impact of BRCA testing in young Black breast cancer survivors
T2  - Psycho-Oncology
TI  - Psychosocial impact of BRCA testing in young Black breast cancer survivors
VL  - 27
ID  - 2836
ER  - 

TY  - JOUR
AB  - Background: The debate about returning research results has revealed different perspectives among researchers, participants and advisory groups with participants generally interested in obtaining their results. Given this preference, policies regarding return of individual research results may affect whether a potential subject chooses to participate in a study. Public attitudes, particularly those of African-Americans, toward this issue have been understudied. Methods: In 2008-2009, we convened 10 focus groups in Durham, N.C. to explore attitudes about returning research results and how different policies might influence their likelihood to participate in genetic/genomic studies. Transcripts were complimented by a short anonymous survey. Of 100 participants, 73% were female and 76% African-American with a median age of 40-49 years. Results: Although there was general interest in obtaining genetics research results, particularly individual results, discussants recognized many potential complexities. The option to obtain research results (individual or summary) was clearly valued and lack thereof was potentially a deterrent for genetic/genomic research enrollment. Conclusions: Providing the option to learn research results may help strengthen relationships between investigators and participants and thereby serve as a positive influencing factor for minority communities. Consideration of the broader implications of returning research results is warranted. Engaging diverse publics is essential to gain a balance between the interests and burdens of participants and investigators. Copyright (C) 2011 S. Karger AG, Basel
AN  - WOS:000295161300004
AU  - O'Daniel, J.
AU  - Haga, S. B.
DO  - 10.1159/000324933
IS  - 6
N1  - 21555865
PY  - 2011
SN  - 1662-4246
SP  - 346-355
ST  - Public Perspectives on Returning Genetics and Genomics Research Results
T2  - Public Health Genomics
TI  - Public Perspectives on Returning Genetics and Genomics Research Results
VL  - 14
ID  - 3105
ER  - 

TY  - JOUR
AB  - Patient trust in personal medical information is critical to increasing adherence to physician recommendations and medications. One of the anticipated benefits of learning of one's genomic risk for common diseases is the increased adoption of screening, preventive care and lifestyle changes. However, the equivocal results thus far reported of the positive impact of knowledge of genomic risk on behavior change may be due to lack of patients' trust in the results. As part of a clinical study to compare two methods of communication of genomic risk results for Type 2 diabetes mellitus (T2DM), we assessed patients' trust and preferred methods of delivery of genomic risk information. A total of 300 participants recruited from the general public in Durham, NC were randomized to receive their genomic risk for T2DM in-person from a genetic counselor or online through the testing company's web-site. Participants completed a baseline survey and three follow-up surveys after receiving results. Overall, participants reported high levels of trust in the test results. Participants who received their results in-person from the genetic counselor were significantly more likely to trust their results than those who reviewed their results on-line (p = 0.005). There was not a statistically significant difference in levels of trust among participants with increased genetic risk, as compared to other those with decreased or same as population risk (p = 0.1154). In the event they undergo genomic risk testing again, 55 % of participants overall indicated they would prefer to receive their results online compared to 28 % that would prefer to receive future results in-person. Of those participants preferring to receive results online, 77 % indicated they would prefer to have the option to speak to someone if they had questions with the online results (compared to accessing results online without the option of professional consultation). This is the first study to assess satisfaction with genomic risk testing by the method of delivery of the test result. The higher rate of trust in results delivered in-person suggests that online access reports may not result in serious consideration of results and lack of adoption of recommended preventive recommendations.
AN  - WOS:000336334600012
AU  - Mills, R.
AU  - Barry, W.
AU  - Haga, S. B.
DA  - Jun
DO  - 10.1007/s10897-013-9674-3
IS  - 3
N1  - 24292896
PY  - 2014
SN  - 1059-7700
SP  - 401-408
ST  - Public Trust in Genomic Risk Assessment for Type 2 Diabetes Mellitus
T2  - Journal of Genetic Counseling
TI  - Public Trust in Genomic Risk Assessment for Type 2 Diabetes Mellitus
VL  - 23
ID  - 3008
ER  - 

TY  - JOUR
AB  - Women frequently fail to recognize that coronary heart disease (CHD), not breast cancer, is the primary cause of female mortality. CHD mortality among U.S. mainland Puerto Rican (PR) women is second only to African American women. It is unknown what PR women understand about their risk, what factors they believe contribute to CHD, or whether they know the atypical symptoms often experienced by women. Most CHD studies exclude Hispanic women. Those that do often aggregate their results, making subgroup variations invisible. This study explored awareness of CHD symptoms, risks, and help-seeking behaviors among 12 PR women. Focus group methodology revealed that participants were unaware of their risk and had misconceptions about CHD symptoms and contributing factors. Barriers to early recognition and treatment included lack of knowledge, gender role conflict (caregiver vs. care recipient), and fears of falsely alarming family members or the embarrassment of feeling 'dismissed' by health care providers.
AD  - Fairfield University, Fairfield, Connecticut 06430, USA. jlange@fairfield.edu
AN  - 105333166. Language: English. Entry Date: 20091127. Revision Date: 20150820. Publication Type: Journal Article
AU  - Lange, J.
AU  - Evans-Benard, S.
AU  - Cooper, J.
AU  - Fahey, E.
AU  - Kalapos, M.
AU  - Tice, D.
AU  - Wang-D'Amato, N.
AU  - Watsky, N.
DB  - CINAHL Complete
DO  - 10.1177/1054773809346539
DP  - EBSCOhost
IS  - 4
KW  - Attitude to Illness
Cardiovascular Risk Factors
Health Knowledge
Hispanic Americans
Adult
Attitude to Illness -- Evaluation
Audiorecording
Conceptual Framework
Descriptive Research
Female
Field Notes
Focus Groups
Funding Source
Health Beliefs -- Evaluation
Health Knowledge -- Evaluation
Leininger's Theory of Culture Care Diversity and Universality
Middle Age
New England
Puerto Rico
Qualitative Studies
Questionnaires
Research Subject Recruitment
Human
N1  - research. Journal Subset: Core Nursing; Nursing; Peer Reviewed; USA. Grant Information: Funded by a Fairfield University faculty research grant. NLM UID: 9208508.
PMID: NLM19741240.
PY  - 2009
SN  - 1054-7738
SP  - 291-306
ST  - Puerto Rican women's perceptions of heart disease risk
T2  - Clinical Nursing Research
TI  - Puerto Rican women's perceptions of heart disease risk
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105333166&site=ehost-live&scope=site
VL  - 18
ID  - 2039
ER  - 

TY  - JOUR
AB  - Is there a survival advantage in having lung metastasectomy for colorectal cancer? That is the research question of the PulMiCC trial (Pulmonary Metastasectomy in Colorectal Cancer). It is routine practice to screen patients for recurrence after primary excision. Lung metastases are the easiest to see as radio dense nodules against the black air‐filled lung on CT scans. But they are very rarely a cause of death and the fact is that they contribute little to the clinical course. From first principles it seem implausible that their removal of will alter survival other than in the theoretically possible situation when the visible lung nodules are the only remaining systemic blood borne dissemination. Practice is supported by a many observational studies reporting survival rates among patients with favourable prognostic features. There have never been control data presented. PulMiCC asks teams to acknowledge at the outset that because advice on metastasectomy is 'no' for many and 'yes' for a selected few, there must be a tipping point where there is uncertainty. Patients for whom there is uncertainty are the ones to be offered randomisation. PulMiCC has recruited >300 patients into the evaluation phase and >80 are randomised. PulMiCC is open to recruitment internationally.
AN  - CN-01473548
AU  - Treasure, T.
AU  - Brew-Graves, C.
AU  - Russell, C.
AU  - Macbeth, F.
DO  - 10.1111/codi.13054
KW  - *European
*colorectal cancer
*metastasis resection
*society
Blood
Cause of death
Computer assisted tomography
Disease course
Excision
Human
Lung
Lung metastasis
Lung nodule
Observational study
Patient
Randomization
Survival
Survival rate
Telecommunication
M3  - Journal: Conference Abstract
PY  - 2015
SP  - 103
ST  - PulMiCC trial (Pulmonary Metastasectomy in Colorectal Cancer)
T2  - Colorectal disease
TI  - PulMiCC trial (Pulmonary Metastasectomy in Colorectal Cancer)
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01473548/full
VL  - 17
ID  - 1626
ER  - 

TY  - JOUR
AB  - A physiology-oriented compartmental kinetics (POCK) model of alveolar retention of respirable, insoluble particles in rats was used to simulate the results of two subchronic inhalation tests with male Fischer rats exposed to submicron anatase TiO2 particles of either 250 or 20 nm average size (Oberdorster et al., 1994). Earlier, the ultrafine variety had been used in a lifetime study with female Wistar rats (Heinrich &amp; Fuhst, 1992) and the results were also subjected to POCK simulations. The database on anatase was not as extensive as in case of previous studies that used submicrometer carbonaceous aerosols. However, besides the usual results for the patterns of total lung burden and lymph node load, the new subchronic tests provided, for the first time, some data on anatase burdens of both the macrophage pool and the interstitium. Due to the scarcity of the data, the POCK simulation was not entirely unique, but good data representation was achieved with plausible model parameters. The substantial increase in interstitial deposits of the ultrafine anatase in comparison to the coarser sample required an increase by an order of magnitude for the rate coefficient of free particle mass transfer through the epithelial wall. The translocation of overloaded macrophages to the interstitium indicated a similar change, but Wistar rats appeared to have a lower base value. In general, the results of the simulations seem to confirm the usefulness and consistency of the model concept. At the end of the lifetime exposure study with ultra-fine anatase, conducted under high exposure rate indices up to 1330 mg/m3 × h/wk to achieve overload, Heinrich and Fuhst found lung tumors in 32% of the rats. This confirmed that overload carcinogenesis in rats is not related to molecular, DNA-reactive carcinogens. A previously proposed hypothesis of a critical dose for overload carcinogenesis in rats, which had been derived from experimental diesel soot and carbon black aerosol inhalation studies, yielded tumor induction characteristics for ultrafine anatase that were commensurable with the parameter values found for carbonaceous aerosols. This suggests that the integral over the residence time of the interstitial retention may be a consistent relative dose surrogate for overload lung tumor induction in rats. Its critical dose would correspond to a no-effect threshold. For the female Wistar rats and ultrafine anatase, this value was about 4000 mg × days. It matched closely, although probably by coincidence, the value for the female Wistar rats derived earlier from experimental diesel soot data. © 1995 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted.
AD  - Chemical Industry Institute of Toxicology, Research Triangle Park, NC, United States
Department of Environmental Medicine, University of Rochester, Medical School, Rochester, NY, United States
AU  - Stöber, W.
AU  - Morrow, P. E.
AU  - Oberdörster, G.
DB  - Scopus
DO  - 10.3109/08958379509002567
IS  - 7
M3  - Article
N1  - Cited By :7
Export Date: 22 March 2021
PY  - 1995
SP  - 1059-1074
ST  - Pulmonary retention of inhaled anatase (tio2) aerosols and lung tumor induction in rats simulated by a physiology-oriented model
T2  - Inhalation Toxicology
TI  - Pulmonary retention of inhaled anatase (tio2) aerosols and lung tumor induction in rats simulated by a physiology-oriented model
UR  - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0344635908&doi=10.3109%2f08958379509002567&partnerID=40&md5=1d2c8fe705fa238678f78f879cfc6d0e
VL  - 7
ID  - 2657
ER  - 

TY  - JOUR
AB  - BACKGROUND: Significant efforts have been made to increase access and accrual to clinical trials for minority cancer patients (MP). This meta-analysis looked for differences in survival and baseline quality of life (QOL) between MP and non-minority cancer patients (NMP). MATERIALS AND METHODS: Baseline QOL and overall survival times from 47 clinical trials (6513 patients) conducted at Mayo Clinic Cancer Center/North Central Cancer Treatment Group were utilized. Assessments included Uniscale, Linear Analogue Self Assessment, Symptom Distress Scale (SDS), Profile of Mood States and Functional Assessment of Cancer Therapy - General, each transformed into a 0-100 scale with higher scores indicating better outcomes. This transformation involves subtracting the lowest possible value from the assessment, dividing by the range of the scale (the maximum minus the minimum), and multiplying by 100. Analyses included Fisher's Exact tests, linear regression, Kaplan-Meier curves, and Cox proportional hazards models. RESULTS: Eight percent of patients self-reported as MP (0.45% American Indian/Alaskan Native, 0.7% Asian, 5% Black/African American, 1.5% Hispanic, 0.1% Native Hawaiian and 0.3% Other). MP had no meaningful deficits relative to non-MP in overall QOL but were slightly worse on FACT-G total score, physical, social/family, functional, and SDS nausea severity. MP with lung, neurological or GI cancers had significantly worse mean scores in nausea (58 vs. 69), sleep problems (34 vs. 54); emotional (53 vs. 74); and social/family (60 vs. 67), respectively. Regression models confirmed these results. After adjusting for disease site, there were no significant differences in survival. CONCLUSION: MP on these clinical trials indicated small deficits in physical, social, and emotional subscales at baseline compared to NMP. Within cancer sites, MP experienced large deficits for selected QOL domains that bear further attention.
AD  - Alliance Statistics and Data Center, Division of Biomedical Statistics Informatics, Mayo Clinic, Rochester, Minnesota, USA.
Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA.
Bixby Medical Center/Hickman Cancer Center, Sylvania, Ohio, USA.
College of Medicine, Ohio State University, Columbus, OH, USA.
AN  - 28691116
AU  - Tan, A. D.
AU  - Novotny, P. J.
AU  - Kaur, J. S.
AU  - Buckner, J. C.
AU  - Mowat, R. B.
AU  - Paskett, E.
AU  - Sloan, J. A.
C2  - PMC5500226
C6  - NIHMS870139
DA  - Mar-Aug
DP  - NLM
ET  - 2016/03/01
IS  - 1
LA  - eng
N1  - Tan, A D
Novotny, P J
Kaur, J S
Buckner, J C
Mowat, R B
Paskett, E
Sloan, J A
U10 CA037404/CA/NCI NIH HHS/United States
U54 CA153605/CA/NCI NIH HHS/United States
UG1 CA189823/CA/NCI NIH HHS/United States
U10 CA035415/CA/NCI NIH HHS/United States
U10 CA025224/CA/NCI NIH HHS/United States
Journal Article
J Cancer Clin Oncol. 2016 Mar-Aug;2(1):100112. Epub 2016 Nov 16.
PY  - 2016
ST  - QOL and Survival Comparisons by Race in Oncology Clinical Trials
T2  - J Cancer Clin Oncol
TI  - QOL and Survival Comparisons by Race in Oncology Clinical Trials
VL  - 2
ID  - 219
ER  - 

TY  - JOUR
AB  - A qualitative age interaction is defined as the reversal of relative risks or rates according to age at onset, and is often evident in studies that examine the etiology, prognosis and treatment of breast cancer. For example, incidence rates (or risks) are higher for aggressive when compared with indolent breast cancers prior to age 40-50 years, after which rates are higher for indolent tumors. Nulliparity and obesity decrease breast cancer risk in younger women, but increase risk in older women. Curves depicting the annual hazard of breast cancer death are shaped differently for the early- and late-onset tumors. Clinical trials for mammography screening, fenretinide chemoprevention and neo-adjuvant chemotherapy show opposite effects in younger and older women. Finally, high-risk/early onset breast cancers are more common among African-American women than Caucasian women, and this may partly account for the racial survival disparities. Taken together, these examples imply that aging may modify breast cancer risk, prognosis and treatment. These qualitative age interactions (or effect modifications) are important because they suggest that high-risk/early-onset and low-risk/late-onset breast cancers are different diseases, derived from different carcinogenic pathways. When age interactions are suspected, breast cancer studies should be stratified by early versus late age of onset or analyzed age specifically.
AD  - Division of Surgical Oncology, Department of Surgery, University of Texas Health Science Center, San Antonio, TX, USA. jatoi@uthscsa.edu
AN  - 21142663
AU  - Jatoi, I.
AU  - Anderson, W. F.
DA  - Nov
DO  - 10.2217/fon.10.139
DP  - NLM
ET  - 2010/12/15
IS  - 11
KW  - Age of Onset
Breast Neoplasms/*epidemiology/mortality/pathology
Continental Population Groups
Female
Humans
Randomized Controlled Trials as Topic
Risk Factors
LA  - eng
N1  - 1744-8301
Jatoi, Ismail
Anderson, William F
Intramural NIH HHS/United States
Journal Article
Research Support, N.I.H., Intramural
Review
England
Future Oncol. 2010 Nov;6(11):1781-8. doi: 10.2217/fon.10.139.
PY  - 2010
SN  - 1479-6694
SP  - 1781-8
ST  - Qualitative age interactions in breast cancer studies: a mini-review
T2  - Future Oncol
TI  - Qualitative age interactions in breast cancer studies: a mini-review
VL  - 6
ID  - 406
ER  - 

TY  - JOUR
AB  - This article presents a formative evaluation of a CDC Racial and Ethnic Approaches to Community Health (REACH) 2010 faith-based breast and cervical cancer early detection and prevention intervention for African American women living in urban communities. Focus groups were conducted with a sample of women (N = 94) recruited from each church participating in the intervention. One focus group was conducted in each of the nine participating churches following completion of the 6-month REACH 2010 intervention. Transcribed data were coded to identify relevant themes. Key findings included (a) the acceptability of receiving cancer education within the context of a faith community, (b) the importance of pastoral input, (c) the effectiveness of personal testimonies and lay health advocates, (d) the saliency of biblical scripture in reinforcing health messages, (e) the effectiveness of multimodal learning aids, and (f) the relationship between cervical cancer and social stigma. Study findings have implications for enhancing faith-based breast and cervical cancer prevention efforts in African American communities.
AN  - WOS:000240620200008
AU  - Matthews, A. K.
AU  - Berrios, N.
AU  - Darnell, J. S.
AU  - Calhoun, E.
DA  - Oct
DO  - 10.1177/1090198106288498
IS  - 5
N1  - 16861590
PY  - 2006
SN  - 1090-1981
SP  - 643-663
ST  - A qualitative evaluation of a faith-based breast and cervical cancer screening intervention for African American women
T2  - Health Education & Behavior
TI  - A qualitative evaluation of a faith-based breast and cervical cancer screening intervention for African American women
VL  - 33
ID  - 3209
ER  - 

TY  - JOUR
AB  - Although community partner engagement is a key component in faith-based health promotion/ disease prevention intervention research, the perspective of community partners on their experiences in the intervention process has been infrequently investigated. Semi-structured indepth interviews were conducted with 12 African- American community partners [i.e. four pastors and eight lay health co-ordinators (LHCs)] from eight churches in greater Baltimore, MD, USA, that engaged in a breast cancer educational intervention that followed a community-based participatory research (CBPR) approach. Audiotaped interviews were transcribed, coded and content analysis was used to identify themes across the codes. Findings show that pastors support a holistic approach to health and that LHCs act as a link between the pastors, participants and academic researchers. In addition, pastors and LHCs emphasized that the religious and/or spiritual program elements should not overpower the importance of reaching participants with critical health information regardless of their religious or spiritual beliefs. Study findings suggest that faith-based educational intervention efforts that follow a CBPR approach are important in promoting cancer awareness in the African- American community. Including community partner assessment can further elucidate critical intervention impacts and helps to address health disparities in underserved communities. (PsycINFO Database Record (c) 2016 APA, all rights reserved)
AD  - Rodriguez, Elisa M., Department of Health Behavior, School of Public Health and Health Professions, The State University of New York at Buffalo, 3435 Main Street, 321 Kimball Tower, Buffalo, NY, US, 14214
AN  - 2009-16320-003
AU  - Rodriguez, Elisa M.
AU  - Bowie, Janice V.
AU  - Frattaroli, Shannon
AU  - Gielen, Andrea
DB  - psyh
DO  - 10.1093/her/cyp010
DP  - EBSCOhost
IS  - 5
KW  - community partner experience
faith-based breast cancer educational intervention
health promotion
disease prevention
Adult
African Americans
Aged
Breast Neoplasms
Community-Based Participatory Research
Female
Health Education
Humans
Male
Mass Screening
Middle Aged
Religion and Medicine
Community Involvement
Faith Based Organizations
Prevention
Communities
N1  - Department of Health Behavior, School of Public Health and Health Professions, The State University of New York at Buffalo, Buffalo, NY, US. Release Date: 20090928. Correction Date: 20130909. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: English. Major Descriptor: Breast Neoplasms; Community Involvement; Faith Based Organizations; Health Promotion; Prevention. Minor Descriptor: Communities. Classification: Promotion & Maintenance of Health & Wellness (3365). Population: Human (10); Male (30); Female (40). Location: US. Age Group: Adulthood (18 yrs & older) (300); Thirties (30-39 yrs) (340); Middle Age (40-64 yrs) (360); Aged (65 yrs & older) (380). Methodology: Empirical Study; Longitudinal Study; Qualitative Study. References Available: Y. Page Count: 12. Issue Publication Date: Oct, 2009. Publication History: Accepted Date: Jan 28, 2009; First Submitted Date: Jul 14, 2008. Copyright Statement: All rights reserved. The Author. 2009.
Sponsor: Johns Hopkins Bloomberg, School of Public Health, Department of Health, Behavior and Society. Recipients: No recipient indicated
Sponsor: Susan G. Komen for the Cure. Grant: POP0403187. Recipients: No recipient indicated
PY  - 2009
SN  - 0268-1153
1465-3648
SP  - 760-771
ST  - A qualitative exploration of the community partner experience in a faith-based breast cancer educational intervention
T2  - Health Education Research
TI  - A qualitative exploration of the community partner experience in a faith-based breast cancer educational intervention
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2009-16320-003&site=ehost-live&scope=site
emr4@buffalo.edu
VL  - 24
ID  - 1790
ER  - 

TY  - JOUR
AB  - Study objective: The incidence of breast cancer increases with advancing age and yet women 65 and older (hereinafter referred to as 'older' women) do not always receive the most intensive treatments, such as adjuvant chemotherapy. The causes of underutilization of chemotherapy in this age group are poorly delineated. The purpose of the study was to explore older breast cancer patients' attitudes towards chemotherapy and factors that influenced their decisions to use or not use this treatment modality. Design: Qualitative methods were used to conduct race/ethnicity-specific focus groups. A thematic analysis was performed using NVIVO. Setting and Participants: Drawn from the Washington, DC area, participants were 34 ethnically diverse older breast cancer survivors (18 Caucasians, 10 African-Americans, and 6 Latinas). Focus groups were conducted in a local church; a senior center, and the Lombardi Cancer Center. Main Results: Results showed that many women felt they had no 'choice' and did what the doctor told them to do. For those who reported participation in the decision, time spent exchanging information with the woman's physician and the inclusion of family members promoted perceptions of optimum decision-making leading to the use of chemotherapy. Two barriers to using chemotherapy were negative expectations about side effects and lack of information specific to the woman's individuals' circumstances. Women of color reported less physician communication and information, in part due to language difficulties and perceived bias; these factors acted as barriers to chemotherapy. Conclusion: Physicians could provide specific and limited information to patients and family members to promote realistic expectations and optimum decisions about chemotherapy, given the risks involved in this treatment modality. Interventions should be developed and tested to enhance communication that is sensitive to older women's culture, family structure, illness experiences, preferences, and expectations. Copyright © 2006 John Wiley & Sons, Ltd.
AD  - J.S. Mandelblatt, Department of Oncology, Cancer Control Program, Georgetown University Medical Center, 3300 Whitehaven St. NW, Washington, DC 20007, United States
AU  - Kreling, B.
AU  - Figueiredo, M. I.
AU  - Sheppard, V. L.
AU  - Mandelblatt, J. S.
DB  - Embase
Medline
DO  - 10.1002/pon.1042
IS  - 12
KW  - tamoxifen
adjuvant chemotherapy
African American
aged
article
breast cancer
cancer center
cancer chemotherapy
cancer incidence
cancer patient
cancer survivor
Caucasian
clinical article
controlled study
cultural anthropology
doctor patient relationship
ethnicity
expectation
female
Hispanic
human
language
medical decision making
medical information
patient attitude
patient decision making
patient participation
personal experience
qualitative research
race
religion
thematic analysis
United States
LA  - English
M3  - Article
N1  - L46040594
2007-01-31
PY  - 2006
SN  - 1057-9249
1099-1611
SP  - 1065-1076
ST  - A qualitative study of factors affecting chemotherapy use in older women with breast cancer: Barriers, promoters, and implications for intervention
T2  - Psycho-Oncology
TI  - A qualitative study of factors affecting chemotherapy use in older women with breast cancer: Barriers, promoters, and implications for intervention
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L46040594&from=export
http://dx.doi.org/10.1002/pon.1042
VL  - 15
ID  - 1236
ER  - 

TY  - JOUR
AB  - Purpose. Participation in clinical trials (CTs) is low among rural communities. Investigators report difficulty recruiting rural individuals for CTs. The study pus pose was to identify recruitment barriers, motivators, and strategies to help increase access to and participation in CM in rural and urban communities. Approach. Qualitative focus groups/interviews. Setting. Rural and urban counties in one southeastern state. Participants. Two hundred twelve African-American and while men and women ages 21+. Method. Nineteen focus groups and nine interviews were conducted. Audio files were transcribed and organized into NVivo10 Recurring themes were examined by geographic location. Results. Although similar barriers, motivators, and strategies were reported by urban and rural groups, perceptions regarding their importance varied. Recruitment barriers mentioned in both rural and urban groups included few; side effects, limited understanding, limited time, and mistrust. Rural groups were more mindful of time commitment involved. Both rural and urban participants reported financial incentives as the top motivator to CT participation, followed by personal illness (urban groups) and benefits to family (rural groups). Recruitment strategies suggested by rural participants involved working with schools/churches and using word of mouth, whereas partnering with schools, word of mouth, and media were recommended most by urban groups. Conclusion. Perceived recruitment barriers, motivators, and strategies did not differ considerably between. rural and urban groups. Major barriers identified by participants should be addressed in future CT recruitment and education. efforts. Findings can. inform recruitment and communication strategies for reaching both urban and rural communities.
AN  - WOS:000354072100009
AU  - Friedman, D. B.
AU  - Foster, C.
AU  - Bergeron, C. D.
AU  - Tanner, A.
AU  - Kim, S. H.
DA  - May-Jun
DO  - 10.4278/ajhp.130514-QUAL-247
IS  - 5
N1  - 24670073
PY  - 2015
SN  - 0890-1171
SP  - 332-338
ST  - A Qualitative Study of Recruitment Barriers, Motivators, and Community-Based Strategies for Increasing Clinical Trials Participation Among Rural and Urban Populations
T2  - American Journal of Health Promotion
TI  - A Qualitative Study of Recruitment Barriers, Motivators, and Community-Based Strategies for Increasing Clinical Trials Participation Among Rural and Urban Populations
VL  - 29
ID  - 2978
ER  - 

TY  - JOUR
AB  - PURPOSE: Because insurers use performance and quality metrics to inform reimbursement, identifying remediable causes of poor-quality cancer care is imperative. We undertook this descriptive cohort study to assess key predictors of women's perceived quality of their breast cancer care and actual guideline-concordant quality of care received. PATIENTS AND METHODS: We surveyed inner-city women with newly diagnosed and surgically treated early-stage breast cancer requiring adjuvant treatment who were enrolled onto a randomized controlled trial (RCT) of patient assistance to reduce disparities in care. We assessed women's perceived quality of care and perceived quality of the process of getting care, such as getting referrals, test results, and treatments; we abstracted records to determine the actual quality of care. RESULTS: Of the 374 new patients with early-stage breast cancer enrolled onto the RCT, only a slight majority of women (55%) perceived their quality of care as excellent; 88% actually received good-quality, guideline-concordant care. Excellent perceived quality (P < .001) was significantly associated with patients' perception of the quality of the process of getting care (adjusted relative risk [RR], 1.78; 95% CI, 1.65 to 1.87). Also associated with perceived quality-and mediated by race-were trust in one's physician (adjusted RR, 1.43; 95% CI, 1.16 to 1.64) and perceived racism, which affected black women more than women of other races/ethnicities (black race-adjusted RR for perceived racism, 0.33 [95% CI, 0.10 to 0.87]; black race-adjusted RR for trust, 1.61 [95% CI, 0.97 to 1.90]; c = 0.82 for the model; P < .001). Actual quality of care provided did not affect perceived quality of care received. CONCLUSION: Patients' perceived quality of care differs from their receipt of high-quality care. Mutable targets to improve perceived quality of care include the processes of getting care and trusting their physician.
AD  - Mount Sinai School of Medicine, New York, NY 10029, USA. nina.bickell@mssm.edu
AN  - 22493417
AU  - Bickell, N. A.
AU  - Neuman, J.
AU  - Fei, K.
AU  - Franco, R.
AU  - Joseph, K. A.
C2  - PMC3383180 found at the end of this article.
DA  - May 20
DO  - 10.1200/jco.2011.38.7605
DP  - NLM
ET  - 2012/04/12
IS  - 15
KW  - Adult
Aged
Aged, 80 and over
Breast Neoplasms/diagnosis/ethnology/psychology/*therapy
Ethnic Groups/psychology
Female
Guideline Adherence
Health Care Surveys
*Health Knowledge, Attitudes, Practice/ethnology
Humans
Logistic Models
*Mastectomy/standards
Middle Aged
Neoplasm Staging
New York City
Odds Ratio
Patient Satisfaction
Patients/*psychology
*Perception
Physician-Patient Relations
Practice Guidelines as Topic
*Quality of Health Care/standards
Randomized Controlled Trials as Topic
*Urban Health Services/standards
LA  - eng
N1  - 1527-7755
Bickell, Nina A
Neuman, Jennifer
Fei, Kezhen
Franco, Rebeca
Joseph, Kathie-Ann
R01 CA107051/CA/NCI NIH HHS/United States
5R01CA107051-06/CA/NCI NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
J Clin Oncol. 2012 May 20;30(15):1791-5. doi: 10.1200/JCO.2011.38.7605. Epub 2012 Apr 9.
PY  - 2012
SN  - 0732-183X (Print)
0732-183x
SP  - 1791-5
ST  - Quality of breast cancer care: perception versus practice
T2  - J Clin Oncol
TI  - Quality of breast cancer care: perception versus practice
VL  - 30
ID  - 371
ER  - 

TY  - JOUR
AB  - Purpose/Objectives: To investigate whether quality of life (QOL) assessed before weight loss intervention predicts weight loss and, in turn, what the effect of weight loss is on QOL measures after 12 months in early-stage breast cancer survivors. Design: A clinical trial of a weight loss intervention in breast cancer survivors. Setting: Communitywide recruitment in Detroit, MI. Sample: 39 breast cancer survivors (body mass index = 30-44 kg/m(2)), within three years of initial diagnosis and at least three months after chemotherapy or radiation therapy. Methods: Participants were randomized to one of three weight loss methods or a control group. The Functional Assessment of Cancer Therapy-Anemia (FACT-An) QOL questionnaire was administered at baseline and after the intervention. Main Research Variables: Six subscales of the FACT-An and weight change. Findings: Modest but statistically significant associations were found for the physical and functional subscales of the FACT-An with weight loss for 39 subjects who completed 12 months of the study. Those reporting relatively impaired physical or functional QOL at baseline lost more weight, which accounted for 8%-9% of the weight loss variance beyond that resulting from the diet arm assignment. At 12 months, greater weight loss was associated with significant improvements in overall FACT-An score and in the physical, functional, fatigue, and anemia subscales (p < 0.05). Conclusions: Relatively low physical function at baseline was not a barrier to weight loss; indeed, it may have been a motivating factor in adherence to the weight loss intervention. Weight loss was associated with improvement in several QOL subscale measures in breast cancer survivors, but the emotional and social subscales were not affected. Implications for Nursing: Counseling for weight loss that includes recommendations for exercise should not be withheld for patients with relatively low physical functioning.
AN  - WOS:000243441000018
AU  - Darga, L. L.
AU  - Magnan, M.
AU  - Mood, D.
AU  - Hryniuk, W. M.
AU  - DiLaura, N. M.
AU  - Djuric, Z.
DA  - Jan
DO  - 10.1188/07.ONF.86-92
IS  - 1
N1  - 17562636
PY  - 2007
SN  - 0190-535X
SP  - 86-92
ST  - Quality of life as a predictor of weight loss in obese, early-stage breast cancer survivors
T2  - Oncology Nursing Forum
TI  - Quality of life as a predictor of weight loss in obese, early-stage breast cancer survivors
VL  - 34
ID  - 3204
ER  - 

TY  - JOUR
AB  - Social norms imposing a prevailing silence around breast cancer in rural African American communities have made it difficult for survivors to express their quality-of-life (QOL) concerns. In this article, the authors describe how they blended the photovoice method (providing participants with cameras so they can record, discuss, and relate the realities of their lives) with grounded theory techniques to assist 13 African American breast cancer survivors from rural eastern North Carolina in (a) exploring how they perceive and address their QOL within their own social context and (b) developing a conceptual framework of survivorship QOL. The framework that emerged reveals that three social forces (racism, stigmas regarding cancer, and cultural expectations of African American women) drive four QOL concerns (seeking safe sources of support, adjusting to the role of cancer survivor, feeling comfortable about the future, and serving as role models) and that survivors address these concerns by relying on spiritual faith and devising strategies to maintain social standing. © 2005 Sage Publications.
AD  - E.D.S. López, University of Florida at Gainesville, College of Public Health and Health Professions, Department of Clinical and Health Psychology, 101 S. Newell Drive, Gainesville, FL 32610-3151, United States
AU  - López, E. D. S.
AU  - Eng, E.
AU  - Randall-David, E.
AU  - Robinson, N.
DB  - Embase
Medline
DO  - 10.1177/1049732304270766
IS  - 1
KW  - adult
African American
aged
article
breast cancer
cancer patient
cancer survival
clinical article
concept formation
cultural anthropology
female
human
methodology
patient participation
priority journal
quality of life
race difference
religion
social status
social support
theoretical study
United States
videorecorder
LA  - English
M3  - Article
N1  - L41358750
2005-10-09
PY  - 2005
SN  - 1049-7323
SP  - 99-115
ST  - Quality-of-life concerns of African American breast cancer survivors within rural North Carolina: Blending the techniques of photovoice and grounded theory
T2  - Qualitative Health Research
TI  - Quality-of-life concerns of African American breast cancer survivors within rural North Carolina: Blending the techniques of photovoice and grounded theory
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L41358750&from=export
http://dx.doi.org/10.1177/1049732304270766
VL  - 15
ID  - 1275
ER  - 

TY  - JOUR
AB  - 1. * Purpose of project (one or two sentences): The feasibility phase of the proposed study is comprised of a two‐arm randomized pilot trial to evaluate the feasibility, satisfaction, and preliminary efficacy of 'Quit & Fit'. Women (N=40) will receive 12 weekly smoking cessation telephone counseling sessions. Participants will be randomized to either a fitness intervention (Quit & Fit) or a contact time control (Quit for Life). 2. * Study design (for example, hypothesis, research questions, standard and experimental procedures/drugs/devices or equipment, etc.): The Quit & Fit intervention will be designed as a 12‐week, tailored multiple health outcome intervention to promote smoking cessation, achieve energy balance, and reduce post‐cessation weight gain through regular PA and healthy nutrition for AAW smokers. Culturally tailored comprehensive interventions that address smoking‐cessation and obesity/weight‐control among AAW are needed. The conceptual basis of the proposal is Albert Bandura's social cognitive Theory (SCT), which posits that people learn through observation and modeling of behaviors, attitudes, and emotional reactions. When applied to smoking cessation and health behavior change, social learning can be viewed as a transition through stages of increased knowledge, self‐efficacy, and social support, culminating in readiness to change behaviors. The SCT model allows for targeting of factors relevant to a given individual and tailoring messages to each each participant's cultural values. Participants will be randomized into one of the study groups: the 'control arm' or the 'exercise arm'. Both groups will receive 12 weeks of smoking cessation counseling, telephone counseling and and will receive 10 weeks of nicotine replacement therapy (NRT) in the form of nicotine lozenges. Participants who are randomized to the 'control arm' will be asked to maintain their current daily activities for 12 weeks. They will also be required to visit the study site 3 times per week for 12 weeks to view videos on different wellness topics. Control participants will have anthropometric measurements of weight, height, hip size and waist size taken at the beginning of the study, 6 weeks, and at 12 weeks. Control participants will also have a fitness test on a treadmill, full body scan, blood pressure, heart rate and questionnaires given at the beginning of the study, 6 weeks and at 12 weeks. Participants who are randomized to the 'intervention arm' will be asked to come to the study site to exercise 3 days per week for 12 weeks. The exercise duration will increase over time from 75 minutes per week to 150 minutes per week. Intervention participants will have anthropometric measurements of weight, height, hip size and waist size taken at the beginning of the study, 6 weeks, and at 12 weeks. Intervention participants will also have a fitness test on a treadmill, full body scan, blood pressure, heart rate and questionnaires given at the beginning of the study, 6 weeks and at 12 weeks. The proposed design of the intervention is to provide high does of education, support, NR, and structured exercise to optimize success experiences that can build self‐doses in the first sessions. As the intervention progresses, support through mobile phones will be used to assist with problem solving and social support as participants transition to self‐management. Content will be based on the extant literature on tobacco cessation, nutrition, and exercise interventions, with emphasis given to published descriptions of interventions tailored for AAW. Examples of resources from which content may be drawn include Commit to Quit, Smoke Free Woman (NCI), Pathways to Freedom (2003 version), and the Diabetes Prevention Program. Key content messages will be developed for each counseling session. all print materials will be specifically targeted with visual images and content that has been found to engage AAW. Focus groups will be conducted with women representing the targeting population in order to develop the messages and visual content These qualitative data will be critical in the development of intervention materials that engage and connect with the women. Focus groups will be conducted during the first 3 months of the award, with the primary goal of furthering tailoring intervention materials and protocols to the lives of African‐American women residing in urban District of Columbia (DC) neighborhoods. A total of 4 groups will be run with 8 women in each. The demographic makeup of the groups will resemble that of our target population on such factors as educational attainment and socio‐economic status (SES). Participants will be recruited through outreach methods (flyers, community talks) used successfully by Dr. Adams‐Campbell's community lab. The multiple principal investigators (MPIs) will refine the focus group facilitator's guide and review focus group transcripts and notes to maintain protocol integrity. Open‐ended questions will probe views on target health behaviors as well as preferred information delivery modalities and ways to remain in contact and provide optimal support. All focus groups will be audio‐taped, with a research assistant taking notes at each of the sessions. Audiotapes will then be transcribed and translated in order to analyze their content. 3. * Rationale and justification for study (i.e. historical background, investigator's personal experience, pertinent medical literature, etc.): Smoking is the leading cause of preventable morbidity and mortality in the US. African Americans experience clear disparities in disease and death from smoking. African American women (AAW) are an important subgroup to study because they are distinct from non‐AAW and their male African American counterparts on biopsychosocial factors that are relevant to smoking behavior. In particular, AAW have lower smoking rates compared to Caucasian women (CAW) yet similar lung cancer rates. Additional evidence indicates that AAW are more likely to develop cancer of the larynx, esophageal cancer, cerebrovascular disease, and cardiovascular disease than CAW. African American smokers are less likely to be screened by providers for tobacco use, receive advice to quit, or use cessation aids during a quit attempt, even after controlling for health service use and socioeconomic factors. Smoking cessation is the single most important preventative health behavior AAW can engage in to significantly reduce their chances of morbidity and premature mortality related to smoking related illnesses. Due to their disparate smoking‐related health outcomes, targeted and tailored smoking cessation interventions are extremely critical for AAW. Along with the disease burden of tobacco use, sedentary lifestyles and obesity pose heightened concerns for chronic diseases such as diabetes and vascular disease among AAW. In 2008, AAW had higher incidence of and mortality attributed to coronary heart disease, stroke, heart failure, and high blood pressure, as compared to non‐Hispanic Whites or Hispanics. Energy balance is defined as the balance between energy taken in, generally by food and drink, and energy expanded. Lifestyle behaviors strongly linked to obesity are taken in, generally by low levels of physical activity (sedentary lifestyle) or high consumption rates of high‐fat or energy‐dense diets, or both. African Americans have been found to have different dietary traditions than Caucasians and to consume a higher percentage of calories from fat even after controlling for individual characteristics and neighborhood SES. Despite robust evidence of the cancer‐protective and health promoting influence of physical activity (PA), more than 50% of Americans do not engage in adequate levers of PA. A recent study identified both physical inactivity and smoking as two health behaviors for which relative inequalities are increasing among those with less formal education compared with those with more. SES‐related obesity disparities are also increasing in women and among African Americans. There is indeed a public health call for evidence‐based research on both egionally and culturally targeted energy balance strategies that can effectively reach and engage African Americans. Nearly all evidence‐based smoking cessation programs address the importance of post‐cessation weight gain through dietary choices and PA. However, these issues are not typically emphasized as centrally important to the likelihood of success of the cessation attempt. Likewise, weight control programs and initiatives that promote PA give only minimal attention to tobacco cessation. Questions remain about the most effective ways to implement interventions that simultaneously address multiple health behaviors. However, evidence continues to emerge to suggest that such interventions are not only feasible, but have advantages over approaches that focus on a single health promotion behavior. A targeted multiple health outcome intervention has promise to change health behaviors that will lead to improved health and ultimately reduce cancer death disparities among AAW. Culturally tailored comprehensive interventions that address smoking‐cessation and obesity/weight‐control among AAW are needed. This pilot project seeks to develop a combined health promotion intervention tailored for urban AAW smokers. "Quit & Fit" will be designed as a 12‐week program to promote smoking cessation and achieve energy balance through regular PA and healthy nutrition. The first several weeks of the intervention will provide maximum structured in‐person support which will be tapered over time and followed by tailored mobile phone sessions to provide ongoing support, counseling, and assist with the transition from initial structured counseling to self‐management. The program will employ evidence‐based strategies that meet the needs and preferences of AAW in an urban environment. Many studies have focused on the various health problems we aim to target, but in the other studies, these interventions have focused on only one aspect of the problem, e.g., smoking cessation alone or PA alone. The success of the proposed multiple health outcome intervention would also contribute novel findings to addressing the leading health behaviors (tobacco use, PA, diet) associated with morbidity and mortality among minority and low‐income populations in this country. The opportunity to engage women at one time across multiple behaviors in a targeted and cost‐effective way has significant implications. Moreover, the use of technology (cell phones) to provide support for adherence to the programs is at the cutting edge of health care delivery. Cell phones are a cost‐effective way to maintain contact with, and provide support to difficult‐to‐engage patients. As reviewed, tailored messages delivered by phone have been found effective to change energy balance among urban African Americans. Moreover, the focus of the study on building self‐efficacy through structured exercise and counseling in the initial sessions and then providing support transitioning behaviors from the structured sessions to the home environments is a unique design that can optimize retention and sustained behavior change. This program could have a profound impact on reducing tobacco‐related health disparities with important implications for developing cost‐efficient ways of engaging this and many other patient populations.
AN  - CN-01544747
AU  - Nct
PY  - 2014
ST  - Quit and Fit: a Tobacco Cessation and Energy Balance Pilot for African Americans
T2  - https://clinicaltrials.gov/show/NCT02103582
TI  - Quit and Fit: a Tobacco Cessation and Energy Balance Pilot for African Americans
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01544747/full
ID  - 1401
ER  - 

TY  - JOUR
AB  - BACKGROUND: It is unclear whether the disproportionately higher incidence and mortality from colorectal cancer among blacks compared with whites reflect differences in health-care utilization or colorectal cancer susceptibility. METHODS: A total of 60, 572 non-Hispanic white and black participants in the ongoing Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial underwent trial-sponsored screening flexible sigmoidoscopy (FSG) without biopsy at baseline in 10 geographically dispersed centers from November 1993 to July 2001. Subjects with polyps or mass lesions detected by FSG were referred to their physicians for diagnostic workup, the cost of which was not covered by PLCO. The records of follow-up evaluations were collected and reviewed. We used log binomial modeling with adjustment for age, education, sex, body mass index, smoking, family history of colorectal cancer, colon examination within previous 3 years, personal history of polyps, and screening center to examine whether utilization of diagnostic colonoscopy and yield of neoplasia differed by race. RESULTS: Among 57 561 whites and 3011 blacks who underwent FSG, 13,743 (23.9%) and 767 (25.5%) had abnormal examinations, respectively. A total of 9944 (72.4%) whites and 480 (62.6%) blacks had diagnostic colonoscopy within 1 year following the abnormal FSG screening. When compared with whites, blacks were less likely to undergo diagnostic evaluation (adjusted risk ratio = 0.88, 95% confidence interval = 0.83 to 0.93). Overall, among subjects with diagnostic colonoscopy (n = 10 424), there was no statistically significant difference by race in the prevalence of adenoma, advanced adenoma, advanced pathology in small adenomas (high-grade dysplasia or villous histology in adenomas <10 mm), or colorectal cancer. CONCLUSIONS: We observed a lower follow-up for screen-detected abnormalities among blacks when compared with whites but little difference in the yield of colorectal neoplasia. Health-care utilization may be playing more of a role in colorectal cancer racial disparity than biology.
AD  - Department of Medicine, Howard University College of Medicine, Howard University Cancer Center, Washington, DC 20060, USA. adeyinka.laiyemo@howard.edu
AN  - 20357245
AU  - Laiyemo, A. O.
AU  - Doubeni, C.
AU  - Pinsky, P. F.
AU  - Doria-Rose, V. P.
AU  - Bresalier, R.
AU  - Lamerato, L. E.
AU  - Crawford, E. D.
AU  - Kvale, P.
AU  - Fouad, M.
AU  - Hickey, T.
AU  - Riley, T.
AU  - Weissfeld, J.
AU  - Schoen, R. E.
AU  - Marcus, P. M.
AU  - Prorok, P. C.
AU  - Berg, C. D.
C2  - PMC2857802
DA  - Apr 21
DO  - 10.1093/jnci/djq068
DP  - NLM
ET  - 2010/04/02
IS  - 8
KW  - African Americans/*statistics & numerical data
Aged
Colonoscopy
Colorectal Neoplasms/*epidemiology/ethnology/genetics/mortality/*prevention &
control
Delivery of Health Care/*statistics & numerical data
Early Detection of Cancer
European Continental Ancestry Group/*statistics & numerical data
Female
Genetic Predisposition to Disease
Healthcare Disparities/*statistics & numerical data
Humans
Incidence
Lung Neoplasms/prevention & control
Male
Mass Screening/methods/statistics & numerical data
Middle Aged
Ovarian Neoplasms/prevention & control
Prostatic Neoplasms/prevention & control
Randomized Controlled Trials as Topic
Risk Factors
Sigmoidoscopy
Socioeconomic Factors
United States/epidemiology
LA  - eng
N1  - 1460-2105
Laiyemo, Adeyinka O
Doubeni, Chyke
Pinsky, Paul F
Doria-Rose, V Paul
Bresalier, Robert
Lamerato, Lois E
Crawford, E David
Kvale, Paul
Fouad, Mona
Hickey, Thomas
Riley, Thomas
Weissfeld, Joel
Schoen, Robert E
Marcus, Pamela M
Prorok, Philip C
Berg, Christine D
N01-CN-25524/CN/NCI NIH HHS/United States
N01-CN-25513/CN/NCI NIH HHS/United States
N01-CN-25511/CN/NCI NIH HHS/United States
N01-CN-75022/CN/NCI NIH HHS/United States
N01-CN-25514/CN/NCI NIH HHS/United States
N01-CN-25512/CN/NCI NIH HHS/United States
N01-CN-25515/CN/NCI NIH HHS/United States
K01 CA127118/CA/NCI NIH HHS/United States
R01 CA151736/CA/NCI NIH HHS/United States
N01-CN-25404/CN/NCI NIH HHS/United States
N01-CN-25516/CN/NCI NIH HHS/United States
N01-CN-25476/CN/NCI NIH HHS/United States
N01-CN-25518/CN/NCI NIH HHS/United States
U01 CA151736/CA/NCI NIH HHS/United States
N01-CN-25522/CN/NCI NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
J Natl Cancer Inst. 2010 Apr 21;102(8):538-46. doi: 10.1093/jnci/djq068. Epub 2010 Mar 31.
PY  - 2010
SN  - 0027-8874 (Print)
0027-8874
SP  - 538-46
ST  - Race and colorectal cancer disparities: health-care utilization vs different cancer susceptibilities
T2  - J Natl Cancer Inst
TI  - Race and colorectal cancer disparities: health-care utilization vs different cancer susceptibilities
VL  - 102
ID  - 427
ER  - 

TY  - JOUR
AB  - Purpose:ASCO recommends early involvement of palliative care for patients with advanced cancers on the basis of evidence from 18 randomized trials. We examined racial and ethnic minority representation in these trials and the role of race and ethnicity in the statistical analyses. The goal was to identify specific gaps in the palliative care evidence base for these individuals and potential strategies to address them.Methods:We reviewed the 18 trials cited in the 2012 and 2017 ASCO clinical statements on integrating palliative care into oncology. We extracted data on the reporting and categorization of race and ethnicity, on the enrollment of specific racial and ethnic minority groups, and on how race and ethnicity were addressed in the analyses.Results:One third of patient trials reported representation of specific racial and ethnic minority groups, one third reported rates of white versus other, and one third did not report race or ethnicity data. Among the patient trials with race and ethnicity data, 9.9% of participants were Asian, 8.8% Hispanic/Latino, and 5.7% African American. Analyses that used race and ethnicity were primarily baseline comparisons among randomized groups.Conclusion:Race and ethnicity were inconsistently reported in the trials. Among those that provided race and ethnicity data, representation of specific racial and ethnic minority groups was low. In addition to more research in centers with large minority populations, consistent reporting of race and ethnicity and supplementary data collection from minority patients who participate in trials may be strategies for improvement.
AN  - WOS:000437899100003
AU  - Pirl, W. F.
AU  - Saez-Flores, E.
AU  - Schlumbrecht, M.
AU  - Nipp, R.
AU  - Traeger, L. N.
AU  - Kobetz, E.
DA  - Jun
DO  - 10.1200/JOP.17.00016
IS  - 6
N1  - 29813013
PY  - 2018
SN  - 1554-7477
SP  - 374-+
ST  - Race and Ethnicity in the Evidence for Integrating Palliative Care Into Oncology
T2  - Journal of Oncology Practice
TI  - Race and Ethnicity in the Evidence for Integrating Palliative Care Into Oncology
VL  - 14
ID  - 2858
ER  - 

TY  - JOUR
AB  - BACKGROUND: The association between black race and worse outcomes in operable breast cancer reported in previous studies has been attributed to a higher incidence of more aggressive triple-negative disease, disparities in care, and comorbidities. We evaluated associations between black race and outcomes, by tumor hormone receptor and HER2 expression, in patients who were treated with contemporary adjuvant therapy. METHODS: The effect of black race on disease-free and overall survival was evaluated using Cox proportional hazards models adjusted for multiple covariates in a clinical trial population that was treated with anthracycline- and taxane-containing chemotherapy. Categorical variables were compared using the Fisher exact test. All P values are two-sided. RESULTS: Of 4817 eligible patients, 405 (8.4%) were black. Compared with nonblack patients, black patients had a higher rate of triple-negative disease (31.9% vs 17.2%; P < .001) and a higher body mass index (median: 31.7 vs 27.4 kg/m(2); P < .001). Black race was statistically significantly associated with worse disease-free survival (5-year disease-free survival, black vs nonblack: 76.7% vs 84.5%; hazard ratio of recurrence or death = 1.58, 95% confidence interval = 1.19 to 2.10, P = .0015) and overall survival (5-year overall survival, black vs nonblack: 87.6% vs 91.9%; hazard ratio of death = 1.49, 95% confidence interval = 1.05 to 2.12, P = .025) in patients with hormone receptor-positive HER2-negative disease but not in patients with triple-negative or HER2-positive disease. In a model that included black race, hormone receptor-positive HER2-negative disease vs other subtypes, and their interaction, the interaction term was statistically significant for disease-free survival (P = .027) but not for overall survival (P = .086). CONCLUSION: Factors other than disparities in care or aggressive disease contribute to increased recurrence in black women with hormone receptor-positive breast cancer.
AD  - Albert Einstein College of Medicine, Montefiore Medical Center-Weiler Division, 1825 Eastchester Rd, 2S-Rm 47, Bronx, NY 10461, USA. jsparano@montefiore.org
AN  - 22250182
AU  - Sparano, J. A.
AU  - Wang, M.
AU  - Zhao, F.
AU  - Stearns, V.
AU  - Martino, S.
AU  - Ligibel, J. A.
AU  - Perez, E. A.
AU  - Saphner, T.
AU  - Wolff, A. C.
AU  - Sledge, G. W., Jr.
AU  - Wood, W. C.
AU  - Davidson, N. E.
C2  - PMC3295746
DA  - Mar 7
DO  - 10.1093/jnci/djr543
DP  - NLM
ET  - 2012/01/18
IS  - 5
KW  - Adult
African Americans/*statistics & numerical data
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Biomarkers, Tumor/*analysis
Breast Neoplasms/chemistry/drug therapy/*ethnology/mortality/*pathology
Chemotherapy, Adjuvant
Clinical Trials, Phase III as Topic
Disease-Free Survival
Female
Healthcare Disparities
Humans
Kaplan-Meier Estimate
Mastectomy/methods
Middle Aged
Multivariate Analysis
Neoplasm Recurrence, Local/diagnosis/prevention & control
Neoplasm Staging
Odds Ratio
Randomized Controlled Trials as Topic
Receptor, ErbB-2/analysis
Receptors, Estrogen/analysis
Receptors, Progesterone/analysis
Retrospective Studies
Risk Factors
Survival Analysis
Taxoids/administration & dosage
Treatment Outcome
United States/epidemiology
LA  - eng
N1  - 1460-2105
Sparano, Joseph A
Wang, Molin
Zhao, Fengmin
Stearns, Vered
Martino, Silvana
Ligibel, Jennifer A
Perez, Edith A
Saphner, Tom
Wolff, Antonio C
Sledge, George W Jr
Wood, William C
Davidson, Nancy E
U10 CA023318/CA/NCI NIH HHS/United States
U10 CA066636/CA/NCI NIH HHS/United States
Comparative Study
Journal Article
J Natl Cancer Inst. 2012 Mar 7;104(5):406-14. doi: 10.1093/jnci/djr543. Epub 2012 Jan 16.
PY  - 2012
SN  - 0027-8874 (Print)
0027-8874
SP  - 406-14
ST  - Race and hormone receptor-positive breast cancer outcomes in a randomized chemotherapy trial
T2  - J Natl Cancer Inst
TI  - Race and hormone receptor-positive breast cancer outcomes in a randomized chemotherapy trial
VL  - 104
ID  - 376
ER  - 

TY  - JOUR
AN  - 10564668
AU  - Brawley, O. W.
AU  - Freeman, H. P.
DA  - Nov 17
DO  - 10.1093/jnci/91.22.1908
DP  - NLM
ET  - 1999/11/24
IS  - 22
KW  - African Americans/*statistics & numerical data
Antineoplastic Agents/*therapeutic use
Chemotherapy, Adjuvant
Clinical Medicine/standards
Clinical Trials as Topic/standards
Colonic Neoplasms/*drug therapy/*ethnology/surgery
European Continental Ancestry Group/*statistics & numerical data
Humans
National Institutes of Health (U.S.)
Randomized Controlled Trials as Topic
Survival Analysis
Survival Rate
Treatment Outcome
United States/epidemiology
LA  - eng
N1  - Brawley, O W
Freeman, H P
Comment
Editorial
United States
J Natl Cancer Inst. 1999 Nov 17;91(22):1908-9. doi: 10.1093/jnci/91.22.1908.
PY  - 1999
SN  - 0027-8874 (Print)
0027-8874
SP  - 1908-9
ST  - Race and outcomes: is this the end of the beginning for minority health research?
T2  - J Natl Cancer Inst
TI  - Race and outcomes: is this the end of the beginning for minority health research?
VL  - 91
ID  - 709
ER  - 

TY  - JOUR
AB  - BACKGROUND: Previous research suggests that disparities in non-small-cell lung cancer (NSCLC) survival can be explained in part by disparities in the receipt of cancer treatment. Few studies, however, have considered race and sex disparities in the timing and appropriateness of treatment across stages of diagnosis. OBJECTIVE: To evaluate the relationship of sex and race with the receipt of timely and clinically appropriate NSCLC treatment for each stage of diagnosis. METHOD: Surveillance Epidemiology and End Result data linked to Medicare claims for beneficiaries diagnosed with NSCLC between 1995 and 1999 were used to evaluate the relationship between race and sex with timely and appropriate NSCLC treatment while controlling for other demographic characteristics, comorbidities, socioeconomic status, and provider supply (N = 22,145). RESULTS: Overall adjusted rates of timely and appropriate treatment are 37.2%, 58.1%, and 29.2% for Medicare beneficiaries diagnosed with stage I or II, III, and IV NSCLC, respectively. Among stage I or II patients, women were 25% less likely to receive timely surgical resection relative to men, and blacks were 66% less likely to receive timely and appropriate treatment than whites. Black men were least likely to receive resection (22.2% compared with 43.7% for white men). Blacks were 34% less likely to receive timely surgery, chemotherapy, or radiation for stage III disease and were 51% less likely to receive chemotherapy in a timely fashion for stage IV disease relative to whites. CONCLUSION: Significant variations in appropriate timely treatment were found within and across stages of diagnosis, confirming that sex and race differences in NSCLC treatment exist.
AD  - RAND Corporation, 1776 Main Street, Santa Monica, CA 90407-2138, USA. lisas@rand.org
AN  - 19536007
AU  - Shugarman, L. R.
AU  - Mack, K.
AU  - Sorbero, M. E.
AU  - Tian, H.
AU  - Jain, A. K.
AU  - Ashwood, J. S.
AU  - Asch, S. M.
DA  - Jul
DO  - 10.1097/MLR.0b013e3181a393fe
DP  - NLM
ET  - 2009/06/19
IS  - 7
KW  - African Americans/ethnology/*statistics & numerical data
Aged
Aged, 80 and over
Carcinoma, Non-Small-Cell Lung/diagnosis/ethnology/*therapy
European Continental Ancestry Group/ethnology/*statistics & numerical data
Female
Guideline Adherence/statistics & numerical data
Health Services Accessibility/statistics & numerical data
Health Services Research
Healthcare Disparities/*statistics & numerical data
Humans
Insurance Claim Reporting/statistics & numerical data
Logistic Models
Lung Neoplasms/diagnosis/ethnology/*therapy
Male
Medicare/statistics & numerical data
Men
Multivariate Analysis
Patient Selection
Practice Guidelines as Topic
Practice Patterns, Physicians'/statistics & numerical data
SEER Program
Sensitivity and Specificity
Sex Factors
United States/epidemiology
Women
LA  - eng
N1  - 1537-1948
Shugarman, Lisa R
Mack, Katherine
Sorbero, Melony E S
Tian, Haijun
Jain, Arvind K
Ashwood, J Scott
Asch, Steven M
R04-RH03596-01-00/PHS HHS/United States
Comparative Study
Journal Article
Research Support, U.S. Gov't, P.H.S.
United States
Med Care. 2009 Jul;47(7):774-81. doi: 10.1097/MLR.0b013e3181a393fe.
PY  - 2009
SN  - 0025-7079
SP  - 774-81
ST  - Race and sex differences in the receipt of timely and appropriate lung cancer treatment
T2  - Med Care
TI  - Race and sex differences in the receipt of timely and appropriate lung cancer treatment
VL  - 47
ID  - 462
ER  - 

TY  - JOUR
AB  - PURPOSE: We assessed the impact of race on survival in men treated with external beam radiotherapy with or without hormonal therapy for localized prostate cancer in Radiation Therapy Oncology Group randomized trials. MATERIALS AND METHODS: Between 1975 and 1992, 2,048 men were treated for clinically localized prostate cancer in 1 of 4 consecutive prospective phase III randomized trials. After excluding nonblack and nonwhite men 2,012 remained for analysis. Patients were included in this analysis if they were deemed evaluable and eligible for the trial, and followup information and centrally reviewed pathological results were available. Short-term hormonal therapy consisted of goserelin acetate and flutamide administered 2 months before and during radiotherapy. Long-term hormonal therapy consisted of adjuvant goserelin acetate, which was generally given for 2 years or more. Pretreatment prostate specific antigen (PSA) findings were available in 430 cases (21%), including 213 treated with radiotherapy alone, 60 treated with short-term hormonal therapy and 157 on long-term hormonal therapy. Mean pretreatment PSA was 68.8 and 35.2 ng./ml. in black and white patients, respectively. Cox proportional hazards models were used to identify the impact of previously defined risk groups on overall and disease specific survival. Multivariate analysis was done for the significance of race using a stratified Cox model. Median followup in patients treated in early and late studies exceeded 11 and 6 years, respectively. RESULTS: On univariate analysis black race was associated with lower overall and disease specific survival (p = 0.04, RR = 1.24 and p = 0.016, RR = 1.41, respectively). After adjusting for risk group and treatment type (with or without short-term or long-term hormonal therapy) race was no longer associated with outcome (p >0.05). The trend for a persistent difference in survival was likely due to the higher tumor burden in black men, as reflected in higher PSA. CONCLUSIONS: As previously reported, tumor grade (Gleason score), palpation T stage, lymph node status, pretreatment PSA and treatment type are major predictors of overall and disease specific survival. We noted no evidence that race has independent prognostic significance in patients treated for prostate cancer in Radiation Therapy Oncology Group prospective randomized trials.
AD  - Department of Radiation Oncology, University of California-San Francisco, 1600 Divisadero Street, San Francisco, CA 94143-1708, USA.
AN  - 12478146
AU  - Roach, M., 3rd
AU  - Lu, J.
AU  - Pilepich, M. V.
AU  - Asbell, S. O.
AU  - Mohiuddin, M.
AU  - Grignon, D.
DA  - Jan
DO  - 10.1097/01.ju.0000041412.57484.cd
DP  - NLM
ET  - 2002/12/13
IS  - 1
KW  - *African Americans
Androgen Antagonists/therapeutic use
Antineoplastic Agents, Hormonal/therapeutic use
Clinical Trials, Phase III as Topic
Combined Modality Therapy
*European Continental Ancestry Group
Flutamide/therapeutic use
Goserelin/therapeutic use
Humans
Male
Multivariate Analysis
Prognosis
Proportional Hazards Models
Prospective Studies
Prostatic Neoplasms/*ethnology/mortality/radiotherapy/therapy
Randomized Controlled Trials as Topic
Risk Factors
Survival Rate
LA  - eng
N1  - Roach, Mack 3rd
Lu, Jiandong
Pilepich, Miljenko V
Asbell, Sucha O
Mohiuddin, Mohammed
Grignon, David
U10 CA 21661/CA/NCI NIH HHS/United States
U10 CA 32115/CA/NCI NIH HHS/United States
U10 CA 37422/CA/NCI NIH HHS/United States
Journal Article
Research Support, U.S. Gov't, P.H.S.
United States
J Urol. 2003 Jan;169(1):245-50. doi: 10.1097/01.ju.0000041412.57484.cd.
PY  - 2003
SN  - 0022-5347 (Print)
0022-5347
SP  - 245-50
ST  - Race and survival of men treated for prostate cancer on radiation therapy oncology group phase III randomized trials
T2  - J Urol
TI  - Race and survival of men treated for prostate cancer on radiation therapy oncology group phase III randomized trials
VL  - 169
ID  - 659
ER  - 

TY  - JOUR
AB  - Background: The impact of age-, gender-, and race-based differences on safety and efficacy in phase I clinical trials has not been well studied. Methods: We analyzed data from phase I clinical trials evaluating targeted biologic agents in patients with advanced solid malignancies. Race and gender distribution of enrolled patients was compared to the referral population demographics at the city, metro, and state levels. The association between age, gender, and race with type, frequency, and severity of treatment-emergent toxicities and clinical benefit was assessed using univariate and multivariable models. Results: Data from 117 eligible patients - Blacks/Caucasians/Others (27/85/5); male/female (66/51) - were obtained. Blacks were younger than Caucasian patients (median age of 56 vs. 62 years, p = 0.004). Nausea/vomiting was more frequent in female patients (43 vs. 24%, p = 0.03), while hematologic toxicity was more likely in Whites. While median time on treatment was comparable (113 vs. 91; p = 0.840), the median overall survival was significantly shorter for Blacks versus Caucasians (7.4 vs. 11.4 months; p = 0.0227). Black race (HR 2.11; 95% CI 1.24-3.60; p = 0.006) and older age (HR 1.03; 95% CI 1.00-1.06; p = 0.029) were associated with an increased risk of death. Conclusions: Age-, gender-, and race-based disparities were observed with specific toxicity and survival outcomes on phase I clinical trials of anticancer agents.
AU  - Owonikoko, T. K.
AU  - Busari, A. K.
AU  - Kim, S.
AU  - Chen, Z.
AU  - Akintayo, A.
AU  - Lewis, C.
AU  - Carthon, B. C.
AU  - Alese, O. B.
AU  - El-Rayes, B. F.
AU  - Ramalingam, S. S.
AU  - Harvey, R. D.
DB  - Embase
Medline
DO  - 10.1159/000488763
IS  - 3
KW  - NCT00406276
NCT00720148
NCT01183364
NCT01218555
NCT01529138
antineoplastic agent
axitinib
bortezomib
docetaxel
everolimus
ganetespib
lenalidomide
sunitinib
temsirolimus
adult
age
article
Black person
cancer survival
Caucasian
colorectal cancer
demography
disease severity
drug efficacy
drug safety
female
head and neck cancer
hematologic disease
human
kidney cancer
lung cancer
major clinical study
male
malignant neoplasm
middle aged
molecularly targeted therapy
mortality risk
nausea and vomiting
overall survival
pancreas cancer
phase 1 clinical trial (topic)
priority journal
race difference
salivary gland cancer
sex difference
thyroid cancer
toxic hepatitis
treatment duration
United States
university hospital
LA  - English
M3  - Article
N1  - L622682562
2018-06-28
2018-09-13
PY  - 2018
SN  - 1423-0232
0030-2414
SP  - 138-146
ST  - Race-, Age-, and Gender-Based Characteristics and Toxicities of Targeted Therapies on Phase i Trials
T2  - Oncology (Switzerland)
TI  - Race-, Age-, and Gender-Based Characteristics and Toxicities of Targeted Therapies on Phase i Trials
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L622682562&from=export
http://dx.doi.org/10.1159/000488763
VL  - 95
ID  - 889
ER  - 

TY  - JOUR
AB  - Purpose: Risk of multiple myeloma is increased in African American (AA) populations compared with European American (EA) cohorts. Current estimates of risk of progression of monoclonal gammopathy of undetermined significance (MGUS) are based largely on studies in EA cohorts. Prospective analyses of this risk in AA cohorts are lacking. Patients and Methods: Between 2003 and 2011, 331 eligible patients with IgG/A monoclonal gammopathy were enrolled in a prospective observational trial (SWOG S0120). Results: Of 331 eligible patients, 57 (17%) were of AA descent. The risk of transformation to clinical malignancy in AA patients was significantly lower than in non-AA cohort (2-year risk 5% vs. 15%; 5-year risk 13% vs. 24%; log-rank P ¼ 0.047). Differences in risk were evident for both MGUS and asymptomatic multiple myeloma. Gene expression profile (GEP) of CD138-purified plasma cells revealed that all molecular multiple myeloma subsets can be identified in both cohorts. However, the proportion of patients with high-risk GEP risk score (GEP-70 gene risk > -0.26) was lower in the AA cohort (0% vs. 33%, P ¼ 0.01). AA cohorts also have higher levels of antibodies against Epstein-Barr nuclear antigen-1 (EBNA-1; P < 0.001). Conclusions: These data provide the first prospective evidence that multiple myeloma precursor states in AA patients may have lower risk of disease compared with non-AA counterparts with lower incidence of high-risk GEP and increased EBV seropositivity. Race-dependent differences in biology and clinical risk of gammopathy may impact optimal management of these patients.
AD  - M.V. Dhodapkar, Emory University, 1364 Clifton Road Northeast, Atlanta, GA, United States
AU  - Dhodapkar, M. V.
AU  - Sexton, R.
AU  - Hoering, A.
AU  - van Rhee, F.
AU  - Barlogie, B.
AU  - Orlowski, R.
DB  - Embase
Medline
DO  - 10.1158/1078-0432.CCR-20-2119
IS  - 22
KW  - adult
American
article
cancer patient
cohort analysis
controlled study
Epstein Barr virus
female
gene expression profiling
genomics
human
human cell
incidence
major clinical study
male
monoclonal immunoglobulinemia
multiple myeloma
nonhuman
prospective study
protein expression
race
risk assessment
endogenous compound
Epstein Barr virus antigen 1
immunoglobulin G
syndecan 1
LA  - English
M3  - Article
N1  - L2011043076
2021-03-02
PY  - 2020
SN  - 1557-3265
1078-0432
SP  - 5814-5819
ST  - Race-dependent differences in risk, genomics, and Epstein-barr virus exposure in monoclonal gammopathies: Results of SWOG S0120
T2  - Clinical Cancer Research
TI  - Race-dependent differences in risk, genomics, and Epstein-barr virus exposure in monoclonal gammopathies: Results of SWOG S0120
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L2011043076&from=export
http://dx.doi.org/10.1158/1078-0432.CCR-20-2119
VL  - 26
ID  - 779
ER  - 

TY  - JOUR
AB  - BACKGROUND & AIMS: Colorectal cancer risk differs based on patient demographics. We aimed to measure the prevalence of significant colorectal polyps in average-risk individuals and to determine differences based on age, sex, race, or ethnicity. METHODS: In a prospective study, colonoscopy data were collected, using an endoscopic report generator, from 327,785 average-risk adults who underwent colorectal cancer screening at 84 gastrointestinal practice sites from 2000 to 2011. Demographic characteristics included age, sex, race, and ethnicity. The primary outcome was the presence of suspected malignancy or large polyp(s) >9 mm. The benchmark risk for age to initiate screening was based on white men, 50-54 years old. RESULTS: Risk of large polyps and tumors increased progressively in men and women with age. Women had lower risks than men in every age group, regardless of race. Blacks had higher risk than whites from ages 50 through 65 years and Hispanics had lower risk than whites from ages 50 through 80 years. The prevalence of large polyps was 6.2% in white men 50-54 years old. The risk was similar among the groups of white women 65-69 years old, black women 55-59 years old, black men 50-54 years old, Hispanic women 70-74 years old, and Hispanic men 55-59 years old. The risk of proximal large polyps increased with age, female sex, and black race. CONCLUSIONS: There are differences in the prevalence and location of large polyps and tumors in average-risk individuals based on age, sex, race, and ethnicity. These findings could be used to select ages at which specific groups should begin colorectal cancer screening.
AD  - Division of Gastroenterology, Department of Medicine, Oregon Health & Science University, Portland, Oregon. Electronic address: lieberma@ohsu.edu.
Division of Gastroenterology, Department of Medicine, Oregon Health & Science University, Portland, Oregon.
Department of Medical Informatics and Clinical Epidemiology, Oregon Health & Science University, Portland, Oregon.
Department of Family Medicine, Public Health and Preventive Medicine, Oregon Health & Science University, Portland, Oregon.
AN  - 24786894
AU  - Lieberman, D. A.
AU  - Williams, J. L.
AU  - Holub, J. L.
AU  - Morris, C. D.
AU  - Logan, J. R.
AU  - Eisen, G. M.
AU  - Carney, P.
C2  - PMC4121117
C6  - NIHMS590706
DA  - Aug
DO  - 10.1053/j.gastro.2014.04.037
DP  - NLM
ET  - 2014/05/03
IS  - 2
KW  - Adult
Age Factors
Aged
Aged, 80 and over
Colon/*pathology
Colonic Neoplasms/*diagnosis/*ethnology/pathology
Colonic Polyps/*diagnosis/*ethnology/pathology
*Colonoscopy
*Continental Population Groups
Disease Progression
*Ethnic Groups
Female
Humans
Male
Middle Aged
Patient Selection
Predictive Value of Tests
Prevalence
Prospective Studies
Risk Assessment
Risk Factors
Sex Factors
Time Factors
Tumor Burden
United States/epidemiology
Crc
Colon Cancer
Early Detection
Rate
organization that receives funding from federal and industry sources. This potential
conflict of interest has been reviewed and managed by the OHSU and Portland VA
Conflict of Interest in Research Committees. All other authors have no potential
conflicts of interest to disclose.
LA  - eng
N1  - 1528-0012
Lieberman, David A
Williams, J Lucas
Holub, Jennifer L
Morris, Cynthia D
Logan, Judith R
Eisen, Glenn M
Carney, Patricia
R33 DK061778/DK/NIDDK NIH HHS/United States
U01DK57132/DK/NIDDK NIH HHS/United States
R21 CA131626/CA/NCI NIH HHS/United States
U01 DK057132/DK/NIDDK NIH HHS/United States
R33-DK61778-01/DK/NIDDK NIH HHS/United States
R21-CA131626/CA/NCI NIH HHS/United States
Comparative Study
Journal Article
Research Support, N.I.H., Extramural
Webcast
Gastroenterology. 2014 Aug;147(2):351-8; quiz e14–5. doi: 10.1053/j.gastro.2014.04.037. Epub 2014 Apr 29.
PY  - 2014
SN  - 0016-5085 (Print)
0016-5085
SP  - 351-8; quiz e14–5
ST  - Race, ethnicity, and sex affect risk for polyps >9 mm in average-risk individuals
T2  - Gastroenterology
TI  - Race, ethnicity, and sex affect risk for polyps >9 mm in average-risk individuals
VL  - 147
ID  - 289
ER  - 

TY  - JOUR
AB  - BACKGROUND: Whether African-American women have biologically more aggressive breast carcinoma compared with white women and whether race acts as a significant independent prognostic factor for survival have not been determined. Alternatively, race merely may be a surrogate for socioeconomic status (SES). METHODS: A literature review was performed of clinical trials and retrospective studies in the U.S. that compared survival between white women and black women with breast carcinoma after adjustment for known prognostic factors (patient age, disease stage, lymph node status, and estrogen receptor status) to assess the impact of race and SES. RESULTS: Single institutional and clinical studies suggest that, when black patients are treated appropriately and other prognostic variables are controlled, their survival is similar to the survival of white patients. Twelve retrospective studies and 1 analysis of a clinical trial included SES and race as variables for survival. Only three of those studies revealed race as a significant prognostic factor for survival after adjusting for SES. CONCLUSIONS: SES replaces race as a predictor of worse outcome after women are diagnosed with breast carcinoma in many studies. However, black women present with more advanced disease that appear more aggressive biologically, and they present at a younger age compared with white women. Further research should be conducted concerning the precise elements of SES that account for the incidence of breast carcinoma, age at diagnosis, hormone receptor status, and survival to devise better strategies to improve outcome.
AD  - Joint Center for Radiation Therapy, Beth Israel Deaconess Medical Center, Brigham and Women's Hospital, Dana-Farber Cancer Institute, and Harvard Medical School, Boston, Massachusetts 02115, USA. ccross@partners.org
AN  - 12404294
AU  - Cross, C. K.
AU  - Harris, J.
AU  - Recht, A.
DA  - Nov 1
DO  - 10.1002/cncr.10830
DP  - NLM
ET  - 2002/10/31
IS  - 9
KW  - *African Americans
African Continental Ancestry Group
Age Factors
Breast Neoplasms/*ethnology/mortality/pathology
Clinical Trials as Topic
European Continental Ancestry Group
Female
Humans
Lymphatic Metastasis
Prognosis
Socioeconomic Factors
Survival Rate
United States/epidemiology
LA  - eng
N1  - Cross, Chaundré K
Harris, Jay
Recht, Abram
Comparative Study
Journal Article
Review
United States
Cancer. 2002 Nov 1;95(9):1988-99. doi: 10.1002/cncr.10830.
PY  - 2002
SN  - 0008-543X (Print)
0008-543x
SP  - 1988-99
ST  - Race, socioeconomic status, and breast carcinoma in the U.S: what have we learned from clinical studies
T2  - Cancer
TI  - Race, socioeconomic status, and breast carcinoma in the U.S: what have we learned from clinical studies
VL  - 95
ID  - 662
ER  - 

TY  - JOUR
AB  - OBJECTIVE: We examined prostate cancer patients' perceived engagement in treatment decision-making and associated factors by race/ethnicity in a multiethnic sample. METHOD: We identified patients through the California Cancer Registry. Patients completed a cross-sectional telephone interview in English, Spanish, Cantonese, or Mandarin. Multivariable logistic regression models, stratified by race/ethnicity, estimated the associations of patient demographic and health status characteristics on (1) doctor asked patient to help decide treatment plan and (2) patient and doctor worked out a treatment plan together. RESULTS: We included 855 prostate cancer patients: African American (19%), Asian American (15%), Latino (24%), and White (42%). Asian American patients were less likely than White patients to report that their doctors asked them to help decide a treatment plan (OR = 0.31; 95% CI = 0.18-0.53) and that they worked out a treatment plan with their doctors (OR = 0.54; 95% CI = 0.33-0.90). Language of interview was a significant contributing factor in stratified analysis for both outcomes. CONCLUSION: Asian American prostate cancer patients reported less engagement in treatment decision-making, with Chinese language being a significant contributing factor. Future research should identify patient-centered strategies that effectively engage underserved patients and support healthcare providers in shared decision-making with multiethnic and multilingual patients.
AD  - Division of General Internal Medicine at Zuckerberg San Francisco General Hospital, Department of Medicine, University of California, 1001 Potrero Avenue, Building 10, 3rd Floor, UCSF Box 1364, San Francisco, CA, 94143, USA. nynikka.palmer@ucsf.edu.
Division of General Internal Medicine, Department of Medicine, University of California San Francisco, San Francisco, CA, USA.
AN  - 29516434
AU  - Palmer, N. R.
AU  - Gregorich, S. E.
AU  - Livaudais-Toman, J.
AU  - Jih, J.
AU  - Kaplan, C. P.
C2  - PMC6526935
C6  - NIHMS1028084
DA  - Dec
DO  - 10.1007/s40615-018-0475-0
DP  - NLM
ET  - 2018/03/09
IS  - 6
KW  - Adult
African Americans
Aged
Asian Americans
*Cancer Survivors
Cross-Sectional Studies
Decision Making
*Ethnic Groups
European Continental Ancestry Group
Healthcare Disparities/*ethnology
Hispanic Americans
Humans
Logistic Models
Male
Middle Aged
Multivariate Analysis
*Patient Participation
Prostatic Neoplasms/*therapy
*Disparities
*Engagement
*Men
*Prostate cancer
*Treatment decision-making
Jane Jih, and Celia Kaplan declare that they have no conflict of interest.
LA  - eng
N1  - 2196-8837
Palmer, Nynikka R
Gregorich, Steven E
Livaudais-Toman, Jennifer
Jih, Jane
Kaplan, Celia P
R03 AG050880/AG/NIA NIH HHS/United States
HHSN261201000140C/CA/NCI NIH HHS/United States
HHSN261201000035C/CA/NCI NIH HHS/United States
P30 AG015272/AG/NIA NIH HHS/United States
HHSN261201000035I/CA/NCI NIH HHS/United States
HHSN261201000034C/CA/NCI NIH HHS/United States
U58 DP003862/DP/NCCDPHP CDC HHS/United States
L60 MD009289/MD/NIMHD NIH HHS/United States
Journal Article
J Racial Ethn Health Disparities. 2018 Dec;5(6):1273-1283. doi: 10.1007/s40615-018-0475-0. Epub 2018 Mar 7.
PY  - 2018
SN  - 2197-3792 (Print)
2196-8837
SP  - 1273-1283
ST  - Racial and Ethnic Differences in Prostate Cancer Survivors' Perceived Engagement in Treatment Decision-Making
T2  - J Racial Ethn Health Disparities
TI  - Racial and Ethnic Differences in Prostate Cancer Survivors' Perceived Engagement in Treatment Decision-Making
VL  - 5
ID  - 131
ER  - 

TY  - JOUR
AB  - Objective: To assess racial and ethnic disparities in care for Medicare fee-for-service (FFS) beneficiaries and whether disparities differ between health system-affiliated physician organizations (POs) and nonaffiliated POs. Data Sources: We used Medicare Data on Provider Practice and Specialty (MD-PPAS), Medicare Provider Enrollment, Chain, and Ownership System (PECOS), IRS Form 990, 100% Medicare FFS claims, and race/ethnicity estimated using the Medicare Bayesian Improved Surname Geocoding 2.0 algorithm. Study Design: Using a sample of 16 007 POs providing primary care in 2015, we assessed racial/ethnic disparities on 12 measures derived from claims (2 cancer screenings; diabetic eye examinations; continuity of care; two medication adherence measures; three measures of follow-up visits after acute care; all-cause emergency department (ED) visits, all-cause readmissions, and ambulatory care-sensitive admissions). We decomposed these “total” disparities into within-PO and between-PO components using models with PO random effects. We then pair-matched 1853 of these POs that were affiliated with health systems to similar nonaffiliated POs. We examined differences in within-PO disparities by affiliation status by interacting each nonwhite race/ethnicity with an affiliation indicator. Data Collection/Extraction methods: Medicare Data on Provider Practice and Specialty identified POs billing Medicare; PECOS and IRS Form 990 identified health system affiliations. Beneficiaries age 18 and older were attributed to POs using a plurality visit rule. Principal Findings: We observed total disparities in 12 of 36 comparisons between white and nonwhite beneficiaries; nonwhites received worse care in 10. Within-PO disparities exceeded between-PO disparities and were substantively important (>=5 percentage points or>=0.2 standardized differences) in nine of the 12 comparisons. Among these 12, nonaffiliated POs had smaller disparities than affiliated POs in two comparisons (P <.05): 1.6 percentage points smaller black-white disparities in follow-up after ED visits and 0.6 percentage points smaller Hispanic-white disparities in breast cancer screening. Conclusions: We find no evidence that system-affiliated POs have smaller racial and ethnic disparities than nonaffiliated POs. Where differences existed, disparities were slightly larger in affiliated POs. © Health Research and Educational Trust
AD  - RAND, Arlington, VA, United States
RAND, Santa Monica, CA, United States
David Geffen School of Medicine at UCLA and UCLA Fielding School of Public Health, Los Angeles, CA, United States
AU  - Timbie, J. W.
AU  - Kranz, A. M.
AU  - DeYoreo, M.
AU  - Eshete-Roesler, B.
AU  - Elliott, M. N.
AU  - Escarce, J. J.
AU  - Totten, M. E.
AU  - Damberg, C. L.
DB  - Scopus
DO  - 10.1111/1475-6773.13581
IS  - S3
KW  - delivery of health care
health care disparities
primary health care
quality of health care
race factors
M3  - Article
N1  - Cited By :2
Export Date: 22 March 2021
PY  - 2020
SP  - 1107-1117
ST  - Racial and ethnic disparities in care for health system-affiliated physician organizations and non-affiliated physician organizations
T2  - Health Services Research
TI  - Racial and ethnic disparities in care for health system-affiliated physician organizations and non-affiliated physician organizations
UR  - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85093847806&doi=10.1111%2f1475-6773.13581&partnerID=40&md5=71af77f740561585028ae30e9aebf81c
VL  - 55
ID  - 2172
ER  - 

TY  - JOUR
AB  - PURPOSE: We examined racial and ethnic disparities in patient-provider communication (PPC), perceived care quality, and patient activation among long-term cancer survivors. METHODS: In 2005 to 2006, survivors of breast, prostate, colorectal, ovarian, and endometrial cancers completed a mailed survey on cancer follow-up care. African American, Asian/Pacific Islander (Asian), Hispanic, and non-Hispanic white (white) survivors who had seen a physician for follow-up care in the past 2 years (n = 1,196) composed the analytic sample. We conducted linear and logistic regression analyses to identify racial and ethnic differences in PPC (overall communication and medical test communication), perceived care quality, and patient activation in clinical care (self-efficacy in medical decisions and perceived control). We further examined the potential contribution of PPC to racial and ethnic differences in perceived care quality and patient activation. RESULTS: Compared with white survivors (mean score, 85.16), Hispanic (mean score, 79.95) and Asian (mean score, 76.55) survivors reported poorer overall communication (P = .04 and P < .001, respectively), and Asian survivors (mean score, 79.97) reported poorer medical test communication (P = .001). Asian survivors were less likely to report high care quality (odds ratio, 0.47; 95% CI, 0.30 to 0.72) and reported lower self-efficacy in medical decisions (mean score, 74.71; P < .001) compared with white survivors (mean score, 84.22). No disparity was found in perceived control. PPC was positively associated with care quality (P < .001) and self-efficacy (P < .001). After adjusting for PPC and other covariates, when compared with whites, Asian disparities remained significant. CONCLUSION: Asian survivors report poorer follow-up care communication and care quality. More research is needed to identify contributing factors beyond PPC, such as cultural influences and medical system factors.
AD  - Nynikka R.A. Palmer, San Francisco General Hospital, University of California, San Francisco, San Francisco; Ingrid Oakley-Girvan, Cancer Prevention Institute of California, Fremont; Ann S. Hamilton, Keck School of Medicine, University of Southern California, Los Angeles, CA; Erin E. Kent, Neeraj K. Arora, Julia H. Rowland, Danielle Blanch-Hartigan, National Cancer Institute, National Institutes of Health; Noreen M. Aziz, National Institute of Nursing Research, National Institutes of Health, Bethesda, MD; Laura P. Forsythe, Patient-Centered Outcomes Research Institute, Washington, DC; and Kathryn E. Weaver, Wake Forest School of Medicine, Winston-Salem, NC. palmern@medsfgh.ucsf.edu.
Nynikka R.A. Palmer, San Francisco General Hospital, University of California, San Francisco, San Francisco; Ingrid Oakley-Girvan, Cancer Prevention Institute of California, Fremont; Ann S. Hamilton, Keck School of Medicine, University of Southern California, Los Angeles, CA; Erin E. Kent, Neeraj K. Arora, Julia H. Rowland, Danielle Blanch-Hartigan, National Cancer Institute, National Institutes of Health; Noreen M. Aziz, National Institute of Nursing Research, National Institutes of Health, Bethesda, MD; Laura P. Forsythe, Patient-Centered Outcomes Research Institute, Washington, DC; and Kathryn E. Weaver, Wake Forest School of Medicine, Winston-Salem, NC.
AN  - 25403220
AU  - Palmer, N. R.
AU  - Kent, E. E.
AU  - Forsythe, L. P.
AU  - Arora, N. K.
AU  - Rowland, J. H.
AU  - Aziz, N. M.
AU  - Blanch-Hartigan, D.
AU  - Oakley-Girvan, I.
AU  - Hamilton, A. S.
AU  - Weaver, K. E.
C2  - PMC4265119 online at www.jco.org. Author contributions are found at the end of this article.
DA  - Dec 20
DO  - 10.1200/jco.2014.55.5060
DP  - NLM
ET  - 2014/11/19
IS  - 36
KW  - Adult
African Americans
Aged
Aged, 80 and over
Asian Continental Ancestry Group
*Communication
European Continental Ancestry Group
Female
*Healthcare Disparities
Hispanic Americans
Humans
Logistic Models
Male
Middle Aged
Neoplasms/ethnology/*therapy
*Patient Participation
*Physician-Patient Relations
*Quality of Health Care
Survivors
LA  - eng
N1  - 1527-7755
Palmer, Nynikka R A
Kent, Erin E
Forsythe, Laura P
Arora, Neeraj K
Rowland, Julia H
Aziz, Noreen M
Blanch-Hartigan, Danielle
Oakley-Girvan, Ingrid
Hamilton, Ann S
Weaver, Kathryn E
N01-PC-35139/PC/NCI NIH HHS/United States
HHSN261201100189P/PHS HHS/United States
R25-CA-122061/CA/NCI NIH HHS/United States
L30 CA153405/CA/NCI NIH HHS/United States
R25 CA122061/CA/NCI NIH HHS/United States
N01PC35136/CA/NCI NIH HHS/United States
N01PC35139/CA/NCI NIH HHS/United States
N01-PC-35136/PC/NCI NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
J Clin Oncol. 2014 Dec 20;32(36):4087-94. doi: 10.1200/JCO.2014.55.5060. Epub 2014 Nov 17.
PY  - 2014
SN  - 0732-183X (Print)
0732-183x
SP  - 4087-94
ST  - Racial and ethnic disparities in patient-provider communication, quality-of-care ratings, and patient activation among long-term cancer survivors
T2  - J Clin Oncol
TI  - Racial and ethnic disparities in patient-provider communication, quality-of-care ratings, and patient activation among long-term cancer survivors
VL  - 32
ID  - 271
ER  - 

TY  - JOUR
AB  - PURPOSE/OBJECTIVES: To characterize the perspectives of partners (husbands or significant others) of patients with breast cancer in the treatment decision-making process and to evaluate racial and ethnic differences in decision outcomes. DESIGN: A cross-sectional survey. SETTING: Los Angeles, CA, and Detroit, MI. SAMPLE: 517 partners of a population-based sample of patients with breast cancer four years post-treatment. METHODS: A self-administered mailed questionnaire. Chi-square tests and logistic regression were used to assess associations between race and ethnicity and decision outcomes. MAIN RESEARCH VARIABLES: Decision regret and three elements of the decision process: information received, actual involvement, and desired involvement. FINDINGS: Most partners reported receiving sufficient information (77%), being involved in treatment decisions (74%), and having sufficient involvement (73%). Less-acculturated Hispanic partners were more likely than their Caucasian counterparts to report high decision regret (45% versus 14%, p<0.001). Factors significantly associated (p<0.05) with high decision regret were insufficient receipt of treatment information, low involvement in decision making, and a desire for more involvement. CONCLUSIONS: Partners were generally positive regarding their perspectives about participating in the breast cancer treatment decision-making process. However, less acculturated Hispanic partners were most vulnerable to decision regret. In addition, high decision regret was associated with modifiable elements of the decision-making process. IMPLICATIONS FOR NURSING: Attention should be paid to ensuring racial and ethnic minority partners are sufficiently involved in breast cancer treatment decisions and receive decision support.
AD  - Minneapolis Veterans Affairs Medical Center in Minnesota.
Department of Health Behavior and Health Education, University of Michigan in Ann Arbor.
School of Nursing, University of Michigan in Ann Arbor.
Cancer Institute of New Jersey, Robert Wood Johnson Medical School, New Brunswick, NJ.
Department of Family Medicine, Wayne State University, Detroit, MI.
Department of Preventive Medicine, University of Southern California in Los Angeles.
Department of Internal Medicine, University of Michigan.
Department of Internal Medicine, University of Michigan and Ann Arbor Veterans Affairs Healthcare System.
AN  - 24368235
AU  - Lillie, S. E.
AU  - Janz, N. K.
AU  - Friese, C. R.
AU  - Graff, J. J.
AU  - Schwartz, K.
AU  - Hamilton, A. S.
AU  - Gay, B. B.
AU  - Katz, S. J.
AU  - Hawley, S. T.
C2  - PMC5058443
C6  - NIHMS560810
DA  - Jan 1
DO  - 10.1188/14.Onf.13-20
DP  - NLM
ET  - 2013/12/26
IS  - 1
KW  - Acculturation
African Americans/psychology
Attitude to Health
Breast Neoplasms/*ethnology/psychology/therapy
Chemotherapy, Adjuvant/psychology
Cross-Sectional Studies
*Decision Making
*Emotions
European Continental Ancestry Group/psychology
Female
Health Care Surveys
Hispanic Americans/psychology
Humans
Indians, North American/psychology
Informed Consent
Los Angeles
Male
Mastectomy/methods/psychology
Michigan
Patient Education as Topic
*Patient Participation/psychology
Radiotherapy, Adjuvant/psychology
SEER Program
Sexual Partners/*psychology
Surveys and Questionnaires
breast cancer
decision making
family and caregivers
LA  - eng
N1  - 1538-0688
Lillie, Sarah E
Janz, Nancy K
Friese, Christopher R
Graff, John J
Schwartz, Kendra
Hamilton, Ann S
Gay, Brittany Bartol
Katz, Steven J
Hawley, Sarah T
R00 NR010750/NR/NINR NIH HHS/United States
R01 CA088370/CA/NCI NIH HHS/United States
R01 CA109696/CA/NCI NIH HHS/United States
Comparative Study
Journal Article
Multicenter Study
Oncol Nurs Forum. 2014 Jan 1;41(1):13-20. doi: 10.1188/14.ONF.13-20.
PY  - 2014
SN  - 0190-535X (Print)
0190-535x
SP  - 13-20
ST  - Racial and ethnic variation in partner perspectives about the breast cancer treatment decision-making experience
T2  - Oncol Nurs Forum
TI  - Racial and ethnic variation in partner perspectives about the breast cancer treatment decision-making experience
VL  - 41
ID  - 299
ER  - 

TY  - JOUR
AB  - Background: Existing studies evaluating racial and ethnic disparities focus on describing differences in procedure type and the proportion of women who undergo reconstruction following mastectomy. This study seeks to examine racial and ethnic variations in clinical and patient-reported outcomes (PROs) following breast reconstruction. Methods: The Mastectomy Reconstruction Outcomes Consortium is an 11 center, prospective cohort study collecting clinical and PROs following autologous and implant-based breast reconstruction. Mixed-effects regression models, weighted to adjust for non-response, were performed to evaluate outcomes at one-year postoperatively. Results: The cohort included 2703 women who underwent breast reconstruction. In multivariable models, Hispanic or Latina patients were less likely to experience any complications and major complications. Black or African-American women reported greater improvements in psychosocial and sexual well-being. Conclusions: Despite differences in pertinent clinical and socioeconomic variables, racial and ethnic minorities experienced equivalent or better outcomes. These findings provide reassurance in the context of numerous racial and ethnic health disparities and build upon our understanding of the delivery of surgical care to women with or at risk for developing breast cancer. (C) 2017 Elsevier Inc. All rights reserved.
AN  - WOS:000410627700026
AU  - Berlin, N. L.
AU  - Momoh, A. O.
AU  - Qi, J.
AU  - Hamill, J. B.
AU  - Kim, H. M.
AU  - Pusic, A. L.
AU  - Wilkins, E. G.
DA  - Aug
DO  - 10.1016/j.amjsurg.2017.02.009
IS  - 2
N1  - 28215963
PY  - 2017
SN  - 0002-9610
SP  - 312-317
ST  - Racial and ethnic variations in one-year clinical and patient-reported outcomes following breast reconstruction
T2  - American Journal of Surgery
TI  - Racial and ethnic variations in one-year clinical and patient-reported outcomes following breast reconstruction
VL  - 214
ID  - 2892
ER  - 

TY  - JOUR
AB  - Purpose: African American women are more likely to be diagnosed with metastatic breast cancer at the time of presentation than whites, and have shorter survival once diagnosed. This study examines racial differences in clinical outcomes in the setting of two large cooperative group randomized clinical trials. Patients and Methods: The study cohort consisted of 787 white (80%) and 195 African American (20%) patients with metastatic breast cancer enrolled in two successive Cancer and Leukemia Group B (CALGB) trials using taxanes in the metastatic setting. Differences in overall survival (OS), response incidence, and time to treatment failure (TTF) were examined by race. In addition, differences in the incidence of baseline and treatment-related toxicities were examined. Results: With 779 deaths (166 African Americans and 613 whites), median OS was 14.3 months for African Americans and 18.75 months for whites (hazard ratio [HR] = 1.37; 95% CI, 1.15 to 1.63). When adjusted for prognostic factors, African Americans had a 24% increase in the hazard of death compared with whites (HR = 1.24; 95% CI, 1.02 to 1.51). No significant differences in TTF or overall response to therapy were seen. No clinically significant toxicity differences were seen. Conclusion: African Americans with metastatic breast cancer have an increased hazard of death compared with whites despite the receipt of similar per-protocol treatment, but experience no differences in TTF or overall response to therapy. We hypothesize that more direct and robust measures of comorbidities, and perhaps other factors such as receipt of subsequent therapy could help further explain the observed survival difference. © 2008 by American Society of Clinical Oncology.
AD  - B. N. Polite, University of Chicago Medical Center, MC 2115, 5841 South Maryland Ave, Chicago, IL 60637-1470, United States
AU  - Polite, B. N.
AU  - Cirrincione, C.
AU  - Fleming, G. F.
AU  - Berry, D. A.
AU  - Seidman, A.
AU  - Muss, H.
AU  - Norton, L.
AU  - Shapiro, C.
AU  - Bakri, K.
AU  - Marcom, K.
AU  - Lake, D.
AU  - Schwartz, J. H.
AU  - Hudis, C.
AU  - Winer, E. P.
DB  - Embase
Medline
DO  - 10.1200/JCO.2007.13.9782
IS  - 16
KW  - paclitaxel
trastuzumab
adult
aged
anemia
article
breast cancer
cancer chemotherapy
cancer mortality
cancer survival
clinical trial
cohort analysis
comorbidity
confidence interval
controlled clinical trial
controlled study
female
hazard ratio
human
infection
leukopenia
lymphocytopenia
major clinical study
metastasis
motor neuropathy
priority journal
prognosis
race difference
randomized controlled trial
sensory neuropathy
thrombocytopenia
treatment failure
treatment response
LA  - English
M3  - Article
N1  - L352319137
2008-10-21
PY  - 2008
SN  - 0732-183X
SP  - 2659-2665
ST  - Racial differences in clinical outcomes from metastatic breast cancer: A pooled analysis of CALGB 9342 and 9840 - Cancer and leukemia group B
T2  - Journal of Clinical Oncology
TI  - Racial differences in clinical outcomes from metastatic breast cancer: A pooled analysis of CALGB 9342 and 9840 - Cancer and leukemia group B
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L352319137&from=export
http://dx.doi.org/10.1200/JCO.2007.13.9782
http://jco.ascopubs.org/cgi/reprint/26/16/2659
VL  - 26
ID  - 1202
ER  - 

TY  - JOUR
AB  - PURPOSE: African American women are more likely to be diagnosed with metastatic breast cancer at the time of presentation than whites, and have shorter survival once diagnosed. This study examines racial differences in clinical outcomes in the setting of two large cooperative group randomized clinical trials. PATIENTS AND METHODS: The study cohort consisted of 787 white (80%) and 195 African American (20%) patients with metastatic breast cancer enrolled in two successive Cancer and Leukemia Group B (CALGB) trials using taxanes in the metastatic setting. Differences in overall survival (OS), response incidence, and time to treatment failure (TTF) were examined by race. In addition, differences in the incidence of baseline and treatment-related toxicities were examined. RESULTS: With 779 deaths (166 African Americans and 613 whites), median OS was 14.3 months for African Americans and 18.75 months for whites (hazard ratio [HR] = 1.37; 95% CI, 1.15 to 1.63). When adjusted for prognostic factors, African Americans had a 24% increase in the hazard of death compared with whites (HR = 1.24; 95% CI, 1.02 to 1.51). No significant differences in TTF or overall response to therapy were seen. No clinically significant toxicity differences were seen. CONCLUSION: African Americans with metastatic breast cancer have an increased hazard of death compared with whites despite the receipt of similar per-protocol treatment, but experience no differences in TTF or overall response to therapy. We hypothesize that more direct and robust measures of comorbidities, and perhaps other factors such as receipt of subsequent therapy could help further explain the observed survival difference.
AD  - The University of Chicago Medical Center, 5841 South Maryland Ave, MC 2115, Chicago, IL 60637-1470, USA. bpolite@medicine.bsd.uchicago.edu
AN  - 18509177
AU  - Polite, B. N.
AU  - Cirrincione, C.
AU  - Fleming, G. F.
AU  - Berry, D. A.
AU  - Seidman, A.
AU  - Muss, H.
AU  - Norton, L.
AU  - Shapiro, C.
AU  - Bakri, K.
AU  - Marcom, K.
AU  - Lake, D.
AU  - Schwartz, J. H.
AU  - Hudis, C.
AU  - Winer, E. P.
C2  - PMC4830463
C6  - NIHMS548559 potential conflicts of interest.
DA  - Jun 1
DO  - 10.1200/jco.2007.13.9782
DP  - NLM
ET  - 2008/05/30
IS  - 16
KW  - Adult
*African Americans
Aged
Antineoplastic Agents, Phytogenic/therapeutic use
Breast Neoplasms/drug therapy/ethnology/*mortality
*European Continental Ancestry Group
Female
Humans
Logistic Models
Middle Aged
Multicenter Studies as Topic
Neoplasm Metastasis
Paclitaxel/therapeutic use
Randomized Controlled Trials as Topic
*Survival Analysis
Time Factors
Treatment Failure
LA  - eng
N1  - 1527-7755
Polite, Blase N
Cirrincione, Constance
Fleming, Gini F
Berry, Donald A
Seidman, Andrew
Muss, Hyman
Norton, Larry
Shapiro, Charles
Bakri, Kamal
Marcom, Kelly
Lake, Diana
Schwartz, Joel H
Hudis, Clifford
Winer, Eric P
U10 CA047577/CA/NCI NIH HHS/United States
U10 CA032291/CA/NCI NIH HHS/United States
CA33601/CA/NCI NIH HHS/United States
U10 CA077658/CA/NCI NIH HHS/United States
CA77406/CA/NCI NIH HHS/United States
CA47577/CA/NCI NIH HHS/United States
CA32291/CA/NCI NIH HHS/United States
U10 CA045564/CA/NCI NIH HHS/United States
CA41287/CA/NCI NIH HHS/United States
U10 CA035279/CA/NCI NIH HHS/United States
U10 CA045808/CA/NCI NIH HHS/United States
CA77651/CA/NCI NIH HHS/United States
U10 CA033601/CA/NCI NIH HHS/United States
U10 CA045389/CA/NCI NIH HHS/United States
U10 CA180821/CA/NCI NIH HHS/United States
U10 CA077597/CA/NCI NIH HHS/United States
U10 CA035421/CA/NCI NIH HHS/United States
U10 CA045418/CA/NCI NIH HHS/United States
U10 CA077440/CA/NCI NIH HHS/United States
U10 CA041287/CA/NCI NIH HHS/United States
U10 CA047559/CA/NCI NIH HHS/United States
U10 CA077651/CA/NCI NIH HHS/United States
U10 CA180882/CA/NCI NIH HHS/United States
CA47559/CA/NCI NIH HHS/United States
U10 CA074811/CA/NCI NIH HHS/United States
CA77658/CA/NCI NIH HHS/United States
U10 CA047642/CA/NCI NIH HHS/United States
U10 CA003927/CA/NCI NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
J Clin Oncol. 2008 Jun 1;26(16):2659-65. doi: 10.1200/JCO.2007.13.9782.
PY  - 2008
SN  - 0732-183X (Print)
0732-183x
SP  - 2659-65
ST  - Racial differences in clinical outcomes from metastatic breast cancer: a pooled analysis of CALGB 9342 and 9840--Cancer and Leukemia Group B
T2  - J Clin Oncol
TI  - Racial differences in clinical outcomes from metastatic breast cancer: a pooled analysis of CALGB 9342 and 9840--Cancer and Leukemia Group B
VL  - 26
ID  - 494
ER  - 

TY  - JOUR
AB  - BACKGROUND: Colorectal cancer (CRC) incidence and mortality rates are higher in African-Americans as compared with other racial/ethnic groups. The women's health initiative (WHI) study sample was used to determine whether differences in CRC risk factors explain racial/ethnic differences in incidence and mortality. METHODS: The WHI is a longitudinal study of postmenopausal women recruited from 40 centers. Baseline questionnaires were used to collect sociodemographic and health status information. All CRC diagnoses were centrally adjudicated. Cox regression models were used to compute hazard ratios (HRs) and 95% confidence intervals (CIs) for invasive CRC by race/ethnicity. RESULTS: The study sample included 131,481 (83.7%) White, 14,323 (9.1%) African-American, 6,362 (4.1%) Hispanic, 694 (0.4%) Native American and 4,148 (2.6%) Asian/Pacific Islanders. After a mean follow-up of 10.8 years (SD 2.9), CRC incidence was the highest in African-Americans (annualized rate = 0.14%), followed by Whites and Native Americans (0.12% each), Asian/Pacific Islanders (0.10%), and Hispanics (0.08%). After adjustment for age and trial assignment, Hispanics had a lower risk compared with Whites, HR 0.73 (95% CI: 0.54-0.97) (P = 0.03), and African-Americans had a marginally greater risk, HR 1.16 (95% CI: 0.99-1.34), P = 0.06. Multivariable adjustment attenuated the difference in incidence between African-Americans and Whites (HR 0.99, 95% CI: 0.82-1.20), while strengthening the lower HR for Hispanics (HR 0.68, 95% CI: 0.48-0.97). CONCLUSIONS: African-American/White differences in CRC risk are likely due to sociodemographic/cultural factors other than race. IMPACT: A number of modifiable exposures could be a focus for reducing CRC risk in African-Americans.
AD  - Karmanos Cancer Institute, Department of Oncology, Detroit, MI, USA. simonm@karmanos.org
AN  - 21602308
AU  - Simon, M. S.
AU  - Thomson, C. A.
AU  - Pettijohn, E.
AU  - Kato, I.
AU  - Rodabough, R. J.
AU  - Lane, D.
AU  - Hubbell, F. A.
AU  - O'Sullivan, M. J.
AU  - Adams-Campbell, L.
AU  - Mouton, C. P.
AU  - Abrams, J.
AU  - Chlebowski, R. T.
C2  - PMC3784999
C6  - NIHMS514521
DA  - Jul
DO  - 10.1158/1055-9965.Epi-11-0027
DP  - NLM
ET  - 2011/05/24
IS  - 7
KW  - Aged
Colorectal Neoplasms/*epidemiology
Female
Humans
Incidence
Middle Aged
Odds Ratio
Proportional Hazards Models
Risk Factors
Women's Health/*ethnology
LA  - eng
N1  - 1538-7755
Simon, Michael S
Thomson, Cynthia A
Pettijohn, Erin
Kato, Ikuko
Rodabough, Rebecca J
Lane, Dorothy
Hubbell, F Allan
O'Sullivan, Mary Jo
Adams-Campbell, Lucille
Mouton, Charles P
Abrams, Judith
Chlebowski, Rowan T
N01 WH044221/WH/WHI NIH HHS/United States
N01WH42129-32/WH/WHI NIH HHS/United States
N01 WH042107/WH/WHI NIH HHS/United States
N01WH32100-2/WH/WHI NIH HHS/United States
ZIA AG000190-03/Intramural NIH HHS/United States
N01WH32108-9/WH/WHI NIH HHS/United States
N01WH42107-26/WH/WHI NIH HHS/United States
N01WH32122/WH/WHI NIH HHS/United States
N01WH32105-6/WH/WHI NIH HHS/United States
P30 CA022453/CA/NCI NIH HHS/United States
N01WH32111-13/WH/WHI NIH HHS/United States
N01WH32118-32119/WH/WHI NIH HHS/United States
N01WH42118/WH/WHI NIH HHS/United States
P30CA022453/CA/NCI NIH HHS/United States
N01 WH042120/WH/WHI NIH HHS/United States
N01WH32115/WH/WHI NIH HHS/United States
N01WH44221/WH/WHI NIH HHS/United States
N01WH22110/WH/WHI NIH HHS/United States
N01WH24152/WH/WHI NIH HHS/United States
Journal Article
Multicenter Study
Research Support, N.I.H., Extramural
Cancer Epidemiol Biomarkers Prev. 2011 Jul;20(7):1368-78. doi: 10.1158/1055-9965.EPI-11-0027. Epub 2011 May 20.
PY  - 2011
SN  - 1055-9965 (Print)
1055-9965
SP  - 1368-78
ST  - Racial differences in colorectal cancer incidence and mortality in the Women's Health Initiative
T2  - Cancer Epidemiol Biomarkers Prev
TI  - Racial differences in colorectal cancer incidence and mortality in the Women's Health Initiative
VL  - 20
ID  - 393
ER  - 

TY  - JOUR
AB  - BACKGROUND: Whether doctor-patient communication differs by race was investigated in patients with pulmonary nodules or lung cancer. METHODS: Eligible patients (n = 137) had pulmonary nodules or lung cancer and were seen in thoracic surgery or oncology clinics for initial treatment recommendations at a large southern Veterans Affairs Medical Center from 2001-2004. Doctor-patient consultations were audiotaped. Audiotapes were transcribed, unitized into utterances, and utterances were coded as doctors' information-giving or patients' and companions' active participation (asking questions, expressing concerns, and making assertions). Data were compared by patient race and doctor-patient racial concordance using t-tests or chi-square tests as appropriate. Mixed linear regression was used to determine the independent predictors of doctor's information-giving after controlling for clustering of patients by doctor. RESULTS: Patient age, gender, marital status, clinical site, and health status were similar by race (P > .20), but black patients were somewhat less likely to have education beyond high school and to bring a companion to the visit (P = .06) than white patients. Black patients and their companions received significantly less information from doctors (49.3 vs. 87.3 mean utterances; P < .001) and produced significantly fewer active participation utterances (21.4 vs. 37.2; P < .001) than white patients. In mixed regression analyses, after adjusting for patients' and companions' participation, clustering by doctor, and other factors, race no longer predicted information-giving (P = .54). Patients in racially discordant interactions received significantly less information and were significantly less active participants (P < .001) when compared with patients in racially concordant interactions, and after controlling for patients' participation and other factors using mixed regression, racial discordance did not predict information-giving. CONCLUSIONS: The results indicate a pattern of communication that may perpetuate patient passivity and limited information exchange where black patients and patients in discordant interactions do less to prompt doctors for information and doctors in turn provide less information to these patients.
AD  - Jesse Brown Veterans Affairs Medical Center, Chicago, Illinois, USA. hgordon@bcm.edu
AN  - 16909424
AU  - Gordon, H. S.
AU  - Street, R. L., Jr.
AU  - Sharf, B. F.
AU  - Souchek, J.
DA  - Sep 15
DO  - 10.1002/cncr.22122
DP  - NLM
ET  - 2006/08/16
IS  - 6
KW  - African Americans/*statistics & numerical data
Aged
Communication
European Continental Ancestry Group/*statistics & numerical data
Female
Humans
Male
Models, Statistical
Patient Education as Topic/statistics & numerical data
*Patient Participation
*Physician-Patient Relations
Practice Patterns, Physicians'/statistics & numerical data
LA  - eng
N1  - Gordon, Howard S
Street, Richard L Jr
Sharf, Barbara F
Souchek, Julianne
P01 HS10876/HS/AHRQ HHS/United States
Comparative Study
Journal Article
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, U.S. Gov't, P.H.S.
United States
Cancer. 2006 Sep 15;107(6):1313-20. doi: 10.1002/cncr.22122.
PY  - 2006
SN  - 0008-543X (Print)
0008-543x
SP  - 1313-20
ST  - Racial differences in doctors' information-giving and patients' participation
T2  - Cancer
TI  - Racial differences in doctors' information-giving and patients' participation
VL  - 107
ID  - 556
ER  - 

TY  - JOUR
AB  - BACKGROUND: Lower enrolment of minorities into research studies has been reported frequently. Most studies have little information about nonparticipants, making it difficult to identify characteristics associated with enrolment and how they might vary by race. METHODS: Women who had previously participated in a population-based, case-control study of breast cancer in North Carolina were invited to enroll in a cancer genetics registry. Detailed questionnaire data on sociodemographic characteristics and cancer risk factors were available for all women. We compared characteristics of women who agreed to be in the registry with those who were deceased, were unlocatable, or declined enrolment. Unconditional logistic regression analyses were done to identify predictors of enrolment. RESULTS: Enrolment rates were markedly lower among African Americans than Whites (15% and 36%, respectively) due to both lower contact rates (41% versus 63%) and lower enrolment rates among those contacted (37% versus 58%). Logistic regression models suggested that racial differences in enrolment were not due to socioeconomic characteristics or other cancer risk factors; race was the only significant predictor of enrolment in multivariable models (odds ratio 0.41, 95% confidence interval 0.23-0.72). CONCLUSIONS: Although all women had previously taken part in a research study, African American women were less likely to enroll in the cancer genetics registry than White women. A possible explanation of these findings is that studies of genetics may present particular concerns for African Americans. Further research is needed to identify attitudes and issues that present barriers to participation among minorities.
AD  - Cancer Prevention Detection and Control Research Program, Duke University Medical Center, 239 Hanes House, Trent Drive, Box 2949, Durham, NC 27710, USA. patricia.moorman@duke.edu
AN  - 15298957
AU  - Moorman, P. G.
AU  - Skinner, C. S.
AU  - Evans, J. P.
AU  - Newman, B.
AU  - Sorenson, J. R.
AU  - Calingaert, B.
AU  - Susswein, L.
AU  - Crankshaw, T. S.
AU  - Hoyo, C.
AU  - Schildkraut, J. M.
DA  - Aug
DP  - NLM
ET  - 2004/08/10
IS  - 8
KW  - Adult
African Americans/*genetics/statistics & numerical data
Analysis of Variance
Attitude to Health/*ethnology
Breast Neoplasms/*ethnology/*genetics
Case-Control Studies
Educational Status
European Continental Ancestry Group/*genetics/statistics & numerical data
Female
Humans
Logistic Models
Middle Aged
Minority Groups
*Patient Selection
Prevalence
Probability
Registries
Research/standards/trends
Risk Assessment
Socioeconomic Factors
Surveys and Questionnaires
LA  - eng
N1  - Moorman, Patricia G
Skinner, Celette Sugg
Evans, James P
Newman, Beth
Sorenson, James R
Calingaert, Brian
Susswein, Lisa
Crankshaw, T Sydnee
Hoyo, Cathrine
Schildkraut, Joellen M
Comparative Study
Journal Article
United States
Cancer Epidemiol Biomarkers Prev. 2004 Aug;13(8):1349-54.
PY  - 2004
SN  - 1055-9965 (Print)
1055-9965
SP  - 1349-54
ST  - Racial differences in enrolment in a cancer genetics registry
T2  - Cancer Epidemiol Biomarkers Prev
TI  - Racial differences in enrolment in a cancer genetics registry
VL  - 13
ID  - 623
ER  - 

TY  - JOUR
AB  - BACKGROUND: Prostate cancer is the most common cancer among US men, however, the etiology remains unclear. Yet, one consistency is that black non-Hispanic men are at increased risk for prostate cancer compared to white, non-Hispanic men. The goal of this study was to assess relations between demographic and other potential prostate cancer risk factors in the context of the US military healthcare system, which provides equal access to all US servicemen. METHODS: Military healthcare and demographic data were used to describe risk factors for prostate cancer in the US military from September 1993 to September 2003. Cox's proportional hazards regression was employed to model the time to prostate cancer hospitalization. RESULTS: Four hundred eight first prostate cancer hospitalizations were identified among 2,761,559 servicemen. The adjusted rate per 100,000 persons rose from 1.41 to 3.62 for white non-Hispanic men and 1.43 to 6.08 for black non-Hispanic men by the end of the study. The increasing incidence over time for combined race/ethnic groups was similar to trends reported in the Surveillance, Epidemiology, and End Results Program for the US civilian population. No association was observed between occupation and prostate cancer hospitalization. However, black non-Hispanic men were at increased risk compared with white non-Hispanic men (hazard ratio = 2.72, 95% confidence interval: 2.12, 3.49). CONCLUSIONS: No association was observed between occupation and prostate cancer hospitalization. In this relatively young cohort, black non-Hispanic race/ethnicity was found to be predictive of prostate cancer, and this association existed regardless of access to care and socioeconomic status.
AD  - Air Force Research Laboratory, Wright-Patterson Air Force Base, Dayton, Ohio 45433, USA. timothy.wells@wpafb.af.mil
AN  - 20033887
AU  - Wells, T. S.
AU  - Bukowinski, A. T.
AU  - Smith, T. C.
AU  - Smith, B.
AU  - Dennis, L. K.
AU  - Chu, L. K.
AU  - Gray, G. C.
AU  - Ryan, M. A.
DA  - May 15
DO  - 10.1002/pros.21105
DP  - NLM
ET  - 2009/12/25
IS  - 7
KW  - Adult
African Americans
Age Factors
European Continental Ancestry Group
*Health Services Accessibility
Humans
Male
*Military Personnel
Patient Selection
Prostatic Neoplasms/*ethnology
Risk
Risk Factors
SEER Program
United States
LA  - eng
N1  - 1097-0045
Wells, Timothy S
Bukowinski, Anna T
Smith, Tyler C
Smith, Besa
Dennis, Leslie K
Chu, Laura K
Gray, Gregory C
Ryan, Margaret A K
Journal Article
Research Support, U.S. Gov't, Non-P.H.S.
United States
Prostate. 2010 May 15;70(7):727-34. doi: 10.1002/pros.21105.
PY  - 2010
SN  - 0270-4137
SP  - 727-34
ST  - Racial differences in prostate cancer risk remain among US servicemen with equal access to care
T2  - Prostate
TI  - Racial differences in prostate cancer risk remain among US servicemen with equal access to care
VL  - 70
ID  - 438
ER  - 

TY  - JOUR
AB  - Although differences in prostate cancer incidence and mortality between black and white men are widely accepted, the existence of racial differences in treatment outcomes remains controversial. We conducted a systematic review of racial differences in prostate cancer treatment outcomes. Systematic review of literature from 1992-2002 was conducted. Database searches were performed using the terms: "prostate cancer" (keyword) or "prostate neoplasm" (subject heading) + "blacks" (subject heading) or "blacks" (keyword) + "African-Americans" (subject heading or "African-Americans" (keyword). Two hundred fifty-eight relevant articles were identified; 29 fit the inclusion criteria. All but 3 were retrospective. Seven (24%) studies were conducted at Veterans Affairs medical centers. Treatment included radical prostatectomy (15 studies), hormonal therapy (5 studies), and radiotherapy (12 studies). Three studies included more than 1 treatment. Twenty-three (79%) studies, observed no significant difference in treatment outcomes between races. The remainder found worse outcomes among black men, including worse 5-year survival (HR range, 2.35-96.74) and higher rates of PSA failure (OR range, 1.15-1.69). Most studies investigating racial differences in prostate cancer treatment outcomes over the past 10 years found no difference between races after controlling for tumor and patient characteristics. Efforts to narrow the gap between black and white prostate cancer mortality should focus on ensuring that all patients receive optimal treatment and that all patients become informed about the use of screening for early cancer detection. Research should focus on interventions to reduce advanced presentation of the disease and disease-related mortality among black men.
AD  - University of Pennsylvania School of Nursing, Pennsylvania, USA. npeters@nursing.upenn.edu
AN  - 15815180
AU  - Peters, N.
AU  - Armstrong, K.
DA  - Mar-Apr
DO  - 10.1097/00002820-200503000-00004
DP  - NLM
ET  - 2005/04/09
IS  - 2
KW  - African Americans/ethnology/genetics/*statistics & numerical data
European Continental Ancestry Group/ethnology/genetics/*statistics & numerical data
Health Services Needs and Demand
Humans
Incidence
Male
Mass Screening
Nurse's Role
Patient Education as Topic
Patient Selection
Prostatectomy
Prostatic Neoplasms/ethnology/genetics/mortality/*therapy
Radiotherapy
Randomized Controlled Trials as Topic
Research Design
Retrospective Studies
Socioeconomic Factors
Survival Analysis
Survival Rate
Treatment Outcome
United States/epidemiology
LA  - eng
N1  - Peters, Nikki
Armstrong, Katrina
Journal Article
Review
Systematic Review
United States
Cancer Nurs. 2005 Mar-Apr;28(2):108-18. doi: 10.1097/00002820-200503000-00004.
PY  - 2005
SN  - 0162-220X (Print)
0162-220x
SP  - 108-18
ST  - Racial differences in prostate cancer treatment outcomes: a systematic review
T2  - Cancer Nurs
TI  - Racial differences in prostate cancer treatment outcomes: a systematic review
VL  - 28
ID  - 606
ER  - 

TY  - JOUR
AB  - BACKGROUND: If discovered at an early stage, non-small-cell lung cancer is potentially curable by surgical resection. However, two disparities have been noted between black patients and white patients with this disease. Blacks are less likely to receive surgical treatment than whites, and they are likely to die sooner than whites. We undertook a population-based study to estimate the disparity in the rates of surgical treatment and to evaluate the extent to which this disparity is associated with differences in overall survival. METHODS: We studied all black patients and white patients 65 years of age or older who were given a diagnosis of resectable non-small-cell lung cancer (stage I or II) between 1985 and 1993 and who resided in 1 of the 10 study areas of the Surveillance, Epidemiology, and End Results (SEER) program (10,984 patients). Data on the diagnosis, stage of disease, treatment, and demographic characteristics of the patients were obtained from the SEER data base. Information on coexisting illnesses, type of Medicare coverage, and survival was obtained from linked Medicare inpatient-discharge records. RESULTS: The rate of surgery was 12.7 percentage points lower for black patients than for white patients (64.0 percent vs. 76.7 percent, P<0.001), and the five-year survival rate was also lower for blacks (26.4 percent vs. 34.1 percent, P<0.001). However, among the patients undergoing surgery, survival was similar for the two racial groups, as it was among those who did not undergo surgery. Furthermore, analyses in which adjustments were made for factors that are predictive of either candidacy for surgery or survival did not alter the influence of race on these outcomes. CONCLUSIONS: Our analyses suggest that the lower survival rate among black patients with early-stage, non-small-cell lung cancer, as compared with white patients, is largely explained by the lower rate of surgical treatment among blacks. Efforts to increase the rate of surgical treatment for black patients appear to be a promising way of improving survival in this group.
AD  - Health Outcomes Research Group, Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
AN  - 10519898
AU  - Bach, P. B.
AU  - Cramer, L. D.
AU  - Warren, J. L.
AU  - Begg, C. B.
DA  - Oct 14
DO  - 10.1056/nejm199910143411606
DP  - NLM
ET  - 1999/10/16
IS  - 16
KW  - *African Continental Ancestry Group
Aged
Carcinoma, Non-Small-Cell Lung/*ethnology/mortality/surgery
Comorbidity
*European Continental Ancestry Group
Female
Health Services Accessibility
Humans
Lung/surgery
Lung Neoplasms/*ethnology/mortality/surgery
Male
Medicare
Patient Selection
Pneumonectomy/statistics & numerical data
SEER Program
Social Class
Survival Rate
United States/epidemiology
Empirical Approach
Professional Patient Relationship
LA  - eng
N1  - Bach, P B
Cramer, L D
Warren, J L
Begg, C B
Comparative Study
Journal Article
United States
N Engl J Med. 1999 Oct 14;341(16):1198-205. doi: 10.1056/NEJM199910143411606.
PY  - 1999
SN  - 0028-4793 (Print)
0028-4793
SP  - 1198-205
ST  - Racial differences in the treatment of early-stage lung cancer
T2  - N Engl J Med
TI  - Racial differences in the treatment of early-stage lung cancer
VL  - 341
ID  - 715
ER  - 

TY  - JOUR
AN  - 10691492
AU  - Campbell, D. E.
AU  - Greenberg, E. R.
DA  - Feb 17
DO  - 10.1056/nejm200002173420716
DP  - NLM
ET  - 2000/02/26
IS  - 7
KW  - *African Continental Ancestry Group
Aged
Aged, 80 and over
Carcinoma, Non-Small-Cell Lung/*ethnology/surgery
Comorbidity
Confounding Factors, Epidemiologic
European Continental Ancestry Group
Humans
Lung Neoplasms/*ethnology/surgery
Medicare
Patient Selection
Socioeconomic Factors
United States
Professional Patient Relationship
LA  - eng
N1  - Campbell, D E
Greenberg, E R
Comment
Letter
United States
N Engl J Med. 2000 Feb 17;342(7):517; author reply 518-9. doi: 10.1056/NEJM200002173420716.
PY  - 2000
SN  - 0028-4793 (Print)
0028-4793
SP  - 517; author reply 518-9
ST  - Racial differences in the treatment of early-stage lung cancer
T2  - N Engl J Med
TI  - Racial differences in the treatment of early-stage lung cancer
VL  - 342
ID  - 706
ER  - 

TY  - JOUR
AB  - Comments on the article by P. B. Bach et al (see record [rid]1999-01267-001[/rid]) concerning racial differences in the treatment of early-stage lung cancer. The authors believe that racial differences in social and economic factors and in coexisting illness may have confounded the finding, that black patients with early-stage non-small-cell lung cancer were less likely to receive surgical treatment and to survive than similar white patients. The authors offer 4 suggestions for dealing with these potential confounding variables more effectively. (PsycINFO Database Record (c) 2016 APA, all rights reserved)
AN  - 2000-13817-006
AU  - Campbell, Diane E.
AU  - Greenberg, E. Robert
DB  - psyh
DP  - EBSCOhost
IS  - 7
KW  - different rates of surgical treatment
overall survival rate
Blacks vs Whites with early stage cancer
commentary
African Continental Ancestry Group
Aged
Aged, 80 and over
Carcinoma, Non-Small-Cell Lung
Comorbidity
Confounding Factors (Epidemiology)
European Continental Ancestry Group
Humans
Lung Neoplasms
Medicare
Patient Selection
Socioeconomic Factors
United States
Mortality Rate
Neoplasms
Race and Ethnic Discrimination
Surgery
Treatment Outcomes
Blacks
Lung
Racial and Ethnic Differences
Whites
N1  - Norris Cotton Cancer Ctr, Lebanon, NH, US. Release Date: 20000501. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Print. Document Type: Comment/Reply. Language: English. Major Descriptor: Mortality Rate; Neoplasms; Race and Ethnic Discrimination; Surgery; Treatment Outcomes. Minor Descriptor: Blacks; Lung; Racial and Ethnic Differences; Whites. Classification: Medical Treatment of Physical Illness (3363). Population: Human (10). Page Count: 1. Issue Publication Date: Feb, 2000.
PY  - 2000
SN  - 0028-4793
1533-4406
SP  - 517-517
ST  - 'Racial differences in the treatment of early-stage lung cancer':Commentary
T2  - The New England Journal of Medicine
TI  - 'Racial differences in the treatment of early-stage lung cancer':Commentary
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2000-13817-006&site=ehost-live&scope=site
VL  - 342
ID  - 1807
ER  - 

TY  - JOUR
AB  - Background: Despite declining death rates from colorectal cancer (CRC), racial disparities have continued to increase. In this study, the authors examined disparities in a racially diverse group of insured patients. Methods: This study was conducted among patients who were diagnosed with CRC from 1993 to 1998, when they were enrolled in integrated healthcare systems. Patients were identified from tumor registries and were linked to information in administrative databases. The sample was restricted to non-Hispanic whites (n = 10,585), non-Hispanic blacks (n = 1479), Hispanics (n = 985), and Asians/ Pacific Islanders (n = 909). Differences in tumor stage and survival were analyzed by using polytomous and Cox regression models, respectively. Results: In multivariable regression analyses, blacks were more likely than whites to have distant or unstaged tumors. In Cox models that were adjusted for nonmutable factors, blacks had a higher risk of death from CRC (hazard ratio [HR], 1.17; 95% confidence interval [95% CI], 1.06–1.30). Hispanics had a risk of death similar to whites (HR, 1.04; 95% CI, 0.92–1.18), whereas Asians/Pacific Islanders had a lower risk of death from CRC (HR, 0.89; 95% CI, 0.78–1.02). Adjustment for tumor stage decreased the HR to 1.11 for blacks, and the addition of receipt of surgical therapy to the model decreased the HR further to 1.06. The HR among Hispanics and Asians/ Pacific Islanders was stable to adjustment for tumor stage and surgical therapy. Conclusions: The relation between race and survival from CRC was complex and appeared to be related to differences in tumor stage and therapy received, even in insured populations. Targeted interventions to improve the use of effective screening and treatment among vulnerable populations may be needed to eliminate disparities in CRC. (PsycINFO Database Record (c) 2016 APA, all rights reserved)
AD  - Doubeni, Chyke A., Department of Family Medicine and Community Health, University of Massachusetts Medical School, 55 Lake Avenue North, Worcester, MA, US, 01655
AN  - 2008-13417-002
AU  - Doubeni, Chyke A.
AU  - Field, Terry S.
AU  - Buist, Diana S. M.
AU  - Korner, Eli J.
AU  - Bigelow, Carol
AU  - Lamerato, Lois
AU  - Herrinton, Lisa
AU  - Quinn, Virginia P.
AU  - Hart, Gene
AU  - Hornbrook, Mark C.
AU  - Gurwitz, Jerry H.
AU  - Wagner, Edward H.
DB  - psyh
DO  - 10.1002/cncr.22437
DP  - EBSCOhost
IS  - 3
KW  - racial differences
tumor stage
survival
colorectal cancer
insured population
death rates
Adult
African Continental Ancestry Group
Aged
Aged, 80 and over
Asian Continental Ancestry Group
Colorectal Neoplasms
Ethnic Groups
European Continental Ancestry Group
Female
Hispanic Americans
Humans
Insurance, Health
Male
Middle Aged
Neoplasm Staging
Prognosis
Survival Rate
Death and Dying
Health Insurance
Neoplasms
Racial and Ethnic Differences
Survivors
Blacks
Whites
N1  - Department of Family Medicine and Community Health, University of Massachusetts Medical School, Worcester, MA, US. Release Date: 20090921. Correction Date: 20130128. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: English. Grant Information: Doubeni, Chyke A. Major Descriptor: Death and Dying; Health Insurance; Neoplasms; Racial and Ethnic Differences; Survivors. Minor Descriptor: Blacks; Whites. Classification: Cancer (3293). Population: Human (10); Male (30); Female (40). Location: US. Age Group: Adulthood (18 yrs & older) (300); Young Adulthood (18-29 yrs) (320); Thirties (30-39 yrs) (340); Middle Age (40-64 yrs) (360); Aged (65 yrs & older) (380). Methodology: Empirical Study; Quantitative Study. References Available: Y. Page Count: 9. Issue Publication Date: Feb, 2007.
Sponsor: National Cancer Institute, US. Grant: U19 CA079689. Other Details: Cancer Research Network. Recipients: No recipient indicated
Sponsor: National Cancer Institute, US. Grant: U19 CA079689-06. Other Details: Cancer Research Network. Recipients: Doubeni, Chyke A.
Sponsor: American Cancer Society, US. Grant: CRTG-03-024-01-CCE. Recipients: Buist, Diana S. M.
PY  - 2007
SN  - 0008-543X
1097-0142
SP  - 612-620
ST  - Racial differences in tumor stage and survival for colorectal cancer in an insured population
T2  - Cancer
TI  - Racial differences in tumor stage and survival for colorectal cancer in an insured population
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2008-13417-002&site=ehost-live&scope=site
ORCID: 0000-0001-7495-0285
chyke.doubeni@umassmed.edu
VL  - 109
ID  - 1785
ER  - 

TY  - JOUR
AB  - Objective: To determine whether racial differences exist in patient preferences for prostate cancer treatment after being informed about options using a patient-centered vs. a standard decision aid (DA). Methods: This article reports secondary analyses of a large study of men diagnosed with early stage prostate cancer. Men were recruited from 4 VA Health Systems and randomized to receive a patient-centered or standard DA about prostate cancer treatment options. Data were collected at 1) baseline, 2) after reading the DA but prior to diagnosis, and 3) after receiving a cancer diagnosis and meeting with a urologist. Results: White patients who received the patient-centered DA written at a 7th grade reading level were more likely to prefer active surveillance and less likely to prefer radiation compared to those who received the standard DA written at >9th grade reading level. African American patients’ treatment preferences did not differ as a function of DA. Conclusions: When informed about prostate cancer treatment options through a patient-centered DA, White patients changed their treatment preferences but African American patients did not. Practice Implications: As DAs are increasingly being used in clinical practice, more research is needed regarding the efficacy, relevance, and receptivity of DAs for African Americans.
AD  - A.T. Langford, Department of Population Health, 227 East 30th Street, Room 645, New York, NY, United States
AU  - Langford, A. T.
AU  - Scherer, L. D.
AU  - Ubel, P. A.
AU  - Holmes-Rovner, M.
AU  - Scherr, K. A.
AU  - Fagerlin, A.
DB  - Embase
Medline
DO  - 10.1016/j.pec.2020.06.004
IS  - 12
KW  - prostate specific antigen
adult
African American
anxiety
article
cancer diagnosis
cancer radiotherapy
cancer therapy
clinical practice
comparative study
controlled study
decision support system
disease surveillance
early cancer
education
European American
exploratory mediation analysis
gender
Gleason score
health literacy
human
major clinical study
male
middle aged
patient care
patient decision making
patient preference
priority journal
prostate cancer
prostatectomy
race difference
randomized controlled trial
reading
secondary analysis
statistical analysis
urologist
veteran
LA  - English
M3  - Article
N1  - L2006842504
2020-07-08
PY  - 2020
SN  - 1873-5134
0738-3991
SP  - 2460-2467
ST  - Racial differences in veterans’ response to a standard vs. patient-centered decision aid for prostate cancer: Implications for decision making in African American and White men
T2  - Patient Education and Counseling
TI  - Racial differences in veterans’ response to a standard vs. patient-centered decision aid for prostate cancer: Implications for decision making in African American and White men
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L2006842504&from=export
http://dx.doi.org/10.1016/j.pec.2020.06.004
VL  - 103
ID  - 775
ER  - 

TY  - JOUR
AB  - Background: We analyzed the racial differences in physical well-being, social/family well-being, functional well-being, emotional well-being, and prostate cancer specific concerns among men with clinically localized prostate cancer. Methods: In this prospective cohort study, we recruited 121 Caucasian and 77 African American men with newly diagnosed prostate cancer. Participants completed the Functional Assessment of Cancer Therapy-Prostate (FACT-P) instrument at baseline and at 3, 6, 12 and 24 months follow-up. To determine the between and within group differences on all functional measures (physical well-being, social/family well-being, functional well-being, emotional well-being, and prostate cancer specific concerns), we used repeated measures ANOVA. Results: Except for education, income and hospital type, the two racial groups had comparable socio-demographic and clinical attributes. At 3 months post-treatment, both groups experienced a decline in physical well-being and increase in prostate cancer specific concerns. Baseline values of these measures were not recovered by 24-month follow-up. In particular, lack of energy was the most prominent contributor to declining physical well-being. The ability to have and maintain an erection was the most severe prostate cancer specific concern. Lack of energy and concern regarding erection ability varied between the two groups over the follow-up period. For African American patients, there was substantial temporal variation in this item, whereas Caucasian patients reported improved energy over time. Conclusions: Our findings provide an insight into not only the overall racial variation in physical well-being and prostate cancer specific concern, but also the temporal differences in these measures that can occur over a 24-month follow-up. This has important implications for effective management of localized prostate cancer patients from different racial groups and merits further research. Implications for cancer survivors: Addressing the issue of lack of energy and concern regarding ability to have and maintain an erection can help improve physical well-being and alleviate prostate-specific concerns in survivors of localized prostate cancer. (PsycINFO Database Record (c) 2016 APA, all rights reserved)
AD  - Chhatre, Sumedha, Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, US
AN  - 2011-10588-009
AU  - Chhatre, Sumedha
AU  - Wein, Alan J.
AU  - Malkowicz, S. Bruce
AU  - Jayadevappa, Ravishankar
DB  - psyh
DO  - 10.1007/s11764-011-0170-1
DP  - EBSCOhost
IS  - 2
KW  - racial differences
physical well being
cancer concerns
prostate cancer patients
family well being
social well being
functional well being
emotional well being
men
African Americans
Aged
Cohort Studies
European Continental Ancestry Group
Humans
Male
Middle Aged
Prospective Studies
Prostatic Neoplasms
Emotional States
Neoplasms
Physical Activity
Prostate
Well Being
Family
Human Males
Patients
Racial and Ethnic Differences
N1  - Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, US. Release Date: 20110919. Correction Date: 20120618. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: English. Major Descriptor: Emotional States; Neoplasms; Physical Activity; Prostate; Well Being. Minor Descriptor: Family; Human Males; Patients; Racial and Ethnic Differences. Classification: Cancer (3293). Population: Human (10); Male (30); Inpatient (50); Outpatient (60). Location: US. Age Group: Adulthood (18 yrs & older) (300); Aged (65 yrs & older) (380). Tests & Measures: Functional Assessment of Cancer Therapy-Prostate-Version 4; Trial Outcomes Index; Charlson Comorbidity Index; Functional Assessment of Cancer Therapy General Scale. Methodology: Empirical Study; Followup Study; Longitudinal Study; Prospective Study; Retrospective Study; Quantitative Study. References Available: Y. Page Count: 9. Issue Publication Date: Jun, 2011. Publication History: First Posted Date: Jan 28, 2011; Accepted Date: Jan 7, 2011; First Submitted Date: Jul 27, 2010. Copyright Statement: Springer Science+Business Media, LLC. 2011.
Sponsor: US Department of Defense, Prostate Cancer Research Program, US. Grant: W81XWH-04-1-0257. Recipients: No recipient indicated
PY  - 2011
SN  - 1932-2259
1932-2267
SP  - 182-190
ST  - Racial differences in well-being and cancer concerns in prostate cancer patients
T2  - Journal of Cancer Survivorship
TI  - Racial differences in well-being and cancer concerns in prostate cancer patients
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2011-10588-009&site=ehost-live&scope=site
rasu@mail.med.upenn.edu
VL  - 5
ID  - 1753
ER  - 

TY  - JOUR
AB  - BACKGROUND: Racial disparities in cancer outcomes have been observed in several malignancies. However, it is unclear if survival differences persist after adjusting for clinical, demographic, and treatment variables. Our objective was to determine whether racial disparities in survival exist among patients enrolled in consecutive trials conducted by the Southwest Oncology Group (SWOG). METHODS: We identified 19 457 adult cancer patients (6676 with breast, 2699 with lung, 1244 with colon, 1429 with ovarian, and 1843 with prostate cancers; 1291 with lymphoma; 2067 with leukemia; and 2208 with multiple myeloma) who were treated on 35 SWOG randomized phase III clinical trials from October 1, 1974, through November 29, 2001. Patients were grouped according to studies of diseases with similar histology and stage. Cox regression was used to evaluate the association between race and overall survival within each disease site grouping, controlling for available prognostic factors plus education and income, which are surrogates for socioeconomic status. Median and ten-year overall survival estimates were derived by the Kaplan-Meier method. All statistical tests were two-sided. RESULTS: Of 19 457 patients registered, 2308 (11.9%, range = 3.9%-21.6%) were African American. After adjustment for prognostic factors, African American race was associated with increased mortality in patients with early-stage premenopausal breast cancer (hazard ratio [HR] for death = 1.41, 95% confidence interval [CI] = 1.10 to 1.82; P = .007), early-stage postmenopausal breast cancer (HR for death = 1.49, 95% CI = 1.28 to 1.73; P < .001), advanced-stage ovarian cancer (HR for death = 1.61, 95% CI = 1.18 to 2.18; P = .002), and advanced-stage prostate cancer (HR for death = 1.21, 95% CI = 1.08 to 1.37; P = .001). No statistically significant association between race and survival for lung cancer, colon cancer, lymphoma, leukemia, or myeloma was observed. Additional adjustments for socioeconomic status did not substantially change these observations. Ten-year (and median) overall survival rates for African American vs all other patients were 68% (not reached) vs 77% (not reached), respectively, for early-stage, premenopausal breast cancer; 52% (10.2 years) vs 62% (13.5 years) for early-stage, postmenopausal breast cancer; 13% (1.3 years) vs 17% (2.3 years) for advanced ovarian cancer; and 6% (2.2 years) vs 9% (2.7 years) for advanced prostate cancer. CONCLUSIONS: African American patients with sex-specific cancers had worse survival than white patients, despite enrollment on phase III SWOG trials with uniform stage, treatment, and follow-up.
AD  - Department of Medicine, Loyola University Chicago Stritch School of Medicine, Maywood, IL, USA. kalbain@lumc.edu
AN  - 19584328
AU  - Albain, K. S.
AU  - Unger, J. M.
AU  - Crowley, J. J.
AU  - Coltman, C. A., Jr.
AU  - Hershman, D. L.
C2  - PMC2724852
DA  - Jul 15
DO  - 10.1093/jnci/djp175
DP  - NLM
ET  - 2009/07/09
IS  - 14
KW  - Adult
African Americans/*statistics & numerical data
Aged
Breast Neoplasms/mortality
Clinical Trials, Phase III as Topic
Colorectal Neoplasms/mortality
Confidence Intervals
Confounding Factors, Epidemiologic
Educational Status
European Continental Ancestry Group/statistics & numerical data
Female
*Health Status Disparities
Humans
Income
Kaplan-Meier Estimate
Leukemia/mortality
Lung Neoplasms/mortality
Lymphoma/mortality
Male
Middle Aged
Multiple Myeloma/mortality
Neoplasm Staging
Neoplasms/*mortality/pathology/therapy
Odds Ratio
Ovarian Neoplasms/mortality
Prognosis
Proportional Hazards Models
Prostatic Neoplasms/mortality
Randomized Controlled Trials as Topic
Risk Assessment
Risk Factors
Socioeconomic Factors
Survival Rate
United States/epidemiology
LA  - eng
N1  - 1460-2105
Albain, Kathy S
Unger, Joseph M
Crowley, John J
Coltman, Charles A Jr
Hershman, Dawn L
CA22433/CA/NCI NIH HHS/United States
CA32102/CA/NCI NIH HHS/United States
CA38926/CA/NCI NIH HHS/United States
CA46282/CA/NCI NIH HHS/United States
Journal Article
Meta-Analysis
Research Support, N.I.H., Extramural
J Natl Cancer Inst. 2009 Jul 15;101(14):984-92. doi: 10.1093/jnci/djp175. Epub 2009 Jul 7.
PY  - 2009
SN  - 0027-8874 (Print)
0027-8874
SP  - 984-92
ST  - Racial disparities in cancer survival among randomized clinical trials patients of the Southwest Oncology Group
T2  - J Natl Cancer Inst
TI  - Racial disparities in cancer survival among randomized clinical trials patients of the Southwest Oncology Group
VL  - 101
ID  - 458
ER  - 

TY  - JOUR
AB  - BACKGROUND: Federal and Pennsylvania state policies instituted in the late 1990s were designed to improve access to postmastectomy breast reconstruction. We sought to evaluate the impact of these policy changes on access to care among racial minorities. METHODS: Mastectomy patients ≥18 years old were identified in the Pennsylvania Health Care Cost Containment Council inpatient database (1994-2004) and classified by immediate breast reconstruction (IBR) status. Rates of IBR were calculated by patient characteristics and year. Patients were stratified by race before (1994-1997) and after (2001-2004) policy changes, and relative odds of IBR were estimated by univariate and multivariate logistic regression analyses with adjustment for known confounders. RESULTS: Overall rates of IBR were significantly higher in the time period after policy change compared to before policy change (18.5 vs. 32.7 %, p < 0.01). White, black, and Asian patients all saw a significant rise in rates of IBR. However, after adjustment for potential confounders, black patients, Asian patients, and those of mixed or other races all remained less likely to undergo IBR when compared to white patients after policy changes (odds ratio [OR] 0.66, 95 % confidence interval [CI] 0.55-0.80; OR 0.30, 95 % CI 0.18-0.49; OR 0.29, 95 % CI 0.16-0.51, respectively). CONCLUSIONS: Rates of IBR increased across all racial groups after policy changes. However, not all races were affected equally, and thus disparities remained. Future studies are needed to investigate the role of other factors, including cultural preferences in utilization of IBR that might explain residual disparities.
AD  - Department of Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA, USA. srachel@mail.med.upenn.edu
AN  - 23054106
AU  - Yang, R. L.
AU  - Newman, A. S.
AU  - Reinke, C. E.
AU  - Lin, I. C.
AU  - Karakousis, G. C.
AU  - Czerniecki, B. J.
AU  - Wu, L. C.
AU  - Kelz, R. R.
DA  - Feb
DO  - 10.1245/s10434-012-2607-9
DP  - NLM
ET  - 2012/10/12
IS  - 2
KW  - Adult
African Americans/*statistics & numerical data
Aged
Breast Neoplasms/*surgery
European Continental Ancestry Group/*statistics & numerical data
Female
Health Policy/*legislation & jurisprudence
Healthcare Disparities/*legislation & jurisprudence
Humans
Mammaplasty/*legislation & jurisprudence
*Mastectomy
Middle Aged
Patient Selection
Pennsylvania
Prognosis
Retrospective Studies
LA  - eng
N1  - 1534-4681
Yang, Rachel L
Newman, Andrew S
Reinke, Caroline E
Lin, Ines C
Karakousis, Giorgos C
Czerniecki, Brian J
Wu, Liza C
Kelz, Rachel R
Journal Article
United States
Ann Surg Oncol. 2013 Feb;20(2):399-406. doi: 10.1245/s10434-012-2607-9. Epub 2012 Oct 3.
PY  - 2013
SN  - 1068-9265
SP  - 399-406
ST  - Racial disparities in immediate breast reconstruction after mastectomy: impact of state and federal health policy changes
T2  - Ann Surg Oncol
TI  - Racial disparities in immediate breast reconstruction after mastectomy: impact of state and federal health policy changes
VL  - 20
ID  - 353
ER  - 

TY  - JOUR
AB  - PURPOSE: Intravenous (IV) bisphosphonates reduce the risk of skeletal-related events in patients with multiple myeloma (MM). However, data describing racial differences in IV bisphosphonate utilization outside of clinical trial settings are limited. We evaluated population-level IV bisphosphonate initiation and discontinuation among patients of age ≥ 65 years with MM. METHODS: We conducted a retrospective cohort study of patients of age ≥ 65 years diagnosed with first primary MM between 2001 and 2011. Patients were identified using the SEER-Medicare linked database and followed through December 2013. Cumulative incidences of IV bisphosphonate initiation and time to discontinuation among users were compared between racial and ethnic groups. In Fine and Gray competing risk models, we estimated subdistribution hazard ratios (SHRs) and 95% CIs for initiation and discontinuation. RESULTS: We included 14,231 eligible patients with MM (median age, 76 years; 52% male). Over a median follow-up of 23.1 months, 54% of patients received at least one IV bisphosphonate dose. Our final analytical sample included 10,456 non-Hispanic (NH) Whites, 2,267 NH Blacks, 548 Asian and Pacific islanders, and 815 Hispanic and Latino patients. A higher proportion of White patients (56.1%) newly received IV bisphosphonates after MM diagnosis compared with NH Blacks (45.4%). Compared with White patients, NH Black patients were less likely to initiate IV bisphosphonates (SHR, 0.74; 95% CI, 0.70 to 0.79) and slightly more likely to discontinue treatment (SHR, 1.10; 95% CI, 1.01 to 1.19). CONCLUSION: Approximately half of the patients with MM of age ≥ 65 years did not receive IV bisphosphonates, with significant delay among racial minority groups. These findings highlight the need for improvement of IV bisphosphonate uptake in patients with MM of age ≥ 65 years.
AU  - Zhou, J.
AU  - Sweiss, K.
AU  - Nutescu, E. A.
AU  - Han, J.
AU  - Patel, P. R.
AU  - Ko, N. Y.
AU  - Lee, T. A.
AU  - Chiu, B. C. H.
AU  - Calip, G. S.
DB  - Medline
DO  - 10.1200/OP.20.00479
KW  - aged
article
Black person
cancer patient
Caucasian
clinical trial
cohort analysis
controlled study
cumulative incidence
drug therapy
drug withdrawal
ethnic group
female
follow up
Hispanic
human
major clinical study
male
medicare
minority group
multiple myeloma
Pacific Islander
retrospective study
risk assessment
bisphosphonic acid derivative
LA  - English
M3  - Article in Press
N1  - L634044682
2021-02-03
PY  - 2021
SN  - 2688-1535
SP  - OP2000479
ST  - Racial Disparities in Intravenous Bisphosphonate Use Among Older Patients With Multiple Myeloma Enrolled in Medicare
T2  - JCO oncology practice
TI  - Racial Disparities in Intravenous Bisphosphonate Use Among Older Patients With Multiple Myeloma Enrolled in Medicare
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L634044682&from=export
http://dx.doi.org/10.1200/OP.20.00479
ID  - 758
ER  - 

TY  - JOUR
AN  - 20357246
AU  - Ayanian, J. Z.
DA  - Apr 21
DO  - 10.1093/jnci/djq089
DP  - NLM
ET  - 2010/04/02
IS  - 8
KW  - African Americans/*statistics & numerical data
Colorectal Neoplasms/*epidemiology/ethnology/genetics/mortality/*prevention &
control
Delivery of Health Care/*statistics & numerical data
Early Detection of Cancer/statistics & numerical data/trends
European Continental Ancestry Group/*statistics & numerical data
Female
Genetic Predisposition to Disease
Healthcare Disparities/*statistics & numerical data
Humans
Incidence
Lung Neoplasms/prevention & control
Male
Mass Screening/methods/statistics & numerical data
Ovarian Neoplasms/prevention & control
Prostatic Neoplasms/prevention & control
Randomized Controlled Trials as Topic
Risk Factors
Socioeconomic Factors
United States/epidemiology
LA  - eng
N1  - 1460-2105
Ayanian, John Z
Comment
Editorial
United States
J Natl Cancer Inst. 2010 Apr 21;102(8):511-3. doi: 10.1093/jnci/djq089. Epub 2010 Mar 31.
PY  - 2010
SN  - 0027-8874
SP  - 511-3
ST  - Racial disparities in outcomes of colorectal cancer screening: biology or barriers to optimal care?
T2  - J Natl Cancer Inst
TI  - Racial disparities in outcomes of colorectal cancer screening: biology or barriers to optimal care?
VL  - 102
ID  - 426
ER  - 

TY  - JOUR
AB  - INTRODUCTION: African American men have the highest rates of prostate cancer of any racial group, but very little is known about the psychological functioning of African American men in response to prostate cancer diagnosis and treatment. PURPOSE: In this secondary analysis of a national trial testing a psychological intervention for prostate cancer patients, we report on the traumatic stress symptoms of African American and non-African American men. METHODS: This analysis includes 317 men (African American: n = 30, 9%; non-African American: n = 287, 91%) who were enrolled in the intervention trial, which included 12 weeks of group psychotherapy and 24 months of follow-up. Using mixed model analysis, total score on the Impact of Events Scale (IES) and its Intrusion and Avoidance subscales were examined to determine mean differences in traumatic stress across all time points (0, 3, 6, 12, 18, and 24 months). In an additional analysis, relevant psychosocial, demographic, and clinical variables were added to the model. RESULTS: Results showed significantly higher levels of traumatic stress for African American men compared to non-African American men in all models independently of the intervention arm, demographics, and relevant clinical variables. African Americans also had a consistently higher prevalence of clinically significant traumatic stress symptoms (defined as IES total score ≥ 27). These elevations remained across all time points over 24 months. CONCLUSIONS: This is the first study to show a racial disparity in traumatic stress specifically as an aspect of overall psychological adjustment to prostate cancer. Recommendations are made for appropriate assessment, referral, and treatment of psychological distress in this vulnerable population.
AD  - Washington University in St. Louis, Health Communication Research Laboratory, 700 Rosedale Ave., Campus Box 1009, St. Louis, MO 63112, USA. jpurnell@gwbmail.wustl.edu
AN  - 20414685
AU  - Purnell, J. Q.
AU  - Palesh, O. G.
AU  - Heckler, C. E.
AU  - Adams, M. J.
AU  - Chin, N.
AU  - Mohile, S.
AU  - Peppone, L. J.
AU  - Atkins, J. N.
AU  - Moore, D. F.
AU  - Spiegel, D.
AU  - Messing, E.
AU  - Morrow, G. R.
C2  - PMC3110634
C6  - NIHMS269749
DA  - Jul
DO  - 10.1007/s00520-010-0880-3
DP  - NLM
ET  - 2010/04/24
IS  - 7
KW  - Adaptation, Psychological
Adult
African Americans/*statistics & numerical data
Aged
Aged, 80 and over
European Continental Ancestry Group/*statistics & numerical data
*Health Status Disparities
Health Status Indicators
Humans
Male
Middle Aged
Prostatic Neoplasms/epidemiology/*psychology
Psychometrics
Quality of Life/psychology
Stress Disorders, Post-Traumatic/epidemiology/*psychology
*Stress, Psychological
United States/epidemiology
LA  - eng
N1  - 1433-7339
Purnell, Jason Q
Palesh, Oxana G
Heckler, Charles E
Adams, M Jacob
Chin, Nancy
Mohile, Supriya
Peppone, Luke J
Atkins, James N
Moore, Dennis F
Spiegel, David
Messing, Edward
Morrow, Gary R
R25 CA102618-06A1/CA/NCI NIH HHS/United States
CA037420/CA/NCI NIH HHS/United States
R25CA102618/CA/NCI NIH HHS/United States
U10 CA037420/CA/NCI NIH HHS/United States
R25 CA102618/CA/NCI NIH HHS/United States
Comparative Study
Journal Article
Research Support, N.I.H., Extramural
Support Care Cancer. 2011 Jul;19(7):899-907. doi: 10.1007/s00520-010-0880-3. Epub 2010 Apr 23.
PY  - 2011
SN  - 0941-4355 (Print)
0941-4355
SP  - 899-907
ST  - Racial disparities in traumatic stress in prostate cancer patients: secondary analysis of a National URCC CCOP Study of 317 men
T2  - Support Care Cancer
TI  - Racial disparities in traumatic stress in prostate cancer patients: secondary analysis of a National URCC CCOP Study of 317 men
VL  - 19
ID  - 422
ER  - 

TY  - JOUR
AB  - PURPOSE: Black women with breast cancer have poorer survival than do white women, but little is known about racial disparities in male breast cancer. We analyzed race and other predictors of treatment and survival among men with stage I-III breast cancer. PATIENTS AND METHODS: We used the Surveillance, Epidemiology, and End Results (SEER) Medicare database to identify men 65 years of age or older diagnosed with stage I-III breast cancer from 1991 to 2002. Multivariate regression was used to compare those treated with those not treated with either chemotherapy or radiation therapy, adjusting for known clinical and demographic factors. Cox proportional hazards regression models were used to analyze survival. RESULTS: Of 510 male breast cancer cases (456 white, 34 black), 94% underwent mastectomy, 28% received adjuvant chemotherapy, and 29% received radiation therapy. Among those with known hormone receptors, 95% had hormone-sensitive tumors. In a multivariate analysis, chemotherapy was associated with younger age, advanced stage, and hormone receptor-negative tumors. Radiation therapy was associated with younger age and advanced stage. Black men were approximately 50% less likely to undergo consultation with an oncologist and subsequently receive chemotherapy; however, the results did not reach statistical significance. The breast cancer-specific mortality hazard ratio was more than tripled for black versus white men (hazard ratio = 3.29; 95% CI, 1.10 to 9.86). CONCLUSION: After adjustment for known clinical, demographic, and treatment factors, there was an association of black race with increased male breast cancer-specific mortality. Although male breast cancer is rare, the reasons for these disparities need to be better understood.
AD  - Department of Medicine and the Herbert Irving Comprehensive Cancer Center, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA. dlh23@columbia.edu
AN  - 17369572
AU  - Crew, K. D.
AU  - Neugut, A. I.
AU  - Wang, X.
AU  - Jacobson, J. S.
AU  - Grann, V. R.
AU  - Raptis, G.
AU  - Hershman, D. L.
DA  - Mar 20
DO  - 10.1200/jco.2006.09.1710
DP  - NLM
ET  - 2007/03/21
IS  - 9
KW  - African Americans/*statistics & numerical data
Age Factors
Aged
Aged, 80 and over
Breast Neoplasms, Male/ethnology/*mortality/pathology/*therapy
Chemotherapy, Adjuvant/statistics & numerical data
European Continental Ancestry Group/*statistics & numerical data
Follow-Up Studies
Humans
Kaplan-Meier Estimate
Male
Mastectomy/statistics & numerical data
Medicare
Neoplasm Staging
Odds Ratio
Patient Selection
Predictive Value of Tests
Prognosis
Proportional Hazards Models
Radiotherapy, Adjuvant/statistics & numerical data
Referral and Consultation/statistics & numerical data
SEER Program
Time Factors
Treatment Outcome
United States/epidemiology
LA  - eng
N1  - 1527-7755
Crew, Katherine D
Neugut, Alfred I
Wang, Xiaoyan
Jacobson, Judith S
Grann, Victor R
Raptis, George
Hershman, Dawn L
CA95597/CA/NCI NIH HHS/United States
K05 CA89155/CA/NCI NIH HHS/United States
T32-CA09529/CA/NCI NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
United States
J Clin Oncol. 2007 Mar 20;25(9):1089-98. doi: 10.1200/JCO.2006.09.1710.
PY  - 2007
SN  - 0732-183x
SP  - 1089-98
ST  - Racial disparities in treatment and survival of male breast cancer
T2  - J Clin Oncol
TI  - Racial disparities in treatment and survival of male breast cancer
VL  - 25
ID  - 532
ER  - 

TY  - JOUR
AB  - Data characterizing demographics, treatment patterns, and clinical outcomes in black patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) are limited. registHER is a large, observational cohort study of patients (n = 1,001) with HER2-positive MBC diagnosed ≤6 months of enrollment and followed until death, disenrollment, or June 2009 (median follow-up of 27 months). Demographics, treatment patterns, and clinical outcomes were described for black (n = 126) and white patients (n = 793). Progression-free survival (PFS) following first-line therapy and overall survival (OS) were examined. Multivariate analyses adjusted for baseline and treatment factors. Black patients were more likely than white patients to be obese (body mass index ≥30), to have diabetes, and to have a history of cardiovascular disease; they were also less likely to have estrogen receptor or progesterone receptor positive disease. In patients treated with trastuzumab, the incidence of cardiac safety events (grade ≥3) was higher in black patients (10.9 %) than in white patients (7.9 %). Unadjusted median OS and PFS (months) were significantly lower in black patients than in white patients (OS: black: 27.1, 95 % confidence interval [CI] 21.3-32.1; white: 37.3, 95 % CI 34.6-41.1; PFS: black: 7.0, 95 % CI 5.7-8.2; white: 10.2, 95 % CI 9.3-11.2). The adjusted OS hazard ratio (HR) for black patients compared with white patients was 1.29 (95 % CI 1.00-1.65); adjusted PFS HR was 1.29 (95 % CI 1.05-1.59). This real-world evaluation of a large cohort of patients with HER2-positive MBC shows poorer prognostic factors and independently worse clinical outcomes in black versus white patients. Further research is needed to identify potential biologic differences that could have predictive impact for black patients or that could explain these differences. © 2013 The Author(s).
AD  - H.S. Rugo, University of California San Francisco, Helen Diller Family Comprehensive Cancer Center, 1600 Divisadero Street, Box 1710, San Francisco, CA 94143-1710, United States
AU  - Rugo, H. S.
AU  - Brufsky, A. M.
AU  - Yood, M. U.
AU  - Tripathy, D.
AU  - Kaufman, P. A.
AU  - Mayer, M.
AU  - Yoo, B.
AU  - Abidoye, O. O.
AU  - Yardley, D. A.
DB  - Embase
Medline
DO  - 10.1007/s10549-013-2697-5
IS  - 3
KW  - NCT00105456
epidermal growth factor receptor 2
estrogen receptor
hormone
progesterone receptor
trastuzumab
adult
aged
angina pectoris
article
metastatic breast cancer
cancer chemotherapy
cancer hormone therapy
cardiovascular disease
Caucasian
cohort analysis
congestive heart failure
demography
diabetes mellitus
drug efficacy
drug safety
female
follow up
heart atrium arrhythmia
heart disease
heart infarction
heart left ventricle failure
heart ventricle arrhythmia
HER2 positive metastatic breast cancer
human
incidence
major clinical study
male
medical history
multicenter study (topic)
Black person
obesity
observational study
outcome assessment
overall survival
pericardial effusion
priority journal
prognosis
progression free survival
race difference
LA  - English
M3  - Article
N1  - L370187868
2013-11-29
PY  - 2013
SN  - 0167-6806
1573-7217
SP  - 461-470
ST  - Racial disparities in treatment patterns and clinical outcomes in patients with HER2-positive metastatic breast cancer
T2  - Breast Cancer Research and Treatment
TI  - Racial disparities in treatment patterns and clinical outcomes in patients with HER2-positive metastatic breast cancer
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L370187868&from=export
http://dx.doi.org/10.1007/s10549-013-2697-5
VL  - 141
ID  - 1070
ER  - 

TY  - JOUR
AB  - OBJECTIVES: To perform a review of patient and disease characteristics and response and survival outcomes of patients with metastatic androgen-independent prostate cancer. Racial differences in prostate cancer have usually been attributed to socioeconomic status, quality of care, comorbidities, and dietary factors. In a clinical trial population, some of these factors, such as access to care and performance status, are likely to be relatively uniform. METHODS: The patients included in the review had been registered in clinical trials between 1991 and 2001 at Wayne State University. RESULTS: Of 145 patients, 90 (62%) were white Americans and 55 (38%) were black Americans, 27% were 70 years or older, and 34% had minimal metastatic disease (axial bony involvement and/or lymph node involvement) and 66% had extensive disease (appendicular skeleton and/or visceral involvement). The chi-square test demonstrated no statistically significant difference by race in the distribution of the patient and disease characteristics. The prostate-specific antigen response rate was 41% in whites and 29% in blacks (P = 0.12). Log-rank analysis revealed race to be the only statistically significant factor predictive of the time to prostate-specific antigen progression (P = 0.02, median 4.6 months in whites and 2.3 months in blacks). No statistically significant difference by race was found in overall survival. Poor performance status, extensive disease, elevated alkaline phosphatase and lactate dehydrogenase levels, and a lack of prostate-specific antigen response were statistically significant predictors of worse overall survival. CONCLUSIONS: In patients with androgen-independent metastatic prostate cancer studied in clinical trials, race was an independent predictor of therapeutic outcome. Additional investigation of the biologic and genetic differences underlying this clinical disparity is warranted.
AD  - Division of Oncology, Department of Medicine, Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, Michigan 48201, USA.
AN  - 15491712
AU  - Thatai, L. C.
AU  - Banerjee, M.
AU  - Lai, Z.
AU  - Vaishampayan, U.
DA  - Oct
DO  - 10.1016/j.urology.2004.05.024
DP  - NLM
ET  - 2004/10/20
IS  - 4
KW  - Adenocarcinoma/blood/drug therapy/*ethnology/mortality/radiotherapy/secondary
*African Americans
Aged
Aged, 80 and over
Alkaline Phosphatase/blood
Antineoplastic Agents/therapeutic use
Biomarkers, Tumor/blood
Bone Neoplasms/ethnology/secondary
Cell Differentiation
Clinical Trials as Topic
Combined Modality Therapy
Disease Progression
Disease-Free Survival
*European Continental Ancestry Group
Humans
L-Lactate Dehydrogenase/blood
Lymphatic Metastasis
Male
Middle Aged
Neoplasm Proteins/blood
Prognosis
Prostate-Specific Antigen/blood
Prostatic Neoplasms/blood/drug therapy/*ethnology/mortality/pathology/radiotherapy
Retrospective Studies
Survival Analysis
Treatment Outcome
LA  - eng
N1  - 1527-9995
Thatai, Lata Chandi
Banerjee, Mousumi
Lai, Zongshan
Vaishampayan, Ulka
Comparative Study
Journal Article
Research Support, Non-U.S. Gov't
Review
United States
Urology. 2004 Oct;64(4):738-43. doi: 10.1016/j.urology.2004.05.024.
PY  - 2004
SN  - 0090-4295
SP  - 738-43
ST  - Racial disparity in clinical course and outcome of metastatic androgen-independent prostate cancer
T2  - Urology
TI  - Racial disparity in clinical course and outcome of metastatic androgen-independent prostate cancer
VL  - 64
ID  - 617
ER  - 

TY  - JOUR
AB  - Background: The gap in prostate cancer (PCa) survival between Blacks and Whites has widened over the past decade. Investigators hypothesize that this disparity may be partially attributable to differences in rates of definitive therapy between races. Objective: To examine facility level variation in the use of definitive therapy among Black and White men for localized PCa. Design, setting, and participants: Using data from the National Cancer Data Base, we identified 223 873 White and 59 262 Black men ≥40 yr of age receiving care within the USA with biopsy confirmed localized intermediate/high-risk PCa diagnosed between January 2004 and December 2013. Outcome measurements and statistical analysis: Multilevel logistic regression was fitted to predict the odds of receiving definitive therapy for PCa. Sensitivity and subgroup analyses were performed to adjust for inherent patient and facility-level differences when appropriate. Results and limitations: Eighty-three percent (n = 185 647) of White men received definitive therapy compared with 74% (n = 43 662) of Black men between 2004 and 2013. Overall rates of definitive therapy during that time increased for both White (81% vs 83%, p < 0.001) and Black (73% vs 75%, p = 0.001) men. However, 39% of treating facilities demonstrated significantly higher rates of definitive therapy in White men, compared with just 1% favoring Black men. Our study is limited by potential selection bias and effect modification. Conclusions: After adjusting for sociodemographic and clinical factors, we found that most facilities favored definitive therapy in Whites. Health care providers should be aware of these inherit biases when counseling patients on treatment options for localized PCa. Our study is limited by the retrospective nature of the cohort. Patient summary: We found significant differences in rates of radiation and surgical treatment for prostate cancer among White and Black men, with most facilities favoring Whites. Nonclinical factors such as treatment facility type and location influenced rates of therapy. We show that significant variation in rates of definitive therapy for intermediate/high-risk localized prostate cancer exists between White and Black men. This nonclinical variation represents a potential target for quality of care initiatives recently launched by US health care agencies.
AD  - Q.-D. Trinh, Harvard Medical School, 45 Francis Street, ASB II-3, Boston, MA, United States
AU  - Friedlander, D. F.
AU  - Trinh, Q. D.
AU  - Krasnova, A.
AU  - Lipsitz, S. R.
AU  - Sun, M.
AU  - Nguyen, P. L.
AU  - Kibel, A. S.
AU  - Choueiri, T. K.
AU  - Weissman, J. S.
AU  - Menon, M.
AU  - Abdollah, F.
DB  - Embase
Medline
DO  - 10.1016/j.eururo.2017.07.023
IS  - 3
KW  - adult
aged
article
Black person
cancer localization
cancer patient
cancer risk
cancer staging
cancer therapy
Caucasian
Charlson Comorbidity Index
Charlson Deyo Comorbidity Index
cohort analysis
Gleason score
health care delivery
health care disparity
high risk patient
highest income group
human
human tissue
insurance
intermediate risk patient
major clinical study
male
medicare
middle aged
outcome assessment
patient selection
priority journal
prostate adenocarcinoma
prostate biopsy
race difference
reference database
social status
tumor biopsy
LA  - English
M3  - Article
N1  - L617624534
2017-08-08
2018-02-23
PY  - 2018
SN  - 1873-7560
0302-2838
SP  - 445-451
ST  - Racial Disparity in Delivering Definitive Therapy for Intermediate/High-risk Localized Prostate Cancer: The Impact of Facility Features and Socioeconomic Characteristics
T2  - European Urology
TI  - Racial Disparity in Delivering Definitive Therapy for Intermediate/High-risk Localized Prostate Cancer: The Impact of Facility Features and Socioeconomic Characteristics
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L617624534&from=export
http://dx.doi.org/10.1016/j.eururo.2017.07.023
VL  - 73
ID  - 905
ER  - 

TY  - JOUR
AB  - BACKGROUND: To better understand patient-reported quality of life (PRQOL) for patients with head and neck cancer, PRQOL scores were collected in a clinical trial. METHODS: Patients were randomized to arm A (70 Gy of radiation with cisplatin) or arm B (70 Gy of radiation with cisplatin plus erlotinib at 150 mg daily). PRQOL scores were measured on days -7 (arm B only), 0, 30, and 180 with the University of Washington Quality of Life Questionnaire. Associations with clinical factors and outcomes were explored with linear mixed, logistic, and Cox regression models. RESULTS: One hundred eighty-nine patients (97 in arm A and 92 in arm B) consented to PRQOL collection. Patients were balanced apart from more females in arm A (20 [21%] vs 8 [9%]; P=.02). There were 17 black patients (18%) in arm A and 12 (13%) in arm B (P=.39). There was no change in the mean scores in arm B from day -7 to day 0 (P=.36). Scores were lower in both arms at day 30 (P for both<.0001), with no difference by arm (P=.10). Scores on day 180 remained lower for arm A (-6.79; 95% confidence interval [CI], -12.6 to -1.0; P=.02). In arm B, this difference was not significant, and this suggested that the scores had returned to the baseline by day 180 (P=.73). After adjustments for potential confounders, black race was an independent predictor for inferior scores (-11.4; 95% CI, -16.84 to -5.94; P<.0001), complete response rates (odds ratio, 0.34; 95% CI, 0.12-0.91; P=.03), and overall survival (hazard ratio, 3.71; 95% CI, 1.63-8.47; P<.01). CONCLUSIONS: PRQOL scores predictably worsened during and improved after chemoradiation. Black patients had inferior PRQOL and overall survival. (C) 2018 American Cancer Society.
AN  - WOS:000435440900024
AU  - Guerriero, M. K.
AU  - Redman, M. W.
AU  - Baker, K. K.
AU  - Martins, R. G.
AU  - Eaton, K.
AU  - Chow, L. Q.
AU  - Santana-Davila, R.
AU  - Baik, C.
AU  - Goulart, B. H.
AU  - Lee, S.
AU  - Rodriguez, C. P.
DA  - Jul
DO  - 10.1002/cncr.31407
IS  - 13
N1  - 29669181
PY  - 2018
SN  - 0008-543X
SP  - 2841-2849
ST  - Racial disparity in oncologic and quality-of-life outcomes in patients with locally advanced head and neck squamous cell carcinomas enrolled in a randomized phase 2 trial
T2  - Cancer
TI  - Racial disparity in oncologic and quality-of-life outcomes in patients with locally advanced head and neck squamous cell carcinomas enrolled in a randomized phase 2 trial
VL  - 124
ID  - 2854
ER  - 

TY  - JOUR
AB  - Objectives. Population studies have revealed that black Americans with renal cell carcinoma (RCC) have a shorter survival than do white Americans. Differences in socioeconomic status and treatment are frequently cited as the reasons for this disparity. The effect of these social obstacles may be reduced by studying a patient population with advanced RCC enrolled in clinical trials, because patients in these trials are likely to be similar in terms of their access to care, compliance, and performance status. Methods. A retrospective review of all patients with metastatic RCC enrolled in clinical trials at Wayne State University from 1992 to 2002 was conducted. Log-rank survival analysis by age, sex, race, smoking history, nephrectomy history, prior therapy, type of protocol therapy (immunotherapy versus other), performance status (0 versus 1 to 2), and number of metastatic sites was conducted. Univariate and multivariate comparisons by race were performed for overall survival and time to progression. Results. A total of 122 patients (median age 57 years) were enrolled; 21 (17%) were black and 101 (83%) were white. Overall survival was significantly shorter for the black Americans (P = 0.0027). The median survival for black Americans and white Americans was 6.9 and 11.5 months, respectively. On multivariate analysis, black race and performance status of 0 versus 1 and 2 were significant predictors of shorter survival. The presence of liver metastases and/or the absence of prior nephrectomy also influenced the length of overall survival through an interaction effect. Conclusions. Within a clinical trial patient population with RCC, race was a significant predictor of overall survival.
AN  - WOS:000240565800016
AU  - Tripathi, R. T.
AU  - Heilbrun, L. K.
AU  - Jain, V.
AU  - Vaishampayan, U. N.
DA  - Aug
DO  - 10.1016/j.urology.2006.02.036
IS  - 2
N1  - 39th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
MAY 31-JUN 03, 2003
Chicago, IL
Amer Soc Clin Oncol (ASCO)
16904440
PY  - 2006
SN  - 0090-4295
SP  - 296-301
ST  - Racial disparity in outcomes of a clinical trial population with metastatic renal cell carcinoma
T2  - Urology
TI  - Racial disparity in outcomes of a clinical trial population with metastatic renal cell carcinoma
VL  - 68
ID  - 3215
ER  - 

TY  - JOUR
AB  - BACKGROUND: African Americans (AAs) in the United States are known to have a higher incidence and mortality for Prostate Cancer (PCa). The drivers of this epidemiological disparity are multifactorial, including socioeconomic factors leading to lifestyle and dietary issues, healthcare access problems, and potentially tumor biology. RECENT FINDINGS: Although recent evidence suggests once access is equal, AA men have equal outcomes to Caucasian American (CA) men, differences in PCa incidence remain, and there is much to do to reverse disparities in mortality across the USA. A deeper understanding of these issues, both at the clinical and molecular level, can facilitate improved outcomes in the AA population. This review first discusses PCa oncogenesis in the context of its diverse hallmarks before benchmarking key molecular and genomic differences for PCa in AA men that have emerged in the recent literature. Studies have emphasized the importance of tumor microenvironment that contributes to both the unequal cancer burden and differences in clinical outcome between the races. Management of comorbidities like obesity, hypertension, and diabetes will provide an essential means of reducing prostate cancer incidence in AA men. Although requiring further AA specific research, several new treatment strategies such as immune checkpoint inhibitors used in combination PARP inhibitors and other emerging vaccines, including Sipuleucel-T, have demonstrated some proven efficacy. CONCLUSION: Genomic profiling to integrate clinical and genomic data for diagnosis, prognosis, and treatment will allow physicians to plan a "Precision Medicine" approach to AA men. There is a pressing need for further research for risk stratification, which may allow early identification of AA men with higher risk disease based on their unique clinical, genomic, and immunological profiles, which can then be mapped to appropriate clinical trials. Treatment options are outlined, with a concise description of recent work in AA specific populations, detailing several targeted therapies, including immunotherapy. Also, a summary of current clinical trials involving AA men is presented, and it is important that policies are adopted to ensure that AA men are actively recruited. Although it is encouraging that many of these explore the lifestyle and educational initiatives and therapeutic interventions, there is much still work to be done to reduce incidence and mortality in AA men and equalize current racial disparities.
AD  - The Department of Urology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
AN  - 33599076
AU  - Dovey, Z. S.
AU  - Nair, S. S.
AU  - Chakravarty, D.
AU  - Tewari, A. K.
DA  - Feb 17
DO  - 10.1002/cnr2.1340
DP  - NLM
ET  - 2021/02/19
KW  - actionable ideas
biomarkers
genomic differences
immunotherapy
molecular differences
racial disparity
socioeconomic issues
LA  - eng
N1  - 2573-8348
Dovey, Zachary S
Orcid: 0000-0002-2231-8429
Nair, Sujit S
Orcid: 0000-0002-3039-523x
Chakravarty, Dimple
Orcid: 0000-0002-5021-4440
Tewari, Ashutosh K
Orcid: 0000-0002-3146-4524
Deane Prostate Health, ISMMS/
The Arthur M. Blank Family Foundation/
Journal Article
Review
United States
Cancer Rep (Hoboken). 2021 Feb 17:e1341. doi: 10.1002/cnr2.1340.
PY  - 2021
SN  - 2573-8348
SP  - e1341
ST  - Racial disparity in prostate cancer in the African American population with actionable ideas and novel immunotherapies
T2  - Cancer Rep (Hoboken)
TI  - Racial disparity in prostate cancer in the African American population with actionable ideas and novel immunotherapies
ID  - 4
ER  - 

TY  - JOUR
AN  - 10519904
AU  - King, T. E., Jr.
AU  - Brunetta, P.
DA  - Oct 14
DO  - 10.1056/nejm199910143411612
DP  - NLM
ET  - 1999/10/16
IS  - 16
KW  - *African Continental Ancestry Group
Aged
Biomedical Research
Carcinoma, Non-Small-Cell Lung/*ethnology/surgery
European Continental Ancestry Group
Health Services Accessibility
Humans
Lung Neoplasms/*ethnology/prevention & control/surgery
Patient Selection
Physician-Patient Relations
Prejudice
Survival Rate
United States
Professional Patient Relationship
LA  - eng
N1  - King, T E Jr
Brunetta, P
Comment
Editorial
United States
N Engl J Med. 1999 Oct 14;341(16):1231-3. doi: 10.1056/NEJM199910143411612.
PY  - 1999
SN  - 0028-4793 (Print)
0028-4793
SP  - 1231-3
ST  - Racial disparity in rates of surgery for lung cancer
T2  - N Engl J Med
TI  - Racial disparity in rates of surgery for lung cancer
VL  - 341
ID  - 714
ER  - 

TY  - JOUR
AB  - BACKGROUND: Relatively little is known about the relationship between race/ethnicity and patient-reported outcomes after contemporary treatments for localized prostate cancer. OBJECTIVE: To test the hypothesis that treatment-related changes in urinary, bowel, sexual, and hormonal function vary by race/ethnicity. DESIGN, SETTING, AND PARTICIPANTS: The Comparative Effectiveness Analysis of Surgery and Radiation (CEASAR) study is a prospective, population-based, observational study that enrolled 3708 men diagnosed with localized prostate cancer in 2011-2012. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Patient-reported disease-specific function was measured using the 26-item Expanded Prostate Index Composite (EPIC) at baseline and 6 and 12 mo after enrollment. Mean treatment differences in function were compared by race using risk-adjusted generalized estimating equations. RESULTS AND LIMITATIONS: While all race/ethnic groups reported considerable declines in scores for urinary incontinence after radical prostatectomy (RP) when compared to active surveillance, African-American men reported a greater difference than white men did (adjusted difference-in-differences 8.4 points, 95% confidence interval 2.0-14.8; p=0.01). No difference in bother scores was noted and the overall proportion of explained variation attributable to race/ethnicity was relatively small in comparison to primary treatment and baseline function. No clinically significant racial variation was noted for the sexual, bowel, irritative voiding, or hormone domains. Limitations include the lack of well-established thresholds for clinical significance using the EPIC instrument. CONCLUSION: While these data demonstrate that incontinence at 1 yr after RP may be worse for African-American compared to white men, the difference appears to be modest overall. Treatment selection and baseline function explain a much greater proportion of the variation in function after treatment. PATIENT SUMMARY: We observed that the effect of treatment for prostate cancer on patient-reported function did not vary dramatically by race/ethnicity. Compared to white men, African-American men experienced a somewhat more pronounced decline in urinary continence after radical prostatectomy, but the corresponding changes in bother scores were not significantly different between the two groups.
AD  - Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, TN, USA. Electronic address: mark.tyson@vanderbilt.edu.
Department of Biostatistics, Vanderbilt University School of Medicine, Nashville, TN, USA.
Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, TN, USA; Department of Health Policy, Vanderbilt University School of Medicine, Nashville, TN, USA; The Geriatric Research, Education, and Clinical Center, Tennessee Valley Veterans Affairs Health Care System, Nashville, TN, USA.
School of Public Health, Louisiana State University Health Sciences Center, New Orleans, LA, USA.
Department of Urology, University of California, San Francisco Medical Center, San Francisco, CA, USA.
Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, USA.
Center for Health Policy Research and Department of Medicine, University of California, Irvine, CA, USA.
Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Department of Family and Preventive Medicine and Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
Rutgers Cancer Institute of New Jersey, Rutgers University, New Brunswick, NJ, USA.
Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, TN, USA; The Geriatric Research, Education, and Clinical Center, Tennessee Valley Veterans Affairs Health Care System, Nashville, TN, USA.
Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, TN, USA.
AN  - 27816300
AU  - Tyson, M. D.
AU  - Alvarez, J.
AU  - Koyama, T.
AU  - Hoffman, K. E.
AU  - Resnick, M. J.
AU  - Wu, X. C.
AU  - Cooperberg, M. R.
AU  - Goodman, M.
AU  - Greenfield, S.
AU  - Hamilton, A. S.
AU  - Hashibe, M.
AU  - Paddock, L. E.
AU  - Stroup, A.
AU  - Chen, V. W.
AU  - Penson, D. F.
AU  - Barocas, D. A.
C2  - PMC5413424
C6  - NIHMS827596
DA  - Aug
DO  - 10.1016/j.eururo.2016.10.036
DP  - NLM
ET  - 2016/11/07
IS  - 2
KW  - *African Americans
Aged
Comparative Effectiveness Research
*European Continental Ancestry Group
Gastrointestinal Diseases/ethnology/physiopathology
*Hispanic Americans
Humans
Longitudinal Studies
Male
Middle Aged
*Patient Reported Outcome Measures
Prospective Studies
*Prostatectomy/adverse effects
Prostatic Neoplasms/*ethnology/pathology/physiopathology/*therapy
*Radiotherapy, Intensity-Modulated/adverse effects
Sexual Behavior/ethnology
Treatment Outcome
United States/epidemiology
Urinary Incontinence/ethnology/physiopathology
Urination
*Active surveillance
*Comparative effectiveness
*Patient-reported function
*Prostate cancer
*Radiation
*Surgery
LA  - eng
N1  - 1873-7560
Tyson, Mark D
Alvarez, JoAnn
Koyama, Tatsuki
Hoffman, Karen E
Resnick, Matthew J
Wu, Xiao-Cheng
Cooperberg, Matthew R
Goodman, Michael
Greenfield, Sheldon
Hamilton, Ann S
Hashibe, Mia
Paddock, Lisa E
Stroup, Antoinette
Chen, Vivien W
Penson, David F
Barocas, Daniel A
R01 HS019356/HS/AHRQ HHS/United States
R01 HS022640/HS/AHRQ HHS/United States
T32 CA106183/CA/NCI NIH HHS/United States
Comparative Study
Journal Article
Multicenter Study
Observational Study
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.
Eur Urol. 2017 Aug;72(2):307-314. doi: 10.1016/j.eururo.2016.10.036. Epub 2016 Nov 3.
PY  - 2017
SN  - 0302-2838 (Print)
0302-2838
SP  - 307-314
ST  - Racial Variation in Patient-Reported Outcomes Following Treatment for Localized Prostate Cancer: Results from the CEASAR Study
T2  - Eur Urol
TI  - Racial Variation in Patient-Reported Outcomes Following Treatment for Localized Prostate Cancer: Results from the CEASAR Study
VL  - 72
ID  - 195
ER  - 

TY  - JOUR
AB  - PURPOSE: Oncotype DX (ODX) is a tumor gene-profiling test that aids in adjuvant chemotherapy decision-making. ODX has the potential to improve quality of care; however, if not equally accessible across racial groups, disparities in cancer care quality may persist or worsen. We examined racial disparities in ODX testing uptake. METHODS: We used data from the Carolina Breast Cancer Study, phase III, a longitudinal, population-based study of 2,998 North Carolina women who received a diagnosis of breast cancer between 2008 and 2014. Our primary analysis used modified Poisson regression to determine the association between race and whether ODX testing was ordered among two strata: node-negative and node-positive breast cancer. RESULTS: A total of 1,468 women with estrogen receptor-positive, human epidermal growth factor receptor-2-negative, stage I or II breast cancer met inclusion criteria. Black patients had higher-grade and larger tumors, more comorbidities, younger age at diagnosis, and lower socioeconomic status than non-black women. Overall, 42% of women had ODX test results in their pathology reports. Compared with those who did not receive ODX testing, women who received ODX testing tended to be younger and have medium tumor size and grade. Our regression analyses indicated no racial disparities in ODX uptake among node-negative patients. However, racial differences were detected among node-positive patients, with black patients being 46% less likely to receive ODX testing than non-black women (adjusted relative risk, 0.54; 95% CI, 0.35 to 0.84; P = .006). CONCLUSION: We did not find racial disparities in ODX testing for node-negative patients for whom ODX testing is guideline recommended and widely covered by insurers. However, our findings suggest that a newer, non-guideline-concordant application of ODX testing for node-positive breast cancer was accessed less by black women than by non-black women, reflecting more guideline concordant care among black women.
AD  - Megan C. Roberts, Morris Weinberger, Stacie B. Dusetzina, Katherine E. Reeder-Hayes, Lisa A. Carey, Melissa A. Troester, and Stephanie B. Wheeler, University of North Carolina at Chapel Hill, Chapel Hill; Morris Weinberger, Durham Veterans Affairs Medical Center for Health Services Research; and Michaela A. Dinan, Duke Clinical Research Institute and Duke Cancer Institute, Durham, NC. mclarker@unc.edu.
Megan C. Roberts, Morris Weinberger, Stacie B. Dusetzina, Katherine E. Reeder-Hayes, Lisa A. Carey, Melissa A. Troester, and Stephanie B. Wheeler, University of North Carolina at Chapel Hill, Chapel Hill; Morris Weinberger, Durham Veterans Affairs Medical Center for Health Services Research; and Michaela A. Dinan, Duke Clinical Research Institute and Duke Cancer Institute, Durham, NC.
AN  - 26598755
AU  - Roberts, M. C.
AU  - Weinberger, M.
AU  - Dusetzina, S. B.
AU  - Dinan, M. A.
AU  - Reeder-Hayes, K. E.
AU  - Carey, L. A.
AU  - Troester, M. A.
AU  - Wheeler, S. B.
C2  - PMC4872005 online at www.jco.org. Author contributions are found at the end of this article.
DA  - Jan 10
DO  - 10.1200/jco.2015.63.2489
DP  - NLM
ET  - 2015/11/26
IS  - 2
KW  - Adult
African Americans/*statistics & numerical data
Aged
Breast Neoplasms/chemistry/*ethnology/*pathology
Clinical Trials, Phase II as Topic
Confounding Factors, Epidemiologic
ErbB Receptors/analysis
Female
Gene Expression Profiling/economics/*statistics & numerical data
Healthcare Disparities/*ethnology/statistics & numerical data
Humans
Insurance Coverage
Lymphatic Metastasis
Middle Aged
*Molecular Targeted Therapy/methods/statistics & numerical data
Neoplasm Staging
North Carolina/epidemiology
Poisson Distribution
Practice Guidelines as Topic
Precision Medicine/methods/statistics & numerical data
Predictive Value of Tests
Research Design
Risk Assessment
Risk Factors
LA  - eng
N1  - 1527-7755
Roberts, Megan C
Weinberger, Morris
Dusetzina, Stacie B
Dinan, Michaela A
Reeder-Hayes, Katherine E
Carey, Lisa A
Troester, Melissa A
Wheeler, Stephanie B
UL1 TR001111/TR/NCATS NIH HHS/United States
P30 ES010126/ES/NIEHS NIH HHS/United States
5K12HD001441-12/HD/NICHD NIH HHS/United States
R25 CA57726/CA/NCI NIH HHS/United States
1-K-12 HS019468-01/HS/AHRQ HHS/United States
UL1TR001111/TR/NCATS NIH HHS/United States
P30 CA016086/CA/NCI NIH HHS/United States
P50 CA058223/CA/NCI NIH HHS/United States
P50-CA58223/CA/NCI NIH HHS/United States
K12 HS019468/HS/AHRQ HHS/United States
K99 HS022189/HS/AHRQ HHS/United States
8389741/PHS HHS/United States
K12 HD001441/HD/NICHD NIH HHS/United States
R00 HS022189/HS/AHRQ HHS/United States
R25 CA057726/CA/NCI NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, U.S. Gov't, P.H.S.
J Clin Oncol. 2016 Jan 10;34(2):130-8. doi: 10.1200/JCO.2015.63.2489. Epub 2015 Nov 23.
PY  - 2016
SN  - 0732-183X (Print)
0732-183x
SP  - 130-8
ST  - Racial Variation in the Uptake of Oncotype DX Testing for Early-Stage Breast Cancer
T2  - J Clin Oncol
TI  - Racial Variation in the Uptake of Oncotype DX Testing for Early-Stage Breast Cancer
VL  - 34
ID  - 226
ER  - 

TY  - JOUR
AB  - Objectives: To test the hypotheses that African American patients and older patients with stage IV colorectal cancer were less likely to receive newer chemotherapy agents. Study Design: Retrospective cohort design. Methods: Among 5068 Surveillance, Epidemiology, and End Results -- Medicare patients diagnosed as having stage IV colorectal cancer between 2000 and 2002, a total of 2466 received chemotherapy and were included in the analysis. Irinotecan hydrochloride was the first of the 'newer' chemotherapy agents and was marketed in 2000 as a first-line add-on agent. Descriptive statistics were generated, and a multivariable logistic regression was run to estimate the odds of receiving irinotecan among African American patients and older patients and within 2 months of chemotherapy initiation. Results: African American patients had lower odds of initiating treatment with a newer chemotherapy than white patients (adjusted odds ratio, 0.641; 95% confidence interval, 0.453-0.907). An age disparity was also found, with all older age groups being significantly less likely to initiate treatment with a newer chemotherapy than the youngest age group: the adjusted odds of receiving newer chemotherapy agents (relative to patients aged 66-70 years) were lower and significant among patients aged 71 to 75, 76 to 80, and older than 80 years (odds ratios, 0.708, 0.527, and 0.213, respectively). Conclusions: Disparities in chemotherapy selection exist among patients receiving chemotherapy for stage IV colorectal cancer. On initiating chemotherapy, African American patients and older patients were less likely to receive a newer agent.
AD  - Department of Pharmaceutical Health Services Research, University of Maryland, Baltimore, MD; nobeidat@khibc.jo
AN  - 105071475. Language: English. Entry Date: 20100924. Revision Date: 20150711. Publication Type: Journal Article
AU  - Obeidat, N. A.
AU  - Pradel, F. G.
AU  - Zuckerman, I. H.
AU  - Trovato, J. A.
AU  - Palumbo, F. B.
AU  - DeLisle, S.
AU  - Mullins, C. D.
DB  - CINAHL Complete
DP  - EBSCOhost
IS  - 7
KW  - Age Factors
Chemotherapy, Cancer -- Evaluation -- In Old Age
Colorectal Neoplasms -- Drug Therapy -- In Old Age
Patient Selection
Race Factors
Aged
Aged, 80 and Over
Bivariate Statistics
Black Persons
Chi Square Test
Clinical Assessment Tools
Confidence Intervals
Data Analysis Software
Data Analysis, Statistical
Descriptive Statistics
Female
Funding Source
Human
Male
Odds Ratio
P-Value
Retrospective Design
Sex Factors
White Persons
N1  - research; tables/charts. Journal Subset: Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Health Services Administration; Peer Reviewed; USA. Instrumentation: Charlson Comorbidity Index (CCI). Grant Information: Sanofi-aventis. NLM UID: 9613960.
PMID: NLM20645667.
PY  - 2010
SN  - 1088-0224
SP  - 515-522
ST  - Racial/ethnic and age disparities in chemotherapy selection for colorectal cancer
T2  - American Journal of Managed Care
TI  - Racial/ethnic and age disparities in chemotherapy selection for colorectal cancer
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105071475&site=ehost-live&scope=site
VL  - 16
ID  - 2046
ER  - 

TY  - JOUR
AB  - BACKGROUND This study examined racial/ethnic differences among patients in clinical trial (CT) enrollment, refusal rates, ineligibility, and desire to participate in research within the National Cancer Institute's Community Cancer Centers Program (NCCCP) Clinical Trial Screening and Accrual Log. METHODS Data from 4509 log entries were evaluated in this study. Four logistic regression models were run using physical/medical conditions, enrollment into a CT, patient eligible but declined a CT, and no desire to participate in research as dependent variables. RESULTS Age ≥ 65 years (OR = 1.51, 95% CI = 1.28-1.79), males (OR = 2.28, 95% CI = 1.92-2.71), and non-Hispanic black race (OR = 1.53, 95% CI = 1.2-1.96) were significantly associated with more physical/medical conditions. Age ≥ 65 years was significantly associated with lower CT enrollment (OR = 0.83, 95% CI = 0.7-0.98). Males (OR = 0.78, 95% CI = 0.65-0.94) and a higher grade level score for consent form readability (OR = 0.9, 95% CI = 0.83-0.97) were significantly associated with lower refusal rates. Consent page length ≥ 20 was significantly associated with lower odds of "no desire to participate in research" among CT decliners (OR = 0.75, 95% CI = 0.58-0.98). CONCLUSIONS There were no racial/ethnic differences in CT enrollment, refusal rates, or "no desire to participate in research" as the reason given for CT refusal. Higher odds of physical/medical conditions were associated with older age, males, and non-Hispanic blacks. Better management of physical/medical conditions before and during treatment may increase the pool of eligible patients for CTs. Future work should examine the role of comorbidities, sex, age, and consent form characteristics on CT participation. Cancer 2014;120:877-884. © 2013 American Cancer Society. There were no racial/ethnic differences in clinical trial (CT) enrollment, refusal rates, or "no desire to participate in research" as the reason given for CT refusal; however, higher odds of physical/medical conditions were associated with older age, males, and non-Hispanic blacks. Better management of physical/medical conditions before and during treatment may increase the pool of eligible patients for CTs. © 2013 American Cancer Society.
AD  - A.T. Langford, University of Michigan, School of Public Health, 1415 Washington Heights, Ann Arbor, MI 48109, United States
AU  - Langford, A. T.
AU  - Resnicow, K.
AU  - Dimond, E. P.
AU  - Denicoff, A. M.
AU  - Germain, D. S.
AU  - McCaskill-Stevens, W.
AU  - Enos, R. A.
AU  - Carrigan, A.
AU  - Wilkinson, K.
AU  - Go, R. S.
DB  - Embase
Medline
DO  - 10.1002/cncr.28483
IS  - 6
KW  - adult
aged
article
breast cancer
clinical trial (topic)
colorectal cancer
ethnic difference
female
human
informed consent
interpersonal communication
logistic regression analysis
major clinical study
male
middle aged
Black person
priority journal
race difference
refusal to participate
scoring system
urogenital tract cancer
LA  - English
M3  - Article
N1  - L52915341
2013-12-18
2014-03-21
PY  - 2014
SN  - 0008-543X
1097-0142
SP  - 877-884
ST  - Racial/ethnic differences in clinical trial enrollment, refusal rates, ineligibility, and reasons for decline among patients at sites in the National Cancer Institute's Community Cancer Centers Program
T2  - Cancer
TI  - Racial/ethnic differences in clinical trial enrollment, refusal rates, ineligibility, and reasons for decline among patients at sites in the National Cancer Institute's Community Cancer Centers Program
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L52915341&from=export
http://dx.doi.org/10.1002/cncr.28483
VL  - 120
ID  - 1034
ER  - 

TY  - JOUR
AB  - To examine whether (a) non-minority participants differed from racial minority participants in the understanding of biospecimens collected for research purposes, (b) patients differed from comparison group in their understanding of the ways their biospecimens could be used by researchers, and (c) participants received adequate information before consenting to donate blood for research studies. We analyzed cross-sectional data from female breast cancer patients scheduled to receive chemotherapy at the National Cancer Institute (NCI) Community Oncology Research Program (NCORP) clinical sites and a healthy comparison group. After reading a consent form related to biospecimens and consenting to participate in a clinical trial, participants' understanding of biospecimen collection was evaluated. Linear models were used to compare scores between non-minority and racial minority participants as well as cancer and non-cancer comparisons adjusting for possible confounding factors. A total of 650 participants provided evaluable data; 592 were non-minority (Caucasian) and 58 participants were a racial minority (71% Black and 29% other). There were 427 cancer patients and 223 comparisons. Non-minority participants scored higher than racial minorities on relevance-to-care items (diff. = 0.48, CI 0.13-0.80, p = 0.001). Comparison group scored higher than cancer patients on relevance-to-care items (diff. = 0.58, CI 0.37-0.78). A moderate number of the participants exhibited a poor understanding of biospecimen collection across all racial/ethnic backgrounds, but racial minority participants' scores remained lower in the relevance-to-care subscale even after adjusting for education and reading level. Differences were also noted among the patients and comparison group. Researchers should facilitate comprehension of biospecimen collection for all study participants, especially racial minority participants.
AD  - Department of Public Health, Robbins College of Health and Human Sciences, Baylor University, One Bear Place, Waco, TX, 97343, USA. matt_asare@baylor.edu.
James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA.
National Cancer Institute (NCI), Bethesda, MD, USA.
National Institute of Health (NIH), Bethesda, MD, USA.
Association for the Accreditation of Human Research Protection Programs, Inc. (AAHRPP), Washington, DC, USA.
Cancer Research Consortium of West Michigan NCORP, Grand Rapids, MI, USA.
Dayton Clinical Oncology Program, Dayton, OH, USA.
Wisconsin NCORP, Marshfield, WI, USA.
AN  - 30612315
AU  - Asare, M.
AU  - Heckler, C. E.
AU  - Culakova, E.
AU  - Kamen, C. S.
AU  - Kleckner, A. S.
AU  - Minasian, L. M.
AU  - Wendler, D. S.
AU  - Feige, M.
AU  - Weil, C. J.
AU  - Long, J.
AU  - Cole, S. K.
AU  - Onitilo, A. A.
AU  - Peppone, L. J.
AU  - Morrow, G. R.
AU  - Janelsins, M. C.
C2  - PMC6612536
C6  - NIHMS1518064
DA  - Apr
DO  - 10.1007/s13187-018-1464-z
DP  - NLM
ET  - 2019/01/07
IS  - 2
KW  - Adult
African Americans/education
Aged
Aged, 80 and over
Biological Specimen Banks/*statistics & numerical data
Breast Neoplasms/drug therapy/*ethnology/psychology
Case-Control Studies
Clinical Trials as Topic/*statistics & numerical data
*Comprehension
Cross-Sectional Studies
Ethnic Groups/*education/*psychology
European Continental Ancestry Group/education
Female
Health Knowledge, Attitudes, Practice
*Health Status Disparities
Humans
Middle Aged
Patient Participation
Specimen Handling
Young Adult
*Biospecimens
*Consent
*Consent form
*Disparities
*Race
Care in Cancer Author Disclosure Declaration. There are no disclosures to report by
any of the authors.
LA  - eng
N1  - 1543-0154
Asare, Matthew
Heckler, Charles E
Culakova, Eva
Kamen, Charles S
Kleckner, Amber S
Minasian, Lori M
Wendler, David S
Feige, Michelle
Weil, Carol J
Long, Joan
Cole, Sharon K
Onitilo, Adedayo A
Peppone, Luke J
Morrow, Gary R
Janelsins, Michelle C
K07 CA168886/CA/NCI NIH HHS/United States
UG1 CA189961/CA/NCI NIH HHS/United States
R25 CA102618/CA/NCI NIH HHS/United States
T32 CA102618/CA/NCI NIH HHS/United States
U10 CA037420/CA/NCI NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
J Cancer Educ. 2020 Apr;35(2):292-300. doi: 10.1007/s13187-018-1464-z.
PY  - 2020
SN  - 0885-8195 (Print)
0885-8195
SP  - 292-300
ST  - Racial/Ethnic Differences in Comprehension of Biospecimen Collection: a Nationwide University of Rochester Cancer Center NCI Community Oncology Research Program Study
T2  - J Cancer Educ
TI  - Racial/Ethnic Differences in Comprehension of Biospecimen Collection: a Nationwide University of Rochester Cancer Center NCI Community Oncology Research Program Study
VL  - 35
ID  - 88
ER  - 

TY  - JOUR
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
Harvard Medical School, Department of Health Care Policy, Boston, Massachusetts
Cancer Registry of Greater California, Public Health Institute, Sacramento
Division of General Internal Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts
AN  - 103801901. Language: English. Entry Date: 20150521. Revision Date: 20200708. Publication Type: Journal Article
AU  - Freedman, Rachel A.
AU  - Kouri, Elena M.
AU  - West, Dee W.
AU  - Keating, Nancy L.
DB  - CINAHL Complete
DO  - 10.1001/jamaoncol.2015.20
DP  - EBSCOhost
IS  - 2
KW  - Race Factors
Ethnic Groups
Patient Selection -- Evaluation
Surgeons
Hospitals -- Evaluation
Breast Neoplasms -- Surgery
Oncology
Human
Female
Breast Neoplasms -- Physiopathology
Patient Care -- Methods
Surveys
Breast Neoplasms -- Diagnosis
Hispanic Americans
Black Persons
California
Marriage
Education
Literacy
Health Knowledge -- Evaluation
Independent Variable
Dependent Variable
Insurance Carriers
Data Analysis
Chi Square Test
Fisher's Exact Test
Kruskal-Wallis Test
Logistic Regression
Decision Making
N1  - research; tables/charts. Journal Subset: Peer Reviewed; USA. Special Interest: Oncologic Care.
PMID: NLM26181027.
PY  - 2015
SN  - 2374-2437
SP  - 222-230
ST  - Racial/Ethnic Differences in Patients' Selection of Surgeons and Hospitals for Breast Cancer Surgery
T2  - JAMA Oncology
TI  - Racial/Ethnic Differences in Patients' Selection of Surgeons and Hospitals for Breast Cancer Surgery
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=103801901&site=ehost-live&scope=site
VL  - 1
ID  - 2047
ER  - 

TY  - JOUR
AB  - Background: Five-year breast cancer survival rates are lower among Hispanic and African-American women than among Non-Hispanic White women. Differences in breast cancer treatment likely play a role. Adjuvant hormonal therapies increase overall survival among women with hormone receptor-positive breast cancer. Methods: We examined racial/ethnic differences in use and duration of adjuvant hormonal therapy among 3,588 postmenopausal women enrolled in the Women's Health Initiative (WHI) Extension Study. Women diagnosed with hormone receptor-positive localized or regional stage breast cancer after study enrollment were surveyed between September 2009 and August 2010 and asked to recall prior use and duration of adjuvant hormonal breast cancer therapy. ORs comparing self-reported use and duration with race/ethnicity (Hispanic, African-American, Asian/Pacific Islander vs. Non-Hispanic White) were estimated using multivariableadjusted logistic regression. Results: Of the 3,588 women diagnosed from 1994 to 2009; 3,039 (85%) reported any use of adjuvant hormonal therapy, and 67% of women reporting ever-use who were diagnosed before 2005 reported using adjuvant hormonal therapy for the optimal duration of 5 years or more. In adjusted analysis, no statistically significant differences in use or duration by race/ethnicity were observed. Conclusions: This study did not find significant differences in use or duration of use of adjuvant hormonal therapy by race/ethnicity. Impact: Findings should be confirmed in other population-based samples, and potential reasons for discontinuation of therapy across all racial/ethnic groups should be explored. © 2013 American Association for Cancer Research.
AD  - J.C. Livaudais, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA 98109, United States
AU  - Livaudais, J. C.
AU  - LaCroix, A.
AU  - Chlebowski, R. T.
AU  - Li, C. I.
AU  - Habel, L. A.
AU  - Simon, M. S.
AU  - Thompson, B.
AU  - Erwin, D. O.
AU  - Hubbell, F. A.
AU  - Coronado, G. D.
DB  - Embase
Medline
DO  - 10.1158/1055-9965.EPI-12-1225
IS  - 3
KW  - anastrozole
exemestane
letrozole
tamoxifen
toremifene
adult
aged
article
body mass
breast cancer
cancer adjuvant therapy
cancer diagnosis
cancer epidemiology
cancer grading
cancer hormone therapy
cancer size
cancer staging
cancer survival
drug use
ethnic difference
female
follow up
health insurance
histology
human
major clinical study
observational study
postmenopause
priority journal
questionnaire
survival rate
treatment duration
women's health
LA  - English
M3  - Article
N1  - L368778057
2013-05-01
2013-05-06
PY  - 2013
SN  - 1055-9965
SP  - 365-373
ST  - Racial/ethnic differences in use and duration of adjuvant hormonal therapy for breast cancer in the women's health initiative
T2  - Cancer Epidemiology Biomarkers and Prevention
TI  - Racial/ethnic differences in use and duration of adjuvant hormonal therapy for breast cancer in the women's health initiative
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L368778057&from=export
http://dx.doi.org/10.1158/1055-9965.EPI-12-1225
http://cebp.aacrjournals.org/content/22/3/365.full.pdf+html
VL  - 22
ID  - 1088
ER  - 

TY  - JOUR
AB  - Background: We studied the effect of race and ethnicity on disease characteristics and survival in gastrointestinal neuroendocrine tumors. Methods: The Surveillance, Epidemiology, and End Results database was used to select patients with non-pancreatic gastrointestinal neuroendocrine tumors diagnosed between 2004 and 2015. Trends in survival were evaluated among three groups: Hispanic, non-Hispanic White, and non-Hispanic Black. Kaplan–Meier and Cox regression methods were performed to calculate overall survival and cause-specific survival after adjusting for patient and tumor characteristics. Results: A total of 26,399 patients were included in the study: 65.1% were non-Hispanic White, 19.9% were non-Hispanic Black, and 15% were Hispanic. Non-Hispanic White patients were more likely to be male (50.0%, p < 0.001), older than 60 years (48.0%, p < 0.001), and present with metastatic disease (17.7%, p < 0.001). Non-Hispanic White patients had small intestine neuroendocrine tumors, while Hispanic and non-Hispanic Black patients had rectum neuroendocrine tumors as the most common primary site. Hispanic patients had better overall survival, while non-Hispanic Black patients had better cause-specific survival versus non-Hispanic White patients. This finding was confirmed on multivariable analysis where Hispanic patients had improved overall survival compared to non-Hispanic White patients (Hazard ratio (HR): 0.89 (0.81–0.97)), whereas non-Hispanic Black patients had better cause-specific survival compared to non-Hispanic White patients (HR: 0.89 (0.80–0.98)). Conclusions: Race/ethnicity is an independent prognostic factor in patients with gastrointestinal neuroendocrine tumors.
AD  - S.M. Kazmi, Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX, United States
S.M. Kazmi, Division of Hematology and Oncology, UT Southwestern Medical Center, Dallas, TX, United States
AU  - Goksu, S. Y.
AU  - Ozer, M.
AU  - Beg, M. S.
AU  - Sanford, N. N.
AU  - Ahn, C.
AU  - Fangman, B. D.
AU  - Goksu, B. B.
AU  - Verma, U.
AU  - Sanjeevaiah, A.
AU  - Hsiehchen, D.
AU  - Jones, A. L.
AU  - Kainthla, R.
AU  - Kazmi, S. M.
DB  - Embase
DO  - 10.3390/cancers12102990
IS  - 10
KW  - adult
age
appendix tumor
article
Black person
cancer diagnosis
cancer epidemiology
cancer prognosis
cancer staging
cancer survival
Caucasian
cause specific survival
clinical feature
cohort analysis
colon tumor
controlled study
data base
esophagus tumor
ethnic difference
female
gastrointestinal tumor
gender
health disparity
Hispanic
human
major clinical study
male
middle aged
neuroendocrine tumor
outcome assessment
overall survival
pancreas islet cell tumor
patient selection
race difference
rectum tumor
retrospective study
small intestine tumor
stomach tumor
survival analysis
trend study
tumor localization
tumor volume
LA  - English
M3  - Article
N1  - L2005227544
2020-10-22
2020-10-28
PY  - 2020
SN  - 2072-6694
SP  - 1-13
ST  - Racial/ethnic disparities and survival characteristics in non-pancreatic gastrointestinal tract neuroendocrine tumors
T2  - Cancers
TI  - Racial/ethnic disparities and survival characteristics in non-pancreatic gastrointestinal tract neuroendocrine tumors
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L2005227544&from=export
http://dx.doi.org/10.3390/cancers12102990
VL  - 12
ID  - 786
ER  - 

TY  - JOUR
AB  - PURPOSE OF REVIEW: To review recent research in racial/ethnic disparities in breast and gynecologic cancers, focusing on disparities occurring postdiagnosis. RECENT FINDINGS: Mortality statistics show that of the cancers under study, breast cancer has the greatest impact, and of racial/ethnic groups, African Americans suffer the greatest disparities, with highest mortality rates for breast, uterine and cervical cancers, and second highest for ovarian cancer. Recent studies demonstrated that black breast cancer patients suffer more underuse of appropriate adjuvant therapy, and greater delays in diagnosis and institution of treatments, and blacks and Hispanics suffered greater postsurgical pain and symptomatology. Data indicate that the biology of some breast cancers in blacks is unique and more aggressive. One study demonstrated that more black breast cancer patients died of nonbreast cancer causes and that excessive comorbidity in blacks explained substantial amounts of survival disparity. Research is beginning to identify important disparities in nonblack minority racial/ethnic groups, including Hispanics and South Asian Americans. SUMMARY: Research is continuing to identify and explain an important group of disparities - African American disparities in breast cancer outcomes. Disparities in other minority racial/ethnic groups, and in ovarian, uterine and cervical cancers, are at an emerging stage. Continuing efforts at all fronts are needed.
AD  - Department of Community Health Sciences, Brock University, St Catharines, Ontario, Canada. martin.tammemagi@brocku.ca
AN  - 17218849
AU  - Tammemagi, C. M.
DA  - Feb
DO  - 10.1097/GCO.0b013e3280117cf8
DP  - NLM
ET  - 2007/01/16
IS  - 1
KW  - African Americans
Asian Americans
Breast Neoplasms/*ethnology/mortality/therapy
Clinical Trials as Topic
European Continental Ancestry Group
Female
Hispanic Americans
Humans
Ovarian Neoplasms/*ethnology/mortality/therapy
Quality of Life
Survival Rate
United States/ethnology
Uterine Neoplasms/*ethnology/mortality/therapy
LA  - eng
N1  - Tammemagi, C Martin
Journal Article
Review
England
Curr Opin Obstet Gynecol. 2007 Feb;19(1):31-6. doi: 10.1097/GCO.0b013e3280117cf8.
PY  - 2007
SN  - 1040-872X (Print)
1040-872x
SP  - 31-6
ST  - Racial/ethnic disparities in breast and gynecologic cancer treatment and outcomes
T2  - Curr Opin Obstet Gynecol
TI  - Racial/ethnic disparities in breast and gynecologic cancer treatment and outcomes
VL  - 19
ID  - 536
ER  - 

TY  - JOUR
AB  - Ethnic and racial minority groups in the U.S. receive fewer colorectal cancer (CRC) screening tests and are less likely to be up-to-date with CRC screening than the population as a whole. Access, limited awareness of CRC and barriers may, in part, be responsible for inhibiting widespread adoption of CRC screening among racial and ethnic minority groups. The purpose of this study was to examine the role of self-efficacy, fatalism and CRC risk perception across racial and ethnic groups in a diverse sample. This study was a cross-sectional analysis from baseline measures gathered on a group of patients recruited into a trial to track colorectal cancer screening in underserved adults over 50. Out of 470 Participants, 42% were non-Hispanic; 27% Hispanic and 28% non-Hispanic White. Hispanic and non-Hispanic Blacks were more likely to have fatalistic beliefs about CRC than non-Hispanic Whites. Non-Hispanic Blacks perceived higher risk of getting colon cancer. Self-efficacy for completing CRC screening was higher among Non-Hispanic Blacks than among Hispanics. Racial and ethnic differences in risk perceptions, fatalism and self-efficacy should be taken into consideration in future CRC interventions with marginalized and uninsured populations.
AD  - Center Department of Family Medicine, University of Kansas Medical Center, Kansas City, Kansas, 66160, USA.
AN  - 24244894
AU  - Lumpkins, C.
AU  - Cupertino, P.
AU  - Young, K.
AU  - Daley, C.
AU  - Yeh, H.
AU  - Greiner, K.
C2  - PMC3826433
C6  - NIHMS506963
DA  - Jan 25
DO  - 10.4172/2161-0711.1000196
DP  - NLM
ET  - 2013/11/19
KW  - Colon cancer risk
Colorectal cancer screening
Computer-tailored intervention
Ethnicity
Race
LA  - eng
N1  - 2161-0711
Lumpkins, Cy
Cupertino, P
Young, K
Daley, C
Yeh, Hw
Greiner, Ka
R01 CA123245/CA/NCI NIH HHS/United States
R24 HD050924/HD/NICHD NIH HHS/United States
U54 CA154253/CA/NCI NIH HHS/United States
Journal Article
J Community Med Health Educ. 2013 Jan 25;3:11284. doi: 10.4172/2161-0711.1000196.
PY  - 2013
SN  - 2161-0711 (Print)
ST  - Racial/Ethnic Variations in Colorectal Cancer Screening Self-Efficacy, Fatalism and Risk Perception in a Safety-Net Clinic Population: Implications for Tailored Interventions
T2  - J Community Med Health Educ
TI  - Racial/Ethnic Variations in Colorectal Cancer Screening Self-Efficacy, Fatalism and Risk Perception in a Safety-Net Clinic Population: Implications for Tailored Interventions
VL  - 3
ID  - 307
ER  - 

TY  - JOUR
AB  - A number of different models for assessing individual risk of breast cancer use known risk factors such as age, age at menarche, age at first live birth, previous breast biopsies, and family history. High bone mass in white women is also associated with an increased breast cancer risk; however, bone mass as a risk factor has not been studied in African-American women. We conducted a case-control study to evaluate bone mineral density as a risk factor for breast cancer in white and African-American women. We recruited 221 women with newly diagnosed breast cancer from a comprehensive breast cancer center at a large university hospital, and 197 control women who were frequency matched for ethnicity and age. Odds ratios were based on proximal and distal radial bone density measured by peripheral bone densitometry (Norland pDEXA) and expressed as a standardized "Z-score" (age and ethnicity specific). Logistic regression models were fitted controlling for body mass index, menopausal status, age, and HRT use (ever/never and duration). With proximal bone density Z-score included in the model as a continuous variable, a one-unit increase in radial shaft bone density increased the risk of breast cancer by 25% (p=0.02). When proximal bone density Z-score was analyzed as a dichotomous variable (less than or equal to0, >0) the odds ratio was 1.98 (95% CI, 1.32 to 2.97); that is, having an above average proximal bone density (age-specific) doubles the risk of breast cancer. There were no significant interactions with, and no appreciable confounding effects by, other covariates. An above-average radial shaft Z-score is a significant risk factor for breast cancer in both white and African-American women. The present study extends the association between bone mass and breast cancer risk to African-Americans, and suggests another potential application for bone density testing.
AN  - WOS:000222320500004
AU  - Nelson, D. A.
AU  - Darga, L. L.
AU  - Simon, M. S.
AU  - Severson, R. K.
DA  - Jul
DO  - 10.1007/s00198-003-1576-z
IS  - 7
N1  - 11
14760517
PY  - 2004
SN  - 0937-941X
SP  - 535-540
ST  - Radial bone density and breast cancer risk in white and African-American women
T2  - Osteoporosis International
TI  - Radial bone density and breast cancer risk in white and African-American women
VL  - 15
ID  - 2681
ER  - 

TY  - JOUR
AB  - OBJECTIVES: To summarize the ongoing prevention of Alzheimer's disease (AD) by vitamin E and selenium (PREADViSE) trial as an ancillary study to SELECT (a large prostate cancer prevention trial) and to present the blinded results of the first year as an exposure study. DESIGN: PREADViSE was designed as a double blind randomized controlled trial (RCT). SETTING: SELECT terminated after median of 5.5 years of exposure to supplements due to a futility analysis. Both trials then converted into an exposure study. PARTICIPANTS: In the randomized component PREADViSE enrolled 7,547 men age 62 or older (60 if African American). Once the trial terminated 4,246 of these men volunteered for the exposure study. Demographics were similar for both groups with exposure volunteers having baseline mean age 67.3 ± 5.2 years, 15.3 ± 2.4 years of education, 9.8% African Americans, and 22.0% reporting a family history of dementia. INTERVENTION: In the RCT men were randomly assigned to either daily doses of 400 IU of vitamin E or placebo and 200 µg of selenium or placebo using a 2x2 factorial structure. MEASUREMENTS: In the RCT, participants completed the memory impairment screen (MIS), and if they failed, underwent a longer screening (based on an expanded Consortium to Establish a Registry in AD [CERAD] battery). CERAD failure resulted in visits to their clinician for medical examination with records of these examinations forwarded to the PREADViSE center for further review. In the exposure study, men are contacted by telephone and complete the telephone version of the memory impairment screen (MIS-T) screen. If they fail the MIS-T, a modified telephone interview of cognitive status (TICS-M) exam is given. A failed TICS-M exam also leads to a visit to their clinician for an in-depth examination and forwarding of records for a centralized consensus diagnosis by expert clinicians. A subgroup of the men who pass the MIS-T also take the TICS-M exam for validation purposes. RESULTS: While this ancillary trial was open to all 427 SELECT clinical sites, only 130 (30.0%) of the sites chose to participate in PREADViSE. Staff turnover at the sites presented challenges when training persons unfamiliar with cognitive testing procedures to conduct the memory screens. In the RCT few participants (1.6%) failed the MIS screen and among those who passed this screen a significant practice effect was encountered. In the exposure study 3,581 men were reached by phone in year 1, 15.7% could not be reached after 5 calls, and of those contacted 6.0% refused the screen even after consenting to the procedures at their clinical site. Most notable is that the failure rate for the MIS-T increased fourfold to 7.2%. Of the 257 men who took the TICS-M, 84.0% failed and were asked to contact their physicians for a more detailed memory assessment, and approximately half of these had some form of dementia or cognitive impairment. Several of these dementia cases are not AD. CONCLUSION: Partnering with SELECT led to an AD prevention trial conducted at a very reasonable cost by taking advantage of the experience and efficient clinical trial management found in a cancer cooperative group (Southwest Oncology Group or SWOG). Once unblinded, the RCT and exposure study data have the potential to yield new information on long term exposure to antioxidant supplements under controlled conditions.
AD  - University of Kentucky Sanders-Brown Center on Aging, Department of Biostatistics, Lexington, KY, USA.
AN  - 23299383
AU  - Kryscio, R. J.
AU  - Abner, E. L.
AU  - Schmitt, F. A.
AU  - Goodman, P. J.
AU  - Mendiondo, M.
AU  - Caban-Holt, A.
AU  - Dennis, B. C.
AU  - Mathews, M.
AU  - Klein, E. A.
AU  - Crowley, J. J.
C2  - PMC3636980
C6  - NIHMS456736
DA  - Jan
DO  - 10.1007/s12603-012-0083-3
DP  - NLM
ET  - 2013/01/10
IS  - 1
KW  - Aged
Alzheimer Disease/*prevention & control
Antioxidants/administration & dosage
*Dietary Supplements
Double-Blind Method
Follow-Up Studies
Humans
Male
Middle Aged
Selenium/*administration & dosage
Vitamin E/*administration & dosage
LA  - eng
N1  - 1760-4788
Kryscio, R J
Abner, E L
Schmitt, F A
Goodman, P J
Mendiondo, M
Caban-Holt, A
Dennis, B C
Mathews, M
Klein, E A
Crowley, J J
SELECT Investigators
U10 CA037429/CA/NCI NIH HHS/United States
U19 AG010483/AG/NIA NIH HHS/United States
U10 CA038926/CA/NCI NIH HHS/United States
R01 AG019241/AG/NIA NIH HHS/United States
AG019241/AG/NIA NIH HHS/United States
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
J Nutr Health Aging. 2013 Jan;17(1):72-5. doi: 10.1007/s12603-012-0083-3.
PY  - 2013
SN  - 1279-7707 (Print)
1279-7707
SP  - 72-5
ST  - A randomized controlled Alzheimer's disease prevention trial's evolution into an exposure trial: the PREADViSE Trial
T2  - J Nutr Health Aging
TI  - A randomized controlled Alzheimer's disease prevention trial's evolution into an exposure trial: the PREADViSE Trial
VL  - 17
ID  - 342
ER  - 

TY  - JOUR
AB  - BACKGROUND: The objective of the current study was to improve colorectal cancer (CRC) screening uptake with the fecal immunochemical test (FIT). The current study investigated the differential impact of a multicomponent, targeted, low-literacy educational intervention compared with a standard, nontargeted educational intervention. METHODS: Patients aged 50 to 75 years who were of average CRC risk and not up-to-date with CRC screening were recruited from either a federally qualified health center or a primary care community health clinic. Patients were randomized to the intervention condition (targeted photonovella booklet/DVD plus FIT kit) or comparison condition (standard Centers for Disease Control and Prevention brochure plus FIT kit). The main outcome was screening with FIT within 180 days of delivery of the intervention. RESULTS: Of the 416 participants, 54% were female; the participants were racially and ethnically diverse (66% white, 10% Hispanic, and 28% African American), predominantly of low income, and insured (the majority had county health insurance). Overall, the FIT completion rate was 81%, with 78.1% of participants in the intervention versus 83.5% of those in the comparison condition completing FIT (P =  .17). In multivariate analysis, having health insurance was found to be the primary factor predicting a lack of FIT screening (adjusted odds ratio, 2.10; 95% confidence interval, 1.04-4.26 [P =  .04]). CONCLUSIONS: The multicomponent, targeted, low-literacy materials were not found to be significantly different or more effective in increasing FIT uptake compared with the nontargeted materials. Provision of a FIT test plus education may provide a key impetus to improve the completion of CRC screening. The type of educational material (targeted vs nontargeted) may matter less. The findings of the current study provide a unique opportunity for clinics to adopt FIT and to choose the type of patient education materials based on clinic, provider, and patient preferences. Cancer 2017;123:1390-1400. © 2016 American Cancer Society.
AD  - Health Education and Behavioral Science, Rutgers School of Public Health, Piscataway, New Jersey.
Division of Population Science, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
Department of Oncologic Sciences, Morsani College of Medicine, University of South Florida, Tampa, Florida.
Florida Department of Health, St. Petersburg, Florida.
Premier Community HealthCare Group Inc, Dade City, Florida.
Department of Surgery, University of Tennessee Health Science Center, Memphis, Tennessee.
AN  - 27906448
AU  - Davis, S. N.
AU  - Christy, S. M.
AU  - Chavarria, E. A.
AU  - Abdulla, R.
AU  - Sutton, S. K.
AU  - Schmidt, A. R.
AU  - Vadaparampil, S. T.
AU  - Quinn, G. P.
AU  - Simmons, V. N.
AU  - Ufondu, C. B.
AU  - Ravindra, C.
AU  - Schultz, I.
AU  - Roetzheim, R. G.
AU  - Shibata, D.
AU  - Meade, C. D.
AU  - Gwede, C. K.
C2  - PMC5384866
C6  - NIHMS830592
DA  - Apr 15
DO  - 10.1002/cncr.30481
DP  - NLM
ET  - 2016/12/03
IS  - 8
KW  - Aged
Colorectal Neoplasms/*diagnosis/*epidemiology
*Early Detection of Cancer
Feces/*chemistry
Female
Humans
Male
Mass Screening
Middle Aged
Odds Ratio
*Patient Education as Topic
Risk Factors
*colorectal cancer
*fecal immunochemical test
*health promotion
*intervention studies
*medically underserved
LA  - eng
N1  - 1097-0142
Davis, Stacy N
Christy, Shannon M
Chavarria, Enmanuel A
Abdulla, Rania
Sutton, Steven K
Schmidt, Alyssa R
Vadaparampil, Susan T
Quinn, Gwendolyn P
Simmons, Vani N
Ufondu, Chukwudi B
Ravindra, Chitra
Schultz, Ida
Roetzheim, Richard G
Shibata, David
Meade, Cathy D
Gwede, Clement K
P30 CA076292/CA/NCI NIH HHS/United States
R25 CA090314/CA/NCI NIH HHS/United States
U54 CA153509/CA/NCI NIH HHS/United States
Journal Article
Randomized Controlled Trial
Cancer. 2017 Apr 15;123(8):1390-1400. doi: 10.1002/cncr.30481. Epub 2016 Dec 1.
PY  - 2017
SN  - 0008-543X (Print)
0008-543x
SP  - 1390-1400
ST  - A randomized controlled trial of a multicomponent, targeted, low-literacy educational intervention compared with a nontargeted intervention to boost colorectal cancer screening with fecal immunochemical testing in community clinics
T2  - Cancer
TI  - A randomized controlled trial of a multicomponent, targeted, low-literacy educational intervention compared with a nontargeted intervention to boost colorectal cancer screening with fecal immunochemical testing in community clinics
VL  - 123
ID  - 191
ER  - 

TY  - JOUR
AB  - BACKGROUND: Guidelines recommend that women in their 40's consider individual risk and personal values in deciding the age at which to begin breast cancer screening. However, it is unknown whether a decision aid (DA) that includes tailored risk information for younger women will increase the quality of decision making and impact the age at which women choose to start mammography screening. METHODS: We conducted a RCT in 2014‐2015 to evaluate a web based decision aid (DA) delivered within a clinical practice network compared to usual care on knowledge, decisional conflict, and mammography intentions. Women were eligible if aged 39 to 48, enrolled in a participating primary care clinics (family practice, obstetrics and gynecology, and internal medicine), and had not had a previous mammogram. Recruitment took place in‐clinic directly prior to the visit with randomization using concealed assignments occurring after obtainment of informed consent. A follow‐up survey was conducted at 6 weeks. The DA tool was self‐navigated by the patient, included risk estimates based on the NCI Breast Cancer Risk Assessment Tool, comparative risk information, value elicitation, and coaching to encourage shared decision making. Bivariate analysis was conducted to compare 3 pre‐specified primary outcomes between groups; knowledge as measured on a 5‐item scale (0‐low to 5‐high), decisional conflict as measured by the 16 item Decision Conflict Scale (DCS), and intended number of years before having a first mammogram. A p‐value of 0.017 was considered significant. Exploratory analyses were conducted on outcomes of DC subdomains (Uncertainty, Informed, Values, Support, Effective Decision Making), anticipated regret, and breast cancer worry. RESULTS: There were 204 participants enrolled in the study; DA group (102) and control group (102) with 54.9 % (n = 112) completing the follow‐up survey. The median age at the time of the follow‐up survey was 40.1 years (range 39‐49), 48 % were white, and 41 % were black. Ninety‐one percent (91 %, n = 49) of women in the intervention group who completed the follow‐up survey also completed the DA. At follow‐up, knowledge (range 0‐5) was greater in the DA vs. Control group (mean; difference, 95 %CI). (3.07 vs. 2.52, Diff: 0.57, 95 % CI: 0.14 to 0.98). A trend towards lower DCS scores was found in the DAvs. Control group (1.99 vs. 2.29, Diff: ‐0.30, 95 % CI: ‐0.63 to 0.38). There was no difference between groups in the intended number of years before having a first mammogram (2.6 vs. 1.6, Diff: 1.0, 95 %CI: ‐0.29 to 2.31). In exploratory analyses, women in the DA group trended towards decreased DCS scores in the Values domain (2.08 vs. 2.43, Diff: ‐0.36, 95 %CI: ‐0.73 to 0.01) and Support domain (1.83 vs. 2.13, Diff:‐0.30, 95 %CI: ‐0.62 to 0.03). There was no difference in the other DCS subdomains. There was no difference between groups in anticipated regret (7 point scale from 1‐low to 7‐high) of not having a mammogram in your 40's and having cancer detected at a later date (5.45 vs. 5.70, Diff: ‐0.25, 95 %CI: ‐0.97 to 0.46) or having a mammogram in your 40's and facing unnecessary follow up tests or procedures: (3.47 vs. 3.28, Diff: 0.19, 95 %CI: ‐0.55 to 0.93). Breast cancer worry (1‐low to 12‐high) did not differ between groups (5.42 vs. 5.07, Diff: 0.36, 95 %CI: ‐0.36 to 1.07). CONCLUSIONS: A web based DA tailored to individualized risk and delivered in a practice setting increased knowledge and trended towards a decrease in decisional conflict when compared to a control of usual care. This study supports the use of a risk based DA to improve the quality of decision making regarding mammography initiation among younger women.
AN  - CN-01160494
AU  - Schapira, M. M.
AU  - Hubbard, R.
AU  - Seitz, H.
AU  - Conant, E.
AU  - Schnall, M.
AU  - Capella, J.
AU  - Harrington, T.
AU  - Inge, C. A.
AU  - Armstrong, K.
IS  - 2
KW  - *female
*human
*internal medicine
*mammography
*randomized controlled trial
*risk
*screening
*society
Bivariate analysis
Breast cancer
Cancer risk
Cancer screening
Clinical practice
Control group
Decision making
Follow up
General practice
Gynecology
Hospital
Informed consent
Neoplasm
Obstetrics
Patient
Patient worry
Personal value
Primary medical care
Procedures
Randomization
Risk assessment
Statistical significance
M3  - Journal: Conference Abstract
PY  - 2016
SP  - S105‐
ST  - A randomized controlled trial of a risk based mammography screening decision aid for women 39-48 years of age
T2  - Journal of general internal medicine
TI  - A randomized controlled trial of a risk based mammography screening decision aid for women 39-48 years of age
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01160494/full
VL  - 31
ID  - 1645
ER  - 

TY  - JOUR
AB  - Objectives: Considerable morbidity persists among survivors of breast cancer (BC) including high levels of psychological stress, anxiety, depression, fear of recurrence, and physical symptoms including pain, fatigue, and sleep disturbances, and impaired quality of life. Effective interventions are needed during this difficult transitional period. Methods: We conducted a randomized controlled trial of 84 female BC survivors (Stages 0-III) recruited from the H. Lee Moffitt Cancer and Research Institute. All subjects were within 18 months of treatment completion with surgery and adjuvant radiation and/or chemotherapy. Subjects were randomly assigned to a 6-week Mindfulness-Based Stress Reduction (MBSR) program designed to self-regulate arousal to stressful circumstances or symptoms (n = 41) or to usual care (n = 43). Outcome measures compared at 6 weeks by random assignment included validated measures of psychological status (depression, anxiety, perceived stress, fear of recurrence, optimism, social support) and psychological and physical subscales of quality of life (SF-36). Results: Compared with usual care, subjects assigned to MBSR(BC) had significantly lower (two-sided p < 0.05) adjusted mean levels of depression (6.3 vs 9.6), anxiety (28.3 vs 33.0), and fear of recurrence (9.3 vs 11.6) at 6 weeks, along with higher energy (53.5 vs 49.2), physical functioning (50.1 vs 47.0), and physical role functioning (49.1 vs 42.8). In stratified analyses, subjects more compliant with MBSR tended to experience greater improvements in measures of energy and physical functioning. Conclusions: Among BC survivors within 18 months of treatment completion, a 6-week MBSR(BC) program resulted in significant improvements in psychological status and quality of life compared with usual care. Copyright (C) 2009 John Wiley & Sons, Ltd
AN  - WOS:000272734500003
AU  - Lengacher, C. A.
AU  - Johnson-Mallard, V.
AU  - Post-White, J.
AU  - Moscoso, M. S.
AU  - Jacobsen, P. B.
AU  - Klein, T. W.
AU  - Widen, R. H.
AU  - Fitzgerald, S. G.
AU  - Shelton, M. M.
AU  - Barta, M.
AU  - Goodman, M.
AU  - Cox, C. E.
AU  - Kip, K. E.
DA  - Dec
DO  - 10.1002/pon.1529
IS  - 12
N1  - 19235193
PY  - 2009
SN  - 1057-9249
SP  - 1261-1272
ST  - Randomized controlled trial of mindfulness-based stress reduction (MBSR) for survivors of breast cancer
T2  - Psycho-Oncology
TI  - Randomized controlled trial of mindfulness-based stress reduction (MBSR) for survivors of breast cancer
VL  - 18
ID  - 3133
ER  - 

TY  - JOUR
AB  - Background Latinas with breast cancer suffer symptom and psychosocial health disparities. Effective interventions have not been developed for or tested in this population. Purpose We describe community-based participatory research methods used to develop and implement the Nuevo Amanecer program, a culturally tailored, peer-delivered cognitive-behavioral stress management intervention for low-income Spanish-speaking Latinas with breast cancer, and unique considerations in implementing a randomized controlled trial to test the program in community settings. Methods We applied an implementation science framework to delineate the methodological phases used to develop and implement the Nuevo Amanecer program and trial, emphasizing community engagement processes. Results In phase 1, we established project infrastructure: academic and community co-principal investigators, community partners, community advisory board, steering committee, and funding. In phase 2, we identified three program inputs: formative research, a community best-practices model, and an evidence-based intervention tested in non-Latinas. In phase 3, we created the new program by integrating and adapting intervention components from the three sources, making adaptations to accommodate low literacy, Spanish language, cultural factors, community context, and population needs. In phase 4, we built community capacity for the program and trial by training field staff (recruiters and interventionists embedded in community sites), compensating field staff, and creating a system for identifying potential participants. In phase 5, we implemented and monitored the program and trial. Engaging community partners in all phases has resulted in a new, culturally tailored program that is suitable for newly diagnosed Latinas with breast cancer and a trial that is acceptable and supported by community and clinical partners. Lessons learned Engagement of community-based organizations and cancer survivors as research partners and hiring recruiters and interventionists from the community were critical to successful implementation in community settings. Having culturally and linguistically competent research staff with excellent interpersonal skills facilitated implementation. Facilitating and maintaining excellent communication among community partners was imperative to troubleshoot implementation issues. Randomization was challenging due to community concerns about assigning women to a control group. Patient privacy regulations and the need for extensive outreach to establish relationships between community partners and clinical sites hampered initial recruitment. Limitations These were resource-intensive processes to develop and implement the program that need to be compared to less-intensive alternatives. Conclusion Engaging community members in design and implementation of community-based programs and trials enhances cultural appropriateness and congruence with the community context. If the randomized trial demonstrates that the intervention is effective, it will fill a gap in evidence-based programs to address ethnic disparities in quality of life among Spanish-speaking Latinas with breast cancer.
AN  - WOS:000333645300010
AU  - Napoles, A. M.
AU  - Santoyo-Olsson, J.
AU  - Ortiz, C.
AU  - Gregorich, S.
AU  - Lee, H. E.
AU  - Duron, Y.
AU  - Graves, K.
AU  - Luce, J. A.
AU  - McGuire, P.
AU  - Diaz-Mendez, M.
AU  - Stewart, A. L.
DA  - Apr
DO  - 10.1177/1740774514521906
IS  - 2
N1  - 24577971
PY  - 2014
SN  - 1740-7745
SP  - 230-238
ST  - Randomized controlled trial of Nuevo Amanecer: A peer-delivered stress management intervention for Spanish-speaking Latinas with breast cancer
T2  - Clinical Trials
TI  - Randomized controlled trial of Nuevo Amanecer: A peer-delivered stress management intervention for Spanish-speaking Latinas with breast cancer
VL  - 11
ID  - 3014
ER  - 

TY  - JOUR
AB  - PURPOSE: This study examines the impact of yoga, including physical poses, breathing, and meditation exercises, on quality of life (QOL), fatigue, distressed mood, and spiritual well-being among a multiethnic sample of breast cancer patients. PATIENTS AND METHODS: One hundred twenty-eight patients (42% African American, 31% Hispanic) recruited from an urban cancer center were randomly assigned (2:1 ratio) to a 12-week yoga intervention (n = 84) or a 12-week waitlist control group (n = 44). Changes in QOL (eg, Functional Assessment of Cancer Therapy) from before random assignment (T1) to the 3-month follow-up (T3) were examined; predictors of adherence were also assessed. Nearly half of all patients were receiving medical treatment. RESULTS: Regression analyses indicated that the control group had a greater decrease in social well-being compared with the intervention group after controlling for baseline social well-being and covariates (P < .0001). Secondary analyses of 71 patients not receiving chemotherapy during the intervention period indicated favorable outcomes for the intervention group compared with the control group in overall QOL (P < .008), emotional well-being (P < .015), social well-being (P < .004), spiritual well-being (P < .009), and distressed mood (P < .031). Sixty-nine percent of intervention participants attended classes (mean number of classes attended by active class participants = 7.00 +/- 3.80), with lower adherence associated with increased fatigue (P < .001), radiotherapy (P < .0001), younger age (P < .008), and no antiestrogen therapy (P < .02). CONCLUSION: Despite limited adherence, this intent-to-treat analysis suggests that yoga is associated with beneficial effects on social functioning among a medically diverse sample of breast cancer survivors. Among patients not receiving chemotherapy, yoga appears to enhance emotional well-being and mood and may serve to buffer deterioration in both overall and specific domains of QOL.
AD  - Albert Einstein College of Medicine, Department of Epidemiology and Population Health, Bronx, NY 10461, USA. moadel@aecom.yu.edu
AN  - 17785709
AU  - Moadel, A. B.
AU  - Shah, C.
AU  - Wylie-Rosett, J.
AU  - Harris, M. S.
AU  - Patel, S. R.
AU  - Hall, C. B.
AU  - Sparano, J. A.
DA  - Oct 1
DO  - 10.1200/jco.2006.06.6027
DP  - NLM
ET  - 2007/09/06
IS  - 28
KW  - Adaptation, Psychological
Adult
Aged
Breast Neoplasms/ethnology/psychology/*therapy
Female
Humans
Middle Aged
*Quality of Life
Regression Analysis
Social Adjustment
*Yoga
LA  - eng
N1  - 1527-7755
Moadel, Alyson B
Shah, Chirag
Wylie-Rosett, Judith
Harris, Melanie S
Patel, Sapana R
Hall, Charles B
Sparano, Joseph A
R03 CA88598-01A1/CA/NCI NIH HHS/United States
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
United States
J Clin Oncol. 2007 Oct 1;25(28):4387-95. doi: 10.1200/JCO.2006.06.6027. Epub 2007 Sep 4.
PY  - 2007
SN  - 0732-183x
SP  - 4387-95
ST  - Randomized controlled trial of yoga among a multiethnic sample of breast cancer patients: effects on quality of life
T2  - J Clin Oncol
TI  - Randomized controlled trial of yoga among a multiethnic sample of breast cancer patients: effects on quality of life
VL  - 25
ID  - 513
ER  - 

TY  - JOUR
AB  - Purpose: A multicenter double-blind, randomized, placebo controlled clinical trial was performed to assess the effect of zoledronic acid, a potent new bisphosphonate, on bone mineral density during androgen deprivation therapy for nonmetastatic prostate cancer. Materials and Methods: Men with MO (no distant metastases) prostate cancer beginning androgen deprivation therapy were randomly assigned to receive 4 mg. zoledronic acid or placebo intravenously every 3 months for 1 year. The primary efficacy variable was the percent change from baseline to 1 year in bone mineral density of the lumbar spine as measured by dual energy x-ray absorptiometry. Results: A total of 106 men were enrolled in the trial. Mean bone mineral density in the lumbar spine increased by 5.6% in men receiving zoledronic acid and decreased by 2.2% in those given placebo (mean difference 7.8%, 95% confidence interval 5.6%-10.0%, p <0.001). Mean bone mineral density of the femoral neck, trochanter and total hip also increased in the zoledronic acid group and decreased in the placebo group. Zoledronic acid was well tolerated. Conclusions: Zoledronic acid increases bone mineral density in the hip and spine during androgen deprivation therapy for nonmetastatic prostate cancer. Indications:Prevention of bone loss in 55 patients on androgen deprivation therapy. Coexisting disease: prostate cancer in all patients. Patients:106 male patients. Zometa group: n=55, mean age 71.1±8.6 years (median 73 years), 47 Whites, 3 Blacks, 2 Orientals, 8 dropouts (2 due to side effects). Placebo group: n=51, mean age 70.2±9.3 years (median 72 years), 37 Whites, 8 Blacks, 2 Orientals, 8 dropouts (3 due to side effects). TypeofStudy:A multicenter double-blind, randomized, placebo controlled study assessing the effect of Zometa on bone mineral density in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. DosageDuration:4 mg iv for 15 minutes in 100 ml of 0.9% saline every 3 months for 1 year. Results:In the Zometa group 47 (86%) and in the placebo group 42 (82%) men completed the study. Lumbar spine bone mineral density increased 5.6% from baseline to 1 year in the Zometa group (p <0.001 for within treatment change from baseline) and decreased 2.2% in the placebo group (p = 0.012 for within treatment change from baseline). The difference of 7.8% in mean percent change at 1 year between the 2 groups was statistically significant (p <0.001). The difference in change from baseline in lumbar spine bone mineral density between the Zometa and placebo treatment groups was also significant in the treatment subgroups, in men with normal baseline lumbar spine bone mineral density (T-score -1 or greater) and in those with low baseline bone mineral density (T-score less than -1, -3 or greater). In the Zometa group bone mineral density also increased significantly from baseline in the femoral neck, trochanter and total hip. The mean difference in percent change from baseline differed significantly between Zometa and placebo in the femoral neck, tro-chanter, and total hip (p <0.001) but not in the nondominant forearm. No patient had a clinical (symptomatic) fracture. There were 5 radiographically diagnosed new or worsening vertebral fractures in the Zometa group and 3 in the placebo group (p = 0.29). Of the 8 men with vertebral body fractures 3 had low baseline bone mineral density of the spine and/or hip (T-scores less than - 1.0). Mean total testosterone decreased to castrate levels (less than 50 ng/dl) in both groups at 12 weeks and remained suppressed throughout the study. Mean prostate specific antigen (PSA) also decreased significantly from baseline to the end of the study in both groups. There were no statistically significant differences between the Zometa and placebo groups in the mean change from baseline in either total testosterone or PSA (p = 0.98 and p = 0.55, respectively). Severe (grade 3 or 4) adverse events were reported in 13/55 (24%) of men in the Zometa group and 20/51 (39%) in the placebo group. 2 men in the Zometa group and 3 in the placebo group withdrew from the study due to an adverse event. No adverse event of renal failure, increased serum creatinine or renal impairment was reported for any patient. AdverseEffects:32 patients experienced hot flushes, 21 fatigue, 12 arthralgia, 9 constipation, 9 nocturia, 8 urinary frequency, 7 dysuria, 7 limb pain, 7 weakness, 6 back pain, 6 erectile dysfunction, and 6 hematuria. Severe (grade 3 or 4) adverse events were reported in 13 patients. No patient experienced renal failure, increased serum creatinine or renal impairment. 2 patients withdrew due to side effects. AuthorsConclusions:Intermittent administration of zoledronic acid not only prevents treatment related bone loss, but also increases bone mineral density in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. FreeText:Androgen deprivation therapy consisted of gonadotropin releasing hormone (Gn-RH) agonist (n=31), Gn-RH agonist plus antiandrogen (23), and orchiectomy (1). Other concomitant medications included calcium supplement (500 mg) and multivitamin containing vitamin D (400 IU) daily in all patients. The primary efficacy variable was the percent change from baseline to the end of the study (1 year) in bone mineral density of lumbar vertebrae L2-L4 as measured by dual energy x-ray absorptiometry. Bone mineral density of the total hip, femoral neck, trochanteric region and nondominant forearm was also measured by dual energy x-ray absorptiometry. The incidence of new and worsening vertebral fractures was assessed by radiological survey of the spine (anterolateral and lateral cervical, thoracic and lumbar spine) at baseline and at the end of the study. Safety assessments included serum chemistry, complete blood count, and urinalysis.
AU  - Smith, M. R.
AU  - Eastham, J.
AU  - Gleason, D. M.
AU  - Shasha, D.
AU  - Tchekmedyian, S.
AU  - Zinner, N.
DB  - Scopus
DO  - 10.1097/01.ju.0000063820.94994.95
IS  - 6
KW  - Bone density
Diphosphonates
Osteoporosis
Prostatic neoplasms
M3  - Article
N1  - Cited By :563
Export Date: 22 March 2021
PY  - 2003
SP  - 2008-2012
ST  - Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer
T2  - Journal of Urology
TI  - Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer
UR  - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0038075478&doi=10.1097%2f01.ju.0000063820.94994.95&partnerID=40&md5=8180cac51a4fb692d60967de817a0f46
VL  - 169
ID  - 2613
ER  - 

TY  - JOUR
AB  - Organizational barriers play a key role in colorectal cancer (CRC) screening disparities in low-income minorities. This is a prospective, randomized trial to determine whether a patient navigator (PN) can help overcome the organizational barriers low-income minorities face in trying to obtain screening colonoscopy. Patients of average risk for CRC were referred by their primary care physician for screening colonoscopy. After the PN received the referral, patients were randomly assigned to either receive navigation (PN+) to screening colonoscopy or not receive navigation (PN-). We hypothesized that a PN would increase patient compliance with screening colonoscopy. A total of 21 patients were enrolled in the pilot study (PN+ = 13, PN- = 8); 54% of navigated patients completed screening colonoscopy versus 13% of nonnavigated patients (p = 0.058). Eighty-six percent of navigated patients had an excellent or very good colon prep; however, there was no difference in prep quality between groups ( p = 0.10). One-hundred percent of navigated patients were very satisfied with navigation services. A PN improves compliance with screening colonoscopy in low-income minorities. Larger studies are needed to evaluate what features of navigation are most effective in facilitating completion of screening colonoscopy.
AD  - Department of Medicine, Mount Sinai School of Medicine, New York, NY, USA. jennifer.christie@emoryhealthcare.org
AN  - 18390020
AU  - Christie, J.
AU  - Itzkowitz, S.
AU  - Lihau-Nkanza, I.
AU  - Castillo, A.
AU  - Redd, W.
AU  - Jandorf, L.
DA  - Mar
DO  - 10.1016/s0027-9684(15)31240-2
DP  - NLM
ET  - 2008/04/09
IS  - 3
KW  - African Americans
Appointments and Schedules
Attitude to Health
Colonoscopy/*statistics & numerical data
Colorectal Neoplasms/*diagnosis/ethnology/prevention & control
Female
Health Behavior
*Health Services Accessibility
Hispanic Americans
Humans
Male
Mass Screening/*statistics & numerical data
Middle Aged
*Minority Health
*Patient Acceptance of Health Care
Patient Education as Topic
Patient Satisfaction
*Poverty
Prospective Studies
Reminder Systems
Socioeconomic Factors
United States
LA  - eng
N1  - Christie, Jennifer
Itzkowitz, Steven
Lihau-Nkanza, Irene
Castillo, Anabella
Redd, William
Jandorf, Lina
U01-CA86107/CA/NCI NIH HHS/United States
Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
United States
J Natl Med Assoc. 2008 Mar;100(3):278-84. doi: 10.1016/s0027-9684(15)31240-2.
PY  - 2008
SN  - 0027-9684 (Print)
0027-9684
SP  - 278-84
ST  - A randomized controlled trial using patient navigation to increase colonoscopy screening among low-income minorities
T2  - J Natl Med Assoc
TI  - A randomized controlled trial using patient navigation to increase colonoscopy screening among low-income minorities
VL  - 100
ID  - 502
ER  - 

TY  - JOUR
AB  - BACKGROUND: The objective of this study was to evaluate 3 different doses of (7α)-21-(4-[(diethylamino)methyl]-2 methoxyphenoxy)-7 methyl-19 norpregna-1,3,5(10)-trien-3-ol 2-hydroxy-1,2,3-propanetricarboxylate (TAS-108) in patients with recurrent, hormone-responsive breast cancer. METHODS: In this randomized, double-blind, multicenter study, TAS-108 was administered daily at a dose of 40 mg, 80 mg, or 120 mg to postmenopausal patients with locally advanced, or inoperable, or metastatic hormone-receptor positive breast cancer. The primary efficacy outcome was clinical benefit (CB), defined as the total number of patients who achieved a complete response, a partial response, or stable disease for ≥24 weeks. The study was a 2-stage design in which 19 patients per dose group were planned in the first stage. If at least 3 patients in any dose group achieved a CB, then that dose group was to be allowed to continue enrolling for the second stage, and the group could include up to a total of 60 patients. RESULTS: The 40-mg and 80-mg groups met the criterion and enrolled patients into the second stage. In the 40-mg group, there were 13 CB events in 60 patients (21.7%); and, in the 80-mg group, there were 12 CB events in 60 patients (20%). The 120-mg daily dose was stopped early, because it failed to achieve the criterion. For the 40-mg and 80-mg groups, the median time to progression was 15.0 weeks and 15.9 weeks, respectively. Only 1 drug-related serious adverse event (grade 3 hyperglycemia) was reported. CONCLUSIONS: TAS-108 at 40 mg and 80 mg daily demonstrated clinical activity with an encouraging duration of benefit. Because of its superior safety profile, TAS-108 40 mg daily is recommended for further development. © 2011 American Cancer Society.
AD  - A. Buzdar, University of Texas, MD Anderson Cancer Center, Unit 1354, 1515 Holcombe Boulevard, Houston, TX, United States
AU  - Buzdar, A.
AU  - Vogel, C.
AU  - Schwartzberg, L.
AU  - Garin, A.
AU  - Perez, A.
AU  - Ingle, J.
AU  - Houghton, M.
AU  - Zergebel, C.
AU  - Kimball, B.
C1  - tas 108
DB  - Embase
Medline
DO  - 10.1002/cncr.26419
IS  - 13
KW  - 21 (4 diethylaminomethyl 2 methoxyphenoxy) 7alpha methyl 19 norpregna 1,3,5(10) trien 3 ol
aromatase inhibitor
estrogen receptor
progesterone receptor
tamoxifen
adult
arthralgia
article
Asian
backache
bone density
breast cancer
cancer grading
Caucasian
Chile
constipation
controlled study
coughing
diarrhea
double blind procedure
drug dose comparison
drug efficacy
drug fatality
drug safety
drug withdrawal
dyspnea
ethnic difference
fatigue
female
headache
Hispanic
hot flush
human
hyperglycemia
major clinical study
Mexico
multicenter study
multiple cycle treatment
nausea
Black person
Pacific Islander
phase 2 clinical trial
postmenopause
priority journal
progression free survival
randomized controlled trial
cancer recurrence
Russian Federation
sample size
side effect
thromboembolism
treatment duration
treatment outcome
treatment response
United States
vomiting
tas 108
LA  - English
M3  - Article
N1  - L51698109
2011-11-04
2012-07-04
PY  - 2012
SN  - 0008-543X
1097-0142
SP  - 3244-3253
ST  - Randomized double-blind phase 2 trial of 3 doses of TAS-108 in patients with advanced or metastatic postmenopausal breast cancer
T2  - Cancer
TI  - Randomized double-blind phase 2 trial of 3 doses of TAS-108 in patients with advanced or metastatic postmenopausal breast cancer
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L51698109&from=export
http://dx.doi.org/10.1002/cncr.26419
VL  - 118
ID  - 1114
ER  - 

TY  - JOUR
AB  - Number: 16 Rationale: It has been postulated that aromatase inhibitor (AI) therapy may sensitize ER+ breast cancer to lower doses of estrogen therapy as second‐line endocrine treatment for advanced breast cancer (ABC). We therefore conducted a randomized trial of 30mg generic estradiol daily (10 mg t.i.d.‐ recommended dose) versus 6 mg (2 mg t.i.d ‐ experimental dose). Materials and Methods: Major eligibility: Postmenopausal ER+ ABC treated with an AI with 24+ wks progression free survival, or relapse after 2+ yrs of adjuvant AI; RECIST measureable non‐bone metastases or WHO assessable bone lesions, with elevated tumor markers >2X ULN. Major exclusions: History venous thrombosis, heart disease, uncontrolled hypercalcemia and fulvestant in the last 12 months. FDG PET scans were conducted at baseline and after 24 hours to assess metabolic flare as a predictor of response (pre‐defined as a 12% increase in FDG uptake). Results: Sixty‐six patients were enrolled (82% White, 15% Black); mean age 59 years, range 36‐84. 34 received 6 mg and 32 received 30 mg. Estradiol levels will be provided at the meeting. There were more patients experiencing grade 3+ SAE on the 30 mg arm versus the 6 mg arm (11 vs. 4; P=0.06) with one venous thrombosis on each arm. There was no difference in total FACTB QOL scores at one month by treatment arm, QOL decline was associated with more severe estrogen side effects, especially amongst patients on the 30 mg arm (P=0.006). Uterine bleeding was successfully controlled with intermittent progestin therapy. Clinical benefit rates (stable disease at least 24 weeks plus response ‐ intent to treat population) were 25% (CI: 15‐37%, 1PR and 7SD out of 32) on the 30 mg arm and 29% (CI: 19‐42%, 3PR and 7SD out of 34) on the 6 mg arm. Patients with clinical benefit to estradiol could be retreated with original AI after progression and to date one PR out of three patients with repeat AI therapy noted. There were 44 patients evaluable for the interaction between PET ‐flare and response. Flare was seen in all responders (3/3), 9 of 13 patients with SD and only 3 of 30 patients with PD (p<0.0001). PPV for PET flare was therefore 12/15 (80%, CI: 61‐92%) and NPV 27/31 (87%, CI: 76‐94%). Conclusions: The Protocol Review and Monitoring Committee closed the 30 mg arm early after they concluded that the 6 mg arm was as effective as the 30 mg arm with greater safety. We therefore recommend 6 mg as the appropriate dose for the palliative treatment of advanced ER+ breast cancer. FDG PET flare can be used to identify patients who have a high chance of clinical benefit. Supported by an AVON NCI Partners in Progress Award: Grant # P30 CA091842‐S4.
AN  - CN-00990800
AU  - Ellis, M. J.
AU  - Dehdahti, F.
AU  - Kommareddy, A.
AU  - Jamalabadi-Majidi, S.
AU  - Crowder, R.
AU  - Jeffe, D. B.
AU  - Gao, F.
AU  - Fleming, G.
AU  - Silverman, P.
AU  - Dickler, M.
AU  - et al.
PY  - 2008
ST  - A randomized phase 2 trial of low dose (6 mg daily) versus high dose (30 mg daily) estradiol for patients with estrogen receptor positive aromatase inhibitor resistant advanced breast cancer
TI  - A randomized phase 2 trial of low dose (6 mg daily) versus high dose (30 mg daily) estradiol for patients with estrogen receptor positive aromatase inhibitor resistant advanced breast cancer
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00990800/full
ID  - 1654
ER  - 

TY  - JOUR
AB  - Background: The combination of PD‐1 and CTLA‐4 inhibition has demonstrated activity in the second line therapy setting for SCLC. Radiotherapy enhanced the effectiveness of immunotherapy in NSCLC. We conducted this signal finding study to assess the efficacy of combined ICI with or without radiation in relapsed SCLC. Methods: Patients with relapsed SCLC who have received not more than 2 lines of therapy were enrolled and randomized to either Arm A: [Tremelimumab (T) 1500mg/durvalumab (D) 75mg i.v. every 4 weeks without SBRT] or Arm B: T/D with immune sensitizing SBRT to one selected tumor site (9 Gy x 3 fractions). Treatment continued until progression or maximum of 2 years. Paired tumor biopsies and serial samples of peripheral blood were employed for correlative endpoints (changes in intratumoral and circulating lymphocyte repertoire and immune cytokines). The study was designed to show a promising efficacy signal in either Arm with a hypothesized median PFS of 7 months (10 patients give 87% power at 1‐sided alpha of 0.1). Results: Study randomized 17 patients to Arm A (8 patients) or B (9 patients); median age of 70 yrs; females 41.2%; White, 70%, Black 17.6%. Best response in 14 overall evaluable patients was PD in 9 (64.3%), PR in 2 (14%) and SD in 3 (21.4%); median PFS of 2.76 months and OS of 4.47 months. There was no significant difference in efficacy between Arms A and B but a trend of improved PFS and OS with T/D plus SBRT (see table): Median PFS of 2.1 vs. 3.3 months [HR: 2.44 (0.75‐7.93); p = 0.122] and median OS of 2.6 vs. 5.7 months [HR: 1.50 (0.45‐4.99); p = 0.5068]. Observed grade ≥ 3 adverse events were: Cytopenia (4), Dyspnea (1), and endocrine disorders (3) in Arm A; diarrhea (3) and cytopenias (1) in Arm B. There was an increase in circulating CD8(+) lymphocytes on treatment versus baseline in patients with objective tumor response. Conclusions:The study did not show sufficient signal of efficacy for ICI with or without SBRT in relapsed SCLC. Detailed result of the biomarker analysis will be available at the meeting.
AN  - CN-01990780
AU  - Owonikoko, T. K.
AU  - Higgins, K. A.
AU  - Chen, Z.
AU  - Zhang, C.
AU  - Pillai, R. N.
AU  - Steuer, C. E.
AU  - Saba, N. F.
AU  - Pakkala, S.
AU  - Shin, D. M.
AU  - Zhang, G.
AU  - et al.
DO  - 10.1200/JCO.2019.37.15_suppl.8515
KW  - *cancer patient
*cancer radiotherapy
*cancer recurrence
*non small cell lung cancer
Aged
Clinical article
Comparative effectiveness
Conference abstract
Controlled study
Cytopenia
Diarrhea
Dyspnea
Endocrine disease
Female
Human
Human cell
Lymphocyte
Phase 2 clinical trial
Randomized controlled trial
Stereotactic body radiation therapy
Tumor biopsy
M3  - Journal: Conference Abstract
PY  - 2019
ST  - A randomized phase II study of tremelimumab and durvalumab with or without radiation for patients with relapsed small cell lung cancer (SCLC)
T2  - Journal of clinical oncology
TI  - A randomized phase II study of tremelimumab and durvalumab with or without radiation for patients with relapsed small cell lung cancer (SCLC)
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01990780/full
VL  - 37
ID  - 1625
ER  - 

TY  - JOUR
AB  - Objective: The objective of the study is to test theoretical intervention fidelity and feasibility of MOVING ON, a self-directed, home-based, randomized controlled trial to increase exercise outcome expectations (OEs) (what one expects to obtain or avoid as a result of a behavior or lack thereof), among breast cancer survivors. Method: Stage Ia to IIb survivors (n = 60) were given the MOVING ON intervention or control booklet. Data were collected through online surveys and an accelerometer at baseline, 4, 8, and 12 weeks postintervention. Fidelity was measured by questions assessing participant perceptions of MOVING ON (score ≥2) and direction of intervention effects. Feasibility was measured by recruitment rate (target of 60 participants in 6 months), retention (total attrition <17%), and acquisition of accelerometer data (% ≥subjective exercise data obtained). Analyses consisted of descriptive statistics, mixed models, and content analysis. Results: Fidelity met a priori criteria (mean = 3.31, SD = 0.87). Outcome expectations increased 0.01 points, and weekly steps increased by 970 every 4 weeks in the intervention arm compared to the control arm. All effect sizes were small, ranging from 0.01 to 0.09. Target enrollment, achieved in 17 weeks, met a priori feasibility criteria. Retention (66%) and accelerometer data acquisition (60%) (compared to 73% of subjective exercise data) did not. Conclusion: MOVING ON influenced OEs as intended and was well received by participants. A fully powered study, of this low-cost, easy-to-implement intervention, is warranted. Intervention and measurement strategies used in MOVING ON can be incorporated in any study targeting OEs as a mediator of exercise or collecting exercise data with an accelerometer.
AD  - R. Hirschey, University of North Carolina, Chapel Hill, NC, United States
AU  - Hirschey, R.
AU  - Kimmick, G.
AU  - Hockenberry, M.
AU  - Shaw, R.
AU  - Pan, W.
AU  - Page, C.
AU  - Lipkus, I.
C1  - arimidex
aromasin
femara
DB  - Embase
Medline
DO  - 10.1002/pon.4849
IS  - 10
KW  - NCT02348710
accelerometer
Fitbit
anastrozole
exemestane
letrozole
adult
African American
article
Black person
breast cancer
cancer staging
cancer survivor
Caucasian
content analysis
controlled study
data analysis
descriptive research
effect size
employment status
exercise
expectation
feasibility study
human
information processing
lumpectomy
major clinical study
marriage
mastectomy
medical research
middle aged
online system
outcome assessment
partial mastectomy
patient attitude
patient participation
phase 2 clinical trial
randomized controlled trial
arimidex
aromasin
femara
LA  - English
M3  - Article
N1  - L623932412
2018-09-24
2018-10-11
PY  - 2018
SN  - 1099-1611
1057-9249
SP  - 2450-2457
ST  - A randomized phase II trial of MOVING ON: An intervention to increase exercise outcome expectations among breast cancer survivors
T2  - Psycho-Oncology
TI  - A randomized phase II trial of MOVING ON: An intervention to increase exercise outcome expectations among breast cancer survivors
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L623932412&from=export
http://dx.doi.org/10.1002/pon.4849
VL  - 27
ID  - 881
ER  - 

TY  - JOUR
AB  - Background: Chemotherapy‐induced peripheral neuropathy (CIPN) is a common and potentially disabling effect of taxanes. There are no effective preventive therapies. Electro‐acupuncture (EA) uses acupuncture needles attached to an electrostimulator that generate a low electrical current, and is used to treat acute and chronic pain. Methods: Women with stage IIII breast cancer undergoing 12 weekly taxane treatments were randomized to receive a standardized protocol of either 12 true (EA) or sham (SEA) weekly treatments concurrently. Subjects completed the Functional Assessment of Cancer TherapyNeurotaxane scale (FACT‐NTX), Brief Pain Inventory‐Short Form (BPI‐SF), Neuropathy Pain Scale (NPS), and a grooved pegboard test at baseline, weeks 6, 12, and 16. Chi square analyses and t‐tests examined differences between the two groups. A clinically significant change in the FACT‐NTX was defined as > 5‐point decrease (worse CIPN) from baseline. Results: A total of 180 subjects were screened, 63 enrolled and 46 completed (25 EA, 21 SEA). Mean age was 50; 25.4% were White, 25.4% Black, and 42.86% Hispanic; 52.4% had no prior chemotherapy. No imbalances by arm were observed. The proportion of subjects with a > 5‐point FACT‐NTX decrease from baseline at 12 weeks was 44% with EA and 67% with SEA, p = 0.12. At 12 weeks both the SEA and EA groups had an increase in mean BPI Score, but no between group differences were found (mean 2.81 vs. 2.64, p = 0.86). However by 16 weeks (4 weeks after completion of therapy) the SEA group returned to baseline while the EA group continued to worsen (mean 1.65 vs. 3.40, p = 0.03). The NPS score did not differ between groups at 12 weeks, however at 16 weeks the EA group had higher (worse) scores compared to SEA (2.84 vs. 1.59, p = 0.05). Both quality of life and grooved pegboard scores worsened over time, but no between group differences seen. No adverse events were reported. Conclusions: We failed to find a significant difference in pain or neuropathy between groups at 12 weeks. However, of concern, subjects on EA had a slower recovery after taxane completion than SEA subjects. Future studies should focus on EA for treatment as opposed to prevention of CIPN.
AN  - CN-01129792
AU  - Awad, D.
AU  - Greenlee, H.
AU  - Crew, K. D.
AU  - Buono, D.
AU  - Capodice, J.
AU  - Kalinsky, K.
AU  - Maurer, M. A.
AU  - Hershman, D. L.
IS  - 15 SUPPL. 1
KW  - *American
*acupuncture
*oncology
*peripheral neuropathy
*prevention
*society
Acupuncture needle
Arm
Breast cancer
Brief Pain Inventory
Chemotherapy
Chi square test
Chronic pain
Electric current
Female
Functional assessment
Grooved pegboard test
Hispanic
Human
Neoplasm
Neuropathy
Pain
Pain assessment
Patient history of chemotherapy
Prophylaxis
Quality of life
Student t test
Therapy
M3  - Journal: Conference Abstract
PY  - 2015
ST  - Randomized sham controlled pilot trial of weekly electro-acupuncture for the prevention of taxane-induced peripheral neuropathy
T2  - Journal of clinical oncology
TI  - Randomized sham controlled pilot trial of weekly electro-acupuncture for the prevention of taxane-induced peripheral neuropathy
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01129792/full
VL  - 33
ID  - 1638
ER  - 

TY  - JOUR
AB  - To investigate the effect of electro-acupuncture (EA) as a non-pharmacological intervention to prevent or reduce chemotherapy-induced peripheral neuropathy (CIPN) in breast cancer patients undergoing chemotherapy of taxane. Women with stage I-III breast cancer scheduled to receive taxane therapy were randomized to receive a standardized protocol of 12 true or sham EA (SEA) weekly treatments concurrent with taxane treatment. Subjects completed the Brief Pain Inventory-Short Form (BPI-SF), Functional Assessment of Cancer Therapy-Taxane neurotoxicity subscale (FACT-NTX), and other assessments at baseline and weeks 6, 12, and 16. A total of 180 subjects were screened, 63 enrolled and 48 completed week 16 assessments. Mean age was 50 with 25 % white, 25 % black, and 43 % Hispanic; 52 % had no prior chemotherapy. At week 12, both groups reported an increase in mean BPI-SF worst pain score, but no mean differences were found between groups (SEA 2.8 vs. EA 2.6, P = .86). By week 16, the SEA group returned to baseline, while the EA group continued to worsen (SEA 1.7 vs. EA 3.4, P = .03). The increase in BPI-SF worst pain score was 1.62 points higher in the EA group than in the SEA group at week 16 (P = .04). In a randomized, sham-controlled trial of EA for prevention of taxane-induced CIPN, there were no differences in pain or neuropathy between groups at week 12. Of concern, subjects on EA had a slower recovery than SEA subjects. Future studies should focus on EA for treatment as opposed to prevention of CIPN.
AD  - Mailman School of Public Health, Columbia University, New York, NY, USA. hg2120@columbia.edu.
Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, USA. hg2120@columbia.edu.
Columbia University, 722 W. 168th Street, Room 733, New York, NY, 10032, USA. hg2120@columbia.edu.
Mailman School of Public Health, Columbia University, New York, NY, USA.
Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, USA.
College of Physicians and Surgeons, Columbia University, New York, NY, USA.
Mount Sinai School of Medicine, New York, NY, USA.
AN  - 27013473
AU  - Greenlee, H.
AU  - Crew, K. D.
AU  - Capodice, J.
AU  - Awad, D.
AU  - Buono, D.
AU  - Shi, Z.
AU  - Jeffres, A.
AU  - Wyse, S.
AU  - Whitman, W.
AU  - Trivedi, M. S.
AU  - Kalinsky, K.
AU  - Hershman, D. L.
C2  - PMC4924571
C6  - NIHMS772719
DA  - Apr
DO  - 10.1007/s10549-016-3759-2
DP  - NLM
ET  - 2016/03/26
IS  - 3
KW  - Adult
Aged
Breast Neoplasms/*drug therapy/ethnology/*pathology
Bridged-Ring Compounds/*adverse effects/therapeutic use
Double-Blind Method
Electroacupuncture/*methods
Female
Humans
Middle Aged
Peripheral Nervous System Diseases/chemically induced/*prevention & control
Pilot Projects
Taxoids/*adverse effects/therapeutic use
Treatment Outcome
Acupuncture
Breast cancer
Chemotherapy-induced peripheral neuropathy
Electro-acupuncture
Taxane
LA  - eng
N1  - 1573-7217
Greenlee, Heather
Crew, Katherine D
Capodice, Jillian
Awad, Danielle
Buono, Donna
Shi, Zaixing
Jeffres, Anne
Wyse, Sharon
Whitman, Wendy
Trivedi, Meghna S
Kalinsky, Kevin
Hershman, Dawn L
K23 CA141052/CA/NCI NIH HHS/United States
K23CA141052/CA/NCI NIH HHS/United States
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Breast Cancer Res Treat. 2016 Apr;156(3):453-464. doi: 10.1007/s10549-016-3759-2. Epub 2016 Mar 25.
PY  - 2016
SN  - 0167-6806 (Print)
0167-6806
SP  - 453-464
ST  - Randomized sham-controlled pilot trial of weekly electro-acupuncture for the prevention of taxane-induced peripheral neuropathy in women with early stage breast cancer
T2  - Breast Cancer Res Treat
TI  - Randomized sham-controlled pilot trial of weekly electro-acupuncture for the prevention of taxane-induced peripheral neuropathy in women with early stage breast cancer
VL  - 156
ID  - 216
ER  - 

TY  - JOUR
AB  - OBJECTIVES: Few decision aids are tailored for African-American men. We sought to determine if web-based decision aids increased knowledge of prostate cancer screening among African men. METHODS: This postintervention, quasiexperimental research measured knowledge of prostate cancer screening among African-American men following receipt of 1 of 2 web-based decision aids: enhanced or usual care. Men ages 40-65 were recruited at the annual convention of the Prince Hall Masons in the summer of 2007, which was attended by 1170 masons. The primary outcome was knowledge of prostate cancer screening. RESULTS: There were 87 participants in the sample with a mean age of 52 years (standard deviation = 6.9). Forty-six masons were randomized to the enhanced decision aid, and 41 masons were randomized to the usual care decision aid. Knowledge scores were statistically significantly higher among the men receiving the enhanced decision aid compared to the usual care decision aid after simultaneously adjusting for age, educational level, marital status, family history, previous prostate specific antigen test and digital rectal exam (p = 0.01). CONCLUSION: We found evidence that the enhanced web decision aid was significantly more effective than the usual care decision aid in promoting knowledge of the benefits, limitations and risks of prostate cancer screening. Web-based sites may be effective in facilitating discussions about screening between patients and health care providers.
AD  - Department of Family and Community Medicine, School of Medicine, University of Maryland, Baltimore, MD, USA. gellison@som.umaryland.edu
AN  - 18942274
AU  - Ellison, G. L.
AU  - Weinrich, S. P.
AU  - Lou, M.
AU  - Xu, H.
AU  - Powell, I. J.
AU  - Baquet, C. R.
C2  - PMC3883720
C6  - NIHMS525639
DA  - Oct
DO  - 10.1016/s0027-9684(15)31481-4
DP  - NLM
ET  - 2008/10/24
IS  - 10
KW  - Adult
*African Americans
Aged
Decision Making, Computer-Assisted
*Health Knowledge, Attitudes, Practice
Humans
*Internet
Male
Middle Aged
*Prostatic Neoplasms
United States
LA  - eng
N1  - Ellison, Gary L
Weinrich, Sally P
Lou, Mimi
Xu, Hongyan
Powell, Isaac J
Baquet, Claudia R
U01 CA114650/CA/NCI NIH HHS/United States
Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
J Natl Med Assoc. 2008 Oct;100(10):1139-45. doi: 10.1016/s0027-9684(15)31481-4.
PY  - 2008
SN  - 0027-9684 (Print)
0027-9684
SP  - 1139-45
ST  - A randomized trial comparing web-based decision aids on prostate cancer knowledge for African-American men
T2  - J Natl Med Assoc
TI  - A randomized trial comparing web-based decision aids on prostate cancer knowledge for African-American men
VL  - 100
ID  - 485
ER  - 

TY  - JOUR
AB  - Background: The addition of abiraterone or docetaxel has shown overall survival (OS) benefit in mHSPC. There is adequate rationale for clinical efficacy of enzalutamide and ADT combination inmHSPC. We compared the combination of enzalutamide (Arm A) or bicalutamide (Arm B), each with ADT in mHSPC. Methods: The primary endpoint was the seven month PSA remission (SMPR), with PSA nadir of<4 ng/ml, as this is an accepted surrogate for overall survival (OS) outcomes. Secondary endpoints were toxicities, biochemical and radiologic progression free survival (PFS), and OS. Stratification was by presence of bone pain (yes/no) and race; (AA or other). PSA was monitored monthly for first 7 months and then every 3 months. Metastatic site biopsies were mandatory pretherapy and optional post therapy. Results: 71 men; 29 African American (AA),41 Caucasian and 1 Asian were enrolled. The median age was 67 years (range 46‐87 years) and median baseline PSA was 56.3 ng/ ml in Arm A (4.2‐ 10,431 ng/ml) and 60 (4.9‐12,030 ng/ml) in Arm B. 26 pts (39%) had bone pain and 37(52%) had extensive disease. Predominant grade 3+ adverse events on Arm A were: Hypertension (13%), infection (7%), and syncope (7%) and on Arm B were: Hypertension (21%), Fatigue (7%), and Hematuria (7%). No seizures were noted. PSA nadir< 4ng/ml at month 7 was achieved in 29/31 (94%) pts in arm A and 16/24 (67%) pts in arm B. 53% on arm A and 43% on Arm B continue to maintain PSA< 4 ng/ml. 4 (11%) deaths have occurred on enzalutamide arm as compared to 13 (37.1%) deaths on Arm B. Among AA patients, SMPR was 100% on Arm A and 46% on Arm B. 53 (75%) biopsy samples had tumor tissue available. TMPRSS‐ERG fusion gene and CXCR4 expression and androgen biosynthetic enzyme levels were determined in metastatic biopsies. Patients with low copy number of ERG had an increased likelihood of SMPR (19/20 or 95%) as compared to high copy number (14/20 or 70%). Conclusions: Early enzalutamide use in mHSPC improved PSA remission rates and has the potential to subsequently improve OS outcomes High ERG copy number was associated with decreased SMPR. This is the first randomized trial to report efficacy results of the combination of ADT and enzalutamide compared with ADT and bicalutamide inmHSPC.
AN  - CN-01961671
AU  - Vaishampayan, U. N.
AU  - Heilbrun, L.
AU  - Monk, P.
AU  - Sonpavde, G.
AU  - Tejwani, S.
AU  - Heath, E. I.
AU  - Fontana, J.
AU  - Chinni, S.
DO  - 10.1093/annonc/mdy284.012
KW  - *androgen deprivation therapy
*prostate cancer
Adult
Adverse event
African American
Aged
Biopsy
Bone pain
Cancer survival
Caucasian
Conference abstract
Controlled study
Death
Drug combination
Drug therapy
Faintness
Fatigue
Fusion gene
Gene amplification
Gene expression
Hematuria
Human
Human tissue
Hypertension
Infection
Major clinical study
Male
Overall survival
Progression free survival
Protein expression
Randomized controlled trial
Remission
Seizure
Stratification
M3  - Journal: Conference Abstract
PY  - 2018
SP  - viii276‐
ST  - Randomized trial of androgen deprivation therapy (ADT) 1 enzalutamide (Arm A) versus ADT 1 bicalutamide (Arm B) in metastatic hormone sensitive prostate cancer (mHSPC)
T2  - Annals of oncology
TI  - Randomized trial of androgen deprivation therapy (ADT) 1 enzalutamide (Arm A) versus ADT 1 bicalutamide (Arm B) in metastatic hormone sensitive prostate cancer (mHSPC)
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01961671/full
VL  - 29
ID  - 1537
ER  - 

TY  - JOUR
AB  - PURPOSE: Most breast cancer survivors experience hot flashes; many use complementary or alternative remedies for these symptoms. We undertook a randomized clinical trial of black cohosh, a widely used herbal remedy for menopausal symptoms, among breast cancer patients. PATIENTS AND METHODS: Patients diagnosed with breast cancer who had completed their primary treatment were randomly assigned to black cohosh or placebo, stratified on tamoxifen use. At enrollment, patients completed a questionnaire about demographic factors and menopausal symptoms. Before starting to take the pills and at 30 and 60 days, they completed a 4-day hot flash diary. At the final visit, they completed another menopausal symptom questionnaire. Follicle-stimulating hormone (FSH) and luteinizing hormone (LH) levels were measured in a subset of patients at the first and final visits. RESULTS: Of 85 patients (59 on tamoxifen, 26 not on tamoxifen) enrolled in the study, 42 were assigned to treatment and 43 were assigned to placebo; 69 completed all three hot flash diaries. Both treatment and placebo groups reported declines in number and intensity of hot flashes; the differences between the groups were not statistically significant. Both groups also reported improvements in menopausal symptoms that were, for the most part, not significantly different. Changes in blood levels of FSH and LH also did not differ in the two groups. CONCLUSION: Black cohosh was not significantly more efficacious than placebo against most menopausal symptoms, including number and intensity of hot flashes. Our study illustrates the feasibility and value of standard clinical trial methodology in assessing the efficacy and safety of herbal agents.
AD  - Herbert Irving Comprehensive Cancer Center and Joseph L. Mailman School of Public Health, Columbia University, and Weill-Cornell Medical College, New York, NY 10032, USA.
AN  - 11352967
AU  - Jacobson, J. S.
AU  - Troxel, A. B.
AU  - Evans, J.
AU  - Klaus, L.
AU  - Vahdat, L.
AU  - Kinne, D.
AU  - Lo, K. M.
AU  - Moore, A.
AU  - Rosenman, P. J.
AU  - Kaufman, E. L.
AU  - Neugut, A. I.
AU  - Grann, V. R.
DA  - May 15
DO  - 10.1200/jco.2001.19.10.2739
DP  - NLM
ET  - 2001/05/16
IS  - 10
KW  - Antineoplastic Agents, Hormonal/adverse effects/*therapeutic use
Breast Neoplasms/*drug therapy/radiotherapy
Combined Modality Therapy
Double-Blind Method
Female
Follicle Stimulating Hormone/blood
Hot Flashes/*drug therapy
Humans
Luteinizing Hormone/blood
Middle Aged
Plant Extracts/*therapeutic use
Tamoxifen/adverse effects/*therapeutic use
LA  - eng
N1  - Jacobson, J S
Troxel, A B
Evans, J
Klaus, L
Vahdat, L
Kinne, D
Lo, K M
Moore, A
Rosenman, P J
Kaufman, E L
Neugut, A I
Grann, V R
Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
United States
J Clin Oncol. 2001 May 15;19(10):2739-45. doi: 10.1200/JCO.2001.19.10.2739.
PY  - 2001
SN  - 0732-183X (Print)
0732-183x
SP  - 2739-45
ST  - Randomized trial of black cohosh for the treatment of hot flashes among women with a history of breast cancer
T2  - J Clin Oncol
TI  - Randomized trial of black cohosh for the treatment of hot flashes among women with a history of breast cancer
VL  - 19
ID  - 684
ER  - 

TY  - JOUR
AB  - BACKGROUND: Black men are disproportionately affected by prostate cancer, the most common non-cutaneous malignancy among men in the USA. The United States Preventive Services Task Force (USPSTF) encourages prostate-specific antigen (PSA) testing decisions to be based on shared decision-making (SDM) clinician professional judgment, and patient preferences. However, evidence suggests that SDM is underutilized in clinical practice, especially among the most vulnerable patients. The purpose of this study is to evaluate the efficacy of a community health worker (CHW)-led decision-coaching program to facilitate SDM for prostate cancer screening among Black men in the primary care setting, with the ultimate aim of improving/optimizing decision quality. METHODS: We proposed a CHW-led decision-coaching program to facilitate SDM for prostate cancer screening discussions in Black men at a primary care FQHC. This study enrolled Black men who were patients at the participating clinical site and up to 15 providers who cared for them. We estimated to recruit 228 participants, ages 40-69 to be randomized to either (1) a decision aid along with decision coaching on PSA screening from a CHW or (2) receiving a decision aid along with CHW-led interaction on modifying dietary and lifestyle to serve as an attention control. The independent randomization process was implemented within each provider and we controlled for age by dividing patients into two strata: 40-54 years and 55-69 years. This sample size sufficiently powered the detection differences in the primary study outcomes: knowledge, indicative of decision quality, and differences in PSA screening rates. Primary outcome measures for patients will be decision quality and decision regarding whether to undergo PSA screening. Primary outcome measures for providers will be acceptability and feasibility of the intervention. We will examine how decision coaching about prostate cancer screening impact patient-provider communication. These outcomes will be analyzed quantitatively through objective, validated scales and qualitatively through semi-structured, in-depth interviews, and thematic analysis of clinical encounters. Through a conceptual model combining elements of the Preventative Health Care Model (PHM) and Informed Decision-Making Model, we hypothesize that the prostate cancer screening decision coaching intervention will result in a preference-congruent decision and decisional satisfaction. We also hypothesize that this intervention will improve physician satisfaction with counseling patients about prostate cancer screening. DISCUSSION: Decision coaching is an evidence-based approach to improve decision quality in many clinical contexts, but its efficacy is incompletely explored for PSA screening among Black men in primary care. Our proposal to evaluate a CHW-led decision-coaching program for PSA screening has high potential for scalability and public health impact. Our results will determine the efficacy, cost-effectiveness, and sustainability of a CHW intervention in a community clinic setting in order to inform subsequent widespread dissemination, a critical research area highlighted by USPSTF. TRIAL REGISTRATION: The trial was registered prospectively with the National Institute of Health registry ( www.clinicaltrials.gov ), registration number NCT03726320 , on October 31, 2018.
AD  - VA New York Harbor Healthcare System, 423 E 23rd St, New York, NY, USA. Danil.Makarov@nyulangone.org.
Departments of Urology, NYU Langone Health, 227 E 30th St, New York, NY, USA. Danil.Makarov@nyulangone.org.
Population Health, NYU Langone Health, 227 E 30th St, New York, NY, USA. Danil.Makarov@nyulangone.org.
VA New York Harbor Healthcare System, 423 E 23rd St, New York, NY, USA.
Departments of Urology, NYU Langone Health, 227 E 30th St, New York, NY, USA.
Population Health, NYU Langone Health, 227 E 30th St, New York, NY, USA.
Department of Population Health Sciences, University of Utah School of Medicine, Salt Lake City, UT, USA.
NYU College of Nursing, 433 First Avenue, New York, NY, USA.
Sunset Park Health Council, Brooklyn, NY, USA.
National Center for Bioethics in Research and Health Care, Tuskegee University, Tuskegee, USA.
The Fuqua School of Business, Duke University, Durham, NC, USA.
AN  - 33568208
AU  - Makarov, D. V.
AU  - Feuer, Z.
AU  - Ciprut, S.
AU  - Lopez, N. M.
AU  - Fagerlin, A.
AU  - Shedlin, M.
AU  - Gold, H. T.
AU  - Li, H.
AU  - Lynch, G.
AU  - Warren, R.
AU  - Ubel, P.
AU  - Ravenell, J. E.
C2  - PMC7876807
DA  - Feb 10
DO  - 10.1186/s13063-021-05064-4
DP  - NLM
ET  - 2021/02/12
IS  - 1
KW  - Community health worker
Psa
Prostate cancer
Racial disparity
Randomized controlled trial
Screening
Shared decision-making
LA  - eng
N1  - 1745-6215
Makarov, Danil V
Orcid: 0000-0002-0565-9272
Feuer, Zachary
Ciprut, Shannon
Lopez, Natalia Martinez
Fagerlin, Angela
Shedlin, Michele
Gold, Heather T
Li, Huilin
Lynch, Gina
Warren, Rueben
Ubel, Peter
Ravenell, Joseph E
R01MD012243/MD/NIMHD NIH HHS/United States
Journal Article
Trials. 2021 Feb 10;22(1):128. doi: 10.1186/s13063-021-05064-4.
PY  - 2021
SN  - 1745-6215
SP  - 128
ST  - Randomized trial of community health worker-led decision coaching to promote shared decision-making for prostate cancer screening among Black male patients and their providers
T2  - Trials
TI  - Randomized trial of community health worker-led decision coaching to promote shared decision-making for prostate cancer screening among Black male patients and their providers
VL  - 22
ID  - 5
ER  - 

TY  - JOUR
AB  - Background: Addition of abiraterone or docetaxel has overall survival (OS) benefit in metastatic hormone sensitive prostate cancer (mHSPC). The clinical outcomes with early enzalutamide in mHSPC are unknown. We compared the combinations of enzalutamide (Arm A) or bicalutamide (Arm B) each with LHRH analogue therapy in mHSPC. Methods: The primary endpoint was PSA nadir < 4 ng/ml after 7 months of therapy, as this has been recognized as a powerful surrogate for overall survival (OS) outcomes. A minimum of 29 African American (AA) patients were required to be enrolled to evaluate the effect of race on the primary endpoint. Secondary endpoints were toxicities, biochemical and radiologic progression free survival (PFS), and OS. Stratification was by presence of bone pain and race; AA or other. PSA was monitored monthly for first 7 months and then every 3 months. The target sample size was 82 evaluable patients but the study was stopped when early abiraterone showed OS benefit in mHSPC. Metastatic site biopsies were mandatory pretherapy and optional post therapy. Results: 71 men; 29 black, 41 white and 1 Asian were enrolled. The median age was 67 years (range 46‐87 years) and median baseline PSA was 56.3 ng/ml in Arm A (4.2‐10,431 ng/ml) and 60 (4.9‐12,030 ng/ml) in Arm B. 27 pts (38.5%) had bone pain and 13 had visceral metastases. No seizures were noted in either arm. Grade 3+ AE's on Arm A were: Hypertension (13%), infection (7%), and Snycope (7%) and on Arm B were: Hypertension (21%), Fatigue (7%), and Hematuria (7%). By intent to treat PSA nadir < 4ng/ml at month 7 was achieved in 96.3% pts in arm A and 66.7% pts in arm B and in 71.7% of AA men and 89.7% of Caucasians. The 6‐month PSA remission duration rates after month 7 on Arms A and B were 86% and 79%, respectively. 53 (75%) biopsy samples had tumor tissue available. Tmprss2‐Erg fusion gene expression and androgen biosynthetic enzyme levels were determined in metastatic biopsies and will be correlated with clinical endpoints. Conclusions: Early enzalutamide use in mHSPC has the potential to improve PSA remission rates and subsequently improve PFS and OS outcomes.
AN  - CN-01778112
AU  - Vaishampayan, U. N.
AU  - Heilbrun, L. K.
AU  - Monk, P.
AU  - Tejwani, S.
AU  - Sonpavde, G.
AU  - Smith, D.
AU  - Jasti, P.
AU  - Dobson, K.
AU  - Heath, E. I.
AU  - Cher, M. L.
AU  - et al.
DO  - 10.1200/JCO.2018.36.6_suppl.190
IS  - 6
KW  - *prostate cancer
Adult
African American
Aged
Biopsy
Bone pain
Cancer patient
Cancer survival
Caucasian
Conference abstract
Controlled study
Drug combination
Drug therapy
Fatigue
Fusion gene
Hematuria
Human
Human tissue
Hypertension
Infection
Major clinical study
Male
Overall survival
Progression free survival
Protein expression
Randomized controlled trial
Remission
Sample size
Seizure
Stratification
Visceral metastasis
M3  - Journal: Conference Abstract
PY  - 2018
ST  - Randomized trial of enzalutamide versus bicalutamide in combination with androgen deprivation in metastatic hormone sensitive prostate cancer: a Prostate Cancer Clinical Trials Consortium trial
T2  - Journal of clinical oncology
TI  - Randomized trial of enzalutamide versus bicalutamide in combination with androgen deprivation in metastatic hormone sensitive prostate cancer: a Prostate Cancer Clinical Trials Consortium trial
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01778112/full
VL  - 36
ID  - 1461
ER  - 

TY  - JOUR
AB  - Purpose: This paper describes an ongoing randomized controlled trial designed to assess the impact of genetic and environmental risk assessment (GERA) on colorectal cancer (CRC) screening. Methods: The trial includes asymptomatic patients who are 50-79 years and are not up-to-date with CRC screening guidelines. Patients who responded to a baseline telephone survey are randomized to a GERA or Control group. GERA group participants meet with a nurse, decide whether to have a GERA blood test (a combination of genetic polymorphism and folate), and, if tested, receive GERA feedback. Follow-up telephone surveys are conducted at 1 and 6 months. A chart audit is performed at 6 months. Results: Of 2,223 eligible patients, 562 (25%) have enrolled. Patients who enrolled in the study were significantly younger than those who did not (p<0.001). Participants tended to be 5059 years (64%), female (58%), white (52%), married (51%), and have more than a high school education (67%). At baseline, most participants had some knowledge of CRC screening and GERA, viewed CRC screening favorably, and reported that they had decided to do screening. Almost half had worries and concerns about CRC. Conclusions: One in four eligible primary care patients enrolled in the study. Age was negatively associated with enrollment. Prospective analyses using data for all participants will provide more definitive information on GERA uptake and the impact of GERA feedback (C) 2010 Elsevier Inc. All rights reserved.
AN  - WOS:000286552500004
AU  - Myers, R. E.
AU  - Manne, S. L.
AU  - Wilfond, B.
AU  - Sifri, R.
AU  - Ziring, B.
AU  - Wolf, T. A.
AU  - Cocroft, J.
AU  - Ueland, A.
AU  - Petrich, A.
AU  - Swan, H.
AU  - DiCarlo, M.
AU  - Weinberg, D. S.
DA  - Jan
DO  - 10.1016/j.cct.2010.08.013
IS  - 1
N1  - 20828635
PY  - 2011
SN  - 1551-7144
SP  - 25-31
ST  - A randomized trial of genetic and environmental risk assessment (GERA) for colorectal cancer risk in primary care: Trial design and baseline findings
T2  - Contemporary Clinical Trials
TI  - A randomized trial of genetic and environmental risk assessment (GERA) for colorectal cancer risk in primary care: Trial design and baseline findings
VL  - 32
ID  - 3102
ER  - 

TY  - JOUR
AB  - PURPOSE: We designed a peer counseling program to improve sexual function, increase knowledge about reproductive health, and decrease menopausal symptoms and infertility-related distress for African American breast cancer survivors. PATIENTS AND METHODS: Women were randomly assigned to immediate counseling or a 3-month waitlist. Three peer counselors conducted a 3-session intervention using a detailed workbook. Questionnaires at baseline, after the waitlist period, at posttreatment, and at 3-month follow-up assessed spirituality, sexual function, menopause symptoms, emotional distress, relationship satisfaction, fertility concerns, and knowledge about reproductive health and breast cancer. At the postcounseling assessment, women rated the workbook, their counselor, and the program. RESULTS: Of 93 women screened, 60 women (65%) enrolled in the study. Women who completed counseling (80%; N = 48) had a mean age of 49 years (standard deviation [SD], 8 years) and a mean follow-up of 4.5 years (SD, 3.8 years) since cancer diagnosis. Almost all rated the workbook as very easy to understand (94%) and their counselor as very knowledgeable (96%) and very skillful (98%). Eighty-one percent rated the program as "very useful to me." Immediate counseling and waitlist groups did not differ at baseline in psychologic adjustment, nor did scores change during the waitlist period. Therefore, the groups were combined in analyzing outcomes. Knowledge of reproductive issues improved significantly from baseline to 3-month follow-up (P < .0001), as did emotional distress (P = .0047) and menopause symptoms (P = .0128). Sexually dysfunctional women became less distressed (P = .0167). CONCLUSION: Women valued the Sisters Peer Intervention in Reproductive Issues After Treatment program highly and found it relevant. The program had positive effects on knowledge and target symptoms.
AD  - University of Texas M.D. Anderson Cancer Center and Sisters Network Inc, National Headquarters, Houston, TX 77230-1439, USA. Lschover@mdanderson.org
AN  - 16575013
AU  - Schover, L. R.
AU  - Jenkins, R.
AU  - Sui, D.
AU  - Adams, J. H.
AU  - Marion, M. S.
AU  - Jackson, K. E.
DA  - Apr 1
DO  - 10.1200/jco.2005.04.7159
DP  - NLM
ET  - 2006/04/01
IS  - 10
KW  - Adaptation, Psychological
Adult
African Americans
Aged
Breast Neoplasms/ethnology/*psychology
*Counseling
Female
Hot Flashes/prevention & control
Humans
Knowledge
Middle Aged
*Reproductive Medicine
LA  - eng
N1  - 1527-7755
Schover, Leslie R
Jenkins, Rosell
Sui, Dawen
Adams, Jennifer Harned
Marion, Michelle S
Jackson, Karen Eubanks
1R01 CA 102097-01/CA/NCI NIH HHS/United States
3P30 CA16672-2652/CA/NCI NIH HHS/United States
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
United States
J Clin Oncol. 2006 Apr 1;24(10):1620-6. doi: 10.1200/JCO.2005.04.7159.
PY  - 2006
SN  - 0732-183x
SP  - 1620-6
ST  - Randomized trial of peer counseling on reproductive health in African American breast cancer survivors
T2  - J Clin Oncol
TI  - Randomized trial of peer counseling on reproductive health in African American breast cancer survivors
VL  - 24
ID  - 573
ER  - 

TY  - JOUR
AB  - OBJECTIVE: Although African American (AA) men are at elevated risk for prostate cancer, medical guidelines do not present consistent screening recommendations for this group. However, all guidelines stress the need for screening decision making with a provider. This study evaluated the effectiveness of a brochure for the female partners of AA men, designed to help promote such discussion on the part of their mates. We also explored the effect of the partner's monitoring style (i.e., the extent to which the partner typically attends to health threats) on promoting discussion. METHODS: Female partners of AA men (N = 231) were randomized to receive either a prostate cancer screening Centers for Disease Control brochure for AA men, combined with a 'partner' brochure containing strategies to promote men's initiation of a provider visit to discuss screening, or the Centers for Disease Control brochure only and completed preintervention and post-intervention surveys online. RESULTS: The message groups did not differ on taking active steps to engage in provider discussion: relative risk ratio (RRR) = 0.99, p = .98; thinking about it: RRR = 1.13, p = .74. However, among partners who received the partner brochure, monitoring style was associated with 'thinking about initiating a provider visit' on the part of the mate (RRR = 1.74, p < .01). Across conditions, monitoring style was also associated with 'taking active steps to initiate a provider visit' on the part of the mate (RRR = 1.38, p < .05). CONCLUSIONS: High monitoring partners may be effective in influencing their AA mates to initiate provider discussion, particularly when tailored messaging is provided.
AD  - Department of Psychosocial and Behavioral Medicine, Fox Chase Cancer Center, Philadelphia, PA, USA.
AN  - 24130097
AU  - Miller, S. M.
AU  - Roussi, P.
AU  - Scarpato, J.
AU  - Wen, K. Y.
AU  - Zhu, F.
AU  - Roy, G.
C2  - PMC4091779
C6  - NIHMS558811
DA  - Apr
DO  - 10.1002/pon.3437
DP  - NLM
ET  - 2013/10/17
IS  - 4
KW  - Adult
*African Americans
Age Factors
Decision Making
*Early Detection of Cancer
Female
Humans
Male
Middle Aged
Odds Ratio
*Pamphlets
Patient Education as Topic/*methods
Patient Participation
Prostatic Neoplasms/*diagnosis/ethnology
Spouses/*education
AA men
communication messages
monitoring style
partner
prostate cancer
LA  - eng
N1  - 1099-1611
Miller, Suzanne M
Roussi, Pagona
Scarpato, John
Wen, Kuang-Yi
Zhu, Fang
Roy, Gem
P30 CA006927/CA/NCI NIH HHS/United States
R01 CA158019/CA/NCI NIH HHS/United States
RC1 CA145063/CA/NCI NIH HHS/United States
P30 CA06927/CA/NCI NIH HHS/United States
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Psychooncology. 2014 Apr;23(4):404-11. doi: 10.1002/pon.3437. Epub 2013 Oct 15.
PY  - 2014
SN  - 1057-9249 (Print)
1057-9249
SP  - 404-11
ST  - Randomized trial of print messaging: the role of the partner and monitoring style in promoting provider discussions about prostate cancer screening among African American men
T2  - Psychooncology
TI  - Randomized trial of print messaging: the role of the partner and monitoring style in promoting provider discussions about prostate cancer screening among African American men
VL  - 23
ID  - 312
ER  - 

TY  - JOUR
AB  - BACKGROUND: Incidence rates for many types of cancer are higher among African American men than in the general population, yet African American men are less likely to participate in cancer screening trials. This paper describes the outcomes of a randomized trial (the AAMEN Project) designed to recruit African American men aged 55-74 years to a prostate, lung and colorectal cancer screening trial. METHODS: The recruitment interventions address four types of barriers to clinical trial participation: sociocultural barriers, economic barriers, individual barriers and barriers inherent in study design. Subjects were randomized to a control group or one of three increasingly intensive intervention arms, which used different combinations of mail, phone and in person church-based recruitment. RESULTS: Of the 39,432 African American men residing in the geographically defined study population (southeastern Michigan and northern Ohio), 17,770 men (45%) could be contacted, and 12,400 (31% of 39,432) were found to be eligible to participate. No statistically significant differences in age, education or income level were found among participants in the four study arms. A significantly greater enrollment yield (3.9%) was seen in the most intensive, church-based intervention arm, compared to the enrollment yields in the other two intervention arms (2.5 and 2.8%) or the control group (2.9%) (P < 0.01). CONCLUSIONS: The intervention that involved the highest rate of face-to-face contact with the study participants produced the highest enrollment yield, but several strategies that were thought could improve yield had no effect. These findings, which are consistent with current literature on population-based recruitment, should facilitate the development of future recruitment efforts involving older African American men.
AD  - Department of Medicine, Section of Health Services Research, Baylor College of Medicine Veterans Affairs Medical Center, Houston, TX 77030, USA. mford@bmc.tmc.edu
AN  - 16279272
AU  - Ford, M. E.
AU  - Havstad, S. L.
AU  - Davis, S. D.
DO  - 10.1191/1740774504cn029oa
DP  - NLM
ET  - 2005/11/11
IS  - 4
KW  - *African Americans
Aged
Colorectal Neoplasms/*diagnosis
Female
Humans
Lung Neoplasms/*diagnosis
Male
Middle Aged
Ovarian Neoplasms/*diagnosis
*Patient Selection
Prostatic Neoplasms/*diagnosis
Socioeconomic Factors
United States
LA  - eng
N1  - Ford, Marvella E
Havstad, Suzanne L
Davis, Shawna D
N01-CN-25512/CN/NCI NIH HHS/United States
P 30 AG 5286/AG/NIA NIH HHS/United States
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, U.S. Gov't, P.H.S.
England
Clin Trials. 2004;1(4):343-51. doi: 10.1191/1740774504cn029oa.
PY  - 2004
SN  - 1740-7745 (Print)
1740-7745
SP  - 343-51
ST  - A randomized trial of recruitment methods for older African American men in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial
T2  - Clin Trials
TI  - A randomized trial of recruitment methods for older African American men in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial
VL  - 1
ID  - 584
ER  - 

TY  - JOUR
AB  - Healthful dietary patterns, including eating fruits and vegetables (F&V) and avoiding obesity, may decrease the risk of cancer and other chronic diseases. In addition to promoting health for the general population, a cancer diagnosis may provide a "teachable moment," facilitating the adoption of more healthful eating habits and leading to lower risk of chronic disease and better overall health. This study was designed to test the effectiveness of two health communication interventions in increasing F&V consumption and physical activity in a sample of older adults (average age of 66 years), including both colorectal cancer (CRC) survivors and noncolorectal cancer-affected (N-CRC) individuals. CRC survivors and N-CRC individuals were recruited from a population-based case-control study and randomly assigned to four conditions using a 2 x 2 design. We tested two different methods of communicating and promoting health behavior change alone or in combination: tailored print communication (TPC) and brief telephone-based motivational interviewing (TMI). A significant increase in F&V consumption was found for the combined intervention group in the entire sample (p < 0.05). When stratified by cancer survivor status, the effect was concentrated in the N-CRC subset (p < 0.01) versus CRC survivors. The combined intervention was also found to be most cost-effective for the N-CRC group, with TPC more cost-effective than TMI. For physical activity, none of the interventions produced statistically significant improvements. This study indicates that combining tailoring and motivational interviewing may be an effective and cost-effective method for promoting dietary behavior change among older healthy adults. More research is needed to identify the optimal dose and timing for intervention strategies to promote dietary and physical activity change among both CRC survivors and the general population.
AN  - WOS:000272780500001
AU  - Campbell, M. K.
AU  - Carr, C.
AU  - DeVellis, B.
AU  - Switzer, B.
AU  - Biddle, A.
AU  - Amamoo, M. A.
AU  - Walsh, J.
AU  - Zhou, B. Q.
AU  - Sandler, R.
DA  - Oct
DO  - 10.1007/s12160-009-9140-5
IS  - 2
N1  - 20012809
PY  - 2009
SN  - 0883-6612
SP  - 71-85
ST  - A Randomized Trial of Tailoring and Motivational Interviewing to Promote Fruit and Vegetable Consumption for Cancer Prevention and Control
T2  - Annals of Behavioral Medicine
TI  - A Randomized Trial of Tailoring and Motivational Interviewing to Promote Fruit and Vegetable Consumption for Cancer Prevention and Control
VL  - 38
ID  - 3137
ER  - 

TY  - JOUR
AB  - BACKGROUND: Ethnic minorities, especially African Americans and Latinos, bear a disproportionate burden of colorectal cancer (CRC), as reflected in incidence, cancer stage, and mortality statistics. In all ethnic groups, first-degree relatives (FDRs) of CRC cases are at an elevated disease risk. However, underuse of CRC screening persists and is particularly evident among minority groups. The current study tested a stepped intervention to increase CRC screening among an ethnically diverse sample of FDRs of CRC cases. METHODS: A statewide cancer registry was used to recruit CRC cases and through them their FDRs. Relatives who were not current on CRC screening were randomized to intervention or usual-care control arms. The stepped intervention consisted of ethnically targeted and individually tailored print materials followed by telephone counseling for those unscreened at 6 months. RESULTS: The study sample of 1280 individuals consisted of 403 Latino, 284 African American, 242 Asian, and 351 white FDRs. Statistically significant effects were observed for the cumulative print plus telephone intervention at 12 months (26% in the intervention vs 18% in the control group) and the print intervention alone at 6 months (15% in the intervention vs 10% in the control group). The effect of the print intervention alone versus the cumulative interventions was not statistically significantly different. Stratified analyses indicated that the intervention was effective among white, Latino, and Asian individuals, but not among African-Americans. CONCLUSIONS: Overall, the intervention was effective in increasing screening rates. Oversampling racial/ethnic minorities allowed for the examination of effects within subgroups, revealing no effect among African American individuals. This finding illustrates the importance of including sufficient numbers of participants from diverse ethnic subgroups in intervention research to enable such stratified analyses.
AD  - Fielding School of Public Health, Jonsson Comprehensive Cancer Center, UCLA Kaiser Permanente Center for Health Equity, University of California at Los Angeles, Los Angeles, California.
Department of Epidemiology and Biostatistics, Institute for Health Promotion Research, University of Texas Health Science Center at San Antonio, San Antonio, Texas.
Department of Statistics, Volgenau School of Engineering, George Mason University, Fairfax, Virginia.
AN  - 25946376
AU  - Bastani, R.
AU  - Glenn, B. A.
AU  - Maxwell, A. E.
AU  - Ganz, P. A.
AU  - Mojica, C. M.
AU  - Alber, S.
AU  - Crespi, C. M.
AU  - Chang, L. C.
C2  - PMC4545725
C6  - NIHMS679274
DA  - Sep 1
DO  - 10.1002/cncr.29403
DP  - NLM
ET  - 2015/05/07
IS  - 17
KW  - Adult
African Americans
Aged
Asian Americans
Colorectal Neoplasms/*diagnosis
Early Detection of Cancer/*statistics & numerical data
Female
Hispanic Americans
Humans
Male
Middle Aged
colorectal cancer
disparities
first-degree relatives
intervention research
screening
authors.
LA  - eng
N1  - 1097-0142
Bastani, Roshan
Glenn, Beth A
Maxwell, Annette E
Ganz, Patricia A
Mojica, Cynthia M
Alber, Susan
Crespi, Catherine M
Chang, L Cindy
KL2 TR001118/TR/NCATS NIH HHS/United States
CA16024/CA/NCI NIH HHS/United States
P30 CA016042/CA/NCI NIH HHS/United States
UL1 TR001120/TR/NCATS NIH HHS/United States
R01 CA075367/CA/NCI NIH HHS/United States
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Cancer. 2015 Sep 1;121(17):2951-9. doi: 10.1002/cncr.29403. Epub 2015 May 6.
PY  - 2015
SN  - 0008-543X (Print)
0008-543x
SP  - 2951-9
ST  - Randomized trial to increase colorectal cancer screening in an ethnically diverse sample of first-degree relatives
T2  - Cancer
TI  - Randomized trial to increase colorectal cancer screening in an ethnically diverse sample of first-degree relatives
VL  - 121
ID  - 245
ER  - 

TY  - JOUR
AB  - Background: Cancer screening rates are suboptimal for low-income patients. Objective: To assess an intervention to increase cancer screening among patients in a safety-net primary care practice. Design: Patients at an inner-city family practice who were overdue for cancer screening were randomized to intervention or usual care. Screening rates at 1 year were compared using the chi-square test, and multivariable analysis was performed to adjust for patient factors. Subjects: All average-risk patients at an inner-city family practice overdue for mammography or colorectal cancer (CRC) screening. Patients’ ages were 40 to 74 years (mean 53.9, SD 8.7) including 40.8 % African Americans, 4.2 % Latinos, 23.2 % with Medicaid and 10.9 % without any form of insurance. Interventions: The 6-month intervention to promote cancer screening included letters, automated phone calls, prompts and a mailed Fecal Immunochemical Testing (FIT) Kit. Main Measures: Rates of cancer screening at 1 year. Key Results: Three hundred sixty-six patients overdue for screening were randomly assigned to intervention (n = 185) or usual care (n = 181). Primary analysis revealed significantly higher rates of cancer screening in intervention subjects: 29.7 % vs. 16.7 % for mammography (p = 0.034) and 37.7 % vs. 16.7 % for CRC screening (p = 0.0002). In the intervention group, 20 % of mammography screenings and 9.3 % of CRC screenings occurred at the early assessment, while the remainder occurred after repeated interventions. Within the CRC intervention group 44 % of screened patients used the mailed FIT kit. On multivariable analysis the CRC screening rates remained significantly higher in the intervention group, while the breast cancer screening rates were not statistically different. Conclusions: A multimodal intervention significantly increased CRC screening rates among patients in a safety-net primary care practice. These results suggest that relatively inexpensive letters and automated calls can be combined for a larger effect. Results also suggest that mailed screening kits may be a promising way to increase average-risk CRC screening. (PsycINFO Database Record (c) 2016 APA, all rights reserved)
AD  - Hendren, Samantha, Department of Surgery, University of Michigan, 2124 Taubman Center, 1500 E. Medical Center Dr., SPC-5343, Ann Arbor, MI, US, 48109
AN  - 2014-00632-015
AU  - Hendren, Samantha
AU  - Winters, Paul
AU  - Humiston, Sharon
AU  - Idris, Amna
AU  - Li, Shirley X. L.
AU  - Ford, Patricia
AU  - Specht, Raymond
AU  - Marcus, Stephen
AU  - Mendoza, Michael
AU  - Fiscella, Kevin
DB  - psyh
DO  - 10.1007/s11606-013-2506-1
DP  - EBSCOhost
IS  - 1
KW  - multimodal intervention
cancer screening
primary care practice
family practice
clinical trials
Adult
Aged
Breast Neoplasms
Colorectal Neoplasms
Correspondence as Topic
Early Detection of Cancer
Female
Health Promotion
Healthcare Disparities
Humans
Male
Mammography
Middle Aged
New York
Patient Acceptance of Health Care
Primary Health Care
Socioeconomic Factors
Telephone
Urban Health Services
Intervention
N1  - Department of Surgery, University of Michigan, Ann Arbor, MI, US. Other Publishers: Blackwell Publishing. Release Date: 20140512. Correction Date: 20140519. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: English. Major Descriptor: Cancer Screening; Clinical Trials; Intervention; Primary Health Care. Classification: Promotion & Maintenance of Health & Wellness (3365). Population: Human (10); Male (30); Female (40). Location: US. Age Group: Adulthood (18 yrs & older) (300); Middle Age (40-64 yrs) (360); Aged (65 yrs & older) (380). Methodology: Clinical Trial; Empirical Study; Quantitative Study. References Available: Y. Page Count: 9. Issue Publication Date: Jan, 2014. Publication History: First Posted Date: Jul 2, 2013; Accepted Date: May 16, 2013; Revised Date: Mar 14, 2013; First Submitted Date: Oct 1, 2012. Copyright Statement: Society of General Internal Medicine. 2013.
Sponsor: American Cancer Society, US. Grant: RSGT-08-077-01-CPHPS. Recipients: No recipient indicated
PY  - 2014
SN  - 0884-8734
1525-1497
SP  - 41-49
ST  - Randomized, controlled trial of a multimodal intervention to improve cancer screening rates in a safety-net primary care practice
T2  - Journal of General Internal Medicine
TI  - Randomized, controlled trial of a multimodal intervention to improve cancer screening rates in a safety-net primary care practice
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2014-00632-015&site=ehost-live&scope=site
hendren@med.umich.edu
VL  - 29
ID  - 1743
ER  - 

TY  - JOUR
AB  - BACKGROUND: Coenzyme Q10 (CoQ10) is a common antioxidant supplement with known cardioprotective effects and potential anticancer benefits. OBJECTIVES: We performed a randomized, double-blind, placebo-controlled study of oral CoQ10 in female breast cancer patients with the primary objective of determining CoQ10's effects on self-reported fatigue, depression, and quality of life (QOL). Methods Eligible women with newly diagnosed breast cancer and planned adjuvant chemotherapy were randomized to oral supplements of 300 mg CoQ10 or placebo, each combined with 300 IU vitamin E, divided into 3 daily doses. Treatment was continued for 24 weeks. Blood tests, QOL measures, and levels of plasma CoQ10 and vitamin E were obtained at baseline and at 8, 16, and 24 weeks. Mixed-effects models were used to assess treatment differences in outcomes over time. RESULTS: Between September 2004 and March 2009, 236 women were enrolled. Treatment arms were well balanced with respect to age (range, 28-85 years), pathologic stage (stage 0, 91%; stage 1, 8%; stage II, 1%), ethnicity (white, 87%; black, 11%; Hispanic, 2%), and planned therapy. Baseline CoQ10 levels in the CoQ10 and placebo arms were 0.70 and 0.73 microg/mL, respectively; the 24-week CoQ10 levels were 1.83 and 0.79 microg/mL, respectively. There were no significant differences between the CoQ10 and placebo arms at 24 weeks for scores on the Profile of Mood States-Fatigue questionnaire (least squares means, 7.08 vs 8.24, P = .257), the Functional Assessment of Chronic Illness Therapy-Fatigue tool (37.6 vs 37.6, P = .965), the Functional Assessment of Cancer Therapy-Breast Cancer instrument (111.9 vs 110.4, P = .577), or the Center for Epidemiologic Studies-Depression scale (11.6 vs 12.3, P = .632). CONCLUSIONS: Supplementation with conventional doses of CoQ10 led to sustained increases in plasma CoQ10 levels but did not result in improved self-reported fatigue or QOL after 24 weeks of treatment.
AD  - Department of Internal Medicine, Section on Hematology and Oncology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA. glesser@wakehealth.edu
AN  - 22682875
AU  - Lesser, G. J.
AU  - Case, D.
AU  - Stark, N.
AU  - Williford, S.
AU  - Giguere, J.
AU  - Garino, L. A.
AU  - Naughton, M. J.
AU  - Vitolins, M. Z.
AU  - Lively, M. O.
AU  - Shaw, E. G.
C2  - PMC3501550
C6  - NIHMS376872
DA  - Mar
DO  - 10.1016/j.suponc.2012.03.003
DP  - NLM
ET  - 2012/06/12
IS  - 1
KW  - Administration, Oral
Adult
Aged
Aged, 80 and over
Antineoplastic Agents/*adverse effects
Breast Neoplasms/*complications/diagnosis/drug therapy
Dietary Supplements
Double-Blind Method
Fatigue/chemically induced/*drug therapy
Female
Follow-Up Studies
Humans
Middle Aged
*Outcome Assessment, Health Care
Patient Participation
Prognosis
Quality of Life
Self Report/*statistics & numerical data
Ubiquinone/administration & dosage/*analogs & derivatives
Vitamins/*administration & dosage
LA  - eng
N1  - 1879-596x
Lesser, Glenn J
Case, Doug
Stark, Nancy
Williford, Susan
Giguere, Jeff
Garino, L Astrid
Naughton, Michelle J
Vitolins, Mara Z
Lively, Mark O
Shaw, Edward G
Wake Forest University Community Clinical Oncology Program Research Base
P30 CA012197/CA/NCI NIH HHS/United States
U10 CA081851/CA/NCI NIH HHS/United States
U10 CA81851/CA/NCI NIH HHS/United States
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
J Support Oncol. 2013 Mar;11(1):31-42. doi: 10.1016/j.suponc.2012.03.003.
PY  - 2013
SN  - 1544-6794 (Print)
1544-6794
SP  - 31-42
ST  - A randomized, double-blind, placebo-controlled study of oral coenzyme Q10 to relieve self-reported treatment-related fatigue in newly diagnosed patients with breast cancer
T2  - J Support Oncol
TI  - A randomized, double-blind, placebo-controlled study of oral coenzyme Q10 to relieve self-reported treatment-related fatigue in newly diagnosed patients with breast cancer
VL  - 11
ID  - 365
ER  - 

TY  - JOUR
AB  - Background: Epithelial growth factor receptor pathway (EGFR) is expressed in TNBC and may be important in a subset of this heterogeneous disease. We evaluated the efficacy and toxicity of an anti‐EGFR antibody (cetuximab) combined with ixabepilone given to the TNBC patients (pts) in the neoadjuvant setting. This study was designed to detect an increase in pathological complete response (pCR) rate, defined as no residual disease in the breast, from 20% to 40% in each arm, using a Simon optimal two stage design, with one‐sided alpha=10% and power=80%. At least three responses out of 12 patients were needed to proceed with second stage for each arm. Methods: All pts received 4 cycles of preoperative ixabepilone 40 mg/m2 every 3 weeks. In addition, patients were randomized to receive either 12 infusions of weekly cetuximab (400mg/m2 on week 1, then 250 mg/m2) or not. Race, proliferation rate, and TILs was correlated with pCR. Results: To date, a total of36 pts with stage II‐IIIA TNBC were enrolled. Median age was 54 years (range 35‐79 years) with median tumor size of 6.1 cm (range 2‐18 cm). The median proliferation rate (Ki‐67) was 67.2% (range 8%‐95%). Pts were Hispanic (36%), White (39%), African‐American (19%) and others (6%). In ixabepilone alone arm, pCR was observed in only 14.3%, and this monotherapy arm did not progress to second stage. To date, pCR was observed in 31.3% in ixabepilone/cetuximab arm, with 6 patients still on treatment. Adverse events for the combination arm were modest, mainly grade 1‐2 (neutropenia: 4%, skin: 83 %, GI: 50 %, fatigue: 100 %). Grade 3 febrile neutropenia in 3 % were observed. No statistically significant correlation with race, Ki67, and TILs with pCR rate was observed. Conclusions: The addition of cetuximab to ixabepilone may improve the rate of pathological complete response in TNBC pts. There was no association between race or proliferation and response to ixabepilone and cetuximab. Evaluation of EGFR, p‐EGFR and EGFR pathway ‐associated genes, PTEN, mutational analysis of PI3K/mTOR pathway and next generation genomic analysis is underway to evaluate for potential predictive biomarkers of response to EGFR inhibition.
AN  - CN-01057204
AU  - Rodriguez, A. A.
AU  - Salazar, N.
AU  - Patel, T. A.
AU  - Mejia, J. A.
AU  - Froehlich, A.
AU  - Sneige, N.
AU  - Amin, S.
AU  - Weiss, H.
AU  - Rivera, E.
AU  - Chang, J. C. N.
IS  - 15 SUPPL. 1
KW  - *arm
*cetuximab
*human
*ixabepilone
*oncology
*patient
*phase 2 clinical trial
*society
*triple negative breast cancer
African American
Antibody
Biological marker
Breast
Fatigue
Febrile neutropenia
Gene
Growth factor receptor
Hispanic
Infusion
Minimal residual disease
Monotherapy
Mutational analysis
Neutropenia
Skin
Toxicity
Tumor volume
M3  - Journal: Conference Abstract
PY  - 2014
ST  - A randomized, parallel-arm, phase II trial to assess the efficacy of preoperative ixabepilone with or without cetuximab in patients with triple-negative breast cancer (TNBC)
T2  - Journal of clinical oncology
TI  - A randomized, parallel-arm, phase II trial to assess the efficacy of preoperative ixabepilone with or without cetuximab in patients with triple-negative breast cancer (TNBC)
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01057204/full
VL  - 32
ID  - 1544
ER  - 

TY  - JOUR
AB  - Abnormalities in taste and smell are commonly reported in patients receiving chemotherapy and may hinder appetite, dietary intake, nutritional well-being, and quality of life. Oral zinc has been used to treat taste and smell abnormalities in several altered physiologic states, including renal failure, liver disease, head trauma, and pregnancy, with varying results. The authors conducted a double-blinded, placebo-controlled randomized clinic trial over 3 months. Eligible patients were those taking chemotherapy that had alterations in taste and/or smell. The measurement of the primary end point, improvement in altered taste and smell, was made using a 0-100 scale (100 describing no loss or distortion in taste and smell, and 0 describing the worst distortion or loss of taste and smell). Twenty-nine subjects were enrolled in each treatment group, of whom 31 were white, 26 African American, and 1 Native American. Forty-one patients were female. A wide range of cancer types was represented, with breast the most common (21 patients). The zinc dose was 220 mg orally twice daily (equivalent of 50 mg elemental zinc twice daily). There was no statistically significant improvement in loss or distortion of taste or smell with the addition of zinc. There was a trend toward improvement over time in all groups, except in the zinc group where there was a nonsignificant worsening in loss of smell over time. Zinc at standard doses did not provide significant benefit to taste or smell in patients receiving chemotherapy.
AD  - Division of Hematology/Oncology and Palliative Care, Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298-0230, USA. lyckholm@vcu.edu
AN  - 22764846
AU  - Lyckholm, L.
AU  - Heddinger, S. P.
AU  - Parker, G.
AU  - Coyne, P. J.
AU  - Ramakrishnan, V.
AU  - Smith, T. J.
AU  - Henkin, R. I.
C2  - PMC4042409
C6  - NIHMS582757 alone are responsible for the content and writing of the paper.
DA  - Jun
DO  - 10.3109/15360288.2012.676618
DP  - NLM
ET  - 2012/07/07
IS  - 2
KW  - Antineoplastic Agents/*adverse effects/therapeutic use
Double-Blind Method
Female
Humans
Male
Middle Aged
Neoplasms/drug therapy
Olfaction Disorders/chemically induced/*drug therapy
Taste Disorders/chemically induced/*drug therapy
Time Factors
Treatment Outcome
Zinc Sulfate/administration & dosage/*therapeutic use
LA  - eng
N1  - 1536-0539
Lyckholm, Laurel
Heddinger, Steven P
Parker, Gwendolyn
Coyne, Patrick J
Ramakrishnan, Viswanathan
Smith, Thomas J
Henkin, Robert I
P30 CA006973/CA/NCI NIH HHS/United States
Journal Article
Randomized Controlled Trial
J Pain Palliat Care Pharmacother. 2012 Jun;26(2):111-4. doi: 10.3109/15360288.2012.676618.
PY  - 2012
SN  - 1536-0288 (Print)
1536-0288
SP  - 111-4
ST  - A randomized, placebo controlled trial of oral zinc for chemotherapy-related taste and smell disorders
T2  - J Pain Palliat Care Pharmacother
TI  - A randomized, placebo controlled trial of oral zinc for chemotherapy-related taste and smell disorders
VL  - 26
ID  - 361
ER  - 

TY  - JOUR
AB  - Background: In the United States certain minority groups, such as racial/ethnic immigrant women, are less likely than non-Hispanic White women to be screened for cervical cancer. Barriers to such care include health insurance, cost, knowledge, attitudes, health literacy, and cultural norms and practices. Among the most promising approaches to increase screening in these groups are patient navigators that can link women to sources of appropriate care. Another recent promising approach is using human papilloma virus (HPV) self-sampling. In this manuscript, we describe our National Cancer Institute-sponsored study testing such approaches among immigrant minority women. Design: The South Florida Center for the Reduction of Cancer Health Disparities (SUCCESS) is conducting a three-arm randomized trial among Hispanic, Haitian, and African American women in Miami-Dade County. Community health workers (CHW) based in each of three communities are recruiting 200 women at each site (600 total). Eligibility criteria include women aged 30-65 years who have not had a Pap smear test in the last 3 years. Prior to randomization, all women undergo a standardized structured interview. Women randomized to public health outreach, Group 1, receive culturally tailored educational materials. Women in Group 2 receive an individualized comprehensive cervical cancer CHW-led education session followed by patient navigation to obtain the Pap smear test at community-based facilities. Women in Group 3 have the option of navigation to a Pap smear test or performing HPV self-sampling. The primary outcome is self-report of completed screening through a Pap smear test or HPV self-sampling within 6 months after enrollment. Discussion: SUCCESS is one of the first trials testing HPV self-sampling as a screening strategy among underserved minority women. If successful, HPV self-sampling may be an important option in community outreach programs aimed at reducing disparities in cervical cancer.
AN  - WOS:000339927200001
AU  - Carrasquillo, O.
AU  - McCann, S.
AU  - Amofah, A.
AU  - Pierre, L.
AU  - Rodriguez, B.
AU  - Alonzo, Y.
AU  - Ilangovan, K.
AU  - Gonzalez, M.
AU  - Trevil, D.
AU  - Byrne, M. M.
AU  - Koru-Sengul, T.
AU  - Kobetz, E.
DA  - Jul
DO  - 10.1186/1745-6215-15-299
N1  - 299
25056208
PY  - 2014
SN  - 1745-6215
ST  - Rationale and design of the research project of the South Florida Center for the Reduction of Cancer Health Disparities (SUCCESS): study protocol for a randomized controlled trial
T2  - Trials
TI  - Rationale and design of the research project of the South Florida Center for the Reduction of Cancer Health Disparities (SUCCESS): study protocol for a randomized controlled trial
VL  - 15
ID  - 3002
ER  - 

TY  - JOUR
AB  - The American Cancer Society (ACS) defines cancer survivorship as beginning at diagnosis with cancer and continuing for the balance of life and views quality of life (QOL) as a key outcome. In this article, the authors describe the rationale, methodology, and sample characteristics of the 2 ACS Studies of Cancer Survivors (SCS): 1) a longitudinal study identifying and surveying survivors approximately 1 year postdiagnosis that includes plans to resurvey the panel at 2 years, 7 years, and 12 years postdiagnosis to identify predictors of QOL; and 2) a cross-sectional study of QOL among 3 separate cohorts of survivors who were approximately 3 years, 6 years, and 11 years postdiagnosis at the time of data collection. Survivors of prostate, breast, lung, colorectal, bladder, skin, kidney, ovarian, and uterine cancers and of non-Hodgkin lymphoma were sampled from 25 different central cancer registries, with African-American and Hispanic survivors over sampled. Survivors completed either mail or telephone surveys that described their physical, psychological, social, and spiritual functioning. The overall recruitment rate was 34.0%; 15411 participants completed surveys, of whom 40.1% had a high school education or less and 19.4% were racial/ethnic minorities. The SCS surveys provide a large diagnostically, geographically, and demographically diverse database on cancer survivorship that was designed to overcome some of the limitations of past research. Future reports will compare QOL of survivors at different well-defined times postdiagnosis, investigate the issues of understudied populations and diagnostic groups, and describe survivor QOL at state levels. Insights valuable to those considering registry-based studies are offered on issues of ascertainment, sampling, and recruitment.
AD  - Behavioral Research Center, American Cancer Society, Atlanta, Georgia 30329, USA. tenbroeck.smith@cancer.org
AN  - 17146781
AU  - Smith, T.
AU  - Stein, K. D.
AU  - Mehta, C. C.
AU  - Kaw, C.
AU  - Kepner, J. L.
AU  - Buskirk, T.
AU  - Stafford, J.
AU  - Baker, F.
DA  - Jan 1
DO  - 10.1002/cncr.22387
DP  - NLM
ET  - 2006/12/06
IS  - 1
KW  - Adolescent
Adult
American Cancer Society
Continental Population Groups
Cross-Sectional Studies
Female
Humans
Longitudinal Studies
Male
Middle Aged
Minority Groups
Neoplasms/*mortality
Patient Selection
Quality of Life
Registries
Surveys and Questionnaires
*Survivors
United States/epidemiology
LA  - eng
N1  - Smith, Tenbroeck
Stein, Kevin D
Mehta, C Christina
Kaw, Chiewkwei
Kepner, James L
Buskirk, Trent
Stafford, Jeremy
Baker, Frank
Journal Article
Research Support, Non-U.S. Gov't
United States
Cancer. 2007 Jan 1;109(1):1-12. doi: 10.1002/cncr.22387.
PY  - 2007
SN  - 0008-543X (Print)
0008-543x
SP  - 1-12
ST  - The rationale, design, and implementation of the American Cancer Society's studies of cancer survivors
T2  - Cancer
TI  - The rationale, design, and implementation of the American Cancer Society's studies of cancer survivors
VL  - 109
ID  - 542
ER  - 

TY  - JOUR
AN  - 15003967
AU  - Ambrosone, C. B.
AU  - Jandorf, L.
AU  - Furberg, H.
AU  - Britton, J. A.
AU  - Bovbjerg, D. H.
AU  - Erwin, D. O.
DA  - Mar 15
DO  - 10.1093/aje/kwh076
DP  - NLM
ET  - 2004/03/09
IS  - 6
KW  - *African Americans
Breast Neoplasms/epidemiology
Case-Control Studies
*Epidemiologic Methods
Female
*Hispanic Americans
Humans
Lung Neoplasms/epidemiology
*Patient Selection
San Francisco/epidemiology
United States/epidemiology
LA  - eng
N1  - Ambrosone, Christine B
Jandorf, Lina
Furberg, Helena
Britton, Julie A
Bovbjerg, Dana H
Erwin, Deborah O
Comment
Letter
United States
Am J Epidemiol. 2004 Mar 15;159(6):620; author reply 621. doi: 10.1093/aje/kwh076.
PY  - 2004
SN  - 0002-9262 (Print)
0002-9262
SP  - 620; author reply 621
ST  - Re: "Population- and community-based recruitment of African Americans and Latinos: the San Francisco Bay Area Lung Cancer Study"
T2  - Am J Epidemiol
TI  - Re: "Population- and community-based recruitment of African Americans and Latinos: the San Francisco Bay Area Lung Cancer Study"
VL  - 159
ID  - 635
ER  - 

TY  - JOUR
AN  - 11562395
AU  - Mirchandani, D.
AU  - Muggia, F.
DA  - Sep 19
DO  - 10.1093/jnci/93.18.1420-a
DP  - NLM
ET  - 2001/09/20
IS  - 18
KW  - Adult
African Continental Ancestry Group
Age Factors
Aged
Antineoplastic Agents, Hormonal/adverse effects/*therapeutic use
Breast Neoplasms/chemistry/*drug therapy/mortality/pathology
*Chemotherapy, Adjuvant
Clinical Trials as Topic/methods
Disease-Free Survival
Ethnic Groups
Female
Humans
Lymph Nodes/pathology
Middle Aged
Neoplasm Proteins/analysis/drug effects
Neoplasm Recurrence, Local
Neoplasm Staging
Patient Selection
Prognosis
Receptors, Estrogen/analysis/drug effects
Risk
Risk Assessment
Selective Estrogen Receptor Modulators/adverse effects/*therapeutic use
Tamoxifen/adverse effects/therapeutic use
Thrombophilia/chemically induced/mortality
Treatment Outcome
LA  - eng
N1  - Mirchandani, D
Muggia, F
Comment
Comparative Study
Letter
United States
J Natl Cancer Inst. 2001 Sep 19;93(18):1420-1; author reply 1421-2. doi: 10.1093/jnci/93.18.1420-a.
PY  - 2001
SN  - 0027-8874 (Print)
0027-8874
SP  - 1420-1; author reply 1421-2
ST  - Re: Prognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary lymph nodes
T2  - J Natl Cancer Inst
TI  - Re: Prognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary lymph nodes
VL  - 93
ID  - 679
ER  - 

TY  - JOUR
AN  - 15126615
AU  - Lee, C. T.
DA  - May 5
DO  - 10.1093/jnci/djh139
DP  - NLM
ET  - 2004/05/06
IS  - 9
KW  - African Continental Ancestry Group/*statistics & numerical data
*Brachytherapy
European Continental Ancestry Group/*statistics & numerical data
Humans
Male
*Prostatectomy
Prostatic Neoplasms/*mortality/*therapy
Quality of Life
Randomized Controlled Trials as Topic
Survival Rate
Treatment Outcome
United States/epidemiology
LA  - eng
N1  - 1460-2105
Lee, Cheryl T
Comment
Letter
United States
J Natl Cancer Inst. 2004 May 5;96(9):718-9. doi: 10.1093/jnci/djh139.
PY  - 2004
SN  - 0027-8874
SP  - 718-9
ST  - Re: Racial differences in mortality among Medicare recipients after treatment for localized prostate cancer
T2  - J Natl Cancer Inst
TI  - Re: Racial differences in mortality among Medicare recipients after treatment for localized prostate cancer
VL  - 96
ID  - 631
ER  - 

TY  - JOUR
AN  - 20075368
AU  - Dignam, J. J.
DA  - Feb 24
DO  - 10.1093/jnci/djp505
DP  - NLM
ET  - 2010/01/16
IS  - 4
KW  - African Americans/*statistics & numerical data
Breast Neoplasms/mortality
European Continental Ancestry Group/*statistics & numerical data
Female
*Health Status Disparities
Humans
Multicenter Studies as Topic
Neoplasms/ethnology/*mortality
Odds Ratio
*Randomized Controlled Trials as Topic
Risk Assessment
Risk Factors
Socioeconomic Factors
Survival Rate
United States/epidemiology
LA  - eng
N1  - 1460-2105
Dignam, James J
Comment
Letter
United States
J Natl Cancer Inst. 2010 Feb 24;102(4):279-80; author reply 280-2. doi: 10.1093/jnci/djp505. Epub 2010 Jan 14.
PY  - 2010
SN  - 0027-8874
SP  - 279-80; author reply 280-2
ST  - Re: Racial disparities in cancer survival among randomized clinical trials of the Southwest Oncology Group
T2  - J Natl Cancer Inst
TI  - Re: Racial disparities in cancer survival among randomized clinical trials of the Southwest Oncology Group
VL  - 102
ID  - 435
ER  - 

TY  - JOUR
AB  - A Breast Health Research Champion training program was a developed targeting self-identified community breast health advocates from a predominant African-American community with a significant breast cancer mortality disparity. Twelve individuals completed the program that provided training in breast cancer risk and screening, breast cancer research, biospecimen in cancer research, and human research subject protection. The training emphasized four key messages to be disseminated to the community. Trainees hosted a minimum of two social chats with individuals from their social networks and functioned as community researchers, acquiring consent and gathering follow-up data from attendees. Trainees reached 199 individuals from their social networks, and chats were diverse in the venue selected, mode of message transmission, and the audience reached. Post/pre questionnaire data from attendees at the chats showed significant improvement in knowledge, attitudes, and intended behaviors as it relates to breast cancer screening, clinical research, and biospecimen in research. Forty percent of attendees provided 4-week follow-up information. Of respondents eligible for mammography, 38 % had taken action to be screened, and 86 % of respondents had spoken about the information to someone else in their social network. Trainees expressed feelings of empowerment after completing the project, "feeling like the expert," and all trainees were surprised at the enthusiastic response from attendees of their chats. Trainees continued to disseminate the information learned from the training program during the 6 months following the training, reaching an additional 786 individuals in the community.
AD  - Massey Cancer Center, Virginia Commonwealth University, 1201 East Marshall Street, P.O. Box 980070, 23298-0070, Richmond, VA, USA, crafie@vcu.edu.
AN  - 25171905
AU  - Rafie, C.
AU  - Ayers, A.
AU  - Cadet, D.
AU  - Quillin, J.
AU  - Hackney, M. H.
C2  - PMC4345135
C6  - NIHMS624936
DA  - Sep
DO  - 10.1007/s13187-014-0720-0
DP  - NLM
ET  - 2014/08/31
IS  - 3
KW  - Adult
*African Americans
Aged
Biomedical Research/organization & administration
Breast Neoplasms/*diagnosis/ethnology/*prevention & control
Community Health Workers/education/*organization & administration
Early Detection of Cancer
Female
Health Education/*methods
*Health Knowledge, Attitudes, Practice
Health Status Disparities
Humans
Information Dissemination/methods
Mammography
Middle Aged
Research Subjects
Risk Assessment
Risk Factors
LA  - eng
N1  - 1543-0154
Rafie, Carlin
Ayers, Antoinette
Cadet, Debbie
Quillin, John
Hackney, Mary H
U10 CA052784/CA/NCI NIH HHS/United States
U10CA052784/CA/NCI NIH HHS/United States
U10CA052784-20S2/CA/NCI NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
J Cancer Educ. 2015 Sep;30(3):599-606. doi: 10.1007/s13187-014-0720-0.
PY  - 2015
SN  - 0885-8195 (Print)
0885-8195
SP  - 599-606
ST  - Reaching Hard to Reach Populations with Hard to Communicate Messages: Efficacy of a Breast Health Research Champion Training Program
T2  - J Cancer Educ
TI  - Reaching Hard to Reach Populations with Hard to Communicate Messages: Efficacy of a Breast Health Research Champion Training Program
VL  - 30
ID  - 277
ER  - 

TY  - JOUR
AB  - BACKGROUND: The large registry, PROVENGE Registry for the Observation, Collection, and Evaluation of Experience Data (PROCEED)(NCT01306890), evaluated sipuleucel-T immunotherapy for asymptomatic/minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC). METHODS: PROCEED enrolled patients with mCRPC receiving 3 biweekly sipuleucel-T infusions. Assessments included overall survival (OS), serious adverse events (SAEs), cerebrovascular events (CVEs), and anticancer interventions (ACIs). Follow-up was for ≥3 years or until death or study withdrawal. RESULTS: In 2011-2017, 1976 patients were followed for 46.6 months (median). The median age was 72 years, and the baseline median prostate-specific antigen level was 15.0 ng/mL; 86.7% were white, and 11.6% were African American. Among the patients, 1902 had 1 or more sipuleucel-T infusions. The median OS was 30.7 months (95% confidence interval [CI], 28.6-32.2 months). Known prognostic factors were independently associated with OS in a multivariable analysis. Among the 1255 patients who died, 964 (76.8%) died of prostate cancer (PC) progression. The median time from the first infusion to PC death was 42.7 months (95% CI, 39.4-46.2 months). The incidence of sipuleucel-T-related SAEs was 3.9%. The incidence of CVEs was 2.8%, and the rate per 100 person-years was 1.2 (95% CI, 0.9-1.6). The CVE incidence among 11,972 patients with mCRPC from the Surveillance, Epidemiology, and End Results-Medicare database was 2.8%; the rate per 100 person-years was 1.5 (95% CI, 1.4-1.7). One or more ACIs (abiraterone, enzalutamide, docetaxel, cabazitaxel, or radium 223) were received by 77.1% of the patients after sipuleucel-T; 32.5% and 17.4% of the patients experienced 1- and 2-year treatment-free intervals, respectively. CONCLUSIONS: PROCEED provides contemporary survival data for sipuleucel-T-treated men in a real-world setting of new life-prolonging agents, which will be useful in discussing treatment options with patients and in powering future trials with sipuleucel-T. The safety and tolerability of sipuleucel-T in PROCEED were consistent with previous findings.
AD  - Division of Medical Oncology, Departments of Medicine and Urology, University of Washington and Fred Hutchinson Cancer Research Center, Seattle, Washington.
Division of Medical Oncology, Duke University Medical Center, Duke Cancer Institute, Duke University, Durham, North Carolina.
Division of Urology, Duke University Medical Center, Duke Cancer Institute, Duke University, Durham, North Carolina.
Section of Hematology and Medical Oncology, Department of Medicine, Tulane Cancer Center and Tulane University School of Medicine, New Orleans, Louisiana.
Division of Hematology/Oncology, Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada.
Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York.
Department of Surgery, Center for Prostate Disease Research at the Uniformed Services of Health Sciences, Bethesda, Maryland.
Associated Medical Professionals, Syracuse, New York.
Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, Tennessee.
Department of Health Policy, Vanderbilt University Medical Center, Nashville, Tennessee.
Department of Urology, Carolina Urologic Research Center, Myrtle Beach, South Carolina.
New York Cancer and Blood Specialists, New York, New York.
Urology Associates PC, Nashville, Tennessee.
Chesapeake Urology, Towson, Maryland.
Department of Medical Oncology, GU Research Network, Omaha, Nebraska.
Division of Medical Oncology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California.
Advanced Urology, Atlanta, Georgia.
Prostate Cancer Research Institute, Marina del Rey, California.
Department of Biometrics, Dendreon Pharmaceuticals LLC, Seattle, Washington.
Department of Medical Affairs, Dendreon Pharmaceuticals LLC, Seattle, Washington.
Department of Urology, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California.
Department of Epidemiology and Biostatistics, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California.
AN  - 31483485
AU  - Higano, C. S.
AU  - Armstrong, A. J.
AU  - Sartor, A. O.
AU  - Vogelzang, N. J.
AU  - Kantoff, P. W.
AU  - McLeod, D. G.
AU  - Pieczonka, C. M.
AU  - Penson, D. F.
AU  - Shore, N. D.
AU  - Vacirca, J.
AU  - Concepcion, R. S.
AU  - Tutrone, R. F.
AU  - Nordquist, L. T.
AU  - Quinn, D. I.
AU  - Kassabian, V.
AU  - Scholz, M. C.
AU  - Harmon, M.
AU  - Tyler, R. C.
AU  - Chang, N. N.
AU  - Tang, H.
AU  - Cooperberg, M. R.
C2  - PMC6856402
C6  - NIHMS1043017
DA  - Dec 1
DO  - 10.1002/cncr.32445
DP  - NLM
ET  - 2019/09/05
IS  - 23
KW  - Aged
Humans
Male
Neoplasm Metastasis
Prospective Studies
Prostatic Neoplasms, Castration-Resistant/*drug therapy/pathology
Registries
Tissue Extracts/pharmacology/*therapeutic use
*immunotherapy
*overall survival
*prostate cancer
*safety
Bayer, Blue Earth Diagnostics, Churchill Pharma, Clovis Oncology, Dendreon,
Endocyte, Ferring, Medivation, Orion Corporation, and Pfizer
she has also
participated in sponsored research for Aptevo, Bayer, Aragon Pharma, Astellas,
AstraZeneca, Dendreon, Genentech, Hoffman‐LaRoche, Medivation, Sanofi, and Pfizer,
and her spouse was in a leadership role for CTI Biopharma. Andrew J. Armstrong has
received grants and personal fees from Dendreon, Pfizer/Astellas, Janssen, Bayer,
and Sanofi‐Aventis during this study as well as grants from Novartis, Gilead,
Bristol‐Myers Squibb, and Genentech/Roche outside the submitted work. A. Oliver
Sartor has served as a consultant for and received personal fees from Advanced
Accelerator Applications, Astellas, AstraZeneca, Bavarian‐Nordic, Bayer, Bellicum,
Blue Earth Diagnostics, Celgene, Constellation, Dendreon, EMD Serono, Endocyte,
Johnson & Johnson, Bristol‐Myers Squibb, Myovant, Pfizer, Progenics, Sanofi, Teva,
and Hinova during this study
he has also received grants from AstraZeneca, Bayer,
Constellation, Dendreon, Endocyte, Johnson & Johnson, Bristol‐Myers Squibb,
Progenics, Sanofi, Innocrin, Invitae, Merck, Roche, and Sotio. Philip W. Kantoff has
received personal fees from Astellas, Bayer, Bellicum, BIND Biosciences, Bavarian
Nordic Immunotherapies, DRGT, Genentech/Roche, Ipsen Pharmaceuticals, Janssen,
Metamark, Merck, Millennium/Prometrika, MTG, Omnitura, OncoCell MDx, OncoGenex,
Progenity, Sanofi, Tarveda Pharmaceuticals, Thermo Fisher, GE Healthcare, Context
Therapeutics, New England Research Institutes, SEER Biosciences, and Placon
he also
has investment interests in DRGT, Tarveda Pharmaceuticals, Context Therapeutics,
SEER Biosciences, and Placon. Christopher M. Pieczonka has received personal fees as
a consultant for Dendreon, Bayer, Janssen, and Pfizer and as an investigator for
Dendreon, Bayer, Janssen, Pfizer, Merck, AstraZeneca, Taiho, Innocrin, and Myovant
outside the submitted work. David F. Penson has received personal fees from Dendreon
and Janssen as well as a grant from the Vanderbilt University Research Center. Neal
D. Shore has served as a consultant for and received personal fees from Ferring,
Bayer, Amgen, Janssen, Dendreon, Tolmar, Astellas, Pfizer, AstraZeneca,
Genentech/Roche, Myovant Sciences, Merck, Bristol Meyers Squibb, and Nymox outside
the submitted work. Raoul S. Concepcion has served in an advisory role for Dendreon
and received personal fees outside the submitted work. David I. Quinn has been
involved in payments to the University of Southern California for trial conduct with
Dendreon
he has also acted as an advisor for and received personal fees from
Dendreon, Bayer, Janssen, Pfizer, Astellas, Genzyme, Clovis, and AstraZeneca. Vahan
Kassabian has served as a consultant or speaker for Dendreon, Amgen, Astellas,
Pfizer, Janssen, Bayer, UroGPO, Tolmar, and Genomic Health outside the submitted
work and is a shareholder of UroGPO. Matt Harmon reports stock ownership in Amgen.
Robert C. Tyler has been an employee of Janssen, Dendreon, Medivation, Pfizer, and
Innocrin. Nancy N. Chang was a full‐time employee of Dendreon at the time of the
analyses and drafting of this manuscript. Hong Tang was a full‐time employee of
Dendreon at the time of the analyses and drafting of the manuscript
is a
nonexecutive director of OnQuality Pharmaceuticals
and owns stock in BeiGene,
Nektar, Sangamo Therapeutics, Tesaro, Verastem, Editas Medicine, and CVS Health
Corporation. Matthew R. Cooperberg has received personal fees from Dendreon in
relation to a PROCEED trial steering committee and has served in an advisory or
consultancy role for Bayer, MDx Health, and Myriad Genetics
he has also
participated in a registry steering committee for Astellas. The other authors made
no disclosures.
LA  - eng
N1  - 1097-0142
Higano, Celestia S
Armstrong, Andrew J
Orcid: 0000-0001-7012-1754
Sartor, A Oliver
Orcid: 0000-0002-8777-7343
Vogelzang, Nicholas J
Kantoff, Philip W
McLeod, David G
Pieczonka, Christopher M
Penson, David F
Shore, Neal D
Vacirca, Jeffrey
Concepcion, Raoul S
Tutrone, Ronald F
Nordquist, Luke T
Quinn, David I
Kassabian, Vahan
Scholz, Mark C
Harmon, Matt
Tyler, Robert C
Chang, Nancy N
Tang, Hong
Cooperberg, Matthew R
P30 CA008748/CA/NCI NIH HHS/United States
R01 CA233585/CA/NCI NIH HHS/United States
Dendreon Pharmaceuticals LLC/International
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Cancer. 2019 Dec 1;125(23):4172-4180. doi: 10.1002/cncr.32445. Epub 2019 Sep 4.
PY  - 2019
SN  - 0008-543X (Print)
0008-543x
SP  - 4172-4180
ST  - Real-world outcomes of sipuleucel-T treatment in PROCEED, a prospective registry of men with metastatic castration-resistant prostate cancer
T2  - Cancer
TI  - Real-world outcomes of sipuleucel-T treatment in PROCEED, a prospective registry of men with metastatic castration-resistant prostate cancer
VL  - 125
ID  - 64
ER  - 

TY  - JOUR
AB  - Studied the reasons for the prolonged intervals between initial medical consultation and establishment of breast cancer diagnosis. 367 female breast cancer patients (aged 20–79 yrs) from a Black/White cancer survival study were interviewed. Reasons for a delay of >4 wks were categorized into system-oriented or patient-oriented. Results showed that in about 25%, the delay was attributed to the patient herself. The most common reason given was that the S felt the problem to be unimportant. In about 45%, the provider and health care system were said to be responsible for the delay through difficulties in scheduling or physician inaction, while in another 17% both the system and the patient were responsible. Results suggest the need to reduce the time required to get an appointment with a physician or a diagnostic test, as well as to educate physicians and the women themselves regarding the importance of breast symptoms and the value of prompt evaluation, diagnosis, and treatment. (PsycINFO Database Record (c) 2016 APA, all rights reserved)
AN  - 1996-04273-012
AU  - Caplan, Lee S.
AU  - Helzlsouer, Kathy J.
AU  - Shapiro, Sam
AU  - Wesley, Margaret N.
AU  - Edwards, Brenda K.
DB  - psyh
DO  - 10.1006/pmed.1996.0049
DP  - EBSCOhost
IS  - 2
KW  - patient oriented vs system oriented reasons
prolonged intervals between initial medical consultation & establishment of breast cancer diagnosis
20–79 yr old females with breast cancer
Adult
African Americans
Aged
Breast Neoplasms
Case-Control Studies
Cohort Studies
European Continental Ancestry Group
Female
Georgia
Health Services Accessibility
Health Services Research
Humans
Louisiana
Middle Aged
San Francisco
Survival Analysis
Time Factors
Urban Health
Client Participation
Medical Diagnosis
Professional Consultation
Reasoning
Cancer Screening
Human Females
N1  - Ctr for Disease Control & Prevention, NCCDPHP, DCPC, ESB, Atlanta, GA, US. Release Date: 19960101. Correction Date: 20130211. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Print. Document Type: Journal Article. Language: English. Major Descriptor: Breast Neoplasms; Client Participation; Medical Diagnosis; Professional Consultation; Reasoning. Minor Descriptor: Cancer Screening; Human Females. Classification: Medical Treatment of Physical Illness (3363); Cancer (3293). Population: Human (10); Female (40). Age Group: Adulthood (18 yrs & older) (300); Young Adulthood (18-29 yrs) (320); Thirties (30-39 yrs) (340); Middle Age (40-64 yrs) (360); Aged (65 yrs & older) (380). Methodology: Empirical Study. Page Count: 7. Issue Publication Date: Mar, 1996.
PY  - 1996
SN  - 0091-7435
SP  - 218-224
ST  - Reasons for delay in breast cancer diagnosis
T2  - Preventive Medicine: An International Journal Devoted to Practice and Theory
TI  - Reasons for delay in breast cancer diagnosis
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=1996-04273-012&site=ehost-live&scope=site
VL  - 25
ID  - 1794
ER  - 

TY  - JOUR
AB  - In the era of precision medicine, efforts are needed to identify and tailor screening recommendations among elevated-risk patients. Individuals younger than 50 years are an important target population, as they comprise 15% of colorectal (CRC) cases and often present with more advanced disease than their 50 + counterparts. In this large study, 2470 patients ages 25–49 used a tablet-based program that assessed risks, matched risks with screening guidelines, and generated tailored printed guideline-concordant recommendations for patients and their providers. The tablet-based program identified 121 (4.9%) patients with risk factors warranting screening before age 50. Likelihood of risk warranting screening was greater for ages 40–49 than < 40 years (OR: 2.38), females than males (OR: 1.82), and African Americans (OR: 1.69) and non-Hispanic Whites (OR: 2.89) compared to Hispanics. Most common risk factors were family history of polyps (23.1%), personal history of inflammatory bowel disease (19.8%), and combined family history of CRC + polyps (18.2%). Receipt of guideline-concordant screening within 6 months of identification was low, including only 5.3% of those who needed colonoscopy and 13.3% for whom colonoscopy or FIT was recommended. Although elevated-risk patients younger than 50 years can be readily identified, more than notification is necessary to facilitate screening participation.
AD  - C.S. Skinner, UT Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX, United States
AU  - Skinner, C. S.
AU  - Ahn, C.
AU  - Halm, E. A.
AU  - Bishop, W. P.
AU  - McCallister, K.
AU  - Sanders, J. M.
AU  - Farrell, D.
AU  - Santini, N.
AU  - Singal, A. G.
DB  - Embase
Medline
DO  - 10.1016/j.ypmed.2017.06.014
KW  - adult
African American
age
article
cancer risk
cancer screening
Caucasian
colon polyp
colonoscopy
colorectal cancer
ethnic difference
family history
female
high risk patient
Hispanic
human
inflammatory bowel disease
major clinical study
male
medical history
mobile application
patient identification
patient participation
practice guideline
primary medical care
priority journal
risk assessment
sex ratio
LA  - English
M3  - Article
N1  - L617012234
2017-07-05
2018-06-08
PY  - 2017
SN  - 1096-0260
0091-7435
SP  - 20-23
ST  - Recommendation of colorectal cancer testing among primary care patients younger than 50 with elevated risk
T2  - Preventive Medicine
TI  - Recommendation of colorectal cancer testing among primary care patients younger than 50 with elevated risk
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L617012234&from=export
http://dx.doi.org/10.1016/j.ypmed.2017.06.014
VL  - 102
ID  - 927
ER  - 

TY  - JOUR
AB  - In a study of psychosocial factors related to prostate cancer screening (PCS) of African American men, researchers achieved significant success in recruitment. Key strategies included addressing specific barriers to PCS for African American men and placing recruitment efforts in a conceptual framework that addressed cultural issues (PEN-3 model). To conduct cancer prevention research in the African American community, to engage in health promotion in collaboration with churches, and to recruit African American men, a culturally competent approach that incorporates the values of the community is essential. Implications for addressing specific barriers to recruitment and building partnerships in health promotion research are discussed.
AD  - Graduate School of Psychology, Fuller Theological Seminary, Pasadena, CA 91101, USA. aabernet@fuller.edu
AN  - 16009743
AU  - Abernethy, A. D.
AU  - Magat, M. M.
AU  - Houston, T. R.
AU  - Arnold, H. L., Jr.
AU  - Bjorck, J. P.
AU  - Gorsuch, R. L.
DA  - Aug
DO  - 10.1177/1090198104272253
DP  - NLM
ET  - 2005/07/13
IS  - 4
KW  - African Americans/*psychology
Culture
Diagnostic Tests, Routine/*statistics & numerical data
Gender Identity
Health Behavior/*ethnology
Health Promotion/*methods
Health Services Accessibility
Health Services Research
Humans
Male
Patient Acceptance of Health Care/*ethnology
*Patient Selection
Prostatic Neoplasms/ethnology/*prevention & control
Religion
Social Environment
Socioeconomic Factors
Sociology, Medical
LA  - eng
N1  - Abernethy, Alexis D
Magat, Maricar M
Houston, Tina R
Arnold, Harold L Jr
Bjorck, Jeffrey P
Gorsuch, Richard L
Journal Article
Research Support, Non-U.S. Gov't
United States
Health Educ Behav. 2005 Aug;32(4):441-51. doi: 10.1177/1090198104272253.
PY  - 2005
SN  - 1090-1981 (Print)
1090-1981
SP  - 441-51
ST  - Recruiting African American men for cancer screening studies: applying a culturally based model
T2  - Health Educ Behav
TI  - Recruiting African American men for cancer screening studies: applying a culturally based model
VL  - 32
ID  - 596
ER  - 

TY  - JOUR
AB  - PURPOSE: This study evaluated the process of recruiting African American women to participate in genetic counseling research for BRCA1 and BRCA2 (BRCA1/2) mutations with respect to referral, study enrollment, and participation in genetic counseling. PATIENTS AND METHODS: African American women (n = 783) were referred for study enrollment. RESULTS: Of 783 referrals, 164 (21%) women were eligible for enrollment. Eligible women were most likely to be referred from oncology clinics (44%) and were least likely to be referred from general medical practices (11%; chi(2) = 96.80; P = .0001). Overall, 62% of eligible women enrolled onto the study and 50% of enrollees completed genetic counseling. Women with a stronger family history of cancer (odds ratio [OR] = 3.18; 95% CI, 1.36 to 7.44; P = .01) and those referred from oncology clinics and community oncology resources (OR = 2.97; 95% CI, 1.34 to 6.58; P = .01) were most likely to enroll onto the study. Referral from oncology clinics was associated significantly with participation in genetic counseling (OR = 5.46; 95% CI, 1.44 to 20.60; P = .01). CONCLUSION: Despite receiving a large number of referrals, only a small subset of women were eligible for enrollment. Oncology settings were the most effective at identifying eligible African American women and general medical practices were the least effective. Factors associated with enrollment included having a stronger family history of cancer and being referred from oncology clinics and community oncology resources. Referral from oncology clinics was the only factor associated significantly with participation in genetic counseling. Education about hereditary breast cancer may be needed among primary care providers to enhance appropriate referral of African American women to genetic counseling for BRCA1/2 mutations.
AD  - Abramson Cancer Center, Department of Psychiatry, University of Pennsylvania, Philadelphia, 19104, USA. Chanita@mail.med.upenn.edu
AN  - 16258097
AU  - Halbert, C. H.
AU  - Brewster, K.
AU  - Collier, A.
AU  - Smith, C.
AU  - Kessler, L.
AU  - Weathers, B.
AU  - Stopfer, J. E.
AU  - Domchek, S.
AU  - Wileyto, E. P.
DA  - Nov 1
DO  - 10.1200/jco.2004.00.4952
DP  - NLM
ET  - 2005/11/01
IS  - 31
KW  - African Continental Ancestry Group/genetics/psychology/*statistics & numerical data
Attitude to Health/ethnology
Breast Neoplasms/*ethnology/*genetics/psychology
Female
*Genes, BRCA1
*Genes, BRCA2
Genetic Counseling/psychology/*statistics & numerical data
Humans
Middle Aged
Mutation
Patient Selection
Referral and Consultation/*statistics & numerical data
Risk Factors
Socioeconomic Factors
LA  - eng
N1  - Halbert, Chanita Hughes
Brewster, Kiyona
Collier, Aliya
Smith, Chachira
Kessler, Lisa
Weathers, Benita
Stopfer, Jill E
Domchek, Susan
Wileyto, E Paul
Journal Article
Research Support, U.S. Gov't, Non-P.H.S.
United States
J Clin Oncol. 2005 Nov 1;23(31):7967-73. doi: 10.1200/JCO.2004.00.4952.
PY  - 2005
SN  - 0732-183X (Print)
0732-183x
SP  - 7967-73
ST  - Recruiting African American women to participate in hereditary breast cancer research
T2  - J Clin Oncol
TI  - Recruiting African American women to participate in hereditary breast cancer research
VL  - 23
ID  - 586
ER  - 

TY  - JOUR
AB  - Prostate cancer is the most common cause of cancer in men and the second leading cause of cancer deaths. African-American men bear a disproportionate burden of prostate cancer diagnosis and mortality. Current guidelines for prostate cancer screening differ among various medical organizations. Therefore, it is important that African-American men have the appropriate information needed to make informed decisions about prostate cancer screening. Unfortunately, a large percentage of African-American men could potentially be excluded from receiving culturally appropriate prostate cancer education. Therefore, a study was designed to recruit and intervene with African-American men and barbershops for increasing prostate cancer screening decision-making. The purpose of this study was to learn effective strategies for recruiting African-American barbershops for prostate cancer education and to determine barbershop proprietors' willingness to allow their barbershops to be used for research. In this paper, we present the outcomes of our recruitment methods for African-American barbershops, including a comparative description of participating and nonparticipating barbershops using the iMark Data System. One-hundred percent of the surveyed proprietors reported that they would allow their clients to learn about prostate cancer. Ninety-six percent reported they would consider allowing their clients to have access to handheld computers to learn about prostate cancer. We conclude from this study that African-American barbershops in general are welcoming environments in which to implement community-based prostate cancer education and public health research.
AD  - Massey Cancer Center, Richmond, VA, USA. ahart@vcu.edu
AN  - 18807428
AU  - Hart, A., Jr.
AU  - Underwood, S. M.
AU  - Smith, W. R.
AU  - Bowen, D. J.
AU  - Rivers, B. M.
AU  - Jones, R. A.
AU  - Parker, D.
AU  - Allen, J. C.
DA  - Sep
DO  - 10.1016/s0027-9684(15)31437-1
DP  - NLM
ET  - 2008/09/24
IS  - 9
KW  - Adult
*African Americans
*Barbering
Health Education/*methods
Humans
Male
Prostatic Neoplasms/*prevention & control
United States
LA  - eng
N1  - Hart, Alton Jr
Underwood, Sandra M
Smith, Wally R
Bowen, Deborah J
Rivers, Brian M
Jones, Randy A
Parker, Dennis
Allen, Johnnie Chip
Journal Article
Research Support, Non-U.S. Gov't
United States
J Natl Med Assoc. 2008 Sep;100(9):1012-20. doi: 10.1016/s0027-9684(15)31437-1.
PY  - 2008
SN  - 0027-9684 (Print)
0027-9684
SP  - 1012-20
ST  - Recruiting African-American barbershops for prostate cancer education
T2  - J Natl Med Assoc
TI  - Recruiting African-American barbershops for prostate cancer education
VL  - 100
ID  - 487
ER  - 

TY  - JOUR
AB  - BACKGROUND: Improving the health of black and minority ethnic (BME) men in the US continues to be a public health priority. Compared with men of other races and ethnicities, African-American men have higher rates of mortality and morbidity from chronic illness and diseases including cancer, heart disease, prostate cancer, diabetes and HIV/AIDS. One way to address these disparities is to include African-American men in health research, to elicit their perspectives on health risks and protective factors. These can then inform interventions aimed at reducing health disparities. However, challenges remain in recruiting and engaging African-American men in health research. AIM: To provide strategies for recruiting African-American men in health research, using as an exemplar a qualitative study of fathers' perspectives of sexual health promotion with young African-American males. DISCUSSION: Efforts are needed to increase the representation of African-American men in health research. Ensuring that researchers are aware of the cultural, social and environmental factors related to decisions to participate in research can lead to effective methods to recruit and engage them. CONCLUSION: There are several essential strategies for increasing African-American men's participation in health research: ensuring the research team is culturally and gender-sensitive; recruiting in trusted environments; using respected gatekeepers; developing trust with participants; and being transparent. IMPLICATIONS FOR PRACTICE: Implementing strategies to include African-American men in health research has the potential to improve health disparities in the US.
AD  - Duke University School of Nursing, Durham, North Carolina, United States.
University of North Carolina at Greensboro, North Carolina, United States.
North Carolina A&T State University/University of North Carolina at Greensboro, North Carolina, United States.
AN  - 29738190
AU  - Randolph, S.
AU  - Coakley, T.
AU  - Shears, J.
DA  - Jun 7
DO  - 10.7748/nr.2018.e1569
DP  - NLM
ET  - 2018/05/09
IS  - 1
KW  - Adult
African Americans/*statistics & numerical data
Aged
Aged, 80 and over
Biomedical Research/*methods
Ethnic Groups/*statistics & numerical data
Female
Humans
Male
Middle Aged
Minority Groups/*statistics & numerical data
*Patient Selection
Qualitative Research
Socioeconomic Factors
United States
African-American men
culture
health research
men’s health
participation
racial equality
recruitment
LA  - eng
N1  - Randolph, Schenita
Coakley, Tanya
Shears, Jeffrey
Journal Article
England
Nurse Res. 2018 Jun 7;26(1):8-12. doi: 10.7748/nr.2018.e1569. Epub 2018 May 8.
PY  - 2018
SN  - 1351-5578 (Print)
1351-5578
SP  - 8-12
ST  - Recruiting and engaging African-American men in health research
T2  - Nurse Res
TI  - Recruiting and engaging African-American men in health research
VL  - 26
ID  - 121
ER  - 

TY  - JOUR
AB  - BACKGROUND: The effectiveness of multiple innovative recruitment strategies for enrolling Black/African American participants to the Adventist Health Study-2 (AHS-2) is described. The study's focus is diet and breast, prostate and colon cancer. METHODS: Promotions centered on trust, relationship building and incentives for increasing enrollment and questionnaire return rate. Of the sub-studies described, one had a randomized control group, and the others, informal controls. The subjects are from all states of the U.S. and some provinces of Canada. The offer of a Black art piece, follow-up calls, a competitive tournament as well as other strategies accounted for nearly 3,000 additional returns even though they were often used in small subsets. RESULTS: Flexibility and multiple strategies proved advantageous in gaining the cooperation of Blacks, who are usually reluctant to participate in research studies. CONCLUSIONS: Lessons learned during initial enrollment should help us retain our final Black cohort of 26,000, and obtain new information when required.
AD  - School of Public Health, Health Promotion & Education, Loma Linda University, 24951 North Circle Dr, NH 1511, Loma Linda, CA 92350, USA. pherring@llu.edu.
AN  - 24708740
AU  - Herring, P.
AU  - Butler, T.
AU  - Hall, S.
AU  - Bennett, H.
AU  - Montgomery, S. B.
AU  - Fraser, G.
C2  - PMC3992147
DA  - Apr 3
DO  - 10.1186/1471-2288-14-46
DP  - NLM
ET  - 2014/04/09
KW  - African Americans/*psychology
Breast Neoplasms/epidemiology
Canada/epidemiology
Cohort Studies
Colonic Neoplasms/epidemiology
Cost-Benefit Analysis
Diet
Female
Humans
Male
*Motivation
*Patient Selection
Physician-Patient Relations
Prostatic Neoplasms/epidemiology
Reward
*Surveys and Questionnaires
United States/epidemiology
LA  - eng
N1  - 1471-2288
Herring, Patti
Butler, Terry
Hall, Sonja
Bennett, Hannelore
Montgomery, Susanne B
Fraser, Gary
5R01 CA 094594/CA/NCI NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
BMC Med Res Methodol. 2014 Apr 3;14:46. doi: 10.1186/1471-2288-14-46.
PY  - 2014
SN  - 1471-2288
SP  - 46
ST  - Recruiting and motivating black subjects to complete a lengthy survey in a large cohort study: an exploration of different strategies
T2  - BMC Med Res Methodol
TI  - Recruiting and motivating black subjects to complete a lengthy survey in a large cohort study: an exploration of different strategies
VL  - 14
ID  - 291
ER  - 

TY  - JOUR
AB  - OBJECTIVE: The goal of the prospective Adventist Health Study-2 (AHS-2) was to examine the relationship between diet and risk of breast, prostate and colon cancers in Black and White participants. This paper describes the study design, recruitment methods, response rates, and characteristics of Blacks in the AHS-2, thus providing insights about effective strategies to recruit Blacks to participate in research studies. DESIGN: We designed a church-based recruitment model and trained local recruiters who used various strategies to recruit participants in their churches. Participants completed a 50-page self-administered dietary and lifestyle questionnaire. PARTICIPANTS: Participants are Black Seventh-day Adventists, aged 30-109 years, and members of 1,209 Black churches throughout the United States and Canada. RESULTS: Approximately 48,328 Blacks from an estimated target group of over 90,000 signed up for the study and 25,087 completed the questionnaire, comprising about 26% of the larger 97,000 AHS-2-member cohort. Participants were diverse in age, geographic location, education, and income. Seventy percent were female with a median age of 59 years. CONCLUSION: In spite of many recruitment challenges and barriers, we successfully recruited a large cohort whose data should provide some answers as to why Blacks have poorer health outcomes than several other ethnic groups, and help explain existing health disparities.
AD  - Department of Health Promotion and Education, Loma Linda University, School of Public Health, 24951 North Circle Drive, Nichol Hall 1410, Loma Linda, CA 92350, USA. pherring@llu.edu
AN  - 21305834
AU  - Herring, R. P.
AU  - Butler, T.
AU  - Hall, S.
AU  - Montgomery, S. B.
AU  - Fraser, G. E.
C2  - PMC3172000
C6  - NIHMS320619
DA  - Autumn
DP  - NLM
ET  - 2011/02/11
IS  - 4
KW  - Adult
*African Americans
Aged
Aged, 80 and over
Breast Neoplasms/*ethnology
Canada
Cohort Studies
Colonic Neoplasms/*ethnology
*Diet
Female
Humans
Male
Middle Aged
*Patient Selection
Program Development
Prostatic Neoplasms/*ethnology
Protestantism
Research Design
United States
LA  - eng
N1  - Herring, R Patti
Butler, Terry
Hall, Sonja
Montgomery, Susanne B
Fraser, Gary E
P20 MD001632/MD/NIMHD NIH HHS/United States
P20 MD006988/MD/NIMHD NIH HHS/United States
U01 CA152939/CA/NCI NIH HHS/United States
5R01 CA 094594/CA/NCI NIH HHS/United States
R01 CA094594/CA/NCI NIH HHS/United States
P20 MD001632-04/MD/NIMHD NIH HHS/United States
R25 GM060507/GM/NIGMS NIH HHS/United States
R25 GM060507-02/GM/NIGMS NIH HHS/United States
R25 GM060507-01A1/GM/NIGMS NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
Ethn Dis. 2010 Autumn;20(4):437-43.
PY  - 2010
SN  - 1049-510X (Print)
1049-510x
SP  - 437-43
ST  - Recruiting black Americans in a large cohort study: the Adventist Health Study-2 (AHS-2) design, methods and participant characteristics
T2  - Ethn Dis
TI  - Recruiting black Americans in a large cohort study: the Adventist Health Study-2 (AHS-2) design, methods and participant characteristics
VL  - 20
ID  - 399
ER  - 

TY  - JOUR
AB  - In 1998, an estimated 184,500 cases of prostate cancer will be diagnosed and approximately 39,200 men will die from this disease (1). Black men have higher prostate cancer incidence and mortality rates than white men (2). Representation of blacks in clinical trials that investigate the treatment of cancer is proportional to the burden of this disease in the black population (3). However, blacks have generally been underrepresented in clinical trials of preventive interventions (4). To determine the effect of socioeconomic status (SES) on the enrollment of black men in a trial that includes screening for prostate cancer, the African American Men (AAMEN) project in Detroit, Michigan, analyzed data from local recruitment efforts. This report summarizes preliminary results of this analysis, which indicate that SES was not an important factor in refusal to participate in the screening trial.
AN  - 9733417
DA  - Aug 28
DP  - NLM
ET  - 1998/09/11
IS  - 33
KW  - African Americans
*African Continental Ancestry Group
Aged
*Clinical Protocols
Clinical Trials as Topic
Humans
Male
Michigan
Middle Aged
Patient Selection
Prostatic Neoplasms/*ethnology/*prevention & control
LA  - eng
N1  - Centers for Disease Control and Prevention (CDC)
Journal Article
United States
MMWR Morb Mortal Wkly Rep. 1998 Aug 28;47(33):694-6.
PY  - 1998
SN  - 0149-2195 (Print)
0149-2195
SP  - 694-6
ST  - Recruiting black men to a clinical trial to evaluate prostate cancer screening--Detroit, Michigan, 1998
T2  - MMWR Morb Mortal Wkly Rep
TI  - Recruiting black men to a clinical trial to evaluate prostate cancer screening--Detroit, Michigan, 1998
VL  - 47
ID  - 728
ER  - 

TY  - JOUR
AB  - BACKGROUND: Black/African American men die of prostate cancer at a greater rate relative to other males. During the period from 1992 to 1998, prostate cancer incidence rates in the United States were 234.2 per 100,000 persons among non-Hispanic black males and 144.6 per 100,000 persons among white males. The reasons for these increased rates of prostate cancer among black males are largely unknown, but increased mortality is associated with late detection. The authors conducted a longitudinal study of black men that investigated prostate cancer prevention behaviors within this population. The purpose of the current article is to identify successful recruitment strategies that were reported by participants in this study of prevention behaviors. METHODS: Qualitative research methods were used to elucidate men's thoughts, attitudes, beliefs, and practices regarding prostate cancer prevention behaviors and to identify strategies for attracting black men to research programs and retaining them in these programs. RESULTS: Ethnocentric recruitment strategies that were identified included the development of tailored printed materials; the use of targeted locations; and a personalized, participatory approach for engaging potential participants. We contacted 498 black men and enrolled a cohort of 277 non-Hispanic black males (75% of whom were recruited within a 9-week period) in the current study. CONCLUSIONS: Unlike other studies that reported difficulty in recruiting African American men, the current study did not encounter such difficulties. The authors attribute their success to culturally attractive Afrocentric materials; cultural sensitivity; a caring, professional, personalized ethnic approach; respect; and participatory involvement of the target population. Nonetheless, the authors did encounter barriers, such as lack of physician interest and lack of trust in quality medical care. These barriers must be overcome before black males can be engaged and retained in research studies on prostate cancer prevention.
AD  - Department of Health Promotion and Education, School of Public Health, Loma Linda University, Loma Linda, California 92350, USA. vwoods@sph.llu.edu
AN  - 14983498
AU  - Woods, V. D.
AU  - Montgomery, S. B.
AU  - Herring, R. P.
DA  - Mar 1
DO  - 10.1002/cncr.20029
DP  - NLM
ET  - 2004/02/26
IS  - 5
KW  - African Americans/*statistics & numerical data
Aged
Attitude to Health/*ethnology
California
Educational Status
Focus Groups
Health Behavior/ethnology
Humans
Male
Mass Screening/*methods
Middle Aged
Patient Compliance
*Patient Selection
Prostatic Neoplasms/*prevention & control
Research
Risk Assessment
Socioeconomic Factors
LA  - eng
N1  - Woods, V Diane
Montgomery, Susanne B
Herring, R Patti
U36/CCU300430-22/CC/ODCDC CDC HHS/United States
Journal Article
Research Support, U.S. Gov't, P.H.S.
United States
Cancer. 2004 Mar 1;100(5):1017-25. doi: 10.1002/cncr.20029.
PY  - 2004
SN  - 0008-543X (Print)
0008-543x
SP  - 1017-25
ST  - Recruiting Black/African American men for research on prostate cancer prevention
T2  - Cancer
TI  - Recruiting Black/African American men for research on prostate cancer prevention
VL  - 100
ID  - 636
ER  - 

TY  - JOUR
AB  - Background: Colorectal cancer (CRC) survival rates are increasing. Effective strategies to recruit CRC survivors to surveillance studies are needed. Objective: We analyzed the barriers encountered while recruiting CRC survivors to a study assessing their surveillance care experiences. Methods: The study included three phases: (I) focus groups/key informant interviews; (II) cognitive interviews; and (III) a statewide population-based telephone survey. Participants: In Phases I-II, clinic-based data and cancer center registries were used to identify CRC survivors who had received CRC resection within the past 18 months. In Phase III, survivors who had received CRC resection within the past two years were identified via a statewide, population-based cancer registry. Results: In Phase I, 16 survivors participated in focus groups at two National Cancer Center-affiliated sites (response rate = 29.6%). Eighteen additional survivors participated in individual interviews (response rate = 50%). In Phase II, 11 survivors participated in cognitive interviews (response rate = 81.8%). In Phase III, 150 survivors participated in the statewide survey (response rate = 62.2%). Conclusions: Group-based/in-person recruitment efforts were unsuccessful due to scheduling barriers, lack of transportation, and remaining discomfort from previous resection surgery. Telephone-based data collection strategies produced higher response rates. Practice implications: To enhance CRC surveillance research, future studies could incorporate CRC survivor-centered recruitment strategies. (C) 2016 Published by Elsevier Ireland Ltd.
AN  - WOS:000401081500016
AU  - Ford, M. E.
AU  - Sterba, K. R.
AU  - Bearden, J. D.
AU  - Gansauer, L.
AU  - Moore, L. A.
AU  - Zapka, J.
DA  - Mar
DO  - 10.1016/j.pec.2016.10.006
IS  - 3
N1  - 28277291
PY  - 2017
SN  - 0738-3991
SP  - 526-533
ST  - Recruiting colorectal cancer survivors to a surveillance study: Barriers and successful strategies
T2  - Patient Education and Counseling
TI  - Recruiting colorectal cancer survivors to a surveillance study: Barriers and successful strategies
VL  - 100
ID  - 2904
ER  - 

TY  - JOUR
AB  - Low participation among underserved populations in health research constrains progress in public health practices. From 2003 to 2005, Women's Health Clinic patients at the VCU Health System were-recruited to a trial investigating breast cancer risk communication. In secondary analyses, we examined dimensions of the recruitment of these diverse women. The sample characteristics (age, insurance, race and previous mammograms) were compared to the overall clinic. Of recruitment attempts for eligible women, 45% consented; of those who declined, the top cited reasons were lack of time (40%) and lack of interest (18%). Of 899 participants, 35% qualified for the indigent care program, compared to 31% of the overall clinic (P<.001). Forty-five percent of participants were African American, compared to 54% of overall clinic patients (P<.001). Participants were younger (50 vs. 53 years, P<.001) than the overall clinic population. Nonrepresentative enrollment of patients in clinical trials is common and could lead to suboptimal applicability of findings. Although there were statistically significant race and age differences between the study sample and the overall population, we demonstrate that waiting room recruitment can engage diverse women in a clinical trial and cancer risk communication.
AD  - J.N. Bodurtha, Department of Human Genetics, Virginia Commonwealth University, 1101 E. Marshall St., Richmond, VA 23298, United States
AU  - Bodurtha, J. N.
AU  - Quillin, J. M.
AU  - Tracy, K. A.
AU  - Borzelleca, J.
AU  - McClish, D.
AU  - Wilson, D. B.
AU  - Jones, R. M.
AU  - Quillin, J.
AU  - Bowen, D.
DB  - Embase
Medline
IS  - 8
KW  - article
breast cancer
cancer risk
health care
health insurance
human
interpersonal communication
mammography
medical research
priority journal
public health service
race difference
statistical significance
waiting room
women's health
LA  - English
M3  - Article
N1  - L47255137
2007-08-01
PY  - 2007
SN  - 0027-9684
SP  - 917-922
ST  - Recruiting diverse patients to a breast cancer risk communication trial - Waiting rooms can improve access
T2  - Journal of the National Medical Association
TI  - Recruiting diverse patients to a breast cancer risk communication trial - Waiting rooms can improve access
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L47255137&from=export
VL  - 99
ID  - 1225
ER  - 

TY  - JOUR
AB  - Low participation among underserved populations in health research constrains progress in public health practices. From 2003 to 2005, Women's Health Clinic patients at the VCU Health System were recruited to a trial investigating breast cancer risk communication. In secondary analyses, we examined dimensions of the recruitment of these diverse women. The sample characteristics (age, insurance, race and previous mammograms) were compared to the overall clinic. Of recruitment attempts for eligible women, 45% consented; of those who declined, the top cited reasons were lack of time (40%) and lack of interest (18%). Of 899 participants, 35% qualified for the indigent care program, compared to 31% of the overall clinic (P<0.001). Forty-five percent of participants were African American, compared to 54% of overall clinic patients (P<0.001). Participants were younger (50 vs. 53 years, P<0.001) than the overall clinic population. Nonrepresentative enrollment of patients in clinical trials is common and could lead to suboptimal applicability of findings. Although there were statistically significant race and age differences between the study sample and the overall population, we demonstrate that waiting room recruitment can engage diverse women in a clinical trial and cancer risk communication.
AD  - Department of Human Genetics, Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298, USA. bodurtha@vcu.edu
AN  - 17722671
AU  - Bodurtha, J. N.
AU  - Quillin, J. M.
AU  - Tracy, K. A.
AU  - Borzelleca, J.
AU  - McClish, D.
AU  - Wilson, D. B.
AU  - Jones, R. M.
AU  - Quillin, J.
AU  - Bowen, D.
C2  - PMC2574304
DA  - Aug
DP  - NLM
ET  - 2007/08/29
IS  - 8
KW  - Adult
Aged
Breast Neoplasms/*therapy
*Communication
Female
Humans
Middle Aged
*Patient Acceptance of Health Care
*Patient Selection
*Randomized Controlled Trials as Topic
Risk
LA  - eng
N1  - Bodurtha, Joann N
Quillin, John M
Tracy, Kelly A
Borzelleca, Joseph
McClish, Donna
Wilson, Diane Baer
Jones, Resa M
Quillin, Julie
Bowen, Deborah
R01 CA94213/CA/NCI NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
J Natl Med Assoc. 2007 Aug;99(8):917-22.
PY  - 2007
SN  - 0027-9684 (Print)
0027-9684
SP  - 917-22
ST  - Recruiting diverse patients to a breast cancer risk communication trial--waiting rooms can improve access
T2  - J Natl Med Assoc
TI  - Recruiting diverse patients to a breast cancer risk communication trial--waiting rooms can improve access
VL  - 99
ID  - 514
ER  - 

TY  - JOUR
AB  - Barriers to engaging African Americans as research participants may be accentuated among older single African American women partly because of financial, social, physical, and cognitive factors. This article shows the multifaceted strategies and experiences used in the recruitment of 65 yr old and older single African American women in a breast cancer prevention and control study. The study was based on a community-based intervention study aiming to increase breast screening in older single African American women living in 10 public housing complexes in Nashville, Tennessee. Out of 367 eligible women, 325 participated in the study. The results suggest that a strategy which targets the cultural, perceptive, and cognitive characteristics of the population was effective for increasing the enrollment of Ss in this population. Because the single constitute 75% of African American women aged 65 and older, and the incidence and mortality of cancer are especially high in elderly African Americans, these experiences are encouraging for cancer prevention and control research in the population. (PsycINFO Database Record (c) 2016 APA, all rights reserved)
AD  - Zhu, Kangmin, Meharry Medical Coll, Dept of Occupational & Preventive Medicine, School of Medicine, 1005 D. B. Todd Jr. Blvd., Nashville, TN, US, 37208
AN  - 2001-10059-001
AU  - Zhu, Kangmin
AU  - Hunter, Sandra
AU  - Bernard, Louis J.
AU  - Payne-Wilks, Kathleen
AU  - Roland, Chanel L.
AU  - Levine, Robert S.
DB  - psyh
DP  - EBSCOhost
IS  - 4
KW  - breast cancer screening
study recruitment
African American women
elderly
cancer prevention and control studies
single women
African Americans
African Continental Ancestry Group
Aged
Aged, 80 and over
Clinical Trials as Topic
Female
Humans
Motivation
Neoplasms
Patient Selection
Blacks
Breast Neoplasms
Cancer Screening
Human Females
Prevention
Participation
Single Persons
N1  - Meharry Medical Coll, Depts of Occupational & Preventive Medicine & of Surgery, Nashville, TN, US. Other Publishers: Elsevier Science. Release Date: 20020227. Correction Date: 20160502. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Print. Document Type: Journal Article. Language: English. Major Descriptor: Blacks; Breast Neoplasms; Cancer Screening; Human Females; Prevention. Minor Descriptor: Participation; Single Persons. Classification: Health & Mental Health Services (3370). Population: Human (10); Female (40). Location: US. Age Group: Adulthood (18 yrs & older) (300); Aged (65 yrs & older) (380). Methodology: Empirical Study. References Available: Y. Page Count: 7. Issue Publication Date: Apr, 2000.
PY  - 2000
SN  - 0027-9684
1943-4693
SP  - 169-175
ST  - Recruiting elderly African-American women in cancer prevention and control studies: A multifaceted approach and its effectiveness
T2  - Journal of the National Medical Association
TI  - Recruiting elderly African-American women in cancer prevention and control studies: A multifaceted approach and its effectiveness
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2001-10059-001&site=ehost-live&scope=site
VL  - 92
ID  - 1745
ER  - 

TY  - JOUR
AB  - PURPOSE: Cancer genetic services (counseling/testing) are recommended for women diagnosed with breast cancer younger than 45 years old (young breast cancer survivors-YBCS) and at-risk relatives. We present recruitment of YBCS, identification and recruitment of at-risk relatives, and YBCS willingness to contact their cancer-free, female relatives. METHODS: A random sample of 3,000 YBCS, stratified by race (Black vs. White/Other), was identified through a population-based cancer registry and recruited in a randomized trial designed to increase use of cancer genetic services. Baseline demographic, clinical, and family characteristics, and variables associated with the Theory of Planned Behavior (TPB) were assessed as predictors of YBCS' willingness to contact at-risk relatives. RESULTS: The 883 YBCS (33.2% response rate; 40% Black) who returned a survey had 1,875 at-risk relatives and were willing to contact 1,360 (72.5%). From 853 invited at-risk relatives (up to two relatives per YBCS), 442 responded (51.6% response rate). YBCS with larger families, with a previous diagnosis of depression, and motivated to comply with recommendations from family members were likely to contact a greater number of relatives. Black YBCS were more likely to contact younger relatives and those living further than 50 miles compared to White/Other YBCS. CONCLUSION: It is feasible to recruit diverse families at risk for hereditary cancer from a population-based cancer registry. This recruitment approach can be used as a paradigm for harmonizing processes and increasing internal and external validity of large-scale public health genomic initiatives in the era of precision medicine.
AD  - Nursing Science, Faculty of Medicine, Bernoullistrasse 28, 4056, Basel, Switzerland. maria.katapodi@unibas.ch.
University of Michigan School of Nursing, 400 North Ingalls Building, Ann Arbor, MI, 48109, USA. maria.katapodi@unibas.ch.
Michigan Department of Health and Human Services, 333 S. Grand Ave., P.O. Box 30195, Lansing, MI, 48909, USA.
University of Michigan School of Nursing, 400 North Ingalls Building, Ann Arbor, MI, 48109, USA.
Nursing Science, Faculty of Medicine, Bernoullistrasse 28, 4056, Basel, Switzerland.
Ohio State University College of Nursing, 1585 Neil Ave, Columbus, OH, 43210, USA.
University of Michigan Comprehensive Cancer Center, 1500 East Medical Center Drive, CCGC 6-303, Ann Arbor, MI, 48109-0944, USA.
Swiss Tropical and Public Health Institute, University of Basel, Socinstrasse 57, 4051, Basel, Switzerland.
University of Michigan, School of Medicine, 1500 E Medical Center Dr, Ann Arbor, MI, 48109, USA.
University of Michigan, School of Public Health, 1415 Washington Heights, Ann Arbor, MI, 48109, USA.
Michigan Cancer Surveillance Program, 333 S. Grand Ave, P.O. Box 30195, Lansing, MI, 48909, USA.
AN  - 28197806
AU  - Katapodi, M. C.
AU  - Duquette, D.
AU  - Yang, J. J.
AU  - Mendelsohn-Victor, K.
AU  - Anderson, B.
AU  - Nikolaidis, C.
AU  - Mancewicz, E.
AU  - Northouse, L. L.
AU  - Duffy, S.
AU  - Ronis, D.
AU  - Milliron, K. J.
AU  - Probst-Herbst, N.
AU  - Merajver, S. D.
AU  - Janz, N. K.
AU  - Copeland, G.
AU  - Roberts, S.
DA  - Mar
DO  - 10.1007/s10552-017-0858-2
DP  - NLM
ET  - 2017/02/16
IS  - 3
KW  - Adult
Breast Neoplasms/*genetics/psychology
Counseling
Depression
Family/psychology
Female
Humans
Middle Aged
Ovarian Neoplasms/*genetics/psychology
*Patient Selection
*Registries
Risk Factors
Surveys and Questionnaires
Survivors
*At-risk relatives
*Cancer registry
*Public health genomic trials
*Recruitment
*Young breast cancer survivors
LA  - eng
N1  - 1573-7225
Katapodi, Maria C
Orcid: 0000-0003-3903-3750
Duquette, Deb
Yang, James J
Mendelsohn-Victor, Kari
Anderson, Beth
Nikolaidis, Christos
Mancewicz, Emily
Northouse, Laurel L
Duffy, Sonia
Ronis, David
Milliron, Kara J
Probst-Herbst, Nicole
Merajver, Sofia D
Janz, Nancy K
Copeland, Glenn
Roberts, Scott
Journal Article
Netherlands
Cancer Causes Control. 2017 Mar;28(3):191-201. doi: 10.1007/s10552-017-0858-2. Epub 2017 Feb 14.
PY  - 2017
SN  - 0957-5243
SP  - 191-201
ST  - Recruiting families at risk for hereditary breast and ovarian cancer from a statewide cancer registry: a methodological study
T2  - Cancer Causes Control
TI  - Recruiting families at risk for hereditary breast and ovarian cancer from a statewide cancer registry: a methodological study
VL  - 28
ID  - 182
ER  - 

TY  - JOUR
AB  - OBJECTIVES To determine (a) the respondents' perceptions of 4 unclear or conflicting cancer screening guidelines: prostate-specific antigen (PSA) for men over 50, mammography for wornen 40-49, colorectal screening by fecal occult blood testing (FOBT), and colonoscopy for patients over 40; and (b) the influence of various factors on the decision to order these tests. STUDY DESIGN National Canadian mail survey of randomly selected family physicians. POPULATION Family physicians in active practice (n=565) selected from rural and urban family medicine sites in 5 provinces representing the main regions in Canada. OUTCOME MEASURED Agreement with guideline statements, and decision to order screening test in 6 clinical vignettes. RESULTS Of 565 surveys mailed, 351 (62.1%) were returned. Most respondents agreed with the Canadian Task Force recommendations, and most believed that various guidelines for 3 of the 4 screens were conflicting (PSA 86.6%; mammography 67.5%. FOBT 62.4%). Patient anxiety about cancer, patient expectations of being tested, and a positive family history of cancer increased the odds that the 4 tests would be ordered. A good quality patient-MD relationship decreased the odds of ordering a mammogram. Screening decisions were also significantly influenced by the respondents' beliefs about whether screening was recommended and whether screening Could cause more harm than good. A physician's sensitivity to his or her colleagues' practice influenced screening decisions regarding PSA and mammography. CONCLUSIONS These results suggest a conceptual framework for understanding the determinants of screening behavior when guidelines are unclear or conflicting.
AN  - WOS:000177968700009
AU  - Welsh, J.
AU  - Adam, P.
AU  - Fontaine, P.
AU  - Gjerdingen, D.
DA  - Sep
IS  - 9
N1  - 5
12366895
PY  - 2002
SN  - 0094-3509
SP  - 760-+
ST  - Recruiting for a randomized controlled trial from an ethnically diverse population: Lessons from the Maternal Infection and Preterm Labor Study
T2  - Journal of Family Practice
TI  - Recruiting for a randomized controlled trial from an ethnically diverse population: Lessons from the Maternal Infection and Preterm Labor Study
VL  - 51
ID  - 2700
ER  - 

TY  - JOUR
AB  - Objectives: In this pilot study we evaluated the feasibility of and methods for assessing the quality of life of long term survivors of European Organisation for Research and Treatment of Cancer (EORTC) phase III clinical trials. Here we report the results pertaining to the feasibility of conducting such research. Methods: In this cross-sectional study, we recruited long-term, disease-free survivors from two mature EORTC clinical trials in testicular and prostate cancer from centres in Northern and Southern Europe, and the United Kingdom (UK). Results: A number of challenges were encountered in recruiting participating centres, obtaining medical ethical approval and in recruiting survivors and collecting the health-related quality of life (HRQoL) data in a timely manner. The efficiency with which the study could be conducted varied widely across centres and countries. Time to obtain medical ethical approval for the study ranged from 1.5 to 25 months. We encountered most problems with ethical approval in the UK, Italy and Belgium. In most cases, data collection was completed within 3 months (range 10 weeks-1 year). Completed questionnaires were obtained from 68% and 56%, respectively, of the testicular and prostate cancer survivors who were approached. Conclusions: HRQoL research among long-term survivors of EORTC phase III clinical trials is possible, but the process of ethical approval and data collection is a lengthy one. To minimise many of the logistical problems, long-term follow-up of patients should be an integral part of future clinical trials. Moreover, regulations governing medical ethical approval for clinical research within the EU should be carefully evaluated to facilitate long-term follow-up of cancer survivors in Europe. (C) 2014 Elsevier Ltd. All rights reserved.
AN  - WOS:000339220100012
AU  - van Leeuwen, M.
AU  - Efficace, F.
AU  - Fossa, S. D.
AU  - Bolla, M.
AU  - De Giorgi, U.
AU  - de Wit, R.
AU  - Holzner, B.
AU  - van de Poll-Franse, L. V.
AU  - van Poppel, H.
AU  - White, J.
AU  - Collette, L.
AU  - Osanto, S.
AU  - Aaronson, N. K.
DA  - Jul
DO  - 10.1016/j.ejca.2014.04.018
IS  - 11
N1  - 24820932
PY  - 2014
SN  - 0959-8049
SP  - 1957-1963
ST  - Recruiting long-term survivors of European Organisation for Research and Treatment of Cancer phase III clinical trials into quality of life studies: Challenges and opportunities
T2  - European Journal of Cancer
TI  - Recruiting long-term survivors of European Organisation for Research and Treatment of Cancer phase III clinical trials into quality of life studies: Challenges and opportunities
VL  - 50
ID  - 3003
ER  - 

TY  - JOUR
AB  - Objective. The study goals were (1) to assess the feasibility of using an existing telephone health information and referral service for low-income, ethnically diverse women to recruit women for research participation; (2) to assess the feasibility of recruiting low-income, African American and Latino men into health research through the women callers to the telephone service; and (3) to describe the challenges women face and the strategies they use when talking to men about the men's health and research participation. Design. We recruited women for individual semi-structured qualitative interviews via the Every Woman Counts (EWC) telephone information and referral service, a California Department of Health Services Cancer Detection Program. This paper describes our eligibility and recruitment assessment, and our qualitative data from 23 interviews with low-income African American and Latino women who called EWC. Results. We found that it was feasible to recruit women, but not to recruit men through women who call this telephone service. Almost 50% (113) of women demographically eligible for recruitment, completed our screening questionnaire, despite calling EWC for a different purpose. Some 48% (54) of those women were eligible for an interview. Of interview-eligible women, 58% (10) of African Americans and 35% (13) of Latinos completed an interview. Only 17% (4) of women referred a man for participation in an interview for our study. Several themes emerged from our analysis of interview data: (1) women's role in men's health can be significant but is often uneasy; (2) challenges when talking to men about their health include health access, gender dynamics, and men's fear of health care; (3) women's understanding of research may be limited; (4) women use a range of strategies to address and overcome men's resistance to taking care of their health and participating in research. Conclusions. The challenges women face when talking with men about their health affect their ability to effectively speak to men about research participation. However, EWC and similar telephone health services may be an effective means for recruiting low-income women to chemoprevention and other studies requiring healthy participants.
AN  - WOS:000251367500006
AU  - Joseph, G.
AU  - Kaplan, C. P.
AU  - Pasick, R. J.
DO  - 10.1080/13557850701616961
IS  - 5
N1  - 17978946
PY  - 2007
SN  - 1355-7858
SP  - 497-519
ST  - Recruiting low-income healthy women to research: An exploratory study
T2  - Ethnicity & Health
TI  - Recruiting low-income healthy women to research: An exploratory study
VL  - 12
ID  - 3203
ER  - 

TY  - JOUR
AB  - PURPOSE: This article describes the demographic characteristics of participants in a randomized trial (the AAMEN Project) designed to recruit older (aged 55+ years) African American men to a cancer screening trial. DESIGN AND METHODS: The AAMEN Project is a recruitment trial developed for African American men aged 55+ years living in southeastern Michigan. RESULTS: Of the 34,376 African American men in the study, 37.6% had low incomes and 62.4% had moderate-to-high incomes. The average age of the men was 63.3 years (SD = 5.9 years). Among men who were eligible and interested in participating, the proportion of men with low incomes was significantly greater than the proportion of men with moderate-to-high incomes (p <.001). IMPLICATIONS: The AAMEN Project demonstrated success in recruiting a substantial proportion of men with low incomes as well as men with moderate-to-high incomes. These findings may facilitate the development of future recruitment efforts involving older African American men.
AD  - Department of Medicine, Baylor College of Medicine, Veterans Affairs Medical Center, Houston, TX 77030, USA. mford@bcm.tmc.edu
AN  - 12604743
AU  - Ford, M. E.
AU  - Havstad, S. L.
AU  - Tilley, B. C.
DA  - Feb
DO  - 10.1093/geront/43.1.27
DP  - NLM
ET  - 2003/02/27
IS  - 1
KW  - *African Americans
Aged
Analysis of Variance
Chi-Square Distribution
Humans
Male
Mass Screening/*methods
Michigan/ethnology
Middle Aged
*Patient Selection
Pilot Projects
Prostatic Neoplasms/*diagnosis/ethnology
Socioeconomic Factors
LA  - eng
N1  - Ford, Marvella E
Havstad, Suzanne L
Tilley, Barbara C
N01-CN-25512/CN/NCI NIH HHS/United States
P 30 AG 5286/AG/NIA NIH HHS/United States
Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, U.S. Gov't, P.H.S.
United States
Gerontologist. 2003 Feb;43(1):27-35. doi: 10.1093/geront/43.1.27.
PY  - 2003
SN  - 0016-9013 (Print)
0016-9013
SP  - 27-35
ST  - Recruiting older African American men to a cancer screening trial (the AAMEN Project)
T2  - Gerontologist
TI  - Recruiting older African American men to a cancer screening trial (the AAMEN Project)
VL  - 43
ID  - 655
ER  - 

TY  - JOUR
AB  - Background. Minority groups are underrepresented in research, making it difficult to apply medical advances with confidence. In this study, we explored whether community-based cancer education sites and educators serving the African American community could be used to recruit Minority participants to research. Methods. We invited Individuals at community education sites to provide buccal scrapings, saliva samples, psychometric data, and personal information anonymously. Results. Culturally aligned Community sites (100%) collaborated in the research recruitment, as did 83% of the individuals at those sites. Conclusion. Community-based education sites offer exceptional promise for teaching about research benefits and recruiting members of minority groups to research Studies.
AN  - WOS:000235599900010
AU  - Sadler, G. R.
AU  - Peterson, M.
AU  - Wasserman, L.
AU  - Mills, P. L.
AU  - Malcarne, V. L.
AU  - Rock, C.
AU  - Ancoli-Israel, S.
AU  - Moore, A.
AU  - Weldon, R. N.
AU  - Garcia, T.
AU  - Kolodner, R. D.
DA  - Win
DO  - 10.1207/s15430154jce2004_12
IS  - 4
N1  - 15th Scientific Meeting of the European Association for Cancer Education
MAY 03, 2002
NIJMEGEN, NETHERLANDS
European Assoc Canc Educ
16497136
PY  - 2005
SN  - 0885-8195
SP  - 235-239
ST  - Recruiting research participants at community education sites
T2  - Journal of Cancer Education
TI  - Recruiting research participants at community education sites
VL  - 20
ID  - 3230
ER  - 

TY  - JOUR
AB  - More than 80% of women with breast cancer are now reported to be using complementary and alternative medicine (CAM) therapies during conventional treatment. A randomized clinical trial (RCT) of reflexology with late stage breast cancer patients serves as the data source for this article. The purposes were to investigate: (i) reasons for refusal to participate in a RCT of reflexology; (ii) the differences between those who completed the baseline interview and those who dropped out before baseline; and (iii) the utility of the Palliative Prognostic Score (PPS) as a prognostic screening tool in minimizing early attrition (before baseline) from the trial. Eligible women (N = 400) approached at 12 cancer centers in the Midwest had advanced breast cancer, were on chemotherapy or hormonal therapy, and had a PPS of 11 or less. Comparisons of those who dropped out early (N = 33) to those who stayed in the trial (N = 240) were carried out using Wilcoxon rank, t-, chi-squared and Fisher's exact tests. The reasons of being "too sick" or "overwhelmed" were given by less than 12% of the women who refused to participate. There was a higher early dropout rate among black women compared to other (primarily white) women (P = .01). Cancer recurrence and metastasis, age, and the PPS were not predictive of early retention of women. Specialized techniques may be needed to ensure black women remain in the trial once consented. Women with advanced disease were likely to enter and remain in the trial despite deterioration in health.
AD  - Department of Statistics and Probability, College of Natural Science, Michigan State University, East Lansing, MI 48824, USA.
AN  - 19620179
AU  - Sikorskii, A.
AU  - Wyatt, G. K.
AU  - Siddiqi, A. E.
AU  - Tamkus, D.
C2  - PMC3137428
DO  - 10.1093/ecam/nep051
DP  - NLM
ET  - 2009/07/22
LA  - eng
N1  - 1741-4288
Sikorskii, Alla
Wyatt, Gwen K
Siddiqi, Azfar-E-Alam
Tamkus, Deimante
R01 CA104883/CA/NCI NIH HHS/United States
Journal Article
Evid Based Complement Alternat Med. 2011;2011:734517. doi: 10.1093/ecam/nep051. Epub 2011 Feb 14.
PY  - 2011
SN  - 1741-427X (Print)
1741-427x
SP  - 734517
ST  - Recruitment and early retention of women with advanced breast cancer in a complementary and alternative medicine trial
T2  - Evid Based Complement Alternat Med
TI  - Recruitment and early retention of women with advanced breast cancer in a complementary and alternative medicine trial
VL  - 2011
ID  - 455
ER  - 

TY  - JOUR
AB  - PURPOSE/OBJECTIVES: To describe recruitment and retention strategies of a psychosocial intervention with African American and Latina American breast cancer survivors (BCSs). DESIGN: Prospective design with pre- and post-testing. SETTING: A mailed survey and assignment to telephone counseling or education booklet only. SAMPLE: 587 African American and Latina American BCSs were recruited. METHODS: The sample was drawn from the population-based California cancer and hospital registries, as well as community agencies. Mailed self-report health-related quality-of-life assessments were at baseline and 4-6 months follow-up. MAIN RESEARCH VARIABLES: Accrual outcomes; recruitment and retention strategies. FINDINGS: A total of 375 (64%) completed the baseline survey and 320 (55%) completed both baseline and follow-up assessments. The recruitment outcomes suggest that very special attention must be paid to the initial recruitment of Latina Americans to engage their interest and participation. For African Americans, particular attention must be devoted to their retention to address potential attrition. CONCLUSIONS: Findings suggest that the inclusion of lower-income and ethnic minority cancer survivors in a longitudinal intervention study is doable. The results indicate that recruitment outcomes are influenced by participant and study characteristics. Successful enrollment requires investigations that attend to culturally and socioecologically informed recruitment and retention strategies, from staff selection, training, and supervision to overall study approach protocol, to address barriers to participation. IMPLICATIONS FOR NURSING: Nursing research and practice have championed survivorship care, including psychosocial care. This article outlines practical strategies to recruit and retain population-based samples, ethnic minorities, and underserved survivors.
AD  - Department of Population Sciences, Center of Community Alliance for Research and Education, City of Hope National Medical Center, Duarte, CA, USA. kashing@coh.org
AN  - 22940523
AU  - Ashing-Giwa, K.
AU  - Rosales, M.
DA  - Sep
DO  - 10.1188/12.Onf.E434-e442
DP  - NLM
ET  - 2012/09/04
IS  - 5
KW  - Adult
African Americans/*psychology
Aged
Breast Neoplasms/*psychology
California
Female
Follow-Up Studies
Health Surveys
Hispanic Americans/*psychology
Humans
Income
Middle Aged
Pamphlets
*Patient Dropouts/psychology
Patient Education as Topic
Patient Participation
*Patient Selection
Prospective Studies
Quality of Life
Socioeconomic Factors
Survivors/*psychology
Telephone
Young Adult
LA  - eng
N1  - 1538-0688
Ashing-Giwa, Kimlin
Rosales, Monica
Journal Article
Research Support, U.S. Gov't, Non-P.H.S.
United States
Oncol Nurs Forum. 2012 Sep;39(5):E434-42. doi: 10.1188/12.ONF.E434-E442.
PY  - 2012
SN  - 0190-535x
SP  - E434-42
ST  - Recruitment and retention strategies of African American and Latina American breast cancer survivors in a longitudinal psycho-oncology study
T2  - Oncol Nurs Forum
TI  - Recruitment and retention strategies of African American and Latina American breast cancer survivors in a longitudinal psycho-oncology study
VL  - 39
ID  - 355
ER  - 

TY  - JOUR
AB  - The African American Hereditary Prostate Cancer (AAHPC) Study is an ongoing multicenter genetic linkage study organized by Howard University and the National Human Genome Research Institute (NHGRI), with support from the Office for Research on Minority Health and the National Cancer Institute. The goals of the study are to: (i) look for evidence of involvement of chromosome 1q24-25 (HPC1) in African American men with hereditary prostate cancer (HPC) and (ii) conduct a genome-wide search for other loci associated with HPC in African American men. To accomplish these goals, a network has been established including Howard University, the NHGRI, and six Collaborative Recruitment Centers (CRCs). The CRCs are responsible for the identification and enrollment of 100 African American families. To date, 43 families have been enrolled. Recruitment strategies have included mass media campaigns, physician referrals, community health-fairs/prostate cancer screenings, support groups, tumor registries, as well as visits to churches, barber shops, and universities. By far, the most productive recruitment mechanisms have been physician referrals and tumor registries, yielding a total of 35 (81%) families. Approximately 41% (n = 3400) of probands initially contacted by phone or mail expressed interest in participating; the families of 2% of these met the eligibility criteria, and 75% of those families have been enrolled in the study, indicating a 0.5% recruitment yield (ratio of participants to contacts). As the first large-scale genetic linkage study of African Americans, on a common disease, the challenges and successes of the recruitment process for the AAHPC Study should serve to inform future efforts to involve this population in similar studies.
AD  - National Human Genome Center, Howard University, Washington, DC 20059, USA. croyal@howard.edu
AN  - 11189095
AU  - Royal, C.
AU  - Baffoe-Bonnie, A.
AU  - Kittles, R.
AU  - Powell, I.
AU  - Bennett, J.
AU  - Hoke, G.
AU  - Pettaway, C.
AU  - Weinrich, S.
AU  - Vijayakumar, S.
AU  - Ahaghotu, C.
AU  - Mason, T.
AU  - Johnson, E.
AU  - Obeikwe, M.
AU  - Simpson, C.
AU  - Mejia, R.
AU  - Boykin, W.
AU  - Roberson, P.
AU  - Frost, J.
AU  - Faison-Smith, L.
AU  - Meegan, C.
AU  - Foster, N.
AU  - Furbert-Harris, P.
AU  - Carpten, J.
AU  - Bailey-Wilson, J.
AU  - Trent, J.
AU  - Berg, K.
AU  - Dunston, G.
AU  - Collins, F.
DA  - Nov
DO  - 10.1016/s1047-2797(00)00194-0
DP  - NLM
ET  - 2001/02/24
IS  - 8 Suppl
KW  - *African Americans
*Clinical Trials as Topic
Family
Humans
Male
Methods
*Patient Selection
Prostatic Neoplasms/*ethnology/*genetics
United States
LA  - eng
N1  - Royal, C
Baffoe-Bonnie, A
Kittles, R
Powell, I
Bennett, J
Hoke, G
Pettaway, C
Weinrich, S
Vijayakumar, S
Ahaghotu, C
Mason, T
Johnson, E
Obeikwe, M
Simpson, C
Mejia, R
Boykin, W
Roberson, P
Frost, J
Faison-Smith, L
Meegan, C
Foster, N
Furbert-Harris, P
Carpten, J
Bailey-Wilson, J
Trent, J
Berg, K
Dunston, G
Collins, F
N01-HG-75418/HG/NHGRI NIH HHS/United States
Journal Article
Research Support, U.S. Gov't, P.H.S.
United States
Ann Epidemiol. 2000 Nov;10(8 Suppl):S68-77. doi: 10.1016/s1047-2797(00)00194-0.
PY  - 2000
SN  - 1047-2797 (Print)
1047-2797
SP  - S68-77
ST  - Recruitment experience in the first phase of the African American Hereditary Prostate Cancer (AAHPC) study
T2  - Ann Epidemiol
TI  - Recruitment experience in the first phase of the African American Hereditary Prostate Cancer (AAHPC) study
VL  - 10
ID  - 694
ER  - 

TY  - JOUR
AB  - Oxidative DNA damage (ODD) can result from numerous endogenous metabolic processes as well as from exposure to environmental and dietary oxidants. One important type of ODD that may have a role in carcinogenesis is the formation of hydroxylated DNA bases. Our major purpose was to determine the potential for subject accrual for a multisite case-control study of ODD and breast cancer risk within a large urban university medical center. We examined the levels of a hydroxylated thymine residue, 5-hydroxymethyl-2'-deoxyuridine in DNA obtained from the peripheral blood of 26 women with breast cancer and an age-matched group of 29 control women without breast cancer. The isolated DNA was analyzed for levels of 5-hydroxymethyl-2'-deoxyuridine by gas chromatography with mass spectral detection. Our recruitment methods resulted in a relatively high yield of eligible cases (72%) and a lower yield of controls (46%). We evaluated the dose-response relationship of ODD level to breast cancer risk, using quartiles of ODD. The covariate-adjusted odds ratio of breast cancer exceeded 2.0 for women in the highest quartile of ODD (compared with the lowest quartile), although this result was not statistically significant. ODD levels were significantly more variable among African-American controls (SD = 224.1) than among white controls (SD = 57.5), p < 0.001. Overall, these results suggest a possible slight increase in breast cancer risk among women in the highest ODD quartile, after adjusting for race, menopausal status, and family history of breast cancer.
AD  - Karmanos Cancer Institute, Division of Hematology and Oncology, Wayne State University School of Medicine, Detroit, Michigan, USA. Simonm@karmanos.org
AN  - 10857894
AU  - Simon, M. S.
AU  - Heilbrun, L. K.
AU  - Stephens, D.
AU  - Lababidi, S.
AU  - Djuric, Z.
DA  - Jun
DO  - 10.1097/00000421-200006000-00015
DP  - NLM
ET  - 2000/06/17
IS  - 3
KW  - Antineoplastic Agents/*blood
Breast Neoplasms/*blood/etiology
Case-Control Studies
*DNA Damage
Female
Humans
Logistic Models
Middle Aged
Molecular Epidemiology
Oxidants/*adverse effects
*Patient Selection
Pilot Projects
Risk Factors
Thymidine/*analogs & derivatives/blood
LA  - eng
N1  - Simon, M S
Heilbrun, L K
Stephens, D
Lababidi, S
Djuric, Z
CA-22453/CA/NCI NIH HHS/United States
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.
United States
Am J Clin Oncol. 2000 Jun;23(3):283-7. doi: 10.1097/00000421-200006000-00015.
PY  - 2000
SN  - 0277-3732 (Print)
0277-3732
SP  - 283-7
ST  - Recruitment for a pilot case control study of oxidative DNA damage and breast cancer risk
T2  - Am J Clin Oncol
TI  - Recruitment for a pilot case control study of oxidative DNA damage and breast cancer risk
VL  - 23
ID  - 702
ER  - 

TY  - JOUR
AN  - 15647088
AU  - Patterson, A.
AU  - Davis, H.
AU  - Euhus, D.
AU  - Neuhausen, S.
AU  - Strong, L.
AU  - Tomlinson, G.
DA  - Jan-Feb
DO  - 10.1111/j.1075-122X.2005.21542.x
DP  - NLM
ET  - 2005/01/14
IS  - 1
KW  - African Americans/*genetics
Breast Neoplasms/*ethnology/*genetics/prevention & control
Female
*Genetic Predisposition to Disease
Humans
*Medically Underserved Area
*Patient Selection
United States
Women's Health
LA  - eng
N1  - Patterson, Annette
Davis, Helen
Euhus, David
Neuhausen, Susan
Strong, Louise
Tomlinson, Gail
R01-CA74415/CA/NCI NIH HHS/United States
R03-CA70472/CA/NCI NIH HHS/United States
U24-CA78142/CA/NCI NIH HHS/United States
Letter
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, U.S. Gov't, P.H.S.
United States
Breast J. 2005 Jan-Feb;11(1):79-82. doi: 10.1111/j.1075-122X.2005.21542.x.
PY  - 2005
SN  - 1075-122X (Print)
1075-122x
SP  - 79-82
ST  - Recruitment for breast cancer predisposition studies in an underserved African American population
T2  - Breast J
TI  - Recruitment for breast cancer predisposition studies in an underserved African American population
VL  - 11
ID  - 610
ER  - 

TY  - JOUR
AB  - Objective: Recruitment of healthy subjects to long-term randomized controlled trials (RCTs) of cancer prevention or early detection has proven to be a difficult task. To quantify recruitment yield as well as characteristics of successfully recruited participants, we examined recruitment outcomes at 1 of the 10 centers participating in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial, a National Cancer Institute-funded RCT of cancer screening modalities. Materials and Methods: During the early recruitment phase of PLCO (1993-1997), data on recruitment outcome were collected at the Henry Ford Health System (HFHS) in Detroit, Michigan. In this phase, HFHS identified potential participants using patient databases. Records were used to assess recruitment success by age, sex, race, household income (using area-based U.S. Census data), and preexisting morbidity. Logistic regression was used to assess whether enrollment success differed significantly according to these factors. Results: Of 74,139 persons ages 55 to 74 invited by HFHS to participate, 8,250 (11%) enrolled. In multivariate analyses, the odds of enrolling were modestly but significantly higher for women, Caucasians, persons in their 60's, and persons living in census blocks with higher median household income. Persons with two or more preexisting morbidities had significantly lower odds of enrolling compared to those with one or no preexisting morbidities. Conclusions: These data suggest that only a small fraction of persons invited to enroll in long-term RCTs of cancer screening modalities actually do so. In this urban, Midwestern setting, certain characteristics including age, race, and income influenced recruitment success, albeit modestly.
AN  - WOS:000254969000013
AU  - Lamerato, L. E.
AU  - Marcus, P. M.
AU  - Jacobsen, G.
AU  - Johnson, C. C.
DA  - Apr
DO  - 10.1158/1055-9965.EPI-06-0528
IS  - 4
N1  - 18398023
PY  - 2008
SN  - 1055-9965
SP  - 827-833
ST  - Recruitment in the prostate, lung, colorectal, and ovarian (PLCO) cancer screening trial: The first phase of recruitment at Henry Ford Health System
T2  - Cancer Epidemiology Biomarkers & Prevention
TI  - Recruitment in the prostate, lung, colorectal, and ovarian (PLCO) cancer screening trial: The first phase of recruitment at Henry Ford Health System
VL  - 17
ID  - 3172
ER  - 

TY  - JOUR
AB  - Given that Black women remain underrepresented in clinical research studies, we sought to recruit a population-based sample of young Black women with breast cancer through a state cancer registry. Demographic and clinical information on all Black women diagnosed with invasive breast cancer at or below age 50 between 2009 and 2012 in Florida was obtained through the state cancer registry. Survivors were invited to participate in the study through state-mandated recruitment methods. Participant demographic and clinical characteristics were compared using Chi-squared tests for categorical variables and the two sample t-test for continuous variables to identify differences between: (i) consented participants versus all other eligible; and (ii) living versus deceased. Of the 1,647 young Black women with breast cancer, mean age at diagnosis was 42.5, with the majority having localized or regional disease, unmarried, privately insured, and employed. There were no significant differences in demographic and clinical variables between the 456 consented study participants versus the remaining 1,191 presumed eligible individuals. Compared to potential participants, women determined to be deceased prior to recruitment (n = 182) were significantly more likely to have distant disease and a triple-negative phenotype. They were also significantly more likely to be unemployed, and uninsured or have public insurance (i.e., Medicaid or Medicare). Our results demonstrate that recruitment of a population-based sample of breast cancer survivors through a state cancer registry is a feasible strategy in this underserved and underrepresented population. However, survival bias, which was observed due to the lag time between diagnosis and recruitment, is important to adjust for when generalizing findings to all young Black breast cancer patients.
AD  - T. Pal, H. Lee Moffitt Cancer Center, Department of Cancer Epidemiology, Moffitt Cancer Center, Departments of Oncologic Sciences, University of South Florida, 12902 Magnolia Drive, Tampa, FL, United States
AU  - Bonner, D.
AU  - Cragun, D.
AU  - Reynolds, M.
AU  - Vadaparampil, S. T.
AU  - Pal, T.
DB  - Embase
Medline
DO  - 10.1111/tbj.12545
IS  - 2
KW  - adult
African American
article
breast cancer
cancer patient
cancer registry
cancer survivor
clinical research
comparative study
disease predisposition
female
health insurance
human
major clinical study
medical history
medical record
medically uninsured
unemployment
LA  - English
M3  - Article
N1  - L607308519
2015-12-23
2016-03-18
PY  - 2016
SN  - 1524-4741
1075-122X
SP  - 166-172
ST  - Recruitment of a population-based sample of young black women with breast cancer through a state cancer registry
T2  - Breast Journal
TI  - Recruitment of a population-based sample of young black women with breast cancer through a state cancer registry
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L607308519&from=export
http://dx.doi.org/10.1111/tbj.12545
VL  - 22
ID  - 979
ER  - 

TY  - JOUR
AB  - Objective: To describe the strategies and costs associated with recruiting both African American and White postmenopausal women into a randomized controlled trial. Design: The Beneficial Effects of Soy Trial (BEST) was a randomized, controlled trial designed to determine the effects of a dietary soy supplement on lipoproteins, lipoprotein subclasses, and menopausal symptoms in African American and White postmenopausal women. The goal was to have >= 80 African American and >= 80 White women complete the study. Results: A total of 705 postmenopausal women (381 African American, 324 White) were screened, and of those, 217 were randomized (105 African American, 112 White), and 192 (91 African American, 101 White) completed the study. Direct mailings to targeted zip codes proved the most successful recruitment strategy for recruiting African Americans (52% of African Americans recruited) and the second most effective for recruiting Whites (32% of Whites recruited). Newspaper advertisements yielded the highest number of White participants (36%) but proved less successful for recruiting African Americans (8%). Airing advertisements on the radio was the second most effective strategy for recruiting African Americans (15%), yet it was one of the least effective approaches for recruiting Whites (5%). The total cost of recruitment was $49,036.25, which averaged $255.40 per participant who completed the study. The three most successful strategies, direct mailings, newspaper ads, and radio ads, were the three most expensive approaches but yielded 73% of all participants who completed the study. Conclusions: A variety of targeted recruitment strategies are required to ensure a diverse response to advertisements and promotions. Given the extra time and effort needed to recruit minorities, researchers must include adequate resources to cover the cost of recruitment in their budgets.
AN  - WOS:000241238400028
AU  - Lindenstruth, K. A.
AU  - Curtis, C. B.
AU  - Allen, J. K.
DA  - Fal
IS  - 4
N1  - 17061750
PY  - 2006
SN  - 1049-510X
SP  - 938-942
ST  - Recruitment of African American and White postmenopausal women into clinical trials: The Beneficial Effects of Soy Trial Experience
T2  - Ethnicity & Disease
TI  - Recruitment of African American and White postmenopausal women into clinical trials: The Beneficial Effects of Soy Trial Experience
VL  - 16
ID  - 3211
ER  - 

TY  - JOUR
AB  - Rural, Southern, African American, women comprise a population that can be difficult to reach for health education. With the health disparity regarding early detection of breast cancer greater among African American women than Caucasian women, a successful program for recruitment of participants is needed. Recruitment strategies used in a study using a 2-group, pre-post intervention design with a booster treatment and a follow-up at 1 and 2 months post-intervention design is described Innovative recruitment methods were implemented to include snowballing, community participation, rural churches, and culturally appropriate interventions. Study findings included a successful recruitment of 159 rural African American participants with 86% retention in the intervention group and 68% retention in the control group. Implications for future studies include using collaborative work between different agencies within rural communities to reach underserved minority populations. Nurses are important partners to reach women in their own communities.
AN  - 104871607. Language: English. Entry Date: 20110610. Revision Date: 20150820. Publication Type: Journal Article
AU  - Kelley, Mary Ann
DB  - CINAHL Complete
DP  - EBSCOhost
IS  - 1
KW  - Black Persons
Breast Neoplasms -- Diagnosis
Early Diagnosis
Health Education
Research Subject Recruitment
Research Subject Retention
Rural Areas
Breast Self-Examination
Churches
Communication
Conceptual Framework
Cultural Sensitivity
Descriptive Statistics
Environment
Female
Group Processes
Healthy People 2010
Human
Nursing Theory
Patient Compliance
Personal Boundaries
Risk Assessment
Snowball Sample
Southeastern United States
Time Factors
Transcultural Care
N1  - research; tables/charts. Journal Subset: Blind Peer Reviewed; Expert Peer Reviewed; Nursing; Peer Reviewed; USA. NLM UID: 101135885.
PY  - 2011
SN  - 1538-0696
SP  - 15p-15p
ST  - Recruitment of African American women for research on breast cancer early detection: using culturally appropriate interventions
T2  - Southern Online Journal of Nursing Research
TI  - Recruitment of African American women for research on breast cancer early detection: using culturally appropriate interventions
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104871607&site=ehost-live&scope=site
VL  - 11
ID  - 2070
ER  - 

TY  - JOUR
AB  - In 2000, using National Institutes of Health/National Cancer Institute (NIH/NCI) U54 funds, a clinical trials shared resource was established at Nashville General Hospital at Meharry to attract more African Americans to national cancer clinical trials. This Report from the Field describes the model used to achieve this end.
AN  - WOS:000274701100006
AU  - Wujcik, D.
AU  - Wolff, S. N.
DA  - Feb
IS  - 1
N1  - S
20173284
PY  - 2010
SN  - 1049-2089
SP  - 38-50
ST  - Recruitment of African Americans to National Oncology Clinical Trials through a Clinical Trial Shared Resource
T2  - Journal of Health Care for the Poor and Underserved
TI  - Recruitment of African Americans to National Oncology Clinical Trials through a Clinical Trial Shared Resource
VL  - 21
ID  - 3127
ER  - 

TY  - JOUR
AB  - BACKGROUND: African-Americans have the highest overall age-adjusted cancer incidence and mortality rates of any population group in the United States. Despite this fact, this group remains underrepresented in cancer prevention and control research studies, primarily because most recruitment strategies result in limited access to African-American populations. METHODS: As part of three large-scale cancer prevention and control studies, effective strategies for recruiting African-American participants were developed and implemented. RESULTS: Eight strategies have been identified as successful recruitment strategies for involving African-Americans in cancer prevention and control studies. Utilizing these strategies resulted in recruiting a representative number of African-American participants, in relation to the local population, into the three studies. CONCLUSIONS: African-Americans can be recruited to participate in cancer control and prevention studies if plans include special strategies targeted to addressing unique barriers, beliefs, and concerns.
AD  - Department of Public Health Sciences, Bowman Gray School of Medicine, Winston-Salem, NC 27157-1063.
AN  - 8888322
AU  - Paskett, E. D.
AU  - DeGraffinreid, C.
AU  - Tatum, C. M.
AU  - Margitić, S. E.
DA  - Sep-Oct
DO  - 10.1006/pmed.1996.0088
DP  - NLM
ET  - 1996/09/01
IS  - 5
KW  - Adult
*African Americans
Breast Neoplasms/prevention & control
Clinical Trials, Phase III as Topic
Colonic Polyps/prevention & control
Female
Health Education/*methods
Humans
Male
Mass Screening
Neoplasms/*prevention & control
North Carolina
*Patient Selection
Prostatic Neoplasms/prevention & control
Randomized Controlled Trials as Topic
Uterine Cervical Neoplasms/prevention & control
LA  - eng
N1  - Paskett, E D
DeGraffinreid, C
Tatum, C M
Margitić, S E
CA-57016-03/CA/NCI NIH HHS/United States
M01-RR-07122/RR/NCRR NIH HHS/United States
N01-CN-05322/CN/NCI NIH HHS/United States
Journal Article
Research Support, U.S. Gov't, P.H.S.
United States
Prev Med. 1996 Sep-Oct;25(5):547-53. doi: 10.1006/pmed.1996.0088.
PY  - 1996
SN  - 0091-7435 (Print)
0091-7435
SP  - 547-53
ST  - The recruitment of African-Americans to cancer prevention and control studies
T2  - Prev Med
TI  - The recruitment of African-Americans to cancer prevention and control studies
VL  - 25
ID  - 738
ER  - 

TY  - JOUR
AB  - Introduction: We sought to understand the factors associated with recruitment activities while conducting a registry-based study of black women found to have breast cancer <age 50 to investigate mutations in the BRCA1 and BRCA2 genes. Methods: State mandated recruitment methods included TWO mailings, followed by a telephone response card for patients who did not wish to be contacted by phone. If no response was received within 3 weeks of the second mailing, the study team contacted the patient by phone. Results: Of the 209 eligible patients identified by the cancer registry, contact was established in 87, of whom 82 were eligible for study participation. The overall rate of interest in study participation was 80% (including 93% for those with passive follow-up and 68% for those with active follow-up), with the primary factor cited being the desire to understand more about the risk of cancer for family members. Conclusion: This is the first study conducted through a State Cancer Registry, in which the primary goal was to recruit participants for genetic counseling and testing for inherited breast cancer. In contrast to many prior studies, our results suggest that young black women with breast cancer are interested in participating in genetics studies.
AN  - WOS:000286654300012
AU  - Pal, T.
AU  - Rocchio, E.
AU  - Garcia, A.
AU  - Rivers, D.
AU  - Vadaparampil, S.
DA  - Jan-Feb
DO  - 10.1089/gtmb.2010.0098
IS  - 1-2
N1  - 21117951
PY  - 2011
SN  - 1945-0265
SP  - 69-77
ST  - Recruitment of Black Women for a Study of Inherited Breast Cancer Using a Cancer Registry-Based Approach
T2  - Genetic Testing and Molecular Biomarkers
TI  - Recruitment of Black Women for a Study of Inherited Breast Cancer Using a Cancer Registry-Based Approach
VL  - 15
ID  - 3103
ER  - 

TY  - JOUR
AB  - The recruitment of African Americans into cancer prevention and control studies has presented a major challenge to scientific investigators. Scientific findings, whether biomedical or behavioral, may not be appropriate and applicable to ethnic minority populations unless they are adequately represented as study participants. Moreover, the need to involve greater numbers of ethnic minorities is quite urgent due to the poor morbidity and mortality outcomes associated with ethnic minority group membership. Such is the case with breast cancer survivorship. The purpose of the study was to test a personalized recruitment strategy on response rate in African-American women. The response rate of 45% (n = 117) African Americans and 64% (n = 161) white subjects indicated only limited success in the recruitment of the African-American breast cancer survivors. The recruitment result suggests that culturally relevant recruitment strategies (e.g., inclusion of African-American investigators, culturally consistent letter of recruitment) may be insufficient in adequately increasing research participation. Therefore, further studies on investigating factors that influence research participation (eg, type of incentives, and schedule of payment as well as type of stationery and stamps used) are needed.
AD  - California School of Professional Psychology, Alhambra 91803-1360, USA.
AN  - 10365546
AU  - Ashing-Giwa, K.
C2  - PMC2608496
DA  - May
DP  - NLM
ET  - 1999/06/12
IS  - 5
KW  - African Americans/statistics & numerical data
*African Continental Ancestry Group
Breast Neoplasms/*ethnology/mortality/*prevention & control
European Continental Ancestry Group/statistics & numerical data
Female
Humans
Middle Aged
*Patient Selection
LA  - eng
N1  - Ashing-Giwa, K
CA63028/CA/NCI NIH HHS/United States
Journal Article
Research Support, U.S. Gov't, P.H.S.
J Natl Med Assoc. 1999 May;91(5):255-60.
PY  - 1999
SN  - 0027-9684 (Print)
0027-9684
SP  - 255-60
ST  - The recruitment of breast cancer survivors into cancer control studies: a focus on African-American women
T2  - J Natl Med Assoc
TI  - The recruitment of breast cancer survivors into cancer control studies: a focus on African-American women
VL  - 91
ID  - 719
ER  - 

TY  - JOUR
AB  - This report describes recruitment of minority cancer survivors for a randomized trial of I Can Cope, a support program of the American Cancer Society. Survivor Education and Evaluation (SURE), was designed to recruit patients, age 19 and older, with a primary cancer diagnosis. Recruitment was primarily carried out in a public hospital in Birmingham, Alabama. Of 373 patients approached, 226 were eligible for the study, 175 consented, and 140 were randomized during the 20-month recruitment period. Only 43 declined participation. This resulted in a 61.9% recruitment yield. The mean age of participants was 54.2 years (SD=10.9), 92 (65.7%) were female, and 111 (79.3%) were African American. Twenty-three different cancers were represented including breast (37.1%), colorectal (12.1%), hematologic (12.9%), and lung (7.1%). Over half (63%) had been diagnosed within 12 months. The experience of the SURE project provides evidence for optimism in recruiting racial minorities to cancer research studies.
AD  - Prevention Research Center, University of Kentucky, USA.
AN  - 21841287
AU  - Dignan, M.
AU  - Evans, M.
AU  - Kratt, P.
AU  - Pollack, L. A.
AU  - Pisu, M.
AU  - Smith, J. L.
AU  - Prayor-Patterson, H.
AU  - Houston, P.
AU  - Watson, C.
AU  - Hullett, S.
AU  - Martin, M. Y.
DA  - Aug
DO  - 10.1353/hpu.2011.0069
DP  - NLM
ET  - 2011/08/16
IS  - 3
KW  - *Adaptation, Psychological
Adult
African Americans/education
Aged
Alabama
American Cancer Society
Female
Health Education/*methods
Humans
Male
Middle Aged
Minority Groups/*education
Neoplasms/*ethnology
*Patient Selection
*Poverty
Program Evaluation
Survivors/*psychology
United States
LA  - eng
N1  - 1548-6869
Dignan, Mark
Evans, Mary
Kratt, Polly
Pollack, Lori A
Pisu, Maria
Smith, Judith Lee
Prayor-Patterson, Heather
Houston, Peter
Watson, Christopher
Hullett, Sandral
Martin, Michelle Y
U48/DP000567-1/DP/NCCDPHP CDC HHS/United States
Journal Article
Randomized Controlled Trial
Research Support, U.S. Gov't, P.H.S.
United States
J Health Care Poor Underserved. 2011 Aug;22(3):912-24. doi: 10.1353/hpu.2011.0069.
PY  - 2011
SN  - 1049-2089
SP  - 912-24
ST  - Recruitment of low income, predominantly minority cancer survivors to a randomized trial of the I Can Cope cancer education program
T2  - J Health Care Poor Underserved
TI  - Recruitment of low income, predominantly minority cancer survivors to a randomized trial of the I Can Cope cancer education program
VL  - 22
ID  - 386
ER  - 

TY  - JOUR
AB  - Purpose In March 2001, the National Colorectal Cancer Research Alliance (NCCRA) and OncoLink (http://www.oncolink.org) established a database to facilitate patient enrollment onto clinical trials. This study describes the population registering with the database and identifies discrepancies between individuals registering through the Internet and those registering through a telephone call center. Methods Participants registered with the NCCRA/OncoLink database through the Internet or a telephone call center. All participants entering the database completed a questionnaire regarding basic demographics, colon cancer risk factors, and indicated how they became aware of the database. Comparisons were made between individuals registering through the Internet and those registering through the telephone call center. Results A total of 2,162 participants registered during the first 16 months of the database. Most patients registered through the Internet rather than the telephone call center (88% v 12%; P < .001). More females than males registered (73% v 27%; P < .001). The majority (89%) were white. Participants registering through the Internet were younger than those registering through the call center (mean, 48.8 v 55.0 years; P < .001). There was no difference between the two groups with regard to sex or ethnicity. Conclusion The Internet has the potential to increase the likelihood that interested individuals find appropriate clinical trials. Some of the discrepancies that are known to exist for access to the Internet were also seen for those registering with the database through the Internet. Despite these differences, the potential to increase clinical trial enrollment with this type of Internet-based database is high. (C) 2004 by American Society of Clinical Oncology
AN  - WOS:000226236600012
AU  - Wei, S. J.
AU  - Metz, J. M.
AU  - Coyle, C.
AU  - Hampshire, M.
AU  - Jones, H. A.
AU  - Markowitz, S.
AU  - Rustgi, A. K.
DA  - Dec 1
DO  - 10.1200/JCO.2004.07.103
IS  - 23
N1  - 15
15570073
PY  - 2004
SN  - 0732-183X
SP  - 4730-4736
ST  - Recruitment of patients into an internet-based clinical trials database: The experience of OncoLink and the National Colorectal Cancer Research Alliance
T2  - Journal of Clinical Oncology
TI  - Recruitment of patients into an internet-based clinical trials database: The experience of OncoLink and the National Colorectal Cancer Research Alliance
VL  - 22
ID  - 2672
ER  - 

TY  - JOUR
AB  - Successful outcomes for studies on health disparities depend on recruitment of research participants. Obtaining willing participants, protecting their rights, and acknowledging their contribution to research is as important as seeking answers to the study phenomena. Recruiting research participants can be an arduous process for investigators. Although literature has published participant recruitment methods, investigators sometimes underestimate the time and intensity required to attract eligible participants into research studies. This article reports on methods used to recruit 42 African American generational triads (grandmothers, mothers, and granddaughters) into a hypertension genetics study, the lessons learned, and suggestions for successful recruitment.
AN  - WOS:000264453100010
AU  - Taylor, J. Y.
DA  - Apr
DO  - 10.1177/1043659608330352
IS  - 2
N1  - 19129518
PY  - 2009
SN  - 1043-6596
SP  - 219-226
ST  - Recruitment of Three Generations of African American Women Into Genetics Research
T2  - Journal of Transcultural Nursing
TI  - Recruitment of Three Generations of African American Women Into Genetics Research
VL  - 20
ID  - 3153
ER  - 

TY  - JOUR
AB  - Prostate cancer is the most common cancer in men in the United States. This is a complex disease with high heterogeneity and the exact causes are unknown in population-specific samples. Family history is a primary risk factor irrespective of race. Identifying prostate cancer families with multiple affected cancer cases is challenging. Herein we document recruitment techniques and present prostate cancer clinical factors described in a cohort of African Americans and Caucasians with or without a strong family history. A total of 521 prostate cancer patients (241 African Americans and 280 Caucasians) were identified using a novel cooperative methodology involving a combination of treating physicians and tumor registries. Higher prostate-specific antigen (PSA, P=0.0269) was found in familial cases as compared to sporadic cases in African-American men. In addition, PSA values for familial cases were higher (P=0.0093) in African-American as compared to Caucasian men. No differences were detected in Gleason score values in either race, regardless of family history. These findings remained the same after adjustment was made for age at diagnosis. In conclusion, methodologies for cohort acquisition, and clinical characteristics, are described for men with and without a family history of prostate cancer using both Caucasian and African-American populations.
AD  - Department of Genetics, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA. dmanda@Isuhsc.edu
AN  - 18268528
AU  - Mandal, D. M.
AU  - Sartor, O.
AU  - Halton, S. L.
AU  - Mercante, D. E.
AU  - Bailey-Wilson, J. E.
AU  - Rayford, W.
C2  - PMC2593398
C6  - NIHMS78458
DO  - 10.1038/pcan.2008.5
DP  - NLM
ET  - 2008/02/13
IS  - 3
KW  - Adult
African Americans/*statistics & numerical data
Age of Onset
Aged
Aged, 80 and over
Algorithms
Cohort Studies
European Continental Ancestry Group/*statistics & numerical data
*Family Health/ethnology
Humans
Male
Mass Screening/statistics & numerical data
Middle Aged
*Patient Selection
Prostate-Specific Antigen/blood
Prostatic Neoplasms/blood/diagnosis/epidemiology/*ethnology
LA  - eng
N1  - 1476-5608
Mandal, D M
Sartor, O
Halton, S L
Mercante, D E
Bailey-Wilson, J E
Rayford, W
R03 CA097778/CA/NCI NIH HHS/United States
R03 CA097778-03S1/CA/NCI NIH HHS/United States
1 RO3 CA97778-01/CA/NCI NIH HHS/United States
H57/CCH 624034-01/PHS HHS/United States
Comparative Study
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.
Prostate Cancer Prostatic Dis. 2008;11(3):274-9. doi: 10.1038/pcan.2008.5. Epub 2008 Feb 12.
PY  - 2008
SN  - 1365-7852 (Print)
1365-7852
SP  - 274-9
ST  - Recruitment strategies and comparison of prostate cancer-specific clinical data on African-American and Caucasian males with and without family history
T2  - Prostate Cancer Prostatic Dis
TI  - Recruitment strategies and comparison of prostate cancer-specific clinical data on African-American and Caucasian males with and without family history
VL  - 11
ID  - 505
ER  - 

TY  - JOUR
AB  - BACKGROUND: The importance of recruiting and retaining women from diverse populations is well recognized; however, the recruitment process often presents greater challenges at higher costs than initially anticipated. OBJECTIVES: To describe recruitment strategies and costs from a study evaluating women's preferences regarding tamoxifen use for primary prevention of breast cancer. DESIGN: Description and analysis of recruitment strategies, outcomes, and costs for a cross-sectional interview study. SETTING: University hospital and community sites. PARTICIPANTS: 932 racially and ethnically diverse women respondents, of whom 771 completed the screening process (aged 27-87). INTERVENTION: Women were recruited and screened by using the Breast Cancer Risk Assessment Program (BCRA version 1, National Cancer Institute). Eligibility required an estimated five-year breast cancer risk of at least 1.7%. Recruitment goals targeted a high percentage of ethnic minorities. METHODS: Recruitment strategies included direct mail, flyers, newspapers, media advertising, and community outreach. RESULTS: Of the 771 screened women, 341 (44%) met eligibility criteria and 255 (33%) completed interviews (76.9% White, 10.6% Latina, 7.0% Asian, 3.9% African American, 1.6% Native American). Recruitment costs averaged US $113/screened participant. Direct mail and community contact yielded the largest number of participants (312 screened, 205 eligible). Radio advertising provided few participants (one screened, one eligible) at high cost. CONCLUSIONS: Recruiting an ethnically diverse sample presented multiple challenges. We recommend that future studies budget adequately for recruitment time and costs, develop ongoing relationships with key community leaders, evaluate recruitment strategies closely, and report detailed recruitment findings to the research community.
AD  - Center for Health Services Research in Primary Care, University of California, Davis, Sacramento, CA 95817, USA. janet.keyzer@ucdmc.ucdavis.edu
AN  - 16108298
AU  - Keyzer, J. F.
AU  - Melnikow, J.
AU  - Kuppermann, M.
AU  - Birch, S.
AU  - Kuenneth, C.
AU  - Nuovo, J.
AU  - Azari, R.
AU  - Oto-Kent, D.
AU  - Rooney, M.
DA  - Summer
DP  - NLM
ET  - 2005/08/20
IS  - 3
KW  - Adult
Advertising
Aged
Aged, 80 and over
Anticarcinogenic Agents/therapeutic use
Breast Neoplasms/prevention & control
California
Community-Institutional Relations
Cross-Sectional Studies
Female
Humans
Interviews as Topic
Middle Aged
*Minority Groups
Patient Acceptance of Health Care
Patient Education as Topic
*Patient Selection
Postal Service
Research/economics/*organization & administration
Tamoxifen/therapeutic use
LA  - eng
N1  - Keyzer, Janet Fulton
Melnikow, Joy
Kuppermann, Miriam
Birch, Stephen
Kuenneth, Christina
Nuovo, Jim
Azari, Rahman
Oto-Kent, Debra
Rooney, Mairin
R01 CA 86043/CA/NCI NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, P.H.S.
United States
Ethn Dis. 2005 Summer;15(3):395-406.
PY  - 2005
SN  - 1049-510X (Print)
1049-510x
SP  - 395-406
ST  - Recruitment strategies for minority participation: challenges and cost lessons from the POWER interview
T2  - Ethn Dis
TI  - Recruitment strategies for minority participation: challenges and cost lessons from the POWER interview
VL  - 15
ID  - 591
ER  - 

TY  - JOUR
AB  - The National Lung Cancer Screening Trial (NLST) randomized current or former smokers who had quit within 15 years, 55‐75 years of age, to low dose CT or chest x‐ray and demonstrated a 20% reduction in lung cancer mortality.[1] Screening for lung cancer is different from other screening programs as those at risk are not clearly defined by age or sex. Potential recruitment strategies include provider referral; media or internet campaigns; or mass mailing to individuals identified through mailing lists. Direct mailing was used by the NLST, ITALUNG, NELSON, and the Prostate, Lung, Colorectal and Ovarian (PLCO) Screening trials [2,3,4,5]. This reached large numbers of potential participants but it was inefficient and costly. Almost 35% of the total enrollment in the NLST was recruited by direct mailing but this is only 0.2‐3.7% of those contacted by mail[2]. Media advertising and community outreach were used in PLCO, but were ineffective [4]. The Lung Screening Study (LSS) mailed 653,417 potential participants, and 4,828 (0.7% of the original mailing) were eligible [6]. The Pan Canadian Early Detection of Lung Cancer Study (PanCan) used mass mailing but also media, posters, websites, and general practitioners and a toll‐ free number. Of 7044 individuals initially considered, 36% were ultimately eligible for screening [7]. The Veterans Affairs Lung Cancer Screening Program used the Electronic Medical Record (EMR) to identify potential participants but primary care physicians determined if patients were appropriate for screening. Of 18,083 potential candidates, only 5035 were assessed by their primary care physician. Of those considered appropriate, 50% went on to be screened. Tthe participation of the primary care physician was key to successful recruitment [8]. The UK Lung Screen (ULKLS) used a population based approach through local primary care records, 23,794 (26.8%) of those contacted indicated willingness to participate in a screening study. Ex‐smokers, those of higher socioeconomic status and in the 66‐70 year age group were more likely to participate. Men and women were equally willing to participate[9]. Wake Forest University School of Medicine identified that their NLST participants` did not reflect local demographics as only 3% of participants were black whereas blacks represented 25% of the local population [10]. PLCO strategies to increase participation among the black population included support from a prominent black business owner and local churches, including black individuals in the planning team, in community outreach and as interviewers. Focus groups or semi‐structured interviews have identified that using members of ethnic minorities to promote or recruit are more likely to be successful in these groups [11]. Recruitment through primary care or other respected individuals in the community is also important. [12] Observations from NLST included: “go to where the smokers are”; build trust through local physicians; and use recruiters of the same ethnicity as target populations [3]. Interviews with current smokers identified themes that may contribute to reduced participation including fatalism, fear of diagnosis/ treatment, pessimism about survival and stigma that lung cancer was a self‐inflicted disease [13] Cancer Care Ontario High Risk Lung Cancer Screening Pilot: Cancer Care Ontario (CCO) launched a pilot screening program on June 1, 2017, at three centers that differed based on demographics, geography and academic or community hospital. Individuals are recruited, assessed for eligibility, screened and followed. The Tammemӓgi Risk Prediction model was used to identify eligible individuals. Those with a risk score ≥2% were eligible. Provider and public‐led recruitment strategies were used. A major aim of the pilot was to recruit individuals who are known to have the highest rates of cigarette smoking: lower socioeconomic status (SES) and First Nations, Inuit and Metis.Areas of predicted high risk populations were identified within the catchment area of each pilot site. Marke research was used to recommend recruitment modalities (eg TV, radio or print) for specific sub‐groups such as lower SES, older middle‐income suburbanites, and rural populations. An accredited Continuing Professional Development course was developed for primary care and collaborative educational sessions were held with primary care providers and First Nations, Inuit and Métis provider groups. In the first year, 3294 individuals were recruited. The majority 3294 (81%) were physician referred (Table 1). The leading methods of recruitment were physician referrals (65%), newspaper advertisements (11%), word of mouth (6%) and nurse practitioners (6%). Only 4% of individuals identified as First Nations, Inuit or Métis. Level of education at high school or lower was self‐reported by 48% of individuals. Based on early results, June – November 2017, approximately 27% of eligible individuals were recruited from low income postal codes (average annual household income < $70,000 CAD).Health Sciences North used primary care providers to identify and refer potential participants leading to the highest participation rate across all three centres. The Ottawa Hospital utilized media recruitment methods which led to a high number of applicants but eligibility was lower than for physician referred participants. Provider‐led recruitment was more successful at reaching target populations and enlisting eligible participants. At Lakeridge Heath, provider‐led strategies were less successful, so public‐led recruitment strategies were increased. Public‐led methods such as road shows and newspaper were used and led to a boost in volumes. Conclusions: First year CCO pilot results have shown that provider‐led recruitment strategies have been effective in enrolling appropriate individuals and is the primary source of recruitment for the pilot. Importantly, the proportion of eligible individuals recruited through their primary care physician is double that reported in the PANCAN study. Providers were also important in the VHA study. Use of Emr is helpful in identification of potentially eligible individuals. Mass mailing may reach more individuals, but is costly and inefficient. Our results demonstrate that support from primary care physicians is important in successful recruitment to lung cancer screening. Recruitment of First Nations, Inuit or Métis and those with a lower socioeconomic status remains a challenge. Utilizing previously identified strategies such as respected individuals in FNIM communities as well as members of ethnic minorities to promote the program and recruit participants will likely improve recruitment in these hard to reach populations. References: 1. Aberle DR, Adams AM, Berg CD et al. Reduced lung cancer mortality with low‐dose computed tomographic screening, NEng J Med. 2011; 365:395‐409 2. Marcus PM, Sammons D, Balc W, Garg K. Recruitment methods employed in the National Lung Screening Trial. J Med Screen 2012; 19:94‐102. https://doi.org/10.1256/jms.2012.012016. 3, Simpson NK, Johnson CC, Trocky N, et al. Recruitment Strategies in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: The first six years. Control Clin Trials 2000; 21: 356S‐378S. 4. Lopes PA, Picozzi G, Mascalchi M, et al. Design, recruitment and baseline results of the ITALUNG trial for lung cancer screening with low‐dose CT. Lung Cancer. 2009; 64: 34‐40. https://doi.org/10.1016/j.lungcan.2008.07.003 5. Yousaf‐Khan U, Horeweg N, van der Aalst C, et al. Baseline characteristics and mortality outcomes of control group participants and eligible non‐responders in the NELSON Lung Cancer Screening Study. J Thorac Oncol 2015; 10:747‐53. https://doi.org/10.1097/JTO.0000000000000488.] 6. Gohagan J, Marcus P, Fagerstrom R, et al. Baseline findings of a randomized feasibility trial of lung cancer screening with spiral CT scan vs chest radiograph. Chest 2004; 126: 114‐121. 7. Tammemagi, MC, Schmidt H, Martel S, et al. Participant selection for lung cancer screening by risk modelling (the Pan‐Canadian Early De ection of Lung Cancer [PanCan] study): a single‐arm, prospective study. Lancet Oncol. 2017; 18: 1523‐31. https://doi.org/10.1016/S1470‐2045(1730597‐1). 8. Kisinger LS, Anderson C, Kim J et al. Implementation of Lung Cancer Screening in the Veterans Health Administration. JAMA Intern Med. 2017; 177: 399‐406. https://doi.org/10.001/jamainternmed.2016.9022. 9. McRonald FE, Yadegarfar G, Baldwin DR. et al. The UK Lung Screen (UKLS): Demographic Profile of first 88,897 approaches provides recommendation for population screening. Cancer Prev Res. 2014;7: 362‐371. https://doi.org/1‐.1158/1940‐6206. 10. Hinshaw LB, Jackson SA, Chen MY. Direct mailing was a successful recruitment strategy for a lung‐cancer screening trial. J Clin Epidem. 2007; 60:853‐857. 11. Stallings FL, Ford ME, Simpson NK, et al. Black Participation in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. Control Clin Trials 2000; 21: 379S‐389S. 12. das Nair R, Orr KS, Vedhara K, Kendrick D. Exploring recruitment barriers and facilitators in early cancer detection trials: the use of pre‐trial focus groups. Trials 2014; 15: 98. 13. Quaife SL, Marlow LAV, McEwen A, Janes SM, Wardle J. Attitudes towards lung cancer screening in socioeconomically deprived and heavy smoking communities: informing screening communication. Health Expectations 2017; 20: 563‐573. https://doi.org/10.1111/hex.12481 [Figure presented]
AN  - CN-01654328
AU  - Darling, G.
AU  - Sandhu, N.
AU  - Mora, L.
DO  - 10.1016/j.jtho.2018.08.155
IS  - 10
KW  - *cancer screening
*lung cancer
Advertising
Aged
Black person
Cancer mortality
Cancer survival
Catchment
Cigarette smoking
Colorectal cancer
Community hospital
Conference abstract
Controlled study
Demography
Diagnosis
Early cancer diagnosis
Electronic medical record
Ethnicity
Expectation
Fear
Feasibility study
Female
First Nation
Forest
General practitioner
Health science
High risk population
High school
Household income
Human
Internet
Inuit
Low drug dose
Lowest income group
Major clinical study
Male
Marketing
Metis
Middle income group
Multicenter study
Nurse practitioner
Ontario
Ovary cancer
Patient referral
Pessimism
Prediction
Professional development
Prospective study
Prostate cancer
Publication
Randomized controlled trial
Religion
Rural population
Semi structured interview
Spiral computer assisted tomography
Stigma
Suburban population
Thorax radiography
Trust
Veterans health
M3  - Journal: Conference Abstract
PY  - 2018
SP  - S273‐S274
ST  - Recruitment Strategies for the Lung Cancer Screening
T2  - Journal of thoracic oncology
TI  - Recruitment Strategies for the Lung Cancer Screening
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01654328/full
VL  - 13
ID  - 1497
ER  - 

TY  - JOUR
AD  - Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL, USA, Center for Molecular Innovation and Drug Discovery, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
Department of Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
Health Economics Center, Institute for Health Care Studies, Northwestern University Feinberg School of Medicine, Chicago, IL, USA, Department of Psychiatry and Behavioral Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
Clinical and Translational Sciences Institute, Northwestern University Feinberg School of Medicine, IL, USA
AN  - 104259064. Language: English. Entry Date: 20130408. Revision Date: 20200708. Publication Type: Journal Article
AU  - Dew, Alexander
AU  - Khan, Seema
AU  - Babinski, Christie
AU  - Michel, Nancy
AU  - Heffernan, Marie
AU  - Stephan, Stefanie
AU  - Jordan, Neil
AU  - Jovanovic, Borko
AU  - Carney, Paula
AU  - Bergan, Raymond
DB  - CINAHL Complete
DO  - 10.1177/1740774512471452
DP  - EBSCOhost
IS  - 2
KW  - Breast Neoplasms -- Prevention and Control
Minority Groups
Research Subject Recruitment -- Illinois
Costs and Cost Analysis
Clinical Trials
Human
Advertising
Illinois
Genistein -- Therapeutic Use
Isoflavones -- Therapeutic Use
Adult
Middle Age
White Persons
Black Persons
Asians
Native Americans
Hispanic Americans
Fisher's Exact Test
Funding Source
N1  - research; tables/charts. Journal Subset: Biomedical; Europe; UK & Ireland. Grant Information: This research was conducted with funding from the US National Institutes of Health, N01-CN-35157 (to R.B.) and UL1RR025741, and from the Avon Foundation (to S.K.).. NLM UID: 101285473.
PMID: NLM23321266.
PY  - 2013
SN  - 1740-7745
SP  - 292-299
ST  - Recruitment strategy cost and impact on minority accrual to a breast cancer prevention trial
T2  - Clinical Trials
TI  - Recruitment strategy cost and impact on minority accrual to a breast cancer prevention trial
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104259064&site=ehost-live&scope=site
VL  - 10
ID  - 2072
ER  - 

TY  - JOUR
AB  - BACKGROUND: Recruiting ethnically diverse Black participants to an innovative, community-based research study to reduce colorectal cancer screening disparities requires multipronged recruitment techniques. OBJECTIVES: This article describes active, passive, and snowball recruitment techniques, and challenges and lessons learned in recruiting a diverse sample of Black participants. METHODS: For each of the three recruitment techniques, data were collected on strategies, enrollment efficiency (participants enrolled/participants evaluated), and reasons for ineligibility. RESULTS: Five hundred sixty individuals were evaluated, and 330 individuals were enrolled. Active recruitment yielded the highest number of enrolled participants, followed by passive and snowball. Snowball recruitment was the most efficient technique, with enrollment efficiency of 72.4%, followed by passive (58.1%) and active (55.7%) techniques. There were significant differences in gender, education, country of origin, health insurance, and having a regular physician by recruitment technique (p < .05). DISCUSSION: Multipronged recruitment techniques should be employed to increase reach, diversity, and study participation rates among Blacks. Although each recruitment technique had a variable enrollment efficiency, the use of multipronged recruitment techniques can lead to successful enrollment of diverse Blacks into cancer prevention and control interventions.
AD  - Stacy N. Davis, PhD, MPH, is Instructor, School of Public Health, the Rutgers, the State University of New Jersey, New Brunswick. At the time this research was completed, she was a Postdoctoral Fellow at Health Outcomes and Behavior, Moffitt Cancer Center and Research Institute, Tampa, Florida. Swapamthi Govindaraju, BA, was Research Assistant, Moffitt Cancer Center and Research Institute, Tampa, Florida, when the research was conducted. Brittany Jackson, MPH, was Research Assistant, Moffitt Cancer Center and Research Institute, Tampa, Florida, when the research was conducted. Kimberly R. Williams, MPH, MS, is Research Assistant, Moffitt Cancer Center and Research Institute, Tampa, Florida. Shannon M. Christy, PhD, is Assistant Professor, University of Tennessee Health Science Center, Memphis. At the time this research was completed, she was a Postdoctoral Fellow at Health Outcomes and Behavior, Moffitt Cancer Center and Research Institute, Tampa, Florida. Susan T. Vadaparampil, PhD, is Senior Member, Moffitt Cancer Center and Research Institute, Tampa, Florida, and Professor, University of South Florida College of Medicine, Tampa, Florida. Gwendolyn P. Quinn, PhD, is Livia Wan Endowed Chair, New York University Medical Center, New York. At the time this research was completed, she was a Senior Member at Health Outcomes and Behavior, Moffitt Cancer Center and Research Institute, Tampa, Florida, and Professor University of South Florida College of Medicine, Tampa, Florida. David Shibata, MD, is Professor, University of Tennessee Health Science Center, Memphis. At the time this research was underway, he was a Senior Member at Moffitt Cancer Center and Research Institute, Tampa, Florida. Richard Roetzheim, MD, is Senior Member, Moffitt Cancer Center and Research Institute, Tampa, Florida, and Professor, University of South Florida College of Medicine, Tampa, Florida. Cathy D. Meade, PhD, RN, FAAN, is Senior Member, Moffitt Cancer Center and Research Institute, Tampa, Florida, and Professor, University of South Florida College of Medicine, Tampa, Florida. Clement K. Gwede, PhD, MPH, RN, FAAN, is Senior Member, Moffitt Cancer Center and Research Institute, Tampa, Florida, and Professor, University of South Florida College of Medicine, Tampa, Florida.
AN  - 29698327
AU  - Davis, S. N.
AU  - Govindaraju, S.
AU  - Jackson, B.
AU  - Williams, K. R.
AU  - Christy, S. M.
AU  - Vadaparampil, S. T.
AU  - Quinn, G. P.
AU  - Shibata, D.
AU  - Roetzheim, R.
AU  - Meade, C. D.
AU  - Gwede, C. K.
C2  - PMC5925754
C6  - NIHMS932227
DA  - May/Jun
DO  - 10.1097/nnr.0000000000000274
DP  - NLM
ET  - 2018/04/27
IS  - 3
KW  - *African Americans
Colorectal Neoplasms/diagnosis/*prevention & control
Community-Based Participatory Research
*Early Detection of Cancer
Educational Status
Emigrants and Immigrants
Female
Humans
Insurance, Health
Male
Middle Aged
*Patient Selection
Sex Factors
United States
LA  - eng
N1  - 1538-9847
Davis, Stacy N
Govindaraju, Swapamthi
Jackson, Brittany
Williams, Kimberly R
Christy, Shannon M
Vadaparampil, Susan T
Quinn, Gwendolyn P
Shibata, David
Roetzheim, Richard
Meade, Cathy D
Gwede, Clement K
P30 CA076292/CA/NCI NIH HHS/United States
R25 CA090314/CA/NCI NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Nurs Res. 2018 May/Jun;67(3):212-221. doi: 10.1097/NNR.0000000000000274.
PY  - 2018
SN  - 0029-6562 (Print)
0029-6562
SP  - 212-221
ST  - Recruitment Techniques and Strategies in a Community-Based Colorectal Cancer Screening Study of Men and Women of African Ancestry
T2  - Nurs Res
TI  - Recruitment Techniques and Strategies in a Community-Based Colorectal Cancer Screening Study of Men and Women of African Ancestry
VL  - 67
ID  - 126
ER  - 

TY  - JOUR
AB  - Reducing or eliminating persistent disparities in lung cancer incidence and survival has been challenging because our current understanding of lung cancer biology is derived primarily from populations of European descent. Here we show results from a targeted sequencing panel using NCI-MD Case Control Study patient samples and reveal a significantly higher prevalence of PTPRT and JAK2 mutations in lung adenocarcinomas among African Americans compared with European Americans. This increase in mutation frequency was validated with independent WES data from the NCI-MD Case Control Study and TCGA. We find that patients carrying these mutations have a concomitant increase in IL-6/STAT3 signaling and miR-21 expression. Together, these findings suggest the identification of these potentially actionable mutations could have clinical significance for targeted therapy and the enrollment of minority populations in clinical trials.
AD  - Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, Bethesda, MD, 20892, USA.
Genetics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, 20892, USA.
Palantir Technologies, 1025 Thomas Jefferson St, Washington, DC, 20007, USA.
Cancer Data Science Laboratory, Center for Cancer Research, National Cancer Institute, Bethesda, MD, 20892, USA.
NIAID Collaborative Bioinformatics Resource, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, 20892, USA.
Advanced Biomedical Computational Science, Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, Frederick, MD, 21702, USA.
Personal Genome Diagnostics, Baltimore, MD, 21124, USA.
Rutgers Cancer Institute of New Jersey, Robert Wood Johnson Medical School, Rutgers, The State University of New Jersey, New Brunswick, NJ, 08854, USA.
Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, Bethesda, MD, 20892, USA. Brid.Ryan@nih.gov.
AN  - 31844068
AU  - Mitchell, K. A.
AU  - Nichols, N.
AU  - Tang, W.
AU  - Walling, J.
AU  - Stevenson, H.
AU  - Pineda, M.
AU  - Stefanescu, R.
AU  - Edelman, D. C.
AU  - Girvin, A. T.
AU  - Zingone, A.
AU  - Sinha, S.
AU  - Bowman, E.
AU  - Rossi, E. L.
AU  - Arauz, R. F.
AU  - Jack Zhu, Y.
AU  - Lack, J.
AU  - Weingartner, E.
AU  - Waterfall, J. J.
AU  - Pine, S. R.
AU  - Simmons, J.
AU  - Meltzer, P.
AU  - Ryan, B. M.
C2  - PMC6915783
DA  - Dec 16
DO  - 10.1038/s41467-019-13732-y
DP  - NLM
ET  - 2019/12/18
IS  - 1
KW  - Adenocarcinoma of Lung/*genetics
African Americans/*genetics
Aged
Case-Control Studies
DNA Mutational Analysis
European Continental Ancestry Group/genetics
Female
Health Status Disparities
Humans
Interleukin-6/metabolism
Janus Kinase 2/*genetics
Lung Neoplasms/*genetics
Male
MicroRNAs/metabolism
Middle Aged
Mutation
Receptor-Like Protein Tyrosine Phosphatases, Class 2/*genetics
STAT3 Transcription Factor/metabolism
Signal Transduction/genetics
LA  - eng
N1  - 2041-1723
Mitchell, Khadijah A
Orcid: 0000-0001-7639-9351
Nichols, Noah
Orcid: 0000-0001-9309-1295
Tang, Wei
Orcid: 0000-0002-7089-4391
Walling, Jennifer
Orcid: 0000-0003-0591-1287
Stevenson, Holly
Orcid: 0000-0002-6143-7615
Pineda, Marbin
Stefanescu, Roxana
Edelman, Daniel C
Girvin, Andrew T
Zingone, Adriana
Sinha, Sanju
Bowman, Elise
Rossi, Emily L
Arauz, Rony F
Orcid: 0000-0001-7382-0913
Jack Zhu, Yuelin
Lack, Justin
Weingartner, Elizabeth
Waterfall, Joshua J
Orcid: 0000-0002-3762-5050
Pine, Sharon R
Orcid: 0000-0001-5318-0277
Simmons, John
Meltzer, Paul
Ryan, Bríd M
Orcid: 0000-0003-0038-131x
P30 CA072720/CA/NCI NIH HHS/United States
R01 CA239093/CA/NCI NIH HHS/United States
Journal Article
Research Support, N.I.H., Intramural
Nat Commun. 2019 Dec 16;10(1):5735. doi: 10.1038/s41467-019-13732-y.
PY  - 2019
SN  - 2041-1723
SP  - 5735
ST  - Recurrent PTPRT/JAK2 mutations in lung adenocarcinoma among African Americans
T2  - Nat Commun
TI  - Recurrent PTPRT/JAK2 mutations in lung adenocarcinoma among African Americans
VL  - 10
ID  - 56
ER  - 

TY  - JOUR
AB  - Background: In Ethiopia, there were greater than 2000 adult and 200 pediatric cancer patients annually in 2010, but the estimated number of cancer patients were increasing. Oncologic rehabilitation treatment may result in improved physical and mental impairment. There is a paucity of information about rehabilitation service utilization among cancer patients in Ethiopia. Hence, the purpose of this study was to assess the rehabilitation service for cancer patient and associated factors at Black Lion hospital, Addis Ababa, Ethiopia. Methods: A hospital-based cross-sectional quantitative study was conducted from March to April 2014. Convenient sampling method was employed to recruit the study participants. Interviewer administered questionnaire was used to collect data. Data were entered into EPI data version 3.1 and exported to SPSS (16.0) software for analysis. Descriptive analysis, binary and multiple logistic regression were carried out. Significance association was interpreted using adjusted odds ratio at 95% confidence interval and p-value less than 0.05. Result: A sample of 423 patients aged 18 years and older were involved in the study. Breast cancer (25%), colorectal cancer (20.6%), cervical cancer (14.7%), lymphoma (7.7%), lung (7.2%), leukemia (5.4%), kidney (3.6%) and prostate cancer (2.6%) were the common forms of cancer diagnosed at cancer unit of the Black Lion Hospital. Twenty six percent of cancer patients received rehabilitation service at least once. The main rehabilitation services given were nutritional and psychological support. Unavailability of supplies, lack of professionals and cost of service were among the barriers to receiving rehabilitation services. Conclusion: Only a few cancer patients received cancer rehabilitation services. Increasing the knowledge of the professionals, stocking cancer units with necessary supplies, and other comprehensive programs are needed.
AD  - College of Health and Medical Sciences, Haramaya University, PO. Box 235, Harar, Ethiopia
School of Allied Health, Department of Nursing and Midwifery, College of Health Science, Addis Ababa University, Addis Ababa, Ethiopia
AN  - 126279373. Language: English. Entry Date: 20171122. Revision Date: 20180205. Publication Type: Article
AU  - Worku, Teshager
AU  - Semahegn, Agumasie
AU  - Tesfaye, Gezahegn
AU  - Mengistu, Zuriash
DB  - CINAHL Complete
DO  - 10.1186/s12904-017-0235-7
DP  - EBSCOhost
KW  - Cancer Patients -- Evaluation
Rehabilitation, Cancer
Hospitals
Human
Cross Sectional Studies
Ethiopia
Geographic Locations
Oncology
Physical Activity
Mental Health
Quantitative Studies
Questionnaires
Research Subject Recruitment
Data Analysis Software
Interviews
Odds Ratio
Confidence Intervals
Breast Neoplasms -- Diagnosis
Colorectal Neoplasms
Cervix Neoplasms
Female
Lymphoma
Health Resource Utilization
Male
Adolescence
Adult
Middle Age
N1  - research; tables/charts. Journal Subset: Biomedical; Europe; Nursing; UK & Ireland. NLM UID: 101088685.
PY  - 2017
SN  - 1472-684X
SP  - 1-7
ST  - Rehabilitation for cancer patients at Black Lion hospital, Addis Ababa, Ethiopia: a cross-sectional study
T2  - BMC Palliative Care
TI  - Rehabilitation for cancer patients at Black Lion hospital, Addis Ababa, Ethiopia: a cross-sectional study
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=126279373&site=ehost-live&scope=site
VL  - 16
ID  - 2074
ER  - 

TY  - JOUR
AB  - Objectives: We assessed the relation of childhood sexual abuse (CSA), intimate partner violence (IPV), and depression to HIV sexual risk behaviors among Black men who have sex with men (MSM). Methods: Participants were 1522 Black MSM recruited from 6 US cities between July 2009 and December 2011. Univariate and multivariable logistic regression models were used. Results: Participants reported sex before age 12 years with someone at least 5 years older (31.1%), unwanted sex when aged 12 to 16 years (30%), IPV (51.8%), and depression (43.8%). Experiencing CSA when aged 12 to 16 years was inversely associated with any receptive condomless anal sex with a male partner (adjusted odds ratio [AOR] = 0.50; 95% confidence interval [CI] = 0.29, 0.86). Pressured or forced sex was positively associated with any receptive anal sex (AOR = 2.24; 95% CI = 1.57, 3.20). Experiencing CSA when younger than 12 years, physical abuse, emotional abuse, having been stalked, and pressured or forced sex were positively associated with having more than 3 male partners in the past 6 months. Among HIV-positive MSM (n = 337), CSA between ages 12 and 16 years was positively associated with having more than 3 male partners in the past 6 months. Conclusions: Rates of CSA, IPV, and depression were high, but associations with HIV sexual risk outcomes were modest. (PsycINFO Database Record (c) 2017 APA, all rights reserved)
AD  - Williams, John K., University of California, Los Angeles, Department of Psychiatry and Biobehavioral Sciences, Semel Institute for Neuroscience and Human Behavior, 760 Westwood Plaza, 38-260, Los Angeles, CA, US, 90024-1759
AN  - 2015-51572-016
AU  - Williams, John K.
AU  - Wilton, Leo
AU  - Magnus, Manya
AU  - Wang, Lei
AU  - Wang, Jing
AU  - Dyer, Typhanye Penniman
AU  - Koblin, Beryl A.
AU  - Hucks-Ortiz, Christopher
AU  - Fields, Sheldon D.
AU  - Shoptaw, Steve
AU  - Stephenson, Rob
AU  - O'Cleirigh, Conall
AU  - Cummings, Vanessa
DB  - psyh
DO  - 10.2105/AJPH.2015.302878
DP  - EBSCOhost
IS  - 12
KW  - sexual abuse
intimate partner violence
depression
risk factors
HIV
Blacks
men who have sex with men
Same Sex Intercourse
N1  - Department of Psychiatry and Biobehavioral Sciences, Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles (UCLA), Los Angeles, CA, US. Institutional Authors: HIV Prevention Trials Network 061 Study Team. Release Date: 20161215. Correction Date: 20170306. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: English. Major Descriptor: Blacks; HIV; Intimate Partner Violence; Risk Factors; Same Sex Intercourse. Minor Descriptor: Sexual Abuse. Classification: Psychological & Physical Disorders (3200). Population: Human (10); Male (30). Location: US. Age Group: Adulthood (18 yrs & older) (300); Young Adulthood (18-29 yrs) (320); Thirties (30-39 yrs) (340); Middle Age (40-64 yrs) (360). Tests & Measures: Center for Epidemiologic Studies Depression Scale. Methodology: Empirical Study; Quantitative Study. Page Count: 9. Issue Publication Date: Dec, 2015. Publication History: Accepted Date: Aug 18, 2015.
Sponsor: National Institute of Allergy and Infectious Diseases/National Institute on Drug Abuse/National Institute of Mental Health, US. Grant: Cooperative Agreements UM1 AI068619; UM1 AI068617; UM1 AI068613. Other Details: HIV Prevention Trials Network (HPTN) 061. Recipients: No recipient indicated
Sponsor: Harvard University Centers for AIDS Research (CFAR), Fenway Institute CRS, US. Grant: P30 AI060354. Recipients: No recipient indicated
Sponsor: Clinical Trials Unit (CTU) for HIV Prevention and Microbicide Research. Recipients: No recipient indicated
Sponsor: George Washington University, District of Columbia Developmental CFAR, US. Grant: P30 AI087714. Other Details: CRS. Recipients: No recipient indicated
Sponsor: Columbia University, Harlem Prevention Center CRS, NY Blood Center/Union Square CRS, US. Grant: 5U01 AI069466. Recipients: No recipient indicated
Sponsor: Sponsor name not included. Grant: 3U01 AI069466-03S1. Other Details: American Recovery and Reinvestment Act (ARRA) funding. Recipients: No recipient indicated
Sponsor: Emory University, HIV/AIDS CTU, Hope Clinic, Emory Vaccine Center CRS, Ponce de Leon Center CRS, US. Grant: 5U01 AI069418. Recipients: No recipient indicated
Sponsor: Emory University, HIV/AIDS CTU, CFAR, US. Grant: P30 AI050409. Recipients: No recipient indicated
Sponsor: Sponsor name not included. Grant: UL1 RR025008. Other Details: Clinical and Translational Science Awards (CTSA). Recipients: No recipient indicated
Sponsor: San Francisco Vaccine and Prevention CRS, US. Grant: 3U01 AI069496-03S1; 3U01 AI069496-03S2. Other Details: ARRA. Recipients: No recipient indicated
Sponsor: UCLA, UCLA Department of Medicine, Division of Infectious Diseases CTU, US. Grant: U01 AI069424. Other Details: Vine Street CRS. Recipients: No recipient indicated
Sponsor: UCLA, Center for HIV Identification, Prevention, and Treatment Services, US. Grant: P30MH58107. Recipients: No recipient indicated
PY  - 2015
SN  - 0090-0036
1541-0048
SP  - 2473-2481
ST  - Relation of childhood sexual abuse, intimate partner violence, and depression to risk factors for HIV among Black men who have sex with men in 6 US cities
T2  - American Journal of Public Health
TI  - Relation of childhood sexual abuse, intimate partner violence, and depression to risk factors for HIV among Black men who have sex with men in 6 US cities
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2015-51572-016&site=ehost-live&scope=site
keoniwmd@aol.com
VL  - 105
ID  - 1744
ER  - 

TY  - JOUR
AB  - We investigated the relationship of body size and prostate cancer risk in the Multiethnic Cohort, a longitudinal study of individuals ages 45 to 75 in Hawaii and in California. Self-reported measures of height and weight were obtained at baseline. Of 83,879 men enrolled from 1993 to 1996, a total of 5,554 were diagnosed with prostate cancer during an average of 9.6 years of follow-up. The influence of baseline weight and weight change since age 21 varied by ethnic group. Whites gaining more than 10 lbs had a nonlinear, increased risk of advanced and high-grade prostate cancer [relative risks (RR), 2.12; 95% confidence intervals (CI), 1.19-3.78 for 25-39.9 lbs; P trend 0.43; and RR, 1.49; 95% CI, 1.04-2.14, for ≥40 lbs; P trend 0.20, respectively]. African American men gaining 40 lbs or more (relative to <10 lbs) had a nonmonotonic, increased risk of localized prostate cancers (RR, 1.26; 95% CI, 1.02-1.54; P trend 0.09) and those who gained 25 lbs or more were at increased risk of low-grade disease (RR, 1.28; 95% CI, 1.03-1.58, for ≥40 versus 10 lbs, respectively; P trend 0.07). Japanese men had a statistically significant, inverse association of weight gain and localized disease (RR, 0.80; 95% CI, 0.65-0.99 for ≥40 versus 10 lbs; P trend 0.05). Our findings provide evidence that adiposity and changes in adiposity between younger and older adulthood influence the development of prostate cancer. Ethnic differences in risk may be explained by variation in the distribution of accumulated body fat that could differentially affect prostate carcinogenesis. Copyright © 2009 American Association for Cancer Research.
AD  - B. Y. Hernandez, 1236 Lauhala Street, Honolulu, HI 96813, United States
AU  - Hernandez, B. Y.
AU  - Park, S. Y.
AU  - Wilkens, L. R.
AU  - Henderson, B. E.
AU  - Kolonel, L. N.
DB  - Embase
Medline
DO  - 10.1158/1055-9965.EPI-09-0293
IS  - 9
KW  - adult
aged
anthropometry
article
body height
body mass
body size
cancer risk
controlled study
disease severity
ethnic difference
human
major clinical study
male
obesity
priority journal
prostate cancer
United States
body weight change
body weight gain
LA  - English
M3  - Article
N1  - L355317534
2009-10-27
PY  - 2009
SN  - 1055-9965
SP  - 2413-2421
ST  - Relationship of body mass, height, and weight gain to prostate cancer risk in the multiethnic cohort
T2  - Cancer Epidemiology Biomarkers and Prevention
TI  - Relationship of body mass, height, and weight gain to prostate cancer risk in the multiethnic cohort
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L355317534&from=export
http://dx.doi.org/10.1158/1055-9965.EPI-09-0293
http://cebp.aacrjournals.org/content/18/9/2413.full.pdf+html
VL  - 18
ID  - 1181
ER  - 

TY  - JOUR
AB  - Background: Early-onset baldness has been linked to prostate cancer; however, little is known about this relationship in AfricanAmericans who are at elevated prostate cancer risk. Methods: We recruited 219 African-American controls and 318 African-American prostate cancer cases. We determined age-stratified associations of baldness with prostate cancer occurrence and severity defined by high stage (T3/T4) or high grade (Gleason 7+.) Associations of androgen metabolism genotypes (CYP3A4, CYP3A5, CYP3A43, AR-CAG, SRD5A2 A49T, and SRD5A2 V89L), family history, alcohol intake, and smoking were examined by baldness status and age group by using multivariable logistic regression models. Results: Baldness was associated with odds of prostate cancer [OR 1.69; 95% confidence interval (CI), 1.05- 2.74]. Frontal baldness was associated with high-stage (OR 2.61; 95% CI, 1.10-6.18) and high-grade (OR 2.20; 95% CI, 1.05-4.61) tumors. Formendiagnosed less than the age of 60 years, frontal baldness was associated with high stage (OR 6.51; 95% CI, 2.11-20.06) and high grade (OR 4.23; 95% CI, 1.47-12.14). We also observed a suggestion of an interaction among smoking, median age, and any baldness (P 0.02). Conclusions: We observed significant associations between early-onset baldness and prostate cancer in African-American men. Interactions with age and smoking were suggested in these associations. Studies are needed to investigate the mechanisms influencing the relationship between baldness and prostate cancer in African-American men. Impact: African-American men present with unique risk factors including baldness patterns that may contribute to prostate cancer disparities. © 2013 American Association for Cancer Research.
AD  - C. Zeigler-Johnson, Department of Biostatistics and Epidemiology, University of Pennsylvania School of Medicine, 220 Blockley Hall, 423 Guardian Drive, Philadelphia, PA 19104, United States
AU  - Zeigler-Johnson, C.
AU  - Morales, K. H.
AU  - Spangler, E.
AU  - Chang, B. L.
AU  - Rebbeck, T. R.
DB  - Embase
Medline
DO  - 10.1158/1055-9965.EPI-12-0944
IS  - 4
KW  - androgen
cytochrome P450 3A5
steroid 5alpha reductase 2
adult
African American
aged
alcohol consumption
alopecia
androgen metabolism
article
cancer grading
cancer risk
cancer staging
controlled study
disease severity
early onset baldness
family history
genotype
Gleason score
human
major clinical study
male
men's health
onset age
priority journal
prostate cancer
smoking
LA  - English
M3  - Article
N1  - L368778035
2013-05-01
2013-05-06
PY  - 2013
SN  - 1055-9965
SP  - 589-596
ST  - Relationship of early-onset baldness to prostate cancer in african-american men
T2  - Cancer Epidemiology Biomarkers and Prevention
TI  - Relationship of early-onset baldness to prostate cancer in african-american men
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L368778035&from=export
http://dx.doi.org/10.1158/1055-9965.EPI-12-0944
http://cebp.aacrjournals.org/content/22/4/589.full.pdf+html
VL  - 22
ID  - 1083
ER  - 

TY  - JOUR
AB  - PURPOSE: The Anal Cancer HSIL Outcomes Research (ANCHOR) trial aims to determine whether treating precancerous anal high-grade squamous intraepithelial lesions (HSIL), versus active surveillance, is effective in reducing anal cancer incidence in HIV-infected individuals. We evaluated the reliability (i.e., internal consistency, test-retest) and between-group stability of a 25-item ANCHOR Health-Related Symptom Index (A-HRSI). METHODS: ANCHOR participants at least 1-month post-randomization to treatment or active surveillance completed the A-HRSI via telephone. Participants were contacted 7-10 days later to complete the A-HRSI and a participant global impression of change (PGIC) item. RESULTS: Participants (n = 100) were enrolled (mean age = 51.4, 79% cisgender-male, 73% African American, 9% Hispanic) from five ANCHOR sites. Cronbach's α was good for the physical symptoms (0.82) domain and fair for the physical impacts (0.79) and psychological symptoms (0.73) domains. Intraclass correlation coefficients were good for each of respective domains (i.e., 0.80, 0.85, and 0.82). There were no significant differences in PGIC between the treatment (n = 56) and active surveillance (n = 44) groups (F(1,98) = 2.03, p = 0.16). CONCLUSIONS: The A-HRSI is able to reliably assess participant-reported symptoms and impacts of anal HSIL across a 7-10 days of timeframe. Future work will involve the establishment of construct and discriminant validity prior to inclusion in the full ANCHOR trial.
AD  - Memorial Sloan Kettering Cancer Center, New York, NY, USA. atkinsot@mskcc.org.
University of California-San Francisco, San Francisco, CA, USA.
Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Laser Surgery Care, New York, NY, USA.
Montefiore Medical Center, New York, NY, USA.
Weill Cornell Medicine, New York, NY, USA.
Anal Dysplasia Clinic Midwest, Chicago, IL, USA.
Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
AN  - 30617704
AU  - Atkinson, T. M.
AU  - Palefsky, J.
AU  - Li, Y.
AU  - Webb, A.
AU  - Berry, J. M.
AU  - Goldstone, S.
AU  - Levine, R.
AU  - Wilkin, T. J.
AU  - Bucher, G.
AU  - Cella, D.
AU  - Burkhalter, J. E.
C2  - PMC6472969
C6  - NIHMS1006367
DA  - May
DO  - 10.1007/s11136-018-2089-8
DP  - NLM
ET  - 2019/01/09
IS  - 5
KW  - Acquired Immunodeficiency Syndrome/complications
Adult
Anus Neoplasms/*prevention & control
Female
Humans
Male
Middle Aged
Quality of Life/*psychology
Reproducibility of Results
*Self Report
Squamous Intraepithelial Lesions of the Cervix/pathology/*psychology/*therapy
Surveys and Questionnaires
Treatment Outcome
Watchful Waiting/*methods
ANCHOR trial
Clinical outcome assessments
Health-related quality of life
Neoplasms
Patient-reported outcomes
LA  - eng
N1  - 1573-2649
Atkinson, Thomas M
Palefsky, Joel
Li, Yuelin
Webb, Andrew
Berry, J Michael
Goldstone, Stephen
Levine, Rebecca
Wilkin, Timothy J
Bucher, Gary
Cella, David
Burkhalter, Jack E
ANCHOR HRQoL Implementation Group
U54 CA137788/CA/NCI NIH HHS/United States
P30CA08748/NH/NIH HHS/United States
P30 CA008748/CA/NCI NIH HHS/United States
UL1 TR002384/TR/NCATS NIH HHS/United States
3U54CA137788-08S1/NH/NIH HHS/United States
UM1 CA121947/CA/NCI NIH HHS/United States
U01 CA121947/CA/NCI NIH HHS/United States
2 UM1 CA121947-09/NH/NIH HHS/United States
U54 CA132378/CA/NCI NIH HHS/United States
Journal Article
Qual Life Res. 2019 May;28(5):1265-1269. doi: 10.1007/s11136-018-2089-8. Epub 2019 Jan 7.
PY  - 2019
SN  - 0962-9343 (Print)
0962-9343
SP  - 1265-1269
ST  - Reliability and between-group stability of a health-related quality of life symptom index for persons with anal high-grade squamous intraepithelial lesions: an AIDS Malignancy Consortium Study (AMC-A03)
T2  - Qual Life Res
TI  - Reliability and between-group stability of a health-related quality of life symptom index for persons with anal high-grade squamous intraepithelial lesions: an AIDS Malignancy Consortium Study (AMC-A03)
VL  - 28
ID  - 87
ER  - 

TY  - JOUR
AB  - Background/Objective: The terminology of ductal carcinoma in situ (DCIS) has received national recognition due to its possible effects on patient anxiety in the setting of a favorable prognosis. However, alternative terminology such as ductal intraepithelial neoplasia (DIN) has not been widely adopted in favor of DCIS in the clinical setting. The purpose of this pilot study was to assess whether replacing the term DCIS with DIN in discussions of treatment options would alter patient decisionmaking. Methods: Women with a normal mammogram and no personal history of DCIS or breast cancer were recruited to discuss treatment for a hypothetical breast lesion. Exclusion criteria included a first‐degree relative with breast cancer/DCIS and a history of genetic susceptibility to breast cancer. Participants were interviewed about treatment options for DCIS/DIN. Identical scripts were used for interviews with the exception of the term DCIS/ DIN and scripts were randomly assigned. At the conclusion of the interview the State‐Trait Anxiety Inventory was administered. Statistical analysis was conducted with the Fisher's Exact test. Qualitative analysis was performed to assess the rationale for treatment choice. Results: Of the 25 participants, the majority had > high school education (54%), were African American (63%) and had an average income of <$50,000 (58%). The mean age was 62 years. The majority of participants chose surgical treatment (72%) over surveillance with a preference for breast conservation (83%). There was no difference between DCIS and DIN groups in choosing surgical treatment versus surveillance or in type of surgery (Table). However, of those choosing treatment, only 33% of the DIN group agreed to preventive endocrine therapy versus 87% of the DCIS group (p=0.08). The average reported anxiety levels were elevated (DCIS = 47, DIN = 45) with no difference between the groups (p=1). There were no independent predictors of treatment choice. On qualitative analysis, the most common theme regarding treatment choices in both groups was the desire to alleviate anxiety induced by the diagnosis. Conclusions: This study suggests that avoiding the term carcinoma does not affect surgical treatment decisions for DCIS in this patient population. However, removing carcinoma from these discussions may result in fewer patients choosing chemoprophylaxis. The driving factor in treatment decisions appeared to be anxiety about a DCIS diagnosis although removing the term carcinoma did not affect reported anxiety levels. Further research is needed to define the optimal terminology for discussing DCIS with patients to minimize anxiety and enhance informed decision‐making. (Table Presented).
AN  - CN-01613445
AU  - Hessler, L.
AU  - Comotto, J.
AU  - Dromi, S.
AU  - Zuckerman, D.
AU  - Bellavance, E.
DO  - 10.1245/s10434-018-6534-2
IS  - 2
KW  - *cancer surgery
*intraductal carcinoma
Adult
African American
Breast cancer
Breast lesion
Cancer patient
Chemoprophylaxis
Clinical article
Conference abstract
Controlled study
Decision making
Diagnosis
Female
First‐degree relative
High school
Hormonal therapy
Human
Interview
Mammography
Middle aged
Nomenclature
Pilot study
Prevention
Qualitative analysis
Randomized controlled trial
State Trait Anxiety Inventory
Statistical analysis
Surgery
M3  - Journal: Conference Abstract
PY  - 2018
SP  - 100‐101
ST  - Removing the term carcinoma when discussing a diagnosis of ductal carcinoma in situ does not affect decisions about surgical treatment
T2  - Annals of surgical oncology
TI  - Removing the term carcinoma when discussing a diagnosis of ductal carcinoma in situ does not affect decisions about surgical treatment
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01613445/full
VL  - 25
ID  - 1449
ER  - 

TY  - JOUR
AN  - 9220692
AU  - Morgan, R. C., Jr.
C2  - PMC2568085
DA  - Jul
DP  - NLM
ET  - 1997/07/01
IS  - 7
KW  - Adult
African Americans
*African Continental Ancestry Group
Breast Neoplasms/diagnostic imaging/*prevention & control
Consensus Development Conferences, NIH as Topic
Female
Guidelines as Topic
Humans
*Mammography
*Mass Screening
Middle Aged
Randomized Controlled Trials as Topic
United States
LA  - eng
N1  - Morgan, R C Jr
Journal Article
J Natl Med Assoc. 1997 Jul;89(7):440-3.
PY  - 1997
SN  - 0027-9684 (Print)
0027-9684
SP  - 440-3
ST  - Report of the NMA panel on mammography
T2  - J Natl Med Assoc
TI  - Report of the NMA panel on mammography
VL  - 89
ID  - 734
ER  - 

TY  - JOUR
AB  - BACKGROUND: Incidence and mortality rates for cancers vary by ethnic background and patient age. Accrual of diverse patient populations to cancer clinical trials is essential in order to ensure that findings related to new management strategies can be generalized. The goal of this study was to evaluate accrual patterns for patients participating in the American College of Surgeons Oncology Group (ACOSOG) cancer protocols. Ethnic diversity among clinical trial investigators may also influence accrual patterns, so the ethnic background of the ACOSOG membership was also evaluated. STUDY DESIGN: Demographics for the patients registered on ACOSOG breast, thoracic, and colorectal clinical trials were evaluated and compared with data on the general population and the cancer population in the United States. Accrual patterns for patients from other reported cancer clinical trials were also presented, and the self-reported ethnic distribution of the ACOSOG membership was analyzed. RESULTS: Distribution of African Americans, Hispanic Americans, and Asian Americans to the ACOSOG breast and colorectal clinical trials was relatively proportionate to the cancer population. African Americans were underrepresented in the thoracic clinical trials, and this disparity was partially offset by data on the proportion of African Americans with stage-eligible lung cancer. Accrual rates for patients age 65 years and older were better than those reported by most other clinical trialists. CONCLUSIONS: Elderly patients are successfully recruited into surgical clinical trials, and this will provide important data for future analyses regarding cancer outcomes in this growing population of cancer patients. Aggressive outreach to minority-ethnicity cancer patients for accrual into clinical trials should continue.
AD  - Department of Surgery, University of Michigan, Ann Arbor, MI 48167, USA.
AN  - 15454152
AU  - Newman, L. A.
AU  - Hurd, T.
AU  - Leitch, M.
AU  - Kuerer, H. M.
AU  - Diehl, K.
AU  - Lucci, A.
AU  - Giuliano, A.
AU  - Hunt, K. K.
AU  - Putnam, W.
AU  - Wells, S. A.
DA  - Oct
DO  - 10.1016/j.jamcollsurg.2004.05.282
DP  - NLM
ET  - 2004/09/30
IS  - 4
KW  - Age Factors
Aged
Clinical Trials as Topic/*statistics & numerical data
Continental Population Groups/statistics & numerical data
Ethnic Groups/*statistics & numerical data
Female
Humans
Male
Neoplasms/ethnology/*therapy
*Patient Selection
United States
LA  - eng
N1  - Newman, Lisa A
Hurd, Thelma
Leitch, Marilyn
Kuerer, Henry M
Diehl, Kathleen
Lucci, Anthony
Giuliano, Armando
Hunt, Kelly K
Putnam, William
Wells, Samuel A
Journal Article
United States
J Am Coll Surg. 2004 Oct;199(4):644-51. doi: 10.1016/j.jamcollsurg.2004.05.282.
PY  - 2004
SN  - 1072-7515 (Print)
1072-7515
SP  - 644-51
ST  - A report on accrual rates for elderly and minority-ethnicity cancer patients to clinical trials of the American College of Surgeons Oncology Group
T2  - J Am Coll Surg
TI  - A report on accrual rates for elderly and minority-ethnicity cancer patients to clinical trials of the American College of Surgeons Oncology Group
VL  - 199
ID  - 618
ER  - 

TY  - JOUR
AB  - Racial and ethnic minorities are significantly underrepresented in clinical research trials. Several socio-cultural and systemic barriers, ranging from discrimination by the health care system, medical mistrust, to low physician referral rates and lack of knowledge of research studies have been identified as impacting participation. One hundred and fifteen participants were culturally matched and were interviewed followed by up to an additional four interviews over a 12 month period. Responses were analyzed to understand the perceived benefits to participating in a prospective, randomized, longitudinal clinical research trial about screening colonoscopy. Over two-thirds (64.4%) of participants reported 'knowledge, awareness, and/or information about colonoscopy and general health' as being the greatest benefit they received. Desire to undergo the screening and the pride of completing the study was ranked second and third, respectively. Understanding the reasons that participants choose to participate in research studies will ultimately assist researchers close the gap in minority representation, allowing for greater generalizability of research findings.
AD  - Mount Sinai School of Medicine, 1425 Madison Avenue, Box 1130 New York 10029 USA
Mount Sinai School of Medicine, 1425 Madison Avenue, Box 1130, Room 270 New York 10029 USA
Memorial Sloan Kettering Cancer Center, 641 Lexington Avenue, 7th floor New York 10022 USA
AN  - 104630537. Language: English. Entry Date: 20120131. Revision Date: 20200708. Publication Type: Journal Article
AU  - Castillo, Anabella
AU  - Jandorf, Lina
AU  - Thélémaque, Linda
AU  - King, Sheba
AU  - Duhamel, Katherine
DB  - CINAHL Complete
DO  - 10.1007/s10900-011-9416-0
DP  - EBSCOhost
IS  - 1
KW  - Research Subjects -- Psychosocial Factors
Colonoscopy -- Evaluation
Colorectal Neoplasms -- Diagnosis
Funding Source
Human
Interviews
Randomized Controlled Trials
Prospective Studies
Descriptive Statistics
Black Persons
Health Knowledge -- Evaluation
Male
Female
Middle Age
N1  - research; tables/charts; randomized controlled trial. Journal Subset: Biomedical; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; Public Health; USA. Special Interest: Oncologic Care; Public Health. Grant Information: This project was supported by Grant R01 CA104130-01 from the National Cancer Institute.. NLM UID: 7600747.
PMID: NLM21644025.
PY  - 2012
SN  - 0094-5145
SP  - 59-64
ST  - Reported Benefits of Participation in a Research Study
T2  - Journal of Community Health
TI  - Reported Benefits of Participation in a Research Study
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104630537&site=ehost-live&scope=site
VL  - 37
ID  - 2076
ER  - 

TY  - JOUR
AB  - The authors analyzed data from almost 150,000 subjects aged 55-74 years enrolled in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial who completed a self-administered baseline questionnaire (1993-2001) that included items about family history of cancer. Male respondents reported significantly less family history of cancer than females. The relative underreporting by male respondents relative to females was greater for female family members (28% lower for sisters and 21% lower for mothers) than for male family members (13% lower for brothers and 9% lower for fathers). Black, Hispanic, and Asian respondents reported significantly less family history of cancer than Whites. Reported family history prevalences for parents decreased with respondents' age, while those for siblings increased with respondents' age. The four most commonly reported cancers in families were breast (11.8%), lung (10.1%), colorectal (9.4%), and prostate (7.3%) cancer. Expected prevalences in family members of history of cancer overall and history of specific types of cancer were calculated using incidence rates and life table data obtained from the Surveillance, Epidemiology, and End Results Program. Overall, the ratio of reported cancer rates to expected cancer rates in family members was approximately 0.7. Liver, bone, stomach, and brain cancer had greater-than-average reported:expected ratios, while lymphoma, bladder cancer, melanoma, and testicular cancer had lower-than-average ratios.
AD  - Division of Cancer Prevention, National Cancer Institute, Bethesda, MD 20892, USA. pinskyp@mail.nih.gov
AN  - 12727673
AU  - Pinsky, P. F.
AU  - Kramer, B. S.
AU  - Reding, D.
AU  - Buys, S.
DA  - May 1
DO  - 10.1093/aje/kwg043
DP  - NLM
ET  - 2003/05/03
IS  - 9
KW  - Aged
Colorectal Neoplasms/epidemiology/etiology/genetics/prevention & control
Ethnic Groups
Family
Female
Genetic Predisposition to Disease/*epidemiology/etiology
Humans
Lung Neoplasms/epidemiology/etiology/genetics/prevention & control
Male
Middle Aged
Neoplasms/*epidemiology/etiology/genetics/*prevention & control
Ovarian Neoplasms/epidemiology/etiology/genetics/prevention & control
Prevalence
Prostatic Neoplasms/epidemiology/etiology/genetics/prevention & control
Reproducibility of Results
SEER Program/statistics & numerical data
*Self Disclosure
Sex Factors
Surveys and Questionnaires/*standards
United States/epidemiology
LA  - eng
N1  - Pinsky, Paul F
Kramer, Barnett S
Reding, Douglas
Buys, Saundra
PLCO Project Team
Journal Article
Validation Study
United States
Am J Epidemiol. 2003 May 1;157(9):792-9. doi: 10.1093/aje/kwg043.
PY  - 2003
SN  - 0002-9262 (Print)
0002-9262
SP  - 792-9
ST  - Reported family history of cancer in the prostate, lung, colorectal, and ovarian cancer screening trial
T2  - Am J Epidemiol
TI  - Reported family history of cancer in the prostate, lung, colorectal, and ovarian cancer screening trial
VL  - 157
ID  - 650
ER  - 

TY  - JOUR
AB  - Health disparities in breast cancer outcomes according to race/ethnicity are well documented. Randomized clinical trials (RCT) offer an opportunity to evaluate differences in disease biology and response to therapy that may contribute to disparities. We conducted a PubMed search to identify all English language original reports of breast cancer RCT from October 2001 to October 2006. The primary outcomes of interest were reporting of accrual and results by race or ethnicity of trial subjects. We evaluated the correlation between study characteristics and reporting of race/ethnicity. A total of 197 eligible trials were identified among 29 journals. Accrual was reported by race in 17% of studies and results analyzed by race in only 2%. Reporting of race was associated with National Cancer Institute funding (38 vs. 13%, P = 0.001), US cooperative group trials (52 vs. 13%, P < 0.0001), trials with US sites (43 vs. 5%, P < 0.0001), and trials enrolling > 500 subjects (24 vs. 12%, P = 0.055). Pharmaceutical industry funding, # of centers, stage of disease, nature of experimental intervention and study outcomes were not associated with reporting of race. Among US studies reporting trial accrual by race/ethnicity, the mean accrual distribution was 81% white, 7.6% black, 9.6% Asian, and 7.2% Hispanic subjects. The majority of breast cancer RCT fail to report the race/ethnicity of participants. Low accrual of black subjects and failure to report accrual and outcomes by race in RCT may contribute to difficulty in understanding and overcoming health disparities in breast cancer.
AD  - Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC, USA.
AN  - 19444602
AU  - Mitchell, K. W.
AU  - Carey, L. A.
AU  - Peppercorn, J.
DA  - Dec
DO  - 10.1007/s10549-009-0411-4
DP  - NLM
ET  - 2009/05/16
IS  - 3
KW  - Breast Neoplasms/*ethnology
*Clinical Trials, Phase III as Topic
Continental Population Groups
*Epidemiologic Research Design
Ethnic Groups
Female
*Health Status Disparities
Humans
*Randomized Controlled Trials as Topic
LA  - eng
N1  - 1573-7217
Mitchell, Kelly W
Carey, Lisa A
Peppercorn, Jeffrey
Journal Article
Research Support, Non-U.S. Gov't
Netherlands
Breast Cancer Res Treat. 2009 Dec;118(3):511-7. doi: 10.1007/s10549-009-0411-4. Epub 2009 May 15.
PY  - 2009
SN  - 0167-6806
SP  - 511-7
ST  - Reporting of race and ethnicity in breast cancer research: room for improvement
T2  - Breast Cancer Res Treat
TI  - Reporting of race and ethnicity in breast cancer research: room for improvement
VL  - 118
ID  - 469
ER  - 

TY  - JOUR
AB  - BACKGROUND: The National Cancer Institute (NCI)-sponsored clinical trials cooperative groups place more than 25 000 American patients in treatment trials every year. Equal access and proportional representation of all races/ethnicities is desired. PURPOSE: Our objectives were to evaluate the inclusion of African-Americans, Hispanics, and non-Hispanic whites in NCI-sponsored treatment trials and to determine if there is proportional racial/ethnic representation. METHODS: During the period of January 1, 1991, through June 30, 1994, 99 495 cancer patients were enrolled in clinical trials and declared themselves as non-Hispanic black, non-Hispanic white, or Hispanic (of any race). In the analysis, participants in NCI treatment trials were subdivided into three age groups: birth to 19 years, 20-49 years, and 50 or more years. The racial/ethnic composition of each of these age groups was compared with the racial/ethnic makeup of the American population with cancer. Estimates of the number of incident cancer cases per year were made for each racial/ethnic group within each age group using data from the Surveillance, Epidemiology, and End Results (SEER) Program and the 1990 Census. The percentage of all cancer patients who were in each racial/ethnic group were compared with the population that entered clinical trials. Comparisons are also made separately for patients with leukemia and breast, colorectal, lung, and prostate cancers. RESULTS: Among patients 0-19 years old, 20-49 years old, and 50 years old or older there is relatively proportional representation of non-Hispanic blacks, Hispanics, and non-Hispanic whites in trials. It is noted that more than 70% of cancer patients aged 0-19 years are estimated to enter cooperative group clinical trials compared with 4.0% of cancer patients aged 20-49 years and 1.5% of patients aged 50 years or older. CONCLUSIONS: Accrual of American cancer patients to NCI-sponsored treatment trials generally parallels the incident burden of disease among non-Hispanic African-Americans, Hispanics, and non-Hispanic whites. IMPLICATIONS: This study shows that the NCI clinical trials are, as a whole, racially/ethnically representative of the American population and suggests that there is equal access to NCI clinical trials.
AD  - St. Peter's Medical Center (UMDNJ), Department of Medicine, New Brunswick, NJ 08903-0591, USA.
AN  - 8637047
AU  - Tejeda, H. A.
AU  - Green, S. B.
AU  - Trimble, E. L.
AU  - Ford, L.
AU  - High, J. L.
AU  - Ungerleider, R. S.
AU  - Friedman, M. A.
AU  - Brawley, O. W.
DA  - Jun 19
DO  - 10.1093/jnci/88.12.812
DP  - NLM
ET  - 1996/06/19
IS  - 12
KW  - African Americans/*statistics & numerical data
Clinical Trials as Topic/*statistics & numerical data
European Continental Ancestry Group/*statistics & numerical data
Hispanic Americans/*statistics & numerical data
Humans
National Institutes of Health (U.S.)
Neoplasms/*therapy
United States
LA  - eng
N1  - Tejeda, H A
Green, S B
Trimble, E L
Ford, L
High, J L
Ungerleider, R S
Friedman, M A
Brawley, O W
Journal Article
United States
J Natl Cancer Inst. 1996 Jun 19;88(12):812-6. doi: 10.1093/jnci/88.12.812.
PY  - 1996
SN  - 0027-8874 (Print)
0027-8874
SP  - 812-6
ST  - Representation of African-Americans, Hispanics, and whites in National Cancer Institute cancer treatment trials
T2  - J Natl Cancer Inst
TI  - Representation of African-Americans, Hispanics, and whites in National Cancer Institute cancer treatment trials
VL  - 88
ID  - 740
ER  - 

TY  - JOUR
AB  - Multiple myeloma (MM) occurs in all races, but the incidence in non-Hispanic black patients (NHBs) is two to three times higher than in non-Hispanic white patients (NHWs). We determined the representation of minorities and elderly patients in MM clinical trials. Enrollment data from all therapeutic trials reported in ClinicalTrials.gov from 2000 to 2016 were analyzed. Enrollment fraction (EF) was defined as the number of trial enrollees divided by the 2014 MM prevalence. Participation in MM clinical trials varied significantly across racial and ethnic groups; NHWs were more likely to be enrolled in clinical trials (EF 0.18%) than NHBs (EF 0.06%, p < .0001) and Hispanic patients (EF 0.04%, p < .0001). The median age of trial participants was 62 years, with 7,956 participants (66%) being less than 65 years of age. Collaborations between investigators, sponsors, and the community are necessary to increase access to clinical trials to our minority and elderly patients.
AD  - Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA duma.narjust@mayo.edu.
Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
Internal Medicine, Rutgers University-New Jersey Medical School, Newark, New Jersey, USA.
Hematology, Mayo Clinic, Jacksonville, Florida, USA.
AN  - 29700207
AU  - Duma, N.
AU  - Azam, T.
AU  - Riaz, I. B.
AU  - Gonzalez-Velez, M.
AU  - Ailawadhi, S.
AU  - Go, R.
C2  - PMC6192659
DA  - Sep
DO  - 10.1634/theoncologist.2017-0592
DP  - NLM
ET  - 2018/04/28
IS  - 9
KW  - Aged
Female
Humans
Male
Minority Groups
Multiple Myeloma/*epidemiology
*Clinical trials
*Elderly
*Hematologic malignancies
*Minorities
*Multiple myeloma
article.
LA  - eng
N1  - 1549-490x
Duma, Narjust
Orcid: 0000-0002-7814-1773
Azam, Tariq
Riaz, Irbaz Bin
Gonzalez-Velez, Miguel
Ailawadhi, Sikander
Go, Ronald
P50 CA186781/CA/NCI NIH HHS/United States
Journal Article
Oncologist. 2018 Sep;23(9):1076-1078. doi: 10.1634/theoncologist.2017-0592. Epub 2018 Apr 26.
PY  - 2018
SN  - 1083-7159 (Print)
1083-7159
SP  - 1076-1078
ST  - Representation of Minorities and Elderly Patients in Multiple Myeloma Clinical Trials
T2  - Oncologist
TI  - Representation of Minorities and Elderly Patients in Multiple Myeloma Clinical Trials
VL  - 23
ID  - 125
ER  - 

TY  - JOUR
AB  - PURPOSE: Many cancer clinical trials lack appropriate representation of specific patient populations, limiting their generalizability. Therefore, we determined the representation of ethnic minorities and women in cancer clinical trials. METHODS: Enrollment data from all therapeutic trials reported as completed in ClinicalTrials.gov from 2003 to 2016 were analyzed. We calculated enrollment fractions (EFs) for each group, defined as the number of enrollees divided by the 2013 Surveillance, Epidemiology, and End Results (SEER) database cancer prevalence. RESULTS: Of 1,012 clinical trials, 310 (31%) reported ethnicity with a total of 55,689 enrollees. Participation varied significantly across ethnic groups. Non-Hispanic whites were more likely to be enrolled in clinical trials (EF, 1.2%) than African Americans (EF, 0.7%; P < .001) and Hispanics (EF, 0.4%; P < .001). A decrease in African American (6% v 9.2%) and Hispanic (2.6% v 3.1%) enrollment was observed when compared with historical data from 1996 to 2002. Younger patients (age younger than 65 years) were more likely to be enrolled in clinical trials than the elderly (64% v 36%; P < .001). Low recruitment of female patients was observed in clinical trials for melanoma (35%), lung cancer (39%), and pancreatic cancer (40%). CONCLUSION: We observed a decrease in recruitment of minorities over the past 14 years compared with historical data. African Americans, Hispanics, and women were less likely to be enrolled in cancer clinical trials. Future trials should take extra measures to recruit participants that adequately represent the US cancer population.
AD  - Mayo Clinic, Rochester, MN; and Rutgers University-New Jersey Medical School, Newark, NJ.
AN  - 29099678
AU  - Duma, N.
AU  - Vera Aguilera, J.
AU  - Paludo, J.
AU  - Haddox, C. L.
AU  - Gonzalez Velez, M.
AU  - Wang, Y.
AU  - Leventakos, K.
AU  - Hubbard, J. M.
AU  - Mansfield, A. S.
AU  - Go, R. S.
AU  - Adjei, A. A.
DA  - Jan
DO  - 10.1200/jop.2017.025288
DP  - NLM
ET  - 2017/11/04
IS  - 1
KW  - *Clinical Trials as Topic
Female
Humans
Medical Oncology/*trends
Minority Groups
Neoplasms
LA  - eng
N1  - 1935-469x
Duma, Narjust
Vera Aguilera, Jesus
Paludo, Jonas
Haddox, Candace L
Gonzalez Velez, Miguel
Wang, Yucai
Leventakos, Konstantinos
Hubbard, Joleen M
Mansfield, Aaron S
Go, Ronald S
Adjei, Alex A
Journal Article
Review
United States
J Oncol Pract. 2018 Jan;14(1):e1-e10. doi: 10.1200/JOP.2017.025288. Epub 2017 Nov 3.
PY  - 2018
SN  - 1554-7477
SP  - e1-e10
ST  - Representation of Minorities and Women in Oncology Clinical Trials: Review of the Past 14 Years
T2  - J Oncol Pract
TI  - Representation of Minorities and Women in Oncology Clinical Trials: Review of the Past 14 Years
VL  - 14
ID  - 150
ER  - 

TY  - JOUR
AB  - Background: Many clinical trials supporting new drug applications underrepresent minority patients. Trials conducted by the National Cancer Institute's National Clinical Trial's Network (NCTN) have greater outreach to community sites, potentially allowing better representation. We compared the representation of Black patients in pharmaceutical company-sponsored cancer clinical trials with NCTN trials and with the US cancer population. Methods: We established a large cohort of study publications representing the results of trials that supported new US Food and Drug Administration drug approvals from 2008 to 2018. NCTN trial data were from the SWOG Cancer Research Network. US cancer population rates were estimated using Surveillance, Epidemiology, and End Results survey data. We compared the proportion of Black patients by enrollment year for each cancer type and overall. Tests of proportions were used. All statistical tests were 2-sided. Results: A total 358 trials (pharmaceutical company-sponsored trials, 85; SWOG trials, 273) comprised of 93 825 patients (pharmaceutical company-sponsored trials, 46 313; SWOG trials, 47 512) for 15 cancer types were analyzed. Overall, the proportion of Black patients was 2.9% for pharmaceutical company-sponsored trials, 9.0% for SWOG trials, and 12.1% for the US cancer population (P<.001 for each pairwise comparison). These findings were generally consistent across individual cancer types. Conclusions: The poor representation of Black patients in pharmaceutical company-sponsored trials supporting new drug applications could result in the use of new drugs with little data about efficacy or side effects in this key population. Moreover, because pharmaceutical company-sponsored trials test the newest available therapies, limited access to these trials represents a disparity in access to potential breakthrough therapies.
AD  - J.M. Unger, SWOG Statistical and Data Management Center, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, M3-C102, Seattle, WA, United States
AU  - Unger, J. M.
AU  - Hershman, D. L.
AU  - Osarogiagbon, R. U.
AU  - Gothwal, A.
AU  - Anand, S.
AU  - Dasari, A.
AU  - Overman, M.
AU  - Loree, J. M.
AU  - Raghav, K.
DB  - Embase
DO  - 10.1093/JNCICS/PKAA034
IS  - 4
KW  - new drug
adult
article
Black person
bladder cancer
breast cancer
cancer patient
cancer research
clinical trial (topic)
cohort analysis
colorectal cancer
controlled study
drug approval
drug industry
esophagus cancer
female
female genital tract cancer
Food and Drug Administration
glioblastoma
head and neck cancer
human
kidney cancer
leukemia
lung cancer
lymphoma
major clinical study
male
malignant neoplasm
melanoma
national health organization
pancreas cancer
phase 1 clinical trial (topic)
phase 2 clinical trial (topic)
phase 3 clinical trial (topic)
priority journal
prostate cancer
publication
sarcoma
stomach cancer
United States
LA  - English
M3  - Article
N1  - L2011008643
2021-02-22
2021-03-01
PY  - 2021
SN  - 2515-5091
ST  - Representativeness of black patients in cancer clinical trials sponsored by the national cancer institute compared with pharmaceutical companies
T2  - JNCI Cancer Spectrum
TI  - Representativeness of black patients in cancer clinical trials sponsored by the national cancer institute compared with pharmaceutical companies
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L2011008643&from=export
http://dx.doi.org/10.1093/JNCICS/PKAA034
VL  - 4
ID  - 767
ER  - 

TY  - JOUR
AB  - BACKGROUND: The research goals of the Cancer Care Outcomes Research and Surveillance (CanCORS) Consortium are to determine how characteristics and beliefs of patients, providers, and health care organizations influence the treatments and outcomes of individuals with newly diagnosed lung and colorectal cancers. As CanCORS results will inform national policy, it is important to know how they generalize to the United States population with these cancers. RESEARCH DESIGN: This study assessed the representativeness of the CanCORS cohort of 10,547 patients with lung cancer (LC) or colorectal cancer (CRC) enrolled between 2003 and 2005. We compared characteristics (sex, race, age, and disease stage) with the Surveillance, Epidemiology, and End Results (SEER) population of 234,464 patients with new onset of these cancers during the CanCORS recruitment period. RESULTS: The CanCORS sample is well matched to the SEER Program for both cancers. In CanCORS, 41% LC/47% CRC were female versus 47% LC/49% CRC in SEER. African American, Hispanic, and Asian cases differed by no more than 5 percentage points between CanCORS and SEER. The SEER population is slightly older, with the percentage of patients older than 75 years 33.1% LC/37.3% CRC in SEER versus 26.9% LC/29.4% in CanCORS, and also has a slightly higher proportion of early stage patients. We also found that the CanCORS cohort was representative within specific SEER regions that map closely to CanCORS sites. CONCLUSIONS: This study demonstrates that the CanCORS Consortium was successful in enrolling a demographically representative sample within the CanCORS regions.
AD  - Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA 02215-5450, USA. pcata@jimmy.harvard.edu
AN  - 22406968
AU  - Catalano, P. J.
AU  - Ayanian, J. Z.
AU  - Weeks, J. C.
AU  - Kahn, K. L.
AU  - Landrum, M. B.
AU  - Zaslavsky, A. M.
AU  - Lee, J.
AU  - Pendergast, J.
AU  - Harrington, D. P.
C2  - PMC3654676
C6  - NIHMS455401
DA  - Feb
DO  - 10.1097/MLR.0b013e318222a711
DP  - NLM
ET  - 2012/03/13
IS  - 2
KW  - Adult
Aged
Colorectal Neoplasms/epidemiology/ethnology/*therapy
Female
Health Services Research
Humans
Interviews as Topic
Lung Neoplasms/epidemiology/ethnology/*therapy
Male
Middle Aged
Population Surveillance
Program Development
Program Evaluation
*Registries
SEER Program
United States/epidemiology
LA  - eng
N1  - 1537-1948
Catalano, Paul J
Ayanian, John Z
Weeks, Jane C
Kahn, Katherine L
Landrum, Mary Beth
Zaslavsky, Alan M
Lee, Jeannette
Pendergast, Jane
Harrington, David P
Cancer Care Outcomes Research Surveillance Consortium
U01 CA093329/CA/NCI NIH HHS/United States
U01 CA093348/CA/NCI NIH HHS/United States
U01 CA093324/CA/NCI NIH HHS/United States
U01 CA093339/CA/NCI NIH HHS/United States
U01 CA093344/CA/NCI NIH HHS/United States
U01 CA093326/CA/NCI NIH HHS/United States
U01 CA093332/CA/NCI NIH HHS/United States
Comparative Study
Journal Article
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, U.S. Gov't, P.H.S.
Med Care. 2013 Feb;51(2):e9-15. doi: 10.1097/MLR.0b013e318222a711.
PY  - 2013
SN  - 0025-7079 (Print)
0025-7079
SP  - e9-15
ST  - Representativeness of participants in the cancer care outcomes research and surveillance consortium relative to the surveillance, epidemiology, and end results program
T2  - Med Care
TI  - Representativeness of participants in the cancer care outcomes research and surveillance consortium relative to the surveillance, epidemiology, and end results program
VL  - 51
ID  - 372
ER  - 

TY  - JOUR
AB  - Background Triple-negative (ie, estrogen receptor [ER], progesterone receptor, and HER2 negative) breast cancer occurs disproportionately among African American women compared with white women and is associated with a worse prognosis than ER-positive (ER+) breast cancer. Hormonally mediated risk factors may be differentially related to risk of triple-negative and ER+ breast cancers. Methods Using data from 155723 women enrolled in the Women's Health Initiative, we assessed associations between reproductive and menstrual history, breastfeeding, oral contraceptive use, and subtype-specific breast cancer risk. We used Cox regression to evaluate associations with triple-negative (N = 307) and ER+ (N = 2610) breast cancers and used partial likelihood methods to test for differences in subtype-specific hazard ratios (HRs). Results Reproductive history was differentially associated with risk of triple-negative and ER+ breast cancers. Nulliparity was associated with decreased risk of triple-negative breast cancer (HR = 0.61, 95% confidence interval [CI] = 0.37 to 0.97) but increased risk of ER+ breast cancer (HR = 1.35, 95% CI = 1.20 to 1.52). Age-adjusted absolute rates of triple-negative breast cancer were 2.71 and 1.54 per 10000 person-years in parous and nulliparous women, respectively; by comparison, rates of ER+ breast cancer were 21.10 and 28.16 per 10000 person-years in the same two groups. Among parous women, the number of births was positively associated with risk of triple-negative disease (HR for three births or more vs one birth = 1.46, 95% CI = 0.82 to 2.63) and inversely associated with risk of ER+ disease (HR = 0.88, 95% CI = 0.74 to 1.04). Ages at menarche and menopause were modestly associated with risk of ER+ but not triple-negative breast cancer; breastfeeding and oral contraceptive use were not associated with either subtype. Conclusion The association between parity and breast cancer risk differs appreciably for ER+ and triple-negative breast cancers. These findings require further confirmation because the biological mechanisms underlying these differences are uncertain. © 2011 The Author. Published by Oxford University Press. All rights reserved.
AD  - A. I. Phipps, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave North, Seattle, WA 98109-1024, United States
AU  - Phipps, A. I.
AU  - Chlebowski, R. T.
AU  - Prentice, R.
AU  - McTiernan, A.
AU  - Wactawski-Wende, J.
AU  - Kuller, L. H.
AU  - Adams-Campbell, L. L.
AU  - Lane, D.
AU  - Stefanick, M. L.
AU  - Vitolins, M.
AU  - Kabat, G. C.
AU  - Rohan, T. E.
AU  - Li, C. I.
DB  - Embase
Medline
DO  - 10.1093/jnci/djr030
IS  - 6
KW  - estrogen
estrogen receptor
gestagen
oral contraceptive agent
adult
aged
article
birth
breast cancer
breast feeding
cancer diagnosis
cancer hormone therapy
cancer incidence
cancer risk
clinical assessment
controlled study
female
hazard ratio
human
major clinical study
menarche
menopause
menstrual cycle
multicenter study
nullipara
oral contraception
priority journal
randomized controlled trial
reproduction
risk factor
women's health
LA  - English
M3  - Article
N1  - L361472802
2011-03-29
2011-03-31
PY  - 2011
SN  - 0027-8874
1460-2105
SP  - 470-477
ST  - Reproductive history and oral contraceptive use in relation to risk of triple-negative breast cancer
T2  - Journal of the National Cancer Institute
TI  - Reproductive history and oral contraceptive use in relation to risk of triple-negative breast cancer
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L361472802&from=export
http://dx.doi.org/10.1093/jnci/djr030
VL  - 103
ID  - 1142
ER  - 

TY  - JOUR
AN  - 105917479. Language: English. Entry Date: 20080104. Revision Date: 20150711. Publication Type: Journal Article
AU  - Broome, B.
DA  - Summer2007
DB  - CINAHL Complete
DP  - EBSCOhost
IS  - 2
KW  - Medically Underserved
Research Subjects
Aged
Australia
Black Persons
Immunization -- In Old Age
Patient Attitudes
Prostatic Neoplasms
Race Factors
Transcultural Care
N1  - editorial. Journal Subset: Blind Peer Reviewed; Core Nursing; Double Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Nursing; Peer Reviewed; USA. NLM UID: 9439196.
PMID: NLM19175243.
PY  - 2007
SN  - 1071-5568
SP  - 55-55
ST  - Research and under represented groups
T2  - Journal of Cultural Diversity
TI  - Research and under represented groups
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105917479&site=ehost-live&scope=site
VL  - 14
ID  - 2080
ER  - 

TY  - JOUR
AB  - Background: Black men are three times more likely to develop prostate cancer (PCa) and often present with more aggressive disease. Nevertheless, black men are consistently underrepresented in research studies. We aimed to get more insight into the reasons for this reduced recruitment, as it is important for future research to include results that are also applicable to black men with PCa. Methods: Two focus groups (n = 10 and n = 6) of black males currently under treatment for PCa at Guys Hospital, London, UK were held to gather information regarding the understanding of and exposure to research, as well as the barriers and facilitators for recruitment into research studies. Results: Barriers to recruitment included; mistrust of researchers, lack of understanding of the research process and the mechanisms of PCa and a reliance on herbal medicine. Suggested facilitators for recruitment improvement included thorough explanations of the research process, media advertisement and word of mouth. Financial incentives were also discussed but received mixed reception. Conclusion: We uncovered a number of barriers to recruitment of black men with PCa into research and accompanying strategies for improving involvement. Many are consistent with the literature, emphasising that current efforts have not been successful in ameliorating the concerns of the black community. Beliefs in herbal medicine and aversion to financial incentives appear to be novel themes, and so further insight into these issues could prove beneficial.
AD  - M. Van Hemelrijck, King's College London, Division of Cancer Studies, Cancer Epidemiology Group, London, United Kingdom
AU  - Toms, C.
AU  - Cahill, F.
AU  - George, G.
AU  - Van Hemelrijck, M.
DB  - Embase
DO  - 10.3332/ecancer.2016.695
KW  - adult
advertising
article
Black person
cancer research
clinical article
comprehension
controlled study
health belief
herbal medicine
human
information processing
male
patient participation
prostate cancer
trust
LA  - English
M3  - Article
N1  - L613529345
2016-12-14
2017-01-11
PY  - 2016
SN  - 1754-6605
ST  - Research engagement among black men with prostate cancer
T2  - ecancermedicalscience
TI  - Research engagement among black men with prostate cancer
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L613529345&from=export
http://dx.doi.org/10.3332/ecancer.2016.695
VL  - 10
ID  - 956
ER  - 

TY  - JOUR
AB  - BACKGROUND: Myeloma occurs disproportionately in African Americans, with disparities in outcomes potentially caused by access to care, cytogenetics, and immunity. A gap in knowledge of immune function dissimilarities between African Americans and whites exists. Data for other diseases suggest innate differences in immunity and inflammatory markers, with potential implications for therapeutic monoclonal antibodies reliant on secondary immune activation for activity. METHODS: Patients receiving daratumumab or elotuzumab, lenalidomide, and dexamethasone were retrospectively studied with a primary endpoint of response at 2 (daratumumab) or 4 months (elotuzumab). Secondary endpoints included stable disease or better at the same points, treatment duration, time to best response, and adverse events. RESULTS: Eighty patients were included; baseline characteristics were balanced with the exception of the stage at diagnosis, which was more advanced in African Americans. No statistically significant difference in response was seen: 37.9% in whites versus 11.8% in African Americans with daratumumab (P = .090) and 60% in whites versus 44% in African Americans with elotuzumab (P = .462). There were no differences in the duration of treatment, the time to best response, or adverse events. Common potential immune-related adverse events in both arms were fatigue (39%), back pain (30%), and infusion reactions (40%). Anemia was significantly associated with a response to daratumumab (P = .02); no patients without anemia responded at 2 months, whereas 34.4% of patients with anemia did. CONCLUSIONS: No significant difference in response, duration of treatment, or time to response was seen by race, although a trend toward greater early response rates in whites was observed. In these cohorts, as in other analyses, African American patients tended to present with later stage disease.
AD  - Department of Pharmaceutical Services, Emory University Hospital, Atlanta, Georgia.
Biostatistics and Bioinformatics Shared Resource, Winship Cancer Institute of Emory University, Atlanta, Georgia.
Department of Hematology and Medical Oncology, Emory University School of Medicine and Winship Cancer Institute of Emory University, Atlanta, Georgia.
Department of Pharmacology, Emory University School of Medicine, Atlanta, Georgia.
AN  - 30303526
AU  - Chehab, S.
AU  - Zhang, C.
AU  - Panjic, E. H.
AU  - Chen, Z.
AU  - Kaufman, J. L.
AU  - Lonial, S.
AU  - Nooka, A.
AU  - Harvey, R. D.
DA  - Nov 15
DO  - 10.1002/cncr.31746
DP  - NLM
ET  - 2018/10/12
IS  - 22
KW  - Adult
African Americans/statistics & numerical data
Aged
Aged, 80 and over
Antibodies, Monoclonal/adverse effects/therapeutic use
Antibodies, Monoclonal, Humanized/adverse effects/therapeutic use
Antineoplastic Agents, Immunological/adverse effects/*therapeutic use
Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use
Clinical Trials as Topic
Dexamethasone/adverse effects/therapeutic use
European Continental Ancestry Group/statistics & numerical data
Female
Humans
Lenalidomide/adverse effects/therapeutic use
Male
Middle Aged
Multiple Myeloma/*drug therapy/*ethnology
Retrospective Studies
Survival Analysis
Treatment Outcome
*African American
*Caucasian
*anemia
*daratumumab
*elotuzumab
*myeloma
*race.
LA  - eng
N1  - 1097-0142
Chehab, Sarah
Zhang, Chao
Panjic, Elyse H
Chen, Zhengjia
Kaufman, Jonathan L
Lonial, Sagar
Nooka, Ajay
Orcid: 0000-0003-4165-6869
Harvey, R Donald
Comparative Study
Journal Article
United States
Cancer. 2018 Nov 15;124(22):4358-4365. doi: 10.1002/cncr.31746. Epub 2018 Oct 10.
PY  - 2018
SN  - 0008-543x
SP  - 4358-4365
ST  - Response to therapeutic monoclonal antibodies for multiple myeloma in African Americans versus whites
T2  - Cancer
TI  - Response to therapeutic monoclonal antibodies for multiple myeloma in African Americans versus whites
VL  - 124
ID  - 97
ER  - 

TY  - JOUR
AB  - Background Hypovolemia can cause postoperative complications, circulatory collapse and death, regardless if the cause is blood loss or loss of other fluids. Therefore, doctors are giving fluid intravenously to patients undergoing surgery, and often in an amount larger than the measured losses. Recent studies, however, have shown that also fluid overload plays a part in complication development after surgery (1‐3). It is therefore important to find the optimal fluid treatment for surgical patients. In Denmark, approximately 3500 patients are undergoing surgery every year for colorectal cancer, and in addition, operations are performed for benign diseases. However, the complication rate after colorectal surgery remains high (approximately 30%). Disagreement about which fluid treatment is optimal exist between three "schools for fluid therapy": 1. "Standard fluid therapy" which in addition to replacing external fluid loss (blood loss, urine and evaporation) include fluid to replace a "third space loss" and fluid to counteract low blood pressure (4‐5). Standard therapy is poorly defined and differ between hospitals. It cause a bodyweight increase by 3‐6 kilo (6‐7). 2. "Goal‐directed fluid therapy", where volume is given in a bolus injection of a colloid (typically hydroxyethyl starch (HES)) in order to keep the patient's stroke volume (SV) at a near maximum level (1). The heart is brought close to maximum performance. In theory, hypovolemia is prevented and oxygen supply to the tissues increased. In the studies available, HES is given on top of "standard therapy" and "Goal‐directed fluid therapy" therefore result in a weight gain not measured in the available studies. 3. "Restrictive fluid therapy", replace only measurable fluid losses and strive to maintain the patient's normal (preoperative) body weight. The hypothesis is that excess fluid cause interstitial edema which may be harmful to the healing of tissue and function. (2,3,8). "Standard fluid therapy" is meaningful if a benefit exists in giving fluid to a possible third space loss and treat the vasodilatation caused by epidural analgesia by volume. However, a recent critical review of the literature poses serious doubts about the existence of a third space loss (9), and no beneficial effect of volume treatment of the vasodilatation caused by epidural analgesia been shown. "Goal‐directed fluid therapy" tests the hypothesis that a near maximal stroke volume (SV) during surgery improves tissue oxygen supply, thus preventing the harmful effects of hypovolemia. Unfortunately, all studies that have tested "goal‐directed fluid therapy" with esophageal Doppler monitoring have chosen to use a not well‐defined "standard fluid regime" as their control group, and in the intervention groups they have chosen to first provide "standard fluid therapy" and then give a further HES to maximum stroke volume (10‐16). In addition, length of hospital stay (LOS) were the primary endpoint not morbidity or mortality, and patients were not followed after discharge. The results of these studies differ. Most studies have shown shorter LOS in the intervention group, but only 3 of the studies have been blinded (11, 13, 16). Some studies have shown a lower complication rate in the intervention groups (12, 13, 16) some studies have not shown a difference in complication rate (10, 14, 15, 17) and some have raised suspicions that the intervention has been harmful, with increased mortality (15, 18). "Restrictive fluid treatment" is based on the following logic: If there is no third space loss, it is pointless to give saline to replace it, and if epidural vasodilatation is not corrected with volume, it is pointless to give fluid to increase BP. The hypothesis is that fluid overload might result in interstitial edema, harmful to tissue healing and cardiovascular function. Only a few studies have tested the effect of "restrictive fluid treatment" on the development of complications following major surgical procedures, but the results have been consistent: "Restrictive fluid treat ent" has reduced the complication rate after elective abdominal surgery (2, 3). Purpose To investigate whether perioperative fluid therapy controlled by esophageal Doppler monitoring reduces postoperative complications compared to perioperative fluid therapy controlled by measuring external fluid loss and body weight. In addition, to investigate whether patients receiving "restrictive fluid therapy" develop hypovolemia with reduced SV during surgery. Design Clinical randomized double‐blinded multicenter study, stratified for each center, and for laparoscopic and open surgery. This will result in a simultaneous stratification of combined epidural and general anesthesia (used in open surgery) and general anesthesia alone (as used in laparoscopic surgery). The patients are block randomized with a number of patients in each block unknown to the doctors performing the randomization. Several centers are participating to complete the trial within a reasonable time. The patients are following an enhanced recovery program in both arms. Material 150 patients undergoing elective colorectal resection will be included. The number was determined using data from complication databases, which shows a postoperative complication rate of approximately 30%. 2α is set at 5% and β is set at 15%, increasing the credibility of a possible negative result. A number of n > 67.5 patients in each group was calculated, and inclusion of 75 patients in each group (total 150 patients) was decided. Outcome The composite endpoint of mortality and postoperative complications is the primary endpoint. An event is accepted as a complication if it demands clinical treatment and fulfills given diagnostic criteria. Based on the following hypotheses; subgroup analysis are planned: Both hypovolemia and hypervolemia may be harmful to the cardiac function (low oxygen supply and congestion) and cause cardiovascular complications such as: • Newly developed arrhythmias, AMI, pneumonia, pulmonary congestion, newly developed pleural exudation, pulmonary edema or ARDS. Both hypovolemia and hypervolemia may be harmful to tissue healing (low oxygen supply and interstitial edema) and cause complications related to tissue healing and infection: • Infections of the wound, bursting of the wound (superficial and deep), leakage from the anastomosis and separation of a stoma. In addition, data for physiological changes in HR, BP, SV, Hemoglobin concentration, diuresis etc. will be analyzed. Method: A trial profile will account for all patients undergoing elective colorectal resections in the inclusion period. I.e. all patients undergoing elective colorectal resections must be consecutively screened for inclusion and asked to participate if no exclusion criteria is met. The information will take place the day before surgery. The information will be based on the written information (see appendix), and will be given in an easily understandable language and in an appropriate manner adapted to the individual. Patients are randomized to either "restrictive fluid treatment" (R group) or "fluid treatment to maximum SV" (SV group). Preoperative fluid treatment: All patients may drink until 2 hours before anesthesia. If supplemental intravenous fluids are needed, it is given in accordance with the loss, i.e.: Glucose isotonic (5%) replaces insensible perspiration (if diabetes insulin and if needed potassium is added). Registration of fluid intake begins at midnight on the day of the operation. Perioperative monitoring: Standard anesthesia monitoring as recommended by the Danish Anesthesiological Society is used. A catheter in the radial artery monitor the BP and is used for blood sampling. BP and HR are measured at least 3 times before induction of anesthesia and every five minutes during anesthesia. Immediately after the induction of anesthesia, all patients have a Doppler placed in the esophagus to measure the flow rate in the aorta, thereby calculating the stroke volume (SV). The SV is measured before surgery is started, and every 15 minutes throughout the operation. In the "Rest ictive Group", the Doppler measurements are recorded to a black box (see later). Anesthesia: Routine premedication is given. In open surgery, combined epidural and general anesthesia are used: The Epidural catheter is inserted at the Th8‐Th10 level, tested, and a continuous infusion of Bupivacaine 0.5% is running until sufficient blockade. General anesthesia is induced with Thiopental / Propofol, Fentanyl and Rocuronium (Esmerone®) for a neuromuscular blockade. Anesthesia is maintained with Sevoflurane / Fentanyl or Propofol / Remifentanil (Ultiva®). For laparoscopic surgery, only general anesthesia is used. In case of conversion from laparoscopic to open surgery, an epidural catheter is placed postoperatively. Perioperative fluid treatment: If the preoperative fluid intake <500 ml. it is supplemented to 500 ml. with saline in both groups. In addition, saline is given with the medicine. Lost blood is replaced volume by volume with HES (Voluven ®) with an allowance of 500 ml extra. In the SV group, a bolus injection of 200 ml Voluven® is given until the increase in SV is <10%. Blinding: Only the anesthesiologist know the randomization group and perioperative fluid treatment. It is unknown to the patient and to the project surgeon. As all patients in the study will receive NaCl 0.9%, Voluven ®, and other IV fluids, and as all patients are monitored with a Doppler in the esophagus, effective blinding of the surgeons can be achieved. In order to avoid bias of the anesthesiologist, the SV measurements are recorded to a black box in the restrictive group. Postoperative fluid treatment: Throughout the rest of the day of the operation, fluid is given to meet the basic needs, i.e. approx. 1000 ml K‐Na‐glucose, K‐glucose or glucose 5%. The patient is encouraged to drink and eat as soon as it is safe to swallow. Nutrition is started as soon as possible (preferably in recovery) with protein drinks. In the surgical department, fluid charts and weight changes, allowing a body weight increase of two kilograms without treatment, monitor fluid treatment. If the weight increases more than two kilogram, furosemide is given to increase the diuresis. The patient's body weight is measured in the morning before surgery, and then every morning until discharge or the seventh post‐operative day. The same set of scales are used throughout the course. Blood tests: Venous blood is taken in the morning on the day of the operation and every morning the following 5 days or until the patient is discharged. Surgery: Patients are operated with either open or laparoscopic technique. Antibiotic prophylaxis follows the department's routine. The bowel is not cleansed except for an enema before rectal surgery. Postoperative analgesia: In open surgical procedures, continuous, patient‐controlled, epidural analgesia is given for a maximum of 4 days. In addition 1 g Paracetamol is given x 3‐4, and / or Ibuprofen 400 mg x 3‐4 if there are no contraindications. Supplemental Morphine p.n. is allowed. Nausea is treated with Ondansetron, Metoclopramide or DHB, depending on the cause of the patient's nausea. In case of suspicion of ventricular retention, a ventricular tube is applied for suction. Data collection The project doctor or surgeon see the patient every day and evaluates the patient's condition, prescribes fluid treatment, and assesses the presence and treatment of any complications. In addition, the patient is visiting the outpatient clinic approximately 30 days postoperatively. Any complications after discharge is recorded. Analysis The following analysis are planned: ‐ "Intention‐to‐treat analysis" analyses all included patients for the primary endpoint. ‐ "Per‐protocol analysis" analyses those patients who have not been excluded following randomization (to be completed at > 10 exclusions only) ‐ Analyzes of the above subgroups. ‐ Analysis of the physiological data
AN  - CN-01663421
AU  - Nct
PY  - 2018
ST  - Restrictive or Doppler-guided Fluid Treatment in Colorectal Surgery
T2  - https://clinicaltrials.gov/show/NCT03677622
TI  - Restrictive or Doppler-guided Fluid Treatment in Colorectal Surgery
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01663421/full
ID  - 1662
ER  - 

TY  - JOUR
AB  - Background: Daratumumab (dara) is a human CD38‐directed monoclonal antibody indicated for the treatment of patients (pts) with multiple myeloma (MM) who have received >3 prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent (IMID) or who are double‐refractory to a PI and an IMID. Accelerated approval was granted in the United States (US) in November 201 5, based largely on the results of MMY2002, a pivotal phase 2 study in this pt population. Methods: The objectives of this multicenter, open‐label early access treatment protocol (EAP) were to provide early access to dara treatment and collect safety and patient‐reported outcome (PRO) data in this pt population. Eligibility criteria were similar to those of pivotal study MMY2002 and included age >18 years, documented MM, progression by IMWG criteria following the most recent therapy, >3 prior lines of therapy including a PI and an IMID or disease double‐refractory to a PI and an IMID, ECOG performance status score 0‐2, no known chronic obstructive pulmonary disease or persistent asthma, no ongoing MM therapy, and no prior exposure to anti‐CD38 antibody therapy. Pts received dara 16 mg/kg IV weekly for 8 weeks, then every 2 weeks for 16 weeks, and then every 4 weeks until disease progression, unacceptable toxicity, or 60 days after US approval. Pre‐and post‐infusion medications were administered as in study MMY2002. Serious adverse events (SAEs), grade 3‐4 AEs, infusion related reactions (IRRs), and PRO data were collected. Results: In total, 400 pts were screened and 348 pts were enrolled and dosed at 39 US sites from July to November 2015. Median age was 65 (range 27‐94) years; 72% were white, and 17% were African American. Three‐fourths of pts were symptomatic with an ECOG score of 1 (58%) or 2 (16%). Pts received a median of 8 (range 1‐17) doses, and median treatment exposure was 1.9 (range 0.03‐6.0) months. Median durations of infusion were 7.4, 4.4, and 3.5 hours for the first, second, and all subsequent infusions, respectively. Half of pts (52%) transitioned to commercial drug after marketing authorization, whereas 37% discontinued due to progressive disease. Treatment emergent grade >3 AEs were reported in 51% of pts. The most common grade >3 AEs were thrombocytopenia (15%) and anemia (14%). SAEs occurred in 35% of pts, including 12% of pts with SAEs which were reported by investigators as drug‐related. The most common SAEs were infections, which occurred in 11% of pts. Nine percent of pts discontinued therapy due to AEs, including 3% for drug‐related AEs. Thirteen (4%) pts had an AE with a fatal outcome, including 2 (0.6%) pts with drug‐related AEs (pyrexia, thrombocytopenia/subdural hematoma). IRRs occurred in 56% of pts, including 8% with grade >3 IRRs. IRRs occurred in 56%, 2%, and 2% of first, second, and all subsequent infusions, respectively; the most common IRRs were respiratory or thoracic symptoms (cough, dyspnea, throat irritation, nasal congestion), which occurred in 31% of pts. The median change from baseline in all the domains of the EQ‐5D‐5L and EORTC QLQ‐C30 scales after 1 and 2 cycles as well as at pts' last assessment was 0, with the exception of EQ‐5D‐5L VAS, which showed a median increase of 1 and 2 units after 1 and 2 cycles, respectively. Conclusions: EAP results in US pts confirmed the safety profile of dara in MM pts with >3 prior therapies including a PI and IMID or who were refractory to both PI and IMID. SAEs occurred in one‐third of pts, but only 12% of pts experienced a drug‐related SAE. More than half of pts experienced IRRs, which primarily occurred during the first infusion and were grade 1‐2 in severity. Pts maintained their health‐related quality of life during a median duration of 2 months of therapy.
AN  - CN-01334823
AU  - Chari, A.
AU  - Mark, T. M.
AU  - Krishnan, A.
AU  - Stockerl-Goldstein, K.
AU  - Usmani, S. Z.
AU  - Londhe, A.
AU  - Etheredge, D.
AU  - Parros, H.
AU  - Fleming, S.
AU  - Liu, B.
AU  - et al.
IS  - 22) (no pagination
KW  - *United States
*clinical protocol
*daratumumab
*multiple myeloma
Adult
Adverse drug reaction
African American
Aged
Anemia
Asthma
CD38 antigen
Cancer epidemiology
Chronic obstructive lung disease
Clinical trial
Controlled clinical trial
Controlled study
Coughing
Disease duration
Drug infusion
Drug therapy
Dyspnea
Endogenous compound
Exposure
Fatality
Fever
Human
Infection
Infusion related reaction
Major clinical study
Marketing
Multicenter study
Nose obstruction
Patient reported outcome
Pharmacokinetics
Phase 2 clinical trial
Proteasome inhibitor
Quality of life
Safety
Side effect
Subdural hematoma
Symptom
Thorax
Throat irritation
Thrombocytopenia
Toxicity
Tumor resistance
Young adult
M3  - Journal: Conference Abstract
PY  - 2016
ST  - Results of an early access treatment protocol (EAP) of daratumumab in United States patients with relapsed or refractory multiple myeloma
T2  - Blood. Conference: 58th annual meeting of the american society of hematology, ASH 2016. United states. Conference start: 20161203. Conference end: 20161206
TI  - Results of an early access treatment protocol (EAP) of daratumumab in United States patients with relapsed or refractory multiple myeloma
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01334823/full
VL  - 128
ID  - 1434
ER  - 

TY  - JOUR
AB  - Although retention is a critical component of longitudinal cancer genetics research, limited empirical data are available on predictors of study retention among populations that are difficult to enroll. We evaluated predictors of retention in cancer genetics research among African American women at increased risk for having a BRCA1 and BRCA2 (BRCA1/2) mutation. Participants were African American women (n = 192) at increased risk for hereditary breast-ovarian cancer who were enrolled in a longitudinal genetic counseling research study. Retention was evaluated separately for the 1-and 6-month follow-ups and in terms of overall retention (e.g., completion of both telephone interviews). Seventy-three percent of women and 65% of women were retained at the 1- and 6-month follow-ups respectively; in terms of overall retention, 60% of women were retained in both follow-up telephone interviews. Predictors of retention at 1-month included being employed (OR = 2.47, 95% CI = 1.24, 4.93, P = 0.01) whereas predictors of overall retention included having a personal history of breast and/or ovarian cancer (OR = 2.06, 95% CI = 1.07, 3.95, P = 0.03) and having completed genetic counseling (OR = 2.63, 95% CI = 1.39, 4.98, P = 0.003). These data suggest that once enrolled in genetic counseling research, the majority of African American women will continue to participate, especially if concrete clinical services are provided. © 2007 Wiley-Liss, Inc.
AD  - C.H. Halbert, University of Pennsylvania, 3535 Market Street, Philadelphia, PA 19104, United States
AU  - Halbert, C. H.
AU  - Love, D.
AU  - Mayes, T.
AU  - Collier, A.
AU  - Weathers, B.
AU  - Kessler, L.
AU  - Stopfer, J.
AU  - Bowen, D.
AU  - Domchek, S.
DB  - Embase
Medline
DO  - 10.1002/ajmg.a.32067
IS  - 2
KW  - adult
African American
article
brca2 oncogene
breast cancer
cancer genetics
cancer research
cancer risk
hereditary tumor syndrome
female
follow up
gene mutation
genetic counseling
human
longitudinal study
major clinical study
oncogene
ovary cancer
priority journal
LA  - English
M3  - Article
N1  - L351041992
2008-01-23
PY  - 2008
SN  - 1552-4825
1552-4833
SP  - 166-173
ST  - Retention of African American women in cancer genetics research
T2  - American Journal of Medical Genetics, Part A
TI  - Retention of African American women in cancer genetics research
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L351041992&from=export
http://dx.doi.org/10.1002/ajmg.a.32067
VL  - 146
ID  - 1217
ER  - 

TY  - JOUR
AB  - Background: Disproportionally low retention of minority populations can adversely affect the generaliz-ability of clinical research trials. We determine the overall retention rates for White and Black participants from the Selenium and Vitamin E Cancer Prevention Trial (SELECT) and explore participant and site characteristics associated with retention failure (study disengagement) for these groups. Methods: A secondary analysis of 28,118 White (age ≥55), and 4,322 Black (age ≥ 50) SELECT participants used multivariate Cox regression to estimate overall retention rates and to calculate HRs and 95% confidence intervals (CI). Results: Blacks had higher age-adjusted risk of disengagement than Whites (HR, 1.92; 95% CI, 1.77-2.08). Among Black participants, those ages 50 to 54 were at three times the risk of disengagement than those ≥65 years of age (HR, 3.61; 95% CI, 2.41-5.41). Blacks age ≥65 had 1.6 times the risk of disengagement than Whites age >65 (HR, 1.60; 95% CI, 1.38-1.87). By 6 years after randomization, 84% of Whites and 69% of Blacks remained engaged in the study. Current smoking status was an independent risk factor for study disengagement for both White and Black participants. For both groups, sites whose staffs missed SELECT training sessions or who received SELECT Retention and Adherence grants were associated with increased and decreased disengagement risks, respectively. Conclusions: SELECT retention was disproportionately lower for Blacks than for Whites. Impact: The observed difference in retention rates for Blacks and Whites and factors identified by race for study disengagement in SELECT may inform retention efforts for future long-term, cancer prevention trials.
AD  - K.B. Arnold, SWOG Statistical Center, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, Seattle, WA, United States
AU  - Arnold, K. B.
AU  - Hermos, J. A.
AU  - Anderson, K. B.
AU  - Minasian, L.
AU  - Tangen, C. M.
AU  - Probstfield, J. F.
AU  - Cook, E. D.
DB  - Embase
Medline
DO  - 10.1158/1055-9965.EPI-14-0724
IS  - 12
KW  - NCT00006392
alpha tocopherol
selenium
adult
aged
article
Black person
cancer prevention
Caucasian
comorbidity
controlled clinical trial
controlled study
double blind procedure
human
major clinical study
male
phase 3 clinical trial
prostate cancer
race difference
risk factor
smoking
LA  - English
M3  - Article
N1  - L600988207
2014-12-25
2015-06-12
PY  - 2014
SN  - 1055-9965
SP  - 2895-2905
ST  - Retention of black and white participants in the selenium and vitamin E cancer prevention trial (SWOG-coordinated intergroup study S0000)
T2  - Cancer Epidemiology Biomarkers and Prevention
TI  - Retention of black and white participants in the selenium and vitamin E cancer prevention trial (SWOG-coordinated intergroup study S0000)
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L600988207&from=export
http://dx.doi.org/10.1158/1055-9965.EPI-14-0724
VL  - 23
ID  - 1022
ER  - 

TY  - JOUR
AB  - Background Differential attrition by minority participants can be as limiting to interpreting final results as poor initial recruitment of minority participants. This is especially important in drug abuse treatment studies, as minorities are over-represented in substance abuse clinical treatment programs. Purpose The specific aims of this secondary data analysis were to: (1) determine if there are differences in study retention rates by race/ethnicity and age, and (2) explore other client characteristics, as well as protocol and treatment program factors, that could account for differential retention rates. Methods We conducted a secondary analysis using data from 1737 participants in the first six clinical trials whose databases were locked in the NIDA Clinical Trials Network. Protocol level characteristics were also abstracted from these studies, and we used data from a study which assessed characteristics of community treatment programs that participated in these studies. Logistic regression was used to study the effect on retention of: client, protocol, and program characteristics. Results In the model of client characteristics, a significant age by race/ethnicity interaction term was detected based on a threshold of 0.1, with younger African Americans having the lowest odds of retention. Primary drug of abuse was also a significant factor in determining study retention, with heroin, methadone, and opiate users having the greatest odds of retention and polydrug users the lowest. Similar analyses testing treatment program characteristics found that only the presence of HIV risk screening and decreasing levels of female admissions (as a percent of total admissions) were related to study retention. In our final model, there was an effect of age, but not race/ethnicity, with younger participants having lower odds of retention. A multivariable model including protocol variables could not be developed due to the high correlation among protocol variables. Limitations We excluded those of multi-race/ethnicity and those from minority groups other than Hispanic or African American due to small numbers. Additionally, only three therapy types were represented among the six studies. Some potential variables that would influence retention, such as client housing, and client comorbidities, the race/ethnicity and gender of the staff who conducted study follow-up assessments, and reasons for loss to follow-up, were not collected by the CTN. Conclusions Although in our client model older African Americans and Caucasians had the greatest odds of retention and younger African Americans the lowest, in our final model, only age was significantly related to study retention. Additionally, primary drug of abuse, having HIV risk screening as a program benefit, and lower percentages of female admissions were significantly related to study retention. Efforts should be made to increase the study retention of younger participants to improve the validity and generalizability of drug abuse treatment study results. Clinical Trials 2009; 6: 252-260. http://ctj.sagepub.com
AN  - WOS:000267619600006
AU  - Magruder, K. M.
AU  - Ouyang, B.
AU  - Miller, S.
AU  - Tilley, B. C.
DA  - Jun
DO  - 10.1177/1740774509105224
IS  - 3
N1  - 19528134
PY  - 2009
SN  - 1740-7745
SP  - 252-260
ST  - Retention of Under-represented Minorities in Drug Abuse Treatment Studies
T2  - Clinical Trials
TI  - Retention of Under-represented Minorities in Drug Abuse Treatment Studies
VL  - 6
ID  - 3145
ER  - 

TY  - JOUR
AB  - BACKGROUND: Recruitment of controls remains a challenge in case-control studies and particularly in studies involving minority populations. METHODS: We compared characteristics of controls recruited through random digit dialing (RDD) to those of community controls enrolled through churches, health events and other outreach sources among women of African ancestry (AA) participating in the Women's Circle of Health Study, a case-control study of breast cancer. Odds ratios and 95% confidence intervals were also computed using unconditional logistic regression to evaluate the impact of including the community controls for selected variables relevant to breast cancer and for which there were significant differences in distribution between the two control groups. RESULTS: Compared to community controls (n=347), RDD controls (n=207) had more years of education and higher income, lower body mass index, were more likely to have private insurance, and less likely to be single. While the percentage of nulliparous women in the two groups was similar, community controls tended to have more children, have their first child at a younger age, and were less likely to breastfeed their children. Dietary intake was similar in the two groups. Compared to census data, the combination of RDD and community controls seems to be more representative of the general population than RDD controls alone. Furthermore, the inclusion of the community group had little impact on the magnitude of risk estimates for most variables, while enhancing statistical power. CONCLUSIONS: Community-based recruitment was found to be an efficient and feasible method to recruit AA controls.
AD  - The Cancer Institute of New Jersey, Robert Wood Johnson Medical School, 195 Little Albany Street, New Brunswick, NJ 08901, USA. elisa.bandera@umdnj.edu
AN  - 23721229
AU  - Bandera, E. V.
AU  - Chandran, U.
AU  - Zirpoli, G.
AU  - McCann, S. E.
AU  - Ciupak, G.
AU  - Ambrosone, C. B.
C2  - PMC3681587
DA  - May 31
DO  - 10.1186/1471-2288-13-71
DP  - NLM
ET  - 2013/06/01
KW  - Adult
African Continental Ancestry Group
Aged
Breast Neoplasms/*epidemiology
Carcinoma, Intraductal, Noninfiltrating/*epidemiology
*Case-Control Studies
*Control Groups
European Continental Ancestry Group
Female
Humans
Male
Middle Aged
*Minority Groups
Patient Selection
Research Design
Risk Factors
Young Adult
LA  - eng
N1  - 1471-2288
Bandera, Elisa V
Chandran, Urmila
Zirpoli, Gary
McCann, Susan E
Ciupak, Gregory
Ambrosone, Christine B
P30 CA072720/CA/NCI NIH HHS/United States
P01 CA151135/CA/NCI NIH HHS/United States
P30CA072720/CA/NCI NIH HHS/United States
R01 CA100598/CA/NCI NIH HHS/United States
N01PC-2010-00027/PC/NCI NIH HHS/United States
K22 CA138563/CA/NCI NIH HHS/United States
1US58DP003931-01/DP/NCCDPHP CDC HHS/United States
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, U.S. Gov't, P.H.S.
BMC Med Res Methodol. 2013 May 31;13:71. doi: 10.1186/1471-2288-13-71.
PY  - 2013
SN  - 1471-2288
SP  - 71
ST  - Rethinking sources of representative controls for the conduct of case-control studies in minority populations
T2  - BMC Med Res Methodol
TI  - Rethinking sources of representative controls for the conduct of case-control studies in minority populations
VL  - 13
ID  - 330
ER  - 

TY  - JOUR
AB  - OBJECTIVE: African American men have higher prostate cancer incidence rates than White men, for reasons not completely understood. This review summarizes the existing literature of race-specific associations between risk factors and prostate cancer in order to examine whether associations differ. METHODS: We reviewed epidemiologic studies published between January 1970 and December 2008 that reported race-specific effect estimates. We focused mainly on modifiable risk factors related to lifestyle and health. A total of 37 articles from 21 study populations met our inclusion criteria. RESULTS: We found no evidence of racial differences in associations between prostate cancer and alcohol intake, tobacco use, and family history of prostate cancer. Research suggests that a modest positive association may exist between height and prostate cancer risk (all prostate cancer and advanced prostate cancer) among Whites only. No clear patterns were observed for associations with physical activity, weight/body mass index, dietary factors, occupational history, sexual behavior, sexually transmissible infections, and other health conditions. DISCUSSION: Our results suggest few differences in prostate cancer risk factors exist between racial groups and underscore areas where additional research is needed. Future studies should enroll higher numbers of African American participants and report results for advanced prostate cancer.
AD  - Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina, CB #7435, McGavran-Greenberg Hall, Chapel Hill, NC, USA.
AN  - 21184263
AU  - Mordukhovich, I.
AU  - Reiter, P. L.
AU  - Backes, D. M.
AU  - Family, L.
AU  - McCullough, L. E.
AU  - O'Brien, K. M.
AU  - Razzaghi, H.
AU  - Olshan, A. F.
C2  - PMC3443558
C6  - NIHMS318727
DA  - Mar
DO  - 10.1007/s10552-010-9712-5
DP  - NLM
ET  - 2010/12/25
IS  - 3
KW  - African Americans/statistics & numerical data
African Continental Ancestry Group/*statistics & numerical data
European Continental Ancestry Group/*statistics & numerical data
Humans
Life Style
Male
Prostatic Neoplasms/*ethnology/pathology
Retrospective Studies
Risk Factors
LA  - eng
N1  - 1573-7225
Mordukhovich, Irina
Reiter, Paul L
Backes, Danielle M
Family, Leila
McCullough, Lauren E
O'Brien, Katie M
Razzaghi, Hilda
Olshan, Andrew F
P30 ES010126/ES/NIEHS NIH HHS/United States
R25 CA57726/CA/NCI NIH HHS/United States
T32ES007018/ES/NIEHS NIH HHS/United States
T32 ES007018/ES/NIEHS NIH HHS/United States
T32 CA009330/CA/NCI NIH HHS/United States
2-T32-CA09330/CA/NCI NIH HHS/United States
R24 HD050924/HD/NICHD NIH HHS/United States
P30ES10126/ES/NIEHS NIH HHS/United States
R25 CA057726/CA/NCI NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
Review
Cancer Causes Control. 2011 Mar;22(3):341-57. doi: 10.1007/s10552-010-9712-5. Epub 2010 Dec 24.
PY  - 2011
SN  - 0957-5243 (Print)
0957-5243
SP  - 341-57
ST  - A review of African American-white differences in risk factors for cancer: prostate cancer
T2  - Cancer Causes Control
TI  - A review of African American-white differences in risk factors for cancer: prostate cancer
VL  - 22
ID  - 404
ER  - 

TY  - JOUR
AB  - OBJECTIVE: The purpose of this paper is to critically review intervention studies that aimed to increase African-Americans' participation in colorectal cancer (CRC) screening. DATA SOURCE: Potential studies were identified using a combination of key words in five computerized databases. STUDY INCLUSION AND EXCLUSION CRITERIA: Articles were selected if they met all of the inclusion criteria: (1) The study's purpose was to test an intervention to increase CRC screening. (2) At least 50% of the sample was African-American. (3) The study focused on individuals 50 years and older. (4) The study was published between 2000 and 2008. DATA EXTRACTION: Abstracts and reference lists were scanned to determine relevance and a copy of the article was obtained. DATA SYNTHESIS: Data from each study were extracted and placed in a matrix for synthesis. RESULTS: Interventions focused on recruitment from health care centers, churches, housing projects, and senior centers. Both direct and indirect strategies were used to identify the barriers to CRC screening. CONCLUSIONS: Findings suggest that interventions are most successful when they target individuals or communities, address known barriers to screening, deliver tailored messages, use multiple methods of message delivery, and are delivered over multiple time points.
AD  - Underserved Populations Research, Behavioral Research Center, American Cancer Society, 250 Williams Street, Atlanta, GA 30303, USA. Barbara.Powe@cancer.org
AN  - 21039289
AU  - Powe, B. D.
AU  - Faulkenberry, R.
AU  - Harmond, L.
DA  - Nov-Dec
DO  - 10.4278/ajhp.080826-LIT-162
DP  - NLM
ET  - 2010/11/03
IS  - 2
KW  - African Americans/*psychology
Colorectal Neoplasms/*diagnosis/*ethnology/prevention & control
Community Participation
Community-Institutional Relations
Early Detection of Cancer/methods/psychology
Health Promotion/*methods
Humans
Middle Aged
United States
LA  - eng
N1  - 2168-6602
Powe, Barbara D
Faulkenberry, Rachel
Harmond, Lokie
Journal Article
Review
United States
Am J Health Promot. 2010 Nov-Dec;25(2):92-9. doi: 10.4278/ajhp.080826-LIT-162.
PY  - 2010
SN  - 0890-1171
SP  - 92-9
ST  - A review of intervention studies that seek to increase colorectal cancer screening among African-Americans
T2  - Am J Health Promot
TI  - A review of intervention studies that seek to increase colorectal cancer screening among African-Americans
VL  - 25
ID  - 407
ER  - 

TY  - JOUR
AB  - QUESTION: Does aromatherapy (treatment with aromatic plant extracts known as essential oils) have an effect on clinical outcomes in patients with various conditions? Data sources: Clinical trials that were published in any language up to June 1999 were identified by searching Medline, EMBASE/Excerpta Medica, British Nursing Index, CISCOM, and AMED using the terms alternative medicine, massage, essential oils, and aromatherapy; and by contacting experts. Study selection: Randomised controlled trials of the use of aromatherapy in human patients were included. Studies of the local effects of aromatherapy (eg, antiseptic effects of tea tree oil) and pre-clinical studies of healthy volunteers were excluded. Data extraction: Data were extracted on the condition under investigation, sample characteristics, type of intervention and placebo, outcomes, and results. Methodological quality of studies was assessed using the Jadad scale (randomisation, blinding, and accounting for dropouts). Main results: 12 studies were identified. 6 trials evaluated the effects of aromatherapy massage on anxiety or wellbeing in patients with cancer, patients who had cardiac surgery, and patients in an intensive care unit. All interventions were given by nurses in hospital settings. Jadad scores for methodological quality ranged from 0-2 out of 5, with a rating of 5 indicating the highest quality. Study results could not be pooled because of study heterogeneity. 5 of the studies reported that patients who received aromatherapy massage had small reductions in anxiety or improvements in wellbeing immediately after the intervention: foot massage with plain oil plus orange blossom oil; massage with oil plus aroma; massage plus lavender oil; and full body massage with bland oil plus chamomile oil (2 studies). 1 study of massage with almond oil plus English lavender oil compared with spike lavender oil found no group differences for anxiety. The remaining 6 trials each dealt with the effects of a unique intervention on a specific condition. 5 of the trials found a benefit of aromatherapy over placebo or control: inhalation of a vaporised aromatic mixture to improve pulmonary function in the common cold; oral aromatic liquid to prevent relapse of bronchitis; dummy cigarettes with black pepper smell or menthol smell for smoking withdrawal symptoms; inhalation of steam plus aroma for anxiety; and scalp massage of carrier oils plus essential oils for alopecia areata. 1 study found no difference for bath water with natural or synthetic lavender oil and placebo for perineal discomfort after childbirth. Conclusions: Aromatherapy massage has a small, transient effect on reduction of anxiety immediately after administration. Individual studies suggest possible benefits of inhaled or oral aromatherapy for various conditions.
AD  - Lecturer, Centre for Evidence Based Nursing, University of York, York, UK
AN  - 107143315. Language: English. Entry Date: 20001101. Revision Date: 20150820. Publication Type: Journal Article
AU  - Flemming, K.
DB  - CINAHL Complete
DP  - EBSCOhost
KW  - Aromatherapy
Massage
Anxiety -- Prevention and Control
Clinical Trials
Systematic Review
Treatment Outcomes
Psychological Well-Being
Cancer Patients
Cardiac Patients
Critically Ill Patients
N1  - abstract; commentary. Journal Subset: Core Nursing; Europe; Nursing; Peer Reviewed; UK & Ireland. NLM UID: 9815947.
PY  - 2000
SN  - 1367-6539
SP  - 118-118
ST  - Review: aromatherapy massage is associated with small, transient reductions in anxiety...commentary on Cooke B, Ernst E. Aromatherapy: a systematic review. BR J GEN PRACT 2000 Jan;50:493-6
T2  - Evidence Based Nursing
TI  - Review: aromatherapy massage is associated with small, transient reductions in anxiety...commentary on Cooke B, Ernst E. Aromatherapy: a systematic review. BR J GEN PRACT 2000 Jan;50:493-6
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=107143315&site=ehost-live&scope=site
ID  - 2082
ER  - 

TY  - JOUR
AB  - Introduction: Lymphedema is a potentially debilitating condition that occurs among breast cancer survivors. This study examines the incidence of self-reported lymphedema, timing of lymphedema onset, and associations between sociodemographic, clinical and lifestyle factors and lymphedema risk across racial-ethnic groups using data from a multicenter, multiethnic prospective cohort study of breast cancer survivors, the Health, Eating, Activity and Lifestyle Study. Methods: A total of 666 women diagnosed with breast cancer staged as in situ, localized or regional disease at ages 35 to 64years were recruited through the Surveillance, Epidemiology, and End Results registries in New Mexico (non-Hispanic white and Hispanic white), Los Angeles County (black), and Western Washington (non-Hispanic white) and followed for a median of 10.2years. We evaluated sociodemographic factors, breast cancer- and treatment-related factors, comorbidities, body mass index (BMI), hormonal factors, and lifestyle factors in relation to self-reported lymphedema by fitting Cox proportional hazards models, estimating hazard ratios (HR) and 95% confidence intervals (CI). Results: Over the follow-up period, 190 women (29%) reported lymphedema. The median time from breast cancer diagnosis to onset of lymphedema was 10.5months (range: 0.5 to 134.9months). Factors independently associated with lymphedema were total/modified radical mastectomy (versus partial/less than total mastectomy; HR = 1.37, 95% CI: 1.01 to 1.85), chemotherapy (versus no chemotherapy; HR = 1.48, 95% CI: 1.09 to 2.02), no lymph nodes removed (versus ≥10 lymph nodes removed; HR = 0.17, 95% CI: 0.08 to 0.33), pre-diagnostic BMI ≥30kg/m2 (versus BMI <25kg/m2; HR = 1.59, 95% CI: 1.09 to 2.31), and hypertension (versus no hypertension; HR = 1.49, 95% CI: 1.06 to 2.10). After adjusting for demographics and breast cancer- and treatment-related factors, no significant difference in lymphedema risk was observed across racial/ethnic groups. Analyses stratified by race/ethnicity showed that hypertension and chemotherapy were lymphedema risk factors only for black women. Conclusions: Breast cancer patients who have undergone extensive surgery or extensive lymph node dissection, or who have a higher BMI should be closely monitored for detection and treatment of lymphedema. Further studies are needed to understand the roles of chemotherapy and hypertension in the development of lymphedema.
AD  - L. Bernstein, Beckman Research Institute, Division of Cancer Etiology, Department of Population Sciences, City of Hope, 1500 E Duarte Road, Duarte, CA, United States
AU  - Togawa, K.
AU  - Ma, H.
AU  - Sullivan-Halley, J.
AU  - Neuhouser, M. L.
AU  - Imayama, I.
AU  - Baumgartner, K. B.
AU  - Smith, A. W.
AU  - Alfano, C. M.
AU  - McTiernan, A.
AU  - Ballard-Barbash, R.
AU  - Bernstein, L.
DB  - Embase
Medline
DO  - 10.1186/s13058-014-0414-x
IS  - 4
KW  - contraceptive agent
estrogen
gestagen
tamoxifen
adult
article
Black person
body mass
breast cancer
cancer chemotherapy
cancer staging
cancer survivor
Caucasian
cohort analysis
comorbidity
controlled clinical trial
controlled study
demography
female
follow up
Hispanic
human
hypertension
lifestyle
lymphedema
major clinical study
mastectomy
multicenter study
prospective study
risk assessment
risk factor
self report
social status
LA  - English
M3  - Article
N1  - L606757069
2015-11-17
2015-11-19
PY  - 2014
SN  - 1465-542X
1465-5411
ST  - Risk factors for self-reported arm lymphedema among female breast cancer survivors: A prospective cohort study
T2  - Breast Cancer Research
TI  - Risk factors for self-reported arm lymphedema among female breast cancer survivors: A prospective cohort study
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L606757069&from=export
http://dx.doi.org/10.1186/s13058-014-0414-x
VL  - 16
ID  - 1030
ER  - 

TY  - JOUR
AB  - Active surveillance (AS) has emerged as the preferred management strategy for many men with prostate cancer (PC); however, insufficient longitudinal monitoring may increase the risk of poor outcomes. We sought to determine rates of patients becoming lost to follow-up (LTFU) and associated risk factors in a large AS cohort. The Michigan Urologic Surgery Improvement Collaborative (MUSIC) maintains a prospective registry of PC patients from 44 academic and community urology practices. Over a 6-yr period (2011-2017), we identified patients managed with AS. LTFU was defined as any 18-mo period where no pertinent surveillance testing was entered in the registry. With a median surveillance period of 32 mo, the estimated 2-yr LTFU-free probability calculated by Kaplan-Meier method was 90% (95% confidence interval [CI]=89-92%). Both African American race (hazard ratio [HR]: 2.77, 95% CI=1.81-4.24) and Charlson comorbidity index ≥1 (HR: 1.55, 95% CI=1.08-2.23) were independently associated with increased risk of LTFU. There was variability in rates of estimated 2-yr LTFU-free survival across MUSIC practices, ranging from 52% (95% CI=21-100%) to 99% (95% CI=97-100%), with a median of 96% (interquartile range: 94-98%), although this did not reach statistical significance (p=0.076). These data reveal opportunities for urology practices to identify systems to reduce rates of LTFU and improve the long-term safety of AS. PATIENT SUMMARY: With a median observation period of 32 mo, an estimated 10% of patients will be lost to follow-up at the 2 yr time point while on AS. African American men and generally unhealthy patients were at increased risk, and there was variability from one urology practice to another. There is ample opportunity to improve the quality of the performance of AS.
AD  - Department of Urology, Wayne State University, School of Medicine, Detroit, MI, USA.
Department of Urology, University of Michigan, School of Medicine, Ann Arbor, MI, USA; Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Department of Urology, University of Michigan, School of Medicine, Ann Arbor, MI, USA.
Department of Urology, Wayne State University, School of Medicine, Detroit, MI, USA. Electronic address: mcher@med.wayne.edu.
AN  - 30177290
AU  - Ginsburg, K. B.
AU  - Auffenberg, G. B.
AU  - Qi, J.
AU  - Powell, I. J.
AU  - Linsell, S. M.
AU  - Montie, J. E.
AU  - Miller, D. C.
AU  - Cher, M. L.
DA  - Dec
DO  - 10.1016/j.eururo.2018.08.010
DP  - NLM
ET  - 2018/09/05
IS  - 6
KW  - African Americans
Aged
Comorbidity
Disease Progression
European Continental Ancestry Group
Health Status
Humans
*Lost to Follow-Up
Male
Michigan/epidemiology
Middle Aged
Population Surveillance
Prostatic Neoplasms/*diagnosis/ethnology/mortality/*therapy
Registries
Risk Assessment
Risk Factors
Time Factors
*Watchful Waiting
*Active surveillance
*Prostate cancer
*Quality improvement
LA  - eng
N1  - 1873-7560
Ginsburg, Kevin B
Auffenberg, Gregory B
Qi, Ji
Powell, Isaac J
Linsell, Susan M
Montie, James E
Miller, David C
Cher, Michael L
Journal Article
Research Support, Non-U.S. Gov't
Switzerland
Eur Urol. 2018 Dec;74(6):704-707. doi: 10.1016/j.eururo.2018.08.010. Epub 2018 Aug 31.
PY  - 2018
SN  - 0302-2838
SP  - 704-707
ST  - Risk of Becoming Lost to Follow-up During Active Surveillance for Prostate Cancer
T2  - Eur Urol
TI  - Risk of Becoming Lost to Follow-up During Active Surveillance for Prostate Cancer
VL  - 74
ID  - 107
ER  - 

TY  - JOUR
AB  - BACKGROUND: Gastrointestinal perforation is a serious adverse event associated with bevacizumab, an inhibitor of vascular endothelial growth factor (VEGF) widely used in current cancer treatment. The association is highlighted by a black-box warning issued by the US Food and Drug Administration, recommending that bevacizumab be permanently discontinued in patients with gastrointestinal perforation. However, no significant association has yet been established between bevacizumab and gastrointestinal perforation in randomised controlled trials. We did a systematic review and meta-analysis of published randomised controlled trials to assess the overall risk of gastrointestinal perforation associated with bevacizumab treatment. METHODS: We searched PubMed and Web of Science for articles published between January, 1966, and July, 2008. Additionally, abstracts presented at American Society of Clinical Oncology conferences held between January, 2000, and July, 2008, were searched to identify relevant clinical trials. Eligible studies included prospective randomised controlled trials in which bevacizumab was compared with controls in combination with standard anti-neoplastic therapy. Summary incidence rates, relative risks, and 95% CIs were calculated using a fixed-effects or random-effects model, depending on the heterogeneity of the included studies. FINDINGS: 12,294 patients with a variety of solid tumours from 17 randomised controlled trials were included in our analysis. The incidence of gastrointestinal perforation was 0.9% (95% CI 0.7-1.2) among patients receiving bevacizumab, with a mortality of 21.7% (11.5-37.0). Patients treated with bevacizumab had a significantly increased risk of gastrointestinal perforation compared with patients treated with control medication, with a relative risk of 2.14 (95% CI 1.19-3.85; p=0.011). Risk varied with bevacizumab dose and tumour type. Relative risks for patients receiving bevacizumab at 5 and 2.5 mg/kg per week were 2.67 (95% CI 1.14-6.26) and 1.61 (0.76-3.38), respectively. Higher risks were observed in patients with colorectal carcinoma (relative risk 3.10, 95% CI 1.26-7.63) and renal cell cancer (relative risk 5.67, 0.66-48.42). INTERPRETATION: The addition of bevacizumab to cancer therapy significantly increased the risk of gastrointestinal perforation compared with controls. The risk may vary with bevacizumab dose and tumour type. Further studies are recommended to investigate the use of bevacizumab in selected patients who have recovered from gastrointestinal perforation. FUNDING: Stony Brook University Research Foundation.
AD  - Division of Hematology and Medical Oncology, Department of Medicine, Stony Brook University Medical Center, Stony Brook, NY 11794-9447, USA.
AN  - 19482548
AU  - Hapani, S.
AU  - Chu, D.
AU  - Wu, S.
DA  - Jun
DO  - 10.1016/s1470-2045(09)70112-3
DP  - NLM
ET  - 2009/06/02
IS  - 6
KW  - Antibodies, Monoclonal/*adverse effects/*therapeutic use
Antibodies, Monoclonal, Humanized
Bevacizumab
Controlled Clinical Trials as Topic
Gastrointestinal Diseases/*chemically induced/etiology
Humans
Intestinal Perforation/*chemically induced/etiology
Neoplasms/*drug therapy
Risk Factors
LA  - eng
N1  - 1474-5488
Hapani, Sanjaykumar
Chu, David
Wu, Shenhong
Journal Article
Meta-Analysis
Research Support, Non-U.S. Gov't
Review
Systematic Review
England
Lancet Oncol. 2009 Jun;10(6):559-68. doi: 10.1016/S1470-2045(09)70112-3.
PY  - 2009
SN  - 1470-2045
SP  - 559-68
ST  - Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis
T2  - Lancet Oncol
TI  - Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis
VL  - 10
ID  - 467
ER  - 

TY  - JOUR
AB  - Purpose: To evaluate the performance of apparent diffusion coefficient (ADC) and lesion volume in potentially risk-stratifying patients with prostate cancer (PCa). Materials and Methods: Men with elevated prostate-specific antigen or abnormal digital rectal exam underwent a 3T multiparametric magnetic resonance imaging (mpMRI) with endorectal coil. ADC maps were calculated using b values of 0, 500, 1000, and 1500; additional images were obtained with b value of 2000. We prospectively enrolled 312 men with lesions suspicious for cancer (suspicion score 2–5) on mpMRI. MRI/ultrasound fusion-guided prostate biopsies were performed. Mean ADC of suspicious lesions were correlated against lesion volume, Gleason and D'Amico risk. Results: The cancer detection rate of fusion biopsy per lesion was 45.6% (206/452). Cancerous lesions were larger (median volume: 0.40 vs. 0.30 cm3; P = 0.016). The median ADC (×10−6 mm2/sec) for lesions negative and positive for PCa were 984.5 and 666.5, respectively (P &lt; 0.0001). The AUC of ADC in predicting PCa was 0.79. Larger lesions were associated with higher risk PCa (Gleason and D'Amico) and lower ADC (all P &lt; 0.0001). Conclusion: The mean ADC of suspicious lesions on mpMRI was inversely correlated, while lesion volume had a direct correlation with PCa detection. Future follow-up studies are needed to assess longitudinal cancer risks of suspicious mpMRI lesions. Level of Evidence: 2. J. Magn. Reson. Imaging 2017;45:610–616. © 2016 International Society for Magnetic Resonance in Medicine
AD  - Department of Urology, University of Michigan Medical School, Ann Arbor, MI, United States
Department of Radiology, Hofstra North Shore-LIJ School of Medicine, New Hyde Park, NY, United States
Department of Pathology, Hofstra North Shore-LIJ School of Medicine, New Hyde Park, NY, United States
Molecular Imaging Program, National Institutes of Health, Bethesda, MD, United States
Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, United States
AU  - Salami, S. S.
AU  - Ben-Levi, E.
AU  - Yaskiv, O.
AU  - Turkbey, B.
AU  - Villani, R.
AU  - Rastinehad, A. R.
DB  - Scopus
DO  - 10.1002/jmri.25363
IS  - 2
KW  - active surveillance
fusion biopsy
prostate cancer screening
M3  - Article
N1  - Cited By :12
Export Date: 22 March 2021
PY  - 2017
SP  - 610-616
ST  - Risk stratification of prostate cancer utilizing apparent diffusion coefficient value and lesion volume on multiparametric MRI
T2  - Journal of Magnetic Resonance Imaging
TI  - Risk stratification of prostate cancer utilizing apparent diffusion coefficient value and lesion volume on multiparametric MRI
UR  - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84994103549&doi=10.1002%2fjmri.25363&partnerID=40&md5=3f55f80e0a4d1019b812cab0d6571cb9
VL  - 45
ID  - 2322
ER  - 

TY  - JOUR
AB  - Background: Tamoxifen has been US Food and Drug Administration-approved for primary prevention of breast cancer since 1998 but has not been widely adopted, in part because of increased risk of serious side effects. Little is known about the risk-benefit profiles of women who use chemoprevention outside of a clinical trial. We examined characteristics associated with initiation and discontinuation of tamoxifen for primary prevention of breast cancer within a large cohort of women with a first-degree family history of breast cancer. Methods: This research was conducted within The Sister Study, a cohort of 50 884 US and Puerto Rican women age 35 to 74 years enrolled from 2003 to 2009. Eligible women were breast cancer-free at enrollment and had a sister who had been diagnosed with breast cancer. Participants reported tamoxifen use, ages started and stopped taking tamoxifen, and total duration of use at enrollment. We identified 788 tamoxifen users and 3131 nonusers matched on age and year of enrollment who had no history of contraindicating factors (stroke, transient ischemic attack, cataract, endometrial or uterine cancer). Characteristics associated with tamoxifen initiation were evaluated with multivariable conditional logistic regression. All statistical tests were two-sided. Results: Based on published risk-benefit indices, 20% of women who used tamoxifen had insufficient evidence that the benefits of tamoxifen outweigh the risk of serious side effects. After 4.5 years, 46% of women had discontinued tamoxifen. Conclusions: While the majority of women who used tamoxifen for primary prevention of breast cancer were likely to benefit, substantial discontinuation of tamoxifen before five years and use by women at risk of serious side effects may attenuate benefits for breast cancer prevention.
AD  - H.B. Nichols, Department of Epidemiology, University of North Carolina, Gillings School of Global Public Health, 2102A McGavran-Greenberg Hall, 135 Dauer Drive, Chapel Hill, NC, United States
AU  - Nichols, H. B.
AU  - DeRoo, L. A.
AU  - Scharf, D. R.
AU  - Sandler, D. P.
DB  - Embase
Medline
DO  - 10.1093/jnci/dju354
IS  - 1
KW  - tamoxifen
adult
African American
age
aged
article
breast cancer
cancer prevention
cancer risk
Caucasian
cohort analysis
drug use
family history
female
first-degree relative
human
hysterectomy
major clinical study
ovariectomy
primary prevention
priority journal
Puerto Rican
race difference
risk benefit analysis
sensitivity analysis
telephone interview
treatment duration
LA  - English
M3  - Article
N1  - L604756144
2015-06-11
2016-05-13
PY  - 2015
SN  - 1460-2105
0027-8874
ST  - Risk-benefit profiles of women using tamoxifen for chemoprevention
T2  - Journal of the National Cancer Institute
TI  - Risk-benefit profiles of women using tamoxifen for chemoprevention
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L604756144&from=export
http://dx.doi.org/10.1093/jnci/dju354
VL  - 107
ID  - 1015
ER  - 

TY  - JOUR
AN  - 10547378
AU  - Taylor, A. L.
AU  - Adams-Campbell, L. L.
AU  - Wright, J. T., Jr.
DA  - Nov 3
DO  - 10.1093/jnci/91.21.1792
DP  - NLM
ET  - 1999/11/05
IS  - 21
KW  - African Americans/statistics & numerical data
Anticarcinogenic Agents/*adverse effects
Breast Neoplasms/ethnology/*prevention & control
Endometrial Neoplasms/chemically induced
Estrogen Receptor Modulators/*adverse effects
European Continental Ancestry Group/statistics & numerical data
Female
Humans
Practice Guidelines as Topic
Randomized Controlled Trials as Topic
Risk
Selective Estrogen Receptor Modulators/*adverse effects
Stroke/chemically induced
Tamoxifen/*adverse effects
Venous Thrombosis/chemically induced
LA  - eng
N1  - Taylor, A L
Adams-Campbell, L L
Wright, J T Jr
Comment
Editorial
United States
J Natl Cancer Inst. 1999 Nov 3;91(21):1792-3. doi: 10.1093/jnci/91.21.1792.
PY  - 1999
SN  - 0027-8874 (Print)
0027-8874
SP  - 1792-3
ST  - Risk/benefit assessment of tamoxifen to prevent breast cancer-still a work in progress?
T2  - J Natl Cancer Inst
TI  - Risk/benefit assessment of tamoxifen to prevent breast cancer-still a work in progress?
VL  - 91
ID  - 711
ER  - 

TY  - JOUR
AB  - Objective: African-American children have higher rates of tobacco-associated morbidity. Few studies have objectively measured racial differences in the exposure of children to tobacco smoke. The objective of this study was to test whether African-American children have higher levels of cotinine compared to white children while accounting for ambient measures of tobacco smoke. Setting: Community-based sample of asthmatic children (n = 220) enrolled in an environmental tobacco smoke (ETS) reduction trial. Participants: A biracial sample (55% African American) of children with asthma aged 5 to 12 years who were routinely exposed to ETS. Measurements: We measured cotinine levels in serum and hair samples at baseline, 6 months, and 12 months. We measured the level of ETS exposure over a 6-month period by placing air nicotine dosimeters in the homes of the children at baseline and at 6-month study visits. Results: African-American children had significantly higher levels of cotinine at all time points in the study. At the 12-month visit, African-American children had higher levels of serum cotinine (1.39 mu g/dL vs 0.80 mu g/dL, p = 0.001) and hair cotinine (0.28 ng/mg vs 0.08 ng/mg, p < 0.0001) when compared with white children. In a repeated-measures analysis, African-American children had significantly higher levels of serum cotinine (beta = 0.28, p = 0.04) and hair cotinine (beta = 1.40, p < 0.0001) compared with white children. Air nicotine levels and housing volume were independently associated with higher levels of cotinine. Conclusions: Among children with asthma, African-American children have higher levels of serum and hair cotinine compared with white children.
AN  - WOS:000245072900035
AU  - Wilson, S. E.
AU  - Kahn, R. S.
AU  - Khoury, J.
AU  - Lanphear, B. P.
DA  - Mar
DO  - 10.1378/chest.06-2123
IS  - 3
N1  - Annual Meeting of the Pediatric-Academic-Societies
APR 29-MAY 02, 2006
San Francisco, CA
Pediat Acad Soc
17356104
PY  - 2007
SN  - 0012-3692
SP  - 856-862
ST  - The role of air nicotine in explaining racial differences in cotinine among tobacco-exposed children
T2  - Chest
TI  - The role of air nicotine in explaining racial differences in cotinine among tobacco-exposed children
VL  - 131
ID  - 3200
ER  - 

TY  - JOUR
AB  - OBJECTIVES: This article assesses pastor-level factors that affect the successful recruitment and implementation of community-based health promotion programs in Black churches. METHODS: Semistructured interviews with 16 pastors of Black churches were analyzed for content. RESULTS: We found that although the involvement of Black pastors in an array of secular activities makes them open to participate in health programs, their overcommitment to other issues can negatively influence their ability to participate. Second, although Black pastors appreciate being included in and benefiting from health research, minorities' history of being underserved and exploited can lead to suspiciousness and reluctance to participate. CONCLUSIONS: Our findings suggest that those interested in developing church-based health programs in the Black community must be attuned to how the same factors can both facilitate and hinder a program's development.
AD  - Department of Sociology, Temple University, Philadelphia, Pa 19122-6089, USA. markens@temple.edu
AN  - 11988451
AU  - Markens, S.
AU  - Fox, S. A.
AU  - Taub, B.
AU  - Gilbert, M. L.
C2  - PMC1447165
DA  - May
DO  - 10.2105/ajph.92.5.805
DP  - NLM
ET  - 2002/05/04
IS  - 5
KW  - Adult
African Americans/*psychology
Attitude to Health/*ethnology
Breast Neoplasms/diagnostic imaging/*ethnology
Clergy/*psychology
Community Health Services/*organization & administration
Female
Health Knowledge, Attitudes, Practice
Health Promotion/*organization & administration
Humans
Interviews as Topic
Los Angeles
*Mammography/statistics & numerical data
Organizational Case Studies
*Religion and Medicine
Role
LA  - eng
N1  - 1541-0048
Markens, Susan
Fox, Sarah A
Taub, Bonnie
Gilbert, Mary Lou
R01 CA065880/CA/NCI NIH HHS/United States
1 R01 CA65880/CA/NCI NIH HHS/United States
Journal Article
Research Support, U.S. Gov't, P.H.S.
Am J Public Health. 2002 May;92(5):805-10. doi: 10.2105/ajph.92.5.805.
PY  - 2002
SN  - 0090-0036 (Print)
0090-0036
SP  - 805-10
ST  - Role of Black churches in health promotion programs: lessons from the Los Angeles Mammography Promotion in Churches Program
T2  - Am J Public Health
TI  - Role of Black churches in health promotion programs: lessons from the Los Angeles Mammography Promotion in Churches Program
VL  - 92
ID  - 669
ER  - 

TY  - JOUR
AB  - Lung cancers with an epidermal growth factor receptor (EGFR) gene mutation account for ~40 % of adenocarcinomas in East Asians and ~15 % of those in Caucasians and African Americans, which makes them one of the most common molecularly defined lung cancer subsets. The discriminative clinical and pathological features of lung cancers with EGFR mutations have been intensively studied, and the predictive role of an EGFR mutation for treatment with EGFR tyrosine kinase inhibitors (EGFR-TKIs) is well established. However, controversial issues remain regarding the clinical and therapeutic implications of EGFR mutations in lung cancers. These include the prognostic impact of the EGFR mutation, its predictive implication for successful treatment with anticancer agents other than EGFR-TKIs, appropriate cytotoxic agents for lung cancers with this mutation, and the chemosensitivity of EGFR-mutation-positive lung cancers after acquisition of resistance to EGFR-TKIs. In this review, we discuss these unanswered but important questions, referring to in vitro studies, basic research, retrospective analyses, and the results of phase III clinical trials.
AD  - Division of Thoracic Surgery, Department of Surgery, Kinki University Faculty of Medicine, 377-2 Ohno-Higashi, Osaka-Sayama, 589-8511, Japan, ascaris@surg2.med.kyushu-u.ac.jp.
AN  - 25983263
AU  - Suda, K.
AU  - Mitsudomi, T.
DA  - Aug
DO  - 10.1007/s00204-015-1524-7
DP  - NLM
ET  - 2015/05/20
IS  - 8
KW  - Animals
Antineoplastic Agents/administration & dosage/*therapeutic use
Clinical Trials, Phase III as Topic
Drug Resistance, Neoplasm/*genetics
ErbB Receptors/antagonists & inhibitors/*genetics
Humans
Lung Neoplasms/drug therapy/*genetics/pathology
*Mutation
Prognosis
Protein-Tyrosine Kinases/*antagonists & inhibitors
LA  - eng
N1  - 1432-0738
Suda, Kenichi
Mitsudomi, Tetsuya
Journal Article
Research Support, Non-U.S. Gov't
Review
Germany
Arch Toxicol. 2015 Aug;89(8):1227-40. doi: 10.1007/s00204-015-1524-7. Epub 2015 May 17.
PY  - 2015
SN  - 0340-5761
SP  - 1227-40
ST  - Role of EGFR mutations in lung cancers: prognosis and tumor chemosensitivity
T2  - Arch Toxicol
TI  - Role of EGFR mutations in lung cancers: prognosis and tumor chemosensitivity
VL  - 89
ID  - 242
ER  - 

TY  - THES
AB  - Family health history (FHH) has been recognized as an important tool in cancer prevention and health promotion. To date, literature on FHH discussions about cancer have largely focused on patient-physician communication or the dissemination of cancer-specific genetic tests results within the family. Fewer studies have sought to identify family factors that may promote FHH discussions, yet this type of information could be used to identify families needing support in having these conversations. Thus, the present study examined relations between family organization (cohesion and flexibility), communication openness, and FHH communication about cancer within a diverse group of women recruited from an urban, safety-net women's health clinic. Participants were enrolled in a randomized control trial examining the effects of an educational intervention on family communication about hereditary breast and colon cancers (Kin Fact Study). For the present study, baseline survey data for 472 women were analyzed. Participants completed measures on demographics, family organization, communication openness, and FHH communication. Average age was 34 years and 59% reported being Black. Thirty-one percent had graduated high school and 28% reported having commercial health insurance. Seventy-five percent of women reported a family history of cancer in a first or second degree relative. Descriptive statistics, correlations, and multiple linear regression and hierarchical logistic regressions, adjusting for key factors, were performed. Nineteen percent of women actively collected FHH information about cancer and 11% reported actively sharing cancer risk information with relatives. Being older, having a greater educational attainment, and having a family history of cancer was associated with having collected FHH; while being older and reporting higher levels of cohesion/flexibility was associated with sharing cancer risk information. Adjusting for demographic variables, cohesion, flexibility, and openness were not significant predictors of collecting or sharing FHH. Family history of cancer did not moderate the relationship between family organization and FHH. Cohesion and flexibility levels did significantly predict communication openness. This study contributes to a small but emergent literature in the field of FHH communication about cancer as it explores family context factors that may aid in the development of prevention interventions. Clinical implications and directions for future research are discussed. (PsycINFO Database Record (c) 2016 APA, all rights reserved)
AN  - 2014-99160-424
AU  - Rodriguez, Vivian M.
DB  - psyh
DP  - EBSCOhost
KW  - family organization
communication openness
family history
family health history
health history communication
patient-physician communication
cancer-specific genetic tests
family communication
hierarchical logistic regressions
cancer risk information
cancer prevention
prevention interventions
family context factors
commercial health insurance
health promotion
health clinic
colon cancers
family factors
baseline survey data
flexibility levels
degree relative
emergent literature
safety-net women
demographic variables
educational intervention
Clinical implications
multiple linear regression
educational attainment
Descriptive statistics
hereditary breast
sharing cancer
key factors
randomized control
Average age
Neoplasms
School Based Intervention
Family Relations
History
Organizations
N1  - Accession Number: 2014-99160-424. Other Journal Title: Dissertation Abstracts International. Partial author list: First Author & Affiliation: Rodriguez, Vivian M.; Virginia Commonwealth U., US. Release Date: 20141006. Publication Type: Dissertation Abstract (0400). Format Covered: Electronic. Document Type: Dissertation. Dissertation Number: AAI3597680. ISBN: 978-1-303-45858-3. Language: English. Major Descriptor: Health Promotion; Neoplasms; School Based Intervention; Family History. Minor Descriptor: Family Relations; History; Organizations. Classification: Health & Mental Health Treatment & Prevention (3300). Population: Human (10); Female (40). Age Group: Adulthood (18 yrs & older) (300); Thirties (30-39 yrs) (340). Methodology: Empirical Study; Quantitative Study.
PB  - ProQuest Information & Learning
PY  - 2014
SN  - 0419-4217
978-1-303-45858-3
ST  - The role of family organization in family health history communication about cancer
TI  - The role of family organization in family health history communication about cancer
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2014-99160-424&site=ehost-live&scope=site
VL  - 75
ID  - 1711
ER  - 

TY  - JOUR
AB  - BACKGROUND: Public willingness to donate tissue samples is critical to genetic research. Prior work has linked minority status and mistrust with less willingness to provide specimens. Some have suggested recruitment of prior research participants to address these barriers. We present data from a genetic epidemiology study with a request for blood and/or saliva specimens to (1) measure willingness to donate tissue/blood samples, (2) identify demographic, trust, and other factors associated with willingness to donate samples, and (3) measure willingness to participate in future genetic research. METHODS: We surveyed participants in the North Carolina Colorectal Cancer Study, which included biologic sample collection from consenting participants. Participants were later asked about sample provision; trust in researchers, and future research participation. RESULTS: African Americans were less likely to give a blood sample, when compared with whites (21% vs. 13%, P < 0.05). After controlling for "trust," this difference was no longer statistically significant (17% vs. 13%, P = 0.27). Those who had given samples were more likely to express willingness to participate in future research. CONCLUSION: Despite prior participation in a genetic epidemiology study, factors associated with provision of tissue samples reflected many previously identified demographic factors (race and trust). Interventions to improve and demonstrate the trustworthiness of the research team and recruitment of subjects with a record of sample donation might enhance future study participation.
AD  - School of Medicine, Emory University, Atlanta, Georgia 30331, USA. jcbusse@emory.edu
AN  - 20098329
AU  - Bussey-Jones, J.
AU  - Garrett, J.
AU  - Henderson, G.
AU  - Moloney, M.
AU  - Blumenthal, C.
AU  - Corbie-Smith, G.
C2  - PMC3114600
C6  - NIHMS272900
DA  - Feb
DO  - 10.1097/GIM.0b013e3181cd6689
DP  - NLM
ET  - 2010/01/26
IS  - 2
KW  - African Continental Ancestry Group/*psychology
*Blood Donors
European Continental Ancestry Group/*psychology
Female
*Genetic Research
Humans
Male
Middle Aged
*Tissue and Organ Procurement
*Trust
LA  - eng
N1  - 1530-0366
Bussey-Jones, Jada
Garrett, Joanne
Henderson, Gail
Moloney, Mairead
Blumenthal, Connie
Corbie-Smith, Giselle
P50 HG004488-01/HG/NHGRI NIH HHS/United States
U54RR024383/RR/NCRR NIH HHS/United States
P50 HG004488/HG/NHGRI NIH HHS/United States
R01 HG002830-02/HG/NHGRI NIH HHS/United States
R01 HG002830/HG/NHGRI NIH HHS/United States
R01 HG002830-01/HG/NHGRI NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
Genet Med. 2010 Feb;12(2):116-21. doi: 10.1097/GIM.0b013e3181cd6689.
PY  - 2010
SN  - 1098-3600 (Print)
1098-3600
SP  - 116-21
ST  - The role of race and trust in tissue/blood donation for genetic research
T2  - Genet Med
TI  - The role of race and trust in tissue/blood donation for genetic research
VL  - 12
ID  - 433
ER  - 

TY  - JOUR
AB  - Black/African–American women are more likely to get breast cancer at a young age and/or be diagnosed at a late disease stage, pointing to a greater need to promote mammography for Black women at earlier ages than are currently recommended. This study explores how perceived neighborhood social capital, that is, perceptions of how tight-knit a neighborhood is and what power that confers to neighborhood members, relates to use of mammography for Black women in Philadelphia. Living in a community with tight social ties (social cohesion) or that have a collective motivation for community change (collective efficacy) may increase the likelihood that an individual woman in that community will hear health messages from other community members and neighbors (diffusion of information) and will have access to health-related resources that allow them to engage in healthy behaviors. No prior studies have explored the role of social capital in decisions for mammography use. Using multilevel logistic regression, we analyzed self-report of mammography in the past year for 2586, Black women over age 40 across 381 Philadelphia, Pennsylvania USA census tracts. Our study included individual demographic and aggregates of individual-level social capital data from the Public Health Management Corporation's 2004, 2006, and 2008 Community Health Database waves, and 2000 US Census sociodemographic characteristics. Individual perceptions that a Black woman's neighborhood had high social capital, specifically collective efficacy, had a positive and statistically significant association with mammography use (OR = 1.40, CI: 1.05, 1.85). Our findings suggest that an individual woman's perception of greater neighborhood social capital may be related to increased mammography use. Although this analysis could not determine the direction of causality, it suggests that social capital may play a role in cancer preventive screening for African–American women in Philadelphia, which warrants further study. (PsycINFO Database Record (c) 2016 APA, all rights reserved)
AD  - Dean, Lorraine, 2237, Jackson St, Philadelphia, PA, US, 19145
AN  - 2014-08471-020
AU  - Dean, Lorraine
AU  - Subramanian, S. V.
AU  - Williams, David R.
AU  - Armstrong, Katrina
AU  - Charles, Camille Zubrinsky
AU  - Kawachi, Ichiro
DB  - psyh
DO  - 10.1016/j.socscimed.2013.11.057
DP  - EBSCOhost
KW  - Black/African–American
Cancer
Community participation
Mammography
Screening
Social capital
USA
Blacks
Cancer Screening
Human Females
Community Involvement
N1  - University of Pennsylvania, School of Medicine, Department of Biostatistics and Epidemiology, Philadelphia, PA, US. Release Date: 20141110. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: English. Major Descriptor: Blacks; Cancer Screening; Human Females; Mammography; Social Capital. Minor Descriptor: Community Involvement. Classification: Promotion & Maintenance of Health & Wellness (3365). Population: Human (10); Female (40). Location: US. Age Group: Adulthood (18 yrs & older) (300); Middle Age (40-64 yrs) (360). Tests & Measures: Southeastern Pennsylvania Household Health Survey. Methodology: Empirical Study; Mathematical Model; Quantitative Study. Page Count: 9. Issue Publication Date: Mar, 2014. Publication History: First Posted Date: Dec 13, 2013. Copyright Statement: All rights reserved. Elsevier Ltd. 2013.
Sponsor: National Institutes of Health, National Cancer Institute, US. Grant: 1F31CA136236. Recipients: No recipient indicated
PY  - 2014
SN  - 0277-9536
1873-5347
SP  - 148-156
ST  - The role of social capital in African–American women's use of mammography
T2  - Social Science & Medicine
TI  - The role of social capital in African–American women's use of mammography
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2014-08471-020&site=ehost-live&scope=site
drltdean@gmail.com
VL  - 104
ID  - 1767
ER  - 

TY  - JOUR
AB  - Diabetes is one of the most common chronic diseases in the United States. An estimated 18.2 million people in the US (6.3%) have diabetes; among them 2.8 million are African Americans (AAs). On average, AAs are twice as likely to have diabetes as European Americans (EAs) of similar age. AAs disproportionately suffer from various diseases in the US. Many of these diseases include hypertension, cardiovascular disease (CVD), diabetes mellitus (DM-beta predominantly Type II), and cancers of the prostate and pancreas. A number of risk factors such as smoking, a high fat diet, little physical activity, stress, and meager access to health care have been the subject of numerous investigations. However, the factor of the interaction between genetics and the environment has received very little attention in the scientific community. Of note, the content of zinc in pancreatic beta gells is among the highest in the body; however, very little is known about the uptake and storage of zinc inside these cells. We hypothesize that one of the major reason AAs disproportionally suffer from DM (as well as some other illnesses like prostate cancer, CVD and hypertension) is due to their inherent inability to transport appropriate amount of zinc in the crucial cell types that require relatively higher amount of zinc than the other cell types. In this article, we will explore in detail the possible genetic and environmental link between human zinc transporters (hZIPs) and their differential expressions in the islet beta cells from AAs as compared to other racial groups, particularly EAs, in both normal healthy individuals and diabetic patients. We hypothesize that the hZIPs play an important role in the development of diabetes, and the main reason AAs disproportionately suffer from DM (as well as other illnesses like prostate and pancreatic cancers, hypertension, and CVD) as compared to EAs may be due the low degree of expressions of the critical zinc transporters in the beta cells. Understanding the molecular events in the pathogenesis of DM with regards to regulation of zinc uptake would be critical to the evaluation of the natural history of diabetes in humans and especially in various racial groups. If a direct link between zinc transport and diabetes can be established, then a special nutritional formula, medication or other intervention might be especially designed to test the ability to decrease the incidence of this disease in DM susceptible groups, particularly in AAs.
AD  - South Carolina Cancer Center, University of South Carolina, Columbia, SC 29203, USA.
AN  - 16043303
AU  - Quraishi, I.
AU  - Collins, S.
AU  - Pestaner, J. P.
AU  - Harris, T.
AU  - Bagasra, O.
DO  - 10.1016/j.mehy.2005.02.047
DP  - NLM
ET  - 2005/07/27
IS  - 5
KW  - Carrier Proteins/*genetics/*metabolism
Clinical Trials as Topic
Diabetes Mellitus/*epidemiology/genetics/*metabolism
Genetic Predisposition to Disease/genetics
Genetic Testing/methods
Humans
Islets of Langerhans/*metabolism
*Models, Biological
Risk Assessment/methods
Risk Factors
Zinc/*metabolism
LA  - eng
N1  - Quraishi, Iram
Collins, Sibrina
Pestaner, Joseph P
Harris, Twaina
Bagasra, Omar
Journal Article
Research Support, U.S. Gov't, Non-P.H.S.
United States
Med Hypotheses. 2005;65(5):887-92. doi: 10.1016/j.mehy.2005.02.047.
PY  - 2005
SN  - 0306-9877 (Print)
0306-9877
SP  - 887-92
ST  - Role of zinc and zinc transporters in the molecular pathogenesis of diabetes mellitus
T2  - Med Hypotheses
TI  - Role of zinc and zinc transporters in the molecular pathogenesis of diabetes mellitus
VL  - 65
ID  - 594
ER  - 

TY  - JOUR
AB  - CONTEXT: Geographic and racial variations in cancer incidence have been observed. Studies of colorectal carcinoma indicate a higher incidence and mortality rate for blacks than for whites in the United States. PURPOSE: We evaluated the effect of rural versus urban residence on colon cancer risk and stage of disease at diagnosis in blacks and whites. METHODS: Interviews were conducted with 558 colon cancer cases and 952 controls enrolled in the North Carolina Colon Cancer Study, a population-based case-control study of blacks and whites residing in 33 contiguous counties. FINDINGS: Residence in a rural area was associated with increased colon cancer risk (odds ratio, 1.4; 95% confidence interval, 1.1-1.8). This association was no longer significant after controlling for recent use of colorectal cancer screening tests (odds ratio, 1.2; 95% confidence interval, 0.9-1.6). Risk estimates were not modified by race nor were they markedly different for extent of disease at diagnosis. However, colorectal cancer screening rates were lower for blacks than for whites. CONCLUSION: Our findings suggest that rural blacks and whites are at increased risk of colon cancer regardless of stage of disease at diagnosis than their urban counterparts; this relationship may be mediated by screening behavior.
AD  - Cancer Control and Population Sciences Program, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah 84112, USA. anita.kinney@hci.utah.edu
AN  - 16606423
AU  - Kinney, A. Y.
AU  - Harrell, J.
AU  - Slattery, M.
AU  - Martin, C.
AU  - Sandler, R. S.
DA  - Spring
DO  - 10.1111/j.1748-0361.2006.00020.x
DP  - NLM
ET  - 2006/04/12
IS  - 2
KW  - *African Americans
Aged
Aged, 80 and over
*Colonic Neoplasms
*European Continental Ancestry Group
Female
Humans
Interviews as Topic
Male
Middle Aged
North Carolina
*Risk Assessment
*Rural Population
*Urban Population
LA  - eng
N1  - Kinney, Anita Yeomans
Harrell, Janna
Slattery, Marty
Martin, Christopher
Sandler, Robert S
K07 CA82121/CA/NCI NIH HHS/United States
R01 CA 66635/CA/NCI NIH HHS/United States
R25 CA57726/CA/NCI NIH HHS/United States
Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
England
J Rural Health. 2006 Spring;22(2):124-30. doi: 10.1111/j.1748-0361.2006.00020.x.
PY  - 2006
SN  - 0890-765X (Print)
0890-765x
SP  - 124-30
ST  - Rural-urban differences in colon cancer risk in blacks and whites: the North Carolina Colon Cancer Study
T2  - J Rural Health
TI  - Rural-urban differences in colon cancer risk in blacks and whites: the North Carolina Colon Cancer Study
VL  - 22
ID  - 571
ER  - 

TY  - JOUR
AB  - STUDY QUESTION Can asoprisnil, a selective progesterone receptor modulator, provide clinically meaningful improvements in heavy menstrual bleeding (HMB) associated with uterine fibroids with an acceptable safety profile? SUMMARY ANSWER Uninterrupted treatment with asoprisnil for 12 months effectively controlled HMB and reduced fibroid and uterine volume with few adverse events. WHAT IS KNOWN ALREADY In a 3‐month study, asoprisnil (5, 10 and 25 mg) suppressed uterine bleeding, reduced fibroid and uterine volume, and improved hematological parameters in a dose‐dependent manner. STUDY DESIGN, SIZE, DURATION In two Phase 3, double‐blind, randomized, placebo‐controlled, multicentre studies, women received oral asoprisnil 10 mg, asoprisnil 25 mg or placebo (2:2:1) once daily for up to 12 months. PARTICIPANTS/MATERIALS, SETTING, METHODS Premenopausal women ≥18 years of age in North America with HMB associated with uterine fibroids were included (N = 907). The primary efficacy endpoint was the percentage of women who met all three predefined criteria at 12 months or the final month for patients who prematurely discontinued: (1) ≥50% reduction in monthly blood loss (MBL) by menstrual pictogram, (2) hemoglobin concentration ≥11 g/dL or an increase of ≥1 g/dL, and (3) no interventional therapy for uterine fibroids. Secondary efficacy endpoints included changes in other menstrual bleeding parameters, volume of the largest fibroids, uterine volume and health‐related quality of life (HRQL). MAIN RESULTS AND THE ROLE OF CHANCE In all, 90% and 93% of women in the asoprisnil 10‐mg and 25‐mg groups, respectively, and 35% of women in the placebo group met the primary endpoint (P < 0.001). Similar results were observed at month 6 (P < 0.001). The percentage of women who achieved amenorrhea in any specified month ranged from 66‐78% in the asoprisnil 10‐mg group and 83‐93% in the asoprisnil 25‐mg group, significantly higher than with placebo (3‐12%, P < 0.001). Hemoglobin increased rapidly (by month 2) with asoprisnil treatment and was significantly higher versus placebo throughout treatment. The primary fibroid and uterine volumes were significantly reduced from baseline through month 12 with asoprisnil 10 mg (median changes up to‐48% and‐28%, respectively) and 25 mg (median changes up to‐63% and‐39%, respectively) versus placebo (median changes up to +16% and +13%, respectively; all P < 0.001). Dose‐dependent, significant improvements in HRQL (Uterine Fibroid Symptom and Quality of Life instrument) were observed with asoprisnil treatment. Asoprisnil was generally well tolerated. Endometrial biopsies indicated dose‐and time‐dependent decreases in proliferative patterns and increases in quiescent or minimally stimulated endometrium at month 12 of treatment. Although not statistically significantly different at month 6, mean endometrial thickness at month 12 increased by ∼2 mm in both asoprisnil groups compared with placebo (P < 0.01). This effect was associated with cystic changes in the endometrium on MRI and ultrasonography, which led to invasive diagnostic and therapeutic procedures in some asoprisnil‐treated women. LIMITATIONS, REASONS FOR CAUTION Most study participants were black; few Asian and Hispanic women participated. The study duration may have been insufficient to fully characterize the endometrial effects. WIDER IMPLICATIONS OF THE FINDINGS Daily uninterrupted treatment with asoprisnil was highly effective in controlling menstrual bleeding, improving anemia, reducing fibroid and uterine volume, and increasing HRQL in women with HMB associated with uterine fibroids. However, this treatment led to an increase in endometrial thickness and invasive diagnostic and therapeutic procedures, with potential unknown consequences. STUDY FUNDING/COMPETING INTEREST(S) This trial was funded by AbbVie Inc. (prior sponsors: TAP Pharmaceutical Products Inc., Abbott Laboratories). E.A. Stewart was a site investigator in the Phase 2 study of asoprisnil and consulted for TAP during the design nd conduct of these studies while at Harvard Medical School and Brigham and Women's Hospital. She received support from National Institutes of Health grants HD063312, HS023418 and HD074711 and research funding, paid to Mayo Clinic for patient care costs related to an NIH‐funded trial from InSightec Ltd. She consulted for AbbVie, Allergan, Bayer HealthCare AG, Gynesonics, and Welltwigs. She received royalties from UpToDate and the Med Learning Group. M.P. Diamond received research funding for the conduct of the studies paid to the institution and consulted for AbbVie. He is a stockholder and board and director member of Advanced Reproductive Care. He has also received funding for study conduct paid to the institution from Bayer and ObsEva. A.R.W. Williams consulted for TAP and Repros Therapeutics Inc. He has current consultancies with PregLem SA, Gedeon Richter, HRA Pharma and Bayer. B.R. Carr consulted for and received research funding from AbbVie. E.R. Myers consulted for AbbVie, Allergan and Bayer. R.A. Feldman received compensation for serving as a principal investigator and participating in the conduct of the trial. W. Elger was co‐inventor of several patents related to asoprisnil. C. Mattia‐Goldberg is a former employee of AbbVie and may own AbbVie stock or stock options. B.M. Schwefel and K. Chwalisz are employees of AbbVie and may own AbbVie stock or stock options. TRIAL REGISTRATION NUMBER NCT00152269, NCT00160381 (clinicaltrials.gov). TRIAL REGISTRATION DATE 7 September 2005; 8 September 2005. DATE OF FIRST PATIENT'S ENROLMENT 12 September 2002; 6 September 2002.
AN  - CN-01942378
AU  - Stewart, E. A.
AU  - Diamond, M. P.
AU  - Williams, A. R. W.
AU  - Carr, B. R.
AU  - Myers, E. R.
AU  - Feldman, R. A.
AU  - Elger, W.
AU  - Mattia-Goldberg, C.
AU  - Schwefel, B. M.
AU  - Chwalisz, K.
DO  - 10.1093/humrep/dez007
IS  - 4
KW  - *menorrhagia /drug therapy /side effect
*uterus bleeding /drug therapy
*uterus myoma
Abdominal distension /side effect
Abdominal pain /side effect
Adenosarcoma
Administration, Oral
Adult
Amenorrhea
Anemia
Arthropathy /side effect
Article
Asthenia /side effect
Bacterial infection /side effect
Bladder disease /side effect
Bloating /side effect
Breast disease /side effect
Cholecystitis /side effect
Connective tissue disease /side effect
Controlled study
Dose response
Double blind procedure
Double‐Blind Method
Drug efficacy
Drug safety
Drug tolerability
Drug withdrawal
Echography
Edema /side effect
Endometrial thickness
Endometrium [drug effects]
Endometrium biopsy
Endometrium hyperplasia
Endometrium polyp
Estrenes [administration & dosage, *adverse effects, *therapeutic use]
Female
Flatulence /side effect
Follow‐Up Studies
Gastrointestinal pain /side effect
Genital system disease /side effect
Gilbert disease
Headache /side effect
Hematological parameters
Hemoglobin determination
Hot flush /side effect
Human
Humans
Hyperbilirubinemia /side effect
Hypertransaminasemia /side effect
Influenza /side effect
Leiomyoma [complications, *drug therapy]
Major clinical study
Menorrhagia [complications, *drug therapy]
Menstruation
Middle Aged
Multicenter study
Musculoskeletal disease /side effect
Myalgia /side effect
Mycosis /side effect
Myopathy /side effect
Nausea and vomiting /side effect
Nuclear magnetic resonance imaging
Oximes [administration & dosage, *adverse effects, *therapeutic use]
Patient Reported Outcome Measures
Patient‐reported outcome
Peripheral vascular disease /side effect
Phase 3 clinical trial
Premenopause
Premenstrual syndrome /side effect
Quality of Life
Randomized controlled trial
Receptors, Progesterone [*drug effects]
Spotting
Treatment Outcome
Treatment duration
Tumor Burden [drug effects]
Upper respiratory tract infection /side effect
Urethra disease /side effect
Uterine Neoplasms [complications, *drug therapy]
Vulvovaginal disease /side effect
M3  - Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non‐U.S. Gov't
PY  - 2019
SP  - 623‐634
ST  - Safety and efficacy of the selective progesterone receptor modulator asoprisnil for heavy menstrual bleeding with uterine fibroids: pooled analysis of two 12-month, placebo-controlled, randomized trials
T2  - Human reproduction (Oxford, England)
TI  - Safety and efficacy of the selective progesterone receptor modulator asoprisnil for heavy menstrual bleeding with uterine fibroids: pooled analysis of two 12-month, placebo-controlled, randomized trials
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01942378/full
VL  - 34
ID  - 1655
ER  - 

TY  - JOUR
AB  - Black cohosh (Actaea racemosa/Cimicifuga racemosa) is a North American perennial plant that has been used for traditional medicinal purposes by the native Indian population. Its modern day application is the treatment of menopausal symptoms. Unlike conventional non-herbal medications, herbal preparations have not been systematically evaluated for their safety. However, the evidence from in vitro, animal and clinical studies all suggest that black cohosh is a safe herbal therapy for menopausal women if taken for a limited period. More research is needed to evaluate the safety of this herb over longer periods of time, and also to further investigate its mechanism of action.
AD  - Universities of Exeter and Plymouth, Complementary Medicine, Peninsula Medical School, 25 Victoria Park Road, Exeter, EX2 4NT, UK. alyson.huntley@pms.ac.uk
AN  - 15500420
AU  - Huntley, A.
DA  - Nov
DO  - 10.1517/14740338.3.6.615
DP  - NLM
ET  - 2004/10/27
IS  - 6
KW  - Adverse Drug Reaction Reporting Systems
Animals
Antineoplastic Agents, Hormonal/adverse effects/therapeutic use
Breast Neoplasms/drug therapy
Cimicifuga/*adverse effects
Contraindications
Drug Evaluation, Preclinical
Drug Interactions
Drug Synergism
Estrogen Receptor Modulators/adverse effects/therapeutic use
Estrogens
Female
Hepatitis, Autoimmune/etiology
Hot Flashes/chemically induced/*drug therapy
Humans
Menopause/*drug effects
Mice
Middle Aged
Neoplasms, Hormone-Dependent/drug therapy
Osteoporosis, Postmenopausal/drug therapy/prevention & control
Phytotherapy/*adverse effects
Plant Extracts/*adverse effects/pharmacology/therapeutic use
Randomized Controlled Trials as Topic
Rats
Receptors, Neurotransmitter/drug effects
Selective Estrogen Receptor Modulators/adverse effects/therapeutic use
LA  - eng
N1  - 1744-764x
Huntley, Alyson
Journal Article
Review
England
Expert Opin Drug Saf. 2004 Nov;3(6):615-23. doi: 10.1517/14740338.3.6.615.
PY  - 2004
SN  - 1474-0338
SP  - 615-23
ST  - The safety of black cohosh (Actaea racemosa, Cimicifuga racemosa)
T2  - Expert Opin Drug Saf
TI  - The safety of black cohosh (Actaea racemosa, Cimicifuga racemosa)
VL  - 3
ID  - 616
ER  - 

TY  - JOUR
AB  - BACKGROUND: Awareness that cancer impacts not only the person with the disease but also the family has increased, yet existing data provide limited information, primarily because of reliance on small geographically restricted samples. The current study used population-based sampling to develop a formula to compute the probability of survivors completing a survivor survey and nominating their family caregivers. METHODS: Eleven SEER/NPCR state cancer registries participated in the American Cancer Society Study of Cancer Survivors survey, providing information about the survivors, including their age, race/ethnicity, gender, type of cancer, and stage of cancer. A total of 19,294 cancer survivors met the inclusion criteria (>/=18 years old and diagnosed with one of the 10 common cancers). RESULTS: Approximately 30% of survivors identified from state cancer registries completed the survivor survey, of whom 42% nominated a caregiver. Logistic regression analysis revealed that middle-aged, female, or non-black survivors and survivors diagnosed with breast or ovarian cancer were more likely to complete the survey and nominate a caregiver, whereas survivors with bladder or lung cancer and survivors with advanced-stage cancer were less likely to complete the survey and nominate a caregiver. CONCLUSIONS: Using the formula based on the logistic regression analysis results, a number of certain groups of survivors to be recruited from state registry can be calculated in order to have a present number of caregivers to contact for participation into a caregiver study. This is practical and valuable information, which fosters research that uses state cancer registries and increases the generalizability of findings to multiple types of cancer and different stages of cancer.
AD  - American Cancer Society, Atlanta, GA, USA. ykim@psy.miami.edu
AN  - 19655274
AU  - Kim, Y.
AU  - Kashy, D. A.
AU  - Kaw, C. K.
AU  - Smith, T.
AU  - Spillers, R. L.
DA  - Oct
DO  - 10.1007/s11136-009-9518-7
DP  - NLM
ET  - 2009/08/06
IS  - 8
KW  - Adult
Aged
Aged, 80 and over
Awareness
*Biomedical Research
Caregivers/*statistics & numerical data
Female
Health Surveys
Humans
Logistic Models
Male
Middle Aged
Neoplasms/*mortality
Prospective Studies
Quality of Life
Regression Analysis
SEER Program
Survival Analysis
United States
LA  - eng
N1  - 1573-2649
Kim, Youngmee
Kashy, Deborah A
Kaw, Chiew Kwei
Smith, Tenbroeck
Spillers, Rachel L
Journal Article
Research Support, Non-U.S. Gov't
Netherlands
Qual Life Res. 2009 Oct;18(8):981-9. doi: 10.1007/s11136-009-9518-7. Epub 2009 Aug 5.
PY  - 2009
SN  - 0962-9343
SP  - 981-9
ST  - Sampling in population-based cancer caregivers research
T2  - Qual Life Res
TI  - Sampling in population-based cancer caregivers research
VL  - 18
ID  - 452
ER  - 

TY  - JOUR
AN  - 8797765
AU  - Reynolds, T.
DA  - Sep 18
DO  - 10.1093/jnci/88.18.1265
DP  - NLM
ET  - 1996/09/18
IS  - 18
KW  - African Americans/statistics & numerical data
Breast Neoplasms/prevention & control
*Clinical Trials as Topic
Female
Hispanic Americans/statistics & numerical data
Humans
Male
Mass Screening/*statistics & numerical data
Minority Groups/*statistics & numerical data
Neoplasms/*prevention & control
Prostatic Neoplasms/prevention & control
United States
LA  - eng
N1  - Reynolds, T
News
United States
J Natl Cancer Inst. 1996 Sep 18;88(18):1265-7. doi: 10.1093/jnci/88.18.1265.
PY  - 1996
SN  - 0027-8874 (Print)
0027-8874
SP  - 1265-7
ST  - Screening and prevention trials step up minority recruitment
T2  - J Natl Cancer Inst
TI  - Screening and prevention trials step up minority recruitment
VL  - 88
ID  - 737
ER  - 

TY  - JOUR
AN  - 8078076
AU  - Patterson, E. A.
C2  - PMC2607751
DA  - Jun
DP  - NLM
ET  - 1994/06/01
IS  - 6
KW  - Adult
*African Continental Ancestry Group
Age Factors
Breast Neoplasms/*prevention & control
Clinical Trials as Topic
Female
Guidelines as Topic
Humans
*Mammography
Mass Screening
Middle Aged
Randomized Controlled Trials as Topic
United States
LA  - eng
N1  - Patterson, E A
News
J Natl Med Assoc. 1994 Jun;86(6):415-6.
PY  - 1994
SN  - 0027-9684 (Print)
0027-9684
SP  - 415-6
ST  - Screening guidelines for African-American women: looking at the facts and sorting out the confusion
T2  - J Natl Med Assoc
TI  - Screening guidelines for African-American women: looking at the facts and sorting out the confusion
VL  - 86
ID  - 747
ER  - 

TY  - JOUR
AB  - Screening with FIT or colonoscopy can reduce CRC mortality. In our pragmatic, randomized trial of screening outreach over three years, patients annually received mailed FITs or colonoscopy invitations. We examined screening initiation after each mailing and crossover from the invited to other modality. Eligible patients (50-64 years, ≥1 primary-care visit before randomization, and no history of CRC) received mailed FIT kits (n = 2400) or colonoscopy invitations (n = 2400) from March 2013 through July 2016. Among those invited for colonoscopy, we used multinomial logistic regression to identify factors associated with screening initiation with colonoscopy vs. FIT vs. no screening after the first mailing. Most patients were female (61.8%) and Hispanic (48.9%) or non-Hispanic black (24.0%). Among those invited for FIT, 56.6% (n = 1359) initiated with FIT, whereas 3.3% (n = 78) crossed over to colonoscopy; 151 (15.7%) and 61 (7.7%) initiated with FIT after second and third mailings. Among those invited for colonoscopy, 25.5% (n = 613) initiated with colonoscopy whereas 18.8% (n = 452) crossed over to FIT; 112 (8.4%) and 48 (4.2%) initiated with colonoscopy after second and third mailings. Three or more primary-care visits prior to randomization were associated with initiating with colonoscopy (OR 1.49, 95% CI 1.17-1.91) and crossing over to FIT (OR 1.63, 95% CI 1.19-2.23). Although nearly half of patients initiated screening after the first mailing, few non-responders in either outreach group initiated after a second or third mailing. More patients invited to colonoscopy crossed over to FIT than those assigned to FIT crossed over to colonoscopy.
AD  - Department of Clinical Sciences, University of Texas Southwestern Medical Center, Dallas, TX, United States of America; Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, United States of America; Harold C. Simmons Comprehensive Cancer Center, Dallas, TX, United States of America; Department of Medicine, UC San Diego Medical Center, San Diego, CA, United States of America; Veterans Affairs San Diego Healthcare System, San Diego, CA, United States of America. Electronic address: caitlin.murphy@utsouthwestern.edu.
Department of Clinical Sciences, University of Texas Southwestern Medical Center, Dallas, TX, United States of America; Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, United States of America; Harold C. Simmons Comprehensive Cancer Center, Dallas, TX, United States of America; Department of Medicine, UC San Diego Medical Center, San Diego, CA, United States of America; Veterans Affairs San Diego Healthcare System, San Diego, CA, United States of America.
AN  - 30508552
AU  - Murphy, C. C.
AU  - Ahn, C.
AU  - Pruitt, S. L.
AU  - Hughes, A. E.
AU  - Halm, E. A.
AU  - Gupta, S.
AU  - Santini, N. O.
AU  - McCallister, K.
AU  - Sanders, J. M.
AU  - Singal, A. G.
AU  - Skinner, C. S.
C2  - PMC6362977
C6  - NIHMS1516449
DA  - Jan
DO  - 10.1016/j.ypmed.2018.11.020
DP  - NLM
ET  - 2018/12/07
KW  - *Colonoscopy
Colorectal Neoplasms/*diagnosis
*Early Detection of Cancer
Female
Health Promotion
Humans
Male
Middle Aged
*Occult Blood
Primary Health Care
Randomized Controlled Trials as Topic
*Colorectal neoplasms
*Health promotion
*Mass screening
*Pragmatic clinical trial
*Safety-net providers
interest or financial disclosures.
LA  - eng
N1  - 1096-0260
Murphy, Caitlin C
Ahn, Chul
Pruitt, Sandi L
Hughes, Amy E
Halm, Ethan A
Gupta, Samir
Santini, Noel O
McCallister, Katharine
Sanders, Joanne M
Singal, Amit G
Skinner, Celette Sugg
UL1 TR001105/TR/NCATS NIH HHS/United States
KL2 TR001103/TR/NCATS NIH HHS/United States
P30 CA142543/CA/NCI NIH HHS/United States
R25 CA057712/CA/NCI NIH HHS/United States
T32 CA057712/CA/NCI NIH HHS/United States
U54 CA163308/CA/NCI NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
Prev Med. 2019 Jan;118:332-335. doi: 10.1016/j.ypmed.2018.11.020. Epub 2018 Dec 1.
PY  - 2019
SN  - 0091-7435 (Print)
0091-7435
SP  - 332-335
ST  - Screening initiation with FIT or colonoscopy: Post-hoc analysis of a pragmatic, randomized trial
T2  - Prev Med
TI  - Screening initiation with FIT or colonoscopy: Post-hoc analysis of a pragmatic, randomized trial
VL  - 118
ID  - 95
ER  - 

TY  - JOUR
AB  - Objectives: To study the impact of eliminating cost sharing for screening mammography on mammography rates in a large Medicare Advantage (MA) health plan which in 2010 eliminated cost sharing in anticipation of the Affordable Care Act mandate. Study Setting: Large MA health maintenance organization offering individual-subscriber MA insurance and employer-supplemented group MA insurance. Study Design: We investigated the impact on breast cancer screening of a policy that eliminated a $20 copayment for screening mammography in 2010 among 53,188 women continuously enrolled from 2007 to 2012 in an individual-subscriber MA plan, compared with 42,473 women with employer-supplemented group MA insurance in the same health maintenance organization who had full screening coverage during this period. We used differences-in-differences analysis to study the impact of cost-sharing elimination on mammography rates. Principal Findings: Annual screening rates declined over time for both groups, with similar trends pre-2010 and a slower decline after 2010 among women whose copayments were eliminated. Among women aged 65–74 years in the individual-subscriber MA plan, 44.9 percent received screening in 2009 compared with 40.9 percent in 2012, while 49.5 percent of women in the employer-supplemented MA plan received screening in 2009 compared with 44.1 percent in 2012, that is, a difference-in-difference effect of 1.4 percentage points less decline in screening among women experiencing the cost-sharing elimination. Effects were concentrated among women without recent screening. There were no differences by neighborhood socioeconomic status or race/ethnicity. Conclusions: Eliminating cost sharing for screening mammography was associated with modesty lower decline in screening rates among women with previously low screening adherence. © Health Research and Educational Trust
AD  - Department of Health Care Policy, Harvard Medical School, Boston, MA, United States
Division of Research, Kaiser Permanente, Oakland, CA, United States
Mongan Institute for Health Policy, Massachusetts General Hospital, Boston, MA, United States
Institute for Technology Assessment, Massachusetts General Hospital, Boston, MA, United States
AU  - Jena, A. B.
AU  - Huang, J.
AU  - Fireman, B.
AU  - Fung, V.
AU  - Gazelle, S.
AU  - Landrum, M. B.
AU  - Chernew, M.
AU  - Newhouse, J. P.
AU  - Hsu, J.
DB  - Scopus
DO  - 10.1111/1475-6773.12486
IS  - 1
KW  - Affordable Care Act
Cost sharing
mammography
M3  - Article
N1  - Cited By :17
Export Date: 22 March 2021
PY  - 2017
SP  - 191-206
ST  - Screening Mammography for Free: Impact of Eliminating Cost Sharing on Cancer Screening Rates
T2  - Health Services Research
TI  - Screening Mammography for Free: Impact of Eliminating Cost Sharing on Cancer Screening Rates
UR  - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84961285261&doi=10.1111%2f1475-6773.12486&partnerID=40&md5=9b1a80a2f7e1031252a833e0bd7af04d
VL  - 52
ID  - 2323
ER  - 

TY  - JOUR
AB  - OBJECTIVE: HIV-infected women (WLHIV) have more than 10-fold higher risk for squamous cell cancer of the anus. Experts suggest cytology-based strategies developed for cervical cancer screening may prevent anal cancer by detecting anal cytologic or histological high-grade squamous intraepithelial lesion (hHSIL) for treatment. Currently, there is no consensus on anal-hHSIL screening strategies for WLHIV. DESIGN: Between 2014 and 2016, 276 WLHIV were recruited at 12 US AIDS Malignancy Consortium clinical trials sites to evaluate hHSIL prevalence and (test) screening strategies. METHODS: Participants completed detailed questionnaire, underwent anal assessments including high-risk human papillomavirus (hrHPV) testing using hrHPV-Hybrid Capture 2 (HC2) and hrHPV-APTIMA, anal cytology, and concurrent high-resolution anoscopy. Screening test characteristics for predicting hHSIL validated by central review of histologic diagnosis were estimated sensitivity, specificity, positive predictive value, and false-omission rate. Paired analyses compared sensitivity and specificity for hrHPV single tests to anal cytology alone. RESULTS: 83% (229/276) of enrolled WLHIV had complete anal assessment data and were included in this analysis. Mean age was 50, 62% black and 60 (26%) had hHSIL. Anal cyotology (>atypical squamous cells of undetermined significance), hrHPV-HC2, and hrHPV-APTIMA sensitivity estimates were similarly high (83, 77, and 75%, respectively, P values > 0.2). Specificity was higher for both hrHPV-APTIMA and hrHPV-HC2 compared with anal cytology (67 vs. 50%, P < 0.001) and (61 vs. 50%, P = 0.020), respectively. CONCLUSION: Anal hrHPV testing demonstrated similar sensitivity for anal cytology (>atypical squamous cells of undetermined significance) to predict anal hHSIL. Among tests with similar sensitivity, the specificity was significantly higher for hrHPV-APTIMA and hrHPV-HC2. Thus, anal hrHPV testing may be an important alternative strategy to anal cytology for anal hHSIL screening among WLHIV.
AD  - Department of Epidemiology and General Oncology, University of Texas- MD Anderson Cancer Center, Houston, Texas.
Department of Biostatistics, University of Arkansas for Medical Sciences, Little Rock, Arkansas.
School of Nursing, University of California, Los Angeles, Los Angeles, California.
Department of Management Policy and Community Health, School of Public Health, The University of Texas Health Science Center at Houston, Houston, Texas.
Department of Pathology, UCSF Mt. Zion Medical Center, San Francisco, California.
Department of OB/GYN & Women's Health, Rutgers-NJMS, Newark, New Jersey.
Department of Medicine, Anal Neoplasia Clinic, Research, and Education Center.
Division of Hematology Oncology.
Department of Medicine, University of California, San Francisco, San Francisco, California.
Clinical Trials Unit, Department of Medicine, Cornell University, New York, New York.
Department of Internal Medicine (Infectious Diseases), Wake Forest University Health Sciences, Winston-Salem, North Carolina, USA.
University of Vic, Hospital Germans Trias i Pujol, Barcelona, Spain.
Department of Surgery, Montefiore, Bronx, New York.
Department of Medicine.
Department of Microbiology & Medical Zoology, University of Puerto Rico School of Medicine, San Juan, Puerto Rico.
Division of Infectious Diseases, CORE Center/Stroger Hospital of Cook County, Chicago, Illinois.
Department of Pathology, Baylor College of Medicine, Houston, Texas.
Department of Pathology, George Washington University, Washington, District of Columbia.
Department of Surgery, Icahn School of Medicine at Mount Sinai, New York, New York.
Department of Obstetrics and Gynecology, Boston University School of Medicine, Boston, Massachusetts, USA.
AN  - 32947592
AU  - Chiao, E. Y.
AU  - Lensing, S. Y.
AU  - Wiley, D. J.
AU  - Deshmukh, A. A.
AU  - Lee, J.
AU  - Darragh, T. M.
AU  - Einstein, M. H.
AU  - Jay, N.
AU  - Berry-Lawhorn, J. M.
AU  - Palefsky, J. M.
AU  - Wilkin, T.
AU  - Barroso, L. F.
AU  - Cranston, R. D.
AU  - Levine, R.
AU  - Guiot, H. M.
AU  - French, A. L.
AU  - Citron, D.
AU  - Rezaei, M. K.
AU  - Goldstone, S. E.
AU  - Stier, E. A.
DA  - Dec 1
DO  - 10.1097/qad.0000000000002694
DP  - NLM
ET  - 2020/09/19
IS  - 15
KW  - *Anus Neoplasms/diagnosis/pathology/virology
Early Detection of Cancer
Female
*HIV Infections/pathology
Humans
Middle Aged
*Papillomavirus Infections/pathology
*Squamous Intraepithelial Lesions/diagnosis/pathology/virology
LA  - eng
N1  - 1473-5571
Chiao, Elizabeth Y
Lensing, Shelly Y
Wiley, Dorothy J
Deshmukh, Ashish A
Lee, Jeannette
Darragh, Teresa M
Einstein, Mark H
Jay, Naomi
Berry-Lawhorn, John Michael
Palefsky, Joel M
Wilkin, Timothy
Barroso, Luis F
Cranston, Ross D
Levine, Rebecca
Guiot, Humberto M
French, Audrey L
Citron, Deborah
Rezaei, Masoumeh Katayoon
Goldstone, Stephen E
Stier, Elizabeth A
R01 CA163103/CA/NCI NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
England
AIDS. 2020 Dec 1;34(15):2249-2258. doi: 10.1097/QAD.0000000000002694.
PY  - 2020
SN  - 0269-9370
SP  - 2249-2258
ST  - Screening strategies for the detection of anal high-grade squamous intraepithelial lesions in women living with HIV
T2  - Aids
TI  - Screening strategies for the detection of anal high-grade squamous intraepithelial lesions in women living with HIV
VL  - 34
ID  - 23
ER  - 

TY  - JOUR
AB  - BACKGROUND: African American women have higher incidences of breast and cervical cancers and African American men present with more advanced stages of colon and prostate cancers than do their non-African American counterparts. Since the church is central to the organization of the African American community, the authors set out to determine whether a church-directed educational project could influence parishioners to obtain cancer screening. METHODS: Three African American churches having memberships of 250, 500, and 1,500, respectively, were selected for their different socioeconomic strata: one congregation was composed mostly of working poor, the second was more affluent, and the third consisted primarily of retirees. During a five-week summer period, appropriate literature, health fairs, testimonials by cancer survivors, and visits by representatives of the medical community were used to increase awareness of cancer screening. Surveys regarding cancer-screening behaviors were distributed at the end of church services. Using the guidelines established by the American Cancer Society, individual recommendations for screening examinations were developed and sent to parishioners based on their survey responses. RESULTS: Of 437 parishioners surveyed (73% female, 27% male), 75% were 40 years old or older. Many reported up-to-date screening for breast (84%), cervical (78%), colon (62%), and prostate (89%) cancers. The results were remarkably similar in all three churches. Telephone follow-up seven months after the survey directed at the 120 parishioners identified as noncompliant for at least one cancer screening revealed that 49% had obtained the appropriate screenings. CONCLUSIONS: These African American churchgoers were well screened compared with estimated national averages, possibly due to previous efforts of the activist ministers in the churches selected. The message for cancer screening is heeded when delivered through the African American church.
AD  - MCP Hahnemann School of Medicine, Philadelphia, Pennsylvania 19129, USA. mannb@auhs.edu
AN  - 10730804
AU  - Mann, B. D.
AU  - Sherman, L.
AU  - Clayton, C.
AU  - Johnson, R. F.
AU  - Keates, J.
AU  - Kasenge, R.
AU  - Streeter, K.
AU  - Goldberg, L.
AU  - Nieman, L. Z.
DA  - Spring
DO  - 10.1080/08858190009528653
DP  - NLM
ET  - 2000/03/24
IS  - 1
KW  - Adult
*African Americans
Aged
Attitude to Health/*ethnology
Female
Follow-Up Studies
Health Education/*organization & administration
Humans
Male
Mass Screening/*organization & administration
Middle Aged
Neoplasms/ethnology/*prevention & control
Patient Participation
Philadelphia
Population Surveillance
*Religion and Medicine
Surveys and Questionnaires
LA  - eng
N1  - Mann, B D
Sherman, L
Clayton, C
Johnson, R F
Keates, J
Kasenge, R
Streeter, K
Goldberg, L
Nieman, L Z
Journal Article
Research Support, Non-U.S. Gov't
England
J Cancer Educ. 2000 Spring;15(1):46-50. doi: 10.1080/08858190009528653.
PY  - 2000
SN  - 0885-8195 (Print)
0885-8195
SP  - 46-50
ST  - Screening to the converted: an educational intervention in African American churches
T2  - J Cancer Educ
TI  - Screening to the converted: an educational intervention in African American churches
VL  - 15
ID  - 704
ER  - 

TY  - JOUR
AB  - Background: The tyrosine kinase inhibitor pazopanib is used for treatment of sarcoma. Recent studies have suggested that the use of pazopanib may lead to the development of pneumothorax, an unexpected adverse effect in patients with sarcoma metastatic to the chest. Methods: We conducted a retrospective case control study of patients with sarcoma with metastases to the chest with pneumothorax (cases) and without pneumothorax (controls). The control population was selected from tumor registry in a 1:4 (cases to controls) ratio. The primary outcome of interest was the association between pazopanib and pneumothorax risk in patients with sarcoma metastatic to the chest. Secondary objective was to evaluate risk factors for pneumothorax. Results: We identified 41 cases and 164 controls. Using purposeful selection method the odds of developing pneumothorax while being on pazopanib was not significant in univariate (p =.06) and multivariable analysis (p =.342). On univariate analysis risk factors of pneumothorax in patients with sarcoma were age, male sex, African American race, the presence of cavitary lung nodules/masses, and the presence of pleural-based nodules/masses. On multivariate analysis, only the presence of cavitary lung nodules/masses (P <.001) and the presence of pleural-based nodules/masses (P <.001) remained as risk factors for developing pneumothorax. Conclusion: Pazopanib does not increase the risk of pneumothorax in patients with sarcoma and evidence of metastatic disease to the chest. Presence of cavitary lung nodules/masses and the presence of pleural-based nodules/masses were found to be risk factors for pneumothorax.
AD  - H.B. Grosu, Department of Pulmonary Medicine, Unit 1462, University of Texas, MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, United States
AU  - Sabath, B.
AU  - Muhammad, H. A.
AU  - Balagani, A.
AU  - Ost, D. E.
AU  - Vakil, E.
AU  - Ahmed, T.
AU  - Vial, M. R.
AU  - Grosu, H. B.
DB  - Embase
Medline
DO  - 10.1186/s12885-018-4858-8
IS  - 1
KW  - pazopanib
adult
African American
age
article
cancer registry
cancer risk
case control study
case report
clinical article
controlled study
disease association
disease course
human
lung nodule
metastasis
outcome assessment
patient selection
retrospective study
risk factor
sarcoma
sex difference
spontaneous pneumothorax
LA  - English
M3  - Article
N1  - L624102342
2018-10-09
2018-10-15
PY  - 2018
SN  - 1471-2407
ST  - Secondary spontaneous pneumothorax in patients with sarcoma treated with Pazopanib, a case control study
T2  - BMC Cancer
TI  - Secondary spontaneous pneumothorax in patients with sarcoma treated with Pazopanib, a case control study
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L624102342&from=export
http://dx.doi.org/10.1186/s12885-018-4858-8
VL  - 18
ID  - 882
ER  - 

TY  - JOUR
AB  - Preclinical, epidemiological, and phase III data from randomized, placebo-controlled clinical trials suggest that both selenium and vitamin E have potential efficacy in prostate cancer prevention. In vitro evidence suggests that selenium and vitamin E work synergistically to cause cell-cycle arrest, induce caspase-mediated apoptosis, and act as antiandrogens in arresting clonal expansion of nascent tumors. The Selenium and Vitamin E Cancer Prevention Trial (SELECT), sponsored by the National Cancer Institute, is an intergroup Phase III, randomized, double-blind, placebo-controlled, population-based clinical trial designed to test the efficacy of selenium and vitamin E alone and in combination in the prevention of prostate cancer. The study has a 2 x 2 factorial design with a target accrual of 32,400. Eligibility criteria include an age of at least 50 years for African Americans and of at least 55 years for Caucasians; a DRE not suspicious for cancer; a serum PSA no greater than 4 ng/mL; and a normal blood pressure. Randomization will be equally distributed among the four study arms, with intervention consisting of a daily oral dose of study supplement (200 mug l-selenomethionine or 400 mg of racemic alpha-tocopheryl) or matched placebo. Study duration is planned for 12 years, with a 5-year uniform accrual period and a minimum of 7 and maximum of 12 years of intervention. The primary endpoint for SELECT is the clinical incidence of prostate cancer as determined by a recommended routine clinical diagnostic work-up, including yearly DRE and serum PSA level. SELECT is the second large-scale study of chemoprevention for prostate cancer. Enrollment began in 2001, with final results anticipated in 2013.
AD  - Glickman Urological Institute, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA. kleine@ccf.org
AN  - 15753149
AU  - Klein, E. A.
DA  - Dec
DO  - 10.1196/annals.1331.023
DP  - NLM
ET  - 2005/03/09
KW  - African Continental Ancestry Group
European Continental Ancestry Group
Humans
Male
Middle Aged
National Institutes of Health (U.S.)
Neoplasms/*prevention & control
Prostate-Specific Antigen/blood
Prostatic Neoplasms/prevention & control
*Randomized Controlled Trials as Topic
Selenium/administration & dosage/*therapeutic use
United States
Vitamin E/administration & dosage/*therapeutic use
LA  - eng
N1  - Klein, Eric A
Journal Article
Review
United States
Ann N Y Acad Sci. 2004 Dec;1031:234-41. doi: 10.1196/annals.1331.023.
PY  - 2004
SN  - 0077-8923 (Print)
0077-8923
SP  - 234-41
ST  - Selenium and vitamin E cancer prevention trial
T2  - Ann N Y Acad Sci
TI  - Selenium and vitamin E cancer prevention trial
VL  - 1031
ID  - 608
ER  - 

TY  - JOUR
AB  - Prostate cancer continues to be both a major health threat, especially among African-American men, and a public health burden. However, growing evidence suggests that selenium and vitamin E may decrease the risk of this disease. The Selenium and Vitamin E Cancer Prevention Trial (SELECT), a phase III randomized, placebo-controlled study, is designed to determine whether selenium and vitamin E, alone or in combination, decrease the risk of prostate cancer in healthy men. SELECT opened to accrual on 25 July 2001 in more than 400 clinical sites across the United States, Puerto Rico, and Canada; the goal was to randomize 32,400 men. Accrual was completed in June 2004, 2 years ahead of schedule, with a total of 35,534 men randomized. Eligibility requirements include age of at least 55 years (African-American men at least 50 years), and no evidence of prostate cancer as determined by a serum PSA level of no more than 4 ng/ml and a digital rectal exam (DRE) not suspicious for prostate cancer. Participants were randomized to receive selenium (200 microg/ day of l-selenomethionine) and/or vitamin E (400 IU/day of all-rac-alpha-tocopheryl acetate) supplementation for a minimum of 7 years (maximum of 12 years). The rationale for choosing these agents was based on preclinical data as well as analyses of secondary endpoints in cancer prevention clinical trials. The primary endpoint of SELECT is occurrence of prostate cancer based on community standards of diagnosis. Several other non-cancer endpoints are also being explored.
AD  - National Cancer Institute NIH, Division of Cancer Prevention, Bethesda, MD 20852, USA.
AN  - 19213568
AU  - Dunn, B. K.
AU  - Ryan, A.
AU  - Ford, L. G.
DO  - 10.1007/978-3-540-69297-3_17
DP  - NLM
ET  - 2009/02/14
KW  - Antioxidants/*therapeutic use
Clinical Trials as Topic
Humans
Male
Prostatic Neoplasms/*prevention & control
Selenium/*therapeutic use
Vitamin E/*therapeutic use
LA  - eng
N1  - Dunn, Barbara K
Ryan, Anne
Ford, Leslie G
Journal Article
Review
Germany
Recent Results Cancer Res. 2009;181:183-93. doi: 10.1007/978-3-540-69297-3_17.
PY  - 2009
SN  - 0080-0015 (Print)
0080-0015
SP  - 183-93
ST  - Selenium and Vitamin E Cancer Prevention Trial: a nutrient approach to prostate cancer prevention
T2  - Recent Results Cancer Res
TI  - Selenium and Vitamin E Cancer Prevention Trial: a nutrient approach to prostate cancer prevention
VL  - 181
ID  - 477
ER  - 

TY  - JOUR
AN  - 9719074
AU  - Taylor, P. R.
AU  - Albanes, D.
DA  - Aug 19
DO  - 10.1093/jnci/90.16.1184
DP  - NLM
ET  - 1998/08/27
IS  - 16
KW  - African Americans/statistics & numerical data
Humans
Male
Prostatic Neoplasms/ethnology/*prevention & control
Randomized Controlled Trials as Topic
Selenium/*therapeutic use
Vitamin E/*therapeutic use
LA  - eng
N1  - Taylor, P R
Albanes, D
Comment
Editorial
United States
J Natl Cancer Inst. 1998 Aug 19;90(16):1184-5. doi: 10.1093/jnci/90.16.1184.
PY  - 1998
SN  - 0027-8874 (Print)
0027-8874
SP  - 1184-5
ST  - Selenium, vitamin E, and prostate cancer--ready for prime time?
T2  - J Natl Cancer Inst
TI  - Selenium, vitamin E, and prostate cancer--ready for prime time?
VL  - 90
ID  - 730
ER  - 

TY  - JOUR
AB  - PURPOSE: To determine the reasons why men fail to participate in a free prostate cancer screening. DESIGN: Survey and secondary analyses using correlational design. SETTING: Community sites in the Southeastern United States. SAMPLE: The sample (N = 241) ranged in age from 40-68 years. Mean age was 50 years (SD = 7.4). Most of the men were African American (79%) and married (70%). Almost half of the subjects (44%) earned between $9,601 and $25,020 per year. METHOD: Telephone survey of men who did not participate in initial prostate cancer screening after educational program. MAIN RESEARCH VARIABLES: Demographics, self-reported reasons men decided not to participate in a free screening following a prostate cancer educational program, and predictors for subsequent participation in screening. FINDINGS: The main self-reported reason for not participating in a free prostate cancer screening opportunity was time problems. A significant relationship between income and physician problems existed among the men who did not participate. Twenty-one percent of the 241 men participated in a second opportunity for free prostate cancer screening. Men who cited "lost packet" as their reason for not participating in the first free screening were more than twice as likely to go for the second opportunity for free screening when offered another packet or voucher for a free screening with their physician of choice. CONCLUSIONS: "Time problems" was the most frequent self-reported reason men gave for failure to participate. Providing a follow-up phone call and vouchers a second time for reimbursement of the cost associated with a screening increased participation. Men often need assistance with locating physicians and nurse practitioners who will file for financial reimbursement. Appointment reminders are critical. IMPLICATIONS FOR NURSING: The findings of this study of the significant relationship between income and "physician problems" for not participating has implications for healthcare providers. Future programs could provide telephone follow-up with men and remail vouchers, as needed. In addition, men could be encouraged to designate one place in their households for health-related papers (for safekeeping).
AD  - School of Nursing, University of Louisville, KY, USA. sally.weinrich@louisville.edu
AN  - 12515993
AU  - Weinrich, S. P.
AU  - Weinrich, M. C.
AU  - Priest, J.
AU  - Fodi, C.
DA  - Jan-Feb
DO  - 10.1188/03.Onf.E12-e16
DP  - NLM
ET  - 2003/01/08
IS  - 1
KW  - Adult
African Americans/statistics & numerical data
Aged
European Continental Ancestry Group/statistics & numerical data
*Health Knowledge, Attitudes, Practice
Health Services Accessibility/*statistics & numerical data
Humans
Male
Mass Screening/*statistics & numerical data
Middle Aged
Patient Acceptance of Health Care/*statistics & numerical data
Patient Participation
Population Surveillance
Prostatic Neoplasms/nursing/*prevention & control
Socioeconomic Factors
Southeastern United States/epidemiology
LA  - eng
N1  - 1538-0688
Weinrich, Sally P
Weinrich, Martin C
Priest, Julie
Fodi, Cathy
R01 CA60561-01/CA/NCI NIH HHS/United States
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.
United States
Oncol Nurs Forum. 2003 Jan-Feb;30(1):E12-6. doi: 10.1188/03.ONF.E12-E16.
PY  - 2003
SN  - 0190-535x
SP  - E12-6
ST  - Self-reported reasons men decide not to participate in free prostate cancer screening
T2  - Oncol Nurs Forum
TI  - Self-reported reasons men decide not to participate in free prostate cancer screening
VL  - 30
ID  - 657
ER  - 

TY  - JOUR
AB  - Background. The most common tracers used for lymphatic mapping in sentinel lymph node dissection (SLND) are blue dye and radio-colloid. The former is associated with hypersensitivity, and the latter is not available in some institutions. It is still unclear as to which subsets of patients benefit most from SLND. In this study, we tried to evaluate the usefulness of activated carbon in SLND in the early stages of breast cancer. Methods. Patients with palpable lesions diagnosed as ductal carcinoma in situ (DCIS) or intraductal carcinoma with micro-invasion (DCMI) ftorn their core-needle biopsy specimens were eligible for the study. A 0.4-0.6 cc emulsion of activated carbon particles (ACP) was injected peri-lesionally or subdermally, 5 minutes before modified radical mastectomy. When the axillary compartment was entered, the black-stained sentinel nodes (SLNs) were dissected and examined with H&E stain by frozen section. The extension of subsequent axillary lymph node dissection (ALND) was determined by the status of the sentinel nodes. Results. Twenty-eight patients were diagnosed as DCIS and 10 as DCMI initially. The SLNs were successfully localized in 33 patients (86.8%), with an average of 2.4 SLNs dissected. The SLNs were positive for metastasis in three patients, and the non-sentinel axillary lymph nodes (ALNs) were also positive in one of them. The final diagnosis of these patients turned out to be infiltrating ductal carcinoma. The SLNs were negative for metastasis in 30 patients, and all the ALNs of these patients were also negative. Among these 33 patients, the final diagnosis was up-graded in nine (27.3%), including the three patients with positive SLNs. The SLNs were not identified in five patients, and the ALNs were positive for metastasis in one of them. Conclusions. ACP is an acceptable tracer for lymphatic mapping in SLND. For patients with palpable, biopsy-proven DCIS or DCMI, SLND can be used to select patients for ALND.
AD  - C.-L. Liu, Department of General Surgery, Mackay Memorial Hospital, 92 Sec. 2 Chung-San North Road, Taipe 104 Taiwan, Taiwan
AU  - Liu, C. L.
AU  - Yang, T. L.
AU  - Chen, B. F.
DB  - Embase
Medline
IS  - 7
KW  - activated carbon
dye
tracer
article
axillary lymph node
breast cancer
breast carcinoma
metastatic breast cancer
cancer staging
carcinoma in situ
clinical article
clinical trial
controlled clinical trial
controlled study
dose response
emulsion
frozen section
human
human tissue
intraductal carcinoma
invasive carcinoma
lymph node dissection
mastectomy
needle biopsy
palpation
patient selection
preoperative evaluation
sentinel lymph node
staining
surgical technique
treatment outcome
LA  - English
M3  - Article
N1  - L37265565
2003-10-29
PY  - 2003
SN  - 1726-4901
SP  - 406-410
ST  - Sentinel lymph node mapping with emulsion of activated carbon particles in patients with pre-mastectomy diagnosis of intraductal carcinoma of the breast
T2  - Journal of the Chinese Medical Association
TI  - Sentinel lymph node mapping with emulsion of activated carbon particles in patients with pre-mastectomy diagnosis of intraductal carcinoma of the breast
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L37265565&from=export
VL  - 66
ID  - 1290
ER  - 

TY  - JOUR
AB  - Background: Colorectal cancer (CRC) screening uptake remains limited, despite considerable efforts. Colonoscopy and fecal immunochemical tests (FIT) are considered top‐tier tests by guidelines, which suggest offering multiple options or sequential choice of colonoscopy then FIT. Behavioral economic insights about ‘choice architecture’ suggest that screening participation could be influenced by how people are presented choices. We compare response rates to mailed outreach with sequential choice (colonoscopy then FIT) or active choice (colonoscopy or FIT), as compared to offering colonoscopy alone. Methods: This is a three‐arm pragmatic randomized controlled trial conducted between November 2017 and March 2018 at two primary care practices at an academic health system. Patients aged 50‐74 with at least 2 primary care visits in the 2‐year pre‐enrollment period were included. Through automated data extraction and chart review, patients were excluded if they were up‐to‐date with screening according to guidelines, had a history of CRC, polyps, inflammatory bowel disease, gastrointestinal bleeding, colectomy, or a family CRC history. Eligible patients received initial outreach through mail about CRC screening and the opportunity to participate. They were randomized in a 1:1:1 allocation ratio to the following arms: (1) a direct phone number to call for scheduling colonoscopy (colonoscopy only); (2) a direct phone number for colonoscopy, and a mailed FIT kit if no response within 4 weeks (sequential choice); or (3) a direct phone number for colonoscopy and a mailed FIT kit (active choice). All patients who did not participate received a reminder at 4 weeks after initial outreach. The primary outcome was CRC screening completion (FIT or colonoscopy) within 4 months of initial outreach. The secondary outcome was choice of screening test between FIT and colonoscopy. Results: 438 patients were included in the intent‐to‐treat analysis (Table 1). 55% of participants were women, 49% were non‐Hispanic white, 36% non‐Hispanic black, and 77% had commercial insurance. 5.5% of participants randomized to colonoscopy alone completed screening compared to 12.3% in the sequential choice (P=0.04), and 12.3% in the active choice arm (P=0.04). 3.4% of participants in the sequential choice arm completed colonoscopy but no patients had colonoscopy in the active choice arm. Conclusions: Mailed CRC screening outreach offering the choice of colonoscopy or FIT had higher completion rates than offering colonoscopy alone. Sequential choice of colonoscopy then FIT resulted in a higher rate of colonoscopy as compared to active choice. Future studies could evaluate the response and durability of different choice architecture in a broader population, including comparison to FIT outreach alone. [Table presented] [Table presented]
AN  - CN-01962941
AU  - Mehta, S. J.
AU  - Induru, V. R.
AU  - Santos, D.
AU  - Reitz, C.
AU  - McAuliffe, T.
AU  - Orellana, C.
AU  - Volpp, K.
AU  - Asch, D. A.
AU  - Doubeni, C. A.
DO  - 10.1016/S0016-5085(19)37251-8
IS  - 6
KW  - Adult
Aged
Cancer patient
Cancer screening
Cancer surgery
Colon resection
Colonoscopy
Colorectal cancer
Conference abstract
Controlled study
Data extraction
Female
Gastrointestinal hemorrhage
Human
Inflammatory bowel disease
Insurance
Major clinical study
Medical record review
Middle aged
Occult blood test
Outcome assessment
Polyp
Practice guideline
Primary medical care
Randomized controlled trial
Screening test
Surgery
M3  - Journal: Conference Abstract
PY  - 2019
SP  - S‐185‐
ST  - SEQUENTIAL OR ACTIVE CHOICE FOR COLORECTAL CANCER SCREENING OUTREACH: a RANDOMIZED CLINICAL TRIAL
T2  - Gastroenterology
TI  - SEQUENTIAL OR ACTIVE CHOICE FOR COLORECTAL CANCER SCREENING OUTREACH: a RANDOMIZED CLINICAL TRIAL
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01962941/full
VL  - 156
ID  - 1637
ER  - 

TY  - JOUR
AB  - Selective estrogen receptor modulators (SERMs) are an exciting new class of pharmacotherapeutics that may have application in a wide variety of disease states. The science, both basic and clinical, that would guide the usage of these agents is in some respects at a relatively early developmental stage. Thus, the research community has an opportunity, before their use becomes widespread, to structure clinical trials such that the most complete profiles of benefits and risks are described. Tamoxifen is the SERM that has been most extensively studied and for which there are indications for both treatment and prevention of breast cancer based on trials involving more than 50,000 women. Despite this seemingly adequate sample size, an extremely important question remains unanswered--namely, whether there are ethnic differences in benefit and adverse effects of SERMs. It has generally been the case that new pharmacologic agents are tested in relatively small numbers of subjects, often only male, in North America and western Europe. While the populations are multi-ethnic, clinical trial subjects are most often not representative of the ethnic variability of these areas. Guidelines for usage of new drugs based on data from small, ethnically limited population groups are then generalized to other population groups, without consideration that differences in drug metabolism and/or responsiveness might exist.
AD  - Division of Cardiology, Mayo Medical School, Minneapolis, Minnesota 55455, USA. taylo135@umn.edu
AN  - 11795365
AU  - Taylor, A. L.
DA  - Dec
DO  - 10.1111/j.1749-6632.2001.tb04035.x
DP  - NLM
ET  - 2002/01/25
KW  - African Continental Ancestry Group
Breast Neoplasms/*prevention & control
Clinical Trials as Topic/*standards
Ethnic Groups
Female
Humans
Selective Estrogen Receptor Modulators/*adverse effects/*therapeutic use
Tamoxifen/adverse effects/therapeutic use
United States
LA  - eng
N1  - Taylor, A L
Comparative Study
Journal Article
Review
United States
Ann N Y Acad Sci. 2001 Dec;949:292-4. doi: 10.1111/j.1749-6632.2001.tb04035.x.
PY  - 2001
SN  - 0077-8923 (Print)
0077-8923
SP  - 292-4
ST  - SERMs, ethnicity, and clinical trials: opportunities and challenges
T2  - Ann N Y Acad Sci
TI  - SERMs, ethnicity, and clinical trials: opportunities and challenges
VL  - 949
ID  - 673
ER  - 

TY  - JOUR
AB  - Background: Evidence is mounting that intraprostatic inflammation influences prostate cancer development. Uric acid crystals depositing in the prostate could result in injury and inflammation, increasing prostate cancer risk. Methods: Included were 6,574 men ages 45–64 years who enrolled in the Atherosclerosis Risk in Communities study in 1987 to 1989. We used Cox proportional hazards regression to estimate the association of serum urate concentration alone and to improve accuracy, jointly with a genetic risk score (GRS, N ¼ 4,983) derived from variants predictive of urate concentration, with prostate cancer (N ¼ 813) risk. Results: Serum urate concentration or joint categories of urate concentration and GRS were not associated with prostate cancer risk (Ptrend for quartiles ¼ 0.3). Results were generally similar by race and after excluding users of medications that influence uric acid. Conclusions: Serum urate alone and with a urate-associated GRS were not associated with prostate cancer risk. Impact: It is unlikely that circulating urate concentration influences prostate cancer development. © 2019 American Association for Cancer Research.
AD  - Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States
Welch Center for Prevention, Epidemiology, and Clinical Research, Baltimore, MD, United States
Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, United States
Department of Urology, James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD, United States
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, United States
Institute of Genetic Epidemiology, Faculty of Medicine and Medical Center, University of Freiburg, Freiburg, Germany
AU  - Wang, A.
AU  - Barber, J. R.
AU  - Tin, A.
AU  - De Marzo, A. M.
AU  - Kottgen, A.
AU  - Joshu, C. E.
AU  - Platz, E. A.
DB  - Scopus
DO  - 10.1158/1055-9965.EPI-19-0161
IS  - 7
M3  - Article
N1  - Export Date: 22 March 2021
PY  - 2019
SP  - 1259-1261
ST  - Serum urate, genetic variation, and prostate cancer risk: Atherosclerosis risk in Communities (ARIC) study
T2  - Cancer Epidemiology Biomarkers and Prevention
TI  - Serum urate, genetic variation, and prostate cancer risk: Atherosclerosis risk in Communities (ARIC) study
UR  - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85068776969&doi=10.1158%2f1055-9965.EPI-19-0161&partnerID=40&md5=a6736b49d19adf6e791b2f6966a52b72
VL  - 28
ID  - 2247
ER  - 

TY  - JOUR
AB  - Background: Previous studies regarding the association between serum 25-hydroxyvitamin D (25OHD(3)) and breast cancer risk have not been conclusive. The aim of this study was to investigate the potential association between pre-diagnostic serum 25OHD(3) levels and the risk of different subtypes of breast cancer. Materials and methods: The study was based on The Malmo Diet and Cancer Study recruiting 17,035 women from 1991 to 1996. A total of 764 incident breast cancers with matched controls were analysed for 25OHD(3) in samples collected at baseline, before diagnosis. A logistic regression analysis was used to calculate odds ratios with 95% confidence intervals for tertiles of 25OHD(3) in relation to different subtypes of breast cancer, i.e. defined according to tumour type, tumour size, lymph node involvement, histological grade, oestrogen receptor (ER) status, progesterone receptor (PgR) status, Ki67, cyclin D1 and p27. Results: As compared to the 1st tertile of 25OHD(3), the second tertile had a statistically significantly lower risk of ER negative tumours, PgR negative tumours and tumours with a high expression of Ki67, A similar pattern was seen in relation to large tumours (>= 21 mm), grade III tumours, and tumours with low p27 expression, but these associations did not reach statistical significance. The third tertile had a similar risk as the first tertile. Conclusions: We found that women with low levels of 25OHD(3), as compare to women in the middle tertile, had a high risk of breast tumours with an unfavourable prognosis. (C) 2016 Elsevier Ltd. All rights reserved.
AN  - WOS:000379683300028
AU  - Shirazi, L.
AU  - Almquist, M.
AU  - Borgquist, S.
AU  - Malm, J.
AU  - Manjer, J.
DA  - Aug
DO  - 10.1016/j.breast.2016.06.002
N1  - 27326980
PY  - 2016
SN  - 0960-9776
SP  - 184-190
ST  - Serum vitamin D (25OHD(3)) levels and the risk of different subtypes of breast cancer: A nested case-control study
T2  - Breast
TI  - Serum vitamin D (25OHD(3)) levels and the risk of different subtypes of breast cancer: A nested case-control study
VL  - 28
ID  - 2937
ER  - 

TY  - JOUR
AB  - OBJECTIVE: To determine factors that influence sexual minority women's coping responses and adjustment to breast cancer. METHODS: We conducted a cross-sectional study with 64 sexual minority women with breast cancer who were recruited through targeted community-based sampling. In this study, sexual minority women consisted of three sexual orientation groups: those who self-reported partnering with women and those with a lesbian or bisexual identity. We determined the number of years of sexual minority status and disclosure of sexual orientation and used standardized measures to assess these women's coping and adjustment to breast cancer. Data were analyzed using statistical methods as appropriate for the level of data. RESULTS: We determined that sexual minority factors, such as sexual orientation group, influenced coping and adjustment even after illness and social support factors were controlled. In multivariate analyses, women who identified as lesbians or bisexuals used less maladaptive coping compared with women who reported partnering with women. The association between reporting a lesbian identity and lower distress approached significance in multivariate regression equations. CONCLUSIONS: Of the sexual minority factors that were considered, sexual orientation group, number of years of sexual minority status, and disclosure of sexual minority status, only sexual orientation group was related to coping and lower distress. Contrary to expectations, disclosure of sexual orientation did not relate to coping and lower distress. The findings support the need for future studies to include different aspects of sexual minority status, in particular, clearly defined sexual orientation groups.
AD  - Dept of Health Services, Boston University School of Public Health, Boston, MA
AN  - 106490915. Language: English. Entry Date: 20050729. Revision Date: 20200708. Publication Type: Journal Article
AU  - Boehmer, U.
AU  - Linde, R.
AU  - Freund, K. M.
DB  - CINAHL Complete
DO  - 10.1089/jwh.2005.14.214
DP  - EBSCOhost
IS  - 3
KW  - Attitude to Illness
Breast Neoplasms -- Psychosocial Factors
Minority Groups -- Psychosocial Factors
Adaptation, Psychological
Analysis of Variance
Attitude Measures
Audiorecording
Bisexuality
Black Persons
Breast Neoplasms -- Drug Therapy
Breast Neoplasms -- Surgery
Breast Neoplasms -- Therapy
Confidence Intervals
Coping
Dependent Variable
Descriptive Statistics
Female
Fisher's Exact Test
Hispanic Americans
Independent Variable
Lesbians
Odds Ratio
Pearson's Correlation Coefficient
Psychological Tests
Questionnaires
Research Subject Recruitment
Scales
Secondary Analysis
Self Report
Semi-Structured Interview
Stress, Psychological
Support, Psychosocial
T-Tests
Human
N1  - research; tables/charts. Journal Subset: Biomedical; Peer Reviewed; USA. Instrumentation: Profile of Mood States (POMS); Mental Adjustment to Cancer (MAC) scale. NLM UID: 101159262.
PMID: NLM15857267.
PY  - 2005
SN  - 1540-9996
SP  - 214-223
ST  - Sexual minority women's coping and psychological adjustment after a diagnosis of breast cancer
T2  - Journal of Women's Health (15409996)
TI  - Sexual minority women's coping and psychological adjustment after a diagnosis of breast cancer
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106490915&site=ehost-live&scope=site
VL  - 14
ID  - 2085
ER  - 

TY  - JOUR
AB  - Background. Sexually transmitted infections (STIs), including human immunodeficiency virus (HIV), disproportionately affect adolescents and young adults (AYAs) ages 13-24 years. Sexually transmitted infections likewise are a risk factor for HIV acquisition and transmission; however, there is a lack of data on STI acquisition in HIV-infected AYAs. Methods We determined the incidence of STIs in HIV-infected AYAs 12.5 <25 years of age in the International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) P1074 observational cohort study. Univariate and multivariable logistic regression models were used to evaluate the association of HIV control (mean viral load <500 copies/mL and CD4(+) T cells >500 cells/mm(3) in the year preceding STI diagnosis) and other risk factors with STI occurrence. Results. Of 1201 enrolled subjects, 1042 participants met age criteria and were included (49% male, 61% black, 88% perinatally infected; mean age 18.3 years). One hundred twenty participants had at least 1 STI on study, of whom 93 had their first lifetime STI (incidence rate = 2.8/100 person-years). For individual STI categories, 155 incident category-specific events were reported; human papillomavirus (HPV) and chlamydial infections were the most common. In the multivariable model, having an STI was associated with older age (adjusted odds ratio [aOR] = 1.13; 95% confidence interval [CI], 1.05-1.22), female sex (aOR = 2.65; 95% CI, 1.67-4.21), nonperinatal HIV acquisition (aOR = 2.33; 95% CI, 1.29-4.22), and uncontrolled HIV infection (aOR = 2.05; 95% CI, 1.29-3.25). Conclusions. Sexually transmitted infection acquisition in HIV-infected AYAs is associated with older age, female sex, nonperinatal HIV acquisition, and poorly controlled HIV infection. Substantial rates of STIs among HIV-infected AYAs support enhanced preventive interventions, including safe-sex practices and HPV vaccination, and antiretroviral adherence strategies.
AN  - WOS:000416622700003
AU  - Camacho-Gonzalez, A. F.
AU  - Chernoff, M. C.
AU  - Williams, P. L.
AU  - Chahroudi, A.
AU  - Oleske, J. M.
AU  - Traite, S.
AU  - Chakraborty, R.
AU  - Purswani, M. U.
AU  - Abzug, M. J.
DA  - Sep
DO  - 10.1093/jpids/piw039
IS  - 3
N1  - 27440505
PY  - 2017
SN  - 2048-7193
SP  - E22-E29
ST  - Sexually Transmitted Infections in Youth With Controlled and Uncontrolled Human Immunodeficiency Virus Infection
T2  - Journal of the Pediatric Infectious Diseases Society
TI  - Sexually Transmitted Infections in Youth With Controlled and Uncontrolled Human Immunodeficiency Virus Infection
VL  - 6
ID  - 2887
ER  - 

TY  - JOUR
AB  - BACKGROUND: It is unclear whether the higher burden from colorectal cancer among blacks is due to an increased biological susceptibility. OBJECTIVE: To determine whether non-Hispanic blacks (blacks) have a higher risk of adenoma recurrence than non-Hispanic whites (whites) after removal of colorectal adenoma. DESIGN: Secondary analysis of the Polyp Prevention Trial (PPT) data. SETTING: United States. PATIENTS: Patients were 1668 self-identified whites and 153 blacks who completed the 4-year trial. Of these, 688 whites and 55 blacks enrolled in a posttrial, passive Polyp Prevention Trial Continued Follow-up Study (PPT-CFS) and underwent another colonoscopy. MAIN OUTCOME MEASUREMENTS: Recurrence and location of the adenoma and advanced adenoma by race-ethnicity during PPT and cumulative recurrence over a mean follow-up of 8.3 years (range, 4.9-12.4 years) among PPT-CFS enrollees. RESULTS: Blacks had similar risk of recurrence of adenoma (39.2% vs 39.4%; incidence risk ratio [RR] = .98; 95% CI, .80-1.20) and advanced adenoma (8.5% vs 6.4%; RR = 1.18; 95% CI, .68-2.05) as whites at the end of PPT. Recurrence risk did not differ by colon subsite. Among PPT-CFS enrollees, the cumulative recurrence rate over a maximal follow-up period of 12 years was similar for blacks and whites for adenoma (67.3% vs 67.0%; RR = 1.01; 95% CI, .84-1.21) and advanced adenoma (14.5% vs 16.9%; RR = 1.03; 95% CI, .60-1.79). LIMITATION: There were few blacks in the long-term follow-up study. CONCLUSIONS: Adenoma and advanced adenoma recurrence did not differ by race. Our study does not support more frequent surveillance colonoscopies for blacks with a personal history of adenoma as an intervention to reduce colorectal cancer disparity.
AD  - Department of Medicine, Howard University Hospital, Washington, DC, USA. adeyinka.laiyemo@howard.edu.
AN  - 23337636
AU  - Laiyemo, A. O.
AU  - Doubeni, C.
AU  - Brim, H.
AU  - Ashktorab, H.
AU  - Schoen, R. E.
AU  - Gupta, S.
AU  - Charabaty, A.
AU  - Lanza, E.
AU  - Smoot, D. T.
AU  - Platz, E.
AU  - Cross, A. J.
C2  - PMC3651852
C6  - NIHMS468747
DA  - Mar
DO  - 10.1016/j.gie.2012.11.027
DP  - NLM
ET  - 2013/01/23
IS  - 3
KW  - Adenoma/*ethnology/surgery
Adult
African Americans/*statistics & numerical data
Aged
Chi-Square Distribution
Colonoscopy
Colorectal Neoplasms/*ethnology/surgery
Confidence Intervals
European Continental Ancestry Group/*statistics & numerical data
Female
Humans
Incidence
Male
Middle Aged
Neoplasm Recurrence, Local/*ethnology
Statistics, Nonparametric
United States/epidemiology
LA  - eng
N1  - 1097-6779
Laiyemo, Adeyinka O
Doubeni, Chyke
Brim, Hassan
Ashktorab, Hassan
Schoen, Robert E
Gupta, Samir
Charabaty, Aline
Lanza, Elaine
Smoot, Duane T
Platz, Elizabeth
Cross, Amanda J
5U54CA091431-09 S1/CA/NCI NIH HHS/United States
P30 CA006973/CA/NCI NIH HHS/United States
U54 CA091431/CA/NCI NIH HHS/United States
K01 CA127118/CA/NCI NIH HHS/United States
5K01CA127118/CA/NCI NIH HHS/United States
Z99 CA999999/Intramural NIH HHS/United States
U01 CA151736/CA/NCI NIH HHS/United States
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, N.I.H., Intramural
Gastrointest Endosc. 2013 Mar;77(3):447-54. doi: 10.1016/j.gie.2012.11.027. Epub 2013 Jan 18.
PY  - 2013
SN  - 0016-5107 (Print)
0016-5107
SP  - 447-54
ST  - Short- and long-term risk of colorectal adenoma recurrence among whites and blacks
T2  - Gastrointest Endosc
TI  - Short- and long-term risk of colorectal adenoma recurrence among whites and blacks
VL  - 77
ID  - 340
ER  - 

TY  - JOUR
AB  - PURPOSE: Among patients with small-cell lung carcinoma, African Americans have lower survival rates than non-African Americans. We investigated whether the disparity in survival would persist when patients were treated with similar therapies (ie, phase II/III Cancer and Leukemia Group B [CALGB] trials). PATIENTS AND METHODS: We assessed 995 patients (928 non-African American and 67 African American) receiving chemotherapy in CALGB studies for extensive-stage small-cell lung cancer (ES-SCLC). Clinical and demographic characteristics, treatment received, and survival data were obtained from the CALGB database. The Cox proportional hazards model was used to assess the effect of race/ethnicity on survival after adjustment for other known prognostic factors. All statistical tests were two sided. RESULTS: The unadjusted survival distribution of African American patients was not significantly different from that of non-African American patients; median survival was 11.5 months (95% CI, 9.4 to 13.4 months) for African American patients versus 9.9 months (95% CI, 9.6 to 10.3 months) for non-African American patients. Multivariable adjustment for the effect of treatment arm, histology, and metastatic site at presentation did not alter the outcome for African American patients. Survival was similar even though African American patients were more likely to have a poorer performance status, present with significant weight loss, and be Medicaid recipients (20% v 6%), which is an indicator of lower socioeconomic status. CONCLUSION: African American patients tended to present with prognostic features associated with a worse survival. However, when offered equivalent therapy, the outcome for African American patients was the same as that observed for non-African American patients.
AD  - Department of Radiation Oncology, Wake Forest University School of Medicine, Winston-Salem, NC 27157, USA. ablackst@wfubmc.edu
AN  - 16365181
AU  - Blackstock, A. W.
AU  - Herndon, J. E., 2nd
AU  - Paskett, E. D.
AU  - Miller, A. A.
AU  - Lathan, C.
AU  - Niell, H. B.
AU  - Socinski, M. A.
AU  - Vokes, E. E.
AU  - Green, M. R.
DA  - Jan 20
DO  - 10.1200/jco.2005.02.1436
DP  - NLM
ET  - 2005/12/21
IS  - 3
KW  - Adult
African Americans/*statistics & numerical data
Aged
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Carcinoma, Small Cell/*drug therapy/ethnology/*mortality/pathology
Clinical Trials, Phase II as Topic
Clinical Trials, Phase III as Topic
Female
Humans
Lung Neoplasms/*drug therapy/ethnology/*mortality/pathology
Male
Middle Aged
Multivariate Analysis
Prognosis
Proportional Hazards Models
Retrospective Studies
Risk Assessment
Risk Factors
Survival Analysis
Treatment Outcome
United States/epidemiology
LA  - eng
N1  - 1527-7755
Blackstock, A William
Herndon, James E 2nd
Paskett, Electra D
Miller, Antonius A
Lathan, Christopher
Niell, Harvey B
Socinski, Mark A
Vokes, Everett E
Green, Mark R
Cancer and Leukemia Group B
CA31946/CA/NCI NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
United States
J Clin Oncol. 2006 Jan 20;24(3):407-12. doi: 10.1200/JCO.2005.02.1436. Epub 2005 Dec 19.
PY  - 2006
SN  - 0732-183x
SP  - 407-12
ST  - Similar outcomes between African American and non-African American patients with extensive-stage small-cell lung carcinoma: report from the Cancer and Leukemia Group B
T2  - J Clin Oncol
TI  - Similar outcomes between African American and non-African American patients with extensive-stage small-cell lung carcinoma: report from the Cancer and Leukemia Group B
VL  - 24
ID  - 576
ER  - 

TY  - JOUR
AB  - Video-assisted thoracic surgery is gradually replacing conventional open thoracotomy as the method of choice for the treatment of early-stage non-small cell lung cancers, and thoracic surgical trainees must learn and master this technique. Simulation-based training could help trainees overcome the first part of the learning curve, but no virtual-reality simulators for thoracoscopy are commercially available. This study aimed to investigate whether training on a laparoscopic simulator enables trainees to perform a thoracoscopic lobectomy. Twenty-eight surgical residents were randomized to either virtual-reality training on a nephrectomy module or traditional black-box simulator training. After a retention period they performed a thoracoscopic lobectomy on a porcine model and their performance was scored using a previously validated assessment tool. The groups did not differ in age or gender. All participants were able to complete the lobectomy. The performance of the black-box group was significantly faster during the test scenario than the virtual-reality group: 26.6 min (SD 6.7 min) versus 32.7 min (SD 7.5 min). No difference existed between the two groups when comparing bleeding and anatomical and non-anatomical errors. Simulation-based training and targeted instructions enabled the trainees to perform a simulated thoracoscopic lobectomy. Traditional black-box training was more effective than virtual-reality laparoscopy training. Thus, a dedicated simulator for thoracoscopy should be available before establishing systematic virtual-reality training programs for trainees in thoracic surgery.
AN  - WOS:000336395400009
AU  - Jensen, K.
AU  - Ringsted, C.
AU  - Hansen, H. J.
AU  - Petersen, R. H.
AU  - Konge, L.
DA  - Jun
DO  - 10.1007/s00464-013-3392-7
IS  - 6
N1  - 24442678
PY  - 2014
SN  - 0930-2794
SP  - 1821-1829
ST  - Simulation-based training for thoracoscopic lobectomy: a randomized controlled trial
T2  - Surgical Endoscopy and Other Interventional Techniques
TI  - Simulation-based training for thoracoscopic lobectomy: a randomized controlled trial
VL  - 28
ID  - 3009
ER  - 

TY  - JOUR
AB  - BACKGROUND: Video-assisted thoracic surgery is gradually replacing conventional open thoracotomy as the method of choice for the treatment of early-stage non-small cell lung cancers, and thoracic surgical trainees must learn and master this technique. Simulation-based training could help trainees overcome the first part of the learning curve, but no virtual-reality simulators for thoracoscopy are commercially available. This study aimed to investigate whether training on a laparoscopic simulator enables trainees to perform a thoracoscopic lobectomy. METHODS: Twenty-eight surgical residents were randomized to either virtual-reality training on a nephrectomy module or traditional black-box simulator training. After a retention period they performed a thoracoscopic lobectomy on a porcine model and their performance was scored using a previously validated assessment tool. RESULTS: The groups did not differ in age or gender. All participants were able to complete the lobectomy. The performance of the black-box group was significantly faster during the test scenario than the virtual-reality group: 26.6 min (SD 6.7 min) versus 32.7 min (SD 7.5 min). No difference existed between the two groups when comparing bleeding and anatomical and non-anatomical errors. CONCLUSION: Simulation-based training and targeted instructions enabled the trainees to perform a simulated thoracoscopic lobectomy. Traditional black-box training was more effective than virtual-reality laparoscopy training. Thus, a dedicated simulator for thoracoscopy should be available before establishing systematic virtual-reality training programs for trainees in thoracic surgery.
AD  - Department of Cardiothoracic Surgery, University Hospital of Copenhagen, Rigshospitalet, Thoraxkirurgisk afd. 2152, Blegdamsvej 9, 2100, Copenhagen, Denmark, katrine.jensen@regionh.dk.
AN  - 24442678
AU  - Jensen, K.
AU  - Ringsted, C.
AU  - Hansen, H. J.
AU  - Petersen, R. H.
AU  - Konge, L.
DA  - Jun
DO  - 10.1007/s00464-013-3392-7
DP  - NLM
ET  - 2014/01/21
IS  - 6
KW  - Adult
Animals
Carcinoma, Non-Small-Cell Lung/surgery
*Computer Simulation
Computer-Assisted Instruction/*methods
Female
Humans
Internship and Residency/*methods
Learning Curve
Male
Pneumonectomy/*methods
Swine
Thoracic Surgery, Video-Assisted/*education
Thoracoscopy/*education
*User-Computer Interface
LA  - eng
N1  - 1432-2218
Jensen, Katrine
Ringsted, Charlotte
Hansen, Henrik Jessen
Petersen, René Horsleben
Konge, Lars
Comparative Study
Journal Article
Randomized Controlled Trial
Germany
Surg Endosc. 2014 Jun;28(6):1821-9. doi: 10.1007/s00464-013-3392-7. Epub 2014 Jan 18.
PY  - 2014
SN  - 0930-2794
SP  - 1821-9
ST  - Simulation-based training for thoracoscopic lobectomy: a randomized controlled trial: virtual-reality versus black-box simulation
T2  - Surg Endosc
TI  - Simulation-based training for thoracoscopic lobectomy: a randomized controlled trial: virtual-reality versus black-box simulation
VL  - 28
ID  - 297
ER  - 

TY  - JOUR
AB  - Few eligible postmenopausal women participate in clinical trial research to prevent breast cancer or coronary heart disease, making it impossible to adequately assess the efficacy of tested interventions for this vulnerable group. To elucidate the causal factors and decision model underlying participation behavior, 180 white, African American, and Hispanic postmenopausal women judged their likelihood of participation in a breast cancer or coronary heart disease prevention clinical trial in scenarios with varied cost/remuneration, perceived risk, doctor's recommendation, and expected toxicity. In addition, 293 white, African American, and Hispanic male and female physicians judged the strength of their participation recommendation in scenarios with varied cost/remuneration, expected toxicity, patient's age, and the source of the information about the clinical trial. An additive and constant-weight-averaging model were rejected. The same configural-weight-range model accounted for judgments in both breast cancer and coronary heart disease scenarios, with different parameter values for each group. According to this model, white and Hispanic women under 70 years of age are most likely to participate, even under somewhat adverse conditions; costs and high toxicity levels act as severe barriers to physicians' positive recommendations and women's participation. Perceived risk was the most important factor for women, yet only 8% and 15% reported ever having received risk information from their doctor for breast cancer and coronary heart disease, respectively. For these two diseases, respectively, 75% and 48% of women rated their risk of the disease as low and 76% and 88% reported they had never heard of a randomized clinical trial or of a prevention clinical trial being conducted. These results have implications for education, information dissemination, and prevention clinical-trial planners.
AD  - RAND Publications Department, 1700 Main Street, Santa Monica, CA 90407-2138, USA.
AN  - 15271272
AU  - Veit, C. T.
DA  - Jul-Aug
DO  - 10.1177/0272989x04267007
DP  - NLM
ET  - 2004/07/24
IS  - 4
KW  - Aged
Aged, 80 and over
Breast Neoplasms/ethnology/*prevention & control
Clinical Trials as Topic/*methods/psychology
Coronary Disease/ethnology/*prevention & control
*Decision Support Techniques
Ethnic Groups
Female
Humans
Male
Middle Aged
Motivation
*Patient Participation
*Physician's Role
*Postmenopause
Risk Assessment
LA  - eng
N1  - Veit, Clairice T
Journal Article
Research Support, Non-U.S. Gov't
United States
Med Decis Making. 2004 Jul-Aug;24(4):330-50. doi: 10.1177/0272989X04267007.
PY  - 2004
SN  - 0272-989X (Print)
0272-989x
SP  - 330-50
ST  - A single mathematical model predicts physicians' recommendations and postmenopausal women's decisions to participate in a clinical trial to prevent breast cancer or coronary heart disease
T2  - Med Decis Making
TI  - A single mathematical model predicts physicians' recommendations and postmenopausal women's decisions to participate in a clinical trial to prevent breast cancer or coronary heart disease
VL  - 24
ID  - 625
ER  - 

TY  - JOUR
AB  - INTRODUCTION: Recruiting racial, ethnic, and other underserved minorities into conventional clinic-based and other trials is known to be challenging. The Sistas Inspiring Sistas Through Activity and Support (SISTAS) Program was a one-year randomized controlled trial (RCT) to promote physical activity and healthy eating among AA women in SC to reduce inflammatory biomarkers, which are linked to increased breast cancer (BrCa) risk and mortality. This study describes the development, recruitment, and implementation of the SISTAS clinical trial and provides baseline characteristics of the study participants. METHODS: SISTAS was developed using community-based participatory research (CBPR) approaches. At baseline, study participants completed assessments and underwent clinical measurements and blood draws to measure C-reactive protein (CRP) and interleukin-6 (IL-6). Participants randomized to the intervention received 12 weekly classes followed by nine monthly booster sessions. Post-intervention measurements were assessed at 12-week and 12-month follow-ups. RESULTS: We recruited a total of 337 women who tended to: be middle-aged (mean age 48.2 years); have some college education; be employed full-time; have Medicare as their primary insurance; be non-smokers; and perceive their personal health as good. On average, the women were pre-hypertensive at baseline (mean systolic blood pressure = 133.9 mm Hg; mean diastolic blood pressure = 84.0 mm Hg) and morbidly obese (mean BMI >40.0 kg/m(2)); the mean fat mass and fat-free mass among participants were 106.4 lb and 121.0 lb, respectively. CONCLUSION: The SISTAS RCT addresses some of the gaps in the literature with respect to CBPR interventions targeting AA women, such as implementing diet and physical activity in CBPR-based studies to decrease BrCa risk.
AD  - Cancer Prevention and Control Program, Arnold School of Public Health, University of South Carolina.
College of Nursing, University of South Carolina.
Department of Health Promotion, Education, and Behavior, Arnold School of Public Health, University of South Carolina.
Department of Epidemiology and Biostatistics, Arnold School of Public Health, University of South Carolina.
Community Works, Bon Secours Baltimore Health Systems; Baltimore, Maryland.
Department of Pathology, Microbiology, and Immunology, School of Medicine, University of South Carolina.
AN  - 29725191
AU  - Bevel, M.
AU  - Babatunde, O. A.
AU  - Heiney, S. P.
AU  - Brandt, H. M.
AU  - Wirth, M. D.
AU  - Hurley, T. G.
AU  - Khan, S.
AU  - Johnson, H.
AU  - Wineglass, C. M.
AU  - Warren, T. Y.
AU  - Murphy, E. A.
AU  - Sercy, E.
AU  - Thomas, A. S.
AU  - Hébert, J. R.
AU  - Adams, S. A.
C2  - PMC5926857
DA  - Spring
DO  - 10.18865/ed.28.2.75
DP  - NLM
ET  - 2018/05/05
IS  - 2
KW  - African Americans/psychology/statistics & numerical data
Community-Based Participatory Research
*Diet, Healthy/ethnology/psychology
*Exercise/physiology/psychology
Female
Health Knowledge, Attitudes, Practice
Health Promotion/methods
Humans
Middle Aged
*Obesity, Morbid/diagnosis/ethnology/psychology
Outcome Assessment, Health Care
Patient Selection
United States/epidemiology
*African American
*Breast Cancer
*Community-Based Participatory Research
*Diet
*Physical Activity
LA  - eng
N1  - 1945-0826
Bevel, Malcolm
Babatunde, Oluwole A
Heiney, Sue P
Brandt, Heather M
Wirth, Michael D
Hurley, Thomas G
Khan, Samira
Johnson, Hiluv
Wineglass, Cassandra M
Warren, Tatiana Y
Murphy, E Angela
Sercy, Erica
Thomas, Amanda S
Hébert, James R
Adams, Swann Arp
K05 CA136975/CA/NCI NIH HHS/United States
R15 CA179355/CA/NCI NIH HHS/United States
F99 CA222722/CA/NCI NIH HHS/United States
R44 DK103377/DK/NIDDK NIH HHS/United States
U54 CA153461/CA/NCI NIH HHS/United States
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Ethn Dis. 2018 Apr 26;28(2):75-84. doi: 10.18865/ed.28.2.75. eCollection 2018 Spring.
PY  - 2018
SN  - 1049-510X (Print)
1049-510x
SP  - 75-84
ST  - Sistas Inspiring Sistas Through Activity and Support (SISTAS): Study Design and Demographics of Participants
T2  - Ethn Dis
TI  - Sistas Inspiring Sistas Through Activity and Support (SISTAS): Study Design and Demographics of Participants
VL  - 28
ID  - 123
ER  - 

TY  - JOUR
AB  - African American women are substantially underrepresented in breast cancer genetic research studies and clinical trials, yet they are more likely to die from breast cancer. Lack of trust in the medical community is a major barrier preventing the successful recruitment of African Americans into research studies. When considering the city of Memphis, TN, where the percentage of African Americans is significantly higher than the national average and it has a high rate of breast cancer mortality inequities among African American women, we evaluated the feasibility of utilizing a community-based participatory (CBPR) approach for recruiting African American women into a breast cancer genetic study, called the Sistas Taking A Stand for Breast Cancer Research (STAR) study. From June 2016 and December 2017, African American women age 18 and above were recruited to provide a 2 mL saliva specimen and complete a health questionnaire. A total of 364 African American women provided a saliva sample and completed the health questionnaire. Greater than 85% agreed to be contacted for future studies. Educational workshops on the importance of participating in cancer genetic research studies, followed by question and answer sessions, were most successful in recruitment. Overall, the participants expressed a strong interest and a willingness to participate in the STAR study. Our findings highlight the importance of implementing a CBPR approach that provides an educational component detailing the importance of participating in cancer genetic research studies and that includes prominent community advocates to build trust within the community.
AD  - Department of Genetics, Genomics and Informatics, University of Tennessee Health Science Center, Memphis, TN 38163, USA. aantoin1@uthsc.edu.
Department of Medicine, The University of Tennessee West Cancer Center, Memphis, TN 38163, USA. gvidal1@uthsc.edu.
Division of Hematology and Oncology, Department of Medicine, University of Tennessee Health Science Center, 7945 Wolf River Boulevard, Memphis, TN 38138, USA. gvidal1@uthsc.edu.
Department of Medicine, The University of Tennessee West Cancer Center, Memphis, TN 38163, USA. fpritcha@uthsc.edu.
College of Nursing, University of Tennessee Health Science Center, Memphis, TN 38163, USA. rblue2@uthsc.edu.
Department of Preventive Medicine, University of Tennessee Health Science Center, Memphis, TN 38163, USA. mmart126@uthsc.edu.
School of Health Sciences, Online Learning, Stratford University, 3201 Jermantown Road, Ste 500, Fairfax, VA 22030, USA. lashantajrice@gmail.com.
Carin and Sharin Breast Cancer Support Group, Memphis, TN 38613, USA. gwendolynnbro@gmail.com.
Department of Genetics, Genomics and Informatics, University of Tennessee Health Science Center, Memphis, TN 38163, USA. astarlar@uthsc.edu.
AN  - 30567326
AU  - Smith, A.
AU  - Vidal, G. A.
AU  - Pritchard, E.
AU  - Blue, R.
AU  - Martin, M. Y.
AU  - Rice, L. J.
AU  - Brown, G.
AU  - Starlard-Davenport, A.
C2  - PMC6313663
DA  - Dec 18
DO  - 10.3390/ijerph15122899
DP  - NLM
ET  - 2018/12/21
IS  - 12
KW  - Adolescent
Adult
*African Americans
Aged
Aged, 80 and over
Breast Neoplasms/ethnology/*genetics
Community-Based Participatory Research/*methods
Feasibility Studies
Female
Follow-Up Studies
*Genetic Research
*Health Status Disparities
*Healthcare Disparities
Humans
Middle Aged
Tennessee
Young Adult
*African American women
*Memphis
*tn
*breast cancer
*community-based participatory research
*genetics
*health equity
LA  - eng
N1  - 1660-4601
Smith, Alana
Vidal, Gregory A
Pritchard, Elizabeth
Blue, Ryan
Martin, Michelle Y
Rice, LaShanta J
Brown, Gwendolynn
Starlard-Davenport, Athena
Journal Article
Research Support, Non-U.S. Gov't
Int J Environ Res Public Health. 2018 Dec 18;15(12):2899. doi: 10.3390/ijerph15122899.
PY  - 2018
SN  - 1661-7827 (Print)
1660-4601
ST  - Sistas Taking a Stand for Breast Cancer Research (STAR) Study: A Community-Based Participatory Genetic Research Study to Enhance Participation and Breast Cancer Equity among African American Women in Memphis, TN
T2  - Int J Environ Res Public Health
TI  - Sistas Taking a Stand for Breast Cancer Research (STAR) Study: A Community-Based Participatory Genetic Research Study to Enhance Participation and Breast Cancer Equity among African American Women in Memphis, TN
VL  - 15
ID  - 92
ER  - 

TY  - JOUR
AB  - The Sister Study, a landmark national study investigating the causes of breast cancer, wants to recruit as ethnically diverse a participant sample as possible. And nurses can help spread the word.
AN  - 106256714. Language: English. Entry Date: 20070330. Revision Date: 20150711. Publication Type: Journal Article
AU  - Wessling, S.
DA  - 2006 Fall
DB  - CINAHL Complete
DP  - EBSCOhost
KW  - Breast Neoplasms -- Familial and Genetic
Minority Groups
Research Subject Recruitment
Siblings
Adult
Aged
Asians
Black Persons
Cultural Diversity
Environment
Female
Hispanic Americans
Middle Age
National Institutes of Health (U.S.)
Native Americans
Prospective Studies
Puerto Rico
Transcultural Nursing
United States
White Persons
N1  - pictorial. Journal Subset: Nursing; USA. NLM UID: 9800496.
PY  - 2006
SN  - 1076-7223
SP  - 30-33
ST  - Sisterhood is powerful: the Sister Study breast cancer research
T2  - Minority Nurse
TI  - Sisterhood is powerful: the Sister Study breast cancer research
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106256714&site=ehost-live&scope=site
ID  - 2089
ER  - 

TY  - JOUR
AB  - Background: Chemoprevention crossover trials of tea can be more efficient than parallel designs but the attrition and compliance rates with such trials are unknown. Methods: Attrition (dropouts) and compliance with treatment were assessed in a 25-week randomized, placebo controlled, crossover, feasibility clinical trial of four tea treatments to investigate the effect of tea on oral cancer biomarkers. Each treatment lasted 4 weeks with 2 weeks of washout in between. Participants were 32 smokers and 33 non-smokers without any evidence of premalignant oral lesions. The interventions consisted of packets of green tea, black tea, caffeinated water, or placebo. Participants were assigned to each treatment for four weeks, and were instructed to drink five packets per day while on the treatment. Dropout from the trial and compliance (consumption of 85% of the prescribed treatment packets) are the main outcome measures reported. Results: There was a high rate of dropout (51%) from the study, and the rates were significantly higher among smokers (64%) than non-smokers (36%). Among participants who completed the study the rate of compliance was 72%. The highest rates of dropouts occurred between the first and second treatment visits in both smokers (38% dropout) and non-smokers (18% dropout). Throughout the study smokers were more likely to dropout than non-smokers. Black tea treatment was associated with the highest rates of dropout among smokers (37%), but was associated with the lowest rate of dropout among non-smokers (4%). Conclusions: In a study conducted to test the feasibility of a four-treatment crossover tea trial, a high rate of dropout among smokers and non-smokers was observed. Multi-arm crossover tea trials might pose a higher burden on participants and research is needed to improve adherence and treatment compliance in such trials. Trial registration number: ISRCTN70410203
AD  - Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, D.C, USA
College of Dentistry, Howard University, Washington, D.C, USA
Tea Solutions, Hara Office Inc, Tokyo, Japan
Department of Otolaryngology, Georgetown University, Washington, D.C, USA
Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, D.C, USA; Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Research Building, E501, 3970 Reservoir Rd, N.W, Washington, D.C, USA
AN  - 104504740. Language: English. Entry Date: 20120224. Revision Date: 20200708. Publication Type: Journal Article
AU  - Dash, Chiranjeev
AU  - Fung-Lung, Chung
AU  - Phillips Rohan, Joy Ann
AU  - Greenspan, Emily
AU  - Christopher, Patrick D.
AU  - Makambi, Kepher
AU  - Yukihiko, Hara
AU  - Newkirk, Kenneth
AU  - Davidson, Bruce
AU  - Adams-Campbell, Lucile L.
DB  - CINAHL Complete
DO  - 10.1186/1472-6882-12-96
DP  - EBSCOhost
IS  - 1
KW  - Chemoprevention
Tea -- Therapeutic Use
Smoking
Neoplasms -- Symptoms
Biological Markers
Human
Pilot Studies
Crossover Design
Randomized Controlled Trials
Random Assignment
Research Dropouts
Patient Compliance
Descriptive Statistics
Academic Medical Centers
Male
Female
Adolescence
Adult
Middle Age
District of Columbia
Chi Square Test
Fisher's Exact Test
Models, Statistical
Funding Source
N1  - research; tables/charts; randomized controlled trial. Journal Subset: Alternative/Complementary Therapies; Biomedical; Europe; Expert Peer Reviewed; Peer Reviewed; UK & Ireland. Grant Information: This work was supported by the National Cancer Institute at the National Institutes of Health, USA [5R01 CA 113449, PI: FLC].. NLM UID: 101088661.
PY  - 2012
SN  - 1472-6882
SP  - 96-103
ST  - A six-month crossover chemoprevention clinical trial of tea in smokers and non-smokers: methodological issues in a feasibility study
T2  - BMC Complementary & Alternative Medicine
TI  - A six-month crossover chemoprevention clinical trial of tea in smokers and non-smokers: methodological issues in a feasibility study
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104504740&site=ehost-live&scope=site
VL  - 12
ID  - 1835
ER  - 

TY  - JOUR
AB  - BACKGROUND: This study examines smoking trends in the United States by race, gender, education, and occupation. METHODS: The data were collected between 1969 and 1995 through a hospital-based case-control study on tobacco-related cancers, including 21,057 male and 14,448 female control subjects who had been diagnosed of non-smoking-related diseases. Smoking measures were adjusted through direct standardization and regression methods. RESULTS: Despite the decline in smoking, daily cigarette consumption remained high among current smokers. Women's smoking prevalence decreased more slowly than men's and their age at smoking initiation also declined, while the inverse effects on smoking by education and occupation were more pronounced in men than in women. Smoking prevalence was higher, but daily cigarette consumption was lower in blacks compared to caucasians. CONCLUSIONS: Despite an overall downward trend in smoking, lung cancer remains a major public health concern, particularly among women, blacks, and white men with low education. The development of a systematic mechanism for more detailed, regular monitoring of tobacco use by various subpopulations is, therefore, crucial to future public health planning. Copyright (c) 1998 by Academic Press
AD  - Department of Biostatistics, Novartis Pharmaceutical Corporation, Building 419, Room 2182, 59 Route 10, East Hanover, NJ 07936-1080. E-mail: edith.zang@pharma.novartis.com
AN  - 107189687. Language: English. Entry Date: 19990501. Revision Date: 20150711. Publication Type: Journal Article
AU  - Zang, E. A.
AU  - Wynder, E. L.
DB  - CINAHL Complete
DP  - EBSCOhost
IS  - 6
KW  - Smoking -- Trends
Case Control Studies
Research Subject Recruitment
Interviews
Data Analysis, Statistical
Race Factors
Sex Factors
Socioeconomic Factors
Black Persons
White Persons
Inpatients
Male
Female
Funding Source
Human
N1  - research; tables/charts. Journal Subset: Biomedical; Peer Reviewed; USA. Grant Information: Public Health Service Grant CA32617 from the National Cancer Institute. NLM UID: 0322116.
PMID: NLM9922068.
PY  - 1998
SN  - 0091-7435
SP  - 854-861
ST  - Smoking trends in the United States between 1969 and 1995 based on patients hospitalized with non-smoking-related diseases
T2  - Preventive Medicine
TI  - Smoking trends in the United States between 1969 and 1995 based on patients hospitalized with non-smoking-related diseases
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=107189687&site=ehost-live&scope=site
VL  - 27
ID  - 2090
ER  - 

TY  - JOUR
AB  - PURPOSE: Breast cancer outcomes are worse among black women and women of lower socioeconomic status. The purpose of this study was to investigate racial and social differences in selection of breast cancer adjuvant chemotherapy regimens. METHODS: Detailed information on patient, disease, and treatment factors was collected prospectively on 957 patients who were receiving breast cancer adjuvant chemotherapy in 101 oncology practices throughout the United States. Adjuvant chemotherapy regimens included in any of several published guidelines were considered standard. Receipt of nonstandard regimens was examined according to clinical and nonclinical factors. Differences between groups were assessed using chi2 tests. Multivariate logistic regression was used to identify factors associated with use of nonstandard regimens. RESULTS: Black race (P = .008), lower educational attainment (P = .003), age 70 years (P = .001), higher stage (P < .0001), insurance type (P = .048), employment status (P = .045), employment type (P = .025), and geographic location (P = .021) were associated with the use of nonstandard regimens in univariate analyses. In multivariate analysis, black race (P = .020), lower educational attainment (P = .024), age > or = 70 years (P = .032), and higher stage (P < .0001) were associated with receipt of nonstandard regimens. CONCLUSION: The more frequent use of non-guideline-concordant adjuvant chemotherapy regimens in black women and women with lower educational attainment may contribute to less favorable outcomes in these populations. Addressing such differences in care may improve cancer outcomes in vulnerable populations.
AD  - University of Rochester, Rochester, NY, USA. jengrigg@umich.edu
AN  - 17577029
AU  - Griggs, J. J.
AU  - Culakova, E.
AU  - Sorbero, M. E.
AU  - Poniewierski, M. S.
AU  - Wolff, D. A.
AU  - Crawford, J.
AU  - Dale, D. C.
AU  - Lyman, G. H.
DA  - Jun 20
DO  - 10.1200/jco.2006.10.2749
DP  - NLM
ET  - 2007/06/20
IS  - 18
KW  - Adult
Age Factors
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Breast Neoplasms/*drug therapy/*ethnology
Chemotherapy, Adjuvant
Chi-Square Distribution
Educational Status
Employment/statistics & numerical data
Female
Guideline Adherence
Humans
Insurance, Health/statistics & numerical data
Logistic Models
Middle Aged
Neoplasm Staging
Patient Selection
Prospective Studies
Risk Factors
Treatment Outcome
United States
LA  - eng
N1  - 1527-7755
Griggs, Jennifer J
Culakova, Eva
Sorbero, Melony E S
Poniewierski, Marek S
Wolff, Debra A
Crawford, Jeffrey
Dale, David C
Lyman, Gary H
Journal Article
Research Support, Non-U.S. Gov't
United States
J Clin Oncol. 2007 Jun 20;25(18):2522-7. doi: 10.1200/JCO.2006.10.2749.
PY  - 2007
SN  - 0732-183x
SP  - 2522-7
ST  - Social and racial differences in selection of breast cancer adjuvant chemotherapy regimens
T2  - J Clin Oncol
TI  - Social and racial differences in selection of breast cancer adjuvant chemotherapy regimens
VL  - 25
ID  - 525
ER  - 

TY  - JOUR
AB  - PURPOSE: A sample survey was conducted to assess the feasibility of recruiting participants, specifically African Americans, and to determine social factors influencing participation in a prostate cancer chemoprevention trial. METHODS: A convenience sample of adults visiting a hospital was identified and asked to participate in the survey. The survey included brief background information about prostate cancer and questions concerning four independent (age, marital status, race, insurance status) and three dependent (willingness to join a trial, involvement in long-term drug intake, interest in receiving more information) variables. RESULTS: The study analyzed 165 responses. Of the 165 respondents, 67% were African American. Marital status was a significant predictor of general willingness to participate (p = 0.047) for male respondents. No significant predictor was found for female respondents. Furthermore, for men, ethnicity/race showed a significant difference (30% white men vs 70% of minority men) for willingness to take the pills. CONCLUSION: The results suggest that African Americans are receptive to participating in chemopreventive trials. Thus, future studies exploring chemoprevention trials as an effective tool for reaching African Americans are warranted.
AD  - Department of Radiation and Cellular Oncology, Michael Reese/University of Chicago Center for Radiation Therapy, Illinois 60616, USA.
AN  - 10397483
AU  - Lee, M. M.
AU  - Chamberlain, R. M.
AU  - Catchatourian, R.
AU  - Hiang, J.
AU  - Kopnick, M.
AU  - Ray, P.
AU  - Vijayakumar, S.
DA  - Summer
DO  - 10.1080/08858199909528586
DP  - NLM
ET  - 1999/07/09
IS  - 2
KW  - African Americans/*statistics & numerical data
Analysis of Variance
Anticarcinogenic Agents/*therapeutic use
Chemoprevention
*Clinical Trials as Topic/statistics & numerical data
Data Collection
Female
Humans
Male
Middle Aged
*Patient Participation/statistics & numerical data
Prostatic Neoplasms/*prevention & control
Socioeconomic Factors
United States
LA  - eng
N1  - Lee, M M
Chamberlain, R M
Catchatourian, R
Hiang, J
Kopnick, M
Ray, P
Vijayakumar, S
Journal Article
England
J Cancer Educ. 1999 Summer;14(2):88-92. doi: 10.1080/08858199909528586.
PY  - 1999
SN  - 0885-8195 (Print)
0885-8195
SP  - 88-92
ST  - Social factors affecting interest in participating in a prostate cancer chemoprevention trial
T2  - J Cancer Educ
TI  - Social factors affecting interest in participating in a prostate cancer chemoprevention trial
VL  - 14
ID  - 717
ER  - 

TY  - JOUR
AB  - Greater attention to social factors, such as race/ethnicity, socioeconomic position, and others, are needed across the cancer continuum, including breast cancer, given differences in tumor biology and genetic variants have not completely explained the persistent Black/White breast cancer mortality disparity. In this commentary, we use examples in breast cancer risk assessment and survivorship to demonstrate how the failure to appropriately incorporate social factors into the design, recruitment, and analysis of research studies has resulted in missed opportunities to reduce persistent cancer disparities. The conclusion offers recommendations for how to better document and use information on social factors in cancer research and care by (1) increasing education and awareness about the importance of inclusion of social factors in clinical research; (2) improving testing and documentation of social factors by incorporating them into journal guidelines and reporting stratified results; and (3) including social factors to refine extant tools that assess cancer risk and assign cancer care. Implementing the recommended changes would enable more effective design and implementation of interventions and work toward eliminating cancer disparities by accounting for the social and environmental contexts in which cancer patients live and are treated.
AD  - Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health and Department of Oncology, Johns Hopkins School of Medicine, 615 N Wolfe St, E6650, Baltimore, MD, 21205, USA. lori.dean@jhu.edu.
College of Social Work, University of South Carolina, Columbia, SC, USA.
Cancer Prevention Program, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Behavioral Research Program Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD, United States.
Epidemiology and Genomics Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD, USA.
Department of Biostatistics, College of Global Public Health, New York University, New York, NY, USA.
Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health and Department of Oncology, Johns Hopkins School of Medicine, 615 N Wolfe St, E6650, Baltimore, MD, 21205, USA.
Department of Public Health Sciences, College of Medicine, Pennsylvania State University, Hershey, PA, USA.
AN  - 29846844
AU  - Dean, L. T.
AU  - Gehlert, S.
AU  - Neuhouser, M. L.
AU  - Oh, A.
AU  - Zanetti, K.
AU  - Goodman, M.
AU  - Thompson, B.
AU  - Visvanathan, K.
AU  - Schmitz, K. H.
C2  - PMC5999161
DA  - Jul
DO  - 10.1007/s10552-018-1043-y
DP  - NLM
ET  - 2018/05/31
IS  - 7
KW  - Continental Population Groups
*Ethnic Groups
Humans
Neoplasms/ethnology/*psychology
Risk Factors
Socioeconomic Factors
*Survivorship
*Breast cancer
*Disparities
*Race/ethnicity
*Social determinants
*United States
The authors declare no potential conflicts of interest.
LA  - eng
N1  - 1573-7225
Dean, Lorraine T
Orcid: 0000-0002-2272-2755
Gehlert, Sarah
Neuhouser, Marian L
Oh, April
Zanetti, Krista
Goodman, Melody
Thompson, Beti
Visvanathan, Kala
Schmitz, Kathryn H
R25 MH083620/MH/NIMH NIH HHS/United States
P30 AI094189/AI/NIAID NIH HHS/United States
P30 CA006973/CA/NCI NIH HHS/United States
K01 CA184288/CA/NCI NIH HHS/United States
U54 CA155850/CA/NCI NIH HHS/United States
U01 CA116850/CA/NCI NIH HHS/United States
U54 CA155496/CA/NCI NIH HHS/United States
Journal Article
Cancer Causes Control. 2018 Jul;29(7):611-618. doi: 10.1007/s10552-018-1043-y. Epub 2018 May 30.
PY  - 2018
SN  - 0957-5243 (Print)
0957-5243
SP  - 611-618
ST  - Social factors matter in cancer risk and survivorship
T2  - Cancer Causes Control
TI  - Social factors matter in cancer risk and survivorship
VL  - 29
ID  - 119
ER  - 

TY  - JOUR
AB  - OBJECTIVES: This study assessed the importance of socioeconomic status, race, and likelihood of receiving surgery in explaining mortality among patients with stage-I non-small cell lung cancer. METHODS: Analyses focused on Black and White individuals 75 years of age and younger (n = 5189) diagnosed between 1980 and 1982 with stage-I non-small cell lung cancer in Detroit, San Francisco, and Seattle. The main outcome measure was months of survival after diagnosis. RESULTS: Patients in the highest income decile were 45% more likely to receive surgical treatment and 102% more likely to attain 5-year survival than those in the lowest decile. Whites were 20% more likely to undergo surgery than Blacks and 31% more likely to survive 5 years. Multivariate procedures controlling for age and sex confirmed these observations. CONCLUSIONS: Socioeconomic status and race appear to independently influence likelihood of survival. Failure to receive surgery explains much excess mortality.
AD  - School of Public Administration, University of Southern California, Sacramento 95814-2919, USA. greenwa@usc.edu
AN  - 9807536
AU  - Greenwald, H. P.
AU  - Polissar, N. L.
AU  - Borgatta, E. F.
AU  - McCorkle, R.
AU  - Goodman, G.
C2  - PMC1508564
DA  - Nov
DO  - 10.2105/ajph.88.11.1681
DP  - NLM
ET  - 1998/11/10
IS  - 11
KW  - African Americans/*statistics & numerical data
Aged
Carcinoma, Non-Small-Cell Lung/*mortality/*surgery
European Continental Ancestry Group/*statistics & numerical data
Female
Humans
Income/*statistics & numerical data
Lung Neoplasms/*mortality/*surgery
Male
Michigan
Middle Aged
Multivariate Analysis
Patient Selection
SEER Program
San Francisco
Socioeconomic Factors
Survival Analysis
Washington
LA  - eng
N1  - 1541-0048
Greenwald, H P
Polissar, N L
Borgatta, E F
McCorkle, R
Goodman, G
Comparative Study
Journal Article
Research Support, Non-U.S. Gov't
Am J Public Health. 1998 Nov;88(11):1681-4. doi: 10.2105/ajph.88.11.1681.
PY  - 1998
SN  - 0090-0036 (Print)
0090-0036
SP  - 1681-4
ST  - Social factors, treatment, and survival in early-stage non-small cell lung cancer
T2  - Am J Public Health
TI  - Social factors, treatment, and survival in early-stage non-small cell lung cancer
VL  - 88
ID  - 725
ER  - 

TY  - JOUR
AB  - Purpose Little is known about Latina breast cancer survivors' social networks or their perceived social support to achieve and maintain a healthy diet. This paper describes the social networks and perceived support for healthy eating in a sample of breast cancer survivors of predominantly Dominican descent living in New York City. Methods Spanish-speaking Latina breast cancer survivors enrolled in a randomized controlled trial of a culturally tailored dietary intervention. Social networks were assessed using Cohen's Social Network Index and a modified General Social Survey Social Networks Module that included assessments of shared health promoting behaviors. Perceived social support from family and friends for healthy, food-related behaviors was assessed. Results Participants' networks consisted predominantly of family and friends. Family members were more likely than other individuals to be identified as close network members. Participants were more likely to share food-related activities than exercise activities with close network members. Perceived social support for healthy eating was high, although perceived support from spouses and children was higher than support from friends. Despite high levels of perceived support, family was also identified as a barrier to eating healthy foods by nearly half of women. Conclusions Although friends are part of Latina breast cancer survivors' social networks, spouses and children may provide greater support for healthy eating than friends. Implications for Cancer Survivors Involving family members in dietary interventions for Latina breast cancer survivors may tap into positive sources of support for women, which could facilitate uptake and maintenance of healthy eating behaviors.
AN  - WOS:000373079800008
AU  - Crookes, D. M.
AU  - Shelton, R. C.
AU  - Tehranifar, P.
AU  - Aycinena, C.
AU  - Gaffney, A. O.
AU  - Koch, P.
AU  - Contento, I. R.
AU  - Greenlee, H.
DA  - Apr
DO  - 10.1007/s11764-015-0475-6
IS  - 2
N1  - 26202538
PY  - 2016
SN  - 1932-2259
SP  - 291-301
ST  - Social networks and social support for healthy eating among Latina breast cancer survivors: implications for social and behavioral interventions
T2  - Journal of Cancer Survivorship
TI  - Social networks and social support for healthy eating among Latina breast cancer survivors: implications for social and behavioral interventions
VL  - 10
ID  - 2949
ER  - 

TY  - JOUR
AB  - Purpose: To describe the social processes used by African American (AA) women ages >=50 years in making decisions about mammography screening. Design: Grounded theory methodology. Methods: Tape-recorded interviews with a researcher-designed, semi-structured interview guide with an initial and theoretical sample of 30 AA women ages 52 to 71 of diverse socioeconomic status. Interviews occurred in various settings such as the church rectory, women's homes, and work settings. Extensive written field notes and tapes were transcribed verbatim immediately after the interviews by an experienced transcriptionist. Findings: The women's decisions about mammography screening were associated with five social processes: (a) acknowledging prior experiences with healthcare providers and systems; (b) reporting fears and fatalistic beliefs of breast cancer and related treatment; (c) valuing the opinions of significant others; (d) relying on religious beliefs and supports; and (e) caregiving responsibilities of significant others. The processes were further differentiated by three distinct decision-making styles: taking charge, enduring, and protesting. Conclusions: Each of the social processes was reported equally and emphasized by the diverse sample of AA women in decisions related to mammography screening. Mammography screening decisions were heavily influenced by caregiving responsibilities. Further research is needed to explain and understand this social process on the health and well-being of AA women over time.
AD  - Professor, College of Nursing and Health, Wright State University, 3640 Colonel Glenn Highway, Dayton, OH 45435-0001; barbara.fowler@wright.edu
AN  - 106204204. Language: English. Entry Date: 20070105. Revision Date: 20200708. Publication Type: Journal Article
AU  - Fowler, B. A.
DA  - 2006 3rd Quarter
DB  - CINAHL Complete
DO  - 10.1111/j.1547-5069.2006.00110.x
DP  - EBSCOhost
IS  - 3
KW  - Black Persons
Decision Making
Mammography
Aged
Audiorecording
Churches
Coding
Constant Comparative Method
Decision Making -- Classification
Female
Field Notes
Funding Source
Grounded Theory
Health Beliefs
Interview Guides
Knowledge
Middle Age
Qualitative Validity
Research Subject Recruitment
Semi-Structured Interview
Socialization
Socioeconomic Factors
Theoretical Sample
Human
N1  - research. Supplement Title: 2006 3rd Quarter. Journal Subset: Core Nursing; Double Blind Peer Reviewed; Expert Peer Reviewed; Nursing; Peer Reviewed; USA. NLM UID: 100911591.
PMID: NLM17044342.
PY  - 2006
SN  - 1527-6546
SP  - 247-254
ST  - Social processes used by African American women in making decisions about mammography screening
T2  - Journal of Nursing Scholarship
TI  - Social processes used by African American women in making decisions about mammography screening
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106204204&site=ehost-live&scope=site
VL  - 38
ID  - 2094
ER  - 

TY  - JOUR
AB  - Patient navigation (PN) is a new initiative in health care aimed at reducing disparities by assisting patients in overcoming barriers within the health care system. As PN programs grow around the country, it is important to consult the key stakeholders in the development of these programs. The purpose of this qualitative study was to discuss the needs of medically underserved cancer patients and allow them the opportunity to provide input on models of care to meet their needs. Four focus groups were conducted in three major cities across Tennessee. Research participants (n = 36) were recruited by the staff in area cancer support programs and treatment programs across the state and through recruitment flyers at various treatment centers and community organizations. Findings revealed four key themes in the development of PN programs: (1) the PN needs to address access to quality care issues; (2) the PN needs to address the emotional and practical concerns of the cancer survivor, (3) the PN needs to address family concerns; (4) the PN needs to be involved across the continuum of care from time of diagnosis into long-term survivorship. Oncology social workers have a unique opportunity to meet the needs of medically underserved cancer patients through the PN movement. Our profession is a key stakeholder in this movement. We need to advocate for trained oncology social workers to actively pursue the role of patient navigators to ensure that the needs of medically underserved cancer survivors and their families are met.
AD  - College of Social Work, University of Tennessee, Nashville, Tennessee 37210, USA. cdavis3@utk.edu
AN  - 19860292
AU  - Davis, C.
AU  - Darby, K.
AU  - Likes, W.
AU  - Bell, J.
DO  - 10.1080/00981380902765212
DP  - NLM
ET  - 2009/10/29
IS  - 6
KW  - Adult
African Americans
Aged
Aged, 80 and over
*Breast Neoplasms
Case Management
Family
Female
Focus Groups
Health Knowledge, Attitudes, Practice
Health Services Accessibility
Humans
*Medically Underserved Area
Middle Aged
*Needs Assessment
Quality of Life
*Social Work
*Survivors
Tennessee
Urban Population
LA  - eng
N1  - Davis, Cindy
Darby, Kathleen
Likes, Wendy
Bell, John
Journal Article
Research Support, Non-U.S. Gov't
United States
Soc Work Health Care. 2009;48(6):561-78. doi: 10.1080/00981380902765212.
PY  - 2009
SN  - 0098-1389 (Print)
0098-1389
SP  - 561-78
ST  - Social workers as patient navigators for breast cancer survivors: what do African-American medically underserved women think of this idea?
T2  - Soc Work Health Care
TI  - Social workers as patient navigators for breast cancer survivors: what do African-American medically underserved women think of this idea?
VL  - 48
ID  - 441
ER  - 

TY  - JOUR
AB  - Objective: To develop a better understanding of how men react to being diagnosed with prostate cancer and identify factors that influence these responses, we conducted an observational study to identify sociocultural predictors of men's psychological reactions. Methods: Participants were 70 African American and 124 white prostate cancer patients who completed a structured telephone interview that evaluated psychological reactions in terms of intrusive thoughts about cancer and attempts to avoid cancer-related thoughts and feelings. Perceptions of disease-specific stress, cultural beliefs and values, and social constraints were also assessed during the interview. Results: There were no racial differences in men's reactions to being diagnosed with prostate cancer; however, greater perceptions of disease-specific stress, increasing levels of present temporal orientation, and more social constraints had significant positive effects on avoidant reactions. Greater perceptions of stress also had a significant positive effect on intrusive thoughts. Conclusions: The results of this study highlight the need for individualized approaches to help men address their thoughts and feelings about being diagnosed with prostate cancer. These efforts should include strategies that help men to communicate more effectively with social support resources and address cultural beliefs and values related to temporal orientation. Copyright (C) 2009 John Wiley & Sons, Ltd.
AN  - WOS:000277344400012
AU  - Halbert, C. H.
AU  - Wrenn, G.
AU  - Weathers, B.
AU  - Delmoor, E.
AU  - Ten Have, T.
AU  - Coyne, J. C.
DA  - May
DO  - 10.1002/pon.1574
IS  - 5
N1  - 19408346
PY  - 2010
SN  - 1057-9249
SP  - 553-560
ST  - Sociocultural determinants of men's reactions to prostate cancer diagnosis
T2  - Psycho-Oncology
TI  - Sociocultural determinants of men's reactions to prostate cancer diagnosis
VL  - 19
ID  - 3115
ER  - 

TY  - JOUR
AB  - PURPOSE: To assess the degree to which the sociodemographic characteristics of patients enrolled in Radiation Therapy Oncology Group (RTOG) clinical trails are representative of the general population. METHODS AND MATERIALS: Sociodemographic data were collected on 4016 patients entered in 33 open RTOG studies between July 1991 and June 1994. The data analyzed included educational attainment, age, gender, and race. For comparison, we obtained similar data from the U.S. Department of Census. We also compared our RTOG data with Surveillance Epidemiology and End Results (SEER) data for patients who received radiation therapy, to determine how RTOG patients compared with cancer patients in general, and with patients with cancers at sites typically treated with radiotherapy. RESULTS: Overall, the sociodemographic characteristics of patients entered in RTOG trials were similar to those of the Census data. We found that, in every age group of African-American men and at nearly every level of educational attainment, the proportion of RTOG trial participants mirrored the proportion in the census data. Significant differences were noted only in the youngest category of African-American men, where the RTOG accrues more in the lower educational categories and fewer with college experience. For African-American women, we found a similar pattern in every age group and at each level of educational attainment. As with men, RTOG trials accrued a considerably larger proportion of younger, less educated African-American women than the census reported. Using SEER for comparison, the RTOG enrolled proportionately more African-American men to trials all cancer sites combined, and for prostate and head and neck cancer. In head and neck trials, the RTOG enrolled nearly twice as many African-American men than would be predicted by SEER data. In lung cancer trials, RTOG underrepresented African-American men significantly; however, there was no difference for brain cancer trials. There were no racial differences in RTOG accrual and SEER incidence data for women on trials in brain, lung, and head and neck cancer. However, the RTOG trials accrued nearly twice the proportion of African-American women in cervical cancer trials and in all sites combined, compared to the SEER data. CONCLUSIONS: Comparisons with the U.S. Census and SEER show that African-Americans are proportionally well represented in cancer clinical trials conducted by the Radiation Therapy Oncology Group. The comparative analysis indicates that all educational levels in each age group of African-Americans generally mirror the U.S. Census, with one exception. The exception is a significant overrepresentation of less-educated African-Americans in the youngest age category. This exception is counter to the expectation that better-educated patients are more likely to enroll in trials. When compared with SEER data, the RTOG trials either parallel or overrepresent African-American men and women, with the only exception being in lung cancer, where men are underrepresented. These results show that, in comparison to the Census and SEER data, the RTOG has fulfilled its commitment to enroll African-American patients in its clinical trials.
AD  - Department of Epidemiology, The University of Texas M. D. Anderson Cancer Center, Houston 77030, USA.
AN  - 9422552
AU  - Chamberlain, R. M.
AU  - Winter, K. A.
AU  - Vijayakumar, S.
AU  - Porter, A. T.
AU  - Roach, M., 3rd
AU  - Streeter, O.
AU  - Cox, J. D.
AU  - Bondy, M. L.
DA  - Jan 1
DO  - 10.1016/s0360-3016(97)00833-x
DP  - NLM
ET  - 1998/01/09
IS  - 1
KW  - Adult
African Americans/*statistics & numerical data
Age Distribution
Aged
Clinical Trials as Topic/*statistics & numerical data
*Demography
Educational Status
European Continental Ancestry Group/*statistics & numerical data
Female
Humans
Male
Middle Aged
Neoplasms/ethnology/radiotherapy
Radiation Oncology/*statistics & numerical data
SEER Program
Sex Distribution
LA  - eng
N1  - Chamberlain, R M
Winter, K A
Vijayakumar, S
Porter, A T
Roach, M 3rd
Streeter, O
Cox, J D
Bondy, M L
CA21661/CA/NCI NIH HHS/United States
CA32115/CA/NCI NIH HHS/United States
CA37422/CA/NCI NIH HHS/United States
Comparative Study
Journal Article
Research Support, U.S. Gov't, P.H.S.
United States
Int J Radiat Oncol Biol Phys. 1998 Jan 1;40(1):9-15. doi: 10.1016/s0360-3016(97)00833-x.
PY  - 1998
SN  - 0360-3016 (Print)
0360-3016
SP  - 9-15
ST  - Sociodemographic analysis of patients in radiation therapy oncology group clinical trials
T2  - Int J Radiat Oncol Biol Phys
TI  - Sociodemographic analysis of patients in radiation therapy oncology group clinical trials
VL  - 40
ID  - 733
ER  - 

TY  - JOUR
AB  - OBJECTIVES: African Americans have the highest incidence and mortality rates from colorectal cancer in the United States. Endoscopic screening, while effective in reducing both, is greatly underutilized. This research sought to understand sociodemographic factors related to stage of readiness for endoscopic screening. DESIGN: One hundred fifty nine African American women (76.1%) and men (mean age = 57.0 years) who were non-adherent to endoscopic screening guidelines were recruited and asked to complete semi-structured interviews. SETTING: Participants were all being seen for a non-acute primary care medical visit at one of two urban hospitals. The theoretical framework that informed this study was the Trans-theoretical Model (TTM) and the emphasis on Stage of Change or intention for undergoing endoscopic screening. MAIN OUTCOME AND MEASURES: Based on their stage of readiness to undergo screening, 67 (42%) were categorized as precontemplative (Has no plans to have a colonoscopy) while 92 were categoriezed as being in a contemplative or preparation stage. Using chi-square and Student t-tests, differences were examined between the two groups. RESULTS: No sociodemographic variables distinguished the two groups. However, people in the contemplative/preparation group were more likely to: have a regularly seen healthcare professional (63.7% vs 36.3%; P = .005), have had a previous recommendation for screening (65.7% vs 34.3%; P = .003); had heard of a colonoscopy (63.6% vs 36.4%; P = .000) and have been told by a healthcare professional that they needed a colonoscopy (73.1% vs 26.9%; P = .000). CONCLUSIONS: This study helps us to better understand the relevance of sociodemographic characteristics that may be associated with completing endoscopic colorectal cancer screening. In addition, we confirm that physician recommendation and individual awareness of the procedure are significant factors in readiness to get screened.
AD  - Emory University School of Medicine, Department of Medicine, Atlanta, GA 30322, USA. Jennifer.Christie@emory.edu
AN  - 19769016
AU  - Christie, J.
AU  - Jandorf, L.
AU  - Itzkowitz, S.
AU  - Halm, E.
AU  - Freeman, K.
AU  - King, S.
AU  - Dhulkifl, R.
AU  - McNair, M.
AU  - Thelemaque, L.
AU  - Lawsin, C.
AU  - Duhamel, K.
C2  - PMC2859842
C6  - NIHMS187460
DA  - Summer
DP  - NLM
ET  - 2009/09/23
IS  - 3
KW  - African Americans/*statistics & numerical data
Colonoscopy
Colorectal Neoplasms/ethnology/*prevention & control
Demography
Female
*Guideline Adherence
Humans
Male
Mass Screening/methods/*statistics & numerical data
Middle Aged
Patient Acceptance of Health Care/*ethnology
Physician-Patient Relations
Prospective Studies
Socioeconomic Factors
Urban Population/statistics & numerical data
LA  - eng
N1  - Christie, Jennifer
Jandorf, Lina
Itzkowitz, Steven
Halm, Ethan
Freeman, Kim
King, Sheba
Dhulkifl, Rayhana
McNair, Michelle
Thelemaque, Linda
Lawsin, Catalina
Duhamel, Katherine
P30 CA008748/CA/NCI NIH HHS/United States
R01 CA104130/CA/NCI NIH HHS/United States
R01 CA104130-01/CA/NCI NIH HHS/United States
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Ethn Dis. 2009 Summer;19(3):323-9.
PY  - 2009
SN  - 1049-510X (Print)
1049-510x
SP  - 323-9
ST  - Sociodemographic correlates of stage of adoption for colorectal cancer screening in African Americans
T2  - Ethn Dis
TI  - Sociodemographic correlates of stage of adoption for colorectal cancer screening in African Americans
VL  - 19
ID  - 444
ER  - 

TY  - JOUR
AB  - To better elucidate the socioeconomic and racial differences in women who received postmastectomy radiation therapy with or without a chest wall boost, the records from 4747 women included in the California Cancer Registry were reviewed. Poor and Hispanic women were more likely to receive a chest wall boost than were more affluent and non-Hispanic women. INTRODUCTION: Healthcare disparities in breast cancer treatment have been well documented. We investigated the socioeconomic status (SES) and racial factors in women with locally advanced breast cancer from the California Cancer Registry who had received postmastectomy radiation therapy (PMRT) with or without a chest wall boost (CWB). PATIENTS AND METHODS: The records of 4747 women with invasive breast cancer, diagnosed from 2005 to 2009, who had undergone PMRT, were reviewed and stratified by treatment with (n = 2686 [57%]) or without (n = 2061 [43%]) a CWB. Various patient demographic and biologic factors were analyzed using univariate and multivariate analysis. RESULTS: Receipt of a CWB was associated with race/ethnicity (P < .001), SES (P < .001), tumor size (P = .038), tumor grade (P = .033), human epidermal growth factor 2 (HER2) status (P = .015), American Joint Committee on Cancer stage (P = .001), number of nodes examined (P = .001), and number of positive nodes (P = .037) on univariate analysis. After controlling for confounding factors, race/ethnicity and SES remained independently predictive of a CWB. Hispanic women were more likely to receive a CWB than Asian (hazard ratio [HR], 0.74; 95% confidence interval [CI], 0.60-0.90), black (HR, 0.63; 95% CI, 0.48-0.83), or white (HR, 0.81; 95% CI, 0.69-0.95) women. Also, women of low SES were more likely to receive a CWB than women of high SES (HR, 0.74; 95% CI, 0.64-0.86). CONCLUSION: We found that poor and Hispanic women were more commonly treated with a CWB than were more affluent and non-Hispanic women with a similar cancer stage, cancer biology, and treatment paradigm.
AD  - Department of Radiation Oncology, University of California, Davis, Comprehensive Cancer Center, Sacramento, CA.
Mercer University School of Medicine, Macon, GA.
Public Health Institute, Cancer Registry of Greater California, Sacramento, CA.
Public Health Institute, Cancer Registry of Greater California, Sacramento, CA; Department of Public Health Sciences, University of California, Davis, School of Medicine, Davis, CA.
Department of Radiation Oncology, University of California, Davis, Comprehensive Cancer Center, Sacramento, CA. Electronic address: jyoti.mayadev@ucdmc.ucdavis.edu.
AN  - 25499694
AU  - Hess, C.
AU  - Lee, A.
AU  - Fish, K.
AU  - Daly, M.
AU  - Cress, R. D.
AU  - Mayadev, J.
C2  - PMC4484791
C6  - NIHMS688161
DA  - Jun
DO  - 10.1016/j.clbc.2014.11.007
DP  - NLM
ET  - 2014/12/17
IS  - 3
KW  - Adult
Aged
Breast Neoplasms/*epidemiology/pathology/*radiotherapy/surgery
California/epidemiology
Ethnic Groups/*statistics & numerical data
Female
Healthcare Disparities/*statistics & numerical data
Humans
Mastectomy
Middle Aged
Patient Selection
Radiotherapy/statistics & numerical data
Retrospective Studies
SEER Program
Socioeconomic Factors
*Thoracic Wall
Breast cancer
Healthcare disparities
Hispanic ethnicity
Minority populations
Postmastectomy radiation therapy
LA  - eng
N1  - 1938-0666
Hess, Clayton
Lee, Anna
Fish, Kari
Daly, Megan
Cress, Rosemary D
Mayadev, Jyoti
P30 CA093373/CA/NCI NIH HHS/United States
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Clin Breast Cancer. 2015 Jun;15(3):212-8. doi: 10.1016/j.clbc.2014.11.007. Epub 2014 Dec 1.
PY  - 2015
SN  - 1526-8209 (Print)
1526-8209
SP  - 212-8
ST  - Socioeconomic and racial disparities in the selection of chest wall boost radiation therapy in californian women after mastectomy
T2  - Clin Breast Cancer
TI  - Socioeconomic and racial disparities in the selection of chest wall boost radiation therapy in californian women after mastectomy
VL  - 15
ID  - 267
ER  - 

TY  - JOUR
AB  - black triangle Sorafenib is an oral multikinase inhibitor that targets the mitogen-activated protein kinase signalling pathway and receptor tyrosine kinases involved in tumour proliferation and angiogenesis.black triangle In the large, phase III, randomised, double-blind, multicentre Treatment Approaches in Renal Cancer Global Evaluation Trial (TARGET) of patients with advanced clear-cell renal cell cancer in whom previous systemic therapy had failed, median progression-free survival was doubled in patients receiving sorafenib compared with those receiving placebo (5.9 vs 2.8mo).black triangle Significantly more patients receiving sorafenib than those receiving placebo in the phase III trial experienced complete or partial responses or stable disease.black triangle Age, risk-assessment score, prior treatment, metastasis in lung or liver, or time from diagnosis did not affect the improved progression-free survival in sorafenib recipients.black triangle In a randomised, phase II discontinuation trial of patients with advanced renal cancer, in which only those showing stable disease with sorafenib were randomised to further sorafenib or placebo, more patients receiving sorafenib were free of progressive disease 12 weeks after randomisation than were those receiving placebo, and median progression-free survival was longer in sorafenib recipients.black triangle In clinical trials, most drug-related adverse events were mild to moderate in severity. Grade 3/4 hand-foot skin reaction and hypertension occurred more often with sorafenib than with placebo.
AD  - Wolters Kluwer Health, Adis, Auckland, New Zealand. demail@adis.co.nz
AN  - 17335301
AU  - McKeage, K.
AU  - Wagstaff, A. J.
DO  - 10.2165/00003495-200767030-00009
DP  - NLM
ET  - 2007/03/06
IS  - 3
KW  - Antineoplastic Agents/adverse effects/pharmacokinetics/pharmacology/*therapeutic use
Benzenesulfonates/adverse effects/pharmacokinetics/pharmacology/*therapeutic use
Carcinoma, Renal Cell/*drug therapy
Cell Proliferation/drug effects
Humans
Kidney Neoplasms/*drug therapy
MAP Kinase Signaling System/drug effects
Neovascularization, Pathologic/drug therapy
Niacinamide/analogs & derivatives
Phenylurea Compounds
Pyridines/adverse effects/pharmacokinetics/pharmacology/*therapeutic use
Randomized Controlled Trials as Topic
Receptor Protein-Tyrosine Kinases/drug effects
Sorafenib
LA  - eng
N1  - McKeage, Kate
Wagstaff, Antona J
Journal Article
Review
New Zealand
Drugs. 2007;67(3):475-83; discussion 484-5. doi: 10.2165/00003495-200767030-00009.
PY  - 2007
SN  - 0012-6667 (Print)
0012-6667
SP  - 475-83; discussion 484-5
ST  - Sorafenib: in advanced renal cancer
T2  - Drugs
TI  - Sorafenib: in advanced renal cancer
VL  - 67
ID  - 534
ER  - 

TY  - JOUR
AB  - Sotrastaurin, a novel protein-kinase-C inhibitor, blocks early T-cell activation. In this 12-month, Phase II study, de novo renal-transplant patients were randomized to sotrastaurin (200 mg b.i.d.) + standard-exposure tacrolimus (SET) or reduced-exposure tacrolimus (RET) (SET: n = 76; RET: n = 66), or control (SET + mycophenolic acid [MPA, 720 mg b.i.d.]; n = 74). In both sotrastaurin groups, patients were converted from tacrolimus to MPA after Month 3, achieving calcineurin inhibitor-free immunosuppression. The primary endpoint was composite efficacy failure (treated biopsy-proven acute rejection, graft loss, death or loss to follow-up). The key secondary endpoint was glomerular filtration rate (GFR). Composite efficacy failure rates were: 4.1%, 5.4% and 1.5% at Month 3 (preconversion) and 7.8%, 44.8% and 34.1% at study end in the control, sotrastaurin + SET and sotrastaurin + RET groups, respectively; these results led to premature study discontinuation. Median GFR at Month 6 was: 57.0, 53.0 and 60.0 mL/min/1.73 m2, respectively. Study-drug discontinuations due to adverse events occurred in 16.2%, 18.4% and 12.1%, respectively. Leukopenia and neutropenia occurred more frequently preconversion in control versus sotrastaurin groups: 13.7%, 5.6%, and 4.6%; and 11.1%, 4.3% and 3.1%, respectively. The initial sotrastaurin + tacrolimus regimen was efficacious and well tolerated but the postconversion sotrastaurin + MPA regimen showed inadequate efficacy. Longer-term evaluation of sotrastaurin + tacrolimus is warranted. © 2010 The American Society of Transplantation and the American Society of Transplant Surgeons. AdverseEffects:16 (21.6%) patients had anemia, 5 (6.8%) leukocytosis, 10 (13.5%) leukopenia, 1 (1.4%) tachycardia, 12 (16.2%) abdominal pain, 12 (16.2%) abdominal pain upper, 19 (25.7%) constipation, 38 (51.4%) diarrhea, 10 (13.5%) dyspepsia, 10 (13.5%) flatulence, 19 (25.7%) nausea, 12 (16.2%) vomiting, 2 (2.7%) pain, 14 (18.9%) peripheral edema, 7 (9.5%) pyrexia, 3 (4.1%) Cytomegalovirus infection, 10 (13.5%) nasopharyngitis, 25 (33.8%) urinary tract infection, 10 (13.5%) wound complication, 9 (12.2%) blood creatinine increased, 11 (14.9%) diabetes mellitus, 6 (8.1%) hypercholesterolemia, 4 (5.4%) hyperlipidemia, 2 (2.7%) hypocalcemia, 29 (39.2%) hypomagnesemia, 16 (21.6%) hypophosphatemia, 3 (4.1%) arthralgia, 9 (12.2%) back pain, 7 (9.5%) headache, 18 (24.3%) tremor, 2 (2.7%) anxiety, 16 (21.6%) insomnia, 5 (6.8%) hematuria, 4 (5.4%) proteinuria, 8 (10.8%) acne, 26 (35.1%) bacterial infection, 9 (12.2%) Escherichia coli infection, 14 (18.9%) viral infection, 2 (2.7%) BK virus infection, 3 (4.1%) fungal infection, 37 (50%) unknown type of infection and 12 (16.4%) elevated alanine aminotransferase. AuthorsConclusions:In conclusion, the results of this study indicate that the use of sotrastaurin + MPA [mycophenolic acid] in a CNI-free regimen failed to maintain adequate efficacy for prevention of rejection in renal-transplant recipients. However, sotrastaurin warrants further investigation as a promising new drug offering potential benefits due to its distinct mechanism of action compared with CNIs. Studies are underway to determine the optimal regimen for sotrastaurin as part of multidrug immunosuppressive therapy. FreeText:TAC target levels were: Month 1: 8-15 ng/mL (SET) or 5-8 ng/mL (RET), Months 2-3: 6-12 ng/mL (SET) or 3-6 ng/mL (RET). SOT-treated recipients who met conversion criteria [absence of acute rejection, stable graft function (serum creatinine <2.5 mg/dL and no change >30% from nadir) and the absence of proteinuria >1 g/24 hours or major hematologic abnormalities (leukocytes<2500/lL, neutrophils<1500/lL, hemoglobin <10 g/dL)] at Month 3 were converted to a calcineurin inhibitor (CNI)-free regimen of SOT plus Myfortic over a 2-week period, introducing Myfortic 360 mg twice daily as add-on treatment a week before TAC was reduced to 50% and Myfortic was increased to full dose, with complete TAC discontinuation after another week. TAC target levels from Month 4 onwards were 5-10 ng/mL. All patients received two doses of basiliximab induction therapy. Steroids were started and tapered to ≥5 mg daily prednisone. The primary endpoint was composite efficacy failure [treated biopsy-proven acute rejection (BPAR), graft loss, death, or loss to follow-up]. Secondary endpoint was renal function [glomerular filtration rate (GFR)]. Safety measures: adverse events (AEs), infections, hematologic and biochemical laboratory parameters, vital signs and electrocardiograms (ECGs). Indications:Graft rejection prophylaxis in 169 patients who underwent renal transplantation. Coexisting diseases: 5 diabetes mellitus and 5 hypertension. Patients:216 de novo patients. SOT/SET group: n=76; 54 males and 12 females; age range 18-65 years (mean 43.7 years); 73 Caucasian, 1 black and 2 other; 9 received grafts from living unrelated donors, 19 from living related donors and 50 from cadaver donors; end-stage renal disease leading to transplant 16 glomerulonephritis, 15 polycystic disease, 2 diabetes mellitus, 9 hypertension, 5 unknown, 29 others; 53 were converted to Myfortic; 70 dropouts, 18 due to side effects. SOT/RET group: n=66, 48 males and 18 females, mean age 44.9 years, age range 18-67 years; 63 Caucasian, 1 black and 2 other; 8 received grafts from living unrelated donors; 14 from living related donors and 3 from cadaver donors; end-stage renal disease leading to transplant 14 glomerulonephritis, 13 polycystic disease, 1 diabetes mellitus, 2 hypertension, 4 unknown, 31 others; 43 were converted to Myfortic; 51 dropouts, 14 due to side effects. SET/Myfortic (control) group: n=74, 53 males and 21 females, mean age 44.6 years, age range 19-70 years; 71 Caucasian, 2 black and 1 other; 10 received grafts from living unrelated donors, 14 from living related donors and 50 from cadaver donors; end-stage renal disease leading to transplant 21 glomerulonephritis, 15 polycystic disease, 5 diabetes mellitus, 5 hypertension, 5 unknown, 23 others; 52 dropouts, 15 due to side effects. TypeofStudy:A 12-month, Phase II, multicenter, open-label, randomized study evaluating the efficacy of sotrastaurin (SOT) plus standard-exposure tacrolimus (SET) or reduced-exposure tacrolimus (RET), with subsequent conversion from tacrolimus (TAC) to Myfortic, or SET plus Myfortic in de novo renal transplant patients. NCT00403416. DosageDuration:In SET/Myfortic group: 720 mg bid (=1440 mg daily). During conversion: started at 360 mg bid (=720 mg daily) then increased to 720 mg bid (=1440 mg daily). Duration was 12 months. ComparativeDrug:Sotrastaurin was given at 200 mg bid (=400 mg daily). Duration was 12 months. Results:More patients in the SOT/SET and SOT/RET groups were ineligible for conversion at Month 3 vs. the SET/Myfortic group (14.5% and 23.6% vs. 8.3%). A similar number of patients in all groups were ineligible due to acute rejections; the most common reasons for ineligibility were 'poor/unstable renal function', and 'compelling reason prohibiting full-dose MPA or discontinuation of TAC'. In the control and SOT/SET groups, most patients were within the target trough range over Months 1, 2 and 3 (63% control, 74.2% SOT/SET and 77.4% SOT/RET). TAC levels achieved in the SOT/RET group were 30-40% lower vs. SOT/SET group; a substantial proportion of trough levels were above target at Months 1, 2 and 3 (45.3%, 55.4% and 46.4%, respectively). Mean daily Myfortic doses at Month 6 were 1233 mg, 1352 mg and 1331 mg for SET/Myfortic, SOT/SET and SOT/RET, respectively. During the 3-month preconversion period, both SOT/TAC regimens showed comparable efficacy to control. After conversion from TAC to Myfortic, both SOT/Myfortic regimens were inferior to the SET/Myfortic for the primary composite endpoint. Median GFR was not significantly different for the 3 groups at any time point. The most frequent AEs were gastrointestinal (GI) disorders and metabolism and nutrition disorders. The most frequent serious AEs (SAEs) were: kidney-transplant rejection (1.4% SET/Myfortic, 6.7% SOT/SET and 6.2% SOT/RET), cytomegalovirus infection (4.1%, 2.7% and 6.2%), gastroenteritis (1.4%, 4.0% and 6.2%), urinary tract infection (UTI; 4.1%, 2.7% and 6.2%), complications of the transplanted kidney (2.7%, 5.3% and 0%) and increased blood creatinine (1.4%, 12.0% and 10.8%). The highest incidence of SAEs was reported in the SOT/RET group, in part due to a higher incidence of infection SAEs. 3 (4.6%) patients in the SOT/RET group reported dysgeusia. Diarrhea was the most common GI AE and occurred more frequently in SET/Myfortic vs. SOT patients. Diarrhea caused the most drug dose reduction/interruption in the first 3 months (13.5% SET/Myfortic vs. 1.3%SOT/SET and 3.1% SOT/RET: 3.1%). The other GI AEs, vomiting, constipation and nausea were reported more frequently in the SOT groups. 1 patient in the SOT/RET group discontinued drug due to vomiting. Cardiac AEs were reported in 21.6%, 22.7% and 27.7% of the SET/Myfortic, SOT/SET and SOT/RET groups, respectively. Tachycardia occurred more frequently in both SOT groups vs. control. The incidence of new-onset diabetes mellitus (NODM) AEs in the control group was approximately twice that of the SOT groups. The incidence of hypertension and dyslipidemia AEs was similar between the groups. Prior to conversion from TAC to Myfortic at Month 3, the incidence of leukopenia and neutropenia was higher in the control compared vs. the SOT/SET and SOT/RET groups while the incidence of leukocytosis was lower in the control vs. the SOT groups up to Month 3. Over the study period the incidence of neutropenia, leukopenia and elevated alanine aminotransferase (ALT) occurred more frequently in the SET/Myfortic vs. the SOT/SET and SOT/RET groups. Infections considered to be serious occurred more frequently in the SOT/RET group compared with the SOT/SET and control groups. The most common serious infections were Cytomegalovirus and urinary tract infection; the incidence was comparable between groups. BK virus infection occurred in 2.7%, 4.0% and 0% of patients in the control, SOT/SET and SOT/RET groups, respectively. 1 patient in the SOT/RET group died on Day 163 from a sudden, massive pulmonary embolism. 4 patients died after study-drug discontinuation: 2 related to immunosuppressive treatment, 1 in the control group (cardiac arrest possibly due to a pulmonary embolism following a CMV chest infection diagnosed on Day 237. The patient died on Day 246, 3 days after study-drug discontinuation); and 1 in the SOT/SET group (septicemia following a Clostridium difficile infection and graft loss due to irreversible rejection. The patient died on Day 293, 28 days after study-drug discontinuation). 1 death in the SOT/RET group (pancreatic c rcinoma on Day 251, 160 days after discontinuation) and 1 in the control group (GI hemorrhage on Day 47, 38 days after discontinuation) were considered unrelated to immunosuppressive treatment.
AD  - Department of Nephrology, Charité University, Berlin, Germany
Department of Nephrology, University of Heidelberg, Heidelberg, Germany
Department of Visceral and Transplant Surgery, Hannover Medical School, Hannover, Germany
Department of Nephrology and Transplant, University Hospital of Wales, Cardiff, United Kingdom
Department of Nephrology, University Hospital Essen, Essen, Germany
Nephrology Department, Ciutat Sanitaria i Universitaria de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain
Department of Surgery and Organ Transplantation, University of Padua, Padua, Italy
Department of Nephrology and Clinical Immunology, CHU Nantes, Nantes, France
Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States
Novartis Pharma AG, Basel, Switzerland
Department of Surgery, University Hospital Zurich, Zurich, Switzerland
AU  - Budde, K.
AU  - Sommerer, C.
AU  - Becker, T.
AU  - Asderakis, A.
AU  - Pietruck, F.
AU  - Grinyo, J. M.
AU  - Rigotti, P.
AU  - Dantal, J.
AU  - Ng, J.
AU  - Barten, M. J.
AU  - Weber, M.
DB  - Scopus
DO  - 10.1111/j.1600-6143.2009.02980.x
IS  - 3
KW  - Calcineurin inhibitor toxicity
Drug development
Efficacy
Mycophenolic acid
Renal function
Renal transplantation
Safety
T-cell activation
Tacrolimus
M3  - Article
N1  - Cited By :69
Export Date: 22 March 2021
PY  - 2010
SP  - 571-581
ST  - Sotrastaurin, a novel small molecule inhibiting protein kinase C: First clinical results in renal-transplant recipients
T2  - American Journal of Transplantation
TI  - Sotrastaurin, a novel small molecule inhibiting protein kinase C: First clinical results in renal-transplant recipients
UR  - https://www.scopus.com/inward/record.uri?eid=2-s2.0-76949090843&doi=10.1111%2fj.1600-6143.2009.02980.x&partnerID=40&md5=c0d0256407cd0d6d98b2c3c3c9a0a914
VL  - 10
ID  - 2507
ER  - 

TY  - JOUR
AB  - A case-control study on lung cancer in African-Americans has been conducted to assess whether a novel African-American-specific polymorphism in the CYP1A1 gene increases the susceptibility to tobacco-related lung cancer. The prevalence of the AA RFLP was 17.1% in the DNA extracted from archived tissue blocks from 76 incident cases of lung cancer, and was 163% in peripheral blood lymphocyte DNA of 123 healthy African-American volunteers recruited from a community in the eastern United States. The analysis by histological type showed an association between adenocarcinoma (AC) of the lung and the AA RFLP (odds ratio, 2.6; 95% confidence interval, 1.1-63). One homozygous variant subject was present among the AC cases. The risk of AC in subjects who both smoke and carry the AA RFLP was more than double, in comparison to subjects who only smoke (relative interaction magnitude under the additive model, 24%). The mean value of pack-year in AC with the polymorphism was 5.0 ± 2.5 and in AC without the polymorphism was 37.2 ± 6S(P < 0.05). Our data suggest that a selective association exists between the AA polymorphism and adenocarcinoma of the lung and that a lower dose of tobacco is sufficient to exert carcinogenic effects on the adenomatous tissue of subjects carrying the AA polymorphism. © 1995, American Association for Cancer Research. All rights reserved.
AD  - Institute of Environmental Medicine, Kaplan Comprehensive Cancer Center, New York University Medical Center, New York, New York 10010, United States
AU  - Taioli, E.
AU  - Crofts, F.
AU  - Trachman, J.
AU  - Demopoulos, R.
AU  - Toniolo, P.
AU  - Garte, S. J.
DB  - Scopus
IS  - 3
M3  - Article
N1  - Cited By :69
Export Date: 22 March 2021
PY  - 1995
SP  - 472-473
ST  - A Specific African-American CYP1A1 Polymorphism Is Associated with Adenocarcinoma of the Lung
T2  - Cancer Research
TI  - A Specific African-American CYP1A1 Polymorphism Is Associated with Adenocarcinoma of the Lung
UR  - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0028919248&partnerID=40&md5=038d06bc1078efe4bf43717047ab65ba
VL  - 55
ID  - 2655
ER  - 

TY  - JOUR
AB  - PURPOSE: Cognitive changes are common among breast cancer survivors. There is limited evidence to guide management of cognitive changes. This randomized controlled pilot evaluated the preliminary efficacy of a speed of processing (SOP) training among middle-aged and older breast cancer survivors. METHODS: Sixty breast cancer survivors  with self-reported cognitive changes were recruited to the SOAR study. Participants were randomized to either a home-based SOP training (n = 30) or no-contact control group (n = 30). Primary outcomes were SOP (Useful Field of View Test(®)), and executive function (NIH Toolbox Cognition Battery). Neuropsychological assessments were completed at baseline, 6 weeks, and 6 months post study entry. Data were analyzed using repeated measures t tests, analysis of covariance, and sensitivity analyses. RESULTS: SOP training resulted in improvement in objective measures of SOP and executive function. Immediate (6 week) posttest and 6-month follow-up demonstrated large SOP training effects over time. Large representation of African American women (51.2%) and 96% retention in the SOAR study add to study strengths. CONCLUSION: Home-based SOP training shows promise for remediating cognitive changes following breast cancer treatment, particularly improved SOP, and executive function.
AD  - School of Nursing, University of Alabama at Birmingham, Birmingham, AL, USA.
Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, USA.
School of Health Professions, University of Alabama at Birmingham, Birmingham, AL, USA.
School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
Center for Translational Research on Aging and Mobility, University of Alabama at Birmingham, Birmingham, AL, USA.
School of Nursing, University of Alabama at Birmingham, Birmingham, AL, USA. jfranf@uab.edu.
Office of Research and Scholarship, School of Nursing, University of Alabama at Birmingham, Medical Towers 501H1, 1720 Second Avenue South, Birmingham, AL, 35294-4410, USA. jfranf@uab.edu.
AN  - 29128897
AU  - Meneses, K.
AU  - Benz, R.
AU  - Bail, J. R.
AU  - Vo, J. B.
AU  - Triebel, K.
AU  - Fazeli, P.
AU  - Frank, J.
AU  - Vance, D. E.
C2  - PMC5823754
C6  - NIHMS927276
DA  - Feb
DO  - 10.1007/s10549-017-4564-2
DP  - NLM
ET  - 2017/11/13
IS  - 1
KW  - Adult
Age Factors
Breast Neoplasms/*complications/mortality/therapy
*Cancer Survivors
Cognition/physiology
Cognition Disorders/diagnosis/etiology/*therapy
Executive Function/physiology
Female
Humans
Middle Aged
Neuropsychological Tests
Pilot Projects
*Practice, Psychological
Quality of Life
Reaction Time/*physiology
Self Report
Treatment Outcome
Aging
Breast cancer survivors
Cognitive changes
Cognitive impairment
Speed of processing interventions
for the SOP training in this study. All other authors declare no conflict of
interest.
LA  - eng
N1  - 1573-7217
Meneses, Karen
Benz, Rachel
Bail, Jennifer R
Vo, Jacqueline B
Triebel, Kristen
Fazeli, Pariya
Frank, Jennifer
Orcid: 0000-0001-5816-3935
Vance, David E
R01 MH106366/MH/NIMH NIH HHS/United States
R00 AG048762/AG/NIA NIH HHS/United States
MRSG-14-204-01/American Cancer Society/
P30 AG022838/National Institutes on Aging/
R21 NR016632/NR/NINR NIH HHS/United States
5R01MH106366-02/National Institute of Mental Health/
P30 AG022838/AG/NIA NIH HHS/United States
DSCN-17-076-01/American Cancer Society/
GTDR15329376/Susan G. Komen Graduate Training in Disparities Research/
DSCN-16-066-01/American Cancer Society/
#72592/Robert Wood Johnson Foundation/
R00 AG048762/National Institute on Aging/
1R21NR016632-01/National Institute of Nursing Research/
Journal Article
Randomized Controlled Trial
Breast Cancer Res Treat. 2018 Feb;168(1):259-267. doi: 10.1007/s10549-017-4564-2. Epub 2017 Nov 11.
PY  - 2018
SN  - 0167-6806 (Print)
0167-6806
SP  - 259-267
ST  - Speed of processing training in middle-aged and older breast cancer survivors (SOAR): results of a randomized controlled pilot
T2  - Breast Cancer Res Treat
TI  - Speed of processing training in middle-aged and older breast cancer survivors (SOAR): results of a randomized controlled pilot
VL  - 168
ID  - 149
ER  - 

TY  - JOUR
AB  - The qualitative study used data from interviews with 18 African American breast cancer survivors in the southeast regarding the women's live experiences of spiritual support during the process of breast cancer diagnosis and treatment. Through a thematic content analysis, four primary sources of spiritual support were identified: God, members of religious communities, family members and friends, and health care professionals. Some participants reported negative experiences associated with the reactions of religious community members to their breast cancer. Those who received spiritual support from their health care providers reported welcoming such support.
AD  - Professor emerita, School of Social Work, University of Alabama, Box 870314, Tuscaloosa, AL 35487; lroff@sw.ua.edu
AN  - 105426638. Language: English. Entry Date: 20090918. Revision Date: 20200708. Publication Type: Journal Article
AU  - Roff, L. L.
AU  - Simon, C. E.
AU  - Nelson-Gardell, D.
AU  - Pleasants, H. M.
DB  - CINAHL Complete
DO  - 10.1177/0886109909337372
DP  - EBSCOhost
IS  - 3
KW  - Breast Neoplasms
Cancer Survivors
Spirituality
Support, Psychosocial
Advertising
Audiorecording
Black Persons
Churches
Coding
Content Analysis
Data Analysis Software
Descriptive Statistics
Educational Status
Female
Funding Source
Interviews
Marital Status
Middle Age
Neoplasm Staging
Public Health
Qualitative Studies
Research Subject Recruitment
Research Subjects -- Economics
Sample Size
Human
N1  - research. Journal Subset: Allied Health; Peer Reviewed; USA. Grant Information: Michael Figures Initiative and the African American Studies Department at the University of Alabama. NLM UID: 9882541.
PY  - 2009
SN  - 0886-1099
SP  - 285-299
ST  - Spiritual support and African American breast cancer survivors
T2  - Affilia: Journal of Women & Social Work
TI  - Spiritual support and African American breast cancer survivors
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105426638&site=ehost-live&scope=site
VL  - 24
ID  - 2096
ER  - 

TY  - JOUR
AB  - African Americans remain underrepresented in health-related research. We examined the association between spirituality using the Self-Rating Spirituality Scale (range 6-24) and self-reported willingness to participate in health-related research studies among African Americans. Covariates included gender, education level, employment status, and previous research experience. Adjusted associations were calculated with logistic regression models, with multiple imputation to account for missing data. Results from the logistic regression model show that each one-point increase in the Self-Rating Spirituality Scale was associated with a 24% increase in the odds of being very likely to participate in research (OR: 1.24, 95% CI: 1.07-1.44). Those with less than a college degree (OR: 3.59, 95% CI: 1.51-8.54), who were unemployed (OR: 2.34, 95% CI: 1.03-5.33), and had previous research experience (OR: 2.92, 95% CI: 1.22-6.99) reported increased willingness to participate. This work offers new insight for developing recruitment initiatives within African American spiritual communities.
AN  - WOS:000426428600028
AU  - Ojukwu, E.
AU  - Powell, L. R.
AU  - Person, S. D.
AU  - Rosal, M. C.
AU  - Lemon, S. C.
AU  - Allison, J.
DA  - Feb
IS  - 1
N1  - 29503308
PY  - 2018
SN  - 1049-2089
SP  - 400-414
ST  - Spirituality and Willingness to Participate in Health-Related Research Among African Americans
T2  - Journal of Health Care for the Poor and Underserved
TI  - Spirituality and Willingness to Participate in Health-Related Research Among African Americans
VL  - 29
ID  - 2873
ER  - 

TY  - JOUR
AB  - Spirituality has been shown to be associated with health, and is an important component in the lives of many African Americans. Recent research proposes that spirituality is a multidimensional construct. The present study proposes a two-dimensional model in which spirituality encompasses a belief and behavioral dimension. This hypothesis was examined, as were relationships between these dimensions and spiritual health locus of control, breast cancer beliefs and mammography utilization among African American women. The belief dimension played a more important role in adaptive breast cancer beliefs and mammography utilization that did the behavioral dimension. These findings suggest the importance of spiritual belief systems for health, and implications for spiritual cancer communication interventions are discussed.
AD  - Health Communication Research Laboratory, Department of Community Health, School of Public Health, Saint Louis University, MO 63104; holtcl@slu.edu
AN  - 106544174. Language: English. Entry Date: 20051125. Revision Date: 20200708. Publication Type: Journal Article
AU  - Holt, C. L.
AU  - Lukwago, S. N.
AU  - Kreuter, M. W.
DB  - CINAHL Complete
DO  - 10.1177/13591053030083008
DP  - EBSCOhost
IS  - 3
KW  - Black Persons -- Missouri
Breast Neoplasms -- Prevention and Control
Health Beliefs -- Evaluation
Mammography -- Utilization
Spirituality
Adult
Age Factors
Chi Square Test
Christianity
Confidence Intervals
Descriptive Statistics
Factor Analysis
Female
Health Knowledge -- Evaluation
Locus of Control -- Evaluation
Logistic Regression
Middle Age
Missouri
Models, Theoretical -- Evaluation
Multivariate Analysis of Covariance
Odds Ratio
Pearson's Correlation Coefficient
Questionnaires
Race Factors
Research Subject Recruitment
Rural Areas
Scales
Test-Retest Reliability
Theory Construction
Funding Source
Human
N1  - research; tables/charts. Journal Subset: Biomedical; Blind Peer Reviewed; Europe; Peer Reviewed; UK & Ireland. Grant Information: National Cancer Institute #CA-81872-04. NLM UID: 9703616.
PMID: NLM14670216.
PY  - 2003
SN  - 1359-1053
SP  - 383-396
ST  - Spirituality, breast cancer beliefs and mammography utilization among urban African American women
T2  - Journal of Health Psychology
TI  - Spirituality, breast cancer beliefs and mammography utilization among urban African American women
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106544174&site=ehost-live&scope=site
VL  - 8
ID  - 2097
ER  - 

TY  - JOUR
AB  - Colorectal cancer screening, while effective for reducing mortality, remains underutilized particularly among underserved populations such as African Americans. The present study evaluated a spiritually based approach to increasing Health Belief Model-based pre-screening outcomes in a Community Health Advisor-led intervention conducted in African American churches. Sixteen urban churches were randomized to receive either the spiritually based intervention or a nonspiritual comparison of the same structure and core colorectal cancer content. Trained Community Health Advisors led a series of two educational sessions on colorectal cancer early detection. The educational sessions were delivered over a 1-month period. Participants (N = 316) completed a baseline survey at enrollment and a follow-up survey one month after the first session. Both interventions resulted in significant pre/post increases in knowledge, perceived benefits of screening, and decreases in perceived barriers to screening. Among women, the spiritually based intervention resulted in significantly greater increases in perceived benefits of screening relative to the nonspiritual comparison. This finding was marginal in the sample as a whole. In addition, perceived benefits to screening were associated with behavioral intention for screening. It is concluded that in this population, the spiritually based was generally as effective as the nonspiritual (secular) communication.
AD  - Department of Behavioral and Community Health, School of Public Health, University of Maryland, College Park, Maryland 20742, USA. cholt14@umd.edu
AN  - 22724562
AU  - Holt, C. L.
AU  - Scarinci, I. C.
AU  - Debnam, K.
AU  - McDavid, C.
AU  - Litaker, M.
AU  - McNeal, S. F.
AU  - Southward, V.
AU  - Lee, C.
AU  - Eloubeidi, M.
AU  - Crowther, M.
AU  - Bolland, J.
AU  - Martin, M. Y.
DO  - 10.1080/10810730.2012.665418
DP  - NLM
ET  - 2012/06/26
IS  - 9
KW  - African Americans/*education/psychology
Aged
Colorectal Neoplasms/*ethnology
Female
Follow-Up Studies
Health Education/*methods
Health Knowledge, Attitudes, Practice/*ethnology
Humans
Male
Middle Aged
Program Evaluation
*Spirituality
Urban Population
LA  - eng
N1  - 1087-0415
Holt, Cheryl L
Scarinci, Isabel C
Debnam, Katrina
McDavid, Chastity
Litaker, Mark
McNeal, Sandre F
Southward, Vivian
Lee, Crystal
Eloubeidi, Mohamad
Crowther, Martha
Bolland, John
Martin, Michelle Y
5U48DP00046-03/DP/NCCDPHP CDC HHS/United States
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.
United States
J Health Commun. 2012;17(9):1028-49. doi: 10.1080/10810730.2012.665418. Epub 2012 Jun 22.
PY  - 2012
SN  - 1081-0730
SP  - 1028-49
ST  - Spiritually based intervention to increase colorectal cancer awareness among african americans: intermediate outcomes from a randomized trial
T2  - J Health Commun
TI  - Spiritually based intervention to increase colorectal cancer awareness among african americans: intermediate outcomes from a randomized trial
VL  - 17
ID  - 363
ER  - 

TY  - JOUR
AB  - Introduction: Few lung cancer studies have focused on lung cancer survival in underserved populations. We conducted a prospective cohort study among 81,697 racially diverse and medically underserved adults enrolled in the Southern Community Cohort Study throughout an 11-state area of the Southeast from March 2002 to September 2009. Methods: Using linkages with state cancer registries, we identified 501 incident non-small-cell lung cancer cases. We applied Cox proportional hazards models to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for subsequent mortality among black and white participants. Results: The mean observed follow-up time (the time from diagnosis to death or end of follow-up) was 1.25 years (range, 0-8.3 years) and 75% (n = 376) of cases died during follow-up. More blacks were diagnosed at distant stage than whites (57 versus 45%; p = 0.03). In multivariable analyses adjusted for pack-years of smoking, age, body mass index, health insurance, socioeconomic status and disease stage, the lung cancer mortality HR was higher for men versus women (HR = 1.41; 95% CI, 1.09-1.81) but similar for blacks versus whites (HR = 0.99; 95% CI, 0.74-1.32). Conclusion: These findings suggest that although proportionally more blacks present with distant-stage disease there is no difference in stage-adjusted lung cancer mortality between blacks and whites of similar low socioeconomic status. Copyright © 2013 by the International Association for the Study of Lung Cancer.
AD  - M.C. Aldrich, Department of Thoracic Surgery and Medicine, Vanderbilt University Medical Center, 609 Oxford House, 1313 21st Avenue South, Nashville, TN 37232, United States
AU  - Aldrich, M. C.
AU  - Grogan, E. L.
AU  - Munro, H. M.
AU  - Signorello, L. B.
AU  - Blot, W. J.
DB  - Embase
Medline
DO  - 10.1097/JTO.0b013e3182a406f6
IS  - 10
KW  - adult
age
article
body mass
cancer diagnosis
cancer incidence
cancer mortality
cancer registry
cancer staging
cancer survival
Caucasian
cohort analysis
confidence interval
controlled study
female
follow up
health insurance
human
lowest income group
non small cell lung cancer
major clinical study
male
middle aged
Black person
priority journal
proportional hazards model
prospective study
randomized controlled trial
smoking
social status
LA  - English
M3  - Article
N1  - L372113901
2014-01-22
2014-01-27
PY  - 2013
SN  - 1556-0864
1556-1380
SP  - 1248-1254
ST  - Stage-adjusted lung cancer survival does not differ between low-income blacks and whites
T2  - Journal of Thoracic Oncology
TI  - Stage-adjusted lung cancer survival does not differ between low-income blacks and whites
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L372113901&from=export
http://dx.doi.org/10.1097/JTO.0b013e3182a406f6
VL  - 8
ID  - 1065
ER  - 

TY  - JOUR
AB  - Standardized quality of life measures have been developed and used primarily with Caucasian and middle-class cancer patients. This study assessed the ability of several widely used standardized measures to capture the concerns and problems of 89 African American breast cancer patients. Concerns and problems were assessed using both an open-ended format and standardized measures. The degree of overlap in responses from these two formats was examined. The most frequently reported problems in the open-ended format included physical (43%), financial (40%), and worry about others (30%). Overall, standardized measures had significant overlap with open-ended concerns and problems. The Cancer Rehabilitation Evaluation System-Short Form subscales/items were associated with corresponding open-ended physical, financial, and social problems (R2 change = 0.07-0.16, p's < or = 0.02), the Interpersonal Support Evaluation List-Short Form was associated with open-ended social problems (R2 change = 0.11, p = 0.004), and the Mental Health Inventory was associated with open-ended psychological distress problems (R2 change = 0.08, p = 0.01). One category of open-ended problems, worry about others, was not captured by standardized measures. With the exception of associations between open-ended physical problems and psychological distress measures, there were few significant correlations between standardized measures and dissimilar problem categories. These findings suggest that the standardized measures in this study reflected the concerns and problems of African American breast cancer patients. Additional studies are needed to evaluate the utility of other widely used standardized measures that have not been developed or standardized among non-white samples.
AD  - Department of Psychology, Ohio State University, OH, USA.
AN  - 16155965
AU  - Shelby, R. A.
AU  - Lamdan, R. M.
AU  - Siegel, J. E.
AU  - Hrywna, M.
AU  - Taylor, K. L.
DA  - May
DO  - 10.1002/pon.959
DP  - NLM
ET  - 2005/09/13
IS  - 5
KW  - *Adaptation, Psychological
Adult
*African Americans/psychology
Aged
Aged, 80 and over
Breast Neoplasms/ethnology/psychology/*rehabilitation
Data Collection/*methods
District of Columbia
Female
Humans
Linear Models
Middle Aged
Philadelphia
Psychometrics
*Quality of Life
Randomized Controlled Trials as Topic
Reference Standards
LA  - eng
N1  - Shelby, Rebecca A
Lamdan, Ruth M
Siegel, Jamie E
Hrywna, Mary
Taylor, Kathryn L
Comparative Study
Journal Article
Multicenter Study
England
Psychooncology. 2006 May;15(5):382-97. doi: 10.1002/pon.959.
PY  - 2006
SN  - 1057-9249 (Print)
1057-9249
SP  - 382-97
ST  - Standardized versus open-ended assessment of psychosocial and medical concerns among African American breast cancer patients
T2  - Psychooncology
TI  - Standardized versus open-ended assessment of psychosocial and medical concerns among African American breast cancer patients
VL  - 15
ID  - 588
ER  - 

TY  - JOUR
AB  - BACKGROUNDPatient navigation programs are emerging that aim to address disparities in clinical trial participation among medically underserved populations, including racial/ethnic minorities. However, there is a lack of consensus on the role of patient navigators within the clinical trial process as well as outcome measures to evaluate program effectiveness. METHODSA review of the literature was conducted of PubMed, Medline, CINHAL, and other sources to identify qualitative and quantitative studies on patient navigation in clinical trials. The search yielded 212 studies, of which only 12 were eligible for this review. RESULTSThe eligible studies reported on the development of programs for patient navigation in cancer clinical trials, including training and implementation among African Americans, American Indians, and Native Hawaiians. A low rate of clinical trial refusal (range, 4%-6%) was reported among patients enrolled in patient navigation programs. However, few studies reported on the efficacy of patient navigation in increasing clinical treatment trial enrollment. CONCLUSIONSOutcome measures are proposed to assist in developing and evaluating the efficacy and/or effectiveness of patient navigation programs that aim to increase participation in cancer clinical trials. Future research is needed to evaluate the efficacy of patient navigators in addressing barriers to clinical trial participation and increasing enrollment among medically underserved cancer patients. Cancer 2014;120(7 suppl):1122-30. (c) 2014 American Cancer Society. Patient navigation programs are emerging that aim to address disparities in cancer clinical trial participation among medically underserved populations, including racial/ethnic minorities. A review of the literature identifies studies that describe curriculum development, training, implementation, and program evaluation of navigation programs to increasing minority clinical trial participation. Outcome measures are proposed to assist in developing and evaluating the efficacy and/or effectiveness of a patient navigation clinical trial program.
AN  - WOS:000332916200006
AU  - Ghebre, R. G.
AU  - Jones, L. A.
AU  - Wenzel, J. A.
AU  - Martin, M. Y.
AU  - Durant, R. W.
AU  - Ford, J. G.
DA  - Apr
DO  - 10.1002/cncr.28570
N1  - 7
SI
24643650
PY  - 2014
SN  - 0008-543X
SP  - 1122-1130
ST  - State- of- the- Science of Patient Navigation as a Strategy for Enhancing Minority Clinical Trial Accrual
T2  - Cancer
TI  - State- of- the- Science of Patient Navigation as a Strategy for Enhancing Minority Clinical Trial Accrual
VL  - 120
ID  - 3016
ER  - 

TY  - JOUR
AB  - BACKGROUND: Cancer screening rates are lowest in those without insurance or a regular provider. Since 2008, the Colorectal Cancer Prevention Network (CCPN) has provided open access colonoscopy to uninsured residents of South Carolina through established, statewide partnerships and patient navigation. Herein, we describe the structure, implementation, and clinical outcomes of this program. METHODS: The CCPN provides access to colonoscopy screening at no cost to uninsured, asymptomatic patients aged 50-64 years (African Americans age 45-64 years are eligible) who live at or below 150% of the poverty line and seek medical care in free medical clinics, federally qualified health centers, or hospital-based indigent practices in South Carolina. Screening is performed by board-certified gastroenterologists. Descriptive statistics and regression analysis are used to describe the population screened, and to assess compliance rates and colonoscopy quality metrics. RESULTS: Out of >4000 patients referred to the program, 1854 were deemed eligible, 1144 attended an in-person navigation visit, and 1030 completed a colonoscopy; 909 were included in the final sample. Nearly 90% of participants exhibited good-to-excellent bowel preparation. An overall cecal intubation rate of 99% was measured. The polyp detection rate and adenoma detection rate were 63% and 36%, respectively, with male sex and urban residence positively associated with adenoma detection. Over 13% of participants had an advanced polyp, and 1% had a cancer diagnosis or surgical intervention. CONCLUSION: The CCPN program is characterized by strong collaboration with clinicians statewide, low no-show rates, and high colonoscopy quality. Future work will assess the effectiveness of the navigation approach and will explore the mechanisms driving higher adenoma detection in urban participants. Cancer 2018;124:1912-20. © 2018 American Cancer Society.
AD  - F.G. Berger, Center for Colon Cancer Research, University of South Carolina, Columbia, SC, United States
AU  - Eberth, J. M.
AU  - Thibault, A.
AU  - Caldwell, R.
AU  - Josey, M. J.
AU  - Qiang, B.
AU  - Peña, E.
AU  - LaFrance, D.
AU  - Berger, F. G.
DB  - Embase
Medline
DO  - 10.1002/cncr.31250
IS  - 9
KW  - adult
advanced cancer
African American
article
cancer screening
certification
clinical outcome
clinical practice
colonoscopy
colorectal adenoma
colorectal cancer
colorectal polyp
digestive tract intubation
disease association
female
gastroenterologist
gender
health care planning
health care quality
health center
health program
help seeking behavior
human
intestine preparation
major clinical study
male
medically uninsured
middle aged
patient care
patient compliance
patient participation
patient referral
poverty
priority journal
South Carolina
urban population
LA  - English
M3  - Article
N1  - L620605516
2018-02-13
2018-05-08
PY  - 2018
SN  - 1097-0142
0008-543X
SP  - 1912-1920
ST  - A statewide program providing colorectal cancer screening to the uninsured of South Carolina
T2  - Cancer
TI  - A statewide program providing colorectal cancer screening to the uninsured of South Carolina
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L620605516&from=export
http://dx.doi.org/10.1002/cncr.31250
VL  - 124
ID  - 898
ER  - 

TY  - JOUR
AD  - Office of Research on Women's Health, National Institutes of Health
AN  - 107372537. Language: English. Entry Date: 19960601. Revision Date: 20150820. Publication Type: Journal Article. Journal Subset: Core Nursing
AU  - Pinn, V. W.
DB  - CINAHL Complete
DP  - EBSCOhost
IS  - 1
KW  - Women's Health
Research
Black Persons
Female
National Institutes of Health (U.S.)
Breast Neoplasms -- Ethnology
Breast Neoplasms -- Epidemiology
Mammography
Socioeconomic Factors
Clinical Trials
Research Subjects
Minority Groups
N1  - Nursing; Peer Reviewed; USA. NLM UID: 8703519.
PMID: NLM9128542.
PY  - 1996
SN  - 0885-6028
SP  - 8-19
ST  - The status of women's health research: where are African American women?
T2  - Journal of National Black Nurses Association
TI  - The status of women's health research: where are African American women?
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=107372537&site=ehost-live&scope=site
VL  - 8
ID  - 2129
ER  - 

TY  - JOUR
AB  - This study combined the African American tradition of oral storytelling with the Hispanic medium of Fotonovelas. A staggered pretest posttest control group design was used to evaluate four Storytelling Slide Shows on health that featured community members. A total of 212 participants were recruited for the intervention and 217 for the comparison group from residents of senior affordable housing complexes located in Washington, DC, and Maryland. Participants significantly increased their eating decision scores as well as their knowledge of high blood pressure between pre- and postassessment (both p values <.001) versus no change among comparison participants These findings suggest that participants mastered the importance of food selection, physical activity, and stress management. Self-efficacy was measured by two indexes, each containing 15 items on confidence in performing diabetes and high blood pressure management behaviors. Significant pre-post increases occurred in diabetes and in high blood pressure self-efficacy in the intervention (both p values <.000) but not the comparison group. Increasing age was positively associated with increases in self-efficacy while health literacy was inversely associated with self-efficacy increases. These results suggest that the Storytelling Slide Shows and the skill building activities were of benefit in increasing self-efficacy, especially among the oldest participants and those with the lowest health literacy. A community health education policy that makes this approach more widely available has the potential to reduce learning disadvantages in older, lower health literacy populations, in a way that reduces health disparities while increasing community involvement.
AN  - WOS:000338006600001
AU  - Bertera, E. M.
DO  - 10.1080/03601277.2014.894381
IS  - 11
PY  - 2014
SN  - 0360-1277
SP  - 785-800
ST  - Storytelling Slide Shows to Improve Diabetes and High Blood Pressure Knowledge and Self-Efficacy: Three-Year Results Among Community Dwelling Older African Americans
T2  - Educational Gerontology
TI  - Storytelling Slide Shows to Improve Diabetes and High Blood Pressure Knowledge and Self-Efficacy: Three-Year Results Among Community Dwelling Older African Americans
VL  - 40
ID  - 3025
ER  - 

TY  - JOUR
AB  - BACKGROUND: Black women are more likely to experience adverse effects from cancer treatment such as lymphedema. Thus, black women may particularly benefit from research regarding interventions to improve lymphedema. Herein, the authors report the challenges and strategies related to the recruitment of minority survivors of breast cancer and to the recruitment of survivors of breast cancer with lymphedema into the Women In Steady Exercise Research (WISER) Survivor Clinical Trial. METHODS: Subjects for this community-based trial were recruited from the Philadelphia area through active (mailings) and passive (printed materials and Web site) recruitment strategies. In addition, education sessions coordinated through partner hospitals in communities with a predominantly minority population were conducted to increase awareness of lymphedema in survivors of breast cancer. Women who were interested in the study were screened for lymphedema via telephone questionnaire and invited to see a study-related certified lymphedema therapist to confirm the presence of lymphedema. RESULTS: Screening was conducted among 2295 women: 628 were eligible, 450 consented, and 351 were randomized. Minority women comprised 38% of the study population. Letters to women on state and hospital registries resulted in a 0.4% randomization rate; education sessions yielded a 10% randomization rate. The authors observed that approximately 23.6% of the study sample had no previous diagnosis of lymphedema. CONCLUSIONS: The WISER Survivor Clinical Trial faced multiple recruitment challenges and used unique strategies to successfully enroll minority survivors of breast cancer into a lifestyle intervention. Cancer 2018;124:95-104. © 2017 American Cancer Society.
AD  - Department of Public Health Sciences, Pennsylvania State University, Hershey, Pennsylvania.
Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, Pennsylvania.
Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
EXOS, Phoenix, Arizona.
Division of Population Sciences, Dana-Farber Cancer Institute, Boston, Massachusetts.
College of Public Health, Temple University, Philadelphia, Pennsylvania.
Department of Population Health, New York University, New York City, New York.
AN  - 28881471
AU  - Sturgeon, K. M.
AU  - Hackley, R.
AU  - Fornash, A.
AU  - Dean, L. T.
AU  - Laudermilk, M.
AU  - Brown, J. C.
AU  - Sarwer, D. B.
AU  - DeMichele, A. M.
AU  - Troxel, A. B.
AU  - Schmitz, K. H.
C2  - PMC5743016
C6  - NIHMS896092
DA  - Jan 1
DO  - 10.1002/cncr.30935
DP  - NLM
ET  - 2017/09/08
IS  - 1
KW  - *African Americans
Aged
Breast Cancer Lymphedema/complications/*therapy
*Breast Neoplasms
*Cancer Survivors
Ethnic Groups
*European Continental Ancestry Group
*Exercise Therapy
Female
Humans
Middle Aged
Minority Groups
Obesity/complications/*therapy
Overweight/complications/therapy
*Patient Selection
Randomized Controlled Trials as Topic
Weight Loss
*Weight Reduction Programs
African American
body weight
breast cancer lymphedema
exercise
patient recruitment
patient selection
following companies: BARONovoa, Ethicon, Medtronic, and Novo Nordisk. These
relationships had no impact on the research described in the manuscript. All other
authors declare that they have no conflicts of interest.
LA  - eng
N1  - 1097-0142
Sturgeon, Kathleen M
Orcid: 0000-0001-9602-7897
Hackley, Renata
Fornash, Anna
Dean, Lorraine T
Laudermilk, Monica
Brown, Justin C
Orcid: 0000-0001-7540-4913
Sarwer, David B
DeMichele, Angela M
Troxel, Andrea B
Schmitz, Kathryn H
P30 AI094189/AI/NIAID NIH HHS/United States
R25 MH083620/MH/NIMH NIH HHS/United States
P30 CA006973/CA/NCI NIH HHS/United States
K01 CA184288/CA/NCI NIH HHS/United States
P30 AI045008/AI/NIAID NIH HHS/United States
U54 CA155850/CA/NCI NIH HHS/United States
Journal Article
Cancer. 2018 Jan 1;124(1):95-104. doi: 10.1002/cncr.30935. Epub 2017 Sep 7.
PY  - 2018
SN  - 0008-543X (Print)
0008-543x
SP  - 95-104
ST  - Strategic recruitment of an ethnically diverse cohort of overweight survivors of breast cancer with lymphedema
T2  - Cancer
TI  - Strategic recruitment of an ethnically diverse cohort of overweight survivors of breast cancer with lymphedema
VL  - 124
ID  - 158
ER  - 

TY  - JOUR
AB  - The enrollment of ethnically diverse populations in genetic and genomic research is vital to the parity of benefits resulting from research with biological specimens. Herein, we discuss strategies that may effectively improve the recruitment of African Americans into genetics studies. Specifically, we show that engaging physicians, genetic counselors, and community members is essential to enrolling participants into genetic studies. We demonstrate the impact of utilizing African American genetic counselors on study enrollment rates and implementing a two-page consent form that improved on a lengthy and inefficient consenting process. Lastly, we provided participants with the option of donating saliva instead of blood for study purposes. Descriptive statistics were used. Using the aforementioned strategies, recruitment goals for the Genetic Basis of Breast Cancer Subtype Study at Howard University (HU) were met. Our overall results yielded 182 participants in 18 months. Recruitment strategies that involve the engagement of physicians, genetic counselors, and community members may help researchers increase the enrollment of ethnically diverse and hard-to-reach participants into genetic studies.
AD  - Department of Health, Behavior and Society, The Johns Hopkins University Bloomberg School of Public Health, 624 N. Broadway St., Room 904, Baltimore, MD, 21205, USA, altovisee@gmail.com.
AN  - 24882437
AU  - Ewing, A.
AU  - Thompson, N.
AU  - Ricks-Santi, L.
C2  - PMC4254900
C6  - NIHMS601011
DA  - Mar
DO  - 10.1007/s13187-014-0669-z
DP  - NLM
ET  - 2014/06/03
IS  - 1
KW  - African Americans/*genetics
Biomedical Research/*organization & administration
Breast Neoplasms/*genetics/*prevention & control
Female
*Genetic Research
Health Knowledge, Attitudes, Practice
Humans
Patient Compliance
*Patient Participation
*Patient Selection
LA  - eng
N1  - 1543-0154
Ewing, Altovise
Thompson, Nicole
Ricks-Santi, Luisel
G12 RR003048/RR/NCRR NIH HHS/United States
U54 CA091431/CA/NCI NIH HHS/United States
UL1 RR031975/RR/NCRR NIH HHS/United States
Journal Article
J Cancer Educ. 2015 Mar;30(1):108-15. doi: 10.1007/s13187-014-0669-z.
PY  - 2015
SN  - 0885-8195 (Print)
0885-8195
SP  - 108-15
ST  - Strategies for enrollment of African Americans into cancer genetic studies
T2  - J Cancer Educ
TI  - Strategies for enrollment of African Americans into cancer genetic studies
VL  - 30
ID  - 287
ER  - 

TY  - JOUR
AB  - BACKGROUND: Recruitment for research and clinical trials continues to be challenging. Prostate cancer is the most commonly diagnosed cancer in men and disproportionately affects African American men; thus, effective recruitment strategies are essential for this population. OBJECTIVES: The aim of this study was to focus on innovative and effective recruitment strategies for research on prostate cancer with minorities. METHODS: A systematic description is provided of the recruitment efforts for a hermeneutic phenomenological qualitative study of African American men's experiences in decision making on whether to have a prostate cancer screening. RESULTS: Seventeen African American men were enrolled from rural Central Virginia. Recruiting strategies were targeted on places where African American men usually are found but that are rarely used for recruitment: barbershops, community health centers, and churches. Word of mouth was also used, and most of the participants (n = 11) were reached through this method. DISCUSSION: Recruitment efforts have been noted to be particularly challenging among minorities, for numerous reasons. Making minority recruitment a priority in any research or clinical trial is essential in gaining a representative sample. Word of mouth is a powerful tool that is often forgotten but should be looked at in further detail.
AD  - School of Nursing, University of Virginia, Charlottesville, VA 22908-0782, USA. raj9c@virginia.edu
AN  - 19918156
AU  - Jones, R. A.
AU  - Steeves, R.
AU  - Williams, I.
C2  - PMC2886148
C6  - NIHMS202896
DA  - Nov-Dec
DO  - 10.1097/NNR.0b013e3181b4bade
DP  - NLM
ET  - 2009/11/18
IS  - 6
KW  - Adult
*African Americans/psychology
Aged
Decision Making
Humans
Male
Middle Aged
*Patient Selection
Prostatic Neoplasms/*diagnosis
Virginia
LA  - eng
N1  - 1538-9847
Jones, Randy A
Steeves, Richard
Williams, Ishan
P20 NR009009/NR/NINR NIH HHS/United States
P20 NR009009-03/NR/NINR NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Nurs Res. 2009 Nov-Dec;58(6):452-6. doi: 10.1097/NNR.0b013e3181b4bade.
PY  - 2009
SN  - 0029-6562 (Print)
0029-6562
SP  - 452-6
ST  - Strategies for recruiting African American men into prostate cancer screening studies
T2  - Nurs Res
TI  - Strategies for recruiting African American men into prostate cancer screening studies
VL  - 58
ID  - 440
ER  - 

TY  - JOUR
AB  - BackgroundRecruitment and retention are two significant barriers in research, particularly for historically underrepresented groups, including racial and ethnic minorities, patients who are low-income, or people with substance use or mental health issues. Chronic obstructive pulmonary disease (COPD) is the third leading cause of death and disproportionately affects many underrepresented groups. The lack of representation of these groups in research limits the generalizability and applicability of clinical research and results. In this paper we describe our experience and rates of recruitment and retention of underrepresented groups for the Aides in Respiration (AIR) COPD Health Coaching Study.MethodsA priori design strategies included minimizing exclusion criteria, including patients in the study process, establishing partnerships with the community clinics, and ensuring that the health coaching intervention was flexible enough to accommodate patient needs.ResultsChallenges to recruitment included lack of spirometric data in patient records, space constraints at the clinic sites, barriers to patient access to clinic sites, lack of current patient contact information and poor patient health. Of 282 patients identified as eligible, 192 (68%) were enrolled in the study and 158 (82%) completed the study. Race, gender, educational attainment, severity of disease, health literacy, and clinic site were not associated with recruitment or retention. However, older patients were less likely to enroll in the study and patients who used home oxygen or had more than one hospitalization during the study period were less likely to complete the study. Three key strategies to maximize recruitment and retention were identified during the study: incorporating the patient perspective, partnering with the community clinics, and building patient rapport.ConclusionsWhile the AIR study included design features to maximize the recruitment and retention of patients from underrepresented groups, additional challenges were encountered and responded to during the study. We also identified three key strategies recommended for future studies of COPD and similar conditions. Incorporating the approaches described into future studies may increase participation rates from underrepresented groups, providing results that can be more accurately applied to patients who carry a disparate burden of disease.Trial registrationThis trial was registered at ClinicalTrial.gov at identifier NCT02234284 on August 12, 2014.Descriptor number: 2.9 Racial, ethnic, or social disparities in lung disease and treatment.
AN  - WOS:000459449800002
AU  - Huang, B.
AU  - De Vore, D.
AU  - Chirinos, C.
AU  - Wolf, J.
AU  - Low, D.
AU  - Willard-Grace, R.
AU  - Tsao, S.
AU  - Garvey, C.
AU  - Donesky, D.
AU  - Su, G.
AU  - Thom, D. H.
DA  - Feb
DO  - 10.1186/s12874-019-0679-y
N1  - 39
30791871
PY  - 2019
SN  - 1471-2288
ST  - Strategies for recruitment and retention of underrepresented populations with chronic obstructive pulmonary disease for a clinical trial
T2  - Bmc Medical Research Methodology
TI  - Strategies for recruitment and retention of underrepresented populations with chronic obstructive pulmonary disease for a clinical trial
VL  - 19
ID  - 2829
ER  - 

TY  - JOUR
AB  - BACKGROUND: Although African American women have an overall lower incidence of breast cancer, African American women <40 years of age are more likely than Caucasian women of all ages and postmenopausal African American women to be diagnosed with breast cancer and exhibit tumor characteristics associated with poorer survival. To begin to address this disparity, studies must be conducted to examine breast cancer preventive factors in this subpopulation of women. However, the strategies needed to recruit younger African American women have not been well defined. METHODS: In this study, we assessed methods used for recruiting and retaining healthy premenopausal African American women into the African American Nutrition for Life (A NULIFE) Study. The number of women contacted, enrolled, and retained by each recruitment strategy and the efficiency of individual strategies were calculated. RESULTS: Overall, recruitment through social networking was most effective in contacting large numbers of healthy premenopausal African American women. The worksite recruitment method was the most efficient recruitment strategy employed, with a ratio of 40%. The study participants (n = 164) were more likely to be >or=35 years of age and have completed some college. Additionally, the interpersonal relationships recruitment approach proved most efficient (33%) in retaining participants who completed the yearlong study. CONCLUSIONS: The findings from this study add to the evolving research literature on minority recruitment strategies for research studies but specifically address effective recruitment of healthy young premenopausal African American women. The results demonstrate the need to use multiple recruitment strategies when recruiting this subgroup of African American women.
AD  - The University of Texas, MD Anderson Cancer Center, Center for Research on Minority Health, Houston, Texas 77230, USA. dking@mdanderson.org
AN  - 20392156
AU  - King, D. W.
AU  - Duello, T. M.
AU  - Miranda, P. Y.
AU  - Hodges, K. P.
AU  - Shelton, A. J.
AU  - Chukelu, P.
AU  - Jones, L. A.
C2  - PMC2940542
DA  - May
DO  - 10.1089/jwh.2009.1682
DP  - NLM
ET  - 2010/04/16
IS  - 5
KW  - Adult
African Continental Ancestry Group/*psychology/statistics & numerical data
Breast Neoplasms/ethnology/*prevention & control
Female
Humans
Patient Acceptance of Health Care/*ethnology
*Patient Selection
Pilot Projects
Premenopause/ethnology/*psychology
*Women's Health
LA  - eng
N1  - 1931-843x
King, Denae W
Duello, Theresa M
Miranda, Patricia Y
Hodges, Kelly P
Shelton, Andrea J
Chukelu, Paul
Jones, Lovell A
5P60MD00503/MD/NIMHD NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
J Womens Health (Larchmt). 2010 May;19(5):855-62. doi: 10.1089/jwh.2009.1682.
PY  - 2010
SN  - 1540-9996 (Print)
1540-9996
SP  - 855-62
ST  - Strategies for Recruitment of Healthy Premenopausal Women into the African American Nutrition for Life (A NULIFE) Study
T2  - J Womens Health (Larchmt)
TI  - Strategies for Recruitment of Healthy Premenopausal Women into the African American Nutrition for Life (A NULIFE) Study
VL  - 19
ID  - 425
ER  - 

TY  - JOUR
AD  - Division of Digestive and Liver Diseases, UT Southwestern Medical Center, Dallas, TX 75390-8887, USA. samir.gupta@utsouthwestern.edu
AN  - 22271128
AU  - Gupta, S.
AU  - Shah, J.
AU  - Balasubramanian, B. A.
DA  - Jan 23
DO  - 10.1001/archinternmed.2011.594
DP  - NLM
ET  - 2012/01/25
IS  - 2
KW  - Adult
African Continental Ancestry Group/*statistics & numerical data
Colorectal Neoplasms/ethnology/*prevention & control
Health Promotion
Humans
Mass Screening/*statistics & numerical data
Middle Aged
Patient Participation
Practice Guidelines as Topic
SEER Program
United States/epidemiology
LA  - eng
N1  - 1538-3679
Gupta, Samir
Shah, Jessica
Balasubramanian, Bijal A
T32-DK007745/DK/NIDDK NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
United States
Arch Intern Med. 2012 Jan 23;172(2):182-4. doi: 10.1001/archinternmed.2011.594.
PY  - 2012
SN  - 0003-9926
SP  - 182-4
ST  - Strategies for reducing colorectal cancer among blacks
T2  - Arch Intern Med
TI  - Strategies for reducing colorectal cancer among blacks
VL  - 172
ID  - 375
ER  - 

TY  - JOUR
AN  - 15150300
AU  - Vanchieri, C.
DA  - May 19
DO  - 10.1093/jnci/96.10.735
DP  - NLM
ET  - 2004/05/20
IS  - 10
KW  - African Continental Ancestry Group/statistics & numerical data
Animals
Breast Neoplasms/metabolism/prevention & control
Calcitriol/administration & dosage/*metabolism
Calcium/adverse effects/metabolism
Clinical Trials as Topic
Colonic Neoplasms/metabolism/prevention & control
Disease Models, Animal
European Continental Ancestry Group/statistics & numerical data
Female
Humans
Male
Neoplasms/metabolism/*prevention & control
Prostatic Neoplasms/epidemiology/metabolism/prevention & control
Radiation-Sensitizing Agents/pharmacology
Scandinavian and Nordic Countries/epidemiology
*Sunlight
Vitamin D/*administration & dosage/biosynthesis/*pharmacology
Vitamin D Deficiency/etiology/*prevention & control
LA  - eng
N1  - 1460-2105
Vanchieri, Cori
News
United States
J Natl Cancer Inst. 2004 May 19;96(10):735-6. doi: 10.1093/jnci/96.10.735.
PY  - 2004
SN  - 0027-8874
SP  - 735-6
ST  - Studies shedding light on vitamin D and cancer
T2  - J Natl Cancer Inst
TI  - Studies shedding light on vitamin D and cancer
VL  - 96
ID  - 629
ER  - 

TY  - JOUR
AB  - BACKGROUND: Breast cancer survival rates are significantly lower among African-American women compared to white women. In addition, African-American women with breast cancer are more likely than white women to die from co-morbid conditions. Obesity is common among African-American women, and it contributes to breast cancer progression and the development and exacerbation of many weight-related conditions. Intervening upon obesity may decrease breast cancer and all-cause mortality among African-American breast cancer survivors. METHODS/DESIGN: Moving Forward is a weight loss intervention being evaluated in a randomized trial with a projected sample of 240 African American breast cancer survivors. Outcomes include body mass index, body composition, waist:hip ratio, and behavioral, psychosocial and physiological measures. Survivors are randomized to either a 6-month guided weight loss intervention that involves twice weekly classes and text messaging or a self-guided weight loss intervention based on the same materials offered in the guided program. The guided intervention is being conducted in partnership with the Chicago Park District at park facilities in predominantly African-American neighborhoods in Chicago. Recruitment strategies include direct contact to women identified in hospital cancer registries, as well as community-based efforts. Data collection occurs at baseline, post-intervention (6 months) and at a 12-month follow-up. DISCUSSION: This study evaluates a community-based, guided lifestyle intervention designed to improve the health of African-American breast cancer survivors. Few studies have addressed behavioral interventions in this high-risk population. If successful, the intervention may help reduce the risk for breast cancer recurrence, secondary cancers, and co-morbid conditions, as well as improve quality of life. TRIAL REGISTRATION: U.S. Clinicaltrials.gov number: NCT02482506, April 2015.
AD  - Cancer Center and Department of Medicine, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI, 53226-3548, USA. mstolley@mcw.edu.
Institute for Health Research and Policy, University of Illinois at Chicago (UIC), Chicago, IL, USA. mstolley@mcw.edu.
Institute for Health Research and Policy, University of Illinois at Chicago (UIC), Chicago, IL, USA. sharpl@uic.edu.
Department of Pharmacy Systems, Outcome & Policy, UIC, College of Pharmacy, Chicago, IL, USA. sharpl@uic.edu.
Department of Kinesiology and Nutrition, UIC, College of Applied Health Sciences, Chicago, IL, USA. giamila@uic.edu.
Cancer Center and Department of Medicine, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI, 53226-3548, USA. carroy5@uic.edu.
School of Nursing, Loyola University, Maywood, IL, 60153, USA. psheean1@luc.edu.
Cancer Center and Department of Medicine, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI, 53226-3548, USA. lschiff@uic.edu.
Institute for Health Research and Policy, University of Illinois at Chicago (UIC), Chicago, IL, USA. dcamp@uic.edu.
Cancer Center and Department of Medicine, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI, 53226-3548, USA. bgerber@uic.edu.
Institute for Health Research and Policy, University of Illinois at Chicago (UIC), Chicago, IL, USA. bgerber@uic.edu.
AN  - 26715447
AU  - Stolley, M. R.
AU  - Sharp, L. K.
AU  - Fantuzzi, G.
AU  - Arroyo, C.
AU  - Sheean, P.
AU  - Schiffer, L.
AU  - Campbell, R.
AU  - Gerber, B.
C2  - PMC4696142
DA  - Dec 29
DO  - 10.1186/s12885-015-2004-4
DP  - NLM
ET  - 2015/12/31
KW  - African Americans/*psychology
Breast Neoplasms/*mortality/psychology
Chicago/ethnology
Female
Humans
Quality of Life
Random Allocation
Survivors/*psychology
Treatment Outcome
Weight Loss
LA  - eng
N1  - 1471-2407
Stolley, Melinda R
Sharp, Lisa K
Fantuzzi, Giamila
Arroyo, Claudia
Sheean, Patricia
Schiffer, Linda
Campbell, Richard
Gerber, Ben
R01 CA154406/CA/NCI NIH HHS/United States
R01CA15440/CA/NCI NIH HHS/United States
Clinical Trial
Journal Article
Research Support, N.I.H., Extramural
BMC Cancer. 2015 Dec 29;15:1018. doi: 10.1186/s12885-015-2004-4.
PY  - 2015
SN  - 1471-2407
SP  - 1018
ST  - Study design and protocol for moving forward: a weight loss intervention trial for African-American breast cancer survivors
T2  - BMC Cancer
TI  - Study design and protocol for moving forward: a weight loss intervention trial for African-American breast cancer survivors
VL  - 15
ID  - 224
ER  - 

TY  - JOUR
AN  - 15082727
AU  - Brawley, O. W.
DA  - Jun 1
DO  - 10.1200/jco.2004.02.926
DP  - NLM
ET  - 2004/04/15
IS  - 11
KW  - African Americans
*Breast Neoplasms
*Clinical Trials as Topic
Female
Health Care Surveys
*Health Services Accessibility
Humans
*Minority Groups
*Patient Selection
United States
LA  - eng
N1  - Brawley, Otis W
Comment
Editorial
United States
J Clin Oncol. 2004 Jun 1;22(11):2039-40. doi: 10.1200/JCO.2004.02.926. Epub 2004 Apr 13.
PY  - 2004
SN  - 0732-183X (Print)
0732-183x
SP  - 2039-40
ST  - The study of accrual to clinical trials: can we learn from studying who enters our studies?
T2  - J Clin Oncol
TI  - The study of accrual to clinical trials: can we learn from studying who enters our studies?
VL  - 22
ID  - 632
ER  - 

TY  - JOUR
AB  - Tamoxifen reduced the risk of invasive breast cancer by 49% among women at increased risk for breast cancer in the Breast Cancer Prevention Trial P-1, and raloxifene reduced breast cancer incidence by more than 70% in the Multiple Outcomes of Raloxifene Evaluation osteoporosis trial. These findings led the National Surgical Adjuvant Breast and Bowel Project to design and launch the Study of Tamoxifen and Raloxifene. Risk-eligible women are = 35 years of age and postmenopausal; they have either lobular carcinoma in situ (LCIS) or a 5-year risk of invasive breast cancer of at least 1.67% as determined by the Gail model. Participants are randomly assigned to receive either tamoxifen 20 mg or raloxifene 60 mg daily. The trial opened for accrual on July 1, 1999. After 32 months of recruitment at 194 clinical centers in North America, risk assessments have been performed in 107,855 women (83.8% white, 9.4% black, 3.8% Hispanic, 3.1% other race/ethnic groups). Of the eligible patients, 12,637 have been randomized (20.9% of risk-eligible women); the median age is 58 years (mean, 58 years), and the median 5-year risk of breast cancer is 3.3% (mean, 4.0%). LCIS was reported in 8.4% of women prior to randomization. Gail model risk was = 3.0% in 5 years for 59.3% of white women, 45.0% of black women, and 44.5% of Hispanic women. The trial will recruit a total of 22,000 postmenopausal women and is powered to demonstrate superior efficacy of either agent or their equivalence in reducing the incidence of primary breast
AD  - The National Surgical Adjuvant Breast and Bowel Project, NSABP Foundation Inc, Pittsburgh, PA, USA. vvogel@mail.magee.edu
AN  - 12123540
AU  - Vogel, V. G.
AU  - Costantino, J. P.
AU  - Wickerham, D. L.
AU  - Cronin, W. M.
AU  - Wolmark, N.
DA  - Jun
DO  - 10.3816/CBC.2002.n.020
DP  - NLM
ET  - 2002/07/19
IS  - 2
KW  - Adult
Aged
Anticarcinogenic Agents/adverse effects/*therapeutic use
Breast Neoplasms/*etiology/pathology/*prevention & control
Female
Humans
Middle Aged
Neoplasm Invasiveness/prevention & control
Patient Participation/*statistics & numerical data
Raloxifene Hydrochloride/adverse effects/*therapeutic use
Risk Assessment
Risk Factors
Selective Estrogen Receptor Modulators/adverse effects/*therapeutic use
Tamoxifen/adverse effects/*therapeutic use
LA  - eng
N1  - Vogel, Victor G
Costantino, Joseph P
Wickerham, D Lawrence
Cronin, Walter M
Wolmark, Norman
Clinical Trial
Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.
United States
Clin Breast Cancer. 2002 Jun;3(2):153-9. doi: 10.3816/CBC.2002.n.020.
PY  - 2002
SN  - 1526-8209 (Print)
1526-8209
SP  - 153-9
ST  - The study of tamoxifen and raloxifene: preliminary enrollment data from a randomized breast cancer risk reduction trial
T2  - Clin Breast Cancer
TI  - The study of tamoxifen and raloxifene: preliminary enrollment data from a randomized breast cancer risk reduction trial
VL  - 3
ID  - 667
ER  - 

TY  - JOUR
AB  - Black Americans are stricken disproportionately with cancer. However, they continue to be underrepresented in clinical trials aimed at systematically investigating treatment methods or studying the effectiveness of cancer detection and prevention. Because participation in clinical trials can offer patients access to state-of-the-art therapy in a research concert, it is imperative that black Americans have proportional representation in such trials. The purpose of this article is to describe findings from the first phase of a two-phase project on recruitment of black Americans into clinical trials. In the first phase, physicians and data managers in a large, urban prestigious cancer center were asked to identify factors they believed prevent black Americans from participating in clinical trials. Findings from this study were congruent with the literature about why physicians and other health care providers believe black Americans do not participate in clinical trials. However, the Findings were examined through a cultural competence lens, adding a fresh perspective to the consideration of what interventions can be developed to eradicate underrepresentation of black Americans in clinical trials. The second phase will assess the knowledge, beliefs, attitudes, and behaviors of black Americans related to clinical trials in the geographic area of the cancer center.
AN  - WOS:000165595500005
AU  - Outlaw, F. H.
AU  - Bourjolly, J. N.
AU  - Barg, F. K.
DA  - Dec
DO  - 10.1097/00002820-200012000-00006
IS  - 6
N1  - 35
11128123
PY  - 2000
SN  - 0162-220X
SP  - 444-451
ST  - A study on recruitment of black Americans into clinical trials through a cultural competence lens
T2  - Cancer Nursing
TI  - A study on recruitment of black Americans into clinical trials through a cultural competence lens
VL  - 23
ID  - 2711
ER  - 

TY  - JOUR
AB  - INTRODUCTION: Colorectal cancer (CRC) is preventable, as screening leads to the identification and removal of precancerous polyps. African-American men consistently have the highest CRC mortality rates, and their CRC-screening uptake remains low for complex reasons. Culture-specific masculinity barriers to care may contribute to the low uptake among African-American men. Examining these barriers to care is vital as CRC screening may challenge cultural role expectations of African-American men, whose tendency is to delay help-seeking medical care. Barbershops provide a pathway for reaching African-American men with masculinity barriers to care who are not regularly receiving healthcare services and CRC screening. This study aims to develop and pilot test a theory-driven, culture-specific, barbershop-based intervention targeting masculinity barriers to care and CRC-screening uptake among African-American men ages 45-75. METHODS AND ANALYSIS: Guided by the theory of planned behaviour and the behaviour change wheel, we will use a multistage mixed-methods study design, beginning with an exploratory sequential approach to validate items for subsequent use in a pilot mixed-methods intervention. First, we will collect and analyse qualitative data from focus groups, cognitive interviews and expert item review to validate and test a culture-specific Masculinity Barriers to Care Scale (MBCS) among African-American men. Next, we will administer the MBCS to our target population as an online quantitative survey and evaluate the association between scores and CRC-screening uptake. Then, we will consider existing evidence-based approaches, our integrated results (qualitative +quantitative), and community input to design a culture-specific, behavioural intervention aimed at increasing CRC-screening uptake among African-American men and feasible for barbershop delivery. We will test the peer intervention in a pilot study with a two-arm cluster randomised design (six barbershops, randomised by site) to reduce contamination and account for barbershop culture differences. Our primary outcomes for the pilot are recruitment, sample size estimation, preliminary efficacy and acceptability. ETHICS AND DISSEMINATION: Ethics approval was obtained from the University of Utah Institutional Review Board (00113679), who will also be responsible for receiving communication updates regarding important protocol modifications. To ensure confidentiality, data dispersed to project team members will be blinded of any identifying participant information. Study results will be disseminated through publications in peer-reviewed journals, community dialogue sessions, and presentations at conferences. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov identifier: NCT03733197 (Pre-results);https://clinicaltrials.gov/ct2/show/NCT03733197.
AD  - Family & Preventive Medicine, University of Utah School of Medicine, Salt Lake City, Utah, USA.
Internal Medicine, College of Medicine, Ohio State University, Columbus, Ohio, USA.
Program for Research on Men's Health, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA.
Sorenson Impact Center, University of Utah Eccles School of Business, Salt Lake City, Utah, USA.
College of Dental Medicine, Roseman University of Health Sciences, South Jordan, Utah, USA.
Internal Medicine, University of Utah, Salt Lake City, Utah, USA.
Department of Family Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA.
AN  - 31345981
AU  - Rogers, C. R.
AU  - Okuyemi, K.
AU  - Paskett, E. D.
AU  - Thorpe, R. J., Jr.
AU  - Rogers, T. N.
AU  - Hung, M.
AU  - Zickmund, S.
AU  - Riley, C.
AU  - Fetters, M. D.
C2  - PMC6661686
DA  - Jul 24
DO  - 10.1136/bmjopen-2019-030000
DP  - NLM
ET  - 2019/07/28
IS  - 7
KW  - *African Americans
Aged
Attitude to Health/*ethnology
Barbering
Colorectal Neoplasms/*diagnosis/ethnology
Data Collection/methods
*Early Detection of Cancer
Focus Groups
Humans
Male
*Masculinity
Middle Aged
Patient Acceptance of Health Care/ethnology/*psychology
Pilot Projects
*african-americans
*colonic neoplasms
*community-based participatory research
*men’s health
*minority health
LA  - eng
N1  - 2044-6055
Rogers, Charles R
Okuyemi, Kola
Paskett, Electra D
Thorpe, Roland J Jr
Rogers, Tiana N
Hung, Man
Zickmund, Susan
Riley, Colin
Fetters, Michael D
K01 CA234319/CA/NCI NIH HHS/United States
K02 AG059140/AG/NIA NIH HHS/United States
U54 MD000214/MD/NIMHD NIH HHS/United States
Clinical Trial Protocol
Journal Article
Research Support, N.I.H., Extramural
BMJ Open. 2019 Jul 24;9(7):e030000. doi: 10.1136/bmjopen-2019-030000.
PY  - 2019
SN  - 2044-6055
SP  - e030000
ST  - Study protocol for developing #CuttingCRC: a barbershop-based trial on masculinity barriers to care and colorectal cancer screening uptake among African-American men using an exploratory sequential mixed-methods design
T2  - BMJ Open
TI  - Study protocol for developing #CuttingCRC: a barbershop-based trial on masculinity barriers to care and colorectal cancer screening uptake among African-American men using an exploratory sequential mixed-methods design
VL  - 9
ID  - 71
ER  - 

TY  - JOUR
AB  - Background: One of the most prevalent long-term consequences of surviving breast cancer is fear of cancer recurrence (FCR), which is associated with higher (mental) healthcare costs and lower surveillance rates. The majority of breast cancer survivors report a need for professional help in dealing with FCR. An easy-accessible and cost-effective evidence-based psychological intervention for reducing FCR is lacking. In the current study an online self-help training to reduce FCR will be evaluated. In addition, the secondary aim of this study is to identify factors that predict whether women can benefit from the online self-help training or not. Methods/Design: A multi-centre, parallel-groups, randomised controlled trial will be conducted to evaluate the (cost-) effectiveness of the CAREST-trial. A sample of 454 women with curatively treated breast cancer will be recruited from 8 hospitals in the Netherlands. Participants will be randomised to the intervention or usual care group (1: 1). Self-report measures will be completed at baseline, 3 (post-intervention), 9, and 24 months. Primary outcome is FCR severity; secondary outcomes are healthcare costs, health status, and psychological distress. The online tailored self-help training "Less fear after cancer" is based on cognitive behavioural therapy and consists of 2 basic modules (psycho-education; basic principles of cognitive behavioural therapy) and 4 optional modules (rumination; action; relaxation; reassurance) to choose from. Each module consists of an informative part (texts, videos, audio files) and a practical part (exercises). For every patient, the intervention will be available for three months. Personal online support by an e-mail coach is available. Discussion: Online self-help training may be an easy-accessible and cost-effective treatment to reduce the impact of FCR at an early stage in a large group of breast cancer survivors. A strength is the 24 months follow-up period in the health economic evaluation. The results of the study will provide information on the possible strengths and benefits of online self-help training for FCR in breast cancer survivors. Trial registration: This study is registered at the Netherlands Trial Register (NTR4119, date registered: August 15, 2013).
AN  - WOS:000381199000010
AU  - van Helmondt, S. J.
AU  - van der Lee, M. L.
AU  - de Vries, J.
DA  - Jul
DO  - 10.1186/s12885-016-2562-0
N1  - 527
27455846
PY  - 2016
ST  - Study protocol of the CAREST-trial: a randomised controlled trial on the (cost-) effectiveness of a CBT-based online self-help training for fear of cancer recurrence in women with curatively treated breast cancer
T2  - Bmc Cancer
TI  - Study protocol of the CAREST-trial: a randomised controlled trial on the (cost-) effectiveness of a CBT-based online self-help training for fear of cancer recurrence in women with curatively treated breast cancer
VL  - 16
ID  - 2939
ER  - 

TY  - JOUR
AB  - African American adults experience a disproportionate burden and increased mortality for most solid tumor cancers and their adolescent children are negatively impacted by the illness experience. The purpose of this randomized clinical trial is to evaluate the efficacy of a culturally sensitive family-based intervention program developed for African American families coping with solid tumor parental cancer using an intention-to-treat approach. Primary outcome is adolescent depressive symptoms at end of treatment. A sample of 172 African American families will be enrolled from two diverse oncology centers (Helen Graham Cancer Center in Newark, DE, and Kimmel Cancer Center in Philadelphia, PA). Eligible families will be randomized either to a 5-session intervention Families Fighting Cancer Together (FFCT) or a 5-session parent-only psycho-educational (PED) program. Assessments will occur at weeks 0 (baseline), 8 (end-of-treatment), 24, and 52. Treatments to help African American adolescents cope with the impact of parental cancer are scarce and urgently needed. If successful, this proposed research will change the nature of intervention support options available to African Americans, who are overrepresented and underserved by existing services or programs.
AN  - WOS:000451294400002
AU  - McKinney, N. S.
AU  - Virtue, S.
AU  - Lewis, F. M.
AU  - Willis, A. I.
AU  - Pettyjohn, T.
AU  - Harmon, L. R.
AU  - Davey, A.
DA  - Nov
DO  - 10.1186/s12885-018-5052-8
N1  - 1140
30453906
PY  - 2018
SN  - 1471-2407
ST  - Study protocol: a randomized control trial of African American families fighting parental cancer together
T2  - Bmc Cancer
TI  - Study protocol: a randomized control trial of African American families fighting parental cancer together
VL  - 18
ID  - 2839
ER  - 

TY  - JOUR
AN  - 13130105
AU  - Reynolds, T.
DA  - Sep 17
DO  - 10.1093/jnci/95.18.1356
DP  - NLM
ET  - 2003/09/18
IS  - 18
KW  - African Americans/*psychology/*statistics & numerical data
African Continental Ancestry Group/*genetics
Humans
Male
*Patient Selection
Prostatic Neoplasms/ethnology/*genetics
*Trust
United States/epidemiology
LA  - eng
N1  - 1460-2105
Reynolds, Tom
News
United States
J Natl Cancer Inst. 2003 Sep 17;95(18):1356-7. doi: 10.1093/jnci/95.18.1356.
PY  - 2003
SN  - 0027-8874
SP  - 1356-7
ST  - Study seeks to clarify genetic basis of prostate cancer in African Americans
T2  - J Natl Cancer Inst
TI  - Study seeks to clarify genetic basis of prostate cancer in African Americans
VL  - 95
ID  - 642
ER  - 

TY  - JOUR
AB  - BACKGROUND: Inclusion of minorities is an important but challenging aspect of epidemiologic studies in the United States. One aspect of this challenge that has received little attention is the actual number of minorities with specific cancers. The authors aimed to understand how population characteristics affect the numbers of minority cancer cases in Surveillance, Epidemiology, and End Results (SEER) regions. METHODS: By using SEER data, the authors identified 6 cancers with higher incidence rates in racial and ethnic minorities and reviewed the annual number of cases of those cancers in SEER areas where there are large numbers of blacks, Hispanics, and Asians. The authors examined the age characteristics of the populations in SEER areas using data from the US Census. RESULTS: Although there are substantial numbers of cases for the most common cancers with higher incidence in blacks, their numbers are quite small for other cancers, <150 cases, and in many areas, <100 per year. Few registries have substantial numbers of Hispanics or Asians. As expected, the proportion of minority populations is lower in older age groups, whereas the proportion of non-Hispanic whites is larger. CONCLUSIONS: Because of the sharp decline in minority populations associated with age and the high age-specific incidence rates of most cancers, the actual number of minority cases is quite small for several cancers. Thus, the inclusion of minority groups in studies of any but the most common cancers presents a challenge. Copyright © 2011 American Cancer Society.
AD  - Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY, United States
Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, United States
Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY, United States
Memorial Sloan-Kettering Cancer Center, 307 East 63rd Street, New York NY 10065, United States
AU  - Olson, S. H.
AU  - Layne, T. M.
AU  - Simon, J. A.
AU  - Ludwig, E.
AU  - O'Reilly, E.
AU  - Allen, P. J.
AU  - Kurtz, R. C.
DB  - Scopus
DO  - 10.1002/cncr.25871
IS  - 12
KW  - cancer
epidemiology
minorities
minority recruitment
population characteristics
M3  - Article
N1  - Cited By :4
Export Date: 22 March 2021
PY  - 2011
SP  - 2762-2769
ST  - Studying cancer in minorities: A look at the numbers
T2  - Cancer
TI  - Studying cancer in minorities: A look at the numbers
UR  - https://www.scopus.com/inward/record.uri?eid=2-s2.0-79958805102&doi=10.1002%2fcncr.25871&partnerID=40&md5=5e9b2efc4a40d2c5ea4f3182b8893469
VL  - 117
ID  - 2474
ER  - 

TY  - JOUR
AB  - Background: The CORRECT trial (NCT01103323 ) showed that REG improves overall survival (OS) vs placebo (PBO) in patients with mCRC who failed approved therapies (OS HR 0.77; 1‐sided p=0.0052; Grothey 2013). A total of 760 patients were randomized to REG (n=505) or PBO (n=255) in more than 100 centers across North America, Europe, Asia, and Australia. We conducted a post‐hoc exploratory subgroup analysis of the 83 (11%) patients from 18 US centers. Methods: Eligible patients had an ECOG PS <1 and had received approved therapies, including a fluoropyrimidine, oxaliplatin, irinotecan, and bevacizumab, and if KRAS wild‐type cetuximab and/or panitumumab. Data from the overall cohort, including US patients, are provided for perspective. Descriptive statistics are shown. Results: Of the 83 US patients, 36 (43%) were randomized to PBO and 47 (57%) to REG. Baseline characteristics of the US group were consistent with the overall cohort: median age in the US was 58 yr (range, 34 ‐ 85) vs 61 (22 ‐ 85) overall, 49% of US patients were ECOG PS1 (vs 46%), and 46% received < 3 treatments for mCRC (vs 52%). KRAS status mutant/wild‐type was 57%/34% in the US vs 57%/39% overall. All patients in the trial had prior bevacizumab and 57% of US patients also had prior cetuximab and/or panitumumab (vs 51% overall). However, higher proportion of patients in the US were Black (11% vs 2%), KRAS status unknown (10% vs 4%), and had colon as the primary disease site (82% vs 65%). Mean percentages of planned REG dose were similar (76% US vs 79% overall) and mean REG treatment duration was 3.1 mos in US vs 2.8 mos overall. Rates of dose modifications REG/PBO were 87%/47% in the US vs 76%/38% overall and grade >3 adverse events REG/PBO were 74%/64% vs 78%/49%, respectively. Based on 44 total death events, the HR for OS in the US subgroup was 0.46 (95%CI 0.25 ‐ 0.84) favoring REG; median OS was 4.7 mos for PBO, but could not be estimated for REG due to censored data. However, this analysis was based on a relatively small sample size and event count. Conclusions: Patients treated in the CORRECT study in the US appear similar to the overall cohort and results are generally consistent with the overall findings of the trial.
AN  - CN-01087820
AU  - Lenz, H. J.
AU  - Van Cutsem, E.
AU  - Verma, U. N.
AU  - Saltzman, M.
AU  - Fuloria, J.
AU  - Khojasteh, A.
AU  - Wiesenfeld, M.
AU  - Cihon, F.
AU  - Wagner, A.
AU  - Grothey, A.
IS  - 3 SUPPL. 1
KW  - *United States
*digestive system cancer
*human
*metastatic colorectal cancer
*patient
*phase 3 clinical trial
*regorafenib
Asia
Australia
Bevacizumab
Cetuximab
Death
Electrocorticography
Europe
Fluoropyrimidine
Irinotecan
North America
Overall survival
Oxaliplatin
Panitumumab
Placebo
Sample size
Statistics
Therapy
Treatment duration
Wild type
M3  - Journal: Conference Abstract
PY  - 2015
ST  - Subgroup analysis of patients enrolled in the United States in the CORRECT phase 3 trial of the multikinase inhibitor regorafenib (REG) in metastatic colorectal cancer (mCRC)
T2  - Journal of clinical oncology
TI  - Subgroup analysis of patients enrolled in the United States in the CORRECT phase 3 trial of the multikinase inhibitor regorafenib (REG) in metastatic colorectal cancer (mCRC)
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01087820/full
VL  - 33
ID  - 1639
ER  - 

TY  - JOUR
AB  - OBJECTIVE: The aim of this analysis is to evaluate the relative weight of different epidemiological risk factors on the development of different breast cancer subtypes (i.e. luminal, Her2+ overexpressed or triple negative). METHODS: De-identified datasets of female participants recruited within the Prostate, Lung, Colorectal, and Ovarian (PLCO) trial were accessed. Multivariate Cox regression analysis was utilized to assess factors affecting the development of breast cancer (regardless of subtype). Additional multivariate analyses were conducted to assess factors affecting the development of the three principal subtypes of breast cancer (ER+/Her2- breast cancer; Her2 overexpressed breast cancer and ER-/Her2- breast cancer). RESULTS: A total of 73,570 eligible participants were evaluated in the current analysis of which 2370 participants subsequently developed breast cancer. The following factors were associated with a higher risk of ER+/Her2- breast cancer: white race (P < 0.001), nulliparity (P < 0.001), higher body mass index (P = 0.003), prior exposure to hormone treatment (P = 0.004) and breast cancer in first-degree female relatives (P < 0.001). The following factors were associated with a higher risk of Her2 overexpressed breast cancer: prior exposure to hormone treatment (P = 0.002) and breast cancer in first-degree female relatives (P = 0.001). The following factors were associated with a higher risk of ER-/Her2- breast cancer: black race (P = 0.013), younger age (P = 0.017) and breast cancer in first-degree female relatives (P 0.023). CONCLUSIONS: There is considerable heterogeneity in risk factors among patients with different subtypes of breast cancer. In particular, factors associated with high estrogen levels seem to be associated with luminal breast cancer rather than other breast cancer subtypes.
AD  - Clinical Oncology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt. omar.abdelsalam@ahs.ca.
Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada. omar.abdelsalam@ahs.ca.
Department of Oncology, Tom Baker Cancer Centre, University of Calgary, Calgary, AB, T2N4N1, Canada.
AN  - 32157561
AU  - Abdel-Rahman, O.
AU  - Tang, P. A.
AU  - Cheung, W. Y.
DA  - Oct
DO  - 10.1007/s12094-020-02329-3
DP  - NLM
ET  - 2020/03/12
IS  - 10
KW  - Breast cancer
Epidemiology
Risk factors
Subtypes
LA  - eng
N1  - 1699-3055
Abdel-Rahman, O
Orcid: 0000-0002-5117-2502
Tang, P A
Cheung, W Y
Journal Article
Italy
Clin Transl Oncol. 2020 Oct;22(10):1885-1891. doi: 10.1007/s12094-020-02329-3. Epub 2020 Mar 10.
PY  - 2020
SN  - 1699-048x
SP  - 1885-1891
ST  - Subtype-specific risk factors for postmenopausal breast cancer: findings from the PLCO trial
T2  - Clin Transl Oncol
TI  - Subtype-specific risk factors for postmenopausal breast cancer: findings from the PLCO trial
VL  - 22
ID  - 50
ER  - 

TY  - JOUR
AN  - 105751908. Language: English. Entry Date: 20080627. Revision Date: 20150711. Publication Type: Journal Article
AU  - Heiney, S.
AU  - Wells, L.
AU  - Johnson, H.
DB  - CINAHL Complete
DP  - EBSCOhost
IS  - 3
KW  - Black Persons
Breast Neoplasms
Cancer Patients
Research Subject Recruitment
Social Marketing
Teleconferencing
Conceptual Framework
Descriptive Statistics
Print Materials
United States
Human
N1  - abstract; research. Journal Subset: Core Nursing; Double Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Nursing; Peer Reviewed; USA. NLM UID: 7809033.
PY  - 2008
SN  - 0190-535X
SP  - 494-494
ST  - Successful recruitment of African American breast cancer patients for telephone group intervention
T2  - Oncology Nursing Forum
TI  - Successful recruitment of African American breast cancer patients for telephone group intervention
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105751908&site=ehost-live&scope=site
VL  - 35
ID  - 2104
ER  - 

TY  - JOUR
AD  - Divison of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston.
Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia.
Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City.
AN  - 33496790
AU  - Hahn, A. W.
AU  - Bilen, M. A.
AU  - Agarwal, N.
DA  - Jan 4
DO  - 10.1001/jamanetworkopen.2020.34652
DP  - NLM
ET  - 2021/01/27
IS  - 1
KW  - African Americans
*Androgen Antagonists
Androgens
Anilides
Humans
Male
Nitriles
Phenylthiohydantoin/analogs & derivatives
*Prostatic Neoplasms/therapy
Tosyl Compounds
Treatment Outcome
LA  - eng
N1  - 2574-3805
Hahn, Andrew W
Bilen, Mehmet A
Agarwal, Neeraj
Comment
Journal Article
United States
JAMA Netw Open. 2021 Jan 4;4(1):e2034652. doi: 10.1001/jamanetworkopen.2020.34652.
PY  - 2021
SN  - 2574-3805
SP  - e2034652
ST  - Successful Recruitment of Black Men to Prostate Cancer Clinical Trials-A Lesson in Achievement
T2  - JAMA Netw Open
TI  - Successful Recruitment of Black Men to Prostate Cancer Clinical Trials-A Lesson in Achievement
VL  - 4
ID  - 11
ER  - 

TY  - GEN
AD  - Divison of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston
Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia
Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City
AU  - Hahn, Andrew W.
AU  - Bilen, Mehmet A.
AU  - Agarwal, Neeraj
CY  - Chicago, Illinois
DB  - CINAHL Complete
DO  - 10.1001/jamanetworkopen.2020.34652
DP  - EBSCOhost
J2  - JAMA Network Open
KW  - Research Subject Recruitment
Black Persons
Prostatic Neoplasms -- Drug Therapy
Neoplasm Metastasis -- Drug Therapy
Androgen Antagonists -- Therapeutic Use
Bicalutamide -- Therapeutic Use
Clinical Trials
Treatment Outcomes
N1  - Accession Number: 148386497. Language: English. Entry Date: 20210204. Revision Date: 20210225. Publication Type: Opinion; commentary.
PB  - American Medical Association
PY  - 2021
SP  - e2034652-e2034652
ST  - Successful Recruitment of Black Men to Prostate Cancer Clinical Trials—A Lesson in Achievement
TI  - Successful Recruitment of Black Men to Prostate Cancer Clinical Trials—A Lesson in Achievement
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=148386497&site=ehost-live&scope=site
VL  - 4
ID  - 2105
ER  - 

TY  - JOUR
AB  - BACKGROUND: Study of genomic data obtained from patient biospecimens is frequent in research of subjects with prostate and other epithelial malignancies. Understanding of the characteristics of healthy men who participate in genomic research is limited. METHODS: Patients were identified through the Prostate Cancer Genetic Risk Evaluation of SNPs Study and the Indiana University Cancer Biomarker Study, 2 population-based biomarker and cohort studies. Between 2006 and 2010, healthy Caucasian (n = 774) and healthy African American (n = 381) men were recruited and enrolled at high-volume free community health fairs. Each participant completed a demographic questionnaire and provided a blood sample for genomic research investigations. Frequency differences between demographic features of healthy African American and Caucasian men were compared and analyzed by 2-sample t test and multivariate logistic regression after adjusting potential confounding variables with significance at the P < .05 level. Features examined included: age, body mass index (BMI), income, education, marital status, tobacco, alcohol, family history, prostate-specific antigen (PSA) level, and prior prostate cancer screening history. RESULTS: Significant differences between healthy Caucasian and African American men participating in genomic research included: marital status (married, 69% Caucasian vs 46% African American, P< < .001), mean age (years, 58 Caucasian vs 54 African American, P < .001), mean BMI (kg/m(2), 30.9 Caucasian vs 32.3 African American, P = .004), annual income (P = .038), education (P = .002), and mean PSA (ng/mL, 1.2 Caucasian vs 2.0 African American, P = .005). CONCLUSIONS: Significant demographic differences exist between healthy Caucasian and African American men choosing to participate in genomic research. These differences may be important in designing genomic research study recruitment strategies.
AD  - Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana 46202, USA.
AN  - 21766294
AU  - Patel, Y. R.
AU  - Carr, K. A.
AU  - Magjuka, D.
AU  - Mohammadi, Y.
AU  - Dropcho, E. F.
AU  - Reed, A. D.
AU  - Moore, M. L.
AU  - Waddell, M. J.
AU  - Shedd-Steele, R.
AU  - Sweeney, C. J.
AU  - Hahn, N. M.
DA  - Feb 15
DO  - 10.1002/cncr.26328
DP  - NLM
ET  - 2011/07/19
IS  - 4
KW  - *African Americans
Age Factors
Biomedical Research/*trends
Community Health Services/*trends
Educational Status
European Continental Ancestry Group
Genetic Predisposition to Disease/ethnology/genetics
Humans
Indiana
Male
Marital Status
*Metagenomics
Middle Aged
*Minority Groups
*Patient Selection
Polymorphism, Single Nucleotide/genetics
Prostatic Neoplasms/epidemiology/ethnology/*genetics
Retrospective Studies
Risk Factors
Socioeconomic Factors
LA  - eng
N1  - 1097-0142
Patel, Yash R
Carr, Katherine A
Magjuka, David
Mohammadi, Yousef
Dropcho, Edward F
Reed, Angela D
Moore, Marietta L
Waddell, Mary Jane
Shedd-Steele, Rivienne
Sweeney, Christopher J
Hahn, Noah M
Comparative Study
Journal Article
Research Support, Non-U.S. Gov't
United States
Cancer. 2012 Feb 15;118(4):1075-82. doi: 10.1002/cncr.26328. Epub 2011 Jul 15.
PY  - 2012
SN  - 0008-543x
SP  - 1075-82
ST  - Successful recruitment of healthy African American men to genomic studies from high-volume community health fairs: implications for future genomic research in minority populations
T2  - Cancer
TI  - Successful recruitment of healthy African American men to genomic studies from high-volume community health fairs: implications for future genomic research in minority populations
VL  - 118
ID  - 390
ER  - 

TY  - JOUR
AB  - Background: Study of genomic data obtained from patient biospecimens is frequent in research of subjects with prostate and other epithelial malignancies. Understanding of the characteristics of healthy men who participate in genomic research is limited. Methods: Patients were identified through the Prostate Cancer Genetic Risk Evaluation of SNPs Study and the Indiana University Cancer Biomarker Study, 2 population-based biomarker and cohort studies. Between 2006 and 2010, healthy Caucasian (n = 774) and healthy African American (n = 381) men were recruited and enrolled at high-volume free community health fairs. Each participant completed a demographic questionnaire and provided a blood sample for genomic research investigations. Frequency differences between demographic features of healthy African American and Caucasian men were compared and analyzed by 2-sample t test and multivariate logistic regression after adjusting potential confounding variables with significance at the P < .05 level. Features examined included: age, body mass index (BMI), income, education, marital status, tobacco, alcohol, family history, prostate-specific antigen (PSA) level, and prior prostate cancer screening history. Results: Significant differences between healthy Caucasian and African American men participating in genomic research included: marital status (married, 69% Caucasian vs 46% African American, P << .001), mean age (years, 58 Caucasian vs 54 African American, P < .001), mean BMI (kg/m², 30.9 Caucasian vs 32.3 African American, P = .004), annual income (P = .038), education (P = .002), and mean PSA (ng/mL, 1.2 Caucasian vs 2.0 African American, P = .005). Conclusions: Significant demographic differences exist between healthy Caucasian and African American men choosing to participate in genomic research. These differences may be important in designing genomic research study recruitment strategies. (PsycINFO Database Record (c) 2016 APA, all rights reserved)
AD  - Hahn, Noah M., Indiana University, Melvin and Bren Simon Cancer Center, Indiana Cancer Pavilion Room RT445, 535 Barnhill Drive, Indianapolis, IN, US, 46202
AN  - 2012-03352-026
AU  - Patel, Yash R.
AU  - Carr, Katherine A.
AU  - Magjuka, David
AU  - Mohammadi, Yousef
AU  - Dropcho, Edward F.
AU  - Reed, Angela D.
AU  - Moore, Marietta L.
AU  - Waddell, Mary Jane
AU  - Shedd‐Steele, Rivienne
AU  - Sweeney, Christopher J.
AU  - Hahn, Noah M.
DB  - psyh
DO  - 10.1002/cncr.26328
DP  - EBSCOhost
IS  - 4
KW  - African American men
genomic studies recruitment
community health fairs
prostate cancer
African Americans
Age Factors
Biomedical Research
Community Health Services
Educational Status
European Continental Ancestry Group
Genetic Predisposition to Disease
Humans
Indiana
Male
Marital Status
Metagenomics
Middle Aged
Minority Groups
Patient Selection
Polymorphism, Single Nucleotide
Prostatic Neoplasms
Retrospective Studies
Risk Factors
Socioeconomic Factors
Experimental Subjects
Genome
Neoplasms
Prostate
Blacks
Human Males
Community Health
N1  - Indiana University, Melvin and Bren Simon Cancer Center, Indianapolis, IN, US. Release Date: 20120514. Correction Date: 20151207. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: English. Major Descriptor: Experimental Subjects; Genome; Neoplasms; Prostate. Minor Descriptor: Blacks; Human Males; Community Health. Classification: Cancer (3293). Population: Human (10); Male (30). Location: US. Age Group: Adulthood (18 yrs & older) (300). Methodology: Empirical Study; Longitudinal Study; Prospective Study; Quantitative Study. References Available: Y. Page Count: 8. Issue Publication Date: Feb 15, 2012. Publication History: First Posted Date: Jul 15, 2011; Accepted Date: May 12, 2011; Revised Date: Dec 31, 2010; First Submitted Date: Oct 26, 2010. Copyright Statement: American Cancer Society. 2011.
Sponsor: Walther Cancer Research Institute. Recipients: No recipient indicated
Sponsor: Clarian Health Partners. Recipients: No recipient indicated
Sponsor: Indiana University, School of Medicine, US. Other Details: Institutional Research. Recipients: No recipient indicated
PY  - 2012
SN  - 0008-543X
1097-0142
SP  - 1075-1082
ST  - Successful recruitment of healthy African American men to genomic studies from high‐volume community health fairs
T2  - Cancer
TI  - Successful recruitment of healthy African American men to genomic studies from high‐volume community health fairs
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2012-03352-026&site=ehost-live&scope=site
nhahn@iupui.edu
VL  - 118
ID  - 1717
ER  - 

TY  - JOUR
AB  - Objective: To determine whether prior success in recruiting African Americans to an in-house cancer genetics registry could be duplicated when recruiting to a national registry requiring a significantly increased level of commitment. Additionally, to determine which recruitment sources and practices yielded the highest number of African American participants. Methods: A retrospective analysis of recruitment sources, practices, and results for recruitment to the Cancer Genetics Network (CGN; a national research registry), from 2000 to 2005 was conducted. These results were compared to previous experience in recruiting African Americans to the Family Cancer Registry (FCR; an in-house registry) during the period 1992-2005. Results: In the 1st year of recruitment to the CGN, African Americans accounted for 24% of those consenting to participate in the CGN registry from our center. This compares to an average annual rate of 27% for the FCR during the years 1998-2005, and a rate of less than 1% from 1992 to 1998. By 2005, African Americans accounted for 27% of CGN participants recruited through the University of Texas Southwestern Medical Center, one of eighteen participating institutions in the CGN. Hospital-based resources such as cancer treatment clinics and tumor registries yielded the highest percentage of African American participants (66.5%), and self-referral yielded the lowest (0%). Seventy-seven percent of African Americans were actively sought out and recruited from treatment clinics, whereas the vast majority of Caucasian participants were recruited passively during the course of genetic counseling sessions that were scheduled for reasons unrelated to participation in cancer research. There were no known instances of African Americans contacting CGN staff after reading printed recruitment materials or internet advertisements. Conclusions: The increased level of commitment required of CGN participants did not deter African Americans from participating in cancer genetics research. Recruitment strategies responsible for dramatically increasing recruitment rates to the FCR from 1998 to 2000 were equally effective when used for recruitment to the CGN. The most effective recruitment sources were high-yield venues such as cancer treatment clinics and tumor registries, and active recruitment methods yielded the highest number of African American participants. Advertising through internet announcements and printed recruitment materials did not appear to be effective. Copyright © 2008 S. Karger AG.
AD  - Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, United States
Departments of Pediatrics and Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, United States
University of Texas Health Science Center of San Antonio, Department of Pediatrics, 7703 Floyd Curl Drive, San Antonio, TX 78229, United States
AU  - Patterson, A. R.
AU  - Davis, H.
AU  - Shelby, K.
AU  - McCoy, J.
AU  - Robinson, L. D.
AU  - Rao, S. K.
AU  - Banerji, P.
AU  - Tomlinson, G. E.
DB  - Scopus
DO  - 10.1159/000116881
IS  - 4
KW  - African American
Cancer genetic studies
Hereditary breast cancer
Minority recruitment
M3  - Article
N1  - Cited By :11
Export Date: 22 March 2021
PY  - 2008
SP  - 208-214
ST  - Successful strategies for increasing African American participation in cancer genetic studies: Hopeful signs for equalizing the benefits of genetic medicine
T2  - Community Genetics
TI  - Successful strategies for increasing African American participation in cancer genetic studies: Hopeful signs for equalizing the benefits of genetic medicine
UR  - https://www.scopus.com/inward/record.uri?eid=2-s2.0-42349096703&doi=10.1159%2f000116881&partnerID=40&md5=6a290a670a685f91b24bd72518c0c5a0
VL  - 11
ID  - 2538
ER  - 

TY  - JOUR
AB  - BACKGROUND: Inadequate participant recruitment, which may lead to unrepresentative study samples that threaten a study's validity, is often a major challenge in the conduct of research studies. PURPOSE: The purpose of this article is to describe the development and implementation of a recruitment plan and evaluate the different recruitment strategies for a prostate cancer behavioral intervention trial. METHODS: Our recruitment plan was based on a framework (The Heiney-Adams Recruitment Model) that we developed, which combines relationship building and social marketing. We evaluated the success of our model using several different recruitment sources including: mailed letters, physician referral, and self-referral. RESULTS: Recruitment rates ranged from 67% for a support services department mailing to 100% for physician referral. While our original list of contacted patients was comprised of only 13% African American (AA) men, 22% of our recruited participants were AA. LIMITATIONS: One of the strongest barriers to recruitment was strict patient eligibility. Another significant barrier was the lack of electronic records systems to allow for the identification of large numbers of potential participants. CONCLUSIONS: In conclusion, our model incorporating social marketing and relationship building was quite successful in recruiting for a prostate cancer behavioral study, particularly AA participants. In developing strategies, future researchers should attend to issues of staffing, financial resources, physician support, and eligibility criteria in the light of study accrual.
AD  - University of South Carolina, Columbia, USA.
AN  - 20571136
AU  - Heiney, S. P.
AU  - Arp Adams, S.
AU  - Drake, B. F.
AU  - Bryant, L. H.
AU  - Bridges, L.
AU  - Hebert, J. R.
C2  - PMC2959175
C6  - NIHMS236632
DA  - Aug
DO  - 10.1177/1740774510373491
DP  - NLM
ET  - 2010/06/24
IS  - 4
KW  - Adult
African Americans/*psychology/*statistics & numerical data
Aged
Aged, 80 and over
Data Collection/*methods
Humans
Information Systems/organization & administration
Male
Middle Aged
*Patient Selection
*Prostatic Neoplasms
Research Design
Social Marketing
Socioeconomic Factors
LA  - eng
N1  - 1740-7753
Heiney, Sue P
Arp Adams, Swann
Drake, Bettina F
Bryant, Lisa H
Bridges, Lynne
Hebert, James R
K05 CA136975/CA/NCI NIH HHS/United States
K05 CA136975-02/CA/NCI NIH HHS/United States
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Clin Trials. 2010 Aug;7(4):411-7. doi: 10.1177/1740774510373491. Epub 2010 Jun 22.
PY  - 2010
SN  - 1740-7745 (Print)
1740-7745
SP  - 411-7
ST  - Successful subject recruitment for a prostate cancer behavioral intervention trial
T2  - Clin Trials
TI  - Successful subject recruitment for a prostate cancer behavioral intervention trial
VL  - 7
ID  - 419
ER  - 

TY  - JOUR
AB  - BACKGROUND: Attention to psycho-socio-spiritual needs is considered critical by patients with life-threatening illnesses and their caregivers. Palliative care interventions that address these needs--particularly spirituality--are lacking. OBJECTIVE: To evaluate the effects of an innovative program to address psycho-socio-spiritual needs in patients with life-threatening illnesses. DESIGN: A group intervention entitled Life-Threatening Illness Supportive-Affective Group Experience (LTI-SAGE) was developed for reducing patient spiritual, emotional, and death-related distress. SETTING/SUBJECTS: African American and Caucasian patients (n = 69) from two hospitals in St. Louis, Missouri, with life-threatening medical conditions (cancer; human immunodeficiency virus/acquired immune deficiency syndrome [HIV/AIDS]; geriatric frailty; liver, kidney, pulmonary, or cardiovascular disease) were randomly assigned to intervention or control groups. Intervention patients participated in a maximum of 12 LTI-SAGE groups over a 12-month period. Control patients received standard care. MEASUREMENTS: Outcome measures were depression symptoms, anxiety, spiritual well-being, and death-related emotional distress. RESULTS: After attrition, 51 (73.9%) patients completed the trial. At the end of the trial, after factoring in compliance, intervention patients had significantly fewer depression symptoms and death-related feelings of meaninglessness and significantly better spiritual well-being than did control patients. CONCLUSIONS: The use of the LTI-SAGE model for enhancing the end-of-life illness experience is promising.
AD  - Center for Aging Research, Indiana University School of medicine, 1050 Wishard Boulevard RG-6, Indianapolis, IN 46202, USA. dokmille@iupui.edu
AN  - 15890044
AU  - Miller, D. K.
AU  - Chibnall, J. T.
AU  - Videen, S. D.
AU  - Duckro, P. N.
DA  - Apr
DO  - 10.1089/jpm.2005.8.333
DP  - NLM
ET  - 2005/05/14
IS  - 2
KW  - Analysis of Variance
Anxiety/therapy
Chi-Square Distribution
Depression/therapy
Female
Humans
Longitudinal Studies
Male
Middle Aged
Palliative Care/*psychology
Principal Component Analysis
Program Evaluation
Psychotherapy, Group/*methods
*Spirituality
Terminally Ill/*psychology
LA  - eng
N1  - Miller, Douglas K
Chibnall, John T
Videen, Susan D
Duckro, Paul N
Clinical Trial
Comparative Study
Journal Article
Randomized Controlled Trial
United States
J Palliat Med. 2005 Apr;8(2):333-43. doi: 10.1089/jpm.2005.8.333.
PY  - 2005
SN  - 1096-6218 (Print)
1557-7740
SP  - 333-43
ST  - Supportive-affective group experience for persons with life-threatening illness: reducing spiritual, psychological, and death-related distress in dying patients
T2  - J Palliat Med
TI  - Supportive-affective group experience for persons with life-threatening illness: reducing spiritual, psychological, and death-related distress in dying patients
VL  - 8
ID  - 603
ER  - 

TY  - JOUR
AB  - Background. Mixed reports exist about the impact of supportive-expressive group therapy (SEGT) on survival. Methods: From 485 women with advanced breast cancer recruited between 1996-2002, 227 (47%) consented and were randomized within an average 10 months of cancer recurrence in a 2:1 ratio to intervention with I year or more of weekly SEGT plus three classes of relaxation therapy (147 women) or to control receiving three classes of relaxation therapy (80 women). The primary outcome was survival; psychosocial well-being was appraised secondarily. Analysis was by intention-to-treat. Results: SEGT did not prolong survival (median survival 24.0 months in SEGT and 18.3 in controls; univariate hazard ratio for death 0.92 195% CI, 0.69-1.26]; multivariate hazard ratio, 1.06 195% CI, 0.74-1.51]). Significant predictors of survival were treatment with chemotherapy and hormone therapy (p < 0.001), visceral metastases (p < 0.001) and advanced disease at first diagnosis (p < 0.05). SEGT ameliorated and prevented new DSM-IV depressive disorders (P = 0.002), reduced hopeless-helplessness (p = 0.004), trauma symptoms (p = 0.04) and improved social functioning (p = 0.03). Conclusions: SEGT did not prolong survival. It improved quality of life, including treatment of and protection against depression. Copyright (c) 2007 John Wiley & Sons, Ltd.
AN  - WOS:000245847900001
AU  - Kissane, D. W.
AU  - Grabsch, B.
AU  - Clarke, D. M.
AU  - Smith, G. C.
AU  - Love, A. W.
AU  - Bloch, S.
AU  - Snyder, R. D.
AU  - Li, Y. L.
DA  - Apr
DO  - 10.1002/pon.1185
IS  - 4
N1  - 17385190
PY  - 2007
SN  - 1057-9249
SP  - 277-286
ST  - Supportive-expressive group therapy for women with metastatic breast cancer: survival and psychosocial outcome from a randomized controlled trial
T2  - Psycho-Oncology
TI  - Supportive-expressive group therapy for women with metastatic breast cancer: survival and psychosocial outcome from a randomized controlled trial
VL  - 16
ID  - 3198
ER  - 

TY  - JOUR
AB  - CONTEXT: There is concern that mastectomy is overused in the United States. OBJECTIVES: To evaluate the association of patient-reported initial recommendations by surgeons and those given when a second opinion was sought with receipt of initial mastectomy; and to assess the use of mastectomy after attempted breast-conserving surgery (BCS). DESIGN, SETTING, AND PATIENTS: A survey of women aged 20 to 79 years with intraductal or stage I and II breast cancer diagnosed between June 2005 and February 2007 and reported to the National Cancer Institute's Surveillance, Epidemiology, and End Results registries for the metropolitan areas of Los Angeles, California, and Detroit, Michigan. Patients were identified using rapid case ascertainment, and Latinas and blacks were oversampled. Of 3133 patients sent surveys, 2290 responded (73.1%). A mailed survey was completed by 96.5% of respondents and 3.5% completed a telephone survey. The final sample included 1984 female patients (502 Latinas, 529 blacks, and 953 non-Hispanic white or other). MAIN OUTCOME MEASURES: The rate of initial mastectomy and the perceived reason for its use (surgeon recommendation, patient driven, medical contraindication) and the rate of mastectomy after attempted BCS. RESULTS: Of the 1984 patients, 1468 had BCS as an initial surgical therapy (75.4%) and 460 had initial mastectomy, including 13.4% following surgeon recommendation and 8.8% based on patient preference. Approximately 20% of patients (n = 378) sought a second opinion; this was more common for those patients advised by their initial surgeon to undergo mastectomy (33.4%) than for those advised to have BCS (15.6%) or for those not receiving a recommendation for one procedure over another (21.2%) (P < .001). Discordance in treatment recommendations between surgeons occurred in 12.1% (n = 43) of second opinions and did not differ on the basis of patient race/ethnicity, education, or geographic site. Among the 1459 women for whom BCS was attempted, additional surgery was required in 37.9% of patients, including 358 with reexcision (26.0%) and 167 with mastectomy (11.9%). Mastectomy was most common in patients with stage II cancer (P < .001). CONCLUSION: Breast-conserving surgery was recommended by surgeons and attempted in the majority of patients evaluated, with surgeon recommendation, patient decision, and failure of BCS all contributing to the mastectomy rate.
AD  - Breast Surgery Service, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA. morrowm@mskcc.org
AN  - 19826024
AU  - Morrow, M.
AU  - Jagsi, R.
AU  - Alderman, A. K.
AU  - Griggs, J. J.
AU  - Hawley, S. T.
AU  - Hamilton, A. S.
AU  - Graff, J. J.
AU  - Katz, S. J.
C2  - PMC4137962
C6  - NIHMS530222
DA  - Oct 14
DO  - 10.1001/jama.2009.1450
DP  - NLM
ET  - 2009/10/15
IS  - 14
KW  - Adult
Aged
Breast Neoplasms/*surgery
Contraindications
Female
Health Care Surveys
Humans
Mastectomy/psychology/*statistics & numerical data
Mastectomy, Segmental
Middle Aged
Patient Participation
Patient Satisfaction
Practice Patterns, Physicians'
*Referral and Consultation
United States
Urban Population
Young Adult
LA  - eng
N1  - 1538-3598
Morrow, Monica
Jagsi, Reshma
Alderman, Amy K
Griggs, Jennifer J
Hawley, Sarah T
Hamilton, Ann S
Graff, John J
Katz, Steven J
K05CA111340/CA/NCI NIH HHS/United States
N01-PC-35145/PC/NCI NIH HHS/United States
R01 CA088370/CA/NCI NIH HHS/United States
N01 PC035139/PC/NCI NIH HHS/United States
N01-PC-35139/PC/NCI NIH HHS/United States
P01 CA163233/CA/NCI NIH HHS/United States
K05 CA111340/CA/NCI NIH HHS/United States
U58 DP000807/DP/NCCDPHP CDC HHS/United States
N01PC54404/CA/NCI NIH HHS/United States
N01PC35145/CA/NCI NIH HHS/United States
N01PC35139/CA/NCI NIH HHS/United States
N01-PC-54404/PC/NCI NIH HHS/United States
R01 CA109696/CA/NCI NIH HHS/United States
1U58DP00807-01/DP/NCCDPHP CDC HHS/United States
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
JAMA. 2009 Oct 14;302(14):1551-6. doi: 10.1001/jama.2009.1450.
PY  - 2009
SN  - 0098-7484 (Print)
0098-7484
SP  - 1551-6
ST  - Surgeon recommendations and receipt of mastectomy for treatment of breast cancer
T2  - Jama
TI  - Surgeon recommendations and receipt of mastectomy for treatment of breast cancer
VL  - 302
ID  - 442
ER  - 

TY  - JOUR
AB  - BACKGROUND AND PURPOSE: While variation in breast cancer quality indicators has been studied, to date there have been no studies examining the degree of surgeon-level variation in patient-reported outcomes. The purpose of this study is to examine surgeon-level variation in patient appraisals of their breast cancer care experiences. METHODS: Survey responses and clinical data from breast cancer patients reported to Detroit and Los Angeles Surveillance, Epidemiology and End Results registries from 6/2005 to 2/2007 were merged with attending surgeon surveys (1,780 patients, 291 surgeons). Primary outcomes were patient reports of access to care, care coordination, and decision satisfaction. Random-effects models examined variation due to individual surgeons for these three outcomes. RESULTS: Mean values on each patient-reported outcome scale were high. The amount of variation attributable to individual surgeons in the unconditional models was low to modest: 5.4% for access to care, 3.3% for care coordination, and 7.5% for decision satisfaction. Few factors were independently associated with patient reports of better access to or coordination of care, but less-acculturated Latina patients had lower decision satisfaction. CONCLUSIONS: Patients reported generally positive experiences with their breast cancer treatment, though we found disparities in decision satisfaction. Individual surgeons did not substantively explain the variation in any of the patient-reported outcomes.
AD  - Division of General Medicine, University of Michigan Health System, Center for Clinical Management Research, Ann Arbor VA Medical Center, Ann Arbor, MI, USA. sarahawl@umich.edu
AN  - 23054105
AU  - Hawley, S. T.
AU  - Lillie, S. E.
AU  - Morris, A.
AU  - Graff, J. J.
AU  - Hamilton, A.
AU  - Katz, S. J.
C2  - PMC5584635
C6  - NIHMS888252
DA  - Jan
DO  - 10.1245/s10434-012-2582-1
DP  - NLM
ET  - 2012/10/12
IS  - 1
KW  - African Americans/statistics & numerical data
Aged
Appointments and Schedules
Breast Neoplasms/*surgery
Clinical Competence
*Critical Pathways
European Continental Ancestry Group/statistics & numerical data
Female
Health Services Accessibility
Hispanic Americans/statistics & numerical data
Humans
Interdisciplinary Communication
Male
Middle Aged
Patient Participation
*Patient Satisfaction
Specialization
Surveys and Questionnaires
Young Adult
LA  - eng
N1  - 1534-4681
Hawley, Sarah T
Lillie, Sarah E
Morris, Arden
Graff, John J
Hamilton, Ann
Katz, Steven J
R01 CA088370/CA/NCI NIH HHS/United States
R01 CA109696/CA/NCI NIH HHS/United States
R01CA08870/CA/NCI NIH HHS/United States
R01CA109696/CA/NCI NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
Ann Surg Oncol. 2013 Jan;20(1):7-14. doi: 10.1245/s10434-012-2582-1. Epub 2012 Oct 6.
PY  - 2013
SN  - 1068-9265 (Print)
1068-9265
SP  - 7-14
ST  - Surgeon-level variation in patients' appraisals of their breast cancer treatment experiences
T2  - Ann Surg Oncol
TI  - Surgeon-level variation in patients' appraisals of their breast cancer treatment experiences
VL  - 20
ID  - 354
ER  - 

TY  - JOUR
AB  - Background: Age-related disparities in colon cancer treatment exist, with older patients being less likely to receive recommended therapy. However, to the authors' knowledge, few studies to date have focused on receipt of surgery. The objective of the current study was to describe patterns of surgery in patients aged ≥ 80 years with colon cancer and examine outcomes with and without colectomy. Methods: Medicare beneficiaries aged ≥ 80 years with colon cancer who were diagnosed between 1992 and 2005 were identified from the Surveillance, Epidemiology, and End Results-Medicare database. Multivariable logistic regression analysis was used to assess factors associated with nonoperative management. Kaplan-Meier survival analysis determined 1-year overall and colon cancer-specific survival. Results: Of 31,574 patients, 80% underwent colectomy. Approximately 46% were diagnosed during an urgent/emergent hospital admission, with decreased 1-year overall survival (70% vs 86% for patients diagnosed during an elective admission) noted among these individuals. Factors found to be most predictive of nonoperative management included older age, black race, more hospital admissions, use of home oxygen, use of a wheelchair, being frail, and having dementia. For both operative and nonoperative patients, the 1-year overall survival rate was lower than the colon cancer-specific survival rate (operative patients: 78% vs 89%; nonoperative patients: 58% vs 78%). Conclusions: The majority of older patients with colon cancer undergo surgery, with improved outcomes noted compared with nonoperative management. However, many patients who are not selected for surgery die of unrelated causes, reflecting good surgical selection. Patients undergoing surgery during an urgent/emergent admission have an increased short-term mortality risk. Because the earlier detection of colon cancer may increase the percentage of older patients undergoing elective surgery, the findings of the current study may have policy implications for colon cancer screening and suggest that age should not be the only factor driving cancer screening recommendations. Cancer 2013. © 2012 American Cancer Society.
AD  - H.B. Neuman, Department of Surgery, University of Wisconsin, School of Medicine and Public Health, 600 Highland Ave, Madison, WI 53792-7375, United States
AU  - Neuman, H. B.
AU  - O'Connor, E. S.
AU  - Weiss, J.
AU  - Loconte, N. K.
AU  - Greenblatt, D. Y.
AU  - Greenberg, C. C.
AU  - Smith, M. A.
DB  - Embase
Medline
DO  - 10.1002/cncr.27765
IS  - 3
KW  - oxygen
age distribution
aged
article
cancer diagnosis
cancer mortality
cancer prognosis
cancer registry
cancer specific survival
cancer surgery
colon cancer
colon resection
controlled study
dementia
elective surgery
female
frail elderly
hospital admission
human
major clinical study
male
Black person
outcome assessment
overall survival
oxygen therapy
patient selection
priority journal
survival time
treatment outcome
LA  - English
M3  - Article
N1  - L52166228
2012-08-20
2013-02-07
PY  - 2013
SN  - 0008-543X
1097-0142
SP  - 639-647
ST  - Surgical treatment of colon cancer in patients aged 80 years and older: Analysis of 31,574 patients in the SEER-Medicare database
T2  - Cancer
TI  - Surgical treatment of colon cancer in patients aged 80 years and older: Analysis of 31,574 patients in the SEER-Medicare database
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L52166228&from=export
http://dx.doi.org/10.1002/cncr.27765
VL  - 119
ID  - 1095
ER  - 

TY  - JOUR
AB  - Personalized cancer vaccines show great potential in cancer immunotherapy by inducing an effective and durable antitumor response. However, the limitation of neoantigen identification, low immunogenicity, and weak immune response hamper the development of personalized cancer vaccines. The surgically removed tumor contains tumor antigens specific to the patient, which provides a promising source for personalized cancer vaccines. Here, we utilized the surgically removed tumor to prepare a personalized photothermal vaccine combined with the PD-1 checkpoint blockade antibody to prevent tumor relapse and metastasis. Black phosphorus quantum dot nanovesicles (BPQD-CCNVs) coated with surgically removed tumor cell membrane were prepared and loaded into a thermosensitive hydrogel containing GM-CSF and LPS. The sustained release of GM-CSF from the hypodermic injection of Gel-BPQD-CCNVs effectively recruited dendritic cells to capture tumor antigen. NIR irradiation and LPS stimulated the expansion and activation of DCs, which then traveled to the lymph nodes to present antigen to CD8 + T cells. Moreover, the combination with PD-1 antibody significantly enhanced tumor-specific CD8 + T cell elimination of the surgical residual and lung metastatic tumor. Hence, our work may provide a promising strategy for the clinical development of a personalized cancer vaccine. © 2019 American Chemical Society.
AD  - School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou, 510275, China
School of Life Sciences, Tsinghua University, Beijing, 100084, China
School of Medicine, Sun Yat-sen University, Guangzhou, 510080, China
Graduate School at Shenzhen, Tsinghua University, Shenzhen, 518055, China
Institute of Functional Nano and Soft Materials, Jiangsu Key Laboratory for Carbon-Based Functional Materials, Soochow University, Suzhou, 215123, China
School of Life Science, Lanzhou University, Lanzhou, 730000, China
AU  - Ye, X.
AU  - Liang, X.
AU  - Chen, Q.
AU  - Miao, Q.
AU  - Chen, X.
AU  - Zhang, X.
AU  - Mei, L.
DB  - Scopus
DO  - 10.1021/acsnano.8b07371
IS  - 3
KW  - Black phosphorus
cancer cell membrane
immunotherapy
personal vaccine
photothermal
M3  - Article
N1  - Cited By :77
Export Date: 22 March 2021
PY  - 2019
SP  - 2956-2968
ST  - Surgical Tumor-Derived Personalized Photothermal Vaccine Formulation for Cancer Immunotherapy
T2  - ACS Nano
TI  - Surgical Tumor-Derived Personalized Photothermal Vaccine Formulation for Cancer Immunotherapy
UR  - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85063550197&doi=10.1021%2facsnano.8b07371&partnerID=40&md5=fe9e44c3eb580e17702012aa6c7dbc19
VL  - 13
ID  - 2237
ER  - 

TY  - JOUR
AN  - 108184584. Language: English. Entry Date: 20120507. Revision Date: 20150712. Publication Type: Journal Article. Journal Subset: Biomedical
AU  - Binder, Stefanie Petrou
DB  - CINAHL Complete
DP  - EBSCOhost
IS  - 5
KW  - Prostatic Neoplasms -- Therapy
Disease Surveillance
Time Factors
Disease Progression
Black Persons
United States
Prostate-Specific Antigen
Patient Selection
N1  - Peer Reviewed; USA. NLM UID: 0422725.
PY  - 2012
SN  - 0093-9722
SP  - 10-12
ST  - Surveillance viable in carefully selected PCa patients
T2  - Urology Times
TI  - Surveillance viable in carefully selected PCa patients
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=108184584&site=ehost-live&scope=site
VL  - 40
ID  - 2109
ER  - 

TY  - JOUR
AB  - Introduction Recently published articles have established that a substantial number of cancer patients utilize the Internet to gather information about their respective diagnoses. The challenges for medical providers include understanding the prevalence and characteristics of patients using the Internet, reasons for Internet use, and the effectiveness of currently available websites in providing useful health-related information to patients. Material and methods Adults with cancer were asked to complete a self-administered, anonymous, 21-item questionnaire upon registration at the Alvin J. Siteman Cancer Center at the Washington University School of Medicine. Results There were 500 respondents (mean age 58 years (range 18-90), 83% Caucasian and 15% African-American). Three hundred ninety-eight participants (80%) reported access to the Internet, and 315 (63%) reported searching for information about cancer on the Internet. Patients accessing the Internet for cancer information were younger than those who did not (median age 56 vs. 63 years; p<0.001). Internet usage for cancer information also differed by race (p<0.0001) and education (p<0.0001). Among patients who searched the Internet for cancer information, 13.3% of patients had their decisions towards treatments affected or changed, and 11.4% of patients had their choice in physicians affected or changed because of Internet use; 23.5% of patients sought information on clinical trials, and 9.5% of patients were influenced or changed their decision regarding clinical trial enrollment due to Internet information. Discussion Approximately two thirds of patients with cancer used the Internet to obtain information about their disease. Factors affecting Internet use for cancer information included age, race, and education. Clinical decisions can be affected by Internet use.
AN  - WOS:000292306700014
AU  - Castleton, K.
AU  - Fong, T.
AU  - Wang-Gillam, A.
AU  - Waqar, M. A.
AU  - Jeffe, D. B.
AU  - Kehlenbrink, L.
AU  - Gao, F.
AU  - Govindan, R.
DA  - Aug
DO  - 10.1007/s00520-010-0935-5
IS  - 8
N1  - 20556435
PY  - 2011
SN  - 0941-4355
SP  - 1183-1190
ST  - A survey of Internet utilization among patients with cancer
T2  - Supportive Care in Cancer
TI  - A survey of Internet utilization among patients with cancer
VL  - 19
ID  - 3090
ER  - 

TY  - JOUR
AB  - BACKGROUND: Racial disparities in cancer outcomes have been described. To the authors' knowledge, it remains unclear whether patients of Hispanic ethnicity have better or worse survival outcomes. In the current study, the authors evaluated whether Hispanic participants in SWOG clinical trials had different survival outcomes compared with non-Hispanics. METHODS: Adult patients registered in SWOG phase 2/3 clinical trials between 1986 and 2012 were analyzed. Studies of similar histology and stage of disease were combined. Within each analysis, Kaplan-Meier survival curves were generated to examine differences in outcome by ethnicity. Multivariate Cox regression was used to estimate the association between ethnicity and survival outcomes, controlling for major disease-specific prognostic factors and demographic variables plus area-level income and education to account for socioeconomic status. RESULTS: A total of 29,338 patients registered to 38 trials were included; 5% of these patients were Hispanic. Hispanic patients were more likely to be younger and from areas of lower income and education (all P<.05). No differences in survival were observed across tumor types except in the patients with advanced stage prostate cancer, in whom the authors observed an association between Hispanic ethnicity and worse overall survival (hazard ratio [HR], 1.40; P = .006), progression-free survival (HR, 1.36; P = .007), and cancer-specific survival (HR, 1.42; P = .013). After adjusting for multiple comparisons, no differences in outcomes were noted. CONCLUSIONS: Hispanic patients participating in SWOG trials who received uniform treatment and follow-up were found to have similar survival outcomes compared with non-Hispanic patients, with the single exception of those patients with advanced stage prostate cancer. The results of the current study demonstrate that Hispanic patients receiving uniform treatment and follow-up have similar outcomes compared with non-Hispanics. Cancer 2018;124:1760-9. © 2018 American Cancer Society.
AD  - Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
SWOG Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Division of Medical Oncology, Columbia University Medical Center, New York, New York.
AN  - 29370458
AU  - Chavez-MacGregor, M.
AU  - Unger, J. M.
AU  - Moseley, A.
AU  - Ramsey, S. D.
AU  - Hershman, D. L.
C2  - PMC5963502
C6  - NIHMS932992
DA  - Apr 15
DO  - 10.1002/cncr.31241
DP  - NLM
ET  - 2018/01/26
IS  - 8
KW  - African Americans/statistics & numerical data
Age Factors
Aged
Clinical Trials, Phase II as Topic
Clinical Trials, Phase III as Topic
Disease Progression
European Continental Ancestry Group/statistics & numerical data
Female
Follow-Up Studies
Health Status Disparities
Healthcare Disparities/ethnology/statistics & numerical data
Hispanic Americans/*statistics & numerical data
Humans
Kaplan-Meier Estimate
Male
Middle Aged
Mortality/*ethnology
Neoplasms/ethnology/*mortality/therapy
Socioeconomic Factors
United States/epidemiology
*Hispanics
*disparities
*ethnicity
*outcome
*race
LA  - eng
N1  - 1097-0142
Chavez-MacGregor, Mariana
Orcid: 0000-0002-7189-0763
Unger, Joseph M
Moseley, Anna
Ramsey, Scott D
Hershman, Dawn L
UG1 CA189974/CA/NCI NIH HHS/United States
Comparative Study
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Cancer. 2018 Apr 15;124(8):1760-1769. doi: 10.1002/cncr.31241. Epub 2018 Jan 25.
PY  - 2018
SN  - 0008-543X (Print)
0008-543x
SP  - 1760-1769
ST  - Survival by Hispanic ethnicity among patients with cancer participating in SWOG clinical trials
T2  - Cancer
TI  - Survival by Hispanic ethnicity among patients with cancer participating in SWOG clinical trials
VL  - 124
ID  - 137
ER  - 

TY  - JOUR
AB  - BACKGROUND: Population-based studies have shown improved survival for patients diagnosed with metastatic breast cancer over time, presumably because of the availability of new and more effective therapies. The objective of the current study was to determine whether survival improved for patients who developed distant recurrence of breast cancer after receiving adjuvant therapy. METHODS: Adjuvant chemotherapy trials coordinated by the Eastern Cooperative Oncology Group that accrued patients between 1978 and 2002 were reviewed. Survival after distant disease recurrence was estimated for progressive time periods, and adjusted for baseline covariates in a Cox proportional hazards model. RESULTS: Of the 13,785 patients who received adjuvant chemotherapy in 11 trials, 3447 (25%) developed distant disease recurrence; the median survival after recurrence was 20 months (95% confidence interval, 19 months-21 months). Factors associated with inferior survival included a shorter distant recurrence-free interval (DRFI), estrogen receptor-negative and progesterone receptor-negative disease, the number of positive axillary lymph nodes present at the time of diagnosis, and black race (P < .0001 for all). When the time period of recurrence was added to the model, it was not found to be significantly associated with survival for the general population with disease recurrence. Survival improved over time only in those patients with hormone receptor-negative disease with a DRFI ≤ 3 years, both among the 5 most recent and the entire trial data sets (P = .01 and P = .05, respectively). CONCLUSIONS: In contrast to reports from population-based studies, no general improvement in survival was observed over the last 30 years for patients who developed distant disease recurrence after adjuvant chemotherapy after adjusting for DRFI. Improved survival for patients with hormone receptor-negative disease with a short DRFI suggests a benefit from trastuzumab.
AD  - Medical Oncology Clinic, University of Wisconsin Carbone Comprehensive Cancer Center, Madison, Wisconsin 53705-2275, USA. at4@medicine.wisc.edu
AN  - 23065954
AU  - Tevaarwerk, A. J.
AU  - Gray, R. J.
AU  - Schneider, B. P.
AU  - Smith, M. L.
AU  - Wagner, L. I.
AU  - Fetting, J. H.
AU  - Davidson, N.
AU  - Goldstein, L. J.
AU  - Miller, K. D.
AU  - Sparano, J. A.
C2  - PMC3593800
C6  - NIHMS402501
DA  - Mar 15
DO  - 10.1002/cncr.27819
DP  - NLM
ET  - 2012/10/16
IS  - 6
KW  - Adult
Aged
Aged, 80 and over
Breast Neoplasms/*drug therapy/*mortality/pathology
*Chemotherapy, Adjuvant
Clinical Trials, Phase III as Topic
Combined Modality Therapy
Disease-Free Survival
Female
Humans
Middle Aged
Neoplasm Metastasis
Recurrence
Young Adult
LA  - eng
N1  - 1097-0142
Tevaarwerk, Amye J
Gray, Robert J
Schneider, Bryan P
Smith, Mary Lou
Wagner, Lynne I
Fetting, John H
Davidson, Nancy
Goldstein, Lori J
Miller, Kathy D
Sparano, Joseph A
CA21076/CA/NCI NIH HHS/United States
U10 CA027525/CA/NCI NIH HHS/United States
CA14958/CA/NCI NIH HHS/United States
UL1 TR000427/TR/NCATS NIH HHS/United States
U10 CA014958/CA/NCI NIH HHS/United States
CA66636/CA/NCI NIH HHS/United States
U10 CA021115/CA/NCI NIH HHS/United States
U10 CA049883/CA/NCI NIH HHS/United States
U10 CA017145/CA/NCI NIH HHS/United States
P30 CA082709/CA/NCI NIH HHS/United States
U10 CA021076/CA/NCI NIH HHS/United States
U10 CA066636/CA/NCI NIH HHS/United States
U10 CA039229/CA/NCI NIH HHS/United States
U10 CA037403/CA/NCI NIH HHS/United States
CA39229/CA/NCI NIH HHS/United States
CA17145/CA/NCI NIH HHS/United States
U10 CA016116/CA/NCI NIH HHS/United States
U10 CA023318/CA/NCI NIH HHS/United States
CA49883/CA/NCI NIH HHS/United States
CA21115/CA/NCI NIH HHS/United States
CA23318/CA/NCI NIH HHS/United States
CA16116/CA/NCI NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Cancer. 2013 Mar 15;119(6):1140-8. doi: 10.1002/cncr.27819. Epub 2012 Oct 12.
PY  - 2013
SN  - 0008-543X (Print)
0008-543x
SP  - 1140-8
ST  - Survival in patients with metastatic recurrent breast cancer after adjuvant chemotherapy: little evidence of improvement over the past 30 years
T2  - Cancer
TI  - Survival in patients with metastatic recurrent breast cancer after adjuvant chemotherapy: little evidence of improvement over the past 30 years
VL  - 119
ID  - 351
ER  - 

TY  - JOUR
AB  - Background: African American (AA) men in the general US population are more than twice as likely to die of prostate cancer (PC) compared with non-Hispanic white (NHW) men. The authors hypothesized that receiving care through the Veterans Affairs (VA) health system, an equal-access medical system, would attenuate this disparity. Methods: A longitudinal, centralized database of >20 million veterans was used to assemble a cohort of 60,035 men (18,201 AA men [30.3%] and 41,834 NHW men [69.7%]) who were diagnosed with PC between 2000 and 2015. Results: AA men were more likely to live in regions with a lower median income ($40,871 for AA men vs $48,125 for NHW men; P <.001) and lower high school graduation rates (83% for AA men vs 88% for NHW men; P <.001). At the time of diagnosis, AA men were younger (median age, 63.0 years vs 66.0 years; P <.001) and had a higher prostate-specific antigen level (median, 6.7 ng/mL vs 6.2 ng/mL; P <.001), but were less likely to have Gleason score 8 to 10 disease (18.8% among AA men vs 19.7% among NHW men; P <.001), a clinical T classification ≥3 (2.2% vs 2.9%; P <.001), or distant metastatic disease (2.7% vs 3.1%; P = 0.01). The 10-year PC-specific mortality rate was slightly lower for AA men (4.4% vs 5.1%; P =.005), which was confirmed in multivariable competing-risk analysis (subdistribution hazard ratio, 0.85; 95% CI, 0.78-0.93; P <.001). Conclusions: AA men diagnosed with PC in the VA health system do not appear to present with more advanced disease or experience worse outcomes compared with NHW men, in contrast to national trends, suggesting that access to care is an important determinant of racial equity.
AD  - B.S. Rose, Department of Radiation Medicine and Applied Sciences, University of California at San Diego, La Jolla, CA, United States
AU  - Riviere, P.
AU  - Luterstein, E.
AU  - Kumar, A.
AU  - Vitzthum, L. K.
AU  - Deka, R.
AU  - Sarkar, R. R.
AU  - Bryant, A. K.
AU  - Bruggeman, A.
AU  - Einck, J. P.
AU  - Murphy, J. D.
AU  - Martínez, M. E.
AU  - Rose, B. S.
DB  - Embase
Medline
DO  - 10.1002/cncr.32666
IS  - 8
KW  - prostate specific antigen
adult
African American
age distribution
article
cancer classification
cancer survival
Caucasian
cohort analysis
controlled study
distant metastasis
Gleason score
health care access
health care delivery
health care system
health care utilization
highest income group
human
longitudinal study
lowest income group
major clinical study
male
mortality rate
patient selection
priority journal
prostate cancer
risk assessment
LA  - English
M3  - Article
N1  - L2004154783
2020-02-04
2020-04-29
PY  - 2020
SN  - 1097-0142
0008-543X
SP  - 1683-1690
ST  - Survival of African American and non-Hispanic white men with prostate cancer in an equal-access health care system
T2  - Cancer
TI  - Survival of African American and non-Hispanic white men with prostate cancer in an equal-access health care system
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L2004154783&from=export
http://dx.doi.org/10.1002/cncr.32666
VL  - 126
ID  - 811
ER  - 

TY  - JOUR
AB  - Purpose: Breast cancer survivors face numerous challenges after diagnosis and treatment. Several models have been developed to attempt to improve quality of care. Here, we describe characteristics and outcomes of patients who participated in survivorship visits (SV) at Johns Hopkins (JH). Methods: We retrospectively reviewed charts of breast cancer patients who participated in an optional SV 1–3 months after completing locoregional therapy and initial systemic therapy. We report patient demographics, comorbidities, tumor characteristics, treatments, and responses to symptom questionnaires. We compared the characteristics of SV participants to stage I–III analytical cases in the 2010–2015 JH Cancer Registry (JHCR). Results: We identified 87 women with stage I–III breast cancer who participated in SVs from 2010 to 2016. Compared to patients in the JHCR (n = 2942), SV participants were younger, more likely to be African American and more likely to have a higher TNM stage, hormone receptor-negative disease, and HER2-positive disease. They were more likely to have received chemotherapy and radiation therapy. They also have similar recurrence rates despite the SV cohort’s shorter median follow-up time. Among SV participants, the prevalence of comorbidities including peripheral neuropathy, anemia, lymphedema, anxiety, deep vein thrombosis, and depression increased significantly from time of diagnosis to most recent follow-up. Conclusions: Compared to the JHCR cohort, SV participants had higher risk cancers and a high frequency of comorbidities potentially associated with breast cancer and therapy. These high-risk patients may benefit most from specific interventions targeting survivorship care, and their experiences may help improve care delivery models.
AD  - A.C. Wolff, The Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, United States
AU  - Skuli, S. J.
AU  - Sheng, J. Y.
AU  - Bantug, E. T.
AU  - Zafman, N.
AU  - Riley, C.
AU  - Ruck, J. M.
AU  - Smith, K. C.
AU  - Snyder, C. F.
AU  - Smith, K. L.
AU  - Stearns, V.
AU  - Wolff, A. C.
DB  - Embase
Medline
DO  - 10.1007/s10549-018-5028-z
IS  - 3
KW  - antineoplastic agent
adult
African American
aged
anemia
article
breast cancer
cancer chemotherapy
cancer radiotherapy
cancer recurrence
cancer registry
cancer staging
cancer survivor
comorbidity
deep vein thrombosis
demography
depression
female
follow up
high risk population
human
human epidermal growth factor receptor 2 positive breast cancer
lymphedema
major clinical study
medical record review
middle aged
patient participation
peripheral neuropathy
prevalence
priority journal
questionnaire
retrospective study
survivorship
systemic therapy
LA  - English
M3  - Article
N1  - L624841682
2018-11-15
PY  - 2019
SN  - 1573-7217
0167-6806
SP  - 701-708
ST  - Survivorship care visits in a high-risk population of breast cancer survivors
T2  - Breast Cancer Research and Treatment
TI  - Survivorship care visits in a high-risk population of breast cancer survivors
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L624841682&from=export
http://dx.doi.org/10.1007/s10549-018-5028-z
VL  - 173
ID  - 857
ER  - 

TY  - JOUR
AB  - This study examined the relationships among the demographic characteristics, symptom distress, spirituality, and quality of life (QOL) of African American breast cancer survivors. A convenience sample of 30 survivors with a mean age of 56 years and a mean survival of 6 years was recruited from African American breast cancer support groups and churches in the Southeastern United States. Data were collected through face-to-face interviews using a demographic questionnaire, the Quality of Life Index-Cancer Version, the Symptom Distress Scale, and the Spiritual Perspective Scale. Statistically significant relationships were found between symptoms and QOL (r = -0.62, P < .05) and between spirituality and QOL (r = 0.70, P < .05). No statistically significant relationships were found between age at diagnosis, income, or education and QOL. This research suggests that symptoms and spirituality are associated with QOL. Culturally appropriate care should be provided to these women to reduce health disparities and to improve their QOL.
AD  - School of Nursing, Duke University, Durham, USA; ashley_leak@hotmail.com
AN  - 106012794. Language: English. Entry Date: 20080307. Revision Date: 20150820. Publication Type: Journal Article
AU  - Leak, A.
AU  - Hu, J.
AU  - King, C. R.
DB  - CINAHL Complete
DP  - EBSCOhost
IS  - 1
KW  - Black Persons -- United States
Breast Neoplasms
Cancer Survivors
Quality of Life
Spirituality
Symptom Distress
Adult
Aged
Coefficient Alpha
Conceptual Framework
Convenience Sample
Correlational Studies
Descriptive Research
Descriptive Statistics
Educational Status
Female
Ferrans and Powers Quality of Life Index
Income
Interviews
Middle Age
Models, Theoretical
Pearson's Correlation Coefficient
Quality of Life -- Evaluation
Questionnaires
Research Subject Recruitment
Scales
Southeastern United States
Summated Rating Scaling
Symptom Distress Scale
Symptom Distress -- Evaluation
United States
Human
N1  - research; tables/charts. Journal Subset: Core Nursing; Double Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Nursing; Peer Reviewed; USA. Instrumentation: Spiritual Perspective Scale (SPS); Symptom Distress Scale (SDS) (McCorkle and Young); Ferrans and Powers Quality of Life Index. NLM UID: 7805358.
PMID: NLM18176122.
PY  - 2008
SN  - 0162-220X
SP  - E15-21
ST  - Symptom distress, spirituality, and quality of life in African American breast cancer survivors
T2  - Cancer Nursing
TI  - Symptom distress, spirituality, and quality of life in African American breast cancer survivors
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106012794&site=ehost-live&scope=site
VL  - 31
ID  - 2110
ER  - 

TY  - JOUR
AB  - BACKGROUND: There is a persistent racial survival disparity between African American (AA) and white women with breast cancer. There is evidence that symptom incidence, associated distress, and overall cancer-related distress may be unexplored, important contributing factors. The purpose of the current study was to: 1) describe and compare the number of chemotherapy-related symptoms and associated distress among AA women with breast cancer over the course of chemotherapy at 3 time points (at baseline before initiating chemotherapy, midpoint, and at the completion of chemotherapy); and 2) to describe the relationship between the number of chemotherapy-related symptoms and overall cancer distress compared with the ability to receive at least 85% of the prescribed chemotherapy within the prescribed timeframe. METHODS: Descriptive, comparative, and correlational analyses of symptom incidence, symptom distress, cancer-related distress, and prescribed chemotherapy dose received among a cohort of AA women receiving chemotherapy for breast cancer were performed. RESULTS: AA women (121 women) experienced worsening symptoms from baseline to midpoint in chemotherapy and then stabilized for the duration of therapy. The inability to receive 85% of the prescribed chemotherapy within a prescribed time point was found to be significantly correlated with midpoint symptom distress. CONCLUSIONS: The main findings of the current study were that AA women experience a deterioration in symptom distress over the course of chemotherapy from baseline (before chemotherapy) to the midpoint, which was found to be associated with less adherence to chemotherapy overall. Thus, the incidence and management of physical and emotional symptoms, as measured through a multidimensional symptom measurement tool, may be contributing to breast cancer dose disparity and should be explored further. Cancer 2017;123:2061-2069. © 2017 American Cancer Society.
AD  - Department of Medical Oncology at Dana-Farber/Brigham and Women's Cancer Center in clinical affiliation with South Shore Hospital, Harvard University, Cambridge, Massachusetts.
Department of Epidemiology, School of Nursing and Graduate School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania.
School of Nursing, University of Pittsburgh, Pittsburgh, Pennsylvania.
Department of Hematology/Oncology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
Acute and Tertiary Care Department, University of Pittsburgh School of Nursing, Pittsburgh, Pennsylvania.
AN  - 28199006
AU  - Yee, M. K.
AU  - Sereika, S. M.
AU  - Bender, C. M.
AU  - Brufsky, A. M.
AU  - Connolly, M. C.
AU  - Rosenzweig, M. Q.
DA  - Jun 1
DO  - 10.1002/cncr.30575
DP  - NLM
ET  - 2017/02/16
IS  - 11
KW  - Adult
African Americans/*psychology
Antineoplastic Combined Chemotherapy Protocols/adverse effects
Body Image/psychology
Breast Neoplasms/drug therapy/*psychology
Fatigue/chemically induced/epidemiology/psychology
Female
Gastrointestinal Diseases/chemically induced/epidemiology/psychology
Humans
Incidence
Medication Adherence/*psychology
Middle Aged
Randomized Controlled Trials as Topic
Sleep Initiation and Maintenance Disorders/chemically
induced/epidemiology/psychology
Stress, Psychological/*psychology
Women/*psychology
*breast cancer
*chemotherapy
*distress
*racial disparity
*symptoms
LA  - eng
N1  - 1097-0142
Yee, Melissa K
Sereika, Susan M
Bender, Catherine M
Brufsky, Adam M
Connolly, Mary C
Rosenzweig, Margaret Q
Journal Article
Research Support, Non-U.S. Gov't
United States
Cancer. 2017 Jun 1;123(11):2061-2069. doi: 10.1002/cncr.30575. Epub 2017 Feb 15.
PY  - 2017
SN  - 0008-543x
SP  - 2061-2069
ST  - Symptom incidence, distress, cancer-related distress, and adherence to chemotherapy among African American women with breast cancer
T2  - Cancer
TI  - Symptom incidence, distress, cancer-related distress, and adherence to chemotherapy among African American women with breast cancer
VL  - 123
ID  - 181
ER  - 

TY  - JOUR
AB  - The main objective of this review was to systematically review, assess, and report on the studies that have assessed health related quality of life (HRQOL) after VATS and thoracotomy for resection of lung cancer. We performed a systematic review of six databases. The Downs and Black tool was used to assess the risk of bias. Five studies were included. In general, patients undergoing VATS have a better HRQOL when compared to thoracotomy; however, there was a high risk of bias in the included studies. The consistent use of a lung cancer specific questionnaire for measuring HRQOL after surgery is encouraged.
AD  - Depratment of Surgery, University of Alberta, Edmonton, AB, Canada T6G 2B7 ; 416 Community Services Center, Royal Alexandra Hospital, 10240 Kingsway Avenue, Edmonton, AB, Canada T6G 2B7.
AN  - 24302870
AU  - Gazala, S.
AU  - Pelletier, J. S.
AU  - Storie, D.
AU  - Johnson, J. A.
AU  - Kutsogiannis, D. J.
AU  - Bédard, E. L.
C2  - PMC3835912
DA  - Nov 3
DO  - 10.1155/2013/789625
DP  - NLM
ET  - 2013/12/05
KW  - Carcinoma, Non-Small-Cell Lung/psychology/*surgery
Clinical Trials as Topic
Humans
Lung Neoplasms/psychology/*surgery
Multicenter Studies as Topic
Observational Studies as Topic
*Patient Satisfaction
Patients/psychology
Publication Bias
*Quality of Life
Surveys and Questionnaires
*Thoracic Surgery, Video-Assisted/psychology
*Thoracotomy/psychology
Treatment Outcome
LA  - eng
N1  - 1537-744x
Gazala, Sayf
Pelletier, Jean-Sébastien
Storie, Dale
Johnson, Jeffrey A
Kutsogiannis, Demetrios J
Bédard, Eric L R
Comparative Study
Journal Article
Meta-Analysis
Review
Systematic Review
ScientificWorldJournal. 2013 Nov 3;2013:789625. doi: 10.1155/2013/789625.
PY  - 2013
SN  - 2356-6140 (Print)
1537-744x
SP  - 789625
ST  - A systematic review and meta-analysis to assess patient-reported outcomes after lung cancer surgery
T2  - ScientificWorldJournal
TI  - A systematic review and meta-analysis to assess patient-reported outcomes after lung cancer surgery
VL  - 2013
ID  - 305
ER  - 

TY  - JOUR
AB  - BACKGROUND: Cancer prevention educational resources intended for members of ethnically diverse populations should be tailored to the specific cancer knowledge and beliefs of individual ethnic groups. Culturally sensitive printed materials on cancer prevention have been proposed in the literature. OBJECTIVES: 1) To explore definitions of the term cultural sensitivity (CS) and their application to the development and testing of cancer prevention education materials for ethnic minority groups; and 2) to assess the use of instruments or scales used to measure the CS of cancer information resources. DESIGN: A list of articles explicitly on the CS of cancer prevention education materials was assembled by searching the databases of PubMed, CancerLit, PsycINFO, and Sociological Abstracts for articles published between 1994-2004. RESULTS: Ten studies that met inclusion criteria were included in this review. Most articles included breast cancer resources (90%) and targeted African American populations (70%). Few studies defined the term CS (n=4). Only three studies employed instruments to evaluate the CS of printed cancer information resources, and none of them explicitly listed standard measures of validity or reliability. CONCLUSIONS: Best practice definitions and guidelines for culturally sensitive cancer prevention education need to be established. Ethnic minority individuals' cancer-related knowledge and beliefs must be incorporated into all printed cancer education efforts.
AD  - Department of Health Studies and Gerontology, Faculty of Applied Sciences, University of Waterloo, Waterloo, Ontario, Canada. lhgoetz@uwaterloo.ca
AN  - 17061755
AU  - Hoffman-Goetz, L.
AU  - Friedman, D. B.
DA  - Autumn
DP  - NLM
ET  - 2006/10/26
IS  - 4
KW  - Clinical Trials as Topic
Cross-Cultural Comparison
*Cultural Characteristics
Cultural Diversity
*Ethnic Groups
Health Promotion
Health Resources
Humans
*Minority Groups
Neoplasms/*ethnology/pathology/*prevention & control
Reproducibility of Results
Research Design
United States/epidemiology
LA  - eng
N1  - Hoffman-Goetz, Laurie
Friedman, Daniela B
Journal Article
Research Support, Non-U.S. Gov't
Review
Systematic Review
United States
Ethn Dis. 2006 Autumn;16(4):971-7.
PY  - 2006
SN  - 1049-510X (Print)
1049-510x
SP  - 971-7
ST  - A systematic review of culturally sensitive cancer prevention resources for ethnic minorities
T2  - Ethn Dis
TI  - A systematic review of culturally sensitive cancer prevention resources for ethnic minorities
VL  - 16
ID  - 544
ER  - 

TY  - JOUR
AB  - African Americans experience colorectal cancer (CRC) related disparities compared to other racial groups in the United States. African Americans are frequently diagnosed with CRC at a later stage, screening is underutilized, and mortality rates are highest in this group. This systematic review focused on intervention studies using stool blood CRC screening among African Americans in primary care and community settings. Given wide accessibility, low cost, and ease of dissemination of stool-based CRC screening tests, this review aims to determine effective interventions to improve participation rates. This systematic review included intervention studies published between January 1, 2000 and March 16, 2019. After reviewing an initial search of 650 studies, 11 studies were eventually included in this review. The included studies were studies conducted in community and clinical settings, using both inreach and outreach strategies to increase CRC screening. For each study, an unadjusted odds ratio (OR) for the CRC screening intervention compared to the control arm was calculated based on the data in each study to report effectiveness. The eleven studies together recruited a total of 3334 participants. The five studies using two-arm experimental designs ranged in effectiveness with ORs ranging from 1.1 to 13.0 using interventions such as mailed reminders, patient navigation, and tailored educational materials. Effective strategies to increase stool blood testing included mailed stool blood tests augmented by patient navigation, tailored educational materials, and follow-up calls or mailings to increase trust in the patient-provider relationship. More studies are needed on stool blood testing interventions to determine effectiveness in this population.
AD  - Department of Family and Community Medicine, Pennsylvania State University Health Milton S. Hershey Medical Center, Hershey, PA, USA
Department of Cancer Control, Penn State Cancer Institute, Hershey, PA, USA
College of Nursing, Florida State University, Tallahassee, FL, USA
College of Nursing, University of South Florida, Tampa, FL, USA
College of Pharmacy and Pharmaceutical Sciences, Institute of Public Health, Florida A&M University, 1415 South Martin Luther King, Jr. Blvd, 32307, Tallahassee, FL, USA
University Libraries, University of South Florida, Tampa, FL, USA
Division of Population Sciences, Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL, USA
AN  - 147998798. Language: English. Entry Date: 20210112. Revision Date: 20210113. Publication Type: Article
AU  - Roy, Siddhartha
AU  - Dickey, Sabrina
AU  - Wang, Hsiao-Lan
AU  - Washington, Alexandria
AU  - Polo, Randy
AU  - Gwede, Clement K.
AU  - Luque, John S.
DB  - CINAHL Complete
DO  - 10.1007/s10900-020-00867-z
DP  - EBSCOhost
IS  - 1
KW  - Cancer Screening
Feces -- Analysis
Colorectal Neoplasms
Occult Blood -- Methods
Black Persons
Human
Systematic Review
CINAHL Database
Colonoscopy
N1  - research; systematic review; tables/charts. Journal Subset: Biomedical; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; Public Health; USA. Special Interest: Evidence-Based Practice. NLM UID: 7600747.
PY  - 2021
SN  - 0094-5145
SP  - 232-244
ST  - Systematic Review of Interventions to Increase Stool Blood Colorectal Cancer Screening in African Americans
T2  - Journal of Community Health
TI  - Systematic Review of Interventions to Increase Stool Blood Colorectal Cancer Screening in African Americans
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=147998798&site=ehost-live&scope=site
VL  - 46
ID  - 2111
ER  - 

TY  - JOUR
AB  - BACKGROUND: Exercise in the preoperative period, or prehabilitation, continues to evolve as an important tool in optimising patients awaiting major intra-abdominal surgery. It has been shown to reduce rates of post-operative morbidity and length of hospital stay. The mechanism by which this is achieved remains poorly understood. Adaptations in mesenteric flow in response to exercise may play a role in improving post-operative recovery by reducing rates of ileus and anastomotic leak. AIMS: To systematically review the existing literature to clarify the impact of exercise on mesenteric arterial blood flow using Doppler ultrasound. METHODS: PubMed, EMBASE and the Cochrane library were systematically searched to identify clinical trials using Doppler ultrasound to investigate the effect of exercise on flow through the superior mesenteric artery (SMA). Data were extracted including participant characteristics, frequency, intensity, timing and type of exercise and the effect on SMA flow. The quality of each study was assessed using the Downs and Black checklist. RESULTS: Sixteen studies, comprising 305 participants in total, were included. Methodological quality was generally poor. Healthy volunteers were used in twelve studies. SMA flow was found to be reduced in response to exercise in twelve studies, increased in one and unchanged in two studies. Clinical heterogeneity precluded a meta-analysis. CONCLUSION: The weight of evidence suggests that superior mesenteric arterial flow is reduced immediately following exercise. Differences in frequency, intensity, timing and type of exercise make a consensus difficult. Further studies are warranted to provide a definitive understanding of the impact of exercise on mesenteric flow.
AD  - Department of Surgery, Queen Elizabeth University Hospital, 1345 Govan Road, Glasgow, G51 4TF, UK.
Department of Surgery, Royal Alexandra Hospital NHS Trust, Corsebar Road, Paisley, PA2 2PN, UK.
Academic Unit of Cancer Sciences, Faculty of Medicine, University of Southampton, South Block, Mail Point 816, Southampton University Hospital, Southampton, SO16 6YD, UK. M.West@soton.ac.uk.
AN  - 28243813
AU  - Knight, K. A.
AU  - Moug, S. J.
AU  - West, M. A.
C2  - PMC5360832
DA  - Mar
DO  - 10.1007/s10151-017-1589-9
DP  - NLM
ET  - 2017/03/01
IS  - 3
KW  - Abdomen/surgery
Adult
Aged
Anastomotic Leak/etiology/prevention & control
Clinical Trials as Topic
Digestive System Surgical Procedures/methods/*rehabilitation
Echocardiography, Doppler/methods
Exercise/*physiology
Exercise Therapy/*methods
Female
Humans
Ileus/etiology/prevention & control
Male
Mesenteric Arteries/*diagnostic imaging/physiology
Middle Aged
Preoperative Period
Splanchnic Circulation/*physiology
Treatment Outcome
Young Adult
Cancer
Colorectal
Mesenteric blood flow
Prehabilitation
This article does not contain any studies with human participants or animals
performed by any of the authors. INFORMED CONSENT: For this type of study formal
consent is not required.
LA  - eng
N1  - 1128-045x
Knight, K A
Moug, S J
West, M A
Journal Article
Review
Systematic Review
Tech Coloproctol. 2017 Mar;21(3):185-201. doi: 10.1007/s10151-017-1589-9. Epub 2017 Feb 27.
PY  - 2017
SN  - 1123-6337 (Print)
1123-6337
SP  - 185-201
ST  - Systematic review: the impact of exercise on mesenteric blood flow and its implication for preoperative rehabilitation
T2  - Tech Coloproctol
TI  - Systematic review: the impact of exercise on mesenteric blood flow and its implication for preoperative rehabilitation
VL  - 21
ID  - 178
ER  - 

TY  - JOUR
AB  - Aim: African-Americans (AA) have increased prostate cancer risk and a greater mortality rate than European-Americans (EA). AA exhibit a high prevalence of vitamin D deficiency. We examined the global prostate transcriptome in AA and EA, and the effect of vitamin D3 supplementation. Patients & methods: Twenty-seven male subjects (ten AA and 17 EA), slated to undergo prostatectomy were enrolled in the study. Fourteen subjects received vitamin D3 (4000 IU daily) and 13 subjects received placebo for 2 months prior to surgery. Results: AA show higher expression of genes associated with immune response and inflammation. Conclusion: Systems level analyses support the concept that Inflammatory processes may contribute to disease progression in AA. These transcripts can be modulated by a short course of vitamin D3 supplementation.
AD  - G. Hardiman, Department of Medicine and Public Health, Medical University of South Carolina, Charleston, SC, United States
AU  - Hardiman, G.
AU  - Savage, S. J.
AU  - Hazard, E. S.
AU  - Wilson, R. C.
AU  - Courtney, S. M.
AU  - Smith, M. T.
AU  - Hollis, B. W.
AU  - Halbert, C. H.
AU  - Gattoni-Celli, S.
C2  - Carlson Laboratories(United States)
DB  - Embase
Medline
DO  - 10.2217/pgs-2016-0025
IS  - 10
KW  - colecalciferol
growth differentiation factor 15
placebo
transcriptome
vitamin D
adult
African American
aged
article
cancer mortality
cancer risk
clinical article
controlled study
disease course
European American
gene expression
gene expression profiling
Gleason score
high throughput sequencing
human
human tissue
immune response
inflammation
male
middle aged
open study
prevalence
prostate biopsy
prostate cancer
prostatectomy
race difference
randomized controlled trial
system analysis
vitamin D deficiency
vitamin supplementation
LA  - English
M3  - Article
N1  - L611406827
2016-08-02
2016-08-08
PY  - 2016
SN  - 1744-8042
1462-2416
SP  - 1129-1143
ST  - Systems analysis of the prostate transcriptome in African-American men compared with European-American men
T2  - Pharmacogenomics
TI  - Systems analysis of the prostate transcriptome in African-American men compared with European-American men
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L611406827&from=export
http://dx.doi.org/10.2217/pgs-2016-0025
VL  - 17
ID  - 970
ER  - 

TY  - JOUR
AB  - African American men bear disproportionate burden of prostate cancer (PCa) that can be reduced by early detection. A 15-minute culturally appropriate PCa education intervention developed to communicate effective, relevant, and balanced PCa screening information to low-income African American men was evaluated in men 42 years and older who had not been screened in one year. Of 539 men enrolled, 392 (72.7%) completed the six-month follow-up. Mean age was 54.4±8.9, 34.7% had no high school diploma, and 65.3% earned less than $25,000 annually. Barriers to screening included health insurance (41.4%), discomfort of digital rectal exam (32.1%), and fear of cancer diagnosis (29.9%). Mean knowledge score of 21 points increased from 13.27±3.51 to 14.95±4.14 (p<.001), and prostate-specific antigen screening from 22.1% to 62.8%. Men without high school diploma recorded the lowest post-intervention PCa knowledge and screening rate (47.7%), suggestive of the need for more than a single education session. Annual physicals with free prostate examination can maintain the positive trend observed.
AD  - Department of Surgery, Meharry Medical College, Nashville, TN 37208, USA. fukoli@mmc.edu
AN  - 23377736
AU  - Ukoli, F. A.
AU  - Patel, K.
AU  - Hargreaves, M.
AU  - Beard, K.
AU  - Moton, P. J.
AU  - Bragg, R.
AU  - Beech, D.
AU  - Davis, R.
DA  - Feb
DO  - 10.1353/hpu.2013.0033
DP  - NLM
ET  - 2013/02/05
IS  - 1
KW  - Adult
African Americans/*education/psychology
Aged
Aged, 80 and over
Early Detection of Cancer/*psychology/statistics & numerical data
Health Knowledge, Attitudes, Practice
Health Services Accessibility
Humans
Male
Middle Aged
Patient Education as Topic/*methods
Poverty/psychology/statistics & numerical data
Prostatic Neoplasms/diagnosis/*psychology
LA  - eng
N1  - 1548-6869
Ukoli, Flora A
Patel, Kushal
Hargreaves, Margaret
Beard, Katina
Moton, Pierre J
Bragg, Richard
Beech, Derrick
Davis, Rodney
1I0CMS030208/0/PHS HHS/United States
Clinical Trial
Journal Article
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, U.S. Gov't, P.H.S.
United States
J Health Care Poor Underserved. 2013 Feb;24(1):311-31. doi: 10.1353/hpu.2013.0033.
PY  - 2013
SN  - 1049-2089
SP  - 311-31
ST  - A tailored prostate cancer education intervention for low-income African Americans: impact on knowledge and screening
T2  - J Health Care Poor Underserved
TI  - A tailored prostate cancer education intervention for low-income African Americans: impact on knowledge and screening
VL  - 24
ID  - 339
ER  - 

TY  - JOUR
AB  - OBJECTIVE: Despite efforts to reduce cancer disparities, Black women remain underrepresented in cancer research. Virtual health assistants (VHAs) are one promising digital technology for communicating health messages and promoting health behaviors to diverse populations. This study describes participant responses to a VHA-delivered intervention promoting colorectal cancer (CRC) screening with a home-stool test. METHODS: We recruited 53 non-Hispanic Black women 50 to 73 years old to participate in focus groups and think-aloud interviews and test a web-based intervention delivered by a race- and gender-concordant VHA. A user-centered design approach prioritized modifications to three successive versions of the intervention based on participants' comments. RESULTS: Participants identified 26 cues relating to components of the VHA's credibility, including trustworthiness, expertise, and authority. Comments on early versions revealed preferences for communicating with a human doctor and negative critiques of the VHA's appearance and movements. Modifications to specific cues improved the user experience, and participants expressed increased willingness to engage with later versions of the VHA and the screening messages it delivered. Informed by the Modality, Agency, Interactivity, Navigability Model, we present a framework for developing credible VHA-delivered cancer screening messages. CONCLUSIONS: VHAs provide a systematic way to deliver health information. A culturally sensitive intervention designed for credibility promoted user interest in engaging with guideline-concordant CRC screening messages. We present strategies for effectively using cues to engage audiences with health messages, which can be applied to future research in varying contexts.
AD  - STEM Translational Communication Center, College of Journalism & Communications, University of Florida, Gainesville, Florida, USA.
Department of Chemistry, Bethune-Cookman University, Daytona Beach, Florida, USA.
Department of Computer & Information Science & Engineering, College of Engineering, University of Florida, Gainesville, Florida, USA.
Department of Health Outcomes & Biomedical Informatics, College of Medicine, University of Florida, Gainesville, Florida, USA.
Division of Hematology & Oncology, College of Medicine, University of Florida, Gainesville, Florida, USA.
Department of Community Health & Family Medicine, College of Medicine, University of Florida, Gainesville, Florida, USA.
AN  - 32893399
AU  - Vilaro, M. J.
AU  - Wilson-Howard, D. S.
AU  - Griffin, L. N.
AU  - Tavassoli, F.
AU  - Zalake, M. S.
AU  - Lok, B. C.
AU  - Modave, F. P.
AU  - George, T. J.
AU  - Carek, P. J.
AU  - Krieger, J. L.
C2  - PMC7821126
DA  - Dec
DO  - 10.1002/pon.5538
DP  - NLM
ET  - 2020/09/08
IS  - 12
KW  - *colorectal neoplasms
*cues
*early detection of cancer
*health communication
*internet-based intervention
*oncology
*psycho-oncology
*qualitative research
LA  - eng
N1  - 1099-1611
Vilaro, Melissa J
Orcid: 0000-0003-3975-0274
Wilson-Howard, Danyell S
Griffin, Lauren N
Tavassoli, Fatemeh
Zalake, Mohan S
Lok, Benjamin C
Orcid: 0000-0002-1190-3729
Modave, Francois P
Orcid: 0000-0003-4366-0757
George, Thomas J
Orcid: 0000-0002-6249-9180
Carek, Peter J
Krieger, Janice L
Orcid: 0000-0001-9950-9170
R01 CA207689/CA/NCI NIH HHS/United States
R01CA207689/CA/NCI NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
Psychooncology. 2020 Dec;29(12):2048-2056. doi: 10.1002/pon.5538. Epub 2020 Sep 15.
PY  - 2020
SN  - 1057-9249 (Print)
1057-9249
SP  - 2048-2056
ST  - Tailoring virtual human-delivered interventions: A digital intervention promoting colorectal cancer screening for Black women
T2  - Psychooncology
TI  - Tailoring virtual human-delivered interventions: A digital intervention promoting colorectal cancer screening for Black women
VL  - 29
ID  - 28
ER  - 

TY  - JOUR
AB  - BACKGROUND: Polymorphic CYP2D6 is primarily responsible for metabolic activation of tamoxifen to endoxifen. We previously reported that by increasing the daily tamoxifen dose to 40 mg/day in CYP2D6 intermediate metabolizer (IM), but not poor metabolizer (PM), patients achieve endoxifen concentrations similar to those of extensive metabolizer patients on 20 mg/day. We expanded enrollment to assess the safety of CYP2D6 genotype-guided dose escalation and investigate concentration differences between races. METHODS: PM and IM breast cancer patients currently receiving tamoxifen at 20 mg/day were enrolled for genotype-guided escalation to 40 mg/day. Endoxifen was measured at baseline and after 4 months. Quality-of-life data were collected using the Functional Assessment of Cancer Therapy-Breast (FACT-B) and Breast Cancer Prevention Trial Menopausal Symptom Scale at baseline and after 4 months. RESULTS: In 353 newly enrolled patients, genotype-guided dose escalation eliminated baseline concentration differences in IM (p = .08), but not PM (p = .009), patients. Endoxifen concentrations were similar in black and white patients overall (p = .63) and within CYP2D6 phenotype groups (p > .05). In the quality-of-life analysis of 480 patients, dose escalation did not meaningfully diminish quality of life; in fact, improvements were seen in several measures including the FACT Breast Cancer subscale (p = .004) and limitations in range of motion (p < .0001) in IM patients. CONCLUSION: Differences in endoxifen concentration during treatment can be eliminated by doubling the tamoxifen dose in IM patients, without an appreciable effect on quality of life. Validation of the association between endoxifen concentration and efficacy or prospective demonstration of improved efficacy is necessary to warrant clinical uptake of this personalized treatment strategy. IMPLICATIONS FOR PRACTICE: This secondary analysis of a prospective CYP2D6 genotype-guided tamoxifen dose escalation study confirms that escalation to 40 mg/day in patients with low-activity CYP2D6 phenotypes (poor or intermediate metabolizers) increases endoxifen concentrations without any obvious increases in treatment-related toxicity. It remains unknown whether endoxifen concentration is a useful predictor of tamoxifen efficacy, and thus, there is no current role in clinical practice for CYP2D6 genotype-guided tamoxifen dose adjustment. If future studies confirm the importance of endoxifen concentrations for tamoxifen efficacy and report a target concentration, this study provides guidance for a dose-adjustment approach that could maximize efficacy while maintaining patient quality of life.
AD  - University of Michigan, Ann Arbor, Michigan, USA.
University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Moffitt Cancer Center, Tampa, Florida, USA.
Laboratory Corporation of America, Burlington, North Carolina, USA.
Moses Cone Health Cancer Center, Greensboro, North Carolina, USA.
REX Hematology Oncology Associates, Raleigh, North Carolina, USA.
Brody School of Medicine at East Carolina University, Greenville, North Carolina, USA.
Levine Cancer Institute, Charlotte, North Carolina, USA.
Palmetto Hematology Oncology, Spartanburg, South Carolina, USA.
Levine Cancer Institute Concord, Concord, North Carolina, USA.
Waverly Hematology/Oncology, Cary, North Carolina, USA.
Duke University, Durham, North Carolina, USA.
Indiana University, Indianapolis, Indiana, USA.
University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA Bon Secours Cancer Institute, Richmond, Virginia, USA william_irvin@bshsi.org.
AN  - 27226358
AU  - Hertz, D. L.
AU  - Deal, A.
AU  - Ibrahim, J. G.
AU  - Walko, C. M.
AU  - Weck, K. E.
AU  - Anderson, S.
AU  - Magrinat, G.
AU  - Olajide, O.
AU  - Moore, S.
AU  - Raab, R.
AU  - Carrizosa, D. R.
AU  - Corso, S.
AU  - Schwartz, G.
AU  - Graham, M.
AU  - Peppercorn, J. M.
AU  - Jones, D. R.
AU  - Desta, Z.
AU  - Flockhart, D. A.
AU  - Evans, J. P.
AU  - McLeod, H. L.
AU  - Carey, L. A.
AU  - Irvin, W. J., Jr.
C2  - PMC4943390
DA  - Jul
DO  - 10.1634/theoncologist.2015-0480
DP  - NLM
ET  - 2016/05/27
IS  - 7
KW  - Adult
Aged
Aged, 80 and over
Antineoplastic Agents, Hormonal/*administration & dosage
Breast Neoplasms/*drug therapy/metabolism/psychology
Cytochrome P-450 CYP2D6/*genetics
Female
Genotype
Humans
Middle Aged
Prospective Studies
Quality of Life
Tamoxifen/*administration & dosage/adverse effects/*analogs &
derivatives/blood/metabolism
*cyp2d6
*Endoxifen
*Genotype
*Pharmacogenetics
*Quality of life
*Race
*Tamoxifen
*Toxicity
article.
LA  - eng
N1  - 1549-490x
Hertz, Daniel L
Deal, Allison
Ibrahim, Joseph G
Walko, Christine M
Weck, Karen E
Anderson, Steven
Magrinat, Gustav
Olajide, Oludamilola
Moore, Susan
Raab, Rachel
Carrizosa, Daniel R
Corso, Steven
Schwartz, Garry
Graham, Mark
Peppercorn, Jeffrey M
Jones, David R
Desta, Zeruesenay
Flockhart, David A
Evans, James P
McLeod, Howard L
Carey, Lisa A
Irvin, William J Jr
P50 CA058223/CA/NCI NIH HHS/United States
T32 GM008425/GM/NIGMS NIH HHS/United States
U01 GM061373/GM/NIGMS NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Oncologist. 2016 Jul;21(7):795-803. doi: 10.1634/theoncologist.2015-0480. Epub 2016 May 25.
PY  - 2016
SN  - 1083-7159 (Print)
1083-7159
SP  - 795-803
ST  - Tamoxifen Dose Escalation in Patients With Diminished CYP2D6 Activity Normalizes Endoxifen Concentrations Without Increasing Toxicity
T2  - Oncologist
TI  - Tamoxifen Dose Escalation in Patients With Diminished CYP2D6 Activity Normalizes Endoxifen Concentrations Without Increasing Toxicity
VL  - 21
ID  - 212
ER  - 

TY  - JOUR
AB  - BACKGROUND: Competing causes of mortality in the elderly decrease the potential net benefit from colorectal cancer screening and increase the likelihood of potential harms. Individualized decision making has been recommended, so that the elderly can decide whether or not to undergo colorectal cancer (CRC) screening. The objective is to develop and test a decision aid designed to promote individualized colorectal cancer screening decision making for adults age 75 and over. METHODS: We used formative research and cognitive testing to develop and refine the decision aid. We then tested the decision aid in an uncontrolled trial. The primary outcome was the proportion of patients who were prepared to make an individualized decision, defined a priori as having adequate knowledge (10/15 questions correct) and clear values (25 or less on values clarity subscale of decisional conflict scale). Secondary outcomes included overall score on the decisional conflict scale, and preferences for undergoing screening. RESULTS: We enrolled 46 adults in the trial. The decision aid increased the proportion of participants with adequate knowledge from 4% to 52% (p < 0.01) and the proportion prepared to make an individualized decision from 4% to 41% (p < 0.01). The proportion that preferred to undergo CRC screening decreased from 67% to 61% (p = 0. 76); 7 participants (15%) changed screening preference (5 against screening, 2 in favor of screening) CONCLUSION: In an uncontrolled trial, the elderly participants appeared better prepared to make an individualized decision about whether or not to undergo CRC screening after using the decision aid.
AD  - Department of Medicine, University of North Carolina, Chapel Hill , NC, USA. carmen_lewis@med.unc.edu
AN  - 20849625
AU  - Lewis, C. L.
AU  - Golin, C. E.
AU  - DeLeon, C.
AU  - Griffith, J. M.
AU  - Ivey, J.
AU  - Trevena, L.
AU  - Pignone, M.
C2  - PMC2949695
DA  - Sep 17
DO  - 10.1186/1472-6947-10-54
DP  - NLM
ET  - 2010/09/21
KW  - African Continental Ancestry Group/psychology/statistics & numerical data
Aged
Aged, 80 and over
Colonoscopy/*psychology
Colorectal Neoplasms/*diagnosis/ethnology
*Decision Support Techniques
Educational Status
European Continental Ancestry Group/psychology/statistics & numerical data
Female
Health Literacy
Humans
Informed Consent
Male
Mass Screening/*psychology
Patient Education as Topic
Patient Selection
Visually Impaired Persons/psychology/statistics & numerical data
LA  - eng
N1  - 1472-6947
Lewis, Carmen L
Golin, Carol E
DeLeon, Chris
Griffith, Jennifer M
Ivey, Jena
Trevena, Lyndal
Pignone, Michael
K05 CA129166/CA/NCI NIH HHS/United States
5K07CA104128/CA/NCI NIH HHS/United States
K07 CA104128-05/CA/NCI NIH HHS/United States
K07 CA104128/CA/NCI NIH HHS/United States
K07 CA104128-04/CA/NCI NIH HHS/United States
Clinical Trial
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
BMC Med Inform Decis Mak. 2010 Sep 17;10:54. doi: 10.1186/1472-6947-10-54.
PY  - 2010
SN  - 1472-6947
SP  - 54
ST  - A targeted decision aid for the elderly to decide whether to undergo colorectal cancer screening: development and results of an uncontrolled trial
T2  - BMC Med Inform Decis Mak
TI  - A targeted decision aid for the elderly to decide whether to undergo colorectal cancer screening: development and results of an uncontrolled trial
VL  - 10
ID  - 413
ER  - 

TY  - JOUR
AB  - Personalized/individualized/tailored therapy for each patient is an important goal for improving the outcome of patients with colorectal adenocarcinoma and includes the intention to maximize efficacy and minimize toxicity of chemotherapeutic agents. Numerous barriers must be overcome to reach this goal because outcome is affected by an unholy trinity of tumor characteristics that include somatic alterations at the DNA, RNA, and protein level; patient characteristics that include germline genetic differences such as polymorphisms in enzymes affecting the metabolism of chemotherapeutic agents; and environmental exposures and factors that include diet and physical activity. At present, evaluation of epidermal growth factor receptor (EGFR) expression by immunohistochemistry in colorectal adenocarcinoma is generally required for treatment with one of the monoclonal antibody therapies directed against that target, despite the absence of evidence for predictive value of the assay, whereas EGFR fluorescent in situ hybridization (FISH) may be predictive. In addition, the Food and Drug Administration of the United States now requires a 'black box' warning on the packaging of irinotecan for evaluation of germline polymorphism in UGT1A1, the gene mutated in Gilbert's syndrome, for potential reduction of drug dosage in patients with the UGT1A1*28 polymorphism. Numerous other potential markers have been identified but have not yet reached levels of evidence that support their routine usage. For example, KRAS gene mutation appears to preclude improved survival after therapy with monoclonal antibody therapy directed at EGFR, and extensive DNA methylation is associated with lack of efficacy of 5-fluorouracil (5-FU)-based chemotherapy. Additional markers will come into routine usage as reports of research studies continue to appear in the literature. Clinical trials driven by molecular targets and agents directed against them, and understanding of the conflicting data on utility of markers reported in the literature, are needed to advance the field.
AD  - Department of Pathology, Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. shamilto@mdanderson.org
AN  - 18437170
AU  - Hamilton, S. R.
DA  - May
DO  - 10.1038/modpathol.2008.14
DP  - NLM
ET  - 2008/06/24
KW  - Adenocarcinoma/*drug therapy
Antineoplastic Agents/*therapeutic use
Biomarkers, Tumor/*analysis
Clinical Trials as Topic
Colorectal Neoplasms/*drug therapy
Drug Delivery Systems/*trends
Genomics/*trends
Humans
Pathology, Clinical
Physicians
LA  - eng
N1  - Hamilton, Stanley R
Journal Article
Review
United States
Mod Pathol. 2008 May;21 Suppl 2:S23-30. doi: 10.1038/modpathol.2008.14.
PY  - 2008
SN  - 0893-3952 (Print)
0893-3952
SP  - S23-30
ST  - Targeted therapy of cancer: new roles for pathologists in colorectal cancer
T2  - Mod Pathol
TI  - Targeted therapy of cancer: new roles for pathologists in colorectal cancer
VL  - 21 Suppl 2
ID  - 493
ER  - 

TY  - JOUR
AB  - The purpose of this study was to describe and classify the barriers to breast self-examinations (BSE) and mammography in African American women. A total of 125 African American women were recruited from historically black colleges, churches and community organizations in Nashville, Tennessee. Their responses to a comprehensive open- and closed-ended questionnaire about barriers to BSE and mammography were coded using a hierarchical coding system and analyzed according to participants' stage of behavior change assignment. On the average, each woman reported 3.1 barriers to BSE (2.5 psychological and 0.6 environmental) and 2.5 barriers to mammography (1.5 psychological and 1.0 environmental). Barriers cited included fear of finding cancer, forgetting, lack of time, lack of knowledge, competing demands, costs, pain, emotional consequences, cultural attitudes towards medicine, uncertainty about benefits and laziness. For BSE, the number of psychological barriers exceeded environmental barriers, while for mammography, the number of psychological and environmental barriers was similar. For BSE, but not mammography, psychological barriers appeared most important for women in the precontemplation, contemplation and preparation stages of behavior change. Overcoming barriers to BSE and mammography could increase early detection rates in African American women. Interventions based on stage of change theory may be especially applicable.
AN  - WOS:000188977500007
AU  - Hargreaves, M. K.
AU  - Schlundt, D. G.
AU  - Takizala, Z.
AU  - Brownlee, A.
AU  - Buchowski, M.
DA  - Dec
IS  - 8
N1  - 4
14983990
PY  - 2003
SN  - 0145-5680
SP  - 1219-1228
ST  - A taxonomy of obstacles to breast examinations in African American women
T2  - Cellular and Molecular Biology
TI  - A taxonomy of obstacles to breast examinations in African American women
VL  - 49
ID  - 2691
ER  - 

TY  - JOUR
AB  - Background: We have previously shown in animal models that combination anti‐HER2 therapy leads to complete tumor regression of HER2+ breast cancer (BC). We translated these findings in a neoadjuvant trial of 12 weeks (wks) of L+T (TBCRC006) that demonstrated a meaningful pathologic complete response (pCR) and near pCR (in ER+ tumors) in patients with locally advanced HER2+ BC. In the present trial, we sought to determine whether longer treatment would lead to a higher rate of pCR without the use of chemotherapy by converting near pCR to pCR especially in the ER+ subset. Methods: TBCRC023 (NCT00999804) is a randomized phase II trial combining a Simon Phase 2 design in the experimental arm with a pick‐the‐winner design, not powered for direct comparison. Women with HER2+ BC measuring 2 cm or larger were eligible and were randomized in a 1:2 ratio to 12 vs. 24 wks of L+T. Letrozole (along with ovarian suppression if premenopausal) was also administered in patients whose tumors were also ER+. Serial tumor biopsies were obtained at baseline, wk 1, wk 12, and at the time of surgery. All evaluable patients were assessed for pCR, defined as no residual invasive carcinoma in the breast. Patients did not undergo surgery, withdrew consent, or received additional neoadjuvant therapy were counted as non‐responders. Results: Ninety‐seven patients were enrolled (33 in 12‐wk arm and 64 in 24‐wk arm), of whom 95 were evaluable. Seventy seven percent of patients were white and 18% were black. Twenty percent were of Hispanic ethnicity. Median age was 51 and 55% were postmenopausal. Median tumor size was 5 cm and 65% were ER+. Study treatment was well tolerated with grade 1‐2 diarrhea (24% in 12‐wk arm, 31% in 24‐wk arm) and grade 1‐2 acneform rash (12% in 12‐wk arm, 19% in 24‐wk arm) being the most common toxicities. Grade 3 toxicities were uncommon and were mostly in the 24‐wk arm (elevated liver function test: 9%, diarrhea 2%, mucositis 2%), while the 12‐wk arm had one grade 3 anemia and the study's only serious adverse event (acute kidney injury). There were no grade 4 toxicities. The experimental arm completed stage 2 accrual and pCR rate was numerically superior to control, entirely due to better results in ER+ (Table 1), but lower than the expected pCR rate of 36% needed in the planned analysis to conclude in favor of enhanced efficacy with extended therapy. pCR rates were also lower in the control arm than in the previous study. Conclusions: Treatment with L+T (with endocrine therapy in ER+ tumors) for 24 weeks leads to doubling of the pCR rate in women with HER2+ breast cancer without using cytotoxic chemotherapy. This approach is effective and well tolerated and warrants study as part of a de‐escalation strategy that may spare some patients the cost and toxicity of chemotherapy. Tissue obtained on this trial will provide a valuable resource to validate correlative findings from our prior studies and discover new biomarkers to help guide proper patient selection for treatment.
AN  - CN-01100237
AU  - Rimawi, M. F.
AU  - Niravath, P. A.
AU  - Wang, T.
AU  - Rexer, B.
AU  - Forero, A.
AU  - Wolff, A. C.
AU  - Nanda, R.
AU  - Storniolo, A. M.
AU  - Krop, I.
AU  - Goetz, M. P.
AU  - et al.
DO  - 10.1158/1538-7445.SABCS14-S6-02
IS  - 9 SUPPL. 1
KW  - *breast cancer
*chemotherapy
*human
*lapatinib
*patient
*therapy
*trastuzumab
Acute kidney failure
Adjuvant therapy
Anemia
Animal model
Arm
Biological marker
Breast
Diarrhea
Ethnicity
Female
Hispanic
Hormonal therapy
Invasive carcinoma
Letrozole
Liver function test
Mucosa inflammation
Neoplasm
Patient selection
Phase 2 clinical trial
Rash
Surgery
Tissues
Toxicity
Tumor biopsy
Tumor regression
Tumor volume
M3  - Journal: Conference Abstract
PY  - 2015
ST  - TBCRC023: a randomized multicenter phase II neoadjuvant trial of lapatinib plus trastuzumab, with endcorine therapy and without chemotherapy, for 12 vs. 24 weeks in patients with HER2 overexpressing breast cancer
T2  - Cancer research
TI  - TBCRC023: a randomized multicenter phase II neoadjuvant trial of lapatinib plus trastuzumab, with endcorine therapy and without chemotherapy, for 12 vs. 24 weeks in patients with HER2 overexpressing breast cancer
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01100237/full
VL  - 75
ID  - 1477
ER  - 

TY  - JOUR
AB  - Purpose/Objectives: To determine the effectiveness of a multifaceted, culturally sensitive breast cancer education program for African American women in the Arkansas Mississippi River Delta. Design: Experimental (i.e., post-test only, control group design). Setting: African American churches and a county Extension Homemakers Club sponsored through the Arkansas Extension Homemakers council. Sample: 53 African American women. The experimental group included 30 participants who had a mean age of 56 years, and the control group consisted of 23 participants with a mean age of 51 years. Methods: After the presentation of a multifaceted, culturally sensitive breast cancer education program, a variety of instruments were administered to participants in the experimental group that measured dependent variables. Subjects in the control group completed the same instruments in the absence of a viable intervention. Data were analyzed using t tests. Main Research Variables: Knowledge and beliefs about breast cancer. Findings: The experimental group's mean scores were significantly higher than the control group's on the Breast Cancer Knowledge Test and the susceptibility scale of the Breast Cancer Screening Belief Scales. The experimental group also scored significantly higher than the control group on the confidence scale of the Breast Cancer Screening Belief Scales. Conclusions: The multifaceted, culturally sensitive breast cancer education program appeared to be responsible for the differences in scores between the experimental and control groups. Implications for Nursing: Culturally sensitive group educational programs aimed at helping African American women in the rural South become more knowledgeable about breast cancer and early detection clearly are needed. Such efforts also must focus on increasing women's confidence in effectively performing regular breast self-examination as well as their understanding of personal risk. Healthcare professionals play a major role in the development and implementation of these programs.
AD  - Assistant Professor, Department of Nursing, Arkansas State University, Jonesboro, AR; chall@astate.edu
AN  - 106507191. Language: English. Entry Date: 20050902. Revision Date: 20200708. Publication Type: Journal Article
AU  - Hall, C. P.
AU  - Wimberley, P. D.
AU  - Hall, J. D.
AU  - Pfriemer, J. T.
AU  - Hubbard, E. M.
AU  - Stacy, A. S.
AU  - Gilbert, J. D.
DB  - CINAHL Complete
DO  - 10.1188/05.ONF.857-863
DP  - EBSCOhost
IS  - 4
KW  - Black Persons -- Arkansas
Breast Neoplasms -- Prevention and Control
Breast Self-Examination -- Education
Cancer Screening -- Education
Adult
Arkansas
Bandura's Social Cognitive Theory
Checklists
Chi Square Test
Conceptual Framework
Confidence -- Evaluation
Consumer Satisfaction -- Evaluation
Convenience Sample
Cultural Sensitivity
Data Analysis Software
Descriptive Statistics
Experimental Studies
Female
Fisher's Exact Test
Funding Source
Health Belief Model
Health Beliefs -- Evaluation
Health Knowledge -- Evaluation
Middle Age
Outcomes of Education -- Evaluation
Print Materials
Questionnaires
Random Assignment
Research Subject Recruitment
Summated Rating Scaling
T-Tests
Videorecording
Human
N1  - research; tables/charts. Journal Subset: Core Nursing; Double Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Nursing; Peer Reviewed; USA. Grant Information: Supported by a grant form the Arkansas affiliate of the Susan G. Komen Breast Cancer Foundation and by additional funding from the College of Nursing and Health Professions, Arkansas State University. NLM UID: 7809033.
PMID: NLM15990915.
PY  - 2005
SN  - 0190-535X
SP  - 857-863
ST  - Teaching breast cancer screening to African American women in the Arkansas Mississippi River Delta
T2  - Oncology Nursing Forum
TI  - Teaching breast cancer screening to African American women in the Arkansas Mississippi River Delta
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106507191&site=ehost-live&scope=site
VL  - 32
ID  - 2113
ER  - 

TY  - JOUR
AB  - A. Specific Aims Aim One The major aim of the proposed study is to compare the effects of a TG by conference call for AAWBC with usual psychosocial care. We hypothesize that AAWBC who receive the TG by teleconference will have significantly greater cancer knowledge, less fear, less isolation, better social connection, better mood, and better QOL than a control group receiving usual psychosocial care. Aim One A: Substantiate intervention integrity (purity, dosage, specificity and interventionist competency) of first 14 waves of study. Aim One B: Establish reliability and validity of measures (Profile of Mood States and Functional Assessment of Cancer Therapy ‐ Breast Cancer Version, Social Support Questionnaire) Aim Two To have a strong intervention, it is essential to identify the processes of change that lead to beneficial outcomes.29, 30 Therefore, the second aim of the proposed study is to identify the mediators of the intervention that predict successful treatment outcomes. Aim Three Since it is particularly important to identify AA women's characteristics and sociocultural factors which may affect their responses to the intervention,30, 31 the third aim of the study is to identify the effects of demographic, health and socio‐cultural variables as moderators of treatment effects on social connection, and QOL. Aim Three A: Examine baseline moderators and concept of social connection to establish associations. C. EXPERIMENTAL DESIGN & METHODS Design The proposed study will be conducted as a multiple‐group randomized trial to compare the TG intervention with a control group receiving usual psychosocial care. A maximum of 10 subjects will be assigned randomly to each of two groups during a common time period, with one group receiving the TG intervention and the other receiving usual care. The randomization will be stratified by treatment type (chemo therapy only or radiation therapy only or chemotherapy and radiation therapy combined). Multiple time periods will be used to achieve the required number of subjects for the entire trial. Subjects will be evaluated at three time points in a repeated measures fashion: (1) at baseline before the intervention begins, (2) at the end of the intervention period, and (3) 16 weeks from baseline. Mediating, moderating and outcome variable data will be collected at all three time periods. These measurement times have been chosen for several reasons. The intervention will be delivered during the stressful time after diagnosis when the patient is facing fears, side effects (especially body image changes), and negative community attitudes. During this time, patients are challenged to learn about the disease and its treatment and are emotionally open to using positive coping strategies.133‐136 The T‐2 measurement will provide information on the immediate effects of the treatment and T‐3 will provide information on the sustainability of the intervention effects. Setting South Carolina is an ideal setting within which to test the proposed intervention, TG by teleconference. AA represent about 31 % of the population. Unlike other parts of the US, SC is mostly rural (and 46 % of its AA are rural) and the AA population has experienced very little in‐migration over the past several centuries.137 Furthermore, religious affiliation is largely fundamentalist Christian (African Methodist Episcopal, Baptist and Pentecostal Churches),138 and a spiritual focus permeates the community, which is known as the "Buckle" of the Bible Belt. Major statewide initiatives to decrease health disparities are in progress and these efforts have resulted in multiple networks for communication with key SC community leaders and health providers. We will use the Cancer Research Network, SC Cancer Alliance, Women's Cancer Coalition and the Best Chance Network to enhance recruitment efforts. Palmetto Health and the University of South Carolina are exceptional bases from which to conduct this research. Palmetto Health is South Carolina's most comprehensive health resource, a locally owned, not‐for‐p ofit healthcare system with Palmetto Health Baptist Easley in upstate SC and two Columbia hospitals, Palmetto Health Baptist and Palmetto Health Richland. Palmetto Health's Comprehensive Breast Center (PHCBC) was established to improve treatment using national guidelines and decrease mortality. Over the past several years, major strides have been made in attaining these goals through detection of smaller tumors and use of sentinel node biopsy. Two multi‐disciplinary and multi‐specialty breast cancer tumor conferences are held weekly. Additionally, Palmetto Health has made a strong commitment to decrease health disparities in the communities it serves through its Cancer Community Health Initiative. The 6 year‐old initiative has targeted AAs and is working to improve individual and community health by providing services to underserved and uninsured populations especially cancer screening. One of the oldest and most comprehensive public universities in the United States, USC has been designated a research institution of "very high research activity," the only university in South Carolina to have this designation, granted to 62 public and 32 private research institutions. University libraries in Columbia house over 7,000,000 processed items including 2,639,171 volumes and approximately 4,075,413 units in microform. Some 17,405 current periodicals are received. Thomas Cooper Library. Included in the seating are more than 900 private locked facilities for faculty and graduate students involved in research. Special areas in the library include the Student Computer Labs, the Science Library, Special Collections, and the Map Library. Access to the collection is obtained through the USCAN/NOTIS Online Card Catalog with terminals located throughout the building. CD ROM stations are available for user searching of multiple databases. The Thomas Cooper Library offers access to literature from international sources through the on‐line computer‐assisted reference department. The computerized reference service provides bibliographic citations, statistics, and international news from recent literature on a wide range of subjects. This service is particularly strong in the natural and social sciences. Also included are government activities, publications, and grant sources. Data bases in nursing include Medline, Nursing and Allied Health, and Health Planning and Administration. Data bases related to nursing include Psychological Abstracts and Mental Health Abstracts. New data bases are added regularly, and information on them is available in the Reference Department. The majority of participants in the proposed study will be recruited from the two cancer treatment sites within Palmetto Health, which treats about 600 breast cancer patients annually. Of those, more than 225 are AAWBC. Other recruitment will be statewide.
AN  - CN-01486090
AU  - Nct
KW  - Breast Neoplasms
PY  - 2011
ST  - Teleconference Group: breast Cancer in African Americans (STORY)
T2  - https://clinicaltrials.gov/show/NCT01339351
TI  - Teleconference Group: breast Cancer in African Americans (STORY)
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01486090/full
ID  - 1431
ER  - 

TY  - JOUR
AB  - ObjectiveGreater mental health symptomatology of Latina breast cancer (LBC) patients along with the paucity of intervention trials to reduce distress underscores the scientific and practice gaps in comprehensive care. This trial investigated the effect of a paraprofessionally delivered, telephonic-based psycho-educational intervention on depressive symptoms among LBC patients. MethodsLatina breast cancer patients were recruited from the California Cancer Registry, hospital registries, and support groups. Participants were randomly assigned to the intervention or control condition. The primary outcome was level of depressive symptoms as measured by the Center for Epidemiological Studies Depression scale. ResultsOne hundred ninety-nine LBC patients (84 English language preferred and 115 Spanish language preferred) participated. The overall trial outcomes demonstrated a statistically significant decrease in depressive symptoms among LBC patients in the intervention condition compared with LBC patients in the control condition, after controlling for depressive symptoms at T1 and language (p<0.05). At follow-up, 63% of intervention LBC patients reported at least a five-point decrease in symptoms compared with 26% of control LBC patients (p<0.05). English language-preferred and Spanish language-preferred LBC patients in the intervention condition showed approximately an eight-point mean decrease in depressive symptoms from baseline (M=23.5 and M=26.6, respectively) to follow-up (M=15.7 and M=18.4, respectively) (p<0.001), whereas those in the control condition showed no significant change. ConclusionsResults demonstrate the effectiveness of a culturally responsive, paraprofessionally delivered intervention to reduce depressive symptoms among LBC patients. Therefore, community oncology practices can affiliate with trained paraprofessionals to implement mental health services to address distress among our growing and increasingly ethnically, linguistically, and economically diverse oncology patient population. Copyright (c) 2013 John Wiley & Sons, Ltd.
AN  - WOS:000333767200003
AU  - Ashing, K.
AU  - Rosales, M.
DA  - May
DO  - 10.1002/pon.3441
IS  - 5
N1  - 24217994
PY  - 2014
SN  - 1057-9249
SP  - 507-515
ST  - A telephonic-based trial to reduce depressive symptoms among Latina breast cancer survivors
T2  - Psycho-Oncology
TI  - A telephonic-based trial to reduce depressive symptoms among Latina breast cancer survivors
VL  - 23
ID  - 3013
ER  - 

TY  - JOUR
AN  - WOS:000165106700008
AU  - Chung, T. D. K.
AU  - Park, II
AU  - Ignacio, L.
AU  - Catchatourian, R.
AU  - Kopnick, M.
AU  - Davison, E.
AU  - Conrad, G.
AU  - Awan, A. M.
AU  - Crawford, D.
AU  - Vijayakumar, S.
DA  - Oct 20
IS  - 5
N1  - 1
11091355
PY  - 2000
SN  - 0020-7136
SP  - 302-304
ST  - Television and news print media are effective in recruiting potential participants in a prostate cancer chemoprevention trial
T2  - International Journal of Cancer
TI  - Television and news print media are effective in recruiting potential participants in a prostate cancer chemoprevention trial
VL  - 90
ID  - 2719
ER  - 

TY  - JOUR
AB  - Background. Lack of access to available cancer clinical trials has been cited as a key factor limiting trial accrual, particularly among medically underserved populations. We examined the trends and factors in clinical trial availability within a major U.S. safety-net hospital system. Materials and Methods. We identified cancer clinical trials activated at the Harold C. Simmons Cancer from 1991 to 2014 and recorded the characteristics of the trials that were and were not activated at the Parkland Health and Hospital System satellite site. We used univariate and multivariate logistic regression to determine the association between trial characteristics and nonactivation status, and chi-square analysis to determine the association between the trial characteristics and the reasons for nonactivation. Results. A total of 773 trials were identified, of which 152 (20%) were not activated at Parkland. In multivariable analysis, nonactivation at Parkland was associated with trial year, sponsor, and phase. Compared with the 1991-2006 period, clinical trials in the 2007-2014 period were almost eightfold more likely not to be activated at Parkland. The most common reasons for nonactivation at Parkland were an inability to perform the study procedures (27%) and the startup costs (15%). Conclusion. Over time, in this single-center setting, a decreasing proportion of cancer clinical trials were available to underserved populations. Trial complexity and costs appeared to account for much of this trend. Efforts to overcome these barriers will be key to equitable access to clinical trials, efficient accrual, and the generalizability of the results.
AN  - WOS:000356684400019
AU  - Gerber, D. E.
AU  - Lakoduk, A. M.
AU  - Priddy, L. L.
AU  - Yan, J. S.
AU  - Xie, X. J.
DA  - Jun
DO  - 10.1634/theoncologist.2015-0083
IS  - 6
N1  - 26018661
PY  - 2015
SN  - 1083-7159
SP  - 674-682
ST  - Temporal Trends and Predictors for Cancer Clinical Trial Availability for Medically Underserved Populations
T2  - Oncologist
TI  - Temporal Trends and Predictors for Cancer Clinical Trial Availability for Medically Underserved Populations
VL  - 20
ID  - 2974
ER  - 

TY  - JOUR
AB  - Adjuvant endocrine therapy (AET) is used to prevent recurrence and reduce mortality for women with hormone receptor positive breast cancer. Poor adherence to AET is a significant problem and contributes to increased medical costs and mortality. A variety of problematic symptoms associated with AET are related to non-adherence and early discontinuation of treatment. The goal of this study is to test a novel, telephone-based coping skills training that teaches patients adherence skills and techniques for coping with problematic symptoms (CST-AET). Adherence to AET will be assessed in real-time for 18 months using wireless smart pill bottles. Symptom interference (i.e., pain, vasomotor symptoms, sleep problems, vaginal dryness) and cost-effectiveness of the intervention protocol will be examined as secondary outcomes. Participants (N = 400) will be recruited from a tertiary care medical center or community clinics in medically underserved or rural areas. Participants will be randomized to receive CST-AET or a general health education intervention (comparison condition). CST-AET includes ten nurse-delivered calls delivered over 6 months. CST-AET provides systematic training in coping skills for managing symptoms that interfere with adherence. Interactive voice messaging provides reinforcement for skills use and adherence that is tailored based on real-time adherence data from the wireless smart pill bottles. Given the high rates of non-adherence and recent recommendations that women remain on AET for 10 years, we describe a timely trial. If effective, the CST-AET protocol may not only reduce the burden of AET use but also lead to cost-effective changes in clinical care and improve breast cancer outcomes.
AN  - WOS:000456756800016
AU  - Shelby, R. A.
AU  - Dorfman, C. S.
AU  - Bosworth, H. B.
AU  - Keefe, F.
AU  - Sutton, L.
AU  - Owen, L.
AU  - Corsino, L.
AU  - Erkanli, A.
AU  - Reed, S. D.
AU  - Arthur, S. S.
AU  - Somers, T.
AU  - Barrett, N.
AU  - Huettel, S.
AU  - Gonzalez, J. M.
AU  - Kimmick, G.
DA  - Jan
DO  - 10.1016/j.cct.2018.11.010
N1  - 30472215
PY  - 2019
SN  - 1551-7144
SP  - 120-131
ST  - Testing a behavioral intervention to improve adherence to adjuvant endocrine therapy (AET)
T2  - Contemporary Clinical Trials
TI  - Testing a behavioral intervention to improve adherence to adjuvant endocrine therapy (AET)
VL  - 76
ID  - 2832
ER  - 

TY  - JOUR
AB  - Background/Rationale: Prostate cancer is the second leading cause of cancer related death among men in the United States, and accounts for 29% of all cancers diagnosed in men. Furthermore, approximately one in six men will be diagnosed with prostate cancer in their lifetime. Thus, 17% of male Veterans will be asked to make a decision about the treatment of their prostate cancer. The burden of this disease is further magnified when one considers that most patients will live for years following their diagnosis and with any adverse effects of therapy. Given that there have been no clinical trials showing that any prostate cancer treatment produces an increased likelihood of survival; men are asked to actively participate in treatment decisions. Previous research has revealed that men are often uninformed about their prostate cancer, particularly African American men and men with lower educational attainment. Thus, it is critical to develop and test decision aids that can help all men (especially men with low literacy skills) make an informed decision. Objective(s): The goal of the study is to compare the impact of a plain language decision aid (DA) to a conventional DA on prostate cancer patients' decision making experience and communication with their physician. Methods: This study is a randomized controlled trial. Men undergoing a prostate biopsy will be recruited at the time of biopsy and complete a baseline interview (at pre‐biopsy or biopsy appointment). Those patients diagnosed with localized prostate cancer will complete two additional interviews: at physician visit (diagnosis), and 7‐10 days following physician visit (phone survey). The treatment discussion between patients and their physician will be audio recorded. Major characteristics: All men, without a prior history of prostate cancer, undergoing a prostate biopsy will be screened for eligibility and enrolled by the study coordinator. Additional inclusion criteria include ability to speak English, provide informed consent, and have a PSA < 20. Physicians can refuse to allow a patient participate in the study at the time of biopsy. Men will be recruited from 4 VA hospitals (Ann Arbor, Durham, Pittsburgh, and San Francisco) and randomized to receive one of two decision aid booklets (plain language vs. conventional). Major variables and source(s) of data: All survey data will be collected from either face‐to‐face or phone interviews. The surveys include measures of literacy, numeracy, anxiety, preference for shared decision making, knowledge, treatment preferences, risk perceptions, perception of patient‐physician communication, and confidence and satisfaction with the decision making process. All survey questions were read aloud and responses recorded. Status: Recruitment began in September 2008 and concluded in May of 2012. 1552 men were approached to participate in the study with 1028 agreeing. 1023 completed the Time 1 interview. Of the 334 subjects eligible to continue with study activities, 285 subjects completed the Time 2 interview (biopsy results visit), and 244 completed the Time 3 phone interview.
AN  - CN-01514236
AU  - Nct
KW  - Prostatic Neoplasms
PY  - 2007
ST  - Testing the Helpfulness of 2 Decision Aids for Prostate Cancer
T2  - https://clinicaltrials.gov/show/NCT00432601
TI  - Testing the Helpfulness of 2 Decision Aids for Prostate Cancer
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01514236/full
ID  - 1423
ER  - 

TY  - JOUR
AB  - Objective: To increase accrual among Hispanics to the Cancer Genetics Network national cancer genetics registry. Methods: Drawing from South Texas cancer registries, 444 Hispanic men and women were randomly assigned to one of three experimental conditions: standard direct-mailed procedures (X1), X1 plus culturally tailored materials (X2), and X2 plus interpersonal phone contact (X3). Participants were also surveyed about the effectiveness of the education materials and the phone contact. A refusal survey was provided for those who declined to join the study. Results: A total of 154 individuals joined the Cancer Genetics Network. The X3 condition yielded the greatest accrual (43.2%) compared to X1 (30.9%) and X2 (29.9%; p < 0.05). Tailored materials appeared to have no effect but were highly regarded. The main reasons for not participating were a lack of interest and time requirements. Conclusion: Interpersonal communication can have a powerful effect on recruitment. However, more research is needed to determine the cost-efficacy of more labor-intensive approaches to registry accrual. Copyright (C) 2008 S. Karger AG, Basel.
AN  - WOS:000255110000006
AU  - Ramirez, A. G.
AU  - Miller, A. R.
AU  - Gallion, K.
AU  - de Majors, S. S. M.
AU  - Chalela, P.
AU  - Aramburo, S. G.
DO  - 10.1159/000116882
IS  - 4
N1  - 18417969
PY  - 2008
SN  - 1422-2795
SP  - 215-223
ST  - Testing three different cancer genetics registry recruitment methods with Hispanic cancer patients and their family members previously registered in local cancer registries in Texas
T2  - Community Genetics
TI  - Testing three different cancer genetics registry recruitment methods with Hispanic cancer patients and their family members previously registered in local cancer registries in Texas
VL  - 11
ID  - 3179
ER  - 

TY  - JOUR
AB  - OBJECTIVE: Our objective was to update the guidelines for the evaluation and treatment of androgen deficiency syndromes in adult men published previously in 2006. PARTICIPANTS: The Task Force was composed of a chair, selected by the Clinical Guidelines Subcommittee of The Endocrine Society, five additional experts, a methodologist, and a medical writer. The Task Force received no corporate funding or remuneration. CONCLUSIONS: We recommend making a diagnosis of androgen deficiency only in men with consistent symptoms and signs and unequivocally low serum testosterone levels. We suggest the measurement of morning total testosterone level by a reliable assay as the initial diagnostic test. We recommend confirmation of the diagnosis by repeating the measurement of morning total testosterone and, in some men in whom total testosterone is near the lower limit of normal or in whom SHBG abnormality is suspected by measurement of free or bioavailable testosterone level, using validated assays. We recommend testosterone therapy for men with symptomatic androgen deficiency to induce and maintain secondary sex characteristics and to improve their sexual function, sense of well-being, muscle mass and strength, and bone mineral density. We recommend against starting testosterone therapy in patients with breast or prostate cancer, a palpable prostate nodule or induration or prostate-specific antigen greater than 4 ng/ml or greater than 3 ng/ml in men at high risk for prostate cancer such as African-Americans or men with first-degree relatives with prostate cancer without further urological evaluation, hematocrit greater than 50%, untreated severe obstructive sleep apnea, severe lower urinary tract symptoms with International Prostate Symptom Score above 19, or uncontrolled or poorly controlled heart failure. When testosterone therapy is instituted, we suggest aiming at achieving testosterone levels during treatment in the mid-normal range with any of the approved formulations, chosen on the basis of the patient's preference, consideration of pharmacokinetics, treatment burden, and cost. Men receiving testosterone therapy should be monitored using a standardized plan.
AD  - Boston University School of Medicine, Boston, Massachusetts 02118, USA.
AN  - 20525905
AU  - Bhasin, S.
AU  - Cunningham, G. R.
AU  - Hayes, F. J.
AU  - Matsumoto, A. M.
AU  - Snyder, P. J.
AU  - Swerdloff, R. S.
AU  - Montori, V. M.
DA  - Jun
DO  - 10.1210/jc.2009-2354
DP  - NLM
ET  - 2010/06/09
IS  - 6
KW  - Adult
Aged
Androgens/*deficiency
Evidence-Based Medicine
HIV Infections/complications
Humans
Hypogonadism/diagnosis/drug therapy
Male
Middle Aged
Monitoring, Physiologic
Randomized Controlled Trials as Topic
Sexual Dysfunction, Physiological/complications
Syndrome
Testosterone/administration & dosage/adverse effects/blood/*therapeutic use
LA  - eng
N1  - 1945-7197
Bhasin, Shalender
Cunningham, Glenn R
Hayes, Frances J
Matsumoto, Alvin M
Snyder, Peter J
Swerdloff, Ronald S
Montori, Victor M
Task Force, Endocrine Society
Guideline
Journal Article
Review
United States
J Clin Endocrinol Metab. 2010 Jun;95(6):2536-59. doi: 10.1210/jc.2009-2354.
PY  - 2010
SN  - 0021-972x
SP  - 2536-59
ST  - Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline
T2  - J Clin Endocrinol Metab
TI  - Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline
VL  - 95
ID  - 420
ER  - 

TY  - JOUR
AB  - Introduction: Tetrabenazine (TBZ) is a centrally acting, dopamine (DA) depleting drug that has been used for treatment of hyperkinetic movement disorders. It was not commercially available in the USA until 2008, when the Food and Drug Administration (FDA) approved TBZ for the management of chorea associated with Huntington's disease (HD) under an orphan drug designation. Areas covered: This article provides a brief overview of HD, and highlights key studies on pharmacodynamics, pharmacokinetics, clinical efficacy and safety of TBZ for treatment of HD chorea. Expert opinion: TBZ, the first FDA-approved therapy for HD, provides symptomatic relief of chorea but there is no evidence that it alters the natural course of HD through a disease-modifying effect. While sedation, insomnia, mood changes, parkinsonism and restlessness may occur, these adverse effects can be managed effectively with appropriate titration and monitoring. A black box warning against depression and suicidality warrants careful patient selection, close monitoring and judicious use of antidepressants. TBZ possesses a unique mechanism of action as a pre-synaptic DA depletor that offers possible advantages over DA receptor blocking drugs. TBZ has a strong potential for application in other hyperkinetic movement disorders, particularly tardive dyskinesia and Tourette syndrome, but randomized controlled clinical trials are lacking. © Informa UK, Ltd.
AD  - J. Jankovic, Department of Neurology, Baylor College of Medicine, Parkinson's Disease Center, 6550 Fannin, Houston, TX 77030, United States
AU  - Jimenez-Shahed, J.
AU  - Jankovic, J.
C1  - xenazine
DB  - Embase
DO  - 10.1517/21678707.2013.787358
IS  - 5
KW  - amantadine
apomorphine
dopamine
fluoxetine
memantine
nabilone
orphan drug
paroxetine
placebo
pridopidine
quinidine
riluzole
tetrabenazine
akathisia
article
binding affinity
breast cancer
depression
drug binding
drug bioavailability
drug blood level
drug brain level
drug dose reduction
drug dose titration
drug efficacy
drug excretion
drug half life
drug indication
drug induced cancer
drug megadose
drug metabolism
drug safety
drug tolerability
drug withdrawal
emotional disorder
fatigue
Gilles de la Tourette syndrome
human
Huntington chorea
insomnia
long term care
maximum plasma concentration
mood change
motor dysfunction
nonhuman
parkinsonism
patient compliance
patient selection
phase 1 clinical trial (topic)
phase 3 clinical trial (topic)
prostatitis
quality of life
randomized controlled trial (topic)
restlessness
sedation
side effect
somnolence
subarachnoid hemorrhage
suicidal ideation
suicide attempt
systematic review (topic)
tardive dyskinesia
xenazine
LA  - English
M3  - Article
N1  - L372281715
2014-03-10
2014-03-14
PY  - 2013
SN  - 2167-8707
SP  - 423-436
ST  - Tetrabenazine for treatment of chorea associated with Huntington's disease and other potential indications
T2  - Expert Opinion on Orphan Drugs
TI  - Tetrabenazine for treatment of chorea associated with Huntington's disease and other potential indications
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L372281715&from=export
http://dx.doi.org/10.1517/21678707.2013.787358
VL  - 1
ID  - 1098
ER  - 

TY  - JOUR
AB  - Black men are suffering disproportionately from most illnesses. Action is needed to decrease the current health disparity. An important step in decreasing this disparity is to understand social factors that act as motivators and barriers to seeking care. This article examines how social factors influence health-seeking behaviors of Black men using two theoretical frameworks: Leininger's Culture Care Diversity and Universality Theory and the Health Belief Models. By understanding the impact of social factors on health seeking behaviors, nurses can develop appropriate behavioral interventions for Black men.
AD  - Assistant Professor, University of Maryland, Baltimore, School of Nursing, Baltimore, MD; plowden@son.umaryland.edu
AN  - 106788503. Language: English. Entry Date: 20031212. Revision Date: 20150820. Publication Type: Journal Article
AU  - Plowden, K. O.
DA  - Summer2003
DB  - CINAHL Complete
DP  - EBSCOhost
IS  - 1
KW  - Black Persons
Health Belief Model
Help Seeking Behavior
Leininger's Theory of Culture Care Diversity and Universality
Men's Health
Attitude to Health
Clinical Trials
Health Services Accessibility
Male
Motivation
Prostatic Neoplasms
Research Subjects
Self-Efficacy
Socioeconomic Factors
N1  - tables/charts. Journal Subset: Core Nursing; Double Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Nursing; Peer Reviewed; USA. NLM UID: 9711138.
PY  - 2003
SN  - 1086-4431
SP  - 27-31
ST  - A theoretical approach to understanding black men's health-seeking behavior
T2  - Journal of Theory Construction & Testing
TI  - A theoretical approach to understanding black men's health-seeking behavior
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106788503&site=ehost-live&scope=site
VL  - 7
ID  - 1837
ER  - 

TY  - JOUR
AB  - BACKGROUND: Unplanned visits to the emergency department (ED) and inpatient setting are expensive and associated with poor outcomes in thoracic surgery. We assessed 30-d postoperative ED visits and inpatient readmissions following thoracotomy, a high morbidity procedure. MATERIALS AND METHODS: We retrospectively analyzed inpatient and ED administrative data from California, Florida, and New York, 2010-2011. "Return to care" was defined as readmission to inpatient facility or ED within 30 d of discharge. Factors associated with return to care were analyzed via multivariable logistic regressions with a fixed effect for hospital variability. RESULTS: Of 30,154 thoracotomies, 6.3% were admitted to the ED and 10.2% to the inpatient setting within 30 d of discharge. Increased risk of inpatient readmission was associated with Medicare (odds ratio [OR] 1.30; P < 0.001) and Medicaid (OR 1.31; P < 0.0001) insurance status compared to private insurance and black race (OR 1.18; P = 0.02) compared to white race. Lung cancer diagnosis (OR 0.83; P < 0.001) and higher median income (OR 0.89; P = 0.04) were associated with decreased risk of inpatient readmission. Postoperative ED visits were associated with Medicare (OR 1.24; P < 0.001) and Medicaid insurance status (OR 1.59; P < 0.001) compared to private insurance and Hispanic race (OR 1.19; P = 0.04) compared to white race. CONCLUSIONS: Following thoracotomy, postoperative ED visits and inpatient readmissions are common. Patients with public insurance were at high risk for readmission, while patients with underlying lung cancer diagnosis had a lower readmission risk. Emphasizing postoperative management in at-risk populations could improve health outcomes and reduce unplanned returns to care.
AD  - Stanford University School of Medicine, Stanford, California.
Department of Cardiothoracic Surgery, Stanford University School of Medicine, Stanford, California.
Department of Surgery, Palo Alto VA, Palo Alto, California.
Department of Surgery, Palo Alto VA, Palo Alto, California; Department of Medicine, Stanford University School of Medicine, Stanford, California. Electronic address: boussard@stanford.edu.
AN  - 30100026
AU  - Shaffer, R.
AU  - Backhus, L.
AU  - Finnegan, M. A.
AU  - Remington, A. C.
AU  - Kwong, J. Z.
AU  - Curtin, C.
AU  - Hernandez-Boussard, T.
C2  - PMC6732253
C6  - NIHMS1043444
DA  - Oct
DO  - 10.1016/j.jss.2018.04.065
DP  - NLM
ET  - 2018/08/14
KW  - Aged
California
Emergency Service, Hospital/economics/*statistics & numerical data
Female
Florida
Health Care Rationing/economics/methods
Humans
Lung Neoplasms/*surgery
Male
Middle Aged
New York
Patient Readmission/economics/*statistics & numerical data
Patient Selection
Pleurisy/surgery
Pneumonia/surgery
Pneumothorax/surgery
Postoperative Care/economics/methods
Postoperative Complications/economics/etiology/prevention & control/*therapy
Pulmonary Atelectasis/surgery
Quality Improvement/economics
Retrospective Studies
Thoracotomy/*adverse effects/economics
*Lung cancer
*Readmissions
*Thoracotomy
in any product mentioned or concept discussed in this article.
LA  - eng
N1  - 1095-8673
Shaffer, Robyn
Backhus, Leah
Finnegan, Micaela A
Remington, Austin C
Kwong, Jereen Z
Curtin, Catherine
Hernandez-Boussard, Tina
R01 HS024096/HS/AHRQ HHS/United States
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.
J Surg Res. 2018 Oct;230:117-124. doi: 10.1016/j.jss.2018.04.065. Epub 2018 May 25.
PY  - 2018
SN  - 0022-4804 (Print)
0022-4804
SP  - 117-124
ST  - Thirty-day unplanned postoperative inpatient and emergency department visits following thoracotomy
T2  - J Surg Res
TI  - Thirty-day unplanned postoperative inpatient and emergency department visits following thoracotomy
VL  - 230
ID  - 110
ER  - 

TY  - JOUR
AB  - Background: New intervention models are needed for HIV prevention among drug-using women. Methods: The Women Fighting Infection Together (Women FIT) feasibility study enrolled 189 women in three U.S. cities (Providence, New York, Philadelphia) with drug-using histories, who also reported risky sexual behavior. Eligible women had participated previously in a yearlong study of HIV Counseling and Testing (HIVCT) and limited case management. Two thirds of the sample were black, most were unemployed, and about two thirds reported prior or current crack use. Women were randomized into two groups. In one group, women participated in a manualized, four-session, peer-led, interactive group intervention that stressed body knowledge, woman-initiated HIV/sexually transmitted infection (HIV/STI) prevention, including a focus on women’s health (reproductive health screening, sexual violence, self-breast examination, STI signs, symptoms), which aimed to increase comfort with and pride in their bodies. Control group women received HIV-CT enriched by female condom counseling. Outcomes included study retention, session attendance and ratings, changes in knowledge, and use of protection methods. Results: The study successfully retained 95% of the participants for a 2-month follow-up. Positive assessments from participants and peer leaders exceeded preset thresholds for success. Pre-post changes in body knowledge (p < 0.0001) and protection methods knowledge (p < 0.01) was greater among the intervention women than the control women. Conclusions: The body empowerment model deserves further elaboration in interventions focusing on women at high risk of HIV/STI acquisition. (PsycINFO Database Record (c) 2016 APA, all rights reserved)
AD  - Gollub, Erica L., Department of Epidemiology and Biostatistics, Robert Stempel College of Public Health and Social Work, Florida International University, 11200 SW 8th Street, Miami, FL, US, 33199
AN  - 2010-19572-006
AU  - Gollub, Erica L.
AU  - Morrow, Kathleen M.
AU  - Mayer, Kenneth H.
AU  - Koblin, Beryl A.
AU  - Peterside, Pamela Brown
AU  - Husnik, Marla J.
AU  - Metzger, David S.
DB  - psyh
DO  - 10.1089/jwh.2009.1778
DP  - EBSCOhost
IS  - 9
KW  - body empowerment
HIV
AIDS prevention
intervention
drug use histories
Women Fighting Infection Together
Women FIT
Feasibility Studies
Female
Group Processes
HIV Infections
Health Education
Health Knowledge, Attitudes, Practice
Humans
Male
Patient Selection
Pilot Projects
Power (Psychology)
Risk Reduction Behavior
Safe Sex
Substance-Related Disorders
United States
Drug Usage
Empowerment
History
Human Body
N1  - Department of Epidemiology and Biostatistics, Robert Stempel College of Public Health and Social Work, Florida International University, Miami, FL, US. Release Date: 20110117. Correction Date: 20120618. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: English. Major Descriptor: AIDS Prevention; Drug Usage; HIV; Intervention. Minor Descriptor: Empowerment; History; Human Body. Classification: Immunological Disorders (3291); Health & Mental Health Treatment & Prevention (3300). Population: Human (10); Female (40). Location: US. Age Group: Adulthood (18 yrs & older) (300); Young Adulthood (18-29 yrs) (320); Thirties (30-39 yrs) (340); Middle Age (40-64 yrs) (360). Methodology: Empirical Study; Longitudinal Study; Prospective Study; Qualitative Study; Quantitative Study. References Available: Y. Page Count: 9. Issue Publication Date: Sep, 2010. Copyright Statement: Mary Ann Liebert, Inc.
Sponsor: HIVNET. Recipients: No recipient indicated
Sponsor: US Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases, US. Grant: NO1-AI-35176. Recipients: No recipient indicated
Sponsor: Abt Associates, Inc.. Grant: NO1-AI-45200. Recipients: No recipient indicated
Sponsor: Fred Hutchinson Cancer Research Center. Recipients: No recipient indicated
Sponsor: Fenway Community Health Center. Recipients: No recipient indicated
Sponsor: New York Blood Center. Recipients: No recipient indicated
Sponsor: University of Pennsylvania, US. Recipients: No recipient indicated
PY  - 2010
SN  - 1540-9996
1931-843X
SP  - 1705-1713
ST  - Three city feasibility study of a body empowerment and HIV prevention intervention among women with drug use histories: Women FIT
T2  - Journal of Women's Health
TI  - Three city feasibility study of a body empowerment and HIV prevention intervention among women with drug use histories: Women FIT
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2010-19572-006&site=ehost-live&scope=site
erica.gollub@fiu.edu
VL  - 19
ID  - 1810
ER  - 

TY  - JOUR
AB  - For women with hormone receptor‐positive breast cancer, long‐term use of adjuvant endocrine therapy (AET) significantly reduces the risk of hospitalizations, cancer recurrence and mortality, and increases quality of life. Despite the known benefits of AETs, many patients are nonadherent due to adverse side effects. Furthermore, lower AET adherence among black women may be contributing to the large and growing disparities in mortality outcomes. Real‐time monitoring of treatment‐related adverse symptoms and adherence could result in more effective management of symptoms, higher medication adherence, and ultimately lower recurrence and mortality. To date, however, only a few interventions have aimed to improve AET adherence, even fewer have targeted symptom management as a means to improve adherence, and none have found a statistically significant improvement on adherence. Our proposed study will fill this research gap by testing a web‐enabled app designed with the explicit goal of improving long‐term AET adherence. Patient‐reported symptoms will be integrated directly with the patient's electronic health record, and concerning reports will trigger an alert to the patient's care team in order to improve timely patient‐provider communication and care outside of clinic visits. In a small pilot trial of the study app, we found that participants who had recently initiated a new AET and received weekly reminders to use the app reported significantly higher adherence to AETs at 8 weeks compared with a control group (91% vs. 68%, p=0.02). The proposed study builds on the success of our pilot by: 1) expanding the intervention period to six months in order to capture later‐onset adverse symptoms that are slower to develop; 2) following participants for one to three years, depending on enrollment year, to test longer‐term effects of the intervention on medication adherence and other outcomes; 3) including a larger sample powered to test multiple levels of the intervention; and 4) race‐stratifying to test for a differential impact by race. We will randomize 360 participants to one of three arms: 1) an "App" group (n=120) that will receive weekly reminders to use the study app; 2) an "App+Feedback" group (n=120) that will receive weekly reminders and personalized feedback based on their use of the app; or 3) a "Usual Care" group (n=120) that will receive usual care only. The app will include questions about AET adherence and adverse symptoms with built‐in alerts sent to the patient's care team if any concerning symptoms or trends are reported. We hypothesize that monitoring symptoms and adherence with actionable alerts and tailored feedback reports to patients will result in timelier symptom management and higher long‐term adherence to AET. By evaluating the impact of the intervention on a comprehensive set of measures, including AET adherence, patient outcomes, racial disparities and resource use‐related costs, our study will provide valuable and actionable results for providers, policy makers, and insurers who strive to achieve the "Triple Aim" ‐ reduce costs while improving health outcomes and the patient experience.
AN  - CN-01661258
AU  - Nct
KW  - Breast Neoplasms
PY  - 2018
ST  - THRIVE Breast Cancer App Study
T2  - https://clinicaltrials.gov/show/NCT03592771
TI  - THRIVE Breast Cancer App Study
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01661258/full
ID  - 1594
ER  - 

TY  - JOUR
AB  - BACKGROUND: Long-term use of adjuvant endocrine therapy (AET) among women with early-stage, hormone receptor-positive breast cancer significantly reduces the risk of hospitalizations, cancer recurrence, and mortality. AET is associated with adverse symptoms that often result in poor adherence. A web-enabled app offers a novel way to communicate and manage symptoms for women on AET. In a region with significant racial disparities in breast cancer outcomes, our study tests the impact of a web-enabled app that collects and transmits patient-reported symptoms to healthcare teams to facilitate timely and responsive symptom management on medication adherence. METHODS: In this randomized controlled trial, we randomize 300 patients initiating AET to one of three arms: 1) an "App" group (n = 100) that receives weekly reminders to use the THRIVE study app; 2) an "App+Feedback" group (n = 100) that receives weekly reminders and tailored feedback based on their use of the app; or 3) a "Usual Care" group (n = 100) that receives usual care only. Participants are stratified by race: 50% White and 50% Black. The duration of the intervention is six months following enrollment, and outcomes are assessed at 12-months. The primary outcome is adherence, which is captured using an electronic monitoring pillbox. Secondary outcomes include symptom burden, quality of life, self-efficacy for managing symptoms, and healthcare costs. We also evaluate the impact of the intervention on racial disparities in adherence. Data are derived from three sources: electronic health record data to capture treatment changes, healthcare utilization, and health outcomes; self-report survey data related to adherence, symptom burden, and quality of life; and an electronic medication monitoring device that captures adherence. DISCUSSION: A successful web-enabled intervention could be disseminated across systems, conditions, and populations. By evaluating the impact of this intervention on a comprehensive set of measures, including AET adherence, patient outcomes, and costs, our study will provide valuable and actionable results for providers, policy makers, and insurers who strive to achieve the "Triple Aim" - reduce costs while improving health outcomes and the patient care experience. TRIAL REGISTRATION: NCT03592771. Prospectively registered on July 19, 2018.
AD  - Department of Health Policy and Management, Emory University, Rollins School of Public Health, 1518 Clifton Road, Atlanta, GA, USA.
The West Cancer Center & Research Institute, Memphis, TN, USA.
College of Nursing, The University of Tennessee Health Science Center, 920 Madison Avenue, Memphis, TN, USA.
Department of Preventive Medicine, The University of Tennessee Health Science Center, College of Medicine, 66 N Pauline St, Memphis, TN, USA.
Department of Health Management and Policy, The University of Kentucky, College of Public Health, Lexington, KY, USA.
Department of Patient Reported Outcomes, Vector Oncology, Memphis, TN, USA.
Department of Health Policy and Management, Emory University, Rollins School of Public Health, 1518 Clifton Road, Atlanta, GA, USA. ilana.graetz@emory.edu.
Department of Preventive Medicine, The University of Tennessee Health Science Center, College of Medicine, 66 N Pauline St, Memphis, TN, USA. ilana.graetz@emory.edu.
AN  - 31856812
AU  - Paladino, A. J.
AU  - Anderson, J. N.
AU  - Krukowski, R. A.
AU  - Waters, T.
AU  - Kocak, M.
AU  - Graff, C.
AU  - Blue, R.
AU  - Jones, T. N.
AU  - Buzaglo, J.
AU  - Vidal, G.
AU  - Schwartzberg, L.
AU  - Graetz, I.
C2  - PMC6924011
DA  - Dec 19
DO  - 10.1186/s12913-019-4588-x
DP  - NLM
ET  - 2019/12/21
IS  - 1
KW  - African Americans/statistics & numerical data
Breast Neoplasms/*drug therapy/psychology
Combined Modality Therapy
European Continental Ancestry Group/statistics & numerical data
Female
Humans
Internet/statistics & numerical data
Medication Adherence/statistics & numerical data
*Mobile Applications
Neoplasm Recurrence, Local/drug therapy
Patient Compliance
Quality of Life
Randomized Controlled Trials as Topic
Reminder Systems/statistics & numerical data
Self Report
Surveys and Questionnaires
Adjuvant endocrine therapy
Breast cancer
Medication adherence
Mhealth
Patient-reported outcomes
Randomized controlled trial
LA  - eng
N1  - 1472-6963
Paladino, Andrew J
Anderson, Janeane N
Krukowski, Rebecca A
Waters, Teresa
Kocak, Mehmet
Graff, Carolyn
Blue, Ryan
Jones, Tameka N
Buzaglo, Joanne
Vidal, Gregory
Schwartzberg, Lee
Graetz, Ilana
Orcid: 0000-0003-3664-5815
R01 CA218155/CA/NCI NIH HHS/United States
1R01CA218155/CA/NCI NIH HHS/United States
Clinical Trial Protocol
Journal Article
BMC Health Serv Res. 2019 Dec 19;19(1):977. doi: 10.1186/s12913-019-4588-x.
PY  - 2019
SN  - 1472-6963
SP  - 977
ST  - THRIVE study protocol: a randomized controlled trial evaluating a web-based app and tailored messages to improve adherence to adjuvant endocrine therapy among women with breast cancer
T2  - BMC Health Serv Res
TI  - THRIVE study protocol: a randomized controlled trial evaluating a web-based app and tailored messages to improve adherence to adjuvant endocrine therapy among women with breast cancer
VL  - 19
ID  - 55
ER  - 

TY  - JOUR
AB  - OBJECTIVES: To determine the delay between the onset and the diagnosis and treatment of patients with lung cancer in two cancer centres in the Eastern Black Sea Region of Turkey. SUBJECTS AND METHODS: The records of 226 patients (217 males, 9 females) were evaluated retrospectively for the dates noted for the onset of symptoms, first presentation to a physician, histopathological diagnosis and start of treatment. The median time intervals from the appearance of the first symptom to definitive diagnosis and treatment were calculated. RESULTS: The patients presented to their physicians 30 (range 2-365) days after their complaints began. The time that elapsed between admission and histopathological diagnosis and between the diagnosis and initiation of therapy were 8 (range 1-210) and 17.5 days (range 0-206), respectively. The median time span from presentation to treatment was 30 days (range 1-253). There were no significant time interval differences between onset of symptoms and first presentation and the subsequent diagnostic and therapeutic processes for histopathology, stage of the tumour and treatment procedures (p > 0.05). CONCLUSION: Reasons for the delayed treatment of lung cancer patients were late presentation to the physician and the long time interval between tissue diagnosis and treatment. This delay was mostly associated with a large number of patients and delayed appointments for imaging procedures--the result of organisational problems within the health services of Turkey.
AD  - Department of Chest Diseases, Karadeniz Technical University Medical School, TR-61080 Trabzon, Turkey. tozlu@meds.ktu.edu.tr
AN  - 15181326
AU  - Ozlü, T.
AU  - Bülbül, Y.
AU  - Oztuna, F.
AU  - Can, G.
DA  - Jul-Aug
DO  - 10.1159/000078318
DP  - NLM
ET  - 2004/06/08
IS  - 4
KW  - Delivery of Health Care
Female
Humans
Lung Neoplasms/*diagnosis/*therapy
Male
Middle Aged
Neoplasm Staging
Patient Participation
Referral and Consultation
Retrospective Studies
Time Factors
Turkey
LA  - eng
N1  - Ozlü, Tevfik
Bülbül, Yilmaz
Oztuna, Funda
Can, Gamze
Journal Article
Multicenter Study
Switzerland
Med Princ Pract. 2004 Jul-Aug;13(4):211-4. doi: 10.1159/000078318.
PY  - 2004
SN  - 1011-7571 (Print)
1011-7571
SP  - 211-4
ST  - Time course from first symptom to the treatment of lung cancer in the Eastern Black Sea Region of Turkey
T2  - Med Princ Pract
TI  - Time course from first symptom to the treatment of lung cancer in the Eastern Black Sea Region of Turkey
VL  - 13
ID  - 628
ER  - 

TY  - JOUR
AB  - OBJECTIVES: Recruiting underserved women in breast cancer research studies remains a significant challenge. We present our experience attempting to locate and recruit minority and medically underserved women identified in a Nashville, Tennessee public hospital for a mammography follow-up study. STUDY DESIGN: The study design was a retrospective hospital-based case-control study. METHODS: We identified 227 women (88 African-American, 65 Caucasian, 36 other minority, 38 race undocumented in the medical record) who had undergone screening mammography and received an abnormal result during 2003-2004. Of the 227 women identified, 159 women were successfully located with implementation of a tracking protocol and more rigorous attempts to locate the women using online directory assistance and public record search engines. Women eligible for the study were invited to participate in a telephone research survey. Study completion was defined as fully finishing the telephone survey. RESULTS: An average of 4.6 telephone calls (range 1-19) and 2.7 months (range 1-490 days) were required to reach the 159 women contacted. Within three contact attempts, more cases were located than controls (61% cases vs. 49% controls, p=0.03). African-American women cases were four times likely to be recruited than African-American controls, (OR, 4.07; 95% CI, 1.59-10.30) (p=0.003). After 3 months of effort, we located 67% of African-American women, 63% of Caucasian women, and 56% of other minorities. Ultimately, after a maximum of 12 attempts to contact women, 77% of African-American women and 71% of Caucasian women were eventually found. Of these, 59% of African-American women, 69% Caucasian women, and 50% other minorities were located and completed the study survey for an overall response rate of 59%, 71%, and 47% respectively. CONCLUSIONS: Data collection and study recruitment efforts were more challenging in racial and ethnic minorities. Continuing attempts to contact women may increase minority group study participation but does not guarantee retention or study completion.
AD  - Department of Surgery, Meharry Medical College, 1005 Dr. D.B. Todd Boulevard, Nashville, TN 37208, USA. afair@mmc.edu
AN  - 18289943
AU  - Fair, A. M.
AU  - Wujcik, D.
AU  - Lin, J. M.
AU  - Egan, K. M.
AU  - Grau, A. M.
AU  - Zheng, W.
C2  - PMC2483696
C6  - NIHMS54713
DA  - Jul
DO  - 10.1016/j.cct.2008.01.003
DP  - NLM
ET  - 2008/02/22
IS  - 4
KW  - Adult
African Americans/statistics & numerical data
Aged
Breast Neoplasms/*diagnosis/prevention & control
Case-Control Studies
European Continental Ancestry Group/statistics & numerical data
Female
Follow-Up Studies
Humans
*Mammography
Mass Screening
*Medically Underserved Area
Middle Aged
*Minority Groups
*Patient Selection
*Research Design
Surveys and Questionnaires
Time Factors
United States
LA  - eng
N1  - 1559-2030
Fair, Alecia Malin
Wujcik, Debra
Lin, Jin-Mann S
Egan, Kathleen M
Grau, Ana M
Zheng, Wei
U54 CA915408-04/CA/NCI NIH HHS/United States
U54 CA091408/CA/NCI NIH HHS/United States
U54 CA091408-04/CA/NCI NIH HHS/United States
P20 MD000516-03/MD/NIMHD NIH HHS/United States
U54 CA091408-06A1/CA/NCI NIH HHS/United States
P20RR011792/RR/NCRR NIH HHS/United States
P20 RR011792/RR/NCRR NIH HHS/United States
U54 CA915408-06/CA/NCI NIH HHS/United States
5 P20 MD000516-03/MD/NIMHD NIH HHS/United States
P20 RR011792-08/RR/NCRR NIH HHS/United States
U54 CA091408-05/CA/NCI NIH HHS/United States
P20 MD000516/MD/NIMHD NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Contemp Clin Trials. 2008 Jul;29(4):537-46. doi: 10.1016/j.cct.2008.01.003. Epub 2008 Jan 17.
PY  - 2008
SN  - 1551-7144 (Print)
1551-7144
SP  - 537-46
ST  - Timing is everything: methodologic issues locating and recruiting medically underserved women for abnormal mammography follow-up research
T2  - Contemp Clin Trials
TI  - Timing is everything: methodologic issues locating and recruiting medically underserved women for abnormal mammography follow-up research
VL  - 29
ID  - 503
ER  - 

TY  - JOUR
AB  - Ages at menarche and first birth are established risk factors for breast cancer. The interval between these ages may also affect risk, since the breast is more susceptible to carcinogenic insults during this period than during the parous period. However, few investigators have studied this relation. Using logistic regression, the authors evaluated associations between the timing of reproductive events and breast cancer risk among 4,013 cases and 4,069 controls enrolled in a multicenter, population-based US case-control study of White and African-American women (1994-1998). For White, parous premenopausal and postmenopausal women, those who had an interval of ≥16 years between the ages of menarche and first birth had 1.5-fold (95% confidence interval (CI): 1.0, 2.2) and 1.4-fold (95% CI: 1.1, 1.8) increased risks of breast cancer, respectively, in comparison with those who had ≤5 years between these ages. Adjusting for age at first birth altered these risk estimates somewhat, to odds ratios of 1.5 (95% CI: 0.8, 2.9) and 1.0 (95% CI: 0.6, 1.5), respectively. These associations were stronger for lobular and hormone-receptor-positive tumors but were absent among premenopausal African-American women. The authors conclude that the interval between age at menarche and age at first birth is associated with the risk of hormonally sensitive types of breast cancer, particularly among White women. © The Author 2007. Published by the Johns Hopkins Bloomberg School of Public Health. All rights reserved.
AD  - C.I. Li, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, M4-C308, Seattle, WA 98109-1024, United States
AU  - Li, C. I.
AU  - Malone, K. E.
AU  - Daling, J. R.
AU  - Potter, J. D.
AU  - Bernstein, L.
AU  - Marchbanks, P. A.
AU  - Strom, B. L.
AU  - Simon, M. S.
AU  - Press, M. F.
AU  - Ursin, G.
AU  - Burkman, R. T.
AU  - Folger, S. G.
AU  - Norman, S.
AU  - McDonald, J. A.
AU  - Spirtas, R.
DB  - Embase
Medline
DO  - 10.1093/aje/kwm271
IS  - 2
KW  - adult
article
breast cancer
cancer risk
clinical trial
controlled study
disease association
female
health hazard
human
lung carcinoma
menarche
multicenter study
reproduction
LA  - English
M3  - Article
N1  - L351138459
2008-02-06
PY  - 2008
SN  - 0002-9262
1476-6256
SP  - 230-239
ST  - Timing of menarche and first full-term birth in relation to breast cancer risk
T2  - American Journal of Epidemiology
TI  - Timing of menarche and first full-term birth in relation to breast cancer risk
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L351138459&from=export
http://dx.doi.org/10.1093/aje/kwm271
VL  - 167
ID  - 1219
ER  - 

TY  - JOUR
AB  - Public health actions to improve African American men's ability to make informed decisions about participation in prostate cancer control activities have a greater likelihood of success when they are theory driven and informed by members of the target population. This article reports on formative research to evaluate the usefulness of the theory of reasoned action as a model to explain and predict prostate cancer information-seeking behavior by African American men. Fifty-two men participated in eight focus group interviews. Positive behavioral beliefs for obtaining prostate cancer information from physicians included increasing awareness of and obtaining accurate information about the disease, early detection and screening, and treatment. Negative beliefs included fear, distrust, and inconvenience. Significant others, peers, siblings, and religious leaders were identified as individuals who could influence this behavior. These findings provide additional insight into ways to reach and intervene with African American men to influence this important cancer control activity.
AD  - Institute of Public Health, College of Pharmacy and Pharmaceutical Sciences, Florida A&M University, Tallahassee, FL 32307, USA. levi.ross@famu.edu
AN  - 17142243
AU  - Ross, L.
AU  - Kohler, C. L.
AU  - Grimley, D. M.
AU  - Green, B. L.
AU  - Anderson-Lewis, C.
DA  - Jun
DO  - 10.1177/1090198106290751
DP  - NLM
ET  - 2006/12/05
IS  - 3
KW  - Adult
*African Americans
Aged
Alabama
Focus Groups
Humans
Information Services/*statistics & numerical data
Male
Middle Aged
Mississippi
*Models, Theoretical
Patient Acceptance of Health Care
*Patient Education as Topic
Patient Participation
*Prostatic Neoplasms
LA  - eng
N1  - Ross, Levi
Kohler, Connie L
Grimley, Diane M
Green, B Lee
Anderson-Lewis, Charkarra
U01 CA086128/CA/NCI NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
United States
Health Educ Behav. 2007 Jun;34(3):422-40. doi: 10.1177/1090198106290751. Epub 2006 Nov 29.
PY  - 2007
SN  - 1090-1981 (Print)
1090-1981
SP  - 422-40
ST  - Toward a model of prostate cancer information seeking: identifying salient behavioral and normative beliefs among African American men
T2  - Health Educ Behav
TI  - Toward a model of prostate cancer information seeking: identifying salient behavioral and normative beliefs among African American men
VL  - 34
ID  - 543
ER  - 

TY  - JOUR
AB  - Chronic inhalation of fibrous and nonfibrous particles by rats at high concentrations results in lung tumor formation if the particles are poorly soluble in the lung. Even rather benign nonfibrous particles such as TiO2 produce this result. One significant change during a chronic inhalation exposure of poorly soluble particles of low cytotoxicity ( PSP) is an impairment of normal clearance mechanisms in the alveolar region of the lung in rats, resulting in a continued buildup to high lung burdens accompanied by chronic alveolar inflammation, fibrosis, and mutational events. Since these are obviously high-dose effects, questions about their extrapolation to humans exposed to much lower concentrations have been raised. Results of key studies reported for chronic inhalation of PSP in rats indicate that mechanisms of PSP-induced lung tumors at high doses do not operate at low dose levels. Furthermore, the existence of two thresholds can be postulated: One is a dosimetric threshold for the endpoint alveolar macrophage-mediated clearance, which is related to lung particle overload. The other is a mechanistic threshold for the endpoint mutation, which is determined by the level of antioxidant defenses to counterbalance reactive oxidant species released by activated inflammatory cells. A no-observed-adverse-effect level ( NOAEL) could therefore be based on avoiding alteration of the toxicokinetic of the particles such that the lung burdens stay below the dosimetric threshold. The suggestion that PSP-associated organic compounds (e.g., diesel particulate matter) contribute to the lung tumor responses in rats observed in chronic inhalation studies is not supported by experimental data from in vivo studies. It can be concluded that high-dose rat lung tumors due to PSP should not be used for low-dose extrapolations, and no significant contribution to human lung cancer risk can be predicted from levels of PSP below lung overload. With respect to the pulmonary toxicokinetics of inhaled fibrous particles, the biopersistence of long fibers ( >20 mum) which cannot be phagocytized by alveolar macrophages is a key parameter related to long-term carcinogenic effects. Long fibers with a very low biopersistence should not be considered as carcinogenic. Since the clearance kinetics of fibers can generally be described by a biphasic or multiphasic pattern-fast initial and slow final phase-it is essential that the slow phase of the retention kinetics of fibers longer than 20 mum is considered in a biopersistence assay. Based on the results of such assay, fibers can be classified into one of two categories: a biopersistent fiber that cannot be dissolved in the lung within an acceptable time period; or a biosoluble fiber when even long nonphagocytizable fibers will be disappearing rapidly from the lung. However, in addition to biopersistence, it should be mandatory to evaluate fiber toxicity in an appropriate assay relative to a fiber whose long-term effects are well known. Moreover, for organic fibers it is likely that different rules may have to be established for characterization of their toxic and carcinogenic potential.
AN  - WOS:000172902100003
AU  - Oberdorster, G.
DA  - Jan
DO  - 10.1080/089583701753338622
IS  - 1
N1  - DFG Workshop on Evaluation of Fiber and Particle Toxicity
OCT 26-27, 2000
MUNICH, GERMANY
143
12122559
PY  - 2002
SN  - 0895-8378
SP  - 29-56
ST  - Toxicokinetics and effects of fibrous and nonfibrous particles
T2  - Inhalation Toxicology
TI  - Toxicokinetics and effects of fibrous and nonfibrous particles
VL  - 14
ID  - 2704
ER  - 

TY  - JOUR
AB  - Breast cancer is the second most common cause of cancer death in women. Black women are less likely than white women to develop breast cancer but, they are more likely to die of the disease. Some of this survival discrepancy is likely due to underuse of adjuvant therapies proven to increase survival. Breast cancer treatment often requires coordination among surgeons, pathologists, primary care physicians, medical and radiation oncologists. In NYC, black and Hispanic women who accessed care and underwent surgical treatment of their breast cancer were twice as likely as whites to experience underuse of adjuvant treatment. Disturbingly, 1/3 of these underuse cases were episodes in which the surgeon recommended treatment, the patient did not refuse and yet, care did not ensue. Underuse in such circumstances is attributable to system failures than to specific provider or patient factors. In this proposed randomized controlled trial, the investigators aim to test the effectiveness of a Tracking and Feedback (T&F) registry innovation to increase rates of completed oncology consultation and reduce both underuse of needed adjuvant therapy and racial disparities in receipt of these treatments. The investigators also aim to assess the feasibility of implementing a T&F Registry in these high‐risk hospitals by evaluating implementation effectiveness for that innovation. The investigators have recruited 10 hospitals that serve large proportions of minority women with breast cancer. The investigators will randomize hospitals and aim to recruit 354 women with a new breast cancer, 177 per intervention arm. The investigators choose these "high risk" hospitals because they serve predominantly minority populations, and such hospitals have higher rates of the system failure cause of underuse, and particularly, the type of underuse targeted by our Tracking and Feedback Registry.
AN  - CN-01591303
AU  - Nct
KW  - Breast Neoplasms
PY  - 2012
ST  - Tracking & Feedback Registry to Reduce Breast Cancer Treatment Disparities
T2  - https://clinicaltrials.gov/show/NCT01544374
TI  - Tracking & Feedback Registry to Reduce Breast Cancer Treatment Disparities
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01591303/full
ID  - 1585
ER  - 

TY  - JOUR
AB  - INTRODUCTION: For lung cancer screening, the available data are often derived from patients enrolled prospectively in clinical trials. We, therefore, investigated lung cancer screening patterns among individuals eligible for, but not enrolled in, a screening trial. PATIENTS AND METHODS: From February 2017 through February 2019, we enrolled subjects in a trial examining telephone-based navigation during low-dose computed tomography (LDCT) for lung cancer screening. We identified patients for whom LDCT was ordered and who were approached, but not enrolled, in the trial. We categorized nonenrollment as the patient had declined or could not be reached. We compared the characteristics and LDCT completion rates among these groups and the enrolled population using the 2-sample t test and χ(2) test. RESULTS: Of 900 individuals approached for participation (mean age, 62 years; 45% women, 53% black), 447 were enrolled in the screening clinical trial. No significant demographic differences were found between the enrolled and nonenrolled cohorts. Of the 453 individuals not enrolled, 251 (55%) had declined participation and 202 (45%) could not be reached, despite up to 6 attempts. LDCT completion was significantly associated with enrollment status: 81% of enrolled individuals, 73% of individuals who declined participation, and 49% of those who could not be reached (P < .001). CONCLUSIONS: In the present single-center study, demographic factors did not predict for participation in a lung cancer screening trial. Lung cancer screening adherence rates were substantially lower for those not enrolled in a screening trial, especially for those who could not be contacted. These findings may inform the broader implementation of screening programs.
AD  - Department of Population and Data Sciences, University of Texas Southwestern Medical Center, Dallas, TX; Division of Hematology-Oncology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX; Division of Hematology-Oncology, Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX. Electronic address: david.gerber@utsouthwestern.edu.
Department of Psychology, University of Arizona, Tucson, AZ; Department of Family and Community Medicine, University of Arizona, Tucson, AZ.
Department of Population and Data Sciences, University of Texas Southwestern Medical Center, Dallas, TX.
Parkland Health and Hospital System, Dallas, TX.
Parkland Health and Hospital System, Dallas, TX; Department of Radiology, University of Texas Southwestern Medical Center, Dallas, TX.
Parkland Health and Hospital System, Dallas, TX; Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX.
Parkland Health and Hospital System, Dallas, TX; Division of General Internal Medicine, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX.
Department of Population and Data Sciences, University of Texas Southwestern Medical Center, Dallas, TX; Division of Hematology-Oncology, Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX.
AN  - 32184050
AU  - Gerber, D. E.
AU  - Hamann, H. A.
AU  - Chavez, C.
AU  - Dorsey, O.
AU  - Santini, N. O.
AU  - Browning, T.
AU  - Ochoa, C. D.
AU  - Adesina, J.
AU  - Natchimuthu, V. S.
AU  - Steen, E.
AU  - Zhu, H.
AU  - Lee, S. J. C.
C2  - PMC7305960
C6  - NIHMS1576794
DA  - Jul
DO  - 10.1016/j.cllc.2020.02.010
DP  - NLM
ET  - 2020/03/19
IS  - 4
KW  - *Adherence
*Communication
*Computed tomography
*Demographics
*Underserved
LA  - eng
N1  - 1938-0690
Gerber, David E
Hamann, Heidi A
Chavez, Claudia
Dorsey, Olivia
Santini, Noel O
Browning, Travis
Ochoa, Cristhiaan D
Adesina, Joyce
Natchimuthu, Vijaya Subbu
Steen, Eric
Zhu, Hong
Lee, Simon J Craddock
K01 CA234425/CA/NCI NIH HHS/United States
K24 CA201543/CA/NCI NIH HHS/United States
P30 CA142543/CA/NCI NIH HHS/United States
R24 HS022418/HS/AHRQ HHS/United States
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Clin Lung Cancer. 2020 Jul;21(4):326-332. doi: 10.1016/j.cllc.2020.02.010. Epub 2020 Feb 26.
PY  - 2020
SN  - 1525-7304 (Print)
1525-7304
SP  - 326-332
ST  - Tracking the Nonenrolled: Lung Cancer Screening Patterns Among Individuals not Accrued to a Clinical Trial
T2  - Clin Lung Cancer
TI  - Tracking the Nonenrolled: Lung Cancer Screening Patterns Among Individuals not Accrued to a Clinical Trial
VL  - 21
ID  - 48
ER  - 

TY  - JOUR
AB  - Background: Rural African American (AA) seniors may experience significant challenges during cancer treatment. Previous research suggests community health workers (CHWs) can provide effective cancer patient navigation (CPN) support. Objectives: To develop a Train the Trainers (TTT) program for CHWs in rural Central Virginia who would navigate local AA seniors with cancer and train their support persons to provide similar types of assistance. Methods: We conducted focus groups with rural AA seniors, consulted with experienced CHW trainers, recruited and trained CHWs through a combination of online learning and distance education, evaluated the TTT via surveys and focus groups, and hired CHWs to the study team. Results/Lessons Learned: Lessons learned from our TTT experience include the value of incorporating CHW trainers and trainees as full members of the research team. Conclusions: Training should be accessible and flexible, providing trainees community-level resources and enriched educational experiences. Findings have informed a culturally tailored support CHW intervention to address cancer diagnosis and treatment needs for older rural AAs.
AN  - WOS:000313396400010
AU  - Klimmek, R. K.
AU  - Noyes, E.
AU  - Edington-Saunders, K.
AU  - Logue, C.
AU  - Jones, R.
AU  - Wenzel, J.
DA  - Sum
DO  - 10.1353/cpr.2012.0017
IS  - 2
N1  - 22820226
PY  - 2012
SN  - 1557-0541
SP  - 167-174
ST  - Training of Community Health Workers to Deliver Cancer Patient Navigation to Rural African American Seniors
T2  - Progress in Community Health Partnerships-Research Education and Action
TI  - Training of Community Health Workers to Deliver Cancer Patient Navigation to Rural African American Seniors
VL  - 6
ID  - 3066
ER  - 

TY  - JOUR
AB  - In a previous report, we demonstrated the efficacy of an intervention to promote colorectal cancer screening among African Americans in a controlled community intervention trial. Participants in the intervention, named EPICS (Educational Program to Increase Colorectal Cancer Screening), were twice as likely to be screened after six months as those in the control group. In the current project, we put the intervention into practice through an academic-health department partnership, and the intervention performed as well as it had in the controlled trial. This success may be due to the community-based participatory methods used in designing and testing the intervention.
AD  - Morehouse School of Medicine, Community Health & Preventive Medicine, Georgia, USA.
AN  - 23067354
AU  - Smith, S.
AU  - Johnson, L.
AU  - Wesley, D.
AU  - Turner, K. B.
AU  - McCray, G.
AU  - Sheats, J.
AU  - Blumenthal, D.
C2  - PMC3476058
C6  - NIHMS388093
DA  - Oct
DO  - 10.1111/j.1752-8062.2012.00439.x
DP  - NLM
ET  - 2012/10/17
IS  - 5
KW  - *African Americans/statistics & numerical data
Colorectal Neoplasms/*diagnosis/epidemiology/ethnology
Controlled Clinical Trials as Topic
*Early Detection of Cancer/statistics & numerical data
Female
Georgia/epidemiology
Humans
Incidence
Male
*Translational Medical Research/statistics & numerical data
LA  - eng
N1  - 1752-8062
Smith, Selina
Johnson, Larry
Wesley, Diane
Turner, Kim B
McCray, Gail
Sheats, Joyce
Blumenthal, Daniel
U54 MD007588/MD/NIMHD NIH HHS/United States
DP000049-01/DP/NCCDPHP CDC HHS/United States
U54 CA118623/CA/NCI NIH HHS/United States
5U48DP001907/DP/NCCDPHP CDC HHS/United States
1U01CA114625/CA/NCI NIH HHS/United States
U54 CA118638/CA/NCI NIH HHS/United States
UL1 TR000454/TR/NCATS NIH HHS/United States
U01 CA114652/CA/NCI NIH HHS/United States
U48 DP001907/DP/NCCDPHP CDC HHS/United States
U54CA 118638/CA/NCI NIH HHS/United States
UL1 RR025008/RR/NCRR NIH HHS/United States
U54 CA118948/CA/NCI NIH HHS/United States
P20 RR011104/RR/NCRR NIH HHS/United States
G12 MD007585/MD/NIMHD NIH HHS/United States
U48 DP000049-01/DP/NCCDPHP CDC HHS/United States
Journal Article
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, P.H.S.
Clin Transl Sci. 2012 Oct;5(5):412-5. doi: 10.1111/j.1752-8062.2012.00439.x. Epub 2012 Aug 7.
PY  - 2012
SN  - 1752-8054 (Print)
1752-8054
SP  - 412-5
ST  - Translation to practice of an intervention to promote colorectal cancer screening among African Americans
T2  - Clin Transl Sci
TI  - Translation to practice of an intervention to promote colorectal cancer screening among African Americans
VL  - 5
ID  - 350
ER  - 

TY  - JOUR
AB  - Background Adults with chronic disease are often unable to meet medication and food needs, but no study has examined the relationship between cost-related medication underuse and food insecurity in a nationally representative sample. We examined which groups most commonly face unmet food and medication needs. Methods Cross-sectional analysis of data from chronically ill participants (self-report of arthritis, diabetes mellitus, cancer, asthma, chronic obstructive pulmonary disease, stroke, hypertension, coronary heart disease, or presence of a "psychiatric problem") aged ≥20 years, in the 2011 National Health Interview Survey. We fit logistic regression models to identify factors associated with food insecurity, cost-related medication underuse, or both. Results There were 9696 adult National Health Interview Survey (NHIS) participants who reported chronic illness; 23.4% reported cost-related medication underuse; 18.8% reported food insecurity; and 11% reported both. Adults who reported food insecurity were significantly more likely to report cost-related medication underuse (adjusted odds ratio [aOR] 4.03). Participants with both cost-related medication underuse and food insecurity were more likely to be Hispanic (aOR 1.58), non-Hispanic black (aOR 1.58), and have more chronic conditions (aOR per additional chronic condition 1.56) than patients reporting neither. They also were less likely to have public, non-Medicare insurance (aOR 0.70) and report participation in the Special Supplemental Nutrition Assistance Program for Woman, Infants, and Children (aOR 0.39). Conclusions Approximately 1 in 3 chronically ill NHIS participants are unable to afford food, medications, or both. WIC and public health insurance participation are associated with less food insecurity and cost-related medication underuse. © 2014 Elsevier Inc. All rights reserved.
AD  - S.A. Berkowitz, General Medicine Division, Department of Medicine, Massachusetts General Hospital, 50 Staniford St., Boston, MA 02141, United States
AU  - Berkowitz, S. A.
AU  - Seligman, H. K.
AU  - Choudhry, N. K.
DB  - Embase
Medline
DO  - 10.1016/j.amjmed.2014.01.002
IS  - 4
KW  - adult
arthritis
article
asthma
basic needs
cerebrovascular accident
chronic disease
chronic obstructive lung disease
chronic patient
controlled study
cost related medication underuse
cross-sectional study
diabetes mellitus
drug cost
female
food assistance
food insecurity
health survey
Hispanic
human
hypertension
ischemic heart disease
major clinical study
male
malignant neoplasm
medically underserved
medication compliance
mental disease
middle aged
needs assessment
patient participation
priority journal
public health insurance
self report
socioeconomics
young adult
LA  - English
M3  - Article
N1  - L372676498
2014-04-02
2014-04-04
PY  - 2014
SN  - 0002-9343
1555-7162
SP  - 303-310.e3
ST  - Treat or eat: Food insecurity, cost-related medication underuse, and unmet needs
T2  - American Journal of Medicine
TI  - Treat or eat: Food insecurity, cost-related medication underuse, and unmet needs
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L372676498&from=export
http://dx.doi.org/10.1016/j.amjmed.2014.01.002
VL  - 127
ID  - 1033
ER  - 

TY  - JOUR
AB  - The objective of this study is to use the novel approach of neuro‐reinforcement based on decoded fMRI information to reduce fear responses to fearful stimuli (e.g., spiders, heights) in individuals with phobias, directly and unconsciously in the brain, without repeatedly exposing participants to their feared stimuli. Specific Aims (1) confirm that our method engages the neurobiological target (amygdala reactivity to images of a feared object) in a population of individuals with specific phobia; and (2) to determine dosage‐response optimization. The investigators aim to enroll a total of 60 participants (30 patients and 30 controls in the R61 phase). The investigators seek female and male participants in equal proportions. The age range of the subjects will be between 18 and 65. The investigators will work to achieve an ethnic and racial distribution that is consistent with the very diverse community found in the Los Angeles area and the UCLA campus: Hispanic/Latino 56.4%, African American 7.7%; Asian/Filipino/Pacific Islander 15.8%; White (non‐Hispanic) 17.5% (California Health Interview Survey). Potential research participants' eligibility will be confirmed at the beginning of the first session, but eligibility criteria will also be listed in recruitment materials. A research assistant or other personnel possessing current CITI and HIPAA certification will conduct an eligibility screening interview in a private room. Following onset of the study, subjects who are unable to attend to or respond to stimuli as required by the experimental protocol will be excluded. Anxiety disorders, the most common group of mental disorders in the United States, represent a major mental health problem. Phobias, in which fear and anxiety are triggered by a specific stimulus or situation, are the largest category of anxiety disorders and affect 5 ‐ 12% of the world's population. The treatment of anxiety disorders represents almost one third of mental health costs annually. Specific phobias and other anxiety disorders, such as PTSD, represent a significant driving force in seeking mental health‐related treatment. These disorders present a major challenge, and researchers have previously explored various ways to address this challenge. One of the most effective psychotherapy methods for the treatment of phobias involves exposure, or repeated approach towards feared stimuli, often in a hierarchy of least to most anxiety‐provoking distances or situations. Exposure‐based therapies are effective in reducing symptoms, but their effectiveness depends on the individual's capacity or willingness to consciously confront their feared object. The associated distress can be so extreme that it prevents patients from seeking treatment, and contributes to attrition from exposure once treatment begins: estimated dropout rates can top 70%, with three out of five refusing to even begin treatment, meaning that as low as 12% of patients receive adequate treatment. Even other therapies that require conscious engagement with the aversive stimulus, such as cognitive therapies, show high dropout rates. As a result, there is an unmet need for treatment that minimizes attrition and subjective patient discomfort, especially for clinical populations for whom conventional exposure‐based therapies are prohibitively aversive. This problem has led some researchers to develop less aversive exposure‐based therapies—for example, by showing the phobic stimulus very briefly, and immediately following it with a visual mask. However, in general, learning effects are weak and short‐lasting when stimuli are fully masked because masking greatly reduces the signal strength of neural representation in the visual system. It would seem ideal if the investigators could capitalize on the potential benefits of fully unconscious presentation without sacrificing neural signal strength of the relevant visual representation. In the R61 phase, the investigators will enroll 30 patients, who will be required to meet the DSM‐5 criteria for specific phobias. Patients w ll be assessed by trained clinical personnel using the Anxiety and Related Disorders Interview Schedule (ADIS) for DSM‐5 ‐ Adult version, a structured clinical interview based on the DSM‐5 criteria (Brown & Barlow 2014) and the Fear Survey Schedule (Wolpe & Lang 1964). Participants presenting with post‐traumatic stress disorder (PTSD), Obsessive Compulsive Disorder, Substance Use Disorder, Current Major Depression, Bipolar Disorder, Psychosis, neurologic diagnoses or unstable serious medical conditions will be excluded. Participants will also be excluded if (a) if they can touch the phobic object category during the pre‐training BAT without presenting significant distress, and/or (b) if they are currently prescribed psychotropic medication. Importantly, participants who cannot even view images of a feared stimulus without presenting significant distress will also be excluded, as the pre‐treatment and post‐treatment tests of biological target engagement require that participants view images belonging to the feared object category. The investigators will enroll 30 healthy individuals (controls) who obtain subclinical scores on the Fear Survey Schedule (Wolpe & Lang 1964). Roles and Responsibilities Our study procedures and results will be monitored by the Principal (Hakwan Lau) and Co‐Principal (Michelle Craske) Investigators, the UCLA Institutional Review Board, and an independent Data Safety and Monitoring Board. Drs. Lau and Craske will monitor adherence to the confidentiality rules, the quality of the data, their timeliness, and the correctness of their entry into computer files. This is a routine part of their supervision of postdoctoral fellows, graduate students and assistants. Every two weeks, data safety will be reviewed. Trial Safety Specific Events That Would Preclude a Participant from Continuing the Intervention A participant will be precluded from continuing the intervention in the event of an adverse event rated 3 ‐5 according to the scale in the Reporting Adverse Events section below. Such events could include an injury or other event resulting in hospitalization or a persistent or significant disability or incapacity, a life‐threatening or disabling event, or a fatal event. Procedures for Managing Any Medication Related issues N/A Potential Risks and Protections Against Risk (see Human Subjects for more details) There are no known physical, social, legal, or other adverse effects associated with participation in this study. The risks from this study to the subject are minimal. At all times, participants will be informed that they are welcome to stop any part of the procedures at any time without penalty and to discuss their concerns or ask questions of the research staff at any time. Subjects will be informed that they should contact the PIs if they experience a research‐related injury. It is possible that some participants may become uncomfortable revealing personal information when completing questionnaires and/or become fatigued and bored during the experimental procedures. Participants may become physically uncomfortable with the electrodes attached to their person and/or with sitting for long periods of time during the psychophysiological procedures. They also may become anxious when exposed to the psychophysiological equipment and procedures. It is possible that participants may experience emotional distress when presented with feared stimuli at the outset of the study. All on‐site study personnel will be clinicians who will be available to address participants' needs in this regard. Clinical interviewing will be conducted by trained advanced clinical psychology PhD students who are sensitive to the potential discomfort that participants may have while discussing personal matters. All diagnostic procedures will be conducted by staff members experienced in performance of similar clinical studies, with appropriate Human Subjects and HIPAA certifications. Interviews will be conducted in sound protected rooms. All of the procedures, including fear conditioning, have been used exte sively in prior studies without adverse events. Our instrumentation for psychophysiological recordings meets all standards for non‐ invasive recordings, is well maintained, and has approval from the US Food and Drug Administration. Standard application procedures are observed to minimize risk of infection. When participants arrive for their first session, they will participate in a familiarization period in the experimental room in Franz Hall and they will be allowed and encouraged to ask questions about the equipment and procedures during and after the equipment is set‐up. Subjects will be protected by: a) respecting their right to refuse to attempt or continue any task, b) providing reassurance or intervention if needed, and c) terminating the experimental procedures for participants that become acutely distressed during a session. To minimize the risks of fatigue, all participants appearing fatigued during the procedures will be allowed to take a break. During both the decoder construction and the neuro‐reinforcement sessions, participants will not be viewing images belonging to the Active or Control fear stimuli categories, so discomfort should be minimal. However, in the event that some subjects are unable to comfortably tolerate such long scanning times, sessions may be broken up into shorter sessions. Decoder construction can be separated into two 1‐hour sessions, and neuro‐reinforcement can be broken into twice as many 45‐minute sessions. For example, instead of 3 days 1.5‐hour sessions of neuro‐reinforcement, a subject could undertake 6 days of 45‐minute sessions. There are no known significant side effects associated with MRI procedures. The magnetic fields, at the strengths used, are assumed to be without harm, as our MRI scanning procedures fall within the FDA guidelines for radiofrequency electromagnetic field exposure. The investigators feel these are safe levels and are less hazardous than a comparable X‐ray computed tomography examination. Exceptions include if a person has electrically, magnetically, or mechanically activated implants (such as cardiac pacemakers), clips on blood vessels in his or her brain, or other metallic objects in his or her body such as shrapnel, bullets, buckshot, or metal fragments; subjects with such attributes will not be allowed to participate. Although there are no known risks of an MRI scan to the unborn fetus, the investigators will not permit anyone who is or is suspected to be pregnant to participate. Subjects will thus be given an MRI screening questionnaire prior to participation, and will be excluded from participating in brain imaging studies if they indicate any risk factors on this questionnaire. The most serious potential risks are related to the possibility of ferromagnetic objects in the vicinity of the high‐ field magnet in the scanner. These objects could conceivably become projectiles due to the powerful magnetic field. Therefore, subjects will be asked to place all metallic and magnetic objects in their possession (e.g., keys, jewelry, credit cards) in a locker outside the magnet room. Most people do not find magnetic resonance scans uncomfortable, although mild discomfort has been reported on some occasions: 1. Some subjects may experience claustrophobia (fear of enclosed spaces) as they will be lying on a table in a horizontal cylinder that is only slightly wider in all directions than their body, and extra movement will be minimized as their head is secured. They will be instructed to notify the researcher in charge of the scan beforehand if they are prone to claustrophobia. 2. The MR scanner makes loud knocking or beeping sounds during imaging; earplugs will be provided to help reduce this noise. 3. Due to the rapid rate of change in magnetic gradients during imaging, the possibility exists for peripheral nerve stimulation. If this happens, subjects may feel creeping or tingling sensations, typically along their arms or lower back. 4. Dizziness and nausea may occur if the subjects move their head quickly in the bore of the magnet. 5. Finally, there may be some heating from the radio frequency coils, the cables to the coils, or response and physiological monitoring devices. The machine will be calibrated so that this heating will be no more than one degree of body temperature. Subjects will be instructed to immediately notify the investigators if they feel uncomfortable at any time, for whatever reason. Subjects will be able to contact the research staff at any point in the study via a microphone mounted on the MRI scanner. They will also be instructed on how to use the emergency handheld device to inform the operator if they wish to immediately stop scanning and be removed from the magnet. The MRI can be stopped at any time at their request. There is no known radiological risk of MRI scanning. Subjects will be screened in a standard fashion for magnet sensitive substances (metal prosthesis, etc.), for claustrophobia, and for other medical and psychiatric conditions prior to the study. In addition, any participant who has been told he or she has cardiovascular disease, or who is pregnant or nursing will be excluded. Participants will also be screened for neurological, psychiatric and substance abuse problems and a history of other medical problems or medical treatment related to cerebral metabolism and blood flow. Because the magnetism of the fMRI machine attracts certain metals, people with these metals in them (specifically pacemakers, infusion pumps, aneurysm clips, metal prostheses, joints, rods, or plates) will be excluded from the study. The "metal" in dental fillings is less susceptible to magnetism and is therefore allowed. Procedures that will minimize discomfort during the scanning include the option of an MRI simulation laboratory and for an initial familiarization session in the scanner. Also, the use of headphones and video systems will minimize the potential discomfort of the scanner environment. Participants will be encouraged to ask questions about the equipment and procedures. Experimental procedures will be terminated if participants become overly distressed. A protocol outlining the specific steps on how to act if patients become overly distressed during these tasks will be available to all staff members. To ensure safety during MRI sessions, every researcher in the lab will complete a safety training course, every year. Subjects will be carefully screened to make sure they do not have any metal before being taken into the room with the MRI scanner. Subjects will wear earplugs to protect their hearing while in the MRI scanner. Volunteers who exhibit contraindications for MRI exams, such as pacemakers, surgical aneurysm clips and known metal fragments embedded in the body including eyes, will be excluded. Women of childbearing age will not be included in this study if they are or think they might be pregnant. Subjects with suspected cerebrovascular or pulmonary disease or a history of such will be excluded. Subjects who have experienced claustrophobia, or who have a history of migraine, arterial hypertension, coronary heart disease, asthma, or anemia will be excluded. Based on our current ethics protocol approved by UCLA, in all MRI studies the investigators will also exclude subjects with any history of epilepsy or other neurological disorders. Subjects will be carefully screened for these conditions prior to scanning, using a standardized form/checklist. Subjects will also be instructed not to use any recreational drugs (e.g., marijuana, cocaine) within 48 hours before participating, nor consume more than 3 units of alcoholic beverages within 24 hours before taking part in the study. Subjects will receive these instructions a week before participating, and their compliance will be checked again on the day of the experiment. Consent Procedures and Subject Privacy Signed consent will be obtained from each participant. Member(s) of the study staff will meet with the prospective participants in a private room to review the consent documents and/or provide an oral explanation of the study. Any experiments involving MRI scanning will be ndertaken in compliance with the safety guidelines for MRI research, and prior to participating in the study, subjects will be informed of the risks and benefits of the study, and will fill out and sign the screening questionnaire and informed consent form. Individuals will be given a chance to ask questions before making a considered decision about whether or not to participate in the study. Subjects will be given as long as necessary to decide whether they wish to participate in the study. The investigator or study team member(s) will confirm that subjects understand the information conveyed during the consent process. Study procedures and consent forms will be reviewed and approved by the UCLA Institutional Review Boards. Participants will be provided a copy of the consent form and the original will be maintained in laboratory files. Trial Stopping Rules Please see the procedures described in the Reporting Adverse Events section below. Management of Incidental Findings If the Depression, Anxiety and Stress Scale reveals scores at any point of assessment that are in the severe range for depression, participants will be evaluated by PI Craske for consideration of referral to alternative treatment. In addition, Dr. Craske will follow a detailed, written action plan if the participant discloses suicidal intent/plan. There is a small chance that the MRI scan will discover a brain injury, such as a brain tumor. In that case, the investigators will send the participant's scan to a radiologist, who will check the scan. If the finding is confirmed to be a clinically relevant abnormality that can be treated, this information is passed on to the participant's general practitioner. Each participant will be required to provide the name and address of his or her general practitioner. Process for Disclosure of Conflicts of Interest N/A Data Security Please see the data security measures described in the Data Management, Analysis, and Quality Assurance section below. Reporting Adverse Events Per UCLA IRB requirements, the investigators will report any Adverse Events (including Serious Adverse Events) that meet the definition of an Unanticipated Problem to the IRB within 10 working days of PI/Co‐PI awareness, with the exception of unexpected internal (on‐site) death, which would be reported within 3 working days. The investigators will comply with the NIMH Reportable Events Policy. In addition to Unanticipated Problems Involving Risks to Subjects or Others, the following adverse events will be monitored: deaths, suicide attempts, study dropout, psychiatric hospitalizations, and clinical deterioration, defined as emergent suicidal ideation or suicidal plan, development of serious substance abuse, or emergence of a new psychiatric or medical diagnosis or behavior posing significant risk to the subjects of others. The following grading system will be used to assess the seriousness of any adverse events: 0 No adverse event or within normal limits 1. Mild adverse event 2. Moderate adverse event 3. Severe adverse event resulting in hospitalization or a persistent or significant disability/incapacity 4. Life‐threatening or disabling adverse event 5. Fatal adverse event The Ph.D. level project coordinator will be trained in what events to look for and to report any such events to Drs. Lau and Craske. If the event is graded 2‐4, Dr. Craske, a licensed clinical psychologist, will interview the participant and take the appropriate action. The UCLA IRB and NIH will be notified within 24 hours of any serious adverse events (SAEs), in the 3‐5 range. All SAEs will be reported to the DSMB within 2 days of their occurrence. Within a week of any SAEs, the DSMB together with Drs. Lau and Craske will determine whether the adverse event affects the Risk/Benefit ratio of the study and whether modifications to the protocol (at Risks to Subjects) or consent form (at Risks and Inconveniences) are required. Furthermore, the DSMB shall have the discretion and responsibility to recommend that the study be terminated. Drs. Lau and Craske will conduct a eview of all non‐serious adverse events at least quarterly. They will evaluate the types, frequency, and severity of the adverse events and determine if modifications to the protocol or consent form are required. A summary of the non‐serious adverse events will be reported to the IRB and DSMB periodically or, at minimum, when yearly re‐approval of the IRB protocol is sought. The summary will include number of Participants enrolled, treatment retention and reasons for drop‐out, and a description of graded adverse events to date. Drs. Lau or Craske or the IRB has the authority to stop or modify the study. Data Management, Analysis and Quality Assurance All data will be specifically obtained for research purposes during individual test sessions. Sources of material obtained from participants will include amygdala reactivity, skin conductance response (SCR), and subjective fear ratings in both the R61 and R33 phases. In the R33 phase the investigators will also assess spontaneous recovery with the Behavioral Approach Test (BAT) and Anxiety and Related Disorders Interview Schedule (ADIS). The identifying information that will be collected from study participants includes all information required to create a GUID: sex, first name, last name, middle name, date of birth, and city/municipality of birth. The investigators will also collect email addresses. A member of the research team with current CITI and HIPAA certification will assign a code number to each data file. The key pairing each code number with each participant's name and other identifying information will be stored separately from the data files themselves, in a locked filing cabinet to which only declared research personnel have access. All of the interviews and study procedures will be conducted in private, locked room where only the experimenter and participant are present in order to protect each participant's privacy. The data collected will be used only for this study. Upon completion of the study, all data files will be stripped of personal identifiers and/or the key to the code destroyed. The investigators agree to follow the OHRPP Data Security in Research guidance and procedures. The investigators will recruit subjects through community outreach. Patients meeting the DSM‐5 criteria for specific phobias will be recruited through the UCLA Anxiety and Depression Research Center and advertising in the local community. In order to maximize the fidelity and reliability of the between‐subjects decoder for fearful objects, it is necessary to establish a pool of hyper‐realigned brain activity patterns from control subjects matching the demographics of the patient population. Therefore, the investigators will attempt to achieve a high level of diversity in our sample by placement of advertisements and flyers in local community recreational centers and religious centers in areas more densely populated by Asians, Hispanics, and African Americans as well as through Internet‐based advertisements. Every month, the investigators will monitor the ethnic and racial distributions in the recruited sample. If the investigators observe that the investigators are not reaching the targeted level of diversity, the investigators will make further outreach efforts.
AN  - CN-01662871
AU  - Nct
KW  - Phobic Disorders
PY  - 2018
ST  - Treating Phobia With Multivoxel Neuro-reinforcement
T2  - https://clinicaltrials.gov/show/NCT03655262
TI  - Treating Phobia With Multivoxel Neuro-reinforcement
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01662871/full
ID  - 1586
ER  - 

TY  - JOUR
AB  - OBJECTIVE: Few decision aids emphasize active surveillance (AS) for localized prostate cancer. Concept mapping was used to produce a conceptual framework incorporating AS and treatment. METHODS: Fifty-four statements about what men need to make a decision for localized prostate cancer were derived from focus groups with African American, Latino and white men previously screened for prostate cancer and partners (n = 80). In the second phase, 89 participants sorted and rated the importance of statements. RESULTS: An eight cluster map was produced for the overall sample. Clusters were labelled Doctor-patient exchange, Big picture comparisons, Weighing the options, Seeking and using information, Spirituality and inner strength, Related to active treatment, Side-effects and Family concerns. A major division was between medical and home-based clusters. Ethnic groups and genders had similar sorting, but some variation in importance. Latinos rated Big picture comparisons as less important. African Americans saw Spirituality and inner strength most important, followed by Latinos, then whites. Ethnic- and gender-specific concept maps were not analysed because of high similarity in their sorting patterns. CONCLUSIONS: We identified a conceptual framework for management of early-stage prostate cancer that included coverage of AS. Eliciting the conceptual framework is an important step in constructing decision aids which will address gaps related to AS.
AD  - Institute for Social and Economic Research University of Essex, Colchester, UK.
School of Public Health, The University of Texas Health Sciences Center, Houston, TX, USA.
Department of Family and Community Medicine, Texas Tech University Health Sciences Center, El Paso, TX, USA.
Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Graduate College of Social Work, University of Houston, Houston, TX, USA.
Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
AN  - 24506829
AU  - McFall, S. L.
AU  - Mullen, P. D.
AU  - Byrd, T. L.
AU  - Cantor, S. B.
AU  - Le, Y. C.
AU  - Torres-Vigil, I.
AU  - Pettaway, C.
AU  - Volk, R. J.
C2  - PMC4128894
C6  - NIHMS609467
DA  - Dec
DO  - 10.1111/hex.12175
DP  - NLM
ET  - 2014/02/11
IS  - 6
KW  - Aged
*Decision Making
*Decision Support Techniques
Disease Management
Focus Groups
Humans
Male
Middle Aged
*Patient Participation
Physician-Patient Relations
Prostatic Neoplasms/ethnology/*therapy
Watchful Waiting/*methods
cancer
concept mapping
decision making
prostate neoplasms
qualitative research
LA  - eng
N1  - 1369-7625
McFall, Stephanie L
Mullen, Patricia D
Byrd, Theresa L
Cantor, Scott B
Le, Yen-Chi
Torres-Vigil, Isabel
Pettaway, Curtis
Volk, Robert J
K01 CA151785/CA/NCI NIH HHS/United States
R25 CA057712/CA/NCI NIH HHS/United States
1U48DP001949-01/DP/NCCDPHP CDC HHS/United States
K01 CA151785-04/CA/NCI NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, P.H.S.
Health Expect. 2015 Dec;18(6):2079-90. doi: 10.1111/hex.12175. Epub 2014 Feb 9.
PY  - 2015
SN  - 1369-6513 (Print)
1369-6513
SP  - 2079-90
ST  - Treatment decisions for localized prostate cancer: a concept mapping approach
T2  - Health Expect
TI  - Treatment decisions for localized prostate cancer: a concept mapping approach
VL  - 18
ID  - 296
ER  - 

TY  - JOUR
AB  - PURPOSE The treatment of childhood nasopharyngeal carcinoma has been adapted from adult regimens; pediatric-specific studies are limited. The ARAR0331 study sought to evaluate the impact of induction chemotherapy (IC) and concurrent chemoradiotherapy (CCR). PATIENTS AND METHODS Patients with American Joint Committee on Cancer stages IIb to IV were scheduled to receive three cycles of IC with cisplatin and fluorouracil, followed by CCR with three cycles of cisplatin. Patients with complete or partial response to IC received 61.2 Gy to the nasopharynx and neck, and patients with stable disease received 71.2 Gy. RESULTS Between February 2006 and January 2012, 111 patients (75 male) were enrolled. Median age was 15 years, and 46.8% of the patients were African American. After a feasibility analysis, the study was amended to reduce cisplatin to two cycles during CCR. The 5-year event-free survival (EFS) and overall survival estimates were 84.3% and 89.2%, respectively. The 5-year EFS for stages IIb, III, and IV were 100%, 82.8%, and 82.7%, respectively. The 5-year cumulative incidence estimates of local, distant, and combined relapse were 3.7%, 8.7%, and 1.8%, respectively. Patients treated with three versus two CCR cycles of cisplatin had improved 5-year postinduction EFS (90.7% v 81.2%, P = .14). CONCLUSION Patients in ARAR0331 were characterized by advanced disease and by a high proportion of black children and adolescents. Treatment with IC and CRT resulted in excellent outcomes. A radiation dose reduction is possible for patients responding to IC. Although the outcomes are comparable, we observed a trend toward decreased EFS for patients assigned to receive fewer doses of cisplatin during CCR.
AD  - C. Rodriguez-Galindo, Departments of Global Pediatric Medicine and Oncology, St Jude Children's Research Hospital, 262 Danny Thomas Pl, Memphis, TN, United States
AU  - Rodriguez-Galindo, C.
AU  - Krailo, M. D.
AU  - Krasin, M. J.
AU  - Huang, L.
AU  - Beth McCarville, M.
AU  - Hicks, J.
AU  - Pashankar, F.
AU  - Pappo, A. S.
DB  - Embase
Medline
DO  - 10.1200/JCO.19.01276
IS  - 35
KW  - amifostine
cisplatin
fluorouracil
adolescent
adult
article
bone metastasis
cancer recurrence
cancer survival
chemoradiotherapy
child
childhood cancer
clinical trial
conformal radiotherapy
continuous infusion
epithelioid sarcoma
event free survival
female
follow up
human
induction chemotherapy
intensity modulated radiation therapy
lung metastasis
major clinical study
male
multiple cycle treatment
nasopharynx
nasopharynx carcinoma
neck
overall survival
priority journal
radiation dose
radiation dose reduction
LA  - English
M3  - Article
N1  - L2004303261
2020-01-01
2020-01-14
PY  - 2019
SN  - 1527-7755
0732-183X
SP  - 3369-3376
ST  - Treatment of childhood nasopharyngeal carcinoma with induction chemotherapy and concurrent chemoradiotherapy: Results of the Children's Oncology Group ARAR0331 study
T2  - Journal of Clinical Oncology
TI  - Treatment of childhood nasopharyngeal carcinoma with induction chemotherapy and concurrent chemoradiotherapy: Results of the Children's Oncology Group ARAR0331 study
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L2004303261&from=export
http://dx.doi.org/10.1200/JCO.19.01276
VL  - 37
ID  - 863
ER  - 

TY  - JOUR
AB  - Premature menopause occurs frequently in breast cancer patients (BC), but there are no specific data about its management. Although hormone therapy (HT) is very efficient in relieving menopausal symptoms, the prescription of this type of drug is still not indicated for BC patients, since in one randomized study (of two existing) an increased rate of new breast cancer (BC) occurrence in HT users was reported. The efficacy of other medications, such as serotonin re-uptake inhibitors, clonidine, veralipride, gabapentin, is much lower than that of HT. The efficacy of black cohosh and phyto-oestrogens remains to be proven. The safety of medications other than HT has not been established either in BC patients. There is a need for randomised trials assessing the safety of these drugs. In the meantime, patients should be informed about the absence of safety data. Prevention and treatment of urogenital atrophy is achieved by using vaginal moistures and weak oestrogen topical preparations. Prevention and treatment of osteoporosis is achieved by a healthy life style, adequate calcium and vitamin D intake and if necessary biphosphonate therapy.
AD  - Department of Obstetrics and Gynaecology, Free Universities of Brussels (VUB-ULB) CHU Saint-Pierre, Brussels, Belgium.
AN  - 17685250
AU  - Deniz, G.
AU  - Antoine, C.
AU  - Liebens, F.
AU  - Carly, B.
AU  - Pastijn, A.
AU  - Rozenberg, S.
DA  - Jun
DO  - 10.1080/00015458.2007.11680053
DP  - NLM
ET  - 2007/08/10
IS  - 3
KW  - Breast Neoplasms/*complications/therapy
Climacteric/drug effects
Clinical Trials as Topic
Contraindications
Estrogen Replacement Therapy
Female
Humans
Menopause, Premature/*drug effects
Osteoporosis, Postmenopausal/drug therapy/etiology
LA  - eng
N1  - Deniz, G
Antoine, C
Liebens, F
Carly, B
Pastijn, A
Rozenberg, S
Journal Article
Review
England
Acta Chir Belg. 2007 Jun;107(3):263-6. doi: 10.1080/00015458.2007.11680053.
PY  - 2007
SN  - 0001-5458 (Print)
0001-5458
SP  - 263-6
ST  - Treatment of premature menopause in breast cancer patients
T2  - Acta Chir Belg
TI  - Treatment of premature menopause in breast cancer patients
VL  - 107
ID  - 515
ER  - 

TY  - JOUR
AB  - PURPOSE: Small cell lung cancer (SCLC) historically has had poor prognosis. Clinical trials have demonstrated improved survival among patients receiving standard platinum-/etoposide-based chemotherapy. Whereas treatment patterns and outcomes have been evaluated for patients with SCLC in clinical trials, population-based practice patterns are not well known. METHODS: The National Cancer Institute's Patterns of Care study was used to evaluate patient and provider factors associated with standard treatment, clinical trial enrollment, and 12-month relative hazard of death. RESULTS: Among 931 patients with SCLC diagnosed in 2007 in academic and community settings, 72.2% of patients with limited-stage (LS) disease received chemoradiation and 42.2% of patients with extensive-stage (ES) disease received chemotherapy only; the expected treatment scenarios by stage. Less than 1% of the patients enrolled in clinical trials and 2.1% of the patients with LS disease and 3.4% of the patients with ES disease refused any type of treatment. Patients 80 years or older at diagnosis and those with pneumonia/lung collapse were less likely to receive chemoradiation for LS disease. Patients treated in hospitals with residency programs were more likely to receive chemotherapy for ES disease, and patients 80 years or older were less likely to receive chemotherapy for ES disease. Finally, female patients with LS disease, black patients with ES disease, and all patients who received chemotherapy compared to receiving radiation alone or no therapy experienced significantly lower mortality. DISCUSSION: Despite the demonstrated lower mortality, a relatively large proportion of patients with SCLC are not treated with a standard treatment regimen. Future studies should evaluate efforts to promote use of appropriate treatment regimens and encourage clinical trial participation.
AD  - From the *Applied Research Program, National Cancer Institute, Bethesda, MD; †Information Management Services, Inc, Calverton, MD; and ‡Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD.
AN  - 24667952
AU  - Parsons, H. M.
AU  - Harlan, L. C.
AU  - Stevens, J. L.
AU  - Ullmann, C. D.
C2  - PMC3999900
C6  - NIHMS565172
DA  - Mar-Apr
DO  - 10.1097/ppo.0000000000000039
DP  - NLM
ET  - 2014/03/29
IS  - 2
KW  - Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols/administration & dosage
Cisplatin/administration & dosage
Clinical Trials as Topic
Combined Modality Therapy
Etoposide/administration & dosage
Female
Humans
Male
Middle Aged
Neoplasm Staging
Small Cell Lung Carcinoma/*drug therapy/*epidemiology/pathology
*Standard of Care
LA  - eng
N1  - 1540-336x
Parsons, Helen M
Harlan, Linda C
Stevens, Jennifer L
Ullmann, Claudio Dansky
HHSN261201000034C/PHS HHS/United States
HHSN261201000028C/PHS HHS/United States
N01PC35143/CA/NCI NIH HHS/United States
HHSN261201000031C/PHS HHS/United States
N01PC35138/CA/NCI NIH HHS/United States
N01PC54402/CA/NCI NIH HHS/United States
HHSN261201000025C/PHS HHS/United States
HHSN261201000032C/PHS HHS/United States
N01PC35141/CA/NCI NIH HHS/United States
HHSN261201000035C/PHS HHS/United States
HHSN261201000030C/PHS HHS/United States
N01PC35137/CA/NCI NIH HHS/United States
HHSN261201000027C/PHS HHS/United States
HHSN261201000026C/PHS HHS/United States
N01PC35133/CA/NCI NIH HHS/United States
N01PC54403/CA/NCI NIH HHS/United States
N01PC35142/CA/NCI NIH HHS/United States
N01PC54404/CA/NCI NIH HHS/United States
N01PC35135/CA/NCI NIH HHS/United States
N01PC54405/CA/NCI NIH HHS/United States
N01PC35145/CA/NCI NIH HHS/United States
K07 CA175063/CA/NCI NIH HHS/United States
HHSN261201000024C/PHS HHS/United States
HHSN261201000037C/PHS HHS/United States
HHSN261201000029C/PHS HHS/United States
HHSN261201000140C/PHS HHS/United States
HHSN261201000033C/PHS HHS/United States
N01PC35136/CA/NCI NIH HHS/United States
N01PC35139/CA/NCI NIH HHS/United States
K07CA175063/CA/NCI NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
Cancer J. 2014 Mar-Apr;20(2):97-104. doi: 10.1097/PPO.0000000000000039.
PY  - 2014
SN  - 1528-9117 (Print)
1528-9117
SP  - 97-104
ST  - Treatment of small cell lung cancer in academic and community settings: factors associated with receiving standard therapy and survival
T2  - Cancer J
TI  - Treatment of small cell lung cancer in academic and community settings: factors associated with receiving standard therapy and survival
VL  - 20
ID  - 292
ER  - 

TY  - JOUR
AB  - PURPOSE: Women of African ancestry (AA) have lower WBC counts and are more likely to have treatment delays and discontinue adjuvant breast cancer therapy early compared with white women. We assessed the association between race and treatment discontinuation/delay, WBC counts, and survival in women enrolled onto breast cancer clinical trials. PATIENTS AND METHODS: AA and white women from Southwest Oncology Group adjuvant breast cancer trials (S8814/S8897) were matched by age and protocol. Only the treatment arms in which patients were scheduled to receive six cycles of chemotherapy were analyzed. RESULTS: A total of 317 pairs of patients (n = 634) were analyzed. At baseline, AA women had higher body-surface area (P < .0001) and lower WBC (P = .0009). AA women were more likely to have tumors that were > or = 2 cm (P = .01) and hormone receptor negative (P < .0001). AA women, versus white women, were marginally more likely to discontinue treatment early (11% v 7%, respectively; P = .07) or have one or more treatment delays (85% v 79%, respectively; P = .07) and were significantly more likely to experience the combined end point (discontinuation/delay; 87% v 81%, respectively; P = .04). The mean relative dose-intensity (RDI) was similar for both groups (87% in AA women v 86% in white women); however, overall, 43% had an RDI of less than 85%. After adjusting for baseline WBC and prognostic factors in a multivariate model, AA women had worse disease-free survival (hazard ratio [HR] = 1.56; 95% CI, 1.15 to 2.11; P = .005) and overall survival (HR = 1.95; 95% CI, 1.36 to 2.78; P = .0002). The inclusion of RDI and treatment delivery/quality in the regression had little impact on the results. CONCLUSION: On cooperative group breast cancer trials, AA and white women had similar RDIs, but AA women were more likely to experience early discontinuation or treatment delay. Despite correcting for these factors and known predictors of outcome, AA women still had worse survival.
AD  - Columbia University, New York, NY, USA.
AN  - 19307504
AU  - Hershman, D. L.
AU  - Unger, J. M.
AU  - Barlow, W. E.
AU  - Hutchins, L. F.
AU  - Martino, S.
AU  - Osborne, C. K.
AU  - Livingston, R. B.
AU  - Albain, K. S.
C2  - PMC2674002 found at the end of this article.
DA  - May 1
DO  - 10.1200/jco.2008.19.1163
DP  - NLM
ET  - 2009/03/25
IS  - 13
KW  - Adult
*African Americans
Aged
Breast Neoplasms/blood/*drug therapy/*ethnology/mortality
Chemotherapy, Adjuvant
Clinical Trials, Phase III as Topic
*European Continental Ancestry Group
Female
Health Status Disparities
Humans
Leukocyte Count
Middle Aged
Treatment Outcome
LA  - eng
N1  - 1527-7755
Hershman, Dawn L
Unger, Joseph M
Barlow, William E
Hutchins, Laura F
Martino, Silvana
Osborne, C Kent
Livingston, Robert B
Albain, Kathy S
CA37981/CA/NCI NIH HHS/United States
U10 CA037981/CA/NCI NIH HHS/United States
N01 CA032102/CA/NCI NIH HHS/United States
N01 CA013612/CA/NCI NIH HHS/United States
U10 CA013612/CA/NCI NIH HHS/United States
CA68183/CA/NCI NIH HHS/United States
CA46282/CA/NCI NIH HHS/United States
U10 CA032102/CA/NCI NIH HHS/United States
U10 CA046282/CA/NCI NIH HHS/United States
N01 CA038926/CA/NCI NIH HHS/United States
U10 CA038926/CA/NCI NIH HHS/United States
U10 CA068183/CA/NCI NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
J Clin Oncol. 2009 May 1;27(13):2157-62. doi: 10.1200/JCO.2008.19.1163. Epub 2009 Mar 23.
PY  - 2009
SN  - 0732-183X (Print)
0732-183x
SP  - 2157-62
ST  - Treatment quality and outcomes of African American versus white breast cancer patients: retrospective analysis of Southwest Oncology studies S8814/S8897
T2  - J Clin Oncol
TI  - Treatment quality and outcomes of African American versus white breast cancer patients: retrospective analysis of Southwest Oncology studies S8814/S8897
VL  - 27
ID  - 473
ER  - 

TY  - JOUR
AB  - Men treated by androgen deprivation therapy (ADT) for localized prostate cancer are at risk for fracture, but it is not known which men require pharmacologic treatment. We found that 33% of men on ADT had osteoporosis of spine, hip, or forearm by dual-energy X-ray absorptiometry (DXA), thus requiring treatment. Using the new fracture prediction algorithm (FRAX) tool with corrected femoral neck T-score identified only 17% requiring treatment, and, if calculated without femoral neck, 54% were identified to need treatment. INTRODUCTION: Men treated with androgen deprivation therapy (ADT) for prostate carcinoma live long enough to fracture. A new fracture prediction method, FRAX, is based on femoral neck DXA plus risk factors. Thus, DXA or FRAX could determine which men should receive osteoporosis therapy. METHODS: Of 115 men undergoing ADT referred for DXA testing, those with bone mineral density (BMD) in spine, hip, or forearm of >or=2.5 standard deviations below a normal male ethnicity-adjusted mean were considered treatment candidates. Using FRAX with and without femoral neck BMD, men were treatment candidates if the 10-year hip fracture risk was >or=3% or the major osteoporotic fracture risk was >or=20%. RESULTS: The men averaged 77 years old; 58% were African-American, and 14.8% were current smokers. Mean femoral neck T-score was -1.4. Using DXA, 38 (33%) men would need treatment. When FRAX was calculated including the femoral neck T-score, only 20 men met criteria for treatment. However, when FRAX was calculated without the T-score, 62 men met criteria for treatment. Overlap among the groups was surprisingly modest. CONCLUSIONS: DXA and FRAX identify different ADT men for treatment.
AD  - McGuire Veterans Affairs Medical Center, Richmond, VA 23249, USA. Robert.adler@va.gov
AN  - 19533207
AU  - Adler, R. A.
AU  - Hastings, F. W.
AU  - Petkov, V. I.
DA  - Apr
DO  - 10.1007/s00198-009-0984-0
DP  - NLM
ET  - 2009/06/18
IS  - 4
KW  - Adenocarcinoma/therapy
Aged
Aged, 80 and over
Algorithms
Androgen Antagonists/*adverse effects
Antineoplastic Agents, Hormonal/adverse effects
Bone Density/drug effects
Bone Density Conservation Agents/*therapeutic use
Femur Neck/physiopathology
Humans
Male
Orchiectomy/adverse effects
Osteoporosis/*drug therapy/etiology/physiopathology
Osteoporotic Fractures/etiology/prevention & control
Patient Selection
Prostatic Neoplasms/therapy
Risk Assessment/methods
LA  - eng
N1  - 1433-2965
Adler, R A
Hastings, F W
Petkov, V I
Journal Article
England
Osteoporos Int. 2010 Apr;21(4):647-53. doi: 10.1007/s00198-009-0984-0. Epub 2009 Jun 17.
PY  - 2010
SN  - 0937-941x
SP  - 647-53
ST  - Treatment thresholds for osteoporosis in men on androgen deprivation therapy: T-score versus FRAX
T2  - Osteoporos Int
TI  - Treatment thresholds for osteoporosis in men on androgen deprivation therapy: T-score versus FRAX
VL  - 21
ID  - 464
ER  - 

TY  - JOUR
AB  - Men treated by androgen deprivation therapy (ADT) for localized prostate cancer are at risk for fracture, but it is not known which men require pharmacologic treatment. We found that 33% of men on ADT had osteoporosis of spine, hip, or forearm by dual-energy Xray absorptiometry (DXA), thus requiring treatment. Using the new fracture prediction algorithm (FRAX™) tool with corrected femoral neck T-score identified only 17% requiring treatment, and, if calculated without femoral neck, 54% were identified to need treatment. Introduction Men treated with androgen deprivation therapy (ADT) for prostate carcinoma live long enough to fracture. A new fracture prediction method, FRAX™, is based on femoral neck DXA plus risk factors. Thus, DXA or FRAX™ could determine which men should receive osteoporosis therapy. Methods Of 115 men undergoing ADT referred for DXA testing, those with bone mineral density (BMD) in spine, hip, or forearm of ≥2.5 standard deviations below a normal male ethnicity-adjusted mean were considered treatment candidates. Using FRAX™ with and without femoral neck BMD, men were treatment candidates if the 10-year hip fracture risk was≥3% or the major osteoporotic fracture risk was >20%. Results The men averaged 77 years old; 58%> were African-American, and 14.8% were current smokers. Mean femoral neck T-score was -1.4. Using DXA, 38 (33%) men would need treatment. When FRAX™ was calculated including the femoral neck T-score, only 20 men met criteria for treatment. However, when FRAX™ was calculated without the T-score, 62 men met criteria for treatment. Overlap among the groups was surprisingly modest. Conclusions DXA and FRAX™ identify different ADT men for treatment. © International Osteoporosis Foundation and National Osteoporosis Foundation 2009.
AD  - R. A. Adler, McGuire Veterans Affairs Medical Center, 1201 Broad Rock Boulevard, Richmond, VA 23249, United States
AU  - Adler, R. A.
AU  - Hastings, F. W.
AU  - Petkov, V. I.
DB  - Embase
Medline
DO  - 10.1007/s00198-009-0984-0
IS  - 4
KW  - antiandrogen
goserelin
African American
age
aged
androgen deprivation therapy
article
bone densitometry
bone density
cancer survival
cigarette smoking
software
controlled study
dual energy X ray absorptiometry
ethnicity
forearm fracture
fracture
fragility fracture
hip fracture
human
major clinical study
male
osteoporosis
patient selection
prediction
priority journal
prostate carcinoma
risk assessment
risk factor
scoring system
spine fracture
FRAX
LA  - English
M3  - Article
N1  - L50551178
2010-04-23
2010-04-29
PY  - 2010
SN  - 0937-941X
1433-2965
SP  - 647-653
ST  - Treatment thresholds for osteoporosis in men on androgen deprivation therapy: T-score versus FRAX™
T2  - Osteoporosis International
TI  - Treatment thresholds for osteoporosis in men on androgen deprivation therapy: T-score versus FRAX™
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L50551178&from=export
http://dx.doi.org/10.1007/s00198-009-0984-0
VL  - 21
ID  - 1167
ER  - 

TY  - JOUR
AB  - BACKGROUND: Colorectal cancer (CRC) is the second leading cause of cancer death in the United States. CRC incidence and mortality rates are higher among blacks than among whites, and screening rates are lower in blacks than in whites. For the current study, the authors tested 3 interventions that were intended to increase the rate of CRC screening among African Americans. METHODS: The following interventions were chosen to address evidence gaps in the Centers for Disease Control and Prevention's Guide to Community Preventive Services: one-on-one education, group education, and reducing out-of-pocket costs. Three hundred sixty-nine African-American men and women aged > or =50 years were enrolled in this randomized, controlled community intervention trial. The main outcome measures were postintervention increase in CRC knowledge and obtaining a screening test within 6 months. RESULTS: There was substantial attrition: Two hundred fifty-seven participants completed the intervention and were available for follow-up 3 months to 6 months later. Among completers, there were significant increases in knowledge in both educational cohorts but in neither of the other 2 cohorts. By the 6-month follow-up, 17.7% (11 of 62 participants) of the Control cohort reported having undergone screening compared with 33.9% (22 of 65 participants) of the Group Education cohort (P = .039). Screening rate increases in the other 2 cohorts were not statistically significant. CONCLUSIONS: The current results indicated that group education could increase CRC cancer screening rates among African Americans. The screening rate of <35% in a group of individuals who participated in an educational program through multiple sessions over a period of several weeks indicated that there still are barriers to overcome.
AD  - Department of Community Health and Preventive Medicine, Morehouse School of Medicine, 720 Westview Drive SW, Atlanta, GA 30310, USA. dblumenthal@msm.edu
AN  - 20052732
AU  - Blumenthal, D. S.
AU  - Smith, S. A.
AU  - Majett, C. D.
AU  - Alema-Mensah, E.
C2  - PMC2819540
C6  - NIHMS158481
DA  - Feb 15
DO  - 10.1002/cncr.24842
DP  - NLM
ET  - 2010/01/07
IS  - 4
KW  - *African Americans
Aged
Colorectal Neoplasms/*diagnosis/economics/*ethnology
Continuity of Patient Care
*Early Detection of Cancer
Female
Financing, Organized
Humans
Male
Middle Aged
Outcome Assessment, Health Care
*Patient Education as Topic
LA  - eng
N1  - 1097-0142
Blumenthal, Daniel S
Smith, Selina A
Majett, Charlye D
Alema-Mensah, Ernest
U54 MD007588/MD/NIMHD NIH HHS/United States
U54 CA118638-01S1/CA/NCI NIH HHS/United States
U54 CA118638-03/CA/NCI NIH HHS/United States
5U48DP000049/DP/NCCDPHP CDC HHS/United States
U54 CA118623/CA/NCI NIH HHS/United States
U54 CA118638-010008/CA/NCI NIH HHS/United States
1U01CA1146520/CA/NCI NIH HHS/United States
U54 CA118638-02/CA/NCI NIH HHS/United States
U57CCU42068/PHS HHS/United States
UL1RR025008/RR/NCRR NIH HHS/United States
U54 CA118638-04S3/CA/NCI NIH HHS/United States
1UL1RR025008/RR/NCRR NIH HHS/United States
UL1 RR025008-01/RR/NCRR NIH HHS/United States
U54 CA118638/CA/NCI NIH HHS/United States
2U54CA118638/CA/NCI NIH HHS/United States
U54 CA118638-04/CA/NCI NIH HHS/United States
UL1 TR000454/TR/NCATS NIH HHS/United States
U54 CA118638-04S2/CA/NCI NIH HHS/United States
UL1 RR025008/RR/NCRR NIH HHS/United States
U54 CA118948/CA/NCI NIH HHS/United States
U48 DP000049/DP/NCCDPHP CDC HHS/United States
R01 CA166785/CA/NCI NIH HHS/United States
U54 CA118638-04S1/CA/NCI NIH HHS/United States
U01 CA114652-05/CA/NCI NIH HHS/United States
G12 MD007585/MD/NIMHD NIH HHS/United States
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, P.H.S.
Cancer. 2010 Feb 15;116(4):922-9. doi: 10.1002/cncr.24842.
PY  - 2010
SN  - 0008-543X (Print)
0008-543x
SP  - 922-9
ST  - A trial of 3 interventions to promote colorectal cancer screening in African Americans
T2  - Cancer
TI  - A trial of 3 interventions to promote colorectal cancer screening in African Americans
VL  - 116
ID  - 437
ER  - 

TY  - JOUR
AB  - Human health experiments systematically expose people to conditions beyond the boundaries of medical evidence. Such experiments have included legal-medical collaboration, exemplified in the U.S. by the Public Health Service (PHS) Syphilis Study (Tuskegee). That medical experiment was legal, conforming to segregationist protocols and specific legislative authorization which excluded a selected group of African Americans from any medical protection from syphilis. Subsequent corrective action outlawed unethical medical experiments but did not address other forms of collaboration, including PHS submission to laws which may have placed African American women at increased risk from AIDS and breast cancer. Today, anti-lobbying law makes it a felony for PHS workers to openly challenge legally anointed suspension of medical evidence. African Americans and other vulnerable populations may thereby face excess risks-not only from cancer, but also from motor vehicle crashes, firearm assault, end stage renal disease, and other problems-with PHS workers as silent partners.
AD  - Department of Family and Community Medicine, Meharry Medical College
AN  - 104306211. Language: English. Entry Date: 20130322. Revision Date: 20200708. Publication Type: Journal Article
AU  - Levine, Robert S.
AU  - Williams, Jamila C.
AU  - Kilbourne, Barbara A.
AU  - Juarez, Paul D.
DB  - CINAHL Complete
DO  - 10.1353/hpu.2012.0174
DP  - EBSCOhost
IS  - 4, Supp
KW  - Black Persons
Breast Neoplasms
Health Policy
HIV Infections
Research Subjects
Syphilis
Adolescence
Adult
Aged
Alabama
Cancer Screening
Civil Rights
Comparative Studies
Confidence Intervals
Contact Tracing
Correlation Coefficient
Demography
Experimental Studies -- Legislation and Jurisprudence
Female
Health Services Accessibility
Health Status Disparities
HIV Infections -- Mortality
Human
Legislation
Male
Mammography
Medicare
Middle Age
Probability Sample
Prospective Studies
Race Factors
Research Ethics
Research Protocols
Research, Medical -- Legislation and Jurisprudence
Socioeconomic Factors
United States
United States Department of Health and Human Services
White Persons
N1  - case study; research; tables/charts. Journal Subset: Health Services Administration; Peer Reviewed; Public Health; USA. Special Interest: Men's Health; Oncologic Care; Public Health; Women's Health. NLM UID: 9103800.
PMID: NLM23124504.
PY  - 2012
SN  - 1049-2089
SP  - 104-125
ST  - Tuskegee redux: evolution of legal mandates for human experimentation
T2  - Journal of Health Care for the Poor & Underserved
TI  - Tuskegee redux: evolution of legal mandates for human experimentation
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104306211&site=ehost-live&scope=site
VL  - 23
ID  - 2134
ER  - 

TY  - JOUR
AB  - Randomized clinical trials conducted over 24 months and including nearly 1300 renal transplant patients compared the efficacy and safety of two dose levels of sirolimus versus azathioprine (United States) or placebo (Global) comparators administered with a cyclosporine (CsA) and prednisone (Pred) baseline regimen. Analysis of 24-month data revealed that patients in the 5 mg/d sirolimus groups experienced a significant delay in the onset and reduction in the incidence of acute rejection episodes compared with azathioprine (Aza) or placebo groups (P = .02/P = .001). Graft and patient survival rates and also the occurrence of transplant-related infections, lymphoproliferative disorders, or malignancies were similar among all treatment arms. Between 12 and 24 months, patients treated with 2 mg/d sirolimus displayed relatively stable mean serum creatinine values, namely 1.9-1.8 mg/dL for the US and 1.8-1.8 mg/dL for the Global (P = NS) studies, which remained higher than those of the comparators. Both 5 mg/d groups showed an increase in mean serum creatinine during this interval, which was significantly higher than the value in both comparators at 24 months. Both sirolimus groups showed persistently elevated triglyceride levels compared with Aza-treated patients at month 24. The Global trial showed a less-pronounced difference in mean fasting triglyceride values compared with placebo. Data from both trials demonstrate that the addition of sirolimus to a CsA-Pred treatment regimen yielded a durable immunosuppressive effect associated with a progressive resolution of adverse side effects over time except for hyperlipidemia, which required continued countermeasure therapy. Indications:Graft rejection prophylaxis in 1260 patients who underwent kidney transplantation. Coexisting diseases: 280 hypertension, and 223 diabetes mellitus. Patients:1260 patients, follow-up was 2 years. U.S. Trial (n=710 patients) - Neoral/sirolimus 2 mg/prednisone group: n=281, 76 females, 208 males, 160 whites, 63 blacks, 48 Hispanics, 7 Asians, 6 other race, age range 16-79 years (mean 44.9±13.6 years), 180 cadaver donor, 86 living-related donor, 18 living unrelated donor, reasons for RTx was renal failure due to glomerulonephritis (64), hypertension (72), diabetes mellitus (59), other/unknown (89), 157 dropouts (33 due to side effects). Neoral/sirolimus 5 mg/prednisone group: n=269, 104 females, 170 males, 154 whites, 62 blacks, 42 Hispanics, 10 Asians, 6 other race, age range 13-76 years (mean 46.8±13.0 years), 167 cadaver donor, 83 living-related donor, 24 living unrelated donor, reasons for RTx was renal failure due to glomerulonephritis (50), hypertension (77), diabetes mellitus (53), other/unknown (94), 169 dropouts (57 due to side effects). Neoral/azathioprine/prednisone group: n=160, 70 females, 91 males, 92 whites, 41 blacks, 15 Hispanics, 10 Asians, 3 other race, age range 12-69 years (mean 45.6±13.0 years), 119 cadaver donor, 33 living-related donor, 9 living unrelated donor, reasons for RTx was renal failure due to glomerulonephritis (18), hypertension (47), diabetes mellitus (32), other/unknown (64), 94 dropouts (21 due to side effects). Global Trial (n=550) - Neoral/sirolimus 2 mg/prednisone group: n=218, 79 females, 148 males, 172 whites, 26 blacks, 6 Hispanics, 10 Asians, 13 other race, age range 15-71 years (mean 45.7±12.3 years), 173 cadaver donor, 39 living-related donor, 15 living unrelated donor, reasons for RTx was renal failure due to glomerulonephritis (65), hypertension (35), diabetes mellitus (28), other/unknown (99), 128 dropouts (36 due to side effects). Neoral/sirolimus 5 mg/prednisone group: n=208, 70 females, 149 males, 175 whites, 27 blacks, 2 Hispanics, 7 Asians, 8 other race, age range 17-68 years (mean 45.1±12.2 years), 174 cadaver donor, 29 living-related donor, 16 living unrelated donor, reasons for RTx was renal failure due to glomerulonephritis (51), hypertension (27), diabetes mellitus (34), other/unknown (107), 154 dropouts (59 due to side effects). Neoral/placebo/prednisone group: n=124, 39 females, 91 males, 103 whites, 13 blacks, 4 Hispanics, 3 Asians, 7 other race, age range 16-71 years (mean 46.0±13.1 years), 99 cadaver donor, 27 living-related donor, 4 living unrelated donor, reasons for RTx was renal failure due to glomerulonephritis (32), hypertension (22), diabetes mellitus (17), other/unknown (59), 75 dropouts (13 due to side effects). TypeofStudy:Two randomized, double-blind, parallel, controlled, multicenter, phase III studies comparing the effects of the addition of sirolimus, azathioprine or placebo to Sandimmun Neoral-based immunosuppressive regimens in renal transplantation (RTx). Open study for Neoral. DosageDuration:Initially 9-12 mg/kg/ daily as oral microemuslion administered in the morning within 48 hours of transplantations and adjusted to maintain whole blood trough concentrations (Cminss) within the range of 200-350 ng/mL during month 1, 200-300 ng/mL during month 2, and 150-250 ng/mL thereafter. Duration: 2 years. Results:In both trials, the Neoral doses were tapered over each time interval during 24 months, in accordance with protocol-mandated trough concentration targets, resulting in a significantly decreased Cminss exposure at 24 compared with 12 months. Patients under azathioprine or placebo treatment required significantly higher doses of Neoral than those in the sirolimus cohorts to achieve equal drug exposure. Dose-normalized Neoral exposure was significantly lower among patients in the azathioprine and placebo groups than in the sirolimus group. The area under the curve (AUC) revealed mean overall intersubject variabilities for the 2 mg/d (n = 19) and the 5 mg/d (n = 23) sirolimus arms. The corresponding intrasubject variabilities were 24% and 41%, respectively. The mean overall intersubject variabilities of Neoral exposure were only slightly less than that of sirolimus. The mean intrasubject variabilities for Neoral were %CV = 25% for the US trial and %CV = 28% for the Global trial, which was similar to that of sirolimus. A significant delay in the onset of biopsy-confirmed acute rejection episodes among patients treated with sirolimus 5 mg/day compared with those receiving azathioprine or placebo was observed. Furthermore, this dose provided a significant reduction in the incidence of acute rejection episodes at 24 months in both the US and Global trials. Graft survival rates at 24 months showed no significant differences between treatment groups in both trials. The second most common causes of graft loss were acute rejection (n = 33; 2.5%) or acute tubular necrosis (n = 30; 2.3%). Patient survival at 24 months showed similar rates among treatment groups in the US and Global trials. Pairwise comparisons of the mean 24-month serum creatinine concentrations to determine graft function revealed that the aggregate values of all patients in the 2 and the 5 mg/day study groups were higher than those of patients in the azathioprine (1.5 mg/dL) or the placebo cohorts (1.6 mg/dL). Mean values at 24 months in the comparator and the 2 mg/day groups were fairly similar to those at 12 months. Recipients in the 5 mg/day sirolimus groups showed slightly higher values at 24 months. Changes in mean calculated creatinine clearances were consistent with the creatinine data. The overall rates of discontinuation were similar among all groups in both trials except for the 5 mg/day cohort in the Global study. The primary reason for discontinuations in the comparator groups was poor efficacy; conversely, the sirolimus 5 mg/d group showed higher rates of discontinuation due to adverse events or intercurrent medical problems (US study). Sirolimus treatment was not associated with an increased risk of malignancy within 24 months. The distribution of malignancies and the incidence of posttransplant lymphoproliferative disease (PTLD) across treatment groups were similar at 24 months. Bacterial infections occurred at similar frequencies among recipients in both trials except for urinary tract infections, which occurred less often among patients receiving sirolimus 2 mg/day in the US study. Some commonly reported adverse events included peripheral edema, hypertension, and headache. The incidence of clinically important events associated with Neoral toxicity such as tremor and serious infections (US trial), hypertension (Global trial), and diabetes (both trials) were not affected by the addition of sirolimus. However, an increased incidence of diarrhea, rash, epistaxis, and HSV infection seemed to be attributable to the addition of sirolimus to a Neoral-prednisone regimen. The increase in adjusted mean aspartate aminotransferase (AST) values, which had been noted by pairwise comparisons of values at earlier time points, proved to be transient and were not sustained at 24 months. Although the mean platelet counts were not significantly different from the comparators at 24 months, the cumulative incidence of investigator-reported thrombocytopenia was higher among the sirolimus groups. Although hemoglobin values at 24 months were not significantly differ nt among all treatment groups in the US trial, patients in the sirolimus 2 and 5 mg/day groups of the Global study displayed significantly lower hemoglobin values than those receiving placebo. Only 2 patients in each trial discontinued study medication because of anemia. AdverseEffects:219 patients discontinued due to side effects. 16 patients experienced lymphoma/posttransplant lymphoproliferative disorder, 20 basal cell carcinoma, 19 squamous cell carcinoma, 3 melanoma, 2 breast cancer, 4 lung cancer, 1 prostate cancer, 1 renal cancer, 1 pancreas cancer, 2 gastrointestinal cancer, 3 genitourinary cancer, 2 other cancers, 2 anemia (led to withdrawal), 509 hypertension, 481 hypercholesterolemia, 191 hyperkalemia, 708 peripheral edema, 349 diarrhea, 116 leukopenia, 187 thrombocytopenia, 510 hyperlipidemia, 303 arthralgia, 136 rash, 340 headache, 72 epistaxis, 107 diabetes mellitus. Unspecified number had hypertriglyceridemia (21 led to withdrawal), increased alanine aminotransferase blood level, increased lactate dehydrogenase blood level, urinary tract infection/pyelonephritis, sepsis, pneumonia, wound infection, cytomegalovirus infection, herpes simplex virus infection, herpes zoster virus infection, and Epstein-Barr virus infection. AuthorsConclusions:Data from both trials demonstrate that the addition of sirolimus to a CsA [cyclosporin A]-Pred [prednisone]treatment regimen yielded a durable immunosuppressive effect associated with a progressive resolution of adverse side effects over time except for hyperlipidemia, which required continued countermeasure therapy. FreeText:Concomitant medications included sirolimus (maintenance dose of 2 or 5 mg daily) as an oral solution (1 or 2.5 mg/mL) administered in 2 mL dose 4 hours after the morning dose of Neoral after a single 6 mL loading dose of 6 or 15 mg, azathioprine (2-3 mg/kg daily), prednisone, and placebo. The primary efficacy endpoint was efficacy failure defined as the composite of the first occurrence of graft loss, death, or biopsy-confirmed acute rejection episode. Secondary endpoints were patient and graft survival at 24 months, as well as the time to, histologic grade of, and need for antibody therapy for treatment of the first biopsy-confirmed acute rejection episode.
AD  - Univ. of TX Med. School at Houston, Department of Surgery, Div. of Immunol./Organ Transplant., Houston, TX, United States
Univ. of TX Med. School at Houston, Department of Surgery, Div. of Immunol./Organ Transplant., 6431 Fannin, Houston, TX 77030, United States
AU  - Kahan, B. D.
DB  - Scopus
DO  - 10.1016/S0041-1345(03)00353-1
IS  - 3 SUPPL.
M3  - Conference Paper
N1  - Cited By :75
Export Date: 22 March 2021
PY  - 2003
SP  - S37-S51
ST  - Two-year results of multicenter phase III trials on the effect of the addition of sirolimus to cyclosporine-based immunosuppressive regimens in renal transplantation
T2  - Transplantation Proceedings
TI  - Two-year results of multicenter phase III trials on the effect of the addition of sirolimus to cyclosporine-based immunosuppressive regimens in renal transplantation
UR  - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0038637990&doi=10.1016%2fS0041-1345%2803%2900353-1&partnerID=40&md5=ce5e4e1185cff444efeaba6b2f0571ff
VL  - 35
ID  - 2619
ER  - 

TY  - JOUR
AB  - 6061 Background: Attempts to improve the outcome of locally advanced SCCHN have generally added chemotherapy to radiation, though the optimal manner of integration has been controversial. To impact distant and local control, we utilized neoadjuvant chemotherapy followed by concomitant boost radiation (CBR) with docetaxel as a radiosensitizer. To improve cytoprotection, subcutaneous amifostine was added during radiotherapy.Methods: From April 2003-March 2007 46 patients with stage III or IV newly diagnosed SCCHN were enrolled (30 Caucasian, 16 African-American). Treatment consisted of 3 cycles of neoadjuvant chemotherapy with cisplatin 75 mg/m2 and docetaxel 75 mg/m2 intravenously at 21 day intervals followed by CBR and concurrent dose-escalated weekly docetaxel starting at 20 mg/m2. Standard 2D radiotherapy was used in the majority of patients. Subcutaneous amifostine was administered at 500 mg during each day of radiation.Results: 39 patients were evaluable. The neoadjuvant chemotherapy was well tolerated by the majority of patients and appeared effective; no patient had progressive disease while on therapy. Three patients required a change to carboplatin due to toxicity. Weekly docetaxel during all weeks of CBR was not tolerable due to severe mucositis and the phase I component defined the MTD of concurrent docetaxel as 20 mg/m2 for 4 cycles during CBR. 4 patients (10%) had persistent disease at completion of treatment. Amifostine administration was well tolerated though 4 patients required discontinuation of the drug. The majority of recurrences have been localized at the primary site (6 patients). 3 patients developed isolated pulmonary metastasis. Only 2 patients remain PEG dependent with median follow-up of 24 months.Conclusions: Induction chemotherapy using cisplatin and docetaxel is feasible and easy to administer in the outpatient setting; those patients who had a major radiographic and clinical response did particularly well in follow-up. Weekly docetaxel can be safely and effectively administered during CBR with good local control. Amifostine can be safely administered via the subcutaneous route; the benefit in locally advanced patients is difficult to assess. No significant financial relationships to disclose.
AD  - UAB, Birmingham, AL; The Brody School of Medicine, East Carolina University, NC; University of Alabama, Birmingham, AL
AN  - 120350464. Language: English. Entry Date: In Process. Revision Date: 20161223. Publication Type: journal article. Supplement Title: 5/21/2009 Supplement Part 1 of 2. Journal Subset: Biomedical
AU  - Nabell, L. M.
AU  - Peters, G.
AU  - Meredith, R.
AU  - Carroll, W.
AU  - Bonner, J.
AU  - Ove, R.
AU  - Spencer, S.
DB  - CINAHL Complete
DP  - EBSCOhost
N1  - Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA. NLM UID: 8309333.
PMID: NLM27961927.
PY  - 2009
SN  - 0732-183X
SP  - 6061-6061
ST  - UAB 0210: A phase I/II trial of induction chemotherapy followed by concomitant docetaxel/radiotherapy with subcutaneous amifostine for advanced squamous cell carcinoma of the head and neck (SCCHN)
T2  - Journal of Clinical Oncology
TI  - UAB 0210: A phase I/II trial of induction chemotherapy followed by concomitant docetaxel/radiotherapy with subcutaneous amifostine for advanced squamous cell carcinoma of the head and neck (SCCHN)
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=120350464&site=ehost-live&scope=site
VL  - 27
ID  - 2135
ER  - 

TY  - JOUR
AB  - Background: Increasing Black patients' participation in cancer clinical trials is important because of the population's lower survival rate. Accrual for Blacks is the lowest of all groups at 0.5‐1.5%. Our study aims to increase trial participation rates among Black breast cancer patients by testing the effectiveness of a culturally tailored video intervention on the decision to participate in a clinical trial. Methods: We hypothesized that the intervention would increase clinical trial enrollment by 6 percentage points compared to our 2012 enrollment baseline of 6% (22/384). Self‐ identified Black patients with invasive breast cancer at 5 MedStar Hospitals watched a 15' video about clinical trials, targeting six cultural and attitudinal barriers to participation. The Attitudes and Intention to Enroll in therapeutic clinical Trials (AIET) pre‐/post‐/follow‐up tests with 31 items was used to determine the impact of the video on three domains: actual trial enrollment; likely participation in trials; and attitudes toward trials. The pre‐test was conducted at baseline; post‐test immediately after video; and follow‐up 7‐21 days after the intervention. Participants were followed for 6 months to assess trial enrollment status. Descriptive statistics were used to describe study subjects with respect to basic characteristics; means and standard deviations for continuous variables; and frequencies and percentages for categorical variables. Repeated measures analysis of variance was used to examine whether the changes in attitudinal barriers were statistically significant over time. The primary outcome measure was the proportion of Black breast cancer patients who signed consent and/or enrolled in a therapeutic clinical trial. Results: From Mar/2014 to Sept/2015, 279 patients were approached to join INSPIRE‐BrC prior to discussion about therapeutic clinical trials; 52 declined participation. 208 signed consent and 200 completed it. Average age was 59 yrs (SD=12), 75% were stage I‐III; 29% were married; 85% had 1 or more children; 29% attended some college or technical school; 53% had private insurance, 31% Medicare, 16% Medicaid; and 53% had a household income <$40,000/yr. A total of 41 INSPIRE‐BrC participants (20.5%) signed consent and 29 (14.5%) enrolled onto a therapeutic study (one‐sided p=0.027 vs H0: P=0.06). Pre‐video, 52% of patients expressed that it was likely they would participate in a hypothetical therapeutic clinical trial; immediately post‐video, 67% (p=<0.001) and 7‐21 days after the intervention, 64% (p=0.003). Among 31 AIET items, 25 (81%) showed statistically significant and positive change after the intervention. Specifically, trust in the doctor increased and, suspicion in trials decreased (p<0.001). Further, patient views on fairness for treatment of poor people and Blacks became significantly more positive (p<0.001). Conclusion: Study findings show that the video is a promising tool for rapid dissemination of a theory‐driven, evidence‐based model to enhance clinical trial accrual among Black cancer patients. The video also has the potential to positively change attitudes about clinical trial participation.
AN  - CN-01363795
AU  - Penault-Llorca, F.
AU  - Kwiatkovski, F.
AU  - Grenier, J.
AU  - Levy, C.
AU  - Leheurteur, M.
AU  - Uwer, L.
AU  - Derbel, O.
AU  - Le Rol, A.
AU  - Jacquin, J. P.
AU  - Jouannaud, C.
AU  - et al.
DO  - 10.1158/1538-7445.SABCS16-P2-05-10
IS  - 4 Supplement 1) (no pagination
KW  - *decision making
*genetic predisposition
Adult
Analysis of variance
Black person
Breast cancer
Cancer patient
Clinical trial
College
Controlled clinical trial
Controlled study
Female
Follow up
Hospital
Household income
Human
Major clinical study
Married person
Medicaid
Medicare
Middle aged
Multicenter study
Pretest posttest design
Statistics
Theoretical model
Trust
Videorecording
M3  - Conference Abstract
PY  - 2017
ST  - UCBG 2-14: a prospective multicenter non-randomized trial evaluating the effect of EndoPredict (EPclin) clinico-genomic test on treatment decision making among patients with intermediate clinical risk
T2  - Cancer research. Conference: 39th annual CTRC-AACR san antonio breast cancer symposium. United states
TI  - UCBG 2-14: a prospective multicenter non-randomized trial evaluating the effect of EndoPredict (EPclin) clinico-genomic test on treatment decision making among patients with intermediate clinical risk
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01363795/full
VL  - 77
ID  - 1433
ER  - 

TY  - JOUR
AB  - Background: It is now recognized that Cimicifuga foetida (C. foetida) extract is effective in alleviating menopausal symptoms. But the durations reported were usually short. The aim of this study was to investigate the effects of Cimicifuga foetida extract therapy and different estrogen and progesterone sequential therapies, on the breasts of early postmenopausal women. Methods: This was a prospective randomized trial. Ninety-six early menopausal women were recruited and randomly assigned into three groups treated with different therapies for 2 years. Patients were given Cimicifuga foetida extract in Group A, estradiol valerate and medroxyprogesterone acetate in Group B, and estradiol valerate and progesterone in Group C. Ultrasonography was used to monitor changes in breast during treatment. Results: In comparing breast glandular section thickness before and after 1 and 2 years of treatment, no significant difference was observed in Group A (11.97 +/- 2.84 mm vs. 12.09 +/- 2.58 mm and 12.61 +/- 3.73 mm, P > 0.05); in Group B glandular section thickness had increased significantly (10.98 +/- 2.34 mm vs. 11.84 +/- 2.72 mm and 11.90 +/- 3.33 mm, P < 0.05) after treatment, the same as Group C (11.56 +/- 3.03 mm vs. 12.5 +/- 3.57 mm and 12.22 +/- 4.39 mm P < 0.05). In comparing breast duct width before and after 1 and 2 years of treatment, no significant difference was seen in Group A (1.07 +/- 0.19 mm vs. 1.02 +/- 0.18 mm and 0.98 +/- 0.21 mm, P > 0.05); in Group B the duct width had a downward trend after treatment (0.99 +/- 0.14 mm vs. 0.96 +/- 0.22 mm and 0.90 +/- 0.18 mm, P < 0.05), the same as Group C (1.07 +/- 0.20 mm vs. 1.02 +/- 0.17 mm and 0.91 +/- 0.19 mm, P < 0.05). The nodules detected before treatment had disappeared after 1-year of treatment or exhibited no distinct changes in the three groups. However, new breast nodules had appeared after 2 years of treatment: There was one case in Group A, two cases in Group B and four cases in Group C, with breast hyperplasia after the molybdenum target check. Conclusions: In early postmenopausal patients, Cimicifuga foetida extract therapy and estrogen and progesterone therapy at low doses did not increase the incidence of malignant breast tumors.
AN  - WOS:000353563300002
AU  - Gaowa, S.
AU  - Sun, A. J.
AU  - Jiang, Y.
AU  - He, F. W.
AU  - Zheng, T. P.
AU  - Wang, Y. P.
DA  - Apr
DO  - 10.4103/0366-6999.155052
IS  - 8
N1  - 25881590
PY  - 2015
SN  - 0366-6999
SP  - 1000-1004
ST  - Ultrasonographic Observation of the Breast in Early Postmenopausal Women during Therapy with Cimicifuga Foetida Extract and Sequential Therapy with Estrogen and Progestin
T2  - Chinese Medical Journal
TI  - Ultrasonographic Observation of the Breast in Early Postmenopausal Women during Therapy with Cimicifuga Foetida Extract and Sequential Therapy with Estrogen and Progestin
VL  - 128
ID  - 2981
ER  - 

TY  - THES
AB  - Watchful waiting has been proposed as a reasonable alternative for older men with localized prostate cancer. However, this option is controversial, and men electing watchful waiting live with continual uncertainty. The purpose of this study was to test the efficacy of the Living with Uncertainty Intervention (LUI). The intervention was based on the Reconceptualized Uncertainty in Illness Theory and interviews with men electing watchful waiting (Bailey & Mishel, 1997; Mishel, 1990).The investigator used an experimental design and enrolled a convenience sample of 41 men. Experimental subjects received 5 weekly intervention calls from the nurse intervener. Thirty-seven subjects participated in a follow-up phone call at the end of the study to respond to interview questions concerning social support, religion, and their individual spiritual beliefs.Descriptive analyses were conducted for all demographic and outcome variables. Repeated measures of analyses of variance (ANOVA) were used to test the efficacy of the LUI. Functional status, number of health problems, and length of time since electing watchful were evaluated as moderators.The sample was 86% Caucasian and 14% African American, with an average age of 75.4 years. Intervention subjects came to view their lives in a new light (p = .02) and experienced a decrease in their confusion (p = .04) and depression (p = .06) levels from Time 1 to Time 2, as compared with controls. Additionally, intervention subjects reported an improvement in their quality of life over that reported by controls (p = .01) and believed their quality of life in the future (6 months) would be better than did the controls (p = .01).Low functional status moderated the effect of the LUI on confusion ( p =.03) and cognitive refraining (p = .08). High numbers of health problems moderated the effect of the LUI on depression ( p = .06) and future quality of life (p = .02). Greater length of time in watchful waiting moderated the effect of the intervention on cognitive reframing (p = .08). This study's findings documented the benefit of nursing intervention for patients living with continued uncertainty. The findings provided additional information about the experience of men electing watchful waiting and supported the theory (Mishel, 1990).
AU  - Bailey, D. E., Jr.
DB  - CINAHL Complete
DP  - EBSCOhost
KW  - Prostatic Neoplasms -- Psychosocial Factors
Uncertainty
Male
Conceptual Framework
Psychological Theory
Convenience Sample
Experimental Studies
Interviews
Quality of Life
Descriptive Statistics
Repeated Measures
Analysis of Variance
Functional Status
Time Factors
Aged
Support, Psychosocial
Telephone
Nursing Interventions
Human
M1  - Ph.D.
N1  - Accession Number: 109876523. Language: English. Entry Date: 20030815. Revision Date: 20150923. Publication Type: Doctoral Dissertation; research.
UMI Order AAI3046961
PB  - University of North Carolina at Chapel Hill
PY  - 2002
SN  - 9780493609331
SP  - 145 p-145 p
ST  - Uncertainty and watchful waiting in men with prostate cancer
TI  - Uncertainty and watchful waiting in men with prostate cancer
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=109876523&site=ehost-live&scope=site
ID  - 2136
ER  - 

TY  - JOUR
AB  - BACKGROUND US Food and Drug Administration (FDA) approval of new drugs depends on results from clinical trials that must be generalized to the US population. However, racial minorities are frequently under-represented in clinical studies. The enrollment of racial minorities was compared in key clinical studies submitted to the FDA in the last 10 years in support of potential marketing approval for prostate cancer (PCa) prevention or treatment. METHODS Patient demographic data were obtained from archival data sets of large registration trials submitted to the FDA to support proposed PCa indications. Six countries/regions were analyzed: the United States, Canada, Australia, Europe, the United Kingdom, and Eastern Europe. Background racial demographics were collected from national census data. RESULTS Seventeen key PCa clinical trials were analyzed. These trials were conducted in the past 20 years, comprising 39,574 patients with known racial information. Most patients were enrolled in the United States, but there appeared to be a trend toward increased non-US enrollment over time. In all countries, racial minorities were generally under-represented. There was no significant improvement in racial minority enrollment over time. The United States enrolled the largest nonwhite population (7.1%). CONCLUSIONS Over the past 20 years, racial minorities were consistently under-represented in key PCa trials. There is a need for effective measures that will improve enrollment of racial minorities. With increased global enrollment, drug developers should aim to recruit a patient population that resembles the racial demographics of the patient population to which drug use will be generalized upon approval.
AD  - P.G. Kluetz, Office of Hematology and Oncology Products, Office of New Drugs, Center for Drug Evaluation Research, US Food and Drug Administration, Building 22, 10903 New Hampshire Avenue, Silver Spring, MD, United States
AU  - Wissing, M. D.
AU  - Kluetz, P. G.
AU  - Ning, Y. M.
AU  - Bull, J.
AU  - Merenda, C.
AU  - Murgo, A. J.
AU  - Pazdur, R.
C2  - Ferring(Switzerland)
Bayer(Germany)
GPC Biotech(Germany)
Sanofi Aventis(France)
GlaxoSmithKline(United Kingdom)
Actavis(Ireland)
Abbott(United States)
AbbVie(United States)
Amgen(United States)
Dendreon(United States)
Janssen Biotech(United States)
Medivation(United States)
Merck and Co(United States)
DB  - Embase
Medline
DO  - 10.1002/cncr.28809
IS  - 19
KW  - abiraterone acetate
atrasentan
cabazitaxel
degarelix
denosumab
docetaxel
dutasteride
enzalutamide
finasteride
leuprorelin
radium chloride ra 223
satraplatin
sipuleucel T
triptorelin
Alaska Native
American Indian
article
Asian
Australia
Black person
Canada
Canadian
cancer prevention
castration resistant prostate cancer
Caucasian
clinical trial
controlled study
drug approval
drug marketing
drug use
Eastern Europe
Europe
Food and Drug Administration
Hispanic
human
indigenous people
major clinical study
minority group
Pacific Islander
priority journal
prostate cancer
trend study
United Kingdom
United States
LA  - English
M3  - Article
N1  - L605267729
2015-07-27
2015-07-29
PY  - 2014
SN  - 1097-0142
0008-543X
SP  - 3025-3032
ST  - Under-representation of racial minorities in prostate cancer studies submitted to the US Food and Drug Administration to support potential marketing approval, 1993-2013
T2  - Cancer
TI  - Under-representation of racial minorities in prostate cancer studies submitted to the US Food and Drug Administration to support potential marketing approval, 1993-2013
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L605267729&from=export
http://dx.doi.org/10.1002/cncr.28809
VL  - 120
ID  - 1062
ER  - 

TY  - JOUR
AB  - BACKGROUND: Studies have documented the underrepresentation of women and blacks in clinical trials, and their recruitment is now federally mandated. However, little is known about the level of participation of elderly patients. We determined the rates of enrollment of patients 65 years of age or older in trials of treatment for cancer. METHODS: We analyzed data on 16,396 patients consecutively enrolled in 164 Southwest Oncology Group treatment trials between 1993 and 1996 according to sex, race (black or white), and age under 65 years or 65 or older. These rates were compared with the corresponding rates in the general population of patients with cancer, derived from the 1990 U.S. Census and from the National Cancer Institute's Surveillance, Epidemiology, and End Results Program for the period from 1992 through 1994. Fifteen types of cancer were included in the analysis. RESULTS: The overall proportions of women and blacks enrolled in Southwest Oncology Group trials were similar to or the same as the estimated proportions in the U.S. population of patients with cancer (women, 41 percent and 43 percent; blacks, 10 percent and 10 percent, respectively). In contrast, patients 65 years of age or older were underrepresented overall (25 percent vs. 63 percent, P<0.001) and in trials involving all 15 types of cancer except lymphoma. The underrepresentation was particularly notable in trials of treatment for breast cancer (9 percent vs. 49 percent, P<0.001). The findings were similar when data on patients who were 70 years of age or older were analyzed, when 15 trials that excluded older patients were eliminated from the analysis, and when community-based enrollment was analyzed separately from enrollment at academic centers. CONCLUSIONS: There is substantial underrepresentation of patients 65 years of age or older in studies of treatment for cancer. The reasons should be clarified, and policies adopted to correct this underrepresentation.
AD  - Department of Medicine, University of Arkansas for Medical Sciences, Little Rock, USA.
AN  - 10615079
AU  - Hutchins, L. F.
AU  - Unger, J. M.
AU  - Crowley, J. J.
AU  - Coltman, C. A., Jr.
AU  - Albain, K. S.
DA  - Dec 30
DO  - 10.1056/nejm199912303412706
DP  - NLM
ET  - 1999/12/30
IS  - 27
KW  - African Continental Ancestry Group
Age Factors
Aged
Clinical Trials as Topic/economics/*statistics & numerical data
Female
Health Services Accessibility
Humans
Neoplasms/epidemiology/ethnology/*therapy
*Patient Selection
*Research Subjects
Retrospective Studies
Therapeutic Human Experimentation
United States/epidemiology
Biomedical and Behavioral Research
Empirical Approach
Southwest Oncology Group
LA  - eng
N1  - Hutchins, L F
Unger, J M
Crowley, J J
Coltman, C A Jr
Albain, K S
CA32102/CA/NCI NIH HHS/United States
CA37981/CA/NCI NIH HHS/United States
CA38926/CA/NCI NIH HHS/United States
etc.
Journal Article
Research Support, U.S. Gov't, P.H.S.
United States
N Engl J Med. 1999 Dec 30;341(27):2061-7. doi: 10.1056/NEJM199912303412706.
PY  - 1999
SN  - 0028-4793 (Print)
0028-4793
SP  - 2061-7
ST  - Underrepresentation of patients 65 years of age or older in cancer-treatment trials
T2  - N Engl J Med
TI  - Underrepresentation of patients 65 years of age or older in cancer-treatment trials
VL  - 341
ID  - 707
ER  - 

TY  - JOUR
AB  - Background To reduce colorectal cancer (CRC) screening disparities, it is important to understand correlates of different types of cancer worry among ethnically diverse individuals. Objectives The current study examined the prevalence of three types of cancer worry (i.e., general cancer worry, CRC-specific worry, and worry about CRC test results) as well as sociodemographic and health-related predictors for each type of cancer worry. Methods Participants were aged 50-75, at average CRC risk, nonadherent to CRC screening guidelines, and enrolled in a randomized controlled trial to increase CRC screening. Participants completed a baseline questionnaire assessing sociodemographics, health beliefs, healthcare experiences, and three cancer worry measures. Associations between study variables were examined with separate univariate and multivariable logistic regression models. Results Responses from a total of 416 participants were used. Of these, 47% reported experiencing moderate-to-high levels of general cancer worry. Predictors of general cancer worry were salience and coherence (aOR = 1.1, 95% CI [1.0, 1.3]), perceived susceptibility (aOR = 1.2, 95% CI [1.1, 1.3), and social influence (aOR = 1.1, 95% CI [1.0, 0.1]). Fewer (23%) reported moderate-to-high levels of CRC-specific worry or CRC test worry (35%). Predictors of CRC worry were perceived susceptibility (aOR = 1.4, 95% CI [1.3, 1.6]) and social influence (aOR = 1.1, 95% CI [1.0, 1.2]); predictors of CRC test result worry were perceived susceptibility (aOR = 1.2, 95% CI [1.1, 1.3) and marital status (aOR = 2.0, 95% CI [1.1, 3.7] for married/partnered vs. single and aOR = 2.3, 95% CI [1.3, 4.1] for divorced/widowed vs. single). Discussion Perceived susceptibility consistently predicted the three types of cancer worry, whereas other predictors varied between cancer worry types and in magnitude of association. The three types of cancer worry were generally predicted by health beliefs, suggesting potential malleability. Future research should include multiple measures of cancer worry and clear definitions of how cancer worry is measured.
AN  - WOS:000438539700003
AU  - Christy, S. M.
AU  - Schmidt, A.
AU  - Wang, H. L.
AU  - Sutton, S. K.
AU  - Davis, S. N.
AU  - Chavarria, E.
AU  - Abdulla, R.
AU  - Quinn, G. P.
AU  - Vadaparampil, S. T.
AU  - Schultz, I.
AU  - Roetzheim, R.
AU  - Shibata, D.
AU  - Meade, C. D.
AU  - Gwede, C. K.
DA  - Jul-Aug
DO  - 10.1097/NNR.0000000000000275
IS  - 4
N1  - 29870517
PY  - 2018
SN  - 0029-6562
SP  - 275-285
ST  - Understanding Cancer Worry Among Patients in a Community Clinic-Based Colorectal Cancer Screening Intervention Study
T2  - Nursing Research
TI  - Understanding Cancer Worry Among Patients in a Community Clinic-Based Colorectal Cancer Screening Intervention Study
VL  - 67
ID  - 2851
ER  - 

TY  - JOUR
AU  - Printz, C.
DB  - Embase
Medline
DO  - 10.1002/cncr.29247
IS  - 3
KW  - African American
breast cancer
cancer center
cancer incidence
cancer mortality
cancer prevention
cancer research
Caucasian
colorectal cancer
diet
ethnic group
health disparity
human
lifestyle
lung cancer
medical society
neoplasm
prostate cancer
residential area
risk factor
short survey
smoking
LA  - English
M3  - Short Survey
N1  - L601705753
2015-02-03
2015-02-09
PY  - 2015
SN  - 1097-0142
0008-543X
SP  - 325-327
ST  - Understanding disparity: Researchers strive to recruit more African Americans and other minorities to studies
T2  - Cancer
TI  - Understanding disparity: Researchers strive to recruit more African Americans and other minorities to studies
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L601705753&from=export
http://dx.doi.org/10.1002/cncr.29247
VL  - 121
ID  - 1013
ER  - 

TY  - JOUR
AB  - Purpose: Understanding genetic factors that contribute to racial differences in cancer outcomes may reduce racial disparities in cancer morbidity and mortality. Achieving this goal will be limited by low rates of African American participation in cancer genetics research. Method: We conducted a qualitative study with African American adults (n = 91) to understand attitudes about participating in cancer genetics research and to identify factors that are considered when making a decision about participating in this type of research. Results: Participants would consider the potential benefits to themselves, family members, and their community when making a decision to participate in cancer genetics research. However, concerns about exploitation, distrust of researchers, and investigators' motives were also important to participation decisions. Individuals would also consider who has access to their personal information and what would happen to these data. Side effects, logistical issues, and the potential to gain knowledge about health issues were also described as important factors in decision making. Conclusion: African Americans may consider a number of ethical, legal, and social issues when making a decision to participate in cancer genetics research. These issues should be addressed as part of recruitment efforts.
AN  - WOS:000309845900001
AU  - McDonald, J. A.
AU  - Barg, F. K.
AU  - Weathers, B.
AU  - Guerra, C. E.
AU  - Troxel, A. B.
AU  - Domchek, S.
AU  - Bowen, D.
AU  - Shea, J. A.
AU  - Halbert, C. H.
DA  - Jul-Aug
DO  - 10.1016/S0027-9684(15)30172-3
IS  - 7-8
N1  - 23092046
PY  - 2012
SN  - 0027-9684
SP  - 324-330
ST  - Understanding Participation by African Americans in Cancer Genetics Research
T2  - Journal of the National Medical Association
TI  - Understanding Participation by African Americans in Cancer Genetics Research
VL  - 104
ID  - 3064
ER  - 

TY  - JOUR
AB  - This paper presents findings from formative research exploring Black Seventh-day Adventist church members' attitudes about Black non-participation in past studies, and Suggestions for recruiting 45,000 Blacks to an upcoming longitudinal cohort study. Data were collected in California and Pennsylvania, using 15 key informant interviews and 6 focus groups. Key findings supported and elucidated existing literature on the barriers to minority recruitment, and included: a general mistrust of the medical/scientific community; a perception that providing informed consent relinquishes, rather than protects, an individual's rights; a perception of being "studied" rather than "studying" clue to the paucity of Black investigators; and a perceived lack of cultural sensitivity in the recruitment of Blacks, and in the conduct of the research itself. Building trust throughout the process, from clearly demonstrating the benefits of participation, at the individual and community level, to including Blacks in the study design from conceptualization to data analysis and presentation, emerged as a critical component in garnering Black participation in future Studies.
AN  - WOS:000223093600015
AU  - Herring, P.
AU  - Montgomery, S.
AU  - Yancey, A. K.
AU  - Williams, D.
AU  - Fraser, G.
DA  - Sum
IS  - 3
N1  - 50
15328945
PY  - 2004
SN  - 1049-510X
SP  - 423-430
ST  - Understanding the challenges in recruiting blacks to a longitudinal cohort study: The adventist health study
T2  - Ethnicity & Disease
TI  - Understanding the challenges in recruiting blacks to a longitudinal cohort study: The adventist health study
VL  - 14
ID  - 2683
ER  - 

TY  - JOUR
AB  - African Americans are disproportionately affected by prostate cancer, yet less is known about the most salient psychosocial dimensions of quality of life. The purpose of this study was to explore the perceptions of African American prostate cancer survivors and their spouses of psychosocial issues related to quality of life. Twelve African American couples were recruited from a National Cancer Institute Comprehensive Cancer Center registry and a state-based non-profit organization to participate in individual interviews. The study was theoretically based on Ferrell’s Quality of Life Conceptual Model. Common themes emerged regarding the psychosocial needs of African American couples. These themes were categorized into behavioral, social, psychological, and spiritual domains. Divergent perspectives were identified between male prostate cancer survivors and their female spouses. This study delineated unmet needs and areas for future in-depth investigations into psychosocial issues. The differing perspectives between patients and their spouses highlight the need for couple-centered interventions. (PsycINFO Database Record (c) 2016 APA, all rights reserved)
AD  - Rivers, Brian M., Health Outcomes & Behavior Program, H. Lee Moffitt Cancer Center & Research Institute, 12902 Magnolia Drive, Tampa, FL, US, 33612
AN  - 2014-36564-024
AU  - Rivers, Brian M.
AU  - August, Euna M.
AU  - Quinn, Gwendolyn P.
AU  - Gwede, Clement K.
AU  - Pow-Sang, Julio M.
AU  - Green, B. Lee
AU  - Jacobsen, Paul B.
DB  - psyh
DO  - 10.1007/s13187-012-0360-1
DP  - EBSCOhost
IS  - 3
KW  - Prostate cancer
Survivorship
Psychosocial factors
African Americans
Quality of life
Qualitative methods
Aged
Female
Health Status
Humans
Interpersonal Relations
Male
Mental Health
Middle Aged
Patient Education as Topic
Perception
Prostatic Neoplasms
Qualitative Research
Spouses
Stress, Psychological
Survivors
Blacks
Neoplasms
Prostate
Couples
N1  - Health Outcomes & Behavior Program, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, US. Other Publishers: Lawrence Erlbaum; Taylor & Francis. Release Date: 20151102. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: English. Major Descriptor: Blacks; Neoplasms; Prostate. Minor Descriptor: Couples; Quality of Life. Classification: Cancer (3293). Population: Human (10); Male (30); Female (40). Location: US. Age Group: Adulthood (18 yrs & older) (300). Methodology: Empirical Study; Interview; Qualitative Study. References Available: Y. Page Count: 13. Issue Publication Date: Jun, 2012. Publication History: First Posted Date: Apr 29, 2012. Copyright Statement: Springer Science+Business Media, LLC. 2012.
Sponsor: American Cancer Society, US. Grant: 60132530120. Other Details: Institutional Research grant. Recipients: No recipient indicated
PY  - 2012
SN  - 0885-8195
1543-0154
SP  - 546-558
ST  - Understanding the psychosocial issues of African American couples surviving prostate cancer
T2  - Journal of Cancer Education
TI  - Understanding the psychosocial issues of African American couples surviving prostate cancer
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2014-36564-024&site=ehost-live&scope=site
ORCID: 0000-0002-0345-9728
brian.rivers@moffitt.org
VL  - 27
ID  - 1733
ER  - 

TY  - JOUR
AB  - African Americans and Latinos are underrepresented in clinical trials. The purpose of this study was to elicit solutions to participation barriers from African Americans and Latinos. Fifty-seven adults (32 African Americans, 25 Latinos) ages 50 years and older participated. The Institute of Medicine's Unequal Treatment conceptual framework was used. Six racially/ethnically homogenous focus groups were conducted at five sites in three counties. Themes within groups and cross-cutting themes were identified. The NVIVO program was used for data classification. The data were reviewed for final coding and consensus. Shared solutions included addressing costs, recruiting in community contexts, conducting community and individualized patient education, and sharing patient safety information. Participants were unanimously in favor of clinical trials navigation recruitment interventions. Solutions specific to African Americans included diversifying research teams, recognizing past research abuses, and increasing community trust. Solutions specific to Latinos included providing low-literacy materials, providing Spanish-speaking clinicians and advocates, and clarifying that immigration status would neither be documented nor prevent participation. Solutions from African Americans and Latinos reflect their cultural backgrounds and historical experiences. The results suggest the importance of developing a tailored, barriers-focused navigation intervention to improve participation among diverse racial and ethnic populations.
AN  - WOS:000315631300004
AU  - Ford, M. E.
AU  - Siminoff, L. A.
AU  - Pickelsimer, E.
AU  - Mainous, A. G.
AU  - Smith, D. W.
AU  - Diaz, V. A.
AU  - Soderstrom, L. H.
AU  - Jefferson, M. S.
AU  - Tilley, B. C.
DA  - Feb
DO  - 10.1093/hsw/hlt001
IS  - 1
N1  - 23539894
PY  - 2013
SN  - 0360-7283
SP  - 29-38
ST  - Unequal Burden of Disease, Unequal Participation in Clinical Trials: Solutions from African American and Latino Community Members
T2  - Health & Social Work
TI  - Unequal Burden of Disease, Unequal Participation in Clinical Trials: Solutions from African American and Latino Community Members
VL  - 38
ID  - 3050
ER  - 

TY  - JOUR
AB  - Low unit response rates can increase bias and compromise study validity. Response rates have continued to fall over the past decade despite all efforts to increase participation. Many factors have been linked to reduced response, yet relatively few studies have employed multivariate approaches to identify characteristics that differentiate respondents from nonrespondents since it is hard to collect information on the latter. We aimed to assess factors contributing to enrollment of prostate cancer (PCa) patients. We combined data from the North Carolina-Louisiana (LA) PCa Project's LA cohort, with additional sources such as US census tract and LA tumor registry data. We included specific analyses focusing on blacks, a group often identified as hard to enroll in health-related research. The ability to study the effect of Hurricane Katrina, which occurred amidst enrollment, as a potential determinant of nonresponse makes our study unique. Older age (≥ 70) for blacks (OR 0.65) and study phase with respect to Hurricane Katrina for both races (OR 0.59 for blacks, OR 0.48 for whites) were significant predictors of participation with lower odds. Neighborhood poverty for whites (OR 1.53) also was a significant predictor of participation, but with higher odds. Among blacks, residence in Orleans parish was associated with lower odds of participation (OR 0.33) before Katrina. The opposite occurred in whites, with lower odds (OR 0.43) after Katrina. Our results overall underscore the importance of tailoring enrollment approaches to specific target population characteristics to confront the challenges posed by nonresponse. Our results also show that recruitment-related factors may change when outside forces bring major alterations to a population's environment and demographics.
AD  - Biostatistics Program, LSUHSC School of Public Health, New Orleans, Louisiana, United States of America.
Consultant Epidemiologist, New Orleans, Louisiana, United States of America.
Health Policy and Systems Management Program, LSUHSC School of Public Health, New Orleans, Louisiana, United States of America.
Department of Mathematical Sciences, McNeese State University, Lake Charles, Louisiana, United States of America.
Department of Epidemiology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States of America.
Department of Urology, Roswell Park Cancer Institute, Buffalo, NY, United States of America.
Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.
Epidemiology Program, LSUHSC School of Public Health, New Orleans, Louisiana, United States of America.
AN  - 27992587
AU  - Oral, E.
AU  - Simonsen, N.
AU  - Brennan, C.
AU  - Berken, J.
AU  - Su, L. J.
AU  - Mohler, J. L.
AU  - Bensen, J. T.
AU  - Fontham, E. T.
C2  - PMC5161356
DO  - 10.1371/journal.pone.0168364
DP  - NLM
ET  - 2016/12/20
IS  - 12
KW  - Adenocarcinoma/*epidemiology/pathology
Adult
Aged
Bias
Epidemiologic Research Design
Humans
Louisiana/epidemiology
Male
Middle Aged
Neoplasm Invasiveness
North Carolina/epidemiology
Patient Participation/*statistics & numerical data
Prostatic Neoplasms/*epidemiology/pathology
*Surveys and Questionnaires
Survival Analysis
LA  - eng
N1  - 1932-6203
Oral, Evrim
Orcid: 0000-0003-2976-0778
Simonsen, Neal
Brennan, Christine
Berken, Jennifer
Su, L Joseph
Mohler, James L
Bensen, Jeannette T
Fontham, Elizabeth T H
R15 CA151031/CA/NCI NIH HHS/United States
Journal Article
PLoS One. 2016 Dec 16;11(12):e0168364. doi: 10.1371/journal.pone.0168364. eCollection 2016.
PY  - 2016
SN  - 1932-6203
SP  - e0168364
ST  - Unit Nonresponse in a Population-Based Study of Prostate Cancer
T2  - PLoS One
TI  - Unit Nonresponse in a Population-Based Study of Prostate Cancer
VL  - 11
ID  - 189
ER  - 

TY  - JOUR
AB  - This article uses a historical framework of postcolonialism; discourse analytic concepts (significance, identity, and relationships); and 5 social and cultural linguistic principles of emergence, positionality, indexicality, relationality, and partialness as a theoretical and methodological triangulation approach to data analysis of focus group discussion. Exemplars of focus group data from a study exploring African American participation in research demonstrate the application of this combined framework as a useful tool for analysis. This approach allows for examination of identity and interaction and generates a more rigorous and complete understanding of how individuals use language to construct identity as participants or nonparticipants in research.
AN  - WOS:000335979300006
AU  - Somayaji, D.
AU  - Cloyes, K. G.
DA  - Jan-Mar
DO  - 10.1097/ANS.0000000000000015
IS  - 1
N1  - 24469087
PY  - 2014
SN  - 0161-9268
SP  - 32-47
ST  - Uniting Postcolonial, Discourse, and Linguistic Theory to Explore Participation of African Americans in Cancer Research as an Effect of Social and Historical Race Relationships
T2  - Advances in Nursing Science
TI  - Uniting Postcolonial, Discourse, and Linguistic Theory to Explore Participation of African Americans in Cancer Research as an Effect of Social and Historical Race Relationships
VL  - 37
ID  - 3027
ER  - 

TY  - JOUR
AB  - Research increasingly points to inadequate treatment as a factor in the excess breast cancer mortality experiencedby African Americans. Likely causes include lack of guideline‐concordant care, underuse of medical advances, andlimited opportunities to participate in clinical trials and genetic counseling. African Americans are disproportionatelyaffected because they are more likely to receive care in low‐resource settings. Importantly, emerging researchshows that NCI‐designated Comprehensive Cancer Centers (CCCs) have the best cancer outcomes compared withother clinical settings ‐ yet African Americans and Latinx are under‐represented as patients in CCCs. It is as if the leading cancer clinicians and the resources at their disposal are locked in a vault inaccessible to those with the greatest need. We used ethnographic methods to explore the feasibility of and extent to which the simplemechanism of a CCC 2nd opinion can improve the quality of treatment offered to African American breast cancerpatients receiving care in a range of other institutions. Through community outreach, 14 patients were recruited and17 CCC consultations were conducted at no charge. Each visit was observed and audio‐taped to capture the consulting oncologist's recommendations. Patients were interviewed 3 weeks after the consultation and again up to1 year later to document the impact of the consultation on their treatment. Consulting oncologists were alsointerviewed. Our findings reveal a variety of ways in which the CCC 2nd opinion substantially improved the quality oftreatment for African American breast cancer patients. In all cases CCC clinicians offered important recommendations, from complete revision of a treatment plan to adding/changing medications, modifying the planfor monitoring, and/or improving management of side effects. Patients reported that all major recommendationswere implemented by their treating clinicians. In one dramatic case, chemotherapy was failing to slow the growth ayoung public hospital patient's stage 3 tumor associated with a P53 mutation. The CCC clinician recommended andadvocated for an entirely different treatment. In remission two years later, the patient has had another child. To ourknowledge, this is the first study to explore the CCC consultation as an intervention to reduce mortality disparities. Itappears highly feasible to target CCC 2nd opinions to vulnerable patients at relatively low cost to the CCC. ManyCCC clinicians are eager to see high‐risk under‐represented patients, and go beyond the consultation bycommunicating with treating clinicians and seeing patients more than once. Patients readily recognized theexpertise of CCC clinicians and were deeply grateful for the opportunity. Based on this pilot study, the 2nd opinionconcept warrants further testing via a randomized trial. Comprehensive Cancer Centers can and must take greaterresponsibility for disparities in their region through innovations that extend their expertise beyond their walls.
AN  - CN-02213312
AU  - Pasick, R. J.
AU  - Campbell, B.
AU  - Rugo, H. S.
AU  - Dillard, C.
AU  - Harris, M.
AU  - Joseph, G.
DO  - 10.1158/1538-7755.DISP19-D078
IS  - 6 SUPPL 2
KW  - *African American
*breast cancer
*cancer center
Cancer chemotherapy
Cancer patient
Cancer staging
Child
Clinical article
Conference abstract
Consultation
Controlled study
Feasibility study
Female
Gene mutation
Human
Mortality
Oncologist
Pilot study
Public hospital
Randomized controlled trial
Remission
Risk assessment
Side effect
Treatment failure
M3  - Journal: Conference Abstract
PY  - 2020
ST  - Unlocking the vault: can 2nd opinions byComprehensive Cancer Center breast oncologistsimprove treatment quality for African Americans?
T2  - Cancer epidemiology biomarkers and prevention
TI  - Unlocking the vault: can 2nd opinions byComprehensive Cancer Center breast oncologistsimprove treatment quality for African Americans?
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02213312/full
VL  - 29
ID  - 1397
ER  - 

TY  - JOUR
AB  - PURPOSE Cancer clinical trial accrual rates are low, and information about contributing factors is needed. We examined video-recorded clinical interactions to identify circumstances under which patients potentially eligible for a trial at a major cancer center were offered a trial. METHODS We conducted a qualitative directed content analysis of 62 recorded interactions with physicians (n = 13) and patients with intermediate- or high-risk prostate cancer (n = 43). Patients were screened and potentially eligible for a trial. We observed and coded the interactions in 3 steps: (1) classification of all interactions as explicit offer, offer pending, trial discussed/not offered, or trial not discussed; (2) in interactions with no explicit offer, classification of whether the cancer had progressed; (3) in interactions classified as progression but no trial offered, identification of factors discussed that may explain the lack of an offer. RESULTS Of the 62 interactions, 29% were classified as explicit offer, 12% as offer pending, 18% as trial discussed/not offered, and 39% as trial not discussed. Of those with no offer, 57% included information that the cancer had not progressed. In 68% of the remaining interactions with patients whose cancer had progressed but did not receive an offer, reasons for the lack of offer were identified, but in 32%, no explanation was provided. CONCLUSION Even in optimal circumstances, few patients were offered a trial, often because their cancer had not progressed. Findings support professional recommendations to broaden trial inclusion criteria. Findings suggest accrual rates should reflect the proportion of eligible patients who enroll.
AD  - L.M. Hamel, 4100 John R. MM03CB, Detroit, MI, United States
AU  - Hamel, L. M.
AU  - Dougherty, D. W.
AU  - Albrecht, T. L.
AU  - Wojda, M.
AU  - Jordan, A.
AU  - Moore, T. F.
AU  - Senft, N.
AU  - Carducci, M.
AU  - Heath, E. I.
AU  - Manning, M. A.
AU  - Penner, L. A.
AU  - Kim, S.
AU  - Eggly, S.
DB  - Embase
Medline
DO  - 10.1200/JOP.19.00444
IS  - 2
KW  - adult
African American
aged
article
cancer center
cancer patient
Caucasian
classification
clinical article
clinical study
clinical trial (topic)
content analysis
convenience sample
doctor patient relationship
high risk patient
human
male
oncologist
patient selection
prostate cancer
qualitative analysis
secondary analysis
videorecording
LA  - English
M3  - Article
N1  - L2005865623
2020-05-19
2020-05-27
PY  - 2020
SN  - 2688-1535
2688-1527
SP  - E124-E131
ST  - Unpacking trial offers and low accrual rates: A qualitative analysis of clinic visits with physicians and patients potentially eligible for a prostate cancer clinical trial
T2  - JCO Oncology Practice
TI  - Unpacking trial offers and low accrual rates: A qualitative analysis of clinic visits with physicians and patients potentially eligible for a prostate cancer clinical trial
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L2005865623&from=export
http://dx.doi.org/10.1200/JOP.19.00444
VL  - 16
ID  - 816
ER  - 

TY  - JOUR
AB  - INTRODUCTION: The aim of this clinical update is to summarize articles and guidelines published in the last year with the potential to change current clinical practice as it relates to women's health. METHODS: We used two independent search strategies to identify articles relevant to women's health published between March 1, 2007 and February 29, 2008. First, we reviewed the Cochrane Database of Systematic Reviews and journal indices from the ACP Journal Club, Annals of Internal Medicine, Archives of Internal Medicine, British Medical Journal, Circulation, Diabetes, JAMA, JGIM, Journal of Women's Health, Lancet, NEJM, Obstetrics and Gynecology, and Women's Health Journal Watch. Second, we performed a MEDLINE search using the medical subject heading term "sex factors." The authors, who all have clinical and/or research experience in the area of women's health, reviewed all article titles, abstracts, and, when indicated, full publications. We excluded articles related to obstetrical aspects of women's health focusing on those relevant to general internists. We had two acceptance criteria, scientific rigor and potential to impact women's health. We also identified new and/or updated women's health guidelines released during the same time period. RESULTS: We identified over 250 publications with potential relevance to women's health. Forty-six articles were selected for presentation as part of the Clinical Update, and nine were selected for a more detailed discussion in this paper. Evidence-based women's health guidelines are listed in Table 1. Table 1 Important Women's Health Guidelines in 2007-2008: New or Updated Topic Issuing organization Updated recommendations and comments Mammography screening in women 40-4917 ACP Individualized risk assessment and informed decision making should be used to guide decisions about mammography screening in this age group. To aid in the risk assessment, a discussion of the risk factors, which if present in a woman in her 40s increases her risk to above that of an average 50-year-old woman, is provided in the guidelines. In addition, available risk prediction models, such as the NIH Web site calculator (http://www.cancer.gov/bcrisktool/) can also be used to estimate quantitative breast cancer risk. This model was updated in 2008 with race-specific data for calculating risk in African-American women.18 The harms and benefits of mammography should be discussed and incorporated along with a woman's preferences and breast cancer risk profile into the decision on when to begin screening. If a woman decides to forgo mammography, the decision should be readdressed every 1 to 2 years. STD screening guidelines19 USPSTF and CDC Routine screening for this infection is now recommended for ALL sexually active women age 24 and under, based on the recent high prevalence estimates for chlamydia It is not recommended for women (pregnant or nonpregnant) age 25 and older, unless they are at increased risk for infection. STD treatment guidelines20 CDC Flouroquinolones are NO longer recommended for treatment of N. gonorrhea, due to increasing resistance (as high as 15% of isolates in 2006). For uncomplicated infections, treatment of gonorrhea should be initiated with ceftriaxone 125 mg IM or cefixime 400 mg PO and co-treatment for chlamydia infection (unless ruled out with testing). Recent estimates demonstrate that almost 50% of persons with gonorrhea have concomitant chlamydia infection21. STD = sexually transmitted disease, NIH = National Institutes of Health, ACP = American College of Physicians, USPSTF = United States Prevention Services Task Force, CDC = Centers for Disease Control.
AD  - Rush University Medical Center/Stroger Hospital of Cook County, Chicago, IL, USA. Pamela_Ganschow@rush.edu
AN  - 19259751
AU  - Ganschow, P. S.
AU  - Jacobs, E. A.
AU  - Mackinnon, J.
AU  - Charney, P.
C2  - PMC2686759
DA  - Jun
DO  - 10.1007/s11606-009-0917-9
DP  - NLM
ET  - 2009/03/05
IS  - 6
KW  - Clinical Trials as Topic/standards/trends
Female
Humans
Practice Guidelines as Topic/standards
Risk Factors
*Women's Health
LA  - eng
N1  - 1525-1497
Ganschow, Pamela S
Jacobs, Elizabeth A
Mackinnon, Jennifer
Charney, Pamela
Journal Article
Review
J Gen Intern Med. 2009 Jun;24(6):765-70. doi: 10.1007/s11606-009-0917-9. Epub 2009 Mar 4.
PY  - 2009
SN  - 0884-8734 (Print)
0884-8734
SP  - 765-70
ST  - Update in women's health
T2  - J Gen Intern Med
TI  - Update in women's health
VL  - 24
ID  - 476
ER  - 

TY  - JOUR
AB  - Uterine fibroids (leiomyomas) are the most common benign neoplasm of the female pelvis and have a lifetime prevalence exceeding 80% among African American women and approaching 70% among Caucasian women. Approximately 50% of women with fibroids experience symptoms which may include menorrhagia that may result in anemia, bulk symptoms with bladder and bowel dysfunction and abdominal protrusion, dysmenorrhea, and infertility. Hysterectomy remains the most common treatment option for fibroids and concerns have been raised about the overuse of this procedure. Uterine artery embolization (UAE) is now a well-established uterine preserving and minimally invasive therapy for symptomatic fibroids. Since its introduction, strong evidence for safety and efficacy of UAE has been generated with low rates of complications. This review will discuss UAE for the management of symptomatic uterine fibroids with special focus on emerging technical approaches and novel periprocedural patient care.
AD  - M.P. Kohi, Department of Radiology and Biomedical Imaging, University of California, San Francisco, 505 Parnassus Avenue, M-361, San Francisco, CA, United States
AU  - Kohi, M. P.
AU  - Spies, J. B.
DB  - Embase
DO  - 10.1055/s-0038-1636521
IS  - 1
KW  - NCT02884960
intrauterine contraceptive device
gonadorelin agonist
lidocaine
steroid
adenomyosis
amenorrhea
analgesia
article
blood vessel injury
clinical outcome
disability severity
female fertility
femoral artery
human
hypogastric nerve
infection
leiomyosarcoma
lung embolism
medical device complication
minimally invasive procedure
myomectomy
nuclear magnetic resonance imaging
pain
patient care
patient safety
patient satisfaction
patient selection
postmenopause
pregnancy
preoperative treatment
priority journal
septicemia
therapy effect
tumor vascularization
urinary tract infection
uterine artery embolization
uterus myoma
vagina discharge
vascular access
LA  - English
M3  - Article
N1  - L621576004
2018-04-13
2018-04-18
PY  - 2018
SN  - 1098-8963
0739-9529
SP  - 48-55
ST  - Updates on Uterine Artery Embolization
T2  - Seminars in Interventional Radiology
TI  - Updates on Uterine Artery Embolization
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L621576004&from=export
http://dx.doi.org/10.1055/s-0038-1636521
VL  - 35
ID  - 907
ER  - 

TY  - JOUR
AB  - The aim of the present study was to update, refine, and evaluate a study brochure to promote participation in a population-based study of BRCA mutations among AA women with a personal history of early-onset breast cancer. A multi-step approach was used to develop this brochure and included: (1) feedback from community members (through a Community Advisory Panel (CAP)) to develop and refine the study brochure, (2) pilot testing of materials with the target audience, and (3) review of pilot testing results with the CAP. Based on the feedback received at each step, the study brochure was refined. In phase 1, the major changes included emphasizing the concept of leaving a legacy and family, using the terms Black and women of color, and use of patient vignettes and photos. In phase 2, attraction and cultural acceptability were identified as two areas for improvement in the study brochure. These results demonstrate that involvement of community members and target study population in the development of a study-specific brochure can provide invaluable feedback to optimize recruitment strategies. This approach can be readily adapted to develop study recruitment materials for individuals from a variety of cultural and ethnic backgrounds. © Springer-Verlag 2010.
AD  - S. T. Vadaparampil, Division of Cancer Prevention and Control, Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL 33612, United States
AU  - Vadaparampil, S. T.
AU  - Pal, T.
DB  - Embase
DO  - 10.1007/s12687-010-0010-4
IS  - 2
KW  - African American
article
breast cancer
cancer registry
cancer risk
cultural factor
female
gene mutation
genetic screening
health education
heredity
high risk population
human
patient participation
pilot study
population genetics
priority journal
publication
tumor suppressor gene
LA  - English
M3  - Article
N1  - L50923683
2011-03-15
2011-03-23
PY  - 2010
SN  - 1868-310X
1868-6001
SP  - 63-71
ST  - Updating and refining a study brochure for a cancer registry-based study of BRCA mutations among young African American breast cancer patients: Lessons learned
T2  - Journal of Community Genetics
TI  - Updating and refining a study brochure for a cancer registry-based study of BRCA mutations among young African American breast cancer patients: Lessons learned
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L50923683&from=export
http://dx.doi.org/10.1007/s12687-010-0010-4
VL  - 1
ID  - 1164
ER  - 

TY  - JOUR
AB  - BACKGROUND: Recent advances in mobile technologies have created new opportunities to reach broadly into populations that are vulnerable to health disparities. However, mobile health (mHealth) strategies could paradoxically increase health disparities, if low socioeconomic status individuals lack the technical or literacy skills needed to navigate mHealth programs. OBJECTIVE: The aim of this study was to determine whether patients from vulnerable populations could successfully navigate and complete an mHealth patient decision aid. METHODS: We analyzed usability data from a randomized controlled trial of an iPad program designed to promote colorectal cancer (CRC) screening. The trial was conducted in six primary care practices and enrolled 450 patients, aged 50-74 years, who were due for CRC screening. The iPad program included a self-survey and randomly displayed either a screening decision aid or a video about diet and exercise. We measured participant ability to complete the program without assistance and participant-rated program usability. RESULTS: Two-thirds of the participants (305/450) were members of a vulnerable population (limited health literacy, annual income < US $20,000, or black race). Over 92% (417/450) of the participants rated the program highly on all three usability items (90.8% for vulnerable participants vs 96.6% for nonvulnerable participants, P=.006). Only 6.9% (31/450) of the participants needed some assistance to complete the program. In multivariable logistic regression, being a member of a vulnerable population was not associated with needing assistance. Only older age, less use of text messaging (short message service, SMS), and lack of Internet use predicted needing assistance. CONCLUSIONS: Individuals who are vulnerable to health disparities can successfully use well-designed mHealth programs. Future research should investigate whether mHealth interventions can reduce health disparities.
AD  - Wake Forest School of Medicine, Department of Internal Medicine, Winston-Salem, NC, United States.
Wake Forest School of Medicine, Department of Social Sciences & Health Policy, Winston-Salem, NC, United States.
Wake Forest School of Medicine, Department of Biostatistical Sciences, Winston-Salem, NC, United States.
Wake Forest Health Sciences, Enterprise Information Management, Winston-Salem, NC, United States.
University of Texas Dell Medical School, Department of Internal Medicine, Austin, TX, United States.
Wake Forest School of Medicine, Department of Family & Community Medicine, Winston-Salem, NC, United States.
AN  - 28400354
AU  - Miller, D. P., Jr.
AU  - Weaver, K. E.
AU  - Case, L. D.
AU  - Babcock, D.
AU  - Lawler, D.
AU  - Denizard-Thompson, N.
AU  - Pignone, M. P.
AU  - Spangler, J. G.
C2  - PMC5405290
DA  - Apr 11
DO  - 10.2196/mhealth.7268
DP  - NLM
ET  - 2017/04/13
IS  - 4
KW  - decision support techniques
health literacy
primary care
technology assessment
vulnerable populations
LA  - eng
N1  - 2291-5222
Miller, David P Jr
Orcid: 0000-0001-7879-4427
Weaver, Kathryn E
Orcid: 0000-0001-9006-4064
Case, L Doug
Orcid: 0000-0002-5706-4377
Babcock, Donald
Orcid: 0000-0003-1899-5731
Lawler, Donna
Orcid: 0000-0001-6737-9818
Denizard-Thompson, Nancy
Orcid: 0000-0002-8498-0792
Pignone, Michael P
Orcid: 0000-0002-6657-7342
Spangler, John G
Orcid: 0000-0002-7949-7050
R01 CA178941/CA/NCI NIH HHS/United States
UL1 TR001420/TR/NCATS NIH HHS/United States
Journal Article
JMIR Mhealth Uhealth. 2017 Apr 11;5(4):e43. doi: 10.2196/mhealth.7268.
PY  - 2017
SN  - 2291-5222 (Print)
2291-5222
SP  - e43
ST  - Usability of a Novel Mobile Health iPad App by Vulnerable Populations
T2  - JMIR Mhealth Uhealth
TI  - Usability of a Novel Mobile Health iPad App by Vulnerable Populations
VL  - 5
ID  - 174
ER  - 

TY  - JOUR
AB  - Objective To study the impact of genomic testing in shared decision making for men with clinically low-risk prostate cancer (PCa). Materials and Methods Patients with clinically low-risk PCa were enrolled in a prospective, multi-institutional study of a validated 17-gene tissue-based reverse transcription polymerase chain reaction assay (Genomic Prostate Score [GPS]). In this paper we report on outcomes in the first 297 patients enrolled in the study with valid 17-gene assay results and decision-change data. The primary end points were shared decision on initial management and persistence on active surveillance (AS) at 1 year post diagnosis. AS utilization and persistence were compared with similar end points in a group of patients who did not have genomic testing (baseline cohort). Secondary end points included perceived utility of the assay and patient decisional conflict before and after testing. Results One-year results were available on 258 patients. Shift between initial recommendation and shared decision occurred in 23% of patients. Utilization of AS was higher in the GPS-tested cohort than in the untested baseline cohort (62% vs 40%). The proportion of men who selected and persisted on AS at 1 year was 55% and 34% in the GPS and baseline cohorts, respectively. Physicians reported that GPS was useful in 90% of cases. Mean decisional conflict scores declined in patients after GPS testing. Conclusion Patients who received GPS testing were more likely to select and persist on AS for initial management compared with a matched baseline group. These data indicate that GPS help guide shared decisions in clinically low-risk PCa. © 2017 The Authors
AD  - Urology of Virginia, Virginia Beach, VA, United States
Regional Urology LLC, Shreveport, LA, United States
Genomic Health Inc., Redwood City, CA, United States
The Iowa Clinic, West Des Moines, IA, United States
Wichita Urology, Wichita, KS, United States
Premier Medical Group, Poughkeepsie, NY, United States
AU  - Eure, G.
AU  - Germany, R.
AU  - Given, R.
AU  - Lu, R.
AU  - Shindel, A. W.
AU  - Rothney, M.
AU  - Glowacki, R.
AU  - Henderson, J.
AU  - Richardson, T.
AU  - Goldfischer, E.
AU  - Febbo, P. G.
AU  - Denes, B. S.
DB  - Scopus
DO  - 10.1016/j.urology.2017.02.052
M3  - Article
N1  - Cited By :19
Export Date: 22 March 2021
PY  - 2017
SP  - 67-75
ST  - Use of a 17-Gene Prognostic Assay in Contemporary Urologic Practice: Results of an Interim Analysis in an Observational Cohort
T2  - Urology
TI  - Use of a 17-Gene Prognostic Assay in Contemporary Urologic Practice: Results of an Interim Analysis in an Observational Cohort
UR  - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85023602714&doi=10.1016%2fj.urology.2017.02.052&partnerID=40&md5=4595fbdac9edbe44bdb26cc41f7f7c19
VL  - 107
ID  - 2301
ER  - 

TY  - JOUR
AB  - Background: For postmenopausal women with hormone receptor‐positive breast cancer, use of aromatase inhibitors (AI) significantly reduces the risk of cancer recurrence and improves survival, but many patients are nonadherent due to adverse side effects. We conducted a pilot randomized controlled trial of a web‐enabled application (app) to provide real‐time symptom monitoring between visits and facilitate management of treatmentrelated adverse symptoms among patients with hormone receptor‐positive breast cancer and a new AI prescription. Methods: Patients were randomized into two groups: (1) App+Reminder: had access to the app and received weekly reminders via text or email to use it, or (2) App: had access to the app but did not receive reminders. The app asked patients about their AI use in the last 7 days and about new symptoms related to the treatment. New symptoms with severity in a clinically‐relevant range or AI nonadherence triggered email alerts to the patient's providers. The main analyses compared AI adherence and changes in quality of life. Results: We enrolled 44 patients, 21 in the App+Reminder and 23 in the App group; 83% of patients approached agreed to participate, 23% were African‐American, and 32% were over the age of 65. Overall, 74% of participants in the App+Reminder group used the app at least once per week compared with 38% in the App group (p<0.01). Reported AI adherence 8 weeks after initiation was significantly higher among those in the App+Reminder group compared with the App group (100% vs. 72%, p=0.01). Using a differences‐indifferences analysis, we found that the decrease in quality of life 8 weeks after AI initiation was substantially larger, but not statistically significant, in the App group compared with App+Reminder (difference=7.6, p=0.191). Conclusions: Use ofa web‐enabled app to provide real‐time monitoring of AI adherence and treatment‐related symptoms with weekly reminders significantly improves short‐term AI adherence and may limit reductions in quality of life.If short‐term gains in adherence persist, this low‐cost intervention could improve survival outcomes for women with hormone receptor‐positive breast cancer.
AN  - CN-01409765
AU  - Graetz, I.
AU  - McKillop, C. N.
AU  - Stepanski, E. J.
AU  - Vidal, G. A.
AU  - Schwartzberg, L. S.
IS  - 15
KW  - *breast cancer
*symptom
African American
Aged
Clinical article
Controlled clinical trial
Controlled study
Drug therapy
E‐mail
Female
Human
Monitoring
Prescription
Quality of life
Randomized controlled trial
M3  - Journal: Conference Abstract
PY  - 2017
ST  - Use of a web-based app to improve breast cancer symptom management and aromatase inhibitor adherence: a pilot randomized controlled trial
T2  - Journal of clinical oncology
TI  - Use of a web-based app to improve breast cancer symptom management and aromatase inhibitor adherence: a pilot randomized controlled trial
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01409765/full
VL  - 35
ID  - 1517
ER  - 

TY  - JOUR
AB  - Introduction African-American women have higher rates of early-onset breast cancer compared with their Caucasian counterparts; yet, when diagnosed with breast cancer at a young age, they underuse genetic counseling and testing to manage their risk of developing future cancers. Methods Self-reported baseline data were collected between September 2012 and January 2013 and analyzed in 2014 from a subpopulation of 340 African-American young breast cancer survivors (YBCSs) enrolled in an RCT. YBCSs were diagnosed with invasive breast cancer or ductal carcinoma in situ between ages 20 and 45 years and were randomly selected from a statewide cancer registry. Logistic regression examined predictors of using cancer genetics services. Results Overall, 28% of the sample reported having genetic counseling and 21% reported having genetic testing, which were significantly lower (p≤0.005) compared with white/other YBCSs participating in the parent study. In a multivariate analysis, income was positively associated with counseling (B=0.254, p≤0.01) and testing (B=0.297, p≤0.01), whereas higher education levels (B=−0.328, p≤0.05) and lack of access to healthcare services owing to cost (B=−1.10, p≤0.03) were negatively associated with genetic counseling. Lower income and lack of care because of high out-of-pocket costs were commonly reported barriers. Conclusions Despite national recommendations for genetic evaluation among women with early-onset breast cancer, few African-American YBCSs reported undergoing genetic counseling and testing. Most reported that their healthcare provider did not recommend these services. Interventions addressing patient, provider, and structural healthcare system barriers to using genetic counseling and testing in this population are needed.
AD  - M.C. Katapodi, Nursing Science, Faculty of Medicine, University of Basel, Bernoullistrasse 28, Room 113, Basel, Switzerland
AU  - Jones, T.
AU  - Lockhart, J. S.
AU  - Mendelsohn-Victor, K. E.
AU  - Duquette, D.
AU  - Northouse, L. L.
AU  - Duffy, S. A.
AU  - Donley, R.
AU  - Merajver, S. D.
AU  - Milliron, K. J.
AU  - Roberts, J. S.
AU  - Katapodi, M. C.
DB  - Embase
Medline
DO  - 10.1016/j.amepre.2016.03.016
IS  - 4
KW  - NCT01612338
adult
African American
article
breast cancer
breast carcinoma
cancer genetics
cancer registry
cancer survivor
controlled study
educational status
female
genetic counseling
genetic screening
genetic service
health care cost
health service
human
logistic regression analysis
major clinical study
multivariate analysis
patient-reported outcome
randomized controlled trial
tumor invasion
LA  - English
M3  - Article
N1  - L610650775
2016-06-14
2016-11-08
PY  - 2016
SN  - 1873-2607
0749-3797
SP  - 427-436
ST  - Use of Cancer Genetics Services in African-American Young Breast Cancer Survivors
T2  - American Journal of Preventive Medicine
TI  - Use of Cancer Genetics Services in African-American Young Breast Cancer Survivors
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L610650775&from=export
http://dx.doi.org/10.1016/j.amepre.2016.03.016
VL  - 51
ID  - 961
ER  - 

TY  - JOUR
AB  - PURPOSE: The treatment of cancer-induced anemia with erythropoietin-stimulating agents (ESAs) is reviewed. SUMMARY: Before the introduction of ESAs, the only treatment option for cancer-related anemia was red blood cell (RBC) transfusion. The use of ESAs in multiple disease states has been well established and is now considered first-line treatment for many forms of anemia. Chang et al. evaluated the effect of epoetin alfa (40,000 units administered subcutaneously every week) and standard-of-care therapy on quality of life (QOL), transfusion requirements, and hemoglobin levels in 354 patients with breast cancer who had a baseline hemoglobin concentration of <15 g/dL. The authors concluded that early initiation of treatment with epoetin alfa in patients with breast cancer is effective in maintaining hemoglobin levels, reducing transfusions, and improving QOL. Leyland-Jones et al. conducted a study evaluating the effects of early intervention with epoetin alfa (40,000 units administered subcutaneously every week) on survival and QOL of mainly nonanemic patients with metastatic breast cancer. In contrast to Chang et al., this study was discontinued because of lower overall survival rates within the epoetin alfa group. In 2008, the Food and Drug Administration issued a black-box warning for both epoetin alfa and darbepoetin alfa. The warning acknowledges that ESAs have shortened overall survival and time to disease progression in patients with advanced breast cancer who are given these agents to achieve a target hemoglobin concentration of > or =12 g/dL. CONCLUSION: When used in patients with cancer-induced anemia, ESAs should only be given at the lowest dose possible to prevent RBC transfusions. During treatment, hemoglobin levels should be monitored closely and ESA doses need to be adjusted accordingly.
AD  - Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ 08854, USA.
AN  - 19535656
AU  - Crouch, Z.
AU  - DeSantis, E. R.
DA  - Jul 1
DO  - 10.2146/ajhp080214
DP  - NLM
ET  - 2009/06/19
IS  - 13
KW  - Anemia/*drug therapy/etiology/mortality
Blood Transfusion
Breast Neoplasms/*complications/mortality
Darbepoetin alfa
Drug Labeling
Drug Monitoring/methods
Epoetin Alfa
Erythropoietin/adverse effects/analogs & derivatives/therapeutic use
Female
Hematinics/adverse effects/*therapeutic use
Hemoglobins/drug effects/metabolism
Humans
Quality of Life
Randomized Controlled Trials as Topic
Recombinant Proteins
Survival Rate
LA  - eng
N1  - 1535-2900
Crouch, Zachary
DeSantis, Evelyn R Hermes
Journal Article
Review
England
Am J Health Syst Pharm. 2009 Jul 1;66(13):1180-5. doi: 10.2146/ajhp080214.
PY  - 2009
SN  - 1079-2082
SP  - 1180-5
ST  - Use of erythropoietin-stimulating agents in breast cancer patients: a risk review
T2  - Am J Health Syst Pharm
TI  - Use of erythropoietin-stimulating agents in breast cancer patients: a risk review
VL  - 66
ID  - 463
ER  - 

TY  - JOUR
AB  - Background: Daratumumab (dara), a human CD38‐directed monoclonal antibody indicated for the treatment of patients (pts) with multiple myeloma (MM) who have received >3 prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent (IMID) or who are double‐refractory to a PI and an IMID, was granted accelerated approval in the United States (US) in November 201 5. CD38 is expressed on airway smooth muscle cells, and infusion related reactions (IRRs) in registration studies were marked by symptoms (cough, wheezing, rhinorrhea) similar to those of allergic rhinitis. Anecdotal reports indicated that premedication with montelukast, a leukotriene receptor antagonist, may reduce the IRR rate associated with dara therapy. Methods: A multicenter, open‐label early access treatment protocol (EAP) was conducted to provide early access to dara treatment and collect safety data including IRRs. Eligibility criteria were similar to those of pivotal study MMY2002 in pts with double‐refractory MM or >3 prior therapies including a PI and an IMID, age >18 years, documented MM, progression by IMWG criteria following the most recent therapy, >3 prior lines of therapy including a PI and an IMID or disease double‐refractory to a PI and an IMID, ECOG performance status score 0‐2, no known chronic obstructive pulmonary disease or persistent asthma, no ongoing MM therapy, and no prior exposure to anti‐CD38 antibody therapy. Pts received dara 16 mg/kg IV weekly for 8 weeks, then every 2 weeks for 16 weeks, and then every 4 weeks until disease progression, unacceptable toxicity, or 60 days after US approval. Pre‐and post‐infusion medications were administered as in study MMY2002 and included pre‐and post‐infusion systemic corticosteroids for all pts as well as post‐infusion inhaled corticosteroids and bronchodilators for pts with obstructive lung disorders. Montelukast was not recommended but was allowed at the investigator's discretion. Results: In total, 400 pts were screened and 348 pts were enrolled and dosed at 39 US sites from July to November 2015. Median age was 65 (range 27‐94) years; 72% were white, and 17% were African American. Most (74%) pts were symptomatic with an ECOG score of 1 or 2. Pts received a median of 8 (range 1‐17) doses, and median treatment exposure was 1.9 (range 0.03‐6.01) months. Median durations of infusion were 7.4, 4.4, and 3.5 hours for the first, second, and all subsequent infusions, respectively. IRRs occurred in 56% of pts, including 8% with grade >3 IRRs. IRRs occurred in 56%, 2%, and 2% of first, second, and all subsequent infusions, respectively. The most common IRRs at the first infusion were respiratory or thoracic symptoms, which occurred in 31% of pts and included cough (14%), dyspnea (8%), throat irritation (6%), and nasal congestion (5%). Fifty pts received montelukast 10 mg given >30 minutes prior to the first infusion, and 298 pts did not. The IRR rate at first infusion was 38.0% and 58.5% (respiratory symptoms 20% and 32%), respectively, in pts who did or did not receive montelukast. Gastrointestinal symptoms were observed in 4% and 11% of pts who did or did not receive montelukast, respectively, while chills were observed in 14% of pts in both groups. Median time for first infusion was 6.7 and 7.6 hours for pts who did or did not receive montelukast, respectively, while times for the second and all subsequent infusions were similar in both groups. Conclusions: The findings of the EAP study in US pts with MM who had received >3 prior therapies including a PI and IMID or were double‐refractory observed that the IRR rate during the first dara infusion was one‐third lower in pts who received 10 mg of montelukast >30 min prior to the first dara infusion. Respiratory and gastrointestinal symptoms were lower in pts who received montelukast, whereas chills were observed at a similar rate in both groups. The median time for the first infusion was 0.9 hours shorter in pts who received montelukast. Additional studies of montelukast to mitigate the IRRs associated with the first infusion of dara are indicated.
AN  - CN-01334755
AU  - Chari, A.
AU  - Mark, T. M.
AU  - Krishnan, A.
AU  - Stockerl-Goldstein, K.
AU  - Usmani, S. Z.
AU  - Londhe, A.
AU  - Etheredge, D.
AU  - Parros, H.
AU  - Fleming, S.
AU  - Liu, B.
AU  - et al.
IS  - 22) (no pagination
KW  - *United States
*clinical protocol
*daratumumab
*drug infusion
*montelukast
*multiple myeloma
Adult
Adverse drug reaction
African American
Aged
Asthma
Bronchodilating agent
CD38 antigen
Cancer epidemiology
Chill
Chronic obstructive lung disease
Clinical trial
Controlled clinical trial
Controlled study
Corticosteroid
Coughing
Disease course
Drug therapy
Dyspnea
Endogenous compound
Exposure
Gastrointestinal symptom
Human
Infusion related reaction
Major clinical study
Multicenter study
Nose obstruction
Pharmacokinetics
Proteasome inhibitor
Safety
Side effect
Thorax
Throat irritation
Toxicity
Tumor resistance
Young adult
M3  - Journal: Conference Abstract
PY  - 2016
ST  - Use of montelukast to reduce infusion reactions in an early access treatment protocol of daratumumab in united states patients with relapsed or refractory multiple myeloma
T2  - Blood. Conference: 58th annual meeting of the american society of hematology, ASH 2016. United states. Conference start: 20161203. Conference end: 20161206
TI  - Use of montelukast to reduce infusion reactions in an early access treatment protocol of daratumumab in united states patients with relapsed or refractory multiple myeloma
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01334755/full
VL  - 128
ID  - 1443
ER  - 

TY  - JOUR
AB  - Objectives: To determine the rate of Gleason Grade Group (GGG) upgrading in African-American (AA) men with a prior diagnosis of low-grade prostate cancer (GGG 1 or GGG 2) on 12-core systematic biopsy (SB) after multiparametric magnetic resonance imaging (mpMRI) and fusion biopsy (FB); and whether AA men who continued active surveillance (AS) after mpMRI and FB fared differently than a predominantly Caucasian (non-AA) population. Patients and methods: A database of men who had undergone mpMRI and FB was queried to determine rates of upgrading by FB amongst men deemed to be AS candidates based on SB prior to referral. After FB, Kaplan–Meier curves were generated for AA men and non-AA men who then elected AS. The time to GGG upgrading and time continuing AS were compared using the log-rank test. Results: AA men referred with GGG 1 disease on previous SB were upgraded to GGG ≥3 by FB more often than non-AA men, 22.2% vs 12.7% (P = 0.01). A total of 32 AA men and 258 non-AA men then continued AS, with a median (interquartile range) follow-up of 39.19 (24.24–56.41) months. The median time to progression was 59.7 and 60.5 months, respectively (P = 0.26). The median time continuing AS was 61.9 months and not reached, respectively (P = 0.80). Conclusions: AA men were more likely to be upgraded from GGG 1 on SB to GGG ≥3 on initial FB; however, AA and non-AA men on AS subsequently progressed at similar rates following mpMRI and FB. A greater tendency for SB to underestimate tumour grade in AA men may explain prior studies that have shown AA men to be at higher risk of progression during AS.
AD  - P.A. Pinto, Urologic Oncology Branch, NCI, NIH, Bethesda, MD, United States
AU  - Bloom, J. B.
AU  - Lebastchi, A. H.
AU  - Gold, S. A.
AU  - Hale, G. R.
AU  - Sanford, T.
AU  - Mehralivand, S.
AU  - Ahdoot, M.
AU  - Rayn, K. N.
AU  - Czarniecki, M.
AU  - Smith, C.
AU  - Valera, V.
AU  - Wood, B. J.
AU  - Merino, M. J.
AU  - Choyke, P. L.
AU  - Parnes, H. L.
AU  - Turkbey, B.
AU  - Pinto, P. A.
DB  - Embase
Medline
DO  - 10.1111/bju.14835
IS  - 5
KW  - nuclear magnetic resonance scanner
active surveillance
adult
African American
article
cancer epidemiology
cancer growth
Caucasian
cohort analysis
controlled study
follow up
fusion biopsy
Gleason score
human
human tissue
major clinical study
male
multiparametric magnetic resonance imaging
patient referral
patient selection
priority journal
prospective study
prostate biopsy
prostate cancer
retrospective study
Achieva
LA  - English
M3  - Article
N1  - L628342905
2019-07-05
2019-11-07
PY  - 2019
SN  - 1464-410X
1464-4096
SP  - 768-774
ST  - Use of multiparametric magnetic resonance imaging and fusion-guided biopsies to properly select and follow African-American men on active surveillance
T2  - BJU International
TI  - Use of multiparametric magnetic resonance imaging and fusion-guided biopsies to properly select and follow African-American men on active surveillance
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L628342905&from=export
http://dx.doi.org/10.1111/bju.14835
VL  - 124
ID  - 834
ER  - 

TY  - JOUR
AB  - Many cancer treatment and prevention trials as well as surveillance programs suffer from a disproportionately low rate of accrual and a high rate of noncompliance or dropouts of racial minorities and the poor. One suggested strategy to help remediate this trend is to directly involve those targeted populations within the development, implementation, and evaluation of these services. The Radiation Oncology Community Outreach Group (ROCOG) and Neighborhood Cancer Care Cooperative (NCCC) are designed based upon this type of highly collaborative organizational structure, consistent with the general principles of community-based participatory research. Funded by the National Cancer Institute Cancer Disparities Research Partnership program, ROCOG/NCCC provide oncology-focused, community hospital-based initiatives intended to help close the cancer disparities gap. This article presents a descriptive case study of the organizational and political process that preceded our grant proposal submission, the potential benefits and difficulties associated with our extensive collaborative model, and an example of how highly competitive health care organizations can become partners in narrowly focused initiatives aimed at a greater social good.
AN  - WOS:000208103600001
AU  - Morgenlander, K. H.
AU  - Heron, D. E.
AU  - Schenken, L. L.
DO  - 10.1080/15433710802671668
IS  - 4
N1  - SI
19517297
PY  - 2009
SN  - 1937-1918
SP  - 277-304
ST  - Use of Partnership Strategies to Build Radiation Oncology Disparities Research Programs in Five Western Pennsylvania Communities: An Organizational Case Study
T2  - Social Work in Public Health
TI  - Use of Partnership Strategies to Build Radiation Oncology Disparities Research Programs in Five Western Pennsylvania Communities: An Organizational Case Study
VL  - 24
ID  - 3160
ER  - 

TY  - JOUR
AB  - BACKGROUND: Despite recommendations for preventive health services and routine HIV care for HIV-positive women, limited data are available regarding uptake of recommendations. METHODS: We used data from the 2013-2014 data cycles of the Medical Monitoring Project. We calculated weighted estimates and used multivariable logistic regression with adjusted prevalence ratios and 95% confidence intervals to examine associations between preventive health screenings, routine HIV care [based on viral load (VL) and CD4 measures as proxies], and sociodemographic factors. RESULTS: Of 2766 women, 47.7% were 50 years and older, 61.7% non-Hispanic black, 37.2% had >high school education, 63.3% had been living with HIV for ≥10 years, 68.4% were living ≤the federal poverty level, 67.3% had public health insurance, 93.8% were prescribed antiretroviral therapy, and 66.1% had sustained/durable suppression (12 months). For women aged 18 years and older, cervical cancer, breast cancer, and sexually transmitted infection screenings were documented for 44.3%, 27.6%, and 34.7%, respectively; 26% did not meet 6-month, and 37% did not meet 12-month, VL and CD4 test measure goals. In multivariable analyses, women with no VLs in the past 6 months were less likely to be durably suppressed, and women who did not have ≥3 CD4 or VL tests (past 12 months) were less likely to be living above the poverty level and more likely to have public insurance compared with private health insurance (P < 0.05). CONCLUSION: Receipt of recommended preventive care was suboptimal. Targeted interventions are warranted to help ensure access to comprehensive HIV care and prevention services for women.
AD  - Division of Infectious Diseases, Department of Medicine, University of Pennsylvania, Philadelphia, PA.
Division of HIV/AIDS Prevention, National Centers for HIV, Viral Hepatitis, STD and TB Prevention, Centers for Disease Control and Prevention Atlanta, GA.
Department of Obstetrics and Gynecology, Morehouse School of Medicine, Atlanta, GA.
ICF, Atlanta, GA.
AN  - 31335584
AU  - Short, W. R.
AU  - Sutton, M. Y.
AU  - Luo, Q.
AU  - Frazier, E. L.
DA  - Nov 1
DO  - 10.1097/qai.0000000000002141
DP  - NLM
ET  - 2019/07/25
IS  - 3
KW  - Adolescent
Adult
Anti-Retroviral Agents/therapeutic use
Breast Neoplasms/epidemiology
CD4 Lymphocyte Count
Female
HIV Infections/*epidemiology/*prevention & control/*therapy
Humans
Insurance, Health
Logistic Models
Middle Aged
Patient Participation
Prevalence
*Preventive Health Services/statistics & numerical data
Sexually Transmitted Diseases/epidemiology
Socioeconomic Factors
United States/epidemiology
Uterine Cervical Neoplasms/epidemiology
Viral Load
Young Adult
LA  - eng
N1  - 1944-7884
Short, William R
Sutton, Madeline Y
Luo, Qingwei
Frazier, Emma L
Journal Article
United States
J Acquir Immune Defic Syndr. 2019 Nov 1;82(3):234-244. doi: 10.1097/QAI.0000000000002141.
PY  - 2019
SN  - 1525-4135
SP  - 234-244
ST  - Use of Recommended Preventive Health Care Services and Variations in HIV Care Among Women With HIV in the United States, 2013-2014: Opportunities for Expanded Partnerships in Support of Ending the HIV Epidemic
T2  - J Acquir Immune Defic Syndr
TI  - Use of Recommended Preventive Health Care Services and Variations in HIV Care Among Women With HIV in the United States, 2013-2014: Opportunities for Expanded Partnerships in Support of Ending the HIV Epidemic
VL  - 82
ID  - 72
ER  - 

TY  - JOUR
AB  - BACKGROUND: Disparities in cancer outcome among different subsets of the American population related to ethnic background have been well documented. Clinical trials represent the most powerful strategy for improving cancer treatments, but racial and ethnic minority patients are frequently underrepresented among patients accrued to these protocols. Proof of comparable efficacy for a promising cancer therapy in different groups of patients requires diversity in the clinical trial populations so that study results will be generalizable. Appropriate targets for accrual of minority ethnicity patients have not previously been defined. METHODS: The National Cancer Database (NCDB) is maintained jointly by the American Cancer Society and the American College of Surgeons. Information submitted by tumor registries throughout the United States represents an estimated 70% of newly diagnosed cancer cases. The authors analyzed NCDB reports on ethnic distribution of patients with breast, prostate, nonsmall cell lung, and colorectal cancer, stratified by stage of disease at diagnosis. RESULTS: African Americans with cancer of the breast and prostate had the most notable patterns of disproportionate representation among populations with advanced-stage disease. The authors compiled a table of suggested accrual targets for selected solid-organ cancers based on NCDB stage-specific reports. CONCLUSIONS: Clinical trial results will be more meaningful if participating patients reflect the site- and stage-specific populations that are under study. The authors recommended that clinical trial investigators incorporate accrual targets for minority ethnicity populations into the study design.
AD  - Department of Surgery, University of Michigan, Ann Arbor, Michigan, USA. Lanewman@umich.edu
AN  - 16333856
AU  - Newman, L. A.
AU  - Lee, C. T.
AU  - Parekh, L. P.
AU  - Stewart, A. K.
AU  - Thomas, C. R., Jr.
AU  - Beltran, R. A.
AU  - Lucci, A.
AU  - Green, B.
AU  - Ota, D.
AU  - Nelson, H.
DA  - Jan 1
DO  - 10.1002/cncr.21592
DP  - NLM
ET  - 2005/12/08
IS  - 1
KW  - American Cancer Society
*Clinical Trials as Topic
*Databases, Factual
Humans
*Minority Groups
Neoplasms/*ethnology
*Patient Selection
United States/epidemiology
LA  - eng
N1  - Newman, Lisa A
Lee, Cheryl T
Parekh, Lina Patel
Stewart, Andrew K
Thomas, Charles R Jr
Beltran, Robert A
Lucci, Anthony
Green, Bettye
Ota, David
Nelson, Heidi
American College of Surgeons Oncology Group (ACOSOG) Special Population Committee
Journal Article
United States
Cancer. 2006 Jan 1;106(1):188-95. doi: 10.1002/cncr.21592.
PY  - 2006
SN  - 0008-543X (Print)
0008-543x
SP  - 188-95
ST  - Use of the National Cancer Data Base to develop clinical trials accrual targets that are appropriate for minority ethnicity patients: a report from the American College of Surgeons Oncology Group (ACOSOG) Special Population Committee
T2  - Cancer
TI  - Use of the National Cancer Data Base to develop clinical trials accrual targets that are appropriate for minority ethnicity patients: a report from the American College of Surgeons Oncology Group (ACOSOG) Special Population Committee
VL  - 106
ID  - 579
ER  - 

TY  - JOUR
AB  - BACKGROUND. Disparities in cancer outcome among different subsets of the American population related to ethnic background have been well documented. Clinical trials represent the most powerful strategy for improving cancer treatments, but racial and ethnic minority patients are frequently underrepresented among patients accrued to these protocols. Proof of comparable efficacy for a promising cancer therapy in different groups of patients requires diversity in the clinical trial populations so that study results will be generalizable. Appropriate targets for accrual of minority ethnicity patients have not previously been defined. METHODS. The National Cancer Database (NCDB) is maintained jointly by the American Cancer Society and the American College of Surgeons. Information submitted by tumor registries throughout the United States represents an estimated 70% of newly diagnosed cancer cases. The authors analyzed NCDB reports on ethnic distribution of patients with breast, prostate, nonsmall cell lung, and colorectal cancer, stratified by stage of disease at diagnosis. RESULTS. African Americans with cancer of the breast and prostate had the most notable patterns of disproportionate representation among populations with advanced-stage disease. The authors compiled a table of suggested accrual targets for selected solid-organ cancers based on NCDB stage-specific reports. CONCLUSIONS. Clinical trial results will be more meaningful if participating patients reflect the site- and stage-specific populations that are under study. The authors recommended that clinical trial investigators incorporate accrual targets for minority ethnicity populations into the study design. © 2005 American Cancer Society.
AD  - L.A. Newman, Breast Care Center, University of Michigan Comprehensive Cancer Center, 3308 Cancer Center, 1500 E. Medical Center Drive, Ann Arbor, MI 48109-0932, United States
AU  - Newman, L. A.
AU  - Lee, C. T.
AU  - Parekh, L. P.
AU  - Stewart, A. K.
AU  - Thomas Jr, C. R.
AU  - Beltran, R. A.
AU  - Lucci, A.
AU  - Green, B.
AU  - Ota, D.
AU  - Nelson, H.
DB  - Embase
Medline
DO  - 10.1002/cncr.21592
IS  - 1
KW  - African American
article
breast cancer
cancer registry
cancer research
clinical research
colorectal cancer
ethnology
health care planning
health care policy
health care quality
human
non small cell lung cancer
minority group
priority journal
prostate cancer
United States
LA  - English
M3  - Article
N1  - L43032564
2006-01-23
PY  - 2006
SN  - 0008-543X
SP  - 188-195
ST  - Use of the National Cancer Data Base to develop clinical trials accrual targets that are appropriate for minority ethnicity patients: A report from the American College of Surgeons Oncology Group (ACOSOG) special populations committee
T2  - Cancer
TI  - Use of the National Cancer Data Base to develop clinical trials accrual targets that are appropriate for minority ethnicity patients: A report from the American College of Surgeons Oncology Group (ACOSOG) special populations committee
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L43032564&from=export
http://dx.doi.org/10.1002/cncr.21592
VL  - 106
ID  - 1255
ER  - 

TY  - JOUR
AD  - Department of Psychology, Wichita State University, Kansas, USA.
AN  - 16708456
AU  - Lewis, R. K.
DA  - Aug
DO  - 10.1177/1090198104272254
DP  - NLM
ET  - 2006/05/20
IS  - 4
KW  - African Americans/*psychology
Culture
*Diagnostic Tests, Routine
Health Services Research
Humans
Male
Patient Acceptance of Health Care/*ethnology
*Patient Selection
Prostatic Neoplasms/ethnology/*prevention & control
Refusal to Participate
LA  - eng
N1  - Lewis, Rhonda K
Comment
Journal Article
United States
Health Educ Behav. 2005 Aug;32(4):452-4. doi: 10.1177/1090198104272254.
PY  - 2005
SN  - 1090-1981 (Print)
1090-1981
SP  - 452-4
ST  - Using a culturally relevant theory to recruit African American men for prostate cancer screening
T2  - Health Educ Behav
TI  - Using a culturally relevant theory to recruit African American men for prostate cancer screening
VL  - 32
ID  - 567
ER  - 

TY  - JOUR
AB  - Comments on the article by Abernethy et al. (see record [rid]2005-07626-002[/rid]) which presents a successful strategy to recruit African American men for prostate cancer screening. The authors applied the PEN-3 model (Airhihenbuwa, 1995) of health education, an educational diagnosis of behavior, and cultural appropriateness to recruit African American men for PCS. This application of the PEN-3 model provided a rich context in which to explore ways to recruit African American men not only for prostate cancer but for other health screenings as well. This study strongly suggests that applying culturally relevant theories to health might change the health behavior patterns of African Americans. The current authors suggest that Abernethy et al. need to focus more on ways to disseminate their findings to other health professionals targeting health disparities. (PsycINFO Database Record (c) 2016 APA, all rights reserved)
AD  - Lewis, Rhonda K., Department of Psychology,Wichita State University, 1845 N. Fairmount, Box 34, Wichita, KS, US, 67260-0034
AN  - 2005-07626-003
AU  - Lewis, Rhonda K.
DB  - psyh
DO  - 10.1177/1090198104272254
DP  - EBSCOhost
IS  - 4
KW  - psychosocial factors
prostate cancer screening
African American men
recruitment efforts
cultural issues
African Americans
Culture
Diagnostic Tests, Routine
Health Services Research
Humans
Male
Patient Acceptance of Health Care
Patient Selection
Prostatic Neoplasms
Refusal to Participate
Blacks
Cancer Screening
Cultural Sensitivity
Health Promotion
Prostate
N1  - Health Education Quarterly. Partial author list: First Author & Affiliation: Lewis, Rhonda K.; Department of Psychology,Wichita State University, Wichita, KS, US. Release Date: 20050718. Correction Date: 20110725. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Comment/Reply. Language: English. Major Descriptor: Blacks; Cancer Screening; Cultural Sensitivity; Health Promotion; Psychosocial Factors. Minor Descriptor: Prostate. Classification: Promotion & Maintenance of Health & Wellness (3365). References Available: Y. Page Count: 3. Issue Publication Date: Aug, 2005.
PY  - 2005
SN  - 1090-1981
1552-6127
SP  - 452-454
ST  - Using a Culturally Relevant Theory to Recruit African American Men for Prostate Cancer Screening: Comment
T2  - Health Education & Behavior
TI  - Using a Culturally Relevant Theory to Recruit African American Men for Prostate Cancer Screening: Comment
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2005-07626-003&site=ehost-live&scope=site
rhonda.lewis@wichita.edu
VL  - 32
ID  - 1789
ER  - 

TY  - JOUR
AB  - Background: Screening for colorectal cancer (CRC) is suboptimal, particularly for vulnerable populations. Effective intervention programs are needed to increase screening rates. We used a discrete choice experiment (DCE) to learn about how vulnerable individuals in North Carolina value different aspects of CRC screening programs. Methods: We enrolled English-speaking adults ages 50-75 at average risk of CRC from rural North Carolina communities with low rates of CRC screening, targeting those with public or no insurance and low incomes. Participants received basic information about CRC screening and potential program features, then completed a 16 task DCE and survey questions that examined preferences for four attributes of screening programs: testing options available; travel time required; money paid for screening or rewards for completing screening; and the portion of the cost of follow-up care paid out of pocket. We used Hierarchical Bayesian methods to calculate individual-level utilities for the 4 attributes' levels and individual-level attribute importance scores. For each individual, the attribute with the highest importance score was considered the most important attribute. Individual utilities were then aggregated to produce mean utilities for each attribute. We also compared DCE-based results with those from direct questions in a post-DCE survey. Results: We enrolled 150 adults. Mean age was 57.8 (range 50-74); 55% were women; 76% White and 19% African-American; 87% annual household income under $ 30,000; and 51% were uninsured. Individuals preferred shorter travel; rewards or small copayments compared with large copayments; programs that included stool testing as an option; and greater coverage of follow-up costs. Follow-up cost coverage was most frequently found to be the most important attribute from the DCE (47%); followed by test reward/copayment (33%). From the survey, proportion of follow-up costs paid was most frequently cited as most important (42% of participants), followed by testing options (32%). There was moderate agreement (45%) in attribute importance between the DCE and the single question in the post-DCE survey. Conclusions: Screening test copayments and follow-up care coverage costs are important program characteristics in this vulnerable, rural population.
AN  - WOS:000347354300001
AU  - Pignone, M. P.
AU  - Crutchfield, T. M.
AU  - Brown, P. M.
AU  - Hawley, S. T.
AU  - Laping, J. L.
AU  - Lewis, C. L.
AU  - Lich, K. H.
AU  - Richardson, L. C.
AU  - Tangka, F. K. L.
AU  - Wheeler, S. B.
DA  - Nov
DO  - 10.1186/s12913-014-0611-4
N1  - 611
25433801
PY  - 2014
SN  - 1472-6963
ST  - Using a discrete choice experiment to inform the design of programs to promote colon cancer screening for vulnerable populations in North Carolina
T2  - Bmc Health Services Research
TI  - Using a discrete choice experiment to inform the design of programs to promote colon cancer screening for vulnerable populations in North Carolina
VL  - 14
ID  - 2994
ER  - 

TY  - JOUR
AB  - Objective: To identify and recruit an unknown and presumably small subgroup of survivors, that is, lesbian or bisexual women with breast cancer. Methods: This report describes our multistep approach to recruit a representative sample of heterosexual and sexual minority breast cancer survivors. We used census data to identify geographic areas with a greater prevalence of sexual minority women (SMW), that is, lesbian and bisexual women. We then obtained the breast cancer cases from a cancer registry for these geographic areas. In the absence of sexual orientation data in cancer registries, all potentially eligible women with breast cancer needed to be contacted by telephone to determine their sexual orientation. Results: Among the 1341 women screened who answered the question about sexual orientation, 6.3% were SMW. Overall, we processed 4143 cases to obtain completed data on 69 SMW and 257 heterosexual women with breast cancer. Conclusions: Our findings suggest that it is resource intensive but feasible to recruit a representative sample of breast cancer survivors of different sexual orientations. Our findings can inform future studies that seek to recruit sexual minority populations from cancer registries about some of the limitations to this approach.
AD  - Department of Community Health Sciences, Boston University School of Public Health, Boston, Massachusetts
AN  - 105045944. Language: English. Entry Date: 20100910. Revision Date: 20200708. Publication Type: Journal Article
AU  - Boehmer, U.
AU  - Clark, M.
AU  - Glickman, M.
AU  - Timm, A.
AU  - Sullivan, M.
AU  - Bradford, J.
AU  - Bowen, D. J.
DB  - CINAHL Complete
DO  - 10.1089/jwh.2009.1744
DP  - EBSCOhost
IS  - 7
KW  - Bisexuals
Breast Neoplasms
Cancer Survivors
Lesbians
Registries, Disease
Research Subject Recruitment
Research Subjects
Adult
Aged
Aged, 80 and Over
Black Persons
Breast Neoplasms -- Classification
Chi Square Test
Confidence Intervals
Confidentiality (Research)
Descriptive Statistics
Female
Funding Source
Hispanic Americans
Human
Marital Status
Massachusetts
Middle Age
Random Assignment
Self Report
Surveys
T-Tests
White Persons
N1  - research; tables/charts. Journal Subset: Biomedical; Peer Reviewed; USA. Grant Information: American Cancer Society, grant RSGT-06-135-01-CPPB PI. NLM UID: 101159262.
PMID: NLM20575681.
PY  - 2010
SN  - 1540-9996
SP  - 1289-1297
ST  - Using cancer registry data for recruitment of sexual minority women: successes and limitations
T2  - Journal of Women's Health (15409996)
TI  - Using cancer registry data for recruitment of sexual minority women: successes and limitations
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105045944&site=ehost-live&scope=site
VL  - 19
ID  - 2138
ER  - 

TY  - JOUR
AB  - The Deep South Network for Cancer Control (DSNCC), initiated in 2000, is a dual-state, community-based participatory research infrastructure composed of academic and community partners committed to reducing cancer disparities among underserved African Americans in 12 designated counties of the Alabama Black Belt and the Mississippi Delta, 2 historically underserved areas of the country. Local residents trained as Community Health Advisors as Research Partners implemented a 3-tier community action plan (CAP) focused on promoting cancer screening, physical activity, and nutrition. Breast, cervical and colorectal cancer screening, healthy eating habits, and physical activity levels increased among many, but not all, African American women in the 12-county DSNCC coverage area. Seeking to improve our reach to include participants who reported they had never heard of the DSNCC or participated in the CAP, we conducted in-depth conversations with community residents about reasons for selective nonparticipation and ways to improve participation in the DSNCC community health interventions. Three patterns and their associated themes described ways to improve the penetration of CAP strategies and tailor them to effectively reach underserved African Americans in the intervention counties. We conclude with lessons learned for future interventions. (PsycINFO Database Record (c) 2016 APA, all rights reserved)
AD  - Wynn, Theresa A., University of Alabama at Birmingham, Medical Towers Building, 1717 11th Ave South, Birmingham, AL, US, 35294
AN  - 2016-44344-003
AU  - Wynn, Theresa A.
AU  - Wyatt, Sharon B.
AU  - Hardy, Claudia M.
AU  - Walker, Shundra S.
AU  - Thomas, Tammi Floyd
AU  - Williams, Angela G.
AU  - Partridge, Edward E.
DB  - psyh
DO  - 10.1097/FCH.0000000000000101
DP  - EBSCOhost
IS  - 4
KW  - African Americans
cancer screening
community-based participatory research
nutrition
physical activity
Blacks
Community Involvement
Action Research
Community Health
Feedback
Intervention
Health Disparities
N1  - Division of Preventive Medicine, University of Alabama at Birmingham, Birmingham, AL, US. Release Date: 20161006. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: English. Major Descriptor: Blacks; Cancer Screening; Community Involvement; Action Research; Community Health. Minor Descriptor: Feedback; Intervention; Nutrition; Physical Activity; Health Disparities. Classification: Community & Social Services (3373). Population: Human (10); Male (30); Female (40). Location: US. Age Group: Adulthood (18 yrs & older) (300); Middle Age (40-64 yrs) (360). Methodology: Empirical Study; Interview; Qualitative Study. Page Count: 8. Issue Publication Date: Oct-Dec, 2016. Copyright Statement: All rights reserved. Wolters Kluwer Health, Inc. 2016.
PY  - 2016
SN  - 0160-6379
1550-5057
SP  - 234-241
ST  - Using community feedback to improve community interventions: Results from the Deep South Network for Cancer Control project
T2  - Family & Community Health: The Journal of Health Promotion & Maintenance
TI  - Using community feedback to improve community interventions: Results from the Deep South Network for Cancer Control project
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2016-44344-003&site=ehost-live&scope=site
twynn@uabmc.edu
VL  - 39
ID  - 1712
ER  - 

TY  - JOUR
AB  - PURPOSE: To adapt ethnically appropriate radio and newspaper messages in order to increase information-seeking and recruitment to the high-risk Prostate Cancer Risk Assessment Program (PRAP) using input from focus groups. METHODS: We conducted four gender- and ethnic specific-focus groups composed of up to eight participants each. Group participants ranged in age from 35-69 and were either at risk for prostate cancer or were married to someone at risk. Participants evaluated both print and radio advertisements for a PRAP media recruitment campaign, and their recommendations were used to adapt the advertisements. RESULTS: Trigger words, e.g,, "research program," were found to be a particular issue for African-American men who cited concerns about "experimentation," while the other groups cited concerns about time commitments and cost. In the print messages, familial themes garnered an overall favorable response, but Caucasian-American participants responded negatively to the use of photos of age-appropriate models. CONCLUSION: Focus groups are useful in checking health professional assumptions about health messages prior to developing awareness or recruitment advertisements or materials. There was an implied preference for "younger" models among Caucasian Americans. Radio and print messages were adapted using the focus group recommendations, i.e., focusing on familial themes, adding race-specific risk estimates and using younger-than-target group models.
AD  - School of Nursing, University of Pennsylvania, PA, USA.
AN  - 18595569
AU  - Bryan, C. J.
AU  - Wetmore-Arkader, L.
AU  - Calvano, T.
AU  - Deatrick, J. A.
AU  - Giri, V. N.
AU  - Bruner, D. W.
C2  - PMC2700360
C6  - NIHMS113755
DA  - Jun
DO  - 10.1016/s0027-9684(15)31340-7
DP  - NLM
ET  - 2008/07/04
IS  - 6
KW  - Adult
Aged
Communication
Continental Population Groups
Decision Making
Female
*Focus Groups
*Health Education
Humans
Male
Mass Media
*Mass Screening
Middle Aged
Motivation
Patient Acceptance of Health Care/*ethnology
*Patient Selection
Pennsylvania
Prostatic Neoplasms/*diagnosis/ethnology
Risk
LA  - eng
N1  - Bryan, Charlene J
Wetmore-Arkader, Lindsay
Calvano, Tammy
Deatrick, Janet A
Giri, Veda N
Bruner, Deborah Watkins
R01 CA114321/CA/NCI NIH HHS/United States
R01 CA114321-01A1/CA/NCI NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
J Natl Med Assoc. 2008 Jun;100(6):674-82. doi: 10.1016/s0027-9684(15)31340-7.
PY  - 2008
SN  - 0027-9684 (Print)
0027-9684
SP  - 674-82
ST  - Using focus groups to adapt ethnically appropriate, information-seeking and recruitment messages for a prostate cancer screening program for men at high risk
T2  - J Natl Med Assoc
TI  - Using focus groups to adapt ethnically appropriate, information-seeking and recruitment messages for a prostate cancer screening program for men at high risk
VL  - 100
ID  - 492
ER  - 

TY  - JOUR
AB  - Purpose: To adapt ethnically appropriate radio and newspaper messages in order to increase information-seeking and recruitment to the high-risk Prostate Cancer Risk Assessment Program (PRAP) using input from focus groups. Methods: We conducted four gender- and ethnic specific-focus groups composed of up to eight participants each. Group participants ranged in age from 35-69 and were either at risk for prostate cancer or were married to someone at risk. Participants evaluated both print and radio advertisements for a PRAP media recruitment campaign, and their recommendations were used to adapt the advertisements. Results: Trigger words, e.g., 'research program,' were found to be a particular issue for African-American men who cited concerns about 'experimentation,' while the other groups cited concerns about time commitments and cost. In the print messages, familial themes garnered an overall favorable response, but Caucasian-American participants responded negatively to the use of photos of age-appropriate models. Conclusion: Focus groups are useful in checking health professional assumptions about health messages prior to developing awareness or recruitment advertisements or materials. There was on implied preference for 'younger' models among Caucasian Americans. Radio and print messages were adapted using the focus group recommendations, i.e., focusing on familial themes, adding race-specific risk estimates and using younger-than-target group models. (PsycINFO Database Record (c) 2019 APA, all rights reserved)
AD  - Watkins Bruner, Deborah, University of Pennsylvania, School of Nursing, Claire M. Fagin Hall, 418 Curie Blvd., Philadelphia, PA, US, 19104-6096
AN  - 2008-08701-002
AU  - Bryan, Charlene J.
AU  - Wetmore-Arkader, Lindsay
AU  - Calvano, Tammy
AU  - Deatrick, Janet A.
AU  - Giri, Veda N.
AU  - Watkins Bruner, Deborah
DB  - psyh
DO  - 10.1016/S0027-9684(15)31340-7
DP  - EBSCOhost
IS  - 6
KW  - ethnically appropriate messages
information seeking
recruitment messages
prostate cancer screening program
high risk men
focus groups
Adult
Aged
Communication
Continental Population Groups
Decision Making
Female
Health Education
Humans
Male
Mass Media
Mass Screening
Middle Aged
Motivation
Patient Acceptance of Health Care
Patient Selection
Pennsylvania
Prostatic Neoplasms
Risk
At Risk Populations
Cancer Screening
Messages
Racial and Ethnic Groups
Focus Group
N1  - School of Nursing, University of Pennsylvania, Philadelphia, PA, US. Other Publishers: Elsevier Science. Release Date: 20090831. Correction Date: 20190211. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Print. Document Type: Journal Article. Language: English. Major Descriptor: At Risk Populations; Cancer Screening; Information Seeking; Messages; Racial and Ethnic Groups. Minor Descriptor: Focus Group. Classification: Promotion & Maintenance of Health & Wellness (3365). Population: Human (10); Male (30); Female (40). Location: US. Age Group: Adulthood (18 yrs & older) (300); Thirties (30-39 yrs) (340); Middle Age (40-64 yrs) (360); Aged (65 yrs & older) (380). Methodology: Empirical Study; Interview; Focus Group; Qualitative Study. References Available: Y. Page Count: 9. Issue Publication Date: Jun, 2008.
Sponsor: National Cancer Institute, US. Other Details: Ethnic Differences in Media Response and Recruitment. Recipients: No recipient indicated
PY  - 2008
SN  - 0027-9684
1943-4693
SP  - 674-682
ST  - Using focus groups to adopt ethnically appropriate, information-seeking and recruitment messages for a prostate cancer screening program for men at high risk
T2  - Journal of the National Medical Association
T3  - Cancer
TI  - Using focus groups to adopt ethnically appropriate, information-seeking and recruitment messages for a prostate cancer screening program for men at high risk
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2008-08701-002&site=ehost-live&scope=site
wbruner@nursing.upenn.edu
VL  - 100
ID  - 1797
ER  - 

TY  - JOUR
AB  - Purpose: Surveys of cancer patients are an important means of collecting data necessary to improve cancer prevention and control. However, health surveys generally are characterized by declining response rates, with incentives often employed to encourage participation. While successful, magnitude of effect is partially dependent upon situational characteristics of respondents, including health status. Given the health challenges experienced by cancer patients, it is unclear to what extent incentives can improve survey participation. In this study, we examine the effectiveness of monetary and non-monetary incentives in improving response to cancer patient surveys. Methods: We reviewed the available experimental literature regarding efforts to improve response rates among cancer patients/survivors via incentives. Relevant studies were identified through searches of the MEDLINE, PubMed, and PsychINFO databases from 1975 to 2012. Seed sources (e.g., Cancer Causes & Control, Cancer Epidemiology, Biomarkers & Prevention, and BMC Medical Research Methodology) were also referenced extensively in order to establish a comprehensive set of studies. Results: Although limited, evidence does suggest that token incentives may be less effective for improving survey participation among cancer patients, relative to other population groups. These results are contrary to well-established evidence regarding the efficacy of incentives in improving survey participation generally. Potential reasons why incentives may be less effective in this population are explored. Conclusions: While more research is necessary, results suggest that survey research strategies targeting cancer patients be purposively designed in a manner that gives consideration to the distress associated with the condition, including selection of alternative strategies to improve response. © 2012 Springer Science+Business Media Dordrecht.
AD  - J.B. Vangeest, College of Public Health, Kent State University, P.O. Box 5190, Kent, OH 44242-0001, United States
AU  - Vangeest, J. B.
AU  - Johnson, T. P.
DB  - Embase
Medline
DO  - 10.1007/s10552-012-0082-z
IS  - 12
KW  - adult
African American
aged
article
Asian
cancer patient
cancer research
cancer survivor
childhood cancer
colorectal cancer
cooperation
disease surveillance
economic aspect
ethnic difference
health survey
Hispanic
human
incentive
major clinical study
patient participation
population research
priority journal
race difference
LA  - English
M3  - Article
N1  - L52262241
2012-10-20
2013-06-26
PY  - 2012
SN  - 0957-5243
1573-7225
SP  - 2047-2052
ST  - Using incentives in surveys of cancer patients: Do "best practices" apply?
T2  - Cancer Causes and Control
TI  - Using incentives in surveys of cancer patients: Do "best practices" apply?
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L52262241&from=export
http://dx.doi.org/10.1007/s10552-012-0082-z
VL  - 23
ID  - 1105
ER  - 

TY  - JOUR
AB  - Background: Data on the social determinants of health can help primary care practices target improvement efforts, yet relevant data are rarely available. Our family practice located in Toronto, Ontario routinely collects patient-level sociodemographic data via a pilot-tested survey developed by a multi-organizational steering committee. We sought to use these data to assess the relationship between the social determinants and colorectal, cervical and breast cancer screening, and to describe the opportunities and challenges of using data on social determinants from a self-administered patient survey. Methods: Patients of the family practice eligible for at least one of the three cancer screening types, based on age and screening guidelines as of June 30, 2015 and who had answered at least one question on a socio-demographic survey were included in the study. We linked self-reported data from the sociodemographic survey conducted in the waiting room with patients' electronic medical record data and cancer screening records. We created an individual-level income variable (low-income cut-off) that defined a poverty threshold and took household size into account. The sociodemographic characteristics of patients who were overdue for screening were compared to those who were up-to-date for screening for each cancer type using chi-squared tests. Results: We analysed data for 5766 patients for whom we had survey data. Survey participants had significantly higher screening rates (72.9, 78.7, 74.4% for colorectal, cervical and breast cancer screening respectively) than the 13, 036 patients for whom we did not have survey data (59.2, 65.3, 58.9% respectively). Foreign-born patients were significantly more likely to be up-to-date on colorectal screening than their Canadian-born peers but showed no significant differences in breast or cervical cancer screening. We found a significant association between the low-income cut-off variable and cancer screening; neighbourhood income quintile was not significantly associated with cancer screening. Housing status was also significantly associated with colorectal, cervical and breast cancer screening. There was a large amount of missing data for the low-income cut-off variable, approximately 25% across the three cohorts. Conclusion: While we were able to show that neighbourhood income might under-estimate income-related disparities in screening, individual-level income was also the most challenging variable to collect. Future work in this area should target the income disparity in cancer screening and simultaneously explore how best to collect measures of poverty.
AD  - Department of Family & Community Medicine, St. Michael's Hospital, 30 Bond Street, Toronto, ON M5B 1W8, Canada
Department of Family & Community Medicine, University of Toronto, 500 University Avenue, 5th Floor, Toronto, ON M5G 1V7, Canada
Centre for Urban Health Solutions, Li Ka Shing Knowledge Institute, St. Michael's Hospital, 30 Bond Street, Toronto, ON M5B 1W8, Canada
Dalla Lana School of Public Health, University of Toronto, Health Sciences Building, 155 College Street, 6th Floor, Toronto, ON M5T 3M7, Canada
Department of Surgery, Li Ka Shing Knowledge Institute, St. Michael's Hospital, 30 Bond Street, Toronto, ON M5B 1W8, Canada
Cancer Care Ontario, 620 University Avenue, Toronto, ON M5G 2L7, Canada
Institute for Clinical Evaluative Sciences, 2075 Bayview Avenue, Toronto, Ontario M4N 3M5, Canada
AN  - 121510340. Language: English. Entry Date: 20170307. Revision Date: 20180530. Publication Type: Article
AU  - Lofters, A. K.
AU  - Schuler, A.
AU  - Slater, M.
AU  - Baxter, N. N.
AU  - Persaud, N.
AU  - Pinto, A. D.
AU  - Kucharski, E.
AU  - Davie, S.
AU  - Nisenbaum, R.
AU  - Kiran, T.
DB  - CINAHL Complete
DO  - 10.1186/s12875-017-0599-z
DP  - EBSCOhost
KW  - Early Detection of Cancer -- Methods
Primary Health Care
Self Report
Social Determinants of Health
Breast Neoplasms -- Diagnosis
Canada
Cervix Neoplasms
Family Practice
Cancer Screening
Human
Income
Mammography
Ontario
Poverty
Residence Characteristics
Social Class
Socioeconomic Factors
Surveys
Healthcare Disparities -- Evaluation
Urban Areas
Geographic Locations
Research Subject Recruitment
Outcomes (Health Care)
Data Analysis Software
Adult
Middle Age
Aged
Male
Female
Immigrants
White Persons
Asians
Black Persons
Hispanic Americans
Middle East
Funding Source
N1  - research; tables/charts. Journal Subset: Biomedical; Europe; Expert Peer Reviewed; Peer Reviewed; UK & Ireland. Grant Information: This study was supported by a research grant from the St. Michael’sFoundationTranslational Innovation Fund. Dr. Lofters. Dr. Pinto, Dr. Persaud and Dr. Kiranare supported as Clinician Scientists by the University of Toronto Departmentof Family & Community Medicine. Dr. Lofters is supported by a CanadianCancer Society Research Institute Career Development Award in CancerPrevention. Dr. Kiran is supported by a Canadian Institutes of Health Research Embedded Clinician Researcher Award. Dr. Persaud is funded by a PSI GrahamFarquharson Knowledge Translation Fellowship.. NLM UID: 100967792.
PY  - 2017
SN  - 1471-2296
SP  - 1-11
ST  - Using self-reported data on the social determinants of health in primary care to identify cancer screening disparities: opportunities and challenges
T2  - BMC Family Practice
TI  - Using self-reported data on the social determinants of health in primary care to identify cancer screening disparities: opportunities and challenges
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=121510340&site=ehost-live&scope=site
VL  - 18
ID  - 2140
ER  - 

TY  - JOUR
AN  - 22187266
AU  - Slomski, A.
DA  - Dec 21
DO  - 10.1001/jama.2011.1804
DP  - NLM
ET  - 2011/12/22
IS  - 23
KW  - Advisory Committees
African Americans
Aged
Biopsy
Decision Making
Humans
Male
Mass Screening/*standards
Prostate-Specific Antigen/*blood
Prostatic Neoplasms/*diagnosis/ethnology/mortality/pathology
Randomized Controlled Trials as Topic
Risk
United States/epidemiology
Unnecessary Procedures
Urology/trends
LA  - eng
N1  - 1538-3598
Slomski, Anita
News
United States
JAMA. 2011 Dec 21;306(23):2549-51. doi: 10.1001/jama.2011.1804.
PY  - 2011
SN  - 0098-7484
SP  - 2549-51
ST  - USPSTF finds little evidence to support advising PSA screening in any man
T2  - Jama
TI  - USPSTF finds little evidence to support advising PSA screening in any man
VL  - 306
ID  - 378
ER  - 

TY  - JOUR
AB  - BACKGROUND: While information websites have been developed by major cancer organizations, their appropriateness for patients in multiethnic, multilingual public hospital settings has received limited attention. OBJECTIVE: The objective of the study was to determine the utility of cancer information websites for a public hospital patient population. METHODS: A 70-item questionnaire was developed to evaluate cancer information seeking behavior, Internet access and use, and content appropriateness of two cancer information websites: People Living with Cancer from the American Society of Clinical Oncology (ASCO) and Breast Cancer Info from the Susan Komen Breast Cancer Foundation (SKF). Interviews were conducted with consecutive consenting oncology patients seen in a public hospital oncology clinic. RESULTS: Fifty-nine persons participated in the survey. The response rate was 80%. Participants were Caucasian (25%), African American (19%), Hispanic (42%), and Asian/Pacific Islander (11%). English was the primary language in 53% of participants, 56% had a high school education or less, and 74% had an annual income less than US 35000 dollars. With respect to computer and Internet use, 71% had computer access, and 44% searched for cancer information online, with more being interested in obtaining online information in the future (63%). Participants who had computer access were likely to be English speaking (P = .04). Those less likely to have previously used a computer tended to have a lower annual income (P = .02) or to be males aged 55 years or older (P < .05). When shown sample content from the two websites, almost all participants stated that it was "easy to understand" (ASCO 96%, SKF 96%) and had "easy to understand terms" (ASCO 94%, SKF 92%). Somewhat fewer respondents agreed that the websites provided "information they could use" (ASCO 88%, SKF 80%) or that they would return to these websites (ASCO 73%, SKF 68%). The majority planned to "discuss website information with their oncologists" (ASCO 82%, SKF 70%). CONCLUSIONS: Multiethnic, multilingual cancer patients at a public county hospital commonly had Internet access and found the content of two websites representative of major cancer organizations to be both understandable and useful.
AD  - Los Angeles Biomedical Research Institute, Harbor UCLA Medical Center, Torrance, CA 90502, USA.
AN  - 15998619
AU  - Nguyen, K. D.
AU  - Hara, B.
AU  - Chlebowski, R. T.
C2  - PMC1550661
DA  - Jul 1
DO  - 10.2196/jmir.7.3.e28
DP  - NLM
ET  - 2005/07/07
IS  - 3
KW  - American Cancer Society/*organization & administration
Attitude to Computers
*Cross-Sectional Studies
Educational Status
*Ethnic Groups
Female
*Health Surveys
Hospitals, Public
Humans
Income
*Internet
Male
Neoplasms/*psychology
Patient Selection
Reproducibility of Results
Surveys and Questionnaires
United States
LA  - eng
N1  - 1438-8871
Nguyen, Katherine D
Hara, Belinda
Chlebowski, Rowan T
Journal Article
J Med Internet Res. 2005 Jul 1;7(3):e28. doi: 10.2196/jmir.7.3.e28.
PY  - 2005
SN  - 1438-8871
SP  - e28
ST  - Utility of two cancer organization websites for a multiethnic, public hospital oncology population: comparative cross-sectional survey
T2  - J Med Internet Res
TI  - Utility of two cancer organization websites for a multiethnic, public hospital oncology population: comparative cross-sectional survey
VL  - 7
ID  - 597
ER  - 

TY  - JOUR
AB  - Aims: We evaluated the immunogenicity, efficacy, and safety of succinylnorcocaine conjugated to cholera toxin B protein as a vaccine for cocaine dependence. Methods: This 6-site, 24 week Phase III randomized double-blind placebo-controlled trial assessed efficacy during weeks 8 to 16. We measured urine cocaine metabolites thrice weekly as the main outcome. Results: The 300 subjects (76% male, 72% African-American, mean age 46 years) had smoked cocaine on average for 13 days monthly at baseline. We hypothesized that retention might be better and positive urines lower for subjects with anti-cocaine IgG levels of ≥42. μg/mL (high IgG), which was attained by 67% of the 130 vaccine subjects receiving five vaccinations. Almost 3-times fewer high than low IgG subjects dropped out (7% vs 20%). Although for the full 16 weeks cocaine positive urine rates showed no significant difference between the three groups (placebo, high, low IgG), after week 8, more vaccinated than placebo subjects attained abstinence for at least two weeks of the trial (24% vs 18%), and the high IgG group had the most cocaine-free urines for the last 2 weeks of treatment (OR. = 3.02), but neither were significant. Injection site reactions of induration and tenderness differed between placebo and active vaccine, and the 29 serious adverse events did not lead to treatment related withdrawals, or deaths. Conclusions: The vaccine was safe, but it only partially replicated the efficacy found in the previous study based on retention and attaining abstinence.
AD  - T.R. Kosten, Michael E. DeBakey VA Medical Center, Baylor College of Medicine, 2002 Holcombe, Bldg. 121, Rm 141, Houston, TX, United States
AU  - Kosten, T. R.
AU  - Domingo, C. B.
AU  - Shorter, D.
AU  - Orson, F.
AU  - Green, C.
AU  - Somoza, E.
AU  - Sekerka, R.
AU  - Levin, F. R.
AU  - Mariani, J. J.
AU  - Stitzer, M.
AU  - Tompkins, D. A.
AU  - Rotrosen, J.
AU  - Thakkar, V.
AU  - Smoak, B.
AU  - Kampman, K.
DB  - Embase
Medline
DO  - 10.1016/j.drugalcdep.2014.04.003
KW  - cocaine
drugs used in the treatment of addiction
immunoglobulin G antibody
placebo
succinylnorcocaine cholera toxin B conjugate
unclassified drug
vaccine
adult
alcohol intoxication
article
breast disease
chronic obstructive lung disease
cocaine dependence
cognitive therapy
controlled study
depression
double blind procedure
drug efficacy
drug fatality
drug safety
drug tolerability
drug withdrawal
ear disease
erectile dysfunction
eye disease
female
gastrointestinal disease
heart disease
hematologic disease
human
immunogenicity
immunopathology
infection
injection site induration
injection site reaction
kidney disease
leg ulcer
major clinical study
male
mental disease
middle aged
multicenter study
musculoskeletal disease
neoplasm
neurologic disease
phase 3 clinical trial
priority journal
randomized controlled trial
respiratory tract disease
side effect
skin disease
suicidal behavior
urinary tract disease
urogenital tract disease
vaccination
vascular disease
LA  - English
M3  - Article
N1  - L53122126
2014-05-12
2015-04-08
PY  - 2014
SN  - 1879-0046
0376-8716
SP  - 42-47
ST  - Vaccine for cocaine dependence: A randomized double-blind placebo-controlled efficacy trial
T2  - Drug and Alcohol Dependence
TI  - Vaccine for cocaine dependence: A randomized double-blind placebo-controlled efficacy trial
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L53122126&from=export
http://dx.doi.org/10.1016/j.drugalcdep.2014.04.003
VL  - 140
ID  - 1058
ER  - 

TY  - JOUR
AB  - BACKGROUND: Socioculturally relevant measures of medical mistrust are needed to better address health disparities, especially among Black men, a group with lower life expectancy and higher death rates compared to other race/gender groups. OBJECTIVES: The study aim was to investigate the psychometric properties of the Group-Based Medical Mistrust Scale (GBMMS) in a Black male sample. DESIGN: Data were collected as part of a randomized controlled trial testing educational strategies to support Black men's decisions about prostate cancer screening. PARTICIPANTS: Participants included 201 Black men ages 40-75 years recruited in New York City during 2006-2007. MAIN MEASURES: The primary measures included: race-based medical mistrust, health care participation, avoidance of health care, perceived access to health care, health care satisfaction, racial identity, residential racial segregation, attitudes towards prostate cancer screening, and past prostate cancer screening behavior. KEY RESULTS: An exploratory factor analysis suggested a three-factor structure. Confirmatory factor analysis supported the three-factor model. Internal consistency was high for the total GBMMS and the three sub-scales: Suspicion, Discrimination, and Lack of Support. Construct validity was supported by: significant positive correlations between GBMMS and avoidance of health care and racial identity as well as significant negative correlations with health care access, health care satisfaction, and attitudes about prostate cancer screening. ANOVA showed that the GBMMS was associated with greater residential racial segregation. Higher total GBMMS scores were associated with not visiting a physician in the last year and not having a regular physician. CONCLUSIONS: The present findings provide strong additional evidence that the GBMMS is a valid and reliable measure that may be used among urban Black men.
AD  - Department of Oncological Science/Cancer Prevention and Control, Mount Sinai School of Medicine, 1425 Madison Avenue, Box 1130, New York, NY 10029, USA. rshelton@post.harvard.edu
AN  - 20195782
AU  - Shelton, R. C.
AU  - Winkel, G.
AU  - Davis, S. N.
AU  - Roberts, N.
AU  - Valdimarsdottir, H.
AU  - Hall, S. J.
AU  - Thompson, H. S.
C2  - PMC2869405
DA  - Jun
DO  - 10.1007/s11606-010-1288-y
DP  - NLM
ET  - 2010/03/03
IS  - 6
KW  - Adult
African Continental Ancestry Group/*psychology
Aged
Factor Analysis, Statistical
*Healthcare Disparities
Humans
Male
Middle Aged
New York City
Psychometrics/methods
Randomized Controlled Trials as Topic
*Trust
Urban Population
LA  - eng
N1  - 1525-1497
Shelton, Rachel C
Winkel, Gary
Davis, Stacy N
Roberts, Nicole
Valdimarsdottir, Heiddis
Hall, Simon J
Thompson, Hayley S
R25 CA081137/CA/NCI NIH HHS/United States
5R25-CA081137/CA/NCI NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.
Validation Study
J Gen Intern Med. 2010 Jun;25(6):549-55. doi: 10.1007/s11606-010-1288-y. Epub 2010 Mar 2.
PY  - 2010
SN  - 0884-8734 (Print)
0884-8734
SP  - 549-55
ST  - Validation of the group-based medical mistrust scale among urban black men
T2  - J Gen Intern Med
TI  - Validation of the group-based medical mistrust scale among urban black men
VL  - 25
ID  - 429
ER  - 

TY  - JOUR
AB  - Context. The Patient Care Monitor (PCM) is a review of systems survey delivered by means of an electronic patient-reported outcomes (ePRO) data capture system that uses wireless tablet computers. Although the PCM 1.0 is validated, the updated PCM 2.0 has not been validated nor tested in the academic setting. Objectives. To validate and test the PCM 2.0 in three cancer populations. Methods. Two hundred seventy-five individuals participated in three clinical trials enrolling breast (n = 65), gastrointestinal (n = 113), and lung (n = 97) cancer patients. Internal consistency was evaluated using Cronbach's alpha coefficients calculated for six PCM subscales (general physical symptoms, treatment side effects, distress, despair, impaired performance, and impaired ambulation) and a Quality-of-Life Index. Construct validity was evaluated through Pearson's correlation between PCM subscales and subscales of the Functional Assessment of Cancer Therapy General (FACT-G), the M.D. Anderson Symptom Inventory (MDASI), and the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F). The participants had the following characteristics: mean age was 58 years (standard deviation: 11), 52% were females, 79% were whites, 17% were blacks, 62% had no college degree, and 78% had metastatic or recurrent disease. Results. Raw and normalized scores for PCM 2.0 subscales were internally consistent across study cohorts. PCM 2.0 subscales correlated significantly (P < 0.05) with the corresponding subscales on FACT-G, MDASI, and FACIT-F, with the exception of FACT-G social well-being, particularly for the lung cancer population. These correlations demonstrated construct validity. PCM 2.0 results followed expected patterns by cancer etiology. Prior reports demonstrate patient satisfaction with PCM 2.0. Conclusion. Within three unique academic oncology populations, PCM 2.0 is a valid ePRO instrument for assessing symptoms with seven patient-centered subscale or index domains. J Pain Symptom Manage 2010;40:545-558. (C) 2010 U.S. Cancer Pain Relief Committee. Published by Elsevier Inc. All rights reserved.
AN  - WOS:000283476200007
AU  - Abernethy, A. P.
AU  - Zafar, S. Y.
AU  - Uronis, H.
AU  - Wheeler, J. L.
AU  - Coan, A.
AU  - Rowe, K.
AU  - Shelby, R. A.
AU  - Fowler, R.
AU  - Herndon, J. E.
DA  - Oct
DO  - 10.1016/j.jpainsymman.2010.01.017
IS  - 4
N1  - 20579839
PY  - 2010
SN  - 0885-3924
SP  - 545-558
ST  - Validation of the Patient Care Monitor (Version 2.0): A Review of System Assessment Instrument for Cancer Patients
T2  - Journal of Pain and Symptom Management
TI  - Validation of the Patient Care Monitor (Version 2.0): A Review of System Assessment Instrument for Cancer Patients
VL  - 40
ID  - 3108
ER  - 

TY  - JOUR
AB  - PURPOSE: We performed a multiregistry analysis to assess relative differences in accrual sufficiency and race/ethnicity reporting in trials of common urological cancers and other nonurological solid organ tumors. MATERIALS AND METHODS: We queried ClinicalTrials.gov and the ISRCTN (International Standard Randomised Controlled Trial Number) Registry for closed phase III and IV trials focused on prostate, colorectal, kidney, bladder, testicular, breast and lung cancer. Identified trials were cross-verified with appropriate published data sources. Comparative accrual sufficiency and rates of race/ethnicity reporting were calculated. Multivariable logistic regression analysis was performed to determine factors associated with accrual status and race/ethnicity reporting. RESULTS: A total of 326 trials were identified based on our prespecified criteria, of which 63% reported sufficient accrual by time of closure and 58% reported data by race/ethnicity. Nonurological trials were significantly more likely to mention race data than urological trials (OR 3.25, 95% CI 1.24-8.55, p = 0.02). Industry sponsored trials were more likely to meet accrual targets than government funded projects (OR 5.44, 95% CI 1.64-18.20, p = 0.001). Although funding source did not influence race reporting, the reported recruitment of participants of African ethnicity was lower in industry sponsored trials (11.49% vs 3.18%, p <0.01). Two-thirds of the studies did not report baseline characteristics by African American race/ethnicity. CONCLUSIONS: Insufficient accrual and inadequate race/ethnicity reporting are prevalent issues, limiting interpretation of the results of clinical trials of major solid organ malignancies. Addressing these shortcomings would enhance result validity by raising statistical power and improving the transparency of reporting to better evaluate the generalizability of results.
AD  - Department of Urology, University of Minnesota , Minneapolis , Minnesota.
School of Public Health, University of Minnesota , Minneapolis , Minnesota.
AN  - 31074679
AU  - Paul, K.
AU  - Sathianathen, N.
AU  - Dahm, P.
AU  - Le, C.
AU  - Konety, B. R.
DA  - Aug
DO  - 10.1097/ju.0000000000000294
DP  - NLM
ET  - 2019/05/11
IS  - 2
KW  - *Clinical Trial Protocols as Topic
Clinical Trials as Topic/*methods/*statistics & numerical data
Continental Population Groups/*statistics & numerical data
Ethnic Groups/*statistics & numerical data
Female
Humans
Male
*Neoplasms
Registries
Research Design/*statistics & numerical data
United States
*Urologic Neoplasms
*African Americans
*registries
*research design
*urogenital neoplasms
LA  - eng
N1  - 1527-3792
Paul, Koushik
Sathianathen, Niranjan
Dahm, Philipp
Le, Chap
Konety, Badrinath R
Journal Article
United States
J Urol. 2019 Aug;202(2):385-391. doi: 10.1097/JU.0000000000000294. Epub 2019 Jul 8.
PY  - 2019
SN  - 0022-5347
SP  - 385-391
ST  - Variation in Accrual and Race/Ethnicity Reporting in Urological and Nonurological Related Cancer Trials
T2  - J Urol
TI  - Variation in Accrual and Race/Ethnicity Reporting in Urological and Nonurological Related Cancer Trials
VL  - 202
ID  - 76
ER  - 

TY  - JOUR
AB  - BACKGROUND: Prostate cancer is ubiquitous in older men; differential screening patterns and variations in biopsy recommendations and acceptance will affect which man is diagnosed and, therefore, evaluation of cancer risk factors. We describe a statistical method to reduce prostate cancer detection bias among African American (n = 3398) and Non-Hispanic White men (n = 22,673) who participated in the Selenium and Vitamin E Cancer Prevention trial (SELECT) and revisit a previously reported association between race, obesity and prostate cancer risk. METHODS: For men with screening values suggesting prostate cancer but in whom biopsy was not performed, the Prostate Cancer Prevention Trial Risk Calculator was used to estimate probability of prostate cancer. Associations of body mass index (BMI) and race with incident prostate cancer were compared for observed versus imputation-enhanced outcomes using incident density ratios. RESULTS: Accounting for differential biopsy assessment, the previously reported positive linear trend between BMI and prostate cancer in African American men was not observed; no BMI association was found among Non-Hispanic White men. CONCLUSIONS: Differential disease classification among men who may be recommended to undergo and then consider whether to accept a prostate biopsy leads to inaccurate identification of prostate cancer risk factors. Imputing a man's prostate cancer status reduces detection bias. Covariate adjustment does not address the problem of outcome misclassification. Cohorts evaluating incident prostate cancer should collect longitudinal screening and biopsy data to adjust for this potential bias.
AD  - From the SWOG Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA, United States. Electronic address: ctangen@fredhutch.org.
Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States.
From the SWOG Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA, United States.
Department of Psychosocial and Community Health, The University of Washington, Seattle, WA, United States.
Department of Pathology, The University of Colorado Denver School of Medicine, Denver, CO, United States.
The Cancer Therapy and Research Center, Christus Santa Rosa Medical Center, San Antonio, TX, United States.
AN  - 31639607
AU  - Tangen, C. M.
AU  - Schenk, J.
AU  - Till, C.
AU  - Goodman, P. J.
AU  - Barrington, W.
AU  - Lucia, M. S.
AU  - Thompson, I. M.
C2  - PMC6938232
C6  - NIHMS1543440
DA  - Dec
DO  - 10.1016/j.canep.2019.101619
DP  - NLM
ET  - 2019/10/23
KW  - African Americans/*statistics & numerical data
Age Factors
Aged
Biopsy/methods/*statistics & numerical data
*Body Mass Index
Canada/epidemiology
European Continental Ancestry Group/*statistics & numerical data
Humans
Male
Middle Aged
Prostatic Neoplasms/epidemiology/*ethnology/*pathology/therapy
Puerto Rico/epidemiology
Randomized Controlled Trials as Topic
Referral and Consultation/statistics & numerical data
Risk Factors
United States/epidemiology
*Differential misclassification
*Prevention
*Prostate cancer
*Risk factor
LA  - eng
N1  - 1877-783x
Tangen, Catherine M
Schenk, Jeannette
Till, Cathee
Goodman, Phyllis J
Barrington, Wendy
Lucia, M Scott
Thompson, Ian M
UG1 CA189974/CA/NCI NIH HHS/United States
U01 CA086402/CA/NCI NIH HHS/United States
UG1 CA233324/CA/NCI NIH HHS/United States
P30 CA054174/CA/NCI NIH HHS/United States
UM1 CA182883/CA/NCI NIH HHS/United States
U10 CA037429/CA/NCI NIH HHS/United States
U01 CA182883/CA/NCI NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
Cancer Epidemiol. 2019 Dec;63:101619. doi: 10.1016/j.canep.2019.101619. Epub 2019 Oct 19.
PY  - 2019
SN  - 1877-7821 (Print)
1877-7821
SP  - 101619
ST  - Variations in prostate biopsy recommendation and acceptance confound evaluation of risk factors for prostate cancer: Examining race and BMI
T2  - Cancer Epidemiol
TI  - Variations in prostate biopsy recommendation and acceptance confound evaluation of risk factors for prostate cancer: Examining race and BMI
VL  - 63
ID  - 60
ER  - 

TY  - JOUR
AB  - IMPORTANCE: Colorectal cancers are a leading cause of cancer mortality, and their primary prevention by diet is highly desirable. The relationship of vegetarian dietary patterns to colorectal cancer risk is not well established. OBJECTIVE: To evaluate the association between vegetarian dietary patterns and incident colorectal cancers. DESIGN, SETTING, AND PARTICIPANTS: The Adventist Health Study 2 (AHS-2) is a large, prospective, North American cohort trial including 96,354 Seventh-Day Adventist men and women recruited between January 1, 2002, and December 31, 2007. Follow-up varied by state and was indicated by the cancer registry linkage dates. Of these participants, an analytic sample of 77,659 remained after exclusions. Analysis was conducted using Cox proportional hazards regression, controlling for important demographic and lifestyle confounders. The analysis was conducted between June 1, 2014, and October 20, 2014. EXPOSURES: Diet was assessed at baseline by a validated quantitative food frequency questionnaire and categorized into 4 vegetarian dietary patterns (vegan, lacto-ovo vegetarian, pescovegetarian, and semivegetarian) and a nonvegetarian dietary pattern. MAIN OUTCOMES AND MEASURES: The relationship between dietary patterns and incident cancers of the colon and rectum; colorectal cancer cases were identified primarily by state cancer registry linkages. RESULTS: During a mean follow-up of 7.3 years, 380 cases of colon cancer and 110 cases of rectal cancer were documented. The adjusted hazard ratios (HRs) in all vegetarians combined vs nonvegetarians were 0.78 (95% CI, 0.64-0.95) for all colorectal cancers, 0.81 (95% CI, 0.65-1.00) for colon cancer, and 0.71 (95% CI, 0.47-1.06) for rectal cancer. The adjusted HR for colorectal cancer in vegans was 0.84 (95% CI, 0.59-1.19); in lacto-ovo vegetarians, 0.82 (95% CI, 0.65-1.02); in pescovegetarians, 0.57 (95% CI, 0.40-0.82); and in semivegetarians, 0.92 (95% CI, 0.62-1.37) compared with nonvegetarians. Effect estimates were similar for men and women and for black and nonblack individuals. CONCLUSIONS AND RELEVANCE: Vegetarian diets are associated with an overall lower incidence of colorectal cancers. Pescovegetarians in particular have a much lower risk compared with nonvegetarians. If such associations are causal, they may be important for primary prevention of colorectal cancers.
AD  - School of Public Health, Loma Linda University, Loma Linda, California2School of Medicine, Loma Linda University, Loma Linda, California.
School of Public Health, Loma Linda University, Loma Linda, California.
AN  - 25751512
AU  - Orlich, M. J.
AU  - Singh, P. N.
AU  - Sabaté, J.
AU  - Fan, J.
AU  - Sveen, L.
AU  - Bennett, H.
AU  - Knutsen, S. F.
AU  - Beeson, W. L.
AU  - Jaceldo-Siegl, K.
AU  - Butler, T. L.
AU  - Herring, R. P.
AU  - Fraser, G. E.
C2  - PMC4420687
C6  - NIHMS670872 from the Northern California Conference of Seventh-Day Adventists to partially defray travel expenses for a speaking engagement at which he gave an overview and update of Adventist Health Studies research and a small honorarium from the Southern California Conference of Seventh-Day Adventists for a speaking engagement at which he lectured on lifestyle approaches for chronic disease prevention. No other conflicts are reported.
DA  - May
DO  - 10.1001/jamainternmed.2015.59
DP  - NLM
ET  - 2015/03/10
IS  - 5
KW  - Adult
Aged
Cohort Studies
*Colorectal Neoplasms/mortality/prevention & control/psychology
Diet, Vegetarian/*psychology
*Feeding Behavior
Female
Humans
Incidence
*Life Style
Male
Middle Aged
Mortality
Prospective Studies
Registries/statistics & numerical data
Risk
Surveys and Questionnaires
United States/epidemiology
LA  - eng
N1  - 2168-6114
Orlich, Michael J
Singh, Pramil N
Sabaté, Joan
Fan, Jing
Sveen, Lars
Bennett, Hannelore
Knutsen, Synnove F
Beeson, W Lawrence
Jaceldo-Siegl, Karen
Butler, Terry L
Herring, R Patti
Fraser, Gary E
HHSN261201300071C/CA/NCI NIH HHS/United States
U01 CA152939/CA/NCI NIH HHS/United States
1U01CA152939/CA/NCI NIH HHS/United States
HHSN261201300071/PHS HHS/United States
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
JAMA Intern Med. 2015 May;175(5):767-76. doi: 10.1001/jamainternmed.2015.59.
PY  - 2015
SN  - 2168-6106 (Print)
2168-6106
SP  - 767-76
ST  - Vegetarian dietary patterns and the risk of colorectal cancers
T2  - JAMA Intern Med
TI  - Vegetarian dietary patterns and the risk of colorectal cancers
VL  - 175
ID  - 252
ER  - 

TY  - JOUR
AB  - Background: End‐of‐life decision‐making is important to patients, including whether or not to attempt cardiopulmonary resuscitation (CPR). Doctors often rely solely on verbal descriptions to communicate information regarding CPR. Video decision support tools have the potential to improve patients' understanding of CPR by providing visual images of what this intervention entails. The objective of this study was to examine the effect of a CPR video among patients with advanced cancer on their preferences and knowledge of CPR. Methods: A randomized controlled trial of 150 subjects with diverse advanced cancers (< 1‐year prognosis) recruited from 4 cancer centers in the United States. Subjects were randomized to either a verbal narrative describing CPR, or to a video with verbal narrative. The video depicts CPR and reviews the success rate in advanced cancer. Study endpoints were subjects' CPR preferences, knowledge of CPR (knowledge scores ranged from 0‐4, higher score indicating more knowledge), and perceived value of the video. Chi‐square tests were used to compare the distributions of categorical outcomes and two‐sample t‐tests were used to compare the means between the two groups. Results: A total of 150 subjects were randomized to a verbal narrative (n=80) or video with verbal narrative (n=70). Mean age was 62, 49% were women, 47% White, 34% Black, and 47% had lung or colon cancer. Among subjects receiving the verbal narrative, 38 (47.5%) preferred to have CPR attempted; 41 (51.2%) chose not to have CPR; and 1 (1.3%) was uncertain. In the video group, 14 (20%) preferred to have CPR attempted; 55 (78.6%) chose not to have CPR; and 1 (1.4%) was uncertain (P<0.001). The mean knowledge score was higher in the video group than in the verbal group (3.3 vs. 2.6 respectively; P<0.001). Of the subjects who viewed the video, 94.1% stated they were comfortable watching the video, 97.1% found the video helpful, and 100% would recommend the video. Conclusions: Compared to subjects who only heard a verbal description, subjects with advanced cancer who viewed a CPR video were more likely to prefer not having CPR, and were more knowledgeable about CPR. The majority of subjects found the video helpful, comfortable to view, and would recommend it to others.
AN  - CN-01008196
AU  - Volandes, A. E.
AU  - Michael, P. O.
AU  - Areej, E. J.
AU  - Mitchell, S. L.
AU  - Kemeny, M.
AU  - Hartshorn, K. L.
AU  - Jackson, V. A.
AU  - Barry, M. J.
AU  - Davis, A. D.
AU  - Lopez, L.
AU  - et al.
IS  - 15
KW  - *advanced cancer
*decision support system
*human
*oncology
*randomized controlled trial
*society
*videorecording
Cancer center
Chi square test
Colon cancer
Decision making
Female
Lung
Narrative
Patient
Physician
Prognosis
Resuscitation
Retina image
Student t test
United States
M3  - Journal: Conference Abstract
PY  - 2012
ST  - A video decision support tool for CPR in advanced cancer: a randomized controlled trial
T2  - Journal of clinical oncology
TI  - A video decision support tool for CPR in advanced cancer: a randomized controlled trial
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01008196/full
VL  - 30
ID  - 1618
ER  - 

TY  - JOUR
AB  - There is a striking racial and ethnic disparity in incidence and mortality of cancer yet minorities remain markedly underrepresented in clinical trials. This pilot study set out to determine the impact of a 15-min culturally tailored educational video on three outcomes relating to clinical trials: likely participation, attitudes (assessed based on six barriers), and actual enrollment. Breast cancer patients with Stage I-III, if diagnosed within previous 6 months, or metastatic disease who self-identified as black or African American were invited to participate. The primary outcome measure was the decision to participate in a therapeutic clinical trial after the intervention. Patients' intention to enroll on a therapeutic clinical trial and the change in attitudes toward clinical trials were measured by the previously developed Attitudes and Intention to Enroll in Therapeutic Clinical Trials (AIET) questionnaire. Of the 200 patients that participated, 39 (19.5%) patients signed consent to participate in a therapeutic clinical trial; 27 (13.5%) patients enrolled, resulting in a 7.5% increase from our baseline comparison of 6% clinical trial enrollment rate in black cancer patients (p < .001). Pre-test versus post-test assessment demonstrated the proportion of patients expressing likelihood to enroll in a therapeutic trial following the intervention increased by 14% (p < .001). Among 31 AIET items, 25 (81%) showed statistically significant and positive change post-intervention. The findings suggest the promising utility of a culturally tailored video intervention for improving black patients' attitudes regarding clinical trial participation and resultant enrollment. Future efforts should continue to target facilitators of population-specific recruitment, enrollment, and retention in therapeutic and non-therapeutic clinical trials.
AD  - MedStar Health Research Institute, Hyattsville, MD USA. ISNI: 0000 0004 0391 7375. GRID: grid.415232.3
Washington Cancer Institute, MedStar Washington Hospital Center, Washington, DC USA. ISNI: 0000 0000 8585 5745. GRID: grid.415235.4
Lombardi Comprehensive Cancer Center, MedStar Georgetown University Hospital, Washington, DC USA.
MedStar Union Memorial Hospital, Baltimore, MD USA. ISNI: 0000 0004 0444 3298. GRID: grid.415233.2
MedStar Harbor Hospital, Baltimore, MD USA. ISNI: 0000 0004 0444 3167. GRID: grid.413670.7
MedStar Franklin Square Medical Center, Baltimore, MD USA. ISNI: 0000 0000 9148 7539. GRID: grid.415030.3
Virginia Commonwealth University School of Medicine, Richmond, VA USA. ISNI: 0000 0004 0458 8737. GRID: grid.224260.0
AN  - 28944289
AU  - Robinson, B. N.
AU  - Newman, A. F.
AU  - Tefera, E.
AU  - Herbolsheimer, P.
AU  - Nunes, R.
AU  - Gallagher, C.
AU  - Randolph-Jackson, P.
AU  - Omogbehin, A.
AU  - Dilawari, A.
AU  - Pohlmann, P. R.
AU  - Mohebtash, M.
AU  - Lee, Y.
AU  - Ottaviano, Y.
AU  - Mohapatra, A.
AU  - Lynce, F.
AU  - Brown, R.
AU  - Mete, M.
AU  - Swain, S. M.
C2  - PMC5603544 Amgen, and Merrimack. R.N. received travel from Caris Life Sciences. C.G. and A.D. have a consultant or advisory role with Genomic Health. P.R.P. has a leadership role and stock ownership with Immunonet BioSciences, a consulting or advisory role with Personalized Cancer Therapy, OncoPlex Diagnostics, Immunonet BioSciences, and patent No. US 20120201820. M.M. declares a consulting or advisory role with AstraZeneca and Bayer Compositions as Cancer Therapeutics. S.M.S. received honoraria from Roche, Clinigen Group, AstraZeneca, and Pfizer, has a consulting or advisory role with Genentech/Roche, Clinigen Group, OncoPlex Diagnostics, Lilly, and Pieris Pharmaceuticals, and received research Funding from Puma Biotechnology, Roche, Genentech, Pfizer, Merrimack, Lilly and received travel from Genentech/Roche. B.N.R., A.F.N., E.T., P.R.J., A.O., Y.L., Y.L.O., A.M., F.C.L., and M.M. declare that they have no competing financial interests.
DO  - 10.1038/s41523-017-0039-1
DP  - NLM
ET  - 2017/09/26
LA  - eng
N1  - 2374-4677
Robinson, Brandi N
Newman, Antoinette F
Tefera, Eshetu
Herbolsheimer, Pia
Nunes, Raquel
Gallagher, Christopher
Randolph-Jackson, Pamela
Omogbehin, Adedamola
Dilawari, Asma
Pohlmann, Paula R
Orcid: 0000-0001-7914-5162
Mohebtash, Mahsa
Lee, Young
Ottaviano, Yvonne
Mohapatra, Avani
Lynce, Filipa
Brown, Richard
Mete, Mihriye
Swain, Sandra M
Orcid: 0000-0002-1320-3830
P30 CA051008/CA/NCI NIH HHS/United States
RC1 MD004185/MD/NIMHD NIH HHS/United States
UL1 TR001409/TR/NCATS NIH HHS/United States
Journal Article
NPJ Breast Cancer. 2017 Sep 18;3:36. doi: 10.1038/s41523-017-0039-1. eCollection 2017.
PY  - 2017
SN  - 2374-4677 (Print)
2374-4677
SP  - 36
ST  - Video intervention increases participation of black breast cancer patients in therapeutic trials
T2  - NPJ Breast Cancer
TI  - Video intervention increases participation of black breast cancer patients in therapeutic trials
VL  - 3
ID  - 155
ER  - 

TY  - JOUR
AB  - Background: Obesity is associated with higher breast cancer recurrence and death, and poorer health and quality of life. African‐American (AA) women have the highest prevalence of obesity, obesity‐related comorbidities, and breast cancer mortality compared with other racial/ethnic groups. Weight loss after breast cancer diagnosis may lower rates of recurrence and improve fitness, fatigue, and quality of life. Methods: This 6‐month randomized controlled trial pilot‐tests the use of a Fitbit activity tracker (Fitbit only group) versus Fitbit plus SparkPeople, a free web‐based weight loss program (combined group) among 70 AA breast cancer survivors. Paired t‐tests assess changes from baseline to 6‐months among each participant in primary (weight, body mass index [BMI], percent body fat) and secondary (24‐hour caloric intake, daily number of steps, quality of life, self‐monitoring strategies, self‐efficacy) outcomes. Two‐group t‐tests assess differences in outcomes between the two groups. Results: Currently, 36 of 46 (78.3%) eligible participants have enrolled and completed baseline assessments. Mean age of participants is 61.7 years (SD 8.7) and mean BMI is 36.9 (SD 7.0). Analyses of the first 25 participants who completed 3‐month assessments (Fitbit only N = 12; combined group N = 13) show significant weight loss in both groups; Fitbit only: mean weight change ‐6.73 pounds, SD 4.61, p < 0.001; mean BMI change ‐0.96 kg/m , SD 0.84, p = 0.002; combined group: mean weight change ‐5.95 pounds, 2 SD 5.84, p = 0.003; mean BMI change ‐1.03 kg/m , SD 0.77, p < 0.001. All participants significantly increased tracking of diet (Fitbit only p = 0.016; combined group p < 0.001) and physical activity (Fitbit only p < 0.001; combined group p = 0.001). Though not significant, combined group participants showed greater increases in self‐efficacy for eating healthy and reducing fat and calories, and increases in daily steps (+1308 vs. +285 for Fitbit only group). Preliminary analyses show no statistically significant difference in changes in outcomes from baseline to 3 months between the two groups. Conclusions: Both programs show potential as convenient and efficient weight loss methods for African‐American breast cancer survivors.
AN  - CN-01423654
AU  - Ferrante, J. M.
AU  - Doose, M.
AU  - Bator, A.
AU  - Devine, K.
AU  - Strickland, P. O.
AU  - Angelino, A.
AU  - Lee, J.
AU  - Koransky, A.
AU  - Hwang, K.
AU  - Bandera, E.
IS  - 5
KW  - *African American
*breast cancer
*cancer survivor
*female
*male
*weight loss program
Activity tracker
Adult
Body fat
Body mass
Caloric intake
Clinical article
Controlled clinical trial
Controlled study
Diet
Eating
Human
Middle aged
Physical activity
Quality of life
Randomized controlled trial
Self monitoring
Student t test
M3  - Journal: Conference Abstract
PY  - 2017
ST  - Virtual weight loss program for African-American breast cancer survivors: preliminary results
T2  - Journal of clinical oncology
TI  - Virtual weight loss program for African-American breast cancer survivors: preliminary results
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01423654/full
VL  - 35
ID  - 1482
ER  - 

TY  - JOUR
AB  - Purpose: The association between vitamin D and prostate biopsy outcomes has not been evaluated. We examine serum vitamin D levels with prostate biopsy results in men with an abnormal prostate-specific antigen and/or digital rectal examination. Experimental Design: Serum 25-hydroxyvitamin D (25-OH D) was obtained from 667 men, ages 40 to 79 years, prospectively enrolled from Chicago urology clinics undergoing first prostate biopsy. Logistic regression was used to evaluate the associations between 25-OH D status and incident prostate cancer, Gleason score, and tumor stage. Results: Among European American (EA) men, there was an association of 25-OH D <12 ng/mL with higher Gleason score≥4+4 [OR, 3.66;95%confidence interval (CI), 1.41-9.50; P=0.008] and tumor stage [stage≥cT2b vs. ≤cT2a, OR, 2.42 (1.14-5.10); P=0.008]. In African American (AA) men, we find increased odds of prostate cancer diagnosis on biopsy with 25-OHD< 20 ng/mL [OR, 2.43 (1.20-4.94); P=0.01]. AA men demonstrated an association between 25-OH D < 12 ng/mL and Gleason ≥ 4+4 [OR, 4.89 (1.59-15.07); P=0.006]. There was an association with tumor stage≥cT2b vs.≤cT2a [OR, 4.22 (1.52-11.74); P= 0.003]. Conclusions: In AA men, vitamin D deficiency was associated with increased odds of prostate cancer diagnosis on biopsy. In both EA and AAmen, severe deficiency was positively associated with higher Gleason grade and tumor stage. © 2014 AACR.
AD  - A.B. Murphy, Northwestern University, 300 E Superior, Chicago, IL 60611, United States
AU  - Murphy, A. B.
AU  - Nyame, Y.
AU  - Martin, I. K.
AU  - Catalona, W. J.
AU  - Hollowell, C. M. P.
AU  - Nadler, R. B.
AU  - Kozlowski, J. M.
AU  - Perry, K. T.
AU  - Kajdacsy-Balla, A.
AU  - Kittles, R.
DB  - Embase
Medline
DO  - 10.1158/1078-0432.CCR-13-3085
IS  - 9
KW  - 25 hydroxyvitamin D
prostate specific antigen
vitamin D
25 hydroxycolecalciferol blood level
adult
African American
aged
article
cancer diagnosis
cancer staging
controlled clinical trial
controlled study
digital rectal examination
disease association
European American
Gleason score
human
human tissue
major clinical study
male
outcome assessment
prediction
priority journal
prospective study
prostate biopsy
prostate cancer
urology
vitamin blood level
vitamin D deficiency
vitamin supplementation
LA  - English
M3  - Article
N1  - L373006477
2014-05-14
2014-05-28
PY  - 2014
SN  - 1557-3265
1078-0432
SP  - 2289-2299
ST  - Vitamin D deficiency predicts prostate biopsy outcomes
T2  - Clinical Cancer Research
TI  - Vitamin D deficiency predicts prostate biopsy outcomes
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L373006477&from=export
http://dx.doi.org/10.1158/1078-0432.CCR-13-3085
VL  - 20
ID  - 1032
ER  - 

TY  - JOUR
AB  - The effects of blood levels of 25-hydroxyvitamin D (25-OHD) on the risk of total, low-, and high-grade prostate cancer were examined in the Selenium and Vitamin E Cancer Prevention Trial (SELECT) and the Prostate Cancer Prevention Trial (PCPT). In the SELECT study, plasma 25-OHD levels were associated with a linear decrease in prostate cancer risk for high-grade cancers in African American men and an apparent "U"-shaped effect in other men. The "U-shaped" curve may reflect detection bias. In the PCPT study, in which detection bias was minimized, serum 25-OHD levels were associated with a linear decrease in the risk of high-grade prostate cancers. The results from these large prevention trials support the hypothesis that circulating levels of 25-OHD decrease the risk of clinically relevant prostate cancers.
AD  - Departments of Cancer Biology, Urology, and Epidemiology and Prevention, Wake Forest University School of Medicine, Winston-Salem, North Carolina gschwart@wakehealth.edu.
AN  - 25085835
AU  - Schwartz, G. G.
DA  - Aug
DO  - 10.1158/1055-9965.Epi-14-0520
DP  - NLM
ET  - 2014/08/03
IS  - 8
KW  - Humans
Male
Prostatic Neoplasms/*blood/*prevention & control
Randomized Controlled Trials as Topic
Selenium/therapeutic use
Vitamin D/*blood
Vitamin E/therapeutic use
LA  - eng
N1  - 1538-7755
Schwartz, Gary G
Journal Article
Review
United States
Cancer Epidemiol Biomarkers Prev. 2014 Aug;23(8):1447-9. doi: 10.1158/1055-9965.EPI-14-0520.
PY  - 2014
SN  - 1055-9965
SP  - 1447-9
ST  - Vitamin D in blood and risk of prostate cancer: lessons from the Selenium and Vitamin E Cancer Prevention Trial and the Prostate Cancer Prevention Trial
T2  - Cancer Epidemiol Biomarkers Prev
TI  - Vitamin D in blood and risk of prostate cancer: lessons from the Selenium and Vitamin E Cancer Prevention Trial and the Prostate Cancer Prevention Trial
VL  - 23
ID  - 280
ER  - 

TY  - JOUR
AB  - OBJECTIVES: Primary ‐ To determine the accrual rate of African Americans with adenomatous polyps to a 6‐month randomized intervention trial comprising supplementation with either cholecalciferol (vitamin D3) or placebo. ‐ To determine the compliance rates in patients treated with these regimens. Secondary ‐ To compare changes in pre‐ and post‐treatment vitamin D levels in patients treated with these regimens. ‐ To correlate vitamin D levels with vitamin D modifiers, such as levels of skin pigmentation, dietary vitamin D intake, and sun exposure in this patient population. OUTLINE: Patients are randomized to 1 of 2 arms. ‐ Arm I: Patients receive oral cholecalciferol (vitamin D3) supplementation daily for up to 6 months in the absence of disease progression or unacceptable toxicity. ‐ Arm II: Patients receive oral placebo supplementation daily for up to 6 months in the absence of disease progression or unacceptable toxicity. Patients complete questionnaires about demographics, dietary vitamin D intake, personal history (e.g., ancestry, alcohol and tobacco intake, occupation, height, and weight), medical history (e.g., personal and family history of colorectal cancer and polyps), and ultraviolet radiation exposure. Blood samples are collected at baseline and at 6 months for correlative laboratory studies. Blood samples are analyzed for vitamin D levels by enzyme immunoassay. Patients also undergo assessment of skin pigmentation in sunprotected and sunexposed areas of skin by reflectance spectrometry at baseline.
AN  - CN-01500186
AU  - Nct
KW  - Cholecalciferol
Colonic Neoplasms
Colorectal Neoplasms
Ergocalciferols
Precancerous Conditions
Vitamin D
Vitamins
PY  - 2009
ST  - Vitamin D Supplement in Preventing Colon Cancer in African Americans With Colon Polyps
T2  - https://clinicaltrials.gov/show/NCT00870961
TI  - Vitamin D Supplement in Preventing Colon Cancer in African Americans With Colon Polyps
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01500186/full
ID  - 1424
ER  - 

TY  - JOUR
AB  - Black Americans have lower levels of serum 25(OH)D but superior bone health compared to white Americans. There is controversy over whether they should be screened for vitamin D deficiency and have higher vitamin D requirements than recommended by the Institute of Medicine (IOM). The purpose of this trial was to determine whether Vitamin D supplementation in elderly black women prevents bone loss. A total of 260 healthy black American women, 60 years of age and older were recruited to take part in a two-arm, double-dummy 3-year randomized controlled trial (RCT) of vitamin D3 versus placebo. The study was conducted in an ambulatory clinical research center. Vitamin D3 dose was adjusted to maintain serum 25(OH)D above 75 nmol/L. Bone mineral density (BMD) and serum were measured for parathyroid hormone (PTH), C-terminal crosslink telopeptide (CTX), and bone-specific alkaline phosphatase (BSAP) every 6 months. Baseline serum 25(OH)D3 was 54.8 ± 16.8 nmol/L. There was no group × time interaction effect for any BMD measurement. For all BMD measurements, except for total body and spine, there was a statistically significant negative effect of time (p < 0.001). An equivalency analysis showed that the treatment group was equivalent to the control group. Serum PTH and BSAP declined, with a greater decline of PTH in the treatment group. The rate of bone loss with serum 25(OH)D above 75 nmol/L is comparable to the rate of loss with serum 25(OH)D at the Recommended Dietary Allowance (RDA) of 50 nmol/L. Black Americans should have the same exposure to vitamin D as white Americans. © 2018 American Society for Bone and Mineral Research.
AD  - J. Aloia, Bone Mineral Research Center, New York University (NYU) Winthrop Hospital, Mineola, NY, United States
AU  - Aloia, J.
AU  - Fazzari, M.
AU  - Islam, S.
AU  - Mikhail, M.
AU  - Shieh, A.
AU  - Katumuluwa, S.
AU  - Dhaliwal, R.
AU  - Stolberg, A.
AU  - Usera, G.
AU  - Ragolia, L.
DB  - Embase
Medline
DO  - 10.1002/jbmr.3521
IS  - 11
KW  - NCT011533568
25 hydroxyvitamin D
alkaline phosphatase bone isoenzyme
calcium carbonate
carboxy terminal telopeptide
colecalciferol
parathyroid hormone
placebo
African American
aged
aging
alkaline phosphatase blood level
application site reaction
article
benign neoplasm
bone density
breast disease
clinical research
congenital disorder
connective tissue disease
controlled study
dietary reference intake
double blind procedure
drug dose increase
ear disease
endocrine disease
eye disease
familial disease
female
femur
gastrointestinal disease
genetic disorder
heart disease
hematologic disease
hepatobiliary disease
human
hypercalciuria
immunopathology
infection
infestation
injury
inner ear disease
intoxication
kidney disease
lymphatic system disease
major clinical study
malignant neoplasm
mediastinum disease
medication compliance
mental disease
metabolic disorder
musculoskeletal disease
neurologic disease
nutritional disorder
osteolysis
osteoporosis
parathyroid hormone blood level
patient compliance
prospective study
protein cross linking
randomized controlled trial
respiratory tract disease
risk reduction
serum
side effect
skin disease
spine
thorax disease
urinary tract disease
vascular disease
vitamin blood level
vitamin supplementation
LA  - English
M3  - Article
N1  - L623271505
2018-08-02
2018-11-14
PY  - 2018
SN  - 1523-4681
0884-0431
SP  - 1916-1922
ST  - Vitamin D Supplementation in Elderly Black Women Does Not Prevent Bone Loss: A Randomized Controlled Trial
T2  - Journal of Bone and Mineral Research
TI  - Vitamin D Supplementation in Elderly Black Women Does Not Prevent Bone Loss: A Randomized Controlled Trial
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L623271505&from=export
http://dx.doi.org/10.1002/jbmr.3521
VL  - 33
ID  - 877
ER  - 

TY  - JOUR
AB  - Vitamin D promotes the differentiation of prostate cancer cells, raising the possibility that vitamin D deficiency over time may contribute to the progression from subclinical prostate cancer to clinical disease. Since low-risk prostate cancers are monitored over time in an effort to determine which progress into clinically important, more aggressive cancers, they provide an excellent model in which to study, over an extended period of time, the effects of enhancing vitamin D status and related changes in tumor progression. This is particularly relevant to African-American men, who exhibit a high prevalence of vitamin D deficiency as well as higher incidence of prostate cancer and higher mortality rates from prostate cancer than Caucasians. Our research team has recently completed an open-label clinical trial aimed at assessing the safety and potential efficacy of vitamin D-3 supplementation at 4000 international units (IU) per day for one year in subjects diagnosed with early stage, low-risk prostate cancer. The results of this clinical study suggest that supplementation with vitamin D-3 at 4000 IU per day may benefit patients with early stage, low-risk prostate cancer on active surveillance, because of the improved outcome (a decreased number of positive cores at repeat biopsy) in more than half of the subjects enrolled in the trial. We also observed that, after one year of supplementation, there was no difference in circulating levels of vitamin D between African-American and Caucasian subjects who completed the study. These clinical results also suggest that robust and sustained vitamin D-3 supplementation can reduce prostate cancer-related health disparities in African-American men and that these health disparities are at least in part the result of widespread hypovitaminosis D within the African-American population. This article is part of a Special Issue entitled 'Vitamin D Workshop'.
AN  - WOS:000321405800049
AU  - Hollis, B. W.
AU  - Marshall, D. T.
AU  - Savage, S. J.
AU  - Garrett-Mayer, E.
AU  - Kindy, M. S.
AU  - Gattoni-Celli, S.
DA  - Jul
DO  - 10.1016/j.jsbmb.2012.11.012
N1  - 15th Vitamin D Workshop
JUN 20-22, 2012
Houston, TX
SI
23220550
PY  - 2013
SN  - 0960-0760
SP  - 233-237
ST  - Vitamin D-3 supplementation, low-risk prostate cancer, and health disparities
T2  - Journal of Steroid Biochemistry and Molecular Biology
TI  - Vitamin D-3 supplementation, low-risk prostate cancer, and health disparities
VL  - 136
ID  - 3040
ER  - 

TY  - JOUR
AB  - Vitamin D promotes the differentiation of prostate cancer cells, raising the possibility that vitamin D deficiency over time may contribute to the progression from subclinical prostate cancer to clinical disease. Since low-risk prostate cancers are monitored over time in an effort to determine which progress into clinically important, more aggressive cancers, they provide an excellent model in which to study, over an extended period of time, the effects of enhancing vitamin D status and related changes in tumor progression. This is particularly relevant to African-American men, who exhibit a high prevalence of vitamin D deficiency as well as higher incidence of prostate cancer and higher mortality rates from prostate cancer than Caucasians. Our research team has recently completed an open-label clinical trial aimed at assessing the safety and potential efficacy of vitamin D3 supplementation at 4000 international units (IU) per day for one year in subjects diagnosed with early stage, low-risk prostate cancer. The results of this clinical study suggest that supplementation with vitamin D3 at 4000IU per day may benefit patients with early stage, low-risk prostate cancer on active surveillance, because of the improved outcome (a decreased number of positive cores at repeat biopsy) in more than half of the subjects enrolled in the trial. We also observed that, after one year of supplementation, there was no difference in circulating levels of vitamin D between African-American and Caucasian subjects who completed the study. These clinical results also suggest that robust and sustained vitamin D3 supplementation can reduce prostate cancer-related health disparities in African-American men and that these health disparities are at least in part the result of widespread hypovitaminosis D within the African-American population. This article is part of a Special Issue entitled 'Vitamin D Workshop'.
AD  - Department of Pediatrics, Medical University of South Carolina, 169 Ashley Avenue, Charleston, SC 29425, USA.
AN  - 23220550
AU  - Hollis, B. W.
AU  - Marshall, D. T.
AU  - Savage, S. J.
AU  - Garrett-Mayer, E.
AU  - Kindy, M. S.
AU  - Gattoni-Celli, S.
DA  - Jul
DO  - 10.1016/j.jsbmb.2012.11.012
DP  - NLM
ET  - 2012/12/12
KW  - African Americans
Cholecalciferol/*administration & dosage
Clinical Trials as Topic
Dietary Supplements
Healthcare Disparities/standards
Humans
Male
Prostatic Neoplasms/etiology/pathology/*prevention & control
Risk
Vitamin D/analogs & derivatives/blood
Vitamin D Deficiency/blood/complications
LA  - eng
N1  - 1879-1220
Hollis, Bruce W
Marshall, David T
Savage, Stephen J
Garrett-Mayer, Elizabeth
Kindy, Mark S
Gattoni-Celli, Sebastiano
P30 CA138313/CA/NCI NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.
Review
England
J Steroid Biochem Mol Biol. 2013 Jul;136:233-7. doi: 10.1016/j.jsbmb.2012.11.012. Epub 2012 Dec 7.
PY  - 2013
SN  - 0960-0760
SP  - 233-7
ST  - Vitamin D3 supplementation, low-risk prostate cancer, and health disparities
T2  - J Steroid Biochem Mol Biol
TI  - Vitamin D3 supplementation, low-risk prostate cancer, and health disparities
VL  - 136
ID  - 348
ER  - 

TY  - JOUR
AB  - BACKGROUND: Studies on informed consent to medical research conducted in low or middle-income settings have increased, including empirical investigations of consent to genetic research. We investigated voluntary participation and comprehension of informed consent among women involved in a genetic epidemiological study on breast cancer in an urban setting of Nigeria comparing women in the case and control groups. METHODS: Surveys were administered in face-to-face interviews with 215 participants following their enrollment in the genetic study (106 patients, 109 controls). Audio-taped in-depth interviews were conducted with a sub-sample of 17 (8%) women who completed the survey. RESULTS: The majority of all participants reported being told that participation in the genetic study was voluntary (97%), that they did not feel pressured to participate in the study (99%), and that they could withdraw from the study (81%). The majority of the breast cancer patients (83%) compared to 58% of women in the control group reported that the study purpose was to learn about the genetic inheritance of breast cancer (OR 3.44; 95% CI =1.66, 7.14, p value = 0.001). Most participants reported being told about study procedures (95%) and study benefits (98%). Sixty-eight percent of the patients, compared to 47% of the control group reported being told about study risks (p-value <0.001). Of the 165 married women, 19% reported asking permission from their husbands to enroll in the breast cancer study; no one sought permission from local elders. In-depth interviews highlight the use of persuasion and negotiation between a wife and her husband regarding study participation. CONCLUSIONS: The global expansion of genetic and genomic research highlights our need to understand informed consent practices for studies in ethnically diverse cultural environments such as Africa. Quantitative and qualitative empirical investigations of the informed consent process for genetic and genomic research will further our knowledge of complex issues associated with communication of information, comprehension, decisional authority and voluntary participation. In the future, the development and testing of innovative strategies to promote voluntary participation and comprehension of the goals of genomic research will contribute to our understanding of strategies that enhance the consent process.
AD  - Department of Bioethics, School of Medicine, Room TA 227Case Western Reserve University10900 Euclid Avenue Cleveland, Ohio 44106-4976 Cleveland, USA. pam20@case.edu.
AN  - 24885380
AU  - Marshall, P. A.
AU  - Adebamowo, C. A.
AU  - Adeyemo, A. A.
AU  - Ogundiran, T. O.
AU  - Strenski, T.
AU  - Zhou, J.
AU  - Rotimi, C. N.
C2  - PMC4032563
DA  - May 13
DO  - 10.1186/1472-6939-15-38
DP  - NLM
ET  - 2014/06/03
KW  - Adult
African Continental Ancestry Group
Breast Neoplasms/*epidemiology/*genetics/psychology
*Comprehension
Female
Genetic Predisposition to Disease
*Genetic Research/ethics
Health Knowledge, Attitudes, Practice
Humans
*Informed Consent/ethics
Male
Molecular Epidemiology
Nigeria/epidemiology/ethnology
Patient Selection
Refusal to Participate/ethnology
Surveys and Questionnaires
Third-Party Consent/ethics/*statistics & numerical data
LA  - eng
N1  - 1472-6939
Marshall, Patricia A
Adebamowo, Clement A
Adeyemo, Adebowale A
Ogundiran, Temidayo O
Strenski, Teri
Zhou, Jie
Rotimi, Charles N
P20 MD006899/MD/NIMHD NIH HHS/United States
2 R01 HG002207-04/HG/NHGRI NIH HHS/United States
P50-HG-03390/HG/NHGRI NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
BMC Med Ethics. 2014 May 13;15:38. doi: 10.1186/1472-6939-15-38.
PY  - 2014
SN  - 1472-6939
SP  - 38
ST  - Voluntary participation and comprehension of informed consent in a genetic epidemiological study of breast cancer in Nigeria
T2  - BMC Med Ethics
TI  - Voluntary participation and comprehension of informed consent in a genetic epidemiological study of breast cancer in Nigeria
VL  - 15
ID  - 286
ER  - 

TY  - JOUR
AB  - PURPOSE: Most breast cancer (BC) survivorship research focuses on the general population of survivors. Scant research investigates the potentially unique experiences of minorities, especially during and after the difficult transition from primary treatment to post-treatment. This qualitative study explored African American BC survivors' and caregivers' quality-of-life in the post-treatment period with a focus on social and spiritual well-being. METHODS: Participants included a convenience sample of African American women with stage I-III BC (N = 23) who completed treatment 6-24 months before enrollment. Primary caregivers (N = 22) included friends, spouses and other family members (21 complete dyads). Participants completed separate semi-structured telephone interviews. Template analysis was used to evaluate themes related to religiousness and spirituality, both across and within dyads. RESULTS: After treatment, religiousness and spirituality played a major role in both survivors' and caregivers' lives by: (1) providing global guidance, (2) guiding illness management efforts and (3) facilitating recovery. Participants described a spiritual connectedness with God and others in their social networks. Dyad members shared the goal of keeping a positive attitude and described positive growth from cancer. Few future concerns were expressed due to the belief that survivors were healed and "done" with cancer. Beyond practical and emotional support, provision of spiritual assistance was common. CONCLUSIONS: Results highlight the principal, positive role of religiousness and spirituality for African American BC survivors and caregivers after treatment. Findings emphasize the need to assess the importance of religious and spiritual beliefs and practices, and if appropriate, to provide resources that promote spiritual well-being.
AU  - Sterba, K. R.
AU  - Burris, J. L.
AU  - Heiney, S. P.
AU  - Ruppel, M. B.
AU  - Ford, M. E.
AU  - Zapka, J.
DB  - Medline
DO  - 10.1007/s11136-014-0654-3
IS  - 7
KW  - adult
African American
aged
attitude to health
breast tumor
caregiver
clinical trial
cultural anthropology
female
human
middle aged
multicenter study
psychology
qualitative research
quality of life
religion
social support
survivor
LA  - English
M3  - Article
N1  - L604182436
2015-05-08
PY  - 2014
SN  - 1573-2649
SP  - 1909-1920
ST  - "We both just trusted and leaned on the Lord": a qualitative study of religiousness and spirituality among African American breast cancer survivors and their caregivers
T2  - Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation
TI  - "We both just trusted and leaned on the Lord": a qualitative study of religiousness and spirituality among African American breast cancer survivors and their caregivers
UR  - https://www.embase.com/search/results?subaction=viewrecord&id=L604182436&from=export
http://dx.doi.org/10.1007/s11136-014-0654-3
VL  - 23
ID  - 1029
ER  - 

TY  - JOUR
AB  - Project HEAL (Health through Early Awareness and Learning) is an implementation trial that compared two methods of training lay peer community health advisors (CHAs)-in-person ("Traditional") versus web-based ("Technology")-to conduct a series of three evidence-based cancer educational workshops in African American churches. This analysis reports on participant outcomes from Project HEAL. Fifteen churches were randomized to the two CHA training methods and the intervention impact was examined over 24 months. This study was conducted in Prince George's County, MD, and enrolled 375 church members age 40-75. Participants reported on knowledge and screening behaviors for breast, prostate, and colorectal cancer. Overall, cancer knowledge in all areas increased during the study period (p < .001). There were significant increases in digital rectal exam (p < .05), fecal occult blood test (p < .001), and colonoscopy (p < .01) at 24 months; however, this did not differ by study group. Mammography maintenance (56% overall) was evidenced by women reporting multiple mammograms within the study period. Participants attending all three workshops were more likely to report a fecal occult blood test or colonoscopy at 24 months (p < .05) than those who attended only one. These findings suggest that lay individuals can receive web-based training to successfully implement an evidence-based health promotion intervention that results in participant-level outcomes comparable with (a) people trained using the traditional classroom method and (b) previous efficacy trials. Findings have implications for resources and use of technology to increase widespread dissemination of evidence-based health promotion interventions through training lay persons in community settings.
AD  - Department of Behavioral and Community Health, School of Public Health, University of Maryland, College Park, MD, USA.
Scheirer Consulting, Princeton, NJ, USA.
Department of Health, Behavior and Society, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
School of Public Health, Institute for Applied Environmental Health, University of Maryland, College Park, MD, USA.
Community Ministry of Prince George's County, Upper Marlboro, MD, USA.
AN  - 29955889
AU  - Holt, C. L.
AU  - Tagai, E. K.
AU  - Santos, S. L. Z.
AU  - Scheirer, M. A.
AU  - Bowie, J.
AU  - Haider, M.
AU  - Slade, J.
C2  - PMC7184874
DA  - Jul 16
DO  - 10.1093/tbm/iby065
DP  - NLM
ET  - 2018/06/30
IS  - 4
KW  - Adult
African Americans/education
Aged
Awareness
Breast Neoplasms/diagnosis/epidemiology
Cluster Analysis
Colonoscopy/methods
Colorectal Neoplasms/diagnosis/epidemiology
Community Health Workers/*education/trends
Early Detection of Cancer/methods
Education/statistics & numerical data
Female
Health Knowledge, Attitudes, Practice/ethnology
Health Promotion/*methods
Humans
Internet-Based Intervention/*statistics & numerical data
Male
Mammography/methods
Maryland/ethnology
Mass Screening/psychology
Middle Aged
Occult Blood
Prostatic Neoplasms/diagnosis/epidemiology
*African Americans
*Cancer early detection
*Community health advisors
*Implementation
*Web-based learning
LA  - eng
N1  - 1613-9860
Holt, Cheryl L
Tagai, Erin K
Santos, Sherie Lou Zara
Scheirer, Mary Ann
Bowie, Janice
Haider, Muhiuddin
Slade, Jimmie
R01 CA147313/CA/NCI NIH HHS/United States
Comparative Study
Journal Article
Randomized Controlled Trial
Transl Behav Med. 2019 Jul 16;9(4):573-582. doi: 10.1093/tbm/iby065.
PY  - 2019
SN  - 1869-6716 (Print)
1613-9860
SP  - 573-582
ST  - Web-based versus in-person methods for training lay community health advisors to implement health promotion workshops: participant outcomes from a cluster-randomized trial
T2  - Transl Behav Med
TI  - Web-based versus in-person methods for training lay community health advisors to implement health promotion workshops: participant outcomes from a cluster-randomized trial
VL  - 9
ID  - 116
ER  - 

TY  - JOUR
AB  - BACKGROUND: In response to findings from the Breast Cancer Prevention Trial that tamoxifen treatment produced a 49% reduction in the risk of invasive breast cancer in a population of women at elevated risk, the National Cancer Institute sponsored a workshop on July 7 and 8, 1998, to develop information to assist in counseling and in weighing the risks and benefits of tamoxifen. Our study was undertaken to develop tools to identify women for whom the benefits outweigh the risks. METHODS: Information was reviewed on the incidence of invasive breast cancer and of in situ lesions, as well as on several other health outcomes, in the absence of tamoxifen treatment. Data on the effects of tamoxifen on these outcomes were also reviewed, and methods were developed to compare the risks and benefits of tamoxifen. RESULTS: The risks and benefits of tamoxifen depend on age and race, as well as on a woman's specific risk factors for breast cancer. In particular, the absolute risks from tamoxifen of endometrial cancer, stroke, pulmonary embolism, and deep vein thrombosis increase with age, and these absolute risks differ between white and black women, as does the protective effect of tamoxifen on fractures. Tables and aids are developed to describe the risks and benefits of tamoxifen and to identify classes of women for whom the benefits outweigh the risks. CONCLUSIONS: Tamoxifen is most beneficial for younger women with an elevated risk of breast cancer. The quantitative analyses presented can assist health care providers and women in weighing the risks and benefits of tamoxifen for reducing breast cancer risk.
AD  - Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA. gailm@exchange.nih.gov
AN  - 10547390
AU  - Gail, M. H.
AU  - Costantino, J. P.
AU  - Bryant, J.
AU  - Croyle, R.
AU  - Freedman, L.
AU  - Helzlsouer, K.
AU  - Vogel, V.
DA  - Nov 3
DO  - 10.1093/jnci/91.21.1829
DP  - NLM
ET  - 1999/11/05
IS  - 21
KW  - Age Factors
Anticarcinogenic Agents/adverse effects/*therapeutic use
Breast Neoplasms/pathology/*prevention & control
Carcinoma in Situ
Cataract/prevention & control
Controlled Clinical Trials as Topic
Counseling
Education
Endometrial Neoplasms/chemically induced
Estrogen Receptor Modulators/adverse effects/*therapeutic use
Female
Fractures, Bone/epidemiology/prevention & control
Humans
National Institutes of Health (U.S.)
Neoplasm Invasiveness
Patient Education as Topic
Pulmonary Embolism/chemically induced
Risk
Risk Factors
Selective Estrogen Receptor Modulators/adverse effects/*therapeutic use
Stroke/chemically induced
Tamoxifen/adverse effects/*therapeutic use
United States
Venous Thrombosis/chemically induced
LA  - eng
N1  - Gail, M H
Costantino, J P
Bryant, J
Croyle, R
Freedman, L
Helzlsouer, K
Vogel, V
Journal Article
Research Support, Non-U.S. Gov't
Review
United States
J Natl Cancer Inst. 1999 Nov 3;91(21):1829-46. doi: 10.1093/jnci/91.21.1829.
PY  - 1999
SN  - 0027-8874 (Print)
0027-8874
SP  - 1829-46
ST  - Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer
T2  - J Natl Cancer Inst
TI  - Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer
VL  - 91
ID  - 710
ER  - 

TY  - JOUR
AB  - Purpose Observational study evidence has associated overweight/obesity with decreased survival in women with breast cancer and with several other cancers. Although full-scale, definitive weight loss adjuvant intervention trials with cancer end points remain to be conducted, a number of randomized controlled trials have evaluated weight loss interventions in survivors of cancer in women. Findings from these trials in breast, endometrial, and ovarian cancer are reviewed. Methods A systematic review of randomized controlled clinical trials evaluating weight loss interventions was updated (for studies published 2013 to 2016), and clinical trials registers were searched for ongoing trials. Results Six new randomized trials in breast cancer survivors and two randomized trials in endometrial cancer survivors were identified. Evidence from these trials and the 10 earlier randomized trials in female cancer survivors provide support for the feasibility of recruiting women closer to the cancer diagnosis and efficacy for achieving weight loss, in particular with telephone-based interventions, and have identified the challenge of achieving significant weight loss in African American cancer survivors and of maintaining weight loss in any cancer survivor group. Seven ongoing randomized trials are evaluating the influence of weight loss interventions on cancer end points (five in breast cancer, one in ovarian cancer, and one in endometrial cancer). Conclusion After a decade of preliminary studies, ongoing randomized, controlled clinical trials will potentially provide definitive assessment of whether weight loss can improve breast cancer clinical outcome. Longer-term interventions (> 2 years' duration) may be needed to optimize weight loss maintenance and any potential benefits on cancer end points.
AD  - Rowan T. Chlebowski, Harbor-University of California, Los Angeles Medical Center, Torrance, CA; and Marina M. Reeves, The University of Queensland, Brisbane, Queensland, Australia.
AN  - 27903147
AU  - Chlebowski, R. T.
AU  - Reeves, M. M.
C2  - PMC5455319 online at www.jco.org. Author contributions are found at the end of this article.
DA  - Dec 10
DO  - 10.1200/jco.2016.69.4026
DP  - NLM
ET  - 2016/12/03
IS  - 35
KW  - Breast Neoplasms/*complications/metabolism/*prevention & control
Endometrial Neoplasms/*complications/metabolism/*prevention & control
Female
Health Behavior
Humans
Obesity/*complications/metabolism/*prevention & control
Ovarian Neoplasms/*complications/metabolism/*prevention & control
Prognosis
Randomized Controlled Trials as Topic
Survivors
*Weight Loss
LA  - eng
N1  - 1527-7755
Chlebowski, Rowan T
Reeves, Marina M
N01WH22110/WH/WHI NIH HHS/United States
Journal Article
Review
Systematic Review
J Clin Oncol. 2016 Dec 10;34(35):4238-4248. doi: 10.1200/JCO.2016.69.4026. Epub 2016 Nov 7.
PY  - 2016
SN  - 0732-183X (Print)
0732-183x
SP  - 4238-4248
ST  - Weight Loss Randomized Intervention Trials in Female Cancer Survivors
T2  - J Clin Oncol
TI  - Weight Loss Randomized Intervention Trials in Female Cancer Survivors
VL  - 34
ID  - 192
ER  - 

TY  - JOUR
AB  - There is a lack of mobile app which aims to improve health screening uptake developed for men. As part of the study to develop an effective mobile app to increase health screening uptake in men, we conducted a needs assessment to find out what do men want from a health screening mobile app. In-depth interviews and focus group discussions were conducted with 31 men from a banking institution in Kuala Lumpur. The participants were purposely sampled according to their job position, age, ethnicity and screening status. The recruitment was stopped once data saturation was achieved. The audio-recorded interviews were transcribed verbatim and analyzed using thematic approach. Three themes emerged from the analysis and they were: content, feature and dissemination. In terms of the content, men wanted the app to provide information regarding health screening and functions that can assess their health; which must be personalized to them and are trustable. The app must have user-friendly features in terms of information delivery, ease of use, attention allocation and social connectivity. For dissemination, men proposed that advertisements, recommendations by health professionals, providing incentive and integrating the app as into existing systems may help to increase the dissemination of the app. This study identified important factors that need to be considered when developing a mobile app to improve health screening uptake. Future studies on mobile app development should elicit users' preference and need in terms of its content, features and dissemination strategies to improve the acceptability and the chance of successful implementation.
AN  - WOS:000391641500093
AU  - Teo, C. H.
AU  - Ng, C. J.
AU  - White, A.
DA  - Jan
DO  - 10.1371/journal.pone.0169435
IS  - 1
N1  - e0169435
28060953
PY  - 2017
SN  - 1932-6203
ST  - What Do Men Want from a Health Screening Mobile App? A Qualitative Study
T2  - Plos One
TI  - What Do Men Want from a Health Screening Mobile App? A Qualitative Study
VL  - 12
ID  - 2911
ER  - 

TY  - JOUR
AB  - Professional guidelines suggest that men should learn about risks and benefits of screening to make informed decisions consistent with their preferences. We used concept mapping to investigate views of informed decision making (IDM) of minority men. Statements about what men need for IDM about prostate cancer screening were sorted by similarity and rated for importance by 16 Hispanic and 15 African-American men. Multidimensional scaling and cluster analysis were used to develop a concept map for IDM. The 10-cluster solution was selected. The clusters rated most important were labeled Future Considerations, What to Know and Decision to Make. Clusters labeled Social Support and Sharing Perspectives depicted social aspects of the decision and were intermediate in importance. There was strong correlation in relative importance ratings of clusters by African-American and Hispanic men. However, African-American men gave higher importance ratings than Hispanic men. Concept mapping, a method with strong participatory elements, was useful in identifying conceptual frameworks for IDM of African-American and Hispanic men. Health education to support IDM requires some shifts in focus and strategy. It is important that interventions with minority men build upon a strong conceptual framework.
AD  - The University of Texas School of Public Health, San Antonio Regional Campus, San Antonio, TX 78229, USA. stephanie.l.mcfall@uth.tmc.edu
AN  - 18469320
AU  - McFall, S. L.
AU  - Ureda, J.
AU  - Byrd, T. L.
AU  - Valdes, A.
AU  - Morales, P.
AU  - Scott, D. B.
AU  - Williams, D.
AU  - Calderon-Mora, J.
AU  - Casillas, M. E.
AU  - Chan, E. C.
DA  - Apr
DO  - 10.1093/her/cyn018
DP  - NLM
ET  - 2008/05/13
IS  - 2
KW  - Adult
*African Americans
*Decision Making
*Hispanic Americans
Humans
Male
*Mass Screening
Middle Aged
Patient Education as Topic
*Patient Participation
Prostatic Neoplasms/*diagnosis
South Carolina
LA  - eng
N1  - McFall, Stephanie L
Ureda, John
Byrd, Theresa L
Valdes, Adriana
Morales, Pat
Scott, Delores B
Williams, Deloris
Calderon-Mora, Jessica
Casillas, Myryam E
Chan, Evelyn C Y
Journal Article
Research Support, U.S. Gov't, P.H.S.
England
Health Educ Res. 2009 Apr;24(2):280-91. doi: 10.1093/her/cyn018. Epub 2008 May 9.
PY  - 2009
SN  - 0268-1153 (Print)
0268-1153
SP  - 280-91
ST  - What is needed for informed decisions about prostate cancer screening: perspectives of African-American and Hispanic men
T2  - Health Educ Res
TI  - What is needed for informed decisions about prostate cancer screening: perspectives of African-American and Hispanic men
VL  - 24
ID  - 495
ER  - 

TY  - JOUR
AB  - BACKGROUND: The patient voice remains underrepresented in clinical and public health interventions. To inform interventions that strive to improve access to breast and cervical cancer screening and follow-up among low-income populations, we explored recommendations from low-income women pursuing health care in the safety net. METHODS: Semi-structured interviews were conducted among women receiving follow-up care for an abnormal breast or cervical cancer screening result or a positive cancer diagnosis in federally qualified health centers, free clinics, or an academic cancer center in the Chicago metropolitan area. FINDINGS: Of the 138 women interviewed in the parent study, 52 women provided recommendations for improving access to screening and follow-up care. Most were between 41 and 65 years old (62%) and African American (60%) or White (25%). Recommendations included strengthening community-based health education with more urgent messaging, strategic partnerships, and active learning experiences to increase patient engagement, which women regarded as a key driver of access. Women also suggested increasing access by way of changes to health care delivery systems and policy, including more direct patient-provider and patient-clinic communications, addressing delays caused by high patient volume, combining preventive services, expanding insurance coverage, and adjusting screening guidelines. CONCLUSIONS: This exploratory study demonstrates important insights from the patient lens that may help to increase the acceptability and efficacy of community and clinical interventions aimed at improving access to breast and cervical cancer screening and follow-up. Further research is needed to identify appropriate integration of patient input into interventions, practice, and policy change.
AD  - Department of Obstetrics and Gynecology, Northwestern University, Chicago, Illinois.
Institute for Public Health and Medicine, Northwestern University, Chicago, Illinois; Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois.
Institute for Public Health and Medicine, Northwestern University, Chicago, Illinois.
Rush Institute for Healthy Aging, Rush University Medical Center, Chicago, Illinois.
Department of Obstetrics and Gynecology, Northwestern University, Chicago, Illinois; Institute for Public Health and Medicine, Northwestern University, Chicago, Illinois; Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois; Department of Preventive Medicine, Northwestern University, Chicago, Illinois. Electronic address: m-simon2@northwestern.edu.
AN  - 25213744
AU  - Ragas, D. M.
AU  - Nonzee, N. J.
AU  - Tom, L. S.
AU  - Phisuthikul, A. M.
AU  - Luu, T. H.
AU  - Dong, X.
AU  - Simon, M. A.
C2  - PMC4840460
C6  - NIHMS627125
DA  - Sep-Oct
DO  - 10.1016/j.whi.2014.06.011
DP  - NLM
ET  - 2014/09/13
IS  - 5
KW  - Adult
Aged
Breast Neoplasms/*diagnosis
Chicago
Community Participation
*Continuity of Patient Care
Early Detection of Cancer
Female
*Health Education
Health Knowledge, Attitudes, Practice
*Health Services Accessibility
*Health Services Needs and Demand
Humans
Interviews as Topic
Mammography
Mass Screening
Middle Aged
Poverty
Qualitative Research
Risk Factors
Uterine Cervical Neoplasms/*diagnosis
Vaginal Smears
LA  - eng
N1  - 1878-4321
Ragas, Daiva M
Nonzee, Narissa J
Tom, Laura S
Phisuthikul, Ava M
Luu, Thanh Ha
Dong, XinQi
Simon, Melissa A
K12 HD050121/HD/NICHD NIH HHS/United States
R24 MD001650/MD/NIMHD NIH HHS/United States
TL1 TR000121/TR/NCATS NIH HHS/United States
U01 CA116875/CA/NCI NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Womens Health Issues. 2014 Sep-Oct;24(5):511-8. doi: 10.1016/j.whi.2014.06.011.
PY  - 2014
SN  - 1049-3867 (Print)
1049-3867
SP  - 511-8
ST  - What women want: patient recommendations for improving access to breast and cervical cancer screening and follow-up
T2  - Womens Health Issues
TI  - What women want: patient recommendations for improving access to breast and cervical cancer screening and follow-up
VL  - 24
ID  - 276
ER  - 

TY  - JOUR
AB  - BACKGROUND: The role of primary care providers (PCPs) in decision making around cancer care remains largely unknown. We evaluated how frequently men with localized prostate cancer report receiving help from their PCP about their treatment, and whether those men who do are less likely to receive definitive treatment. METHODS: We mailed surveys to men newly diagnosed with localized prostate cancer between 2012 and 2014 in the greater Philadelphia region. Participants were asked whether their PCP helped decide how to treat their cancer. The outcome was receipt of definitive treatment (either radical prostatectomy or radiotherapy). RESULTS: A total of 2386 men responded (adjusted response rate, 51.1%). Among these men, 38.2% reported receiving help from their PCP regarding choosing a treatment, and 79.6% received definitive treatment. In adjusted analyses, non-Hispanic black men (odds ratio, 1.76; 95% confidence interval, 1.37-2.27) were more likely than non-Hispanic white men to report receiving help from their PCP. However, men who did receive help were not more likely to forgo definitive treatment overall (P = .58) or in the subgroups of men who may be least likely to benefit from definitive treatment. CONCLUSIONS: Though a substantial proportion of men reported receiving help from their PCP about prostate cancer treatment, these discussions were not associated with different treatment patterns. Further effort is needed to determine how to optimize the role of PCPs in supporting patients to make preference-sensitive cancer decisions.
AD  - From the Division of General Internal Medicine, Johns Hopkins University, Baltimore, MD (AR, CEP); the Division of General Internal Medicine, Hospital of the University of Pennsylvania Philadelphia (DG, CS); the Department of Biostatistics and Epidemiology, Hospital of the University of Pennsylvania (MR, NM); the Department of Radiation Oncology, Hospital of the University of Pennsylvania (JB); and the Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore (CEP). aradhak3@jhu.edu.
From the Division of General Internal Medicine, Johns Hopkins University, Baltimore, MD (AR, CEP); the Division of General Internal Medicine, Hospital of the University of Pennsylvania Philadelphia (DG, CS); the Department of Biostatistics and Epidemiology, Hospital of the University of Pennsylvania (MR, NM); the Department of Radiation Oncology, Hospital of the University of Pennsylvania (JB); and the Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore (CEP).
AN  - 28484062
AU  - Radhakrishnan, A.
AU  - Grande, D.
AU  - Ross, M.
AU  - Mitra, N.
AU  - Bekelman, J.
AU  - Stillson, C.
AU  - Pollack, C. E.
C2  - PMC5870832
C6  - NIHMS881334
DA  - May-Jun
DO  - 10.3122/jabfm.2017.03.160359
DP  - NLM
ET  - 2017/05/10
IS  - 3
KW  - Adenocarcinoma/psychology/*therapy
Adult
Aged
Aged, 80 and over
*Clinical Decision-Making
Humans
Male
Middle Aged
Patient Participation/*statistics & numerical data
Patient Preference
Philadelphia
*Physician's Role
Physician-Patient Relations
Practice Patterns, Physicians'/*statistics & numerical data
Primary Health Care/*methods/statistics & numerical data
Prostatectomy/statistics & numerical data
Prostatic Neoplasms/psychology/*therapy
Radiotherapy/statistics & numerical data
Primary Care Physicians
Primary Health Care
Prostate Cancer
Surveys and Questionnaires
LA  - eng
N1  - 1558-7118
Radhakrishnan, Archana
Grande, David
Ross, Michelle
Mitra, Nandita
Bekelman, Justin
Stillson, Christian
Pollack, Craig Evan
K07 CA151910/CA/NCI NIH HHS/United States
K07 CA163616/CA/NCI NIH HHS/United States
P60 MD006900/MD/NIMHD NIH HHS/United States
T32 HL007180/HL/NHLBI NIH HHS/United States
Journal Article
J Am Board Fam Med. 2017 May-Jun;30(3):298-307. doi: 10.3122/jabfm.2017.03.160359.
PY  - 2017
SN  - 1557-2625 (Print)
1557-2625
SP  - 298-307
ST  - When Primary Care Providers (PCPs) Help Patients Choose Prostate Cancer Treatment
T2  - J Am Board Fam Med
TI  - When Primary Care Providers (PCPs) Help Patients Choose Prostate Cancer Treatment
VL  - 30
ID  - 167
ER  - 

TY  - JOUR
AB  - PURPOSE: To identify factors significantly influencing accrual to clinical protocols by analyzing radiation Patterns of Care Study (PCS) surveys of 3,047 randomly selected radiotherapy (RT) patients. METHODS AND MATERIALS: Patterns of Care Study surveys from disease sites studied for the periods 1992-1994 and 1996-1999 (breast cancer, n = 1,080; prostate cancer, n = 1,149; esophageal cancer, n = 818) were analyzed. The PCS is a National Cancer Institute-funded national survey of randomly selected RT institutions in the United States. Patients with nonmetastatic disease who received RT as definitive or adjuvant therapy were randomly selected from eligible patients at each institution. To determine national estimates, individual patient records were weighted by the relative contribution of each institution and patients within each institution. Data regarding participation in clinical trials were recorded. The factors age, gender, race, type of insurance, and practice type of treating institution (academic or not) were studied by univariate and multivariate analyses. RESULTS: Overall, only 2.7% of all patients were accrued to clinical protocols. Of these, 57% were enrolled on institutional review board-approved institutional trials, and 43% on National Cancer Institute collaborative group studies. On multivariate analysis, patients treated at academic facilities (p = 0.0001) and white patients (vs. African Americans, p = 0.0002) were significantly more likely to participate in clinical oncology trials. Age, gender, type of cancer, and type of insurance were not predictive. CONCLUSIONS: Practice type and race significantly influence enrollment onto clinical oncology trials. This suggests that increased communication and education regarding protocols, particularly focusing on physicians in nonacademic settings and minority patients, will be essential to enhance accrual.
AD  - Department of Radiation Oncology, Henry Ford Health System, 2799 West Grand Boulevard, Detroit, MI 48202, USA. bmovsas@hfhs.org
AN  - 17418963
AU  - Movsas, B.
AU  - Moughan, J.
AU  - Owen, J.
AU  - Coia, L. R.
AU  - Zelefsky, M. J.
AU  - Hanks, G.
AU  - Wilson, J. F.
DA  - Jul 15
DO  - 10.1016/j.ijrobp.2007.01.051
DP  - NLM
ET  - 2007/04/10
IS  - 4
KW  - Academies and Institutes/statistics & numerical data
Adult
African Continental Ancestry Group/statistics & numerical data
Aged
Analysis of Variance
Breast Neoplasms/radiotherapy
Clinical Trials as Topic/standards/*statistics & numerical data
Esophageal Neoplasms/radiotherapy
European Continental Ancestry Group/statistics & numerical data
Female
Humans
Insurance, Health
Male
Middle Aged
Neoplasms/ethnology/*radiotherapy
*Patient Selection
Professional Practice/statistics & numerical data
Prostatic Neoplasms/radiotherapy
*Radiation Oncology/classification/statistics & numerical data
Sex Factors
United States
LA  - eng
N1  - Movsas, Benjamin
Moughan, Jennifer
Owen, Jean
Coia, Lawrence R
Zelefsky, Michael J
Hanks, Gerald
Wilson, J Frank
CA 65435/CA/NCI NIH HHS/United States
Journal Article
Multicenter Study
Research Support, N.I.H., Extramural
United States
Int J Radiat Oncol Biol Phys. 2007 Jul 15;68(4):1145-50. doi: 10.1016/j.ijrobp.2007.01.051. Epub 2007 Apr 9.
PY  - 2007
SN  - 0360-3016 (Print)
0360-3016
SP  - 1145-50
ST  - Who enrolls onto clinical oncology trials? A radiation Patterns Of Care Study analysis
T2  - Int J Radiat Oncol Biol Phys
TI  - Who enrolls onto clinical oncology trials? A radiation Patterns Of Care Study analysis
VL  - 68
ID  - 529
ER  - 

TY  - JOUR
AB  - BACKGROUND: The current study examined how patients' sociodemographic, cancer-related, and subjective affective factors impacted their role in treatment decision-making. METHODS: The patient sample (N = 788) was taken from a prospective follow-up study of a population-based cohort. Participants included 343 African American and 445 Caucasian-American patients with clinically localized prostate cancer. Multinomial logistic regression was used to investigate relations between the explanatory variables and the nominal 3-level decision-making variable: patient-only, patient-physician shared, and physician-only. RESULTS: Approximately 41% of patients reported patient-only decision-making, 45% reported shared decision-making, and 13% reported physician-only decision-making. The odds of patient-only over physician-only decision-making were greater for younger men (vs those aged ≥ 65 years) (odds ratio [OR], 1.68; 95% confidence interval [95% CI], 1.03-2.74), and were less for men with high (vs low) cancer aggressiveness (OR,0.29; 95% CI, 0.15-0.55). The odds of shared over physician-only decision-making were less for men with high (vs low) cancer aggressiveness (OR, 0.40; 95% CI, 0.22-0.73). Greater odds of patient-only and shared decision-making also were found to be associated with greater concerns about the physical impact of treatment and having enough time for decision-making and lower scores of receiving advice from others. CONCLUSIONS: The findings of the current study indicate that, to facilitate a more patient-oriented decision-making process regarding treatment in those with clinically localized prostate cancer, clinicians need to tailor their interventions according to patient age and cancer aggressiveness, help reduce patient concerns and misconceptions regarding the physical impact of treatments, allow sufficient time for patients to consider treatment options, and assist patients in balancing advice and information received from different sources.
AD  - Adult and Geriatric Health Division, School of Nursing, and Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599-7460, USA. lsong@unc.edu
AN  - 22786794
AU  - Song, L.
AU  - Chen, R. C.
AU  - Bensen, J. T.
AU  - Knafl, G. J.
AU  - Nielsen, M. E.
AU  - Farnan, L.
AU  - Wallen, E. M.
AU  - Mishel, M.
AU  - Pruthi, R. S.
AU  - Mohler, J. L.
AU  - Godley, P. A.
C2  - PMC7671233
C6  - NIHMS1618614
DA  - Jan 15
DO  - 10.1002/cncr.27738
DP  - NLM
ET  - 2012/07/13
IS  - 2
KW  - Aged
*Decision Making
Disease Management
Humans
Logistic Models
Male
Middle Aged
*Patient Participation
*Physician's Role
Prospective Studies
Prostatic Neoplasms/*therapy
LA  - eng
N1  - 1097-0142
Song, Lixin
Chen, Ronald C
Bensen, Jeannette T
Knafl, George J
Nielsen, Matthew E
Farnan, Laura
Wallen, Eric M
Mishel, Merle
Pruthi, Raj S
Mohler, James L
Godley, Paul A
T32 NR007091/NR/NINR NIH HHS/United States
U54 CA153602/CA/NCI NIH HHS/United States
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Cancer. 2013 Jan 15;119(2):421-8. doi: 10.1002/cncr.27738. Epub 2012 Jul 11.
PY  - 2013
SN  - 0008-543X (Print)
0008-543x
SP  - 421-8
ST  - Who makes the decision regarding the treatment of clinically localized prostate cancer--the patient or physician?: results from a population-based study
T2  - Cancer
TI  - Who makes the decision regarding the treatment of clinically localized prostate cancer--the patient or physician?: results from a population-based study
VL  - 119
ID  - 360
ER  - 

TY  - JOUR
AB  - Comments on an article by S. C. Palmer et al. (see record [rid]2011-05701-015[/rid]). Palmer et al. in their reply seem to agree on some critical points, but state that I undercut my credibility by overstating and dramatizing, and they end up by discarding my suggested proposal for a complementary quasi-experimental design as being worse. Before discussing their objections to my proposal I must comment on their questioning of my credibility. Palmer et al. then totally disregard my quasi-experimental suggestion to make the trial closer to clinical complexity by constituting the experimental arm with those desiring treatment and the control arm with those uninterested in treatment. In my Letter I questioned the white card of RCTs and explicitly looked for a discussion of complementary designs to incorporate the subjective mind. I regret that none of the repliers, as authorities in intervention research, looked beyond the RCT. I interpret the silence as saying that there is no interest in opening up the black box—the subjective mind is not a topic on the agenda. (PsycINFO Database Record (c) 2016 APA, all rights reserved)
AD  - Salander, Pär
AN  - 2011-07527-013
AU  - Salander, Pär
DB  - psyh
DO  - 10.1002/pon.1956
DP  - EBSCOhost
IS  - 4
KW  - psychosocial intervention
randomized control trials
breast cancer rehabilitation
cognitive behavioral therapy
existential therapy
psychosocial oncology
Humans
Male
Middle Aged
Neoplasms
Randomized Controlled Trials as Topic
Research Design
Breast Neoplasms
Clinical Trials
Intervention
Psychosocial Rehabilitation
Oncology
Cognitive Behavior Therapy
Treatment Effectiveness Evaluation
N1  - Department of Social Work, Umed University, Sweden. Release Date: 20110711. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Print. Document Type: Comment/Reply. Language: English. Major Descriptor: Breast Neoplasms; Clinical Trials; Intervention; Psychosocial Rehabilitation; Oncology. Minor Descriptor: Cognitive Behavior Therapy; Existential Therapy; Treatment Effectiveness Evaluation. Classification: Cancer (3293); Behavioral & Psychological Treatment of Physical Illness (3361). Population: Human (10). References Available: Y. Page Count: 2. Issue Publication Date: Apr, 2011. Copyright Statement: John Wiley & Sons, Ltd. 2010.
PY  - 2011
SN  - 1057-9249
1099-1611
SP  - 441-442
ST  - Why doesn't mind matter when we are to find out what is helpful?
T2  - Psycho-Oncology
TI  - Why doesn't mind matter when we are to find out what is helpful?
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2011-07527-013&site=ehost-live&scope=site
par.salander@socw.umu.se
VL  - 20
ID  - 1782
ER  - 

TY  - JOUR
AB  - It is well known that black American women are poorly represented in medically oriented research and that this has far reaching implications for their personal health, the health of their families and the overall health of the larger society. The research reported was premised on the assumption that learning more about black American women's beliefs and values regarding health and illness could inform public policy initiatives in the area of cancer prevention and control so that a more equitable basis for participation could be achieved in future medical and scientific research. Qualitative methods of research were used in this investigation. A semi-structured interview guide was used in 36 h. of in-depth and face-to-face interviews with 13 black American women recruited to the study using a snowball technique. The women interviewed were middle-class, professional and semi-professional women. The results of the study indicate that there is a poor understanding by the dominant white medical community concerning the beliefs and values of black patients and that this compromises their health and illness care. The Tuskegee Syphilis Experiment is often used as the rationale for the low recruitment of black women into clinical trials both therapeutic and non-therapeutic. The women interviewed do not agree with this claim. These women suggest that if they were asked to participate in trials and the trial was relevant to their primary medical concerns they would consider joining. The research results indicate the importance of using specific research methodologies and a number of recommendations are presented.
AD  - University of Pennsylvania, School of Nursing, Philadelphia 19104-6096, USA.
AN  - 9722113
AU  - Freedman, T. G.
DA  - Oct
DO  - 10.1016/s0277-9536(98)00167-1
DP  - NLM
ET  - 1998/08/29
IS  - 7
KW  - Adult
African Americans/*psychology
Aged
*Attitude to Health
Breast Neoplasms/prevention & control
Clinical Trials as Topic/psychology
Female
Health Services Needs and Demand
Humans
Interviews as Topic
Middle Aged
Physician-Patient Relations
Religion
Social Values
United States
Women/*psychology
LA  - eng
N1  - Freedman, T G
R03 CA 70599/CA/NCI NIH HHS/United States
R03 CA 77101/CA/NCI NIH HHS/United States
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.
England
Soc Sci Med. 1998 Oct;47(7):941-7. doi: 10.1016/s0277-9536(98)00167-1.
PY  - 1998
SN  - 0277-9536 (Print)
0277-9536
SP  - 941-7
ST  - "Why don't they come to Pike Street and ask us"?: Black American women's health concerns
T2  - Soc Sci Med
TI  - "Why don't they come to Pike Street and ask us"?: Black American women's health concerns
VL  - 47
ID  - 729
ER  - 

TY  - JOUR
AB  - Perceived risk to a health problem is formed by inferential rules called heuristics and by comparative judgments that assess how one's risk compares to the risk of others. The purpose of this cross-sectional, community-based survey was to examine how experiences with breast cancer, knowledge of risk factors, and specific heuristics inform risk judgments for oneself, for friends/peers, and comparative judgments for breast cancer (risk friends/peers - risk self). We recruited an English-speaking, multicultural (57% nonwhite) sample of 184 middle-aged (47 + or - 12 years old), well-educated women. Fifty percent of participants perceived that their breast cancer risk was the same as the risk of their friends/peers; 10% were pessimistic (risk friends/peers - risk self < 0), whereas 40% were optimistic (risk friends/peers - risk self > 0). Family history of breast cancer and worry informed risk judgments for oneself. The availability and cultural heuristics specific for black women informed risk judgments for friends/peers. Knowledge of risk factors and interactions of knowledge with the availability, representativeness, and simulation heuristics informed comparative judgments (risk friends/peers - risk self). We discuss cognitive mechanisms with which experiences, knowledge, and heuristics influence comparative breast cancer risk judgments. Risk communication interventions should assess knowledge deficits, contextual variables, and specific heuristics that activate differential information processing mechanisms.
AD  - University of Michigan School of Nursing, Ann Arbor, MI, USA. mkatapo@umich.edu
AN  - 105286383. Language: English. Entry Date: 20100226. Revision Date: 20151008. Publication Type: Journal Article
AU  - Katapodi, M. C.
AU  - Dodd, M. J.
AU  - Facione, N. C.
AU  - Humphreys, J. C.
AU  - Lee, K. A.
DB  - CINAHL Complete
DO  - 10.1097/NCC.0b013e3181b430f9
DP  - EBSCOhost
IS  - 1
KW  - Attitude to Illness
Breast Neoplasms -- Risk Factors
Adult
Aged
Aged, 80 and Over
Attitude to Illness -- Evaluation
Biopsy
California
Coefficient Alpha
Cross Sectional Studies
Descriptive Research
Descriptive Statistics
Effect Size
Family History
Female
Funding Source
Health Knowledge -- Evaluation
Human
Independent Variable
Judgment
Middle Age
Questionnaires
Regression
Research Subject Recruitment
T-Tests
N1  - research; tables/charts. Journal Subset: Core Nursing; Double Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Nursing; Peer Reviewed; USA. Instrumentation: Behavioral Risk Factor Surveillance System (BRFSS); Knowledge of Breast Cancer Risk Factors Index. Grant Information: Department of Defense Medical Research, Breast Cancer Research Program, Clinical Nurse Research Grant. NLM UID: 7805358.
PMID: NLM19926972.
PY  - 2010
SN  - 0162-220X
SP  - 64-73
ST  - Why some women have an optimistic or a pessimistic bias about their breast cancer risk: experiences, heuristics, and knowledge of risk factors
T2  - Cancer Nursing
TI  - Why some women have an optimistic or a pessimistic bias about their breast cancer risk: experiences, heuristics, and knowledge of risk factors
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105286383&site=ehost-live&scope=site
VL  - 33
ID  - 2143
ER  - 

TY  - JOUR
AB  - IMPORTANCE: Black individuals are underrepresented in cancer clinical trials. OBJECTIVE: To examine whether Black and White men with prostate cancer differ in their willingness to discuss clinical trials with their physicians and, if so, whether patient-level barriers statistically mediate racial differences. DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional survey study used baseline data from Partnering Around Cancer Clinical Trials, a randomized clinical trial to increase Black individuals' enrollment in prostate cancer clinical trials. Data were collected from 2016 through 2019 at 2 National Cancer Institute-designated comprehensive cancer centers; participants were Black and White men with intermediate-risk to high-risk prostate cancer. In mediation analysis, path models regressed willingness onto race and each potential mediator, simultaneously including direct paths from race to each mediator. Significant indirect effect sizes served as evidence for mediation. EXPOSURES: Race was the primary exposure. Potential mediators included age, education, household income, perceived economic burden, pain/physical limitation, health literacy, general trust in physicians, and group-based medical suspicion. MAIN OUTCOMES AND MEASURES: The primary outcome was the answer to a single question: "If you were offered a cancer clinical trial, would you be willing to hear more information about it?" RESULTS: A total of 205 participants were included (92 Black men and 113 White men), with a mean (range) age of 65.7 (45-89) years; 32% had a high school education or lower, and 27.5% had a household income of less than $40 000. Most (88.3%) reported being definitely or probably willing to discuss trials, but White participants were more likely to endorse this highest category of willingness than Black participants (82% vs 64%; χ22 = 8.81; P = .01). Compared with White participants, Black participants were younger (F1,182 = 8.67; P < .001), less educated (F1,182 = 22.79; P < .001), with lower income (F1,182 = 79.59; P < .001), greater perceived economic burden (F1,182 = 42.46; P < .001), lower health literacy (F1,184 = 9.84; P = .002), and greater group-based medical suspicion (F1,184 = 21.48; P < .001). Only group-based medical suspicion significantly mediated the association between race and willingness to discuss trials (indirect effect, -0.22; P = .002). CONCLUSIONS AND RELEVANCE: In this study of men with prostate cancer, most participants were willing to discuss trials, but Black men were significantly less willing than White men. Black men were more likely to believe that members of their racial group should be suspicious of the health care system, and this belief was associated with lower willingness to discuss trials. Addressing medical mistrust may improve equity in clinical research.
AD  - Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
Karmanos Cancer Institute, Wayne State University, Detroit, Michigan.
The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland.
AN  - 32940630
AU  - Senft, N.
AU  - Hamel, L. M.
AU  - Manning, M. A.
AU  - Kim, S.
AU  - Penner, L. A.
AU  - Moore, T. F.
AU  - Carducci, M. A.
AU  - Heath, E. I.
AU  - Lansey, D. G.
AU  - Albrecht, T. L.
AU  - Wojda, M.
AU  - Jordan, A.
AU  - Eggly, S.
C2  - PMC7499244 National Cancer Institute during the conduct of the study. No other disclosures were reported.
DA  - Sep 17
DO  - 10.1001/jamaoncol.2020.3697
DP  - NLM
ET  - 2020/09/18
IS  - 11
LA  - eng
N1  - 2374-2445
Senft, Nicole
Hamel, Lauren M
Manning, Mark A
Kim, Seongho
Penner, Louis A
Moore, Tanina Foster
Carducci, Michael A
Heath, Elisabeth I
Lansey, Dina G
Albrecht, Terrance L
Wojda, Mark
Jordan, Alice
Eggly, Susan
T32 HS026122/HS/AHRQ HHS/United States
Journal Article
JAMA Oncol. 2020 Sep 17;6(11):1-5. doi: 10.1001/jamaoncol.2020.3697.
PY  - 2020
SN  - 2374-2437 (Print)
2374-2437
SP  - 1-5
ST  - Willingness to Discuss Clinical Trials Among Black vs White Men With Prostate Cancer
T2  - JAMA Oncol
TI  - Willingness to Discuss Clinical Trials Among Black vs White Men With Prostate Cancer
VL  - 6
ID  - 24
ER  - 

TY  - JOUR
AB  - Background: The goal of the WISDOM study (Women Informed to Screen Depending on Measures of risk) is to examine the effectiveness of a personalized approach to breast cancer screening and to bring clarity and objective recommendations to the current debate regarding mammography screening frequency. The WISDOM study, funded by PCORI, is a randomized trial with a preference‐tolerant design that aims to determine if risk‐based (RBS), vs. annual screening, is as safe, less morbid, enables prevention and is preferred by women. A pilot was conducted to test the logistics and examine the acceptance of the study. Methods: Women were recruited from the UCSF site of the Athena Breast Health Network, a clinical care‐research cohort including 100,000 women from the 5 UC Medical Centers and Sanford Health. We recruited women 40 ‐74 years of age that had no history of breast cancer and had a normal mammogram in the past year. The Breast Cancer Surveillance Consortium model (standard risk factors, ethnicity, breast density and SNP risk alleles) in addition to gene panel testing was used to calculate breast cancer risks to inform the start and frequency of screening. Results: An online electronic enrollment process, e‐Consent and patient engagement portal was successfully implemented. To date, 623 women were invited, 220 registered, and 159 have completed intake. 72% chose to be randomized, and 28% chose to self‐assign, of whom 70% chose annual screening. Mean age of pilot participants was 56 years old. The ethnic breakdown of the cohort is: 80% White, 10% Asian, 4% Latino, 3% Black and 3% other. 30% of participants identify as having Jewish ancestry. Initial patient interviews reveal overall enthusiasm for the study and provide ongoing feedback to improve the study materials. The pilot will conclude April 2016 when the full trial is launched. Additional data on distribution of personal risk estimates, and exit survey data evaluating uptake of screening recommendations will be presented. Conclusions: Our pilot reveals that the majority of women are willing to be randomized to answer the important question on optimal breast cancer screening. This pilot study is designed to inform the implementation of the 100,000 women WISDOM Study.
AN  - CN-01717755
AU  - Theiner, S.
AU  - Kaplan, C.
AU  - Sarrafan, S.
AU  - Cabrera, J.
AU  - Sawyer, S. D.
AU  - Liang, A. S.
AU  - Rosenberg-Wohl, S.
AU  - Frick, M.
AU  - Wong, E. C.
AU  - Tice, J.
AU  - et al.
KW  - *breast cancer
*cancer screening
Adult
Aged
Allele
Animal model
Breast density
Cancer risk
Controlled clinical trial
Controlled study
Disease model
Ethnicity
Female
Genetic predisposition
Hispanic
Human
Interview
Major clinical study
Mammography
Pilot study
Randomized controlled trial
Risk factor
Single nucleotide polymorphism
M3  - Journal: Conference Abstract
PY  - 2016
ST  - The WISDOM study pilot: evaluating a preference-tolerant RCT of risk-based vs. annual breast cancer screening
T2  - Journal of clinical oncology
TI  - The WISDOM study pilot: evaluating a preference-tolerant RCT of risk-based vs. annual breast cancer screening
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01717755/full
VL  - 34
ID  - 1648
ER  - 

TY  - THES
AB  - African American men have the highest incidence and mortality rates of prostate cancer in the United States and the world. The purpose of this study was to investigate knowledge and attitudes of wives regarding prostate cancer and prostate cancer screening among African American men 40 to 65 years old, to evaluate how involved the wives are in addressing this disease. A correlational, non-experimental design was used to investigate the relationship between wives’ knowledge and attitudes regarding the disease and screening, with the health belief model as a guide. The research questions focused on the relationship of the wives’ knowledge and attitudes when education and income are considered. A sample of 154 wives was recruited from African American churches in metropolitan Phoenix. A researcher-designed survey was used to collect data on the respondents’ characteristics and the variables of knowledge, attitudes, education, and income. Descriptive statistics, logistic regression, and Spearman rho were used for the analysis. The results showed a positive relationship between wives’ knowledge of prostate cancer and screening, and no relationship between wives’ attitudes and screening. Wives with more education and higher incomes tended to have higher scores on the knowledge section. Attitudes toward screening were positively correlated with income, but not the total number of years of academic education completed. This study leads to positive social change by providing information to public health professionals on the role that wives may play regarding prostate cancer and screenings to engage their husbands in a dialog about this health issue. (PsycINFO Database Record (c) 2016 APA, all rights reserved)
AN  - 2015-99031-050
AU  - Williams, Paula V.
DB  - psyh
DP  - EBSCOhost
KW  - highest incidence
researcher-designed survey
Blacks
Cancer Screening
Mortality Rate
Neoplasms
Wives
Ideology
N1  - Accession Number: 2015-99031-050. Other Journal Title: Dissertation Abstracts International. Partial author list: First Author & Affiliation: Williams, Paula V.; Walden U., US. Release Date: 20150216. Publication Type: Dissertation Abstract (0400). Format Covered: Electronic. Document Type: Dissertation. Dissertation Number: AAI3616978. ISBN: 978-1-303-84019-7. Language: English. Major Descriptor: Blacks. Minor Descriptor: Cancer Screening; Mortality Rate; Neoplasms; Wives; Ideology. Classification: Social Processes & Social Issues (2900). Population: Human (10); Male (30); Female (40). Location: US. Age Group: Adulthood (18 yrs & older) (300); Middle Age (40-64 yrs) (360); Aged (65 yrs & older) (380). Methodology: Empirical Study; Experimental Replication; Quantitative Study.
PB  - ProQuest Information & Learning
PY  - 2015
SN  - 0419-4209
978-1-303-84019-7
ST  - Wives' knowledge and attitudes regarding prostate cancer and prostate cancer screening among African American men
TI  - Wives' knowledge and attitudes regarding prostate cancer and prostate cancer screening among African American men
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2015-99031-050&site=ehost-live&scope=site
VL  - 75
ID  - 1727
ER  - 

TY  - JOUR
AB  - Lack of adequate participation by African American and Hispanic women in breast cancer genetic research studies sustains a knowledge gap in our understanding of new and innovative scientific advances and outcomes in breast cancer research/genomics. The purpose of this study is to suggest strategies to increase African American and Hispanic women's participation in breast cancer genetic research. A review of literature reveals that historical, community involvement, cultural, discrimination!somatizations concerns, and economic factors may impact participation in breast cancer genetic research investigations. Future research investigations should involve members of the minority community as recruiters, acknowledge anticipated historical concerns up-front, address anticipated concerns of discrimination/stigmatizations, and recognize and respect a person's culture and try to work within it when attempting to recruit minority women for breast cancer genetic research.
AD  - University of Rochester, School of Nursing
Department of Public Health, Robbins College of Health and Human Sciences, Baylor University
University of Wisconsin-Milwaukee, College of Nursing
AN  - 139005698. Language: English. Entry Date: 20191011. Revision Date: 20210311. Publication Type: Article
AU  - Reifenstein, Karen
AU  - Asare, Matt
AU  - Millon-Underwood, Sandra
DA  - Fall2019
DB  - CINAHL Complete
DP  - EBSCOhost
IS  - 3
KW  - Breast Neoplasms
Research, Medical
Women -- Psychosocial Factors
Consumer Participation -- Psychosocial Factors
Black Persons
Hispanic Americans
Human
Systematic Review
Psycinfo
Cochrane Library
PubMed
Medline
CINAHL Database
Decision Making
N1  - research; systematic review; tables/charts. Journal Subset: Blind Peer Reviewed; Core Nursing; Double Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Nursing; Peer Reviewed; USA. Special Interest: Evidence-Based Practice. NLM UID: 9439196.
PY  - 2019
SN  - 1071-5568
SP  - 108-117
ST  - WOMEN AND BREAST CANCER RESEARCH
T2  - Journal of Cultural Diversity
TI  - WOMEN AND BREAST CANCER RESEARCH
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=139005698&site=ehost-live&scope=site
VL  - 26
ID  - 2145
ER  - 

TY  - JOUR
AB  - Question: How do women decide whether and when to seek medical evaluation of self discovered breast symptoms? Design: Analysis of narratives generated from 16 focus groups. Setting: San Francisco, California, USA. Participants: 80 women aged >/=21 years who were recruited through community organisations, women's groups, churches, and senior centres. Methods: Focus groups (6 groups of black women, 4 groups of white women, and 6 groups of Latino women) were held in homes and community meeting rooms and lasted 90-120 minutes. Women were asked what it would be like to discover a problem in their breast, what they thought they would do, and to relate the experiences of women in their families or communities. Sessions were audiotaped, data were transcribed and narratives were independently analysed by 3 researchers. Main findings: Women related 101 narratives of personal experiences with self discovered breast symptoms, as well as those of friends and family. They gave vivid descriptions of the place and time of symptom discovery and understood that the passage of time without treatment added to the threat of the symptom. Some disclosed the symptom to partners or friends, which led to prompt, self initiated visits to a healthcare provider; others failed to disclose the discovery until their disease was advanced. Some women had difficulty interpreting the threat of the symptom and delayed evaluation. Some refused to give the symptom importance, and some blocked it from conscious awareness. Some avoided the term cancer, referring instead to 'the big C'; some thought that by avoiding the term, they could exert power over the cancer; and others thought that talking about cancer would cause women to get it. Women generally endorsed alternative therapies, often in conjunction with traditional medical treatments. Views on the role of God and spirituality varied, but none spoke of religious beliefs that prohibited evaluation or treatment of symptoms. Those who decided not to lose the breast through surgery were seen by some as making a breast conserving choice, by others as experiencing drastic repercussions, and by others as sparing the woman a loss of her femininity. Feelings about symptom discovery included fear of cancer and its treatment and guilt at not discovering symptoms earlier. Experiences with the provider visit included embarrassment during the physical examination, annoyance with the discomfort of the examination, and insensitive or rushed providers. Some women delayed or refused treatment because they feared abandonment by male partners. In some instances, male partners actually obstructed diagnosis or treatment. Poverty inhibited decisions to seek evaluation of symptoms because financial resources were needed for other family problems. Conclusion: Women's stories revealed several factors that delayed breast cancer diagnosis: unwillingness to disclose symptoms, incorrect interpretation of the threat of symptoms, a decision not to undergo surgery, embarrassment related to physical examination, fear of abandonment by male partners, and poverty. [Original article accession number: 1999008141 (research, tables/charts)]
AD  - Assistant Professor, School of Nursing, McMaster University, Hamilton, Ontario, Canada
AN  - 107098108. Language: English. Entry Date: 20000301. Revision Date: 20150820. Publication Type: Journal Article
AU  - Ingram, C.
DB  - CINAHL Complete
DP  - EBSCOhost
KW  - Breast Neoplasms -- Psychosocial Factors
Breast Neoplasms -- Diagnosis
Patient Attitudes
Help Seeking Behavior
Symptoms
Research Subject Recruitment
Focus Groups
California
Patient Attitudes -- Evaluation
Narratives
Thematic Analysis
Qualitative Studies
Adult
Middle Age
Female
N1  - abstract; commentary. Journal Subset: Core Nursing; Europe; Nursing; Peer Reviewed; UK & Ireland. NLM UID: 9815947.
PY  - 1999
SN  - 1367-6539
SP  - 93-93
ST  - Women's decisions to seek evaluation of self discovered breast symptoms occurred in a complex social context [commentary on Facione NC, Giancarlo CA. Narratives of breast symptom discovery and cancer diagnosis: psychologic risk for advanced cancer at diagnosis. CANCER NURS 1998;21(6):430-40]
T2  - Evidence Based Nursing
TI  - Women's decisions to seek evaluation of self discovered breast symptoms occurred in a complex social context [commentary on Facione NC, Giancarlo CA. Narratives of breast symptom discovery and cancer diagnosis: psychologic risk for advanced cancer at diagnosis. CANCER NURS 1998;21(6):430-40]
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=107098108&site=ehost-live&scope=site
ID  - 2146
ER  - 

TY  - JOUR
AB  - BACKGROUND: Prior to 1991, little research had focused on health issues unique to, or more common for, women. This was especially the case for studies of chronic diseases and their prevention in mature women. These conditions (coronary heart disease, cancer, and osteoporosis) are the leading causes of impairment of quality of life, morbidity, and mortality in post‐menopausal United States women. The WHI, mandated by Congress, was established in 1991 by the National Institutes of Health and located in the Office of the Director (OD). The Clinical Coordinating Center for the clinical trial/observational study was funded in September 1992 and the 16 Vanguard Clinical Centers were funded in March 1993. The initial protocol was developed jointly by the Clinical Coordinating Center and the Program Office and was reviewed and approved by the Investigators Committee on April 20, 1993. Additional clinical centers were funded in 1994. On October 1, 1997, administration of the WHI was transferred to the NHLBI where it is conducted as a consortium effort led by the NHLBI in cooperation with the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), the National Cancer Institute (NCI), and the National Institute on Aging (NIA). DESIGN NARRATIVE: As has been described in the objective, the WHI has three major components: a randomized controlled clinical trial, an observational study, and a study of community approaches to developing healthful behaviors. Recruitment for the WHI began in September 1993 and ended in December 1998. Six clinical centers completed recruitment in January 1997. The remaining 34 centers completed recruitment in December 1998. CLINICAL TRIAL COMPONENT The clinical trial component consists of three subtrials: the hormone replacement trial, the dietary modification trial, and the calcium /vitamin D supplementation trial. Approximately 27,500 women aged 50 to 79 are participating in the HRT, which tests whether long‐term HRT reduces coronary heart disease and fractures without increasing breast cancer risk. Women with a uterus were randomized to receive either estrogen plus progestin or a placebo. Progestin was added to protect women with a uterus from endometrial cancer. Women who have had a hysterectomy were randomized to receive either estrogen alone or a placebo. The estrogen plus progestin trial was stopped early on July 8, 2002 after an average follow‐up of 5.2 years on the recommendation of the Data and Safety Monitoring Board. The estrogen alone study continued unchanged until March 2, 2004 when the NIH instructed participants to stop taking their study pills and to begin the follow‐up phase of the study. . Participants in the estrogen alone study will be followed for eight to 12 years and have clinic visits every six months to assure safety and assess their health. The dietary modification trial component studies the effect of a low‐fat, high fruit, vegetable and grain diet on breast cancer, colorectal cancer and heart disease in 48,000 postmenopausal women. Participants are randomized to a comparison group which maintains usual dietary habits or to a dietary change group. Women in the dietary change group decrease their fat intake to 20 percent of total daily calories, increase fruit and vegetable consumption to five or more servings per day, and increase grains to six or more servings per day. Additionally, they monitor their food intake and attend nutrition group meetings to learn more about changing their diets in the first year. Thereafter they attend four meetings per year. The calcium/vitamin D supplementation subtrial tests whether calcium and vitamin D supplements reduce the risk of hip and other fractures and colorectal cancer in postmenopausal women. Women in the hormone replacement therapy and the dietary modification trials are encouraged to join the calcium/vitamin D supplementation study. Approximately 45,000 postmenopausal women are randomized into one of two study groups. One group was randomly assigned to receive 1,000 mg of elemental calcium (as alcium carbonate) and 400 International Units of vitamin D₃daily. The second group received a matching placebo. Women already taking calcium supplements can continue to take them. Participants will be followed for eight to 11 years and contacted by their clinical center every six months to assure their safety and assess their health. Total number of trial participants in all three subtrials is 68,135. OBSERVATIONAL STUDY The several goals of the study include: to give reliable estimates of extent to which known risk factors predict heart disease, cancers, and fractures; to identify new risk factors for these and other diseases in women; to compare risk factors, presence of disease at the start of the study and new occurrences of disease during the WHI in all study components; and to create a future resource to identify biological indicators of disease, especially substances and factors found in blood. The study enrolled 93,726 postmenopausal women and will track them for an average of nine years. Participants fill out periodic health forms and visit the clinic three years after enrollment. They take no medication and do not change their health habits. COMMUNITY PREVENTION STUDY The community prevention study consists of 12 separate studies conducted at eight of the Centers for Disease Control and Prevention's (CDC) University‐based Prevention Research Centers through a cooperative agreement between NIH and CDC. The 12 studies began in October 1995 and continue for an additional five years. The collaboration supports health promotion and disease prevention research and demonstration projects that are community‐based and focus on healthy behaviors that prevent the major causes of death and disability and that promote health practices that lead to more effective public health interventions. Each project provides research dissemination and translation of findings into community interventions. Topics under study include: attitudes towards hysterectomy, oophorectomy, and surgical menopause among African Americans; reducing cardiovascular disease risk among Black women; environmental and policy interventions to increase physical activity among minority women ages 40 to 75; peer support intervention for cardiovascular disease risk among African American women, aged 40 and older; assessing the effectiveness of a brief medical‐provider educational intervention for osteoporosis in minority women aged 40 and older; improving the delivery of diabetes care to women in minority groups; and assessment of moderate physical activity among women.
AN  - CN-02031568
AU  - Nct
KW  - Bone Diseases
Breast Neoplasms
Cardiovascular Diseases
Colonic Neoplasms
Coronary Artery Disease
Coronary Disease
Estrogens
Heart Diseases
Hormones
Ischemia
Myocardial Ischemia
Neoplasms
Osteoporosis
Progestins
Vitamin D
PY  - 1999
ST  - Women's Health Initiative (WHI)
T2  - https://clinicaltrials.gov/show/NCT00000611
TI  - Women's Health Initiative (WHI)
UR  - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02031568/full
ID  - 1441
ER  - 

TY  - JOUR
AB  - This randomized clinical trial examined the feasibility of low-fat dietary interventions among postmenopausal women of diverse backgrounds. During 1992-1994, 2,208 women aged 50-79 years, 28% of whom were black and 16% Hispanic, enrolled at clinics in Atlanta, Georgia, Birmingham, Alabama, and Miami, Florida. Intervention/support groups met periodically with a nutritionist to reduce fat intake to 20% of energy and to make other diet modifications. At 6 months postrandomization, the intervention group reduced fat intake from 39.7% of energy at baseline to 26.4%, a reduction of 13.3% of energy, compared with 2.3% among controls. Saturated fatty acid and cholesterol intakes were reduced, but intakes of fruits and vegetables, but not grain products, increased. Similar effects were observed at 12 and 18 months. Black and non-Hispanic white women had similar levels of reduction in fat, but the decrease in Hispanic women was less. Changes did not vary significantly by education. While bias in self-reported intakes may have resulted in somewhat overestimated changes in fat intake, the reported reduction was similar to the approximately 10% of energy decrease found in most trials and suggests that large changes in fat consumption can be attained in diverse study populations and in many subgroups.
AN  - WOS:000080814200004
AU  - Coates, R. J.
AU  - Bowen, D. J.
AU  - Kristal, A. R.
AU  - Feng, Z. D.
AU  - Oberman, A.
AU  - Hall, W. D.
AU  - George, V.
AU  - Lewis, C. E.
AU  - Kestin, M.
AU  - Davis, M.
AU  - Evans, M.
AU  - Grizzle, J. E.
AU  - Clifford, C. K.
DA  - Jun 15
IS  - 12
N1  - 56
10369504
PY  - 1999
SN  - 0002-9262
SP  - 1104-1112
ST  - The Women's Health Trial Feasibility Study in Minority Populations: Changes in dietary intakes
T2  - American Journal of Epidemiology
TI  - The Women's Health Trial Feasibility Study in Minority Populations: Changes in dietary intakes
VL  - 149
ID  - 2726
ER  - 

TY  - JOUR
AB  - OBJECTIVE: To assess the knowledge of the risks and benefits of oral contraceptives (OCs) in a heterogeneous group of women and to identify their sources of information. METHODS: A self-administered questionnaire assessing demographics, contraception history, knowledge of risks and benefits of OCs, and information sources was given to literate English- and Spanish-speaking women waiting for appointments at 4 clinics serving distinct populations in Portland, Oregon. RESULTS: Approximately half of the 211 women studied were of the opinion that OCs decreased the risk of acne, dysmenorrhea, and menorrhagia and increased the risk of weight gain, headaches, and thrombosis. Less than 15% knew of the decreased risk of anemia, endometrial cancer, colon cancer and pelvic inflammatory disease, but 28% understood the decreased risk of ovarian cancer. Seven percent to 36% of women used their own experiences in assessing the effect of OCs on a variety of general and reproductive factors. Women relied primarily on printed information for knowledge of OCs' effects on cardiovascular health and cancer. CONCLUSION: Women in this heterogeneous population of women were unaware of several benefits of OCs. Women relied heavily on their own experiences in assessing the risks and benefits of OCs. Women cited printed information more frequently than medical personnel as major sources of information on cardiovascular and oncological risks and benefits of OCs. The Internet, however, played a minimal, if any role in educating women about OCs.
AD  - Department of Obstetrics and Gynecology, Oregon Health and Science University, Portland
AN  - 106876772. Language: English. Entry Date: 20031017. Revision Date: 20150711. Publication Type: Journal Article
AU  - Picardo, C. M.
AU  - Nichols, M.
AU  - Edelman, A.
AU  - Jensen, J. T.
DA  - Spring2003
DB  - CINAHL Complete
DP  - EBSCOhost
IS  - 2
KW  - Contraceptives, Oral -- Therapeutic Use
Health Knowledge
Women's Health
Adolescence
Adult
Analysis of Variance
Attitude to Health
Black Persons
Cardiovascular Diseases -- Prevention and Control
Chi Square Test
Data Analysis Software
Descriptive Statistics
Evaluation Research
Female
Genital Neoplasms, Female -- Prevention and Control
Headache -- Chemically Induced
Hispanic Americans
Middle Age
Native Americans
Obesity -- Chemically Induced
Oregon
Questionnaires
Research Subject Recruitment
Self Report
Socioeconomic Factors
Surveys
Thrombosis -- Chemically Induced
White Persons
Funding Source
Human
N1  - research; tables/charts. Journal Subset: Biomedical; Peer Reviewed; USA. Grant Information: Supported by the Oregon Health and Science University Center for Women's Health and the Women's Reproductive Health Research Scholar Career Development Program HD 01243-03. NLM UID: 7503064.
PMID: NLM12744425.
PY  - 2003
SN  - 0098-8421
SP  - 112-116
ST  - Women's knowledge and sources of information on the risks and benefits of oral contraception
T2  - Journal of the American Medical Women's Association
TI  - Women's knowledge and sources of information on the risks and benefits of oral contraception
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106876772&site=ehost-live&scope=site
VL  - 58
ID  - 2147
ER  - 

TY  - JOUR
AB  - PURPOSES: This study examined women's satisfaction with their breast and gynecological (GYN) cancer screening, clinical breast examination (CBE), mammogram (MAM), and pelvic examination (PE). Selected predictors (characteristics of the exam and characteristics of the health care provider) of satisfaction with their screening exams also were assessed. METHODS: Women (N = 242) ages 19 years and older were recruited from a residential mailing list, and from church and community organizations. Participants completed questionnaires in their homes or in the community setting where they had been recruited. Descriptive statistics were used to describe the level of women's satisfaction with their most recent exams. Hierarchical multiple regression was used to determine the influence of exam and health care provider characteristics on women's satisfaction with exams. RESULTS: We found that women were very satisfied with care received during all three screening exams. Women were more satisfied during CBE and PE if they perceived these exams as informative, clear and complete and if they perceived the provider as informative and responsive to them when they ask questions. Women also were more satisfied with all three exams when the provider was perceived as relaxed during these exams.
AD  - University of Nebraska Medical Center, College of Nursing; mfoxall@unmc.edu
AN  - 106758683. Language: English. Entry Date: 20040723. Revision Date: 20150820. Publication Type: Journal Article
AU  - Foxall, M. J.
AU  - Barron, C. R.
AU  - Houfek, J.
DB  - CINAHL Complete
DP  - EBSCOhost
IS  - 1
KW  - Breast Neoplasms -- Diagnosis
Cancer Screening -- Standards
Mammography -- Standards
Physical Examination -- Standards
Uterine Neoplasms -- Diagnosis
Women's Health Services -- Standards
Adult
Aged
Black Persons
Clinical Competence
Content Validity
Convenience Sample
Descriptive Research
Descriptive Statistics
Female
Health Services Accessibility
Hispanic Americans
Literature Review
Mail
Mammography -- Psychosocial Factors
Middle Age
Midwestern United States
Multiple Regression
Native Americans
Palpation -- Psychosocial Factors
Palpation -- Standards
Physical Examination -- Psychosocial Factors
Power Analysis
Professional-Patient Relations
Questionnaires
Random Sample
Regression
Research Subject Recruitment
Research Subjects -- Economics
Sample Size
Scales
Secondary Analysis
Summated Rating Scaling
Surveys
United States
White Persons
Human
N1  - research; tables/charts. Journal Subset: Biomedical; Double Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA. NLM UID: 9421509.
PMID: NLM14535604.
PY  - 2003
SN  - 0363-0242
SP  - 21-36
ST  - Women's satisfaction with breast and gynecological cancer screening
T2  - Women & Health
TI  - Women's satisfaction with breast and gynecological cancer screening
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106758683&site=ehost-live&scope=site
VL  - 38
ID  - 2148
ER  - 

TY  - JOUR
AD  - University of Manchester, UK
AN  - 105886953. Language: English. Entry Date: 20080418. Revision Date: 20150820. Publication Type: Journal Article
AU  - Stevinson, C.
AU  - Moadel, A. B.
AU  - Hall, C. B.
DB  - CINAHL Complete
DP  - EBSCOhost
IS  - 1
KW  - Cancer Survivors
Functional Status
Psychological Well-Being
Yoga
Affect
Black Persons
Breast Neoplasms
Clinical Trials
Fatigue
Female
Hispanic Americans
New York
Outpatients
Patient Compliance
Quality of Life
Research Subject Recruitment
Research Subject Retention
Spirituality
Waiting Lists
N1  - abstract; commentary; response. Original Study: Moadel AB, Shah C, Wylie-Rosett J, Harris MS, Patel SR, Hall CB, Sparano JA. Randomized controlled triral of yoga among a multiethnic sample of breast cancer patients: effects on quality of life. J CLIN ONCOL 2007; 25: 4387-95. Journal Subset: Alternative/Complementary Therapies; Editorial Board Reviewed; Europe; Peer Reviewed; UK & Ireland. NLM UID: 9806970.
PY  - 2008
SN  - 1465-3753
SP  - 46-47
ST  - Yoga associated with improved social well-being for multi-ethnic women with breast cancer
T2  - Focus on Alternative & Complementary Therapies
TI  - Yoga associated with improved social well-being for multi-ethnic women with breast cancer
UR  - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105886953&site=ehost-live&scope=site
VL  - 13
ID  - 2149
ER  - 

TY  - JOUR
AB  - Medical and research professionals who discuss clinical trials and research studies with potential participants face an often daunting challenge, particularly when recruiting from minority and underserved populations. This study reports on findings from a focus group study of 63 research coordinators, study nurses, professional recruiters, and other professionals in Indianapolis, IN and Miami, FL who work to recruit from minority and underserved populations. These professionals discussed the importance of creating a sense of connection with potential participants as part of the recruitment and retention process. Building a relationship, however fleeting, involved a number of concrete behaviors, including listening to personal information, expressing empathy, and then providing reciprocal self-disclosures; having repeated contact, usually by working in the same environment over an extended period of time; demonstrating respect through politeness and the use of honorifics; going the extra mile for participants; offering flexibility in scheduling follow-up appointments; and creating a sense of personal and community trust by being truthful. The implications of these findings for clinical trial and research study accrual are discussed.
AN  - WOS:000396776200001
AU  - Morgan, S. E.
AU  - Occa, A.
AU  - Potter, J.
AU  - Mouton, A.
AU  - Peter, M. E.
DO  - 10.1080/10810730.2016.1256356
IS  - 2
N1  - 28085636
PY  - 2017
SN  - 1081-0730
SP  - 95-101
ST  - "You Need to Be a Good Listener": Recruiters' Use of Relational Communication Behaviors to Enhance Clinical Trial and Research Study Accrual
T2  - Journal of Health Communication
TI  - "You Need to Be a Good Listener": Recruiters' Use of Relational Communication Behaviors to Enhance Clinical Trial and Research Study Accrual
VL  - 22
ID  - 2919
ER  - 

TY  - JOUR
AB  - Zinc is an essential dietary element that has been implicated in the pathogenesis of prostate cancer, a cancer that disproportionately affects men of African descent. Studies assessing the association of zinc intake and prostate cancer have yielded inconsistent results. Furthermore, very little is known about the relationship between zinc intake and prostate cancer among African Americans. We examined the association between self-reported zinc intake and prostate cancer in a hospital-based case-control study of African Americans. We then compared our results with previous studies by performing a meta-analysis to summarize the evidence regarding the association between zinc and prostate cancer. Newly diagnosed African American men with histologically confirmed prostate cancer (n = 127) and controls (n = 81) were recruited from an urban academic urology clinic in Washington, DC. Controls had higher zinc intake, with a mean of 14 mg/day versus 11 mg/day for cases. We observed a non-significant, non-linear increase in prostate cancer when comparing tertiles of zinc intake (OR <6.5 vs 6.5-12.5mg/day 1.8, 95% CI: 0.6,5.6; OR <6.5 vs >12.5mg/day 1.3, 95% CI: 0.2,6.5). The pooled estimate from 17 studies (including 3 cohorts, 2 nested case-control, 11 case-control studies, and 1 randomized clinical trial, with a total of 111,199 participants and 11,689 cases of prostate cancer) was 1.07hi vs lo 95% CI: 0.98-1.16. Using a dose-response meta-analysis, we observed a non-linear trend in the relationship between zinc intake and prostate cancer (p for nonlinearity = 0.0022). This is the first study to examine the relationship between zinc intake in black men and risk of prostate cancer and systematically evaluate available epidemiologic evidence about the magnitude of the relationship between zinc intake and prostate cancer. Despite of the lower intake of zinc by prostate cancer patients, our meta-analysis indicated that there is no evidence for an association between zinc intake and prostate cancer.
AD  - Department of Kinesiology and Nutrition and Department of Physical Therapy, School of Applied Health Sciences, University of Illinois at Chicago, Chicago, Illinois, United States of America.
Department of Pathology, South Egypt Cancer Institute, Assiut University, Assiut, Egypt.
Division of Epidemiology and Biostatistics, School of Public Health, University of Illinois at Chicago, Chicago, Illinois, United States of America.
James R. & Helen D. Russell Institute for Research & Innovation, Advocate Lutheran General Hospital, Park Ridge, Illinois, United States of America.
Department of Surgery, College of Medicine, University of Arizona, Tucson, Arizona, United States of America.
AN  - 27824905
AU  - Mahmoud, A. M.
AU  - Al-Alem, U.
AU  - Dabbous, F.
AU  - Ali, M. M.
AU  - Batai, K.
AU  - Shah, E.
AU  - Kittles, R. A.
C2  - PMC5100936
DO  - 10.1371/journal.pone.0165956
DP  - NLM
ET  - 2016/11/09
IS  - 11
KW  - African Americans/statistics & numerical data
Case-Control Studies
Humans
Male
Prostate/drug effects
Prostatic Neoplasms/*prevention & control
Risk Factors
Zinc/*therapeutic use
LA  - eng
N1  - 1932-6203
Mahmoud, Abeer M
Al-Alem, Umaima
Dabbous, Firas
Ali, Mohamed M
Batai, Ken
Shah, Ebony
Kittles, Rick A
U54 CA091431/CA/NCI NIH HHS/United States
Journal Article
Meta-Analysis
PLoS One. 2016 Nov 8;11(11):e0165956. doi: 10.1371/journal.pone.0165956. eCollection 2016.
PY  - 2016
SN  - 1932-6203
SP  - e0165956
ST  - Zinc Intake and Risk of Prostate Cancer: Case-Control Study and Meta-Analysis
T2  - PLoS One
TI  - Zinc Intake and Risk of Prostate Cancer: Case-Control Study and Meta-Analysis
VL  - 11
ID  - 194
ER  -